<SEC-DOCUMENT>0001628280-25-004179.txt : 20250717
<SEC-HEADER>0001628280-25-004179.hdr.sgml : 20250717
<ACCEPTANCE-DATETIME>20250205212053
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001628280-25-004179
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		27
FILED AS OF DATE:		20250206
<PUBLIC-REL-DATE>20250717
DATE AS OF CHANGE:		20250205

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Heartflow, Inc.
		CENTRAL INDEX KEY:			0001464521
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				260506743
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-07711
		FILM NUMBER:		25595153

	BUSINESS ADDRESS:	
		STREET 1:		331 E EVELYN AVENUE
		CITY:			MOUNTAIN VIEW
		STATE:			CA
		ZIP:			94041
		BUSINESS PHONE:		650-241-1221

	MAIL ADDRESS:	
		STREET 1:		331 E EVELYN AVENUE
		CITY:			MOUNTAIN VIEW
		STATE:			CA
		ZIP:			94041

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cardiovascular Simulation, Inc.
		DATE OF NAME CHANGE:	20090519
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<html><head><title>HeartFlow, Inc. - DRS</title></head><body><div style="background-color: #E4E4E4; font-family: Arial, Sans Serif; word-wrap: break-word;"><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 783pt;"><div style="width: 594pt;"></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 594pt;"><div style="line-height: 7.28pt; position: absolute; top: 0pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 603pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 36pt;"></font></font><font style="left: 639pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 36pt;"></font></font></font></div></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_679" style="position: absolute; top: 9pt;"></div><div style="line-height: 5.46pt; position: absolute; top: 9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: bold; left: 131.31pt; position: absolute; text-decoration: none; white-space: pre;">As confidentially submitted to the U.S. Securities and Exchange Commission on February 5, 2025.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 18pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: bold; left: 9pt; position: absolute; text-decoration: none; white-space: pre;">This draft registration statement has not been publicly filed with the U.S. Securities and Exchange Commission and all information herein remains strictly confidential.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: bold; left: 505.18pt; position: absolute; text-decoration: none; white-space: pre;">Registration No. 333-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="position: absolute; top: 47pt; width: 612pt;"><div style="font-size: 0pt; left: 9pt; position: absolute; top: 0pt; width: 594pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 594pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 3pt;"><td style="border-bottom: 3pt double #000000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 58pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 266.32pt; position: absolute; text-decoration: none; white-space: pre;">UNIT<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 289.63pt; position: absolute; text-decoration: none; white-space: pre;">ED STAT<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 332.36pt; position: absolute; text-decoration: none; white-space: pre;">ES<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 73pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 199.98pt; position: absolute; text-decoration: none; white-space: pre;">SECURITIES AND EXCHANGE COMMISSION<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 85pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 249.38pt; position: absolute; text-decoration: none; white-space: pre;">Washington, D.C. 20549<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 100pt; width: 612pt;"><div style="font-size: 0pt; left: 256.12pt; position: absolute; top: 0pt; width: 99.75pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 99.75pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 11.64pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 267.8pt; position: absolute; text-decoration: none; white-space: pre;">FORM S-1<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 16pt; line-height: 11.64pt; position: absolute; top: 135.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 194.49pt; position: absolute; text-decoration: none; white-space: pre;">REGISTRATION STATEM<font style="display: inline-block; height: 11.64pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 385.52pt; position: absolute; text-decoration: none; white-space: pre;">ENT<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 154.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 288.23pt; position: absolute; text-decoration: none; white-space: pre;">UNDER<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 166.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 232.17pt; position: absolute; text-decoration: none; white-space: pre;">THE SECURITIES ACT OF 1933<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 181.4pt; width: 612pt;"><div style="font-size: 0pt; left: 256.12pt; position: absolute; top: 0pt; width: 99.75pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 99.75pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 16.01pt; position: absolute; top: 197.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 22pt; font-style: normal; font-weight: bold; left: 230.85pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow, Inc.<font style="display: inline-block; height: 16.01pt;"></font></font></div><div style="line-height: 5.09pt; position: absolute; top: 223.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 219.93pt; position: absolute; text-decoration: none; white-space: pre;">(Exact name of registrant as specified in its charter)<font style="display: inline-block; height: 5.09pt;"></font></font></div><div style="position: absolute; top: 235.2pt; width: 612pt;"><div style="font-size: 0pt; left: 256.12pt; position: absolute; top: 0pt; width: 99.75pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 99.75pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="position: absolute; top: 251.2pt; width: 612pt;"><div style="font-size: 0pt; left: 9pt; position: absolute; top: 0pt; width: 594pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 198pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 198pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 198pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 11.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 198pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 2.63pt; width: 198pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 83.64pt; position: absolute; text-decoration: none; white-space: pre;">Delaware<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 0pt; width: 198pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 2.63pt; width: 198pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 91.22pt; position: absolute; text-decoration: none; white-space: pre;">3841<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 396pt; position: absolute; top: 0pt; width: 198pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 2.63pt; width: 198pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 80.33pt; position: absolute; text-decoration: none; white-space: pre;">26-0506743<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td></tr><tr style="height: 18pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 11.25pt; width: 198pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 2.63pt; width: 198pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 51.03pt; position: absolute; text-decoration: none; white-space: pre;">(State or other jurisdiction of<font style="display: inline-block; height: 5.09pt;"></font></font></div><div style="line-height: 5.09pt; position: absolute; top: 11.03pt; width: 198pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 49.09pt; position: absolute; text-decoration: none; white-space: pre;">incorporation or organization)<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 11.25pt; width: 198pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 2.63pt; width: 198pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 51.99pt; position: absolute; text-decoration: none; white-space: pre;">(Primary Standard Industrial<font style="display: inline-block; height: 5.09pt;"></font></font></div><div style="line-height: 5.09pt; position: absolute; top: 11.03pt; width: 198pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 51.21pt; position: absolute; text-decoration: none; white-space: pre;">Classification Code Number)<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 396pt; position: absolute; top: 11.25pt; width: 198pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 2.63pt; width: 198pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 72.2pt; position: absolute; text-decoration: none; white-space: pre;">(I.R.S. Employer<font style="display: inline-block; height: 5.09pt;"></font></font></div><div style="line-height: 5.09pt; position: absolute; top: 11.03pt; width: 198pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 61.9pt; position: absolute; text-decoration: none; white-space: pre;">Identification Number)<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td></tr></table></div></div></div><div style="position: absolute; top: 285.45pt; width: 612pt;"><div style="font-size: 0pt; left: 256.12pt; position: absolute; top: 0pt; width: 99.75pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 99.75pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="font-size: 12pt; line-height: 5.09pt; position: absolute; top: 296.45pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 270.05pt; position: absolute; text-decoration: none; white-space: pre;">331 E. Evelyn Avenue<font style="display: inline-block; height: 5.09pt;"></font></font></div><div style="font-size: 12pt; line-height: 5.09pt; position: absolute; top: 304.85pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 252.77pt; position: absolute; text-decoration: none; white-space: pre;">Mountain View, California 94041<font style="display: inline-block; height: 5.09pt;"></font></font></div><div style="font-size: 12pt; line-height: 5.09pt; position: absolute; top: 313.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 282.08pt; position: absolute; text-decoration: none; white-space: pre;">(650) 241-1221<font style="display: inline-block; height: 5.09pt;"></font></font></div><div style="line-height: 5.09pt; position: absolute; top: 321.65pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 113.13pt; position: absolute; text-decoration: none; white-space: pre;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)<font style="display: inline-block; height: 5.09pt;"></font></font></div><div style="position: absolute; top: 333.05pt; width: 612pt;"><div style="font-size: 0pt; left: 256.12pt; position: absolute; top: 0pt; width: 99.75pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 99.75pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 5.09pt; position: absolute; top: 348.05pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 273.18pt; position: absolute; text-decoration: none; white-space: pre;">John C.M. Farquhar<font style="display: inline-block; height: 5.09pt;"></font></font></div><div style="line-height: 5.09pt; position: absolute; top: 356.45pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 243.64pt; position: absolute; text-decoration: none; white-space: pre;">President and Chief Executive Officer <font style="display: inline-block; height: 5.09pt;"></font></font></div><div style="line-height: 5.09pt; position: absolute; top: 364.85pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 282.11pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow, Inc.<font style="display: inline-block; height: 5.09pt;"></font></font></div><div style="line-height: 5.09pt; position: absolute; top: 373.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 270.05pt; position: absolute; text-decoration: none; white-space: pre;">331 E. Evelyn Avenue<font style="display: inline-block; height: 5.09pt;"></font></font></div><div style="line-height: 5.09pt; position: absolute; top: 381.65pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 252.77pt; position: absolute; text-decoration: none; white-space: pre;">Mountain View, California 94041<font style="display: inline-block; height: 5.09pt;"></font></font></div><div style="line-height: 5.09pt; position: absolute; top: 390.05pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 282.08pt; position: absolute; text-decoration: none; white-space: pre;">(650) 241-1221 <font style="display: inline-block; height: 5.09pt;"></font></font></div><div style="font-size: 12pt; line-height: 5.09pt; position: absolute; top: 398.45pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 137.99pt; position: absolute; text-decoration: none; white-space: pre;">(Name, address, including zip code, and telephone number, including area code, of agent for servi<font style="display: inline-block; height: 5.09pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 463.90000000000003pt; position: absolute; text-decoration: none; white-space: pre;">ce)<font style="display: inline-block; height: 5.09pt;"></font></font></div><div style="position: absolute; top: 409.85pt; width: 612pt;"><div style="font-size: 0pt; left: 256.12pt; position: absolute; top: 0pt; width: 99.75pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 99.75pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 5.09pt; position: absolute; top: 417.85pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: italic; font-weight: bold; left: 288.91pt; position: absolute; text-decoration: none; white-space: pre;">Copies to&#58;<font style="display: inline-block; height: 5.09pt;"></font></font></div><div style="position: absolute; top: 426.25pt; width: 612pt;"><div style="font-size: 0pt; left: 9pt; position: absolute; top: 0pt; width: 594pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 198pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 198pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 198pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 9pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 9pt; left: 0pt; overflow: hidden; position: absolute; top: 0pt; width: 198pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 2.63pt; width: 198pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 75.1pt; position: absolute; text-decoration: none; white-space: pre;">Shelly Heyduk<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 9pt; left: 198pt; overflow: hidden; position: absolute; top: 0pt; width: 198pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 2.63pt; width: 198pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 74.52pt; position: absolute; text-decoration: none; white-space: pre;">Angela Ahmad<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 9pt; left: 396pt; overflow: hidden; position: absolute; top: 0pt; width: 198pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 2.63pt; width: 198pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 75.1pt; position: absolute; text-decoration: none; white-space: pre;">Dave Peinsipp<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td></tr><tr style="height: 9pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 9pt; left: 0pt; overflow: hidden; position: absolute; top: 9pt; width: 198pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 2.63pt; width: 198pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 75.49pt; position: absolute; text-decoration: none; white-space: pre;">Ryan Coombs<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 9pt; left: 198pt; overflow: hidden; position: absolute; top: 9pt; width: 198pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 2.63pt; width: 198pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 75.11pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow, Inc.<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 9pt; left: 396pt; overflow: hidden; position: absolute; top: 9pt; width: 198pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 2.63pt; width: 198pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 68.89pt; position: absolute; text-decoration: none; white-space: pre;">Kristin VanderPas<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td></tr><tr style="height: 9pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 9pt; left: 0pt; overflow: hidden; position: absolute; top: 18pt; width: 198pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 2.63pt; width: 198pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 59.36pt; position: absolute; text-decoration: none; white-space: pre;">O&#8217;Melveny &#38; Myers LLP<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 9pt; left: 198pt; overflow: hidden; position: absolute; top: 18pt; width: 198pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 2.63pt; width: 198pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 63.05pt; position: absolute; text-decoration: none; white-space: pre;">331 E. Evelyn Avenue<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 9pt; left: 396pt; overflow: hidden; position: absolute; top: 18pt; width: 198pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 2.63pt; width: 198pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 79.77pt; position: absolute; text-decoration: none; white-space: pre;">Denny Won<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td></tr><tr style="height: 9pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 9pt; left: 0pt; overflow: hidden; position: absolute; top: 27pt; width: 198pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 2.63pt; width: 198pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 37.61pt; position: absolute; text-decoration: none; white-space: pre;">610 Newport Center Drive, 17th Floor<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 9pt; left: 198pt; overflow: hidden; position: absolute; top: 27pt; width: 198pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 2.63pt; width: 198pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 45.77pt; position: absolute; text-decoration: none; white-space: pre;">Mountain View, California 94041<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 9pt; left: 396pt; overflow: hidden; position: absolute; top: 27pt; width: 198pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 2.63pt; width: 198pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 74.33pt; position: absolute; text-decoration: none; white-space: pre;">Charles S. Kim<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td></tr><tr style="height: 9pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 9pt; left: 0pt; overflow: hidden; position: absolute; top: 36pt; width: 198pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 2.63pt; width: 198pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 44.79pt; position: absolute; text-decoration: none; white-space: pre;">Newport Beach, California 92660<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 9pt; left: 198pt; overflow: hidden; position: absolute; top: 36pt; width: 198pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 2.63pt; width: 198pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 75.08pt; position: absolute; text-decoration: none; white-space: pre;">(650) 241-1221 <font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 9pt; left: 396pt; overflow: hidden; position: absolute; top: 36pt; width: 198pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 2.63pt; width: 198pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 79.77pt; position: absolute; text-decoration: none; white-space: pre;">Cooley LLP<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td></tr><tr style="height: 9pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 9pt; left: 0pt; overflow: hidden; position: absolute; top: 45pt; width: 198pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 2.63pt; width: 198pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 75.08pt; position: absolute; text-decoration: none; white-space: pre;">(949) 823-6900<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 9pt; left: 396pt; overflow: hidden; position: absolute; top: 45pt; width: 198pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 2.63pt; width: 198pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 42.86pt; position: absolute; text-decoration: none; white-space: pre;">3 Embarcadero Center, 20th Floor<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td></tr><tr style="height: 9pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 9pt; left: 396pt; overflow: hidden; position: absolute; top: 54pt; width: 198pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 2.63pt; width: 198pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 46.35pt; position: absolute; text-decoration: none; white-space: pre;">San Francisco, California 94111<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td></tr><tr style="height: 9pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 9pt; left: 396pt; overflow: hidden; position: absolute; top: 63pt; width: 198pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 2.63pt; width: 198pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 75.08pt; position: absolute; text-decoration: none; white-space: pre;">(415) 693-2000<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td></tr></table></div></div></div><div style="position: absolute; top: 506.25pt; width: 612pt;"><div style="font-size: 0pt; left: 256.12pt; position: absolute; top: 0pt; width: 99.75pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 99.75pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 5.46pt; position: absolute; top: 522.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: bold; left: 9pt; position: absolute; text-decoration: none; white-space: pre;">Approximate date of commencement of proposed sale to the public&#58;<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 251.74pt; position: absolute; text-decoration: none; white-space: pre;"> As soon as practicable after the effective date of this Registration Statement.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 531.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 9pt; position: absolute; text-decoration: none; white-space: pre;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.78pt; position: absolute; top: 540.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 9pt; position: absolute; text-decoration: none; white-space: pre;">box. <font style="display: inline-block; height: 5.78pt;"></font></font><font style="font-family: &#39;Wingdings&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 25.25pt; position: absolute; text-decoration: none; white-space: pre;">o<font style="display: inline-block; height: 5.78pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 549.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 9pt; position: absolute; text-decoration: none; white-space: pre;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.78pt; position: absolute; top: 558.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 9pt; position: absolute; text-decoration: none; white-space: pre;">registration statement number of the earlier effective registration statement for the same offering. <font style="display: inline-block; height: 5.78pt;"></font></font><font style="font-family: &#39;Wingdings&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 331.08pt; position: absolute; text-decoration: none; white-space: pre;">o<font style="display: inline-block; height: 5.78pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 567.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 9pt; position: absolute; text-decoration: none; white-space: pre;">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.78pt; position: absolute; top: 576.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 9pt; position: absolute; text-decoration: none; white-space: pre;">of the earlier effective registration statement for the same offering. <font style="display: inline-block; height: 5.78pt;"></font></font><font style="font-family: &#39;Wingdings&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 229.46pt; position: absolute; text-decoration: none; white-space: pre;">o<font style="display: inline-block; height: 5.78pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 585.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 9pt; position: absolute; text-decoration: none; white-space: pre;">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.78pt; position: absolute; top: 594.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 9pt; position: absolute; text-decoration: none; white-space: pre;">of the earlier effective registration statement for the same offering. <font style="display: inline-block; height: 5.78pt;"></font></font><font style="font-family: &#39;Wingdings&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 229.46pt; position: absolute; text-decoration: none; white-space: pre;">o<font style="display: inline-block; height: 5.78pt;"></font></font></div><div style="font-size: 12pt; line-height: 5.46pt; position: absolute; top: 603.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 9pt; position: absolute; text-decoration: none; white-space: pre;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging <font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 540.73pt; position: absolute; text-decoration: none; white-space: pre;">growth<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 563.22pt; position: absolute; text-decoration: none; white-space: pre;"> company. <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 612.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 9pt; position: absolute; text-decoration: none; white-space: pre;">See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="position: absolute; top: 621.25pt; width: 612pt;"><div style="font-size: 0pt; left: 9pt; position: absolute; top: 0pt; width: 593.25pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 269.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 27pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 269.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 27.75pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 11.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 269.25pt;"><div><div style="line-height: 5.46pt; position: absolute; top: 2.72pt; width: 269.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Large accelerated filer<font style="display: inline-block; height: 5.46pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 269.25pt; position: absolute; top: 0pt; width: 27pt;"><div><div style="line-height: 5.78pt; position: absolute; top: 2.63pt; width: 27pt;"><font style="font-family: &#39;Wingdings&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">o<font style="display: inline-block; height: 5.78pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 296.25pt; position: absolute; top: 0pt; width: 269.25pt;"><div><div style="line-height: 5.46pt; position: absolute; top: 2.72pt; width: 269.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Accelerated filer<font style="display: inline-block; height: 5.46pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 565.5pt; position: absolute; top: 0pt; width: 27.75pt;"><div><div style="line-height: 5.78pt; position: absolute; top: 2.63pt; width: 27.75pt;"><font style="font-family: &#39;Wingdings&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">o<font style="display: inline-block; height: 5.78pt;"></font></font></div></div></div></td></tr><tr style="height: 11.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 11.25pt; width: 269.25pt;"><div><div style="line-height: 5.46pt; position: absolute; top: 2.72pt; width: 269.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Non-accelerated filer<font style="display: inline-block; height: 5.46pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 269.25pt; position: absolute; top: 11.25pt; width: 27pt;"><div><div style="line-height: 5.78pt; position: absolute; top: 2.63pt; width: 27pt;"><font style="font-family: &#39;Wingdings&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">x<font style="display: inline-block; height: 5.78pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 296.25pt; position: absolute; top: 11.25pt; width: 269.25pt;"><div><div style="line-height: 5.46pt; position: absolute; top: 2.72pt; width: 269.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Smaller reporting company<font style="display: inline-block; height: 5.46pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 565.5pt; position: absolute; top: 11.25pt; width: 27.75pt;"><div><div style="line-height: 5.78pt; position: absolute; top: 2.63pt; width: 27.75pt;"><font style="font-family: &#39;Wingdings&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">o<font style="display: inline-block; height: 5.78pt;"></font></font></div></div></div></td></tr><tr style="height: 11.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 296.25pt; position: absolute; top: 22.5pt; width: 269.25pt;"><div><div style="line-height: 5.46pt; position: absolute; top: 2.72pt; width: 269.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Emerging growth company<font style="display: inline-block; height: 5.46pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 565.5pt; position: absolute; top: 22.5pt; width: 27.75pt;"><div><div style="line-height: 5.78pt; position: absolute; top: 2.63pt; width: 27.75pt;"><font style="font-family: &#39;Wingdings&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">x<font style="display: inline-block; height: 5.78pt;"></font></font></div></div></div></td></tr></table></div></div></div><div style="line-height: 5.46pt; position: absolute; top: 668pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 9pt; position: absolute; text-decoration: none; white-space: pre;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.78pt; position: absolute; top: 677pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 9pt; position: absolute; text-decoration: none; white-space: pre;">accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. <font style="display: inline-block; height: 5.78pt;"></font></font><font style="font-family: &#39;Wingdings&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 284.75pt; position: absolute; text-decoration: none; white-space: pre;">o<font style="display: inline-block; height: 5.78pt;"></font></font></div><div style="position: absolute; top: 693pt; width: 612pt;"><div style="font-size: 0pt; left: 256.12pt; position: absolute; top: 0pt; width: 99.75pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 99.75pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 5.46pt; position: absolute; top: 704pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: bold; left: 9pt; position: absolute; text-decoration: none; white-space: pre;">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 713pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: bold; left: 9pt; position: absolute; text-decoration: none; white-space: pre;">amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 722pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: bold; left: 9pt; position: absolute; text-decoration: none; white-space: pre;">amended, or until the registration statement shall become effective on such date as the U.S. Securities and Exchange Commission, acting pursuant to said Section <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 731pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: bold; left: 9pt; position: absolute; text-decoration: none; white-space: pre;">8(a), may determine.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="position: absolute; top: 743pt; width: 612pt;"><div style="font-size: 0pt; left: 9pt; position: absolute; top: 0pt; width: 594pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 594pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 3pt;"><td style="border-bottom: 3pt double #000000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_682" style="position: absolute; top: 72pt;"></div><div style="line-height: 11.64pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">EXPLANATORY NOTE<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 107.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Pursuant to the applicable provisions of the Fixing America&#8217;s Surface Transportation Act, we are omitting <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 119.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our unaudited interim financial statements as of September 30, 2024 and for the nine months ended <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 131.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">September 30, 2024 and 2023 because they relate to historical periods that we believe will not be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 143.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">required to be included in the prospectus at the time of the contemplated offering. We intend to amend the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 155.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">registration statement to include all financial information required by Regulation S-X at the date of such <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 167.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">amendment before distributing a preliminary prospectus to investors.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 756pt;"><div style="width: 540pt;"></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 540pt;"></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_685" style="position: absolute; top: 36pt;"></div><div style="line-height: 7.28pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 36pt; width: 612pt;"><font style="color: #f1665f; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 36pt; position: absolute; text-decoration: none; white-space: pre; width: 539.9pt;">The information in this preliminary prospectus is not complete and may be changed. We may not sell these<font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #f1665f; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 575.9pt; position: absolute; text-decoration: none; white-space: pre; width: 2.77pt;"> <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 48pt; width: 612pt;"><font style="color: #f1665f; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 36pt; position: absolute; text-decoration: none; white-space: pre; width: 539.87pt;">securities until the registration statement filed with the U.S. Securities and Exchange Commission is effective.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #f1665f; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 575.87pt; position: absolute; text-decoration: none; white-space: pre; width: 2.77pt;"> <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 60pt; width: 612pt;"><font style="color: #f1665f; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 36pt; position: absolute; text-decoration: none; white-space: pre; width: 539.96pt;">This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these<font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #f1665f; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 575.96pt; position: absolute; text-decoration: none; white-space: pre; width: 2.77pt;"> <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; text-align: justify; text-align-last: var(--justify); top: 72pt; width: 612pt;"><font style="color: #f1665f; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 36pt; position: absolute; text-decoration: none; white-space: pre; width: 324.72pt;">securities in any jurisdiction where the offer or sale is not permitted.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 92pt; width: 612pt;"><font style="color: #f1665f; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 36pt; position: absolute; text-decoration: none; white-space: pre;">Subject to Completion, dated&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 36pt; position: absolute; text-decoration: none; white-space: pre;">Preliminary prospectus<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 18pt; line-height: 13.1pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 18pt; font-style: italic; font-weight: bold; left: 36pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 13.1pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 18pt; font-style: italic; font-weight: bold; left: 161pt; position: absolute; text-decoration: none; white-space: pre;">shares<font style="display: inline-block; height: 13.1pt;"></font></font></div><div style="position: absolute; top: 169.6pt; width: 612pt;"><div style="left: 36pt; position: absolute; top: 0pt;"><div style="position: absolute;"><img style="height: 57.27pt; width: 331.2pt;" src="heartflowlogo.jpg" alt="heartflowlogo.jpg"></div></div></div><div style="font-size: 18pt; line-height: 13.1pt; position: absolute; top: 239.87pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 18pt; font-style: italic; font-weight: bold; left: 36pt; position: absolute; text-decoration: none; white-space: pre;">Common <font style="display: inline-block; height: 13.1pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 18pt; font-style: italic; font-weight: bold; left: 118.96pt; position: absolute; text-decoration: none; white-space: pre;">stock<font style="display: inline-block; height: 13.1pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 269.47pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 36pt; position: absolute; white-space: pre;">This <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 57.65pt; position: absolute; text-decoration: none; white-space: pre;">is<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 64.87pt; position: absolute; white-space: pre;"> an initial public offering of shares of common stock of Heartflow, Inc. We are offering&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 281.47pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 36pt; position: absolute; white-space: pre;">common stock to be sold in this offering. The initial public offering price is expected to be between $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; and $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 293.47pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 36pt; position: absolute; white-space: pre;">share. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 313.47pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 36pt; position: absolute; white-space: pre;">Prior to this offering, there has been no public market for our common stock. We intend to apply to list our common stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 325.47pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 36pt; position: absolute; white-space: pre;">on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; under the trading symbol &#8220;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;,&#8221; and this offering is contingent upon obtaining such approval.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 345.47pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 36pt; position: absolute; white-space: pre;">We are an &#8220;emerging growth company&#8221; as defined under the U.S. federal securities laws and, as such, have elected to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 357.47pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 36pt; position: absolute; white-space: pre;">comply with certain reduced public company reporting requirements in this prospectus and may elect to do so in future <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 369.47pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 36pt; position: absolute; white-space: pre;">filings. See the section titled &#8220;Prospectus summary&#8212;Implications of being an emerging growth company.&#8221;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 389.47pt; width: 612pt;"><div style="font-size: 0pt; left: 36.75pt; position: absolute; top: 0pt; width: 538.5pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 402pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 12pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 405pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 26.21pt; position: absolute; text-decoration: none; white-space: pre;">Per share<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 473.25pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 43.54pt; position: absolute; text-decoration: none; white-space: pre;">Total<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 12pt; width: 402pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.63pt; width: 402pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Initial public offering price<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 109.53999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 110.11999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 110.16pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 110.17pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 405pt; position: absolute; top: 12pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 473.25pt; position: absolute; top: 12pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 26.25pt; width: 402pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.63pt; width: 402pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Underwriting discounts and commissions<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 174.64pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(1)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 182.17pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 184.48pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 185.64pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 185.68pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 185.7pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 405pt; position: absolute; top: 26.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 473.25pt; position: absolute; top: 26.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 40.5pt; width: 402pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.63pt; width: 402pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Proceeds to Heartflow, Inc., before expenses<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 191.48pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 193.79pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 194.95pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 195.1pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 195.14pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 195.16pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 195.17pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 405pt; position: absolute; top: 40.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 473.25pt; position: absolute; top: 40.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 5.46pt; position: absolute; top: 452.22pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 36pt; position: absolute; text-decoration: none; white-space: pre;">(1)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 54pt; position: absolute; text-decoration: none; white-space: pre;">See the section titled &#8220;Underwriting&#8221; for a description of the compensation payable to the underwriters.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 469.22pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 36pt; position: absolute; white-space: pre;">We have granted the underwriters an option for a period of 30 days to purchase up to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;additional shares of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 481.22pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 36pt; position: absolute; white-space: pre;">common stock. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 501.22pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 36pt; position: absolute; white-space: pre;">Investing in our common stock involves a high degree of risk. Please see &#8220;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 391.28pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_697">Risk factors</a><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 448.49pt; position: absolute; white-space: pre;">&#8221; beginning on page <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 547.79pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_697">18</a><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 558.91pt; position: absolute; white-space: pre;">.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 521.22pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 36pt; position: absolute; white-space: pre;">Neither the Securities and Exchange Commission (&#8220;SEC&#8221;) nor any state securities commission has approved or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 533.22pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 36pt; position: absolute; white-space: pre;">disapproved of these securities&#160;or determined if this prospectus is truthful or complete. Any representation to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 545.22pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 36pt; position: absolute; white-space: pre;">the contrary is a criminal offense.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 565.22pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 36pt; position: absolute; text-decoration: none; white-space: pre;">The underwriters expect to deliver the shares of common stock to the purchasers on or about&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 637.22pt; width: 612pt;"><div style="font-size: 0pt; left: 37.12pt; position: absolute; top: 0pt; width: 537.75pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 165.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 20.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 165.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 20.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 165.75pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 20.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 165.75pt;"><div><div style="line-height: 11.64pt; position: absolute; top: 3.75pt; width: 165.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">J.P. Morgan<font style="display: inline-block; height: 11.64pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 186pt; position: absolute; top: 0pt; width: 165.75pt;"><div><div style="line-height: 11.64pt; position: absolute; top: 3.75pt; width: 165.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 23.35pt; position: absolute; text-decoration: none; white-space: pre;">Morgan Stanley<font style="display: inline-block; height: 11.64pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 372pt; position: absolute; top: 0pt; width: 165.75pt;"><div><div style="line-height: 11.64pt; position: absolute; top: 3.75pt; width: 165.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 60.04pt; position: absolute; text-decoration: none; white-space: pre;">Piper Sandler<font style="display: inline-block; height: 11.64pt;"></font></font></div></div></div></td></tr></table></div></div></div><div style="position: absolute; top: 670.47pt; width: 612pt;"><div style="font-size: 0pt; left: 37.12pt; position: absolute; top: 0pt; width: 537.75pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 179.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 179.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 179.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 20.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 179.25pt;"><div><div style="line-height: 10.92pt; position: absolute; top: 4.68pt; width: 179.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 15pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Stifel<font style="display: inline-block; height: 10.92pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 358.5pt; position: absolute; top: 0pt; width: 179.25pt;"><div><div style="line-height: 10.92pt; position: absolute; top: 4.68pt; width: 179.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 15pt; font-style: normal; font-weight: bold; left: 39.15pt; position: absolute; text-decoration: none; white-space: pre;">Canaccord Genuity<font style="display: inline-block; height: 10.92pt;"></font></font></div></div></div></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 740.72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 36pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 88.63pt; position: absolute; text-decoration: none; white-space: pre;">2025<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 304.89pt; position: absolute; text-decoration: none; white-space: pre;">i<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_688" style="position: absolute; top: 72pt;"></div><div style="font-size: 12pt; line-height: 11.64pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Table of contents<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="position: absolute; top: 107.2pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 432.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 35.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 432.75pt; position: absolute; top: 0pt; width: 35.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 2.63pt; width: 35.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 13.53pt; position: absolute; text-decoration: none; white-space: pre;">Page<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td></tr><tr style="height: 6pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 20.25pt; width: 432.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 432.75pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_691">Prospectus summary</a><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 96.50999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 98.82pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 99.39999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 99.69pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 99.77pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 99.78pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 432.75pt; position: absolute; top: 20.25pt; width: 35.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 35.25pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 27.06pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_691">1</a><font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 6pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 40.5pt; width: 432.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 432.75pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_697">Risk factors</a><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 54.830000000000005pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 54.980000000000004pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 55.06pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 55.1pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 55.11pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 432.75pt; position: absolute; top: 40.5pt; width: 35.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 35.25pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 21.5pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_697">18</a><font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 6pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 60.75pt; width: 432.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 432.75pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1039">Special note regarding forward-looking statements</a><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 225.4pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 227.71pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 228.87pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 229.45pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 229.6pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 229.68pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 432.75pt; position: absolute; top: 60.75pt; width: 35.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 35.25pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 21.5pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1039">68</a><font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 6pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 81pt; width: 432.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 432.75pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1064">Market and industry data</a><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 112.61999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 113.78pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 114.36pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 114.64999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 114.8pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 114.88pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 114.89999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 432.75pt; position: absolute; top: 81pt; width: 35.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 35.25pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 21.5pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1064">70</a><font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 6pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 101.25pt; width: 432.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 432.75pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1089">Use of proceeds</a><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 75.41pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 77.72pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 78.88pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 79.46pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 79.61pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 79.64999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 79.67pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 79.67999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 432.75pt; position: absolute; top: 101.25pt; width: 35.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 35.25pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 21.5pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1089">71</a><font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 6pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 121.5pt; width: 432.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 432.75pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1114">Dividend policy</a><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 69.86pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 70.00999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 70.08999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 70.11pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 432.75pt; position: absolute; top: 121.5pt; width: 35.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 35.25pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 21.5pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1114">73</a><font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 6pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 141.75pt; width: 432.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 432.75pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1139">Capitalization</a><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 62.63pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 63.79pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 64.37pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 64.66pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 64.81pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 64.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 64.9pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 432.75pt; position: absolute; top: 141.75pt; width: 35.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 35.25pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 21.5pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1139">74</a><font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 6pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 162pt; width: 432.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 432.75pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1164">Dilution</a><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 35.96pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 38.27pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 39.43pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 39.720000000000006pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 432.75pt; position: absolute; top: 162pt; width: 35.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 35.25pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 21.5pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1164">76</a><font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 6pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 182.25pt; width: 432.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 432.75pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_533">Management&#8217;s discussion and analysis of financial condition and results of operations</a><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 381.34pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 383.65pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 384.23pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 384.52pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 384.67pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 384.75pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 384.77pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 432.75pt; position: absolute; top: 182.25pt; width: 35.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 35.25pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 21.5pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_533">80</a><font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 6pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 202.5pt; width: 432.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 432.75pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1189">Business</a><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 43.190000000000005pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 44.35pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 44.93pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 44.940000000000005pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 432.75pt; position: absolute; top: 202.5pt; width: 35.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 35.25pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 21.5pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1189">95</a><font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 6pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 222.75pt; width: 432.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 432.75pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1233">Management</a><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 60.980000000000004pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 63.29pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 64.45pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 64.6pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 64.67999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 64.72pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 64.74pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 432.75pt; position: absolute; top: 222.75pt; width: 35.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 35.25pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 15.94pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1233">139</a><font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 6pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 243pt; width: 432.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 432.75pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1258">Executive and director compensation</a><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 166.51999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 168.82999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 169.41pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 169.7pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 169.78pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 432.75pt; position: absolute; top: 243pt; width: 35.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 35.25pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 15.94pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1258">148</a><font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 6pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 263.25pt; width: 432.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 432.75pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1286">Certain relationships and related-party transactions</a><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 228.73pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 229.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 229.97pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 229.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 230pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 432.75pt; position: absolute; top: 263.25pt; width: 35.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 35.25pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 15.94pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1286">155</a><font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 6pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 283.5pt; width: 432.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 432.75pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1309">Principal stockholders</a><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 99.85pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 100pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 100.08pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 100.1pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 100.11pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 432.75pt; position: absolute; top: 283.5pt; width: 35.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 35.25pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 15.94pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1309">161</a><font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 6pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 303.75pt; width: 432.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 432.75pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1337">Description of capital stock</a><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 121.49pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 123.8pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 124.38pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 124.67pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 124.75pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 124.77pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 124.78pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 432.75pt; position: absolute; top: 303.75pt; width: 35.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 35.25pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 15.94pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1337">165</a><font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 6pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 324pt; width: 432.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 432.75pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1360">Shares eligible for future sale</a><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 132.04999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 134.35999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 134.65pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 134.79999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 134.82pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 134.82999999999998pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 432.75pt; position: absolute; top: 324pt; width: 35.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 35.25pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 15.94pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1360">171</a><font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 6pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 344.25pt; width: 432.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 432.75pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1408">Material U.S. federal income tax consequences to non-U.S. holders</a><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 300.90999999999997pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 303.21999999999997pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 304.38pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 304.67pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 304.71pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 304.71999999999997pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 432.75pt; position: absolute; top: 344.25pt; width: 35.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 35.25pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 15.94pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1408">174</a><font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 6pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 364.5pt; width: 432.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 432.75pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1434">Underwriting</a><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 58.74pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 59.900000000000006pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 59.980000000000004pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 60pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 432.75pt; position: absolute; top: 364.5pt; width: 35.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 35.25pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 15.94pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1434">178</a><font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 6pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 384.75pt; width: 432.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 432.75pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1505">Legal matters</a><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 63.18pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 64.34pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 64.92pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 64.94pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 432.75pt; position: absolute; top: 384.75pt; width: 35.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 35.25pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 15.94pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1505">190</a><font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 6pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 405pt; width: 432.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 432.75pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1531">Experts</a><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 36.510000000000005pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 38.82pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 39.400000000000006pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 39.690000000000005pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 39.77pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 39.78pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 432.75pt; position: absolute; top: 405pt; width: 35.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 35.25pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 15.94pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1531">190</a><font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 6pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 425.25pt; width: 432.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 432.75pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1578">Where you can find additional information</a><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 186.5pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 188.81pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 189.39pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 189.68pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 189.76pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 189.78pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 432.75pt; position: absolute; top: 425.25pt; width: 35.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 35.25pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 15.94pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_1578">190</a><font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 6pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 445.5pt; width: 432.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 432.75pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_77">Index to consolidated financial statements</a><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 188.17pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 189.32999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 189.91pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 189.93pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 189.94pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 432.75pt; position: absolute; top: 445.5pt; width: 35.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 35.25pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 17.63pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_77">F-</a><font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 27.06pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_77">1</a><font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 579.95pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Through and including &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025 (the 25th day after the date of this prospectus), all dealers effecting <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 591.95pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">transactions in our common stock, whether or not participating in this offering, may be required to deliver <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 603.95pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">a prospectus. This delivery requirement is in addition to a dealer&#8217;s obligation to deliver a prospectus when <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 615.95pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">acting as an underwriter and with respect to an unsold allotment or subscription.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 635.95pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We have not, and the underwriters have not, authorized anyone to provide you any information or to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 647.95pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">make any representations other than those contained in this prospectus or in any free writing prospectus <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 659.95pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prepared by or on behalf of us or to which we have referred you. Neither we nor the underwriters take <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 671.95pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">responsibility for, or provide any assurance as to the reliability of, any other information others may give <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 683.95pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">you. We and the underwriters are offering to sell only the shares offered hereby, and only under <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 695.95pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">circumstances and in jurisdictions where it is lawful to do so. We are not, and the underwriters are not, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 707.95pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. The <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 303.78pt; position: absolute; text-decoration: none; white-space: pre;">ii<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">information contained in this prospectus is accurate only as of the date of this prospectus, regardless of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the time of delivery of this prospectus or any sale of the shares of our common stock. Our business, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">financial condition, and results of operations may have changed since that date.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">For investors outside the United States&#58; We have not, and the underwriters have not, done anything that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">would permit this offering or the possession or distribution of this prospectus or any free writing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prospectus in connection with this offering in any jurisdiction where action for that purpose is required, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">other than in the United States. Persons outside the United States who come into possession of this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prospectus must inform themselves about, and observe any restrictions relating to, the offering of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">shares of common stock and the distribution of this prospectus outside the United States. &#8220;Heartflow,&#8221; the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Heartflow logos, and other trade names, trademarks, or service marks of Heartflow appearing in this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prospectus are the property of Heartflow. Other trade names, trademarks, or service marks appearing in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">this prospectus are the property of their respective holders. We do not intend our use or display of other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">companies&#8217; trade names, trademarks, or service marks to imply a relationship with, or endorsement or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">sponsorship of us, by these other companies. Solely for convenience, trade names, trademarks, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">service marks referred to in this prospectus appear without the &#174;, &#8482;, and <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 398.72pt; position: absolute; top: -2.548pt; vertical-align: super; white-space: pre;">SM<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 408.46pt; position: absolute; white-space: pre;"> symbols, but those <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">references are not intended to indicate, in any way, that we will not assert, to the fullest extent under <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 272pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">applicable law, our rights or that the applicable owner will not assert its rights, to these trade names, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 284pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">trademarks, and service marks.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="background-image: url(&#39;data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHN0eWxlPSJwb2ludGVyLWV2ZW50czogbm9uZTsiPjxwYXRoIHN0eWxlPSJmaWxsOiB0cmFuc3BhcmVudDsgc3Ryb2tlOiAjMDAwMDAwOyBzdHJva2UtbGluZWNhcDogc3F1YXJlOyBzdHJva2Utd2lkdGg6IDAuNXB0OyIgZD0iTSA0OC4zMyA0OC4zMyBWIDk4My42NyBIIDc2Ny42NyBWIDQ4LjMzIEggNDguMzMiPjwvcGF0aD48L3N2Zz4=&#39;); background-size: 612pt 792pt; height: 792pt; position: absolute; width: 612pt;"></div><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 303.22pt; position: absolute; text-decoration: none; white-space: pre;">1<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_691" style="position: absolute; top: 72pt;"></div><div style="font-size: 12pt; line-height: 11.64pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Prospectus summary<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 107.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">This summary highlights select information contained in greater detail elsewhere in this prospectus. This <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 119.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">summary is not complete and does not contain all of the information you should consider in making your <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 131.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">investment decision. Before investing in our common stock, you should carefully read this entire <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 143.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prospectus. You should carefully consider, among other things, the sections titled &#8220;Risk factors,&#8221; &#8220;Special <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 155.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">note regarding forward-looking statements,&#8221; &#8220;Business,&#8221; and &#8220;Management&#8217;s discussion and analysis of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 167.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">financial condition and results of operations&#8221; and our consolidated financial statements and the related <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 179.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">notes included elsewhere in this prospectus before making an investment decision. Unless the context <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 191.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">otherwise requires, the terms &#8220;Heartflow,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; in this prospectus refer to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 203.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Heartflow, Inc. and its wholly owned subsidiaries, or either or both of them as the context may require.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 223.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Overview<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 245.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We have pioneered the use of software and AI to delive<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 316.78pt; position: absolute; text-decoration: none; white-space: pre;">r a more ac<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 367.32pt; position: absolute; white-space: pre;">curate and clinically effective non-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 257.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">invasive solution for diagnosing and managing coronary artery disease (&#8220;CAD&#8221;), a leading cause of death <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 269.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">worldwide. As of December 31, 2024<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 234.76pt; position: absolute; text-decoration: none; white-space: pre;">, our Heartflow Platform has been used to assess CAD in more than <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 281.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">375,000 patients, including 132,000 in 2024 alone. <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 298.13pt; position: absolute; white-space: pre;">We believe that we are the most widely adopted AI-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 293.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">powered test for CAD. Our novel platform leverages <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 303.6pt; position: absolute; text-decoration: none; white-space: pre;">AI<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 313.03pt; position: absolute; white-space: pre;"> and advanced computational fluid dynamics to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 305.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">create a personalized 3D model of a patient&#8217;s heart from a single coronary computed tomography <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 317.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">angiography (&#8220;CCTA&#8221;), a specialized type of scan that provides detailed images of the heart&#8217;s arteries. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 329.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our Heartflow Platform delivers actionable insights on blood flow, stenosis, plaque volume and plaque <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 341.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">composition thereby overcoming the limitations of traditional non-invasive imaging tests which rely on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 353.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">indirect measures of coronary disease and lead to high false negative and false positive rates. We believe <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 365.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the differentiated accuracy and clinical utility of our Heartflow Platform, along with its ability to enhance <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 377.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">workflows, will continue to support our growth and advance the &#8220;CCTA + Heartflow&#8221; pathway as the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 389.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">definitive standard for the non-invasive diagnosis and management of CAD.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 409.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Cardiovascular disease is the leading cause of death worldwide, with CAD being the most lethal form. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 421.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">CAD occurs when plaque&#8212;a buildup of cholesterol, fat, calcium and other substances&#8212;accumulates on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 433.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the walls of the coronary arteries, restricting blood flow and increasing the risk of heart attack or stroke. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 445.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">This condition is responsible for half of all cardiovascular-related deaths globally. In the United States <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 457.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">alone, the Centers for Disease Control (&#8220;CDC&#8221;) estimates that approximately 805,000 people suffer a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 469.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">heart attack each year. Despite significant advancements in therapeutic and interventional treatments, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 481.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">CAD remains the leading cause of death globally because healthcare systems generally lack scalable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 493.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">methods to efficiently detect, diagnose and quantify CAD at a personalized level. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 513.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We estimate that there were approximately <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 264.53999999999996pt; position: absolute; text-decoration: none; white-space: pre;">9.5<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 278.43pt; position: absolute; white-space: pre;"> million non-invasive tests (&#8220;NITs&#8221;) in the United States in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 525.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2023 for patients experiencing stable or acute chest pain, which we refer to as symptomatic CAD <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 537.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">patients. These NITs primarily include stress tests, such as single-photon emission computed tomography <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 549.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(&#8220;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 78.66pt; position: absolute; text-decoration: none; white-space: pre;">SPECT&#8221;), echocardiography, and positron emission tomography (&#8220;PET&#8221;),<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 399.51pt; position: absolute; white-space: pre;"> which infer the presence of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 561.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">heart disease based on how well blood is supplied to the heart, and do not measure the actual disease <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 573.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">itself. Accordingly, these tests have been shown to be unreliable and inconsistent. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 593.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">CCTA has emerged as a leading non-invasive imaging method for evaluating CAD, offering direct and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 605.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">detailed visualization of the coronary arteries. Unlike traditional stress-based NITs, CCTA enables <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 617.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">physicians to identify the presence and extent of coronary blockage. As a result, CCTA has become the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 629.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">preferred first-line test for patients with suspected CAD. However, while CCTA provides superior <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 641.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">anatomical imaging, it does not independently quantify the severity of CAD, assess blood flow limitations, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 653.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or characterize plaque composition&#8212;critical factors for determining the most appropriate, personalized <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 665.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">course of treatment for a patient.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 685.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our Heartflow Platform builds upon the well established strengths of CCTA by going beyond its limitations <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 697.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and providing new quantified insights and compelling visualizations of data. By applying our advanced AI-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 709.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">powered technology to a single CCTA scan, we generate a precise, patient-specific analysis that <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="background-image: url(&#39;data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHN0eWxlPSJwb2ludGVyLWV2ZW50czogbm9uZTsiPjxwYXRoIHN0eWxlPSJmaWxsOiB0cmFuc3BhcmVudDsgc3Ryb2tlOiAjMDAwMDAwOyBzdHJva2UtbGluZWNhcDogc3F1YXJlOyBzdHJva2Utd2lkdGg6IDAuNXB0OyIgZD0iTSA0OC4zMyA0OC4zMyBWIDk4My42NyBIIDc2Ny42NyBWIDQ4LjMzIEggNDguMzMiPjwvcGF0aD48L3N2Zz4=&#39;); background-size: 612pt 792pt; height: 792pt; position: absolute; width: 612pt;"></div><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 303.22pt; position: absolute; text-decoration: none; white-space: pre;">2<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">quantifies blood flow, measures plaque burden, and characterizes plaque composition&#8212;at every point in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the major coronary arteries. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">To date, we have developed three software products under the Heartflow Platform that provide physicians <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">with the critical insights needed to effectively diagnose and manage CAD&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 136pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow RoadMap Analysis<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 218.32pt; position: absolute; text-decoration: none; white-space: pre;"> offers a highly intuitive anatomic visualization of the coronary arteries, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 148pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">helping physicians quickly identify clinically relevant areas to focus their review.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 168pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: italic; font-weight: normal; left: 154.4pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 163.06pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 203.05pt; position: absolute; text-decoration: none; white-space: pre;"> calculates blood flow and pinpoints functionally significant CAD at every <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 180pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">point in the major coronary arteries, guiding decisions on whether a patient requires invasive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 192pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">revascularization.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow Plaque Analysis<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 206.09pt; position: absolute; text-decoration: none; white-space: pre;"> provides a comprehensive assessment of coronary plaque, enabling <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">optimized medical treatment strategies.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We believe we are the first and most widely-adopted AI-powered test for CAD. With over a decade of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">commercial presence, we have established a competitively differentiated data set of over 100 million <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">annotated images, driving continuous training and refinement of our algorithms for over 10 years and the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">ability to train new AI models for future products.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 300pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We believe our Heartflow Platform delivers the following key benefits&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 320pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">More accurate non-invasive test for CAD<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 282.68pt; position: absolute; text-decoration: none; white-space: pre;">, clinically validated to provide superior assessment of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 332pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">blood flow, plaque volume and plaque characterization. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">More informed assessments, personalized care, and better risk stratification<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 452.03pt; position: absolute; text-decoration: none; white-space: pre;">, positively <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 364pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">impacting physician decisions on which patients should receive an intervention, supporting more <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">efficient intervention planning and driving more personalized medical management.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Superior economic efficiency and enhanced interventional treatment planning<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 460.25pt; position: absolute; text-decoration: none; white-space: pre;">, accurately <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">identifying more patients who need interventional treatment while reducing unnecessary invasive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">procedures&#8212;significantly improving the efficiency of the catheterization lab and therefore hospital <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 432pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">economics.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 452pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Proprietary, secure bi-directional data communication with customers <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 425.31pt; position: absolute; text-decoration: none; white-space: pre;">that feeds a growing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 464pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">database of over 100 million annotated CCTA images that we leverage to improve the Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 476pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Platform&#8217;s accuracy, automation and clinical utility and seamlessly deliver new features and workflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 488pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">efficiencies to our customers.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 508pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Improved workflow<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 181.03pt; position: absolute; text-decoration: none; white-space: pre;"> through our Heartflow RoadMap Analysis that reduces CCTA interpretation times <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 520pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">by approximately 25% and reduces variability between reviewing physicians by approximately 50%, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 532pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">leading to more consistent diagnoses and standardized patient care. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Better patient and provider experience<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 272.66999999999996pt; position: absolute; text-decoration: none; white-space: pre;">, by leveraging a single CCTA for all of our products, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 564pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">patients complete their test in<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 219.96pt; position: absolute; text-decoration: none; white-space: pre;"> approximately 20 mi<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 312.16999999999996pt; position: absolute; text-decoration: none; white-space: pre;">nutes with significantly lower radiation exposure <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">compared to nuclear imaging tests such as SPECT and PET that take multiple hours and require <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">radioactive tracers to be injected into the bloodstream. By providing a definitive diagnosis upfront, the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 600pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow Platform eliminates the need for layered testing, streamlining the patient journey and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">reducing anxiety associated with uncertain or inconclusive results.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 632pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We estimate our current market opportunity in the United States is approximately $5 billion. We believe <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 153.62pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 162.28pt; position: absolute; white-space: pre;"> Analysis is applicable to approximately 33% of NIT patients annually and the majority <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of patients experiencing acute chest pain, which represents 3.1 million patients and an estimated market <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 668pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">opportunity of approximately $3.3 billion in the United States. We believe our Heartflow Plaque Analysis is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 680pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">applicable to approximately 60% of NIT patients annually and the majority of patients experiencing acute <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 692pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">chest pain, which represents 5.5 million patients and an estimated market opportunity of an incremental <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 704pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">approximately $1.7 billion in the United States. <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 280.28pt; position: absolute; text-decoration: none; white-space: pre;">Beyond the commercialization of Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 491.88pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 500.54pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="background-image: url(&#39;data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHN0eWxlPSJwb2ludGVyLWV2ZW50czogbm9uZTsiPjxwYXRoIHN0eWxlPSJmaWxsOiB0cmFuc3BhcmVudDsgc3Ryb2tlOiAjMDAwMDAwOyBzdHJva2UtbGluZWNhcDogc3F1YXJlOyBzdHJva2Utd2lkdGg6IDAuNXB0OyIgZD0iTSA0OC4zMyA0OC4zMyBWIDk4My42NyBIIDc2Ny42NyBWIDQ4LjMzIEggNDguMzMiPjwvcGF0aD48L3N2Zz4=&#39;); background-size: 612pt 792pt; height: 792pt; position: absolute; width: 612pt;"></div><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 303.22pt; position: absolute; text-decoration: none; white-space: pre;">3<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">and Heartflow Plaque Analysis in symptomatic CAD, we see a significant market opportunity for our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">technologies in at-risk individuals who show no symptoms, a segment comprised of approximately 200 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">million people globally. To unlock this potential, we are continuing to evaluate new product opportunities <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">and appropriate clinical evidence supporting eventual regulatory approval, payor coverage and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">commercialization. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We believe the Heartflow Platform is the most extensively studied AI-enabled test for CAD. Its accuracy, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">clinical utility and economic benefits have been evaluated in over 100 clinical studies and more than <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">130,000 patients, including two large randomized controlled trials, with results published in over 600 peer-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reviewed clinical publications. Our studies have consistently demonstrated that the Heartflo<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 474.16pt; position: absolute; text-decoration: none; white-space: pre;">w Platform is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">more accu<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 118.67pt; position: absolute; text-decoration: none; white-space: pre;">rate than traditional no<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 218.1pt; position: absolute; text-decoration: none; white-space: pre;">n-invasive tests and highly concordant to invasive testing, reduces <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">unnecessary<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 128.69pt; position: absolute; white-space: pre;"> invasive testing, and enables physicians to optimize treatment and ultimately provide more <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">efficient care.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 131.24pt; position: absolute; text-decoration: none; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We have developed a highly scalable, capital efficient commercial model that combines Territory Sales <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Managers (&#8220;TSMs&#8221;) who drive new account adoption with Territory Account Managers (&#8220;TAMs&#8221;) who focus <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">on increasing utilization by educating referring physicians. Our commercial team does not cover cases or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">otherwise spend time in an operating room or lab setting, which enables them to focus solely on driving <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">commercial adoption and educational activities. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 300pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our technology is simple and intuitive and does not require the purchase of any capital equipment. Our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 312pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">onboarding process seamlessly integrates the Heartflow Platform into the customer&#8217;s daily wo<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 486.01pt; position: absolute; text-decoration: none; white-space: pre;">rkflow. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 324pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">These unique attributes of our business model afford our commercial organization a differentiated level of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 336pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">efficiency and scalability.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 356pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Current clinical guidelines and reimbursement policies strongly support the adoption of the Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 368pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Platform. The CCTA + Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 236.23pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 246.58pt; position: absolute; white-space: pre;">Analysis pathway is supported by the American Heart Association <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 380pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(&#8220;AHA&#8221;) and American College of Cardiology (&#8220;ACC&#8221;) guidelines, with CCTA identified as a Class 1, Level <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 392pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">A test and Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 183.6pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 193.95pt; position: absolute; white-space: pre;">Analysis identified as a <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 298.37pt; position: absolute; text-decoration: none; white-space: pre;">Class 2a, Level B<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 376.13pt; position: absolute; white-space: pre;"> test for the diagnosis of CAD in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 404pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">certain patients with stable or acute chest pain and no known CAD. Our Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 455.21pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 463.87pt; position: absolute; white-space: pre;"> Analysis is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 416pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reimbursed under a dedicated Category 1 Current Procedural Terminology (&#8220;CPT&#8221;) code, effective as of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 428pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">January 1, 2024, and has established coverage policies representing approximately 99% of covered lives <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 440pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">in the United States. A Category 1 CPT code was also recently established for <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 418.94pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 463.92pt; position: absolute; white-space: pre;">Plaque Analysis, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 452pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">which will take effect in January 2026, and it is covered by all seven Medicare administrative contractor <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 464pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(&#8220;MACs&#8221;). <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 484pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We primarily generate revenue on a &#8220;pay per click&#8221; basis each time a physician chooses to review either <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 496pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 89.22pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 134.2pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 153.62pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 162.28pt; position: absolute; white-space: pre;"> Analysis, <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 207.26pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 252.24pt; position: absolute; white-space: pre;">Plaque Analysis, or both. <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 364.99pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 409.97pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 429.39pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 438.05pt; position: absolute; white-space: pre;"> Analysis has served <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 508pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">as our commercial foundation, representing&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of our revenue in 2024. In the second half of 2023, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 520pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">we initiated limited market education efforts for <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 280.63pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 325.61pt; position: absolute; white-space: pre;">Plaque Analysis, our second commercial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 532pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">product. Our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 130.31pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 175.29000000000002pt; position: absolute; white-space: pre;">RoadMap Analysis is generally provided as a workflow efficiency tool to drive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 544pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">customer retention and loyalty and is not a stand-alone product. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We have experienced significant revenue growth since we began commercializing the Heartflow Platform <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">in 2015. We recognized revenue of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;million for the year ended December 31, 2024, compared to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">revenue of $87.2 million for the year ended December 31, 2023, representing&#160;&#160;&#160;&#160;&#160;&#160;&#160;% year-over-year <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 600pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">growth. The software-based nature of our Heartflow Platform produces an attractive gross margin profile, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">which continues to expand as we leverage AI to automate an increasing portion of our &#8220;human-in-the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">loop&#8221; quality control process, where learnings are fed back into our algorithms to make them smarter and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 636pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">more efficient. For the twelve months ended December 31, 2024, we generated gross margins of&#160;&#160;&#160;&#160;&#160;&#160;&#160;%, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 648pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">an increase of&#160;&#160;&#160;&#160;&#160;&#160;&#160; percentage points year-over-year. Our net losses were $95.7 million and $&#160;&#160;&#160;&#160;&#160;&#160;&#160;million <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for the years ended December 31, 2023 and 2024, respectively.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="background-image: url(&#39;data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHN0eWxlPSJwb2ludGVyLWV2ZW50czogbm9uZTsiPjxwYXRoIHN0eWxlPSJmaWxsOiB0cmFuc3BhcmVudDsgc3Ryb2tlOiAjMDAwMDAwOyBzdHJva2UtbGluZWNhcDogc3F1YXJlOyBzdHJva2Utd2lkdGg6IDAuNXB0OyIgZD0iTSA0OC4zMyA0OC4zMyBWIDk4My42NyBIIDc2Ny42NyBWIDQ4LjMzIEggNDguMzMiPjwvcGF0aD48L3N2Zz4=&#39;); background-size: 612pt 792pt; height: 792pt; position: absolute; width: 612pt;"></div><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 303.22pt; position: absolute; text-decoration: none; white-space: pre;">4<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 8.73pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Market overview and opportunity <font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 94.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Overview of CAD <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 114.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Cardiovascular disease is the leading cause of death worldwide, with CAD being the most lethal form. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 126.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">CAD occurs when plaque&#8212;a buildup of cholesterol, fat, calcium and other substances&#8212;accumulates on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 138.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the walls of the coronary arteries, restricting blood flow and increasing the risk of heart attack or stroke. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 150.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">This condition is responsible for half of all cardiovascular-related deaths globally.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 170.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Key risk factors, including high cholesterol, hypertension, smoking, diabetes, obesity, physical inactivity, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 182.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and genetic predisposition, accelerate plaque formation and destabilization. In the United States alone, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 194.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the CDC estimates that approximately 805,000 people suffer a heart attack each year. CAD can be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 206.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">effectively treated with well-established therapeutics designed to reduce plaque progression and change <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 218.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">its composition, or interventional procedures used to open the arteries and restore blood flow. However, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 230.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">achieving an accurate diagnosis for the condition has historically been the primary roadblock for the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 242.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">effective care and management of CAD. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 262.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">NITs are the first line approach for detecting CAD in symptomatic patients. With 9.5 million tests <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 274.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">performed for the diagnosis of CAD in the United States in 2023, NITs are by far the most widely used <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 286.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">method to diagnose CAD. However, traditional NITs are not able to measure lesion-specific blood flow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 298.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and are not an efficient or effective way to calculate plaque volume and composition. As a result, they lack <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 310.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the key metrics physicians need to guide treatment decisions and have been clinically shown to be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 322.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">unreliable and inconsistent for diagnosing CAD.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 342.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Limitations of traditional non-invasive tests for CAD<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 362.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">There are two primary types of NITs&#58; (i) stress tests, which infer the presence of CAD based on blood <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 374.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">perfusion, and (ii) CCTA which directly images the patient&#8217;s coronary arteries. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 394.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Stress-based NITs include SPECT, PET and<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 267.3pt; position: absolute; white-space: pre;"> stress <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 299.5pt; position: absolute; text-decoration: none; white-space: pre;">echocardiography<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 378.24pt; position: absolute; white-space: pre;">. Stress-based NITs rely on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 406.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">surrogate markers of CAD to deduce the disease in the coronary artery without actually assessing the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 418.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">disease itself. As a result, approximately 20-50% of patients who undergo stress-b<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 434.72pt; position: absolute; text-decoration: none; white-space: pre;">ased<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 456.4pt; position: absolute; white-space: pre;"> NITs go home <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 430.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">with false negatives, or undetected CAD that should have required an intervention. In addition, up to 55% <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 442.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of patients receive false positives and are sent to the cardiac catheterization lab for an invasive diagnostic <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 454.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">angiography when an intervention was never needed exposing patients to unnecessary risks including <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 466.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">vascular injury and bleeding complications. This results in significant additional costs to the healthcare <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 478.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">system and poor patient experience.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 498.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">CCTA is a high-resolution 3D imaging method that uses X-rays to produce detailed pictures of the heart's <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 510.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">arteries and other structures. Unlike stress tests that rely on indirect measures to infer heart disease, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 522.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">CCTA provides direct visualization of the patient&#8217;s anatomy and can allow for a comprehensive visual <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 534.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">assessment of coronary stenosis and plaque burden. CCTA has been clinically demonstrated to have the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 546.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">highest diagnostic performance of all traditional non-invasive imaging tests for CAD. In recognition of its <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 558.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">superior diagnostic accuracy, in October 2021 the AHA and ACC elevated CCTA to a first line Class 1, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 570.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Level A test in the guidelines for certain patients with stable or acute chest pain and no known CAD, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 582.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">above stress testing which is Class 1, Level B. While CCTA accurately identifies stenosis in the coronary <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 594.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">arteries, it does not calculate the blood flow through the arteries to identify whether the stenosis is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 606.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">clinically significant and does not provide plaque quantification or composition without significant and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 618.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">time-consuming and variable manual calculations. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 638.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our Heartflow Platform significantly improves the clinical utility of CCTA and addresses the limitations of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 650.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">traditional non-invasive CAD testing by combining existing CCTA images with our AI algorithms to provide <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 662.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">actionable data on blood flow, stenosis, plaque volume and plaque composition. This delivers superior <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 674.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">clinical utility relative to other NITs and compelling economic benefits, which are supported by extensive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 686.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">clinical evidence. As a result, we believe the CCTA + Heartflow pathway will become the standard of care <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 698.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for the non-invasive diagnosis of CAD over time<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 283.07pt; position: absolute; text-decoration: none; white-space: pre;">. <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="background-image: url(&#39;data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHN0eWxlPSJwb2ludGVyLWV2ZW50czogbm9uZTsiPjxwYXRoIHN0eWxlPSJmaWxsOiB0cmFuc3BhcmVudDsgc3Ryb2tlOiAjMDAwMDAwOyBzdHJva2UtbGluZWNhcDogc3F1YXJlOyBzdHJva2Utd2lkdGg6IDAuNXB0OyIgZD0iTSA0OC4zMyA0OC4zMyBWIDk4My42NyBIIDc2Ny42NyBWIDQ4LjMzIEggNDguMzMiPjwvcGF0aD48L3N2Zz4=&#39;); background-size: 612pt 792pt; height: 792pt; position: absolute; width: 612pt;"></div><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 303.22pt; position: absolute; text-decoration: none; white-space: pre;">5<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="position: absolute; top: 72pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 101.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 98.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 126pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 142.5pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 15.75pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="4"><div style="left: 0pt; position: absolute; top: 0pt; width: 468pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 4.87pt; width: 468pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: underline; white-space: pre;">Traditional NITs vs. Heartflow<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 15.75pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 15.75pt; width: 101.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 6.75pt; width: 101.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: normal; left: 9.11pt; position: absolute; text-decoration: none; white-space: pre;">Stress Echocardiogram<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 101.25pt; position: absolute; top: 15.75pt; width: 98.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 6.75pt; width: 98.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: normal; left: 19.22pt; position: absolute; text-decoration: none; white-space: pre;">SPECT and PET<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 199.5pt; position: absolute; top: 15.75pt; width: 126pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 6.75pt; width: 126pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: normal; left: 52.42pt; position: absolute; text-decoration: none; white-space: pre;">CCTA<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 325.5pt; position: absolute; top: 15.75pt; width: 142.5pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 6.75pt; width: 142.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: normal; left: 26.28pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow FFR<font style="display: inline-block; height: 5.82pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 5.2pt; font-style: normal; font-weight: normal; left: 77.75999999999999pt; position: absolute; text-decoration: none; top: 2.037pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 3.7830000000000004pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: normal; left: 84.68pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td></tr><tr style="height: 182.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="3"><div style="left: 0pt; position: absolute; top: 31.5pt; width: 325.5pt;"><div><div style="position: absolute; top: 1.6pt; width: 325.5pt;"><div style="left: 0.75pt; position: absolute; top: 0pt;"><div style="position: absolute;"><img style="height: 175.19pt; width: 324pt;" src="prospectussummary1b.jpg" alt="prospectussummary1b.jpg"></div></div></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 325.5pt; position: absolute; top: 31.5pt; width: 142.5pt;"><div><div style="position: absolute; top: 15.55pt; width: 142.5pt;"><div style="left: 2.85pt; position: absolute; top: 0pt;"><div style="position: absolute;"><img style="height: 147.27pt; width: 136.8pt;" src="picture5.jpg" alt="picture5.jpg"></div></div></div></div></div></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 302.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Figure 1&#58; A comparison of the visual output of traditional non-invasive tests. Left&#58; Stress echocardiogram. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 314.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Center&#58; SPECT and PET. Right&#58; CCTA image.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 276.86pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 279.63pt; position: absolute; white-space: pre;">Far Right&#58; Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: italic; font-weight: normal; left: 390.66pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 399.32pt; position: absolute; white-space: pre;"> Analysis image which color <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 326.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">codes coronary blood flow to identify clinically significant blockages.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 346.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Our symptomatic CAD market opportunity<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 366.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We estimate our current market opportunity in the United States is approximately $5 billion. We estimate <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 378.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">that there were approximately 9.5 million NITs in the United States for the diagnosis of CAD in 2023, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 390.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">8.6<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 85.89pt; position: absolute; white-space: pre;"> million patients that were addressable with CCTA after accounting for layered testing and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 402.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">contraindications to CCTA. CCTA testing volumes have grown rapidly, and we believe they will continue to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 414.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">outpace the broader market growth driven by the recently established Class 1, Level A guidelines, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 426.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">superior clinical utility to stress tests and improved reimbursement. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 446.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 91.43pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 136.41pt; position: absolute; text-decoration: none; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 155.82999999999998pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 164.49pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis is reimbursed for use on any CCTA showing 40% to 90% stenosis, which <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 458.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">we estimate to be approximately 33% of all CCTAs annually. We believe that CCTA + Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 514.14pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 470.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Analysis therefore is applicable to 33% of the NIT market and a majority of patients experiencing acute <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 482.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">chest pain, which represents 3.1 million patients and an estimated market opportunity of approximately <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 494.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">$3.3 billion in the United States. Our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 234.71pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 279.69pt; position: absolute; text-decoration: none; white-space: pre;">Plaque Analysis is reimbursed for plaque identified on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 506.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">CCTA with 1% to 69% stenosis, which we estimate to cover approximately 60% of all CCTAs annually and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 518.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">a majority of patients experiencing acute chest pain. We believe that CCTA + Heartflow Plaque Analysis is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 530.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">therefore applicable to 60% of the NIT market, which represents 5.5 million patients and an estimated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 542.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">market opportunity of an incremental approximately $1.7 billion in the United State<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 434.71pt; position: absolute; text-decoration: none; white-space: pre;">s<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 439.71pt; position: absolute; white-space: pre;">. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 562.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">While our current focus is on the United States, we also have a commercial presence and regulatory <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 574.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">approval in certain international markets, including the United Kingdom, European Union and Japan, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 586.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">which we estimate represents an additional 4.2 million potential CCTA patients. In the future we may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 598.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">expand our international presence beyond these markets and extend our platform to additional <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 610.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">indications.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 630.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Our technology<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 653.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Heartflow enhances CCTA, the most advanced non-invasive imaging modality for assessing CAD, with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 665.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">AI-powered analysis to deliver more accurate and clinically actionable insights for diagnosing and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 677.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">managing CAD. The Heartflow Platform applies deep learning, an advanced form of AI, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 689.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">computational fluid dynamics to CCTA images to create a personalized 3D model of a patient&#8217;s heart <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 701.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">based on a single CCTA image. This model provides actionable insights into blood flow, stenosis, plaque <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="background-image: url(&#39;data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHN0eWxlPSJwb2ludGVyLWV2ZW50czogbm9uZTsiPjxwYXRoIHN0eWxlPSJmaWxsOiB0cmFuc3BhcmVudDsgc3Ryb2tlOiAjMDAwMDAwOyBzdHJva2UtbGluZWNhcDogc3F1YXJlOyBzdHJva2Utd2lkdGg6IDAuNXB0OyIgZD0iTSA0OC4zMyA0OC4zMyBWIDk4My42NyBIIDc2Ny42NyBWIDQ4LjMzIEggNDguMzMiPjwvcGF0aD48L3N2Zz4=&#39;); background-size: 612pt 792pt; height: 792pt; position: absolute; width: 612pt;"></div><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 303.22pt; position: absolute; text-decoration: none; white-space: pre;">6<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">volume and plaque composition allowing precise diagnosis, risk stratification, and treatment planning &#8211; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">without the need for an invasive <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 215.31pt; position: absolute; text-decoration: none; white-space: pre;">procedure.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 263.1pt; position: absolute; text-decoration: none; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The CCTA + Heartflow pathway addresses the limitations of traditional non-invasive tests that only assess <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">indirect measures for coronary disease and therefore result in high rates of false negative and false <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">positive CAD diagnoses. We believe the differentiated accuracy and clinical utilit<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 425.46pt; position: absolute; text-decoration: none; white-space: pre;">y of the CCTA + <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow pathway will continue to support our growth and advance the standard for the non-invasive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">diagnosis and management of CAD. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 172pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">We designed our AI-powered software platform to be highly scalable, seamlessly integrate into existing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 184pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">physician workflows for diagnosing CAD, and improve as we ingest more data over time. By leveraging AI <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 196pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">to process massive volumes of cases and a &#8220;human-in-the loop&#8221; quality control process, where learnings <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 208pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">are fed back into our algorithms to improve their performance and efficiency, we have rapidly scaled our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">platform to deliver accurate, timely results to benefit physicians and patients alike.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 240pt; width: 612pt;"><div style="left: 72pt; position: absolute; top: 0pt;"><div style="position: absolute;"><img style="height: 166.48pt; width: 468pt;" src="picture4.jpg" alt="picture4.jpg"></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 419.48pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;"> Figure 2&#58; The CCTA + Heartflow pathway<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 439.48pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Our product portfolio <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 459.48pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">To date, we have created three software products in a unified platform and user experience that provide <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 471.48pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the critical data physicians need to effectively manage patients with suspected CAD. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 491.48pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow RoadMap Analysis&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 212.47pt; position: absolute; text-decoration: none; white-space: pre;"> The Heartflow RoadMap Analysis <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="height: 165.6pt; left: 399pt; position: absolute; top: 494.73pt; width: 134.76pt; z-index: 1;"><div><div><div style="position: absolute;"><img style="height: 165.6pt; width: 134.76pt;" src="prospectussummary3ba.jpg" alt="prospectussummary3ba.jpg"></div></div></div></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 503.48pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">provides a highly intuitive anatomic visualization of the patient&#8217;s <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 515.48pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">coronary anatomy based on CCTA images. It rapidly orients the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 527.48pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">imaging physician to clinically relevant areas of the patient anatomy <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 539.48pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">and provides a preview of what they will review in the native CCTA <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 551.48pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">images to aid the physician in accurately, efficiently and consistently <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 563.48pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">identifying stenosis in the coronary arteries. <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 266.96000000000004pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 311.94pt; position: absolute; text-decoration: none; white-space: pre;">RoadMap <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 575.48pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Analysis supports more efficient radiology workflow, improving CCTA <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 587.48pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">read times by 25% and increasing consistency between reviewing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 599.48pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">physicians by approximately 50%. Physicians use <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 294.77pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 339.75pt; position: absolute; text-decoration: none; white-space: pre;">Roadmap <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 611.48pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Analysis as a first-line assessment tool along with CCTA interpretation <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 623.48pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">to determine whether to order our more detailed <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 286.40999999999997pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 331.39pt; position: absolute; text-decoration: none; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 350.81pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 635.48pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Analysis or <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 123.65pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 168.63pt; position: absolute; text-decoration: none; white-space: pre;">Plaque Analysis reports. We generally provide <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 647.48pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 116.97999999999999pt; position: absolute; text-decoration: none; white-space: pre;">RoadMap Analysis to accounts as an integrated feature to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 659.48pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">enhance the efficiency and consistency of their CCTA programs and it <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 671.48pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">is not a stand-alone product. We believe the efficiency that <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 333.24pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 378.22pt; position: absolute; text-decoration: none; white-space: pre;">RoadMap Analysis provides our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 683.48pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">customers has resulted in enhanced customer loyalty and retention.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 371.43pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 0.72pt; position: absolute; top: 703.48pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 1pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"> <font style="display: inline-block; height: 0.72pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="background-image: url(&#39;data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHN0eWxlPSJwb2ludGVyLWV2ZW50czogbm9uZTsiPjxwYXRoIHN0eWxlPSJmaWxsOiB0cmFuc3BhcmVudDsgc3Ryb2tlOiAjMDAwMDAwOyBzdHJva2UtbGluZWNhcDogc3F1YXJlOyBzdHJva2Utd2lkdGg6IDAuNXB0OyIgZD0iTSA0OC4zMyA0OC4zMyBWIDk4My42NyBIIDc2Ny42NyBWIDQ4LjMzIEggNDguMzMiPjwvcGF0aD48L3N2Zz4=&#39;); background-size: 612pt 792pt; height: 792pt; position: absolute; width: 612pt;"></div><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 303.22pt; position: absolute; text-decoration: none; white-space: pre;">7<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: bold; left: 139.72pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 148.38pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 192.25pt; position: absolute; white-space: pre;">&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 195.57999999999998pt; position: absolute; white-space: pre;"> Our flagship product, <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 293.88pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 338.86pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 358.28pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 366.94pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="height: 165.6pt; left: 396.24pt; position: absolute; top: 70.2pt; width: 134.76pt; z-index: 2;"><div><div><div style="position: absolute;"><img style="height: 165.6pt; width: 134.76pt;" src="prospectussummary4b.jpg" alt="prospectussummary4b.jpg"></div></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Analysis, consists of a patient-specific, interactive, 3D anatomical <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reconstruction of the coronary anatomy that identifies functionally <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">significant CAD at every point in the major coronary arteries to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">determine the need for intervention. Our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 251.96pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 296.94pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 316.36pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 325.02pt; position: absolute; white-space: pre;"> Analysis has <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the highest diagnostic accuracy for a non-invasive CAD test and has <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">demonstrated a high level of concordance to invasive fractional flow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 156pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reserve (&#8220;FFR&#8221;). Current AHA and ACC guidelines designated CCTA as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 168pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">a Class 1, Level A test for CAD in certain patients with stable or acute <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 180pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">chest pain and no known CAD, and <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 231.43pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 276.40999999999997pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 295.83000000000004pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 304.49pt; position: absolute; white-space: pre;"> Analysis as a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 192pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Class 2a, Level B test to help physicians guide patient treatment <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 204pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">decisions. As of December 31, 2024, <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 237.53pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 282.51pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 301.93pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 310.59000000000003pt; position: absolute; white-space: pre;"> Analysis <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 216pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">represented over &#160;&#160;&#160;&#160;&#160;% of our total revenue.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; white-space: pre;">H<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 79.22pt; position: absolute; text-decoration: none; white-space: pre;">eartflow Plaque Analysis&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 200.25pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 203.02pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 248pt; position: absolute; white-space: pre;">Plaque Analysis transforms <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="height: 165.6pt; left: 396.24pt; position: absolute; top: 232.25pt; width: 134.76pt; z-index: 3;"><div><div><div style="position: absolute;"><img style="height: 165.6pt; width: 134.76pt;" src="prospectussummary5b.jpg" alt="prospectussummary5b.jpg"></div></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">coronary plaque assessment from a time-consuming and variable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">manual process, which is seldom clinically used, into a rapid, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 272pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">automated, and highly precise AI-driven solution. The Heartflow Plaque <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 284pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Analysis automatically provides a comprehensive 3D assessment of a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 296pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">patient&#8217;s coronary plaque, including a characterization of plaque types <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and quantification of plaque volumes at every point in the major <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 320pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">coronary arteries. The <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 172.35pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 217.33pt; position: absolute; white-space: pre;">Plaque Analysis has been validated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 332pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">against the reference standard of invasive i<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 262.53999999999996pt; position: absolute; text-decoration: none; white-space: pre;">ntrava<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 290.32pt; position: absolute; text-decoration: none; white-space: pre;">scular ultrasound<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 366.44pt; position: absolute; text-decoration: none; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 344pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(&#8220;IVUS&#8221;)<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 108.63pt; position: absolute; white-space: pre;"> and shown to have a 95% agreement with IVUS in quantifying <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 356pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">total coronary plaque volume. Because coronary plaque volume is a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 368pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">strong predictor of a patient&#8217;s risk of having a heart attack, this data <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 380pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">offers incremental predictive power over risk factors and stenosis alone <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 392pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and can aid the physician in optimizing medical management. Our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 404pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 116.97999999999999pt; position: absolute; white-space: pre;">Plaque Analysis was cleared by the Food and Drug <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 416pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Administration (&#8220;FDA&#8221;) in October 2022. We began our<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 313.40999999999997pt; position: absolute; text-decoration: none; white-space: pre;"> limited market education efforts<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 454.85pt; position: absolute; white-space: pre;"> in the second half <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 428pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of 2023, and we expect to broaden our market education efforts as payor coverage for <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 455.11pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 500.09pt; position: absolute; white-space: pre;">Plaque <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 440pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Analysis increases. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 460pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Key benefits of our Heartflow Platform<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We believe the unique features of our technology allow us to offer superior clinical utility and economic <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 492pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">value to our customers and the broader healthcare system. The key benefits offered by our Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 504pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Platform include&#58; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 524pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">More accurate non-invasive test for CAD&#58; <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 288.78pt; position: absolute; text-decoration: none; white-space: pre;">Our Heartflow products provide a more accurate non-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 536pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">invasive assessment of blood flow, plaque characterization and plaque volume compared to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 548pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">traditional non-invasive tests. Our clinical trials have demonstrated that Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 469.88pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 478.54pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 560pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow Plaque Analysis have a high level of concordance to the invasive reference standards of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 572pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">FFR and IVUS, respectively, and that Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 321.35pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 330.01pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis has superior diagnostic accuracy to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 584pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">CCTA alone as well as both SPECT and PET.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 604pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">More informed assessments and personalized care&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 336pt; position: absolute; text-decoration: none; white-space: pre;"> Our Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 422.6pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 431.26pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis and Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 616pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Plaque Analysis have been clinically demonstrated to improve physician decisions on intervention <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 628pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">and treatment planning. Multiple studies and registries have demonstrated that physicians changed <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 640pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">their treatment approach after reviewing our AI-powered reports.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="background-image: url(&#39;data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHN0eWxlPSJwb2ludGVyLWV2ZW50czogbm9uZTsiPjxwYXRoIHN0eWxlPSJmaWxsOiB0cmFuc3BhcmVudDsgc3Ryb2tlOiAjMDAwMDAwOyBzdHJva2UtbGluZWNhcDogc3F1YXJlOyBzdHJva2Utd2lkdGg6IDAuNXB0OyIgZD0iTSA0OC4zMyA0OC4zMyBWIDk4My42NyBIIDc2Ny42NyBWIDQ4LjMzIEggNDguMzMiPjwvcGF0aD48L3N2Zz4=&#39;); background-size: 612pt 792pt; height: 792pt; position: absolute; width: 612pt;"></div><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 303.22pt; position: absolute; text-decoration: none; white-space: pre;">8<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Superior economic efficiency&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 232.68pt; position: absolute; text-decoration: none; white-space: pre;"> Our PRECISE prospective randomized controlled trial demonstrated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">that our Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 191.05pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 199.70999999999998pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis was 78% more likely to identify patients in need of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">revascularization and showed a 69% reduction in unnecessary invasive tests as compared to a &#8220;usual <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">care&#8221; pathway. The net effect of this pathway was 2x the yield of invasive coronary angiography <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">leading to a revascularization procedure. As a result, our internal analysis based on the PRECISE <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">data demonstrated a 20% increase in net revenue for the cardiac catheterization lab, on average. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Improved workflow&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 184.36pt; position: absolute; text-decoration: none; white-space: pre;"> Our Heartflow RoadMap Analysis offers significant workflow benefits, including <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">improving workflow efficiency by reducing CCTA interpretation times by approximately 25%. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 184pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Enhanced interventional treatment planning&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 302.03pt; position: absolute; text-decoration: none; white-space: pre;"> The additional detail on individual patient anatomy <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 196pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">and disease state provided by our Heartflow Platform allows for pre-operative selection of appropriate <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 208pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">tools. We believe this saves valuable cardiac catheterization lab time and facilitates a more efficient <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">procedure.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 240pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Better patient and provider experience&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 276pt; position: absolute; text-decoration: none; white-space: pre;"> By leveraging a single CCTA for all of our products, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 252pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">patients complete their test in approximately 20 minutes with significantly lower radiation exposure <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 264pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">compared to nuclear imaging tests such as SPECT and PET that take multiple hours and require <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 276pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">radioactive tracers to be injected into the bloodstream. By providing a definitive diagnosis upfront, the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 288pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow Platform eliminates the need for layered testing, streamlining the patient journey and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 300pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">reducing anxiety associated with uncertain or inconclusive results.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 320pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We believe the benefits of our Heartflow Platform add significant value across all the subspecialties that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 332pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">impact cardiovascular care including referring cardiologists, imaging physicians and interventionalists. We <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 344pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">have structured our sales force to efficiently call on these key physician stakeholders, with a primary <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 356pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">focus on the imaging physicians who are instrumental in new account adoption and the referring <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 368pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">physicians who are critical to driving volume growth at our existing accounts. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 388pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Our success factors<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 410.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We believe the continued growth of our company will primarily be driven by the following success factors&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 430.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Differentiated approach to the non-invasive diagnosis and management of CAD <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 450.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Market leader in AI-powered quantitative CAD <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 309.28999999999996pt; position: absolute; text-decoration: none; white-space: pre;">analysis<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 348.73pt; position: absolute; text-decoration: none; white-space: pre;"> with <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 374.24pt; position: absolute; text-decoration: none; white-space: pre;">strong customer relationships <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 470.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Attractive revenue model with significant operating leverage potential <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 490.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Large addressable market opportunity with a significant unmet need <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 510.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Robust and compelling portfolio of clinical evidence <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 530.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Established reimbursement coverage and favorable society support<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 550.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">U<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 97.22pt; position: absolute; text-decoration: none; white-space: pre;">nique and scalable AI, data and R&#38;D capabilities<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 327.58000000000004pt; position: absolute; text-decoration: none; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 570.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Experienced leadership team<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 590.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Our growth strategies<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 612.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We believe the following <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 182.35pt; position: absolute; text-decoration: none; white-space: pre;">key<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 197.91pt; position: absolute; white-space: pre;"> strategies will play a critical role in our continued growth&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 632.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Expand adoption of our Heartflow Platform by new accounts <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 652.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Broaden awareness of the CCTA + Heartflow pathway to drive volume at existing accounts <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Launch and drive adoption of our Heartflow Plaque Analysis product <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 692.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Invest in additional clinical evidence to support adoption and expand our indications <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="background-image: url(&#39;data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHN0eWxlPSJwb2ludGVyLWV2ZW50czogbm9uZTsiPjxwYXRoIHN0eWxlPSJmaWxsOiB0cmFuc3BhcmVudDsgc3Ryb2tlOiAjMDAwMDAwOyBzdHJva2UtbGluZWNhcDogc3F1YXJlOyBzdHJva2Utd2lkdGg6IDAuNXB0OyIgZD0iTSA0OC4zMyA0OC4zMyBWIDk4My42NyBIIDc2Ny42NyBWIDQ4LjMzIEggNDguMzMiPjwvcGF0aD48L3N2Zz4=&#39;); background-size: 612pt 792pt; height: 792pt; position: absolute; width: 612pt;"></div><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 303.22pt; position: absolute; text-decoration: none; white-space: pre;">9<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Extend our technology leadership through continued investment in our platform <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 92pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Leverage our platform to pursue adjacent and international markets<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 112pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Risk factors <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 143.97pt; position: absolute; text-decoration: none; white-space: pre;">su<font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 157.97pt; position: absolute; text-decoration: none; white-space: pre;">mmary<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 134.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our business is subject to a number of risks and uncertainties, as more fully described in the section titled <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 146.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">&#8220;Risk factors&#8221; immediately following this prospectus summary. You should read these risks before you <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 158.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">invest in our common stock. These risks include, among others, the following&#58; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 178.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">We have incurred significant net losses since our inception, we expect to incur additional substantial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 190.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">losses in the foreseeable future and we may not be able to achieve or sustain profitability. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 210.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Our revenue is currently generated almost entirely from the sales of only one product, Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 222.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 109.42pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 118.08pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis, and we are therefore highly dependent on the success of this product, which makes <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 234.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">it difficult to evaluate our current business, predict our future prospects and forecast our financial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 246.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">performance and any growth. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 266.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">If healthcare providers are unwilling to change their standard practice regarding the evaluation of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 278.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">CAD, our business, financial condition, results of operations and prospects will be adversely affected.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 298.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">If third-party payors, including government payors, do not cover and provide adequate, or any, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 310.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">reimbursement for the Heartflow Platform, or if existing payment amounts are reduced or coding <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 322.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">changes, adoption of the Heartflow Platform by healthcare providers will be negatively impacted, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 334.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our business, financial condition, results of operations and prospects will be adversely affected. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 354.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">To date we have derived a significant amount of our revenue from a small number of customers, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 366.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">face risks associated with a more concentrated customer base.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 386.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">We face significant competition in an environment of rapid technological change, and there is a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 398.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">possibility that our competitors may develop products that are more effective, accurate, reliable, cost-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 410.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">effective or more advanced than ours, which may harm our financial condition. If we are unable to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 422.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">compete successfully or our potential market share is reduced, we may be unable to increase or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 434.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">sustain our revenue or achieve profitability.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 454.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">The commercialization of the Heartflow Plaque Analysis product is nascent, and we may not be able <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 466.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">to achieve or maintain sufficient market acceptance or the levels of utilization we expect from the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 478.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow Plaque Analysis product or any other future product.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 498.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">We face risks associated with our use and development of artificial intelligence models, which may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 510.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">result in operational challenges, legal liability, reputational concerns and competitive risks.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 530.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">If we fail to properly manage our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 235.51pt; position: absolute; text-decoration: none; white-space: pre;">future<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 261.06pt; position: absolute; text-decoration: none; white-space: pre;"> growth, our business could suff<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 401.41pt; position: absolute; text-decoration: none; white-space: pre;">er.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 550.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Our business could be disrupted by catastrophic events.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 570.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">We depend on our information technology systems, and any failure of these systems could harm our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 582.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">business and adversely affect our business and operating results.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 602.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Our networks and those of our third-party service providers may become the target of bad actors or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 614.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">security breaches that we cannot anticipate or successfully defend, which could have an adverse <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 626.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">impact on our business.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 646.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">We face extensive, regulatory requirements to bring our products to market, and our failure to receive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 658.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">and maintain regulatory clearances or approvals of our current and future products in the United <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 670.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">States or abroad or to comply with medical device regulatory requirements could adversely affect our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 682.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">business.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="background-image: url(&#39;data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHN0eWxlPSJwb2ludGVyLWV2ZW50czogbm9uZTsiPjxwYXRoIHN0eWxlPSJmaWxsOiB0cmFuc3BhcmVudDsgc3Ryb2tlOiAjMDAwMDAwOyBzdHJva2UtbGluZWNhcDogc3F1YXJlOyBzdHJva2Utd2lkdGg6IDAuNXB0OyIgZD0iTSA0OC4zMyA0OC4zMyBWIDk4My42NyBIIDc2Ny42NyBWIDQ4LjMzIEggNDguMzMiPjwvcGF0aD48L3N2Zz4=&#39;); background-size: 612pt 792pt; height: 792pt; position: absolute; width: 612pt;"></div><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">10<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">If we are unable to obtain and maintain sufficient intellectual property rights, or the scope of our rights <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">is not sufficiently broad, third-parties could develop and commercialize technology and products <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">similar or identical to ours, and our ability to successfully commercialize our technology and products <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">may be adversely affected.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Our credit agreement contains certain restrictions that may limit our ability to operate our business. If <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">we raise additional capital through debt financing, the terms of any new debt could further restrict our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">ability to operate our business.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 172pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; white-space: pre;">There is substantial doubt about our ability to continue as a going concern.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 192pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">We have identified material weaknesses in our internal control over financial reporting and may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 204pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">identify additional material weaknesses in the future or fail to remedy these material weaknesses or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 216pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">otherwise continue to fail to maintain effective internal control over financial reporting, which may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 228pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">result in material misstatements of our consolidated financial statements or cause us to fail to meet <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 240pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our periodic reporting obligations or cause our access to the capital markets to be impaired.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The summary risk factors described above should be read together with the text of the full risk factors in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 272pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the section titled &#8220;Risk factors&#8221; and the other information set forth in this prospectus, including our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 284pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">consolidated financial statements and the related notes. The risks summarized above or described in full <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 296pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">elsewhere in this prospectus are not the only risks that we face. Additional risks and uncertainties not <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">presently known to us, or that we currently deem to be immaterial, may also materially adversely affect <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 320pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our business, financial condition, results of operations, and prospects.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Corporate information<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 362.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We were incorporated under the laws of the State of Delaware in 2007. On March 1, 2021, we completed <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 374.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">an internal reorganization in which a newly formed parent holding company was put in place. The <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 386.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">previous holders of our common stock and preferred securities became holders of common stock and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 398.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">preferred securities of HeartFlow Holding, Inc. The equity incentive plan, outstanding equity awards, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 410.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">outstanding warrants and certain other equity-related agreements of HeartFlow, Inc. were assumed by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 422.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">HeartFlow Holding, Inc. Our operations and business activities remained at HeartFlow, Inc., and the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 434.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">wholly-owned non-U.S. subsidiaries of HeartFlow, Inc. remained in place. On&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 446.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">consolidated HeartFlow Holding, Inc. into HeartFlow, Inc. and the previous holders of HeartFlow Holding, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 458.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Inc. common stock and preferred securities became holders of our common stock and preferred <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 470.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">securities, and the equity incentive plan, outstanding equity awards, warrants and certain other equity-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 482.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">related agreements of HeartFlow Holding, Inc. were assumed by us. In connection with this consolidation, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 494.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">we changed our name to Heartflow, Inc., whose name appears on the cover of this prospectus. Our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 506.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">principal executive offices are located at 331 E. Evelyn Avenue, Mountain View, California 94041, and our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 518.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">telephone number is (650) 241-1221. Our corporate website address is www.heartflow.com. Information <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 530.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">contained on, or accessible through, our website shall not be deemed incorporated into and is not a part <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 542.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of this prospectus or the registration statement of which it forms a part. We have included our website in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 554.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">this prospectus solely as an inactive textual reference.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 578.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Implications of being an emerging growth company<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 604.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We qualify as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 616.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2012 (the &#8220;JOBS Act&#8221;). We will remain an emerging growth company until the earliest of&#58; (i) the last day of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 628.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the fiscal year following the fifth anniversary of the completion of this offering&#59; (ii) the last day of the fiscal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 640.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">year in which we have total annual gross revenue of at least $1.235 billion&#59; (iii) the last day of the fiscal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 652.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">year in which we are deemed to be a &#8220;large accelerated filer&#8221; as defined in Rule 12b-2 under the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 664.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), which would occur if the market <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 676.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">value of our common stock held by non-affiliates exceeded $700.0 million as of the last business day of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 688.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the second fiscal quarter of such year&#59; or (iv) the date on which we have issued more than $1.0 billion in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 700.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">non-convertible debt securities during the prior three-year period. An emerging growth company may take <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="background-image: url(&#39;data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHN0eWxlPSJwb2ludGVyLWV2ZW50czogbm9uZTsiPjxwYXRoIHN0eWxlPSJmaWxsOiB0cmFuc3BhcmVudDsgc3Ryb2tlOiAjMDAwMDAwOyBzdHJva2UtbGluZWNhcDogc3F1YXJlOyBzdHJva2Utd2lkdGg6IDAuNXB0OyIgZD0iTSA0OC4zMyA0OC4zMyBWIDk4My42NyBIIDc2Ny42NyBWIDQ4LjMzIEggNDguMzMiPjwvcGF0aD48L3N2Zz4=&#39;); background-size: 612pt 792pt; height: 792pt; position: absolute; width: 612pt;"></div><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.81pt; position: absolute; text-decoration: none; white-space: pre;">11<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">advantage of specified reduced reporting requirements and is relieved of certain other significant <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">requirements that are otherwise generally applicable to public companies. As a result, the information that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">we provide to our stockholders may be different than you might receive from other public reporting <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">companies in which you hold equity interests.&#160;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">As an emerging growth company, we have elected to take advantage of certain reduced disclosure <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">obligations in the registration statement that this prospectus is a part of, and may elect to take advantage <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of other reduced reporting requirements in future filings. In particular&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 172pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">we will present in this prospectus only two years of audited financial statements, plus any required <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 184pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">unaudited financial statements, and related management&#8217;s discussion and analysis of financial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 196pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">condition and results of operations&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 216pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">we will avail ourselves of the exemption from the requirement to obtain an attestation and report from <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 228pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our independent registered public accounting firm on the assessment of our internal control over <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 240pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">financial reporting pursuant to the Sarbanes-Oxley Act of 2002&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">we will avail ourselves of relief from compliance with the requirements of the Public Company <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 272pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Accounting Oversight Board regarding the communication of critical audit matters in the auditor&#8217;s <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 284pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">report on the financial statements&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">we will provide less extensive disclosure about our executive compensation arrangements&#59; and<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 324pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">we will not be required to hold stockholder non-binding advisory votes on executive compensation or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 336pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">golden parachute arrangements.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 356pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 368pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">transition period for complying with new or revised accounting standards. This provision allows an <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 380pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">emerging growth company to delay the adoption of some accounting standards until those standards <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 392pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">would otherwise apply to private companies. We have elected to use the extended transition period for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 404pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">any other new or revised accounting standards during the period in which we remain an emerging growth <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 416pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">company&#59; however, we may adopt certain new or revised accounting standards early. As a result of these <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 428pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">elections, the information that we provide in this prospectus, including our financial statements, may be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 440pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">different than the information you may receive from other public companies in which you hold equity <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 452pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">interests. In addition, it is possible that some investors will find our common stock less attractive as a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 464pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">result of these elections, which may result in a less active trading market for our common stock and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 476pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">higher volatility in our share price.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 496pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Basis of presentation<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 518.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Certain monetary amounts, percentages, and other figures included elsewhere in this prospectus have <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 530.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">been subject to rounding adjustments. Accordingly, figures shown as totals in certain tables or charts may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 542.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">not be the arithmetic aggregation of the figures that precede them, and figures expressed as percentages <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 554.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">in the text may not total 100% or, as applicable, when aggregated may not be the arithmetic aggregation <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 566.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of the percentages that precede them.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 586.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The consolidated financial statements include the accounts of HeartFlow Holding, Inc. and its <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 598.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">subsidiaries. Prior to the completion of this offering, we will complete a consolidation pursuant to which <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 610.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the previous holders of HeartFlow Holding, Inc. common stock and preferred securities will become <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 622.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">holders of our common stock and preferred securities and the equity incentive plan, outstanding equity <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 634.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">awards, the warrants and other equity agreements of HeartFlow Holding, Inc. will be assumed by us. We <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 646.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">expect that the consolidation will not have a material effect on our consolidated financial statements <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 658.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">included elsewhere in this prospectus. The consolidated financial statements of HeartFlow Holding, Inc. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 670.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">are that of Heartflow, Inc., the registrant whose name appears on the cover of this prospectus. <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="background-image: url(&#39;data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHN0eWxlPSJwb2ludGVyLWV2ZW50czogbm9uZTsiPjxwYXRoIHN0eWxlPSJmaWxsOiB0cmFuc3BhcmVudDsgc3Ryb2tlOiAjMDAwMDAwOyBzdHJva2UtbGluZWNhcDogc3F1YXJlOyBzdHJva2Utd2lkdGg6IDAuNXB0OyIgZD0iTSA0OC4zMyA0OC4zMyBWIDk4My42NyBIIDc2Ny42NyBWIDQ4LjMzIEggNDguMzMiPjwvcGF0aD48L3N2Zz4=&#39;); background-size: 612pt 792pt; height: 792pt; position: absolute; width: 612pt;"></div><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">12<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_1008" style="position: absolute; top: 72pt;"></div><div style="font-size: 12pt; line-height: 11.64pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">The offering<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="position: absolute; top: 107.2pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 162pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 303pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 162pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 162pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Common stock offered by us<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 140.31pt; position: absolute; text-decoration: none; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 143.07999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 144.24pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 144.25pt; position: absolute; text-decoration: none; white-space: pre;"> . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 165pt; position: absolute; top: 0pt; width: 303pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 303pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 9.75pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 59.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 24pt; width: 162pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 162pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Option to purchase additional <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 14.63pt; width: 162pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">shares<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 34.86pt; position: absolute; text-decoration: none; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 37.63pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 38.79pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 39.080000000000005pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 39.160000000000004pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 39.2pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 39.220000000000006pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 165pt; position: absolute; top: 24pt; width: 303pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 12.37pt; width: 303pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">We have granted the underwriters an option for a period of 30 days <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 24.37pt; width: 303pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">to purchase up to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;additional shares of common stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 36.37pt; width: 303pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">from us at the public offering price, less underwriting discounts and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 48.37pt; width: 303pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">commissions on the same terms as set forth in this prospectus.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 9.75pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 35.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 93pt; width: 162pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 162pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Common stock to be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 14.63pt; width: 162pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">outstanding after this offering<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 144.7pt; position: absolute; text-decoration: none; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 147.47pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 148.63pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 148.92pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 149.07pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 149.15pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 149.19pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 149.21pt; position: absolute; text-decoration: none; white-space: pre;"> . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 165pt; position: absolute; top: 93pt; width: 303pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 12.37pt; width: 303pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares (or&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares if the underwriters exercise <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 24.37pt; width: 303pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">in full their option to purchase additional shares).<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 9.75pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 386.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 138pt; width: 162pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 162pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Use of proceeds<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 80.36999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 83.14pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 83.72pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 84.00999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 84.16pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 84.24pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 84.25999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 84.27pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 165pt; position: absolute; top: 138pt; width: 303pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 303pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">We estimate that the net proceeds from this offering will be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 14.63pt; width: 303pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million (or approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million if the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 26.63pt; width: 303pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">underwriters exercise in full their option to purchase up <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 38.63pt; width: 303pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; additional shares of common stock), based on the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 50.63pt; width: 303pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">assumed initial public offering price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share, which is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 62.63pt; width: 303pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">the midpoint of the estimated price range set forth on the cover <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 74.63pt; width: 303pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">page of this prospectus, after deducting estimated underwriting <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 86.63pt; width: 303pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">discounts and commissions and estimated offering expenses <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 98.63pt; width: 303pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">payable by us.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 118.63pt; width: 303pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">In connection with the completion of this offering, we are obligated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 130.63pt; width: 303pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">to use certain of the net proceeds from this offering to repay $50.0 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 142.63pt; width: 303pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">million (or $55.0 million if the underwriters exercise their option to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 154.63pt; width: 303pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">purchase additional shares of common stock) of the indebtedness <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 166.63pt; width: 303pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">outstanding under the amended credit agreement and guaranty <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 178.63pt; width: 303pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">(the &#8220;2024 Credit Agreement&#8221;) with Hayfin Services, LLP (&#8220;Hayfin&#8221;) <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 190.63pt; width: 303pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">and to pay approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million of fees in connection <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 202.63pt; width: 303pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">therewith. We expect to use the remainder of the net proceeds <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 214.63pt; width: 303pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">from this offering, together with our existing cash and cash <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 226.63pt; width: 303pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">equivalents, to fund our sales and marketing efforts, fund research <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 238.63pt; width: 303pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">and product development activities and for other general corporate <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 250.63pt; width: 303pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">purposes, including working capital, operating expenses, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 262.63pt; width: 303pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">capital expenditures. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 282.63pt; width: 303pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">We may also use a portion of the net proceeds from this offering to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 294.63pt; width: 303pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">acquire complementary businesses, products, services, or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 306.63pt; width: 303pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">technologies. We periodically evaluate strategic opportunities&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 318.63pt; width: 303pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">however, we have no current understandings or commitments to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 330.63pt; width: 303pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">enter into any such acquisitions or make any such investments.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 350.63pt; width: 303pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">We will have broad discretion in the way that we use the net <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 362.63pt; width: 303pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">proceeds of this offering. See the section titled &#8220;Use of proceeds&#8221; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 374.63pt; width: 303pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">for additional information.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 9.75pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 50.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 534pt; width: 162pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 162pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Risk factors<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 59.84pt; position: absolute; text-decoration: none; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 62.61pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 63.77pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 64.06pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 64.21pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 165pt; position: absolute; top: 534pt; width: 303pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 303pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">You should read the section titled &#8220;Risk factors&#8221; for a discussion of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 14.63pt; width: 303pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">factors to consider carefully, together with all the other information <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 26.63pt; width: 303pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">included in this prospectus, before deciding to invest in our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 38.63pt; width: 303pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">common stock.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr></table></div></div></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="background-image: url(&#39;data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHN0eWxlPSJwb2ludGVyLWV2ZW50czogbm9uZTsiPjxwYXRoIHN0eWxlPSJmaWxsOiB0cmFuc3BhcmVudDsgc3Ryb2tlOiAjMDAwMDAwOyBzdHJva2UtbGluZWNhcDogc3F1YXJlOyBzdHJva2Utd2lkdGg6IDAuNXB0OyIgZD0iTSA0OC4zMyA0OC4zMyBWIDk4My42NyBIIDc2Ny42NyBWIDQ4LjMzIEggNDguMzMiPjwvcGF0aD48L3N2Zz4=&#39;); background-size: 612pt 792pt; height: 792pt; position: absolute; width: 612pt;"></div><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">13<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="position: absolute; top: 72pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 162pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 303pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 9.75pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 9.75pt; width: 162pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 162pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Proposed&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;trading symbol<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 148pt; position: absolute; text-decoration: none; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 150.76999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 153.07999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 153.66pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 153.95pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 154.03pt; position: absolute; text-decoration: none; white-space: pre;"> .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 165pt; position: absolute; top: 9.75pt; width: 303pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 303pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">&#8220;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8221;<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 109pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The number of shares of our common stock to be outstanding after this offering is based on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 121pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">shares of our common stock outstanding as of December 31, 2024 and excludes&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 141pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock issuable upon the exercise of outstanding stock options as of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 153pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">December 31, 2024 under our HeartFlow Holding, Inc. Amended and Restated 2009 Equity Incentive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 165pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Plan (the &#8220;2009 Equity Incentive Plan&#8221;), with a weighted-average exercise price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 185pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock issuable upon the exercise of outstanding stock options granted <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 197pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">subsequent to December 31, 2024 under our 2009 Equity Incentive Plan, with a weighted-average <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 209pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">exercise price of $&#160;&#160;&#160;&#160;&#160;&#160;per share&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 229pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock issuable upon the exercise of warrants outstanding as of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 241pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">December 31, 2024 held by Hayfin, with an exercise price of $0.01 per share&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 261pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock reserved for future issuance under our 2009 Equity Incentive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 273pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Plan&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 293pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock to be reserved for future issuance under our 2025 Performance <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 305pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Incentive Plan (the &#8220;2025 Plan&#8221;), which will become effective as of the date immediately prior to the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 317pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">date our registration statement relating to this offering becomes effective, from which we will grant <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 329pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">restricted stock units (&#8220;RSUs&#8221;) covering approximately &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock concurrently <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 341pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">with this offering (based on the assumed initial public offering price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share, which is the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 353pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">midpoint of the price range set forth on the cover page of this prospectus), as well as any future <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 365pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">increases in the number of shares of common stock reserved for issuance under the 2025 Plan&#59; and<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 385pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock reserved for future issuance under our 2025 Employee Stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 397pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Purchase Plan (the &#8220;ESPP&#8221;), which will become effective immediately prior to the date our registration <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 409pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">statement relating to this offering becomes effective, as well as any future increases in the number of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 421pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">shares of common stock reserved for issuance under the ESPP.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 441pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Unless otherwise indicated, all information contained in this prospectus assumes or gives effect to&#58;&#160;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 461pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the adoption, filing, and effectiveness of our amended and restated certificate of incorporation, to be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 473pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">in effect immediately prior to the completion of this offering, and the adoption of our amended and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 485pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">restated bylaws, to be in effect upon the effectiveness of the registration statement of which this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 497pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">prospectus forms a part&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 517pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the automatic conversion of all the outstanding shares of our Series A, Series B-1, Series B-2, Series <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 529pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">C, Series D, Series E, Series F and Series F-1 redeemable convertible preferred stock (collectively, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 541pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our &#8220;r<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 113.88pt; position: absolute; text-decoration: none; white-space: pre;">edeemable convertible preferred stock&#8221;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 287.22pt; position: absolute; text-decoration: none; white-space: pre;">) as of December 31, 2024 into an aggregate <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 553pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock, the conversion of which will occur immediately prior to the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 565pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">completion of this offering (the &#8220;Preferred Stock Conversion&#8221;)&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 585pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the automatic conversion of $48,356,153.27 of convertible promissory notes with original maturity <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 597pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">dates of 48 months from the dates of issuance into an aggregate of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 609pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">stock (the &#8220;2025 Convertible Notes&#8221;), assuming the assumed initial public offering price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 621pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">per share, which is the midpoint of the estimated price range set forth on the cover page of this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 633pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">prospectus, issued by us in January 2025, which will be automatically converted upon the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 645pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">effectiveness of this offering into an aggregate of&#160; &#160; &#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock (the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 657pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">&#8220;Convertible Notes Conversion&#8221;)&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 677pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">a &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-for- &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;reverse stock split of our common stock, which we effected on &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025 and a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 689pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">corresponding adjustment to the ratio of the Preferred Stock Conversion, the Convertible Note <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 701pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Conversion and adjustment to our outstanding warrants&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="background-image: url(&#39;data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHN0eWxlPSJwb2ludGVyLWV2ZW50czogbm9uZTsiPjxwYXRoIHN0eWxlPSJmaWxsOiB0cmFuc3BhcmVudDsgc3Ryb2tlOiAjMDAwMDAwOyBzdHJva2UtbGluZWNhcDogc3F1YXJlOyBzdHJva2Utd2lkdGg6IDAuNXB0OyIgZD0iTSA0OC4zMyA0OC4zMyBWIDk4My42NyBIIDc2Ny42NyBWIDQ4LjMzIEggNDguMzMiPjwvcGF0aD48L3N2Zz4=&#39;); background-size: 612pt 792pt; height: 792pt; position: absolute; width: 612pt;"></div><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">14<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">no exercise, settlement or termination of the outstanding options or warrants described above&#59; and<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 92pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">no exercise by the underwriters of their option to purchase up to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; additional shares of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">common stock in this offering.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="background-image: url(&#39;data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHN0eWxlPSJwb2ludGVyLWV2ZW50czogbm9uZTsiPjxwYXRoIHN0eWxlPSJmaWxsOiB0cmFuc3BhcmVudDsgc3Ryb2tlOiAjMDAwMDAwOyBzdHJva2UtbGluZWNhcDogc3F1YXJlOyBzdHJva2Utd2lkdGg6IDAuNXB0OyIgZD0iTSA0OC4zMyA0OC4zMyBWIDk4My42NyBIIDc2Ny42NyBWIDQ4LjMzIEggNDguMzMiPjwvcGF0aD48L3N2Zz4=&#39;); background-size: 612pt 792pt; height: 792pt; position: absolute; width: 612pt;"></div><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">15<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_694" style="position: absolute; top: 72pt;"></div><div style="font-size: 16pt; line-height: 11.64pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Summary<font style="display: inline-block; height: 11.64pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 144.88pt; position: absolute; text-decoration: none; white-space: pre;"> consolidated financial data<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 107.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The following tables summarize our consolidated <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 290.87pt; position: absolute; text-decoration: none; white-space: pre;">financial<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 327.53999999999996pt; position: absolute; white-space: pre;"> data for the periods and as of the dates <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 119.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">indicated. The following summary consolidated statements of operations data for the years ended <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 131.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">December 31, 2023 and 2024 and our consolidated balance sheet data as of December 31, 2024 have <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 143.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">been derived from our audited consolidated financial statements and related notes included elsewhere in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 155.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">this prospectus. Our audited consolidated financial statements included elsewhere in this prospectus <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 167.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 179.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">historical results are not necessarily indicative of the results that may be expected for any period in the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 191.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">future. You should read the following summary consolidated financial data together with our audited <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 203.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">consolidated financial statements and the related notes included elsewhere in this prospectus and the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 215.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">section titled &#8220;Management&#8217;s discussion and analysis of financial condition and results of operations.&#8221; The <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 227.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">summary consolidated financial data included in this section are not intended to replace the consolidated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 239.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">financial statements and the related notes included elsewhere in this prospectus and are qualified in their <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 251.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">entirety by the consolidated financial statements and the related notes thereto included elsewhere in this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 263.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prospectus.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 283.2pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 331.5pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 12pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="3"><div style="left: 334.5pt; position: absolute; top: 0pt; width: 133.5pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3pt; width: 133.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 33.64pt; position: absolute; text-decoration: none; white-space: pre;">Year ended December 31,<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 12pt; width: 331.5pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3pt; width: 331.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">(in thousands, except share and per share amounts)<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 12pt; width: 65.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 44.86pt; position: absolute; text-decoration: none; white-space: pre;">2023<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 12pt; width: 65.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 44.86pt; position: absolute; text-decoration: none; white-space: pre;">2024<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 24pt; width: 331.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.24pt; width: 331.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Consolidated statements of operations data&#58;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 38.25pt; width: 331.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.21pt; width: 331.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Revenue<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 40.64pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 42.95pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 43.53pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 43.82pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 43.970000000000006pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 44.050000000000004pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 44.09pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 44.11pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 44.120000000000005pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 38.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 24.4pt;"></font></font><font style="left: 32.31pt; position: absolute;">87,174<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 38.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 52.5pt; width: 331.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.21pt; width: 331.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Cost of revenue<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 69.63pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 71.94pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 72.52pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 72.6pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 52.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 29.68pt;"></font></font><font style="left: 32.31pt; position: absolute;">29,123<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 66.75pt; width: 331.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.24pt; width: 331.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Operating expenses&#58;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 81pt; width: 331.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.21pt; width: 331.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Research and development<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 130.73pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 133.04pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 133.62pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 133.91pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 134.06pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 134.14000000000001pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 134.18pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 81pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 29.68pt;"></font></font><font style="left: 32.31pt; position: absolute;">35,854<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 95.25pt; width: 331.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.21pt; width: 331.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Selling, general and administrative<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 159.72pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 162.03pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 162.60999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 162.65pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 162.66pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 95.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 29.68pt;"></font></font><font style="left: 32.31pt; position: absolute;">95,111<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 109.5pt; width: 331.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.21pt; width: 331.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 26.63pt; position: absolute; text-decoration: none; white-space: pre;">Total operating expenses <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 134.8pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 137.11pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 138.27pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 138.56pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 138.71pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 138.79pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 138.83pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 138.85pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 138.86pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 109.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 24.4pt;"></font></font><font style="left: 27.029999999999998pt; position: absolute;">130,965<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 123.75pt; width: 331.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.21pt; width: 331.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Loss from operations <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 93.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 96.19999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 96.35pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 123.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 26.52pt;"></font></font><font style="left: 29.15pt; position: absolute;">(72,914)<font style="display: inline-block; height: 6.91pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 138pt; width: 331.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.21pt; width: 331.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Interest income (expense), net<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 142.81pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 143.39pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 143.68pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 143.82999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 143.91pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 138pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 26.52pt;"></font></font><font style="left: 29.15pt; position: absolute;">(19,237)<font style="display: inline-block; height: 6.91pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 152.25pt; width: 331.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.21pt; width: 331.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Other income (expense), net<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 134.9pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 137.21pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 138.37pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 138.66pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 138.81pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 138.85pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 138.86pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 152.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 31.8pt;"></font></font><font style="left: 34.43pt; position: absolute;">(2,957)<font style="display: inline-block; height: 6.91pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 166.5pt; width: 331.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.21pt; width: 331.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Loss before provision from income taxes<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 173.03pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 175.34pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 176.5pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 176.79pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 166.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 26.52pt;"></font></font><font style="left: 29.15pt; position: absolute;">(95,108)<font style="display: inline-block; height: 6.91pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 180.75pt; width: 331.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.21pt; width: 331.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Provision for income taxes<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 125.94pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 128.25pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 129.41pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 129.42000000000002pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 180.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 39.71pt;"></font></font><font style="left: 42.34pt; position: absolute;">(547)<font style="display: inline-block; height: 6.91pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 195pt; width: 331.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.21pt; width: 331.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Net loss<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 36.92pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 39.230000000000004pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 39.38pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 39.46pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 39.470000000000006pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 195pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 21.24pt;"></font></font><font style="left: 29.15pt; position: absolute;">(95,655)<font style="display: inline-block; height: 6.91pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 195pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">$<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 209.25pt; width: 331.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.24pt; width: 331.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Cumulative dividends on Series C redeemable convertible preferred stock<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 324.33pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 326.64pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 327.8pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 328.38pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 328.42pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 209.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 31.8pt;"></font></font><font style="left: 34.43pt; position: absolute;">(1,239)<font style="display: inline-block; height: 6.91pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 24.75pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 223.5pt; width: 331.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.76pt; width: 331.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Deemed dividend upon down round of redeemable convertible preferred <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 14.16pt; width: 331.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 23.63pt; position: absolute; text-decoration: none; white-space: pre;">stock<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 45.79pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 48.099999999999994pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 48.68pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 48.83pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 48.87pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 48.89pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 223.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 14.35pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 26.52pt;"></font></font><font style="left: 29.15pt; position: absolute;">(26,794)<font style="display: inline-block; height: 6.91pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 248.25pt; width: 331.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.21pt; width: 331.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Net loss attributable to common stockholders<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 192.01pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 194.32pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 195.48pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 195.63pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 195.71pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 195.75pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 195.76999999999998pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 248.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 15.96pt;"></font></font><font style="left: 23.869999999999997pt; position: absolute;">(123,688)<font style="display: inline-block; height: 6.91pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 248.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">$<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 262.5pt; width: 331.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.21pt; width: 331.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Net loss per share attributable to common stockholders, basic and diluted<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 311.24pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(1)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 318.77pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 319.06pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 319.21pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 319.29pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 319.33pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 319.35pt; position: absolute; text-decoration: none; white-space: pre;"> . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 262.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 31.8pt;"></font></font><font style="left: 39.71pt; position: absolute;">(8.67)<font style="display: inline-block; height: 6.91pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 262.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">$<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 24.75pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 276.75pt; width: 331.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.76pt; width: 331.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Weighted-average shares used to compute net loss per share attributable to <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 14.16pt; width: 331.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 11.63pt; position: absolute; text-decoration: none; white-space: pre;">common stockholders, basic and diluted<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 180.47pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(1)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 188pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 190.31pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 190.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 191.04pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 191.07999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 191.09pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 276.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 14.35pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 11.21pt;"></font></font><font style="left: 13.84pt; position: absolute;">14,265,293<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 24.75pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 301.5pt; width: 331.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.76pt; width: 331.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Pro forma net loss per share attributable to common stockholders, basic and <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 14.16pt; width: 331.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 11.63pt; position: absolute; text-decoration: none; white-space: pre;">diluted (unaudited)<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 90.25pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(1)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 97.78pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 100.08999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 100.67pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 100.96pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 101pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 101.00999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 301.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 14.35pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">$<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 24.75pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 326.25pt; width: 331.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.76pt; width: 331.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Pro forma weighted-average shares used to compute net loss per share <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 14.16pt; width: 331.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 11.63pt; position: absolute; text-decoration: none; white-space: pre;">attributable to common stockholders, basic and diluted (unaudited)<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 291.24pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(1)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 298.77pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 299.93pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 300.21999999999997pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 300.26pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 300.28pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 5.46pt; position: absolute; top: 642.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(1)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">See Note 2 to our consolidated financial statements included elsewhere in this prospectus for an explanation of the calculation of our <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 651.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">basic and diluted net loss per share attributable to common stockholders and the weighted-average number of shares used in the <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 660.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">computation of the per share amounts. <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="font-size: 12pt; line-height: 5.46pt; position: absolute; top: 677.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(2)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Unaudited pro forma net loss per share attributable to common stockholders, basic and diluted, for the year ended December 31, 2024 <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="font-size: 12pt; line-height: 5.46pt; position: absolute; top: 686.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">is calculated by giving effect to (i)&#160; removal of the effect of interest expense related to the partial repayment of indebtedness with Hayfin, <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="font-size: 12pt; line-height: 5.46pt; position: absolute; top: 695.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">(ii) reversal of accretion of cumulative dividends on Series C redeemable convertible preferred stock, (iii) the Preferred Stock <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="font-size: 12pt; line-height: 5.46pt; position: absolute; top: 704.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Conversion, as if the shares resulting from the Preferred Stock Conversion were outstanding as of the beginning of the period <font style="display: inline-block; height: 5.46pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="background-image: url(&#39;data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHN0eWxlPSJwb2ludGVyLWV2ZW50czogbm9uZTsiPjxwYXRoIHN0eWxlPSJmaWxsOiB0cmFuc3BhcmVudDsgc3Ryb2tlOiAjMDAwMDAwOyBzdHJva2UtbGluZWNhcDogc3F1YXJlOyBzdHJva2Utd2lkdGg6IDAuNXB0OyIgZD0iTSA0OC4zMyA0OC4zMyBWIDk4My42NyBIIDc2Ny42NyBWIDQ4LjMzIEggNDguMzMiPjwvcGF0aD48L3N2Zz4=&#39;); background-size: 612pt 792pt; height: 792pt; position: absolute; width: 612pt;"></div><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">16<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="font-size: 12pt; line-height: 5.46pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">presented, and (iv) the Convertible Notes Conversion, as if the shares resulting from the Convertible Notes Conversion were <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="font-size: 12pt; line-height: 5.46pt; position: absolute; top: 81pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">outstanding as of the beginning of the period presented. The following table summarizes our unaudited pro forma net loss per share for <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="font-size: 12pt; line-height: 5.46pt; position: absolute; top: 90pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the year ended Decembe<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 174.17000000000002pt; position: absolute; text-decoration: none; white-space: pre;">r 31, 2024&#58;<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="position: absolute; top: 107pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 399.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 32.25pt;"><td style="border-top: 1.5pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-top: 1.5pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000000; border-top: 1.5pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 4.05pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 19.56pt; position: absolute; text-decoration: none; white-space: pre;">Year ended <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 13.65pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 10.67pt; position: absolute; text-decoration: none; white-space: pre;">December 31, <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 23.25pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 44.86pt; position: absolute; text-decoration: none; white-space: pre;">2024<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="border-bottom: 1pt solid #000000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 32.25pt; width: 399.75pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3pt; width: 399.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">(in thousands, except share and per share amounts)<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000000; border-top: 1pt solid #000000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; border-top: 1pt solid #000000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 44.25pt; width: 399.75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 399.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Numerator&#58;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 58.5pt; width: 399.75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 399.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Net loss attributable to common stockholders, basic and diluted<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 268.51pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 268.8pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 268.95pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 269.03pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 269.07pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 269.09pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 269.1pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 58.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">$<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 72.75pt; width: 399.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 399.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Pro forma adjustment to remove interest expense related to debt repayment<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 338.13pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 340.44pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 341.6pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 341.68pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 341.71999999999997pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 341.74pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 341.75pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 87pt; width: 399.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 399.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Pro forma adjustment to reverse the accretion of cumulative dividends<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 312.02pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 312.1pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 312.12pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 101.25pt; width: 399.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 399.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Pro forma net loss attributable to common stockholders<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 247.01999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 247.1pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 247.12pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 101.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">$<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 115.5pt; width: 399.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 399.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Denominator&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 26.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 129.75pt; width: 399.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 399.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Weighted-average shares used in computing net loss per share attributable to common <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 15.32pt; width: 399.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 11.63pt; position: absolute; text-decoration: none; white-space: pre;">stockholders, basic and diluted<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 148.29999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 150.60999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 151.19pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 151.48pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 151.63pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 151.71pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 151.75pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 151.76999999999998pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 156pt; width: 399.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 399.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Pro forma adjustment to reflect the Preferred Stock Conversion<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 281.43pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 282.01pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 282.05pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 282.06pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 170.25pt; width: 399.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 399.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Pro forma adjustment to reflect the Convertible Notes Conversion<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 291.45pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 292.03pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 292.05pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 292.06pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 24.75pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 184.5pt; width: 399.75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.89pt; width: 399.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Pro forma weighted-average shares used in computing pro forma net loss per share <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 14.29pt; width: 399.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 11.63pt; position: absolute; text-decoration: none; white-space: pre;">attributable to common stockholders, basic and diluted<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 240.59pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 240.67pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 240.69pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 240.7pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 209.25pt; width: 399.75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 399.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Pro forma net loss per share attributable to common stockholders, basic and diluted<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 353.95pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 354.24pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 354.39pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 354.40999999999997pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 354.42pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000000; border-top: 1pt solid #000000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 209.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">$<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 15.75pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="position: absolute; top: 359.25pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 263.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 12pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="5"><div style="left: 266.25pt; position: absolute; top: 0pt; width: 201.75pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3pt; width: 201.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 53.81pt; position: absolute; text-decoration: none; white-space: pre;">As of December 31, 2024<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td></tr><tr style="height: 21.75pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 12pt; width: 263.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 12.75pt; width: 263.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">(in thousands)<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 12pt; width: 65.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 12.75pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 38.21pt; position: absolute; text-decoration: none; white-space: pre;">Actual<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 12pt; width: 65.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 12.75pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 18.53pt; position: absolute; text-decoration: none; white-space: pre;">Pro forma<font style="display: inline-block; height: 5.82pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 5.2pt; font-style: normal; font-weight: bold; left: 56.27pt; position: absolute; text-decoration: none; top: -2.037pt; vertical-align: super; white-space: pre;">(1)<font style="display: inline-block; height: 3.7830000000000004pt;"></font></font></div></div></div></td><td style="border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 12pt; width: 65.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3.15pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 24.88pt; position: absolute; text-decoration: none; white-space: pre;">Pro forma<font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 12.75pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 5.98pt; position: absolute; text-decoration: none; white-space: pre;">as adjusted<font style="display: inline-block; height: 5.82pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 5.2pt; font-style: normal; font-weight: bold; left: 49.92pt; position: absolute; text-decoration: none; top: -2.037pt; vertical-align: super; white-space: pre;">(2)(3)<font style="display: inline-block; height: 3.7830000000000004pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 33.75pt; width: 263.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.24pt; width: 263.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Consolidated balance sheet data&#58;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 48pt; width: 263.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.21pt; width: 263.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Cash and cash equivalents<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 116.61999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 117.78pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 118.07pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 118.22pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 118.25999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 48pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 48pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 48pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 62.25pt; width: 263.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.21pt; width: 263.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Working capital<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 67.35pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(4)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 74.88pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 75.46pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 75.61pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 75.69pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 76.5pt; width: 263.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.21pt; width: 263.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Total assets<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 52.75pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 55.06pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 56.220000000000006pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 56.370000000000005pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 56.410000000000004pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.42pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 90.75pt; width: 263.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.21pt; width: 263.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">2024 Term Loan<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 71.06pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 73.36999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 74.53pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 75.11pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 75.25999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 75.3pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 75.32pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 105pt; width: 263.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.21pt; width: 263.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">2025 Convertible Notes<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 101.83pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 102.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 103.57pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 103.86pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 103.94pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 103.97999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 103.99pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 119.25pt; width: 263.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.21pt; width: 263.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Redeemable convertible preferred stock<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 170.94pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 173.25pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 174.41pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 174.7pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 174.85pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 174.89pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 133.5pt; width: 263.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.21pt; width: 263.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Accumulated deficit<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 84.92999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 85.08pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 85.16pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 85.19999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 85.22pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 85.22999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 147.75pt; width: 263.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.21pt; width: 263.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Total stockholders&#8217; equity (deficit)<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 142.07pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 142.10999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 142.12pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 3pt;"><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 5.46pt; position: absolute; top: 529.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(1)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">The pro forma column above reflects (a) the issuance and sale of the 2025 Convertible Notes and the 2024 Term Loan Conversion (as <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 538.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">defined in the section titled &#8220;Certain relationships and related-party transactions&#8221;) that occurred subsequent to December 31, 2024&#59; (b) <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 547.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the Preferred Stock Conversion&#59; (c) the Convertible Notes Conversion&#59; and (d) the adoption, filing, and effectiveness of our amended <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 556.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">and restated certificate of incorporation, to be in effect immediately prior to the completion of this offering.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 573.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(2)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">The pro forma as adjusted column gives effect to (a) the pro forma adjustments set forth in (1) above and (b) the issuance and sale <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 582.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock in this offering at the assumed initial offering price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; per share, which is the midpoint of <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 591.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the estimated price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="font-size: 12pt; line-height: 5.46pt; position: absolute; top: 600.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">commissions and estimated offering expenses payable by us and (c) assuming the repayment of <font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 411.89pt; position: absolute; text-decoration: none; white-space: pre;">$50.0 million<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 453.95pt; position: absolute; text-decoration: none; white-space: pre;"> of the indebtedness <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 609.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">outstanding under the 2024 Credit Agreement and payment of approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million of fees in connection therewith.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 626.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(3)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">The pro forma as adjusted information above is illustrative only and will depend on the actual initial public offering price and other terms <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 635.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">of this offering determined at pricing. Each $1.00 increase or decrease in the assumed initial public offering price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 644.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">of our common stock, which is the midpoint of the estimated price range set forth on the cover page of this prospectus, would increase <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 653.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">or decrease, as applicable, each of our pro forma as adjusted cash and cash equivalents, working capital, total assets, and total <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 662.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">stockholders&#8217; equity (deficit) by approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million, assuming the number of shares offered by us, as set forth on the cover <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 671.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 680.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">offering expenses payable by us. Similarly, each increase or decrease of 1.0 million shares in the number of shares of common stock <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 689.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">offered by us would increase or decrease, as applicable, each of our pro forma as adjusted cash and cash equivalents, working capital, <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 698.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">total assets, and total stockholders&#8217; equity (deficit) by approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million, assuming the assumed initial public offering price of <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 707.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; per share of our common stock, which is the midpoint of the estimated price range set forth on the cover page of this <font style="display: inline-block; height: 5.46pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="background-image: url(&#39;data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHN0eWxlPSJwb2ludGVyLWV2ZW50czogbm9uZTsiPjxwYXRoIHN0eWxlPSJmaWxsOiB0cmFuc3BhcmVudDsgc3Ryb2tlOiAjMDAwMDAwOyBzdHJva2UtbGluZWNhcDogc3F1YXJlOyBzdHJva2Utd2lkdGg6IDAuNXB0OyIgZD0iTSA0OC4zMyA0OC4zMyBWIDk4My42NyBIIDc2Ny42NyBWIDQ4LjMzIEggNDguMzMiPjwvcGF0aD48L3N2Zz4=&#39;); background-size: 612pt 792pt; height: 792pt; position: absolute; width: 612pt;"></div><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">17<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 5.46pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 81pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">expenses payable by us.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 98pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(4)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Working capital is defined as current assets less current liabilities. See our consolidated financial statements and related notes included <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 107pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">elsewhere in this prospectus for further details regarding our current assets and current liabilities.<font style="display: inline-block; height: 5.46pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">18<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_697" style="position: absolute; top: 72pt;"></div><div style="line-height: 11.64pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Risk factors<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 107.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 119.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">described below, as well as the other information in this prospectus, including our financial statements <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 131.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and the related notes and &#8220;Management&#8217;s discussion and analysis of financial condition and results of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 143.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">operations,&#8221; before deciding whether to invest in our common stock. The occurrence of any of the events <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 155.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or developments described below could have a material adverse effect on our business, financial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 167.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">condition, results of operations and prospects. In such an event, the market price of our common stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 179.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">could decline, and you may lose all or part of your investment. Additional risks and uncertainties not <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 191.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">presently known to us or that we currently believe are not material may also impair our business, financial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 203.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">condition, results of operations and prospects. Please also see the sections titled &#8220;Special note regarding <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 215.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">forward-looking statements&#8221; and &#8220;Market and industry data.&#8221;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 235.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Risks related to our business and industry<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 257.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">We have incurred significant net losses since our inception, we expect to incur additional <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 269.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">substantial losses in the foreseeable future and we may not be able to achieve or sustain <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 281.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">profitability. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 301.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We have incurred significant net losses since our inception in 2007, and we expect to incur additional <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 313.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">substantial losses in the foreseeable future. For the fiscal years ended December 31, 2023 and 2024, we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 325.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">incurred net losses of $95.7 million and $&#160;&#160;&#160;&#160;&#160;&#160;&#160;million, respectively. As of December 31, 2024, we had an <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 337.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">accumulated deficit of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million. Since inception, we have spent significant amounts of cash to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 349.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">develop the Heartflow Platform, to fund research and development, including our preclinical research and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 361.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">development activities and clinical trials related to our products, to scale our commercial operations and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 373.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to recruit and retain key talent. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 393.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The net losses we incur may fluctuate significantly from quarter to quarter and year to year, such that a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 405.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">period-to-period comparison of our results of operations may not be a good indication of our future <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 417.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">performance. We expect to continue to incur significant research and development, sales and marketing, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 429.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">regulatory and other expenses as we expand our marketing efforts to increase adoption of our products, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 441.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">expand existing relationships with our customers, obtain regulatory clearances or approvals for our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 453.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">planned or future products, conduct clinical trials to extend applicability of our platform into new <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 465.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">indications or to develop new products or add new features to our existing products. The investments in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 477.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our business may be more costly than we expect, and&#160;if we do not achieve the benefits anticipated from <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 489.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">these investments, or if the realization of these benefits is delayed, they may not result in increased <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 501.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">revenue or growth in our business. In addition to the anticipated costs of growing our business, we expect <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 513.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our general and administrative expenses to increase following this offering due to the additional costs of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 525.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">being a public company. If our revenue growth does not increase to more than offset the anticipated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 537.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">increases in our operating expenses, we may not be able to achieve or sustain profitability and our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 549.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">business, financial condition, results of operations and prospects will be harmed.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 569.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition, our revenue may decline or our revenue growth, if any, may be constrained. Our ability to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 581.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">increase sales is uncertain, and we may never be able to achieve or sustain profitability for many <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 593.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reasons, including that&#58; our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 194.76pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 239.74pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 259.15999999999997pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 267.82pt; position: absolute; white-space: pre;"> Analysis may not achieve widespread adoption among <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 605.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">healthcare providers and we may be unable to increase revenue generated from sales of our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 484.22pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 617.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 91.42pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 100.08pt; position: absolute; white-space: pre;"> Analysis&#59; our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 162.28pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 207.26pt; position: absolute; white-space: pre;">Plaque Analysis may not achieve widespread adoption among healthcare <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 629.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">providers and we may be unable to generate sufficient revenue from sales of our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 430.67pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 475.65pt; position: absolute; white-space: pre;">Plaque <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 641.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Analysis&#59; payors, such as insurance companies and government insurance programs, may decide not to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 653.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reimburse for our products, may set the amount of such reimbursement too low or reduce the amount of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 665.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">such reimbursement&#59; healthcare industry trends, including growth in CCTA usage, may move in directions <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 677.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">that do not allow for adoption of our products or that do not provide adequate incentives for the adoption <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 689.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of our products&#59; competitors may develop or acquire a product that successfully competes with ours&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 701.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">manufacturers of CT scanners may partner with our competitors or develop or acquire a competing <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">19<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">product and integrate one or more products that successfully competes with ours&#59; we may not be able to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">obtain regulatory approval for future versions of our products (including improved versions of our AI <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">algorithms), new indications for use of our products or other future products&#59; and there may be changes in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">existing or anticipated clinical guidelines, including the current ACC and AHA Class 1, Level A guidelines <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for CCTA and Class 2a, Level B guidelines for <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 277.31pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 322.28999999999996pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 341.71pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 350.37pt; position: absolute; white-space: pre;"> Analysis for certain patients with stable or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">acute chest pain and no known CAD, or the timing of adoption of positive clinical guidelines that support <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the use of the <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 135.31pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 180.29000000000002pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 199.70999999999998pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 208.37pt; position: absolute; white-space: pre;"> Analysis. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Because of these and the other risks and uncertainties described in this prospectus, we are unable to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">predict the extent to which we will be able to increase sales, if at all, or the timing for when or the extent to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">which we will become profitable, if ever. We will need to generate significant additional revenue to achieve <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and sustain profitability, and even if we do achieve profitability, we may not be able to sustain or increase <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">profitability. Our failure to become and remain profitable would depress the value of our company and our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock price and could impair our ability to raise capital, fund our research and development efforts, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">expand our business, diversify our product offerings or continue our operations. A decline in the value of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our company could cause you to lose all or part of your investment.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Our revenue is currently generated almost entirely from the sales of only one product, Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: italic; font-weight: bold; left: 91.42pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 100.08pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis, and we are therefore highly dependent on the success of this product, which <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">makes it difficult to evaluate our current business, predict our future prospects and forecast our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">financial performance and any growth. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 324pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In 2024, our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 128.1pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 173.07999999999998pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 192.5pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 201.16pt; position: absolute; white-space: pre;"> Analysis represented approximately&#160;&#160;&#160;&#160;&#160;&#160;% of our revenues. In the second <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 336pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">half of 2023, we began limited market education efforts of our second product, <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 419.53pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 464.51pt; position: absolute; white-space: pre;">Plaque Analysis. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 348pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Over the next several years, we expect to continue to devote a substantial amount of resources to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">increase sales of our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 166.99pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 211.97pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 231.39pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 240.05pt; position: absolute; white-space: pre;"> Analysis and also expand our commercialization efforts and drive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">increased adoption of our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 187.56pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 232.54pt; position: absolute; white-space: pre;">Plaque Analysis. However, we may not succeed in increasing sales <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 384pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 100.32pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 145.3pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 164.72pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 173.38pt; position: absolute; white-space: pre;"> Analysis or in increasing adoption of our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 355.58pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 400.56pt; position: absolute; white-space: pre;">Plaque Analysis. We expect to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">continue to derive almost all of our revenue from sales of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 325.83000000000004pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 370.81pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 390.23pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 398.89pt; position: absolute; white-space: pre;"> Analysis for the foreseeable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">future, so we are highly dependent on its success. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 428pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition, because we plan to devote substantial resources to increase sales of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 431.41pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 476.39pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 495.81pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 504.47pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 440pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Analysis and rely on it as our main source of revenue, any factors that negatively impact these efforts, our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 452pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 116.97999999999999pt; position: absolute; white-space: pre;">Plaque Analysis commercialization efforts or our ability to diversify our products would have a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 464pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">material adverse effect on our business, financial condition, results of operations and prospects.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 484pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Therefore, it is difficult to predict our future prospects and forecast our financial performance and any <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 496pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">growth, and any such forecasts are inherently limited and subject to a number of uncertainties. If our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 508pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">assumptions regarding the risks and uncertainties we face, which we use to plan our business, are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 520pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">incorrect or change due to circumstances in our business or our markets, or if we do not address these <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 532pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">risks successfully, our operating and financial results could differ materially from our expectations and our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 544pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">business, financial condition, results of operations and prospects could suffer.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">If healthcare providers are unwilling to change their standard practice regarding the evaluation of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">CAD, our business, financial condition, results of operations and prospects will be adversely <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">affected.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 608pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our success depends on physicians, hospitals and other healthcare providers adopting and using the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 620pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Heartflow Platform to aid in the evaluation of CAD. While we have had some recent success in achieving <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 632pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">broader adoption of the Heartflow Platform, we have in the past faced, and may in the future face, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">challenges in achieving higher rates of adoption. Many healthcare providers have extensive experience <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">with existing non-invasive tests for CAD and have established relationships with the companies that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 668pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">provide these tests or in some instances own or manage the equipment for these tests in their offices. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 680pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Existing tests are performed in a high enough volume that healthcare providers generate sufficient <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 692pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">revenue from their use and are well versed in their use, reimbursement and outcomes. The outcomes and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 704pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">workflow efficiencies that we believe our Heartflow Platform provides may not be valued by healthcare <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">20<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">providers as highly as we expect or at all. In addition, healthcare providers have been, and may continue <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to be, slower to adopt or recommend our products because we have a more limited commercial track <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">record and healthcare providers may feel they can generate more revenue from existing tests. Healthcare <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">providers also may not find our clinical data compelling and may not recommend or use our products until <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">they receive additional recommendations from other healthcare providers that our products have a clinical <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">benefit, or at all. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition, the Heartflow Platform relies on healthcare providers following the ACC and AHA guidelines <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">by referring certain patients with stable or acute chest pain and no known CAD to undergo a CCTA, with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the CCTA images to be analyzed by our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 250.67pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 295.65pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 315.07pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 323.73pt; position: absolute; white-space: pre;"> Analysis. Although the ACC and AHA guidelines <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">support CCTA plus our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 175.12pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 220.1pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 239.52pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 248.18pt; position: absolute; white-space: pre;"> Analysis as the preferred pathway for diagnosing and managing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">CAD in certain patients with stable or acute chest pain and no known CAD, these guidelines may not be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">widely adopted by healthcare providers. Moreover, healthcare providers may choose not to adopt the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Heartflow Platform if they are not able to obtain an adequate CCTA. Further, if future studies and trials or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">other events, including reimbursement rates of CCTA, adversely impact the rate of use of CCTAs in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">practice, then healthcare providers may be less willing to adopt a technology that uses CCTAs.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Also, the Heartflow Platform may be more difficult than we expect to integrate into standard practice <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">because a provider may be resistant to introduce our embedded information technology and workflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">infrastructure. Due to different laws, policies and preferences of healthcare providers regarding patient <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">privacy both in the United States and abroad, they may be averse to sending data externally (outside of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">their facility) or abroad. Furthermore, if healthcare providers using the Heartflow Platform experience what <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">they perceive to be false negative result or imprecise readings, including due to user error, they may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">determine not to continue using our platform going forward.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We expect that addressing these and similar issues will require a significant amount of our time and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">resources, and if we are unsuccessful, we would be unable to achieve broader adoption of the Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 384pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Platform by healthcare providers. If our products do not gain broader acceptance by healthcare providers, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our business, financial condition, results of operations and prospects will be adversely affected.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 416pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">If third-party payors, including government payors, do not cover and provide adequate, or any, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 428pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">reimbursement for the Heartflow Platform, or if existing payment amounts are reduced or coding <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 440pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">changes, adoption of the Heartflow Platform by healthcare providers will be negatively impacted, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 452pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">and our business, financial condition, results of operations and prospects will be adversely <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 464pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">affected. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 484pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our ability to grow sales and revenue from our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 279.73pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 324.71000000000004pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 344.13pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 352.79pt; position: absolute; white-space: pre;"> Analysis and to successfully <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 496pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">commercialize our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 155.88pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 200.86pt; position: absolute; white-space: pre;">Plaque Analysis depend, in large part, on whether third-party payors, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 508pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">including private health insurers, managed care plans and government healthcare programs, such as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 520pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Medicare and Medicaid, cover and adequately reimburse for the use of the Heartflow Platform and the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 532pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">underlying CCTA. Patients generally rely on payors to reimburse all or a significant part of the costs <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 544pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">associated with their treatment. As a result, coverage determinations and reimbursement levels are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 556pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">critical to the commercial success of the Heartflow Platform. Reimbursement is obtained from a variety of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 568pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">sources, including government sponsored and private health insurance plans, and varies by country and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 580pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">by region within some countries. These payors determine whether to provide coverage and payment for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 592pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">specific products and procedures. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition, payors continually review new technologies and can, without notice, deny coverage. As a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">result, the coverage determination process is often time consuming and costly, with no assurance that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 636pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">coverage and adequate reimbursement will be obtained or maintained if obtained. If payors change their <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 648pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reimbursement policies, including if the current Category 1 CPT codes related to our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 446.18pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 491.16pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 510.58pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 519.24pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Analysis or future Category 1 CPT codes related to our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 317.3pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 362.28pt; position: absolute; white-space: pre;">Plaque Analysis are not favorably <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">priced, we would be unable to obtain favorable Medicare reimbursement for the Heartflow Platform. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 684pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Moreover, physicians, hospitals and other healthcare providers may decline to adopt or reduce usage of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 696pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the Heartflow Platform due to the economic impact a change in reimbursement may have on their <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">21<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">business and, as a result, we may experience a significant loss of revenue, which would have a material <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">adverse effect on our business, financial condition, results of operations and prospects.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Given the evolving nature of the healthcare industry and ongoing healthcare cost reforms, we are and will <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">continue to be subject to effects of changes in the level of Medicare reimbursement for our products. A <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reduction in coverage or payment by the Medicare program could cause some commercial third-party <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">payors to implement similar reductions in their coverage or payment amounts for the Heartflow Platform. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Unfavorable coverage or payment determinations at the national or local level could adversely affect our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">business, financial condition, results of operations and prospects. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 184pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">To date we have derived a significant amount of our revenue from a small number of customers, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 196pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">and face risks associated with a more concentrated customer base.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 216pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We derive a significant amount of our revenue from a small number of customers. As of December 31, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 228pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2024, we have derived&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of our revenue from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;customers. In addition, although our Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 240pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Platform had an installed base of over 1,100 accounts in the United States as of December 31, 2024, the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 252pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">decision-making function for many of these accounts is concentrated in a relatively small number of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 264pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">customers, such that the loss of one customer could result in a disproportionate loss across our accounts. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 276pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We cannot guarantee that that we will continue to generate revenue from these customers, whether due <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 288pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to increase in competition, new technologies, our customers&#8217; ability to terminate their contracts with us or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 300pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reduce order volumes, or other factors outside of our control. If we do not increase the number of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 312pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">customers and drive increased use of the Heartflow Platform as the preferred non-invasive testing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 324pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">method for assessing CAD, we will continue to face risks associated with a more concentrated customer <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 336pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">base.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 356pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Revenue from these customers may fluctuate from time to time due to demand for the Heartflow Platform, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 368pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the timing of which may be affected by seasonality or other factors outside of our control such as CT <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 380pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">scanner capacity, contrast availability and staffing availability. These customers could also potentially <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 392pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">pressure us to reduce the prices we charge for the Heartflow Platform, which could have a material <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 404pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">adverse effect on our margins and business. In addition, if any of our largest customers terminates its <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 416pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">relationship with us or otherwise reduces its FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 287.49pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 296.15pt; position: absolute; white-space: pre;"> Analysis volumes for any reason, we may be unable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 428pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to replace them with a customer who refers a similar number of patients for the Heartflow Platform, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 440pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">such termination or reduction in volume could have a material adverse effect on our business, financial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 452pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">condition, results of operations and prospects. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 472pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">We face significant competition in an environment of rapid technological change, and there is a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 484pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">possibility that our competitors may develop products that are more effective, accurate, reliable, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 496pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">cost-effective or more advanced than ours, which may harm our financial condition. If we are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 508pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">unable to compete successfully or our potential market share is reduced, we may be unable to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 520pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">increase or sustain our revenue or achieve profitability.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The medical technology industry is highly competitive, subject to rapid change and significantly affected <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">by the introduction of new products and technologies and other activities of industry participants. Because <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of the size of the market opportunity for the treatment of CAD, we believe current and potential future <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">competitors will dedicate significant resources to aggressively promote their products or develop new <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">products or treatments. Our principal competition comes from companies that provide traditional non-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 600pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">invasive tests that aid physicians in the evaluation of CAD, such as SPECT, stress echocardiography and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">PET. Established, traditional non-invasive tests for CAD have been used for many years and are therefore <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">difficult to change or supplement. Many of the companies that sell these traditional non-invasive tests or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 636pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the equipment they require have established relationships with healthcare providers. One of the major <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 648pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">hurdles to adoption of our products is overcoming established testing patterns, which requires education <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of physicians and supportive clinical data. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 680pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The companies that sell the traditional non-invasive tests for CAD include companies that offer&#58; (i) cardiac <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 692pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">specific tests to primary care and cardiology offices, such as manufacturers of capital equipment for <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">22<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stress echocardiography and SPECT, including GE Healthcare, Siemens Healthineers AG and Koninklijke <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Philips N.V.&#59; and (ii) products used for the invasive fractional flow reserve (&#8220;FFR&#8221;) testing market.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">With the greater resources of some of these competitors and their more diversified product offerings, it is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">possible that they or other entrants into the market may develop competing products or technologies that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">could be more effective, accurate, reliable, cost-effective, more advanced or otherwise improved relative <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to the Heartflow Platform, which could render our products obsolete or less competitive. In addition, one <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or more competitors could develop and market an on-premise solution, which may be more appealing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">than our cloud-based offering. Moreover, new treatments, such as GLP-1s, may indirectly reduce stenosis <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or plaque build-up, which could reduce the market opportunity for non-invasive CAD tests and, as a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">result, our Heartflow Platform. In addition, we currently target our Heartflow Platform for use only on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">symptomatic patients and expanding the Heartflow Platform for asymptomatic patients may take years, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">with potential delays due to the high-risk nature of the effort. Our competitors who offer traditional non-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">invasive tests offer those tests to both symptomatic and asymptomatic patients, and this increased market <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">penetration could create additional price pressure for our products.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition, the field of cardiovascular genomics is subject to rapidly changing technology, and others may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">invent and commercialize technology platforms such as next generation sequencing approaches that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">could compete with our products or could make our products or any product we may sell in the future <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">obsolete. We also face competition and price pressure from companies that have developed or are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">developing AI-based platforms that leverage CCTA to diagnose CAD, including earlier-stage companies <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">such as Cleerly, Inc., Elucid Bioimaging Inc. and Keya Medical Technology Co., Ltd. We may also face <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">competition from companies developing AI-based platforms, even if they are not currently in the CAD <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">market and recent and future advances in AI may allow other companies to quickly create competing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">products, and they may be able to create such products less expensively and benefit from FDA and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 364pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reimbursement approvals we and others have obtained. For us to remain competitive, we must <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">continuously work on our products&#8217; design and features, improve our algorithms, and invest in and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 388pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">develop new technologies, including in the rapidly evolving area of AI. If we are unable to introduce <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 400pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">products, features and improvements aimed at increasing the value proposition of the Heartflow Platform <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 412pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for our customers, or if the products, features and improvements we introduce are viewed less favorably <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 424pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">than our competitors&#8217; products, we may be unable to compete successfully. If we are unable to compete <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 436pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">successfully against our current or future competitors, we may be unable to increase market acceptance <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 448pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for our products, which could prevent us from increasing or sustaining our revenue or achieving <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 460pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">profitability and could cause the market price of our common stock to decline.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition, the Heartflow Platform relies on a CCTA first being performed. A number of companies <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 492pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">manufacture CT scanners, including, among others, GE Healthcare, Hitachi, Ltd., Koninklijke Philips N.V., <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 504pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Samsung Electronics Co., Ltd., Siemens Healthineers AG and Canon Medical Systems Corporation. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 516pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">These companies are more diversified than we are and have substantial financial, manufacturing, sales <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 528pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and marketing distribution and other resources. Any of these companies or others could determine to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">develop, partner with or acquire and offer a product that competes with ours or manufacture CT scanners <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">that are no longer compatible with our Heartflow Platform. Further, these larger companies have market <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">penetration in the CT scanner market and understand the market for CAD and, if they are able to develop, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">partner with or acquire a competing product, they may offer it as a bundle with the purchase of a CT <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">scanner, which could prevent us from increasing or sustaining our revenue or achieving profitability. In the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 600pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">past, three of these companies, Siemens Healthineers AG, Koninklijke Philips N.V. and Canon Medical <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Systems Corporation, considered development of a local workstation-based technology prototype aimed <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">at deriving CT-based blood flow data without an invasive procedure. If these companies decide to further <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 636pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">pursue this technology and obtain regulatory approval or clinical validation, it may become competitive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 648pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">with our products. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 668pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; white-space: pre;">There is substantial doubt about our ability to continue as a going concern.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 688pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We have prepared cash flow forecasts which indicate that, based on our expected operating losses and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 700pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">negative cash flows, there is substantial doubt about our ability to continue as a going concern for the <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">23<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">twelve months after the date that our consolidated financial statements for the year ended December 31, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2023 are issued. As a result, management has included disclosures in Note 1 of the financial statements <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and our independent registered public accounting firm has included an explanatory paragraph in its report <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">on our consolidated financial statements for the fiscal year ended December 31, 2023 with respect to this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">uncertainty. Our future viability as an ongoing business is dependent on our ability to generate cash from <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our operating activities and to raise additional capital to finance our operations.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">There is no assurance that we will succeed in obtaining sufficient funding on terms acceptable to us to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">fund continuing operations, if at all. The perception that we might be unable to continue as a going <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">concern may also make it more difficult to obtain financing for the continuation of our operations on terms <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">that are favorable to us, or at all, and could result in the loss of confidence by investors and employees. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our financial statements do not include any adjustments that might result from the outcome of this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">uncertainty. If we are unable to continue as a going concern, we may have to liquidate our assets and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">may receive less than the value at which those assets are carried on our financial statements, and it is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">likely that our investors will lose all or a part of their investment.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">The size and expected growth of our addressable market may be smaller than we estimate.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 276pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our estimate of the addressable market for our current products and any future products is subject to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 288pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">significant uncertainty and is based on assumptions and estimates, including our internal analysis and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 300pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">industry experience. While we believe our assumptions and the data underlying our estimates are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 312pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reasonable, these assumptions and estimates may not be correct. As a result, our estimates of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 324pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">addressable market for our current or future products may prove to be incorrect. Moreover, our ability to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 336pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">serve a significant portion of this estimated market is subject to many factors, including our success in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 348pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">promoting the use of CCTA as a non-invasive diagnostic test that can be combined with the Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Platform, which is subject to many risks and uncertainties, and relies on the availability and proximity of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">healthcare facilities with active CCTA programs to the patients in our estimated market. Accordingly, if we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 384pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">are unable to increase the use of CCTA at the rates we estimate, if the actual number of patients who <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">would benefit from our products is less than we estimate, or if the price at which we can sell future <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">products or the reimbursement rate received by healthcare providers is less than we estimate, the size <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and expected growth of our addressable market would be smaller than our estimates, which could have a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 432pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">material adverse effect on our business, financial condition, results of operations and prospects.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 452pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">We may not be successful in updating or otherwise enhancing the Heartflow Platform. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 472pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">A part of our strategy is bringing new enhancements to our customers through updates to the Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 484pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Platform, which may include offering new products, additional features, applications and improvements to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 496pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our technology. We expect to make significant investments to advance these efforts, and enhancing the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 508pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Heartflow Platform is a complex and time-consuming endeavor. New products, additional features, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 520pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">applications and improvements to our technology that initially show promise may fail to achieve the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 532pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">desired results or may not achieve acceptable levels of analytical accuracy, utility or user friendliness. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 544pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Product development and improvement is expensive, may take months or years to complete and can <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 556pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">have uncertain outcomes. Failure can occur at any stage of the development or improvement process <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 568pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and may occur only after substantial work has been completed, or after completion. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Even if, after development, an updated product appears successful, we may, depending on the nature of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 600pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the update, need to obtain regulatory clearances, authorizations or approvals before we can market the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">updated product. Such regulatory clearances, authorizations or approvals are likely to require significant <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">time and expenditures and the applicable regulatory authority may not clear, authorize or approve any <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 636pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">product, update or new product we develop. Obtaining such clearances, authorizations or approvals may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 648pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">require data from clinical trials, which can be costly and time-consuming to obtain. In certain jurisdictions <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or in certain cases, clinical data may also be required in order to obtain reimbursement coverage, and this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">clinical data may be in addition to data required to obtain regulatory clearances, authorizations or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 684pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">approvals. Some clinical studies may fail to meet their endpoints, introducing risk or delay in the ability to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 696pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">commercialize a new feature or product. In light of these requirements, we may choose to limit the scope <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 708pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of any new products, additional features, applications and improvements we seek to develop. <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">24<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Even if we develop a product update or new product that receives regulatory clearance, authorization or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">approval, and for which we obtain sufficient commercial third-party and government reimbursement <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">coverage, we would need to commit substantial resources to commercialize and market the updated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">product, new product or new application of our existing product, which may never achieve market <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">acceptance among various stakeholders or be commercially successful. Further, the applicable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">regulations or the application of those regulations could change in ways that would impact the Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Platform and our ability to successfully manufacture or market our products. The expenses or losses <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 156pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">associated with unsuccessful updates to or expansion of the Heartflow Platform could adversely affect our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 168pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">business, financial condition, results of operations and prospects. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">The commercialization of Heartflow Plaque Analysis is nascent, and we may not be able to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">achieve or maintain sufficient market acceptance or the levels of utilization we expect from <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow Plaque Analysis or any other future product.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We began limited market education efforts for our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 293.24pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 338.22pt; position: absolute; white-space: pre;">Plaque Analysis in the second half of 2023, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and we have generated very minimal revenue from this product. <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 356.97pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 401.95pt; position: absolute; white-space: pre;">Plaque Analysis has taken <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">time and significant resources to develop, and we may not be able to achieve customer acceptance or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">broad commercial reimbursement coverage, which could limit its adoption. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 288pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The market for alternative plaque analysis products is competitive in terms of development, availability, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 300pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">pricing, product quality and time-to-market. We face competition from companies that provide or are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 312pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">developing similar plaque analysis products, which may distinguish themselves from us through, among <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 324pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">other things, perceived product quality, style and visuals, sleek design, enhanced user-friendliness and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 336pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">innovative features. In addition, some of these competitors are agile, early-stage companies that may be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 348pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">able to respond more quickly and effectively than we can to new or changing opportunities, technologies, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">standards or customer requirements in the plaque analysis category. Some of these competitors <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">commercially launched competing plaque analysis products prior to our launch of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 432.55pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 477.53pt; position: absolute; white-space: pre;">Plaque <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 384pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Analysis and may have a first-mover advantage as a result. For more information on risks related to our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">competition, see the risk factor titled &#8220;We face significant competition in an environment of rapid <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">technological change, and there is a possibility that our competitors may develop products that are more <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">effective, accurate, reliable, cost-effective or more advanced than ours, which may harm our financial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 432pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">condition. If we are unable to compete successfully or our potential market share is reduced, we may be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 444pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">unable to increase or sustain our revenue or achieve profitability.&#8221; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 464pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our competitors may also be able to offer plaque analysis products similar or superior to ours at a more <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 476pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">attractive price than we can or may be better positioned to serve certain segments of our market, which <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 488pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">could create additional price pressure. For example, our competitors have in the past, and may in the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 500pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">future, offer plaque analysis and other products at a more attractive price than we can such that current or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 512pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">potential customers may select our competitors&#8217; products in lieu of purchasing and using our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 481.58pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 524pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Plaque Analysis. Moreover, our competitors have in the past, and may in the future, suggest that their <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 536pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">plaque analysis and other products could replace both our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 331.46pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 376.44pt; position: absolute; white-space: pre;">Plaque Analysis and our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 486.44pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 548pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 91.42pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 100.08pt; position: absolute; white-space: pre;"> Analysis, which would adversely affect our ability to achieve sufficient market acceptance for our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 560pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 116.97999999999999pt; position: absolute; white-space: pre;">Plaque Analysis, could affect sales of our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 301.2pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 346.18pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 365.6pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 374.26pt; position: absolute; white-space: pre;"> Analysis and could cause our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 572pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 116.97999999999999pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 136.4pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 145.06pt; position: absolute; white-space: pre;"> Analysis to lose market share. While we believe <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 361.11pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 406.09pt; position: absolute; white-space: pre;">Plaque Analysis represents a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 584pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">significant long-term opportunity for us, there can be no assurances that we will successfully compete in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 596pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">such market and our business, financial condition, results of operations and prospects could be materially <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 608pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and adversely affected.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 628pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">We face risks associated with our use and development of AI models, which may result in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 640pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">operational challenges, legal liability, reputational concerns and competitive risks. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We use and develop AI and automated analysis and decision-making technologies, including proprietary <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">AI algorithms and models and computational fluid dynamics (collectively, &#8220;AI Technologies&#8221;) to power the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 684pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Heartflow Platform. In addition, we use AI Technologies to drive improvements in the performance of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 696pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Heartflow Platform. We expect that significant increased investment will be required in the future to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 708pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">improve our use and development of AI Technologies. <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">25<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">As with many technological innovations, there are significant risks involved in developing, maintaining and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">deploying these technologies. In particular, if the AI Technologies underlying our Heartflow Platform are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">incorrectly designed or implemented&#59; trained or reliant on incomplete, inadequate, inaccurate or otherwise <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">poor quality data&#59; used without sufficient oversight and quality control&#59; misused or used outside of scope <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">of applicable regulatory authorizations&#59; and&#47;or adversely impacted by unforeseen bugs, defects, technical <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">challenges, cybersecurity threats or material performance issues, the performance of our Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Platform and business, as well as our reputation and the reputations of our customers, could suffer or we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 156pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">could incur liability resulting from the violation of laws or contracts to which we are a party, regulatory <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 168pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">enforcement actions or civil claims. This could result in fines, penalties and damage awards and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 180pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">disgorgement of any output, development or technology developed as a result of such violations.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition, we leverage a human-in-the-loop AI system that combines advanced algorithms with an <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">analyst-based quality inspection and monitoring process to create patient-specific reports based on CCTA <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">images. While we constantly work to improve our Heartflow Platform and algorithms, the AI Technologies <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">we work with are novel and complex, and we cannot assure you that our AI Technologies will be able to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">perform as intended under all circumstances, or that our analyst-based review process will identify and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">correct any errors in the outputs of our AI Technologies.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The regulatory framework for AI Technologies is rapidly evolving as many federal, state and foreign <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">government bodies and agencies have introduced or are currently considering additional laws, regulations <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and guidance. For example, the FDA has issued guidance documents relating to the incorporation of AI <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Technologies into medical devices and marketing submissions for AI-enabled devices. Specifically, draft <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">guidance issued on January 7, 2025, titled Artificial Intelligence-Enabled Device Software Functions&#58; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Lifecycle Management and Marketing Submission Recommendations, proposes recommendations for the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">design, development and implementation of AI-enabled devices that FDA encourages manufacturers <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 364pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">consider using throughout the total product lifecycle. In addition, the California Privacy Protection Agency <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">has approved for rulemaking regulations under the CCPA regarding the use of automated decision-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 388pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">making that may require risks and providing notice and rights to opt-out and access to information <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 400pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">underlying the logic and outputs. Colorado passed the Colorado AI Act, which will go into effect in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 412pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">February 2026. This law creates duties for developers and deployers to use reasonable care to protect <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 424pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">consumers from any known or reasonably foreseeable risks of &#8220;algorithmic discrimination&#8221; arising from <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 436pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the intended and contracted uses of &#8220;high-risk AI systems,&#8221; including those that impact healthcare <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 448pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">services. Such additional laws, regulations and guidance may impact our ability to develop, use and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 460pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">commercialize AI Technologies in the future. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">It is possible that further new laws and regulations will be adopted in the United States and in other non-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 492pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">U.S. jurisdictions, or that existing laws and regulations, including competition and antitrust laws, may be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 504pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">interpreted in ways that would limit our ability to use AI Technologies for our business, or require us to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 516pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">change the way we use AI Technologies in a manner that negatively affects the performance of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 528pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Heartflow Platform and the way in which we use AI Technologies. We may need to expend resources to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">adjust our&#160;Heartflow Platform in certain jurisdictions if the laws, regulations or decisions are not consistent <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">across jurisdictions. Further, the cost to comply with such laws, regulations or decisions and&#47;or guidance <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">interpreting existing laws, could be significant and would increase our operating expenses (such as by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">imposing additional reporting obligations regarding our use of AI Technologies). Such an increase in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">operating expenses, as well as any actual or perceived failure to comply with such laws and regulations, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 600pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">could materially and adversely affect our business, financial condition, results of operations and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prospects.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 632pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Our Heartflow Platform and the data and models it generates could have bugs, defects or errors, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">including human quality control errors, or otherwise fail to meet the expectations of patients, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">physicians and third-party payors, which could adversely affect our reputation, business and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 668pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">operating results.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 688pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We cannot provide assurance that the proprietary technology and algorithms used in our Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 700pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Platform do not contain undetected bugs, defects or errors or that our analyst-based review process will <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">26<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">identify and correct any errors in the outputs of our AI Technologies. We cannot provide assurance that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">limitations of the inbound CCTA images and image quality will always allow a true representation of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">patient anatomy, and any such limitations in CCTA images could affect the results of our analyses. We <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">have in the past, and may in the future, experience defects or errors in our Heartflow Platform or the data <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and models it generates that remain undetected by our analyst-based review process, our reputation, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">business and operating results could be adversely affected.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Furthermore, the success of the Heartflow Platform depends in part on patients&#8217;, physicians&#8217; and third-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">party payors&#8217; confidence that our platform can provide reliable, high-quality actionable data and analysis <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">that will improve clinical decision making. We believe that patients, physicians and third-party payors are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">likely to be sensitive to product defects and errors in the use of our products, including if the defects and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">errors affect a physician&#8217;s ability to use the CCTA imaging results or result in a misdiagnosis. As a result, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the failure of our Heartflow Platform to perform as expected, including to reduce unnecessary invasive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">testing or fail to enable physicians to optimize treatment planning or provide more efficient care, could <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">significantly impact a physician&#8217;s willingness to use and rely on the Heartflow Platform, which would <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">impair our operating results and our reputation. In addition, we may be subject to legal claims arising from <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">any such failures.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Bugs, defects or errors in the Heartflow Platform or the failure of third-party service providers we rely on, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">such as AWS or other cloud storage and telecommunications services providers, to block a virus or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prevent a security breach could harm our reputation and adversely impact our results of operations. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Defects may cause our products to be vulnerable to security attacks, cause them to fail to produce <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">accurate results or temporarily interrupt our commercial operations. Because the techniques used by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">computer hackers to access or sabotage networks change frequently and generally are not recognized <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">until launched against a target, we or our third party services providers may be unable to anticipate these <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 364pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">techniques and provide a corrective measure in time to protect the Heartflow Platform and our networks. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Potential defects may further cause the platform to be unavailable for a period of time, affect ability of a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 388pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">customer to access information, result in a slow or suboptimal user experience, impact turnaround time of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 400pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">an analysis, or provide other forms of degradation to the overall service. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">We depend on our talent to grow and operate our business, and if we are unable to hire, integrate, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 432pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">develop, motivate and retain our personnel, including highly qualified, technical personnel, we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 444pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">may not be able to grow effectively and this could adversely affect our business.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 464pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">To execute our growth plan, we must attract and retain highly qualified, technical personnel. Competition <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 476pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for these personnel is intense, especially for engineers with high levels of expertise in AI, cloud <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 488pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">architecture, 3D visualization, research scientists and senior sales executives with experience in the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 500pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">cardiology industry. We may experience difficulty in hiring and retaining employees with appropriate <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 512pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">qualifications. Many of the companies with which we compete for experienced personnel have greater <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 524pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">resources than we have. We also compete with companies that are believed to have high potential growth <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 536pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">opportunities or that have experienced rapid recent growth. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 556pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our future success depends in part on our ability to continue to retain our executive officers and other key <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 568pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">employees and to recruit and hire new employees, including engineers, research scientists, case analysts <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 580pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and production team members. We do not maintain &#8220;key person&#8221; insurance for any of our executives or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 592pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">other employees. The loss of the services of any of these persons could impede the achievement of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 604pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">development, research and commercialization objectives. Any of our executive officers and other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 616pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">employees may terminate employment with us at any time with no advance notice. The replacement of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 628pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">any of our key personnel likely would involve significant time and costs, may significantly delay or prevent <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 640pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the achievement of our business objectives and may harm our business. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition, job candidates and existing employees often consider the value of the stock awards they <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">receive in connection with their employment. If the perceived value of our stock awards declines or is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 684pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">perceived to be less valuable than stock awards of other competing employers, it may adversely affect <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 696pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our ability to recruit and retain highly skilled employees. In addition, many of our employees have become <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 708pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or will soon become vested in a substantial amount of stock or number of stock options. Our employees <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">27<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">may be more likely to leave us if the shares they own or the shares underlying their vested options have <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">significantly appreciated in value relative to the original purchase prices of the shares or the exercise <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prices of the options, or if the exercise prices of the options that they hold are significantly below the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">market price of our common stock. If we fail to attract new personnel, or fail to retain and motivate our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">current personnel, our business and prospects could be adversely affected.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">If we fail to properly manage our future growth, our business could suffer.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 160pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We intend to continue to grow and may experience periods of rapid growth and expansion, which could <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 172pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">place a significant additional strain on our limited personnel, information technology systems and other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 184pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">resources. Our future growth will impose significant added responsibilities on management, including the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 196pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">need to identify, recruit, train and integrate additional employees. In order to manage our operations and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 208pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">growth we will need to continue to improve our operational and management controls, administrative and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">operational infrastructure, reporting and information technology systems and financial internal control <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">procedures. Due to our limited financial resources and the limited experience of our management team in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">managing a company with such future growth expectations, we may not be able to effectively manage the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">expected expansion of our operations or recruit and train additional qualified personnel. Moreover, the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">expected expansion of our operations may lead to significant costs and may divert our management and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">business development resources. Any inability to manage growth could delay the execution of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">business plans or disrupt our operations.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 312pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition, as demand for the Heartflow Platform increases, we will need to scale our capacity, expand <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 324pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">customer service and enhance our internal quality assurance program. We may fail to implement any <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 336pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">increases in scale, related improvements and quality assurance, and we may fail to find appropriate <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 348pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">personnel to facilitate the growth of our business. Due to our limited resources, we may not be able to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">effectively manage this simultaneous execution and expansion of our operations. This may result in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">weaknesses in our infrastructure, give rise to operational mistakes, legal or regulatory compliance <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 384pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">failures, loss of business opportunities, loss of employees and reduced productivity among remaining <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">employees. The expansion of our operations may lead to significant costs and may divert financial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">resources from other projects, such as the development of any new products. If our management is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">unable to effectively manage our expected development and expansion, our expenses may increase <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 432pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">more than expected, our ability to generate or increase our revenue could be reduced and we may not be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 444pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">able to implement our business strategy. Our future financial performance and our ability to compete <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 456pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">effectively and commercialize our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 222.35pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 267.33000000000004pt; position: absolute; white-space: pre;">Plaque Analysis or any of our future products will depend in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 468pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">part on our ability to effectively manage the future growth and expansion of our company. If we are unable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to manage our growth effectively, it may be difficult for us to execute our business strategy and our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 492pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">business, financial condition, results of operations and prospects may be adversely affected.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 512pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Our business could be disrupted by catastrophic events.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 532pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The occurrence of any catastrophic event, including earthquake, fire, flood, tsunami or other weather <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 544pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">event, power loss, telecommunications failure, software or hardware malfunctions, pandemics, political <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 556pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">unrest, geopolitical instability, severe or prolonged economic downturn, cyberattack (including a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 568pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">ransomware attack), war or terrorist attack, could result in lengthy interruptions in our ability to serve our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 580pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">customers. In addition, acts of terrorism could cause disruptions to the internet or the economy as a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 592pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">whole and could disproportionately affect us given our reliance on the internet and cloud-based services. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 604pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Specifically, our corporate headquarters are located in Mountain View, California and our production <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 616pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">related computers are currently located in our Mountain View office and in Austin, Texas. California is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 628pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">considered to be an active earthquake zone, is prone to catastrophic fires, severe weather events and the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 640pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">follow-on effects thereof, including tsunamis, mudslides, flooding, power outages and other events that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 652pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">could disrupt our business. Texas is also subject to severe weather events, power outages and other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 664pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">events that could disrupt our business. Any event that prevents our access to such facilities, physically or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 676pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">virtually, would prevent us from operating our business and have an adverse effect on our business, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 688pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">financial condition, results of operations and prospects. <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">28<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition, we rely on our network and third-party infrastructure, including our cloud-based infrastructure <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">which we outsource to Amazon Web Services (&#8220;AWS&#8221;), and enterprise applications, internal technology <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">systems and our website, for our development, marketing, operational support hosted services and sales <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">activities. In the event of a catastrophic event, we may be unable to continue our operations and may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">endure system interruptions, delays in our ability to generate reports and output them to physicians, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reputational harm, delays in our product development, breaches of data security and loss of critical data, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">all of which could have an adverse effect on our future operating results. If we are unable to develop <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 156pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">adequate plans to ensure that our business functions continue to operate during and after a disaster and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 168pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to execute successfully on those plans in the event of a disaster or emergency, our business would be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 180pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">harmed. Even with our disaster recovery arrangements and insurance coverage, the ability of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 192pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">customers to access and utilize our Heartflow Platform could be interrupted, or we could close critical <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 204pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">data, which would have a negative impact on our business.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition, the occurrence of a catastrophic event could impact providers of CCTAs, contrast agents for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">CCTAs or suppliers of iodinated contrast media or similar supplies that are necessary to perform CCTAs. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">For example, in 2022, the shutdown of an iodinated contrast media manufacturing facility led to a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">significant shortage of iodinated contrast media, which resulted in the cancellation or rescheduling of non-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 272pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">urgent contrast-requiring cardiac procedures and imaging. Any of these events could affect demand for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 284pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the Heartflow Platform, which could have a material adverse effect on our business, financial condition, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 296pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">results of operations and prospects. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Consolidation&#160;among healthcare providers could have an adverse effect on our business, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">financial condition, results of operations and prospects.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 348pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In the United States, there has been a trend of consolidation among healthcare providers and purchasers <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of medical technology devices, often to gain greater market power. As healthcare providers consolidate, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">they may try to use their market power to negotiate price concessions or reductions for the products and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 384pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">services they purchase and use, including our Heartflow Platform. As result, it is unknown whether such <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">purchasers will decide to stop purchasing our Heartflow Platform or demand discounts on our prices. If we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reduce our prices in response to these industry trends, our revenue would decrease, which could have a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">material adverse effect on our business, financial condition, results of operations and prospects.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 440pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">We may acquire other companies, solutions or technologies, which could divert our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 452pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">management&#8217;s attention, result in additional dilution to our stockholders and otherwise disrupt <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 464pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">our operations and adversely affect our operating results.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 484pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We may in the future seek to acquire or invest in companies, solutions or technologies that we believe <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 496pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">could complement or expand our products, enhance our technical capabilities or otherwise offer growth <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 508pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">opportunities. The pursuit of potential acquisitions or other investment opportunities may divert the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 520pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">attention of management and cause us to incur various expenses in identifying, investigating and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 532pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">pursuing suitable transactions, whether or not they are consummated. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">If we acquire any businesses, we may not be able to integrate the acquired personnel, operations and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">technologies successfully, or effectively manage the combined business following the acquisition. We also <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">may not achieve the anticipated benefits from the acquired business due to a number of factors, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">including&#58; inability to integrate or benefit from acquired technologies or services in a profitable manner&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 600pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">unanticipated costs or liabilities associated with the acquisition&#59; incurrence of acquisition related costs&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">difficulty integrating the accounting systems, operations and personnel of the acquired business&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">difficulties and additional expenses associated with supporting legacy products and hosting infrastructure <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 636pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of the acquired business&#59; diversion of management&#8217;s attention from other business concerns&#59; use of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 648pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">resources that are needed in other parts of our business&#59; adverse effects to our existing business <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">relationships with business partners and customers as a result of the acquisition&#59; the potential loss of key <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">employees&#59; and use of substantial portions of our available cash to consummate the acquisition.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 692pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition, a significant portion of the purchase price of any companies, solutions or technologies that we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 704pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">may acquire may be allocated to acquired goodwill and other intangible assets, which must be assessed <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">29<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for impairment at least annually. If our acquisitions do not yield expected returns, we may be required to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">take charges to our operating results based on this impairment assessment process, which could <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">adversely affect our results of operations.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Acquisitions could also result in dilutive issuances of equity securities or the incurrence of debt, which <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">could adversely affect our operating results and cause the market price of our common stock to decline. If <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">an acquired company, solution or technology fails to meet our expectations and does not complement or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">expand our products, enhance our technical capabilities or otherwise offer growth opportunities, our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">business, financial condition, results of operations and prospects may suffer. In addition, the 2024 Credit <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Agreement restricts our ability to pursue certain mergers, acquisitions, amalgamations or consolidations <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">that we may believe to be in our best interest.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 208pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Sales to customers outside the United States or with international operations expose us to risks <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">inherent in international sales.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 240pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In our fiscal years ended December 31, 2023 and 2024, sales to customers outside the United States <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 252pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">accounted for approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of our revenue, respectively. One element of our growth <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 264pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">strategy is to further expand our international operations and worldwide customer base. Operating in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 276pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">international markets requires significant resources and management attention and subjects us to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 288pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">regulatory, economic and political risks that are different from those in the United States.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We have limited operating experience in international markets, and we cannot assure you that our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 320pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">existing presence in the United Kingdom, Europe and Japan or any expansion efforts into other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 332pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">international markets will be successful. Our experience in the United States and international markets <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 344pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">may not be relevant to our ability to expand in other markets. Our international expansion efforts may not <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 356pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">be successful in creating further demand for our products outside of the United States or in effectively <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 368pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">selling our products in the international markets we enter. In addition, expansion into other international <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 380pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">markets will be costly and will impose additional burdens on our executive and administrative personnel, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 392pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">finance and legal teams, sales and marketing teams and general managerial resources. If our efforts to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 404pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">introduce our products into other international markets are not successful, we may have expended <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 416pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">significant resources without realizing the expected benefit. Ultimately, the investment required for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 428pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">international expansion could exceed the results of operations generated from this expansion.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 448pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition, we operate in an industry which is subject to significant enforcement scrutiny by both U.S. and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 460pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">non-U.S. government authorities. Our international business requires us to comply with U.S. and foreign <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 472pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">laws and regulations, such as various anti-bribery and anti-corruption laws, including the U.S. Foreign <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 484pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Corrupt Practices Act (&#8220;FCPA&#8221;), the U.S. Fraud Act and in certain cases the U.K. Bribery Act of 2010. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 496pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Compliance with these is costly and exposes us to significant civil and criminal penalties for non-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 508pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">compliance. Any failure to comply with applicable legal and regulatory obligations could impact us in a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 520pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">variety of ways that include, but are not limited to, significant criminal, civil and administrative fines, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 532pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">penalties and disgorgement of profits, including imprisonment of individuals, denial of export privileges, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 544pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">seizure of shipments, restrictions on certain business activities and exclusion or debarment from <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 556pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">government contracting. Our international operations expose us to risks inherent in operating in foreign <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 568pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">jurisdictions that could adversely affect our business.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">If we do not obtain and maintain international regulatory registrations, clearances or approvals for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 600pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">our Heartflow Platform, we will be unable to market and sell our products outside of the United <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">States.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 632pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Any future sales of our products outside of the United States are subject to foreign regulatory <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">requirements that vary widely from country to country. While the regulations of some countries may not <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">impose barriers to marketing and selling our products or only require notification, others require that we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 668pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">obtain the clearance or approval of a specified regulatory authority or a Certificate of Conformity of a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 680pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">notified body. Complying with foreign regulatory requirements, including obtaining registrations, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 692pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">clearances or approvals, can be expensive and time consuming and we may not receive regulatory <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 704pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">clearances or approvals in each country in which we plan to market our products or we may be unable to <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">30<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">do so on a timely basis. The time required to obtain registrations, clearances or approvals, if required by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">other countries, may be longer than that required for FDA clearance or approval, and requirements for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">such registrations, clearances or approvals may significantly differ from FDA requirements. If we modify <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our products, we may need to apply for regulatory clearances or approvals before we are permitted to sell <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the modified product.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition, AI governing regulations around medical devices evolve rapidly and we may not continue to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">meet the quality and safety standards required to maintain the authorizations that we have received. If we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">are unable to maintain our authorizations in a particular country, we will no longer be able to sell the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">applicable product in that country.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 196pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Regulatory registration, clearance, marketing authorization, or approval by the FDA does not ensure <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 208pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">registration, clearance, marketing authorization, or approval by foreign regulatory authorities or authorized <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">representatives in other countries. Registration, clearance, marketing authorization, or approval by one or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">more foreign regulatory authorities or authorized representatives do not ensure registration, clearance, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">marketing authorization, or approval by regulatory authorities in other foreign countries or by the FDA. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">However, a failure or delay in obtaining registration or regulatory clearance or approval in one country <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">may have a negative effect on the regulatory process in others.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 288pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Risks related to data privacy and information technology<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 310.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Failure to comply with laws and regulations affecting the transmission, security and privacy of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 322.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">health information could result in significant penalties.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 342.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Federal, state and foreign government bodies and authorities have adopted, are considering adopting, or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 354.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">may adopt laws and regulations regarding the collection, use, processing, storage and disclosure of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 366.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">personal information obtained from consumers and individuals. Numerous federal and state laws and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 378.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">regulations, including the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 390.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;), <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 402.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">govern the collection, dissemination, security, use and confidentiality of patient identifiable health <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 414.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">information. HIPAA and the HITECH Act require us to comply with standards for the use and disclosure of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 426.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">health information within our company and with third-parties. The Standards for Privacy of Individually <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 438.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Identifiable Health Information (&#8220;Privacy Standards&#8221;), and the Security Standards for the Protection of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 450.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Electronic Protected Health Information (&#8220;Security Standards&#8221;), under HIPAA establish a set of basic <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 462.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">national privacy and security standards for the protection of individually identifiable health information by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 474.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">health plans, healthcare clearinghouses and certain healthcare providers, referred to as covered entities, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 486.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and the business associates with whom such covered entities contract for services. As a result, both <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 498.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">covered entities and business associates can be subject to significant civil and criminal penalties for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 510.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">failure to comply with the Privacy Standards or the Security Standards.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 530.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">HIPAA, the HITECH Act and the Affordable Care Act (&#8220;ACA&#8221;) also include standards for common <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 542.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">healthcare electronic transactions and code sets, such as claims information, plan eligibility, payment <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 554.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">information and the use of electronic signatures, unique identifiers, operating rules. Companies that bill <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 566.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">payors for healthcare-related services and device use are required to conform to the transaction <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 578.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">standards. CMS, on behalf of HHS, has the authority to investigate complaints and audit for compliance <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 590.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">with the HIPAA standards for transactions, code sets, unique identifiers and operating rules, including the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 602.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Administrative Simplification provisions of HIPAA and the ACA. Failure to comply with these standards, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 614.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and any investigation or audit and penalties imposed may have an adverse impact on our business. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 626.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">HIPAA requires covered entities and business associates to develop and maintain policies and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 638.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">procedures with respect to protected health information that is used or disclosed, including the adoption of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 650.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">administrative, physical and technical safeguards to protect such information. The HITECH Act expands <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 662.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the notification requirement for breaches of patient identifiable health information, restricts certain <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 674.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">disclosures and sales of patient identifiable health information and provides a tiered system for civil <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 686.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">monetary penalties for HIPAA violations. The Final HIPAA Omnibus Rule modifies the breach reporting <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 698.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">standard in a manner that will likely make more data security incidents qualify as reportable breaches. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 710.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The HITECH Act also increased the civil and criminal penalties that may be imposed against covered <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">31<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">entities, business associates and possibly other persons and gave state attorneys general new authority <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">attorney fees and costs associated with pursuing federal civil actions. Additionally, states have adopted <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">comparable privacy and security laws and regulations that differ somewhat from federal and other states&#8217; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">laws, and that govern where more stringent than federal law.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">As a business associate under HIPAA, if we do not comply with the requirements of HIPAA, the HITECH <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Act or applicable state privacy and security laws, we could be subject to criminal or civil sanctions that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">could adversely affect our financial condition. The costs of complying with privacy and security related <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">legal and regulatory requirements are substantial and could have an adverse effect on our business. In <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">addition, we are unable to predict what changes to the HIPAA Privacy Standards and Security Standards <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">might be made in the future or how those changes could affect our business. Any new legislation or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">regulation in the area of privacy and security of personal information, including personal health <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">information, could also adversely affect our business operations. In addition, a security breach could <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">require reporting to federal and state government entities, notification to affected individuals, expensive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">investigation and remediation and mitigation. Government agencies could, in their discretion, impose fines <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and penalties relating to the breach, that would have an adverse effect on our business.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Foreign data privacy regulations, such as the General Data Protection Regulation (E.U.) 2016&#47;679 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(&#8220;GDPR&#8221;), the European Union&#8217;s Data Protection Directive (Directive 95&#47;46&#47;EC), and the country specific <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">regulations that implement Directive 95&#47;46&#47;EC, also govern the processing of personally identifiable data, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and a number of these regulations are stricter than U.S. laws.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 336pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition, many states have laws, regulations and other authorities that govern data privacy, security <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 348pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and breach notification. While some of these laws exempt protected health information subject to HIPAA, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">they may apply to other personal information we collect, including personal information collected from <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">employees or from visitors to our website. Failure to comply with these authorities may have an adverse <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 384pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">impact on our business.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 404pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We expect to expend significant resources to comply with these laws and regulations. The functional and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 416pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">operational requirements and costs of compliance with such laws and regulations may adversely impact <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 428pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our business, and failure to enable our solutions to comply with such laws and regulations could lead to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 440pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">significant fines and penalties imposed by regulators, as well as claims, lawsuits and contractual <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 452pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">indemnification obligations by or for our customers or third-parties and significant reputational harm. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 472pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">We depend on our information technology systems, and any failure of these systems could harm <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 484pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">our business and adversely affect our business and operating results.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 504pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Information technology and telecommunications systems are vulnerable to damage from a variety of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 516pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">sources, including telecommunications or network failures, failures during the processes of upgrading or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 528pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">replacing software, power outages, hardware failures, user or human errors and natural disasters. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Moreover, despite network security and back up measures, some of our servers are potentially vulnerable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to cybersecurity incidents, including phishing attacks by computer hackers or other malicious human acts, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">computer viruses, ransomware, malware and similar disruptive problems or other methods of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">compromising employee or customer administrator credentials to access protected health information and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our internal data. Failures or significant downtime of our information technology or telecommunications <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 600pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">systems could prevent us from operating our business. Any disruption or loss of information technology or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">telecommunications systems on which critical aspects of our operations depend could have an adverse <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">effect on our business and our operating results may suffer.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition, our brand, reputation and ability to attract, retain and serve our customers are dependent <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">upon the reliable performance of our Heartflow Platform, including our underlying information technology <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 668pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">systems and infrastructure. Our technical infrastructure may not be adequately designed with sufficient <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 680pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reliability and redundancy to avoid performance delays or outages that could be harmful to our business. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 692pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">If our Heartflow Platform is unavailable when physicians attempt to access it, or if it does not load as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 704pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">quickly as they expect, physicians may not use our Heartflow Platform as often in the future, or at all. As <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">32<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our customer base continues to grow, we will need an increasing amount of technical infrastructure, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">including network capacity and computing power, to continue to satisfy the needs of our users. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">We rely upon AWS to operate our cloud offering&#59; any disruption of or interference with our use of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">AWS would adversely affect our business, results of operations and financial condition.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 136pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We outsource all of our cloud-based infrastructure to AWS. Our customers need to be able to access our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 148pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">cloud-based infrastructure at any time, without interruption or degradation of performance. AWS runs its <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 160pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">own platform that we access, and we are, therefore, vulnerable to service interruptions at AWS. We may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 172pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">experience interruptions, delays and outages in service and availability from time to time as a result of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 184pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">problems with our AWS provided infrastructure. For example, in September 2015, AWS suffered a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 196pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">significant outage that had a widespread impact on cloud-based software and services companies. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 208pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Although our customers were not affected by that outage, a similar outage could render our cloud offering <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">inaccessible to customers. Additionally, AWS has suffered outages at specific customer locations in the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">past, rendering the customer unable to access our offering for periods of time. Lack of availability of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">AWS infrastructure could be due to a number of potential causes including technical failures, natural <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">disasters, fraud or security attacks that we cannot predict or prevent. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 276pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition, if the security of the AWS infrastructure is compromised or believed to have been <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 288pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">compromised, our business, results of operations and financial condition could be adversely affected. It is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 300pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">possible that our customers and potential customers would hold us accountable for any breach of security <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 312pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">affecting the AWS infrastructure and we may incur significant liability from those customers and from third-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 324pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">parties with respect to any breach affecting AWS systems. For more information, see the risk factor titled <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 336pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">&#8220;Failure to comply with laws and regulations affecting the transmission, security and privacy of health <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 348pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">information could result in significant penalties.&#8221; Because our agreement with AWS limits AWS&#8217; liability for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">damages, we may not be able to recover a material portion of our liabilities to our customers and third-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">parties from AWS. Customers and potential customers may refuse to do business with us because of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 384pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">perceived or actual failure of our cloud offering as hosted by AWS and our operating results could be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">harmed.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 416pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our agreement with AWS allows AWS to terminate the agreement by providing 30 days&#8217; advance notice, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 428pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and allows AWS to terminate in case of a material breach of contract if such breach is uncured for 30 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 440pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">days following receipt of notice of such breach, or to terminate immediately upon notice to us (i) if AWS <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 452pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">has the right to suspend our account&#59; (ii) if AWS&#8217; relationship with a third-party software or technology <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 464pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">provider terminates, expires or requires AWS to change the way it provides its services&#59; or (iii) in order to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 476pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">comply with the law or requests of governmental entities. Although we expect that we could receive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 488pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">similar services from other third-parties, if any of our arrangements with AWS are terminated, we could <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 500pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">experience interruptions on our platform and in our ability to make our platform available to customers, as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 512pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">well as delays and additional expenses in arranging alternative cloud infrastructure services.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 532pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">If we fail to offer high quality customer support, our business and reputation could suffer.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our customers rely on our customer support teams to resolve technical and operational issues if and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">when they arise. We may be unable to respond quickly enough to accommodate short-term increases in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">customer demand for customer support. We also may be unable to modify the nature, scope and delivery <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of our customer support to compete with changes in customer support services provided by our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 600pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">competitors or to adapt to product and industry developments. Increased customer demand for customer <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">support, without corresponding revenue, could increase costs and harm our results of operations. In <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">addition, as we continue to grow our operations and reach a large global customer base, we need to be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 636pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">able to provide efficient customer support that meets our customers&#8217; needs globally at scale. The number <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 648pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of our customers has grown significantly, and that growth has and will continue to put additional pressure <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">on our support organization. As our business scales, we may need to engage third-party customer <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">support service providers, which could negatively impact the quality of our customer support if such third-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 684pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">parties are unable to provide customer support that is as effective as that we provide ourselves. Our sales <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 696pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">are highly dependent on our business reputation and on positive recommendations from our existing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 708pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">customers. Accordingly, high quality customer support is important for the renewal and expansion of our <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">33<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">agreements with existing customers and any failure to maintain such standards of customer support, or a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">market perception that we do not maintain high quality customer support, could harm our reputation, our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">ability to sell product to existing and prospective customers and our business, financial condition, results <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of operations and prospects.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">We invest significantly in research and development, and to the extent our research and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">development investments do not translate into new products, features or improvements to our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">current products, or if we do not use those investments efficiently, our business, financial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">condition, results of operations and prospects would be harmed.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 184pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">A key element of our strategy is to invest significantly in our research and development efforts to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 196pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">introduce new products, features and improvements aimed at increasing the value proposition of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 208pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Heartflow Platform for our customers. For the years ended December 31, 2023 and 2024, our research <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and development expenses were 41.2% and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of our revenue, respectively. If we do not spend our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">research and development budget efficiently or effectively on compelling innovation and technologies, our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">business may be harmed and we may not realize the expected benefits of our strategy. Moreover, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">research and development projects can be technically challenging and expensive. The nature of these <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">research and development cycles may cause us to experience delays between the time we incur <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">expenses associated with research and development and the time we are able to offer compelling <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">solutions and generate revenue, if any, from such investment. For example, investments made to expand <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the Heartflow Platform to asymptomatic patients may be expensive, technically challenging, experience <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">delays and may not be successful. Additionally, anticipated customer demand for a product or feature we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">are developing could decrease after the development cycle has commenced, and we would nonetheless <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">be unable to avoid substantial costs associated with the development of any such product or features. If <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">we expend a significant amount of resources on research and development and our efforts do not lead to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 364pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the successful introduction or improvement of products or features that are competitive in our current or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">future markets, it would harm our business, financial condition, results of operations and prospects.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Our networks and those of our third-party service providers may become the target of bad actors <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">or security breaches that we cannot anticipate or successfully defend, which could have an <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">adverse impact on our business.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 440pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Heartflow Platform involves the storage and transmission of our customers&#8217; personal information or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 452pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">identifying information of their patients. Increasingly, we and other companies are subject to a wide variety <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 464pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of attacks on their networks on an ongoing basis. In addition to attacks from traditional computer <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 476pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">&#8220;hackers,&#8221; malicious code (such as viruses and worms), employee theft or misuse, ransomware attacks <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 488pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and denial of service attacks, sophisticated nation state and nation state supported actors now engage in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 500pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">intrusions and attacks (including advanced persistent threat intrusions), and add to the risks to our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 512pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">internal networks and the information they store and process. Additionally, such bad actors frequently <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 524pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">attempt to fraudulently induce employees or customers into disclosing sensitive information such as user <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 536pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">names, passwords or other information in order to gain access to our customers&#8217; data, their patient&#8217;s data <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 548pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or our data, including our intellectual property and other confidential business information, or our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 560pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">information technology systems. Because techniques used to obtain unauthorized access or to sabotage <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 572pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">systems change frequently and generally are not recognized until successfully launched against a target, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 584pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">we may be unable to anticipate these techniques or to implement adequate preventative measures. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 596pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Despite significant efforts to create process and security barriers to such threats, it is virtually impossible <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 608pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for us to entirely mitigate these risks. Any such breach could compromise our networks, creating system <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 620pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">disruptions or slowdowns and exploiting security vulnerabilities of our products, and the information stored <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 632pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">on our networks could be accessed, publicly disclosed, lost or stolen, which could subject us to liability <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and cause us significant financial harm. Such breaches often result in reputational damage, negative <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">publicity, loss of industry data security certifications, customers and sales, increased costs to remedy any <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 668pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">problem, costly litigation and contractual indemnification obligations by or for impacted customers or third-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 680pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">parties any of which could adversely affect our business. In addition, although we have, and intend to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 692pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">maintain, insurance with respect to any such indemnification obligations, the coverage limits of our <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">34<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">insurance policies may not be adequate and one or more successful claims brought against us may have <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">an adverse effect on our business, financial condition, results of operations and prospects.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We also rely on third-party service providers, such as cloud storage and telecommunications services <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">providers. Such service providers are also potentially vulnerable to cybersecurity incidents that could <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">result in the interruption of their services to us or unauthorized access, use or disclosure of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">confidential information and confidential information of our customers and protected health information of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">their patients. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 172pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our products are also targets for malicious cybersecurity acts. While some of our products contain <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 184pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">encryption or security algorithms to protect third-party content or patient information or other data stored <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 196pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">in our products, these products could still be hacked or targeted by malicious software programs or other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 208pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">attacks or the encryption schemes could be compromised, breached or circumvented by motivated or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">sophisticated hackers, which could harm our business and our reputation. In addition, see the risk factor <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">titled &#8220;Our Heartflow Platform and the data and models it generates could have bugs, defects or errors, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">including human quality control errors, or otherwise fail to meet the expectations of patients, physicians <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and third-party payors, which could adversely affect our reputation, business and operating results&#8221; for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">more information on bugs, defects or errors in the Heartflow Platform. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 288pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Risks related to legal and regulatory matters<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 310.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">We face extensive, regulatory requirements to bring our products to market, and our failure to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 322.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">receive and maintain regulatory clearances or approvals of our current and future products in the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 334.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">United States or abroad or to comply with medical device regulatory requirements could <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 346.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">adversely affect our business.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 366.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In order to market any product, we must establish and comply with numerous and varying regulatory <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 378.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">requirements that vary by country and by region within certain countries. Approval, clearance or marketing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 390.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">authorization in the United States by the FDA or by a regulatory authority or other body in another country <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 402.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">does not ensure approval by the regulatory authorities in other countries or jurisdictions or ensure <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 414.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">approval, clearance or other marketing authorization for the same conditions of use. Approval processes <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 426.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">vary among countries and can involve additional product testing and validation and additional <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 438.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">administrative review periods. In general, unless an exemption applies, in the U.S. current and future <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 450.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">versions of our products must receive pre-market notification (&#8220;510(k)&#8221;), de novo classification (&#8220;de novo&#8221;) <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 462.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or pre-market approval (&#8220;PMA&#8221;) from the FDA before they can be marketed in the United States. We <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 474.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">cannot provide assurance that any of our future products, to the extent required, will be cleared, approved <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 486.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or otherwise authorized by the FDA through any of its pre-market review processes, or that the FDA will <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 498.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">provide export certificates that are necessary to export certain products to certain countries. In addition, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 510.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the national health or social security organizations of certain foreign countries, including those outside <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 522.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Europe, require our products to be qualified before they can be marketed in those countries. Failure to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 534.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">receive, or delays in the receipt of, relevant foreign qualifications in the European Economic Area or other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 546.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">foreign countries could have an adverse effect on our business.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 566.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Pre-market notification, de novo classification request or PMA applications may require support by data <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 578.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">from clinical trials. We are subject to requirements to publicly register and report the results of our clinical <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 590.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">trials. We must also abide by good clinical practice (&#8220;GCP&#8221;) requirements in the conduct and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 602.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">documentation of our clinical trials and report to the FDA significant financial interests of investigators in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 614.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">any clinical trials we submit to support marketing applications for our products. We, the FDA or an <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 626.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">institutional review board (&#8220;IRB&#8221;), may suspend or terminate clinical trials at any time on various grounds, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 638.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">including a finding that patients are being exposed to an unacceptable health risk or that the treatment <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 650.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">does not have any effect. If the FDA considers data from our clinical trials to be actually or potentially <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 662.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">biased due to investigators&#8217; financial interests, or unreliable due to GCP noncompliance, it can require us <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 674.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to implement extensive data analyses or other corrective actions, or exclude data from consideration in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 686.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">support of our marketing applications. These outcomes could result in delay or denial of FDA clearance or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 698.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">approval and could result in the need to conduct additional, costly and time-consuming clinical trials. <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">35<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Additionally, we are required to obtain pre-market clearance or approval to market significantly modified <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">versions of our currently cleared Heartflow Platform, as well as to market the existing product for new <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">indications. The FDA requires us to make and document a determination as to whether or not a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">modification requires a new 510(k) clearance, de novo classification or PMA approval&#59; however, the FDA <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">can review and disagree with our decision. Although we have received 510(k) clearance from the FDA for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the current version of the Heartflow Platform, we may not be successful in receiving clearances, de novo <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">classifications or approvals in the future or the FDA may not agree with our decisions not to seek <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 156pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">clearances, de novo classifications or approvals for any new products or particular product modifications <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 168pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or updates. The FDA may require us to obtain a new 510(k) clearance, de novo classifications or approval <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 180pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for any past or future modification or a new indication for our existing products. Such submissions may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 192pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">require the development and submission of additional data, may be time consuming and costly, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 204pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">ultimately may not be cleared or approved by the FDA.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">If the FDA requires us to obtain pre-market clearances, de novo classifications or approvals for any <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">marketed modification to a previously cleared version of the Heartflow Platform, we may be required to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">cease manufacturing and marketing of the modified product or to recall the modified product until we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">obtain such FDA marketing authorization. The FDA may not clear, grant or approve such submissions in a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 272pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">timely manner, if at all. The FDA also may change its policies, adopt additional regulations, or revise <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 284pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">existing regulations, each of which could prevent or delay pre-market clearance, de novo classification or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 296pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">approval of our devices, or could impact our ability to market a device that was previously cleared. Any of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the foregoing could adversely impact our business and financial condition.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition, the FDA and other comparable foreign regulatory authorities may delay, limit or deny <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">clearance, de novo classification or approval of future versions of or future indications for our products or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">any other potential product for many reasons, including, among others&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the results of our clinical trials may not meet the level of statistically significant and clinically <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 384pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">meaningful efficacy with an acceptable safety profile as required by FDA, or other comparable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">regulatory authorities in other countries, for marketing approval&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 416pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the FDA or other comparable regulatory authorities in other countries may disagree with the number, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 428pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">design, size, conduct or implementation of our clinical trials&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 448pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the FDA or other comparable regulatory authorities in other countries may disagree with our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 460pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">interpretation of data from our clinical trials&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the FDA or other comparable regulatory authorities in other countries may not accept data generated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 492pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">at one or more of our clinical trial sites&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 512pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">if our 510(k) notifications, de novo classification requests, PMA applications, or similar notifications or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 524pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">applications, if and when submitted, are reviewed by the FDA or other comparable regulatory <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 536pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">authorities, as applicable, the regulatory authorities may have difficulties scheduling the necessary <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 548pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">review meetings in a timely manner, or may recommend against clearance or approval of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 560pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">application&#59; or<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 580pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the FDA may determine that our 510(k) notifications for new indications, if and when submitted, must <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 592pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">follow a different regulatory pathway than we have attempted, and there may be potentially extended <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 604pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">standards, timelines, reviews (such as by an FDA Advisory Committee) and costs in order to pursue <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 616pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">approval. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 636pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Any of these factors, many of which are beyond our control, could jeopardize our ability to obtain <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 648pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">regulatory clearance, de novo classification or approval for current or future versions of the Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Platform and could result in difficulties and costs for us. If we fail to comply with regulatory requirements in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">international markets or to obtain and maintain required marketing authorizations, or if marketing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 684pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">authorizations in international markets are delayed, our ability to realize the full market potential of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 696pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">product candidates will be limited.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">36<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Healthcare policy changes, including recently enacted legislation reforming the U.S. healthcare <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">system could have an adverse effect on our business, financial condition, results of operations <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">and prospects. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In the United States, there have been and continue to be a number of legislative and regulatory initiatives <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to contain healthcare costs. Federal and state lawmakers regularly propose and, at times, enact <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">legislation that would result in significant changes to the U.S. healthcare system, some of which are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">intended to contain or reduce the costs of medical products and services, including our own products. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Current and future legislative proposals to further reform healthcare or reduce healthcare costs may limit <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">coverage of or lower reimbursement for the diagnostic tests associated with the use of our products. The <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">cost containment measures that payors and providers are instituting and the effect of any healthcare <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reform initiative implemented in the future could impact our revenue from the sale of our products.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We expect additional state and federal healthcare policies and reform measures to be adopted in the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">future, particularly in light of the recent changes in the White House and Congress, any of which could <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">limit reimbursement for healthcare products and services or otherwise result in reduced demand for our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">products or additional pricing pressure and have a material adverse effect on our industry generally and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">on our customers. We cannot predict what other healthcare programs and regulations will ultimately be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">implemented at the federal or state level or whether any future legislation or regulation in the United <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">States may negatively affect our business, financial condition, results of operations and prospects. The <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">continuing efforts of the government, insurance companies, managed care organizations and other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">payors of healthcare services to contain or reduce costs of healthcare may adversely affect our ability to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">set a price that we believe is fair for our products, our ability to generate revenue and achieve or maintain <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">profitability and the availability of capital.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Any changes of, or uncertainty with respect to, future coverage or reimbursement rates could affect <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">demand for our products, which may prevent us from being able to generate additional revenue or attain <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 384pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">profitability.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 404pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">We are subject to many laws and governmental regulations affecting our marketed products, both <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 416pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">domestically and internationally, and any adverse regulatory action may adversely affect our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 428pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">business, financial condition, results of operations and prospects.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 448pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Heartflow Platform is subject to regulation by numerous government authorities, including the FDA <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 460pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and comparable foreign authorities, after clearance or approval of current and future versions of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 472pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">product. To varying degrees, each of these authorities requires us to comply with laws and regulations <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 484pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">governing the development, design, testing, manufacture, labeling, advertising, promotion, distribution, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 496pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">import and export of our products. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 516pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We currently have ongoing responsibilities under U.S., U.K., European Economic Area, Switzerland, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 528pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Canada, Australia, Japan, Saudi Arabia, United Arab Emirates, Bahrain and Israel (registered or licensed <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">regions) regulations. We are subject to periodic inspections and audits by the FDA, notified bodies, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">authorized representatives and comparable foreign authorities to determine compliance with regulatory <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">requirements, including good manufacturing practices such as the Quality System Regulation of the FDA, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Medical Device Single Auditing Program, ISO 13485&#58;2016, and EN ISO 13485&#58;2021 concerning the EU, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">establishment registration and device listing, medical device reporting, vigilance reporting of adverse <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 600pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">events, notification of corrections, recalls, field safety corrective actions and product labeling and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">marketing. These inspections and audits can result in inspectional observations or reports, warning letters <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or other forms of enforcement action. If the FDA or comparable foreign authorities conclude, as a result of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 636pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">these inspections or audits or from any other source of information, that we are not in compliance with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 648pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">applicable laws or regulations, or that our products are ineffective or pose an unreasonable health risk, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">such authorities could ban these products, suspend or cancel our marketing authorizations, impose &#8220;stop <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">sale&#8221; and &#8220;stop import&#8221; orders, refuse to issue export certificates, detain or seize adulterated or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 684pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">misbranded products, order a recall, repair, replacement, correction or refund of such products, require us <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 696pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to conduct post-market surveillance studies or change the labeling for our products, or require us to notify <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 708pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">health professionals and others that the products present unreasonable risks of substantial harm to the <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">37<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">public health. Failure to comply with regulatory requirements may also subject us to additional <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">administrative and judicially imposed sanctions, warning letters, civil and criminal penalties, injunctions, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">interruption of manufacturing or clinical trials, total or partial suspension of production and resulting <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">adverse publicity. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Discovery of previously unknown problems with our products&#8217; design or manufacture may result in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">restrictions on the use of the Heartflow Platform, restrictions placed on us or our suppliers or withdrawal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of the existing regulatory clearance of the Heartflow Platform. The FDA or comparable foreign authorities <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">may also impose operating restrictions, enjoin and restrain violations of applicable law pertaining to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">medical devices, assess civil or criminal penalties against our officers, employees or us or recommend <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">criminal prosecution of our company. Adverse regulatory action of a certain magnitude may restrict us <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">from effectively marketing and selling our products. In addition, negative publicity or product liability <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">claims resulting from any adverse regulatory action could have an adverse effect on our business, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">financial condition, results of operations and prospects.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In many of the foreign countries in which we market our products, we are subject to extensive medical <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">device regulations that are similar to those of the FDA, including those in Europe. The regulation of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">products in Europe falls within the European Economic Area, which consists of the 27 member states of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the European Union, as well as Iceland, Liechtenstein and Norway. Only medical devices that comply with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">certain conformity requirements of the Medical Devices Regulation (E.U.) 2017&#47;745 (&#8220;MDR&#8221;) concerning <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Medical Devices, or the E.U. Medical Devices Directive, Directive 2006&#47;114&#47;EC are allowed to be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">marketed within the European Economic Area. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 336pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Foreign governmental regulations have become increasingly stringent and more extensive, and we may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 348pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">become subject to even more rigorous regulation by foreign governmental authorities in the future. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Penalties for a company&#8217;s noncompliance with foreign governmental regulation could be severe, including <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">revocation or suspension of a company&#8217;s business license and civil or criminal sanctions. In some <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 384pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">jurisdictions, such as Germany, any violation of a law related to medical devices is also considered to be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">a violation of unfair competition law. In such cases, governmental authorities, our competitors and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">business or consumer associations may then file lawsuits to prohibit us from commercializing the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Heartflow Platform in such jurisdictions. Our competitors may also sue us for damages. Any domestic or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 432pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">foreign governmental law or regulation imposed in the future may have an adverse effect on our business, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 444pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">financial condition, results of operations and prospects.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 464pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Delays in the commencement or completion of future or ongoing clinical testing could result in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 476pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">increased costs to us and delay our ability to market the Heartflow Platform for additional <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 488pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">indications. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 508pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We are currently enrolling patients for our DECIDE clinical trial to evaluate our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 418.92pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 463.9pt; position: absolute; white-space: pre;">Plaque Analysis <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 520pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">in a real-world setting. We do not know whether our DECIDE clinical trial will be completed on schedule, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 532pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or at all. The commencement or completion of clinical trials can be disrupted for a variety of reasons, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 544pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">including difficulties in&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">recruiting and enrolling patients to participate in, and investigators to conduct, a clinical trial&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 584pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">reaching agreements on acceptable terms with prospective clinical research organizations and trial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 596pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">sites&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 616pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">obtaining approval of an investigational device exemption (&#8220;IDE&#8221;), application from the FDA or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 628pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">equivalent authorization from foreign regulatory authorities, if required&#59; or<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 648pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">obtaining IRB approval to conduct a clinical trial at a prospective site.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">38<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">A clinical trial may also be suspended or terminated by us, an IRB, the FDA or other regulatory authorities <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">due to a number of factors, including&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">failure to conduct the clinical trial in accordance with regulatory requirements or in accordance with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our clinical protocols&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 136pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 148pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">in the imposition of a clinical hold&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 168pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">safety or effectiveness issues&#59; or<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">lack of adequate funding to continue the clinical trial.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 208pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition, changes in regulatory requirements and guidance may occur, and we may need to amend <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">clinical trial protocols to respond to such changes, which could impact the cost, timing or successful <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">completion of a clinical trial. If we experience delays in the commencement or completion of our clinical <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">trials, the commercial prospects for additional indications for our products will be harmed.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 264pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Interim, &#8220;top-line&#8221; and preliminary data from our clinical trials that we announce or publish from <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 276pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">time to time may change as more patient data become available and are subject to audit and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 288pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">verification procedures that could result in material changes in the final data. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">From time to time, we may publicly disclose interim, top-line or preliminary data from our clinical trials, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 320pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">including our DECIDE clinical trial, which is based on a preliminary analysis of then-available data, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 332pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the results and related findings and conclusions are subject to change following a more comprehensive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 344pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">review of the data related to the particular trial or additional data collected at a later time. We also make <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 356pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 368pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, top-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 380pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">line or preliminary results that we report may differ from future results of the same trial, or different <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 392pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">conclusions or considerations may qualify such results, once additional data have been received and fully <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 404pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">evaluated. Interim, top-line or preliminary data also remain subject to audit and verification procedures <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 416pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">that may result in the final data being materially different from the interim, top-line or preliminary data we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 428pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">previously announced. As a result, interim, top-line and preliminary data should be viewed with caution <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 440pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">until the final data are available. Adverse differences between interim data and final data could <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 452pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 464pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">could result in volatility in our share price.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 484pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Further, others, including the FDA and other regulatory authorities or other bodies, may not accept or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 496pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 508pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the importance of data differently, which could impact the value of the particular trial, or the approvability <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 520pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or potential for commercialization of the particular medical device. In addition, the information we choose <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 532pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 544pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">information, and others may not agree with what we determine is material or otherwise appropriate <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 556pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">information to include in our disclosure. The interim, top-line or preliminary data that we report may differ <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 568pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">from final results, and regulatory authorities and other bodies may disagree with the conclusions reached, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 580pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">which may harm our ability to obtain marketing authorization for, and commercialize, our future products, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 592pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">which could harm our business, financial condition, results of operations and prospects.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">We may face product liability claims that could result in costly litigation and significant liabilities. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">We may not be able to maintain adequate product liability insurance.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Development, marketing and clinical testing of our products may expose us to product liability and other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">tort claims. Although we have, and intend to maintain, liability insurance, the coverage limits of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 668pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">insurance policies may not be adequate and one or more successful claims brought against us may have <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 680pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">an adverse effect on our business, financial condition, results of operations and prospects. For example, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 692pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the U.S. Supreme Court declined to hear an appeal where the U.S. Court of Appeals for the Ninth Circuit <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 704pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">ruled that the 1976 Medical Device Amendments to the Federal Food, Drug and Cosmetic Act did not <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">39<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">preempt state laws in a product liability case involving a medical device company. If other courts in the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">United States adopt similar rulings, we may be subject to increased litigation risk in connection with our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">products. Product liability claims could negatively affect our reputation, product sales, and our ability to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">obtain and maintain regulatory approval for our products.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition, although we have product liability and clinical study liability insurance, this insurance is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">subject to deductibles and coverage limitations. Our current product liability insurance may not continue to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">be available to us on acceptable terms, if at all, and, if available, coverage may not be adequate to protect <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">us against any future product liability claims. If we are unable to obtain insurance at an acceptable cost, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">on acceptable terms with adequate coverage, or at all, or otherwise protect against potential product <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">liability claims, we will be exposed to significant liabilities, which may harm our business. A product liability <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">claim, recall or other claim with respect to uninsured liabilities or for amounts in excess of insured <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">liabilities could have an adverse effect on our reputation, business, financial condition, results of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">operations and prospects.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">The Heartflow Platform may be subject to recalls, which could be costly and could harm our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">reputation and business. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 276pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We are subject to ongoing medical device reporting regulations that require us to report to the FDA or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 288pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">similar governmental authorities in other countries if our products cause, or contribute to, death or serious <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 300pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">injury, or if they malfunction and would be likely to cause, or contribute to, death or serious injury if the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 312pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">malfunction were to recur. We could voluntarily elect to, or the FDA and similar governmental authorities <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 324pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">in other countries could require us to, perform a correction, field safety corrective action, removal or other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 336pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">recall of our products in the event of material deficiencies or defects in design, manufacturing or labeling <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 348pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">that could cause harm. Our products have been in the past, and may in the future, be the subject of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">medical device reports of adverse events with the FDA&#8217;s Manufacturer and User Facility Device <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Experience database, including reports of false negative results and incorrect or imprecise results or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 384pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">readings. A government mandated or voluntary correction, field safety corrective action, removal or other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">recall could occur as a result of manufacturing errors or design defects, including defects in labeling. Any <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">correction, field safety corrective action, removal or other recall would divert managerial and financial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">resources and could lead to a substantial loss of physician and patient confidence in our products and, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 432pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">consequently, have an adverse effect on our growth prospects or operating results. A correction, field <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 444pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">safety corrective action, removal or other recall could also result in substantial litigation, including product <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 456pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">liability claims, with liabilities well in excess of our insurance coverage limits. Any of these events could <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 468pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">have an adverse effect on our reputation, business, financial condition, results of operations and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prospects.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 500pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Off-label or other unlawful promotion of our products could result in costly investigations and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 512pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">sanctions from the FDA and other regulatory bodies.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 532pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Heartflow Platform has been cleared by the FDA, and the equivalent regulatory authorities in Israel, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 544pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Saudi Arabia, United Arab Emirates, licensed in Bahrain, CE Marked in the European Economic Area, the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 556pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">United Kingdom and Australia, received medical device licensing in Canada and been approved for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 568pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">marketing authorization in Japan by the Pharmaceuticals and Medical Devices Agency (&#8220;PMDA&#8221;), all for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 580pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">specific indications for use. We may only promote or market our products for their specifically cleared or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 592pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">approved indications. We train our marketing and sales force against promoting our products for uses <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 604pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">outside of the cleared or approved indications for use (&#8220;off-label use&#8221;).<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">If the FDA determines that our promotional materials or training constitute promotion of an off-label use, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 636pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or of claims that are not adequately substantiated or that are otherwise false or misleading, it could <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 648pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">request that we modify our training or promotional materials or subject us to regulatory or enforcement <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">actions, including the issuance of an untitled letter, a warning letter, injunction, seizure, civil fine or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">criminal penalties. It is also possible that other federal, state or foreign enforcement authorities, including <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 684pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the Federal Trade Commission or Department of Justice, might take action if they consider our business <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 696pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">activities to constitute promotion of an off-label use or other unlawful promotion, which could result in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 708pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">significant penalties, including criminal, civil and administrative penalties, damages, fines, disgorgement, <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">40<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">exclusion from participation in government healthcare programs and the curtailment of our operations. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Any of these events could significantly harm our business, results of operations, financial condition and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prospects.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Further, the advertising and promotion of our products are subject to European Economic Area Member <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">States laws implementing the Medical Devices Directive concerning misleading and comparative <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">advertising, and Directive 2005&#47;29&#47;EC on unfair commercial practices, as well as other European <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Economic Area Member State legislation governing the advertising and promotion of medical devices. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">European Economic Area Member State legislation may also restrict or impose limitations on our ability to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">advertise our products directly to the general public. In addition, voluntary E.U. and national codes of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">conduct provide guidelines on the advertising and promotion of our products to the general public and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">may impose limitations on our promotional activities with healthcare professionals harming our business, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">financial condition, results of operations and prospects.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">We are subject to numerous federal, state and foreign healthcare fraud and abuse, compliance, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">transparency and privacy laws and regulations, and a failure to comply with such laws and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">regulations could have an adverse effect on our business&#59; similarly, an investigation, inquiry or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">audit by a government agency that alleges violations of law or regulations may have an adverse <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">effect on our business. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 300pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our operations are, and will continue to be, directly and indirectly affected by various federal, state and&#47;or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 312pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">foreign healthcare laws, including those described below. In particular, because the use of our products <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 324pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">are directly or indirectly reimbursed by U.S. federal health care programs, for example Medicare, we are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 336pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">subject to the federal Anti-Kickback Statute, a criminal law that prohibits, among other things, any person <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 348pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or entity from knowingly and willfully offering, paying, soliciting or receiving any remuneration in cash or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">in-kind (including any kickback or bribe, but also common forms of remuneration, such as service or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">consulting fees, service fees, meals, travel expenses, discounts or rebates), directly or indirectly, overtly <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 384pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or covertly, in cash or in kind, in return for or to induce the referring, ordering, leasing, purchasing or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">arranging for or recommending the referring, ordering, purchasing or leasing of any good, facility, item or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">service, for which payment may be made, in whole or in part, under federal healthcare programs, such as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the Medicare and Medicaid programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 432pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">anything of value. Although there are a number of statutory exceptions and regulatory safe harbors <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 444pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">protecting certain common activities, the exceptions and safe harbors are drawn narrowly. Failure to meet <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 456pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">all of the requirements of a statutory exception or regulatory safe harbor does not make the conduct per <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 468pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">se illegal under the Anti-Kickback Statute. Instead, the arrangement will be evaluated on a case-by-case <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">basis based on a cumulative review of all of its facts and circumstances. Several courts have interpreted <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 492pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 504pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">remuneration is to induce referrals of (or purchases, uses or recommendations of prescriptions, uses or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 516pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">purchases related to) federal healthcare program covered business, the Anti-Kickback Statute has been <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 528pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">implicated and potentially violated. Our practices may not in all cases meet all of the criteria for safe <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">harbor protection from Anti-Kickback Statute liability. Further, the ACA, amends the intent requirement of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the federal Anti-Kickback Statute and certain criminal healthcare fraud statutes. A person or entity no <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">longer needs to have actual knowledge of the statute or specific intent to violate it. In addition, the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">government may assert that a claim for payment by a government health care program including items or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">services resulting from a violation of the Anti-Kickback Statute constitutes a false or fraudulent claim for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 600pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">purposes of the false claims laws.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 620pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The U.S. civil False Claims Act prohibits, among other things, any person or entity from knowingly <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 632pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">presenting, or causing to be presented, a false or fraudulent claim for payment or approval to the federal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">government or knowingly making, using, or causing to be made or used a false record or statement <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">material to a false or fraudulent claim to the federal government. A claim includes &#8220;any request or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 668pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">demand&#8221; for money or property presented to the U.S. government. The civil False Claims Act also applies <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 680pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to false submissions that cause the government to not receive a benefit to which it is entitled, such as a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 692pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">discounted sales price for products covered by federal healthcare programs. Intent to deceive is not <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 704pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">required to establish liability under the civil False Claims Act. In addition, the civil False Claims Act <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">41<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">includes a whistleblower provision that allows private citizens to bring claims on behalf of the U.S. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">government alleging violations of the law. Whistleblowers may be entitled to up to as much as thirty <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">percent (30%) of the government&#8217;s financial recovery resulting from such claims. This incentivizes <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">potential whistleblowers to file complaints in federal court, which complaints are relied upon heavily by the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">government to investigate and prosecute allegations of violations of both the civil False Claims Act and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the Anti-Kickback Statute. U.S. enforcement authorities or private whistleblowers acting on behalf of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">U.S. government may file complaints under the civil False Claims Act alleging that we have caused one or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 156pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">more of our customers to submit false submissions for reimbursement from federal health care programs, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 168pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">including Medicare, Medicaid, or the Veterans Affairs program due to alleged kickbacks, the sale of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 180pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">adulterated or misbranded products, or the provision of false or misleading information to our customers <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 192pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or other third-parties.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Additionally, under the federal Civil Money Penalty Statute, the Department of Health and Human <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Services (&#8220;HHS&#8221;) may impose civil money penalties against entities that make offers to transfer or transfer <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">remuneration, including gifts, payments or routine waivers of co-payments or deductibles, to any <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Medicare beneficiary in order to influence such individual to order or receive any item or service for which <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">payment may be made, in whole or in part, under Medicare and&#47;or a State health care program.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Violations of these laws and regulations may result in significant criminal and&#47;or civil fines and penalties, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">as well as potential exclusion from participation in federal health care programs, that could significantly <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">impact our business and operations.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 324pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We are also subject to other federal and state fraud and abuse laws, including HIPAA&#8217;s fraud provisions, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 336pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">which among other things, are criminal laws that prohibit, among other actions, knowingly and willfully <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 348pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">executing, or attempting to execute, a scheme or artifice to defraud any healthcare benefit program, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">including private payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">willfully preventing, obstructing, misleading, delaying or attempting to delay a criminal investigation of a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 384pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">healthcare offense and knowingly and willfully falsifying, concealing or covering up a material fact or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">making any materially false, fictitious or fraudulent statement or representation in connection with the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">delivery of or payment for healthcare benefits, items or services. Many of these state laws closely mirror <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the federal Anti-Kickback Statute or civil False Claims Act, but apply more broadly to products and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 432pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">services that are paid for in any way, whereas the federal law pertains only to those reimbursed by federal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 444pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">health care programs. In addition, many states have also adopted laws prohibiting fee-splitting (the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 456pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">sharing of professional fees with non-state licensed persons or entities), restricting marketing activities <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 468pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">with physicians and&#47;or prohibiting the practice of medicine (or the direction of the practice of medicine) by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">corporations or others that are not specifically licensed to practice medicine within the state. While under <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 492pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our model, licensed practitioners independently are providing any and all medical treatment and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 504pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">diagnostic services for which a state license is required, these state laws still may apply to us. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 524pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We also are subject to foreign fraud and abuse laws and regulations, which vary by country, and can <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 536pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prohibit many of the same activities addressed by U.S. laws.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 556pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We are also subject to the federal and state transparency reporting laws and regulations, gift bans and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 568pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">compliance reporting provisions. The Physician Payments Sunshine Act (also known as Open Payments) <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 580pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 592pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">under Medicare, Medicaid or the State Children&#8217;s Health Insurance Program to report annually to the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 604pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Centers for Medicare and Medicaid Services information related to payments and other transfers of value <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 616pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">provided directly or indirectly to physicians (defined to include doctors, dentists, optometrists, podiatrists <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 628pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and chiropractors), other healthcare providers (such as physician assistants and nurse practitioners) and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 640pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">teaching hospitals. Such manufacturers are also required to annually report certain ownership and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 652pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">investment interests held by such U.S. physicians and their immediate family members. Certain states, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 664pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">like Massachusetts and Vermont have similar reporting requirements. Some states, like Vermont, prohibit <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 676pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">gifts and certain benefits from being provided to physicians licensed within that state. Other states, such <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 688pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">as California and Nevada mandate implementation of compliance programs to ensure compliance with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 700pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">fraud and abuse laws and regulations, as well as with industry codes of conduct, such as the AdvaMed <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">42<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Code of Ethics on Interactions with Health Care Professionals. Our business is subject to these many <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">requirements, which can be nuanced and lacking in clear guidance. Our failure to comply with these laws <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or regulations could result in substantial fines or penalties. Further, our reports made pursuant to these <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">laws may be used by enforcement authorities or whistleblowers to raise or substantiate allegations <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">against us.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We are also subject to the federal physician self-referral prohibitions, commonly known as the Stark Law, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">which prohibits, among other things, physicians who have a financial relationship, including an <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">investment, ownership or compensation relationship with an entity that submits claims for payment to the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Medicare or Medicaid programs, from referring Medicare or Medicaid patients for certain &#8220;designated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">health services,&#8221; which include diagnostic imaging services related to our products, unless an exception <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">applies. Similarly, entities may not bill Medicare or any other party for services furnished pursuant to a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prohibited referral. Many states have their own self-referral laws as well, which in some cases apply to all <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">payors, not just Medicare and Medicaid.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">If our operations are found to be in violation of any of the laws described above or any other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">governmental regulations that apply to us now or in the future, we may be subject to significant penalties, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">including civil and criminal penalties, damages, fines, disgorgement, exclusion from governmental <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">healthcare programs and the curtailment or restructuring of our operations, any of which could adversely <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">affect our ability to operate our business and our financial results.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 312pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We also note that there is risk of our being found in violation of these laws by the fact that many of them <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 324pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">have not been fully, clearly or consistently interpreted by the regulatory authorities or the courts, and their <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 336pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 348pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">we successfully defend against it, could cause us to incur significant legal expenses and divert our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">management&#8217;s attention from the operation of our business. Moreover, to achieve compliance with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">applicable federal and state privacy, security and electronic transaction laws, we may be required to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 384pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">modify our operations with respect to the handling of patient information. Similarly, to achieve compliance <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">with other applicable federal and state anti-fraud, open payments or other healthcare regulations, we may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">be required to modify our operations. Implementing any of these modifications may prove costly. At this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">time, we are not able to determine the full consequences to us, including the total cost of compliance, of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 432pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">these various federal and state laws.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 452pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">We are subject to U.S. and foreign anti-corruption and anti-money laundering laws with respect to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 464pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">our operations and non-compliance with such laws can subject us to criminal and&#47;or civil liability <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 476pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">and harm our business.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: italic; font-weight: bold; left: 184.68pt; position: absolute; text-decoration: none; top: -2.548pt; vertical-align: super; white-space: pre;"> <font style="display: inline-block; height: 4.732pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 496pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We are subject to the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 508pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">U.S.&#160;Travel Act, the USA PATRIOT Act, the U.K. Bribery Act of 2010 and Proceeds of Crime Act 2002 and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 520pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">possibly other state and national anti-bribery and anti-money laundering laws in countries in which we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 532pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 544pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">employees and third-party intermediaries from authorizing, promising, offering or providing, directly or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 556pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">indirectly, improper payments or benefits to recipients in the public or private sector. We use third-party <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 568pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">representatives to support sales of our products abroad. In addition, as we increase our international <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 580pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">sales and business, we may engage with additional business partners and third-party intermediaries to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 592pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">sell our products abroad and to obtain necessary permits, licenses and other regulatory approvals. We or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 604pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our third-party intermediaries may have direct or indirect interactions with officials and employees of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 616pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">government agencies or state owned or affiliated entities. We can be held liable for the corrupt or other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 628pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">illegal activities of these third-party intermediaries, our employees, representatives, contractors, partners <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 640pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and agents, even if we do not explicitly authorize or have actual knowledge of such activities.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Noncompliance with anti-corruption and anti-money laundering laws could subject us to whistleblower <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">complaints, investigations, sanctions, settlements, prosecution, other enforcement actions, disgorgement <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 684pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of profits, significant fines, damages, other civil and criminal penalties or injunctions, suspension or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 696pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">debarment from contracting with certain persons, the loss of export privileges, reputational harm, adverse <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 708pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">media coverage and other collateral consequences. If any subpoenas or investigations are launched, or <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">43<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">governmental or other sanctions are imposed, or if we do not prevail in any possible civil or criminal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">litigation, our business, results of operations and financial condition could be materially harmed. In <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">addition, responding to any action will likely result in a materially significant diversion of management&#8217;s <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">attention and resources and significant defense and compliance costs and other professional fees. In <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">certain cases, enforcement authorities may even cause us to appoint an independent compliance monitor, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">which can result in added costs and administrative burdens. As a general matter, enforcement actions <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and sanctions could harm our business, financial condition, results of operations and prospects.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">We are subject to governmental export and import controls that could impair our ability to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">compete in international markets due to licensing requirements and subject us to liability if we are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">not in compliance with applicable laws. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 208pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our products are subject to export control and import laws and regulations, including the U.S. Export <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Administration Regulations, U.S. Customs regulations and various economic and trade sanctions <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Control. Exports of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our products must be made in compliance with these laws and regulations. If we fail to comply with these <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">laws and regulations, we and certain of our employees could be subject to substantial civil or criminal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">penalties, including&#58; the possible loss of export or import privileges&#59; fines, which may be imposed on us <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and responsible employees or managers&#59; and, in extreme cases, the incarceration of responsible <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">employees or managers. Obtaining the necessary authorizations, including any required license, for a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">particular sale may be time consuming, is not guaranteed and may result in the delay or loss of sales <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">opportunities. In addition, changes in our products or changes in applicable export or import regulations <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">may create delays in the introduction and sale of our products in international markets, prevent our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">customers with international operations from deploying our products or, in some cases, prevent the export <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or import of our products to certain countries, governments or persons altogether. Any change in export or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 364pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">import regulations, shift in the enforcement or scope of existing regulations or change in the countries, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">governments, persons or technologies targeted by such regulations, could also result in decreased use of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 388pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our products, or in our decreased ability to export or sell our products to existing or potential customers <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 400pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">with international operations. Any decreased use of our products or limitation on our ability to export or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 412pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">sell our products would likely adversely affect our business.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 432pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Furthermore, we incorporate encryption technology into certain of our products. Various countries <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 444pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">regulate the import of certain encryption technology, including through import permitting and licensing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 456pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">requirements, and have enacted laws that could limit our ability to distribute our products or could limit our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 468pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">customers&#8217; ability to implement our products in those countries. Encrypted products and the underlying <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">technology may also be subject to export control restrictions. Governmental regulation of encryption <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 492pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">technology and regulation of imports or exports of encryption products, or our failure to obtain required <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 504pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">import or export approval for our products, when applicable, could harm our international sales and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 516pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">adversely affect our revenue. Compliance with applicable regulatory requirements regarding the export of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 528pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our products, including with respect to new releases of our products, may create delays in the introduction <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of our products in international markets, prevent our customers with international operations from <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">deploying our products throughout their globally distributed systems or, in some cases, prevent the export <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of our products to some countries altogether.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 584pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Moreover, U.S. export control laws and economic sanctions programs prohibit the shipment of certain <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 596pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">products and services to countries, governments and persons that are subject to U.S. economic <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 608pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">embargoes and trade sanctions. Any violations of such economic embargoes and trade sanction <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 620pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">regulations could have negative consequences, including government investigations, penalties and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 632pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reputational harm.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 652pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Any future litigation against us could be costly and time-consuming to defend.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We have been in the past, and we may become in the future, subject to legal proceedings and claims that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 684pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">arise in the ordinary course of business, such as claims brought by our third-party vendors, our customers <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 696pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or their patients in connection with contractual disputes or the use of our Heartflow Platform, claims <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 708pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">brought by us or by competitors related to intellectual property or employment claims made by our current <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">44<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or former employees. Litigation might result in substantial costs and may divert management&#8217;s attention <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and resources, which might seriously harm our business, financial condition, results of operations and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prospects. Insurance might not cover such claims, might not provide sufficient payments to cover all the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">costs to resolve one or more such claims, and might not continue to be available at all or on terms <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">acceptable to us (including premium increases or the imposition of large deductible or co-insurance <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">requirements). A claim brought against us that is uninsured or underinsured could result in unanticipated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">costs, potentially harming our business, financial condition, results of operations and prospects. In <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 156pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">addition, we cannot be sure that our existing insurance coverage will continue to be available on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 168pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">acceptable terms or at all or that our insurers will not deny coverage as to any future claim.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Risks related to our intellectual property <font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 210.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">If we are unable to obtain and maintain sufficient intellectual property rights, or the scope of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 222.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">rights is not sufficiently broad, third-parties could develop and commercialize technology and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 234.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">products similar or identical to ours, and our ability to successfully commercialize our technology <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 246.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">and products may be adversely affected. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 266.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our commercial success will depend, in part, on our ability to continue obtaining and maintaining <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 278.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">intellectual property protection for our technology and products, in both the United States and certain <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 290.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">other countries, successfully defending this intellectual property against third-party challenges and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 302.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">successfully enforcing this intellectual property to prevent third-party infringement. We rely upon a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 314.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">combination of patents, trade secrets, know-how, copyrights, trademarks, license agreements and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 326.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">contractual provisions to establish our intellectual property rights and protect our products.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 346.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our ability to protect our technologies and products from unauthorized or infringing use by third-parties <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 358.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">depends in substantial part on our ability to obtain and maintain valid and enforceable patents in both the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 370.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">United States and certain other countries. The patent positions of medical technology and software <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 382.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">companies can be highly uncertain and involve complex legal, scientific and factual questions for which <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 394.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">important legal principles remain unresolved. In addition, the patent prosecution process is expensive, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 406.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce, defend or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 418.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">license all necessary or desirable patents or patent applications at a reasonable cost or in a timely <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 430.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">manner, or in all jurisdictions. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 450.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We cannot guarantee that any patents will issue from any pending or future patent applications owned by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 462.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or licensed to us, or if issued, the breadth of such patent coverage. In particular, during prosecution of any <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 474.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">patent application, the issuance of any patents based on the application may depend upon our ability to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 486.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">generate additional preclinical or clinical data that support the patentability of our proposed claims. We <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 498.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">may not be able to generate sufficient additional data on a timely basis, or at all. It is also possible that we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 510.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">may fail to identify patentable aspects of inventions made in the course of our development and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 522.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">commercial activities before it is too late to obtain patent protection on such inventions. If we fail to timely <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 534.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">file for patent protection in any jurisdiction, we may be precluded from doing so at a later date.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 554.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The issuance of a patent is not conclusive as to its inventorship, ownership, scope, validity or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 566.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">enforceability, and our owned or licensed patents may be challenged in the courts or the patent offices of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 578.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the United States or abroad. Such challenges may result in a loss of exclusivity or in the patent&#8217;s claims <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 590.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 602.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">third-parties from using or commercializing similar or identical products, or limit the duration of patent <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 614.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">protection for our technology and products. In addition, changes in either the patent laws, implementing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 626.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">regulations or interpretations of patent laws in the United States or foreign countries may diminish the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 638.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">value of our patent rights.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 658.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Even if unchallenged, our owned or licensed patents may not provide us with exclusivity or commercial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 670.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">value for our products or any significant protection against competitive products or prevent others from <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 682.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">designing around our claims. Our competitors might conduct research and development activities in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 694.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">countries where we do not have patent rights (or in those countries where we do, under safe harbor <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 706.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">provisions) and then use the information learned from such activities to develop competitive products for <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">45<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">sale in our major commercial markets. Further, if we encounter delays in regulatory approvals, the period <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of time during which we could market our products under patent protection could be reduced. Any of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">these outcomes could impair our ability to prevent competition from third-parties, which may have an <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">adverse impact on our business.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Patent applications are generally maintained in confidence until publication. In the United States, for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">example, patent applications are maintained in secrecy for up to 18 months after their filing. Similarly, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">publication of discoveries in scientific or patent literature often lag behind actual discoveries. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Consequently, we cannot be certain that we or our licensors were the first to invent, or the first to file <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">patent applications on our products. There is also no assurance that all of the potentially relevant prior art <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">relating to our patents and patent applications has been found, which could be used by a third-party to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">challenge validity of our patents or prevent a patent from issuing from a pending patent application. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition to patents, proprietary trade secrets and unpatented know-how are important to our business. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">For information about risks related to these intellectual property rights, see the risk factor titled &#8220;If we are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">unable to protect the disclosure and use of our confidential information and trade secrets, the value of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">products and technologies and our business and competitive position could be harmed&#8221; below. We also <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">rely on the trademarks we own to distinguish our products from the products of our competitors. We <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">cannot guarantee that any trademark applications filed by us will be approved. Third-parties may also <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">oppose or attempt to cancel our trademark applications or trademarks, or otherwise challenge our use of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the trademarks. In the event that the trademarks we use are successfully challenged, we could be forced <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to rebrand our products, which could result in loss of brand recognition, and could require us to devote <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">resources to advertising and marketing new brands. Competitors or other parties may adopt trade names <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">market confusion. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Further, we cannot provide assurance that competitors will not infringe the trademarks we use, or that we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 384pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">will have adequate resources to enforce these trademarks. If we attempt to enforce our trademarks and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">assert trademark infringement claims, a court may determine that the marks we have asserted are invalid <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or unenforceable, or that the party against whom we have asserted trademark infringement has superior <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">rights to the marks in question. In this case, we could ultimately be forced to cease use of such <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 432pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">trademarks. We may license our trademarks and trade names to third-parties, such as distributors. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 444pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Though these license agreements may provide guidelines for how our trademarks and trade names may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 456pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">be used, a breach of these agreements or misuse of our trademarks and trade names by our licensees <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 468pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Over the long term, if we are unable to establish name recognition based on our trademarks and trade <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 492pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">names, then we may not be able to compete effectively and our business may be adversely affected.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 512pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">For information about risks related to our inability to protect our intellectual property rights outside the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 524pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">United States, see the risk factor titled &#8220;We may not be able to adequately protect our intellectual property <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 536pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">rights throughout the world&#8221; below.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 556pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">If we are unable to protect the disclosure and use of our confidential information and trade <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 568pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">secrets, the value of our products and technologies and our business and competitive position <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 580pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">could be harmed.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 600pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition to patent protection, we also rely on other intellectual property rights, including trade secrets, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">know-how, and&#47;or other proprietary information that is not patentable or that we elect not to patent. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">However, trade secrets can be difficult to protect, and some courts are less willing or unwilling to protect <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 636pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">trade secrets. Although we have taken steps to protect our trade secrets and unpatented know-how, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 648pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">including by entering into confidentiality agreements with third-parties, and proprietary information and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">invention agreements with our employees, consultants and advisors, third-parties may still obtain this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">information or we may be unable to protect our rights. There can be no assurance that binding <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 684pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">agreements will not be breached, that we would have adequate remedies for any breach, or that our trade <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 696pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">secrets and unpatented know-how will not otherwise become known or be independently discovered by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 708pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our competitors. We also seek to preserve the integrity and confidentiality of our data and trade secrets <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">46<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">by maintaining physical security of our premises and physical and electronic security of our information <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">technology systems. While we have confidence in these individuals, organizations and systems, our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">security measures may be breached, and we may not have adequate remedies for any such breach. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">would have no right to prevent them, or those to whom they communicate it, from using that information to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">compete with us. Any exposure of our trade secrets and other proprietary information would impair our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">competitive advantages and could have a material adverse effect on our business, financial condition, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">results of operations and prospects. In particular, a failure to protect our proprietary rights may allow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">competitors to copy our products or technologies, which could adversely affect our pricing and market <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">share. Unauthorized parties may also attempt to copy or reverse engineer certain aspects of our products <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or technologies that we consider proprietary. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Costly and time-consuming litigation could be necessary to enforce and determine the scope of our trade <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">secret rights and related confidentiality, non-disclosure and non-use provisions, and outcomes of such <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">litigation are unpredictable. Enforcing a claim that a party illegally disclosed, used or misappropriated a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">trade secret can be difficult, expensive and time-consuming, and the outcome is unpredictable. While we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">use commonly accepted security measures, trade secret claims are often based on a combination of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">federal and state law in the United States, and the criteria for protection of trade secrets can vary among <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">different jurisdictions. If the steps we have taken to maintain our trade secrets are deemed inadequate, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">we may have insufficient recourse against third-parties for misappropriating the trade secret. In addition, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">agreement terms that address non-competition are difficult to enforce in many jurisdictions and might not <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">be enforceable in certain cases. Even if we were to be successful in the enforcement of our claims, we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">may not be able to obtain adequate remedies. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Reliance on third-parties requires us to share our trade secrets, which increases the possibility <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">that a competitor will discover them or that our trade secrets will be misappropriated or disclosed <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 384pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">to others. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 404pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Any collaboration or other engagement with third-parties for the development of our products may require <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 416pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">us, at times, to share trade secrets with them. We may also conduct joint research and development <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 428pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">programs that may require us to share trade secrets under the terms of our research and development <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 440pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">partnerships or similar agreements. We seek to protect our trade secrets and other proprietary technology <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 452pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">in part by entering into confidentiality agreements with third-parties prior to beginning research or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 464pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">disclosing proprietary information. These agreements typically limit the rights of the third-parties to use or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 476pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">disclose our confidential information, including our trade secrets. Despite the contractual provisions <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 488pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">employed when working with third-parties, the need to share trade secrets and other confidential <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 500pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">information increases the risk that such trade secrets become known by our competitors, are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 512pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">inadvertently incorporated into the technology of others, or are disclosed or used in violation of these <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 524pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">agreements. Given that our proprietary Heartflow Platform is based, in part, on our know-how and trade <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 536pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure could have <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 548pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">an adverse effect on our business, financial condition, results of operations and prospects. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 568pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 580pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">contractors and consultants to publish data potentially relating to our trade secrets. Despite our efforts to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 592pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">protect our trade secrets, we may not be able to prevent the unauthorized disclosure or use of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 604pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">technical know-how or other trade secrets by the parties to these agreements. Moreover, we cannot <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 616pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">guarantee that we have entered into such agreements with each party that may have or have had access <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 628pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to our confidential information or proprietary technology and processes. Monitoring unauthorized uses <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 640pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and disclosures is difficult, and we do not know whether the steps we have taken to protect our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 652pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">proprietary technologies will be effective. If any of the collaborators, scientific advisors, employees, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 664pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">contractors and consultants who are parties to these agreements breaches or violates the terms of any of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 676pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">these agreements, we may not have adequate remedies for any such breach or violation, and we could <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 688pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">lose our trade secrets as a result. Moreover, if confidential information that is licensed or disclosed to us <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 700pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">by our partners, collaborators, or others is inadvertently disclosed or subject to a breach or violation, we <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">47<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">may be exposed to liability to the owner of that confidential information. Enforcing a claim that a third-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">party illegally obtained and is using our trade secrets, like patent litigation, is expensive and time <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">consuming, and the outcome is unpredictable. In addition, courts outside the United States are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">sometimes less willing to protect trade secrets, and we may need to share our trade secrets and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">proprietary know-how with current or future partners, collaborators, contractors and others located in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">foreign actors, and those affiliated with or controlled by state actors.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Obtaining and maintaining our patent protection depends on compliance with various procedural, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">document submission, fee payment and other requirements imposed by governmental patent <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">agencies, and our patent protection could be reduced or eliminated for noncompliance with these <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">requirements. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) and various foreign governmental patent agencies <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">require compliance with a number of procedural, documentary, fee payment and other similar provisions <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">during the patent application process. In addition, periodic maintenance fees, renewal fees, annuity fees, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and various other government fees on patents and&#47;or applications will be due to be paid to the USPTO <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and various governmental patent agencies outside of the United States over the lifetime of our patents <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and&#47;or applications and any patent rights we may obtain in the future. We have systems in place to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">remind us to pay these fees, and we employ outside firms to remind us to pay annuity fees due to patent <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">agencies on our patents and pending patent applications. In many cases, an inadvertent lapse can be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">cured by payment of a late fee or by other means in accordance with the applicable rules. However, there <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">are situations in which noncompliance can result in abandonment or lapse of the patent or patent <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">event, our competitors might be able to enter the relevant market, which would have an adverse effect on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 364pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our business. Noncompliance events that could result in abandonment or lapse of a patent or patent <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">application include failure to respond to official actions within prescribed time limits, non-payment of fees <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 388pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and failure to properly legalize and submit formal documents.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Changes in patent law, precedents and policies in the United States and other jurisdictions could <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">diminish the value of patents in general, thereby impairing our ability to protect our products. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 440pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our ability to obtain patents is highly uncertain because, to date, some legal principles remain unresolved, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 452pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and there has not been a consistent policy regarding the breadth or interpretation of claims allowed in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 464pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">patents in the United States. Furthermore, the specific content of patents and patent applications that are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 476pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">necessary to support and interpret patent claims is highly uncertain due to the complex nature of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 488pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">relevant legal, scientific, and factual issues. The United States Supreme Court has ruled on several <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 500pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">patent cases in recent years, either narrowing the scope of patent protection available in certain <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 512pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">circumstances or weakening the rights of patent owners in certain situations. Changes in either the patent <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 524pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">laws or interpretations of patent laws in the United States or other jurisdictions may diminish the value of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 536pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our intellectual property. In the United States, in certain circumstances, court rulings may narrow the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 548pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">scope of patent protection and weaken the rights of patent owners. We cannot predict how decisions by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 560pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the courts, the U.S. Congress, the USPTO or changes in the patent laws of other jurisdictions may impact <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 572pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the value of our patents. Changes in the laws, regulations, precedents and procedures governing patents <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 584pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 596pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our intellectual property in the future, which could have a material adverse effect on our business, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 608pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">financial condition, results of operations and prospects.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 628pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Further, patent coverage in medical devices and technologies is a subject of evolution and differences <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 640pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">between countries. This is especially true of the definition of patentable subject matter which affects both <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 652pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">computer related inventions and biological inventions. This evolution may cause current granted patents <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 664pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to be considered non-patent eligible or prevent us from protecting future inventions. U.S. Supreme Court <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 676pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and Federal Circuit decisions interpreting and&#47;or limiting the scope of patentable subject matter under 35 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 688pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">U.S.C. &#167; 101, in addition to examination guidelines from the USPTO, have made it more difficult for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 700pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">patentees to obtain and&#47;or maintain patent claims in the United States that are directed to medical <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">48<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">technologies involving computer-implemented applications. Several precedential decisions regarding <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">patentable subject matter are of particular relevance to patents in the computer-implemented applications <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">space. Our efforts to seek patent protection for our technologies and products may be impacted by the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">evolving case law and guidance or procedures issued by the USPTO or authorities in other jurisdictions <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">based on such evolving case law.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Similarly, changes in patent laws and regulations in other countries or jurisdictions, changes in the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">governmental bodies that enforce them or changes in how the relevant governmental authority enforces <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">obtain in the future. For example, the complexity and uncertainty of European patent laws have also <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">increased in recent years. In Europe, a new unitary patent system took effect June 1, 2023, which will <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">significantly impact European patents, including those granted before the introduction of the new unitary <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">patent system. Under the unitary patent system, European applications have the option, upon grant of a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(&#8220;UPC&#8221;). As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of any litigation. Patents granted before the implementation of the UPC have the ability to opt out of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">jurisdiction of the UPC and remain as national patents in the UPC countries. The UPC will provide our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 272pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">competitors with a new forum to centrally revoke European patents, and allow for the possibility of a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 284pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">competitor to obtain pan-European injunctions, since patents that remain under the jurisdiction of the UPC <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 296pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 320pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">long-term effects of any potential changes.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">same manner as the laws of the United States and Europe. As a result, we may encounter significant <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 364pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">problems in protecting and defending our intellectual property both in the United States and abroad. For <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">example, if the issuance in a given country of a patent covering an invention is not followed by the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 388pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">issuance in other countries of patents covering the same invention, or if any judicial interpretation of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 400pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">validity, enforceability or scope of the claims or the written description or enablement, in a patent issued in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 412pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">one country is not similar to the interpretation given to the corresponding patent issued in another country, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 424pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our ability to protect our intellectual property in those countries may be limited. Changes in either patent <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 436pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">laws or in interpretations of patent laws in the United States and other countries may materially diminish <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 448pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the value of our intellectual property or narrow the scope of our patent protection.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 468pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition, on September 16, 2011, the Leahy-Smith America Invents Act (the &#8220;Leahy-Smith Act&#8221;) was <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 492pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Assuming that other requirements for patentability are met, prior to March 16, 2013, in the United States, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 504pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the first to invent the claimed invention was entitled to the patent, while outside the United States, the first <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 516pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to file a patent application was entitled to the patent. On or after March 16, 2013, under the Leahy-Smith <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 528pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Act, the United States transitioned to a first inventor to file system in which, assuming that other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">requirements for patentability are met, the first inventor to file a patent application will be entitled to the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">patent on an invention regardless of whether a third-party was the first to invent the claimed invention. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Under this system, a third-party that files a patent application in the USPTO before us could be awarded a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">patent covering an invention of ours even if we had made the invention before it was made by such third-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">party. Since patent applications in the United States and most other countries are confidential for a period <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 600pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i) <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">file any patent application related to our products or (ii) invent any of the inventions claimed in our or our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">licensors&#8217; patents or patent applications.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Leahy-Smith Act also changed the way patent applications are prosecuted, including by allowing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">third-party submission of prior art to the USPTO during patent prosecution and additional procedures to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 668pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">challenge the validity of a patent by USPTO administered post-grant proceedings to attack the validity of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 680pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">a patent. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 692pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">standard in U.S. federal courts necessary to invalidate a patent claim, a third-party could potentially <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 704pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">49<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">same evidence might not be sufficient to invalidate the claim if presented in a district court action. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Accordingly, third-parties may use USPTO proceedings to invalidate our patent claims that would not <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">have been invalidated if first challenged in a district court action. Therefore, the Leahy-Smith Act and its <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">implementation could increase the uncertainties and costs surrounding the prosecution of our patent <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">applications and the enforcement or defense of our issued patents, which could have a material adverse <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">effect on our business, financial condition, results of operations and prospects.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">We may not be able to adequately protect our intellectual property rights throughout the world. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 172pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our patent portfolio includes patents and patent applications in countries outside of the United States, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 184pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">including Japan, Korea, China, Canada, Australia, Israel, India and countries in Europe. The requirements <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 196pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for patentability differ from country to country, the breadth of allowed patent claims can be inconsistent, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 208pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the scope of coverage provided by these patents varies and the laws of some foreign countries may not <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">protect our intellectual property rights to the same extent as laws in the United States. In addition, filing, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prosecuting and defending patents on our products in all countries throughout the world would be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prohibitively expensive. For those countries where we do not have granted patents, we may not have any <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">ability to prevent the unauthorized sale of our products. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 276pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition, we may decide to abandon national and regional patent applications before they are granted. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 288pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The examination of each national or regional patent application is an independent proceeding. As a result, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 300pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">patent applications in the same family may issue as patents in some jurisdictions, such as in the United <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 312pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">States, but may issue as patents with claims of different scope or may even be refused in other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 324pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">jurisdictions. It is also quite common that depending on the country, the scope of patent protection may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 336pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">vary for the same product or technology. For example, certain jurisdictions do not allow for patent <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 348pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">protection with respect to methods of treatment.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 368pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Consequently, we may not be able to prevent third-parties from practicing our inventions in all countries <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 380pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">outside the United States. Competitors may use our technologies in jurisdictions where we have not <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 392pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">obtained patent protection to develop their own products and, further, may export otherwise infringing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 404pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">products to territories in which we have patent protection that may not be sufficient to terminate infringing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 416pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">activities. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 428pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">world may be inadequate to obtain a significant commercial advantage from the intellectual property that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 440pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">we develop or license.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 460pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 472pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">licenses to third-parties, government agencies or government contractors. In these countries, the patent <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 484pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">owner may have limited remedies, which could materially diminish the value of such patent. If we or any <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 496pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of our licensors is forced to grant a license to third-parties with respect to any patents relevant to our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 508pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">business, our competitive position may be impaired, and our business, financial condition, results of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 520pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">operations and prospects may be adversely affected.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We do not seek or have patent rights in certain foreign countries in which a market may exist. Accordingly, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our efforts to protect our intellectual property rights in such countries may be inadequate, which may have <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">an adverse effect on our ability to successfully commercialize our products in all of our expected <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">significant foreign markets. Moreover, in foreign jurisdictions where we do have patent rights, proceedings <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to enforce such rights could result in substantial costs and divert our efforts and attention from other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 600pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, and our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">patent applications at risk of not issuing. Additionally, such proceedings could provoke third-parties to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 636pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">remedies awarded, if any, may not be commercially meaningful. Thus, we may not be able to stop a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 648pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">competitor from marketing and selling in foreign countries products that are the same as or similar to our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">products, and our competitive position in the international market would be harmed.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">50<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">We may be involved in lawsuits to protect or enforce our patents or other intellectual property, or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">the patents of our licensors, which could be expensive, time consuming and unsuccessful. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Competitors or other third-parties may infringe, misappropriate or otherwise violate our owned or licensed <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">patents, trade secrets or other intellectual property. To counter infringement or unauthorized use, we may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">be compelled to file infringement or misappropriation claims, which can be expensive and time <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">consuming. We do not carry intellectual property insurance that would cover such claims. In certain <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">circumstances it may not be practicable or cost effective for us to enforce our intellectual property rights <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">fully, particularly in certain developing countries or where the initiation of a claim might harm our business <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">relationships. If we initiate legal proceedings against a third-party to enforce a patent covering our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">products, the defendant could counterclaim that our patent(s) are invalid and&#47;or unenforceable. In patent <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">litigation in the United States, counterclaims alleging invalidity and&#47;or unenforceability are common, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">there are numerous grounds upon which a third-party can assert invalidity or unenforceability of a patent. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In an infringement proceeding, a court may decide that a patent we own or license is not valid, is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">unenforceable or is not infringed, or may refuse to stop the other party from using the technology at issue <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">on the grounds that our patents do not cover the technology in question. The outcome following legal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 272pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">example, we cannot be certain that there is no invalidating prior art. If a defendant were to prevail on a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 284pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">legal assertion of invalidity and&#47;or unenforceability, we may lose some, and perhaps all, of the patent <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 296pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">protection covering our products. An adverse result in any litigation or defense proceeding could put one <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or more of our patents at risk of being invalidated or interpreted narrowly, could put our patent <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 320pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">applications at risk of not issuing and could have a material adverse impact on our business.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our defense of litigation may fail and, even if successful, may result in substantial costs and distract our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">management and other employees. Even if we establish infringement, the court may decide not to grant <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 364pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">an injunction against further infringing activity and instead award only monetary damages, which may or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">may not be an adequate remedy. For example, the amount of any monetary damages may be inadequate <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 388pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to compensate us for damage as a result of the infringement and the proceedings. We may not be able to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 400pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prevent, alone or with our suppliers, misappropriation of intellectual property rights important to our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 412pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">business, particularly in countries where the laws may not protect those rights as fully as in the United <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 424pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">States.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 444pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Furthermore, because of the substantial amount of discovery required in connection with intellectual <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 456pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">property litigation, there is a risk that some of our confidential information could be compromised by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 468pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">disclosure during this type of litigation. There could also be public announcements of the results of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">hearings, motions or other interim proceedings or developments. If securities analysts or investors <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 492pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">perceive these results to be negative, it could have an adverse effect on the price of our common stock.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 512pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Third-party defendants may challenge any patent we own or in-license through adversarial proceedings in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 524pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the issuing offices, which could result in the invalidation or unenforceability of some or all of the relevant <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 536pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">patent claims. If a third-party asserts a substantial new question of patentability against any claim of a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 548pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">U.S. patent we own or license, the USPTO may grant a request for reexamination, which may result in a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 560pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">loss of scope of some claims or a loss of the entire patent. The adoption of the Leahy-Smith Act has <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 572pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">established additional opportunities for third-parties to invalidate U.S. patent claims, including inter partes <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 584pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">review and post grant review, on the basis of lower legal standards than reexamination and additional <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 596pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">grounds. Outside of the United States, patents we own or license may become subject to patent <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 608pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">opposition or similar proceedings, which may result in loss of scope of some claims or loss of the entire <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 620pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">patent. Participation in adversarial proceedings is very complex, expensive and may divert our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 632pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">management&#8217;s attention from our core business and may result in unfavorable outcomes that could <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">adversely affect our ability to prevent third-parties from competing with us.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">51<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">We may be subject to claims challenging the inventorship or ownership of our patents and other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">intellectual property rights or alleging that we have violated the intellectual property rights or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">other proprietary rights of third-parties. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our commercial success depends, in part, upon our ability to develop, manufacture, market and sell our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">products and use our proprietary technologies without infringing the proprietary rights and intellectual <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">property of third-parties. The medical device industry is characterized by extensive and complex litigation <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">regarding patents and other intellectual property rights. We may be exposed to, or threatened with, future <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">litigation by third-parties having patent or other intellectual property rights alleging that our products or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">proprietary technologies infringe on their intellectual property rights. There is a risk that third-parties may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">party patents are valid, enforceable and infringed, which could have a negative impact on our ability to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">commercialize our products. This includes litigation, or threatened litigation, with non-practicing entities <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">that have no relevant product revenue and against whom our own patent portfolio may have no deterrent <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">effect. The legal threshold for initiating litigation or contested proceedings is low, so that even lawsuits or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">proceedings with a low probability of success might be initiated and require significant resources to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 272pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">defend. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We may also be subject to claims that former employees, collaborators or other third-parties have an <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">ownership interest in our patent rights or other intellectual property, for example, based on conflicting <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">obligations of consultants or others who are involved in developing our products. Although it is our policy <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to require our employees and contractors who may be involved in the conception or development of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">intellectual property to execute agreements assigning such intellectual property to us, we may be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">unsuccessful in executing such an agreement with each party who, in fact, conceives or develops <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 364pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">intellectual property that we regard as our own, and we cannot be certain that our agreements with such <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 388pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">may not have an adequate remedy. The assignment of intellectual property rights may not be self-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 400pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">executing or the assignment agreements may be breached, and litigation may be necessary to defend <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 412pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">against these and other claims challenging inventorship or ownership. If we fail in defending any such <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 424pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 436pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 448pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">material adverse effect on our business. Even if we are successful in defending against such claims, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 460pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">litigation could result in substantial costs and be a distraction to management and other employees. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We employ individuals who were previously employed at other medical technology companies. In <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 492pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">addition, we use publications that are subject to copyright, as well as proprietary information and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 504pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">materials from third-parties in our research. Some of the information and materials we use from third-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 516pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">parties may be subject to agreements that include restrictions on use or disclosure. Although we strive to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 528pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">ensure proper safeguards, we cannot guarantee strict compliance with such agreements, nor can we be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">sure that our employees, consultants and advisors do not use proprietary information, materials or know-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">how of others in their work for us. In addition, we may be subject to claims that we or our employees, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">consultants or independent contractors have inadvertently or otherwise used or disclosed alleged trade <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">secrets or other proprietary information of former employers or other third-parties. Although we have <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">procedures in place that seek to prevent our employees and consultants from using the intellectual <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 600pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">property, proprietary information, know how or trade secrets of others in their work for us, we may in the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">future be subject to claims that we caused an employee to breach the terms of his or her non-competition <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or non-solicitation agreement, or that we or these individuals have, inadvertently or otherwise, used or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 636pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">disclosed the alleged trade secrets or other proprietary information of a former employer or competitor. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 648pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We may also be subject to claims that former employers or other third-parties have an ownership interest <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">in our future patents. In addition, we may be subject to claims that we are infringing other intellectual <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">property rights, such as trademarks or copyrights, and to the extent that our employees, consultants or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 684pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">contractors use intellectual property or proprietary information owned by others in their work for us, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 696pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">disputes may arise as to the rights in related or resulting know-how and inventions. Litigation may be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 708pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">necessary to defend against these claims. There is no guarantee of success in defending these claims, <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">52<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and even if we are successful, litigation could result in substantial cost and be a distraction to our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">management and other employees.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">An unfavorable outcome for any such claim could require us to cease using the related technology or to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">party does not offer us a license on commercially reasonable terms. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 148pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">If a third-party claims that we infringe its intellectual property rights, we may face a number of issues, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 160pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">including&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 180pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">infringement and other intellectual property claims which, regardless of merit, may be expensive and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 192pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">time consuming to litigate and may divert our management&#8217;s attention from our core business&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">substantial damages for infringement, which we may have to pay if a court decides that the product at <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">issue infringes or violates the third-party&#8217;s rights, and if the court finds that the infringement was <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">willful, we could be ordered to pay treble damages and the patent owner&#8217;s attorneys&#8217; fees&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">a court prohibiting us from selling or licensing the product unless the third-party licenses its product <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">rights to us, which it is not required to do&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 288pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">if a license is available from a third-party, we may have to pay substantial royalties, upfront fees or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 300pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">grant cross licenses to intellectual property rights for our products&#59; and<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 320pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">redesigning our products or processes so they do not infringe, which may not be possible or may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 332pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">require substantial monetary expenditures and time.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In order to successfully challenge the validity of a U.S. patent in federal court, we would need to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 364pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">overcome a presumption of validity. As this burden is a high one requiring us to present clear and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 388pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of competent jurisdiction would invalidate the claims of any such U.S. patent. Foreign courts will have <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 400pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">similar burdens to overcome in order to successfully challenge a third-party claim of patent infringement.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 432pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">than we can because they have substantially greater resources. In addition, any uncertainties resulting <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 444pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">from the initiation and continuation of any litigation could have an adverse effect on our ability to raise <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 456pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">additional funds or on our business, financial condition, results of operations and prospects. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 476pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">The terms of our patents may not be sufficiently long to effectively protect our products and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 488pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">business.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 508pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 520pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">years after its first effective non-provisional filing date, but can be shorter due to terminal disclaimers or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 532pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">similar term reductions in other jurisdictions. Although various extensions may be available, the term of a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 544pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">patent, and the protection it affords, is limited. Even if patents covering our technologies or products are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 556pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">obtained, once the patent term has expired, we may be open to competition. In addition, although upon <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 568pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">issuance in the United States, a patent&#8217;s term can be increased based on certain delays caused by the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 580pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 592pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">applicant during patent prosecution. Given the amount of time required for the development, testing and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 604pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">regulatory review of products, patents protecting such product candidates might expire before or shortly <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 616pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">after such products are commercialized. If we do not have sufficient patent life to protect our technologies <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 628pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and products, our business, financial condition, results of operations and prospects will be adversely <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 640pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">affected.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">If we do not obtain additional protection under the Hatch-Waxman Amendments or similar foreign <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">legislation, our business may be materially affected. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 692pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Depending upon the timing, duration and specifics of FDA marketing approval for our future products, one <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 704pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or more of our U.S. patents may be eligible for limited patent term restoration under the Drug Price <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">53<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Competition and Patent Term Restoration Act of 1984 (the &#8220;Hatch-Waxman Amendments&#8221;). The Hatch-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Waxman Amendments permit a patent term extension of up to five years beyond the normal expiration of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the patent as compensation for patent term lost during product development and the FDA regulatory <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">review process, which is limited to the approved indication (or any additional indications approved during <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the period of extension). This extension is limited to one patent that covers the approved product, the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">approved use of the product, or a method of manufacturing the product. A patent term extension cannot <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">extend the remaining term of a patent beyond a total of 14 years from the date of product approval, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 156pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">only those claims covering such approved product, a method for using it or a method for manufacturing it <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 168pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">may be extended. However, the applicable authorities, including the FDA and the USPTO in the United <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 180pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">States, and any equivalent regulatory authority in other countries or areas, may not agree with our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 192pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">assessment of whether such extensions are available, and may refuse to grant extensions to our patents, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 204pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or may grant more limited extensions than we request. We may not be granted an extension because of, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 216pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 228pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 240pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">scope of patent protection afforded could be less than we request. If we are unable to obtain patent term <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 252pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">extension or restoration of the term of any such extension is less than we request, our competitors may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 264pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">obtain approval for competing products following our patent expiration, and our ability to generate <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 276pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">revenues may be adversely affected. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 296pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Open-source software licenses often impose unanticipated or unclear restrictions on us or could <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">expose us to litigation, and using open-source software has inherent risks, any of which could <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 320pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">impair our ability to successfully commercialize the Heartflow Platform.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our technology platform implements software modules licensed to us by third-parties under &#8220;open source&#8221; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">licenses. The terms of many open source licenses have not been interpreted by U.S. courts, and there is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 364pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">a risk that these licenses could be construed in ways that could impose unanticipated conditions or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">restrictions on our ability to commercialize our products. Moreover, we cannot be certain that our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 388pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">processes for controlling our use of open-source software in connection with our products will be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 400pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">effective. From time to time, we may face claims from third-parties asserting ownership of, or demanding <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 412pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">release of, the open-source software or derivative works that we developed using such software (which <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 424pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">could include our proprietary source code), or otherwise seeking to enforce the terms of the applicable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 436pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">open source license. These claims could result in litigation. If we are held to have breached the terms of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 448pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">an open source software license, we could be required to seek licenses from third-parties to continue <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 460pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">offering our products on terms that are not economically feasible, to re-engineer our proprietary code, to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 472pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">discontinue the sale of our products if re-engineering could not be accomplished on a timely or cost <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 484pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">effective basis, or to make generally available, in source code form, our proprietary code, any of which <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 496pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">could adversely affect our business, financial condition, results of operations and prospects.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 516pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The use of open-source software may entail greater risks than the use of third-party commercial software, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 528pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">as open source licensors generally do not provide warranties or other contractual protections regarding <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">infringement or the quality or ownership of the code. Many of these risks cannot be eliminated, and could, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">if not properly addressed, negatively affect our business. We cannot be sure that all open source software <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">is submitted for approval prior to use in connection with our products.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 584pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition, some open-source licenses contain requirements that we make available source code for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 596pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">modifications or derivative works we create based upon the type of open-source software we use. If we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 608pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">combine our proprietary software with open-source software in a certain manner, we could, under certain <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 620pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">open-source licenses, be required to release portions of the source code of our proprietary software to the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 632pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">public. This would allow our competitors to create similar products with less development effort and time <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and ultimately could result in a loss of sales for us.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">54<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Intellectual property rights do not necessarily address all potential threats to our competitive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">advantage. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The degree of future protection afforded by our intellectual property rights is uncertain because <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">intellectual property rights have limitations and may not adequately protect our business or permit us to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">maintain our competitive advantage. The following examples are illustrative&#58; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 148pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">others may be able to make products that are similar to or otherwise competitive with our product <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 160pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">candidates but that are not covered by the claims of our current or future patents&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 180pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">an in-license necessary for the manufacture, use, sale, offer for sale or importation of one or more of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 192pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our product candidates may be terminated by the licensor&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">we or future collaborators might not have been the first to make the inventions covered by our issued <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">or future issued patents or our pending patent applications&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">we or future collaborators might not have been the first to file patent applications covering certain of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our inventions&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 276pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">others may independently develop similar or alternative technologies or duplicate any of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 288pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">technologies without infringing our intellectual property rights&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">it is possible that our pending patent applications will not lead to issued patents&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">issued patents that we own or in-license may be held invalid or unenforceable as a result of legal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">challenges by our competitors&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">issued patents that we own or in-license may not provide coverage for all aspects of our product <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">candidates in all countries&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 392pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our competitors might conduct research and development activities in countries where we do not <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 404pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">have patent rights and then use the information learned from such activities to develop competitive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 416pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">products for sale in our major commercial markets&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 436pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">we may not develop additional proprietary technologies that are patentable&#59; and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 456pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the patents of others may have an adverse effect on our business.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 476pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Should any of these events occur, they could significantly harm our business, results of operations and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 488pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prospects.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 508pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Risks related to financing and tax matters<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 530.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">We have identified material weaknesses in our internal control over financial reporting and may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 542.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">identify additional material weaknesses in the future or otherwise continue to fail to maintain <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 554.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">effective internal control over financial reporting, which may result in material misstatements of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 566.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">our consolidated financial statements or cause us to fail to meet our periodic reporting <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 578.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">obligations or cause our access to the capital markets to be impaired.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 598.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We have been a private company and had limited accounting and financial reporting personnel and other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 610.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">resources with which to address our internal control over financial reporting. In connection with the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 622.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">preparation of our consolidated financial statements, we identified material weaknesses in our internal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 634.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 646.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">internal control over financial reporting such that there is a reasonable possibility that a material <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 658.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">misstatement of our annual or interim financial statements will not be prevented or detected on a timely <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 670.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">basis. The material weaknesses identified are as follows&#58; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 690.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">We did not design and maintain an effective control environment commensurate with our financial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 702.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">reporting requirements. Specifically, we did not maintain a sufficient complement of personnel with an <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">55<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">appropriate degree of internal controls and accounting knowledge, experience, and training to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">appropriately analyze, record and disclose accounting matters timely and accurately. Additionally, the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">insufficient complement of personnel resulted in an inability to consistently establish appropriate <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">authorities and responsibilities in pursuit of financial reporting objectives, as demonstrated by, among <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">other things, insufficient segregation of duties in our finance and accounting functions. This material <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">weakness contributed to the following additional material weaknesses described below. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">We did not design and maintain effective controls to analyze, account for and disclose non-routine, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">unusual or complex transactions. Specifically, we did not design and maintain controls to timely <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">analyze and account for warrants issued in connection with financial instruments, to account for an <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">amendment to our debt agreement as a debt modification and to account for features related to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">features of our preferred stock financing. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">These material weaknesses resulted in material adjustments to the redeemable convertible preferred <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock, accumulated deficit and deemed dividend accounts and related disclosures in the consolidated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">financial statements for the year ended December 31, 2023. Additionally, during the years ended <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">December 31, 2019, 2020, 2021 and 2022, these material weaknesses resulted in audit adjustments to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prepaid expenses and other current assets, accounts payable, stock-based compensation expense, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">accrued expenses<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 153.14pt; position: absolute; text-decoration: underline; white-space: pre;">,<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 155.91pt; position: absolute; text-decoration: line-through; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 158.68pt; position: absolute; white-space: pre;">other current liabilities, warrant liabilities, other income (expense), additional paid-in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">capital,<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 103.66pt; position: absolute; text-decoration: underline; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 106.43pt; position: absolute; white-space: pre;">which were recorded prior to the issuance of the consolidated financial statements.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 312pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Additionally, these material weaknesses could result in a misstatement of substantially all of our accounts <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 324pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or disclosures that would result in a material misstatement to the annual or interim consolidated financial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 336pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">statements that would not be prevented or detected.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 356pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The following additional material weakness was also identified&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">We did not design and maintain effective controls over information technology (&#8220;IT&#8221;) general controls <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 388pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">for information systems that are relevant to the preparation of our consolidated financial statements. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 400pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Specifically, we did not design and maintain&#58; (i) program change management controls to ensure that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 412pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">information technology program and data changes affecting financial IT applications and underlying <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 424pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">accounting records are identified, tested, authorized and implemented appropriately&#59; (ii) user access <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 436pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">controls to ensure appropriate segregation of duties and that adequately restrict user and privileged <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 448pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">access to financial applications, programs and data to appropriate personnel&#59; (iii) computer <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 460pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">operations controls to ensure data backups are authorized and monitored&#59; and (iv) testing and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 472pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">approval controls for program development to ensure that new software development is aligned with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 484pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">business and IT requirements. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 504pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">These IT deficiencies did not result in any adjustments to the consolidated financial statements. However, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 516pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the deficiencies, when aggregated, could impact maintaining effective segregation of duties, as well as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 528pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the effectiveness of IT-dependent controls (such as automated controls that address the risk of material <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">misstatement to one or more assertions, along with the IT controls and underlying data that support the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">effectiveness of system-generated data and reports) that could result in misstatements potentially <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">impacting all financial statement accounts and disclosures that would not be prevented or detected.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 510.29pt; position: absolute; text-decoration: underline; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Accordingly, management has determined these deficiencies in the aggregate constitute a material <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">weakness. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 608pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">With the oversight of senior management and our audit committee, we have executed implementation of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 620pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">remediation steps. These efforts focused on (i) the hiring of personnel with technical accounting and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 632pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">financial reporting experience, (ii) the engagement of a third-party firm to assist in the design and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">implementation of controls, (iii) the design and implementation of accounting and financial reporting, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">IT general controls to improve the completeness, timeliness and accuracy of our financial reporting and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 668pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">disclosures including non-routine, unusual or complex transactions such as the assessment of accounting <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 680pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for warrants, debt modifications and preferred stock financing. We continue to test the operating <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 692pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">effectiveness of the controls designed and implemented. We are committed to continuing to improve our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 704pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">internal control over financial reporting.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">56<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">While we continue to evaluate the controls we implemented to address the material weaknesses including <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">operating effectiveness for a sufficient period of time to support remediation, we cannot predict the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">success of such plan or the outcome of our assessment of these plans at this time. We can give no <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">assurance that the controls designed and implemented will operate effectively to remediate these <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">deficiencies in internal control over financial reporting or that additional material weaknesses in our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">internal control over financial reporting will not be identified in the future. Our failure to implement and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">maintain effective internal control over financial reporting could result in material misstatements in our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 156pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">financial statements that could result in a restatement of our financial statements, causing us to fail to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 168pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">meet our reporting obligations. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">As a public company, we will be required to provide a report by management on the effectiveness of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">internal control over financial reporting in connection with each annual report on Form 10-K to be filed <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">with the SEC. Once we cease to be an emerging growth company, our independent registered public <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">accounting firm will also be required to audit the effectiveness of our internal control over financial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reporting in connection with each annual report on Form 10-K to be filed with the SEC. We will be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">required to disclose changes made in our internal control over financial reporting that have materially <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">affected, or are reasonably likely to materially affect, our internal control over financial reporting on a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 272pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">quarterly basis. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">We may require additional capital to support business growth, and this capital might not be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">available on terms favorable to us, or at all, and may dilute ownership of our common stock for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">our stockholders, including purchasers of common stock in this offering.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 336pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We intend to continue to make investments to support our business growth and may require additional <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 348pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">funds to respond to business challenges and opportunities, including the need to develop new products, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">enhance our existing products, enhance our operating infrastructure, potentially expand internationally <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and potentially acquire complementary businesses and technologies. In order to achieve these objectives, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 384pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">we may make future commitments of capital resources. Accordingly, we may need to engage in equity or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">debt financings to secure additional funds. If we raise additional funds through further issuances of equity <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or convertible debt securities, our stockholders, including any purchasers of common stock in this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">offering, could suffer significant dilution, and any new equity securities we issue could have rights, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 432pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">preferences and privileges superior to those of holders of our common stock. In addition, our ability to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 444pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">incur indebtedness is subject to limitations under the 2024 Credit Agreement and, if incurred, would <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 456pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">increase our fixed obligations and could include covenants or other restrictions that would impede our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 468pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">ability to manage our operations. Further, if additional financing is needed, we may not be able to obtain <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">additional financing on terms favorable to us or at all. Our inability to obtain adequate financing or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 492pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">financing on terms satisfactory to us, when we require it, could significantly limit our ability to continue <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 504pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">supporting our business growth and responding to business challenges and opportunities.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 524pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Our operating results may fluctuate significantly, which makes our future operating results <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 536pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">difficult to predict and could cause our operating results to fall below expectations or any <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 548pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">guidance we may provide.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 568pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our quarterly revenue and results of operations may fluctuate from quarter to quarter due to, among <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 580pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">others, the following reasons&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 600pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the level of physicians&#8217; acceptance and adoption of our products, and changes in the rates at which <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">physicians order our Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 247.18pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 255.84pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis or the percentage of CCTA scans for which our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 154.4pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 164.75pt; position: absolute; text-decoration: none; white-space: pre;">Analysis is ordered&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">determinations, including the timing of determinations, by payers concerning coverage and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">reimbursement of our products&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 676pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">changes in coverage amounts or government and payers&#8217; reimbursement policies&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 696pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the timing, expense and results of research and development activities, clinical trials and any <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 708pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">additional regulatory approvals&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">57<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">changes in AHA or ACC guidelines, or guidelines in other countries, that lower support for our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">products or elevate alternative products as the preferred pathway for diagnosis and management of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">CAD&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">fluctuations in our expenses associated with expanding our commercial operations and operating as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">a public company&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 148pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">patients meeting their annual health insurance deductible later in the calendar year&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 168pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the introduction of new products and technologies by our competitors&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">changes in our pricing policies or in the pricing policies of our competitors&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 208pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the productivity of our sales and marketing teams, and their ability to identify physicians who <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">consistently refer appropriate patients for CCTAs in accordance with AHA and ACC guidelines&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 240pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">quality problems with our products or the Heartflow Platform&#59; and<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the impact of catastrophic events such as a pandemic.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Because of these and other factors, it is likely that in some future period our operating results will not <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">meet investor expectations or those of public market analysts. Any unanticipated change in revenue or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">operating results is likely to cause our stock price to fluctuate. New information may cause investors and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">analysts to revalue our business, which could cause a decline in our stock price.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 336pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Our credit agreement contains certain restrictions that may limit our ability to operate our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 348pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">business. If we raise additional capital through debt financing, the terms of any new debt could <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">further restrict our ability to operate our business.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 380pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The terms of the 2024 Credit Agreement and related collateral documents contain, and any future debt <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 392pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">agreements would likely contain, a number of restrictive covenants that impose significant operating and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 404pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">financial restrictions on us, including restrictions on our ability, and the ability of our subsidiaries, to take <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 416pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">actions that may be in our best interests, including, among others, disposing of assets, entering into <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 428pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">change of control transactions, mergers or acquisitions, incurring additional indebtedness, granting liens <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 440pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">on our assets and declaring and paying dividends. Our ability to meet covenants can be affected by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 452pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">events beyond our control, and we may not be able to continue to meet such covenants. We have in the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 464pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">past, and may in the future, breach our covenants under the 2024 Credit Agreement. In March 2023, we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 476pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">entered into an agreement with Hayfin to temporarily waive certain covenant requirements that had not <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 488pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">been met pursuant to our prior credit agreement with Hayfin. In the future, a breach of the covenants or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 500pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the occurrence of other events (including, among others, a material adverse effect or the inability to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 512pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">generate cash to service our obligations under our debt agreements) specified in the 2024 Credit <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 524pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Agreement and&#47;or the related collateral documents or a future debt agreement could result in an event of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 536pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">default. Upon the occurrence of an event of default, our lenders could elect to declare all obligations <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 548pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">owing under the debt documents, if any, to be immediately due and payable, terminate all commitments to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 560pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">extend further credit and&#47;or proceed against the collateral, if any, pledged to them to secure such <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 572pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">indebtedness. For example, we have pledged substantially all of our assets, including, among others, our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 584pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">intellectual property, all of Heartflow&#8217;s ownership interests in Heartflow, Inc. and our foreign subsidiaries <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 596pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">as collateral under the 2024 Credit Agreement and related collateral documents. For additional <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 608pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">information on the 2024 Credit Agreement, see the section titled &#8220;Management&#8217;s discussion and analysis <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 620pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of financial condition and results of operations&#8212;Liquidity and capital resources&#8212;Hayfin credit <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 632pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">agreement.&#8221; If lenders accelerate the repayment of borrowings, if any, we may not have sufficient funds to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">repay our existing debt and the lenders could seize collateral that was pledged as guarantee for the loan, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">which would harm our business and financial condition. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 676pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Amounts borrowed under the 2024 Credit Agreement can be repaid at any time, subject to applicable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 688pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prepayment fees, prior to the June 14, 2028 maturity date, at which time all obligations owing under the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 700pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">debt documents will be due and payable. The 2024 Credit Agreement contains customary affirmative and <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">58<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">negative covenants, indemnification provisions and events of default. The affirmative covenants include, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">among others, covenants requiring us to deliver certain financial reports and to maintain our legal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">existence, regulatory authorizations and certain intellectual property rights. The negative covenants <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">include, among others, restrictions on changing our business activities, incurring additional indebtedness <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and creating liens on our assets, requirements to maintain certain levels of liquidity and minimum net <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">sales, restrictions on making investments, paying dividends, issuing securities, engaging in mergers or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">acquisitions, licensing our assets or making other distributions, in each case subject to customary <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 156pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">exceptions. If we default under the 2024 Credit Agreement, Hayfin will be able to declare all obligations <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 168pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">immediately due and payable and take control of our pledged assets, which may require us to renegotiate <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 180pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our agreement on terms less favorable to us or to immediately cease operations. Any event of default by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 192pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">us could significantly harm our business, financial condition, results of operations and prospects and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 204pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">could cause the price of our common shares to decline. Further, if we are liquidated, Hayfin&#8217;s right to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 216pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">repayment would be senior to the rights of the holders of our common shares to receive any proceeds <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 228pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">from the liquidation.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In connection with the completion of this offering, we are obligated to repay indebtedness outstanding <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">under the 2024 Credit Agreement in an amount equal to the lesser of (i) net cash proceeds in excess of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 272pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">$150 million and (ii) $50 million (or $55 million if the underwriters exercise their option to purchase <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 284pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">additional shares). While we currently anticipate paying off $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million of outstanding indebtedness <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 296pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">under the 2024 Credit Agreement immediately following the completion of this offering, a portion of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">indebtedness under the 2024 Credit Agreement will remain outstanding and we will be subject to the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 320pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">ongoing requirements of the 2024 Credit Agreement and related collateral documents. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">We are subject to risks associated with currency fluctuations, and changes in foreign currency <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">exchange rates could impact our results of operations.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">All of our revenue and the majority of our expense and capital purchasing activities through the year <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 384pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">ended December 31, 2024 were transacted in U.S. dollars. Approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of our 2024 revenue <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and approximately 11% of our 2023 revenue was generated from customers outside the United States. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">However, because a portion of our operations consists of business activities outside of the United States, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">we have foreign currency operating expenses as well as asset and liability balances. During the year <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 432pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">ended December 31, 2024, we were exposed to foreign currency risks in connection with our non-U.S. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 444pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">operations, and we anticipate that, over time, an increasing portion of our international agreements may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 456pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">provide for payment denominated in foreign currencies. Changes in the exchange rates between such <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 468pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">foreign currencies and the U.S. dollar could therefore materially impact our reported results of operations <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and distort period-to-period comparisons. Fluctuations in foreign currency exchange rates also impact the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 492pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reporting of our receivables and payables in non-U.S. currencies. As a result of such foreign currency <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 504pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">fluctuations, it could be more difficult to detect underlying trends in our business and results of operations. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 516pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition, to the extent that fluctuations in currency exchange rates cause our results of operations to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 528pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">differ from our expectations or the expectations of our investors, the trading price of our common stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">could be adversely affected.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 560pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We do not currently engage in currency hedging activities to limit the risk of exchange rate fluctuations. In <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 572pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the future, we may engage in exchange rate hedging activities in an effort to mitigate the impact of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 584pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">exchange rate fluctuations but we may not be successful in doing so. If our hedging activities are not <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 596pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">effective, changes in currency exchange rates may have a more significant impact on our results of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 608pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">operations.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 628pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Our ability to use our net operating losses and tax credits to offset future taxable income and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 640pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">taxes may be subject to certain limitations.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">As of December 31, 2024, we had net operating loss (&#8220;NOL&#8221;) carryforwards of approximately <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million and $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million for federal and state income tax purposes, respectively, which may be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 684pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">utilized against future federal and state income taxes. Federal NOL carryforwards we generated in tax <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 696pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">years through December&#160;31, 2017 generally may be carried forward for 20 years and may fully offset <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 708pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">taxable income in the year utilized, and federal NOLs we generated in tax years beginning after <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">59<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">December&#160;31, 2017 generally may be carried forward indefinitely but may only be used to offset 80% of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our taxable income annually for tax years beginning after December&#160;31, 2017.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In general, under Section 382 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its pre-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">change NOLs, carryforwards and other tax attributes, such as research and development tax credits, to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">offset future taxable income and taxes. In general, an ownership change occurs if the aggregate stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">ownership of certain stockholders, generally stockholders beneficially owning five percent or more of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">common stock, applying certain look through and aggregation rules, increases by more than 50% over <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">such stockholders&#8217; lowest percentage ownership during the testing period, generally three years. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Purchases of our common stock in amounts greater than specified levels, which will be beyond our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">control, could create a limitation on our ability to utilize our NOLs for tax purposes in the future. We are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">currently completing a 382 study to determine whether the use of our NOLs is impaired. We may have <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">previously undergone an &#8220;ownership change.&#8221; In addition, this offering or future issuances or sales of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock, including certain transactions involving our stock that are outside of our control, could result in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">future &#8220;ownership changes.&#8221; &#8220;Ownership changes&#8221; that have occurred in the past or that may occur in the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">future, including in connection with this offering, could result in the imposition of an annual limit on the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 272pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">amount of pre-ownership change NOLs and other tax attributes we can use to reduce our taxable income, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 284pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">potentially increasing and accelerating our liability for income taxes, and also potentially causing those tax <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 296pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">attributes to expire unused.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">If we are limited in our ability to use our NOLs and tax credits in future years in which we have taxable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">income, we will pay more taxes than if we were able to fully utilize our NOLs and tax credits, and we could <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">be required to pay taxes earlier than we would otherwise be required, which could cause such NOLs to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">expire unused. This could adversely affect our results of operations. Furthermore, we may not be able to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 364pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">generate sufficient taxable income to utilize our pre-2018 NOLs before they expire beginning in 2030. If <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">any of these events occur, we may not derive some or all of the expected benefits from our NOLs, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 388pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our business, financial condition, results of operations and prospects may be adversely affected as a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 400pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">result.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Our international operations subject us to potentially adverse tax consequences.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 440pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We currently report our taxable income in various jurisdictions based upon our business operations in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 452pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">those jurisdictions, including in the United States, United Kingdom, and Japan. We may in the future be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 464pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">subject to reporting requirements in other foreign jurisdictions. The international nature and organization <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 476pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of our business activities are subject to complex transfer pricing regulations administered by taxing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 488pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">authorities in various jurisdictions. The relevant taxing authorities may disagree with our determinations <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 500pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">as to the income and expenses attributable to specific jurisdictions. If such a disagreement were to occur, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 512pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and our position were not sustained, we could be required to pay additional taxes, interest and penalties, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 524pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">which could result in one time tax charges, higher effective tax rates, reduced cash flows and lower <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 536pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">overall profitability of our operations. We believe that our consolidated financial statements reflect <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 548pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">adequate reserves to cover such a contingency, but there can be no assurances in that regard.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 568pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Our effective tax rate may vary significantly from period to period. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Various internal and external factors may have favorable or unfavorable effects on our future effective tax <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 600pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">rate. These factors include, but are not limited to, changes in tax laws, regulations or rates, both within <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and outside the United States, structural changes in our business, new accounting pronouncements or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">changes to existing accounting pronouncements, non-deductible goodwill impairments, changing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 636pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">interpretations of existing tax laws or regulations, changes in the relative proportions of revenue and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 648pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">income before taxes in the various jurisdictions in which we operate that have different statutory tax rates, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the future levels of tax benefits of equity-based compensation, changes in overall levels of pretax <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">earnings or changes in the valuation of our deferred tax assets and liabilities. Additionally, we could be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 684pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">challenged by state and local tax authorities as to the propriety of our sales tax compliance, and our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 696pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">results could be materially impacted by these compliance determinations. <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">60<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition, our effective tax rate may vary significantly depending on the market price of our common <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock. The tax effects of the accounting for share-based compensation may significantly impact our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">effective tax rate from period to period. In periods in which the market price of our common stock is higher <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">than the grant price of the share-based compensation vesting in that period, we will recognize excess tax <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">benefits that will decrease our effective tax rate. In future periods in which our stock price is lower than <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the grant price of the share-based compensation vesting in that period, our effective tax rate may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">increase. The amount and value of share-based compensation issued relative to our earnings in a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 156pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">particular period will also affect the magnitude of the impact of share-based compensation on our effective <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 168pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">tax rate. These tax effects are dependent on the market price of our common stock, which we do not <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 180pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">control, and a decline in our stock price could significantly increase our effective tax rate and adversely <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 192pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">affect our financial condition.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Taxing authorities may successfully assert that we should have collected or in the future should <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">collect sales and use, value added or similar taxes, and we could be subject to tax liabilities with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">respect to past or future sales, which could adversely affect our results of operations.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We do not collect sales and use, value added and similar taxes in all jurisdictions in which we have sales, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">based on our belief that such taxes are not applicable or that we are not required to collect such taxes <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">with respect to the jurisdiction. Sales and use, value added and similar tax laws and rates vary greatly by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">jurisdiction. Certain jurisdictions in which we do not collect such taxes may assert that such taxes are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">applicable, which could result in tax assessments, penalties and interest, and we may be required to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">collect such taxes in the future. Such tax assessments, penalties and interest or future requirements may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">adversely affect our results of operations.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 348pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Risks related to our common stock and this offering<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 370.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">There may not be an active trading market for our common stock, which may cause shares of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 382.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">common stock to trade at a discount from the initial public offering price and make it difficult to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 394.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">sell the shares of common stock you purchase. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 414.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Prior to this offering, there was no public market for our common stock. It is possible that after this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 426.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">offering, an active trading market will not develop or, if developed, that any market will not be sustained, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 438.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">which would make it difficult for you to sell your shares of common stock at an attractive price or at all. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 450.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The initial public offering price per share of common stock was determined by agreement among us and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 462.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the representatives of the underwriters and may not be indicative of the price at which shares of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 474.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">common stock will trade in the public market, if any, after this offering. The market value of our common <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 486.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock may decrease from the initial public offering price. It is possible that in one or more future periods <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 498.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our results of operations may be below the expectations of public market analysts and investors, and, as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 510.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">a result of these and other factors, the price of our common stock may fall. Furthermore, an inactive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 522.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">market may also impair our ability to raise capital in the future by selling shares of our common stock.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 542.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">The market price of our common stock may be volatile, which could cause the value of your <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 554.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">investment to decline and could result in substantial losses for investors purchasing shares in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 566.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">this offering. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 586.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">This initial public offering price may vary from the market price of our common stock after the offering. The <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 598.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">market price of our common stock may be highly volatile and could be subject to wide fluctuations. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 610.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Securities markets worldwide experience significant price and volume fluctuations. This market volatility, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 622.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">as well as general economic, market or political conditions, could reduce the market price of our common <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 634.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock regardless of our operating performance. These fluctuations may be even more pronounced in the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 646.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">trading market for our stock shortly following this offering. You may be unable to resell your shares of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 658.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">common stock at or above the initial public offering price or at all. <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">61<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">We are an emerging growth company, and the reduced reporting requirements applicable to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">emerging growth companies could make our common stock less attractive to investors. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. We will remain an &#8220;emerging growth <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">company&#8221; until the earliest to occur of&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 136pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the last day of the fiscal year during which our total annual revenue equals or exceeds $1.235 billion <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 148pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">(subject to adjustment for inflation)&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 168pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the last day of the fiscal year following the fifth anniversary of this offering&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the date on which we have, during the previous three-year period, issued more than $1 billion in non-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">convertible debt&#59; or<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the date on which we are deemed to be a &#8220;large accelerated filer&#8221; under the Exchange Act.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 240pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">As a result of our &#8220;emerging growth company&#8221; status, we may take advantage of exemptions from various <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 252pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reporting requirements that would otherwise be applicable to public companies including, but not limited <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 264pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 276pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">statements and exemptions from the requirements of holding a nonbinding advisory vote on executive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 288pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">compensation and stockholder approval of any golden parachute payments not previously approved. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Investors may find our common stock less attractive because we may rely on these exemptions. If some <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 320pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">investors find our common stock less attractive as a result, there may be a less active trading market for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 332pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our common stock and the market price of our common stock may be adversely affected and more <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 344pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">volatile.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 364pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">We will incur increased costs and become subject to additional regulations and requirements as a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">result of becoming a public company, which could lower our profits or make it more difficult to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 388pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">run our business. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">As a public company, we will incur significant legal, accounting and other expenses that we have not <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">incurred as a private company, including costs associated with public company reporting requirements. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 432pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We have also incurred and will continue to incur costs associated with the Sarbanes-Oxley Act and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 444pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">related rules implemented by the SEC and the listing requirements of the&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. The expenses <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 456pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">generally incurred by public companies for reporting and corporate governance purposes have been <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 468pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">increasing. We expect these rules and regulations to increase our legal and financial compliance costs <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and to make some activities more time-consuming and costly, although we are currently unable to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 492pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">estimate these costs with any degree of certainty. These laws and regulations also could make it more <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 504pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">difficult or costly for us to obtain certain types of insurance, including director and officer liability <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 516pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">insurance, and we may be forced to accept reduced policy limits and coverage or incur substantially <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 528pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">higher costs to obtain the same or similar coverage. These laws and regulations could also make it more <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">difficult for us to attract and retain qualified persons to serve on our board of directors, on our board <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">committees or as our executive officers. Furthermore, if we are unable to satisfy our obligations as a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">public company, we could be subject to delisting of our common stock, fines, sanctions, other regulatory <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">action and potentially civil litigation. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 596pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">If we are unable to design, implement and maintain effective internal control over financial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 608pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">reporting in the future, investors may lose confidence in the accuracy and completeness of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 620pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">financial reports and the market price of our common stock may decline.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 640pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">As a public company, we will be required to maintain internal control over financial reporting and to report <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 652pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">any material weaknesses in such internal controls. In addition, beginning with our second annual report <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 664pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">on Form 10-K, we will be required to furnish a report by management on the effectiveness of our internal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 676pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">control over financial reporting, pursuant to the rules and regulations of the SEC regarding compliance <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 688pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">with Section 404 of the Sarbanes-Oxley Act. The process of designing, implementing and testing the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 700pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">internal control over financial reporting required to comply with this obligation is time consuming, costly <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">62<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and complicated. We have identified control deficiencies including material weaknesses and may identify <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">control deficiencies, including material weaknesses in our internal control over financial reporting, in the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">accurately report our financial condition, results of operations or cash flows. Further, if we identify one or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">more material weaknesses in our internal control over financial reporting, if we are unable to comply with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner or if we or, if required, our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">auditors, are unable to assert that our internal control over financial reporting is effective, investors may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 156pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">lose confidence in the accuracy and completeness of our financial reports and the market price of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 168pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">common stock could decline, and we could also become subject to investigations by the stock exchange <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 180pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">on which our common stock is listed, the SEC or other regulatory authorities, which could require <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 192pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">additional financial and management resources. Failure to remedy any material weakness in our internal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 204pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">control over financial reporting, or to implement or maintain other effective control systems required of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 216pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">public companies, could also restrict our future access to the capital markets.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Upon effectiveness of the registration statement of which this prospectus forms a part, we will become <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">subject to the periodic reporting requirements of the Exchange Act. Our disclosure controls and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">procedures are designed to reasonably ensure that information required to be disclosed by us in reports <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">we file or submit under the Exchange Act is accumulated and communicated to management and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">recorded, processed, summarized and reported within the time periods specified in the rules and forms of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the SEC. We believe that our disclosure controls and procedures as well as internal control over financial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reporting, no matter how well conceived and operated, can provide only reasonable, not absolute, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">assurance that the objectives of the control system are and will be met. These inherent limitations include <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the realities that judgments in decision making can be faulty and that breakdowns can occur because of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 364pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 388pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the inherent limitations in our control system, misstatements due to error or fraud may occur and not be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 400pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">detected.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">If our estimates or judgments relating to our critical accounting policies are based on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 432pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">assumptions that change or prove to be incorrect, our operating results could fall below our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 444pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">publicly announced guidance or the expectations of securities analysts and investors, resulting in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 456pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">a decline in the market price of our common stock.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 476pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The preparation of financial statements in conformity with the United States generally accepted <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 488pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 500pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reported amounts of assets, liabilities, revenue, expenses and related disclosures. We base our estimates <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 512pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">on historical experience and various other factors that we believe are reasonable under the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 524pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">circumstances, the results of which form the basis for making judgments about the carrying value of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 536pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">assets and liabilities that are not readily apparent from other sources. Actual results may differ from these <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 548pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">estimates under different assumptions or conditions and any such differences may be material. If our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 560pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">assumptions change or if actual circumstances differ from our assumptions, our operating results may be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 572pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">adversely affected and could fall below our publicly announced guidance or the expectations of analysts <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 584pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and investors, resulting in a decline in the market price of our common stock.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 604pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Our principal stockholders and management own a significant percentage of our stock and will be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 616pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">able to exert significant control over matters subject to stockholder approval.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 636pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Prior to this offering, as of December 31, 2024, our executive officers, directors, owners of more than 5% <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 648pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of our capital stock and their respective affiliates beneficially owned approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">outstanding shares and, upon the completion of this offering, that same group will beneficially own <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of our outstanding shares (assuming no exercise of the underwriters&#8217; option to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 684pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">purchase additional shares). Therefore, even after this offering, these stockholders will have the ability to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 696pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">influence us through this ownership position. These stockholders may be able to determine all matters <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 708pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">requiring stockholder approval. For example, these stockholders may be able to control elections of <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">63<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">directors, amendments of our organizational documents, or approval of any merger, sale of assets or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">offers for our common stock that you may feel are in your best interest as one of our stockholders.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">A significant portion of our total outstanding shares is restricted from immediate resale but may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">be sold into the market in the near future, and any sales of a substantial number of shares of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">common stock in the public market could cause our stock price to decline significantly, even if <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">our business is doing well.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 172pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Sales of a substantial number of shares of our common stock in the public market could occur at any <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 184pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">time. These sales, or the perception in the market that the holders of a large number of shares of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 196pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">common stock intend to sell shares, could reduce the market price of our common stock. If our existing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 208pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">market after the lock-up agreements, market standoff and other legal restrictions on resale discussed in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">this prospectus, including as described under the section titled &#8220;Shares eligible for future sale&#8212;Lock-up <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">agreements,&#8221; lapse, the trading price of our common stock could decline. Based upon the number of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">shares outstanding as of December 31, 2024 and assuming (i) the Preferred Stock Conversion, (ii) the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Convertible Notes Conversion, (iii) no exercise of the underwriters&#8217; option to purchase additional shares of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our common stock, and (iv) no exercise of outstanding options or warrants, upon the completion of this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">offering, we will have outstanding a total of &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock. Of these shares, all of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">shares of our common stock sold in this offering, plus any shares sold upon exercise of the underwriters&#8217; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">option to purchase additional shares, if any, will be freely tradable, without restriction, in the public market <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">immediately following this offering, other than shares purchased by our &#8220;affiliates&#8221; (as such term is defined <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">in Rule 144 under the Securities Act). See the section titled &#8220;Shares eligible for future sale&#8221; in this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prospectus for restrictions applicable to our affiliates. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We and each of our directors, our executive officers and substantially all of our other securityholders have <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 384pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">entered or will enter into lock-up agreements with the underwriters prior to the completion of this offering, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">which are described in the section titled &#8220;Underwriting&#8221;. After the expiration of the lock-up agreements, as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of December 31, 2024, up to approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;million additional shares of common stock will be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">eligible for sale in the public market, approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of which shares are owned by directors, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 432pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">executive officers and other owners of more than 5% of our outstanding common stock, stock options, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 444pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">warrants and securities convertible into our common stock and will be subject to Rule 144 under the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 456pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Securities Act. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 476pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Furthermore, an additional approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of our outstanding common stock, stock options, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 488pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">warrants and other securities convertible into or exercisable or exchangeable for our common stock are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 500pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">subject to market standoff restrictions with us that include restrictions on the sale, transfer or other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 512pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">disposition of shares, among other things and subject to certain exceptions, for a period of 180 days <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 524pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">commencing on the date of this prospectus. As a result of the foregoing, substantially all of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 536pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">outstanding common stock, stock options, warrants and other securities convertible into or exercisable or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 548pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">exchangeable for our common stock are subject to a lock-up agreement or market standoff provisions for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 560pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">a period of 180 days commencing on the date of this prospectus. See the section titled &#8220;Shares eligible <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 572pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for future sale&#8221; for additional information.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 592pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">After this offering, based upon the number of shares outstanding as of December 31, 2024, the holders of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 604pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million shares of our common stock, or approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of our total outstanding <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 616pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">common stock, will be entitled to rights with respect to the registration of their shares under the Securities <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 628pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Act, subject to the lock-up agreements and market standoff restrictions described above. Registration of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 640pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">these shares under the Securities Act would result in the shares becoming freely tradable without <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 652pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">restriction under the Securities Act, except for shares purchased by affiliates. Any sales of securities by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 664pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">these stockholders or any perception that these shares may be sold could have a material adverse effect <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 676pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">on the trading price of our common stock. In addition, a security holder who is not subject to market <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 688pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">standoff restrictions with us nor a lock-up agreement with the underwriters may be able to sell, short sell, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 700pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">transfer, pledge or otherwise dispose of their equity interests at any time.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">64<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Our amended and restated certificate of incorporation will provide that the Court of Chancery of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">the State of Delaware (or, if such court does not have jurisdiction, Delaware federal district court) <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">will be the exclusive forum for certain disputes between us and our stockholders, which could <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">directors, officers or employees. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our amended and restated certificate of incorporation will provide that, unless we consent in writing to the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">selection of an alternative forum, the Court of Chancery of the State of Delaware (or, in the event that the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware) is the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">claim of breach of fiduciary duty owed by any of our current or former directors, officers, employees or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stockholders to us or to our stockholders, any action asserting a claim against us arising pursuant to the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Delaware General Corporation Law, our amended and restated certificate of incorporation, or our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">amended and restated bylaws (as either may be amended from time to time) or as to which the Delaware <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">General Corporation Law confers jurisdiction on the Delaware Court of Chancery, or any action asserting <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">a claim against us that is governed by the internal affairs doctrine of the State of Delaware. Our amended <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and restated certificate of incorporation will also provide that the federal district courts of the United States <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 272pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">will be the exclusive forum for the resolution of any complaint asserting a cause of action arising under <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 284pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the Securities Act. Further, our amended and restated certificate of incorporation will provide that the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 296pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">foregoing choice of forum provisions will not apply to suits brought to enforce any liability or duty created <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">by the Exchange Act, or any other claim for which the federal courts of the United States have exclusive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 320pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">jurisdiction. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our amended and restated certificate of incorporation will also provide that any person or entity <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">purchasing or otherwise acquiring or holding any interest in any of our securities shall be deemed to have <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 364pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">notice of and consented to the foregoing provisions of the amended and restated certificate of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">incorporation. Although our amended and restated certificate of incorporation will contain the choice of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 388pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">forum provision described above, it is possible that a court could find that such a provision is inapplicable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 400pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for a particular claim or action or that such provision is unenforceable. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We believe these provisions may benefit us by providing increased consistency in the application of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 432pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Delaware law and federal securities laws by chancellors and judges, as applicable, particularly <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 444pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">experienced in resolving corporate disputes, efficient administration of cases on a more expedited <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 456pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">schedule relative to other forums, and protection against the burdens of multi-forum litigation. However, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 468pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">this choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 492pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">which may discourage lawsuits with respect to such claims, although our stockholders will not be deemed <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 504pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to have waived our compliance with federal securities laws and the rules and regulations thereunder. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 516pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217; certificates of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 528pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">incorporation has been challenged in legal proceedings, and it is possible that a court could find these <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">types of provisions to be inapplicable or unenforceable. While the Delaware courts have determined that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">a venue other than those designated in the exclusive forum provisions, and there can be no assurance <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">that such provisions will be enforced by a court in those other jurisdictions. If a court were to find the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">choice of forum provision that will be contained in our amended and restated certificate of incorporation to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 600pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">such action in other jurisdictions, which could adversely affect our business, financial condition, results of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">operations and prospects. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 644pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">General risk factors<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 666.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">We will have broad discretion in the use of net proceeds to us from this offering and may not use <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 678.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">them effectively. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 698.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In connection with the completion of this offering, we are obligated to use certain of the net proceeds from <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 710.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">this offering to repay approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million of the indebtedness outstanding under the 2024 <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">65<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Credit Agreement and to pay approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million of fees in connection therewith. We expect to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">use the remainder to fund our sales and marketing efforts, fund research and product development <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">activities and for other general corporate purposes, including working capital, operating expenses, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">capital expenditures. We may also use a portion of the net proceeds from this offering to acquire <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">complementary businesses, products, services, or technologies. We periodically evaluate strategic <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">opportunities&#59; however, we have no current understandings or commitments to enter into any such <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">acquisitions or make any such investments. The expected use of net proceeds from this offering <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 156pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">represents our intentions based upon our present plans and business conditions. We cannot predict with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 168pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">certainty all of the particular uses for the proceeds of this offering or the amounts that we will actually <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 180pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">spend on the uses set forth above. Accordingly, our management will have broad discretion in applying <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 192pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the net proceeds of this offering, including for any of the purposes described in the section titled &#8220;Use of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 204pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">proceeds,&#8221; and you will not have the opportunity as part of your investment decision to assess whether <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 216pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the net proceeds are being used appropriately. The timing and amount of our actual expenditures will be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 228pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">based on many factors, including cash flows from operations and the anticipated growth of our business. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 240pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Pending their use, we intend to invest the net proceeds of this offering in a variety of capital-preservation <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 252pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">investments, including government securities and money market funds. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 272pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">If we do not use the net proceeds that we receive in this offering effectively, our business, financial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 284pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">condition, results of operations and prospects could be harmed, and the market price of our common <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 296pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock could decline. Pending their use, we intend to invest the net proceeds of this offering in a variety of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">capital-preservation investments, including government securities and money market funds. These <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 320pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">investments may not yield a favorable return to our investors.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Investors in this offering will experience immediate and substantial dilution. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The initial public offering price of our common stock is substantially higher than the pro forma as adjusted <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">net tangible book value per share of our common stock. Therefore, if you purchase shares of our common <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 384pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock in this offering, you will pay a price per share that substantially exceeds our pro forma as adjusted <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">net tangible book value per share after this offering. Based on the initial public offering price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">share, you will experience immediate dilution of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share, representing the difference between <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our pro forma as adjusted net tangible book value per share after giving effect to this offering and the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 432pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">initial public offering price. In addition, purchasers of common stock in this offering will have <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 444pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">contributed&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of the aggregate price paid by all purchasers of our common stock but will own only <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 456pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of our total equity outstanding after this offering. Furthermore, you will experience <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 468pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">additional dilution if the underwriters exercise their option to purchase additional shares, outstanding <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">options and warrants are exercised, upon the vesting of outstanding restricted stock awards or when we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 492pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">otherwise issue additional shares of common stock. For a further description of the dilution that you will <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 504pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">experience immediately after this offering, see the section titled &#8220;Dilution&#8221; included elsewhere in this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 516pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prospectus.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 536pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">We do not intend to pay dividends in the foreseeable future. As a result, your ability to achieve a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 548pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">return on your investment will depend on appreciation in the market price of our common stock.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 568pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 580pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">available funds and any future earnings, if any, to fund the development and expansion of our business, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 592pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and we do not anticipate paying any cash dividends in the foreseeable future. Any future determinations <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 604pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">regarding the declaration and payment of dividends, if any, will be at the discretion of our board of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 616pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">directors, subject to applicable law, and will depend upon then-existing conditions, including our financial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 628pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">condition, results of operations, contractual restrictions, general business conditions, capital <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 640pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">requirements, and other factors our board of directors may deem relevant. In addition, our ability to pay <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 652pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">cash dividends is currently restricted by the terms of the 2024 Credit Agreement. Our ability to pay cash <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 664pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">dividends on our capital stock in the future may also be limited by the terms of any preferred securities we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 676pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">may issue or agreements governing any additional indebtedness we may incur.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">66<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">If our operating and financial performance in any given period does not meet any guidance that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">we provide to the public, the market price of our common stock may decline. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We may, but are not obligated to, provide public guidance on our expected operating and financial results <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for future periods. Any such guidance will be comprised of forward-looking statements subject to the risks <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and uncertainties described in this prospectus, including in the section titled &#8220;Risk factors,&#8221; and in our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">future public filings and public statements. Our actual results may not always be in line with or exceed any <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">guidance we have provided, especially in times of economic uncertainty. If actual circumstances differ <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">from those in our assumptions, our operating and financial results could fall below our publicly announced <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">guidance or the expectations of investors. If, in the future, our operating or financial results for a particular <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">period do not meet any guidance we provide or the expectations of investment analysts or investors <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">generally, or if we reduce our guidance for future periods, the market price of our common stock may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">decline. Even if we do issue public guidance, there can be no assurance that we will continue to do so in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the future. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">If securities or industry analysts do not publish research or reports about our business, or if they <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">issue an adverse or misleading opinion regarding our stock, our stock price and trading volume <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">could decline. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 288pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The trading market for our common stock will be influenced by the research and reports that industry or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 300pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">securities analysts publish about us or our business. We do not currently have and may never obtain <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 312pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">research coverage by securities and industry analysts. If no or few securities or industry analysts <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 324pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">commence coverage of us, the market price for our stock would be negatively impacted. In the event we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 336pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">obtain securities or industry analyst coverage, if any of the analysts who cover us downgrade their <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 348pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">evaluations of our stock or issue an adverse opinion regarding us, our business model, our intellectual <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">property or our stock performance, or if our results of operations fail to meet the expectations of analysts, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 384pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our stock price or trading volume to decline. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 416pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">We may be subject to securities litigation, which is expensive and could divert management <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 428pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">attention.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 448pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In the past, following periods of volatility in the overall market and the market price of a company&#8217;s <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 460pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">securities, securities class action litigation has often been instituted against these companies. Because of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 472pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the potential volatility of our stock price, we may become the target of securities litigation in the future. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 484pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">These events may also result in or be concurrent with investigations by the SEC. We may be exposed to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 496pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">such litigation or investigation even if no wrongdoing occurred. Such litigation, if instituted against us, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 508pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">could result in substantial costs and a diversion of our management&#8217;s attention and resources, which <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 520pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">could seriously harm our business. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Provisions in our charter documents and under Delaware law could discourage a takeover that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">stockholders may consider favorable and may lead to entrenchment of management. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 572pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">O<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 79.77pt; position: absolute; text-decoration: none; white-space: pre;">ur amended and restated certificate of incorporation, to be in effect immediately prior to the completion <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 584pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">of this offering, and our amended and restated bylaws, to be in effect upon the effectiveness of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 596pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">registration statement of which this prospectus forms a part, <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 339.13pt; position: absolute; white-space: pre;">will contain provisions that could delay or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 608pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prevent changes in control or changes in our management without the consent of our board of directors. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 620pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">These provisions will include the following&#58; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 640pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">a classified board of directors with three-year staggered terms, which may delay the ability of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 652pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">stockholders to change the membership of a majority of our board of directors&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our directors may be removed by our stockholders only for cause&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 692pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">no cumulative voting in the election of directors, which limits the ability of minority stockholders to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 704pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">elect director candidates&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">67<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the exclusive right of our board of directors to change the size of the board of directors and to elect a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">director to fill a new directorship created by the expansion of the board of directors or a vacancy <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">created by the resignation, death or removal of a director, which prevents stockholders from being <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">able to change the board&#8217;s size or fill new directorships and vacancies on our board of directors&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the ability of our board of directors to authorize the issuance of shares of preferred stock and to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">determine the price and other terms of those shares, including preferences and voting rights, without <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">adopt a stockholder rights plan&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 184pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the ability of our board of directors to alter our amended and restated bylaws without obtaining <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 196pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">stockholder approval&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 216pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the required approval of at least sixty-six and two-thirds percent (66-2&#47;3%) of the voting power of all <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 228pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">then-outstanding shares of capital stock entitled to vote generally in the election of directors to adopt, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 240pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">amend, alter or repeal our amended and restated bylaws and certain provisions of our amended and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 252pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">restated certificate of incorporation&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 272pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 284pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">an annual or special meeting of our stockholders&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the requirement that a special meeting of stockholders may be called only by our secretary at the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">request of our board of directors, the chairman of our board of directors, or our chief executive officer, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">which may delay the ability of our stockholders to force consideration of a proposal or to take action, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">including the removal of directors&#59; and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">advance notice procedures that stockholders must comply with in order to nominate candidates to our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 384pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">own slate of directors or otherwise attempting to obtain control of us.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 416pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We are also subject to the anti-takeover provisions contained in Section 203 of the Delaware General <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 428pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Corporation Law (&#8220;Section 203&#8221;). Under Section 203, a corporation may not, in general, engage in a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 440pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">business combination (as defined in Section 203) with any interested stockholder (generally defined by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 452pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Section 203 to include holders of 15% or more of our capital stock) unless the interested stockholder has <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 464pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">held the stock for three years or, among other exceptions and exclusions, the board of directors has <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 476pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">approved the business combination transaction or the transaction that resulted in the stockholder <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 488pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">becoming an interested stockholder. For a description of our capital stock, see the section titled <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 500pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">&#8220;Description of capital stock.&#8221;<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">68<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_1039" style="position: absolute; top: 72pt;"></div><div style="line-height: 11.64pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Special note regarding forward-looking statements<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 107.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">This prospectus, including the sections titled &#8220;Prospectus summary,&#8221; &#8220;Risk factors,&#8221; &#8220;Management&#8217;s <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 119.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">discussion and analysis of financial condition and results of operations,&#8221; and &#8220;Business,&#8221; contains express <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 131.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or implied forward-looking statements about us and our industry that involve substantial risks and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 143.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">uncertainties. All statements other than statements of historical facts contained in this prospectus, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 155.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">including statements regarding our strategy, future financial condition, future operations, projected costs, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 167.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prospects, plans, objectives of management, and expected market growth, are forward-looking <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 179.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">statements. In some cases, you can identify forward-looking statements by words such as &#8220;may,&#8221; &#8220;will,&#8221; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 191.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">&#8220;shall,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;could,&#8221; &#8220;intends,&#8221; &#8220;target,&#8221; &#8220;projects,&#8221; &#8220;contemplates,&#8221; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 203.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">&#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;goal,&#8221; &#8220;objective,&#8221; &#8220;seeks,&#8221; or &#8220;continue&#8221; or the negative of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 215.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">these words or other similar terms or expressions that concern our expectations, strategy, plans, or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 227.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">intentions. Forward-looking statements contained in this prospectus include, but are not limited to, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 239.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">statements about&#58; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 259.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our business model and strategic plans for our products, technologies and business, including our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 271.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">implementation thereof&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 291.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our ability to continue improving our products and technologies, including our AI Technologies&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 311.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our expectations regarding government and third-party payer coverage and reimbursement&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 331.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the implementation of our business model and strategic plans&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 351.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our ability to commercialize, manage and grow our business by increasing our sales to existing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 363.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">customers or introducing our products to new customers&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 383.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our ability to compete with other companies engaged in the development of products, including <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 395.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">algorithm-based diagnostic analysis products, that provide existing non-invasive tests that aid in the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 407.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">evaluation of CAD&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 427.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our expectations regarding the potential addressable market size for our products&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 447.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our expectation about market trends&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 467.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our ability to attract, hire and retain key personnel and additional qualified personnel&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 487.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our ability to effectively manage our growth&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 507.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 519.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">including potential effects of evolving and&#47;or extensive government regulation&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 539.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our ability to obtain, maintain and expand regulatory clearances for our products and any new <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 551.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">products we create&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 571.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our ability to establish and maintain intellectual property protection for our products or avoid claims of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 583.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">infringement&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 603.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our expectations regarding the use of the net proceeds from this offering and our existing cash and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 615.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">cash equivalents&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 635.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">estimates of our expenses, future revenue, capital requirements, needs for additional financing and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 647.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our ability to obtain additional capital&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 667.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our ability to expand internationally&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 687.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">general economic, industry, and market conditions, including rising interest rates and inflation&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 707.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our future financial performance&#59; and<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">69<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">other risks and uncertainties, including those listed under the caption &#8220;Risk factors.&#8221;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 92pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">You should not rely on forward-looking statements as predictions of future events. We have based the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">forward-looking statements contained in this prospectus primarily on our current expectations, estimates, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">forecasts, and projections about future events and trends that we believe may affect our business, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">financial condition, results of operations, and prospects. Although we believe that we have a reasonable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">basis for each forward-looking statement contained in this prospectus, we cannot guarantee that the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">future results, levels of activity, performance, or events and circumstances reflected in the forward-looking <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">statements will be achieved or occur at all. The outcome of the events described in these forward-looking <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">statements is subject to risks, uncertainties, and other factors described in the section titled &#8220;Risk factors&#8221; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and elsewhere in this prospectus. Moreover, we operate in a very competitive and rapidly changing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">all risks and uncertainties that could have an impact on the forward-looking statements contained in this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prospectus. The results, events, and circumstances reflected in the forward-looking statements may not <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">be achieved or occur, and actual results, events, or circumstances could differ materially from those <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">described in the forward-looking statements. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The forward-looking statements made in this prospectus relate only to events as of the date on which the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">statements are made. We undertake no obligation to update any forward-looking statements made in this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prospectus to reflect events or circumstances after the date of this prospectus or to reflect new <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">information or the occurrence of unanticipated events, except as required by law. We may not actually <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">not place undue reliance on our forward-looking statements. Our forward-looking statements do not <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, or investments <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">we may make.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 384pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">relevant subject. These statements are based upon information available to us as of the date of this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prospectus, and while we believe such information forms a reasonable basis for such statements, such <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">information may be limited or incomplete, and our statements should not be read to indicate that we have <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 432pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">statements are inherently uncertain, and you are cautioned not to unduly rely on these statements.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 452pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">You should read this prospectus and the documents that we reference in this prospectus and have filed <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 464pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">as exhibits to the registration statement, of which this prospectus is a part, completely and with the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 476pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">understanding that our actual future results may be materially different from what we expect. We qualify <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 488pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">all of the forward-looking statements in this prospectus by these cautionary statements.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">70<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_1064" style="position: absolute; top: 72pt;"></div><div style="line-height: 11.64pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Market and industry data<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 107.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">This prospectus contains estimates, projections, and other information concerning our industry and our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 119.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">business, as well as data regarding market research, estimates, and forecasts prepared by our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 131.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">management or third parties, including but not limited to, Clarivate&#8482;. Information that is based on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 143.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">estimates, forecasts, projections, market research, or similar methodologies is inherently subject to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 155.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">uncertainties, and actual events or circumstances may differ materially from events and circumstances <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 167.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">that are assumed in this information. These data and the industry in which we operate is subject to a high <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 179.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">degree of uncertainty and risk due to a variety of factors, including those described in the section titled <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 191.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">&#8220;Risk factors.&#8221; These and other factors could cause results to differ materially from those expressed in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 203.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">these estimates, publications, and reports made by third parties or us.&#160;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 223.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Unless otherwise expressly stated, we obtained such industry, business, market, and other data from <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 235.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reports, research surveys, studies, and similar data prepared by market research firms and other third <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 247.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">parties, industry and general publications, government data, and similar sources. In some cases, we do <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 259.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 271.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">more sources of this type of data in any paragraph, you should assume that other data of this type <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 283.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">appearing in the same paragraph is derived from sources which we paid for, sponsored, or conducted, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 295.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">unless otherwise expressly stated or the context otherwise requires. The content of these third-party <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 307.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">sources, except to the extent specifically set forth in this prospectus, does not constitute a portion of this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 319.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prospectus and is not incorporated herein.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 339.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Forecasts and other forward-looking information with respect to industry, business, market, and other data <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 351.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">are subject to the same qualifications and additional uncertainties regarding the other forward-looking <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 363.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">statements in this prospectus. See the section titled &#8220;Special note regarding forward-looking statements.&#8221;<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">71<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_1089" style="position: absolute; top: 72pt;"></div><div style="line-height: 11.64pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Use of proceeds<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 107.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We estimate that the net proceeds from this offering will be approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million (or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 119.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million if the underwriters exercise in full their option to purchase up <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 131.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;additional shares of common stock), based on the assumed initial public offering price of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 143.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share, which is the midpoint of the estimated price range set forth on the cover page of this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 155.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prospectus, after deducting estimated underwriting discounts and commissions and estimated offering <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 167.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">expenses payable by us.&#160;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 187.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Each $1.00 increase or decrease in the assumed initial public offering price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 199.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">common stock, which is the midpoint of the estimated price range set forth on the cover page of this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 211.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prospectus, would increase or decrease, as applicable, the net proceeds to us from this offering by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 223.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million, assuming the number of shares offered by us, as set forth on the cover <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 235.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">page of this prospectus, remains the same, and after deducting estimated underwriting discounts and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 247.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">commissions and estimated offering expenses payable by us. Similarly, each increase or decrease of 1.0 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 259.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">million shares in the number of shares of common stock offered by us would increase or decrease, as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 271.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">applicable, the net proceeds to us from this offering by approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million, assuming the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 283.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">assumed initial public offering price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share of our common stock, which is the midpoint of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 295.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the estimated price range set forth on the cover page of this prospectus, remains the same, and after <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 307.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">deducting estimated underwriting discounts and commissions and estimated offering expenses payable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 319.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">by us.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 339.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In connection with the completion of this offering, we are obligated to use certain of the net proceeds from <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 351.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">this offering to repay <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 165.12pt; position: absolute; text-decoration: none; white-space: pre;">$50.0 million (or $55.0 million if the underwriters exercise their option to purchase <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 363.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">additional shares of common stock) o<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 237.54pt; position: absolute; white-space: pre;">f the indebtedness outstanding under the 2024 Credit Agreement <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 375.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and to pay approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million of fees in connection therewith. We expect to use the remainder <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 387.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of the net proceeds from this offering, together with our existing cash and cash equivalents, to fund our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 399.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">sales and marketing efforts, fund research and product development activities and for other general <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 411.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">corporate purposes, including working capital, operating expenses, and capital expenditures. The 2024 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 423.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Credit Agreement bears interest equal to the sum of (i) 7.0% (or 6.0% if the alternative base rate is in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 435.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">effect) plus (ii) the greater of (x) the forward-looking term rate based on the Secured Overnight Financing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 447.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Rate (&#8220;SOFR&#8221;) for a respective tenor (or the alternative base rate, if applicable), and (y) 2.0%. The <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 459.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">alternative base rate equals to the sum of (i) 6.0% plus (ii) the greater of (1) the Wall Street Journal Prime <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 471.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Rate, plus 0.5%, (2) the Federal Reserve Bank of New York rate plus 0.5% or (3) CBA Term SOFR for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 483.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">one month tenor plus 1.0%. The 2024 Credit Agreement matures on June 14, 2028. Borrowings under the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 495.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2024 Credit Agreement were used to refinance outstanding indebtedness. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 515.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We may also use a portion of the net proceeds from this offering to acquire complementary businesses, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 527.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">products, services, or technologies. We periodically evaluate strategic opportunities&#59; however, we have no <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 539.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">current understandings or commitments to enter into any such acquisitions or make any such <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 551.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">investments.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 571.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Based on our current operating plan, we estimate that our existing cash and cash equivalents as of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 583.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">date of this prospectus, together with the estimated net proceeds from this offering, will be sufficient to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 595.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">fund our planned operations through&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. We have based this estimate on our current <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 607.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">assumptions, which may prove to be wrong, and we may exhaust our available capital resources sooner <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 619.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">than we expect. The expected use of net proceeds from this offering represents our intentions based <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 631.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">upon our present plans and business conditions. We cannot predict with certainty all of the particular uses <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 643.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for the proceeds of this offering or the amounts that we will actually spend on the uses set forth above. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 655.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Accordingly, our management will have broad discretion in applying the net proceeds of this offering, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 667.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">investors will be relying on the judgment of our management regarding the application of these net <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 679.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">proceeds. The timing and amount of our actual expenditures will be based on many factors, including <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 691.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">cash flows from operations and the anticipated growth of our business. Pending their use, we intend to <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">72<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">invest the net proceeds of this offering in a variety of capital-preservation investments, including <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">government securities and money market funds.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">73<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_1114" style="position: absolute; top: 72pt;"></div><div style="line-height: 11.64pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Dividend policy<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 107.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 119.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">available funds and any future earnings, if any, to fund the development and expansion of our business, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 131.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and we do not anticipate paying any cash dividends in the foreseeable future. Any future determinations <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 143.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">regarding the declaration and payment of dividends, if any, will be at the discretion of our board of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 155.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">directors, subject to applicable law, and will depend upon then-existing conditions, including our financial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 167.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">condition, results of operations, contractual restrictions, general business conditions, capital <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 179.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">requirements, and other factors our board of directors may deem relevant. In addition, <font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 453.59pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">our ability to pay </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 191.2pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">cash dividends is currently restricted by the terms of our 2024 Credit Agreement. Our ability to pay cash </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 203.2pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">dividends on our capital stock in the future may also be limited by the terms of any preferred securities we </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 215.2pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">may issue or agreements governing any additional indebtedness we may incur.</font><font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">74<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_1139" style="position: absolute; top: 72pt;"></div><div style="line-height: 11.64pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Capitalization<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 107.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The following table sets forth our cash and cash equivalents and our capitalization, as of December 31, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 119.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2024&#58;&#160;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 139.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">on an actual basis&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 159.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">on a pro for<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 141.1pt; position: absolute; text-decoration: none; white-space: pre;">ma basis, to give effect to&#58; (i) the issuance and sale of the 2025 Convertible Notes and the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 171.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">2024 Term Loan Conversion that occurred subsequent to December 31, 2024&#59; (ii) the Preferred Stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 183.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Conversion&#59; (iii) the Convertible Notes Conversion&#59; and (iv) the adoption, filing, and effectiveness of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 195.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our amended and restated certificate of incorporation, to be in effect immediately prior to the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 207.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">completion of this offering&#59; and<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 225.9pt; position: absolute; text-decoration: none; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 227.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">on a pro forma as adjusted basis, giving effect to (i) the pro forma adjustments discussed above, (ii) <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 239.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the issuance and sale of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock in this offering at the assumed initial offering <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 251.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share, which is the midpoint of the estimated price range set forth on the cover <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 263.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">page of this prospectus, after deducting estimated underwriting discounts and commissions and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 275.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">estimated offering expenses payable by us and <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 301.49pt; position: absolute; text-decoration: none; white-space: pre;">(iii) the repayment of $50.0 million of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 287.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">indebtedness outstanding under the 2024 Credit Agreement and payment of approximately <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 299.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million of fees in connection therewith<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 294.88pt; position: absolute; text-decoration: none; white-space: pre;">. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 319.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">You should read this table together with the sections titled &#8220;Summary consolidated financial data,&#8221; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 331.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">&#8220;Management&#8217;s discussion and analysis of financial condition and results of operations&#8221; and our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 343.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">consolidated financial statements and the related notes included elsewhere in this prospectus. The pro <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 355.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">forma as adjusted information below is illustrative only and our capitalization following the completion of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 367.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">this offering will depend on the actual initial public offering price and other terms of this offering <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 379.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">determined at pri<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 146.99pt; position: absolute; text-decoration: none; white-space: pre;">cing.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 399.2pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 263.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 12pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="5"><div style="left: 266.25pt; position: absolute; top: 0pt; width: 201.75pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 2.63pt; width: 201.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 53.81pt; position: absolute; text-decoration: none; white-space: pre;">As of December 31, 2024<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td></tr><tr style="height: 21.75pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 12pt; width: 263.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 12.75pt; width: 263.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">(in thousands, except share and per share amounts)<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 12pt; width: 65.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 12.75pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 38.21pt; position: absolute; text-decoration: none; white-space: pre;">Actual<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 12pt; width: 65.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 12.75pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 24.88pt; position: absolute; text-decoration: none; white-space: pre;">Pro forma<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 12pt; width: 65.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3.15pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 13.78pt; position: absolute; text-decoration: none; white-space: pre;">Pro forma as <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 12.75pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 23.43pt; position: absolute; text-decoration: none; white-space: pre;">adjusted<font style="display: inline-block; height: 5.82pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 5.2pt; font-style: normal; font-weight: bold; left: 56.27pt; position: absolute; text-decoration: none; top: -2.037pt; vertical-align: super; white-space: pre;">(1)<font style="display: inline-block; height: 3.7830000000000004pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 33.75pt; width: 263.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.63pt; width: 263.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Cash and cash equivalents<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 116.61999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 117.78pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 118.07pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 118.22pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 118.25999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 33.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 7.37pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 33.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 7.37pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 33.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 7.37pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 48pt; width: 263.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.63pt; width: 263.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">2024 Term Loan<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 71.06pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 73.36999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 74.53pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 75.11pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 75.25999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 75.3pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 75.32pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 62.25pt; width: 263.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.63pt; width: 263.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">2025 Convertible Notes<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 101.83pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 102.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 103.57pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 103.86pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 103.94pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 103.97999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 103.99pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 62.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 7.37pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 62.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 7.37pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 62.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 7.37pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 59.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 76.5pt; width: 263.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.63pt; width: 263.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Redeemable convertible preferred stock, $0.001 par <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 14.03pt; width: 263.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 11.63pt; position: absolute; text-decoration: none; white-space: pre;">value&#59;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares authorized&#59;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 25.43pt; width: 263.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 11.63pt; position: absolute; text-decoration: none; white-space: pre;">issued and outstanding, actual&#59; no shares authorized, <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 36.83pt; width: 263.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 11.63pt; position: absolute; text-decoration: none; white-space: pre;">issued or outstanding, pro forma and pro forma as <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 48.23pt; width: 263.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 11.63pt; position: absolute; text-decoration: none; white-space: pre;">adjusted<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 47.52pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 49.830000000000005pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 50.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 51.57pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 51.61pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 51.63pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 76.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 48.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 7.37pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 76.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 48.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 43.93pt;"></font></font><font style="left: 51.84pt; position: absolute;">&#8212;<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 76.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 48.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 43.93pt;"></font></font><font style="left: 51.84pt; position: absolute;">&#8212;<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 135.75pt; width: 263.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.63pt; width: 263.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Stockholders&#8217; equity (deficit)&#58;<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 123.6pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 125.91pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 127.07pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 127.36pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 127.44pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 127.47999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 127.5pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 71.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 150pt; width: 263.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.63pt; width: 263.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Preferred stock, $0.001 par value&#59; no shares authorized, <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 14.03pt; width: 263.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 23.63pt; position: absolute; text-decoration: none; white-space: pre;">issued and outstanding, actual&#59;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 25.43pt; width: 263.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 23.63pt; position: absolute; text-decoration: none; white-space: pre;">authorized, no shares issued or outstanding, pro <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 36.83pt; width: 263.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 23.63pt; position: absolute; text-decoration: none; white-space: pre;">forma&#59;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares authorized <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 48.23pt; width: 263.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 23.63pt; position: absolute; text-decoration: none; white-space: pre;">and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares issued and outstanding, pro <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 59.63pt; width: 263.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 23.63pt; position: absolute; text-decoration: none; white-space: pre;">forma as adjusted<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 99.07pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 99.36pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 99.39999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 99.42pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 99.42999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 81.75pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 221.25pt; width: 263.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.63pt; width: 263.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Common stock, $0.001 par value&#59;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 14.03pt; width: 263.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 23.63pt; position: absolute; text-decoration: none; white-space: pre;">authorized,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares issued and <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 25.43pt; width: 263.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 23.63pt; position: absolute; text-decoration: none; white-space: pre;">outstanding, actual&#59;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares authorized <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 36.83pt; width: 263.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 23.63pt; position: absolute; text-decoration: none; white-space: pre;">and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares issued and outstanding, pro <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 48.23pt; width: 263.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 23.63pt; position: absolute; text-decoration: none; white-space: pre;">forma&#59;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares authorized <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 59.63pt; width: 263.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 23.63pt; position: absolute; text-decoration: none; white-space: pre;">and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares issued and outstanding, pro <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 71.03pt; width: 263.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 23.63pt; position: absolute; text-decoration: none; white-space: pre;">forma as adjusted<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 99.07pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 99.36pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 99.39999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 99.42pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 99.42999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 303pt; width: 263.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.63pt; width: 263.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Additional paid-in capital<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 117.52pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 118.1pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 118.25pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 118.33pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 118.35pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">75<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="position: absolute; top: 72pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 263.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 263.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.63pt; width: 263.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Accumulated deficit<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 96.92999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 98.08999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 98.67pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 98.96pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 99.11pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 99.19pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 99.22999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 99.24pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 14.25pt; width: 263.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.63pt; width: 263.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Total stockholders&#8217; equity (deficit)<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 142.07pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 142.10999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 142.12pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 28.5pt; width: 263.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.63pt; width: 263.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Total capitalization<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 80.19pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 80.33999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 80.42pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 80.46pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 80.47999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 80.49pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 28.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 7.37pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 28.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 7.37pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 28.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 7.37pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 5.46pt; position: absolute; top: 122.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(1)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Each $1.00 increase or decrease in the assumed initial public offering price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share of our common stock, which is the <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 131.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">midpoint of the estimated price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, each of <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 140.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our pro forma as adjusted cash and cash equivalents, additional paid-in-capital, total stockholders&#8217; equity (deficit), and total <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 149.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">capitalization by approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million, assuming the number of shares offered by us, as set forth on the cover page of this <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 158.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 167.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">expenses payable by us. Similarly, each increase or decrease of 1.0 million shares in the number of shares of common stock offered by <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 176.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">us would increase or decrease, as applicable, each of our pro forma as adjusted cash and cash equivalents, additional paid-in-capital, <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 185.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">total stockholders&#8217; equity (deficit), and total capitalization by approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million, assuming the assumed initial public offering <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 194.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share of our common stock remains the same, and after deducting estimated underwriting discounts and <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 203.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">commissions and estimated offering expenses payable by us.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">If the underwriters exercise in full their option to purchase up to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;additional shares of common <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock, pro forma as adjusted cash and cash equivalents, 2024 Term Loan, additional paid-in capital, total <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stockholders&#8217; equity (deficit), total capitalization, and shares of common stock outstanding as of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">December 31, 2024 would be $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">respectively.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 288.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The number of shares of our common stock to be outstanding after this offering, pro forma and pro forma <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 300.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">as adjusted, in the table above is based on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock outstanding as of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 312.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">December 31, 2024, after giving effect to (i) the issuance and sale of the 2025 Convertible Notes and the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 324.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2024 Term Loan Conversion that occurred subsequent to December 31, 2024, (ii) the Preferred Stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 336.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Conversion, (iii) the Convertible Notes Conversion and (iv) <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 332.51pt; position: absolute; text-decoration: none; white-space: pre;">the adoption, filing, and effectiveness of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 348.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">amended and restated certificate of incorporation, to be in effect immediately prior to the completion of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">this offering<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 123.47pt; position: absolute; white-space: pre;">, and excludes&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 380.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock issuable upon the exercise of outstanding stock options as of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 392.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">December 31, 2024 under our 2009 Equity Incentive Plan, with a weighted-average exercise price of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 404.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;per share&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 424.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock issuable upon the exercise of outstanding stock options <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 436.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">granted subsequent to December 31, 2024 under our 2009 Equity Incentive Plan, with a weighted-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 448.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">average exercise price of $ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 468.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock issuable upon the exercise of warrants outstanding as of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">December 31, 2024 held by Hayfin, with an exercise price of $0.01 per share&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 500.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock reserved for future issuance under our 2009 Equity Incentive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 512.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Plan&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 532.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of our common stock to be reserved for future issuance under the 2025 Plan, which <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 544.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">will become effective as of the date immediately prior to the date our registration statement relating to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 556.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">this offering becomes effective, from which we will grant RSUs covering approximately &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 568.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">shares of common stock concurrently with this offering (based on the assumed initial public offering <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 580.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">price of $ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share, which is the midpoint of the price range set forth on the cover page of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 592.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">this prospectus), as well as any future increases in the number of shares of common stock reserved <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 604.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">for issuance under the 2025 Plan&#59; and<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of our common stock reserved for future issuance under the ESPP, which will <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 636.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">become effective on the date immediately prior to the date our registration statement relating to this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 648.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">offering becomes effective, as well as any future increases in the number of shares of common stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">reserved for issuance under the ESPP.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">76<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_1164" style="position: absolute; top: 72pt;"></div><div style="line-height: 11.64pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Dilution<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 107.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">If you purchase shares of our common stock in this offering, your ownership interest will be immediately <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 119.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and substantially diluted to the extent of the difference between the initial public offering price per share of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 131.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our common stock and the pro forma as adjusted net tangible book value per share of our common stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 143.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">immediately after this offering.&#160;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 163.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">As of December 31, 2024, our historical net tangible book value (deficit) was $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million, or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 175.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share of our common stock. Our historical net tangible book value (deficit) is the amount of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 187.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our total tangible assets less our total liabilities, excluding the carrying values of our redeemable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 199.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">convertible preferred stock, which is not included within stockholders&#8217; deficit. Our historical net tangible <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 211.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">book value (deficit) per share represents historical net tangible book value (deficit) divided by the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 223.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">aggregate number of shares of our common stock outstanding as of December 31, 2024. Total tangible <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 235.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">assets represents total assets less capitalized internal-use software, capitalized contract costs, deferred <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 247.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">debt financing costs, unamortized debt discount and issuance costs, and deferred initial public offering <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 259.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">costs. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 279.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our pro forma net tangible book value (deficit) as of December 31, 2024 was $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million, or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 291.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share. Pro forma net tangible book value per share represents total tangible assets, less total <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 303.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">liabilities, divided by the total aggregate number of shares of our common stock outstanding as of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 315.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">December 31, 2024, after giving effect to&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 335.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the issuance and sale of the 2025 Convertible Notes and the 2024 Term Loan Conversion that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 347.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">occurred subsequent to December 31, 2024&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 367.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the Preferred Stock Conversion&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 387.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the Convertible Notes Conversion&#59; and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 407.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the adoption, filing, and effectiveness of our amended and restated certificate of incorporation, to be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 419.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">in effect immediately prior to the completion of this offering.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 439.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">After giving further effect to the issuance and sale by us of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock in this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 451.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">offering at the assumed initial public offering price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share, which is the midpoint of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 463.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">estimated price range set forth on the cover page of this prospectus, and after deducting estimated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 475.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">underwriting discounts and commissions and estimated offering expenses payable by us <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 465.71pt; position: absolute; text-decoration: none; white-space: pre;">and <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 485.16pt; position: absolute; text-decoration: none; white-space: pre;">the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 487.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">repayment of $50.0 million of the indebtedness outstanding under the 2024 Credit Agreement and to pay <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 499.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million of fees in connection therewith<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 341.88pt; position: absolute; text-decoration: none; white-space: pre;">,<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 344.65pt; position: absolute; white-space: pre;"> our pro forma as adjusted net tangible <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 511.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">book value (deficit) as of December 31, 2024 would have been $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million, or $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 523.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">This represents an immediate increase in pro forma net tangible book value to existing stockholders of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 535.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share and an immediate dilution in pro forma net tangible book value to new investors of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 547.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share. Dilution per share represents the difference between the price per share to be paid by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 559.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">new investors for the shares of our common stock sold in this offering and the pro forma as adjusted net <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 571.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">tangible book value per share immediately after this offering.&#160;<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">77<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The following <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 133.65pt; position: absolute; text-decoration: none; white-space: pre;">table illustrates this dilution on a per sh<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 305.83000000000004pt; position: absolute; white-space: pre;">are basis&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 92pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 337.5pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 337.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 337.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Assumed initial public offering price per share<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 193.96pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 196.26999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 196.85pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 197pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 197.07999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 197.09pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 24.75pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 14.25pt; width: 337.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.89pt; width: 337.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Historical net tangible book value (deficit) per share as of December 31, <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 14.29pt; width: 337.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 23.63pt; position: absolute; text-decoration: none; white-space: pre;">2024<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 44.75pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 45.33pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 45.62pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 45.64pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 337.5pt; position: absolute; top: 14.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 14.35pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 4.74pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 24.75pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 39pt; width: 337.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.89pt; width: 337.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Pro forma increase in net tangible book value per share as of December 31, <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 14.29pt; width: 337.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 23.63pt; position: absolute; text-decoration: none; white-space: pre;">2024 attributable to the pro forma adjustments described above<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 290.04pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 291.2pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 291.78pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 291.93pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 292.01pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 292.02pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 63.75pt; width: 337.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 337.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Pro forma net tangible book value per share as of December 31, 2024<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 308.46999999999997pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 310.78pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 310.86pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 310.9pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 310.92pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 24.75pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 78pt; width: 337.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.89pt; width: 337.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Increase in pro forma net tangible book value per share attributable to new <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 14.29pt; width: 337.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 23.63pt; position: absolute; text-decoration: none; white-space: pre;">investors participating in this offering<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 176.96pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 178.12pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 178.26999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 178.31pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 178.32pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 102.75pt; width: 337.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 337.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Pro forma as adjusted net tangible book value per share after this offering<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 311.57pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 313.88pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 315.04pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 315.33pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 315.48pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 315.5pt; position: absolute; text-decoration: none; white-space: pre;"> . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 117pt; width: 337.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 337.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Dilution per share to new investors participating in this offering<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 263.57pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 263.71999999999997pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 263.76pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 117pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 239.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The dilution information discussed above is illustrative only and may change based on the actual initial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 251.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">public offering price, the number of shares we sell, and other terms of this offering that will be determined <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 263.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">at pricing. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 283.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Each $1.00 increase or decrease in the assumed initial public offering price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share, which is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 295.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the midpoint of the estimated price range set forth on the cover page of this prospectus, would increase or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 307.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">decrease, as applicable, our pro forma as adjusted net tangible book value per share after this offering by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 319.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share and the dilution per share to investors participating in this offering by $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 331.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">assuming that the number of shares of common stock offered by us, as set forth on the cover page of this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 343.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prospectus, remains the same, and after deducting estimated underwriting discounts and commissions <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 355.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and estimated offering expenses payable by us. Similarly, each 1.0 million share increase in the number <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 367.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of shares offered by us would increase our pro forma as adjusted net tangible book value per share after <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 379.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">this offering by $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share and decrease the dilution per share to investors participating in this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 391.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">offering by $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share, and each 1.0 million share decrease in the number of shares offered by us <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 403.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">would decrease our pro forma as adjusted net tangible book value per share after this offering by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 415.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share and increase the dilution per share to investors participating in this offering by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 427.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share, in each case assuming the initial public offering price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share remains the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 439.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">same, and after deducting estimated underwriting discounts and commissions and estimated offering <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 451.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">expenses payable by us.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 471.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">If the underwriters exercise in full their option to purchase up to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;additional shares of common <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 483.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock, the pro forma as adjusted net tangible book value (deficit) per share of our common stock after this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 495.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">offering would be $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share, and the dilution per share to investors participating in this offering <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 507.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">would be $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share, assuming the assumed initial public offering price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share, which <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 519.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">is the midpoint of the estimated price range set forth on the cover page of this prospectus.&#160;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 539.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The following table summarizes, as of December 31, 2024, on a pro forma as adjusted basis as described <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 551.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">above, the number of shares of our common stock, the total consideration and the average price per <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 563.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">share (i) paid to us by existing stockholders and (ii) to be paid by new investors acquiring our common <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 575.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock in this offering at the assumed initial public offering price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share, the midpoint of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 587.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">estimated price range set forth on the cover page of this prospectus, before deducting estimated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 599.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">underwriting discounts and commissions and estimated offering expenses payable by us. As the table <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 611.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">below shows, investors participating in this offering will pay an average price per share substantially <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 623.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">higher than our existing stockholders paid.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">78<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="position: absolute; top: 72pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 156pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 60pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 60pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 60pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 60pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 60pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 17.25pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="3"><div style="left: 156pt; position: absolute; top: 0pt; width: 123pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 8.25pt; width: 123pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 51.12pt; position: absolute; text-decoration: none; white-space: pre;">Shares purchased<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="3"><div style="left: 282pt; position: absolute; top: 0pt; width: 123pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 8.25pt; width: 123pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 46.7pt; position: absolute; text-decoration: none; white-space: pre;">Total consideration<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="2" colspan="1"><div style="left: 408pt; position: absolute; top: 0pt; width: 60pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 6.3pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 18.76pt; position: absolute; text-decoration: none; white-space: pre;">Weighted- <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 15.9pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 5.87pt; position: absolute; text-decoration: none; white-space: pre;">average price <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 25.5pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 21.41pt; position: absolute; text-decoration: none; white-space: pre;">per share<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td></tr><tr style="height: 17.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 156pt; position: absolute; top: 17.25pt; width: 60pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 8.25pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 27.18pt; position: absolute; text-decoration: none; white-space: pre;">Number<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 219pt; position: absolute; top: 17.25pt; width: 60pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 8.25pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 28.07pt; position: absolute; text-decoration: none; white-space: pre;">Percent<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 282pt; position: absolute; top: 17.25pt; width: 60pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 8.25pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 27.19pt; position: absolute; text-decoration: none; white-space: pre;">Amount<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 345pt; position: absolute; top: 17.25pt; width: 60pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 8.25pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 28.07pt; position: absolute; text-decoration: none; white-space: pre;">Percent<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 34.5pt; width: 156pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 156pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Existing stockholders<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 91.8pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 94.11pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 95.27pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 95.85pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 96pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 96.03999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 96.05pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 219pt; position: absolute; top: 34.5pt; width: 60pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 50.81pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 282pt; position: absolute; top: 34.5pt; width: 60pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 60pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 4.75pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 345pt; position: absolute; top: 34.5pt; width: 60pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 50.81pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 408pt; position: absolute; top: 34.5pt; width: 60pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 60pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 4.75pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 48.75pt; width: 156pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 156pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">New investors<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 62.25pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 62.830000000000005pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 63.120000000000005pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 63.2pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 63.220000000000006pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 408pt; position: absolute; top: 48.75pt; width: 60pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 60pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 5.4pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 63pt; width: 156pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 156pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Total<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 22.68pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 24.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 25.07pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 25.11pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 25.13pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 25.14pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 219pt; position: absolute; top: 63pt; width: 60pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 31.81pt; position: absolute;"><font style="display: inline-block; height: 6.91pt;"></font></font><font style="left: 31.81pt; position: absolute;">100<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font><font style="left: 50.81pt; position: absolute;">%<font style="display: inline-block; height: 6.91pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 282pt; position: absolute; top: 63pt; width: 60pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 60pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 4.75pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 345pt; position: absolute; top: 63pt; width: 60pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 31.81pt; position: absolute;"><font style="display: inline-block; height: 6.91pt;"></font></font><font style="left: 31.81pt; position: absolute;">100<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font><font style="left: 50.81pt; position: absolute;">%<font style="display: inline-block; height: 6.91pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 408pt; position: absolute; top: 63pt; width: 60pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 60pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 4.75pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 165.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Each $1.00 increase or decrease in the assumed initial public offering price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share, which is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 177.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the midpoint of the estimated price range set forth on the cover page of this prospectus, would increase or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 189.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">decrease, as applicable, the total consideration paid by new investors and total consideration paid by all <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 201.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stockholders by approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million, assuming that the number of shares of common stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 213.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">offered by us, as set forth on the cover page of this prospectus, remains the same, before deducting <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 225.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">estimated underwriting discounts and commissions and estimated offering expenses payable by us. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 237.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Similarly, each 1.0 million share increase or decrease in the number of shares offered by us would <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 249.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">increase or decrease, as applicable, the total consideration paid by new investors and total consideration <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 261.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">paid by all stockholders by $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million, assuming the assumed initial public offering price of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 273.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share of common stock remains the same, before deducting estimated underwriting discounts <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 285.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and commissions.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 305.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Except as otherwise indicated, the above discussion and tables assume no exercise of the underwriters&#8217; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 317.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">option to purchase additional shares. If the underwriters exercise in full their option to purchase up <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 329.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;additional shares of common stock, our existing stockholders would own&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;%, and our new <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 341.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">investors would own&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of the total number of shares of our common stock outstanding upon the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 353.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">completion of this offering.&#160;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 373.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The foregoing tables and calculations (other than historical net tangible book value) are based <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 385.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock outstanding as of December 31, 2024, after giving effect to (i) the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 397.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">issuance and sale of the 2025 Convertible Notes and the 2024 Term Loan Conversion that occurred <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 409.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">subsequent to December 31, 2024, (ii) the Preferred Stock Conversion, (iii) the Convertible Notes <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 421.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Conversion and (iv) <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 161.44pt; position: absolute; text-decoration: none; white-space: pre;">the adoption, filing, and effectiveness of our amended and restated certificate of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 433.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">incorporation, to be in effect immediately prior to the completion of this offering<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 418.2pt; position: absolute; white-space: pre;">, and excludes&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 453.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock issuable upon the exercise of outstanding stock options as of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 465.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">December 31, 2024 under our 2009 Equity Incentive Plan, with a weighted-average exercise price of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 477.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 497.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock issuable upon the exercise of outstanding stock options <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 509.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">granted subsequent to December 31, 2024 under our 2009 Equity Incentive Plan, with a weighted-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 521.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">average exercise price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 541.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock issuable upon the exercise of warrants outstanding as of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 553.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">December 31, 2024 held by Hayfin, with an exercise price of $0.01 per share&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 573.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock reserved for future issuance under our 2009 Equity Incentive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 585.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Plan&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 605.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of our common stock to be reserved for future issuance under the 2025 Plan, which <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 617.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">will become effective as of the date immediately prior to the date our registration statement relating to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 629.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">this offering becomes effective, from which we will grant RSUs covering approximately &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 641.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">shares of common stock concurrently with this offering (based on the assumed initial public offering <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 653.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">price of $ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share, which is the midpoint of the price range set forth on the cover page of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 665.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">this prospectus), as well as any future increases in the number of shares of common stock reserved <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 677.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">for issuance under the 2025 Plan&#59; and<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 697.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of our common stock reserved for future issuance under the ESPP, which will <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 709.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">become effective on the date immediately prior to the date our registration statement relating to this <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">79<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">offering becomes effective, as well as any future increases in the number of shares of common stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">reserved for issuance under the ESPP.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">To the extent that any outstanding options are exercised, new options or other equity awards are issued <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">under our equity incentive plans, or we issue additional shares in the future, there will be further dilution to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">new investors participating in this offering. In addition, we may choose to raise additional capital because <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of market conditions or strategic considerations, even if we believe that we have sufficient funds for our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">current or future operating plans. If we raise additional capital through the sale of equity or convertible <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">debt securities, the issuance of these securities could result in further dilution to our stockholders.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">80<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_533" style="position: absolute; top: 72pt;"></div><div style="line-height: 11.64pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Management&#8217;s discussion and analysis of financial condition <font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 16pt; line-height: 11.64pt; position: absolute; top: 91.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">and results of operat<font style="display: inline-block; height: 11.64pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 230.12pt; position: absolute; text-decoration: none; white-space: pre;">ions<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 126.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">You should read the following discussion and analysis of our financial condition and results of operations <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 138.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">in conjunction with our consolidated financial statements and the related notes and other financial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 150.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">information included elsewhere in this prospectus. This discussion and analysis and other parts of this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 162.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prospectus contain forward-looking statements based upon our current plans and expectations that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 174.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 186.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">expectations, intentions and beliefs. Our actual results and the timing of events could differ materially <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 198.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">from those anticipated in these forward-looking statements as a result of various factors, including those <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 210.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">set forth under the section titled &#8220;Risk factors&#8221; and elsewhere in this prospectus. You should carefully read <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 222.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the section titled &#8220;Risk factors&#8221; to gain an understanding of the important factors that could cause actual <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 234.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">results to differ materially from our forward-looking statements. Please also see the section titled &#8220;Special <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 246.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">note regarding forward-looking statements.&#8221; Our historical results are not necessarily indicative of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 258.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">results that may be expected for any period in the future.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 278.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Overview<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 300.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We have pioneered the use of software and AI to deliver a more accurate and clinically effective non-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 312.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">invasive solution for diagnosing and managing coronary artery disease (&#8220;CAD&#8221;), the leading cause of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 324.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">death worldwide. As of December 31, 2024, our Heartflow Platform has been used to assess CAD in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 336.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">more than 375,000 patients, including 132,000 in 2024 alone. We believe that we are the most widely <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 348.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">adopted AI-powered test for CAD. Our novel platform leverages AI and advanced computational fluid <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">dynamics to create a personalized 3D model of a patient&#8217;s heart from a single coronary computed <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">tomography angiography (&#8220;CCTA&#8221;), a specialized type of scan that provides detailed images of the heart&#8217;s <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 384.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">arteries. Our Heartflow Platform delivers actionable insights on blood flow, stenosis, plaque volume and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">plaque composition thereby overcoming the limitations of traditional non-invasive imaging tests which rely <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">on indirect measures of coronary disease and lead to high false negative and false positive rates. We <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">believe the differentiated accuracy and clinical utility of our Heartflow Platform, along with its ability to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 432.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">enhance workflows, will continue to support our growth and advance the &#8220;CCTA + Heartflow&#8221; pathway as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 444.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the definitive standard for the non-invasive diagnosis and management of CAD.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 464.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">To date, we have developed three software products<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 303.65999999999997pt; position: absolute; text-decoration: none; white-space: pre;"> under the Heartflow Platform<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 433.61pt; position: absolute; white-space: pre;"> that provide physicians <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 476.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">with the critical insights needed to effectively diagnose and manage CAD&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 496.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow RoadMap Analysis<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 218.32pt; position: absolute; text-decoration: none; white-space: pre;"> offers a highly intuitive anatomic visualization of the coronary arteries, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 508.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">helping physicians quickly identify clinically relevant areas to focus their review.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 528.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: italic; font-weight: normal; left: 154.4pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 163.06pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 203.05pt; position: absolute; text-decoration: none; white-space: pre;"> calculates blood flow and pinpoints functionally significant CAD at every <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">point in the major coronary arteries, guiding decisions on whether a patient requires invasive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">revascularization.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 572.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow Plaque Analysis<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 206.09pt; position: absolute; text-decoration: none; white-space: pre;"> provides a comprehensive assessment of coronary plaque, enabling <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 584.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">optimized medical treatment strategies.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 604.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Heartflow Platform is currently commercially available in the United States, United Kingdom, Europe, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 616.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and Japan.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 121.46000000000001pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;"> </font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 124.22999999999999pt; position: absolute; white-space: pre;">We have developed a highly scalable, capital efficient commercial model that combines <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 628.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Territory Sales Managers (&#8220;TSMs&#8221;) who drive new account adoption with Territory Account Managers <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 640.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(&#8220;TAMs&#8221;) who focus on increasing utilization by educating referring physicians. Our commercial team does <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 652.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">not cover cases or otherwise spend time in an operating room or lab setting, which enables them to focus <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 664.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">solely on driving commercial adoption and educational activities. We also have small, direct commercial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 676.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">teams in our international markets. In the future, we may expand our international presence beyond these <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 688.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">markets. <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">81<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our technology is simple and intuitive and does not require the purchase of any capital equipment. Our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">onboarding process seamlessly integrates the Heartflow Platform into the customer&#8217;s daily workflow. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">These unique attributes of our business model afford our commercial organization a differentiated level of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">efficiency and scalability.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We have experienced considerable revenue growth since we <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 344.06pt; position: absolute; text-decoration: none; white-space: pre;">began commercializing<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 446.3pt; position: absolute; white-space: pre;"> the Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Platform in 2015<font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 144.76pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">, </font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 150.3pt; position: absolute; white-space: pre;">driven primarily by growth in our account base and increasing test volumes at existing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">accounts. We recognized revenue of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million for the year ended December 31, 2024, compared to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">revenue of $87.2 million for the year ended December 31, 2023. Substantially all of our revenue is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">generated on<font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 130.91pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;"> a &#8220;pay per click&#8221; basis </font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 233.1pt; position: absolute; white-space: pre;">each time a physician chooses to review either our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 459.74pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 504.72pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 524.14pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 532.8pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Analysis, <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 114.75999999999999pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 159.74pt; position: absolute; white-space: pre;">Plaque Analysis, or both and we recognize usage-driven fee revenue upon delivery of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the requested analysis to the physician. <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 249.76pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 294.74pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 314.15999999999997pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 322.82pt; position: absolute; white-space: pre;"> Analysis has served as our commercial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">foundation, representing&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of our revenue in 2024. In the second half of 2023, we initiated limited <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">market education efforts for <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 196.22pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 241.2pt; position: absolute; white-space: pre;">Plaque Analysis, our second commercial product.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 459.52pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;"> Our </font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 481.72pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">RoadMap Analysis is generally provided as a workflow efficiency tool to drive customer retention and </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">loyalty and is not a stand-alone product. </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">To date, we have primarily funded our operations with proceeds from sales of shares of our redeemable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">convertible preferred stock, common stock and convertible promissory notes, borrowings under our term <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">loans and revenue received from our customers. As of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 314.19pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2024<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 401.98pt; position: absolute; white-space: pre;">, we had $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million in cash <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and cash equivalents. In January 2025, we issued $48.4 million in aggregate principle amount of the 2025 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Convertible Notes to investors, including related parties, with original maturity dates of 48 months from <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the dates of issuance. The consideration for the issuance of the 2025 Convertible Notes was comprised <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of $25.4 million in cash and the exchange of $23 million of outstanding indebtedness under the 2024 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Credit Agreement (as defined below).<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We have incurred significant operating losses and negative cash flows since our inception. Our net loss <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 384pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for the year ended December 31, 2024 and <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 265.89pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 353.68pt; position: absolute; white-space: pre;"> was $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million and <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 460.81pt; position: absolute; text-decoration: none; white-space: pre;">$95.7 million<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 516.9200000000001pt; position: absolute; white-space: pre;">, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 396pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">respectively. As of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 154.56pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2024<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 242.35pt; position: absolute; white-space: pre;">, we had an accumulated deficit of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 429.46pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">million.</font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 416pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Key factors affecting our results of operations and performance <font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 438.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We believe there are several important factors that have impacted and that we expect will continue to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 450.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">impact our operating performance and results of operations for the foreseeable future. These factors <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 462.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">include, among others&#58; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 482.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Rate of adoption of CCTA in the market and our ability to increase adoption of the CCTA + Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 494.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">pathway among both referring and reading physicians.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 514.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Ability to successfully introduce our Heartflow Plaque Analysis and other new products and the rate at <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 526.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">which they are adopted by physicians. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 546.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Ability to automate an increasing number of the manual components of our production process and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 558.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the rate at which we hire and train analysts to full productivity. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 578.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">We experience seasonality throughout the year b<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 307.03999999999996pt; position: absolute; text-decoration: none; white-space: pre;">ased on a number of factors, including staff <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 590.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">availability, vacations, weather and other macro economic events.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 610.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Publications of clinical results by us and third-parties.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 630.4pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">Heartflow revenue cases</font><font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 652.8pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">We regularly review a number of operating and financial metrics to evaluate our business, measure our </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 664.8pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">performance, identify trends affecting our business, formulate our business plan and make strategic </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 676.8pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">decisions. Substantially all of our revenue is generated on a &#8220;pay per click&#8221; basis each time a physician </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 688.8pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">chooses to review either our </font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 199.76pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 244.74pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">FFR</font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 264.15999999999997pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;"><font style="background-color: inherit;">CT</font><font style="display: inline-block; height: 4.732pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 272.82pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;"> Analysis, </font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 317.8pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 362.78pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">Plaque Analysis, or both and we </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 700.8pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">recognize usage-driven fee revenue upon delivery of the requested analysis to the physician. We define a </font><font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">82<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">&#8220;Heartflow revenue case&#8221; as each time an account orders and we deliver the requested analysis to the </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">physician. For example, the ordering of both an </font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 283.63pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 328.61pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">FFR</font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 348.03pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 356.69pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;"> Analysis and a </font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 426.68pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 471.66pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">Plaque </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">Analysis from a single CCTA counts as two revenue cases. We define an &#8220;account&#8221; as any individual </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">facility that orders a Heartflow analysis. Accounts may have more than one reading physician or CT </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">machine. The following </font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 176.8pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">table</font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 198.47pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;"> lists these revenue cases in each of the three month periods as indicated&#58;</font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 140pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 465.75pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 60.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 33.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 33.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 33.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 33.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 33.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 33.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 33.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 33.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 33.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 33.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 33.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 33.75pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 11.25pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 60.75pt; position: absolute; top: 0pt; width: 33.75pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 3.19pt; width: 33.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 4.29pt; position: absolute; text-decoration: none; white-space: pre;">Q1 2022<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 94.5pt; position: absolute; top: 0pt; width: 33.75pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 3.19pt; width: 33.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 4.29pt; position: absolute; text-decoration: none; white-space: pre;">Q2 2022<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 128.25pt; position: absolute; top: 0pt; width: 33.75pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 3.19pt; width: 33.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 4.29pt; position: absolute; text-decoration: none; white-space: pre;">Q3 2022<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 162pt; position: absolute; top: 0pt; width: 33.75pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 3.19pt; width: 33.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 4.29pt; position: absolute; text-decoration: none; white-space: pre;">Q4 2022<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 195.75pt; position: absolute; top: 0pt; width: 33.75pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 3.19pt; width: 33.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 4.29pt; position: absolute; text-decoration: none; white-space: pre;">Q1 2023<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 229.5pt; position: absolute; top: 0pt; width: 33.75pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 3.19pt; width: 33.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 4.29pt; position: absolute; text-decoration: none; white-space: pre;">Q2 2023<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 263.25pt; position: absolute; top: 0pt; width: 33.75pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 3.19pt; width: 33.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 4.29pt; position: absolute; text-decoration: none; white-space: pre;">Q3 2023<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 297pt; position: absolute; top: 0pt; width: 33.75pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 3.19pt; width: 33.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 4.29pt; position: absolute; text-decoration: none; white-space: pre;">Q4 2023<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 330.75pt; position: absolute; top: 0pt; width: 33.75pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 3.19pt; width: 33.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 4.29pt; position: absolute; text-decoration: none; white-space: pre;">Q1 2024<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 364.5pt; position: absolute; top: 0pt; width: 33.75pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 3.19pt; width: 33.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 4.29pt; position: absolute; text-decoration: none; white-space: pre;">Q2 2024<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 398.25pt; position: absolute; top: 0pt; width: 33.75pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 3.19pt; width: 33.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 4.29pt; position: absolute; text-decoration: none; white-space: pre;">Q3 2024<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 432pt; position: absolute; top: 0pt; width: 33.75pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 3.19pt; width: 33.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: bold; left: 4.29pt; position: absolute; text-decoration: none; white-space: pre;">Q4 2024<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td></tr><tr style="height: 11.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 11.25pt; width: 60.75pt;"><div><div style="line-height: 5.46pt; position: absolute; top: 2.68pt; width: 60.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Revenue cases<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 54.31pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 54.35pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 54.370000000000005pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 5.46pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 54.38pt; position: absolute; text-decoration: none; white-space: pre;"> .<font style="display: inline-block; height: 5.46pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 60.75pt; position: absolute; top: 11.25pt; width: 33.75pt;"><div><div style="line-height: 5.46pt; position: absolute; top: 2.72pt; width: 33.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 5.46pt; width: 4.95pt;"></font></font><font style="left: 7.58pt; position: absolute;">12,316<font style="display: inline-block; height: 5.46pt; width: 2.49pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 94.5pt; position: absolute; top: 11.25pt; width: 33.75pt;"><div><div style="line-height: 5.46pt; position: absolute; top: 2.72pt; width: 33.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 5.46pt; width: 4.95pt;"></font></font><font style="left: 7.58pt; position: absolute;">12,701<font style="display: inline-block; height: 5.46pt; width: 2.49pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 128.25pt; position: absolute; top: 11.25pt; width: 33.75pt;"><div><div style="line-height: 5.46pt; position: absolute; top: 2.72pt; width: 33.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 5.46pt; width: 4.95pt;"></font></font><font style="left: 7.58pt; position: absolute;">14,865<font style="display: inline-block; height: 5.46pt; width: 2.49pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 162pt; position: absolute; top: 11.25pt; width: 33.75pt;"><div><div style="line-height: 5.46pt; position: absolute; top: 2.72pt; width: 33.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 5.46pt; width: 4.95pt;"></font></font><font style="left: 7.58pt; position: absolute;">16,697<font style="display: inline-block; height: 5.46pt; width: 2.49pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 195.75pt; position: absolute; top: 11.25pt; width: 33.75pt;"><div><div style="line-height: 5.46pt; position: absolute; top: 2.72pt; width: 33.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 5.46pt; width: 4.95pt;"></font></font><font style="left: 7.58pt; position: absolute;">19,537<font style="display: inline-block; height: 5.46pt; width: 2.49pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 229.5pt; position: absolute; top: 11.25pt; width: 33.75pt;"><div><div style="line-height: 5.46pt; position: absolute; top: 2.72pt; width: 33.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 5.46pt; width: 4.95pt;"></font></font><font style="left: 7.58pt; position: absolute;">21,769<font style="display: inline-block; height: 5.46pt; width: 2.49pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 263.25pt; position: absolute; top: 11.25pt; width: 33.75pt;"><div><div style="line-height: 5.46pt; position: absolute; top: 2.72pt; width: 33.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 5.46pt; width: 4.95pt;"></font></font><font style="left: 7.58pt; position: absolute;">23,195<font style="display: inline-block; height: 5.46pt; width: 2.49pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 297pt; position: absolute; top: 11.25pt; width: 33.75pt;"><div><div style="line-height: 5.46pt; position: absolute; top: 2.72pt; width: 33.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 5.46pt; width: 4.95pt;"></font></font><font style="left: 7.58pt; position: absolute;">24,897<font style="display: inline-block; height: 5.46pt; width: 2.49pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 3pt;"><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 178.5pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">The period-to-period change in Heartflow revenue cases is an indicator of our ability to drive adoption and </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 190.5pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">generate sales revenue, and is helpful in tracking the progress of our business. We believe that Heartflow </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 202.5pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">revenue cases are representative of our current business&#59; however, we anticipate this metric may be </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 214.5pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">substituted for additional or different metrics as our business grows.</font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 234.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Components of our results of operations<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Revenue<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 276.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Substantially all of our revenue comprises usage-driven fees from accounts who <font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 428.63pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">order either our </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 288.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 116.97999999999999pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">FFR</font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 136.4pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 145.06pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;"> Analysis, </font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 190.04000000000002pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 235.02pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">Plaque Analysis, or both</font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 342.23pt; position: absolute; white-space: pre;">. <font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 347.77pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">We recognize usage-driven fee revenue </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 300.9pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">upon delivery of the requested analysis to the physician. </font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 323.09000000000003pt; position: absolute; text-decoration: none; white-space: pre;">Key factors that drive our revenue include the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 312.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">success of our sales force in expanding adoption of the Heartflow Platform in new accounts and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 324.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">expanding the utilization of our system in existing accounts. No single customer accounted for 10% or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 336.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">more of our revenue during the year ended December 31, 2023. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 356.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our revenue has fluctuated, and we expect it to continue to fluctuate from quarter-to-quarter due to a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 368.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">variety of factors includ<font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 174.19pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">ing the number of active accounts, the volume of Heartflow Platform usage at </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 380.9pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">existing accounts and seasonality. We may experience fluctuations in the volume of Heartflow Platform </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 392.9pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">usage by our customers based on seasonal factors that impact the number of radiologists and support </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 404.9pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">staff available to conduct CCTAs at customer accounts. </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 424.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Cost of revenue and gross margin<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 444.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Cost of revenue consists of personnel and related expenses, including stock-based compensation costs, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 456.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">primarily related to our production team. Additional costs include third-party hosting fees, amortization of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 468.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">capitalized internal-use software, amortization of contract fulfillment costs as well as royalties associated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">with technology licenses used in connection with the delivery of our product and allocated overhead, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 492.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">which includes facilities expenses, equipment, depreciation and technology services. The role of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 504.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">production team is to support our patient case volume revenue by performing defined quality-related <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 516.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">activities on CCTA scans submitted by our customers for analysis. The portion of these costs that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 528.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">supports patient case volume revenue is recorded as cost of revenue. The production team also supports <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">activities in our clinical trials and research and development, which are allocated as research and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">development expense. We expect cost of revenue to increase as we hire additional personnel in our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">production team to support our increasing patient case volume.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 584.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We calculate gross margin as gross profit divided by revenue. Our gross margin has been and will <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 596.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">continue to be affected by a variety of factors, primarily by our production team costs, the timing of hiring <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 608.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">new production team members and training them to full productivity, the timing of our acquisition of new <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 620.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">customers and pricing and commercialization of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 285.87pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 330.85pt; position: absolute; white-space: pre;">Plaque Analysis and other new products. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 632.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Although, we expect our gross margin to fluctuate from period to period, based upon the factors described <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">above, we believe our gross margin will increase over the long term as we leverage the AI-based nature <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of our software platform to automate an increasing number of the manual components of our production <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 668.9pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">teams&#8217; p</font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 109.4pt; position: absolute; white-space: pre;">rocess, thereby lowering the cost of revenue per analysis. We also expect increased revenues <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 680.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">from our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 111.97999999999999pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 156.95999999999998pt; position: absolute; white-space: pre;">Plaque Analysis, to positively impact our gross margin, as it runs on the same CCTA <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 692.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">scan as <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 109.22pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 154.2pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 173.62pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 182.28pt; position: absolute; white-space: pre;"> Analysis.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">83<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Operating expenses<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 92pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Research and development<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 112pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Research and development expenses are incurred in connection with the advancement of the Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 124pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Platform with the goal to introduce products, features and improvements aimed at increasing the value <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 136pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">proposition for our custome<font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 193.1pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">rs by expanding its applicability to additional disease states and patient </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 148pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">populations. Research and development expenses </font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 299.26pt; position: absolute; white-space: pre;">consist primarily of<font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 382.01pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;"> </font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 384.78pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">engineering, product development, </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 160pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">consulting services, clinical studies to develop and support our products, regulatory activities, medical </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 172pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">affairs,</font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 101.8pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;"> </font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 104.57pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">and ot</font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 132.35pt; position: absolute; text-decoration: none; white-space: pre;">her costs associated with products and technologies that are in development<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 470.67pt; position: absolute; white-space: pre;">. <font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 476.21pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">Rese</font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 499.55pt; position: absolute; white-space: pre;">arch and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 184pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">development expenses consist of personnel and related expenses, including stock-based compensation <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 196pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">costs, clinical trials, third-party consulting costs, the portion of the costs incurred by our production team <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 208pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to support clinical trials and research and development efforts, and allocated overhead, including facilities <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">expenses, equipment and depreciation. Our research and development (&#8220;R&#38;D&#8221;) team is comprised of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">PhD research scientists with expertise in AI-based algorithms and medical imaging, alongside software <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">engineers skilled in cloud architecture, AI algorithms, machine and deep learning and 3D visualization, as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">well as product managers and designers who ensure optimal customer experience and design. We record <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">research and development expenses in the periods in which they are incurred. We expect our research <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and development expenses to increase as we conduct clinical studies for expanded indications for use <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and to hire additional personnel to develop new product offerings and product enhancements.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 312pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Selling, general and administrative<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 332pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Selling, general and administrative expenses consist of personnel and related expenses, including stock-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 344pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">based compensation costs, related to selling and marketing, commercial operations, reimbursement, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 356pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">finance, legal, information technology and human resources functions. Other expenses include sales <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 368pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">commission, marketing initiatives, professional service fees (including legal, audit, accounting and tax <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 380pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">fees), market access work to secure reimbursement for our technologies, travel expenses, conferences <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 392pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and trade shows, and allocated overhead, which includes facilities expenses, software licenses, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 404pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">depreciation and other miscellaneous expenses.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 424pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We expect that our selling, general and administrative expenses will increase in the future as a result of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 436pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">expanding our operations, including hiring personnel, to both drive and support anticipated growth as well <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 448pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">as various incremental costs associated with operating as a public company. We expect that our costs will <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 460pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">increase related to legal, audit, accounting fees, consulting fees, regulatory and tax-related services <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 472pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">associated with maintaining compliance with exchange listing and SEC requirements, director and officer <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 484pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">insurance costs, investor and public relations costs and other expenses that we did not incur as a private <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 496pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">company. However, we expect selling, general and administrative expenses to decrease as a percentage <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 508pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of revenue primarily as, and to the extent, our revenue grows.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 528pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Interest income (expense), net<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 548pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Interest income (expense), net consists primarily of interest expense on our 2024 Term Loan and related <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 560pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">amortization of debt discount and debt issuance costs. Interest income is primarily interest earned on our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 572pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">cash and cash equivalents. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 592pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Other income (expense), net <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Other income (expense), net consists primarily of changes in fair value related to our Convertible Notes, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">common stock warrant and derivative liability as well as foreign exchange transaction gains or losses <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 636pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">from transactions and asset and liability balances denominated in currencies other than the U.S. dollar. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 648pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We will continue to record adjustments to the estimated fair value of the common stock warrant until the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">warrants are exercised or expire and on the<font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 264.77pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;"> derivative liability until a </font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 375.28pt; position: absolute; white-space: pre;">business combination or repayment <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of the 2024 Term Loan.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">84<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Provision for income taxes<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 92pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Provision for income taxes consists of income tax expense in foreign jurisdictions. To date, we have not <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">recorded any U.S. federal or state income tax expense. We have net deferred tax assets for U.S. federal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">income taxes for which we provide a full valuation allowance. Due to our history of net operating losses <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">since inception, we expect to maintain a full valuation allowance in the foreseeable future due to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">uncertainties regarding our ability to realize these assets.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 160pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Results of operations<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 182.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Comparison of years ended December 31, 2023 and 2024 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 202.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The following table summarizes our results of operations for the years ended <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 413.61pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 501.4pt; position: absolute; white-space: pre;"> and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 214.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">2024<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 94.24pt; position: absolute; white-space: pre;">&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 234.4pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 201pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 64.5pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 64.5pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 64.5pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 64.5pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 12pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="3"><div style="left: 201pt; position: absolute; top: 0pt; width: 132pt;"><div><div style="font-size: 12pt; line-height: 5.82pt; position: absolute; top: 3pt; width: 132pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 32.14pt; position: absolute; text-decoration: none; white-space: pre;">Year ended <font style="display: inline-block; height: 5.82pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 77.42pt; position: absolute; text-decoration: none; white-space: pre;">December 31,<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="3"><div style="left: 336pt; position: absolute; top: 0pt; width: 132pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3pt; width: 132pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 100.08pt; position: absolute; text-decoration: none; white-space: pre;">Change<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 12pt; width: 201pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3pt; width: 201pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">(dollars in thousands)<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 201pt; position: absolute; top: 12pt; width: 64.5pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3pt; width: 64.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 44.11pt; position: absolute; text-decoration: none; white-space: pre;">2023<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 268.5pt; position: absolute; top: 12pt; width: 64.5pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3pt; width: 64.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 44.11pt; position: absolute; text-decoration: none; white-space: pre;">2024<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 336pt; position: absolute; top: 12pt; width: 64.5pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3pt; width: 64.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 57.43pt; position: absolute; text-decoration: none; white-space: pre;">$<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 403.5pt; position: absolute; top: 12pt; width: 64.5pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3pt; width: 64.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 54.76pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 24pt; width: 201pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 201pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Revenue<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 42.650000000000006pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 43.230000000000004pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 43.31pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 201pt; position: absolute; top: 24pt; width: 64.5pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 64.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 21.66pt;"></font></font><font style="left: 29.849999999999998pt; position: absolute;">87,174<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 38.25pt; width: 201pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 201pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Cost of revenue<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 73.17999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 73.33pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 73.35pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 73.36pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 201pt; position: absolute; top: 38.25pt; width: 64.5pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 64.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 27.22pt;"></font></font><font style="left: 29.849999999999998pt; position: absolute;">29,123<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 52.5pt; width: 201pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 201pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Gross profit<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 54.27pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 56.580000000000005pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 57.74pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 57.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 57.970000000000006pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 57.99pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 201pt; position: absolute; top: 52.5pt; width: 64.5pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 64.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 27.22pt;"></font></font><font style="left: 29.849999999999998pt; position: absolute;">58,051<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 66.75pt; width: 201pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 201pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Operating expenses<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 81pt; width: 201pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 201pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Research and development<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 136.88pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 138.04pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 138.19pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 138.23pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 138.24pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 201pt; position: absolute; top: 81pt; width: 64.5pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 64.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 27.22pt;"></font></font><font style="left: 29.849999999999998pt; position: absolute;">35,854<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 95.25pt; width: 201pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 201pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Selling, general and administrative<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 167.4pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 167.98pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 168.26999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 168.28pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 201pt; position: absolute; top: 95.25pt; width: 64.5pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 64.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 27.22pt;"></font></font><font style="left: 29.849999999999998pt; position: absolute;">95,111<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 109.5pt; width: 201pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 201pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Total operating expenses<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 113.75999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 116.07pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 117.22999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 117.81pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 117.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 117.92999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 117.94pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 201pt; position: absolute; top: 109.5pt; width: 64.5pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 64.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 21.66pt;"></font></font><font style="left: 24.29pt; position: absolute;">130,965<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 123.75pt; width: 201pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 201pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Loss from operations<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 95.96pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 97.11999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 97.69999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 97.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 98.14pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 98.14999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 201pt; position: absolute; top: 123.75pt; width: 64.5pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 64.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 23.89pt;"></font></font><font style="left: 26.52pt; position: absolute;">(72,914)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 138pt; width: 201pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 201pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Interest income (expense), net<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 137.60999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 138.19pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 138.26999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 138.31pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 201pt; position: absolute; top: 138pt; width: 64.5pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 64.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 23.89pt;"></font></font><font style="left: 26.52pt; position: absolute;">(19,237)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 152.25pt; width: 201pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 201pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Other income (expense), net<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 129.28pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 131.59pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 132.75pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 132.9pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 132.98pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 132.99pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 201pt; position: absolute; top: 152.25pt; width: 64.5pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 64.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 29.45pt;"></font></font><font style="left: 32.08pt; position: absolute;">(2,957)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 166.5pt; width: 201pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 201pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Loss before provision for income taxes<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 173.73pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 176.04pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 177.2pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 177.78pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 177.93pt; position: absolute; text-decoration: none; white-space: pre;"> . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 201pt; position: absolute; top: 166.5pt; width: 64.5pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 64.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 23.89pt;"></font></font><font style="left: 26.52pt; position: absolute;">(95,108)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 180.75pt; width: 201pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 201pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Provision for income taxes<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 119.83pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 122.14pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 122.72pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 123.00999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 123.03pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 201pt; position: absolute; top: 180.75pt; width: 64.5pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 64.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 37.78pt;"></font></font><font style="left: 40.410000000000004pt; position: absolute;">(547)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 195pt; width: 201pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 201pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Net loss<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 38.730000000000004pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 41.04pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 42.2pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 42.78pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 42.93pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 201pt; position: absolute; top: 195pt; width: 64.5pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 64.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 18.33pt;"></font></font><font style="left: 26.52pt; position: absolute;">(95,655)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 3.75pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 460.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; white-space: pre;">Revenue<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Revenue increased $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million, or&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;%, to $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million during the year ended December 31, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 492.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2024, compared to <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 158.11pt; position: absolute; text-decoration: none; white-space: pre;">$87.2 million<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 214.22pt; position: absolute; white-space: pre;"> during the year ended <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 317pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 404.79pt; position: absolute; white-space: pre;">. The increase in revenue was <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 504.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">primarily attributable to an increase in volume from new and existing active accounts, partially offset by a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 516.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">modest reduction in average sales price.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 536.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; white-space: pre;">Cost of revenue and gross <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 200.79pt; position: absolute; text-decoration: none; white-space: pre;">margin<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 556.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Cost of revenue increased $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million, or&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;%, to $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; million during the year ended December <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 568.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">31, 2024, compared to <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 174.76999999999998pt; position: absolute; text-decoration: none; white-space: pre;">$29.1 million<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 230.88pt; position: absolute; white-space: pre;"> during the year ended <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 333.66pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 421.45pt; position: absolute; white-space: pre;">. This increase was <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 580.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">attributable to $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million in personnel and related expenses<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 352.48pt; position: absolute; text-decoration: none; white-space: pre;">,<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 355.25pt; position: absolute; white-space: pre;"> $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million in allocated overhead, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 592.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million in amortization of capitalized internal-use software, $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million in third-party hosting <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 604.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">fees and $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million in royalties. Personnel and related expenses included $ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million and $0.4 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 616.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">million of stock-based compensation costs during the year ended December 31, 2024 and 2023, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 628.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">respectively. Gross margin for the year ended December 31, 2024 increased to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% as compared to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 640.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">67%<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 92.01pt; position: absolute; white-space: pre;"> for the year ended <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 178.66pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 266.45pt; position: absolute; white-space: pre;">.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; white-space: pre;">Research and development expenses<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 680.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Research and development expenses increased $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million, or&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;%, to $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million during the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 692.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">year ended December 31, 2024, compared to <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 276.45pt; position: absolute; text-decoration: none; white-space: pre;">$35.9 million<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 332.56pt; position: absolute; white-space: pre;"> during the year ended <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 435.34pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 523.13pt; position: absolute; white-space: pre;">. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 704.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The increase in research and development expenses was primarily attributable to an increase of <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">85<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 105.25999999999999pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">million</font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 133.59pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;"> in personnel and related expenses, $</font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.27pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 327.97pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">million in allocated overhead, $</font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 465.19pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 492.89pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">million in </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">third-party consulting costs and $</font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 218.65pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 246.35pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">million in clinical trial expenses, partially offset by $</font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 471.1pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 498.8pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">million of </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">capitalized research and development expenses</font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 285.93pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">. Personnel</font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 336.48pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;"> and related expenses included $</font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 483.17pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 510.87pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">million </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">and $3.3 million of stock-based compensation costs during the year ended December 31, 2024 and 2023, </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">respectively. </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; white-space: pre;">Selling, general and administrative expenses<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 160pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Selling, general and administrative expenses increased $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million, or&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;%, to $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 172pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">during the year ended December 31, 2024, compared to <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 323.66999999999996pt; position: absolute; text-decoration: none; white-space: pre;">$95.1 million<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 379.78pt; position: absolute; white-space: pre;"> during the year ended <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 184pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 159.79000000000002pt; position: absolute; white-space: pre;">. The increase in selling, general and administrative expenses was primarily <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 196pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">attributable to an increase of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million in personnel and related expenses, $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million in allocated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 208pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">overhead, $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million in legal, audit and other professional fees, $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million in third-party consulting <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">costs, $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million in travel and related expenses and $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million in marketing expenses. Personnel <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and related expenses included $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million and $8.7 million of stock-based compensation costs for the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">year ended December 31, 2024 and 2023, respectively.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 264pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; white-space: pre;">Interest income (expense), net<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 284pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Interest income (expense), net increased to expense of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million during the year ended December <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 296pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">31, 2024, compared to expense of $19.2 million during the year ended <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 385.33pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 473.12pt; position: absolute; white-space: pre;">. This <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">increased expense was attributable to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. As of December 31, 2024 and 2023, the aggregate <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 320pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">outstanding principal balance (including interest paid-in-kind) under our 2024 Term Loan was <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 332pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million and $138.1 million, respectively.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; white-space: pre;">Other income (expense), net<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 206.36pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Other income (expense), net increased to an expense of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million during the year ended December <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 384pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">31, 2024, compared to expense of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 226.44pt; position: absolute; text-decoration: none; white-space: pre;">$3.0 million<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 276.99pt; position: absolute; white-space: pre;"> during the year ended <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 379.77pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 467.56pt; position: absolute; white-space: pre;">. The increase <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">was primarily attributable to the remeasurement and recognition of the changes in fair value related to our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Convertible Notes, common stock warrant and derivative liability.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 428pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Provision for income taxes<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 448pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Provision for income taxes was $547,000 for the year ended December 31, 2023 related to our foreign <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 460pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">taxes.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 480pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Selected quarterly results of operations data<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 502.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The following table sets forth selected unaudited quarterly statements of operations data for each of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 514.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">four fiscal quarters ended <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 187.54000000000002pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 275.33000000000004pt; position: absolute; white-space: pre;"> and <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.55pt; position: absolute; text-decoration: none; white-space: pre;">2024<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 319.78999999999996pt; position: absolute; white-space: pre;">. The unaudited information for each of these <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 526.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">quarters has been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;), <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 538.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">on the same basis as our audited annual consolidated financial statements included elsewhere in this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 550.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prospectus and includes, in the opinion of management, all adjustments, consisting only of normal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 562.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">recurring adjustments, necessary for the fair statement of the results of operations for these periods. This <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 574.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">data should be read in conjunction with our consolidated financial statements and related notes included <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 586.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">elsewhere in this prospectus. These historical quarterly operating results are not necessarily indicative of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 598.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our operating results for the full year or any future per<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 308.05pt; position: absolute; text-decoration: none; white-space: pre;">iod.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 618.4pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 108pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 39.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 39.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 45pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 45pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 39.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 39.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 45pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 45pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 11.25pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="15"><div style="left: 108pt; position: absolute; top: 0pt; width: 360pt;"><div><div style="line-height: 4.73pt; position: absolute; top: 3.66pt; width: 360pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: bold; left: 293.51pt; position: absolute; text-decoration: none; white-space: pre;">Three months ended <font style="display: inline-block; height: 4.73pt;"></font></font></div></div></div></td></tr><tr style="height: 18.75pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 11.25pt; width: 108pt;"><div><div style="line-height: 4.73pt; position: absolute; top: 11.16pt; width: 108pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">(in thousands)<font style="display: inline-block; height: 4.73pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 108pt; position: absolute; top: 11.25pt; width: 39.75pt;"><div><div style="line-height: 4.73pt; position: absolute; top: 3.36pt; width: 39.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: bold; left: 7.18pt; position: absolute; text-decoration: none; white-space: pre;">March 31, <font style="display: inline-block; height: 4.73pt;"></font></font></div><div style="line-height: 4.73pt; position: absolute; top: 11.16pt; width: 39.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: bold; left: 22.68pt; position: absolute; text-decoration: none; white-space: pre;">2023<font style="display: inline-block; height: 4.73pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 150.75pt; position: absolute; top: 11.25pt; width: 39.75pt;"><div><div style="line-height: 4.73pt; position: absolute; top: 3.36pt; width: 39.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: bold; left: 11.14pt; position: absolute; text-decoration: none; white-space: pre;">June 30, <font style="display: inline-block; height: 4.73pt;"></font></font></div><div style="line-height: 4.73pt; position: absolute; top: 11.16pt; width: 39.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: bold; left: 22.68pt; position: absolute; text-decoration: none; white-space: pre;">2023<font style="display: inline-block; height: 4.73pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 193.5pt; position: absolute; top: 11.25pt; width: 45pt;"><div><div style="line-height: 4.73pt; position: absolute; top: 3.36pt; width: 45pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: bold; left: 8.82pt; position: absolute; text-decoration: none; white-space: pre;">September <font style="display: inline-block; height: 4.73pt;"></font></font></div><div style="line-height: 4.73pt; position: absolute; top: 11.16pt; width: 45pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: bold; left: 17.11pt; position: absolute; text-decoration: none; white-space: pre;">30, 2023<font style="display: inline-block; height: 4.73pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 241.5pt; position: absolute; top: 11.25pt; width: 45pt;"><div><div style="line-height: 4.73pt; position: absolute; top: 3.36pt; width: 45pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: bold; left: 6.8pt; position: absolute; text-decoration: none; white-space: pre;">December <font style="display: inline-block; height: 4.73pt;"></font></font></div><div style="line-height: 4.73pt; position: absolute; top: 11.16pt; width: 45pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: bold; left: 9.87pt; position: absolute; text-decoration: none; white-space: pre;">31, 2023<font style="display: inline-block; height: 4.73pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 289.5pt; position: absolute; top: 11.25pt; width: 39.75pt;"><div><div style="line-height: 4.73pt; position: absolute; top: 3.36pt; width: 39.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: bold; left: 7.18pt; position: absolute; text-decoration: none; white-space: pre;">March 31, <font style="display: inline-block; height: 4.73pt;"></font></font></div><div style="line-height: 4.73pt; position: absolute; top: 11.16pt; width: 39.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: bold; left: 22.68pt; position: absolute; text-decoration: none; white-space: pre;">2024<font style="display: inline-block; height: 4.73pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 332.25pt; position: absolute; top: 11.25pt; width: 39.75pt;"><div><div style="line-height: 4.73pt; position: absolute; top: 3.36pt; width: 39.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: bold; left: 11.14pt; position: absolute; text-decoration: none; white-space: pre;">June 30, <font style="display: inline-block; height: 4.73pt;"></font></font></div><div style="line-height: 4.73pt; position: absolute; top: 11.16pt; width: 39.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: bold; left: 22.68pt; position: absolute; text-decoration: none; white-space: pre;">2024<font style="display: inline-block; height: 4.73pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 375pt; position: absolute; top: 11.25pt; width: 45pt;"><div><div style="line-height: 4.73pt; position: absolute; top: 3.36pt; width: 45pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: bold; left: 8.82pt; position: absolute; text-decoration: none; white-space: pre;">September <font style="display: inline-block; height: 4.73pt;"></font></font></div><div style="line-height: 4.73pt; position: absolute; top: 11.16pt; width: 45pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: bold; left: 17.11pt; position: absolute; text-decoration: none; white-space: pre;">30, 2024<font style="display: inline-block; height: 4.73pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 423pt; position: absolute; top: 11.25pt; width: 45pt;"><div><div style="line-height: 4.73pt; position: absolute; top: 3.36pt; width: 45pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: bold; left: 10.98pt; position: absolute; text-decoration: none; white-space: pre;">December <font style="display: inline-block; height: 4.73pt;"></font></font></div><div style="line-height: 4.73pt; position: absolute; top: 11.16pt; width: 45pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: bold; left: 17.11pt; position: absolute; text-decoration: none; white-space: pre;">31, 2024<font style="display: inline-block; height: 4.73pt;"></font></font></div></div></div></td></tr><tr style="height: 11.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 30pt; width: 108pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 3.15pt; width: 108pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Revenue<font style="display: inline-block; height: 5.09pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 30.63pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 5.09pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 31.209999999999997pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 5.09pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 31.5pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 5.09pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 31.65pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 5.09pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 31.73pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 5.09pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: normal; left: 31.77pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 11.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 41.25pt; width: 108pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 3.15pt; width: 108pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Gross profit<font style="display: inline-block; height: 5.09pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 38.77pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 5.09pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 38.85pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 5.09pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: normal; left: 38.870000000000005pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 11.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 52.5pt; width: 108pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 3.15pt; width: 108pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Total operating expenses<font style="display: inline-block; height: 5.09pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 80.39pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 5.09pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 80.67999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 5.09pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: normal; left: 80.83pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . .<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 11.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 63.75pt; width: 108pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 3.15pt; width: 108pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Loss from operations<font style="display: inline-block; height: 5.09pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 67.94pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 5.09pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 69.1pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 5.09pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 69.67999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 5.09pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 69.97pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 5.09pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 70.11999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 5.09pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 70.14pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 5.09pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: normal; left: 70.14999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . .<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 11.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 75pt; width: 108pt;"><div><div style="line-height: 5.09pt; position: absolute; top: 3.15pt; width: 108pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Net loss<font style="display: inline-block; height: 5.09pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 27.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 5.09pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 28.18pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 5.09pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 7pt; font-style: normal; font-weight: normal; left: 28.33pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 5.09pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">86<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">Quarterly</font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 116.43pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;"> trends</font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 92pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">Revenue</font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 112pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">Our quarterly revenue increased sequentially in each of the periods presented primarily due to the </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 124pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">addition of new customers and revenue growth from the expansion of revenue cases volume within our </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 136pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">existing customer base.</font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 156pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">Cost of revenue and gross margin</font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">With the exception of the three months ended September 30, 2023, cost of revenue generally increased </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">sequentially in each of the quarters presented, driven by increased sales. During the three months ended </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">September 30, 2023, cost of revenue decreased as we introduced the </font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 383.65pt; position: absolute; white-space: pre;">automation of certain manual <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">components of our production <font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 207pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">teams p</font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 242.55pt; position: absolute; white-space: pre;">rocess thereby resulting in decreased <font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 411.44pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">personnel and related </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">expenses and allocated overhead.</font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">Our quarterly gross margins have fluctuated between</font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 306.98pt; position: absolute; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 334.68pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">% and</font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 363.02pt; position: absolute; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 390.72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">% in each period presented.</font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 264pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Operating expenses<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 284pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Total operating expenses have generally increased sequentially in each period presented with the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 296pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">exception of the three months ended September 30, 2023. Operating expenses fluctuate due to t<font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 499.18pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">iming of </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">consulting projects, legal expenses, clinical studies, stock-based compensation and the </font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 460.32pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">capitalization of </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 320pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">research and</font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 130.35pt; position: absolute; text-decoration: none; white-space: pre;"> development expenses.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Operating expenses also increased in the three months ended December 31, 2023 due to an increase<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 523.13pt; position: absolute; text-decoration: none; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 525.9pt; position: absolute; white-space: pre;">of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">$<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 77.56pt; position: absolute; text-decoration: none; white-space: pre;"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 116.34pt; position: absolute; white-space: pre;">million in allowance for credit losses and increases in the corporate bonus accrual and legal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 364pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and other professional fees.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 384pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Liquidity and capital resources<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 406.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Sources of liquidity<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 426.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Since inception, we have primarily funded our operations with proceeds from sales of shares of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 438.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">redeemable convertible preferred stock, common stock and convertible promissory notes, borrowings <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 450.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">under our term loans and revenue received from our customers. As of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 382.51pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2024<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 470.3pt; position: absolute; white-space: pre;">, we had <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 462.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million in cash and cash equivalents, accumulated deficit of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million and $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 474.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">outstanding under our 2024 Term Loan. On January 24, 2025 and January 31, 2025, we reduced our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 486.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">outstanding indebtedness under our 2024 Term Loan by $23.0 million and received $25.4 million, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 498.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">respectively, in cash in exchange for the issuance of $48.4 million in aggregate principal amount of 2025 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 510.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Convertible Notes, as described below.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 530.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our losses primarily resulted from the costs incurred in the development and sales and marketing of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 542.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">products and providing general and administrative support for our operations. We expect to continue to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 554.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">incur losses and to expend significant amounts of cash in the foreseeable future as we continue to scale <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 566.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our business, invest in research and development activities, increase sales and marketing efforts to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 578.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">support commercial expansion, and increase general and administrative expenses to support being a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 590.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">publicly-traded company.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 610.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Hayfin credit agreement<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 630.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">On June 14, 2024, we entered into a Credit Agreement and Guaranty for a $138.1 million term loan to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 642.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">refinance the outstanding obligations under the initial credit agreement we entered into with Hayfin on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 654.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">January 19, 2021 and the additional term loans entered into with Hayfin on March 17, 2022 in exchange <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 666.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for the payment of exit fees and early prepayment fees in the aggregate amount of $8.3 million payable in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 678.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">sixteen equal quarterly installments, or immediately upon the occurrence of a financing event, including <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 690.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">but not limited, to the completion of this offering. On January 24, 2025, in connection with the issuance of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 702.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the 2025 Convertible Notes as further described below, we entered into Amendment No. 1 to the Credit <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">87<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Agreement and Guaranty (as amended, the &#8220;2024 Credit Agreement&#8221;) to amend the terms and conditions <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">governing the term loan outstanding thereunder (as amended, the &#8220;2024 <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 394.05pt; position: absolute; text-decoration: none; white-space: pre;">Term Loan&#8221;).<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The 2024 Term Loan matures on June 14, 2028 and bears interest equal to the sum of (i) 7.0% (or 6.0% if <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the alternative base rate (&#8220;ABR&#8221;) is in effect) plus (ii) the greater of (x) the forward-looking term rate based <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">on Secured Overnight Financing Rate (&#8220;SOFR&#8221;) for a respective tenor in effect on such day (or the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">alternative base rate, if applicable), and (y) 2.0%. The ABR equals to the sum of (i) 6.0% plus (ii) the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">greater of (1) the Wall Street Journal Prime Rate, plus 0.5%, (2) the Federal Reserve Bank of New York <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">rate plus 0.5% or (3) CBA Term SOFR for one month tenor plus 1.0%. We have an option to pay interest <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">in-kind at the rate equal to the cash interest rate plus 1.0% through the last interest period ending before <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the 18th month anniversary of the 2024 Credit Agreement. We have an option to prepay the 2024 Term <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Loan subject to a prepayment fee of 1.5% for prepayments after the second anniversary but on or prior to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the third anniversary of the 2024 Term Loan and a prepayment fee of 3% for prepayments thereafter. The <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2024 Term Loan must be repaid in full immediately upon the occurrence of a change in control. In <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">connection with the completion of this offering, we are obligated to use certain of the net proceeds from <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">this offering to repay the 2024 Term Loan in an amount equal to the lesser of (i) the net cash proceeds of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">this offering in excess of $150.0 million and (ii) $50.0 million (or $55.0 million if the underwriters exercise <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 272pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">their option to purchase additional shares).<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The 2024 Credit Agreement contains customary representations and warranties, events of default and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">affirmative and negative covenants, including, among others, covenants that limit or restrict our (and our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">subsidiaries) ability to incur additional indebtedness, grant liens, merge or consolidate, make acquisitions, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">pay dividends or other distributions or repurchase equity, make investments, dispose of assets and enter <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">into certain transactions with affiliates, in each case subject to certain exceptions. Financial covenants <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">require us to maintain a $15.0 million minimum liquidity balance in cash and cash equivalents at all times <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 364pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and minimum net sales for twelve consecutive month periods ending on the last day of a fiscal quarter, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">which is not tested as long as the we maintain minimum liquidity of at least $60.0 million and there has <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 388pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">been no decline in net sales for two-consecutive fiscal quarters at the end of such fiscal quarter. The <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 400pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">minimum twelve months trailing net sales covenant increases each quarter and is $78.8 million for the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 412pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">quarter ended June 30, 2024 up to a minimum net sales amount of $110.0 million for the quarter ended <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 424pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">June 30, 2025 and each quarter thereafter. Events of default in the 2024 Credit Agreement include, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 436pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">among others, non-payment of principal, interest or fees, violation of covenants, inaccuracy of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 448pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 460pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">material contracts and events constituting a change of control. Upon the occurrence of an event of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 472pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">default, the interest rate applicable to the 2024 Term Loan shall increase by 3.0% per annum and the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 484pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">outstanding principal balance, along with any accrued interest, shall become immediately due and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 496pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">payable. As of December 31, 2024, we were in compliance with the 2024 Credit Agreement covenants.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 516pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Convertible notes<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 536pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">During the period from September 2022 through December 2022, we issued convertible promissory notes <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 548pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(the &#8220;Convertible Notes&#8221;) to certain investors, with an aggregate principal amount of $40.0 million. The <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 560pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Convertible Notes bore interest at a rate of 8% per annum, compounded monthly. The aggregate principal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 572pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">amount and interest accrued on the Convertible Notes was due September 30, 2026, and could not be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 584pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prepaid by us without the consent of a majority of the Convertible Note investors.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 604pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In March 2023, we completed a Qualified Financing (as defined in the Convertible Notes) and all of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 616pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Convertible Notes, including principal and interest, were converted into 21,465,064 shares of our Series <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 628pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">F-1 redeemable convertible preferred stock. In connection with the conversion of the Convertible Notes <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 640pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">into the shares of our Series F-1 redeemable convertible preferred stock, we derecognized the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 652pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Convertible Notes in our consolidated balance sheet. We remeasured the fair value of the Convertible <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 664pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Notes immediately before the conversion and recognized a $5.1 million loss from the change in fair value <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 676pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">in the consolidated statement of operations and comprehensive loss for the year ended <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 459.76pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 688pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 94.24pt; position: absolute; white-space: pre;">.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">88<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In January 2025, we issued convertible promissory notes to certain existing investors and certain <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">employees (the &#8220;Requisite Holders&#8221;) in the amount of up to $75.0 million (the &#8220;2025 Convertible Notes&#8221;). <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">Th</font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 83.66pt; position: absolute; white-space: pre;">e 2025 Convertible Notes are due and payable in full 48 months from the issue date. Upon completion <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of an IPO transaction, the 2025 Convertible Notes shall automatically convert into shares of our common <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock at the IPO price per share at the lower of a 20% discount and a valuation cap of $2.0 billion on a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">pre-money basis. In the event we complete a sale of shares of our preferred stock, the Requisite Holders <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">may elect to convert the outstanding 2025 Convertible Notes into shares of such series of preferred stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 156pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">at the same terms. Further, upon a change of control transaction, the Requisite Holders may elect to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 168pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">convert the outstanding 2025 Convertible Notes into shares of our common stock at the lower of a 20% <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 180pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">discount to the implied price per share of common stock in the change of control transaction and a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 192pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">valuation cap of $2.0 billion on a pre-money basis, or receive payment of all principal and any accrued but <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 204pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">unpaid 2025 Convertible Notes paid in-kind (&#8220;PIK&#8221;) interest. The 2025 Convertible Notes do not accrue <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 216pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">interest for one year following the date of issuance. Following the one-year anniversary of the issue date <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 228pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and for the remainder of the term, the 2025 Convertible Notes interest will accrue on an annual basis at <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 240pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the rate of 7.0% per annum. All PIK interest accrued and payable will be paid by capitalizing such interest <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 252pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">on an annual basis and adding it to the outstanding principal amount of the 2025 Convertible Notes.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 272pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In connection with the issuance of the 2025 Convertible Notes, we entered into Amendment No.1 to the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 284pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2024 Credit Agreement, in which our lender, Hayfin, converted $23.0 million of principal under the 2024 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 296pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Term Loan to 2025 Convertible Notes under the same terms as the other purchasers of the 2025 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Convertible Notes. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Cash flows<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 348pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The following table summarizes our cash flows for each of the periods presented&#58; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 368pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 334.5pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 12pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="3"><div style="left: 334.5pt; position: absolute; top: 0pt; width: 133.5pt;"><div><div style="font-size: 12pt; line-height: 5.82pt; position: absolute; top: 3pt; width: 133.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 33.64pt; position: absolute; text-decoration: none; white-space: pre;">Year ended <font style="display: inline-block; height: 5.82pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 78.92pt; position: absolute; text-decoration: none; white-space: pre;">December 31,<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 12pt; width: 334.5pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3pt; width: 334.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">(in thousands)<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 12pt; width: 65.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 44.86pt; position: absolute; text-decoration: none; white-space: pre;">2023<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 12pt; width: 65.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 44.86pt; position: absolute; text-decoration: none; white-space: pre;">2024<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 24pt; width: 334.5pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 334.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Net cash used in operating activities<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 162.60999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 164.92pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 166.07999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 166.37pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 166.45pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 166.47pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 24pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 19.08pt;"></font></font><font style="left: 27.27pt; position: absolute;">(76,434)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 38.25pt; width: 334.5pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 334.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Net cash used in investing activities<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 160.38pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 161.54pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 161.69pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 161.73pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 161.74pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 38.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 30.2pt;"></font></font><font style="left: 32.83pt; position: absolute;">(6,105)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 52.5pt; width: 334.5pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 334.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Net cash provided by financing activities<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 180.39pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 181.54999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 181.7pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 181.74pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 52.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 22.41pt;"></font></font><font style="left: 25.04pt; position: absolute;">169,318<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 450.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Net cash used in operating activities<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 470.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Net cash used in operating activities for the year ended December 31, 2024 was $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 482.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">attributable to a net loss of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million and a net change in operating assets and liabilities of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 494.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million, partially offset by non-cash charges of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 374.39pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;"> The non-cash charges primarily </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 506.75pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">consisted of stock-based compensation expense, change in fair value of common stock warrant, change </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 518.75pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">in fair value of derivative liability, depreciation and amortization, and amortization of debt discount and </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 530.75pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">debt issuance costs. The increase in net operating assets was primarily due to an increase in accounts </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 542.75pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">receivable and a decrease in operating lease liabilities, partially offset by an increase in accrued </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 554.75pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">expenses and other current liabilities.</font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 574.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Net cash used in operating activities was <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 255.3pt; position: absolute; text-decoration: none; white-space: pre;">$76.4 million<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 311.40999999999997pt; position: absolute; white-space: pre;"> for the year ended <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 398.06pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 485.85pt; position: absolute; white-space: pre;">, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 586.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">attributable to a net loss of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 191.95pt; position: absolute; text-decoration: none; white-space: pre;">$95.7 million<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 248.06pt; position: absolute; white-space: pre;"> and a net change in operating assets and liabilities of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 488.59pt; position: absolute; text-decoration: none; white-space: pre;">$8.5 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 598.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">million<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 100.33pt; position: absolute; white-space: pre;">, partially offset by non-cash charges of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 276.77pt; position: absolute; text-decoration: none; white-space: pre;">$27.8 million<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 332.88pt; position: absolute; white-space: pre;">. Non-cash charges primarily consisted of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 610.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">$11.9 million in stock-based compensation expense, <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 305.71000000000004pt; position: absolute; text-decoration: none; white-space: pre;">$5.1 million<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 356.26pt; position: absolute; white-space: pre;"> of change in fair value of convertible <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 622.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">note, <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 96.99pt; position: absolute; text-decoration: none; white-space: pre;">$4.7 million<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 147.54000000000002pt; position: absolute; white-space: pre;"> of depreciation and amortization, <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 298.07pt; position: absolute; text-decoration: none; white-space: pre;">$3.6 million<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 348.62pt; position: absolute; white-space: pre;"> of amortization of debt discount and debt <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 634.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">issuance costs and <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 159.78pt; position: absolute; text-decoration: none; white-space: pre;">$2.3 million<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 210.33pt; position: absolute; white-space: pre;"> of change in fair value of common stock warrant, partially offset by <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 508.38pt; position: absolute; text-decoration: none; white-space: pre;">$4.2 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 646.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">million<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 100.33pt; position: absolute; white-space: pre;"> of change in fair value of derivative liability. The net changes in operating assets and liabilities <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 658.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">primarily consisted of an increase of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 234.19pt; position: absolute; text-decoration: none; white-space: pre;">$9.4 million<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 284.74pt; position: absolute; white-space: pre;"> in accounts receivable and a decrease of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 471.96pt; position: absolute; text-decoration: none; white-space: pre;">$1.8 million<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 522.51pt; position: absolute; white-space: pre;"> in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 670.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">operating lease liabilities, partially offset by an increase of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 329.54pt; position: absolute; text-decoration: none; white-space: pre;">$3.8 million<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 380.09pt; position: absolute; white-space: pre;"> in accrued expenses and other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 682.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">current liabilities.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">89<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Net cash used in investing activities<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 92pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">Net cash used in investing activities for the year ended December 31, 2024 was $</font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 433.07pt; position: absolute; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 460.77pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">million consisting </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">of purchases of property and equipment.</font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 124pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Net cash used in investing activities for the year ended <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 316.4pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 404.19pt; position: absolute; white-space: pre;"> was <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 427.51pt; position: absolute; text-decoration: none; white-space: pre;">$6.1 million<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 478.06pt; position: absolute; white-space: pre;"> consisting of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 136pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">purchases of property and equipment.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 156pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Net cash provided by financing activities<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">Net cash provided by financing activities for the year ended December 31, 2024 of $</font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 443.63pt; position: absolute; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 471.33pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">million </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">primarily related to proceeds of $</font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 217.53pt; position: absolute; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 245.23pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">million from our 2024 Term Loan re-financing and $</font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 471.15pt; position: absolute; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 498.85pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">million in </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">proceeds from the exercise of stock options.</font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Net cash provided by financing activities for the year ended <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 336.41pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 424.2pt; position: absolute; white-space: pre;"> was <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 447.52pt; position: absolute; text-decoration: none; white-space: pre;">$169.3 million<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 509.19pt; position: absolute; white-space: pre;">, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 232pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">primarily attributable to net proceeds of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 247.51pt; position: absolute; text-decoration: none; white-space: pre;">$169.0 million<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 309.18pt; position: absolute; white-space: pre;"> from the issuance of our Series F redeemable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">convertible preferred stock.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 264pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Future funding requirements<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 284pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our recurring losses from operations and negative cash flows raise substantial doubt about our ability to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 296pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">continue as a going concern within 12 months after the issuance date of the consolidated financial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">statements as of and for the year ended December 31, 2023. See Note 1 to our consolidated financial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 320pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">statements included elsewhere in this prospectus for additional information on our assessment. Similarly, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 332pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our independent registered public accounting firm included an explanatory paragraph in its report on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 344pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">these financial statements as of and for the year ended December 31, 2023, describing the existence of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 356pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">substantial doubt about our ability to continue as a going concern.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Based on our current operating plan, we believe that the estimated net proceeds from this offering <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 388pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">together with the expected cash generated from revenue transactions with customers and our existing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 400pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">cash and cash equivalents, <font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 195.34pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">will be sufficient to fund our planned operating expenses and capital </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 412pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">expenditure requirements for at least the next 12 months. We </font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 345.64pt; position: absolute; white-space: pre;">have based this estimate on assumptions <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 424pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">that may prove to be wrong, and we could deplete our capital resources sooner than we expect. We may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 436pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">experience lower than expected cash generated from operating activities or greater than expected capital <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 448pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">expenditures, cost of revenue, or operating expenses, and may need to raise additional capital to fund <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 460pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">operations, further research and development activities, or acquire, invest in, or in-license other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 472pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">businesses, assets, or technologies.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 492pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our future funding requirements will depend on many factors, including the following&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 512pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the market acceptance of our products&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 532pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the timing, scope, rate of progress, results and costs of our research and development activities&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the number, scope and duration of current or future clinical studies and additional regulatory <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">clearances or approval&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 584pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the effect of competing technological and market developments&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 604pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the costs and timing of future commercialization activities, including marketing and sales, f<font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 487.68pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">or </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 616pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 134.98pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">Plaque Analysis and any other new products&#894;</font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 636pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the amount of revenue, if any, received from commercial sales of our Heartflow Plaque Analysis and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 648pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">any other new products&#894;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 668pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the impact of competitors&#8217; products and technological advances and other market developments&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 688pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the expenses needed to attract and retain skilled personnel&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">90<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the size of the markets and degree of market acceptance of any products in territories in which we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">receive regulatory approval, including product pricing, product coverage, and the adequacy of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">reimbursement by third-party payors&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Whether we acquire third-party companies, products or technologies&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 136pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Restructuring, refinancing or repayment of debt&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 156pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the increase in the number of our employees to support growth initiatives&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the cost of attaining, defending and enforcing our patents and other intellectual property rights&#894;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 196pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the timing of when we pay our operating expenses&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 216pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the costs associated with being a public company&#894; and<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">other factors, including economic uncertainty, geopolitical tensions, healthcare reform <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 469.21pt; position: absolute; text-decoration: none; white-space: pre;">and changes in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">administration<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 152.22pt; position: absolute; text-decoration: none; white-space: pre;">, which may exacerbate the magnitude of the factors discussed above.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Furthermore, our operating plans may change, and we may need additional funds to meet operational <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">needs and capital requirements for clinical trials and other research and development expenditures.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 300pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Contractual obligations and commitments<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 322.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our contractual commitments will have an impact on our future liquidity. These commitments include <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 334.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">future payments on non-cancellable facility leases, purchase obligations related to research and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 346.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">development and professional services under non-cancellable contracts, royalty obligations for exclusive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 358.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">technology licensing agreements and future payments on our 2024 Term Loan. Where applicable, we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 370.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">calculate our obligation based on termination fees that can be paid to exit the contract. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 390.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Lease agreements<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 410.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We have operating lease arrangements for office space in Mountain View, California, Austin, Texas, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 422.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Tokyo, Japan. As of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 161.42000000000002pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2024<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 249.21pt; position: absolute; white-space: pre;">, we had total lease payment obligations under non-cancelable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 434.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">leases of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million, including $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million payable through December 31, 2025. See Note 6 and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 446.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Note 18 to our consolidated financial statements included elsewhere in this prospectus.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 466.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Royalty payments<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 486.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We entered into various exclusive technology licensing agreements that requires us to make annual <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 498.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">royalty payments in fixed amounts as well as certain milestone and revenue-based payments. As of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 510.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2024<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 159.79000000000002pt; position: absolute; white-space: pre;">, we had total royalty obligations under these agreements of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million, including <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 522.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million payable through December 31, 2025. See Note 7 to our consolidated financial statements <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 534.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">included elsewhere in this prospectus.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 554.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">2024 Term Loan<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 574.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Principal payments required on debt outstanding under our 2024 Term Loan as of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 434.04pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2024<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 521.8299999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 586.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">was $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million, which includes $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million of interest payable. See Note 8 and Note 18 to our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 598.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">consolidated financial statements included elsewhere in this prospectus.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 618.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Recently issued accounting pronouncements<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 640.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">A description of recently issued accounting pronouncements that may potentially impact our financial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 652.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">position, results of operations or cash flows is disclosed in Note 2 to our consolidated financial statements <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 664.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">included elsewhere in this prospectus.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">91<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 8.73pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Critical accounting policies and estimates<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 94.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 106.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">on our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 118.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">preparation of these consolidated financial statements requires us to make estimates and assumptions <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 130.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosures. Our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 142.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">estimates are based on our historical experience and various other factors that we believe are reasonable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 154.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">under the circumstances, the results of which form the basis for making judgments about the carrying <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 166.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">value of assets and liabilities that are not readily apparent from other sources. Actual results may differ <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 178.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">from these estimates under different assumptions or conditions and any such differences may be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 190.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">material. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 210.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">While our significant accounting policies are described in more detail in Note 2 to our consolidated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 222.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">financial statements included elsewhere in this prospectus, we believe that the following discussion <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 234.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">addresses our most critical accounting policies, which are those most important to our financial condition <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 246.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and results of operations and require our most difficult, subjective and complex judgments.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 266.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Common stock warrants<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 286.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We have issued freestanding warrants to purchase shares of common stock in connection with our 2024 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 298.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Term Loan. We classify these warrants as a liability because they do not meet the equity indexation <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 310.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">criteria. We record the fair value of the warrant on the consolidated balance sheet upon issuance and is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 322.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">subject to remeasurement at each balance sheet date. The changes in the fair value of the warrants are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 334.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">recorded in the consolidated statement of operations and comprehensive loss. We utilize the Black-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 346.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Scholes option-pricing model, which incorporates assumptions and estimates, to value the common stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 358.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">warrant liability. Significant estimates and assumptions impacting fair value include the stock price, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 370.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">contractual term, expected volatility and weighted average risk-free interest rate.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 390.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The estimated aggregate fair value of the warrants issued in connection with the 2024 Term Loan in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 402.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">January 2021 and March 2022 was $4.3 million and $3.5 million, respectively. We recognized a $2.3 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 414.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">million loss from the change in fair value in the consolidated statement of operations and comprehensive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 426.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">loss during the year ended December 31, 2023.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 446.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Derivative liability<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 466.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We determined that our 2024 Term Loan contains certain prepayment features, default put option and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 478.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">default interest adjustment features that were determined to be embedded derivatives requiring <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 490.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">bifurcation and separate accounting as a single compound derivative. The impact of bifurcation of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 502.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">embedded derivative on the date of issuance was reflected as a debt discount. The instrument was <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 514.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">classified as a liability on the consolidated balance sheet and is subject to remeasurement at each <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 526.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">balance sheet date. Any change in fair value of the derivative liability is recognized in the consolidated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 538.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">statement of operations and comprehensive loss.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 558.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We utilize both the Black-Scholes-Merton and option-pricing method, which incorporates certain <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 570.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">assumptions and estimates, to value the derivative liability. These include the estimated time and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 582.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">probability of a business combination or IPO, default, change of control and incurrence of new debt, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 594.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">weighted common stock value, debt yield, expected volatility and risk-free interest rate.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 614.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The estimated fair value of the derivative liability was $2.1 million at the issuance date in January 2021. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 626.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We recognized a gain of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 182.36pt; position: absolute; text-decoration: none; white-space: pre;">$4.2 million<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 232.91pt; position: absolute; white-space: pre;"> from the change in fair value in the consolidated statement of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 638.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">operations and comprehensive loss during the year ended <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 332.03pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 419.82pt; position: absolute; white-space: pre;">.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 658.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Stock-based compensation<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 678.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Stock-based compensation related to share-based awards granted to employees, consultants and to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 690.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">members of our board of directors is measured at fair value. Compensation expense for those awards is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 702.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">recognized on a straight-line basis over the requisite service period, which is generally the vesting period. <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">92<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">For performance-based stock options, we assess the probability of performance conditions being <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">achieved in each reporting period. The amount of stock-based compensation expense recognized in any <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">one period related to performance-based stock options can vary based on the achievement or anticipated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">achievement of the performance conditions. We account for forfeitures of stock-based awards as they <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">occur. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We estimate the fair value of each option award on the date of grant using the Black-Scholes option -<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">pricing model. This model requires the use of highly subject assumptions to determine the fair value, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">including&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 184pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Fair value of common stock.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 214.95999999999998pt; position: absolute; text-decoration: none; white-space: pre;"> See the subsection titled &#8220;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 332.7pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">&#8212;</font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 342.7pt; position: absolute; text-decoration: none; white-space: pre;">Determination of fair value of common <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 196pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">stock&#8221; below.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 216pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Expected term.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 157.2pt; position: absolute; text-decoration: none; white-space: pre;"> The expected term represents the period that the stock-based awards are expected to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 228pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">be outstanding. The expected term for our stock options was calculated based on the weighted-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 240pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">average vesting term of the awards and the contract period, or simplified method.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Expected volatility.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 172.75pt; position: absolute; text-decoration: none; white-space: pre;"> Since we are not yet a public company and do not have any trading history for our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 272pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">common stock, the expected volatility was estimated based on the average historical volatilities of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 284pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">common stock of comparable publicly traded entities over a period equal to the expected term of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 296pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">stock option grants. The comparable companies were chosen based on their size, stage of their life <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">cycle or area of specialty. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Risk-free interest rate.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 188.29000000000002pt; position: absolute; text-decoration: none; white-space: pre;"> The risk-free interest rate is based on the U.S. Treasury yield in effect at the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">time of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the expected <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">term of the awards.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Expected dividend yield.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 197.78pt; position: absolute; text-decoration: none; white-space: pre;"> The expected dividend yield is zero as we have not paid dividends nor do we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 384pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">anticipate paying any dividends on our common stock. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 404pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We expect to continue to grant equity-based awards in the future, and to the extent that we do, our stock-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 416pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">based compensation expense recognized in future periods will likely increase.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 436pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Determination of fair value of common stock<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 456pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">As there has been no public market for our common stock to date, the estimated fair value of our common <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 468pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock underlying our share-based awards was estimated on each grant date by our management and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">approved by our board of directors. Our board of directors exercised reasonable judgment and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 492pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">considered a number of objective and subjective factors, as well as valuations prepared by independent <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 504pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">third-party valuation firms. The methodologies used to estimate the enterprise value are performed using <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 516pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">methodologies, approaches and assumptions consistent with the American Institute of Certified Public <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 528pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Accountants Accounting and Valuation Guide, <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 276.8pt; position: absolute; white-space: pre;">Valuation of Privately-Held-Company Equity Securities <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Issued as Compensation<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 182.01pt; position: absolute; white-space: pre;"> (the Practice Aid).<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 560pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition to considering the results of independent third-party valuations, our board of directors <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 572pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">considered various objective and subjective factors to determine the fair value of common stock as of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 584pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">each grant date, including&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 604pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">contemporaneous valuations performed by independent third-party specialists&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the prices, rights, preferences and privileges of our redeemable convertible preferred stock relative to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 636pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">those of our common stock&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the prices of common or preferred stock sold to third-party investors by us and in secondary <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 668pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">transactions or repurchased by us in arms-length transactions&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 688pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">lack of marketability of our common stock&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 708pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our actual operating and financial performance&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">93<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">current business conditions and projections&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 92pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our stage of development&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 112pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">likelihood of achieving a liquidity event, such as an initial public offering or a merger or acquisition of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 124pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our company given prevailing market conditions&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the market performance of comparable publicly traded companies&#59; and<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the U.S. and global capital market conditions.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 184pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">For our valuations performed, the allocation of these enterprise values to each our share classes utilized <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 196pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the hybrid method. The hybrid method considered the stay private scenario and IPO exit scenario. In the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 208pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stay private scenario, three market methodologies were employed including (i) a market indexing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">valuation analysis based on the Series F Preferred financing round, (ii) a guideline public company <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">analysis based on historical and forecast operating metrics for us, and (iii) a guideline transaction analysis <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">based on historical and forecast operating metrics for us. In the IPO exit scenario, the total equity value <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">was estimated based on the expected timing, offering size and pre-money valuation.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 276pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The assumptions underlying these valuations represented management&#8217;s best estimate, which involved <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 288pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">inherent uncertainties and the application of management&#8217;s judgment. As a result, if we had used <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 300pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">significantly different assumptions or estimates, the fair value of our common stock and our stock-based <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 312pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">compensation expense could be materially different.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 332pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Once a public trading market for our common stock has been established in connection with the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 344pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">completion of this offering, it will no longer be necessary for our board of directors to estimate the fair <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 356pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">value of our common stock in connection with our accounting for share-based payments, as the fair value <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 368pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of our common stock will be based on the quoted market price of our common stock.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 388pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Off-balance&#160;sheet&#160;arrangements<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 410.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">During the periods presented we did not have, nor do we currently&#160;have,&#160;any&#160;off-balance&#160;sheet <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 422.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">arrangements as defined in the rules and regulations of the SEC.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 442.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Quantitative and qualitative disclosures about market risks<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 464.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Interest rate risk<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 484.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">As of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 97.53pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2024<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 185.32pt; position: absolute; white-space: pre;">, we had cash and cash equivalents of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million. Our cash and cash <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 496.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">equivalents are held for working capital purposes. We do not enter into investments for trading or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 508.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">speculative purposes. Due to the short-term nature of our cash equivalents, we have not been exposed <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 520.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to, nor do we anticipate being exposed to, material risks due to changes in interest rates.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our exposures to market risk for changes in interest rates relate primarily to our 2024 Term Loan <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(described above) which bears floating interest rates and a rising interest rate environment will increase <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the amount of interest paid on these loans. Each 100 basis point increase in these initial rates would <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">increase annual interest expense by approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million assuming the 2024 Term Loan remain <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">outstanding for the annual period.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 608.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Credit risk <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 628.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our cash and cash equivalents, which at times may exceed federally insured limits, is maintained with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 640.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">large financial institutions. As of the issuance date of the financial statements included in this report, we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 652.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">have not experienced any losses on our deposits and all of our cash deposits have been accessible to us.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our accounts receivable primarily relate to revenue from the sale of our products to medical <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 684.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">providers.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;customer and no customer represented 10% or more of our accounts receivable as of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 696.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">December 31, 2024 and 2023, respectively.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">94<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Foreign currency exchange risk<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 92pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The vast majority of our cash generated from revenue is denominated in U.S. dollars, with a small amount <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">denominated in&#160;other foreign currencies. Our expenses are generally denominated in the currencies of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the jurisdictions in which we conduct our operations, which are primarily in the United States, United <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Kingdom&#160;and&#160;Japan. Our results of operations and cash flows are, therefore, subject to fluctuations due to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">changes in foreign currency exchange rates. The effect of a hypothetical 10% change in foreign currency <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">exchange rates applicable to our business would not have had a material impact on our consolidated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">financial statements during the year ended December 31, 2024. As the impact of foreign currency <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">exchange rates has not been material to our historical operating results, we have not entered into <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">derivative or hedging transactions, but we may do so in the future if our exposure to foreign currency <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">becomes more significant.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Effects of inflation<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 240pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Inflation generally affects us by increasing our cost of labor and overhead costs. We do not believe that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 252pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">inflation has had a material impact on our business, results of operations, or financial condition, or on our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 264pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">consolidated financial statements included elsewhere in this prospectus.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 284pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Emerging growth company status<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 306.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We are an &#8220;emerging growth company&#8221; under the JOBS Act, which permits us to take advantage of an <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 318.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">extended transition period to comply with new or revised accounting standards applicable to public <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 330.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">companies. We have elected to use this extended transition period until we are no longer an emerging <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 342.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">growth company or until we affirmatively and irrevocably opt out of the extended transition period. As a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 354.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">result, our consolidated financial statements may not be comparable to companies that comply with new <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 366.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or revised accounting pronouncements applicable to public companies. The JOBS Act also exempts us <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 378.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">from having to provide an attestation and report from our independent registered public accounting firm <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 390.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">on the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 402.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2002.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 422.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We will remain an emerging growth company until the earliest of&#58; (i) the last day of the fiscal year <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 434.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">following the fifth anniversary of the completion of this offering&#59; (ii) the last day of the fiscal year in which <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 446.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">we have total annual gross revenue of at least $1.235 billion&#59; (iii) the last day of the fiscal year in which <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 458.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">we are deemed to be a &#8220;large accelerated filer&#8221; as defined in Rule 12b-2 under the Exchange Act, which <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 470.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">would occur if the market value of our common stock held by non-affiliates exceeded $700.0 million as of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 482.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the last business day of the second fiscal quarter of such year&#59; or (iv) the date on which we have issued <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 494.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">more than $1.0 billion in non-convertible debt securities during the prior three-year period.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">95<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_1189" style="position: absolute; top: 72pt;"></div><div style="line-height: 11.64pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Business <font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 107.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Overview<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 129.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">We have pioneered the use of software and AI to deliver a more accurate and clinically effective non-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 141.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">invasive solution for diagnosing and managing coronary artery disease<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 384.25pt; position: absolute; white-space: pre;"> (&#8220;CAD&#8221;), a leading cause of death <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 153.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">worldwide. As of December 31, 2024<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 234.76pt; position: absolute; text-decoration: none; white-space: pre;">, our Heartflow Platform has been used to assess CAD in more than <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 165.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">375,000 patients, including 132,000 in 2024 alone. <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 298.13pt; position: absolute; white-space: pre;">We believe that we are the most widely adopted AI-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 177.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">powered test for CAD. Our novel platform leverages <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 303.6pt; position: absolute; text-decoration: none; white-space: pre;">AI<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 313.03pt; position: absolute; white-space: pre;"> and advanced computational fluid dynamics to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 189.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">create a personalized 3D model of a patient&#8217;s heart from a single coronary computed tomography <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 201.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">angiography (&#8220;CCTA&#8221;), a specialized type of scan that provides detailed images of the heart&#8217;s arteries. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 213.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our Heartflow Platform delivers actionable insights on blood flow, stenosis, plaque volume and plaque <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 225.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">composition thereby overcoming the limitations of traditional non-invasive imaging tests which rely on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 237.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">indirect measures of coronary disease and lead to high false negative and false positive rates. We believe <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 249.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the differentiated accuracy and clinical utility of our Heartflow Platform, along with its ability to enhance <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 261.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">workflows, will continue to support our growth <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 275.83000000000004pt; position: absolute; text-decoration: none; white-space: pre;">and advance the &#8220;CCTA + Heartflow&#8221; pathway<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 478.66pt; position: absolute; white-space: pre;"> as the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 273.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">definitive standard for the non-invasive diagnosis and management of CAD.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 293.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">CAD occurs when plaque&#8212;a buildup of cholesterol, fat, calcium and other substances&#8212;accumulates on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 305.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the walls of the coronary arteries, restricting blood flow and increasing the risk of heart attack or stroke. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 317.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">This condition is responsible for half of all cardiovascular-related deaths globally. In the United States <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 329.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">alone, the Centers for Disease Control (&#8220;CDC&#8221;) estimates that approximately 805,000 people suffer a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 341.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">heart attack each year. Despite significant advancements in therapeutic and interventional treatments, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 353.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">CAD remains the leading cause of death globally because healthcare systems generally lack scalable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 365.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">methods to efficiently detect, diagnose and quantify CAD at a personalized level. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 385.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We estimate that there were approximately 9.5 million non-invasive tests (&#8220;NITs&#8221;) in the United States in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 397.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2023 for patients experiencing stable or acute chest pain, which we refer to as symptomatic CAD <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 409.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">patients. These NITs primarily include stress tests, such as single-photon emission computed tomography <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 421.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(&#8220;SPECT&#8221;), echocardiography and positron emission tomography (&#8220;PET&#8221;), which infer the presence of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 433.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">heart disease based on how well blood is supplied to the heart, and do not measure the actual disease <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 445.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">itself. Accordingly, these tests have been shown to be unreliable and inconsistent. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 465.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">CCTA has emerged as a leading non-invasive imaging method for evaluating CAD, offering direct and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 477.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">detailed visualization of the coronary arteries. Unlike traditional stress-based NITs, CCTA enables <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 489.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">physicians to identify the presence and extent of coronary blockage. As a result, CCTA has become the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 501.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">preferred first-line test for patients with suspected CAD. However, while CCTA provides superior <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 513.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">anatomical imaging, it does not independently quantify the severity of CAD, assess blood flow limitations, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 525.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or characterize plaque composition&#8212;critical factors for determining the most appropriate, personalized <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 537.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">course of treatment for a patient.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 557.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our Heartflow Platform builds upon the well established strengths of CCTA by going beyond its limitations <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 569.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and providing new quantified insights and compelling visualizations of data. By applying our advanced AI-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 581.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">powered technology to a single CCTA scan, we generate a precise, patient-specific analysis that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 593.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">quantifies blood flow, measures plaque burden, and characterizes plaque composition&#8212;at every point in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 605.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the major coronary arteries. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 625.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">To date, we have developed three software products under the Heartflow Platform that provide physicians <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 637.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">with the critical insights needed to effectively diagnose and manage CAD&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 657.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow RoadMap Analysis<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 218.32pt; position: absolute; text-decoration: none; white-space: pre;"> offers a highly intuitive anatomic visualization of the coronary arteries, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 669.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">helping physicians quickly identify clinically relevant areas to focus their review.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">96<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: italic; font-weight: normal; left: 154.4pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 163.06pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 203.05pt; position: absolute; text-decoration: none; white-space: pre;"> calculates blood flow and pinpoints functionally significant CAD at every <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">point in the major coronary arteries, guiding decisions on whether a patient requires invasive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">revascularization.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow Plaque Analysis<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 206.09pt; position: absolute; text-decoration: none; white-space: pre;"> provides a comprehensive assessment of coronary plaque, enabling <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">optimized medical treatment strategies.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 148pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We believe we are the first and most widely-adopted AI-powered test for CAD. With over a decade of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 160pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">commercial presence, we have established a competitively differentiated data set of over 100 million <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 172pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">annotated images, driving continuous training and refinement of our algorithms for over 10 years and the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 184pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">ability to train new AI models for future products.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 204pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We believe our Heartflow Platform delivers the following key benefits&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">More accurate non-invasive test for CAD<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 282.68pt; position: absolute; text-decoration: none; white-space: pre;">, clinically validated to provide superior assessment of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">blood flow, plaque volume and plaque characterization compared to traditional non-invasive methods. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">More informed assessments, personalized care, and better risk stratification<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 452.03pt; position: absolute; text-decoration: none; white-space: pre;">, positively <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">impacting physician decisions on which patients should receive an intervention, supporting more <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">efficient intervention planning and driving more personalized medical management.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 300pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Superior economic efficiency and enhanced interventional treatment planning<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 460.25pt; position: absolute; text-decoration: none; white-space: pre;">, accurately <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 312pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">identifying more patients who need interventional treatment while reducing unnecessary invasive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 324pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">procedures&#8212;significantly improving the efficiency of the catheterization lab and therefore hospital <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 336pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">economics.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 356pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Proprietary, secure bi-directional data communication with customers <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 425.31pt; position: absolute; text-decoration: none; white-space: pre;">that feeds a growing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 368pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">database of over 100 million annotated CCTA images that we leverage to improve the Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 380pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Platform&#8217;s <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 137.01pt; position: absolute; text-decoration: none; white-space: pre;">accuracy, automation and clinical utility and seamlessly deliver new features and workflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 392pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">efficiencies to our customers. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 412pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Improved workflow<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 181.03pt; position: absolute; text-decoration: none; white-space: pre;"> through our Heartflow RoadMap Analysis that reduces CCTA interpretation times <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 424pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">by approximately 25% and reduces variability between reviewing physicians by approximately 50%, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 436pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">leading to more consistent diagnoses and standardized patient care. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 456pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Better patient and provider experience<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 272.66999999999996pt; position: absolute; text-decoration: none; white-space: pre;">, by leveraging a single CCTA for all of our products, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 468pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">patients complete their test in approximately 20 minutes with significantly lower radiation exposure <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">compared to nuclear imaging tests such as SPECT and PET that take multiple hours and require <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 492pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">radioactive tracers to be injected into the bloodstream. By providing a definitive diagnosis upfront, the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 504pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow Platform eliminates the need for layered testing, streamlining the patient journey and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 516pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">reducing anxiety associated with uncertain or inconclusive results.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 536pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We estimate our current market opportunity in the United States is approximately $5 billion. We believe <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 548pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 153.62pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 162.28pt; position: absolute; white-space: pre;"> Analysis is applicable to approximately 33% of NIT patients annually and the majority <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 560pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of patients experiencing acute chest pain, which represents 3.1 million patients and an estimated market <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 572pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">opportunity of approximately $3.3 billion in the United States. We believe our Heartflow Plaque Analysis is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 584pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">applicable to approximately 60% of NIT patients annually and the majority of patients experiencing acute <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 596pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">chest pain, which represents 5.5 million patients and an estimated market opportunity of an incremental <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 608pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">approximately $1.7 billion in the United States. <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 280.28pt; position: absolute; text-decoration: none; white-space: pre;">Beyond the commercialization of Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 491.88pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 500.54pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 620pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">and Heartflow Plaque Analysis in symptomatic CAD, we see a significant market opportunity for our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 632pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">technologies in at-risk individuals who show no symptoms, a segment comprised of approximately 200 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">million people globally. To unlock this potential, we are continuing to evaluate new product opportunities <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">and appropriate clinical evidence supporting eventual regulatory approval, payor coverage and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 668pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">commercialization. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 688pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We believe the Heartflow Platform is the most extensively studied AI-enabled test for CAD. Its accuracy, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 700pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">clinical utility and economic benefits have been evaluated in over 100 clinical studies and more than <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">97<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">130,000 patients, including two large randomized controlled trials, with results published in over 600 peer-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reviewed clinical publications. Our studies have consistently demonstrated that the Heartflow Platform is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">more accurate than traditional non-invasive tests and highly concordant to invasive testing, reduces <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">unnecessary invasive testing, and enables physicians to optimize treatment and ultimately provide more <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">efficient care.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We have developed a highly scalable, capital efficient commercial model that combines Territory Sales <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Managers (&#8220;TSMs&#8221;) who drive new account adoption with Territory Account Managers (&#8220;TAMs&#8221;) who focus <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">on increasing utilization by educating referring physicians. Our commercial team does not cover cases or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">otherwise spend time in an operating room or lab setting, which enables them to focus solely on driving <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">commercial adoption and educational activities. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 208pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our technology is simple and intuitive and does not require the purchase of any capital equipment. Our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">onboarding process seamlessly integrates the Heartflow Platform into the customer&#8217;s daily workflow. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">These unique attributes of our business model afford our commercial organization a differentiated level of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">efficiency and scalability.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 264pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Current clinical guidelines and reimbursement policies strongly support the adoption of the Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 276pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Platform. The CCTA + <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 171.82999999999998pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 216.81pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 236.23pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 246.58pt; position: absolute; white-space: pre;">Analysis pathway is supported by the American Heart Association <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 288pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(&#8220;AHA&#8221;) and American College of Cardiology (&#8220;ACC&#8221;) guidelines, with CCTA identified as a Class 1, Level <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 300pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">A test and <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 119.2pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 164.18pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 183.6pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 193.95pt; position: absolute; white-space: pre;">Analysis identified as a Class 2a, Level B test for the diagnosis of CAD in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 312pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">certain patients with stable or acute chest pain and no known CAD. Our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 390.81pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 435.79pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 455.21pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 463.87pt; position: absolute; white-space: pre;"> Analysis is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 324pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reimbursed under a dedicated Category 1 Current Procedural Terminology (&#8220;CPT&#8221;) code, effective as of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 336pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">January 1, 2024, and has established coverage policies representing approximately 99% of covered lives <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 348pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">in the United States. A Category 1 CPT code was also recently established for <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 418.94pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 463.92pt; position: absolute; white-space: pre;">Plaque Analysis, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">which will take effect in January 2026, and it is covered by all seven Medicare administrative contractor <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(&#8220;MACs&#8221;).<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 392pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We primarily generate revenue on a &#8220;pay per click&#8221; basis each time a physician chooses to review either <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 404pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 89.22pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 134.2pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 153.62pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 162.28pt; position: absolute; white-space: pre;"> Analysis, <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 207.26pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 252.24pt; position: absolute; white-space: pre;">Plaque Analysis, or both. <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 364.99pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 409.97pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 429.39pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 438.05pt; position: absolute; white-space: pre;"> Analysis has served <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 416pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">as our commercial foundation, representing&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of our revenue in 2024. In the second half of 2023, we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 428pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">initiated limited market education efforts for <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 265.08000000000004pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 307.28999999999996pt; position: absolute; white-space: pre;"> Plaque Analysis, our second commercial product. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 440pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 91.43pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 136.41pt; position: absolute; white-space: pre;">RoadMap Analysis is generally provided as a workflow efficiency tool to drive customer <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 452pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">retention and loyalty and is not a stand-alone product. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 472pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We have experienced significant revenue growth since we began commercializing the Heartflow Platform <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 484pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">in 2015. We recognized revenue of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million for the year ended December 31, 2024, compared to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 496pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">revenue of $87.2 million for the year ended December 31, 2023, representing&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% year-over-year <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 508pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">growth. The software-based nature of our Heartflow Platform produces an attractive gross margin profile, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 520pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">which continues to expand as we leverage AI to automate an increasing portion of our &#8220;human-in-the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 532pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">loop&#8221; quality control process, where learnings are fed back into our algorithms to make them smarter and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 544pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">more efficient. For the twelve months ended December 31, 2024, we generated gross margins of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;%, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 556pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">an increase of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;percentage points year-over-year. Our net losses were $95.7 million and $ &#160;&#160;&#160;&#160;&#160;&#160;&#160;million <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 568pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for the years ended December 31, 2023 and 2024, respectively.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 588pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Our success factors<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 610.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We believe the continued growth of our company will primarily be driven by the following suc<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 479.53pt; position: absolute; text-decoration: none; white-space: pre;">cess factors&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 630.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Differentiated approach to the non-invasive diagnosis and management of CAD&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 470.25pt; position: absolute; text-decoration: none; white-space: pre;"> We are the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 642.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">first medical technology company authorized for marketing in the United States to leverage software <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 654.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">and AI to accurately and non-invasively diagnose and manage CAD using a single CCTA. As of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 666.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">December 31, 2024, our Heartflow Platform has been used to assess CAD in more than 375,000 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 678.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">patients, including 132,000 in 2024 alone. Our Heartflow Platform applies AI and advanced <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 690.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">computational fluid dynamics to generate a personalized 3D model of a patient&#8217;s heart, delivering <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 702.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">actionable data on blood flow, stenosis, plaque volume and plaque composition. This enables <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">98<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">physicians to diagnose CAD, assess risk and develop individualized care plans without requiring an <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">invasive procedure. Unlike traditional NITs that use surrogate measures to diagnose heart disease, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">which results in higher rates of false negatives and false positives, the Heartflow Platform measures <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">and quantifies the actual disease and has been proven to more accurately diagnose CAD. Our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">proprietary database of more than 100 million annotated CCTA images, growing daily, has fueled <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">ongoing AI-driven algorithm refinement for over a decade&#8212;enhancing our platform&#8217;s value for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">patients, physicians, and payors. We believe the unique software technology attributes of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 156pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow Platform will continue to support our commercial presence and help us establish the CCTA <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 168pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">+ Heartflow pathway as the standard of care for the non-invasive diagnosis and management of CAD. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Market leader in AI-powered quantitative CAD analysis with strong customer relationships&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 521.35pt; position: absolute; text-decoration: none; white-space: pre;"> We <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">believe our Heartflow Platform is the most widely adopted AI-powered test for CAD, to date, with an <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">installed base of over 1,100 accounts in the United States as of December 31, 2024, including leading <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">academic institutions, integrated delivery networks, physician offices and outpatient imaging centers. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Our value proposition resonates across multiple subspecialties, including radiology, cardiology, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">interventional cardiology. Our deep integration into customer workflows and IT infrastructure, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">including electronic medical record systems, ensures seamless utilization and efficiency. We believe <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 272pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our long-standing customer relationships, continuously improving AI-powered software and the highly <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 284pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">embedded nature of our customer integrations will continue to support the rapid adoption of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 296pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Platform. Additionally, as we expand our AI capabilities, introduce new applications such as Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Plaque Analysis, and further optimize workflow integration, we expect our Platform&#8217;s value proposition <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 320pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">to grow&#8212;deepening customer reliance on our solutions and accelerating broader market penetration.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Attractive revenue model with significant operating leverage potential&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 424.19pt; position: absolute; text-decoration: none; white-space: pre;"> We primarily generate <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">revenue on a scalable &#8220;pay per click&#8221; model, in which we charge per physician review of our Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 364pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">FFRCT Analysis, Heartflow Plaque Analysis, or both. Utilization rates for Heartflow FFRCT Analysis <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">typically scale rapidly after onboarding, approaching approximately 33% of eligible CCTA tests within <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 388pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">an account&#8212;a level that is generally sustained over time. As CCTA + Heartflow referral volumes <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 400pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">increase, these stable utilization rates translate into increasing Heartflow revenue cases.These <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 412pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">aspects of our revenue model afford us significant predictability and consistency. Additionally, the AI-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 424pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">based nature of our software platform produces an attractive gross margin profile that has improved <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 436pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">over time as we have leveraged AI to automate an increasing number of the manual components of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 448pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our &#8220;human-in-the loop&#8221; quality control process thereby lowering the cost of revenue per analysis. For <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 460pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the twelve months ended December 31, 2024, we generated gross margins of&#160;&#160;&#160;&#160;&#160;&#160;&#160;%, an increase <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 472pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">of&#160;&#160;&#160;&#160;&#160;&#160;&#160;% year-over-year. Given our established relationships and bi-directional data sharing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 484pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">infrastructure with customers, we also have the opportunity to add and rapidly scale revenue streams <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 496pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">from new software products or indications, such as Heartflow Plaque Analysis, with minimal additional <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 508pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">setup and installation cost and effort for our customers. Since Heartflow Plaque Analysis runs on the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 520pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">same CCTA scan as Heartflow FFRCT Analysis, we expect favorable operating and gross margin <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 532pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">leverage as its adoption increases. We have also developed a highly scalable enterprise commercial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 544pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">model that combines TSMs who focus on driving new account adoption with TAMs who educate <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 556pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">referring physicians and drive increased volumes at existing accounts. Unlike traditional medical <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 568pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">technology companies, our software is fully cloud-based, simple to implement, and does not require <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 580pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">case coverage or on-site support. This streamlined, capital-light model enables us to scale efficiently <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 592pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">while maintaining a lean commercial footprint. We believe these structural advantages will enable us <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 604pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">to continue investing in growth while advancing towards profitability.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Large addressable market opportunity with a significant unmet need&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 418.07pt; position: absolute; text-decoration: none; white-space: pre;"> CAD is the leading cause <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 636pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">of death and a highly prevalent condition worldwide with well-established pathways for diagnosis, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 648pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">primarily through NITs. In the United States alone, approximately 9.5 million NITs were performed for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the diagnosis of CAD in 2023. However, the majority of these tests measure only surrogate markers <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">for CAD and are therefore often inaccurate leading to missed diagnosis or unnecessary invasive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 684pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">procedures. By contrast, CCTA imaging combined with our Heartflow Platform provides a more <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 696pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">accurate and actionable NIT for CAD, driving rapid adoption. We believe this approach will ultimately <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 708pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">become the standard of care. Accordingly, we believe our market opportunity represents the 8.6 <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.44pt; position: absolute; text-decoration: none; white-space: pre;">99<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">million patients non-invasively tested for CAD in 2023 that are indicated for our Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 504.32pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Analysis and Heartflow Plaque Analysis products based on their stenosis and plaque levels, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">respectively, representing a market value of approximately $5&#160;billion in the United States alone. While <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">we have rapidly scaled the adoption of our Heartflow Platform to achieve $&#160;&#160;&#160;&#160;&#160;&#160;&#160;million of revenue in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">2024, we believe the Heartflow Platform analyzed only approximately 10% of U.S. CCTA volumes and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">represented less than 1% of all NITs in 2023, highlighting a substantial runway for growth. Looking <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">ahead, we see the potential to expand both our geographic footprint and clinical applications. Beyond <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 156pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">symptomatic CAD, we believe our technology can play a pivotal role in risk stratification and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 168pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">preventive therapy optimization for the approximately 200 million asymptomatic individuals globally <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 180pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">considered high risk for a cardiac event. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Robust and compelling portfolio of clinical evidence&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 341.39pt; position: absolute; text-decoration: none; white-space: pre;"> We believe the Heartflow Platform is the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">most extensively studied AI-enabled test for CAD. The accuracy, clinical utility and economic benefits <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">of our Heartflow Platform have been evaluated in over 100 clinical studies, encompassing more than <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">130,000 patients, including two large randomized controlled trials. These findings have been <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">published in over 600 peer-reviewed clinical publications. These studies have consistently <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">demonstrated that the Heartflow Platform is more accurate than traditional non-invasive tests and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 272pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">highly concordant to invasive testing. As a result, the clinical evidence demonstrates that the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 284pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow Platform reduces unnecessary invasive testing, and enables physicians to make more <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 296pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">informed revascularization decisions, delivering more efficient, cost-effective care. For example, our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">PRECISE randomized controlled trial showed that our Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 394.89pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 405.24pt; position: absolute; text-decoration: none; white-space: pre;">Analysis was 78% more likely <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 320pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">than traditional testing to identify patients in need of intervention and 69% less likely to progress <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 332pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">patients to unnecessary invasive testing, leading to 2x the yield of ICA leading to revascularization <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 344pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">such as percutaneous coronary intervention (&#8220;PCI&#8221;) or coronary artery bypass grafting (&#8220;CABG&#8221;), <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 356pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">compared to standard care. This reduction in unnecessary diagnostic procedures and higher rate of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 368pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">revascularization procedures represents a clinical benefit for patients and significant economic benefit <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 380pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">for providers. We believe that our extensive body of clinical evidence will drive continued adoption, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 392pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">and we expect to continue to invest in evidence generation that will expand the applicability of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 404pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow Platform into new indications. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 424pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Established reimbursement coverage and favorable society support&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 415.92pt; position: absolute; text-decoration: none; white-space: pre;"> Our rapid growth is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 436pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">underpinned by a favorable reimbursement landscape and strong clinical guidelines that drive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 448pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">adoption of the Heartflow Platform. Our Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 330.43pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 340.78pt; position: absolute; text-decoration: none; white-space: pre;">Analysis is reimbursed under a dedicated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 460pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Category 1 CPT code, effective as of January 1, 2024, and has established coverage policies <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 472pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">encompassing approximately 99% of covered lives in the United States. In addition, a Category 1 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 484pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">CPT code was also recently established for our Heartflow Plaque Analysis, set to take effect in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 496pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">January 2026. Heartflow Plaque Analysis is already covered by all seven local MAC regions, with five <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 508pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">of the seven MACs issuing final local coverage determinations (&#8220;LCD&#8221;). We expect to leverage our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 520pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">experience in establishing commercial policies for Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 376.61pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 386.96pt; position: absolute; text-decoration: none; white-space: pre;">Analysis to efficiently establish <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 532pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">commercial coverage for our Heartflow Plaque Analysis. In addition, CCTA combined with our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 544pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 154.4pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 164.75pt; position: absolute; text-decoration: none; white-space: pre;">Analysis is supported by the AHA and ACC guidelines, with CCTA a Class 1, Level A <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 556pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">test and FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 147.74pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 158.09pt; position: absolute; text-decoration: none; white-space: pre;">a Class 2a, Level B test for the diagnosis of CAD in <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 387.44pt; position: absolute; white-space: pre;">certain patients with stable or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 568pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; white-space: pre;">acute chest pain and no known CAD<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 251.66pt; position: absolute; text-decoration: none; white-space: pre;">. We believe our favorable reimbursement and society support <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 580pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">provides a strong foundation and tailwind for our continued growth. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 600pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Unique and scalable AI, data and R&#38;D capabilities&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 330.90999999999997pt; position: absolute; text-decoration: none; white-space: pre;"> We designed our AI-powered software <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">platform to be high quality, highly scalable, integrate seamlessly with physician workflows and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">improve as we ingest more data, and leverage that data to improve our algorithms&#8217; performance and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 636pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our business efficiency. Our proprietary technology stack includes secure data transfer software, a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 648pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">scalable cloud database, a web and mobile interface, quality review tools and an AI algorithm pipeline <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">that delivers diagnostic accuracy, utility, workflow efficiency, and operational scalability. By harnessing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">AI to process massive volumes of cases while maintaining a &#8220;human-in-the loop&#8221; quality control <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 684pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">process, where learnings are fed back into our algorithms to improve their performance and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 696pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">efficiency, we have been able to rapidly grow our platform while delivering accurate, timely results for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 708pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">physicians and patients. We have also built a substantial and growing data asset that has driven <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">100<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">ongoing refinement of our algorithms for more than 10 years with over 100 million annotated CCTA <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">images. Additionally, our bi-directional data sharing relationship with our customers enables us to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">deliver even greater value by ensuring they benefit from ongoing feature additions, workflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">enhancements and performance improvements. Unlike traditional CAD diagnostic tools, our AI <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">platform can be updated with improved features, better performance and can improve from one of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">largest CCTA datasets globally, creating a competitive advantage that continues to grow over time. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">We believe our differentiated AI, data and R&#38;D capabilities and proven dedication to continuous <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 156pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">improvement ensures that Heartflow remains at the forefront of precision coronary care. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Experienced leadership team&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 231.6pt; position: absolute; text-decoration: none; white-space: pre;"> Our senior management team consists of seasoned executives with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">deep industry expertise across various disciplines, including biomedical and software engineering, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">clinical evidence, medical technology and medical imaging, AI, data science and sales and marketing. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">With backgrounds at leading medical technology companies, our leadership has a proven track <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">record of scaling businesses, securing market adoption and driving innovation.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The convergence of AI advancements, cutting-edge imaging technologies, and broad-based guideline <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">adoption is accelerating a shift toward more precise, personalized approaches to cardiovascular care. By <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">integrating anatomical and physiological insights, our technology enables physicians to tailor therapies <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">more effectively, optimizing treatment decisions and improving patient outcomes. With Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 518.1600000000001pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 526.8199999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Analysis reimbursement firmly established, growing physician acceptance, and a proven track record of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">real-world impact, Heartflow is well-positioned to lead the transformation of coronary care on a global <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">scale.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 336pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Our growth strategies<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 358.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We believe the following strategies will play a critical role in our continued growth&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 378.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Expand adoption of our Heartflow Platform by new accounts&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 380.27pt; position: absolute; text-decoration: none; white-space: pre;"> We believe that all accounts with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 390.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">an active CCTA program would benefit from adopting the Heartflow Platform into their workflow in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 402.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">order to improve efficiency and patient care. We estimate that as of December 31, 2023, there were <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 414.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">approximately 2,700 hospitals and outpatient facilities in the United States that perform CCTA, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 426.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">this target account base has grown at a 10% CAGR from 2018 to 2023. As of December 31, 2024, we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 438.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">have successfully deployed our Heartflow Platform in 1,100 accounts in the United States. Our TSMs <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 450.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">are responsible for acquiring new accounts. Our TSMs engage with physicians to communicate the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 462.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">value proposition of the Heartflow Platform, leveraging our large base of clinical evidence to extoll its <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 474.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">clinical and economic benefits. Once onboarded, providers typically reach utilization rates <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 486.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">approaching 33% of CCTAs eligible for Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 328.63pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 338.98pt; position: absolute; text-decoration: none; white-space: pre;">Analysis<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 376.2pt; position: absolute; text-decoration: none; white-space: pre;">. Unlike traditional sales models, our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 498.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">TSMs are not required to support case coverage or ongoing account maintenance, allowing them to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 510.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">focus on new account acquisition efficiently. We intend to drive further adoption by leveraging our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 522.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">existing&#160; 40 TSMs, as of December 31, 2024, while selectively expanding our team to capture <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 534.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">additional geographic opportunities. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 554.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Broaden awareness of the CCTA + Heartflow pathway to drive volume at existing accounts&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 523.31pt; position: absolute; text-decoration: none; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 566.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">While we have achieved significant commercial adoption to date, including 132<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 437.76pt; position: absolute; text-decoration: none; white-space: pre;">,000 patients <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 497.75pt; position: absolute; text-decoration: none; white-space: pre;">on our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 578.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow Platform in 2024 alone, we believe this represented less than 1% of our overall market <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 590.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">opportunity of 9.5 million total NITs, and approximately 10%, of current U.S. CCTA volumes. To <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 602.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">expand adoption, we are actively educating physicians on the AHA and ACC chest pain guidelines <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 614.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">that support CCTA plus Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 259.73pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 268.39pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis as the preferred pathway for diagnosis and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 626.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">management of CAD. Our commercial team includes TAMs who are responsible for educating the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 638.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">cardiologists who refer patients to our active accounts and driving increasing Heartflow Platform <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 650.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">volumes. These TAMs utilize our extensive clinical compendium to educate and train physicians on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 662.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the benefits of our platform. Similar to our TSMs, our TAM model is highly efficient and scalable. We <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 674.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">also invest in robust medical education, including peer-to-peer discussions, symposiums, podium <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 686.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">presentations, and other educational events. These initiatives, combined with strong society support, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 698.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our leading field presence, and continued technology investment, contribute to the expansion of both <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 710.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the CCTA market and the CCTA + Heartflow pathway.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">101<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Launch and drive adoption of our Heartflow Plaque Analysis product&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 419.66pt; position: absolute; text-decoration: none; white-space: pre;"> We initiated l<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 479.44pt; position: absolute; text-decoration: none; white-space: pre;">imited<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 506.1pt; position: absolute; text-decoration: none; white-space: pre;"> market <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">education efforts for our second product, Heartflow Plaque Analysis, in the second half of 2023. We <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">believe there is broad recognition among the cardiology physician community of the importance of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">quantifying and characterizing plaque composition as a key indicator of cardiovascular risk. Existing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">clinical trials have demonstrated plaque volume and plaque composition correlate with heart attack <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">risk. There are also multiple pharmaceutical therapies that have proven to slow or halt plaque <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">progression and reduce the risk of cardiovascular events. However, current non-invasive risk <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 156pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">assessment methods are often inadequate due to their reliance on manual, time-consuming, or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 168pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">largely visual assessments, leaving physicians with limited actionable data for prescribing optimal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 180pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">therapies. Our Heartflow Plaque Analysis fills this critical gap in care by enabling rapid and precise <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 192pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">quantification of plaque volume and composition at the vessel and patient level, down to the cubic <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 204pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">millimeter. We believe that broad commercial reimbursement coverage will be important for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 216pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">widespread adoption of Heartflow Plaque Analysis and are working to secure coverage. In 2024, CMS <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 228pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">assigned Heartflow Plaque Analysis a Category 1 CPT Code, which will be effective as of January <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 240pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">2026, and as of December 2024, Heartflow Plaque Analysis is covered by all MACs. We intend to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 252pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">leverage our learnings from the successful reimbursement coverage expansion and commercial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 264pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">launch of Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 197.73000000000002pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 208.07999999999998pt; position: absolute; text-decoration: none; white-space: pre;">Analysis to drive commercial coverage and adoption of Heartflow Plaque <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 276pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Analysis. Since Heartflow Plaque Analysis runs on the same CCTA scan as Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 489.13pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 497.79pt; position: absolute; text-decoration: none; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 288pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Analysis, we expect favorable operating and gross margin leverage as its adoption increases.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Invest in additional clinical evidence to support adoption and expand our indications&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 495.66pt; position: absolute; text-decoration: none; white-space: pre;"> We <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 320pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">believe we have developed the largest clinical evidence base supporting a non-invasive AI-powered <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 332pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">diagnostic for CAD and that our extensive evidence demonstrates the superior accuracy, clinical utility <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 344pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">and economic benefits of our Heartflow Platform relative to other non-invasive methods. We expect to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 356pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">continue to invest in clinical evidence to extend our leadership position. For example, we are currently <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 368pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">conducting the DECIDE registry, a 20,000-patient study which aims to demonstrate how Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 380pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Plaque Analysis impacts physician decision-making. <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 322.77pt; position: absolute; text-decoration: none; white-space: pre;">Beyond the commercialization of Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 392pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 109.42pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 118.08pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis and Heartflow Plaque Analysis in symptomatic CAD, we see a significant market <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 404pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">opportunity for our technologies in at-risk individuals who show no symptoms, a segment comprised <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 416pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">of approximately 200 million people globally. To unlock this potential, we are continuing to evaluate <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 428pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">new product opportunities and appropriate clinical evidence supporting eventual regulatory approval, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 440pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">payor coverage and commercialization. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 460pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Extend our technology leadership through continued investment in our platform<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 470.71pt; position: absolute; text-decoration: none; white-space: pre;">&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 474.04pt; position: absolute; text-decoration: none; white-space: pre;"> Our ongoing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 472pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">research and development initiatives are focused on introducing products, features and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 484pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">improvements to maximize customer value. We prioritize advancements in four key areas including&#58; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 496pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">improving our algorithms by leveraging extensive clinical data to improve accuracy and efficiency&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 508pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">optimizing clinical utility to better support physicians in diagnosis, patient management, and treatment <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 520pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">planning&#59; enhancing ease of use through seamless workflow integration to improve operational <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 532pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">efficiency&#59; and expanding our platform&#8217;s applications to serve a broader patient population. By <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 544pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">executing on these priorities, we aim to deepen engagement with existing customers, attract new <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 556pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">ones, and further solidify our leadership in AI-driven cardiovascular diagnostics.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Leverage our platform to pursue adjacent and international markets&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 414.77pt; position: absolute; text-decoration: none; white-space: pre;"> We believe our installed <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">base and deeply integrated <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 213.35pt; position: absolute; white-space: pre;">platform technology approach allows us to add on new analysis and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 600pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; white-space: pre;">insights within the same product experience<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 283.88pt; position: absolute; text-decoration: none; white-space: pre;">. Our relationships with referring and imaging physicians <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">provide us with insights into unmet clinical and workflow needs, while our extensive database of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">CCTA images and AI capabilities enable us to develop and integrate new algorithm-based solutions. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 636pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Additionally, while our current commercial focus is on the U.S. market, we have an existing presence <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 648pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">in the United Kingdom, European Union and Japan which we believe collectively represents a market <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">opportunity of approximately 4.2 million NITs annually or approximately half that of the United States. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">In the future we may choose to selectively expand our geographic footprint by strengthening our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 684pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">presence in existing international markets, entering new international markets, or exploring adjacent <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 696pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">market opportunities in the U.S. and abroad.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">102<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 8.73pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Market overview and opportunity<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 94.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Overview of CAD <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 114.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Cardiovascular disease is the leading cause of death worldwide, with CAD being the most lethal form. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 126.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">CAD occurs when plaque&#8212;a buildup of cholesterol, fat, calcium and other substances&#8212;accumulates on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 138.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the walls of the coronary arteries, restricting blood flow and increasing the risk of heart attack or stroke. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 150.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">This condition is responsible for half of all cardiovascular-related deaths globally. Key risk factors, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 162.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">including high cholesterol, hypertension, smoking, diabetes, obesity, physical inactivity, and genetic <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 174.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">predisposition, accelerate plaque formation and destabilization. In the United States alone, the CDC <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 186.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">estimates that approximately 805,000 people suffer a heart attack each year<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 407.9pt; position: absolute; text-decoration: none; white-space: pre;">. <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 413.26pt; position: absolute; white-space: pre;">T<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 419.36pt; position: absolute; text-decoration: none; white-space: pre;">he CDC estimates that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 198.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">approximately 1 in 20 adults over the age of 20 have CAD, which is approximately 12.5 million individuals <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 210.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">with CAD in the United States. The CDC also estimates that CAD killed 371,506 people in 2022. Given its <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 222.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">morbidity and mortality, CAD places a significant cost burden on the healthcare system and is projected to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 234.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">reach $215 billion by 2035.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 254.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">CAD is caused by the build-up of calcified and non-calcified plaque in the coronary arteries.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 475.29pt; position: absolute; text-decoration: none; white-space: pre;"> This plaque <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 266.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">build-up results in a narrowing of the arteries, or stenosis, which may require an intervention<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 478.04pt; position: absolute; white-space: pre;"> if the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 278.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reduction in blood flow caused by the stenosis is determined to be clinically significant. Effectively <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 290.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">diagnosing CAD in order to inform the optimal treatment pathway requires a measurement of the blood <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 302.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">flow through the stenosis as well as quantifying the amount and type of plaque causing the stenosis. For <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 314.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">example, the foundational FAME 1 and FAME 2 randomized controlled trials showed that deferring <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 326.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">intervention is superior when blood flow, as measured by fractional flow reserve (&#8220;FFR&#8221;), was greater than <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 338.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">0.80 but that when FFR was below this same level, intervention was superior to optimal medical therapy. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 350.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Similarly, a follow-up analysis to the foundational SCOT-HEART trial showed that plaque volumes greater <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 362.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">than 238 mm<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 130.32999999999998pt; position: absolute; top: -2.548pt; vertical-align: super; white-space: pre;">3<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 133.94pt; position: absolute; white-space: pre;"> resulted in a 7x greater risk of heart attack than lower plaque volumes and higher <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 374.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">concentrations of low-attenuation plaque burden were associated with a nearly 5x greater risk of heart <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 386.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">attack. This is due to the unstable nature of low-attenuation plaque, which can result in a higher risk of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 398.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">rupture leading to occlusion of coronary blood flow. Based on these trials, the cardiology community has <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 410.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">recognized the importance of accurately measuring FFR values and characterizing plaque, and has <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 422.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">supported this perspective with clinical guidelines that stratify treatment recommendations based on FFR <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 434.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">values and plaque metrics.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 454.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Traditional methods for the non-invasive diagnosis of CAD and their limitations<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 474.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">When patients present with symptoms of CAD, such as chest pain, they are typically referred for a NIT. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 486.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">There are two primary types of NITs&#58; stress-based tests, which measure surrogate markers for CAD to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 498.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">infer the presence of heart disease based on blood perfusion, or CCTA which directly images the patient&#8217;s <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 510.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">coronary arteries. Based on the output of a patient&#8217;s NIT, the imaging physician and managing physician <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 522.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">determine the appropriate next step which can include sending the patient home with only lifestyle <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 534.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">modifications if the disease is not determined to be significant, initiating pharmaceutical therapy if there is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 546.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">assumed plaque burden without significant stenosis, or sending the patient to catheterization lab for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 558.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">intervention if there is significant stenosis.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 578.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">When appropriately diagnosed and managed, CAD can be effectively treated with well-established <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 590.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">therapeutics and devices. These therapeutics, which include statins, PCSK-9s and GLP-1s, among <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 602.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">others, have been proven to effectively manage CAD by reducing plaque progression, changing plaque <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 614.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">composition, and reducing the risks of a major adverse cardiovascular event. Similarly, when indicated, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 626.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">procedures to open the arteries, including percutaneous coronary intervention with intravascular <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 638.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">lithotripsy, atherectomy and&#47;or stenting, and coronary artery bypass grafting, have been shown over <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 650.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">decades to be highly efficacious in reducing mortality risk and relieving the symptoms of CAD. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 670.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Stress tests<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 690.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Stress-based NITs include SPECT, PET and stress echocardiography. These tests use imaging to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 702.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">evaluate heart function under exercise or pharmacologically-induced stress. The tests image the heart <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">103<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">muscles and identify the differences in blood perfusion to the myocardium between the rest and stress <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">state images to infer the presence of CAD. Stress-based NITs rely on surrogate markers of CAD to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">deduce the disease in the coronary artery without actually assessing the coronary arteries or the disease <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">itself. Therefore, these NITs are inaccurate, a majority of the time, and often result in either missed CAD <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">diagnoses or unnecessary invasive procedures. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">As a result, approximately 20&#8211;50% of patients who undergo stress-based NITs go home with false <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">negatives, or undetected CAD that should have required an intervention. In addition, up to 55% of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">patients receive false positives and are sent to the cardiac catheterization lab for an invasive diagnostic <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">angiography when an intervention was never needed exposing patients to unnecessary risks including <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">vascular injury and bleeding complications. This results in significant additional costs to the healthcare <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">system and poor patient experience.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 220pt; width: 612pt;"><div style="left: 144pt; position: absolute; top: 0pt;"><div style="position: absolute;"><img style="height: 146.06pt; width: 324pt;" src="business1a.jpg" alt="business1a.jpg"></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 379.06pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Figure 3&#58; Traditional non-invasive tests. Left&#58; Stress echocardiogram. Right&#58; SPECT and PET<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 399.06pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">CCTA<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 419.06pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">CCTA is a high-resolution 3D imaging method that uses X-rays to produce detailed pictures of the heart&#8217;s <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 431.06pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">arteries and other structures. CT imaging itself has been widely available and its use in cardiology is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 443.06pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">growing rapidly. In October 2021, the AHA and ACC elevated CCTA to a first line Class 1, Level A test in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 455.06pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the guidelines for certain patients with stable or acute chest pain and no known CAD, above stress testing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 467.06pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">which is Class 1, Level B. This made CCTA a first line test for CAD owing to the strong evidence <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 479.06pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">supporting its differentiated clinical utility. As of December 31, 2023, we estimate there were <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 491.06pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">approximately 2,700 sites with an active CCTA program in the United States. Similarly, CCTA now has <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 503.06pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">guideline support from the European Society of Cardiology Clinical Practice guidelines on Chronic <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 515.06pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Coronary Syndromes (1B), is included in the National Institute for Health and Care Excellence (&#8220;NICE&#8221;) <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 527.06pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">guidelines in the United Kingdom, and in the Japanese Circulation Society (&#8220;JCS&#8221;) 2022 Guidelines in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 539.06pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Japan. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 559.06pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Unlike stress-based NITs that rely on indirect functional assessments of heart muscle activity to infer <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 571.06pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">CAD, CCTA enables direct visualization of the patient&#8217;s coronary anatomy and can allow for a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 583.06pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">comprehensive assessment of coronary stenosis and plaque burden. CCTA has been clinically <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 595.06pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">demonstrated to have the highest diagnostic performance of all traditional non-invasive imaging tests for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 607.06pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">CAD. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 627.06pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The foundational SCOT-HEART randomized controlled trial, highlighted the clinical superiority of CCTA <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 639.06pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">over traditional stress-based NITs. The study found a significant 41% reduction in the rate of death or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 651.06pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">non-fatal heart attacks after five years in patients who underwent CCTA evaluations. The study also <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 663.06pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">demonstrated that patients in the CCTA group were more likely to be started on lipid lowering, anti-<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">104<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">hypertensive, anti-platelet, and anti-anginal medication, which improved outcomes in patients with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">disease that may not have been detected with stress-based testing alone. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 104pt; width: 612pt;"><div style="left: 193.51pt; position: absolute; top: 0pt;"><div style="position: absolute;"><img style="height: 144pt; width: 224.98pt;" src="business2ba.jpg" alt="business2ba.jpg"></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 261pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Figure 4&#58; CCTA image<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 281pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">With the elevation of CCTA to a Class 1, Level A guideline recommendation by the AHA and ACC <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 293pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">guidelines in 2021, CCTA test volumes have grown at a 22% CAGR from 2018 to 2023 while SPECT <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 305pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">volumes have grown at a 2% CAGR over the same time period<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 350.28pt; position: absolute; text-decoration: none; white-space: pre;">.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 353.05pt; position: absolute; white-space: pre;"> We believe CCTA test volumes will <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 317pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">continue to grow rapidly, ultimately replacing other NIT methods based on increasing awareness of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 329pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">superior diagnostic accuracy, workflow efficiencies and clinical guideline recommendations. Furthermore, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 341pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">favorable reimbursement trends are expected to accelerate adoption. In 2025, CMS reimbursement levels <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 353pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for hospital outpatient CCTA are set to increase by 104% based on the OPPS final rule, published in the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 365pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Federal Register on November 27, 2024.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 385pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Catheterization lab-based invasive diagnostics for CAD<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 405pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Invasive methods of diagnosing CAD are typically performed in the catheterization lab and provide highly <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 417pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">accurate assessments of blood-flow and plaque. However, they are not practical or cost-effective as a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 429pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">first-line diagnostic due to procedural risks, patient discomfort, as well as cost and availability of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 441pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">catheterization lab time. As a result, these technologies are utilized downstream in the catheterization lab <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 453pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">after a patient has been identified as having suspected CAD based on an NIT and referred for an <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 465pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">interventional procedure. Because of the invasive nature of these tests, they serve as valuable reference <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 477pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">points for validating the accuracy of our technology, however, we do not directly compete with them.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 497pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">These invasive catheter-based procedures, which include FFR and <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 370.87pt; position: absolute; text-decoration: none; white-space: pre;">Intravascular ultrasound (&#8220;IVUS&#8221;),<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 519.71pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 509pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">have been the reference standard for obtaining FFR values and assessing plaque burden for decades. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 521pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">FFR requires inserting a pressure wire into the coronary arteries under stress conditions to assess the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 533pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">severity of blood flow restriction and IVUS uses a catheter-based ultrasound probe to directly image <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 545pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">plaque within the arteries.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 565pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Our symptomatic CAD market opportunity<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 587.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We estimate our current market opportunity in the United States is approximately $5 billion. We estimate <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 599.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">that there were approximately 9.5 million NITs performed for the diagnosis of CAD in the United States in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 611.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2023. This includes an estimated 6.8 million SPECTs, 0.8 million PETs, 1.2 million stress <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 623.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">echocardiograms, and 0.7 million CCTAs.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">105<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="position: absolute; top: 72pt; width: 612pt;"><div style="left: 201.6pt; position: absolute; top: 0pt;"><div style="position: absolute;"><img style="height: 224.1pt; width: 208.8pt;" src="business3ba.jpg" alt="business3ba.jpg"></div></div></div><div style="line-height: 5.46pt; position: absolute; top: 309.1pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(1)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Definitive Heath, CMS claims data, CAGR 2018 - 2023<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 326.1pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(2)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">&#126;73,000 Heartflow tests billed in FY23<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 343.1pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Figure 5&#58; Pie chart of U.S. non-invasive test market<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 363.1pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">CCTA testing volumes have grown 22% between 2018 and 2023, and we believe they will continue to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 375.1pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">outpace the broader NIT market growth driven by the recently established Class 1, Level A guidelines, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 387.1pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">due to superior clinical utility compared to stress-based tests, and improved reimbursement. Of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 399.1pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">approximately 9.5 million NITs performed for the diagnosis of CAD in the United States in 2023, we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 411.1pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">believe there were approximately 8.6 million patients that were addressable for CCTA after accounting for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 423.1pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">layered testing due to the inconclusive nature of traditional tests and the need for multiple re-tests and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 435.1pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">contraindications to CCTA.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 455.1pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our Heartflow Platform significantly improves the clinical utility of CCTA and addresses the limitations of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 467.1pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">traditional non-invasive CAD testing by combining existing CCTA images with our AI algorithms to provide <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 479.1pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">actionable data on blood flow, stenosis, plaque volume and plaque composition. This delivers superior <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 491.1pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">clinical utility relative to other NITs and compelling economic benefits, which are supported by extensive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 503.1pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">clinical evidence. As a result, we believe the CCTA + Heartflow pathway will become the standard of care <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 515.1pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for the non-invasive diagnosis of CAD over time.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 535.1pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Addressing the limitations of traditional CAD testing<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 555.1pt; width: 612pt;"><div style="left: 144.42pt; position: absolute; top: 0pt;"><div style="position: absolute;"><img style="height: 144pt; width: 323.15pt;" src="business4ba.jpg" alt="business4ba.jpg"></div></div></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">106<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Figure 6&#58; Image of SPECT test result on left&#59; image of Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: italic; font-weight: normal; left: 376.25pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 384.91pt; position: absolute; white-space: pre;"> Analysis result on right<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 92pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 91.43pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 136.41pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 155.82999999999998pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 164.49pt; position: absolute; white-space: pre;"> Analysis is reimbursed for use on any CCTA showing 40% to 90% stenosis, which <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">we estimate to be approximately 33% of all CCTAs annually. We believe the CCTA + Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 511.37pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 520.03pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Analysis therefore is applicable to 33% of the NIT market and the majority of patients experiencing acute <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">chest pain, which represents 3.1 million patients and an estimated market opportunity of approximately <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">$3.3 billion in the United States. Our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 234.71pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 279.69pt; position: absolute; white-space: pre;">Plaque Analysis is reimbursed for plaque identified on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">CCTA with 1% to 69% stenosis, which we estimate to cover approximately 60% of all CCTAs annually and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the majority of patients experiencing acute chest pain. We believe the CCTA + Heartflow Plaque Analysis <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">is therefore applicable to 60% of the NIT market, which represents 5.5 million patients and an estimated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">market opportunity of an incremental approximately $1.7 billion in the United States. While our current <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">focus is on the United States, we also have a commercial presence and regulatory approval in certain <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">international markets, including the United Kingdom, European Union and Japan, which we estimate <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">represents an additional 4.2 million potential CCTA patients. In the future we may expand our international <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">presence beyond these markets and extend our platform to additional indications.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Asymptomatic CAD market opportunity<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 276pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">For asymptomatic patients, current clinical practice guidelines (Class 1, Level B) recommend using risk <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 288pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">factors such as age, sex, smoking status, hyperlipidemia, hypertension, and diabetes, among others, to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 300pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">calculate a risk score, called an ASCVD score, for assessing overall cardiovascular event risk and guiding <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 312pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">preventive therapy. However, this approach does not account for the actual disease state of an <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 324pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">individual&#8217;s arteries leading to imprecise risk assessment and suboptimal management. As a result, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 336pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">despite the widespread availability of proven, preventative pharmaceutical treatments, up to 25% of heart <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 348pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">attacks occur in those with no symptoms and approximately 50% of heart deaths occur without any prior <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">diagnosis or testing. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 380pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We believe there is a significant opportunity for our Heartflow Platform to materially improve risk <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 392pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stratification and patient management. Clinical data supports our belief that AI-based risk calculation <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 404pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">predicated on the combination of individual-specific CAD measures enables more accurate and effective <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 416pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">management and preventative measures as compared to those based on an ASCVD score alone. For <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 428pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">example, our EMERALD 2 study showed that combining certain CCTA-derived quantitative features from <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 440pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">coronary physiology via <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 179.23000000000002pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 224.21pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 243.63pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 252.29pt; position: absolute; white-space: pre;"> Analysis and from plaque metrics via <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 420.03pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 465.01pt; position: absolute; white-space: pre;">Plaque Analysis <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 452pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">predicted future plaque rupture more accurately than CCTA alone. Serial AI-based risk assessment of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 464pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">asymptomatic patients can also capture temporal changes in disease state and cardiovascular risk, which <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 476pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">can be used to personalize preventative medical therapy over time. We estimate that there are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 488pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">approximately 200 million patients globally with a high risk of cardiovascular events, of which 71 million <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 500pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">live in the United States. In the future, we believe certain sub-segments of this population may be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 512pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">appropriate candidates for our platform. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 532pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Beyond the commercialization of Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 283.6pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 293.95pt; position: absolute; white-space: pre;">Analysis and Heartflow Plaque Analysis in symptomatic <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 544pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">CAD, we see a significant market opportunity for our technologies in at-risk individuals who show no <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 556pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">symptoms, a segment comprised of approximately 200 million people globally. To unlock this potential, we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 568pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">are continuing to evaluate new product opportunities and appropriate clinical evidence supporting <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 580pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">eventual regulatory approval, payor coverage and commercialization.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 600pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Our technology<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 620pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Heartflow enhances CCTA, the most advanced non-invasive imaging modality for assessing CAD, with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 632pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">AI-powered analysis to deliver more accurate and clinically actionable insights for diagnosing and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">managing CAD. The Heartflow Platform applies deep learning, an advanced form of AI, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">computational fluid dynamics to CCTA images to create a personalized 3D model of a patient&#8217;s heart <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 668pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">based on a single CCTA image. This model provides actionable insights into blood flow, stenosis, plaque <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 680pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">volume and plaque composition allowing precise diagnosis, risk stratification, and treatment planning &#8211; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 692pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">without the need for an invasive procedure. <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">107<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The CCTA + Heartflow pathway addresses the limitations of traditional non-invasive tests that only assess <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">indirect measures for coronary disease and therefore result in high rates of false negative and false <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">positive CAD diagnoses. We believe the differentiated accuracy and clinical utility of the CCTA + <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Heartflow pathway will continue to support our growth and advance the standard for the non-invasive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">diagnosis and management of CAD.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We designed our AI-powered software platform to be highly scalable, seamlessly integrate into existing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">physician workflows for diagnosing CAD, and improve as we ingest more data over time. By leveraging AI <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to process massive volumes of cases and a &#8220;human-in-the loop&#8221; quality control process, where learnings <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">are fed back into our algorithms to improve their performance and efficiency, we have rapidly scaled our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">platform to deliver accurate, timely results to benefit physicians and patients alike. Our cloud-based <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">technology has enabled us to rapidly scale to an installed base of over 1,100 accounts in the United <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">States as of December 31, 2024. We have also built a substantial and growing data asset that has driven <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">continuous refinement of our algorithms for over 10 years and as of December 31, 2024, we have <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">analyzed and annotated over 100 million annotated CCTA images. Additionally, through our bi-directional <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">data sharing relationship with our customers we ensure continuous platform enhancements, delivering <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">immediate and tangible benefits through new features, workflow efficiencies, and improved performance.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">The CCTA + Heartflow pathway<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 300pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">When a patient presents with symptoms of CAD and their physician follows the AHA and ACC Class 1, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 312pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Level A chest pain guidelines by referring the patient for a CCTA, the patient will undergo standard CCTA <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 324pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">imaging at the relevant hospital or outpatient facility. At Heartflow-enabled accounts, CCTA images are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 336pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">securely transmitted directly to our cloud-based platform through our embedded software in the hospital <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 348pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or outpatient imaging center. Leveraging proprietary AI and advanced computational fluid dynamics, we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">create a personalized, 3D digital model of the patient&#8217;s coronary arteries, unlocking critical insights <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">beyond what is visible on standard imaging.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 392pt; width: 612pt;"><div style="left: 79.48pt; position: absolute; top: 0pt;"><div style="position: absolute;"><img style="height: 144pt; width: 453.03pt;" src="business6ba.jpg" alt="business6ba.jpg"></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 549pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Figure 7&#58; The CCTA + Heartflow pathway<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 569pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our Heartflow Platform includes a suite of innovative, AI-powered products designed to deliver <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 581pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">comprehensive coronary artery assessment&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 601pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">1)<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow RoadMap Analysis&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 230.47pt; position: absolute; text-decoration: none; white-space: pre;"> Coronary anatomy modeling that enables clinicians to interpret CCTA <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 613pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">accurately, efficiently and consistently while identifying whether the patient requires further evaluation <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 625pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">with our other products. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 645pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">2)<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: bold; left: 157.72pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 168.18pt; position: absolute; text-decoration: none; white-space: pre;">Analysis&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 212.61pt; position: absolute; text-decoration: none; white-space: pre;"> Accurate 3D model of blood flow that identifies clinically-significant CAD <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 657pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">at the lesion level to inform whether the patient requires revascularization and identifies which lesions <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 669pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">should be addressed. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 689pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">3)<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow Plaque Analysis&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 218.25pt; position: absolute; text-decoration: none; white-space: pre;"> Precise quantification of plaque volume and plaque composition down <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 701pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">to the cubic millimeter to help assess risk and determine optimal medical treatment.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">108<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">These analyses provide the critical complementary data that are lacking from other non-invasive tests but <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">that we believe physicians need to diagnose, assess risk and make optimal, patient-specific decisions <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">about medical and interventional therapies. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 116pt; width: 612pt;"><div style="left: 98.5pt; position: absolute; top: 0pt;"><div style="position: absolute;"><img style="height: 194.4pt; width: 414.99pt;" src="business7ba.jpg" alt="business7ba.jpg"></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 315.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Figure 8&#58; The Heartflow Portfolio<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 335.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our Heartflow Platform seamlessly integrates into our customer workflows, providing clinically actionable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 347.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">insights directly to the account in a median turnaround time of 1.6 hours, which we believe is sufficient for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 359.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the workflows of our customers. We deliver the Heartflow RoadMap Analysis automatically to the imaging <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 371.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">cardiologist or radiologist for every acceptable CCTA patient at our accounts to help drive more efficient <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 383.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">CCTA interpretation and workflows. In conjunction with the Heartflow RoadMap Analysis, we also provide <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 395.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">physicians with a case list that catalogs all their CCTAs and identifies the cases where our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 472.26pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 407.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 91.42pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 101.77pt; position: absolute; white-space: pre;">Analysis, <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 144.53pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 189.51pt; position: absolute; white-space: pre;">Plaque Analysis or both would enable them to accurately diagnose clinically <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 419.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">significant CAD and plan treatment. With a single click, Physicians can access these analyses on-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 431.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">demand, and we bill the account directly for each product selected. Because <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 411.96pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 456.94pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 476.36pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 485.02pt; position: absolute; white-space: pre;"> Analysis <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 443.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 91.45pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 136.43pt; position: absolute; white-space: pre;">Plaque Analysis have distinct clinical indications and dedicated billing codes, our workflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 455.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">helps ensure physicians can order the most appropriate analyses for each patient, supporting both high-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 467.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">quality care and efficient reimbursement processes.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 487.4pt; width: 612pt;"><div style="left: 72pt; position: absolute; top: 0pt;"><div style="position: absolute;"><img style="height: 197.95pt; width: 468pt;" src="business8ba.jpg" alt="business8ba.jpg"></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 698.35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Figure 9&#58; The Heartflow Platform and workflow<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">109<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">The Heartflow Platform portfolio<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 92pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; white-space: pre;">Heartflow RoadMap Analysis<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 209.14pt; position: absolute; white-space: pre;">&#58; <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 214.5pt; position: absolute; text-decoration: none; white-space: pre;">The<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 231.72pt; position: absolute; white-space: pre;"> Heartflow RoadMap Analysis <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="height: 176.94pt; left: 397.65pt; position: absolute; top: 90.38pt; width: 144pt; z-index: 1;"><div><div><div style="position: absolute;"><img style="height: 176.94pt; width: 144pt;" src="prospectussummary3ba.jpg" alt="prospectussummary3ba.jpg"></div></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">provides a highly intuitive anatomic visualization of the patient&#8217;s <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">coronary anatomy based on CCTA images. It rapidly orients the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">imaging physician to clinically relevant areas of the patient anatomy <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and provides a preview of what they will review in the native CCTA <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">images to aid the physician in accurately, efficiently and consistently <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">identifying stenosis in the coronary arteries. <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 266.96000000000004pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 311.94pt; position: absolute; white-space: pre;">RoadMap <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Analysis supports more efficient radiology workflow, improving CCTA <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">read times by 25% and increasing consistency between reviewing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">physicians by approximately 50%. Physicians use <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 294.77pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 339.75pt; position: absolute; white-space: pre;">Roadmap <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Analysis as a first-line assessment tool along with CCTA interpretation <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to determine whether to order our more detailed <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 286.40999999999997pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 331.39pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 350.81pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Analysis or <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 123.65pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 168.63pt; position: absolute; white-space: pre;">Plaque Analysis reports. <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 278.43pt; position: absolute; text-decoration: none; white-space: pre;">The <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 298.41999999999996pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 343.4pt; position: absolute; text-decoration: none; white-space: pre;">RoadMap <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Analysis was cleared by the FDA in October 2022, and we began <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">providing it to our customers in the second quarter of 2023. <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 335.84pt; position: absolute; white-space: pre;">We <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 272pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">generally provide <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 150.9pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 195.88pt; position: absolute; white-space: pre;">RoadMap Analysis to accounts as an <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 284pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">integrated feature to enhance the efficiency and consistency of their CCTA programs and it is not a stand-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 296pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">alone product. We believe the efficiency that <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 270.48pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 315.46000000000004pt; position: absolute; white-space: pre;">RoadMap Analysis provides our customers has <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">resulted in enhanced customer loyalty and retention.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; white-space: pre;">Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: bold; left: 139.72pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 150.18pt; position: absolute; white-space: pre;">Analysis&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 194.61pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 197.38pt; position: absolute; text-decoration: none; white-space: pre;">Our<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 214.04pt; position: absolute; white-space: pre;"> flagship product, <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 292.90999999999997pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 337.89pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 357.31pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font></div><div style="height: 176.94pt; left: 397.65pt; position: absolute; top: 329.5pt; width: 144pt; z-index: 2;"><div><div><div style="position: absolute;"><img style="height: 176.94pt; width: 144pt;" src="prospectussummary4b.jpg" alt="prospectussummary4b.jpg"></div></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Analysis, consists of a patient-specific, interactive, 3D anatomical <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reconstruction of the coronary anatomy that identifies functionally <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 364pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">significant CAD at every point in the major coronary arteries to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">determine the need for intervention. The model is color-coded along <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 388pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">vessel length, indicating Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 245.28pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 255.63pt; position: absolute; white-space: pre;">Analysis values which assist <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 400pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the physician in rapidly and precisely assessing blood flow through the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 412pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">coronary arteries. Our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 171.97pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 216.95pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 236.37pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 246.72pt; position: absolute; white-space: pre;">Analysis has the highest <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 424pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">diagnostic accuracy for a non-invasive CAD test and has demonstrated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 436pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">a high level of concordance to invasive FFR. Our product can measure <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 448pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the FFR value and determine whether a lesion is clinically significant &#8211; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 460pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">a &#8220;clinically significant lesion&#8221; means an FFR value of below 0.80. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 472pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Because FFR values <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 167.53pt; position: absolute; text-decoration: none; white-space: pre;">are the guideline directed measure to determine <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 484pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the need for invasive revascularization, this data offers a more clinically <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 496pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">accurate, non-invasive basis for determining the need for interventional <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 508pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">treatment. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 528pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Current AHA and ACC guidelines support CCTA + <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 294.26pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 339.24pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 358.66pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 369.01pt; position: absolute; white-space: pre;">Analysis as a more efficient care <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">pathway. The guidelines designate CCTA as a Class 1, Level A recommendation as the first-line test for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">CAD in intermediate-high risk patients with stable chest pain and no known CAD, with our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 470.23pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 91.42pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 101.77pt; position: absolute; white-space: pre;">Analysis given a Class 2a, Level B recognition to help physicians guide patient treatment <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">decisions. This CCTA + <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 177.97pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 222.95pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 242.37pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 252.72pt; position: absolute; white-space: pre;">Analysis pathway enables physicians to identify lesions that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">require revascularization&#160;in less than two hours, and guidelines recommend patients with positive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 600pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 116.97999999999999pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 136.4pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 146.75pt; position: absolute; white-space: pre;">Analysis<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 183.97pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;"> <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 185.76999999999998pt; position: absolute; white-space: pre;">findings be sent directly to the cardiac catheterization lab for possible treatment. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Comparatively, AHA and ACC guidelines provide stress-based testing a Class 1, Level B <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">recommendation, suggesting patients with suspected CAD and positive stress-based test findings first <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 298.03pt; position: absolute; text-decoration: none; white-space: pre;">110<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">initiate guideline directed medical therapy. Only if symptoms are not resolved by medical therapy, which <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">can last weeks or months, are patients then sent to the cardiac catheterization lab.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 104pt; width: 612pt;"><div style="left: 72pt; position: absolute; top: 0pt;"><div style="position: absolute;"><img style="height: 159.46pt; width: 468pt;" src="business11ba.jpg" alt="business11ba.jpg"></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 276.46pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Figure 10&#58; AHA and ACC chest pain guidelines<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 296.46pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 91.43pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 136.41pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 155.82999999999998pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 166.18pt; position: absolute; white-space: pre;">Analysis is indicated for patients with stenosis levels between 40% and 90% in any <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308.46pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">vessel because a physician&#8217;s review of a CCTA alone may not appropriately identify the need for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 320.46pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">treatment in these cases. For example, in the figure below, two patients with &#62;70% stenosis based on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 332.46pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">CCTA alone would likely be referred for invasive coronary angiography. However, <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 432.71pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 477.69pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 497.11pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 505.77pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 344.46pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Analysis reveals that while Patient A has an FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 286.37pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 295.03pt; position: absolute; white-space: pre;"> value &#62;0.80&#8212;indicating no need for intervention&#8212;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 356.46pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Patient B has an FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 167.5pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 176.16pt; position: absolute; white-space: pre;"> value &#60;0.80 and should be referred for revascularization. As of December 31, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 368.46pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2024, our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 117pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 161.98000000000002pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 181.4pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 191.75pt; position: absolute; white-space: pre;">Analysis<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 228.97pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;"> <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 230.77pt; position: absolute; white-space: pre;">represented over&#160;&#160;&#160;&#160;&#160;&#160;% of our total revenues.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 388.46pt; width: 612pt;"><div style="left: 99.37pt; position: absolute; top: 0pt;"><div style="position: absolute;"><img style="height: 172.8pt; width: 413.25pt;" src="business12ba.jpg" alt="business12ba.jpg"></div></div></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 574.26pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Figure 11<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 114.22pt; position: absolute; white-space: pre;">&#58; <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 119.75999999999999pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 164.74pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: italic; font-weight: normal; left: 184.16pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT&#160; <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 196.42000000000002pt; position: absolute; white-space: pre;">Analysis<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: italic; font-weight: normal; left: 233.64pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;"> <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 235.44pt; position: absolute; white-space: pre;">Significantly Improves CCTA &#8211; anatomy from CCTA + Physiology <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 586.26pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">from <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 94.76pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 139.74pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: italic; font-weight: normal; left: 159.16pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 169.62pt; position: absolute; white-space: pre;">Analysis<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: italic; font-weight: normal; left: 206.84pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;"> <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 208.64pt; position: absolute; white-space: pre;">better informs clinical decisions<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 298.4pt; position: absolute; text-decoration: none; white-space: pre;">111<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 92pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; white-space: pre;">Heartflow Plaque Analysis<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 196.92000000000002pt; position: absolute; white-space: pre;">&#58; <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 202.46pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 244.67pt; position: absolute; white-space: pre;"> Plaque Analysis transforms <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="height: 186.69pt; left: 381.45pt; position: absolute; top: 95.65pt; width: 151.92pt; z-index: 3;"><div><div><div style="position: absolute;"><img style="height: 186.69pt; width: 151.92pt;" src="prospectussummary5b.jpg" alt="prospectussummary5b.jpg"></div></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">coronary plaque assessment from a time-consuming and variable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">manual process, which is seldom clinically used, into a rapid, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">automated, and highly precise AI-driven solution. The Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Plaque Analysis automatically provides a comprehensive 3D <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">assessment of a patient&#8217;s coronary plaque, including a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">characterization of plaque types and quantification of plaque <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">volumes at every point in the major coronary arteries. The <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Heartflow Plaque Analysis has been validated against the reference <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">standard of invasive IVUS and shown to have a 95% agreement <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">with IVUS in quantifying total coronary plaque volume. Because <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">coronary plaque volume is a strong predictor of a patient&#8217;s risk of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">having a heart attack regardless of ASCVD risk score, calcium <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">score, or stenosis, this data offers incremental predictive power <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">over risk factors and stenosis alone and can aid the physician in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 272pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">optimizing medical management. Furthermore, only quantified <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 284pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">plaque analysis based on CCTA can assess non-calcified plaque, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 296pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">which has a higher risk for causing a heart attack as compared to calcified plaque. We believe that our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 116.97999999999999pt; position: absolute; white-space: pre;">Plaque Analysis is applicable to the approximately 60% of CCTA patients identified as having <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 320pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">1% to 69% stenosis and adds significant value over review of CCTA alone, which is unable to precisely <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 332pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">quantify or characterize the type or volume of plaque that would impact a physician&#8217;s treatment plan. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow Plaque Analysis guides medical man<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 295.18pt; position: absolute; text-decoration: none; white-space: pre;">agement <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 372pt; width: 612pt;"><div style="left: 72pt; position: absolute; top: 0pt;"><div style="position: absolute;"><img style="height: 196.02pt; width: 468pt;" src="business14ba.jpg" alt="business14ba.jpg"></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 581.02pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Figure 12&#58; Plaque is critical to guide medical management, regardless of FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: italic; font-weight: normal; left: 414.14pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 422.8pt; position: absolute; white-space: pre;"> results<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 601.02pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition to its comprehensive plaque assessment capabilities, Heartflow Plaque Analysis incorporates <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 613.02pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">a nomogram derived from an extensive international cohort of over 11,000 patients. This nomogram <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 625.02pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stratifies coronary atherosclerotic plaque volumes by age and sex, providing physicians with a valuable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 637.02pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reference to contextualize individual patient data against population-based benchmarks. By leveraging <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 649.02pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">this tool, clinicians can more precisely assess a patient's CAD risk, facilitating personalized treatment <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 661.02pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">strategies. This integration of large-scale data enhances the actionable insights delivered by Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 673.02pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Plaque Analysis, supporting more informed clinical decision-making.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 298.03pt; position: absolute; text-decoration: none; white-space: pre;">112<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 91.43pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 136.41pt; position: absolute; white-space: pre;">Plaque Analysis was cleared by the FDA in October 2022. We began our limited market <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">education efforts in the second half of 2023, and we expect to broaden our market education efforts as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">payor<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 97.01pt; position: absolute; white-space: pre;"> coverage for <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 158.11pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 203.09pt; position: absolute; white-space: pre;">Plaque Analysis increases. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Key benefits of our Heartflow Platform<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 136pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We believe the unique features of our technology allow us to offer superior clinical utility and economic <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 148pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">value to our customers and the broader healthcare system. The key benefits offered by our Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 160pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Platform include&#58; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 180pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">More accurate non-invasive test for CAD&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 286.01pt; position: absolute; text-decoration: none; white-space: pre;"> Our Heartflow products have been clinically validated to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 192pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">provide a more accurate non-invasive assessment of blood flow, plaque characterization and plaque <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 204pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">volume compared to traditional non-invasive tests, parameters that have been established to be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 216pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">highly clinically relevant. Our prospective, core-lab adjudicated NXT trial demonstrated that Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 228pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 109.42pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 119.77pt; position: absolute; text-decoration: none; white-space: pre;">Analysis is able to accurately calculate lesion-specific FFR values with a high level of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 240pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">concordance to the invasive reference standard of FFR. In addition, our retrospective, core-lab <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 252pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">adjudicated PACIFIC trial demonstrated that our Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 369.14pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 379.49pt; position: absolute; text-decoration: none; white-space: pre;">Analysis offered superior diagnostic <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 264pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">accuracy relative to CCTA alone as well as SPECT and PET. Individually and collectively, these <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 276pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">studies support the differentiated level of precision that Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 398.61pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 408.96pt; position: absolute; text-decoration: none; white-space: pre;">Analysis offers relative to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 288pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">other non-invasive tests as well as its clinical reliability. Similarly, our prospective REVEALPLAQUE <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 300pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">study validated our Heartflow Plaque Analysis relative to the invasive reference standard of IVUS, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 312pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">demonstrating 95% agreement for overall plaque volume and excellent agreement in identifying <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 324pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">plaque volume and sub-types at the lesion level. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 344pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">More informed assessments and personalized care&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 336pt; position: absolute; text-decoration: none; white-space: pre;"> Our Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 422.6pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 432.95pt; position: absolute; text-decoration: none; white-space: pre;">Analysis has been <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 356pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">clinically demonstrated in multiple studies to positively impact physician decisions on intervention and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 368pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">patient management. The ADVANCE prospective registry which included over 5,000 patients globally <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 380pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">showed that in 67% of cases physicians changed their patient management plans, predominantly with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 392pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">respect to revascularization, based on review of Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 368.26pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 378.61pt; position: absolute; text-decoration: none; white-space: pre;">Analysis relative to CCTA alone. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 404pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Similarly, our DECODE study, which included 100 patients, demonstrated that in 66% of cases <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 416pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">physicians changed preventative medical therapy plans based on a review of Heartflow Plaque <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 428pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Analysis relative to CCTA alone. Further supporting the value of our Heartflow Plaque Analysis <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 440pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">product, among patients with a calcium score of 0, physicians revised their management plan in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 452pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">nearly 50% of cases after reviewing our Heartflow Plaque Analysis report. In 63% of cases in the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 464pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">DECODE study, physicians increased the dosage of the patient&#8217;s medication, indicating that patients <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 476pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">were being under-treated based on conventional non-invasive testing methods that fail to both <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 488pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">quantify and characterize plaque volumes. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 508pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Superior economic efficiency&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 232.68pt; position: absolute; text-decoration: none; white-space: pre;"> Our Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 319.28pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 329.63pt; position: absolute; text-decoration: none; white-space: pre;">Analysis has been clinically demonstrated to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 520pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">reduce rates of false positive CAD diagnoses relative to other non-invasive tests and more accurately <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 532pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">identify the patients that actually need an invasive procedure. Our PRECISE prospective randomized <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 544pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">controlled trial which enrolled over 2,100 patients and compared Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 440.5pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 450.85pt; position: absolute; text-decoration: none; white-space: pre;">Analysis with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 556pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">standard of care, demonstrated that our Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 332.7pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 343.05pt; position: absolute; text-decoration: none; white-space: pre;">Analysis was 78% more likely to identify <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 568pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">patients in need of revascularization and showed a 69% reduction in false positives, or unnecessary <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 580pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">invasive coronary angiography tests. It also showed 2x the yield of invasive coronary angiography <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 592pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">leading to a revascularization procedure such as a<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 312.78999999999996pt; position: absolute; text-decoration: none; white-space: pre;"> PCI or CABG.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 377.72pt; position: absolute; text-decoration: none; white-space: pre;"> These are economically important <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 604pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">procedures for our customers which, when done in place of a diagnostic only catheterization, result in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 616pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">more efficient use of valuable cardiac catheterization lab facilities and staff time. As a result, our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 628pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">calculations based on the PRECISE trial indicate that net average cardiac catheterization lab revenue <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 640pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">increase<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 127.78999999999999pt; position: absolute; text-decoration: none; white-space: pre;">d 20%. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Improved workflow&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 184.36pt; position: absolute; text-decoration: none; white-space: pre;"> Our Heartflow Platform offers significant workflow benefits, including improving <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">workflow efficiency and reducing CCTA interpretation times. Our SmartCT study demonstrated that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 684pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the use of our Heartflow RoadMap Analysis reduced read time by approximately 25%. In addition to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 696pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">reducing read times, our Heartflow RoadMap Analysis enhances consistency across a radiology <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 708pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">program resulting in a more than 50% increase in inter-reader agreement. Given the intense <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 298.03pt; position: absolute; text-decoration: none; white-space: pre;">113<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">demands on radiologist time resulting from an increasing number of images to review on a daily <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">basis, we believe this added efficiency and consistency strengthens the competitive differentiation of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our platform.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Enhanced interventional treatment planning<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 298.7pt; position: absolute; text-decoration: none; white-space: pre;">&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 302.03pt; position: absolute; text-decoration: none; white-space: pre;"> Once the patient is diagnosed with clinically <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">significant CAD and referred to the catheterization lab for an intervention, our Heartflow Platform <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">provides information that is useful to interventional cardiologists in planning for the most efficient <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">treatment based on individual anatomy and disease s<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 326.12pt; position: absolute; text-decoration: none; white-space: pre;">tate.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 345.55pt; position: absolute; text-decoration: none; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 348.14pt; position: absolute; text-decoration: none; white-space: pre;">The Heartflow Platform enables early, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">detailed pre-operative planning, allowing physicians to triage patients to the most appropriate site of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">service&#8212;whether a hospital-based catheterization lab or an outpatient interventional center. By <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">identifying the complexity and severity of disease in advance, our technology ensures that high-risk <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">patients receive care in fully equipped facilities, while lower-risk cases can be efficiently managed in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">outpatient settings, reducing strain on hospital resources. <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 345.52pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow&#8217;s 3D model provides a precise <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">preview of the anatomy corresponding to specific views used in invasive catheterizations. <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 486.62pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 109.42pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 118.08pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis and <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 179.74pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 224.72pt; position: absolute; text-decoration: none; white-space: pre;">Plaque Analysis provide quantitative and visual insights on lesion <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">severity, plaque burden and type, and hemodynamic significance, which enable more precise pre-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">selection of interventional tools. This allows catheterization labs to be better prepared with the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 272pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">necessary guidewires, catheters, and adjunctive devices before the procedure, thereby reducing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 284pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">inefficiencies. With growing demand for complex structural heart procedures&#8212;such as transcatheter <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 296pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">aortic valve replacemen<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 195.56pt; position: absolute; text-decoration: none; white-space: pre;">t, left atrial appendage c<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 302.2pt; position: absolute; text-decoration: none; white-space: pre;">losure, and transcatheter mitral interventions&#8212;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">catheterization lab capacity is increasingly a constraint for hospitals. By reducing unnecessary <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 320pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">diagnostic angiograms and increasing the efficiency of PCI planning, we believe the Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 332pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Platform frees up catheterization lab time for these higher-acuity, resource-intensive procedures.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Better patient and provider experience&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 276pt; position: absolute; text-decoration: none; white-space: pre;"> By leveraging a single CCTA for all of our products, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 364pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">patients complete their test in approximately 20 minutes with significantly lower radiation exposure <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">compared to nuclear imaging tests such as SPECT and PET that take multiple hours and require <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 388pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">radioactive tracers to be injected into the bloodstream. A fundamental challenge with traditional <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 400pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">stress-based testing is the lack of a definitive diagnosis, which often results in a cascade of follow-up <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 412pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">tests. Stress tests frequently produce inconclusive or false-positive results, requiring additional <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 424pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">imaging studies such as cardiac catheterization to confirm or rule out disease. This layered testing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 436pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">approach prolongs the diagnostic journey, delays appropriate treatment, and adds unnecessary costs <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 448pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">and inconvenience for patients. The Heartflow Platform offers an entirely digital and non-invasive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 460pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">experience that better serves both patients and providers. The CCTA + Heartflow Pathway provides a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 472pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">fulsome array of insights with only a single patient exam. All results can then be viewed and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 484pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">distributed digitally to all of the patient&#8217;s care providers. In addition, our platform offers the flexibility to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 496pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">add new visualizations, insights and updates as the technology evolves, and physicians can receive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 508pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the benefits of these updates conveniently through the same software platform. For example, when <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 520pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow RoadMap Analysis and Heartflow Plaque Analysis were introduced, our accounts were able <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 532pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">to access these technologies through the same connection infrastructure and platform that they <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 544pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">utilized for Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 202.70999999999998pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 213.06pt; position: absolute; text-decoration: none; white-space: pre;">Analysis without the need to buy new equipment or establish new <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 556pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">connections. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Our production process<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 596pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our production process involves a sophisticated and highly refined system that combines advanced <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 608pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">machine learning algorithms with &#8220;human-in-the loop&#8221; quality control process, where learnings are fed <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 620pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">back into our algorithms to improve their performance and efficiency. After the CCTA test is complete, the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 632pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">patient&#8217;s images are securely transferred to our cloud-based system through our established software that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">integrates directly into the account&#8217;s infrastructure. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 664pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">When the images arrive, we leverage multiple machine learning algorithms which have been trained from <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 676pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">a database of millions of annotated CCTA images to precisely segment CCTA data and extract patient-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 688pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">specific 3D anatomy, which includes the coronary tree, myocardium and other anatomic features. The <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 700pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">quality of CT images and the anatomy extracted by our algorithms is inspected through propriety software <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 298.03pt; position: absolute; text-decoration: none; white-space: pre;">114<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">that guides quality-oriented production analysts through each step to review and potentially correct the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">segmentation, as needed. Our machine learning algorithms then utilize any analyst inputs to generate a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">final 3D model of the coronary vessels. Our algorithms then compute stenosis, plaque volumes and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">plaque characteristics as well as blood flow simulation with computational fluid dynamics over the entire <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">coronary tree. The simulated blood flow and pressures allow calculation of quantitative <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 456.21pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 501.19pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 520.61pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Analysis values at every point on the coronary tree. Once complete, our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 391.38pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 436.36pt; position: absolute; white-space: pre;">RoadMap Analysis, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 116.97999999999999pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 136.4pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 146.75pt; position: absolute; white-space: pre;">Analysis and <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 206.19pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 251.17pt; position: absolute; white-space: pre;">Plaque Analysis are securely delivered directly to the physician in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 156pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">multiple formats&#58; an interactive web experience where they can explore the data in detail, PDF <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 168pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">summaries, and direct delivery into the electronic medical record. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The corrections and changes from the analyst quality inspection step are stored in a database as labels <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for training our algorithms. New and improved versions of our algorithms using the latest machine <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">learning methodologies are trained with incrementally more labels and released over time and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">incorporated into our platform. The core algorithms for the 3D coronary anatomic model and <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 480.08pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 91.42pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 101.77pt; position: absolute; white-space: pre;">Analysis are now on their 3<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 221.75pt; position: absolute; top: -2.548pt; vertical-align: super; white-space: pre;">rd<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 227.52pt; position: absolute; white-space: pre;"> generation with improvements over time. This iterative approach of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">combining improved algorithms with human quality control processes continues to enhance the accuracy <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and efficiency of our technology. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We have also invested significantly in automating our production process through improved algorithm <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">performance, visualization, and internal workflow enhancements, which have materially reduced our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">analyst processing times from 69 minutes in 2021 to 26 minutes in the fourth quarter of 2024, significantly <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">enhancing our margin profile.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 336pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; white-space: pre;">Our data security<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 356pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our Heartflow Platform relies on industry-leading security controls, including encryption at rest and in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 368pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">transit, multi-factor and single-sign on authentication, granular authorization and a secure development <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 380pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">lifecycle. We have designed the Heartflow Platform to de-identify data for processing, ensuring the most <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 392pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">identifiable sensitive data (including PHI) remains segregated, encrypted, and within source regions, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 404pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">limiting privacy and security risk. Our commitment to information security is demonstrated by our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 416pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">HITRUST, ISO 27001, and SOC 2 Type II certifications.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 436pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Our clinical results and economic evidence<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 456pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We believe the Heartflow Platform is the most studied AI-enabled test for CAD. The accuracy, clinical <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 468pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">utility and economic benefits of our Heartflow Platform have been evaluated in over 100 clinical studies <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and more than 130,000 patients, including two large randomized controlled trials, with results published in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 492pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">over 600 peer-reviewed clinical publications. Collectively, this extensive body of clinical evidence has <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 504pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">supported regulatory approvals for our products, established broad payor coverage and society guideline <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 516pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">inclusion for our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 145.32pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 190.3pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 209.72pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 218.38pt; position: absolute; white-space: pre;"> Analysis, and is driving rapid commercial adoption of our portfolio of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 528pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">products. We have sponsored 50 of the 100 clinical studies and are continuing to invest in evidence that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">highlights the clinical utility and economic benefits of our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 323.06pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 368.04pt; position: absolute; white-space: pre;">Plaque Analysis to support expansion <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of payor coverage and commercial adoption. In the future we may also invest in clinical studies of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Heartflow Platform to expand indications to broader populations.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 584pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our clinical programs have been focused on (i) validating the accuracy and reproducibility of our product <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 596pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">offerings relative to invasive reference standards and non-invasive alternatives, (ii) establishing the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 608pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">differentiated clinical utility of our products relative to non-invasive alternatives, and (iii) demonstrating the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 620pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">economic benefits associated with our products including reduced costs for payors and improved <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 632pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">efficiency for providers. Our studies have consistently demonstrated that the Heartflow Platform is more <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">accurate than traditional non-invasive tests and highly concordant to invasive testing, reduces <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">unnecessary invasive testing, and enables physicians to optimize treatment and ultimately provide more <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 668pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">efficient care.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 298.03pt; position: absolute; text-decoration: none; white-space: pre;">115<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Our Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: italic; font-weight: bold; left: 160.25pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 168.91pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 92pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: underline; white-space: pre;">Accuracy and reproducibility<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 197pt; position: absolute; white-space: pre;">&#58; Numerous foundational clinical trials in cardiology, including the FAME 1 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and FAME 2 RCTs have demonstrated that FFR values are the most accurate predictors of the need for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">intervention in patients with CAD. Key clinical studies that have supported the accuracy and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reproducibility of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 147.54000000000002pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 192.51999999999998pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 211.94pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 220.6pt; position: absolute; white-space: pre;"> Analysis relative to invasive FFR testing and non-invasive alternatives <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">include&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 160pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">NXT&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 113.31pt; position: absolute; text-decoration: none; white-space: pre;"> Our NXT trial was the was the basis for de novo 510(k) FDA clearance of Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 505.18pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 513.8399999999999pt; position: absolute; text-decoration: none; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 172pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Analysis. It was a prospective, blinded, core-lab adjudicated trial in which CCTA was performed prior <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 184pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">to non-emergent invasive coronary angiography in stable patients with suspected CAD. Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 196pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 109.42pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 119.77pt; position: absolute; text-decoration: none; white-space: pre;">Analysis values based on the CCTA were compared to invasive FFR values. The trial also <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 208pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">compared the efficacy of Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 265.86pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 274.52pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis relative to CCTA alone for predicting FFR values. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">NXT enrolled 254 patients and studied 484 vessels at 10 centers in Europe, the United Kingdom, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Japan, Korea, and Australia. The results showed that Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 391.39pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 400.05pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis is highly accurate <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">compared to the reference standard of invasive FFR, with a per vessel accuracy of 86% compared <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">with 65% for CCTA alone. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 276pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">PACIFIC&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 133.29pt; position: absolute; text-decoration: none; white-space: pre;"> The PACIFIC trial was an investigator-initiated, prospective study to evaluate in a head-to-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 288pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">head manner the diagnostic performance of several non-invasive tests commonly used to identify <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 300pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">functionally significant CAD. A total of 208 patients with suspected stable CAD underwent CCTA, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 312pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">SPECT and PET, and then used ICA with invasive FFR as the reference standard. The Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 324pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 109.42pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 118.08pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis was not initially included in the PACIFIC study, but the investigators subsequently <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 336pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">undertook a retrospective PACIFIC FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 266.4pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 275.06pt; position: absolute; text-decoration: none; white-space: pre;"> sub-study to evaluate the diagnostic performances of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 348pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 154.4pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 163.06pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis compared to CCTA, SPECT, and PET. Using invasive FFR as the reference <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">standard, the Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 215.5pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 224.16pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis demonstrated the highest diagnostic performance for vessel-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">specific ischemia of all tested noninvasive tests, with an AUC (Area Under the Curve) of 0.94 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 384pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">compared with PET (0.87), CTA (0.83), and SPECT (0.70).<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 404pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: underline; white-space: pre;">Differentiated utility, improved clinical and economic outcomes<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 346.59pt; position: absolute; white-space: pre;">&#58; Numerous studies have demonstrated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 416pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">that use of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 121.42pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 166.4pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 185.82pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 194.48000000000002pt; position: absolute; white-space: pre;"> Analysis favorably impacts clinical management, supporting physicians in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 428pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">making more informed and better patient-specific decisions about intervention which drives more efficient <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 440pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">use of resources. Key company-sponsored clinical studies that demonstrated the impact of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 475.28pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 452pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 91.42pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 100.08pt; position: absolute; white-space: pre;"> Analysis on clinical decision-making, outcomes and provider and payor economics include&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 472pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">ADVANCE&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 142.75pt; position: absolute; text-decoration: none; white-space: pre;"> Our ADVANCE prospective registry studied approximately 5,000 patients in the United <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 484pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">States, United Kingdom, Europe, and Japan whose CCTA showed CAD, in order to determine <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 496pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">whether the incremental addition of Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 312.71000000000004pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 321.37pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis resulted in a change in patient <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 508pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">management. Results at 90 days showed that Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 359.93pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 368.59pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis findings drove a change in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 520pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">management plan for 67% of patients and that Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 362.15pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 370.81pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis values &#62;0.80 were <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 532pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">correlated with good outcomes, despite overwhelmingly non-invasive patient management. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 544pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Additionally, CCTA-based stenosis severity was determined to be a poor predictor of Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 528.95pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 537.61pt; position: absolute; text-decoration: none; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 556pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Analysis values, demonstrating that CCTA alone was not as effective for clinical decision-making. A <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 568pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">review of outcomes at one year showed that physician management decisions were safe and durable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 580pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">and that deferral of an invasive procedure based on Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 385.51pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 394.17pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis was safe and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 592pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">appropriate, as it was highly unlikely to result in a later revascularization or adverse clinical event. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">PRECISE&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 137.18pt; position: absolute; text-decoration: none; white-space: pre;"> Our PRECISE trial was a prospective randomized controlled study conducted in the US, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Canada, the United Kingdom, and Europe which compared decision-making and outcomes based on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 636pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">a CCTA + Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 200.01pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 208.67000000000002pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis pathway with the &#8220;usual care&#8221; pathway which involved alternative <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 648pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">non-invasive or invasive testing methods. The study included 2,103 participants and had a median <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">follow up of 11.8 months found that, compared with the &#8220;usual care&#8221; pathways, CCTA + Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 109.42pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 118.08pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis was 78% more likely to identify patients in need of revascularization, and resulted in a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 684pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">69% reduction in diagnostic-only invasive coronary angiography. The net effect of this pathway was <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 696pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">2x the yield of invasive coronary angiography leading to a revascularization procedure, from 30.5% of <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 298.03pt; position: absolute; text-decoration: none; white-space: pre;">116<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">cases to 71.9% of cases. As a result, our internal analysis based on the PRECISE data demonstrated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">a 20% increase in net revenue for the cardiac catheterization lab, on average. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">PLATFORM&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 148.82999999999998pt; position: absolute; text-decoration: none; white-space: pre;"> Our PLATFORM trial was a prospective controlled study of sequential cohorts that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">enrolled 584 patients in the United Kingdom and Europe and assessed the clinical and economic <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">impacts of using a CCTA + Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 274.99pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 285.34000000000003pt; position: absolute; text-decoration: none; white-space: pre;">Analysis pathway to select patients for invasive coronary <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">angiography. The study compared outcomes between cohorts with a &#8220;usual care&#8221; invasive pathway to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">a CCTA + Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 200.01pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 208.67000000000002pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis pathway. The study found that the CCTA + Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 504.93pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 513.5899999999999pt; position: absolute; text-decoration: none; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Analysis pathway reduced the rate of unnecessary invasive coronary angiography by 83% from 73% <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">to 12% and showed a 23% reduction in costs at 90 days and a 26% reduction in costs at one year <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">based primarily on the avoidance of unnecessary invasive procedures.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 208pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Our Heartflow Plaque Analysis<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 228pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our clinical portfolio includes 10 studies and over 25 peer-reviewed publications specific to <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 474.74pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 240pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Plaque Analysis. These studies and publications, which include large, multi-center, international trials, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 252pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">document the performance, accuracy and clinical utility of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 328.62pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 373.6pt; position: absolute; white-space: pre;">Plaque Analysis as well as its <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 264pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">positive impact on the physician&#8217;s ability to assess risk and manage outcomes. By providing more <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 276pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">accurate and detailed information on plaque types and volumes than can be achieved with traditional non-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 288pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">invasive tests or risk measures, <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 214.18pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 259.15999999999997pt; position: absolute; white-space: pre;">Plaque Analysis supports more appropriate, precise medical <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 300pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">management. Key company-sponsored studies that support the clinical benefits of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 437.52pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 482.5pt; position: absolute; white-space: pre;">Plaque <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 312pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Analysis include&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 332pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">REVEALPLAQUE&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 175.48000000000002pt; position: absolute; text-decoration: none; white-space: pre;"> Our REVEALPLAQUE study demonstrated the accuracy of Heartflow Plaque <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 344pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Analysis relative to IVUS, the accepted reference standard for coronary plaque measurement and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 356pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">characterization. REVEALPLAQUE was a prospective, blinded, core-lab adjudicated trial that enrolled <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 368pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">237 patients, with 432 lesions, in the US and Japan and compared coronary plaque quantification and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 380pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">characterization between Heartflow Plaque Analysis and IVUS. The study showed that Heartflow&#8217;s <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 392pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Plaque Analysis results for total plaque volume, calcified plaque, and non-calcified plaque were <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 404pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">strongly correlated with IVUS measurements, achieving 95% agreement with IVUS. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 424pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">DECODE&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 136.07999999999998pt; position: absolute; text-decoration: none; white-space: pre;"> Our DECODE study evaluated the impact of the Heartflow Plaque Analysis on clinical <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 436pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">decision-making using data from 100 patients who underwent CCTA. For each case, three <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 448pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">cardiologists with expertise in reading CCTA and preventive therapies aligned on a management plan <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 460pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">based on patient demographics, clinical history, and the CCTA alone. The cardiologists were then <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 472pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">provided with Heartflow Plaque Analysis for the same patients and asked to determine a management <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 484pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">plan. The results showed that the use of Heartflow Plaque Analysis led to changes in treatment plans <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 496pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">for 66% of patients, including 63% of patients who had medical management up-titrated. The <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 508pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">likelihood of changing the management plan increased with higher coronary artery calcium scores <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 520pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">and was more pronounced in patients with significant coronary stenosis, however even 50% of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 532pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">patients with a coronary artery calcium score of 0 had a revised management plan with Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 544pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Plaque Analysis.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">ADVANCEPLAQUE&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 184.38pt; position: absolute; text-decoration: none; white-space: pre;"> Our ADVANCEPLAQUE study is a retrospective analysis of our ADVANCE trial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">after 1-year follow up. In a multi-variate analysis of the data, high total plaque volume as identified by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow Plaque Analysis was shown to be an independent predictor for the risk of adverse clinical <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 600pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">cardiac events. In addition, the risk of an adverse cardiac event was shown to be 2x higher in patients <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">where Heartflow Plaque Analysis showed a higher total plaque burden compared to those with a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">lower plaque burden.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">EMERALD 2<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 147.74pt; position: absolute; text-decoration: none; white-space: pre;">&#58; The EMERALD 2 study enrolled 351 patients who presented with acute coronary <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">syndrome, including specifically-identified culprit plaque rupture, within 3 years following a CCTA. The <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 668pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">study sought to investigate the additive value of AI&#8211;enabled quantitative coronary plaque analysis <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 680pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">together with hemodynamic&#160;analysis as predictors of the subsequent plaque rupture. The study <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 692pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">showed that adding the CCTA-derived, AI-enabled measures derived from FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 439.2pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 447.86pt; position: absolute; text-decoration: none; white-space: pre;"> and Plaque <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 704pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Analyses predicted plaque rupture more accurately the reference model of CCTA alone.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 298.03pt; position: absolute; text-decoration: none; white-space: pre;">117<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">DECIDE<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 127.75pt; position: absolute; text-decoration: none; white-space: pre;">&#58; Based on the success of our DECODE study, which supported CMS coverage for Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Plaque Analysis, we have initiated the DECIDE registry, a prospective real world analysis measuring <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the impact of Heartflow Plaque Analysis on changes in treatment decisions compared to CCTA alone <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">or alternative non-invasive tests. In contrast with DECODE in which physicians retrospectively <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">identified revised patient management plans, physicians in our DECIDE registry will use Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Plaque Analysis information to implement real world patient management changes. The study&#8217;s <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">primary endpoint is change in medical management following Heartflow Plaque Analysis compared to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 156pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">CCTA alone, and the secondary endpoint will examine changes in key outcomes including death, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 168pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">heart attack, revascularization, cardiovascular medication changes and cardiovascular <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 180pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">hospitalizations at both 90-days and one-year follow-up. DECIDE was initiated in March 2024 and we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 192pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">expect to enroll approximately 20,000 patients across approximately 40 sites in the US. As of<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 499.92pt; position: absolute; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 530.39pt; position: absolute; text-decoration: none; white-space: pre;">, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 204pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">2025, we have enrolled over<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 215.57pt; position: absolute; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 246.04pt; position: absolute; text-decoration: none; white-space: pre;">patients. We believe that the outcomes of the DECIDE registry will <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 216pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">support expanded commercial payor coverage and continued adoption of Heartflow Plaque Analysis.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Other Company sponsored clinical studies<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The table below summarizes the results of additional clinical studies of the Heartflow Platform that we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">have sponsored to date.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 288pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468.75pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 85.5pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 76.5pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 306.75pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 12pt;"><td style="border-bottom: 1pt solid #000; border-left: 1pt solid #000; border-right: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 85.5pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3pt; width: 85.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Reference<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-left: 1pt solid #000; border-right: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 85.5pt; position: absolute; top: 0pt; width: 76.5pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3pt; width: 76.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Source<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-left: 1pt solid #000; border-right: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 162pt; position: absolute; top: 0pt; width: 306.75pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3pt; width: 306.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Study summary<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td></tr><tr style="height: 237.75pt;"><td style="border-bottom: 1pt solid #000; border-left: 1pt solid #000; border-right: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 12pt; width: 85.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.63pt; width: 85.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Koo et al. (2011)<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-left: 1pt solid #000; border-right: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 85.5pt; position: absolute; top: 12pt; width: 76.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.63pt; width: 76.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Journal of the <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 14.03pt; width: 76.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">American <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 25.43pt; width: 76.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">College of <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 36.83pt; width: 76.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Cardiology<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-left: 1pt solid #000; border-right: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 162pt; position: absolute; top: 12pt; width: 306.75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.63pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">DISCOVER-FLOW study<font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 22.03pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Authors&#58; Bon-Kwon Koo, James K. Min, Bjarne L. N&#248;rgaard, et al.<font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 41.43pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Institution&#58; Seoul National University Hospital<font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 60.83pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">N&#58; 103<font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 80.23pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Description&#58; Prospective, multicenter trial aimed at evaluating the <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 91.63pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">diagnostic performance of non-invasive fractional flow reserve derived <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 103.03pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">from CCTA in assessing the functional significance of coronary artery <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 114.43pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">disease. The study involved patients with suspected CAD who <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 125.83pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">underwent CCTA and <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 95.32pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 140.29999999999998pt; position: absolute; text-decoration: none; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 158.76pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 166.98pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis, with results compared <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 137.83pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">to invasive FFR as the reference standard.<font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 157.23pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Conclusions&#58; The study concluded that <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 168.13pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 213.10999999999999pt; position: absolute; text-decoration: none; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 231.57pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 239.79pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 169.23pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">demonstrated high diagnostic accuracy in identifying functionally <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 180.63pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">significant coronary stenosis, with improved sensitivity and specificity <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 192.03pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">compared to CCTA alone. These findings support the potential of <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 203.43pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 47.61pt; position: absolute; text-decoration: none; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 66.07pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 74.28999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis as a reliable non-invasive method for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 215.43pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">assessing coronary artery disease, offering a promising alternative to <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 226.83pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">invasive FFR for guiding clinical decision-making.<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr></table></div></div></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 298.03pt; position: absolute; text-decoration: none; white-space: pre;">118<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="position: absolute; top: 72pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468.75pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 85.5pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 76.5pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 306.75pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 12pt;"><td style="border-bottom: 1pt solid #000; border-left: 1pt solid #000; border-right: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 85.5pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3pt; width: 85.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Reference<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-left: 1pt solid #000; border-right: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 85.5pt; position: absolute; top: 0pt; width: 76.5pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3pt; width: 76.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Source<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-left: 1pt solid #000; border-right: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 162pt; position: absolute; top: 0pt; width: 306.75pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3pt; width: 306.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Study summary<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td></tr><tr style="height: 293.25pt;"><td style="border-bottom: 1pt solid #000; border-left: 1pt solid #000; border-right: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 12pt; width: 85.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.63pt; width: 85.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Morris et al. (2023)<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-left: 1pt solid #000; border-right: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 85.5pt; position: absolute; top: 12pt; width: 76.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.63pt; width: 76.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Journal of <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 14.03pt; width: 76.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Cardiovascular <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 25.43pt; width: 76.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Computed <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 36.83pt; width: 76.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Tomography<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-left: 1pt solid #000; border-right: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 162pt; position: absolute; top: 12pt; width: 306.75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.63pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">SMART-CT 2.0<font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 22.03pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Authors&#58; Michael F. Morris, Mahesh Chandrasekhar, Harish Gudi, et al.<font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 41.43pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Institution&#58; Banner University Medical Center, Phoenix<font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 60.83pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">N&#58; 120<font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 80.23pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Description&#58; The SMART-CT study was designed to evaluate the <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 91.63pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">effectiveness of an AI-informed coronary stenosis quantification tool, <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 103.03pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">known as AI-CSQ, in assisting the interpretation of CCTA. This tool, <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 114.43pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">aims to reduce the time required for CCTA interpretation, while <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 125.83pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">maintaining or enhancing the accuracy and confidence of the readers. <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 137.23pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">The study involved 120 CCTAs from patients with stable chest pain or <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 148.63pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">symptoms of CAD. These were analyzed by six readers of varying <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 160.03pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">experience levels, including cardiologists and radiologists, to determine <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 171.43pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">the impact of AI-CSQ on interpretation time, diagnostic accuracy, and <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 182.83pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">inter-reader variability.<font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 202.23pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Conclusions&#58; The study concluded that the use of AI-CSQ significantly <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 213.63pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">decreased the overall time required for CCTA interpretation by 25.8%, <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 225.03pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">regardless of the reader's experience level. It also improved inter-<font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 236.43pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">reader agreement and boosted reader confidence in diagnosing <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 247.83pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">coronary artery disease. These findings underscore the potential of <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 259.23pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">advanced AI tools like AI-CSQ to enhance the efficiency and reliability <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 270.63pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">of CCTA interpretation in clinical practice, addressing challenges such <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 282.03pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">as time-consuming post-processing and variability in reader accuracy.<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 318pt;"><td style="border-bottom: 1pt solid #000; border-left: 1pt solid #000; border-right: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 305.25pt; width: 85.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.63pt; width: 85.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Curzen et al. <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 14.03pt; width: 85.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">(2020)<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-left: 1pt solid #000; border-right: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 85.5pt; position: absolute; top: 305.25pt; width: 76.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.63pt; width: 76.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">The Lancet<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-left: 1pt solid #000; border-right: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 162pt; position: absolute; top: 305.25pt; width: 306.75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.63pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">FORECAST<font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 22.03pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Authors&#58; Nick Curzen, Juliet A. Usher-Smith, John R. Chambers, et al.<font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 41.43pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Institution&#58; Multiple centers across the United Kingdom<font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 60.83pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">N&#58; 1,400<font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 80.23pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Description&#58; The FORECAST (Fractional Flow Reserve Derived from <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 91.63pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Computed Tomography Coronary Angiography in the Assessment and <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 103.03pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Management of Stable Chest Pain) study was a prospective, <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 114.43pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">randomized controlled trial designed to assess the clinical and <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 125.83pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">economic impact of using CCTA combined with <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 202.93pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 247.91pt; position: absolute; text-decoration: none; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 266.37pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 274.59pt; position: absolute; text-decoration: none; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 137.83pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Analysis in the management of patients presenting with stable chest <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 149.23pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">pain. The study compared this approach to standard care pathways <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 160.63pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">that did not include <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 84.92pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 129.9pt; position: absolute; text-decoration: none; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 148.35999999999999pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 156.57999999999998pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis, aiming to determine its <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 172.63pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">effectiveness in reducing unnecessary invasive procedures and <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 184.03pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">improving patient outcomes.<font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 203.43pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Conclusions&#58; The study concluded that the integration of CCTA with <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 214.83pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 47.61pt; position: absolute; text-decoration: none; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 66.07pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 74.28999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis into the diagnostic pathway for stable chest <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 226.83pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">pain resulted in a significant reduction in the need for ICA and <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 238.23pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">unnecessary procedures, without an increase in adverse patient <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 249.63pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">outcomes. It found that random assignment to the study arm using <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 261.03pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">CCTA and our <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 64.71pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 109.69pt; position: absolute; text-decoration: none; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 128.15pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 136.37pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis was associated with a 22% <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 273.03pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">reduction in the need for ICA, a 52% reduction in the frequency of <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 284.43pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">unnecessary ICA, 40% fewer layered non-invasive tests, and no <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 295.83pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">increase in adverse patient outcomes or in costs (in the United <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 307.23pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Kingdom).<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr></table></div></div></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 298.03pt; position: absolute; text-decoration: none; white-space: pre;">119<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="position: absolute; top: 72pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468.75pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 85.5pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 76.5pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 306.75pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 12pt;"><td style="border-bottom: 1pt solid #000; border-left: 1pt solid #000; border-right: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 85.5pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3pt; width: 85.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Reference<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-left: 1pt solid #000; border-right: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 85.5pt; position: absolute; top: 0pt; width: 76.5pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3pt; width: 76.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Source<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-left: 1pt solid #000; border-right: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 162pt; position: absolute; top: 0pt; width: 306.75pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3pt; width: 306.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Study summary<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td></tr><tr style="height: 434.25pt;"><td style="border-bottom: 1pt solid #000; border-left: 1pt solid #000; border-right: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 12pt; width: 85.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.63pt; width: 85.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Min et al. (2012)<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-left: 1pt solid #000; border-right: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 85.5pt; position: absolute; top: 12pt; width: 76.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.63pt; width: 76.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Journal of the <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 14.03pt; width: 76.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">American <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 25.43pt; width: 76.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Medical <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 36.83pt; width: 76.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Association<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-left: 1pt solid #000; border-right: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 162pt; position: absolute; top: 12pt; width: 306.75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.63pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">DeFACTO study<font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 22.03pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Authors&#58; James K. Min, Jonathon Leipsic, Michael J. Pencina, et al<font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 41.43pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Institution&#58; Multiple international centers<font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 60.83pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">N&#58; 252<font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 80.23pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Description&#58; Multicenter diagnostic performance study involving 252 <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 91.63pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">stable patients with suspected or known CAD from 17 centers in 5 <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 103.03pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">countries who underwent CT, invasive coronary angiography (&#8220;ICA&#8221;), <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 114.43pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">FFR, and <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 44.82pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 89.8pt; position: absolute; text-decoration: none; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 108.25999999999999pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 116.47999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis between October 2010 and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 126.43pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">October 2011. Computed tomography, ICA, FFR, and <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 229.09pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 274.07pt; position: absolute; text-decoration: none; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 292.53pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 300.75pt; position: absolute; text-decoration: none; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 138.43pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Analysis were interpreted in blinded fashion by independent core <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 149.83pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">laboratories. Accuracy of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 109.19pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 154.17pt; position: absolute; text-decoration: none; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 172.63pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 180.85pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis plus CT for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 161.83pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">diagnosis of ischemia was compared with an invasive FFR reference <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 173.23pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">standard. Ischemia was defined by an FFR or <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 196.75pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 241.73pt; position: absolute; text-decoration: none; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 260.19pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 268.40999999999997pt; position: absolute; text-decoration: none; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 185.23pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Analysis of 0.80 or less, while anatomically obstructive CAD was <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 196.63pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">defined by a stenosis of 50% or larger on CT and ICA. The primary <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 208.03pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">study outcome assessed whether <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 146.14pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 191.12pt; position: absolute; text-decoration: none; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 209.57999999999998pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 217.79999999999998pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis plus CT <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 220.03pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">could improve the per-patient diagnostic accuracy such that the lower <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 231.43pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">boundary of the 1-sided 95% confidence interval of this estimate <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 242.83pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">exceeded 70%.<font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 262.23pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Conclusions&#58; The study did not meet its primary goal for per-patient <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 273.63pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">diagnostic accuracy, as it resulted in diagnostic accuracy of 73%, with a <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 285.03pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">lower bound of the 95% CI of 67%. However, the use of noninvasive <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 296.43pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 47.61pt; position: absolute; text-decoration: none; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 66.07pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 74.28999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis combined with CT in stable patients with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 308.43pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">suspected or known CAD showed improved diagnostic accuracy and <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 319.83pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">discrimination compared to CT alone for identifying hemodynamically <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 331.23pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">significant CAD, using invasive FFR as the reference standard. This <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 342.63pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">suggests that <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 61.71pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 106.69pt; position: absolute; text-decoration: none; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 125.14999999999999pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 133.37pt; position: absolute; text-decoration: none; white-space: pre;"> Analysis could enhance the noninvasive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 354.63pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">assessment of CAD by providing physiologic insights that CT alone <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 366.03pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">cannot offer, potentially reducing unnecessary invasive procedures. <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 377.43pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Following the completion of the DeFACTO study, we substantially <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 388.83pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">redesigned our technology, which improved product performance. The <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 400.23pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">results of this improvement were validated in the NXT study, which <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 411.63pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">resulted in a per vessel 86% accuracy and was the central evidence for <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 423.03pt; width: 306.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">the initial De Novo 510(k).<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr></table></div></div></div><div style="line-height: 8.73pt; position: absolute; top: 531.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Sales and marketing<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 553.65pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">We believe the Heartflow Platform adds significant value across all the subspecialties that impact <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 565.65pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">cardiovascular care including referring cardiologists, imaging physicians, and interventionalists. We have <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 577.65pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">structured our sales force to efficiently call on these key physician stakeholders, with a primary focus on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 589.65pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">the imaging physicians who are instrumental in new account adoption and the referring physicians who <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 601.65pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">are critical to driving volume growth at our existing accounts. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 621.65pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We market and sell our Heartflow Platform in United States through a direct sales organization. As of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 633.65pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">December 31, 2024, our U.S. commercial team included 40 TSMs focused on opening new accounts, 48 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 645.65pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">TAMs who are focused on broadening referring physician awareness of the CCTA + Heartflow pathway <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 657.65pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and driving increased volumes at our existing accounts, and our customer success organization that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 669.65pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">supports seamless onboarding, implementation and ongoing utilization at our accounts. We support our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 681.65pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">direct commercial efforts with a marketing team that generates demand for the CCTA + Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 693.65pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">pathway and highlights clearly defined value propositions for the various stakeholders across our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 705.65pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">customer base including cardiologists, radiologists and interventional cardiologists.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">120<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our TSMs engage with physicians to communicate the value proposition of the Heartflow Platform, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">leveraging our large base of clinical evidence to highlight its clinical and economic benefits as well as the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">lack of any new capital equipment purchase to drive new account adoption. Our TSMs have substantial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">experience selling into cardiology and radiology practices as well as engaging with broad stakeholders to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">establish new diagnostic and therapeutic solutions, employing an enterprise sales strategy. Our TAMs <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">utilize our extensive clinical compendium to educate and train physicians on the benefits of our platform, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">ultimately driving more referrals to our accounts. Our TAMs have strong backgrounds in establishing new, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 156pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">disruptive therapies and growing a cardiology referral base. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 176pt; width: 612pt;"><div style="left: 72pt; position: absolute; top: 0pt;"><div style="position: absolute;"><img style="height: 172.32pt; width: 468pt;" src="business15ba.jpg" alt="business15ba.jpg"></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 361.32pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Figure 13&#58; Overview of Heartflow call points<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 381.32pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our software is simple, intuitive and does not require case coverage by our sales reps, which affords our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 393.32pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">commercial organization a differentiated level of efficiency relative to most other medical device <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 405.32pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">technology companies. We intend to drive further adoption of our Heartflow Platform by leveraging our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 417.32pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">existing and highly efficient cohort of TSMs and TAMs to continue opening new accounts and driving <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 429.32pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">volume growth. We expect to selectively add additional TSMs to grow our geographic presence where we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 441.32pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">see areas of opportunity and modestly grow our team of TAMs to continue to drive awareness of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 453.32pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">benefits of our technology and broaden our referring physician population as our installed base grows. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 473.32pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We believe that all accounts with a CCTA program would benefit from adopting the Heartflow Platform. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 485.32pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We estimate that as of December 31, 2023, there were approximately 2,700 hospitals and outpatient <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 497.32pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">facilities in the United States that perform CCTA, and this target account base has grown at a 10% CAGR <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 509.32pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">from 2018 to 2023 as accounts increasingly recognize the benefits of a guideline directed CCTA program. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 529.32pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We also have small, direct commercial teams in the United Kingdom and Japan. We may continue to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 541.32pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">expand our commercial activities outside the United States in areas where we see potential opportunity <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 553.32pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and supportive reimbursement dynamics. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 573.32pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Research and development<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 595.72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We have invested significantly in research and development efforts over more than a decade to establish <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 607.72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the first and most widely adopted AI-enabled non-invasive test for CAD that is authorized for marketing in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 619.72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the United States. We have built sophisticated AI-based algorithms and established an intuitive, easy to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 631.72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">use web and mobile customer interface, developed secure data transfer software, a scalable cloud <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 643.72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">database, and quality review software, all while facilitating operational scalability. Our highly skilled and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 655.72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">focused research and development (&#8220;R&#38;D&#8221;) team has been pioneering AI-based coronary imaging for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 667.72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">over a decade and remains uniquely positioned to continuously advance our Heartflow Platform. Our R&#38;D <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 679.72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">team is comprised of PhD research scientists with expertise in AI-based algorithms and medical imaging, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 691.72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">alongside software engineers skilled in cloud architecture, AI algorithms, machine and deep learning and <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">121<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">3D visualization, as well as product managers and designers who ensure optimal customer experience <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and design. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We are continuing to invest in research and development efforts with the goal of driving continuous <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">improvements to the Heartflow Platform and expanding its applicability to additional disease states and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">patient populations. Our near to medium term research and development priorities include&#58; (i) continuing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to train and improve our AI algorithms to drive greater quality and efficiency and reduce manual <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">involvement&#59; (ii) enhancing product features for both <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 305.3pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 350.28pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 369.7pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 378.36pt; position: absolute; white-space: pre;"> Analysis and <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 440.02pt; position: absolute; text-decoration: none; white-space: pre;">Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 485pt; position: absolute; white-space: pre;">Plaque <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Analysis&#59; (iii) developing additional workflow enhancements for our customers&#59; and (iv) expanding <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">indications for our platform, including asymptomatic risk prediction.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 196pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Reimbursement <font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 218.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The ability of our customers to obtain third-party payor coverage and payment for the use of our Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 230.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Platform products for their patients is important to our business. Demand for our existing and new <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 242.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">products is, and will continue to be, affected by the extent to which government healthcare programs such <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 254.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">as Medicare and Medicaid and private health insurers reimburse our customers for the use of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 266.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">products with their patients in the countries where we do business. We have successfully engaged with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 278.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">third-party payors in major markets throughout the world to obtain coverage, coding, and payment rates <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 290.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for our products. Nonetheless, not all third-party payors reimburse our customers for our products in all <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 302.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">situations. Third-party payor reimbursement for the Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 363.38pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 372.04pt; position: absolute; white-space: pre;"> Analysis is broad&#59; however, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 314.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Heartflow Plaque Analysis is our second commercial product and we continue to work to expand <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 326.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">coverage and payment for its use. Even if we develop or acquire a promising new product that has been <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 338.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">cleared for commercial distribution by the FDA, demand for the product may be limited unless our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 350.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">customers are reimbursed at favorable rates by private health insurers and government health care <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 362.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">programs. Our Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 203.6pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 212.26pt; position: absolute; white-space: pre;"> Analysis is reimbursed under a dedicated Category 1 CPT code effective <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 374.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">as of January 1, 2024, and has established coverage policies representing approximately 99% of covered <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 386.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">lives in the United States. A Category 1 CPT code was also recently established for our Heartflow Plaque <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 398.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Analysis, which will take effect in January 2026, and it is covered by the MACs, with five of the seven <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 410.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">MACs issuing final LCDs.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 430.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In the United States, our customers purchase Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 339.68pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 350.03pt; position: absolute; white-space: pre;">Analysis and Heartflow Plaque Analysis <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 442.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reports generated by our products for their patients. These customers then submit a claim to the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 454.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">applicable third-party payor for reimbursement. To the extent that coverage is denied on such claims, or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 466.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the reimbursement paid does not exceed the customer&#8217;s cost for our products, demand for our products <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 478.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">will wane or the charges for our products would have to be materially reduced. Internationally, healthcare <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 490.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reimbursement systems vary significantly. In some countries, our customers, such as hospitals, are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 502.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">constrained by fixed budgets, regardless of the volume and nature of patient treatment. Other countries <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 514.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">require application for, and approval of, government or third-party payor reimbursement. Without both <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 526.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">favorable coverage determinations by, and the financial support of, government and private third-party <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 538.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">payors, the market for of our products would be adversely affected. We cannot be sure that third-party <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 550.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">payors will maintain the current level of coverage and payment to our customers for use of our existing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 562.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">products. Adverse coverage determinations, or reductions in the amount of reimbursement, could harm <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 574.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our business by discouraging customers&#8217; ordering of, and reducing the prices they are willing to pay for, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 586.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our products.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 606.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">It is our intent to complete additional clinical studies and analyses, as needed, to obtain and continue to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 618.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">expand coverage and payment at favorable rates for our products in countries or regions where it makes <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 630.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">economic sense to do so. Nonetheless, coverage and payment for our products can differ from third-party <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 642.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">payor to third-party payor. Further, as a result of their purchasing power, third party payors have <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 654.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">implemented, and are continuing to implement, cost cutting measures such as seeking discounts, price <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 666.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reductions or other incentives from medical products manufacturers, and imposing limitations on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 678.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">coverage and payment for medical technologies and procedures. These trends could compel us to reduce <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 690.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prices for our products and could cause a decrease in the size of the market or a potential increase in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 702.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">competition that could negatively affect our business, financial condition and results of operations.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">122<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition to uncertainties surrounding insurance coverage policies, there are periodic changes to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reimbursement levels by government payors and private health insurers. Third-party payors regularly <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">update reimbursement amounts and also from time to time revise the methodologies used to determine <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reimbursement amounts. This includes routine, annual updates to payments to hospitals under the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">outpatient prospective payment system (&#8220;OPPS&#8221;). These updates could directly impact the demand for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our products. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The overall escalating cost of medical products and services being paid for by the government and private <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">health insurance has led to, and may continue to lead to, increased pressures on the healthcare and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">medical device industries to reduce the costs of products and services. Third-party payors are developing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">increasingly sophisticated methods of controlling healthcare costs through prospective reimbursement <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and capitation programs, group purchasing, redesign of benefits, and exploration of more cost-effective <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">methods of delivering healthcare. In the United States, some insured individuals enroll in managed care <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">programs, which monitor and often require pre-approval of the services that a member will receive. Some <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">managed care programs pay their providers on a per capita (patient) basis, which puts the providers at <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">financial risk for the services provided to their patients by paying these providers a predetermined <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">payment per member per month and, consequently, may limit the willingness of these providers to use <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 272pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our products.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Competition<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 314.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We consider our primary competition to be traditional non-invasive tests for CAD including primarily stress <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 326.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">tests such as SPECT, stress echocardiography and PET. The primary providers of imaging systems that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 338.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">perform these tests include Siemens Healthineers AG, GE Healthcare, Koninklijke Philips N.V. and Canon <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 350.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Medical Systems Corporation. These companies also manufacture CT scanners and therefore have a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 362.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">vested interest in growing the CCTA market in addition to protecting their share of the non-invasive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 374.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">market. These are large, multi-national, commercial organizations with significant resources and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 386.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">distribution capabilities. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 406.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We also face competition from companies that have developed or are developing AI-based platforms that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 418.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">leverage CCTA to diagnose CAD, including earlier-stage companies such as Cleerly, Inc., Elucid <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 430.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Bioimaging Inc. and Keya Medical Technology Co., Ltd. We may also face competition from companies <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 442.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">developing AI-based platforms, even if they are not currently in the CAD market. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 462.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We believe the primary competitive factors in our market include&#58; (i) the accuracy, reliability, and utility of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 474.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the test as demonstrated by the strength and quality of clinical data directly utilizing the test and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 486.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">supporting it&#59; (ii) speed and efficiency of achieving a definitive diagnosis at scale&#59; (iii) per patient <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 498.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">economics including reimbursement rates and relative costs&#59; (iv) availability and ease of use including <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 510.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">integration within hospital systems and clinical workflows as well as customer support&#59; and (v) effective <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 522.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">marketing and physician education efforts as well as ability to impact physician mindshare and historical <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 534.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">practice patterns<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 145.88pt; position: absolute; text-decoration: none; white-space: pre;">. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 554.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Intellectual<font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 134.64pt; position: absolute; text-decoration: none; white-space: pre;"> property<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our success depends in part on our ability to obtain, maintain and defend our patent and other proprietary <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">rights for the Heartflow Platform, the validity and enforceability of our patents, our ability to operate <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 600.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">without infringing the valid and enforceable patents and proprietary rights of third-parties and the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">continued confidentiality of our know-how and trade secrets. We are actively involved in research and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">development and therefore seek to protect the investments we have made into the development of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 636.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Heartflow Platform and our proprietary technology by relying on a combination of patents, trademarks, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 648.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">trade secrets, and licenses, as well as through internal compartmentalization processes, confidentiality <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">agreements and proprietary information agreements with suppliers, employees, consultants and others <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">who may have or gain access to our proprietary information. We seek patent protection in the United <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 684.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">States and key markets internationally for the Heartflow Platform, and any other inventions to which we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 696.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">have rights, where available and appropriate. We also rely upon trademarks to build and maintain the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 708.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">integrity and identity of our brand, and we seek to protect the confidentiality of trade secrets that may be <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">123<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">important to the development of our business, especially where we do not believe patent protection is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">appropriate or obtainable. We license from third parties certain patent rights and proprietary know-how <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">that we believe to be useful to our business.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our patent portfolio, described more fully below, includes claims directed to the Heartflow Platform and its <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">delivery, as embodied in various systems, computer programs, computer implemented methods and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">related methods of use. These claims are directed to various aspects of deriving anatomical and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">physiological information from image data for the Heartflow Platform, aspects of the Heartflow Platform <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">user interface, machine learning methods for generation of the 3D models used for our FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 476.37pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 486.72pt; position: absolute; white-space: pre;">Analysis <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and Plaque Analysis products, and methods of deriving blood flow, anatomy, plaque and organ tissue <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">information from the image data. A number of our issued patents also cover indications other than CAD, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">such as peripheral artery disease, stroke, or aneurysms as well as technical applications related to image <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">data analysis and processing, and platform-related PHI and data transfer methodologies and a number of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">issued patents cover alternative methods such as deriving FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 350.85pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 359.51pt; position: absolute; white-space: pre;"> using purely machine learning methods <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or from other imaging modalities.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">As of December 31, 2024, our owned and licensed patent portfolio includes approximately five hundred <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and eighty-six (586) issued patents and one hundred and three (103) pending patent applications globally, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of which nine (9) are allowed. In the U.S. this includes three hundred and nine (309) issued U.S. patents <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and fifty-six (56) pending non-provisional U.S. patent applications (of which three (3) are allowed). In <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">foreign jurisdictions our owned and licensed patent portfolio includes two-hundred and eighty (280) issued <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">foreign patents and forty-seven (47) pending foreign patent applications (of which five (5) are allowed). <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The two-hundred and eighty (280) issued foreign patents include one or more issued patents in Europe, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Japan, Korea, China, Australia, Canada, India, Hong Kong, and Israel. The forty-seven (47) pending <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">foreign patent applications include one or more pending applications in jurisdictions such as Europe, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 364pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Canada, China, and Japan. We own all of our issued patents except for 7 issued U.S. patents and 8 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">issued foreign patents, for which we have exclusive licenses. All of the issued U.S. patents in the portfolio <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 388pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">are utility patents. Assuming payment of all appropriate maintenance, renewal, annuity or other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 400pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">governmental fees, as applicable, our owned and licensed issued U.S. patents expire between 2018 and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 412pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2041. If issued, our last to expire pending patent application (without accounting for potentially applicable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 424pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">patent term adjustments or extensions) is expected to expire in 2045. Our licensed U.S. patents expire in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 436pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2028. Our patents and applications generally fall into three broad categories&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 456pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">applications and patents relating to our Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 309.40999999999997pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 328.83000000000004pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 339.18pt; position: absolute; text-decoration: none; white-space: pre;">Analysis, including claims directed to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 468pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">segmentation, determining blood flow characteristics using artificial intelligence and&#47;or fluid dynamics, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">and visualization generation&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 500pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">applications and patents relating to our Heartflow Plaque Analysis, including claims directed to plaque <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 512pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">and vessel visualization and characterization&#59; and<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 532pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">applications and patents relating to our Heartflow RoadMap Analysis, including claims directed to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 544pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">image quality and annotation, segmentation, and vascular tree generation.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The term of individual patents depends upon the legal term of the patents in the countries in which they <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">are obtained. In most countries in which we file or intend to file, including the United States, the patent <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">term is 20 years from the earliest date of filing a non-provisional patent application. Additionally, a U.S. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 600pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">provisional patent application expires twelve months from its filing date, and its subject matter can only be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">claimed in an issued patent if, among other things, we timely file a non-provisional patent application <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">making a valid priority claim to that provisional patent application before it expires. In the United States, a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 636pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">patent&#8217;s term may be lengthened by patent term adjustment, which compensates a patentee for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 648pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">administrative delays by the USPTO in examining and granting a patent, or may be shortened if a patent <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">is terminally disclaimed over an earlier filed patent. The coverage sought in a patent application can be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">denied or significantly reduced either before or after the patent is issued. We cannot be sure that patents <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 684pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">will be granted with respect to any current pending patent application or with respect to any patent <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 696pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">applications filed by us in the future, nor can we be certain that any current pending or published patent <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 708pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">application will be granted with the current claims or that any current or future patents will be <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">124<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">commercially useful in protecting the Heartflow Platform and our proprietary technology. In addition, any <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">patents that we may hold, whether owned or licensed, may be challenged, circumvented or invalidated by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">third-parties.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The success of our business strategy also depends in part on our continued ability to protect our brand. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We own registered trademarks for the Heartflow Platform. We also own and maintain registration for a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">number of domain names. As of December 31, 2024, we have registered the trademarks &#8220;HEARTFLOW&#8221; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">word mark and logo with the USPTO. Although we own registered trademarks and domain names in the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">United States and certain other countries, and have filed trademark applications and secured domain <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">name registrations in the United States and in certain other countries, we do not have assurance that our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">trademark portfolio will be adequate to secure or protect all necessary trademarks that we use. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 208pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Heartflow Platform also implements software modules licensed to us by third-party authors under <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">&#8220;open source&#8221; licenses. The use of open source software may entail greater risks than the use of third-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">party commercial software. Please see &#8220;Risk factors&#8212;Risks related to our intellectual property&#8221; for more <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">description of these risks. We have established a review process for screening requests from our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">development organizations for the use of such software that is designed to help us mitigate risks related <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to the quality of any open source software implemented in our technology platform. We also review any <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">open source software used to support our software development, but not directly incorporated into the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Heartflow Platform, as part of our general quality management processes. While these review processes <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">help us mitigate risks associated with the quality of the open source software incorporated into or used in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">developing the Heartflow Platform, we cannot be sure that all open source software is submitted for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">approval prior to use in connection with the Heartflow Platform. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 348pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We also rely on trade secrets, including know-how, unpatented technology and other proprietary <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">information, to strengthen our competitive position. We seek to protect trade secrets and confidential and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">unpatented know-how, in part, by entering into non-disclosure and confidentiality agreements with parties <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 384pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">who have access to such knowledge, such as our employees, collaborators, manufacturers, consultants, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">advisors and other third parties. We also seek to enter into confidentiality and invention or patent <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">assignment agreements with our employees and consultants that obligate them to maintain confidentiality <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and assign their inventions to us. We also seek to preserve the integrity and confidentiality of our data <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 432pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and trade secrets by maintaining the physical security of our premises and physical and electronic <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 444pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">security of our information technology systems.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 464pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our ability to stop third-parties from making, using, selling, offering to sell or importing the Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 476pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Platform depends on the extent to which we have rights under valid and enforceable patents, trade <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 488pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">secrets or other intellectual property and proprietary rights that cover these activities. We pursue <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 500pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">intellectual property protection to the extent we believe it would advance our business objectives. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 512pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Notwithstanding these efforts, there can be no assurance that we will adequately protect our intellectual <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 524pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">property or provide any competitive advantage. For more information regarding risks relating to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 536pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">intellectual property, see &#8220;Risk factors&#8212;Risks related to our intellectual property.&#8221;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 556pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Government regulation<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 578.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">United States regulation of medical devices<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 598.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our products are medical devices subject to extensive and ongoing regulation by the United States Food <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 610.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and Drug Administration (&#8220;FDA&#8221;), the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;), the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 622.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Department of Health and Human Services Office of Inspector General (&#8220;OIG&#8221;) and regulatory bodies in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 634.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the United States and other countries. Regulations govern virtually every critical aspect of a medical <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 646.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">device company&#8217;s business operations, including research activities, product development and testing, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 658.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">manufacturing and production, contracting, reimbursement, product messaging, medical communications, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 670.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">sales, marketing and advertising. In the United States, the Federal Food, Drug and Cosmetic Act <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 682.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(&#8220;FDCA&#8221;) and the implementing regulations of the FDA govern product design and development, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 694.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">preclinical and clinical testing, premarket clearance or approval, product manufacturing, product labeling, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 706.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">product storage, advertising and promotion, product sales and distribution, import, export and post market <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">125<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">clinical surveillance. Our business is subject to federal, state, local, and foreign regulations, such as ISO <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">13485&#58;2016, ISO 14971&#58;2019, FDA&#8217;s Quality System Regulation (&#8220;QSR&#8221;) contained in 21 CFR Part 820, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and the EU&#8217;s Medical Devices Directive 93&#47;42&#47;EEC and its replacement, Regulation (EU) 2017&#47;745. The <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Heartflow Platform consists of three main analyses&#59; Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 366.32pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT <font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 376.67pt; position: absolute; white-space: pre;">Analysis, Heartflow Roadmap <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Analysis, and Heartflow Plaque Analysis. All three are authorized for clinical use in the United States, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Bahrain, Israel, Saudi Arabia, and the United Arab Emirates. Only the FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 399.65pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 408.31pt; position: absolute; white-space: pre;"> Analyses is authorized for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">clinical use in the European Economic Area, United Kingdom, Australia, Canada, and Japan. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">FDA premarket clearance and approval requirements<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 184pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Unless an exemption applies, each medical device commercially distributed in the United States requires <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 196pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">either FDA clearance of a 510(k) premarket notification, grant of a de novo classification request, or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 208pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">approval of a premarket approval (&#8220;PMA&#8221;) application. Our Heartflow Platform is regulated in the United <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">States by the FDA as a Class II medical device. The FDA classifies medical devices into one of three <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">classes. Devices deemed to pose low to moderate risk are designated as either Class I or II. Class I <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">devices are subject to general controls such as establishment registration and device listing, labeling, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">adherence to current good manufacturing practices outlined in the QSR, maintenance and investigation of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">product complaint records, and adverse event reporting, but are usually exempt from premarket <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">notification requirements. Class II devices are subject to the same general controls and may be subject to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">special controls such as performance standards, post-market surveillance, particularized labeling <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">requirements and&#47;or clinical testing prior to clearance. Manufacturers of Class II devices, absent an <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">exemption, are required to submit to the FDA a premarket notification prior to commercial distribution. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Devices are designated as Class III, which requires approval of a PMA application, if they are deemed by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the FDA to pose the greatest risk. These high-risk devices include life sustaining or life supporting <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">devices, certain implantable devices, and other devices that are intended for a use that is of substantial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 364pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">importance in preventing impairment of human health or that present a potential unreasonable risk of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">illness or injury. The PMA approval process is more comprehensive than the 510(k) clearance process <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 388pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and typically takes several years to complete.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">510(k) clearance marketing pathway<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 428pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">A 510(k) notification requires the sponsor to demonstrate that a medical device is substantially equivalent <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 440pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to another marketed device, termed a &#8220;predicate device,&#8221; that is legally marketed in the United States and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 452pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for which a PMA was not required. A device is substantially equivalent to a predicate device if it has the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 464pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">same intended use and technological characteristics as the predicate, or has the same intended use but <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 476pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">different technological characteristics that do not raise new questions of safety and effectiveness, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 488pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">information submitted to the FDA demonstrates that the device is at least as safe and effective as the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 500pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">predicate device.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 520pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">If the FDA agrees that the device is substantially equivalent to a predicate device currently on the market, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 532pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">it will grant 510(k) clearance to commercially market the device. If there is no viable predicate device for a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 544pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">new device because, for example, of a new intended use, the device is automatically designated as a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 556pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Class III device. Unless the De Novo pathway is available for the new device, the device sponsor must <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 568pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">fulfill more rigorous PMA requirements. The PMA process requires that the manufacturer demonstrate <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 580pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">that the device is safe and effective for its intended uses, which generally requires the submission of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 592pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">extensive data, including results from pre-clinical studies and human clinical trials. A PMA must also <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 604pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">contain a full description of the device and its components, the methods, facilities, and controls used for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 616pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">manufacturing, and proposed labeling. The PMA process is burdensome, and in practice, the FDA&#8217;s <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 628pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">review of a PMA application may take up to several years following initial submission. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 648pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">After a device receives 510(k) clearance, any modification that could significantly affect its safety or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">effectiveness, or that would constitute a new or major change in its intended use, requires a new 510(k) <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">clearance, or depending on the modification, could require the filing of a de novo classification request or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 684pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">a PMA application, which would require the submission to the FDA of clinical trial data, among other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 696pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">information. We are required to determine, for each modification to our cleared products, whether to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 708pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">submit a new 510(k) notification for the modification, based on the nature of the modification. If we <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">126<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">determine a new 510(k) submission is not required, the decision and justification are documented in a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">&#8220;letter to file.&#8221; If the FDA disagrees with our determination, the FDA can require us to cease marketing or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">recall the modified device until 510(k) clearance, grant of a de novo classification request or approval of a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">PMA is obtained. We have made, and we plan to continue to make, minor product enhancements to our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">cleared products that we believe do not require new 510(k) clearances and that we document in letters to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">file. We also intend to make product enhancements from time to time that we expect may require new <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">510(k) clearances.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">De novo classification process<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 184pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">A manufacturer can request a risk-based classification determination for a novel device in accordance <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 196pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">with the &#8220;de novo&#8221; process. Medical device types that the FDA has not previously classified as Class I, II, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 208pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or III are automatically classified into Class III regardless of the level of risk they pose. The Food and Drug <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Administration Modernization Act of 1997 established a route to market for low-to-moderate risk medical <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">devices that are automatically placed into Class III due to the absence of a predicate device, called the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">&#8220;Request for Evaluation of Automatic Class III Designation,&#8221; or the de novo classification procedure. This <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">procedure allows a manufacturer whose novel device is automatically classified into Class III to request <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">down-classification of its medical device into Class I or Class II on the basis that the device presents low <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or moderate risk, rather than requiring the submission and approval of a PMA application. Pursuant to the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Food and Drug Administration Safety and Innovation Act (&#8220;FDASIA&#8221;), manufacturers may request de novo <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">classification directly without first submitting a 510(k) pre-market notification to the FDA and receiving a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">not-substantially-equivalent determination. De novo classification requests, like PMA applications and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">510(k) notifications, are subject to the payment of user fees.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 348pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Under the FDASIA, the FDA is required to reach a decision within 120 days following receipt of the de <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">novo request, although the process may take significantly longer. If the manufacturer seeks <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reclassification into Class II, the manufacturer must include a draft proposal for special controls that are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 384pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">necessary to provide a reasonable assurance of the safety and effectiveness of the medical device. If the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">FDA grants the de novo request, the device may be legally marketed in the United States. However, the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">FDA may reject the request if the FDA identifies a legally marketed predicate device that would be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">appropriate for a 510(k) notification, determines that the device is not low-to-moderate risk, or determines <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 432pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">that General Controls would be inadequate to control the risks and&#47;or special controls cannot be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 444pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">developed. After a device receives de novo classification, any modification that could significantly affect <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 456pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">its safety or efficacy, or that would constitute a major change or modification in its intended use, will <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 468pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">require a new 510(k) clearance or, depending on the modification, another de novo request or even PMA <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">approval.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 500pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We obtained initial marketing authorization for Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 341.73pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 350.39pt; position: absolute; white-space: pre;"> Analysis through the FDA&#8217;s &#8220;de novo&#8221; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 512pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">classification process, supported by clinical data from our NXT clinical trial. Through this process, the FDA <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 524pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">agreed that special controls provide reasonable assurance of the safety and effectiveness of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 536pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 136.4pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 145.06pt; position: absolute; white-space: pre;"> Analysis and therefore it can be classified as a Class II device. We received a de novo <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 548pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">authorization on November 26, 2014 for version 1.4 of the Heartflow FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 394.7pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 403.36pt; position: absolute; white-space: pre;"> Analysis. We received the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 560pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">510(k) clearance for version 2.x of the FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 261.94pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 270.6pt; position: absolute; white-space: pre;"> product in January 2015, and 510(k) clearance for a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 572pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">modification to the intended use language in August 2016. Additional clearances were received for a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 584pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">strategic architecture scope change in December 2018, which is the device we refer to as Heartflow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 596pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Platform. The Heartflow Platform version 3.0 received FDA clearance in January 2021, and the newest <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 608pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">product generation, Heartflow Platform version 3.18, adding Roadmap and Plaque functions, received <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 620pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">FDA clearance in October 2022.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 640pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Medical device clinical trials<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Clinical trials are sometimes required to support 510(k) or de novo submissions. All clinical investigations <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of devices to determine safety and effectiveness must be conducted in accordance with the FDA&#8217;s <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 684pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">investigational device exemption (&#8220;IDE&#8221;) regulations which govern investigational device labeling, prohibit <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 696pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">promotion of the investigational device, and specify an array of recordkeeping, reporting and monitoring <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 708pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">responsibilities of study sponsors and study investigators. If the device presents a &#8220;significant risk&#8221; to <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">127<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">human health, as defined by the FDA, the FDA requires the device sponsor to submit an IDE application <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to the FDA, which must become effective prior to commencing human clinical trials. If the device under <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">evaluation does not present a significant risk to human health, then the device sponsor is not required to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">submit an IDE application to the FDA before initiating human clinical trials, but must still comply with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">abbreviated IDE requirements when conducting such trials. A significant risk device is one that presents a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">potential for serious risk to the health, safety or welfare of a patient and either is implanted, used in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">supporting or sustaining human life, substantially important in diagnosing, curing, mitigating or treating <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 156pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">disease or otherwise preventing impairment of human health, or presents a potential for serious risk to a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 168pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">patient in some other way. An IDE application must be supported by appropriate data, such as animal and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 180pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">laboratory test results, showing that it is safe to test the device in humans and that the testing protocol is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 192pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">scientifically sound. The IDE will automatically become effective 30 days after receipt by the FDA unless <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 204pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the FDA notifies the company that the investigation may not begin. If the FDA determines that there are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 216pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">deficiencies or other concerns with an IDE for which it requires modification, the FDA may permit a clinical <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 228pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">trial to proceed under a conditional approval.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Regardless of the degree of risk presented by the medical device, clinical studies must be approved by, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and conducted under the oversight of, an Institutional Review Board (&#8220;IRB&#8221;) for each clinical site. The IRB <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 272pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">is responsible for the initial and continuing review of the clinical study, and may pose additional <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 284pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">requirements for the conduct of the study. If an IDE application is approved by the FDA and one or more <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 296pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">IRBs, human clinical trials may begin at a specific number of investigational sites with a specific number <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of patients, as approved by the FDA. If the device presents a non-significant risk to the patient, a sponsor <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 320pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">may begin the clinical trial after obtaining approval for the trial by one or more IRBs without separate <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 332pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">approval from the FDA, but must still follow abbreviated IDE requirements, such as monitoring the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 344pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">investigation, ensuring that the investigators obtain informed consent, and labeling and record-keeping <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 356pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">requirements. Acceptance of an IDE application for review does not guarantee that the FDA will allow the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 368pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">IDE to become effective and, if it does become effective, the FDA may or may not determine that the data <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 380pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">derived from the trials support the safety and effectiveness of the device or warrant the continuation of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 392pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">clinical trials.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 412pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">During a study, the sponsor is required to comply with the applicable FDA requirements, including, for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 424pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">example, trial monitoring, selecting clinical investigators and providing them with the investigational plan, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 436pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">ensuring IRB review, adverse event reporting, record keeping and prohibitions on the promotion of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 448pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">investigational devices or on making safety or effectiveness claims for them. The clinical investigators in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 460pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the clinical study are also subject to FDA&#8217;s regulations and must obtain patient informed consent, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 472pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">rigorously follow the investigational plan and study protocol, control the disposition of the investigational <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 484pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">device, and comply with all reporting and recordkeeping requirements. Additionally, after a trial begins, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 496pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">we, the FDA or the IRB could suspend or terminate a clinical trial at any time for various reasons, such as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 508pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">strategic business decisions or a belief that the risks to study subjects may outweigh the anticipated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 520pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">benefits.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Expedited development and review programs<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 560pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Following passage of the 21st Century Cures Act, the FDA implemented the Breakthrough Devices <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 572pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Program, which is a voluntary program offered to manufacturers of certain medical devices and device-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 584pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">led combination products that may provide for more effective treatment or diagnosis of life-threatening or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 596pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">irreversibly debilitating diseases or conditions. The goal of the program is to provide patients and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 608pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">healthcare providers with more timely access to qualifying devices by expediting their development, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 620pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">assessment and review, while preserving the statutory standards for PMA approval, 510(k) clearance and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 632pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">de novo classification. The program is available for medical devices that meet certain eligibility criteria, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">including that the device provides more effective treatment or diagnosis of a life-threatening or irreversibly <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">debilitating disease or condition, and that&#58; (i) the device represents a breakthrough technology, (ii) no <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 668pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">approved or cleared alternatives exist, (iii) the device offers significant advantages over existing approved <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 680pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or cleared alternatives, or (iv) the availability of the device is in the best interest of patients. Breakthrough <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 692pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Device Designation provides certain benefits to device developers, including more interactive and timely <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 704pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">communications with FDA staff&#59; use of post-market data collection, when scientifically appropriate, to <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">128<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">facilitate expedited and efficient development and review of the device&#59; opportunities for more efficient <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and flexible clinical study design&#59; and prioritized review of premarket submissions. When reviewing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Breakthrough Device Designation requests, the FDA may require a combination of literature or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">preliminary bench, animal or clinical data to demonstrate a reasonable likelihood of clinical and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">technological success. Receiving a Breakthrough Device Designation from the FDA does not guarantee <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">that the FDA will grant marketing authorization for the device.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Post-market regulation<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 172pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">After a device is approved or cleared and placed in commercial distribution, numerous FDA regulatory <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 184pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">requirements apply. These include, but are not limited to, requirements to&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 204pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">register establishments and list devices with the FDA&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">maintain a quality system that is compliant with the QSR, which governs design, development, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">manufacture of devices&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">establish various specifications and controls for incoming components and finished devices&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 276pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">ensure that devices are designed to meet user needs&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 296pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">verify that finished devices are manufactured to the appropriate controls and that they meet <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">specifications&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">ensure that devices are assigned and labeled with a Unique Device Identifier (&#8220;UDI&#8221;) and that certain <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">UDI information is provided to FDA&#8217;s Global Unique Identification Database (&#8220;GUDID&#8221;)&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">ensure that labeling and advertising and promotional activities are consistent with cleared&#47;approved <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">uses, adequately substantiated, and truthful and not misleading&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 392pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">analyze quality data to identify and correct quality problems&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 412pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">submit notifications or applications for clearance or approval of product modifications that could <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 424pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">significantly affect safety or effectiveness or that would constitute a major change in intended use&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 444pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">review, evaluate and investigate complaints and report adverse events to the FDA when a device may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 456pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">have caused or contributed to a death or serious injury or malfunctioned in a way that would be likely <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 468pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">to cause or contribute to a death or serious injury if the malfunction were to recur&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 488pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">report to FDA corrections and removals undertaken to reduce a risk to health posed by the device or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 500pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">to remedy a violation of the FDCA that may present a risk to health. In addition, FDA may order a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 512pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">mandatory recall if there is a reasonable probability that the device would cause serious adverse <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 524pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">health consequences or death&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 544pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">comply with any post-approval restrictions or conditions, including requirements to conduct post-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 556pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">market surveillance studies to establish continued safety data&#59; and<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">conduct clinical studies in accordance with good clinical practices and applicable regulations, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">including requirements for clinical trial registration and results reporting on ClinicalTrials.gov.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 608pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Manufacturing processes for medical devices are required to comply with the applicable portions of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 620pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">QSR, which cover the methods and the facilities and controls for the design, manufacture, testing, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 632pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">production processes and controls, quality assurance, labeling, packaging, distribution, installation and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">servicing of finished devices intended for human use. The QSR also requires, among other things, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">maintenance of a device master file, device history file, device history record and complaint files. As a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 668pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">manufacturer, we are subject to periodic scheduled or unscheduled inspections by the FDA. Failure to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 680pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">maintain compliance with the QSR requirements could result in the shutdown of, or restrictions on, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 692pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">manufacturing operations and the recall or seizure of marketed products. In February 2024, the FDA <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 704pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">issued the Quality Management System Regulation Final Rule (&#8220;QMSR&#8221;) to amend the QSR, <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">129<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">incorporating by reference the international standard for medical device quality management systems, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">ISO 13485&#58;2016. The rule becomes effective on February 2, 2026. Until then, manufacturers are required <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to comply with the QSR. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The FDA polices these requirements by inspection, review of required reports or submissions, and market <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">surveillance, and the agency has broad enforcement powers to address any violations. The FDA may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">conduct announced or unannounced facility inspections to determine compliance with the QSR and other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">regulations, and these inspections may include our manufacturing facilities. Failure to comply with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">applicable regulatory requirements can result in enforcement action by the FDA or other regulatory <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">authorities, which may result in sanctions and related consequences, including&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 196pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">untitled letters or warning letters or it has come to our attention letters&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 216pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">injunctions or consent decrees&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">fines or civil penalties&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">recall, detention, or seizure of our product&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 276pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">operating restrictions, partial suspension, or total shutdown of production&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 296pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the FDA&#8217;s refusal of or delay in granting 510(k) clearance or premarket approval of new or modified <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">products&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">withdrawal of 510(k) clearances or PMA approvals&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 348pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the FDA&#8217;s refusal to grant export certificates&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 368pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">criminal prosecution&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 388pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">unanticipated expenditures to address or defend such actions&#59; and<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">reputational harm resulting from such actions.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 428pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Other regulatory authorities overseeing the implementation and adherence of applicable state, federal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 440pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and analogous foreign regulatory authorities may also conduct unannounced inspections. Such <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 452pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">inspections may result in similar administrative, civil and criminal penalties. The discovery of previously <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 464pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">unknown problems with marketed medical devices, including unanticipated adverse events or adverse <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 476pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">events of increasing severity or frequency, whether resulting from the use of the device within the scope <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 488pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of its clearance or off-label by a physician in the practice of medicine, could result in restrictions on the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 500pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">device, including the removal of the product from the market or voluntary or mandatory device recalls.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 520pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">International regulation &#8212; European Union, United Kingdom, Japan and Canada<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In order to market and sell our product outside of the United States, we must comply with numerous and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">varying regulatory requirements of other countries and jurisdictions regarding quality, safety, and efficacy <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and governing, among other things, clinical trials, marketing authorization, commercial sales and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">distribution of our product.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 596pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Although many of the regulatory issues we face in the United States are similar to the issues in other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 608pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">geographies, the approval or certification process varies between countries and jurisdictions and can <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 620pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">involve additional testing and additional administrative review periods. The time required to obtain <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 632pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">approval or certification in other countries and jurisdictions might differ from and be longer than that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">required to obtain clearance from the FDA. Regulatory approval or certification in one country or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">jurisdiction does not ensure regulatory approval or certification in another, but a failure or delay in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 668pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">obtaining regulatory approval or certification in one country or jurisdiction may negatively impact the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 680pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">regulatory process in others.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">130<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">European Union<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 92pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The primary regulatory environment in Europe is that of the European Union, which includes most of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">major countries in Europe. The law regarding medical devices is harmonized in the European Union. Until <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">a few years ago, medical devices were governed by the Medical Devices Directive 93&#47;42&#47;EEC (&#8220;MDD&#8221;) <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and the Active Implantable Medical Devices Directive 90&#47;385&#47;EEC (&#8220;AIMD&#8221;), implemented by the member <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">states of the European Union into their national law. However, on May 26, 2021,the Medical Devices <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Regulation (EU) 2017&#47;745 (&#8220;MDR&#8221;) entered into application, repealing and replacing the MDD and the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">AIMD. As a Regulation, the MDR is directly applicable in all member states of the European Union and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">does not require further implementation into national law. The MDR and its associated guidance <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">documents and harmonized standards govern, among other things, device design and development, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">preclinical and clinical or performance testing, premarket conformity assessment, registration and listing, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">manufacturing, labeling, storage, claims, sales and distribution, export and import and post-market <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">surveillance, vigilance, and market surveillance. The MDR is based on very similar general system as the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">MDD, but adds obligations on manufacturers and distributors of medical devices. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Since May 26, 2021, medical devices placed on the European Union market must conform to the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">requirements set out by the MDR. Medical devices must comply with the General Safety and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Performance Requirements (&#8220;GSPRs&#8221;) set out in Annex I of the MDR. Compliance with these <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">requirements is a prerequisite to be able to affix the CE mark to devices, without which they cannot be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">marketed or sold in the European Union. To demonstrate compliance with the GSPRs provided in the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">MDR and obtain the right to affix the CE mark, medical devices manufacturers must undergo a conformity <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">assessment procedure. The conformity assessment procedure varies depending on the class of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">product, but most cases involve an assessment by a Notified Body. Depending on the relevant conformity <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">assessment procedure, this assessment may consist of a review of the technical file submitted by the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 364pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">manufacturer, an audit of the quality system of the manufacturer, and testing of the product of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">manufacturer. Even though a Notified Body is a private organization in one of the member states of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 388pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">European Union, all Notified Bodies in the European Union are designated and accredited by a national <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 400pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">government of the European Union based on stringent criteria. Only such accredited Notified Bodies may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 412pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">give a CE Certificate of Conformity following successful completion of a conformity assessment procedure <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 424pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">conducted in relation to the medical device and its manufacturer and their conformity with the GSPRs. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 436pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The CE Certificate of Conformity confirms the conformity of the device to the GSPRs and allows the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 448pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">applicant to affix the CE mark on the assessed medical device and to commercialize it in the European <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 460pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Union after having prepared and signed a related European Union Declaration of Conformity. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">As a general rule, demonstration of conformity of medical devices and their manufacturers with the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 492pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">GSPRs must be based, among other things, on the evaluation of clinical data supporting the safety and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 504pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">performance of the products during normal conditions of use. Specifically, a manufacturer must <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 516pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">demonstrate that the device achieves its intended performance during normal conditions of use and that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 528pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">against the benefits of its intended performance, and that any claims made about the performance and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">safety of the device (e.g., product labeling and instructions for use) are supported by suitable evidence. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">This assessment must be based on clinical data, which can be obtained from (i) clinical studies conducted <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">on the devices being assessed, (ii) scientific literature from similar devices whose equivalence with the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">assessed device can be demonstrated or (iii) both clinical studies and scientific literature. The conduct of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 600pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">clinical studies in the European Union is governed by detailed regulatory obligations. These may include <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the requirement of prior authorization by the Competent Authorities of the country in which the study takes <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">place and the requirement to obtain a positive opinion from a competent Ethics Committee. This process <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 636pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">can be expensive and time-consuming. After a device is placed on the market in the European Union, it <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 648pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">remains subject to significant regulatory requirements.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 668pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The MDR also establishes transitional provisions, amended by Regulation (EU) 2023&#47;607, permitting <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 680pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">certain devices that have been CE marked in accordance with the MDD or the AIMD to continue to be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 692pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">placed on the European Union market under strict conditions and for a specific period of time depending <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 704pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">on the risk classification of the device and the date of issuance of any related CE Certificate of <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">131<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Conformity. Accordingly, CE Certificates of Conformity issued by Notified Bodies in accordance with the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">MDD or the AIMD from May 25, 2017, and which remained valid on May 26, 2021 and have not since <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">been withdrawn will, with certain exceptions, remain valid until December 31, 2027 for Class III and Class <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">IIb implantable medical devices and until December 31, 2028 for other Class IIb, Class IIa and Class I <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">devices with a measuring function or which are sterile. Class I medical devices, for which the conformity <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">assessment procedure in accordance with the MDD or the AIMD did not require the involvement of a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Notified Body but will require the involvement of a Notified Body in accordance with the MDR and for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 156pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">which an European Union Declaration of Conformity was issued in accordance with the MDD or the AIMD <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 168pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prior to May 26, 2021, can continue to be placed on the European Union market until December 31, 2028. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Manufacturers of medical devices may only benefit from the above extended transitional provisions <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">deadlines if the following conditions are fulfilled&#58; (i) the devices continue to comply with the requirements <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of the MDD or AIMD, as applicable, (ii) there are no significant changes in the design and intended <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">purpose, (iii) the devices do not present an unacceptable risk to the health or safety of patients, users or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">other persons, or to other aspects of the protection of public health, (iv) the manufacturer implements a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">quality management system by May 26, 2024 which complies with the requirements of the MDR, (v) by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">May 26, 2024 an application is lodged with a Notified Body for conduct of the conformity assessment of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 272pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the devices covered by the CE Certificate of Conformity, or the devices intended to substitute for such <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 284pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">devices, in accordance with the MDR and a related written agreement is signed with the Notified Body by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 296pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">September 26, 2024, and (vi) from May 26, 2021, compliance with the MDR relating to post-market <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">surveillance, market surveillance, vigilance, registration of economic operators and of devices is ensured <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 320pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">in place of the corresponding requirements in the MDD or AIMD.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition, CE Certificates of Conformity issued by Notified Bodies in accordance with the MDD or the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">AIMD from May 25, 2017, which were valid on May 26, 2021 and have not been withdraw since but which <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 364pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">expired before March 20, 2023, will only continue to be valid in accordance with the extended transitional <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">deadlines above if either (i) the manufacturer signed a written agreement with a Notified Body for the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 388pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">conformity assessment of the device covered by the expired CE Certificate of Conformity, or the device <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 400pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">intended to substitute that device, in accordance with the MDR before the date of expiry of the CE <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 412pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Certificate of Conformity, or (ii) a competent authority of an European Union Member State has granted a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 424pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">derogation from the application conformity assessment procedure in accordance with Article 59(1) or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 436pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Article 97(1) of the MDR.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 456pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">On July 26, 2011, our Notified Body at the time, TUV Nord, issued a CE Certificate of Conformity for, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 468pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">thus allowed us to affix the CE mark, version 1.0 of the Heartflow Platform (July 26, 2011). The CE <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Certificate of Conformity was subsequently reviewed for version 2.x of the Heartflow Platform and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 492pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">confirmed in March of 2017. Our current version, version 3.x is also CE marked under the MDD <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 504pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(November 20, 2019). We currently rely on the transitional provisions of the MDR to continue to place <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 516pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">version 3.x of the Heartflow Platform on the market in the European Union.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 536pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition, TUV Nord assessed the conformity of our quality management system (&#8220;QMS&#8221;) with the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 548pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">industry standard, EN ISO 13485, and TUV Nord issued the certificate confirming that we meet all EN ISO <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 560pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">13485 requirements. Based on the EN ISO certificate, TUV Nord also issued a certificate under the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 572pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">MDSAP (Medical Device Single Audit Program), stating that the requirements of EN ISO 13485&#58;2016 for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 584pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">quality management systems are met in Australia, Canada, USA and Japan.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 604pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In the second half of 2024, we changed Notified Bodies from TUV Nord to BSI by an agreement between <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 616pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">TUV Nord, BSI and us. BSI has taken over Notified Body responsibilities concerning all MDD&#47;MDR <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 628pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">requirements. BSI has also taken over our QMS certifications. After this transfer, all certificates issued by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 640pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">TUV Nord remain valid and in effect. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The advertising and promotion of medical devices in the European Union is subject to the national laws of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the individual European Union Member States that implemented the MDD, the AIMD and that apply the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 684pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">MDR, Directive 2006&#47;114&#47;EC concerning misleading and comparative advertising, and Directive 2005&#47;29&#47;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 696pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">EC on unfair commercial practices, as well as other national legislation of individual European Union <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 708pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Member States governing the advertising and promotion of medical devices. European Union Member <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">132<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">States&#8217; national legislation may also restrict or impose limitations on our ability to advertise our products <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">directly to the general public. In addition, voluntary European Union and national industry Codes of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Conduct provide guidelines on the advertising and promotion of our products to the general public and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">may impose limitations on our promotional activities with healthcare professionals.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition, other countries, such as Switzerland, have voluntarily adopted laws and regulations relating to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">medical devices that mirror those of the European Union. Medical devices certified by a Notified Body and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">CE marked in the European Union may be placed on Swiss market.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 172pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">United Kingdom<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 192pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The United Kingdom left the European Union in January of 2020 and the transitional period ended on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 204pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">December 31, 2020. In light of the fact that the CE Marking process is set out in European Union law, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 216pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">which no longer applies in the United Kingdom, the United Kingdom has devised a new route to market <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 228pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">culminating in a UKCA Mark to replace the CE Mark. Northern Ireland will, however, continue to be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 240pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">covered by the regulations governing CE Marks. The United Kingdom Medicines and Healthcare products <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 252pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Regulatory Agency (&#8220;MHRA&#8221;) has established transitional provision to recognize the acceptance of certain <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 264pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">CE marked medical devices on the Great Britain market until June 30, 2030, at the latest, depending on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 276pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the type of device and its classification. Accordingly, medical devices which, for example, meet all <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 288pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">requirements of the European Union MDD and have a valid CE Certificate of Conformity and European <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 300pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Union Declaration of conformity issued under the MDD prior to May 26, 2021, may be placed on the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 312pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">market until the sooner of expiry of the CE Certificate of Conformity or June 30, 2028. Medical devices <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 324pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">which meet all requirements of the European Union MDR may be placed on the market until June 30, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 336pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2030. Manufacturers of medical devices located outside the United Kingdom, including manufacturers of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 348pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">CE marked medical devices, need to appoint a United Kingdom Responsible Person before the devices <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">may be placed on the United Kingdom market. The United Kingdom government plans on introducing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">new legislation governing medical devices which will be delivered though secondary legislation. The first <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 384pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">piece of legislation was laid in 2024 and updates post-market surveillance requirements. Additional <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">instruments will follow in 2025 and 2026 to introduce new pre-market requirements including international <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reliance, and further enhancements to the regulations.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 428pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Japan<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 448pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We applied for marketing authorization with the PMDA in Japan in February 2015, which was approved in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 460pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">November 2016. As a result, we are able to commercially market the product in Japan. Our initial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 472pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">SHONIN application is still current and includes a minor change notification.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 492pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Canada<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 512pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Heartflow received our initial Canadian Medical Device License in August 2015. This remains current and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 524pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">updated frequently with amendments for every minor software release. As well, Canada recognizes the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 536pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Heartflow Mobile application as a separate device identified within our Heartflow device family and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 548pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">requires amendments for Mobile updates.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 568pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Other regulations &#8212; federal and state fraud and abuse, data privacy and security and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 580pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">transparency laws<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 600pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition to FDA restrictions on marketing and promotion of medical devices, there are numerous U.S. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">federal and state laws, regulations, and guidance documents pertaining to healthcare compliance <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">protections against fraud and abuse, including anti-kickback laws, payment transparency laws, patient <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 636pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">inducement laws, and false claims laws, and, in some states, prohibitions against the corporate practice <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 648pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of medicine and the unlicensed practice of medicine (collectively, fraud and abuse laws and regulations). <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our relationships with physicians, hospitals and other healthcare providers and referral sources for our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">products are subject to scrutiny under these laws. Violations of these laws may be punishable by criminal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 684pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and civil sanctions, including, in some instances, imprisonment and exclusion from participation in federal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 696pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and state healthcare programs, including the Medicare, Medicaid and Veterans Administration health <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">133<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">programs. Because of the breadth and far-reaching nature of these laws, we may be required to alter or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">discontinue one or more of our business practices to be in compliance with these laws.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">These healthcare fraud and abuse laws and regulations are complex, and even minor departures from <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">what is expressly permitted under the laws and regulations can potentially give rise to claims that a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">statute or regulation has been violated in a manner that could result in serious criminal or civil <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">consequences. Several of the more significant healthcare fraud and abuse laws and regulations that may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">affect our business or ability to operate are summarized below.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 172pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The federal Anti-Kickback Statute is a criminal law that prohibits, among other things, knowingly and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 184pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">willfully offering, paying, soliciting, or receiving any remuneration in cash or in-kind (including any <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 196pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">kickback or bribe, but also common forms of remuneration, such as service or consulting fees, service <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 208pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">fees, meals, travel expenses, discounts, or rebates), directly or indirectly, overtly or covertly, to induce or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of any item or service reimbursable, in whole or in part, under Medicare, Medicaid or other federal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Although there are a number of statutory exceptions and regulatory safe harbors protecting some <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">common activities, the exceptions and safe harbors are drawn narrowly. Practices that involve <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">remuneration that may be alleged to be intended to induce prescribing, uses, purchases, or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">recommendations of prescriptions, uses, or purchases of our products may be subject to scrutiny if they <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">basis based on a review of all relevant facts and circumstances. Several courts have interpreted the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 364pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to induce referrals of (or purchases, uses, or recommendations of prescriptions, uses, or purchases) <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">federal healthcare program covered business, the Anti-Kickback Statute has been implicated and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 388pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">potentially violated.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Additionally, the Anti-Kickback Statute was amended by the ACA. Specifically, as noted above, under the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Anti-Kickback Statute, the government must prove that a defendant acted &#8220;knowingly&#8221; to prove a violation. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 432pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The ACA added a provision that clarifies that with respect to violations of the Anti-Kickback Statute, &#8220;a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 444pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">person need not have actual knowledge&#8221; of the Statute or specific intent to commit a violation of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 456pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Statute. This change effectively overturns case law interpretations that set a higher standard under which <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 468pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prosecutors had to prove the specific intent to violate the law. In addition, the ACA codified case law that a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">claim including items or services resulting from a violation of the federal Anti-Kickback Statute may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 492pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">constitute a false or fraudulent claim for purpose of the federal civil False Claims Act.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 512pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The federal civil U.S. False Claims Act prohibits, among other things, any person or entity from knowingly <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 524pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">presenting, or causing to be presented, a false or fraudulent claim for payment or approval to the federal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 536pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">government or knowingly making, using or causing to be made or used a false record or statement <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 548pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">material to a false or fraudulent claim to the federal government. A claim includes &#8220;any request or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 560pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">demand&#8221; for money or property presented to the United States government. The civil False Claims Act <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 572pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">also applies to false submissions that cause the government to not receive a benefit to which it is entitled, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 584pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">such as a discounted sales price for products covered by federal healthcare programs. Intent to deceive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 596pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">is not required to establish liability under the civil False Claims Act. In addition, the civil False Claims Act <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 608pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">includes a whistleblower provision that allows private citizens to bring claims on behalf of the United <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 620pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">States government alleging violations of the law. Whistleblowers may be entitled to up to as much as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 632pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">thirty percent (30%) of the government&#8217;s financial recovery resulting from such claims. This incentivizes <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">potential whistleblowers to file complaints in federal court, which complaints are relied upon heavily by the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">government to investigate and prosecute allegations of violations of both the civil False Claims Act and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 668pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the Anti-Kickback Statute.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 688pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Many medical device, pharmaceutical, biotech and other healthcare companies have been investigated or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 700pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prosecuted under these healthcare fraud and abuse laws and regulations. Investigations, prosecutions <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">134<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(and settlements) relate to a wide range of activities, including among other things, improper clinical <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">studies, provision of consulting fees to physicians for services that were not commercially reasonable, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">providing free product to customers to induce them to do business with the manufacturer, providing high <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">value meals to customers to induce them to do business with the manufacturer, or providing non-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">compliant discounts or rebates to customers, with the expectation that the customers would bill federal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">programs for the product or the medical services that involve the product. Other companies have been <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">investigated or prosecuted for causing false claims to be submitted by, among other things, marketing of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 156pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">products for unapproved, and thus noncovered, uses, or for promotion of uses inconsistent with approved <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 168pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">labeling (&#8220;off label&#8221; promotion).<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The United States government may further prosecute conduct constituting a false claim under the criminal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">False Claims Act. The criminal False Claims Act prohibits the making or presenting of a claim to the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">government knowing such claim to be false, fictitious, or fraudulent and, unlike the civil False Claims Act, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">requires proof of intent to submit a false claim.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition to the Anti-Kickback Statute and the civil and criminal False Claims Acts, the United States <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">federal government has the authority to seek civil monetary penalties, assessments and exclusions <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">against an individual or entity based on a wide variety of prohibited conduct. For example, the Civil <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Monetary Penalties Law authorizes the imposition of substantial civil money penalties against an entity <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">that engages in activities including&#58; (i) knowingly presenting or causing to be presented, a claim for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">services not provided as claimed or which is otherwise false or fraudulent in any way&#59; (ii) knowingly giving <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or causing to be given false or misleading information reasonably expected to influence the decision to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">discharge a patient&#59; (iii) offering or giving remuneration to any beneficiary of a federal healthcare program <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">likely to influence the receipt of reimbursable items or services&#59; (iv) arranging for reimbursable services <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">with an entity which is excluded from participation from a federal healthcare program&#59; (v) knowingly or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 364pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">willfully soliciting or receiving remuneration for a referral of a federal healthcare program beneficiary&#59; or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(vi) using a payment intended for a federal healthcare program beneficiary for another use.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">There are other federal anti-fraud laws, including the Health Information Portability and Accountability <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Act&#8217;s fraud provisions, that prohibit, among other actions, knowingly and willfully executing, or attempting <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to execute, a scheme to defraud any healthcare benefit program, including private payors, knowingly and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 432pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 444pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 456pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">material fact or making any materially false, fictitious or fraudulent statement in connection with the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 468pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">delivery of or payment for healthcare benefits, items or services.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 488pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Finally, many states and foreign countries have similar healthcare fraud and abuse statutes or regulations <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 500pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">that may be broader in scope and may apply regardless of payor, in addition to items and services <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 512pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reimbursed under Medicaid and other state programs.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 532pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Violations any of these laws or any other governmental regulations that may apply to us may result in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 544pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 556pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">exclusion of devices from government-funded healthcare programs, such as Medicare and Medicaid or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 568pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">comparable foreign programs.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Physician Payment Sunshine Act<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 608pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Transparency laws regarding payments or other transfers of value provided to certain licensed healthcare <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 620pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">professionals and teaching hospitals may also impact our business practices. The federal Physician <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 632pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Payment Sunshine Act requires most medical device manufacturers, including Heartflow, to track and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">report annually to the Secretary of the United States Department of Health and Human Services (&#8220;HHS&#8221;) <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">financial arrangements, payments, and other transfers of value made by that entity to physicians (defined <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 668pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to include doctors, dentists, optometrists, podiatrists, and chiropractors), other healthcare providers (such <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 680pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">as physician assistants and nurse practitioners) and teaching hospitals, as well as ownership and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 692pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">investment interests held by such physicians and their immediate family members. The payment <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 704pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">information is made publicly available in a searchable format on the CMS Open Payments website. <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">135<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Similar laws have been enacted or are under consideration in several states and foreign jurisdictions, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">including states such as Massachusetts and Vermont, and countries like France, which has adopted the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Loi Bertrand, or French Sunshine Act, which became effective in 2013. We will need to dedicate <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">significant resources to establish and maintain systems and processes in order to comply with these <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">regulations. Failure to comply with these federal reporting requirements can result in significant civil <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">monetary penalties. In addition, information reported to HHS, since it is publicly reported, can potentially <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">be used by a whistleblower to bring claims under the civil False Claims Act alleging that certain payments <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 156pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or transfers of value gave rise to kickbacks or false claims.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">The Foreign Corrupt Practices Act<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 196pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The U.S. Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) prohibits any U.S. individual or business from promising, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 208pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">offering, paying, providing or authorizing the provision of money or anything else of value, directly or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">indirectly, to any foreign official, political party candidate or certain other persons (including health care <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">professionals of state-funded hospitals) for the purpose of influencing any act or decision of the foreign <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">entity in order to assist the individual or business in obtaining, retaining or directing business. The FCPA <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">also obligates companies whose securities are listed in the United States to comply with accounting <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">provisions requiring them to maintain books and records that accurately and fairly reflect all transactions <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of the corporation, including international subsidiaries, and to devise and maintain an adequate system of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">internal accounting controls for domestic and international operations. Activities that violate the FCPA, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">even if they occur wholly outside the United States, can result in criminal and civil fines, imprisonment, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">disgorgement, oversight, and debarment from government contracts. In addition, several other domestic <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and international anti-corruption or anti-bribery laws within and outside the United States apply to our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">business.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Privacy, security and breach notification<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 380pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Other federal and state laws and regulations restrict or otherwise impact our business practices. These <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 392pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">laws include, without limitation, data privacy, security and breach notification authorities.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 412pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">HIPAA, as amended by HITECH, requires health plans, certain healthcare providers and healthcare <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 424pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">clearinghouses, referred to as &#8220;Covered Entities,&#8221; to protect the privacy and security of certain types of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 436pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">health information, referred to as protected health information (&#8220;PHI&#8221;). HIPAA also imposes various <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 448pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">requirements on &#8220;Business Associates&#8221; &#8212; entities performing services for, or on behalf of, a Covered <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 460pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Entity that has access to the Covered Entity&#8217;s PHI in connection with providing those services as well as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 472pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">their covered subcontractors. Three key sets of federal regulations implementing HIPAA &#8212; the Privacy, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 484pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Security Breach Notification and Omnibus Rules (collectively, &#8220;HIPAA Rules&#8221;) set forth a number of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 496pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">standards that Covered Entities and Business Associates must meet with respect to protecting the privacy <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 508pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and security of PHI. HIPAA also regulates standardization of data content, codes and formats used in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 520pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">healthcare transactions and standardization of identifiers for health plans and providers.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our customers are Covered Entities under HIPAA, and, in some cases, Heartflow may be considered a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Business Associate to such Covered Entities when they pay Heartflow for certain services that involve the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">sharing of PHI with Heartflow. When Heartflow bills payors directly for the services, Heartflow is acting as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">a Covered Entity. Whether acting as a Business Associate, covered subcontractor, or a Covered Entity, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Heartflow has obligations to comply with HIPAA and the HIPAA Rules, and either contractual obligations <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 600pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to its Covered Entity Customers or statutory and contractual obligations to ensure that any sub-Business <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Associates comply. This requires risk assessments and a wide range of compliance policies, procedures <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and practices to safeguard.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Penalties for violations of HIPAA regulations include civil and criminal penalties. Our failure to comply with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">HIPAA could result in significant criminal and civil penalties and other damages which could adversely <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 668pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">affect our results of operations, financial position or cashflows. We have developed and implemented <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 680pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">processes designed to comply with HIPAA and are continuing to assess the need for additional <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 692pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">safeguards, policies, procedures, and programing and to develop them where necessary. The <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 704pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">requirements under HIPAA may change periodically and could have an effect on our business operations <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">136<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">if compliance becomes substantially more costly than under current requirements. Additionally, a breach <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of unsecured PHI, such as by employee error or an attack by an outsider, could have an adverse effect on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our business in terms of potential penalties and corrective action required, in addition to reputational <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">damage.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition to HIPAA and other federal privacy regulations, there are a number of state laws governing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">privacy, confidentiality and security of health information that apply to our business. Most states also have <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">authorities governing breach notification. New laws governing privacy, security, and breach notification <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">may be adopted in the future as well. We have undertaken measures to comply with health information <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">privacy requirements to which we know we are subject. However, we can provide no assurance that we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">are or will always remain in compliance with diverse and changing privacy, security, and breach <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">notification requirements in all of the jurisdictions in which we do business. Failure to comply with privacy <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">security or breach notification requirements could result in civil or criminal penalties, which could have an <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">adverse effect on our business. Our failure to adequately protect personal or health related information <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">could have an adverse effect on our business. A wide variety of provincial, state, national and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">international laws and regulations apply to the creation, collection, use, retention, protection, disclosure, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">transfer, and other processing of personal data, including protected health information. These data <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 272pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">protection and privacy and security related laws and regulations are evolving and being tested in courts, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 284pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and may result in ever increasing regulatory and public scrutiny and escalating levels of enforcement and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 296pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">sanctions. Our failure to comply with applicable laws and regulations, or to protect such data, could result <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">in enforcement action against us, including fines, imprisonment of company officials and public censure, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 320pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">claims for damages by end customers and other affected individuals, damage to our reputation and loss <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 332pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of goodwill (both in relation to existing end customers and potential end customers), any of which could <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 344pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">have an adverse effect on our operations, financial performance, and business. Evolving and changing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 356pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">definitions of personal data and personal information, within the European Union, the United States and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 368pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">elsewhere, especially relating to classification of IP addresses, machine identification, location data, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 380pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">other information, may limit or inhibit our ability to operate or expand our business. Even the perception of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 392pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">privacy concerns, whether or not valid, may harm our reputation and inhibit adoption of our product by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 404pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">current and future end customers.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 424pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Healthcare reform<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 444pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Current and future U.S. legislative proposals to further reform healthcare or reduce healthcare costs may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 456pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">result in low, or even no, reimbursement for our product, or for the procedures associated with the use of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 468pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our product, or limit coverage of our product. The cost containment measures that payors and providers <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">are instituting and the effect of any healthcare reform initiative implemented in the future could <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 492pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">significantly reduce our revenues from the sale of our product. Alternatively, the shift away from fee-for-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 504pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">service agreements to capitated payment models supports the value of our product, as they are intended <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 516pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to reduce longitudinal resource utilization, which can be cost saving for both payors and providers.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 536pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The ACA was enacted in March 2010. As a U.S.-based company with anticipated sales in the United <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 548pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">States, these healthcare reform laws will materially impact our business. Certain provisions of the ACA <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 560pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">are still set to become effective in future years and the administrative agencies responsible for issuing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 572pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">regulations that implement some aspects of the laws have yet to do so.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 592pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">There have been numerous legal challenges and Congressional actions and amendments to certain <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 604pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">aspects of the ACA. For example, on August 16, 2022, the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) was <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 616pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">signed into law, which, among other things, extends enhanced subsidies for individuals purchasing health <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 628pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 640pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 652pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">maximum out-of-pocket cost and creating a new manufacturer discount program. Further, it is unclear <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 664pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">whether the Trump administration and Republicans in the Congress and the states who oppose these <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 676pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">policies may try once again to repeal the ACA outright or pare back its subsidies and enrollment periods.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 696pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The uncertain fate of the ACA notwithstanding, we expect that the ACA, as well as other healthcare <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 708pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reform measures that may be adopted in the future, particularly in light of the recent changes in the White <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">137<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">House and Congress, may result in more rigorous coverage criteria and in additional downward pressure <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">on the price that we may receive for our products. Any reduction in payments from Medicare or other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">government programs may result in a similar reduction in payments from private payors. The <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">implementation of cost containment measures or other healthcare reforms may prevent us from being <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">able to generate additional revenue or attain profitability.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Employees and human capital resources<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 162.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">As of December 31, 2024, we had 626 full-time employees globally. We believe the success of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 174.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">business will depend, in part, on our ability to attract and retain qualified personnel, in particular highly <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 186.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">skilled technology personnel. Our employees are not subject to a collective bargaining agreement, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 198.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">we believe that we have good relations with our employees.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 218.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our human capital resources objectives include attracting and retaining top talent, investing in our talent <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 230.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">with leadership development and job-related technical training, and increasing diverse representation in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 242.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our employee base through inclusivity initiatives that build on our culture of inclusion and belonging. The <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 254.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">principal purposes of our equity incentive plans are to attract, retain and motivate employees, consultants <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 266.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and directors through the granting of stock-based compensation awards and cash-based performance <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 278.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">bonus awards.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 298.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Facilities<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 320.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our corporate headquarters and research and development facilities are located in Mountain View, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 332.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">California, where we lease approximately 61,500 square feet of office space under a lease agreement <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 344.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">that expires in August 2030. We also lease and occupy approximately 26,402 square feet in Austin, Texas <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 356.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">primarily for additional production personnel under a lease agreement that expires in December 2025. We <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 368.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">do not own any real property. We believe that these facilities are adequate for the foreseeable future.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 388.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Legal proceedings<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 411.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We have become, and we may become in the future, involved in various legal proceedings arising from <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 423.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the normal course of business activities. We are not presently a party to any litigation the outcome of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 435.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">which, we believe, if determined adversely to us, would individually or taken together, materially and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 447.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">adversely affect our business, financial condition, or results of operations. However, we may from time to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 459.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">time be involved in various claims and legal proceedings of a nature we believe are normal and incidental <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 471.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to a business such as ours. These matters may include employment, contract, intellectual property, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 483.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">product liability and other general claims. Regardless of outcome, litigation can have an adverse impact <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 495.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">on us because of defense and settlement costs, diversion of management resources and other factors.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 515.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Corporate information<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 537.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We were incorporated under the laws of the State of Delaware in 2007. On March 1, 2021, we completed <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 549.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">an internal reorganization in which a newly formed parent holding company was put in place. The <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 561.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">previous holders of our common stock and preferred securities became holders of common stock and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 573.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">preferred securities of HeartFlow Holding, Inc. The equity incentive plan, outstanding equity awards, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 585.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">outstanding warrants and certain other equity-related agreements of HeartFlow, Inc. were assumed by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 597.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">HeartFlow Holding, Inc. Our operations and business activities remained at HeartFlow, Inc., and the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 609.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">wholly-owned non-U.S. subsidiaries of HeartFlow, Inc. remained in place. On&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 621.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">consolidated HeartFlow Holding, Inc. into HeartFlow, Inc. and the previous holders of HeartFlow Holding, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 633.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Inc. common stock and preferred securities became holders of our common stock and preferred <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 645.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">securities and the equity incentive plan, outstanding equity awards, outstanding warrants and certain <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 657.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">other equity-related agreements of HeartFlow Holding, Inc. were assumed by us. In connection with this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 669.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">consolidation, we changed our name to Heartflow, Inc. Our principal executive offices are located at 331 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 681.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">E. Evelyn Avenue, Mountain View, California 94041, and our telephone number is (650) 241-1221. Our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 693.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">corporate website address is www.heartflow.com. Information contained on, or accessible through, our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 705.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">website shall not be deemed incorporated into and is not a part of this prospectus or the registration <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">138<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">statement of which it forms a part. We have included our website in this prospectus solely as an inactive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">textual reference.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">139<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_1233" style="position: absolute; top: 72pt;"></div><div style="line-height: 11.64pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Management<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 107.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The following table sets forth information regarding our executive officers and directors, including their <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 119.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">ages as of December 31, 2024&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 139.2pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 189.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 30pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 242.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 12pt;"><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 189.75pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3pt; width: 189.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Name<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 192.75pt; position: absolute; top: 0pt; width: 30pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3pt; width: 30pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 7.45pt; position: absolute; text-decoration: none; white-space: pre;">Age<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 225.75pt; position: absolute; top: 0pt; width: 242.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3pt; width: 242.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Position(s)<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td></tr><tr style="height: 26.25pt;"><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 12pt; width: 189.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 189.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Executive officers and employee <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 14.63pt; width: 189.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 11.63pt; position: absolute; text-decoration: none; white-space: pre;">director<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 38.25pt; width: 189.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 189.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">John C.M. Farquhar<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 91.5pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 91.78999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 91.94pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 92.02pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 92.06pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 92.08pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 192.75pt; position: absolute; top: 38.25pt; width: 30pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 30pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 9.44pt; position: absolute; text-decoration: none; white-space: pre;">52<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 225.75pt; position: absolute; top: 38.25pt; width: 242.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 242.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">President, Chief Executive Officer and Director<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 52.5pt; width: 189.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 189.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Vikram Verghese<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 78.56pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 80.86999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 81.44999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 81.74pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 81.78pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 192.75pt; position: absolute; top: 52.5pt; width: 30pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 30pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 9.44pt; position: absolute; text-decoration: none; white-space: pre;">41<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 225.75pt; position: absolute; top: 52.5pt; width: 242.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 242.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Chief Financial Officer<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 66.75pt; width: 189.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 189.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Tim A. Fonte<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 58.88pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 61.190000000000005pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 61.77pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 61.81pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 192.75pt; position: absolute; top: 66.75pt; width: 30pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 30pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 9.44pt; position: absolute; text-decoration: none; white-space: pre;">42<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 225.75pt; position: absolute; top: 66.75pt; width: 242.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 242.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Chief Technology Officer<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 81pt; width: 189.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 189.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Campbell D.K. Rogers, M.D.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 128.68pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 130.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 131.57pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 131.72pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 131.79999999999998pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 192.75pt; position: absolute; top: 81pt; width: 30pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 30pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 9.44pt; position: absolute; text-decoration: none; white-space: pre;">63<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 225.75pt; position: absolute; top: 81pt; width: 242.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 242.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Chief Medical Officer<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 95.25pt; width: 189.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 189.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Non-employee directors<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 109.5pt; width: 189.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 189.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">William C. Weldon <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 86.83999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 86.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 87.07pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 87.11pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 192.75pt; position: absolute; top: 109.5pt; width: 30pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 30pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 9.44pt; position: absolute; text-decoration: none; white-space: pre;">76<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 225.75pt; position: absolute; top: 109.5pt; width: 242.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 242.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Director and Chair of the Board of Directors<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 123.75pt; width: 189.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 189.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Timothy C. Barabe<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 85.56pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 86.72pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 86.86999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 86.94999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 86.99pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 192.75pt; position: absolute; top: 123.75pt; width: 30pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 30pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 9.44pt; position: absolute; text-decoration: none; white-space: pre;">71<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 225.75pt; position: absolute; top: 123.75pt; width: 242.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 242.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Director<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 138pt; width: 189.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 189.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Julie A. Cullivan<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 73.17pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 75.47999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 76.64pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 76.72pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 76.74pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 76.75pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 192.75pt; position: absolute; top: 138pt; width: 30pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 30pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 9.44pt; position: absolute; text-decoration: none; white-space: pre;">58<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 225.75pt; position: absolute; top: 138pt; width: 242.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 242.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Director<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 152.25pt; width: 189.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 189.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Nicholas Downing, M.D.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 109.27pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 111.58pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 111.72999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 111.81pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 111.85pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 111.86pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 192.75pt; position: absolute; top: 152.25pt; width: 30pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 30pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 9.44pt; position: absolute; text-decoration: none; white-space: pre;">39<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 225.75pt; position: absolute; top: 152.25pt; width: 242.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 242.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Director<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 166.5pt; width: 189.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 189.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Jeffrey C. Lightcap<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 85.75999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 86.92pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 87pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 192.75pt; position: absolute; top: 166.5pt; width: 30pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 30pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 9.44pt; position: absolute; text-decoration: none; white-space: pre;">65<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 225.75pt; position: absolute; top: 166.5pt; width: 242.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 242.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Director<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 180.75pt; width: 189.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 189.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Wayne J. Riley, M.D.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 94.78999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 95.94999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 96.53pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 96.82pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 96.89999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 96.91pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 192.75pt; position: absolute; top: 180.75pt; width: 30pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 30pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 9.44pt; position: absolute; text-decoration: none; white-space: pre;">65<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 225.75pt; position: absolute; top: 180.75pt; width: 242.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 242.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Director<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 195pt; width: 189.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 189.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Lonnie M. Smith<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 74.83pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 75.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 76.57pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 76.86pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 76.89999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 76.91pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 192.75pt; position: absolute; top: 195pt; width: 30pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 30pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 9.44pt; position: absolute; text-decoration: none; white-space: pre;">80<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 225.75pt; position: absolute; top: 195pt; width: 242.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 242.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Director<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 209.25pt; width: 189.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 189.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Casey M. Tansey<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 79.11pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 81.42pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 81.71pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 81.78999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 81.83pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 81.83999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 192.75pt; position: absolute; top: 209.25pt; width: 30pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 30pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 9.44pt; position: absolute; text-decoration: none; white-space: pre;">67<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 225.75pt; position: absolute; top: 209.25pt; width: 242.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 242.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Director<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 223.5pt; width: 189.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 189.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Charles A. Taylor, Jr., Ph.D.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 124.05pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 126.36pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 126.64999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 126.8pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 126.82pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 126.83pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 192.75pt; position: absolute; top: 223.5pt; width: 30pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 30pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 9.44pt; position: absolute; text-decoration: none; white-space: pre;">61<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 225.75pt; position: absolute; top: 223.5pt; width: 242.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 242.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Director<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 5.46pt; position: absolute; top: 384.95pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(1)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Member of our audit committee. <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 401.95pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(2)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Member of our compensation committee. <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 418.95pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(3)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Member of our nominating and corporate governance committee. <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 435.95pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Executive officers and employee director<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 458.35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; white-space: pre;">John C.M. Farquhar<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 165.79000000000002pt; position: absolute; white-space: pre;"> has served as our Chief Executive Officer and as a member of our board of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 470.35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">directors since March 2022, and as our President since January 2022, and he served as our Chief <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 482.35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Operating Officer from July 2021 to March 2022. Prior to joining the Company, from March 2008 to July <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 494.35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2021, Mr. Farquhar held numerous positions of increasing responsibility across the cardiovascular and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 506.35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">diabetes portfolios of Medtronic plc (&#8220;Medtronic&#8221;), a global medical technology company, most recently <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 518.35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">serving as a President and General Manager from June 2018 until July 2021. Prior to that, Mr. Farquhar <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 530.35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">served as a Marketing Manager at General Mills, Inc., a multinational manufacturer and marketer of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 542.35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">branded processed consumer foods, from January 2004 until March 2008. He received a B.A. in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 554.35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Psychology and History from Duke University and an M.B.A. from Northwestern University&#8217;s Kellogg <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 566.35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">School of Management. We believe that Mr. Farquhar&#8217;s extensive experience in the medical sector <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 578.35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">qualifies Mr. Farquhar to serve on our board of directors and his role as our Chief Executive Officer <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 590.35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">provides a vital link between our board of directors and our management team.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 610.35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; white-space: pre;">Vikram Verghese<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 153.09pt; position: absolute; white-space: pre;"> has served as our Chief Financial Officer since June 2023. He joined the Company in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 622.35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">November 2021 as Senior Vice President of Upstream Marketing, Business Development, and Strategy. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 634.35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Prior to that, Mr. Verghese held various positions at Medtronic from 2008 until 2021 in various leadership <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 646.35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">roles spanning global marketing, regulatory and clinical affairs and business development. After <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 658.35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">completing his undergraduate degree in Electrical and Electronic Engineering in India, Mr. Verghese <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 670.35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">received an M.S. in Biomedical Engineering from the University of Southern California and an M.B.A. from <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 682.35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">University of Pennsylvania&#8217;s The Wharton School. He is also a CFA charter holder. <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">140<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; white-space: pre;">Timothy A. Fonte<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 153.57pt; position: absolute; white-space: pre;"> has served as our Chief Technology Officer since November 2023. Mr. Fonte joined <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the Company in 2010 and held various roles spanning product, technology, and commercial leadership <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prior to becoming the Company&#8217;s Chief Technology Officer. Prior to joining the Company, Mr. Fonte led <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">design engineering at Cameron Health, Inc. (acquired by Boston Scientific Corporation), a cardioverter-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">defibrillator medical device company, from 2006 until 2010. Mr. Fonte also co-founded Bespoke, Inc. (d&#47;b&#47;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">a Sculpt), a company developing custom-fit healthcare products, and was a researcher in blood flow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">modeling from medical image data at Stanford University from 2004 through 2005. He received a B.S. in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 156pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Mechanical Engineering from Rensselaer Polytechnic Institute and an M.S. in Mechanical Engineering <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 168pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">from Stanford University. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; white-space: pre;">Campbell D.K. Rogers, M.D.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 203.55pt; position: absolute; white-space: pre;"> has served as our Chief Medical Officer since March 2012. Prior to joining <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the Company, Dr. Rogers was the Chief Scientific Officer and Global Head of Research and Development <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">at Cordis Corporation (&#8220;Cordis&#8221;), a medical device company that was formerly part of the Johnson &#38; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Johnson family of companies, from July 2006 until February 2012, where he was responsible for leading <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">investments and research in cardiovascular devices. Prior to Cordis, Dr. Rogers was an Associate <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Technology from July 1994 until July 2006, and a director of the Cardiac Catheterization and Experimental <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 272pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Cardiovascular Interventional Laboratories at Brigham and Women&#8217;s Hospital in Massachusetts from <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 284pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">October 2000 until June 2006, where he was responsible for clinical care, education and research. Dr. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 296pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Rogers served as a Principal Investigator for numerous interventional cardiology device, diagnostic, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">pharmacology trials, is the author of numerous publications in the area of coronary artery and other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 320pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">cardiovascular diseases, and was the recipient of research grant awards from the National Institute of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 332pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Health and American Heart Association. He received an A.B. in English from Harvard College and an <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 344pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">M.D. from Harvard Medical School.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 364pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Non-employee directors<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 386.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; white-space: pre;">William C. Weldon<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 158.55pt; position: absolute; white-space: pre;"> has served as Chair of our board of directors since June 2017 and as a member of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 398.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our board of directors since September 2014. Mr. Weldon is the former Chairman of the board and Chief <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 410.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Executive Officer of Johnson &#38; Johnson (Nasdaq&#58; JNJ), a global developer and manufacturer of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 422.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">healthcare products, having served in those positions from 2002 until his retirement in 2012. Mr. Weldon <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 434.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">previously served in a variety of senior executive positions during his 41-year career with Johnson &#38; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 446.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Johnson until his appointment as Chairman of the board and Chief Executive Officer. Mr. Weldon <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 458.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">previously served as a director of CVS Health Corporation (NYSE&#58; CVS) until his retirement from that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 470.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">board in May 2023, Exxon Mobil Corporation (NYSE&#58; XOM) until his retirement from that board in May <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 482.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2021, JPMorgan Chase &#38; Co. (NYSE&#58; JPM) until his retirement from that board in May 2019, and The <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 494.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Chubb Corporation until its acquisition by ACE Limited in January 2016. He is a member of various not-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 506.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for-profit organizations and is also a member of the Board of Trustees for Quinnipiac University. Mr. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 518.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Weldon received his B.A. in Biology from Quinnipiac University. We believe that Mr. Weldon&#8217;s knowledge <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 530.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of the healthcare industry and his experience as chief executive officer and chairman of the board at <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 542.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Johnson &#38; Johnson and on the boards of other publicly traded companies, which have exposed him to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 554.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reporting and governance requirements, qualify him to serve on our board of directors.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 574.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; white-space: pre;">Timothy C. Barabe<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 160.26999999999998pt; position: absolute; white-space: pre;"> has served as a member of our board of directors since January 2022. Mr. Barabe <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 586.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">served as the Chief Financial Officer and Executive Vice President at Affymetrix Inc. (acquired by Thermo <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 598.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Fisher Scientific, Inc.), a provider of life science productions and molecular diagnostic products, from <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 610.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2010 until his retirement in June 2013. Prior to that, Mr. Barabe served as Senior Vice President and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 622.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Chief Financial Officer of Human Genome Sciences, Inc., a biopharmaceutical company, from July 2006 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 634.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">until March 2010. From 2004 until 2006, he served as Chief Financial Officer of Regent Medical Limited, a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 646.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">U.K.-based, privately held surgical supply company, and with Novartis AG, a pharmaceutical company, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 658.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">from 1982 until August 2004 in a succession of senior executive positions in finance and general <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 670.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">management, most recently as the Chief Financial Officer of Sandoz GmbH, the generic pharmaceutical <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 682.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">subsidiary of Novartis AG. Prior to that, Mr. Barabe served as the President of the Specialty Lens <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 694.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Business Franchise and Group Vice President and Chief Financial Officer of CIBA Vision Corporation, a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 706.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">contact lenses and lens care product manufacturer, until 2003. Mr. Barabe has served on the board of <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">141<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">directors of Cartesian Therapeutics, Inc. (Nasdaq&#58; RNAC) since 2016 and previously served on the board <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of directors of Veeva Systems Inc. (NYSE&#58; VEEV) from September 2015 until June 2021, ArQule, Inc., <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">from 2001 until January 2020, and Opexa Therapeutics, Inc. from 2014 until 2017. Mr. Barabe also <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">currently serves on the board of directors of Vigilant Biosciences, Inc., a private company. Mr. Barabe <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">received a B.B.A. in General Business, Finance from the University of Massachusetts at Amherst and an <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">M.B.A. from the University of Chicago. We believe that Mr. Barabe&#8217;s extensive finance experience, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">his service on the board of directors of several other publicly traded companies, qualifies Mr. Barabe to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 156pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">serve on our board of directors.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; white-space: pre;">Julie A. Cullivan<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 149.14pt; position: absolute; white-space: pre;"> has served as a member of our board of directors since November 2020. She currently <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">serves as a Special Advisor to Brighton Park Capital, L.P., an investment firm specializing in software, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">information services and technology-enabled services, and previously served as the Chief Technology <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and People Officer at Forescout Technologies Inc. (&#8220;Forescout&#8221;), a network security software company, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">from June 2017 until January 2021. Prior to joining Forescout, Ms. Cullivan served as the Executive Vice <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">President, Business Operations and Chief Information Officer of FireEye, Inc., an enterprise cybersecurity <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">company, from January 2013 until May 2017, and as a Senior Vice President at McAfee Corp., a global <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">computer security software company, from April 2008 until October 2011. Earlier in her career, Ms. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 272pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Cullivan held executive roles at Autodesk, Inc., EMC Corporation, and Oracle Corporation. Ms. Cullivan <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 284pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">has served on the board of directors of Axon Enterprise, Inc. (Nasdaq&#58; AXON) since 2017, Cobalt Labs <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 296pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Inc. (dba Cobalt.io) since 2022 and OPSWAT Inc. since 2021, and previously served on the boards of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Astra Space Inc. (Nasdaq&#58; ASTR), AaDya Security Inc. (dba Judy Security) and SADA, Inc. Ms. Cullivan <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 320pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">received a B.S. in Finance from Santa Clara University. We believe that Ms. Cullivan&#8217;s extensive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 332pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">experience in the technology sector, including her past roles at leading technology, cybersecurity and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 344pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">digital infrastructure companies, qualifies Ms. Cullivan to serve on our board of directors.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 364pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; white-space: pre;">Nicholas Downing, M.D.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 185.2pt; position: absolute; white-space: pre;"> has served as a member of our board of directors since March 2023. Since <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2018, Dr. Downing has worked at Bain Capital, a private investment firm, currently serving as a Managing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 388pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Director on the Bain Capital Life Sciences team. Prior to joining Bain Capital, Dr. Downing was a Resident <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 400pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Physician at the Brigham and Women&#8217;s Hospital in Boston from 2015 until 2018. Dr. Downing is the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 412pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">author of over 40 peer-reviewed scientific articles. Prior to his medical career, Dr. Downing was a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 424pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Consultant at McKinsey and Company, a global management consulting firm, where he worked with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 436pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">clients in the pharmaceutical, hospital and financial services industries. Dr. Downing received an A.B. in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 448pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Chemistry from Harvard College and an M.D. from Yale University School of Medicine. We believe that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 460pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Dr. Downing&#8217;s extensive investment and financial experience, particularly in the medical sector, as well as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 472pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">his medical background qualifies Dr. Downing to serve on our board of directors.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 492pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; white-space: pre;">Jeffrey C. Lightcap<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 161.94pt; position: absolute; white-space: pre;"> has served as a member of our board of directors since December 2011. Since <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 504pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2007, Mr. Lightcap has served as a Senior Managing Director at HealthCor Partners Management, L.P. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 516pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(&#8220;HealthCor Partners&#8221;), a venture capital investment manager focused on late-stage venture and early <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 528pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">commercial stage healthcare companies in the diagnostic, therapeutic and medtech sectors. Since 2019, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Mr. Lightcap has also served as a Senior Managing Director at Healthcare Venture Partners, LLC, a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">venture capital investment manager focused on healthcare companies. From 1997 until 2006, Mr. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Lightcap served as a Senior Managing Director at JLL Partners, a leading middle-market private equity <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">firm. Prior to JLL Partners, from 1993 until 1997, Mr. Lightcap served as a Managing Director in the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">mergers and acquisitions group at Merrill Lynch &#38; Co., Inc. (&#8220;Merrill Lynch&#8221;), a global financial services <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 600pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">company. Prior to joining Merrill Lynch, Mr. Lightcap was a Senior Vice President in the mergers and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">acquisitions group at Kidder, Peabody &#38; Co., a brokerage company, and at Salomon Brothers, a global <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">financial institution. Mr. Lightcap currently serves on the board of directors of Careview Communications, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 636pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Inc. (OTC&#58; CRVW), RTI Surgical Inc. and KellBenx, Inc. Mr. Lightcap also previously served on the board <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 648pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of directors of a number of HealthCor Partners&#8217; portfolio of private companies, including AccessClosure, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Inc., Sadra Medical, Inc., Practice Partners in Healthcare, Inc. and Paradigm Spine, LLC. Mr. Lightcap <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">received a B.E. in Mechanical Engineering from the State University of New York at Stony Brook and an <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 684pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">M.B.A. from the University of Chicago. We believe that Mr. Lightcap&#8217;s extensive experience in the medical <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 696pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">sector, including his service on the boards of directors of multiple healthcare companies, qualifies Mr. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 708pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Lightcap to serve on our board of directors.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">142<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; white-space: pre;">Wayne J. Riley, M.D.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 168.59pt; position: absolute; white-space: pre;"> has served as a member of our board of directors since November 2021. Dr. Riley <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">has served as the President of the State University of New York Downstate Health Sciences University <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">since April 2017, where he is also a Tenured Professor of Internal Medicine and Health Policy and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Management. From 2013 until 2017, Dr. Riley was an Adjunct Professor of Healthcare Management at <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Owen Graduate School of Management, Vanderbilt University and a Clinical Professor of Medicine at <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Vanderbilt University School of Medicine. From 2007 until 2013, Dr. Riley served as President and Chief <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Executive Officer of Meharry Medical College, and from 2003 until 2006, served as Vice President and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 156pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Vice Dean of Health Affairs and Governmental Relations at Baylor College of Medicine. Dr. Riley has <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 168pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">served on the board of directors of Compass Pathways, plc (Nasdaq&#58; CMPS) since 2021 and HCA <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 180pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Healthcare, Inc. (NYSE&#58; HCA) since 2012, where he also serves as the chair of the patient safety and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 192pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">quality committee and as a member of the audit and compliance committee and nominating and corporate <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 204pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">governance committee. Dr. Riley previously served as a director of Vertex Pharmaceuticals Inc. (Nasdaq&#58; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 216pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">VTRX) from 2010 until 2015, Pinnacle Financial Partners, Inc. from 2007 until 2013, and the Federal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 228pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Reserve Bank of Atlanta, Nashville Branch Bank Board from January 2013 to June 2013. He is President <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 240pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Emeritus of the American College of Physicians and an elected member of the National Academy of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 252pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Medicine. Dr. Riley is also a commissioner of the Medicare Payment Advisory Commission, chair of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 264pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Board of Trustees and of The New York Academy of Medicine since 2019. Dr. Riley received a B.A. in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 276pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Anthropology from Yale University, an M.P.H. in Health Systems Management from the Tulane University <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 288pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">School of Public Health and Topical Medicine, an M.D. from the Morehouse School of Medicine, and an <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 300pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">M.B.A. from Rice University&#8217;s Jesse H. Jones Graduate School of Business. We believe that Dr. Riley&#8217;s <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 312pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">experience as a practicing physician and his leadership, executive management and patient care skills at <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 324pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">other leading medical and educational institutions, as well as his prior public company board service, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 336pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">qualify him to serve on our board of directors. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 356pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; white-space: pre;">Lonnie M. Smith<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 149.12pt; position: absolute; white-space: pre;"> has served as a member of our board of directors since September 2011. From 1997 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 368pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">until April 2020, Mr. Smith was the President and Chief Executive Officer and then Chairman of Intuitive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 380pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Surgical, Inc., a developer and manufacturer of surgical robotic products designed to improve clinical <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 392pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">outcomes of patients. From 1978 until 1997, Mr. Smith was Senior Executive Vice President of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 404pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Hillenbrand Industries, a manufacturer and provider of products and services for the health care and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 416pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">funeral services industries. During his tenure at Hillenbrand Industries, he was a member of the executive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 428pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">committee, the office of the president and the board of directors. Mr. Smith has also held positions at The <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 440pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Boston Consulting Group, a management consulting firm, and International Business Machines Corp, a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 452pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">technology and consulting company. Mr. Smith served as chairman of the board of Tandem Diabetes <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 464pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Care, Inc. (Nasdaq&#58; TNDM), from 2013 until 2015. Mr. Smith received a B.S.E.E. from Utah State <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 476pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">University and an M.B.A. from Harvard Business School. We believe that Mr. Smith&#8217;s extensive medical, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 488pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">management and directorship experience in the medical sector qualifies him to serve on our board of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 500pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">directors.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 520pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; white-space: pre;">Casey M. Tansey<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 152.54000000000002pt; position: absolute; white-space: pre;"> has served as a member of our board of directors since August 2010. Since 2005, he <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 532pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">has served as a General Partner of U.S. Venture Partners, a venture capital firm. From 2001 until 2004, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 544pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Mr. Tansey served as the Chief Executive Officer and President of Epicor Medical, a medical device <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 556pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">company. Prior to Epicor Medical, Mr. Tansey was Chief Executive Officer and President of Heartport, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 568pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Inc., a medical device company, which is now part of the Johnson &#38; Johnson family of companies. Prior <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 580pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to that, he was with the cardiovascular division at Baxter Edward, a medical technology company, for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 592pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">nearly ten years, holding various sales and marketing positions. Mr. Tansey currently serves on the board <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 604pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of directors and as a member of the organization and compensation committee of Inspire Medical <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 616pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Systems, Inc. (NYSE&#58; INSP) and previously served on the board of directors of Intersect ENT, Inc. from <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 628pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2006 until 2017. He also serves on the board of directors for a number of U.S. Venture Partners&#8217; portfolio <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 640pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of private companies, including Cagent Vascular LLC, Dstillery, HighLife Medical Inc., Luminopia, Inc., <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 652pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">MicroTransponder Inc., Neochord, Inc., Neuros Medical, Inc., ShiraTronics, Inc. and Shoulder <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 664pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Innovations. Mr. Tansey received a B.S. and an M.B.A. from the Notre Dame De Namur University. We <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 676pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">believe that Mr. Tansey&#8217;s extensive experience as a venture capital investor and as a member of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 688pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">boards of directors of multiple companies in the medical sector qualify him to serve on our board of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 700pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">directors.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">143<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; white-space: pre;">Charles A. Taylor, Ph.D.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 185.23000000000002pt; position: absolute; white-space: pre;"> is one of our founders, and has served as a member of our board of directors <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">since July 2007. He is currently the W.A. &#8220;Tex&#8221; Moncrief, Jr., Chair in Computational Medicine, and a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Professor in the Department of Internal Medicine and the Oden Institute for Computational Engineering <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and Sciences at the University of Texas at Austin. Dr. Taylor served as the Chief Technology Officer from <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">April 2010 to February 2022 and then Chief Scientific Officer of the Company from February 2022 through <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">December 2023. Prior to joining the Company, Dr. Taylor was an Associate Professor in the Department <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of Bioengineering and Surgery at Stanford University from July 1997 until August 2010, where he held <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 156pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">courtesy faculty appointments in the Departments of Mechanical Engineering and Radiology. He received <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 168pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">a B.S. in Mechanical Engineering, M.S. in Mechanical Engineering and M.S. in Mathematics from <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 180pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Rensselaer Polytechnic Institute and a Ph.D. in Mechanical Engineering from Stanford University. Dr. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 192pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Taylor has published over 450 publications in scientific journals and conference papers related to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 204pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">cardiovascular bioengineering and patient-specific modeling of blood flow in the cardiovascular system <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 216pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and is also an inventor on more than 300 issued patents worldwide. In 2024, Dr. Taylor was inducted into <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 228pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the U.S. National Academy of Engineering. We believe that Dr. Taylor&#8217;s extensive knowledge of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 240pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Company as its founder, Chief Technology Officer and Chief Scientific Officer, experience as an inventor <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 252pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and knowledge of our industry qualifies him to serve on our board of directors.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 272pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Family relationships <font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 294.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">There are no family relationships among any of our executive officers or directors.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 314.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Board composition<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 336.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our business and affairs are managed under the direction of our board of directors. Our board of directors <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 348pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">currently consists of ten members&#58; Mr. Barabe, Ms. Cullivan, Dr. Downing, Mr. Farquhar, Mr. Lightcap, Dr. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 359.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Riley, Mr. Smith, Mr. Tansey, Dr. Taylor, and Mr. Weldon. The authorized number of directors may be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 370.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">changed by resolution of our board of directors, subject to the terms of our amended and restated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 381.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">certificate of incorporation. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 400.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Director independence<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 423.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We have applied to have our common stock listed on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; and this offering is contingent upon <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 435.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">obtaining such approval. Under the listing rules of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(&#8220;Listing Rules&#8221;), independent directors <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 447.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">must comprise a majority of a listed company&#8217;s board of directors within a specified period following <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 459.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">completion of this offering. In addition, the Listing Rules require that, subject to specified exceptions, each <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 471.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">member of a listed company&#8217;s audit, compensation, and nominating and corporate governance <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 483.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">committees be independent. Under these rules, a director will only qualify as an &#8220;independent director&#8221; if, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 495.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">in the business judgment of the company&#8217;s board of directors, that person does not have a relationship <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 507.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">that would interfere with the exercise of independent judgment in carrying out the responsibilities of a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 519.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">director. Under the Listing Rules, certain types of relationships generally occurring within the last three <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 531.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">years will automatically disqualify a director as independent, such as if the director is one of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 543.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">employees, is in receipt of direct compensation from us in excess of $120,000 in a twelve-month period, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 555.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or is engaged, directly or indirectly in certain business dealings with us in excess of specified thresholds. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 575.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our board of directors has determined that none of Mr. Barabe, Ms. Cullivan, Dr. Downing, Mr. Lightcap, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 587.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Dr. Riley, Mr. Smith, Mr. Tansey, Dr. Taylor or Mr. Weldon has a relationship that would interfere with the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 599.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">exercise of independent judgment in carrying out the responsibilities of a director, and that each of such <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 611.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">individuals are &#8220;independent directors&#8221; in accordance with the listing rules of the&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(the &#8220;Listing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 623.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Rules&#8221;). In making these determinations, our board of directors reviewed and discussed information <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 635.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">provided by the directors and us with regard to each director&#8217;s business and personal activities and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 647.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">relationships as they may relate to us and our management. Mr. Farquhar is not considered independent <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 659.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">by virtue of his position as our Chief Executive Officer, and Dr. Taylor is not considered independent by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 671.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">virtue of his former employment with us within the last three years.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">144<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 8.73pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Classified board of directors<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 94.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In accordance with our amended and restated certificate of incorporation, which will be effective <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 106.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">immediately prior to the completion of this offering, our board of directors will be divided into three classes <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 118.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">with staggered three-year terms. At each annual general meeting of stockholders, the successors to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 130.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">directors whose terms then expire will be elected to serve from the time of election and qualification until <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 142.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the third annual meeting following election. Our directors will be divided among the three classes as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 154.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">follows&#58;&#160;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 174.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">The Class I directors will be &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, and &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, and their terms will expire at the first <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 186.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">annual meeting of stockholders following the completion of this offering&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 206.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">The Class II directors will be &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, and &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, and their terms will expire at the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 218.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">second annual meeting of stockholders following the completion of this offering&#59; and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 238.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">The Class III directors will be &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, and &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, and their terms will <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 250.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">expire at the third annual meeting of stockholders following the completion of this offering. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 270.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The division of our board of directors into three classes with staggered three-year terms may delay or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 282.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prevent a change of our management or a change in control.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 302.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Leadership structure of the board<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 324.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our corporate governance guidelines to be in place immediately prior to the completion of this offering will <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 336.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">provide our board of directors with flexibility to combine or separate the positions of Chair of the board of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 348.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">directors and Chief Executive Officer and to implement a lead independent director in accordance with its <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">determination regarding which structure would be in the best interests of our company.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 380.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Mr. Weldon currently serves as our Chair of the board of directors and Mr. Farquhar serves as our Chief <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 392.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Executive Officer. Our board of directors has concluded that our current leadership structure is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 404.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">appropriate at this time. However, our board of directors will continue to periodically review our leadership <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 416.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">structure and may make such changes in the future as it deems appropriate.&#160;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 436.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Board committees<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 459.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our board of directors has established an audit committee, a compensation committee, and a nominating <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 471.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and corporate governance committee. Our board of directors may establish other committees to facilitate <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 483.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the management of our business. The composition and functions of each committee are described below. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 495.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Members serve on these committees until their resignation or until otherwise determined by our board of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 507.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">directors. Each committee intends to adopt a written charter that satisfies the applicable rules and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 519.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) and Listing Rules, which we will post <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 531.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">on our website at www.heartflow.com upon the completion of this offering.&#160;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 551.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Audit committee<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 573.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our audit committee oversees our corporate accounting and financial reporting process and the quality <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 585.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and integrity of our financial statements, the qualifications and performance of our independent registered <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 597.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">public accounting firm, our internal audit function and our risk management program. Among other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 609.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">matters, the audit committee&#58; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 629.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">oversees our independent registered public accounting firm, and has sole responsibility for the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 641.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">appointment, compensation, retention and oversight of the work of our independent registered public <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 653.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">accounting firm&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 673.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">evaluates the independent registered public accounting firm&#8217;s qualifications, independence, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 685.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">performance&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">145<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">reviews and approves the scope of the annual audit and pre-approves all audit and non-audit fees <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">and services to be performed by our independent registered public accounting firm&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">reviews with management and our independent registered public accounting firm the results of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">annual audit and the review of our interim financial statements, and reviews our financial statements <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">and our management&#8217;s discussion and analysis of financial condition and results of operations to be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">included in our annual and quarterly reports to be filed with the SEC&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 160pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">oversees our internal audit function&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 180pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">oversees our risk management program and reviews risks related to major financial risk exposures, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 192pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">information security, regulatory compliance, and the steps our management has taken to monitor and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 204pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">control these risks and exposures&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">establishes procedures for the receipt, retention, and treatment of any complaints received by us <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">regarding accounting, internal accounting controls, or auditing matters&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">reviews and approves all related person transactions&#59; and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 276pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">reviews the audit committee charter and the audit committee&#8217;s performance on an annual basis.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 296pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our audit committee consists of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. Our board of directors has determined that all <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">members are independent under the Listing Rules and Rule 10A-3(b)(1) of the Exchange Act. The chair <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 320pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of our audit committee is &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. Our board of directors has determined that&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;are each an <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 332pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">&#8220;audit committee financial expert&#8221; as such term is currently defined in Item 407(d)(5) of Regulation S-K. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 344pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our board of directors has also determined that each member of our audit committee can read and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 356pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">understand fundamental financial statements as required by the Listing Rules. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 376pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Compensation committee&#160;<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 398.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our compensation committee oversees our compensation policies, plans and benefit programs, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 410.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">particularly as they apply to our executive officers. Among other matters, the compensation committee&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 430.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">reviews and approves corporate goals and objectives relevant to compensation of our Chief <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 442.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Executive Officer, evaluates the performance of the Chief Executive Officer in light of those goals and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 454.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">objectives and approves the compensation of Chief Executive Officer based on such evaluations&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 474.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">reviews and approves the compensation of our other executive officers&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 494.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">reviews and makes recommendations to our board of directors regarding non-employee director <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 506.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">compensation&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 526.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">reviews and approves or makes recommendations to our board of directors regarding the issuance of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 538.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">stock options and other equity awards under our performance incentive plans&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 558.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">engages in risk assessments of our compensation programs&#59; and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 578.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">reviews the compensation committee charter and the compensation committee&#8217;s performance on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 590.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">annual basis.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 610.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our compensation committee consists of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. Our board of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 622.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">directors has determined that all members are independent under the Listing Rules and are non-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 634.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">employee directors, as defined by Rule 16b-3 promulgated under the Exchange Act. The chair of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 646.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">compensation committee is&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">146<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 8.73pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Nominating and corporate governance committee&#160;<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 94.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our nominating and corporate governance committee oversees the nomination process for our directors <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 106.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and policies relating to our corporate governance. Among other matters, the nominating and corporate <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 118.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">governance committee&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 138.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">identifies individuals qualified to be members of our board of directors, including candidates <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 150.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">recommended by stockholders, consistent with criteria approved by our board of directors&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 170.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">evaluates and makes recommendations to our board of directors of candidates for membership on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 182.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our board of directors and on each of the board&#8217;s committees&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 202.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">develops and reviews the adequacy of our corporate governance guidelines and code of business <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 214.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">conduct and ethics and recommends and proposed changes to our board of directors&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 234.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">oversees the process of evaluating the performance of our board of directors&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 254.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">oversees management succession planning&#59; and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 274.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">assists our board of directors on corporate governance matters and board of directors performance <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 286.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">matters, including recommendations regarding the size, structure and composition of our board of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 298.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">directors and its committees.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 318.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our nominating and corporate governance committee consists of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. Our board of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 330.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">directors has determined that all members are independent under the Listing Rules. The chair of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 342.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">nominating and corporate governance committee is&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 362.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Compensation committee interlocks and insider participation&#160;<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 384.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">None of the members of our compensation committee (&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;) is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or has been during the past fiscal year one of our employees or has been at any time one of our officers, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and none of such individuals has any relationship requiring disclosure under SEC rules applicable to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">related person transactions. None of our executive officers currently serves, or has served during the last <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 432.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">fiscal year, as a member of the board of directors or compensation committee (or other board committee <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 444.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">performing equivalent functions) of any entity that has one or more executive officers serving as a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 456.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">member of our board of directors or on our compensation committee.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 476.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Code of business conduct and ethics&#160;<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 499.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In connection with this offering, our board of directors intends to adopt a written code of business conduct <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 511.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and ethics that applies to all of our directors, executive officers, and employees, including our principal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 523.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">executive officer, principal financial officer, and principal accounting officer or controller, or persons <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 535.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">performing similar functions. The full text of our code of business conduct and ethics will be posted on our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 547.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">website at www.heartflow.com upon the completion of this offering. The nominating and corporate <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 559.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">governance committee of our board of directors will be responsible for overseeing our code of business <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 571.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">conduct and ethics. We intend to disclose any future amendments to or waivers of our code of business <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 583.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">conduct and ethics applicable to our directors and officers, including our principal executive officer, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 595.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">principal financial officer, principal accounting officer or controller, or persons performing similar functions <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 607.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to the extent required by applicable rules of the SEC or&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, on our website at the address <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 619.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">identified above. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 639.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Limitations on liability and indemnification matters&#160;<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 661.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our amended and restated certificate of incorporation, which will become effective immediately prior to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 673.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the completion of this offering, limit our directors&#8217; and officers&#8217; liability to us and our stockholders for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 685.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">monetary damages for breach of fiduciary duty as a director or officer to the fullest extent permitted under <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">147<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the General Corporation Law of the State of Delaware (the &#8220;DGCL&#8221;). Such provision will not eliminate or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">limit the liability of&#58; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">a director or officer for any breach of the director&#8217;s or officer&#8217;s duty of loyalty to the corporation or its <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">stockholders&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 136pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">a director or officer for any act or omission not in good faith or that involves intentional misconduct or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 148pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">a knowing violation of law&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 168pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">a director for an unlawful payment of dividends or redemption of shares&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">a director or officer for any transaction from which the director or officer derived an improper personal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">benefit&#59; or<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">an officer in any action by or in the right of the corporation. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 240pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">These limitations of liability do not apply to liabilities arising under federal securities laws and do not affect <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 252pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the availability of equitable remedies such as injunctive relief or rescission. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 272pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">As permitted by the DGCL, our amended and restated certificate of incorporation provides that we will, in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 284pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">certain situations, indemnify our directors and officers and may indemnify other employees and other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 296pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">agents, to the fullest extent permitted by law. Any indemnified person is also entitled, subject to certain <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">limitations, to payment of expenses (including attorneys&#8217; fees) in advance of the final disposition of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 320pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">proceeding. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition, we have entered, and intend to continue to enter, into separate indemnification agreements <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">with our directors and officers. These indemnification agreements, among other things, require us to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 364pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">indemnify our directors and officers for certain expenses, including attorneys&#8217; fees, judgments, fines, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">settlement amounts incurred by a director or officer in any action or proceeding arising out of their <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 388pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">services as a director or officer, or any other company or enterprise to which the person provides services <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 400pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">at our request. We also maintain a directors&#8217; and officers&#8217; insurance policy pursuant to which our directors <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 412pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and officers are insured against liability for actions taken in their capacities as directors and officers. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 432pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We believe that these provisions in our amended and restated certificate of incorporation and these <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 444pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">indemnification agreements are necessary to attract and retain qualified persons as directors and officers.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 464pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 476pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">officers, or control persons, in the opinion of the SEC, such indemnification is against public policy, as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 488pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">expressed in the Securities Act and is therefore unenforceable.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">148<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_1258" style="position: absolute; top: 72pt;"></div><div style="line-height: 11.64pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Executive and director compensation<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 107.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">This section discusses the material components of the executive compensation program for our executive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 119.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">officers who are named in the &#8220;Summary Compensation Table&#8221; below. In 2024, our &#8220;named executive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 131.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">officers,&#8221; comprised of our principal executive officer and the two most highly compensated executive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 143.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">officers (other than our principal executive officer) and their positions with the Company, were as follows&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 163.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">John C.M. Farquhar, President and Chief Executive Officer&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 183.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Vikram Verghese, Chief Financial Officer&#59; and<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 203.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Timothy A. Fonte, Chief Technology Officer.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 223.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">As an &#8220;emerging growth company&#8221; as defined in the JOBS Act, we are not required to include a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 235.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Compensation Discussion and Analysis section and have elected to comply with the scaled disclosure <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 247.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">requirements applicable to emerging growth companies. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 267.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">2024 summary compensation table<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 289.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The following <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 133.65pt; position: absolute; text-decoration: none; white-space: pre;">table<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 155.32pt; position: absolute; white-space: pre;"> sets forth information concerning the compensation of our named executive officers <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 301.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for the year ended December 31, 2024&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 321.6pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 142.5pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 60pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 60pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 60pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 41.25pt;"><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 142.5pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 32.25pt; width: 142.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Name and principal position<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 145.5pt; position: absolute; top: 0pt; width: 60pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 22.65pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 33.39pt; position: absolute; text-decoration: none; white-space: pre;">Salary<font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 32.25pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 47.61pt; position: absolute; text-decoration: none; white-space: pre;">($)<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 208.5pt; position: absolute; top: 0pt; width: 60pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 13.05pt; width: 60pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 31.63pt; position: absolute; text-decoration: none; white-space: pre;">Option <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 22.65pt; width: 60pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 29.84pt; position: absolute; text-decoration: none; white-space: pre;">awards<font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 32.25pt; width: 60pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 41.26pt; position: absolute; text-decoration: none; white-space: pre;">($)<font style="display: inline-block; height: 5.82pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 5.2pt; font-style: normal; font-weight: bold; left: 51.019999999999996pt; position: absolute; text-decoration: none; top: -2.037pt; vertical-align: super; white-space: pre;">(1)<font style="display: inline-block; height: 3.7830000000000004pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 271.5pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3.45pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 20.91pt; position: absolute; text-decoration: none; white-space: pre;">Non-equity <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 13.05pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 9.36pt; position: absolute; text-decoration: none; white-space: pre;">incentive plan <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 22.65pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 8.47pt; position: absolute; text-decoration: none; white-space: pre;">compensation <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 32.25pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 46.51pt; position: absolute; text-decoration: none; white-space: pre;">($)<font style="display: inline-block; height: 5.82pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 5.2pt; font-style: normal; font-weight: bold; left: 56.269999999999996pt; position: absolute; text-decoration: none; top: -2.037pt; vertical-align: super; white-space: pre;">(2)<font style="display: inline-block; height: 3.7830000000000004pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 339.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 13.05pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 30.22pt; position: absolute; text-decoration: none; white-space: pre;">All other <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 22.65pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 8.47pt; position: absolute; text-decoration: none; white-space: pre;">compensation <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 32.25pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 46.51pt; position: absolute; text-decoration: none; white-space: pre;">($)<font style="display: inline-block; height: 5.82pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 5.2pt; font-style: normal; font-weight: bold; left: 56.269999999999996pt; position: absolute; text-decoration: none; top: -2.037pt; vertical-align: super; white-space: pre;">(3)<font style="display: inline-block; height: 3.7830000000000004pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 408pt; position: absolute; top: 0pt; width: 60pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 32.25pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 26.31pt; position: absolute; text-decoration: none; white-space: pre;">Total ($)<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 41.25pt; width: 142.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 142.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">John C.M. Farquhar<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 87.03pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 87.61pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 87.64999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 87.67pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 145.5pt; position: absolute; top: 41.25pt; width: 60pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 19.15pt;"></font></font><font style="left: 21.779999999999998pt; position: absolute;">590,480<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 208.5pt; position: absolute; top: 41.25pt; width: 60pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 11.24pt;"></font></font><font style="left: 13.870000000000001pt; position: absolute;">1,030,400<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 271.5pt; position: absolute; top: 41.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 24.4pt;"></font></font><font style="left: 27.029999999999998pt; position: absolute;">654,369<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 339.75pt; position: absolute; top: 41.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 34.96pt;"></font></font><font style="left: 37.59pt; position: absolute;">5,200<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 408pt; position: absolute; top: 41.25pt; width: 60pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 11.24pt;"></font></font><font style="left: 13.870000000000001pt; position: absolute;">2,280,449<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td></tr><tr style="height: 23.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 55.5pt; width: 142.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 1.47pt; width: 142.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: italic; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">President and Chief <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 12.87pt; width: 142.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: italic; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Executive Officer<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 15.75pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 78.75pt; width: 142.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 5.29pt; width: 142.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Vikram Verghese<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 74.75pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 77.06pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 77.64pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 77.78999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 77.86999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 77.91pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 77.92999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 145.5pt; position: absolute; top: 78.75pt; width: 60pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 5.35pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 19.15pt;"></font></font><font style="left: 21.779999999999998pt; position: absolute;">400,548<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 208.5pt; position: absolute; top: 78.75pt; width: 60pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 5.35pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 11.24pt;"></font></font><font style="left: 13.870000000000001pt; position: absolute;">1,067,295<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 271.5pt; position: absolute; top: 78.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 5.35pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 24.4pt;"></font></font><font style="left: 27.029999999999998pt; position: absolute;">222,338<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 339.75pt; position: absolute; top: 78.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 5.35pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 34.96pt;"></font></font><font style="left: 37.59pt; position: absolute;">5,200<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 408pt; position: absolute; top: 78.75pt; width: 60pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 5.35pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 11.24pt;"></font></font><font style="left: 13.870000000000001pt; position: absolute;">1,695,381<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td></tr><tr style="height: 15.75pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 94.5pt; width: 142.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 5.37pt; width: 142.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: italic; font-weight: normal; left: 11.4pt; position: absolute; text-decoration: none; white-space: pre;">Chief Financial Officer<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 15.75pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 110.25pt; width: 142.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 5.29pt; width: 142.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Timothy A. Fonte<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 74.00999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 76.32pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 77.47999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 77.77pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 77.85pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 145.5pt; position: absolute; top: 110.25pt; width: 60pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 5.35pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 19.15pt;"></font></font><font style="left: 21.779999999999998pt; position: absolute;">358,750<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 208.5pt; position: absolute; top: 110.25pt; width: 60pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 5.35pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 19.15pt;"></font></font><font style="left: 21.779999999999998pt; position: absolute;">998,784<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 271.5pt; position: absolute; top: 110.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 5.35pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 24.4pt;"></font></font><font style="left: 27.029999999999998pt; position: absolute;">202,125<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 339.75pt; position: absolute; top: 110.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 5.35pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 34.96pt;"></font></font><font style="left: 37.59pt; position: absolute;">5,200<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 408pt; position: absolute; top: 110.25pt; width: 60pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 5.35pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 11.24pt;"></font></font><font style="left: 13.870000000000001pt; position: absolute;">1,564,859<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td></tr><tr style="height: 15.75pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 126pt; width: 142.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 5.37pt; width: 142.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: italic; font-weight: normal; left: 8.63pt; position: absolute; text-decoration: none; white-space: pre;">Chief Technology Officer<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 5.46pt; position: absolute; top: 471.35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(1)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Amounts reflect the grant date fair value of stock options granted during 2024 computed in accordance with ASC Topic 718, rather than <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 480.35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the amounts paid to or realized by the named individual. See Note&#160;14&#160;of the consolidated financial statements elsewhere included in <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 489.35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">this prospectus for a discussion of valuation assumptions made in determining the grant date fair value and compensation expense of <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 498.35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our stock options.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 515.35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(2)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Amounts represent annual bonuses earned by each named executive officer in 2024 which were paid by us after certification of <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 524.35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">performance achievement in early 2025. See &#8220;2024 Bonuses&#8221; below. <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 541.35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(3)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Amounts disclosed reflect Company contributions to our 401(k) plan.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 558.35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Narrative to the summary compensation table<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 580.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Elements of compensation<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 600.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">2024 salaries<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 620.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In 2024, the named executive officers received an annual base salary to compensate them for services <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 632.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">rendered to the company. The base salary payable to each named executive officer is intended to provide <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">a fixed component of compensation reflecting the executive&#8217;s skill set, experience, role, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">responsibilities.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 676.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">For fiscal year 2024, Mr. Farquhar&#8217;s annual base salary was $594,881&#160;effective as of&#160;March 3, 2024&#160;(and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 688.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">it was $572,000&#160;prior),&#160;Mr. Verghese&#8217;s base salary was $404,250&#160;effective as of&#160;March 3, 2024&#160;(and it <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">149<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">was $385,000&#160;prior) and&#160;Mr. Fonte&#8217;s base salary was $367,500&#160;effective as of&#160;March 3, 2024&#160;(and it was <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">$350,000&#160;prior). <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">2024 bonuses<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 124pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In 2024, Mr. Farquhar, Mr. Verghese and&#160;Mr. Fonte&#160;were eligible to earn annual cash bonuses targeted at <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 136pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">100%, 50% and 50%, respectively, of their annual base salaries. Pursuant to our annual cash bonus <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 148pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">program, each named executive officer was eligible to earn his annual cash bonus based on the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 160pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">attainment of pre-established annual company objectives. These pre-established objectives include <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 172pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">revenue, with a target of $&#160; &#160; million (weighted 40%), gross margin, with a target of&#160; &#160;  % (weighted 20%), <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 184pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">interactive product validation (weighted 20%), asymptomatic strategy (weighted 10%) and patient care <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 196pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(weighted 10%). The actual achieved bonus amount was paid in 2025 based on achievement of such <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 208pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">objectives.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 228pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Equity compensation<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Each of our named executive officers currently holds outstanding stock option awards granted pursuant to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the Company&#8217;s 2009 Equity Incentive Plan. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In connection with this offering, we intend to adopt the 2025 Plan (as defined below) in order to facilitate <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the grant of cash and equity incentives to directors, employees (including our named executive officers) <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and consultants of our company and certain of our subsidiaries (if any) and to enable us to obtain and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">retain the services of these individuals, which is essential to our long-term success. We expect that the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2025 Plan will be effective as of the date immediately preceding the date on which this offering is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">completed. For additional information about the 2025 Plan, please see the section titled &#8220;&#8212;2025 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">performance incentive plan&#8221; below.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Other elements of compensation<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 392pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Retirement plans <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 412pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We maintain a 401(k) retirement savings plan for our employees, including our named executive officers, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 424pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">who satisfy certain eligibility requirements. Our named executive officers are eligible to participate in the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 436pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">401(k) plan on the same terms as other full-time employees. We anticipate that, following the completion <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 448pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of this offering, our named executive officers will continue to participate in this 401(k) plan on the same <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 460pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">terms as other full-time employees. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Employee benefits and perquisites <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 500pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">All of our full-time employees, including our named executive officers, are eligible to participate in our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 512pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">health and welfare plans, including&#58; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 532pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">medical, dental, and vision benefits&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">medical and dependent care flexible spending accounts&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 572pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">short-term and long-term disability insurance&#59; and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 592pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">life insurance.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We believe that the employee benefits described above are necessary and appropriate to provide a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">competitive compensation package to our named executive officers. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">No tax gross-ups<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 664pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We do not make gross-up payments to cover our named executive officers&#8217; personal income taxes that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 676pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">may pertain to any of the compensation or perquisites paid or provided by the Company.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">150<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Outstanding equity awards at fiscal year-end<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 94.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The following <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 133.65pt; position: absolute; text-decoration: none; white-space: pre;">table<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 155.32pt; position: absolute; white-space: pre;"> summarizes the number of shares of common stock underlying outstanding equity <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 106.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">incentive plan awards for each named executive officer as of December 31, 2024&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 126.4pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 126.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 12pt;"><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="2" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 126.75pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 92.25pt; width: 126.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Name <font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="2" colspan="1"><div style="left: 129.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 92.25pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 22.67pt; position: absolute; text-decoration: none; white-space: pre;">Grant date<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="7"><div style="left: 198pt; position: absolute; top: 0pt; width: 270pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3pt; width: 270pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Option awards<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td></tr><tr style="height: 89.25pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 12pt; width: 65.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 22.65pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 22.67pt; position: absolute; text-decoration: none; white-space: pre;">Number of <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 32.25pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 25.33pt; position: absolute; text-decoration: none; white-space: pre;">securities <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 41.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 21.79pt; position: absolute; text-decoration: none; white-space: pre;">underlying <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 51.45pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 16.01pt; position: absolute; text-decoration: none; white-space: pre;">unexercised <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 61.05pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 28.9pt; position: absolute; text-decoration: none; white-space: pre;">options - <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 70.65pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 19.11pt; position: absolute; text-decoration: none; white-space: pre;">exercisable <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 80.25pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 46.51pt; position: absolute; text-decoration: none; white-space: pre;">(#)<font style="display: inline-block; height: 5.82pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 5.2pt; font-style: normal; font-weight: bold; left: 56.269999999999996pt; position: absolute; text-decoration: none; top: -2.037pt; vertical-align: super; white-space: pre;">(1)<font style="display: inline-block; height: 3.7830000000000004pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 12pt; width: 65.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 22.65pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 22.67pt; position: absolute; text-decoration: none; white-space: pre;">Number of <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 32.25pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 25.33pt; position: absolute; text-decoration: none; white-space: pre;">securities <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 41.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 21.79pt; position: absolute; text-decoration: none; white-space: pre;">underlying <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 51.45pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 16.01pt; position: absolute; text-decoration: none; white-space: pre;">unexercised <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 61.05pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 28.9pt; position: absolute; text-decoration: none; white-space: pre;">options -<font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 70.65pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 9.35pt; position: absolute; text-decoration: none; white-space: pre;">unexercisable <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 80.25pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 46.51pt; position: absolute; text-decoration: none; white-space: pre;">(#)<font style="display: inline-block; height: 5.82pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 5.2pt; font-style: normal; font-weight: bold; left: 56.269999999999996pt; position: absolute; text-decoration: none; top: -2.037pt; vertical-align: super; white-space: pre;">(2)<font style="display: inline-block; height: 3.7830000000000004pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 12pt; width: 65.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 61.05pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 36.88pt; position: absolute; text-decoration: none; white-space: pre;">Option <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 70.65pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 9.34pt; position: absolute; text-decoration: none; white-space: pre;">exercise price <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 80.25pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 52.86pt; position: absolute; text-decoration: none; white-space: pre;">($)<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 12pt; width: 65.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 70.65pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 36.88pt; position: absolute; text-decoration: none; white-space: pre;">Option <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 80.25pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 5.81pt; position: absolute; text-decoration: none; white-space: pre;">expiration date<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 101.25pt; width: 126.75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 126.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">John C.M. Farquhar<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 87.03pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 89.33999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 90.5pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 90.53999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 90.56pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 90.57pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 129.75pt; position: absolute; top: 101.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 12.87pt; position: absolute; text-decoration: none; white-space: pre;">8&#47;24&#47;2021<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 55.089999999999996pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(3)<font style="display: inline-block; height: 4.4915pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 101.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 28.31pt; position: absolute; text-decoration: none; white-space: pre;">166,666<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 101.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 33.59pt; position: absolute; text-decoration: none; white-space: pre;">33,334<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 101.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 34.96pt;"></font></font><font style="left: 42.870000000000005pt; position: absolute;">2.85<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 101.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 20.4pt; position: absolute; text-decoration: none; white-space: pre;">8&#47;24&#47;2031<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 129.75pt; position: absolute; top: 115.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 12.87pt; position: absolute; text-decoration: none; white-space: pre;">3&#47;23&#47;2022<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 55.089999999999996pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(3)<font style="display: inline-block; height: 4.4915pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 115.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 28.31pt; position: absolute; text-decoration: none; white-space: pre;">206,250<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 115.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 33.59pt; position: absolute; text-decoration: none; white-space: pre;">93,750<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 115.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 34.96pt;"></font></font><font style="left: 42.870000000000005pt; position: absolute;">2.85<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 115.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 20.4pt; position: absolute; text-decoration: none; white-space: pre;">3&#47;23&#47;2032<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 129.75pt; position: absolute; top: 129.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 20.4pt; position: absolute; text-decoration: none; white-space: pre;">7&#47;10&#47;2023<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 129.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 20.4pt; position: absolute; text-decoration: none; white-space: pre;">1,367,644<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 129.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 20.4pt; position: absolute; text-decoration: none; white-space: pre;">4,482,084<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 129.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 34.96pt;"></font></font><font style="left: 42.870000000000005pt; position: absolute;">0.76<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 129.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 20.4pt; position: absolute; text-decoration: none; white-space: pre;">7&#47;10&#47;2033<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 129.75pt; position: absolute; top: 144pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 15.12pt; position: absolute; text-decoration: none; white-space: pre;">12&#47;26&#47;2024<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 144pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 34.29pt; position: absolute; text-decoration: none; white-space: pre;">11,666<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 144pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 28.31pt; position: absolute; text-decoration: none; white-space: pre;">548,334<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 144pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 34.96pt;"></font></font><font style="left: 42.870000000000005pt; position: absolute;">3.28<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 144pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 15.12pt; position: absolute; text-decoration: none; white-space: pre;">12&#47;26&#47;2034<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 158.25pt; width: 126.75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 126.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Vikram Verghese<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 74.75pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 75.91pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 76.49pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 76.53pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 76.53999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 129.75pt; position: absolute; top: 158.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 12.87pt; position: absolute; text-decoration: none; white-space: pre;">3&#47;23&#47;2022<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 55.089999999999996pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(3)<font style="display: inline-block; height: 4.4915pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 158.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 53.12pt; position: absolute; text-decoration: none; white-space: pre;">&#8212;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 158.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 33.59pt; position: absolute; text-decoration: none; white-space: pre;">22,917<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 158.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 34.96pt;"></font></font><font style="left: 42.870000000000005pt; position: absolute;">2.85<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 158.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 20.4pt; position: absolute; text-decoration: none; white-space: pre;">3&#47;23&#47;2032<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 129.75pt; position: absolute; top: 172.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 20.4pt; position: absolute; text-decoration: none; white-space: pre;">7&#47;10&#47;2023<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 172.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 53.12pt; position: absolute; text-decoration: none; white-space: pre;">&#8212;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 172.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 28.31pt; position: absolute; text-decoration: none; white-space: pre;">226,042<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 172.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 34.96pt;"></font></font><font style="left: 42.870000000000005pt; position: absolute;">0.76<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 172.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 20.4pt; position: absolute; text-decoration: none; white-space: pre;">7&#47;10&#47;2033<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 129.75pt; position: absolute; top: 186.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 15.12pt; position: absolute; text-decoration: none; white-space: pre;">12&#47;24&#47;2023<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 186.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 53.12pt; position: absolute; text-decoration: none; white-space: pre;">&#8212;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 186.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 28.31pt; position: absolute; text-decoration: none; white-space: pre;">325,963<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 186.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 34.96pt;"></font></font><font style="left: 42.870000000000005pt; position: absolute;">0.76<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 186.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 15.12pt; position: absolute; text-decoration: none; white-space: pre;">12&#47;24&#47;2033<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 129.75pt; position: absolute; top: 201pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 15.12pt; position: absolute; text-decoration: none; white-space: pre;">12&#47;26&#47;2024<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 201pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 53.12pt; position: absolute; text-decoration: none; white-space: pre;">&#8212;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 201pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 28.31pt; position: absolute; text-decoration: none; white-space: pre;">576,916<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 201pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 34.96pt;"></font></font><font style="left: 42.870000000000005pt; position: absolute;">3.28<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 201pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 15.12pt; position: absolute; text-decoration: none; white-space: pre;">12&#47;26&#47;2034<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 215.25pt; width: 126.75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 126.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Timothy A. Fonte<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 74.00999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 76.32pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 76.39999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 76.44pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 76.46pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 76.47pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 129.75pt; position: absolute; top: 215.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 21.1pt; position: absolute; text-decoration: none; white-space: pre;">7&#47;11&#47;2017<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 215.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 33.59pt; position: absolute; text-decoration: none; white-space: pre;">15,000<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 215.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 53.12pt; position: absolute; text-decoration: none; white-space: pre;">&#8212;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 215.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 34.96pt;"></font></font><font style="left: 42.870000000000005pt; position: absolute;">2.85<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 215.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 21.1pt; position: absolute; text-decoration: none; white-space: pre;">7&#47;11&#47;2027<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 129.75pt; position: absolute; top: 229.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 20.4pt; position: absolute; text-decoration: none; white-space: pre;">9&#47;20&#47;2019<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 229.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 38.87pt; position: absolute; text-decoration: none; white-space: pre;">5,000<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 229.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 53.12pt; position: absolute; text-decoration: none; white-space: pre;">&#8212;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 229.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 34.96pt;"></font></font><font style="left: 42.870000000000005pt; position: absolute;">2.85<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 229.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 20.4pt; position: absolute; text-decoration: none; white-space: pre;">9&#47;20&#47;2029<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 129.75pt; position: absolute; top: 243.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 20.4pt; position: absolute; text-decoration: none; white-space: pre;">2&#47;28&#47;2020<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 243.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 33.59pt; position: absolute; text-decoration: none; white-space: pre;">20,000<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 243.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 53.12pt; position: absolute; text-decoration: none; white-space: pre;">&#8212;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 243.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 34.96pt;"></font></font><font style="left: 42.870000000000005pt; position: absolute;">2.85<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 243.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 20.4pt; position: absolute; text-decoration: none; white-space: pre;">2&#47;28&#47;2030<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 129.75pt; position: absolute; top: 258pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 20.4pt; position: absolute; text-decoration: none; white-space: pre;">4&#47;22&#47;2020<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 258pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 38.87pt; position: absolute; text-decoration: none; white-space: pre;">3,600<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 258pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 53.12pt; position: absolute; text-decoration: none; white-space: pre;">&#8212;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 258pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 34.96pt;"></font></font><font style="left: 42.870000000000005pt; position: absolute;">2.85<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 258pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 20.4pt; position: absolute; text-decoration: none; white-space: pre;">4&#47;22&#47;2030<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 129.75pt; position: absolute; top: 272.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 25.68pt; position: absolute; text-decoration: none; white-space: pre;">4&#47;2&#47;2021<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 272.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 38.87pt; position: absolute; text-decoration: none; white-space: pre;">9,166<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 272.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 46.78pt; position: absolute; text-decoration: none; white-space: pre;">834<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 272.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 34.96pt;"></font></font><font style="left: 42.870000000000005pt; position: absolute;">2.85<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 272.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 25.68pt; position: absolute; text-decoration: none; white-space: pre;">4&#47;2&#47;2031<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 129.75pt; position: absolute; top: 286.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 20.4pt; position: absolute; text-decoration: none; white-space: pre;">4&#47;12&#47;2021<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 286.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 38.87pt; position: absolute; text-decoration: none; white-space: pre;">4,264<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 286.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 46.78pt; position: absolute; text-decoration: none; white-space: pre;">186<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 286.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 34.96pt;"></font></font><font style="left: 42.870000000000005pt; position: absolute;">2.85<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 286.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 20.4pt; position: absolute; text-decoration: none; white-space: pre;">4&#47;12&#47;2031<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 129.75pt; position: absolute; top: 300.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 20.4pt; position: absolute; text-decoration: none; white-space: pre;">7&#47;10&#47;2023<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 300.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 33.59pt; position: absolute; text-decoration: none; white-space: pre;">46,041<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 300.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 33.59pt; position: absolute; text-decoration: none; white-space: pre;">83,959<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 300.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 34.96pt;"></font></font><font style="left: 42.870000000000005pt; position: absolute;">0.76<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 300.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 20.4pt; position: absolute; text-decoration: none; white-space: pre;">7&#47;10&#47;2033<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 129.75pt; position: absolute; top: 315pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 15.12pt; position: absolute; text-decoration: none; white-space: pre;">12&#47;24&#47;2023<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 315pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 33.59pt; position: absolute; text-decoration: none; white-space: pre;">31,048<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 315pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 28.31pt; position: absolute; text-decoration: none; white-space: pre;">293,974<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 315pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 34.96pt;"></font></font><font style="left: 42.870000000000005pt; position: absolute;">0.76<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 315pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 15.12pt; position: absolute; text-decoration: none; white-space: pre;">12&#47;24&#47;2033<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 129.75pt; position: absolute; top: 329.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 15.12pt; position: absolute; text-decoration: none; white-space: pre;">12&#47;26&#47;2024<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 329.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 53.12pt; position: absolute; text-decoration: none; white-space: pre;">&#8212;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 329.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 28.31pt; position: absolute; text-decoration: none; white-space: pre;">539,883<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 329.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 34.96pt;"></font></font><font style="left: 42.870000000000005pt; position: absolute;">3.28<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 329.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 15.12pt; position: absolute; text-decoration: none; white-space: pre;">12&#47;26&#47;2034<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 5.46pt; position: absolute; top: 477.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(1)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Amounts disclosed in this column reflect the number of options granted to our named executive officers that were subject to time-based <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 486.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">vesting and have vested.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 503.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(2)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Unless otherwise noted, the stock option vests and becomes exercisable as to 1&#47;48th of the total number of shares underlying the stock <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 512.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">option monthly following the vesting commencement date, subject to the applicable named executive officer&#8217;s continued service through <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 521.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the applicable vesting date.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="font-size: 12pt; line-height: 5.46pt; position: absolute; top: 538.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(3)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">The<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 102.92pt; position: absolute; text-decoration: none; white-space: pre;"> stock option vests and becomes exercisable as to 1&#47;4th of the total number of shares underlying the stock option on the first <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 547.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">anniversary of the vesting commencement date and 1&#47;48th monthly thereafter, subject to the applicable named executive officer&#8217;s <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 556.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">continued service through the applicable vesting date.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 573.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Executive compensation arrangements<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 596.3pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In connection with the completion of this offering, we will enter into employment agreements or offer <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 608.3pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">letters with each of our named executive officers setting forth the terms and conditions of such executive&#8217;s <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 620.3pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">employment with us. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 640.3pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">2024 non-employee director compensation table <font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 662.7pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We have paid certain of our non-employee directors, Mr. Weldon, Mr. Barabe, Mr. Riley, Mr. Smith, Mr. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 674.7pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Taylor and Ms. Cullivan, cash fees as set forth in the table below for their service on our board. From time <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 686.7pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to time, we have granted equity awards to certain non-employee directors for their service on our board of <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">151<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">directors during the 2024 fiscal year. We have also reimbursed our directors for expenses associated with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">attending meetings of our board of directors and committees of our board of directors. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">In addition to his service on the board, <font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 243.63pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">Mr. Taylor serves as a consultant to us and was paid a cash fee of </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">$3,178 in consideration of his consulting services.</font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 136pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The following<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 130.88pt; position: absolute; text-decoration: none; white-space: pre;"> table<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 155.32pt; position: absolute; white-space: pre;"> sets forth information regarding the compensation of our non-employee directors for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 148pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the fiscal year ended December 31, 2024&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 168pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 195pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 32.25pt;"><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 195pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 23.25pt; width: 195pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Name <font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 4.05pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 5.8pt; position: absolute; text-decoration: none; white-space: pre;">Fees earned or<font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 13.65pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 16.46pt; position: absolute; text-decoration: none; white-space: pre;">paid in cash <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 23.25pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 52.86pt; position: absolute; text-decoration: none; white-space: pre;">($)<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 13.65pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 7.13pt; position: absolute; text-decoration: none; white-space: pre;">Option awards<font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 23.25pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 46.51pt; position: absolute; text-decoration: none; white-space: pre;">($)<font style="display: inline-block; height: 5.82pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 5.2pt; font-style: normal; font-weight: bold; left: 56.269999999999996pt; position: absolute; text-decoration: none; top: -2.037pt; vertical-align: super; white-space: pre;">(1)<font style="display: inline-block; height: 3.7830000000000004pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 4.05pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 30.22pt; position: absolute; text-decoration: none; white-space: pre;">All other <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 13.65pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 8.47pt; position: absolute; text-decoration: none; white-space: pre;">compensation <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 23.25pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 52.86pt; position: absolute; text-decoration: none; white-space: pre;">($)<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 13.65pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 43.54pt; position: absolute; text-decoration: none; white-space: pre;">Total<font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 23.25pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 52.86pt; position: absolute; text-decoration: none; white-space: pre;">($)<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 32.25pt; width: 195pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 195pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">William C. Weldon <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 82.61999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 83.19999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 83.28pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 83.28999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 32.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 29.68pt;"></font></font><font style="left: 32.31pt; position: absolute;">65,000<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 32.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 49.21pt;"></font></font><font style="left: 51.84pt; position: absolute;">&#8212;<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 32.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 49.21pt;"></font></font><font style="left: 51.84pt; position: absolute;">&#8212;<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 32.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 29.68pt;"></font></font><font style="left: 32.31pt; position: absolute;">65,000<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 46.5pt; width: 195pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 195pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Timothy C. Barabe<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 81.39999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 82.56pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 83.14pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 83.16pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 83.17pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 46.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 29.68pt;"></font></font><font style="left: 32.31pt; position: absolute;">40,000<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 46.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 49.21pt;"></font></font><font style="left: 51.84pt; position: absolute;">&#8212;<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 46.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 49.21pt;"></font></font><font style="left: 51.84pt; position: absolute;">&#8212;<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 46.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 29.68pt;"></font></font><font style="left: 32.31pt; position: absolute;">40,000<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 60.75pt; width: 195pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 195pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Julie A. Cullivan<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 69.64pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 71.94999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 73.11pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 73.39999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 73.44pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 73.46pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 73.47pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 60.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 29.68pt;"></font></font><font style="left: 32.31pt; position: absolute;">40,000<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 60.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 49.21pt;"></font></font><font style="left: 51.84pt; position: absolute;">&#8212;<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 60.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 49.21pt;"></font></font><font style="left: 51.84pt; position: absolute;">&#8212;<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 60.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 29.68pt;"></font></font><font style="left: 32.31pt; position: absolute;">40,000<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 75pt; width: 195pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 195pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Nicholas Downing, M.D.<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 103.92pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 106.22999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 106.52pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 106.67pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 106.75pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 106.75999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 49.21pt;"></font></font><font style="left: 51.84pt; position: absolute;">&#8212;<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 49.21pt;"></font></font><font style="left: 51.84pt; position: absolute;">&#8212;<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 49.21pt;"></font></font><font style="left: 51.84pt; position: absolute;">&#8212;<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 49.21pt;"></font></font><font style="left: 51.84pt; position: absolute;">&#8212;<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 89.25pt; width: 195pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 195pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Jeffrey C. Lightcap<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 81.58pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 82.74pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 83.03pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 83.17999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 83.19pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 89.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 49.21pt;"></font></font><font style="left: 51.84pt; position: absolute;">&#8212;<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 89.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 49.21pt;"></font></font><font style="left: 51.84pt; position: absolute;">&#8212;<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 89.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 49.21pt;"></font></font><font style="left: 51.84pt; position: absolute;">&#8212;<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 89.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 49.21pt;"></font></font><font style="left: 51.84pt; position: absolute;">&#8212;<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 103.5pt; width: 195pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 195pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Wayne J. Riley, M.D.<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 90.17pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 92.47999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 92.56pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 92.58pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 103.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 29.68pt;"></font></font><font style="left: 32.31pt; position: absolute;">40,000<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 103.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 49.21pt;"></font></font><font style="left: 51.84pt; position: absolute;">&#8212;<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 103.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 49.21pt;"></font></font><font style="left: 51.84pt; position: absolute;">&#8212;<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 103.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 29.68pt;"></font></font><font style="left: 32.31pt; position: absolute;">40,000<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 117.75pt; width: 195pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 195pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Lonnie M. Smith<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 71.19999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 73.50999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 73.58999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 73.61pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 73.61999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 117.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 29.68pt;"></font></font><font style="left: 32.31pt; position: absolute;">40,000<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 117.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 49.21pt;"></font></font><font style="left: 51.84pt; position: absolute;">&#8212;<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 117.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 49.21pt;"></font></font><font style="left: 51.84pt; position: absolute;">&#8212;<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 117.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 29.68pt;"></font></font><font style="left: 32.31pt; position: absolute;">40,000<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 132pt; width: 195pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 195pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Casey M. Tansey<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 75.27pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 77.58pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 78.16pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 78.24pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 78.28pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 78.3pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 132pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 49.21pt;"></font></font><font style="left: 51.84pt; position: absolute;">&#8212;<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 132pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 49.21pt;"></font></font><font style="left: 51.84pt; position: absolute;">&#8212;<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 132pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 49.21pt;"></font></font><font style="left: 51.84pt; position: absolute;">&#8212;<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 132pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 49.21pt;"></font></font><font style="left: 51.84pt; position: absolute;">&#8212;<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 146.25pt; width: 195pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 195pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Charles A. Taylor, Jr., Ph.D.<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 117.96pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 120.27pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 120.85pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 120.92999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 120.94999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 120.96pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 146.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 29.68pt;"></font></font><font style="left: 32.31pt; position: absolute;">40,000<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 146.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 49.21pt;"></font></font><font style="left: 51.84pt; position: absolute;">&#8212;<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 146.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 34.96pt;"></font></font><font style="left: 37.59pt; position: absolute;">3,178<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 146.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 29.68pt;"></font></font><font style="left: 32.31pt; position: absolute;">43,178<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 5.46pt; position: absolute; top: 336.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(1)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">The aggregate number of stock option awards (whether exercisable or unexercisable) held as of December 31, 2024, by Mr. Weldon, <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 345.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Mr. Barabe, Ms. Cullivan, Dr. Downing, Mr. Lightcap, Mr. Riley, Mr. Smith, Mr. Tansey and Mr. Taylor was&#160;520,730, 100,730, 87,188, 0, <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 354.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">0,&#160;185,000, 135,000, 0&#160;and 460,301, respectively.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 371.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In connection with the completion of this offering, we intend to approve and implement a compensation <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 383.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">program for our non-employee directors that consists of annual retainer fees and long-term equity <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 395.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">awards.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 415.5pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">2025 performance incentive plan</font><font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 437.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The following summarizes the material terms of our Amended and Restated 2009 Equity Incentive Plan <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 449.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(the &#8220;2009 Plan&#8221;), under which we have previously made periodic grants of equity and equity-based <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 461.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">awards to our named executive officers and other key employees. In addition, we intend to adopt a 2025 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 473.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Performance Incentive Plan (the &#8220;2025 Plan&#8221;) and an employee stock purchase plan (the &#8220;ESPP&#8221;), which <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 485.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">will become effective in connection with the completion of this offering. The terms of the 2025 Plan and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 497.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the ESPP have not yet been finalized.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 517.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Amended and restated 2009 equity incentive plan<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540.3pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The 2009 Plan was adopted by the board of directors of Heartflow, Inc. in 2009 and was amended and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552.3pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">restated effective March 1, 2021 in connection with a reorganization of Heartflow, Inc. in which the 2009 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564.3pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Plan and all outstanding award agreements thereunder were assigned to and assumed by HeartFlow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576.3pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Holding, Inc. As of December 31, 2024, a total of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock were then subject to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588.3pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">outstanding awards granted under the 2009 Plan, and an additional&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock were <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 600.3pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">then available for new award grants under the 2009 Plan. With respect to the stock options then-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612.3pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">outstanding on this date, the weighted-average exercise price of such options was $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624.3pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the weighted-average remaining term of these options was&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;years.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644.3pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Purpose<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 664.3pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The purpose of the 2009 Plan is to attract and retain the best available personnel for positions of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 676.3pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">substantial responsibility, to provide additional incentive to employees, directors and consultants, and to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 688.3pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">promote the success of our business. <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">152<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Administration<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 142.49pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 92pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The 2009 Plan is administered by our board of directors (the &#8220;Board&#8221;) or a committee thereof (the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">&#8220;Administrator&#8221;). The Administrator has the discretion to (i) determine the fair market value of our common <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock, (ii) select the employees, directors and consultants to whom awards may be granted under the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2009 Plan, (iii) determine the number of shares of our common stock to be covered by each award <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">granted under the 2009 Plan, (iv) approve forms of award agreements for use under the 2009 Plan, (v) <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">determine the terms and conditions of any award granted under the 2009 Plan, (vi) institute and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">determine the terms and conditions of an award exchange, (vii) construe and interpret the terms of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2009 Plan and awards granted thereunder, (viii) prescribe, amend and rescind rules and regulations <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">relating to the 2009 Plan, (ix) modify or amend outstanding awards granted under the 2009 Plan, subject <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to certain restrictions set forth in the 2009 Plan, (x) determine procedures for recipients to satisfy <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">withholding tax obligations, (xi) authorize any person to execute on our behalf any instrument required to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">effect the grant of an award previously granted by the Administrator, (xii) allow a recipient to defer the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">receipt of the payment of cash or the delivery of shares that otherwise would be due to such recipient <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">under an award, (xiii) establish additional rules to accommodate the rules or laws of applicable non-U.S. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">jurisdictions and afford recipients who are foreign nationals or are employed outside the United States <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 272pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">favorable treatment under such rules or laws, and (xiv) make all other determinations deemed necessary <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 284pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or advisable for administering the 2009 Plan. All decisions, or actions taken, by the plan administrator or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 296pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">in connection with the administration of the 2009 Plan shall be final, conclusive and binding on all persons <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">having an interest in the 2009 Plan.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Eligibility<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 348pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our employees and consultants, employees and consultants of our parents or subsidiaries (if any), and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">non-employee members of our Board are eligible to receive awards under the 2009 Plan, provided that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">only employees may be granted awards intended as incentive stock options. As of December 31, 2024, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 384pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;of our and our subsidiaries&#8217; officers and employees (including all of our named <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">executive officers), and each of the&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;non-employee members of our Board, were considered eligible <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">under the 2009 Plan. In addition, approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;individual consultants and advisors engaged by us <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and our subsidiaries were then considered eligible under the 2009 Plan.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 440pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Share reserve<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 460pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">As of December 31, 2024, a total of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock had been authorized for issuance <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 472pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">under the 2009 Plan,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares were subject to stock options then-outstanding under the 2009 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 484pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Plan,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares were subject to restricted stock and restricted stock unit awards then-outstanding <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 496pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">under the 2009 Plan, and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares were available for issuance under the 2009 Plan.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 516pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Types of awards <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 536pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The 2009 Plan authorizes the grant of stock options, stock appreciation rights, restricted stock and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 548pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">restricted stock units. Awards granted under the 2009 Plan are generally not transferable by the recipient <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 560pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">other than by will or the laws of descent and distribution and are generally exercisable, during the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 572pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">recipient&#8217;s lifetime, only by the recipient. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 592pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Stock Options<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 152.2pt; position: absolute; text-decoration: none; white-space: pre;">. A stock option is the right to purchase shares of our common stock at a future date at <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 604pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">a specified price per share (the &#8220;exercise price&#8221;). The per share exercise price of an option generally <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 616pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">may not be less than the fair market value of a share of our common stock on the date of grant. The <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 628pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">maximum term of an option is ten years from the date of grant. An option may either be an incentive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 640pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">stock option or a non-qualified stock option. Incentive stock option benefits are taxed differently from <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 652pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">nonqualified stock options, are subject to more restrictive terms, and are limited in amount by the U.S. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 664pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Internal Revenue Code and the 2009 Plan. Incentive stock options may only be granted to our and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 676pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our subsidiaries&#8217; employees.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 696pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Stock Appreciation Rights<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 204.42000000000002pt; position: absolute; text-decoration: none; white-space: pre;">. A stock appreciation right is the right to receive payment of an amount <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 708pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">equal to the excess of the fair market value of share of our common stock on the date of exercise of <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">153<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the stock appreciation right over the base price of the stock appreciation right. The base price will be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">established by the Administrator at the time of grant of the stock appreciation right and generally may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">not be less than the fair market value of a share of our common stock on the date of grant. Stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">appreciation rights may be granted in connection with other awards or independently. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Restricted Stock<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 162.75pt; position: absolute; text-decoration: none; white-space: pre;">. A share of restricted stock is granted subject to vesting, transfer restrictions and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">other restrictions as determined by the Administrator, or is a share issued pursuant to the early <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">exercise of a stock option. Recipients of restricted stock, unlike recipients of stock options and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">restricted stock units, have voting rights and the right to receive dividends, if any, prior to the time <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">restrictions lapse with respect to such shares, however, extraordinary dividends will generally be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">placed in escrow, and will not be released until restrictions are removed or expire.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 208pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Restricted Stock Units<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 188.29000000000002pt; position: absolute; text-decoration: none; white-space: pre;">. A restricted stock unit is a bookkeeping entry representing an amount equal to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the fair market value of a share that is granted subject to vesting, transfer restrictions and other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">restrictions as determined by the Administrator. Unlike restricted stock, shares underlying restricted <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">stock units will not be issued until the restricted stock units have vested, and recipients of restricted <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">stock units generally have no voting or dividend rights prior such conditions being satisfied.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 276pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Adjustments <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 296pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">As is customary in incentive plans of this nature, the share limit, the number and kind of shares available <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">under the 2009 Plan, any outstanding awards as well as the exercise or purchase prices of awards, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 320pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">performance targets under certain types of performance-based awards, are subject to adjustment in the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 332pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">event of certain reorganizations, mergers, combinations, recapitalizations, stock splits, stock dividends, or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 344pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">other similar events that change the number or kind of shares outstanding, and extraordinary dividends or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 356pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">distributions of property to the stockholders.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Assumption and termination of awards<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">If an event occurs that results in a change in control of us or in which we otherwise do not survive (or do <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">not survive as a public company in respect of our common stock), including, without limitation, a merger, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">combination, consolidation, conversion, exchange of securities, or other reorganization, or a sale of all or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 432pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">substantially all of our business, stock or assets, awards then-outstanding under the 2009 Plan will not <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 444pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">automatically become fully vested pursuant to the provisions of the 2009 Plan so long as such awards are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 456pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">assumed or substituted. However, if awards then-outstanding under the 2009 Plan are to be terminated in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 468pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">such circumstances (without being assumed or substituted), such awards would generally become fully <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">vested (with any performance goals applicable to the award being deemed met at the &#8220;target&#8221; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 492pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">performance level and all other terms and conditions met), subject to any exceptions that the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 504pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Administrator may provide for in an applicable award agreement. The Administrator also has the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 516pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">discretion to establish other change in control provisions with respect to awards granted under the 2009 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 528pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Plan. If we are wound up pursuant to a dissolution or liquidation, awards then-outstanding under the 2009 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Plan will terminate immediately prior to such event.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 560pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">No limit on other authority<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 580pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The 2009 Plan does not limit the authority of the Board or any committee thereof to grant awards or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 592pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">authorize any other compensation, with or without reference to our common stock, under any other plan <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 604pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or authority.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Termination of or changes to the 2009 plan<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Board may amend or terminate the 2009 Plan at any time and in any manner. Stockholder approval <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for an amendment will be required only to the extent then required by applicable law or deemed <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 668pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">necessary or advisable by the Board. Unless terminated earlier by the Board, the authority to grant new <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 680pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">awards under the 2009 Plan will terminate on March 21, 2031. Outstanding awards, as well as the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 692pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Administrator&#8217;s authority with respect thereto, generally will continue following the expiration or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 704pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">termination of the 2009 Plan. Generally speaking, outstanding awards may be amended by the <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">154<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Administrator (except for a repricing), but the consent of the award holder is required if the amendment <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(or any plan amendment) impair the rights of the holder.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">155<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_1286" style="position: absolute; top: 72pt;"></div><div style="line-height: 11.64pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Certain relationships and related-party transactions<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 107.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The following includes a summary of transactions since January 1, 2022 and any currently proposed <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 119.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">transactions to which we were or are expected to be a participant in which (i) the amount involved <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 131.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">exceeded or will exceed $120,000, and (ii) any of our directors, executive officers, or holders of more than <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 143.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">5% of our capital stock, or any affiliate or member of the immediate family of the foregoing persons, had <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 155.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or will have a direct or indirect material interest, other than compensation and other arrangements that are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 167.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">described under the section titled &#8220;Executive and director compensation.&#8221;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 187.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">2025 convertible promissory notes financing<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 209.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In January 2025, we entered into a note purchase agreement with various investors, pursuant to which <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 221.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">we issued an aggregate of $48,356,153.27&#160;in principal amount of subordinated convertible promissory <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 233.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">notes (the &#8220;2025 Convertible Notes&#8221;) to investors, including related parties, with original maturity dates of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 245.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">48 months from the initial issuance of the notes. The first closing occurred on January 24, 2025, at which <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 257.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">time we issued $44,656,153.27 in principal amount of the 2025 Convertible Notes. The second closing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 269.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">occurred on January 31, 2025, at which time we issued $3,700,000.00 in principal amount of the 2025 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 281.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Convertible Notes. The aggregate principal amount outstanding under the 2025 Convertible Notes will be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 293.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">automatically converted upon the effectiveness of this offering into shares of our common stock without <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 305.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">interest.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 325.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The following related parties, or their respective affiliates, participated in the 2025 Convertible Notes <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 337.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">offering&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 107.92pt; position: absolute; top: -2.548pt; vertical-align: super; white-space: pre;"> <font style="display: inline-block; height: 4.732pt;"></font></font></div><div style="position: absolute; top: 357.6pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 384.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 80.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 21.75pt;"><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 384.75pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 12.75pt; width: 384.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Name<font style="display: inline-block; height: 5.82pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 5.2pt; font-style: normal; font-weight: bold; left: 24.39pt; position: absolute; text-decoration: none; top: -2.037pt; vertical-align: super; white-space: pre;">(1)<font style="display: inline-block; height: 3.7830000000000004pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 0pt; width: 80.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3.15pt; width: 80.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 38.12pt; position: absolute; text-decoration: none; white-space: pre;">Aggregate <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 12.75pt; width: 80.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 8.82pt; position: absolute; text-decoration: none; white-space: pre;">purchase price ($)<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 21.75pt; width: 384.75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 384.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Hayfin HeartFlow UK Limited<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 124.47999999999999pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(2)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 132.01pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 134.32pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 134.9pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 135.19pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 135.26999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 135.29pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 135.29999999999998pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 21.75pt; width: 80.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 80.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 7.74pt;"></font></font><font style="left: 15.649999999999999pt; position: absolute;">23,000,000.00<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 36pt; width: 384.75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 384.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">BCLS Fund III Investments, LP<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 132.89pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(3)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 140.42pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 142.73pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 143.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 144.47pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 144.62pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 144.66pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 144.68pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 36pt; width: 80.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 80.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 13.02pt;"></font></font><font style="left: 20.93pt; position: absolute;">6,595,648.51<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 50.25pt; width: 384.75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 384.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Capricorn Entities<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 77.53999999999999pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(4)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 85.07pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 87.38pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 87.67pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 87.82pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 87.89999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 87.94pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 87.94999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 50.25pt; width: 80.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 80.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 13.02pt;"></font></font><font style="left: 20.93pt; position: absolute;">2,078,516.75<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 64.5pt; width: 384.75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 384.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Timothy C. Barabe<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 81.39999999999999pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(5)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 88.92999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 91.24pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 92.39999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 92.55pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 92.58999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 92.6pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 64.5pt; width: 80.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 80.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 13.02pt;"></font></font><font style="left: 20.93pt; position: absolute;">2,000,000.00<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 78.75pt; width: 384.75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 384.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Lonnie M. Smith<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 71.19999999999999pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(6)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 78.72999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 78.75pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 78.75999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 78.75pt; width: 80.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 80.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 13.02pt;"></font></font><font style="left: 20.93pt; position: absolute;">1,822,713.44<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 93pt; width: 384.75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 384.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">HCPCIV 1, LLC<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 69.08999999999999pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(7)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 76.61999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 77.78pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 78.36pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 78.50999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 78.55pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 78.57pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 93pt; width: 80.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 80.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 13.02pt;"></font></font><font style="left: 20.93pt; position: absolute;">1,460,234.00<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 107.25pt; width: 384.75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 384.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">U.S. Venture Partners Funds<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 123.94999999999999pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(8)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 131.48pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 133.79pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 134.95pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 135.24pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 107.25pt; width: 80.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 80.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 20.93pt;"></font></font><font style="left: 28.84pt; position: absolute;">811,558.22<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 121.5pt; width: 384.75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 384.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Casey M. Tansey<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 75.27pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(9)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 82.8pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 83.38pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 83.42pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 83.44pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 121.5pt; width: 80.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 80.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 20.93pt;"></font></font><font style="left: 28.84pt; position: absolute;">250,000.00<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 135.75pt; width: 384.75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 384.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Vikram Verghese<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 74.75pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(10)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 85.71pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 86.86999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 87.44999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 87.74pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 87.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 87.97pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 88.00999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 88.02pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 135.75pt; width: 80.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 80.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 20.93pt;"></font></font><font style="left: 28.84pt; position: absolute;">144,650.88<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 5.46pt; position: absolute; top: 515.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(1)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">For additional information regarding these stockholders and their equity holdings, see the section titled &#8220;Principal stockholders.&#8221; <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 532.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(2)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Hayfin HeartFlow UK Limited and entities affiliated with Hayfin HeartFlow UK Limited own more than 5% of our outstanding capital.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 549.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(3)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">BCLS Fund III Investments, LP owns more than 5% of our outstanding capital. Mr. Nicholas Downing, M.D. is a member of our board of <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 558.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">directors and is a managing director of Bain Capital Life Sciences.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 575.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(4)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Consists of $1,929,687.95 in principal amount of the 2025 Convertible Notes purchased by Capricorn Healthcare Special Opportunities <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 584.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">II, L.P., $57,996.00 in principal amount of the 2025 Convertible Notes purchased by The Skoll Foundation, $52,169.37 in principal <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 593.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">amount of the 2025 Convertible Notes purchased by Capricorn Healthcare Special Opportunities II-A, L.P., and $38,663.43 in principal <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 602.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">amount of the 2025 Convertible Notes purchased by The Skoll Fund. Capricorn Entities own more than 5% of our outstanding capital.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 619.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(5)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Mr. Timothy C. Barabe is a member of our board of directors.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 636.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(6)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Mr. Lonnie M. Smith and entities affiliated with Mr. Smith own more than 5% of our outstanding capital. Mr. Smith is a member of our <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 645.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">board of directors.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 662.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(7)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">HCPCIV 1, LLC and entities affiliated with HCPCIV 1, LLC own more than 5% of our outstanding capital. Mr. Jeffrey C. Lightcap is a <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 671.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">member of our board of directors and is a controlling member of HCPCIV 1, LLC.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 688.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(8)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Consists of $786,399.92 in principal amount of the 2025 Convertible Notes purchased by U.S. Venture Partners X, L.P. and $25,158.30 <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 697.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">in principal amount of the 2025 Convertible Notes purchased by USVP X Affiliates, L.P. U.S. Venture Partners Funds own more than 5% <font style="display: inline-block; height: 5.46pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">156<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 5.46pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">of our outstanding capital. Mr. Casey M. Tansey is a member of our board of directors and is a controlling member of U.S. Venture <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 81pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Partners Funds.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 98pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(9)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Mr. Casey M. Tansey is a member of our board of directors.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 115pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(10)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Mr. Vikram Verghese is our Chief Financial Officer.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Amendment No. 1 to 2024 Credit Agreement and related matters<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 154.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">On January 24, 2025, in connection with the issuance of the 2025 Convertible Notes, we entered into <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 166.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Amendment No. 1 to the 2024 Credit Agreement, pursuant to which our lender, Hayfin, converted $23.0 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 178.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">million of outstanding indebtedness under the 2024 Term Loan to 2025 Convertible Notes (the &#8220;2024 Term <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 190.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Loan Conversion&#8221;) under the same terms as the other purchasers of the 2025 Convertible Notes, as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 202.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">described above. As a result, Hayfin became a holder of 5% or more of our capital stock. For more <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 214.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">information about the 2024 Credit Agreement, as amended, see &#8220;Management&#8217;s discussion and analysis <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 226.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of financial condition and results of operations&#8212;Liquidity and capital resources&#8212;Hayfin credit agreement&#8221; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 238.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and Note 18 to our consolidated financial statements included elsewhere in this prospectus. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 258.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In connection with the prior credit agreement with Hayfin that was refinanced by the 2024 Credit <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 270.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Agreement, we issued warrants to purchase an aggregate of 541,389 shares of common stock to Hayfin. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 282.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">As a result of the Series F redeemable convertible preferred stock financing referred to below, the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 294.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">antidilution adjustments of these warrants resulted in the issuance to Hayfin in March 2023 of additional <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 306.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">warrants to purchase an aggregate of 4,269,801 shares of our common stock. The warrants have an <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 318.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">exercise price of $0.01 per share of common stock. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 338.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Series F and Series F-1 redeemable convertible preferred stock financing<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In March 2023, we entered into a Series F and Series F-1 redeemable convertible preferred stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">purchase agreement with various investors, pursuant to which we issued an aggregate of 61,344,029 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 384.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">shares of Series F redeemable convertible preferred stock at a cash purchase price of $2.8505 per share <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for gross proceeds of $174.9 million in multiple closings and 21,465,064 shares of Series&#160;F-1 redeemable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">convertible preferred stock at a purchase price of $1.9098 per share for gross proceeds of $41.0 million <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(the &#8220;Series F and Series F-1 redeemable convertible preferred stock financing&#8221;). The Series F-1 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 432.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">redeemable convertible preferred stock was issued upon conversion of the indebtedness under <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 444.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">outstanding subordinated convertible promissory notes issued by the Company from September 30, 2022 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 456.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to December 16, 2022, in the aggregate principal amount of $40.0 million.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 476.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The table below sets forth the number of shares of our Series F and Series F-1 redeemable convertible <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 488.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">preferred stock purchased by our executive officers, directors, holders of more than 5% of our capital <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 500.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock at the time of the transaction, and their affiliated entities or immediate family members. Each share <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">157<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of Series F and Series F-1 redeemable convertible preferred stock in the table below will convert into one <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">share of our common stock upon the effectiveness of this offering.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 104pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 248.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 80.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 50.25pt;"><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 248.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 41.25pt; width: 248.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Name<font style="display: inline-block; height: 5.82pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 5.2pt; font-style: normal; font-weight: bold; left: 24.39pt; position: absolute; text-decoration: none; top: -2.037pt; vertical-align: super; white-space: pre;">(1)<font style="display: inline-block; height: 3.7830000000000004pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 251.25pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 2.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 31.54pt; position: absolute; text-decoration: none; white-space: pre;">Series F <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 12.45pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 18.22pt; position: absolute; text-decoration: none; white-space: pre;">redeemable <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 22.05pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 20.01pt; position: absolute; text-decoration: none; white-space: pre;">convertible <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 31.65pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 4.47pt; position: absolute; text-decoration: none; white-space: pre;">preferred stock <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 41.25pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 52.86pt; position: absolute; text-decoration: none; white-space: pre;">(#)<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 319.5pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 2.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 24.44pt; position: absolute; text-decoration: none; white-space: pre;">Series F-1 <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 12.45pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 18.22pt; position: absolute; text-decoration: none; white-space: pre;">redeemable <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 22.05pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 20.01pt; position: absolute; text-decoration: none; white-space: pre;">convertible <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 31.65pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 4.47pt; position: absolute; text-decoration: none; white-space: pre;">preferred stock <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 41.25pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 52.86pt; position: absolute; text-decoration: none; white-space: pre;">(#)<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 0pt; width: 80.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 22.05pt; width: 80.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 38.12pt; position: absolute; text-decoration: none; white-space: pre;">Aggregate <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 31.65pt; width: 80.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 20.8pt; position: absolute; text-decoration: none; white-space: pre;">purchase price <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 41.25pt; width: 80.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 61.51pt; position: absolute; text-decoration: none; white-space: pre;">($)<font style="display: inline-block; height: 5.82pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 5.2pt; font-style: normal; font-weight: bold; left: 71.27pt; position: absolute; text-decoration: none; top: -2.037pt; vertical-align: super; white-space: pre;">(2)<font style="display: inline-block; height: 3.7830000000000004pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 50.25pt; width: 248.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 248.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">BCLS Fund III Investments, LP<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 132.89pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(3)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 140.42pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 141pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 141.15pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 141.23pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 141.26999999999998pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 251.25pt; position: absolute; top: 50.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 11.21pt;"></font></font><font style="left: 13.84pt; position: absolute;">35,081,564<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 319.5pt; position: absolute; top: 50.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 49.21pt;"></font></font><font style="left: 51.84pt; position: absolute;">&#8212;<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 50.25pt; width: 80.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 80.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 7.74pt;"></font></font><font style="left: 15.649999999999999pt; position: absolute;">99,999,998.18<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 64.5pt; width: 248.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 248.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">The Lonnie and Cheryl Smith Family Trust<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 179.88pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(4)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 187.41pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 188.57pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 188.60999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 188.62pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 251.25pt; position: absolute; top: 64.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 49.21pt;"></font></font><font style="left: 51.84pt; position: absolute;">&#8212;<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 319.5pt; position: absolute; top: 64.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 16.49pt;"></font></font><font style="left: 19.119999999999997pt; position: absolute;">8,068,125<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 64.5pt; width: 80.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 80.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 7.74pt;"></font></font><font style="left: 15.649999999999999pt; position: absolute;">15,408,505.15<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 78.75pt; width: 248.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 248.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Hayfin HeartFlow UK Limited<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 124.47999999999999pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(5)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 132.01pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 134.32pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 135.48pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 136.06pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 136.14pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 136.16pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 136.17pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 251.25pt; position: absolute; top: 78.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 16.49pt;"></font></font><font style="left: 19.119999999999997pt; position: absolute;">3,508,156<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 319.5pt; position: absolute; top: 78.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 16.49pt;"></font></font><font style="left: 19.119999999999997pt; position: absolute;">2,689,375<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 78.75pt; width: 80.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 80.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 7.74pt;"></font></font><font style="left: 15.649999999999999pt; position: absolute;">15,136,167.06<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 93pt; width: 248.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 248.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">HCPCIV 1, LLC<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 69.08999999999999pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(6)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 76.61999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 78.92999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 79.22pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 79.36999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 79.41pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 79.42999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 251.25pt; position: absolute; top: 93pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 16.49pt;"></font></font><font style="left: 19.119999999999997pt; position: absolute;">3,905,025<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 319.5pt; position: absolute; top: 93pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 16.49pt;"></font></font><font style="left: 19.119999999999997pt; position: absolute;">1,321,383<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 93pt; width: 80.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 80.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 7.74pt;"></font></font><font style="left: 15.649999999999999pt; position: absolute;">13,654,851.50<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 107.25pt; width: 248.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 248.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Wellington Investors<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 87.92pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(7)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 95.44999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 97.75999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 98.33999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 98.36pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 98.36999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 251.25pt; position: absolute; top: 107.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 16.49pt;"></font></font><font style="left: 19.119999999999997pt; position: absolute;">4,169,444<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 319.5pt; position: absolute; top: 107.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 49.21pt;"></font></font><font style="left: 51.84pt; position: absolute;">&#8212;<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 107.25pt; width: 80.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 80.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 7.74pt;"></font></font><font style="left: 15.649999999999999pt; position: absolute;">11,885,000.12<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 121.5pt; width: 248.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 248.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">U.S. Venture Partners Funds<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 123.94999999999999pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(8)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 131.48pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 131.76999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 131.81pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 131.82999999999998pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 251.25pt; position: absolute; top: 121.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 16.49pt;"></font></font><font style="left: 19.119999999999997pt; position: absolute;">3,508,156<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 319.5pt; position: absolute; top: 121.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 49.21pt;"></font></font><font style="left: 51.84pt; position: absolute;">&#8212;<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 121.5pt; width: 80.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 80.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 13.02pt;"></font></font><font style="left: 20.93pt; position: absolute;">9,999,998.68<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 135.75pt; width: 248.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 248.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Capricorn Entities<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 77.53999999999999pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(9)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 85.07pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 87.38pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 88.53999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 88.69pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 88.77pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 88.81pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 88.82pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 251.25pt; position: absolute; top: 135.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 16.49pt;"></font></font><font style="left: 19.119999999999997pt; position: absolute;">3,013,904<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 319.5pt; position: absolute; top: 135.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 49.21pt;"></font></font><font style="left: 51.84pt; position: absolute;">&#8212;<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 135.75pt; width: 80.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 80.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 13.02pt;"></font></font><font style="left: 20.93pt; position: absolute;">8,591,133.35<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 150pt; width: 248.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 248.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">The Schiehallion Fund Limited<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 130.32pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(10)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 141.28pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 141.32pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 141.34pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 251.25pt; position: absolute; top: 150pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 16.49pt;"></font></font><font style="left: 19.119999999999997pt; position: absolute;">2,490,791<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 319.5pt; position: absolute; top: 150pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 49.21pt;"></font></font><font style="left: 51.84pt; position: absolute;">&#8212;<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 150pt; width: 80.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 80.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 13.02pt;"></font></font><font style="left: 20.93pt; position: absolute;">7,099,999.75<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 164.25pt; width: 248.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 248.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">William C. Weldon<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 79.99pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(11)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 90.5pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 92.81pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 93.39pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 93.53999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 93.61999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 251.25pt; position: absolute; top: 164.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 29.68pt;"></font></font><font style="left: 32.31pt; position: absolute;">73,469<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 319.5pt; position: absolute; top: 164.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 6.91pt; width: 29.68pt;"></font></font><font style="left: 32.31pt; position: absolute;">80,898<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 164.25pt; width: 80.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 80.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 20.93pt;"></font></font><font style="left: 28.84pt; position: absolute;">363,922.46<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 5.46pt; position: absolute; top: 290.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(1)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">For additional information regarding these stockholders and their equity holdings, see the section titled &#8220;Principal stockholders.&#8221;<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 307.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(2)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">The consideration for the Series F-1 redeemable convertible preferred stock was funded through the conversion of outstanding <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 316.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">subordinated convertible promissory notes.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 333.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(3)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">BCLS Fund III Investments, LP owns more than 5% of our outstanding capital. Mr. Nicholas Downing, M.D. is a member of our board of <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 342.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">directors and is a managing director of Bain Capital Life Sciences.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 359.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(4)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Mr. Lonnie M. Smith and entities affiliated with Mr. Smith own more than 5% of our outstanding capital. Mr. Smith is a member of our <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 368.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">board of directors.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 385.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(5)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Hayfin HeartFlow UK Limited and entities affiliated with Hayfin HeartFlow UK Limited own more than 5% of our outstanding capital.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 402.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(6)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">HCPCIV 1, LLC and entities affiliated with HCPCIV 1, LLC own more than 5% of our outstanding capital. Mr. Jeffrey C. Lightcap is a <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 411.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">member of our board of directors and is a controlling member of HCPCIV 1, LLC.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 428.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(7)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Consists of 3,176,720 shares of Series F redeemable convertible preferred stock held by Hadley Harbor Master Investors (Cayman) II <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 437.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">LP and 992,724 shares of Series F redeemable convertible preferred stock held by Texas Hidalgo CoInvestment Fund, L.P. Wellington <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 446.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Investors own more than 5% of our outstanding capital.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 463.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(8)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Consists of 3,399,403 shares of Series F redeemable convertible preferred stock held by U.S. Venture Partners X, L.P. and 108,753 <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 472.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">shares of Series F redeemable convertible preferred stock held by USVP X Affiliates, L.P. U.S. Venture Partners Funds own more than <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 481.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">5% of our outstanding capital.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 498.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(9)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Consists of 1,402,222 shares of Series F redeemable convertible preferred stock held by Capricorn Healthcare Special Opportunities II, <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 507.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">L.P., 37,909 shares of Series F redeemable convertible preferred stock held by Capricorn Healthcare Special Opportunities II-A, L.P., <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 516.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">12,729 shares of Series F redeemable convertible preferred stock held by Carthage, LP, 1,142,851 shares of Series F redeemable <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 525.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">convertible preferred stock held by Pacific Sequoia Holdings, LLC, 223,661 shares of Series F redeemable convertible preferred stock <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 534.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">held by The Skoll Foundation, and 194,532 shares of Series F redeemable convertible preferred stock held by The Skoll Fund. <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 543.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Capricorn Entities own more than 5% of our outstanding capital.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 560.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(10)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">The Schiehallion Fund Limited and Baillie Gifford Funds affiliated with The Schiehallion Fund Limited own more than 5% of our <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 569.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">outstanding capital.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 586.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(11)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Mr. William C. Weldon is a member of our board of directors<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 603.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">2022 convertible promissory notes financing <font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 625.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In September 2022, we entered into a note purchase agreement with various investors, pursuant to which <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 637.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">we issued an aggregate of $40.0 million in principal amount of subordinated convertible promissory notes <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 649.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(the &#8220;2022 Convertible Notes&#8221;) to investors with original maturity dates of 48 months from the dates of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 661.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">issuance. The 2022 Convertible Notes automatically converted into shares of Series F-1 convertible <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 673.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">preferred stock on March 2, 2023. For more information, see the subsection titled &#8220;&#8212;Series F and Series <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 685.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">F-1 redeemable convertible preferred stock financing.&#8221;<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">158<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The following related parties, or their respective affiliates, participated in the 2022 Convertible Notes <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">offering&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 107.92pt; position: absolute; top: -2.548pt; vertical-align: super; white-space: pre;"> <font style="display: inline-block; height: 4.732pt;"></font></font></div><div style="position: absolute; top: 104pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 390pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 75pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 21.75pt;"><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 390pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 12.75pt; width: 390pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Name<font style="display: inline-block; height: 5.82pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 5.2pt; font-style: normal; font-weight: bold; left: 24.39pt; position: absolute; text-decoration: none; top: -2.037pt; vertical-align: super; white-space: pre;">(1)<font style="display: inline-block; height: 3.7830000000000004pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 393pt; position: absolute; top: 0pt; width: 75pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3.15pt; width: 75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 32.87pt; position: absolute; text-decoration: none; white-space: pre;">Aggregate <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 12.75pt; width: 75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 3.57pt; position: absolute; text-decoration: none; white-space: pre;">purchase price ($)<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 21.75pt; width: 390pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 390pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">The Lonnie and Cheryl Smith Family Trust<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 179.88pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(2)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 187.41pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 187.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 188.14pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 188.22pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 393pt; position: absolute; top: 21.75pt; width: 75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 2.49pt;"></font></font><font style="left: 10.399999999999999pt; position: absolute;">15,000,000.00<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 36pt; width: 390pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 390pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Hayfin HeartFlow UK Limited<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 124.47999999999999pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(3)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 132.01pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 134.32pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 135.48pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 135.63pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 135.71pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 135.75pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 135.76999999999998pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 393pt; position: absolute; top: 36pt; width: 75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 7.77pt;"></font></font><font style="left: 15.68pt; position: absolute;">5,000,000.00<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 50.25pt; width: 390pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 390pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">HCPCIV 1, LLC<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 69.08999999999999pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(4)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 76.61999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 78.92999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 79.00999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 79.02pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 393pt; position: absolute; top: 50.25pt; width: 75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 7.77pt;"></font></font><font style="left: 15.68pt; position: absolute;">2,458,284.00<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 64.5pt; width: 390pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 390pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">William C. Weldon<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 79.99pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(5)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 87.52pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 88.1pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 88.39pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 88.53999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 88.61999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 88.64pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 88.64999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 393pt; position: absolute; top: 64.5pt; width: 75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 6.91pt; width: 15.68pt;"></font></font><font style="left: 23.59pt; position: absolute;">150,501.65<font style="display: inline-block; height: 6.91pt; width: 3.16pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 5.46pt; position: absolute; top: 190.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(1)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">For additional information regarding these stockholders and their equity holdings, see the section titled &#8220;Principal stockholders.&#8221; <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 207.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(2)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Mr. Lonnie M. Smith and entities affiliated with Mr. Smith own more than 5% of our outstanding capital. Mr. Smith is a member of our <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 216.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">board of directors.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 233.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(3)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Hayfin HeartFlow UK Limited and entities affiliated with Hayfin HeartFlow UK Limited own more than 5% of our outstanding capital.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 250.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(4)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">HCPCIV 1, LLC and entities affiliated with HCPCIV 1, LLC own more than 5% of our outstanding capital. Mr. Jeffrey C. Lightcap is a <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 259.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">member of our board of directors and is a controlling member of HCPCIV 1, LLC.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 276.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(5)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Mr. William C. Weldon is a member of our board of directors.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 293.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Investors&#8217; rights agreement<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We are party to an amended and restated investors&#8217; rights agreement, as amended, dated March 2, 2023, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">with the purchasers of our outstanding redeemable convertible preferred stock, including certain of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">directors, holders of more than 5% of our capital stock and entities with which certain of our directors are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">affiliated. Following the completion of this offering, the holders of approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million shares <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 364.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of our common stock issuable upon the conversion of our outstanding redeemable convertible preferred <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock are entitled to rights with respect to the registration of their shares under the Securities Act. For a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 388.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">more detailed description of these registration rights, see the section titled &#8220;Shares eligible for future sale<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 400.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">&#8212;Registration rights.&#8221;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 420.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Voting agreement<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 442.55pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We are party to an amended and restated voting agreement, as amended, with certain holders of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 454.55pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">common stock and redeemable convertible preferred stock, including certain of our directors and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 466.55pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">executive officers, holders of more than 5% of our capital stock, and entities with which certain of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 478.55pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">directors are affiliated. Upon the completion of this offering, the amended and restated voting agreement <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 490.55pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">will terminate. Members previously elected to our board of directors pursuant to this agreement will <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 502.55pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">continue to serve as directors until they resign, are removed or their successors are duly elected by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 514.55pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">holders of our common stock. The composition of our board of directors after this offering is described in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 526.55pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">more detail in the section title &#8220;Management&#8212;Board composition.&#8221;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 546.55pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Right of first refusal and co-sale agreement<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 568.95pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We are party to an amended and restated right of first refusal and co-sale agreement with certain holders <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 580.95pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of our common stock and redeemable convertible preferred stock, including certain of our directors, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 592.95pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">holders of more than 5% of our capital stock, and entities with which certain of our directors are affiliated. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 604.95pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">This agreement provides for rights of first refusal and co-sale relating to the shares of our common stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 616.95pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and convertible securities, other than Series F and Series F-1 redeemable convertible preferred stock and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 628.95pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the common stock issuable upon conversion of such preferred stock, held by certain parties to the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 640.95pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">agreement. Upon the completion of this offering, the amended and restated right of first refusal and co-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 652.95pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">sale agreement will terminate.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 672.95pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Management rights letters<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 695.35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In connection with the issuance of our Series F and Series F-1 convertible preferred stock, we entered <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 707.35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">into management rights letters with certain purchasers of our redeemable convertible preferred stock, <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">159<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">including holders of more than 5% of our capital stock and entities with which certain of our directors or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">officers are affiliated, pursuant to which such entities were granted certain management rights, including <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the right to consult with and advise our management on significant business issues, review our operating <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">plans, examine our books and records and inspect our facilities. These management rights letters and the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">rights granted to the parties thereto will terminate upon completion of this offering. Certain of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">obligations under the management rights letters will remain in effect after the completion of this offering, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">including certain tax reporting and financial disclosures.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Letter agreement with Bain Capital Life Science<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 186.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In connection with our Series F redeemable convertible preferred stock financing, we entered into a letter <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 198.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">agreement with BCLS Fund III Investments, LP (the &#8220;BCLS Letter Agreement&#8221;), which holds more than <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 210.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">5% of our outstanding capital stock. Pursuant to the BCLS Letter Agreement, BCLS Fund III Investments, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 222.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">LP was granted the right to designate a board observer in a nonvoting capacity, which right will terminate <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 234.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">upon the completion of this offering. Certain of our obligations under the BCLS Letter Agreement will <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 246.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">remain in effect after the completion of this offering, including certain indemnification obligations.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 266.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Letter agreement with Wellington Investors<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 288.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In connection with our Series F redeemable convertible preferred stock financing, we entered into a letter <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 300.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">agreement with the Wellington Investors (the &#8220;Wellington Letter Agreement&#8221;), which collectively hold more <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 312.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">than 5% of our outstanding capital stock. Pursuant to the Wellington Letter Agreement, the Wellington <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 324.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Investors were granted the right to designate a board observer in a nonvoting capacity, which right will <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 336.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">terminate upon the completion of this offering. The Wellington Letter Agreement will terminate by its terms <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 348.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">in connection with the completion of this offering and the Wellington Investors will not have any continuing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">rights following this offering.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 380.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Letter agreement with Capricorn Entities<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 403.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In connection with our Series F redeemable convertible preferred stock financing, we entered into a letter <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 415.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">agreement with the Capricorn Entities (the &#8220;Capricorn Letter Agreement&#8221;), which collectively hold more <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 427.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">than 5% of our outstanding capital stock. Pursuant to the Capricorn Letter Agreement, the Capricorn <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 439.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Entities were granted the right to designate a board observer in a nonvoting capacity. The Capricorn <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 451.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Letter Agreement will terminate by its terms in connection with the completion of this offering and the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 463.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Capricorn Entities will not have any continuing rights following this offering.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 483.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">2023 Taylor Trust repurchase<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 505.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">On March 29, 2023, we entered into a common stock repurchase agreement in connection with the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 517.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Series F and Series F-1 redeemable convertible preferred stock financing, pursuant to which we <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 529.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">repurchased 300,000 shares of common stock from the Taylor Family Revocable Trust, a family trust held <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 541.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">by Charles A. Taylor, Jr., Ph.D., one of our directors, at $2.8505 per share for an aggregate purchase <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 553.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">price of $855,150.00.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 573.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Other<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 596pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Michael Smith, a relative of Mr. Lonnie M. Smith, one of our directors, has been one of our non-executive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 608pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">employees since 2014. His overall cash compensation for each of 2022, 2023 and 2024 did not exceed <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 620pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">$300,000. He did not receive any equity compensation in 2024, and has received an aggregate of less <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 632pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">than 50,000 incentive stock options during his employment with us.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 652pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Executive officer and director compensation<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 674.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Please see the section titled &#8220;Executive and director compensation&#8221; for information regarding the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 686.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">compensation of our directors and executive officers.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">160<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 8.73pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Employment agreements<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 94.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We have entered into change in control and severance agreements with our executive officers that, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 106.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">among other things, provide for certain compensatory and change-in-control benefits, as well as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 118.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">severance benefits. For a description of these agreements with our named executive officers, see the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 130.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">section titled &#8220;Executive and director compensation.&#8221;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 150.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Indemnification agreements<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 172.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We have entered into indemnification agreements with certain of our current directors and executive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 184.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">officers and intend to enter into new indemnification agreements with each of our current directors and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 196.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">executive officers before the completion of this offering. Our amended and restated certificate of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 208.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">incorporation and our amended and restated bylaws will provide that we will indemnify our directors and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">officers to the fullest extent permitted by applicable law. Further, we have purchased a policy of directors&#8217; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and officer&#8217; liability insurance that insures our directors and officers against the cost of defense, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">settlement or payment of a judgment under certain circumstances. See the section titled &#8220;Management&#8212;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Limitations on liability and indemnification matters.&#8221;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 276.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Policies and procedures for related-party transactions<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 299.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Prior to the completion of this offering, our board of directors will adopt a written related-party transaction <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 311.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">policy, to be effective upon the completion of this offering, setting forth the policies and procedures for the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 323.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">review and approval or ratification of related-party transactions. This policy will cover, with certain <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 335.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">exceptions set forth in Item 404 of Regulation S-K, any transaction, arrangement, or relationship, or any <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 347.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">series of similar transactions, arrangements, or relationships, in which we were or are to be a participant, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 359.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">where the amount involved exceeds $120,000 and a related person had or will have a direct or indirect <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 371.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">material interest, including without limitation purchases of goods or services by or from the related person <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 383.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 395.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and employment by us of a related person. In reviewing and approving any such transactions, our audit <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 407.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">committee is tasked to consider all relevant facts and circumstances, including but not limited to whether <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 419.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the transaction is on terms comparable to those that could be obtained in an arm&#8217;s length transaction with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 431.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">an unrelated third party and the extent of the related person&#8217;s interest in the transaction. All of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 443.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">transactions described in this section occurred prior to the adoption of this policy.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">161<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_1309" style="position: absolute; top: 72pt;"></div><div style="line-height: 11.64pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Principal stockholders<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 107.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The following table sets forth, as of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, information regarding beneficial ownership of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 119.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">capital stock by&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 139.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 151.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">common stock&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 171.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">each of our named executive officers&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 191.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">each of our directors&#59; and<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 211.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">all of our executive officers and directors as a group.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 231.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The percentage ownership information under the column titled &#8220;Beneficial ownership prior to this offering&#8221; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 243.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">is based on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock outstanding as of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 255.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">including&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock resulting from the<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 350.21pt; position: absolute; text-decoration: none; white-space: pre;"> Preferred Stock<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 422.4pt; position: absolute; white-space: pre;"> Conversion <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 267.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock resulting from the conversion of the 2025 Convertible Notes, in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 279.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">each case as if such conversion had occurred as of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025. The ownership information under <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 291.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the column titled &#8220;Beneficial ownership after this offering&#8221; assumes the foregoing and the issuance <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 303.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock in this offering and assumes no exercise of the underwriters&#8217; option <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 315.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to purchase additional shares. In addition, the following table does not reflect any shares of common <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 327.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock that may be purchased in this offering.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 347.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We have determined beneficial ownership according to the rules and regulations of the SEC, which <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 359.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">generally means that a person has beneficial ownership of a security if they or it possesses sole or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 371.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">shared voting or investment power of that security. In addition, shares of common stock issuable upon the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 383.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">exercise of stock options or warrants that are currently exercisable or exercisable within 60 days <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 395.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025 are included in the following table. These shares are deemed to be outstanding and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 407.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">beneficially owned by the person holding those options or warrants for the purpose of computing the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 419.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">percentage ownership of that person, but they are not treated as outstanding for the purpose of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 431.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">computing the percentage ownership of any other person. The information contained in the following table <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 443.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">does not necessarily indicate beneficial ownership for any other purpose. Unless otherwise indicated, the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 455.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">persons or entities identified in this table have sole voting and investment power with respect to all shares <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 467.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">shown as beneficially owned by them, subject to applicable community property laws.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 487.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Unless otherwise noted below, the address for each beneficial owner listed in the table below is c&#47;o <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 499.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Heartflow, Inc., 331 E. Evelyn Avenue, Mountain View, California 94041.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">162<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="position: absolute; top: 72pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 195pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 21.75pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="3"><div style="left: 198pt; position: absolute; top: 0pt; width: 133.5pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3.15pt; width: 133.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 50.97pt; position: absolute; text-decoration: none; white-space: pre;">Beneficial ownership <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 12.75pt; width: 133.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 54.54pt; position: absolute; text-decoration: none; white-space: pre;">prior to this offering<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="3"><div style="left: 334.5pt; position: absolute; top: 0pt; width: 133.5pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3.15pt; width: 133.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 50.97pt; position: absolute; text-decoration: none; white-space: pre;">Beneficial ownership <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 12.75pt; width: 133.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 65.19pt; position: absolute; text-decoration: none; white-space: pre;">after this offering<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td></tr><tr style="height: 41.25pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 21.75pt; width: 195pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 32.25pt; width: 195pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Name of beneficial owner<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 21.75pt; width: 65.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3.45pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 22.67pt; position: absolute; text-decoration: none; white-space: pre;">Number of <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 13.05pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 36.87pt; position: absolute; text-decoration: none; white-space: pre;">shares <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 22.65pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 19.12pt; position: absolute; text-decoration: none; white-space: pre;">beneficially <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 32.25pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 37.32pt; position: absolute; text-decoration: none; white-space: pre;">owned<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 21.75pt; width: 65.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 13.05pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 9.8pt; position: absolute; text-decoration: none; white-space: pre;">Percentage of <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 22.65pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 25.78pt; position: absolute; text-decoration: none; white-space: pre;">beneficial <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 32.25pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 22.67pt; position: absolute; text-decoration: none; white-space: pre;">ownership<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 21.75pt; width: 65.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3.45pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 22.67pt; position: absolute; text-decoration: none; white-space: pre;">Number of <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 13.05pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 36.87pt; position: absolute; text-decoration: none; white-space: pre;">shares <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 22.65pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 19.12pt; position: absolute; text-decoration: none; white-space: pre;">beneficially <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 32.25pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 37.32pt; position: absolute; text-decoration: none; white-space: pre;">owned<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 21.75pt; width: 65.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 13.05pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 9.8pt; position: absolute; text-decoration: none; white-space: pre;">Percentage of <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 22.65pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 25.78pt; position: absolute; text-decoration: none; white-space: pre;">beneficial <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 32.25pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 22.67pt; position: absolute; text-decoration: none; white-space: pre;">ownership<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 63pt; width: 195pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 195pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: italic; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">5% and greater stockholders&#58;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 77.25pt; width: 195pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 195pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">BCLS Fund III Investments, LP<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 132.89pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(1)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 140.42pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 142.73pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 143.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 144.47pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 144.51pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 144.53pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 144.54pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 77.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 77.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 91.5pt; width: 195pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 195pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">HealthCor Partners Funds<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 112.89pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(2)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 120.42pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 121pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 121.14999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 121.19pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 121.19999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 91.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 91.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 105.75pt; width: 195pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 195pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Wellington Investors<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 87.92pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(3)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 95.44999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 96.61pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 97.19pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 97.33999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 97.38pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 105.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 105.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 120pt; width: 195pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 195pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Capricorn Funds<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 72.81pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(4)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 80.33999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 82.64999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 82.94pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 83.02pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 83.06pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 83.07pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 120pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 120pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 134.25pt; width: 195pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 195pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Entities affiliated with Hayfin Services, LLP <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 184.25pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(5)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 191.78pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 192.07pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 192.22pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 192.29999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 192.32pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 134.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 134.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 148.5pt; width: 195pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 195pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Lonnie M. Smith<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 71.19999999999999pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(6)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 78.72999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 81.03999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 82.19999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 82.78pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 82.86pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 82.89999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 82.92pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 148.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 148.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 162.75pt; width: 195pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 195pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">U.S. Venture Partners Funds<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 123.94999999999999pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(7)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 131.48pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 133.79pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 134.95pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 135.1pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 135.10999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 162.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 162.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 177pt; width: 195pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 195pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Baillie Gifford Funds<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 87.91pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(8)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 95.44pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 96.6pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 97.17999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 97.33pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 97.36999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 97.38pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 177pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 177pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 191.25pt; width: 195pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 195pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: italic; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Named executive officers and directors&#58;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 205.5pt; width: 195pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 195pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">John C.M. Farquhar<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 87.03pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(9)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 94.56pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 96.86999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 97.16pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 97.24pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 97.28pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 97.28999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 205.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 205.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 219.75pt; width: 195pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 195pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Vikram Verghese<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 74.75pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(10)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 85.71pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 86.86999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 87.44999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 87.74pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 87.82pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 87.86pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 87.88pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 219.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 219.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 234pt; width: 195pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 195pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Timothy A. Fonte<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 74.00999999999999pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(11)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 84.52pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 86.83pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 87.41pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 87.69999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 87.74pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 87.75pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 234pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 234pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 248.25pt; width: 195pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 195pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Campbell D.K. Rogers, M.D.<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 122.35pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(12)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 133.31pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 134.47pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 135.04999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 135.2pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 135.28pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 135.29999999999998pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 248.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 248.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 262.5pt; width: 195pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 195pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">William C. Weldon<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 79.99pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(13)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 90.94999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 92.11pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 92.39999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 92.55pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 92.63pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 92.67pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 262.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 262.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 276.75pt; width: 195pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 195pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Timothy C. Barabe<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 81.39999999999999pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(14)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 92.36pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 92.64999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 92.72999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 92.77pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 92.78999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 92.8pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 276.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 276.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 291pt; width: 195pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 195pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Julie A. Cullivan<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 69.64pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(15)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 80.6pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 82.91pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 83.06pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 83.08pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 83.08999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 291pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 291pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 305.25pt; width: 195pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 195pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Nicholas Downing, M.D.<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 103.92pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(16)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 114.88pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 116.03999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 116.33pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 116.36999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 116.38pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 305.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 305.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 319.5pt; width: 195pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 195pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Jeffrey C. Lightcap<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 81.58pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(2)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 89.11pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 91.42pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 92pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 92.28999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 92.44pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 92.47999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 319.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 319.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 333.75pt; width: 195pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 195pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Wayne Riley, M.D.<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 80.16pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(17)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 91.11999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 92.28pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 92.57pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 92.64999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 92.67pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 92.67999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 333.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 333.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 348pt; width: 195pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 195pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Lonnie M. Smith<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 71.19999999999999pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(6)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 78.72999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 81.03999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 82.19999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 82.78pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 82.86pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 82.89999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 82.92pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 348pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 348pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 362.25pt; width: 195pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 195pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Casey M. Tansey<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 75.27pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(7)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 82.8pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 83.08999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 83.24pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 83.28pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 83.3pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 83.31pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 362.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 362.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 376.5pt; width: 195pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 195pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Charles A. Taylor, Jr., Ph.D.<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 117.96pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(18)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 128.92000000000002pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 130.08pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 130.37pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 130.52pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 130.56pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 130.58pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 130.59pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 376.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 376.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 24pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 390.75pt; width: 195pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.14pt; width: 195pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">All current directors and executive officers as <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 13.54pt; width: 195pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 11.63pt; position: absolute; text-decoration: none; white-space: pre;">a group (13 persons)<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.175pt; font-style: normal; font-weight: normal; left: 99.74pt; position: absolute; text-decoration: none; top: -2.4185pt; vertical-align: super; white-space: pre;">(19)<font style="display: inline-block; height: 4.4915pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 110.69999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 111.28pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 111.57pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 111.64999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 111.69pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 111.69999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 390.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 13.6pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 390.75pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 13.6pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 56.06pt; position: absolute; text-decoration: none; white-space: pre;">%<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 5.46pt; position: absolute; top: 494.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">*<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Indicates beneficial ownership of less than 1% of the total outstanding common stock.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 511.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(1)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Consists of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock issuable upon conversion of our Series F redeemable convertible preferred stock. Bain <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 520.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Capital Life Sciences Investors, LLC (&#34;BCLSI&#34;) is the manager of Bain Capital Life Sciences III General Partner, LLC, which is the <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 529.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">general partner of Bain Capital Life Sciences Fund III, L.P., which is the managing member of BCLS Fund III Investments GP, LLC, <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 538.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">which is the general partner of BCLS Fund III Investments, LP. As a result, BCLSI may be deemed to share voting and dispositive <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 547.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">power with respect to the securities held by BCLS Fund III Investments, LP. The principal address for BCLS Fund III Investments, LP is <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 556.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">200 Clarendon Street, Boston, Massachusetts 02116.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 573.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(2)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Consists of (A) shares of our common stock issuable upon conversion of our redeemable convertible preferred stock expected to be <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 582.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">held by the following entities, collectively referred to as &#8220;HealthCor Partners Funds&#8221;&#58; (i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock issuable upon <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 591.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">conversion of our redeemable convertible preferred stock held by HCPCIV 1, LLC&#59; (ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock issuable upon <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 600.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">conversion of our redeemable convertible preferred stock held by HealthCor Partners Fund, L.P&#59; and (iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 609.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">stock issuable upon conversion of our redeemable convertible preferred stock held by HealthCor Partners Fund II, L.P. and (B) <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 618.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock issuable upon conversion of the 2025 Convertible Notes purchased by HCPCIV 1, LLC. Mr. Lightcap, a <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 627.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">member of our board of directors, is a controlling member of each of the HealthCor Partners Funds. Mr. Lightcap disclaims beneficial <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 636.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">ownership of these shares except to the extent of his pecuniary interest therein. The address for the HealthCor Partners Funds is 186 <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 645.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Seven Farms Drive, Suite F-371, Daniel Island, South Carolina 29492. <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 662.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(3)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Consists of (i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock issuable upon conversion of our redeemable convertible preferred stock held by Hadley <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 671.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Harbor Master Investors (Cayman) II LP and (ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock issuable upon conversion of our redeemable <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 680.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">convertible preferred stock expected to be held by Texas Hidalgo Co-Investment Fund, L.P. (each a &#8220;Wellington Investor&#8221; and, <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 689.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">collectively, the &#8220;Wellington Investors&#8221;). Wellington Management Company LLP, a registered investment adviser under the Investment <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 698.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Advisers Act of 1940, as amended, is the investment adviser to each Wellington Investor, and Wellington Alternative Investments LLC is <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 707.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">its general partner. Wellington Management Investment, Inc. is the managing member of Wellington Alternative Investments LLC. <font style="display: inline-block; height: 5.46pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">163<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 5.46pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Wellington Management Company LLP is an indirect subsidiary of Wellington Management Group LLP. Wellington Management Group <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 81pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">LLP and Wellington Management Company LLP may be deemed beneficial owners with shared voting and investment power over the <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 90pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">shares held by each Wellington Investor. The address for each Wellington Investor and the Wellington entities is 280 Congress Street, <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 99pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Boston, Massachusetts 02210. <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(4)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Consists of (A) shares of our common stock issuable upon conversion of our redeemable convertible preferred stock held by the <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 125pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">following entities, collectively referred to as the &#8220;Capricorn Funds&#8221;&#58; (i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock issuable upon conversion of our <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 134pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">redeemable convertible preferred stock held by Capricorn Healthcare and Special Opportunities, LP&#59; (ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 143pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">stock issuable upon conversion of our redeemable convertible preferred stock held by Capricorn Healthcare and Special Opportunities <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">II, LP&#59; (iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock issuable upon conversion of our redeemable convertible preferred stock held by Capricorn <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 161pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Healthcare and Special Opportunities II-A, LP&#59; (iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock issuable upon conversion of our redeemable <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 170pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">convertible preferred stock held by Capricorn S.A. SICAV&#8201;&#8212;&#8201;SIF&#8201;&#8212;&#8201;Global Non-Marketable Strategies Sub-Fund&#59; (v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 179pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">common stock issuable upon conversion of our redeemable convertible preferred stock held by Carthage, LP&#59; (vi)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">common stock issuable upon conversion of our redeemable convertible preferred stock held by CHSO CIG, LP&#59; (vii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 197pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">common stock issuable upon conversion of our redeemable convertible preferred stock held by CHSO SFP, LP&#59; (viii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 206pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">common stock issuable upon conversion of our redeemable convertible preferred stock held by CHSO TSF, LP&#59; (ix)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 215pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">common stock issuable upon conversion of our redeemable convertible preferred stock held by Pacific Sequoia Holdings, LLC&#59; <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">(x)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock issuable upon conversion of our redeemable convertible preferred stock held by The Skoll <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 233pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Foundation&#59; and (xi)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock issuable upon conversion of our redeemable convertible preferred stock held by <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 242pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">The Skoll Fund and (B) &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock issuable upon conversion of the 2025 Convertible Notes purchased by <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 251pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Capricorn Healthcare Special Opportunities II, L.P.,&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock issuable upon conversion of the 2025 Convertible <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Notes purchased by The Skoll Foundation,&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock issuable upon conversion of the 2025 Convertible Notes <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 269pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">purchased by Capricorn Healthcare Special Opportunities II-A, L.P., and&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock issuable upon conversion of <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 278pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the 2025 Convertible Notes purchased by The Skoll Fund. <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 295pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">CHSO Partners, LLC, is the general partner of Capricorn Healthcare and Special Opportunities, LP, CHSO CIG, LP, CHSO SFP, LP, <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">and CHSO TSF, LP. CHSO Partners, LLC has sole investment and voting authority over the shares held by these funds. Voting and <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 313pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">dispositive decisions on behalf of CHSO Partners LLC are made by the separate decisions of Barry Uphoff, the Principal Manager of <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 322pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">CHSO Partners LLC and a majority of the CIG Managers of CHSO Partners. Messrs. Eric Techel and Ion Yadigaroglu are the CIG <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 331pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Managers of CHSO Partners LLC. Messrs. Uphoff, Techel and Yadigaroglu may be deemed to have shared voting and investment <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">control with respect to the shares held by the funds managed by CHSO Partners LLC.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 357pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">CHSO Partners II, LLC, is the general partner of Capricorn Healthcare and Special Opportunities II, LP and Capricorn Healthcare &#38; <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 366pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Special Opportunities II-A, LP. CHSO Partners II, LLC has sole investment and voting authority over the shares held by these funds. <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 375pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Voting and dispositive decisions on behalf of CHSO Partners II, LLC are made by the separate decisions of Barry Uphoff, the Principal <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 384pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Manager of CHSO Partners II, LLC and one designated representative of Capricorn Investment Group, LLC. Mr. Uphoff and Capricorn <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 393pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Investment Group may be deemed to have shared voting and investment control with respect to the shares held by the funds managed <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 402pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">by CHSO Partners II, LLC.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 419pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Capricorn Investment Group, LLC is the general partner of Carthage, LP and the investment manager of Pacific Sequoia Holdings, LLC, <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 428pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">The Skoll Foundation and The Skoll Fund.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 445pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">The address for each of the Capricorn Funds is c&#47;o Capricorn Investment Group LLC, 250 University Avenue, Palo Alto, California <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 454pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">94301. CHSO Partners, LLC and CHSO Partners II, LLC&#8217;s address is 2020 K Street NW, STE 720, Washington, DC 20006<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 471pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(5)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Consists of (A) (i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock issuable upon conversion of our redeemable convertible preferred stock <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 480pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">expected to be held by Hayfin Heartflow UK Limited and (ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock subject to warrants exercisable by <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 489pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Hayfin Tourmaline Luxco S.a.r.l. within 60 days of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025 and (B)&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock issuable upon conversion of <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 498pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the 2025 Convertible Notes purchased by H. The principal address for the Hayfin Services, LLP is 65 Davies Street, London W1K5JL.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 515pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(6)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Consists of (A) (i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock issuable upon conversion of our redeemable convertible preferred stock <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 524pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">expected to be held by Lonnie M. Smith HeartFlow IV Grantor Retained Annuity Trust u&#47;a June 24, 2023, (ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 533pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">common stock issuable upon conversion of our redeemable convertible preferred stock held by Lonnie M. Smith HeartFlow GRAT III, <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 542pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock issuable upon conversion of our redeemable convertible preferred stock held by McKram <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 551pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Investment Capital II LLC, (iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock issuable upon conversion of our redeemable convertible preferred <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 560pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">stock held directly by Mr. Smith and (v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock subject to options exercisable by Mr. Smith within 60 days <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 569pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025 and (B)&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock issuable upon conversion of the 2025 Convertible Notes purchased by <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 578pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Lonnie M. Smith. Mr. Smith has voting and investment power over the shares held by McKram Investment Capital II LLC. <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 595pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(7)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Consists of (A) shares of our common stock issuable upon conversion of our redeemable convertible preferred stock expected to be <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 604pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">held by the following entities, collectively referred to as the &#8220;U.S. Venture Partners Funds&#8221;&#58; (i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock issuable <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 613pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">upon conversion of our redeemable convertible preferred stock held by U.S. Venture Partners X, L.P. and (ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 622pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">stock issuable upon conversion of our redeemable convertible preferred stock held by USVP X Affiliates, L.P. and (B)&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 631pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">common stock issuable upon conversion of the 2025 Convertible Notes purchased by U.S. Venture Partners X, L.P. and&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 640pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">of common stock issuable upon conversion of the 2025 Convertible Notes purchased by USVP X Affiliates, L.P. Presidio Management <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 649pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Group X, L.L.C. (&#8220;PMG X&#8221;) is the general partner of the U.S. Venture Partners Funds. The managing members of PMG X are Irwin <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 658pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Federman, Steven M. Krausz, Rick Lewis, Paul Matteucci, Jonathan D. Root and Casey Tansey, all of whom may be deemed to share <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 667pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">voting and investment power over these shares, but disclaim beneficial ownership except to the extent of their pecuniary interests <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 676pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">therein. The address for the U.S. Venture Partners Funds is 2735 Sand Hill Road, Menlo Park, California 94025. <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 693pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(8)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Consists of shares of our common stock issuable upon conversion of our redeemable convertible preferred stock expected to be held <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 702pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">by the following entities, collectively referred to as &#8220;Baillie Gifford Funds&#8221;&#58; (i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock issuable upon conversion <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 711pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">of our redeemable convertible preferred stock held by Host-Plus Pty Limited, (ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock issuable upon <font style="display: inline-block; height: 5.46pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">164<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 5.46pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">conversion of our redeemable convertible preferred stock held by Interventure Equity Investments Limited, (iii) an aggregate <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 81pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock issuable upon conversion of our redeemable convertible preferred stock held by Scottish Mortgage <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 90pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Investment Trust plc, (iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock issuable upon conversion of our redeemable convertible preferred stock held <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 99pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">by The Board of Trustees of the Saskatchewan Healthcare Employees' Pension Plan, (v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock issuable <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">upon conversion of our redeemable convertible preferred stock held by The Schiehallion Fund Limited, (vi)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 117pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">stock issuable upon conversion of our redeemable convertible preferred stock held by The States of Jersey Public Employees <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 126pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Contributory Retirement Scheme, (vii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock issuable upon conversion of our redeemable convertible <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 135pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">preferred stock held by Vision Super Pty Ltd, and (viii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock issuable upon conversion of our redeemable <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">convertible preferred stock held by Warman Investments Pty Limited. Baillie Gifford Overseas Limited has been appointed to act for and <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 153pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">on behalf of, as direct investment manager, for each of the Baillie Gifford Funds with full voting and investment power. The address for <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 162pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the Baillie Gifford Funds is Calton Square, 1 Greenside Row, Edinburgh EH1 3AN, Scotland, United Kingdom. <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 179pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(9)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Consists of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock subject to options exercisable within 60 <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">days of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 205pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(10)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Consists of (A)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock subject to options exercisable within 60 <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 214pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">days of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025 and (B)&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock issuable upon conversion of the 2025 Convertible Notes purchased by <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 223pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Vikram Verghese.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 240pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(11)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Consists of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock subject to options exercisable within 60 <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 249pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">days of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 266pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(12)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Consists of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock subject to options exercisable within 60 <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 275pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">days of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025. Includes&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares expected to be held by family trusts established by Dr. Rogers for the benefit of certain <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 284pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">members of his family and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares expected to be held by a trust beneficially owned by his wife. Dr. Rogers may be deemed to <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 293pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">beneficially own such shares.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 310pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(13)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Consists of (i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock, (ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock issuable upon conversion of our <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 319pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">redeemable convertible preferred stock and (iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock subject to options exercisable within 60 days <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 345pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(14)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Consists of (A)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock subject to options exercisable within 60 <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 354pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">days of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025 and (B)&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock issuable upon conversion of the 2025 Convertible Notes purchased by <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 363pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Timothy C. Barabe.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 380pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(15)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Consists of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock subject to options exercisable within 60 <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 389pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">days of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 406pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(16)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Does not include shares of our common stock issuable upon conversion of our Series F convertible preferred stock held by BCLS Fund <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 415pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">III Investments, LP. Dr. Downing is a managing director of Bain Capital Life Sciences.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 432pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(17)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Consists of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock subject to options exercisable within 60 days of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 449pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(18)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Consists of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock subject to options exercisable within 60 <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 458pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">days of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025. Includes&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares expected to be held by various family trusts established by Dr. Taylor <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 467pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares expected to be held by various family members. Dr. Taylor may be deemed to benefi<font style="display: inline-block; height: 5.82pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: normal; left: 437.24pt; position: absolute; text-decoration: none; white-space: pre;">cially own such <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 476.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">shares.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares expected to be held by Dr. Taylor have been pledged to Section Capital Partners, LP.<font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="font-size: 12pt; line-height: 5.46pt; position: absolute; top: 494.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(19)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Includes the shares described in footnotes 1, 2, 6, 7 and 9 through 18 above and&#160; &#160; &#160; &#160; &#160; &#160; &#160;  shares of common stock subject to options <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="font-size: 12pt; line-height: 5.46pt; position: absolute; top: 503.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">that are exercisable within 60 days of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025<font style="display: inline-block; height: 5.46pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">165<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_1337" style="position: absolute; top: 72pt;"></div><div style="line-height: 11.64pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Description of capital stock<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 107.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The following descriptions are summaries of our capital stock and the material terms of our amended and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 119.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">restated certificate of incorporation and our amended and restated bylaws, which will become effective <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 131.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">immediately prior to the completion of this offering. Because the following descriptions are only <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 143.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">summaries, they do not contain all of the information that may be important to you. Reference is made to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 155.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the more detailed provisions of, and the descriptions are qualified in their entirety by reference to, these <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 167.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">documents, copies of which are filed with the SEC as exhibits to the registration statement of which this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 179.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prospectus is a part, and applicable law.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 199.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">General<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 221.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Upon the completion of this offering and the filing of our amended and restated certificate of incorporation, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 233.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our authorized capital stock will consist of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of capital stock, par value $0.001 per share, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 245.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of which&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 265.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares are designated as common stock&#59; and<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 285.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares are designated as preferred stock.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 305.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">As of December 31, 2024, there were &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of common stock outstanding, held of record <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 317.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">by&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;stockholders, assuming the conversion of all our outstanding shares of preferred stock or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 329.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">convertible securities into&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock immediately prior to the completion of this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 341.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">offering. On&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, we consummated a &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-for-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;reverse stock split of our common <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 353.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 373.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Common stock<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Voting rights<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 416pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Holders of our common stock are entitled to one vote per share on all matters submitted to a vote of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 428pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stockholders.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 448pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our amended and restated certificate of incorporation will not provide for cumulative voting for the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 460pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">election of directors. Subject to the rights of the holders of one or more series of preferred stock, director <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 472pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">candidates standing for election will be elected by a plurality of the votes cast by our stockholders present <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 484pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">in person or represented by proxy at the meeting and entitled to vote thereon. Our amended and restated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 496pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">certificate of incorporation will retain a classified board of directors, divided into three classes with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 508pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">staggered three-year terms. Only one class of directors will be elected at each annual meeting of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 520pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stockholders, with the other classes continuing for the remainder of their respective terms. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Dividend rights<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 560pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Subject to preferences that may be applicable to any preferred stock, the holders of our common stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 572pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">will be entitled to receive ratably, on a per share basis, any dividends declared by our board of directors <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 584pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">out of assets legally available.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 604pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Liquidation rights<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Subject to preferences that may be applicable to any preferred stock, in the event of any voluntary or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 636pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">involuntary liquidation, dissolution or winding up, after payment or provision for payment of our debts and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 648pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">other liabilities, the holders of shares of our common stock will be entitled to receive, ratably in proportion <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to the number of shares held by the holder, all our remaining assets available for distribution to our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stockholders.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">166<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">No preemptive or similar rights<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 92pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The holders of our common stock will not be entitled to preemptive, subscription or conversion rights. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">There will be no redemption or sinking fund provisions.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 124pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Preferred stock<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 146.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our amended and restated certificate of incorporation will authorize&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of preferred stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 158.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and will provide that preferred stock may be issued from time to time in one or more series. Our board of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 170.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">directors will be authorized to fix the voting rights, if any, designations, powers, preferences, the relative, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 182.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">participating, optional, special and other rights and any qualifications, limitations and restrictions thereof, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 194.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">applicable to the shares of each series. Our board of directors will be able to, without stockholder <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 206.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">approval, issue shares of preferred stock with voting and other rights that could adversely affect the voting <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 218.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">power and other rights of the holders of the common stock and could have anti-takeover effects. The <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 230.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">ability of our board of directors to issue shares of preferred stock without stockholder approval could have <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 242.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the effect of delaying, deferring or preventing a change of control or the removal of existing management.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 262.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Stock options<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 284.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">As of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, we had outstanding&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;options to acquire our common stock, of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 296.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">which&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;were vested, with a weighted average exercise price of approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">share, and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;were unvested, with a weighted average exercise price of approximately <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 320.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share. For additional information regarding the terms of our equity incentive plans, see the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 332.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">section titled &#8220;Executive and director compensation&#8212;2025 Performance incentive plan.&#8221;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 352.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Warrants<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 375.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">As of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025, we had outstanding warrants to purchase an aggregate of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 387.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our common stock, with an exercise price of $0.01 per share, issuable upon the exercise of such <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 399.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">outstanding warrants.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 419.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Registration rights<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 441.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Upon the completion of this offering and subject to the lock-up agreements entered into in connection with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 453.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">this offering and federal securities laws, holders of shares of our common stock that will be issued upon <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 465.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the conversion of our redeemable convertible preferred stock in connection with this offering and the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 477.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">holder of shares of our common stock issuable or issued upon exercise of certain outstanding warrants to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 489.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">purchase shares of our common stock will initially be entitled to certain registration rights under the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 501.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Securities Act. These securities are referred to as registrable securities. The holders of these registrable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 513.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">securities possess registration rights pursuant to the terms of our amended and restated investors&#8217; rights <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 525.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">agreement and are described in additional detail below. The registration of shares of our common stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 537.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">pursuant to the exercise of the registration rights described below would enable the holders to trade the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 549.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">registered shares without restriction under the Securities Act when the applicable registration statement is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 561.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">declared effective. We will pay the registration expenses, other than underwriting discounts, selling <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 573.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">commissions, stock transfer taxes, and fees and disbursements in excess of $100,000 to one counsel for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 585.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the holders, of the securities registered pursuant to the demand, Form S-3 and piggyback registrations <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 597.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">described below. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 617.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Generally, in an underwritten offering, the managing underwriter, if any, has the right, subject to specified <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 629.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">conditions and limitations, to limit the number of securities the holders may include. The demand, Form <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 641.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">S-3 and piggyback registration rights described below will terminate upon the earliest to occur of (i) a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 653.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Liquidation Event (as defined in the amended and restated certificate of incorporation, dated March 2, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 665.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2023, of HeartFlow Holding, Inc.) where the stockholders receive cash and&#47;or publicly traded securities or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 677.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the holders receive reasonably comparable registration rights, (ii) with respect to each holder, such time <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 689.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">after the completion of this offering after which Rule 144 of the Securities Act (&#8220;Rule 144&#8221;) or another <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 701.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">similar exemption under the Securities Act is available for the sale of all of such holder&#8217;s shares without <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">167<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">limitation, during a three-month period without registration and such holder holds less than 1% of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">outstanding capital stock of the company or (iii) the date three years after the completion of this offering.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Demand registration rights <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 124pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Upon the completion of this offering, holders of up to approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million shares of our common <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 136pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock issued upon conversion of our redeemable convertible preferred stock and the holder of warrants to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 148pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">purchase up to an aggregate of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock will be entitled to certain demand <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 160pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">registration rights. Beginning six months after the effectiveness of the registration statement of which this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 172pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prospectus is a part, holders holding, collectively, at least a majority of the registrable securities held by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 184pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the holders of common stock issued upon conversion of our redeemable convertible preferred stock then <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 196pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">outstanding may, on not more than two occasions, request that we register at least 40% of the registrable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 208pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">securities held by the holders of common stock issued upon conversion of our redeemable convertible <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">preferred stock then outstanding on a Form S-1 registration statement, subject to certain specified <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">exceptions. If we determine that it would be seriously detrimental to us and our stockholders to effect <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">such a demand registration, we have the right to defer such registration, not more than twice in any 12-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">month period, for a period of up to 120 days. In addition, we will not be required to effect a demand <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">registration during the period beginning 60 days prior to our good faith estimate of the date of the filing of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and ending on a date 180 days following the effectiveness of a registration statement relating to a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">registration initiated by us or if registration on Form S-3 is available.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 312pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Form S-3 registration rights<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 332pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Upon the completion of this offering, holders of up to approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million shares of our common <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 344pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock issued upon conversion of our redeemable convertible preferred stock and the holder of warrants to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 356pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">purchase up to an aggregate of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock will be entitled to certain Form S-3 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 368pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">registration rights. At any time when the company is qualified to file a Form S-3 registration statement, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 380pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">holders holding, collectively, at least 30% of the registrable securities then outstanding may request that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 392pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">we register registrable securities having an anticipated aggregate offering price of at least $10.0 million, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 404pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">net of underwriting discounts and certain other expenses. These holders may make an unlimited number <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 416pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of requests for registration on Form S-3&#59; however, we will not be required to effect a registration on Form <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 428pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">S-3 if we have effected two such registrations pursuant to such requests within the 12-month period <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 440pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">preceding the date of the request. In addition, if we determine that it would be seriously detrimental to us <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 452pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and our stockholders to effect such a registration, we have the right to defer such registration, not more <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 464pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">than twice in any 12-month period, for a period of up to 120 days. Lastly, we will not be required to effect a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 476pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">registration on Form S-3 during the period beginning 30 days prior to our good faith estimate of the date <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 488pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of the filing of and ending on a date 90 days following the effectiveness of a registration statement relating <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 500pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to a registration initiated by us. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 520pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Piggyback registration rights <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Pursuant to the investor rights agreement, if we register any of our securities either for our own account or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for the account of other security holders, other than through this offering, holders of up to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million shares of our common stock issued upon conversion of our redeemable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">convertible preferred stock and the holder of warrants to purchase up to an aggregate of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our common stock will be entitled to customary &#8220;piggyback&#8221; registration rights allowing them to include <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 600pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">their securities in such registration, subject to specified conditions, limitations and exceptions.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 620pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Anti-takeover effects of provisions of the proposed amended and restated <font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 634.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">certificate of incorporation and bylaws and applicable law<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our amended and restated certificate of incorporation and bylaws will contain provisions that could have <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 668.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the effect of delaying, deferring or discouraging another party from acquiring control of us. These <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 680.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">provisions and certain provisions of Delaware law, which are summarized below, could discourage <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 692.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">takeovers, coercive or otherwise, and as a consequence, they might also inhibit temporary fluctuations in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 704.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the market price of our common stock that often result from actual or rumored hostile takeover attempts. <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">168<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">These provisions are also designed, in part, to encourage persons seeking to acquire control of us to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">negotiate first with our board of directors. It is also possible that these provisions might have the effect of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">preventing changes in our management and could make it more difficult to accomplish transactions that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stockholders might otherwise deem to be in their best interests.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Classified board of directors<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 148pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our amended and restated certificate of incorporation will provide that our board of directors be classified <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 160pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">into three classes of directors, with each class serving a staggered three-year term. As a result, in most <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 172pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">circumstances, a person can gain control of our board of directors only by successfully engaging in a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 184pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">proxy contest at two or more annual meetings of our stockholders.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 204pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Authorized but unissued shares<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our authorized but unissued common stock and preferred stock will be available for future issuances <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">without stockholder approval and could be utilized for a variety of corporate purposes, including future <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">offerings to raise additional capital, acquisitions and employee benefit plans. The existence of authorized <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">but unissued and unreserved common stock and preferred stock could render more difficult or discourage <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 272pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Written consent&#59; special meeting of stockholders<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 312pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our amended and restated certificate of incorporation and bylaws will provide that stockholder action may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 324pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">not be taken by written consent, which forces stockholder action to be taken at an annual or special <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 336pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">meeting of our stockholders.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 356pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our amended and restated certificate of incorporation and bylaws will provide that, subject to the rights of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 368pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">any holders of preferred stock, special meetings of our stockholders, for any purpose or purposes, may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 380pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">be called only by (i) the chair of the board, (ii) the chief executive officer or (iii) the secretary at the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 392pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">direction of our board of directors pursuant to a resolution adopted by a majority of our board of directors.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 412pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Advance notice requirements for stockholder proposals and director nominations <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 432pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our amended and restated bylaws will provide that stockholders seeking to bring business before the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 444pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">annual meeting of our stockholders or to nominate candidates for election as directors at the annual <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 456pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">meeting of our stockholders or, in certain instances as provided in our bylaws, a special meeting of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 468pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stockholders must provide timely notice of their intent in writing. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 488pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">To give timely notice, the notice must be delivered to the secretary at our principal executive offices not <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 500pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">later than the close of business on the 90th day nor earlier than the 120th day prior to the first anniversary <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 512pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of the preceding year&#8217;s annual meeting. However, if the date of the annual meeting is more than 30 days <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 524pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">before or more than 70 days after such anniversary date, the notice must be delivered not earlier than the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 536pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">120th day prior to such annual meeting and not later than the close of business on the later of the 90th <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 548pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">day prior to such annual meeting or the tenth day following the day on which public announcement of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 560pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">date of the annual meeting is first made or sent by us.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 580pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our amended and restated bylaws will also specify certain informational and other requirements as to the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 592pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">form and content of the notice. These provisions, if not satisfied on a timely basis or at all, may preclude <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 604pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our stockholders from bringing business or director nominations before the meeting of our stockholders.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Election and removal of directors<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our amended and restated certificate of incorporation and bylaws will contain provisions that establish <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">specific procedures for appointing and removing members of the board of directors.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 676pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Under the amended and restated certificate of incorporation, our directors may be removed from office, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 688pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">but only for cause, which requires approval by the holders of a majority of our outstanding capital stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 700pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">then entitled to vote in the election of directors.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">169<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Vacancies and newly created directorships on our board of directors may be filled only by a majority vote <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of the directors then in office, even if less than a quorum, or by a sole remaining director (and not by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stockholders). Any new director shall hold office for the remainder of the full term of the class of directors <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to which the new directorship was added or in which the vacancy occurred and until his or her successor <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">has been elected and qualified, subject, however, to such director&#8217;s earlier death, resignation, retirement, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">disqualification or removal. The treatment of vacancies has the effect of making it more difficult for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stockholders to change the composition of the board of directors.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">No cumulative voting<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 184pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The DGCL provides that stockholders are not entitled to cumulate votes in the election of directors unless <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 196pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">a corporation&#8217;s certificate of incorporation provides otherwise. Our amended and restated certificate of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 208pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">incorporation will not authorize cumulative voting rights for our stockholders.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 228pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The absence of cumulative voting makes it more difficult for a minority stockholder to gain a seat on our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 240pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">board of directors to influence a decision by our board of directors, including regarding any potential <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 252pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">merger, tender offer or other potential takeover transaction.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 272pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Amendments to our certificate of incorporation and bylaws<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our amended and restated certificate of incorporation and bylaws will provide that the affirmative vote of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">holders of at least sixty-six and two-thirds percent (66-2&#47;3%) of the voting power of all then-outstanding <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">shares of capital stock entitled to vote generally in the election of directors is required to amend certain <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">provisions of our certificate of incorporation, including provisions relating to the size of the board, removal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of directors, special meetings, actions by written consent and cumulative voting. The affirmative vote of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">holders of at least sixty-six and two-thirds percent (66-2&#47;3%) of the voting power of all of the then <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 364pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">outstanding shares of capital stock entitled to vote generally in the election of directors will be required to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">amend or repeal our bylaws, although our bylaws may be amended by a simple majority vote of our board <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 388pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of directors. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Delaware anti-takeover statute <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 428pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We are subject to the provisions of Section 203 of the DGCL regulating corporate takeovers. In general, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 440pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Section 203 prohibits a publicly held Delaware corporation from engaging, under certain circumstances, in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 452pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">a business combination with an interested stockholder for a period of three years following the date the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 464pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">person became an interested stockholder unless&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 484pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">prior to the date of the transaction, our board of directors approved either the business combination or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 496pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the transaction that resulted in the stockholder becoming an interested stockholder&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 516pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">upon completion of the transaction that resulted in the stockholder becoming an interested <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 528pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">outstanding at the time the transaction commenced, excluding for purposes of determining the voting <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">stock outstanding, but not the outstanding voting stock owned by the interested stockholder, (A) <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">shares owned by persons who are directors and also officers and (B) shares owned by employee <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">stock plans in which employee participants do not have the right to determine confidentially whether <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">shares held subject to the plan will be tendered in a tender or exchange offer&#59; or<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 608pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">at or subsequent to the date of the transaction, the business combination is approved by our board of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 620pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">directors and authorized at an annual or special meeting of stockholders, and not by written consent, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 632pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">by the affirmative vote of at least sixty-six and two-thirds percent (66-2&#47;3%) of the outstanding voting <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">stock that is not owned by the interested stockholder.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 664pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Generally, a business combination includes a merger, asset or stock sale, or other transaction resulting in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 676pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">a financial benefit to the interested stockholder. Subject to certain exceptions, an &#8220;interested stockholder&#8221; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 688pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">is a person who, together with affiliates and associates, owns or, within three years prior to the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 700pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">determination of interested stockholder status, owned 15% or more of our outstanding voting stock. This <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">170<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">provision is expected to have an anti-takeover effect with respect to transactions our board of directors <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">does not approve in advance. Moreover, Section 203 may discourage attempts that might result in a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">premium over the market price for the shares of our common stock held by stockholders.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Choice of forum <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 136pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our amended and restated certificate of incorporation will generally designate, unless we otherwise <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 148pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">consent in writing, the Court of Chancery (or, if such court does not have subject matter jurisdiction <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 160pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">thereof, the federal district court of the State of Delaware) as the sole and exclusive forum for (i) any <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 172pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 184pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">fiduciary duty owed by any current or former director, officer, employee or agent to us or our stockholders, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 196pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or any claim for aiding and abetting any such alleged breach, (iii) any action asserting a claim arising <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 208pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or bylaws or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware or (iv) any <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">action asserting a claim governed by the internal affairs doctrine of the law of the State of Delaware. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 252pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our amended and restated certificate of incorporation will also provide that the federal district courts of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 264pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the United States will be the exclusive forum for the resolution of any complaint asserting a cause of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 276pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">action arising under the Securities Act. Further, our amended and restated certificate of incorporation will <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 288pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">provide that the foregoing choice of forum provisions will not apply to suits brought to enforce any liability <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 300pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or duty created by the Exchange Act, or any other claim for which the federal courts of the United States <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 312pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">have exclusive jurisdiction. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 332pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our amended and restated certificate of incorporation will also provide that any person or entity <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 344pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">purchasing or otherwise acquiring or holding any interest in any of our securities shall be deemed to have <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 356pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">notice of and consented to the foregoing provisions of the amended and restated certificate of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 368pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">incorporation. Although our amended and restated certificate of incorporation will contain the choice of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 380pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">forum provision described above, it is possible that a court could find that such a provision is inapplicable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 392pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for a particular claim or action or that such provision is unenforceable.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 412pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">This choice of forum provision may limit a stockholder's ability to bring a claim in a judicial forum that it <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 424pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 436pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">which may discourage lawsuits with respect to such claims, although our stockholders will not be deemed <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 448pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to have waived our compliance with federal securities laws and the rules and regulations thereunder. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 460pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Furthermore, the enforceability of similar choice of forum provisions in other companies' certificates of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 472pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">incorporation has been challenged in legal proceedings, and it is possible that a court could find these <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 484pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">types of provisions to be inapplicable or unenforceable.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 504pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Limitations on liability and indemnification<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 524pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">For a discussion of liability and indemnification, see the section titled &#8220;Management&#8212;Limitations on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 536pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">liability and indemnification matters.&#8221;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 556pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Transfer agent and registrar<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 578.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The transfer agent and registrar for our common stock will be&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. The transfer agent&#8217;s address <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 590.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">is&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 610.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; white-space: pre;">&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 116.32pt; position: absolute; text-decoration: none; white-space: pre;">listing <font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 632.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We intend to apply to list our common stock on the&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;under the symbol &#8220;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,&#8221; and this offering is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">contingent upon obtaining such approval. <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">171<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_1360" style="position: absolute; top: 72pt;"></div><div style="line-height: 11.64pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Shares eligible for future sale<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 107.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Prior to this offering, there has been no public market for our common stock, and a liquid trading market <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 119.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for our common stock may not develop or be sustained after this offering. Future sales of our common <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 131.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock, including shares issued upon the Preferred Stock Conversion, the Convertible Notes Conversion <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 143.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and the exercise of outstanding options or warrants, in the public market after the completion of this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 155.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">offering, or the perception that those sales may occur, could adversely affect the prevailing market price <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 167.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for our common stock from time to time or impair our ability to raise equity capital in the future. Although <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 179.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">we have applied to have our common stock listed on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, we cannot assure you that there will <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 191.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">be an active public market for our common stock. As described below, only a limited number of shares of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 203.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our common stock will be available for sale in the public market for a period of several months after the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 215.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">completion of this offering due to contractual and legal restrictions on resale described below. Future <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 227.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">sales of our common stock in the public market either before or after restrictions lapse, or the perception <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 239.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">that those sales may occur, could adversely affect the prevailing market price of our common stock at <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 251.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">such time and our ability to raise equity capital at a time and price we deem appropriate.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 271.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Sale of restricted shares<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 293.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Based on the number of shares of our common stock outstanding as of December 31, 2024, upon the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 305.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">completion of this offering and assuming (i) the Preferred Stock Conversion, (ii) the Convertible Notes <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 317.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Conversion, (iii) no exercise of the underwriters&#8217; option to purchase additional shares of our common <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 329.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock and (iv) no exercise of outstanding options or warrants, we will have outstanding an aggregate <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 341.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 361.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Of these shares, all of the&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock to be sold in this offering will be freely <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 373.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">tradable in the public market without restriction or further registration under the Securities Act, unless the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 385.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">shares are held by any of our &#8220;affiliates&#8221; as such term is defined in Rule 144 or subject to lock-up <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 397.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">agreements. All remaining shares of common stock held by existing stockholders will be &#8220;restricted <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 409.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">securities,&#8221; as such term is defined in Rule 144. These restricted securities were issued and sold by us in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 421.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">private transactions and are eligible for public sale only if registered under the Securities Act or if they <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 433.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">qualify for an exemption from registration under the Securities Act, including the exemptions provided by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 445.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Rule 144 or Rule 701 of the Securities Act (&#8220;Rule 701&#8221;), which rules are summarized below.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 465.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">As a result of the lock-up agreements referred to below and the provisions of Rule 144 and Rule 701, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 477.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">based on the number of shares of our common stock outstanding (calculated as of December 31, 2024 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 489.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">on the basis of the assumptions described above and assuming no exercise of the underwriters&#8217; option to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 501.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">purchase additional shares, if any, and no exercise of outstanding options), the shares of our common <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 513.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock (excluding the shares sold in this offering) that will be available for sale in the public market are as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 525.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">follows&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 545.6pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 84.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 380.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 21.75pt;"><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 84.75pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3.15pt; width: 84.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Approximate <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 12.75pt; width: 84.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">number of shares<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 87.75pt; position: absolute; top: 0pt; width: 380.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 12.75pt; width: 380.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">First date available for sale into public market<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td></tr><tr style="height: 33.75pt;"><td style="border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 21.75pt; width: 84.75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.63pt; width: 84.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 26.63pt; position: absolute; text-decoration: none; white-space: pre;">shares<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 33.75pt; left: 87.75pt; overflow: hidden; position: absolute; top: 21.75pt; width: 380.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 2.63pt; width: 380.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">181 days after the date of this prospectus, upon expiration of the lock-up market stand-off <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 14.03pt; width: 380.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">agreements referred to below, subject in some cases to applicable volume, manner of <font style="display: inline-block; height: 6.91pt;"></font></font></div><div style="line-height: 6.91pt; position: absolute; top: 25.43pt; width: 380.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">sale and other limitations under Rule 144 and Rule 701.<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 617.1pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We may issue shares of common stock from time to time as consideration for future acquisitions, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 629.1pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">investments, or other corporate purposes. In the event that any such acquisition, investment, or other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 641.1pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">transaction is significant, the number of shares of common stock that we may issue may in turn be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 653.1pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">significant. We may also grant registration rights covering those shares of common stock issued in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 665.1pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">connection with any such acquisition and investment.&#160;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 685.1pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition, the shares of common stock reserved for future issuance under the 2025 Plan will become <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 697.1pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">172<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the lock-up agreements, a registration statement under the Securities Act, or an exemption from <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">registration, including Rule 144 and Rule 701.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Rule 144<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 126.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Under Rule 144, as currently in effect, once we have been subject to the public company reporting <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 138.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">requirements of the Exchange Act for at least 90 days, and we are current in our Exchange Act reporting <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 150.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">at the time of sale, a person (or persons whose shares are required to be aggregated) who is not deemed <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 162.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to have been one of our &#8220;affiliates&#8221; for purposes of Rule 144 at any time during the 90 days preceding a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 174.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">sale and who has beneficially owned restricted securities within the meaning of Rule 144 for at least six <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 186.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">months, including the holding period of any prior owner other than one of our &#8220;affiliates,&#8221; is entitled to sell <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 198.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">those shares in the public market (subject to the lock-up agreement referred to below, if applicable) <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 210.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">without complying with the manner of sale, volume limitations, or notice provisions of Rule 144, but <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 222.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">subject to compliance with the public information requirements of Rule 144. If such a person <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 234.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">has&#160;beneficially owned the shares proposed to be sold for at least one year, including the holding period <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 246.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of any prior owner other than &#8220;affiliates,&#8221; then such person is entitled to sell such shares in the public <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 258.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">market without complying with any of the requirements of Rule 144 (subject to the lock-up agreement <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 270.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">referred to below, if applicable).<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 290.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In general, under Rule 144, as currently in effect, once we have been subject to the public company <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 302.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reporting requirements of the Exchange Act for at least 90 days, our &#8220;affiliates,&#8221; as defined in Rule 144, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 314.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">who have beneficially owned the shares proposed to be sold for at least six months, are entitled to sell in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 326.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the public market, upon expiration of any applicable lock-up agreements and within any three-month <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 338.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">period, a number of those shares of our common stock that does not exceed the greater of&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 358.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">1% of the number of shares of common stock then outstanding, which will equal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 370.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of common stock immediately upon the completion of this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 382.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">offering (calculated as of December 31, 2024 on the basis of the assumptions described above and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 394.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">assuming no exercise of the underwriters&#8217; option to purchase additional shares and no exercise of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 406.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">outstanding options or warrants subsequent to December 31, 2024)&#59; or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 426.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the average weekly trading volume of our common stock on the&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;during the four <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 438.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">calendar weeks preceding the filing of a notice on Form 144 with respect to such sale. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 458.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Such sales under Rule 144 by our &#8220;affiliates&#8221; or persons selling shares on behalf of our &#8220;affiliates&#8221; are also <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 470.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">subject to certain manner of sale provisions, notice requirements, and requirements related to the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 482.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">availability of current public information about us. Notwithstanding the availability of Rule 144, the holders <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 494.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of substantially all of our restricted securities have entered into lock-up agreements as referenced above, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 506.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and their restricted securities will become eligible for sale (subject to the above limitations under Rule <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 518.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">144) upon the expiration of the restrictions set forth in those agreements.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 538.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Rule 701<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 560.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In general, under Rule 701 as currently in effect, any of our employees, directors, officers, consultants, or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 572.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">advisors who acquired common stock from us in connection with a written compensatory stock or option <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 584.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">plan or other written agreement in compliance with Rule 701 before the effective date of the registration <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 596.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">statement of which this prospectus is a part (to the extent such common stock is not subject to a lock-up <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 608.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">agreement) and who are not our &#8220;affiliates&#8221; as defined in Rule 144 during the immediately preceding 90 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 620.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">days, is entitled to rely on Rule 701 to resell such shares beginning 90 days after the date of this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 632.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prospectus in reliance on Rule 144, but without complying with the notice, manner of sale, public <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">information requirements, or volume limitation provisions of Rule 144. Persons who are our &#8220;affiliates&#8221; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">may resell those shares beginning 90 days after the date of this prospectus without compliance with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 668.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">minimum holding period requirements under Rule 144 (subject to the terms of the lock-up agreement <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 680.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">referred to below, if applicable).<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">173<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 8.73pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Lock-up and market stand-off agreements<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 94.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In connection with this offering, we, our directors, our executive officers, and the holders of substantially <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 106.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">all of our common stock, stock options, and other securities convertible into or exercisable or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 118.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">exchangeable for our common stock, have agreed, that without the prior written consent of J.P. Morgan <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 130.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Securities LLC, Morgan Stanley &#38; Co. LLC and Piper Sandler &#38; Co. on behalf of the underwriters, subject <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 142.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to certain exceptions more fully described under the section titled &#8220;Underwriting&#8221;, we and they will not, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 154.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">among other things, sell or otherwise transfer or dispose of any of our securities during the period from <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 166.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the date of this prospectus continuing through the date 180 days after the date of this prospectus. See the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 178.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">section titled &#8220;Underwriting&#8221; for additional information.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 198.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition to the restrictions contained in the lock-up agreements described above, we have entered into <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 210.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">agreements with certain securityholders, including the amended and restated investors&#8217; rights agreement, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 222.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our standard form of option agreement and warrants that contain market stand-off provisions or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 234.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">incorporate market stand-off provisions from our equity incentive plan imposing restrictions on the ability <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 246.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of such securityholders to offer, sell, or transfer our equity securities for a period of 180 days following the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 258.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">date of this prospectus.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 278.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Following the lock-up periods set forth in the agreements described above, and assuming that J.P. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 290.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Morgan Securities LLC, Morgan Stanley &#38; Co. LLC and Piper Sandler &#38; Co. do not release any parties <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 302.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">from these agreements, all of the shares of our common stock that are restricted securities or are held by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 314.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our affiliates as of the date of this prospectus will be eligible for sale in the public market in compliance <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 326.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">with Rule 144 under the Securities Act.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 346.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Registration rights<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 368.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Upon the completion of this offering, the holders of approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 380.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">will be entitled to rights with respect to the registration of their shares under the Securities Act, subject to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 392.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the lock-up agreements described under &#8220;&#8212;Lock-up agreements&#8221; above. Registration of these shares <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 404.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">under the Securities Act would result in the shares becoming freely tradable without restriction under the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 416.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Securities Act, except for shares purchased by affiliates, immediately upon the effectiveness of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 428.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">relevant filed registration statement, subject to the terms of the lock-up agreements described above. Any <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 440.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">sales of securities by these stockholders could have a material adverse effect on the trading price of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 452.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">common stock.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 472.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Equity incentive plans<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 495.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We intend to file with the SEC a registration statement on Form S-8 under the Securities Act to register <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 507.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our shares issued or reserved for issuance under our equity incentive plans. Such registration statement <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 519.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">is expected to be filed and become effective as soon as practicable after the completion of this offering. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 531.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Accordingly, shares registered under such registration statement will be available for sale in the open <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 543.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">market following its effective date, subject to Rule 144 volume limitations, vesting restrictions, and the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 555.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">lock-up agreements described above, if applicable.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 575.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Rule 10b5-1 trading plans<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 597.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Following the completion of this offering, certain of our officers, directors, and significant stockholders may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 609.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">adopt written plans, known as Rule 10b5-1 trading plans, in which they will contract with a broker to buy <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 621.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or sell shares of our common stock on a periodic basis to diversify their assets and investments. Under <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 633.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">these Rule 10b5-1 trading plans, a broker may execute trades pursuant to parameters established by the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 645.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">officer, director, or stockholder when entering into the plan, without further direction from such officer, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 657.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">director, or stockholder. Such sales would not commence until the expiration of the applicable lock-up <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 669.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">agreements entered into by such officer, director, or stockholder in connection with this offering.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">174<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_1408" style="position: absolute; top: 72pt;"></div><div style="line-height: 11.64pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Material U.S. federal income tax consequences to non-U.S. <font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="line-height: 11.64pt; position: absolute; top: 91.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">holders<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 126.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The following discussion is a summary of the material U.S. federal income tax consequences to Non-U.S. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 138.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Holders (as defined below) of the purchase, ownership, and disposition of our common stock issued <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 150.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">pursuant to this offering, but does not purport to be a complete analysis of all potential tax effects. The <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 162.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local, or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 174.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">non-U.S. tax laws are not discussed. This discussion is based on the U.S. Internal Revenue Code of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 186.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">1986, as amended (the &#8220;Code&#8221;), Treasury Regulations promulgated thereunder, judicial decisions, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 198.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">published rulings and administrative pronouncements of the U.S. Internal Revenue Service (the &#8220;IRS&#8221;), in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 210.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">each case in effect as of the date hereof. These authorities may change or be subject to differing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 222.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">interpretations. Any such change or differing interpretation may be applied retroactively in a manner that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 234.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">could adversely affect a Non-U.S. Holder. We have not sought and will not seek any rulings from the IRS <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 246.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">regarding the matters discussed below. There can be no assurance the IRS or a court will not take a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 258.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">contrary position to that discussed below regarding the tax consequences of the purchase, ownership, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 270.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and disposition of our common stock.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 290.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">This discussion is limited to Non-U.S. Holders that hold our common stock as a &#8220;capital asset&#8221; within the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 302.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">meaning of Section 1221 of the Code (generally, property held for investment). This discussion does not <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 314.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">address all U.S. federal income tax consequences relevant to a Non-U.S. Holder&#8217;s particular <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 326.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">circumstances, including the impact of the Medicare contribution tax on net investment income and the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 338.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">alternative minimum tax. In addition, it does not address consequences relevant to Non-U.S. Holders <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 350.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">subject to special rules, including, without limitation&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 370.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">U.S. expatriates and former citizens or long-term residents of the United States&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 390.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">persons holding our common stock as part of a hedge, straddle, or other risk reduction strategy or as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 402.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">part of a conversion transaction or other integrated investment&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 422.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">banks, insurance companies, and other financial institutions&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 442.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">brokers, dealers, or traders in securities&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 462.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">&#8220;controlled foreign corporations,&#8221; &#8220;passive foreign investment companies,&#8221; and corporations that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 474.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">accumulate earnings to avoid U.S. federal income tax&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 494.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 506.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">purposes (and investors therein)&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 526.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">tax-exempt organizations or governmental organizations&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 546.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">persons deemed to sell our common stock under the constructive sale provisions of the Code&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 566.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">persons who hold or receive our common stock pursuant to the exercise of any employee stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 578.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">option or otherwise as compensation&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 598.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">tax-qualified retirement plans&#59; and<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 618.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">&#8220;qualified foreign pension funds&#8221; as defined in Section 897(l)(2) of the Code and entities all of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 630.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">interests of which are held by qualified foreign pension funds.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 650.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">If an entity treated as a partnership for U.S. federal income tax purposes holds our common stock, the tax <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 662.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">treatment of a partner in the partnership will depend on the status of the partner, the activities of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 674.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">partnership, and certain determinations made at the partner level. Accordingly, partnerships holding our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 686.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">common stock and the partners in such partnerships should consult their tax advisors regarding the U.S. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 698.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">federal income tax consequences to them.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">175<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; white-space: pre;">THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; white-space: pre;">INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; white-space: pre;">OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; white-space: pre;">ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP, AND DISPOSITION OF OUR <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; white-space: pre;">COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; white-space: pre;">THE LAWS OF ANY STATE, LOCAL, OR NON-U.S. TAXING JURISDICTION OR UNDER ANY <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; white-space: pre;">APPLICABLE INCOME TAX TREATY.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Definition of a Non-U.S. Holder<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 186.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">For purposes of this discussion, a &#8220;Non-U.S. Holder&#8221; is any beneficial owner of our common stock that is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 198.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">neither a &#8220;U.S. person&#8221; nor an entity treated as a partnership for U.S. federal income tax purposes. A U.S. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 210.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">person is any person that, for U.S. federal income tax purposes, is or is treated as any of the following&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 230.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">an individual who is a citizen or resident of the United States&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 250.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">a corporation created or organized under the laws of the United States, any state thereof or the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 262.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">District of Columbia&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 282.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">an estate, the income of which is subject to U.S. federal income tax regardless of its source&#59; or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 302.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">a trust that (i) is subject to the primary supervision of a U.S. court and all substantial decisions of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 314.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">which are subject to the control of one or more &#8220;United States persons&#8221; (within the meaning of Section <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 326.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">7701(a)(30) of the Code), or (ii) has a valid election in effect to be treated as a United States person <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 338.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">for U.S. federal income tax purposes.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 358.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Distributions<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 380.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">As described in the section titled &#8220;Dividend policy,&#8221; we do not anticipate paying any cash dividends in the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 392.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">foreseeable future. However, if we do make distributions of cash or property on our common stock, such <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 404.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 416.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">current or accumulated earnings and profits, as determined under U.S. federal income tax principles. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 428.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Amounts not treated as dividends for U.S. federal income tax purposes will constitute a return of capital <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 440.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and first be applied against and reduce a Non-U.S. Holder&#8217;s adjusted tax basis in its common stock, but <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 452.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">not below zero. Any excess will be treated as capital gain and will be treated as described under the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 464.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">subsection titled &#8220;&#8212;Sale or other taxable disposition&#8221; below.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 484.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Subject to the discussion below regarding effectively connected income, dividends paid to a Non-U.S. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 496.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Holder will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 508.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(or such lower rate specified by an applicable income tax treaty, provided the Non-U.S. Holder furnishes a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 520.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">valid IRS Form W-8BEN or W-8BEN-E (or other applicable documentation) certifying qualification for the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 532.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">lower treaty rate). A Non-U.S. Holder that does not timely furnish the required documentation, but that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 544.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">qualifies for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 556.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">appropriate claim for refund with the IRS. Non-U.S. Holders should consult their tax advisors regarding <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 568.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">their entitlement to benefits under any applicable tax treaties.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">If dividends paid to a Non-U.S. Holder are effectively connected with the Non-U.S. Holder&#8217;s conduct of a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 600.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">trade or business within the United States (and, if required by an applicable income tax treaty, the Non-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">U.S. Holder maintains a permanent establishment in the United States to which such dividends are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">attributable), the Non-U.S. Holder will be exempt from the U.S. federal withholding tax described above. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 636.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">To claim the exemption, the Non-U.S. Holder must furnish to the applicable withholding agent a valid IRS <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 648.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Form W-8ECI, certifying that the dividends are effectively connected with the Non-U.S. Holder&#8217;s conduct <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of a trade or business within the United States.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 680.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Any such effectively connected dividends will be subject to U.S. federal income tax on a net income basis <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 692.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">at the regular rates applicable to U.S. persons. A Non-U.S. Holder that is a corporation also may be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 704.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">176<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">treaty) on such effectively connected dividends, as adjusted for certain items. Non-U.S. Holders should <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">consult their tax advisors regarding any applicable tax treaties that may provide for different rules.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Sale or other taxable disposition<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 126.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">A Non-U.S. Holder will not be subject to U.S. federal income tax on any gain realized upon the sale or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 138.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">other taxable disposition of our common stock unless&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 158.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the gain is effectively connected with the Non-U.S. Holder&#8217;s conduct of a trade or business within the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 170.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">United States (and, if required by an applicable income tax treaty, the Non-U.S. Holder maintains a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 182.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">permanent establishment in the United States to which such gain is attributable)&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 202.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the Non-U.S. Holder is a nonresident alien individual present in the United States for 183 days or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 214.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">more during the taxable year of the disposition and certain other requirements are met&#59; or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 234.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our common stock constitutes a U.S. real property interest (&#8220;USRPI&#8221;) by reason of our status as a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 246.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">U.S. real property holding corporation (&#8220;USRPHC&#8221;) for U.S. federal income tax purposes.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 266.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Gain described in the first bullet point above generally will be subject to U.S. federal income tax on a net <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 278.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">income basis at the regular rates applicable to U.S. persons. A Non-U.S. Holder that is a corporation also <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 290.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 302.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">income tax treaty) on such effectively connected gain, as adjusted for certain items.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 322.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">A Non-U.S. Holder described in the second bullet point above will be subject to U.S. federal income tax at <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 334.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">a rate of 30% (or such lower rate specified by an applicable income tax treaty) on gain realized upon the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 346.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">sale or other taxable disposition of our common stock, which may be offset by certain U.S. source capital <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 358.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">losses of the Non-U.S. Holder (even though the individual is not considered a resident of the United <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 370.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">States), provided the Non-U.S. Holder has timely filed U.S. federal income tax returns with respect to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 382.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">such losses.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 402.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">With respect to the third bullet point above, we believe we currently are not, and do not anticipate <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 414.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">becoming, a USRPHC. Because the determination of whether we are a USRPHC depends, however, on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 426.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the fair market value of our USRPIs relative to the fair market value of our non-U.S. real property interests <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 438.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and our other business assets, there can be no assurance we currently are not a USRPHC or will not <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 450.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">become one in the future. Even if we are or were to become a USRPHC, gain arising from the sale or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 462.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">other taxable disposition of our common stock by a Non-U.S. Holder will not be subject to U.S. federal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 474.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">income tax if our common stock is &#8220;regularly traded,&#8221; as defined by applicable Treasury Regulations, on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 486.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">an established securities market, and such Non-U.S. Holder owned, actually and constructively, 5% or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 498.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">less of our common stock throughout the shorter of the five-year period ending on the date of the sale or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 510.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">other taxable disposition or the Non-U.S. Holder&#8217;s holding period.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 530.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Non-U.S. Holders should consult their tax advisors regarding any applicable tax treaties that may provide <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 542.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for different rules.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 562.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Information reporting and backup withholding<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 584.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Payments of dividends on our common stock will not be subject to backup withholding, provided the Non-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 596.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">U.S. Holder certifies its non-U.S. status, such as by furnishing a valid IRS Form W-8BEN, W-8BEN-E, or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 608.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">W-8ECI, or otherwise establishes an exemption. However, information returns are required to be filed with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 620.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the IRS in connection with any distributions on our common stock paid to the Non-U.S. Holder, regardless <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 632.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of whether such distributions constitute dividends or whether any tax was actually withheld. In addition, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">proceeds of the sale or other taxable disposition of our common stock within the United States or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">conducted through certain U.S.-related brokers generally will not be subject to backup withholding or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 668.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">information reporting if the applicable withholding agent receives the certification described above or the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 680.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Non-U.S. Holder otherwise establishes an exemption. Proceeds of a disposition of our common stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 692.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">conducted through a non-U.S. office of a non-U.S. broker that does not have certain enumerated <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">177<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">relationships with the United States generally will not be subject to backup withholding or information <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reporting.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Copies of information returns that are filed with the IRS may also be made available under the provisions <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of an applicable treaty or agreement to the tax authorities of the country in which the Non-U.S. Holder <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">resides or is established.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 148pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 160pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">may be allowed as a refund or a credit against a Non-U.S. Holder&#8217;s U.S. federal income tax liability, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 172pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">provided the required information is timely furnished to the IRS.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 192pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Additional withholding tax on payments made to foreign accounts<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 214.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Withholding taxes may be imposed under Sections 1471 to 1474 of the Code (such Sections commonly <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 226.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">referred to as the Foreign Account Tax Compliance Act (&#8220;FATCA&#8221;)) on certain types of payments made to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 238.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">non-U.S. financial institutions and certain other non-U.S. entities. Specifically, a 30% withholding tax may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 250.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">be imposed on dividends on, or (subject to the proposed Treasury Regulations discussed below) gross <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 262.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">proceeds from the sale or other disposition of, our common stock paid to a &#8220;foreign financial institution&#8221; or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 274.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">a &#8220;non-financial foreign entity&#8221; (each as defined in the Code), unless (i) the foreign financial institution <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 286.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">undertakes certain diligence and reporting obligations, (ii) the non-financial foreign entity either certifies it <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 298.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">does not have any &#8220;substantial United States owners&#8221; (as defined in the Code) or furnishes identifying <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 310.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">information regarding each substantial United States owner, or (iii) the foreign financial institution or non-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 322.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">financial foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 334.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">financial institution and is subject to the diligence and reporting requirements in (i) above, it must enter <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 346.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">into an agreement with the U.S. Department of the Treasury requiring, among other things, that it <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 358.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">undertake to identify accounts held by certain &#8220;specified United States persons&#8221; or &#8220;United States owned <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 370.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">foreign entities&#8221; (each as defined in the Code), annually report certain information about such accounts, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 382.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and withhold 30% on certain payments to non-compliant foreign financial institutions and certain other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 394.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">account holders. Foreign financial institutions located in jurisdictions that have an intergovernmental <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 406.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">agreement with the United States governing FATCA may be subject to different rules.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 426.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Under applicable Treasury Regulations and administrative guidance, withholding under FATCA generally <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 438.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">applies to payments of dividends on our common stock. While withholding under FATCA would have <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 450.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">applied also to payments of gross proceeds from the sale or other disposition of our common stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 462.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">beginning on January 1, 2019, proposed Treasury Regulations eliminate FATCA withholding on payments <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 474.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of gross proceeds entirely. Taxpayers generally may rely on these proposed Treasury Regulations until <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 486.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">final Treasury Regulations are issued.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 506.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Prospective investors should consult their tax advisors regarding the potential application of withholding <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 518.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">under FATCA to their investment in our common stock.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">178<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_1434" style="position: absolute; top: 72pt;"></div><div style="line-height: 11.64pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Underwriting<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 107.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We are offering the shares of common stock described in this prospectus through a number of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 119.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">underwriters. J.P. Morgan Securities LLC, Morgan Stanley &#38; Co. LLC and Piper Sandler &#38; Co. are acting <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 131.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">as joint book-running managers of the offering and as representatives of the underwriters. We have <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 143.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">entered into an underwriting agreement with the underwriters. Subject to the terms and conditions of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 155.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">underwriting agreement, we have agreed to sell to the underwriters, and each underwriter has severally <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 167.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">agreed to purchase, at the public offering price less the underwriting discounts and commissions set forth <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 179.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">on the cover page of this prospectus, the number of shares of common stock listed next to its name in the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 191.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">following table&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 211.2pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 390.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 74.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 21.75pt;"><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 390.75pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 12.75pt; width: 390.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Name<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 393.75pt; position: absolute; top: 0pt; width: 74.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 12.75pt; width: 74.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 3.7pt; position: absolute; text-decoration: none; white-space: pre;">Number of shares<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 21.75pt; width: 390.75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 390.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">J.P. Morgan Securities LLC<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 116.92999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 117.50999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 117.8pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 117.83999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 117.85pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 36pt; width: 390.75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 390.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Morgan Stanley &#38; Co. LLC<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 115.52pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 116.67999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 117.25999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 117.55pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 117.69999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 117.72pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 50.25pt; width: 390.75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 390.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Piper Sandler &#38; Co.<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 86.5pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 88.81pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 89.1pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 89.17999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 89.22pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 64.5pt; width: 390.75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 390.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Stifel, Nicolaus &#38; Company, Incorporated<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 175.48pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 177.79pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 178.95pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 179.1pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 179.18pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 78.75pt; width: 390.75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 390.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Canaccord Genuity LLC<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 103.94pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 106.25pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 107.41pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 107.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 108.03pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 93pt; width: 390.75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 390.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Total<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 22.68pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 22.97pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 23.05pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 23.09pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 23.11pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 334.45pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The underwriters are committed to purchase all the shares of common stock offered by us if they <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 346.45pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">purchase any shares. The underwriting agreement also provides that if an underwriter defaults, the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 358.45pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">purchase commitments of non-defaulting underwriters may also be increased or the offering may be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 370.45pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">terminated.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 390.45pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The underwriters propose to offer the shares of common stock directly to the public at the initial public <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 402.45pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">offering price set forth on the cover page of this prospectus and to certain dealers at that price less a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 414.45pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">concession not in excess of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share. After the initial offering of the shares to the public, if all of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 426.45pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the shares of common stock are not sold at the initial public offering price, the underwriters may change <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 438.45pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the offering price and the other selling terms. Sales of any shares made outside of the United States may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 450.45pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">be made by affiliates of the underwriters.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 470.45pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The underwriters have an option to buy up to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;additional shares of common stock from us to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 482.45pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">cover sales of shares by the underwriters which exceed the number of shares specified in the table <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 494.45pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">above. The underwriters have 30 days from the date of this prospectus to exercise this option to purchase <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 506.45pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">additional shares. If any shares are purchased with this option to purchase additional shares, the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 518.45pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">underwriters will purchase shares in approximately the same proportion as shown in the table above. If <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 530.45pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">any additional shares of common stock are purchased, the underwriters will offer the additional shares on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 542.45pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the same terms as those on which the shares are being offered.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 562.45pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The underwriting fee is equal to the public offering price per share of common stock less the amount paid <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 574.45pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">by the underwriters to us per share of common stock. The underwriting fee is $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share. The <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 586.45pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">following table shows the per share and total underwriting discounts and commissions to be paid to the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 598.45pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">underwriters assuming both no exercise and full exercise of the underwriters&#8217; option to purchase <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 610.45pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">additional shares.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 630.45pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 334.5pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 41.25pt;"><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3.45pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 6.27pt; position: absolute; text-decoration: none; white-space: pre;">Without option <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 13.05pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 17.35pt; position: absolute; text-decoration: none; white-space: pre;">to purchase <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 22.65pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 24.9pt; position: absolute; text-decoration: none; white-space: pre;">additional <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 32.25pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 2.68pt; position: absolute; text-decoration: none; white-space: pre;">shares exercise<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 3.45pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 4.49pt; position: absolute; text-decoration: none; white-space: pre;">With full option <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 13.05pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 17.35pt; position: absolute; text-decoration: none; white-space: pre;">to purchase <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 22.65pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 24.9pt; position: absolute; text-decoration: none; white-space: pre;">additional <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="line-height: 5.82pt; position: absolute; top: 32.25pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 2.68pt; position: absolute; text-decoration: none; white-space: pre;">shares exercise<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 41.25pt; width: 334.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 334.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Per Share<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 45.36pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 46.52pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 47.1pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 47.25pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 47.27pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 47.28pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 41.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 4.74pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 41.25pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 4.74pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 55.5pt; width: 334.5pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 334.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Total<font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 22.68pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 23.259999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 23.55pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 23.63pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 23.669999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 23.68pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 55.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 4.74pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 55.5pt; width: 65.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 4.74pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">179<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We estimate that the total expenses of this offering, including registration, filing and listing fees, printing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">fees and legal and accounting expenses, but excluding the underwriting discounts and commissions, will <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">be approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;. We have agreed to reimburse the underwriters for expenses relating to the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">clearance of this offering with the Financial Industry Regulatory Authority, Inc. in an amount up to $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">A prospectus in electronic format may be made available on the web sites maintained by one or more <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">underwriters, or selling group members, if any, participating in the offering. The underwriters may agree to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">allocate a number of shares to underwriters and selling group members for sale to their online brokerage <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">account holders. Internet distributions will be allocated by the representatives to underwriters and selling <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">group members that may make Internet distributions on the same basis as other allocations.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 196pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We have agreed that we will not, subject to certain exceptions, (i) offer, pledge, sell, contract to sell, sell <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 208pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">any option or contract to purchase, purchase any option or contract to sell, grant any option, right or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">warrant to purchase, hedge, lend, or otherwise transfer or dispose of, directly or indirectly, or submit to, or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">file with, the SEC a registration statement under the Securities Act relating to, any shares of our common <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock or any securities convertible into or exercisable or exchangeable for any shares of our common <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock, or (ii) enter into any swap, hedging, or other agreement that transfers, in whole or in part, any of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">economic consequences of ownership of any shares of common stock or any such other securities, or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">publicly disclose the intention to undertake any of the foregoing (regardless of whether any of these <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">transactions are to be settled by the delivery of shares of common stock or such other securities, in cash <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or otherwise), in each case without the prior written consent of J.P. Morgan Securities LLC, Morgan <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Stanley &#38; Co. LLC and Piper Sandler &#38; Co. for a period of 180 days after the date of this prospectus, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">other than the shares of our common stock to be sold in this offering.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 348pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The restrictions on our actions, as described above, do not apply to certain transactions, including (i) the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">issuance of shares of common stock or securities convertible into or exercisable for shares of our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">common stock pursuant to the conversion or exchange of convertible or exchangeable securities or the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 384pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">exercise of warrants or options (including net exercise) or the settlement of RSUs (including net <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">settlement), in each case outstanding on the date of the underwriting agreement and described in this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prospectus&#59; (ii) grants of stock options, stock awards, restricted stock, RSUs, or other equity awards and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the issuance of shares of our common stock or securities convertible into or exercisable or exchangeable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 432pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for shares of our common stock (whether upon the exercise of stock options or otherwise) to our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 444pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">employees, officers, directors, advisors, or consultants pursuant to the terms of an equity compensation <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 456pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">plan in effect as of the closing date of this offering and described in this prospectus, provided that such <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 468pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">recipients enter into a lock-up agreement with the underwriters&#59; (iii) the issuance of up to 5% of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">outstanding shares of our common stock, or securities convertible into, exercisable for, or which are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 492pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">otherwise exchangeable for, our common stock, immediately following the closing date of this offering, in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 504pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">acquisitions or other similar strategic transactions, provided that such recipients enter into a lock-up <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 516pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">agreement with the underwriters&#59; or (iv) the filing of any registration statement on Form S-8 relating to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 528pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">securities granted or to be granted pursuant to any plan in effect on the date of the underwriting <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">agreement and described in this prospectus or any assumed benefit plan pursuant to an acquisition or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">similar strategic transaction.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 572pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our directors and executive officers, and substantially all of our securityholders (such persons, the &#8220;lock-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 584pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">up parties&#8221;) have entered into lock-up agreements with the underwriters prior to the commencement of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 596pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">this offering pursuant to which each lock-up party, with limited exceptions, for a period of 180 days after <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 608pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the date of this prospectus (such period, the &#8220;restricted period&#8221;), may not and may not cause any of their <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 620pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">direct or indirect affiliates to, without the prior written consent of J.P. Morgan Securities LLC, Morgan <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 632pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Stanley &#38; Co. LLC and Piper Sandler &#38; Co., (i) offer, pledge, sell, contract to sell, sell any option or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of our common stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 668pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or any securities convertible into or exercisable or exchangeable for our common stock (including without <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 680pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">limitation, our common stock or such other securities which may be deemed to be beneficially owned by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 692pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the lock-up party in accordance with the rules and regulations of the SEC and securities which may be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 704pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">issued upon exercise of a stock option or warrant) (collectively with our common stock and any common <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">180<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock of HeartFlow Holding, Inc. prior to the consolidation of HeartFlow Holding, Inc. into HeartFlow, Inc., <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the &#8220;lock-up securities&#8221;), (ii) enter into any hedging, swap or other agreement or transaction that transfers, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">in whole or in part, any of the economic consequences of ownership of the lock-up securities, whether <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">any such transaction described in clause (i) or (ii) above is to be settled by delivery of the lock-up <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">securities, in cash or otherwise, (iii) make any demand for or exercise any right with respect to the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">registration of any lock-up securities, or (iv) publicly disclose the intention to do any of the foregoing.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Such persons or entities have further acknowledged that these undertakings preclude them from <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">engaging in any hedging or other transactions or arrangements (including, without limitation, any short <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or any other derivative transaction or instrument, however described or defined) designed or intended, or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">which could reasonably be expected to lead to or result in, a sale or disposition or transfer (whether by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the lock-up party or any other person) of any economic consequences of ownership, in whole or in part, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">directly or indirectly, of any lock-up securities, whether any such transaction or arrangement (or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">instrument provided for thereunder) would be settled by delivery of lock-up securities, in cash or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">otherwise. Such persons or entities further confirmed that they have furnished the representatives with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 260pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the details of any transaction such persons or entities, or any of their respective affiliates, is a party to as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 272pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of the date of the lock-up agreements, which transaction would have been restricted by the lock-up <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 284pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">agreements if it had been entered into by such persons or entities during the restricted period.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The restrictions described in the immediately preceding paragraph and contained in the lock-up <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">agreements between the underwriters and the lock-up parties do not apply, subject in certain cases to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">various conditions, to certain transactions, including (a) transfers of lock-up securities&#58; (i) as a bona fide <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">gift or gifts or charitable contribution, or for bona fide estate planning purposes, (ii) by will or intestacy or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">any other testamentary document, (iii) to any member of the lock-up party&#8217;s immediate family or to any <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 364pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">trust for the direct or indirect benefit of the lock-up party or the immediate family of the lock-up party, or if <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the lock-up party is a trust, to a trustor, trustee or beneficiary of the trust or to the estate of a trustor, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 388pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">trustee or beneficiary of such trust (for purposes of the lock-up agreement, &#8220;immediate family&#8221; means any <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 400pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">relationship by blood, current or former marriage, domestic partnership or adoption, not more remote than <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 412pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">first cousin), (iv) to a corporation, partnership, limited liability company, investment fund or other entity (A) <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 424pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of which the lock-up party and&#47;or the immediate family of the lock-up party are the legal and beneficial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 436pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">owner of all of the outstanding equity securities or similar interests, or (B) controlled by, or under common <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 448pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">control with, the lock-up party or the immediate family of the lock-up party, (v) to a nominee or custodian <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 460pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of a person or entity to whom a disposition or transfer would be permissible under clauses (i) through (iv) <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 472pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">above, (vi) in the case of a corporation, partnership, limited liability company, trust or other business <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 484pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">entity, (A) to another corporation, partnership, limited liability company, trust or other business entity that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 496pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">is an affiliate of the lock-up party, or to any investment fund or other entity controlling, controlled by, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 508pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">managing or managed by or under common control or common investment management with the lock-up <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 520pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">party or its affiliates or (B) as part of a disposition, transfer or distribution to limited partners, members or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 532pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">shareholders of the lock-up party&#59; (vii) by operation of law, such as pursuant to a qualified domestic order, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 544pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">divorce settlement, divorce decree or separation agreement, (viii) to us upon death or disability of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 556pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">lock-up party, or, if the lock-up party is an employee of ours upon death, disability or termination of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 568pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">employment, in each case, of such employee, (ix) as part of a sale or transfer of lock-up securities <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 580pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">acquired (A) from the underwriters in this offering or (B) in open market transactions after the completion <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 592pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of this offering, (x) to us in connection with the vesting, settlement, or exercise of restricted stock units, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 604pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">options, warrants or other rights to purchase shares of our common stock (including, in each case, by way <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 616pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of &#8220;net&#8221; or &#8220;cashless&#8221; exercise), including for the payment of exercise price and tax and remittance <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 628pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">payments due as a result of the vesting, settlement, or exercise of such restricted stock units, options, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 640pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">warrants or rights, provided that any such shares of our common stock received upon such exercise, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 652pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">vesting or settlement shall be subject to the terms of the lock-up agreement, and provided further that any <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 664pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">such restricted stock units, options, warrants or rights are held by the lock-up party pursuant to an <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 676pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">agreement or equity awards granted under a stock incentive plan or other equity award plan, each such <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 688pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">agreement or plan which is described herein, or (xi) pursuant to a bona fide third-party tender offer, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 700pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">merger, consolidation or other similar transaction that is approved by the Board of Directors and made to <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">181<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">all holders of our capital stock involving a Change of Control (for purposes hereof, &#8220;Change of Control&#8221; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">means the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">transaction or a series of related transactions, to a person or group of affiliated persons, of shares of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">capital stock if, after such transfer, such person or group of affiliated persons would hold more than 50% <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of our outstanding voting securities (or the surviving entity))&#59; provided that in the event that such tender <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">offer, merger, consolidation or other similar transaction is not completed, the lock-up party&#8217;s lock-up <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">securities shall remain subject to the restrictions in the immediately preceding paragraph&#59; (b) exercise of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 156pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the options, settlement of RSUs or other equity awards, or the exercise of warrants granted pursuant to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 168pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">plans described in this prospectus, provided that any lock-up securities received upon such exercise, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 180pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">vesting or settlement be subject to restrictions similar to those in the immediately preceding paragraph&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 192pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(c) the conversion of outstanding preferred stock, warrants to acquire preferred stock, or convertible <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 204pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">securities into shares of our common stock or warrants to acquire shares of our common stock, provided <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 216pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">that any common stock or warrant received upon such conversion would be subject to restrictions similar <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 228pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to those in the immediately preceding paragraph&#59; and (d) the establishment by lock-up parties of trading <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 240pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">plans under Rule 10b5-1 under the Exchange Act, provided that (1) such plans do not provide for the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 252pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">transfer of lock-up securities during the restricted period and (2) any required public announcement or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 264pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">filing under the Exchange Act made by any person regarding the establishment of such plan during the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 276pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">restricted period shall include a statement that the lock-up party is not permitted to transfer, sell or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 288pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">otherwise dispose of lock-up securities under such plan during the restricted period in contravention of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 300pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">lock-up agreement and no public filing, report or announcement by any party shall be made voluntarily in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 312pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">connection with such trading plan.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 332pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">J.P. Morgan Securities LLC, Morgan Stanley &#38; Co. LLC and Piper Sandler &#38; Co., in their sole discretion, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 344pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">may release the securities subject to any of the lock-up agreements with the underwriters described <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 356pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">above, in whole or in part at any time.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 388pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Securities Act.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We will apply to have our common stock approved for listing on the &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; under the symbol &#8220;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8221; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and this offering is contingent upon obtaining approval of such listing.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 440pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In connection with this offering, the underwriters may engage in stabilizing transactions, which involves <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 452pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">making bids for, purchasing and selling shares of common stock in the open market for the purpose of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 464pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">preventing or retarding a decline in the market price of the common stock while this offering is in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 476pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">progress. These stabilizing transactions may include making short sales of common stock, which involves <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 488pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the sale by the underwriters of a greater number of shares of common stock than they are required to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 500pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">purchase in this offering, and purchasing shares of common stock on the open market to cover positions <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 512pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">created by short sales. Short sales may be &#8220;covered&#8221; shorts, which are short positions in an amount not <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 524pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">greater than the underwriters&#8217; option to purchase additional shares referred to above, or may be &#8220;naked&#8221; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 536pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">shorts, which are short positions in excess of that amount.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 556pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The underwriters may close out any covered short position either by exercising their option to purchase <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 568pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">additional shares, in whole or in part, or by purchasing shares in the open market. In making this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 580pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">determination, the underwriters will consider, among other things, the price of shares available for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 592pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">purchase in the open market compared to the price at which the underwriters may purchase shares <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 604pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">through the option to purchase additional shares. A naked short position is more likely to be created if the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 616pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">underwriters are concerned that there may be downward pressure on the price of the common stock in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 628pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the open market that could adversely affect investors who purchase in this offering. To the extent that the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 640pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">underwriters create a naked short position, they will purchase shares in the open market to cover the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 652pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">position.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The underwriters have advised us that, pursuant to Regulation M of the Securities Act, they may also <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 684pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">engage in other activities that stabilize, maintain or otherwise affect the price of the common stock, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 696pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">including the imposition of penalty bids. This means that if the representatives of the underwriters <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 708pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">purchase common stock in the open market in stabilizing transactions or to cover short sales, the <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">182<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">representatives can require the underwriters that sold those shares as part of this offering to repay the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">underwriting discount received by them.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">These activities may have the effect of raising or maintaining the market price of the common stock or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">preventing or retarding a decline in the market price of the common stock, and, as a result, the price of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the common stock may be higher than the price that otherwise might exist in the open market. If the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">underwriters commence these activities, they may discontinue them at any time. The underwriters may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">carry out these transactions on &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, in the over-the-counter market or otherwise.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 172pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Prior to this offering, there has been no public market for our common stock. The initial public offering <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 184pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">price will be determined by negotiations between us and the representatives of the underwriters. In <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 196pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">determining the initial public offering price, we and the representatives of the underwriters expect to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 208pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">consider a number of factors including&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 228pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the information set forth in this prospectus and otherwise available to the representatives&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 248pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our prospects and the history and prospects for the industry in which we compete&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">an assessment of our management&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 288pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">our prospects for future earnings&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the general condition of the securities markets at the time of this offering&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the recent market prices of, and demand for, publicly traded common stock of generally comparable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">companies&#59; and<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">other factors deemed relevant by the underwriters and us.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 380pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Neither we nor the underwriters can assure investors that an active trading market will develop for shares <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 392pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of our common stock, or that the shares will trade in the public market at or above the initial public offering <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 404pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">price.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 424pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Other relationships<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 446.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Certain of the underwriters and their affiliates have provided in the past to us and our affiliates and may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 458.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">provide from time to time in the future certain commercial banking, financial advisory, investment banking <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 470.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and other services for us and such affiliates in the ordinary course of their business, for which they have <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 482.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">received and may continue to receive customary fees and commissions. In addition, from time to time, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 494.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">certain of the underwriters and their affiliates may effect transactions for their own account or the account <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 506.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of customers, and hold on behalf of themselves or their customers, long or short positions in our debt or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 518.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">equity securities or loans, and may do so in the future.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 538.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Selling restrictions<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 560.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Other than in the United States, no action has been taken by us or the underwriters that would permit a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 572.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 584.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 596.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">may this prospectus or any other offering material or advertisements in connection with the offer and sale <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 608.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of any such securities be distributed or published in any jurisdiction, except under circumstances that will <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 620.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 632.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">possession this prospectus comes are advised to inform themselves about and to observe any <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">restrictions relating to the offering and the distribution of this prospectus. This prospectus does not <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 668.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">jurisdiction in which such an offer or a solicitation is unlawful. <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">183<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 8.73pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Notice to prospective investors in the European Economic Area<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 94.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In relation to each Member State of the European Economic Area (each a &#8220;Relevant State&#8221;), no shares <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 106.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">have been offered or will be offered pursuant to the offering to the public in that Relevant State prior to the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 118.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">publication of a prospectus in relation to the shares which has been approved by the competent authority <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 130.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">in that Relevant State or, where appropriate, approved in another Relevant State and notified to the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 142.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 154.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">offers of shares may be made to the public in that Relevant State at any time under the following <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 166.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">exemptions under the Prospectus Regulation&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 186.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(i)<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">to any legal entity which is a qualified investor as defined under Article 2 of the Prospectus <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 198.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Regulation&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 218.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(ii)<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 230.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the Prospectus Regulation), subject to obtaining the prior consent of the underwriters&#59; or<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 250.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(iii)<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">in any other circumstances falling within Article 1(4) of the Prospectus Regulation,<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 270.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">provided that no such offer of shares shall require us or any underwriter to publish a prospectus pursuant <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 282.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 294.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Prospectus Regulation. and each person who initially acquires any shares or to whom any offer is made <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 306.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">will be deemed to have represented, acknowledged and agreed to and with each of the underwriters and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 318.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to us that it is a &#8220;qualified investor&#8221; within the meaning of Article 2(e) of the Prospectus Regulation. In the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 330.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">case of any shares being offered to a financial intermediary as that term is used in the Prospectus <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 342.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Regulation, each such financial intermediary will be deemed to have represented, acknowledged and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 354.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">agreed that the shares acquired by it in the offer have not been acquired on a non-discretionary basis on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 366.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 378.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">which may give rise to an offer of any shares to the public other than their offer or resale in a Relevant <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 390.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">State to qualified investors as so defined or in circumstances in which the prior consent of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 402.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">underwriters have been obtained to each such proposed offer or resale. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 422.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to shares in any <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 434.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Relevant State means the communication in any form and by any means of sufficient information on the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 446.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 458.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">subscribe for any shares, and the expression &#8220;Prospectus Regulation&#8221; means Regulation (EU) 2017&#47;1129.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 478.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Notice to prospective investors in the United Kingdom<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 500.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">No shares have been offered or will be offered pursuant to the offering to the public in the United Kingdom <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 512.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prior to the publication of a prospectus in relation to the shares which (i) has been approved by the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 524.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Financial Conduct Authority or (ii) is to be treated as if it had been approved by the Financial Conduct <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 536.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Authority in accordance with the transitional provisions in Article 74 (transitional provisions) of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 548.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Prospectus Amendment etc (EU Exit) Regulations 2019&#47;1234, except that the shares may be offered to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 560.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the public in the United Kingdom at any time&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 580.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(i)<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 592.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Regulation&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(ii)<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">the UK Prospectus Regulation), subject to obtaining the prior consent of underwriters for any such <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 636.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">offer&#59; or<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(iii)<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">in any other circumstances falling within Section 86 of the FSMA,<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 676.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">provided that no such offer of the shares shall require the Issuer or any Manager to publish a prospectus <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 688.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">pursuant to Section 85 of the FSMA or supplement a prospectus pursuant to Article 23 of the UK <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 700.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Prospectus Regulation. For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">184<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">relation to the shares in the United Kingdom means the communication in any form and by any means of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">decide to purchase or subscribe for any shares and the expression &#8220;UK Prospectus Regulation&#8221; means <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Regulation (EU) 2017&#47;1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Act 2018.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 152pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">any offer subsequently made may only be directed at persons who are &#8220;qualified investors&#8221; (as defined in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 164pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the Prospectus Regulation) (i) who have professional experience in matters relating to investments falling <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 188pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">amended (the &#8220;Order&#8221;) and&#47;or (ii) who are high net worth companies (or persons to whom it may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">otherwise be lawfully communicated) falling within Article 49(2)(a) to (d) of the Order (all such persons <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 212pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">together being referred to as &#8220;relevant persons&#8221;) or otherwise in circumstances which have not resulted <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 224pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and will not result in an offer to the public of the shares in the United Kingdom within the meaning of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 236pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Financial Services and Markets Act 2000.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Any person in the United Kingdom that is not a relevant person should not act or rely on the information <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">included in this document or use it as basis for taking any action. In the United Kingdom, any investment <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or investment activity that this document relates to may be made or taken exclusively by relevant persons.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 300pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Notice to prospective investors in Canada<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 322.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 334.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 346.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 358.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 370.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 382.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">requirements of applicable securities laws.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 402.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 414.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for rescission or damages if this prospectus (including any amendment thereto) contains a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 426.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 438.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">within the time limit prescribed by the securities legislation of the purchaser&#8217;s province or territory. The <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 450.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#8217;s <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 462.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">province or territory for particulars of these rights or consult with a legal advisor.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 482.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Pursuant to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 494.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 506.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">underwriter conflicts of interest in connection with this offering.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 526.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Notice to prospective investors in Switzerland<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 548.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">This prospectus does not constitute an offer to the public or a solicitation to purchase or invest in any <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 560.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">shares. No shares have been offered or will be offered to the public in Switzerland, except that offers of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 572.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">shares may be made to the public in Switzerland at any time under the following exemptions under the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 584.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Swiss Financial Services Act (&#8220;FinSA&#8221;)&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 604.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(i)<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">to any person which is a professional client as defined under the FinSA&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(ii)<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">to fewer than 500 persons (other than professional clients as defined under the FinSA), subject to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 636.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">obtaining the prior consent of the representatives of the underwriters for any such offer&#59; or<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(iii)<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">in any other circumstances falling within Article 36 FinSA in connection with Article 44 of the Swiss <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 668.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Financial Services Ordinance,<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 688.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">provided that no such offer of shares shall require the Company or any investment bank to publish a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 700.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prospectus pursuant to Article 35 FinSA.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">185<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The shares have not been and will not be listed or admitted to trading on a trading venue in Switzerland.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 92pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Neither this document nor any other offering or marketing material relating to the shares constitutes a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prospectus as such term is understood pursuant to the FinSA and neither this document nor any other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">offering or marketing material relating to the shares may be publicly distributed or otherwise made publicly <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">available in Switzerland.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 148pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Notice to prospective investors in the Dubai International Financial Centre<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 170.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">This document relates to an Exempt Offer in accordance with the Markets Law, DIFC Law No. 1 of 2012, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 182.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">as amended. This document is intended for distribution only to persons of a type specified in the Markets <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 194.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Law, DIFC Law No. 1 of 2012, as amended. It must not be delivered to, or relied on by, any other person. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 206.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Dubai Financial Services Authority (DFSA) has no responsibility for reviewing or verifying any <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 218.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">documents in connection with Exempt Offers. The DFSA has not approved this prospectus supplement <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 230.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">nor taken steps to verify the information set forth herein and has no responsibility for this document. The <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 242.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">securities to which this document relates may be illiquid and&#47;or subject to restrictions on their resale. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 254.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Prospective purchasers of the securities offered should conduct their own due diligence on the securities. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 266.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">If you do not understand the contents of this document you should consult an authorized financial advisor.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 286.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In relation to its use in the DIFC, this document is strictly private and confidential and is being distributed <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 298.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to a limited number of investors and must not be provided to any person other than the original recipient, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 310.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and may not be reproduced or used for any other purpose. The interests in the securities may not be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 322.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">offered or sold directly or indirectly to the public in the DIFC.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 342.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Notice to prospective investors in the United Arab Emirates<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 364.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The shares have not been, and are not being, publicly offered, sold, promoted or advertised in the United <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Arab Emirates (including the Dubai International Financial Centre) other than in compliance with the laws <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 388.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of the United Arab Emirates (and the Dubai International Financial Centre) governing the issue, offering <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 400.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and sale of securities. Further, this prospectus does not constitute a public offer of securities in the United <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 412.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Arab Emirates (including the Dubai International Financial Centre) and is not intended to be a public offer. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 424.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">This prospectus has not been approved by or filed with the Central Bank of the United Arab Emirates, the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 436.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Securities and Commodities Authority, Financial Services Regulatory Authority (FSRA) or the Dubai <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 448.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Financial Services Authority (DFSA).&#160;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 468.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Notice to prospective investors in Australia <font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 491.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">This prospectus&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 511.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">does not constitute a disclosure document or a prospectus under Chapter 6D.2 of the Corporations <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 523.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Act 2001 (Cth) (the &#8220;Corporations Act&#8221;)&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 543.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">has not been, and will not be, lodged with the Australian Securities and Investments Commission <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 555.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">(&#8220;ASIC&#8221;), as a disclosure document for the purposes of the Corporations Act and does not purport to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 567.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">include the information required of a disclosure document for the purposes of the Corporations Act&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 579.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">and<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 599.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">may only be provided in Australia to select investors who are able to demonstrate that they fall within <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 611.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">one or more of the categories of investors, available under section 708 of the Corporations Act <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 623.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">(&#8220;Exempt Investors&#8221;).<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 643.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The shares may not be directly or indirectly offered for subscription or purchased or sold, and no <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 655.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">invitations to subscribe for or buy the shares may be issued, and no draft or definitive offering <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 667.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">memorandum, advertisement or other offering material relating to any shares may be distributed in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 679.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Australia, except where disclosure to investors is not required under Chapter 6D of the Corporations Act <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 691.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 703.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">application for the shares, you represent and warrant to us that you are an Exempt Investor.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">186<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">As any offer of shares of our common stock under this prospectus will be made without disclosure in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Australia under Chapter 6D.2 of the Corporations Act, the offer of those securities for resale in Australia <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">within 12 months may, under section 707 of the Corporations Act, require disclosure to investors under <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Chapter 6D.2 if none of the exemptions in section 708 applies to that resale. By applying for the shares of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">our common stock you undertake to us that you will not, for a period of 12 months from the date of issue <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of the shares, offer, transfer, assign or otherwise alienate those shares of our common stock to investors <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">in Australia except in circumstances where disclosure to investors is not required under Chapter 6D.2 of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 156pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 176pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Notice to prospective investors in Japan<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 198.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The shares have not been and will not be registered pursuant to Article 4, Paragraph 1 of the Financial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 210.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Instruments and Exchange Act. Accordingly, none of the shares nor any interest therein may be offered or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 222.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">sold, directly or indirectly, in Japan or to, or for the benefit of, any &#8220;resident&#8221; of Japan (which term as used <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 234.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">herein means any person resident in Japan, including any corporation or other entity organized under the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 246.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">laws of Japan), or to others for re-offering or resale, directly or indirectly, in Japan or to or for the benefit of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 258.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 270.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">in compliance with, the Financial Instruments and Exchange Act and any other applicable laws, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 282.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">regulations and ministerial guidelines of Japan in effect at the relevant time.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 302.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Notice to prospective investors in Hong Kong<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 324.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 336.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">document, other than (a) to &#8220;professional investors&#8221; as defined in the Securities and Futures Ordinance <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 348.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(Cap. 571 of the Laws of Hong Kong) (the &#8220;SFO&#8221;) of Hong Kong and any rules made thereunder&#59; or (b) in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">other circumstances which do not result in the document being a &#8220;prospectus&#8221; as defined in the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 372.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong) (the &#8220;CO&#8221;) or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 384.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">which do not constitute an offer to the public within the meaning of the CO. No advertisement, invitation or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 396.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">document relating to the shares has been or may be issued or has been or may be in the possession of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 432.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 444.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">be disposed of only to persons outside Hong Kong or only to &#8220;professional investors&#8221; as defined in the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 456.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">SFO and any rules made thereunder.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 476.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Notice to prospective investors in Singapore<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 499.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 511.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Accordingly, no shares have been or will be offered or sold and no shares have been or will be made the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 523.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">subject of an invitation for subscription or purchase, and no prospectus or any other document or material <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 535.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">in connection with the offer or sale, or invitation for subscription or purchase, of the shares, has been or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 547.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">will be circulated or distributed, whether directly or indirectly, to any person in Singapore other than (i) to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 559.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">an institutional investor (as defined in Section 4A of the Securities and Futures Act 2001 of Singapore, as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 571.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">modified or amended from time to time (the &#8220;SFA&#8221;)) pursuant to Section 274 of the SFA, (ii) to a relevant <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 583.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">person (as defined in Section 275(2) of the SFA) pursuant to Section 275(1) of the SFA, or any person <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 595.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">pursuant to Section 275(1A) of the SFA, and in accordance with the conditions specified in Section 275 of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 607.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the SFA, or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 619.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">provision of the SFA.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 639.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Singapore SFA Product Classification &#8212; In connection with Section 309B of the SFA and the CMP <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 651.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Regulations 2018, unless otherwise specified before an offer of shares of our common stock, we have <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 663.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">determined, and hereby notify all relevant persons (as defined in Section 309A(1) of the SFA), that the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 675.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">shares of common stock are &#8216;&#8216;prescribed capital markets products&#8217;&#8217; (as defined in the CMP Regulations <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 687.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2018) and Excluded Investment Products (as defined in MAS Notice SFA 04-N12&#58; Notice on the Sale of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 699.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Investment Products and MAS Notice FAA-N16&#58; Notice on Recommendations on Investment Products).<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">187<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 8.73pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Notice to prospective investors in Bermuda<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 94.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Shares may be offered or sold in Bermuda only in compliance with the provisions of the Investment <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 106.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Business Act of 2003 of Bermuda which regulates the sale of securities in Bermuda. Additionally, non-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 118.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Bermudian persons (including companies) may not carry on or engage in any trade or business in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 130.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Bermuda unless such persons are permitted to do so under applicable Bermuda legislation.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 150.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Notice to prospective investors in Saudi Arabia<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 172.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">This document may not be distributed in the Kingdom of Saudi Arabia except to such persons as are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 184.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">permitted under the Rules on the Offer of Securities and Continuing Obligations Regulations as issued by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 196.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the board of the Saudi Arabian Capital Market Authority (&#8220;CMA&#8221;) pursuant to resolution number <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 208.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">3-123-2017 dated 27 December 2017, as amended (the &#8220;CMA Regulations&#8221;). The CMA does not make <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">any representation as to the accuracy or completeness of this document and expressly disclaims any <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this document. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Prospective purchasers of the securities offered hereby should conduct their own due diligence on the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">accuracy of the information relating to the securities. If you do not understand the contents of this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 268.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">document, you should consult an authorised financial adviser.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 288.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Notice to prospective investors in the British Virgin Islands<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 311.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The shares are not being, and may not be offered to the public or to any person in the British Virgin <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 323.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Islands for purchase or subscription by or on behalf of us. The shares may be offered to companies <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 335.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">incorporated under the BVI Business Companies Act, 2004 (British Virgin Islands), &#8220;BVI Companies&#8221;), but <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 347.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">only where the offer will be made to, and received by, the relevant BVI Company entirely outside of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 359.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">British Virgin Islands.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 379.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Notice to prospective investors in China<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 401.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">This prospectus will not be circulated or distributed in the PRC and the shares will not be offered or sold, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 413.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and will not be offered or sold to any person for re-offering or resale directly or indirectly to any residents <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 425.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of the PRC (for such purposes, not including the Hong Kong and Macau Special Administrative Regions <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 437.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or Taiwan), except pursuant to any applicable laws and regulations of the PRC. Neither this prospectus <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 449.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">nor any advertisement or other offering material may be distributed or published in the PRC, except under <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 461.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">circumstances that will result in compliance with applicable laws and regulations.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 481.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Notice to prospective investors in Korea<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 504pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The shares have not been and will not be registered under the Financial Investments Services and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 516pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Capital Markets Act of Korea and the decrees and regulations thereunder (the &#8220;FSCMA&#8221;), and the shares <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 528pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">have been and will be offered in Korea as a private placement under the FSCMA. None of the shares <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">may be offered, sold or delivered directly or indirectly, or offered or sold to any person for re-offering or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">resale, directly or indirectly, in Korea or to any resident of Korea except pursuant to the applicable laws <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and regulations of Korea, including the FSCMA and the Foreign Exchange Transaction Law of Korea and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the decrees and regulations thereunder (the &#8220;FETL&#8221;). Furthermore, the purchaser of the shares shall <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">comply with all applicable regulatory requirements (including but not limited to requirements under the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 600pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">FETL) in connection with the purchase of the shares. By the purchase of the shares, the relevant holder <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">thereof will be deemed to represent and warrant that if it is in Korea or is a resident of Korea, it purchased <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the shares pursuant to the applicable laws and regulations of Korea.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 644pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Notice to prospective investors in Malaysia<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 666.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">No prospectus or other offering material or document in connection with the offer and sale of the shares <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 678.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">has been or will be registered with the Securities Commission of Malaysia (&#8220;Commission&#8221;) for the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 690.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Commission&#8217;s approval pursuant to the Capital Markets and Services Act 2007. Accordingly, this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 702.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prospectus and any other document or material in connection with the offer or sale, or invitation for <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">188<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">subscription or purchase, of the shares may not be circulated or distributed, nor may the shares be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">indirectly, to persons in Malaysia other than (i) a closed end fund approved by the Commission&#59; (ii) a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">holder of a Capital Markets Services Licence&#59; (iii) a person who acquires the shares, as principal, if the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 120pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">offer is on terms that the shares may only be acquired at a consideration of not less than RM250,000 (or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">its equivalent in foreign currencies) for each transaction&#59; (iv) an individual whose total net personal assets <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 144pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or total net joint assets with his or her spouse exceeds RM3 million (or its equivalent in foreign <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 156pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">currencies), excluding the value of the primary residence of the individual&#59; (v) an individual who has a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 168pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">gross annual income exceeding RM300,000 (or its equivalent in foreign currencies) per annum in the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 180pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">preceding twelve months&#59; (vi) an individual who, jointly with his or her spouse, has a gross annual income <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 192pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of RM400,000 (or its equivalent in foreign currencies), per annum in the preceding twelve months&#59; (vii) a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 204pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">corporation with total net assets exceeding RM10 million (or its equivalent in a foreign currencies) based <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 216pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">on the last audited accounts&#59; (viii) a partnership with total net assets exceeding RM10 million (or its <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 228pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">equivalent in foreign currencies)&#59; (ix) a bank licensee or insurance licensee as defined in the Labuan <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 240pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Financial Services and Securities Act 2010&#59; (x) an Islamic bank licensee or takaful licensee as defined in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 252pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the Labuan Financial Services and Securities Act 2010&#59; and (xi) any other person as may be specified by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 264pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the Commission&#59; provided that, in the each of the preceding categories (i) to (xi), the distribution of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 276pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">shares is made by a holder of a Capital Markets Services License who carries on the business of dealing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 288pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">in securities. The distribution in Malaysia of this prospectus is subject to Malaysian laws. This prospectus <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 300pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">does not constitute and may not be used for the purpose of public offering or an issue, offer for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 312pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">subscription or purchase, invitation to subscribe for or purchase any securities requiring the registration of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 324pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">a prospectus with the Commission under the Capital Markets and Services Act 2007.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 344pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Notice to prospective investors in Taiwan<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 366.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The shares have not been and will not be registered with the Financial Supervisory Commission of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 378.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Taiwan pursuant to relevant securities laws and regulations and may not be sold, issued or offered within <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 390.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Taiwan through a public offering or in circumstances which constitutes an offer within the meaning of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 402.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Securities and Exchange Act of Taiwan that requires a registration or approval of the Financial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 414.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorised to offer, sell, give <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 426.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">advice regarding or otherwise intermediate the offering and sale of the shares in Taiwan.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 446.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Notice to prospective investors in South Africa<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 468.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Due to restrictions under the securities laws of South Africa, no &#8220;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 355.79pt; position: absolute; white-space: pre;">offer to the public<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 432.43pt; position: absolute; white-space: pre;">&#8221; (as such term is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">defined in the South African Companies Act, No. 71 of 2008 (as amended or re-enacted) (the &#8220;South <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 492.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">African Companies Act&#8221;) is being made in connection with the issue of the shares in South Africa. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 504.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Accordingly, this document does not, nor is it intended to, constitute a &#8220;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 384.5pt; position: absolute; white-space: pre;">registered prospectus<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 480.62pt; position: absolute; white-space: pre;">&#8221; (as that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 516.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">term is defined in the South African Companies Act) prepared and registered under the South African <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 528.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Companies Act and has not been approved by, and&#47;or filed with, the South African Companies and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Intellectual Property Commission or any other regulatory authority in South Africa. The shares are not <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">offered, and the offer shall not be transferred, sold, renounced or delivered, in South Africa or to a person <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">with an address in South Africa, unless one or other of the following exemptions stipulated in section 96 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(1) applies&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 596.8pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 480.75pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 94.5pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 386.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 94.5pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 94.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Section 96 (1) (a)<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 94.5pt; position: absolute; top: 0pt; width: 386.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 386.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">the offer, transfer, sale, renunciation or delivery is to&#58; <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 5.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 24pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 24pt; left: 94.5pt; overflow: hidden; position: absolute; top: 19.5pt; width: 386.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 386.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">(i) persons whose ordinary business, or part of whose ordinary business, is to deal in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 14.63pt; width: 386.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">securities, as principal or agent&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 5.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 94.5pt; position: absolute; top: 48.75pt; width: 386.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 386.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">(ii) the South African Public Investment Corporation&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 5.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 94.5pt; position: absolute; top: 68.25pt; width: 386.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 386.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">(iii) persons or entities regulated by the Reserve Bank of South Africa&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 5.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 94.5pt; position: absolute; top: 87.75pt; width: 386.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 386.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">(iv) authorised financial service providers under South African law&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 5.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 94.5pt; position: absolute; top: 107.25pt; width: 386.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 386.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">(v) financial institutions recognised as such under South African law&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr></table></div></div></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">189<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="position: absolute; top: 72pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 480.75pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 94.5pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 386.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 5.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 50.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 94.5pt; position: absolute; top: 5.25pt; width: 386.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 386.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">(vi) a wholly-owned subsidiary of any person or entity contemplated in (c), (d) or (e), <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 14.63pt; width: 386.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">acting as agent in the capacity of an authorised portfolio manager for a pension fund, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 26.63pt; width: 386.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">or as manager for a collective investment scheme (in each case duly registered as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 38.63pt; width: 386.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">such under South African law)&#59; or <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 5.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 94.5pt; position: absolute; top: 60.75pt; width: 386.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 386.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">(vii) any combination of the person in (i) to (vi)&#59; or<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 5.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 50.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 80.25pt; width: 94.5pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 94.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Section 96 (1) (b) <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 94.5pt; position: absolute; top: 80.25pt; width: 386.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 386.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">the total contemplated acquisition cost of the securities, for any single addressee <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 14.63pt; width: 386.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">acting as principal is equal to or greater than ZAR1,000,000 or such higher amount as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 26.63pt; width: 386.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">may be promulgated by notice in the Government Gazette of South Africa pursuant to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 38.63pt; width: 386.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">section 96(2)(a) of the South African Companies Act.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 215.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Information made available in this prospectus should not be considered as &#8220;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 406.43pt; position: absolute; white-space: pre;">advice<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 435.33pt; position: absolute; white-space: pre;">&#8221; as defined in the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 227.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">South African Financial Advisory and Intermediary Services Act, 2002. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 247.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Notice to prospective investors in Israel<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 269.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">This prospectus does not constitute a prospectus under the Israeli Securities Law, 5728-1968, or the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 281.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Israeli Securities Law, and has not been filed with or approved by the Israel Securities Authority. In Israel, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 293.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">this prospectus is being distributed only to, and is directed only at, and any offer of the shares is directed <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 305.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">only at, (i) a limited number of persons in accordance with the Israeli Securities Law and (ii) investors <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 317.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">listed in the first addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of joint <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 329.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 341.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 353.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">equity in excess of NIS 50 million and &#8220;qualified individuals,&#8221; each as defined in the Addendum (as it may <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 365.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">be amended from time to time), or, collectively referred to as qualified investors (in each case, purchasing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 377.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for their own account or, where permitted under the Addendum, for the accounts of their clients who are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 389.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">investors listed in the Addendum). Qualified investors are required to submit written confirmation that they <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 401.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">fall within the scope of the Addendum, are aware of the meaning of same and agree to it.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 297.66pt; position: absolute; text-decoration: none; white-space: pre;">190<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_1505" style="position: absolute; top: 72pt;"></div><div style="line-height: 11.64pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Legal matters<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 107.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The validity of the issuance of our common stock offered in this prospectus will be passed upon for us by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 119.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">O&#8217;Melveny &#38; Myers LLP. King &#38; Spalding LLP is acting as regulatory counsel to us in connection with this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 131.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">offering and will pass upon certain legal matters. Certain legal matters in connection with this offering will <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 143.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">be passed upon for the underwriters by Cooley LLP, San Francisco, California.&#160;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div id="i2341357d54884756b9e9172f0a83cd6b_1531" style="position: absolute; top: 163.2pt;"></div><div style="line-height: 11.64pt; position: absolute; top: 163.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Experts<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 198.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The financial statements as of December 31, 2023 and for the year then ended included in this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 210.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Prospectus have been so included in reliance on the report (which contains an explanatory paragraph <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 222.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">relating to the Company&#8217;s ability to continue as a going concern as described in Note 1 to the financial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 234.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">statements) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 246.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the authority of said firm as experts in auditing and accounting.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div id="i2341357d54884756b9e9172f0a83cd6b_1578" style="position: absolute; top: 266.4pt;"></div><div style="line-height: 11.64pt; position: absolute; top: 266.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Where you can find additional information<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 301.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We have filed with the SEC a registration statement on Form S-1, including exhibits and schedules, under <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 313.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the Securities Act, with respect to the shares of common stock being offered by this prospectus. This <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 325.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prospectus, which constitutes part of the registration statement, does not contain all of the information in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 337.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the registration statement and its exhibits. For further information with respect to us and the common <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 349.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock offered by this prospectus, we refer you to the registration statement and its exhibits. Statements <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 361.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">contained in this prospectus as to the contents of any contract or any other document referred to are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 373.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">summary in nature and not necessarily complete, and in each instance, we refer you to the copy of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 385.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">contract or other document filed as an exhibit to the registration statement. Each of these statements is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 397.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">qualified in all respects by reference to the full text of such contract or other document.&#160;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 417.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">You may read our SEC filings, including this registration statement, over the Internet at the SEC&#8217;s website <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 429.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">at www.sec.gov. Upon the completion of this offering, we will be subject to the information reporting <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 441.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">requirements of the Exchange Act, and we will file reports, proxy statements, and other information with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 453.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the SEC. These reports, proxy statements, and other information will be available for review at the SEC&#8217;s <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 465.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">website referred to above. We also maintain a website at www.heartflow.com, at which, following the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 477.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">completion of this offering, you may access these materials free of charge as soon as reasonably <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 489.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">practicable after they are electronically filed with, or furnished to, the SEC. Information contained on or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 501.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">accessible through our website is not a part of this prospectus or the registration statement of which it <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 513.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">forms a part, and the inclusion of our website address in this prospectus is an inactive textual reference <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 525.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">only. You should not consider the contents of our website in making an investment decision with respect <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 537.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to our common stock.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 298.5pt; position: absolute; text-decoration: none; white-space: pre;">F-1<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_77" style="position: absolute; top: 72pt;"></div><div style="line-height: 11.64pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 91.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 151.75pt; position: absolute; text-decoration: none; white-space: pre;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="position: absolute; top: 113.6pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 432.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 35.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="border-bottom: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 432.75pt; position: absolute; top: 0pt; width: 35.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 35.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 10.45pt; position: absolute; text-decoration: none; white-space: pre;">Page<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 14.25pt; width: 432.75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 432.75pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_113">Report of Independent Registered Public Accounting Firm</a><font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 244.79pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 245.07999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 245.16pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 245.2pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 245.22pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 245.23pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 432.75pt; position: absolute; top: 14.25pt; width: 35.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 35.25pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 18.38pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_113">F-2</a><font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 28.5pt; width: 432.75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 432.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Financial Statements&#58;<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 42.75pt; width: 432.75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 432.75pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 20.63pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_461">Consolidated Balance Sheet</a><font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 140.42000000000002pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 140.71pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 140.86pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 140.94pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 432.75pt; position: absolute; top: 42.75pt; width: 35.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 35.25pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 18.38pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_461">F-3</a><font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 57pt; width: 432.75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 432.75pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 20.63pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_447">Consolidated Statement of Operations and Comprehensive Loss</a><font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 291.82pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 292.4pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 292.55pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 292.59pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 432.75pt; position: absolute; top: 57pt; width: 35.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 35.25pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 18.38pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_447">F-4</a><font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 71.25pt; width: 432.75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 432.75pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 20.63pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_432">Consolidated Statement of Redeemable Convertible Preferred Stock and Stockholders&#8217; Deficit</a><font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 414.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 415.46999999999997pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 415.76pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 415.8pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 415.81pt; position: absolute; text-decoration: none; white-space: pre;"> . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 432.75pt; position: absolute; top: 71.25pt; width: 35.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 35.25pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 18.38pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_432">F-5</a><font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 85.5pt; width: 432.75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 432.75pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 20.63pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_418">Consolidated Statement of Cash Flows</a><font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 184.7pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 187.01pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 187.59pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 187.88pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 188.03pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 432.75pt; position: absolute; top: 85.5pt; width: 35.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 35.25pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 18.38pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_418">F-6</a><font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 99.75pt; width: 432.75pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.79pt; width: 432.75pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 20.63pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_129">Notes to the Consolidated Financial Statements</a><font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 221.1pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 221.39pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 221.47pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 221.51pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 6.91pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 221.53pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 432.75pt; position: absolute; top: 99.75pt; width: 35.25pt;"><div><div style="line-height: 6.91pt; position: absolute; top: 3.85pt; width: 35.25pt;"><font style="color: #0000ff; font-family: &#39;Arial&#39;, sans-serif; font-size: 9.5pt; font-style: normal; font-weight: normal; left: 18.38pt; position: absolute; text-decoration: underline; white-space: pre;"><a style="color: inherit; text-decoration: inherit; z-index: 1;" href="#i2341357d54884756b9e9172f0a83cd6b_129">F-7</a><font style="display: inline-block; height: 6.91pt;"></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 298.5pt; position: absolute; text-decoration: none; white-space: pre;">F-2<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_113" style="position: absolute; top: 72pt;"></div><div style="line-height: 11.64pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Report of Independent Registered Public Accounting Firm<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 107.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">To the Board of Directors and Stockholders of HeartFlow Holding, Inc.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 127.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; white-space: pre;">Opinion on the Financial Statements<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 147.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We have audited the accompanying consolidated balance sheet of HeartFlow Holding, Inc. and its <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 159.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">subsidiaries (the &#34;Company&#34;) as of December 31, 2023, and the related consolidated statements of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 171.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">operations and comprehensive loss, of redeemable convertible preferred stock and stockholders&#8217; deficit <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 183.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and of cash flows for the year then ended, including the related notes (collectively referred to as the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 195.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">&#34;consolidated financial statements&#34;). In our opinion, the consolidated financial statements present fairly, in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 207.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">all material respects, the financial position of the Company as of December 31, 2023, and the results of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 219.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">its operations and its cash flows for the year then ended in conformity with accounting principles generally <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 231.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">accepted in the United States of America.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 251.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Substantial Doubt About the Company's Ability to Continue as a Going Concern<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 271.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The accompanying consolidated financial statements have been prepared assuming that the Company <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 283.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 295.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Company has incurred recurring losses from operations and negative cash outflows from operating <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 307.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">activities that raise substantial doubt about its ability to continue as a going concern. Management's plans <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 319.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">in regard to these matters are also described in Note 1. The consolidated financial statements do not <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 331.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">include any adjustments that might result from the outcome of this uncertainty.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 351.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; white-space: pre;">Basis for Opinion<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 371.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 383.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 395.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 407.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(United States) (PCAOB) and are required to be independent with respect to the Company in accordance <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 419.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">with the U.S. federal securities laws and the applicable rules and regulations of the Securities and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 431.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Exchange Commission and the PCAOB.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 451.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We conducted our audit of these consolidated financial statements in accordance with the standards of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 463.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the PCAOB and in accordance with auditing standards generally accepted in the United States of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 475.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">America. Those standards require that we plan and perform the audit to obtain reasonable assurance <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 487.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">about whether the consolidated financial statements are free of material misstatement, whether due to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 499.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">error or fraud.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 519.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Our audit included performing procedures to assess the risks of material misstatement of the consolidated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 531.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">financial statements, whether due to error or fraud, and performing procedures that respond to those <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 543.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">risks. Such procedures included examining, on a test basis, evidence regarding the amounts and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 555.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">disclosures in the consolidated financial statements. Our audit also included evaluating the accounting <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 567.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">principles used and significant estimates made by management, as well as evaluating the overall <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 579.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">presentation of the consolidated financial statements. We believe that our audit provides a reasonable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 591.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">basis for our opinion.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 631.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#47;s&#47; PricewaterhouseCoopers LLP<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 643.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">San Jose, California<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 655.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">February <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 114.77000000000001pt; position: absolute; text-decoration: none; white-space: pre;">5<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 120.33pt; position: absolute; text-decoration: none; white-space: pre;">, 2025<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 675.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">We have served as the Company&#8217;s auditor since 2009, which includes periods before the Company <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 687.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">became subject to SEC reporting requirements.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 298.5pt; position: absolute; text-decoration: none; white-space: pre;">F-3<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_461" style="position: absolute; top: 72pt;"></div><div style="line-height: 11.64pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 91.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 225.35pt; position: absolute; text-decoration: none; white-space: pre;">Consolidated Balance Sheet<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 105.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 181.92pt; position: absolute; text-decoration: none; white-space: pre;">(in thousands, except share and per share amounts)<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 133.6pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 402.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 24pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.26pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 3.38pt; position: absolute; text-decoration: none; white-space: pre;">December 31, <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 14.06pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 22.62pt; position: absolute; text-decoration: none; white-space: pre;">2023<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 24pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Assets<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 38.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Current assets&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 52.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Cash and cash equivalents<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 134.65pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 134.94pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 135.02pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 135.06pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 135.08pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 135.09pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 52.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 16.85pt;"></font></font><font style="left: 25.04pt; position: absolute;">122,767<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 66.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Accounts receivable, net of allowance for credit losses of $1,058<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 299.03pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 299.61pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 299.9pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 299.98pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 300.02pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.03pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 66.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">20,546<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 81pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Prepaid expenses and other current assets<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 205.19pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 207.5pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 208.66pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 209.24pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 209.53pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 209.60999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 209.65pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 209.66pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 81pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">5,134<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 95.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 26.63pt; position: absolute; text-decoration: none; white-space: pre;">Total current assets<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 113.28pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 114.44pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 114.72999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 114.88pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 114.96pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 95.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 22.41pt;"></font></font><font style="left: 25.04pt; position: absolute;">148,447<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 109.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Property and equipment, net<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 128.73pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 129.89000000000001pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 129.97pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 129.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 130pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 109.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">9,921<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 123.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Operating lease right-of-use assets<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 158.17pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 159.32999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 159.91pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 159.93pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 159.94pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 123.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">20,961<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 138pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Restricted cash<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 71.50999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 73.82pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 74.39999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 74.69pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 74.77pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 74.78pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 138pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">4,467<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 152.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Other non-current assets<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 113.17pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 114.33pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 114.91pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 114.92999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 114.94pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 152.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">1,255<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 166.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 26.63pt; position: absolute; text-decoration: none; white-space: pre;">Total assets<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 79.4pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 79.98pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 80.06pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 166.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 16.85pt;"></font></font><font style="left: 25.04pt; position: absolute;">185,051<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 15.75pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 196.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Liabilities, redeemable convertible preferred stock and stockholders' deficit<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 210.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Current liabilities&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 225pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Accounts payable<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 93.53pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 94.69pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 94.83999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 94.92pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 94.96pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 94.97999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 94.99pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 225pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">2,887<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 239.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Accrued expenses and other current liabilities<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 216.29pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 218.6pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 219.18pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 219.47pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 219.62pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 219.7pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 219.74pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 219.76pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 219.76999999999998pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 239.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">24,790<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 253.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Operating lease liabilities, current<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 162.38pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 164.69pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 164.84pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 164.85999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 253.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">5,138<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 267.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 26.63pt; position: absolute; text-decoration: none; white-space: pre;">Total current liabilities<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 122.16pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 124.47pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 124.75999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 124.83999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 267.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">32,815<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 282pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Term loan<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 46.52pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 48.830000000000005pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 49.410000000000004pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 49.7pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 49.78pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 282pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 22.41pt;"></font></font><font style="left: 25.04pt; position: absolute;">134,008<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 296.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Common stock warrant liability<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 138.15pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 139.31pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 139.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 139.93pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 139.94pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 296.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">4,440<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 310.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Derivative liability<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 79.83pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 79.97999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 80.06pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 80.1pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 80.11pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 310.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 41.86pt;"></font></font><font style="left: 44.49pt; position: absolute;">903<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 324.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Operating lease liabilities, non-current <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 173.16pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 174.32pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 174.9pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 174.94pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 324.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">21,454<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 339pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Other non-current liabilities<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 122.05pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 124.36pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 124.64999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 124.8pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 124.82pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 124.83pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 339pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 41.86pt;"></font></font><font style="left: 44.49pt; position: absolute;">429<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 353.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 26.63pt; position: absolute; text-decoration: none; white-space: pre;">Total liabilities<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 88.28pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 89.44pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 89.73pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 89.88pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 89.96pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 353.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 22.41pt;"></font></font><font style="left: 25.04pt; position: absolute;">194,049<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 367.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Commitments and contingencies (Note 7)<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 38.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 381.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Redeemable convertible preferred stock issuable in series, $0.001 par value&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 15.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 11.63pt; position: absolute; text-decoration: none; white-space: pre;">122,231,454 shares authorized, issued and outstanding as of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 284.98pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 372.77pt; position: absolute; text-decoration: none; white-space: pre;">&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 27.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 11.63pt; position: absolute; text-decoration: none; white-space: pre;">aggregate liquidation value of $951,917 as of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 213.85999999999999pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 301.65pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 303.96pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 304.54pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 304.69pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 304.77pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 304.79pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 304.8pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 381.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 27.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 22.41pt;"></font></font><font style="left: 25.04pt; position: absolute;">768,566<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 420pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Stockholders&#8217; deficit&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 26.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 434.25pt; width: 402.75pt;"><div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Common stock, $0.001 par value&#59; 210,000,000 shares authorized as of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 319.84pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 15.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 11.63pt; position: absolute; text-decoration: none; white-space: pre;">2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 33.87pt; position: absolute; text-decoration: none; white-space: pre;">&#59; 14,427,925 shares issued and outstanding as of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 254.98pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 342.77pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 343.93pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 344.51pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 344.8pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 344.88pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 344.9pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 344.90999999999997pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 434.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 15.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 47.42pt;"></font></font><font style="left: 50.050000000000004pt; position: absolute;">14<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 460.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Additional paid-in capital<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 110.96pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 113.27pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 114.42999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 114.72pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 460.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">97,456<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 474.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Accumulated other comprehensive loss<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 177.07999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 179.39pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 179.68pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 179.82999999999998pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 474.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 38.53pt;"></font></font><font style="left: 41.160000000000004pt; position: absolute;">(501)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 489pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Accumulated deficit<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 89.28pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 89.86pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 90.00999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90.05pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 489pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 19.08pt;"></font></font><font style="left: 21.709999999999997pt; position: absolute;">(874,533)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 503.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 26.63pt; position: absolute; text-decoration: none; white-space: pre;">Total stockholders&#8217; deficit<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 137.35pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 139.66pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 139.81pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 139.85pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 139.86pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 503.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 19.08pt;"></font></font><font style="left: 21.709999999999997pt; position: absolute;">(777,564)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 517.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 26.63pt; position: absolute; text-decoration: none; white-space: pre;">Total liabilities, redeemable convertible preferred stock and stockholders&#8217; deficit<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 376.21999999999997pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 378.53pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 379.69pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 379.73pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 379.75pt; position: absolute; text-decoration: none; white-space: pre;"> . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 517.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 16.85pt;"></font></font><font style="left: 25.04pt; position: absolute;">185,051<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 681.35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 111.29pt; position: absolute; text-decoration: none; white-space: pre;">The accompanying notes are an integral part of these consolidated financial statements.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 298.5pt; position: absolute; text-decoration: none; white-space: pre;">F-4<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_447" style="position: absolute; top: 72pt;"></div><div style="line-height: 11.64pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 91.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 122.07pt; position: absolute; text-decoration: none; white-space: pre;">Consolidated Statement of Operations and Comprehensive Loss<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 105.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 181.92pt; position: absolute; text-decoration: none; white-space: pre;">(in thousands, except share and per share amounts)<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 133.6pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 402.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 35.25pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.71pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 7.89pt; position: absolute; text-decoration: none; white-space: pre;">Year Ended <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="font-size: 12pt; line-height: 6.55pt; position: absolute; top: 14.51pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 3.38pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="font-size: 12pt; line-height: 6.55pt; position: absolute; top: 25.31pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 22.62pt; position: absolute; text-decoration: none; white-space: pre;">2023<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 35.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Revenue<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 42.650000000000006pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 43.81pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 44.39pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 44.68pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 44.830000000000005pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 44.870000000000005pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 44.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 44.900000000000006pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 35.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 22.41pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">87,174<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 49.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Cost of revenue<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 73.17999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 74.33999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 74.92pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 74.94pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 49.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">29,123<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 63.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Gross profit<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 54.27pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 54.85pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 55pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 55.04pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 55.050000000000004pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 63.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">58,051<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 78pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Operating expenses&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 94.86pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 95.00999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 95.08999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 95.11pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 92.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Research and development<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 136.88pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 139.19pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 139.77pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 139.81pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 92.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">35,854<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 106.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Selling, general and administrative<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 167.4pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 169.71pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 169.85999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 106.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">95,111<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 120.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Total operating expenses<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 113.75999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 114.92pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 115pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 120.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 22.41pt;"></font></font><font style="left: 25.04pt; position: absolute;">130,965<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 135pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Loss from operations<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 95.96pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 98.27pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 99.42999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 99.72pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 135pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 24.64pt;"></font></font><font style="left: 27.27pt; position: absolute;">(72,914)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 149.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Interest income<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 70.94999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 73.25999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 74.42pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 74.71pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 74.72pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 149.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">5,457<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 163.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Interest expense<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 76.52pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 78.83pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 79.41pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 79.69999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 79.78pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 163.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 24.64pt;"></font></font><font style="left: 27.27pt; position: absolute;">(24,694)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 177.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Change in fair value of convertible note<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 175.95pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 178.26pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 179.42pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 179.71pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 179.72pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 177.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 30.2pt;"></font></font><font style="left: 32.83pt; position: absolute;">(5,120)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 192pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Change in fair value of common stock warrant liability<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 238.69pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 239.85pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 239.93pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 239.97pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 239.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 240pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 192pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 30.2pt;"></font></font><font style="left: 32.83pt; position: absolute;">(2,320)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 206.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Change in fair value of derivative liability<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 180.93pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 183.24pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 184.4pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 184.69pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 184.71pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 184.72pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 206.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">4,158<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 220.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Other income (expense), net<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 129.28pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 129.86pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 130.01pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 130.05pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 220.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 45.94pt; position: absolute; text-decoration: none; white-space: pre;">325<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 234.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Loss before provision for income taxes<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 173.73pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 174.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 174.97pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 174.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 175pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 234.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 24.64pt;"></font></font><font style="left: 27.27pt; position: absolute;">(95,108)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 249pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Provision for income taxes<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 119.83pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 119.97999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 120.06pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 120.1pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 120.11pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 249pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 38.53pt;"></font></font><font style="left: 41.160000000000004pt; position: absolute;">(547)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 263.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Net loss<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 38.730000000000004pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 39.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 39.970000000000006pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 39.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 40pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 263.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 19.08pt;"></font></font><font style="left: 27.27pt; position: absolute;">(95,655)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 277.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Cumulative dividends on Series C redeemable convertible preferred stock<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 328.73pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 329.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 329.96999999999997pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 329.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 330pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 277.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 30.2pt;"></font></font><font style="left: 32.83pt; position: absolute;">(1,239)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 291.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Deemed dividend upon down round of redeemable convertible preferred stock<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 347.65999999999997pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 348.82pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 349.4pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 349.69pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 349.84pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 349.88pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 349.9pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 291.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 24.64pt;"></font></font><font style="left: 27.27pt; position: absolute;">(26,794)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 306pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Net loss attributable to common stockholders<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 202.04pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 204.35pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 204.64pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 204.79pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 204.82999999999998pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 306pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 13.52pt;"></font></font><font style="left: 21.709999999999997pt; position: absolute;">(123,688)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 320.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Comprehensive loss&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 95.97pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 98.28pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 99.44pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 99.58999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 99.67pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 99.71pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 99.72999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 99.74pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 334.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Net loss<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 38.730000000000004pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 39.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 39.970000000000006pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 39.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 40pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 334.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 19.08pt;"></font></font><font style="left: 27.27pt; position: absolute;">(95,655)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 348.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Other comprehensive loss&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 121.50999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 123.82pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 124.39999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 124.69pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 124.77pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 124.78pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 363pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Foreign currency translation loss<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 159.06pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 159.64pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 159.93pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 160.01pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 160.03pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 363pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 38.53pt;"></font></font><font style="left: 41.160000000000004pt; position: absolute;">(504)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 377.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Total comprehensive loss<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 114.86pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 115.00999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 115.08999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 115.11pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 377.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 19.08pt;"></font></font><font style="left: 27.27pt; position: absolute;">(96,159)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 15.75pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 407.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Net loss per share attributable to common stockholders, basic and diluted<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 327.59pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 328.75pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 329.33pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 329.62pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 329.77pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 329.85pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 329.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 329.9pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 407.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 30.2pt;"></font></font><font style="left: 38.39pt; position: absolute;">(8.67)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 26.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 421.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Weighted-average shares used to compute net loss per share attributable to common <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 15.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 11.63pt; position: absolute; text-decoration: none; white-space: pre;">stockholders, basic and diluted<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 148.29999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 149.46pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 149.75pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 149.9pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 149.94pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 149.96pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 421.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 15.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 8.52pt;"></font></font><font style="left: 11.149999999999999pt; position: absolute;">14,265,293<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 597.35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 111.29pt; position: absolute; text-decoration: none; white-space: pre;">The accompanying notes are an integral part of these consolidated financial statements.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 612pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 792pt;"><div style="left: 0pt; position: absolute; top: 540pt;"><div style="width: 648pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 792pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 388.5pt; position: absolute; text-decoration: none; white-space: pre;">F-5<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 648pt;"></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_432" style="position: absolute; top: 72pt;"></div><div style="line-height: 11.64pt; position: absolute; top: 72pt; width: 792pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 307.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="line-height: 8.73pt; position: absolute; top: 91.2pt; width: 792pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 128.44pt; position: absolute; text-decoration: none; white-space: pre;">Consolidated Statement of Redeemable Convertible Preferred Stock and Stockholders&#8217; Deficit<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 105.6pt; width: 792pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 271.92pt; position: absolute; text-decoration: none; white-space: pre;">(in thousands, except share and per share amounts<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 516.75pt; position: absolute; white-space: pre;">)<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 133.6pt; width: 792pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 648pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 153pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 62.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 50.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 60pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 47.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 51pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 72.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 62.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 32.25pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="3"><div style="left: 153pt; position: absolute; top: 0pt; width: 115.5pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 11.51pt; width: 115.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 5.29pt; position: absolute; text-decoration: none; white-space: pre;">Redeemable Convertible <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 22.31pt; width: 115.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 24.27pt; position: absolute; text-decoration: none; white-space: pre;">Preferred Stock<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td><td style="border-right: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-left: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="3"><div style="left: 274.5pt; position: absolute; top: 0pt; width: 110.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 22.31pt; width: 110.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 22.15pt; position: absolute; text-decoration: none; white-space: pre;">Common Stock<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="2" colspan="1"><div style="left: 387.75pt; position: absolute; top: 0pt; width: 51pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 13.46pt; width: 51pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 3.53pt; position: absolute; text-decoration: none; white-space: pre;">Additional <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 24.26pt; width: 51pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 10.51pt; position: absolute; text-decoration: none; white-space: pre;">Paid-In <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 35.06pt; width: 51pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 10.51pt; position: absolute; text-decoration: none; white-space: pre;">Capital<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="2" colspan="1"><div style="left: 441.75pt; position: absolute; top: 0pt; width: 72.75pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 2.66pt; width: 72.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 8.15pt; position: absolute; text-decoration: none; white-space: pre;">Accumulated <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 13.46pt; width: 72.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 24.38pt; position: absolute; text-decoration: none; white-space: pre;">Other <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 24.26pt; width: 72.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 2.65pt; position: absolute; text-decoration: none; white-space: pre;">Comprehensive <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 35.06pt; width: 72.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 5.9pt; position: absolute; text-decoration: none; white-space: pre;">Income (Loss)<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="2" colspan="1"><div style="left: 517.5pt; position: absolute; top: 0pt; width: 62.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 24.26pt; width: 62.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 2.9pt; position: absolute; text-decoration: none; white-space: pre;">Accumulated <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 35.06pt; width: 62.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 17.39pt; position: absolute; text-decoration: none; white-space: pre;">Deficit<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="2" colspan="1"><div style="left: 582.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 13.46pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 21.89pt; position: absolute; text-decoration: none; white-space: pre;">Total <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 24.26pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 2.9pt; position: absolute; text-decoration: none; white-space: pre;">Stockholders&#8217; <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 35.06pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 18.89pt; position: absolute; text-decoration: none; white-space: pre;">Deficit<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 12.75pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 153pt; position: absolute; top: 32.25pt; width: 62.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 2.81pt; width: 62.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 16.13pt; position: absolute; text-decoration: none; white-space: pre;">Shares<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td><td style="border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 218.25pt; position: absolute; top: 32.25pt; width: 50.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 2.81pt; width: 50.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 8.15pt; position: absolute; text-decoration: none; white-space: pre;">Amount<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td><td style="border-right: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-left: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 274.5pt; position: absolute; top: 32.25pt; width: 60pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 2.81pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 15pt; position: absolute; text-decoration: none; white-space: pre;">Shares<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td><td style="border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 337.5pt; position: absolute; top: 32.25pt; width: 47.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 2.81pt; width: 47.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 6.65pt; position: absolute; text-decoration: none; white-space: pre;">Amount<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 45pt; width: 153pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 153pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Balance at January 1, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 129.83pt; position: absolute; text-decoration: none; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 132.6pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 134.91pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 135.06pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 135.1pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 135.10999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 153pt; position: absolute; top: 45pt; width: 62.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 62.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 5.52pt;"></font></font><font style="left: 8.149999999999999pt; position: absolute;">39,422,361<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 218.25pt; position: absolute; top: 45pt; width: 50.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 50.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 1.85pt;"></font></font><font style="left: 10.04pt; position: absolute;">538,423<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; border-right: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-left: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 274.5pt; position: absolute; top: 45pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 3.27pt;"></font></font><font style="left: 5.9pt; position: absolute;">14,436,169<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 337.5pt; position: absolute; top: 45pt; width: 47.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 47.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 23.86pt;"></font></font><font style="left: 32.050000000000004pt; position: absolute;">14<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 45pt; width: 51pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 51pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 8.16pt;"></font></font><font style="left: 16.35pt; position: absolute;">58,427<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 441.75pt; position: absolute; top: 45pt; width: 72.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 72.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 54.92pt;"></font></font><font style="left: 63.11pt; position: absolute;">3<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 517.5pt; position: absolute; top: 45pt; width: 62.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 62.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 10.52pt;"></font></font><font style="left: 18.709999999999997pt; position: absolute;">(752,084)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 582.75pt; position: absolute; top: 45pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 13.52pt;"></font></font><font style="left: 21.709999999999997pt; position: absolute;">(693,640)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 38.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 59.25pt; width: 153pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 153pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Issuance of common stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 15.32pt; width: 153pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 23.63pt; position: absolute; text-decoration: none; white-space: pre;">upon exercise of stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 27.32pt; width: 153pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 23.63pt; position: absolute; text-decoration: none; white-space: pre;">options<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 55.86pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 58.17pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 59.33pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 59.91pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 59.92999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 59.94pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 153pt; position: absolute; top: 59.25pt; width: 62.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 27.37pt; width: 62.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 45.54pt;"></font></font><font style="left: 48.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 218.25pt; position: absolute; top: 59.25pt; width: 50.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 27.37pt; width: 50.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.54pt;"></font></font><font style="left: 36.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; border-right: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-left: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 274.5pt; position: absolute; top: 59.25pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 27.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 17.16pt;"></font></font><font style="left: 19.79pt; position: absolute;">291,756<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 337.5pt; position: absolute; top: 59.25pt; width: 47.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 27.37pt; width: 47.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 30.54pt;"></font></font><font style="left: 33.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 59.25pt; width: 51pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 27.37pt; width: 51pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 27.61pt;"></font></font><font style="left: 30.24pt; position: absolute;">589<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 441.75pt; position: absolute; top: 59.25pt; width: 72.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 27.37pt; width: 72.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 56.04pt;"></font></font><font style="left: 58.67pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 517.5pt; position: absolute; top: 59.25pt; width: 62.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 27.37pt; width: 62.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 45.54pt;"></font></font><font style="left: 48.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 582.75pt; position: absolute; top: 59.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 27.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 41.86pt;"></font></font><font style="left: 44.49pt; position: absolute;">589<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 62.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 97.5pt; width: 153pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 153pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Issuance of Series F <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 15.32pt; width: 153pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 23.63pt; position: absolute; text-decoration: none; white-space: pre;">redeemable convertible <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 27.32pt; width: 153pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 23.63pt; position: absolute; text-decoration: none; white-space: pre;">preferred stock at $2.8505 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 39.32pt; width: 153pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 23.63pt; position: absolute; text-decoration: none; white-space: pre;">per share, net of issuance <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 51.32pt; width: 153pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 23.63pt; position: absolute; text-decoration: none; white-space: pre;">costs of $5,904<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 91.39999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 93.71pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 94.86999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 94.94999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 94.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 95pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 153pt; position: absolute; top: 97.5pt; width: 62.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 51.37pt; width: 62.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 5.52pt;"></font></font><font style="left: 8.149999999999999pt; position: absolute;">61,344,029<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 218.25pt; position: absolute; top: 97.5pt; width: 50.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 51.37pt; width: 50.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 7.41pt;"></font></font><font style="left: 10.04pt; position: absolute;">168,957<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; border-right: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-left: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 274.5pt; position: absolute; top: 97.5pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 51.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 43.29pt;"></font></font><font style="left: 45.92pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 337.5pt; position: absolute; top: 97.5pt; width: 47.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 51.37pt; width: 47.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 30.54pt;"></font></font><font style="left: 33.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 97.5pt; width: 51pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 51.37pt; width: 51pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 34.29pt;"></font></font><font style="left: 36.92pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 441.75pt; position: absolute; top: 97.5pt; width: 72.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 51.37pt; width: 72.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 56.04pt;"></font></font><font style="left: 58.67pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 517.5pt; position: absolute; top: 97.5pt; width: 62.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 51.37pt; width: 62.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 45.54pt;"></font></font><font style="left: 48.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 582.75pt; position: absolute; top: 97.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 51.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 48.54pt;"></font></font><font style="left: 51.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 74.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 159.75pt; width: 153pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 153pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Issuance of Series F-1 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 15.32pt; width: 153pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 23.63pt; position: absolute; text-decoration: none; white-space: pre;">redeemable convertible <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 27.32pt; width: 153pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 23.63pt; position: absolute; text-decoration: none; white-space: pre;">preferred stock at $1.9098 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 39.32pt; width: 153pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 23.63pt; position: absolute; text-decoration: none; white-space: pre;">per share upon conversion <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 51.32pt; width: 153pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 23.63pt; position: absolute; text-decoration: none; white-space: pre;">of convertible notes and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 63.32pt; width: 153pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 23.63pt; position: absolute; text-decoration: none; white-space: pre;">accrued interest<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 94.74pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 95.03pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 95.17999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 95.25999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 95.3pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 95.32pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 95.33pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 153pt; position: absolute; top: 159.75pt; width: 62.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 63.37pt; width: 62.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 5.52pt;"></font></font><font style="left: 8.149999999999999pt; position: absolute;">21,465,064<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 218.25pt; position: absolute; top: 159.75pt; width: 50.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 63.37pt; width: 50.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 12.97pt;"></font></font><font style="left: 15.600000000000001pt; position: absolute;">61,186<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; border-right: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-left: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 274.5pt; position: absolute; top: 159.75pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 63.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 43.29pt;"></font></font><font style="left: 45.92pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 337.5pt; position: absolute; top: 159.75pt; width: 47.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 63.37pt; width: 47.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 30.54pt;"></font></font><font style="left: 33.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 159.75pt; width: 51pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 63.37pt; width: 51pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 34.29pt;"></font></font><font style="left: 36.92pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 441.75pt; position: absolute; top: 159.75pt; width: 72.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 63.37pt; width: 72.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 56.04pt;"></font></font><font style="left: 58.67pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 517.5pt; position: absolute; top: 159.75pt; width: 62.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 63.37pt; width: 62.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 45.54pt;"></font></font><font style="left: 48.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 582.75pt; position: absolute; top: 159.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 63.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 48.54pt;"></font></font><font style="left: 51.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 38.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 234pt; width: 153pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 153pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Deemed dividend upon down <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 15.32pt; width: 153pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 23.63pt; position: absolute; text-decoration: none; white-space: pre;">round of redeemable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 27.32pt; width: 153pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 23.63pt; position: absolute; text-decoration: none; white-space: pre;">convertible preferred stock<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 141.4pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 143.71pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 144.87pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 144.95pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 144.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 145pt; position: absolute; text-decoration: none; white-space: pre;"> .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 153pt; position: absolute; top: 234pt; width: 62.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 27.37pt; width: 62.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 45.54pt;"></font></font><font style="left: 48.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 218.25pt; position: absolute; top: 234pt; width: 50.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 27.37pt; width: 50.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.54pt;"></font></font><font style="left: 36.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; border-right: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-left: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 274.5pt; position: absolute; top: 234pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 27.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 43.29pt;"></font></font><font style="left: 45.92pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 337.5pt; position: absolute; top: 234pt; width: 47.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 27.37pt; width: 47.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 30.54pt;"></font></font><font style="left: 33.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 234pt; width: 51pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 27.37pt; width: 51pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 13.72pt;"></font></font><font style="left: 16.35pt; position: absolute;">26,794<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 441.75pt; position: absolute; top: 234pt; width: 72.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 27.37pt; width: 72.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 56.04pt;"></font></font><font style="left: 58.67pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 517.5pt; position: absolute; top: 234pt; width: 62.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 27.37pt; width: 62.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 21.64pt;"></font></font><font style="left: 24.27pt; position: absolute;">(26,794)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 582.75pt; position: absolute; top: 234pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 27.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 48.54pt;"></font></font><font style="left: 51.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 272.25pt; width: 153pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 153pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Repurchase of common stock<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 146.85pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 149.16pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 149.74pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 153pt; position: absolute; top: 272.25pt; width: 62.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 62.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 45.54pt;"></font></font><font style="left: 48.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 218.25pt; position: absolute; top: 272.25pt; width: 50.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 50.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.54pt;"></font></font><font style="left: 36.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; border-right: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-left: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 274.5pt; position: absolute; top: 272.25pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 13.83pt;"></font></font><font style="left: 16.46pt; position: absolute;">(300,000)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 337.5pt; position: absolute; top: 272.25pt; width: 47.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 47.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 30.54pt;"></font></font><font style="left: 33.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 272.25pt; width: 51pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 51pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 24.28pt;"></font></font><font style="left: 26.91pt; position: absolute;">(228)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 441.75pt; position: absolute; top: 272.25pt; width: 72.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 72.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 56.04pt;"></font></font><font style="left: 58.67pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 517.5pt; position: absolute; top: 272.25pt; width: 62.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 62.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 45.54pt;"></font></font><font style="left: 48.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 582.75pt; position: absolute; top: 272.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 38.53pt;"></font></font><font style="left: 41.160000000000004pt; position: absolute;">(228)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 26.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 286.5pt; width: 153pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 153pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Stock-based compensation <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 15.32pt; width: 153pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 23.63pt; position: absolute; text-decoration: none; white-space: pre;">expense<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 61.42999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 63.739999999999995pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 64.9pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 64.98pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 65pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 153pt; position: absolute; top: 286.5pt; width: 62.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 15.37pt; width: 62.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 45.54pt;"></font></font><font style="left: 48.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 218.25pt; position: absolute; top: 286.5pt; width: 50.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 15.37pt; width: 50.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.54pt;"></font></font><font style="left: 36.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; border-right: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-left: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 274.5pt; position: absolute; top: 286.5pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 15.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 43.29pt;"></font></font><font style="left: 45.92pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 337.5pt; position: absolute; top: 286.5pt; width: 47.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 15.37pt; width: 47.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 30.54pt;"></font></font><font style="left: 33.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 286.5pt; width: 51pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 15.37pt; width: 51pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 13.72pt;"></font></font><font style="left: 16.35pt; position: absolute;">11,874<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 441.75pt; position: absolute; top: 286.5pt; width: 72.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 15.37pt; width: 72.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 56.04pt;"></font></font><font style="left: 58.67pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 517.5pt; position: absolute; top: 286.5pt; width: 62.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 15.37pt; width: 62.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 45.54pt;"></font></font><font style="left: 48.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 582.75pt; position: absolute; top: 286.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 15.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 24.64pt;"></font></font><font style="left: 27.27pt; position: absolute;">(11,874)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 26.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 312.75pt; width: 153pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 153pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Foreign currency translation <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 15.32pt; width: 153pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 23.63pt; position: absolute; text-decoration: none; white-space: pre;">loss<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 41.41pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 43.72pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 44.879999999999995pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 44.959999999999994pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 45pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 153pt; position: absolute; top: 312.75pt; width: 62.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 15.37pt; width: 62.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 45.54pt;"></font></font><font style="left: 48.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 218.25pt; position: absolute; top: 312.75pt; width: 50.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 15.37pt; width: 50.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.54pt;"></font></font><font style="left: 36.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; border-right: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-left: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 274.5pt; position: absolute; top: 312.75pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 15.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 43.29pt;"></font></font><font style="left: 45.92pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 337.5pt; position: absolute; top: 312.75pt; width: 47.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 15.37pt; width: 47.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 30.54pt;"></font></font><font style="left: 33.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 312.75pt; width: 51pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 15.37pt; width: 51pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 34.29pt;"></font></font><font style="left: 36.92pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 441.75pt; position: absolute; top: 312.75pt; width: 72.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 15.37pt; width: 72.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 46.03pt;"></font></font><font style="left: 48.660000000000004pt; position: absolute;">(504)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 517.5pt; position: absolute; top: 312.75pt; width: 62.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 15.37pt; width: 62.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 45.54pt;"></font></font><font style="left: 48.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 582.75pt; position: absolute; top: 312.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 15.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 38.53pt;"></font></font><font style="left: 41.160000000000004pt; position: absolute;">(504)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 339pt; width: 153pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 153pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Net loss<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 50.730000000000004pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 53.04pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 54.2pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 54.78pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 54.93pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 153pt; position: absolute; top: 339pt; width: 62.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 62.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 45.54pt;"></font></font><font style="left: 48.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 218.25pt; position: absolute; top: 339pt; width: 50.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 50.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.54pt;"></font></font><font style="left: 36.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; border-right: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-left: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 274.5pt; position: absolute; top: 339pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 43.29pt;"></font></font><font style="left: 45.92pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 337.5pt; position: absolute; top: 339pt; width: 47.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 47.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 30.54pt;"></font></font><font style="left: 33.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 339pt; width: 51pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 51pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 34.29pt;"></font></font><font style="left: 36.92pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 441.75pt; position: absolute; top: 339pt; width: 72.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 72.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 56.04pt;"></font></font><font style="left: 58.67pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 517.5pt; position: absolute; top: 339pt; width: 62.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 62.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 21.64pt;"></font></font><font style="left: 24.27pt; position: absolute;">(95,655)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 582.75pt; position: absolute; top: 339pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 24.64pt;"></font></font><font style="left: 27.27pt; position: absolute;">(95,655)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 353.25pt; width: 153pt;"><div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 3.37pt; width: 153pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Balance at <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 55.39pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 145.4pt; position: absolute; text-decoration: none; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 148.17pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 149.32999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 149.91pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 150.06pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 150.14pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 153pt; position: absolute; top: 353.25pt; width: 62.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 62.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt;"></font></font><font style="left: 2.63pt; position: absolute;">122,231,454<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 218.25pt; position: absolute; top: 353.25pt; width: 50.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 50.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 1.85pt;"></font></font><font style="left: 10.04pt; position: absolute;">768,566<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; border-right: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-left: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 274.5pt; position: absolute; top: 353.25pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 3.27pt;"></font></font><font style="left: 5.9pt; position: absolute;">14,427,925<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 337.5pt; position: absolute; top: 353.25pt; width: 47.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 47.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 23.86pt;"></font></font><font style="left: 32.050000000000004pt; position: absolute;">14<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 353.25pt; width: 51pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 51pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 8.16pt;"></font></font><font style="left: 16.35pt; position: absolute;">97,456<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 441.75pt; position: absolute; top: 353.25pt; width: 72.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 72.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 40.47pt;"></font></font><font style="left: 48.660000000000004pt; position: absolute;">(501)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 517.5pt; position: absolute; top: 353.25pt; width: 62.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 62.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 10.52pt;"></font></font><font style="left: 18.709999999999997pt; position: absolute;">(874,533)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 582.75pt; position: absolute; top: 353.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 13.52pt;"></font></font><font style="left: 21.709999999999997pt; position: absolute;">(777,564)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 517.1pt; width: 792pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 202.68pt; position: absolute; text-decoration: none; white-space: pre;">The accompanying notes are an integral part of these consolidated financial statements<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 298.5pt; position: absolute; text-decoration: none; white-space: pre;">F-6<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_418" style="position: absolute; top: 72pt;"></div><div style="line-height: 11.64pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 91.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 195.05pt; position: absolute; text-decoration: none; white-space: pre;">Consolidated Statement of Cash <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 382.96000000000004pt; position: absolute; text-decoration: none; white-space: pre;">Flows<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 105.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 271.59pt; position: absolute; text-decoration: none; white-space: pre;">(in thousands)<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 125.6pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 402.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 32.25pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 5.82pt; position: absolute; top: 4.05pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 10.65pt; position: absolute; text-decoration: none; white-space: pre;">Year Ended <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="font-size: 12pt; line-height: 5.82pt; position: absolute; top: 13.65pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 6.65pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, <font style="display: inline-block; height: 5.82pt;"></font></font></div><div style="font-size: 12pt; line-height: 5.82pt; position: absolute; top: 23.25pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 8pt; font-style: normal; font-weight: bold; left: 23.74pt; position: absolute; text-decoration: none; white-space: pre;">2023<font style="display: inline-block; height: 5.82pt;"></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 32.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Cash flows from operating activities&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 12pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 44.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Net loss<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 38.730000000000004pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 39.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 39.970000000000006pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 39.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 40pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 402.75pt; overflow: hidden; position: absolute; top: 44.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 19.08pt;"></font></font><font style="left: 27.27pt; position: absolute;">(95,655)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 56.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Adjustments to reconcile net loss to net cash used in operating activities&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 12pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 68.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Depreciation and amortization<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 147.41pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 149.72pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 149.79999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 149.84pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 149.85999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 149.87pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 402.75pt; overflow: hidden; position: absolute; top: 68.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">4,744<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 80.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Stock-based compensation expense<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 175.76999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 178.07999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 179.24pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 179.53pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 179.68pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 179.7pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 179.71pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 402.75pt; overflow: hidden; position: absolute; top: 80.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">11,874<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 92.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Amortization of debt discount and debt issuance costs<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 253.49pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 254.65pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 254.94pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 254.96pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 254.97pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 402.75pt; overflow: hidden; position: absolute; top: 92.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">3,642<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 104.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Amortization of right-of-use asset<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 161.25pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 163.56pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 164.72pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 164.74pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 164.75pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 104.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">2,889<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 118.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Change in fair value of convertible note<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 187.95pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 189.10999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 189.69pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 189.84pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 189.92pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 189.93pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 402.75pt; overflow: hidden; position: absolute; top: 118.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">5,120<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 130.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Change in fair value of common stock warrant liability<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 250.69pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 253pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 254.16pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 254.45pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 254.6pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 254.68pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 254.7pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 254.71pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 402.75pt; overflow: hidden; position: absolute; top: 130.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">2,320<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 142.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Change in fair value of derivative liability<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 192.93pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 194.09pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 194.67pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 194.82pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 194.9pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 194.92pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 194.93pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 402.75pt; overflow: hidden; position: absolute; top: 142.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 30.2pt;"></font></font><font style="left: 32.83pt; position: absolute;">(4,158)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 154.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Paid-in-kind interest<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 102.94999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 104.11pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 104.69pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 104.83999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 104.92pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 104.92999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 402.75pt; overflow: hidden; position: absolute; top: 154.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 41.86pt;"></font></font><font style="left: 44.49pt; position: absolute;">144<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 166.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Allowance for credit losses<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 132.94pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 134.1pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 134.68pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 134.83pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 134.91pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 134.93pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 402.75pt; overflow: hidden; position: absolute; top: 166.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">1,190<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 178.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Changes in assets and liabilities&#58;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 159.62pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 159.91pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 160.06pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 160.07999999999998pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 12pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 190.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 26.63pt; position: absolute; text-decoration: none; white-space: pre;">Accounts receivable, net<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 135.51pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 137.82pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 138.98pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 139.56pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 139.64000000000001pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 139.68pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 139.69pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 402.75pt; overflow: hidden; position: absolute; top: 190.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 30.2pt;"></font></font><font style="left: 32.83pt; position: absolute;">(9,350)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 202.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 26.63pt; position: absolute; text-decoration: none; white-space: pre;">Prepaid expenses and other current assets<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 217.19pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 219.5pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 219.79pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 219.82999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 219.84pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 402.75pt; overflow: hidden; position: absolute; top: 202.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 38.53pt;"></font></font><font style="left: 41.160000000000004pt; position: absolute;">(357)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 214.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 26.63pt; position: absolute; text-decoration: none; white-space: pre;">Other non-current assets<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 137.17000000000002pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 139.48pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 139.77pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 139.81pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 139.83pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 139.84pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 402.75pt; overflow: hidden; position: absolute; top: 214.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 38.53pt;"></font></font><font style="left: 41.160000000000004pt; position: absolute;">(402)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 226.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 26.63pt; position: absolute; text-decoration: none; white-space: pre;">Accounts payable<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 105.53pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 107.83999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 109pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 109.58pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 109.66pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 109.67999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 109.69pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 402.75pt; overflow: hidden; position: absolute; top: 226.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 38.53pt;"></font></font><font style="left: 41.160000000000004pt; position: absolute;">(623)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 238.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 26.63pt; position: absolute; text-decoration: none; white-space: pre;">Accrued expenses and other current liabilities<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 228.29pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 229.45pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 229.74pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 229.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 229.93pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 229.95pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 229.96pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 402.75pt; overflow: hidden; position: absolute; top: 238.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">3,759<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 250.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 26.63pt; position: absolute; text-decoration: none; white-space: pre;">Operating lease liabilities<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 137.73pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 138.89000000000001pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 139.47pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 139.76pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 139.84pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 139.88pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 139.9pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 139.91pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 402.75pt; overflow: hidden; position: absolute; top: 250.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 30.2pt;"></font></font><font style="left: 32.83pt; position: absolute;">(1,761)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 262.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 26.63pt; position: absolute; text-decoration: none; white-space: pre;">Other non-current liabilities<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 146.05pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 148.36pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 149.52pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 149.67000000000002pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 149.71pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 149.73pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 149.74pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 402.75pt; overflow: hidden; position: absolute; top: 262.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 41.86pt;"></font></font><font style="left: 44.49pt; position: absolute;">190<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 274.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 38.63pt; position: absolute; text-decoration: none; white-space: pre;">Net cash used in operating activities<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 198.60999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 199.76999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 199.92pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 199.96pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 199.98pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 199.99pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 402.75pt; overflow: hidden; position: absolute; top: 274.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 24.64pt;"></font></font><font style="left: 27.27pt; position: absolute;">(76,434)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 12pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 298.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Cash flows from investing activities<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 12pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 310.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Purchase of property and equipment<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 176.29999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 178.60999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 179.19pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 179.48pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 179.63pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 179.71pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 179.75pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 179.76999999999998pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 402.75pt; overflow: hidden; position: absolute; top: 310.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 30.2pt;"></font></font><font style="left: 32.83pt; position: absolute;">(6,105)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 322.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 38.63pt; position: absolute; text-decoration: none; white-space: pre;">Net cash used in investing activities <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 199.15pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 199.73pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 200.01999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 200.03pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 402.75pt; overflow: hidden; position: absolute; top: 322.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 30.2pt;"></font></font><font style="left: 32.83pt; position: absolute;">(6,105)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 12pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 346.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Cash flows from financing activities<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 26.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 358.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Proceeds from issuance of Series F redeemable convertible preferred shares, net of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 15.32pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 23.63pt; position: absolute; text-decoration: none; white-space: pre;">issuance costs<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 89.19pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 89.77pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 89.92pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 90.03999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90.05pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 358.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 15.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 22.41pt;"></font></font><font style="left: 25.04pt; position: absolute;">168,957<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 384.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Proceeds from exercise of stock options<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 191.82pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 194.13pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 194.71pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 194.79pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 194.81pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 402.75pt; overflow: hidden; position: absolute; top: 384.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 41.86pt;"></font></font><font style="left: 44.49pt; position: absolute;">589<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 396.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Repurchase of common stock<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 146.85pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 149.16pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 149.74pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 149.78pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 149.79999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 149.81pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 402.75pt; overflow: hidden; position: absolute; top: 396.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 38.53pt;"></font></font><font style="left: 41.160000000000004pt; position: absolute;">(228)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 408.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 38.63pt; position: absolute; text-decoration: none; white-space: pre;">Net cash provided by financing activities <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 219.16pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 219.74pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 220.03pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 402.75pt; overflow: hidden; position: absolute; top: 408.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 22.41pt;"></font></font><font style="left: 25.04pt; position: absolute;">169,318<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 420.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Effect of foreign exchange rates<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 143.53pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 144.69pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 144.84pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 144.92pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 144.96pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 144.98pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 144.99pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 402.75pt; overflow: hidden; position: absolute; top: 420.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 38.53pt;"></font></font><font style="left: 41.160000000000004pt; position: absolute;">(504)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 432.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Net increase in cash, cash equivalents and restricted cash<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 260.39pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 262.7pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 263.86pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 264.44pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 264.59pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 264.67pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 264.68pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 402.75pt; overflow: hidden; position: absolute; top: 432.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">86,275<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 444.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Balance, beginning of period<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 141.31pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 143.62pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 144.2pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 144.49pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 144.64pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 144.72pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 144.76pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 144.76999999999998pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 402.75pt; overflow: hidden; position: absolute; top: 444.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">40,959<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 456.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Balance, end of period<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 114.63pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 114.92pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 115.07pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 115.08pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 402.75pt; overflow: hidden; position: absolute; top: 456.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 16.85pt;"></font></font><font style="left: 25.04pt; position: absolute;">127,234<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 468.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Supplemental disclosure of cash flow information&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 12pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 480.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Cash paid for taxes<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 100.72999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 103.03999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 104.19999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 104.49pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 104.64pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 104.67999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 104.69999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 104.71pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 402.75pt; overflow: hidden; position: absolute; top: 480.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 36.3pt;"></font></font><font style="left: 44.49pt; position: absolute;">405<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 492.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Cash paid for interest<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 109.61pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 109.89999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 110.05pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 110.07pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 110.08pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 402.75pt; overflow: hidden; position: absolute; top: 492.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 22.41pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">20,800<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 504.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Supplemental disclosure of non-cash investing and financing activities&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 12pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 516.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Purchases of property and equipment included in accounts payable<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 312.43pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 314.74pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 314.82pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 314.86pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 314.87pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 402.75pt; overflow: hidden; position: absolute; top: 516.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 36.3pt;"></font></font><font style="left: 44.49pt; position: absolute;">808<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 528.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Reduction in right-of-use asset and lease obligation due to amendment in lease terms<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 392.94pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 394.1pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 394.68pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 394.83pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 394.90999999999997pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 394.93pt; position: absolute; text-decoration: none; white-space: pre;"> .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 402.75pt; overflow: hidden; position: absolute; top: 528.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">1,776<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 540.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Deemed dividend upon down round of redeemable convertible preferred stock<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 359.65999999999997pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 359.95pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 360.03pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 360.07pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 360.09pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 402.75pt; overflow: hidden; position: absolute; top: 540.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 22.41pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">26,794<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 12pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 0pt; overflow: hidden; position: absolute; top: 552.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Conversion of convertible note into Series F-1 redeemable convertible preferred stock<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 393.48pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 394.64pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 394.93pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 394.96999999999997pt; position: absolute; text-decoration: none; white-space: pre;"> .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="height: 12pt; left: 402.75pt; overflow: hidden; position: absolute; top: 552.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 22.41pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">61,186<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 706.35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 111.29pt; position: absolute; text-decoration: none; white-space: pre;">The accompanying notes are an integral part of these consolidated financial statements.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 298.5pt; position: absolute; text-decoration: none; white-space: pre;">F-7<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"><div style="line-height: 11.64pt; position: absolute; top: 36pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 55.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 180.72pt; position: absolute; text-decoration: none; white-space: pre;">Notes to Consolidated Financial <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 366.64pt; position: absolute; text-decoration: none; white-space: pre;">Statements<font style="display: inline-block; height: 8.73pt;"></font></font></div></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_129" style="position: absolute; top: 90pt;"></div><div id="i2341357d54884756b9e9172f0a83cd6b_161" style="position: absolute; top: 109.2pt;"></div><div style="line-height: 8.73pt; position: absolute; top: 109.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">1. Business Overview<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 131.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Description of Business<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 151.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">HeartFlow Holding, Inc. (the &#8220;Company&#8221;) was incorporated in the state of Delaware in July 2007 as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 163.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Cardiovascular Simulation, Inc. and changed its name to HeartFlow, Inc. in May 2009. On March 1, 2021, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 175.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the Company completed an internal reorganization in which a newly formed parent holding company, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 187.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">HeartFlow Holding, Inc., was established. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 207.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company is a <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 155.87pt; position: absolute; text-decoration: none; white-space: pre;">commercial-stage<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 234.76pt; position: absolute; white-space: pre;"> medical technology company that has pioneered the use of software <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 219.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and AI to deliver a non-invasive solution for diagnosing and managing coronary artery disease (&#8220;CAD&#8221;). <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 231.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company&#8217;s novel HeartFlow Platform uses AI<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 292.31pt; position: absolute; text-decoration: none; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 295.08000000000004pt; position: absolute; white-space: pre;">and advanced computational fluid dynamics to create a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 243.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">personalized 3D model of a patient&#8217;s heart based off a single coronary computed tomography <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 255.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">angiography (&#8220;CCTA&#8221;). This results in actionable data on blood flow, stenosis, plaque volume and plaque <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 267.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">composition.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 128.11pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;"> The Company&#8217;s HeartFlow FFR</font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 271.02pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;"><font style="background-color: inherit;">CT </font><font style="display: inline-block; height: 4.732pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 281.37pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">Analysis software assists physicians in diagnosing, </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 279.6pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">managing and delivering precision care to patients with CAD.</font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 341.97pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;"> The Company was awarded Conformit&#233; </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 291.6pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">Europ&#233;ene Mark (&#8220;CE Mark&#8221;) for its HeartFlow FFR</font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 298.55pt; position: absolute; text-decoration: none; top: 2.548pt; vertical-align: sub; white-space: pre;"><font style="background-color: inherit;">CT </font><font style="display: inline-block; height: 4.732pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 308.9pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">Analysis in July 2011. Th</font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 418.51pt; position: absolute; text-decoration: none; white-space: pre;">e Company received <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 303.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">clearance from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in November 2014. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 323.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company&#8217;s United States (&#8220;U.S.&#8221;) headquarters is located in Mountain View, California, and the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 335.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Company also has offices in Austin, Texas, and Tokyo, Japan. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 355.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company had the following wholly-owned subsidiaries as of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 358.65pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 446.44pt; position: absolute; white-space: pre;">&#58; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 375.6pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 234pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 234pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 12.75pt;"><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 234pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 2.81pt; width: 234pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 91.02pt; position: absolute; text-decoration: none; white-space: pre;">Entity Name<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 234pt; position: absolute; top: 0pt; width: 234pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 2.81pt; width: 234pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 64.07pt; position: absolute; text-decoration: none; white-space: pre;">Country of Incorporation<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 12.75pt; width: 234pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 234pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow, Inc.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 234pt; position: absolute; top: 12.75pt; width: 234pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 234pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">United States<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 27pt; width: 234pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 234pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Japan G.K.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 234pt; position: absolute; top: 27pt; width: 234pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 234pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Japan<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 41.25pt; width: 234pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 234pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow International Sarl <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 234pt; position: absolute; top: 41.25pt; width: 234pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 234pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Switzerland<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 55.5pt; width: 234pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 234pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow U.K. Ltd<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 234pt; position: absolute; top: 55.5pt; width: 234pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 234pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">United Kingdom<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 69.75pt; width: 234pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 234pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Technology U.K. Limited<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 234pt; position: absolute; top: 69.75pt; width: 234pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 234pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">United Kingdom<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 475.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Effective July 2024, HeartFlow International Sarl was dissolved.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 495.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Liquidity and Going Concern<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 515.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company has incurred operating losses and negative cash flows from operations since its inception <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 527.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and has an accumulated deficit of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 223.65pt; position: absolute; text-decoration: none; white-space: pre;">$874.5<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 254.22pt; position: absolute; white-space: pre;"> million as of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 312.52pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 400.31pt; position: absolute; white-space: pre;">. The Company expects to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 539.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">incur losses for the foreseeable future. Historically, the Company&#8217;s activities have been financed through <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 551.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">sales of shares of redeemable convertible preferred stock, common stock and convertible promissory <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 563.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">notes, borrowings under term loans and revenue received from customers.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 583.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Management does not believe that the Company&#8217;s existing cash and cash equivalents of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 465.7pt; position: absolute; text-decoration: none; white-space: pre;">$122.8<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 496.27pt; position: absolute; white-space: pre;"> million <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 595.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">as of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 96.43pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 184.22pt; position: absolute; white-space: pre;"> as well as its expected revenues will provide sufficient funds to allow the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 607.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Company to continue its planned operations for at least the next 12 months from the date of the issuance <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 619.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of these consolidated financial statements. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 639.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company expects to seek additional funding in the form of debt or equity financings to make strategic <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 651.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">investments in its business&#59; however, there can be no assurance that such efforts will be successful or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 663.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">that, in the event that they are successful, the terms and conditions of such financing will be favorable. If <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 675.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the Company&#8217;s revenue levels are not sufficient or if the Company is unable to secure additional funding <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 687.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">when desired, the Company may need to delay or abandon some or all of its development programs and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 699.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">scale back its business and operations, which could materially harm the Company&#8217;s business, financial <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 298.5pt; position: absolute; text-decoration: none; white-space: pre;">F-8<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"><div style="line-height: 11.64pt; position: absolute; top: 36pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 55.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 180.72pt; position: absolute; text-decoration: none; white-space: pre;">Notes to Consolidated Financial <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 366.64pt; position: absolute; text-decoration: none; white-space: pre;">Statements<font style="display: inline-block; height: 8.73pt;"></font></font></div></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 90pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">condition and results of operations. These factors raise substantial doubt about the Company&#8217;s ability to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 102pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">continue as a going concern.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 122pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The accompanying consolidated financial statements do not include any adjustments that might result <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 134pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">from the outcome of this uncertainty. Accordingly, the consolidated financial statements have been <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 146pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prepared on a basis that assumes the Company will continue as a going concern and which contemplates <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 158pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div id="i2341357d54884756b9e9172f0a83cd6b_403" style="position: absolute; top: 178pt;"></div><div style="line-height: 8.73pt; position: absolute; top: 178pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">2. Summary of Significant Accounting Policies<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 200.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Basis of Presentation<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The accompanying consolidated financial statements include the accounts of the Company as well as its <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">wholly owned subsidiaries and have been prepared in accordance with accounting principles generally <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">accepted in the United States of America (&#8220;U.S. GAAP&#8221;). All significant intercompany balances and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">transactions have been eliminated in consolidation.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 276.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Use of Estimates<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 296.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The preparation of financial statements in conformity with U.S. GAAP requires management to make <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">estimates and assumptions that affect the amounts reported in the financial statements and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 320.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">accompanying notes. Management used significant judgement when making estimates in the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 332.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">determination of the fair value of its common stock and stock options, deferred income tax valuation <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 344.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">allowance, capitalized internal-use software, depreciation of property and equipment, allowance for credit <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 356.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">losses, revenue recognition, valuation of operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 368.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">liabilities, and the fair value of convertible debt, warrants to purchase common stock and embedded <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 380.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">derivatives. Management evaluates its estimates and assumptions on an ongoing basis using historical <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 392.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">experience and other factors and adjusts those estimates and assumptions as facts and circumstances <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 404.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">dictate. Actual results could materially differ from those estimates.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 424.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Segment <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 116.97pt; position: absolute; text-decoration: none; white-space: pre;">Information<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 444.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company operates and manages its business as one reportable and operating segment, which is the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 456.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">business of research and development of non-invasive coronary artery detection solutions. The <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 468.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Company&#8217;s Chief Executive Officer, who is the chief operating decision maker, reviews financial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">information on an aggregate basis for purposes of allocating resources and evaluating financial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 492.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">performance. The Company&#8217;s long-lived assets are primarily in t<font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 354.37pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">he United States of America</font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 478.22pt; position: absolute; white-space: pre;">.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 512.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Cash, Cash Equivalents and Restricted Cash<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 532.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company considers all highly liquid investments that are readily convertible to known amounts of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 544.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">cash and purchased with an original maturity of three months or less to be cash equivalents. Cash <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 556.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">equivalents consist primarily of amounts invested in money market accounts. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The following table provides a reconciliation of cash, cash equivalents and restricted cash within the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">consolidated balance sheet to the total shown in the consolidated statement of cash flows (in thousands)&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 608.4pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 402.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 24pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.26pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 3.38pt; position: absolute; text-decoration: none; white-space: pre;">December 31, <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 14.06pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 22.62pt; position: absolute; text-decoration: none; white-space: pre;">2023<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 24pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Cash and cash equivalents<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 122.64999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 123.81pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 124.39pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 124.67999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 124.83pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 124.86999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 124.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 124.89999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 24pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 16.85pt;"></font></font><font style="left: 25.04pt; position: absolute;">122,767<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 38.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Restricted cash<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 71.50999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 73.82pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 74.39999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 74.69pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 74.77pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 74.78pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 38.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">4,467<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 52.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Total cash, cash equivalents and restricted cash<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 214.84pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 214.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 215.07pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 215.10999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 52.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 16.85pt;"></font></font><font style="left: 25.04pt; position: absolute;">127,234<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 691.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">As of December 31, 2023, restricted cash represents deposits held as security in connection with the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 703.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Company&#8217;s facility lease agreements.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 298.5pt; position: absolute; text-decoration: none; white-space: pre;">F-9<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"><div style="line-height: 11.64pt; position: absolute; top: 36pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 55.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 180.72pt; position: absolute; text-decoration: none; white-space: pre;">Notes to Consolidated Financial <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 366.64pt; position: absolute; text-decoration: none; white-space: pre;">Statements<font style="display: inline-block; height: 8.73pt;"></font></font></div></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 90pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Fair Value of Financial Instruments<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 110pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 122pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">is an exit price, representing the amount that would be received to sell an asset or paid to transfer a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 134pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">liability in an orderly transaction between market participants. As such, fair value is a market-based <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 146pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">measurement that should be determined based on assumptions that market participants would use in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 158pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">pricing an asset or a liability.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 178pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 190pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 202pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">priority to valuations based upon unadjusted quoted prices in active markets for identical assets or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 214pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 226pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">that are significant to the valuation (Level 3 measurements). The accounting guidance establishes three <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 238pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">levels of the fair value hierarchy as follows&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 258pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Level 1 -<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 110.33pt; position: absolute; white-space: pre;"> Observable inputs, such as quoted prices in active markets for identical assets or liabilities&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 278pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Level 2 -<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 110.33pt; position: absolute; white-space: pre;"> Observable inputs other than Level 1 prices, such as quoted prices for similar assets or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 290pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 302pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">corroborated by observable market data for substantially the full term of the assets or liabilities&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 322pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Level 3 -<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 110.33pt; position: absolute; white-space: pre;"> Unobservable inputs that are supported by little or no market activity and that are significant to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 334pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the fair value of the assets or liabilities.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 354pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 366pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 378pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">particular input to the fair value measurement in its entirety requires management to make judgments and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 390pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">considers factors specific to the asset or liability.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 410pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">As of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 97.53pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 185.32pt; position: absolute; white-space: pre;">, the carrying amounts of the Company&#8217;s financial instruments, including cash <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 422pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 434pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">their relatively short maturities and market interest rates, if applicable. Management believes that the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 446pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Company&#8217;s Term Loan bears interest at the prevailing market rates for instruments with similar <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 458pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">characteristics&#59; accordingly, the carrying value of this instrument approximates its fair value. Fair value <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 470pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">accounting is applied to the convertible notes, common stock warrant liability and derivative liability. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 490pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Concentration of Credit Risk and Significant Customers<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 510pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Financial instruments that potentially subject the Company to credit risk consist primarily of cash and cash <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 522pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">equivalents, restricted cash and accounts receivable. The Company maintains bank deposits in federally <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 534pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">insured financial institutions and these deposits may at times exceed federally insured limits. To date, the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 546pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Company has not experienced any losses on its cash deposits. The Company currently has full control of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 558pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">its cash and cash equivalents balance. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 578pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">On March 10, 2023, Silicon Valley Bank (&#8220;SVB&#8221;) was closed by the California Department of Financial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 590pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 602pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">receiver. On March 13, 2023, the FDIC announced that it had transferred all insured and uninsured <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 614pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">deposits and substantially all assets of SVB to a newly created, full-service FDIC-operated &#8220;bridge bank&#8221; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 626pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">called Silicon Valley Bridge Bank, N.A. (&#8220;SVBB&#8221;), where depositors would have full access to their money <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 638pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">immediately. On March 27, 2023, First Citizens BancShares, Inc. (&#8220;First Citizens Bank&#8221;) acquired SVBB <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 650pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">from the FDIC and operated SVBB as Silicon Valley Bank, a division of First Citizens Bank. The Company <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 662pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">successfully transferred all funds to another financial institution and did not incur any losses on its <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 674pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">deposits as a result of SVB&#8217;s closure.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 694pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">No single customer represented more than 10% of the Company&#8217;s revenue during the year ended <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 706pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 159.79000000000002pt; position: absolute; white-space: pre;">.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 295.72pt; position: absolute; text-decoration: none; white-space: pre;">F-10<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"><div style="line-height: 11.64pt; position: absolute; top: 36pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 55.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 180.72pt; position: absolute; text-decoration: none; white-space: pre;">Notes to Consolidated Financial <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 366.64pt; position: absolute; text-decoration: none; white-space: pre;">Statements<font style="display: inline-block; height: 8.73pt;"></font></font></div></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 90pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">No single customer represented more than 10% of the Company&#8217;s accounts receivable as of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 102pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 159.79000000000002pt; position: absolute; white-space: pre;">.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 122pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Accounts Receivable<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 142pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company performs ongoing credit evaluations of its customers&#8217; financial conditions and generally <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 154pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">extends credit to customers without requiring collateral. Accounts receivable are recorded at the amounts <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 166pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">billed less estimated allowances for credit losses for any potential uncollectible amounts. The Company <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 178pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">continually monitors customer payments and maintains an allowance for estimated losses resulting from a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 190pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">customer&#8217;s inability to make required payments. The Company considers factors such as historical <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 202pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">experience, credit quality, age of the accounts receivable balances, geographic related risks and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 214pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">economic conditions that may affect a customer&#8217;s ability to pay. Accounts receivable are written-off and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 226pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">charged against an allowance for credit losses when the Company has exhausted collection efforts <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 238pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">without <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 106.43pt; position: absolute; text-decoration: none; white-space: pre;">success<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 142.55pt; position: absolute; white-space: pre;">.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 258pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Property and Equipment<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 278pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Property and equipment are stated at cost less accumulated depreciation or amortization. Depreciation <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 290pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and amortization is computed using the straight-line method over the estimated useful lives of assets, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 302pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">which generally ranges from two to five years. Leasehold improvements are amortized over the lesser of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 314pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">their useful life or the remaining life of the lease. Upon sale or retirement of assets, the cost and related <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 326pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 338pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">in results from operations in the period realized. Maintenance and repairs are expensed as incurred.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 358pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Impairment of Long-Lived Assets<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 378pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company reviews its long-lived assets, including property and equipment, for impairment at least <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 390pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">annually and whenever events or changes in circumstances indicate that the carrying amount of an asset <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 402pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">may not be recoverable. When factors indicate that long-lived assets should be evaluated for possible <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 414pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">impairment, the Company uses an estimate of the related undiscounted future cash flows over the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 426pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">remaining useful life of the long-lived assets in measuring whether they are recoverable. If the carrying <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 438pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">value of the asset exceeds the estimated undiscounted future cash flows, a loss is recorded as the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 450pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">excess of the asset&#8217;s carrying value over its fair value. <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 313.41999999999996pt; position: absolute; text-decoration: none; white-space: pre;">No<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 326.2pt; position: absolute; white-space: pre;"> assets were determined to be impaired during <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 462pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the year ended <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 141.45pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 229.24pt; position: absolute; white-space: pre;">.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 482pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Deferred Offering Costs<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 502pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company capitalizes certain legal, accounting and other third-party fees that are directly associated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 514pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">with in-process equity financings as deferred offering costs until such financings are consummated. After <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 526pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">consummation of the equity financing, these costs are recorded as a reduction of the proceeds from the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 538pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">offering, either as a reduction of the carrying value of preferred stock or in stockholders&#8217; deficit as a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 550pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reduction of additional paid-in capital generated as a result of the offering. Should the in-process equity <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 562pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">financing be abandoned, the deferred offering costs would be expensed immediately as a charge to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 574pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">operating expenses in the consolidated statement of operations and comprehensive loss. No deferred <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 586pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">offering costs were capitalized as of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 232.89pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 320.68pt; position: absolute; white-space: pre;">.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 606pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Internal-Use Software<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 626pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company capitalizes certain costs related to internal-use software during the application <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 638pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">development stage. Costs related to planning and post implementation activities are expensed as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 650pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">incurred. Capitalized internal-use software is amortized on a straight-line basis over the estimated useful <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 662pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">life, which is generally two years, after the product is deployed and ready for use. The Company <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 674pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">evaluates the useful lives of these assets on an annual basis and tests for impairment whenever events <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 686pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or changes in circumstances occur that could impact the recoverability of these assets. Capitalized <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 698pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">internal-use software costs are classified as a component of property and equipment, net.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 296.09pt; position: absolute; text-decoration: none; white-space: pre;">F-11<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"><div style="line-height: 11.64pt; position: absolute; top: 36pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 55.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 180.72pt; position: absolute; text-decoration: none; white-space: pre;">Notes to Consolidated Financial <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 366.64pt; position: absolute; text-decoration: none; white-space: pre;">Statements<font style="display: inline-block; height: 8.73pt;"></font></font></div></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 90pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Leases<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 110pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">At the inception of a contractual arrangement, the Company determines whether the contract contains a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 122pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">lease by assessing whether there is an identified asset and whether the contract conveys the right to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 134pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">control the use of the identified asset in exchange for consideration over a period of time.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 154pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">An <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 86.99pt; position: absolute; text-decoration: none; white-space: pre;">ROU<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 109.2pt; position: absolute; white-space: pre;"> asset and corresponding lease liability are recorded on the consolidated balance sheet based on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 166pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the present value of lease payments over the lease term. An ROU asset represents the right to control the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 178pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">use of an identified asset over the lease term and a lease liability represents the obligation to make lease <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 190pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">payments arising from the lease. Leases with an initial term of 12 months or less are not recorded in the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 202pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">consolidated balance sheet. The Company uses its incremental borrowing rate to determine the present <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 214pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">value of lease payments, as the discount rate implicit in the lease is not readily available. The lease terms <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 226pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">used to calculate the ROU asset and related lease liabilities include options to extend or terminate the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 238pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">lease when it is reasonably certain that the Company will exercise that option. The Company elected to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 250pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">account for contracts that contain lease and non-lease components as a single lease component. For the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 262pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">year ended December 31, 2023, the Company&#8217;s only leases were for its facilities, which are classified as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 274pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">operating leases with lease expense recognized on a straight-line basis over the lease term. Variable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 286pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">lease costs, which primarily consist of common area maintenance, taxes, and utility charges are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 298pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">expensed as incurred. The Company does not have any finance leases.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 318pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Term Loan<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 338pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Term Loan is accounted for at amortized cost. Original debt issuance costs are deferred and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 350pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">presented as a reduction to the carrying value of the Term Loan. Debt discount and debt issuance costs <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 362pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">are amortized using the effective interest method and recorded in interest expense within the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 374pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">consolidated statement of operations and comprehensive loss. Refer to Note 8 for additional information.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 394pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Convertible Notes<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 414pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company issued Convertible Notes from September 2022 to December 2022, which were all <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 426pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">converted to Series F redeemable convertible preferred stock in March 2023. Refer to Notes 9 and 10 for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 438pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">additional information. The Convertible Notes contained embedded features that provided the Note <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 450pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Investors with multiple settlement alternatives. Rather than accounting for the embedded features that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 462pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">qualified as derivatives separately, the Company elected to account for the Convertible Notes at fair value <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 474pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">each reporting period. Debt issuance costs were expensed as incurred. The Company recognized the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 486pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">changes in fair value (including interest) as change in fair value of convertible note within the consolidated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 498pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">statement of operations and comprehensive loss.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 518pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Common Stock Warrants<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 538pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company&#8217;s warrants to purchase common stock that were issued in connection with the <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 482.13pt; position: absolute; text-decoration: none; white-space: pre;">Term Loan <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 550pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">do not meet the equity indexation criteria and are classified as a liability. The warrants are recorded at fair <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 562pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">value upon issuance and are subject to remeasurement to fair value at each balance sheet date, with any <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 574pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">changes in fair value recognized as change in fair value of common stock warrant within the consolidated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 586pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">statement of operations and comprehensive loss. Refer to Note 12 for additional information.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 606pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Embedded Derivative<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 626pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Term Loan contains certain prepayment features, default put option and default interest adjustment <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 638pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">features that were determined to be embedded derivatives requiring bifurcation and separate accounting <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 650pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">as a single compound derivative, as discussed in Note 13. The impact of bifurcation of the embedded <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 662pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">derivative on the date of issuance was reflected as a debt discount. The fair value of the derivative liability <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 674pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">related to the Company&#8217;s Term Loan, as discussed in Note 8, was estimated using a scenario-based <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 686pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">analysis comparing the probability-weighted present value of the Term Loan payoff at maturity with and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 698pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">without the bifurcated features. This method isolates the value of the embedded derivative by measuring <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 710pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the difference in the host contract&#8217;s value with and without the isolated features. The resulting cash flows <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 295.72pt; position: absolute; text-decoration: none; white-space: pre;">F-12<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"><div style="line-height: 11.64pt; position: absolute; top: 36pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 55.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 180.72pt; position: absolute; text-decoration: none; white-space: pre;">Notes to Consolidated Financial <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 366.64pt; position: absolute; text-decoration: none; white-space: pre;">Statements<font style="display: inline-block; height: 8.73pt;"></font></font></div></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 90pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">are discounted at the Company&#8217;s borrowing rate, as adjusted for fluctuations in the market interest rate <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 102pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">from the inception of the Company&#8217;s comparative borrowings to the reporting date, to measure the fair <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 114pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">value of the embedded derivative. The derivative liability is remeasured to fair value at each reporting <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 126pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">period and the related change is reflected as change in fair value of derivative liability on the consolidated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 138pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">statement of operations and comprehensive loss.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 158pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Redeemable Convertible Preferred Stock<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 178pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company records redeemable convertible preferred stock at fair value on the dates of issuance, net <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 190pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of issuance costs. The redeemable convertible preferred stock is recorded outside of stockholders&#8217; deficit <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 202pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">because the preferred shares are contingently redeemable upon the occurrence of an event that is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 214pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">outside of the Company&#8217;s control. The Company has elected not to adjust the carrying values of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 226pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">redeemable convertible preferred stock to the liquidation preferences of such shares because it is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 238pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">uncertain whether or when an event would occur that would obligate the Company to pay the liquidation <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 250pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">preferences to holders of shares of redeemable convertible preferred stock. Subsequent adjustments to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 262pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the carrying values to the liquidation preferences will be made only when it becomes probable that such <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 274pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">liquidation event will occur. The redemption value of each series of redeemable convertible preferred <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 286pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock is equal to their respective original issue price plus accrued but unpaid dividends on Series C <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 298pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">redeemable convertible preferred shares and all declared but unpaid dividends (if any) for other series of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 310pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">redeemable convertible preferred shares. In connection with the Series F redeemable convertible <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 322pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">preferred stock financing, the cumulative dividends payable to holders of Series&#160;C redeemable convertible <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 334pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">preferred stock upon a liquidation event were capped from $6.66 to $8.25 per share depending on the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 346pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">time of issuance, with an aggregate total of $88.5 million. Refer to Note 10 for additional information.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 366pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Revenue <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 116.43pt; position: absolute; text-decoration: none; white-space: pre;">Recognition<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 386pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Compa<font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 124.22pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">ny sells its </font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 173.07999999999998pt; position: absolute; white-space: pre;">HeartFlow Platform<font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 258.59000000000003pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;"> to medical providers in the United States and in select </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 398pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">international markets. </font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 170.13pt; position: absolute; white-space: pre;">The Company determines revenue recognition through the following steps&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 418pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Identification of the contract, or contracts, with a customer&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 438pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Identification of the performance obligations in the contract&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 458pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Determination of the transaction price&#59;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 478pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Allocation of the transaction price to the performance obligations in the contract&#59; and<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 498pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#8226;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Recognition of revenue when, or as, the Company satisfies a performance obligation.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 518pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company identified a single performance obligation, which is comprised of a highly interdependent <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 530pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">bundle of goods or services that are not distinct on their own but are as a group and consists of providing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 542pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">implementation services and the requested analysis, including an image file and related licenses and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 554pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">support. Revenue recognition commences only after completion of installation, implementation and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 566pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">training for new customer accounts. The Company&#8217;s service consists of providing a visualization of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 578pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">patient&#8217;s coronary arteries and enables physicians to create more effective treatment plans. This service <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 590pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">is normally billable upon delivery of the analysis to the physician.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 610pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">Substantially all of the </font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 171.95999999999998pt; position: absolute; white-space: pre;">Company&#8217;s revenue is from usage-driven fees and generated on<font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 456.8pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;"> a &#8220;pay per click&#8221; </font><font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 622pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">basis </font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 98.11pt; position: absolute; white-space: pre;">each time a physician <font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 196.99pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">orders the Company&#8217;s HeartFlow </font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 345.67pt; position: absolute; white-space: pre;">FFR<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 365.09pt; position: absolute; top: 2.548pt; vertical-align: sub; white-space: pre;">CT<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 373.75pt; position: absolute; white-space: pre;"> Analysis. The Company also derives <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 634pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">revenue from <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 133.66pt; position: absolute; text-decoration: none; white-space: pre;">subscription fees from customers accessing the Company&#8217;s hosted software service during <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 646pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">the subscription period. <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 178.1pt; position: absolute; white-space: pre;">During the year ended <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 279.77pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 367.56pt; position: absolute; white-space: pre;">, 98.1% of revenue was from usage-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 658pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">driven fees and the remainder was from subscription fees.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 678pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Revenue is recognized when control of these services is transferred to the customer, at an amount that <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 690pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reflects the consideration the Company expects to be entitled to receive in exchange for those services. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 702pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company recognizes usage-driven fee revenue <font style="display: inline-block; height: 7.28pt;"></font></font><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 304.8pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">upon delivery of the requested analysis to the </font><font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 295.72pt; position: absolute; text-decoration: none; white-space: pre;">F-13<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"><div style="line-height: 11.64pt; position: absolute; top: 36pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 55.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 180.72pt; position: absolute; text-decoration: none; white-space: pre;">Notes to Consolidated Financial <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 366.64pt; position: absolute; text-decoration: none; white-space: pre;">Statements<font style="display: inline-block; height: 8.73pt;"></font></font></div></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 90pt; width: 612pt;"><font style="background-color: #ffffff; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;"><font style="background-color: inherit;">physician, which is when </font><font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 184.20999999999998pt; position: absolute; white-space: pre;">control of these services is transferred to the customer. The Company <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 102pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">recognizes revenue on a straight-line basis over the contract term for subscriptions where the customer <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 114pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">pays a fixed amount upfront for unlimited analyses. <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.28999999999996pt; position: absolute; text-decoration: none; white-space: pre;">Contracts with customers typically include a fixed <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 126pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">amount of consideration and are generally cancellable with <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 334.78pt; position: absolute; text-decoration: none; white-space: pre;">30 days&#8217;<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 371.64pt; position: absolute; text-decoration: none; white-space: pre;"> written notice<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 433.28pt; position: absolute; text-decoration: none; white-space: pre;">.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 146pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The transaction price consists of fixed consideration and variable consideration such as utilization and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 158pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">volume rebates for reimbursement claims from government and commercial payers. The transaction price <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 170pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(inclusive of both fixed consideration and variable consideration that is not constrained) is recognized as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 182pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">revenue when control transfers. The Company uses a portfolio approach to estimate variable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 194pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">consideration using the expected value method. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 214pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Unbilled Receivables<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 234pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Unbilled receivables represent revenue from claims made to third-party payers that are expected to be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 246pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reimbursed upon delivery of the requested analysis to the physician prior to being invoiced. The Company <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 258pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">records unbilled receivables within accounts receivable, net on the consolidated balance sheet, based on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 270pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the Company&#8217;s unconditional right to payment at the end of the applicable period.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 290pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Contract Costs<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 310pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Costs associated with product revenue include a flat rate commission per analysis and new customer site <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 322pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">commissions as well as implementation and onboarding costs. The Company capitalizes new customer <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 334pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">site commissions and certain implementation and onboarding costs that are considered to be incremental <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 346pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to the acquisition of new customer contracts and amortizes these costs over an estimated period of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 358pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">benefit of two years. The estimated period of benefit is determined by evaluating average customer life, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 370pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the nature of the related benefit, and the specific facts and circumstances of its arrangements. The <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 382pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Company evaluates these assumptions at least annually and periodically reviews whether events or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 394pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">changes in circumstances have occurred that could impact the period of benefit.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 414pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company expenses flat rate commissions when incurred as commensurate with its usage-driven fee <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 426pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">revenue recognition and amortizes capitalized new customer site commissions to selling, general and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 438pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">administrative expense in the consolidated statement of operations and comprehensive loss. During the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 450pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">year ended December 31, 2023, new site commission costs were not capitalized as the amount was not <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 462pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">material. Capitalized implementation and onboarding costs are included in prepaid expenses and other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 474pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">current assets in the consolidated balance sheet and are amortized to cost of revenue in the consolidated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 486pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">statement of operations and comprehensive loss.&#160;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 506pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Remaining Performance Obligations<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 526pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Revenue allocated to remaining performance obligations represents the transaction price allocated to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 538pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">performance obligations that are unsatisfied, or partially unsatisfied. It includes contract liabilities and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 550pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">amounts that will be invoiced and recognized as revenue in future periods and does not include contracts <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 562pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">where the customer is not committed. The customer is not considered committed when they are able to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 574pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">terminate for convenience without payment of a substantive penalty under the contract. Additionally, as a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 586pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">practical expedient, the Company has not disclosed the value of unsatisfied performance obligations for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 598pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">contracts with an original expected length of one year or less.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 618pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Contract Liabilities<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 638pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company records contract liabilities when billings or payments are received in advance of revenue <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 650pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">recognition from subscription services. The contract liabilities balance is reduced as the revenue <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 662pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">recognition criteria are met, generally within 12 months. Once services are available to customers, the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 674pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Company records amounts due in accounts receivable, net and contract liabilities within accrued <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 686pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">expenses and other current liabilities on the consolidated balance sheet. To the extent the Company bills <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 698pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">customers in advance of the billing period commencement date, the accounts receivable and <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 295.72pt; position: absolute; text-decoration: none; white-space: pre;">F-14<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"><div style="line-height: 11.64pt; position: absolute; top: 36pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 55.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 180.72pt; position: absolute; text-decoration: none; white-space: pre;">Notes to Consolidated Financial <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 366.64pt; position: absolute; text-decoration: none; white-space: pre;">Statements<font style="display: inline-block; height: 8.73pt;"></font></font></div></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 90pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">corresponding contract liabilities amount are netted to zero on the consolidated balance sheet, unless <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 102pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">such amounts have been paid as of the balance sheet date.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 122pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Cost of Revenue<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 142pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Cost of revenue includes, but is not limited to, personnel and related expenses, stock-based <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 154pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">compensation costs, amortization of capitalized internal-use software, amortization of contract fulfillment <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 166pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">costs as well as royalties associated with technology licenses used in connection with the delivery of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 178pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Company&#8217;s HeartFlow Platform and allocated overhead, including rent, equipment, depreciation, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 190pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">technology services and utilities, related to the Company&#8217;s production team. The role of the production <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 202pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">team is to support the Company&#8217;s patient case volume revenue by performing defined quality-related <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 214pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">activities. The production team also supports clinical trial, research and development, and business <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 226pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">development activities. The portion of these costs that supports patient case volume revenue is recorded <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 238pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">as cost of revenue, the costs to support clinical trials and research and development efforts are recorded <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 250pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">as research and development expense, and the costs incurred in support of business development efforts <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 262pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">are recorded as selling, general and administrative expenses.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 282pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Research and Development<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 302pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Costs related to research, design, development and clinical trials are charged to research and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 314pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">development and are expensed as incurred. These costs include, but are not limited to, personnel and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 326pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">related expenses, clinical trials, stock-based compensation costs, third-party consulting costs, the portion <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 338pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of the costs incurred by the production team to support clinical trials and research and development <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 350pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">efforts, and allocated overhead, including rent, equipment, depreciation and utilities.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 370pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Clinical Trials <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 390pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company accrues and expenses costs for its clinical trial activities performed by third parties, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 402pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">including clinical research organizations and other service providers, based upon estimates of the work <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 414pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">completed over the life of the individual study in accordance with associated agreements. The Company <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 426pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">determines these estimates through discussion with internal personnel and outside service providers as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 438pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to progress or stage of completion of trials or services pursuant to contracts with clinical research <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 450pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">organizations and other service providers and the agreed-upon fee to be paid for such services. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 470pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Advertising Costs<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 490pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company expenses advertising costs as incurred. Advertising costs includes design and production <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 502pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">costs, including website development, testimonial videos, written media campaigns and other items. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 514pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Advertising costs of $778,000 was expensed during the year ended December 31, 2023.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 534pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Stock-Based Compensation<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 554pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company accounts for share-based payments at fair value. The grant date fair value of options <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 566pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">granted is measured using the Black-Scholes option pricing model. Option awards vest based on the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 578pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">satisfaction of a service requirement and stock-based compensation expense is recorded on a straight-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 590pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">line basis over the applicable service period, which is generally four years. For performance-based stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 602pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">options, the Company will assess the probability of performance conditions being achieved in each <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 614pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reporting period. The amount of stock-based compensation expense recognized in any one period related <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 626pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to performance-based stock options can vary based on the achievement or anticipated achievement of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 638pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the performance conditions. Forfeitures are recognized in the period in which the forfeiture occurs.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 658pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Income Taxes<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 678pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company accounts for income taxes under the asset and liability method. Under this method, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 690pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">deferred tax assets and liabilities are determined based on the temporary differences between the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 702pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 295.72pt; position: absolute; text-decoration: none; white-space: pre;">F-15<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"><div style="line-height: 11.64pt; position: absolute; top: 36pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 55.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 180.72pt; position: absolute; text-decoration: none; white-space: pre;">Notes to Consolidated Financial <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 366.64pt; position: absolute; text-decoration: none; white-space: pre;">Statements<font style="display: inline-block; height: 8.73pt;"></font></font></div></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 90pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">which the differences are expected to reverse. As a result of the history of net operating losses, the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 102pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Company has provided for a full valuation allowance against the deferred tax assets for assets that are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 114pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">not more-likely-than-not to be realized.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 134pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company applies a comprehensive model for the recognition, measurement, presentation and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 146pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">disclosure in the consolidated financial statements of any uncertain tax positions that have been taken or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 158pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">expected to be taken on a tax return using a two-step approach. The first step is to evaluate the tax <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 170pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">position taken or expected to be taken in a tax return by determining if the weight of available evidence <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 182pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">indicates that it is more likely than not that the tax position will be sustained upon examination by the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 194pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">relevant taxing authorities, based on the technical merits of the position. For tax positions that are more <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 206pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">likely than not to be sustained upon audit, the second step is to measure the tax benefit in the financial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 218pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">statements as the largest benefit that has a greater than 50% likelihood of being sustained upon <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 230pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">settlement. Significant judgment is required to evaluate uncertain tax positions. Changes in facts and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 242pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">circumstances could have a material impact on the Company&#8217;s effective tax rate and results of operations. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 254pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">The Company recognizes interest and penalties, if any, related to unrecognized tax benefits as a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 266pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">component of provision for income taxes in the consolidated statement of operations and comprehensive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 278pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">loss.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 298pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Comprehensive Loss<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 318pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Comprehensive loss is comprised of net loss and foreign currency translation loss. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 338pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Foreign Currency <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 358pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The functional currency of the Company&#8217;s foreign subsidiaries is the U.S. Dollar, except for HeartFlow <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 370pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Japan G.K., HeartFlow Technology U.K. Limited, and HeartFlow U.K. Limited, which have Japanese Yen <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 382pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and British Pounds as functional currencies, respectively. For all non-functional currency balances, the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 394pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">remeasurement of such balances to the functional currency results in either a foreign exchange <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 406pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">transaction gain or loss, which is recorded within other income (expense), net within the consolidated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 418pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">statement of operations and comprehensive loss. The Company recognized foreign exchange transaction <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 430pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">losses of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 114.21000000000001pt; position: absolute; text-decoration: none; white-space: pre;">$172<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 136.45pt; position: absolute; white-space: pre;">,000 during the year ended <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 258.68pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 346.47pt; position: absolute; white-space: pre;">. During 2023, the Company recognized <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 442pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">$504,000 of foreign currency translation loss in the statement of comprehensive loss related to foreign <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 454pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">subsidiaries which have local functional currencies.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 474pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Net Loss Per Share Attributable to Common Stockholders<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 494pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Basic net loss per common share is calculated by dividing the net loss attributable to common <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 506pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stockholders by the weighted-average&#160;number of shares of common stock outstanding during the period, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 518pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 530pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the net loss attributable to common stockholders by the weighted-average number of shares of common <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 542pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 554pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">share calculation, the redeemable convertible preferred stock, common stock warrants and stock options <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 566pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">are considered to be potentially dilutive securities.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 586pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Basic and diluted net loss attributable to common stockholders per share is presented in conformity with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 598pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the two-class&#160;method required for participating securities as the redeemable convertible preferred stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 610pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and common stock subject to repurchase are considered participating securities. The Company&#8217;s <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 622pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">participating securities do not have a contractual obligation to share in the Company&#8217;s losses. As such, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 634pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the net loss is attributed entirely to common stockholders. Diluted net loss per share is the same as basic <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 646pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">net loss per share because the effects of potentially dilutive items were anti-dilutive given the Company&#8217;s <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 658pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">net loss position during the year ended December 31, 2023.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 295.72pt; position: absolute; text-decoration: none; white-space: pre;">F-16<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"><div style="line-height: 11.64pt; position: absolute; top: 36pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 55.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 180.72pt; position: absolute; text-decoration: none; white-space: pre;">Notes to Consolidated Financial <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 366.64pt; position: absolute; text-decoration: none; white-space: pre;">Statements<font style="display: inline-block; height: 8.73pt;"></font></font></div></div></div><div><div style="line-height: 8.73pt; position: absolute; top: 90pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Recent Accounting Pronouncements<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 112.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 124.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Board (&#8220;FASB&#8221;) or other standard setting bodies and adopted by the Company as of the specified <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 136.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">effective date. The Company qualifies as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 148.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Business Startups Act of 2012 and has elected not to &#8220;opt out&#8221; of the extended transition related to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 160.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">complying with new or revised accounting standards, which means that when a standard is issued or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 172.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">revised and it has different application dates for public and nonpublic companies, the Company will adopt <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 184.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the new or revised standard at the time nonpublic companies adopt the new or revised standard and will <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 196.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">do so until such time that the Company either i)&#160;irrevocably elects to &#8220;opt out&#8221; of such extended transition <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 208.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">period or ii)&#160;no longer qualifies as an emerging growth company. The Company may choose to early <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">adopt any new or revised accounting standards whenever such early adoption is permitted for nonpublic <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">companies.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 252.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Recently Adopted Accounting Pronouncements<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 272.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In June 2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13, <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 444.14pt; position: absolute; white-space: pre;">Financial Instruments<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 539.12pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 284.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">&#8212; <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 84.77pt; position: absolute; white-space: pre;">Credit Losses&#58; Measurement of Credit Losses on Financial Instruments<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 399.16pt; position: absolute; white-space: pre;"> (&#8220;ASU 2016-13&#8221;) which has <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 296.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">been updated by subsequent amendments. ASU 2016-13 revises the measurement of credit losses for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 308.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">most financial instruments measured at amortized cost, including trade receivables, from an incurred loss <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 320.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">methodology to an expected loss methodology which results in earlier recognition of credit losses. Under <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 332.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the incurred loss model, a loss is not recognized until it is probable that the loss-causing event has <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 344.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">already occurred. The ASU introduces a forward-looking expected credit loss model that requires an <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 356.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">estimate of the expected credit losses over the life of the instrument by considering all relevant <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 368.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">information including historical experience, current conditions, and reasonable and supportable forecasts <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 380.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">that affect collectability. The ASU was effective for fiscal year beginning after December 15, 2022 and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 392.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">required a modified-retrospective approach with a cumulative-effect adjustment to retained earnings as of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 404.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the beginning of the first reporting period. Early adoption is permitted. The Company adopted this ASU <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 416.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">effective January 1, 2023, and the adoption did not have a material impact on the Company&#8217;s <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 428.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">consolidated financial statements.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 448.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In August 2020, the FASB issued ASU 2020-06, <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 285.83000000000004pt; position: absolute; white-space: pre;">Debt with Conversion and Other Options <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 460.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(Subtopic&#160;470-20) and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)&#58; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 472.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 422.45pt; position: absolute; white-space: pre;">. This ASU simplifies the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 484.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">accounting for certain financial instruments with characteristics of liabilities and equity, including <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 496.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">convertible instruments and contracts on an entity&#8217;s own equity. Specifically, the ASU removes&#58; (i) major <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 508.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">separation models required under GAAP and (ii) certain settlement conditions that are required for equity <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 520.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 532.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for the exception. For public business entities that meet the definition of an SEC filer, excluding entities <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 544.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">eligible to be smaller reporting companies as defined by the SEC, this ASU is effective for interim and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 556.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">annual reporting periods beginning after December 15, 2021. For all other entities, the amendments are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 568.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 580.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 592.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">including interim periods within those fiscal years. The Company adopted this ASU effective January&#160;1, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 604.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2023, and the adoption did not have an impact on the Company&#8217;s consolidated financial statements.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Recent Accounting Pronouncements Not Yet Adopted<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 644.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In November 2023, the FASB issued ASU 2023-07, <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 301.39pt; position: absolute; white-space: pre;">Segment Reporting (Topic 280)&#58; Improvements to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Reportable Segment Disclosures<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 218.11pt; position: absolute; white-space: pre;">. The amendments in this ASU require disclosures, on an annual and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 668.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">interim basis, of significant segment expenses that are regularly provided to the chief operating decision <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 680.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">maker (&#8220;CODM&#8221;), as well as the aggregate amount of other segment items included in the reported <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 692.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">measure of segment profit or loss. This ASU requires that a public entity disclose the title and position of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 704.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 295.72pt; position: absolute; text-decoration: none; white-space: pre;">F-17<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"><div style="line-height: 11.64pt; position: absolute; top: 36pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 55.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 180.72pt; position: absolute; text-decoration: none; white-space: pre;">Notes to Consolidated Financial <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 366.64pt; position: absolute; text-decoration: none; white-space: pre;">Statements<font style="display: inline-block; height: 8.73pt;"></font></font></div></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 90pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">in assessing segment performance and deciding how to allocate resources. Public entities will be required <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 102pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to provide all annual disclosures currently required by Topic 280 in interim periods, and entities with a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 114pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">single reportable segment are required to provide all the disclosures required by the amendments in this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 126pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">ASU and existing segment disclosures in Topic 280. This ASU is effective for fiscal years beginning after <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 138pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">December&#160;15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 150pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">adoption permitted. The amendments in this ASU should be applied retrospectively to all prior periods <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 162pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">presented in the financial statements. The adoption of this standard will only impact the Company&#8217;s <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 174pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">disclosures in the consolidated financial statements and the Company is currently evaluating the effect of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 186pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">adopting the new disclosure requirements.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 206pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In December 2023, the FASB issued ASU 2023-09, <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 301.39pt; position: absolute; white-space: pre;">Income Taxes (Topic 740)&#58; Improvements to Income <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 218pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Tax Disclosures<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 143.1pt; position: absolute; white-space: pre;">, which requires enhanced income tax disclosures, including specific categories and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 230pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">disaggregation of information in the effective tax rate reconciliation, disaggregated information related to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 242pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">income taxes paid, income or loss from continuing operations before income tax expense or benefit, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 254pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">income tax expense or benefit from continuing operations. This guidance is effective for annual periods <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 266pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">beginning after December 15, 2024, with early adoption permitted. The Company is currently in the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 278pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">process of evaluating the impact of this pronouncement on the disclosures in its consolidated financial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 290pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">statements.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 310pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In November 2024, the FASB issued ASU 2024-03, <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 301.39pt; position: absolute; white-space: pre;">Income Statement &#8211; Reporting Comprehensive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 322pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Income &#8211; Expense Disaggregation Disclosures (Subtopic 220-40)&#58; Disaggregation of Income Statement <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 334pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Expenses<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 115.9pt; position: absolute; white-space: pre;">, which requires more detailed disclosures about specified categories of expenses (including <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 346pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">employee compensation, depreciation, and amortization) included in certain expense captions presented <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 358pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 370pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2026, and for interim periods within fiscal years beginning after December 15, 2027, with early adoption <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 382pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">permitted. The amendments may be applied either (i) prospectively to financial statements issued for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 394pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">reporting periods after the effective date of this ASU or (ii) retrospectively to all prior periods presented in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 406pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the financial statements. The Company is currently evaluating the impact of this pronouncement on the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 418pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">disclosures in its consolidated financial statements.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div id="i2341357d54884756b9e9172f0a83cd6b_388" style="position: absolute; top: 438pt;"></div><div style="line-height: 8.73pt; position: absolute; top: 438pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">3. Revenue and Contract Balances<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 460.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Disaggregation of Revenue<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The following table summarizes total revenue from customers by geographic region (in thousands)&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 500.4pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 402.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 35.25pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.71pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 8.39pt; position: absolute; text-decoration: none; white-space: pre;">Year ended<font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="font-size: 12pt; line-height: 6.55pt; position: absolute; top: 14.51pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 3.38pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="font-size: 12pt; line-height: 6.55pt; position: absolute; top: 25.31pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 22.62pt; position: absolute; text-decoration: none; white-space: pre;">2023<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 35.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">United States<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 62.61pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 63.77pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 64.35pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 64.64pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 64.78999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 64.87pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 64.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 64.9pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 35.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 22.41pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">77,725<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 49.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">United Kingdom<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 73.74pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 74.89999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 74.97999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 75pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 49.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">4,492<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 63.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Japan<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 29.869999999999997pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 30.02pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 30.099999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 30.11pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 63.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">4,003<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 78pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Rest of Europe<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 69.28pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 69.86pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 70.00999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 70.05pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 78pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 41.86pt;"></font></font><font style="left: 44.49pt; position: absolute;">954<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 92.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Total revenue<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 62.64pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 63.800000000000004pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 64.38pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 64.67pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 64.82pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 64.9pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 92.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 22.41pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">87,174<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 622.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Revenues by geography are determined based on the region of the Company's contracting entity, which <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 634.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">may be different than the region of the customer.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 654.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Contract Balances<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 674.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Unbilled receivables included within accounts receivable on the consolidated balance sheet as of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 686.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 159.79000000000002pt; position: absolute; white-space: pre;"> was <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 183.11pt; position: absolute; text-decoration: none; white-space: pre;">$342<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 205.35pt; position: absolute; white-space: pre;">,000.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 295.72pt; position: absolute; text-decoration: none; white-space: pre;">F-18<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"><div style="line-height: 11.64pt; position: absolute; top: 36pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 55.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 180.72pt; position: absolute; text-decoration: none; white-space: pre;">Notes to Consolidated Financial <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 366.64pt; position: absolute; text-decoration: none; white-space: pre;">Statements<font style="display: inline-block; height: 8.73pt;"></font></font></div></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 90pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The following table provides the breakdown of capitalized contract costs as of December 31, 2023 (in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 102pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">thousands)&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 122pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 402.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 24pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.26pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 14.15pt; position: absolute; text-decoration: none; white-space: pre;">Contract <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 14.06pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 20.14pt; position: absolute; text-decoration: none; white-space: pre;">Costs<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 24pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Balance as of January 1, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 137.63pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 138.79pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 139.37pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 139.66pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 139.81pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 139.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 139.9pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 24pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">2,077<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 38.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Contract costs capitalized<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 116.5pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 118.81pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 119.39pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 119.67999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 119.75999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 119.78pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 38.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">3,081<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 52.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Contract costs amortized<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 113.16pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 114.32pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 114.89999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 114.94pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 52.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 30.2pt;"></font></font><font style="left: 32.83pt; position: absolute;">(2,217)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 66.75pt; width: 402.75pt;"><div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Balance as of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 65.95pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 153.74pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 154.9pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 154.98pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 155pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 66.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">2,941<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 81pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Contract costs included in prepaid expenses and other current assets<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 309.29pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 309.87pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 310.02pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 310.04pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 310.05pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 81pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">1,953<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 95.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Long-term contract costs included in other non-current assets<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 274.27pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 274.85pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 275pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 275.04pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 275.05pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 95.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 36.3pt;"></font></font><font style="left: 44.49pt; position: absolute;">988<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 247.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The following table provides the breakdown of contract liabilities included within accrued expenses and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 259.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">other current liabilities on the consolidated balance sheet as of December 31, 2023 (in thousands)&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 279.5pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 402.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 24pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.26pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 14.15pt; position: absolute; text-decoration: none; white-space: pre;">Contract <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 14.06pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 11.89pt; position: absolute; text-decoration: none; white-space: pre;">Liabilities<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 24pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Balance as of January 1, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 137.63pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 138.79pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 139.37pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 139.66pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 139.81pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 139.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 139.9pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 24pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 36.3pt;"></font></font><font style="left: 44.49pt; position: absolute;">118<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 38.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Contract liabilities added<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 111.50999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 113.82pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 114.39999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 114.69pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 114.77pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 114.78pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 38.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 41.86pt;"></font></font><font style="left: 44.49pt; position: absolute;">470<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 52.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Contract liabilities recognized as revenue<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 184.85pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 185pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 185.07999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 185.1pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 185.10999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 52.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 44.09pt;"></font></font><font style="left: 46.720000000000006pt; position: absolute;">(90)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 66.75pt; width: 402.75pt;"><div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Balance as of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 65.95pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 153.74pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 154.9pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 154.98pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 155pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 66.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 36.3pt;"></font></font><font style="left: 44.49pt; position: absolute;">498<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div id="i2341357d54884756b9e9172f0a83cd6b_373" style="position: absolute; top: 376.5pt;"></div><div style="line-height: 8.73pt; position: absolute; top: 376.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">4. Fair Value Measurement<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 398.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The following table summarizes the Company&#8217;s financial assets and liabilities measured at fair value on a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 410.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">recurring basis by level within the fair value hierarchy (in thousands)&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 430.9pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 198pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 12.75pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="7"><div style="left: 198pt; position: absolute; top: 0pt; width: 270pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 2.81pt; width: 270pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 94.51pt; position: absolute; text-decoration: none; white-space: pre;">December 31, 2023<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 12.75pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 12.75pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 2.81pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 17.38pt; position: absolute; text-decoration: none; white-space: pre;">Level 1<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td><td style="border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 12.75pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 2.81pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 17.38pt; position: absolute; text-decoration: none; white-space: pre;">Level 2<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td><td style="border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 12.75pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 2.81pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 17.38pt; position: absolute; text-decoration: none; white-space: pre;">Level 3<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td><td style="border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 12.75pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 2.81pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 21.89pt; position: absolute; text-decoration: none; white-space: pre;">Total<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 25.5pt; width: 198pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 198pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Assets<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 26.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 39.75pt; width: 198pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 198pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Money market funds included in cash and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 15.32pt; width: 198pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 11.63pt; position: absolute; text-decoration: none; white-space: pre;">cash equivalents<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 86.08999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 88.39999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 89.56pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 89.85pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 89.92999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 89.97pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 39.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 15.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 16.85pt;"></font></font><font style="left: 25.04pt; position: absolute;">115,636<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 39.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 15.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 42.98pt;"></font></font><font style="left: 51.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 39.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 15.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 42.98pt;"></font></font><font style="left: 51.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 39.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 15.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 16.85pt;"></font></font><font style="left: 25.04pt; position: absolute;">115,636<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 66pt; width: 198pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 198pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Total<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 23.74pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 24.9pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 25.189999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 25.209999999999997pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 25.22pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 66pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 16.85pt;"></font></font><font style="left: 25.04pt; position: absolute;">115,636<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 66pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 42.98pt;"></font></font><font style="left: 51.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 66pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 42.98pt;"></font></font><font style="left: 51.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 66pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 16.85pt;"></font></font><font style="left: 25.04pt; position: absolute;">115,636<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 80.25pt; width: 198pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 198pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Liabilities<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 94.5pt; width: 198pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 198pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Common stock warrant liability<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 138.15pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 139.31pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 139.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 140.04pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 140.12pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 140.16pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 140.18pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 94.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 42.98pt;"></font></font><font style="left: 51.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 94.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 42.98pt;"></font></font><font style="left: 51.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 94.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">4,440<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 94.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">4,440<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 108.75pt; width: 198pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 198pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Derivative liability<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 79.83pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 80.11999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 80.27pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 80.31pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 80.33pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 108.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 48.54pt;"></font></font><font style="left: 51.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 108.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 48.54pt;"></font></font><font style="left: 51.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 108.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 41.86pt;"></font></font><font style="left: 44.49pt; position: absolute;">903<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 108.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 41.86pt;"></font></font><font style="left: 44.49pt; position: absolute;">903<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 123pt; width: 198pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 198pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Total<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 23.74pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 24.9pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 25.189999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 25.209999999999997pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 25.22pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 123pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 42.98pt;"></font></font><font style="left: 51.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 123pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 42.98pt;"></font></font><font style="left: 51.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 123pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">5,343<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 123pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">5,343<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 295.72pt; position: absolute; text-decoration: none; white-space: pre;">F-19<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"><div style="line-height: 11.64pt; position: absolute; top: 36pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 55.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 180.72pt; position: absolute; text-decoration: none; white-space: pre;">Notes to Consolidated Financial <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 366.64pt; position: absolute; text-decoration: none; white-space: pre;">Statements<font style="display: inline-block; height: 8.73pt;"></font></font></div></div></div><div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 90pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">The<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 89.22pt; position: absolute; white-space: pre;"> following tables present a reconciliation of the Company&#8217;s financial liabilities measured at fair value <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 102pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">as of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 96.43pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 184.22pt; position: absolute; white-space: pre;"> using significant unobservable inputs (Level 3), and the change in fair value (in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 114pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">thousands)&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 134pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 402.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 24pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.26pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 7.9pt; position: absolute; text-decoration: none; white-space: pre;">Convertible <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 14.06pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 20.14pt; position: absolute; text-decoration: none; white-space: pre;">Notes<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 24pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Fair value as of January 1, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 145.39pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 147.7pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 148.85999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 149.44pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 149.59pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 149.67pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 149.68pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 24pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 22.41pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">56,066<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 38.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Change in fair value<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 91.52pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 93.83pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 94.41pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 94.69999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 94.78pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 38.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">5,120<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 24pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 52.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 1.07pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Derecognition of convertible notes upon conversion into redeemable convertible preferred <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 13.07pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 11.63pt; position: absolute; text-decoration: none; white-space: pre;">stock<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 34.96pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 35.11pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 52.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 13.12pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 24.64pt;"></font></font><font style="left: 27.27pt; position: absolute;">(61,186)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 76.5pt; width: 402.75pt;"><div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Fair value as of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 73.71pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 161.5pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 163.81pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 164.39pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 164.68pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 164.76pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 164.78pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 76.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 42.98pt;"></font></font><font style="left: 51.17pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 240.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Convertible Notes, which are not regularly traded, are classified as Level 3, since their values cannot <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 252.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">be determined by using readily observable inputs or measures, such as market prices (see Note 9). The <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 264.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">fair value of the Convertible Notes was estimated as the sum of its components (conversion features and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 276.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the debt component) as of the issuance dates and as of the subsequent balance sheet dates. To value <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 288.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">each of the conversion features, a &#8220;with and without&#8221; methodology was employed. The debt component <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 300.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">was valued using a discounted cash flow method that measured the net present value of the principal and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 312.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">interest payments to be received by the holders of the Convertible Notes (excluding the conversion <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 324.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">features) through the estimated maturity date.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 344.75pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 402.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 45pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 2.66pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 13.14pt; position: absolute; text-decoration: none; white-space: pre;">Common <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 13.46pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 20.38pt; position: absolute; text-decoration: none; white-space: pre;">Stock <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 24.26pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 15.64pt; position: absolute; text-decoration: none; white-space: pre;">Warrant <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 35.06pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 15.64pt; position: absolute; text-decoration: none; white-space: pre;">Liability<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 45pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Fair value as of January 1, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 145.39pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 147.7pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 148.85999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 149.44pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 149.59pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 149.67pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 149.68pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 45pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">2,120<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 59.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Change in fair value<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 91.52pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 93.83pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 94.41pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 94.69999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 94.78pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 59.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">2,320<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 73.5pt; width: 402.75pt;"><div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Fair value as of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 73.71pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 161.5pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 163.81pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 164.39pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 164.68pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 164.76pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 164.78pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 73.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">4,440<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 448.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In determining the fair value of the common stock warrant liability, the Company used the Black-Scholes <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 460.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">option pricing model to estimate the fair value using unobservable inputs including the expected term, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 472.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">expected volatility, risk-free interest rate and dividend yield (see Note 12).<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 492.5pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 402.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 24pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.26pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 11.13pt; position: absolute; text-decoration: none; white-space: pre;">Derivative <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 14.06pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 15.64pt; position: absolute; text-decoration: none; white-space: pre;">Liability<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 24pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Fair value as of January 1, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 145.39pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 147.7pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 148.85999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 149.44pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 149.59pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 149.67pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 149.68pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 24pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">5,061<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 38.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Change in fair value<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 91.52pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 93.83pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 94.41pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 94.69999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 94.78pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 38.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 30.2pt;"></font></font><font style="left: 32.83pt; position: absolute;">(4,158)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 52.5pt; width: 402.75pt;"><div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Fair value as of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 73.71pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 161.5pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 163.81pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 164.39pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 164.68pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 164.76pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 164.78pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 52.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 36.3pt;"></font></font><font style="left: 44.49pt; position: absolute;">903<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 575.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In determining the fair value of the derivative liability, a two-step valuation approach was employed, which <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 587.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">included a probability-weighted scenario valuation method, the Black-Scholes-Merton method, and the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 599.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">option pricing method, using unobservable inputs (see Note 13), which are classified as Level 3 within the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 611.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">fair value hierarchy, and then comparing the instrument&#8217;s value with and without the derivative features to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 623.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">estimate their combined fair value. The debt instrument is carried at amortized cost, which approximates <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 635.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">its fair value.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 295.72pt; position: absolute; text-decoration: none; white-space: pre;">F-20<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"><div style="line-height: 11.64pt; position: absolute; top: 36pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 55.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 180.72pt; position: absolute; text-decoration: none; white-space: pre;">Notes to Consolidated Financial <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 366.64pt; position: absolute; text-decoration: none; white-space: pre;">Statements<font style="display: inline-block; height: 8.73pt;"></font></font></div></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_358" style="position: absolute; top: 90pt;"></div><div style="line-height: 8.73pt; position: absolute; top: 90pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">5. Balance Sheet Components<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 112.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Allowance for Credit Losses<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 132.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The following table presents a reconciliation of the allowance for credit losses (in thousands)&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 152.4pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 402.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 35.25pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.71pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 7.89pt; position: absolute; text-decoration: none; white-space: pre;">Year Ended <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="font-size: 12pt; line-height: 6.55pt; position: absolute; top: 14.51pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 3.38pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="font-size: 12pt; line-height: 6.55pt; position: absolute; top: 25.31pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 22.62pt; position: absolute; text-decoration: none; white-space: pre;">2023<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 35.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Balance at beginning of period<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 137.64pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 138.79999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 139.38pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 139.67pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 139.82pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 139.9pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 35.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 36.3pt;"></font></font><font style="left: 44.49pt; position: absolute;">212<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 49.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Additions<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 43.74pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 44.900000000000006pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 44.980000000000004pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 45pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 49.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">1,190<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 63.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Write-offs<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 45.010000000000005pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 45.09pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 45.11pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 45.120000000000005pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 63.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 38.53pt;"></font></font><font style="left: 41.160000000000004pt; position: absolute;">(344)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 78pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Balance at end of period<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 110.96pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 113.27pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 114.42999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 114.72pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 78pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">1,058<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 260.65pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Property and equipment, net<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280.65pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Property and equipment consisted of the following (in thousands)&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 300.65pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 402.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 24pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.26pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 3.38pt; position: absolute; text-decoration: none; white-space: pre;">December 31,<font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 14.06pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 22.62pt; position: absolute; text-decoration: none; white-space: pre;">2023<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 24pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Property and equipment at cost&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 38.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Computer equipment and software<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 155.96pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 158.26999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 159.43pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 159.72pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 38.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">8,842<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 52.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Furniture, fixtures and equipment<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 149.26999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 149.85pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 150pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 150.04pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 150.04999999999998pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 52.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">1,095<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 66.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Capitalized internal-use software<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 147.62pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 148.78pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 149.35999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 149.65pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 149.79999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 149.88pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 149.9pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 66.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">48,535<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 81pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Leasehold improvements<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 114.32pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 114.89999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 115.05pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 81pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">2,057<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 95.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Construction in progress<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 110.96pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 113.27pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 114.42999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 114.72pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 95.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 47.42pt;"></font></font><font style="left: 50.050000000000004pt; position: absolute;">57<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 109.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Total property and equipment <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 146.85pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 149.16pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 149.74pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 149.78pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 149.79999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 149.81pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 109.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">60,586<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 123.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Less&#58; Accumulated depreciation and amortization<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 220.41pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 222.72pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 223.88pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 224.46pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 224.60999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 224.65pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 224.67pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 224.68pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 123.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 24.64pt;"></font></font><font style="left: 27.27pt; position: absolute;">(50,665)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 138pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Property and equipment, net <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 131.5pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 133.81pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 134.39pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 134.68pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 134.76pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 134.78pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 138pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">9,921<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 468.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company capitalized certain internal-use software costs totaling <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 376.95pt; position: absolute; text-decoration: none; white-space: pre;">$4.6<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 396.4pt; position: absolute; white-space: pre;"> million, including stock-based <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">compensation of $408,000 related to internal-use software development efforts, during the year ended <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 492.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 159.79000000000002pt; position: absolute; white-space: pre;">. Amortization of capitalized internal-use software totaled <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 412.5pt; position: absolute; text-decoration: none; white-space: pre;">$3.2<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 431.95pt; position: absolute; white-space: pre;"> million for the year <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 504.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">ended <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 102.57pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 190.36pt; position: absolute; white-space: pre;">.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 524.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Depreciation and amortization expense related to property and equipment, excluding capitalized internal-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 536.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">use software, was <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 154.75pt; position: absolute; text-decoration: none; white-space: pre;">$1.5<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 174.2pt; position: absolute; white-space: pre;"> million for the year ended <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 291.95pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 379.74pt; position: absolute; white-space: pre;">.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 556.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Other Non-Current Assets<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Other non-current assets are comprised of the following (in thousands)&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 596.9pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 402.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 24pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.26pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 3.38pt; position: absolute; text-decoration: none; white-space: pre;">December 31, <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 14.06pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 22.62pt; position: absolute; text-decoration: none; white-space: pre;">2023<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 24pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Contract costs, net<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 85.92999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 88.24pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 89.39999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 89.69pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 89.71pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 89.72pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 24pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 36.3pt;"></font></font><font style="left: 44.49pt; position: absolute;">988<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 38.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Other<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 27.619999999999997pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 28.779999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 29.36pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 29.65pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 29.8pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 29.88pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 29.9pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 38.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 41.86pt;"></font></font><font style="left: 44.49pt; position: absolute;">267<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 52.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Total other non-current assets <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 137.60999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 138.76999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 139.35pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 139.64pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 139.79pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 139.87pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 139.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 139.9pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 52.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">1,255<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 295.72pt; position: absolute; text-decoration: none; white-space: pre;">F-21<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"><div style="line-height: 11.64pt; position: absolute; top: 36pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 55.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 180.72pt; position: absolute; text-decoration: none; white-space: pre;">Notes to Consolidated Financial <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 366.64pt; position: absolute; text-decoration: none; white-space: pre;">Statements<font style="display: inline-block; height: 8.73pt;"></font></font></div></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 90pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Accrued Expenses and Other Current Liabilities<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 110pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Accrued expenses and other current liabilities are comprised of the following (in thousands)&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 130pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 402.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 24pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.26pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 3.38pt; position: absolute; text-decoration: none; white-space: pre;">December 31,<font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 14.06pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 22.62pt; position: absolute; text-decoration: none; white-space: pre;">2023<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 24pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Accrued payroll and related expenses<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 169.87pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 170.01999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 170.1pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 170.10999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 24pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 22.41pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">15,228<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 38.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Customer contract and rebate liabilities<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 175.38pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 177.69pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 178.85pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 179.43pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 179.57999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 179.66pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 179.68pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 38.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">2,109<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 52.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Accrued royalty<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 71.50999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 73.82pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 74.39999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 74.69pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 74.77pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 74.78pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 52.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">1,604<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 66.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Accrued professional fees<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 117.63pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 118.78999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 119.36999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 119.66pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 119.81pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 119.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 119.89999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 66.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">1,188<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 81pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Accrued clinical trial expenses<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 136.51pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 138.82pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 139.4pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 139.69pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 139.76999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 139.78pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 81pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">1,148<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 95.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Other<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 27.619999999999997pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 28.779999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 29.36pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 29.65pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 29.8pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 29.88pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 29.9pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 95.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">3,513<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 109.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Total accrued expenses and other current liabilities <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 229.84pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 229.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 230.07pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 230.10999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 109.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 22.41pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">24,790<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div id="i2341357d54884756b9e9172f0a83cd6b_343" style="position: absolute; top: 269.75pt;"></div><div style="line-height: 8.73pt; position: absolute; top: 269.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">6. Leases<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company leases office space in Mountain View, California, Austin, Texas, and Tokyo, Japan.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 312.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Mountain View, California<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 332.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In August 2021, the Company entered into a facility lease agreement with MV Campus Owner, LLC. (the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 344.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">&#8220;Landlord&#8221;), for approximately 61,000 rentable square feet in Mountain View, California through August <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 356.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2030. T<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 105.7pt; position: absolute; text-decoration: none; white-space: pre;">he Company received a tenant improvement allowance <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 352.37pt; position: absolute; text-decoration: none; white-space: pre;">of<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 360.7pt; position: absolute; text-decoration: none; white-space: pre;"> $1.8 million, in which the remaining <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 368.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">unused amount of $1.4 million was credited against rent expense <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 362.54pt; position: absolute; white-space: pre;">during the year ended December 31, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 380.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2023. In connection with the lease, the Company established a standby letter of credit for the benefit of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 392.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the landlord in the amount of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 201.42pt; position: absolute; text-decoration: none; white-space: pre;">$4.3<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 220.87pt; position: absolute; white-space: pre;"> million in August 2021, which is classified as non-current restricted <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 404.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">cash on the consolidated balance sheet as of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 274.78pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 362.57pt; position: absolute; white-space: pre;">.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 424.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Austin, Texas<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 444.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">In January 2023, the Company amended its facility lease agreement in Austin, Texas, which provides for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 456.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">approximately 26,000 square feet of space, to extend the lease term which expired in November 2023 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 468.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">with a five-year renewal option to December 2025 with no renewal option<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 394.19pt; position: absolute; white-space: pre;">. In connection with the lease <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">amendment, the Company recorded a reduction of $1.8 million in ROU asset and lease liability from the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 492.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">remeasurement that previously included the renewal option. As of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 364.19pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 451.98pt; position: absolute; white-space: pre;">, a security deposit <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 504.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 83.1pt; position: absolute; text-decoration: none; white-space: pre;">$150<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 105.34pt; position: absolute; white-space: pre;">,000 was recorded as non-current restricted cash on the consolidated balance sheet related to this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 516.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">lease.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 536.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Tokyo, Japan<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 556.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company has one non-cancellable operating lease for its facility in Tokyo, Japan which expires in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 568.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">November <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 120.89pt; position: absolute; text-decoration: none; white-space: pre;">2024<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 143.13pt; position: absolute; white-space: pre;">.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Operating lease cost consisted of the following (in thousands)&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 608.15pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 402.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 24pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.26pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 3.38pt; position: absolute; text-decoration: none; white-space: pre;">December 31,<font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 14.06pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 22.62pt; position: absolute; text-decoration: none; white-space: pre;">2023<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 24pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Operating lease cost<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 94.28999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 94.86999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 95.02pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 95.03999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 95.05pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 24pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 25.3pt;"></font></font><font style="left: 33.49pt; position: absolute;">4,906<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 38.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Variable lease cost<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 86.33pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 88.64pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 89.22pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 89.50999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 89.66pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 89.74pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 89.75999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 89.77pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 38.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">1,120<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 52.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Total lease cost<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 71.50999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 73.82pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 74.39999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 74.69pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 74.77pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 74.78pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 52.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">6,026<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 687.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Cash paid for amounts included in the measurement of operating lease liabilities during the year ended <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 699.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">December 31, 2023 was $4.1 million.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 295.72pt; position: absolute; text-decoration: none; white-space: pre;">F-22<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"><div style="line-height: 11.64pt; position: absolute; top: 36pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 55.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 180.72pt; position: absolute; text-decoration: none; white-space: pre;">Notes to Consolidated Financial <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 366.64pt; position: absolute; text-decoration: none; white-space: pre;">Statements<font style="display: inline-block; height: 8.73pt;"></font></font></div></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 90pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The following table summarizes the maturities of the aggregate lease payments under the Company&#8217;s <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 102pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">operating lease liabilities as of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 208.09pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 295.88pt; position: absolute; white-space: pre;"> (in thousands)&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 122pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 402.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 24pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 402.75pt;"><div><div style="font-size: 12pt; line-height: 6.55pt; position: absolute; top: 14.06pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Year ending <font style="display: inline-block; height: 6.55pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 56.59pt; position: absolute; text-decoration: none; white-space: pre;">December 31,<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.26pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 11.39pt; position: absolute; text-decoration: none; white-space: pre;">Operating <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 14.06pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 17.38pt; position: absolute; text-decoration: none; white-space: pre;">Leases<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 24pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">2024<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 24.869999999999997pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 25.02pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 25.099999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 25.11pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 24pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">5,355<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 38.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">2025<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 24.869999999999997pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 25.02pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 25.099999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 25.11pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 38.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">5,397<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 52.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">2026<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 24.869999999999997pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 25.02pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 25.099999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 25.11pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 52.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">4,859<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 66.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">2027<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 24.869999999999997pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 25.02pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 25.099999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 25.11pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 66.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">5,005<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 81pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">2028<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 24.869999999999997pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 25.02pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 25.099999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 25.11pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 81pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">5,155<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 95.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Thereafter<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 48.730000000000004pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 49.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 49.970000000000006pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 49.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 50pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 95.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">8,952<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 109.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Total minimum lease payments<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 139.84pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 139.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 140.07pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 140.10999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 109.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">34,723<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 123.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Less&#58; Amount of lease payments representing interest<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 252.94pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 254.1pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 254.68pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 254.82999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 254.91pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 254.93pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 123.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 30.2pt;"></font></font><font style="left: 32.83pt; position: absolute;">(8,131)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 138pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Present value of future minimum lease payments<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 219.26pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 219.84pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 219.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 220.03pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 220.04999999999998pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 138pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 22.41pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">26,592<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 152.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Less&#58; current portion<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 105.72999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 108.03999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 109.19999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 109.49pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 109.64pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 109.67999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 109.69999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 109.71pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 152.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">5,138<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 166.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Operating lease liabilities, net of current portion<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 211.47pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 213.78pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 214.35999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 214.65pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 214.73pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 214.76999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 214.78pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 166.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 22.41pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">21,454<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 318.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The following table summarizes additional information related to the Company&#8217;s operating leases (in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 330.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">thousands, except weighted-average data)&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 350.75pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 402.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 24pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.26pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 3.38pt; position: absolute; text-decoration: none; white-space: pre;">December 31,<font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 14.06pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 22.62pt; position: absolute; text-decoration: none; white-space: pre;">2023<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 24pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Right-of-use assets<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 88.72999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 89.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 89.97pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 89.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 24pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 13.52pt;"></font></font><font style="left: 21.709999999999997pt; position: absolute;">20,961<font style="display: inline-block; height: 7.28pt; width: 12.22pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 38.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Weighted-average remaining lease term (years)<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 214.10999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 214.69pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 214.98pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 215.01999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 215.03pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 38.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 48.73pt; position: absolute; text-decoration: none; white-space: pre;">6.5<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 52.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Weighted-average discount rate<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 144.12pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 144.7pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 144.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 145.03pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 52.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 38.39pt; position: absolute;"><font style="display: inline-block; height: 7.28pt;"></font></font><font style="left: 38.39pt; position: absolute;">9.0<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font><font style="left: 55.61pt; position: absolute;">%<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div id="i2341357d54884756b9e9172f0a83cd6b_328" style="position: absolute; top: 433.5pt;"></div><div style="line-height: 8.73pt; position: absolute; top: 433.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">7. Commitments and Contingencies<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 455.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Royalty Commitments<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 475.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company has entered into various exclusive technology licensing agreements and other software <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 487.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">licensing agreements. The terms of the agreements require the Company to make annual royalty <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 499.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">payments in fixed amounts as well as certain milestone and revenue-based payments. The revenue-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 511.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">based royalty percentage is in the low single digits, subject to reductions and offsets in certain <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 523.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">circumstances with a minimum royalty commitment of $50,000&#160;annually. Future minimum royalty <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 535.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">commitments due under the terms of these exclusive agreements as of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 388.61pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 476.4pt; position: absolute; white-space: pre;"> are as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 547.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">follows (in thousands)&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 567.9pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 402.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 35.25pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 402.75pt;"><div><div style="font-size: 12pt; line-height: 6.55pt; position: absolute; top: 25.31pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Year ending <font style="display: inline-block; height: 6.55pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 56.59pt; position: absolute; text-decoration: none; white-space: pre;">December 31,<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.71pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 12.89pt; position: absolute; text-decoration: none; white-space: pre;">Minimum <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 14.51pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 16.39pt; position: absolute; text-decoration: none; white-space: pre;">Royalty <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 25.31pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 2.65pt; position: absolute; text-decoration: none; white-space: pre;">Commitments<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 35.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">2024<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 24.869999999999997pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 25.02pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 25.099999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 25.11pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 35.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 41.86pt;"></font></font><font style="left: 50.050000000000004pt; position: absolute;">50<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 49.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">2025<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 24.869999999999997pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 25.02pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 25.099999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 25.11pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 49.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 47.42pt;"></font></font><font style="left: 50.050000000000004pt; position: absolute;">50<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 63.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">2026<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 24.869999999999997pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 25.02pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 25.099999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 25.11pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 63.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 47.42pt;"></font></font><font style="left: 50.050000000000004pt; position: absolute;">50<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 78pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">2027<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 24.869999999999997pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 25.02pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 25.099999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 25.11pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 78pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 47.42pt;"></font></font><font style="left: 50.050000000000004pt; position: absolute;">50<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 92.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">2028<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 24.869999999999997pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 25.02pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 25.099999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 25.11pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 92.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 47.42pt;"></font></font><font style="left: 50.050000000000004pt; position: absolute;">50<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 106.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Thereafter<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 48.730000000000004pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 49.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 49.970000000000006pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 49.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 50pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 106.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 41.86pt;"></font></font><font style="left: 44.49pt; position: absolute;">100<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 120.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Total minimum royalty commitments<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 161.47pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 163.78pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 164.35999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 164.65pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 164.73pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 164.76999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 164.78pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 120.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 36.3pt;"></font></font><font style="left: 44.49pt; position: absolute;">350<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 295.72pt; position: absolute; text-decoration: none; white-space: pre;">F-23<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"><div style="line-height: 11.64pt; position: absolute; top: 36pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 55.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 180.72pt; position: absolute; text-decoration: none; white-space: pre;">Notes to Consolidated Financial <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 366.64pt; position: absolute; text-decoration: none; white-space: pre;">Statements<font style="display: inline-block; height: 8.73pt;"></font></font></div></div></div><div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 90pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company incurred royalty expense of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 260.32pt; position: absolute; text-decoration: none; white-space: pre;">$2.1<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 279.77pt; position: absolute; white-space: pre;"> million for the year ended <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 397.52pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 485.31pt; position: absolute; white-space: pre;">.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 110pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Purchase Commitments<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 130pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Open purchase commitments are for the purchase of goods and services related to, but not limited to, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 142pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">research and development and professional services under non-cancellable contracts. These amounts <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 154pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">were not recorded as liabilities on the consolidated balance sheet as of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 388.09pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 475.88pt; position: absolute; white-space: pre;"> as the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 166pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Company had not yet received the related goods or services. As of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 369.18pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 456.97pt; position: absolute; white-space: pre;">, the Company <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 178pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">had estimated open purchase commitments for goods and services of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 383.09pt; position: absolute; text-decoration: none; white-space: pre;">$880<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 405.33pt; position: absolute; white-space: pre;">,000 based on management&#8217;s <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 190pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">estimate of patient participation in clinical trials through the next four years.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 210pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Contingencies<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 230pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">From time to time, the Company may identify certain contingent liabilities that arise in the ordinary course <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 242pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of its business activities. The Company accrues a liability for such matters when it is probable that a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 254pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">future loss will be incurred and such loss can be reasonably estimated. As of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 412.5pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 500.29pt; position: absolute; white-space: pre;">, no <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 266pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">accruals were required for such contingencies.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 286pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Indemnifications<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 306pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company provides general indemnifications to management and the members of the Company&#8217;s <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 318pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">board of directors (the &#8220;Board of Directors&#8221;) when they act, in good faith, in the best interest of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 330pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Company. The Company is unable to develop an estimate of the maximum potential amount of future <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 342pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">payments that could potentially result from any hypothetical future claim, but expects the risk of having to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 354pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">make any payments under these general business indemnifications to be remote. The Company also <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 366pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">maintains insurance coverage that would generally enable the Company to recover a portion of any future <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 378pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">amounts paid.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div id="i2341357d54884756b9e9172f0a83cd6b_313" style="position: absolute; top: 398pt;"></div><div style="line-height: 8.73pt; position: absolute; top: 398pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">8. Term Loan<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Initial Term Loan<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 440.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">On January 19, 2021, the Company entered into a Credit Agreement with Hayfin Services, LLP (&#8220;Hayfin&#8221;) <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 452.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for total borrowings of up to $70.0 million (the &#8220;Initial Term Loan&#8221;). The Company received net cash <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 464.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">proceeds of $68.1 million, after deducting $1.3 million of lender fees as a discount to the debt, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 476.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">$629,000 of debt issuance costs. The Company also issued a warrant to the lender to purchase a total of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 488.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">315,810 shares of its common stock. The fair value of the warrant was $4.3 million as of the issuance <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 500.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">date, which was also accounted for as a debt discount. Refer to Note 12 for additional information.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 520.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">New Money Term Loan<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 540.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">On March 17, 2022, the Company entered into Amendment No. 1 to the Credit Agreement with Hayfin for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 552.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">an additional $50.0 million term loan (the &#8220;New Money Term Loan&#8221;), collectively with the Initial Term Loan, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 564.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the &#8220;Term Loan&#8221;) which was considered a modification of the original Credit Agreement for accounting <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 576.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">purposes. Additionally, certain terms of the Initial Term Loan were amended. The Company received net <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 588.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">cash proceeds of $49.2 million, after deducting $820,000 of lender fees as a discount to the debt. Since <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 600.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the issuance of the New Money Term Loan was accounted for as a debt modification, debt issuance costs <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">were expensed as incurred. The Company also issued an additional warrant to the lender to purchase a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">total of 225,579 shares of common stock. The fair value of the warrant was $3.5 million&#160;as of the issuance <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 636.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">date, which was also accounted for as a debt discount. Refer to Note&#160;12 for additional information.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 656.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Other Amendments<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 676.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company entered into Amendments No. 2 and No. 3 to the Credit Agreement in September 2022 and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 688.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">December 2022, which enabled the Company to issue Subordinated Convertible Promissory Notes and to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 700.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">increase the aggregate principal of the Subordinated Convertible Promissory Notes that can be issued to <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 295.72pt; position: absolute; text-decoration: none; white-space: pre;">F-24<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"><div style="line-height: 11.64pt; position: absolute; top: 36pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 55.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 180.72pt; position: absolute; text-decoration: none; white-space: pre;">Notes to Consolidated Financial <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 366.64pt; position: absolute; text-decoration: none; white-space: pre;">Statements<font style="display: inline-block; height: 8.73pt;"></font></font></div></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 90pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">$42.0 million (see Note 9). The two amendments were accounted for as debt modifications. In connection <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 102pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">with these amendments, the Company paid $51,000 in lender fees, which were capitalized as an <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 114pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">additional debt discount to the Term Loans.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 134pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In the first quarter of 2023, the Company entered into three amendments to the Credit Agreement with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 146pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Hayfin. In March 2023, the Company entered into Amendment No. 4 and Waiver to Credit Agreement with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 158pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Hayfin to temporarily waive various covenant requirements that had not been met through the waiver date <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 170pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and to enable the Company to amend certain terms of the Credit Agreement. Under Amendment No. 4, as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 182pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">part of the Series F redeemable convertible preferred stock financing closing (see Note 10), the Company <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 194pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">issued to Hayfin 4,269,801 warrants for shares of common stock for no consideration and committed to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 206pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">sell 2,689,375 and 3,508,156 shares of Series F-1 and Series F redeemable convertible preferred stock, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 218pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">respectively. These shares were issued to Hayfin Heartflow UK Limited upon Convertible Note conversion <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 230pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and upon the initial closing of Series F redeemable convertible preferred stock with the same terms as all <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 242pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">other investors. In March 2023, the Company entered into Amendment No. 5 to the Credit Agreement with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 254pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Hayfin, which required the Company&#8217;s securities at JPMorgan Chase Bank to become a &#8220;Controlled <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 266pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Account&#8221;, as defined by the Credit Agreement. Also in March 2023, the Company entered into <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 278pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Amendment No. 6 to the Credit Agreement with Hayfin, which permitted the reacquisition of 300,000 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 290pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">shares of common stock from an employee&#47;founder of the Company. In connection with these <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 302pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">amendments, the Company paid $94,000 in lender fees, which were recorded as a debt discount. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 314pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Amendments No. 4 through No. 6 were accounted for as debt modifications for accounting purposes.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 334pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Prepayment terms<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 354pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Both the Initial Term Loan and the New Money Term Loan are due January&#160;19, 2026. The Company can <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 366pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prepay the outstanding principal of the Term Loan, in whole or in part, upon five business days of written <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 378pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">notice. In addition, immediately upon the consummation of an initial public offering (&#8220;IPO&#8221;) or acquisition <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 390pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">by Special Purpose Acquisition Company (&#8220;SPAC&#8221;) as defined in the Credit Agreement, the Company <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 402pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">shall repay the Term Loan in an amount equal to the lesser of (i) the net cash proceeds of such IPO or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 414pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">SPAC in excess of $150.0 million and (ii) $35.0 million. Furthermore, the Company shall repay the Term <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 426pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Loans upon certain disposition, certain Event of Loss, incurrence of certain debt securities, Event of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 438pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Default, and Change in Control as defined in the amended Credit Agreement. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 458pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Any prepayment or repayment of the principal balance of the Term Loan are subject to an exit fee. The <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 470pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Company is accreting the exit fee over the loan term using the effective interest method. The exit fee of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 482pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the Initial Term Loan shall equal (i) on or prior to January 19, 2023, 1% of the prepaid or repaid principal, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 494pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(ii) at any time after January 19, 2023 but prior to December 31, 2023, 2% of the prepaid or repaid <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 506pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">principal and (iii) at any time on or after December 31, 2023, 3% of the prepaid or repaid principal. The <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 518pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">exit fee of the New Money Term Loan shall equal (i) at any time prior to December 31, 2023, 2% of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 530pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prepaid or repaid principal and (ii) at any time on or after December 31, 2023, 3% of the prepaid or repaid <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 542pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">principal.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 562pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Any prepayment (except for in connection with certain disposition, certain Event of Loss, and the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 574pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">consummation of an IPO or SPAC) that incurs prior to March 17, 2025 is subject to an early prepayment <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 586pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">fee equal to (i) at any time on or prior to March 17, 2024, an amount equal to 5% of the prepaid principal&#59; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 598pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(ii) at any time after March 17, 2024 and on or prior to March 17, 2025, an amount equal to 3% of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 610pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prepaid principal&#59; and (iii) at any time after March 17, 2025, none. In addition, the early prepayment fee <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 622pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">such that no early prepayment fee should be paid in respect to any voluntary prepayment or repayment in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 634pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">a single principal amount equal to or greater than $20.0 million generated from certain permitted sources.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 654pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Interest<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 674pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Initial Term Loan has an interest rate equal to the sum of the applicable margin of 6.0% plus the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 686pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">higher of LIBOR and 1.0%, and the New Money Term Loan has an interest rate equal to the sum of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 698pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">applicable margin of 15.25% plus the higher of the adjusted term for such interest period and 1.0%. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 710pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Interest payments are due quarterly.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 295.72pt; position: absolute; text-decoration: none; white-space: pre;">F-25<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"><div style="line-height: 11.64pt; position: absolute; top: 36pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 55.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 180.72pt; position: absolute; text-decoration: none; white-space: pre;">Notes to Consolidated Financial <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 366.64pt; position: absolute; text-decoration: none; white-space: pre;">Statements<font style="display: inline-block; height: 8.73pt;"></font></font></div></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 90pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Regarding the Initial Term Loan, the Company may elect to pay the quarterly interest in-kind through the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 102pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">last interest period ending before the second anniversary of the original Credit Agreement. However, if the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 114pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Company elects to pay interest in-kind after the first anniversary, the applicable margin increases by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 126pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">1.0%. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 146pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">With respect to the New Money Term Loan, the Company may elect to pay PIK Interest, provided that, (i) <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 158pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prior to December 31, 2023, a minimum of 3% per annum shall be payable in cash and (ii) on or after <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 170pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">December 31, 2023, a minimum of 6% per annum shall be payable in cash.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 190pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">During the year ended <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 173.67000000000002pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 261.46000000000004pt; position: absolute; white-space: pre;">, <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 267pt; position: absolute; text-decoration: none; white-space: pre;">$144<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 289.24pt; position: absolute; white-space: pre;">,000 of interest was paid-in-kind (&#8220;PIK&#8221;) and was added <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 202pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to the outstanding principal balance of the Term Loan.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 222pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Debt Issuance Costs and Debt Discount<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 242pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Debt issuance costs include third-party costs incurred in connection with the original Credit Agreement. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 254pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Debt discount includes fees paid to the lender, warrants issued to the lender and the embedded derivative <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 266pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">liability as described below.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 286pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Certain prepayment features of the Term Loan, default put option and default interest adjustment features <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 298pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">are embedded derivatives requiring bifurcation and separate accounting for at fair value as a single <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 310pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">compound derivative. The fair value of the derivative liability was $2.1 million, as of the issuance date in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 322pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">January 2021, and is remeasured to fair value at each reporting period. Refer to Note 13 for additional <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 334pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">information.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 354pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The debt issuance costs and debt discount are classified as an offset to the Term Loan on the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 366pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">consolidated balance sheet, and is accreted over the loan term using the effective interest method.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 386pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">As of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 97.53pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 185.32pt; position: absolute; white-space: pre;">, the effective interest rate of the Initial Term Loan and the New Money Term <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 398pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Loan was <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 117.56pt; position: absolute; text-decoration: none; white-space: pre;">16.1%<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 145.9pt; position: absolute; white-space: pre;"> and <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 168.12pt; position: absolute; text-decoration: none; white-space: pre;">26.8%<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 196.45999999999998pt; position: absolute; white-space: pre;">, respectively.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 418pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Collateral and Covenants<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 438pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Term Loan is collateralized by substantially all of the Company&#8217;s assets. The Term Loan Agreement <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 450pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">contains customary representations and warranties, covenants, events of default and termination <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 462pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">provisions. The Company is subject to financial covenants which requires the Company to maintain a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 474pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">$25.0 million minimum liquidity balance in cash and cash equivalents at all times and minimum net sales <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 486pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">for twelve consecutive month periods ending on the last day of a fiscal quarter, which is not tested as long <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 498pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">as the Company maintains minimum liquidity of at least $60.0 million and there has been no decline in net <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 510pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">sales for two-consecutive fiscal quarters at the end of such fiscal quarter. The minimum twelve months <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 522pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">trailing net sales covenant increases each quarter and is $70.0 million for the quarter ended March 31, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 534pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2024 up to a minimum net sales amount of $110.0 million for the quarter ended June 30, 2025 and each <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 546pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">quarter thereafter. Other non-financial covenants are outlined in the agreement. As of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 450.27pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 558pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">2022<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 94.24pt; position: absolute; white-space: pre;">, the Company was not in compliance with several non-financial covenants and therefore, on March <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 570pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2, 2023, the Company entered into Amendment No. 4 and Waiver to Credit Agreement and Guaranty with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 582pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Hayfin, which temporarily waived the specific non-compliance of the covenant violations existing as of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 594pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">December 31, 2022. As of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 190.31pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 278.1pt; position: absolute; white-space: pre;">, the Company was in compliance with the Term Loan <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 606pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">covenants.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 295.72pt; position: absolute; text-decoration: none; white-space: pre;">F-26<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"><div style="line-height: 11.64pt; position: absolute; top: 36pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 55.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 180.72pt; position: absolute; text-decoration: none; white-space: pre;">Notes to Consolidated Financial <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 366.64pt; position: absolute; text-decoration: none; white-space: pre;">Statements<font style="display: inline-block; height: 8.73pt;"></font></font></div></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 90pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Debt Components<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 110pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">As of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 97.53pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 185.32pt; position: absolute; white-space: pre;">, the components of the Term Loan are as follows (in thousands)&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 130pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 402.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 24pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.26pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 3.38pt; position: absolute; text-decoration: none; white-space: pre;">December 31,<font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 14.06pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 22.62pt; position: absolute; text-decoration: none; white-space: pre;">2023<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 24pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Principal value of Term Loan<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 128.55pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 129.71pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 129.86pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 129.94pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 129.98pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 129.99pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 24pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 16.85pt;"></font></font><font style="left: 25.04pt; position: absolute;">120,000<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 38.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">PIK interest added to principal<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 135.93pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 138.24pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 139.4pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 139.69pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 139.71pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 139.72pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 38.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">18,118<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 52.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Accreted exit fee<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 77.05pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 79.36pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 79.64999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 79.8pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 79.82pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 79.83pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 52.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">1,819<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 66.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Debt discount<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 63.74pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 64.9pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 64.98pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 65pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 66.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 30.2pt;"></font></font><font style="left: 32.83pt; position: absolute;">(5,664)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 81pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Debt issuance costs<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 92.07pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 94.38pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 94.67pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 94.82pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 94.83pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 81pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 38.53pt;"></font></font><font style="left: 41.160000000000004pt; position: absolute;">(265)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 95.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Total Term Loan <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 76.33pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 78.64pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 79.22pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 79.50999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 79.66pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 79.74pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 79.75999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 79.77pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 95.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 16.85pt;"></font></font><font style="left: 25.04pt; position: absolute;">134,008<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 255.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Term Loan was classified as long-term on the consolidated balance sheet as of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 443.45pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 531.24pt; position: absolute; white-space: pre;">. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 267.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">As of December 31, 2023, the estimated fair value of the Term Loan was $132.4 million.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div id="i2341357d54884756b9e9172f0a83cd6b_298" style="position: absolute; top: 287.5pt;"></div><div style="line-height: 8.73pt; position: absolute; top: 287.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">9. Convertible Notes<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 309.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">During the period from September 2022 through December 2022, the Company issued convertible <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 321.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">promissory notes to certain investors (the &#8220;Note Investors&#8221;), with an aggregate principal amount of $40.0 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 333.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">million&#160;(the &#8220;Convertible Notes&#8221;). The Convertible Notes bore interest at a rate of 8% per annum, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 345.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">compounded monthly. The aggregate principal amount and interest accrued on the Convertible Notes was <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 357.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">due September&#160;30, 2026, and could not be prepaid by the Company without the consent of a majority of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 369.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the Note Investors.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 389.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The principal and accrued interest on the Convertible Notes was subject to automatic conversion upon a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 401.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Qualified Financing (defined as a transaction or series of transactions in which the Company sells shares <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 413.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of its capital stock for cash proceeds of at least $100 million, including the Convertible Notes) at a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 425.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">conversion price equal to 67% of the price per share paid by the investors purchasing such capital stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 437.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">in such Qualified Financing. Upon a Non-Qualified Financing, whereby the cash proceeds are less than <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 449.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">$100&#160;million, upon the written consent of a majority of the Note Investors, the Convertible Notes shall <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 461.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">convert on the same terms as a Qualified Financing.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 481.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Convertible Notes were also subject to repayment upon a Change of Control. A Change of Control is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 493.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">defined as a sale of all or substantially all of the Company&#8217;s assets, a merger or business combination <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 505.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">with a change in more than 50% of the voting interest, or after a person or group, directly or indirectly, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 517.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">owns more than 35% of the capital stock of the Company after the Company becomes publicly traded.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 537.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In March 2023, the Company completed a Qualified Financing and all of the Convertible Notes, including <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 549.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">principal and interest, were converted into 21,465,064 shares of Series F-1 redeemable convertible <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 561.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">preferred stock and the Company derecognized the Convertible Notes from its consolidated balance <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 573.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">sheet. The Company remeasured the fair value of the Convertible Notes immediately before the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 585.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">conversion and recognized a loss of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 234.23pt; position: absolute; text-decoration: none; white-space: pre;">$5.1<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 253.68pt; position: absolute; white-space: pre;"> million from the change in fair value within the consolidated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 597.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">statement of operations and comprehensive loss for the year ended <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 373.65pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 461.44pt; position: absolute; white-space: pre;">.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div id="i2341357d54884756b9e9172f0a83cd6b_283" style="position: absolute; top: 617.9pt;"></div><div style="line-height: 8.73pt; position: absolute; top: 617.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">10. Redeemable Convertible Preferred Stock<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 640.3pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In March 2023, the Company issued 61,344,029 shares of Series F redeemable convertible preferred <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 652.3pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock to existing and new investors at a price per share of $2.8505 for an aggregate cash consideration of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 664.3pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">$174.9 million, net of $5.9 million&#160;issuance costs. Contemporaneously with the issuance of the Series F <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 676.3pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">redeemable convertible preferred stock, the Company converted all of the outstanding Convertible Notes <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 688.3pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">issued by the Company from September 30, 2022 to December 16, 2022, in the aggregate principal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 700.3pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">amount of $40.0 million plus accrued, unpaid interest of $994,000&#160;into 21,465,064 shares of Series F-1 <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 295.72pt; position: absolute; text-decoration: none; white-space: pre;">F-27<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"><div style="line-height: 11.64pt; position: absolute; top: 36pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 55.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 180.72pt; position: absolute; text-decoration: none; white-space: pre;">Notes to Consolidated Financial <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 366.64pt; position: absolute; text-decoration: none; white-space: pre;">Statements<font style="display: inline-block; height: 8.73pt;"></font></font></div></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 90pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">redeemable convertible preferred stock at a price per share of $1.9098, which represents a discount of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 102pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">33% from the cash purchase price per share. Additionally, in connection with the Series F redeemable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 114pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">convertible preferred stock financing, the cumulative dividends payable to holders of Series C redeemable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 126pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">convertible preferred stock upon a liquidation event were capped from $6.66 to $8.25 per share <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 138pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">depending on the time of issuance, with an aggregate total of $88.5 million.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 158pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The issuance of the Series F redeemable convertible preferred stock triggered the anti-dilution protection <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 170pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">provision for Series B-1, Series B-2, Series C, Series D and Series E stockholders. As a result, the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 182pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Company recorded a $26.8 million deemed dividend in the amount equal to the change in fair value of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 194pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">abovementioned series of convertible preferred stock before and after the anti-dilution adjustment. The <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 206pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">fair value of the Series B-1, Series B-2, Series C, Series D and Series E redeemable convertible preferred <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 218pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock was determined using a &#8220;with-and-without&#8221; model under which the equity value of the Company was <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 230pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">allocated using a hybrid method, whereby the enterprise value in the IPO scenario is allocated to each <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 242pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">class of shares using the fully-diluted shares outstanding and whereby the enterprise value in the non-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 254pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">IPO scenario is allocated using an option-pricing model to reflect the full distribution of possible non-IPO <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 266pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">outcomes, both before and after the anti-dilution adjustment. The following table summarizes information <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 278pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">about the significant Level 3 unobservable inputs used to estimate the fair value of the Company&#8217;s <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 290pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">preferred stock at the modification date&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 310pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 402.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 12.75pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 2.81pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 3.13pt; position: absolute; text-decoration: none; white-space: pre;">March 2, 2023<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 12.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Risk-free interest rate<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 98.14999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 99.31pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 99.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 99.92999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 99.94pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 12.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 38.39pt; position: absolute;"><font style="display: inline-block; height: 7.28pt;"></font></font><font style="left: 38.39pt; position: absolute;">4.8<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font><font style="left: 55.61pt; position: absolute;">%<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 27pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Expected volatility<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 82.61pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 83.77pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 84.35pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 84.64pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 84.78999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 84.86999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 84.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 84.89999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 27pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 32.83pt; position: absolute;"><font style="display: inline-block; height: 7.28pt;"></font></font><font style="left: 32.83pt; position: absolute;">88.0<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font><font style="left: 55.61pt; position: absolute;">%<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 41.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Expected term (in years)<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 111.49pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 113.8pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 114.38pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 114.67pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 114.75pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 114.77pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 114.78pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 41.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 48.73pt; position: absolute; text-decoration: none; white-space: pre;">2.0<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 55.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Expected dividend yield<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 107.64pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 108.8pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 109.38pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 109.67pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 109.82pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 109.89999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 55.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 38.39pt; position: absolute;"><font style="display: inline-block; height: 7.28pt;"></font></font><font style="left: 38.39pt; position: absolute;">0.0<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font><font style="left: 55.61pt; position: absolute;">%<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 395.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Redeemable convertible preferred stock consists of the following (in thousands, except share amounts)&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 415.75pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 198pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 12.75pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="7"><div style="left: 198pt; position: absolute; top: 0pt; width: 270pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 2.81pt; width: 270pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 94.51pt; position: absolute; text-decoration: none; white-space: pre;">December 31, 2023<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 56.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 12.75pt; width: 198pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 46.31pt; width: 198pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Series<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 12.75pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 24.71pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 10.15pt; position: absolute; text-decoration: none; white-space: pre;">Number of <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 35.51pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 17.63pt; position: absolute; text-decoration: none; white-space: pre;">Shares <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 46.31pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 9.15pt; position: absolute; text-decoration: none; white-space: pre;">Authorized<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td><td style="border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 12.75pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.11pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 10.15pt; position: absolute; text-decoration: none; white-space: pre;">Number of<font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 13.91pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 17.63pt; position: absolute; text-decoration: none; white-space: pre;">Shares <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 24.71pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 18.38pt; position: absolute; text-decoration: none; white-space: pre;">Issued <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 35.51pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 24.63pt; position: absolute; text-decoration: none; white-space: pre;">and <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 46.31pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 6.16pt; position: absolute; text-decoration: none; white-space: pre;">Outstanding<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td><td style="border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 12.75pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 35.51pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 14.14pt; position: absolute; text-decoration: none; white-space: pre;">Carrying <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 46.31pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 20.63pt; position: absolute; text-decoration: none; white-space: pre;">Value<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td><td style="border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 12.75pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 35.51pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 8.41pt; position: absolute; text-decoration: none; white-space: pre;">Liquidation <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 46.31pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 20.63pt; position: absolute; text-decoration: none; white-space: pre;">Value<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 69pt; width: 198pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 198pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Series A<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 39.84pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 40.13pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 40.28pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 40.32pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 40.330000000000005pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 69pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 18.16pt; position: absolute; text-decoration: none; white-space: pre;">4,082,965<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 69pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 18.16pt; position: absolute; text-decoration: none; white-space: pre;">4,082,965<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 69pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">2,041<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 69pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">2,041<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 83.25pt; width: 198pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 198pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Series B-1<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 49.28pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 49.86pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 50.150000000000006pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 50.230000000000004pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 50.27pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 50.28pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 83.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 18.16pt; position: absolute; text-decoration: none; white-space: pre;">1,954,846<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 83.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 18.16pt; position: absolute; text-decoration: none; white-space: pre;">1,954,846<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 83.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">6,940<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 83.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">6,940<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 97.5pt; width: 198pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 198pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Series B-2<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 49.28pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 49.86pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 50.150000000000006pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 50.230000000000004pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 50.27pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 50.28pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 97.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 18.16pt; position: absolute; text-decoration: none; white-space: pre;">2,848,263<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 97.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 18.16pt; position: absolute; text-decoration: none; white-space: pre;">2,848,263<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 97.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">10,111<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 97.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">10,111<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 111.75pt; width: 198pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 198pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Series C<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 40.95pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 43.260000000000005pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 44.42pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 44.71pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 44.86pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 44.940000000000005pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 44.96pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 111.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 13.34pt; position: absolute; text-decoration: none; white-space: pre;">11,343,434<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 111.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 13.34pt; position: absolute; text-decoration: none; white-space: pre;">11,343,434<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 111.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 22.41pt;"></font></font><font style="left: 25.04pt; position: absolute;">104,378<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 111.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 22.41pt;"></font></font><font style="left: 25.04pt; position: absolute;">193,167<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 126pt; width: 198pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 198pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Series D<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 40.95pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 43.260000000000005pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 44.42pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 44.71pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 44.86pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 44.940000000000005pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 44.96pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 126pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 18.16pt; position: absolute; text-decoration: none; white-space: pre;">7,151,873<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 126pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 18.16pt; position: absolute; text-decoration: none; white-space: pre;">7,151,873<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 126pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 22.41pt;"></font></font><font style="left: 25.04pt; position: absolute;">110,756<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 126pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 22.41pt;"></font></font><font style="left: 25.04pt; position: absolute;">110,854<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 140.25pt; width: 198pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 198pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Series E<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 40.39pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 42.7pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 43.86pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 44.440000000000005pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 44.730000000000004pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 44.88pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 44.900000000000006pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 140.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 12.6pt; position: absolute; text-decoration: none; white-space: pre;">12,040,980<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 140.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 12.6pt; position: absolute; text-decoration: none; white-space: pre;">12,040,980<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 140.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 22.41pt;"></font></font><font style="left: 25.04pt; position: absolute;">304,197<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 140.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 22.41pt;"></font></font><font style="left: 25.04pt; position: absolute;">305,018<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 154.5pt; width: 198pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 198pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Series F<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 39.830000000000005pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 40.120000000000005pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 40.27pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 40.31pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 40.330000000000005pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 154.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 12.6pt; position: absolute; text-decoration: none; white-space: pre;">61,344,029<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 154.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 12.6pt; position: absolute; text-decoration: none; white-space: pre;">61,344,029<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 154.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 22.41pt;"></font></font><font style="left: 25.04pt; position: absolute;">168,957<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 154.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 22.41pt;"></font></font><font style="left: 25.04pt; position: absolute;">262,295<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 168.75pt; width: 198pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 198pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Series F-1<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 48.720000000000006pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 49.88pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 50.17pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 50.21pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 50.220000000000006pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 168.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 12.6pt; position: absolute; text-decoration: none; white-space: pre;">21,465,064<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 168.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 12.6pt; position: absolute; text-decoration: none; white-space: pre;">21,465,064<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 168.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">61,186<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 168.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">61,491<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 183pt; width: 198pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 198pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Total <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 26.509999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 28.82pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 29.98pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 30pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 183pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 7.04pt; position: absolute; text-decoration: none; white-space: pre;">122,231,454<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 183pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 7.04pt; position: absolute; text-decoration: none; white-space: pre;">122,231,454<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 183pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 16.85pt;"></font></font><font style="left: 25.04pt; position: absolute;">768,566<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 183pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 16.85pt;"></font></font><font style="left: 25.04pt; position: absolute;">951,917<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 629pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The significant rights and obligations of the Company&#8217;s redeemable convertible preferred stock are as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 641pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">follows&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 661pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Dividends<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 681pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The holders of Series A, Series B-1, Series B-2, Series C, Series D, Series E, Series F and Series F-1 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 693pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">redeemable convertible preferred stock are entitled, <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 303.09000000000003pt; position: absolute; text-decoration: none; white-space: pre;">on a pro rata, pari passu basis<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 437.52pt; position: absolute; white-space: pre;">, when and if declared <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 705pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">by the Board of Directors, to non-cumulative dividends out of the Company's assets legally available <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 295.72pt; position: absolute; text-decoration: none; white-space: pre;">F-28<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"><div style="line-height: 11.64pt; position: absolute; top: 36pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 55.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 180.72pt; position: absolute; text-decoration: none; white-space: pre;">Notes to Consolidated Financial <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 366.64pt; position: absolute; text-decoration: none; white-space: pre;">Statements<font style="display: inline-block; height: 8.73pt;"></font></font></div></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 90pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">therefore at the rate of $0.030, $0.284, $0.284, $0.7384, $1.24, $2.026, $0.2281 and $0.1528 per share <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 102pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">per annum, respectively. No distributions will be made with respect to the common stock until all declared <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 114pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">but unpaid dividends on redeemable convertible preferred stock have been paid or set aside for payment <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 126pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to the convertible preferred stockholders. Except with respect to the rights of the holders of Series C <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 138pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">redeemable convertible preferred stock upon a liquidation event, the right to receive dividends on shares <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 150pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of redeemable convertible preferred stock are non-cumulative, <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 349.76pt; position: absolute; text-decoration: none; white-space: pre;">and<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 366.44pt; position: absolute; text-decoration: none; white-space: pre;"> no right to such dividends accrues to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 162pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">holders of redeemable convertible preferred stock by reason of the fact that dividends on such shares are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 174pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">not declared or paid in any years<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 217pt; position: absolute; text-decoration: none; white-space: pre;">. At <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 234.19pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 321.98pt; position: absolute; text-decoration: none; white-space: pre;">, <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 327.52pt; position: absolute; text-decoration: none; white-space: pre;">no<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 338.64pt; position: absolute; text-decoration: none; white-space: pre;"> dividends had been declared or paid.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 194pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Dividends are payable to preferred stockholders in the order of&#58; first, the Series F and Series F-1 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 206pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">redeemable convertible preferred stock, then the Series E redeemable convertible preferred stock, then <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 218pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the Series D redeemable convertible preferred stock, then the Series C redeemable convertible preferred <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 230pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock, then the Series B-1 and B-2 redeemable convertible preferred stock, and then finally, the Series A <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 242pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">redeemable convertible preferred stock. After payment of the full amount of any dividends described <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 254pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">above, any additional dividends shall be distributed among all holders of common stock and all holders of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 266pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">redeemable convertible preferred stock on an as-converted basis.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 286pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The holders of Series C redeemable convertible preferred stock are the only preferred stockholders <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 298pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">entitled to cumulative dividends upon a liquidation event. In connection with the Series F redeemable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 310pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">convertible preferred stock financing, the cumulative dividends payable to holders of Series C redeemable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 322pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">convertible preferred stock upon a liquidation event were capped from $6.66 to $8.25 per share <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 334pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">depending on the time of issuance, with an aggregate total of $88.5 million, provided, however, that the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 346pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Company shall be under no obligation to pay such Series C preferred accruing dividends until a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 358pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">liquidation event&#59; provided further, that a holder of shares of Series C redeemable convertible preferred <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 370pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock shall automatically forfeit any then accrued but unpaid Series C redeemable convertible preferred <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 382pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">accruing dividends with respect to such shares upon conversion of such shares into shares of common <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 394pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock. As of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 125.85pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 213.64pt; position: absolute; white-space: pre;">, the total accumulated, but not yet declared or paid, dividends of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 502.46pt; position: absolute; text-decoration: none; white-space: pre;">$88.5<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 527.47pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 406pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">million related to the Series C redeemable convertible preferred stock was not recorded in the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 418pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">consolidated financial statements as an accrued dividend as such an event was not considered probable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 430pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to occur.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 450pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Liquidation Rights<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 470pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 482pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the holders of Series F, Series F-1, Series E, Series D, Series C, Series B-1, Series B-2 and Series A <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 494pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">redeemable convertible preferred stock are entitled to liquidation preferences in the amount of $4.2758, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 506pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">$2.8647, $25.3317, $15.50, $9.23, $3.55, $3.55, and $0.50 per share, respectively, for each outstanding <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 518pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">share plus all declared but unpaid dividends, if the shares are not converted to common stock. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 538pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Payment of liquidation rights to preferred stockholders are in the order of&#58; first, the Series F and Series <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 550pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">F-1 redeemable convertible preferred stock, then the Series E redeemable convertible preferred stock, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 562pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">then the Series D redeemable convertible preferred stock, then the Series C redeemable convertible <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 574pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">preferred stock, then the Series B-1 and B-2 redeemable convertible preferred stock, and then finally, the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 586pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Series A redeemable convertible preferred stock. The remaining assets, if any, shall be distributed to the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 598pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">holders of common stock. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 618pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">If upon the liquidation, dissolution or winding up of the Company, the assets of the Company legally <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 630pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">available for distribution to the holders of the Series F, Series F-1, Series E, Series D, Series C, Series <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 642pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">B-1, Series B-2 and Series A redeemable convertible preferred stock are insufficient to permit the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 654pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">payment to such holders of the full liquidation preferences to which they are entitled, then the holders of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 666pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the Company&#8217;s common stock will receive nothing in respect of their equity holdings in the Company. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 678pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Upon such an event, the assets of the Company legally available for distribution shall satisfy the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 690pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">respective liquidation preferences of the preferred stockholders with equal pro rata priority in the same <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 702pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">preferential order as described above.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 295.72pt; position: absolute; text-decoration: none; white-space: pre;">F-29<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"><div style="line-height: 11.64pt; position: absolute; top: 36pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 55.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 180.72pt; position: absolute; text-decoration: none; white-space: pre;">Notes to Consolidated Financial <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 366.64pt; position: absolute; text-decoration: none; white-space: pre;">Statements<font style="display: inline-block; height: 8.73pt;"></font></font></div></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 90pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Conversion Rights<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 110pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Each share of Series A, Series B-1, Series B-2, Series C, Series D, Series E, Series F and Series F-1 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 122pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">redeemable convertible preferred stock shall automatically be converted into fully-paid, nonassessable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 134pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">shares of common stock at the then effective conversion rate per share (currently $0.50, $3.02, $3.02, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 146pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">$5.48, $8.21, $12.48, $2.85 and $1.91, respectively) for such share prior to the closing of a firm <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 158pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">commitment underwritten IPO pursuant to an effective registration statement filed under the Securities Act <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 170pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of 1933, as amended, or SPAC transaction covering the offer and sale of the Company&#8217;s common stock, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 182pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">provided that (i) the aggregate gross proceeds to the Company are not less than $100,000,000 and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 194pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(ii)&#160;the per share price of the shares sold in the public offering shall be no less than $4.9884 per share or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 206pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">$5.7010 per share (subject to adjustment from time to time for Recapitalizations and as otherwise set <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 218pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">forth elsewhere herein) so long as a certain investor holds at least 11,693,855 shares of Series F <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 230pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">redeemable convertible preferred stock (a &#8216;&#8216;Qualified Public Offering&#8217;&#8217;) shall automatically be converted <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 242pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">into fully-paid, nonassessable shares of common stock at the then effective conversion rate for such <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 254pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">share upon the written consent of the holders of a majority of the Series F and F-1 redeemable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 266pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">convertible preferred stock (voting as a single class and on an as-converted basis). The conversion rates <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 278pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">per share for previously issued preferred stock were amended as a result of the Series F redeemable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 290pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">convertible preferred stock financing from the original conversion rates per share for Series B-1, Series <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 302pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">B-2, Series C, Series D and Series E redeemable convertible preferred stock ($3.55, $3.55, $9.23, $15.50 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 314pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and 25.3317,&#160;respectively). Upon a Qualified Public Offering, shares of each series of the outstanding <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 326pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">redeemable convertible preferred stock are convertible into the number of shares of common stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 338pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">determined by dividing the original issue price for the relevant series of redeemable convertible preferred <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 350pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock by the conversion price for such series. As of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 299.15999999999997pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 386.95pt; position: absolute; white-space: pre;">, shares of each series of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 362pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">outstanding redeemable convertible preferred stock are convertible into shares of common stock on a 1&#58;1 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 374pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">basis.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 394pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Voting Rights<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 414pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The holder of each share of Series A, Series B-1, Series B-2, Series C, Series D, Series E, Series F and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 426pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Series F-1 redeemable convertible preferred stock is entitled to one vote for each share of common stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 438pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">into which it could be converted.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div id="i2341357d54884756b9e9172f0a83cd6b_268" style="position: absolute; top: 458pt;"></div><div style="line-height: 8.73pt; position: absolute; top: 458pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">11. Common Stock<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 480.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Under the Company&#8217;s Amended and Restated Certificate of Incorporation, the Company is authorized to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 492.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">issue 210,000,000 shares of $0.001 par value common stock.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 512.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Common stock reserved for issuance, on an as-converted basis, consisted of the following as of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 524.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 159.79000000000002pt; position: absolute; white-space: pre;">&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 544.4pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 402.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 35.25pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.71pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 7.89pt; position: absolute; text-decoration: none; white-space: pre;">Year Ended <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="font-size: 12pt; line-height: 6.55pt; position: absolute; top: 14.51pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 3.38pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="font-size: 12pt; line-height: 6.55pt; position: absolute; top: 25.31pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 22.62pt; position: absolute; text-decoration: none; white-space: pre;">2023<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 35.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Redeemable convertible preferred stock<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 179.85999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 180.01pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 180.09pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 180.10999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 35.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 2.96pt;"></font></font><font style="left: 5.59pt; position: absolute;">122,231,454<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 49.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Options to purchase common stock<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 159.28pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 159.85999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 160.01pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 160.04999999999998pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 49.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 8.52pt;"></font></font><font style="left: 11.149999999999999pt; position: absolute;">24,146,541<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 63.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Common stock warrants<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 110.39pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 112.69999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 113.86pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 114.44pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 114.58999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 114.67pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 114.67999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 63.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 14.08pt;"></font></font><font style="left: 16.71pt; position: absolute;">4,811,190<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 78pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Total <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 26.509999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 28.82pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 29.4pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 29.689999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 29.77pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 29.779999999999998pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 78pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 2.96pt;"></font></font><font style="left: 5.59pt; position: absolute;">151,189,185<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div id="i2341357d54884756b9e9172f0a83cd6b_253" style="position: absolute; top: 652.65pt;"></div><div style="line-height: 8.73pt; position: absolute; top: 652.65pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">12. Common Stock Warrant Liability<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 675.05pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">On January 19, 2021, in connection with entering into the Credit Agreement, the Company issued Hayfin&#160; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 687.05pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">a warrant to purchase 315,810 shares of common stock at an exercise price of $0.01 per share. On <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 699.05pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">March 17, 2022, upon amendment to the Credit Agreement, the Company issued Hayfin a warrant to <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 295.72pt; position: absolute; text-decoration: none; white-space: pre;">F-30<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"><div style="line-height: 11.64pt; position: absolute; top: 36pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 55.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 180.72pt; position: absolute; text-decoration: none; white-space: pre;">Notes to Consolidated Financial <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 366.64pt; position: absolute; text-decoration: none; white-space: pre;">Statements<font style="display: inline-block; height: 8.73pt;"></font></font></div></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 90pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">purchase 225,579 shares of common stock at an exercise price of $0.01 per share. On March 3, 2023, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 102pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">upon Amendment No. 4 to the Credit Agreement and as a result of antidilution adjustment provisions in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 114pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">connection with the Series F redeemable convertible preferred stock financing, the Company issued <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 126pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Hayfin a warrant to purchase 4,269,801 shares of common stock at an exercise price of $0.01 per share <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 138pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(collectively, the &#8220;Warrants&#8221;). As of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 225.8pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 313.59000000000003pt; position: absolute; white-space: pre;">, all warrants remained outstanding.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 158pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">These Warrants have a net exercise provision under which their holders may, in lieu of payment of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 170pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">exercise price in cash, surrender the warrant and receive a net amount of shares based on the fair market <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 182pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">value of the Company&#8217;s stock at the time of exercise of the Warrants after deduction of the aggregate <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 194pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">exercise price. The Warrants contain provisions for adjustment of the exercise price and number of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 206pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">shares issuable upon the exercise of the Warrants, if upon the issuance of next round securities, the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 218pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Warrants are then currently exercisable and the next round price is less than $25.3317 per share (as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 230pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">adjusted for any stock splits, recapitalizations, and the like). In such case, the number of exercise shares <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 242pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">shall be increased to equal the quotient obtained by dividing (a) $8.0 million by (b) the next round price. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 254pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Warrants also have customary antidilution protection provisions.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 274pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The aggregate fair value of the Warrants issued in connection with the initial Credit Agreement and the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 286pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">amended Credit Agreement was $4.3 million and $3.5 million, respectively, at issuance and was <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 298pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">recognized as a debt discount and recorded as a warrant liability.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 318pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The warrant liabilities were remeasured to fair value as of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 328.04pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 415.83pt; position: absolute; white-space: pre;">, resulting in a loss of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 330pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">$2.3<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 91.45pt; position: absolute; white-space: pre;">&#160;million within the consolidated statement of operations and comprehensive loss. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 350pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The fair value of the common stock warrant liability was determined using the Black-Scholes option <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 362pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">pricing model based on the following weighted average assumptions&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 382pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 402.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 35.25pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.71pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 7.89pt; position: absolute; text-decoration: none; white-space: pre;">Year Ended<font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="font-size: 12pt; line-height: 6.55pt; position: absolute; top: 14.51pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 3.38pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="font-size: 12pt; line-height: 6.55pt; position: absolute; top: 25.31pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 22.62pt; position: absolute; text-decoration: none; white-space: pre;">2023<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 35.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Stock price<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 52.06pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 54.370000000000005pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 54.660000000000004pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 54.81pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 54.830000000000005pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 35.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 30.86pt;"></font></font><font style="left: 39.050000000000004pt; position: absolute;">0.93<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 49.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Exercise price<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 65.4pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 67.71pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 68.86999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 69.44999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 69.6pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 69.67999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 49.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 30.86pt;"></font></font><font style="left: 39.050000000000004pt; position: absolute;">0.01<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 63.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Contractual term (in years)<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 120.92999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 123.24pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 124.39999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 124.69pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 124.71pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 124.72pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 63.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 42.73pt; position: absolute; text-decoration: none; white-space: pre;">7.6<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 78pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Expected volatility<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 82.61pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 83.77pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 84.35pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 84.64pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 84.78999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 84.86999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 84.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 84.89999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 78pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 32.83pt; position: absolute;"><font style="display: inline-block; height: 7.28pt;"></font></font><font style="left: 32.83pt; position: absolute;">84.5<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font><font style="left: 55.61pt; position: absolute;">%<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 92.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Weighted-average risk-free interest rate<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 178.53pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 179.69pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 179.84pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 179.92pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 179.96pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 179.98pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 179.99pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 92.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 32.83pt; position: absolute;"><font style="display: inline-block; height: 7.28pt;"></font></font><font style="left: 32.83pt; position: absolute;">3.88<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font><font style="left: 55.61pt; position: absolute;">%<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 106.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Dividend yield<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 64.86pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 65.01pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 65.09pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 65.11pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 106.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 39.65pt;"></font></font><font style="left: 42.28pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 12.22pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div id="i2341357d54884756b9e9172f0a83cd6b_238" style="position: absolute; top: 518.75pt;"></div><div style="line-height: 8.73pt; position: absolute; top: 518.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">13. Derivative Liability<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 541.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Term Loan contains certain prepayment features, default put option and default interest adjustment <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 553.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">features that were determined to be embedded derivatives requiring bifurcation and separate accounting <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 565.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">as a single compound derivative, as discussed in Note 8. The fair value of the derivative liability was <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 577.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">recorded at the issuance date as a debt discount and reduction to the carrying value of long-term debt on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 589.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the consolidated balance sheet. The derivative liability is remeasured to fair value at each reporting period <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 601.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and the related changes in fair value are recorded on the consolidated statement of operations and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 613.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">comprehensive loss. The Company will continue to adjust the derivative liability for changes in fair value <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 625.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">until the earlier of the consummation of a business combination, in connection with the sale of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 637.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Company or repayment of the Term Loan.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 657.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Estimating fair values of the derivative liability requires the development of significant and subjective <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 669.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">estimates that may, and are likely to, change over the duration of the instrument with related changes in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 681.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">internal and external market factors. Since the derivative financial instrument is initially and subsequently <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 693.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">carried at fair value, the Company&#8217;s income will reflect the volatility in these estimate and assumption <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 705.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">changes.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 295.72pt; position: absolute; text-decoration: none; white-space: pre;">F-31<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"><div style="line-height: 11.64pt; position: absolute; top: 36pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 55.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 180.72pt; position: absolute; text-decoration: none; white-space: pre;">Notes to Consolidated Financial <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 366.64pt; position: absolute; text-decoration: none; white-space: pre;">Statements<font style="display: inline-block; height: 8.73pt;"></font></font></div></div></div><div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 90pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The derivative liability was remeasured to fair value as of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 325.82pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 413.61pt; position: absolute; white-space: pre;">, resulting in a gain of $4.2 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 102pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">million within the consolidated statement of operations and comprehensive loss. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 122pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The fair value of the derivative liability was estimated using a scenario-based analysis comparing the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 134pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">probability-weighted present value of the Term Loan payoff at maturity with and without the bifurcated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 146pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">features. The Company used both the Black-Scholes-Merton and option pricing method to estimate the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 158pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">fair value of the derivative liability because it believes these techniques are reflective of all significant <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 170pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">assumption types and ranges of assumption inputs that market participants would likely consider in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 182pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">transactions involving compound embedded derivatives. The option pricing method was employed as part <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 194pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of a back-solve analysis to the Company&#8217;s Series F Preferred round of financing. The Company&#8217;s <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 206pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">assumptions used in determining the fair value of the derivative liability as of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 411.37pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 499.16pt; position: absolute; white-space: pre;"> is as <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 218pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">follows&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 238pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 387.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 80.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 24pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 0pt; width: 80.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.26pt; width: 80.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 10.88pt; position: absolute; text-decoration: none; white-space: pre;">December 31, <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 14.06pt; width: 80.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 30.12pt; position: absolute; text-decoration: none; white-space: pre;">2023<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 24pt; width: 387.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 387.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Weighted common stock value (minority, non-marketable)<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 257.23pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 259.54pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 259.83pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 259.84pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 24pt; width: 80.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 80.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 39.64pt;"></font></font><font style="left: 47.830000000000005pt; position: absolute;">0.93<font style="display: inline-block; height: 7.28pt; width: 12.22pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 38.25pt; width: 387.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 387.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Debt yield<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 47.07pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 49.38pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 49.67pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 49.82pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 49.830000000000005pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 38.25pt; width: 80.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 80.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 47.83pt; position: absolute;"><font style="display: inline-block; height: 7.28pt;"></font></font><font style="left: 47.83pt; position: absolute;">17.7<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font><font style="left: 70.61pt; position: absolute;">%<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 52.5pt; width: 387.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 387.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Probability of business combination or IPO (with feature)<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 252pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 254.31pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 254.6pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 254.75pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 254.82999999999998pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 52.5pt; width: 80.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 80.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 47.83pt; position: absolute;"><font style="display: inline-block; height: 7.28pt;"></font></font><font style="left: 47.83pt; position: absolute;">70.0<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font><font style="left: 70.61pt; position: absolute;">%<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 66.75pt; width: 387.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 387.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Event date of business combination or IPO (with feature)<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 253.10999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 254.26999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 254.85pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 254.93pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 254.94pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 66.75pt; width: 80.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 80.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 33.16pt; position: absolute; text-decoration: none; white-space: pre;">6&#47;30&#47;2025<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 81pt; width: 387.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 387.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Probability of Default<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 94.82pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 94.97pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 95.05pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 95.08999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 95.11pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 81pt; width: 80.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 80.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 47.83pt; position: absolute;"><font style="display: inline-block; height: 7.28pt;"></font></font><font style="left: 47.83pt; position: absolute;">10.0<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font><font style="left: 70.61pt; position: absolute;">%<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 95.25pt; width: 387.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 387.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Event date of Default<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 95.92999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 98.24pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 99.39999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 99.69pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 99.71pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 99.72pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 95.25pt; width: 80.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 80.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 33.16pt; position: absolute; text-decoration: none; white-space: pre;">9&#47;30&#47;2025<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 109.5pt; width: 387.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 387.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Probability to incur new debt<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 128.16pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 129.32pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 129.9pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 129.94pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 109.5pt; width: 80.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 80.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 53.39pt; position: absolute;"><font style="display: inline-block; height: 7.28pt;"></font></font><font style="left: 53.39pt; position: absolute;">0.0<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font><font style="left: 70.61pt; position: absolute;">%<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 123.75pt; width: 387.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 387.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Event date to incur new debt<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 129.27pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 129.85pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 130pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 130.04pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 130.05pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 123.75pt; width: 80.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 80.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 65.61pt; position: absolute; text-decoration: none; white-space: pre;">n&#47;a<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 138pt; width: 387.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 387.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Probability of change of control<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 139.82999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 139.98pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 140.06pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 140.1pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 140.10999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 138pt; width: 80.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 80.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 47.83pt; position: absolute;"><font style="display: inline-block; height: 7.28pt;"></font></font><font style="left: 47.83pt; position: absolute;">10.0<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font><font style="left: 70.61pt; position: absolute;">%<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 152.25pt; width: 387.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 387.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Event date of change of control<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 140.94pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 143.25pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 144.41pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 144.7pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 144.72pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 152.25pt; width: 80.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 80.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 33.16pt; position: absolute; text-decoration: none; white-space: pre;">6&#47;30&#47;2025<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 166.5pt; width: 387.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 387.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Event date (without feature)<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 125.36999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 127.67999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 128.84pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 129.42000000000002pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 129.57pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 129.65pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 129.67000000000002pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 129.68pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 166.5pt; width: 80.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 80.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 33.16pt; position: absolute; text-decoration: none; white-space: pre;">1&#47;19&#47;2026<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 180.75pt; width: 387.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 387.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Common equity expected volatility<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 154.28pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 154.85999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 155.01pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 155.04999999999998pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 180.75pt; width: 80.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 80.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 8.37pt; position: absolute; text-decoration: none; white-space: pre;">83.60%-85.20%<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 195pt; width: 387.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 387.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Risk-free interest rate<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 98.14999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 99.31pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 99.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 99.92999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 99.94pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 195pt; width: 80.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 80.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 47.83pt; position: absolute;"><font style="display: inline-block; height: 7.28pt;"></font></font><font style="left: 47.83pt; position: absolute;">3.88<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font><font style="left: 70.61pt; position: absolute;">%<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 209.25pt; width: 387.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 387.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Dividend yield<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 64.86pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 65.01pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 65.09pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 65.11pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 387.75pt; position: absolute; top: 209.25pt; width: 80.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 80.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 54.65pt;"></font></font><font style="left: 57.28pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 12.22pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 477.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Debt yield<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 116.44pt; position: absolute; white-space: pre;"> &#8212; Discount rate that reconciles the total fair value of the Warrants and Credit Agreement with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 489.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the transaction value. Debt yield reflects a change in the credit benchmark for a &#8220;CCC&#8221; rated obligation. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 509.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Expected volatility<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 151.98000000000002pt; position: absolute; white-space: pre;"> &#8212; The expected volatility is the class specific volatility, which is estimated using <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 521.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">comparable public company volatility for a similar expected term and indicated value of related stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 533.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">class. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 553.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Risk-free interest rate<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 167.51999999999998pt; position: absolute; white-space: pre;"> &#8212; The risk-free interest rate is interpolated from U.S. Government Constant <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 565.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Maturity Treasury rates for a period corresponding to the expected date of financing or maturity.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 585.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Expected dividend<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 153.68pt; position: absolute; white-space: pre;"> y<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 161.45pt; position: absolute; white-space: pre;">ield<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 177.01pt; position: absolute; white-space: pre;">&#8212; The Company has never paid dividends and has no plans to pay dividends.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div id="i2341357d54884756b9e9172f0a83cd6b_223" style="position: absolute; top: 605.5pt;"></div><div style="line-height: 8.73pt; position: absolute; top: 605.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">14. Equity Incentive Plan<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 627.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In 2009, the Company adopted its 2009 Equity Incentive Plan (the &#8220;Plan&#8221;) which provides for the grant of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 639.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock options to the Company&#8217;s employees, members of the Board of Directors and consultants. Options <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 651.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">granted under the Plan may be either incentive stock options (&#8220;ISOs&#8221;) or nonqualified stock options <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 663.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(&#8220;NSOs&#8221;). ISOs may be granted only to employees. NSOs, Stock Appreciation Rights, Restricted Stock, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 675.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and Restricted Stock Units may be granted to employees, members of the Board of Directors and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 687.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">consultants. As of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 153.07999999999998pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 240.87pt; position: absolute; white-space: pre;">, the Company reserved <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 350.3pt; position: absolute; text-decoration: none; white-space: pre;">29,741,957<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 400.32pt; position: absolute; white-space: pre;"> shares for issuance under the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 699.9pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Plan.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 295.72pt; position: absolute; text-decoration: none; white-space: pre;">F-32<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"><div style="line-height: 11.64pt; position: absolute; top: 36pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 55.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 180.72pt; position: absolute; text-decoration: none; white-space: pre;">Notes to Consolidated Financial <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 366.64pt; position: absolute; text-decoration: none; white-space: pre;">Statements<font style="display: inline-block; height: 8.73pt;"></font></font></div></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 90pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Options under the Plan have a term of ten years from the grant date. The option exercise price will be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 102pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">determined by the Board of Directors, but will be no less than 100% of the fair market value per share on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 114pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the date of grant. In addition, in the case of an ISO granted to an employee who owns stock representing <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 126pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">more than 10% of the voting power of all classes of stock of the Company, the per share exercise price <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 138pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">will be no less than 110% of the fair market value per share on the date of grant. Through December 31, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 150pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2023, options granted generally vest over (i) four years with 25% vesting on the first anniversary of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 162pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">issuance date and 1&#47;48th per month thereafter or (ii) vesting monthly in equal installments over four <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 174pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">years.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 194pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Stock<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 96.99pt; position: absolute; white-space: pre;"> option activity under the Company&#8217;s 2009 Equity Incentive Plan is set forth below (in thousands, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 206pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">except share and per share amounts)&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 226pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 156pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 60pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 60pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 60pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 60pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 60pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 56.25pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 156pt; position: absolute; top: 0pt; width: 60pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 24.71pt; width: 60pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 15pt; position: absolute; text-decoration: none; white-space: pre;">Shares <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 35.51pt; width: 60pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 3.02pt; position: absolute; text-decoration: none; white-space: pre;">Available for <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 46.31pt; width: 60pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 18.01pt; position: absolute; text-decoration: none; white-space: pre;">Grant<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 219pt; position: absolute; top: 0pt; width: 60pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 35.51pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 7.52pt; position: absolute; text-decoration: none; white-space: pre;">Number of <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 46.31pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 13.02pt; position: absolute; text-decoration: none; white-space: pre;">Options<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 282pt; position: absolute; top: 0pt; width: 60pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.11pt; width: 60pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 13.76pt; position: absolute; text-decoration: none; white-space: pre;">Awards <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 13.91pt; width: 60pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 8.28pt; position: absolute; text-decoration: none; white-space: pre;">Weighted-<font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 24.71pt; width: 60pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 12.26pt; position: absolute; text-decoration: none; white-space: pre;">Average <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 35.51pt; width: 60pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 11.5pt; position: absolute; text-decoration: none; white-space: pre;">Exercise <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 46.31pt; width: 60pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 19pt; position: absolute; text-decoration: none; white-space: pre;">Price<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 345pt; position: absolute; top: 0pt; width: 60pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.11pt; width: 60pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 8.28pt; position: absolute; text-decoration: none; white-space: pre;">Weighted-<font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 13.91pt; width: 60pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 12.26pt; position: absolute; text-decoration: none; white-space: pre;">Average <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 24.71pt; width: 60pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 7.02pt; position: absolute; text-decoration: none; white-space: pre;">Remaining <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 35.51pt; width: 60pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 5.03pt; position: absolute; text-decoration: none; white-space: pre;">Contractual <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 46.31pt; width: 60pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 5.52pt; position: absolute; text-decoration: none; white-space: pre;">Life (Years)<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 408pt; position: absolute; top: 0pt; width: 60pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 24.71pt; width: 60pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 7.77pt; position: absolute; text-decoration: none; white-space: pre;">Aggregate<font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 35.51pt; width: 60pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 12.51pt; position: absolute; text-decoration: none; white-space: pre;">Intrinsic<font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 46.31pt; width: 60pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 18pt; position: absolute; text-decoration: none; white-space: pre;">Value<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 56.25pt; width: 156pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 156pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Balance at December 31, 2022<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 140.41pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 142.72pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 143.01pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 143.09pt; position: absolute; text-decoration: none; white-space: pre;"> . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 156pt; position: absolute; top: 56.25pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 8.83pt;"></font></font><font style="left: 11.46pt; position: absolute;">4,312,292<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 219pt; position: absolute; top: 56.25pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 8.83pt;"></font></font><font style="left: 11.46pt; position: absolute;">9,420,310<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 282pt; position: absolute; top: 56.25pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 28.28pt;"></font></font><font style="left: 36.470000000000006pt; position: absolute;">9.77<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 345pt; position: absolute; top: 56.25pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 37.92pt; position: absolute; text-decoration: none; white-space: pre;">6.17<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 408pt; position: absolute; top: 56.25pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 22.72pt;"></font></font><font style="left: 30.91pt; position: absolute;">3,561<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 70.5pt; width: 156pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 156pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Authorized<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 50.410000000000004pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 52.720000000000006pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 53.010000000000005pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 53.09pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 156pt; position: absolute; top: 70.5pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 3.27pt;"></font></font><font style="left: 5.9pt; position: absolute;">16,018,730<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 219pt; position: absolute; top: 70.5pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 43.29pt;"></font></font><font style="left: 45.92pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 282pt; position: absolute; top: 70.5pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 43.29pt;"></font></font><font style="left: 45.92pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 84.75pt; width: 156pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 156pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Options granted<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 73.74pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 76.05pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 77.21pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 77.78999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 77.86999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 77.91pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 77.92999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 77.94pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 156pt; position: absolute; top: 84.75pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt;"></font></font><font style="left: 2.63pt; position: absolute;">(16,881,199)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 219pt; position: absolute; top: 84.75pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 3.27pt;"></font></font><font style="left: 5.9pt; position: absolute;">16,881,199<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 282pt; position: absolute; top: 84.75pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 28.28pt;"></font></font><font style="left: 36.470000000000006pt; position: absolute;">0.76<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 99pt; width: 156pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 156pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Options exercised<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 82.63pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 83.21pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 83.28999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 83.31pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 156pt; position: absolute; top: 99pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 43.29pt;"></font></font><font style="left: 45.92pt; position: absolute;">&#8212;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 219pt; position: absolute; top: 99pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 13.83pt;"></font></font><font style="left: 16.46pt; position: absolute;">(291,756)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 282pt; position: absolute; top: 99pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 28.28pt;"></font></font><font style="left: 36.470000000000006pt; position: absolute;">2.02<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 113.25pt; width: 156pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 156pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Options forfeited<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 75.94pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 77.1pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 77.67999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 77.97pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 78.11999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 78.14pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 78.14999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 156pt; position: absolute; top: 113.25pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 8.83pt;"></font></font><font style="left: 11.46pt; position: absolute;">1,863,212<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 219pt; position: absolute; top: 113.25pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 5.5pt;"></font></font><font style="left: 8.129999999999999pt; position: absolute;">(1,863,212)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 282pt; position: absolute; top: 113.25pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 28.28pt;"></font></font><font style="left: 36.470000000000006pt; position: absolute;">6.11<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 127.5pt; width: 156pt;"><div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 3.32pt; width: 156pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Balance at <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 52.620000000000005pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 140.41pt; position: absolute; text-decoration: none; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 143.18pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 143.32999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 143.35pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 143.35999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 156pt; position: absolute; top: 127.5pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 8.83pt;"></font></font><font style="left: 11.46pt; position: absolute;">5,313,035<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 219pt; position: absolute; top: 127.5pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 3.27pt;"></font></font><font style="left: 5.9pt; position: absolute;">24,146,541<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 282pt; position: absolute; top: 127.5pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 28.28pt;"></font></font><font style="left: 36.470000000000006pt; position: absolute;">1.41<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 345pt; position: absolute; top: 127.5pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 37.92pt; position: absolute; text-decoration: none; white-space: pre;">8.19<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 408pt; position: absolute; top: 127.5pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 42.17pt;"></font></font><font style="left: 50.36pt; position: absolute;">&#8211;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 26.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 141.75pt; width: 156pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 156pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Vested and exercisable, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 15.32pt; width: 156pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 11.63pt; position: absolute; text-decoration: none; white-space: pre;">December 31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 99.42pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 101.72999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 102.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 102.97pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 102.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 103pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 219pt; position: absolute; top: 141.75pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 15.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 8.83pt;"></font></font><font style="left: 11.46pt; position: absolute;">7,463,990<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 282pt; position: absolute; top: 141.75pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 15.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 28.28pt;"></font></font><font style="left: 36.470000000000006pt; position: absolute;">2.39<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 345pt; position: absolute; top: 141.75pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 15.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.84pt;"></font></font><font style="left: 36.470000000000006pt; position: absolute;">5.59<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 408pt; position: absolute; top: 141.75pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 15.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 42.17pt;"></font></font><font style="left: 50.36pt; position: absolute;">&#8211;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 26.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 168pt; width: 156pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 156pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Vested and expected to vest, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 15.32pt; width: 156pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 11.63pt; position: absolute; text-decoration: none; white-space: pre;">December 31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 99.42pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 101.72999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 102.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 102.97pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 102.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 103pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 219pt; position: absolute; top: 168pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 15.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 3.27pt;"></font></font><font style="left: 5.9pt; position: absolute;">24,146,541<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 282pt; position: absolute; top: 168pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 15.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 28.28pt;"></font></font><font style="left: 36.470000000000006pt; position: absolute;">1.41<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 345pt; position: absolute; top: 168pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 15.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 37.92pt; position: absolute; text-decoration: none; white-space: pre;">8.19<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 408pt; position: absolute; top: 168pt; width: 60pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 15.37pt; width: 60pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 42.17pt;"></font></font><font style="left: 50.36pt; position: absolute;">&#8211;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 436.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">The weighted-average grant date fair value of options granted during the year ended December 31, 2023&#160; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 448.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">was $0.43 per share. The total grant date fair value of options vested was <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 399.52pt; position: absolute; text-decoration: none; white-space: pre;">$3.2 million <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 452.84pt; position: absolute; text-decoration: none; white-space: pre;">during the year <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 460.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">ended December 31, 2023.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 480.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The following table summarizes information about stock options outstanding as of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 434.72pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 522.51pt; position: absolute; white-space: pre;">&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 500.25pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 126.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 56.25pt;"><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 126.75pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 35.51pt; width: 126.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 44.15pt; position: absolute; text-decoration: none; white-space: pre;">Range of<font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 46.31pt; width: 126.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 30.12pt; position: absolute; text-decoration: none; white-space: pre;">Exercise Prices<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 129.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.11pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 15.64pt; position: absolute; text-decoration: none; white-space: pre;">Number <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 13.91pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 6.16pt; position: absolute; text-decoration: none; white-space: pre;">Outstanding <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 24.71pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 22.13pt; position: absolute; text-decoration: none; white-space: pre;">as of <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="font-size: 12pt; line-height: 6.55pt; position: absolute; top: 35.51pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 3.38pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="font-size: 12pt; line-height: 6.55pt; position: absolute; top: 46.31pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 22.62pt; position: absolute; text-decoration: none; white-space: pre;">2023<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.11pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 10.9pt; position: absolute; text-decoration: none; white-space: pre;">Weighted-<font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 13.91pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 14.88pt; position: absolute; text-decoration: none; white-space: pre;">Average <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 24.71pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 9.64pt; position: absolute; text-decoration: none; white-space: pre;">Remaining <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 35.51pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 7.65pt; position: absolute; text-decoration: none; white-space: pre;">Contractual <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 46.31pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 8.14pt; position: absolute; text-decoration: none; white-space: pre;">Life (Years)<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 13.91pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 10.9pt; position: absolute; text-decoration: none; white-space: pre;">Weighted-<font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 24.71pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 14.88pt; position: absolute; text-decoration: none; white-space: pre;">Average <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 35.51pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 14.12pt; position: absolute; text-decoration: none; white-space: pre;">Exercise <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 46.31pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 21.62pt; position: absolute; text-decoration: none; white-space: pre;">Price<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.11pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 15.64pt; position: absolute; text-decoration: none; white-space: pre;">Number <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 13.91pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 7.63pt; position: absolute; text-decoration: none; white-space: pre;">Exercisable <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 24.71pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 22.13pt; position: absolute; text-decoration: none; white-space: pre;">as of<font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="font-size: 12pt; line-height: 6.55pt; position: absolute; top: 35.51pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 3.38pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="font-size: 12pt; line-height: 6.55pt; position: absolute; top: 46.31pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 22.62pt; position: absolute; text-decoration: none; white-space: pre;">2023<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 13.91pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 10.9pt; position: absolute; text-decoration: none; white-space: pre;">Weighted-<font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 24.71pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 14.88pt; position: absolute; text-decoration: none; white-space: pre;">Average <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 35.51pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 14.12pt; position: absolute; text-decoration: none; white-space: pre;">Exercise <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 46.31pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 21.62pt; position: absolute; text-decoration: none; white-space: pre;">Price<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 56.25pt; width: 126.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 126.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">$0.76 - $0.76<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 61.52pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 63.830000000000005pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 64.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 65.57pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 129.75pt; position: absolute; top: 56.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 8.52pt;"></font></font><font style="left: 11.149999999999999pt; position: absolute;">16,568,771<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 56.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 43.17pt; position: absolute; text-decoration: none; white-space: pre;">9.49<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 56.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 41.720000000000006pt; position: absolute;">0.76<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 56.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 14.08pt;"></font></font><font style="left: 16.71pt; position: absolute;">1,618,070<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 56.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 41.720000000000006pt; position: absolute;">0.76<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 70.5pt; width: 126.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 126.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">$2.06 - $2.06<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 61.52pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 63.830000000000005pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 64.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 65.57pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 129.75pt; position: absolute; top: 70.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 22.41pt;"></font></font><font style="left: 25.04pt; position: absolute;">766,695<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 70.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 43.17pt; position: absolute; text-decoration: none; white-space: pre;">0.75<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 70.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 41.720000000000006pt; position: absolute;">2.06<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 70.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 22.41pt;"></font></font><font style="left: 25.04pt; position: absolute;">766,695<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 70.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 41.720000000000006pt; position: absolute;">2.06<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 84.75pt; width: 126.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 126.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">$2.85 - $2.85<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 61.52pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 63.830000000000005pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 64.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 65.57pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 129.75pt; position: absolute; top: 84.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 14.08pt;"></font></font><font style="left: 16.71pt; position: absolute;">6,632,075<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 84.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 43.17pt; position: absolute; text-decoration: none; white-space: pre;">5.93<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 84.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 41.720000000000006pt; position: absolute;">2.85<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 84.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 14.08pt;"></font></font><font style="left: 16.71pt; position: absolute;">4,900,225<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 84.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 41.720000000000006pt; position: absolute;">2.85<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 99pt; width: 126.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 126.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">$4.20 - $4.20<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 61.52pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 63.830000000000005pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 64.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 65.57pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 129.75pt; position: absolute; top: 99pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">15,000<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 99pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 43.17pt; position: absolute; text-decoration: none; white-space: pre;">1.60<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 99pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 41.720000000000006pt; position: absolute;">4.20<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 99pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">15,000<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 99pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 41.720000000000006pt; position: absolute;">4.20<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 113.25pt; width: 126.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 126.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">$4.24 - $4.24<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 61.52pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 63.830000000000005pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 64.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 65.57pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 129.75pt; position: absolute; top: 113.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 22.41pt;"></font></font><font style="left: 25.04pt; position: absolute;">104,000<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 113.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 43.17pt; position: absolute; text-decoration: none; white-space: pre;">2.41<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 113.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 41.720000000000006pt; position: absolute;">4.24<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 113.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 22.41pt;"></font></font><font style="left: 25.04pt; position: absolute;">104,000<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 113.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 41.720000000000006pt; position: absolute;">4.24<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 127.5pt; width: 126.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 126.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">$9.58 - $9.58<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 61.52pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 63.830000000000005pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 64.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 65.57pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 129.75pt; position: absolute; top: 127.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">60,000<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 127.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 43.17pt; position: absolute; text-decoration: none; white-space: pre;">4.86<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 127.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 41.720000000000006pt; position: absolute;">9.58<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 127.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">60,000<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 127.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 41.720000000000006pt; position: absolute;">9.58<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 141.75pt; width: 126.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 126.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">$0.76 - $9.58<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 61.52pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 63.830000000000005pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 64.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 65.57pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 129.75pt; position: absolute; top: 141.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 8.52pt;"></font></font><font style="left: 11.149999999999999pt; position: absolute;">24,146,541<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 198pt; position: absolute; top: 141.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 43.17pt; position: absolute; text-decoration: none; white-space: pre;">8.19<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 266.25pt; position: absolute; top: 141.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 41.720000000000006pt; position: absolute;">1.41<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 334.5pt; position: absolute; top: 141.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 14.08pt;"></font></font><font style="left: 16.71pt; position: absolute;">7,463,990<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 141.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 41.720000000000006pt; position: absolute;">2.39<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 672.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 684.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stock options and the fair value of the Company&#8217;s common stock for stock options that were in-the-money <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 696.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">at each reporting period. The aggregate intrinsic value of stock options exercised for the year ended <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 708.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 159.79000000000002pt; position: absolute; white-space: pre;"> was <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 183.11pt; position: absolute; text-decoration: none; white-space: pre;">$4<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 194.23000000000002pt; position: absolute; white-space: pre;">,000.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 295.72pt; position: absolute; text-decoration: none; white-space: pre;">F-33<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"><div style="line-height: 11.64pt; position: absolute; top: 36pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 55.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 180.72pt; position: absolute; text-decoration: none; white-space: pre;">Notes to Consolidated Financial <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 366.64pt; position: absolute; text-decoration: none; white-space: pre;">Statements<font style="display: inline-block; height: 8.73pt;"></font></font></div></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 90pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Stock-Based Compensation<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 110pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company estimated the fair value of stock options using the Black-Scholes option-pricing model <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 122pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">based on the following weighted-average assumptions for the year ended <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 399.23pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 487.02pt; position: absolute; white-space: pre;">&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 142pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 398.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 69.75pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 35.25pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 398.25pt; position: absolute; top: 0pt; width: 69.75pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.71pt; width: 69.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 10.14pt; position: absolute; text-decoration: none; white-space: pre;">Year Ended<font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="font-size: 12pt; line-height: 6.55pt; position: absolute; top: 14.51pt; width: 69.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 5.63pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="font-size: 12pt; line-height: 6.55pt; position: absolute; top: 25.31pt; width: 69.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 24.87pt; position: absolute; text-decoration: none; white-space: pre;">2023<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 35.25pt; width: 398.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 398.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Expected life (in years)<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 104.27pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 105.42999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 105.47pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 105.49pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 105.5pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 398.25pt; position: absolute; top: 35.25pt; width: 69.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 69.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 53.23pt; position: absolute; text-decoration: none; white-space: pre;">6.0<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 49.5pt; width: 398.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 398.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Expected volatility<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 82.61pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 84.92pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 85.21pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 85.28999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 85.33pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 85.33999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 398.25pt; position: absolute; top: 49.5pt; width: 69.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 69.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 8.99pt; position: absolute; text-decoration: none; white-space: pre;">54.7%-55.7%<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 63.75pt; width: 398.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 398.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Risk-free interest rate<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 98.14999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 99.31pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 99.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 100.17999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 100.33pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 100.36999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 100.39pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 100.39999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 398.25pt; position: absolute; top: 63.75pt; width: 69.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 69.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 42.89pt; position: absolute;"><font style="display: inline-block; height: 7.28pt;"></font></font><font style="left: 42.89pt; position: absolute;">4.2<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font><font style="left: 60.11pt; position: absolute;">%<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 78pt; width: 398.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 398.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Dividend yield<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 64.86pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 65.44pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 65.52pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 65.56pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 398.25pt; position: absolute; top: 78pt; width: 69.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 69.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 51.22pt; position: absolute;"><font style="display: inline-block; height: 7.28pt;"></font></font><font style="left: 51.22pt; position: absolute;">&#8211;<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font><font style="left: 60.11pt; position: absolute;">%<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 250.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The significant assumptions used in these calculations are summarized as follows&#58; <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 270.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Fair value of common stock<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 194.19pt; position: absolute; white-space: pre;">. Because there has been no public market for the Company&#8217;s common stock, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 282.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the fair value of common stock shares underlying stock options has historically been determined by the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 294.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Board of Directors at the time of option grant by considering independent valuation performed by third-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 306.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">party valuation firm as well as a number of objective and subjective factors, including valuation of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 318.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">comparable companies, sales of convertible preferred stock to unrelated third parties, operating and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 330.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">financial performance, the lack of liquidity of capital stock and general and industry specific economic <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 342.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">outlook, among other factors. The fair value of common stock was determined in accordance with <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 354.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">applicable elements of the American Institute of Certified Public Accountants Practice Aid, Valuation of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 366.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Privately-Held-Company Equity Securities Issued as Compensation. In 2023, the Company considered <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 378.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the stay private scenario and IPO exit scenario. In the stay private scenario, three market methodologies <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 390.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">were employed including (i) a market indexing valuation analysis based on the Series F Preferred <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 402.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">financing round, (ii) a guideline public company analysis based on the Company&#8217;s historical and forecast <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 414.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">operating metrics, and (iii) a guideline transaction analysis based on the Company&#8217;s historical and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 426.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">forecast operating metrics. In the IPO exit scenario, the total equity value was estimated based on the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 438.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">expected timing, offering size and pre-money valuation. A hybrid method was used to allocate equity <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 450.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">value to common stock under the stay private and IPO scenarios.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 470.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Expected term<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 136.43pt; position: absolute; white-space: pre;">. The expected term of stock options represents the weighted-average period the stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 482.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">options are expected to remain outstanding. The Company does not have sufficient historical exercise <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 494.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and post-vesting termination activity to provide accurate data for estimating the expected term of options <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 506.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and has opted to use the &#8220;simplified method,&#8221; whereby the expected term equals the arithmetic average <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 518.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of the vesting term and the original contractual term of the option. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 538.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Expected Volatility<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 153.64pt; position: absolute; white-space: pre;">. As the Company is not publicly traded, the expected volatility for the Company&#8217;s stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 550.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">options was determined by using an average of historical volatilities of selected industry peers deemed to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 562.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">be comparable to the Company&#8217;s business corresponding to the expected term of the awards. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 582.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Risk-free interest rate<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 167.51999999999998pt; position: absolute; white-space: pre;">. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 594.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">time of grant for zero-coupon U.S. Treasury notes with maturities corresponding to the expected term of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 606.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the awards. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 626.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Expected dividend yield<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 177.01pt; position: absolute; white-space: pre;">. The expected dividend rate is zero as the Company currently has no history or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 638.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">expectation of declaring dividends on its common stock. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 658.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company also issues stock options with vesting based upon completion of performance goals. The <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 670.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">fair value for these performance-based awards is recognized over the period during which the goals are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 682.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">to be achieved. Stock-based compensation expense recognized at fair value includes the impact of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 694.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">estimated probability that the goals would be achieved, which is assessed prior to the requisite service <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 706.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">period for the specific goals.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 295.72pt; position: absolute; text-decoration: none; white-space: pre;">F-34<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"><div style="line-height: 11.64pt; position: absolute; top: 36pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 55.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 180.72pt; position: absolute; text-decoration: none; white-space: pre;">Notes to Consolidated Financial <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 366.64pt; position: absolute; text-decoration: none; white-space: pre;">Statements<font style="display: inline-block; height: 8.73pt;"></font></font></div></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 90pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Total stock-based compensation expense is as follows (in thousands)&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 110pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 402.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 35.25pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.71pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 7.89pt; position: absolute; text-decoration: none; white-space: pre;">Year Ended<font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="font-size: 12pt; line-height: 6.55pt; position: absolute; top: 14.51pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 3.38pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="font-size: 12pt; line-height: 6.55pt; position: absolute; top: 25.31pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 22.62pt; position: absolute; text-decoration: none; white-space: pre;">2023<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 35.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Cost of revenue<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 73.17999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 74.33999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 74.92pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 74.94pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 35.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 36.3pt;"></font></font><font style="left: 44.49pt; position: absolute;">440<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 49.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Research and development<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 6.5pt; font-style: normal; font-weight: normal; left: 124.88pt; position: absolute; text-decoration: none; top: -2.548pt; vertical-align: super; white-space: pre;">(1)<font style="display: inline-block; height: 4.732pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 132.81pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 133.97pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 134.54999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 134.84pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 134.88pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 134.9pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 134.91pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 49.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">3,339<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 63.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Selling, general and administrative<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 155.4pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 157.71pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 158.87pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 159.45pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 159.6pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 159.68pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 63.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">8,722<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 78pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Total stock-based compensation expense <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 188.76pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 189.92pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 190pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 78pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 22.41pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">12,501<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 5.46pt; position: absolute; top: 210.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(1)<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Includes stock-based compensation expense of $627,000 related to a repurchase of common shares from one employee, as described <font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 219.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">below.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 236.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">As of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 97.53pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 185.32pt; position: absolute; white-space: pre;">, total unrecognized stock-based compensation costs related to unvested stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 248.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">options was <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 127.55pt; position: absolute; text-decoration: none; white-space: pre;">$20.7<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 152.56pt; position: absolute; white-space: pre;"> million, which is expected to be recognized over a remaining weighted-average period <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 260.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 83.1pt; position: absolute; text-decoration: none; white-space: pre;">3.22<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 102.55pt; position: absolute; white-space: pre;"> years.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 280.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In January 2023, the fair value of the Company&#8217;s common stock declined from $14.27 to $0.76 per share, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 292.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">prompting the Company to reduce the exercise price of certain stock options to $0.76, effective July&#160;10, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 304.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2023. No other changes to the stock options&#8217; terms were made. The Company calculated the incremental <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 316.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">fair value by calculating the fair value of the award immediately before and immediately after the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 328.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">modification. The fair value of the award immediately before the repricing is based on assumptions <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 340.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(including volatility, expected term and risk free interest rate) that reflect the facts and circumstances on <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 352.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the modification date and therefore, differ from the fair value calculated on the grant date. The average <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 364.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">additional compensation per award from the modification was $0.09 and the aggregate incremental <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 376.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">expense was $649,000, of which $340,000 was immediately recognized on the modification date and the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 388.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">remaining amount is recognized over the options&#8217; remaining requisite service period.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 408.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In March 2023, the Board of Directors approved a repurchase of 300,000 common shares from an <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 420.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">employee of the Company at a purchase price of $2.8505 per share for total consideration of $855,000. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 432.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The fair value of the repurchased common shares was $228,000, and the difference between the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 444.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">repurchase price and fair value of the common shares of $627,000 was recorded as stock-based <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 456.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">compensation expense within research and development expense in the consolidated statement of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 468.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">operations and comprehensive loss.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div id="i2341357d54884756b9e9172f0a83cd6b_207" style="position: absolute; top: 488.25pt;"></div><div style="line-height: 8.73pt; position: absolute; top: 488.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">15. Employee Retirement Plan<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 510.65pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company has a qualified retirement plan under section 401(k) of the Internal Revenue Code (&#8220;IRC&#8221;) <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 522.65pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">under which participants may contribute up to 100% of their eligible compensation, subject to maximum <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 534.65pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">deferral limits specified by the IRC. The Company may make matching contributions of up to 4.0% of an <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 546.65pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">employee&#8217;s eligible compensation, subject to conditions specified by the IRC. During the year ended <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 558.65pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 159.79000000000002pt; position: absolute; white-space: pre;">, the Company&#8217;s matching contributions totaled <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 370.13pt; position: absolute; text-decoration: none; white-space: pre;">$1.4<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 389.58pt; position: absolute; white-space: pre;"> million.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 295.72pt; position: absolute; text-decoration: none; white-space: pre;">F-35<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"><div style="line-height: 11.64pt; position: absolute; top: 36pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 55.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 180.72pt; position: absolute; text-decoration: none; white-space: pre;">Notes to Consolidated Financial <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 366.64pt; position: absolute; text-decoration: none; white-space: pre;">Statements<font style="display: inline-block; height: 8.73pt;"></font></font></div></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_193" style="position: absolute; top: 90pt;"></div><div style="line-height: 8.73pt; position: absolute; top: 90pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">16. Net Loss Per Share Attributable to Common Stockholders<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 112.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The following table sets forth the computation of basic and diluted net loss per share attributable to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 124.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">common stockholders (in thousands, except share and per share amounts)&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 144.4pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 402.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 35.25pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.71pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 7.89pt; position: absolute; text-decoration: none; white-space: pre;">Year Ended <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="font-size: 12pt; line-height: 6.55pt; position: absolute; top: 14.51pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 3.38pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="font-size: 12pt; line-height: 6.55pt; position: absolute; top: 25.31pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 22.62pt; position: absolute; text-decoration: none; white-space: pre;">2023<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 35.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Numerator&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 49.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Net loss<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 38.730000000000004pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 39.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 39.970000000000006pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 39.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 40pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 49.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 19.08pt;"></font></font><font style="left: 27.27pt; position: absolute;">(95,655)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 63.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Cumulative dividends on Series C redeemable convertible preferred stock<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 328.73pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 329.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 329.96999999999997pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 329.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 330pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 63.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 30.2pt;"></font></font><font style="left: 32.83pt; position: absolute;">(1,239)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 78pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Deemed dividend upon down round of redeemable convertible preferred stock<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 347.65999999999997pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 348.82pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 349.4pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 349.69pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 349.84pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 349.88pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 349.9pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 78pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 24.64pt;"></font></font><font style="left: 27.27pt; position: absolute;">(26,794)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 92.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Net loss attributable to common stockholders <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 204.81pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 204.96pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 205.04pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 205.07999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 205.1pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 205.10999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 92.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 13.52pt;"></font></font><font style="left: 21.709999999999997pt; position: absolute;">(123,688)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 106.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Denominator&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 120.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Weighted-average shares used to compute net loss per share, basic and diluted<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 356.33pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 358.64pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 359.21999999999997pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 359.51pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 359.65999999999997pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 359.74pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 359.76pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 359.77pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 120.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 8.52pt;"></font></font><font style="left: 11.149999999999999pt; position: absolute;">14,265,293<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 135pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Net loss per share attributable to common stockholders, basic and diluted<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 327.59pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 328.75pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 329.33pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 329.62pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 329.77pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 329.85pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 329.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 329.9pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 135pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 30.2pt;"></font></font><font style="left: 38.39pt; position: absolute;">(8.67)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 309.65pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The following outstanding shares of potentially dilutive securities were excluded from the computation of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 321.65pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">diluted net loss per share attributable to common stockholders for the period presented because including <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 333.65pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">them would have been antidilutive&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 353.65pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 402.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 24pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.26pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 3.38pt; position: absolute; text-decoration: none; white-space: pre;">December 31, <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 14.06pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 22.62pt; position: absolute; text-decoration: none; white-space: pre;">2023<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 24pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Redeemable convertible preferred stock<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 179.85999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 180.01pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 180.09pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 180.10999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 24pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 2.96pt;"></font></font><font style="left: 5.59pt; position: absolute;">122,231,454<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 38.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Outstanding options to purchase common stock<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 213.73pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 214.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 214.97pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 214.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 215pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 38.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 8.52pt;"></font></font><font style="left: 11.149999999999999pt; position: absolute;">24,146,541<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 52.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Common stock warrants<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 110.39pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 112.69999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 113.86pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 114.44pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 114.58999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 114.67pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 114.67999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 52.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 14.08pt;"></font></font><font style="left: 16.71pt; position: absolute;">4,811,190<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 66.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Total <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 26.509999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 28.82pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 29.4pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 29.689999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 29.77pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 29.779999999999998pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 66.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 2.96pt;"></font></font><font style="left: 5.59pt; position: absolute;">151,189,185<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div id="i2341357d54884756b9e9172f0a83cd6b_178" style="position: absolute; top: 450.65pt;"></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 450.65pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">17. Income Taxes<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 473.05pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The components of net loss before income taxes are as follows (in thousands)&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 493.05pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 402.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 24pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.26pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 3.38pt; position: absolute; text-decoration: none; white-space: pre;">December 31, <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 14.06pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 22.62pt; position: absolute; text-decoration: none; white-space: pre;">2023<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 24pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">United States<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 62.61pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 63.77pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 64.35pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 64.64pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 64.78999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 64.87pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 64.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 64.9pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 24pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 19.08pt;"></font></font><font style="left: 27.27pt; position: absolute;">(95,634)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 38.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">International<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 57.63pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 58.79pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 59.370000000000005pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 59.660000000000004pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 59.81pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 59.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 59.900000000000006pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 38.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 41.86pt;"></font></font><font style="left: 44.49pt; position: absolute;">526<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 52.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Net loss before income taxes<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 131.5pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 133.81pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 134.39pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 134.68pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 134.76pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 134.78pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 52.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 19.08pt;"></font></font><font style="left: 27.27pt; position: absolute;">(95,108)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 575.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">For the year ended <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 159.20999999999998pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 247pt; position: absolute; text-decoration: none; white-space: pre;">, the Company did <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 330.87pt; position: absolute; text-decoration: none; white-space: pre;">not<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 344.76pt; position: absolute; text-decoration: none; white-space: pre;"> record any federal or state provision for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 587.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">income tax expense. For the year ended <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 253.65pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 341.44pt; position: absolute; text-decoration: none; white-space: pre;">, the Company recorded an income tax <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 599.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">provision of $547,000 from international jurisdictions.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 619.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">The following table presents a reconciliation of the statutory federal rate and the Company&#8217;s effective tax <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 631.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">rate for the year end December 31, 2023 (in thousands)&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 295.72pt; position: absolute; text-decoration: none; white-space: pre;">F-36<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"><div style="line-height: 11.64pt; position: absolute; top: 36pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 55.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 180.72pt; position: absolute; text-decoration: none; white-space: pre;">Notes to Consolidated Financial <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 366.64pt; position: absolute; text-decoration: none; white-space: pre;">Statements<font style="display: inline-block; height: 8.73pt;"></font></font></div></div></div><div><div style="position: absolute; top: 90pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 402.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 35.25pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.71pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 7.89pt; position: absolute; text-decoration: none; white-space: pre;">Year Ended <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="font-size: 12pt; line-height: 6.55pt; position: absolute; top: 14.51pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 3.38pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="font-size: 12pt; line-height: 6.55pt; position: absolute; top: 25.31pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 22.62pt; position: absolute; text-decoration: none; white-space: pre;">2023<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 35.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Tax at federal statutory rate<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 123.69999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 124.86pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 124.94pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 124.97999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 125pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 35.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 19.08pt;"></font></font><font style="left: 27.27pt; position: absolute;">(20,003)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 49.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">State taxes, net of federal benefit<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 149.24pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 149.82pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 149.97pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 150.04999999999998pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 49.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 30.2pt;"></font></font><font style="left: 32.83pt; position: absolute;">(4,032)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 63.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Change in valuation allowance<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 138.21pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 139.37pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 139.66pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 139.81pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 139.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 139.93pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 139.95pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 139.96pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 63.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">20,418<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 78pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Stock-based compensation<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 123.19999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 124.36pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 124.94pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 78pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">3,722<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 92.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Fair value remeasurement<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 119.28999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 119.86999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 120.02pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 120.03999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 120.05pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 92.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">1,075<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 106.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">R&#38;D credits<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 55.940000000000005pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 58.25pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 59.410000000000004pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 59.7pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 59.720000000000006pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 106.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 38.53pt;"></font></font><font style="left: 41.160000000000004pt; position: absolute;">(391)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 120.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Foreign rate differential<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 105.19999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 107.50999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 108.67pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 109.25pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 109.53999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 109.61999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 109.66pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 120.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 44.09pt;"></font></font><font style="left: 46.720000000000006pt; position: absolute;">(50)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 135pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Other<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 27.619999999999997pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 28.779999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 29.36pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 29.65pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 29.8pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 29.88pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 29.9pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 135pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 38.53pt;"></font></font><font style="left: 41.160000000000004pt; position: absolute;">(192)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 149.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Provision for income taxes<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 119.83pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 119.97999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 120.06pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 120.1pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 120.11pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 149.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 32.97pt;"></font></font><font style="left: 41.160000000000004pt; position: absolute;">(547)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 269.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Significant components of the net deferred tax assets for federal and state income taxes are as follows (in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 281.5pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">thousands)&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 301.5pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 402.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 35.25pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.71pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 7.89pt; position: absolute; text-decoration: none; white-space: pre;">Year Ended <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="font-size: 12pt; line-height: 6.55pt; position: absolute; top: 14.51pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 3.38pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="font-size: 12pt; line-height: 6.55pt; position: absolute; top: 25.31pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 22.62pt; position: absolute; text-decoration: none; white-space: pre;">2023<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 35.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Deferred tax assets&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 49.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Net operating loss carry forwards<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 161.26999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 163.57999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 164.74pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 164.75pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 49.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 16.85pt;"></font></font><font style="left: 25.04pt; position: absolute;">142,089<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 63.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Research and development credits<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 169.09pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 169.67pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 169.96pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 170pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 170.01999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 170.03pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 63.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">6,586<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 78pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Stock-based compensation<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 135.2pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 137.51pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 138.67000000000002pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 139.25pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 139.54pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 139.62pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 139.66pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 78pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">1,316<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 92.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Accruals and reserves<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 113.52pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 114.67999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 114.97pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 92.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">8,044<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 106.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Fixed asset and intangible asset basis<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 183.51pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 184.67pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 184.96pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 184.97pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 106.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">7,250<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 120.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Operating lease liabilities<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 125.72999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 128.04pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 129.2pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 129.49pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 129.64000000000001pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 129.68pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 129.7pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 129.71pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 120.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 33.53pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">6,791<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 135pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Section 174 research and development capitalization<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 249.09pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 249.67pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 249.96pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 250pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 250.01999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 250.03pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 135pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 30.599999999999998pt; position: absolute;">12,432<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 149.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Total deferred tax assets<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 111.5pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 113.81pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 114.39pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 114.67999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 114.75999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 114.78pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 149.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 22.41pt;"></font></font><font style="left: 25.04pt; position: absolute;">184,508<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 15.75pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="background-color: #ffffff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 179.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Deferred tax liabilities&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 193.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Capitalized implementation costs<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 160.73pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 163.04pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 164.2pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 164.49pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 164.64pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 164.68pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 164.7pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 164.71pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 193.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 38.53pt;"></font></font><font style="left: 41.160000000000004pt; position: absolute;">(756)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 207.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">Operating lease right-of-use assets<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 170.17pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 172.48pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 173.64pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 174.22pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 174.51pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 174.59pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 174.63pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 174.65pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 174.66pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 207.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 30.2pt;"></font></font><font style="left: 32.83pt; position: absolute;">(5,346)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 222pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Total deferred tax liabilities<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 120.38pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 122.69pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 123.85pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 124.42999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 124.58pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 124.66pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 124.67999999999999pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 222pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 30.2pt;"></font></font><font style="left: 32.83pt; position: absolute;">(6,102)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 236.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Deferred tax assets, net<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 108.71pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 109.86999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 109.94999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 109.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 110pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 236.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 22.41pt;"></font></font><font style="left: 25.04pt; position: absolute;">178,406<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 250.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Valuation allowance<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 90.78999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 93.1pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 94.25999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 94.55pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 94.69999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 94.71pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 250.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 13.52pt;"></font></font><font style="left: 21.709999999999997pt; position: absolute;">(178,406)<font style="display: inline-block; height: 7.28pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 582.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">As the Company has incurred annual net operating losses since inception, a full valuation allowance is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 594.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">provided against U.S. net deferred tax assets due to uncertainties regarding the Company&#8217;s ability to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 606.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">realize these assets. The net valuation allowance increased by <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 351.8pt; position: absolute; text-decoration: none; white-space: pre;">$20.4<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 376.81pt; position: absolute; white-space: pre;"> million during the year ended <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 618.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 159.79000000000002pt; position: absolute; white-space: pre;">.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 638.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">As of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 97.53pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 185.32pt; position: absolute; white-space: pre;">, the Company had net operating loss carryforwards of approximately <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 493.61pt; position: absolute; text-decoration: none; white-space: pre;">$517.2<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 524.1800000000001pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 650.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">million&#160;and <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 122.55pt; position: absolute; text-decoration: none; white-space: pre;">$139.7<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 153.12pt; position: absolute; white-space: pre;"> million available to reduce future taxable income, if any, for federal and state income <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 662.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">tax purposes, respectively. Of these amounts, $330.2 million of federal net operating losses are carried <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 674.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">forward indefinitely, and $187.0 million are limited to 80% of future taxable income. The remaining federal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 686.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">net operating losses will expire starting in 2030. Utilization of net operating loss carryforwards may be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 698.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">subject to an annual limitation in certain situations where changes occur in the stock ownership of a <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 295.72pt; position: absolute; text-decoration: none; white-space: pre;">F-37<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"><div style="line-height: 11.64pt; position: absolute; top: 36pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 55.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 180.72pt; position: absolute; text-decoration: none; white-space: pre;">Notes to Consolidated Financial <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 366.64pt; position: absolute; text-decoration: none; white-space: pre;">Statements<font style="display: inline-block; height: 8.73pt;"></font></font></div></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 90pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">company. In the event the Company has undergone or undergoes a change in ownership, utilization of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 102pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the carryforwards could be limited.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 122pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company also had federal and California research and development credit carryforwards of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 134pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">approximately <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 137pt; position: absolute; text-decoration: none; white-space: pre;">$8.6<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 156.45pt; position: absolute; white-space: pre;"> million and <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 209.77pt; position: absolute; text-decoration: none; white-space: pre;">$6.7<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 229.22pt; position: absolute; white-space: pre;"> million, respectively, as of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 347.87pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 435.66pt; position: absolute; white-space: pre;">. The federal credits <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 146pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">will expire starting in 2030, if not utilized. The California credits have no expiration date.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 166pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Deferred income taxes have not been provided for undistributed earnings of the Company&#8217;s consolidated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 178pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">foreign subsidiaries because of the Company&#8217;s intent to reinvest such earnings indefinitely in active <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 190pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">foreign operations. The Company believes that future domestic cash generation will be sufficient to meet <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 202pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">future domestic cash needs. The Company has not recorded a deferred tax liability on the undistributed <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 214pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">earnings of non-U.S. subsidiaries. The foreign withholding taxes would not have a material impact on the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 226pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Company&#8217;s financial position and results of operation. As of December 31, 2023, the Company had $0.6 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 238pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">million in unremitted earnings that were indefinitely reinvested related to its consolidated foreign <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 250pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">subsidiaries.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 270pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company&#8217;s gross unrecognized tax benefits as of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 312.90999999999997pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 400.7pt; position: absolute; white-space: pre;"> is <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 413.46pt; position: absolute; text-decoration: none; white-space: pre;">$8.2<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 432.91pt; position: absolute; white-space: pre;"> million, all of which <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 282pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">would affect the Company&#8217;s income tax expense if recognized before consideration of the Company&#8217;s <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 294pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">valuation allowance. The Company does not expect its unrecognized tax benefits to change significantly <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 306pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">over the next 12 months. The Company recognizes interest and penalties accrued on any unrecognized <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 318pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">tax benefits as a component of provision for income taxes.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 338pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">The following table summarizes the activity related to unrecognized tax benefits as follows (in thousands)<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 535.81pt; position: absolute; white-space: pre;">&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 358pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 402.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 24pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.26pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 2.9pt; position: absolute; text-decoration: none; white-space: pre;">Unrecognized <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 14.06pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 5.9pt; position: absolute; text-decoration: none; white-space: pre;">Tax Benefits<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 24pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Balance at January 1, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 124.3pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 124.88pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 125.03pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 125.05pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 24pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">7,371<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 38.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Increase related to current year tax provision<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 200.38pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 202.69pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 203.85pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 204.43pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 204.57999999999998pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 204.66pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 204.68pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 38.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;"><font style="display: inline-block; height: 7.28pt; width: 41.86pt;"></font></font><font style="left: 44.49pt; position: absolute;">817<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 52.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Balance at December 31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 140.41pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 142.72pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 143.88pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 144.46pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 144.60999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 144.65pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 144.67pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 144.68pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 52.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 2.63pt; position: absolute;">$<font style="display: inline-block; height: 7.28pt; width: 27.97pt;"></font></font><font style="left: 36.160000000000004pt; position: absolute;">8,188<font style="display: inline-block; height: 7.28pt; width: 3.33pt;"></font></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 440.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company files income tax returns in the U.S. federal jurisdiction, various state and certain foreign <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 451.95pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">jurisdictions. In the normal course of business, the Company is subject to examination by their respective <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 463.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">taxing authorities. The Company has been selected for audit by the Internal Revenue Service for its 2022 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 474.35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">tax year. The examination is at its early stages. However, no tax adjustments are anticipated. The statute <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 485.55pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">of limitations remains effectively open for the U.S. federal and state tax jurisdictions for all tax years from <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 496.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2011 through 2023. Tax years outside the normal statute of limitations remain open to examination by tax <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 507.95pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">authorities due to tax attributes generated in earlier years which have been carried forward and may be <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 519.15pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">examined and adjusted in subsequent years when utilized.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div id="i2341357d54884756b9e9172f0a83cd6b_144" style="position: absolute; top: 538.35pt;"></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 538.35pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">18. Subsequent <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 163.98000000000002pt; position: absolute; text-decoration: none; white-space: pre;">Events<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 560.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Company has reviewed and evaluated subsequent events as of <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 375.9pt; position: absolute; text-decoration: none; white-space: pre;">December&#160;31, 2023<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 463.69pt; position: absolute; white-space: pre;"> through <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 572.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">February 5, 2025, the date that the consolidated financial statements were available to be issued.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 592.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2024 Credit Agreement<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 612.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">On June 14, 2024, the Company entered into a Credit Agreement and Guaranty (the &#8220;2024 Credit <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 624.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Agreement&#8221;) with Hayfin for a $138.1 million term loan (the &#8220;2024 Term Loan&#8221;) to refinance its outstanding <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 636.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">loan obligations under the 2021 Credit Agreement, as amended. In addition, in connection with the 2024 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 648.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Term Loan, the Company entered into several other adjoining agreements with Hayfin. The 2024 Term <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Loan matures on June&#160;14, 2028. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 680.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The 2024 Term Loan bears interest at a floating per annum rate in an amount equal to the sum of (i) 7.0% <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 692.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(or 6.0% if the alternative base rate (&#8220;ABR&#8221;) is in effect) plus (ii) the greater of (x) the forward-looking term <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 704.75pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">rate based on SOFR for a respective tenor (or the alternative base rate, if applicable), and (y) 2.0%. The <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 295.72pt; position: absolute; text-decoration: none; white-space: pre;">F-38<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"><div style="line-height: 11.64pt; position: absolute; top: 36pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 55.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 180.72pt; position: absolute; text-decoration: none; white-space: pre;">Notes to Consolidated Financial <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 366.64pt; position: absolute; text-decoration: none; white-space: pre;">Statements<font style="display: inline-block; height: 8.73pt;"></font></font></div></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 90pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">ABR equals to the sum of (i) 6.0% plus (ii) the greater of (1) the Wall Street Journal Prime Rate, plus <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 102pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">0.5%, (2) the Federal Reserve Bank of New York rate plus 0.5% or (3) CBA Term SOFR for one month <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 114pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">tenor plus 1.0%. The Company has the option to pay interest in-kind at the rate equal to the cash interest <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 126pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">rate plus 1.0%. The Company also has the option to prepay the 2024 Term Loan subject to a prepayment <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 138pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">fee of 1.5% for prepayments after the second anniversary but on or prior to the third anniversary of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 150pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2024 Term Loan and a prepayment fee of 3% for prepayments thereafter. The Company must repay the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 162pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">loan in full immediately upon the occurrence of a change in control. In addition, immediately upon the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 174pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">consummation of an IPO or SPAC, as defined in the terms of the 2024 Credit Agreement, the Company <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 186pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">shall repay the 2024 Term Loan in an amount equal to the lesser of (i) the net cash proceeds of such IPO <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 198pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or SPAC in excess of $150.0 million and (ii) $35.0 million.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 218pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The 2024 Credit Agreement contains certain customary representations and warranties, events of default <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 230pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and affirmative and negative covenants, including, among others, covenants that limit or restrict the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 242pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Company&#8217;s (and its subsidiaries) ability to incur additional indebtedness, grant liens, merge or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 254pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">consolidate, make acquisitions, pay dividends or other distributions or repurchase equity, make <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 266pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">investments, dispose of assets and enter into certain transactions with affiliates, in each case subject to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 278pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">certain exceptions. There were no changes to the financial covenant requirements as described earlier in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 290pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Note 8. Events of Default on the 2024 Term Loan include, among others, non-payment of principal, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 302pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">interest or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 314pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">insolvency events, material judgments, cross-defaults to material contracts and events constituting a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 326pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">change of control. Upon the occurrence of an event of default, the interest rate applicable to the 2024 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 338pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Term Loan shall increase by 3.0% per annum and the outstanding principal balance, along with any <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 350pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">accrued interest, shall become immediately due and payable. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 370pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">On June 14, 2024, concurrently upon entering the 2024 Term Loan, the Company signed a fee letter <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 382pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">agreement with Hayfin under which the Company agreed to pay $9.2 million in fees to Hayfin, which <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 394pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">consists of the exit fee and the early prepayment fee due under the 2021 Credit Agreement, as amended, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 406pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">in the amount of $8.3 million payable in sixteen equal quarterly installments of approximately $518,000 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 418pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">through March 31, 2028, agent fees of $150,000, due in annual installments of $30,000 through March <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 430pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">31, 2028 and an upfront fee of $721,000. The Company paid the $721,000 upfront fee and $30,000 agent <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 442pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">fee upon the closing of the 2024 Term Loan. The exit fee and early prepayment fee must be repaid in full <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 454pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">immediately upon the occurrence of a financing event, including, but not limited to, any IPO, SPAC, or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 466pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">issuance of convertible notes or equity.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 486pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The 2024 Credit Agreement was accounted for as a debt modification for accounting purposes.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 506pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2024 Facility Sublease<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 526pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In October 2024, the Company entered into an agreement to sublease approximately 4,000 rentable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 538pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">square feet of office space in Santa Rosa, California for 29 months commencing on November 1, 2024. In <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 550pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">connection with this sublease, the Company paid a security deposit of $8,000. Monthly base rent is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 562pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">approximately $7,000 during the sublease term.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 582pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2025 Convertible Notes<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 602pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">In January 2025, the Company issued convertible promissory notes to certain existing investors and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 614pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">certain employees (the &#8220;Requisite Holders&#8221;) in the amount of up to $75.0 million (the &#8220;2025 Convertible <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 626pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Notes&#8221;). The 2025 Convertible Notes are due and payable in full 48 months from the issue date. Upon <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 638pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">completion of an IPO transaction, the 2025 Convertible Notes shall automatically convert into shares of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 650pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the Company&#8217;s common stock at the IPO price per share at the lower of a 20% discount and a valuation <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 662pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">cap of $2.0 billion on a pre-money basis. In the event the Company completes a sale of shares of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 674pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">preferred stock, the Requisite Holders may elect to convert the outstanding 2025 Convertible Notes into <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 686pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">shares of such series of preferred stock at the same terms. Further, upon a change of control transaction, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 698pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the Requisite Holders may elect to convert the outstanding 2025 Convertible Notes into shares of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 710pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Company&#8217;s common stock at the lower of a 20% discount to the implied price per share of common stock <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 295.72pt; position: absolute; text-decoration: none; white-space: pre;">F-39<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"><div style="line-height: 11.64pt; position: absolute; top: 36pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 217.17pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc.<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 55.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 180.72pt; position: absolute; text-decoration: none; white-space: pre;">Notes to Consolidated Financial <font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 366.64pt; position: absolute; text-decoration: none; white-space: pre;">Statements<font style="display: inline-block; height: 8.73pt;"></font></font></div></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 90pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">in the change of control transaction and a valuation cap of $2.0 billion on a pre-money basis, or receive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 102pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">payment of all principal and any accrued but unpaid PIK interest. The 2025 Convertible Notes do not <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 114pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">accrue interest for one year following the date of issuance. Following the one-year anniversary of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 126pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">issue date and for the remainder of the term, the 2025 Convertible Notes interest will accrue on an annual <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 138pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">basis at the rate of 7.0% per annum (PIK Interest). All PIK Interest accrued and payable will be paid by <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 150pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">capitalizing such interest on an annual basis and adding it to the outstanding principal amount of the 2025 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 162pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Convertible Notes.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 182pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">2025 Amendment to 2024 Credit Agreement<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 202pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">On January 24, 2025, in connection with the issuance of the 2025 Convertible Notes, the Company <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 214pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">entered into Amendment No.1 to the 2024 Credit Agreement, in which its lender, Hayfin, converted $23.0 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 226pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">million of principal under the 2024 Term Loan to 2025 Convertible Notes under the same terms as the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 238pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">other purchasers of the 2025 Convertible Notes. The principal balance outstanding under the 2024 Term <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 250pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Loan, as amended, is $115.1 million. The minimum liquidity cash balance covenant under the 2024 Term <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 262pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Loan was reduced to $15.0 million from the previous $25.0 million. In addition, the amount immediately <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 274pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">payable upon the consummation of an IPO or SPAC, as defined in the terms of the 2024 Credit <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 286pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Agreement, was amended where repayment of the 2024 Term Loan will be at an amount equal to the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 298pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">lesser of (i) the net cash proceeds of such IPO or SPAC in excess of $150.0 million and (ii) $50.0 million <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 310pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">(or $55.0 million if the underwriters exercise in full their option to purchase additional shares). The exit fee <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 322pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and prepayment fee remaining under the original terms of the 2024 Term Loan, which were immediately <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 334pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">due and payable upon issuance of the 2025 Convertible Notes was also amended to be immediately due <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 346pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and payable upon the next occurrence of a financing event as described above.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_706" style="position: absolute; top: 72pt;"></div><div style="font-size: 12pt; line-height: 13.1pt; position: absolute; top: 179.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 18pt; font-style: italic; font-weight: bold; left: 214.48pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares<font style="display: inline-block; height: 13.1pt;"></font></font></div><div style="position: absolute; top: 287.2pt; width: 612pt;"><div style="left: 140.4pt; position: absolute; top: 0pt;"><div style="position: absolute;"><img style="height: 57.28pt; width: 331.2pt;" src="heartflowlogo.jpg" alt="heartflowlogo.jpg"></div></div></div><div style="line-height: 13.1pt; position: absolute; top: 409.48pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 18pt; font-style: italic; font-weight: bold; left: 241.01pt; position: absolute; text-decoration: none; white-space: pre;">Common stock<font style="display: inline-block; height: 13.1pt;"></font></font></div><div style="line-height: 13.1pt; position: absolute; top: 491.08pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 18pt; font-style: normal; font-weight: bold; left: 205.99pt; position: absolute; text-decoration: none; white-space: pre;">Preliminary prospectus<font style="display: inline-block; height: 13.1pt;"></font></font></div><div style="position: absolute; top: 592.68pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 96pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 69pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 125.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 69pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 108.75pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 20.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 96pt;"><div><div style="line-height: 11.64pt; position: absolute; top: 3.75pt; width: 96pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">J.P. Morgan<font style="display: inline-block; height: 11.64pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 165pt; position: absolute; top: 0pt; width: 125.25pt;"><div><div style="line-height: 11.64pt; position: absolute; top: 3.75pt; width: 125.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 3.1pt; position: absolute; text-decoration: none; white-space: pre;">Morgan Stanley<font style="display: inline-block; height: 11.64pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 359.25pt; position: absolute; top: 0pt; width: 108.75pt;"><div><div style="line-height: 11.64pt; position: absolute; top: 3.75pt; width: 108.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 3.04pt; position: absolute; text-decoration: none; white-space: pre;">Piper Sandler<font style="display: inline-block; height: 11.64pt;"></font></font></div></div></div></td></tr></table></div></div></div><div style="position: absolute; top: 625.93pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 42pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 282.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 143.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 20.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 42pt;"><div><div style="line-height: 10.92pt; position: absolute; top: 4.68pt; width: 42pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 15pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Stifel<font style="display: inline-block; height: 10.92pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 324.75pt; position: absolute; top: 0pt; width: 143.25pt;"><div><div style="line-height: 10.92pt; position: absolute; top: 4.68pt; width: 143.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 15pt; font-style: normal; font-weight: bold; left: 3.15pt; position: absolute; text-decoration: none; white-space: pre;">Canaccord Genuity<font style="display: inline-block; height: 10.92pt;"></font></font></div></div></div></td></tr></table></div></div></div><div style="line-height: 7.28pt; position: absolute; top: 701.18pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 298.78pt; position: absolute; text-decoration: none; white-space: pre;">II-1<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_709" style="position: absolute; top: 72pt;"></div><div style="line-height: 11.64pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Part II<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 107.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Information not required in prospectus<font style="display: inline-block; height: 7.28pt;"></font></font></div><div id="i2341357d54884756b9e9172f0a83cd6b_1386" style="position: absolute; top: 127.2pt;"></div><div style="line-height: 8.73pt; position: absolute; top: 127.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Item 13. Other expenses of issuance and distribution.<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 149.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The following table sets forth the costs and expenses, other than the underwriting discounts and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 161.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">commissions, payable by Heartflow, Inc. (the &#8220;Registrant&#8221;) in connection with the sale of the Registrant&#8217;s <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 173.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), being registered. All amounts are <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 185.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">estimates except for the Securities and Exchange Commission (the &#8220;SEC&#8221;) registration fee, the Financial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 197.6pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Industry Regulatory Authority (&#8220;FINRA&#8221;) filing fee, and the&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;listing fee.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 217.6pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 402.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 65.25pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 24pt;"><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 0pt; width: 65.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.26pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 3.66pt; position: absolute; text-decoration: none; white-space: pre;">Amount to be <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 14.06pt; width: 65.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 23.38pt; position: absolute; text-decoration: none; white-space: pre;">paid<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 24pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">SEC registration fee<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 92.03999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 94.35pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 94.64pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 94.78999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 94.83pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 24pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 3.31pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 38.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">FINRA filing fee<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 72.03pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 74.33999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 74.63pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 74.78pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 74.82pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 74.83pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 38.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 58.73pt; position: absolute; text-decoration: none; white-space: pre;">*<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 52.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; listing fee<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 75.31pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 77.61999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 78.78pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 79.36pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 79.64999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 79.66pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 52.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 58.73pt; position: absolute; text-decoration: none; white-space: pre;">*<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 66.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Transfer agent&#8217;s fees and expenses<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 160.97pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 163.28pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 164.44pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 164.59pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 164.67pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 164.71pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 164.73pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 164.74pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 66.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 58.73pt; position: absolute; text-decoration: none; white-space: pre;">*<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 81pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Printing and engraving expenses<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 148.21pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 149.37pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.6pt; font-style: normal; font-weight: normal; left: 149.66pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 149.81pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 149.89pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 149.93pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 149.95pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 149.96pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 81pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 58.73pt; position: absolute; text-decoration: none; white-space: pre;">*<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 95.25pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Legal fees and expenses<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 113.77pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 114.92999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 114.97pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 114.99pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 115pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 95.25pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 58.73pt; position: absolute; text-decoration: none; white-space: pre;">*<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 109.5pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Accounting fees and expenses<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 138.76pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 139.92pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 140pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 109.5pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 58.73pt; position: absolute; text-decoration: none; white-space: pre;">*<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #ffffff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 123.75pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Miscellaneous expenses<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 9.24pt; font-style: normal; font-weight: normal; left: 111.55pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 2.32pt; font-style: normal; font-weight: normal; left: 113.86pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 1.18pt; font-style: normal; font-weight: normal; left: 114.44pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.16pt; font-style: normal; font-weight: normal; left: 114.72999999999999pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.04pt; font-style: normal; font-weight: normal; left: 114.77pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 114.78pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #ffffff; border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 123.75pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 58.73pt; position: absolute; text-decoration: none; white-space: pre;">*<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="background-color: #cceeff; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 138pt; width: 402.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.32pt; width: 402.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Total<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 4.64pt; font-style: normal; font-weight: normal; left: 23.74pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.32pt; font-style: normal; font-weight: normal; left: 24.9pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 0.08pt; font-style: normal; font-weight: normal; left: 24.98pt; position: absolute; white-space: pre;"> <font style="display: inline-block; height: 7.28pt;"></font></font><font style="color: #b4b4b4; font-family: &#39;Times New Roman&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 25pt; position: absolute; text-decoration: none; white-space: pre;"> . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="background-color: #cceeff; border-bottom: 3pt double #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 402.75pt; position: absolute; top: 138pt; width: 65.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 65.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 3.31pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 3pt double #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 5.46pt; position: absolute; top: 377.85pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">*<font style="display: inline-block; height: 5.46pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">To be filed by amendment.<font style="display: inline-block; height: 5.46pt;"></font></font></div><div id="i2341357d54884756b9e9172f0a83cd6b_1458" style="position: absolute; top: 394.85pt;"></div><div style="line-height: 8.73pt; position: absolute; top: 394.85pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Item 14. Indemnification of directors and officers.&#160;<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 417.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Section 145 of the General Corporation Law of the State of Delaware (the &#8220;Delaware General Corporation <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 429.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Law&#8221;) provides that a corporation may indemnify directors and officers as well as other employees and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 441.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">individuals against expenses (including attorneys&#8217; fees), judgments, fines, and amounts paid in settlement <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 453.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">actually and reasonably incurred by such person in connection with any threatened, pending, or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 465.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">completed actions, suits, or proceedings in which such person is made a party by reason of such person <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 477.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">being or having been a director, officer, employee, or agent to the Registrant. The Delaware General <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 489.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Corporation Law provides that Section 145 is not exclusive of other rights to which those seeking <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 501.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">indemnification may be entitled under any bylaw, agreement, vote of stockholders or disinterested <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 513.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">directors, or otherwise. Article&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;of the Registrant&#8217;s amended and restated certificate of incorporation <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 525.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">provides for indemnification by the Registrant of its directors, officers, and employees to the fullest extent <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 537.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">permitted by the Delaware General Corporation Law. The Registrant has entered into indemnification <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 549.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">agreements with each of its current directors, executive officers, and certain other officers to provide <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 561.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">these directors and officers additional contractual assurances regarding the scope of the indemnification <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 573.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">set forth in the Registrant&#8217;s amended and restated certificate of incorporation and amended and restated <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 585.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">bylaws and to provide additional procedural protections. There is no pending litigation or proceeding <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 597.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">involving a director or executive officer of the Registrant for which indemnification is sought.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 617.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Section 102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 629.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">certificate of incorporation that a director or an officer of the corporation shall not be personally liable to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 641.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or an <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 653.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">officer, except for liability (i) for any breach of the director&#8217;s or officer&#8217;s duty of loyalty to the corporation or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 665.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 677.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">knowing violation of law, (iii) in the case of directors, for unlawful payments of dividends or unlawful stock <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 689.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">repurchases, redemptions, or other distributions, or (iv) for any transaction from which the director or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 701.25pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">officer derived an improper personal benefit&#59; provided that officers may not be indemnified for actions by <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 298.78pt; position: absolute; text-decoration: none; white-space: pre;">II-2<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">or in the right of the corporation. The Registrant&#8217;s amended and restated certificate of incorporation <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">provides for such limitation of liability.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The Registrant maintains standard policies of insurance under which coverage is provided (a) to its <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">directors and officers against loss rising from claims made by reason of breach of duty or other wrongful <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">act and (b) to the Registrant with respect to payments that may be made by the Registrant to such <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">officers and directors pursuant to the above indemnification provision or otherwise as a matter of law.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 160pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The proposed form of underwriting agreement to be filed as Exhibit 1.1. to this registration statement <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 172pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">provides for indemnification of officers and directors of the Registrant by the underwriters against certain <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 184pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">liabilities.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div id="i2341357d54884756b9e9172f0a83cd6b_1483" style="position: absolute; top: 204pt;"></div><div style="line-height: 8.73pt; position: absolute; top: 204pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Item 15. Recent sales of unregistered securities.<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 226.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Since January 1, 2022, the Registrant made sales of the following unregistered securities&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 246.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(a) Equity plan-related issuances<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 266.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">1.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Since January 1, 2022, the Registrant granted to its directors, employees, consultants, and other <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 278.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">service providers options to purchase an aggregate of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of its Common Stock under <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 290.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">its HeartFlow Holding, Inc. Amended and Restated 2009 Equity Incentive Plan (&#8220;2009 Equity Incentive <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 302.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Plan&#8221;), at exercise prices ranging from $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 322.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">2.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Since January 1, 2022, the Registrant issued and sold to its directors, employees, consultants, and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 334.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">other service providers an aggregate of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of its Common Stock upon the exercise of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 346.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">stock options under its 2009 Equity Incentive Plan, at exercise prices ranging from $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 358.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; per share. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 378.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(b) Sales of preferred stock<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 398.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">3.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">In March 2023, the Registrant sold an aggregate of (i) 61,344,029 shares of its Series F redeemable <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 410.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">convertible preferred stock to 29 accredited investors at a purchase price of $2.8505 per share and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 422.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">(ii)&#160;21,465,064 shares of its Series F-1 redeemable convertible preferred stock to 19&#160;accredited <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 434.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">investors at a purchase price of $1.9098 per share, for an aggregate purchase price of $215.9&#160;million. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 446.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">The Series F-1 redeemable convertible preferred stock were issued upon conversion of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 458.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">indebtedness under outstanding subordinated convertible promissory notes.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 478.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(c) Warrants<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 498.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">4.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">On March 17, 2022, the Registrant issued a warrant to Hayfin Tourmaline Luxco S.a.r.l. to purchase <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 510.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">an aggregate of 225,579 shares of its Common Stock at a purchase price of $0.01 per share (the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 522.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">&#8220;2022 Hayfin Warrant&#8221;). <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 542.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">5.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">On March 2, 2023, the warrant issued to Hayfin Tourmaline Luxco S.a.r.l. on January 19, 2021 (the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 554.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">&#8220;2021 Hayfin Warrant&#8221;) was adjusted in connection with the Series F and Series F-1 Convertible <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 566.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Preferred Stock Financing, allowing Hayfin Tourmaline Luxco S.a.r.l. to purchase an aggregate of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 578.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">2,806,525&#160;shares of its Common Stock at a purchase price of $0.01 per share pursuant to the 2021 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 590.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Hayfin Warrant.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 610.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">6.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">On March 2, 2023, the 2022 Hayfin Warrant was adjusted in connection with the Series F and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 622.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Series&#160;F-1 Convertible Preferred Stock Financing, allowing Hayfin Tourmaline Luxco S.a.r.l. to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 634.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">purchase an aggregate of 2,004,665 shares of its Common Stock at a purchase price of $0.01&#160;per <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 646.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">share pursuant to the 2021 Hayfin Warrant. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 666.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(d) Convertible notes<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 686.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">7.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">From September 30, 2022 to December 16, 2022, the Registrant issued $40,000,000 principal <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 698.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">amount of the 2022 Convertible Promissory Notes to investors, including related parties, with original <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 298.78pt; position: absolute; text-decoration: none; white-space: pre;">II-3<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">maturity dates of 48 months from the dates of<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 291.03999999999996pt; position: absolute; white-space: pre;"> issuance<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 333.27pt; position: absolute; text-decoration: none; white-space: pre;">. The 2022 Convertible Notes automatically <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">converted into shares of Series F-1 convertible preferred stock on March 2, 2023. <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="font-size: 12pt; line-height: 7.28pt; position: absolute; top: 104pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">8.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">In January 2025, the Registrant issued <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 263.87pt; position: absolute; text-decoration: none; white-space: pre;">$48,356,153.27<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 333.34000000000003pt; position: absolute; text-decoration: none; white-space: pre;"> principal amount of the 2025 Convertible <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 116pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Promissory Notes to investors, including related parties, with original maturity dates of 48&#160;months <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">from the dates of<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 164.97pt; position: absolute; white-space: pre;"> issuance<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 207.2pt; position: absolute; text-decoration: none; white-space: pre;">. The 2025 Convertible Promissory Notes will be automatically converted <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 140pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">upon the effectiveness of this registration statement into shares of Common Stock.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 160pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">No underwriters were involved in these transactions. The offers, sales, and issuances of the securities <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 172pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">described in paragraphs (1) through (2) were deemed to be exempt from registration under Rule&#160;701 <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 184pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">promulgated under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) as transactions under <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 196pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">compensatory benefit plans and contracts relating to compensation, or under Section&#160;4(a)(2)&#160;of the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 208pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Securities Act as a transaction by an issuer not involving a public offering. The recipients of such <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 220pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">securities were our directors, employees, or bona fide consultants and received the securities under the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 232pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Registrant&#8217;s equity incentive plans. Appropriate legends were affixed to the securities issued in these <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 244pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">transactions. Each of the recipients of securities in these transactions had adequate access, through <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 256pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">employment, business or other relationships, to information about the Registrant.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 276pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The offers, sales, and issuances of the securities described in paragraphs (3) through (8) were deemed to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 288pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">be exempt under Section 4(a)(2) of the Securities Act or Rule 506 of Regulation D under the Securities <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 300pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Act as a transaction by an issuer not involving a public offering. The recipients of securities in each of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 312pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">these transactions acquired the securities for investment only and not with a view to or for sale in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 324pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">connection with any distribution thereof and appropriate legends were affixed to the securities issued in <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 336pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">these transactions. Each of the recipients of securities in these transactions was an accredited investor <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 348pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">within the meaning of Rule&#160;501 of Regulation&#160;D under the Securities Act and had adequate access to <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 360pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">information about the Registrant.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div id="i2341357d54884756b9e9172f0a83cd6b_1555" style="position: absolute; top: 380pt;"></div><div style="line-height: 8.73pt; position: absolute; top: 380pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Item 16. Exhibits and financial statement schedules.<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 402.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(a)<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Exhibits.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 131.62pt; position: absolute; text-decoration: none; white-space: pre;"> See the Exhibit Index attached to this registration statement, which Exhibit Index is <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 414.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">incorporated herein by reference.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 434.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">(b)<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">Consolidated financial statement schedules.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 300.96000000000004pt; position: absolute; text-decoration: none; white-space: pre;"> Schedules not listed above have been omitted <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 446.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">because the information required to be set forth therein is not applicable or is shown in the financial <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 458.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">statements or notes thereto.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div id="i2341357d54884756b9e9172f0a83cd6b_1603" style="position: absolute; top: 478.4pt;"></div><div style="line-height: 8.73pt; position: absolute; top: 478.4pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Item 17. Undertakings.<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 500.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 512.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">officers, and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 524.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Registrant has been advised that in the opinion of the SEC such indemnification is against public policy <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 536.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">as expressed in the Securities Act, and is, therefore, unenforceable. In the event that a claim for <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 548.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 560.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">paid by a director, officer, or controlling person of the Registrant in the successful defense of any action, <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 572.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">suit, or proceeding) is asserted by such director, officer, or controlling person in connection with the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 584.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 596.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 608.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">indemnification by it is against public policy as expressed in the Securities Act and will be governed by the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 620.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">final adjudication of such issue.&#160;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 640.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">The undersigned Registrant hereby undertakes that&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 660.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">1.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">For purposes of determining any liability under the Securities Act, the information omitted from the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 672.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">form of prospectus filed as part of this registration statement in reliance upon Rule&#160;430A and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 684.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">contained in a form of prospectus filed by the Registrant pursuant to Rule&#160;424(b)(1) or (4) or 497(h) <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 696.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">under the Securities Act shall be deemed to be part of this registration statement as of the time it was <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 708.8pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">declared effective.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"><div style="line-height: 7.28pt; position: absolute; top: 22.12pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 298.78pt; position: absolute; text-decoration: none; white-space: pre;">II-4<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="-sec-extract: summary; left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">2.<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">For the purpose of determining any liability under the Securities Act, each post-effective amendment <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">that contains a form of prospectus shall be deemed to be a new registration statement relating to the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 96pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">securities offered therein, and the offering of such securities at that time shall be deemed to be the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 108pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">initial <font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 115.53999999999999pt; position: absolute; text-decoration: none; white-space: pre;">bona fide<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 156.66pt; position: absolute; text-decoration: none; white-space: pre;"> offering thereof.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div id="i2341357d54884756b9e9172f0a83cd6b_2217" style="position: absolute; top: 128pt;"></div><div style="font-size: 12pt; line-height: 8.73pt; position: absolute; top: 128pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Exhibit i<font style="display: inline-block; height: 8.73pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 118.64pt; position: absolute; text-decoration: none; white-space: pre;">ndex<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="position: absolute; top: 150.4pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 50.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 414.75pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 24pt;"><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 50.25pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 3.26pt; width: 50.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Exhibit <font style="display: inline-block; height: 6.55pt;"></font></font></div><div style="line-height: 6.55pt; position: absolute; top: 14.06pt; width: 50.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">number<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td><td style="border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; border-top: 2pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 53.25pt; position: absolute; top: 0pt; width: 414.75pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 14.06pt; width: 414.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 166.91pt; position: absolute; text-decoration: none; white-space: pre;">Exhibit description<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 24pt; width: 50.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 50.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">1.1*<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 53.25pt; position: absolute; top: 24pt; width: 414.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 414.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Form of Underwriting Agreement.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 38.25pt; width: 50.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 50.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">3.1*<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 53.25pt; position: absolute; top: 38.25pt; width: 414.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 414.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Amended and Restated Certificate of Incorporation, as amended, currently in effect.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 26.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 52.5pt; width: 50.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 50.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">3.2*<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 53.25pt; position: absolute; top: 52.5pt; width: 414.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 414.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Form of Amended and Restated Certificate of Incorporation, to be in effect immediately prior <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 14.63pt; width: 414.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">to the completion of this offering.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 78.75pt; width: 50.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 50.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">3.3*<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 53.25pt; position: absolute; top: 78.75pt; width: 414.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 414.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Amended and Restated Bylaws, currently in effect.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 26.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 93pt; width: 50.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 50.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">3.4*<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 53.25pt; position: absolute; top: 93pt; width: 414.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 414.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Form of Amended and Restated Bylaws, to be in effect immediately prior to the completion <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 14.63pt; width: 414.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">of this offering.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 119.25pt; width: 50.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 50.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">4.1*<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 53.25pt; position: absolute; top: 119.25pt; width: 414.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 414.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Form of Common Stock Certificate.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 26.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 133.5pt; width: 50.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 50.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">4.2+<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 53.25pt; position: absolute; top: 133.5pt; width: 414.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 414.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Warrant to Purchase Common Stock, dated January 19, 2021, between Hayfin Tourmaline <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 14.63pt; width: 414.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Luxco S.a.r.l. and HeartFlow, Inc.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 26.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 159.75pt; width: 50.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 50.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">4.3+<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 53.25pt; position: absolute; top: 159.75pt; width: 414.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 414.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Warrant to Purchase Common Stock, dated March 17, 2022, between Hayfin Tourmaline <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 14.63pt; width: 414.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Luxco S.a.r.l. and HeartFlow Holding, Inc.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 26.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 186pt; width: 50.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 50.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">4.4+&#8224;<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 53.25pt; position: absolute; top: 186pt; width: 414.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 414.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Amended and Restated Investors&#8217; Rights Agreement, dated March 2, 2023, by and among <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 14.63pt; width: 414.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc. and the investors listed therein.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 212.25pt; width: 50.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 50.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">5.1*<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 53.25pt; position: absolute; top: 212.25pt; width: 414.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 414.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Opinion of O&#8217;Melveny &#38; Myers LLP.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 26.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 226.5pt; width: 50.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 50.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">10.1#+<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 53.25pt; position: absolute; top: 226.5pt; width: 414.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 414.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc. Amended and Restated 2009 Equity Incentive Plan and forms of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 14.63pt; width: 414.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">award agreements.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 26.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 252.75pt; width: 50.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 50.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">10.2#*<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 53.25pt; position: absolute; top: 252.75pt; width: 414.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 414.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">2025 Performance Incentive Plan, to become effective on the date the registration statement <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 14.63pt; width: 414.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">is declared effective, and forms of award agreements.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 26.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 279pt; width: 50.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 50.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">10.3#*<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 53.25pt; position: absolute; top: 279pt; width: 414.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 414.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">2025 Employee Stock Purchase Plan, to become effective on the date the registration <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 14.63pt; width: 414.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">statement is declared effective, and forms of award agreements.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 305.25pt; width: 50.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 50.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">10.4+&#8224;<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 53.25pt; position: absolute; top: 305.25pt; width: 414.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 414.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Lease, dated August 9, 2021, by and between MV Campus Owner, LLC and HeartFlow, Inc. <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 26.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 319.5pt; width: 50.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 50.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">10.5+&#8224;<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 53.25pt; position: absolute; top: 319.5pt; width: 414.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 414.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Credit Agreement and Guaranty, dated June 14, 2024, by and among HeartFlow, Inc., <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 14.63pt; width: 414.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">HeartFlow Holding, Inc., Hayfin Tourmaline Luxco S.a.r.l. and Hayfin Services, LLP.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 38.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 345.75pt; width: 50.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 50.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">10.6+<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 53.25pt; position: absolute; top: 345.75pt; width: 414.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 414.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Amendment No. 1 to Credit Agreement and Guaranty, dated January 24, 2025, by and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 14.63pt; width: 414.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">among HeartFlow, Inc., HeartFlow Holding, Inc., Hayfin Tourmaline Luxco S.a.r.l. and Hayfin <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 26.63pt; width: 414.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Services, LLP.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 384pt; width: 50.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 50.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">21.1+<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 53.25pt; position: absolute; top: 384pt; width: 414.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 414.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">List of Subsidiaries.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 398.25pt; width: 50.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 50.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">23.1*<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 53.25pt; position: absolute; top: 398.25pt; width: 414.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 414.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 412.5pt; width: 50.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 50.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">23.2*<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 53.25pt; position: absolute; top: 412.5pt; width: 414.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 414.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Consent of O&#8217;Melveny &#38; Myers LLP (included in Exhibit 5.1).<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 426.75pt; width: 50.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 50.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">24.1*<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 53.25pt; position: absolute; top: 426.75pt; width: 414.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 414.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Power of Attorney (reference is made to the signature page to the Registration Statement).<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 441pt; width: 50.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 50.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">107.1*<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 53.25pt; position: absolute; top: 441pt; width: 414.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 2.63pt; width: 414.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">Filing Fee Table.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr></table></div></div></div><div style="line-height: 5.46pt; position: absolute; top: 613.65pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 72pt; position: absolute;">*<font style="display: inline-block; height: 5.46pt; width: 15.09pt;"></font></font><font style="left: 90pt; position: absolute;">To be filed by amendment.<font style="display: inline-block; height: 5.46pt;"></font></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 622.65pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 72pt; position: absolute;">#<font style="display: inline-block; height: 5.46pt; width: 13.83pt;"></font></font><font style="left: 90pt; position: absolute;">Indicates management contract or compensatory plan.&#160;<font style="display: inline-block; height: 5.46pt;"></font></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 631.65pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 72pt; position: absolute;">+<font style="display: inline-block; height: 5.46pt; width: 13.63pt;"></font></font><font style="left: 90pt; position: absolute;">Filed herewith.<font style="display: inline-block; height: 5.46pt;"></font></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 640.65pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; text-decoration: none; white-space: pre;"><font style="left: 72pt; position: absolute;">&#8224;<font style="display: inline-block; height: 5.46pt; width: 13.83pt;"></font></font><font style="left: 90pt; position: absolute;">Annexes, schedules and&#47;or exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant agrees to furnish <font style="display: inline-block; height: 5.46pt;"></font></font></font></div><div style="line-height: 5.46pt; position: absolute; top: 649.65pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 7.5pt; font-style: normal; font-weight: normal; left: 90pt; position: absolute; text-decoration: none; white-space: pre;">supplementally a copy of any omitted attachment to the SEC on a confidential basis upon request.<font style="display: inline-block; height: 5.46pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div id="i2341357d54884756b9e9172f0a83cd6b_712" style="position: absolute; top: 72pt;"></div><div style="line-height: 11.64pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 16pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Signatures<font style="display: inline-block; height: 11.64pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 107.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 119.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 131.2pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Mountain View, State of California on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025.&#160;<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 151.2pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 237.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 15pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 14.25pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 201pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="3"><div style="left: 237.75pt; position: absolute; top: 0pt; width: 230.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 230.25pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: bold; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">HEARTFLOW, INC.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="2"><div style="left: 237.75pt; position: absolute; top: 28.5pt; width: 29.25pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 29.25pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">By&#58;<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 267pt; position: absolute; top: 42.75pt; width: 201pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 201pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">John C.M. Farquhar<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 267pt; position: absolute; top: 57pt; width: 201pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.4pt; width: 201pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 2.63pt; position: absolute; text-decoration: none; white-space: pre;">President and Chief Executive Officer<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr></table></div></div></div><div style="line-height: 8.73pt; position: absolute; top: 235.45pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 12pt; font-style: normal; font-weight: bold; left: 72pt; position: absolute; text-decoration: none; white-space: pre;">Signatures and power of attorney<font style="display: inline-block; height: 8.73pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 257.85pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 269.85pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">appoints Vikram Verghese, Angela Ahmad and Mhairi L. Jones, and each of them, as their true and lawful <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 281.85pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">attorneys-in-fact and agents, each with the full power of substitution, for them and in their name, place, or <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 293.85pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">stead, in any and all capacities, to sign any and all amendments to this registration statement (including <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 305.85pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">post-effective amendments), and to sign any registration statement for the same offering covered by this <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 317.85pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">registration statement that is to be effective upon filing pursuant to Rule 462(b) promulgated under the <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 329.85pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Securities Act, and all post-effective amendments thereto, and to file the same, with exhibits thereto and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 341.85pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">other documents in connection therewith, with the Securities and Exchange Commission, granting unto <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 353.85pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 365.85pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">every act and thing requisite and necessary to be done in and about the premises, as fully to all intents <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 377.85pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">and purposes as they might or could do in person, hereby ratifying and confirming all that said attorneys-<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 389.85pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div><div style="--justify: justify; --position: absolute; background-color: #FFFFFF; border: 1px solid #CCCC; content-visibility: auto; float: none; font-size: 0; height: 792pt; margin: 10px auto 10px auto; overflow: hidden; padding: 0; position: relative; width: 612pt;"><div style="left: 0pt; position: absolute; top: 720pt;"><div style="width: 468pt;"></div></div><div style="left: 0pt; position: absolute; top: 0pt;"><div style="width: 468pt;"></div></div><div><div style="line-height: 7.28pt; position: absolute; top: 72pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed <font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="line-height: 7.28pt; position: absolute; top: 84pt; width: 612pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 72pt; position: absolute; white-space: pre;">by the following persons in the capacities and on the dates indicated.<font style="display: inline-block; height: 7.28pt;"></font></font></div><div style="position: absolute; top: 104pt; width: 612pt;"><div style="font-size: 0pt; left: 72pt; position: absolute; top: 0pt; width: 468pt;"><div><table style="border-collapse: collapse; display: inline-table; width: 100%;"><tr style="height: 0;"><td style="padding: 0; width: 151.5pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 225.75pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 3pt;" rowspan="1" colspan="1"></td><td style="padding: 0; width: 84.75pt;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 0pt; width: 151.5pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 4.31pt; width: 151.5pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 55.02pt; position: absolute; text-decoration: none; white-space: pre;">Signature<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 154.5pt; position: absolute; top: 0pt; width: 225.75pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 4.31pt; width: 225.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 103.63pt; position: absolute; text-decoration: none; white-space: pre;">Title<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 383.25pt; position: absolute; top: 0pt; width: 84.75pt;"><div><div style="line-height: 6.55pt; position: absolute; top: 4.31pt; width: 84.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 9pt; font-style: normal; font-weight: bold; left: 32.63pt; position: absolute; text-decoration: none; white-space: pre;">Date<font style="display: inline-block; height: 6.55pt;"></font></font></div></div></div></td></tr><tr style="height: 14.25pt;"><td style="border-bottom: 1pt solid #000; border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 154.5pt; position: absolute; top: 14.25pt; width: 225.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3pt; width: 225.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 9.67pt; position: absolute; text-decoration: none; white-space: pre;">President, Chief Executive Officer and Director <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 28.5pt; width: 151.5pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 151.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 31.31pt; position: absolute; text-decoration: none; white-space: pre;">John C.M. Farquhar<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 154.5pt; position: absolute; top: 28.5pt; width: 225.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3pt; width: 225.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 51.23pt; position: absolute; text-decoration: none; white-space: pre;">(<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 54.559999999999995pt; position: absolute; text-decoration: none; white-space: pre;">Principal Executive Officer<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 171.18pt; position: absolute; text-decoration: none; white-space: pre;">)<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 383.25pt; position: absolute; top: 28.5pt; width: 84.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 84.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 154.5pt; position: absolute; top: 45.75pt; width: 225.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 225.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 63.82pt; position: absolute; text-decoration: none; white-space: pre;">Chief Financial Officer <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 60pt; width: 151.5pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 151.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 37.78pt; position: absolute; text-decoration: none; white-space: pre;">Vikram Verghese<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 154.5pt; position: absolute; top: 60pt; width: 225.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 225.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 52.9pt; position: absolute; text-decoration: none; white-space: pre;">(<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 56.23pt; position: absolute; text-decoration: none; white-space: pre;">Principal Financial Officer<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 169.52pt; position: absolute; text-decoration: none; white-space: pre;">)<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 383.25pt; position: absolute; top: 60pt; width: 84.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 84.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 154.5pt; position: absolute; top: 77.25pt; width: 225.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 225.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 59.37pt; position: absolute; text-decoration: none; white-space: pre;">Chief Accounting Officer <font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 91.5pt; width: 151.5pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 151.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 41.86pt; position: absolute; text-decoration: none; white-space: pre;">Mhairi L. Jones<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 154.5pt; position: absolute; top: 91.5pt; width: 225.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 225.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 48.17pt; position: absolute; text-decoration: none; white-space: pre;">(<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: italic; font-weight: normal; left: 51.5pt; position: absolute; text-decoration: none; white-space: pre;">Principal Accounting Officer<font style="display: inline-block; height: 7.28pt;"></font></font><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 174.24pt; position: absolute; text-decoration: none; white-space: pre;">)<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 383.25pt; position: absolute; top: 91.5pt; width: 84.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 84.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 15.75pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 124.5pt; width: 151.5pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 151.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 35.03pt; position: absolute; text-decoration: none; white-space: pre;">William C. Weldon<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 154.5pt; position: absolute; top: 124.5pt; width: 225.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 225.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 45.4pt; position: absolute; text-decoration: none; white-space: pre;">Chair of the Board of Directors<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 383.25pt; position: absolute; top: 124.5pt; width: 84.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 84.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 15.75pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 157.5pt; width: 151.5pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 151.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 34.28pt; position: absolute; text-decoration: none; white-space: pre;">Timothy C. Barabe<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 154.5pt; position: absolute; top: 157.5pt; width: 225.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 225.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 95.38pt; position: absolute; text-decoration: none; white-space: pre;">Director<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 383.25pt; position: absolute; top: 157.5pt; width: 84.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 84.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 15.75pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 190.5pt; width: 151.5pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 151.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 40.48pt; position: absolute; text-decoration: none; white-space: pre;">Julie A. Cullivan<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 154.5pt; position: absolute; top: 190.5pt; width: 225.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 225.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 95.38pt; position: absolute; text-decoration: none; white-space: pre;">Director<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 383.25pt; position: absolute; top: 190.5pt; width: 84.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 84.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 15.75pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 223.5pt; width: 151.5pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 151.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 22.43pt; position: absolute; text-decoration: none; white-space: pre;">Nicholas Downing, M.D.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 154.5pt; position: absolute; top: 223.5pt; width: 225.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 225.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 95.38pt; position: absolute; text-decoration: none; white-space: pre;">Director<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 383.25pt; position: absolute; top: 223.5pt; width: 84.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 84.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 15.75pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 256.5pt; width: 151.5pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 151.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 34.18pt; position: absolute; text-decoration: none; white-space: pre;">Jeffrey C. Lightcap<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 154.5pt; position: absolute; top: 256.5pt; width: 225.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 225.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 95.38pt; position: absolute; text-decoration: none; white-space: pre;">Director<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 383.25pt; position: absolute; top: 256.5pt; width: 84.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 84.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 15.75pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 289.5pt; width: 151.5pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 151.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 29.67pt; position: absolute; text-decoration: none; white-space: pre;">Wayne J. Riley, M.D.<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 154.5pt; position: absolute; top: 289.5pt; width: 225.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 225.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 95.38pt; position: absolute; text-decoration: none; white-space: pre;">Director<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 383.25pt; position: absolute; top: 289.5pt; width: 84.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 84.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 15.75pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 322.5pt; width: 151.5pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 151.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 39.65pt; position: absolute; text-decoration: none; white-space: pre;">Lonnie M. Smith<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 154.5pt; position: absolute; top: 322.5pt; width: 225.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 225.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 95.38pt; position: absolute; text-decoration: none; white-space: pre;">Director<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 383.25pt; position: absolute; top: 322.5pt; width: 84.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 84.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 15.75pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 355.5pt; width: 151.5pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 151.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 37.51pt; position: absolute; text-decoration: none; white-space: pre;">Casey M. Tansey<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 154.5pt; position: absolute; top: 355.5pt; width: 225.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 225.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 95.38pt; position: absolute; text-decoration: none; white-space: pre;">Director<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 383.25pt; position: absolute; top: 355.5pt; width: 84.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 84.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr><tr style="height: 3pt;"><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 15.75pt;"><td style="border-bottom: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td></tr><tr style="height: 14.25pt;"><td style="border-top: 1pt solid #000; font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 0pt; position: absolute; top: 388.5pt; width: 151.5pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 151.5pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 16.42pt; position: absolute; text-decoration: none; white-space: pre;">Charles A. Taylor, Jr., Ph.D<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 154.5pt; position: absolute; top: 388.5pt; width: 225.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 225.75pt;"><font style="color: #000000; font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 95.38pt; position: absolute; text-decoration: none; white-space: pre;">Director<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"></td><td style="font-size: 0; text-align: left; vertical-align: top;" rowspan="1" colspan="1"><div style="left: 383.25pt; position: absolute; top: 388.5pt; width: 84.75pt;"><div><div style="line-height: 7.28pt; position: absolute; top: 3.37pt; width: 84.75pt;"><font style="font-family: &#39;Arial&#39;, sans-serif; font-size: 10pt; font-style: normal; font-weight: normal; left: 14.63pt; position: absolute; text-decoration: none; white-space: pre;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2025<font style="display: inline-block; height: 7.28pt;"></font></font></div></div></div></td></tr></table></div></div></div></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ie954142fa5c243c7a438f3d12f8ffa58_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 4.2</font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;ACT&#8221;). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">HEARTFLOW, INC.</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WARRANT TO PURCHASE COMMON STOCK</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">No. W-002</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">January 19, 2021</font></td></tr></table></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Void After January 19, 2031</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">THIS CERTIFIES THAT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, for value received, Hayfin Tourmaline Luxco S.a.r.l. or its permitted assignee (the &#8220;Holder&#8221;) is entitled to subscribe for and purchase at the Exercise Price (as defined below) from </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">HeartFlow, Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, a Delaware corporation, with its principal office at 1400 Seaport Boulevard, Building B, Redwood City, CA 94063 (the &#8220;Company&#8221;), the Exercise Shares (as defined below). Subject to the terms and conditions set forth herein, this Warrant shall be exercisable during the period (the &#8220;Exercise Period&#8221;) commencing on the date hereof and ending on the 10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> anniversary of the issue date of this Warrant (the &#8220;Expiration Date&#8221;).</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Upon completion of the Holdings Restructuring, as defined in that certain Credit Agreement and Guaranty (the &#8220;Credit Agreement&#8221;) entered into in connection with this Warrant, by and among the Company, Hayfin Services LLP and the lenders party thereto the parties shall cause this Warrant to be exchanged for a similar Warrant issued by Holdings, as defined in the Credit Agreement.</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.&#160;&#160;&#160;&#160;DEFINITIONS.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> As used herein, the following terms shall have the following respective meanings&#58;</font></div><div style="margin-bottom:10pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;Change of Control Transaction&#8221; means the consummation of (i) any consolidation or merger of the Company with or into any other corporation or other entity, or any other corporate reorganization (other than a transaction for the purpose of changing the domicile of the Company), in which the stockholders of the Company immediately prior to such consolidation, merger or reorganization do not own, directly or indirectly, capital stock of the entity surviving such merger, consolidation or reorganization (or its parent entity) representing a majority of the combined voting power of the outstanding securities of such entity immediately after such consolidation, merger or reorganization&#59; (ii) any other transaction or series of related transactions, in which capital stock representing in excess of fifty percent (50%) of the Company&#8217;s voting power is transferred to any single third-party entity (or group of related third-party entities) that is (or are) not affiliated with the Company&#59; (iii) a sale, lease, exclusive license or other disposition of all or substantially all of the assets of the Company to a third party not affiliated with the Company&#59; or (iv) any consolidation or merger of the Company or a subsidiary of the Company with or into, or any other corporate reorganization undertaken with, a publicly listed shell company or special purpose acquisition company, or a subsidiary of such an entity&#59; provided, that (A) a transaction or series of related transactions with the principal purpose of raising capital or (B) a reorganization effected in accordance with Section 251(g) of the DGCL, shall not be considered a Change of Control Transaction.</font></div><div style="margin-bottom:10pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;Common Stock&#8221; shall mean the common stock of the Company, par value $0.001 per share.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;DGCL&#8221; shall mean the Delaware General Corporation Law as currently in effect.</font></div><div style="margin-bottom:10pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;Direct Listing&#8221; shall mean the initial listing of shares of the Common Stock on a national securities exchange by means of a registration statement on Form S-1 under the Securities Act of 1933, as amended (the &#8220;Act&#8221;) (or any successor registration form under the Act subsequently adopted by the Securities and Exchange Commission) filed by the Company with the Securities and Exchange Commission that registers shares of existing capital stock of the Company for resale.</font></div><div style="margin-bottom:10pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;Exercise Price&#8221; shall mean $0.01 per share, subject to adjustment pursuant to Section 5.1 below.</font></div><div style="margin-bottom:10pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;Exercise Shares&#8221; shall initially mean three hundred fifteen thousand eight hundred ten (315,810) shares of Common Stock, subject to adjustment pursuant to the terms herein, including adjustment pursuant to Section 5 below.</font></div><div style="margin-bottom:10pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;IPO&#8221; shall mean the first sale of shares of capital stock of the Company pursuant to an effective registration statement under the Act in an underwritten public offering.</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;EXERCISE OF WARRANT. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The rights represented by this Warrant may be exercised in full or in part at any time during the Exercise Period, subject to the Company having a sufficient number of authorized shares of its Common Stock, by delivery of the following to the Company at its address set forth above (or at such other address as it may designate by notice in writing to the Holder)&#58;</font></div><div style="margin-bottom:10pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">An executed Notice of Exercise in the form attached hereto&#59;</font></div><div style="margin-bottom:10pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Payment of the Exercise Price either (i) in cash or by check, or (ii) via net exercise in accordance with Section 2.2 below&#59; and</font></div><div style="margin-bottom:10pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Warrant.</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Upon the exercise of the rights represented by this Warrant, a certificate or certificates for the Exercise Shares so purchased, registered in the name of the Holder or persons affiliated with the Holder, if the Holder so designates (along with a replacement warrant reflecting the balance of the Exercise Shares), shall be issued and delivered to the Holder or such designee within a reasonable time after the rights represented by this Warrant shall have been so exercised and, if this Warrant has not been fully exercised and has not expired, a new warrant of like tenor representing the Exercise Shares for which this Warrant remains exercisable.</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The person in whose name any certificate or certificates for Exercise Shares are to be issued upon exercise of this Warrant shall be deemed to have become the holder of record of such shares on the date on which this Warrant was surrendered and payment of the Exercise Price was made, irrespective of the date of delivery of such certificate or certificates, except that, if the date of such surrender and payment is a date when the stock transfer books of the Company are closed, such person shall be deemed to have become the holder of such shares at the close of business on the next succeeding date on which the stock transfer books are open.</font></div><div style="margin-bottom:10pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Net Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Notwithstanding any provisions herein to the contrary, if the fair market value of one share of the Company&#8217;s Common Stock is greater than the Exercise Price (at the date of calculation as set forth below), in lieu of exercising this Warrant by payment of cash, the Holder may </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">elect to receive shares equal to the value (as determined below) of this Warrant (or the portion thereof being exercised) by surrender of this Warrant at the principal office of the Company together with the properly endorsed Notice of Exercise in which event the Company shall issue to the Holder a number of shares of Common Stock computed using the following formula&#58;</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">X &#61; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Y (A-B)</font></div><div style="margin-bottom:10pt;padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A</font></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.465%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Where </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">X &#61;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the number of shares of Common Stock to be issued to the Holder</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Y &#61;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the number of shares of Common Stock purchasable under this Warrant or, if only a portion of this Warrant is being exercised, the portion of this Warrant being exercised (at the date of such calculation)</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A &#61; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the fair market value of one share of Common Stock (at the date of such calculation)</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B &#61; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exercise Price (as adjusted to the date of such calculation)</font></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For purposes of the above calculation and determining the fair market value of one share of Common Stock, if the Common Stock is then traded or quoted on a nationally recognized securities exchange, inter-dealer quotation system or over-the-counter market (a &#8220;Trading Market&#8221;), the fair market value of one share of Common Stock shall be the closing price or last sale price of a share of Common Stock reported for the business day immediately before the date on which the Holder delivers this Warrant together with its Notice of Exercise to the Company. If the Common Stock is not traded in a Trading Market, the fair market value of one share of Common Stock shall be determined by the Company&#8217;s Board of Directors in good faith.</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;COVENANTS OF THE COMPANY.</font></div><div style="margin-bottom:10pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Covenants as to Exercise Shares. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company covenants and agrees that all Exercise Shares that may be issued upon the exercise of the rights represented by this Warrant will, upon issuance, be validly issued and outstanding, fully paid and nonassessable, and free from all taxes, liens and charges with respect to the issuance thereof. The Company further covenants and agrees that the Company will, prior to the time this Warrant is exercised by the Holder, have authorized and reserved, free from preemptive rights, a sufficient number of shares of its Common Stock to provide for the exercise of the rights represented by this Warrant. If the number of authorized but unissued shares of Common Stock shall not be sufficient to permit exercise of this Warrant, the Company will take such corporate action as may, in the opinion of its counsel, be necessary to increase its share capital to allow for the issuance of such number of shares of Common Stock.</font></div><div style="margin-bottom:10pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Notices of Record Date. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the event of any taking by the Company of a record of the holders of any class of securities for the purpose of determining the holders thereof who are entitled to receive any dividend (other than a cash dividend which is the same as cash dividends paid in previous quarters) or other distribution, the Company shall mail to the Holder, at least ten (10) days prior to the date specified herein, a notice specifying the date on which any such record is to be taken for the purpose of such dividend or distribution.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;REPRESENTATIONS OF HOLDER.</font></div><div style="margin-bottom:10pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Acquisition of Warrant for Personal Account. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Holder represents and warrants that it is acquiring this Warrant and the Exercise Shares for its account for investment and not with a view to or for sale or distribution of said Warrant or Exercise Shares or any part thereof. Holder has not been formed for the specific purpose of acquiring this Warrant or the Exercise Shares.</font></div><div style="margin-bottom:10pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Securities Are Not Registered.</font></div><div style="margin-bottom:10pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Holder understands that this Warrant and the Exercise Shares have not been registered under the Act on the basis that no distribution or public offering of the stock of the Company is to be effected. The Holder realizes that the basis for the exemption may not be present if, notwithstanding its representations, the Holder has a present intention of acquiring the securities for a fixed or determinable period in the future, selling (in connection with a distribution or otherwise), granting any participation in, or otherwise distributing the securities. The Holder has no such present intention.</font></div><div style="margin-bottom:10pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Holder recognizes that this Warrant and the Exercise Shares must be held indefinitely unless they are subsequently registered under the Act or an exemption from such registration is available. The Holder recognizes that the Company has no obligation to register this Warrant or the Exercise Shares of the Company, or to comply with any exemption from such registration.</font></div><div style="margin-bottom:10pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Holder is aware that neither this Warrant nor the Exercise Shares may be sold pursuant to Rule 144 adopted under the Act unless certain conditions are met, including, among other things, the existence of a public market for the shares, the availability of certain current public information about the Company, the resale following the required holding period under Rule 144 and the number of shares being sold during any three month period not exceeding specified limitations. Holder is aware that the conditions for resale set forth in Rule 144 have not been satisfied and that the Company presently has no plans to satisfy these conditions in the foreseeable future.</font></div><div style="margin-bottom:10pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Accredited Investor Status</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Holder is an &#8220;accredited investor&#8221; as such term is defined in Rule 501 under the Act. The Holder is aware of the Company&#8217;s business affairs and financial condition and has acquired sufficient information about the Company to reach an informed and knowledgeable decision regarding its investment in the Company. The Holder is experienced in making investments of this type and has such knowledge and background in financial and business matters that the Holder is capable of evaluating the merits and risks of this investment and protecting the Holder&#8217;s own interests.</font></div><div style="margin-bottom:10pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Foreign Investors. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If the Holder is not a United States person (as defined by Section 7701(a)(30) of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;)), the Holder hereby represents that he, she or it has satisfied itself as to the full observance of the laws of the Holder&#8217;s jurisdiction in connection with any invitation to subscribe for the Securities or any use of this Note, including (a) the legal requirements within the Holder&#8217;s jurisdiction for the purchase of this Warrant and the Exercise Shares, (b) any foreign exchange restrictions applicable to such purchase, (c) any governmental or other consents that may need to be obtained, and (d) the income tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale or transfer of this Warrant and the Exercise Shares. The Holder&#8217;s subscription, payment for and continued beneficial ownership of this Warrant and the Exercise Shares will not violate any applicable securities or other laws of the Holder&#8217;s jurisdiction.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;No &#8220;Bad Actor&#8221; Disqualification. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Holder represents and warrants that neither (a) the Holder nor (b) any entity that controls the Holder or is under the control of, or under common control with, the Holder, is subject to any of the &#8220;bad actor&#8221; disqualifications described in Rule 506(d)(1)(i) through (viii), as modified by Rules 506(d)(2) and (d)(3), under the Act (&#8220;Disqualification Events&#8221;), except for Disqualification Events covered by Rule 506(d)(2)(ii) or (iii) or (d)(3) under the Act and disclosed in writing in reasonable detail to the Company. The Holder represents that the Holder has exercised reasonable care to determine the accuracy of the representation made by the Holder in this Section 4.5 and agrees to notify the Company if the Holder becomes aware of any fact that makes the representation given by the Holder hereunder inaccurate.</font></div><div style="margin-bottom:10pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Forward-Looking Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. With respect to any forecasts, projections of results and other forward-looking statements and information provided to the Holder, the Holder acknowledges that such statements were prepared based upon assumptions deemed reasonable by the Company at the time of preparation. There is no assurance that such statements will prove accurate, and the Company has no obligation to update such statements.</font></div><div style="margin-bottom:10pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Disposition of Warrant and Exercise Shares.</font></div><div style="margin-bottom:10pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Holder further agrees not to make any disposition of all or any part of this Warrant or Exercise Shares in any event unless and until&#58;</font></div><div style="margin-bottom:10pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There is then in effect a registration statement under the Act covering such proposed disposition and such disposition is made in accordance with said registration statement&#59; or</font></div><div style="margin-bottom:10pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Holder shall have notified the Company of the proposed disposition and shall have furnished the Company with a detailed statement of the circumstances surrounding the proposed disposition, and if reasonably requested by the Company, the Holder shall have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, for the Holder to the effect that such disposition will not require registration of such Warrant or Exercise Shares under the Act or any applicable state securities laws.</font></div><div style="margin-bottom:10pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Holder understands and agrees that all certificates evidencing Exercise Shares to be issued to the Holder may bear the following legend&#58;</font></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;ACT&#8221;). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.</font></div><div style="margin-bottom:24pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">THESE SECURITIES ARE SUBJECT TO A LOCK-UP PERIOD IN THE EVENT OF A PUBLIC OFFERING AS SET FORTH IN AN AGREEMENT BETWEEN THE HOLDER AND THE COMPANY.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;ANTI-DILUTION ADJUSTMENT FOR CERTAIN EVENTS.</font></div><div style="margin-bottom:10pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the event of changes in the outstanding Common Stock of the Company by reason of stock dividends, split-ups, recapitalizations, reclassifications, combinations or exchanges of shares, separations, reorganizations, liquidations, or the like, the number and class of shares available under this Warrant in the aggregate and the Exercise Price shall be correspondingly adjusted to give the Holder of this Warrant, on exercise for the same aggregate Exercise Price, the total number, class, and kind of shares as the Holder would have owned had this Warrant been exercised prior to the event and had the Holder continued to hold such shares until after the event requiring adjustment&#59; provided, however, that such adjustment shall not be made with respect to, and this Warrant shall terminate if not exercised prior to, the events set forth in Section 7 below. The form of this Warrant need not be changed because of any adjustment in the number of Exercise Shares subject to this Warrant.</font></div><div style="margin-bottom:10pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If, upon the first issuance of Next Round Securities in the Next Round (the &#8220;Next Round Issuance&#8221;) this Warrant is then currently exercisable in whole or in part and the Next Round Price is less than $25.3317 per share (as adjusted for any stock splits, recapitalizations and the like), the number of Exercise Shares shall be increased to equal the quotient obtained by dividing (a) $8,000,000 by (b) the Next Round Price (subject to adjustment thereafter from time to time in accordance with the provisions of Section 5.1 of this Warrant), net of any Exercise Shares issued prior to the Next Round Issuance. As used herein &#8220;Next Round&#8221; means, at any time prior to the consummation of an IPO or Direct Listing, the first sale or issuance by the Company on or after the original issue date of this Warrant, in a single transaction or series of related transactions, of shares of its convertible preferred stock or other senior equity securities to one or more investors for at least $5 million in gross cash proceeds&#59; &#8220;Next Round Securities&#8221; means the type, class and series of convertible preferred stock or other senior equity security sold or issued by the Company in the Next Round&#59; and &#8220;Next Round Price&#8221; means the price per share paid in cash by purchasers of Next Round Securities issued in the Next Round. For example, if the Company issues Next Round Securities at a Next Round Price of $20.00 and the Warrant is then currently outstanding in whole, the number of Exercise Shares shall be increased from 315,810 to 400,000 ($8,000,000 &#47; $20 &#61; 400,000). In the event this Warrant has been exercised in part prior to the Next Round, the increase in the number of Exercise Shares shall be reduced by the number of Exercise Shares previously issued upon partial exercise of this Warrant. No more than one adjustment shall be made pursuant to this Section 5.2.</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;FRACTIONAL SHARES.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> No fractional shares shall be issued upon the exercise of this Warrant as a consequence of any adjustment pursuant hereto. All Exercise Shares (including fractions) issuable upon exercise of this Warrant may be aggregated for purposes of determining whether the exercise would result in the issuance of any fractional share. If, after aggregation, the exercise would result in the issuance of a fractional share, the Company shall, in lieu of issuance of any fractional share, pay the Holder otherwise entitled to such fraction a sum in cash equal to the product resulting from multiplying the then current fair market value of an Exercise Share by such fraction.</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;TREATMENT OF WARRANT UPON CERTAIN EVENTS.</font></div><div style="margin-bottom:10pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Upon a Change of Control Transaction.</font></div><div style="margin-bottom:10pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the event of a Change of Control Transaction in which the consideration to be received by the Company&#8217;s stockholders consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable Securities (a &#8220;Cash&#47;Public Acquisition&#8221;), and the fair market value of one share of the Company&#8217;s Common Stock as determined in accordance with Section 2.2 above would be greater than the Exercise Price in effect on such date immediately prior to such Cash&#47;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Public Acquisition, and Holder has not exercised this Warrant as to all Exercise Shares, then this Warrant shall automatically be deemed to be net exercised pursuant to Section 2.2 above as to all Exercise Shares effective immediately prior to and contingent upon the consummation of a Cash&#47;Public Acquisition. In connection with such net exercise, Holder shall be deemed to have restated each of the representations and warranties in Section 4 of this Warrant as of the date thereof and the Company shall promptly notify the Holder of the number of Exercise Shares (or such other securities) issued upon exercise. In the event of a Cash&#47;Public Acquisition where the fair market value of one share of the Company&#8217;s Common Stock as determined in accordance with Section 2.2 above would be less than the Exercise Price in effect immediately prior to such Cash&#47;Public Acquisition, then this Warrant will expire immediately prior to the consummation of such Cash&#47;Public Acquisition.</font></div><div style="margin-bottom:10pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company shall provide the Holder with written notice of a Change of Control Transaction (together with such reasonable information as the Holder may reasonably require regarding the treatment of this Warrant in connection with such contemplated Change of Control Transaction giving rise to such notice), which is to be delivered to the Holder not less than five (5) Business Days prior to the closing of the proposed Change of Control Transaction.</font></div><div style="margin-bottom:10pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Upon the closing of any Change of Control Transaction other than a Cash&#47;Public Acquisition defined above, the acquiring, surviving or successor entity shall assume the obligations of this Warrant, and this Warrant shall thereafter be exercisable for the same securities and&#47;or other property as would have been paid for the Exercise Shares issuable upon exercise of the unexercised portion of this Warrant as if such Exercise Shares were outstanding on and as of the closing of such Change in Control Transaction, subject to further adjustment from time to time in accordance with the provisions of this Warrant.</font></div><div style="margin-bottom:10pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As used in this Warrant, &#8220;Marketable Securities&#8221; means securities meeting all of the following requirements&#58; (a) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and is then current in its filing of all required reports and other information under the Act and the Exchange Act&#59; (b) the class and series of shares or other security of the issuer that would be received by the Holder in connection with the Cash&#47;Public Acquisition were the Holder to exercise this Warrant on or prior to the closing thereof is then traded on a Trading Market, and (c) Holder would be able to publicly re-sell, within six (6) months following the closing of such Acquisition, all of the issuer&#8217;s shares and&#47;or other securities that would be received by the Holder in such Cash&#47;Public Acquisition were Holder to exercise this Warrant in full on or prior to the closing of such Cash&#47;Public Acquisition.</font></div><div style="margin-bottom:10pt;padding-right:16pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Automatic Exercise at Expiration. To the extent this Warrant is not previously exercised, and if the fair market value of one Warrant share is greater than the Exercise Price, as adjusted, on the Expiration Date, this Warrant shall be deemed automatically exercised in accordance with Section 2.2 hereof (even if not surrendered) immediately prior to the close of business on the Expiration Date (unless the Expiration Date is not a Business Day, in which case, on the Business Day immediately preceding the Expiration Date). To the extent this Warrant is deemed automatically exercised pursuant to this Section 7, the Company agrees to notify the Holder within a reasonable period of time of the number of Warrant shares the Holder is to receive by reason of such automatic exercise. The Company shall not be required to deliver any certificates evidencing any Exercise Shares issuable upon such automatic exercise unless and until the Company has received the original of this Warrant (or an affidavit reasonably satisfactory to the Company that this Warrant has been lost, stolen or destroyed).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;MARKET STAND-OFF AGREEMENT.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Holder hereby agrees that Holder shall not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, any shares of Common Stock (or other securities) of the Company held by Holder (other than those included in the registration) during the 180-day period following the effective date of the IPO or Direct Listing (or such longer period as the underwriters or the Company shall request in order to facilitate compliance with FINRA Rule 2711 or NYSE Member Rule 472 or any successor or similar rule or regulation). Holder further agrees to execute and deliver such other agreements as may be reasonably requested by the Company or the managing underwriters that are consistent with the foregoing or that are necessary to give further effect thereto. In addition, if requested by the Company or the representative of the underwriters of Common Stock (or other securities) of the Company, Holder shall provide, within ten (10) days of such request, such information as may be required by the Company or such representative in connection with the completion of any public offering of the Company&#8217;s securities pursuant to a registration statement filed under the Act. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to such Common Stock (or other securities) until the end of such period. Holder agrees that any transferee of this Warrant (or other securities of the Company held by Holder) shall be bound by this Section 8 as a condition to the transfer. The underwriters of the Company&#8217;s stock are intended third party beneficiaries of this Section 8 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto.</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;NO STOCKHOLDER RIGHTS.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> This Warrant in and of itself shall not entitle the Holder to any voting rights or other rights as a stockholder of the Company.</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;INFORMATION AND REGISTRATION RIGHTS.</font></div><div style="margin-bottom:10pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subject to Holder&#8217;s entering into a confidentiality agreement in form and substance reasonably acceptable to the Company, the Company will furnish the following reports to Holder so long as this Warrant remains exercisable&#58; (a) as soon as practicable after the end of each fiscal year of the Company, an unaudited consolidated balance sheet of the Company and its subsidiaries, as at the end of such fiscal year, and unaudited consolidated statements of income and cash flows of the Company and its subsidiaries for such year (the &#8220;Fiscal Year Financials&#8221;), prepared in accordance with U.S. generally accepted accounting principles consistently applied, with audited Fiscal Year Financials to be provided when available&#59; (b) as soon as practicable after the end of the first, second and third quarterly accounting periods in each fiscal year of the Company, an unaudited consolidated balance sheet of the Company and its subsidiaries as at the end of such fiscal quarter, and unaudited consolidated statements of income and cash flows of the Company and its subsidiaries for such quarterly period, prepared in accordance with U.S. generally accepted accounting principles consistently applied&#59; and (c) when available, a financial plan and budget for the then current fiscal year. The information rights granted under this Section 10 shall automatically terminate in the event of a Cash&#47;Public Acquisition, an IPO or a Direct Listing and are not transferable to any person not affiliated with the Holder.</font></div><div style="margin-bottom:10pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Exercise Shares shall be &#8220;Registrable Securities&#8221; as such term is defined in the Amended and Restated Investors&#8217; Rights Agreement, dated as of November 20, 2017 (as amended from time to time, the &#8220;Rights Agreement&#8221;) for purposes of Sections 2.1 and 2.2 thereof, and Holder shall have the same rights as, and shall be subject to the same terms and conditions set forth in, Sections 2.1 (Requested Registration) and 2.2 (Company Registration) of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the Rights Agreement as a &#8220;Holder&#8221; thereunder, provided that none of the Exercise Shares shall be counted when determining the Initiating Holders (as defined in the Rights Agreement). Holder shall execute and deliver a joinder to Sections 2.1 and 2.2 of the Rights Agreement following the exercise of this Warrant. The Company shall take such action as may be reasonably necessary to carry out the intent of the foregoing, including, without limitation, amending the Rights Agreement to include the Exercise Shares as Registrable Securities under the Rights Agreement, subject to the limitations set forth in this Section 10.2.</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;TRANSFER OF WARRANT.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Subject to applicable laws and the restriction on transfer set forth on the first page of this Warrant (including without limitation, delivery of a legal opinion reasonably satisfactory to the Company), this Warrant is transferable, in whole or in part, by the Holder in person or by duly authorized attorney to (a) any affiliate (including related funds) of Holder, or (b) subject to the Company&#8217;s consent, which shall not be unreasonably withheld, a person not affiliated with the Holder, in each case, upon delivery of this Warrant and the form of assignment attached hereto to the transferee designated by Holder. In the event of a non-affiliate transfer, the information rights set forth in Section 10 above shall automatically terminate. The transferee shall sign an investment letter in form and substance reasonably satisfactory to the Company for the purpose of providing the representations and warranties in Section 4 hereof. Upon any such transfer the Company shall issue within a reasonable period of time, an appropriate warrant to the transferee(s). The Company may withhold its consent to a transfer of all or any portion of this Warrant to a direct or indirect competitor of the Company. Holder shall reimburse the Company&#8217;s reasonable out of pocket costs and fees (including the Company&#8217;s legal fees) for any transfers of this Warrant occurring after the original issue date of this Warrant.</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;LOST, STOLEN, MUTILATED OR DESTROYED WARRANT.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> If this Warrant is lost, stolen, mutilated or destroyed, the Company may, on such terms as to indemnity or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination and tenor as this Warrant so lost, stolen, mutilated or destroyed. Any such new Warrant shall constitute an original contractual obligation of the Company, whether or not the allegedly lost, stolen, mutilated or destroyed Warrant shall be at any time enforceable by anyone.</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;NOTICES, ETC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> All notices required or permitted hereunder shall be in writing and shall be deemed effectively given&#58; (a) upon personal delivery to the party to be notified, (b) when sent by confirmed email or facsimile if sent during normal business hours of the recipient, if not, then on the next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the Company at the address listed on the signature page and to Holder at Hayfin Capital Management LLP, One Eagle Place, London, SW1Y 6AF, United Kingdom&#59; or at such other address as the Company or Holder may designate by ten (10) days advance written notice to the other parties hereto.</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;ACCEPTANCE.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained herein.</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;GOVERNING LAW.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> This Warrant and all rights, obligations and liabilities hereunder shall be governed by the laws of the State of Delaware.</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Remainder of the page left intentionally blank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.</font></div></div></div><div id="ie954142fa5c243c7a438f3d12f8ffa58_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Company has caused this Warrant to be executed by its duly authorized officer as of January 19, 2021.</font></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.619%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">HEARTFLOW, INC.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#47;s&#47; Dana Mead</font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; Dana G. Mead, Jr.</font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;President and Chief Executive Officer</font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 46pt;text-align:left;text-indent:-45pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Address&#58; 1400 Seaport Boulevard, Building B Redwood City, CA 94063</font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;Signature Page to Warrant to Purchase Common Stock&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.312%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">ACKNOWLEDGED AND AGREED</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">HAYFIN TOURMALINE LUXCO S.A.R.L.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#47;s&#47; Beatrice Methe</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58;</font></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beatrice Methe</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58;</font></td><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manager</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Address&#58;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15 boulevard F.W. Raiffeisen L-2411 Luxembourg</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;Signature Page to Warrant to Purchase Common Stock&#93;</font></div></div></div><div id="ie954142fa5c243c7a438f3d12f8ffa58_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTICE OF EXERCISE</font></div><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TO&#58; HEARTFLOW, INC.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(1)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The undersigned hereby elects to purchase ____________ shares of the Common Stock of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">HEARTFLOW, INC. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(the &#8220;Company&#8221;) pursuant to the terms of the attached Warrant, and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</font></div><div style="margin-bottom:6pt;text-indent:72pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The undersigned hereby elects to purchase ____________ shares of the Common Stock of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">HEARTFLOW, INC. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(the &#8220;Company&#8221;) pursuant to the terms of the net exercise provisions set forth in Section 2.2 of the attached Warrant, and shall tender payment of all applicable transfer taxes, if any.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(2)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Please issue a certificate or certificates representing said shares of Common Stock in the name of the undersigned or in such other name as is specified below&#58;</font></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.443%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Name)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Address)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Date)</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Signature)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Print name)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ASSIGNMENT FORM</font></div><div style="margin-bottom:22pt;padding-left:108pt;padding-right:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(To assign the foregoing Warrant, in whole or part, execute this form and supply required information. Do not use this form to purchase shares.)</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FOR VALUE RECEIVED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the foregoing Warrant and all rights evidenced thereby are hereby assigned to </font></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.965%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Please Print)</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Address&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Please Print)</font></td></tr></table></div><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dated&#58; __________, 20__</font></div><div style="margin-bottom:34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.595%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Holder&#8217;s<br>Signature&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Holder&#8217;s<br>Address&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Signature Guaranteed&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; The signature to this Assignment Form must correspond with the name as it appears on the face of this Warrant, without alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>3
<FILENAME>filename3.htm
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i70ec4b0f2fa544ffac9208ce2f62f2ad_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 4.3</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Execution Version</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;ACT&#8221;). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">HEARTFLOW HOLDING, INC.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WARRANT TO PURCHASE COMMON STOCK</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">No. W-003</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">March 17, 2022</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Void After March 17, 2032</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">THIS CERTIFIES THAT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, for value received, Hayfin Tourmaline Luxco S.a.r.l. or its permitted assignee (the &#8220;Holder&#8221;) is entitled to subscribe for and purchase at the Exercise Price (as defined below) from </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">HeartFlow Holding, Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, a Delaware corporation, with its principal office at 331 E. Evelyn Avenue, Mountain View, CA 94041 (the &#8220;Company&#8221;), the Exercise Shares (as defined below). Subject to the terms and conditions set forth herein, this Warrant shall be exercisable during the period (the &#8220;Exercise Period&#8221;) commencing on the date hereof and ending on the 10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> anniversary of the issue date of this Warrant (the &#8220;Expiration Date&#8221;).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;DEFINITIONS.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> As used herein, the following terms shall have the following respective meanings&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;Business Day&#8221; means any day which is neither a Saturday nor Sunday nor a legal holiday on which banks are authorized or required to be closed in New York, New York or London, England.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;Change of Control Transaction&#8221; means the consummation of (i) any consolidation or merger of the Company with or into any other corporation or other entity, or any other corporate reorganization (other than a transaction for the purpose of changing the domicile of the Company), in which the stockholders of the Company immediately prior to such consolidation, merger or reorganization do not own, directly or indirectly, capital stock of the entity surviving such merger, consolidation or reorganization (or its parent entity) representing a majority of the combined voting power of the outstanding securities of such entity immediately after such consolidation, merger or reorganization&#59; (ii) any other transaction or series of related transactions, in which capital stock representing in excess of fifty percent (50%) of the Company&#8217;s voting power is transferred to any single third-party entity (or group of related third-party entities) that is (or are) not affiliated with the Company&#59; (iii) a sale, lease, exclusive license or other disposition of all or substantially all of the assets of the Company to a third party not affiliated with the Company&#59; or (iv) any consolidation or merger of the Company or a subsidiary of the Company with or into, or any other corporate reorganization undertaken with, a publicly listed shell company or special purpose acquisition company, or a subsidiary of such an entity&#59; provided, that (A) a transaction or series of related transactions with the principal purpose of raising capital or (B) a reorganization effected in accordance with Section 251(g) of the DGCL, shall not be considered a Change of Control Transaction.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;Common Stock&#8221; shall mean the common stock of the Company, par value $0.001 per share.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:0.80pt">1.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;DGCL&#8221; shall mean the Delaware General Corporation Law as currently in effect.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;Direct Listing&#8221; shall mean the initial listing of shares of the Common Stock on a national securities exchange by means of a registration statement on Form S-1 under the Securities Act of 1933, as amended (the &#8220;Act&#8221;) (or any successor registration form under the Act subsequently adopted by the Securities and Exchange Commission) filed by the Company with the Securities and Exchange Commission that registers shares of existing capital stock of the Company for resale.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;Exercise Price&#8221; shall mean $0.01 per share, subject to adjustment pursuant to Section 5.1 below.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;Exercise Shares&#8221; shall initially mean two hundred twenty-five thousand five hundred seventy-nine (225,579) shares of Common Stock, subject to adjustment pursuant to the terms herein, including adjustment pursuant to Section 5 below.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;IPO&#8221; shall mean the first sale of shares of capital stock of the Company pursuant to an effective registration statement under the Act in an underwritten public offering.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">2.&#160;&#160;&#160;&#160;EXERCISE OF WARRANT. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The rights represented by this Warrant may be exercised in full or in part at any time during the Exercise Period, subject to the Company having a sufficient number of authorized shares of its Common Stock, by delivery of the following to the Company at its address set forth above (or at such other address as it may designate by notice in writing to the Holder)&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">An executed Notice of Exercise in the form attached hereto&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Payment of the Exercise Price either (i) in cash or by check, or (ii) via net exercise in accordance with Section 2.2 below&#59; and</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">This Warrant.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Upon the exercise of the rights represented by this Warrant, a certificate or certificates for the Exercise Shares so purchased, registered in the name of the Holder or persons affiliated with the Holder, if the Holder so designates (along with a replacement warrant reflecting the balance of the Exercise Shares), shall be issued and delivered to the Holder or such designee within a reasonable time after the rights represented by this Warrant shall have been so exercised and, if this Warrant has not been fully exercised and has not expired, a new warrant of like tenor representing the Exercise Shares for which this Warrant remains exercisable.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The person in whose name any certificate or certificates for Exercise Shares are to be issued upon exercise of this Warrant shall be deemed to have become the holder of record of such shares on the date on which this Warrant was surrendered and payment of the Exercise Price was made, irrespective of the date of delivery of such certificate or certificates, except that, if the date of such surrender and payment is a date when the stock transfer books of the Company are closed, such person shall be deemed to have become the holder of such shares at the close of business on the next succeeding date on which the stock transfer books are open.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">2.2&#160;&#160;&#160;&#160;Net Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Notwithstanding any provisions herein to the contrary, if the fair market value of one share of the Company&#8217;s Common Stock is greater than the Exercise Price (at the date of calculation as set forth below), in lieu of exercising this Warrant by payment of cash, the Holder may</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:0.80pt">2.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">elect to receive shares equal to the value (as determined below) of this Warrant (or the portion thereof being exercised) by surrender of this Warrant at the principal office of the Company together with the properly endorsed Notice of Exercise in which event the Company shall issue to the Holder a number of shares of Common Stock computed using the following formula&#58;</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">X &#61; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Y (A-B)</font></div><div style="margin-bottom:12pt;padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Where&#160;&#160;&#160;&#160;X &#61;&#160;&#160;&#160;&#160;the number of shares of Common Stock to be issued to the Holder</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Y &#61;&#160;&#160;&#160;&#160;the number of shares of Common Stock purchasable under this Warrant or, if only a portion of this Warrant is being exercised, the portion of this Warrant being exercised (at the date of such calculation)</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A &#61;&#160;&#160;&#160;&#160;the fair market value of one share of Common Stock (at the date of such calculation)</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">B &#61;&#160;&#160;&#160;&#160;Exercise Price (as adjusted to the date of such calculation)</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For purposes of the above calculation and determining the fair market value of one share of Common Stock, if the Common Stock is then traded or quoted on a nationally recognized securities exchange, inter-dealer quotation system or over-the-counter market (a &#8220;Trading Market&#8221;), the fair market value of one share of Common Stock shall be the closing price or last sale price of a share of Common Stock reported for the Business Day immediately before the date on which the Holder delivers this Warrant together with its Notice of Exercise to the Company. If the Common Stock is not traded in a Trading Market, the fair market value of one share of Common Stock shall be determined by the Company&#8217;s Board of Directors in good faith.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;COVENANTS OF THE COMPANY.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.1&#160;&#160;&#160;&#160;Covenants as to Exercise Shares. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company covenants and agrees that all Exercise Shares that may be issued upon the exercise of the rights represented by this Warrant will, upon issuance, be validly issued and outstanding, fully paid and nonassessable, and free from all taxes, liens and charges with respect to the issuance thereof. The Company further covenants and agrees that the Company will, prior to the time this Warrant is exercised by the Holder, have authorized and reserved, free from preemptive rights, a sufficient number of shares of its Common Stock to provide for the exercise of the rights represented by this Warrant. If the number of authorized but unissued shares of Common Stock shall not be sufficient to permit exercise of this Warrant, the Company will take such corporate action as may, in the opinion of its counsel, be necessary to increase its share capital to allow for the issuance of such number of shares of Common Stock.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.2&#160;&#160;&#160;&#160;Notices of Record Date. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the event of any taking by the Company of a record of the holders of any class of securities for the purpose of determining the holders thereof who are entitled to receive any dividend (other than a cash dividend which is the same as cash dividends paid in previous quarters) or other distribution, the Company shall mail to the Holder, at least ten (10) days prior to the date specified herein, a notice specifying the date on which any such record is to be taken for the purpose of such dividend or distribution.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:0.80pt">3.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;REPRESENTATIONS OF HOLDER.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.1&#160;&#160;&#160;&#160;Acquisition of Warrant for Personal Account. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Holder represents and warrants that it is acquiring this Warrant and the Exercise Shares for its account for investment and not with a view to or for sale or distribution of said Warrant or Exercise Shares or any part thereof. Holder has not been formed for the specific purpose of acquiring this Warrant or the Exercise Shares.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.2&#160;&#160;&#160;&#160;Securities Are Not Registered.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Holder understands that this Warrant and the Exercise Shares have not been registered under the Act on the basis that no distribution or public offering of the stock of the Company is to be effected. The Holder realizes that the basis for the exemption may not be present if, notwithstanding its representations, the Holder has a present intention of acquiring the securities for a fixed or determinable period in the future, selling (in connection with a distribution or otherwise), granting any participation in, or otherwise distributing the securities. The Holder has no such present intention.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Holder recognizes that this Warrant and the Exercise Shares must be held indefinitely unless they are subsequently registered under the Act or an exemption from such registration is available. The Holder recognizes that the Company has no obligation to register this Warrant or the Exercise Shares of the Company, or to comply with any exemption from such registration.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Holder is aware that neither this Warrant nor the Exercise Shares may be sold pursuant to Rule 144 adopted under the Act unless certain conditions are met, including, among other things, the existence of a public market for the shares, the availability of certain current public information about the Company, the resale following the required holding period under Rule 144 and the number of shares being sold during any three month period not exceeding specified limitations. Holder is aware that the conditions for resale set forth in Rule 144 have not been satisfied and that the Company presently has no plans to satisfy these conditions in the foreseeable future.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.3&#160;&#160;&#160;&#160;Accredited Investor Status</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Holder is an &#8220;accredited investor&#8221; as such term is defined in Rule 501 under the Act. The Holder is aware of the Company&#8217;s business affairs and financial condition and has acquired sufficient information about the Company to reach an informed and knowledgeable decision regarding its investment in the Company. The Holder is experienced in making investments of this type and has such knowledge and background in financial and business matters that the Holder is capable of evaluating the merits and risks of this investment and protecting the Holder&#8217;s own interests.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.4&#160;&#160;&#160;&#160;Foreign Investors. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If the Holder is not a United States person (as defined by Section 7701(a)(30) of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;)), the Holder hereby represents that he, she or it has satisfied itself as to the full observance of the laws of the Holder&#8217;s jurisdiction in connection with any invitation to subscribe for the Securities or any use of this Note, including (a) the legal requirements within the Holder&#8217;s jurisdiction for the purchase of this Warrant and the Exercise Shares, (b) any foreign exchange restrictions applicable to such purchase, (c) any governmental or other consents that may need to be obtained, and (d) the income tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale or transfer of this Warrant and the Exercise Shares. The Holder&#8217;s subscription, payment for and continued beneficial ownership of this Warrant and the Exercise Shares will not violate any applicable securities or other laws of the Holder&#8217;s jurisdiction.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:0.80pt">4.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">4.5&#160;&#160;&#160;&#160;No &#8220;Bad Actor&#8221; Disqualification. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The Holder represents and warrants that neither (a) the Holder nor (b) any entity that controls the Holder or is under the control of, or under common control with, the Holder, is subject to any of the &#8220;bad actor&#8221; disqualifications described in Rule 506(d)(1)(i) through (viii), as modified by Rules 506(d)(2) and (d)(3), under the Act (&#8220;Disqualification Events&#8221;), except for Disqualification Events covered by Rule 506(d)(2)(ii) or (iii) or (d)(3) under the Act and disclosed in writing in reasonable detail to the Company. The Holder represents that the Holder has exercised reasonable care to determine the accuracy of the representation made by the Holder in this Section 4.5 and agrees to notify the Company if the Holder becomes aware of any fact that makes the representation given by the Holder hereunder inaccurate.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">4.6&#160;&#160;&#160;&#160;Forward-Looking Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. With respect to any forecasts, projections of results and other forward-looking statements and information provided to the Holder, the Holder acknowledges that such statements were prepared based upon assumptions deemed reasonable by the Company at the time of preparation. There is no assurance that such statements will prove accurate, and the Company has no obligation to update such statements.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">4.7&#160;&#160;&#160;&#160;Disposition of Warrant and Exercise Shares.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The Holder further agrees not to make any disposition of all or any part of this Warrant or Exercise Shares in any event unless and until&#58;</font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">There is then in effect a registration statement under the Act covering such proposed disposition and such disposition is made in accordance with said registration statement&#59; or</font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The Holder shall have notified the Company of the proposed disposition and shall have furnished the Company with a detailed statement of the circumstances surrounding the proposed disposition, and if reasonably requested by the Company, the Holder shall have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, for the Holder to the effect that such disposition will not require registration of such Warrant or Exercise Shares under the Act or any applicable state securities laws.</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The Holder understands and agrees that all certificates evidencing Exercise Shares to be issued to the Holder may bear the following legend&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;ACT&#8221;). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.</font></div><div style="margin-bottom:24pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">THESE SECURITIES ARE SUBJECT TO A LOCK-UP PERIOD IN THE EVENT OF A PUBLIC OFFERING AS SET FORTH IN AN AGREEMENT BETWEEN THE HOLDER AND THE COMPANY.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">5.&#160;&#160;&#160;&#160;ANTI-DILUTION ADJUSTMENT FOR CERTAIN EVENTS.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">5.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">In the event of changes in the outstanding Common Stock of the Company by reason of stock dividends, split-ups, recapitalizations, reclassifications, combinations or exchanges of</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:0.80pt">5.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">shares, separations, reorganizations, liquidations, or the like, the number and class of shares available under this Warrant in the aggregate and the Exercise Price shall be correspondingly adjusted to give the Holder of this Warrant, on exercise for the same aggregate Exercise Price, the total number, class, and kind of shares as the Holder would have owned had this Warrant been exercised prior to the event and had the Holder continued to hold such shares until after the event requiring adjustment&#59; provided, however, that such adjustment shall not be made with respect to, and this Warrant shall terminate if not exercised prior to, the events set forth in Section 7 below. The form of this Warrant need not be changed because of any adjustment in the number of Exercise Shares subject to this Warrant.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:110%">5.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">If, upon the first issuance of Next Round Securities in the Next Round (the &#8220;Next Round Issuance&#8221;) this Warrant is then currently exercisable in whole or in part and the Next Round Price is less than $25.3317 per share (as adjusted for any stock splits, recapitalizations and the like), the number of Exercise Shares shall be increased to equal the quotient obtained by dividing (a) $5,714,300 by (b) the Next Round Price (subject to adjustment thereafter from time to time in accordance with the provisions of Section 5.1 of this Warrant), net of any Exercise Shares issued prior to the Next Round Issuance. As used herein &#8220;Next Round&#8221; means, at any time prior to the consummation of an IPO or Direct Listing, the first sale or issuance by the Company on or after the original issue date of this Warrant, in a single transaction or series of related transactions, of shares of its convertible preferred stock or other senior equity securities to one or more investors for at least $5 million in gross cash proceeds&#59; &#8220;Next Round Securities&#8221; means the type, class and series of convertible preferred stock or other senior equity security sold or issued by the Company in the Next Round&#59; and &#8220;Next Round Price&#8221; means the price per share paid in cash by purchasers of Next Round Securities issued in the Next Round. For example, if the Company issues Next Round Securities at a Next Round Price of $20.00 and the Warrant is then currently outstanding in whole, the number of Exercise Shares shall be increased from 225,579 to 285,715 ($5,714,300 &#47; $20 &#61; 285,715). In the event this Warrant has been exercised in part prior to the Next Round, the increase in the number of Exercise Shares shall be reduced by the number of Exercise Shares previously issued upon partial exercise of this Warrant. No more than one adjustment shall be made pursuant to this Section 5.2.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:110%">6.&#160;&#160;&#160;&#160;FRACTIONAL SHARES. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">No fractional shares shall be issued upon the exercise of this Warrant as a consequence of any adjustment pursuant hereto. All Exercise Shares (including fractions) issuable upon exercise of this Warrant may be aggregated for purposes of determining whether the exercise would result in the issuance of any fractional share. If, after aggregation, the exercise would result in the issuance of a fractional share, the Company shall, in lieu of issuance of any fractional share, pay the Holder otherwise entitled to such fraction a sum in cash equal to the product resulting from multiplying the then current fair market value of an Exercise Share by such fraction.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:110%">7.&#160;&#160;&#160;&#160;TREATMENT OF WARRANT UPON CERTAIN EVENTS.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:110%">7.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Upon a Change of Control Transaction.</font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:110%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">In the event of a Change of Control Transaction in which the consideration to be received by the Company&#8217;s stockholders consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable Securities (a &#8220;Cash&#47;Public Acquisition&#8221;), and the fair market value of one share of the Company&#8217;s Common Stock as determined in accordance with Section 2.2 above would be greater than the Exercise Price in effect on such date immediately prior to such Cash&#47;Public Acquisition, and Holder has not exercised this Warrant as to all Exercise Shares, then this Warrant shall automatically be deemed to be net exercised pursuant to Section 2.2 above as to all Exercise Shares effective immediately prior to and contingent upon the consummation of a Cash&#47;Public Acquisition. In connection with such net exercise, Holder shall be deemed to have restated each of the representations and warranties in Section 4 of this Warrant as of the date thereof and the Company shall</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:0.80pt">6.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">promptly notify the Holder of the number of Exercise Shares (or such other securities) issued upon exercise. In the event of a Cash&#47;Public Acquisition where the fair market value of one share of the Company&#8217;s Common Stock as determined in accordance with Section 2.2 above would be less than the Exercise Price in effect immediately prior to such Cash&#47;Public Acquisition, then this Warrant will expire immediately prior to the consummation of such Cash&#47;Public Acquisition.</font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The Company shall provide the Holder with written notice of a Change of Control Transaction (together with such reasonable information as the Holder may reasonably require regarding the treatment of this Warrant in connection with such contemplated Change of Control Transaction giving rise to such notice), which is to be delivered to the Holder not less than five (5) Business Days prior to the closing of the proposed Change of Control Transaction.</font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Upon the closing of any Change of Control Transaction other than a Cash&#47;Public Acquisition defined above, the acquiring, surviving or successor entity shall assume the obligations of this Warrant, and this Warrant shall thereafter be exercisable for the same securities and&#47;or other property as would have been paid for the Exercise Shares issuable upon exercise of the unexercised portion of this Warrant as if such Exercise Shares were outstanding on and as of the closing of such Change in Control Transaction, subject to further adjustment from time to time in accordance with the provisions of this Warrant.</font></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">(iv)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">As used in this Warrant, &#8220;Marketable Securities&#8221; means securities meeting all of the following requirements&#58; (a) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and is then current in its filing of all required reports and other information under the Act and the Exchange Act&#59; (b) the class and series of shares or other security of the issuer that would be received by the Holder in connection with the Cash&#47;Public Acquisition were the Holder to exercise this Warrant on or prior to the closing thereof is then traded on a Trading Market, and (c) Holder would be able to publicly re-sell, within six (6) months following the closing of such Acquisition, all of the issuer&#8217;s shares and&#47;or other securities that would be received by the Holder in such Cash&#47;Public Acquisition were Holder to exercise this Warrant in full on or prior to the closing of such Cash&#47;Public Acquisition.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">7.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Automatic Exercise at Expiration. To the extent this Warrant is not previously exercised, and if the fair market value of one Warrant share is greater than the Exercise Price, as adjusted, on the Expiration Date, this Warrant shall be deemed automatically exercised in accordance with Section 2.2 hereof (even if not surrendered) immediately prior to the close of business on the Expiration Date (unless the Expiration Date is not a Business Day, in which case, on the Business Day immediately preceding the Expiration Date). To the extent this Warrant is deemed automatically exercised pursuant to this Section 7, the Company agrees to notify the Holder within a reasonable period of time of the number of Warrant shares the Holder is to receive by reason of such automatic exercise. The Company shall not be required to deliver any certificates evidencing any Exercise Shares issuable upon such automatic exercise unless and until the Company has received the original of this Warrant (or an affidavit reasonably satisfactory to the Company that this Warrant has been lost, stolen or destroyed).</font></div><div style="margin-bottom:12pt;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">8.&#160;&#160;&#160;&#160;MARKET STAND-OFF AGREEMENT. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Holder hereby agrees that Holder shall not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, any shares of Common Stock (or other securities) of the Company held by Holder (other than those included in the registration) during the 180-day period following the effective date of the IPO or Direct Listing (or such longer period as the underwriters or the Company shall request in order to facilitate compliance with FINRA Rule 2711 or NYSE Member Rule 472 or any successor or similar rule or regulation). Holder further agrees to execute and deliver such other agreements as may be reasonably requested by the Company or the managing</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:0.80pt">7.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">underwriters that are consistent with the foregoing or that are necessary to give further effect thereto. In addition, if requested by the Company or the representative of the underwriters of Common Stock (or other securities) of the Company, Holder shall provide, within ten (10) days of such request, such information as may be required by the Company or such representative in connection with the completion of any public offering of the Company&#8217;s securities pursuant to a registration statement filed under the Act. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to such Common Stock (or other securities) until the end of such period. Holder agrees that any transferee of this Warrant (or other securities of the Company held by Holder) shall be bound by this Section 8 as a condition to the transfer. The underwriters of the Company&#8217;s stock are intended third party beneficiaries of this Section 8 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:110%">9.&#160;&#160;&#160;&#160;NO STOCKHOLDER RIGHTS. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">This Warrant in and of itself shall not entitle the Holder to any voting rights or other rights as a stockholder of the Company.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:110%">10.&#160;&#160;&#160;&#160;INFORMATION AND REGISTRATION RIGHTS.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:110%">10.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Subject to Holder&#8217;s entering into a confidentiality agreement in form and substance reasonably acceptable to the Company, the Company will furnish the following reports to Holder so long as this Warrant remains exercisable&#58; (a) as soon as practicable after the end of each fiscal year of the Company, an unaudited consolidated balance sheet of the Company and its subsidiaries, as at the end of such fiscal year, and unaudited consolidated statements of income and cash flows of the Company and its subsidiaries for such year (the &#8220;Fiscal Year Financials&#8221;), prepared in accordance with U.S. generally accepted accounting principles consistently applied, with audited Fiscal Year Financials to be provided when available&#59; (b) as soon as practicable after the end of the first, second and third quarterly accounting periods in each fiscal year of the Company, an unaudited consolidated balance sheet of the Company and its subsidiaries as at the end of such fiscal quarter, and unaudited consolidated statements of income and cash flows of the Company and its subsidiaries for such quarterly period, prepared in accordance with U.S. generally accepted accounting principles consistently applied&#59; and (c) when available, a financial plan and budget for the then current fiscal year. The information rights granted under this Section 10 shall automatically terminate in the event of a Cash&#47;Public Acquisition, an IPO or a Direct Listing and are not transferable to any person not affiliated with the Holder.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:110%">10.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">The Exercise Shares shall be &#8220;Registrable Securities&#8221; as such term is defined in the Amended and Restated Investors&#8217; Rights Agreement, dated as of November 20, 2017 (as amended from time to time, the &#8220;Rights Agreement&#8221;) for purposes of Sections 2.1 and 2.2 thereof, and Holder shall have the same rights as, and shall be subject to the same terms and conditions set forth in, Sections 2.1 (Requested Registration) and 2.2 (Company Registration) of the Rights Agreement as a &#8220;Holder&#8221; thereunder, provided that none of the Exercise Shares shall be counted when determining the Initiating Holders (as defined in the Rights Agreement). Holder shall execute and deliver a joinder to Sections 2.1 and 2.2 of the Rights Agreement following the exercise of this Warrant. The Company shall take such action as may be reasonably necessary to carry out the intent of the foregoing, including, without limitation, amending the Rights Agreement to include the Exercise Shares as Registrable Securities under the Rights Agreement, subject to the limitations set forth in this Section 10.2.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:110%">11.&#160;&#160;&#160;&#160;TRANSFER OF WARRANT. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Subject to applicable laws and the restriction on transfer set forth on the first page of this Warrant (including without limitation, delivery of a legal opinion reasonably satisfactory to the Company), this Warrant is transferable, in whole or in part, by the Holder in person or by duly authorized attorney to (a) any affiliate (including related funds) of Holder, or (b) subject to the Company&#8217;s consent, which shall not be unreasonably withheld, a person not affiliated with the Holder, in each case, upon delivery of this Warrant and the form of assignment attached hereto to the transferee</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:0.80pt">8.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">designated by Holder. In the event of a non-affiliate transfer, the information rights set forth in Section 10 above shall automatically terminate. The transferee shall sign an investment letter in form and substance reasonably satisfactory to the Company for the purpose of providing the representations and warranties in Section 4 hereof. Upon any such transfer the Company shall issue within a reasonable period of time, an appropriate warrant to the transferee(s). The Company may withhold its consent to a transfer of all or any portion of this Warrant to a direct or indirect competitor of the Company. Holder shall reimburse the Company&#8217;s reasonable out of pocket costs and fees (including the Company&#8217;s legal fees) for any transfers of this Warrant occurring after the original issue date of this Warrant.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;LOST, STOLEN, MUTILATED OR DESTROYED WARRANT. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If this Warrant is lost, stolen, mutilated or destroyed, the Company may, on such terms as to indemnity or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination and tenor as this Warrant so lost, stolen, mutilated or destroyed. Any such new Warrant shall constitute an original contractual obligation of the Company, whether or not the allegedly lost, stolen, mutilated or destroyed Warrant shall be at any time enforceable by anyone.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;NOTICES, ETC. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All notices required or permitted hereunder shall be in writing and shall be deemed effectively given&#58; (a) upon personal delivery to the party to be notified, (b) when sent by confirmed email or facsimile if sent during normal business hours of the recipient, if not, then on the next Business Day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the Company at the address listed on the signature page and to Holder at Hayfin Capital Management LLP, One Eagle Place, London, SW1Y 6AF, United Kingdom, or at such other address as the Company or Holder may designate by ten (10) days advance written notice to the other parties hereto.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;ACCEPTANCE. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained herein.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;GOVERNING LAW. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Warrant and all rights, obligations and liabilities hereunder shall be governed by the laws of the State of Delaware.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Remainder of the page left intentionally blank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:0.80pt">9.</font></div></div></div><div id="i70ec4b0f2fa544ffac9208ce2f62f2ad_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Company has caused this Warrant to be executed by its duly authorized officer as of March 17, 2022. </font></div><div style="margin-bottom:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.940%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">HEARTFLOW HOLDING, INC.</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; &#47;s&#47; John Farquhar</font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; John Farquhar</font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;President and Chief Executive Officer</font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:45pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Address&#58;&#160;&#160;331 E. Evelyn Avenue</font></div><div style="padding-left:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Mountain View, California 94041</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;Signature Page to Warrant to Purchase Common Stock&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">ACKNOWLEDGED AND AGREED</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">HAYFIN TOURMALINE LUXCO S.A.R.L.</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; &#47;s&#47; Lina Kavoliune</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58;</font></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Lina Kavoliune</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Manager</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Address&#58;</font></td><td colspan="12" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21 rue Glesener</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">L-1631 Luxembourg</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;Signature Page to Warrant to Purchase Common Stock&#93;</font></div></div></div><div id="i70ec4b0f2fa544ffac9208ce2f62f2ad_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTICE OF EXERCISE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TO&#58; HEARTFLOW HOLDING, INC.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(1)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The undersigned hereby elects to purchase ________ shares of the Common Stock of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">HEARTFLOW HOLDING, INC. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(the &#8220;Company&#8221;) pursuant to the terms of the attached Warrant, and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</font></div><div style="margin-bottom:6pt;text-indent:72pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The undersigned hereby elects to purchase ________ shares of the Common Stock of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">HEARTFLOW HOLDING, INC. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(the &#8220;Company&#8221;) pursuant to the terms of the net exercise provisions set forth in Section 2.2 of the attached Warrant, and shall tender payment of all applicable transfer taxes, if any.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(2)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Please issue a certificate or certificates representing said shares of Common Stock in the name of the undersigned or in such other name as is specified below&#58;</font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.451%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Name)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Address)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Date)</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Signature)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Print name)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i70ec4b0f2fa544ffac9208ce2f62f2ad_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ASSIGNMENT FORM</font></div><div style="margin-bottom:24pt;padding-left:108pt;padding-right:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(To assign the foregoing Warrant, in whole or part, execute this form and supply required information. Do not use this form to purchase shares.)</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FOR VALUE RECEIVED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; ______________________________________________________________________________</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Please Print)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Address&#58; ____________________________________________________________________________</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Please Print)</font></div><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dated&#58; __________, 20__</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Holder&#8217;s </font></div><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Signature&#58; _____________________________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Holder&#8217;s</font></div><div style="margin-bottom:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Address&#58; ______________________________________________</font></div><div style="margin-bottom:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Signature Guaranteed&#58; ___________________________________</font></div><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; The signature to this Assignment Form must correspond with the name as it appears on the face of this Warrant, without alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>4
<FILENAME>filename4.htm
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i231a88ae40fd49518f02ca002c23cc2b_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 4.4</font></div></div><div style="margin-bottom:150pt;text-align:center"><font><br></font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">HEARTFLOW HOLDING, INC.</font></div><div style="margin-bottom:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AMENDED AND RESTATED INVESTORS&#8217; RIGHTS AGREEMENT</font></div><div style="margin-bottom:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">March 2, 2023</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i231a88ae40fd49518f02ca002c23cc2b_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</font></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.433%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 1 Definitions</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Certain Definitions</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 2 Registration Rights</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Demand Registration</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Company Registration</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Underwriting Requirements</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Obligations of the Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Furnish Information</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Expenses of Registration</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.7</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Delay of Registration</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.8</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indemnification</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.9</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Reports Under Exchange Act</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">13</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.10</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Limitations on Subsequent Registration Rights</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">14</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.11</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Market Stand-Off&#8221; Agreement</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">14</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.12</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Restrictions on Transfer</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">15</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.13</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Termination of Registration Rights</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">16</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.14</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Transfer or Assignment of Registration Rights</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">17</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 3 Covenants of the Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">17</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Information and Inspection Rights</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">17</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Confidentiality</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">19</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Bad Actor&#8221; Notice</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">19</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Employee Agreements</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">19</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Right to Conduct Activities</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">20</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Acknowledgement</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">20</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.7</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Termination of Covenants</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">20</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 4 Right of First Refusal</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">20</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Right of First Refusal to Significant Holders</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">20</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 5 ADDITIONAL COVENANTS</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">22</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Matters Requiring Series F Director Approval</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">22</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Insurance</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">23</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Successor Indemnification</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">23</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Termination of Covenants</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">23</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Employee Stock</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">23</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-i-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(continued) </font></div><div><font><br></font></div></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.433%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section 6 MISCELLANEOUS</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">24</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amendment</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">24</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Notices</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">24</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Governing Law</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">25</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Successors and Assigns</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">25</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Entire Agreement</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">26</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Delays or Omissions</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">26</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.7</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Severability</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">26</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.8</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Titles and Subtitles</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">26</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.9</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Counterparts</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">26</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.10</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Telecopy Execution and Delivery</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">26</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.11</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Dispute Resolution</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">27</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.12</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Further Assurances</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">27</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.13</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Conflict</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">27</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.14</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Attorneys&#8217; Fees</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">27</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.15</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Aggregation of Stock</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">27</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.16</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Waiver of Right of First Refusal</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">28</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-ii-</font></div></div></div><div id="i231a88ae40fd49518f02ca002c23cc2b_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">HEARTFLOW HOLDING, INC.</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AMENDED AND RESTATED INVESTORS&#8217; RIGHTS AGREEMENT</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Amended and Restated Investors&#8217; Rights Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is dated as of March 2, 2023, and is between HeartFlow Holding, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and the persons and entities listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Investor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Investors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, HeartFlow, Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">HeartFlow</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and the Investors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Prior Investors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) entered into that certain Amended and Restated Investors&#8217; Rights Agreement dated November 20, 2017, as amended on March 28, 2018 (as further supplemented from time to time and assumed by the Company, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Prior Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in connection with the sale and issuance of shares of the Company&#8217;s Series E Preferred Stock.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, pursuant to the Assignment and Assumption Agreement dated March 1, 2021, by and between HeartFlow and the Company, HeartFlow assigned the Prior Agreement to the Company, and the Company assumed the Prior Agreement.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, the Company now proposes to sell shares of the Company&#8217;s Series F Preferred Stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Series F Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Series F-1 Preferred Stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Series F-1 Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to certain of the Investors pursuant to the Series F and Series F-1 Preferred Stock Purchase Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of even date herewith (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, in connection with the Financing the Company and the Prior Investors desire to amend and restate the Prior Agreement in its entirety to read as set forth herein.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, as a condition to the Financing, the Investors have agreed to enter into this Agreement.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties therefore agree as follows&#58;</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 1</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">DEFINITIONS</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Certain Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. As used in this Agreement, the following terms shall have the meanings set forth below&#58;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer or director of such Person or any venture capital fund now or hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management company with, such Person, and, with respect to the Baillie Gifford Investor, any person that receives, directly </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-1-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or indirectly, investment management or management advisory services from Baillie Gifford or any of its subsidiaries or owned affiliates.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Bad Actor Disqualification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any &#8220;bad actor&#8221; disqualification described in Rule 506(d)(1)(i) through (viii) under the Securities Act.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Baillie Gifford</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means Baillie Gifford &#38; Co. and any successor or affiliated investment advisor to the Baillie Gifford Investor.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Baillie Gifford Investor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means Scottish Mortgage Investment Trust plc, together with its permitted transferees and assignees.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BCLS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means BCLS Fund III Investments, LP, together with its Affiliates.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commission</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Securities and Exchange Commission or any other federal agency at the time administering the Securities Act.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Common Stock of the Company.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Competitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a Person engaged, directly or indirectly (including through any partnership, limited liability company, corporation, joint venture or similar arrangement (whether now existing or formed hereafter)), in providing coronary cardiac computed tomography angiography-based tests for providing data used in diagnosing coronary artery disease, including FFRct, plaque quantification and characterization and percutaneous coronary intervention planning, but shall not include any financial investment firm or collective investment vehicle that, together with its Affiliates, holds less than ten percent (10)% of the outstanding equity of any Competitor and does not, nor do any of its Affiliates, have a right to designate any members of the board of directors of any Competitor.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Conversion Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean shares of Common Stock issued upon conversion of shares of Preferred Stock.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Damages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any loss, damage, claim or liability (joint or several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon&#58; (i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto&#59; (ii) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading&#59; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-2-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Securities Exchange Act of 1934, as amended, or any similar successor federal statute and the rules and regulations thereunder, all as the same shall be in effect from time to time.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Excluded Registration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (i) a registration relating to the sale or grant of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, equity incentive or similar plan&#59; (ii) a registration relating to an SEC Rule 145 transaction&#59; (iii) a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities&#59; or (iv) a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(m)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Form S-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means such form under the Securities Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(n)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Form S-3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits forward incorporation of substantial information by reference to other documents filed by the Company with the SEC.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(o)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any Investor who holds Registrable Securities and any holder of Registrable Securities to whom the registration rights conferred by this Agreement have been duly and validly transferred in accordance with Section 2.14 of this Agreement.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(p)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Immediate Family Member</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, life partner or similar statutorily-recognized domestic partner, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships of a natural person referred to herein.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(q)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initial Public Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the closing of the Company&#8217;s first firm commitment underwritten public offering of the Company&#8217;s Common Stock registered under the Securities Act.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(r)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initiating Holders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, collectively, Holders who properly initiate a registration request under this Agreement.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(s)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">New Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in Section 4.1(a).</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(t)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Selling Stockholders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean persons other than Holders who, by virtue of agreements with the Company, are entitled to include their Other Shares in certain registrations hereunder.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(u)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean shares of Common Stock, other than Registrable Securities (as defined below), with respect to which registration rights have been granted.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-3-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any individual, corporation, partnership, trust, limited liability company, association or other entity.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(w)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Preferred Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any director of the Company that the holders of record of a class, classes or series of Preferred Stock are entitled to elect pursuant to the Restated Certificate (as defined below in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1(a)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">).</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(x)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series F-1 Preferred Stock of the Company.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(y)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the Recitals.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(z)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Registrable Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean (i) shares of Common Stock issued or issuable pursuant to the conversion of the Preferred Stock, (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and&#47;or exercise of any other securities of the Company acquired by the Investors after the date hereof, (iii) any Common Stock issued as a dividend or other distribution with respect to or in exchange for or in replacement of the shares referenced in (i) above, and (iv) the Warrant Shares&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that Registrable Securities shall not include any shares of Common Stock described in clause (i) or (ii) above which have previously been registered or which have been sold to the public either pursuant to a registration statement or Rule 144, or which have been sold in a private transaction in which the transferor&#8217;s rights under this Agreement are not validly assigned in accordance with this Agreement&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that holders of Warrant Shares shall be excluded from the definition of &#8220;Initiating Holders&#8221;.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(aa)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Registrable Securities then outstanding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the number of shares determined by adding the number of shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and&#47;or convertible securities that are Registrable Securities.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(bb)&#160;&#160;&#160;&#160;The terms &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">registered</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">registration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act and applicable rules and regulations thereunder, and the declaration or ordering of the effectiveness of such registration statement.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(cc)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Registration Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean all expenses incurred in effecting any registration pursuant to this Agreement, including, without limitation, all registration, qualification, and filing fees, printing expenses, escrow fees, fees and disbursements of counsel for the Company, blue sky fees and expenses, and expenses of any regular or special audits incident to or required by any such registration, but shall not include Selling Expenses, fees and disbursements of more than $25,000 to counsel for the Holders and the compensation of regular employees of the Company, which shall be paid in any event by the Company.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(dd)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Restricted Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any Registrable Securities required to bear the first legend set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.12(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-4-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ee)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Rule 144</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean Rule 144 as promulgated by the Commission under the Securities Act, as such Rule may be amended from time to time, or any similar successor rule that may be promulgated by the Commission.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ff)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Rule 145</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean Rule 145 as promulgated by the Commission under the Securities Act, as such Rule may be amended from time to time, or any similar successor rule that may be promulgated by the Commission.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(gg)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Rule 415</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean Rule 415 as promulgated by the Commission under the Securities Act, as such Rule may be amended from time to time, or any similar successor rule that may be promulgated by the Commission.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(hh)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Securities and Exchange Commission.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the Securities Act of 1933, as amended, or any similar successor federal statute and the rules and regulations thereunder, all as the same shall be in effect from time to time.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(jj)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Selling Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all underwriting discounts, selling commissions, and stock transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company in accordance with the terms of this Agreement.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(kk)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Significant Holders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ll)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Warrant Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the shares of Common Stock issued or issuable upon exercise of that certain Warrant to Purchase Common Stock of the Company, issued to Hayfin Tourmaline Luxco S.a.r.l on January 19, 2021 and that certain Warrant to Purchase Common Stock of the Company, issued to Hayfin Tourmaline Luxco S.a.r.l on March 17, 2022.</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 2</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">REGISTRATION RIGHTS</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Demand Registration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Form S-1 Demand</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If at any time after the earlier of (i) five (5) years after the date of this Agreement or (ii) one hundred eighty (180) days after the effective date of the registration statement for the Initial Public Offering, the Company receives a request from Holders of a majority of the Registrable Securities then outstanding that the Company file a Form S-1 registration statement with respect to at least forty percent (40%) of the Registrable Securities then outstanding, then the Company shall&#58; (x) within ten (10) days after the date such request is given, give notice thereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Demand Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to all Holders other than the Initiating Holders&#59; and (y) as soon as practicable, and in any event within sixty (60) days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-5-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 2.1(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2.3.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Form S-3 Demand</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of at least thirty percent (30%) of the Registrable Securities then outstanding that the Company file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $10,000,000, then the Company shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders&#59; and (ii) as soon as practicable, and in any event within forty-five (45) days after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 2.1(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> a certificate signed by the Company&#8217;s chief executive officer stating that in the good faith judgment of the Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Board of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) it would be materially detrimental to the Company and its stockholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company&#59; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential&#59; or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, for a period of not more than one hundred twenty (120) days after the request of the Initiating Holders is given&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the Company may not invoke this right more than twice in any twelve (12) month period&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that the Company shall not register any securities for its own account or that of any other stockholder during such one hundred twenty (120) day period, other than an Excluded Registration.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, (i) during the period that is sixty (60) days before the Company&#8217;s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty (180) days after the effective date of, a Company-initiated registration, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective&#59; (ii) after the Company has effected two (2) registrations pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company shall not be obligated to effect, or to take </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-6-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any action to effect, any registration pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, (i) during the period that is thirty (30) days before the Company&#8217;s good faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a Company-initiated registration, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective&#59; or (ii) if the Company has effected two (2) registrations pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> within the twelve (12) month period immediately preceding the date of such request. A registration shall not be counted as &#8220;effected&#8221; for purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in which case such withdrawn registration statement shall be counted as &#8220;effected&#8221; for purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that if such withdrawal is during a period the Company has deferred taking action pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, then the Initiating Holders may withdraw their request for registration and such registration will not be counted as &#8220;effected&#8221; for purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Company Registration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If the Company proposes to register (including for this purpose a registration effected by the Company for stockholders other than the Holders) any of its securities under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded Registration, a registration relating to a demand pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or the Initial Public Offering), the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.6.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Underwriting Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;If, pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Initiating Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and the Company shall include such information in the Demand Notice. The underwriter(s) will be selected by the Board of Directors and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder&#8217;s Registrable Securities in such registration shall be conditioned upon such Holder&#8217;s participation in such underwriting and the inclusion of such Holder&#8217;s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.4(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting&#59; provided, however, that no Holder (or any of their assignees) shall be required to make any representations, warranties or indemnities except as they relate to such Holder&#8217;s ownership of shares and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-7-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">authority to enter into the underwriting agreement and to such Holder&#8217;s intended method of distribution, and the liability of such Holder shall be several and not joint, and limited to an amount equal to the net proceeds from the offering received by such Holder.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Notwithstanding any other provision of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, if the managing underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the number of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. In connection with any offering involving an underwriting of shares of the Company&#8217;s capital stock pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company shall not be required to include any of the Holders&#8217; Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, or (ii) the number of Registrable Securities included in the offering be reduced below thirty percent (30%) of the total number of securities included in such offering, unless such offering is the Initial Public Offering, in which case the selling Holders may be excluded further if the underwriters make the determination described above and no other stockholder&#8217;s securities are included in such offering. For purposes of the provision in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> concerning apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single &#8220;selling Holder,&#8221; and any pro rata reduction with respect to such &#8220;selling Holder&#8221; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-8-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such &#8220;selling Holder,&#8221; as defined in this sentence.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;For purposes of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a registration shall not be counted as &#8220;effected&#8221; if, as a result of an exercise of the underwriter&#8217;s cutback provisions in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, fewer than fifty percent (50%) of the total number of Registrable Securities that Holders have requested to be included in such registration statement are actually included.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Obligations of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Whenever required under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible&#58;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one hundred twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed&#59; provided, however, that (i) such one hundred twenty (120) day period shall be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120) day period shall be extended for up to an additional one hundred twenty (120) days, if necessary, to keep the registration statement effective until all such Registrable Securities are sold&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders&#59; provided that the Company shall not be required to qualify to do business or to file a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the underwriter(s) of such offering&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-9-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;use its commercially reasonable efforts to cause all such Registrable Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;promptly make available for inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company&#8217;s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed&#59; and</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement such registration statement or prospectus.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, the Company shall ensure that, at all times after any registration statement covering a public offering of securities of the Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company&#8217;s directors may implement a trading program under Rule 10b5-1 of the Exchange Act.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Furnish Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;It shall be a condition precedent to the obligations of the Company to take any action pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder&#8217;s Registrable Securities.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Expenses of Registration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All Registration Expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, including all registration, filing, and qualification fees&#59; printers&#8217; and accounting fees&#59; fees and disbursements of counsel for the Company&#59; and the reasonable fees and disbursements, not to exceed $100,000, of one counsel for the selling Holders selected by Holders of a majority of the Registrable </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-10-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Securities to be registered (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Selling Holder Counsel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), shall be borne and paid by the Company&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one registration pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 2.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, as the case may be&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 2.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2.1(b</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">). All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 (other than fees and disbursements of counsel to any Holder, other than the Selling Holder Counsel, which shall be borne solely by the Holder engaging such counsel) shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Delay of Registration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If any Registrable Securities are included in a registration statement under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members, officers, directors, and stockholders of each such Holder&#59; legal counsel and accountants for each such Holder&#59; any underwriter (as defined in the Securities Act) for each such Holder&#59; and each Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the indemnity agreement contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.8(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such registration.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-11-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Company within the meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such registration&#59; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the indemnity agreement contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.8(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.8(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2.8(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Promptly after receipt by an indemnified party under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, only to the extent that such failure materially prejudices the indemnifying party&#8217;s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either&#58; (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, then, and in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-12-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">each such case, such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties&#8217; relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that, in any such case (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that in no event shall a Holder&#8217;s liability pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.8(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, when combined with the amounts paid or payable by such Holder pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.8(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that any matter expressly provided for or addressed by the foregoing provisions that is not expressly provided for or addressed by the underwriting agreement shall be controlled by the foregoing provisions.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations of the Company and Holders under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall survive the completion of any offering of Registrable Securities in a registration under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and otherwise shall survive the termination of this Agreement or any provision(s) of this Agreement.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Reports Under Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company shall&#58;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;make and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the Initial Public Offering&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements)&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-13-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the Initial Public Offering), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies)&#59; and (ii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form).</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Limitations on Subsequent Registration Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. From and after the date of this Agreement, the Company shall not, without the prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that would (i) provide to such holder or prospective holder the right to include securities in any registration on other than on a subordinate basis after all Holders have had the opportunity to include in the registration and offering all shares of Registrable Securities that they wish to so include&#59; or (ii) allow such holder or prospective holder to initiate a demand for registration of any securities held by such holder or prospective holder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that this limitation shall not apply to Registrable Securities acquired by any additional Investor that becomes a party to this Agreement in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">&#8220;Market Stand-Off&#8221; Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the Initial Public Offering and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days), (i) lend&#59; offer&#59; pledge&#59; sell&#59; contract to sell&#59; sell any option or contract to purchase&#59; purchase any option or contract to sell&#59; grant any option, right, or warrant to purchase&#59; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock held immediately before the effective date of the registration statement for the Initial Public Offering, or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">clause (i</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) or (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ii</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall apply only to the Initial Public Offering, shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement or the transfer of any shares to any trust for the direct or indirect benefit of the Holder or the immediate family of the Holder, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that the trustee of the trust agrees to be bound in writing by the restrictions set forth herein, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that any such transfer shall not involve a disposition for value, and shall be applicable to the Holders only if all officers and directors and all stockholders individually owning more than one percent (1%) of the Company&#8217;s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding Preferred Stock) are subject to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-14-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">same restrictions. The underwriters in connection with such registration are intended third-party beneficiaries of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or that are necessary to give further effect thereto.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Restrictions on Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the provisions and upon the conditions specified in this Agreement. Notwithstanding the foregoing, the Company shall not require any transferee of shares pursuant to an effective registration statement or, following the Initial Public Offering, SEC Rule 144, in each case, to be bound by the terms of this Agreement. No Holder may transfer any Preferred Stock or Registrable Securities to a Competitor or any officer, director or employee of a Competitor, without the prior written consent of the Company.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Each certificate, instrument, or book entry representing (i) the Preferred Stock, (ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">clauses (i</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) and (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ii</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">), upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar event, shall (unless otherwise permitted by the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.12(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) be notated with a legend substantially in the following form&#58;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY.</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Holders consent to the Company making a notation in its records and giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Before any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-15-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction or following the Initial Public Offering, the transfer is made pursuant to SEC Rule 144, the Holder thereof shall give notice to the Company of such Holder&#8217;s intention to effect such sale, pledge, or transfer, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that no such notice shall be required in connection if the intended sale, pledge or transfer complies with SEC Rule 144. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at such Holder&#8217;s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act&#59; (ii) a &#8220;no action&#8221; letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto&#59; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will not require such a notice, legal opinion or &#8220;no action&#8221; letter (x) in any transaction in compliance with SEC Rule 144&#59; or (y) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that with respect to transfers under the foregoing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">clause (y)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, each transferee agrees in writing to be subject to the terms of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each certificate, instrument, or book entry representing the Restricted Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.12(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, except that such certificate instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any provisions of the Securities Act.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Termination of Registration Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The right of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall terminate upon the earliest to occur of&#58;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;the closing of a Liquidation Event, as such term is defined in the Restated Certificate (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> below), in which the consideration received by the Investors in such Liquidation Event is in the form of cash and&#47;or publicly traded securities, or if the Investors receive registration rights from the acquiring company or other successor to the Company reasonably comparable to those set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;such time after the Initial Public Offering as SEC Rule 144 or another similar exemption under the Securities Act is available for the sale of all of such Holder&#8217;s shares without limitation, during a three (3)-month period without registration (and without the requirement for the Company to be in compliance with the current public information required under subsection (c)(1) of SEC Rule 144) and such Holder (together with its &#8220;affiliates&#8221; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-16-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">determined under SEC Rule 144) holds less than one percent (1%) of the outstanding capital stock of the Company&#59; and</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;the third (3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) anniversary of the date the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act (or such later date that is one hundred eighty (180) days following the expiration of all deferrals of the Company&#8217;s obligations pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that remain in effect as of the third (3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) anniversary of such date).</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Transfer or Assignment of Registration Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The rights to cause the Company to register securities granted to a Holder by the Company under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> may be transferred or assigned by a Holder (i) to a transferee or assignee of not less than 2,500,000 shares of Registrable Securities (or, in the case of a transfer or assignment by (y) HeartTech InvestCo, LLC, 500,000 shares of Registrable Securities, or (z) Sandbox Advantage Fund, L.P. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sandbox</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and&#47;or BlueCross BlueShield Venture Partners II, L.P. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BCBS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), an amount in the aggregate by both to a single transferee or group of related transferees of not less than 1,000,000 shares of Registrable Securities) (as presently constituted and subject to subsequent adjustments for stock splits, stock dividends, reverse stock splits, and the like), or (ii) to a subsidiary, parent, general partner, limited partner, retired partner, member or retired member, stockholder or other Affiliate of a Holder that is a corporation, partnership or limited liability company&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that (a) such transfer or assignment of Registrable Securities is effected in accordance with the terms of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and applicable securities laws, (b) the Company is given written notice before said transfer or assignment, stating the name and address of the transferee or assignee and identifying the securities with respect to which such registration rights are intended to be transferred or assigned, and (c) the transferee or assignee of such rights assumes in writing the obligations of such Holder under this Agreement, including without limitation the obligations set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. For purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a &#8220;partnership&#8221;, &#8220;corporation&#8221;, or &#8220;limited liability company&#8221; shall also mean any similar or correlative type of entity not organized under the laws of the United States.</font></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 3</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">COVENANTS OF THE COMPANY</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company hereby covenants and agrees, as follows&#58;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Information and Inspection Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company will furnish the following reports to each Significant Holder (as defined in 3.1(b) below)&#58;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;As soon as practicable after the end of each fiscal year of the Company, and in any event (A) with respect to the fiscal year ended December 31, 2022, within one hundred and eighty (180) days after the end of such fiscal year, and (B) with respect to the fiscal year ending December 31, 2023 and for each fiscal year ending thereafter, within one hundred and twenty (120) days after the end of each such fiscal year of the Company, (x) a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-17-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">consolidated balance sheet of the Company and its subsidiaries, if any, as at the end of such fiscal year, (y) consolidated statements of income and cash flows of the Company and its subsidiaries, if any, for such year and (z) a statement of stockholders&#8217; equity as of the end of such year, in each case of clauses (x)-(z), audited, prepared in accordance with U.S. generally accepted accounting principles consistently applied and certified by independent public accountants of nationally recognized standing selected by the Company&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;As soon as practicable after the end of the first, second and third quarterly accounting periods in each fiscal year of the Company, and in any event within forty- five (45) days after the end of the first, second, and third quarterly accounting periods in each fiscal year of the Company, an unaudited consolidated balance sheet of the Company and its subsidiaries, if any, as of the end of each such quarterly period, and unaudited consolidated statements of income and cash flows of the Company and its subsidiaries, if any, for such period, prepared in accordance with U.S. generally accepted accounting principles consistently applied, subject to changes resulting from normal year-end audit adjustments&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;As soon as practicable after the end of each month, and in any event within thirty (30) days after the end of each month, an unaudited consolidated balance sheet of the Company as of the end of such monthly period, and unaudited consolidated statements of income and cash flows of the Company for such period, prepared in accordance with U.S. generally accepted accounting principles consistently applied, subject to changes resulting from normal year-end audit adjustments&#59; and</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;At least thirty (30) days prior to the beginning of each fiscal year and at other times upon reasonable request, an operating plan and budget for such fiscal year or the then current fiscal year, as applicable that is approved by the Board of Directors.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If, for any period, the Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Inspection Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company will afford to each Holder (counting Sandbox and BCBS in the aggregate as a single holder for purposes of determining the following ownership threshold) who owns at least 2,400,000 (or, in the case of HeartTech InvestCo, LLC, 500,000) (as presently constituted and subject to subsequent adjustments for stock splits, stock dividends, reverse stock splits, and the like) shares of Preferred Stock and&#47;or Conversion Stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Significant Holders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and to such Holder&#8217;s accountants and counsel, reasonable access during normal business hours to all of the Company&#8217;s respective properties, books and records. Each Significant Holder shall have such other access to management and information as is necessary for it to comply with applicable laws and regulations and reporting obligations. The Company shall not be required to disclose details of contracts with or work performed for specific customers and other business partners where to do so would violate confidentiality obligations to those parties. Holders may exercise their rights under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">only for purposes reasonably related to their interests under this Agreement and related agreements. The rights granted pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> may not be assigned or otherwise conveyed by the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-18-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Holders or by any subsequent transferee of any such rights without the prior written consent of the Company except pursuant to a transfer described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereof. Notwithstanding the foregoing, the Company shall not be obligated pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to provide access to any information that it reasonably and in good faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor or make decisions with respect to its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company&#8217;s intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> by such Investor), (b) is or has been independently developed or conceived by such Investor without use of the Company&#8217;s confidential information, or (c) is or has been made known or disclosed to such Investor by a third party without a breach of any obligation of confidentiality such third party may have to the Company&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent reasonably necessary to obtain their services in connection with monitoring its investment in the Company&#59; (ii) with the Company&#8217;s prior written consent, to any prospective purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees to be bound by the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#59; (iii) to any existing Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that such Investor shall be responsible for any breach of the confidentiality obligations set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> by any such existing Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor&#59; or (iv) as may otherwise be required by law, regulation, rule, court order or subpoena, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that such Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure&#59; and provided further, that the Company shall not be required to comply with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> in respect of any Holder that is a Competitor or an officer, employee or director of a Competitor.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">&#8220;Bad Actor&#8221; Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each Investor that is, or will following a Closing (as defined in the Purchase Agreement) be, a beneficial owner of 20% or more of the Company&#8217;s outstanding voting equity securities, calculated on the basis of voting power, will promptly notify the Company in writing if it or, to its knowledge, any person specified in Rule 506(d)(1) under the Securities Act becomes subject to any Bad Actor Disqualification.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Employee Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company will cause (i) each Key Employee (as defined in the Purchase Agreement) and (ii) each person now or hereafter employed by it or by any subsidiary (or engaged by the Company or any subsidiary as a consultant&#47;independent contractor) with access to confidential information and&#47;or trade secrets, to enter into the Company&#8217;s standard form of nondisclosure, nonsolicitation and proprietary rights assignment </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-19-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">agreement or consulting&#47;independent contractor agreement, as applicable. In addition, the Company shall not amend, modify, terminate, waive, or otherwise alter, in whole or in part, any of the above-referenced agreements or any stock purchase, stock option, stock restriction or restricted stock agreement between the Company and any Key Employee without the consent of the Board of Directors, including the Series F Director.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Right to Conduct Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company hereby agrees and acknowledges that Hadley, the Baillie Gifford Investor and BCLS (each together with their respective Affiliates, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VC Investor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) are professional investment funds, and as such invest in numerous portfolio companies, some of which may be deemed competitive with the Company&#8217;s business (as currently conducted or as currently propose to be conducted). The Company hereby agrees that, to the extent permitted under applicable law, no VC Investor shall be liable to the Company for any claim arising out of, or based upon, (i) the investment by any VC Investor in any entity competitive with the Company, or (ii) actions taken by any partner, officer or other representative of any VC Investor to assist any such competitive company, whether or not such action was taken as a member of the board of directors of such competitive company or otherwise, and whether or not such action has a detrimental effect on the Company&#59; provided, however, that the foregoing shall not relieve (x) any of the Investors from liability associated with the unauthorized disclosure of the Company&#8217;s confidential information obtained pursuant to this Agreement, or (y) any director or officer of the Company from any liability associated with his or her fiduciary duties to the Company.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Acknowledgement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company acknowledges that certain of the Investors are in the business of venture capital investing and therefore review the business plans and related proprietary information of many enterprises, including enterprises which may have products or services which compete directly or indirectly with those of the Company. Nothing in this Agreement shall preclude or in any way restrict an Investor in the business of venture capital investing from investing or participating in any particular enterprise whether or not such enterprise has products or services which compete with those of the Company.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Termination of Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The covenants set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall terminate and be of no further force and effect upon (i) the closing of the Initial Public Offering, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon the closing of a Liquidation Event (as such term is defined in the Restated Certificate, whichever occurs first.</font></div><div style="margin-bottom:11pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 4</font></div><div style="margin-bottom:11pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">RIGHT OF FIRST REFUSAL</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Right of First Refusal to Significant Holders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company hereby grants to each Significant Holder, the right of first refusal to purchase its pro rata share of New Securities (as defined in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) which the Company may, from time to time, propose to sell and issue after the date of this Agreement. A Significant Holder&#8217;s pro rata share, for purposes of this right of first refusal, is equal to the ratio of (a) the number of shares of Common Stock (attributable to and assuming full conversion of the shares of Preferred Stock) owned or held by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-20-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">such Significant Holder immediately before the issuance of New Securities to (b) the total number of shares of Common Stock outstanding immediately before the issuance of New Securities (assuming full conversion of the shares of Preferred Stock and full conversion or exercise of all outstanding convertible securities, rights, options and warrants). Each Significant Holder shall have a right of over-allotment such that if any Significant Holder fails to exercise its right hereunder to purchase its pro rata share of New Securities, the other Significant Holders may purchase the non-purchasing Significant Holder&#8217;s portion on a pro rata basis. This right of first refusal shall be subject to the following provisions&#58;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">New Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any capital stock (including Common Stock and&#47;or Preferred Stock) of the Company whether now authorized or not, and rights, convertible securities, options or warrants to purchase such capital stock, and securities of any type whatsoever that are, or may become, exercisable or convertible into capital stock&#59; provided that the term &#8220;New Securities&#8221; does not include&#58;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;the &#8220;Excluded Shares&#8221; as defined in the Amended and Restated Certificate of Incorporation of the Company as in effect (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Restated Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;securities issued or issuable as a dividend or distribution on Preferred Stock of the Company or pursuant to any event for which adjustment is made pursuant to the Restated Certificate&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;securities issued to suppliers or third party service providers in connection with the provision of goods or services pursuant to transactions approved by the Board of Directors, including the Series F Director (as defined in the Restated Certificate)&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;securities of the Company which are otherwise excluded by the unanimous approval of the Board of Directors&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;securities issued pursuant to Section 2.1 of the Purchase Agreement&#59; and</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;any right, option or warrant to acquire any security convertible into the securities excluded from the definition of New Securities pursuant to subsections (i) through (iv) above.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In the event the Company proposes to undertake an issuance of New Securities, it shall give each Significant Holder written notice of its intention, describing the type of New Securities, and their price and the general terms upon which the Company proposes to issue the same. Each Significant Holder shall have twenty (20) days after any such notice is mailed or delivered to agree to purchase such Holder&#8217;s pro rata share of such New Securities and to indicate whether such Holder desires to exercise its over-allotment option for the price and upon the terms specified in the notice by giving written notice to the Company, in substantially the form attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and stating therein the quantity of New Securities to be purchased.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-21-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;In the event the Holders fail to exercise fully the right of first refusal and over-allotment rights, if any, within said twenty (20) day period (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Election Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Company shall have ninety (90) days thereafter to sell or enter into an agreement (pursuant to which the sale of New Securities covered thereby shall be closed, if at all, within ninety (90) days from the date of said agreement) to sell that portion of the New Securities with respect to which the Significant Holders&#8217; right of first refusal option set forth in this Section 4.1 was not exercised, at a price and upon terms no more favorable to the purchasers thereof than specified in the Company&#8217;s notice to Significant Holders delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event the Company has not sold within such ninety (90) day period following the Election Period, or such ninety (90) day period following the date of said agreement, the Company shall not thereafter issue or sell any New Securities, without first again offering such securities to the Significant Holders in the manner provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;The right of first refusal granted under this Agreement shall not be applicable to the Initial Public Offering, and shall expire upon the earlier of (i) the closing of a Liquidation Event and (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;A Significant Holder will not have a right of first refusal to purchase a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">pro</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">rata</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> share of New Securities in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and will not be a Significant Holder for purposes of the right of first refusal granted under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> if, and for so long as, the Significant Holder, any of its directors, executive officers, other officers that may serve as a director or officer of any company in which it invests, general partners or managing members or any person that would be deemed a beneficial owner of the securities of the Company held by the Significant Holder (in accordance with Rule 506(d) of the Securities Act) is subject to any Bad Actor Disqualification, except as set forth in Rule 506(d)(2) or (d)(3) under the Securities Act.</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 5</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ADDITIONAL COVENANTS</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Matters Requiring Series F Director Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. During such time or times as the holders of Series F Preferred Stock and Series F-1 Preferred Stock, voting together as a Single Class are entitled to elect the Series F Director, the Company hereby covenants and agrees with each of the Investors that it shall not, without approval of the Board of Directors, which approval must include the affirmative vote of the then-seated Series F Director&#58;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;make any material loan or advance to, or own any material amount of stock or other securities of, any subsidiary or other corporation, partnership, or other entity unless it is wholly-owned by the Company&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;make any material loan or advance to any person, including, any employee or director, except advances and similar expenditures in the ordinary course of business or under the terms of an employee stock or option plan approved by the Board of Directors&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;guarantee any material indebtedness for borrowed money, except for trade accounts of the Company or any subsidiary arising in the ordinary course of business&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-22-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;make any investment that does not materially comply with any investment policy approved by the Board of Directors&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;incur any indebtedness for borrowed money in excess of $1,500,000 that is not already included in a Board-approved budget, other than trade credit incurred, or other transactions entered into in the ordinary course of business&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;change the principal business of the Company, enter new lines of business, or exit the current line of business&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;sell, assign, license, pledge or encumber material technology or intellectual property, other than licenses granted in the ordinary course of business&#59; or</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;enter into any corporate strategic relationship involving the payment, contribution, or assignment by the Company or to the Company of assets greater than $5,000,000.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company has obtained and shall maintain, from financially sound and reputable insurers, Directors and Officers liability insurance, in an amount and on terms and conditions satisfactory to the Board of Directors (including the Series F Director), and will cause such insurance policy to be maintained until such time as the Board of Directors (including the Series F Director) determines that such insurance should be discontinued. The policy shall not be cancelled by the Company without prior approval by the Board of Directors (including the Series F Director). Notwithstanding any other provision of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to the contrary, for so long as a Preferred Director is serving on the Board of Directors, the Company shall not cease to maintain a Directors and Officers liability insurance policy in an amount of at least $3,000,000 unless approved by such Preferred Director.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Successor Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If the Company or any of its successors or assignees consolidates with or merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Company&#8217;s Bylaws, the Restated Certificate, or elsewhere, as the case may be.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Termination of Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The covenants set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, with the exception of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, shall terminate and be of no further force or effect (i) immediately before the consummation of the Initial Public Offering, or (ii) upon the closing of a Liquidation Event (as defined in the Restated Certificate), whichever event occurs first.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Employee Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Unless otherwise approved by the Board of Directors or a subcommittee of the Board of Directors pursuant to a delegation of authority, all future employees of the Company who purchase, receive options to purchase, or receive awards of shares of the Company&#8217;s capital stock after the date hereof shall be required to execute restricted stock or option agreements, as applicable, providing for (i) vesting of shares over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-23-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">months of continued employment or service, and the remaining shares vesting in equal monthly installments over the following thirty-six (36) months with respect to their initial grant, and (ii) a market stand-off provision substantially similar to that set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Company&#8217;s Amended and Restated Right of First Refusal and Co-Sale Agreement, dated as of the date hereof.</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 6</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">MISCELLANEOUS</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except as expressly provided herein, neither this Agreement nor any term hereof may be amended, waived, discharged or terminated other than by a written instrument referencing this Agreement and signed by (i) the Company and (ii) the Holders holding a majority of the Registrable Securities (excluding any of such shares that have been sold to the public or pursuant to Rule 144) then outstanding (including, at least sixty percent (60%) of the outstanding shares of Series F Preferred Stock and Series F-1 Preferred Stock)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, however, that any individual or entity acquiring shares of Preferred Stock after the date of this Agreement may become a party to this Agreement by executing a counterpart signature page to this Agreement, without any amendment of this Agreement pursuant to this paragraph or any consent or approval of any other Holder. Any such amendment, waiver, discharge or termination effected in accordance with this paragraph shall be binding upon each Holder and each future holder of all such securities of Holder. Each Holder acknowledges that by the operation of this paragraph, except as otherwise expressly set forth herein, the holders of a majority of the Registrable Securities (excluding any of such shares that have been sold to the public or pursuant to Rule 144) (including, at least sixty percent (60%) of the outstanding shares of Series F Preferred Stock and Series F-1 Preferred Stock) will have the right and power to diminish or eliminate all rights of such Holder under this Agreement provided, however,(i) in no event may any amendment, waiver or modification of any kind adversely treat any Holder in a different or disproportionate manner unless such amendment or waiver is agreed to in writing by such adversely affected Holder, and (ii) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and any other section of this Agreement applicable to the Significant Holders (including this clause (ii) of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) may be amended, modified or waived with only the written consent of the Company and the holders of at least a majority of the Registrable Securities then outstanding and held by the Significant Holders.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. All notices and other communications required or permitted hereunder shall be in writing and shall be mailed by registered or certified mail, postage prepaid, sent by facsimile or electronic mail (if to an Investor or Holder) or otherwise delivered by hand, messenger or courier service addressed&#58;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;if to an Investor, to the Investor&#8217;s address, facsimile number or electronic mail address as shown in the Company&#8217;s records, as may be updated in accordance with the provisions hereof&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;if to any Holder, to such address, facsimile number or electronic mail address as shown in the Company&#8217;s records, or, until any such Holder so furnishes an address, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-24-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">facsimile number or electronic mail address to the Company, then to the address, facsimile number or electronic mail address of the last holder of such shares for which the Company has contact information in its records&#59; or</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;if to the Company, to the attention of the President or Chief Executive Officer of the Company at 331 E. Evelyn Avenue, Mountain View, California 94041, or at such other current address as the Company shall have furnished to the Investors or Holders, with a copy (which shall not constitute notice) to Laura Bushnell, King &#38; Spalding LLP, 601 S. California Avenue, Suite 100, Palo Alto, CA 94304.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Each such notice or other communication shall for all purposes of this Agreement be treated as effective or having been given (i) if delivered by hand, messenger or courier service, when delivered (or if sent via a nationally-recognized overnight courier service, freight prepaid, specifying next-business-day delivery, one business day after deposit with the courier), or (ii) if sent via mail, at the earlier of its receipt or five days after the same has been deposited in a regularly-maintained receptacle for the deposit of the United States mail, addressed and mailed as aforesaid, or (iii) if sent via facsimile, upon confirmation of facsimile transfer or, if sent via electronic mail, upon confirmation of delivery when directed to the relevant electronic mail address, if sent during normal business hours of the recipient, or if not sent during normal business hours of the recipient, then on the recipient&#8217;s next business day. If there is any conflict between the Company&#8217;s books and records and this Agreement or any notice delivered hereunder, the Company&#8217;s books and records will control absent fraud or error.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subject to the limitations set forth in Delaware General Corporation Law &#167;232(e), each Investor and Holder consents to the delivery of any notice to stockholders given by the Company under the Delaware General Corporation Law or the Company&#8217;s certificate of incorporation or bylaws by (i) facsimile telecommunication to the facsimile number set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(or to any other facsimile number for the Investor or Holder in the Company&#8217;s records), (ii) electronic mail to the electronic mail address set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(or to any other electronic mail address for the Investor or Holder in the Company&#8217;s records), (iii) posting on an electronic network together with separate notice to the Investor or Holder of such specific posting or (iv) any other form of electronic transmission (as defined in the Delaware General Corporation Law) directed to the Investor or Holder. This consent may be revoked by an Investor or Holder by written notice to the Company and may be deemed revoked in the circumstances specified in Delaware General Corporation Law &#167;232.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement shall be governed by the internal laws of the State of Delaware, without regard to conflict of law principles that would result in the application of any law other than the law of the State of Delaware.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement, and any and all rights, duties and obligations hereunder, shall not be assigned, transferred, delegated or sublicensed by any Investor without the prior written consent of the Company. Any attempt by an Investor without such permission to assign, transfer, delegate or sublicense any rights, duties or obligations that arise under this Agreement shall be void. Subject to the foregoing and except as otherwise </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-25-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">provided herein, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement and the exhibits hereto constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof. No party hereto shall be liable or bound to any other party in any manner with regard to the subjects hereof or thereof by any warranties, representations or covenants except as specifically set forth herein. This Agreement amends and restates the Prior Agreement in its entirety.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Delays or Omissions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except as expressly provided herein, no delay or omission to exercise any right, power or remedy accruing to any party to this Agreement upon any breach or default of any other party under this Agreement shall impair any such right, power or remedy of such non-defaulting party, nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party to this Agreement, shall be cumulative and not alternative.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, portions of such provision, or such provision in its entirety, to the extent necessary, shall be severed from this Agreement, and such court will replace such illegal, void or unenforceable provision of this Agreement with a valid and enforceable provision that will achieve, to the extent possible, the same economic, business and other purposes of the illegal, void or unenforceable provision. The balance of this Agreement shall be enforceable in accordance with its terms.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Titles and Subtitles</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. All references in this Agreement to sections, paragraphs and exhibits shall, unless otherwise provided, refer to sections and paragraphs hereof and exhibits attached hereto.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement may be executed in any number of counterparts, each of which shall be enforceable against the parties that execute such counterparts, and all of which together shall constitute one instrument.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Telecopy Execution and Delivery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. A facsimile, telecopy or other reproduction of this Agreement may be executed by one or more parties hereto and delivered by such party by facsimile or any similar electronic transmission device pursuant to which the signature of or on behalf of such party can be seen. Such execution and delivery shall be considered valid, binding and effective for all purposes. At the request of any party hereto, all parties hereto agree to execute and deliver an original of this Agreement as well as any facsimile, telecopy or other reproduction hereof.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-26-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Dispute Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of Delaware and to the jurisdiction of the United States District Court for the District of Delaware for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of Delaware or the United States District Court for the District of Delaware, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WAIVER OF JURY TRIAL&#58; EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, THE OTHER AGREEMENTS (AS DEFINED IN THE PURCHASE AGREEMENT), THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each party hereto agrees to execute and deliver, by the proper exercise of its corporate, limited liability company, partnership or other powers, all such other and additional instruments and documents and do all such other acts and things as may be necessary to more fully effectuate this Agreement.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Conflict</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If there is any conflict between the terms of this Agreement and the Company&#8217;s certificate of incorporation or its bylaws, the terms of the Company&#8217;s certificate of incorporation or its bylaws, as the case may be, will control.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Attorneys&#8217; Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event that any suit or action is instituted to enforce any provision in this Agreement, the prevailing party in such dispute shall be entitled to recover from the losing party such reasonable fees and expenses of attorneys and accountants, which shall include, without limitation, all fees, costs and expenses of appeals.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Aggregation of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. All shares of capital stock of the Company held or acquired by affiliated entities or persons of an Investor (including but not limited to (i) a constituent partner or a retired partner of an Investor that is a partnership&#59; (ii) a parent, subsidiary </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-27-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or other Affiliate of an Investor that is a corporation&#59; (iii) an immediate family member living in the same household, a descendant, or a trust, in the case of an Investor who is an individual&#59; or (iv) a member of an Investor that is a limited liability company) shall be aggregated together for the purpose of determining the availability of any rights under this Agreement which are triggered by the beneficial ownership of a threshold number of shares of the Company&#8217;s capital stock.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Waiver of Right of First Refusal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of the Prior Agreement, each of the undersigned Prior Investors who together hold a majority of the Registrable Securities (as defined in the Prior Agreement) hereby waive on behalf of themselves and all other Investors the right of first refusal and any notice requirements in connection therewith, as set forth in the Prior Agreement, with respect to any sale and issuance by the Company of shares of Series F Preferred Stock, Series F-1 Preferred Stock, or any securities exercisable therefor or convertible thereinto (including without limitation the convertible promissory notes of the Company that are converting into shares of Series F-1 Preferred Stock at the initial closing of the Financing). </font></div><div style="margin-bottom:11pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(signature page follows)</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-28-</font></div></div></div><div id="i231a88ae40fd49518f02ca002c23cc2b_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.874%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.926%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COMPANY&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">HEARTFLOW HOLDING, INC.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">a Delaware corporation</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; John Farquhar</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">John Farquhar, President and Chief Executive Officer</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.825%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTORS&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BCLS FUND III INVESTMENTS, LP</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; BCLS Fund III Investments GP, LLC</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its general partner</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Bain Capital Life Sciences Fund III, L.P.</font></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its member</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Bain Capital Life Sciences III General Partner, LLC</font></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its general partner</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Bain Capital Life Sciences Investors, LLC</font></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its manager</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey Schwartz</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Jeffrey Schwartz</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Partner</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.343%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTORS&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">HOST-PLUS PTY LIMITED</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Peter Singlehurst</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;Peter Singlehurst</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;Authorised Signatory of Baillie</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Gifford Overseas Limited as agent for and on</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">behalf of Host-Plus Pty Limited</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INTERVENTURE EQUITY</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INVESTMENTS LIMITED</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Peter Singlehurst</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;Peter Singlehurst</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;Authorised Signatory of Baillie</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Gifford Overseas Limited as agent for and on</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">behalf of Interventure Equity Investments</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Limited</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PLUMBING PENSIONS (U.K.)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LIMITED</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Peter Singlehurst</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;Peter Singlehurst</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;Partner of Baillie Gifford &#38; Co as</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agent for and on behalf of Plumbing Pensions</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(U.K.) Limited</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SCOTTISH MORTGAGE</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTMENT TRUST PLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Peter Singlehurst</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;Peter Singlehurst</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;Partner of Baillie Gifford &#38; Co as</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">agent for and on behalf of Scottish Mortgage</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Investment Trust PLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.343%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTORS&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THE BOARD OF TRUSTEES OF THE</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SASKATCHEWAN HEALTHCARE </font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EMPLOYEES' PENSION PLAN</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Peter Singlehurst</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;Peter Singlehurst</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;Authorised Signatory of Baillie</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Gifford Overseas Limited as agent for and on</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">behalf of The Board of Trustees of the</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Saskatchewan Healthcare Employees' </font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Pension Plan</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THE SCHIEHALLION FUND LIMITED</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Peter Singlehurst</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;Peter Singlehurst</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;Authorised Signatory of Baillie</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Gifford Overseas Limited as agent for and on</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">behalf of The Schiehallion Fund Limited</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THE STATES OF JERSEY PUBLIC </font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EMPLOYEES CONTRIBUTORY</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RETIREMENT SCHEME</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Peter Singlehurst</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;Peter Singlehurst</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;Partner of Baillie Gifford &#38; Co as</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">agent for and on behalf of The States of </font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Jersey Public Employees Contributory</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Retirement Scheme</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VISION SUPER PTY LTD</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Peter Singlehurst</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;Peter Singlehurst</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;Authorised Signatory of Baillie</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Gifford Overseas Limited as agent for and on </font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">behalf of Vision Super Pty Ltd</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.343%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTORS&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WARMAN INVESTMENTS PTY</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LIMITED</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Peter Singlehurst</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;Peter Singlehurst</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;Authorised Signatory of Baillie</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Gifford Overseas Limited as agent for and on</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">behalf of Warman Investments PTY Limited</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.343%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTORS&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CAPRICORN HEALTHCARE AND</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SPECIAL OPPORTUNITIES, LP</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; CHSO Partners II, LLC </font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Its General Partner</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Barry Uphoff</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Barry Uphoff </font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;Manager</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CAPRICORN HEALTHCARE AND </font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SPECIAL OPPORTUNITIES II, LP</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; CHSO Partners II, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Its General Partner</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Barry Uphoff</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Barry Uphoff</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;Manager</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CAPRICORN HEALTHCARE AND SPECIAL </font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">OPPORTUNITIES II-A, LP</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; CHSO Partners II, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Its General Partner</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Barry Uphoff</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Barry Uphoff</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;Manager</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.343%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTORS&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CHSO SFP, LP</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; CHSO Partners, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Its General Partner</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Barry Uphoff</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Barry Uphoff </font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;Manager</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CHSO TSF, LP</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; CHSO Partners, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Its General Partner</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Barry Uphoff</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Barry Uphoff</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;Manager</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CHSO CIG, LP</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; CHSO Partners, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Its General Partner</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Barry Uphoff</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Barry Uphoff</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;Manager</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.465%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTORS&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CAPRICORN S.A. SICAV &#8211; SIF &#8211; GLOBAL</font></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NON-MARKETABLE STRATEGIES SUB</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FUND</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Capricorn Investment Group LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Its Investment Manager</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Eric Techel</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Eric Techel</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;Partner &#38; CFO</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CARTHAGE, LP</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Capricorn Investment Group, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Its General Partner</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Eric Techel</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Eric Techel</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;Partner &#38; CFO</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">HIT SPLITTER, LP</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Capricorn Investment Group, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Its General Partner</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Eric Techel</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Eric Techel</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;Partner &#38; CFO</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PACIFIC SEQUOIA HOLDINGS LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Eric Techel</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Eric Techel</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;Manager</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.465%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTORS&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THE SKOLL FOUNDATION</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Capricorn Investment Group, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Its Investment Manager</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Eric Techel</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Eric Techel</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;Partner</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SKOLL FUND</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Capricorn Investment Group, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Its Investment Manager</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Eric Techel</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Eric Techel</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;Partner</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.465%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTORS&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">USVP X AFFILIATES, L.P.</font></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Presidio Management Group X, L.L.C.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The General Partner of Each</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Dale Holladay</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Dale Holladay</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;Attorney-In-Fact</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">U.S. VENTURES PARTNERS X, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Presidio Management Group X, L.L.C.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The General Partner of Each</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Dale Holladay</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Dale Holladay</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;Attorney-In-Fact</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.008%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.664%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTORS&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">HCPCIV 1, LLC</font></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">HealthCor Partners II, L.P., its Managing</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Member</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">HealthCor Partners GP, LLC, its General</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Manager</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey Lightcap</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Jeffrey Lightcap</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Member</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">HEALTHCOR PARTNERS FUND, LP</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">HealthCor Partners Management, LP, its</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Manager</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">HealthCor Partners Management GP, LLC, its </font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">General Partner</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey Lightcap</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Jeffrey Lightcap</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Member</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">HEALTHCOR PARTNERS FUND II, LP</font></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">HealthCor Partners Management, LP, its</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Manager</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">HealthCor Partners Management GP, LLC, its</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">General Partner</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey Lightcap</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Jeffrey Lightcap</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Member</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.343%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTORS&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JOHN H. STEVENS AND MARCIA K.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">STEVENS, TRUSTEES FOR THE JOHN AND</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MARCIA STEVENS FAMILY TRUST,</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">DATED FEBRUARY 4, 1994</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; John H. Stevens</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;John H. Stevens</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Trustee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JOHN H. STEVENS</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; John Stevens</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">HEADWATERS CAPITAL PARTNERS, LLC</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; John Stevens</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;John Stevens</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;Managing member</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.343%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LYNN SCHUSTERMAN IRREVOCABLE TRUST</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Matthew Schneider</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;Matthew Schneider</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;Attorney-in-Fact</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.343%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTORS&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BLUECROSS BLUESHIELD VENTURE</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PARTNERS II, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; John Banta</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;John Banta</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Managing Director</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SANDBOX ADVANTAGE FUND, LP</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Matthew Downs</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;Matthew Downs</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Managing Member</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div style="margin-bottom:27pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INVESTORS&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">HADLEY HARBOR MASTER INVESTORS (CAYMAN) II L.P.</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Wellington Management Company LLP, as </font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">investment adviser</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Jennifer C. Boylan</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Jennifer C. Boylan</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vice President and Counsel</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TEXAS HIDALGO CO-INVESTMENT FUND, L.P.</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:32pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Wellington Management Company LLP, as </font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:32pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">investment adviser</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Jennifer C. Boylan</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Jennifer C. Boylan</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vice President and Counsel</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div style="margin-bottom:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INVESTOR&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.627%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">HEARTTECH INVESTCO, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Jesse Du Bey</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Jesse Du Bey</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Manager</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-indent:36pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div style="margin-bottom:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INVESTOR&#58;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.627%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ADL, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Tre Brashear</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tre Brashear</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">President</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-indent:36pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div style="margin-bottom:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INVESTOR&#58;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Wael Almahmeed</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Investor</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Wael Almahmeed</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Signatory, if different</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Title, if applicable</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Amended</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div style="margin-bottom:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INVESTOR&#58;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.947%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BRADFORD C. O'BRIEN AND JUDITH M.<br>O'BRIEN, TRUSTEES, UTA DTD 7&#47;1&#47;92,<br>AS AMENDED</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Judith M. O&#8217;Brien</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Judith M. O&#8217;Brien</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Trustee</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div style="margin-bottom:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INVESTOR&#58;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.945%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LAURA BUSHNELL</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Laura Bushnell</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div style="margin-bottom:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INVESTOR&#58;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dee Dee Carmody</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Investor</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Dee Dee Carmody</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Signatory, if different</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Title, if applicable</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div style="margin-bottom:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INVESTOR&#58;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.945%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CHARLES A. TAYLOR</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Charles A. Taylor</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div style="margin-bottom:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INVESTORS&#58;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.947%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THE ZARINS FAMILY 1998 TRUST</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Christopher K. Zarins</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Christopher K. Zarins</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Trustee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CHRISTOPHER ZARINS</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Christopher Zarins</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Amended</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div style="margin-bottom:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INVESTOR&#58;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.550%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BERTRAM ZARINS</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Bertram Zarins</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LAIMA I. ZARINS, AS TRUSTEE OF THE </font></div><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BERTRAM ZARINS IRREVOCABLE </font></div><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TRUST &#8211; 2012 U&#47;I&#47;T DATED DECEMBER</font></div><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">19, 2012</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Laima I. Zarins</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Laima I. Zarins</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Trustee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LAIMA ILZE ZARINS</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Laima Ilze Zarins</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ZARINS FAMILY IRREVOCABLE TRUST</font></div><div style="text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">U&#47;D&#47;T AUGUST 19, 2002&#59; TRUSTEE&#58; PHILIP</font></div><div style="text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">M. BRYNE</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Philip M. Byrne</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Philip M. Byrne</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Trustee</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Amended</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div style="margin-bottom:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INVESTOR&#58;</font></div><div style="margin-bottom:99pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.550%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BERTRAM ZARINS</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LAIMA I. ZARINS, AS TRUSTEE OF THE </font></div><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BERTRAM ZARINS IRREVOCABLE </font></div><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TRUST-2012 U&#47;I&#47;T DATED DECEMBER</font></div><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">19, 2012</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Laima I. Zarins</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Trustee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LAIMA ILZE ZARINS</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ZARINS FAMILY IRREVOCABLE TRUST</font></div><div style="text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">U&#47;D&#47;T AUGUST 19, 2002&#59; TRUSTEE&#58; PHILIP</font></div><div style="text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">M. BRYNE</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Philip M. Byrne</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Philip M. Byrne</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Trustee</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div style="margin-bottom:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INVESTOR&#58;</font></div><div style="margin-bottom:36pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Kristen Smith Dayley</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Investor</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Kristen Smith Dayley</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Signatory, if different</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Title, if applicable</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div style="margin-bottom:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INVESTOR&#58;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Derrick Queen and Vivian Kuan</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Investor</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Vivian K. Queen</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Vivian Kuan</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Signatory, if different</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Title, if applicable</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div style="margin-bottom:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INVESTOR&#58;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rebecca Smith Eggleston</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Investor</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Rebecca Smith Eggleston</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Signatory, if different</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Title, if applicable</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.945%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Emergent Medical Associates, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; EMP Partners, L.L.C., Its General Partner</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Robert Brownell</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Robert Brownell</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Signatory, if different</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Managing Director</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Title, if applicable</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.586%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Emergent Medical Partners, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; EMP Partners, L.L.C., Its General Partner</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Robert Brownell</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Robert Brownell</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Signatory, if different</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Managing Director</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Title, if applicable</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.748%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FITZ PARTNERS, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Peter Fitzgerald</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Peter Fitzerald</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Professor of medicine</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.748%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">HAYFIN HEARTFLOW UK LIMITED</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Jennifer Shen</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Jennifer Shen</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Director</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.748%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">HEART-D SERIES OF HCP PRIVATE</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EQUITY INVESTORS, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Gregory P. Hartmann</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Gregory P. Hartmann</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Manager</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.586%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Hiten D Patel and Melissa L Patel, joint tenants with rights of survivorship</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Investor</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Hiten D Patel</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Hiten Patel</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Signatory, if different</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Trustee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Title, if applicable</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.586%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">James J Elacqua Revocable Living Trust</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Investor</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; James J Elacqua</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">James J Elacqua</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Signatory, if different</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Trustee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Title, if applicable</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.227%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MARYAM SMITH KEYSER</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Maryam Smith Keyser</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.586%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">LifeForce Capital-CHS Management, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Investor</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; John Noonan</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">John Noonan</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Signatory, if different</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">GP</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Title, if applicable</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.748%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTORS&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LONNIE M. SMITH HEATFLOW GRAT III</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Lonnie Smith</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Lonnie Smith</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Board Member</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THE LONNIE AND CHERYL SMITH FAMILY TRUST</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Lonnie Smith</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Lonnie Smith</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Trustee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LONNIE SMITH</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Lonnie Smith</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MCKRAM INVESTMENT CAPITAL II LLC</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Lonnie Smith</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Lonnie Smith</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Board Member</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.227%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">KENT A. LUCKEN</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Kent Lucken</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.748%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MACARTHUR HOLDINGS, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Philip Katz</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Philip Katz</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Managing Member</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.748%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MARSHFIELD ADVISERS, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Mitch Laubaugh</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Mitch Laubaugh</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Portfolio Manager</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.586%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Mary A Schedule Irrevocable Trust</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Investor</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; John Schuele</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">John Schuele</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Signatory, if different</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Title, if applicable</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.748%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTORS&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THE MUKESH PATEL ARTICLE FOURTH <br>TRUST</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Bhavnaben Mukesh Patel</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Bhavnaben Mukesh Patel</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;Co-Trustee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BHAVNABEN MUKESH PATEL</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Bhavnaben Mukesh Patel</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.748%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTORS&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PMY PARTNERS, LP</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Phil Young</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Phil Young</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Trustee</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.586%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">FRANK F. RANGO</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Investor</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Frank F. Rango</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Signatory, if different</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Title, if applicable</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.586%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">RCC SO I</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Investor</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Roy Patterson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Roy Patterson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Signatory, if different</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Manager</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Title, if applicable</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JONATHAN ROOT AND BETSY BLUEMENTHAL REVOCABLE TRUST DATED DECEMBER 3, 2009</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Jonathan Root and Betsy Blumenthal Trustees</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Jonathan Root</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Jonathan Root</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Trustee</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.748%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTORS&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RED LINE TRUST PARTNERS, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Michael Smith</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Michael Smith</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title Director</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MICHAEL SMITH</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Michael Smith</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.907%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Robert and Karen May</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Investor</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Robert May</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Robert May</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Signatory, if different</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Title, if applicable</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause. </font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.907%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RANDY ROCHMAN</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Randy Rochman</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause. </font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.908%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ROGER LYLE HAYES AND <br>NOEMI ESPINOSA HAYES FAMILY TRUST</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Nicky Espinosa</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Nicky Espinosa</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title Trustee</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause. </font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.907%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Frederick St. Goar</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Investor</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Frederick St. Goar</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Signatory, if different</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Title, if applicable</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause.</font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.907%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">St. Goar&#47;Cassani T&#47;A DTD 9&#47;12&#47;2001</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Investor</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Frederick St. Goar</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Frederick St. Goar</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Signatory, if different</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Trustee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Title, if applicable</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause. </font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.907%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Herlick-Zoi Family Trust</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Investor</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Zack Herlick</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Zack Herlick</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Signatory, if different</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Trustee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Title, if applicable</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause. </font></div><div style="margin-bottom:9pt;text-indent:0.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:50.103%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.697%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Thomas Fogarty Seperate Property Trust Dated 2&#47;6&#47;87</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Investor</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Jonathon David Fogarty</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Jonathon David Fogarty</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Signatory, if different</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Trustee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Title, if applicable</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause. </font></div><div style="margin-bottom:9pt;text-indent:0.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.907%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Waitt corp Investments, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Investor</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Norm Waitt</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Norm Waitt</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Signatory, if different</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Title, if applicable</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause. </font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.907%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WILLIAM C. WELDON</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; William Weldon</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause. </font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.907%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WFI Co-Investments, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Investor</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Andrea Dawkins</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Andrea Dawkins</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Signatory, if different</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Andrea dawkins, manager</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Title, if applicable</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause. </font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.702%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WS investment Company, LLC (2010A)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Investor</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Jim Hinson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Jim Hinson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Signatory, if different</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Director</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Title, if applicable</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause. </font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.907%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">West Investment Holdings, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Investor</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Man D Harper</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Man D Harper</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Signatory, if different</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Manager</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Title, if applicable</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause. </font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.267%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">YOUNG FAMILY TRUST U&#47;T&#47;D 4&#47;13&#47;98</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Phil Young</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Phil Young</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Trustee</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause. </font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.907%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Blue Horizon ex Ventures II Limited</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Investor</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For and on behalf of Mourant Directors One (Guernsey) Limited as Corporate Director</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Antony Saunders Roxanne Williams</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Antony Saunders and Roxanne Williams</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Signatory, if different</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Authorised Signatories</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Title, if applicable</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause. </font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.907%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Board of Trustees of the Leland <br>Stanford Junior University (PVF)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name of Investor</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Jiayan Zhao</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Jiayan Zhao</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Print Name of Signatory, if different <br>Authorized Signatory on behalf of The <br>Board of Trustees of the Leland <br>Stanford Junior University (PVF)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Title, if applicable</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause. </font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.144%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTORS&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">JANUS HENDERSON GLOBAL LIFE<br>SCIENCES FUND</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Janus Henderson Investors US LLC,<br>its investment advisor</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Daniel S. Lyons</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Daniel S. Lyons</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Authorized Signatory</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">JANUS HENDERSON CAPITAL FUNDS PLC ON<br>BEHALF OF ITS SERIES JANUS HENDERSON<br>GLOBAL LIFE SCIENCES FUND</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; Janus Henderson Investors US LLC,<br>its investment advisor</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Daniel S. Lyons</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Daniel S. Lyons</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Authorized Signatory </font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:21pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause. </font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.267%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTOR&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LEONARD FELNER SPOUSAL LIFETIME ACCESS TRUST</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Shoshana Feiner</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Shoshana Feiner</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title Trustee</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties are signing this Amended and Restated Investors&#8217; Rights Agreement as of the date stated in the introductory clause. </font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.267%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">INVESTORS&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LEFT VENTRICLE LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Andy Lam</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Andy Lam</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Member</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">UPRISING INVESTORS FUND I, L.P.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">By&#58; Uprising Investors (GP1), LLC </font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Its&#58;  General Partner</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Andy Lam</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Andy Lam</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Member</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">UPRISING OPPORTUNITY FUND I, L.P.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">By&#58; Uprising Investors Opportunity (GP1), LLC</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Its&#58;  General Partner </font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Andy Lam</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Andy Lam</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Member</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Address&#58; c&#47;o Uprising Fund, Spaces</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">95 Third St. 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Floor</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">San Francisco, CA 94103 </font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tel&#58; 415-891-7562 </font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">HeartFlow Holding, Inc. &#8211; Amended and Restated Investors&#8217; Rights Agreement</font></div></div></div><div id="i231a88ae40fd49518f02ca002c23cc2b_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:14pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT A</font></div><div style="margin-bottom:27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SCHEDULE OF INVESTORS</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i231a88ae40fd49518f02ca002c23cc2b_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">SCHEDULE 1</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTICE AND WAIVER&#47;ELECTION OF</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RIGHT OF FIRST REFUSAL</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I do hereby waive or exercise, as indicated below, my rights of first refusal under the Amended and Restated Investors&#8217; Rights Agreement dated as of &#91;date&#93;, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#58;</font></div><div style="margin-bottom:11pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;Waiver of &#91;___&#93; days&#8217; notice period in which to exercise right of first refusal&#58; (please check only one)</font></div><div style="margin-bottom:11pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(&#160;&#160;&#160;&#160;)&#160;&#160;&#160;&#160;WAIVE in full, on behalf of all Holders, the &#91;___&#93;-day notice period provided to exercise my right of first refusal granted under the Agreement.</font></div><div style="margin-bottom:11pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(&#160;&#160;&#160;&#160;)&#160;&#160;&#160;&#160;DO NOT WAIVE the notice period described above.</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Issuance and Sale of New Securities&#58; (please check only one)</font></div><div style="margin-bottom:11pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(&#160;&#160;&#160;&#160;)&#160;&#160;&#160;&#160;WAIVE in full the right of first refusal granted under the Agreement with respect to the issuance of the New Securities.</font></div><div style="margin-bottom:11pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(&#160;&#160;&#160;&#160;)&#160;&#160;&#160;&#160;ELECT TO PARTICIPATE in $_____________ (please provide amount) in New Securities proposed to be issued by HeartFlow Holding, Inc., a Delaware corporation, representing LESS than my pro rata portion of the aggregate of $&#91;_________&#93; in New Securities being offered in the financing.</font></div><div style="margin-bottom:11pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(&#160;&#160;&#160;&#160;)&#160;&#160;&#160;&#160;ELECT TO PARTICIPATE in $_____________ in New Securities proposed to be issued by Heartflow Holding, Inc., a Delaware corporation, representing my FULL pro rata portion of the aggregate of $&#91;_________&#93; in New Securities being offered in the financing.</font></div><div style="margin-bottom:11pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(&#160;&#160;&#160;&#160;)&#160;&#160;&#160;&#160;ELECT TO PARTICIPATE in my full pro rata portion of the aggregate of $&#91;_________&#93; in New Securities being made available in the financing AND, to the extent available, the greater of (x) an additional $_____________ (please provide amount) or (y) my pro rata portion of any remaining investment amount available in the event other Significant Holders do not exercise their full rights of first refusal with respect to the $&#91;_________&#93; in New Securities being offered in the financing.</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Date&#58; _________________</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">_______________________________________</font></div><div style="margin-bottom:11pt;text-indent:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;Insert Investor&#8217;s name&#93;</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This is neither a commitment to purchase nor a commitment to issue the New Securities described above. Such issuance can only be made by way of definitive documentation related to such issuance. HeartFlow Holding, Inc. will supply you with such definitive documentation upon request or if you indicate that you would like to exercise your first offer rights in whole or in part.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>5
<FILENAME>filename5.htm
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ic00ac40fee75444899d61de56ec182d5_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">HEARTFLOW HOLDING, INC.</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AMENDED AND RESTATED 2009 EQUITY INCENTIVE PLAN</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Background and Purposes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Background</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. HeartFlow, Inc. adopted the HeartFlow, Inc. 2009 Equity Incentive Plan in 2009 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">HeartFlow, Inc. Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). HeartFlow, Inc. completed a holding company structure, making HeartFlow Holding, Inc. the parent holding company of HeartFlow, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reorganization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). In connection with the Reorganization, HeartFlow, Inc. assigned, and HeartFlow Holding, Inc. assumed, the HeartFlow, Inc. Plan and all outstanding Award Agreements. All outstanding Awards granted under the HeartFlow, Inc. Plan automatically converted into a right to receive shares of HeartFlow Holding, Inc., upon the same terms and conditions as otherwise set forth in the Award Agreement. The HeartFlow, Inc. Plan is amended and restated as set forth herein, effective as of March 1, 2021 to reflect the Reorganization and prior amendments which are currently effective.</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Purposes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The purposes of this Plan are&#58; (i) to attract and retain the best available personnel for positions of substantial responsibility&#59; (ii) to provide additional incentive to Employees, Directors and Consultants&#59; and (iii) to promote the success of the Company&#8217;s business. The Plan permits the grant of Incentive Stock Options, Nonstatutory Stock Options, Stock Appreciation Rights, Restricted Stock and Restricted Stock Units.</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. As used herein, the following definitions will apply&#58;</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Board or any of its Committees as will be administering the Plan, in accordance with Section </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of the Plan.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Applicable Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the requirements relating to the administration of equity-based awards under U.S. state corporate laws, U.S. federal and state securities laws, the Code, any stock exchange or quotation system on which the Common Stock is listed or quoted and the applicable laws of any foreign country or jurisdiction where Awards are, or will be, granted under the Plan.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, individually or collectively, a grant under the Plan of Options, Stock Appreciation Rights, Restricted Stock, or Restricted Stock Units.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Award Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the written or electronic agreement setting forth the terms and provisions applicable to each Award granted under the Plan. The Award Agreement is subject to the terms and conditions of the Plan.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Board of Directors of the Company.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the occurrence of any of the following events&#58;</font></div><div style="margin-bottom:11pt;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Change in Ownership of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. A change in the ownership of the Company which occurs on the date that any one person, or more than one person acting as a group (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), acquires ownership of the stock of the Company that, together with the stock held by such Person, constitutes more than 50% of the total voting power of the stock of the Company, except that any change in the ownership of the stock of the Company as a result of a private financing of the Company that is approved by the Board will not be considered a Change in Control&#59; or</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Change in Effective Control of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If the Company has a class of securities registered pursuant to Section 12 of the Exchange Act, a change in the effective control of the Company which occurs on the date that a majority of members of the Board is replaced during any twelve (12) month period by Directors whose appointment or election is not endorsed by a majority of the members of the Board prior to the date of the appointment or election. For purposes of this subsection (ii), if any Person is considered to be in effective control of the Company, the acquisition of additional control of the Company by the same Person will not be considered a Change in Control&#59; or</font></div><div style="margin-bottom:11pt;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Change in Ownership of a Substantial Portion of the Company&#8217;s Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. A change in the ownership of a substantial portion of the Company&#8217;s assets which occurs on the date that any Person acquires (or has acquired during the twelve (12) month period ending on the date of the most recent acquisition by such person or persons) assets from the Company that have a total gross fair market value equal to or more than 50% of the total gross fair market value of all of the assets of the Company immediately prior to such acquisition or acquisitions. For purposes of this subsection (iii), gross fair market value means the value of the assets of the Company, or the value of the assets being disposed of, determined without regard to any liabilities associated with such assets.</font></div><div style="margin-bottom:11pt;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For purposes of this Section 2(f), persons will be considered to be acting as a group if they are owners of a corporation that enters into a merger, consolidation, purchase or acquisition of stock, or similar business transaction with the Company.</font></div><div style="margin-bottom:11pt;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, a transaction will not be deemed a Change in Control unless the transaction qualifies as a change in control event within the meaning of Code Section 409A, as it has been and may be amended from time to time, and any proposed or final Treasury Regulations and Internal Revenue Service guidance that has been promulgated or may be promulgated thereunder from time to time.</font></div><div style="margin-bottom:11pt;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Further and for the avoidance of doubt, a transaction will not constitute a Change in Control if&#58; (i) its sole purpose is to change the state of the Company&#8217;s incorporation, or (ii) its sole purpose is to create a holding company that will be owned in substantially the same proportions by the persons who held the Company&#8217;s securities immediately before such transaction.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Internal Revenue Code of 1986, as amended. Any reference to a section of the Code herein will be a reference to any successor or amended section of the Code.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a committee of Directors or of other individuals satisfying Applicable Laws appointed by the Board, or by the compensation committee of the Board, in accordance with Section </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">hereof.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the common stock of the Company.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means HeartFlow Holding, Inc., a Delaware corporation, or any successor thereto.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consultant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any individual, including an advisor, engaged by the Company or a Parent or Subsidiary to render services to such entity.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a member of the Board.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(m)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means total and permanent disability as defined in Code Section 22(e)(3), provided that in the case of Awards other than Incentive Stock Options, the Administrator in its </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-2-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">discretion may determine whether a permanent and total disability exists in accordance with uniform and non-discriminatory standards adopted by the Administrator from time to time.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(n)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any person, including officers and Directors, employed by the Company or any Parent or Subsidiary of the Company. Neither service as a Director nor payment of a director&#8217;s fee by the Company will be sufficient to constitute &#8220;employment&#8221; by the Company.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(o)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Securities Exchange Act of 1934, as amended.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(p)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exchange Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a program under which (i) outstanding Awards are surrendered or cancelled in exchange for Awards of the same type (which may have higher or lower exercise prices and different terms), Awards of a different type, and&#47;or cash, (ii) Participants would have the opportunity to transfer any outstanding Awards to a financial institution or other person or entity selected by the Administrator, and&#47;or (iii) the exercise price of an outstanding Award is reduced or increased. The Administrator will determine the terms and conditions of any Exchange Program in its sole discretion.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(q)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fair Market Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, as of any date, the value of Common Stock determined as follows&#58;</font></div><div style="margin-bottom:11pt;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;If the Common Stock is listed on any established stock exchange or a national market system, including without limitation the Nasdaq Global Select Market, the Nasdaq Global Market or the Nasdaq Capital Market of The Nasdaq Stock Market, its Fair Market Value will be the closing sales price for such stock (or the closing bid, if no sales were reported) as quoted on such exchange or system on the day of determination, as reported in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">The Wall Street Journal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or such other source as the Administrator deems reliable&#59;</font></div><div style="margin-bottom:11pt;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;If the Common Stock is regularly quoted by a recognized securities dealer but selling prices are not reported, the Fair Market Value of a Share will be the mean between the high bid and low asked prices for the Common Stock on the day of determination (or, if no bids and asks were reported on that date, as applicable, on the last trading date such bids and asks were reported), as reported in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">The Wall Street Journal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or such other source as the Administrator deems reliable&#59; or</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;In the absence of an established market for the Common Stock, the Fair Market Value will be determined in good faith by the Administrator </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">after taking into consideration all factors which it deems appropriate, including, without limitation, the requirements of Code Section 409A and 422</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(r)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Incentive Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means an Option that by its terms qualifies and is otherwise intended to qualify as an incentive stock option within the meaning of Code Section 422 and the regulations promulgated thereunder.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(s)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Nonstatutory Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means an Option that by its terms does not qualify or is not intended to qualify as an Incentive Stock Option.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(t)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a stock option granted pursuant to the Plan.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(u)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a &#8220;parent corporation,&#8221; whether now or hereafter existing, as defined in Code Section 424(e).</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the holder of an outstanding Award.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-3-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(w)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Period of Restriction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the period during which the transfer of Shares of Restricted Stock are subject to restrictions and therefore, the Shares are subject to a substantial risk of forfeiture. Such restrictions may be based on the passage of time, the achievement of target levels of performance, or the occurrence of other events as determined by the Administrator.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(x)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the HeartFlow Holding, Inc. Amended and Restated 2009 Equity Incentive Plan as stated herein, as may be amended from time to time. The Plan was previously known as the HeartFlow, Inc. 2009 Equity Incentive Plan.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(y)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Restricted Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Shares issued pursuant to an Award of Restricted Stock under Section 8 of the Plan, or issued pursuant to the early exercise of an Option.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(z)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Restricted Stock Unit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a bookkeeping entry representing an amount equal to the Fair Market Value of one Share, granted pursuant to Section </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Restricted Stock Unit represents an unfunded and unsecured obligation of the Company.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(aa)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Service Provider</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means an Employee, Director or Consultant.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(bb)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a share of the Common Stock, as adjusted in accordance with Section 13 of the Plan.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(cc)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Stock Appreciation Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means an Award, granted alone or in connection with an Option, that pursuant to Section 7 is designated as a Stock Appreciation Right.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(dd)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a &#8220;subsidiary corporation,&#8221; whether now or hereafter exist-ing, as defined in Code Section 424(f).</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Stock Subject to the Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Stock Subject to the Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to the provisions of Section 13 of the Plan, the maximum aggregate number of Shares that may be subject to Awards and sold under the Plan is 16,385,301 Shares. The Shares may be authorized but unissued, or reacquired Common Stock.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Lapsed Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If an Award expires or becomes unexercisable without having been exercised in full, is surrendered pursuant to an Exchange Program, or, with respect to Restricted Stock or Restricted Stock Units, is forfeited to or repurchased by the Company due to the failure to vest, the unpurchased Shares (or for Awards other than Options or Stock Appreciation Rights the forfeited or repurchased Shares) which were subject thereto will become available for future grant or sale under the Plan (unless the Plan has terminated). With respect to Stock Appreciation Rights, only Shares actually issued pursuant to a Stock Appreciation Right will cease to be available under the Plan&#59; all remaining Shares under Stock Appreciation Rights will remain available for future grant or sale under the Plan (unless the Plan has terminated). Shares that have actually been issued under the Plan under any Award will not be returned to the Plan and will not become available for future distribution under the Plan&#59; provided, however, that if Shares issued pursuant to Awards of Restricted Stock or Restricted Stock Units are repurchased by the Company or are forfeited to the Company due to the failure to vest, such Shares will become available for future grant under the Plan. Shares used to pay the exercise price of an Award or to satisfy the tax withholding obligations related to an Award will become available for future grant or sale under the Plan. To the extent an Award under the Plan is paid out in cash rather than Shares, such cash payment will not result in reducing the number of Shares available for issuance under the Plan. Notwithstanding the foregoing and, subject to adjustment as provided in Section 13, the maximum </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-4-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">number of Shares that may be issued upon the exercise of Incentive Stock Options will equal the aggregate Share number stated in Section 3(a), plus, to the extent allowable under Code Section 422 and the Treasury Regulations promulgated thereunder, any Shares that become available for issuance under the Plan pursuant to Section 3(b).</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Share Reserve</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company, during the term of this Plan, will at all times reserve and keep available such number of Shares as will be sufficient to satisfy the requirements of the Plan.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Administration of the Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Multiple Administrative Bodies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Different Committees with respect to different groups of Service Providers may administer the Plan.</font></div><div style="margin-bottom:11pt;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Other than as provided above, the Plan will be administered by (A) the Board or (B) a Committee, which Committee will be constituted to satisfy Applicable Laws.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Powers of the Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to the provisions of the Plan, and in the case of a Committee, subject to the specific duties delegated by the Board to such Committee, the Administrator will have the authority, in its discretion&#58;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;to determine the Fair Market Value&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;to select the Service Providers to whom Awards may be granted hereunder&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;to determine the number of Shares to be covered by each Award granted hereunder&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;to approve forms of Award Agreements for use under the Plan&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;to determine the terms and conditions, not inconsistent with the terms of the Plan, of any Award granted hereunder. Such terms and conditions include, but are not limited to, the exercise price, the time or times when Awards may be exercised (which may be based on performance criteria), any vesting acceleration or waiver of forfeiture restrictions, and any restriction or limitation regarding any Award or the Shares relating thereto, based in each case on such factors as the Administrator will determine&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;to institute and determine the terms and conditions of an Exchange Program&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;to construe and interpret the terms of the Plan and Awards granted pursuant to the Plan&#59;</font></div><div style="margin-bottom:11pt;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(viii)&#160;&#160;&#160;&#160;to prescribe, amend and rescind rules and regulations relating to the Plan, including rules and regulations relating to sub-plans established for the purpose of satisfying applicable foreign laws or for qualifying for favorable tax treatment under applicable foreign laws&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-5-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ix)&#160;&#160;&#160;&#160;to modify or amend each Award (subject to Section 18(c) of the Plan), including but not limited to the discretionary authority to extend the post-termination exercisability period of Awards and to extend the maximum term of an Option (subject to Section 6(d))&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(x)&#160;&#160;&#160;&#160;to allow Participants to satisfy withholding tax obligations in a manner prescribed in Section 14&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(xi)&#160;&#160;&#160;&#160;to authorize any person to execute on behalf of the Company any instrument required to effect the grant of an Award previously granted by the Administrator&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(xii)&#160;&#160;&#160;&#160;to allow a Participant to defer the receipt of the payment of cash or the delivery of Shares that otherwise would be due to such Participant under an Award&#59; and</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(xiii)&#160;&#160;&#160;&#160;to make all other determinations deemed necessary or advisable for administering the Plan.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Effect of Administrator&#8217;s Decision</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Administrator&#8217;s decisions, determinations and interpretations will be final and binding on all Participants and any other holders of Awards.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Awards to Foreign Nationals and Employees Outside the United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. To the extent the Administrator deems it necessary, appropriate or desirable to comply with non-U.S. law or practices and to further the purposes of the Plan, the Administrator may (i) establish rules applicable to Awards granted to Participants who are foreign nationals, are employed outside the United States, or both, including rules that differ from those set forth in this Plan, and (ii) grant Awards to such Participants in accordance with those rules.</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Eligibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Nonstatutory Stock Options, Stock Appreciation Rights, Restricted Stock, and Restricted Stock Units may be granted to Service Providers. Incentive Stock Options may be granted only to Employees.</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Stock Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Grant of Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to the terms and provisions of the Plan, the Administrator, at any time and from time to time, may grant Options in such amounts as the Administrator, in its sole discretion, will determine.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Option Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Award of an Option will be evidenced by an Award Agreement that will specify the exercise price, the term of the Option, the number of Shares subject to the Option, the exercise restrictions, if any, applicable to the Option, and such other terms and conditions as the Administrator, in its sole discretion, will determine.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Limitations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Option will be designated in the Award Agreement as either an Incentive Stock Option or a Nonstatutory Stock Option. Notwithstanding such designation, however, to the extent that the aggregate Fair Market Value of the Shares with respect to which Incentive Stock Options are exercisable for the first time by the Participant during any calendar year (under all plans of the Company and any Parent or Subsidiary) exceeds one hundred thousand dollars ($100,000), such Options will be treated as Nonstatutory Stock Options. For purposes of this Section 6(c), Incentive Stock Options will be taken into account in the order in which they were granted, the Fair Market Value of the Shares will be determined as of the time the Option with respect to such Shares is granted, and calculation </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-6-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">will be performed in accordance with Code Section 422 and Treasury Regulations promulgated thereunder.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Term of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The term of each Option will be stated in the Award Agreement&#59; provided, however, that the term will be no more than ten (10) years from the date of grant thereof. In the case of an Incentive Stock Option granted to a Participant who, at the time the Incentive Stock Option is granted, owns stock representing more than ten percent (10%) of the total combined voting power of all classes of stock of the Company or any Parent or Subsidiary, the term of the Incentive Stock Option will be five (5) years from the date of grant or such shorter term as may be provided in the Award Agreement.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Option Exercise Price and Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The per Share exercise price for the Shares to be issued pursuant to the exercise of an Option will be determined by the Administrator, but will be no less than one hundred percent (100%) of the Fair Market Value per Share on the date of grant. In addition, in the case of an Incentive Stock Option granted to an Employee who owns stock representing more than ten percent (10%) of the voting power of all classes of stock of the Company or any Parent or Subsidiary, the per Share exercise price will be no less than one hundred ten percent (110%) of the Fair Market Value per Share on the date of grant. Notwithstanding the foregoing provisions of this Section 6(e)(i), Options may be granted with a per Share exercise price of less than one hundred percent (100%) of the Fair Market Value per Share on the date of grant pursuant to a transaction described in, and in a manner consistent with, Code Section 424(a).</font></div><div style="margin-bottom:11pt;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Waiting Period and Exercise Dates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. At the time an Option is granted, the Administrator will fix the period within which the Option may be exercised and will determine any conditions that must be satisfied before the Option may be exercised.</font></div><div style="margin-bottom:11pt;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Form of Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Administrator will determine the acceptable form of consideration for exercising an Option, including the method of payment. In the case of an Incentive Stock Option, the Administrator will determine the acceptable form of consideration at the time of grant. Such consideration may consist entirely of&#58; (1) cash&#59; (2) check&#59; (3) promissory note, to the extent permitted by Applicable Laws&#59; (4) other Shares, provided that such Shares have a Fair Market Value on the date of surrender equal to the aggregate exercise price of the Shares as to which such Option will be exercised and provided further that accepting such Shares will not result in any adverse accounting consequences to the Company, as the Administrator determines in its sole discretion&#59; (5) consideration received by the Company under cashless exercise program (whether through a broker or otherwise) implemented by the Company in connection with the Plan&#59; (6) by net exercise&#59; (7) such other consideration and method of payment for the issuance of Shares to the extent permitted by Applicable Laws&#59; or (8) any combination of the foregoing methods of payment. In making its determination as to the type of consideration to accept, the Administrator will consider if acceptance of such consideration may be reasonably expected to benefit the Company.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exercise of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Procedure for Exercise&#59; Rights as a Stockholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Any Option granted hereunder will be exercisable according to the terms of the Plan and at such times and under such conditions as determined by the Administrator and set forth in the Award Agreement. An Option may not be exercised for a fraction of a Share.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-7-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">An Option will be deemed exercised when the Company receives&#58; (i) notice of exercise (in such form as the Administrator may specify from time to time) from the person entitled to exercise the Option, and (ii) full payment for the Shares with respect to which the Option is exercised (together with applicable tax withholding). Full payment may consist of any consideration and method of payment authorized by the Administrator and permitted by the Award Agreement and the Plan. Shares issued upon exercise of an Option will be issued in the name of the Participant or, if requested by the Participant, in the name of the Participant and his or her spouse. Until the Shares are issued (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a stockholder will exist with respect to the Shares subject to an Option, notwithstanding the exercise of the Option. The Company will issue (or cause to be issued) such Shares promptly after the Option is exercised. No adjustment will be made for a dividend or other right for which the record date is prior to the date the Shares are issued, except as provided in Section 13 of the Plan.</font></div><div style="margin-bottom:11pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exercising an Option in any manner will decrease the number of Shares thereafter available, both for purposes of the Plan and for sale under the Option, by the number of Shares as to which the Option is exercised.</font></div><div style="margin-bottom:11pt;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Termination of Relationship as a Service Provider</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If a Participant ceases to be a Service Provider, other than upon the Participant&#8217;s termination as the result of the Participant&#8217;s death or Disability, the Participant may exercise his or her Option within thirty (30) days of termination, or such longer period of time as is specified in the Award Agreement (but in no event later than the expiration of the term of such Option as set forth in the Award Agreement) to the extent that the Option is vested on the date of termination. Unless otherwise provided by the Administrator, if on the date of termination the Participant is not vested as to his or her entire Option, the Shares covered by the unvested portion of the Option will revert to the Plan. If after termination the Participant does not exercise his or her Option within the time specified by the Administrator, the Option will terminate, and the Shares covered by such Option will revert to the Plan.</font></div><div style="margin-bottom:11pt;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Disability of Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If a Participant ceases to be a Service Provider as a result of the Participant&#8217;s Disability, the Participant may exercise his or her Option within six (6) months of termination, or such longer period of time as is specified in the Award Agreement (but in no event later than the expiration of the term of such Option as set forth in the Award Agreement) to the extent the Option is vested on the date of termination. Unless otherwise provided by the Administrator, if on the date of termination the Participant is not vested as to his or her entire Option, the Shares covered by the unvested portion of the Option will revert to the Plan. If after termination the Participant does not exercise his or her Option within the time specified herein, the Option will terminate, and the Shares covered by such Option will revert to the Plan.</font></div><div style="margin-bottom:11pt;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Death of Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If a Participant dies while a Service Provider, the Option may be exercised within six (6) months following the Participant&#8217;s death, or within such longer period of time as is specified in the Award Agreement (but in no event later than the expiration of the term of such Option as set forth in the Award Agreement) to the extent that the Option is vested on the date of death, by the Participant&#8217;s designated beneficiary, provided such beneficiary has been designated prior to the Participant&#8217;s death in a form acceptable to the Administrator. If no such beneficiary has been designated by the Participant, then such Option may be exercised by the personal representative of the Participant&#8217;s estate or by the person(s) to whom the Option is transferred pursuant to the Participant&#8217;s will or in accordance with the laws of descent and distribution. Unless otherwise provided by the Administrator, if at the time of death Participant is not vested as to his or her entire Option, the Shares covered by the unvested portion of the Option will immediately revert to the Plan. If the Option is not so </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-8-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">exercised within the time specified herein, the Option will terminate, and the Shares covered by such Option will revert to the Plan.</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Stock Appreciation Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Grant of Stock Appreciation Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to the terms and conditions of the Plan, a Stock Appreciation Right may be granted to Service Providers at any time and from time to time as will be determined by the Administrator, in its sole discretion.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Number of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Administrator will have complete discretion to determine the number of Shares subject to any Award of Stock Appreciation Rights.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exercise Price and Other Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The per Share exercise price for the Shares that will determine the amount of the payment to be received upon exercise of a Stock Appreciation Right as set forth in Section 7(f) will be determined by the Administrator and will be no less than one hundred percent (100%) of the Fair Market Value per Share on the date of grant. Otherwise, the Administrator, subject to the provisions of the Plan, will have complete discretion to determine the terms and conditions of Stock Appreciation Rights granted under the Plan.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Stock Appreciation Right Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Stock Appreciation Right grant will be evidenced by an Award Agreement that will specify the exercise price, the term of the Stock Appreciation Right, the conditions of exercise, and such other terms and conditions as the Administrator, in its sole discretion, will determine.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Expiration of Stock Appreciation Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. A Stock Appreciation Right granted under the Plan will expire upon the date determined by the Administrator, in its sole discretion, and set forth in the Award Agreement. Notwithstanding the foregoing, the rules of Section 6(d) relating to the maximum term and Section 6(f) relating to exercise also will apply to Stock Appreciation Rights.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Payment of Stock Appreciation Right Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Upon exercise of a Stock Appreciation Right, a Participant will be entitled to receive payment from the Company in an amount determined by multiplying&#58;</font></div><div style="margin-bottom:11pt;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;The difference between the Fair Market Value of a Share on the date of exercise over the exercise price&#59; times</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;The number of Shares with respect to which the Stock Appreciation Right is exercised.</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">At the discretion of the Administrator, the payment upon Stock Appreciation Right exercise may be in cash, in Shares of equivalent value, or in some combination thereof.</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Restricted Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Grant of Restricted Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to the terms and provisions of the Plan, the Administrator, at any time and from time to time, may grant Shares of Restricted Stock to Service Providers in such amounts as the Administrator, in its sole discretion, will determine.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Restricted Stock Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Award of Restricted Stock will be evidenced by an Award Agreement that will specify the Period of Restriction, the number of Shares granted, and such other terms and conditions as the Administrator, in its sole discretion, will determine. Unless the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-9-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Administrator determines otherwise, the Company as escrow agent will hold Shares of Restricted Stock until the restrictions on such Shares have lapsed.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Except as provided in this Section 8 or as the Administrator determines, Shares of Restricted Stock may not be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated until the end of the applicable Period of Restriction.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Administrator, in its sole discretion, may impose such other restrictions on Shares of Restricted Stock as it may deem advisable or appropriate.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Removal of Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Except as otherwise provided in this Section 8, Shares of Restricted Stock covered by each Restricted Stock grant made under the Plan will be released from escrow as soon as practicable after the last day of the Period of Restriction or at such other time as the Administrator may determine. The Administrator, in its discretion, may accelerate the time at which any restrictions will lapse or be removed.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Voting Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. During the Period of Restriction, Service Providers holding Shares of Restricted Stock granted hereunder may exercise full voting rights with respect to those Shares, unless the Administrator determines otherwise.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Dividends and Other Distributions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. During the Period of Restriction, Service Providers holding Shares of Restricted Stock will be entitled to receive all dividends and other distributions paid with respect to such Shares, unless the Administrator provides otherwise. If any such dividends or distributions are paid in Shares, the Shares will be subject to the same restrictions on transferability and forfeitability as the Shares of Restricted Stock with respect to which they were paid.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Return of Restricted Stock to Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. On the date set forth in the Award Agreement, the Restricted Stock for which restrictions have not lapsed will revert to the Company and again will become available for grant under the Plan.</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Restricted Stock Units may be granted at any time and from time to time as determined by the Administrator. After the Administrator determines that it will grant Restricted Stock Units, it will advise the Participant in an Award Agreement of the terms, conditions, and restrictions related to the grant, including the number of Restricted Stock Units.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Vesting Criteria and Other Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Administrator will set vesting criteria in its discretion, which, depending on the extent to which the criteria are met, will determine the number of Restricted Stock Units that will be paid out to the Participant. The Administrator may set vesting criteria based upon the achievement of Company-wide, business unit, or individual goals (including, but not limited to, continued employment or service), or any other basis determined by the Administrator in its discretion.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Earning Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Upon meeting the applicable vesting criteria, the Participant will be entitled to receive a payout as determined by the Administrator. Notwithstanding the foregoing, at any time after the grant of Restricted Stock Units, the Administrator, in its sole discretion, may reduce or waive any vesting criteria that must be met to receive a payout.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Form and Timing of Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Payment of earned Restricted Stock Units will be made as soon as practicable after the date(s) determined by the Administrator and set forth in the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-10-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Award Agreement. The Administrator, in its sole discretion, may settle earned Restricted Stock Units in cash, Shares, or a combination of both.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cancellation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. On the date set forth in the Award Agreement, all unearned Restricted Stock Units will be forfeited to the Company.</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Compliance With Code Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Awards will be designed and operated in such a manner that they are either exempt from the application of, or comply with, the requirements of Code Section 409A, except as otherwise determined in the sole discretion of the Administrator. The Plan and each Award Agreement under the Plan is intended to meet the requirements of Code Section 409A and will be construed and interpreted in accordance with such intent, except as otherwise determined in the sole discretion of the Administrator. To the extent that an Award or payment, or the settlement or deferral thereof, is subject to Code Section 409A the Award will be granted, paid, settled or deferred in a manner that will meet the requirements of Code Section 409A, such that the grant, payment, settlement or deferral will not be subject to the additional tax or interest applicable under Code Section 409A. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, neither the Company nor the Administrator will have any liability to any Participant for such tax or penalty.</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Leaves of Absence&#47;Transfer Between Locations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Unless the Administrator provides otherwise, vesting of Awards granted hereunder will be suspended during any unpaid leave of absence. A Participant will not cease to be an Employee in the case of (i) any leave of absence approved by the Company or (ii) transfers between locations of the Company or between the Company, its Parent, or any Subsidiary. For purposes of Incentive Stock Options, no such leave may exceed three (3) months, unless reemployment upon expiration of such leave is guaranteed by statute or contract. If reemployment upon expiration of a leave of absence approved by the Company is not so guaranteed, then six (6) months following the first (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) day of such leave, any Incentive Stock Option held by the Participant will cease to be treated as an Incentive Stock Option and will be treated for tax purposes as a Nonstatutory Stock Option.</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Limited Transferability of Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Unless determined otherwise by the Administrator, Awards may not be sold, pledged, assigned, hypothecated, or otherwise transferred in any manner other than by will or by the laws of descent and distribution, and may be exercised, during the lifetime of the Participant, only by the Participant. If the Administrator makes an Award transferable, such Award may only be transferred (i) by will, (ii) by the laws of descent and distribution, or (iii) as permitted by Rule 701 of the Securities Act of 1933, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Further, until the Company becomes subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act, or after the Administrator determines that it is, will, or may no longer be relying upon the exemption from registration under the Exchange Act as set forth in Rule 12h-1(f) promulgated under the Exchange Act, an Option, or prior to exercise, the Shares subject to the Option, may not be pledged, hypothecated or otherwise transferred or disposed of, in any manner, including by entering into any short position, any &#8220;put equivalent position&#8221; or any &#8220;call equivalent position&#8221; (as defined in Rule 16a-1(h) and Rule 16a-1(b) of the Exchange Act, respectively), other than to (i) persons who are &#8220;family members&#8221; (as defined in Rule 701(c)(3) of the Securities Act) through gifts or domestic relations orders, or (ii) to an executor or guardian of the Participant upon the death or disability of the Participant. Notwithstanding the foregoing sentence, the Administrator, in its sole discretion, may determine to permit transfers to the Company or in connection with a Change in Control or other acquisition transactions involving the Company to the extent permitted by Rule 12h-1(f).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-11-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Adjustments&#59; Dissolution or Liquidation&#59; Merger or Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Adjustments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. In the event that any dividend or other distribution (whether in the form of cash, Shares, other securities, or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase, or exchange of Shares or other securities of the Company, or other change in the corporate structure of the Company affecting the Shares occurs, the Administrator, in order to prevent diminution or enlargement of the benefits or potential benefits intended to be made available under the Plan, will adjust the number and class of Shares that may be delivered under the Plan and&#47;or the number, class, and price of Shares covered by each outstanding Award&#59; provided, however, that the Administrator will make such adjustments to an Award required by Section 25102(o) of the California Corporations Code to the extent the Company is relying upon the exemption afforded thereby with respect to the Award.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Dissolution or Liquidation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. In the event of the proposed dissolution or liquidation of the Company, the Administrator will notify each Participant as soon as practicable prior to the effective date of such proposed transaction. To the extent it has not been previously exercised, an Award will terminate immediately prior to the consummation of such proposed action.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Merger or Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. In the event of a merger or Change in Control, each outstanding Award will be treated as the Administrator determines without a Participant&#8217;s consent, including, without limitation, that (i) Awards will be assumed, or substantially equivalent Awards will be substituted, by the acquiring or succeeding corporation (or an affiliate thereof) with appropriate adjustments as to the number and kind of shares and prices&#59; (ii) upon written notice to a Participant, that the Participant&#8217;s Awards will terminate upon or immediately prior to the consummation of such merger or Change in Control (subject to the provisions of the preceding paragraph)&#59; (iii) outstanding Awards will vest and become exercisable, realizable, or payable, or restrictions applicable to an Award will lapse, in whole or in part prior to or upon consummation of such merger or Change in Control, and, to the extent the Administrator determines, terminate upon or immediately prior to the effectiveness of such merger of Change in Control&#59; (iv) (A) the termination of an Award in exchange for an amount of cash and&#47;or property, if any, equal to the amount that would have been attained upon the exercise of such Award or realization of the Participant&#8217;s rights as of the date of the occurrence of the transaction (and, for the avoidance of doubt, if as of the date of the occurrence of the transaction the Administrator determines in good faith that no amount would have been attained upon the exercise of such Award or realization of the Participant&#8217;s rights, then such Award may be terminated by the Company without payment), or (B) the replacement of such Award with other rights or property selected by the Administrator in its sole discretion&#59; or (v) any combination of the foregoing. In taking any of the actions permitted under this Section 13(c), the Administrator will not be obligated to treat all Awards, all Awards held by a Participant, or all Awards of the same type, similarly.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the event that the successor corporation does not assume or substitute for the Award (or portion thereof), the Participant will fully vest in and have the right to exercise all of his or her outstanding Options and Stock Appreciation Rights, including Shares as to which such Awards would not otherwise be vested or exercisable, all restrictions on Restricted Stock and Restricted Stock Units will lapse, and, with respect to Awards with performance-based vesting, all performance goals or other vesting criteria will be deemed achieved at one hundred percent (100%) of target levels and all other terms and conditions met. In addition, if an Option or Stock Appreciation Right is not assumed or substituted in the event of a merger or Change in Control, the Administrator will notify the Participant in writing or electronically that the Option or Stock Appreciation Right will be exercisable for a period of time determined by the Administrator in its sole discretion, and the Option or Stock Appreciation Right will terminate upon the expiration of such period.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-12-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the purposes of this Section 13(c), an Award will be considered assumed if, following the merger or Change in Control, the Award confers the right to purchase or receive, for each Share subject to the Award immediately prior to the merger or Change in Control, the consideration (whether stock, cash, or other securities or property) received in the merger or Change in Control by holders of Common Stock for each Share held on the effective date of the transaction (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding Shares)&#59; provided, however, that if such consideration received in the merger or Change in Control is not solely common stock of the successor corporation or its Parent, the Administrator may, with the consent of the successor corporation, provide for the consideration to be received upon the exercise of an Option or Stock Appreciation Right or upon the payout of a Restricted Stock Unit, for each Share subject to such Award, to be solely common stock of the successor corporation or its Parent equal in fair market value to the per share consideration received by holders of Common Stock in the merger or Change in Control.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding anything in this Section 13(c) to the contrary, an Award that vests, is earned or paid-out upon the satisfaction of one or more performance goals will not be considered assumed if the Company or its successor modifies any of such performance goals without the Participant&#8217;s consent&#59; provided, however, a modification to such performance goals only to reflect the successor corporation&#8217;s post-Change in Control corporate structure will not be deemed to invalidate an otherwise valid Award assumption.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding anything in this Section 13(c) to the contrary, if a payment under an Award Agreement is subject to Code Section 409A and if the change in control definition contained in the Award Agreement does not comply with the definition of &#8220;change of control&#8221; for purposes of a distribution under Code Section 409A, then any payment of an amount that is otherwise accelerated under this Section will be delayed until the earliest time that such payment would be permissible under Code Section 409A without triggering any penalties applicable under Code Section 409A.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Withholding Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Prior to the delivery of any Shares or cash pursuant to an Award (or exercise thereof), the Company will have the power and the right to deduct or withhold, or require a Participant to remit to the Company, an amount sufficient to satisfy federal, state, local, foreign or other taxes (including the Participant&#8217;s FICA obligation) required to be withheld with respect to such Award (or exercise thereof).</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Withholding Arrangements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Administrator, in its sole discretion and pursuant to such procedures as it may specify from time to time, may permit a Participant to satisfy such tax withholding obligation, in whole or in part by (without limitation) (i) paying cash, (ii) electing to have the Company withhold otherwise deliverable Shares having a Fair Market Value equal to the minimum statutory amount required to be withheld, (iii) delivering to the Company already-owned Shares having a Fair Market Value equal to the statutory amount required to be withheld, provided the delivery of such Shares will not result in any adverse accounting consequences, as the Administrator determines in its sole discretion, or (iv) selling a sufficient number of Shares otherwise deliverable to the Participant through such means as the Administrator may determine in its sole discretion (whether through a broker or otherwise) equal to the amount required to be withheld. The amount of the withholding requirement will be deemed to include any amount which the Administrator agrees may be withheld at the time the election is made, not to exceed the amount determined by using the maximum federal, state or local marginal income tax rates applicable to the Participant with respect to the Award on the date that the amount of tax to be withheld is to be determined. The Fair Market Value of the Shares to be withheld or delivered will be determined as of the date that the taxes are required to be withheld.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-13-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">No Effect on Employment or Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Neither the Plan nor any Award will confer upon a Participant any right with respect to continuing the Participant&#8217;s relationship as a Service Provider with the Company, nor will they interfere in any way with the Participant&#8217;s right or the Company&#8217;s right to terminate such relationship at any time, with or without cause, to the extent permitted by Applicable Laws.</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Date of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The date of grant of an Award will be, for all purposes, the date on which the Administrator makes the determination granting such Award, or such other later date as is determined by the Administrator. Notice of the determination will be provided to each Participant within a reasonable time after the date of such grant.</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Term of Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to Section 21 of the Plan, the Plan will become effective upon its adoption by the Board. Unless sooner terminated under Section 18, it will continue in effect for a term of ten (10) years from the later of (a) the effective date of the Plan, or (b) the earlier of the most recent Board or stockholder approval of an increase in the number of Shares reserved for issuance under the Plan.</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Amendment and Termination of the Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amendment and Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Board may at any time amend, alter, suspend or terminate the Plan.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Stockholder Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company will obtain stockholder approval of any Plan amendment to the extent necessary and desirable to comply with Applicable Laws.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Effect of Amendment or Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No amendment, alteration, suspension or termination of the Plan will impair the rights of any Participant, unless mutually agreed otherwise between the Participant and the Administrator, which agreement must be in writing and signed by the Participant and the Company. Termination of the Plan will not affect the Administrator&#8217;s ability to exercise the powers granted to it hereunder with respect to Awards granted under the Plan prior to the date of such termination.</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Conditions Upon Issuance of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Legal Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Shares will not be issued pursuant to the exercise of an Award unless the exercise of such Award and the issuance and delivery of such Shares will comply with Applicable Laws and will be further subject to the approval of counsel for the Company with respect to such compliance.</font></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Investment Representations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. As a condition to the exercise of an Award, the Company may require the person exercising such Award to represent and warrant at the time of any such exercise that the Shares are being purchased only for investment and without any present intention to sell or distribute such Shares if, in the opinion of counsel for the Company, such a representation is required.</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Inability to Obtain Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The inability of the Company to obtain authority from any regulatory body having jurisdiction, which authority is deemed by the Company&#8217;s counsel to be necessary to the lawful issuance and sale of any Shares hereunder, will relieve the Company of any liability in respect of the failure to issue or sell such Shares as to which such requisite authority will not have been obtained.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-14-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Stockholder Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Plan will be subject to approval by the stockholders of the Company within twelve (12) months after the date the Plan is adopted by the Board. Such stockholder approval will be obtained in the manner and to the degree required under Applicable Laws.</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">22.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Information to Participants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Beginning on the earlier of (i) the date that the aggregate number of Participants under this Plan is five hundred (500) or more and the Company is relying on the exemption provided by Rule 12h-1(f)(1) under the Exchange Act and (ii) the date that the Company is required to deliver information to Participants pursuant to Rule 701 under the Securities Act, and until such time as the Company becomes subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act, is no longer relying on the exemption provided by Rule 12h-1(f)(1) under the Exchange Act or is no longer required to deliver information to Participants pursuant to Rule 701 under the Securities Act, the Company shall provide to each Participant the information described in paragraphs (e)(3), (4), and (5) of Rule 701 under the Securities Act not less frequently than every six (6) months with the financial statements being not more than 180 days old and with such information provided either by physical or electronic delivery to the Participants or by written notice to the Participants of the availability of the information on an Internet site that may be password-protected and of any password needed to access the information. The Company may request that Participants agree to keep the information to be provided pursuant to this section confidential. If a Participant does not agree to keep the information to be provided pursuant to this section confidential, then the Company will not be required to provide the information unless otherwise required pursuant to Rule 12h-1(f)(1) under the Exchange Act or Rule 701 of the Securities Act.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-15-</font></div></div></div><div id="ic00ac40fee75444899d61de56ec182d5_194"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">HEARTFLOW HOLDING, INC.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">AMENDED AND RESTATED 2009 EQUITY INCENTIVE PLAN</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">STOCK OPTION AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Unless otherwise defined herein, the terms defined in the Amended and Restated 2009 Equity Incentive Plan (the&#160;&#8220;Plan&#8221;) shall have the same defined meanings in this Stock Option Agreement (the &#8220;Option Agreement&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">I.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;text-decoration:underline">NOTICE OF STOCK OPTION GRANT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">Name&#58;  &#171;Name&#187;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">The undersigned Participant has been granted an Option to purchase Common Stock of the Company, subject to the terms and conditions of the Plan and this Option Agreement, as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.307%"><tr><td style="width:1.0%"></td><td style="width:40.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Date of Grant&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#171;Grant_Date&#187;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Vesting Commencement Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#171;Vesting_Commencement_Date&#187;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Exercise Price per Share&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#171;Price_Per_Share&#187;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Total Number of Shares Granted&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#171;Number_of_Shares&#187;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Total Exercise Price &#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#171;Total_Purchase_Price&#187;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Type of Option&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#171;Type_of_Option&#187;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Term&#47;Expiration Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#171;Expiration_Date&#187;</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;text-decoration:underline">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">This Option shall be exercisable, in whole or in part, according to the following vesting schedule&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">&#171;Vesting_Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#187;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;text-decoration:underline">Termination Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">This Option shall be exercisable for three (3) months after Participant ceases to be a Service Provider, unless such termination is due to Participant&#8217;s death or Disability, in which case this Option shall be exercisable for twelve (12) months</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">after Participant ceases to be a Service Provider.  Notwithstanding the foregoing sentence, in no event may this Option be exercised after the Term&#47;Expiration Date as provided above and this Option may be subject to earlier termination as provided in Section 13(c) of the Plan.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">II.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;text-decoration:underline">AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;text-decoration:underline">Grant of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.  The Administrator of the Company hereby grants to the Participant named in the Notice of Stock Option Grant in Part I of this Agreement (&#8220;Participant&#8221;), an option (the &#8220;Option&#8221;) to purchase the number of Shares set forth in the Notice of Stock Option Grant, at the exercise price per Share set forth in the Notice of Stock Option Grant (the &#8220;Exercise Price&#8221;), and subject to the terms and conditions of the Plan, which is incorporated herein by reference.  Subject to Section&#160;18(c) of the Plan, in the event of a conflict between the terms and conditions of the Plan and this Option Agreement, the terms and conditions of the Plan shall prevail.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">If designated in the Notice of Stock Option Grant as an Incentive Stock Option (&#8220;ISO&#8221;), this Option is intended to qualify as an Incentive Stock Option as defined in Section&#160;422 of the Code.  Nevertheless, to the extent that it exceeds the $100,000 rule of Code Section&#160;422(d), this Option shall be treated as a Nonstatutory Stock Option (&#8220;NSO&#8221;).  Further, if for any reason this Option (or portion thereof) shall not qualify as an ISO, then, to the extent of such nonqualification, such Option (or portion thereof) shall be regarded as a NSO granted under the Plan.  In no event shall the Administrator, the Company or any Parent or Subsidiary or any of their respective employees or directors have any liability to Participant (or any other person) due to the failure of the Option to qualify for any reason as an ISO.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;text-decoration:underline">Exercise of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;text-decoration:underline">Right to Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.  This Option shall be exercisable during its term in accordance with the Vesting Schedule set out in the Notice of Stock Option Grant and with the applicable provisions of the Plan and this Option Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;text-decoration:underline">Method of Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.  This Option shall be exercisable by delivery of an exercise notice in the form attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit&#160;A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> (the &#8220;Exercise Notice&#8221;) or in a manner and pursuant to such procedures as the Administrator may determine, which shall state the election to exercise the Option, the number of Shares with respect to which the Option is being exercised, and such other representations and agreements as may be required by the Company.  The Exercise Notice shall be accompanied by payment of the aggregate Exercise Price as to all Exercised Shares, together with any applicable tax withholding.  This Option shall be deemed to be exercised upon receipt by the Company of such fully executed Exercise Notice accompanied by the aggregate Exercise Price, together with any applicable tax withholding.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">No Shares shall be issued pursuant to the exercise of an Option unless such issuance and such exercise comply with Applicable Laws.  Assuming such compliance, for income tax purposes the Shares shall be considered transferred to Participant on the date on which the Option is exercised with respect to such Shares.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;text-decoration:underline">Participant&#8217;s Representations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.  In the event the Shares have not been registered under the Securities Act of 1933, as amended, at the time this Option is exercised, Participant shall, if required by the Company, concurrently with the exercise of all or any portion of this Option, deliver to the Company his or her Investment Representation Statement in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit&#160;B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-2-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;text-decoration:underline">Lock-Up Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.  Participant hereby agrees that Participant shall not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any Common Stock (or other securities) of the Company or enter into any swap, hedging or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any Common Stock (or other securities) of the Company held by Participant (other than those included in the registration) for a period specified by the representative of the underwriters of Common Stock (or other securities) of the Company not to exceed one hundred and eighty (180) days following the effective date of any registration statement of the Company filed under the Securities Act (or such other period as may be requested by the Company or the underwriters to accommodate regulatory restrictions on (i)&#160;the publication or other distribution of research reports and (ii)&#160;analyst recommendations and opinions, including, but not limited to, the restrictions contained in NASD Rule&#160;2711(f)(4) or NYSE Rule&#160;472(f)(4), or any successor provisions or amendments thereto). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Participant agrees to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriter which are consistent with the foregoing or which are necessary to give further effect thereto.  In addition, if requested by the Company or the representative of the underwriters of Common Stock (or other securities) of the Company, Participant shall provide, within ten (10) days of such request, such information as may be required by the Company or such representative in connection with the completion of any public offering of the Company&#8217;s securities pursuant to a registration statement filed under the Securities Act.  The obligations described in this Section 4 shall not apply to a registration relating solely to employee benefit plans on Form S-1 or Form S-8 or similar forms that may be promulgated in the future, or a registration relating solely to a Commission Rule 145 transaction on Form S-4 or similar forms that may be promulgated in the future.  The Company may impose stop-transfer instructions with respect to the shares of Common Stock (or other securities) subject to the foregoing restriction until the end of said one hundred and eighty (180) day (or other) period.  Participant agrees that any transferee of the Option or shares acquired pursuant to the Option shall be bound by this Section 4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;text-decoration:underline">Method of Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.  Payment of the aggregate Exercise Price shall be by any of the following, or a combination thereof, at the election of the Participant&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;cash&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;check&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;consideration received by the Company under a formal cashless exercise program adopted by the Company in connection with the Plan&#59; or </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;surrender of other Shares which (i) shall be valued at its Fair Market Value on the date of exercise, and (ii) must be owned free and clear of any liens, claims, encumbrances or security interests, if accepting such Shares, in the sole discretion of the Administrator, shall not result in any adverse accounting consequences to the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;text-decoration:underline">Restrictions on Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.  This Option may not be exercised until such time as the Plan has been approved by the stockholders of the Company, or if the issuance of such Shares upon </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-3-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">such exercise or the method of payment of consideration for such shares would constitute a violation of any Applicable Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;text-decoration:underline">Non-Transferability of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;This Option may not be transferred in any manner otherwise than by will or by the laws of descent or distribution and may be exercised during the lifetime of Participant only by Participant.  The terms of the Plan and this Option Agreement shall be binding upon the executors, administrators, heirs, successors and assigns of Participant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Further, until the Company becomes subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act, or after the Administrator determines that it is, will, or may no longer be relying upon the exemption from registration of Options under the Exchange Act as set forth in Rule 12h-1(f) promulgated under the Exchange Act (the &#8220;Reliance End Date&#8221;), Participant shall not transfer this Option or, prior to exercise, the Shares subject to this Option, in any manner other than (i) to persons who are &#8220;family members&#8221; (as defined in Rule 701(c)(3) of the Securities Act of 1933, as amended) through gifts or domestic relations orders, or (ii) to an executor or guardian of Participant upon the death or disability of Participant.  Until the Reliance End Date, the Options and, prior to exercise, the Shares subject to this Option, may not be pledged, hypothecated or otherwise transferred or disposed of, including by entering into any short position, any &#8220;put equivalent position&#8221; or any &#8220;call equivalent position&#8221; (as defined in Rule 16a-1(h) and Rule 16a-1(b) of the Exchange Act, respectively), other than as permitted in clauses (i) and (ii) of this paragraph.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;text-decoration:underline">Term of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.  This Option may be exercised only within the term set out in the Notice of Stock Option Grant, and may be exercised during such term only in accordance with the Plan and the terms of this Option.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;text-decoration:underline">Tax Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.  Participant agrees to make appropriate arrangements with the Company (or the Parent or Subsidiary employing or retaining Participant) for the satisfaction of all Federal, state, local and foreign income and employment tax withholding requirements applicable to the Option exercise.  Participant acknowledges and agrees that the Company may refuse to honor the exercise and refuse to deliver the Shares if such withholding amounts are not delivered at the time of exercise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;text-decoration:underline">Notice of Disqualifying Disposition of ISO Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.  If the Option granted to Participant herein is an ISO, and if Participant sells or otherwise disposes of any of the Shares acquired pursuant to the ISO on or before the later of (i)&#160;the date two (2) years after the Date of Grant, or (ii)&#160;the date one (1) year after the date of exercise, Participant shall immediately notify the Company in writing of such disposition.  Participant agrees that Participant may be subject to income tax withholding by the Company on the compensation income recognized by Participant. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;text-decoration:underline">Code Section 409A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">  Under Code Section 409A, an Option that was granted with a per Share exercise price that is determined by the Internal Revenue Service (the &#8220;IRS&#8221;) to be less than the Fair Market Value of a Share on the date of grant (a &#8220;discount option&#8221;) may be considered &#8220;deferred compensation.&#8221;  An Option that is a &#8220;discount option&#8221; may result in (i) income recognition by Participant prior to the exercise of the Option, (ii) an additional twenty percent (20%) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-4-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">federal income tax, and (iii) potential penalty and interest charges.  The &#8220;discount option&#8221; may also result in additional state income, penalty and interest tax to the Participant.  Participant acknowledges that the Company cannot and has not guaranteed that the IRS will agree that the per Share exercise price of this Option equals or exceeds the Fair Market Value of a Share on the date of grant in a later examination.  Participant agrees that if the IRS determines that the Option was granted with a per Share exercise price that was less than the Fair Market Value of a Share on the date of grant, Participant shall be solely responsible for Participant&#8217;s costs related to such a determination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;text-decoration:underline">Entire Agreement&#59; Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.  The Plan is incorporated herein by reference.  The Plan and this Option Agreement constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof, and may not be modified adversely to the Participant&#8217;s interest except by means of a writing signed by the Company and Participant.  This Agreement is governed by the internal substantive laws but not the choice of law rules of California.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;text-decoration:underline">No Guarantee of Continued Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.  PARTICIPANT ACKNOWLEDGES AND AGREES THAT THE VESTING OF SHARES PURSUANT TO THE VESTING SCHEDULE HEREOF IS EARNED ONLY BY CONTINUING AS A SERVICE PROVIDER AT THE WILL OF THE COMPANY (OR THE PARENT OR SUBSIDIARY EMPLOYING OR RETAINING PARTICIPANT) AND NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS OPTION OR ACQUIRING SHARES HEREUNDER. PARTICIPANT FURTHER ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS A SERVICE PROVIDER FOR THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND SHALL NOT INTERFERE IN ANY WAY WITH PARTICIPANT&#8217;S RIGHT OR THE RIGHT OF THE COMPANY (OR THE PARENT OR SUBSIDIARY EMPLOYING OR RETAINING PARTICIPANT) TO TERMINATE PARTICIPANT&#8217;S RELATIONSHIP AS A SERVICE PROVIDER AT ANY TIME, WITH OR WITHOUT CAUSE.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Participant acknowledges receipt of a copy of the Plan and represents that he or she is familiar with the terms and provisions thereof, and hereby accepts this Option subject to all of the terms and provisions thereof.  Participant has reviewed the Plan and this Option in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Option and fully understands all provisions of the Option.  Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan or this Option.  Participant further agrees to notify the Company upon any change in the residence address indicated below.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:120%">&#91;Signature Page Follows&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-5-</font></div></div></div><div id="ic00ac40fee75444899d61de56ec182d5_197"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.856%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">PARTICIPANT</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">HEARTFLOW HOLDING, INC.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">By</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#171;Name&#187;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Print Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Print Name</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Title</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Residence Address</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Email Address</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic00ac40fee75444899d61de56ec182d5_200"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">AMENDED AND RESTATED 2009 EQUITY INCENTIVE PLAN</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">EXERCISE NOTICE</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">HeartFlow Holding, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">1700 Seaport Blvd</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Suite 400</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Redwood City, CA  94063</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Attention&#58; Corporate Secretary</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Exercise of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.  Effective as of today, ________________, ____, the undersigned (&#8220;Participant&#8221;) hereby elects to exercise Participant&#8217;s option (the &#8220;Option&#8221;) to purchase ________________&#160;shares of the Common Stock (the &#8220;Shares&#8221;) of HeartFlow Holding, Inc. (the &#8220;Company&#8221;) under and pursuant to the 2009 Equity Incentive Plan (the &#8220;Plan&#8221;) and the Stock Option Agreement dated &#171;Grant_Date&#187; (the &#8220;Option Agreement&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Delivery of Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.  Participant herewith delivers to the Company the full purchase price of the Shares, as set forth in the Option Agreement, and any and all withholding taxes due in connection with the exercise of the Option.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Representations of Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.  Participant acknowledges that Participant has received, read and understood the Plan and the Option Agreement and agrees to abide by and be bound by their terms and conditions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Rights as Stockholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.  Until the issuance of the Shares (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a stockholder shall exist with respect to the Common Stock subject to an Award, notwithstanding the exercise of the Option.  The Shares shall be issued to Participant as soon as practicable after the Option is exercised in accordance with the Option Agreement.  No adjustment shall be made for a dividend or other right for which the record date is prior to the date of issuance except as provided in Section&#160;13 of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Company&#8217;s Right of First Refusal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.  Before any Shares held by Participant or any transferee (either being sometimes referred to herein as the &#8220;Holder&#8221;) may be sold or otherwise transferred (including transfer by gift or operation of law), the Company or its assignee(s) shall have a right of first refusal to purchase the Shares on the terms and conditions set forth in this Section&#160;5 (the &#8220;Right of First Refusal&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Notice of Proposed Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.  The Holder of the Shares shall deliver to the Company a written notice (the &#8220;Notice&#8221;) stating&#58; (i)&#160;the Holder&#8217;s bona fide intention to sell or otherwise transfer such Shares&#59; (ii)&#160;the name of each proposed purchaser or other transferee (&#8220;Proposed Transferee&#8221;)&#59; (iii)&#160;the number of Shares to be transferred to each Proposed Transferee&#59; and (iv)&#160;the bona fide cash price or other consideration for which the Holder proposes to transfer the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Shares (the &#8220;Offered Price&#8221;), and the Holder shall offer the Shares at the Offered Price to the Company or its assignee(s).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Exercise of Right of First Refusal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.  At any time within thirty&#160;(30) days after receipt of the Notice, the Company and&#47;or its assignee(s) may, by giving written notice to the Holder, elect to purchase all, but not less than all, of the Shares proposed to be transferred to any one or more of the Proposed Transferees, at the purchase price determined in accordance with subsection&#160;(c) below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.  The purchase price (&#8220;Purchase Price&#8221;) for the Shares purchased by the Company or its assignee(s) under this Section&#160;5 shall be the Offered Price.  If the Offered Price includes consideration other than cash, the cash equivalent value of the non-cash consideration shall be determined by the Board of Directors of the Company in good faith.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.  Payment of the Purchase Price shall be made, at the option of the Company or its assignee(s), in cash (by check), by cancellation of all or a portion of any outstanding indebtedness of the Holder to the Company (or, in the case of repurchase by an assignee, to the assignee), or by any combination thereof within thirty&#160;(30) days after receipt of the Notice or in the manner and at the times set forth in the Notice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Holder&#8217;s Right to Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.  If all of the Shares proposed in the Notice to be transferred to a given Proposed Transferee are not purchased by the Company and&#47;or its assignee(s) as provided in this Section&#160;5, then the Holder may sell or otherwise transfer such Shares to that Proposed Transferee at the Offered Price or at a higher price, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> that such sale or other transfer is consummated within one hundred and twenty (120) days after the date of the Notice, that any such sale or other transfer is effected in accordance with any applicable securities laws and that the Proposed Transferee agrees in writing that the provisions of this Section&#160;5 shall continue to apply to the Shares in the hands of such Proposed Transferee.  If the Shares described in the Notice are not transferred to the Proposed Transferee within such period, a new Notice shall be given to the Company, and the Company and&#47;or its assignees shall again be offered the Right of First Refusal before any Shares held by the Holder may be sold or otherwise transferred.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Exception for Certain Family Transfers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.  Anything to the contrary contained in this Section&#160;5 notwithstanding, the transfer of any or all of the Shares during the Participant&#8217;s lifetime or on the Participant&#8217;s death by will or intestacy to the Participant&#8217;s immediate family or a trust for the benefit of the Participant&#8217;s immediate family shall be exempt from the provisions of this Section&#160;5.  &#8220;Immediate Family&#8221; as used herein shall mean spouse, lineal descendant or antecedent, father, mother, brother or sister.  In such case, the transferee or other recipient shall receive and hold the Shares so transferred subject to the provisions of this Section&#160;5, and there shall be no further transfer of such Shares except in accordance with the terms of this Section&#160;5.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Termination of Right of First Refusal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.  The Right of First Refusal shall terminate as to any Shares upon the earlier of (i) the first sale of Common Stock of the Company to the general public, or (ii) a Change in Control in which the successor corporation has equity securities that are publicly traded. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Tax Consultation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.  Participant understands that Participant may suffer adverse tax consequences as a result of Participant&#8217;s purchase or disposition of the Shares.  Participant represents </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-2-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">that Participant has consulted with any tax consultants Participant deems advisable in connection with the purchase or disposition of the Shares and that Participant is not relying on the Company for any tax advice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Restrictive Legends and Stop-Transfer Orders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Legends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.  Participant understands and agrees that the Company shall cause the legends set forth below or legends substantially equivalent thereto, to be placed upon any certificate(s) evidencing ownership of the Shares together with any other legends that may be required by the Company or by state or federal securities laws&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE &#8220;ACT&#8221;) AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR, IN THE OPINION OF COUNSEL SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS IN COMPLIANCE THEREWITH.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER AND A RIGHT OF FIRST REFUSAL HELD BY THE ISSUER OR ITS ASSIGNEE(S) AS SET FORTH IN THE EXERCISE NOTICE BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER. SUCH TRANSFER RESTRICTIONS AND RIGHT OF FIRST REFUSAL ARE BINDING ON TRANSFEREES OF THESE SHARES.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFER FOR A PERIOD OF TIME FOLLOWING THE EFFECTIVE DATE OF THE UNDERWRITTEN PUBLIC OFFERING OF THE COMPANY&#8217;S SECURITIES SET FORTH IN AN AGREEMENT BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES AND MAY NOT BE SOLD OR OTHERWISE DISPOSED OF BY THE HOLDER PRIOR TO THE EXPIRATION OF SUCH PERIOD WITHOUT THE CONSENT OF THE COMPANY OR THE MANAGING UNDERWRITER.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Stop-Transfer Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.  Participant agrees that, in order to ensure compliance with the restrictions referred to herein, the Company may issue appropriate &#8220;stop transfer&#8221; instructions to its transfer agent, if any, and that, if the Company transfers its own securities, it may make appropriate notations to&#160;the same effect in its own records.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Refusal to Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.  The Company shall not be required (i)&#160;to transfer on its books any Shares that have been sold or otherwise transferred in violation of any of the provisions of this Exercise Notice or (ii)&#160;to treat as owner of such Shares or to accord the right to vote or pay dividends to any purchaser or other transferee to whom such Shares shall have been so transferred.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-3-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.  The Company may assign any of its rights under this Exercise Notice to single or multiple assignees, and this Exercise Notice shall inure to the benefit of the successors and assigns of the Company.  Subject to the restrictions on transfer herein set forth, this Exercise Notice shall be binding upon Participant and his or her heirs, executors, administrators, successors and assigns.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.  Any dispute regarding the interpretation of this Exercise Notice shall be submitted by Participant or by the Company forthwith to the Administrator, which shall review such dispute at its next regular meeting.  The resolution of such a dispute by the Administrator shall be final and binding on all parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Governing Law&#59; Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.  This Exercise Notice is governed by the internal substantive laws, but not the choice of law rules, of California.  In the event that any provision hereof becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Exercise Notice shall continue in full force and effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.  The Plan and Option Agreement are incorporated herein by reference.  This Exercise Notice, the Plan, the Option Agreement and the Investment Representation Statement constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof, and may not be modified adversely to the Participant&#8217;s interest except by means of a writing signed by the Company and Participant.</font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Submitted by&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Accepted by&#58;</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">PARTICIPANT</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">HEARTFLOW HOLDING, INC.</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#171;Name&#187;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Print Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Print Name</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Title</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Address&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Address&#58;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Email Address</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Date Received</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-4-</font></div></div></div><div id="ic00ac40fee75444899d61de56ec182d5_203"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT B</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">INVESTMENT REPRESENTATION STATEMENT</font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.185%"><tr><td style="width:1.0%"></td><td style="width:34.493%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.475%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">PARTICIPANT </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#171;NAME&#187;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">COMPANY</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">HEARTFLOW HOLDING, INC.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">SECURITY</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">COMMON STOCK</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">AMOUNT</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">DATE</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">In connection with the purchase of the above-listed Securities, the undersigned Participant represents to the Company the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Participant is aware of the Company&#8217;s business affairs and financial condition and has acquired sufficient information about the Company to reach an informed and knowledgeable decision to acquire the Securities.  Participant is acquiring these Securities for investment for Participant&#8217;s own account only and not with a view to, or for resale in connection with, any &#8220;distribution&#8221; thereof within the meaning of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Participant acknowledges and understands that the Securities constitute &#8220;restricted securities&#8221; under the Securities Act and have not been registered under the Securities Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of Participant&#8217;s investment intent as expressed herein.  In this connection, Participant understands that, in the view of the Securities and Exchange Commission, the statutory basis for such exemption may be unavailable if Participant&#8217;s representation was predicated solely upon a present intention to hold these Securities for the minimum capital gains period specified under tax statutes, for a deferred sale, for or until an increase or decrease in the market price of the Securities, or for a period of one (1) year or any other fixed period in the future.  Participant further understands that the Securities must be held indefinitely unless they are subsequently registered under the Securities Act or an exemption from such registration is available.  Participant further acknowledges and understands that the Company is under no obligation to register the Securities. Participant understands that the certificate evidencing the Securities shall be imprinted with any legend required under applicable state securities laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Participant is familiar with the provisions of Rule&#160;701 and Rule&#160;144, each promulgated under the Securities Act, which, in substance, permit limited public resale of &#8220;restricted securities&#8221; acquired, directly or indirectly from the issuer thereof, in a non-public offering subject to the satisfaction of certain conditions.  Rule&#160;701 provides that if the issuer qualifies under Rule&#160;701 at the time of the grant of the Option to Participant, the exercise shall be exempt from registration under the Securities Act.  In the event the Company becomes subject to the reporting requirements of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, ninety&#160;(90) days thereafter (or such longer period as any market stand-off agreement may require) the Securities exempt under Rule&#160;701 may be resold, subject to the satisfaction of the applicable conditions specified by Rule&#160;144, including in the case of affiliates (1)&#160;the availability of certain public information about the Company, (2)&#160;the amount of Securities being sold during any three (3) month period not exceeding specified limitations, (3)&#160;the resale being made in an unsolicited &#8220;broker&#8217;s transaction&#8221;, transactions directly with a &#8220;market maker&#8221; or &#8220;riskless principal transactions&#8221; (as those terms are defined under the Securities Exchange Act of 1934) and (4)&#160;the timely filing of a Form&#160;144, if applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">In the event that the Company does not qualify under Rule&#160;701 at the time of grant of the Option, then the Securities may be resold in certain limited circumstances subject to the provisions of Rule&#160;144, which may require (i)&#160;the availability of current public information about the Company&#59; (ii)&#160;the resale to occur more than a specified period after the purchase and full payment (within the meaning of Rule&#160;144) for the Securities&#59; and (iii)&#160;in the case of the sale of Securities by an affiliate, the satisfaction of the conditions set forth in sections&#160;(2), (3) and (4) of the paragraph immediately above.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Participant further understands that in the event all of the applicable requirements of Rule&#160;701 or 144 are not satisfied, registration under the Securities Act, compliance with Regulation A, or some other registration exemption shall be required&#59; and that, notwithstanding the fact that Rules&#160;144 and 701 are not exclusive, the Staff of the Securities and Exchange Commission has expressed its opinion that persons proposing to sell private placement securities other than in a registered offering and otherwise than pursuant to Rules&#160;144 or 701 shall have a substantial burden of proof in establishing that an exemption from registration is available for such offers or sales, and that such persons and their respective brokers who participate in such transactions do so at their own risk.  Participant understands that no assurances can be given that any such other registration exemption shall be available in such event.</font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.258%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">PARTICIPANT</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Signature</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#171;Name&#187;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Print Name</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Date</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-2-</font></div></div></div><div id="ic00ac40fee75444899d61de56ec182d5_330"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">HEARTFLOW HOLDING, INC.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AMENDED AND RESTATED 2009 EQUITY INCENTIVE PLAN</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RESTRICTED STOCK PURCHASE AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Unless otherwise defined herein, the terms defined in the Amended and Restated 2009 Equity Incentive Plan (the &#8220;Plan&#8221;) shall have the same defined meanings in this Restricted Stock Purchase Agreement (the &#8220;Agreement&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">NOTICE OF GRANT OF RESTRICTED STOCK</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#171;Participant&#187;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The undersigned Participant has been granted a right to purchase Common Stock of the Company, subject to the terms and conditions of the Plan and this Agreement, as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Date of Grant&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#171;Date_of_Grant&#187;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Vesting Commencement Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#171;Vesting_Commencement_Date&#187;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Purchase Price per Share&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#171;Price_Per_Share&#187;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Repurchase Price per Share&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#171;Repurchase_Price&#187;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Total Number of Shares Granted&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#171;Shares&#187;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Total Purchase Price&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#171;Total_Purchase_Price&#187;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Expiration Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#171;Expiration_Date&#187;</font></td></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subject to any accelerated vesting provisions in the Plan, &#171;Vesting_Schedule&#187;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any of the Shares which have not yet been released from the Company&#8217;s Repurchase Option are referred to herein as &#8220;Unreleased Shares.&#8221;  The Shares which have been released from the Company&#8217;s Repurchase Option shall be delivered to Participant at Participant&#8217;s request (see </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;11 of Part&#160;II of this Agreement).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">YOU MUST EXERCISE THIS RESTRICTED STOCK AWARD BEFORE THE EXPIRATION DATE OR IT WILL TERMINATE AND YOU WILL HAVE NO FURTHER RIGHT TO PURCHASE THE SHARES.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">II.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sale of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Administrator of the Company hereby agrees to sell to the Participant named in the Notice of Grant of Restricted Stock in Part&#160;I of this Agreement (&#8220;Participant&#8221;), and Participant hereby agrees to purchase the number of Shares set forth in the Notice of Grant of Restricted Stock, at the Purchase Price per Share set forth in the Notice of Grant of Restricted Stock (the &#8220;Purchase Price&#8221;), and subject to the terms and conditions of the Plan, which is incorporated herein by reference.  Subject to Section 18(c) of the Plan, in the event of a conflict between the terms and conditions of the Plan and this Agreement, the terms and conditions of the Plan shall prevail.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Payment of Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Participant herewith delivers to the Company the aggregate Purchase Price for the Shares by cash or check, together with any and all withholding taxes due in connection with the purchase of the Shares.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Participant&#8217;s Representations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event the Shares have not been registered under the Securities Act of 1933, as amended, at the time this Restricted Stock Award is exercised, Participant shall, if required by the Company, concurrently with the exercise of all or any portion of this Restricted Stock Award, deliver to the Company his or her Investment Representation Statement in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Lock-Up Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Participant hereby agrees that Participant shall not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any Common Stock (or other securities) of the Company or enter into any swap, hedging or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any Common Stock (or other securities) of the Company held by Participant (other than those included in the registration) for a period specified by the representative of the underwriters of Common Stock (or other securities) of the Company not to exceed one hundred and eighty (180) days following the effective date of any registration statement of the Company filed under the Securities Act (or such other period as may be requested by the Company or the underwriters to accommodate regulatory restrictions on (i)&#160;the publication or other distribution of research reports and (ii)&#160;analyst recommendations and opinions, including, but not limited to, the restrictions contained in NASD Rule&#160;2711(f)(4) or NYSE Rule&#160;472(f)(4), or any successor provisions or amendments thereto).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Participant agrees to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriter which are consistent with the foregoing or which are necessary to give further effect thereto. In addition, if requested by the Company or the representative of the underwriters of Common Stock (or other securities) of the Company, Participant shall provide, within ten (10) days of such request, such information as may be required by the Company or such representative in connection with the completion of any public offering of the Company&#8217;s securities pursuant to a registration statement filed under the Securities Act. The obligations described in this Section&#160;4 shall not apply to a registration relating solely to employee benefit plans on Form S-1 or Form S-8 or similar forms that may be promulgated in the future, or a registration relating solely to a Commission Rule 145 transaction </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-2-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">on Form S-4 or similar forms that may be promulgated in the future. The Company may impose stop-transfer instructions with respect to the shares of Common Stock (or other securities) subject to the foregoing restriction until the end of said one hundred and eighty (180) day (or other) period. Participant agrees that any transferee of the Restricted Stock Award or shares acquired pursuant to the Restricted Stock Award shall be bound by this Section&#160;4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Transferability of Restricted Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Restricted Stock Award may not be transferred in any manner otherwise than by will or by the laws of descent or distribution and may be exercised during the lifetime of Participant only by Participant.  The terms of the Plan and this Agreement shall be binding upon the executors, administrators, heirs, successors and assigns of Participant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Tax Consequences</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Participant has reviewed with Participant&#8217;s own tax advisors the federal, state, local and foreign tax consequences of this investment and the transactions contemplated by this Agreement.  Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents.  Participant understands that Participant (and not the Company) shall be responsible for Participant&#8217;s own tax liability that may arise as a result of the transactions contemplated by this Agreement.  Participant understands that Section&#160;83 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), taxes as ordinary income the difference between the purchase price for the Shares and the Fair Market Value of the Shares as of the date any restrictions on the Shares lapse.  In this context, &#8220;restriction&#8221; includes the right of the Company to buy back the Shares pursuant to the Repurchase Option.  Participant understands that Participant may elect to be taxed at the time the Shares are purchased rather than when and as the Repurchase Option expires by filing an election under Section&#160;83(b) of the Code with the IRS within thirty (30) days from the date of purchase.  The form for making this election is attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;B-3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">THE PARTICIPANT ACKNOWLEDGES THAT IT IS THE PARTICIPANT&#8217;S SOLE RESPONSIBILITY AND NOT THE COMPANY&#8217;S TO FILE TIMELY THE ELECTION UNDER SECTION&#160;83(b), EVEN IF THE PARTICIPANT REQUESTS THE COMPANY OR ITS REPRESENTATIVES TO MAKE THIS FILING ON THE PARTICIPANT&#8217;S BEHALF.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Pursuant to such procedures as the Administrator may specify from time to time, the Company shall withhold the minimum amount required to be withheld for the payment of income, employment and other taxes which the Company determines must be withheld (the &#8220;Withholding Taxes&#8221;) with respect to Shares released from the Company&#8217;s Repurchase Option by, in the Administrator&#8217;s discretion&#58; (i) withholding otherwise deliverable Shares upon release from the Company&#8217;s Repurchase Option having a Fair Market Value equal the amount of such Withholding Taxes, (ii) withholding the amount of such Withholding Taxes from Participant&#8217;s paycheck(s), (iii) requiring Participant to make appropriate arrangements with the Company (or the Parent or Subsidiary employing or retaining Participant) for the satisfaction of all Withholding Taxes, or (iv) a combination of the foregoing.  The Company shall not retain fractional Shares to satisfy any portion of the Withholding Taxes.  Accordingly, if any withholding is done through the withholding of Shares, Participant shall pay to the Company an amount in cash sufficient to satisfy the remaining Withholding Taxes due and payable as a result </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-3-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of the Company not retaining fractional Shares.  Should the Company be unable to procure such cash amounts from Participant, Participant agrees and acknowledges that Participant is giving the Company permission to withhold from Participant&#8217;s paycheck(s) an amount equal to the remaining Withholding Taxes due and payable as a result of the Company not retaining fractional Shares.  Participant acknowledges and agrees that the Company may refuse to honor the exercise and refuse to deliver the Shares if such withholding amounts are not delivered at the time of purchase.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">No Guarantee of Continued Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. PARTICIPANT ACKNOWLEDGES AND AGREES THAT THE RELEASE OF SHARES FROM THE REPURCHASE OPTION OF THE COMPANY PURSUANT TO THE VESTING SCHEDULE HEREOF IS EARNED ONLY BY CONTINUING AS A SERVICE PROVIDER AT THE WILL OF THE COMPANY (OR THE PARENT OR SUBSIDIARY EMPLOYING OR RETAINING PARTICIPANT) AND NOT THROUGH THE ACT OF BEING HIRED OR PURCHASING SHARES HEREUNDER.  PARTICIPANT FURTHER ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS A SERVICE PROVIDER FOR THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND SHALL NOT INTERFERE IN ANY WAY WITH PARTICIPANT&#8217;S RIGHT OR THE RIGHT OF THE COMPANY (OR THE PARENT OR SUBSIDIARY EMPLOYING OR RETAINING PARTICIPANT) TO TERMINATE PARTICIPANT&#8217;S RELATIONSHIP AS A SERVICE PROVIDER AT ANY TIME, WITH OR WITHOUT CAUSE.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Repurchase Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;In the event Participant&#8217;s continuous status as a Service Provider terminates for any or no reason (including death or Disability), the Company shall, upon the date of such termination (as reasonably fixed and determined by the Company), have an irrevocable, exclusive option for a period of ninety (90) days from such date to repurchase up to that number of Shares which constitute the Unreleased Shares (as defined in Part&#160;I of this Agreement) at the Repurchase Price per Share set forth in the Notice of Grant of Restricted Stock (the &#8220;Repurchse Price&#8221;) (the &#8220;Repurchase Option&#8221;).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Repurchase Option shall be exercised by the Company by delivering written notice to Participant or Participant&#8217;s executor (with a copy to the Escrow Holder (as defined in Section&#160;11)) AND, at the Company&#8217;s option, (i) by delivering to Participant or Participant&#8217;s executor a check in the amount of the aggregate Repurchase Price, or (ii) by the Company canceling an amount of Participant&#8217;s indebtedness to the Company equal to the aggregate Repurchase Price, or (iii) by a combination of (i) and (ii) so that the combined payment and cancellation of indebtedness equals such aggregate Repurchase Price.  Upon delivery of such notice and the payment of the aggregate Repurchase Price in any of the ways described above, the Company shall become the legal and beneficial owner of the Unreleased Shares being repurchased and all rights and interests therein or relating thereto, and the Company </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-4-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall have the right to retain and transfer to its own name the number of Unreleased Shares being repurchased by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Whenever the Company shall have the right to repurchase the Unreleased Shares hereunder, the Company may designate and assign one or more employees, officers, directors or shareholders of the Company or other persons or organizations to exercise all or a part of the Company&#8217;s Repurchase Option to purchase all or a part of the Unreleased Shares.  If the Fair Market Value of the Unreleased Shares to be repurchased on the date of such designation or assignment (the &#8220;Repurchase FMV&#8221;) exceeds the aggregate Repurchase Price of the Unreleased Shares, then each such designee or assignee shall pay the Company cash equal to the difference between the Repurchase FMV and the aggregate Repurchase Price of Unreleased Shares to be purchased.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;If the Company or its assignee does not elect to exercise the Repurchase Option conferred above by giving the requisite notice within ninety (90) days following Participant&#8217;s termination as a Service Provider, the Repurchase Option shall terminate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Restriction on Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except for the escrow described in Section&#160;11 or transfer of the Shares to the Company or its assignees contemplated by this Agreement, none of the Shares or any beneficial interest therein shall be transferred, encumbered or otherwise disposed of in any way until the release of such Shares from the Company&#8217;s Repurchase Option in accordance with the provisions of this Agreement, other than by will or the laws of descent and distribution.  Any distribution or delivery to be made to Participant under this Agreement shall, if Participant is then deceased, be made to Participant&#8217;s designated beneficiary, or if no beneficiary survives Participant, to the administrator or executor of Participant&#8217;s estate.  Any such transferee must furnish the Company with (a)&#160;written notice of his or her status as transferee, and (b)&#160;evidence satisfactory to the Company to establish the validity of the transfer and compliance with any laws or regulations pertaining to said transfer.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Escrow of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;To ensure the availability for delivery of Participant&#8217;s Unreleased Shares upon exercise of the Repurchase Option by the Company, Participant will, upon execution of this Agreement, deliver and deposit with an escrow holder designated by the Company (the &#8220;Escrow Holder&#8221;) the share certificates representing the Unreleased Shares, together with the Assignment Separate from Certificate (the &#8220;Stock Assignment&#8221;) duly endorsed in blank, attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit B-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Unreleased Shares and Stock Assignment shall be held by the Escrow Holder, pursuant to the Joint Escrow Instructions of the Company and Participant attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit B-2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto, until such time as the Company&#8217;s Repurchase Option expires.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Escrow Holder shall not be liable for any act it may do or omit to do with respect to holding the Unreleased Shares in escrow and while acting in good faith and in the exercise of its judgment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;If the Company or any assignee exercises its Repurchase Option hereunder, the Escrow Holder, upon receipt of written notice of such option exercise from the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-5-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">proposed transferee, shall take all steps necessary to accomplish such transfer.  Participant hereby appoints the Escrow Holder with full power of substitution, as Participant&#8217;s true and lawful attorney-in-fact with irrevocable power and authority in the name and on behalf of Participant to take any action and execute all documents and instruments, including, without limitation, stock powers which may be necessary to transfer the certificate or certificates evidencing such Unreleased Shares to the Company upon such termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;When the Repurchase Option has been exercised or expires unexercised or a portion of the Shares has been released from such Repurchase Option, upon Participant&#8217;s request the Escrow Holder shall promptly cause a new certificate to be issued for such released Shares and shall deliver such certificate to the Company or Participant, as the case may be.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Subject to the terms hereof, Participant shall have all the rights of a shareholder with respect to such Shares while they are held in escrow, including without limitation, the right to vote the Shares and receive any cash dividends declared thereon.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;In the event of any merger, reorganization, consolidation, recapitalization, separation, liquidation, stock dividend, split-up, share combination, or other change in the corporate structure of the Company affecting the Common Stock, the Shares shall be increased, reduced or otherwise changed, and by virtue of any such change Participant shall in his or her capacity as owner of Unreleased Shares that have been awarded to him or her be entitled to new or additional or different shares of stock, cash or securities (other than rights or warrants to purchase securities)&#59; such new or additional or different shares, cash or securities shall thereupon be considered to be &#8220;Unreleased Shares&#8221; and shall be subject to all of the conditions and restrictions which were applicable to the Unreleased Shares pursuant to this Agreement.  If Participant receives rights or warrants with respect to any Unreleased Shares, such rights or warrants may be held or exercised by Participant, provided that until such exercise any such rights or warrants and after such exercise any shares or other securities acquired by the exercise of such rights or warrants shall be considered to be Unreleased Shares and shall be subject to all of the conditions and restrictions which were applicable to the Unreleased Shares pursuant to this Agreement.  The Administrator in its absolute discretion at any time may accelerate the vesting of all or any portion of such new or additional shares of stock, cash or securities, rights or warrants to purchase securities or shares or other securities acquired by the exercise of such rights or warrants.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company&#8217;s Right of First Refusal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to Section&#160;10, before any Shares held by Participant or any transferee (either being sometimes referred to herein as the &#8220;Holder&#8221;) may be sold or otherwise transferred (including transfer by gift or operation of law), the Company or its assignee(s) shall have a right of first refusal to purchase the Shares on the terms and conditions set forth in this Section&#160;12 (the &#8220;Right of First Refusal&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notice of Proposed Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Holder of the Shares shall deliver to the Company a written notice (the &#8220;Notice&#8221;) stating&#58; (i) the Holder&#8217;s bona fide intention to sell or otherwise transfer such Shares&#59; (ii) the name of each proposed purchaser or other transferee (&#8220;Proposed Transferee&#8221;)&#59; (iii) the number of Shares to be transferred to each Proposed Transferee&#59; and (iv) the bona fide cash price or other consideration for which the Holder </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-6-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">proposes to transfer the Shares (the &#8220;Offered Price&#8221;), and the Holder shall offer the Shares at the Offered Price to the Company or its assignee(s).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exercise of Right of First Refusal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  At any time within thirty (30) days after receipt of the Notice, the Company and&#47;or its assignee(s) may, by giving written notice to the Holder, elect to purchase all, but not less than all, of the Shares proposed to be transferred to any one or more of the Proposed Transferees, at the purchase price determined in accordance with subsection&#160;(c) below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The purchase price (&#8220;Right of First Refusal Price&#8221;) for the Shares purchased by the Company or its assignee(s) under this Section&#160;12 shall be the Offered Price.  If the Offered Price includes consideration other than cash, the cash equivalent value of the non-cash consideration shall be determined by the Board in good faith.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Payment of the Right of First Refusal Price shall be made, at the option of the Company or its assignee(s), in cash (by check), by cancellation of all or a portion of any outstanding indebtedness of the Holder to the Company (or, in the case of repurchase by an assignee, to the assignee), or by any combination thereof within thirty (30) days after receipt of the Notice or in the manner and at the times set forth in the Notice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Holder&#8217;s Right to Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If all of the Shares proposed in the Notice to be transferred to a given Proposed Transferee are not purchased by the Company and&#47;or its assignee(s) as provided in this Section&#160;12, then the Holder may sell or otherwise transfer such Shares to that Proposed Transferee at the Offered Price or at a higher price, provided that such sale or other transfer is consummated within one hundred and twenty (120) days after the date of the Notice, that any such sale or other transfer is effected in accordance with any applicable securities laws and that the Proposed Transferee agrees in writing that the provisions of this Section&#160;12 shall continue to apply to the Shares in the hands of such Proposed Transferee.  If the Shares described in the Notice are not transferred to the Proposed Transferee within such period, a new Notice shall be given to the Company, and the Company and&#47;or its assignees shall again be offered the Right of First Refusal before any Shares held by the Holder may be sold or otherwise transferred.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exception for Certain Family Transfers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Anything to the contrary contained in this Section&#160;12 notwithstanding, the transfer of any or all of the Shares during Participant&#8217;s lifetime or on Participant&#8217;s death by will or intestacy to Participant&#8217;s immediate family or a trust for the benefit of Participant&#8217;s immediate family shall be exempt from the provisions of this Section&#160;12.  &#8220;Immediate Family&#8221; as used herein shall mean spouse, lineal descendant or antecedent, father, mother, brother or sister.  In such case, the transferee or other recipient shall receive and hold the Shares so transferred subject to the provisions of this Agreement, including but not limited to this Section&#160;12 and Section&#160;9, and there shall be no further transfer of such Shares except in accordance with the terms of this Section&#160;12.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination of Right of First Refusal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Right of First Refusal shall terminate as to any Shares upon the earlier of (i) the first sale of Common Stock of the Company </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-7-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to the general public, or (ii) a Change in Control in which the successor corporation has equity securities that are publicly traded.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Restrictive Legends and Stop-Transfer Orders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Legends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Participant understands and agrees that the Company shall cause the legends set forth below or legends substantially equivalent thereto, to be placed upon any certificate(s) evidencing ownership of the Shares together with any other legends that may be required by the Company or by state or federal securities laws&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE &#8220;ACT&#8221;) AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR, IN THE OPINION OF COUNSEL SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS IN COMPLIANCE THEREWITH.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER, A RIGHT OF FIRST REFUSAL, AND A REPURCHASE OPTION HELD BY THE ISSUER OR ITS ASSIGNEE(S) AS SET FORTH IN THE RESTRICTED STOCK PURCHASE AGREEMENT BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER.  SUCH TRANSFER RESTRICTIONS, RIGHT OF FIRST REFUSAL AND REPURCHASE OPTION ARE BINDING ON TRANSFEREES OF THESE SHARES.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFER FOR A PERIOD OF TIME FOLLOWING THE EFFECTIVE DATE OF THE UNDERWRITTEN PUBLIC OFFERING OF THE COMPANY&#8217;S SECURITIES SET FORTH IN AN AGREEMENT BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES AND MAY NOT BE SOLD OR OTHERWISE DISPOSED OF BY THE HOLDER PRIOR TO THE EXPIRATION OF SUCH PERIOD WITHOUT THE CONSENT OF THE COMPANY OR THE MANAGING UNDERWRITER.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Stop-Transfer Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Participant agrees that, in order to ensure compliance with the restrictions referred to herein, the Company may issue appropriate &#8220;stop transfer&#8221; instructions to its transfer agent, if any, and that, if the Company  transfers its own securities, it may make appropriate notations to&#160;the same effect in its own records.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Refusal to Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company shall not be required (i)&#160;to transfer on its books any Shares that have been sold or otherwise transferred in violation of any of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-8-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">provisions of this Agreement or (ii)&#160;to treat as owner of such Shares or to accord the right to vote or pay dividends to any purchaser or other transferee to whom such Shares shall have been so transferred.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any notice, demand or request required or permitted to be given by either the Company or Participant pursuant to the terms of this Agreement shall be in writing and shall be deemed given when delivered personally or deposited in the U.S. mail, First Class with postage prepaid, and addressed to the parties at the addresses of the parties set forth at the end of this Agreement or such other address as a party may request by notifying the other in writing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any notice to the Escrow Holder shall be sent to the Company&#8217;s address with a copy to the other party not sending the notice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">No Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Either party&#8217;s failure to enforce any provision or provisions of this Agreement shall not in any way be construed as a waiver of any such provision or provisions, nor prevent that party from thereafter enforcing each and every other provision of this Agreement.  The rights granted both parties herein are cumulative and shall not constitute a waiver of either party&#8217;s right to assert all other legal remedies available to it under the circumstances.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement shall inure to the benefit of the successors and assigns of the Company.  Subject to the restrictions on transfer herein set forth, this Agreement shall be binding upon Participant and his or her heirs, executors, administrators, successors and assigns.  The rights and obligations of Participant under this Agreement may only be assigned with the prior written consent of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any dispute regarding the interpretation of this Agreement shall be submitted by Participant or by the Company forthwith to the Administrator, which shall review such dispute at its next regular meeting.  The resolution of such a dispute by the Administrator shall be final and binding on all parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Additional Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Participant agrees upon request to execute any further documents or instruments necessary or desirable to carry out the purposes or intent of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Governing Law&#59; Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement is governed by the internal substantive laws, but not the choice of law rules, of California.  In the event that any provision hereof becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue in full force and effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Plan is incorporated herein by reference. The Plan and this Agreement (including the exhibits referenced herein) constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-9-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">hereof, and may not be modified adversely to the Participant&#8217;s interest except by means of a writing signed by the Company and Participant. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-10-</font></div></div></div><div id="ic00ac40fee75444899d61de56ec182d5_451"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Participant acknowledges receipt of a copy of the Plan and represents that he or she is familiar with the terms and provisions thereof, and hereby accepts this Agreement subject to all of the terms and provisions thereof.  Participant has reviewed the Plan and this Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Agreement and fully understands all provisions of this Agreement.  Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan or this Agreement.  Participant further agrees to notify the Company upon any change in the residence address indicated below.</font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PARTICIPANT</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">HEARTFLOW HOLDING, INC.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#171;Participant&#187;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Print Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Print Name</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residence Address</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Email Address</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-11-</font></div></div></div><div id="ic00ac40fee75444899d61de56ec182d5_437"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INVESTMENT REPRESENTATION STATEMENT</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">PARTICIPANT&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#58;&#160;&#160;&#160;&#160;&#171;PARTICIPANT&#187;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">COMPANY&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#58;&#160;&#160;&#160;&#160;HEARTFLOW HOLDING, INC.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECURITY&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#58;&#160;&#160;&#160;&#160;COMMON STOCK</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">AMOUNT&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#58;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">DATE&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#58;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In connection with the purchase of the above-listed Securities, the undersigned Participant represents to the Company the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Participant is aware of the Company&#8217;s business affairs and financial condition and has acquired sufficient information about the Company to reach an informed and knowledgeable decision to acquire the Securities. Participant is acquiring these Securities for investment for Participant&#8217;s own account only and not with a view to, or for resale in connection with, any &#8220;distribution&#8221; thereof within the meaning of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Participant acknowledges and understands that the Securities constitute &#8220;restricted securities&#8221; under the Securities Act and have not been registered under the Securities Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of Participant&#8217;s investment intent as expressed herein. In this connection, Participant understands that, in the view of the Securities and Exchange Commission, the statutory basis for such exemption may be unavailable if Participant&#8217;s representation was predicated solely upon a present intention to hold these Securities for the minimum capital gains period specified under tax statutes, for a deferred sale, for or until an increase or decrease in the market price of the Securities, or for a period of one year or any other fixed period in the future. Participant further understands that the Securities must be held indefinitely unless they are subsequently registered under the Securities Act or an exemption from such registration is available. Participant further acknowledges and understands that the Company is under no obligation to register the Securities. Participant understands that the certificate evidencing the Securities shall be imprinted with any legend required under applicable state securities laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Participant is familiar with the provisions of Rule&#160;701 and Rule&#160;144, each promulgated under the Securities Act, which, in substance, permit limited public resale of &#8220;restricted securities&#8221; acquired, directly or indirectly from the issuer thereof, in a non-public offering subject to the satisfaction of certain conditions.  Rule&#160;701 provides that if the issuer qualifies under Rule&#160;701 at the time of the grant of the Restricted Stock Award to Participant, the exercise shall be exempt from registration under the Securities Act.  In the event the Company </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-12-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">becomes subject to the reporting requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, ninety&#160;(90) days thereafter (or such longer period as any market stand-off agreement may require) the Securities exempt under Rule&#160;701 may be resold, subject to the satisfaction of the applicable conditions specified by Rule&#160;144, including in the case of affiliates (1)&#160;the availability of certain public information about the Company, (2)&#160;the amount of Securities being sold during any three (3) month period not exceeding specified limitations, (3)&#160;the resale being made in an unsolicited &#8220;broker&#8217;s transaction&#8221;, transactions directly with a &#8220;market maker&#8221; or &#8220;riskless principal transactions&#8221; (as those terms are defined under the Securities Exchange Act of 1934) and (4)&#160;the timely filing of a Form&#160;144, if applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event that the Company does not qualify under Rule&#160;701 at the time of grant of the Restricted Stock Award, then the Securities may be resold in certain limited circumstances subject to the provisions of Rule&#160;144, which may require (i)&#160;the availability of current public information about the Company&#59; (ii)&#160;the resale to occur more than a specified period after the purchase and full payment (within the meaning of Rule&#160;144) for the Securities&#59; and (iii)&#160;in the case of the sale of Securities by an affiliate, the satisfaction of the conditions set forth in sections&#160;(2), (3) and (4) of the paragraph immediately above.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Participant further understands that in the event all of the applicable requirements of Rule&#160;701 or 144 are not satisfied, registration under the Securities Act, compliance with Regulation A, or some other registration exemption shall be required&#59; and that, notwithstanding the fact that Rules&#160;144 and 701 are not exclusive, the Staff of the Securities and Exchange Commission has expressed its opinion that persons proposing to sell private placement securities other than in a registered offering and otherwise than pursuant to Rules&#160;144 or 701 shall have a substantial burden of proof in establishing that an exemption from registration is available for such offers or sales, and that such persons and their respective brokers who participate in such transactions do so at their own risk. Participant understands that no assurances can be given that any such other registration exemption shall be available in such event.</font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.856%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PARTICIPANT</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signature</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#171;Participant&#187;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Print Name</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-13-</font></div></div></div><div id="ic00ac40fee75444899d61de56ec182d5_423"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT B-1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ASSIGNMENT SEPARATE FROM CERTIFICATE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FOR VALUE RECEIVED I, __________________________, hereby sell, assign and transfer unto HeartFlow Holding, Inc. _____________ shares of the Common Stock of HeartFlow Holding, Inc. standing in my name on the books of said corporation represented by Certificate No.&#160;_____ herewith and do hereby irrevocably constitute and appoint __________________________ to transfer the said stock on the books of the within named corporation with full power of substitution in the premises.</font></div><div style="margin-bottom:24pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Stock Assignment may be used only in accordance with the Restricted Stock Purchase Agreement between HeartFlow Holding, Inc. and the undersigned dated ______________, _____ (the &#8220;Agreement&#8221;).</font></div><div style="margin-bottom:362pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Dated&#58; _______________,____&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Signature&#58;___________________________</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INSTRUCTIONS&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Please do not fill in any blanks other than the signature line.  The purpose of this assignment is to enable the Company to exercise its &#8220;repurchase option,&#8221; as set forth in the Agreement, without requiring additional signatures on the part of the Participant.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-14-</font></div></div></div><div id="ic00ac40fee75444899d61de56ec182d5_333"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT B-2 </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">JOINT ESCROW INSTRUCTIONS</font></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_________________, ____</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Corporate Secretary</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">HeartFlow Holding, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1700 Seaport Blvd</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Suite 400</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Redwood City, CA  94063</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Dear _________________&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As Escrow Agent for both HeartFlow Holding, Inc.(the &#8220;Company&#8221;), and the undersigned purchaser of stock of the Company (the &#8220;Participant&#8221;), you are hereby authorized and directed to hold the documents delivered to you pursuant to the terms of that certain Restricted Stock Purchase Agreement (the &#8220;Agreement&#8221;) between the Company and the undersigned, in accordance with the following instructions&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;In the event the Company and&#47;or any assignee of the Company (referred to collectively for convenience herein as the &#8220;Company&#8221;) exercises the Company&#8217;s repurchase option set forth in the Agreement, the Company shall give to Participant and you a written notice specifying the number of shares of stock to be purchased, the purchase price, and the time for a closing hereunder at the principal office of the Company.  Participant and the Company hereby irrevocably authorize and direct you to close the transaction contemplated by such notice in accordance with the terms of said notice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;At the closing, you are directed (a)&#160;to date the stock assignments necessary for the transfer in question, (b)&#160;to fill in the number of shares being transferred, and (c)&#160;to deliver the stock assignments, together with the certificate evidencing the shares of stock to be transferred, to the Company or its assignee, against the simultaneous delivery to you of the purchase price (by cash, a check, or some combination thereof) for the number of shares of stock being purchased pursuant to the exercise of the Company&#8217;s repurchase option.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Participant irrevocably authorizes the Company to deposit with you any certificates evidencing shares of stock to be held by you hereunder and any additions and substitutions to said shares as defined in the Agreement.  Participant does hereby irrevocably constitute and appoint you as Participant&#8217;s attorney-in-fact and agent for the term of this escrow to execute with respect to such securities all documents necessary or appropriate to make such securities negotiable and to complete any transaction herein contemplated, including but not limited to the filing with any applicable state blue sky authority of any required applications for consent to, or notice of transfer of, the securities.  Subject to the provisions of this paragraph&#160;3, Participant shall exercise all rights and privileges of a stockholder of the Company while the stock is held by you.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;Upon written request of the Participant, but no more than once per calendar year, unless the Company&#8217;s repurchase option has been exercised, you shall deliver to Participant a certificate or certificates representing so many shares of stock as are not then subject to the Company&#8217;s repurchase option.  Within one hundred and twenty (120) days after cessation of Participant&#8217;s continuous employment by or services to the Company, or any parent or subsidiary of the Company, you shall deliver to Participant a certificate or certificates representing the aggregate number of shares held or issued pursuant to the Agreement and not purchased by the Company or its assignees pursuant to exercise of the Company&#8217;s repurchase option.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;If at the time of termination of this escrow you should have in your possession any documents, securities, or other property belonging to Participant, you shall deliver all of the same to Participant and shall be discharged of all further obligations hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.&#160;&#160;&#160;&#160;Your duties hereunder may be altered, amended, modified or revoked only by a writing signed by all of the parties hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.&#160;&#160;&#160;&#160;You shall be obligated only for the performance of such duties as are specifically set forth herein and may rely and shall be protected in relying or refraining from acting on any instrument reasonably believed by you to be genuine and to have been signed or presented by the proper party or parties.  You shall not be personally liable for any act you may do or omit to do hereunder as Escrow Agent or as attorney-in-fact for Participant while acting in good faith, and any act done or omitted by you pursuant to the advice of your own attorneys shall be conclusive evidence of such good faith.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.&#160;&#160;&#160;&#160;You are hereby expressly authorized to disregard any and all warnings given by any of the parties hereto or by any other person or corporation, excepting only orders or process of courts of law and are hereby expressly authorized to comply with and obey orders, judgments or decrees of any court.  In case you obey or comply with any such order, judgment or decree, you shall not be liable to any of the parties hereto or to any other person, firm or corporation by reason of such compliance, notwithstanding any such order, judgment or decree being subsequently reversed, modified, annulled, set aside, vacated or found to have been entered without jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.&#160;&#160;&#160;&#160;You shall not be liable in any respect on account of the identity, authorities or rights of the parties executing or delivering or purporting to execute or deliver the Agreement or any documents or papers deposited or called for hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.&#160;&#160;&#160;&#160;You shall not be liable for the outlawing of any rights under the Statute of Limitations with respect to these Joint Escrow Instructions or any documents deposited with you.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.&#160;&#160;&#160;&#160;You shall be entitled to employ such legal counsel and other experts as you may deem necessary properly to advise you in connection with your obligations hereunder, may rely upon the advice of such counsel, and may pay such counsel reasonable compensation therefor.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.&#160;&#160;&#160;&#160;Your responsibilities as Escrow Agent hereunder shall terminate if you shall cease to be an officer or agent of the Company or if you shall resign by written notice to each party.  In the event of any such termination, the Company shall appoint a successor Escrow Agent.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-2-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.&#160;&#160;&#160;&#160;If you reasonably require other or further instruments in connection with these Joint Escrow Instructions or obligations in respect hereto, the necessary parties hereto shall join in furnishing such instruments.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.&#160;&#160;&#160;&#160;It is understood and agreed that should any dispute arise with respect to the delivery and&#47;or ownership or right of possession of the securities held by you hereunder, you are authorized and directed to retain in your possession without liability to anyone all or any part of said securities until such disputes shall have been settled either by mutual written agreement of the parties concerned or by a final order, decree or judgment of a court of competent jurisdiction after the time for appeal has expired and no appeal has been perfected, but you shall be under no duty whatsoever to institute or defend any such proceedings.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.&#160;&#160;&#160;&#160;Any notice required or permitted hereunder shall be given in writing and shall be deemed effectively given upon personal delivery or upon deposit in the United States Post Office, by registered or certified mail with postage and fees prepaid, addressed to each of the other parties thereunto entitled at the following addresses or at such other addresses as a party may designate by ten (10) days advance written notice to each of the other parties hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.&#160;&#160;&#160;&#160;By signing these Joint Escrow Instructions, you become a party hereto only for the purpose of said Joint Escrow Instructions&#59; you do not become a party to the Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.&#160;&#160;&#160;&#160;This instrument shall be binding upon and inure to the benefit of the parties hereto, and their respective successors and permitted assigns.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18.&#160;&#160;&#160;&#160;These Joint Escrow Instructions shall be governed by the internal substantive laws, but not the choice of law rules, of California.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-3-</font></div></div></div><div id="ic00ac40fee75444899d61de56ec182d5_473"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PARTICIPANT</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">HEARTFLOW HOLDING, INC.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#171;Participant&#187;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Print Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Print Name</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residence Address</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Email Address</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ESCROW AGENT</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Secretary</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-4-</font></div></div></div><div id="ic00ac40fee75444899d61de56ec182d5_336"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT B-3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ELECTION UNDER SECTION 83(b)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">OF THE INTERNAL REVENUE CODE OF 1986</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The undersigned taxpayer hereby elects, pursuant to Sections 55 and 83(b) of the Internal Revenue Code of 1986, as amended, to include in taxpayer&#8217;s gross income or alternative minimum taxable income, as the case may be, for the current taxable year the amount of any compensation taxable to taxpayer in connection with taxpayer&#8217;s receipt of the property described below.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;The name, address, taxpayer identification number and taxable year of the undersigned are as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NAME&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;________________________________  &#160;&#160;&#160;&#160;&#160;SPOUSE&#58; __________________________</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ADDRESS&#58; ________________________________</font></div><div style="margin-bottom:12pt;padding-left:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">________________________________</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">TAXPAYER IDENTIFICATION NO.&#58; _____________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TAXABLE YEAR&#58; ________</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;The property with respect to which the election is made is described as follows&#58; __________&#160;shares (the &#8220;Shares&#8221;) of the Common Stock of HeartFlow Holding, Inc. (the &#8220;Company&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;The date on which the property was transferred is&#58;___________________ ,______.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The property is subject to the following restrictions&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Shares may not be transferred and are subject to forfeiture under the terms of an agreement between the taxpayer and the Company.  These restrictions lapse upon the satisfaction of certain conditions contained in such agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The Fair Market Value at the time of transfer, determined without regard to any restriction other than a restriction which by its terms shall never lapse, of such property is&#58;  $_________________.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.&#160;&#160;&#160;&#160;The amount (if any) paid for such property is&#58;  $_________________.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The undersigned has submitted a copy of this statement to the person for whom the services were performed in connection with the undersigned&#8217;s receipt of the above-described property.  The transferee of such property is the person performing the services in connection with the transfer of said property.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">The undersigned understands that the foregoing election may not be revoked except with the consent of the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Commissioner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dated&#58; ______________________, _____ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;__________________________________________</font></div><div style="margin-bottom:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Taxpayer</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The undersigned spouse of taxpayer joins in this election.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dated&#58; ______________________, _____  &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;__________________________________________</font></div><div style="margin-bottom:12pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Spouse of Taxpayer</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>6
<FILENAME>filename6.htm
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="if43dbd71aed243f78ce9d8c29bad53ba_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.4</font></div></div><div style="margin-bottom:48pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%;text-decoration:underline">LEASE</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">by and between</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">MV CAMPUS OWNER, LLC,</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">a Delaware limited liability company</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">(&#8220;Landlord&#8221;)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">and</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">HEARTFLOW, INC.,</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">a Delaware corporation</font></div><div style="margin-bottom:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">(&#8220;Tenant&#8221;)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">August 9, 2021</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">For Premises Located At&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">331 E. Evelyn Avenue</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">Mountain View, California</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="if43dbd71aed243f78ce9d8c29bad53ba_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.311%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Lease of Premises</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Term</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Possession</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Rental Payments&#59; Advance Rent</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Base Rental</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Additional Rental</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating Expenses</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tenant Taxes&#59; Rent Taxes</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Payments</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Late Charges</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Use Rules</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Alterations</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Repairs</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Landlord&#8217;s Right of Entry</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Insurance</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Waiver of Subrogation</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Default</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Waiver of Breach</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Assignment and Subletting</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Destruction</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tenant&#8217;s Property</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">24</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Services to the Premises</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">24</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Waiver of Jury Trial</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">26</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">24.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Time</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">27</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subordination and Attornment</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">27</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">26.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Estoppel Certificates</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">27.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cumulative Rights</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Holding Over</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.311%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Surrender of the Premises</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">30.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notices</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">31.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Damage or Theft of Personal Property</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">30</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">32.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Eminent Domain</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">30</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">33.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Parties</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">31</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">34.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Liability of Tenant</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">31</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">35.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Force Majeure</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">32</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">36.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Landlord&#8217;s Liability</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">32</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">37.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Landlord&#8217;s Covenant of Quiet Enjoyment</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">33</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">38.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Letter of Credit</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">33</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">39.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Hazardous Substances</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">37</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">40.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Broker</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">38</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">41.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Signage</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">38</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">42.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attorney Fees</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">39</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">43.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tenant&#8217;s Emergency Generator</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">39</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">44.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Terrace Rights</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">40</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">45.</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Miscellaneous</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">40</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit A</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Legal Description of the Land</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A-l</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit B-l</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Floor Plans of the Premises</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B-l</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit B-2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Site Plan of Project</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B-2</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit C</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Work Letter</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">D-l</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit D</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Rules and Regulations</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">G-l</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit E</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Form of Tenant Estoppel Certificate</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">H-l</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div></div></div><div id="if43dbd71aed243f78ce9d8c29bad53ba_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36.93pt;padding-right:36.93pt;text-align:center"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">LEASE</font></div><div style="margin-bottom:12pt;padding-right:-1.06pt;text-align:center;text-indent:39pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Basic Lease Information</font></div><div style="margin-bottom:22pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following Basic Lease Information is incorporated in and made a part of the Lease to which it is attached. If there is any conflict between the Basic Lease Information and the remainder of the Lease, the Basic Lease Information shall control.</font></div><div style="margin-bottom:36pt;padding-left:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.464%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.117%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">August 9, 2021</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Landlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MV CAMPUS OWNER, LLC, </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a Delaware limited liability company</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Landlord&#8217;s Address</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">c&#47;o Rockwood Capital, LLC</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">140 East 45th Street, 34th Floor</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">New York, NY 10017</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attn&#58; General Counsel&#47;Chief Compliance Officer</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">with a copy to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">c&#47;o Rockwood Capital, LLC</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">50 California Street, 30th Floor</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">San Francisco, CA 94111</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attn&#58; 301 &#8211; 381 E Evelyn Asset Manager</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">and to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Kennedy, Lamishaw &#38; Rossi LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">707 Wilshire Boulevard, Suite 1400</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Los Angeles, CA 90017</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attn&#58; William J. Birney, Esq.</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Tenant</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">HEARTFLOW, INC., </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a Delaware corporation</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Tenant&#8217;s Address</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Before the Lease</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commencement Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1400 Seaport Blvd., Bldg. B</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Redwood City, CA 94063</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attn&#58;&#160;&#160;CFO</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With a copy to&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1400 Seaport Blvd., Bldg. B </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Redwood City, CA 94063 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attn&#58;&#160;&#160;Legal</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-i-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:36pt;padding-left:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.464%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.117%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">After the Lease<br>Commencement Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">331 E. Evelyn Avenue</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Mountain View, CA 94041</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attn&#58;&#160;&#160;CFO</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With a copy to&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">331 E. Evelyn Avenue </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Mountain View, CA 94041</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attn&#58;  Legal</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Building&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Building 331-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">331 E. Evelyn Avenue, </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Mountain View, CA 94041</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Project&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The buildings shown on the exhibit attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit B-2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Land, any other improvements now or hereafter constructed on the Land, and the Common Areas, which collectively are commonly referred to as the Mountain View Corporate Center.</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Premises Rentable</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Square Feet&#58;</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">61,496 rentable square feet (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">RSF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). See </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Building Rentable</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Square Feet&#58;</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">67,048 RSF. See </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Project Rentable</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Square Feet&#58;</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">288,638 RSF. See </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Delivery Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Within three (3) Business Days after the complete execution of this Lease.</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Lease Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Eight (8) years after the Rent Commencement Date.</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">61,496 RSF in the Building.</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Use of Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">General office, research and development (&#8220;R&#38;D&#8221;), and ancillary uses thereto.</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Base Rental</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Initially $5.85 per RSF of the Premises per month, for a total per month initially of $359,751.60. Base Rental shall increase by three percent (3.0%) on each anniversary of the Lease Commencement Date during the Lease Term.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Lease Commencement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">January 1, 2022.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:36pt;padding-left:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.464%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.117%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Rent Commencement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 1, 2022.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Expiration Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">August 31, 2030.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Advance Rent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$359,751.60, payable on the execution and delivery of this Lease.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">See </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Tenant&#8217;s Share</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">91.72% of the Building, 21.31% of the Project.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Letter of Credit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$4,317,019.20, due upon the execution and delivery of this Lease and subject to reduction as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 38</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Tenant Improvement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Allowance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58;</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The maximum amount of $1,844,880.00 (i.e., $30.00 per RSF in the Premises).</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Broker(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Newmark Cornish &#38; Carey, representing Landlord and Cushman &#38; Wakefield, representing Tenant. See </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 40</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div></td></tr></table></div><div style="margin-bottom:99pt;text-align:center"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;remainder of page intentionally left blank&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-iii-</font></div></div></div><div id="if43dbd71aed243f78ce9d8c29bad53ba_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">LEASE</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Lease (together with the Basic Lease Information and the Exhibits, which are hereby incorporated into the Lease by this reference, collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">is made as of the date specified in the Basic Lease Information, by and between MV CAMPUS OWNER, LLC, a Delaware limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Landlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and HEARTFLOW, INC., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">who hereby agree as follows&#58;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Lease of Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Lease of Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Landlord hereby leases to Tenant, and Tenant hereby leases from Landlord, for the Lease Term (as defined below) and subject to the covenants to be performed by Tenant, those certain premises (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as described in the Basic Lease Information located in that certain building described in the Basic Lease Information (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Building</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">located on that certain tract of land (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Land</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">more particularly described on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> attached hereto. The Premises are outlined on the floor plan attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit B-l</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Tenant shall have the non-exclusive right and privilege to use the Common Areas of the Project in common with other tenants in the Project. The &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Common Areas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">shall mean all areas, improvements, space, and special services, if any, within the Building or on the Land made available by Landlord from time to time, if at all, for the common or joint use and benefit of all tenants, customers, and invitees of the Building, including, without limitation, those parking areas, parking garages and facilities, access roads, service drives, service areas, driveways, entrances, exits and other means of access, retaining walls, landscaped areas, truck serviceways, loading docks or ramps, pedestrian walkways, overstreet walkways, connecting malls, atriums, walls, ceilings, patios, courtyards, garden areas, plaza areas, park areas, concourses, ramps, sidewalks, corridors, washrooms, signs, maintenance buildings, utility buildings, hallways, lobbies, elevators, elevator foyers, escalators, stairs, common window areas, and trash, garbage or rubbish areas, but specifically excluding any space made available exclusively for the use or benefit of other tenants at the Project. Landlord or its successors or assigns hereby reserve the right from time to time in its sole discretion to change or modify the size, use, shape, location or nature of any of the Project and&#47;or the Common Areas other than the Premises (except as otherwise permitted hereunder), or eliminate them altogether, all without any liability to Tenant, so long as Tenant&#8217;s access to, and use of, the Premises is not materially impaired. There is no easement for light, view or air included in the Premises or being granted hereunder. Except as specifically set forth in this Lease and in the Work Letter attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Work Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Landlord shall not be obligated to provide or pay for any improvement, work or services related to the Premises or the Project. Tenant acknowledges that Landlord has made no representation or warranty regarding the condition of the Premises, the Building, the Common Areas or the Project except as specifically set forth in this Lease.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Calculation of RSF</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Notwithstanding anything set forth in this Lease to the contrary, Landlord and Tenant hereby stipulate and agree that the RSF of the Premises, the Building and the Project are as set forth in the Basic Lease Information. The RSF shall not be subject to recalculation, except with respect to new construction, additions or alterations which increase the floor area of the Premises or the Project, as applicable.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Tenant Requirements</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Concurrent with the execution and delivery of this Lease, Tenant shall deliver to Landlord the following&#58; (i)the Advance Rent (as described in the Basic Lease Information), (ii) the Letter of Credit (as described in the Basic Lease Information), (iii) policies of insurance or duly executed certificates of insurance with respect thereto in accordance with </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 15</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> below.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-1-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Furniture, Fixtures and Equipment</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Upon Landlord's tender of possession of the Premises to Tenant, Landlord shall simultaneously transfer, assign and convey to Tenant all of Landlord's right, title and interest, if any, in and to furniture, fixtures and equipment currently located within the Premises (the &#34;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FF&#38;E</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#34;).</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The FF&#38;E is hereby conveyed by Landlord to Tenant without charge to Tenant in is its current &#34;AS IS&#34;, &#34;WHERE IS&#34;, and &#34;WITH ALL FAULTS&#34; condition and without any representation or warranty by Landlord whatsoever, including, without limitation, that the FF&#38;E is operational and suitable to Tenant's requirements, any implied warranties of merchantability and fitness for any particular purpose, warranties created by any affirmation of fact or promise or by any description of the FF&#38;E conveyed hereunder. In connection with the foregoing, and as material consideration for Landlord transferring, assigning and conveying the FF&#38;E to Tenant, Tenant hereby agrees that Landlord shall have no obligations with respect to the FF&#38;E or compliance with any applicable requirements relating thereto nor shall Landlord be responsible for any damage that may be caused to or by the FF&#38;E. Upon the expiration or earlier termination of this Lease, Tenant shall, at Tenant's sole cost and expense, remove the FF&#38;E from the Premises and repair any damage to the Premises and Building caused thereby.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Term.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term of this Lease (&#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Lease Term</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">shall commence on the Lease Commencement Date and, unless sooner terminated as provided in this Lease, shall end on the expiration of the period designated in the Lease Term above (&#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Expiration Date</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">However, if the Expiration Date would not otherwise fall on the last day of a calendar month, then the Expiration Date shall be the last day of the calendar month in which the Expiration Date would otherwise occur.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Possession</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Landlord shall deliver possession of the Premises on the Delivery Date with the mechanical, electrical and HVAC systems serving the Premises (the &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Building Systems</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in good condition (herein, the &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Delivery Condition</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;. No delay in delivery of possession of the Premises shall operate to extend the term of this Lease or amend Tenant&#8217;s obligations under this Lease&#59; provided, however, that the Rent Commencement Date shall be delayed day for day for each day after the Delivery Date that Landlord does not deliver the Premises to Tenant. In the event that as of the Delivery Date (i) the Building Systems are not in the Delivery Condition and (ii) Tenant delivers to Landlord written notice of the existence of the item or items not in the Delivery Condition (the &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Delivery Condition Notice</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) by the date which is ninety (90) days after the Delivery Date (the &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Delivery Condition Outside Date</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">then Landlord shall, at Landlord&#8217;s sole cost and expense which expense shall not be included in Additional Rental or otherwise chargeable to Tenant, do that which is necessary to put the applicable components of the Building Systems described in the Delivery Notice into the Delivery Condition within thirty (30) days after Landlord&#8217;s receipt of the Delivery Notice&#59; provided, however, that to the extent any such failure in the Delivery Condition is caused by the Tenant Improvements to be constructed in the Premises pursuant to </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit C</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, then Tenant shall perform such work at Tenant&#8217;s sole cost and expense. If Tenant fails to deliver the Delivery Condition Notice to Landlord on or prior to the Delivery Condition Outside Date, Landlord shall have no obligation to perform the work described in the foregoing provisions of this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3(a)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; provided that Landlord shall remain responsible for making all alterations and improvements which are Landlord's responsibility to make pursuant to </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13(a)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Tenant shall have the right to occupy the Premises during the period from the Delivery Date until the day before the Lease Commencement Date (the &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Beneficial Occupancy Period</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">provided that (i) Tenant has accepted the Premises and shall have confirmed same in a writing delivered to Landlord, and (ii) all of the terms and conditions of this Lease shall apply, including, without limitation, Tenant's obligation to pay to Landlord all sums and charges required to be paid by Tenant </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-2-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">under this Lease, including Tenant&#8217;s payment of all Additional Rental from and after the Additional Rental Commencement Date pursuant to </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4(a)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> below, as though the Rent Commencement Date had occurred (although the Rent Commencement Date shall not actually occur until the occurrence of the same pursuant to the terms set forth in the Basic Lease Information) upon such occupancy of any portion of the Premises by Tenant&#59; provided however, during such Beneficial Occupancy Period, Tenant shall not be obligated to pay Base Rental until the Rent Commencement Date actually occurs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Except as set forth herein, Tenant acknowledges and agrees that it has inspected the Premises and agrees to accept the same on the Delivery Date, &#8220;AS IS&#8221; and &#8220;WITH ALL FAULTS&#8221;. TENANT ACKNOWLEDGES THAT LANDLORD HAS NOT MADE, AND WILL NOT MAKE, NOR SHALL LANDLORD BE DEEMED TO HAVE MADE, ANY WARRANTIES TO TENANT WITH RESPECT TO THE QUALITY OF CONSTRUCTION OF ANY LEASEHOLD IMPROVEMENTS OR TENANT FINISH WITHIN THE PREMISES OR AS TO THE CONDITION OF THE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">PREMISES, EITHER EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OR REPRESENTATION AS TO (i) ITS FITNESS, DESIGN OR CONDITION FOR ANY PARTICULAR USE OR PURPOSE, (ii) THE QUALITY OF THE MATERIAL OR WORKMANSHIP THEREIN, (iii) THE EXISTENCE OF ANY DEFECT, LATENT OR PATENT, (iv) LANDLORD&#8217;S TITLE THERETO, (v) VALUE, (vi) COMPLIANCE WITH SPECIFICATIONS, (vii) LOCATION, (viii) USE, (ix) CONDITION, (x) MERCHANTABILITY, (xi) QUALITY, (xii) DESCRIPTION, (xiii) DURABILITY (xiv) OPERATION, (xv) THE EXISTENCE OF ANY HAZARDOUS SUBSTANCE, HAZARDOUS CONDITION OR HAZARDOUS ACTIVITY OR (xvi) COMPLIANCE OF THE PREMISES WITH ANY REGULATIONS OR EASEMENT AGREEMENTS&#59; AND ALL RISKS INCIDENT THERETO ARE TO BE BORNE BY TENANT. TENANT ACKNOWLEDGES THAT THE PREMISES IS OF ITS SELECTION AND TO ITS SPECIFICATIONS AND THAT THE PREMISES HAS BEEN INSPECTED BY TENANT AND IS SATISFACTORY TO IT. IN THE EVENT OF ANY DEFECT OR DEFICIENCY IN ANY OF THE PREMISES OF ANY NATURE, WHETHER LATENT OR PATENT, LANDLORD SHALL NOT HAVE ANY RESPONSIBILITY OR LIABILITY WITH RESPECT THERETO OR FOR ANY INCIDENTAL OR CONSEQUENTIAL DAMAGES (INCLUDING STRICT LIABILITY IN TORT). THE PROVISIONS OF THIS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">SECTION 3(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> HAVE BEEN NEGOTIATED AND ARE INTENDED TO BE A COMPLETE EXCLUSION AND NEGATION OF ANY WARRANTIES BY LANDLORD, EXPRESS OR IMPLIED, WITH RESPECT TO ANY OF THE PREMISES, ARISING PURSUANT TO THE UNIFORM COMMERCIAL CODE OR ANY OTHER LAW NOW OR HEREAFTER IN EFFECT OR ARISING OTHERWISE. TENANT&#8217;S OBLIGATION TO PAY RENT UNDER THIS LEASE IS NOT DEPENDENT UPON THE CONDITION OF THE PREMISES.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Tenant shall, at Tenant&#8217;s sole cost and expense, promptly comply with all laws, ordinances, codes, rules, regulations, orders and other requirements of any government or public authority now in force or which may hereafter be in force, with all requirements of any board of fire underwriters or similar body now or hereafter </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">constituted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, and with all directions, temporary and permanent certificates of occupancy and other relevant rules and regulations of interpretations thereof issued pursuant to any law by any governmental agency or officer, including, without limitation, the Americans with Disabilities Act of 1990 (as amended) (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">insofar as any of the foregoing relate to or are required by the condition, use or occupancy of the Premises or the operation, use or maintenance of any personal property, trade fixtures, machinery, equipment or improvements in the Premises. The judgment of any court of competent jurisdiction or the admission of either party in any judicial action, regardless of whether the other party is a party thereto, that such party has violated any of the foregoing Laws shall be conclusive of that fact as between Landlord and Tenant.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-3-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Rental Payments&#59; Advance Rent</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Commencing on the earlier of (i) Lease Commencement Date and (ii) the date that Tenant commences business operations in the Premises (herein, the &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Additional Rental Commencement Date</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and continuing throughout the Lease Term, Tenant hereby agrees to pay all Rent due and payable under this Lease. Notwithstanding the foregoing, Base Rental shall not be due or payable by Tenant until the Rent Commencement Date. Tenant&#8217;s Operating Expense Rental, together with any and all other amounts payable by Tenant to Landlord pursuant to the terms of this Lease, including without limitation any and all other sums that may become due by reason of any default of Tenant or failure on Tenant&#8217;s part to comply with the agreements, terms, covenants and conditions of this Lease to be performed by Tenant, are hereinafter collectively referred to as the &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Additional Rental,</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and the Base Rental and the Additional Rental are herein collectively referred to as &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Rent.</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; Base Rental and Tenant&#8217;s Forecast Additional Rental shall be due and payable in twelve (12) equal installments (subject to Landlord&#8217;s right to vary Tenant&#8217;s Forecast Additional Rental pursuant to </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6(a)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) on the first day of each calendar month, commencing on the Lease Commencement Date and continuing thereafter throughout the Lease Term and any extensions or renewals thereof. Tenant hereby agrees to pay such Rent to Landlord at Landlord&#8217;s address as provided herein (or such other address as Landlord designates from time to time) monthly in advance. Tenant shall pay all Rent and other sums of money which are due and payable by Tenant to Landlord at the times and in the manner provided in this Lease, without demand, set off, counterclaim or abatement (except as specifically provided to the contrary herein).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Tenant shall deposit with Landlord upon execution of this Lease the sum set forth under &#8220;Advance Rent&#8221; in the Basic Lease Information. Such amount shall be applied by Landlord to the first monthly installment of Base Rental following the Rent Commencement Date as it becomes due hereunder. In the event Tenant fails to take possession of the Premises when required or otherwise fails to comply with any of Tenant&#8217;s obligations or warranties hereunder, the Advance Rent shall be retained by Landlord for application in reduction, but not in satisfaction, of damages suffered by Landlord as a result of Tenant&#8217;s breach. Landlord shall not be required to keep the Advance Rent separate from its general accounts, or to pay interest thereon.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Base Rental</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">From and after the Rent Commencement Date, Tenant shall pay to Landlord a base monthly rental (herein called &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Base Rental</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) equal to the Base Rental set forth in the Basic Lease Information.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Additional Rental</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;For purposes of this Lease, &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tenant&#8217;s Forecast Additional Rental</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Landlord&#8217;s reasonable estimate of Tenant&#8217;s Operating Expense Rental for the initial period of the Lease Term from the Lease Commencement Date until the end of the first calendar year of the Lease Term, and for all subsequent calendar years or portions thereof occurring during the balance of the Lease Term. If at any time it reasonably appears to Landlord that Tenant&#8217;s Operating Expense Rental for the current calendar year will vary from Landlord&#8217;s estimate, Landlord shall have the right to reasonably revise its estimate for such year by notice to Tenant and subsequent payments by Tenant for such year shall be based upon such revised estimate. Failure to make such a revision shall not prejudice Landlord&#8217;s right to collect the full amount of Tenant&#8217;s Operating Expense Rental. Prior to the Lease Commencement Date and thereafter prior to the beginning of each calendar year during the Lease Term, including any extensions thereof, Landlord shall present to Tenant a statement of Tenant&#8217;s Forecast Additional Rental for such calendar year&#59; provided, however, that if such statement is not given prior to the beginning of any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-4-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">calendar year, Tenant shall continue to pay during the next ensuing calendar year on the same basis as in the prior calendar year until the month after such statement is delivered to Tenant. Commencing with the first day of the calendar month following the month in which the Tenant&#8217;s Forecast Additional Rental was delivered to Tenant, Tenant shall pay Tenant&#8217;s Forecast Additional Rental (less amounts, if any, previously paid toward such excess for such year) to Landlord in equal monthly installments over the remainder of such calendar year in advance on the first day of each month.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;For purposes of this Lease, &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tenant&#8217;s Operating Expense Rental</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means for each calendar year (or portion thereof) during the Lease Term Tenant&#8217;s Share of Operating Expenses (as defined below). &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Expense Year</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means each calendar year during the Lease Term and each portion of a calendar year at the beginning and end of the Lease Term. Landlord, upon notice to Tenant, may change the Expense Year from time to time to any other twelve (12) consecutive-month period. In the event of any such change, Tenant&#8217;s Operating Expense Rental shall be equitably adjusted for any Expense Year involved in any change. &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tenant&#8217;s Share</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; as it relates to Operating Expenses for the Building shall be determined by dividing the RSF of the Premises by the total number of RSF in the Building, expressed as a percentage. &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tenant&#8217;s Share</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; as it relates to Operating Expenses for the Project other than the Building shall be determined by dividing the RSF of the Premises by the total number of RSF in the Project, expressed as a percentage. In the event during any Expense Year the Building is less than one hundred percent (100%) occupied on an average annualized basis, Operating Expenses that vary with occupancy of the Building (&#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Variable Operating Expenses</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) shall be adjusted to reflect the Operating Expenses of the Building as though they were one hundred percent (100%) occupied for such year on an average annualized basis, and the increase or decrease in the sums owed pursuant to this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall be based upon such Operating Expenses as so adjusted. Therefore, if the Variable Operating Expenses actually incurred by Landlord are lower than would be incurred if at least than one hundred percent (100%) of the Building were occupied or if Landlord is not furnishing any particular item(s) of work or services (the cost of which would otherwise be included within Operating Expenses) to portions of the Building because (A) such portions are not occupied, (B) such item of work or services is not required or desired by the tenant of such portion and the same is not included in such tenant&#8217;s Operating Expenses under its lease, or (C) such tenant is itself obtaining such item of work or services and the same is not included in such tenant&#8217;s Operating Expenses under its lease, then appropriate adjustments shall be made to determine Variable Operating Expenses for such calendar year as though the Building were actually occupied to the extent less than one hundred percent (100%) of the number of RSF in the Building and as though Landlord had furnished such item of work or services. For the purposes of calculating any management fee payable as part of Operating Expenses, the monthly Base Rental due commencing on the Additional Rental Commencement date shall be deemed to be the applicable amount as set forth in the Basic Lease Information for the first payment of Base Rental hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Within one hundred fifty (150) days after the end of (i) the calendar year in which the Lease Commencement Date occurs and (ii) each Expense Year thereafter during the Lease Term, or as soon thereafter as practicable, Landlord shall provide Tenant a statement showing the Operating Expenses for said Expense Year, as prepared by Landlord, and a statement prepared by Landlord comparing Tenant&#8217;s Forecast Additional Rental with Tenant&#8217;s Operating Expense Rental (the &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reconciliation Statement</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the event Tenant&#8217;s Forecast Additional Rental paid exceeds Tenant&#8217;s Operating Expense Rental for said Expense Year, Landlord shall credit such excess against Rent next due hereunder or, if the Lease Term has expired or is about to expire, refund such excess to Tenant within thirty (30) days after Landlord&#8217;s delivery of such Reconciliation Statement if Tenant is not in default under this Lease (in the instance of a default such excess shall be held as additional security for Tenant&#8217;s performance, may be applied by Landlord to cure any such default, and shall not be refunded until any such default is cured to Landlord&#8217;s reasonable satisfaction). In the event that Tenant&#8217;s Operating Expense </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-5-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Rental exceeds Tenant&#8217;s Forecast Additional Rental paid for said Expense Year, Tenant shall pay Landlord, within thirty (30) days of receipt of the statement, an amount equal to such difference. The provisions of this paragraph (c) shall survive the expiration or earlier termination of this Lease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;For so long as Tenant is not in default under this Lease beyond any applicable notice and cure period, Landlord&#8217;s books and records pertaining to the calculation of Operating Expenses for any Expense Year within the Lease Term may be audited, at Tenant&#8217;s expense, by an Authorized Representative of Tenant for a period of one hundred eighty (180) days following the delivery of a Reconciliation Statement (or any Statement revising the same)&#59; provided, that Tenant shall give Landlord not less than ten (10) Business Days&#8217; (as defined in </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 45(u)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> below) prior written notice of any such audit. For purposes hereof, an &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Authorized Representative</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; of Tenant shall mean a bona fide employee of Tenant, any national or regional accounting firm, or any other party reasonably approved in writing by Landlord, in each case who is not representing, and agrees not to represent, any other tenant or subtenant in the Project regarding Additional Rental and is not working on a contingency basis. In no event shall an Authorized Representative of Tenant include the owner of any office building in the Silicon Valley area or any affiliate of such owner. Prior to the commencement of any audit, Tenant shall cause its Authorized Representative to agree in writing for the benefit of Landlord that such Authorized Representative will keep the results of the audit confidential and that such representative will not disclose or divulge the results of such audit except to Tenant and Landlord and except in connection with any dispute between Landlord and Tenant relating to Operating Expenses. Such audit shall be conducted during reasonable business hours at Landlord&#8217;s office where Landlord&#8217;s books and records are maintained. Tenant shall cause a written audit report to be prepared by its Authorized Representative following any such audit and shall provide Landlord with a copy of such report promptly after receipt thereof by Tenant. If Landlord&#8217;s calculation of Tenant&#8217;s Operating Expense Rental for the audited Expense Year is incorrect, then Tenant shall be entitled to a prompt refund of any overpayment or Tenant shall promptly pay to Landlord the amount of any underpayment, as the case may be. Tenant agrees to pay the cost of such certification and the investigation with respect thereto unless it is determined that the Operating Expenses stated in the Reconciliation Statement were overstated in Landlord&#8217;s favor by five percent (5%) or more, in which case Landlord shall pay the reasonable cost of same, not to exceed Five Thousand Dollars ($5,000.00). Tenant waives the right to dispute or contest, and shall have no right to dispute or contest, any matter relating to the calculation of Operating Expenses or other forms of Rent under the Lease (and waives the right to inspect Landlord&#8217;s records with respect thereto) with respect to each Expense Year during the Lease Term for which a Reconciliation Statement is given to Tenant if no claim or dispute with respect thereto is asserted by Tenant in writing to Landlord within one hundred eighty (180) days of delivery to Tenant of the original or most recent Reconciliation Statement with respect thereto.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Landlord shall have the right, from time to time, to equitably allocate some or all of the Operating Expenses for the Project among different portions or occupants of the Project (the &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cost Pools</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in Landlord&#8217;s reasonable discretion. Such Cost Pools may include, but shall not be limited to, the office space tenants of a building of the Project or of the Project, and the retail space tenants of a building of the Project or of the Project. The Operating Expenses within each such Cost Pool shall be allocated and charged to the tenants within such Cost Pool in an equitable manner.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Expenses</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;For the purposes of this Lease, &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Operating Expenses</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean all expenses, costs, and disbursements (but not specific costs billed to or paid directly by specific tenants of the Project) of every kind and nature, computed on the accrual basis, relating to or incurred or paid by Landlord in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-6-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">connection with the ownership, management, operation, repair and maintenance of the Project, including but not limited to, the following&#58;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;wages, salaries and other costs of all on-site and off-site employees at or below the level of general manager or senior property manager engaged either full or part time in the operation, management, maintenance or access control of the Project, including taxes, insurance and benefits relating to such employees, allocated based upon the time such employees are engaged directly in providing such services&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;the cost of all supplies, tools, equipment, materials and personal property used in the operation, management, maintenance and access control of the Project or otherwise made available in the Common Areas&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;the cost of all utilities for the Common Areas of the Project, including but not limited to the cost of heat, light, steam, electricity, gas, water and sewer services&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;the cost of all cleaning, maintenance and service agreements for the Project and the equipment therein to the extent provided by Landlord, including but not limited to, as applicable, any security and&#47;or alarm service, window cleaning, elevator maintenance, HVAC and other air conditioning maintenance, elevator maintenance, waste recycling service, landscaping maintenance, customary landscaping replacement, and maintenance (including striping and painting) of the surface and structured parking area&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;the cost of repairs and general maintenance of the Project, including the cost of repair following a casualty to the extent not reimbursed by insurance proceeds or other payments from a third party&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(6)&#160;&#160;&#160;&#160;the acquisition and&#47;or installation costs of capital investment items (including security and energy management equipment) which are installed for the purpose of reducing operating expenses, increasing energy efficiency, promoting safety, complying with governmental regulations and requirements not in effect as of the Lease Commencement Date, or maintaining capital investment items which are replacements of items which are obsolete or cannot be repaired in an economically feasible manner, costing less than $.75 per RSF of the Premises on an aggregate annual basis, or to the extent costs per year exceeds $.75 per RSF of the Premises, such costs shall be amortized over their respective useful lives as determined in accordance with generally accepted accounting principles, together with reasonable financing charges (whether or not actually incurred)&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(7)&#160;&#160;&#160;&#160;the cost of casualty, rental loss, liability and other insurance, including earthquake, applicable to the Building and the Project, including commercially reasonable deductibles, and endorsements thereto&#59; provided, however, in the event that Tenant&#8217;s Share of any earthquake deductible is in excess of $150,000 for any particular earthquake event, then Tenant&#8217;s Share of such earthquake deductible shall be amortized on a straight-line basis without interest, with Tenant making equal monthly payments of such amount based upon the unexpired portion of the Lease Term&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(8)&#160;&#160;&#160;&#160;the cost of any transportation services made available to Tenant&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(9)&#160;&#160;&#160;&#160;the cost of trash, waste and garbage removal, recycling, air quality audits, vermin extermination, and snow, ice and debris removal&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(10)&#160;&#160;&#160;&#160;the cost of legal and accounting services incurred by Landlord in connection with the management, maintenance, operation and repair of the Project, excluding the owner&#8217;s </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-7-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">or Landlord&#8217;s general accounting, such as partnership statements and tax returns, and excluding services described in </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7(b)( 12)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> below&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(11)&#160;&#160;&#160;&#160;the cost of complying with the rules and regulations applicable to the Project as mandated by governmental authorities with jurisdiction over the Project, including without limitation any costs related to licenses, permits and inspection fees&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(12)&#160;&#160;&#160;&#160;all &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tax Expenses,</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; which means all taxes, assessments and governmental charges attributable to the Project, whether or not directly paid by Landlord, whether federal, state, county or municipal and whether they be by taxing districts or authorities presently taxing the Project or by others subsequently created or otherwise, and any other taxes and assessments attributable to the Project or its operation (and the costs of contesting any of the same), including community improvement district taxes, sales, use and service taxes, and business license taxes and fees, excluding, however, taxes and assessments imposed on the personal property of the tenants of the Project, federal and state taxes on income, death taxes, franchise taxes, penalties (but only if Landlord is negligent in paying such taxes in a timely manner), interest, transfer taxes, and any taxes (other than business license taxes and fees and taxes on Landlord&#8217;s rental income from the Project but not its other income) imposed or measured on or by the income of Landlord from the operation of the Project&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(13)&#160;&#160;&#160;&#160;management fees and expenses (including fees and expenses for property management, accounting, financial management, data processing and information services) not to exceed 3% of gross rents of the Building&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(14)&#160;&#160;&#160;&#160;any other commercially reasonable expenses of any other kind whatsoever incurred in managing, operating, overseeing, maintaining, and repairing the Project.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;For purposes of this Lease, and notwithstanding anything in any other provision of this Lease to the contrary, &#8220;Operating Expenses&#8221; shall not include the following&#58;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;the cost of any special work or service performed for any tenant (including Tenant) at such tenant&#8217;s cost&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;the cost of installing, operating and maintaining any specialty service, such as an observatory, broadcasting facility, luncheon club, restaurant, cafeteria, retail store, sundry shop, newsstand, or concession, but only to the extent such costs exceed those which would normally be expected to be incurred had such space been general office space&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;compensation paid to officers and executives of Landlord (but it is understood that property management employees may carry a title such as vice president and the salaries and related benefits of these officers&#47;employees of Landlord would be allowable Operating Expenses under </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7(a)( 1)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> above)&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;the cost of any items for which Landlord is reimbursed by insurance, condemnation or warranties&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;the cost of any additions, improvements, changes, replacements, and other items which are made in order to prepare for a new tenant&#8217;s occupancy&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(6)&#160;&#160;&#160;&#160;the cost of repairs incurred by reason of fire or other casualty to the extent reimbursed by insurance proceeds (other than business interruption and rent loss insurance proceeds) under policies maintained or required to be maintained by Landlord&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-8-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(7)&#160;&#160;&#160;&#160;insurance premiums to the extent Landlord is directly reimbursed therefor, other than through Operating Expenses&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(8)&#160;&#160;&#160;&#160;interest on debt or amortization payments on any mortgage or deed of trust and rental under any ground lease or other underlying lease except to the extent, in each case, that the debt which is being amortized was incurred to pay for an expense which is properly included in Operating Expenses pursuant to </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7(a)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(9)&#160;&#160;&#160;&#160;any real estate brokerage commissions or other costs, including attorneys&#8217; fees for the negotiation of leases for tenants, incurred in procuring tenants or any fee in lieu of such commissions&#59;</font></div><div style="margin-bottom:21pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(10)&#160;&#160;&#160;&#160;any advertising and promotional expenses incurred in connection with the marketing of any space that is available for lease&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(11)&#160;&#160;&#160;&#160;any expenses for repairs or maintenance which are covered by warranties and service contracts, to the extent such maintenance and repairs are made at no cost to Landlord&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(12)&#160;&#160;&#160;&#160;legal expenses arising out of the enforcement or negotiation of the provisions of any lease affecting the Land including without limitation this Lease, or relating to the sale, financing, or refinancing of the Project or any interest therein except to the extent directly related to financing in connection with the management, maintenance, operation or repair of the Project&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(13)&#160;&#160;&#160;&#160;fines and penalties assessed by a court or governmental agency to the extent such fines and penalties are based on Landlord&#8217;s violation of law or negligence in failing to perform an act or pay an amount due&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(14)&#160;&#160;&#160;&#160;costs of removing or remediating any Hazardous Substances (as defined in </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 39</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> below) in, on or under the Land to the extent such Hazardous Substances are (i) in existence as of the Delivery Date and in violation of applicable Laws in effect as of the Delivery Date (or become in violation of applicable Laws due to the actions of Landlord or its agents, employees, or contractors or due to Landlord&#8217;s breach of its obligations under this Lease), or (ii) introduced onto the Project after the Delivery Date by Landlord or any of Landlord's agents, employees, contractors, invitees, occupants or tenants (other than Tenant) in violation of applicable Laws in effect at the date of introduction&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(15)&#160;&#160;&#160;&#160;costs of capital improvements or expenditures except as provided in Section 7(a)(6) above&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(16)&#160;&#160;&#160;&#160;any costs or expenses that Tenant incurs directly with its maintenance of the Premises where the inclusion of such expense as an Operating Expense would be duplicative&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(17)&#160;&#160;&#160;&#160;reserves of any kind&#59; bad debt loss&#59; or</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(18)&#160;&#160;&#160;&#160;legal, accounting or consulting and other costs incurred in connection with the acquisition, financing, refinancing or disposition of the Project.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Tenant Taxes&#59; Rent Taxes</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Tenant shall pay promptly when due all taxes directly or indirectly imposed or assessed upon Tenant&#8217;s gross sales, business operations, machinery, equipment, trade fixtures and other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-9-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">personal property or assets, whether the aforementioned are owned or leased by Tenant, and whether such taxes are assessed against Tenant, Landlord, the Building or the Project. In the event that such taxes are imposed or assessed against Landlord, the Building or the Project, Landlord shall furnish Tenant with all applicable tax bills, public charges and other assessments or impositions and Tenant shall forthwith pay the same either directly to the taxing authority or, at Landlord&#8217;s option, to Landlord, in which event Landlord shall pay such amounts to the taxing authority promptly after receipt of the funds from Tenant. In addition, in the event there is imposed at any time a tax upon and&#47;or measured by the rental payable by Tenant under this Lease, whether by way of a sales or use tax or otherwise, Tenant shall be responsible for the payment of such tax and shall pay the same on or prior to the due date thereof&#59; provided, however, that the foregoing shall not include any inheritance, estate, succession, transfer, gift or income tax imposed on Landlord.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Tenant will be responsible for ad valorem taxes on its personal property, whether owned or leased by Tenant and on the value of the leasehold improvements in the Premises (and if the taxing authorities do not separately assess Tenant&#8217;s leasehold improvements, Landlord may make an appropriate allocation of the ad valorem taxes allocated to the Project to give effect to this sentence), and such taxes relating to other tenants of the Project will not be included in Operating Expenses.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Payments</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All payments of Rent and other payments to be made to Landlord shall be made on a timely basis, without demand, notice, abatement (except as expressly set forth herein), deduction or set-off, and shall be payable to Landlord or as Landlord may otherwise designate. All such payments shall be mailed or delivered to Landlord&#8217;s Address designated in the Basic Lease Information above or at such other place or in some other manner as Landlord may designate from time to time in writing. If mailed, all payments shall be mailed in sufficient time and with adequate postage thereon to be received in Landlord&#8217;s account by no later than the due date for such payment. Following Landlord&#8217;s written request Tenant shall deliver payments of Rent and any amounts otherwise due hereunder via wire transfer of immediately available funds to such account or accounts as Landlord may designate. Tenant agrees to pay to Landlord Two Hundred Fifty Dollars ($250.00) for each check presented to Landlord in payment of any obligation of Tenant which is not paid by the bank on which it is drawn. Any sums due to Landlord from Tenant not paid when due shall bear interest at the Interest Rate from the date due until paid. The &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Interest Rate</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean ten percent (10%) per annum compounded (not to exceed the maximum rate permitted by law).</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Late Charges</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any Rent or other amounts payable to Landlord under this Lease, if not paid by the fifth (5th) day of the month with respect to Base Rental and Additional Rental, or within five (5) days after the due date specified on any invoice from Landlord for any other amounts payable hereunder, shall incur a late charge of five percent (5%) of the overdue amount (the &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Late Charge</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) for Landlord&#8217;s administrative expense in processing such delinquent payment and in addition thereto shall bear interest at the Interest Rate from andafter the due date for such payment&#59; provided, however, that such Late Charge and Interest shall not apply to any such delinquency unless either (i) such delinquency is not cured within five (5) Business Days after notice from Landlord, or (ii) Tenant previously received notice from Landlord of a delinquency that occurred earlier in the same calendar year. Tenant agrees that this Late Charge represents a fair and reasonable estimate of the cost Landlord will incur by reason of Tenant&#8217;s late payment. Accepting any Late Charge shall not constitute a waiver by Landlord of Tenant&#8217;s default with respect to any overdue amount nor prevent Landlord from exercising any other rights or remedies available to Landlord.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-10-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Use Rules</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Premises shall be used solely for the purposes set forth in the Basic Lease Information and no other purposes and consistent with the character of the Building and the Project as a Class &#8220;A&#8221; office building and office campus. Tenant shall comply with all Laws regarding the use of the Premises. Noise-producing equipment, including fans and vents, shall be oriented away from residential areas or appropriately screened and muffled. No outside storage, unenclosed uses or outside activity areas shall be permitted except screened refuse disposal containers and equipment reasonably approved by Landlord. Tenant covenants and agrees to abide by the Rules and Regulations attached as </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit D</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in all respects as now set forth or as reasonably changed from time to time by Landlord. Landlord shall have the right at all times during the Lease Term to establish and enforce such reasonable and non-discriminating rules and regulations as it deems necessary in its reasonable discretion to protect the tenantability, safety, operation, and welfare of the Premises and the Project. In the event of any inconsistency between the Lease and the Rules and Regulations, the Lease shall prevail.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">No Obstruction</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Tenant shall not obstruct the areas outside of Tenant&#8217;s doors, or any portion of the Common Areas of the Project with any item, including, without limitation, trash or other debris.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Advertisement</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Except as expressly permitted by </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 41 </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">below, Tenant shall not place or permit to be placed any sign, marquee, awning, decoration or other attachment on or to the storefront, windows (inside or outside), doors (inside or outside), or exterior walls of the Premises or at any other location in or adjacent to the Premises except with the prior written consent of Landlord. Landlord may, without liability to Tenant, enter upon the Premises and remove any such sign, marquee, awning, decoration or attachment affixed in violation of this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11,</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and Tenant agrees to pay the cost of any such removal. Tenant shall not exhibit or affix flags, pennants, banners or similar items on or to the exterior of the Premises or the Building of which the Premises are a part. No advertising medium shall be utilized by Tenant which can be heard or experienced outside the Premises, including, without limitation, flashing lights, searchlights, loudspeakers, phonographs, radios or television. Tenant shall not display, paint, or place, or cause to the displayed, painted or placed, any handbills, bumper stickers or other advertising devices in the Common Areas of the Project or on any vehicle parked in the surface of structured parking area of the Project, including those belonging to Tenant, or to Tenant&#8217;s agent or any other person&#59; nor shall Tenant distribute or cause to be distributed in the Project any handbills or other advertising devices. Except as expressly permitted by </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 41</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> below, any signs, notices, logos, pictures, names or advertisements which are installed or placed outside of the Premises and that have not been individually approved by Landlord may be removed without notice by Landlord at the sole expense of Tenant. Except as expressly permitted by </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 41</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> below, Tenant may not, without the prior written approval of Landlord, install any signs on the exterior of the Building or in the Common Areas of the Building or the Project, or install any other items visible from the exterior of the Premises or Building.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Deliveries</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Tenant agrees to cause its deliveries (including loading and unloading) to be made in such a way as to cause as little inconvenience as reasonably possible to other tenants and neighbors of the Project. In any event, Tenant shall comply with all Laws and reasonable regulations of the Project promulgated by Landlord concerning deliveries, including restrictions on noise levels, loading zones and traffic patterns.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Alterations</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Tenant shall not make, suffer or permit to be made any alterations, additions or improvements to or of the Premises or any part thereof, or remove any portion of the Premises which is </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-11-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">affixed thereto, or permanently attach any fixtures or equipment thereto (collectively, the &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Alterations</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">without first notifying Landlord of such proposed Alterations and obtaining Landlord&#8217;s written consent, which consent shall not be unreasonably withheld and which consent shall be requested by Tenant not legs than ten (10) days prior to the commencement of any such work. Landlord shall notify Tenant of its consent or disapproval to Alterations within ten (10) days following the later to occur of (x) receipt of Tenant&#8217;s notice requesting such consent and (y) the date upon which Landlord receives all documents and information reasonably requested in connection with its evaluation of the proposed Alteration. Tenant&#8217;s request for Landlord&#8217;s consent to any proposed Alterations shall include a description of the proposed Alterations and shall be accompanied by materials sufficient to enable Landlord to evaluate the request. Depending on the nature and extent of the proposed Alterations, it is anticipated that such materials could range from paint chips, internally prepared diagrams, plans and specifications prepared by licensed architects and engineers, a description of proposed construction means and methods, the identity of any contractor or subcontractor to be employed in the construction of the Alterations, the estimated cost of such work and the estimated time for performance thereof. Tenant&#8217;s notice requesting consent shall describe the Alterations and the anticipated commencement date thereon so that Landlord may file a notice of nonresponsibility described in Sections 3094 and 3129 of the California Civil Code. The construction of the Tenant Improvements (as defined in the Work Letter) shall be governed by the terms of the Work Letter. However, Tenant shall not be obligated to obtain Landlord&#8217;s consent for a particular Alteration (although the above notice will always be required) in the following circumstances (&#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Minor Alterations</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#58;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i) the cost of the Alteration in question and all work being done by Tenant in the Premises in connection with such Alteration does not exceed $150,000 and all prior Alterations for which Landlord&#8217;s consent was not required will not exceed $300,000 in any twelve (12) month period&#59; (ii) the Alteration in question will have no effect on the various systems of the Building, including without limitation, the HVAC, plumbing and fire protection systems, the Building structure or the exterior appearance of the Building, and (iii) such Alteration will not cause Tenant to exceed the maximum floor load for the Building. Except for Minor Alterations, Tenant shall pay to Landlord on demand an amount equal to two percent (2%) of all hard costs incurred by Tenant or its contractors or agents in connection with any Alterations to cover Landlord&#8217;s overhead and expenses for plan review, coordination, scheduling and supervision. In addition, except for Minor Alterations, upon demand, Tenant shall reimburse Landlord for all reasonable out-of-pocket costs incurred by Landlord in connection with any Alterations, including, without limitation, the costs of any third-party architects, engineers or consultants hired by Landlord to review drawings for Alterations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Landlord may impose, as a condition of its consent to all Alterations such requirements as Landlord reasonably deems desirable including, but not limited to&#58; (i) the requirement that upon Landlord&#8217;s request, made at the time such consent is given, Tenant shall, at Tenant&#8217;s expense, remove such Alterations upon the expiration or any early termination of the Lease Term and repair any damage to the Premises and Building caused by such removal&#59; (ii) the requirement that Tenant utilize for such purposes only contractors, materials, mechanics and materialmen selected by Tenant and approved by Landlord, which approval shall not be unreasonably withheld or delayed&#59; and&#47;or (iii) require that Tenant fully comply with the provisions of Section 8700 of the California Civil Code or submit evidence satisfactory to Landlord that Tenant is exempt from the requirements of such Section 8700. Notwithstanding the foregoing, to the extent any Alterations would materially affect the systems of the Building, including without limitation, the HVAC, plumbing, and fire protection systems, the exterior of the Building or any equipment located on the exterior of the Building, any portion of the Project outside of the Building or any structural component of the Building, such Alterations shall be subject to Landlord&#8217;s consent in the exercise of its sole discretion&#59; to the extent such Alterations would merely affect the systems of the Building, including without limitation, the HVAC, plumbing, and fire protection systems, but not materially, Tenant shall observe reasonable rules relating thereto established by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-12-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Landlord. Tenant shall construct such Alterations and perform any repairs which Tenant is obligated to perform hereunder at Tenant&#8217;s cost and in conformance with any and all applicable rules and regulations of any federal, state, county or municipal code or ordinance and pursuant to a valid building permit, issued by the city and&#47;or county in which the Building is located, in conformance with Landlord&#8217;s construction rules and regulations. Neither Landlord&#8217;s selection or approval of a contractor nor its approval of the plans, specifications and working drawings for Alterations shall create any responsibility or liability on the part of Landlord for the quality or adequacy of the contractor, for the completeness, design sufficiency, or compliance of such plans, specifications and working drawings with all laws, rules and regulations of governmental agencies or authorities. All work with respect to any Alterations must be done in a good and workmanlike manner and diligently prosecuted to completion to the end that the Premises shall at all times be a complete unit except during the period of work. Tenant shall cause all work to be performed in such manner as not to obstruct access to the Project or the Common Areas for any other tenant of the Project, and as not to obstruct the business of Landlord or other tenants in the Project, or unreasonably interfere with the labor force working on the Project. Promptly upon completion of any Alterations, if required by code, Tenant agrees to cause a Notice of Completion to be recorded in the office of the Recorder of the county in which the Building is located in accordance with Section 8182 of the Civil Code of the State of California or any successor statute, and Tenant shall deliver to Landlord a reproducible copy of the &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">as built</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; drawings of the Alterations and, if available, such drawings in &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CAD</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; format.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;All Alterations which may be installed or placed in or about the Premises, and all signs installed in, on or about the Premises, from time to time, shall be at the sole cost of Tenant and shall be and become the property of Landlord, other than trade fixtures and equipment which may be removed without material damage to the Premises on the expiration of the Lease Term or its earlier termination&#59; provided, however, that to the extent any trade fixtures and equipment were installed or placed in or about the Premises at the cost and expense of Landlord, such trade fixtures and equipment shall remain the property of Landlord upon expiration of the Lease Term or its earlier termination. If Tenant fails to complete such removal and&#47;or to repair any damage caused by the removal of any Alterations, then as a matter which shall survive termination of this Lease, Landlord may do so and may charge the cost thereof to Tenant. Tenant hereby indemnifies and holds Landlord harmless from any liability, cost, obligation, expense or claim of lien in any manner relating to the installation, placement, removal or financing of any Alterations by Tenant or at Tenant&#8217;s behest.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Repairs</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Except as otherwise expressly provided in this Lease, Landlord shall have no obligation to alter, remodel, improve, repair, renovate, redecorate or paint all or any part of the Premises. Landlord shall repair, maintain and replace as necessary and in good condition, as part of Operating Expenses to the extent provided in </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereof, the foundation and structural elements of the Building (including structural load bearing walls and roof structure and roof membrane and skylights), and the Building&#8217;s and Project&#8217;s Common Areas&#59; provided, however, to the extent such maintenance, repairs or replacements are required as a result of any act, neglect, fault or omission of Tenant or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">any of Tenant&#8217;s agents, contractors, employees, invitees, licensees, tenants or assigns (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tenant&#8217;s Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) or because of Tenant&#8217;s specific use of or Alterations to the Premises, Tenant shall pay to Landlord, as Additional Rental, the costs of such maintenance, repairs and replacements to the extent such costs are not covered by insurance proceeds (subject to the waiver of subrogation below). Landlord shall not be liable for any failure to make any such repairs, or to perform any maintenance unless such failure shall persist for an unreasonable time after written notice of the need of such repairs or maintenance is given to Landlord by Tenant. There shall be no abatement of rent and no liability of Landlord by reason of any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-13-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">injury to or interference with Tenant&#8217;s business arising from the making of any repairs, alterations or improvements in or to any portion of the Project, Building or the Premises or in or to fixtures, appurtenances and equipment therein. Landlord shall not be required to make any repairs or improvements to the Premises other than as expressly required under this Lease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Except for Landlord&#8217;s obligations specifically set forth elsewhere in this Lease, Tenant shall at all times and at Tenant&#8217;s sole cost and expense, manage and maintain the Premises (including all Building systems) in a good condition consistent with similar Class &#8220;A&#8221; buildings in Mountain View and shall keep, maintain, clean, repair, and replace, as necessary, the Premises and all parts thereof, including, without limitation, plumbing&#47;pipes and conduits at the point of entry into the Premises and inside the Premises, all HVAC systems located within the Premises, all windows, restrooms, ceilings, interior walls, interior and demising walls, doors, electrical and lighting equipment, sprinkler systems, loading dock areas and doors, fences, signs, sprinkler and electrical systems within the Premises, fire and life safety systems and lighting and HVAC control systems, and any Tenant Improvements and Alterations, so as to keep the Premises in such good condition and repair, reasonable wear and tear and casualty damage excepted. Additionally, Tenant shall be responsible for the expense of installation, operation, and maintenance of its telephone and other communications cabling from the point of entry into the Project to the Premises and throughout the Premises. Tenant shall at once report, in writing, to Landlord any defective or dangerous condition known to Tenant. Tenant shall maintain the Building&#8217;s systems which are located in the interior of the Premises. At Landlord&#8217;s option, if Tenant fails to maintain the Premises or to make such repairs beyond any applicable notice and cure period, Landlord may, but need not, perform such maintenance or make such repairs, in which case Tenant shall pay Landlord the cost thereof, including a percentage of the cost (not to exceed 10%) thereof sufficient to reimburse Landlord for all overhead, general conditions, fees and other costs or expenses arising from Landlord&#8217;s involvement upon being billed for same. Landlord may, but shall not be required to, enter the Premises at all reasonable times to make such repairs and maintenance to the Premises or to any equipment located in the Building as Landlord shall be required to maintain hereunder or as Landlord may be required to do by governmental or quasi-governmental authority or court order or decree. To the fullest extent permitted by Law, Tenant hereby waives and releases all rights to make repairs at the expense of Landlord or in lieu thereof to vacate the Premises as may be provided by</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">any law, statute or ordinance now or hereafter in effect, including Sections 1941 and 1942 of the California Civil Code. Landlord has no obligation and has made no promise to alter, remodel, improve, repair, decorate or paint the Premises or any part thereof, except as specifically and expressly herein set forth. Notwithstanding the foregoing, if (i) a capital repair or replacement to any item described in this Section 13(b) is necessary or required, (ii) such repair or replacement would normally be capitalized under normal accounting practice and is in excess of Twenty Thousand Dollars ($20,000), and (iii) if as a result of such expenditure the useful life of item being repair or replaced (as such useful life is based on the estimated actual life pursuant to generally accepted accounting practices) will extend beyond the Lease Term, then, subject to the requirements set forth in this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Landlord will reimburse Tenant for Landlord's prorata share thereof within thirty (30) days following the substantial completion of the applicable repair or replacement. Landlord's prorata share of such expenditure shall be a fraction, the numerator of which is the number of months remaining on the useful life of the item being repaired or replaced after the expiration or sooner termination of this Lease, and the denominator of which is the total number of months of the useful life of the repaired or replaced item. As a condition precedent to Landlord's obligation to reimburse Tenant for a prorata share of any such expenditure, Tenant shall first obtain Landlord's prior written approval of the contractor, the plans and specifications, the amount of any such expenditure and the useful life resulting from such expenditure, which approval shall not be unreasonably withheld or delayed. Upon such approval, either party shall, at the other party's request, enter into an amendment of this Lease identifying the amount subject to reimbursement by Landlord.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-14-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Tenant shall, at Tenant&#8217;s sole cost and expense, procure and maintain regularly scheduled preventive maintenance&#47;service contracts (copies of which shall be delivered to Landlord upon request), in form and substance approved by Tenant, for&#58; (a) heating, air conditioning and ventilation equipment&#59; (b) boiler, fired or unfired pressure vessels&#59; (c) fire sprinkler and&#47;or standpipe and hose or other automatic fire extinguishing systems, including fire alarm and&#47;or smoke detection&#59; and (d) elevators, to the extent solely within the Premises. All maintenance&#47;service contracts shall include all services recommended by the equipment manufacturer within the operation&#47;maintenance manual and shall become effective (and a copy thereof delivered to Landlord) within thirty (30) days following the Lease Commencement Date. The term of any such service contracts shall not extend beyond the Lease Term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;If Tenant refuses or neglects to repair and maintain the Premises properly as required hereunder to the reasonable satisfaction of Landlord, then at any time following fifteen (15) days from the date on which Landlord makes a written demand on Tenant to effect such repair and maintenance and which is not cured by Tenant, Landlord may (i) enter upon the Premises and perform such maintenance and&#47;or make such repairs, and upon completion thereof, Tenant agrees to pay to Landlord as Additional Rental, Landlord&#8217;s costs for making such repairs plus ten percent (10%) of such costs for overhead, within 30 days after receipt from Landlord of a written itemized bill therefor, or (ii) take over Tenant&#8217;s repair obligations for the remainder of the Term (including any Option Terms), and include the cost of same in Operating Expenses. Any amounts not reimbursed by Tenant within the aforementioned 30-day period will bear interest at the Interest Rate until paid by Tenant. Notwithstanding the foregoing, the initial 15-day period set forth above shall be five (5) days in the event of an emergency which constitutes a dangerous condition to persons or property.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Landlord&#8217;s Right of Entry</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary contained in this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Landlord shall retain duplicate keys to all doors of the Premises and Landlord or any Landlord Party may enter the Premises at any time to&#58; (a) examine and inspect the Premises (including to confirm Tenant&#8217;s compliance with its obligations under this Lease), (b) show the Premises to prospective investors, purchasers, mortgagees, lessors or lessees, (c) make such repairs, alterations, replacements or additions to the Premises (i) which Landlord may elect to perform following Tenant&#8217;s failure to perform or in the event of an emergency, or (ii) for which Landlord is responsible, (d) comply with any Laws, (e) post notices of nonresponsibility and (f) exercise Landlord&#8217;s remedies upon the occurrence and during the continuation of a Default all without being liable to Tenant in any manner whatsoever for any damages arising therefrom&#59; provided, however, that Landlord shall, except in case of emergency, afford Tenant such prior notification of an entry into the Premises as shall be reasonably practicable under the circumstances, but not less than twenty-four (24) hours, unless otherwise agreed to by Tenant. Landlord shall be allowed to take into and through the Premises any and all materials that may be required to make any such repairs, additions, alterations or improvements. Any such entries shall be without the abatement of Rent and shall include the right to take such reasonable steps as are required to accomplish the stated purposes. Tenant hereby waives any claims for damages or for any injuries or inconvenience to or interference with Tenant&#8217;s business, lost profits, any loss of occupancy or quiet enjoyment of the Premises, and any other loss occasioned thereby. In an emergency, Landlord shall have the right to use any means that Landlord may deem proper to open the doors in and to the Premises. Any entry into the Premises in the circumstances and manner described in this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 14</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall not be deemed to be a forcible or unlawful entry into, or a detainer of, the Premises, or an actual or constructive eviction of Tenant from any portion of the Premises. In connection with any entry, Landlord and its agents shall comply with Tenant&#8217;s reasonable security measures.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-15-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Insurance</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Tenant shall procure at its expense and maintain throughout the Lease Term the following policies of insurance&#58;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;commercial general liability insurance including contractual liability and broad form property damage with an each-occurrence limit of Five Million Dollars ($5,000,000) and a general aggregate limit of Five Million Dollars ($5,000,000). Such insurance shall name Landlord and its property manager and their respective officers, partners, members and employees and such additional persons or entities as Landlord may from time-to-time designate in writing as an additional insured, shall specifically include the liability assumed hereunder by Tenant, and is intended to be primary insurance, and not excess over or contributory with any other valid, existing, and applicable insurance in force for or on behalf of Landlord, and shall provide that Landlord shall receive thirty (30) days&#8217; written notice from the insurer prior to any cancellation or change of coverage. Such insurance shall, in addition, extend to provide contractual liability coverage, extending to the indemnities by Tenant provided for in this Lease and to any liability assumed in any contract entered into in the course of Tenant&#8217;s business&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;automobile liability insurance covering owned, hired and non-owned automobiles in amount not less than $1,000,000 each accident&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;&#8220;all risk&#8221; property insurance on a &#8220;special causes of loss&#8221; basis (including boiler and machinery (if applicable)&#59; business income and extra expense&#59; sprinkler damage, including earthquake sprinkler leakage, vandalism and malicious mischief) on the Tenant Improvements, any Alterations installed in the Premises by or on behalf of Tenant, all leasehold improvements installed in the Premises by Tenant at its expense, and all of Tenant&#8217;s personal property, such insurance to include a building ordinance provision (as to those Alterations for which such a provision will apply), a waiver of subrogation from Tenant&#8217;s insurer in favor of Landlord and any parties reasonably designated by Landlord. Such insurance shall be an amount equal to full replacement cost of the aggregate of the foregoing and for business income and extra expense shall equal 12 months of income and shall provide coverage comparable to the coverage in the standard ISO &#8220;special causes of loss&#8221; form, when such form is supplemented with the coverages required above, and the property insurance for leasehold improvements and Alterations shall name Landlord as a loss payee as their interest may appear&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;worker&#8217;s compensation insurance, statutory and employer&#8217;s liability coverage in an amount not less than $1,000,000 Disease-Policy Limit&#59; and</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;such other insurance as may be required by Law or reasonably required by Landlord.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additionally, Tenant shall at a minimum require all of its contractors, subcontractors, and vendors to maintain commercial general liability insurance meeting the commercially reasonable requirements of Landlord, automobile liability per </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 15(a)(2)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and workers&#8217; compensation coverage including employers liability per </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 15(a)(4)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in addition such coverage shall include a Waiver of Subrogation in favor of Landlord, its property manager and their respective officers, partners, members and employees and such additional persons or entities as Landlord may from time-to-timedesignate in writing, and provide evidence of insurance as required by Landlord. At a minimum they shall be required to provide evidence of coverage and such other insurance as may be required by Landlord. Additionally, contractors, subcontractors and vendors participating in the construction of the Tenant Improvements shall be required to provide the insurance specified in the Work Letter.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-16-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All insurance policies required under </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 15(a)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall be issued by carriers licensed to do business in the State of California each with a Best&#8217;s Insurance Reports policy holder&#8217;s rating of not less than A- and a financial size category of not less than Class VIII, shall be written on an &#8220;occurrence basis,&#8221; which shall afford coverage for all claims based on acts, omissions, injury and damage, which occurred or arose (or the onset of which occurred or arose) in whole or in part during the policy period and shall be non-cancellable and not subject to material change except after thirty (30) days&#8217; written notice to Landlord and any mortgagee or underlying ground lessor of Landlord except for non-payment of premium in which case ten (10) days&#8217; notice shall be given. Tenant shall deliver policies of such insurance or certificates thereof to Landlord prior to the date that Tenant occupies the Premises for any reason, and evidence of renewals of such policies shall be delivered to Landlord at least ten (10) days prior to the expiration of each respective policy term. In the event Tenant shall fail to procure and keep such insurance in full force and effect during the Term, or to deliver such policies or certificates within said time frame, Landlord may, at its option, procure same for the account of Tenant, and the cost thereof shall be paid to Landlord as Additional Rental within five (5) Business Days after delivery to Tenant of bills therefor. Tenant shall have the right to satisfy the foregoing insurance requirements pursuant to so-called &#8220;umbrella&#8221;, &#8220;blanket&#8221; or &#8220;excess&#8221; insurance coverage so long as the minimum coverages described above are applicable to the Premises, Landlord and the Project, as applicable. Landlord has the right to reasonably amend and&#47;or increase the insurance requirements contained in this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 15</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; provided that Landlord provides Tenant with at least thirty (30) days&#8217; prior notice to comply with such amended policies and&#47;or increase coverage amounts, but in no event shall such amended policies and&#47;or increase coverage amounts be in excess of that required by landlords of comparable buildings within the vicinity of the Building for tenants of comparable financial strength and consistent with the size of the space leased by such tenants.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Landlord shall maintain at its expense (but with the expense to be included in Operating Expenses) throughout the Lease Term insurance on the Building against fire and risks covered by &#8220;special causes of loss&#8221; form (excluding earthquake and flood) on a 100% &#8220;replacement cost&#8221; basis. At Landlord&#8217;s election, in its sole and absolute discretion, Landlord may procure earthquake coverage as a part of such insurance. Landlord&#8217;s insurance shall&#58; (i) cover the Building&#59; (ii) not cover any Alterations installed in the Premises by or on behalf of Tenant&#59; (iii) have a building ordinance provision&#59; and (iv) provide for rental interruption insurance covering a period of twelve (12) full months. Landlord shall also maintain at its expense (but with the expense to be included inOperating Expenses) commercial general liability insurance including contractual liability coverage (or with contractual liability endorsement) on an occurrence basis in amounts not less than Five Million Dollars ($5,000,000) per occurrence and general aggregate limit of Five Million Dollars ($5,000,000) with respect to bodily injury or death and property damage. Notwithstanding the foregoing obligations of Landlord to carry insurance, Landlord may (x) modify the foregoing coverages if and to the extent it is commercially reasonable to do so, and (y) carry additional insurance, including without limitation earthquake and flood, at its sole discretion, and the cost thereof shall be included in Operating Expenses. Any insurance required or permitted to be carried by Landlord hereunder may be carried under blanket policies covering other properties of Landlord and&#47;or its partners and&#47;or their respective related or affiliated corporations so long as such blanket policies provide insurance at all times for the Project as required by this Lease.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Waiver of Subrogation</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Notwithstanding anything to the contrary in this Lease, to the extent that this waiver does not invalidate or impair their respective insurance policies, Landlord and Tenant waive any right of recovery against the other party for any loss of or damage to property which loss or damage is (or, if the insurance required hereunder had been carried, would have been) covered by the waiving party&#8217;s property insurance, and Landlord and Tenant shall each obtain from their respective insurers under all policies of fire, theft, and other property insurance maintained by either of them at any time during the Term insuring or covering the Project or any portion thereof of its contents therein, a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-17-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">waiver of all rights of subrogation which the insurer of one party might otherwise, if at all, have against the other party. This provision shall not operate to prevent Landlord from including the cost of the deductibles of such insurance in Operating Expenses.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Default</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The following events shall be deemed to be events of default by Tenant under this Lease (each, a &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Default</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#58; (i) Tenant shall fail to pay when due any installment of Rent or any other charge or assessment against Tenant pursuant to the terms hereof, and shall fail to cure such breach within five (5) days after written notice that such amount is past due, but if any such notice shall be given more than once during the twelve (12) month period commencing with the date of the first (1st) such notice, the second (2nd) failure to pay within five (5) business days after due any Rent or any other charge required to be paid to Landlord under this Lease during such twelve (12) month period shall be an Default, without notice&#59; (ii) Tenant shall fail to perform any obligation of Tenant or to comply with any provision of this Lease, other than the payment of the Rent or any other charge or assessment payable by Tenant or compliance with the items in clauses (iii) through (xi) hereof, and shall not cure such failure within thirty (30) days after written notice thereof to Tenant&#59; provided however, that any such notice shall be in lieu of, and not in addition to, any notice required under California Code of Civil Procedure Section 1161 or any similar or successor law&#59; and provided further, that if the nature of such failure is that it cannot reasonably be cured within a thirty (30) day period, Tenant shall not be deemed to be in default if it diligently commences such cure within such period, notifies Landlord within such period that it cannot reasonably complete such cure within thirty (30)days and thereafter diligently proceeds to cure said failure as soon as possible but in no event later than ninety (90) days after receipt of Landlord&#8217;s notice&#59; (iii) abandonment of the Premises by Tenant as defined in California Civil Code Section 1951.3&#59; (iv) Tenant shall make a general assignment for the benefit of creditors, or shall admit in writing its inability to pay its debts as they become due, or shall file a petition in bankruptcy, or shall be adjudicated as bankrupt or insolvent, or shall file a petition in any proceeding seeking any reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation, or shall file an answer admitting or fail timely to contest the material allegations of a petition filed against it in any such proceeding, which is not dismissed within forty-five (45) days&#59; (v) a proceeding is commenced against Tenant seeking any reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation, and such proceeding shall not have been dismissed within forty-five (45) days after the commencement thereof&#59; (vi) a receiver or trustee shall be appointed for the Premises or for all or substantially all of the assets of Tenant&#59; (vii) Tenant shall fail to take possession of the Premises as provided in this Lease&#59; (viii) Tenant shall do or permit to be done anything which creates a lien upon the Premises or the Project and such lien is not removed or discharged within fifteen (15) days after the filing thereof&#59; (ix) Tenant shall fail to return a properly executed instrument to Landlord in accordance with </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 25</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereof within the time period provided therein, which is not cured within three (3) Business Days after notice&#59; or (x) Tenant shall fail to return a properly executed estoppel certificate to Landlord in accordance with </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 26</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereof within the time period provided therein, which is not cured within three (3) Business Days after notice.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In the event of any such Default by Tenant, in addition to any other remedies available to Landlord at law or in equity, Landlord shall have the immediate option to terminate this </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-18-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Lease and all rights of Tenant hereunder and to remove Tenant from the Premises in accordance with law. In the event that Landlord shall elect to so terminate this Lease then Landlord may recover from Tenant&#58;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;the worth at the time of award of any unpaid rent which had been earned at the time of such termination&#59; plus</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the worth at the time of award of the amount by which the unpaid rent which would have been earned after termination until the time of award exceeds the amount of such rental loss that Tenant proves could have been reasonably avoided&#59; plus</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;the worth at the time of award of the amount by which the unpaid rent for the balance of the term after the time of award exceeds the amount of such rental loss that Tenant proves could be reasonably avoided&#59; plus</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;any other amount necessary to compensate Landlord for all the detriment proximately caused by Tenant&#8217;s failure to perform its obligations under this Lease or which in the ordinary course of things would be likely to result therefrom.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As used in </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clauses (i) </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(ii) </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">above, the &#8220;worth at the time of award&#8221; is computed by allowing interest at the maximum rate permitted by law per annum. As used in </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (iii) </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">above, the &#8220;worth at the time of award&#8221; is computed by discounting such amount at the discount rate of the Federal Reserve Bank of San Francisco at the time of award plus one percent (1%).</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;In the event of any Default by Tenant, Landlord shall also have the right, with or without terminating this Lease, but subject to applicable law, to re-enter the Premises and remove all persons and property from the Premises&#59; such property may be removed and stored in a public warehouse or elsewhere at the cost of and for the account of Tenant for such period of time as may be required by applicable law after which time Landlord may dispose of such property in accordance with applicable law. No re-entry or taking possession of the Premises by Landlord pursuant to this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 17(c) </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">shall be construed as an election to terminate this Lease unless a written notice of such intention is given to Tenant or unless the termination thereof be decreed by a court of competent jurisdiction. In addition to its other rights under this Lease, Landlord has the remedy described in California Civil Code Section 1951.4 (Landlord may continue the Lease in effect after Tenant&#8217;s breach and abandonment and recover the rent as it becomes due, if Tenant has the right to sublet or assign, subject only to reasonable limitations).</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Upon the occurrence of a Default, Landlord shall have the right to exercise and enforce all rights and remedies granted or permitted by law. The remedies provided for in this Lease are cumulative and in addition to all other remedies available to Landlord at law or in equity by statute or otherwise. Exercise by Landlord of any remedy shall not be deemed to be an acceptance of surrender of the Premises by Tenant, either by agreement or by operation of law. Surrender of the Premises can be affected only by the written agreement of Landlord and Tenant.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;No reentry or taking possession of the Premises by Landlord or any other action taken by or on behalf of Landlord shall be construed to be an acceptance of a surrender of this Lease or an election by Landlord to terminate this Lease unless written notice of such intention is given to Tenant. Tenant agrees to pay to Landlord all costs and expenses incurred by Landlord in the enforcement of this Lease, including, without limitation, the reasonable fees of Landlord&#8217;s attorneys. Tenant waives any right of redemption arising as a result of Landlord&#8217;s exercise of its remedies under this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 17</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-19-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">18.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Waiver of Breach</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">No waiver of any breach of the covenants, warranties, agreements, provisions, or conditions contained in this Lease shall be construed as a waiver of said covenant, warranty, provision, agreement or condition or of any subsequent breach thereof, and if any breach shall occur and afterwards be cured, compromised, settled or adjusted, this Lease shall continue in full force and effect as if no breach had occurred.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Assignment and Subletting</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Tenant may not directly or indirectly, voluntarily or by operation of law (i) assign this Lease or any interest herein or in the Premises, or mortgage, pledge, encumber, hypothecate or otherwise transfer or sublet the Premises or any part thereof or (ii) permit the use of the Premises by any party other than Tenant, including another tenant of the Project (all of the foregoing are hereinafter sometimes referred to collectively as &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Transfer</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">,&#8221; and any person to whom any Transfer is made or sought to be made is hereinafter sometimes referred to as a &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Transferee</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) without Landlord&#8217;s prior written consent in each instance, which shall not be unreasonably withheld or delayed and subject to </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 19(c)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">19(h)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">19(i),</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> below. In addition, Tenant shall not create or distribute materials or information intended to market the Premises in this Lease to any potential Transferee without disclosing any such materials or information to Landlord prior to distribution. Consent to one or more Transfers shall not operate to waive this requirement for Landlord&#8217;s consent, and all subsequent Transfers shall likewise be made only upon obtaining the prior written consent of Landlord in accordance with this Lease.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;If Tenant desires to effect any Transfer, Tenant shall notify Landlord in writing, which notice (the &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Transfer Notice</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) shall include (i) the proposed effective date of the Transfer, which shall not be less than thirty (30) days nor more than one hundred eighty (180) days after the date of delivery of the Transfer Notice, (ii) a description of the portion of the Premises to be transferred (the &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Subject Space</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), (iii) all of the terms of the proposed Transfer and the consideration therefor, including a calculation of the &#8220;Transfer Premium&#8221; (defined below), the name and address of the proposed Transferee, and a copy of all existing and&#47;or proposed documentation pertaining to the proposed Transfer, including all existing operative documents to be executed to evidence such Transfer or the agreements incidental or related to such Transfer, (iv) current financial statements of the proposed Transferee certified by an officer, partner or owner thereof, and (v) any other information reasonably required by Landlord which will enable Landlord to determine the financial responsibility, character, and reputation of the proposed Transferee, nature of such Transferee&#8217;s business and proposed use of the Subject Space. Within twenty (20) days after Landlord&#8217;s receipt of such Transfer Notice, Landlord shall recapture (to the extent permitted pursuant to </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 19(h))</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, approve, or reasonably disapprove such Transfer. Any Transfer (except to a Permitted Transferee pursuant to </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 19(i)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> below) made without Landlord&#8217;s prior written consent or deemed approval shall, at Landlord&#8217;s option,be void and shall constitute a Default. Whether or not Landlord grants consent, Tenant shall pay Landlord&#8217;s reasonable review and processing fees, as well as any reasonable legal fees and other out of pocket costs incurred by Landlord, within thirty (30) days after written request by Landlord. If Landlord consents to any Transfer (and does not exercise any recapture rights Landlord may have under </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 19(h)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> below), Tenant may within six (6) months after Landlord&#8217;s consent, enter into such agreement to Transfer the Premises or portion thereof, upon materially the same terms and conditions as are set forth in the Transfer Notice.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Notwithstanding </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 19(a)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> above, without otherwise limiting the criteria upon which Landlord may withhold its consent to any proposed Transfer, it shall be reasonable for Landlord to withhold its consent to Transfer if (i) the proposed Transferee is a party who would (or whose </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-20-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">use would) detract from the character of the Project as Class &#8220;A&#8221; office building, such as, without limitation, a dental, medical or chiropractic office or a governmental office&#59; (ii) the proposed assignment or subletting is to a governmental subdivision or agency or any person or entity who enjoys diplomatic or sovereign immunity&#59; (iii) such proposed Transferee is an existing tenant of the Project, and Landlord has comparable space available or becoming available in the Project to meet the Transferee&#8217;s needs&#59; (iv) such proposed assignment, subletting or use would contravene any restrictive covenant (including any exclusive use) granted to any other tenant of the Project&#59; (v) the proposed assignee or subtenant is a person or entity then negotiating with Landlord for the lease of space in the Project, and Landlord has comparable space available or becoming available in the Project to meet the Transferee&#8217;s needs&#59; or (vi) the creditworthiness of the proposed assignee is not reasonably acceptable to Landlord (e.g. there does not exist reasonable evidence that assignee can pay the rent and additional rent to be charged to assignee).</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Sublessees or transferees of the Premises shall become directly liable to Landlord for all obligations of Tenant hereunder pertaining to that portion of the Premises covered by their subleases or other instruments of transfer (e.g., an assignment) without relieving Tenant of any liability therefor (provided that sublessees liability for rent and security deposit shall be as set forth in the sublease), and Tenant shall remain obligated for all liability to Landlord arising under this Lease during the entire remaining Lease Term including any extensions thereof, whether or not authorized herein.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;If Tenant is a partnership, an aggregate withdrawal or change, whether voluntary, involuntary or by operation of law, of partners owning a controlling interest in Tenant shall be deemed a voluntary assignment of this Lease and subject to the foregoing provisions. A change or series of changes in ownership of stock or other ownership interests which would result in direct or indirect change in ownership of less than fifty percent (50%) of the outstanding stock of or other ownership interests in such Tenant as of the date of the execution and delivery of this Lease shall not be considered a change of control. If neither Tenant nor any affiliate which controls Tenant is a corporation, partnership or other entity that is publicly traded on a recognized national stock exchange, then any transaction or series of related or unrelated transactions (including, without limitation, any dissolution, merger, consolidation or other reorganization, any withdrawal or admission of a partner or change in a partner&#8217;s interest, or any issuance, sale, gift, transfer or redemption of any capital stock of or ownership interest in such entity, whether voluntary, involuntary or by operation of law, or any combination of any of the foregoing transactions) resulting in the transfer of control of such Tenant, shall be deemed to be an assignment of this Lease subject to the provisions of this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 19</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The term &#8220;control&#8221; as used in this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 19(e)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> means the power to directly or indirectly direct or cause the direction of the management or policies of Tenant. Any transfer of control of a subtenant which is a corporation or other entity shall be deemed an assignment of any sublease by such subtenant. However, the lack of a consent requirement shall not relieve Tenant of the obligation to deliver a timely Transfer Notice to Landlord.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;Fifty percent (50%) of any consideration, net of Tenant&#8217;s reasonable, out-of-pocket costs incurred in the assignment or subletting (including Tenant&#8217;s reasonable expenses in constructing improvements specifically for the subtenant or assignee and reasonable brokerage commissions in connection with the Transfer), which is in excess of the Rent and other amounts due and payable by Tenant under this Lease, and which is due to Tenant by any assignee of this Lease or successor to Tenant (including pursuant to </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 19(b)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) for its assignment, or by any sublessee under or in connection with its sublease, or otherwise due to Tenant by another party for use and occupancy of the Premises or any portion thereof, on a per-rentable-square foot basis if less than all of the Premises is transferred (the &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Transfer Premium</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">shall be promptly remitted by Tenant to Landlord as Additional Rental hereunder and Tenant shall have no right or claim thereto as against Landlord.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-21-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;No assignment of this Lease consented to by Landlord shall be effective unless and until Landlord shall receive an original assignment and assumption agreement, in form and substance reasonably satisfactory to Landlord, signed by Tenant and Tenant&#8217;s proposed assignee, whereby the assignee assumes due performance of this Lease to be done and performed for the balance of the then remaining Lease Term. No subletting of the Premises, or any part thereof, shall be effective unless and until there shall have been delivered to Landlord an agreement, in form and substance reasonably satisfactory to Landlord, signed by Tenant and the proposed sublessee, whereby the sublessee acknowledges the right of Landlord to continue or terminate any sublease, in Landlord&#8217;s sole discretion, upon termination of this Lease, and such sublessee agrees to recognize and attorn to Landlord in the event that Landlord elects under such circumstances to continue such sublease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary contained in this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 19</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> except paragraph (i) below, upon receipt of any Transfer Notice which contemplates a Transfer that (i) will result in Tenant or its Permitted Transferees (as hereinafter defined) no longer occupying at least fifty percent (50%) of the RSF of the Premises or (ii) has a term that is longer than seventy five percent (75%) of the then remaining Lease Term, Landlord shall have the option exercisable by written notice to Tenant given within twenty (20) days after receipt of the Transfer Notice, to recapture the space proposed to be sublet or assigned (&#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Transfer Space</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If Landlord exercises its option to recapture, the Lease shall terminate with respect to the Transfer Space on the commencement date specified in the Transfer Notice, and if there is no such date then thirty (30) days after Landlord sends its written notice of recapture. In the event of a recapture by Landlord, if this Lease shall be canceled with respect to less than the entire Premises, Landlord and Tenant shall enter into an appropriate amendment to this Lease confirming such partial termination of this Lease, providing for a prorata reduction in and apportionment of Base Rental and Tenant&#8217;s Share on a straight square footage basis, adding commercially reasonable lease provisions for a multi-tenant Building, if applicable, such as reasonable and appropriate access to the Transfer Space through the remainder of the Building and the equitable use of common facilities and parking, and Landlord shall have the right to use or relet the Transfer Space for any legal purpose in its sole discretion. If Landlord elects to recapture the Transfer Space, then Landlord shall separately demise the portion of the Premises so recaptured by Landlord from the balance of the Premises, including, without limitation, capping, re-routing or reconfiguring all mechanical, electrical, plumbing, life-safety and other systems and equipment serving the affected portions of the Premises and construct such other improvements as may be required by law or which Landlord reasonably deems to be necessary or appropriate to so demise the portion of the Premises so recaptured and the reasonable cost of such work shall be paid by Tenant at its sole cost. If Landlord declines or fails to elect in a timely manner to recapture the Transfer Space within such 20-day period, then, provided Landlord has consented or is deemed to have consented to the proposed Transfer, Tenant shall be entitled to proceed to transfer the Transfer Space to the proposed Transferee, subject to the provisions of the last sentence of this grammatical paragraph. Any subsequent proposed Transfer of the applicable space shall be subject to this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 19</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If a proposed Transfer is not consummated within six (6) months after the date of the relevant Transfer Notice, Tenant shall be required to submit a new Transfer Notice to Landlord with respect to any contemplated Transfer of the Transfer Space described in the first Transfer Notice.</font></div><div style="margin-bottom:18pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Notwithstanding </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 19(a)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(b)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, an assignment or subletting by Tenant of all or a portion of the Premises or this Lease to (i) an entity which controls, is under common control, or is controlled or owned by Tenant, directly or indirectly&#59; (ii) any entity which purchases all or substantially all of the assets of Tenant or majority of its stock&#59; (iii) any entity into which Tenant is merged or consolidated&#59; or (iv) the sale or transfer of a controlling interest of the capital stock of Tenant as provided hereinbelow (all such persons or entities described in (i), (ii), (iii) and (iv) being sometimes hereinafter referred to as &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Affiliates</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), shall not require Landlord&#8217;s consent </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and shall not be deemed a Transfer under </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-22-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, provided that (A) any such Affiliate was not formed as a subterfuge to avoid the obligations of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; (B) Tenant gives Landlord at least twenty (20) days&#8217; prior notice of any such assignment or sublease to an Affiliate (or within 20 days thereafter if prior notice is prohibited by law or confidentiality obligations)&#59; (C) such Affiliate shall have, as of the effective date of any such assignment or sublease, a Tangible Net Worth which is equal to or greater than the net worth of Heartflow, Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Original Tenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) as of the Lease Commencement Date&#59; (D) any such assignment or sublease shall be subject and subordinate to all of the terms and provisions of this Lease, and such Affiliate shall assume, in a written document reasonably satisfactory to Landlord and delivered to Landlord upon or prior to the effective date of such assignment or sublease, all the obligations of Tenant under this Lease with respect to the portion of the Premises which is the subject of such assignment or sublease (other than the amount of Base Rental payable by Tenant with respect to a sublease)&#59; and (E) Tenant shall remain fully liable for all obligations to be performed by Tenant under this Lease. Any Affiliate to whom Tenant may assign this Lease or sublease a portion of the Premises as permitted by this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 19(i) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">shall be deemed to be a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Permitted Transferee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;. The terms and provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 19(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">19(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall not be applicable to a Transfer described in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section I9(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. However, no assignment or subletting under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 19(i) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">shall be effective until Tenant and the assignee or sublessee have complied with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 19(g) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">above.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Destruction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;If the Premises are damaged by fire or other casualty, the same shall be repaired as speedily as practicable, subject to reasonable delay for insurance adjustment or other matters beyond Landlord&#8217;s reasonable control under the circumstances, at the expense of Landlord (subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;20(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> below), unless this Lease is terminated as provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Beginning on the date of such casualty and continuing during the period required for repair, a just and proportionate part of the Base Rental and Tenant&#8217;s Operating Expense Rental shall be abated for the time and to the extent the Premises are unfit for occupancy for the purposes permitted under this Lease, and not occupied by Tenant as a result thereof, unless such damage to the Premises is due to the negligence or willful misconduct of Tenant or Tenant&#8217;s employees, contractors, licensees, or invitees, in which event Base Rental and Additional Rental shall be abated only to the extent Landlord is reimbursed from the proceeds of rental income or interruption insurance purchased by Landlord as part of Operating Expenses.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;If the Premises are (i) damaged to such an extent that repairs cannot, in Landlord&#8217;s judgment, be completed within twelve (12) months after the date of the casualty&#59; (ii) damaged or destroyed as a result of a risk which is not insured under standard special form&#47;all risk insurance policies or any other insurance carried (or required to be carried) by Landlord under this Lease&#59; (iii) damaged and the holder of any mortgage on the Project or ground or underlying lessor with respect to the Project and&#47;or the Building requires that the insurance proceeds or any portion thereof be used to retire the mortgage debt or terminates the ground or underlying lease, as the case may be&#59; or (iv) substantially damaged or destroyed during the last twelve (12) months of the Lease Term, as extended if permitted herein, then in any such event Landlord may at its option terminate this Lease by notice in writing given to Tenant within sixty (60) days after the date of such damage or destruction. If the Premises are damaged to such an extent that repairs cannot, in Landlord&#8217;s judgment, be completed within twelve (12) months after the date of the casualty or if the Premises are substantially damaged during the last twelve (12) months of the Lease Term, as it may have been extended if permitted herein, then in either such event Tenant may elect to terminate this Lease by notice in writing to Landlord within thirty (30) days after notice from Landlord of the estimated repair time (which estimate shall be given within sixty &#91;60&#93; days after the date of damage). Unless Landlord or Tenant elects to terminate this Lease as hereinabove provided, this Lease will remain in full force and effect and Landlord shall repair such damage to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-23-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">extent required in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as expeditiously as possible under the circumstances. If Landlord or Tenant terminates the Lease pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, then Tenant shall pay the Base Rental and Additional Rental properly apportioned (and as the same may have been abated in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 20(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">above) up to such date of termination or casualty, as the case may be, and both parties hereto shall thereafter be freed and discharged of all further obligations hereunder, except as provided for in provisions of this Lease which by their terms survive the expiration or earlier termination of the Lease Term.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;If Landlord should elect or be obligated pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 20(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> above to repair because of any damage or destruction, Landlord&#8217;s obligation shall be limited solely to restoration of the Building to the condition provided to Tenant on the Delivery Date and shall not extend to any leasehold improvements in the Premises made by Tenant, furniture, equipment, supplies, trade fixtures or other personal property owned or leased by Tenant, its employees, contractors, invitees or licensees. If the cost of performing such repairs and restoration exceeds the actual proceeds of insurance paid or payable to Landlord on account of such casualty (other than deductible amounts), or if Landlord&#8217;s mortgagee under a mortgage or the lessor under an underlying lease shall require that any insurance proceeds from a casualty loss be paid to it, Landlord may terminate this Lease.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;In no event shall Landlord be liable for any loss or damage sustained by Tenant or its visitors, or injury to Tenant&#8217;s business by reason of casualties mentioned hereinabove or any other accidental casualty.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;The provisions of this Lease, including this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, constitute an express agreement between Landlord and Tenant with respect to any and all damage to, or destruction of, all or any part of the Premises, the Building or any other portion of the Project. Any statute or regulation of the state in which the Building is located including, without limitation, Sections 1932(2) and 1933(4) of the California Civil Code, with respect to any rights or obligations concerning damage or destruction in the absence of an express agreement between the parties, shall have no application to this Lease or any damage or destruction to all or any part of the Premises, the Building or any other portion of the Project.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Tenant&#8217;s Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Tenant shall be permitted to remove its trade fixtures, personal property, equipment and furniture from the Premises at any time during the Lease Term and any extensions thereof, and at the expiration or termination of the Lease, subject to and in accordance with the terms and conditions of this Lease otherwise governing the same.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">22.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Services to the Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Subject to the Rules and Regulations attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and unless access to the Premises is restricted by casualty, condemnation, Force Majeure or any governmental action, Tenant shall have access to the Premises 24 hours per day, 365 days per year, during the Lease Term.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Tenant shall pay for all water, gas, heat, light, power, telephone, sewer, sprinkler system charges, janitorial services, trash collection services, and other utilities and services used on or from the Premises, together with any taxes, penalties, and surcharges or the like pertaining thereto and any maintenance charges for utilities. Tenant shall furnish all electric light bulbs, tubes and ballasts, battery packs for emergency lighting and fire extinguishers. If any such services are not separately metered to Tenant, Tenant shall pay such proportion of all charges jointly metered with other premises as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-24-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">determined by Landlord, in its reasonable discretion. Any such charges paid by Landlord and assessed against Tenant shall be immediately payable to Landlord on demand and shall be Additional Rent hereunder. In addition, if applicable, to the extent any utility is not separately metered to the Premises, Landlord may, at its sole expense, install and shall have access to the Premises to monitor a separate meter (or submeter) to determine the actual use of any utility in the Premises or any shared common area and may make available and share actual whole-project energy and water usage data as necessary to maintain the Building's &#34;green building&#34; certification, if any. If there is no meter or submeter in the Premises, then, upon request, Tenant shall provide monthly utility usage to Landlord in electronic or paper format or provide permission for Landlord to request information regarding Tenant's utility usage directly from the utility company. Tenant will not, without the written consent of Landlord, contract with a utility provider to service the Premises with any utility, including, but not limited to, telecommunications, electricity, water, sewer or gas, which is not previously providing such service to other tenants in the Building. Except as provided in Section 22(f) below, Landlord shall in no event be liable for any interruption or failure of utility services on or to the Premises. If Tenant is billed directly by a public utility with respect to Tenant's energy usage at the Premises, then,</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">upon request, Tenant shall provide monthly energy utility usage for the Premises to Landlord for the period of time requested by Landlord (in electronic or paper format) or, at Landlord's option, provide any written authorization or other documentation required for Landlord to request information regarding Tenant's energy usage with respect to the Premises directly from the applicable utility company.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;At the time of Landlord&#8217;s approval of Tenant&#8217;s Final Working Drawings (as such term is defined in the Work Letter) and of any proposed Alterations, Landlord may designate any improvements which Landlord reasonably determines in good faith will cause there to be wear and tear of any related dedicated HVAC system(s) or other building systems within the Premises or the Project </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(&#8220;Tenant&#8217;s Wear and Tear&#8221;) </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">that is significantly greater than that which would be customary for premises being used for normal general office uses </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(&#8220;Normal Wear and Tear&#8221;), </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">because of the hours during which such dedicated HVAC system(s) or building systems will be in use, the impact which equipment being operated by Tenant within the Premises will have on such dedicated HVAC system(s) or building systems, or other similar factors (the extent to which Tenant&#8217;s Wear and Tear exceeds Normal Wear and Tear being referred to herein as </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Excess Wear and Tear&#8221;). </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If Landlord makes such a designation and Tenant constructs the improvements in question, then the incremental cost of operating the dedicated HVAC system(s) and&#47;or building systems due to the Excess Wear and Tear along with the incremental cost of maintaining, repairing and replacing all or any portion of the dedicated HVAC system(s) and&#47;or building systems resulting from such Excess Wear and Tear shall be paid by Tenant within thirty (30) days after written demand from Landlord as Additional Rental.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;HVAC shall be supplied to the Premises from 8&#58;00 A.M. to 6&#58;00 P.M. Monday through Friday and 9&#58;00 A.M. to 1&#58;00 P.M., Saturdays (collectively, the </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Business Hours&#8221;), </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">except for the date of observation of New Year&#8217;s Day, Independence Day, Labor Day, Memorial Day, Thanksgiving Day, and Christmas Day, and at Landlord&#8217;s good faith discretion, other state and nationally recognized holidays selected by Landlord (collectively, the </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Holidays&#8221;)&#59; </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">provided, however, that if Tenant desires HVAC to be provided to the Premises during hours </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(&#8220;Non-Business Hours&#8221;) </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">other than Business Hours </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(&#8220;After Hours HVAC&#8221;), </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Tenant shall provide Landlord with prior written notice (which at a minimum shall be 24 hours&#8217; written notice of Tenant&#8217;s desired After Hours HVAC use and upon such additional conditions as shall be determined by Landlord from time to time, unless the controls are in the Premises in which case Tenant may turn on such HVAC. Tenant shall pay to Landlord Landlord&#8217;s then prevailing charges (reflecting Landlord&#8217;s good faith estimate of Landlord&#8217;s actual direct and indirect cost of providing such After Hours HVAC to an individual floor or zone including, without limitation, the cost of utility service, accelerated wear and tear and depreciation of Building systems, labor required for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-25-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">processing Tenant After Hours HVAC requests and operating the Building HVAC system, together with a reasonable administration fee) (the </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;After Hours HVAC Rate&#8221;) </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for supplying such After Hours HVAC within thirty (30) days of receipt of a bill therefor, which fee is currently $100 per hour. Tenant shall be responsible for and shall pay to Landlord any reasonable additional costs (including, without limitation, the costs of installation of additional HVAC equipment) incurred by Landlord because of the failure of the HVAC system to perform its function due to the occupancy of the Premises by more than one (1) person per 150 feet of RSF of the Premises, arrangement of partitioning in the Premises or changes or alterations thereto or from any use by Tenant of heat-generating machinery or equipment other than normal office equipment.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Except as provided in </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 22(f)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> below, Tenant agrees that Landlord shall not be liable for damages, by abatement of Rent or otherwise, for failure to furnish or delay in furnishing any service or utility, or for any diminution in the quality or quantity thereof, whether such failure or delay or diminution is occasioned, in whole or in part, by repairs, replacements, or improvements, by Force Majeure, by any strike, lockout or other labor trouble, by inability to secure electricity, gas, water, or other fuel at the Building or Project, by any accident or casualty whatsoever, by act or default of Tenant or other parties, or by any other cause&#59; and such failures or delays or diminution shall never be deemed to constitute an eviction or disturbance of Tenant&#8217;s use and possession of the Premises or, except as expressly provided in this Lease, relieve Tenant from paying Rent or performing any of its obligations under this Lease. Furthermore, Landlord shall not be liable under any circumstances for a loss of, or injury to, property or for injury to, or interference with, Tenant&#8217;s business, including, without limitation, loss of profits, however occurring, through or in connection with or incidental to a failure of Tenant to receive any of the services or utilities as set forth in this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 22.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;In the event that Tenant is prevented from using, and does not use, the Premises or any portion thereof as a result of (i) Landlord's failure to provide to the Premises any of the essential utilities, repairs and&#47;or services required to be provided by Landlord pursuant to this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 22</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, or (ii) any failure by Landlord to provide access to the Premises (each such event herein referred to as an </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Abatement Event&#8221;), </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">then Tenant shall give Landlord notice of such Abatement Event. If such Abatement Event continues for five (5) consecutive Business Days after Landlord's receipt of any such notice from Tenant </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(&#8220;Eligibility Period&#8221;), </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">then Tenant's obligation to pay Base Rental shall be abated or reduced, as the case may be, from and after the first (1st) day following the Eligibility Period and continuing until such time that Tenant is no longer prevented from using, and does not use, the Premises or a portion thereof. Such abatement shall be calculated in the proportion that the rentable square feet of the portion of the Premises that Tenant is prevented from using, and does not use, bears to the total rentable square feet of the Premises. Notwithstanding the foregoing, Tenant shall only be entitled to such abatement of rent pursuant to this Section if the Abatement Event is caused by Landlord's negligence or willful misconduct or breach of this Lease. To the extent Tenant shall be entitled to abatement of rent because of a damage or destruction pursuant to </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 20</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or a taking pursuant to </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 32</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, then the Eligibility Period shall not be applicable.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">23.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Waiver of Jury Trial</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If either party commences litigation against the other for the specific performance of this Lease, for damages for the breach hereof or otherwise for enforcement of any remedy hereunder or at law, the parties hereto agree to and hereby do waive any right to a trial by jury.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-26-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">24.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Time</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Time is of the essence of this Lease and each of its provisions and whenever a certain day is stated for payment or performance of any obligation of Tenant or Landlord, the same enters into and becomes a part of the consideration hereof.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">25.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Subordination and Attornment.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:75pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Except to the extent that Landlord&#8217;s mortgagee (or lessor under a ground lease) elects to make the Lease senior to the mortgage (or ground lease) pursuant to </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 25(b)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Tenant agrees that this Lease and all rights of Tenant hereunder are and shall be subject and subordinate to any ground or underlying lease which may hereafter be in effect regarding the Project or any component thereof, to any mortgage now or hereafter encumbering the Premises or the Project or any component thereof, to all advances made or hereafter to be made upon the security of such mortgage, to all amendments, modifications, renewals, consolidations, extensions, and restatements of such mortgage, and to any replacements and substitutions for such mortgage, provided that Tenant&#8217;s possession of the Premises shall not be disturbed so long as Tenant is not in Default under this Lease. The terms of this provision shall be self-operative, and no further instrument of subordination shall be required. Tenant, upon request of any party in interest, shall execute within ten (10) Business Days of request by Landlord such instrument or certificates as may be reasonably required to carry out the intent hereof, whether said requirement is that of Landlord or any other party in interest, including, without limitation, any mortgagee. If Landlord or its mortgagee requests the same, Tenant agrees to execute, acknowledge and deliver within ten (10) Business Days following demand a subordination, non-disturbance and attornment agreement upon such mortgagee&#8217;s standard and commercially reasonable form evidencing such subordination of this Lease to the lien of the mortgage or lease. Tenant hereby irrevocably authorizes Landlord to execute and deliver in the name of Tenant any such instrument or instruments if Tenant fails to do so within the time period provided above, provided that such authorization shall in no way relieve Tenant from the obligation of executing such instruments or certificates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;If any mortgagee or lessor under a ground or underlying lease elects to have this Lease superior to its mortgage or lease and signifies its election in the instrument creating its lien or lease or by separate recorded instrument, then this Lease shall be superior to such mortgage or lease, as the case may be. The term </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;mortgage&#8221;, </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">asused in this Lease, includes any deed of trust, deed to secure debt, or security deed and any other instrument creating a lien in connection with any other method of financing or refinancing. The term </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;mortgagee&#8221;, </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as used in this Lease, refers to the holder(s) of the indebtedness secured by a mortgage.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;In the event any proceedings are brought for the foreclosure of, or in the event of exercise of the power of sale under, any mortgage covering the Premises or the Project, or in the event the interests of Landlord under this Lease shall be transferred by reason of deed in lieu of foreclosure or other legal proceedings, or in the event of termination of any lease under which Landlord may hold title, Tenant shall attorn to the transferee or purchaser at foreclosure or under power of sale, or the lessor of Landlord upon such lease termination, as the case may be (sometimes hereinafter called &#8220;such person&#8221;), without any deductions or off set whatsoever, and shall recognize and be bound and obligated hereunder to such person as the Landlord under this Lease&#59; provided, however, that no such person shall be (i) bound by any payment of Rent for more than one (1) month in advance, except prepayments in the nature of security for the performance by Tenant of its obligations under this Lease (and then only if such prepayments have been deposited with and are under the control of such person)&#59; (ii) bound by any amendment or modification of this Lease made without the express written consent of the mortgagee or lessor of the Landlord, as the case may be&#59; (iii) obligated to cure any defaults under this Lease of any prior landlord </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-27-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(including Landlord)&#59; provided, however, that such person shall be responsible for ongoing maintenance and repair obligations of the Landlord&#59; (iv) liable for any act or omission of any prior landlord (including Landlord)&#59; (v) subject to any offsets or defenses which Tenant might have against any prior landlord (including Landlord)&#59; or (vi) bound by any warranty or representation of any prior landlord (including Landlord) relating to work performed by any prior landlord (including Landlord) under this Lease. Tenant agrees to execute any attornment agreement not in conflict herewith requested by Landlord, the mortgagee or such person. Tenant&#8217;s obligation to attorn to such person shall survive the exercise of any such power of sale, foreclosure or other proceeding. Tenant agrees that the institution of any suit, action or other proceeding by any mortgagee to realize on Landlord&#8217;s interest in the Premises or the Building pursuant to the powers granted to a mortgagee under its mortgage, shall not, by operation of law or otherwise, result in the cancellation or termination of the obligations of the Tenant hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">26.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Estoppel Certificates</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Within ten (10) Business Days after request therefor from Landlord, Tenant agrees to execute and deliver to Landlord in recordable form an estoppel certificate addressed to Landlord, any mortgagee or assignee of Landlord&#8217;s interest in, or purchaser of, the Premises or the Project or any part thereof, which shall be substantially in the form of </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit E</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> attached hereto or in such other commercially reasonable form as may be required by same. Such certificate shall also include such other information as may reasonably be required by such mortgagee, assignee, purchaser or Landlord. Any such certificate may be relied upon by Landlord, any mortgagee, proposed mortgagee, assignee, purchaser and any other party to whom such certificate is addressed. Failure of Tenant to timely execute and deliver such estoppel certificate or other instruments shall constitute an acceptance of the Premises and an acknowledgment by Tenant that statements included in the form of estoppel certificate delivered by Landlord are true and correct, without exception.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">27.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Cumulative Rights</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All rights, powers and privileges conferred hereunder upon the parties hereto shall be cumulative to, but not restrictive of, or in lieu of those conferred by law.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Holding Over</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If Tenant remains in possession after expiration or termination of the Lease Term with or without the Landlord&#8217;s written consent, Tenant shall become a tenant-at-sufferance, and there shall be no renewal or extension of this Lease by operation of law. During the period of any such holding over, all provisions of this Lease shall be and remain in effect except that the monthly Base Rental shall be (i) one hundred fifty percent (150%) percent of the amount of Base Rental (including any adjustments as provided herein) payable for the last full calendar month of the Lease Term, including renewals or extensions, for the initial three (3) months of holdover and (ii) from and after the beginning of the fourth (4</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) month of holdover two hundred percent (200%) of the amount of Base Rental (including any adjustments as provided herein) payable for the last full calendar month of the Lease Term, including renewals or extensions. The inclusion of the preceding sentence in this Lease shall not be construed as the Landlord&#8217;s consent for Tenant to hold over. Landlord hereby expressly reserves the right to require Tenant to surrender possession of the Premises to Landlord as provided in this Lease upon the expiration or other termination of this Lease. The provisions of this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 28</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall not be deemed to limit or constitute a waiver of any other rights or remedies of Landlord provided herein or at law. If Tenant fails to surrender the Premises upon the termination or expiration of this Lease, in addition to any other liabilities to Landlord accruing therefrom, Tenant shall protect, defend, indemnify and hold Landlord harmless from all loss, costs (including reasonable attorneys&#8217; fees) and liability resulting from such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-28-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">failure, including, without limiting the generality of the foregoing, any claims made by any succeeding tenant founded upon such failure to surrender, any consequential damages and any lost profits resulting therefrom.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">29.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Surrender of the Premises</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Upon the expiration or other termination of this Lease, Tenant shall quit and surrender to Landlord the Premises and every part thereof, and any Alterations, broom clean and in good condition and state of repair, reasonable wear and tear and damage due to casualty or condemnation excepted. Tenant shall remove all personalty and equipment not permanently attached to the Premises that it has placed upon the Premises, and repair any damage caused by such removal. At Landlord&#8217;s option, Tenant shall also be responsible for the removal of all wires and cables installed by Tenant in the Premises and within any risers or other portions of the Building to serve Tenant&#8217;s telecommunications and computer systems in the Premises&#59; provided that the removal of such wires, cables and risers shall be effected by Tenant without damage to the Premises or the Building and without interference with the business or operations of Landlord or any other tenant of the Project. If Tenant shall fail or refuse to remove all of Tenant&#8217;s effects, personalty and equipment from the Premises upon the expiration or termination of this Lease for any cause whatsoever or upon the Tenant being dispossessed by process of law or otherwise, such effects, personalty and equipment shall be deemed conclusively to be abandoned and may be appropriated, sold, stored, destroyed or otherwise disposed of by Landlord without written notice to Tenant or any other party and without obligation to account for them. Tenant shall pay Landlord on demand any and all expenses incurred by Landlord in the removal of such property, including, without limitation, the cost of repairing any damage to the Building or Project caused by the removal of such property and storage charges (if Landlord elects to store such property). Tenant and Landlord shall, at least sixty (60) days before the last day of the Lease Term, arrange to meet together for a joint inspection of the Premises. In the event of either party&#8217;s failure to arrange and participate in such joint inspection, the participating party&#8217;s inspection at Tenant&#8217;s vacation of the Premises shall be deemed correct for purposes of determination of Tenant&#8217;s responsibility for repairs and restoration. The covenants and conditions of this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 29</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall survive any expiration or termination of this Lease.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">30.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Notices</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All notices required or permitted to be given hereunder shall be in writing and may be delivered in person to either party or may be sent by nationally recognized overnight courier or by United States mail, certified, return receipt requested, postage prepaid. Any such notice shall be deemed received by the party to whom it was sent (i) in the case of personal delivery or courier delivery, on the date of delivery to such party, and (ii) in the case of certified mail, on the date receipt is acknowledged on the return receipt for such notice or, if delivery is rejected or refused or the U.S. Postal Service is unable to deliver same because of changed address of which no notice was given pursuant hereto, the first date of such rejection, refusal or inability to deliver. All such notices shall be addressed to Landlord or Tenant at their respective address set forth hereinabove in the Basic Lease Information or at such other address as either party shall have theretofore given to the other by notice as herein provided. If Tenant is notified in writing of the identity and address of the Landlord&#8217;s mortgagee or ground or underlying lessor, Tenant shall give to such mortgagee or ground or underlying lessor written notice of any default by Landlord under the terms of this Lease by registered or certified mail, and such mortgagee or ground or underlying lessor shall be given a reasonable opportunity to cure such default prior to Tenant&#8217;s exercising any remedy available to Tenant.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-29-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">31.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Damage or Theft of Personal Property</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As a material part of the consideration to Landlord, all personal property brought into Premises by Tenant, or Tenant&#8217;s employees or business visitors, shall be at the risk of Tenant only, and Landlord shall not be liable for theft thereof or any damage thereto occasioned by any act or omission of co-tenants, occupants, invitees or other users of the Building or any other person. Tenant acknowledges Landlord shall not be providing any security for the Premises, Building or Project. Landlord shall not at any time be liable for damage to any property in or upon the Premises which results from power surges or other deviations from the constancy of electrical service or from gas, smoke, water, or rain, which issues or leaks from or forms upon any part of the Building or from the pipes or plumbing work of the same, or from any other place whatsoever.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">32.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Eminent Domain</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;If all or part of the Premises is taken for any public or quasi-public use by virtue of the exercise of the power of eminent domain or by private purchase in lieu thereof, this Lease shall terminate as to the part so taken as of the date of taking, and, in the case of a partial taking, either Landlord or Tenant shall have the right to terminate this Lease as to the balance of the Premises by written notice to the other within thirty (30) days after such date&#59; provided, however, that a condition to the exercise by Tenant of such right to terminate shall be that the portion of the Premises taken shall be of such extent and nature as substantially to handicap, impede or impair Tenant&#8217;s use of the balance of the Premises. If title to so much of the Building is taken that a reasonable amount of reconstruction thereof will not in Landlord&#8217;s sole discretion result in the Building being a practical improvement and reasonably suitable for use for the purpose for which it is designed, then this Lease shall terminate on the date that the condemning authority actually takes possession of the part so condemned or purchased.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;If this Lease is terminated under the provisions of this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 32</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Rent shall be apportioned and adjusted as of the date of termination.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;If there is a partial taking of the Building and this Lease is not thereupon terminated under the provisions of this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 32</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, then this Lease shall remain in full force and effect, and Landlord shall, within a reasonable time thereafter, repair or reconstruct the remaining portion of the Building to the extent necessary to make the same a complete architectural unit&#59; provided that in complying with its obligations hereunder Landlord shall not be required to expend more than the net proceeds of the condemnation award which are paid to Landlord, and which the Landlord&#8217;s mortgagee permits Landlord to use for this purpose.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;All compensation awarded or paid upon a total or partial taking of the Premises, or the Building shall belong to and be the property of Landlord without any participation by Tenant. Nothing herein shall be construed to preclude Tenant from prosecuting any claim directly against the condemning authority for moving expenses, loss of business, for damage to, and cost of removal of, trade fixtures, furniture and other personal property belonging to Tenant, and for the unamortized cost of leasehold improvements to the extent same were installed at Tenant&#8217;s expense (and not with the proceeds of the Tenant Improvement Allowance)&#59; provided, however, that no such claim shall diminish or adversely affect Landlord&#8217;s award. In no event shall Tenant have or assert a claim for the value of any unexpired term of this Lease. Subject to the foregoing provisions of this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 32</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Tenant hereby assigns to Landlord any and all of its right, title and interest in or to any compensation awarded or paid for the fee as a result of any such taking.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-30-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary contained in this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 32</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, if, during the Lease Term, the use or occupancy of any part of the Building or the Premises shall be taken or appropriated temporarily for a period of one hundred eighty (180) days or less for any public or quasi-public use under any governmental law, ordinance, or regulations, or by right of eminent domain, this Lease shall be and remain unaffected by such taking or appropriation and Tenant shall continue to pay in full all Rent payable hereunder by Tenant during the Lease Term. In the event of any such temporary appropriation or taking, Tenant shall be entitled to receive that portion of any award which represents compensation for the loss of use or occupancy of the Premises during the Lease Term, and Landlord shall be entitled to receive that portion of any award which represents the cost of restoration and compensation for the loss of use or occupancy of the Premises after the end of the Lease Term.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">33.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Parties</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Landlord,&#8221; </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as used in this Lease, shall include Landlord and its assigns and successors. Should Landlord&#8217;s interest in the Premises cease to exist for any reason during the Lease Term, then notwithstanding the happening of such event, this Lease nevertheless shall remain in full force and effect, and Tenant hereby agrees to attorn to the then owner of the Premises so long as such owner assumes all of the obligations of Landlord hereunder. The term </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Tenant&#8221; </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">shall include Tenant and its heirs, legal representatives and successors, and shall also include Tenant&#8217;s assignees, if this Lease shall be validly assigned for the balance of the Lease Term or any renewals or extensions thereof. Landlord&#8217;s right to transfer or assign Landlord&#8217;s interest in and to the Premises, or any part or parts thereof, shall be unrestricted&#59; in the event of any such transfer or assignment by Landlord which includes the Premises, upon the assignee&#8217;s or transferee&#8217;s assumption of the obligations of Landlord arising after the effective date of the transfer, Landlord&#8217;s obligations first arising thereafter to Tenant hereunder shall cease as of the date of transfer and assumption and Tenant shall look only and solely to Landlord&#8217;s assignee or transferee for performance thereof.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">34.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Liability of Tenant</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Tenant hereby assumes all risk of damage to property and injury to persons, in, on, or about the Premises from any cause whatsoever including without limiting the generality of the foregoing, whether caused by water leakage of any character from the roof, walls, or other portion of the Premises or the Building, the Project, or caused by gas, fire, oil, electricity, or any cause whatsoever (other than the intentional or willful misconduct or gross negligence of Landlord and its agents and employees), in, on, or about the Premises, the Building, the Project or any part thereof and agrees that Landlord, and its partners, joint venturers, members, shareholders, lenders and mortgagees, and their respective officers, agents, property managers, servants, employees, and independent contractors (collectively, </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Landlord Parties&#8221;) </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">shall not be liable for, and are hereby released from any responsibility for, any damage to property or injury to persons or resulting from the loss of use thereof, which damage or injury is sustained by Tenant or by other persons claiming through Tenant.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Except for the gross negligence, willful misconduct or breach of this Lease by Landlord or any Landlord Parties, Tenant shall indemnify and hold the Landlord Parties harmless from and defend Landlord and the other Landlord Parties against any and all loss, cost, damage, injury, expense and liability, including, without limitation, court costs and reasonable attorneys&#8217; fees (collectively, </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Claims&#8221;)&#58; </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i) incurred in connection with or arising from any cause in or on the Premises (including, without limitation, Tenant&#8217;s installation, placement and removal of Tenant Improvements, Alterations, fixtures and&#47;or equipment in, on or about the Premises)&#59; (ii) occurring in, on, or about any other portion of the Project to the extent such injury or damage shall be caused by the negligence or willful misconduct of Tenant or of the contractors, agents, servants, employees, licensees, invitees, guests or visitors of Tenant </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-31-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(collectively, the </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Tenant Parties&#8221;) </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in, on or about the Premises, Building and Project&#59; or (iii) arising from any breach of this Lease by Tenant. Tenant further agrees to indemnify and hold the Landlord Parties harmless from, and defend the Landlord Parties against, any and all Claims arising from the conduct of any work or business of Tenant Parties in or about the Project, including any release, discharge, storage or use of any Hazardous Substance, hazardous waste, toxic substance, oil, explosives, asbestos, or similar material. In the event of a discrepancy between the terms of this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 34</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and the terms of </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 39</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (concerning Hazardous Substance liability), the latter shall control. Nothing in this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 34 </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">is intended to nor shall it be deemed to override the provisions of </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">1</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">6</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">35.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Force Majeure</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any prevention, delay or stoppage due to strikes, lockouts, labor disputes, acts of God, acts of war, terrorist acts, inability to obtain services, labor, or materials or reasonable substitutes therefor, governmental actions, civil commotions, moratorium, adverse weather, delays in receipt of permits, fire or other casualty, and other causes beyond the reasonable control of the party obligated to perform, except with respect to the obligations imposed with regard to Rent and other charges to be paid by Tenant pursuant to this Lease (collectively, a </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Force Majeure&#8221;), </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">notwithstanding anything to the contrary contained in this Lease, shall excuse the performance of such party for a period equal to any such prevention, delay or stoppage and, therefore, if this Lease specifies a time period for performance of an obligation of either party, that time period shall be extended by the period of any delay in such party&#8217;s performance caused by a Force Majeure. The foregoing shall in no event be deemed to cause an extension of the Lease Commencement Date or Expiration Date, or in any way eliminate or defer any obligation of Tenant to pay Rent for the period in which a Force Majeure event occurs, except to the extent set forth in </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 20</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Landlord&#8217;s Liability</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Landlord and the Landlord Parties shall have no personal liability with respect to any of the provisions of this Lease. If Landlord is in default with respect to its obligations under this Lease, Tenant shall look solely to the equity of Landlord in and to the Project for satisfaction of Tenant&#8217;s remedies, if any. It is expressly understood and agreed that Landlord&#8217;s liability under the terms of this Lease shall in no event exceed the amount of its interest in and to said Project. In no event shall any of the Landlord Parties be personally liable with respect to any of the provisions of this Lease and Tenant hereby expressly waives and releases such personal liability on behalf of itself and all persons claiming by, through or under Tenant. Under no circumstances shall Landlord or any of the Landlord Parties be liable for injury to Tenant&#8217;s business or for any loss of income or profit therefrom. All obligations of Landlord hereunder shall be construed as covenants, not conditions&#59; and, except as may be otherwise expressly provided in this Lease, Tenant may not terminate this Lease for breach of Landlord&#8217;s obligations hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Except to the extent caused by the negligence or willful misconduct of any Tenant Party, Landlord shall indemnify and hold Tenant harmless from and against any and all claims or liability for any injury or damage to any person or property including any reasonable attorney&#8217;s fees (but excluding any consequential damages or loss of business) occurring in, on, or about the Project to the extent such injury or damage is caused by the gross negligence, intentional or willful misconduct of Landlord, its employees, its property manager, or its property manager&#8217;s employees&#59; provided, however, that the foregoing indemnity shall not include claims or liability to the extent waived by Tenant pursuant to </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 34</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Further, (i) in the event of a discrepancy between the terms of this Section and the terms of </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 39</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> concerning Hazardous Substances liability, the latter shall control&#59; and (ii) nothing in this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 36(b)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> is intended to nor shall it be deemed to override the provisions of </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;16</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-32-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Notwithstanding anything contained in this Lease to the contrary, Landlord shall in no event be liable to Tenant or any other person for any consequential damages, special or punitive damages, or for loss of business, revenue, income or profits even if caused by the active or passive negligence, or intentional or willful misconduct, of any Landlord Party, and Tenant hereby waives any and all claims for any such damages. Except for Tenant&#8217;s holding over in the Premises, Tenant shall in no event be liable to Landlord or any other person for any consequential damages, special or punitive damages, or for loss of business, revenue, income, or profits even if caused by the active or passive negligence, or intentional or willful misconduct, of Tenant, and Landlord hereby waives any and all claims for any such damages. The provisions of this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 36</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall survive the expiration or sooner termination of this Lease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">37.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Landlord&#8217;s Covenant of Quiet Enjoyment</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Provided Tenant performs the terms, conditions and covenants of this Lease, and subject to the terms and provisions hereof, including Landlord&#8217;s right to perform any Construction Work, and the rights of any mortgagees or ground lessors of the Project, Landlord covenants and agrees to take all necessary steps to secure and to maintain for the benefit of Tenant the quiet and peaceful possession of the Premises, for the Lease Term, without hindrance, claim or molestation by Landlord or any other person lawfully claiming under Landlord. The foregoing covenant is in lieu of any other covenant, express or implied.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">38.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Letter of Credit</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:24pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Delivery of Letter of Credit</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Concurrently with the execution and delivery of this Lease, Tenant shall deliver to Landlord, as protection for the full and faithful performance by Tenant of all of its obligations under this Lease and for all losses and damages Landlord may suffer (or which Landlord reasonably estimates that it may suffer) as a result of any breach or default by Tenant under this Lease, an irrevocable and unconditional negotiable standby letter of credit (the </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Letter of Credit&#8221;) </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">containing the terms required herein, running in favor of Landlord, issued by, a solvent, nationally recognized bank with a long term rating from Standard and Poor&#8217;s Professional Rating Service of A or a comparable rating from Moody&#8217;s Professional Rating Service or higher, under the supervision of the Superintendent of Banks of the State of California, or a national banking association (the </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Bank&#8221;), </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and payable upon presentation to an operating retail branch located in San Francisco, California (or, subject to Landlord&#8217;s subsequent agreement with the applicable Bank and without delay in the Bank&#8217;s processing of any applicable draw on the Letter of Credit, payable upon delivery of a facsimile draw) of such Approved Issuer, in an amount equal to Four Million Three Hundred Seventeen Thousand Nineteen and 20&#47;100 Dollars ($4,317,019.20) (the </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Letter of Credit Amount&#8221;), </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as the same may be reduced pursuant to </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 38(f)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> below. The Letter of Credit shall (i) be &#8220;callable&#8221; at sight, irrevocable and unconditional, (ii) be maintained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">effect, whether through renewal (pursuant to a so-called &#8220;evergreen provision&#8221;) or extension, for the period from the Delivery Date and continuing until the date (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;LC Expiration Date&#8221;) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">that is sixty (60) days after the expiration of the Term, and Tenant shall deliver to Landlord a new Letter of Credit, certificate of renewal or extension amendment at least sixty (60) days prior to the expiration of the Letter of Credit then held by Landlord, without any action whatsoever on the part of Landlord, (iii) be fully transferrable by Landlord, its successors and assigns, (iv) permit partial draws and multiple presentations and drawings, and (v) be otherwise subject to the Uniform Customs and Practices for Documentary Credits (2007-Rev), International Chamber of Commerce Publication #600, or the International Standby Practices-ISP 98, International Chamber of Commerce Publication #590. In addition to the foregoing, the form and terms of the Letter of Credit (and the Bank issuing the same) shall be acceptable to Landlord, in Landlord&#8217;s reasonable discretion. If Landlord notifies Tenant in writing that </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-33-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the Bank which issued the Letter of Credit has become financially unacceptable because the above requirements are not met or the Bank has filed bankruptcy or reorganization proceedings or is placed into a receivership or conservatorship, or the financial condition of the Bank has changed in any other materially adverse way, then Tenant shall have thirty (30) days to provide Landlord with a substitute Letter of Credit complying with all of the requirements of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 38</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If Tenant does not so provide Landlord with a substitute Letter of Credit within such thirty (30) day period, then Landlord, or its then managing agent, shall have the right to draw upon the then current Letter of Credit. In addition to Landlord&#8217;s rights to draw upon the Letter of Credit in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 38(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> below and as otherwise described in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 38</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Landlord, or its then managing agent, shall have the right to draw down an amount up to the face amount of the Letter of Credit if any of the following shall have occurred or be applicable&#58; (A) such amount is past-due beyond applicable notice and cure periods under the terms and conditions of this Lease&#59; (B) Tenant has filed a voluntary petition under the U.S. Bankruptcy Code or any state bankruptcy code (collectively, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Bankruptcy Code&#8221;), (C) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">an involuntary petition has been filed against Tenant under the Bankruptcy Code, (D) the Bank has notified Landlord that the Letter of Credit will not be renewed or extended through the LC Expiration Date, or (E) Tenant has failed to deliver a new Letter of Credit or amendment to the existing Letter of Credit increasing the stated amount as required under the terms of this Lease. The Letter of Credit will be honored by the Bank regardless of whether Tenant disputes Landlord&#8217;s right to draw upon the Letter of Credit. Tenant shall be responsible for paying the Bank&#8217;s fees in connection with the issuance of any Letter of Credit, certificate of renewal or extension amendment.</font></div><div style="margin-bottom:19pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Transfer of Letter of Credit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Letter of Credit shall provide that Landlord, its successors and assigns, may, at any time and without notice to Tenant and without first obtaining Tenant&#8217;s consent thereto, transfer (one or more times) all or any portion of its interest in and to the Letter of Credit to a successor owner of Landlord or its mortgagee. In the event of a transfer of Landlord&#8217;s interest in the Building, Landlord shall transfer the Letter of Credit, in whole or in part, to the transferee and thereupon Landlord shall, without any further agreement between the parties, be released by Tenant from all liability therefor arising after such transfer, and it is agreed that the provisions hereof shall apply to every transfer or assignment of the whole or any portion of said Letter of Credit to a new landlord. In connection with any such transfer of the Letter of Credit by Landlord, Tenant shall, at Tenant&#8217;s sole cost and expense, execute and submit to the Bank such applications, documents and instruments as may be necessary to effectuate such transfer, and Tenant shall be responsible for paying the Bank&#8217;s transfer and processing fees in connection therewith.</font></div><div style="margin-bottom:20pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">In General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If, for any reason, the amount of the Letter of Credit becomes less than the Letter of Credit Amount, Tenant shall within ten (10) Business Days thereafter, either provide Landlord with a cash security deposit equal to such difference or provide Landlord with additional letter(s) of credit in an amount equal to the deficiency (or a replacement letter of credit in the total Letter of Credit Amount), and any such additional (or replacement) letter of credit shall comply with all of the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 38</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, and if Tenant fails to comply with the foregoing, then, notwithstanding anything to the contrary contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 17(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> above, the same shall constitute an incurable default by Tenant under this Lease (without the need for any additional notice and&#47;or cure period). Tenant further covenants and warrants that it will neither assign nor encumber the Letter of Credit or any part thereof and that neither Landlord nor its successors or assigns will be bound by any such assignment, encumbrance, attempted assignment or attempted encumbrance. Without limiting the generality of the foregoing, if the Letter of Credit expires earlier than the LC Expiration Date, Landlord will accept a renewal thereof (such renewal letter of credit to be in effect and delivered to Landlord, as applicable, not later than sixty (60) days prior to the expiration of the Letter of Credit), which shall be irrevocable and automatically renewable as above provided through the LC Expiration Date upon the same terms as the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-34-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:20pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">expiring Letter of Credit or such other terms as may be acceptable to Landlord in its reasonable discretion. However, if the Letter of Credit is not timely renewed, or if Tenant fails to maintain the Letter of Credit in the amount and in accordance with the terms set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 38</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Landlord shall have the right to present the Letter of Credit to the Bank in accordance with the terms of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 38</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, and the proceeds of the Letter of Credit may be applied by Landlord against any Rent payable by Tenant under this Lease that is not paid when due (subject to applicable notice and cure periods) and&#47;or to pay for all losses and damages that Landlord has suffered or that Landlord reasonably estimates that it will suffer as a result of any breach or default by Tenant under this Lease (subject to applicable notice and cure periods), including, but not limited to, all damages or rent due upon termination of this Lease pursuant to Section 1951.2 of the California Civil Code. Any unused proceeds shall constitute the property of Landlord and need not be segregated from Landlord&#8217;s other assets. Landlord agrees to pay to Tenant within thirty (30) days after the LC Expiration Date the amount of any proceeds of the Letter of Credit received by Landlord and not applied against any Rent payable by Tenant under this Lease that was not paid when due or used to pay for any losses and&#47;or damages suffered by Landlord (or reasonably estimated by Landlord that it will suffer) as a result of any breach or default by Tenant </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">under this Lease (including, but not limited to, all damages or rent due upon termination of this Lease pursuant to Section 1951.2 of the California Civil Code)&#59; provided, however, that if prior to the LC Expiration Date a voluntary petition is filed by Tenant, or an involuntary petition is filed against Tenant by any of Tenant&#8217;s creditors, under the Bankruptcy Code, then Landlord shall not be obligated to make such payment in the amount of the unused Letter of Credit proceeds until either all preference issues relating to payments under this Lease have been resolved in such bankruptcy or reorganization case or such bankruptcy or reorganization case has been dismissed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Application of Letter of Credit</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Tenant hereby acknowledges and agrees that Landlord is entering into this Lease in material reliance upon the ability of Landlord to draw upon the Letter of Credit upon the occurrence of any breach or default on the part of Tenant under this Lease. If Tenant shall breach any provision of this Lease or otherwise be in default hereunder, in each case beyond applicable notice and cure periods, Landlord may, but without obligation to do so, and without notice to Tenant, draw upon the Letter of Credit, in part or in whole, to cure any breach or default of Tenant and&#47;or to compensate Landlord for any and all damages of any kind or nature sustained, or that Landlord reasonably estimates that it will sustain, resulting from Tenant&#8217;s breach or default, including, but not limited to, all damages or rent due upon termination of this Lease pursuant to Section 1951.2 of the California Civil Code. The use, application or retention of the Letter of Credit, or any portion thereof, by Landlord shall not prevent Landlord from exercising any other right or remedy provided by this Lease or by any Laws, it being intended that Landlord shall not first be required to proceed against the Letter of Credit, and the use, application or retention of the Letter of Credit shall not operate as a limitation on any recovery to which Landlord may otherwise be entitled. Tenant agrees not to interfere in any way with payment to Landlord of the proceeds of the Letter of Credit, either prior to or following a &#8220;draw&#8221; by Landlord of any portion of the Letter of Credit, regardless of whether any dispute exists between Tenant and Landlord as to Landlord&#8217;s right to draw upon the Letter of Credit. No condition or term of this Lease shall be deemed to render the Letter of Credit conditional to justify the issuer of the Letter of Credit in failing to honor a drawing upon such Letter of Credit in a timely manner. Tenant agrees and acknowledges that (i) the Letter of Credit constitutes a separate and independent contract between Landlord and the Bank, (ii) Tenant is not a third party beneficiary of such contract, (iii) Tenant has no property interest whatsoever in the Letter of Credit or the proceeds thereof, and (iv) in the event Tenant becomes a debtor under any chapter of the Bankruptcy Code, neither Tenant, any trustee, nor Tenant&#8217;s bankruptcy estate shall have any right to restrict or limit Landlord&#8217;s claim and&#47;or rights to the Letter of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-35-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Credit and&#47;or the proceeds thereof by application of Section 502(b)(6) of the U.S. Bankruptcy Code or otherwise.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Security Deposit</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Any proceeds drawn under the Letter of Credit and not applied as set forth above shall be held by Landlord as a security deposit (the </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Deposit&#8221;). </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">No trust relationship is created herein between Landlord and Tenant with respect to the Deposit, and Landlord shall not be required to keep the Deposit separate from its general accounts. The Deposit shall be held by Landlord as security for the faithful performance by Tenant of all of the provisions of this Lease to be performed or observed by Tenant. If Tenant fails to pay any Rent, or otherwise defaults with respect to any provision of this Lease, Landlord may (but shall not be obligated to), and without prejudice to any other remedy available to Landlord, use, apply or retain all or any portion of the Deposit for the payment of any Rent in default or for the payment of any other sum to which Landlord may become obligated by reason of Tenant&#8217;s default, or to compensate Landlord for any loss or damage which Landlord may suffer thereby, including, without limitation, prospective damages and damages recoverable pursuant to California Civil Code Section 1951.2. Tenant waives the provisions of California Civil Code Section 1950.7, or any similar or successor laws now or hereinafter in effect, that restrict Landlord&#8217;s use or application of the Deposit, or that provide specific time periods for return of the Deposit. Without limiting the generality of the foregoing, Tenant expressly agrees that if Landlord terminates this Lease due to an Event of Default or if Tenant terminates this Lease in a bankruptcy proceeding, Landlord shall be entitled to hold the Deposit until the amount of damages recoverable pursuant to California Civil Code Section 1951.2 is finally determined. If Landlord uses or applies all or any portion of the Deposit as provided above, Tenant shall within ten (10) days after demand therefor, deposit cash with Landlord in an amount sufficient to restore the Deposit to the full amount thereof, and Tenant&#8217;s failure to do so shall, at Landlord&#8217;s option, be an Event of Default under this Lease. At any time that Landlord is holding proceeds of the Letter of Credit pursuant to this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 38</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Tenant may deposit a Letter of Credit that complies with all requirements of this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 38</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, in which event Landlord shall return the Deposit to Tenant within ten (10) days after receipt of the Letter of Credit. If Tenant performs all of Tenant&#8217;s obligations hereunder, the Deposit, or so much thereof as has not previously been applied by Landlord, shall be returned, without payment of interest or other increment for its use, to Tenant (or, at Landlord&#8217;s option, to the last assignee, if any, of Tenant&#8217;s interest hereunder) within 60 days following the later of the expiration of the Term or Tenant&#8217;s vacation and surrender of the Premises in accordance with the requirements of this Lease. Landlord&#8217;s return of the Deposit or any part thereof shall not be construed as an admission that Tenant has performed all of its obligations under this Lease. Upon termination of Landlord&#8217;s interest in this Lease, if Landlord transfers the Deposit (or the amount of the Deposit remaining after any permitted deductions) to Landlord&#8217;s successor in interest, and thereafter notifies Tenant of such transfer and the name and address of the transferee, then Landlord shall be relieved of any further liability with respect to the Deposit. Thereafter, Tenant shall look solely to the new owner or lessor for the return of said Deposit. The Deposit shall not be mortgaged, assigned or encumbered by Tenant. In the event of a permitted assignment under this Lease by Tenant, the Deposit may be held by Landlord as a deposit made by the permitted assignee in which event the Landlord shall have no further liability with respect to the return of said Deposit to the original Tenant.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;So long as Tenant is not in monetary or material non-monetary default under this Lease beyond any applicable notice and cure period, the Letter of Credit Amount shall be subject to reduction pursuant to the following provisions of this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 38(f)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:103.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;If (i) Tenant shall have received, in the aggregate, after the date of execution of this Lease, $325,000,000.00 or more in private equity investment(s) and (ii) has at least $350,000,000.00 in cash shown on Tenant&#8217;s balance sheet, the Letter of Credit Amount shall be reduced </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-36-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">by $1,079,254.80 (such that the remaining Letter of Credit Amount shall be $3,237,764.40) upon the date which is fifteen (15) days after Landlord's receipt of such certified financial statements and Tenant's notice to Landlord that Tenant has met such financial criteria&#59; and</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:103.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Upon Tenant reaching (i) positive net cash used in operating activities for two (2) consecutive calendar quarters as evidenced on an audited statement of cash flows and (ii) Tenant showing evidence as of such date of notice that it has a minimum of 350,000,000.00 in cash shown on Tenant&#8217;s balance sheet, the Letter of Credit Amount shall be further reduced by $1,079,254.80 (such that the remaining Letter of Credit Amount shall be $2,158,509.60) upon the date which is fifteen (15) days after Landlord's receipt of such certified financial statements and Tenant's notice to Landlord that Tenant has met such financial criteria.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:103.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any such reduction in the Letter of Credit Amount shall be accomplished through amendment or replacement Letter of Credit to be provided by Tenant to Landlord at Tenant's sole cost and expense.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Hazardous Substances</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Tenant hereby covenants and agrees that Tenant shall not cause or permit any </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Hazardous Substances&#8221; </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(as hereinafter defined) to be generated, placed, held, stored, used, located or disposed of at the Project or any part thereof, except for such Hazardous Substances as are commonly and legally used or stored as a consequence of using the Premises for general office, R&#38;D and administrative purposes, but only so long as the use or storage thereof do not pose a threat to public health or to the environment or would necessitate a &#8220;response action&#8221;, as that term is defined in </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;CERCLA&#8221; </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(as hereinafter defined), and so long as Tenant strictly complies or causes compliance with all applicable governmental rules and regulations concerning the use, storage, production, transportation and disposal of such Hazardous Substances. Promptly upon receipt of Landlord&#8217;s request, Tenant shall submit to Landlord true and correct copies of any reports filed by Tenant with any governmental or quasi-governmental authority regarding the generation, placement, storage, use, treatment or disposal of Hazardous Substances on or about the Premises. For purposes of this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 39</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Hazardous Substances&#8221; </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">shall mean and include those elements or compounds which are contained in the list of Hazardous Substances adopted by the United States Environmental Protection Agency </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(&#8220;EPA&#8221;) </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">or in any list of toxic pollutants designated by Congress or the EPA or which are defined as hazardous, toxic, pollutant, infectious or radioactive by any other federal, state or local statute, law, ordinance, code, rule, regulation, order or decree regulating, relating to or imposing liability (including, without limitation, strict liability) or standards of conduct concerning, any hazardous, toxic or dangerous waste, substance or material, as now or at any time hereinafter in effect (collectively </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Environmental Laws&#8221;). </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Tenant hereby agrees to indemnify Landlord and hold Landlord harmless from and against any and all losses, liabilities, including strict liability, damages, injuries, expenses, including reasonable attorneys&#8217; fees, costs of settlement or judgment and claims of any and every kind whatsoever paid, incurred or suffered by, or asserted against, Landlord by any person, entity or governmental agency for, with respect to, or as a direct or indirect result of, the presence in, or the escape, leakage, spillage, discharge, emission or release from, the Premises of any Hazardous Substances during the Term (including, without limitation, any losses, liabilities, including strict liability, damages, injuries, expenses, including reasonable attorneys&#8217; fees, costs of any settlement or judgment or claims asserted or arising under the Comprehensive Environmental Response, Compensation and Liability Act </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(&#8220;CERCLA&#8221;), </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">any so called federal, state or local </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Superfund&#8221; </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">or </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Superlien&#8221; </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">laws or any other Environmental Law. The obligations of Tenant under this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 39</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall survive any expiration or termination of this Lease.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-37-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">40.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Broker</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Landlord and Tenant represent and warrant to each other that (except with respect to the Brokers identified in the Basic Lease Information) no broker, agent, commission salesperson, or other person has represented Landlord or Tenant in the negotiations for and procurement of this Lease and of the Premises and that (except with respect to the Brokers) no commissions, fees, or compensation of any kind are due and payable in connection herewith to any broker, agent, commission salesperson, or other person as a result of any act or agreement of Landlord or Tenant. Landlord and Tenant agree to indemnify and hold each other harmless from all loss, liability, damage, claim, judgment, cost or expense (including reasonable attorneys&#8217; fees and court costs) suffered or incurred by the other party as a result of a breach by Landlord or Tenant, as applicable, of the representation and warranty contained in the immediately preceding sentence or as a result of Landlord&#8217;s or Tenant&#8217;s failure to pay commissions, fees, or compensation due to any broker who represented Landlord or Tenant, whether or not disclosed, or as a result of any claim for any fee, commission or similar compensation with respect to this Lease made by any broker, agent or finder (other than the Brokers) claiming to have dealt with Landlord or Tenant, whether or not such claim is meritorious. Landlord shall pay the Brokers a commission pursuant to a separate agreement.</font></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">41.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Signage</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Subject to Tenant&#8217;s compliance with the provisions of this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 41</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and Landlord&#8217;s reasonable approval, Tenant shall have the right to install signage on the monument sign for the Building and on the exterior or interior of the Building. If Landlord approves of the installation of any signage, the graphics, materials, color, design, lettering, lighting, size, illumination, specifications and exact location of Tenant's signage shall be subject to the prior written approval of Landlord, which approval shall not be unreasonably withheld, conditioned or delayed, and shall be consistent and compatible with the quality and nature of the Project and Landlord's standard signage program. In addition, Tenant's signage shall be subject to Tenant's receipt of all required governmental permits and approvals and shall be subject to all applicable Laws and to any covenants, conditions and restrictions affecting the Project. Tenant shall be responsible, at its sole cost and expense, for all costs associated with the design, fabrication, permitting, installation, repair, maintenance, replacement, removal of all Tenant&#8217;s signs and the repair of any damage to the Building resulting from the removal of such signage. Any signage rights granted by Landlord to signs on the exterior of the Building are personal to the Original Tenant executing this Lease and may not be assigned, voluntarily or involuntarily, to any person or entity other than the Original Tenant or a Permitted Transferee&#59; provided, however, that the name of such Permitted Transferee is not an Objectionable Name. The sign rights granted to the Original Tenant hereunder are not assignable separate and apart from the Lease, nor may any sign right granted herein be separated from the Lease in any manner, either by reservation or otherwise without Landlord&#8217;s consent or as otherwise expressly permitted in this Lease. </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Objectionable Name&#8221; </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">shall mean any name which relates to an entity which is of a character or reputation, or is associated with a political orientation or faction, which is inconsistent with the quality of the Project, or which would otherwise reasonably offend landlords of Class &#8220;A&#8221; buildings in Mountain View.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any signs, notices, logos, pictures, names or advertisements which are installed outside of the Premises and that are not permitted by the terms of this Lease may be removed without notice by Landlord at the sole expense of Tenant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Notwithstanding anything herein to the contrary, Tenant is solely responsible for obtaining all approvals, consents and permits, if any, from the City of Mountain View and&#47;or any other applicable governmental agency necessary for Tenant to install and&#47;or construct Tenant&#8217;s signage on the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-38-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Building or on any existing monument sign, and Landlord does not represent to Tenant that any signage will be permitted by the City of Mountain View and&#47;or any other applicable governmental agency. Landlord shall at no cost or expense to Landlord, reasonably cooperate with Tenant in securing permits, variances, and all other necessary approvals for the purposes of installing such signage, including signage not permitted as of the date hereof but is sought by Tenant.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Tenant&#8217;s right to maintain the exterior signage granted hereunder is expressly conditioned upon Tenant (or a Permitted Transferee) occupying for the conduct of its business not less than fifty percent (50%) of the Premises.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">42.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Attorney Fees</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the event of any legal action or proceeding brought by either party against the other arising out of this Lease, the Prevailing Party in such action shall be entitled to recover from the non-Prevailing Party therein reasonable attorneys&#8217; fees and costs incurred in such action (including, without limitation, all costs of appeal) and such amount shall be included in any judgment rendered in such proceeding. For purposes of this Lease a party shall be considered the </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Prevailing Party&#8221; </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to the extent that (1) such party initiated the litigation and substantially obtained the relief which it sought whether by judgment, voluntary agreement or action of the other party, trial or alternative dispute resolution process, (2) such party did not initiate the litigation and did not receive judgment in its favor, but the party receiving the judgment did not substantially obtain the relief which it sought, or (3) the other party to the litigation withdrew its claim or action without having substantially received the relief which it was seeking. Notwithstanding the foregoing, however, Landlord shall be deemed the Prevailing Party in any unlawful detainer or other action or proceeding instituted by Landlord based upon any default or alleged default of Tenant hereunder if (i) judgment is entered in favor of Landlord, or (ii) prior to trial or judgment Tenant pays all or any portion of the rent claimed by Landlord, vacates the Premises, or otherwise cures the default claimed by Landlord. If Landlord becomes involved in any litigation or dispute, threatened or actual, by or against anyone not a party to this Lease, but arising by reason of or related to any act or omission of Tenant or any Tenant Party, Tenant agrees to pay Landlord&#8217;s reasonable attorneys&#8217; fees and other costs incurred in connection with the litigation or dispute, regardless of whether a lawsuit is actually filed.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">43.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Tenant&#8217;s Emergency Generator</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:31.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Tenant shall be permitted to install, at Tenant&#8217;s sole cost and expense, one (1) back-up emergency generator </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(&#8220;Tenant&#8217;s Emergency Generator&#8221;), </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">subject to Landlord&#8217;s reasonable approval of the size and location outside the Building where Tenant&#8217;s Emergency Generator will be located and Tenant&#8217;s compliance all other terms and conditions of this Lease. Such generator shall be of such specifications, and include such platforms, fencing, enclosures, sheds and other related materials and equipment, as shall be reasonably approved by Landlord prior to installation. Upon the expiration or earlier termination of this Lease, Tenant shall remove the Tenant&#8217;s Emergency Generator, including, without limitation all electrical switch gear, underground conduit and feeders, enclosure and&#47;or modifications to the generator site, repair any damage caused thereby, and restore the site and other facilities of the Building to their condition existing prior to the installation of Tenant&#8217;s Emergency Generator. For the purposes of determining Tenant's obligations with respect to its use of Tenant&#8217;s Emergency Generator herein provided, the location in which Tenant&#8217;s Emergency Generator is situated shall be deemed to be a portion of the Premises&#59; consequently, all of the provisions of this Lease with respect to Tenant's obligations hereunder shall apply to the installation, use and maintenance of the Tenant&#8217;s Emergency Generator, including without limitation, provisions relating to compliance with requirements as to insurance, indemnity, repairs and maintenance, and compliance with Laws.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-39-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">44.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Terrace Rights</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Tenant&#8217;s use of the balconies and terraces affixed to the Building (collectively, the </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Terraces&#8221;) </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">shall at all times be in compliance with applicable Laws, rules, regulations and requirements, and on the terms and conditions set forth herein. Tenant shall not make any improvements or alterations to the Terraces or affix or place graphics, signs and&#47;or insignias, and&#47;or the like, and&#47;or furniture, fixtures, equipment or other items of any kind whatsoever on the Terraces </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(&#8220;Tenant Terrace Property&#8221;) </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">without Landlord's consent, and subject to any terms and conditions Landlord may impose on the use and installation thereof, all in Landlord&#8217;s reasonable discretion, provided that such Tenant Terrace Property is consistent with Building standards and are new and of a first-class and clean condition. Any such Tenant Terrace Property shall comply with the load requirements of the Terraces (it being understood that Tenant shall not place a load upon either of the Terraces that exceeds fifty (50) pounds per square foot of area &#34;live load&#34;). Any such Tenant Terrace Property must be secured to each applicable Terrace, and the method by which any such items are secured to such Terrace shall be subject to Landlord's prior written approval. Notwithstanding Landlord's review and approval of the method by which the Tenant Terrace Property is secured, Tenant shall remain solely liable for any liability arising from Tenant's placement of Tenant Terrace Property on the Terraces, and Landlord shall have no liability in connection therewith. Landlord shall have in its sole discretion the right to access the Terraces, to landscape and display plants on the Terraces, to make use of the Terraces, to place furniture, fixtures and equipment thereon, and to make any desired alterations or modifications to the Terraces, including the right to construct staircases that connect the same to the ground floor. Tenant, at its sole cost and expense, shall keep the Terraces in a clean condition. Tenant shall remove any Tenant Terrace Property upon the expiration or earlier termination of this Lease and shall return the affected portion of the Terraces to the condition that the Terraces would have been in had no such Tenant Terrace Property been placed or installed thereon.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">45.&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Miscellaneous</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Submission of Lease</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The submission of this Lease for examination or execution does not constitute an offer to lease and this Lease shall be effective only upon execution and delivery hereof by Landlord and Tenant.</font></div><div style="margin-bottom:11pt;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Severability</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If any clause or provision of this Lease is illegal, invalid or unenforceable under present or future laws, the remainder of this Lease shall not be affected thereby, and in lieu of each clause or provision of this Lease which is illegal, invalid or unenforceable, there shall be added as a part of this Lease a clause or provision as nearly identical to the said clause or provision as may be legal, valid and enforceable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Entire Agreement</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. This Lease contains the entire agreement of the parties with respect to the subject matter of this Lease, and no representations, inducements, promises or agreements, oral or otherwise, between the parties not embodied herein shall be of any force or effect. This Lease supersedes and cancels any and all previous negotiations, arrangements, brochures, agreements, and understandings, if any, between the parties hereto or displayed by Landlord to Tenant with respect to the subject matter thereof, and none thereof shall be used to interpret or construe this Lease. This Lease may not be altered, waived, amended or extended except by an instrument in writing signed by Landlord and Tenant. This Lease is not in recordable form, and Tenant agrees not to record or cause to be recorded this Lease or any short form or memorandum thereof.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-40-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Headings</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The use of headings herein is solely for the convenience of indexing the various paragraphs hereof and shall in no event be considered in construing or interpreting any provision of this Lease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Governing Law</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The laws of the State of California shall govern the validity, performance and enforcement of this Lease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Authority</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If Tenant executes this Lease as a corporation, each of the persons executing this Lease on behalf of Tenant does hereby personally represent and warrant that Tenant is a duly incorporated or a duly qualified (if a foreign corporation) corporation and is fully authorized and qualified to do business in the State of California, that the corporation has full right and authority to enter into this Lease, and that each person signing on behalf of the corporation is an officer of the corporation and is authorized to sign on behalf of the corporation. If Tenant signs as a partnership, joint venture, or sole proprietorship or other business entity (each being herein called </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Entity&#8221;), </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">each of the persons executing on behalf of Tenant does hereby covenant and warrant that Tenant is a duly authorized and existing Entity, that Tenant has full right and authority to enter into this Lease, that all persons executing this Lease on behalf of the Entity are authorized to do so on behalf of the Entity, and that such execution is fully binding upon the Entity and its partners, joint venturers, members or principals, as the case may be. Upon the request of Landlord, Tenant shall deliver to Landlord documentation satisfactory to Landlord evidencing Tenant&#8217;s compliance with this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 45(f)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, and Tenant agrees to promptly execute all necessary and reasonable applications or documents as reasonably requested by Landlord or required by the jurisdiction in which the Premises is located, to permit the issuance of necessary permits and certificates for Tenant&#8217;s use and occupancy of the Premises.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">financial Statements</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Upon Landlord&#8217;s written request therefor, but not more often than twice per year, Tenant shall promptly furnish to Landlord its financial statement with respect to Tenant for its most recent fiscal year prepared in accordance with generally accepted accounting principles and certified by a firm of nationally recognized certified public accountants as fairly presenting the financial condition of Tenant and the results of its operations for the previous twelve (12) months, which statement Landlord agrees to keep confidential and not use except in connection with Landlord&#8217;s administration and monitoring of this Lease and any proposed sale, loan or other transactions related to the Project. Notwithstanding the foregoing, for so long as Tenant&#8217;s (but not any Affiliate of Tenant) stock is publicly traded on a nationally recognized stock exchange and Tenant&#8217;s financial statements are publicly filed, the foregoing requirement shall be inapplicable to Tenant.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Joint and Several Liability</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If Tenant comprises more than one person, corporation, partnership or other entity, the liability hereunder of all such persons, corporations, partnerships or other entities shall be joint and several.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Waiver</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No waiver of any provision of this Lease shall be implied by any failure of Landlord or Tenant to enforce any remedy on account of the violation of such provision, even if such violation shall continue or be repeated subsequently. Any waiver by Landlord or Tenant of any provision of this Lease may only be in writing, and no express waiver shall affect any provision other than the one specified in such waiver and that one only for the time and in the manner specifically stated. No receipt of monies by Landlord from Tenant after the termination of this Lease shall in any way alter the length of the Lease Term or of Tenant&#8217;s right of possession hereunder or after the giving of any notice shall reinstate, continue or extend the Lease Term or affect any notice given Tenant prior to the receipt of such monies, it being agreed that after the service of notice or the commencement of a suit or after final </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-41-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">judgment for possession of the Premises, Landlord may receive and collect any Rent due, and the payment of said Rent shall not waive or affect said notice, suit or judgment.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Landlord&#8217;s Right to Cure Default and Payments by Tenant</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:99pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;All covenants and agreements to be kept or performed by Tenant under this Lease shall be performed by Tenant at Tenant&#8217;s sole cost and expense and without any reduction of Rent. If Tenant shall fail to perform any of its performance obligations under this Lease, within a reasonable time after such performance is required by the terms of this Lease, Landlord may, but shall not be obligated to, after reasonable prior notice to Tenant, make any such payment or perform any such act on Tenant&#8217;s part without waiving its right based upon any default of Tenant and without releasing Tenant from any obligations hereunder.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:99pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Except as may be specifically provided to the contrary in this Lease, Tenant shall pay to Landlord, within fifteen (15) days after delivery by Landlord to Tenant of statements therefor&#58; (x) sums equal to expenditures reasonably made and obligations incurred by Landlord in connection with the remedying by Landlord of Tenant&#8217;s defaults pursuant to the provisions of this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 45(j)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; (y) sums equal to all losses, costs, liabilities, damages and expenses referred to in </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 15</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">34</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of this Lease&#59; and (z) sums equal to all expenditures made and obligations incurred by Landlord in collecting or attempting to collect the Rent that is past due or in enforcing or attempting to enforce any rights of Landlord under this Lease or pursuant to law, including, without limitation, all legal fees and other amounts so expended. Tenant&#8217;s obligations under this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 45(j)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall survive the expiration or sooner termination of the Lease Term.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Terms</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The necessary grammatical changes required to make the provisions hereof apply either to corporations, partnerships, limited liability companies, individuals, men or women, as the case may require, shall in all cases be assumed as though in each case fully expressed.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Relationship of Parties</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Nothing contained in this Lease shall be deemed or construed by the parties hereto or by any third party to create the relationship of principal and agent, partnership, joint venture or any association between Landlord and Tenant, it being expressly understood and agreed that neither the method of computation of Rent nor any act of the parties hereto shall be deemed to create any relationship between Landlord and Tenant other than the relationship of landlord and tenant.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(m)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Application of Payments</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Landlord shall have the right to apply payments received from Tenant pursuant to this Lease, regardless of Tenant&#8217;s designation of such payments, to satisfy any obligations of Tenant hereunder, in such order and amounts as Landlord, in its sole discretion, may elect.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(n)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Building Name and Signage</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to Tenant&#8217;s rights under </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 41</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> above, Landlord shall have the right at any time to change the name of the Project and to install, affix and maintain any and all signs on the exterior of any portion of the Project as Landlord may, in Landlord&#8217;s sole discretion, desire. Tenant shall not use the name of the Building or Project or use pictures or illustrations of the Building or Project in advertising or other publicity, without the prior written consent of Landlord.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(o)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibits</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Exhibits and any other attachments specified in the Basic Lease Information, are attached to and made a part of this Lease and incorporated into this Lease by this reference.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-42-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(p)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Transportation Management</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Tenant shall fully comply with all present or future programs intended to manage parking, transportation or traffic in and around the Project, and in connection therewith, Tenant shall take responsible action for the transportation planning and management of all employees located at the Premises by working directly with Landlord, any governmental transportation management organization or any other transportation-related committees or entities. Such programs may include, without limitation&#58; (i) restrictions on the number of peak-hour vehicle trips generated by Tenant&#59; (ii) increased vehicle occupancy&#59; (iii) implementation of an in-house ridesharing program and an employee transportation coordinator&#59; (iv) working with employees and any Project or area-wide ridesharing program manager&#59; (v) instituting employer-sponsored incentives (financial or in-kind) to encourage employees to rideshare&#59; and (vi) utilizing flexible work shifts for employees. Landlord may obtain or has obtained shuttle or similar transportation services (which may include joining an existing shuttle route) in order to provide transportation between the Project and the Mountain View Caltrain station or other locations as determined by Landlord </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(&#8220;Shuttle Services&#8221;). </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The cost of any such Shuttle Services shall be an Operating Expense pursuant to </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 6</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">7</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereof.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(q)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Parking</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Tenant is entitled, at no additional charge, to the non-exclusive use of the parking facilities, as they exist from time to time and subject Landlord&#8217;s rules and regulations regarding the same, including, initially, the right to use three (3) parking spaces per 1,000 RSF of the Premises. The foregoing shall not be deemed to provide Tenant with an exclusive right to any parking spaces or any guaranty of the availability of any particular parking spaces or any specific number of parking spaces throughout the Term. Tenant shall not, at any time, park or permit to be parked any recreational vehicles, inoperative vehicles or equipment in the Common Areas or on any portion of the Project. Landlord may at its election upon ten (10) days&#8217; written notice to Tenant reasonably designate in a non-discriminatory manner the locations within the Project in which Tenant and Tenant&#8217;s employees and visitors may park. Landlord shall be permitted to install and utilize a valet parking system to satisfy Tenant&#8217;s parking requirements hereunder. Tenant agrees to notify its employees and invitees of the parking provisions contained herein. If Tenant or its employees park any vehicle within the Project in violation of these provisions, then Landlord may, upon prior written notice to Tenant giving Tenant one (1) day to remove such vehicle(s), in addition to any other remedies Landlord may have under this Lease, charge Tenant, as Additional Rental, and Tenant agrees to pay, as Additional Rental, One Hundred Dollars ($100) per day for each day or partial day that each such vehicle is so parked within the Project. Landlord reserves the right to grant easements and access rights to others for use of the parking areas on the Project so long as Tenant&#8217;s parking is not reduced materially below Tenant&#8217;s proportional share of non-exclusive use of the parking facilities as they exist from time to time.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(r)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Outdoor Amenities</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Tenant acknowledges that Landlord may make available at the Project certain furniture, equipment, playgrounds, sport courts and other outdoor amenities </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(&#8220;Outdoor Amenities&#8221;) </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and that Landlord may require any and all persons, including any Tenant Parties, to sign a waiver or release on a form provided by Landlord in connection with the use of such Outdoor Amenities. Tenant shall indemnify and hold the Landlord Parties harmless from and defend Landlord and the other Landlord Parties against any and all Claims incurred in connection with the use of the Outdoor Amenities by Tenant and&#47;or any Tenant Parties.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(s)&#160;&#160;&#160;&#160;&#91;Intentionally Deleted&#93;.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(t)&#160;&#160;&#160;&#160;&#91;Intentionally Deleted&#93;.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(u)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Business Days</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. As used herein, the term </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Business Day&#8221; </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">shall mean a day that is not a Saturday, Sunday or legal holiday in the State of California. In the event that the date for the performance of any covenant or obligation under this Lease shall fall on a Saturday, Sunday or legal </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-43-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">holiday under the laws of the State of California, the date for performance thereof shall be extended to the next Business Day.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Construction</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Tenant acknowledges that Landlord may during the Lease Term renovate, improve, alter, or modify the Building, the Project and&#47;or construct additional buildings and improvements at the Project or any adjacent property whether now or hereafter owned by Landlord or its Affiliate </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(&#8220;Construction Work&#8221;). </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Such Construction Work shall be done at Landlord&#8217;s sole discretion and may include, without limitation, the temporary relocation, restriping, or reconfiguration of the parking areas, the replacement and installation of landscaping and hardscaping, application for building permits and other development approvals, parcelization, lot combination or merger, or lot line adjustment of the Project, as well as any modifications to the exterior of the Building desired by Landlord, including without limitation the replacement of all exterior glass and windows and affixing art, graphics, designs and lighting to the Building exterior. In connection with such Construction Work, Landlord may, among other things, erect scaffolding or other necessary structures outside the Building or elsewhere on the Project, temporarily limiting or eliminating access to portions of the Project, including portions of the Common Areas, or perform work on the Project, which work may create noise in the Premises or leave dust or debris on the Project. Tenant hereby agrees that such Construction Work and Landlord&#8217;s actions in connection with such Construction Work shall in no way constitute a breach of the covenant of quiet enjoyment, a constructive eviction of Tenant nor entitle Tenant to any abatement of Rent except as provided in </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 22(f)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> above. Tenant agrees to execute such reasonable documents and take such actions as reasonably necessary to assist Landlord with such efforts and actions, including without limitation executing any necessary amendments following parcelization, lot combination, merger or lot line adjustment to conform the descriptions of the Project, the Common Areas and the Land to any such parcelization, lot combination, merger or lot line adjustment. Provided that Tenant shall at all times retain access to the Premises, Landlord shall have no responsibility or for any reason be liable to Tenant for any direct or indirect injury to or interference with Tenant&#8217;s business arising from the Construction Work, nor shall Tenant be entitled to any compensation or damages from Landlord for loss of the use of the whole or any part of the Premises or the Project or of Tenant&#8217;s personal property or improvements resulting from the Construction Work or Landlord&#8217;s actions in connection with such Construction Work, or for any inconvenience or annoyance occasioned by such Construction Work or Landlord&#8217;s actions in connection with such Construction Work.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(w)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sustainability</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Tenant acknowledges that Landlord may voluntarily cooperate with the efforts of governmental agencies and&#47;or utility suppliers in reducing energy or other resource consumption within the Project. Tenant shall not be entitled to terminate this Lease or to any reduction in or abatement of rent by reason of such cooperation. Tenant agrees at all times to cooperate fully with Landlord and to abide by all rules established by Landlord (i) in order to maximize the efficient operation of the electrical, heating, ventilating and air conditioning systems and all other energy or other resource consumption systems with the Project and&#47;or (ii) in order to comply with the recommendations of utility suppliers and governmental agencies regulating the consumption of energy and&#47;or other resources. Tenant further acknowledges that Landlord may, at its sole cost and not as an Operating Expense, submit the Building for certification under the Leadership in Energy and Environmental Design </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(&#8220;LEED&#8221;) </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">or other similar rating system and that Landlord may adopt rules and regulations in accordance with such rating system and any applicable laws for operation of the Premises, the Building, and&#47;or the balance of the Project so as to minimize environmental impact and waste, reduce energy and water consumption and carbon footprint, and implement sustainable practices. Such measures may include, without limitation, the installation of energy-efficient glass and windows, electric vehicle charging stations and energy-efficient (i.e., LED) lighting systems. Tenant agrees to cooperate with all such efforts and to assist with Landlord&#8217;s efforts to comply with any such rating system or applicable law. In addition to the foregoing, Landlord </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-44-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">may in its sole discretion require Tenant to sort and separate its waste and debris for recycling in accordance with rules and regulations adopted by Landlord, LEED standards or applicable law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(x)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">OF AC</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Tenant, and all beneficial owners of Tenant, are currently (a) in compliance with and shall at all times during the Lease Term remain in compliance with the regulations of the Office of Foreign Assets Control </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(&#8220;OFAC&#8221;) </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of the U.S. Department of Treasury and any statute, executive order, or regulation relating thereto (collectively, the </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;OFAC Rules&#8221;), </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b) not listed on, and shall not during the term of this Lease be listed on, the Specially Designated Nationals and Blocked Persons List maintained by OFAC and&#47;or on any other similar list maintained by OFAC or other governmental authority pursuant to any authorizing statute, executive order, or regulation, and (c) not a person or entity with whom a U.S. person is prohibited from conducting business under the OFAC Rules.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(y)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Energy Usage Disclosures</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Tenant acknowledges that Landlord has complied with California Public Resource Code &#167; 25402.10 and the disclosure regulations issued in connection therewith (e.g., California Code of Regulations, Title 20,Sections 1680 &#8211; 1684) by, among other things, delivering to Tenant the Disclosure Summary Sheet, Statement of Energy Performance, Data Checklist and Facility Summary (as such terms are defined in California Code of Regulations, Title 20, Section 1681) for the Buildings prior to the date hereof. By Tenant&#8217;s execution of this Lease, Tenant acknowledges Tenant&#8217;s receipt of the Disclosure Summary Sheet, Statement of Energy Performance, Data Checklist and Facility Summary.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(z)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Certified Access Specialist</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Tenant acknowledges that Landlord has not engaged a Certified Access Specialist, as such term is defined in California Civil Code Section 55.52, to inspect the Project.</font></div><div style="margin-bottom:36pt;text-align:justify;text-indent:76.5pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(aa)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Counterparts</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. This Lease may be executed in any number of counterparts, each of which shall be deemed an original, but all of which when taken together will constitute one and the same instrument. The signature page of any counterpart may be detached therefrom without impairing the legal effect of the signature(s) thereon provided such signature page is attached to any other counterpart identical thereto except having additional signature pages executed by other parties to this Lease attached thereto. The parties may deliver their signatures to this Lease by facsimile, electronic mail, or other electronic transmission </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(&#8220;Electronic Signatures&#8221;) </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and agree to accept such digital image of this Lease, as executed, as a true and correct original and admissible as if such signatures were original, executed versions of this Lease. Facsimile or electronic signatures to this Lease shall be binding upon the parties and the parties agree to exchange ink-signed originals within three (3) Business Days after the date of this Lease&#59; provided, however, that the failure to deliver such original signature pages shall not diminish the binding nature of any Electronic Signatures.</font></div><div style="margin-bottom:210pt;text-align:center"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#91;Signatures are on the next page&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-45-</font></div></div></div><div id="if43dbd71aed243f78ce9d8c29bad53ba_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;padding-left:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the parties have executed this Lease as of the date first above written.</font></div><div style="margin-bottom:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:41.506%"><tr><td style="width:1.0%"></td><td style="width:10.096%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.506%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">LANDLORD&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MV CAMPUS OWNER, LLC, <br>a Delaware limited liability company</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; Peter Kaye</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Peter Kaye</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Its&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Authorized Signatory</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">TENANT&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">HEARTFLOW, INC.,<br>a Delaware corporation</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Its&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SIGNATURE PAGE</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the parties have executed this Lease as of the date first above written.</font></div><div style="margin-bottom:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:41.506%"><tr><td style="width:1.0%"></td><td style="width:10.096%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.506%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">LANDLORD&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MV CAMPUS OWNER, LLC, <br>a Delaware limited liability company</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Its&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Authorized Signatory</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">TENANT&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">HEARTFLOW, INC.,<br>a Delaware corporation</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; John Stevens</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">John Stevens</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Its&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CEO</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SIGNATURE PAGE</font></div></div></div><div id="if43dbd71aed243f78ce9d8c29bad53ba_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT A</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LEGAL DESCRIPTION OF THE LAND</font></div><div style="margin-bottom:13pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">THE LAND REFERRED TO HEREIN BELOW IS SITUATED IN THE CITY OF MOUNTAIN VIEW, COUNTY OF SANTA CLARA, STATE OF CALIFORNIA AND IS DESCRIBED AS FOLLOWS&#58;</font></div><div style="text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Parcel 1, as shown on that Parcel Map filed for record in the Office of the Recorder of the County of Santa Clara, State of California on February 26, 1988, in Book 584 of Maps, Page(s) 3 and 4, and as amended by Certificate of Correction recorded August 2, 1988 in Book K626, Page 1148, Official Records.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- 1 -</font></div></div></div><div id="if43dbd71aed243f78ce9d8c29bad53ba_19"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT B-l</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FLOOR PLANS OF PREMISES</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;Attached as the immediately following pages.&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="if43dbd71aed243f78ce9d8c29bad53ba_22"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT B-2</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SITE PLAN OF PROJECT</font></div><div style="margin-bottom:500pt;text-align:center"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;Attached as the immediately following page.&#93;</font></div><div style="margin-bottom:38pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This site plan is intended only to show the general layout of the property or a part thereof. Landlord reserves the right to alter, vary, add to, or omit in whole or in part, any structures, and&#47;or improvements, and&#47;or Common Areas shown on this plan. This plan is not to scale, and all measurements and distances are approximate.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT B-2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- 1 -</font></div></div></div><div id="if43dbd71aed243f78ce9d8c29bad53ba_25"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT C</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WORK LETTER</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Work Letter (the &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Work Letter</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) supplements the Lease (the &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Lease</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">) </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">dated August 9, 2021, by and between MVCC Campus Owner, LLC, a Delaware limited liability company, as landlord (&#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Landlord</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and Heartflow, Inc., a Delaware corporation, as tenant (&#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tenant</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), covering certain premises described in the Lease (the &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Premises</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). All terms not defined in this Work Letter shall have the meanings set forth for them, respectively, in the Lease.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 1.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">BASE BUILDING CONSTRUCTION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Landlord has previously constructed the base, shell, and core (i) of the Premises and (ii) of the floors of the Building on which the Premises are located (collectively, the &#34;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Base, Shell, and Core</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#34;), and Tenant shall accept the Base, Shell and Core in its current &#34;As-Is&#34; condition existing as of the date of the Lease and the Delivery Date, subject to Section 3(a) of the Lease. Landlord shall install in the Premises certain &#34;Tenant Improvements&#34; (as defined below) pursuant to the provisions of this Work Letter. Except for the disbursement of the Tenant Improvement Allowance set forth below, Landlord shall not be obligated to make any other alterations or improvements to the Premises, the Building or the Land.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 2.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">TENANT IMPROVEMENTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.1&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tenant Improvement Allowance</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Tenant shall be entitled to a one-time tenant improvement allowance (the &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tenant Improvement Allowance</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) of up to, but not exceeding, $1,844,880.00 (i.e., $30.00 per RSF in the Premises) for the costs of the design (including, but not limited to, permitting, space planning, working drawings and engineering) and construction of Tenant&#8217;s improvements which are built by Tenant pursuant to this Work Letter and permanently affixed to the Premises (the &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tenant Improvements</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) or as set forth below in this Work Letter. In no event shall Landlord be obligated to make disbursements on account of Tenant Improvements which exceed the Tenant Improvement Allowance. All Tenant Improvements for which the Tenant Improvement Allowance has been made available shall be deemed Landlord&#8217;s property under </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12(c) </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of the Lease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.2&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Disbursement of the Tenant Improvement Allowance</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Except as otherwise set forth in this Work Letter, the Tenant Improvement Allowance shall be disbursed pursuant to </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4,5</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereof for costs paid to the Contractor or others for the design, permitting and completion of construction of the Tenant Improvements and for the following items and costs (collectively, the &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tenant Improvement Allowance Items</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#58; (i) payment of the fees of the &#8220;Architect&#8221; and the &#8220;Engineers&#8221; (defined in </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1 </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">below), and payment of the actual, reasonable fees incurred by, and the costs of documents and materials supplied by, Landlord and Landlord&#8217;s consultants in connection with the review of the &#8220;Drawings&#8221; (defined in </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> below)&#59; (ii) the cost of any changes to the Drawings or Tenant Improvements required by applicable building codes (collectively, the &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Codes</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; (iii) the cost of miscellaneous fees relating to the cost of construction of the Tenant Improvements, including without limitation, permit fees, testing and inspection costs, and trash removal costs&#59; (iv) data and telecom cabling and wiring&#59; (v) project management fees&#59; (vi) IT&#47;AV equipment&#59; (vii) the purchase and installation of furniture, fixtures and equipment&#59; (viii) the cost of fabricating and installing Tenant&#8217;s </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT C</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- 1 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">signage&#59; (ix) Tenant moving costs&#59; and (x) any and all other hard and soft costs related to the construction of the Tenant Improvements to and&#47;or Tenant&#8217;s move into the Premises.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.3&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Application of Tenant Improvement Allowance Against Base Rental</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Tenant shall use commercially reasonable efforts to substantially complete the Tenant Improvements by January 1, 2023. Notwithstanding the foregoing, Tenant shall have the right, exercisable by written notice to Landlord (the &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unused Allowance Exercise Notice</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), to elect to use a portion of the Tenant Improvement Allowance then available, but not in excess $1,475,904.00 (i.e., 80% of the Tenant Improvement Allowance (the &#34;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unused Allowance Amount</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#34;), to receive a credit against future installments of Base Rental first coming due under the Lease on and after January 1, 2023 specified in the Unused Allowance Exercise Notice.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 3.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">DRAWINGS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.1&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Selection of Architect&#47;Drawings</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Tenant shall retain a reputable architect&#47;space planner reasonably approved by Landlord </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(&#8220;Architect&#8221;) </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to prepare the </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Final Space Plan</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">,&#8221; &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Design Development Drawings</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">,&#8221; </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">and &#8220;Final Working Drawings</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">,&#8221; all as defined herein below and collectively referred to as </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Drawings.&#8221; </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Tenant shall retain reputable engineering consultants reasonably designated or selected by Tenant and approved by Landlord (&#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Engineers</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to prepare all plans and engineering working drawings relating to the structural, mechanical, electrical, plumbing, HVAC, life safety, and sprinkler work of the Tenant Improvements. All Drawings shall be subject to Landlord&#8217;s approval, which approval shall not be unreasonably conditioned, withheld or delayed. Tenant and Architect shall not rely on any drawings supplied by Landlord and shall verify, in the field, all relevant dimensions and conditions relating to the base Building and shall be solely responsible for the same. Landlord&#8217;s review of the Drawings as set forth in this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall be for its own purposes and shall not imply Landlord&#8217;s review of the same, or obligate Landlord to review the same, for quality, design, compliance with the Codes or other like matters. Accordingly, notwithstanding that any Drawings are reviewed by Landlord or its space planner, architect, engineers and consultants, and notwithstanding any advice or assistance that may be rendered to Tenant by Landlord or Landlord&#8217;s space planner, architect, engineers, and consultants, Landlord shall have no responsibility or liability whatsoever in connection therewith, including any omissions or errors contained in the Drawings, and Tenant&#8217;s waiver and indemnity set forth in </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 34</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of the Lease shall specifically apply to the Drawings.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.2&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Space Plan. </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Tenant and Architect shall prepare and deliver to Landlord with a request for its approval (in at least ten-point type in all capital letters specifying this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, which approval shall not be unreasonably withheld or delayed, the proposed space plan for the Premises. Notwithstanding the preceding sentence, Landlord may withhold its consent, in its sole discretion, to any element of the proposed space plan which would materially and adversely affect the systems of the Building, including without limitation, the HVAC, plumbing and fire protection systems, the Building&#8217;s equipment, the structural integrity of the Building, and&#47;or the exterior appearance of the Building. Landlord shall notify Tenant of its approval or disapproval (with reasons for such disapproval specified) of the proposed space plan within five (5) Business Days after receipt thereof. If Landlord disapproves the proposed space plan, this process shall be repeated until Landlord&#8217;s approval is obtained (except the 5-Business Day period shall be reduced to three (3) Business Days)&#59; provided, however, that Tenant shall only make such changes to the proposed space plan which address the reasons Landlord specified for its disapproval of the proposed space plan. The approved space plan is hereinafter referred to as the </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Final Space Plan</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#8221; Upon Tenant&#8217;s written request at the time the Final Working Drawings are submitted to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT C</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- 2 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Landlord, Landlord shall, at the time of Landlord&#8217;s approval of the Final Space Plan, designate in writing by written notice to Tenant, which, if any, of the Tenant Improvements will need to be removed at the expiration or termination of the Lease Term.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.3&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Design Development Drawings</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Tenant and Architect shall prepare and deliver to Landlord with a request for its approval (in at least ten-point type in all capital letters specifying this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3)</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, which approval shall not be unreasonably withheld or delayed, the proposed design development drawings, which shall be the formalization of the Final Space Plan and the initial set of drawings. Notwithstanding the preceding sentence, Landlord may withhold its consent, in its sole discretion, to any element of the proposed design development drawings which would materially and adversely affect the systems of the Building, including without limitation, the HVAC, plumbing and fire protection systems, the Building&#8217;s equipment, the structural integrity of the Building, and&#47;or the exterior appearance of the Building. Landlord shall notify Tenant of its approval or disapproval (with reasons for such disapproval specified) of the proposed design development drawings within five (5) Business Days after receipt thereof. If Landlord disapproves the proposed design development drawings, this process shall be repeated until Landlord&#8217;s approval is obtained (except the 5-Business Day period shall be reduced to three (3) Business Days)&#59; provided, however, that Tenant shall only make such changes to the proposed design development drawings which address the reasons Landlord specified for its disapproval of the proposed design development drawings. The approved design development drawings are hereinafter referred to as the </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Final Design Development Drawings.&#8221;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.4&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Working Drawings.</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Following completion of the Final Design Development Drawings, the Architect and the Engineers shall complete and deliver to Landlord with a request for its approval, which approval shall not be unreasonably conditioned, withheld or delayed, the proposed architectural and engineering drawings for the Premises, in a form which is sufficiently complete to allow subcontractors to bid on the work and to obtain all applicable permits. Notwithstanding the preceding sentence, Landlord may withhold its consent, in its sole discretion, to any element of the proposed architectural and engineering drawings for the Premises which would materially and adversely affect the systems of the Building, including without limitation, the HVAC, plumbing and fire protection systems, the Building&#8217;s equipment, the structural integrity of the Building, and&#47;or the exterior appearance of the Building. Landlord shall notify Tenant of its approval or disapproval (with reasons for any disapproval specified) of the proposed working drawings within five (5) Business Days after receipt thereof. If Landlord disapproves the proposed working drawings, this process shall be repeated until Landlord&#8217;s approval is obtained (except the 5-Business Day period shall be reduced to three (3) Business Days), although Tenant need only make such changes to the proposed working drawings which address the reasons Landlord specified for its disapproval of the proposed working drawings. The approved proposed working drawings are hereinafter referred to as the &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Final Working Drawings</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#8221;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.5&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Permits. </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Final Working Drawings shall have been approved by Landlord prior to the commencement of the construction of the Tenant Improvements. Following completion of the Final Working Drawings, Tenant shall submit the Final Working Drawings to the appropriate municipal authorities for all applicable building permits necessary to allow Contractor to commence and fully complete the construction of the Tenant Improvements (the &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Permits</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). No changes, modifications or alterations in the Final Space Plan or the Final Working Drawings may be made by Tenant without the prior written consent of Landlord, which consent shall not be unreasonably conditioned, withheld or delayed&#59; provided that Landlord may withhold its consent, in its sole discretion, to any change in the Final Space Plan or the Final Working Drawings if such change would materially and adversely affect the systems of the Building, including without limitation, the HVAC, plumbing and fire protection systems, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT C</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- 3 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the Building&#8217;s equipment, the structural integrity of the Building, and&#47;or the exterior appearance of the Building.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.6&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Time Deadlines.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Promptly following execution of the Lease, Tenant shall submit to Landlord a proposed construction schedule and customary construction milestones for the Tenant Improvements (&#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Approved Plan</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). Tenant shall use good faith and commercially reasonable efforts to abide by each of the deadlines and milestones contained in such Approved Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Tenant shall use its commercially reasonable, good faith, efforts and all due diligence to cooperate with the Architect, the Engineers, and Landlord to complete all phases of the Drawings and the permitting process and to receive the Permits in accordance with the schedule approved by the parties, and, in that regard, shall meet with Landlord as it reasonably requests to discuss Tenant&#8217;s progress in connection with the same. Landlord agrees to cooperate with Tenant at no cost to Landlord, to the extent necessary to facilitate Tenant&#8217;s permitting process.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.7&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Approval of Drawings. </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Without limiting Landlord's rights in any way, Landlord shall be deemed to have reasonably withheld its approval of any portion of the Drawings which&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;exceeds the capacity of, materially and adversely affects, is incompatible with, or impairs Landlord&#8217;s ability to maintain, operate, alter, modify or improve the Building structure or Building systems and&#47;or Landlord reasonably believes will increase the cost of operating or maintaining the Building structure, Building systems or Project&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;does not conform to applicable laws, building codes, insurance regulations or standards for a fire-resistive office building and&#47;or is not approved by any governmental authority having jurisdiction over the Premises&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;locates any equipment, telecommunications wiring or cabling or Tenant&#8217;s personal property on the roof of the Building (except as specifically agreed to by Landlord), in Common Areas or in Common Area telecommunication or electrical closets&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;affects the exterior appearance of the Building or Common Areas&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;violates any agreement which affects the Project or binds Landlord&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;Landlord reasonably believes will reduce the market value of the Premises or the Project at the end of the Term&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;Landlord reasonably believes will infringe on the architectural integrity of the Building.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 4.</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">CONSTRUCTION OF THE TENANT IMPROVEMENTS</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.1&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contractor</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Tenant shall retain a qualified, reputable general contractor reasonably approved by Landlord (the &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contractor</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). Tenant hereby waives all claims against Landlord, and Landlord shall have no responsibility or liability to Tenant, on account of any non-performance or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT C</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- 4 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">any misconduct of any contractor or any subcontractor thereof. Tenant shall use its commercially reasonable efforts to cause the Tenant Improvements to be completed as promptly as reasonably possible. The Tenant Improvements shall be constructed in a first-class manner in accordance with the Final Working Drawings and in compliance with all applicable Codes in effect as of the date of construction. Landlord shall notify Tenant of its approval or disapproval (with reasons for any disapproval specified) of the Contractor within two (2) Business Days after request thereof.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.2&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tenant&#8217;s Agents</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Tenant shall use reputable subcontractors and engineers for the performance of the Tenant Improvements.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.3&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Landlord Fees and Reimbursements.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.3.1&#160;&#160;&#160;&#160;Tenant shall pay a construction supervision and management fee (the &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Construction Management Fee</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to Landlord in an amount equal to one percent (1%) of the Tenant Improvement Allowance, payable ratably as the Tenant Improvement Allowance is disbursed as provided herein. Tenant shall include such ratable portion of the Construction Management Fee in each request disbursing the Tenant Improvement Allowance.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.3.2&#160;&#160;&#160;&#160;In addition to the Construction Management Fee, Tenant shall reimburse Landlord for any reasonable third-party costs and expenses incurred by Landlord in connection with the Tenant Improvements, including, but not limited to, the costs of any architects or engineers hired by Landlord to review any space plans, schematic drawings, design development drawings and architectural and engineering drawings. Such reimbursements shall, at Landlord&#8217;s election, in its sole and absolute discretion, (a) be paid to Landlord within thirty (30) days of invoice or (b) be credited against the remaining available balance of the Tenant Improvement Allowance</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.4&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Construction of the Tenant Improvements</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Prior to Tenant&#8217;s execution of the construction contract and general conditions between Tenant and its Contractor (the &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contract</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), Tenant shall submit the Contract to Landlord for its approval, which approval shall not be unreasonably withheld or delayed. Landlord shall notify Tenant of its approval or disapproval (with reasons for any disapproval specified) of the Contract within five (5) Business Days after request thereof. Prior to the commencement of the construction of the Tenant Improvements, and after Tenant has accepted all bids for the Tenant Improvements, Tenant shall provide Landlord with a detailed breakdown, by trade, of the final costs to be incurred or which have been incurred, in connection with the design and construction of the Tenant Improvements to be performed by or at the direction of Tenant or the Contractor, which costs form a basis for the amount of the Contract (the &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Construction Budget</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">which for the sake of clarity shall include all hard and soft costs for the Tenant Improvements which are subject to reimbursement from the Tenant Improvement Allowance.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.4.1&#160;&#160;&#160;&#160;Prior to commencing construction of the Tenant Improvements, Tenant shall deliver to Landlord the following&#58;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The actual commencement date of construction and the estimated date of completion of the work, including fixturization&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Evidence of all insurance required hereunder&#59; and</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;An executed copy of the Permits.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.4.2&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Contractor Requirements</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. After receipt of the Permits, Tenant shall cause the Contractor to proceed promptly to commence and complete the Tenant Improvements. The Contractor </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT C</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- 5 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and all subcontractors shall be subject to administrative and other supervision by Landlord in their use of the Building. Tenant shall reimburse Landlord within ten (10) days after demand for the cost of repairing any damage to the Building caused by Tenant, the Contractor or any subcontractor during performance of the Tenant Improvements. The Contractor and all subcontractors shall conduct their work and employ labor in such manner as to maintain harmonious labor relations and as not to interfere with or delay any work of Landlord&#8217;s contractors or other contractors in the Building.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.4.3&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Landlord&#8217;s General Conditions for Tenant&#8217;s Agents and Tenant</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Improvement Work</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The construction of the Tenant Improvements by Tenant and Tenant&#8217;s subcontractors, laborers, materialmen, and suppliers, and the Contractor, Tenant&#8217;s Architect and engineer (collectively, &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tenant&#8217;s Agents</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) shall comply with the following&#58; (i) the Tenant Improvements shall be constructed in strict accordance with the Final Working Drawings and all approved change orders&#59; and (ii) Tenant shall abide by all rules made by Landlord&#8217;s building manager with respect to the use of freight, loading dock and service elevators, storage of materials, trash removal, coordination of work with the contractors of other tenants, and any other matter in connection with this Work Letter, including, without limitation, the construction of the Tenant Improvements.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Changes</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Any changes in the Tenant Improvements from the Final Working Drawings (&#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Changes</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) shall be subject to Landlord&#8217;s prior written approval, which approval shall not be unreasonably conditioned, delayed or withheld. Any deviation in construction from the design specifications and criteria set forth herein or from Tenant&#8217;s plans and specifications as approved by Landlord shall be promptly remedied following notice from Landlord or Landlord&#8217;s contractor or any government representative. Only new and&#47;or properly recycled first-class materials shall be used in the construction of the Tenant Improvements, except with the written consent of Landlord, which consent may be withheld in Landlord&#8217;s reasonable discretion.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Trash Removal</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. During the construction of the Tenant Improvements, removal of trash generated by the work of the Tenant Improvements, or otherwise by Tenant, will be done continually at Tenant&#8217;s cost and expense. No trash, or other debris, or other waste may be deposited at any time outside the Premises. If so, upon prior written notice, Landlord may remove it at Tenant&#8217;s expense, which expense shall equal the cost of removal plus five percent (5%) of such costs as a management fee.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Storage of Tools</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Storage of the Contractor&#8217;s construction materials, tools and equipment shall be confined within the Premises and in areas designated for such purposes by Landlord, and should such materials, tools and equipment be assigned space or spaces outside the Premises they shall be moved to such other space as Landlord shall direct from time to time to avoid interference or delays with other work. In no event shall any debris be stored outside of the Premises.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.4.4&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Requirements of Tenant&#8217;s Agents</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each of Tenant&#8217;s Agents shall guarantee to Tenant and for the benefit of Landlord that the portion of the Tenant Improvements for which it is responsible shall be free from any defects in workmanship and materials for a period of not less than one (1) year from the date of completion thereof. Each of Tenant&#8217;s Agents shall be responsible for the replacement or repair, without additional charge, of all work done or furnished in accordance with its contract that shall become defective within one (1) year after the later to occur of (i) completion of the work performed by such contractor or subcontractors and (ii) the Lease Commencement Date. The correction of such work shall include, without additional charge, all additional expenses and damages incurred in connection with such removal or replacement of all or any part of the Tenant Improvements, and&#47;or repair of the Building and&#47;or Common Areas that may be damaged or disturbed thereby. All such warranties or guarantees as to materials or workmanship of or with respect to the Tenant Improvements </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT C</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- 6 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">shall be contained in the Contract and&#47;or, as applicable, in the subcontracts and shall be written such that such guarantees or warranties shall inure to the benefit of both Landlord and Tenant, as their respective interests may appear, and can be directly enforced by either. Tenant covenants to give to Landlord any non-exclusive assignment or other assurances which may be necessary to affect such right of direct enforcement.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.4.5&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnity</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Tenant shall be solely responsible for the actions or omissions of Tenant, as well as the actions or omissions of the Architect, the Contractor and any Tenant&#8217;s Agent and for any loss, liability, claim, cost, damage or expense suffered by Landlord or any other entity or person as a result of the acts or omissions of, or any delay caused by, such persons or entities arising in connection with the planning or construction of the Tenant Improvements. Landlord&#8217;s approval of the Architect, the Contractor or any Tenant&#8217;s Agent, any work performed by any of them, or any documents prepared by any of them shall not be for the benefit of Tenant or any third party, and Landlord shall have no duty to Tenant or to any third parties for the actions or omissions of the Architect, the Contractor or any Tenant&#8217;s Agent. Tenant shall pass through to Landlord all warranties in connection with the Tenant Improvements. Tenant shall indemnify, defend and hold harmless Landlord against any and all losses, costs, damages, claims and liabilities, including the cost to defend, arising from the actions or omissions of Tenant, the Architect, the Contractor, Tenant&#8217;s Agents or any agents, employees or subcontractors of any of them, or in connection with Tenant&#8217;s non-payment of any amount arising out of the Tenant Improvements and&#47;or Tenant&#8217;s disapproval of all or any portion of any request for payment. Such indemnity by Tenant, as set forth in the Lease, shall also apply with respect to any and all costs, losses, damages, injuries and liabilities related in any way to Landlord&#8217;s performance of any ministerial acts reasonably necessary (i) to permit Tenant to complete the Tenant Improvements, and (ii) to enable Tenant to obtain any building permit or certificate of occupancy for the Premises.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.4.6&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Insurance Requirements</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">General Coverages</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. All of Tenant&#8217;s Agents shall carry worker&#8217;s compensation insurance in accordance with State law, and employers liability insurance with minimum limits of $1,000,000 each accident&#47;$l,000,000-poiicy limit for injury by disease, covering all of their respective employees, and shall also carry commercial general liability insurance, including coverage for bodily injury and property damage, including, without limitation, products and completed operations coverage, and Automobile Liability insurance for owner, hired and non-owned vehicles, all with limits, in form and with companies as are required to be carried by Tenant as set forth in the Lease.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Special Coverages</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Tenant or its Contractor shall carry &#8220;Builder&#8217;s All Risk&#8221; insurance in an amount approved by Landlord covering the construction of the Tenant Improvements, and such other insurance as Landlord may reasonably require, it being understood and agreed that the Tenant Improvements shall be insured by Tenant pursuant to the Lease immediately upon completion thereof. Such insurance shall be in amounts and shall include such additional coverage as may be reasonably required by Landlord. Tenant shall require that all of Tenant&#8217;s Contractor carry commercial general liability insurance, including coverage for Products and Completed Operations with limits of not less than $5,000,000 per occurrence, $5,000,000 in general aggregate, and $5,000,000 products and completed operations aggregated in form and with companies as are required to be carried by Tenant as set forth in the Lease.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">General Terms</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Certificates for all insurance carried pursuant to this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4,4,6</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall be delivered to Landlord before the commencement of construction of the Tenant Improvements and before the Contractor&#8217;s equipment is moved onto the site. All such policies of insurance must contain a provision that the company writing said policy, or its authorized agent, will give </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT C</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- 7 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Landlord thirty (30) days&#8217; prior written notice of any cancellation, material change or any reduction in the amounts of such insurance. In the event that the Tenant Improvements are damaged by any cause duringthe course ofthe construction thereof, Tenant shall immediately repair the same at Tenant&#8217;s sole cost and expense. Tenant&#8217;s Agents shall maintain all of the foregoing insurance coverage in force until the Tenant Improvements are fully completed and accepted by Landlord, except for any Products and Completed Operation Coverage insurance required by Landlord, which is to be maintained for ten (10) years following completion of the work and acceptance by Landlord and Tenant. All policies carried under this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.4.6</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall insure Landlord and Tenant. All policies of property insurance and all Workers&#8217; Compensation, maintained by Tenant or Tenant&#8217;s Agents performing operations on the Premises shall preclude subrogation claims by the insurer against Landlord and any additional parties reasonably designated by Landlord. Such insurance shall provide that it is primary insurance as respects the Landlord and that any other insurance maintained by Landlord. The requirements for the foregoing insurance shall not derogate from the provisions for indemnification of Landlord by Tenant under </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.4.5</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of this Work Letter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.4.7&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Governmental Compliance</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Tenant Improvements shall comply in all respects with the following&#58; (i) the Code and other state, federal, city or quasi-governmental laws, codes, ordinances and regulations, as each may apply according to the rulings of the controlling public official, agent or other person&#59; (ii) applicable standards of the American Insurance Association (formerly, the National Board of Fire Underwriters) and the National Electrical Code&#59; and (iii) building material manufacturers&#8217; specifications.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.4.8&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Inspection by Landlord</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Landlord shall have the right to inspect the Tenant Improvements at all times&#59; provided however, that Landlord&#8217;s failure to inspect the Tenant Improvements shall in no event constitute a waiver of any of Landlord&#8217;s rights hereunder nor shall Landlord&#8217;s inspection of the Tenant Improvements constitute Landlord&#8217;s approval of the same. Should Landlord disapprove any portion of the Tenant Improvements, Landlord shall notify Tenant in writing of such disapproval and shall specify the items disapproved. Any defects or deviations in, and&#47;or disapproval by Landlord of, the Tenant Improvements shall be rectified by Tenant at no expense to Landlord&#59; provided however, that in the event Landlord determines that a defect or deviation exists or disapproves of any matter in connection with any portion of the Tenant Improvements and such defect, deviation or matter might materially and adversely affect the mechanical, electrical, plumbing, heating, ventilating and air conditioning or life-safety systems of the Building, the structure or exterior appearance of the Building or any other tenant&#8217;s use of such other tenant&#8217;s leased premises, Landlord may take such action as Landlord deems necessary, at Tenant&#8217;s expense (and if such cost is not promptly reimbursed by Tenant, Landlord may deduct such cost from the Tenant Improvement Allowance) and without incurring any liability on Landlord&#8217;s part, to correct any such defect, deviation and&#47;or matter, including, without limitation, causing the cessation of performance of the construction of the Tenant Improvements until such time as the defect, deviation and&#47;or matter is corrected to Landlord&#8217;s satisfaction.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.4.9&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Meetings</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Commencing upon the execution of this Lease, Tenant shall hold weekly meetings, at a reasonable time, with the Architect and the Contractor regarding the progress of the preparation of the Drawings and the construction of the Tenant Improvements, which meetings shall be held at a location approved by Landlord, and Landlord and&#47;or its agents shall receive prior notice of, and shall have the right to attend, all such meetings, and, upon Landlord&#8217;s request, certain of Tenant&#8217;s Agents shall attend such meetings. In addition, minutes shall be taken by Tenant and&#47;or Tenant&#8217;s Agents at all such meetings, a copy of which minutes shall be promptly delivered to Landlord. Landlord shall be permitted to discuss proposed Landlord Changes or the status of the Landlord&#8217;s Work at all such meetings.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT C</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- 8 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.4.10&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Notices</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Landlord shall have the right to post in a conspicuous location on the Premises, as well as record with the County of Santa Clara, California, a notice of non-responsibility.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.4.11&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Coordination of Work</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. All work to be performed inside or outside of the Premises shall be reasonably coordinated with Landlord and shall be subject to reasonable scheduling requirements of Landlord, and Tenant shall coordinate all after-hours and weekend work and use of the swing elevator with Landlord.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.4.12&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">As-Built Plans</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Tenant shall, upon completion of the Tenant Improvements, submit to Landlord two (2) complete sets of plans (one (1) reproducible) and specifications (including all working drawings) prepared by the Architect and covering all of the Tenant Improvements, including architectural, electrical, and plumbing, as built, plus one (1) copy of the same in &#8220;CAD&#8221; format.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.5&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Payment of Costs of the Tenant Improvements</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Landlord shall bear and pay the cost of the Tenant Improvements up to the amount of the Tenant Improvement Allowance. Tenant shall bear and pay the cost of the Tenant Improvements in excess of the Tenant Improvement Allowance. If the aggregate of the Construction Budget exceeds the Tenant Improvement Allowance (&#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TI Excess</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), Tenant shall be responsible for payment of such excess (the &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tenant Contribution</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), so that the TI Excess will be paid pro rata and pari passu with any amount of Tenant Improvement Allowance is required to be disbursed. The Tenant Contribution shall be funded by Tenant pro rata and pari passu with the disbursement of any portion of the Tenant Improvement Allowance, and such payments shall be pursuant to the same procedures and requirements as the funding of the Tenant Improvement Allowance. In the event of any Changes or any other revisions, changes, or substitutions shall be made to the Final Working Drawings or the contracts for the construction of the Tenant Improvements which would increase the Construction Budget, any additional costs which arise in connection with such revisions, changes or substitutions or any other additional costs shall be TI Excess and such amounts shall be paid by Tenant as an addition to the Tenant Contribution and such amount shall be disbursed pro rata and pari passu with any further disbursement of the Tenant Improvement Allowance. Subject to the terms hereof, and except for Tenant Improvement Allowance Items that are other than payments to contractors and materialman for the construction of the Tenant Improvements, Landlord shall disburse to Tenant from the Tenant Improvement Allowance the amount set forth on Tenant&#8217;s application for payment, less a ten percent (10%) retention (the aggregate amount of such retentions to be known as the </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Final Retention&#8221;). </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Based upon applications for payment prepared, certified, approved and submitted by Tenant, Landlord shall make its payments from the Tenant Improvement Allowance to Tenant or to the Contractor in accordance with the following provisions&#58;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.5.1&#160;&#160;&#160;&#160;Tenant shall submit applications for payment to Landlord in a form reasonably satisfactory to Landlord, certified as correct by an officer of Tenant and by the Architect, for pro rata payment of that portion of the cost of the Tenant Improvements allocable to labor, materials and equipment incorporated in the Premises which were substantially completed. Each application for payment shall set forth such information and shall be accompanied by such supporting documentation as shall be reasonably requested by Landlord, including the following&#58;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Fully executed conditional lien releases in the form prescribed by law from the Contractor and all subcontractors and suppliers furnishing labor or materials during such period and fully executed unconditional lien releases from all such entities covering any prior payment period.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Contractor&#8217;s worksheets showing percentages of completion.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT C</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- 9 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Contractor&#8217;s certification as follows&#58;</font></div><div style="margin-bottom:11pt;padding-left:72pt;padding-right:126pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;There are no known filed mechanics&#8217; or materialmen&#8217;s liens outstanding at the date of this application for payment, all due and payable bills with respect to the Tenant Improvements have been paid to date or shall be paid from the proceeds of this application for payment, and there is no known basis for the filing of any mechanics&#8217; or materialmen&#8217;s liens against the Premises or the Project, and, to the best of our knowledge, waivers from all subcontractors and materialmen are valid and constitute an effective waiver of lien under applicable law to the extent of payments that have been made or shall be made concurrently herewith.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Calculation of the number of RSF in the Premises which were substantially completed for which a payment of the Tenant Improvement Allowance has been requested.Any other materials reasonably requested by Landlord evidencing the work completed, permitting and licensing matters, compliance with Laws, and&#47;or previous progress payments.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.5.2&#160;&#160;&#160;&#160;On or before the 30th day following submission of the application for payment, Landlord shall make payment to Tenant (so long as Tenant is not in default hereunder or under the Lease) of the amount due from Landlord as determined in accordance with this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.5</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Landlord has no obligation to make any payments to material suppliers or subcontractors or to determine whether amounts due them from the Contractor in connection with the Tenant Improvements have, in fact, been paid.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.5.3&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary in this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.5, </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and except for Tenant&#8217;s right to use the Unused Allowance Amount as a credit against future installments of Base Rental pursuant to Section 2.3 above, the Tenant Improvement Allowance shall be available for disbursement pursuant to the terms hereof only for the first eighteen (18) months after the Lease Commencement Date. Accordingly, if any portion of the Tenant Improvement Allowance (other than the Unused Allowance Amount) is not requested by Tenant for disbursement prior to the date that is eighteen (18) months from the Lease Commencement Date (other than by reason of Landlord&#8217;s breach of its disbursement obligations hereunder), such unused portion shall be forfeited by Tenant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.6&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notice of Completion&#59; Copy of Record Set of Plans</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Within ten (10) days after completion of construction of the Tenant Improvements Tenant shall cause a Notice of Completion to be recorded in the office of the Recorder of the County of Santa Clara in accordance with Section 3093 of the Civil Code of the State of California or any successor statute and shall furnish a copy thereof to Landlord upon such recordation. If Tenant fails to do so, Landlord may execute and file the same on behalf of Tenant as Tenant&#8217;s agent for such purpose, at Tenant&#8217;s sole cost and expense. At the conclusion of construction, Tenant shall (i) cause Tenant&#8217;s Architect and the Contractor to certify to the best of their knowledge that the &#8220;record-set&#8221; of reproducible as-built drawings (and the CAD files of the as-built documents for the Tenant Improvements) delivered to Landlord pursuant to </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.4.12</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> are true and correct, which certification shall survive the expiration or termination of the Lease, and (ii) deliver to Landlord a copy of all warranties, guaranties, and operating manuals and information relating to the improvements, equipment, and systems installed by Tenant or Contractor in the Premises.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT C</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- 10 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.7&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Evidence of Completion</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Within thirty (30) days following final completion of the entire Tenant Improvements, Tenant shall submit to Landlord&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.7.1&#160;&#160;&#160;&#160;A statement of Tenant&#8217;s final construction costs, together with receipted evidence showing payment thereof, reasonably satisfactory to Landlord, and, to the extent not previously delivered, fully executed and acknowledged unconditional lien releases in the form prescribed by law from the Contractor and all subcontractors and suppliers, and copies of all invoices from the Contractor and all subcontractors and suppliers related to the Tenant Improvements.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.7.2&#160;&#160;&#160;&#160;All evidence reasonably available from governmental authorities showing compliance with any and all other Laws, orders and regulations of any and all governmental authorities having jurisdiction over the Premises, including, without limitation, a certificate of occupancy, building permit sign-offs, and&#47;or other appropriate authorization for physical occupancy of the Premises.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.7.3&#160;&#160;&#160;&#160;A certificate executed by the Architect confirming that the Tenant Improvements have been substantially completed in accordance with the Final Working Drawings.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.7.4&#160;&#160;&#160;&#160;A written certificate from the Contractor as follows&#58;</font></div><div style="margin-bottom:11pt;padding-left:72pt;padding-right:97.2pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There are no known mechanics&#8217; or materialmen&#8217;s liens outstanding, all due and payable bills with respect to the Tenant Improvements have been paid, and there is no known basis for the filing of any mechanics&#8217; or materialmen&#8217;s liens against the Premises or the Project, and, to the best of our knowledge, waivers from all subcontractors and materialmen are valid and constitute an effective waiver of lien under applicable law.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:108pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.7.5&#160;&#160;&#160;&#160;The as-built plans and specifications referred to above.</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A check for the Final Retention payable jointly to Tenant and Contractor, or directly to Contractor at Landlord's sole discretion, shall be delivered by Landlord to Tenant within forty-five (45) days following the completion of the requirements of this </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.7.5</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.8&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Assignment of Rights Against Architect and Contractor</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Upon the expiration or earlier termination of the Lease, Tenant shall assign to Landlord, upon request of Landlord, any and all rights Tenant may have against the Architect and Contractor relating to the Tenant Improvements, without in any way obligating Landlord to pursue or prosecute such rights.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.9&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Compliance with Civil Code Section 8700</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If the design and construction of the Tenant Improvements requires that Landlord or Tenant comply with California Civil Code Section 8700, it shall be Tenant&#8217;s obligation to comply&#59; and Tenant agrees to comply with said Section in a timely manner and to provide to Landlord, upon request, evidence satisfactory to Landlord of such compliance.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 5.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">MISCELLANEOUS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.1&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tenant&#8217;s Representative. </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Tenant has designated JOOST DE SCHUTTER as its sole representative with respect to the matters set forth in this Work Letter, who, until further notice from </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT C</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- 11 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Tenant to Landlord, shall have full authority and responsibility to act on behalf of the Tenant as required in this Work Letter until further notice from Tenant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.2&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Landlord&#8217;s Representative</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Landlord has designated ALLIE SANCHEZ as its sole representative with respect to the matters set forth in this Work Letter, who, until further notice to Tenant, shall have full authority and responsibility to act on behalf of the Landlord as required in this Work Letter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.3&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Time of the Essence</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Time is of the essence in this Work Letter. Unless otherwise indicated, all references herein to a &#8220;number of days&#8221; shall mean and refer to calendar days. In all instances where Tenant is required to approve or deliver an item, if no written notice of approval is given or the item is not delivered within the stated time period, then at Landlord&#8217;s sole option at the end of such period the item shall automatically be deemed approved or delivered by Tenant and the next succeeding time period shall commence.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.4&#160;&#160;&#160;&#160;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tenant&#8217;s Lease Default</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Notwithstanding any provision to the contrary contained in the Lease, if a Default occurs under the Lease, or a default by Tenant beyond any applicable notice and cure periods under this Work Letter, has occurred at any time on or before the completion of the Tenant Improvements, then in addition to all other rights and remedies granted to Landlord pursuant to the Lease, Landlord shall have the right to withhold payment of all or any portion of the Tenant Improvement Allowance and&#47;or Landlord may cause Contractor to cease the construction of the Premises.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT C</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- 12 -</font></div></div></div><div id="if43dbd71aed243f78ce9d8c29bad53ba_28"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT D</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RULES AND REGULATIONS</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;Except as otherwise provided in the Lease, no sign, picture, advertisement or notice visible from the exterior of the Premises shall be installed, affixed, inscribed, painted or otherwise displayed by Tenant on any part of the Premises or the Building unless the same is first approved by Landlord. Any such sign, picture, advertisement or notice approved by Landlord shall be painted or installed for Tenant at Tenant&#8217;s cost by Landlord or by a party approved by Landlord.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Tenant agrees that its use of electrical current shall never exceed the capacity (as represented by Landlord in the Lease) of existing feeders, risers or wiring installation.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;The Premises shall not be used for storage of merchandise held for sale to the general public, unless otherwise permitted in writing by Landlord. Tenant shall not do or permit to be done in or about the Premises or Project anything which shall increase the rate of insurance on the Project or unreasonably obstruct or interfere, including no canvassing or soliciting, with the rights of other tenants in the Project. The Premises shall not be used for sleeping or lodging. No cooking or related activities (except for food and beverage warming) shall be done or permitted by Tenant in the Premises except with permission of Landlord. Tenant will be permitted to use for its own employees within the Premises small micro wave ovens and Underwriters&#8217; Laboratory approved equipment for brewing coffee, tea, hot chocolate and similar beverages, provided that such use is in accordance with all applicable federal, state, county and city laws, codes, ordinances, rules and regulations, and provided that such use shall not result in the emission of odors from the Premises into the Common Area. No vending machines of any kind will be installed, permitted or used on any part of the Premises without the prior consent of Landlord, which shall not be unreasonably withheld. No part of said Building or Premises shall be used for gambling or immoral or other unlawful purposes. No intoxicating beverage shall be sold in said Building or Premises without prior written consent of the Landlord.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;No birds or animals of any kind shall be brought into the Building (other than trained assist dogs required to be used by the visually impaired). No motorcycles or other motorized vehicles shall be brought into the Building.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The sidewalks, entrances, passages, corridors, halls, elevators, and stairways in the Building shall not be obstructed by Tenant or used for any purposes other than those for which same were intended as ingress and egress. No windows, floors or skylights that reflect or admit light into the Building shall be covered or obstructed by Tenant. Toilets, wash basins and sinks shall not be used for any purpose other than those for which they were constructed, and no sweeping, rubbish, or other obstructing or improper substances shall be thrown therein. Any damage resulting to them, or to heating apparatus, from misuse by Tenant or its employees, shall be borne by Tenant.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.&#160;&#160;&#160;&#160;Following Tenant&#8217;s submission of a space plan, Landlord shall have the right to prescribe the weight, position and manner of installation of heavy articles such as safes, vaults, fireproof file cabinets, machines and other equipment brought into the Building. Landlord may elect to retain an independent structural consultant to review the installation of heavy articles such as safes, fireproof file cabinets, machines and other equipment. Tenant shall reimburse Landlord for all costs associated with such structural review. Landlord will not be responsible for loss of or damage to any such safe or property in any case. Tenant shall not allow the building structure within the Premises (nor shall Tenant cause the elevators of the Building) to be loaded beyond rated capacities. All damage done to any part of the Building, its contents, occupants or visitors by moving or maintaining any such safe or other property </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT D</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- 1 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">shall be the sole responsibility of Tenant and any expense of such damage or injury shall be borne by Tenant. No hand trucks shall be used in passenger elevators. All hand trucks used by Tenant or its service providers for the delivery or receipt of any freight shall be equipped with rubber tires.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.&#160;&#160;&#160;&#160;Tenant shall not cause or permit any gases, liquids or odors to be produced upon or permeate from the Premises, and no flammable, combustible or explosive fluid, chemical or substance shall be brought into the Building, except as provided in </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 39 </font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of the Lease. Smoking shall not be permitted in any Common Areas of the Building or the Project or in any premises within the Building.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.&#160;&#160;&#160;&#160;Tenant, its employees and its agents must be sure that the doors to the Premises are securely closed and locked when leaving the Premises. In case of invasion, mob, riot, public excitement, or other commotion, Landlord reserves the right to prevent access to the Building and&#47;or the Project during the continuance of same by any means it deems appropriate for the safety and protection of life and property.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.&#160;&#160;&#160;&#160;Landlord shall not be responsible for any loss, theft, of or damage to, any property, however occurring and Tenant shall assume all responsibility for protecting the Premises from theft, robbery and pilferage, which includes keeping doors locked and other means of entry to the Premises closed, when the Premises are not occupied. Tenant shall employ contractors for janitorial and cleaning in the Premises, at its sole cost and expense.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.&#160;&#160;&#160;&#160;All glass, locks and trimmings in or upon the doors and windows of the Premises shall be kept whole and in good repair. Tenant shall not injure, overload or deface the Building, the woodwork or the walls of the Premises, nor permit upon the Premises any conduct that other tenants of the Project would reasonably find noisome, noxious, noisy or offensive.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Tenant and its employees and invitees shall observe and obey all parking and traffic regulations as imposed by Landlord. All vehicles shall be parked only in areas designated therefor by Landlord.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Canvassing, peddling, soliciting and distribution of handbills or any other written materials in the Building is prohibited, and Tenant shall cooperate to prevent the same.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Tenant agrees to participate in the waste recycling programs implemented by Landlord for the Building, including any programs and procedures for recycling writing paper, computer paper, shipping paper, boxes, newspapers and magazines and aluminum cans. If Landlord elects to provide collection receptacles for recyclable paper and&#47;or recyclable aluminum cans in the Premises, Tenant shall designate an appropriate place within the Premises for placement thereof, and Tenant shall encourage its employees to place their recyclable papers and&#47;or cans into the applicable such receptacles on a daily basis.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any special work or services requested by Tenant&#8217;s authorized representative to be provided by Landlord shall be provided by Landlord only upon written request received at the Project management office. Building personnel shall not perform any work or provide any services outside of their regular duties unless special instructions have been issued from Landlord or its managing agent.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Landlord may waive any one or more of these Rules and Regulations for the benefit of any particular tenant, but no such waiver by Landlord shall be construed as a waiver of such Rules and Regulations in favor of any other tenant, nor prevent Landlord from thereafter enforcing any such Rules and Regulations against any or all of the other tenants of the Project. The Rules and Regulations shall not be administered in a manner that discriminates against Tenant.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT D</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- 2 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Landlord reserves the right to make such other and reasonable Rules and Regulations as in its judgment may from time to time be needed for the safety, care and cleanliness of the Project, and for the preservation of good order therein, as well as for the convenience of other occupants and tenants therein. Landlord shall not be responsible to Tenant or to any other person for the nonobservance of the Rules and Regulations by another tenant or other person. Tenant shall be deemed to have read these Rules and Regulations and to have agreed to abide by them.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Landlord shall have the right to control and operate the public portions of the Project, the public facilities, and any other facilities furnished for the common use of tenants, in such manner as is customary for comparable buildings in the vicinity of the Building.</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The toilet rooms, urinals, wash bowls and other apparatus shall not be used for any purpose other than that for which they were constructed, and no foreign substance of any kind whatsoever shall be thrown therein. The expense of any breakage, stoppage or damage resulting from the violation of this rule shall be borne by the tenant who, or whose employees or agents, shall have caused it.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17.&#160;&#160;&#160;&#160;Tenant shall not overload the floor of the Premises, nor mark, drive nails or screws, or drill into the partitions, woodwork or plaster or in any way deface the Premises or any part thereof without Landlord&#8217;s consent, which shall not be unreasonably withheld.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">18.&#160;&#160;&#160;&#160;Landlord reserves the right to exclude or expel from the Building and&#47;or Project any person who, in the judgment of Landlord, is intoxicated or under the influence of liquor or drugs, or who shall in any manner do any act in violation of any of these Rules and Regulations.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19.&#160;&#160;&#160;&#160;Tenant shall not waste electricity, water or air conditioning and agrees to cooperate reasonably with Landlord to ensure the most effective operation of the Building&#8217;s heating and air conditioning system.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20.&#160;&#160;&#160;&#160;Tenant shall store all its trash and garbage within the interior of the Premises. No material shall be placed in the trash boxes or receptacles if such material is of such nature that it may not be disposed of in the ordinary and customary manner of removing and disposing of trash and garbage in the city in which the Building are located without violation of any law or ordinance governing such disposal. All trash, garbage and refuse disposal shall be made only through entry-ways and elevators provided for such purposes at such times as Landlord shall designate.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21.&#160;&#160;&#160;&#160;Tenant shall comply with all safety, fire protection and evacuation procedures and regulations established by Landlord or any governmental agency.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">22.&#160;&#160;&#160;&#160;The washing and&#47;or detailing of automobiles and performing general work on automobiles shall not be allowed on the Project.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">23.&#160;&#160;&#160;&#160;Food vendors shall be allowed in the Building. Under no circumstance shall the food vendor display their products in a public or Common Area including corridors and elevator lobbies.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">24.&#160;&#160;&#160;&#160;Tenant must comply with requests by the Landlord to inform Tenant&#8217;s employees of items of importance to the Landlord.</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#91;remainder of page intentionally left blank&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT D</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- 3 -</font></div></div></div><div id="if43dbd71aed243f78ce9d8c29bad53ba_31"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT E</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">FORM OF TENANT ESTOPPEL CERTIFICATE</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The undersigned, as Tenant under that certain Lease (the &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Lease</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) made and entered into as of August 9, 2021, by and between MVCC Campus Owner, LLC, a Delaware limited liability company, as Landlord, and the undersigned as Tenant, for Premises located at _______________, __________ hereby certifies as follows&#58;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;Attached hereto as Exhibit A is a true and correct copy of the Lease and all amendments and modifications thereto. The documents contained in Exhibit A represent the entire agreement between the parties as to the Premises.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;The undersigned has commenced occupancy of the Premises described in the Lease, currently occupies the Premises, and the Lease Term commenced on ____________.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;The Lease is in full force and effect and has not been modified, supplemented or amended in any way except as provided in Exhibit A.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;Tenant has not transferred, assigned, or sublet any portion of the Premises nor entered into any license or concession agreements with respect thereto except as follows&#58;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;No modification to the documents contained in Exhibit A, or prepayment of any amounts owing under the Lease to Landlord in excess of thirty (30) days, shall be binding on Landlord&#8217;s mortgagee, without its written consent.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.&#160;&#160;&#160;&#160;Base Rental became payable on _________________.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.&#160;&#160;&#160;&#160;The Lease Term expires on _____________________subject to the following options to extend&#58; _______________________.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.&#160;&#160;&#160;&#160;To Tenant&#8217;s knowledge, all conditions of the Lease to be performed by Landlord necessary to the enforceability of the Lease have been satisfied and Landlord is not in default thereunder, except as follows&#58; ______________________________________________.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.&#160;&#160;&#160;&#160;No rental has been paid more than thirty (30) days in advance and no security has been deposited with Landlord except as provided in the Lease, except as follows&#58;</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">____________________________________________________________________________________.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.&#160;&#160;&#160;&#160;As of the date hereof, to the undersigned&#8217;s knowledge, there are no existing defenses or offsets that the undersigned has which preclude enforcement of the Lease by Landlord.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.&#160;&#160;&#160;&#160;All monthly installments of Base Rental, all Additional Rental and all monthly installments of estimated Additional Rental have been paid when due through __________________. The current monthly installment of Base Rental is $________________.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12.&#160;&#160;&#160;&#160;Landlord has performed all construction obligations required by the Lease and related to the Premises or the Building in accordance with the terms of the Lease and within the time periods set forth in the Lease. Landlord has paid in full any required contributions toward work to be performed by Tenant under the Lease, if any.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT E</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- 1 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.&#160;&#160;&#160;&#160;The undersigned acknowledges that this Estoppel Certificate may be delivered to Landlord&#8217;s existing or prospective mortgagee, or a prospective purchaser, and acknowledges that it recognizes that if same is done, said mortgagee, or prospective purchaser will be relying upon the statements contained herein.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.&#160;&#160;&#160;&#160;If Tenant is a corporation, limited liability company, or partnership, each individual executing this Estoppel Certificate on behalf of Tenant hereby represents and warrants that Tenant is a duly formed and existing entity qualified to do business in the State of California and that Tenant has full right and authority to execute and deliver this Estoppel Certificate and that each person signing on behalf of Tenant is authorized to do so.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Executed at ______________________ on the ________ day of ________________&#160;&#160;______.</font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.153%"><tr><td style="width:1.0%"></td><td style="width:3.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.719%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.304%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;TENANT&#8221;&#58;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Its&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Its&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT E</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- 2 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;INSERT IF APPLICABLE&#93;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CERTIFICATION OF TENANT&#8217;S GUARANTOR</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The undersigned hereby certifies as follows&#58; (i) the statements of Tenant set forth in this Tenant Estoppel Certificate are true and correct, (ii) that certain Guaranty dated as of ____________, 20___ made by the undersigned in favor of Landlord (the &#8220;</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Guaranty</font><font style="color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is in full force and effect&#59; (iii) a true, correct and complete copy of the Guaranty is attached hereto as Exhibit B&#59; (iv) the Guaranty has not been amended, modified, supplemented or assigned&#59; (v) the undersigned claims no defense as to its obligations under the Guaranty&#59; and (vi) there has not been filed by or against the undersigned a petition in bankruptcy, voluntary or otherwise, any assignment for the benefit of creditors, any petition seeking reorganization or arrangement under the bankruptcy laws of the United States or any state thereof, or any other action brought pursuant to such bankruptcy laws with respect to the undersigned. The undersigned acknowledges that this Certification of Tenant&#8217;s Guarantor may be delivered to Landlord&#8217;s existing or prospective mortgagee, or a prospective purchaser, and acknowledges that it recognizes that if same is done, said mortgagee, or prospective purchaser will be relying upon the statements contained herein.</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.480%"><tr><td style="width:1.0%"></td><td style="width:8.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.931%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;_______________________&#93;,</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a &#91;______________________&#93;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Its&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT E</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- 3 -</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>7
<FILENAME>filename7.htm
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ia98052918b654a0dae4726bfd22e4abd_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.5</font></div><div style="text-align:right;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Execution Version</font></div></div><div style="margin-bottom:70pt;text-align:center"><font><br></font></div><div style="margin-bottom:40pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:48pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CREDIT AGREEMENT AND GUARANTY</font></div><div style="margin-bottom:35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">dated as of June 14, 2024</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">by and among</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">HEARTFLOW, INC.,</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as Borrower,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">HEARTFLOW HOLDING, INC.,</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as Holdings,</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">THE LENDERS PARTY HERETO,</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">HAYFIN SERVICES LLP,</font></div><div style="margin-bottom:40pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as the Agent for the Lenders</font></div><div style="margin-bottom:40pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia98052918b654a0dae4726bfd22e4abd_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</font></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE I DEFINITIONS AND ACCOUNTING TERMS </font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 1.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Defined Terms </font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 1.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Interpretation.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 1.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accounting and Financial Determinations.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 1.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Divisions.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 1.5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rates.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE II THE LOANS </font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 2.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Commitments.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 2.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Borrowing Procedures.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 2.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Funding.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE III REPAYMENTS, PREPAYMENTS, INTEREST AND FEES </font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 3.1 </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Applicable Currency for Repayments and Prepayments&#59; Pro Rata Application </font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 3.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Repayments and Prepayments.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 3.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Application.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 3.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Interest Rate.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 3.5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Default Rate.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 3.6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Payment Dates.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 3.7</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Fees.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 3.8</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Specified Repayment Fees.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 3.9</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Reserved&#93;.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 3.10</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PIK Interest.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 3.11</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Interest Computation.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 3.12</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term SOFR Conforming Changes</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE IV SOFR AND OTHER PROVISIONS </font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 4.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Increased Costs.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 4.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Compensation for Losses.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">32</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 4.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Taxes.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">33</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 4.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Payments, Computations&#59; Proceeds of Collateral, Etc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">36</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 4.5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Setoff.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">36</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-i-</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 4.6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Inability to Determine Rates.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">36</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 4.7</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sharing of Payments.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">37</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 4.8</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Mitigation.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">38</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 4.9</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Illegality.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">38</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 4.10</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Benchmark Replacement Setting.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">38</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE V CONDITIONS PRECEDENT </font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">39</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 5.1 </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Conditions to the Borrowing of the Loans on the Closing Date.</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">39</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE VI REPRESENTATIONS AND WARRANTIES </font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">43</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 6.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Organization, Etc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">43</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 6.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Due Authorization, Non-Contravention, Etc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">44</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 6.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Government Approval, Regulation, Etc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">44</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 6.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Validity, Etc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">44</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 6.5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Financial Information</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">44</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 6.6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No Material Adverse Change</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">44</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 6.7</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Litigation, Labor Matters and Environmental Matters.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">44</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 6.8</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subsidiaries.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">45</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 6.9</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Ownership of Properties.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">45</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 6.10</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Taxes.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">45</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 6.11</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Pension Plans, Etc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">45</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 6.12</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accuracy of Information.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">46</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 6.13</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Regulations U and X.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">46</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 6.14</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Solvency.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">46</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 6.15</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Intellectual Property.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">46</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 6.16</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Data Privacy.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">47</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 6.17</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Material Agreements.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">48</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 6.18</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Permits </font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">48</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 6.19</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Regulatory Matters</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">48</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 6.20</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Transactions with Affiliates.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">50</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 6.21</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Investment Company Act.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">50</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 6.22</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">OFAC.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">50</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 6.23</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Anti-Corruption</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">50</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 6.24</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Deposit and Disbursement Accounts.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">50</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-ii-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 6.25</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Registration Rights</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">51</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 6.26</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Royalty and Other Payments.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">51</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 6.27</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sale and Leaseback.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">51</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 6.28</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Senior Secured Obligations</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">51</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 6.29</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Beneficial Ownership Certification.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">51</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE VII AFFIRMATIVE COVENANTS </font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">51</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 7.1 </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Financial Information, Reports, Notices, Etc</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">51</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 7.2 </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Maintenance of Existence&#59; Compliance with Contracts, Laws, Etc</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">53</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 7.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Maintenance of Properties.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">53</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 7.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Insurance.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">53</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 7.5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Books and Records.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">54</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 7.6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Environmental Law Covenant.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">54</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 7.7</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Use of Proceeds</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">54</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 7.8</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Future Guarantors, Security, Etc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">54</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 7.9</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Obtaining of Permits, Etc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">56</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 7.10</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Product Licenses.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">56</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 7.11</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Maintenance of Regulatory Authorizations, Contracts, Intellectual Property, Etc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">57</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 7.12</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Cash Management.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">57</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE VIII NEGATIVE COVENANTS </font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">58</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 8.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Business Activities.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">58</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 8.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Indebtedness.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">58</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 8.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Liens.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">59</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 8.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Financial Covenants.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">60</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 8.5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Investments.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">62</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 8.6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Restricted Payments, Etc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">62</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 8.7</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Issuance of Capital Securities.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">63</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 8.8</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Consolidation, Merger, Etc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">63</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 8.9</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Permitted Dispositions.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">63</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 8.10</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Modification of Certain Agreements.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">63</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 8.11</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Transactions with Affiliates.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">63</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 8.12</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Restrictive Agreements, Etc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">64</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-iii-</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 8.13</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sale and Leaseback.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">64</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 8.14</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Product Sales.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">64</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 8.15</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Change in Name, Location, Executive Office, or Executive Management&#59; Change in Fiscal Year.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">64</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 8.16</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Negative Pledge.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">64</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 8.17</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sanctions.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">65</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 8.18</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Passive Holding Company.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">65</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 8.19</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">USRPHC Status.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">65</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 8.20</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Hazardous Materials.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">65</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 8.21</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Licenses</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">65</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 8.22</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subordinated Indebtedness.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">66</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE IX EVENTS OF DEFAULT</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">66</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 9.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Listing of Events of Default.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">66</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 9.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Action if Bankruptcy</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">70</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 9.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Action if Other Event of Default.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">70</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE X ADMINISTRATIVE AGENT </font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">70</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 10.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Appointment.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">70</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 10.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rights as a Lender.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">70</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 10.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exculpatory Provisions.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">70</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 10.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Reliance by Agent.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">71</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 10.5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Delegation of Duties.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">71</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 10.6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Resignation of Agent.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">72</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 10.7</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Non-Reliance on Agent and Other Lenders.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">72</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 10.8</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Agent May File Proofs of Claim.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">72</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 10.9</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Collateral and Guaranty Matters.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">73</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE XI MISCELLANEOUS PROVISIONS </font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">74</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 11.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Waivers, Amendments, Etc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">74</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 11.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notices&#59; Time.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">74</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 11.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Payment of Costs and Expenses.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">74</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 11.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Indemnification.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">75</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 11.5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Survival.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">76</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 11.6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Obligations Several.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">76</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 11.7</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Severability.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">76</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-iv-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 11.8 </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Headings.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">76</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 11.9 </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Execution, Effectiveness, Etc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">76</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 11.10 </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Governing Law&#59; Entire Agreement.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">77</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 11.11 </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Register&#59; Successors and Assigns.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">77</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 11.12 </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Other Transactions.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">78</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 11.13 </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Forum Selection and Consent to Jurisdiction.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">78</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 11.14</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Waiver of Jury Trial.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">79</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 11.15</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Interest Rate Limitation.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">79</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 11.16 </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Acknowledgment and Consent to Bail-In of Affected Financial Institutions.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">79</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 11.17</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Judgment Currency.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">80</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 11.18</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Specified Repayment Fee.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">80</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 11.19</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">USA PATRIOT Act.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">80</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 11.20</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Erroneous Payments</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">80</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 11.21</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Reaffirmation.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">81</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE XII GUARANTEE</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">81</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 12.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Guarantee.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">81</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 12.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Obligations Unconditional.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">81</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 12.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Reinstatement.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">82</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 12.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subrogation.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">82</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 12.5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Remedies.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">82</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 12.6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Instrument for the Payment of Money.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">83</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 12.7</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Continuing Guarantee.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">83</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 12.8</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">General Limitation on Guarantee Obligations.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">83</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-v-</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.971%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">SCHEDULES&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Schedule 1.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Key Permits</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Schedule 1.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Specified Holders</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Schedule 2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Loans</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Schedule 2.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Funds Flow Schedule</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Schedule 6.7(a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Litigation</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Schedule 6.8</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Existing Subsidiaries</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Schedule 6.10</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Taxes</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Schedule 6.11</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Pension Plans</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Schedule 6.15(a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Intellectual Property</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Schedule 6.15(c)(i)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Third Party Infringements</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Schedule 6.17</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Material Agreements</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Schedule 6.19(a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Regulatory Authorizations</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Schedule 6.19(d), (f) and (g)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Regulatory Actions</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Schedule 6.20</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Transactions with Affiliates</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Schedule 6.24</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Deposit and Disbursement Accounts</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Schedule 6.25</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Registration Rights Agreements</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Schedule 6.26</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Royalties</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Schedule 8.2(c)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Existing Indebtedness</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Schedule 8.3(b)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Existing Liens</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Schedule 8.5(a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Investments</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Schedule 8.12</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Existing Contracts</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Schedule 11.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notice Information</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.747%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXHIBITS&#58;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit A</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Form of Compliance Certificate</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit B</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Form of Loan Request</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit C</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Form of Perfection Certificate</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit D</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Form of Assignment and Assumption</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit E-1</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Form of U.S. Tax Compliance Certificate (For Foreign Lenders</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">That Are Not Partnerships For U.S. Federal Income Tax Purposes)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit E-2</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Form of U.S. Tax Compliance Certificate (For Foreign Participants <br>That Are Not Partnerships For U.S. Federal Income Tax Purposes)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit E-3</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Form of U.S. Tax Compliance Certificate (For Foreign Participants</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">That Are Partnerships For U.S. Federal Income Tax Purposes)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit E-4</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Form of U.S. Tax Compliance Certificate (For Foreign Lenders <br>That Are Partnerships For U.S. Federal Income Tax Purposes)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit F</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Form of Intercompany Subordination Agreement</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit G</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">AWS Agreement</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-vi-</font></div></div></div><div id="ia98052918b654a0dae4726bfd22e4abd_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CREDIT AGREEMENT AND GUARANTY</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CREDIT AGREEMENT AND GUARANTY dated as of June 14, 2024 (as amended, supplemented or otherwise modified from time to time, this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), is by and among HEARTFLOW, INC., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), HEARTFLOW HOLDING, INC., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Holdings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), certain Subsidiaries of Holdings (as defined herein) from time to party hereto, the lenders from time to time party hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and HAYFIN SERVICES LLP, as administrative agent for the Lenders hereunder (in such capacity, together with its successors and assigns in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, the Borrower, certain Subsidiaries of Holdings from time to time party thereto, the lenders from time to time party thereto and Hayfin Services LLP, as agent, are parties to that certain Credit Agreement and Guaranty, dated as of January 19, 2021 (as amended by that certain Joinder Agreement, dated as March 3, 2021, by that certain Amendment No. 1 to Credit Agreement and Guaranty, dated as of March 17, 2022, by that certain Amendment No. 2 to Credit Agreement and Guaranty, dated as of September 30, 2022, by that certain Amendment No. 3 to Credit Agreement and Guaranty, dated as of December 15, 2022, by that certain Amendment No. 4 and Waiver to Credit Agreement and Guaranty, dated as of March 2, 2023, by that certain Amendment No. 5 to Credit Agreement and Guaranty, dated as of March 16, 2023, and by that certain Amendment No. 6 to Credit Agreement and Guaranty, dated as of March 29, 2023, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Existing Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, the Borrower has requested that the Lenders extend credit to the Borrower in the form of term loans in an aggregate initial principal amount of $138,137,470.97, the proceeds of which shall be used to (i) refinance the outstanding obligations under the Existing Credit Agreement and (ii) pay certain fees, costs, and expenses incurred in connection with such refinancing and entry into this Agreement, the other Loan Documents and the transactions contemplated hereby&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, the Lenders are willing to extend credit to the Borrower on the terms and subject to the conditions set forth herein.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOW, THEREFORE, the parties hereto agree as follows&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE I</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">DEFINITIONS AND ACCOUNTING TERMS</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The following terms (whether or not underscored) when used in this Agreement, including its preamble and recitals, shall, except where the context otherwise requires, have the following meanings (such meanings to be equally applicable to the singular and plural forms thereof)&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ABR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, for any day, a rate per annum equal to the highest of (i) the Prime Rate in effect on such day, (ii) the Federal Funds Rate in effect on such day plus 0.50% and (iii) Term SOFR for a one-month tenor in effect on such day plus 1.00%. Any change in the ABR due to a change in the Prime Rate, the Federal Funds Rate or Term SOFR shall be effective from and including the effective date of such change in the Prime Rate, the Federal Funds Rate or Term SOFR, respectively.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ABR Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a Loan that bears interest based on the ABR.</font></div><div style="margin-bottom:46pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ABR Term SOFR Determination Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in the definition of &#8220;Term SOFR&#8221;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Affected Financial Institution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means (a) any EEA Financial Institution or (b) any UK Financial Institution.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; of any Person means any other Person which, directly or indirectly, controls, is controlled by or is under common control with such Person. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; (and its correlatives) by any Person means the power of such Person, directly or indirectly, (i) to vote 10% or more of the Capital Securities (on a fully diluted basis) of another Person which Capital Securities have ordinary voting power for the election of directors, managing members or general partners (as applicable), or (ii) to direct or cause the direction of the management and policies of such other Person (whether by contract or otherwise).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning specified in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">preamble</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning specified in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">preamble</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Applicable Margin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, for any day, (i) as to any SOFR Loan, 7.00% per annum or (ii) as to any ABR Loan, 6.00% per annum, as the case may be, in each case as such percentage may be increased pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">3.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> that, if the Borrower makes a single voluntary prepayment or repayment of the Loans in an aggregate principal amount equal to or greater than $40,000,000, the source of which is cash received by Holdings in exchange for common equity in Holdings, such percentage shall be decreased by 0.25% per annum.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Assignment and Assumption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means an assignment and assumption entered into by a Lender and an assignee of such Lender in substantially the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Authorized Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, relative to any Credit Party or any of its Subsidiaries, those of its officers, general partners or managing members (as applicable) whose signatures and incumbency shall have been certified to the Agent pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 5.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Available Tenor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, as of any date of determination and with respect to the then-current Benchmark, as applicable, (x) if such Benchmark is a term rate, any tenor for such Benchmark (or component thereof) that is or may be used for determining the length of an interest period pursuant to this Agreement or (y) otherwise, any payment period for interest calculated with reference to such Benchmark (or component thereof) that is or may be used for determining any frequency of making payments of interest calculated with reference to such Benchmark, in each case, as of such date and not including, for the avoidance of doubt, any tenor for such Benchmark that is then-removed from the definition of &#8220;Interest Period&#8221; pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 4.10(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">AWS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means Amazon Web Services, Inc.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">AWS Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means that certain AWS Customer Agreement, by and between AWS and the Borrower, attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, as amended or otherwise modified from time to time in accordance with this Agreement.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Bail-In Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the exercise of any Write-Down and Conversion Powers by the applicable Resolution Authority in respect of any liability of an Affected Financial Institution.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Bail-In Legislation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, (i) with respect to any EEA Member Country implementing Article 55 of Directive 2014&#47;59&#47;EU of the European Parliament and of the Council of the European Union, the implementing law, regulation, rule or requirement for such EEA Member Country from time to time which is described in the EU Bail-In Legislation Schedule and (ii) with respect to the United Kingdom, Part I of the United Kingdom Banking Act 2009 (as amended from time to time) and any other law, regulation or</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">rule applicable in the United Kingdom relating to the resolution of unsound or failing banks, investment firms or other financial institutions or their affiliates (other than through liquidation, administration or other insolvency proceedings).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Benchmark</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8221; means, initially, the Term SOFR Reference Rate&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">, that if a Benchmark Transition Event has occurred with respect to the Term SOFR Reference Rate or the then-current Benchmark, then &#8220;Benchmark&#8221; means the applicable Benchmark Replacement to the extent that such Benchmark Replacement has replaced such prior benchmark rate pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Section 4.10(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Benchmark Replacement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8221; means with respect to any Benchmark Transition Event, the sum of&#58; (i) the alternate benchmark rate that has been selected by the Agent and the Borrower giving due consideration to (x) any selection or recommendation of a replacement benchmark rate or the mechanism for determining such a rate by the Relevant Governmental Body or (y) any evolving or then-prevailing market convention for determining a benchmark rate as a replacement to the then-current Benchmark for Dollar-denominated syndicated credit facilities and (ii) the related Benchmark Replacement Adjustment&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">, that, if such Benchmark Replacement as so determined would be less than 2.00%, such Benchmark Replacement will be deemed to be 2.00% for the purposes of this Agreement and the other Loan Documents.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Benchmark Replacement Adjustment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8221; means, with respect to any replacement of the then-current Benchmark with an Unadjusted Benchmark Replacement, the spread adjustment, or method for calculating or determining such spread adjustment (which may be a positive or negative value or zero), that has been selected by the Agent giving due consideration to (x) any selection or recommendation of a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement by the Relevant Governmental Body or (y) any evolving or then-prevailing market convention for determining a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement for Dollar-denominated syndicated credit facilities.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Benchmark Replacement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8221; means the earliest to occur of the following events with respect to the then-current Benchmark&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(a)&#160;&#160;&#160;&#160;in the case of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">clause (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%"> of the definition of &#8220;Benchmark Transition Event&#8221;, the later of (i) the date of the public statement or publication of information referenced therein and (ii) the date on which the administrator of such Benchmark (or the published component used in the calculation thereof) permanently or indefinitely ceases to provide all Available Tenors of such Benchmark (or such component thereof)&#59; or</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(b)&#160;&#160;&#160;&#160;in the case of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">clause (c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%"> of the definition of &#8220;Benchmark Transition Event&#8221;, the first date on which such Benchmark (or the published component used in the calculation thereof) has been determined and announced by or on behalf of the administrator of such Benchmark (or such component thereof) or the regulatory supervisor for the administrator of such Benchmark (or such component thereof) to be non-representative or non-compliant with or non-aligned with the International Organization of Securities Commissions (IOSCO) Principles for Financial Benchmarks&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">, that such non-representativeness, non-compliance or non-alignment will be determined by reference to the most recent statement or publication referenced in such clause (c) and even if any Available Tenor of such Benchmark (or such component thereof) continues to be provided on such date.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">For the avoidance of doubt, the &#8220;Benchmark Replacement Date&#8221; will be deemed to have occurred in the case of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">clause (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%"> with respect to any Benchmark upon the occurrence of the applicable event or events set forth therein with respect to all then-current Available Tenors of such Benchmark (or the published component used in the calculation thereof).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Benchmark Transition Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the occurrence of one or more of the following events with respect to the then-current Benchmark&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;a public statement or publication of information by or on behalf of the administrator of such Benchmark (or the published component used in the calculation thereof) announcing that such administrator has ceased or will cease to provide all Available Tenors of such Benchmark (or such component thereof), permanently or indefinitely&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that, at the time of such statement or publication, there is no successor administrator that will continue to provide any Available Tenor of such Benchmark (or such component thereof)&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;a public statement or publication of information by the regulatory supervisor for the administrator of such Benchmark (or the published component used in the calculation thereof), the F.R.S. Board, the Federal Reserve Bank of New York, an insolvency official with jurisdiction over the administrator for such Benchmark (or such component), a resolution authority with jurisdiction over the administrator for such Benchmark (or such component) or a court or an entity with similar insolvency or resolution authority over the administrator for such Benchmark (or such component), which states that the administrator of such Benchmark (or such component) has ceased or will cease to provide all Available Tenors of such Benchmark (or such component thereof) permanently or indefinitely&#59; provided that, at the time of such statement or publication, there is no successor administrator that will continue to provide any Available Tenor of such Benchmark (or such component thereof)&#59; or</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;a public statement or publication of information by or on behalf of the administrator of such Benchmark (or the published component used in the calculation thereof) or the regulatory supervisor for the administrator of such Benchmark (or such component thereof) announcing that all Available Tenors of such Benchmark (or such component thereof) are not, or as of a specified future date will not be, representative or in compliance with or aligned with the International Organization of Securities Commissions (IOSCO) Principles for Financial Benchmarks.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the avoidance of doubt, a &#8220;Benchmark Transition Event&#8221; will be deemed to have occurred with respect to any Benchmark if a public statement or publication of information set forth above has occurred with respect to each then-current Available Tenor of such Benchmark (or the published component used in the calculation thereof).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Benchmark Transition Start Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, in the case of a Benchmark Transition Event, the earlier of (i) the applicable Benchmark Replacement Date and (ii) if such Benchmark Transition Event is a public statement or publication of information of a prospective event, the 90th day prior to the expected date of such event as of such public statement or publication of information (or if the expected date of such prospective event is fewer than 90 days after such statement or publication, the date of such statement or publication).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Benchmark Unavailability Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, the period (if any) (i) beginning at the time that a Benchmark Replacement Date has occurred if, at such time, no Benchmark Replacement has replaced the then-current Benchmark for all purposes hereunder and under any Loan Document in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and (ii) ending at the time that a Benchmark Replacement has replaced the then-current Benchmark for all purposes hereunder and under any Loan Document in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Beneficial Ownership Certification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a certification regarding beneficial ownership as required by the Beneficial Ownership Regulation.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Beneficial Ownership Regulation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means 31 C.F.R. &#167; 1010.230.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">preamble</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any day which is neither a Saturday nor Sunday nor a legal holiday on which banks are authorized or required to be closed in New York, New York or London, England.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Capital Expenditures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, for any applicable Fiscal Period for any Person determined on a consolidated basis for such Person and its Subsidiaries in accordance with GAAP, the aggregate amount of (i) all expenditures of such Person and its Subsidiaries for fixed or capital assets made during such Fiscal Period which, in accordance with GAAP, would be classified as capital expenditures and (ii) Capitalized Lease Liabilities incurred by such Person and its Subsidiaries during such Fiscal Period.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Capital Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Person, all shares of, interests or participations in, or other equivalents in respect of (in each case however designated, whether voting or non-voting), such Person&#8217;s capital stock or other equity securities, issued and outstanding as of the date hereof or any time hereafter, including treasury stock.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Capitalized Lease Liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Person, all monetary obligations of such Person and its Subsidiaries under any leasing or similar arrangement which have been (or, in accordance with GAAP, should be) classified as capitalized leases, and for purposes of each Loan Document the amount of such obligations shall be the capitalized amount thereof, determined in accordance with GAAP, and the stated maturity thereof shall be the date of the last payment of rent or any other amount due under such lease prior to the first date upon which such lease may be terminated by the lessee without payment of a premium or a penalty.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Cash Equivalent Investment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, at any time&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;any direct obligation of (or unconditionally guaranteed by) the United States or a state thereof or of the District of Columbia (or any agency or political subdivision thereof, to the extent such obligations are supported by the full faith and credit of the United States or a state thereof or of the District of Columbia) maturing not more than one (1) year after such time&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;commercial paper, or corporate demand notes, maturing not more than 270 days from the date of issue, which is issued by a corporation (other than an Affiliate of a Credit Party or any of its Subsidiaries) organized under the laws of any state of the United States or of the District of Columbia and rated A-1 or higher by S&#38;P or P-1 or higher by Moody&#8217;s&#59; or</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;any certificate of deposit, time deposit or banker&#8217;s acceptance, maturing not more than one year after its date of issuance, which is issued by any bank organized under the laws of the United States (or any state thereof or of the District of Columbia) and which has (x) a credit rating of A2 or higher from Moody&#8217;s or A or higher from S&#38;P and (y) a combined capital and surplus greater than $500,000,000.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;any repurchase agreement entered into with any commercial banking institution meeting the requirements set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> above which (i) is secured by a fully perfected security interest in any obligation of the type described in any of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clauses (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> through </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> above and (ii) has a market value at the time such repurchase agreement is entered into of not less than one-hundred percent (100%) of the repurchase obligation of such commercial banking institution thereunder&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;money market accounts or mutual funds which invest exclusively or substantially in assets satisfying the foregoing requirements&#59; or</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;other short-term liquid investments approved in writing by the Agent.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means and shall be deemed to have occurred if&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;(i) prior to an IPO or SPAC Transaction, the Specified Holders together fail to own and control, directly or indirectly, beneficially and of record, in the aggregate more than 50% of the total economic interest in the Capital Securities or of the Voting Securities, in each case of Holdings&#59; (ii) after an IPO or SPAC Transaction, any &#8220;person&#8221; or &#8220;group&#8221; (within the meaning of Rule 13d-5 of the Exchange Act as in effect on the date hereof), other than the Specified Holders, shall own, directly or indirectly, beneficially or of record, determined on a fully diluted basis, more than 35% of the Capital Securities of Holdings&#59; (iii) a majority of the seats (other than vacant seats) on the board of directors (or equivalent) of Holdings shall at any time be occupied by persons who were not (x) nominated or appointed by the board of directors (or equivalent) of Holdings, (y) nominated or appointed by directors (or equivalent) so nominated or (z) nominated, designated or appointed by any of the Specified Holders&#59; (iv) the sale, lease, transfer, conveyance or other Disposition, in one or more related transactions, of all or substantially all of the assets of Holdings and its Subsidiaries, taken as a whole, occurs&#59; or (v) Holdings shall cease to directly own, beneficially and of record, 100% of the issued and outstanding Capital Securities of the Borrower&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;the Borrower shall cease to directly or indirectly own, beneficially and of record, 100% of the issued and outstanding Capital Securities of each Subsidiary Guarantor, except as otherwise permitted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 8.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#59; or</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;a Change of Control under and as defined in any Subordinated Convertible Promissory Note issued pursuant to that certain Note Purchase Agreement, dated as of September 30, 2022, by and among Holdings and the investors party thereto.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Notwithstanding the foregoing, the consummation of a SPAC Transaction shall not constitute a Change in Control.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Change in Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the occurrence, after the date of this Agreement, of any of the following&#58; (i) the adoption or taking effect of any law, rule, regulation or treaty, (ii) any change in any law, rule, regulation or treaty or in the administration, interpretation, implementation or application thereof by any Governmental Authority or (iii) the making or issuance of any request, rule, guideline or directive (whether or not having the force of law) by any Governmental Authority&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> that, notwithstanding anything herein to the contrary, (x) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith and (y) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to be a &#8220;Change in Law&#8221;, regardless of the date enacted, adopted or issued.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Charged Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 7.8(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means June 14, 2024.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Closing Date Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 5.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the U.S. Internal Revenue Code of 1986, as amended.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Collateral</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any asset or property in which a Lien is purported to be granted under any Loan Document, including future acquired or created assets or property (or all such assets or property, as the context may require)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> that Collateral shall include (i) 100% of the Capital Securities of any Foreign Subsidiaries existing as of the Closing Date, except to the extent as reasonably determined by the Borrower</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">after consulting with the Agent, such pledge would reasonably be expected to result in material adverse tax consequences to the Borrower, in which case Borrower shall not be required to pledge voting Capital Securities in excess of 65% of the issued and outstanding voting Capital Securities of such Foreign Subsidiaries (other than a Foreign Subsidiary that becomes a &#8220;Subsidiary Guarantor&#8221; after the Closing Date pursuant to Section 7.8) and (ii) unless provided otherwise in Section 7.8(e), 100% of the Capital Securities of each Foreign Subsidiary acquired or organized after the Closing Date&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that if the Borrower reasonably determines after consulting with the Agent that the continuation of a pledge of 100% of the voting Capital Securities of any Foreign Subsidiary would, as a result of a Change in Law occurring after the original date of such pledge, result in material adverse tax consequences to the Borrower or Holdings, then Collateral shall not include voting Capital Securities in excess of 65% of the issued and outstanding voting Capital Securities of such Foreign Subsidiary and the amount of such Capital Securities pledged under the Loan Documents shall be adjusted accordingly.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a certificate duly completed and executed by an Authorized Officer of Holdings, substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereto, together with such changes thereto as the Agent or the Majority Lenders may from time to time request for the purpose of monitoring compliance with the financial covenants contained herein.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Conforming Changes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to either the use or administration of Term SOFR or the use, administration, adoption or implementation of any Benchmark Replacement, any technical, administrative or operational changes (including changes to the definition of &#8220;ABR&#8221;, the definition of &#8220;Business Day&#8221;, the definition of &#8220;U.S. Government Securities Business Day&#8221;, the definition of &#8220;Interest Period&#8221; or any similar or analogous definition (or the addition of a concept of &#8220;interest period&#8221;), timing and frequency of determining rates and making payments of interest, timing of borrowing requests or prepayment, conversion or continuation notices, the applicability and length of lookback periods, the applicability of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and other technical, administrative or operational matters) that the Agent decides may be appropriate to reflect the adoption and implementation of any such rate or to permit the use and administration thereof by the Agent in a manner substantially consistent with market practice (or, if the Agent decides that adoption of any portion of such market practice is not administratively feasible or if the Agent determines that no market practice for the administration of any such rate exists, in such other manner of administration as the Agent decides is reasonably necessary in connection with the administration of this Agreement and the other Loan Documents).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Connection Income Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Other Connection Taxes that are imposed on or measured by net income (however denominated) or that are franchise Taxes or branch profits Taxes.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Constitutional Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the constitutional documents of each UK Subsidiary Guarantor being certificate of incorporation, certificate of change of name, memorandum of association and articles of association (if applicable).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Contingent Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any agreement, undertaking or arrangement by which any Person guarantees, endorses or otherwise becomes or is contingently liable upon (by direct or indirect agreement, contingent or otherwise, to provide funds for payment, to supply funds to, or otherwise to invest in, a debtor, or otherwise to assure a creditor against loss) the Indebtedness of any other Person (other than by endorsements of instruments in the course of collection), or guarantees the payment of dividends or other distributions upon the Capital Securities of any other Person. The amount of any Person&#8217;s obligation under any Contingent Liability shall (subject to any limitation set forth therein) be deemed to be the outstanding principal amount of the debt, obligation or other liability guaranteed thereby.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified within the definition of &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Controlled Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.12(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Controlled Account Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Controlled Account, an account control agreement (or equivalent) in favor of, and satisfactory in form and substance to, the Agent (acting on the instructions of the Majority Lenders acting reasonably).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Copyright Security Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any Copyright Security Agreement executed and delivered by any Credit Party and&#47;or any of its Subsidiaries, as applicable, substantially in the form of Exhibit E to the Security Agreement, as amended or otherwise modified from time to time.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Copyrights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means all copyrights and rights in copyrightable subject matter, whether statutory or common law, and all exclusive and nonexclusive licenses from third parties or rights to use copyrights owned by third parties, along with any and all (i) renewals, revisions, extensions, derivative works, enhancements, modifications, updates and new releases thereof, (ii) income, royalties, damages, claims and payments now and hereafter due and&#47;or payable with respect thereto, including, without limitation, damages and payments for past, present or future infringements thereof, (iii) rights to sue for past, present and future infringements thereof, and (iv) foreign copyrights and any other rights corresponding thereto throughout the world.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Credit Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, collectively, the Borrower and the Guarantors.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Data Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.16(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Debenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.8(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any Event of Default or any condition, occurrence or event which, after notice or lapse of time or both, would constitute an Event of Default.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Default Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Designated Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any country or territory to the extent that such country or territory is the subject of any Sanction.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Disposition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; (or similar words such as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Dispose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) means any sale, transfer, lease, contribution or other conveyance (including by way of merger) of, or the granting of options, warrants or other rights to, a Credit Party&#8217;s or its Subsidiaries&#8217; assets (including accounts receivable and Capital Securities of Subsidiaries) to any other Person (other than to the Borrower or a wholly owned Subsidiary Guarantor) in a single transaction or series of transactions.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Disqualified Capital Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Person, any Capital Security of such Person that, by its terms (or by the terms of any security or other Capital Security into which it is convertible or for which it is exchangeable), or upon the happening of any event or condition (i) matures or is mandatorily redeemable (other than solely for Qualified Capital Securities), including pursuant to a sinking fund obligation or otherwise, (ii) is redeemable at the option of the holder thereof (other than solely for Qualified Capital Securities), in whole or in part, (iii) provides for the scheduled payments of dividends in cash, or (iv) is or becomes convertible into or exchangeable for Indebtedness or any other Capital Securities that would constitute Disqualified Capital Securities, in each case, prior to the date that is one hundred eighty (180) days after the Maturity Date.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Disqualified Institution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means (a) any Person designated by the Borrower as a &#8220;Disqualified Institution&#8221; by written notice delivered to the Agent prior to the Closing Date, in form and substance</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">acceptable to the Agent, and any of such Person&#8217;s Affiliates that are readily identifiable as such by their name and (b) any other Person that is a competitor of the Borrower or any of its Subsidiaries (or an affiliate of such competitor) designated by the Borrower as a &#8220;Disqualified Institution&#8221; by written notice delivered to the Agent from time to time and any of such Person&#8217;s Affiliates that are readily identifiable as such by their names&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> that &#8220;Disqualified Institutions&#8221; shall exclude (x) bona fide debt funds and (y) any Person that the Borrower has designated as no longer being a &#8220;Disqualified Institution&#8221; by written notice delivered to the Agent from time to time. The list of Disqualified Institutions shall be made available to any Lender upon written request to the Agent. In no event shall a supplement to the list of Disqualified Institutions apply retroactively to disqualify any Persons that have previously acquired an assignment or participation interest in the Loans that was otherwise permitted prior to such supplementation.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Dollars</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; and the sign &#8220;$&#8221; mean lawful money of the United States.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Domestic Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means a Subsidiary incorporated or organized under the laws of the United States, or any state, commonwealth or other political subdivision thereof (including, for the avoidance of doubt, the District of Columbia).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">EEA Financial Institution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means (i) any credit institution or investment firm established in any EEA Member Country which is subject to the supervision of an EEA Resolution Authority, (ii) any entity established in an EEA Member Country which is a parent of an institution described in clause (i) of this definition, or (iii) any financial institution established in an EEA Member Country which is a subsidiary of an institution described in clauses (i) or (ii) of this definition and is subject to consolidated supervision with its parent.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">EEA Member Country</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any of the member states of the European Union, Iceland, Liechtenstein, and Norway.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">EEA Resolution Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any public administrative authority or any person entrusted with public administrative authority of any EEA Member Country (including any delegee) having responsibility for the resolution of any EEA Financial Institution.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Environmental Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means all federal, state, local or international laws, statutes, rules, regulations, codes, directives, treaties, requirements, ordinances, orders, decrees, judgments, injunctions, notices or binding agreements issued, promulgated or entered into by any Governmental Authority, relating in any way to the environment, natural resources, Hazardous Material or health and safety matters.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Environmental Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any liability, loss, claim, suit, action, investigation, proceeding, damage, commitment or obligation, contingent or otherwise (including any liability for damages, costs of environmental remediation, fines, penalties or indemnities), of or affecting any Credit Party or its Subsidiaries directly or indirectly arising from, in connection with or based upon (i) any Environmental Law or Environmental Permit, (ii) the generation, use, handling, transportation, storage, treatment, recycling, presence, disposal, Release or threatened Release of, or exposure to, any Hazardous Materials or (iii) any contract, agreement, penalty, order, decree, settlement, injunction or other arrangement (including operation of law) pursuant to which liability is assumed, entered into, inherited or imposed with respect to any of the foregoing.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Environmental Permit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 6.7(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">ERISA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the Employee Retirement Income Security Act of 1974, as amended, and any successor statute thereto of similar import, together with the regulations thereunder, in each case as in effect from time to time. References to Sections of ERISA also refer to any successor Sections thereto.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">ERISA Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any person that for purposes of Title I and Title IV of ERISA and Section 412 of the Code would be deemed to be a single employer with the Borrower, pursuant to Section 414(b), (c), (m) or (o) of the Code or Section 4001 of ERISA.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">ERISA Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means (i) any reportable event, as defined in Section 4043 of ERISA, with respect to a Pension Plan, as to which PBGC has not by regulation waived the requirement of Section 4043(a) of ERISA that it be notified of such event, (ii) the filing of a notice of intent to terminate any Pension Plan, if such termination could reasonably be expected to require material additional contributions in order to be considered a standard termination within the meaning of Section 4041(b) of ERISA, the filing under Section 4041(c) of ERISA of a notice of intent to terminate any Pension Plan or the termination of any Pension Plan under Section 4041(c) of ERISA, (iii) the institution of proceedings under Section 4042 of ERISA by the PBGC for the termination of, or the appointment of a trustee to administer, any Pension Plan, (iv) any failure by any Pension Plan to satisfy the minimum funding requirements of Sections 412 and 430 of the Code or Section 302 of ERISA applicable to such Pension Plan, if not waived, (v) the failure to make a required contribution to any Pension Plan that could reasonably be expected to result in the imposition of an encumbrance on a Credit Party, any of its Subsidiaries or any ERISA Affiliate under Section 412 or 430 of the Code, a filing under Section 412 of the Code or Section 302 of ERISA of any request for a minimum funding variance with respect to any Pension Plan or Multiemployer Plan, (vi) an engagement in a non-exempt prohibited transaction within the meaning of Section 4975 of the Code or Section 406 of ERISA with respect to which a Credit Party or any of its Subsidiaries could reasonably be expected to incur liability which could reasonably be expected to have a Material Adverse Effect, (vii) the complete or partial withdrawal of a Credit Party, any of its Subsidiaries or any material ERISA Affiliate from a Multiemployer Plan, (viii) a Credit Party, any of its Subsidiaries or an ERISA Affiliate incurring any material liability under Title IV of ERISA with respect to any Pension Plan (other than premiums due and not delinquent under Section 4007 of ERISA) and (ix) a reasonable determination by an actuary for a Pension Plan that such Pension Plan is in &#8220;at risk&#8221; status (as defined in Section 303(i)(4) of ERISA or Section 430(i)(4) of the Code).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">EU Bail-In Legislation Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the EU Bail-In Legislation Schedule published by the Loan Market Association (or any successor person), as in effect from time to time.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Event of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Event of Loss</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, with respect to any asset of a Credit Party or any of its Subsidiaries, any of the following&#58; (i) any loss, destruction or damage of such asset or (ii) any actual condemnation, seizure or taking, by exercise of the power of eminent domain or otherwise, of such asset, or confiscation of such asset or requisition of the use of such asset.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the Securities Exchange Act of 1934, as amended.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Excluded Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in the Security Agreement.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Excluded Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any of the following Taxes imposed on or with respect to a Recipient or required to be withheld or deducted from a payment to a Recipient, (i) Taxes imposed on or measured by net income (however denominated), franchise Taxes, and branch profits Taxes, in each case, (x) imposed as a result of such Recipient being organized under the laws of, or having its principal office or, in the case of any Lender, its applicable lending office located in, the jurisdiction imposing such Tax (or any political subdivision thereof) or (y) that are Other Connection Taxes, (ii) in the case of a Lender, U.S. federal withholding Taxes imposed on amounts payable to or for the account of such Lender with respect to an applicable interest in a Loan pursuant to a law in effect on the date on which (x) such Lender acquires such interest in a Loan or (y) such Lender changes its lending office, except in each case to the extent that,</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:123%">pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:123%;text-decoration:underline">Section 4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:123%">, amounts with respect to such Taxes were payable either to such Lender&#8217;s assignor immediately before such Lender became a party hereto or to such Lender immediately before it changed its lending office, (iii) Taxes attributable to such Recipient&#8217;s failure to comply with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:123%;text-decoration:underline">Section 4.3(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:123%"> and (iv) any withholding Taxes imposed under FATCA.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Existing Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">recitals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;FATCA&#8221; means Sections 1471 through 1474 of the Code, as of the date of this Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof, any agreements entered into pursuant to Section 1471(b)(1) of the Code and any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental agreement, treaty or convention among Governmental Authorities and implementing such Sections of the Code.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Federal Funds Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, for any day, the greater of (i) the rate calculated by the Federal Reserve Bank of New York based on such day&#8217;s Federal funds transactions by depositary institutions (as determined in such manner as the Federal Reserve Bank of New York shall set forth on its public website from time to time) and published on the next succeeding Business Day by the Federal Reserve Bank of New York as the Federal funds effective rate and (ii) 0%.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the U.S. Food and Drug Administration and any successor entity.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">FD&#38;C Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the U.S. Federal Food, Drug and Cosmetic Act of 1938 (or any successor thereto), as amended from time to time, and the rules and regulations promulgated thereunder.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Fee Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means that certain Fee Letter, dated as of the date hereof, by and among the Borrower, the Agent and the Lenders, as amended or otherwise modified from time to time.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">FFRct</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a coronary vascular physiologic simulation software prescription device that provides simulated functional assessment of blood flow in the coronary vascular system using data extracted from medical device imaging to solve algorithms and yield simulated metrics of physiologic information (e.g., blood flow, coronary flow reserve, fractional flow reserve, myocardial perfusion), which is intended to generate results for use and review by a qualified clinician, de novo 510(k) clearance of which was received on November 26, 2014 for version 1.4 of the HeartFlow Analysis (DEN130045), 510(k) clearance for version 2.x of the Heartflow Analysis was received in January 2016 (510(k) No.&#58; K152733), and 510(k) clearance for a modification to the intended use language in August 2016 (510(k) No.&#58; K161772). Additional clearances were received for a strategic architecture scope change in December 2018 (510(k) No.&#58; K182035), and for the addition of Planner capabilities in August 2019 (510(k) No.&#58; K190925). The Borrower submitted its version 3.x for FDA review in November 2020 and received FDA clearance on January 8, 2021 (510(k) No.&#58; K203329).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Fiscal Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, as applicable, a Fiscal Quarter or a Fiscal Year.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Fiscal Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a quarter ending on the last day of March, June, September or December.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Fiscal Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any period of twelve consecutive calendar months ending on December 31&#59; references to a Fiscal Year with a number corresponding to any calendar year (e.g., the &#8220;2020 Fiscal Year&#8221;) refer to the Fiscal Year ending December 31 of such calendar year.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Excluded Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means at any date of determination, each wholly owned Foreign Subsidiary (together with its Subsidiaries) whose (i) Net Sales during the applicable Measurement Period</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">were equal to or less than 15.0% of the consolidated Net Sales of Holdings and its Subsidiaries for such period and (ii) assets during the applicable Measurement Period were equal to or less than 15.0% of the consolidated assets of Holdings and its Subsidiaries for such period, in each case determined in accordance with GAAP&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, that, for such Measurement Period, the Foreign Excluded Subsidiaries shall not collectively have (x) Net Sales during such Measurement Period equal to or greater than 20.0% of the consolidated Net Sales of Holdings and its Subsidiaries for such period or (y) assets during such Measurement Period equal to or greater than 20.0% of the consolidated assets of Holdings and its Subsidiaries for such period&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, f</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">urther</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, that no Subsidiary that owns any Material Intellectual Property or is party to a Material Agreement may be a Foreign Excluded Subsidiary.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Foreign Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means a Lender that is not a U.S. Person.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Foreign Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any Subsidiary that is not a Domestic Subsidiary.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">F.R.S. Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the Board of Governors of the Federal Reserve System or any successor thereto.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Funded Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; of any Person means Indebtedness of the type described in clauses (a) and (c) of the definition of Indebtedness, and all Contingent Liabilities of such Person in respect of any such Funded Indebtedness.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any national, supranational, federal, state, county, provincial, local, municipal or other government or political subdivision thereof (including any Regulatory Authority), whether domestic or foreign, and any agency, authority, commission, ministry, instrumentality, regulatory body, court, tribunal, arbitrator, central bank or other Person exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to any such government&#59; any entity that contracts with a governmental entity to administer or assist in the administration of a governmental program (including any Medicare or Medicaid administrative contractors)&#59; or any arbitrator with authority to bind a party at law.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Guaranteed Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Guarantors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, collectively, Holdings and each Subsidiary Guarantor.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Hazardous Material</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any material, substance, chemical, mixture or waste which is capable of damaging or causing harm to any living organism, the environment or natural resources, including all explosive, special, hazardous, polluting, toxic, industrial, dangerous, biohazardous, medical, infectious or radioactive substances, materials or wastes, noise, odor, electricity or heat, and including petroleum or petroleum products, byproducts or distillates, asbestos or asbestos-containing materials, urea formaldehyde, polychlorinated biphenyls, radon gas, ozone-depleting substances, greenhouse gases, and all other substances or wastes of any nature regulated pursuant to any Environmental Law or as to which any Governmental Authority requires investigation, reporting or remedial action.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Healthcare Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means all applicable federal, state or local laws that govern the sales, marketing, promotion, distribution, research, development, testing, current good manufacturing practices (cGMPs) and quality system requirements, handling, packaging, labeling, storage, advertising, import, export, or any other use of the Products including, but not limited to, the FD&#38;C Act&#59; the Public Health Service Act&#59; the federal False Claims Act&#59; the federal Anti-Kickback Statute&#59; the Anti-Inducement Law&#59; the Stark Law&#59; privacy and data security laws including without limitation the Health Insurance Portability and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Accountability Act of 1996, as amended, inclusive of the Health Information Technology for Economic and Clinical Health Act (HITECH) and all implementing regulations (HIPAA)&#59; the Medicare Program (Title XVIII of the Social Security Act)&#59; the Medicaid Program (Title XIX of the Social Security Act)&#59; laws pertaining to the corporate practice of medicine or other healthcare professionals&#59; laws pertaining to deceptive trade practices&#59; any and all Permits required under Healthcare Laws&#59; all applicable rules, regulations and licensing requirements of applicable state agencies&#59; any similar state and local laws that address the subject matter of the foregoing&#59; laws and regulations pertaining to federal and state relief programs related to COVID-19&#59; the Federal Trade Commission Act&#59; and all other analogous laws to the foregoing within any other U.S. or foreign or supranational jurisdiction, and applicable rules and regulations issued thereunder (including, without limitation, 21 C.F.R. Parts 801, 803, 806, 807, 812, and 820).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Hedging Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any interest rate, foreign currency, commodity, credit or equity swap, collar, cap, floor or forward rate agreement, or other agreement or arrangement designed to protect against fluctuations in interest rates or currency, commodity or equity values (including any option with respect to any of the foregoing and any combination of the foregoing agreements or arrangements), and any confirmation executed in connection with any such agreement or arrangement.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Hedging Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, with respect to any Person, all liabilities of such Person under currency exchange agreements, interest rate swap agreements, interest rate cap agreements and interest rate collar agreements, and all other agreements or arrangements designed to protect such Person against fluctuations in interest rates or currency exchange rates.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">herein</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">hereof</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">hereto</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">hereunder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; and similar terms contained in any Loan Document refer to such Loan Document as a whole and not to any particular Section, paragraph or provision of such Loan Document.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Holdings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning specified in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">preamble</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Immaterial Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means at any date of determination, each wholly owned Subsidiary (together with its Subsidiaries) whose (i) Net Sales during the applicable Measurement Period were equal to or less than 5.0% of the consolidated Net Sales of Holdings and its Subsidiaries for such period and (ii) assets during the applicable Measurement Period were equal to or less than 5.0% of the consolidated assets of Holdings and its Subsidiaries for such period, in each case determined in accordance with GAAP&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, that, for such Measurement Period, the Immaterial Subsidiaries shall not collectively have (x) Net Sales during such Measurement Period equal to or greater than 10.0% of the consolidated Net Sales of Holdings and its Subsidiaries for such period or (y) assets during such Measurement Period equal to or greater than 10.0% of the consolidated assets of Holdings and its Subsidiaries for such period&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, that no Subsidiary that owns any Material Intellectual Property may be an Immaterial Subsidiary.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Impermissible Qualification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any qualification or exception to the opinion or certification of any independent public accountant as to any financial statement of a Credit Party or any of its Subsidiaries (i) which is of a &#8220;going concern&#8221; or similar nature (other than any such qualification arising from the Loans hereunder maturing on the Maturity Date or by reason of any actual or anticipated financial covenant breach hereunder) or (ii) which relates to the limited scope of examination of matters relevant to such financial statement.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; of any Person means&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;all obligations of such Person for borrowed money or advances and all obligations of such Person evidenced by bonds, debentures, notes or similar instruments&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;all obligations, contingent or otherwise, relative to the face amount of all letters of credit, whether or not drawn, and banker&#8217;s acceptances issued for the account of such Person&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;all Capitalized Lease Liabilities of such Person&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;net Hedging Obligations of such Person and all obligations of such Person arising under Synthetic Leases&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;all obligations issued, undertaken or assumed as the deferred purchase price of property or services, including earn outs, purchase price adjustments and seller notes in connection with acquisitions permitted hereunder (to the extent due and payable and included as a liability on the balance sheet in accordance with GAAP) (other than trade payables entered into in the ordinary course of business)&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;whether or not so included as liabilities in accordance with GAAP, all obligations of such Person to pay the deferred purchase price of property or services (excluding trade accounts payable in the ordinary course of business which are not overdue for a period of more than 90 days or, if overdue for more than 90 days, as to which a dispute exists and adequate reserves in conformity with GAAP have been established on the books of such Person), and indebtedness secured by (or for which the holder of such indebtedness has an existing right, contingent or otherwise, to be secured by) a Lien on property owned or being acquired by such Person (including indebtedness arising under conditional sales or other title retention agreements), whether or not such indebtedness shall have been assumed by such Person or is limited in recourse&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;any Disqualified Capital Securities&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;all Contingent Liabilities of such Person in respect of any of the foregoing clauses (a) through (g) inclusive.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Indebtedness of any Person shall include the Indebtedness of any other Person (including any partnership in which such Person is a general partner) to the extent such Person is liable therefor as a result of such Person&#8217;s ownership interest in or other relationship with such Person, except to the extent the terms of such Indebtedness expressly provide that such Person is not liable therefor.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnified Liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnified Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnified Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means (a) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any obligation of any Credit Party under any Loan Document and (b) to the extent not otherwise described in (a), Other Taxes.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means all (i) Patents, (ii) Trademarks, (iii) Copyrights and other works of authorship (registered or unregistered), and all applications, registrations and renewals therefor, (iv) computer software, databases, data and documentation, (v) Trade Secrets and confidential business information, including know-how, inventions, manufacturing processes and techniques, research and development information, financial, marketing and business data, databases pricing and cost information, business, finance and marketing plans, customer and prospective customer lists and information, and supplier and prospective supplier lists and information, (vi) other intellectual property or similar proprietary rights, (vii) copies and tangible embodiments of any of the foregoing (in whatever form or medium) and (viii) any and all improvements to any of the foregoing.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Intercompany Subordination Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8221; means a subordination agreement to be executed and delivered by each Credit Party and any Subsidiaries thereof, pursuant to which all obligations in respect of any Indebtedness for borrowed money (or equivalent) owing between or among any party to such subordination agreement shall be subordinated to the prior Payment in Full of all Obligations, such agreement to be in substantially the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Exhibit F</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%"> or such other form reasonably acceptable to the Agent.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Interest Payment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8221; means, (i) as to any ABR Loan, (a) the last Business Day of each March, June, September and December and (b) the Maturity Date and (ii) as to any SOFR Loan, (a) the last day of each Interest Period therefor and, in the case of any Interest Period of more than three months&#8217; duration, each day prior to the last day of such Interest Period that occurs at three-month intervals after the first day of such Interest Period, and (b) the Maturity Date.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Interest Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8221; means, (i) initially, as to any Loan, the period beginning on (and including) the date of which the Loans were made and ending on (and including) the last day of the calendar quarter in which the Loans were made and (ii) thereafter, as to any Loan, the period commencing on the date of such Loan and ending on the numerically corresponding day in the calendar month that is three months thereafter (subject to the availability thereof), as specified in the applicable Loan Request&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">, that (i) if any Interest Period would end on a day other than a Business Day, such Interest Period shall be extended to the next succeeding Business Day unless such next succeeding Business Day would fall in the next calendar month, in which case such Interest Period shall end on the next preceding Business Day, (ii) any Interest Period that commences on the last Business Day of a calendar month (or on a day for which there is no numerically corresponding day in the last calendar month of such Interest Period) shall end on the last Business Day of the last calendar month of such Interest Period, (iii) no Interest Period shall extend beyond the Maturity Date and (iv) no tenor that has been removed from this definition pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Section 4.10(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%"> shall be available for specification in such Loan Request. For purposes hereof, the date of a Loan initially shall be the date on which such Loan is made and thereafter shall be the effective date of the most recent conversion or continuation of such Loan.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Investment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8221; means, relative to any Person, (i) any loan, advance or extension of credit made by such Person to any other Person, including the purchase by such Person of any bonds, notes, debentures or other debt securities of any other Person, (ii) Contingent Liabilities in favor of any other Person and (iii) any Capital Securities held by such Person in any other Person. The amount of any Investment shall be the original principal or capital amount thereof less all returns of principal or equity thereon and shall, if made by the transfer or exchange of property other than cash, be deemed to have been made in an original principal or capital amount equal to the fair market value of such property at the time of such Investment.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">IPO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8221; means an underwritten initial public offering of common Capital Securities of Holdings pursuant to an effective registration statement filed with the SEC in accordance with the Securities Act of 1933, as amended.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Key Permits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8221; means all material Permits in favor of the Credit Parties relating to the Products (including all Regulatory Authorizations), including, for the avoidance of doubt, all current and future permits materially relating to (i) FFRct in the United States and (ii) Plaque and Roadmap, in the case of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">clause (ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">, from and after the date on which Plaque and Roadmap collectively contribute 30% or more of Net Sales in the aggregate. As of the Closing Date, the Key Permits are as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Schedule&#160;1.1.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8221; has the meaning specified in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">preamble</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Lien</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8221; means any security interest, mortgage, pledge, hypothecation, assignment, deposit arrangement, encumbrance, lien (statutory or otherwise), charge against or interest in property, or other</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">priority or preferential arrangement of any kind or nature whatsoever, to secure payment of a debt or performance of an obligation.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Liquidity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, at any time, unrestricted, unencumbered cash and Cash Equivalent Investments in one or more Controlled Accounts that is free and clear of all Liens, other than Liens granted under the Loan Documents in favor of the Agent, for the benefit of the Secured Parties.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Liquidity Covenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Liquidity Cure Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Liquidity Cure Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the term loans made on the Closing Date pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in an aggregate principal amount of $138,137,470.97.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Loan Commitment Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means $138,137,470.97.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Loan Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, collectively, this Agreement (as subsequently amended or otherwise modified), the Notes, the Fee Letter, the Security Agreement, the Debenture, any Mortgages, the Intercompany Subordination Agreement, the Copyright Security Agreement, the Patent Security Agreement, the Trademark Security Agreement, any Controlled Account Agreement and each other agreement pursuant to which any of the Agent or any of the other Secured Parties is granted a Lien to secure the Obligations, and each other agreement, certificate, document or instrument delivered in connection with any Loan Document.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Loan Request</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a Loan request and certificate duly executed by an Authorized Officer of the Borrower substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereto.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Majority Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, at any time, Lenders holding more than 50% of the then aggregate unpaid principal amount of the Loans.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Material Adverse Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a material adverse effect on (i) the business, condition (financial or otherwise), operations, performance or properties of any Credit Party and each of its Subsidiaries, taken as a whole, (ii) the rights and remedies of the Agent or any Lender under any Loan Document, or (iii) the ability of any Credit Party or any of its Subsidiaries to perform their respective Obligations under any Loan Document.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Material Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means (i) each contract or agreement to which a Credit Party or any of its Subsidiaries is a party, the loss of which would result in the loss of 30% or more of Net Sales in the aggregate&#59; (ii) the AWS Agreement or any replacement cloud hosting agreement as contemplated in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and (iii) all other contracts or agreements to which a Credit Party is a party, individually or in the aggregate, that if breached or terminated could reasonably be expected to result in a Material Adverse Effect.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Material Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any Intellectual Property owned by, licensed to or otherwise held by any Credit Party or any of its Subsidiaries (including, for the avoidance of doubt, the Stanford Licenses), whether currently owned or acquired, developed, licensed or obtained after the date hereof (i) reasonably required for the business and&#47;or commercialization of FFRct or otherwise materially relating to FFRct, (ii) the loss of which could reasonably be expected to result in a Material Adverse Effect, or (iii) that has a fair market value in excess of $5,000,000.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Maturity Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means June 14, 2028.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Measurement Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any period of four (4) consecutive Fiscal Quarters of Holdings.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Moody&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means Moody&#8217;s Investors Service, Inc. and its successors.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Mortgage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means each mortgage, deed of trust or other agreement which conveys or evidences a Lien in favor of the Agent, for the benefit of the Secured Parties, on real property of a Credit Party, including any amendment, restatement, modification or supplement thereto.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Mortgage Instruments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means such title reports, title insurance, flood certifications and flood insurance, opinions of counsel, surveys, appraisals and environmental reports and other similar information and related certifications as are reasonably requested by, and in form and substance reasonably acceptable to, the Agent from time to time.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Multiemployer Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means a &#8220;multiemployer plan&#8221; (as defined in Section 4001(a)(3) of ERISA) that is subject to Title IV of ERISA contributed to for any employees of a Credit Party, any of its Subsidiaries or any ERISA Affiliate.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Net Cash Proceeds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means when used in respect of (i) any Disposition, (ii) the receipt of any proceeds in connection with any Event of Loss suffered, or (iii) the receipt of any proceeds in connection with an IPO, in the case of clauses (i) and (ii), by a Credit Party or any of its Subsidiaries, and, in the case of clause (iii), by Holdings or any direct or indirect holding company of Holdings, the gross proceeds in cash or Cash Equivalent Investments received by such Person (excluding, in connection with any Disposition, any portion of such proceeds deposited in an escrow account pursuant to the documentation related thereto but including such proceeds subsequently received in respect of noncash consideration initially received and amounts initially placed in escrow that subsequently become available) from such Disposition, Event of Loss or IPO, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">minus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, without duplication, (a) all direct costs and expenses incurred or to be incurred (including sales, commissions and legal, accounting and investment banking fees, commissions and expenses), (b) all federal, state, local and foreign Taxes assessed or to be assessed (if any), in connection therewith, (c) in connection with any Disposition or Event of Loss, amounts required to be applied to the repayment of any Permitted Indebtedness (together with any interest thereon, premium or penalty and any other amount payable with respect thereto) secured by a Permitted Lien that has priority over the Lien, if any, of the Agent on the asset subject to such Disposition or Event of Loss, (d) in connection with any Disposition, reserves for purchase price adjustments and retained liabilities reasonably expected to be payable by Holdings or any Subsidiary in connection therewith, to the extent such reserves have been established in accordance with GAAP&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> that upon the final determination of the amount paid in respect of such purchase price adjustments and retained liabilities, if the actual amount of purchase price adjustments and retained liabilities paid is less than such reserves, the difference shall, at such time, constitute Net Cash Proceeds, and (e) with respect to any Event of Loss, all money actually applied within one hundred eighty (180) days to replace the assets in question or to repair or reconstruct damaged property or property affected by loss, destruction, damage, condemnation, confiscation, requisition, seizure or taking.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Net Income</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, for any applicable Fiscal Period for any Person determined on a consolidated basis for such Person and its Subsidiaries in accordance with GAAP, the aggregate of all amounts (exclusive of all amounts in respect of any extraordinary gains but including extraordinary losses) which would be included as net income on the consolidated financial statements of such Person and its Subsidiaries for such Fiscal Period.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, for any applicable Fiscal Period, the revenue of the Credit Parties and their Subsidiaries from the sale of Products (current or future to the extent the revenue is actually earned and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">recognized during such Fiscal Period) during such Fiscal Period, determined on a consolidated basis in accordance with GAAP.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means a promissory note of the Borrower payable to a Lender (as such promissory note may be amended, endorsed or otherwise modified from time to time), evidencing the aggregate Indebtedness of the Borrower to such Lender resulting from the outstanding amount of the Loans, and also means all other promissory notes accepted from time to time in substitution therefor or renewal thereof.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means all obligations (monetary or otherwise, whether absolute or contingent, matured or unmatured) of any Credit Party or any of its Subsidiaries arising under or in connection with a Loan Document and the principal of and premium, if any, and interest (including interest accruing during the pendency of any proceeding of the type described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 9.1(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, whether or not allowed in such proceeding) on the Loans.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;OFAC&#8221; means the Office of Foreign Assets Control of the United States Department of the Treasury.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Organic Document</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, relative to any Credit Party or any of its Subsidiaries, its certificate of incorporation, by-laws, certificate of partnership, partnership agreement, certificate of formation, limited liability agreement, operating agreement and all shareholder agreements, voting trusts and similar arrangements applicable to such Credit Party&#8217;s or any of its Subsidiaries&#8217; Capital Securities and, with respect to any UK Subsidiary Guarantor, the Constitutional Documents of such UK Subsidiary Guarantor.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Other Administrative Proceeding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any administrative proceeding relating to a dispute involving a patent office or other relevant intellectual property registry which relates to validity, revocation, ownership or enforceability of the relevant Intellectual Property.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Other Connection Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, with respect to any Recipient, Taxes imposed as a result of a present or former connection between such Recipient and the jurisdiction imposing such Tax (other than connections arising from such Recipient having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in any Loan or Loan Document).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Other Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means all present or future stamp, court or documentary, intangible, recording, filing or similar Taxes that arise from any payment made under, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Loan Document, except any such Taxes that are Other Connection Taxes imposed with respect to an assignment.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Participant Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 11.11(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any patent and patent application, including any divisions, continuations, continuations in-part, provisionals, continued prosecution applications, substitutions, reissues, reexaminations, renewals, extensions, restorations, supplemental protection certificates and other additions in connection therewith, whether in or related to the United States or any foreign country or other jurisdiction.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:38pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Patent Security Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any Patent Security Agreement executed and delivered by any Credit Party and&#47;or any of its Subsidiaries, as applicable, in substantially the form of Exhibit C to the Security Agreement, as amended or otherwise modified from time to time.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Patriot Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the USA PATRIOT Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Payment in Full</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the entire principal amount of the Loans, interest thereon and all other Obligations, including all applicable Specified Repayment Fees and fees set forth in the Fee Letter, shall have been indefeasibly paid in full in cash (other than inchoate indemnification, expense reimbursement obligations and other contingent obligations for which no claim has been asserted).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">PBGC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the Pension Benefit Guaranty Corporation, or any entity succeeding to all or any of its functions under ERISA.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Pension Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means a &#8220;pension plan&#8221;, as such term is defined in Section 3(2) of ERISA, which is subject to Title IV of ERISA (other than a Multiemployer Plan), to which a Credit Party, any of its Subsidiaries or any ERISA Affiliate sponsors, contributes to, or provides benefits under, or has any obligation to contribute or provide benefits under, and to which a Credit Party or any of its Subsidiaries or ERISA Affiliate could reasonably be expected to have liability, including any liability by reason of having been a substantial employer under Section 4063 of ERISA at any time during the preceding five years, or by reason of being deemed to be a contributing sponsor under Section 4069 of ERISA.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Perfection Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means a certificate duly completed and executed by an Authorized Officer of the Borrower, substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> hereto, together with such changes thereto as the Agent or the Majority Lenders may from time to time request.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Periodic Term SOFR Determination Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning specified in the definition of &#8220;Term SOFR&#8221;.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Permits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means all permits, licenses, registrations, certificates, orders, approvals, authorizations, consents, waivers, franchises, variances and similar rights issued by or obtained from any Governmental Authority or any other Person, including, without limitation, those relating to Environmental Laws and Healthcare Laws.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Permitted Disposition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any of the following&#58; (i) Dispositions of inventory in the ordinary course of business, (ii) Dispositions of obsolete, damaged, worn out or surplus property in the ordinary course of business, (iii) licenses, sublicenses or similar agreements that are permitted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">8.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, (iv) any issuance, offer, sale, transfer or other Disposition of Qualified Capital Securities of Holdings, (v) the sale, lease, sublease or transfer of property or assets (A) from one Credit Party to another Credit Party, (B) from a Subsidiary that is not a Credit Party to another Subsidiary that is not a Credit Party or to any Credit Party or (C) from a Credit Party to a Subsidiary that is not a Credit Party, in an aggregate amount under this clause (C), together with the aggregate amount of Investments made pursuant to Section 8.5(g), not to exceed $2,000,000, (vi) Dispositions of accounts receivable in connection with the collection or compromise thereof in the ordinary course of business (other than in connection with financing transactions) and (vii) other Dispositions that (x) do not include Material Intellectual Property or Capital Securities with respect to Subsidiaries that directly or indirectly own, or hold a license in respect of, Material Intellectual Property and (y) when taken together with all other Dispositions made during the preceding period of 12 consecutive months pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">clause (vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, do not exceed $2,500,000 in the aggregate.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Permitted Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Permitted Investments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Permitted Lien</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any natural person, corporation, limited liability company, partnership, joint venture, association, trust or unincorporated organization, Governmental Authority or any other legal entity, whether acting in an individual, fiduciary or other capacity.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means all data relating to one or more individual(s) that is personally identifying (i.e., data that identifies an individual or, in combination with any other information or data available to Holdings or its Subsidiaries, is capable of identifying an individual) or capable of identifying a specific device or non-personally identifying, including, without limitation, aggregate or de-identified data and data collected automatically, including data collected through a mobile or other electronic device.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">PIK Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.10(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">PIK Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.10(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Plaque</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the HeartFlow product that provides plaque identification, characterization, and visualization, and is presented with the FFRct model, FDA 510(k) approval for which was received on October 14, 2022 (510(k) No.&#58; K213857).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Prime Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the rate of interest per annum last quoted by The Wall Street Journal as the &#8220;Prime Rate&#8221; in the U.S. or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the F.R.S. Board in Federal Reserve Statistical Release H.15 (519) (Selected Interest Rates) as the &#8220;bank prime loan&#8221; rate or, if such rate is no longer quoted therein, any similar rate quoted therein (as determined by the Agent) or any similar release by the F.R.S. Board (as determined by the Agent). Any change in the Prime Rate shall take effect at the opening of business on the day such change is publicly announced or quoted as being effective.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Privacy and Data Security Policies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.16(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Privacy Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.16(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Pro Rata Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Lender, the percentage (expressed as a decimal and carried out to the ninth decimal place) obtained by dividing (x) the aggregate outstanding principal amount of Loans made hereunder by such Lender, by (y) the aggregate outstanding principal amount of all Loans made hereunder by all Lenders, in each case subject to adjustment as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Pro Rata Share of each Lender in respect of the Loans is set forth opposite the name of such Lender on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> under the caption &#8220;Pro Rata Shares&#8221; or in the Assignment and Assumption pursuant to which such Lender becomes a party hereto, as applicable.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any current product developed, manufactured, licensed, marketed, sold, distributed, or otherwise commercialized by any Credit Party (other than Holdings), including any such product in development or which may be developed.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Product Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means each agreement, license, document, instrument, interest (equity or otherwise) or the like under which one or more Persons grants or receives any right, title or interest with respect to any Product Development and Commercialization Activities in respect of one or more Products specified therein, or receives or is granted the right to exclude any third parties from engaging in any Product Development and Commercialization Activities with respect thereto, including each contract or agreement with suppliers, manufacturers, distributors, clinical research organizations, wholesalers, pharmacies or with any other Person related to any such entity.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Product Development and Commercialization Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8221; means, with respect to any Product, any combination of research, development, manufacture, importation, exportation, use, sale, storage, design, labeling, marketing, promotion, supply, distribution, testing, packaging, purchasing or other commercialization activities, receipt of payment in respect of any of the foregoing, or like activities the purpose of which is to commercially exploit such Product.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Prohibited Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8221; means any bribe, rebate, payoff, influence payment, kickback or other payment or gift of money or anything of value (including meals or entertainment) to any officer, employee or ceremonial office holder of any government or instrumentality thereof, political party or supra-national organization (such as the United Nations), any political candidate, any royal family member or any other person who is connected or associated personally with any of the foregoing that is prohibited under any applicable law or regulation or otherwise for the purpose of influencing any act or decision of such payee in his official capacity, inducing such payee to do or omit to do any act in violation of his lawful duty, securing any improper advantage or inducing such payee to use his influence with a government or instrumentality thereof to affect or influence any act or decision of such government or instrumentality.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Qualified Capital Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8221; means, with respect to any Person, any Capital Security of such Person that is not a Disqualified Capital Security.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Recipient</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8221; means the Agent or any Lender, as applicable.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8221; means any Governmental Authority that is concerned with or has regulatory oversight with respect to the use, control, safety, efficacy, reliability, manufacturing, labeling, packaging, handling, storage, marketing, advertising, promotion, distribution, sale or other Product Development and Commercialization Activities relating to any Product of any Credit Party or any of its Subsidiaries, including the FDA and all equivalents of such agency in other jurisdictions and Standard Bodies.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Regulatory Authorizations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8221; means any and all clearances, approvals, and other forms of authorization, and related internal documentation where applicable, forming the basis for distribution of products (including without limitation, 510(k) clearances, internal decision documentation under FDA guidance on changes to 510(k)-cleared products, and where applicable supplements and amendments, governmental price and reimbursement approvals and approvals of applications for regulatory exclusivity), licenses, registrations, or authorizations of any Governmental Authority necessary for the manufacture, development, testing, distribution, use, storage, import, export, transport, promotion, marketing, sale, or other commercialization of a Product in any country or jurisdiction, and including, with respect to the Products, that each Product has been and is lawfully marketed by the Borrower in conformity and compliance with all applicable laws (including Healthcare Laws), regulations, enforcement policies, and similar pronouncements of any Regulatory Authority respecting any Product of the Borrower.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Related Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8221; means, with respect to any Person, such Person&#8217;s Affiliates and the partners, directors, officers, employees, agents, trustees, administrators, managers, advisors and representatives of such Person and such Person&#8217;s Affiliate.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8221; means any releasing, disposing, discharging, injecting, spilling, leaking, leaching, pumping, pouring, dumping, depositing, emitting, escaping, emptying, seeping, dispersal, migrating or placing, including movement through, into or upon the environment or any natural or man-made structure.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Relevant Governmental Body</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8221; means the F.R.S. Board or the Federal Reserve Bank of New York, or a committee officially endorsed or convened by the F.R.S. Board or the Federal Reserve Bank of New York, or any successor thereto.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Resignation Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.6(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Resolution Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means an EEA Resolution Authority or, with respect to any UK Financial Institution, a UK Resolution Authority.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Restricted Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means (i) the declaration or payment of any dividend (other than dividends payable solely in Capital Securities of a Credit Party or any of its Subsidiaries) on, or the making of any payment or distribution on account of, or setting apart assets for a sinking or other analogous fund for the purchase, redemption, defeasance, retirement or other acquisition of, any class of Capital Securities of a Credit Party or any of its Subsidiaries or any warrants, options or other right or obligation to purchase or acquire any such Capital Securities, whether now or hereafter outstanding or (ii) the making of any other distribution in respect of such Capital Securities, in each case either directly or indirectly, whether in cash, property or obligations of a Credit Party or any of its Subsidiaries or otherwise.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Roadmap</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the HeartFlow product that provides coronary vascular physiologic simulation, FDA 510(k) approval for which was received on October 14, 2022 (510(k) No.&#58; K213857).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">S&#38;P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Standard &#38; Poor&#8217;s Financial Services LLC, a subsidiary of S&#38;P Global Inc., and its successors.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sanction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any international economic sanction administered or enforced by the United States Government (including, without limitation, OFAC), the United Nations Security Council, the European Union or its Member States, Her Majesty&#8217;s Treasury or other relevant sanctions authority.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sanctioned Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any Person that is a target of Sanctions, including without limitation, a Person that is (i) listed on OFAC&#8217;s Specially Designated Nationals and Blocked Persons List, (ii) listed on OFAC&#8217;s Consolidated Non-SDN List, (iii) a legal entity that is deemed by OFAC to be a Sanctions target based on the ownership of such legal entity by Sanctioned Peron(s), or (iv) a Person that is a Sanctions target pursuant to any list-based, territorial or country-based Sanctions program of a Governmental Authority.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Securities and Exchange Commission.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Secured Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, collectively, the Agent and each of the Lenders.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Security Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Security Agreement, dated as of the date hereof, by and among the Borrower, the Subsidiary Guarantors and the Agent, as amended or otherwise modified from time to time.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">SOFR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a rate equal to the secured overnight financing rate as administered by the SOFR Administrator.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">SOFR Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Federal Reserve Bank of New York (or a successor administrator of the secured overnight financing rate).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">SOFR Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a Loan that bears interest at a rate based on Term SOFR, other than pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of the definition of &#8220;ABR&#8221;.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Solvent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, (x) with respect to the Credit Parties and their Subsidiaries on a particular date, that on such date (i) the fair value of the property of the Credit Parties and their Subsidiaries on a consolidated basis is greater than the total amount of liabilities, including Contingent Liabilities, of the</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Credit Parties and their Subsidiaries on a consolidated basis, (ii) the present fair saleable value of the assets of the Credit Parties and their Subsidiaries on a consolidated basis is not less than the amount that will be required to pay the probable liability of the Credit Parties and their Subsidiaries on a consolidated basis on its debts as they become absolute and matured, (iii) &#91;reserved&#93;, (iv) the Credit Parties and their Subsidiaries on a consolidated basis are not engaged in business or a transaction, and the Credit Parties on a consolidated basis are not about to engage in a business or a transaction, for which the property of the Credit Parties and their Subsidiaries on a consolidated basis would constitute an unreasonably small capital and (v) the Credit Parties and their Subsidiaries have not executed this Agreement or any other Loan Document or made any transfer or incurred any obligations hereunder, with actual intent to hinder, delay or defraud either present or future creditors&#59; and (y) with respect to the Borrower on a particular date, that on such date (i) the fair value of the property of the Borrower is greater than the total amount of liabilities, including Contingent Liabilities, of the Borrower, (ii) the present fair saleable value of the assets of the Borrower is not less than the amount that will be required to pay the probable liability of the Borrower on its debts as they become absolute and matured, (iii) &#91;reserved&#93;, (iv) the Borrower is not engaged in business or a transaction, and the Borrower is not about to engage in a business or a transaction, for which the property of the Borrower would constitute an unreasonably small capital and (v) the Borrower have not executed this Agreement or any other Loan Document or made any transfer or incurred any obligations hereunder, with actual intent to hinder, delay or defraud either present or future creditors. The amount of Contingent Liabilities at any time shall be computed as the amount that, in light of all the facts and circumstances existing at such time, can reasonably be expected to become an actual or matured liability.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">SPAC Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8221; means the merger, acquisition, contribution, equity purchase or similar reorganization transaction or series of transactions resulting in the combination of the Borrower (or any corporate successor (including a Subsidiary) thereof) or Holdings and any special purpose acquisition company or similar entity, in each case, where such acquisition company or entity has no material commercial operations and where the common Capital Securities of such surviving entity (or any direct or indirect parent thereof) are publicly listed on any United States national securities exchange.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Specified Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8221; means any of the persons and entities listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Schedule 1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Specified Repayment Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8221; means for any prepayment or repayment of Loans occurring (i) at any time on or prior to the second anniversary of the Closing Date, none, (ii) at any time after the second anniversary of the Closing Date and on or prior to the third anniversary of the Closing Date, an amount equal to one and one-half percent (1.5%) of the aggregate outstanding principal amount of the Loans being prepaid or repaid and (iii) at any time after the third anniversary of the Closing Date and on or prior to the Maturity Date, an amount equal to three percent (3.0%) of the aggregate outstanding principal amount of the Loans being prepaid or repaid.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Standard Bodies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8221; means any of the organizations that create, sponsor and maintain safety, quality or other standards, including ISO, ANSI, CEN, SCC and the like.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Stanford Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8221; means (i) that certain Exclusive Agreement, dated July 22, 2010, by and between the Board of Trustees of the Leland Stanford Junior University, as licensor, and the Borrower, formerly known as Cardiovascular Simulation, Inc., as licensee, (ii) that certain Software Exclusive License Agreement, dated April 20, 2010, by and between the Board of Trustees of the Leland Stanford Junior University, as licensor, and the Borrower, formerly known as Cardiovascular Simulation, Inc., as licensee&#59; as amended by that certain Amendment No. 1, dated August 28, 2014 and that certain Amendment No. 2, dated April 19, 2020, and (iii) that certain Software Exclusive License Agreement, dated June 18, 2009, by and between the Board of Trustees of the Leland Stanford Junior University, as licensor, and the Borrower, formerly known as Cardiovascular Simulation, Inc., as licensee&#59; as amended by that certain Amendment No. 1, dated June 17, 2014 and that certain Amendment No. 2, dated June 17, 2019.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Person, any other Person of which more than 50% of the outstanding Voting Securities (irrespective of whether at the time Capital Securities of any other class or classes of such other Person shall or might have voting power upon the occurrence of any contingency) or the issued Capital Securities of such other Person is at the time directly or indirectly owned or Controlled by such Person, by such Person and one or more other Subsidiaries of such Person, or by one or more other Subsidiaries of such Person. Unless the context otherwise specifically requires, the term &#8220;Subsidiary&#8221; shall be a reference to a Subsidiary of Holdings, whether direct or indirect.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Subsidiary Guarantor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means initially as of the Closing Date, each Subsidiary of Holdings identified under the caption &#8220;SUBSIDIARY GUARANTORS&#8221; on the signature pages hereto, if any, and, thereafter, each Subsidiary of Holdings that becomes a &#8220;Subsidiary Guarantor&#8221; after the Closing Date pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Synthetic Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, as applied to any Person, any lease (including leases that may be terminated by the lessee at any time) of any property (whether real, personal or mixed) (i) that is not a capital lease in accordance with GAAP and (ii) in respect of which the lessee retains or obtains ownership of the property so leased for federal income tax purposes, other than any such lease under which that Person is the lessor.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Systems</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the computers, servers, devices, networks, software, and systems used in connection with the operation of the business of Holdings or any of its Subsidiaries.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means all present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Term SOFR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means,</font></div><div style="margin-bottom:10pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;for any calculation with respect to a SOFR Loan, the Term SOFR Reference Rate for a tenor comparable to the applicable Interest Period on the day (such day, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Periodic Term SOFR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Determination Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) that is two (2) U.S. Government Securities Business Days prior to the first day of such Interest Period, as such rate is published by the Term SOFR Administrator&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that if as of 5&#58;00 p.m. (New York City time) on any Periodic Term SOFR Determination Day the Term SOFR Reference Rate for the applicable tenor has not been published by the Term SOFR Administrator and a Benchmark Replacement Date with respect to the Term SOFR Reference Rate has not occurred, then Term SOFR will be the Term SOFR Reference Rate for such tenor as published by the Term SOFR Administrator on the first preceding U.S. Government Securities Business Day for which such Term SOFR Reference Rate for such tenor was published by the Term SOFR Administrator so long as such first preceding U.S. Government Securities Business Day is not more than three (3) U.S. Government Securities Business Days prior to such Periodic Term SOFR Determination Day, and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;for any calculation with respect to an ABR Loan on any day, the Term SOFR Reference Rate for a tenor of one month on the day (such day, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ABR Term SOFR Determination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) that is two (2) U.S. Government Securities Business Days prior to such day, as such rate is published by the Term SOFR Administrator&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that if as of 5&#58;00 p.m. (New York City time) on any ABR Term SOFR Determination Day the Term SOFR Reference Rate for the applicable tenor has not been published by the Term SOFR Administrator and a Benchmark Replacement Date with respect to the Term SOFR Reference Rate has not occurred, then Term SOFR will be the Term SOFR Reference Rate for such tenor as published by the Term SOFR Administrator on the first preceding U.S. Government Securities Business Day for which such Term SOFR Reference Rate for such tenor was published by the Term SOFR</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Administrator so long as such first preceding U.S. Government Securities Business Day is not more than three (3) U.S. Government Securities Business Days prior to such ABR SOFR Determination Day&#59;</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that if Term SOFR determined as provided above (including pursuant to the proviso under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> above) shall ever be less than 2.00%, then Term SOFR shall be deemed to be 2.00%.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Term SOFR Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means CME Group Benchmark Administration Limited (CBA) (or a successor administrator of the Term SOFR Reference Rate selected by the Agent in its reasonable discretion).</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Term SOFR Reference Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the forward-looking term rate based on SOFR.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the date on which Payment in Full occurs.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Trademark</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any trademark, service mark, trade name, logo, symbol, trade dress, domain name, rights in social media accounts, corporate name and other indicator of source or origin, and all applications and registrations therefor, together with all of the goodwill associated with the therewith.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Trademark Security Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any Trademark Security Agreement executed and delivered by any Credit Party and&#47;or any of its Subsidiaries, as applicable, substantially in the form of Exhibit D to the Security Agreement, as amended or otherwise modified from time to time.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Trade Secrets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean trade secrets and other confidential information data and databases, in each case that derive economic value from not being generally known by the public and not being readily ascertainable by other Persons, and all claims and rights related to any of the foregoing.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Two-Consecutive Fiscal Quarter Net Sales Decline</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean a decrease in Net Sales for two consecutive Fiscal Quarters, in each case as compared to the Fiscal Quarter immediately preceding such two consecutive Fiscal Quarters.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Type</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;, when used in reference to any Loan, refers to whether the rate of interest on such Loan is determined by reference to Term SOFR or ABR.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">UCC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Uniform Commercial Code as in effect from time to time in the State of New York&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that, if, with respect to any financing statement or by reason of any provisions of law, the perfection or the effect of perfection or non-perfection of the security interests granted to the Agent, on behalf of the Secured Parties, pursuant to the applicable Loan Document is governed by the Uniform Commercial Code as in effect in a jurisdiction of the United States other than New York, then &#8220;UCC&#8221; means the Uniform Commercial Code as in effect from time to time in such other jurisdiction for purposes of the provisions of each Loan Document and any financing statement relating to such perfection or effect of perfection or non-perfection.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">UK Financial Institution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any BRRD Undertaking (as such term is defined under the PRA Rulebook (as amended form time to time) promulgated by the United Kingdom Prudential Regulation Authority) or any person falling within IFPRU 11.6 of the FCA Handbook (as amended from time to time) promulgated by the United Kingdom Financial Conduct Authority, which includes certain credit institutions and investment firms, and certain affiliates of such credit institutions or investment firms.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">UK Resolution Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Bank of England or any other public administrative authority having responsibility for the resolution of any UK Financial Institution.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">25</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">UK Subsidiary Guarantor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means each Guarantor incorporated under the laws of England and Wales.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">U.S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the United States of America, its fifty states and the District of Columbia.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">United States Registered IP Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any United States patent, patent application, trademark registration, trademark application or copyright registration.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. Government Securities Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any day except for (i) a Saturday, (ii) a Sunday or (iii) a day on which the Securities Industry and Financial Markets Association recommends that the fixed income departments of its members be closed for the entire day for purposes of trading in United States government securities.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any Person that is a &#8220;United States Person&#8221; as defined in Section 7701(a)(30) of the Code.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Voting Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Person, Capital Securities of any class or kind ordinarily having the power to vote for the election of directors, managers or other voting members of the governing body of such Person.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Warrants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, collectively, each certain Warrant to Purchase Common Stock issued by Holdings pursuant to the Existing Credit Agreement.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Welfare Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a &#8220;welfare plan&#8221;, as such term is defined in Section 3(1) of ERISA, which any Credit Party or any of its Subsidiaries sponsors, contributes to, or provides benefits under, or has any obligation to contribute or provide benefits under.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">wholly owned Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any direct or indirect Subsidiary of Holdings, all of the outstanding Capital Securities of which (other than any director&#8217;s qualifying shares or investments by foreign nationals mandated by applicable laws) is owned directly or indirectly by Holdings.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Withholding Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Credit Parties and the Agent.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Write-Down and Conversion Powers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, (i) with respect to any EEA Resolution Authority, the write-down and conversion powers of such EEA Resolution Authority from time to time under the Bail-In Legislation for the applicable EEA Member Country, which write-down and conversion powers are described in the EU Bail-In Legislation Schedule and (ii) with respect to the United Kingdom, any powers of the applicable Resolution Authority under the Bail-In Legislation to cancel, reduce, modify or change the form of a liability of any UK Financial Institution or any contract or instrument under which that liability arises, to convert all or part of that liability into shares, securities or obligations of that person or any other person, to provide that any such contract or instrument is to have effect as if a right had been exercised under it or to suspend any obligation in respect of that liability or any of the powers under that Bail-In Legislation that are related to or ancillary to any of those powers.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. For all purposes of this Agreement, except as otherwise expressly provided herein or unless the context otherwise requires,</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;the terms defined in this Agreement include the plural as well as the singular and vice versa&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;words importing gender include all genders&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;any reference to a Section, Annex, Schedule or Exhibit refers to a Section of, or Annex, Schedule or Exhibit to, this Agreement&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(d)&#160;&#160;&#160;&#160;any reference to &#8220;this Agreement&#8221; refers to this Agreement, including all Annexes, Schedules and Exhibits hereto, and the words herein, hereof, hereto and hereunder and words of similar import refer to this Agreement and its Annexes, Schedules and Exhibits as a whole and not to any particular Section, Annex, Schedule, Exhibit or any other subdivision&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(e)&#160;&#160;&#160;&#160;references to days, months and years refer to calendar days, months and years, respectively&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(f)&#160;&#160;&#160;&#160;all references herein to &#8220;include&#8221; or &#8220;including&#8221; shall be deemed to be followed by the words &#8220;without limitation&#8221;&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(g)&#160;&#160;&#160;&#160;the word &#8220;from&#8221; when used in connection with a period of time means &#8220;from and including&#8221; and the word &#8220;until&#8221; means &#8220;to but not including&#8221;&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(h)&#160;&#160;&#160;&#160;the words &#8220;asset&#8221; and &#8220;property&#8221; shall be construed to have the same meaning and effect and to refer broadly to any and all assets and properties, whether tangible or intangible, real or personal, including cash, Capital Securities, rights under contractual obligations and permits and any right or interest in any such assets or property&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)&#160;&#160;&#160;&#160;the word &#8220;will&#8221; shall have the same meaning as the word &#8220;shall&#8221;.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Unless otherwise expressly provided herein, references to organizational documents, agreements (including the Loan Documents) and other contractual instruments shall be deemed to include all subsequent amendments, restatements, extensions, supplements and other modifications thereto permitted by the Loan Documents.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 1.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Accounting and Financial Determinations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Unless otherwise specified, all accounting terms used in each Loan Document shall be interpreted, and all accounting determinations and computations thereunder (including under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> and any definitions used in such calculations) shall be made, in accordance with those generally accepted accounting principles (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) applied in the preparation of the financial statements referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 5.1(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Unless otherwise expressly provided, all financial covenants and defined financial terms shall be computed on a consolidated basis for Holdings and its Subsidiaries, in each case without duplication. Notwithstanding any other provision contained herein, all terms of an accounting or financial nature used herein shall be construed, and all computations of amounts and ratios referred to herein, and the determination of Indebtedness hereunder, shall be made without giving effect to Financial Accounting Standards Board (FASB) Standard ASC 842 (Leases) (or any other applicable financial accounting standard having a similar result or effect) and related interpretations, in each case, to the extent any lease (or similar arrangement conveying the right to use) would be required to be treated as a capital lease thereunder where such lease (or similar arrangement) would have been treated as an operating lease under GAAP as in effect immediately prior to the effectiveness of the ASC 842.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 1.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Divisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. For all purposes under the Loan Documents, in connection with any division or plan of division under Delaware law (or any comparable event under a different jurisdiction&#8217;s laws)&#58; (i) if any asset, right, obligation or liability of any Person becomes the asset, right, obligation or liability of a different Person, then it shall be deemed to have been transferred from the original Person to</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">27</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">the subsequent Person, and (ii) if any new Person comes into existence, such new Person shall be deemed to have been organized on the first date of its existence by the holders of its Capital Securities at such time.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">SECTION 1.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Rates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">. The Agent does not warrant or accept responsibility for, and shall not have any liability with respect to (a) the continuation of, administration of, submission of, calculation of or any other matter related to ABR, the Term SOFR Reference Rate or Term SOFR, or any component definition thereof or rates referred to in the definition thereof, or any alternative, successor or replacement rate thereto (including any Benchmark Replacement), including whether the composition or characteristics of any such alternative, successor or replacement rate (including any Benchmark Replacement) will be similar to, or produce the same value or economic equivalence of, or have the same volume or liquidity as, ABR, the Term SOFR Reference Rate, Term SOFR or any other Benchmark prior to its discontinuance or unavailability, or (b) the effect, implementation or composition of any Conforming Changes. The Agent and its affiliates or other related entities may engage in transactions that affect the calculation of ABR, the Term SOFR Reference Rate, Term SOFR, any alternative, successor or replacement rate (including any Benchmark Replacement) or any relevant adjustments thereto, in each case, in a manner adverse to the Borrower. The Agent may select information sources or services in its reasonable discretion to ascertain ABR, the Term SOFR Reference Rate, Term SOFR or any other Benchmark, in each case pursuant to the terms of this Agreement, and shall have no liability to the Borrower, any Lender or any other person or entity for damages of any kind, including direct or indirect, special, punitive, incidental or consequential damages, costs, losses or expenses (whether in tort, contract or otherwise and whether at law or in equity), for any error or calculation of any such rate (or component thereof) provided by any such information source or service.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">ARTICLE II</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">THE LOANS</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">SECTION 2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Commitments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">. On the terms and subject to the conditions of this Agreement, each of the Lenders agrees to make the Loans to the Borrower on the Closing Date in an amount not to exceed the Loan Commitment Amount. No amounts paid or prepaid with respect to any of the Loans may be reborrowed. The Loan Commitment Amount shall automatically and permanently be reduced to zero immediately after the making of the Loans on the Closing Date.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">SECTION 2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Borrowing Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">. Subject to the terms and conditions hereof, the Borrower may irrevocably request that the Loans be made by delivering to the Agent a Loan Request on or before 10&#58;00 a.m. (London, England time) on a Business Day at least two (2) Business Days prior to the proposed Closing Date (or such shorter period as the Agent may agree in its sole discretion).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">SECTION 2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Funding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">. After receipt of a Loan Request for the Loans pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Section&#160;2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">, each applicable Lender shall, on the Closing Date, and subject to the terms and conditions hereof (including the satisfaction of all conditions precedent set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Article V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%"> hereof), make the applicable Loans to the Borrower, in the amounts set forth opposite such Lender&#8217;s name on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Schedule 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%"> that, at the request of the Borrower, the Agent shall cause the proceeds of the Loans to be disbursed, by wire transfer of immediately available funds, in the amount and to the accounts set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Schedule 2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">ARTICLE III</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">REPAYMENTS, PREPAYMENTS, INTEREST AND FEES</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">SECTION 3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Applicable Currency for Repayments and Prepayments&#59; Pro Rata Application</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%"> The Borrower agrees that the Loans, and any fees or interest accrued or accruing thereon, shall be repaid and prepaid solely in Dollars. Except as otherwise provided in this Agreement, each payment (including each repayment and prepayment) by the Borrower will be deemed to be made ratably in accordance with</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">the Pro Rata Shares of the Lenders, and upon receipt of any such payment the Agent will promptly thereafter distribute like funds relating to any such payment to the Lenders in accordance with their Pro Rata Shares.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Repayments and Prepayments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. There will be no scheduled repayments of principal on the Loans prior to the Maturity Date. On the Maturity Date, the Borrower shall repay the entire unpaid principal amount of the Loans in full in cash. Prior thereto, payments, repayments and prepayments of the Loans shall be made as set forth below in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Nothing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> shall be deemed to (or be construed to) permit or authorize any transaction by any Credit Party that otherwise is prohibited or not specifically permitted by this Agreement or any other Loan Document. Unless otherwise expressly provided herein, all payments, repayments and prepayments described in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> shall be subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">&#91;Reserved&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. The Borrower may, upon five (5) Business Days&#8217; prior written notice to the Agent, voluntarily prepay the outstanding principal amount of the Loans in whole or in part.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Dispositions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Upon any Disposition by a Credit Party or any of its Subsidiaries (other than a Permitted Disposition), made in any period of twelve (12) consecutive months that, when taken together with all other Dispositions made during such 12-month period, results in aggregate Net Cash Proceeds from such Dispositions that exceed $2,000,000 for such 12-month period, the Borrower shall, within three (3) Business Days of such Person&#8217;s receipt of such excess proceeds thereof, prepay the outstanding principal amount of the Loans in an amount equal to 100% of such excess Net Cash Proceeds. The provisions of this clause shall not be deemed to be implied consent to any Disposition otherwise prohibited by the terms and conditions of this Agreement.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Events of Loss</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Upon the receipt by a Credit Party or any of its Subsidiaries of any Event of Loss, received in any period of 12 consecutive months, that when taken together with all other Events of Loss during such 12-month period, results in aggregate Net Cash Proceeds from such Events of Loss that exceed $2,000,000 for such 12-month period, the Borrower shall, within three (3) Business Days of such Person&#8217;s receipt of such excess proceeds thereof, prepay the outstanding principal amount of the Loans in an amount equal to 100% of such excess Net Cash Proceeds.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Other Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Upon the issuance, sale or other incurrence of any debt securities or other Indebtedness by a Credit Party or any of its Subsidiaries (other than Permitted Indebtedness), the Borrower shall, within three (3) Business Days of such Person&#8217;s receipt of the proceeds thereof, prepay the outstanding principal amount of the Loans in an amount equal to 100% of the net cash proceeds therefrom. The provisions of this clause shall not be deemed to be implied consent to any such issuance, sale or incurrence otherwise prohibited by the terms and conditions of this Agreement.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Acceleration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Immediately upon any acceleration of the applicable Maturity Date of the Loans pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 9.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, the Borrower shall repay the Loans in full, unless, pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 9.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, only a portion of the Loans are so accelerated (in which case the portion so accelerated shall be so repaid).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Immediately upon the occurrence of a Change in Control, the Borrower shall repay the Loans in full.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">IPO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Immediately upon the consummation of an IPO or a SPAC, the Borrower shall repay the Loans in an amount equal to the lesser of (i) the Net Cash Proceeds of such IPO or SPAC in excess of $150,000,000 and (ii) $35,000,000.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">29</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Application</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Proceeds of each prepayment or repayment of the Loans shall be applied as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 3.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Interest Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, during any applicable Interest Period, (a) each ABR Loan shall accrue interest at a rate per annum equal to the sum of (i) the Applicable Margin, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">plus </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii) ABR and (b) each SOFR Loan shall accrue interest during such Interest Period at a rate per annum equal to the sum of (i) the Applicable Margin, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (ii) Term SOFR for such Interest Period. The interest rate shall be recalculated and, if necessary, adjusted for each Interest Period, in each case pursuant to the terms hereof.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 3.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Default Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Upon the occurrence and during the continuance of an Event of Default, and continuing until such Event of Default is no longer continuing, upon written notice by the Agent (acting pursuant to the instruction of the Majority Lenders (in their sole discretion)), the Applicable Margin shall be increased by 3.00% per annum (such increase, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Default Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). The Default Rate, along with all other interest due and payable on such date, shall be payable in cash on the last Business Day of each calendar month.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 3.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Payment Dates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Interest accrued on the Loans shall be payable in cash, without duplication&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;on the applicable Maturity Date therefor&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;on the date of any payment or prepayment, in whole or in part, of principal outstanding on the Loans, on the principal amount so paid or prepaid&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the last day of each Interest Period for the Loans&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;on that portion of the Loans that is accelerated pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">9.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, immediately upon such acceleration.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Interest accrued on the Loans or any other monetary Obligations after the date such amount is due and payable (whether on the applicable Maturity Date, upon acceleration or otherwise) shall be payable upon demand.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 3.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Credit Parties agree, jointly and severally, to pay to the Agent and the Lenders the fees set forth in the Fee Letter.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 3.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Specified Repayment Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Unless otherwise expressly provided herein, all payments, repayments and prepayments described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and made at any time after the second anniversary of the Closing Date (whether resulting from voluntary or involuntary prepayments or repayments, acceleration (including as a result of the occurrence of any event described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or otherwise)), including, for the avoidance of doubt, on the Maturity Date, shall be subject to the payment of Specified Repayment Fees as described below in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Until Payment in Full occurs, all such Specified Repayment Fees shall continue to be due and payable, including after the occurrence of any Default, acceleration, maturity or otherwise. If all or any portion of the outstanding Loans are repaid or prepaid for any reason after the second anniversary of the Closing Date, including, for the avoidance of doubt, on the Maturity Date, the Borrower shall pay the Specified Repayment Fee to the Agent at the time of such prepayment or repayment, together with any other fees payable hereunder. Specified Repayment Fees shall be nonrefundable once paid.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 3.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#91;Reserved&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 3.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">PIK Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.With respect to the Loans, during the period from the Closing Date until the Interest Payment Date occurring closest to (but not after) the date that is eighteen (18) months after the Closing Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">PIK Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), so long as no Default has occurred and is continuing on such date, by delivery of written notice to the Agent not less than five (5) Business Days prior to any Interest Payment Date, the Borrower may elect to pay all of the interest accrued on the Loans for the Interest Period ending on such Interest Payment Date &#8220;in kind&#8221; (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">PIK Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> that during the PIK Period, the Applicable Margin shall be increased by one percent (1.00%) per annum with respect to any such interest paid as PIK Interest.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;In each case, such election shall only relate to interest that is (x) due and payable on such Interest Payment Date and (y) accrued during the Interest Period ending on such Interest Payment Date. In the event the Borrower elects to pay PIK Interest pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 3.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, such PIK Interest shall be capitalized and added to the outstanding principal amount of the Loans on the applicable Interest Payment Date. For purposes of this Agreement and the other Loan Documents, the amounts so capitalized and added pursuant to the foregoing sentence will constitute a portion of the outstanding principal amount of the Loans as of such Interest Payment Date and will bear interest (which shall be due and payable) in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Sections 3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">3.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> and, to the extent applicable, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Notwithstanding anything to the contrary contained in this Agreement or in any other Loan Document, in the event that any Default has occurred and is continuing on any Interest Payment Date, all interest due and payable on such date must be paid in cash, irrespective of any election at any time by the Borrower to pay such interest in the form of PIK Interest.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 3.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Interest Computation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, each Loan shall initially be a SOFR Loan.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;All interest hereunder shall be computed on the basis of a year of 360 days (or in the case of interest computed by reference to the ABR at times when the ABR is based on the Prime Rate, such interest shall be computed on the basis of a year of 365 days (or 366 days in a leap year)), and in each case shall be payable for the actual number of days elapsed (including the first day but excluding the last day). All interest hereunder on any Loan shall be computed on a daily basis based upon the outstanding principal amount of such Loan as of the applicable date of determination. The applicable ABR or Term SOFR shall be determined by the Agent, and such determination shall be conclusive absent manifest error.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 3.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Term SOFR Conforming Changes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">In connection with the use or administration of Term SOFR, the Agent will have the right to make Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such Conforming Changes will become effective without any further action or consent of any other party to this Agreement or any other Loan Document. The Agent will promptly notify the Borrower and the Lenders of the effectiveness of any Conforming Changes in connection with the use or administration of Term SOFR.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ARTICLE IV</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SOFR AND OTHER PROVISIONS</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Increased Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Increased Costs Generally</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. If any Change in Law shall&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)&#160;&#160;&#160;&#160;impose, modify or deem applicable any reserve, special deposit, compulsory loan, insurance charge or similar requirement against assets of, deposits with or for the account of, or credit extended or participated in by, any Lender&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">31</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(ii)&#160;&#160;&#160;&#160;subject any Recipient to any Taxes (other than (A) Indemnified Taxes, (B) Taxes described in clauses (b) through (d) of the definition of Excluded Taxes and (C) Connection Income Taxes) on its loans, loan principal, letters of credit, commitments, or other obligations, or its deposits, reserves, other liabilities or capital attributable thereto&#59; or</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(iii)&#160;&#160;&#160;&#160;impose on any Lender or the London interbank market any other condition, cost or expense (other than Taxes) affecting this Agreement or Loans made by such Lender or any participation therein (except as otherwise accounted for in the definition of &#8220;Term SOFR&#8221;, as applicable)&#59;</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">and the result of any of the foregoing shall be to increase the cost to such Lender or such other Recipient of making, converting to, continuing or maintaining any Loan or of maintaining its obligation to make any such Loan, or to increase the cost to such Lender or such other Recipient of participating in, or to reduce the amount of any sum received or receivable by such Lender or other Recipient hereunder (whether of principal, interest or any other amount) then, upon request of such Lender or other Recipient, the Borrower will pay to such Lender or other Recipient, as the case may be, such additional amount or amounts as will compensate such Lender or other Recipient, as the case may be, for such additional costs incurred or reduction suffered.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Capital Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">. If any Lender determines that any Change in Law affecting such Lender or any lending office of such Lender or such Lender&#8217;s holding company, if any, regarding capital or liquidity requirements has or would have the effect of reducing the rate of return on such Lender&#8217;s capital or on the capital of such Lender&#8217;s holding company, if any, as a consequence of this Agreement, the Loan Commitments of such Lender or the Loans made by such Lender, to a level below that which such Lender or such Lender&#8217;s holding company, as the case may be, could have achieved but for such Change in Law (taking into consideration such Lender&#8217;s policies and the policies of such Lender&#8217;s holding company with respect to capital adequacy and&#47;or liquidity), then from time to time upon demand of such Lender setting forth in reasonable detail the charge and the calculation of such reduced rate of return (with a copy of such demand to the Agent), the Borrower will pay to such Lender such additional amount or amounts as will compensate such Lender or such Lender&#8217;s holding company for any such reduction suffered.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Certificates for Reimbursement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">. A certificate of a Lender setting forth the amount or amounts necessary to compensate such Lender or its holding company, as the case may be, as specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">paragraph (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%"> of this Section and delivered to the Borrower shall be conclusive absent manifest error. The Borrower shall pay such Lender, as the case may be, the amount shown as due on any such certificate within ten (10) days after receipt thereof.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Delay in Requests</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">. Failure or delay on the part of any Lender to demand compensation pursuant to this Section shall not constitute a waiver of such Lender&#8217;s right to demand such compensation&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%"> that the Borrower shall not be required to compensate a Lender pursuant to this Section for any increased costs incurred or reductions suffered more than nine months prior to the date that such Lender, as the case may be, notifies the Borrower of the Change in Law giving rise to such increased costs or reductions, and of such Lender&#8217;s intention to claim compensation therefor (except that, if the Change in Law giving rise to such increased costs or reductions is retroactive, then the nine-month period referred to above shall be extended to include the period of retroactive effect thereof).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">SECTION 4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Compensation for Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">.In the event of (a) the payment of any principal of any SOFR Loan other than on the last day of the Interest Period applicable thereto (including as a result of an Event of Default), (b) the conversion of any SOFR Loan other than on the last day of the Interest Period applicable thereto (including as a result of an Event of Default), (c) the failure to borrow, convert, continue or prepay any SOFR Loan on the date specified in any notice delivered pursuant hereto, or (d) the</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">assignment of any SOFR Loan other than on the last day of the Interest Period applicable thereto as a result of a request by the Borrower pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 3.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, then, in any such event, the Borrower shall compensate each Lender for any loss, cost and expense attributable to such event, including any loss, cost or expense arising from the liquidation or redeployment of funds. A certificate of any Lender setting forth any amount or amounts that such Lender is entitled to receive pursuant to this Section shall be delivered to the Borrower and shall be conclusive absent manifest error. The Borrower shall pay such Lender the amount shown as due on any such certificate within ten (10) days after receipt thereof.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. For purposes of this Section, the term &#8220;applicable law&#8221; includes FATCA.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Payments Free of Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Any and all payments by or on account of any Obligation of a Credit Party under any Loan Document shall be made without deduction or withholding for any Taxes, except as required by applicable law. If any applicable law (as determined in the good faith discretion of an applicable Withholding Agent) requires the deduction or withholding of any Tax from any such payment by any Withholding Agent, then such Withholding Agent shall be entitled to make such deduction or withholding and shall timely pay the full amount deducted or withheld to the relevant Governmental Authority in accordance with applicable law and, if such Tax is an Indemnified Tax, then the sum payable by such Credit Party shall be increased as necessary so that after such deduction or withholding has been made (including such deductions and withholdings applicable to additional sums payable under this Section) the applicable Recipient receives an amount equal to the sum it would have received had no such deduction or withholding been made.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Payment of Other Taxes by the Credit Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Each Credit Party agrees that, without duplication, it shall, or shall cause the appropriate Credit Party to, timely pay to the relevant Governmental Authority in accordance with applicable law, or at the option of the Agent timely reimburse it for the payment of, any Other Taxes.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Indemnification by Credit Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Each Credit Party agrees that, without duplication, it shall, or shall cause the appropriate Credit Party to, indemnify each Recipient, within ten (10) days after demand therefor, for the full amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under this Section) payable or paid by such Recipient or required to be withheld or deducted from a payment to such Recipient and any reasonable expenses arising therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to a Credit Party by a Lender (with a copy to the Agent), or by the Agent on its own behalf or on behalf of a Lender, shall be conclusive absent manifest error.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Indemnification by the Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Each Lender shall severally indemnify the Agent, within ten (10) days after demand therefor, for (i) any Indemnified Taxes attributable to such Lender (but only to the extent that the Borrower has not already indemnified the Agent for such Indemnified Taxes and without limiting the obligation of the Borrower to do so), (ii) any Taxes attributable to such Lender&#8217;s failure to comply with the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 11.11(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> relating to the maintenance of a Participant Register, and (iii) any Excluded Taxes attributable to such Lender, in each case, that are payable or paid by the Agent in connection with any Loan Document, and any reasonable expenses arising therefrom or with respect thereto, whether or not such Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to any Lender by the Agent shall be conclusive absent manifest error. Each Lender hereby authorizes the Agent to set off and apply any and all amounts at any time owing to such Lender under any Loan Document or otherwise payable by the Agent to such Lender from any other source against any amount due to the Agent under this paragraph (e).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">33</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Evidence of Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. As soon as practicable after any payment of Taxes by any Credit Party to a Governmental Authority pursuant to this Section, such Credit Party shall deliver to the Agent the original or a certified copy of a receipt issued by such Governmental Authority evidencing such payment, a copy of the return reporting such payment or other evidence of such payment satisfactory to the Agent (acting on the instructions of the Majority Lenders acting reasonably).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Status of Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)&#160;&#160;&#160;&#160;Any Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments made under any Loan Document shall deliver to the Borrower and the Agent, at the time or times reasonably requested by the Borrower or the Agent, such properly completed and executed documentation reasonably requested by the Borrower or the Agent as will permit such payments to be made without withholding or at a reduced rate of withholding. In addition, any Lender, if reasonably requested by the Borrower or the Agent, shall deliver such other documentation prescribed by applicable law or reasonably requested by the Borrower or the Agent as will enable the Borrower or the Agent to determine whether or not such Lender is subject to backup withholding or information reporting requirements. Notwithstanding anything to the contrary in the preceding two sentences, the completion, execution and submission of such documentation (other than such documentation set forth in paragraphs </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">(g)(ii)(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">(ii)(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">(ii)(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> of this Section) shall not be required if in such Lender&#8217;s reasonable judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or would materially prejudice the legal or commercial position of such Lender.</font></div><div style="margin-bottom:10pt;text-align:center;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)&#160;&#160;&#160;&#160;Without limiting the generality of the foregoing,</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(A)&#160;&#160;&#160;&#160;any Lender that is a U.S. Person shall deliver to the Borrower and the Agent on or about the date on which such Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Agent), executed copies of IRS Form W-9 certifying that such Lender is exempt from U.S. federal backup withholding tax&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(B)&#160;&#160;&#160;&#160;any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Agent (in such number of copies as shall be requested by the recipient) on or about the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Agent), whichever of the following is applicable&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(1)&#160;&#160;&#160;&#160;in the case of a Foreign Lender claiming the benefits of an income tax treaty to which the United States is a party (x) with respect to payments of interest under any Loan Document, executed copies of IRS Form W-8BEN or IRS Form W-8BEN-E establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the &#8220;interest&#8221; article of such tax treaty and (y) with respect to any other applicable payments under any Loan Document, IRS Form W- 8BEN or IRS Form W-8BEN-E establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the &#8220;business profits&#8221; or &#8220;other income&#8221; article of such tax treaty&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(2)&#160;&#160;&#160;&#160;in the case of a Foreign Lender claiming that its extension of credit will generate U.S. effectively connected income, executed copies of IRS Form W-8ECI&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(3)&#160;&#160;&#160;&#160;in the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under Section 881(c) of the Code, (x) a certificate substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit E-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> to the effect that such Foreign Lender is not a &#8220;bank&#8221; within the meaning of Section 881(c)(3)(A) of the Code, a &#8220;10 percent shareholder&#8221; of the Borrower within the meaning of</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Section 871(h)(3)(B) of the Code, or a &#8220;controlled foreign corporation&#8221; related to the Borrower as described in Section 881(c)(3)(C) of the Code (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">U.S. Tax Compliance Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8221;) and (y) executed copies of IRS Form W-8BEN or IRS Form W-8BEN-E&#59; or</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(4)&#160;&#160;&#160;&#160;to the extent a Foreign Lender is not the beneficial owner, executed copies of IRS Form W-8IMY, accompanied by IRS Form W-8ECI, IRS Form W-8BEN, IRS Form W-8BEN-E, a U.S. Tax Compliance Certificate substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Exhibit E-2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Exhibit E-3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">, IRS Form W-9, and&#47;or other certification documents from each beneficial owner, as applicable&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">that if the Foreign Lender is a partnership and one or more direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such Foreign Lender may provide a U.S. Tax Compliance Certificate substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Exhibit E-4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%"> on behalf of each such direct and indirect partner&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(C)&#160;&#160;&#160;&#160;any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Agent (in such number of copies as shall be requested by the recipient) on or about the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Agent), executed copies of any other form prescribed by applicable law as a basis for claiming exemption from or a reduction in U.S. federal withholding Tax, duly completed, together with such supplementary documentation as may be prescribed by applicable law to permit the Borrower or the Agent to determine the withholding or deduction required to be made&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(D)&#160;&#160;&#160;&#160;if a payment made to a Lender under any Loan Document would be subject to U.S. federal withholding Tax imposed by FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the Code, as applicable), such Lender shall deliver to the Borrower and the Agent at the time or times prescribed by law and at such time or times reasonably requested by the Borrower or the Agent such documentation prescribed by applicable law (including as prescribed by Section 1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested by the Borrower or the Agent as may be necessary for the Borrower and the Agent to comply with their obligations under FATCA and to determine that such Lender has complied with such Lender&#8217;s obligations under FATCA or to determine the amount, if any, to deduct and withhold from such payment. Solely for purposes of this clause (D), &#8220;FATCA&#8221; shall include any amendments made to FATCA after the date of this Agreement.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Each Lender agrees that if any form or certification it previously delivered expires or becomes obsolete or inaccurate in any respect, it shall update such form or certification or promptly notify the Borrower and the Agent in writing of its legal inability to do so.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Treatment of Certain Refunds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">. If any party determines, in its sole discretion exercised in good faith, that it has received a refund of any Taxes as to which it has been indemnified pursuant to this Section (including by the payment of additional amounts pursuant to this Section), it shall pay to the indemnifying party an amount equal to such refund (but only to the extent of indemnity payments made under this Section with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) of such indemnified party and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund). Such indemnifying party, upon the request of such indemnified party, shall repay to such indemnified party the amount paid over pursuant to this paragraph (h) (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) in the event that such indemnified party is required to repay such refund to such Governmental Authority. Notwithstanding anything to the contrary in this paragraph (h), in no event will the indemnified party be required to pay any amount to an indemnifying party pursuant to this paragraph (h) the payment of which would place the indemnified party in a less favorable net after-Tax position than the indemnified party would have been in if the Tax subject to indemnification and giving rise to such refund had not been</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">35</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with respect to such Tax had never been paid. This paragraph shall not be construed to require any indemnified party to make available its Tax returns (or any other information relating to its Taxes that it deems confidential) to the indemnifying party or any other Person.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Each party&#8217;s obligations under this Section shall survive the resignation or replacement of the Agent or any assignment of rights by, or the replacement of, a Lender and the repayment, satisfaction or discharge of all obligations under any Loan Document.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 4.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Payments, Computations&#59; Proceeds of Collateral, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. The parties hereto agree as follows&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;Unless otherwise expressly provided in a Loan Document, all payments by the Borrower pursuant to each Loan Document shall be made without setoff, deduction or counterclaim not later than 11&#58;00 a.m. (New York City time) on the date due in same day or immediately available funds to such account as the Agent shall specify from time to time by notice to the Borrower. Funds received after that time shall be deemed to have been received by the Agent on the next succeeding Business Day. All interest and fees shall be computed on the basis of the actual number of days (including the first day but excluding the last day) occurring during the period for which such interest or fee is payable over a year comprised of 360 days. Payments due on other than a Business Day shall be made on the next succeeding Business Day and such extension of time shall be included in computing interest and fees in connection with that payment.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;All amounts received as a result of the exercise of remedies under the Loan Documents (including from the proceeds of collateral securing the Obligations) or under applicable law shall be applied upon receipt to the Obligations as follows&#58; (i) first, to the payment in full in cash of all interest (including interest accruing after the commencement of a proceeding in bankruptcy, insolvency or similar law, whether or not permitted as a claim under such law) and fees owing under the Loan Documents, and all costs and expenses owing to the Agent and the Lenders (or any of them) pursuant to the terms of the Loan Documents, until paid in full in cash, (ii) second, after payment in full in cash of the amounts specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">clause (b)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, to the payment of the principal amount of the Loans then outstanding, (iii) third, after payment in full in cash of the amounts specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">clauses (b)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">(b)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, to the payment of all other Obligations owing to the Agent and the Lenders (or any of them), and (iv) fourth, after payment in full in cash of the amounts specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">clauses (b)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> through </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">(b)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, and following the Termination Date, to the Borrower or any other Person lawfully entitled to receive such surplus.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 4.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Setoff</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Each Lender and the Agent shall, upon the occurrence and during the continuance of any Default described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">clauses (i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> through </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, inclusive, of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 9.1(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> or, upon the occurrence and during the continuance of any other Event of Default, have the right to appropriate and apply to the payment of the Obligations owing to it (whether or not then due), and (as security for such Obligations) each Credit Party and each of its Subsidiaries hereby grants to each Lender and the Agent a continuing security interest in, any and all balances, credits, deposits, accounts (other than Excluded Accounts) or moneys of each Credit Party and each of its Subsidiaries then or thereafter maintained with such Lender or the Agent, as applicable. Each Lender and the Agent agrees promptly to notify the Borrower after any such appropriation and application made by such Lender or the Agent, as applicable&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> that, the failure to give such notice shall not affect the validity of such setoff and application. The rights of each Lender and the Agent under this Section are in addition to other rights and remedies (including other rights of setoff under applicable law or otherwise) which such Lender or the Agent, as applicable, may have.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 4.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Inability to Determine Rates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">36</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.10,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> if, on or prior to the first day of any Interest Period for any SOFR Loan&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;the Agent determines (which determination shall be conclusive and binding absent manifest error) that &#8220;Term SOFR&#8221; cannot be determined pursuant to the definition thereof, or</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;the Majority Lenders determine that for any reason in connection with any request for a SOFR Loan or a conversion thereto or a continuation thereof that Term SOFR for any requested Interest Period with respect to a proposed SOFR Loan does not adequately and fairly reflect the cost to such Lenders of funding such Loan, and the Majority Lenders have provided notice of such determination to the Agent,</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the Agent will promptly so notify the Borrower and each Lender.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Upon notice thereof by the Agent to the Borrower, any obligation of the Lenders to make SOFR Loans shall be suspended (to the extent of the affected SOFR Loans or affected Interest Periods) until the Agent (with respect to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, at the instruction of the Majority Lenders) revokes such notice. Upon receipt of such notice, (i) the Borrower may revoke any pending request for a borrowing of, conversion to or continuation of SOFR Loans (to the extent of the affected SOFR Loans or affected Interest Periods) or, failing that, the Borrower will be deemed to have converted any such request into a request for a borrowing of or conversion to an ABR Loan in the amount specified therein and (ii) any outstanding affected SOFR Loans will be deemed to have been converted into ABR Loans at the end of the applicable Interest Period. Upon any such conversion, the Borrower shall also pay accrued interest on the amount so converted, together with any additional amounts required pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, if the Agent determines (which determination shall be conclusive and binding absent manifest error) that &#8220;Term SOFR&#8221; cannot be determined pursuant to the definition thereof on any given day, the interest rate on ABR Loans shall be determined by the Agent without reference to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of the definition of &#8220;ABR&#8221; until the Agent revokes such determination.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 4.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sharing of Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If any Lender will, by exercising any right of setoff or counterclaim or otherwise, obtain payment in respect of any principal of or interest on the Loans or other obligations hereunder resulting in such Lender receiving payment of a proportion of the aggregate amount of its Loans and accrued interest thereon or other such obligations greater than its Pro Rata Share thereof as provided herein, then the Lender receiving such greater proportion will (a) notify the Agent of such fact, and (b) purchase (for cash at face value) participations in the Loans and such other obligations of the other Lenders, or make such other adjustments as will be equitable, so that the benefit of all such payments will be shared by the Lenders ratably in accordance with the aggregate amount of principal of and accrued interest on their respective Loans and other amounts owing them&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that, (i) if any such participations are purchased and all or any portion of the payment giving rise thereto is recovered, such participations will be rescinded and the purchase price restored to the extent of such recovery, without interest&#59; and (ii) the provisions of this Section will not be construed to apply to (i) any payment made by the Borrower pursuant to and in accordance with the express terms of this Agreement or (ii) any payment obtained by a Lender as consideration for the assignment of or sale of a participation in its Loans to any assignee or participant, other than to the Borrower or any of their respective Subsidiaries (as to which the provisions of this subsection will apply).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">37</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 4.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Mitigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. If any Lender requests compensation under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, or requires the Borrower to pay any Indemnified Taxes or additional amounts to any Lender or any Governmental Authority for the account of any Lender pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, then such Lender shall use reasonable efforts to designate a different lending office for funding or booking its Loans hereunder or to assign its rights and obligations hereunder to another of its offices, branches or affiliates, if, in the reasonable judgment of such Lender, such designation or assignment (i) would eliminate or reduce amounts payable pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, as the case may be, in the future, and (ii) would not subject such Lender to any unreimbursed cost or expense and would not otherwise be disadvantageous to such Lender. The Borrower hereby agrees to pay all reasonable costs and expenses incurred by any Lender in connection with any such designation or assignment.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 4.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Illegality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. If any Lender determines that any law has made it unlawful, or that any Governmental Authority has asserted that it is unlawful, for any Lender or its applicable lending office to make, maintain or fund Loans whose interest is determined by reference to SOFR, the Term SOFR Reference Rate or Term SOFR, or to determine or charge interest rates based upon SOFR, the Term SOFR Reference Rate or Term SOFR, then, upon notice thereof by such Lender to the Borrower (through the Agent), (a) any obligation of the Lenders to make SOFR Loans, and any right of the Borrower to continue SOFR Loans shall be suspended, and (b) the interest rate on which ABR Loans shall, if necessary to avoid such illegality, be determined by the Agent without reference to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">clause (iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> of the definition of &#8220;ABR&#8221;, in each case until such Lender notifies the Agent and the Borrower that the circumstances giving rise to such determination no longer exist. Upon receipt of such notice, (i) the Borrower shall, if necessary to avoid such illegality, upon demand from any Lender (with a copy to the Agent), prepay or, if applicable, convert all SOFR Loans to ABR Loans (the interest rate on which ABR Loans of such Lender shall, if necessary to avoid such illegality, be determined by the Agent without reference to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">clause (iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> of the definition of &#8220;ABR&#8221;), on the last day of the Interest Period therefor, if all affected Lenders may lawfully continue to maintain such SOFR Loans to such day, or immediately, if any Lender may not lawfully continue to maintain such SOFR Loans to such day, and (ii) if necessary to avoid such illegality, the Agent shall during the period of such suspension compute the ABR without reference to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">clause (iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> of the definition of &#8220;ABR,&#8221; in each case until the Agent is advised in writing by each affected Lender that it is no longer illegal for such Lender to determine or charge interest rates based upon SOFR, the Term SOFR Reference Rate or Term SOFR. Upon any such prepayment or conversion, the Borrower shall also pay accrued interest on the amount so prepaid or converted, together with any additional amounts required pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 4.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Benchmark Replacement Setting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Benchmark Replacement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary herein or in any other Loan Document, upon the occurrence of a Benchmark Transition Event, the Agent and the Borrower may amend this Agreement to replace the then-current Benchmark with a Benchmark Replacement. Any such amendment with respect to a Benchmark Transition Event will become effective at 5&#58;00 p.m. (New York City time) on the fifth (5th) Business Day after the Agent has posted such proposed amendment to all affected Lenders and the Borrower so long as the Agent has not received, by such time, written notice of objection to such amendment from Lenders comprising the Majority Lenders. No replacement of a Benchmark with a Benchmark Replacement pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 4.10(a)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> will occur prior to the applicable Benchmark Transition Start Date.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)&#160;&#160;&#160;&#160;No Hedging Agreement shall be deemed to be a &#8220;Loan Document&#8221; for purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 4.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Benchmark Replacement Conforming Changes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. In connection with the use, administration, adoption or implementation of a Benchmark Replacement, the Agent will have the right to make Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">38</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">any other Loan Document, any amendments implementing such Conforming Changes will become effective without any further action or consent of any other party to this Agreement or any other Loan Document.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Notices&#59; Standards for Decisions and Determinations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. The Agent will promptly notify the Borrower and the Lenders of (i) the implementation of any Benchmark Replacement and (ii) the effectiveness of any Conforming Changes in connection with the use, administration, adoption or implementation of a Benchmark Replacement. The Agent will promptly notify the Borrower of (x) the removal or reinstatement of any tenor of a Benchmark pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 4.10(d</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">) and (y) the commencement of any Benchmark Unavailability Period. Any determination, decision or election that may be made by the Agent or, if applicable, any Lender (or group of Lenders) pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">4.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, including any determination with respect to a tenor, rate or adjustment or of the occurrence or non-occurrence of an event, circumstance or date and any decision to take or refrain from taking any action or any selection, will be conclusive and binding absent manifest error and may be made in its or their sole discretion and without consent from any other party to this Agreement or any other Loan Document, except, in each case, as expressly required pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 4.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Unavailability of Tenor of Benchmark</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Notwithstanding anything to the contrary herein or in any other Loan Document, at any time (including in connection with the implementation of a Benchmark Replacement), (i) if the then-current Benchmark is a term rate (including the Term SOFR Reference Rate) and either (A) any tenor for such Benchmark is not displayed on a screen or other information service that publishes such rate from time to time as selected by the Agent in its reasonable discretion or (B) the administrator of such Benchmark or the regulatory supervisor for the administrator of such Benchmark has provided a public statement or publication of information announcing that any tenor for such Benchmark is not or will not be representative or in compliance with or aligned with the International Organization of Securities Commissions (IOSCO) Principles for Financial Benchmarks, then the Agent may modify the definition of &#8220;Interest Period&#8221; (or any similar or analogous definition) for any Benchmark settings at or after such time to remove such unavailable, non-representative, non-compliant or non-aligned tenor and (ii) if a tenor that was removed pursuant to clause (i) above either (A) is subsequently displayed on a screen or information service for a Benchmark (including a Benchmark Replacement) or (B) is not, or is no longer, subject to an announcement that it is not or will not be representative or in compliance with or aligned with the International Organization of Securities Commissions (IOSCO) Principles for Financial Benchmarks for a Benchmark (including a Benchmark Replacement), then the Agent may modify the definition of &#8220;Interest Period&#8221; (or any similar or analogous definition) for all Benchmark settings at or after such time to reinstate such previously removed tenor.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Benchmark Unavailability Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Upon the Borrower&#8217;s receipt of notice of the commencement of a Benchmark Unavailability Period, the Borrower may revoke any pending request for a SOFR Loan of, conversion to or continuation of SOFR Loans to be made, converted or continued during any Benchmark Unavailability Period and, failing that, the Borrower will be deemed to have converted any such request into a request for or conversion to ABR Loans. During a Benchmark Unavailability Period or at any time that a tenor for the then-current Benchmark is not an Available Tenor, the component of ABR based upon the then-current Benchmark or such tenor for such Benchmark, as applicable, will not be used in any determination of ABR.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ARTICLE V</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">CONDITIONS PRECEDENT</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 5.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Conditions to the Borrowing of the Loans on the Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. The obligation of the Lenders to make the Loans on the Closing Date shall be subject to the execution and delivery of this Agreement by the parties hereto, the delivery of a Loan Request for the Loan Loans pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">39</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, and the prior or concurrent satisfaction of each of the conditions precedent set forth below in this Section.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Secretary&#8217;s Certificate, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Agent shall have received from each Credit Party (x) a copy of a good standing certificate (to the extent such concept it applicable in any relevant jurisdiction), dated a date reasonably close to the Closing Date, for each such Person and (y) a certificate, dated as of the Closing Date, duly executed and delivered by such Person&#8217;s Secretary, Assistant Secretary, or other Authorized Officer, director, managing member or general partner, as applicable, as to&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;resolutions of each such Person&#8217;s board of directors (or other managing body, in the case of other than a corporation) then in full force and effect authorizing the execution, delivery and performance of each Loan Document to be executed by such Person and the transactions contemplated hereby and thereby&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the incumbency and signatures of those of its officers, managing member or general partner, as applicable, authorized to act with respect to each Loan Document to be executed by such Person&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;the full force and validity of each Organic Document of such Person and copies thereof&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;certifying that each copy document relating to it specified in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">5.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> is correct, complete and in full force and effect and has not been amended or superseded as at the date no earlier than the Closing Date&#59;</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in each case, upon which certificates the Agent may conclusively rely until it shall have received a further certificate of the Secretary, Assistant Secretary, director, managing member or general partner, as applicable, of any such Person cancelling or amending the prior certificate of such Person.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Closing Date Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Agent shall have received a certificate, dated as of the Closing Date and duly executed and delivered by an Authorized Officer of the Borrower (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Date Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), which certificate shall be in form and substance satisfactory to the Agent (acting on the instructions of the Majority Lenders acting reasonably) and shall, among other things, represent and warrant that the statements made therein are true and correct as of such date, and, at the time such certificate is delivered, such statements shall in fact be true and correct. The statements in such certificate shall be limited to (i) (x) the representations and warranties set forth herein and in each Loan Document shall, in each case, be true and correct in all material respects as of the Closing Date (unless stated to relate solely to an earlier date, in which case such representations and warranties shall be true and correct in all material respects as of such earlier date)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that any representations and warranties that are by their terms qualified by materiality, Material Adverse Effect or similar qualification shall be true and correct in all respects, and (y) no Default or Event of Default under and as defined in this Agreement shall have occurred and then be continuing and (ii) all of the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> have been satisfied.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Delivery of Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Agent shall have received Notes for each Lender that has requested as such, evidencing the Loans, which Notes shall be duly executed and delivered by an Authorized Officer of the Borrower.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Information, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Agent shall have received&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">40</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)&#160;&#160;&#160;&#160;audited consolidated financial statements of the Borrower and its Subsidiaries for the Fiscal Year ended December 31, 2023&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)&#160;&#160;&#160;&#160;unaudited consolidated balance sheets of the Borrower and its Subsidiaries for the Fiscal Quarter ended March 31, 2024, together with the related consolidated statement of operations, shareholder&#8217;s equity and cash flows for such Fiscal Quarter.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Compliance Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. The Agent shall have received a Compliance Certificate, dated as of the Closing Date, duly executed (and with all schedules thereto duly completed) and delivered by the chief financial or accounting Authorized Officer of the Borrower.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Solvency, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. The Agent shall have received a solvency certificate duly executed and delivered by the chief financial or accounting Authorized Officer of the Borrower, dated as of the Closing Date, in form and substance satisfactory to the Agent.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Fee Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. The Agent shall have received the Fee Letter, dated as of the Closing Date, duly executed and delivered by the Borrower, the Agent and the Lenders.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Security Agreement, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. The Agent shall have received executed counterparts of the Security Agreement, dated as of the Closing Date, duly executed and delivered by the Credit Parties, together with&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)&#160;&#160;&#160;&#160;certificates (in the case of Capital Securities that are securities (as defined in the UCC)) evidencing all of the issued and outstanding Capital Securities owned by each Credit Party, which certificates in each case shall be accompanied by undated instruments of transfer duly executed in blank, or, if any Capital Securities (in the case of Capital Securities that are uncertificated securities (as defined in the UCC)), confirmation and evidence satisfactory to the Agent that the security interest therein has been transferred to and perfected by the Agent in accordance with Articles 8 and 9 of the UCC and all laws otherwise applicable to the perfection of the pledge of such Capital Securities&#59; provided that Borrower shall be required to pledge 100% of the Capital Securities of any Foreign Subsidiaries existing as of the Closing Date, except to the extent as reasonably determined by the Borrower after consulting with the Agent, such pledge would reasonably be expected to result in material adverse tax consequences to the Borrower, in which case Borrower shall not be required to pledge voting Capital Securities in excess of 65% of the issued and outstanding voting Capital Securities of such Foreign Subsidiaries&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)&#160;&#160;&#160;&#160;financing statements suitable in form for naming each Credit Party as a debtor and the Agent for the benefit of the Secured Parties as the secured party, or other similar instruments or documents to be filed under the UCC of all jurisdictions as may be necessary or, in the opinion of the Agent, desirable to perfect the security interests of the Secured Parties pursuant to the Security Agreement&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(iii)&#160;&#160;&#160;&#160;any Patent Security Agreement, Trademark Security Agreement or Copyright Security Agreement required to be provided under the Security Agreement, each dated as of the Closing Date, duly executed and delivered by an Authorized Officer of the applicable Credit Party&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Intercompany Subordination Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. The Agent shall have received executed counterparts of the Intercompany Subordination Agreement, duly executed and delivered by each Credit Party and each of their respective Subsidiaries.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(j)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Material Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Copies of all Material Agreements and license agreements shall have been made available to the Agent upon its request. The Agent shall have received a certificate</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">41</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">from an Authorized Officer of the Borrower certifying that each such contract or agreement is in full force and effect as of the Closing Date and, to the extent applicable, that there have been no changes to each such contract or agreement since the delivery of same in connection with the Existing Credit Agreement. The Agent shall be satisfied in its sole discretion with the terms and conditions of all Material Agreements and license agreements entered into by the Credit Parties and their Subsidiaries.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Opinions of Counsel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Agent shall have received one or more legal opinions, dated as of the Closing Date and addressed to the Agent and the Lenders, from independent legal counsel to the Credit Parties, in each case, in form and substance reasonably acceptable to the Agent.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Fees, Expenses, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Agent shall have received for its own account and for the account of the Lenders and all fees, costs and expenses due and payable pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Fee Letter or any other Loan Documents, including all closing costs and fees and all unpaid reasonable expenses of the Agent and the Lenders incurred in connection with the transactions contemplated hereby (including the Agent&#8217;s legal fees and expenses).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(m)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Anti-Terrorism Laws and Beneficial Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Agent shall have received, as applicable, (i) all documentation and other information required by bank regulatory authorities under applicable &#8220;know your customer&#8221; and anti-money laundering rules and regulations, including the Patriot Act and (ii) if the Borrower qualifies as a &#8220;legal entity customer&#8221; under the Beneficial Ownership Regulation, at least five Business Days prior to the Closing Date, a Beneficial Ownership Certification.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(n)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">No Material Adverse Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. As of the Closing Date, (i) the representations and warranties set forth herein and in each Loan Document are true and correct in all material respects&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that any representations and warranties that are by their terms qualified by materiality, Material Adverse Effect or similar qualification shall be true and correct in all respects, (ii) no Default or Event of Default shall have then occurred and be continuing, and (iii) no Material Adverse Effect shall have occurred since December 31, 2023.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(o)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Satisfactory Legal Form</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. All documents executed or submitted pursuant hereto by or on behalf of any Credit Party shall be satisfactory in form and substance to the Agent, and the Agent and its counsel shall have received all information, approvals, resolutions, opinions, documents or instruments as the Agent may reasonably request.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(p)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Debt Securities and Credit Facilities&#59; Senior Secured Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Agent shall have received a certificate from an Authorized Officer of the Borrower certifying that (i) no Credit Party nor any of its Subsidiaries has issued, or authorized the issuance of, any debt securities or entered into, or authorized the entrance into, any other credit facilities and (ii) the Obligations constitute the sole secured obligations and sole Indebtedness of the Credit Parties (other than Permitted Indebtedness).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(q)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Perfection Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Agent shall have received a Perfection Certificate, dated as of the Closing Date, duly executed (and with all schedules thereto duly completed) and delivered by the Authorized Officer of the Borrower.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(r)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Organizational Chart</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower shall have provided an accurate and complete organization chart reflecting all of the direct and indirect subsidiaries of the Borrower (including the applicable ownership percentages of each entity) as of the Closing Date, and the Agent and the Majority Lenders, in their sole discretion, shall have been satisfied with the direct and indirect equity ownership of the Credit Parties.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">42</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(s)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">. The Agent shall have received&#58; (i) certificates of insurance evidencing that the insurance required to be maintained pursuant to Section 7.4 is in full force and effect, in each case, in form and substance satisfactory to the Agent (acting on the instructions of the Majority Lenders acting reasonably)&#59; and (ii) certified copies of the insurance policies (or binders in respect thereof), from one or more insurance companies satisfactory to the Agent, required to be maintained pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Section&#160;7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(t)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Repayment of Existing Debt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">. On or prior to the Closing Date or substantially concurrently with the funding of the Loans, (i) all Indebtedness of each Credit Party and each Subsidiary thereof under the Existing Credit Agreement and all other documents, agreements and instruments related thereto shall have been repaid in full, together with all fees (except for those fees related to the Existing Credit Agreement set forth in the Fee Letter) and other amounts owing thereon, all commitments under the agreements evidencing such Indebtedness shall have been terminated and all letters of credit, if any, issued pursuant to such agreements shall have been terminated, backstopped or cash collateralized, in each case in accordance with the terms of that certain payoff letter, dated on or about the date hereof, by and among the parties to the Existing Credit Agreement and (ii) all security interests in respect of, and Liens securing, the obligations of each such Credit Party and each such Subsidiary, as applicable, under the Existing Credit Agreement and all other documents, agreements and instruments related thereto shall have been terminated and released (except for those documents, agreements and instruments that will continue to secure the Obligations hereunder), and the Agent shall have received all customary payoff letters with respect to such Indebtedness and such releases and other documents related thereto as may have been requested by the Agent, which releases shall be in customary form, in each case in accordance with the terms of that certain payoff letter, dated on or about the date hereof, by and among the parties to the Existing Credit Agreement. Without limiting the foregoing, the Agent shall have received (or been granted authorization to file) (x) proper termination statements (Form UCC-3 or the appropriate equivalent) for filing under the UCC or equivalent statute or regulation of each jurisdiction where a financing statement or application for registration (Form UCC-1 or the appropriate equivalent) was filed with respect to any Credit Party or any Subsidiary thereof, as applicable, in connection with the security interests created under the Existing Credit Agreement and all other documents, agreements and instruments related thereto, (y) terminations or reassignments of any security interest in any United States Patents, United States Trademarks, United States Copyrights, or similar United States interests of such Credit Party or such Subsidiary, as applicable, on which filings have been made, and (z) if applicable, terminations of all mortgages, leasehold mortgages, hypothecs and deeds of trust created with respect to property of such Credit Party or such Subsidiary, as applicable, in each case, to secure the obligations under the Existing Credit Agreement and all other documents, agreements and instruments related thereto, all of which shall be in a form reasonably satisfactory to the Agent.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">ARTICLE VI</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">REPRESENTATIONS AND WARRANTIES</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">In order to induce the Agent and the Lenders to enter into this Agreement, each Credit Party hereby jointly and severally represents and warrants to the Agent and the Lenders as follows&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">SECTION 6.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Organization, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">.Each Credit Party (i) is validly organized and existing and in good standing under the laws of the jurisdiction of its incorporation or organization (to the extent such concept it applicable in any relevant jurisdiction), (ii) is duly qualified to do business and is in good standing as a foreign entity in each jurisdiction where the nature of its business requires such qualification, (iii) has full power and authority and holds all requisite governmental licenses, permits and other approvals to enter into and perform its Obligations under each Loan Document to which it is a party, to own and hold under lease its property and to conduct its business substantially as currently conducted by it and (iv) in the case of each UK Subsidiary Guarantor, if any, no limit on its powers will be exceeded as a result of the borrowing, grant of security or giving of guarantees contemplated by the Loan Documents to which it is a party&#59; except</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">43</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in the cases of clauses (ii) and (iii), where the failure to do so could not reasonably be expected to result in a Material Adverse Effect.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Due Authorization, Non-Contravention, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The execution, delivery and performance by each Credit Party and each of its Subsidiaries of each Loan Document executed or to be executed by it are in each case within such Person&#8217;s powers, have been duly authorized by all necessary action, and do not&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;contravene (i) any Organic Documents of such Credit Party or such Subsidiary, (ii) any court decree or order binding on or affecting such Credit Party or such Subsidiary, or (iii) any law or governmental regulation binding on or affecting such Credit Party or such Subsidiary&#59; except in the cases of clauses (ii) and (iii), where could not reasonably be expected to result in a Material Adverse Effect&#59; or</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;result in (i) or require the creation or imposition of, any Lien on a Credit Party&#8217;s or any of its Subsidiaries&#8217; properties (except Permitted Liens) or (ii) a default under any contractual restriction binding on or affecting a Credit Party or any of its Subsidiaries, except in the case of this clause (ii) where such default could not reasonably be expected to result in a Material Adverse Effect.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Government Approval, Regulation, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No authorization or approval or other action by, and no notice to or filing with, any Governmental Authority or other Person (other than those that have been, or on the Closing Date will be, duly obtained or made and which are, or on the Closing Date will be, in full force and effect) is required for the due execution, delivery or performance by a Credit Party or any of its Subsidiaries of any Loan Document to which it is a party, except where could not reasonably be expected to result in a Material Adverse Effect. Each Credit Party, each of its Subsidiaries and their respective properties and businesses are in compliance in all material respects with all laws, rules, regulations, orders and court decrees applicable to such Persons, properties or businesses, as the case may be.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Validity, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Loan Document to which a Credit Party or any of its Subsidiaries is a party constitutes the legal, valid and binding obligations of such Person enforceable against such Person in accordance with its respective terms (except, in any case, as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization or similar laws affecting creditors&#8217; rights generally and by principles of equity).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The consolidated financial statements of Holdings or the Borrower, as applicable, and such party&#8217;s Subsidiaries furnished to the Agent pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1(d) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 7.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(b),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> have been prepared in accordance with GAAP consistently applied, and present fairly the consolidated financial condition of the Persons covered thereby as at the dates thereof and the results of their operations for the periods then ended.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">No Material Adverse Change</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Since December 31, 2023, there has been no event, occurrence or other circumstance that has resulted in a Material Adverse Effect.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Litigation, Labor Matters and Environmental Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 6.7(a),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> there are no actions, suits or proceedings by or before any arbitrator or Governmental Authority pending against or threatened against or affecting any Credit Party or any of its Subsidiaries.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;There are no material labor controversies pending against or threatened, in writing, against or affecting any Credit Party or any of its Subsidiaries.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">44</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;No Credit Party nor any of its Subsidiaries (i) has failed to comply with any material Environmental Law or to obtain, maintain or comply with any material Permit under or in connection with any Environmental Law (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Environmental Permit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), (ii) is or has been subject to any Environmental Liability, (iii) has received notice of any Environmental Liability or (iv) knows of any basis for any Environmental Liability, that, in the case of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, could reasonably be expected to result in a Material Adverse Effect.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Subsidiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 6.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> sets forth the name and jurisdiction of incorporation or formation of each direct and indirect Subsidiary of Holdings. Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 6.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, neither Holdings nor any of its Subsidiaries owns or holds, whether beneficially or of record, any Capital Securities of any other Person. All of the outstanding Capital Securities of Holdings&#8217; Subsidiaries as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 6.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> have been validly issued, are fully paid and nonassessable and are owned directly or indirectly by Holdings free and clear of all Liens except for Permitted Liens.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Ownership of Properties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Credit Party and each of its Subsidiaries owns (i) in the case of owned real property, good and marketable fee title to, and (ii) in the case of owned personal property, good and valid title to, or, in the case of leased real or personal property, valid and enforceable leasehold interests (as the case may be) in, all of its material properties and material assets, tangible and intangible, of any nature whatsoever, free and clear in each case of all Liens or claims, except for Permitted Liens.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Credit Party and each of its Subsidiaries has filed all income and other material Tax returns and reports required by law to have been filed by it and each Credit Party has paid all material Taxes owed (whether or not shown on any such Tax returns), except any such Taxes which are being diligently contested in good faith by appropriate proceedings and for which adequate reserves in accordance with GAAP shall have been set aside on its books and that are set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 6.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Pension Plans, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. As of the date hereof, (i) the Borrower is not an &#8220;employee benefit plan&#8221; (as defined in Section 3(3) of ERISA) that is subject to Title I of ERISA nor a &#8220;plan,&#8221; as defined in and subject to Section 4975 of the Code, (ii) none of the assets of any Credit Party or any of their respective Subsidiaries constitute &#8220;plan assets&#8221; of one or more such plans within the meaning of 29 C.F.R. Section 2510.3-101, as modified by Section 3(42) of ERISA, (iii) no Credit Party nor any of its Subsidiaries constitutes a &#8220;governmental plan&#8221; within the meaning of Section 3(32) of ERISA, and (iv) to the knowledge of any Credit Party, transactions by or with a Credit Party are not subject to any statute, rule or regulation regulating investments of, or fiduciary obligations with respect to, &#8220;governmental plans&#8221; within the meaning of Section 3(32) of ERISA. Each Welfare Plan and each &#8220;employee pension benefit plan, as defined in Section 3(1) of ERISA that is sponsored or maintained by any Credit Party, has been established and operated in compliance with applicable law, and there is no liability outstanding with respect to any such Welfare Plan or employee pension benefit plan, except as could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 6.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, no formal steps have been taken to terminate any Pension Plan maintained or contributed to any Credit Party or any of its Subsidiaries. No ERISA Event has occurred with respect to any Pension Plan or Multiemployer Plan which could reasonably be expected to result in the incurrence by any Credit Party, any of its Subsidiaries or any ERISA Affiliate of any liability, fine or penalty which could, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. No Credit Party, nor any of its Subsidiaries has any Contingent Liability with respect to any post-retirement benefit under a Welfare Plan, which could, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. As of the date hereof, there are no Multiemployer Plans to which any Credit Party or any of its Subsidiaries has incurred any Liability.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">45</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 6.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Accuracy of Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> None of the factual information (excluding information of a general economic or industry nature and, for the avoidance of doubt, any budgets, financial statements, forecasts, projections or other forward-looking statements (provided, that, such statements were prepared in good faith based upon assumptions reasonably believed by the preparer)) heretofore or contemporaneously furnished in writing to the Agent or any Lender by or on behalf of any Credit Party or any of its Subsidiaries in connection with this Agreement or any other Loan Document or any transaction contemplated hereby or thereby, when taken as a whole, contains any untrue statement of a material fact, or omits to state any material fact necessary to make any information, in the light of the circumstances under which they were made, not materially misleading.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 6.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Regulations U and X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. No Credit Party and none of its Subsidiaries is engaged in the business of extending credit for the purpose of buying or carrying margin stock, and no proceeds of any of the Loans will be used to purchase or carry margin stock or otherwise for a purpose which violates, or would be inconsistent with, F.R.S. Board Regulation U or Regulation X. Terms for which meanings are provided in F.R.S. Board Regulation U or Regulation X or any regulations substituted therefor, as from time to time in effect, are used in this Section with such meanings.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 6.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Solvency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. The Borrower is Solvent, and the Credit Parties and their Subsidiaries taken as a whole, on a consolidated basis, are Solvent.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 6.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 6.15(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> sets forth a complete and accurate list of all (A) applied for, issued or registered Patents, (B) registered Trademarks and any pending registrations for Trademarks, and (C) registered Copyrights and any other registered Intellectual Property, in each case owned by a Credit Party or any of its Subsidiaries, as applicable&#59; provided that no Intellectual Property that is not Material Intellectual Property shall be required to be listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 6.15(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. For each item of Material Intellectual Property listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 6.15(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, the applicable Credit Party or Subsidiary has, where relevant, indicated the following&#58; the countries in each case in which such item is patented, registered or applied for, the application numbers, the registration or patent numbers, the filing and registration dates, and the owner of such item of Material Intellectual Property.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;Each Credit Party and each of its Subsidiaries owns, free and clear of any and all Liens other than Permitted Liens, or has a valid license to all Intellectual Property material to or otherwise necessary for the operation of the business of such Credit Party and Subsidiary. All Material Intellectual Property set forth or required to be set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 6.15(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> is in full force and effect, and has not expired, lapsed or been forfeited, cancelled or abandoned. Each Credit Party and each of its Subsidiaries is the exclusive owner of all right, title and interest in and to, all such Material Intellectual Property that is owned or purported to be owned by such Person.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;Each Credit Party and each of its Subsidiaries has taken commercially reasonable measures consistent with commercially reasonable practices in the industry in which it operates to maintain and protect its Material Intellectual Property, and there are no unpaid maintenance or renewal fees payable by such Person that are currently overdue or due prior to the Closing Date for any of such registered Material Intellectual Property.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(d)&#160;&#160;&#160;&#160;There is no proceeding challenging the validity or enforceability of any Material Intellectual Property set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 6.15(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, no Credit Party nor any of its Subsidiaries is involved in any such proceeding with any Person and none of such Material Intellectual Property is the subject of any Other Administrative Proceeding.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(e)&#160;&#160;&#160;&#160;Each item of Material Intellectual Property listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 6.15(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> is, to the knowledge of the Credit Parties, valid, enforceable and, where registered, subsisting, and nothing has been</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">46</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">knowingly done or omitted to have been done by the Credit Parties, that could reasonably be expected to affect the validity or enforceability of such Material Intellectual Property.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(f)&#160;&#160;&#160;&#160;Except for as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 6.15(c)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, to the knowledge of the Credit Parties, no third party is infringing, misappropriating or otherwise violating any Material Intellectual Property of any Credit Party or Subsidiary.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(g)&#160;&#160;&#160;&#160;To the knowledge of the Credit Parties, no Credit Party or Subsidiary is infringing, misappropriating or otherwise violating the Intellectual Property rights of any other Person in any material manner.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 6.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;Each Credit Party and each of its Subsidiaries complies with all applicable federal, state, local and foreign laws, rules and regulations pertaining to data privacy (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Privacy Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), except to the extent that any compliance failure would not reasonably be expected to have a Material Adverse Effect. There is no pending, nor has there even been any, complaint, audit, proceeding, investigation, or claim against any Credit Party or any of its Subsidiaries initiated by any Governmental Authority alleging that any collection, storage, use, access, disclosure, processing, security, and transfer of Personal Data (referred to collectively in this Agreement as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Data Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) of the Credit Party and each of its Subsidiaries is in violation of any applicable Privacy Laws, except to the extent that any such complaint, audit, proceeding, investigation or claim would not reasonably be expected to result in a Material Adverse Effect.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;Each Credit Party and each of its Subsidiaries takes commercially reasonable steps to protect Personal Data in its possession or control against damage or loss, and against unauthorized access, acquisition, use, modification, disclosure or other misuse, except to the extent that failure to take such steps would not reasonably result in a Material Adverse Effect. To the knowledge of the Credit Parties, in the past three years, there has been no unauthorized access, use, or disclosure by a third-party of Personal Data in the possession or control of any Credit Party or any of its Subsidiaries with regard to any Personal Data of such Credit Party or such Subsidiary, except to the extent any such unauthorized access or use, either individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;Neither any Credit Party nor any of its Subsidiaries targets its products and services to children (persons under the age of 13), and neither any Credit Party nor any of its Subsidiaries knowingly collect Personal Data from children.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(d)&#160;&#160;&#160;&#160;Holdings and each of its Subsidiaries has implemented applicable written policies relating to Data Activities, including, a publicly posted website privacy policy, mobile app privacy policy and annual privacy statements required by federal, state, local or foreign law, rule, or regulation, as applicable, and a comprehensive information security program that includes appropriate written information security policies (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Privacy and Data Security Policies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;). At all times, Holdings and each of its Subsidiaries has been and is in compliance with all such Privacy and Data Security Policies, and neither Holdings nor any of its Subsidiaries engages in any undisclosed collection of Personal Data on its website or any third-party websites, except to the extent any such noncompliance or undisclosed collection would not reasonably be expected to have a Material Adverse Effect or otherwise result in a material violation of any applicable law.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(e)&#160;&#160;&#160;&#160;Holdings and each of its Subsidiaries have provided notifications to, and have obtained consent from, Persons regarding its Data Activities where such notice or consent is required by Privacy Laws. Holdings and each of its Subsidiaries have collected all Personal Data in accordance with its Privacy Policies and Privacy Laws, and Holdings&#8217; and each of its Subsidiaries&#8217; collection of such</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">47</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Personal Data or any other data from third parties is in accordance with any requirements from such third parties, including written website terms and conditions.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(f)&#160;&#160;&#160;&#160;Holdings and each of its Subsidiaries have taken commercially reasonable steps and implemented commercially reasonable measures and procedures to ensure that Holdings&#8217; and each of its Subsidiaries&#8217; Systems are free from malware and other harmful code, including, but not limited to, the use of commercially available up to date antivirus software.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(g)&#160;&#160;&#160;&#160;Holdings and each of its Subsidiaries is, and at all times has been in compliance with all U.S. federal and state laws and regulations pertaining to sales, marketing, and electronic communications, including, without limitation, the CAN-SPAM Act, the Telephone Consumer Protection Act, and the Telemarketing Sales Rule, except to the extent any such noncompliance would not reasonably be expected to result in a material violation of any applicable law.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 6.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Material Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. As of the Closing Date, set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 6.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> is a complete and accurate list of each Material Agreement of the Credit Parties and their Subsidiaries, with a reasonable description of the parties, subject matter thereof and amendments, waivers and modifications thereto. As of the Closing Date, each such Material Agreement (i) is in full force and effect and is binding upon and enforceable against each Credit Party or Subsidiary party thereto and to the knowledge of such Credit Party or Subsidiary, all other parties thereto in accordance with its terms, and (ii) has not suffered any material default thereunder. As of the Closing Date, no Credit Party nor any of its Subsidiaries has taken any action that could reasonably be expected to permit any other Person party to any Material Agreement to have, and no such Person otherwise has, any material defenses, counterclaims or rights of setoff thereunder.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 6.18&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Permits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> The Credit Parties and their Subsidiaries have all material Permits, including Environmental Permits, necessary or required for the ownership, operation and conduct of its business and the distribution of the Products. All such Permits are validly held and there are no material defaults thereunder.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 6.19&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Regulatory Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. With respect to each Product&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;Set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 6.19(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> is a complete and accurate list of all material Regulatory Authorizations relating to the Credit Parties and their Subsidiaries, the conduct of their business, and the Products (on a per Product basis). All such material Regulatory Authorizations are (i) legally and beneficially owned exclusively by the Credit Parties and their Subsidiaries, as applicable, free and clear of all Liens other than Permitted Liens, and (ii) as applicable, validly registered and on file with the applicable Governmental Authority, in compliance with all filing and maintenance requirements (including any fee requirements) thereof, and are in good standing, valid and enforceable with the applicable Governmental Authority. All required notices, registrations and listings, supplemental applications or notifications, reports (including field alerts, medical device reports (MDRs) and other reports of adverse experiences or product malfunctions, and reports of corrections or removal) and other required filings with respect to the Products for the last five (5) years have been timely filed with the FDA and all other applicable Governmental Authorities.</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;(i) All regulatory filings required by any Regulatory Authority or in respect of any Regulatory Authorization with respect to any Product or any Product Development and Commercialization Activities which represented, in the aggregate, 15% or more of Net Sales in any applicable year, in the last five (5) years have been made, and all such filings above such threshold are complete and correct and have complied in all material respects with all applicable laws and regulations, (ii) all clinical and pre-clinical trials, if any, of investigational Products have been and are being conducted by the Credit Parties and their</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">48</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Subsidiaries in accordance with all applicable laws and regulations along with appropriate monitoring of clinical investigator trial sites for their compliance, and (iii) the Credit Parties and their Subsidiaries have disclosed to the Agent all such regulatory filings and all material communications between representatives of the Credit Parties (and their Subsidiaries) and any Regulatory Authority.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;The Credit Parties, their Subsidiaries and the agents thereof are in compliance in all material respects with all applicable statutes, rules and regulations (including all Healthcare Laws and Regulatory Authorizations) of all applicable Governmental Authorities, including the FDA and all other Regulatory Authorities, with respect to each Product and all Product Development and Commercialization Activities related thereto. The Credit Parties and their Subsidiaries have and maintain in full force and effect all the necessary and requisite Regulatory Authorizations. The Credit Parties and their Subsidiaries are in compliance in all material respects with all applicable registration and listing requirements set forth in the FD&#38;C Act or equivalent regulation of each other Governmental Authority having jurisdiction over such Person. The Credit Parties and their Subsidiaries adhere in all material respects to all applicable regulations of all Regulatory Authorities with respect to the Products and all Product Development and Commercialization Activities related thereto.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(d)&#160;&#160;&#160;&#160;Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 6.19(d),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> no Credit Party nor any of its Subsidiaries has received from any Regulatory Authority any notice of alleged non-compliance or adverse findings with respect to any Product or any Product Development and Commercialization Activities related thereto which represented, in the aggregate, 15% or more of Net Sales in any applicable year, including any FDA Form 483 inspectional observations, notices of violations, Warning Letters, untitled letters, criminal proceeding notices under Section 305 of the FD&#38;C Act, or any other similar communication from any Regulatory Authority within the last five (5) years. Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 6.19(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, there have been no recalls, market withdrawals, field notifications or corrections, detentions, seizures, notifications or allegations of misbranding or adulteration or safety alerts conducted, requested, or threatened by any Regulatory Authority, or (for example in the case of a recall) initiated by Credit Party or any of its Subsidiaries, relating to any Products which represented, in the aggregate, 15% or more of Net Sales in any applicable year within the last five (5) years. No Credit Party nor any of its Subsidiaries has received any written notification that remains unresolved from the FDA or any other Regulatory Authority indicating any breach or violation of any applicable Regulatory Authorization, including that any of the Products is misbranded or adulterated as defined in the FD&#38;C Act, in each case of the foregoing, which represented, in the aggregate, 15% or more of Net Sales in any applicable year within the last five (5) years.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(e)&#160;&#160;&#160;&#160;No Credit Party, nor any of its Subsidiaries, nor any officer, employee or agent thereof, has made an untrue statement of a material fact or fraudulent statements to the FDA or any other Regulatory Authority, failed to disclose a material fact required to be disclosed to the FDA or any other Regulatory Authority, or committed an act, made a statement, or failed to make a statement that, at the time such disclosure was made (or was not made), could reasonably be expected to provide a basis for the FDA or any other Regulatory Authority to invoke its policy respecting Fraud, Untrue Statements of Material Facts, Bribery and Illegal Gratuities, set forth in 56 Fed. Reg. 46191 (September 10, 1991) or any similar policy.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(f)&#160;&#160;&#160;&#160;Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 6.19(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, no Credit Party nor any of its Subsidiaries has received any written notice that the FDA or any other applicable Regulatory Authority has commenced or initiated, or threatened to commence or initiate, any action to withdraw any Regulatory Authorization, requested the recall (whether by correction or removal) of any Products or commenced or initiated or threatened to commence or initiate, any action to enjoin any Product Development and Commercialization Activities of such Credit Party or such Subsidiary, in each case, which represented, in the aggregate, 15% or more of Net Sales in any applicable year,.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">49</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(g)&#160;&#160;&#160;&#160;Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 6.19(g),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> the clinical, preclinical, safety and other studies and tests conducted by or on behalf of or sponsored by the Credit Parties and their Subsidiaries, or in respect of which any Products or Product candidates under development have participated, were (and if still pending, are) being conducted in accordance with all applicable Regulatory Authorizations and Healthcare Laws in all material respects.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(h)&#160;&#160;&#160;&#160;The transactions contemplated by the Loan Documents (or contemplated by the conditions to effectiveness of any Loan Document) will not impair any Credit Party&#8217;s or any of its Subsidiaries&#8217; ownership of or rights under (or the license or the right to use, as the case may be) any Regulatory Authorizations relating to the Products in any material manner, and no consent or other authorization of any Governmental Authority is required in connection with the transactions contemplated hereby, including the Liens granted in connection herewith and the exercise of rights and remedies with respect thereto.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 6.20&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Transactions with Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 6.20,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> no Credit Party and none of its Subsidiaries has entered into, renewed, extended or been a party to, any transaction (including the purchase, sale, lease, transfer or exchange of property or assets of any kind or the rendering of services of any kind) with any Affiliate during the three (3)-year period prior to the Closing Date, which would not be permitted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 8.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 6.21&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Investment Company Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. No Credit Party and none of its Subsidiaries is an &#8220;investment company&#8221; or is &#8220;controlled&#8221; by an &#8220;investment company,&#8221; as such terms are defined in, or subject to regulation under, the Investment Company Act of 1940, as amended.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 6.22&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">OFAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. No Credit Party, any of its Subsidiaries, any Related Party, any of their respective directors, officers, or employees nor any agents or other persons acting on behalf of any of the foregoing (a) is currently the target of any Sanctions, (b) is located, organized or residing in any Designated Jurisdiction, (c) is or has been (within the previous five (5) years) engaged in any transaction with, or for the benefit of, any Person who is now or was then the target of Sanctions or who is located, organized or residing in any Designated Jurisdiction or (d) is or has ever been in violation of or subject to an investigation relating to Sanctions. No Loans, and none of the proceeds from the Loans, have been or will be used, directly or indirectly, to lend, contribute or provide to, or has been or will be otherwise made available to fund, any activity or business in any Designated Jurisdiction or to fund any activity or business of any Person located, organized or residing in any Designated Jurisdiction or who is the subject of any Sanctions, or in any other manner that will result in any violation by any Person (including the Agent, any Lender and its and their respective Affiliates) of Sanctions.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 6.23&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Anti-Corruption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. No Credit Party, any of its Subsidiaries, any Related Party, or any of their respective directors, officers, or employees or any agents or other persons acting on behalf of any of the foregoing, directly or indirectly, has (a) violated or is in violation of any applicable anti-corruption law, (b) made, offered to make, promised to make or authorized the payment or giving of, directly or indirectly, any Prohibited Payment or (c) been subject to any investigation by any Governmental Authority with regard to any actual or alleged Prohibited Payment.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 6.24&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Deposit and Disbursement Accounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 6.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> contains a list of all banks and other financial institutions at which any Credit Party or any of its Subsidiaries maintains deposit accounts, lockboxes, disbursement accounts, investment accounts or other similar accounts, and such Schedule correctly identifies the name and address of each bank or financial institution, the name in which the account is held, the type of account, and the complete account number therefor. Subject to the proviso in Section 7.12(a), each such account (other than each Excluded Account) is a Controlled Account.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">50</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">SECTION 6.25&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Registration Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">. Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Schedule 6.25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">, no Credit Party and none of its Subsidiaries has granted or agreed to grant any registration rights, including piggyback rights, to any Person.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">SECTION 6.26&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Royalty and Other Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">. Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Schedule 6.26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">, no Credit Party and none of its Subsidiaries is obligated to pay any royalty, milestone payment, deferred payment or any other contingent payment in respect of any Product.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">SECTION 6.27&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Sale and Leaseback</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">. No Credit Party and none of its Subsidiaries has entered, directly or indirectly, into any agreement or arrangement providing for the sale or transfer by it of any property (now owned or hereafter acquired) to a Person and the subsequent lease or rental or such property or other similar property from such Person, except for any transactions permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Section&#160;8.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">SECTION 6.28&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Senior Secured Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">. The Obligations constitute the sole senior secured obligations and sole Indebtedness (except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Schedule 8.2(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">) of the Credit Parties and their Subsidiaries.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">SECTION 6.29&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Beneficial Ownership Certification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">. The information included in the Beneficial Ownership Certification is true and correct in all respects.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">ARTICLE VII</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">AFFIRMATIVE COVENANTS</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">The Credit Parties hereby jointly and severally covenant and agree for the benefit of the Agent and the Lenders that, until the Termination Date has occurred, the Credit Parties will perform or cause to be performed by each of their respective Subsidiaries, as applicable, the obligations set forth below.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">SECTION 7.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Financial Information, Reports, Notices, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">. Holdings will furnish the Agent copies of the following financial statements, reports, notices and information&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(a)&#160;&#160;&#160;&#160;as soon as available and in any event within thirty (30) days after the end of each calendar month, an unaudited consolidated balance sheet of Holdings and its Subsidiaries as of the end of such month and consolidated statements of income and cash flow of Holdings and its Subsidiaries for such applicable period, including (in each case), in comparative form the figures for the corresponding month in, and year to date portion of, the immediately preceding Fiscal Year and as provided in the budget delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">clause (e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%"> below for the current Fiscal Year, certified as complete and correct by the chief financial or accounting Authorized Officer of Holdings (subject to normal year-end audit adjustments) together with evidence satisfactory to the Agent (acting on the instructions of the Majority Lenders acting reasonably) that the Credit Parties were in compliance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Section 8.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%"> for such calendar month&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(b)&#160;&#160;&#160;&#160;as soon as available and in any event within forty-five (45) days after the end of each Fiscal Quarter (including the last Fiscal Quarter of each Fiscal Year), an unaudited consolidated balance sheet of Holdings and its Subsidiaries as of the end of such Fiscal Quarter, and consolidated statements of income and cash flow of Holdings and its Subsidiaries for such period, including (in each case), in comparative form the figures for the corresponding Fiscal Quarter in, and year to date portion of, the immediately preceding Fiscal Year, certified as complete and correct by the chief financial or accounting Authorized Officer of Holdings and its Subsidiaries (subject to normal year-end audit adjustments)&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(c)&#160;&#160;&#160;&#160;(i) as soon as available and in any event within one hundred twenty (120) days</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">after the end of each Fiscal Year, an unaudited consolidated balance sheet of Holdings and its Subsidiaries as of the end of such Fiscal Year, and the related unaudited consolidated statements of income and cash</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">51</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">flow of Holdings and its Subsidiaries for such Fiscal Year, setting forth in comparative form the figures for the immediately preceding Fiscal Year, certified as complete and correct by the chief financial or accounting Authorized Officer of Holdings and its Subsidiaries&#59; and (ii) as soon as available and in any event within one hundred twenty (120) days after the end of each Fiscal Year, a copy of the consolidated balance sheet of Holdings and its Subsidiaries, and the related consolidated statements of income and cash flow of Holdings and its Subsidiaries for such Fiscal Year, setting forth in comparative form the figures for the immediately preceding Fiscal Year, audited (without any Impermissible Qualification) by independent public accountants acceptable to the Agent, which shall include a calculation of the financial covenants set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> and stating that, in performing the examination necessary to deliver the audited financial statements of Holdings, no knowledge was obtained of any Event of Default&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(d)&#160;&#160;&#160;&#160;concurrently with the delivery of the financial information required to be delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">clauses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> above for each Fiscal Quarter and each Fiscal Year, a Compliance Certificate, executed by the chief financial or accounting Authorized Officer of Holdings, (i) showing compliance with the financial covenants set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> and stating that no Default has occurred and is continuing (or, if a Default has occurred, specifying the details of such Default and the action that Holdings or any of its Subsidiaries has taken or proposes to take with respect thereto), (ii) stating that no Subsidiary has been formed or acquired since the delivery of the last Compliance Certificate (or, if a Subsidiary has been formed or acquired since the delivery of the last Compliance Certificate, a statement that such Subsidiary has complied with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 7.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">) and (iii) including a list of all Immaterial Subsidiaries and setting forth in reasonable detail the Net Sales and Assets, in each case, attributable to each such Immaterial Subsidiary for the applicable Measurement Period&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(e)&#160;&#160;&#160;&#160;as soon as available and in any event within thirty (30) days after the end of each Fiscal Year, an annual budget, a business plan and financial forecasts of Holdings and its Subsidiaries for the then current Fiscal Year of Holdings, in form and substance as approved by the board of directors (or equivalent) of Holdings, which shall include a projection of income and a projected cash flow statement for each Fiscal Quarter in such Fiscal Year and a projected balance sheet as of the end of each Fiscal Quarter in such Fiscal Year, in each case prepared in reasonable detail, with appropriate presentation and discussion (in reasonable detail) of the principal assumptions upon which such budgets and projections are based, which shall be accompanied by the statement of an Authorized Officer of Holdings to the effect that such budget and projections are based on reasonable and good faith estimates and assumptions made by the management of Holdings for the respective periods covered thereby&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(f)&#160;&#160;&#160;&#160;as soon as possible and in any event within three (3) Business Days after Holdings obtains knowledge of the occurrence of a Default, a statement of an Authorized Officer of Holdings setting forth details of such Default, event or occurrence and the action which Holdings has taken and proposes to take with respect thereto&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(g)&#160;&#160;&#160;&#160;as soon as possible and in any event within three (3) Business Days after Holdings obtains knowledge of (i) the occurrence of any material adverse development with respect to any litigation, action, proceeding or labor controversy described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 6.7(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> and in the following </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">clause (ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> or (ii) the commencement of any litigation, action, proceeding or labor controversy of the type and materiality described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 6.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> or alleging potential or actual violations of any Healthcare Laws, notice thereof and, to the extent the Agent or any Lender requests, copies of all documentation relating thereto&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(h)&#160;&#160;&#160;&#160;as soon as possible and in any event within three (3) Business Days after Holdings obtains knowledge of any return, recovery, dispute or claim related to any Product or inventory that involves more than $1,500,000, written notice thereof from an Authorized Officer of Holdings which notice shall include any statement setting forth details of such return, recovery, dispute or claim&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">52</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(i)&#160;&#160;&#160;&#160;as soon as possible and in any event within three (3) Business Days after becoming aware of the occurrence of any ERISA Event which could reasonably be expected to result in the incurrence by a Credit Party or any of its Subsidiaries of any material liability, fine or penalty, notice thereof and copies of all documentation relating thereto, written notice thereof from an Authorized Officer of Holdings, which notice shall include a statement setting forth details of such events&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(j)&#160;&#160;&#160;&#160;promptly after the sending or filing thereof, copies of all reports, notices, prospectuses and registration statements which any Credit Party or any of its Subsidiaries files with the SEC or any national securities exchange&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(k)&#160;&#160;&#160;&#160;promptly upon receipt thereof, copies of all &#8220;management letters&#8221; (or equivalent) submitted to Holdings or any of its Subsidiaries by the independent public accountants referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Section 7.1(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%"> in connection with each audit made by such accountants&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(l)&#160;&#160;&#160;&#160;such other financial and other information as the Agent or any Lender may from time to time reasonably request (including information and reports in such detail as the Agent or any Lender may request with respect to the terms of and information provided pursuant to the Compliance Certificate).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">SECTION 7.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Maintenance of Existence&#59; Compliance with Contracts, Laws, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">. Each Credit Party will, and will cause each of its Subsidiaries to, (i) preserve and maintain its legal existence (except as otherwise permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Section 8.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">) and (ii) comply in all material respects with all applicable laws, rules, regulations and orders, including all Healthcare Laws and the payment (before the same become delinquent) of all material Taxes imposed upon such Credit Party or such Subsidiary or upon its property, except to the extent being diligently contested in good faith by appropriate proceedings and for which adequate reserves in accordance with GAAP have been set aside on the books of such Credit Party or such Subsidiary.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">SECTION 7.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Maintenance of Properties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">. Each Credit Party will, and will cause each of its Subsidiaries to, maintain, preserve, protect and keep its respective material properties in good repair, working order and condition (ordinary wear and tear excepted), and make necessary material repairs, renewals and replacements so that the business carried on by such Credit Party or such Subsidiary may be properly conducted at all times in all material respects, unless the Disposition of such property is otherwise permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Section 8.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Section 8.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">SECTION 7.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">. Each Credit Party will, and will cause each of its Subsidiaries to, maintain&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(a)&#160;&#160;&#160;&#160;insurance on its property with financially sound and reputable insurance companies against loss and damage in at least the amounts (and with only those deductibles) customarily maintained, and against such risks as are typically insured against in the same general area, by Persons of comparable size engaged in the same or similar business as such Credit Party or such Subsidiary&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(b)&#160;&#160;&#160;&#160;all worker&#8217;s compensation, employer&#8217;s liability insurance or similar insurance as may be required under the laws of any state or jurisdiction in which it may be engaged in business.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Without limiting the foregoing, on or within forty-five (45) days of the Closing Date (or such longer period as the Agent may agree in its reasonable discretion) all insurance policies required pursuant to this Section shall (i) name the Agent, for the benefit of the Secured Parties, as mortgagee (in the case of property insurance) or loss payee or additional insured (in the case of liability insurance), as applicable, and provide that no cancellation or modification of the policies will be made without the prior written notice to the Agent and (ii) be in addition to any requirements to maintain specific types of insurance contained in the other Loan Documents. If any Credit Party or any of its Subsidiaries fails to provide or pay for any such</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">53</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">insurance, the Agent may but is not obligated to, obtains the same at such Credit Party&#8217;s or such Subsidiary&#8217;s expense.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">SECTION 7.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Books and Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">. Each Credit Party will, and will cause each of its Subsidiaries to, keep books and records that accurately reflect all of its business affairs and transactions and permit the Agent, any Lenders or any of their respective representatives, at reasonable times and intervals upon reasonable notice to Holdings, to visit such Credit Party&#8217;s or such Subsidiary&#8217;s offices, to discuss such Credit Party&#8217;s or such Subsidiary&#8217;s financial matters with its officers and employees, and its independent public accountants (and the Credit Parties hereby authorize such independent public accountant to discuss such Credit Party&#8217;s or such Subsidiary&#8217;s financial matters with the Agent, any Lenders or any of their respective representatives whether or not any representative of such Credit Party or such Subsidiary, as applicable, is present) and to examine (and photocopy extracts from) any of its books and records. The Credit Parties will, and will cause each of their Subsidiaries to, pay all fees and expenses of the Agent or such Lender, including any fees of such independent public accountant incurred in connection with the Agent&#8217;s or any Lender&#8217;s exercise of its rights pursuant to this Section&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">, however, that in the absence of a Default and an Event of Default, the Credit Parties shall not be responsible for the costs associated with more than one such visit or inspection during any Fiscal Year.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">SECTION 7.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Environmental Law Covenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">. Each Credit Party will, and will cause each of its Subsidiaries to, (i) use and operate all of its and their businesses, facilities and properties in material compliance with all Environmental Laws, and keep and maintain all Environmental Permits and remain in compliance therewith and (ii) promptly notify the Agent of, and provide the Agent with copies of all material claims, complaints, notices or inquiries relating to, any actual or alleged non-compliance with any Environmental Laws or Environmental Permits or any actual or alleged Environmental Liabilities.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">SECTION 7.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Use of Proceeds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">. Proceeds of the Loans shall be used only to (i) refinance the outstanding obligations under the Existing Credit Agreement and (ii) pay certain fees, costs, and expenses incurred in connection with such refinancing and entry into this Agreement, the other Loan Documents and the transactions contemplated hereby.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">SECTION 7.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Future Guarantors, Security, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">. Each Credit Party agrees that&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(a)&#160;&#160;&#160;&#160;it will, and will cause each of its Subsidiaries, except for Immaterial Subsidiaries and Foreign Excluded Subsidiaries, existing as of the Closing Date to, execute any documents, Mortgages and Mortgage Instruments (subject to the limitation set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Section 7.8(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">), UCC-1 financing statements, UCC-3 termination statements, agreements and instruments, and take all further action that may be required under applicable law, or that the Agent may reasonably request, in order to effectuate the transactions contemplated by the Loan Documents and in order to grant, preserve, protect and perfect the validity and first priority (subject to Permitted Liens) of the Liens created or intended to be created by the Loan Documents&#59; including, without limitation, actions in any non-U.S. jurisdiction or required by the laws of any non-U.S. jurisdiction to create any security interests in assets of the Credit Parties located or titled outside of the United States or to perfect or make enforceable any security interests in any Collateral&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(b)&#160;&#160;&#160;&#160;it will cause each of its Subsidiaries, except for any Immaterial Subsidiary and any Foreign Excluded Subsidiary, that is acquired or organized by it after the Closing Date to, on or within thirty (30) days of such acquisition or organization (or such longer period as the Agent may agree in its sole discretion), to (i) execute a supplement (in form and substance satisfactory to the Agent (acting on the instructions of the Majority Lenders acting reasonably)) to each applicable Loan Document (including the Security Agreement, the Intercompany Subordination Agreement, the Copyright Security Agreement, the Patent Security Agreement, the Trademark Security Agreement and other security documents, and the Subsidiary Guaranty) in favor of the Agent and the other Secured Parties, (ii) execute or deliver such other</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">54</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">UCC-1 financing statements, UCC-3 termination statements, documents, Mortgages and Mortgage Instruments, agreements and instruments as the Agent may reasonably request, and (iii) take all further action that may be required under applicable law, or that the Agent may reasonably request, in order to effectuate the transactions contemplated by the Loan Documents and in order to grant, preserve, protect and perfect the validity and first priority (subject to Permitted Liens) of the Liens created or intended to be created by the Loan Documents&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%"> that no Mortgage or Mortgage Instruments will be required with respect to any real property having a fair market value of less than $2,500,000&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(c)&#160;&#160;&#160;&#160;it will cause each of its Subsidiaries organized under the under the laws of England and Wales, except for any Immaterial Subsidiary and any Foreign Excluded Subsidiary, that is acquired or organized by it after the Closing Date to, on or within thirty (30) days of such acquisition or organization (or such longer period as the Agent may agree in its sole discretion), to deliver to the Agent&#58; (A) a certificate, duly executed and delivered by such Person&#8217;s Secretary or Assistant Secretary, director, managing member or general partner, as applicable, as to&#58; (i) resolutions of each such Person&#8217;s board of directors (or other managing body, in the case of other than a corporation) then in full force and effect authorizing (x) the execution, delivery and performance of each Loan Document to be executed by such Person and the transactions contemplated hereby and thereby and (y) a specified person or persons, on its behalf, to sign and&#47;or despatch all documents and notices to be signed and&#47;or despatched by it under or in connection with the Loan Documents to which it is a party&#59; (ii) a copy of (x) a resolution of the board of directors of such Subsidiary approving the terms of the resolution referred to in sub-clause (i) above&#59; (y) a resolution of all of the shareholders of each such subsidiary approving the terms of the resolution referred to in sub-clause (i) above&#59; and (z) a resolution of the board of directors of each shareholder referred to in the preceding sub-clause (y) that is a corporate body, approving the execution by such corporate shareholder of the resolution referred to in the preceding sub-clause (y)&#59; (iii) the incumbency and signatures of those of its officers, managing member or general partner, as applicable, authorized to act with respect to each Loan Document to be executed by such Person&#59; (iv) the full force and validity of each Organic Document of such Person and copies thereof&#59; and certifying that each copy document relating to it specified in this clause is correct, complete and in full force and effect and has not been amended or superseded as at the date no earlier than the date of such certificate, in each case in this sub-clause (A), upon which certificates the Agent may conclusively rely until it shall have received a further certificate of the Secretary, Assistant Secretary, director, managing member or general partner, as applicable, of any such Person cancelling or amending the prior certificate of such Person&#59; (B) a certificate, duly executed and delivered by a director of such Subsidiary, which certificate shall be in form and substance satisfactory to the Agent (acting on the instructions of the Majority Lenders acting reasonably) and shall certify that borrowing or guaranteeing, as applicable, and securing the Loan Commitment Amount would not cause any borrowing, guarantee, security or any similar limit binding on such Subsidiary to be exceeded&#59; (C) at least two originals of an English law debenture (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Debenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8221;) executed by such Subsidiary created or expressed to be created in favor of the Agent, together with, a copy of all notices required to be sent under the Debenture executed by such Subsidiary and all share certificates, transfers and stock transfer forms or equivalent duly executed by the relevant Subsidiary in blank in relation to the assets subject to or expressed to be subject to the debenture security and other documents of title to be provided under the Debenture&#59; and (D) with respect to each company incorporated in the United Kingdom whose shares are the subject of the Debenture security (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Charged&#160;Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8221;), either&#58; (i) a certificate of an Authorized Officer of Holdings certifying that&#58; (A) each of Holdings and its Subsidiaries has complied within the relevant timeframe with any notice it has received pursuant to Part 21A of the Companies Act 2006 from such Charged Company, (B) no &#8220;warning notice&#8221; or &#8220;restrictions notice&#8221; (in each case as defined in Schedule 1B of the Companies Act 2006) has been issued in respect of those shares and (C) together with a copy of the &#8220;PSC register&#8221; (within the meaning of section 790C(10) of the Companies Act 2006) of such Charged Company, which, in the case of a Charged Company that is a Subsidiary Guarantor, is certified by an Authorized Officer of Holdings to be correct, complete and not amended or superseded as at a date no earlier than the Closing Date&#59; or a certificate of an Authorized</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">55</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Officer of Holdings certifying that such Charged Company is not required to comply with Part 21A of the Companies Act 2006&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(d)&#160;&#160;&#160;&#160;it will promptly notify the Agent of any real property subsequently acquired by it or any of its Subsidiaries, except for Immaterial Subsidiaries and Foreign Excluded Subsidiaries, and will provide the Agent with a description of such real property, the acquisition date thereof and the purchase price therefor, and if reasonably requested by the Agent, on or within sixty (60) days of such acquisition (or such longer period as the Agent may agree in its sole discretion) execute and deliver Mortgages and Mortgage Instruments in order to grant perfected and first priority Liens on such real property&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%"> that no Mortgage or Mortgage Instruments will be required with respect to any real property having a fair market value of less than $2,500,000&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(e)&#160;&#160;&#160;&#160;it will, and will cause each of its Subsidiaries, except for Immaterial Subsidiaries and Foreign Excluded Subsidiaries, to, at its cost and expense, promptly secure the Obligations by pledging or creating, or causing to be pledged or created, perfected Liens with respect to such of its assets and properties as the Agent shall designate, it being agreed that it is the intent of the parties that the Obligations shall at all times be secured by, among other things, substantially all the assets of Credit Parties and such Subsidiaries (including personal property acquired subsequent to the Closing Date), in each case, located in the United States and in any non-U.S. jurisdiction&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%"> that a pledge of 100% of the Capital Securities of any Foreign Subsidiary acquired or organized after the Closing Date shall be required, except to the extent as reasonably determined by the Borrower after consulting with the Agent, such pledge would reasonably be expected to result in material adverse tax consequences to the Borrower or Holdings, in which case Borrower shall not be required to pledge voting Capital Securities in excess of 65% of the issued and outstanding voting Capital Securities of such Foreign Subsidiary&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(f)&#160;&#160;&#160;&#160;it will, and will cause each of its Subsidiaries, except for Immaterial Subsidiaries, and Foreign Excluded Subsidiaries to, at its cost and expense, promptly upon acquisition, filing or issuance of any Patent, Trademark, Copyright, material Product Agreement or other Material Intellectual Property anywhere in the world, notify the Agent of such acquisition, filing or issuance of any Patent, Trademark, Copyright, material Product Agreement or other Material Intellectual Property and execute a supplement (in form and substance satisfactory to the Agent (acting on the instructions of the Majority Lenders acting reasonably)) to each applicable Loan Document (including the Security Agreement, the Copyright Security Agreement, the Patent Security Agreement, the Trademark Security Agreement and other security documents)&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(g)&#160;&#160;&#160;&#160;all Liens described above in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Section 7.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%"> will be created under the Loan Documents in form and substance satisfactory to the Agent (acting on the instructions of the Majority Lenders acting reasonably), and each Credit Party will, and will cause each of its Subsidiaries, except for Immaterial Subsidiaries and Foreign Excluded Subsidiaries, to, deliver or cause to be delivered to the Agent all such instruments and documents (including legal opinions and lien searches) as the Agent shall reasonably request to evidence compliance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Section 7.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">SECTION 7.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Obtaining of Permits, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">. With respect to Products, each Credit Party will, and will cause each of its Subsidiaries to, obtain, maintain and preserve, and take all necessary action to timely renew all Permits (including Key Permits) and accreditations which are necessary in the proper conduct of its business.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">SECTION 7.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Product Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">. Each Credit Party will, and will cause each of its Subsidiaries to, (i) maintain each Permit, including each Regulatory Authorization, from, or file any notice or registration in, each jurisdiction in which such Credit Party or such Subsidiary is required to obtain any Permit or Regulatory Authorization or to file any notice or registration, in order to sell or distribute the</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">56</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Products which represented, in the aggregate, 15% or more of Net Sales in any applicable year and (ii) upon request of the Agent, promptly provide evidence of same to the Agent.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 7.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Maintenance of Regulatory Authorizations, Contracts, Intellectual Property,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. With respect to the Products, each Credit Party will, and will cause each of its Subsidiaries to, (i) maintain in full force and effect all Regulatory Authorizations, contract rights, or other rights necessary for the material operations of its business, (ii) notify the Agent, promptly after learning thereof, of any Product recalls, safety alerts, corrections, withdrawals, marketing suspensions, removals or the like conducted, to be undertaken or issued by such Credit Party, such Subsidiary or its respective suppliers whether or not at the request, demand or order of any Governmental Authority or otherwise with respect to any Product which represented, in the aggregate, 15% or more of Net Sales in any applicable year, or any basis for undertaking or issuing any such action or item, (iii) maintain in full force and effect, and pay all costs and expenses relating to, all Material Intellectual Property owned by such Credit Party or such Subsidiary, (iv) notify the Agent, promptly after learning thereof, of any infringement or other violation by any Person of its Material Intellectual Property and respond to such infringement or other violation in a manner determined within the reasonable judgement and at the sole expense of such Credit Party and (v) notify the Agent, promptly after learning thereof, of (x) any claim by any Person that the conduct of such Credit Party&#8217;s or such Subsidiary&#8217;s business (including the development, manufacture, use, sale or other commercialization of any Product) infringes any material Intellectual Property of such Person and, if requested by the Agent, use commercially reasonable efforts to resolve such claim, or (y) any event, circumstance, act or omission that could reasonably be expected to cause any representation or warranty contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> to be incorrect in any material respect if such representation or warranty was to be made at the time such Credit Party or such Subsidiary learned of such event, circumstance, act or omission.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 7.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Cash Management</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Credit Party will, and will cause each of its Subsidiaries (other than Immaterial Subsidiaries) to&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;maintain all deposit accounts, disbursement accounts, investment accounts (and other similar accounts) and lockboxes (other than Excluded Accounts) with a bank or financial institution that has executed and delivered to the Agent a Controlled Account Agreement in form and substance reasonably acceptable to the Agent&#59; each such deposit account, disbursement account, investment account (or similar account) and lockbox (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Controlled Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) shall be a cash collateral account, with all cash, checks and other similar items of payment in such account securing payment of the Obligations, and the Credit Parties shall have granted a Lien to the Agent, for the benefit of the Secured Parties, over such Controlled Accounts&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that the Credit Parties shall cause each account existing as of the Closing Date to become a Controlled Account on or within sixty (60) days of the Closing Date (or such longer period as the Agent may agree in its reasonable discretion)&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;deposit promptly, and in any event no later than fourteen (14) Business Days after the date of receipt thereof, all checks, drafts, other similar items of payment or cash, in each case, in an amount in excess of $500,000, in each case, relating to or constituting payments made in respect of any and all accounts and other rights and interests into Controlled Accounts.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">At any time after the occurrence and during the continuance of an Event of Default, at the request of the Agent, the Credit Parties and their Subsidiaries will cause all payments constituting proceeds of accounts to be directed into lockbox accounts under Controlled Account Agreements in form and substance satisfactory to the Agent.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">57</font></div></div></div><hr style="page-break-after:always"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE VIII</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NEGATIVE COVENANTS</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">The Credit Parties hereby jointly and severally covenant and agree for the benefit of the Agent and the Lenders that until the Termination Date has occurred unless the Majority Lenders shall otherwise consent in writing, the Credit Parties will perform or cause to be performed by each of their respective Subsidiaries, as applicable, the obligations set forth below.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">SECTION 8.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Business Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">. No Credit Party will, nor will it permit any of its Subsidiaries to, engage in any business activity except those business activities engaged in on the date of this Agreement and activities reasonably incidental or complimentary thereto and reasonable extensions thereof.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">SECTION 8.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">. No Credit Party will, nor will it permit any of its Subsidiaries to, create, incur, assume or permit to exist any Indebtedness, other than the following (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Permitted&#160;Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8221;)&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(a)&#160;&#160;&#160;&#160;Indebtedness in respect of the Obligations&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(b)&#160;&#160;&#160;&#160;unsecured Indebtedness of any Credit Party pursuant to Hedging Agreements solely for purposes of hedging the rate of interest payable on the outstanding principal amount of the Loans&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(c)&#160;&#160;&#160;&#160;Indebtedness existing as of the Closing Date which is identified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Schedule&#160;8.2(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(d)&#160;&#160;&#160;&#160;Indebtedness in respect of performance, surety or appeal bonds provided in the ordinary course of business and consistent with past practice but excluding (in each case) Indebtedness incurred through the borrowing of money or Contingent Liabilities in respect thereof&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(e)&#160;&#160;&#160;&#160;purchase money Indebtedness and Capitalized Lease Liabilities incurred by any Credit Party in an aggregate amount at any time outstanding, when combined with the aggregate principal amount of all Indebtedness incurred pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Section 8.2(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">, not to exceed $4,500,000&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(f)&#160;&#160;&#160;&#160;Indebtedness (i) arising from customary agreements for indemnification related to sales of goods, licensing of Intellectual Property or adjustment of purchase price or similar obligations in any case incurred in connection with the acquisition or Disposition permitted hereunder of any business, assets or Subsidiary of Holdings, (ii) representing deferred compensation to employees of a Credit Party or any of its Subsidiaries incurred in the ordinary course of business consistent with past practice, and (iii) representing customer deposits and advance payments received in the ordinary course of business from customers for goods purchased in the ordinary course of business&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(g)&#160;&#160;&#160;&#160;Indebtedness with respect to cash management obligations and other Indebtedness in respect of automatic clearing house arrangements, netting services, overdraft protection and similar arrangements, in each case incurred in the ordinary course of business&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(h)&#160;&#160;&#160;&#160;unsecured Indebtedness in the nature of account or trade payables originated in the ordinary course of business&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(i)&#160;&#160;&#160;&#160;(i) intercompany Indebtedness of any Credit Party or a Subsidiary thereof owing</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">to another Credit Party or a Subsidiary thereof, in each case, subject to the Intercompany Subordination Agreement&#59; provided that any intercompany Indebtedness made to a Subsidiary that is not a Credit Party shall be for the sole purpose of payroll expenses and other operational costs incurred by such Subsidiary in</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">58</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">the ordinary course of business and consistent with past practice&#59; and (ii) unsecured guarantees of outstanding Permitted Indebtedness made in the ordinary course of business by the Borrower or any Subsidiary of obligations of any Credit Party permitted hereunder in an aggregate amount not to exceed $1,500,000 at any time outstanding&#59; provided that to the extent that any such Permitted Indebtedness is subordinated to the Obligations, such guarantees are similarly subordinated&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(j)&#160;&#160;&#160;&#160;(i) Indebtedness of the Borrower or any Subsidiary Guarantor incurred to finance the acquisition, construction or improvement of any fixed or capital assets&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> that (x) such Indebtedness is incurred prior to or within two hundred seventy (270) days after such acquisition or the completion of such construction or improvement and (y) the aggregate principal amount of Indebtedness permitted by this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 8.2(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, when combined with the aggregate principal amount of all purchase money Indebtedness and Capitalized Lease Liabilities incurred pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 8.2(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, does not exceed $4,500,000 at any time outstanding and (ii) extensions, renewals, refinancings and replacements thereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> that no such extension, renewal, refinancing or replacement shall result in an increase in the outstanding principal amount of such Indebtedness&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(k)&#160;&#160;&#160;&#160;Indebtedness at any time incurred in connection with financing insurance premiums in respect of insurance policies insuring assets or businesses of any Credit Party written or arranged in the ordinary course of business consistent with past practice&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(l)&#160;&#160;&#160;&#160;Indebtedness of any Subsidiary that is not a Credit Party in an aggregate outstanding principal amount not to exceed $2,000,000&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(m)&#160;&#160;&#160;&#160;Indebtedness constituting letters of credit in an aggregate face amount at any time outstanding not to exceed $6,000,000&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, in each case, that any such letter of credit is used solely to secure obligations in respect of a lease or sublease of a Credit Party or any of its Subsidiaries&#59; and other Indebtedness in an aggregate outstanding principal amount not to exceed $1,500,000&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(n)&#160;&#160;&#160;&#160;unsecured Indebtedness of Holdings in respect of any subordinated convertible promissory note, in an aggregate principal amount not to exceed $75,000,000 (plus the amount of interest paid-in-kind thereon pursuant to the terms of such notes on the date of incurrence thereof)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> that (x) such Indebtedness shall not mature before the date that is ninety-one (91) days after the Maturity Date, (y) such Indebtedness shall not permit cash payments with respect to the principal or interest thereon and (z) such Indebtedness shall at all times be subject to a subordination agreement in form and substance satisfactory to the Agent&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> that, no Indebtedness otherwise permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">clauses (e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> shall be assumed, created or otherwise incurred if at the time of such assumption, creation or incurrence, a Default has occurred and is then continuing or could reasonably be expected to result therefrom.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 8.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. No Credit Party will, nor will it permit any of its Subsidiaries to, create, incur, assume or permit to exist any Lien upon any of its property (including Capital Securities of any Person), revenues or assets, whether now owned or hereafter acquired, except for the following (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Permitted Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;)&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;Liens securing payment of the Obligations&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;Liens existing on the Closing Date which are disclosed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 8.3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;Liens in favor of carriers, warehousemen, mechanics, materialmen and landlords granted in the ordinary course of business for amounts not overdue or being diligently contested in good</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">59</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">faith by appropriate proceedings and for which adequate reserves in accordance with GAAP shall have been set aside on its books&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Liens incurred or deposits made in the ordinary course of business in connection with worker&#8217;s compensation, unemployment insurance or other forms of governmental insurance or benefits, or to secure performance of tenders, statutory obligations, bids, leases or other similar obligations (other than for borrowed money) entered into in the ordinary course of business or to secure obligations on surety and appeal bonds or performance bonds&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;judgment Liens in existence for less than sixty (60) days after the entry thereof or with respect to which execution has been stayed or the payment of which is covered in full (subject to a customary deductible) by insurance maintained with responsible insurance companies and which do not otherwise result in an Event of Default under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;easements, rights-of-way, zoning restrictions, minor defects or irregularities in title and other similar encumbrances not interfering in any material respect with the value or use of the property to which such Lien is attached&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;Liens for Taxes not yet due and payable or being diligently contested in good faith by appropriate proceedings and for which adequate reserves in accordance with GAAP shall have been set aside on its books&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;purchase money security interests in real property, improvements thereto, equipment or other assets hereafter acquired (or, in the case of improvements, constructed) by the Borrower or any Subsidiary Guarantor&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that (i) such security interests secure Indebtedness permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, (ii) such security interests are incurred, and the Indebtedness secured thereby is created, within two hundred seventy (270) days after such acquisition (or construction) (or in the case of the first or any successive extensions, renewals or refinancings of the underlying Indebtedness, such security interests are incurred and the security is created within thirty (30) days after the incurrence of such new Indebtedness), (iii) the Indebtedness secured thereby does not exceed the cost of such real property, improvements or equipment at the time of such acquisition (or construction) and (iv) such security interests do not apply to any other property or assets of the Borrower or any Subsidiary&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;any interest or title of a lessor under any lease entered into by the Borrower or any of its Subsidiaries as lessees in the ordinary course of business and covering only the assets so leased&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of customs duties in connection with the importation of goods&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;Liens arising solely by virtue of any statutory or common law provision relating to bankers&#8217; liens, rights of set-off or similar rights&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;the cash collateralization of any letter of credit obligations incurred pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in an amount not to exceed 105% of the face amount thereof&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(m)&#160;&#160;&#160;&#160;other Liens securing Indebtedness and other obligations in an aggregate outstanding principal amount not to exceed $1,500,000.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 8.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Minimum Liquidity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Credit Parties shall maintain at all times Liquidity in an amount equal to or greater than $25,000,000 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Liquidity Covenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that in the event that the Credit Parties fail to comply with the Liquidity Covenant as of any date from and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">60</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">after the date of written notice to, or knowledge of, the Borrower of such noncompliance until the expiration of the thirtieth (30th) Business Day subsequent to such date of such written notice or knowledge, Holdings shall have the right to issue common equity (or other Qualified Capital Securities that are preferred equity or other equity) for cash or otherwise receive cash contributions to its capital and, in either case, directly contribute any such cash to the common equity (or other Qualified Capital Securities that are preferred equity or other equity) capital of the Borrower (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Liquidity Cure Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8221;), and upon the receipt by the Borrower of such cash in an amount not less than the greater of (x) $5,000,000 and (y) the amount necessary to cure the failure to comply with the Liquidity Covenant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Liquidity Cure Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8221;), the calculation of Liquidity as used in the Liquidity Covenant shall be recalculated giving effect to the following pro forma adjustments&#58; (a) Liquidity shall be increased, solely for the purpose of measuring the Liquidity Covenant for each day prior to receipt of the Liquidity Cure Amount for which a Liquidity Cure Right has been exercised in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Section 8.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%"> and not for any determination made following receipt of such Liquidity Cure Amount or for any other purpose under this Agreement, by an amount equal to the Liquidity Cure Amount (it being understood and agreed that previously received proceeds of any exercise of the Liquidity Cure Right shall be counted in calculating Liquidity following receipt thereof to the extent and for so long as such proceeds constitute Liquidity) and (b) if, after giving effect to the foregoing recalculation, the Borrower shall then be in compliance with the Liquidity Covenant, the Borrower shall be deemed to have satisfied the requirements of such covenant as of the relevant date of determination with the same effect as though there had been no failure to comply therewith at such date, and the applicable breach or default that had occurred shall be deemed cured for all purposes of this Agreement.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Minimum Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">. As of the last day of each Fiscal Quarter set forth below, Net Sales for the twelve (12) consecutive month period ending on the last day of such Fiscal Quarter shall not be less than the corresponding amount set forth opposite such Fiscal Quarter&#58;</font></div><div style="margin-bottom:24pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.286%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:20pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Fiscal Quarter Ending</font></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:20pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Net Sales</font></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">June 30, 2024</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$78,872,953&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2024</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$88,399,787&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2024</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$98,680,724&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2025</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$109,528,429&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">June 30, 2025</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$110,000,000&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2025</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$110,000,000&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2025</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$110,000,000&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2026</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$110,000,000&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">June 30, 2026</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$110,000,000&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2026</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$110,000,000&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2026</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$110,000,000&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2027</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$110,000,000&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">June 30, 2027</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$110,000,000&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2027</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$110,000,000&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2027</font></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$110,000,000&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2028</font></td><td colspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$110,000,000&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:top"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%"> that compliance with this covenant shall not be required for any Fiscal Quarter with respect to which (i) the Credit Parties maintain Liquidity in an amount greater than or equal to $60,000,000 as of the end of such Fiscal Quarter and (ii) there has not occurred a Two-Consecutive Fiscal Quarter Net Sales Decline as of the end of such Fiscal Quarter.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">61</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 8.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Investments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No Credit Party will, nor will it permit any of its Subsidiaries to, purchase, make, incur, assume or permit to exist any Investment in any other Person, except (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Permitted Investments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Investments existing on the Closing Date and identified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 8.5(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;cash and Cash Equivalent Investments&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Investments received in connection with the bankruptcy or reorganization of, or settlement of delinquent accounts and disputes with, customers and suppliers, in each case in the ordinary course of business&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Investments consisting of any deferred portion of the sales price received by a Credit Party or any of its Subsidiaries in connection with any Disposition permitted under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;(i) Investments in and loans to any Credit Party and (ii) Investments in and loans</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to any Subsidiary that is not a Credit Party (x) to the extent made by any other Subsidiary that is not a Credit Party or (y) constituting payroll expenses and other operational costs incurred by such Subsidiary in the ordinary course of business consistent with past practice&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;Investments constituting (i) accounts receivable arising, (ii) trade debt granted, or (iii) deposits made in connection with the purchase price of goods or services, in each case in the ordinary course of business&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;Investments and loans by a Credit Party in a Subsidiary that is not a Credit Party that do not include the Disposition of Material Intellectual Property or Capital Securities with respect to Subsidiaries that directly or indirectly own, or hold a license in respect of, Material Intellectual Property, in an aggregate amount, together with the aggregate amount of Permitted Dispositions made pursuant to clause (v)(C) of the definition thereof, not to exceed $2,000,000&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;other Investments that do not include Material Intellectual Property or Capital Securities with respect to Subsidiaries that directly or indirectly own, or hold a license in respect of, Material Intellectual Property in an aggregate amount not to exceed $5,000,000.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 8.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Restricted Payments, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No Credit Party will, nor will it permit any of its Subsidiaries to, declare or make a Restricted Payment, or make any deposit for any Restricted Payment, other than&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Restricted Payments made by Subsidiaries of the Borrower to the Borrower&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;so long as (i) no Default or Event of Default has occurred and is continuing, (or could be reasonably expected to occur as a result thereof) and (ii) Holdings (or any direct or indirect parent of Holdings) is the parent of a consolidated group for U.S. federal income tax purposes that includes the Borrower, Restricted Payments made in cash by the Borrower to Holdings (or such direct or indirect parent of Holdings), the proceeds of which shall be used solely to pay Taxes of Holdings or such direct or indirect parent of Holdings (other than any Taxes attributable to any action or activity that constitutes or results in a breach by Holdings of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">)&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;so long as no Event of Default has occurred and is continuing (or could be reasonably expected to occur as a result thereof), share repurchases in an aggregate amount not to exceed</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">62</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">$1,000,000 per Fiscal Year plus any amounts pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">clause (c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> that were unused in any preceding Fiscal Year.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 8.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Issuance of Capital Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. No Credit Party will, nor will it permit any of its Subsidiaries to, issue any Capital Securities (whether for value or otherwise) to any Person other than&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;in the case of Subsidiaries of the Credit Parties, Qualified Capital Securities issued to a Credit Party so long as such issuance could not reasonably be expected to result in a Default or an Event of Default&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;the issuance of Qualified Capital Securities of Holdings so long as such issuance could not reasonably be expected to result in an Event of Default.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 8.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Consolidation, Merger, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. No Credit Party will, nor will it permit any of its Subsidiaries to, liquidate or dissolve, consolidate with, or merge or amalgamate into or with, any other Person, or purchase or otherwise acquire any other Person or all or substantially all of the assets of any other Person (or any division thereof), except that (i) any Subsidiary (other than the Borrower) of a Credit Party may liquidate or dissolve voluntarily into, and may merge or amalgamate with and into, a Credit Party&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, that such Credit Party is the surviving entity&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, further, that immediately following any such merger or amalgamation, the Credit Parties directly or indirectly hold the same or greater percentage of the issued and outstanding Capital Securities of such Subsidiary as the Credit Parties held immediately prior to such merger or amalgamation&#59; (ii) any Credit Party (other than Holdings) may liquidate or dissolve voluntarily into, and may merge or amalgamate with and into, a Credit Party&#59; provided, that if the Borrower is a party thereto, the Borrower is the surviving entity&#59; and (iii) any Subsidiary that is not a Credit Party may liquidate or dissolve voluntarily into, and may merge or amalgamate with and into, another Subsidiary that is not a Credit Party.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 8.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Permitted Dispositions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. No Credit Party will, nor will it permit any of its Subsidiaries to, Dispose of any of its assets (including accounts receivable and Capital Securities) to any Person in one transaction or series of transactions except for Permitted Dispositions.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 8.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Modification of Certain Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. No Credit Party will, nor will it permit any of its Subsidiaries to, amend, supplement, waive or otherwise modify, consent to any amendment, supplement, waiver or other modification of, or enter into any forbearance from exercising any rights with respect to the terms or provisions contained in (i) any Organic Documents of a Credit Party or any of its Subsidiaries that could reasonably be expected to result in a Material Adverse Effect or in a manner that could be materially adverse to the interests of the Agent or any of the Lenders without the consent of the Agent&#59; provided that a transaction expressly permitted pursuant to Section 8.8 that does not materially adversely effect the interests of the Agent or any of the Lenders shall not require any consent under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 8.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> or (ii)(A) any Material Agreement or any documents relating thereto (in each case, other than any amendments, supplements, waivers, or other modifications to the AWS Agreement (or any replacement cloud hosting agreement that is a Material Agreement) or any documents relating thereto, in each case, that are made from time to time by AWS (or any counterparty to such replacement cloud hosting agreement or any documents relating thereto)), or (B) any material Product Agreement or any documents relating thereto, in any such case in this clause (ii), in a manner that could be materially adverse to the interests of the Agent or any of the Lenders without the consent of the Agent.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 8.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Transactions with Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. No Credit Party will, nor will it permit any of its Subsidiaries to, enter into or cause or permit to exist any arrangement, transaction or contract (including for the purchase, lease or exchange of property or the rendering of services) with any of its other Affiliates, unless such arrangement, transaction or contract (i) is on fair and reasonable terms no less favorable to such</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">63</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Credit Party or such Subsidiary than it could obtain in an arm&#8217;s-length transaction with a Person that is not an Affiliate (it being understood that this Section shall not apply to any transaction that is expressly permitted under this Agreement between or among the Credit Parties and not involving any other Affiliate) or (ii) is set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Schedule 6.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">SECTION 8.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%;text-decoration:underline">Restrictive Agreements, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">. No Credit Party will, nor will it permit any of its Subsidiaries to, enter into any agreement (i) prohibiting the creation or assumption of any Lien upon its properties, revenues or assets, whether now owned or hereafter acquired, or limiting in any way granting to the Secured Parties (or any of them) a Lien on any of its assets, (ii) restricting the ability of a Credit Party or any of its Subsidiaries to amend or otherwise modify any Loan Document, (iii) containing any provision which could reasonably be expected to be violated or breached by a party hereunder by the performance by such party of any of its obligations hereunder or under any other Loan Document, (iv) encumbering or restricting the ability of a Credit Party or any of its Subsidiaries to (a) make any payments, directly or indirectly, to the Borrower, including by way of dividends, advances, repayments of Indebtedness owed to the Borrower, reimbursements of management and other intercompany charges, expenses and accruals or other returns on investments, (b) make loans or advances to the Borrower or (c) transfer any of its assets or properties to the Borrower. The foregoing prohibitions shall not apply to restrictions (x) contained in any Loan Document or (y) in the case of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%;text-decoration:underline">clause (i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">, (I) by reason of applicable law, (II) in any agreement governing any Indebtedness permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%;text-decoration:underline">clause (e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%;text-decoration:underline">Section 8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%"> as to the assets financed with the proceeds of such Indebtedness, (III) in contracts (A) existing as of the Closing Date and set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%;text-decoration:underline">Schedule 8.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%"> or any renewal or extension thereof&#59; provided that any such restriction contained therein relates only to the asset or assets constructed or acquired in connection therewith and (B) of a Person existing at the time such Person becomes a Subsidiary of a Credit Party in a transaction permitted hereunder, provided that any such contract was not created in anticipation of or in connection with the transaction or series of transactions pursuant to which such Person became a Subsidiary of a Credit Party, or (IV) any Permitted Lien or any document or instrument governing any Permitted Lien&#59; provided that any such restriction contained therein relates only to the asset or assets subject to such Permitted Lien.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">SECTION 8.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Sale and Leaseback</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">. Except in a transaction permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Section 8.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">, or transactions with an aggregate fair market value not in excess of $750,000, no Credit Party will, nor will it permit any of its Subsidiaries to, directly or indirectly enter into any agreement or arrangement providing for the sale or transfer by it of any property (now owned or hereafter acquired) to a Person and the subsequent lease or rental of such property or other similar property from such Person.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">SECTION 8.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Product Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">. No Credit Party will, nor will it permit any of its Subsidiaries to, sell or distribute Products which represented, in the aggregate, 15% or more of Net Sales in any applicable year, or permit any sale or distribution of such Products above such threshold where a Credit Party or any of its Subsidiaries is required to obtain any Permit, or to file any notice or registration in any jurisdiction prior to any such sale or distribution of such Products above such threshold, in each case, until such Credit Party or such Subsidiary has obtained such required Permit or filed such notice or registration.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">SECTION 8.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Change in Name, Location, Executive Office, or Executive Management&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Change in Fiscal Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">. No Credit Party will, nor will it permit any of its Subsidiaries to, (i) change its legal name without ten (10) days&#8217; prior written notice to the Agent, (ii) change its jurisdiction of organization or legal structure, (iii) relocate its chief executive office or principal place of business, relocate any other office in which it maintains books or records relating to its business (including the establishment of any new office or facility), except, in each case, within the State of California or into the State of Texas and with ten (10) days&#8217; prior written notice to the Agent, or (iv) change its Fiscal Year or any of its Fiscal Quarters.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">SECTION 8.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;text-decoration:underline">Negative Pledge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">. No Credit Party will, nor will it permit any of its Subsidiaries to, create, permit or suffer to exist any Lien (whether such interest is based on common law, statute, other</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">64</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">law or contract and whether junior or equal or superior in priority to the security interests and Liens created by the Loan Documents) upon any of its property (including Capital Securities of any Person), revenues or assets, whether now owned or hereafter acquired, except Permitted Liens. No Credit Party will, nor will it permit any of its Subsidiaries to, incur senior secured obligations other than the Obligations incurred hereunder. For the avoidance of doubt, this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall not restrict the Credit Parties&#8217; (i) incurrence of Indebtedness (A) secured by Permitted Liens that are permitted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.3(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or (B) constituting letters of credit incurred in reliance upon </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or (ii) cash collateral securing any such letter of credit in reliance upon </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.3(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 8.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sanctions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No Credit Party will, and no Credit Party will permit any of its Affiliates to, use any proceeds of the Loans for the purpose of&#58; (i) providing financing to or otherwise making funds directly or indirectly available to any Sanctioned Person, or (ii) providing financing to or otherwise funding any transaction which would be prohibited by Sanctions or would otherwise cause the Agent or any of the Lenders to be in breach of any Sanction.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;No Credit Party will, and no Credit Party will permit any of its Affiliates to, fund any repayment of the credit with proceeds derived from any transaction that would be prohibited by Sanctions or would otherwise cause the Agent or any of the Lenders to be in breach of any Sanction.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 8.18&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Passive Holding Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Holdings will not conduct, transact or otherwise engage in any active trade or business or operations, incur any Indebtedness or other liability, or own any assets other than Capital Securities of the Borrower&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that the foregoing will not prohibit Holdings from the following&#58; (i) the maintenance of its legal existence and obligations that are incidental thereto (including the ability to incur reasonable fees, costs, expenses and other liabilities directly relating to such maintenance), (ii) obligations that are limited to obligations under the Loan Documents to which it is a party, (iii) the making of contributions to (or other equity investments in) the Borrower, which contributions shall be subordinated to the Obligations, (iv) participating in tax, accounting and other administrative and fiduciary matters as a direct owner of the Borrower, in accordance with the terms of the Loan Documents to which Holdings is a party, (v) providing customary compensation, indemnification and insurance coverage to officers and directors (or equivalent), (vi) the consummation of an IPO or SPAC Transaction, and (vii) making Restricted Payments or issuing any Capital Securities to the extent expressly permitted hereunder.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 8.19&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">USRPHC Status</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No Credit Party will, nor will it permit any of its Subsidiaries to, become a &#8220;United States real property holding corporation&#8221; within the meaning of Section 897(c)(2) of the Code.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 8.20&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Hazardous Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No Credit Party will, nor will it permit any of its Subsidiaries to, cause or suffer to exist a Release of any Hazardous Material at, on, under, to or from any real estate that would violate any Environmental Law, form the basis for any Environmental Liabilities or otherwise adversely affect the value or marketability of any real estate (whether or not owned by any Credit Party or any Subsidiary of any Credit Party), other than such violations, Environmental Liabilities and effects that would not, in the aggregate, reasonably be expected to result in a material liability.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 8.21&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No Credit Party will, nor will it permit any of its Subsidiaries to, grant any license to any Material Intellectual Property other than a license that&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;is in the ordinary course of business&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;is (i) on a non-exclusive basis or (ii) on an exclusive basis so long as each such exclusive license is limited to a particular geographic area (other than the U.S, U.K. or Japan)&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">65</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;will not prevent, restrict or otherwise impair such Credit Party&#8217;s or such Subsidiary&#8217;s or the Agent&#8217;s ability to use or otherwise monetize such Material Intellectual Property&#59; and</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;will not prevent, restrict or otherwise impair the Agent&#8217;s ability to assume such Credit Party&#8217;s or such Subsidiary&#8217;s rights under such license.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 8.22&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Subordinated Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Except as expressly permitted by the subordination agreement with respect to any subordinated Indebtedness, no Credit Party shall make any payment or distribution in respect of such subordinated Indebtedness, other than in the form of Capital Securities (other than Disqualified Capital Securities) of Holdings. No Credit Party shall, without the prior written consent of the Administrative Agent, amend or otherwise modify the terms of any subordinated Indebtedness, except as expressly permitted by the subordination agreement with respect to such subordinated Indebtedness. No Credit Party shall permit the transfer of any subordinated Indebtedness, unless the transferee party is, or becomes, a party to the subordination agreement with respect to such subordinated Indebtedness.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE IX</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EVENTS OF DEFAULT</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 9.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Listing of Events of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each of the following events or occurrences described in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall constitute an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Event of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Payment of Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. (i) The Borrower shall default in the payment or prepayment when due of any principal on the Loans, or (ii) any Credit Party, including the Borrower, shall default in the payment or prepayment of interest or any fee described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or any other monetary Obligation, and in the case of clause (ii) such default shall continue unremedied for a period of three (3) Business Days after such amount was due.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Breach of Representation or Warranty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Any representation or warranty made or deemed to be made by a Credit Party or its Subsidiaries in any Loan Document (including any certificates delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) is or shall be incorrect in any material respect when made or deemed to have been made or, in the case of any representation or warranty that, by its terms, is qualified by materiality, Material Adverse Effect or similar qualification, such representation or warranty is or shall be incorrect in any respect when made or deemed made.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Performance of Certain Covenants and Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. A Credit Party or any of its Subsidiaries shall default in the due performance or observance of any of its obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sections&#160;7.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">7.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">7.1(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">7.1(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">7.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">7.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">7.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> ((i) other than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.10(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and (ii) with respect to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, subject to the Liquidity Cure Right set forth therein).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Performance of Other Covenants and Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. A Credit Party or any of its Subsidiaries shall default in the due performance and observance of any other covenant, obligation or agreement contained in any Loan Document (other than any default of the type contemplated by any other subsection of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) executed by it, and such default shall continue unremedied for a period of thirty (30) days after the earlier to occur of (i) written notice thereof given to Holdings by the Agent or the Majority Lenders or (ii) the date on which a Credit Party or any of its Subsidiaries has knowledge of such default.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">66</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Default on Other Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. A default shall occur in the payment of any amount when due (subject to any applicable grace period), whether by acceleration or otherwise, of any principal or stated amount of, or interest or fees on, any Indebtedness (other than Indebtedness permitted under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) of any Credit Party or any of its Subsidiaries having a principal or stated amount, individually or in the aggregate, in excess of $4,000,000, or a default shall occur in the performance or observance of any obligation or condition with respect to such Indebtedness if the effect of such default is to accelerate the maturity of any such Indebtedness or such default shall continue unremedied for any applicable period of time sufficient to permit the holder or holders of such Indebtedness, or any trustee or agent for such holders, to cause or declare such Indebtedness to become due and payable or to require such Indebtedness to be prepaid, redeemed, purchased or defeased, or require an offer to purchase or defease such Indebtedness to be made, prior to its expressed maturity.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Judgments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Any judgment or order for the payment of money individually or in the aggregate in excess of $4,000,000 (exclusive of any amounts fully covered by insurance (less any applicable deductible) and as to which the insurer has acknowledged its responsibility to cover such judgment or order) shall be rendered against any Credit Party or any of its Subsidiaries and such judgment shall not have been vacated or discharged or stayed or bonded pending appeal within sixty (60) days after the entry thereof or enforcement proceedings shall have been commenced by any creditor upon such judgment or order.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Any Change in Control shall occur.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Bankruptcy, Insolvency, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Any Credit Party or any of its Subsidiaries shall&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;become insolvent or generally fail to pay, or admit in writing its inability or unwillingness generally to pay, debts as they become due&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;apply for, consent to, or acquiesce in the appointment of a trustee, receiver, sequestrator or other custodian for any substantial part of the property of any thereof, or make a general assignment for the benefit of creditors&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;in the absence of such application, consent or acquiescence in or permit or suffer to exist the appointment of a trustee, receiver, sequestrator or other custodian for a substantial part of the property of any thereof, and such trustee, receiver, sequestrator or other custodian shall not be discharged within sixty (60) days&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that, the Credit Parties and their Subsidiaries hereby expressly authorize the Agent to appear in any court conducting any relevant proceeding during such sixth (60) day period to preserve, protect and defend its rights under the Loan Documents&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;permit or suffer to exist the commencement of any bankruptcy, reorganization, debt arrangement or other case or proceeding under any bankruptcy or insolvency law or any dissolution, winding up or liquidation proceeding, in respect thereof, and, if any such case or proceeding is not commenced by a Credit Party or any of its Subsidiaries, such case or proceeding shall be consented to or acquiesced in by a Credit Party or any of its Subsidiaries or shall result in the entry of an order for relief or shall remain for sixty (60) days undismissed&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that, the Credit Parties and their Subsidiaries hereby expressly authorize the Agent to appear in any court conducting any such case or proceeding during such sixty (60) day period to preserve, protect and defend its rights under the Loan Documents&#59; or</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;take any action authorizing, or in furtherance of, any of the foregoing in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> above.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">67</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Impairment of Security, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Any Loan Document or any Lien granted thereunder shall (except in accordance with its terms), in any material respect, terminate, cease to be effective or cease to be the legally valid, binding and enforceable obligation of a Credit Party or any of its Subsidiaries party thereto&#59; any Credit Party or any of its Subsidiaries shall, directly or indirectly, contest in writing such effectiveness, validity, binding nature or enforceability&#59; or, except as permitted under any Loan Document, any Lien securing any Obligation shall, in any material respect, cease to be a perfected first priority Lien, except to the extent that any such loss of perfection results from the failure of the Agent to maintain possession of certificates actually delivered to or representing securities pledged under this Agreement or any other Loan Documents.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(j)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Regulatory Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. If any of the following events or circumstances occur&#58; (i) the FDA or the Department of Justice (DOJ) on its behalf, or any other Governmental Authority (A) makes a final determination that any Product which represented, in the aggregate, 15% or more of Net Sales in any applicable year lacks a required Regulatory Authorization or otherwise takes a regulatory or enforcement action that until and unless successfully resolved through Credit Party responsive action and remediation, dispute resolution, appeal, or other action prohibits or enjoins the distribution of such a Product above such threshold by Credit Party under the then-held Regulatory Authorization, or (B) initiates enforcement action against, including but not limited to issuing a warning letter with respect to, or proposing a consent decree of permanent injunction with respect to, any Products of any Credit Party or any of its Subsidiaries which represented, in the aggregate, 15% or more of Net Sales in any applicable year, in any case that causes such Credit Party or such Subsidiary to discontinue operating in any applicable jurisdiction or (ii) any Credit Party or any of its Subsidiaries enters into a settlement agreement with the FDA and DOJ or any other Governmental Authority that results in aggregate liability as to any single or related series of transactions, incidents or conditions, in excess of $4,000,000.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(k)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Pension Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Any of the following events shall occur with respect to any Pension Plan which would, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)&#160;&#160;&#160;&#160;a contribution failure occurs with respect to any Pension Plan sufficient to give rise to a Lien on any Credit Party or any ERISA Affiliate under Section 303(k) of ERISA or under Section 430(k) of the Code&#59; or</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)&#160;&#160;&#160;&#160;any ERISA Event shall occur that, when taken together with all other ERISA Events that have occurred, could reasonably be expected to result in liability of the Borrower and its Subsidiaries.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(l)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Key Permit Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Any of the following events shall occur&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)&#160;&#160;&#160;&#160;any Key Permit relating to FFRct issued by the United States, any state thereof or any instrumentality of the foregoing is terminated, suspended or amended by the Governmental Authority issuing such Key Permit or a court of competent jurisdiction in a manner that (x) results in the cessation of a material portion of the revenue generating business of a Credit Party or any of its Subsidiaries or (y) requires the commercialization of any of the material Products by a Credit Party or any of its Subsidiaries to be stopped or halted for a material amount of time&#59; or</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)&#160;&#160;&#160;&#160;any other Key Permit is terminated, suspended or amended by the Governmental Authority issuing such Key Permit or a court of competent jurisdiction in a manner that (x) results in the cessation of a material portion of the revenue generating business of a Credit Party or any of its Subsidiaries or (y) requires the commercialization of any of the material Products by a Credit Party or any of its Subsidiaries to be stopped or halted for a material amount of time&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> that, if, after excluding</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">68</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the Net Sales as of the last period for which a Compliance Certificate has been delivered (or was required to be delivered) to the Agent pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for which such Key Permit is necessary, the Credit Parties remain in compliance with the financial covenant set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.4(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (without giving effect to the proviso contained in such Section), as evidenced by calculations in reasonable detail certified by an Authorized Officer of the Borrower to the Agent within two (2) Business Days after such termination, suspension or amendment, no Event of Default shall occur&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that, in each case of the foregoing clauses (i) and (ii), to the extent such termination, suspension or amendment with respect to such Key Permit is of an administrative and technical nature that can be remedied without the consent of any third party or Governmental Authority and is so remedied within five (5) Business Days after the occurrence thereof, no Event of Default shall occur.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(m)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Material Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;Any default or event of default shall occur under any Material Agreement, or any Material Agreement shall cease, for any reason, to be in full force and effect other than upon expiration thereof in accordance with its terms unless the Credit Party party thereto determines in the exercise of its good faith business judgment that termination thereof by Credit Party is beneficial to such Credit Party, or any party to any Material Agreement (other than a Credit Party) shall challenge or repudiate its obligations under such Material Agreement or the enforceability of such Material Agreement, in each case, to the extent that any such occurrence has or could reasonably be expected to have a Material Adverse Effect&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that, for the avoidance of doubt and notwithstanding anything to the contrary in this Agreement or any other Loan Document, in no event shall an Event of Default occur as a result of any termination of the AWS Agreement (x) by the Credit Parties to the extent that, prior to or concurrently with such termination, the Credit Parties have entered into an agreement with another provider for cloud hosting services that (taken as a whole) are not materially worse to the Credit Parties than the cloud hosting services (taken as a whole) provided to the Credit Parties in the AWS Agreement (or, if such cloud hosting services are materially worse, then not materially worse to the Credit Parties than the cloud hosting services (taken as a whole) customarily provided in the market at such time for similarly situated Persons in the same industry as the Credit Parties) or (y) by AWS to the extent that, within thirty (30) days after such termination, the Credit Parties have entered into an agreement with another provider for cloud hosting services that (taken as a whole) are not materially worse to the Credit Parties than the cloud hosting services (taken as a whole) provided to the Credit Parties in the AWS Agreement (or, if such cloud hosting services are materially worse, then not materially worse to the Credit Parties than the cloud hosting services (taken as a whole) customarily provided in the market at such time for similarly situated Persons in the same industry as the Credit Parties).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(n)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Any Patents, the loss of which would constitute a Material Adverse Effect, are found invalid as determined by a court of competent jurisdiction by final and non-appealable judgment.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">69</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 9.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Action if Bankruptcy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. If any Event of Default described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 9.1(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> with respect to any Credit Party or any of its Subsidiaries shall occur, and the outstanding principal amount of the Loans and all other Obligations shall automatically be and become immediately due and payable, without notice, demand or presentment to or on any Person.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 9.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Action if Other Event of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. If any Event of Default (other than any Event of Default described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 9.1(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">) shall occur for any reason, whether voluntary or involuntary, and be continuing, the Agent or the Majority Lenders may, by notice to the Borrower declare all or any portion of the outstanding principal amount of the Loans and other Obligations to be due and payable whereupon the full unpaid amount of the Loans and other Obligations which shall be so declared due and payable shall be and become immediately due and payable, without further notice, demand or presentment to or on any Person.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ARTICLE X</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ADMINISTRATIVE AGENT</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 10.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Appointment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Each of the Lenders hereby irrevocably appoints Hayfin Services LLP to act on its behalf as the Agent hereunder and under the other Loan Documents and authorizes the Agent to take such actions on its behalf and to exercise such powers as are delegated to the Agent by the terms hereof or thereof, together with such actions and powers as are reasonably incidental thereto. The provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Article X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> are solely for the benefit of the Agent and the Lenders, and neither any Credit Party nor any of its respective Subsidiaries will have rights as a third-party beneficiary of any of such provisions. It is understood and agreed that the use of the term &#8220;agent&#8221; herein or in any other Loan Documents (or any other similar term) with reference to the Agent is not intended to connote any fiduciary or other implied (or express) obligations arising under agency doctrine of any applicable law. Instead, such term is used as a matter of market custom and is intended to create or reflect only an administrative relationship between contracting parties.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 10.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Rights as a Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. The Person serving as the Agent hereunder will have the same rights and powers in its capacity as a Lender as any other Lender and may exercise the same as though it were not the Agent, and the term &#8220;Lender&#8221; or &#8220;Lenders&#8221; will, unless otherwise expressly indicated or unless the context otherwise requires, include the Person serving as the Agent hereunder in its individual capacity. Such Person and its Affiliates may accept deposits from, lend money to, own securities of, act as the financial advisor or in any other advisory capacity for, and generally engage in any kind of business with, the Borrower or any of its Affiliates as if such Person were not the Agent hereunder and without any duty to account therefor to the Lenders.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 10.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Exculpatory Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.The Agent will not have any duties or obligations except those expressly set forth herein and in the other Loan Documents, and its duties hereunder are administrative in nature. Without limiting the generality of the foregoing, the Agent&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)&#160;&#160;&#160;&#160;will not be subject to any fiduciary or other implied duties, regardless of whether a Default has occurred and is continuing&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)&#160;&#160;&#160;&#160;will not have any duty to take any discretionary action or exercise any discretionary powers, except discretionary rights and powers expressly contemplated hereby or by the other Loan Documents that the Agent is required to exercise as directed in writing by the Majority Lenders (or such other number or percentage of the Lenders as will be expressly provided for herein or in the other Loan Documents)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> that the Agent will not be required to take any action that, in its opinion or the opinion of its counsel, may expose the Agent to liability or that is contrary to any Loan Document or</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">70</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">applicable law, including for the avoidance of doubt any action that may be in violation of the automatic stay under any debtor relief law&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;will not, except as expressly set forth herein and in the other Loan Documents, have any duty to disclose, and will not be liable for the failure to disclose, any information relating to any Credit Party or any of its Subsidiaries or Affiliates that is communicated to or obtained by the Person serving as the Agent or any of its Affiliates in any capacity.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Agent will not be liable for any action taken or not taken by it (i) with the consent or at the request of the Majority Lenders (or such other number or percentage of the Lenders as will be necessary, or as the Agent believes in good faith will be necessary, under the circumstances as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">9.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) or (ii) in the absence of its own gross negligence or willful misconduct as determined by a court of competent jurisdiction by final and nonappealable judgment. The Agent will be deemed not to have knowledge of any Default or Event of Default unless and until notice describing such Default or Event of Default is given to the Agent in writing by the Borrower or a Lender.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The Agent will not be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or representation made in or in connection with this Agreement or any other Loan Document, (ii) the contents of any certificate, report or other document delivered hereunder or thereunder or in connection herewith or therewith, (iii) the performance or observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of any Default, (iv) the validity, enforceability, effectiveness or genuineness of this Agreement, any other Loan Document or any other agreement, instrument or document or (v) the satisfaction of any condition set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or elsewhere herein, other than to confirm receipt of items expressly required to be delivered to the Agent.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 10.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Reliance by Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Agent will be entitled to rely upon, and will not incur any liability for relying upon, any notice, request, certificate, consent, statement, instrument, document or other writing (including any electronic message, Internet or intranet website posting or other distribution) believed by it to be genuine and to have been signed, sent or otherwise authenticated by the proper Person. The Agent also may rely upon any statement made to it orally or by telephone and believed by it to have been made by the proper Person, and will not incur any liability for relying thereon. In determining compliance with any condition hereunder to the making of the Loans that by its terms must be fulfilled to the satisfaction of a Lender, the Agent may presume that such condition is satisfactory to such Lender unless the Agent has received notice to the contrary from such Lender prior to the making of such Loans. The Agent may consult with legal counsel (who may be counsel for the Borrower or any of its Affiliates), independent accountants and other experts selected by it, and will not be liable for any action taken or not taken by it in accordance with the advice of any such counsel, accountants or experts.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 10.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Delegation of Duties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Agent may perform any and all of its duties and exercise its rights and powers hereunder or under any other Loan Document by or through any one or more sub-agents appointed by the Agent. The Agent and any such sub-agent may perform any and all of its duties and exercise its rights and powers by or through their respective Affiliates. The exculpatory provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> will apply to any such sub-agent and to the Affiliates of the Agent and any such sub-agent and will apply to their respective activities in connection with the syndication of the facility as well as activities as the Agent. The Agent will not be responsible for the negligence or misconduct of any sub-agents except to the extent that a court of competent jurisdiction determines in a final and nonappealable judgment that the Agent acted with gross negligence or willful misconduct in the selection of such sub-agents.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">71</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 10.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Resignation of Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.The Agent may at any time give notice of its resignation to the Lenders and the Borrower. Upon receipt of any such notice of resignation, the Majority Lenders will have the right, with the consent of the Borrower (unless an Event of Default is in existence), to appoint a successor. If no such successor will have been so appointed by the Majority Lenders and will have accepted such appointment within thirty (30) days after the retiring Agent gives notice of its resignation (or such earlier day as will be agreed by the Majority Lenders) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Resignation&#160;Effective&#160;Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), then the retiring Agent may (but will not be obligated to), on behalf of the Lenders, appoint a successor Agent meeting the qualifications set forth above. Whether or not a successor has been appointed, such resignation will become effective in accordance with such notice on the Resignation Effective Date.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;With effect from the Resignation Effective Date (i) the retiring Agent will be discharged from its duties and obligations hereunder and under the other Loan Documents (except that in the case of any Collateral held by the Agent on behalf of the Lenders under any of the Loan Documents, the retiring Agent will continue to hold such Collateral until such time as a successor Agent is appointed) and (ii) except for any indemnity payments owed to the retiring Agent, all payments, communications and determinations provided to be made by, to or through the Agent will instead be made by or to each Lender directly, until such time, if any, as the Majority Lenders appoint a successor Agent as provided for above. Upon the acceptance of a successor&#8217;s appointment as the Agent hereunder, such successor will succeed to and become vested with all of the rights, powers, privileges and duties of the retiring Agent (other than any rights to indemnity payments owed to the retiring Agent), and the retiring Agent will be discharged from all of its duties and obligations hereunder or under the other Loan Documents. The fees payable by the Borrower to a successor Agent will be the same as those payable to its predecessor unless otherwise agreed among the Borrower and such successor. After the retiring Agent&#8217;s resignation hereunder and under the other Loan Documents, the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Article X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> will continue in effect for the benefit of such retiring Agent, its sub-agents and their respective Affiliates in respect of any actions taken or omitted to be taken by any of them while the retiring Agent was acting as the Agent.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 10.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Non-Reliance on Agent and Other Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Each Lender acknowledges that it has, independently and without reliance upon the Agent or any other Lender or any of their respective Affiliates and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Agreement. Each Lender also acknowledges that it will, independently and without reliance upon the Agent or any other Lender or any of their respective Affiliates and based on such documents and information as it will from time to time deem appropriate, continue to make its own decisions in taking or not taking action under or based upon this Agreement, any other Loan Document or any related agreement or any document furnished hereunder or thereunder.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 10.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Agent May File Proofs of Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. In case of the pendency of any insolvency proceeding or any other judicial proceeding relative to the Borrower, the Agent (irrespective of whether the principal of the Loans will then be due and payable as herein expressed or by declaration or otherwise and irrespective of whether the Agent has made any demand on the Borrower) will be entitled and empowered (but not obligated), by intervention in such proceeding or otherwise&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;to file and prove a claim for the whole amount of the principal and interest owing and unpaid in respect of the Loans and all other Obligations that are owing and unpaid hereunder or under any other Loan Document to file such other documents as may be necessary or advisable in order to have the claims of the Lenders and the Agent (including any claim for the reasonable compensation, expenses, disbursements and advances of the Lenders and the Agent and their respective agents and counsel and all other amounts due the Lenders and the Agent under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Sections 3.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">) allowed in such judicial proceeding&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">72</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;to collect and receive any monies or other property payable or deliverable on any such claims and to distribute the same&#59;</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and any custodian, receiver, assignee, trustee, liquidator, sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Lender to make such payments to the Agent and, in the event that the Agent consents to the making of such payments directly to the Lenders, to pay to the Agent any amount due for the reasonable compensation, expenses, disbursements and advances of the Agent and its agents and counsel, and any other amounts due the Agent under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 3.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 10.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Collateral and Guaranty Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.Without limiting the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;10.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Lenders irrevocably authorize the Agent, at its option and in its discretion&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;to release any Lien on any property granted to or held by the Agent under any Loan Document (A) on the Termination Date (or such other date on which all Obligations then outstanding have been paid in full), (B) that is sold or otherwise disposed of or to be sold or otherwise disposed of as part of or in connection with any sale or other disposition permitted under the Loan Documents or (C) subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, if approved, authorized or ratified in writing by the Majority Lenders&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;to release any Guarantor from its obligations under its Guaranty if such Person ceases to be a Subsidiary as a result of a transaction permitted under the Loan Documents.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Upon request by the Agent at any time, the Majority Lenders will confirm in writing the Agent&#8217;s authority to release or subordinate its interest in particular types or items of Collateral, or to release any Guarantor from its obligations under its Guaranty pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Agent will not be responsible for or have a duty to ascertain or inquire into any representation or warranty regarding the existence, value or collectability of the Collateral, the existence, priority or perfection of the Agent&#8217;s Lien thereon, or any certificate prepared by the Borrower in connection therewith, nor will the Agent be responsible or liable to the Lenders for any failure to monitor or maintain any portion of the Collateral.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The Agent is authorized on behalf of all the Lenders, without the necessity of any notice to or further consent from the Lenders, from time to time to take any action with respect to any Collateral or any Security Agreement which may be necessary to perfect and maintain perfected the Liens on the Collateral granted pursuant to any such Security Agreement or protect and preserve the Agent&#8217;s ability to enforce the Liens or realize upon the Collateral.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">73</font></div></div></div><hr style="page-break-after:always"><div style="text-align:center;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ARTICLE XI</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">MISCELLANEOUS PROVISIONS</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 11.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Waivers, Amendments, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Except as otherwise provided herein or in any other Loan Document, (i) no amendment to any provision of this Agreement or any of the other Loan Documents will in any event be effective unless the same is in writing and signed by Holdings, the Borrower (and&#47;or any Guarantor or other party thereto, as applicable), the Agent and the Majority Lenders (or the Agent with the written consent of the Majority Lenders) and (ii) no waiver of any provision of this Agreement or any other Loan Document, or consent to any departure by a Credit Party, any of its Subsidiaries or other party therefrom, will in any event be effective unless the same is in writing and signed by the Agent and the Majority Lenders (or the Agent with the consent of the Majority Lenders). Any such amendment, waiver or consent will be effective only in the specific instance and for the specific purpose for which given&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> that, notwithstanding the foregoing provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, any term or provision of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Article X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> (other than the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 10.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> pertaining to the Borrower&#8217;s consent) may be amended without the agreement or consent of, or prior notice to, a Credit Party or any of its Subsidiaries&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> that such amendment does not add any additional obligations or burdens on such Credit Party or such Subsidiary.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">No failure or delay on the part of the Agent or the Lenders in exercising any power or right under any Loan Document shall operate as a waiver thereof, nor shall any single or partial exercise of any such power or right preclude any other or further exercise thereof or the exercise of any other power or right. No notice to or demand on Holdings, the Borrower or any other Subsidiary in any case shall entitle it to any notice or demand in similar or other circumstances. No waiver or approval by the Agent or the Lenders under any Loan Document shall, except as may be otherwise stated in such waiver or approval, be applicable to subsequent transactions. No waiver or approval hereunder shall require any similar or dissimilar waiver or approval thereafter to be granted hereunder.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 11.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Notices&#59; Time</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. All notices and other communications provided under any Loan Document shall be in writing or by facsimile and addressed, delivered or transmitted, if to Holdings, the Borrower or the Agent, to the applicable Person at its address or facsimile number set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> hereto, or at such other address or facsimile number as may be designated by such party in a notice to the other parties. Any notice, if mailed and properly addressed with postage prepaid or if properly addressed and sent by pre-paid courier service, shall be deemed given when received&#59; any notice, if transmitted by facsimile or email, shall be deemed given when the confirmation of transmission thereof is received by the transmitter. Unless otherwise indicated, all references to the time of a day in a Loan Document shall refer to New York City time.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 11.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Payment of Costs and Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. The Credit Parties agree to, jointly and severally, pay promptly on demand all reasonable and documented or invoiced out-of-pocket expenses of the Agent and the Lenders (or any of them) (including the reasonable fees and documented or invoiced out-of-pocket expenses of DLA Piper LLP (US), U.S. counsel to the Agent and the Lenders and of one local counsel in each relevant jurisdiction, if any, who may reasonably be retained by or on behalf of the Agent and the Lenders (or any of them)) in connection with&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;the negotiation, preparation, execution and delivery of (i) each Loan Document, including schedules and exhibits, whether or not the transactions contemplated hereby are consummated&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> that, with respect to legal fees of DLA Piper LLP (US) (U.S. counsel to the Agent and the Lenders) for services rendered as of the Closing Date, the Credit Parties shall have no obligation to pay more than $250,000 (plus the amount of any out-of-pocket disbursements of such counsel), and (ii) any amendments, waivers, consents, supplements or other modifications to any Loan Document as may from time to time be entered into after the Closing Date&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">74</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;the filing or recording of any Loan Document (including any financing statements) and all amendments, supplements, amendment and restatements and other modifications to any thereof, searches made after the date hereof in jurisdictions where financing statements (or other documents evidencing Liens in favor of the Agent and the other Secured Parties) have been recorded and any and all other documents or instruments of further assurance required to be filed or recorded by the terms of any Loan Document&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;the preparation and review of the form of any document or instrument relevant to any Loan Document, including any amendments or other modifications thereto.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The Credit Parties further agree to, jointly and severally, pay, and to save the Agent and the Lenders harmless from all liability for, any stamp or other taxes which may be payable in connection with the execution or delivery of each Loan Document, the Loans or the issuance of the Notes, excluding any Other Taxes, which are governed by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 4.3(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. The Credit Parties also agree to reimburse the Agent and the Lenders upon demand for all reasonable and documented or invoiced out-of-pocket expenses (including all reasonable and documented or invoiced out-of-pocket attorneys&#8217; fees and legal expenses of counsel to Agent and the Lenders (or any of them)) incurred by the Agent and the Lenders (or any of them) in connection with (i) the negotiation of any restructuring or &#8220;work-out&#8221; with Holdings or the Borrower, whether or not consummated, of any Obligations and (ii) the enforcement of any Obligations.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 11.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Indemnification.Reimbursement by the Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. In consideration of the execution and delivery of this Agreement by the Agent and the Lenders, the Credit Parties hereby, jointly and severally, indemnify, agree to defend, exonerate and hold the Agent, the Lenders and each of their respective officers, directors, employees and agents (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Indemnified Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) free and harmless from and against any and all actions, causes of action, suits, losses, costs, liabilities, obligations and damages, and expenses incurred in connection therewith (irrespective of whether any such Indemnified Party is a party to the action for which indemnification hereunder is sought), including reasonable and documented or invoiced out-of-pocket attorneys&#8217; and professionals&#8217; fees and disbursements, of one primary counsel for all Indemnified Parties (and, in the case of an actual or perceived conflict of interest where the Indemnified Party affected by such conflict notifies the Borrower of the existence of such conflict and thereafter retains its own counsel, another counsel for each such affected Indemnified Party), and one local counsel in each relevant jurisdiction, whether incurred in connection with actions between the parties hereto or the parties hereto and third parties (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Indemnified Liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), incurred by the Indemnified Parties or any of them as a result of, or arising out of, or relating to (i) the entering into and performance of any Loan Document by any of the Indemnified Parties or (ii) any Environmental Liability, any actual or alleged breach of or non-compliance with Environmental Laws or Environmental Permits, any Hazardous Materials, or any other decision, act, omission or matter relating to the environment, natural resources, health, safety or welfare&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> that such indemnity shall not, as to any Indemnified Party, be available to the extent that such Indemnified Liabilities (A) are determined by a court of competent jurisdiction by final and non-appealable judgment to have resulted from the gross negligence or willful misconduct of such Indemnified Party, (B) result from a claim brought by any Credit Party against an Indemnified Party for breach in bad faith of such Indemnified Party&#8217;s obligations hereunder or under any other Loan Document, if such Credit Party has obtained a final and nonappealable judgment in its favor on such claim as determined by a court of competent jurisdiction or (C) result from a claim not involving an act or omission of any Credit Party and that is brought by an Indemnified Party against another Indemnified Party (other than against the Agent in its capacity as such).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;If and to the extent that the foregoing indemnification may be unenforceable for any reason, the Credit Parties agree to, jointly and severally, make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities which is permissible under applicable law. To the fullest extent permitted by applicable law, no party hereunder shall assert, and each hereby waives,</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">75</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">any claim against any other party hereunder, on any theory of liability, for special, indirect, consequential or punitive damages (as opposed to direct or actual damages) arising out of, in connection with, or as a result of, this Agreement, any other Loan Document or any agreement or instrument contemplated hereby, the transactions contemplated hereby or thereby, or the use of the proceeds thereof. No Indemnified Party shall be liable for any damages arising from the use by unintended recipients of any information or other materials distributed by it through telecommunications, electronic or other information transmission systems in connection with this Agreement or the other Loan Documents or the transactions contemplated hereby or thereby. All amounts due under this Section shall be payable promptly after demand therefor. This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall not apply to Taxes, other than any Taxes that represent losses, claims, damages, etc. arising from any non-Tax claim.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Reimbursement by the Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. To the extent that Holdings or the Borrower for any reason fails to pay any amount required under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">subsection (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of this Section to be paid by it to the Agent (or any sub-agent thereof) or any Affiliate thereof, each Lender severally agrees to pay to the Agent (or any such sub-agent) or such Affiliate, as the case may be, such Lender&#8217;s Pro Rata Share (determined as of the time that the applicable unreimbursed expense or indemnity payment is sought based on each Lender&#8217;s Pro Rata Share at such time) of such unpaid amount (including any such unpaid amount in respect of a claim asserted by such Lender)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that the unreimbursed expense or indemnified loss, claim, damage, liability or related expense, as the case may be, was incurred by or asserted against the Agent (or any such sub-agent), or such Affiliate acting for the Agent (or any such sub-agent) in connection with such capacity. The obligations of the Lenders under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">subsection (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> are subject to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 11.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The obligations of the Borrower under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, shall in each case survive any assignment by the Lender and the occurrence of the Termination Date. The representations and warranties made by the Borrower in each Loan Document shall survive the execution and delivery of such Loan Document.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 11.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Obligations Several</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The obligations of the Lenders under the Loan Documents are several. The failure of any Lender or the Agent to carry out its obligations thereunder will not relieve any other Lender or the Agent of any obligations thereunder, nor will any Lender or the Agent be responsible for the obligations of, or any action taken or omitted by, any other Person hereunder or thereunder. Nothing contained in any Loan Documents will be deemed to cause any Lender or the Agent to be considered a partner or a joint venture with any other Lender or Lenders or the Agent.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 11.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Any provision of any Loan Document which is prohibited or unenforceable in any jurisdiction shall, as to such provision and such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions of such Loan Document or affecting the validity or enforceability of such provision in any other jurisdiction.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 11.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The various headings of each Loan Document are inserted for convenience only and shall not affect the meaning or interpretation of such Loan Document or any provisions thereof.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 11.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Execution, Effectiveness, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Execution in Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. This Agreement may be executed by the parties hereto in several counterparts, each of which shall be an original and all of which shall constitute together but one and the same agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">76</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Effectiveness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. This Agreement shall become effective when counterparts hereof executed on behalf of the Borrower and the Lenders shall have been received by the Agent.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Electronic Signatures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Delivery of an executed counterpart of a signature page to this Agreement by email (e.g. &#8220;pdf&#8221; or &#8220;tiff&#8221;) or telecopy shall be effective as delivery of a manually executed counterpart of this Agreement. Any signature (including, without limitation, (x) any electronic symbol or process attached to, or associated with, a contract or other record and adopted by a Person with the intent to sign, authenticate or accept such contract or record and (y) any facsimile or &#8220;pdf&#8221; signature) hereto or the other Loan Documents or to any other certificate, agreement or document related to any Loan Document or the transactions contemplated hereby or by any other Loan Document, and any contract formation or record-keeping, in each case, through electronic means, shall have the same legal validity and enforceability as a manually executed signature or use of a paper-based record-keeping system to the fullest extent permitted by applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any similar state law based on the Uniform Electronic Transactions Act, and the parties hereto hereby waive any objection to the contrary.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 11.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Governing Law&#59; Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. EACH LOAN DOCUMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT CONTEMPLATED HEREBY AND THEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK). THE LOAN DOCUMENTS CONSTITUTE THE ENTIRE UNDERSTANDING AMONG THE PARTIES HERETO WITH RESPECT TO THE SUBJECT MATTER THEREOF AND SUPERSEDE ANY PRIOR AGREEMENTS, WRITTEN OR ORAL, WITH RESPECT THERETO.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 11.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Register&#59; Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.(a)The Agent, acting solely for this purpose as a non-fiduciary agent of the Borrower, shall maintain at one of its offices in the United States a copy of each Assignment and Assumption delivered to it and register for the recordation of the names and addresses of the Lenders, and principal amounts (and stated interest) of the Loans owing to, each Lender pursuant to the terms hereof from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;). The entries in the Register shall be conclusive absent manifest error, and the Borrower, the Agent and the Lenders shall treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes under this Agreement. The Register shall be available for inspection by any Credit Party and any Lender, at any reasonable time and from time to time upon reasonable prior notice.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and permitted assigns&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> that, the Credit Parties may not assign or transfer their rights or obligations hereunder without the prior written consent of the Agent. The Lenders may freely assign, participate or otherwise transfer any or all of their rights and&#47;or obligations hereunder and&#47;or under the other Loan Documents (in each case, other than to a Disqualified Institution)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> that, except in the case of an assignment to a Lender, an Affiliate of a Lender or related funds, (i) so long as no Event of Default pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 9.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 9.1(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> has occurred and is continuing, there shall be no assignment, sale or participation to any Person without the written consent of the Borrower (except in each case with respect to a Disqualified Institution, such consent not to be unreasonably withheld or delayed and such consent to be deemed to have been given if the Borrower has not responded within ten (10) Business Days of a request for such consent), and (ii) any such assignment, sale or participation shall be in an integral multiple of $1,000,000 (or, if less, the entire remaining amount of such Lender&#8217;s then outstanding Loans). In the event of any assignment, the Lender making such assignment shall provide</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">77</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">prompt notice thereof to the Agent so such assignment can be reflected on the Register. Each Lender that sells a participation shall, acting solely for this purpose as a non-fiduciary agent of the Borrower, maintain a register on which it enters the name and address of each participant and the principal amounts (and stated interest) of each participant&#8217;s interest in the Loans or other obligations under the Loan Documents (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Participant Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> that no Lender shall have any obligation to disclose all or any portion of the Participant Register (including the identity of any participant or any information relating to a participant&#8217;s interest in any commitments, loans or its other obligations under any Loan Document) to any Person except to the extent that such disclosure is necessary to establish that such commitment, loan or other obligation is in registered form under Section 5f.103-1(c) of the United States Treasury Regulations. The entries in the Participant Register shall be conclusive absent manifest error, and such Lender shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Agreement notwithstanding any notice to the contrary. For the avoidance of doubt, the Agent (in its capacity as the Agent) shall have no responsibility for maintaining a Participant Register. Each participant shall be entitled to the benefits of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Sections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> (subject to the requirements and limitations therein, including the requirements under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 4.3(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> (it being understood that the documentation required under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 4.3(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> shall be delivered to the participating Lender)) to the same extent as if it were a Lender and had acquired its interest by assignment&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> that such participant shall not be entitled to receive any greater payment under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 4.1 or 4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, with respect to any participation, than its participating lender would have been entitled to receive, except to the extent that such entitlement to receive a greater payment results from a Change in Law that occurs after the participant acquired the applicable participation.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 11.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Other Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Nothing contained herein shall preclude the Agent or any of the Lenders, from engaging in any transaction, in addition to those contemplated by the Loan Documents, with a Credit Party, any of its Subsidiaries or any of their Affiliates in which such Credit Party or such Affiliate is not restricted hereby from engaging with any other Person.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 11.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Forum Selection and Consent to Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH, ANY LOAN DOCUMENT, OR ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN) OR ACTIONS OF THE AGENT, THE LENDERS (OR ANY OF THEM), OR ANY CREDIT PARTY (OR ANY OF ITS SUBSIDIARIES) IN CONNECTION HEREWITH OR THEREWITH SHALL BE BROUGHT AND MAINTAINED IN THE COURTS OF THE BOROUGH OF MANHATTAN IN THE CITY OF NEW YORK IN THE STATE OF NEW YORK OR IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">PROVIDED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> THAT, ANY SUIT SEEKING ENFORCEMENT AGAINST ANY COLLATERAL OR OTHER PROPERTY MAY BE BROUGHT, AT THE AGENT&#8217;S OR SUCH LENDER&#8217;S OPTION, IN THE COURTS OF ANY JURISDICTION WHERE SUCH COLLATERAL OR OTHER PROPERTY MAY BE FOUND. EACH PARTY IRREVOCABLY CONSENTS TO THE SERVICE OF PROCESS BY REGISTERED MAIL, POSTAGE PREPAID, OR BY PERSONAL SERVICE WITHIN OR WITHOUT THE STATE OF NEW YORK AT THE ADDRESS FOR NOTICES SPECIFIED IN </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SECTION 11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. EACH PARTY HEREBY EXPRESSLY AND IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY OBJECTION WHICH IT MAY HAVE OR HEREAFTER MAY HAVE TO THE LAYING OF VENUE OF ANY SUCH LITIGATION BROUGHT IN ANY SUCH COURT REFERRED TO ABOVE AND ANY CLAIM THAT ANY SUCH LITIGATION HAS BEEN BROUGHT IN AN INCONVENIENT FORUM. TO THE EXTENT THAT ANY PARTY HAS OR HEREAFTER MAY ACQUIRE ANY IMMUNITY FROM JURISDICTION OF ANY COURT OR FROM ANY LEGAL PROCESS (WHETHER THROUGH SERVICE OR NOTICE, ATTACHMENT PRIOR TO JUDGMENT, ATTACHMENT IN AID OF EXECUTION OR OTHERWISE) WITH RESPECT TO ITSELF OR ITS PROPERTY, SUCH PARTY HEREBY IRREVOCABLY WAIVES TO THE FULLEST EXTENT</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">78</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">PERMITTED BY LAW SUCH IMMUNITY IN RESPECT OF ITS OBLIGATIONS UNDER THE LOAN DOCUMENTS.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 11.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. THE AGENT, EACH OF THE LENDERS, AND THE CREDIT PARTIES HEREBY KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVE TO THE FULLEST EXTENT PERMITTED BY LAW ANY RIGHTS THEY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH, EACH LOAN DOCUMENT, OR ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN) OR ACTIONS OF THE AGENT, THE LENDERS OR THE CREDIT PARTIES IN CONNECTION THEREWITH. EACH PARTY ACKNOWLEDGES AND AGREES THAT IT HAS RECEIVED FULL AND SUFFICIENT CONSIDERATION FOR THIS PROVISION (AND EACH OTHER PROVISION OF EACH OTHER LOAN DOCUMENT TO WHICH IT IS A PARTY) AND THAT THIS PROVISION IS A MATERIAL INDUCEMENT FOR THE AGENT AND THE LENDERS ENTERING INTO THE LOAN DOCUMENTS.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 11.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Interest Rate Limitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Notwithstanding anything to the contrary contained in any Loan Document, the interest paid or agreed to be paid under the Loan Documents shall not exceed the maximum rate of non-usurious interest permitted by applicable law (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Maximum Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). If the Agent or any Lender shall receive interest in an amount that exceeds the Maximum Rate, the excess interest shall be applied to the principal of the Loans or, if it exceeds such unpaid principal, refunded to the Borrower. In determining whether the interest contracted for, charged, or received by the Agent or a Lender exceeds the Maximum Rate, such Person may, to the extent permitted by applicable law, (a) characterize any payment that is not principal as an expense, fee, or premium rather than interest, (b) exclude voluntary prepayments and the effects thereof, and (c) amortize, prorate, allocate, and spread in equal or unequal parts the total amount of interest throughout the contemplated term of the Obligations hereunder.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 11.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Acknowledgment and Consent to Bail-In of Affected Financial Institutions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Notwithstanding anything to the contrary in any Loan Document or in any other agreement, arrangement or understanding among any such parties, each party hereto acknowledges that any liability of any Affected Financial Institution arising under any Loan Document, to the extent such liability is unsecured, may be subject to the Write-Down and Conversion Powers of the applicable Resolution Authority and agrees and consents to, and acknowledges and agrees to be bound by&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;the application of any Write-Down and Conversion Powers by the applicable Resolution Authority to any such liabilities arising hereunder which may be payable to it by any party hereto that is an Affected Financial Institution&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;the effects of any Bail-In Action on any such liability, including, if applicable&#58;</font></div><div style="margin-bottom:10pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;a reduction in full or in part or cancellation of any such liability&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;a conversion of all, or a portion of, such liability into shares or other instruments of ownership in such Affected Financial Institution, its parent undertaking, or a bridge institution that may be issued to it or otherwise conferred on it, and that such shares or other instruments of ownership will be accepted by it in lieu of any rights with respect to any such liability under this Agreement or any other Loan Document&#59; or</font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;the variation of the terms of such liability in connection with the exercise</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of the Write-Down and Conversion Powers of the applicable Resolution Authority.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">79</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 11.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Judgment Currency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;If, for the purposes of obtaining judgment in any court, it is necessary to convert a sum due hereunder in one currency (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">first currency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) into another currency (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">other currency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), the parties hereto agree, to the fullest extent permitted by law, that the rate of exchange used shall be that at which, in accordance with normal banking procedures, the Agent could purchase the first currency with such other currency at the applicable buying spot rate of exchange in the New York foreign exchange market on the Business Day immediately preceding that on which any such judgment, or any relevant part thereof, is given.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;The obligations of the Credit Parties in respect of any sum due to the Agent hereunder or under the other Loan Documents shall, notwithstanding any judgment in a currency other than Dollars, be discharged only to the extent that on the Business Day following receipt by the Agent of any sum adjudged to be so due in such other currency the Agent may, in accordance with normal banking procedures, purchase Dollars with such other currency. If the amount of Dollars so purchased is less than the sum originally due to the Agent in Dollars, the Credit Parties agree, jointly and severally, to the fullest extent that it may effectively do so, as a separate obligation and notwithstanding any such judgment, to indemnify the Agent against such loss. If the amount of Dollars so purchased exceeds the sum originally due to the Agent in Dollars, the Agent shall remit such excess to the Credit Parties.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 11.18&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Specified Repayment Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. The parties hereto acknowledge and agree that, to the extent the Specified Repayment Fee is applicable to any repayment or prepayment of principal of any Loan at any time, such Specified Repayment Fee is not intended to be a penalty assessed as a result of any such repayment or prepayment of the Loans, but rather is the product of a good faith, arm&#8217;s length commercial negotiation between the Borrower and the Lenders relating to the mutually satisfactory compensation payable to the Lenders by the Borrower in respect of the Loans made hereunder. In furtherance of the foregoing, to the fullest extent permitted by applicable law, the Credit Parties hereby jointly and severally waive any rights or claims any of them may have under any such applicable law (whether or not in effect on the Closing Date) that would prohibit or restrict the payment of the Specified Repayment Fee under any of the circumstances provided herein or in any other Loan Document, including payment after acceleration of the Loans.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 11.19&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">USA PATRIOT Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. The Agent and the Lenders hereby notify the Credit Parties that pursuant to the requirements of the Patriot Act, they are required to obtain, verify and record information that identifies each Credit Party, which information includes the name and address of each Credit Party and other information that shall allow such Person to identify such Credit Party in accordance with the Patriot Act. Promptly following any written request therefor, Holdings or the Borrower shall deliver to the Agent such information and documentation in respect of any Credit Party reasonably requested by the Agent or any Lender for purposes of compliance by the Agent or such Lender with applicable &#8220;know your customer&#8221; requirements under the Patriot Act, the Beneficial Ownership Regulation or other applicable anti-money laundering laws.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 11.20&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Erroneous Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. If a payment is made by the Agent (or its Affiliates) in error (whether known to the recipient or not) or if a Lender or another recipient of funds is not otherwise entitled to receive such funds at such time of such payment or from such Person in accordance with the Loan Documents, then such Lender or recipient shall forthwith on demand repay to the Agent the portion of such payment that was made in error (or otherwise not intended (as determined by the Agent) to be received) in the amount made available by the Agent (or its Affiliate) to such Lender or recipient, with interest thereon, for each day from and including the date such amount was made available by the Agent (or its Affiliate) to it to but excluding the date of payment to the Agent, at the greater of the Federal Funds Rate and a rate determined by the Agent in accordance with banking industry rules on interbank</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">80</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">compensation&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> that, without limiting any other rights or remedies (whether at law or in equity), the Agent may not make any such demand under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 11.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> with respect to such payment unless such demand is made within sixty (60) days of the date of receipt of such payment by the applicable Lender. Each Lender and other party hereto waives the discharge for value defense in respect of any such payment.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 11.21&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Reaffirmation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Each Credit Party as borrower, debtor, grantor, pledgor, guarantor, assignor or in any other similar capacity in which such Credit Party has granted liens or security interests in its property or otherwise acts as accommodation party, under any instruments, documents and agreements entered into in connection with the Existing Credit Agreement that will remain outstanding to secure the Obligations hereunder, hereby (a) ratifies and reaffirms all of its performance and observance obligations and liabilities, whether contingent or otherwise, under each of such instruments, documents and agreements and (ii) ratifies and reaffirms such grant of security interests and liens and confirms and agrees that such security interests and liens hereafter secured all of the Obligations hereunder.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">ARTICLE XII</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">GUARANTEE</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 12.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">The Guarantee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Each of Holdings, the Subsidiary Guarantors and any other Person that becomes a Subsidiary Guarantor after the Closing Date hereby guarantees to the Agent and the Lenders, and their respective successors, endorsees, transferees and assigns, the full and prompt payment in full when due (whether at stated maturity, by required prepayment, declaration, acceleration, demand or otherwise) and performance of the indebtedness, liabilities and other obligations of the Borrower to the Agent and the Lenders under or in connection with this Agreement, the Notes and the other Loan Documents, including all unpaid principal of the Loans, all interest accrued thereon, all fees due under this Agreement and all other amounts payable by the Borrower to the Agent and the Lenders hereunder or in connection herewith. The terms &#8220;indebtedness,&#8221; &#8220;liabilities&#8221; and &#8220;obligations&#8221; are used herein in their most comprehensive sense and include any and all advances, debts, obligations and liabilities, now existing or hereafter arising, whether voluntary or involuntary and whether due or not due, absolute or contingent, liquidated or unliquidated, determined or undetermined, and whether recovery upon such indebtedness, liabilities and obligations may be or hereafter become unenforceable or shall be an allowed or disallowed claim in any insolvency proceeding and including interest that accrues after the commencement by or against any Credit Party or any of its Subsidiaries of any insolvency proceeding naming such Credit Party or such Subsidiary as the debtor in such insolvency proceeding. The foregoing indebtedness, liabilities and other obligations of the Borrower, and all other indebtedness, liabilities and obligations to be paid or performed by Holdings and&#47;or the Subsidiary Guarantors in connection with this Section shall hereinafter be collectively referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Guaranteed Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.&#8221;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 12.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Obligations Unconditional</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. The obligations of Holdings and the Subsidiary Guarantors under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> are absolute and unconditional, irrespective of the value, genuineness, validity, regularity or enforceability of the obligations of the Borrower under this Agreement or any other agreement or instrument referred to herein, or any substitution, release or exchange of any other guarantee of or security for any of the Guaranteed Obligations, and, to the fullest extent permitted by law, irrespective of any other circumstance whatsoever that might otherwise constitute a legal or equitable discharge or defense of a surety or guarantor, it being the intent of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> that the obligations of Holdings and the Subsidiary Guarantors hereunder shall be absolute and unconditional under any and all circumstances other than the Payment in Full of the Guaranteed Obligations. Without limiting the generality of the foregoing, it is agreed that the occurrence of any one or more of the following shall not alter or impair the liability of Holdings or the Subsidiary Guarantors hereunder, which shall remain absolute and unconditional as described above&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">81</font></div></div></div><hr style="page-break-after:always"><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;at any time or from time to time, without notice to Holdings or the Subsidiary Guarantors, the time for any performance of or compliance with any of the Guaranteed Obligations shall be extended, or such performance or compliance shall be waived&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;any of the acts mentioned in any of the provisions of this Agreement or any other agreement or instrument referred to herein shall be done or omitted&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;the maturity of any of the Guaranteed Obligations shall be accelerated, or any of the Guaranteed Obligations shall be modified, supplemented or amended in any respect, or any right under this Agreement or any other Loan Document shall be waived or any other guarantee of any of the Guaranteed Obligations or any security therefor shall be released or exchanged in whole or in part or otherwise dealt with&#59; or</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;any Lien or security interest granted to, or in favor of, the Secured Parties as security for any of the Guaranteed Obligations shall fail to be perfected.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each of Holdings and the Subsidiary Guarantors hereby expressly waives diligence, presentment, demand of payment, protest and all notices whatsoever, and any requirement that the Agent or the Lenders exhaust any right, power or remedy or proceed against the Borrower under this Agreement or any other agreement or instrument referred to herein, or against any other Person under any other guarantee of, or security for, any of the Guaranteed Obligations.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 12.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Reinstatement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The obligations of Holdings and the Subsidiary Guarantors under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article XII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall be automatically reinstated if and to the extent that for any reason any payment by or on behalf of the Borrower in respect of the Guaranteed Obligations is rescinded or must be otherwise restored by any holder of any of the Guaranteed Obligations, whether as a result of any proceedings in bankruptcy or reorganization or otherwise, and each of Holdings and the Subsidiary Guarantors agrees that it will indemnify the Agent and the Lenders on demand for all reasonable costs and expenses (including reasonable fees of one primary counsel and one local counsel in each relevant jurisdiction) incurred by such Persons in connection with such rescission or restoration, including any such costs and expenses incurred in defending against any claim alleging that such payment constituted a preference, fraudulent transfer or similar payment under any bankruptcy, insolvency or similar law.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 12.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Subrogation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Until the Guaranteed Obligations shall be satisfied in full (other than inchoate indemnification, expense reimbursement obligations and other contingent obligations for which no claim has been asserted), neither Holdings nor any Subsidiary Guarantor shall directly or indirectly exercise, (i) any rights that it may acquire by way of subrogation under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article XII,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> by any payment hereunder or otherwise, (ii) any rights of contribution, indemnification, reimbursement or similar suretyship claims arising out of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article XII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or (iii) any other right which it might otherwise have or acquire (in any way whatsoever) which could entitle it at any time to share or participate in any right, remedy or security of the Agent or any Lender as against the Borrower or other Credit Parties (or any of their Subsidiaries), whether in connection with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article XII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, any of the other Loan Documents or otherwise. If any amount shall be paid to Holdings or the Subsidiary Guarantors on account of the foregoing rights at any time when all the Guaranteed Obligations shall not have been paid in full, such amount shall be held in trust for the benefit of the Agent and the Lenders and shall forthwith be paid to the Agent to be credited and applied to the Guaranteed Obligations, whether matured or unmatured, in accordance with the terms of the Loan Documents.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 12.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each of Holdings and the Subsidiary Guarantors agrees that, as between Holdings or any Subsidiary Guarantor, on one hand, and the Agent and the Lenders, on the other hand, the obligations of the Borrower under this Agreement and under the other Loan Documents may be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">82</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">declared to be forthwith due and payable as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (and shall be deemed to have become automatically due and payable in the circumstances provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article IX)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for purposes of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> notwithstanding any stay, injunction or other prohibition preventing such declaration (or such obligations from becoming automatically due and payable) as against the Borrower and that, in the event of such declaration (or such obligations being deemed to have become automatically due and payable), such obligations (whether or not due and payable by the Borrower) shall forthwith become due and payable by Holdings and the Subsidiary Guarantors for purposes of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 12.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Instrument for the Payment of Money</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each of Holdings and the Subsidiary Guarantors hereby acknowledges that the guarantee in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article XII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> constitutes an instrument for the payment of money, and consents and agrees that the Agent and the Lenders, at their sole option, in the event of a dispute by Holdings or any Subsidiary Guarantor in the payment of any moneys due hereunder, shall have the right to proceed by motion for summary judgment in lieu of complaint pursuant to N.Y. Civ. Prac. L&#38;R &#167; 3213.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 12.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Continuing Guarantee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The guarantee in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article XII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> is a continuing guaranty and agreement of subordination relating to any Guaranteed Obligations, including Guaranteed Obligations which may exist continuously or which may arise from time to time under successive transactions, and each of Holdings and the Subsidiary Guarantors expressly acknowledges that the guarantee in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article XII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall remain in full force and effect notwithstanding that there may be periods in which no Guaranteed Obligations exist. The guarantee in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article XII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall continue in effect and be binding upon Holdings and the Subsidiary Guarantors until payment and performance in full of the Guaranteed Obligations (other than inchoate indemnification, expense reimbursement obligations and other contingent obligations for which no claim has been asserted).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 12.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">General Limitation on Guarantee Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. In any action or proceeding involving any provincial, territorial or state corporate law, or any state or federal bankruptcy, insolvency, reorganization or other law affecting the rights of creditors generally, if the obligations of Holdings or any Subsidiary Guarantor under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> would otherwise be held or determined to be void, invalid or unenforceable, or subordinated to the claims of any other creditors, on account of the amount of its liability under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.1,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> then, notwithstanding any other provision hereof to the contrary, the amount of such liability shall, without any further action by Holdings, the Subsidiary Guarantors, the Agent, the Lenders or any other Person, be automatically limited and reduced to the highest amount that is valid and enforceable and not subordinated to the claims of other creditors as determined in such action or proceeding.</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;SIGNATURE PAGES FOLLOW&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">83</font></div></div></div><div id="ia98052918b654a0dae4726bfd22e4abd_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their respective officers thereunto duly authorized as of the day and year first above written.</font></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.885%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">BORROWER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#58;</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">HEARTFLOW, INC.</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By &#47;s&#47; Vikram Verghese</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Vikram Verghese</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Chief Financial Officer</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">HOLDINGS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#58;</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">HEARTFLOW HOLDING, INC. </font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By &#47;s&#47; Vikram Verghese</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Vikram Verghese</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Chief Financial Officer</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:0.80pt">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:0.80pt">Signature Page to Credit Agreement and Guaranty (Heartflow</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:0.80pt">)&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.919%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AGENT&#58;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">HAYFIN SERVICES LLP</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Erica Hughes</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Erica Hughes</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Authorised Signatory</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Signature Page to Credit Agreement and Guaranty (Heartflow</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">)&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.594%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">LENDER&#58;</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">HAYFIN TOURMALINE LUXCO S.A.R.L.</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Choui Min Kon Kam King</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Choui Min Kon Kam King</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Manager</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; John Molloy</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; John Molloy</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Manager</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Signature Page to Credit Agreement and Guaranty (Heartflow</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">)&#93;</font></div></div></div><div id="ia98052918b654a0dae4726bfd22e4abd_94"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT A</font></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">to Credit Agreement</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">FORM OF COMPLIANCE CERTIFICATE</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">COMPUTATION DATE&#58; &#91;___________&#93;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Compliance Certificate (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is delivered pursuant to &#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of, and in connection with the consummation of the transactions contemplated in,&#93; &#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of&#93; that certain Credit Agreement and Guaranty, dated as of June 14, 2024 (as amended or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), by and among HeartFlow, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), HeartFlow Holding, Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Holdings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), certain Subsidiaries of Holdings that may be required to provide Guarantees from time to time thereunder, the lenders from time to time party thereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Hayfin Services LLP, as administrative agent for the Lenders (in such capacity, together with its successors and assigns, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Capitalized terms used herein and not otherwise defined herein are used herein as defined in the Credit Agreement. This Compliance Certificate is a Loan Document executed pursuant to the Credit Agreement and shall (unless otherwise expressly indicated herein) be constructed, administered and applied in accordance with the terms and provisions thereof, including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Article XI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> thereof.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The undersigned, the chief financial or accounting Authorized Officer of Holdings having the name and title set forth below under &#91;his&#93;&#91;her&#93; signature, hereby certifies, on behalf of Holdings for the benefit of the Secured Parties and pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section &#91;5.1(e)&#93;&#91;7.1(d)&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Credit Agreement that such chief financial or accounting Authorized Officer of Holdings is familiar with the Credit Agreement and that, in accordance with each of the following sections of the Credit Agreement, each of the following is true on the date hereof, both before and after giving effect to any Loan to be made on or before the date hereof&#58;</font></div><div style="margin-bottom:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;&#91;In accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Credit Agreement, attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Annex&#160;A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> are the correct and complete copies of the unaudited consolidated balance sheet of Holdings and its Subsidiaries for the Fiscal Quarter ended &#91;_________&#93; required to be delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Credit Agreement and consolidated statements of income and cash flow of Holdings and its Subsidiaries for such period, including (in each case), in comparative form, the figures for the corresponding Fiscal Quarter in, and year to date portion of, the immediately preceding Fiscal Year (subject to normal year-end audit adjustments).&#93;</font></div><div style="margin-bottom:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;&#91;In accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section &#91;5.1(e)&#93;&#91;7.1(c)&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Credit Agreement, attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Annex A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> are the correct and complete copies of the audited consolidated balance sheet of Holdings and its Subsidiaries for the Fiscal Year ended &#91;_________&#93; required to be delivered pursuant to and by the terms of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Credit Agreement and the related consolidated statements of income and cash flow of Holdings and its Subsidiaries for such period, setting forth in comparative form the figures for the immediately preceding Fiscal Year.&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;All other information presented in connection with this Compliance Certificate (including the attachments hereto) is correct and complete in all material respects.</font></div><div style="margin-bottom:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Annex B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> are the calculations used to determine compliance with each financial covenant contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Credit Agreement as of the Computation Date set forth above.</font></div><div style="margin-bottom:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;As of the Computation Date set forth above, no Default or Event of Default is continuing as of the date hereof, and during the &#91;Fiscal Quarter&#93; ended on such Computation Date, no Default or Event of Default occurred&#91;, except as provided for on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Annex C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> attached hereto, which includes a description of the nature and period of existence of such Default or Event of Default and what action Holdings or any of its Subsidiaries has taken, is taking and proposes to take with respect thereto&#93;.</font></div><div style="margin-bottom:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;Set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Annex D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto is a list of all Immaterial Subsidiaries and Foreign Excluded Subsidiaries, together with the Net Sales and Assets, in each case, attributable to each such Immaterial Subsidiary and Foreign Excluded Subsidiary as of the Computation Date set forth above. &#91;Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Annex E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto, subsequent to the date of the last Compliance Certificate submitted by the undersigned pursuant to &#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1(e)&#93;&#91;7.1(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93; of the Credit Agreement, no Subsidiary has been formed or acquired or, if a Subsidiary has been formed or acquired since the delivery of the last Compliance Certificate, such Subsidiary has, to the extent required, complied with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Credit Agreement.&#93;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;SIGNATURE PAGES FOLLOW&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia98052918b654a0dae4726bfd22e4abd_97"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the undersigned has caused this Compliance Certificate to be executed and delivered, and the certification and warranties contained herein to be made, by its chief financial Authorized Officer as of the date above written.</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">HEARTFLOW HOLDING, INC.</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:503pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Signature Page to Compliance Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#93;</font></div></div></div><div id="ia98052918b654a0dae4726bfd22e4abd_100"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Annex A to Compliance Certificate</font></div><div style="margin-bottom:10pt;text-align:center;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;See attached.&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia98052918b654a0dae4726bfd22e4abd_103"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Annex B to Compliance Certificate</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CALCULATIONS OF FINANCIAL COVENANT COMPLIANCE</font></div><div id="ia98052918b654a0dae4726bfd22e4abd_106"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Annex C to Compliance Certificate</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;DEFAULTS OR EVENTS OF DEFAULT&#93;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;If needed.&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia98052918b654a0dae4726bfd22e4abd_109"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Annex D to Compliance Certificate</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SUBSIDIARIES</font></div><div id="ia98052918b654a0dae4726bfd22e4abd_112"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Annex E to Compliance Certificate</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;NEWLY FORMED OR ACQUIRED SUBSIDIARIES&#93;</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;If needed.&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia98052918b654a0dae4726bfd22e4abd_115"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">EXHIBIT B</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">to Credit Agreement</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">FORM OF LOAN REQUEST</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Date&#58; &#91;__________&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">To&#58;&#160;&#160;&#160;&#160;Hayfin Services LLP, as administrative agent</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">One Eagle Place</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">London, SW1Y 6AF</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Attn&#58; Andrew Merrill</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Legal Team&#47;Loan Operations</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Re&#58;  Borrowing under the Credit Agreement</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Ladies and Gentlemen&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Reference is made to that certain Credit Agreement and Guaranty, dated as of June 14, 2024 (as amended or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;), by and among HeartFlow, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;), HeartFlow Holding, Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Holdings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;), certain Subsidiaries of Holdings that may be required to provide Guarantees from time to time thereunder, the lenders from time to time party thereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) and Hayfin Services LLP, as administrative agent for the Lenders (in such capacity, together with its successors and assigns, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;). Capitalized terms used herein and not otherwise defined herein are used herein as defined in the Credit Agreement.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">The undersigned, an Authorized Officer of the Borrower, hereby gives you irrevocable notice, pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Section 2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%"> of the Credit Agreement, of the borrowing of Loans specified herein&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">1.&#160;&#160;&#160;&#160;The Borrowing Date is &#91;__&#93;.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">2.&#160;&#160;&#160;&#160;The amount of the proposed Loans is $&#91;__&#93;.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">3.&#160;&#160;&#160;&#160;The payment instructions with respect to the funds to be made available to the Borrower are as follows&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Bank name&#58;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Bank Address&#58;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Routing Number&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Account Number&#58;</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">The Borrower hereby certifies that the following statements are true and correct&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">a)&#160;&#160;&#160;&#160;the representations and warranties set forth herein and in each Loan Document are, in each case, true and correct in all material respects as of the date hereof (unless stated to relate</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">solely to an earlier date, in which case such representations and warranties are true and correct in all material respects as of such earlier date)&#59; and</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">b)&#160;&#160;&#160;&#160;at the time of and immediately after giving effect to the Loan, no Default or Event of Default has occurred or is continuing.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:110%">Signature Page Follows</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia98052918b654a0dae4726bfd22e4abd_118"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Borrower has caused this Loan Request to be duly executed and delivered as of the day and year first above written.</font></div><div style="margin-bottom:480pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.946%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BORROWER&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">HEARTFLOW, INC.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Signature Page to Loan Request</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#93;</font></div></div></div><div id="ia98052918b654a0dae4726bfd22e4abd_121"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT C</font></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">to Credit Agreement</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">FORM OF PERFECTION CERTIFICATE</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;See attached.&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia98052918b654a0dae4726bfd22e4abd_124"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">EXHIBIT D</font></div><div style="margin-bottom:11pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">to Credit Agreement</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">FORM OF ASSIGNMENT AND ASSUMPTION</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">This Assignment and Assumption (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Assignment and Assumption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) is dated as of the Effective Date set forth below and is entered into by and between &#91;______________&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Assignor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) and &#91;______________&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Assignee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;). Capitalized terms used herein and not otherwise defined herein are used herein as defined in that certain Credit Agreement and Guaranty, dated as of June 14, 2024 (as amended or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), by and among HeartFlow, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), HeartFlow Holding, Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Holdings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), certain Subsidiaries of Holdings that may be required to provide Guarantees from time to time thereunder, the lenders from time to time party thereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) and Hayfin Services LLP, as administrative agent for the Lenders (in such capacity, together with its successors and assigns, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), receipt of a copy of which is hereby acknowledged by the Assignee. The Standard Terms and Conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Annex 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> attached hereto are hereby agreed to and incorporated herein by reference and made a part of this Assignment and Assumption as if set forth herein in full.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">For an agreed consideration, the Assignor hereby irrevocably sells and assigns to the Assignee, and the Assignee hereby irrevocably purchases and assumes from the Assignor, subject to and in accordance with the Standard Terms and Conditions and the Credit Agreement, as of the Effective Date inserted by the Agent as contemplated below (i) all of the Assignor&#8217;s rights and obligations in its capacity as a Lender under the Credit Agreement and any other documents or instruments delivered pursuant thereto to the extent related to the amount and percentage interest identified below of all of such outstanding rights and obligations of the Assignor under the Credit Agreement and (ii) to the extent permitted to be assigned under applicable law, all claims, suits, causes of action and any other right of the Assignor (in its capacity as a Lender) against any Person, whether known or unknown, arising under or in connection with the Credit Agreement, any other documents or instruments delivered pursuant thereto or the loan transactions governed thereby or in any way based on or related to any of the foregoing, including, but not limited to, contract claims, tort claims, malpractice claims, statutory claims and all other claims at law or in equity related to the rights and obligations sold and assigned pursuant to clause (i) above (the rights and obligations sold and assigned by the Assignor to the Assignee pursuant to clauses (i) and (ii) above being referred to herein collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Assigned Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;). Such sale and assignment is without recourse to the Assignor and, except as expressly provided in this Assignment and Assumption, without representation or warranty by the Assignor.</font></div><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.&#160;&#160;&#160;&#160;Assignor&#91;s&#93;&#58; ________________________________________</font></div><div style="margin-bottom:10pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">____________________________________________</font></div><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2.&#160;&#160;&#160;&#160;Assignee&#91;s&#93;&#58; ________________________________________</font></div><div style="margin-bottom:10pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">____________________________________________</font></div><div style="margin-bottom:23pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#91;Assignee is an Affiliate of &#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">identify Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#93;&#93;</font></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3.&#160;&#160;&#160;&#160;Borrower&#58; HeartFlow, Inc.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">4.&#160;&#160;&#160;&#160;Administrative Agent&#58; Hayfin Services LLP</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">5.&#160;&#160;&#160;&#160;Credit Agreement&#58; Credit Agreement and Guaranty, dated as of June 14, 2024 (as amended or otherwise modified from time to time), by and among HeartFlow, Inc., HeartFlow Holding, Inc., certain Subsidiaries of Holdings that may be required to provide Guarantees from time to time thereunder, the lenders from time to time party thereto and Hayfin Services LLP, as administrative agent for the Lenders.</font></div><div style="margin-bottom:13pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.&#160;&#160;&#160;&#160; Assigned Interest&#91;s&#93;&#58;</font></div><div style="margin-bottom:65pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:-1.06pt;text-align:center;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Assignor&#91;s&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;padding-right:-1.06pt;text-align:center;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Assignee&#91;s&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">2</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Aggregate Amount of Commitment&#47;Loans for all Lenders</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Amount of Commitment&#47;Loans Assigned</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">8</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Percentage Assigned of Commitment&#47; Loans<font style="font-size:7.8pt;position:relative;top:-4.2pt;vertical-align:baseline">3</font></font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">%</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">%</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">%</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Signature Page Follows</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#93;</font></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:198pt"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> List each Assignor, as appropriate.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> List each Assignee, as appropriate.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Set forth, to at least 9 decimals, a percentage of the Commitment&#47;Loans of all Lenders thereunder.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia98052918b654a0dae4726bfd22e4abd_127"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Effective Date&#58;&#160;&#160;_____________ ___, 20___ &#91;TO BE INSERTED BY AGENT AND WHICH SHALL BE THE EFFECTIVE DATE OF RECORDATION OF TRANSFER IN THE REGISTER THEREFOR.&#93;</font></div><div style="margin-bottom:26pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The terms set forth in this Assignment and Assumption are hereby agreed to&#58;</font></div><div style="margin-bottom:26pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.970%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.566%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ASSIGNOR</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;NAME OF ASSIGNOR&#93;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="6" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ASSIGNEE</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;NAME OF ASSIGNEE&#93;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="6" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="9" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.156%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.949%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Consented to and Accepted&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">HAYFIN SERVICES LLP, as the Agent</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="6" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Authorised Signatory</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Consented to and Accepted&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">HEARTFLOW, INC., as the Borrower</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="15" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="6" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="6" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#93;</font></td><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"><font style="font-size:7.8pt;position:relative;top:-4.2pt;vertical-align:baseline">4</font></td></tr></table></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:198pt"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#91;NTD&#58; To be included where the Borrower&#8217;s consent is required pursuant to the Credit Agreement.&#93;</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia98052918b654a0dae4726bfd22e4abd_130"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ANNEX 1</font></div><div style="margin-bottom:24pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">STANDARD TERMS AND CONDITIONS</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Representations and Warranties.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Assignor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The Assignor (a) represents and warrants that (i) it is the legal and beneficial owner of the Assigned Interest, (ii) the Assigned Interest is free and clear of any lien, encumbrance or other adverse claim and (iii) it has full power and authority, and has taken all action necessary, to execute and deliver this Assignment and Assumption and to consummate the transactions contemplated hereby&#59; and (b) assumes no responsibility with respect to (i) any statements, warranties or representations made in or in connection with the Credit Agreement or any other Loan Document, (ii) the execution, legality, validity, enforceability, genuineness, sufficiency or value of the Loan Documents or any collateral thereunder, (iii) the financial condition of the Borrower, any of its Subsidiaries or Affiliates or any other Person obligated in respect of any Loan Document or (iv) the performance or observance by the Borrower, any of its Subsidiaries or Affiliates or other Person of any of their respective obligations under any Loan Document.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Assignee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The Assignee (a) represents and warrants that (i) it has full power and authority, and has taken all action necessary, to execute and deliver this Assignment and Assumption and to consummate the transactions contemplated hereby and to become a Lender under the Credit Agreement, (ii) from and after the Effective Date, it shall be bound by the provisions of the Credit Agreement as a Lender thereunder and, to the extent of the Assigned Interest, shall have the obligations of a Lender thereunder, (iii) it is sophisticated with respect to decisions to acquire assets of the type represented by the Assigned Interest and is experienced in acquiring assets of such type, (iv) it has received a copy of the Credit Agreement, and has received or has been accorded the opportunity to receive copies of the most recent financial statements delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Sections 7.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> thereof, as applicable, and such other documents and information as it has deemed appropriate to make its own credit analysis and decision to enter into this Assignment and Assumption and to purchase the Assigned Interest, (v) it has, independently and without reliance upon the Agent or any other Lender and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Assignment and Assumption and to purchase the Assigned Interest, and (vi) attached to the Assignment and Assumption is any documentation required to be delivered by it pursuant to the terms of the Credit Agreement, duly completed and executed by the Assignee&#59; and (b) agrees that (i) it will, independently and without reliance on the Agent, the Assignor or any other Lender, and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit decisions in taking or not taking action under the Loan Documents, and (ii) it will perform in accordance with their terms all of the obligations which by the terms of the Loan Documents are required to be performed by it as a Lender.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Payments. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">From and after the Effective Date, the Agent shall make all payments in respect of the Assigned Interest (including payments of principal, interest, fees and other amounts) to the Assignor for amounts which have accrued to but excluding the Effective Date and to the Assignee for amounts which have accrued from and after the Effective Date. Notwithstanding the foregoing,</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">the Agent shall make all payments of interest, fees or other amounts paid or payable in kind from and after the Effective Date to the Assignee.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">General Provisions. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">This Assignment and Assumption shall be binding upon, and inure to the benefit of, the parties hereto and their respective successors and assigns. This Assignment and Assumption may be executed in any number of counterparts, which together shall constitute one instrument. Delivery of an executed counterpart of a signature page of this Assignment and Assumption by facsimile or in electronic (PDF) format shall be effective as delivery of a manually executed counterpart of this Assignment and Assumption. This Assignment and Assumption shall be governed by, and construed in accordance with, the law of the State of New York, without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that Section 5-1401 of the New York General Obligations Law shall apply.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia98052918b654a0dae4726bfd22e4abd_133"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT E-1</font></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">to Credit Agreement</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">FORM OF U.S. TAX COMPLIANCE CERTIFICATE</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(For Foreign Lenders That Are Not Partnerships for U.S. Federal Income Tax Purposes)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Reference is made to that certain Credit Agreement and Guaranty, dated as of June 14, 2024 (as amended or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), by and among HeartFlow, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), HeartFlow Holding, Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Holdings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), certain Subsidiaries of Holdings that may be required to provide Guarantees from time to time thereunder, the lenders from time to time party thereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Hayfin Services LLP, as administrative agent for the Lenders (in such capacity, together with its successors and assigns, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.3(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Credit Agreement, the undersigned hereby certifies that (i) it is the sole record and beneficial owner of the Loan(s) (as well as any Note(s) evidencing such Loan(s)) in respect of which it is providing this certificate, (ii) it is not a &#8220;bank&#8221; within the meaning of Section 881(c)(3)(A) of the Code, (iii) it is not a &#8220;ten percent shareholder&#8221; of the Borrower within the meaning of Section 871(h)(3)(B) of the Code and (iv) it is not a &#8220;controlled foreign corporation&#8221; related to the Borrower as described in Section&#160;881(c)(3)(C) of the Code.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The undersigned has furnished the Agent and the Borrower with a certificate of its non-U.S. Person status on IRS Form W-8BEN or IRS Form W-8BEN-E. By executing this certificate, the undersigned agrees that (1) if the information provided in this certificate changes, the undersigned shall promptly so inform the Borrower and the Agent, and (2) the undersigned shall have at all times furnished the Borrower and the Agent with a properly completed and currently effective certificate in either the calendar year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments.</font></div><div style="margin-bottom:38pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Unless otherwise defined herein, terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit Agreement.</font></div><div style="margin-bottom:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.774%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;NAME OF LENDER&#93;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;_____________________________________</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; _________ __, 20__</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia98052918b654a0dae4726bfd22e4abd_136"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT E-2</font></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">to Credit Agreement</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">FORM OF U.S. TAX COMPLIANCE CERTIFICATE</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(For Foreign Participants That Are Not Partnerships for U.S. Federal Income Tax Purposes)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Reference is made to that certain Credit Agreement and Guaranty, dated as of June 14, 2024 (as amended or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), by and among HeartFlow, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), HeartFlow Holding, Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Holdings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), certain Subsidiaries of Holdings that may be required to provide Guarantees from time to time thereunder, the lenders from time to time party thereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Hayfin Services LLP, as administrative agent for the Lenders (in such capacity, together with its successors and assigns, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.3(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Credit Agreement, the undersigned hereby certifies that (i) it is the sole record and beneficial owner of the participation in respect of which it is providing this certificate, (ii) it is not a &#8220;bank&#8221; within the meaning of Section 881(c)(3)(A) of the Code, (iii) it is not a &#8220;ten percent shareholder&#8221; of the Borrower within the meaning of Section 871(h)(3)(B) of the Code, and (iv) it is not a &#8220;controlled foreign corporation&#8221; related to the Borrower as described in Section 881(c)(3)(C) of the Code.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The undersigned has furnished its participating Lender with a certificate of its non-U.S. Person status on IRS Form W-8BEN or IRS Form W-8BEN-E. By executing this certificate, the undersigned agrees that (1) if the information provided in this certificate changes, the undersigned shall promptly so inform such Lender in writing, and (2) the undersigned shall have at all times furnished such Lender with a properly completed and currently effective certificate in either the calendar year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments.</font></div><div style="margin-bottom:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Unless otherwise defined herein, terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit Agreement.</font></div><div style="margin-bottom:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.774%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;NAME OF PARTICIPANT&#93;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;_____________________________________</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; _________ __, 20__</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia98052918b654a0dae4726bfd22e4abd_139"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT E-3</font></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">to Credit Agreement</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">FORM OF U.S. TAX COMPLIANCE CERTIFICATE</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(For Foreign Participants That Are Partnerships for U.S. Federal Income Tax Purposes)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Reference is made to that certain Credit Agreement and Guaranty, dated as of June 14, 2024 (as amended or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), by and among HeartFlow, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), HeartFlow Holding, Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Holdings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), certain Subsidiaries of Holdings that may be required to provide Guarantees from time to time thereunder, the lenders from time to time party thereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Hayfin Services LLP, as administrative agent for the Lenders (in such capacity, together with its successors and assigns, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.3(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Credit Agreement, the undersigned hereby certifies that (i) it is the sole record owner of the participation in respect of which it is providing this certificate, (ii) its direct or indirect partners&#47;members are the sole beneficial owners of such participation, (iii) with respect such participation, neither the undersigned nor any of its direct or indirect partners&#47;members is a &#8220;bank&#8221; extending credit pursuant to a loan agreement entered into in the ordinary course of its trade or business within the meaning of Section 881(c)(3)(A) of the Code, (iv) none of its direct or indirect partners&#47;members is a &#8220;ten percent shareholder&#8221; of the Borrower within the meaning of Section 871(h)(3)(B) of the Code and (v) none of its direct or indirect partners&#47;members is a &#8220;controlled foreign corporation&#8221; related to the Borrower as described in Section 881(c)(3)(C) of the Code.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The undersigned has furnished its participating Lender with IRS Form W-8IMY accompanied by one of the following forms from each of its partners&#47;members that is claiming the portfolio interest exemption&#58; (i) an IRS Form W-8BEN or IRS Form W-8BEN-E or (ii) an IRS Form W-8IMY accompanied by an IRS Form W-8BEN or IRS Form W-8BEN-E from each of such partner&#8217;s&#47;member&#8217;s beneficial owners that is claiming the portfolio interest exemption. By executing this certificate, the undersigned agrees that (1) if the information provided in this certificate changes, the undersigned shall promptly so inform such Lender and (2) the undersigned shall have at all times furnished such Lender with a properly completed and currently effective certificate in either the calendar year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments.</font></div><div style="margin-bottom:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Unless otherwise defined herein, terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit Agreement.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Signature Page Follows</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia98052918b654a0dae4726bfd22e4abd_142"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:16pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.774%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;NAME OF PARTICIPANT&#93;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;_____________________________________</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; _________ __, 20__</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia98052918b654a0dae4726bfd22e4abd_145"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT E-4</font></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">to Credit Agreement</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">FORM OF U.S. TAX COMPLIANCE CERTIFICATE</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(For Foreign Lenders That Are Partnerships for U.S. Federal Income Tax Purposes)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Reference is made to that certain Credit Agreement and Guaranty, dated as of June 14, 2024 (as amended or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), by and among HeartFlow, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), HeartFlow Holding, Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Holdings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), certain Subsidiaries of Holdings that may be required to provide Guarantees from time to time thereunder, the lenders from time to time party thereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Hayfin Services LLP, as administrative agent for the Lenders (in such capacity, together with its successors and assigns, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.3(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Credit Agreement, the undersigned hereby certifies that (i) it is the sole record owner of the Loan(s) (as well as any Note(s) evidencing such Loan(s)) in respect of which it is providing this certificate, (ii) its direct or indirect partners&#47;members are the sole beneficial owners of such Loan(s) (as well as any Note(s) evidencing such Loan(s)), (iii) with respect to the extension of credit pursuant to this Credit Agreement or any other Loan Document, neither the undersigned nor any of its direct or indirect partners&#47;members is a &#8220;bank&#8221; extending credit pursuant to a loan agreement entered into in the ordinary course of its trade or business within the meaning of Section 881(c)(3)(A) of the Code, (iv) none of its direct or indirect partners&#47;members is a &#8220;ten percent shareholder&#8221; of the Borrower within the meaning of Section 871(h)(3)(B) of the Code and (v) none of its direct or indirect partners&#47;members is a &#8220;controlled foreign corporation&#8221; related to the Borrower as described in Section 881(c)(3)(C) of the Code.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The undersigned has furnished the Agent and the Borrower with IRS Form W-8IMY accompanied by one of the following forms from each of its partners&#47;members that is claiming the portfolio interest exemption&#58; (i) an IRS Form W-8BEN or IRS Form W-8BEN-E or (ii) an IRS Form W-8IMY accompanied by an IRS Form W-8BEN or IRS Form W-8BEN-E from each of such partner&#8217;s&#47;member&#8217;s beneficial owners that is claiming the portfolio interest exemption. By executing this certificate, the undersigned agrees that (1) if the information provided in this certificate changes, the undersigned shall promptly so inform the Borrower and the Agent, and (2) the undersigned shall have at all times furnished the Borrower and the Agent with a properly completed and currently effective certificate in either the calendar year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments.</font></div><div style="margin-bottom:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Unless otherwise defined herein, terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit Agreement.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Signature Page Follows</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia98052918b654a0dae4726bfd22e4abd_148"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:16pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.774%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;NAME OF LENDER&#93;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;_____________________________________</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; _________ __, 20</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia98052918b654a0dae4726bfd22e4abd_151"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">EXHIBIT F</font></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">to Credit Agreement</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">FORM OF INTERCOMPANY SUBORDINATION AGREEMENT</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">This INTERCOMPANY SUBORDINATION AGREEMENT, dated as of June 14, 2024 (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Subordination Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), is entered into by and among HeartFlow, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), HeartFlow Holding, Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Holdings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), certain Subsidiaries of Holdings that are parties hereto and certain other Subsidiaries of Holdings that may from time to time in the future become parties hereto by executing and delivering a joinder agreement in substantially the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> hereto (any such Subsidiary being herein, individually, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Subsidiary Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; and collectively the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Subsidiary Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), and Hayfin Services LLP, in its capacity as administrative agent for the Lenders under the Credit Agreement (as defined below) (in such capacity, together with its successors and assigns, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Reference is made to that certain Credit Agreement and Guaranty, dated as of the date hereof (as amended or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), by and among the Borrower, Holdings, certain Subsidiaries of Holdings that may be required to provide Guarantees from time to time thereunder, the lenders from time to time party thereto and the Agent. Capitalized terms used herein and not otherwise defined herein are used herein as defined in the Credit Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">One or more of Holdings, the Borrower and the Subsidiary Parties (individually, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">HeartFlow Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">HeartFlow Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), in their capacities as lenders (each such entity, together with its successors, assigns and transferees in such capacity, individually, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Junior Creditor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;, and, collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Junior Creditors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) has made, or may from time to time may make, loans or extend other financings (other than trade payables in the ordinary course of business) to one or more of the HeartFlow Parties that is a Credit Party (each such Credit Party, in its capacity as a borrower from any Junior Creditor (together with its successors, assigns and transferees) being herein, individually, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Debtor Obligor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;, and, collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Debtor Obligors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 8.2(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> of the Credit Agreement. All such Indebtedness for borrowed money resulting from the making of any such loan or financing, together with all principal, interest, fees, premiums, costs, expenses, liabilities, obligations and other amounts of any type or nature at any time owing or arising in respect thereof, including but not limited to any such items or amounts as may accrue or be incurred before or after default or workout or the commencement of any liquidation, dissolution, bankruptcy, receivership or reorganization case by or against any Credit Party, is herein collectively referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Junior Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;. For the avoidance of doubt, trade payables due from one HeartFlow Party to another HeartFlow Party in the ordinary course of business shall not be deemed to be Junior Obligations and shall not be subject to the terms of this Subordination Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Each of the Junior Creditors and each of the Debtor Obligors, for the benefit of the Secured Parties and each of their permitted successors, transferees and assigns, hereby irrevocably and unconditionally agree as follows&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.&#160;&#160;&#160;&#160;All payment obligations and other monetary obligations of any Debtor Obligor arising from time to time under or in connection with any Junior Obligations to any Junior Creditor are,</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">and shall at all times be, subordinated in right of payment and performance to the prior Payment in Full (as defined below) of all Obligations owing under or in connection with the Credit Agreement and the other Loan Documents, whether in respect of principal, interest, fees or other monetary obligations or liabilities of any type or nature, including costs and expenses of enforcement, if any, and including all applicable Early Prepayment Fees and Exit Fees (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Senior Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), notwithstanding the maturity date or amortization date of any Junior Obligations or any acceleration of the maturity date related thereto, any default by or insolvency of any Junior Creditor or any other Person, or otherwise.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2.&#160;&#160;&#160;&#160;The parties hereto agree that this Subordination Agreement is for the benefit of, and shall be enforceable by, the Agent on behalf of the Secured Parties.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3.&#160;&#160;&#160;&#160;At all times from and after the occurrence of an Event of Default until Payment in Full of all Senior Obligations and the termination of all Senior Liens (as defined below) (i) no Debtor Obligor shall make, and no Junior Creditor shall accept, receive or collect from or on behalf of any Debtor Obligor, any direct or indirect payment or distribution of any kind or character whatsoever (whether in cash, securities, other property, by set-off, forgiveness of any Indebtedness of any Secured Party, or otherwise) on account of any of the Junior Obligations, and (ii) under no circumstance shall any payment of any of the Junior Obligations be accelerated, or any other remedy, enforcement action or other action be taken by any Junior Creditor against any Debtor Obligor or any property of any Debtor Obligor or of any other Person, in each case with respect to any of the Junior Obligations (including to assert, enforce or collect any of the Junior Obligations), in each case, without the prior written consent of the Agent.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">4.&#160;&#160;&#160;&#160;No Junior Creditor shall, directly or indirectly, independently or with any other Person, take any action that would be in violation of, or inconsistent with, or result in a breach of this Subordination Agreement or challenge or contest (i) the validity, perfection, priority or enforceability of this Subordination Agreement, any Senior Obligations or any Liens securing the Senior Obligations (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Senior Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), (ii) any of the rights of any Secured Party set forth in the Credit Agreement or any other Loan Document (including with respect to the Senior Liens), or (iii) the validity or enforceability of the Credit Agreement or any other Loan Document or any portion thereof.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">5.&#160;&#160;&#160;&#160;In the event that, prior to Payment in Full of the Senior Obligations, any Junior Creditor shall receive any payment or distribution of any kind or character whatsoever (whether in cash, securities, other property, by set-off, forgiveness of any Indebtedness of any Secured Party, or otherwise) on or in respect of all or any portion of the Junior Obligations which is not permitted to be paid hereunder, then such payment or distribution shall be held in trust by such Junior Creditor for the benefit of, and promptly (and in any event within one (1) Business Day) paid over by such Junior Creditor to the Agent for application of such payment or distribution to repay the Senior Obligations in accordance with the terms thereof, until Payment in Full of the Senior Obligations as confirmed in writing by the Agent to the Borrower.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.&#160;&#160;&#160;&#160;For purposes of this Subordination Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Payment in Full</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, with respect to the Senior Obligations, that all such obligations and other amounts payable constituting Senior Obligations have been indefeasibly paid in full in cash (other than inchoate indemnification and expense reimbursement obligations for which no claim has been asserted).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">7.&#160;&#160;&#160;&#160;Neither any Junior Creditor nor any Debtor Obligor may assign or transfer any of its rights or obligations hereunder, except to another Obligor that becomes bound by the terms of this Subordination Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">8.&#160;&#160;&#160;&#160;This Subordination Agreement is a Loan Document executed pursuant to the Credit Agreement and shall (unless otherwise expressly indicated therein) be construed, administered and applied in accordance with all of the terms and provisions of the Credit Agreement, as amended hereby, including Article XI thereof. The provisions of this Subordination Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective permitted successors and assigns.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.&#160;&#160;&#160;&#160;This Subordination Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument and any of the parties hereto may execute this Subordination Agreement by signing any such counterpart.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.&#160;&#160;&#160;&#160;This Subordination Agreement and the rights and obligations of the parties hereunder shall be governed by, and construed in accordance with, the law of the State of New York, without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that Section 5-1401 of the New York General Obligations Law shall apply.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.&#160;&#160;&#160;&#160;Holdings and any Subsidiary of the Borrower or Holdings may, without the consent of any other party to Subordination Agreement, become a HeartFlow Party under this Subordination Agreement by executing and delivering to the Agent a joinder agreement in substantially the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> hereto.</font></div><div style="margin-bottom:26pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">12.&#160;&#160;&#160;&#160;Except as modified in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> to add Holdings or any Subsidiary of the Borrower or Holdings as an additional HeartFlow Party to this Subordination Agreement, this Subordination Agreement may not be amended, waived or otherwise modified without the prior written consent of each of the parties hereto.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;SIGNATURE PAGE FOLLOWS&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia98052918b654a0dae4726bfd22e4abd_154"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:30pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the parties have caused this Subordination Agreement to be duly executed and delivered as of the date first above written.</font></div><div style="margin-bottom:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">HEARTFLOW, INC.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">HEARTFLOW INTERNATIONAL SARL</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">HEARTFLOW U.K. LTD.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">HEARTFLOW JAPAN G.K.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">HEARTFLOW TECHNOLOGY LIMITED</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">HEARTFLOW TECHNOLOGY U.K. LIMITED</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.188%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.151%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">HAYFIN SERVICES LLP, as the Agent</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Authorised Signatory</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia98052918b654a0dae4726bfd22e4abd_157"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:23pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit A</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FORM OF INTERCOMPANY SUBORDINATION AGREEMENT JOINDER</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This INTERCOMPANY SUBORDINATION AGREEMENT JOINDER, dated as of &#91;DATE&#93; by &#91;NAME OF ADDITIONAL SUBSIDIARY&#93;, a &#91;state of organization&#93; &#91;corporation&#93;&#91;limited liability company&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Additional HeartFlow Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), under that certain Intercompany Subordination Agreement, dated as of June 14, 2024 (as amended or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Subordination Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), by and among HeartFlow, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), HeartFlow Holding, Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Holdings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), certain Subsidiaries of Holdings from time to time party thereto, and Hayfin Services LLP, in its capacity as administrative agent for the Lenders under the Credit Agreement (as defined in the Subordination Agreement) (in such capacity, together with its successors and assigns, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Capitalized terms used herein and not otherwise defined herein are used herein as defined in the Subordination Agreement.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Subordination Agreement, the Additional HeartFlow Party hereby agrees to become a &#8220;HeartFlow Party&#8221; for all purposes of the Subordination Agreement.</font></div><div style="margin-bottom:23pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Additional HeartFlow Party has caused this Subordination Agreement Joinder to be duly executed and delivered as of the day and year first above written.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.443%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;ADDITIONAL HEARTFLOW PARTY&#93;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By </font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>8
<FILENAME>filename8.htm
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ia9c3f014b6bf4f3284cc436d2dd7d13c_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.6</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Execution Version</font></div></div><div style="margin-bottom:11pt;margin-top:24pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AMENDMENT NO. 1 TO CREDIT AGREEMENT AND GUARANTY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, dated as of January 24, 2025 (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), by and among HEARTFLOW, INC., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), HEARTFLOW HOLDING, INC., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Holdings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the lenders party hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and HAYFIN SERVICES LLP, as administrative agent for the Lenders hereunder (in such capacity, together with its successors and assigns in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, the Borrower, Holdings, certain Subsidiaries of Holdings from time to time party thereto, the Lenders from time to time party thereto and the Agent are party to that certain Credit Agreement and Guaranty, dated as of June 14, 2024 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Existing Credit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;, as amended by this Amendment and as may be further amended, amended and restated, supplemented or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, Holdings intends to issue certain unsecured convertible promissory notes (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Subordinated Convertible Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) pursuant to (i) that certain Note Purchase Agreement, dated as of January 24, 2025, by and among Holdings and the investors party thereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Employee Note Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and (ii) those certain Employee Note Purchase Agreements, each dated as of January 24, 2025, by and among Holdings and the applicable investor party thereto (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Employee Note Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Employee Note Purchase Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;&#59; the Employee Note Purchase Agreements, together with the Non-Employee Note Purchase Agreement, each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Note Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Note Purchase Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), which such Subordinated Convertible Notes constitute Indebtedness under the Credit Agreement&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, the Lenders desire to convert, (i) upon receipt by Holdings of net proceeds in an aggregate amount of at least $21,500,000 resulting from the sale of the Subordinated Convertible Notes at the Initial Closing (as defined in the applicable Note Purchase Agreement) (excluding in connection with the Principal Conversion (as defined below) or any other conversion of Indebtedness), $21,000,000 of the principal amount of the Obligations under the Existing Credit Agreement into Subordinated Convertible Notes to be issued to Hayfin Heartflow UK Limited, an Affiliate of the Lenders (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Hayfin Note Investor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), pursuant to the terms of the Non-Employee Note Purchase Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">First Principal Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and (ii) upon receipt by Holdings of net proceeds in an aggregate amount of at least $2,000,000 resulting from the sale of the Subordinated Convertible Notes at a Subsequent Closing (as defined in the applicable Note Purchase Agreement) to occur on or prior to January 31, 2025 (excluding in connection with the Principal Conversion or any other conversion of Indebtedness), $2,000,000 of the principal amount of the Obligations under the Existing Credit Agreement into Subordinated Convertible Notes to be issued to the Hayfin Note Investor, pursuant to the terms of the Non-Employee Note Purchase Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Second Principal Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and, together with the First Principal Conversion, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Principal Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, in connection with the issuance of the Subordinated Convertible Notes, the Borrower has requested, and subject to the terms and conditions set forth herein, the Lenders have agreed, to amend certain provisions of the Existing Credit Agreement as set forth herein in accordance with Section 11.1 thereof.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:17pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOW THEREFORE, in consideration of the foregoing premises and the mutual agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE I</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Definitions</font></div><div style="margin-bottom:17pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 1.1.&#160;&#160;&#160;&#160;Terms used but not defined herein have the respective meanings given to such terms in the Credit Agreement.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE II&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Principal Conversion</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 2.1.&#160;&#160;&#160;&#160;As of the First Amendment Effective Date (as defined below), the First Principal Conversion shall be effective and Holdings shall issue to the Hayfin Note Investor a Subordinated Convertible Note pursuant to the Non-Employee Note Purchase Agreement in a principal amount equal to the principal amount of the Loans being converted pursuant to the First Principal Conversion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 2.2.&#160;&#160;&#160;&#160;On and after the occurrence of the First Principal Conversion, the aggregate amount of Loans outstanding under the Credit Agreement shall be $117,137,470.97.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 2.3.&#160;&#160;&#160;&#160;On the Subsequent Closing Date (as defined below), the Second Principal Conversion shall be consummated and, in connection therewith, Holdings shall issue to the Hayfin Note Investor a Subordinated Convertible Note pursuant to the Non-Employee Note Purchase Agreement in a principal amount equal to the principal amount of the Loans being converted pursuant to the Second Principal Conversion.</font></div><div style="margin-bottom:17pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 2.4.&#160;&#160;&#160;&#160;On and after the occurrence of the Second Principal Conversion, the aggregate amount of Loans outstanding under the Credit Agreement shall be $115,137,470.97.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE III&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Amendments to the Existing Credit Agreement</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 3.1.&#160;&#160;&#160;&#160;As of the First Amendment Effective Date, the Existing Credit Agreement is hereby amended (i) to delete the red or green stricken text (indicated textually in the same manner as the following examples&#58; </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">stricken text</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and </font><font style="color:#70ad47;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">stricken text</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) and (ii) to add the blue or green double-underlined text (indicated textually in the same manner as the following examples&#58; </font><font style="color:#4472c4;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">double-underlined text</font><font style="color:#4472c4;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and </font><font style="color:#70ad47;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">double-underlined text</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">), in each case, as set forth in the marked copy of the Credit Agreement attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:0.80pt">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE IV&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Representations and Warranties</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">SECTION 4.1.&#160;&#160;&#160;&#160;Each Credit Party hereby represents and warrants to the Agent and the Lenders that, as of the First Amendment Effective Date and the Subsequent Closing Date, after giving effect to this Amendment, (a) no Default or Event of Default has occurred and is continuing and (b) the representations and warranties of the Credit Parties contained in the Credit Agreement and the other Loan Documents are true and correct in all material respects on and as of such day (unless stated to relate solely to an earlier date, in which case such representations and warranties shall be true and correct in all material respects as of such earlier date)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that any representations and warranties that are by their terms qualified by materiality, Material Adverse Effect or similar qualification shall be true and correct in all respects.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">SECTION 4.2.&#160;&#160;&#160;&#160;Each Credit Party hereby represents and warrants to the Agent and the Lenders that&#58;</font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;it has taken all necessary action to authorize the execution, delivery and performance of this Amendment&#59;</font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;this Amendment has been duly executed and delivered by such Credit Party and constitutes such Credit Party&#8217;s legal, valid and binding obligation, enforceable in accordance with its terms, except as such enforceability may be subject to (i) bankruptcy, insolvency, reorganization, fraudulent conveyance or transfer, moratorium or similar laws affecting creditors&#8217; rights generally and (ii) general principles of equity (regardless of whether such enforceability is considered in a proceeding at law or in equity)&#59;</font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;no consent, approval, authorization or order of, or filing, registration or qualification with, any court or governmental authority or third party is required in connection with the execution, delivery or performance by such Credit Party of this Amendment&#59;</font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)&#160;&#160;&#160;&#160;the Security Agreement, each Copyright Security Agreement, each Patent Security Agreement, each Trademark Security Agreement and any other security documents (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Security Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) continue to create a valid security interest in, and Lien upon, the Collateral (as defined in the respective Security Document), in favor of the Collateral Agent, for the benefit of the Lenders, which security interests and Liens are perfected in accordance with the terms of the Security Documents and prior to all Liens other than Permitted Liens&#59; and</font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(e)&#160;&#160;&#160;&#160;except as specifically provided in this Amendment, the Obligations are not reduced or modified by this Amendment and are not subject to any offsets, defenses or counterclaims.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">SECTION 4.3.&#160;&#160;&#160;&#160;As of the First Amendment Effective Date, all of the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> have been satisfied. As of the Subsequent Closing Date, all of the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> will have been satisfied.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:0.80pt">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%">ARTICLE V</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Conditions</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">SECTION 5.1.&#160;&#160;&#160;&#160;This Amendment shall become effective upon the satisfaction of the following conditions (the date upon which each such condition has been satisfied in full or waived by the Agent in its sole discretion, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">First Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;)&#58;</font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">This Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">. The execution and delivery of this Amendment by each Credit Party, each Lender and the Agent.</font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">Secretary&#8217;s Certificate, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">. The Agent shall have received from each Credit Party (x) a copy of a good standing certificate (to the extent such concept it applicable in any relevant jurisdiction), dated a date reasonably close to the First Amendment Effective Date, for each such Person and (y) a certificate, dated as of the First Amendment Effective Date, duly executed and delivered by such Person&#8217;s Secretary, Assistant Secretary, or other Authorized Officer, director, managing member or general partner, as applicable, as to&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:41.76pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(i)&#160;&#160;&#160;&#160;resolutions of each such Person&#8217;s board of directors (or other managing body, in the case of other than a corporation) then in full force and effect authorizing the execution, delivery and performance of each Loan Document to be executed by such Person in connection with this Amendment and the transactions contemplated hereby and thereby&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:38.88pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(ii)&#160;&#160;&#160;&#160;the incumbency and signatures of those of its officers, managing member or general partner, as applicable, authorized to act with respect to each such Loan Document to be executed by such Person&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(iii)&#160;&#160;&#160;&#160;the full force and validity of each Organic Document of such Person and copies thereof&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(iv)&#160;&#160;&#160;&#160;certifying that each copy document relating to it specified in this Section 5.1(b) is correct, complete and in full force and effect and, except as attached thereto or noted therein, has not been amended or superseded as at the date no earlier than the First Amendment Effective Date&#59;</font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">in each case, upon which certificate the Agent may conclusively rely until it shall have received a further certificate of the Secretary, Assistant Secretary, director, managing member or general partner, as applicable, of any such Person cancelling or amending the prior certificate of such Person.</font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">First Amendment Effective Date Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:110%">. The Agent shall have received a certificate, dated as of the First Amendment Effective Date (after giving effect to this Amendment and the amendments contemplated herein) and duly executed and delivered by an Authorized Officer of the Borrower, which certificate shall be in form and substance satisfactory to the Agent (acting on the instructions of the Majority Lenders acting reasonably) and shall, among other things, represent and warrant that the statements made therein are true</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:0.80pt">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and correct as of such date (or such earlier date specified therein), and, at the time such certificate is delivered, such statements shall in fact be so true and correct. The statements in such certificate shall be limited to (i) (x) the representations and warranties set forth herein and in each Loan Document are, in each case, true and correct in all material respects as of the First Amendment Effective Date (unless stated to relate solely to an earlier date, in which case such representations and warranties shall be true and correct in all material respects as of such earlier date)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that any representations and warranties that are by their terms qualified by materiality, Material Adverse Effect or similar qualification shall be true and correct in all respects, and (y) no Default or Event of Default under and as defined in the Credit Agreement has occurred and is continuing as of the First Amendment Effective Date, (ii) all of the conditions set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> have been satisfied as of the First Amendment Effective Date and (iii) as of the First Amendment Effective Date, no Material Adverse Effect shall have occurred since December 31, 2023.</font></div><div style="margin-bottom:11pt;padding-left:22.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Solvency, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Agent shall have received a solvency certificate duly executed and delivered by the chief financial or accounting Authorized Officer of the Borrower, dated as of the First Amendment Effective Date, in form and substance satisfactory to the Agent.</font></div><div style="margin-bottom:11pt;padding-left:22.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Fees, Expenses, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Agent shall have received for its own account and for the account of the Lenders and all fees, costs and expenses due and payable pursuant to Section 11.3 of the Credit Agreement, the Fee Letter or any other Loan Documents, including all closing costs and fees and all unpaid reasonable expenses of the Agent and the Lenders incurred in connection with the transactions contemplated hereby (including the Agent&#8217;s legal fees and expenses).</font></div><div style="margin-bottom:11pt;padding-left:22.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Convertible Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. (i) The conditions under the Note Purchase Agreements shall have been satisfied substantially concurrently with the conditions set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and (ii) the Agent shall have received (A) evidence of receipt by Holdings of net proceeds in an aggregate amount of at least $21,500,000 resulting from the sale of the Subordinated Convertible Notes at the Initial Closing (excluding in connection with the Principal Conversion or any other conversion of Indebtedness) issued by Holdings pursuant to the Note Purchase Agreements, (B) evidence of receipt by Holdings of net proceeds in an aggregate amount of at least $21,000,000 resulting from the First Principal Conversion and (C) fully executed copies of (x) each Note Purchase Agreement and each of the Subordinated Convertible Notes issued pursuant thereto at the Initial Closing (including, for the avoidance of doubt, the Subordinated Convertible Notes issued in connection with the First Principal Conversion), (y) each subordination agreement in respect of the Subordinated Convertible Notes issued at the Initial Closing and (z) a side letter between Holdings and the Hayfin Note Investor, and all other documents related to the sale and issuance of the Subordinated Convertible Notes issued at the Initial Closing, in each case, in form and substance satisfactory to the Agent in its sole discretion.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 5.2.&#160;&#160;&#160;&#160;The Second Principal Conversion shall be consummated upon the satisfaction of the following conditions (the date upon which each such condition has been satisfied in full or waived by the Agent in its sole discretion, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Subsequent Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:0.80pt">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Subsequent Closing Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The conditions under the Note Purchase Agreements with respect to a Subsequent Closing shall have been satisfied substantially concurrently with the conditions set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Convertible Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The Agent shall have received (i) evidence of receipt by Holdings of net proceeds in an aggregate amount of at least $2,000,000 resulting from the sale of the Subordinated Convertible Notes at a Subsequent Closing on or prior to January 31, 2025 (excluding in connection with the Principal Conversion or any other conversion of Indebtedness) issued by Holdings pursuant to the Note Purchase Agreements and (B) fully executed copies of, or counterpart signature pages to, (x) each Note Purchase Agreement pursuant to which Subordinated Convertible Notes are issued at such Subsequent Closing (including, for the avoidance of doubt, the Subordinated Convertible Notes issued in connection with the Second Principal Conversion), (y) each subordination agreement in respect of the Subordinated Convertible Notes issued at such Subsequent Closing and (z) all other documents related to the sale and issuance of the Subordinated Convertible Notes issued at such Subsequent Closing, in each case, in form and substance satisfactory to the Agent in its sole discretion.</font></div><div style="margin-bottom:17pt;padding-left:22.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Subsequent Closing Date Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The Agent shall have received a certificate, dated as of the Subsequent Closing Date (after giving effect to this Amendment and the amendments contemplated herein) and duly executed and delivered by an Authorized Officer of the Borrower, which certificate shall be in form and substance satisfactory to the Agent (acting on the instructions of the Majority Lenders acting reasonably) and shall, among other things, represent and warrant that the statements made therein are true and correct as of such date (or such earlier date specified therein), and, at the time such certificate is delivered, such statements shall in fact be so true and correct. The statements in such certificate shall be limited to (i) (x) the representations and warranties set forth herein and in each Loan Document are, in each case, true and correct in all material respects as of the Subsequent Closing Date (unless stated to relate solely to an earlier date, in which case such representations and warranties shall be true and correct in all material respects as of such earlier date)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> that any representations and warranties that are by their terms qualified by materiality, Material Adverse Effect or similar qualification shall be true and correct in all respects, and (y) no Default or Event of Default under and as defined in the Credit Agreement has occurred and is continuing as of the Subsequent Closing Date, (ii) all of the conditions set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> have been satisfied as of the Subsequent Closing Date and (iii) as of the Subsequent Closing Date, no Material Adverse Effect shall have occurred since December 31, 2023.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE VI</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Miscellaneous</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">SECTION 6.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. THIS AMENDMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AMENDMENT CONTEMPLATED HEREBY SHALL BE GOVERNED BY, AND</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:0.80pt">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK). THIS AMENDMENT AND THE LOAN DOCUMENTS CONSTITUTE THE ENTIRE UNDERSTANDING AMONG THE PARTIES HERETO WITH RESPECT TO THE SUBJECT MATTER HEREOF AND THEREOF AND SUPERSEDE ANY PRIOR AGREEMENTS, WRITTEN OR ORAL, WITH RESPECT HERETO AND THERETO.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">SECTION 6.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Severability Clause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Any provision of this Amendment which is prohibited or unenforceable in any jurisdiction shall, as to such provision and such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions of this Amendment or affecting the validity or enforceability of such provision in any other jurisdiction.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">SECTION 6.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Ratification and Reaffirmation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Except as expressly amended hereby, each of the Credit Agreement and the Fee Letter is in all respects ratified and confirmed and all the terms, conditions and provisions thereof shall remain in full force and effect. Each Credit Party hereby consents to this Amendment, agrees that this Amendment shall form a part of the Credit Agreement and the Fee Letter for all purposes and acknowledges that each of the other Loan Documents remains in full force and effect and is hereby ratified and reaffirmed. Each Credit Party as borrower, debtor, grantor, pledgor, guarantor, assignor, or in other any other similar capacity in which such Credit Party grants liens or security interests in its property or otherwise acts as accommodation party or guarantor, as the case may be, hereby (a) ratifies and reaffirms all of its payment and performance obligations, contingent or otherwise, under each of the Loan Documents to which it is a party (after giving effect hereto) and (b) to the extent such Credit Party granted liens on or security interests in any of its property pursuant to any such Loan Document as security for or otherwise guaranteed Obligations under or with respect to the Loan Documents, ratifies and reaffirms such guarantee and grant of security interests and liens and confirms and agrees that such security interests and liens hereafter secure all of the Obligations as amended hereby. The execution of this Amendment shall not operate as a waiver of any right, power or remedy of the Agent or the Lenders, constitute a waiver of any provision of any of the Loan Documents or serve to effect a novation of the Obligations or any other obligation or covenant of the Credit Parties under the Loan Documents. Except as specifically set forth herein, the Agent and the Lenders reserve all of their respective rights and remedies under the Credit Agreement and the other Loan Documents.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">SECTION 6.4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The various headings of this Amendment are inserted for convenience only and shall not affect the meaning or interpretation of this Amendment or any provisions hereof.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">SECTION 6.5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Execution in Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. This Amendment may be executed by the parties hereto in several counterparts, each of which shall be an original and all of which shall constitute together but one and the same agreement.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">SECTION 6.6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Effectiveness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. This Amendment shall become effective when counterparts hereof executed on behalf of the Credit Parties and the Lenders shall have been received by the Agent.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:0.80pt">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 6.7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Electronic Signatures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Delivery of an executed counterpart of a signature page to this Agreement by email (e.g. &#8220;pdf&#8221; or &#8220;tiff&#8221;) or telecopy shall be effective as delivery of a manually executed counterpart of this Amendment. Any signature (including, without limitation, (x) any electronic symbol or process attached to, or associated with, a contract or other record and adopted by a Person with the intent to sign, authenticate or accept such contract or record and (y) any facsimile or &#8220;pdf&#8221; signature) hereto or to any other certificate, agreement or document related hereto or the transactions contemplated hereby, and any contract formation or record-keeping, in each case, through electronic means, shall have the same legal validity and enforceability as a manually executed signature or use of a paper-based record-keeping system to the fullest extent permitted by applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any similar state law based on the Uniform Electronic Transactions Act, and the parties hereto hereby waive any objection to the contrary.</font></div><div style="margin-bottom:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 6.8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Credit Party hereby unconditionally and irrevocably acquits and fully and forever releases and discharges the Agent, the Lenders and all their respective affiliates, partners, subsidiaries, officers, employees, agents, attorneys, principals, directors and shareholders and its respective heirs, legal representatives, successors and permitted assigns (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Releasees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) from any and all claims, demands, causes of action, obligations, remedies, suits, damages and liabilities of any nature whatsoever, whether now known, suspected or claimed, whether arising under common law, in equity or under statute, which such party hereto ever had or now has against any of the Releasees and which has arisen at any time prior to the date hereof directly out of this Amendment, the Credit Agreement or the other Loan Documents or the enforcement or attempted or threatened enforcement by any of the Releasees of any of their respective rights, remedies or recourse related thereto (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Released Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (but in each case referred to in this Section 6.8, excluding any claims, demands, causes of actions, obligations, remedies, suits, damages or liabilities to the extent same occurred by reason of the gross negligence, bad faith or willful misconduct of the Releasee to be indemnified (as determined by a court of competent jurisdiction in a final and non-appealable decision)). Each Credit Party covenants and agrees never to commence, voluntarily aid in any way, prosecute or cause to be commenced or prosecuted against any of the Releasees any action or other proceeding based upon any of the Released Claims.</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;Signature pages follow&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:0.80pt">8</font></div></div></div><div id="ia9c3f014b6bf4f3284cc436d2dd7d13c_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:35pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed by their respective officers thereunto duly authorized as of the day and year first above written.</font></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">BORROWER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HEARTFLOW, INC.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By &#47;s&#47; Vikram Verghese</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;&#160;Vikram Verghese</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;&#160;Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">HOLDINGS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HEARTFLOW HOLDING, INC.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By &#47;s&#47; Vikram Verghese</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;&#160;Vikram Verghese</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;&#160;Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;Signature Page to Amendment No. 1 to Credit Agreement and Guaranty&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.151%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">AGENT&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HAYFIN SERVICES LLP</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47; Jennifer Shen</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Authorised Signatory</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;Signature Page to Amendment No. 1 to Credit Agreement and Guaranty</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.190%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">LENDER&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HAYFIN TOURMALINE LUXCO S.A.R.L.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By &#47;s&#47; John Molloy</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Authorised Signatory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> John Molloy</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By &#47;s&#47; Choui Min Kon Kam King (Diana)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Authorised Signatory </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Choui Min Kon Kam King (Diana)</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#91;Signature Page to Amendment No. 1 to Credit Agreement and Guaranty</font></div></div></div><div id="ia9c3f014b6bf4f3284cc436d2dd7d13c_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Appendix A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(see attached)</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia9c3f014b6bf4f3284cc436d2dd7d13c_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:60pt"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:line-through">Execution Version</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">CONFORMED THROUGH AMENDMENT NO. 1 DATED JANUARY 24, 2025</font></div><div style="margin-bottom:50pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:48pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CREDIT AGREEMENT AND GUARANTY</font></div><div style="margin-bottom:35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">dated as of June 14, 2024</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">by and among</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">HEARTFLOW, INC.,</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as Borrower,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">HEARTFLOW HOLDING, INC.,</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as Holdings,</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">THE LENDERS PARTY HERETO,</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">HAYFIN SERVICES LLP,</font></div><div style="margin-bottom:50pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as the Agent for the Lenders</font></div><div style="margin-bottom:160pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ia9c3f014b6bf4f3284cc436d2dd7d13c_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Page</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE I DEFINITIONS AND ACCOUNTING TERMS</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 1.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Defined Terms</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 1.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Interpretation.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:line-through">26</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">27</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 1.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Accounting and Financial Determinations.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">27</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 1.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Divisions.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">27</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">28</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 1.5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Rates.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">28</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE II THE LOANS</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">28</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 2.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Commitments.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">28</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 2.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Borrowing Procedures.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">28</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 2.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Funding.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">28</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">29</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE III REPAYMENTS, PREPAYMENTS, INTEREST AND FEES</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">28</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">29</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 3.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Applicable Currency for Repayments and Prepayments&#59; Pro Rata Application</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">28</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">29</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 3.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Repayments and Prepayments.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">29</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 3.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Application.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">30</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 3.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Interest Rate.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">30</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 3.5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Default Rate.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">30</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 3.6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Payment Dates.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">30</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 3.7</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Fees.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">30</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">31</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 3.8</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Specified Repayment Fees.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">30</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">31</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 3.9</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;Reserved&#93;.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">30</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">31</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 3.10</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">PIK Interest.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">31</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 3.11</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Interest Computation.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">31</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 3.12</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Term SOFR Conforming Changes.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">31</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">32</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE IV SOFR AND OTHER PROVISIONS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">31</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">32</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 4.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Increased Costs.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">31</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">32</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 4.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Compensation for Losses.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">32</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">33</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 4.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Taxes.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">33</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 4.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Payments, Computations&#59; Proceeds of Collateral, Etc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">36</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 4.5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Setoff.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">36</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">37</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-i-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.433%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 4.6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Inability to Determine Rates.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">36</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">37</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 4.7</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sharing of Payments.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">37</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">38</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 4.8</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Mitigation.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">38</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 4.9</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Illegality.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">38</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 4.10</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Benchmark Replacement Setting.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">38</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">39</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE V CONDITIONS PRECEDENT</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">39</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">40</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 5.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Conditions to the Borrowing of the Loans on the Closing Date.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">39</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">40</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE VI REPRESENTATIONS AND WARRANTIES</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">43</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">44</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 6.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Organization, Etc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">43</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">44</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 6.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Due Authorization, Non-Contravention, Etc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">44</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 6.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Government Approval, Regulation, Etc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">44</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 6.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Validity, Etc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">44</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 6.5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Financial Information.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">44</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 6.6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No Material Adverse Change.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">44</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">45</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 6.7</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Litigation, Labor Matters and Environmental Matters.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">44</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">45</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 6.8</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subsidiaries.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">45</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 6.9</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Ownership of Properties.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">45</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 6.10</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Taxes.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">45</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 6.11</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pension Plans, Etc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">45</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 6.12</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Accuracy of Information</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">46</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 6.13</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regulations U and X.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">46</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 6.14</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Solvency.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">46</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 6.15</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Intellectual Property.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">46</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 6.16</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Data Privacy.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">47</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 6.17</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Material Agreements.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">48</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 6.18</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Permits</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">48</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 6.19</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regulatory Matters.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">48</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 6.20</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Transactions with Affiliates.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">50</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 6.21</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Investment Company Act.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">50</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 6.22</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">OFAC.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">50</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 6.23</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Anti-Corruption.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">50</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">51</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 6.24</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Deposit and Disbursement Accounts.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">50</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">51</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-ii-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.433%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 6.25</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Registration Rights.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">51</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 6.26</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Royalty and Other Payments.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">51</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 6.27</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sale and Leaseback.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">51</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 6.28</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Senior Secured Obligations.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">51</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 6.29</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Beneficial Ownership Certification.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">51</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE VII AFFIRMATIVE COVENANTS</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">51</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 7.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Financial Information, Reports, Notices, Etc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">51</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 7.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Maintenance of Existence&#59; Compliance with Contracts, Laws, Etc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">53</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 7.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Maintenance of Properties.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">53</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 7.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Insurance.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">53</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 7.5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Books and Records.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">54</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 7.6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Environmental Law Covenant.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">54</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 7.7</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Use of Proceeds.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">54</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 7.8</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Future Guarantors, Security, Etc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">54</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 7.9</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Obtaining of Permits, Etc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">56</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">57</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 7.10</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Product Licenses.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">56</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">57</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 7.11</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Maintenance of Regulatory Authorizations, Contracts, Intellectual Property, Etc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">57</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 7.12</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cash Management.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">57</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE VIII NEGATIVE COVENANTS</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">58</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 8.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Business Activities.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">58</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 8.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indebtedness.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">58</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 8.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Liens.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">59</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">60</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 8.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Financial Covenants.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">60</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">61</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 8.5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Investments.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">62</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 8.6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Restricted Payments, Etc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">62</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">63</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 8.7</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Issuance of Capital Securities.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">63</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 8.8</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Consolidation, Merger, Etc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">63</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 8.9</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Permitted Dispositions.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">63</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 8.10</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Modification of Certain Agreements.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">63</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 8.11</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Transactions with Affiliates.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">63</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">64</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 8.12</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Restrictive Agreements, Etc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">64</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-iii-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.433%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 8.13</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sale and Leaseback.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">64</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 8.14</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Product Sales.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">64</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">65</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 8.15</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Change in Name, Location, Executive Office, or Executive Management&#59; Change in Fiscal Year.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">64</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">65</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 8.16</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Negative Pledge.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">64</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">65</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 8.17</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sanctions.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">65</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 8.18</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Passive Holding Company.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">65</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">66</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 8.19</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">USRPHC Status.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">65</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">66</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 8.20</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Hazardous Materials.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">65</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">66</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 8.21</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Licenses.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">65</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">66</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 8.22</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subordinated Indebtedness.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">66</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE IX EVENTS OF DEFAULT</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">66</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">67</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 9.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Listing of Events of Default.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">66</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">67</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 9.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Action if Bankruptcy.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">70</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 9.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Action if Other Event of Default.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">70</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE X ADMINISTRATIVE AGENT</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">70</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 10.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Appointment.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">70</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 10.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Rights as a Lender.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">70</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 10.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exculpatory Provisions.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">70</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">71</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 10.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Reliance by Agent.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">71</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">72</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 10.5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Delegation of Duties.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">71</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">72</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 10.6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Resignation of Agent.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">72</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 10.7</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Non-Reliance on Agent and Other Lenders.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">72</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">73</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 10.8</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Agent May File Proofs of Claim.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">72</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">73</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 10.9</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Collateral and Guaranty Matters.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">73</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE XI MISCELLANEOUS PROVISIONS</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">74</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 11.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Waivers, Amendments, Etc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">74</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 11.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notices&#59; Time.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">74</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 11.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Payment of Costs and Expenses.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">74</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 11.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indemnification.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">75</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 11.5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Survival.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">76</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 11.6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Obligations Several.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">76</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 11.7</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Severability.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">76</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-iv-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.433%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 11.8</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Headings.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">76</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">77</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 11.9</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Execution, Effectiveness, Etc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">76</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">77</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 11.10</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Governing Law&#59; Entire Agreement.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">77</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 11.11</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Register&#59; Successors and Assigns.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">77</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 11.12</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Other Transactions.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">78</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 11.13</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Forum Selection and Consent to Jurisdiction.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">78</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 11.14</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Waiver of Jury Trial.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">79</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 11.15</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Interest Rate Limitation.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">79</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 11.16</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Acknowledgment and Consent to Bail-In of Affected Financial Institutions.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">79</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 11.17</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Judgment Currency.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">80</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 11.18</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Specified Repayment Fee.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">80</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 11.19</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">USA PATRIOT Act.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">80</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 11.20</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Erroneous Payments.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">80</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">81</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 11.21</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Reaffirmation.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">81</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE XII GUARANTEE</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">81</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 12.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Guarantee.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">81</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 12.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Obligations Unconditional.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">81</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 12.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Reinstatement.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">82</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 12.4</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subrogation.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">82</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 12.5</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Remedies.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">82</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">83</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 12.6</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Instrument for the Payment of Money.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">83</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 12.7</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Continuing Guarantee.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">83</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SECTION 12.8</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">General Limitation on Guarantee Obligations.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">83</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-v-</font></div></div></div><div id="ia9c3f014b6bf4f3284cc436d2dd7d13c_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SCHEDULES&#58;</font></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:68.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 1.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Key Permits </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 1.2 </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Specified Holders </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 2 </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Loans </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 2.3 </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Funds Flow Schedule </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 6.7(a) </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Litigation </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 6.8 </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Existing Subsidiaries </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 6.10 </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Taxes </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 6.11 </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pension Plans </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 6.15(a) </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Intellectual Property </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 6.15(c)(i) </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Third Party Infringements </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 6.17 </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Material Agreements</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 6.19(a)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regulatory Authorizations</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 6.19(d), (f) and (g)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regulatory Actions</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 6.20 </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Transactions with Affiliates </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 6.24 </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Deposit and Disbursement Accounts </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 6.25 </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Registration Rights Agreements </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 6.26 </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Royalties </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 8.2(c) </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Existing Indebtedness </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 8.3(b) </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Existing Liens </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 8.5(a) </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investments </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 8.12 </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Existing Contracts </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 11.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notice Information</font></td></tr></table></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EXHIBITS&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.587%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit A</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Form of Compliance Certificate </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit B</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Form of Loan Request </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit C</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Form of Perfection Certificate </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit D</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Form of Assignment and Assumption </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit E-1</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Form of U.S. Tax Compliance Certificate (For Foreign Lenders <br>That Are Not Partnerships For U.S. Federal Income Tax Purposes)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit E-2</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Form of U.S. Tax Compliance Certificate (For Foreign Participants<br>That Are Not Partnerships For U.S. Federal Income Tax Purposes)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit E-3</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Form of U.S. Tax Compliance Certificate (For Foreign Participants <br>That Are Partnerships For U.S. Federal Income Tax Purposes)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit E-4</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Form of U.S. Tax Compliance Certificate (For Foreign Lenders<br>That Are Partnerships For U.S. Federal Income Tax Purposes)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit F</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Form of Intercompany Subordination Agreement</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit G</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AWS Agreement</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-i-</font></div></div></div><div id="ia9c3f014b6bf4f3284cc436d2dd7d13c_19"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CREDIT AGREEMENT AND GUARANTY</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CREDIT AGREEMENT AND GUARANTY dated as of June 14, 2024 (as amended, supplemented or otherwise modified from time to time, this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), is by and among HEARTFLOW, INC., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), HEARTFLOW HOLDING, INC., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Holdings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), certain Subsidiaries of Holdings (as defined herein) from time to party hereto, the lenders from time to time party hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and HAYFIN SERVICES LLP, as administrative agent for the Lenders hereunder (in such capacity, together with its successors and assigns in such capacity, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, the Borrower, certain Subsidiaries of Holdings from time to time party thereto, the lenders from time to time party thereto and Hayfin Services LLP, as agent, are parties to that certain Credit Agreement and Guaranty, dated as of January 19, 2021 (as amended by that certain Joinder Agreement, dated as March 3, 2021, by that certain Amendment No. 1 to Credit Agreement and Guaranty, dated as of March 17, 2022, by that certain Amendment No. 2 to Credit Agreement and Guaranty, dated as of September 30, 2022, by that certain Amendment No. 3 to Credit Agreement and Guaranty, dated as of December 15, 2022, by that certain Amendment No. 4 and Waiver to Credit Agreement and Guaranty, dated as of March 2, 2023, by that certain Amendment No. 5 to Credit Agreement and Guaranty, dated as of March 16, 2023, and by that certain Amendment No. 6 to Credit Agreement and Guaranty, dated as of March 29, 2023, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Existing Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, the Borrower has requested that the Lenders extend credit to the Borrower in the form of term loans in an aggregate initial principal amount of $138,137,470.97, the proceeds of which shall be used to (i) refinance the outstanding obligations under the Existing Credit Agreement and (ii) pay certain fees, costs, and expenses incurred in connection with such refinancing and entry into this Agreement, the other Loan Documents and the transactions contemplated hereby&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, the Lenders are willing to extend credit to the Borrower on the terms and subject to the conditions set forth herein.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOW, THEREFORE, the parties hereto agree as follows&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE I</font></div><div style="margin-bottom:10pt;text-align:center;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">DEFINITIONS AND ACCOUNTING TERMS</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The following terms (whether or not underscored) when used in this Agreement, including its preamble and recitals, shall, except where the context otherwise requires, have the following meanings (such meanings to be equally applicable to the singular and plural forms thereof)&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ABR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, for any day, a rate per annum equal to the highest of (i) the Prime Rate in effect on such day, (ii) the Federal Funds Rate in effect on such day plus 0.50% and (iii) Term SOFR for a one-month tenor in effect on such day plus 1.00%. Any change in the ABR due to a change in the Prime Rate, the Federal Funds Rate or Term SOFR shall be effective from and including the effective date of such change in the Prime Rate, the Federal Funds Rate or Term SOFR, respectively.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ABR Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a Loan that bears interest based on the ABR.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ABR Term SOFR Determination Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in the definition of &#8220;Term SOFR&#8221;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Affected Financial Institution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means (a) any EEA Financial Institution or (b) any UK Financial Institution.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; of any Person means any other Person which, directly or indirectly, controls, is controlled by or is under common control with such Person. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; (and its correlatives) by any Person means the power of such Person, directly or indirectly, (i) to vote 10% or more of the Capital Securities (on a fully diluted basis) of another Person which Capital Securities have ordinary voting power for the election of directors, managing members or general partners (as applicable), or (ii) to direct or cause the direction of the management and policies of such other Person (whether by contract or otherwise).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">preamble</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">preamble</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Applicable Margin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, for any day, (i) as to any SOFR Loan, 7.00% per annum or (ii) as to any ABR Loan, 6.00% per annum, as the case may be, in each case as such percentage may be increased pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">3.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that, if the Borrower makes a single voluntary prepayment or repayment of the Loans in an aggregate principal amount equal to or greater than $40,000,000, the source of which is cash received by Holdings in exchange for common equity in Holdings, such percentage shall be decreased by 0.25% per annum.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Assignment and Assumption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means an assignment and assumption entered into by a Lender and an assignee of such Lender in substantially the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Authorized Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, relative to any Credit Party or any of its Subsidiaries, those of its officers, general partners or managing members (as applicable) whose signatures and incumbency shall have been certified to the Agent pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Available Tenor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, as of any date of determination and with respect to the then-current Benchmark, as applicable, (x) if such Benchmark is a term rate, any tenor for such Benchmark (or component thereof) that is or may be used for determining the length of an interest period pursuant to this Agreement or (y) otherwise, any payment period for interest calculated with reference to such Benchmark (or component thereof) that is or may be used for determining any frequency of making payments of interest calculated with reference to such Benchmark, in each case, as of such date and not including, for the avoidance of doubt, any tenor for such Benchmark that is then-removed from the definition of &#8220;Interest Period&#8221; pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.10(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">AWS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Amazon Web Services, Inc.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">AWS Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means that certain AWS Customer Agreement, by and between AWS and the Borrower, attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, as amended or otherwise modified from time to time in accordance with this Agreement.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Bail-In Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the exercise of any Write-Down and Conversion Powers by the applicable Resolution Authority in respect of any liability of an Affected Financial Institution.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Bail-In Legislation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, (i) with respect to any EEA Member Country implementing Article 55 of Directive 2014&#47;59&#47;EU of the European Parliament and of the Council of the European Union, the implementing law, regulation, rule or requirement for such EEA Member Country from time to time which is described in the EU Bail-In Legislation Schedule and (ii) with respect to the United Kingdom,</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Part I of the United Kingdom Banking Act 2009 (as amended from time to time) and any other law, regulation or rule applicable in the United Kingdom relating to the resolution of unsound or failing banks, investment firms or other financial institutions or their affiliates (other than through liquidation, administration or other insolvency proceedings).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Benchmark</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, initially, the Term SOFR Reference Rate&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that if a Benchmark Transition Event has occurred with respect to the Term SOFR Reference Rate or the then-current Benchmark, then &#8220;Benchmark&#8221; means the applicable Benchmark Replacement to the extent that such Benchmark Replacement has replaced such prior benchmark rate pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.10(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Benchmark Replacement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means with respect to any Benchmark Transition Event, the sum of&#58; (i) the alternate benchmark rate that has been selected by the Agent and the Borrower giving due consideration to (x) any selection or recommendation of a replacement benchmark rate or the mechanism for determining such a rate by the Relevant Governmental Body or (y) any evolving or then-prevailing market convention for determining a benchmark rate as a replacement to the then-current Benchmark for Dollar-denominated syndicated credit facilities and (ii) the related Benchmark Replacement Adjustment&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that, if such Benchmark Replacement as so determined would be less than 2.00%, such Benchmark Replacement will be deemed to be 2.00% for the purposes of this Agreement and the other Loan Documents.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Benchmark Replacement Adjustment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any replacement of the then-current Benchmark with an Unadjusted Benchmark Replacement, the spread adjustment, or method for calculating or determining such spread adjustment (which may be a positive or negative value or zero), that has been selected by the Agent giving due consideration to (x) any selection or recommendation of a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement by the Relevant Governmental Body or (y) any evolving or then-prevailing market convention for determining a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement for Dollar-denominated syndicated credit facilities.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Benchmark Replacement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the earliest to occur of the following events with respect to the then-current Benchmark&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;in the case of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of the definition of &#8220;Benchmark Transition Event&#8221;, the later of (i) the date of the public statement or publication of information referenced therein and (ii) the date on which the administrator of such Benchmark (or the published component used in the calculation thereof) permanently or indefinitely ceases to provide all Available Tenors of such Benchmark (or such component thereof)&#59; or</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;in the case of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of the definition of &#8220;Benchmark Transition Event&#8221;, the first date on which such Benchmark (or the published component used in the calculation thereof) has been determined and announced by or on behalf of the administrator of such Benchmark (or such component thereof) or the regulatory supervisor for the administrator of such Benchmark (or such component thereof) to be non-representative or non-compliant with or non-aligned with the International Organization of Securities Commissions (IOSCO) Principles for Financial Benchmarks&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that such non-representativeness, non-compliance or non-alignment will be determined by reference to the most recent statement or publication referenced in such clause (c) and even if any Available Tenor of such Benchmark (or such component thereof) continues to be provided on such date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the avoidance of doubt, the &#8220;Benchmark Replacement Date&#8221; will be deemed to have occurred in the case of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with respect to any Benchmark upon the occurrence of the applicable event or events set forth therein with respect to all then-current Available Tenors of such Benchmark (or the published component used in the calculation thereof).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Benchmark Transition Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the occurrence of one or more of the following events with respect to the then-current Benchmark&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;a public statement or publication of information by or on behalf of the administrator of such Benchmark (or the published component used in the calculation thereof) announcing that such administrator has ceased or will cease to provide all Available Tenors of such Benchmark (or such component thereof), permanently or indefinitely&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that, at the time of such statement or publication, there is no successor administrator that will continue to provide any Available Tenor of such Benchmark (or such component thereof)&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;a public statement or publication of information by the regulatory supervisor for the administrator of such Benchmark (or the published component used in the calculation thereof), the F.R.S. Board, the Federal Reserve Bank of New York, an insolvency official with jurisdiction over the administrator for such Benchmark (or such component), a resolution authority with jurisdiction over the administrator for such Benchmark (or such component) or a court or an entity with similar insolvency or resolution authority over the administrator for such Benchmark (or such component), which states that the administrator of such Benchmark (or such component) has ceased or will cease to provide all Available Tenors of such Benchmark (or such component thereof) permanently or indefinitely&#59; provided that, at the time of such statement or publication, there is no successor administrator that will continue to provide any Available Tenor of such Benchmark (or such component thereof)&#59; or</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;a public statement or publication of information by or on behalf of the administrator of such Benchmark (or the published component used in the calculation thereof) or the regulatory supervisor for the administrator of such Benchmark (or such component thereof) announcing that all Available Tenors of such Benchmark (or such component thereof) are not, or as of a specified future date will not be, representative or in compliance with or aligned with the International Organization of Securities Commissions (IOSCO) Principles for Financial Benchmarks.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the avoidance of doubt, a &#8220;Benchmark Transition Event&#8221; will be deemed to have occurred with respect to any Benchmark if a public statement or publication of information set forth above has occurred with respect to each then-current Available Tenor of such Benchmark (or the published component used in the calculation thereof).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Benchmark Transition Start Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, in the case of a Benchmark Transition Event, the earlier of (i) the applicable Benchmark Replacement Date and (ii) if such Benchmark Transition Event is a public statement or publication of information of a prospective event, the 90th day prior to the expected date of such event as of such public statement or publication of information (or if the expected date of such prospective event is fewer than 90 days after such statement or publication, the date of such statement or publication).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Benchmark Unavailability Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, the period (if any) (i) beginning at the time that a Benchmark Replacement Date has occurred if, at such time, no Benchmark Replacement has replaced the then-current Benchmark for all purposes hereunder and under any Loan Document in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and (ii) ending at the time that a Benchmark Replacement has replaced the then-current Benchmark for all purposes hereunder and under any Loan Document in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Beneficial Ownership Certification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a certification regarding beneficial ownership as required by the Beneficial Ownership Regulation.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Beneficial Ownership Regulation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means 31 C.F.R. &#167; 1010.230.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">preamble</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any day which is neither a Saturday nor Sunday nor a legal holiday on which banks are authorized or required to be closed in New York, New York or London, England.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Capital Expenditures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, for any applicable Fiscal Period for any Person determined on a consolidated basis for such Person and its Subsidiaries in accordance with GAAP, the aggregate amount of (i) all expenditures of such Person and its Subsidiaries for fixed or capital assets made during such Fiscal Period which, in accordance with GAAP, would be classified as capital expenditures and (ii) Capitalized Lease Liabilities incurred by such Person and its Subsidiaries during such Fiscal Period.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Capital Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Person, all shares of, interests or participations in, or other equivalents in respect of (in each case however designated, whether voting or non-voting), such Person&#8217;s capital stock or other equity securities, issued and outstanding as of the date hereof or any time hereafter, including treasury stock.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Capitalized Lease Liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Person, all monetary obligations of such Person and its Subsidiaries under any leasing or similar arrangement which have been (or, in accordance with GAAP, should be) classified as capitalized leases, and for purposes of each Loan Document the amount of such obligations shall be the capitalized amount thereof, determined in accordance with GAAP, and the stated maturity thereof shall be the date of the last payment of rent or any other amount due under such lease prior to the first date upon which such lease may be terminated by the lessee without payment of a premium or a penalty.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Cash Equivalent Investment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, at any time&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;any direct obligation of (or unconditionally guaranteed by) the United States or a state thereof or of the District of Columbia (or any agency or political subdivision thereof, to the extent such obligations are supported by the full faith and credit of the United States or a state thereof or of the District of Columbia) maturing not more than one (1) year after such time&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;commercial paper, or corporate demand notes, maturing not more than 270 days from the date of issue, which is issued by a corporation (other than an Affiliate of a Credit Party or any of its Subsidiaries) organized under the laws of any state of the United States or of the District of Columbia and rated A-1 or higher by S&#38;P or P-1 or higher by Moody&#8217;s&#59; or</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;any certificate of deposit, time deposit or banker&#8217;s acceptance, maturing not more than one year after its date of issuance, which is issued by any bank organized under the laws of the United States (or any state thereof or of the District of Columbia) and which has (x) a credit rating of A2 or higher from Moody&#8217;s or A or higher from S&#38;P and (y) a combined capital and surplus greater than $500,000,000.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;any repurchase agreement entered into with any commercial banking institution meeting the requirements set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> above which (i) is secured by a fully perfected security interest in any obligation of the type described in any of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clauses (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> through </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> above and (ii) has a</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">market value at the time such repurchase agreement is entered into of not less than one-hundred percent (100%) of the repurchase obligation of such commercial banking institution thereunder&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;money market accounts or mutual funds which invest exclusively or substantially in assets satisfying the foregoing requirements&#59; or</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;other short-term liquid investments approved in writing by the Agent.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means and shall be deemed to have occurred if&#58;</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;(i) prior to an IPO or SPAC Transaction, the Specified Holders together fail to own and control, directly or indirectly, beneficially and of record, in the aggregate more than 50% of the total economic interest in the Capital Securities or of the Voting Securities, in each case of Holdings&#59; (ii) after an IPO or SPAC Transaction, any &#8220;person&#8221; or &#8220;group&#8221; (within the meaning of Rule 13d-5 of the Exchange Act as in effect on the date hereof), other than the Specified Holders, shall own, directly or indirectly, beneficially or of record, determined on a fully diluted basis, more than 35% of the Capital Securities of Holdings&#59; (iii) a majority of the seats (other than vacant seats) on the board of directors (or equivalent) of Holdings shall at any time be occupied by persons who were not (x) nominated or appointed by the board of directors (or equivalent) of Holdings, (y) nominated or appointed by directors (or equivalent) so nominated or (z) nominated, designated or appointed by any of the Specified Holders&#59; (iv) the sale, lease, transfer, conveyance or other Disposition, in one or more related transactions, of all or substantially all of the assets of Holdings and its Subsidiaries, taken as a whole, occurs&#59; or (v) Holdings shall cease to directly own, beneficially and of record, 100% of the issued and outstanding Capital Securities of the Borrower&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;the Borrower shall cease to directly or indirectly own, beneficially and of record, 100% of the issued and outstanding Capital Securities of each Subsidiary Guarantor, except as otherwise permitted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; or</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;a Change of Control under and as defined in any </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:line-through">Subordinated Convertible</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:line-through">Promissory Note</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">subordinated convertible promissory note</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">issued pursuant to </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(i) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">that certain Note Purchase Agreement, dated as of September 30, 2022, by and among Holdings and the investors party thereto</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"> or (ii) that certain Note Purchase Agreement, dated as of January 24, 2025, by and among</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Holdings and the investors party thereto</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, the consummation of a SPAC Transaction shall not constitute a Change in Control.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Change in Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the occurrence, after the date of this Agreement, of any of the following&#58; (i) the adoption or taking effect of any law, rule, regulation or treaty, (ii) any change in any law, rule, regulation or treaty or in the administration, interpretation, implementation or application thereof by any Governmental Authority or (iii) the making or issuance of any request, rule, guideline or directive (whether or not having the force of law) by any Governmental Authority&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that, notwithstanding anything herein to the contrary, (x) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith and (y) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to be a &#8220;Change in Law&#8221;, regardless of the date enacted, adopted or issued.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Charged Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.8(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means June 14, 2024.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Closing Date Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the U.S. Internal Revenue Code of 1986, as amended.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Collateral</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any asset or property in which a Lien is purported to be granted under any Loan Document, including future acquired or created assets or property (or all such assets or property, as the context may require)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that Collateral shall include (i) 100% of the Capital Securities of any Foreign Subsidiaries existing as of the Closing Date, except to the extent as reasonably determined by the Borrower after consulting with the Agent, such pledge would reasonably be expected to result in material adverse tax consequences to the Borrower, in which case Borrower shall not be required to pledge voting Capital Securities in excess of 65% of the issued and outstanding voting Capital Securities of such Foreign Subsidiaries (other than a Foreign Subsidiary that becomes a &#8220;Subsidiary Guarantor&#8221; after the Closing Date pursuant to Section 7.8) and (ii) unless provided otherwise in Section 7.8(e), 100% of the Capital Securities of each Foreign Subsidiary acquired or organized after the Closing Date&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that if the Borrower reasonably determines after consulting with the Agent that the continuation of a pledge of 100% of the voting Capital Securities of any Foreign Subsidiary would, as a result of a Change in Law occurring after the original date of such pledge, result in material adverse tax consequences to the Borrower or Holdings, then Collateral shall not include voting Capital Securities in excess of 65% of the issued and outstanding voting Capital Securities of such Foreign Subsidiary and the amount of such Capital Securities pledged under the Loan Documents shall be adjusted accordingly.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a certificate duly completed and executed by an Authorized Officer of Holdings, substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereto, together with such changes thereto as the Agent or the Majority Lenders may from time to time request for the purpose of monitoring compliance with the financial covenants contained herein.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Conforming Changes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to either the use or administration of Term SOFR or the use, administration, adoption or implementation of any Benchmark Replacement, any technical, administrative or operational changes (including changes to the definition of &#8220;ABR&#8221;, the definition of &#8220;Business Day&#8221;, the definition of &#8220;U.S. Government Securities Business Day&#8221;, the definition of &#8220;Interest Period&#8221; or any similar or analogous definition (or the addition of a concept of &#8220;interest period&#8221;), timing and frequency of determining rates and making payments of interest, timing of borrowing requests or prepayment, conversion or continuation notices, the applicability and length of lookback periods, the applicability of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and other technical, administrative or operational matters) that the Agent decides may be appropriate to reflect the adoption and implementation of any such rate or to permit the use and administration thereof by the Agent in a manner substantially consistent with market practice (or, if the Agent decides that adoption of any portion of such market practice is not administratively feasible or if the Agent determines that no market practice for the administration of any such rate exists, in such other manner of administration as the Agent decides is reasonably necessary in connection with the administration of this Agreement and the other Loan Documents).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Connection Income Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Other Connection Taxes that are imposed on or measured by net income (however denominated) or that are franchise Taxes or branch profits Taxes.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Constitutional Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the constitutional documents of each UK Subsidiary Guarantor being certificate of incorporation, certificate of change of name, memorandum of association and articles of association (if applicable).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Contingent Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any agreement, undertaking or arrangement by which any Person guarantees, endorses or otherwise becomes or is contingently liable upon (by direct or indirect agreement, contingent or otherwise, to provide funds for payment, to supply funds to, or otherwise to invest in, a debtor, or otherwise to assure a creditor against loss) the Indebtedness of any other Person (other than by endorsements of instruments in the course of collection), or guarantees the payment of dividends or other distributions upon the Capital Securities of any other Person. The amount of any Person&#8217;s obligation under any Contingent Liability shall (subject to any limitation set forth therein) be deemed to be the outstanding principal amount of the debt, obligation or other liability guaranteed thereby.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified within the definition of &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Controlled Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.12(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Controlled Account Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Controlled Account, an account control agreement (or equivalent) in favor of, and satisfactory in form and substance to, the Agent (acting on the instructions of the Majority Lenders acting reasonably).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Copyright Security Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any Copyright Security Agreement executed and delivered by any Credit Party and&#47;or any of its Subsidiaries, as applicable, substantially in the form of Exhibit E to the Security Agreement, as amended or otherwise modified from time to time.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Copyrights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means all copyrights and rights in copyrightable subject matter, whether statutory or common law, and all exclusive and nonexclusive licenses from third parties or rights to use copyrights owned by third parties, along with any and all (i) renewals, revisions, extensions, derivative works, enhancements, modifications, updates and new releases thereof, (ii) income, royalties, damages, claims and payments now and hereafter due and&#47;or payable with respect thereto, including, without limitation, damages and payments for past, present or future infringements thereof, (iii) rights to sue for past, present and future infringements thereof, and (iv) foreign copyrights and any other rights corresponding thereto throughout the world.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Credit Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, collectively, the Borrower and the Guarantors.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Data Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.16(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Debenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.8(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any Event of Default or any condition, occurrence or event which, after notice or lapse of time or both, would constitute an Event of Default.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Default Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Designated Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any country or territory to the extent that such country or territory is the subject of any Sanction.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Disposition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; (or similar words such as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Dispose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) means any sale, transfer, lease, contribution or other conveyance (including by way of merger) of, or the granting of options, warrants or other rights to, a Credit Party&#8217;s or its Subsidiaries&#8217; assets (including accounts receivable and Capital Securities of</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Subsidiaries) to any other Person (other than to the Borrower or a wholly owned Subsidiary Guarantor) in a single transaction or series of transactions.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Disqualified Capital Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Person, any Capital Security of such Person that, by its terms (or by the terms of any security or other Capital Security into which it is convertible or for which it is exchangeable), or upon the happening of any event or condition (i) matures or is mandatorily redeemable (other than solely for Qualified Capital Securities), including pursuant to a sinking fund obligation or otherwise, (ii) is redeemable at the option of the holder thereof (other than solely for Qualified Capital Securities), in whole or in part, (iii) provides for the scheduled payments of dividends in cash, or (iv) is or becomes convertible into or exchangeable for Indebtedness or any other Capital Securities that would constitute Disqualified Capital Securities, in each case, prior to the date that is one hundred eighty (180) days after the Maturity Date.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Disqualified Institution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means (a) any Person designated by the Borrower as a &#8220;Disqualified Institution&#8221; by written notice delivered to the Agent prior to the Closing Date, in form and substance acceptable to the Agent, and any of such Person&#8217;s Affiliates that are readily identifiable as such by their name and (b) any other Person that is a competitor of the Borrower or any of its Subsidiaries (or an affiliate of such competitor) designated by the Borrower as a &#8220;Disqualified Institution&#8221; by written notice delivered to the Agent from time to time and any of such Person&#8217;s Affiliates that are readily identifiable as such by their names&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that &#8220;Disqualified Institutions&#8221; shall exclude (x) bona fide debt funds and (y) any Person that the Borrower has designated as no longer being a &#8220;Disqualified Institution&#8221; by written notice delivered to the Agent from time to time. The list of Disqualified Institutions shall be made available to any Lender upon written request to the Agent. In no event shall a supplement to the list of Disqualified Institutions apply retroactively to disqualify any Persons that have previously acquired an assignment or participation interest in the Loans that was otherwise permitted prior to such supplementation.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Dollars</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and the sign &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">$</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; mean lawful money of the United States.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Domestic Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a Subsidiary incorporated or organized under the laws of the United States, or any state, commonwealth or other political subdivision thereof (including, for the avoidance of doubt, the District of Columbia).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EEA Financial Institution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means (i) any credit institution or investment firm established in any EEA Member Country which is subject to the supervision of an EEA Resolution Authority, (ii) any entity established in an EEA Member Country which is a parent of an institution described in clause (i) of this definition, or (iii) any financial institution established in an EEA Member Country which is a subsidiary of an institution described in clauses (i) or (ii) of this definition and is subject to consolidated supervision with its parent.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EEA Member Country</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any of the member states of the European Union, Iceland, Liechtenstein, and Norway.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EEA Resolution Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any public administrative authority or any person entrusted with public administrative authority of any EEA Member Country (including any delegee) having responsibility for the resolution of any EEA Financial Institution.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Environmental Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means all federal, state, local or international laws, statutes, rules, regulations, codes, directives, treaties, requirements, ordinances, orders, decrees, judgments, injunctions, notices or binding agreements issued, promulgated or entered into by any Governmental Authority,</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">relating in any way to the environment, natural resources, Hazardous Material or health and safety matters.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Environmental Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any liability, loss, claim, suit, action, investigation, proceeding, damage, commitment or obligation, contingent or otherwise (including any liability for damages, costs of environmental remediation, fines, penalties or indemnities), of or affecting any Credit Party or its Subsidiaries directly or indirectly arising from, in connection with or based upon (i) any Environmental Law or Environmental Permit, (ii) the generation, use, handling, transportation, storage, treatment, recycling, presence, disposal, Release or threatened Release of, or exposure to, any Hazardous Materials or (iii) any contract, agreement, penalty, order, decree, settlement, injunction or other arrangement (including operation of law) pursuant to which liability is assumed, entered into, inherited or imposed with respect to any of the foregoing.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Environmental Permit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.7(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ERISA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Employee Retirement Income Security Act of 1974, as amended, and any successor statute thereto of similar import, together with the regulations thereunder, in each case as in effect from time to time. References to Sections of ERISA also refer to any successor Sections thereto.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ERISA Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any person that for purposes of Title I and Title IV of ERISA and Section 412 of the Code would be deemed to be a single employer with the Borrower, pursuant to Section 414(b), (c), (m) or (o) of the Code or Section 4001 of ERISA.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ERISA Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means (i) any reportable event, as defined in Section 4043 of ERISA, with respect to a Pension Plan, as to which PBGC has not by regulation waived the requirement of Section 4043(a) of ERISA that it be notified of such event, (ii) the filing of a notice of intent to terminate any Pension Plan, if such termination could reasonably be expected to require material additional contributions in order to be considered a standard termination within the meaning of Section 4041(b) of ERISA, the filing under Section 4041(c) of ERISA of a notice of intent to terminate any Pension Plan or the termination of any Pension Plan under Section 4041(c) of ERISA, (iii) the institution of proceedings under Section 4042 of ERISA by the PBGC for the termination of, or the appointment of a trustee to administer, any Pension Plan, (iv) any failure by any Pension Plan to satisfy the minimum funding requirements of Sections 412 and 430 of the Code or Section 302 of ERISA applicable to such Pension Plan, if not waived, (v) the failure to make a required contribution to any Pension Plan that could reasonably be expected to result in the imposition of an encumbrance on a Credit Party, any of its Subsidiaries or any ERISA Affiliate under Section 412 or 430 of the Code, a filing under Section 412 of the Code or Section 302 of ERISA of any request for a minimum funding variance with respect to any Pension Plan or Multiemployer Plan, (vi) an engagement in a non-exempt prohibited transaction within the meaning of Section 4975 of the Code or Section 406 of ERISA with respect to which a Credit Party or any of its Subsidiaries could reasonably be expected to incur liability which could reasonably be expected to have a Material Adverse Effect, (vii) the complete or partial withdrawal of a Credit Party, any of its Subsidiaries or any material ERISA Affiliate from a Multiemployer Plan, (viii) a Credit Party, any of its Subsidiaries or an ERISA Affiliate incurring any material liability under Title IV of ERISA with respect to any Pension Plan (other than premiums due and not delinquent under Section 4007 of ERISA) and (ix) a reasonable determination by an actuary for a Pension Plan that such Pension Plan is in &#8220;at risk&#8221; status (as defined in Section 303(i)(4) of ERISA or Section 430(i)(4) of the Code).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EU Bail-In Legislation Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the EU Bail-In Legislation Schedule published by the Loan Market Association (or any successor person), as in effect from time to time.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Event of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Event of Loss</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any asset of a Credit Party or any of its Subsidiaries, any of the following&#58; (i) any loss, destruction or damage of such asset or (ii) any actual condemnation, seizure or taking, by exercise of the power of eminent domain or otherwise, of such asset, or confiscation of such asset or requisition of the use of such asset.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Securities Exchange Act of 1934, as amended.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Excluded Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in the Security Agreement.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Excluded Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any of the following Taxes imposed on or with respect to a Recipient or required to be withheld or deducted from a payment to a Recipient, (i) Taxes imposed on or measured by net income (however denominated), franchise Taxes, and branch profits Taxes, in each case, (x) imposed as a result of such Recipient being organized under the laws of, or having its principal office or, in the case of any Lender, its applicable lending office located in, the jurisdiction imposing such Tax (or any political subdivision thereof) or (y) that are Other Connection Taxes, (ii) in the case of a Lender, U.S. federal withholding Taxes imposed on amounts payable to or for the account of such Lender with respect to an applicable interest in a Loan pursuant to a law in effect on the date on which (x) such Lender acquires such interest in a Loan or (y) such Lender changes its lending office, except in each case to the extent that, pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, amounts with respect to such Taxes were payable either to such Lender&#8217;s assignor immediately before such Lender became a party hereto or to such Lender immediately before it changed its lending office, (iii) Taxes attributable to such Recipient&#8217;s failure to comply with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.3(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and (iv) any withholding Taxes imposed under FATCA.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Existing Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">recitals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">FATCA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Sections 1471 through 1474 of the Code, as of the date of this Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof, any agreements entered into pursuant to Section 1471(b)(1) of the Code and any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental agreement, treaty or convention among Governmental Authorities and implementing such Sections of the Code.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Federal Funds Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, for any day, the greater of (i) the rate calculated by the Federal Reserve Bank of New York based on such day&#8217;s Federal funds transactions by depositary institutions (as determined in such manner as the Federal Reserve Bank of New York shall set forth on its public website from time to time) and published on the next succeeding Business Day by the Federal Reserve Bank of New York as the Federal funds effective rate and (ii) 0%.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the U.S. Food and Drug Administration and any successor entity.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">FD&#38;C Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the U.S. Federal Food, Drug and Cosmetic Act of 1938 (or any successor thereto), as amended from time to time, and the rules and regulations promulgated thereunder.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Fee Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means that certain Fee Letter, dated as of the date hereof, by and among the Borrower, the Agent and the Lenders, as amended or otherwise modified from time to time.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">FFRct</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a coronary vascular physiologic simulation software prescription device that provides simulated functional assessment of blood flow in the coronary vascular system using data extracted from medical device imaging to solve algorithms and yield simulated metrics of physiologic</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">information (e.g., blood flow, coronary flow reserve, fractional flow reserve, myocardial perfusion), which is intended to generate results for use and review by a qualified clinician, de novo 510(k) clearance of which was received on November 26, 2014 for version 1.4 of the HeartFlow Analysis (DEN130045), 510(k) clearance for version 2.x of the Heartflow Analysis was received in January 2016 (510(k) No.&#58; K152733), and 510(k) clearance for a modification to the intended use language in August 2016 (510(k) No.&#58; K161772). Additional clearances were received for a strategic architecture scope change in December 2018 (510(k) No.&#58; K182035), and for the addition of Planner capabilities in August 2019 (510(k) No.&#58; K190925). The Borrower submitted its version 3.x for FDA review in November 2020 and received FDA clearance on January 8, 2021 (510(k) No.&#58; K203329).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#8220;First Amendment&#8221; means that certain Amendment No. 1 to Credit Agreement and Guaranty,</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">dated as of the First Amendment Effective Date, by and among the Borrower, Holdings, the Lenders party</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">thereto, and the Agent.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#8220;First Amendment Effective Date&#8221; means January 24, 2025.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Fiscal Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, as applicable, a Fiscal Quarter or a Fiscal Year.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Fiscal Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a quarter ending on the last day of March, June, September or December.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Fiscal Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any period of twelve consecutive calendar months ending on December 31&#59; references to a Fiscal Year with a number corresponding to any calendar year (e.g., the &#8220;2020 Fiscal Year&#8221;) refer to the Fiscal Year ending December 31 of such calendar year.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Excluded Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means at any date of determination, each wholly owned Foreign Subsidiary (together with its Subsidiaries) whose (i) Net Sales during the applicable Measurement Period were equal to or less than 15.0% of the consolidated Net Sales of Holdings and its Subsidiaries for such period and (ii) assets during the applicable Measurement Period were equal to or less than 15.0% of the consolidated assets of Holdings and its Subsidiaries for such period, in each case determined in accordance with GAAP&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that, for such Measurement Period, the Foreign Excluded Subsidiaries shall not collectively have (x) Net Sales during such Measurement Period equal to or greater than 20.0% of the consolidated Net Sales of Holdings and its Subsidiaries for such period or (y) assets during such Measurement Period equal to or greater than 20.0% of the consolidated assets of Holdings and its Subsidiaries for such period&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that no Subsidiary that owns any Material Intellectual Property or is party to a Material Agreement may be a Foreign Excluded Subsidiary.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a Lender that is not a U.S. Person.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any Subsidiary that is not a Domestic Subsidiary.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">F.R.S. Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Board of Governors of the Federal Reserve System or any successor thereto.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Funded Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; of any Person means Indebtedness of the type described in clauses (a) and (c) of the definition of Indebtedness, and all Contingent Liabilities of such Person in respect of any such Funded Indebtedness.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any national, supranational, federal, state, county, provincial, local, municipal or other government or political subdivision thereof (including any Regulatory Authority), whether domestic or foreign, and any agency, authority, commission, ministry,</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">instrumentality, regulatory body, court, tribunal, arbitrator, central bank or other Person exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to any such government&#59; any entity that contracts with a governmental entity to administer or assist in the administration of a governmental program (including any Medicare or Medicaid administrative contractors)&#59; or any arbitrator with authority to bind a party at law.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Guaranteed Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Guarantors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, collectively, Holdings and each Subsidiary Guarantor.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Hazardous Material</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any material, substance, chemical, mixture or waste which is capable of damaging or causing harm to any living organism, the environment or natural resources, including all explosive, special, hazardous, polluting, toxic, industrial, dangerous, biohazardous, medical, infectious or radioactive substances, materials or wastes, noise, odor, electricity or heat, and including petroleum or petroleum products, byproducts or distillates, asbestos or asbestos-containing materials, urea formaldehyde, polychlorinated biphenyls, radon gas, ozone-depleting substances, greenhouse gases, and all other substances or wastes of any nature regulated pursuant to any Environmental Law or as to which any Governmental Authority requires investigation, reporting or remedial action.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Healthcare Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means all applicable federal, state or local laws that govern the sales, marketing, promotion, distribution, research, development, testing, current good manufacturing practices (cGMPs) and quality system requirements, handling, packaging, labeling, storage, advertising, import, export, or any other use of the Products including, but not limited to, the FD&#38;C Act&#59; the Public Health Service Act&#59; the federal False Claims Act&#59; the federal Anti-Kickback Statute&#59; the Anti-Inducement Law&#59; the Stark Law&#59; privacy and data security laws including without limitation the Health Insurance Portability and Accountability Act of 1996, as amended, inclusive of the Health Information Technology for Economic and Clinical Health Act (HITECH) and all implementing regulations (HIPAA)&#59; the Medicare Program (Title XVIII of the Social Security Act)&#59; the Medicaid Program (Title XIX of the Social Security Act)&#59; laws pertaining to the corporate practice of medicine or other healthcare professionals&#59; laws pertaining to deceptive trade practices&#59; any and all Permits required under Healthcare Laws&#59; all applicable rules, regulations and licensing requirements of applicable state agencies&#59; any similar state and local laws that address the subject matter of the foregoing&#59; laws and regulations pertaining to federal and state relief programs related to COVID-19&#59; the Federal Trade Commission Act&#59; and all other analogous laws to the foregoing within any other U.S. or foreign or supranational jurisdiction, and applicable rules and regulations issued thereunder (including, without limitation, 21 C.F.R. Parts 801, 803, 806, 807, 812, and 820).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Hedging Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any interest rate, foreign currency, commodity, credit or equity swap, collar, cap, floor or forward rate agreement, or other agreement or arrangement designed to protect against fluctuations in interest rates or currency, commodity or equity values (including any option with respect to any of the foregoing and any combination of the foregoing agreements or arrangements), and any confirmation executed in connection with any such agreement or arrangement.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Hedging Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Person, all liabilities of such Person under currency exchange agreements, interest rate swap agreements, interest rate cap agreements and interest rate collar agreements, and all other agreements or arrangements designed to protect such Person against fluctuations in interest rates or currency exchange rates.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">herein</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">hereof</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">hereto</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">hereunder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and similar terms contained in any Loan Document refer to such Loan Document as a whole and not to any particular Section, paragraph or provision of such Loan Document.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Holdings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">preamble</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Immaterial Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means at any date of determination, each wholly owned Subsidiary (together with its Subsidiaries) whose (i) Net Sales during the applicable Measurement Period were equal to or less than 5.0% of the consolidated Net Sales of Holdings and its Subsidiaries for such period and (ii) assets during the applicable Measurement Period were equal to or less than 5.0% of the consolidated assets of Holdings and its Subsidiaries for such period, in each case determined in accordance with GAAP&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that, for such Measurement Period, the Immaterial Subsidiaries shall not collectively have (x) Net Sales during such Measurement Period equal to or greater than 10.0% of the consolidated Net Sales of Holdings and its Subsidiaries for such period or (y) assets during such Measurement Period equal to or greater than 10.0% of the consolidated assets of Holdings and its Subsidiaries for such period&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that no Subsidiary that owns any Material Intellectual Property may be an Immaterial Subsidiary.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Impermissible Qualification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any qualification or exception to the opinion or certification of any independent public accountant as to any financial statement of a Credit Party or any of its Subsidiaries (i) which is of a &#8220;going concern&#8221; or similar nature (other than any such qualification arising from the Loans hereunder maturing on the Maturity Date or by reason of any actual or anticipated financial covenant breach hereunder) or (ii) which relates to the limited scope of examination of matters relevant to such financial statement.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; of any Person means&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;all obligations of such Person for borrowed money or advances and all obligations of such Person evidenced by bonds, debentures, notes or similar instruments&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;all obligations, contingent or otherwise, relative to the face amount of all letters of credit, whether or not drawn, and banker&#8217;s acceptances issued for the account of such Person&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;all Capitalized Lease Liabilities of such Person&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;net Hedging Obligations of such Person and all obligations of such Person arising under Synthetic Leases&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;all obligations issued, undertaken or assumed as the deferred purchase price of property or services, including earn outs, purchase price adjustments and seller notes in connection with acquisitions permitted hereunder (to the extent due and payable and included as a liability on the balance sheet in accordance with GAAP) (other than trade payables entered into in the ordinary course of business)&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;whether or not so included as liabilities in accordance with GAAP, all obligations of such Person to pay the deferred purchase price of property or services (excluding trade accounts payable in the ordinary course of business which are not overdue for a period of more than 90 days or, if overdue for more than 90 days, as to which a dispute exists and adequate reserves in conformity with GAAP have been established on the books of such Person), and indebtedness secured by (or for which the holder of such indebtedness has an existing right, contingent or otherwise, to be secured by) a Lien on property owned or being acquired by such Person (including indebtedness arising under</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">conditional sales or other title retention agreements), whether or not such indebtedness shall have been assumed by such Person or is limited in recourse&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;any Disqualified Capital Securities&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:73pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;all Contingent Liabilities of such Person in respect of any of the foregoing clauses (a) through (g) inclusive.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Indebtedness of any Person shall include the Indebtedness of any other Person (including any partnership in which such Person is a general partner) to the extent such Person is liable therefor as a result of such Person&#8217;s ownership interest in or other relationship with such Person, except to the extent the terms of such Indebtedness expressly provide that such Person is not liable therefor.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnified Liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnified Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnified Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means (a) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any obligation of any Credit Party under any Loan Document and (b) to the extent not otherwise described in (a), Other Taxes.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means all (i) Patents, (ii) Trademarks, (iii) Copyrights and other works of authorship (registered or unregistered), and all applications, registrations and renewals therefor, (iv) computer software, databases, data and documentation, (v) Trade Secrets and confidential business information, including know-how, inventions, manufacturing processes and techniques, research and development information, financial, marketing and business data, databases pricing and cost information, business, finance and marketing plans, customer and prospective customer lists and information, and supplier and prospective supplier lists and information, (vi) other intellectual property or similar proprietary rights, (vii) copies and tangible embodiments of any of the foregoing (in whatever form or medium) and (viii) any and all improvements to any of the foregoing.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Intercompany Subordination Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a subordination agreement to be executed and delivered by each Credit Party and any Subsidiaries thereof, pursuant to which all obligations in respect of any Indebtedness for borrowed money (or equivalent) owing between or among any party to such subordination agreement shall be subordinated to the prior Payment in Full of all Obligations, such agreement to be in substantially the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit F</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or such other form reasonably acceptable to the Agent.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Interest Payment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, (i) as to any ABR Loan, (a) the last Business Day of each March, June, September and December and (b) the Maturity Date and (ii) as to any SOFR Loan, (a) the last day of each Interest Period therefor and, in the case of any Interest Period of more than three months&#8217; duration, each day prior to the last day of such Interest Period that occurs at three-month intervals after the first day of such Interest Period, and (b) the Maturity Date.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Interest Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, (i) initially, as to any Loan, the period beginning on (and including) the date of which the Loans were made and ending on (and including) the last day of the calendar quarter in which the Loans were made and (ii) thereafter, as to any Loan, the period commencing on the date of such Loan and ending on the numerically corresponding day in the calendar month that is three months thereafter (subject to the availability thereof), as specified in the applicable Loan Request&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that (i) if any Interest Period would end on a day other than a Business Day, such Interest Period shall be extended to the next succeeding Business Day unless such next succeeding Business Day would fall in</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the next calendar month, in which case such Interest Period shall end on the next preceding Business Day, (ii) any Interest Period that commences on the last Business Day of a calendar month (or on a day for which there is no numerically corresponding day in the last calendar month of such Interest Period) shall end on the last Business Day of the last calendar month of such Interest Period, (iii) no Interest Period shall extend beyond the Maturity Date and (iv) no tenor that has been removed from this definition pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.10(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall be available for specification in such Loan Request. For purposes hereof, the date of a Loan initially shall be the date on which such Loan is made and thereafter shall be the effective date of the most recent conversion or continuation of such Loan.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Investment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, relative to any Person, (i) any loan, advance or extension of credit made by such Person to any other Person, including the purchase by such Person of any bonds, notes, debentures or other debt securities of any other Person, (ii) Contingent Liabilities in favor of any other Person and (iii) any Capital Securities held by such Person in any other Person. The amount of any Investment shall be the original principal or capital amount thereof less all returns of principal or equity thereon and shall, if made by the transfer or exchange of property other than cash, be deemed to have been made in an original principal or capital amount equal to the fair market value of such property at the time of such Investment.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">IPO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means an underwritten initial public offering of common Capital Securities of Holdings pursuant to an effective registration statement filed with the SEC in accordance with the Securities Act of 1933, as amended.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Key Permits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means all material Permits in favor of the Credit Parties relating to the Products (including all Regulatory Authorizations), including, for the avoidance of doubt, all current and future permits materially relating to (i) FFRct in the United States and (ii) Plaque and Roadmap, in the case of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, from and after the date on which Plaque and Roadmap collectively contribute 30% or more of Net Sales in the aggregate. As of the Closing Date, the Key Permits are as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">preamble</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Lien</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any security interest, mortgage, pledge, hypothecation, assignment, deposit arrangement, encumbrance, lien (statutory or otherwise), charge against or interest in property, or other priority or preferential arrangement of any kind or nature whatsoever, to secure payment of a debt or performance of an obligation.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Liquidity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, at any time, unrestricted, unencumbered cash and Cash Equivalent Investments in one or more Controlled Accounts that is free and clear of all Liens, other than Liens granted under the Loan Documents in favor of the Agent, for the benefit of the Secured Parties.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Liquidity Covenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Liquidity Cure Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Liquidity Cure Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the term loans made on the Closing Date pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in an aggregate principal amount of $138,137,470.97</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:line-through">.</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">, which such principal amount was reduced to</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">$117,137,470.97 on the First Amendment Effective Date in connection with the First Principal</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Conversion (as defined in the First Amendment) and will be further reduced to $115,137,470.97 on the</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Subsequent Closing Date (solely to the extent the Second Principal Conversion (as defined in the First</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment) occurs in accordance with the terms of the First Amendment) in connection with the Second</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Principal Conversion.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Loan Commitment Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(i) as of the Closing Date,</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$138,137,470.97</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:line-through">.</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">, (ii) as of the</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">First Amendment Effective Date, $117,137,470.97 and (iii) as of the Subsequent Closing Date,</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">$115,137,470.97 (solely to the extent the Second Principal Conversion (as defined in the First</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment) occurs in accordance with the terms of the First Amendment).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Loan Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, collectively, this Agreement (as subsequently amended or otherwise modified), the Notes, the Fee Letter, the Security Agreement, the Debenture, any Mortgages, the Intercompany Subordination Agreement, the Copyright Security Agreement, the Patent Security Agreement, the Trademark Security Agreement, any Controlled Account Agreement and each other agreement pursuant to which any of the Agent or any of the other Secured Parties is granted a Lien to secure the Obligations, and each other agreement, certificate, document or instrument delivered in connection with any Loan Document.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Loan Request</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a Loan request and certificate duly executed by an Authorized Officer of the Borrower substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereto.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Majority Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, at any time, Lenders holding more than 50% of the then aggregate unpaid principal amount of the Loans.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Material Adverse Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a material adverse effect on (i) the business, condition (financial or otherwise), operations, performance or properties of any Credit Party and each of its Subsidiaries, taken as a whole, (ii) the rights and remedies of the Agent or any Lender under any Loan Document, or (iii) the ability of any Credit Party or any of its Subsidiaries to perform their respective Obligations under any Loan Document.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Material Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means (i) each contract or agreement to which a Credit Party or any of its Subsidiaries is a party, the loss of which would result in the loss of 30% or more of Net Sales in the aggregate&#59; (ii) the AWS Agreement or any replacement cloud hosting agreement as contemplated in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and (iii) all other contracts or agreements to which a Credit Party is a party, individually or in the aggregate, that if breached or terminated could reasonably be expected to result in a Material Adverse Effect.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Material Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any Intellectual Property owned by, licensed to or otherwise held by any Credit Party or any of its Subsidiaries (including, for the avoidance of doubt, the Stanford Licenses), whether currently owned or acquired, developed, licensed or obtained after the date hereof (i) reasonably required for the business and&#47;or commercialization of FFRct or otherwise materially relating to FFRct, (ii) the loss of which could reasonably be expected to result in a Material Adverse Effect, or (iii) that has a fair market value in excess of $5,000,000.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Maturity Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means June 14, 2028.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Measurement Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any period of four (4) consecutive Fiscal Quarters of Holdings.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Moody&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Moody&#8217;s Investors Service, Inc. and its successors.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Mortgage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means each mortgage, deed of trust or other agreement which conveys or evidences a Lien in favor of the Agent, for the benefit of the Secured Parties, on real property of a Credit Party, including any amendment, restatement, modification or supplement thereto.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Mortgage Instruments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means such title reports, title insurance, flood certifications and flood insurance, opinions of counsel, surveys, appraisals and environmental reports and other similar information and related certifications as are reasonably requested by, and in form and substance reasonably acceptable to, the Agent from time to time.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Multiemployer Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a &#8220;multiemployer plan&#8221; (as defined in Section 4001(a)(3) of ERISA) that is subject to Title IV of ERISA contributed to for any employees of a Credit Party, any of its Subsidiaries or any ERISA Affiliate.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Net Cash Proceeds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means when used in respect of (i) any Disposition, (ii) the receipt of any proceeds in connection with any Event of Loss suffered, or (iii) the receipt of any proceeds in connection with an IPO, in the case of clauses (i) and (ii), by a Credit Party or any of its Subsidiaries, and, in the case of clause (iii), by Holdings or any direct or indirect holding company of Holdings, the gross proceeds in cash or Cash Equivalent Investments received by such Person (excluding, in connection with any Disposition, any portion of such proceeds deposited in an escrow account pursuant to the documentation related thereto but including such proceeds subsequently received in respect of noncash consideration initially received and amounts initially placed in escrow that subsequently become available) from such Disposition, Event of Loss or IPO, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">minus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, without duplication, (a) all direct costs and expenses incurred or to be incurred (including sales, commissions and legal, accounting and investment banking fees, commissions and expenses), (b) all federal, state, local and foreign Taxes assessed or to be assessed (if any), in connection therewith, (c) in connection with any Disposition or Event of Loss, amounts required to be applied to the repayment of any Permitted Indebtedness (together with any interest thereon, premium or penalty and any other amount payable with respect thereto) secured by a Permitted Lien that has priority over the Lien, if any, of the Agent on the asset subject to such Disposition or Event of Loss, (d) in connection with any Disposition, reserves for purchase price adjustments and retained liabilities reasonably expected to be payable by Holdings or any Subsidiary in connection therewith, to the extent such reserves have been established in accordance with GAAP&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that upon the final determination of the amount paid in respect of such purchase price adjustments and retained liabilities, if the actual amount of purchase price adjustments and retained liabilities paid is less than such reserves, the difference shall, at such time, constitute Net Cash Proceeds, and (e) with respect to any Event of Loss, all money actually applied within one hundred eighty (180) days to replace the assets in question or to repair or reconstruct damaged property or property affected by loss, destruction, damage, condemnation, confiscation, requisition, seizure or taking.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Net Income</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, for any applicable Fiscal Period for any Person determined on a consolidated basis for such Person and its Subsidiaries in accordance with GAAP, the aggregate of all amounts (exclusive of all amounts in respect of any extraordinary gains but including extraordinary losses) which would be included as net income on the consolidated financial statements of such Person and its Subsidiaries for such Fiscal Period.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, for any applicable Fiscal Period, the revenue of the Credit Parties and their Subsidiaries from the sale of Products (current or future to the extent the revenue is actually earned and recognized during such Fiscal Period) during such Fiscal Period, determined on a consolidated basis in accordance with GAAP.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a promissory note of the Borrower payable to a Lender (as such promissory note may be amended, endorsed or otherwise modified from time to time), evidencing the aggregate Indebtedness of the Borrower to such Lender resulting from the outstanding amount of the Loans, and also means all other promissory notes accepted from time to time in substitution therefor or renewal thereof.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means all obligations (monetary or otherwise, whether absolute or contingent, matured or unmatured) of any Credit Party or any of its Subsidiaries arising under or in connection with a Loan Document and the principal of and premium, if any, and interest (including interest accruing during the pendency of any proceeding of the type described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, whether or not allowed in such proceeding) on the Loans.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">OFAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Office of Foreign Assets Control of the United States Department of the Treasury.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Organic Document</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, relative to any Credit Party or any of its Subsidiaries, its certificate of incorporation, by-laws, certificate of partnership, partnership agreement, certificate of formation, limited liability agreement, operating agreement and all shareholder agreements, voting trusts and similar arrangements applicable to such Credit Party&#8217;s or any of its Subsidiaries&#8217; Capital Securities and, with respect to any UK Subsidiary Guarantor, the Constitutional Documents of such UK Subsidiary Guarantor.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Other Administrative Proceeding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any administrative proceeding relating to a dispute involving a patent office or other relevant intellectual property registry which relates to validity, revocation, ownership or enforceability of the relevant Intellectual Property.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Other Connection Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Recipient, Taxes imposed as a result of a present or former connection between such Recipient and the jurisdiction imposing such Tax (other than connections arising from such Recipient having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in any Loan or Loan Document).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Other Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means all present or future stamp, court or documentary, intangible, recording, filing or similar Taxes that arise from any payment made under, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Loan Document, except any such Taxes that are Other Connection Taxes imposed with respect to an assignment.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Participant Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.11(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any patent and patent application, including any divisions, continuations, continuations in-part, provisionals, continued prosecution applications, substitutions, reissues, reexaminations, renewals, extensions, restorations, supplemental protection certificates and other additions in connection therewith, whether in or related to the United States or any foreign country or other jurisdiction.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Patent Security Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any Patent Security Agreement executed and delivered by any Credit Party and&#47;or any of its Subsidiaries, as applicable, in substantially the form of Exhibit C to the Security Agreement, as amended or otherwise modified from time to time.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Patriot Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the USA PATRIOT Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Payment in Full</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the entire principal amount of the Loans, interest thereon and all other Obligations, including all applicable Specified Repayment Fees and fees set forth in the Fee Letter, shall</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">have been indefeasibly paid in full in cash (other than inchoate indemnification, expense reimbursement obligations and other contingent obligations for which no claim has been asserted).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">PBGC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Pension Benefit Guaranty Corporation, or any entity succeeding to all or any of its functions under ERISA.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Pension Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a &#8220;pension plan&#8221;, as such term is defined in Section 3(2) of ERISA, which is subject to Title IV of ERISA (other than a Multiemployer Plan), to which a Credit Party, any of its Subsidiaries or any ERISA Affiliate sponsors, contributes to, or provides benefits under, or has any obligation to contribute or provide benefits under, and to which a Credit Party or any of its Subsidiaries or ERISA Affiliate could reasonably be expected to have liability, including any liability by reason of having been a substantial employer under Section 4063 of ERISA at any time during the preceding five years, or by reason of being deemed to be a contributing sponsor under Section 4069 of ERISA.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Perfection Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a certificate duly completed and executed by an Authorized Officer of the Borrower, substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereto, together with such changes thereto as the Agent or the Majority Lenders may from time to time request.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Periodic Term SOFR Determination Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in the definition of &#8220;Term SOFR&#8221;.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Permits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means all permits, licenses, registrations, certificates, orders, approvals, authorizations, consents, waivers, franchises, variances and similar rights issued by or obtained from any Governmental Authority or any other Person, including, without limitation, those relating to Environmental Laws and Healthcare Laws.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Permitted Disposition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any of the following&#58; (i) Dispositions of inventory in the ordinary course of business, (ii) Dispositions of obsolete, damaged, worn out or surplus property in the ordinary course of business, (iii) licenses, sublicenses or similar agreements that are permitted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;8.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, (iv) any issuance, offer, sale, transfer or other Disposition of Qualified Capital Securities of Holdings, (v) the sale, lease, sublease or transfer of property or assets (A) from one Credit Party to another Credit Party, (B) from a Subsidiary that is not a Credit Party to another Subsidiary that is not a Credit Party or to any Credit Party or (C) from a Credit Party to a Subsidiary that is not a Credit Party, in an aggregate amount under this clause (C), together with the aggregate amount of Investments made pursuant to Section 8.5(g), not to exceed $2,000,000, (vi) Dispositions of accounts receivable in connection with the collection or compromise thereof in the ordinary course of business (other than in connection with financing transactions) and (vii) other Dispositions that (x) do not include Material Intellectual Property or Capital Securities with respect to Subsidiaries that directly or indirectly own, or hold a license in respect of, Material Intellectual Property and (y) when taken together with all other Dispositions made during the preceding period of 12 consecutive months pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, do not exceed $2,500,000 in the aggregate.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Permitted Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Permitted Investments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Permitted Lien</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any natural person, corporation, limited liability company, partnership, joint venture, association, trust or unincorporated organization, Governmental Authority or any other legal entity, whether acting in an individual, fiduciary or other capacity.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Personal Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means all data relating to one or more individual(s) that is personally identifying (i.e., data that identifies an individual or, in combination with any other information or data available to Holdings or its Subsidiaries, is capable of identifying an individual) or capable of identifying a specific device or non-personally identifying, including, without limitation, aggregate or de-identified data and data collected automatically, including data collected through a mobile or other electronic device.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">PIK Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.10(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">PIK Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.10(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Plaque</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the HeartFlow product that provides plaque identification, characterization, and visualization, and is presented with the FFRct model, FDA 510(k) approval for which was received on October 14, 2022 (510(k) No.&#58; K213857).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Prime Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the rate of interest per annum last quoted by The Wall Street Journal as the &#8220;Prime Rate&#8221; in the U.S. or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the F.R.S. Board in Federal Reserve Statistical Release H.15 (519) (Selected Interest Rates) as the &#8220;bank prime loan&#8221; rate or, if such rate is no longer quoted therein, any similar rate quoted therein (as determined by the Agent) or any similar release by the F.R.S. Board (as determined by the Agent). Any change in the Prime Rate shall take effect at the opening of business on the day such change is publicly announced or quoted as being effective.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Privacy and Data Security Policies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.16(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Privacy Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.16(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Pro Rata Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Lender, the percentage (expressed as a decimal and carried out to the ninth decimal place) obtained by dividing (x) the aggregate outstanding principal amount of Loans made hereunder by such Lender, by (y) the aggregate outstanding principal amount of all Loans made hereunder by all Lenders, in each case subject to adjustment as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Pro Rata Share of each Lender in respect of the Loans is set forth opposite the name of such Lender on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> under the caption &#8220;Pro Rata Shares&#8221; or in the Assignment and Assumption pursuant to which such Lender becomes a party hereto, as applicable.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any current product developed, manufactured, licensed, marketed, sold, distributed, or otherwise commercialized by any Credit Party (other than Holdings), including any such product in development or which may be developed.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Product Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means each agreement, license, document, instrument, interest (equity or otherwise) or the like under which one or more Persons grants or receives any right, title or interest with respect to any Product Development and Commercialization Activities in respect of one or more Products specified therein, or receives or is granted the right to exclude any third parties from engaging in any Product Development and Commercialization Activities with respect thereto, including each contract or agreement with suppliers, manufacturers, distributors, clinical research organizations, wholesalers, pharmacies or with any other Person related to any such entity.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Product Development and Commercialization Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Product, any combination of research, development, manufacture, importation, exportation, use, sale, storage, design, labeling, marketing, promotion, supply, distribution, testing, packaging, purchasing or other commercialization activities, receipt of payment in respect of any of the foregoing, or like activities the purpose of which is to commercially exploit such Product.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Prohibited Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any bribe, rebate, payoff, influence payment, kickback or other payment or gift of money or anything of value (including meals or entertainment) to any officer, employee or ceremonial office holder of any government or instrumentality thereof, political party or supra-national organization (such as the United Nations), any political candidate, any royal family member or any other person who is connected or associated personally with any of the foregoing that is prohibited under any applicable law or regulation or otherwise for the purpose of influencing any act or decision of such payee in his official capacity, inducing such payee to do or omit to do any act in violation of his lawful duty, securing any improper advantage or inducing such payee to use his influence with a government or instrumentality thereof to affect or influence any act or decision of such government or instrumentality.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Qualified Capital Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Person, any Capital Security of such Person that is not a Disqualified Capital Security.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Recipient</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Agent or any Lender, as applicable.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any Governmental Authority that is concerned with or has regulatory oversight with respect to the use, control, safety, efficacy, reliability, manufacturing, labeling, packaging, handling, storage, marketing, advertising, promotion, distribution, sale or other Product Development and Commercialization Activities relating to any Product of any Credit Party or any of its Subsidiaries, including the FDA and all equivalents of such agency in other jurisdictions and Standard Bodies.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Authorizations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any and all clearances, approvals, and other forms of authorization, and related internal documentation where applicable, forming the basis for distribution of products (including without limitation, 510(k) clearances, internal decision documentation under FDA guidance on changes to 510(k)-cleared products, and where applicable supplements and amendments, governmental price and reimbursement approvals and approvals of applications for regulatory exclusivity), licenses, registrations, or authorizations of any Governmental Authority necessary for the manufacture, development, testing, distribution, use, storage, import, export, transport, promotion, marketing, sale, or other commercialization of a Product in any country or jurisdiction, and including, with respect to the Products, that each Product has been and is lawfully marketed by the Borrower in conformity and compliance with all applicable laws (including Healthcare Laws), regulations, enforcement policies, and similar pronouncements of any Regulatory Authority respecting any Product of the Borrower.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Related Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Person, such Person&#8217;s Affiliates and the partners, directors, officers, employees, agents, trustees, administrators, managers, advisors and representatives of such Person and such Person&#8217;s Affiliate.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any releasing, disposing, discharging, injecting, spilling, leaking, leaching, pumping, pouring, dumping, depositing, emitting, escaping, emptying, seeping, dispersal, migrating or placing, including movement through, into or upon the environment or any natural or man-made structure.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Relevant Governmental Body</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the F.R.S. Board or the Federal Reserve Bank of New York, or a committee officially endorsed or convened by the F.R.S. Board or the Federal Reserve Bank of New York, or any successor thereto.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Resignation Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.6(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Resolution Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means an EEA Resolution Authority or, with respect to any UK Financial Institution, a UK Resolution Authority.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Restricted Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means (i) the declaration or payment of any dividend (other than dividends payable solely in Capital Securities of a Credit Party or any of its Subsidiaries) on, or the making of any payment or distribution on account of, or setting apart assets for a sinking or other analogous fund for the purchase, redemption, defeasance, retirement or other acquisition of, any class of Capital Securities of a Credit Party or any of its Subsidiaries or any warrants, options or other right or obligation to purchase or acquire any such Capital Securities, whether now or hereafter outstanding or (ii) the making of any other distribution in respect of such Capital Securities, in each case either directly or indirectly, whether in cash, property or obligations of a Credit Party or any of its Subsidiaries or otherwise.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Roadmap</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the HeartFlow product that provides coronary vascular physiologic simulation, FDA 510(k) approval for which was received on October 14, 2022 (510(k) No.&#58; K213857).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">S&#38;P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Standard &#38; Poor&#8217;s Financial Services LLC, a subsidiary of S&#38;P Global Inc., and its successors.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sanction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any international economic sanction administered or enforced by the United States Government (including, without limitation, OFAC), the United Nations Security Council, the European Union or its Member States, Her Majesty&#8217;s Treasury or other relevant sanctions authority.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sanctioned Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any Person that is a target of Sanctions, including without limitation, a Person that is (i) listed on OFAC&#8217;s Specially Designated Nationals and Blocked Persons List, (ii) listed on OFAC&#8217;s Consolidated Non-SDN List, (iii) a legal entity that is deemed by OFAC to be a Sanctions target based on the ownership of such legal entity by Sanctioned Peron(s), or (iv) a Person that is a Sanctions target pursuant to any list-based, territorial or country-based Sanctions program of a Governmental Authority.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Securities and Exchange Commission.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Secured Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, collectively, the Agent and each of the Lenders.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Security Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Security Agreement, dated as of the date hereof, by and among the Borrower, the Subsidiary Guarantors and the Agent, as amended or otherwise modified from time to time.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">SOFR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a rate equal to the secured overnight financing rate as administered by the SOFR Administrator.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">SOFR Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Federal Reserve Bank of New York (or a successor administrator of the secured overnight financing rate).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">SOFR Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a Loan that bears interest at a rate based on Term SOFR, other than pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of the definition of &#8220;ABR&#8221;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Solvent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means, (x) with respect to the Credit Parties and their Subsidiaries on a particular date, that on such date (i) the fair value of the property of the Credit Parties and their Subsidiaries on a consolidated basis is greater than the total amount of liabilities, including Contingent Liabilities, of the Credit Parties and their Subsidiaries on a consolidated basis, (ii) the present fair saleable value of the assets of the Credit Parties and their Subsidiaries on a consolidated basis is not less than the amount that will be required to pay the probable liability of the Credit Parties and their Subsidiaries on a consolidated basis on its debts as they become absolute and matured, (iii) &#91;reserved&#93;, (iv) the Credit Parties and their Subsidiaries on a consolidated basis are not engaged in business or a transaction, and the Credit Parties on a consolidated basis are not about to engage in a business or a transaction, for which the property of the Credit Parties and their Subsidiaries on a consolidated basis would constitute an unreasonably small capital and (v) the Credit Parties and their Subsidiaries have not executed this Agreement or any other Loan Document or made any transfer or incurred any obligations hereunder, with actual intent to hinder, delay or defraud either present or future creditors&#59; and (y) with respect to the Borrower on a particular date, that on such date (i) the fair value of the property of the Borrower is greater than the total amount of liabilities, including Contingent Liabilities, of the Borrower, (ii) the present fair saleable value of the assets of the Borrower is not less than the amount that will be required to pay the probable liability of the Borrower on its debts as they become absolute and matured, (iii) &#91;reserved&#93;, (iv) the Borrower is not engaged in business or a transaction, and the Borrower is not about to engage in a business or a transaction, for which the property of the Borrower would constitute an unreasonably small capital and (v) the Borrower have not executed this Agreement or any other Loan Document or made any transfer or incurred any obligations hereunder, with actual intent to hinder, delay or defraud either present or future creditors. The amount of Contingent Liabilities at any time shall be computed as the amount that, in light of all the facts and circumstances existing at such time, can reasonably be expected to become an actual or matured liability.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">SPAC Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means the merger, acquisition, contribution, equity purchase or similar reorganization transaction or series of transactions resulting in the combination of the Borrower (or any corporate successor (including a Subsidiary) thereof) or Holdings and any special purpose acquisition company or similar entity, in each case, where such acquisition company or entity has no material commercial operations and where the common Capital Securities of such surviving entity (or any direct or indirect parent thereof) are publicly listed on any United States national securities exchange.</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Specified Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any of the persons and entities listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Specified Repayment Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means for any prepayment or repayment of Loans occurring (i) at any time on or prior to the second anniversary of the Closing Date, none, (ii) at any time after the second anniversary of the Closing Date and on or prior to the third anniversary of the Closing Date, an amount equal to one and one-half percent (1.5%) of the aggregate outstanding principal amount of the Loans being prepaid or repaid and (iii) at any time after the third anniversary of the Closing Date and on or prior to the Maturity Date, an amount equal to three percent (3.0%) of the aggregate outstanding principal amount of the Loans being prepaid or repaid.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Standard Bodies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means any of the organizations that create, sponsor and maintain safety, quality or other standards, including ISO, ANSI, CEN, SCC and the like.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Stanford Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221; means (i) that certain Exclusive Agreement, dated July 22, 2010, by and between the Board of Trustees of the Leland Stanford Junior University, as licensor, and the Borrower, formerly known as Cardiovascular Simulation, Inc., as licensee, (ii) that certain Software Exclusive License Agreement, dated April 20, 2010, by and between the Board of Trustees of the Leland Stanford Junior University, as licensor, and the Borrower, formerly known as Cardiovascular Simulation, Inc., as licensee&#59; as amended by that certain Amendment No. 1, dated August 28, 2014 and that certain</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Amendment No. 2, dated April 19, 2020, and (iii) that certain Software Exclusive License Agreement, dated June 18, 2009, by and between the Board of Trustees of the Leland Stanford Junior University, as licensor, and the Borrower, formerly known as Cardiovascular Simulation, Inc., as licensee&#59; as amended by that certain Amendment No. 1, dated June 17, 2014 and that certain Amendment No. 2, dated June 17, 2019.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#8220;Subsequent Closing Date&#8221; has the meaning specified in the First Amendment.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Person, any other Person of which more than 50% of the outstanding Voting Securities (irrespective of whether at the time Capital Securities of any other class or classes of such other Person shall or might have voting power upon the occurrence of any contingency) or the issued Capital Securities of such other Person is at the time directly or indirectly owned or Controlled by such Person, by such Person and one or more other Subsidiaries of such Person, or by one or more other Subsidiaries of such Person. Unless the context otherwise specifically requires, the term &#8220;Subsidiary&#8221; shall be a reference to a Subsidiary of Holdings, whether direct or indirect.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Subsidiary Guarantor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means initially as of the Closing Date, each Subsidiary of Holdings identified under the caption &#8220;SUBSIDIARY GUARANTORS&#8221; on the signature pages hereto, if any, and, thereafter, each Subsidiary of Holdings that becomes a &#8220;Subsidiary Guarantor&#8221; after the Closing Date pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Synthetic Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, as applied to any Person, any lease (including leases that may be terminated by the lessee at any time) of any property (whether real, personal or mixed) (i) that is not a capital lease in accordance with GAAP and (ii) in respect of which the lessee retains or obtains ownership of the property so leased for federal income tax purposes, other than any such lease under which that Person is the lessor.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Systems</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the computers, servers, devices, networks, software, and systems used in connection with the operation of the business of Holdings or any of its Subsidiaries.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means all present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Term SOFR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means,</font></div><div style="margin-bottom:10pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;for any calculation with respect to a SOFR Loan, the Term SOFR Reference Rate for a tenor comparable to the applicable Interest Period on the day (such day, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Periodic Term SOFR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Determination Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) that is two (2) U.S. Government Securities Business Days prior to the first day of such Interest Period, as such rate is published by the Term SOFR Administrator&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that if as of 5&#58;00 p.m. (New York City time) on any Periodic Term SOFR Determination Day the Term SOFR Reference Rate for the applicable tenor has not been published by the Term SOFR Administrator and a Benchmark Replacement Date with respect to the Term SOFR Reference Rate has not occurred, then Term SOFR will be the Term SOFR Reference Rate for such tenor as published by the Term SOFR Administrator on the first preceding U.S. Government Securities Business Day for which such Term SOFR Reference Rate for such tenor was published by the Term SOFR Administrator so long as such first preceding U.S. Government Securities Business Day is not more than three (3) U.S. Government Securities Business Days prior to such Periodic Term SOFR Determination Day, and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;for any calculation with respect to an ABR Loan on any day, the Term SOFR Reference Rate for a tenor of one month on the day (such day, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ABR Term SOFR Determination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) that is two (2) U.S. Government Securities Business Days prior to such day, as such rate is published by the Term SOFR Administrator&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that if as of 5&#58;00 p.m. (New York City time) on any ABR Term SOFR Determination Day the Term SOFR Reference Rate for the applicable tenor has not been published by the Term SOFR Administrator and a Benchmark Replacement Date with respect to the Term SOFR Reference Rate has not occurred, then Term SOFR will be the Term SOFR Reference Rate for such tenor as published by the Term SOFR Administrator on the first preceding U.S. Government Securities Business Day for which such Term SOFR Reference Rate for such tenor was published by the Term SOFR Administrator so long as such first preceding U.S. Government Securities Business Day is not more than three (3) U.S. Government Securities Business Days prior to such ABR SOFR Determination Day&#59;</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that if Term SOFR determined as provided above (including pursuant to the proviso under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> above) shall ever be less than 2.00%, then Term SOFR shall be deemed to be 2.00%.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Term SOFR Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means CME Group Benchmark Administration Limited (CBA) (or a successor administrator of the Term SOFR Reference Rate selected by the Agent in its reasonable discretion).</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Term SOFR Reference Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the forward-looking term rate based on SOFR.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the date on which Payment in Full occurs.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Trademark</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any trademark, service mark, trade name, logo, symbol, trade dress, domain name, rights in social media accounts, corporate name and other indicator of source or origin, and all applications and registrations therefor, together with all of the goodwill associated with the therewith.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Trademark Security Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any Trademark Security Agreement executed and delivered by any Credit Party and&#47;or any of its Subsidiaries, as applicable, substantially in the form of Exhibit D to the Security Agreement, as amended or otherwise modified from time to time.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Trade Secrets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean trade secrets and other confidential information data and databases, in each case that derive economic value from not being generally known by the public and not being readily ascertainable by other Persons, and all claims and rights related to any of the foregoing.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Two-Consecutive Fiscal Quarter Net Sales Decline</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean a decrease in Net Sales for two consecutive Fiscal Quarters, in each case as compared to the Fiscal Quarter immediately preceding such two consecutive Fiscal Quarters.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Type</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;, when used in reference to any Loan, refers to whether the rate of interest on such Loan is determined by reference to Term SOFR or ABR.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">UCC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Uniform Commercial Code as in effect from time to time in the State of New York&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that, if, with respect to any financing statement or by reason of any provisions of law, the perfection or the effect of perfection or non-perfection of the security interests granted to the Agent, on behalf of the Secured Parties, pursuant to the applicable Loan Document is governed by the Uniform Commercial Code as in effect in a jurisdiction of the United States other than New York, then &#8220;UCC&#8221; means the Uniform Commercial Code as in effect from time to time in such other jurisdiction for purposes of the provisions of each Loan Document and any financing statement relating to such perfection or effect of perfection or non-perfection.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">UK Financial Institution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any BRRD Undertaking (as such term is defined under the PRA Rulebook (as amended form time to time) promulgated by the United Kingdom Prudential Regulation Authority) or any person falling within IFPRU 11.6 of the FCA Handbook (as amended from time to time) promulgated by the United Kingdom Financial Conduct Authority, which includes certain credit institutions and investment firms, and certain affiliates of such credit institutions or investment firms.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">UK Resolution Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Bank of England or any other public administrative authority having responsibility for the resolution of any UK Financial Institution.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">UK Subsidiary Guarantor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means each Guarantor incorporated under the laws of England and Wales.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">U.S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the United States of America, its fifty states and the District of Columbia.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">United States Registered IP Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any United States patent, patent application, trademark registration, trademark application or copyright registration.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. Government Securities Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any day except for (i) a Saturday, (ii) a Sunday or (iii) a day on which the Securities Industry and Financial Markets Association recommends that the fixed income departments of its members be closed for the entire day for purposes of trading in United States government securities.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any Person that is a &#8220;United States Person&#8221; as defined in Section 7701(a)(30) of the Code.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Voting Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to any Person, Capital Securities of any class or kind ordinarily having the power to vote for the election of directors, managers or other voting members of the governing body of such Person.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Warrants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, collectively, each certain Warrant to Purchase Common Stock issued by Holdings pursuant to the Existing Credit Agreement.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Welfare Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a &#8220;welfare plan&#8221;, as such term is defined in Section 3(1) of ERISA, which any Credit Party or any of its Subsidiaries sponsors, contributes to, or provides benefits under, or has any obligation to contribute or provide benefits under.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">wholly owned Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any direct or indirect Subsidiary of Holdings, all of the outstanding Capital Securities of which (other than any director&#8217;s qualifying shares or investments by foreign nationals mandated by applicable laws) is owned directly or indirectly by Holdings.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Withholding Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Credit Parties and the Agent.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Write-Down and Conversion Powers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, (i) with respect to any EEA Resolution Authority, the write-down and conversion powers of such EEA Resolution Authority from time to time under the Bail-In Legislation for the applicable EEA Member Country, which write-down and conversion powers are described in the EU Bail-In Legislation Schedule and (ii) with respect to the United Kingdom, any powers of the applicable Resolution Authority under the Bail-In Legislation to cancel, reduce, modify or change the form of a liability of any UK Financial Institution or any contract or instrument under which that liability arises, to convert all or part of that liability into shares, securities or obligations of that person or any other person, to provide that any such contract or instrument is to have effect as if a right </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">had been exercised under it or to suspend any obligation in respect of that liability or any of the powers under that Bail-In Legislation that are related to or ancillary to any of those powers.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. For all purposes of this Agreement, except as otherwise expressly provided herein or unless the context otherwise requires,</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;the terms defined in this Agreement include the plural as well as the singular and vice versa&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;words importing gender include all genders&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;any reference to a Section, Annex, Schedule or Exhibit refers to a Section of, or</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Annex, Schedule or Exhibit to, this Agreement&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;any reference to &#8220;this Agreement&#8221; refers to this Agreement, including all Annexes, Schedules and Exhibits hereto, and the words herein, hereof, hereto and hereunder and words of similar import refer to this Agreement and its Annexes, Schedules and Exhibits as a whole and not to any particular Section, Annex, Schedule, Exhibit or any other subdivision&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;references to days, months and years refer to calendar days, months and years, respectively&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;all references herein to &#8220;include&#8221; or &#8220;including&#8221; shall be deemed to be followed by the words &#8220;without limitation&#8221;&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;the word &#8220;from&#8221; when used in connection with a period of time means &#8220;from and including&#8221; and the word &#8220;until&#8221; means &#8220;to but not including&#8221;&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;the words &#8220;asset&#8221; and &#8220;property&#8221; shall be construed to have the same meaning and effect and to refer broadly to any and all assets and properties, whether tangible or intangible, real or personal, including cash, Capital Securities, rights under contractual obligations and permits and any right or interest in any such assets or property&#59; and</font></div><div style="margin-bottom:10pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;the word &#8220;will&#8221; shall have the same meaning as the word &#8220;shall&#8221;.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unless otherwise expressly provided herein, references to organizational documents, agreements (including the Loan Documents) and other contractual instruments shall be deemed to include all subsequent amendments, restatements, extensions, supplements and other modifications thereto permitted by the Loan Documents.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 1.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Accounting and Financial Determinations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Unless otherwise specified, all accounting terms used in each Loan Document shall be interpreted, and all accounting determinations and computations thereunder (including under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and any definitions used in such calculations) shall be made, in accordance with those generally accepted accounting principles (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) applied in the preparation of the financial statements referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Unless otherwise expressly provided, all financial covenants and defined financial terms shall be computed on a consolidated basis for Holdings and its Subsidiaries, in each case without duplication. Notwithstanding any other provision contained herein, all terms of an accounting or financial nature used herein shall be construed, and all computations of amounts and ratios referred to herein, and the determination of Indebtedness hereunder, shall be made without giving effect to Financial Accounting Standards Board (FASB) Standard ASC 842 (Leases) (or any other applicable financial accounting standard having a similar result or effect) and related interpretations, in each case, to the extent any lease (or similar arrangement conveying the right </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">to use) would be required to be treated as a capital lease thereunder where such lease (or similar arrangement) would have been treated as an operating lease under GAAP as in effect immediately prior to the effectiveness of the ASC 842.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 1.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Divisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. For all purposes under the Loan Documents, in connection with any division or plan of division under Delaware law (or any comparable event under a different jurisdiction&#8217;s laws)&#58; (i) if any asset, right, obligation or liability of any Person becomes the asset, right, obligation or liability of a different Person, then it shall be deemed to have been transferred from the original Person to the subsequent Person, and (ii) if any new Person comes into existence, such new Person shall be deemed to have been organized on the first date of its existence by the holders of its Capital Securities at such time.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 1.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Rates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Agent does not warrant or accept responsibility for, and shall not have any liability with respect to (a) the continuation of, administration of, submission of, calculation of or any other matter related to ABR, the Term SOFR Reference Rate or Term SOFR, or any component definition thereof or rates referred to in the definition thereof, or any alternative, successor or replacement rate thereto (including any Benchmark Replacement), including whether the composition or characteristics of any such alternative, successor or replacement rate (including any Benchmark Replacement) will be similar to, or produce the same value or economic equivalence of, or have the same volume or liquidity as, ABR, the Term SOFR Reference Rate, Term SOFR or any other Benchmark prior to its discontinuance or unavailability, or (b) the effect, implementation or composition of any Conforming Changes. The Agent and its affiliates or other related entities may engage in transactions that affect the calculation of ABR, the Term SOFR Reference Rate, Term SOFR, any alternative, successor or replacement rate (including any Benchmark Replacement) or any relevant adjustments thereto, in each case, in a manner adverse to the Borrower. The Agent may select information sources or services in its reasonable discretion to ascertain ABR, the Term SOFR Reference Rate, Term SOFR or any other Benchmark, in each case pursuant to the terms of this Agreement, and shall have no liability to the Borrower, any Lender or any other person or entity for damages of any kind, including direct or indirect, special, punitive, incidental or consequential damages, costs, losses or expenses (whether in tort, contract or otherwise and whether at law or in equity), for any error or calculation of any such rate (or component thereof) provided by any such information source or service.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE II</font></div><div style="margin-bottom:10pt;text-align:center;text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">THE LOANS</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Commitments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. On the terms and subject to the conditions of this Agreement, each of the Lenders agrees to make the Loans to the Borrower on the Closing Date in an amount not to exceed the Loan Commitment Amount. No amounts paid or prepaid with respect to any of the Loans may be reborrowed. The Loan Commitment Amount shall automatically and permanently be reduced to zero immediately after the making of the Loans on the Closing Date.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Borrowing Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to the terms and conditions hereof, the Borrower may irrevocably request that the Loans be made by delivering to the Agent a Loan Request on or before 10&#58;00 a.m. (London, England time) on a Business Day at least two (2) Business Days prior to the proposed Closing Date (or such shorter period as the Agent may agree in its sole discretion).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Funding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. After receipt of a Loan Request for the Loans pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, each applicable Lender shall, on the Closing Date, and subject to the terms and conditions hereof (including the satisfaction of all conditions precedent set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereof), make the applicable Loans to the Borrower, in the amounts set forth opposite such Lender&#8217;s name on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">that, at the request of the Borrower, the Agent shall cause the proceeds of the Loans to be disbursed, by wire transfer of immediately available funds, in the amount and to the accounts set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE III</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">REPAYMENTS, PREPAYMENTS, INTEREST AND FEES</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Applicable Currency for Repayments and Prepayments&#59; Pro Rata Application</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> The Borrower agrees that the Loans, and any fees or interest accrued or accruing thereon, shall be repaid and prepaid solely in Dollars. Except as otherwise provided in this Agreement, each payment (including each repayment and prepayment) by the Borrower will be deemed to be made ratably in accordance with the Pro Rata Shares of the Lenders, and upon receipt of any such payment the Agent will promptly thereafter distribute like funds relating to any such payment to the Lenders in accordance with their Pro Rata Shares.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Repayments and Prepayments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. There will be no scheduled repayments of principal on the Loans prior to the Maturity Date. On the Maturity Date, the Borrower shall repay the entire unpaid principal amount of the Loans in full in cash. Prior thereto, payments, repayments and prepayments of the Loans shall be made as set forth below in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Nothing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall be deemed to (or be construed to) permit or authorize any transaction by any Credit Party that otherwise is prohibited or not specifically permitted by this Agreement or any other Loan Document. Unless otherwise expressly provided herein, all payments, repayments and prepayments described in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall be subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#91;Reserved&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower may, upon five (5) Business Days&#8217; prior written notice to the Agent, voluntarily prepay the outstanding principal amount of the Loans in whole or in part.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Dispositions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Upon any Disposition by a Credit Party or any of its Subsidiaries (other than a Permitted Disposition), made in any period of twelve (12) consecutive months that, when taken together with all other Dispositions made during such 12-month period, results in aggregate Net Cash Proceeds from such Dispositions that exceed $2,000,000 for such 12-month period, the Borrower shall, within three (3) Business Days of such Person&#8217;s receipt of such excess proceeds thereof, prepay the outstanding principal amount of the Loans in an amount equal to 100% of such excess Net Cash Proceeds. The provisions of this clause shall not be deemed to be implied consent to any Disposition otherwise prohibited by the terms and conditions of this Agreement.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Events of Loss</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Upon the receipt by a Credit Party or any of its Subsidiaries of any Event of Loss, received in any period of 12 consecutive months, that when taken together with all other Events of Loss during such 12-month period, results in aggregate Net Cash Proceeds from such Events of Loss that exceed $2,000,000 for such 12-month period, the Borrower shall, within three (3) Business Days of such Person&#8217;s receipt of such excess proceeds thereof, prepay the outstanding principal amount of the Loans in an amount equal to 100% of such excess Net Cash Proceeds.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Other Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Upon the issuance, sale or other incurrence of any debt securities or other Indebtedness by a Credit Party or any of its Subsidiaries (other than Permitted Indebtedness), the Borrower shall, within three (3) Business Days of such Person&#8217;s receipt of the proceeds thereof, prepay the outstanding principal amount of the Loans in an amount equal to 100% of the net cash proceeds therefrom. The provisions of this clause shall not be deemed to be implied consent</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to any such issuance, sale or incurrence otherwise prohibited by the terms and conditions of this Agreement.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Acceleration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Immediately upon any acceleration of the applicable Maturity Date of the Loans pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Borrower shall repay the Loans in full, unless, pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, only a portion of the Loans are so accelerated (in which case the portion so accelerated shall be so repaid).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Immediately upon the occurrence of a Change in Control, the Borrower shall repay the Loans in full.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">IPO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Immediately upon the consummation of an IPO or a SPAC, the Borrower shall repay the Loans in an amount equal to the lesser of (i) the Net Cash Proceeds of such IPO or SPAC in excess of $150,000,000 and (ii) $</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:line-through">35,000,000.</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">50,000,000&#59; provided that, in the event any &#8220;green shoe</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">option&#8221; (or overallotment option) is exercised by the financial institutions underwriting such IPO, then,</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">the Borrower shall repay the Loans in an additional principal amount of $5,000,000.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Application</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Proceeds of each prepayment or repayment of the Loans shall be applied as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 3.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Interest Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, during any applicable Interest Period, (a) each ABR Loan shall accrue interest at a rate per annum equal to the sum of (i) the Applicable Margin, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (ii) ABR and (b) each SOFR Loan shall accrue interest during such Interest Period at a rate per annum equal to the sum of (i) the Applicable Margin, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (ii) Term SOFR for such Interest Period. The interest rate shall be recalculated and, if necessary, adjusted for each Interest Period, in each case pursuant to the terms hereof.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 3.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Default Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Upon the occurrence and during the continuance of an Event of Default, and continuing until such Event of Default is no longer continuing, upon written notice by the Agent (acting pursuant to the instruction of the Majority Lenders (in their sole discretion)), the Applicable Margin shall be increased by 3.00% per annum (such increase, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Default Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). The Default Rate, along with all other interest due and payable on such date, shall be payable in cash on the last Business Day of each calendar month.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 3.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Payment Dates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Interest accrued on the Loans shall be payable in cash, without duplication&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;on the applicable Maturity Date therefor&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;on the date of any payment or prepayment, in whole or in part, of principal outstanding on the Loans, on the principal amount so paid or prepaid&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the last day of each Interest Period for the Loans&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;on that portion of the Loans that is accelerated pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;9.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, immediately upon such acceleration.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Interest accrued on the Loans or any other monetary Obligations after the date such amount is due and payable (whether on the applicable Maturity Date, upon acceleration or otherwise) shall be payable upon demand.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 3.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Credit Parties agree, jointly and severally, to pay to the Agent and the Lenders the fees set forth in the Fee Letter.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 3.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Specified Repayment Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Unless otherwise expressly provided herein, all payments, repayments and prepayments described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and made at any time after the second anniversary of the Closing Date (whether resulting from voluntary or involuntary prepayments or repayments, acceleration (including as a result of the occurrence of any event described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or otherwise)), including, for the avoidance of doubt, on the Maturity Date, shall be subject to the payment of Specified Repayment Fees as described below in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Until Payment in Full occurs, all such Specified Repayment Fees shall continue to be due and payable, including after the occurrence of any Default, acceleration, maturity or otherwise. If all or any portion of the outstanding Loans are repaid or prepaid for any reason after the second anniversary of the Closing Date, including, for the avoidance of doubt, on the Maturity Date, the Borrower shall pay the Specified Repayment Fee to the Agent at the time of such prepayment or repayment, together with any other fees payable hereunder. Specified Repayment Fees shall be nonrefundable once paid.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 3.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#91;Reserved&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 3.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">PIK Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.With respect to the Loans, during the period from the Closing Date until the Interest Payment Date occurring closest to (but not after) the date that is eighteen (18) months after the Closing Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">PIK Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), so long as no Default has occurred and is continuing on such date, by delivery of written notice to the Agent not less than five (5) Business Days prior to any Interest Payment Date, the Borrower may elect to pay all of the interest accrued on the Loans for the Interest Period ending on such Interest Payment Date &#8220;in kind&#8221; (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">PIK Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that during the PIK Period, the Applicable Margin shall be increased by one percent (1.00%) per annum with respect to any such interest paid as PIK Interest.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In each case, such election shall only relate to interest that is (x) due and payable on such Interest Payment Date and (y) accrued during the Interest Period ending on such Interest Payment Date. In the event the Borrower elects to pay PIK Interest pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, such PIK Interest shall be capitalized and added to the outstanding principal amount of the Loans on the applicable Interest Payment Date. For purposes of this Agreement and the other Loan Documents, the amounts so capitalized and added pursuant to the foregoing sentence will constitute a portion of the outstanding principal amount of the Loans as of such Interest Payment Date and will bear interest (which shall be due and payable) in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">3.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and, to the extent applicable, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Notwithstanding anything to the contrary contained in this Agreement or in any other Loan Document, in the event that any Default has occurred and is continuing on any Interest Payment Date, all interest due and payable on such date must be paid in cash, irrespective of any election at any time by the Borrower to pay such interest in the form of PIK Interest.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 3.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Interest Computation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, each Loan shall initially be a SOFR Loan.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;All interest hereunder shall be computed on the basis of a year of 360 days (or in the case of interest computed by reference to the ABR at times when the ABR is based on the Prime Rate, such interest shall be computed on the basis of a year of 365 days (or 366 days in a leap year)), and in each case shall be payable for the actual number of days elapsed (including the first day but excluding the last day). All interest hereunder on any Loan shall be computed on a daily basis based upon the outstanding principal amount of such Loan as of the applicable date of determination. The applicable </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ABR or Term SOFR shall be determined by the Agent, and such determination shall be conclusive absent manifest error.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 3.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Term SOFR Conforming Changes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In connection with the use or administration of Term SOFR, the Agent will have the right to make Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such Conforming Changes will become effective without any further action or consent of any other party to this Agreement or any other Loan Document. The Agent will promptly notify the Borrower and the Lenders of the effectiveness of any Conforming Changes in connection with the use or administration of Term SOFR.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE IV</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SOFR AND OTHER PROVISIONS</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Increased Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Increased Costs Generally</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If any Change in Law shall&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;impose, modify or deem applicable any reserve, special deposit, compulsory loan, insurance charge or similar requirement against assets of, deposits with or for the account of, or credit extended or participated in by, any Lender&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii) subject any Recipient to any Taxes (other than (A) Indemnified Taxes, (B) Taxes described in clauses (b) through (d) of the definition of Excluded Taxes and (C) Connection Income Taxes) on its loans, loan principal, letters of credit, commitments, or other obligations, or its deposits, reserves, other liabilities or capital attributable thereto&#59; or</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii) impose on any Lender or the London interbank market any other condition, cost or expense (other than Taxes) affecting this Agreement or Loans made by such Lender or any participation therein (except as otherwise accounted for in the definition of &#8220;Term SOFR&#8221;, as applicable)&#59;</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and the result of any of the foregoing shall be to increase the cost to such Lender or such other Recipient of making, converting to, continuing or maintaining any Loan or of maintaining its obligation to make any such Loan, or to increase the cost to such Lender or such other Recipient of participating in, or to reduce the amount of any sum received or receivable by such Lender or other Recipient hereunder (whether of principal, interest or any other amount) then, upon request of such Lender or other Recipient, the Borrower will pay to such Lender or other Recipient, as the case may be, such additional amount or amounts as will compensate such Lender or other Recipient, as the case may be, for such additional costs incurred or reduction suffered.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Capital Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If any Lender determines that any Change in Law affecting such Lender or any lending office of such Lender or such Lender&#8217;s holding company, if any, regarding capital or liquidity requirements has or would have the effect of reducing the rate of return on such Lender&#8217;s capital or on the capital of such Lender&#8217;s holding company, if any, as a consequence of this Agreement, the Loan Commitments of such Lender or the Loans made by such Lender, to a level below that which such Lender or such Lender&#8217;s holding company, as the case may be, could have achieved but for such Change in Law (taking into consideration such Lender&#8217;s policies and the policies of such Lender&#8217;s holding company with respect to capital adequacy and&#47;or liquidity), then from time to time upon demand of such Lender setting forth in reasonable detail the charge and the calculation of such reduced rate of return (with a copy of such demand to the Agent), the Borrower will pay to such Lender </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">33</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">such additional amount or amounts as will compensate such Lender or such Lender&#8217;s holding company for any such reduction suffered.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Certificates for Reimbursement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. A certificate of a Lender setting forth the amount or amounts necessary to compensate such Lender or its holding company, as the case may be, as specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">paragraph (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of this Section and delivered to the Borrower shall be conclusive absent manifest error. The Borrower shall pay such Lender, as the case may be, the amount shown as due on any such certificate within ten (10) days after receipt thereof.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Delay in Requests</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Failure or delay on the part of any Lender to demand compensation pursuant to this Section shall not constitute a waiver of such Lender&#8217;s right to demand such compensation&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that the Borrower shall not be required to compensate a Lender pursuant to this Section for any increased costs incurred or reductions suffered more than nine months prior to the date that such Lender, as the case may be, notifies the Borrower of the Change in Law giving rise to such increased costs or reductions, and of such Lender&#8217;s intention to claim compensation therefor (except that, if the Change in Law giving rise to such increased costs or reductions is retroactive, then the nine-month period referred to above shall be extended to include the period of retroactive effect thereof).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Compensation for Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.In the event of (a) the payment of any principal of any SOFR Loan other than on the last day of the Interest Period applicable thereto (including as a result of an Event of Default), (b) the conversion of any SOFR Loan other than on the last day of the Interest Period applicable thereto (including as a result of an Event of Default), (c) the failure to borrow, convert, continue or prepay any SOFR Loan on the date specified in any notice delivered pursuant hereto, or (d) the assignment of any SOFR Loan other than on the last day of the Interest Period applicable thereto as a result of a request by the Borrower pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, then, in any such event, the Borrower shall compensate each Lender for any loss, cost and expense attributable to such event, including any loss, cost or expense arising from the liquidation or redeployment of funds. A certificate of any Lender setting forth any amount or amounts that such Lender is entitled to receive pursuant to this Section shall be delivered to the Borrower and shall be conclusive absent manifest error. The Borrower shall pay such Lender the amount shown as due on any such certificate within ten (10) days after receipt thereof.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. For purposes of this Section, the term &#8220;applicable law&#8221; includes FATCA.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Payments Free of Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Any and all payments by or on account of any Obligation of a Credit Party under any Loan Document shall be made without deduction or withholding for any Taxes, except as required by applicable law. If any applicable law (as determined in the good faith discretion of an applicable Withholding Agent) requires the deduction or withholding of any Tax from any such payment by any Withholding Agent, then such Withholding Agent shall be entitled to make such deduction or withholding and shall timely pay the full amount deducted or withheld to the relevant Governmental Authority in accordance with applicable law and, if such Tax is an Indemnified Tax, then the sum payable by such Credit Party shall be increased as necessary so that after such deduction or withholding has been made (including such deductions and withholdings applicable to additional sums payable under this Section) the applicable Recipient receives an amount equal to the sum it would have received had no such deduction or withholding been made.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Payment of Other Taxes by the Credit Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Credit Party agrees that, without duplication, it shall, or shall cause the appropriate Credit Party to, timely pay to the relevant Governmental Authority in accordance with applicable law, or at the option of the Agent timely reimburse it for the payment of, any Other Taxes.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification by Credit Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Credit Party agrees that, without duplication, it shall, or shall cause the appropriate Credit Party to, indemnify each Recipient, within ten (10) days after demand therefor, for the full amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under this Section) payable or paid by such Recipient or required to be withheld or deducted from a payment to such Recipient and any reasonable expenses arising therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to a Credit Party by a Lender (with a copy to the Agent), or by the Agent on its own behalf or on behalf of a Lender, shall be conclusive absent manifest error.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification by the Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Lender shall severally indemnify the Agent, within ten (10) days after demand therefor, for (i) any Indemnified Taxes attributable to such Lender (but only to the extent that the Borrower has not already indemnified the Agent for such Indemnified Taxes and without limiting the obligation of the Borrower to do so), (ii) any Taxes attributable to such Lender&#8217;s failure to comply with the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.11(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> relating to the maintenance of a Participant Register, and (iii) any Excluded Taxes attributable to such Lender, in each case, that are payable or paid by the Agent in connection with any Loan Document, and any reasonable expenses arising therefrom or with respect thereto, whether or not such Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to any Lender by the Agent shall be conclusive absent manifest error. Each Lender hereby authorizes the Agent to set off and apply any and all amounts at any time owing to such Lender under any Loan Document or otherwise payable by the Agent to such Lender from any other source against any amount due to the Agent under this paragraph (e).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Evidence of Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. As soon as practicable after any payment of Taxes by any Credit Party to a Governmental Authority pursuant to this Section, such Credit Party shall deliver to the Agent the original or a certified copy of a receipt issued by such Governmental Authority evidencing such payment, a copy of the return reporting such payment or other evidence of such payment satisfactory to the Agent (acting on the instructions of the Majority Lenders acting reasonably).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Status of Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Any Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments made under any Loan Document shall deliver to the Borrower and the Agent, at the time or times reasonably requested by the Borrower or the Agent, such properly completed and executed documentation reasonably requested by the Borrower or the Agent as will permit such payments to be made without withholding or at a reduced rate of withholding. In addition, any Lender, if reasonably requested by the Borrower or the Agent, shall deliver such other documentation prescribed by applicable law or reasonably requested by the Borrower or the Agent as will enable the Borrower or the Agent to determine whether or not such Lender is subject to backup withholding or information reporting requirements. Notwithstanding anything to the contrary in the preceding two sentences, the completion, execution and submission of such documentation (other than such documentation set forth in paragraphs </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(g)(ii)(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(ii)(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(ii)(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of this Section) shall not be required if in such Lender&#8217;s reasonable judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or would materially prejudice the legal or commercial position of such Lender.</font></div><div style="margin-bottom:10pt;text-align:center;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Without limiting the generality of the foregoing,</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">35</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(A)&#160;&#160;&#160;&#160;any Lender that is a U.S. Person shall deliver to the Borrower and the Agent on or about the date on which such Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Agent), executed copies of IRS Form W-9 certifying that such Lender is exempt from U.S. federal backup withholding tax&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(B)&#160;&#160;&#160;&#160;any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Agent (in such number of copies as shall be requested by the recipient) on or about the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Agent), whichever of the following is applicable&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;in the case of a Foreign Lender claiming the benefits of an income tax treaty to which the United States is a party (x) with respect to payments of interest under any Loan Document, executed copies of IRS Form W-8BEN or IRS Form W-8BEN-E establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the &#8220;interest&#8221; article of such tax treaty and (y) with respect to any other applicable payments under any Loan Document, IRS Form W-8BEN or IRS Form W-8BEN-E establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the &#8220;business profits&#8221; or &#8220;other income&#8221; article of such tax treaty&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;in the case of a Foreign Lender claiming that its extension of credit will generate U.S. effectively connected income, executed copies of IRS Form W-8ECI&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;in the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under Section 881(c) of the Code, (x) a certificate substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit E-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> to the effect that such Foreign Lender is not a &#8220;bank&#8221; within the meaning of Section 881(c)(3)(A) of the Code, a &#8220;10 percent shareholder&#8221; of the Borrower within the meaning of Section 871(h)(3)(B) of the Code, or a &#8220;controlled foreign corporation&#8221; related to the Borrower as described in Section 881(c)(3)(C) of the Code (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. Tax Compliance Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and (y) executed copies of IRS Form W-8BEN or IRS Form W-8BEN-E&#59; or</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;to the extent a Foreign Lender is not the beneficial owner, executed copies of IRS Form W-8IMY, accompanied by IRS Form W-8ECI, IRS Form W-8BEN, IRS Form W-8BEN-E, a U.S. Tax Compliance Certificate substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit E-2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit E-3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, IRS Form W-9, and&#47;or other certification documents from each beneficial owner, as applicable&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that if the Foreign Lender is a partnership and one or more direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such Foreign Lender may provide a U.S. Tax Compliance Certificate substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit E-4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> on behalf of each such direct and indirect partner&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(C)&#160;&#160;&#160;&#160;any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Agent (in such number of copies as shall be requested by the recipient) on or about the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Agent), executed copies of any other form prescribed by applicable law as a basis for claiming exemption from or a reduction in U.S. federal withholding Tax, duly completed, together with such supplementary documentation as may be prescribed by applicable law to permit the Borrower or the Agent to determine the withholding or deduction required to be made&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(D)&#160;&#160;&#160;&#160;if a payment made to a Lender under any Loan Document would be subject to U.S. federal withholding Tax imposed by FATCA if such Lender were to fail to comply</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">36</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the Code, as applicable), such Lender shall deliver to the Borrower and the Agent at the time or times prescribed by law and at such time or times reasonably requested by the Borrower or the Agent such documentation prescribed by applicable law (including as prescribed by Section 1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested by the Borrower or the Agent as may be necessary for the Borrower and the Agent to comply with their obligations under FATCA and to determine that such Lender has complied with such Lender&#8217;s obligations under FATCA or to determine the amount, if any, to deduct and withhold from such payment. Solely for purposes of this clause (D), &#8220;FATCA&#8221; shall include any amendments made to FATCA after the date of this Agreement.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Lender agrees that if any form or certification it previously delivered expires or becomes obsolete or inaccurate in any respect, it shall update such form or certification or promptly notify the Borrower and the Agent in writing of its legal inability to do so.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Treatment of Certain Refunds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If any party determines, in its sole discretion exercised in good faith, that it has received a refund of any Taxes as to which it has been indemnified pursuant to this Section (including by the payment of additional amounts pursuant to this Section), it shall pay to the indemnifying party an amount equal to such refund (but only to the extent of indemnity payments made under this Section with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) of such indemnified party and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund). Such indemnifying party, upon the request of such indemnified party, shall repay to such indemnified party the amount paid over pursuant to this paragraph (h) (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) in the event that such indemnified party is required to repay such refund to such Governmental Authority. Notwithstanding anything to the contrary in this paragraph (h), in no event will the indemnified party be required to pay any amount to an indemnifying party pursuant to this paragraph (h) the payment of which would place the indemnified party in a less favorable net after-Tax position than the indemnified party would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with respect to such Tax had never been paid. This paragraph shall not be construed to require any indemnified party to make available its Tax returns (or any other information relating to its Taxes that it deems confidential) to the indemnifying party or any other Person.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each party&#8217;s obligations under this Section shall survive the resignation or replacement of the Agent or any assignment of rights by, or the replacement of, a Lender and the repayment, satisfaction or discharge of all obligations under any Loan Document.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 4.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Payments, Computations&#59; Proceeds of Collateral, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The parties hereto agree as follows&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Unless otherwise expressly provided in a Loan Document, all payments by the Borrower pursuant to each Loan Document shall be made without setoff, deduction or counterclaim not later than 11&#58;00 a.m. (New York City time) on the date due in same day or immediately available funds to such account as the Agent shall specify from time to time by notice to the Borrower. Funds received after that time shall be deemed to have been received by the Agent on the next succeeding Business Day. All interest and fees shall be computed on the basis of the actual number of days (including the first day but excluding the last day) occurring during the period for which such interest or fee is payable over a year comprised of 360 days. Payments due on other than a Business Day shall be made on the next succeeding Business Day and such extension of time shall be included in computing interest and fees in connection with that payment.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">37</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;All amounts received as a result of the exercise of remedies under the Loan Documents (including from the proceeds of collateral securing the Obligations) or under applicable law shall be applied upon receipt to the Obligations as follows&#58; (i) first, to the payment in full in cash of all interest (including interest accruing after the commencement of a proceeding in bankruptcy, insolvency or similar law, whether or not permitted as a claim under such law) and fees owing under the Loan Documents, and all costs and expenses owing to the Agent and the Lenders (or any of them) pursuant to the terms of the Loan Documents, until paid in full in cash, (ii) second, after payment in full in cash of the amounts specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (b)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, to the payment of the principal amount of the Loans then outstanding, (iii) third, after payment in full in cash of the amounts specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clauses (b)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(b)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, to the payment of all other Obligations owing to the Agent and the Lenders (or any of them), and (iv) fourth, after payment in full in cash of the amounts specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clauses (b)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> through </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(b)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, and following the Termination Date, to the Borrower or any other Person lawfully entitled to receive such surplus.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 4.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Setoff</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Lender and the Agent shall, upon the occurrence and during the continuance of any Default described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clauses (i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> through </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, inclusive, of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or, upon the occurrence and during the continuance of any other Event of Default, have the right to appropriate and apply to the payment of the Obligations owing to it (whether or not then due), and (as security for such Obligations) each Credit Party and each of its Subsidiaries hereby grants to each Lender and the Agent a continuing security interest in, any and all balances, credits, deposits, accounts (other than Excluded Accounts) or moneys of each Credit Party and each of its Subsidiaries then or thereafter maintained with such Lender or the Agent, as applicable. Each Lender and the Agent agrees promptly to notify the Borrower after any such appropriation and application made by such Lender or the Agent, as applicable&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that, the failure to give such notice shall not affect the validity of such setoff and application. The rights of each Lender and the Agent under this Section are in addition to other rights and remedies (including other rights of setoff under applicable law or otherwise) which such Lender or the Agent, as applicable, may have.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 4.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Inability to Determine Rates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, if, on or prior to the first day of any Interest Period for any SOFR Loan&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;the Agent determines (which determination shall be conclusive and binding absent manifest error) that &#8220;Term SOFR&#8221; cannot be determined pursuant to the definition thereof, or</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;the Majority Lenders determine that for any reason in connection with any request for a SOFR Loan or a conversion thereto or a continuation thereof that Term SOFR for any requested Interest Period with respect to a proposed SOFR Loan does not adequately and fairly reflect the cost to such Lenders of funding such Loan, and the Majority Lenders have provided notice of such determination to the Agent,</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the Agent will promptly so notify the Borrower and each Lender.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Upon notice thereof by the Agent to the Borrower, any obligation of the Lenders to make SOFR Loans shall be suspended (to the extent of the affected SOFR Loans or affected Interest Periods) until the Agent (with respect to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, at the instruction of the Majority Lenders) revokes such notice. Upon receipt of such notice, (i) the Borrower may revoke any pending request for a borrowing of, conversion to or continuation of SOFR Loans (to the extent of the affected SOFR Loans or affected Interest Periods) or, failing that, the Borrower will be deemed to have converted any such request into a request for a borrowing of or conversion to an ABR Loan in the amount specified therein and (ii) any outstanding affected SOFR Loans will be deemed to have been converted into ABR Loans at the end of the</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">38</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">applicable Interest Period. Upon any such conversion, the Borrower shall also pay accrued interest on the amount so converted, together with any additional amounts required pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 4.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, if the Agent determines (which determination shall be conclusive and binding absent manifest error) that &#8220;Term SOFR&#8221; cannot be determined pursuant to the definition thereof on any given day, the interest rate on ABR Loans shall be determined by the Agent without reference to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">clause (iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> of the definition of &#8220;ABR&#8221; until the Agent revokes such determination.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 4.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Sharing of Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. If any Lender will, by exercising any right of setoff or counterclaim or otherwise, obtain payment in respect of any principal of or interest on the Loans or other obligations hereunder resulting in such Lender receiving payment of a proportion of the aggregate amount of its Loans and accrued interest thereon or other such obligations greater than its Pro Rata Share thereof as provided herein, then the Lender receiving such greater proportion will (a) notify the Agent of such fact, and (b) purchase (for cash at face value) participations in the Loans and such other obligations of the other Lenders, or make such other adjustments as will be equitable, so that the benefit of all such payments will be shared by the Lenders ratably in accordance with the aggregate amount of principal of and accrued interest on their respective Loans and other amounts owing them&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> that, (i) if any such participations are purchased and all or any portion of the payment giving rise thereto is recovered, such participations will be rescinded and the purchase price restored to the extent of such recovery, without interest&#59; and (ii) the provisions of this Section will not be construed to apply to (i) any payment made by the Borrower pursuant to and in accordance with the express terms of this Agreement or (ii) any payment obtained by a Lender as consideration for the assignment of or sale of a participation in its Loans to any assignee or participant, other than to the Borrower or any of their respective Subsidiaries (as to which the provisions of this subsection will apply).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 4.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Mitigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. If any Lender requests compensation under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, or requires the Borrower to pay any Indemnified Taxes or additional amounts to any Lender or any Governmental Authority for the account of any Lender pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, then such Lender shall use reasonable efforts to designate a different lending office for funding or booking its Loans hereunder or to assign its rights and obligations hereunder to another of its offices, branches or affiliates, if, in the reasonable judgment of such Lender, such designation or assignment (i) would eliminate or reduce amounts payable pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, as the case may be, in the future, and (ii) would not subject such Lender to any unreimbursed cost or expense and would not otherwise be disadvantageous to such Lender. The Borrower hereby agrees to pay all reasonable costs and expenses incurred by any Lender in connection with any such designation or assignment.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 4.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Illegality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. If any Lender determines that any law has made it unlawful, or that any Governmental Authority has asserted that it is unlawful, for any Lender or its applicable lending office to make, maintain or fund Loans whose interest is determined by reference to SOFR, the Term SOFR Reference Rate or Term SOFR, or to determine or charge interest rates based upon SOFR, the Term SOFR Reference Rate or Term SOFR, then, upon notice thereof by such Lender to the Borrower (through the Agent), (a) any obligation of the Lenders to make SOFR Loans, and any right of the Borrower to continue SOFR Loans shall be suspended, and (b) the interest rate on which ABR Loans shall, if necessary to avoid such illegality, be determined by the Agent without reference to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">clause (iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> of the definition of &#8220;ABR&#8221;, in each case until such Lender notifies the Agent and the Borrower that the circumstances giving rise to such determination no longer exist. Upon receipt of such notice, (i) the Borrower shall, if necessary to avoid such illegality, upon demand from any Lender (with a copy to the Agent), prepay or, if applicable, convert all SOFR Loans to ABR Loans (the interest rate on which ABR Loans of such Lender shall, if necessary to avoid such illegality, be determined by the Agent without reference to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">clause (iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> of the definition of &#8220;ABR&#8221;), on the last day of the Interest Period therefor, if all affected Lenders may lawfully continue to maintain such SOFR Loans to such day, or immediately, if any Lender may not lawfully continue to maintain such SOFR Loans to such day, and (ii) if necessary to</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">39</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">avoid such illegality, the Agent shall during the period of such suspension compute the ABR without reference to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">clause (iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> of the definition of &#8220;ABR,&#8221; in each case until the Agent is advised in writing by each affected Lender that it is no longer illegal for such Lender to determine or charge interest rates based upon SOFR, the Term SOFR Reference Rate or Term SOFR. Upon any such prepayment or conversion, the Borrower shall also pay accrued interest on the amount so prepaid or converted, together with any additional amounts required pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 4.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Benchmark Replacement Setting.Benchmark Replacement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(i)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary herein or in any other Loan Document, upon the occurrence of a Benchmark Transition Event, the Agent and the Borrower may amend this Agreement to replace the then-current Benchmark with a Benchmark Replacement. Any such amendment with respect to a Benchmark Transition Event will become effective at 5&#58;00 p.m. (New York City time) on the fifth (5th) Business Day after the Agent has posted such proposed amendment to all affected Lenders and the Borrower so long as the Agent has not received, by such time, written notice of objection to such amendment from Lenders comprising the Majority Lenders. No replacement of a Benchmark with a Benchmark Replacement pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 4.10(a)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> will occur prior to the applicable Benchmark Transition Start Date.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(ii)&#160;&#160;&#160;&#160;No Hedging Agreement shall be deemed to be a &#8220;Loan Document&#8221; for purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 4.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Benchmark Replacement Conforming Changes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. In connection with the use, administration, adoption or implementation of a Benchmark Replacement, the Agent will have the right to make Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such Conforming Changes will become effective without any further action or consent of any other party to this Agreement or any other Loan Document.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Notices&#59; Standards for Decisions and Determinations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. The Agent will promptly notify the Borrower and the Lenders of (i) the implementation of any Benchmark Replacement and (ii) the effectiveness of any Conforming Changes in connection with the use, administration, adoption or implementation of a Benchmark Replacement. The Agent will promptly notify the Borrower of (x) the removal or reinstatement of any tenor of a Benchmark pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 4.10(d</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">) and (y) the commencement of any Benchmark Unavailability Period. Any determination, decision or election that may be made by the Agent or, if applicable, any Lender (or group of Lenders) pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section&#160;4.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, including any determination with respect to a tenor, rate or adjustment or of the occurrence or non-occurrence of an event, circumstance or date and any decision to take or refrain from taking any action or any selection, will be conclusive and binding absent manifest error and may be made in its or their sole discretion and without consent from any other party to this Agreement or any other Loan Document, except, in each case, as expressly required pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 4.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Unavailability of Tenor of Benchmark</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Notwithstanding anything to the contrary herein or in any other Loan Document, at any time (including in connection with the implementation of a Benchmark Replacement), (i) if the then-current Benchmark is a term rate (including the Term SOFR Reference Rate) and either (A) any tenor for such Benchmark is not displayed on a screen or other information service that publishes such rate from time to time as selected by the Agent in its reasonable discretion or (B) the administrator of such Benchmark or the regulatory supervisor for the administrator of such Benchmark has provided a public statement or publication of information announcing that any tenor for such Benchmark is not or will not be representative or in compliance with or aligned with the International Organization of Securities Commissions (IOSCO) Principles for</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">40</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Financial Benchmarks, then the Agent may modify the definition of &#8220;Interest Period&#8221; (or any similar or analogous definition) for any Benchmark settings at or after such time to remove such unavailable, non-representative, non-compliant or non-aligned tenor and (ii) if a tenor that was removed pursuant to clause (i) above either (A) is subsequently displayed on a screen or information service for a Benchmark (including a Benchmark Replacement) or (B) is not, or is no longer, subject to an announcement that it is not or will not be representative or in compliance with or aligned with the International Organization of Securities Commissions (IOSCO) Principles for Financial Benchmarks for a Benchmark (including a Benchmark Replacement), then the Agent may modify the definition of &#8220;Interest Period&#8221; (or any similar or analogous definition) for all Benchmark settings at or after such time to reinstate such previously removed tenor.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Benchmark Unavailability Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Upon the Borrower&#8217;s receipt of notice of the commencement of a Benchmark Unavailability Period, the Borrower may revoke any pending request for a SOFR Loan of, conversion to or continuation of SOFR Loans to be made, converted or continued during any Benchmark Unavailability Period and, failing that, the Borrower will be deemed to have converted any such request into a request for or conversion to ABR Loans. During a Benchmark Unavailability Period or at any time that a tenor for the then-current Benchmark is not an Available Tenor, the component of ABR based upon the then-current Benchmark or such tenor for such Benchmark, as applicable, will not be used in any determination of ABR.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE V</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CONDITIONS PRECEDENT</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 5.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Conditions to the Borrowing of the Loans on the Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The obligation of the Lenders to make the Loans on the Closing Date shall be subject to the execution and delivery of this Agreement by the parties hereto, the delivery of a Loan Request for the Loan Loans pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, and the prior or concurrent satisfaction of each of the conditions precedent set forth below in this Section.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Secretary&#8217;s Certificate, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Agent shall have received from each Credit Party (x) a copy of a good standing certificate (to the extent such concept it applicable in any relevant jurisdiction), dated a date reasonably close to the Closing Date, for each such Person and (y) a certificate, dated as of the Closing Date, duly executed and delivered by such Person&#8217;s Secretary, Assistant Secretary, or other Authorized Officer, director, managing member or general partner, as applicable, as to&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;resolutions of each such Person&#8217;s board of directors (or other managing body, in the case of other than a corporation) then in full force and effect authorizing the execution, delivery and performance of each Loan Document to be executed by such Person and the transactions contemplated hereby and thereby&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the incumbency and signatures of those of its officers, managing member or general partner, as applicable, authorized to act with respect to each Loan Document to be executed by such Person&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;the full force and validity of each Organic Document of such Person and copies thereof&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">41</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;certifying that each copy document relating to it specified in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> is correct, complete and in full force and effect and has not been amended or superseded as at the date no earlier than the Closing Date&#59;</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in each case, upon which certificates the Agent may conclusively rely until it shall have received a further certificate of the Secretary, Assistant Secretary, director, managing member or general partner, as applicable, of any such Person cancelling or amending the prior certificate of such Person.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Closing Date Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Agent shall have received a certificate, dated as of the Closing Date and duly executed and delivered by an Authorized Officer of the Borrower (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Closing&#160;Date Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), which certificate shall be in form and substance satisfactory to the Agent (acting on the instructions of the Majority Lenders acting reasonably) and shall, among other things, represent and warrant that the statements made therein are true and correct as of such date, and, at the time such certificate is delivered, such statements shall in fact be true and correct. The statements in such certificate shall be limited to (i) (x) the representations and warranties set forth herein and in each Loan Document shall, in each case, be true and correct in all material respects as of the Closing Date (unless stated to relate solely to an earlier date, in which case such representations and warranties shall be true and correct in all material respects as of such earlier date)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that any representations and warranties that are by their terms qualified by materiality, Material Adverse Effect or similar qualification shall be true and correct in all respects, and (y) no Default or Event of Default under and as defined in this Agreement shall have occurred and then be continuing and (ii) all of the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> have been satisfied.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Delivery of Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Agent shall have received Notes for each Lender that has requested as such, evidencing the Loans, which Notes shall be duly executed and delivered by an Authorized Officer of the Borrower.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Information, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Agent shall have received&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;audited consolidated financial statements of the Borrower and its Subsidiaries for the Fiscal Year ended December 31, 2023&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;unaudited consolidated balance sheets of the Borrower and its Subsidiaries for the Fiscal Quarter ended March 31, 2024, together with the related consolidated statement of operations, shareholder&#8217;s equity and cash flows for such Fiscal Quarter.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Agent shall have received a Compliance Certificate, dated as of the Closing Date, duly executed (and with all schedules thereto duly completed) and delivered by the chief financial or accounting Authorized Officer of the Borrower.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Solvency, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Agent shall have received a solvency certificate duly executed and delivered by the chief financial or accounting Authorized Officer of the Borrower, dated as of the Closing Date, in form and substance satisfactory to the Agent.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Fee Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Agent shall have received the Fee Letter, dated as of the Closing Date, duly executed and delivered by the Borrower, the Agent and the Lenders.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Security Agreement, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Agent shall have received executed counterparts of the Security Agreement, dated as of the Closing Date, duly executed and delivered by the Credit Parties, together with&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">42</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;certificates (in the case of Capital Securities that are securities (as defined in the UCC)) evidencing all of the issued and outstanding Capital Securities owned by each Credit Party, which certificates in each case shall be accompanied by undated instruments of transfer duly executed in blank, or, if any Capital Securities (in the case of Capital Securities that are uncertificated securities (as defined in the UCC)), confirmation and evidence satisfactory to the Agent that the security interest therein has been transferred to and perfected by the Agent in accordance with Articles 8 and 9 of the UCC and all laws otherwise applicable to the perfection of the pledge of such Capital Securities&#59; provided that Borrower shall be required to pledge 100% of the Capital Securities of any Foreign Subsidiaries existing as of the Closing Date, except to the extent as reasonably determined by the Borrower after consulting with the Agent, such pledge would reasonably be expected to result in material adverse tax consequences to the Borrower, in which case Borrower shall not be required to pledge voting Capital Securities in excess of 65% of the issued and outstanding voting Capital Securities of such Foreign Subsidiaries&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;financing statements suitable in form for naming each Credit Party as a debtor and the Agent for the benefit of the Secured Parties as the secured party, or other similar instruments or documents to be filed under the UCC of all jurisdictions as may be necessary or, in the opinion of the Agent, desirable to perfect the security interests of the Secured Parties pursuant to the Security Agreement&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;any Patent Security Agreement, Trademark Security Agreement or Copyright Security Agreement required to be provided under the Security Agreement, each dated as of the Closing Date, duly executed and delivered by an Authorized Officer of the applicable Credit Party&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Intercompany Subordination Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Agent shall have received executed counterparts of the Intercompany Subordination Agreement, duly executed and delivered by each Credit Party and each of their respective Subsidiaries.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Material Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Copies of all Material Agreements and license agreements shall have been made available to the Agent upon its request. The Agent shall have received a certificate from an Authorized Officer of the Borrower certifying that each such contract or agreement is in full force and effect as of the Closing Date and, to the extent applicable, that there have been no changes to each such contract or agreement since the delivery of same in connection with the Existing Credit Agreement. The Agent shall be satisfied in its sole discretion with the terms and conditions of all Material Agreements and license agreements entered into by the Credit Parties and their Subsidiaries.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Opinions of Counsel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Agent shall have received one or more legal opinions, dated as of the Closing Date and addressed to the Agent and the Lenders, from independent legal counsel to the Credit Parties, in each case, in form and substance reasonably acceptable to the Agent.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Fees, Expenses, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Agent shall have received for its own account and for the account of the Lenders and all fees, costs and expenses due and payable pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Fee Letter or any other Loan Documents, including all closing costs and fees and all unpaid reasonable expenses of the Agent and the Lenders incurred in connection with the transactions contemplated hereby (including the Agent&#8217;s legal fees and expenses).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(m)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Anti-Terrorism Laws and Beneficial Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Agent shall have received, as applicable, (i) all documentation and other information required by bank regulatory authorities under applicable &#8220;know your customer&#8221; and anti-money laundering rules and regulations, including the Patriot</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">43</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Act and (ii) if the Borrower qualifies as a &#8220;legal entity customer&#8221; under the Beneficial Ownership Regulation, at least five Business Days prior to the Closing Date, a Beneficial Ownership Certification.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(n)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">No Material Adverse Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. As of the Closing Date, (i) the representations and warranties set forth herein and in each Loan Document are true and correct in all material respects&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that any representations and warranties that are by their terms qualified by materiality, Material Adverse Effect or similar qualification shall be true and correct in all respects, (ii) no Default or Event of Default shall have then occurred and be continuing, and (iii) no Material Adverse Effect shall have occurred since December 31, 2023.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(o)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Satisfactory Legal Form</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. All documents executed or submitted pursuant hereto by or on behalf of any Credit Party shall be satisfactory in form and substance to the Agent, and the Agent and its counsel shall have received all information, approvals, resolutions, opinions, documents or instruments as the Agent may reasonably request.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(p)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Debt Securities and Credit Facilities&#59; Senior Secured Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Agent shall have received a certificate from an Authorized Officer of the Borrower certifying that (i) no Credit Party nor any of its Subsidiaries has issued, or authorized the issuance of, any debt securities or entered into, or authorized the entrance into, any other credit facilities and (ii) the Obligations constitute the sole secured obligations and sole Indebtedness of the Credit Parties (other than Permitted Indebtedness).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(q)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Perfection Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Agent shall have received a Perfection Certificate, dated as of the Closing Date, duly executed (and with all schedules thereto duly completed) and delivered by the Authorized Officer of the Borrower.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(r)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Organizational Chart</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower shall have provided an accurate and complete organization chart reflecting all of the direct and indirect subsidiaries of the Borrower (including the applicable ownership percentages of each entity) as of the Closing Date, and the Agent and the Majority Lenders, in their sole discretion, shall have been satisfied with the direct and indirect equity ownership of the Credit Parties.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(s)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Agent shall have received&#58; (i) certificates of insurance evidencing that the insurance required to be maintained pursuant to Section 7.4 is in full force and effect, in each case, in form and substance satisfactory to the Agent (acting on the instructions of the Majority Lenders acting reasonably)&#59; and (ii) certified copies of the insurance policies (or binders in respect thereof), from one or more insurance companies satisfactory to the Agent, required to be maintained pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(t)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Repayment of Existing Debt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. On or prior to the Closing Date or substantially concurrently with the funding of the Loans, (i) all Indebtedness of each Credit Party and each Subsidiary thereof under the Existing Credit Agreement and all other documents, agreements and instruments related thereto shall have been repaid in full, together with all fees (except for those fees related to the Existing Credit Agreement set forth in the Fee Letter) and other amounts owing thereon, all commitments under the agreements evidencing such Indebtedness shall have been terminated and all letters of credit, if any, issued pursuant to such agreements shall have been terminated, backstopped or cash collateralized, in each case in accordance with the terms of that certain payoff letter, dated on or about the date hereof, by and among the parties to the Existing Credit Agreement and (ii) all security interests in respect of, and Liens securing, the obligations of each such Credit Party and each such Subsidiary, as applicable, under the Existing Credit Agreement and all other documents, agreements and instruments related thereto shall have been terminated and released (except for those documents, agreements and instruments that will continue to secure the Obligations hereunder), and the Agent shall have received all customary payoff</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">44</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">letters with respect to such Indebtedness and such releases and other documents related thereto as may have been requested by the Agent, which releases shall be in customary form, in each case in accordance with the terms of that certain payoff letter, dated on or about the date hereof, by and among the parties to the Existing Credit Agreement. Without limiting the foregoing, the Agent shall have received (or been granted authorization to file) (x) proper termination statements (Form UCC-3 or the appropriate equivalent) for filing under the UCC or equivalent statute or regulation of each jurisdiction where a financing statement or application for registration (Form UCC-1 or the appropriate equivalent) was filed with respect to any Credit Party or any Subsidiary thereof, as applicable, in connection with the security interests created under the Existing Credit Agreement and all other documents, agreements and instruments related thereto, (y) terminations or reassignments of any security interest in any United States Patents, United States Trademarks, United States Copyrights, or similar United States interests of such Credit Party or such Subsidiary, as applicable, on which filings have been made, and (z) if applicable, terminations of all mortgages, leasehold mortgages, hypothecs and deeds of trust created with respect to property of such Credit Party or such Subsidiary, as applicable, in each case, to secure the obligations under the Existing Credit Agreement and all other documents, agreements and instruments related thereto, all of which shall be in a form reasonably satisfactory to the Agent.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE VI</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">REPRESENTATIONS AND WARRANTIES</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In order to induce the Agent and the Lenders to enter into this Agreement, each Credit Party hereby jointly and severally represents and warrants to the Agent and the Lenders as follows&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Organization, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.Each Credit Party (i) is validly organized and existing and in good standing under the laws of the jurisdiction of its incorporation or organization (to the extent such concept it applicable in any relevant jurisdiction), (ii) is duly qualified to do business and is in good standing as a foreign entity in each jurisdiction where the nature of its business requires such qualification, (iii) has full power and authority and holds all requisite governmental licenses, permits and other approvals to enter into and perform its Obligations under each Loan Document to which it is a party, to own and hold under lease its property and to conduct its business substantially as currently conducted by it and (iv) in the case of each UK Subsidiary Guarantor, if any, no limit on its powers will be exceeded as a result of the borrowing, grant of security or giving of guarantees contemplated by the Loan Documents to which it is a party&#59; except in the cases of clauses (ii) and (iii), where the failure to do so could not reasonably be expected to result in a Material Adverse Effect.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Due Authorization, Non-Contravention, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The execution, delivery and performance by each Credit Party and each of its Subsidiaries of each Loan Document executed or to be executed by it are in each case within such Person&#8217;s powers, have been duly authorized by all necessary action, and do not&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;contravene (i) any Organic Documents of such Credit Party or such Subsidiary, (ii) any court decree or order binding on or affecting such Credit Party or such Subsidiary, or (iii) any law or governmental regulation binding on or affecting such Credit Party or such Subsidiary&#59; except in the cases of clauses (ii) and (iii), where could not reasonably be expected to result in a Material Adverse Effect&#59; or</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;result in (i) or require the creation or imposition of, any Lien on a Credit Party&#8217;s or any of its Subsidiaries&#8217; properties (except Permitted Liens) or (ii) a default under any contractual restriction binding on or affecting a Credit Party or any of its Subsidiaries, except in the case of this clause (ii) where such default could not reasonably be expected to result in a Material Adverse Effect.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">45</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Government Approval, Regulation, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No authorization or approval or other action by, and no notice to or filing with, any Governmental Authority or other Person (other than those that have been, or on the Closing Date will be, duly obtained or made and which are, or on the Closing Date will be, in full force and effect) is required for the due execution, delivery or performance by a Credit Party or any of its Subsidiaries of any Loan Document to which it is a party, except where could not reasonably be expected to result in a Material Adverse Effect. Each Credit Party, each of its Subsidiaries and their respective properties and businesses are in compliance in all material respects with all laws, rules, regulations, orders and court decrees applicable to such Persons, properties or businesses, as the case may be.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Validity, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Loan Document to which a Credit Party or any of its Subsidiaries is a party constitutes the legal, valid and binding obligations of such Person enforceable against such Person in accordance with its respective terms (except, in any case, as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization or similar laws affecting creditors&#8217; rights generally and by principles of equity).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The consolidated financial statements of Holdings or the Borrower, as applicable, and such party&#8217;s Subsidiaries furnished to the Agent pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.1(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 7.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(b),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> have been prepared in accordance with GAAP consistently applied, and present fairly the consolidated financial condition of the Persons covered thereby as at the dates thereof and the results of their operations for the periods then ended.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">No Material Adverse Change</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Since December 31, 2023, there has been no event, occurrence or other circumstance that has resulted in a Material Adverse Effect.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Litigation, Labor Matters and Environmental Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 6.7(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, there are no actions, suits or proceedings by or before any arbitrator or Governmental Authority pending against or threatened against or affecting any Credit Party or any of its Subsidiaries.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;There are no material labor controversies pending against or threatened, in writing, against or affecting any Credit Party or any of its Subsidiaries.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;No Credit Party nor any of its Subsidiaries (i) has failed to comply with any material Environmental Law or to obtain, maintain or comply with any material Permit under or in connection with any Environmental Law (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Environmental Permit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), (ii) is or has been subject to any Environmental Liability, (iii) has received notice of any Environmental Liability or (iv) knows of any basis for any Environmental Liability, that, in the case of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, could reasonably be expected to result in a Material Adverse Effect.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Subsidiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 6.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> sets forth the name and jurisdiction of incorporation or formation of each direct and indirect Subsidiary of Holdings. Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 6.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, neither Holdings nor any of its Subsidiaries owns or holds, whether beneficially or of record, any Capital Securities of any other Person. All of the outstanding Capital Securities of Holdings&#8217; Subsidiaries as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 6.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> have been validly issued, are fully paid and nonassessable and are owned directly or indirectly by Holdings free and clear of all Liens except for Permitted Liens.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Ownership of Properties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Credit Party and each of its Subsidiaries owns (i) in the case of owned real property, good and marketable fee title to, and (ii) in the case of owned personal property, good and valid title to, or, in the case of leased real or personal property, valid and enforceable leasehold interests (as the case may be) in, all of its material properties and material assets,</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">46</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">tangible and intangible, of any nature whatsoever, free and clear in each case of all Liens or claims, except for Permitted Liens.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Credit Party and each of its Subsidiaries has filed all income and other material Tax returns and reports required by law to have been filed by it and each Credit Party has paid all material Taxes owed (whether or not shown on any such Tax returns), except any such Taxes which are being diligently contested in good faith by appropriate proceedings and for which adequate reserves in accordance with GAAP shall have been set aside on its books and that are set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 6.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Pension Plans, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. As of the date hereof, (i) the Borrower is not an &#8220;employee benefit plan&#8221; (as defined in Section 3(3) of ERISA) that is subject to Title I of ERISA nor a &#8220;plan,&#8221; as defined in and subject to Section 4975 of the Code, (ii) none of the assets of any Credit Party or any of their respective Subsidiaries constitute &#8220;plan assets&#8221; of one or more such plans within the meaning of 29 C.F.R. Section 2510.3-101, as modified by Section 3(42) of ERISA, (iii) no Credit Party nor any of its Subsidiaries constitutes a &#8220;governmental plan&#8221; within the meaning of Section 3(32) of ERISA, and (iv) to the knowledge of any Credit Party, transactions by or with a Credit Party are not subject to any statute, rule or regulation regulating investments of, or fiduciary obligations with respect to, &#8220;governmental plans&#8221; within the meaning of Section 3(32) of ERISA. Each Welfare Plan and each &#8220;employee pension benefit plan, as defined in Section 3(1) of ERISA that is sponsored or maintained by any Credit Party, has been established and operated in compliance with applicable law, and there is no liability outstanding with respect to any such Welfare Plan or employee pension benefit plan, except as could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 6.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, no formal steps have been taken to terminate any Pension Plan maintained or contributed to any Credit Party or any of its Subsidiaries. No ERISA Event has occurred with respect to any Pension Plan or Multiemployer Plan which could reasonably be expected to result in the incurrence by any Credit Party, any of its Subsidiaries or any ERISA Affiliate of any liability, fine or penalty which could, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. No Credit Party, nor any of its Subsidiaries has any Contingent Liability with respect to any post-retirement benefit under a Welfare Plan, which could, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. As of the date hereof, there are no Multiemployer Plans to which any Credit Party or any of its Subsidiaries has incurred any Liability.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Accuracy of Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> None of the factual information (excluding information of a general economic or industry nature and, for the avoidance of doubt, any budgets, financial statements, forecasts, projections or other forward-looking statements (provided, that, such statements were prepared in good faith based upon assumptions reasonably believed by the preparer)) heretofore or contemporaneously furnished in writing to the Agent or any Lender by or on behalf of any Credit Party or any of its Subsidiaries in connection with this Agreement or any other Loan Document or any transaction contemplated hereby or thereby, when taken as a whole, contains any untrue statement of a material fact, or omits to state any material fact necessary to make any information, in the light of the circumstances under which they were made, not materially misleading.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Regulations U and X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No Credit Party and none of its Subsidiaries is engaged in the business of extending credit for the purpose of buying or carrying margin stock, and no proceeds of any of the Loans will be used to purchase or carry margin stock or otherwise for a purpose which violates, or would be inconsistent with, F.R.S. Board Regulation U or Regulation X. Terms for which meanings are provided in F.R.S. Board Regulation U or Regulation X or any regulations substituted therefor, as from time to time in effect, are used in this Section with such meanings.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">47</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Solvency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower is Solvent, and the Credit Parties and their Subsidiaries taken as a whole, on a consolidated basis, are Solvent.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 6.15(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> sets forth a complete and accurate list of all (A) applied for, issued or registered Patents, (B) registered Trademarks and any pending registrations for Trademarks, and (C) registered Copyrights and any other registered Intellectual Property, in each case owned by a Credit Party or any of its Subsidiaries, as applicable&#59; provided that no Intellectual Property that is not Material Intellectual Property shall be required to be listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 6.15(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. For each item of Material Intellectual Property listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 6.15(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the applicable Credit Party or Subsidiary has, where relevant, indicated the following&#58; the countries in each case in which such item is patented, registered or applied for, the application numbers, the registration or patent numbers, the filing and registration dates, and the owner of such item of Material Intellectual Property.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Each Credit Party and each of its Subsidiaries owns, free and clear of any and all Liens other than Permitted Liens, or has a valid license to all Intellectual Property material to or otherwise necessary for the operation of the business of such Credit Party and Subsidiary. All Material Intellectual Property set forth or required to be set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 6.15(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> is in full force and effect, and has not expired, lapsed or been forfeited, cancelled or abandoned. Each Credit Party and each of its Subsidiaries is the exclusive owner of all right, title and interest in and to, all such Material Intellectual Property that is owned or purported to be owned by such Person.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Each Credit Party and each of its Subsidiaries has taken commercially reasonable measures consistent with commercially reasonable practices in the industry in which it operates to maintain and protect its Material Intellectual Property, and there are no unpaid maintenance or renewal fees payable by such Person that are currently overdue or due prior to the Closing Date for any of such registered Material Intellectual Property.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;There is no proceeding challenging the validity or enforceability of any Material Intellectual Property set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 6.15(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, no Credit Party nor any of its Subsidiaries is involved in any such proceeding with any Person and none of such Material Intellectual Property is the subject of any Other Administrative Proceeding.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Each item of Material Intellectual Property listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 6.15(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> is, to the knowledge of the Credit Parties, valid, enforceable and, where registered, subsisting, and nothing has been knowingly done or omitted to have been done by the Credit Parties, that could reasonably be expected to affect the validity or enforceability of such Material Intellectual Property.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;Except for as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 6.15(c)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, to the knowledge of the Credit Parties, no third party is infringing, misappropriating or otherwise violating any Material Intellectual Property of any Credit Party or Subsidiary.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;To the knowledge of the Credit Parties, no Credit Party or Subsidiary is infringing, misappropriating or otherwise violating the Intellectual Property rights of any other Person in any material manner.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Each Credit Party and each of its Subsidiaries complies with all applicable federal, state, local and foreign laws, rules and regulations pertaining to data privacy (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Privacy Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), except to the extent that any compliance failure would not reasonably be expected to have a Material Adverse Effect. There is no pending, nor has there even been any, complaint, audit, proceeding,</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">48</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">investigation, or claim against any Credit Party or any of its Subsidiaries initiated by any Governmental Authority alleging that any collection, storage, use, access, disclosure, processing, security, and transfer of Personal Data (referred to collectively in this Agreement as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Data Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) of the Credit Party and each of its Subsidiaries is in violation of any applicable Privacy Laws, except to the extent that any such complaint, audit, proceeding, investigation or claim would not reasonably be expected to result in a Material Adverse Effect.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Each Credit Party and each of its Subsidiaries takes commercially reasonable steps to protect Personal Data in its possession or control against damage or loss, and against unauthorized access, acquisition, use, modification, disclosure or other misuse, except to the extent that failure to take such steps would not reasonably result in a Material Adverse Effect. To the knowledge of the Credit Parties, in the past three years, there has been no unauthorized access, use, or disclosure by a third-party of Personal Data in the possession or control of any Credit Party or any of its Subsidiaries with regard to any Personal Data of such Credit Party or such Subsidiary, except to the extent any such unauthorized access or use, either individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Neither any Credit Party nor any of its Subsidiaries targets its products and services to children (persons under the age of 13), and neither any Credit Party nor any of its Subsidiaries knowingly collect Personal Data from children.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Holdings and each of its Subsidiaries has implemented applicable written policies relating to Data Activities, including, a publicly posted website privacy policy, mobile app privacy policy and annual privacy statements required by federal, state, local or foreign law, rule, or regulation, as applicable, and a comprehensive information security program that includes appropriate written information security policies (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Privacy and Data Security Policies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). At all times, Holdings and each of its Subsidiaries has been and is in compliance with all such Privacy and Data Security Policies, and neither Holdings nor any of its Subsidiaries engages in any undisclosed collection of Personal Data on its website or any third-party websites, except to the extent any such noncompliance or undisclosed collection would not reasonably be expected to have a Material Adverse Effect or otherwise result in a material violation of any applicable law.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Holdings and each of its Subsidiaries have provided notifications to, and have obtained consent from, Persons regarding its Data Activities where such notice or consent is required by Privacy Laws. Holdings and each of its Subsidiaries have collected all Personal Data in accordance with its Privacy Policies and Privacy Laws, and Holdings&#8217; and each of its Subsidiaries&#8217; collection of such Personal Data or any other data from third parties is in accordance with any requirements from such third parties, including written website terms and conditions.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;Holdings and each of its Subsidiaries have taken commercially reasonable steps and implemented commercially reasonable measures and procedures to ensure that Holdings&#8217; and each of its Subsidiaries&#8217; Systems are free from malware and other harmful code, including, but not limited to, the use of commercially available up to date antivirus software.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;Holdings and each of its Subsidiaries is, and at all times has been in compliance with all U.S. federal and state laws and regulations pertaining to sales, marketing, and electronic communications, including, without limitation, the CAN-SPAM Act, the Telephone Consumer Protection Act, and the Telemarketing Sales Rule, except to the extent any such noncompliance would not reasonably be expected to result in a material violation of any applicable law.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">49</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 6.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Material Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. As of the Closing Date, set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 6.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> is a complete and accurate list of each Material Agreement of the Credit Parties and their Subsidiaries, with a reasonable description of the parties, subject matter thereof and amendments, waivers and modifications thereto. As of the Closing Date, each such Material Agreement (i) is in full force and effect and is binding upon and enforceable against each Credit Party or Subsidiary party thereto and to the knowledge of such Credit Party or Subsidiary, all other parties thereto in accordance with its terms, and (ii) has not suffered any material default thereunder. As of the Closing Date, no Credit Party nor any of its Subsidiaries has taken any action that could reasonably be expected to permit any other Person party to any Material Agreement to have, and no such Person otherwise has, any material defenses, counterclaims or rights of setoff thereunder.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 6.18&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Permits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> The Credit Parties and their Subsidiaries have all material Permits, including Environmental Permits, necessary or required for the ownership, operation and conduct of its business and the distribution of the Products. All such Permits are validly held and there are no material defaults thereunder.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 6.19&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Regulatory Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. With respect to each Product&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;Set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 6.19(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> is a complete and accurate list of all material Regulatory Authorizations relating to the Credit Parties and their Subsidiaries, the conduct of their business, and the Products (on a per Product basis). All such material Regulatory Authorizations are (i) legally and beneficially owned exclusively by the Credit Parties and their Subsidiaries, as applicable, free and clear of all Liens other than Permitted Liens, and (ii) as applicable, validly registered and on file with the applicable Governmental Authority, in compliance with all filing and maintenance requirements (including any fee requirements) thereof, and are in good standing, valid and enforceable with the applicable Governmental Authority. All required notices, registrations and listings, supplemental applications or notifications, reports (including field alerts, medical device reports (MDRs) and other reports of adverse experiences or product malfunctions, and reports of corrections or removal) and other required filings with respect to the Products for the last five (5) years have been timely filed with the FDA and all other applicable Governmental Authorities.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;(i) All regulatory filings required by any Regulatory Authority or in respect of any Regulatory Authorization with respect to any Product or any Product Development and Commercialization Activities which represented, in the aggregate, 15% or more of Net Sales in any applicable year, in the last five (5) years have been made, and all such filings above such threshold are complete and correct and have complied in all material respects with all applicable laws and regulations, (ii) all clinical and pre-clinical trials, if any, of investigational Products have been and are being conducted by the Credit Parties and their Subsidiaries in accordance with all applicable laws and regulations along with appropriate monitoring of clinical investigator trial sites for their compliance, and (iii) the Credit Parties and their Subsidiaries have disclosed to the Agent all such regulatory filings and all material communications between representatives of the Credit Parties (and their Subsidiaries) and any Regulatory Authority.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;The Credit Parties, their Subsidiaries and the agents thereof are in compliance in all material respects with all applicable statutes, rules and regulations (including all Healthcare Laws and Regulatory Authorizations) of all applicable Governmental Authorities, including the FDA and all other Regulatory Authorities, with respect to each Product and all Product Development and Commercialization Activities related thereto. The Credit Parties and their Subsidiaries have and maintain in full force and effect all the necessary and requisite Regulatory Authorizations. The Credit Parties and their Subsidiaries are in compliance in all material respects with all applicable registration and listing requirements set forth in the FD&#38;C Act or equivalent regulation of each other Governmental </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">50</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Authority having jurisdiction over such Person. The Credit Parties and their Subsidiaries adhere in all material respects to all applicable regulations of all Regulatory Authorities with respect to the Products and all Product Development and Commercialization Activities related thereto.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 6.19(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, no Credit Party nor any of its Subsidiaries has received from any Regulatory Authority any notice of alleged non-compliance or adverse findings with respect to any Product or any Product Development and Commercialization Activities related thereto which represented, in the aggregate, 15% or more of Net Sales in any applicable year, including any FDA Form 483 inspectional observations, notices of violations, Warning Letters, untitled letters, criminal proceeding notices under Section 305 of the FD&#38;C Act, or any other similar communication from any Regulatory Authority within the last five (5) years. Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 6.19(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, there have been no recalls, market withdrawals, field notifications or corrections, detentions, seizures, notifications or allegations of misbranding or adulteration or safety alerts conducted, requested, or threatened by any Regulatory Authority, or (for example in the case of a recall) initiated by Credit Party or any of its Subsidiaries, relating to any Products which represented, in the aggregate, 15% or more of Net Sales in any applicable year within the last five (5) years. No Credit Party nor any of its Subsidiaries has received any written notification that remains unresolved from the FDA or any other Regulatory Authority indicating any breach or violation of any applicable Regulatory Authorization, including that any of the Products is misbranded or adulterated as defined in the FD&#38;C Act, in each case of the foregoing, which represented, in the aggregate, 15% or more of Net Sales in any applicable year within the last five (5) years.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;No Credit Party, nor any of its Subsidiaries, nor any officer, employee or agent thereof, has made an untrue statement of a material fact or fraudulent statements to the FDA or any other Regulatory Authority, failed to disclose a material fact required to be disclosed to the FDA or any other Regulatory Authority, or committed an act, made a statement, or failed to make a statement that, at the time such disclosure was made (or was not made), could reasonably be expected to provide a basis for the FDA or any other Regulatory Authority to invoke its policy respecting Fraud, Untrue Statements of Material Facts, Bribery and Illegal Gratuities, set forth in 56 Fed. Reg. 46191 (September 10, 1991) or any similar policy.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 6.19(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, no Credit Party nor any of its Subsidiaries has received any written notice that the FDA or any other applicable Regulatory Authority has commenced or initiated, or threatened to commence or initiate, any action to withdraw any Regulatory Authorization, requested the recall (whether by correction or removal) of any Products or commenced or initiated or threatened to commence or initiate, any action to enjoin any Product Development and Commercialization Activities of such Credit Party or such Subsidiary, in each case, which represented, in the aggregate, 15% or more of Net Sales in any applicable year,.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 6.19(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the clinical, preclinical, safety and other studies and tests conducted by or on behalf of or sponsored by the Credit Parties and their Subsidiaries, or in respect of which any Products or Product candidates under development have participated, were (and if still pending, are) being conducted in accordance with all applicable Regulatory Authorizations and Healthcare Laws in all material respects.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;The transactions contemplated by the Loan Documents (or contemplated by the conditions to effectiveness of any Loan Document) will not impair any Credit Party&#8217;s or any of its Subsidiaries&#8217; ownership of or rights under (or the license or the right to use, as the case may be) any Regulatory Authorizations relating to the Products in any material manner, and no consent or other authorization of any Governmental Authority is required in connection with the transactions </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">51</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">contemplated hereby, including the Liens granted in connection herewith and the exercise of rights and remedies with respect thereto.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.20&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Transactions with Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 6.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, no Credit Party and none of its Subsidiaries has entered into, renewed, extended or been a party to, any transaction (including the purchase, sale, lease, transfer or exchange of property or assets of any kind or the rendering of services of any kind) with any Affiliate during the three (3)-year period prior to the Closing Date, which would not be permitted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.21&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Investment Company Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No Credit Party and none of its Subsidiaries is an &#8220;investment company&#8221; or is &#8220;controlled&#8221; by an &#8220;investment company,&#8221; as such terms are defined in, or subject to regulation under, the Investment Company Act of 1940, as amended.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.22&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">OFAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No Credit Party, any of its Subsidiaries, any Related Party, any of their respective directors, officers, or employees nor any agents or other persons acting on behalf of any of the foregoing (a) is currently the target of any Sanctions, (b) is located, organized or residing in any Designated Jurisdiction, (c) is or has been (within the previous five (5) years) engaged in any transaction with, or for the benefit of, any Person who is now or was then the target of Sanctions or who is located, organized or residing in any Designated Jurisdiction or (d) is or has ever been in violation of or subject to an investigation relating to Sanctions. No Loans, and none of the proceeds from the Loans, have been or will be used, directly or indirectly, to lend, contribute or provide to, or has been or will be otherwise made available to fund, any activity or business in any Designated Jurisdiction or to fund any activity or business of any Person located, organized or residing in any Designated Jurisdiction or who is the subject of any Sanctions, or in any other manner that will result in any violation by any Person (including the Agent, any Lender and its and their respective Affiliates) of Sanctions.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.23&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Anti-Corruption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No Credit Party, any of its Subsidiaries, any Related Party, or any of their respective directors, officers, or employees or any agents or other persons acting on behalf of any of the foregoing, directly or indirectly, has (a) violated or is in violation of any applicable anti-corruption law, (b) made, offered to make, promised to make or authorized the payment or giving of, directly or indirectly, any Prohibited Payment or (c) been subject to any investigation by any Governmental Authority with regard to any actual or alleged Prohibited Payment.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.24&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Deposit and Disbursement Accounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 6.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> contains a list of all banks and other financial institutions at which any Credit Party or any of its Subsidiaries maintains deposit accounts, lockboxes, disbursement accounts, investment accounts or other similar accounts, and such Schedule correctly identifies the name and address of each bank or financial institution, the name in which the account is held, the type of account, and the complete account number therefor. Subject to the proviso in Section 7.12(a), each such account (other than each Excluded Account) is a Controlled Account.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.25&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Registration Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 6.25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, no Credit Party and none of its Subsidiaries has granted or agreed to grant any registration rights, including piggyback rights, to any Person.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.26&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Royalty and Other Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 6.26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, no Credit Party and none of its Subsidiaries is obligated to pay any royalty, milestone payment, deferred payment or any other contingent payment in respect of any Product.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.27&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sale and Leaseback</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No Credit Party and none of its Subsidiaries has entered, directly or indirectly, into any agreement or arrangement providing for the sale or transfer by it </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">52</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of any property (now owned or hereafter acquired) to a Person and the subsequent lease or rental or such property or other similar property from such Person, except for any transactions permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;8.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.28&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Obligations constitute the sole senior secured obligations and sole Indebtedness (except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 8.2(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) of the Credit Parties and their Subsidiaries.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 6.29&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Beneficial Ownership Certification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The information included in the Beneficial Ownership Certification is true and correct in all respects.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE VII</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AFFIRMATIVE COVENANTS</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Credit Parties hereby jointly and severally covenant and agree for the benefit of the Agent and the Lenders that, until the Termination Date has occurred, the Credit Parties will perform or cause to be performed by each of their respective Subsidiaries, as applicable, the obligations set forth below.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 7.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Information, Reports, Notices, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Holdings will furnish the Agent copies of the following financial statements, reports, notices and information&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;as soon as available and in any event within thirty (30) days after the end of each calendar month, an unaudited consolidated balance sheet of Holdings and its Subsidiaries as of the end of such month and consolidated statements of income and cash flow of Holdings and its Subsidiaries for such applicable period, including (in each case), in comparative form the figures for the corresponding month in, and year to date portion of, the immediately preceding Fiscal Year and as provided in the budget delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> below for the current Fiscal Year, certified as complete and correct by the chief financial or accounting Authorized Officer of Holdings (subject to normal year-end audit adjustments) together with evidence satisfactory to the Agent (acting on the instructions of the Majority Lenders acting reasonably) that the Credit Parties were in compliance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for such calendar month&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;as soon as available and in any event within forty-five (45) days after the end of each Fiscal Quarter (including the last Fiscal Quarter of each Fiscal Year), an unaudited consolidated balance sheet of Holdings and its Subsidiaries as of the end of such Fiscal Quarter, and consolidated statements of income and cash flow of Holdings and its Subsidiaries for such period, including (in each case), in comparative form the figures for the corresponding Fiscal Quarter in, and year to date portion of, the immediately preceding Fiscal Year, certified as complete and correct by the chief financial or accounting Authorized Officer of Holdings and its Subsidiaries (subject to normal year-end audit adjustments)&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;(i) as soon as available and in any event within one hundred twenty (120) days after the end of each Fiscal Year, an unaudited consolidated balance sheet of Holdings and its Subsidiaries as of the end of such Fiscal Year, and the related unaudited consolidated statements of income and cash flow of Holdings and its Subsidiaries for such Fiscal Year, setting forth in comparative form the figures for the immediately preceding Fiscal Year, certified as complete and correct by the chief financial or accounting Authorized Officer of Holdings and its Subsidiaries&#59; and (ii) as soon as available and in any event within one hundred twenty (120) days after the end of each Fiscal Year, a copy of the consolidated balance sheet of Holdings and its Subsidiaries, and the related consolidated statements of income and cash flow of Holdings and its Subsidiaries for such Fiscal Year, setting forth in comparative form the figures for the immediately preceding Fiscal Year, audited (without any Impermissible </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">53</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Qualification) by independent public accountants acceptable to the Agent, which shall include a calculation of the financial covenants set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and stating that, in performing the examination necessary to deliver the audited financial statements of Holdings, no knowledge was obtained of any Event of Default&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;concurrently with the delivery of the financial information required to be delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clauses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> above for each Fiscal Quarter and each Fiscal Year, a Compliance Certificate, executed by the chief financial or accounting Authorized Officer of Holdings, (i) showing compliance with the financial covenants set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and stating that no Default has occurred and is continuing (or, if a Default has occurred, specifying the details of such Default and the action that Holdings or any of its Subsidiaries has taken or proposes to take with respect thereto), (ii) stating that no Subsidiary has been formed or acquired since the delivery of the last Compliance Certificate (or, if a Subsidiary has been formed or acquired since the delivery of the last Compliance Certificate, a statement that such Subsidiary has complied with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) and (iii) including a list of all Immaterial Subsidiaries and setting forth in reasonable detail the Net Sales and Assets, in each case, attributable to each such Immaterial Subsidiary for the applicable Measurement Period&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;as soon as available and in any event within thirty (30) days after the end of each Fiscal Year, an annual budget, a business plan and financial forecasts of Holdings and its Subsidiaries for the then current Fiscal Year of Holdings, in form and substance as approved by the board of directors (or equivalent) of Holdings, which shall include a projection of income and a projected cash flow statement for each Fiscal Quarter in such Fiscal Year and a projected balance sheet as of the end of each Fiscal Quarter in such Fiscal Year, in each case prepared in reasonable detail, with appropriate presentation and discussion (in reasonable detail) of the principal assumptions upon which such budgets and projections are based, which shall be accompanied by the statement of an Authorized Officer of Holdings to the effect that such budget and projections are based on reasonable and good faith estimates and assumptions made by the management of Holdings for the respective periods covered thereby&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;as soon as possible and in any event within three (3) Business Days after Holdings obtains knowledge of the occurrence of a Default, a statement of an Authorized Officer of Holdings setting forth details of such Default, event or occurrence and the action which Holdings has taken and proposes to take with respect thereto&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;as soon as possible and in any event within three (3) Business Days after Holdings obtains knowledge of (i) the occurrence of any material adverse development with respect to any litigation, action, proceeding or labor controversy described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 6.7(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and in the following </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or (ii) the commencement of any litigation, action, proceeding or labor controversy of the type and materiality described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or alleging potential or actual violations of any Healthcare Laws, notice thereof and, to the extent the Agent or any Lender requests, copies of all documentation relating thereto&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;as soon as possible and in any event within three (3) Business Days after Holdings obtains knowledge of any return, recovery, dispute or claim related to any Product or inventory that involves more than $1,500,000, written notice thereof from an Authorized Officer of Holdings which notice shall include any statement setting forth details of such return, recovery, dispute or claim&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;as soon as possible and in any event within three (3) Business Days after becoming aware of the occurrence of any ERISA Event which could reasonably be expected to result in the incurrence by a Credit Party or any of its Subsidiaries of any material liability, fine or penalty, notice </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">54</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">thereof and copies of all documentation relating thereto, written notice thereof from an Authorized Officer of Holdings, which notice shall include a statement setting forth details of such events&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;promptly after the sending or filing thereof, copies of all reports, notices, prospectuses and registration statements which any Credit Party or any of its Subsidiaries files with the SEC or any national securities exchange&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;promptly upon receipt thereof, copies of all &#8220;management letters&#8221; (or equivalent) submitted to Holdings or any of its Subsidiaries by the independent public accountants referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in connection with each audit made by such accountants&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;such other financial and other information as the Agent or any Lender may from time to time reasonably request (including information and reports in such detail as the Agent or any Lender may request with respect to the terms of and information provided pursuant to the Compliance Certificate).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 7.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Maintenance of Existence&#59; Compliance with Contracts, Laws, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Credit Party will, and will cause each of its Subsidiaries to, (i) preserve and maintain its legal existence (except as otherwise permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) and (ii) comply in all material respects with all applicable laws, rules, regulations and orders, including all Healthcare Laws and the payment (before the same become delinquent) of all material Taxes imposed upon such Credit Party or such Subsidiary or upon its property, except to the extent being diligently contested in good faith by appropriate proceedings and for which adequate reserves in accordance with GAAP have been set aside on the books of such Credit Party or such Subsidiary.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 7.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Maintenance of Properties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Credit Party will, and will cause each of its Subsidiaries to, maintain, preserve, protect and keep its respective material properties in good repair, working order and condition (ordinary wear and tear excepted), and make necessary material repairs, renewals and replacements so that the business carried on by such Credit Party or such Subsidiary may be properly conducted at all times in all material respects, unless the Disposition of such property is otherwise permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 7.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Credit Party will, and will cause each of its Subsidiaries to, maintain&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;insurance on its property with financially sound and reputable insurance companies against loss and damage in at least the amounts (and with only those deductibles) customarily maintained, and against such risks as are typically insured against in the same general area, by Persons of comparable size engaged in the same or similar business as such Credit Party or such Subsidiary&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;all worker&#8217;s compensation, employer&#8217;s liability insurance or similar insurance as may be required under the laws of any state or jurisdiction in which it may be engaged in business.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Without limiting the foregoing, on or within forty-five (45) days of the Closing Date (or such longer period as the Agent may agree in its reasonable discretion) all insurance policies required pursuant to this Section shall (i) name the Agent, for the benefit of the Secured Parties, as mortgagee (in the case of property insurance) or loss payee or additional insured (in the case of liability insurance), as applicable, and provide that no cancellation or modification of the policies will be made without the prior written notice to the Agent and (ii) be in addition to any requirements to maintain specific types of insurance contained in the other Loan Documents. If any Credit Party or any of its Subsidiaries fails to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">55</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">provide or pay for any such insurance, the Agent may but is not obligated to, obtains the same at such Credit Party&#8217;s or such Subsidiary&#8217;s expense.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 7.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Books and Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Credit Party will, and will cause each of its Subsidiaries to, keep books and records that accurately reflect all of its business affairs and transactions and permit the Agent, any Lenders or any of their respective representatives, at reasonable times and intervals upon reasonable notice to Holdings, to visit such Credit Party&#8217;s or such Subsidiary&#8217;s offices, to discuss such Credit Party&#8217;s or such Subsidiary&#8217;s financial matters with its officers and employees, and its independent public accountants (and the Credit Parties hereby authorize such independent public accountant to discuss such Credit Party&#8217;s or such Subsidiary&#8217;s financial matters with the Agent, any Lenders or any of their respective representatives whether or not any representative of such Credit Party or such Subsidiary, as applicable, is present) and to examine (and photocopy extracts from) any of its books and records. The Credit Parties will, and will cause each of their Subsidiaries to, pay all fees and expenses of the Agent or such Lender, including any fees of such independent public accountant incurred in connection with the Agent&#8217;s or any Lender&#8217;s exercise of its rights pursuant to this Section&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, however, that in the absence of a Default and an Event of Default, the Credit Parties shall not be responsible for the costs associated with more than one such visit or inspection during any Fiscal Year.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 7.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Environmental Law Covenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Credit Party will, and will cause each of its Subsidiaries to, (i) use and operate all of its and their businesses, facilities and properties in material compliance with all Environmental Laws, and keep and maintain all Environmental Permits and remain in compliance therewith and (ii) promptly notify the Agent of, and provide the Agent with copies of all material claims, complaints, notices or inquiries relating to, any actual or alleged non-compliance with any Environmental Laws or Environmental Permits or any actual or alleged Environmental Liabilities.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 7.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Use of Proceeds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Proceeds of the Loans shall be used only to (i) refinance the outstanding obligations under the Existing Credit Agreement and (ii) pay certain fees, costs, and expenses incurred in connection with such refinancing and entry into this Agreement, the other Loan Documents and the transactions contemplated hereby.</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 7.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Future Guarantors, Security, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Credit Party agrees that&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;it will, and will cause each of its Subsidiaries, except for Immaterial Subsidiaries and Foreign Excluded Subsidiaries, existing as of the Closing Date to, execute any documents, Mortgages and Mortgage Instruments (subject to the limitation set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.8(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">), UCC-1 financing statements, UCC-3 termination statements, agreements and instruments, and take all further action that may be required under applicable law, or that the Agent may reasonably request, in order to effectuate the transactions contemplated by the Loan Documents and in order to grant, preserve, protect and perfect the validity and first priority (subject to Permitted Liens) of the Liens created or intended to be created by the Loan Documents&#59; including, without limitation, actions in any non-U.S. jurisdiction or required by the laws of any non-U.S. jurisdiction to create any security interests in assets of the Credit Parties located or titled outside of the United States or to perfect or make enforceable any security interests in any Collateral&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;it will cause each of its Subsidiaries, except for any Immaterial Subsidiary and any Foreign Excluded Subsidiary, that is acquired or organized by it after the Closing Date to, on or within thirty (30) days of such acquisition or organization (or such longer period as the Agent may agree in its sole discretion), to (i) execute a supplement (in form and substance satisfactory to the Agent (acting on the instructions of the Majority Lenders acting reasonably)) to each applicable Loan Document (including the Security Agreement, the Intercompany Subordination Agreement, the Copyright Security</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">56</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Agreement, the Patent Security Agreement, the Trademark Security Agreement and other security documents, and the Subsidiary Guaranty) in favor of the Agent and the other Secured Parties, (ii) execute or deliver such other UCC-1 financing statements, UCC-3 termination statements, documents, Mortgages and Mortgage Instruments, agreements and instruments as the Agent may reasonably request, and (iii) take all further action that may be required under applicable law, or that the Agent may reasonably request, in order to effectuate the transactions contemplated by the Loan Documents and in order to grant, preserve, protect and perfect the validity and first priority (subject to Permitted Liens) of the Liens created or intended to be created by the Loan Documents&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> that no Mortgage or Mortgage Instruments will be required with respect to any real property having a fair market value of less than $2,500,000&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;it will cause each of its Subsidiaries organized under the under the laws of England and Wales, except for any Immaterial Subsidiary and any Foreign Excluded Subsidiary, that is acquired or organized by it after the Closing Date to, on or within thirty (30) days of such acquisition or organization (or such longer period as the Agent may agree in its sole discretion), to deliver to the Agent&#58; (A) a certificate, duly executed and delivered by such Person&#8217;s Secretary or Assistant Secretary, director, managing member or general partner, as applicable, as to&#58; (i) resolutions of each such Person&#8217;s board of directors (or other managing body, in the case of other than a corporation) then in full force and effect authorizing (x) the execution, delivery and performance of each Loan Document to be executed by such Person and the transactions contemplated hereby and thereby and (y) a specified person or persons, on its behalf, to sign and&#47;or despatch all documents and notices to be signed and&#47;or despatched by it under or in connection with the Loan Documents to which it is a party&#59; (ii) a copy of (x) a resolution of the board of directors of such Subsidiary approving the terms of the resolution referred to in sub-clause (i) above&#59; (y) a resolution of all of the shareholders of each such subsidiary approving the terms of the resolution referred to in sub-clause (i) above&#59; and (z) a resolution of the board of directors of each shareholder referred to in the preceding sub-clause (y) that is a corporate body, approving the execution by such corporate shareholder of the resolution referred to in the preceding sub-clause (y)&#59; (iii) the incumbency and signatures of those of its officers, managing member or general partner, as applicable, authorized to act with respect to each Loan Document to be executed by such Person&#59; (iv) the full force and validity of each Organic Document of such Person and copies thereof&#59; and certifying that each copy document relating to it specified in this clause is correct, complete and in full force and effect and has not been amended or superseded as at the date no earlier than the date of such certificate, in each case in this sub-clause (A), upon which certificates the Agent may conclusively rely until it shall have received a further certificate of the Secretary, Assistant Secretary, director, managing member or general partner, as applicable, of any such Person cancelling or amending the prior certificate of such Person&#59; (B) a certificate, duly executed and delivered by a director of such Subsidiary, which certificate shall be in form and substance satisfactory to the Agent (acting on the instructions of the Majority Lenders acting reasonably) and shall certify that borrowing or guaranteeing, as applicable, and securing the Loan Commitment Amount would not cause any borrowing, guarantee, security or any similar limit binding on such Subsidiary to be exceeded&#59; (C) at least two originals of an English law debenture (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Debenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) executed by such Subsidiary created or expressed to be created in favor of the Agent, together with, a copy of all notices required to be sent under the Debenture executed by such Subsidiary and all share certificates, transfers and stock transfer forms or equivalent duly executed by the relevant Subsidiary in blank in relation to the assets subject to or expressed to be subject to the debenture security and other documents of title to be provided under the Debenture&#59; and (D) with respect to each company incorporated in the United Kingdom whose shares are the subject of the Debenture security (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Charged&#160;Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), either&#58; (i)a certificate of an Authorized Officer of Holdings certifying that&#58; (A) each of Holdings and its Subsidiaries has complied within the relevant timeframe with any notice it has received pursuant to Part 21A of the Companies Act 2006 from such Charged Company, (B) no &#8220;warning notice&#8221; or &#8220;restrictions notice&#8221; (in each case as defined in Schedule 1B of the Companies Act 2006) has been issued in respect of those shares and (C) together with a copy of the &#8220;PSC register&#8221; (within the meaning </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">57</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of section 790C(10) of the Companies Act 2006) of such Charged Company, which, in the case of a Charged Company that is a Subsidiary Guarantor, is certified by an Authorized Officer of Holdings to be correct, complete and not amended or superseded as at a date no earlier than the Closing Date&#59; or a certificate of an Authorized Officer of Holdings certifying that such Charged Company is not required to comply with Part 21A of the Companies Act 2006&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;it will promptly notify the Agent of any real property subsequently acquired by it or any of its Subsidiaries, except for Immaterial Subsidiaries and Foreign Excluded Subsidiaries, and will provide the Agent with a description of such real property, the acquisition date thereof and the purchase price therefor, and if reasonably requested by the Agent, on or within sixty (60) days of such acquisition (or such longer period as the Agent may agree in its sole discretion) execute and deliver Mortgages and Mortgage Instruments in order to grant perfected and first priority Liens on such real property&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that no Mortgage or Mortgage Instruments will be required with respect to any real property having a fair market value of less than $2,500,000&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;it will, and will cause each of its Subsidiaries, except for Immaterial Subsidiaries and Foreign Excluded Subsidiaries, to, at its cost and expense, promptly secure the Obligations by pledging or creating, or causing to be pledged or created, perfected Liens with respect to such of its assets and properties as the Agent shall designate, it being agreed that it is the intent of the parties that the Obligations shall at all times be secured by, among other things, substantially all the assets of Credit Parties and such Subsidiaries (including personal property acquired subsequent to the Closing Date), in each case, located in the United States and in any non-U.S. jurisdiction&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that a pledge of 100% of the Capital Securities of any Foreign Subsidiary acquired or organized after the Closing Date shall be required, except to the extent as reasonably determined by the Borrower after consulting with the Agent, such pledge would reasonably be expected to result in material adverse tax consequences to the Borrower or Holdings, in which case Borrower shall not be required to pledge voting Capital Securities in excess of 65% of the issued and outstanding voting Capital Securities of such Foreign Subsidiary&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;it will, and will cause each of its Subsidiaries, except for Immaterial Subsidiaries, and Foreign Excluded Subsidiaries to, at its cost and expense, promptly upon acquisition, filing or issuance of any Patent, Trademark, Copyright, material Product Agreement or other Material Intellectual Property anywhere in the world, notify the Agent of such acquisition, filing or issuance of any Patent, Trademark, Copyright, material Product Agreement or other Material Intellectual Property and execute a supplement (in form and substance satisfactory to the Agent (acting on the instructions of the Majority Lenders acting reasonably)) to each applicable Loan Document (including the Security Agreement, the Copyright Security Agreement, the Patent Security Agreement, the Trademark Security Agreement and other security documents)&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;all Liens described above in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> will be created under the Loan Documents in form and substance satisfactory to the Agent (acting on the instructions of the Majority Lenders acting reasonably), and each Credit Party will, and will cause each of its Subsidiaries, except for Immaterial Subsidiaries and Foreign Excluded Subsidiaries, to, deliver or cause to be delivered to the Agent all such instruments and documents (including legal opinions and lien searches) as the Agent shall reasonably request to evidence compliance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">58</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 7.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Obtaining of Permits, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. With respect to Products, each Credit Party will, and will cause each of its Subsidiaries to, obtain, maintain and preserve, and take all necessary action to timely renew all Permits (including Key Permits) and accreditations which are necessary in the proper conduct of its business.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 7.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Product Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Credit Party will, and will cause each of its Subsidiaries to, (i) maintain each Permit, including each Regulatory Authorization, from, or file any notice or registration in, each jurisdiction in which such Credit Party or such Subsidiary is required to obtain any Permit or Regulatory Authorization or to file any notice or registration, in order to sell or distribute the Products which represented, in the aggregate, 15% or more of Net Sales in any applicable year and (ii) upon request of the Agent, promptly provide evidence of same to the Agent.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 7.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Maintenance of Regulatory Authorizations, Contracts, Intellectual Property,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. With respect to the Products, each Credit Party will, and will cause each of its Subsidiaries to, (i) maintain in full force and effect all Regulatory Authorizations, contract rights, or other rights necessary for the material operations of its business, (ii) notify the Agent, promptly after learning thereof, of any Product recalls, safety alerts, corrections, withdrawals, marketing suspensions, removals or the like conducted, to be undertaken or issued by such Credit Party, such Subsidiary or its respective suppliers whether or not at the request, demand or order of any Governmental Authority or otherwise with respect to any Product which represented, in the aggregate, 15% or more of Net Sales in any applicable year, or any basis for undertaking or issuing any such action or item, (iii) maintain in full force and effect, and pay all costs and expenses relating to, all Material Intellectual Property owned by such Credit Party or such Subsidiary, (iv) notify the Agent, promptly after learning thereof, of any infringement or other violation by any Person of its Material Intellectual Property and respond to such infringement or other violation in a manner determined within the reasonable judgement and at the sole expense of such Credit Party and (v) notify the Agent, promptly after learning thereof, of (x) any claim by any Person that the conduct of such Credit Party&#8217;s or such Subsidiary&#8217;s business (including the development, manufacture, use, sale or other commercialization of any Product) infringes any material Intellectual Property of such Person and, if requested by the Agent, use commercially reasonable efforts to resolve such claim, or (y) any event, circumstance, act or omission that could reasonably be expected to cause any representation or warranty contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> to be incorrect in any material respect if such representation or warranty was to be made at the time such Credit Party or such Subsidiary learned of such event, circumstance, act or omission.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 7.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Cash Management</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Credit Party will, and will cause each of its Subsidiaries (other than Immaterial Subsidiaries) to&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;maintain all deposit accounts, disbursement accounts, investment accounts (and other similar accounts) and lockboxes (other than Excluded Accounts) with a bank or financial institution that has executed and delivered to the Agent a Controlled Account Agreement in form and substance reasonably acceptable to the Agent&#59; each such deposit account, disbursement account, investment account (or similar account) and lockbox (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Controlled Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) shall be a cash collateral account, with all cash, checks and other similar items of payment in such account securing payment of the Obligations, and the Credit Parties shall have granted a Lien to the Agent, for the benefit of the Secured Parties, over such Controlled Accounts&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that the Credit Parties shall cause each account existing as of the Closing Date to become a Controlled Account on or within sixty (60) days of the Closing Date (or such longer period as the Agent may agree in its reasonable discretion)&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;deposit promptly, and in any event no later than fourteen (14) Business Days after the date of receipt thereof, all checks, drafts, other similar items of payment or cash, in each case, in</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">59</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">an amount in excess of $500,000, in each case, relating to or constituting payments made in respect of any and all accounts and other rights and interests into Controlled Accounts.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">At any time after the occurrence and during the continuance of an Event of Default, at the request of the Agent, the Credit Parties and their Subsidiaries will cause all payments constituting proceeds of accounts to be directed into lockbox accounts under Controlled Account Agreements in form and substance satisfactory to the Agent.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE VIII</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NEGATIVE COVENANTS</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Credit Parties hereby jointly and severally covenant and agree for the benefit of the Agent and the Lenders that until the Termination Date has occurred unless the Majority Lenders shall otherwise consent in writing, the Credit Parties will perform or cause to be performed by each of their respective Subsidiaries, as applicable, the obligations set forth below.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 8.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Business Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No Credit Party will, nor will it permit any of its Subsidiaries to, engage in any business activity except those business activities engaged in on the date of this Agreement and activities reasonably incidental or complimentary thereto and reasonable extensions thereof.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 8.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No Credit Party will, nor will it permit any of its Subsidiaries to, create, incur, assume or permit to exist any Indebtedness, other than the following (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Permitted&#160;Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Indebtedness in respect of the Obligations&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;unsecured Indebtedness of any Credit Party pursuant to Hedging Agreements solely for purposes of hedging the rate of interest payable on the outstanding principal amount of the Loans&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Indebtedness existing as of the Closing Date which is identified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;8.2(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Indebtedness in respect of performance, surety or appeal bonds provided in the ordinary course of business and consistent with past practice but excluding (in each case) Indebtedness incurred through the borrowing of money or Contingent Liabilities in respect thereof&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;purchase money Indebtedness and Capitalized Lease Liabilities incurred by any Credit Party in an aggregate amount at any time outstanding, when combined with the aggregate principal amount of all Indebtedness incurred pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, not to exceed $4,500,000&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;Indebtedness (i) arising from customary agreements for indemnification related to sales of goods, licensing of Intellectual Property or adjustment of purchase price or similar obligations in any case incurred in connection with the acquisition or Disposition permitted hereunder of any business, assets or Subsidiary of Holdings, (ii) representing deferred compensation to employees of a Credit Party or any of its Subsidiaries incurred in the ordinary course of business consistent with past practice, and (iii) representing customer deposits and advance payments received in the ordinary course of business from customers for goods purchased in the ordinary course of business&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">60</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;Indebtedness with respect to cash management obligations and other Indebtedness in respect of automatic clearing house arrangements, netting services, overdraft protection and similar arrangements, in each case incurred in the ordinary course of business&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;unsecured Indebtedness in the nature of account or trade payables originated in the ordinary course of business&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;(i) intercompany Indebtedness of any Credit Party or a Subsidiary thereof owing to another Credit Party or a Subsidiary thereof, in each case, subject to the Intercompany Subordination Agreement&#59; provided that any intercompany Indebtedness made to a Subsidiary that is not a Credit Party shall be for the sole purpose of payroll expenses and other operational costs incurred by such Subsidiary in the ordinary course of business and consistent with past practice&#59; and (ii) unsecured guarantees of outstanding Permitted Indebtedness made in the ordinary course of business by the Borrower or any Subsidiary of obligations of any Credit Party permitted hereunder in an aggregate amount not to exceed $1,500,000 at any time outstanding&#59; provided that to the extent that any such Permitted Indebtedness is subordinated to the Obligations, such guarantees are similarly subordinated&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;(i) Indebtedness of the Borrower or any Subsidiary Guarantor incurred to finance the acquisition, construction or improvement of any fixed or capital assets&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that (x) such Indebtedness is incurred prior to or within two hundred seventy (270) days after such acquisition or the completion of such construction or improvement and (y) the aggregate principal amount of Indebtedness permitted by this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, when combined with the aggregate principal amount of all purchase money Indebtedness and Capitalized Lease Liabilities incurred pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, does not exceed $4,500,000 at any time outstanding and (ii) extensions, renewals, refinancings and replacements thereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that no such extension, renewal, refinancing or replacement shall result in an increase in the outstanding principal amount of such Indebtedness&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;Indebtedness at any time incurred in connection with financing insurance premiums in respect of insurance policies insuring assets or businesses of any Credit Party written or arranged in the ordinary course of business consistent with past practice&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;Indebtedness of any Subsidiary that is not a Credit Party in an aggregate outstanding principal amount not to exceed $2,000,000&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(m)&#160;&#160;&#160;&#160;Indebtedness constituting letters of credit in an aggregate face amount at any time outstanding not to exceed $6,000,000&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, in each case, that any such letter of credit is used solely to secure obligations in respect of a lease or sublease of a Credit Party or any of its Subsidiaries&#59; and other Indebtedness in an aggregate outstanding principal amount not to exceed $1,500,000&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(n)&#160;&#160;&#160;&#160;unsecured Indebtedness of Holdings in respect of any subordinated convertible promissory note, in an aggregate principal amount not to exceed $75,000,000 (plus the amount of interest paid-in-kind thereon pursuant to the terms of such notes on the date of incurrence thereof)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that (x) such Indebtedness shall not mature before the date that is ninety-one (91) days after the Maturity Date, (y) such Indebtedness shall not permit cash payments with respect to the principal or interest thereon and (z) such Indebtedness shall at all times be subject to a subordination agreement in form and substance satisfactory to the Agent&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that, no Indebtedness otherwise permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clauses (e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall be assumed, created or otherwise incurred if at the time of such assumption, creation or incurrence, a Default has occurred and is then continuing or could reasonably be expected to result therefrom.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">61</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 8.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No Credit Party will, nor will it permit any of its Subsidiaries to, create, incur, assume or permit to exist any Lien upon any of its property (including Capital Securities of any Person), revenues or assets, whether now owned or hereafter acquired, except for the following (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Permitted Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Liens securing payment of the Obligations&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Liens existing on the Closing Date which are disclosed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 8.3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Liens in favor of carriers, warehousemen, mechanics, materialmen and landlords granted in the ordinary course of business for amounts not overdue or being diligently contested in good faith by appropriate proceedings and for which adequate reserves in accordance with GAAP shall have been set aside on its books&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Liens incurred or deposits made in the ordinary course of business in connection with worker&#8217;s compensation, unemployment insurance or other forms of governmental insurance or benefits, or to secure performance of tenders, statutory obligations, bids, leases or other similar obligations (other than for borrowed money) entered into in the ordinary course of business or to secure obligations on surety and appeal bonds or performance bonds&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;judgment Liens in existence for less than sixty (60) days after the entry thereof or with respect to which execution has been stayed or the payment of which is covered in full (subject to a customary deductible) by insurance maintained with responsible insurance companies and which do not otherwise result in an Event of Default under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;easements, rights-of-way, zoning restrictions, minor defects or irregularities in title and other similar encumbrances not interfering in any material respect with the value or use of the property to which such Lien is attached&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;Liens for Taxes not yet due and payable or being diligently contested in good faith by appropriate proceedings and for which adequate reserves in accordance with GAAP shall have been set aside on its books&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;purchase money security interests in real property, improvements thereto, equipment or other assets hereafter acquired (or, in the case of improvements, constructed) by the Borrower or any Subsidiary Guarantor&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that (i) such security interests secure Indebtedness permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, (ii) such security interests are incurred, and the Indebtedness secured thereby is created, within two hundred seventy (270) days after such acquisition (or construction) (or in the case of the first or any successive extensions, renewals or refinancings of the underlying Indebtedness, such security interests are incurred and the security is created within thirty (30) days after the incurrence of such new Indebtedness), (iii) the Indebtedness secured thereby does not exceed the cost of such real property, improvements or equipment at the time of such acquisition (or construction) and (iv) such security interests do not apply to any other property or assets of the Borrower or any Subsidiary&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;any interest or title of a lessor under any lease entered into by the Borrower or any of its Subsidiaries as lessees in the ordinary course of business and covering only the assets soleased&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of customs duties in connection with the importation ofgoods&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">62</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;Liens arising solely by virtue of any statutory or common law provision relating to bankers&#8217; liens, rights of set-off or similar rights&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;the cash collateralization of any letter of credit obligations incurred pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in an amount not to exceed 105% of the face amount thereof&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(m)&#160;&#160;&#160;&#160;other Liens securing Indebtedness and other obligations in an aggregate outstanding principal amount not to exceed $1,500,000.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 8.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Minimum Liquidity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Credit Parties shall maintain at all times Liquidity in an amount equal to or greater than $</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:line-through">25,000,000</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">15,000,000</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Liquidity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Covenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that in the event that the Credit Parties fail to comply with the Liquidity Covenant as of any date from and after the date of written notice to, or knowledge of, the Borrower of such noncompliance until the expiration of the thirtieth (30th) Business Day subsequent to such date of such written notice or knowledge, Holdings shall have the right to issue common equity (or other Qualified Capital Securities that are preferred equity or other equity) for cash or otherwise receive cash contributions to its capital and, in either case, directly contribute any such cash to the common equity (or other Qualified Capital Securities that are preferred equity or other equity) capital of the Borrower (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Liquidity Cure Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and upon the receipt by the Borrower of such cash in an amount not less than the greater of (x) $5,000,000 and (y) the amount necessary to cure the failure to comply with the Liquidity Covenant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Liquidity Cure Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), the calculation of Liquidity as used in the Liquidity Covenant shall be recalculated giving effect to the following pro forma adjustments&#58; (a) Liquidity shall be increased, solely for the purpose of measuring the Liquidity Covenant for each day prior to receipt of the Liquidity Cure Amount for which a Liquidity Cure Right has been exercised in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and not for any determination made following receipt of such Liquidity Cure Amount or for any other purpose under this Agreement, by an amount equal to the Liquidity Cure Amount (it being understood and agreed that previously received proceeds of any exercise of the Liquidity Cure Right shall be counted in calculating Liquidity following receipt thereof to the extent and for so long as such proceeds constitute Liquidity) and (b) if, after giving effect to the foregoing recalculation, the Borrower shall then be in compliance with the Liquidity Covenant, the Borrower shall be deemed to have satisfied the requirements of such covenant as of the relevant date of determination with the same effect as though there had been no failure to comply therewith at such date, and the applicable breach or default that had occurred shall be deemed cured for all purposes of this Agreement.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Minimum Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. As of the last day of each Fiscal Quarter set forth below, Net Sales for the twelve (12) consecutive month period ending on the last day of such Fiscal Quarter shall not be less than the corresponding amount set forth opposite such Fiscal Quarter&#58;</font></div><div style="margin-bottom:23pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Fiscal Quarter Ending</font></div></td><td colspan="3" rowspan="2" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Net Sales</font></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">June 30, 2024</font></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$78,872,953</font></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2024</font></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$88,399,787</font></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2024</font></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$98,680,724</font></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2025</font></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:-2.13pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$109,528,429</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">June 30, 2025</font></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:-2.13pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$110,000,000</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2025</font></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:-2.13pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$110,000,000</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2025</font></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:-2.13pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$110,000,000</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2026</font></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:-2.13pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$110,000,000</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">June 30, 2026</font></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:-2.13pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$110,000,000</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2026</font></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:-2.13pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$110,000,000</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">63</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:23pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2026</font></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$110,000,000</font></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2027</font></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$110,000,000</font></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">June 30, 2027</font></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$110,000,000</font></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">September 30, 2027</font></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$110,000,000</font></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31, 2027</font></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$110,000,000</font></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">March 31, 2028</font></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$110,000,000</font></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that compliance with this covenant shall not be required for any Fiscal Quarter with respect to which (i) the Credit Parties maintain Liquidity in an amount greater than or equal to $60,000,000 as of the end of such Fiscal Quarter and (ii) there has not occurred a Two-Consecutive Fiscal Quarter Net Sales Decline as of the end of such Fiscal Quarter.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 8.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Investments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No Credit Party will, nor will it permit any of its Subsidiaries to, purchase, make, incur, assume or permit to exist any Investment in any other Person, except (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Permitted Investments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Investments existing on the Closing Date and identified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 8.5(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;cash and Cash Equivalent Investments&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Investments received in connection with the bankruptcy or reorganization of, or settlement of delinquent accounts and disputes with, customers and suppliers, in each case in the ordinary course of business&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Investments consisting of any deferred portion of the sales price received by a Credit Party or any of its Subsidiaries in connection with any Disposition permitted under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;(i) Investments in and loans to any Credit Party and (ii) Investments in and loans to any Subsidiary that is not a Credit Party (x) to the extent made by any other Subsidiary that is not a Credit Party or (y) constituting payroll expenses and other operational costs incurred by such Subsidiary in the ordinary course of business consistent with past practice&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;Investments constituting (i) accounts receivable arising, (ii) trade debt granted, or (iii) deposits made in connection with the purchase price of goods or services, in each case in the ordinary course of business&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;Investments and loans by a Credit Party in a Subsidiary that is not a Credit Party that do not include the Disposition of Material Intellectual Property or Capital Securities with respect to Subsidiaries that directly or indirectly own, or hold a license in respect of, Material Intellectual Property, in an aggregate amount, together with the aggregate amount of Permitted Dispositions made pursuant to clause (v)(C) of the definition thereof, not to exceed $2,000,000&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;other Investments that do not include Material Intellectual Property or Capital Securities with respect to Subsidiaries that directly or indirectly own, or hold a license in respect of, Material Intellectual Property in an aggregate amount not to exceed $5,000,000.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 8.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Restricted Payments, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No Credit Party will, nor will it permit any of its Subsidiaries to, declare or make a Restricted Payment, or make any deposit for any Restricted Payment, other than&#58; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">64</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Restricted Payments made by Subsidiaries of the Borrower to the Borrower&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;so long as (i) no Default or Event of Default has occurred and is continuing, (or could be reasonably expected to occur as a result thereof) and (ii) Holdings (or any direct or indirect parent of Holdings) is the parent of a consolidated group for U.S. federal income tax purposes that includes the Borrower, Restricted Payments made in cash by the Borrower to Holdings (or such direct or indirect parent of Holdings), the proceeds of which shall be used solely to pay Taxes of Holdings or such direct or indirect parent of Holdings (other than any Taxes attributable to any action or activity that constitutes or results in a breach by Holdings of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">)&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;so long as no Event of Default has occurred and is continuing (or could be reasonably expected to occur as a result thereof), share repurchases in an aggregate amount not to exceed $1,000,000 per Fiscal Year plus any amounts pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that were unused in any preceding Fiscal Year.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 8.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Issuance of Capital Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No Credit Party will, nor will it permit any of its Subsidiaries to, issue any Capital Securities (whether for value or otherwise) to any Person other than&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;in the case of Subsidiaries of the Credit Parties, Qualified Capital Securities issued to a Credit Party so long as such issuance could not reasonably be expected to result in a Default or an Event of Default&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;the issuance of Qualified Capital Securities of Holdings so long as such issuance could not reasonably be expected to result in an Event of Default.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 8.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Consolidation, Merger, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No Credit Party will, nor will it permit any of its Subsidiaries to, liquidate or dissolve, consolidate with, or merge or amalgamate into or with, any other Person, or purchase or otherwise acquire any other Person or all or substantially all of the assets of any other Person (or any division thereof), except that (i) any Subsidiary (other than the Borrower) of a Credit Party may liquidate or dissolve voluntarily into, and may merge or amalgamate with and into, a Credit Party&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that such Credit Party is the surviving entity&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, further, that immediately following any such merger or amalgamation, the Credit Parties directly or indirectly hold the same or greater percentage of the issued and outstanding Capital Securities of such Subsidiary as the Credit Parties held immediately prior to such merger or amalgamation&#59; (ii) any Credit Party (other than Holdings) may liquidate or dissolve voluntarily into, and may merge or amalgamate with and into, a Credit Party&#59; provided, that if the Borrower is a party thereto, the Borrower is the surviving entity&#59; and (iii) any Subsidiary that is not a Credit Party may liquidate or dissolve voluntarily into, and may merge or amalgamate with and into, another Subsidiary that is not a Credit Party.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 8.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Permitted Dispositions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No Credit Party will, nor will it permit any of its Subsidiaries to, Dispose of any of its assets (including accounts receivable and Capital Securities) to any Person in one transaction or series of transactions except for Permitted Dispositions.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 8.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Modification of Certain Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No Credit Party will, nor will it permit any of its Subsidiaries to, amend, supplement, waive or otherwise modify, consent to any amendment, supplement, waiver or other modification of, or enter into any forbearance from exercising any rights with respect to the terms or provisions contained in (i) any Organic Documents of a Credit Party or any of its Subsidiaries that could reasonably be expected to result in a Material Adverse Effect or in a manner that could be materially adverse to the interests of the Agent or any of the Lenders without the consent of the Agent&#59; provided that a transaction expressly permitted pursuant to Section 8.8 that does not materially adversely effect the interests of the Agent or any of the Lenders shall not require any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">65</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">consent under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 8.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> or (ii)(A) any Material Agreement or any documents relating thereto (in each case, other than any amendments, supplements, waivers, or other modifications to the AWS Agreement (or any replacement cloud hosting agreement that is a Material Agreement) or any documents relating thereto, in each case, that are made from time to time by AWS (or any counterparty to such replacement cloud hosting agreement or any documents relating thereto)), or (B) any material Product Agreement or any documents relating thereto, in any such case in this clause (ii), in a manner that could be materially adverse to the interests of the Agent or any of the Lenders without the consent of the Agent.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 8.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Transactions with Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. No Credit Party will, nor will it permit any of its Subsidiaries to, enter into or cause or permit to exist any arrangement, transaction or contract (including for the purchase, lease or exchange of property or the rendering of services) with any of its other Affiliates, unless such arrangement, transaction or contract (i) is on fair and reasonable terms no less favorable to such Credit Party or such Subsidiary than it could obtain in an arm&#8217;s-length transaction with a Person that is not an Affiliate (it being understood that this Section shall not apply to any transaction that is expressly permitted under this Agreement between or among the Credit Parties and not involving any other Affiliate) or (ii) is set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 6.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 8.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Restrictive Agreements, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. No Credit Party will, nor will it permit any of its Subsidiaries to, enter into any agreement (i) prohibiting the creation or assumption of any Lien upon its properties, revenues or assets, whether now owned or hereafter acquired, or limiting in any way granting to the Secured Parties (or any of them) a Lien on any of its assets, (ii) restricting the ability of a Credit Party or any of its Subsidiaries to amend or otherwise modify any Loan Document, (iii) containing any provision which could reasonably be expected to be violated or breached by a party hereunder by the performance by such party of any of its obligations hereunder or under any other Loan Document, (iv) encumbering or restricting the ability of a Credit Party or any of its Subsidiaries to (a) make any payments, directly or indirectly, to the Borrower, including by way of dividends, advances, repayments of Indebtedness owed to the Borrower, reimbursements of management and other intercompany charges, expenses and accruals or other returns on investments, (b) make loans or advances to the Borrower or (c) transfer any of its assets or properties to the Borrower. The foregoing prohibitions shall not apply to restrictions (x) contained in any Loan Document or (y) in the case of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">clause (i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, (I) by reason of applicable law, (II) in any agreement governing any Indebtedness permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">clause (e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 8.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">as to the assets financed with the proceeds of such Indebtedness, (III) in contracts (A) existing as of the Closing Date and set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 8.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> or any renewal or extension thereof&#59; provided that any such restriction contained therein relates only to the asset or assets constructed or acquired in connection therewith and (B) of a Person existing at the time such Person becomes a Subsidiary of a Credit Party in a transaction permitted hereunder, provided that any such contract was not created in anticipation of or in connection with the transaction or series of transactions pursuant to which such Person became a Subsidiary of a Credit Party, or (IV) any Permitted Lien or any document or instrument governing any Permitted Lien&#59; provided that any such restriction contained therein relates only to the asset or assets subject to such Permitted Lien.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 8.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Sale and Leaseback</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. Except in a transaction permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 8.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, or transactions with an aggregate fair market value not in excess of $750,000, no Credit Party will, nor will it permit any of its Subsidiaries to, directly or indirectly enter into any agreement or arrangement providing for the sale or transfer by it of any property (now owned or hereafter acquired) to a Person and the subsequent lease or rental of such property or other similar property from such Person.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 8.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Product Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. No Credit Party will, nor will it permit any of its Subsidiaries to, sell or distribute Products which represented, in the aggregate, 15% or more of Net Sales in any applicable year, or permit any sale or distribution of such Products above such threshold where a Credit Party or any of its Subsidiaries is required to obtain any Permit, or to file any notice or registration in any</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">66</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">jurisdiction prior to any such sale or distribution of such Products above such threshold, in each case, until such Credit Party or such Subsidiary has obtained such required Permit or filed such notice or registration.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 8.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Change in Name, Location, Executive Office, or Executive Management&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Change in Fiscal Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No Credit Party will, nor will it permit any of its Subsidiaries to, (i) change its legal name without ten (10) days&#8217; prior written notice to the Agent, (ii) change its jurisdiction of organization or legal structure, (iii) relocate its chief executive office or principal place of business, relocate any other office in which it maintains books or records relating to its business (including the establishment of any new office or facility), except, in each case, within the State of California or into the State of Texas and with ten (10) days&#8217; prior written notice to the Agent, or (iv) change its Fiscal Year or any of its Fiscal Quarters.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 8.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Negative Pledge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No Credit Party will, nor will it permit any of its Subsidiaries to, create, permit or suffer to exist any Lien (whether such interest is based on common law, statute, other law or contract and whether junior or equal or superior in priority to the security interests and Liens created by the Loan Documents) upon any of its property (including Capital Securities of any Person), revenues or assets, whether now owned or hereafter acquired, except Permitted Liens. No Credit Party will, nor will it permit any of its Subsidiaries to, incur senior secured obligations other than the Obligations incurred hereunder. For the avoidance of doubt, this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall not restrict the Credit Parties&#8217; (i) incurrence of Indebtedness (A) secured by Permitted Liens that are permitted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.3(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or (B) constituting letters of credit incurred in reliance upon </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or (ii) cash collateral securing any such letter of credit in reliance upon </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.3(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 8.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sanctions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No Credit Party will, and no Credit Party will permit any of its Affiliates to, use any proceeds of the Loans for the purpose of&#58; (i) providing financing to or otherwise making funds directly or indirectly available to any Sanctioned Person, or (ii) providing financing to or otherwise funding any transaction which would be prohibited by Sanctions or would otherwise cause the Agent or any of the Lenders to be in breach of any Sanction.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:74pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;No Credit Party will, and no Credit Party will permit any of its Affiliates to, fund any repayment of the credit with proceeds derived from any transaction that would be prohibited by Sanctions or would otherwise cause the Agent or any of the Lenders to be in breach of any Sanction.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">67</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 8.18&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Passive Holding Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Holdings will not conduct, transact or otherwise engage in any active trade or business or operations, incur any Indebtedness or other liability, or own any assets other than Capital Securities of the Borrower&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that the foregoing will not prohibit Holdings from the following&#58; (i) the maintenance of its legal existence and obligations that are incidental thereto (including the ability to incur reasonable fees, costs, expenses and other liabilities directly relating to such maintenance), (ii) obligations that are limited to obligations under the Loan Documents to which it is a party, (iii) the making of contributions to (or other equity investments in) the Borrower, which contributions shall be subordinated to the Obligations, (iv) participating in tax, accounting and other administrative and fiduciary matters as a direct owner of the Borrower, in accordance with the terms of the Loan Documents to which Holdings is a party, (v) providing customary compensation, indemnification and insurance coverage to officers and directors (or equivalent), (vi) the consummation of an IPO or SPAC Transaction, and (vii) making Restricted Payments or issuing any Capital Securities to the extent expressly permitted hereunder.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 8.19&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">USRPHC Status</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No Credit Party will, nor will it permit any of its Subsidiaries to, become a &#8220;United States real property holding corporation&#8221; within the meaning of Section 897(c)(2) of the Code.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 8.20&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Hazardous Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No Credit Party will, nor will it permit any of its Subsidiaries to, cause or suffer to exist a Release of any Hazardous Material at, on, under, to or from any real estate that would violate any Environmental Law, form the basis for any Environmental Liabilities or otherwise adversely affect the value or marketability of any real estate (whether or not owned by any Credit Party or any Subsidiary of any Credit Party), other than such violations, Environmental Liabilities and effects that would not, in the aggregate, reasonably be expected to result in a material liability.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 8.21&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No Credit Party will, nor will it permit any of its Subsidiaries to, grant any license to any Material Intellectual Property other than a license that&#58;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;is in the ordinary course of business&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;is (i) on a non-exclusive basis or (ii) on an exclusive basis so long as each such exclusive license is limited to a particular geographic area (other than the U.S, U.K. or Japan)&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;will not prevent, restrict or otherwise impair such Credit Party&#8217;s or such Subsidiary&#8217;s or the Agent&#8217;s ability to use or otherwise monetize such Material Intellectual Property&#59; and</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;will not prevent, restrict or otherwise impair the Agent&#8217;s ability to assume such Credit Party&#8217;s or such Subsidiary&#8217;s rights under such license.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 8.22&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Subordinated Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Except as expressly permitted by the subordination agreement with respect to any subordinated Indebtedness, no Credit Party shall make any payment or distribution in respect of such subordinated Indebtedness, other than in the form of Capital Securities (other than Disqualified Capital Securities) of Holdings. No Credit Party shall, without the prior written consent of the Administrative Agent, amend or otherwise modify the terms of any subordinated Indebtedness, except as expressly permitted by the subordination agreement with respect to such subordinated Indebtedness. No Credit Party shall permit the transfer of any subordinated Indebtedness, unless the transferee party is, or becomes, a party to the subordination agreement with respect to such subordinated Indebtedness.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">68</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE IX</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EVENTS OF DEFAULT</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 9.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Listing of Events of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each of the following events or occurrences described in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall constitute an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Event of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Payment of Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. (i) The Borrower shall default in the payment or prepayment when due of any principal on the Loans, or (ii) any Credit Party, including the Borrower, shall default in the payment or prepayment of interest or any fee described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or any other monetary Obligation, and in the case of clause (ii) such default shall continue unremedied for a period of three (3) Business Days after such amount was due.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Breach of Representation or Warranty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Any representation or warranty made or deemed to be made by a Credit Party or its Subsidiaries in any Loan Document (including any certificates delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) is or shall be incorrect in any material respect when made or deemed to have been made or, in the case of any representation or warranty that, by its terms, is qualified by materiality, Material Adverse Effect or similar qualification, such representation or warranty is or shall be incorrect in any respect when made or deemed made.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Performance of Certain Covenants and Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. A Credit Party or any of its Subsidiaries shall default in the due performance or observance of any of its obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sections&#160;7.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">7.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">7.1(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">7.1(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">7.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">7.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">7.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> ((i) other than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.10(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and (ii) with respect to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, subject to the Liquidity Cure Right set forth therein).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Performance of Other Covenants and Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. A Credit Party or any of its Subsidiaries shall default in the due performance and observance of any other covenant, obligation or agreement contained in any Loan Document (other than any default of the type contemplated by any other subsection of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) executed by it, and such default shall continue unremedied for a period of thirty (30) days after the earlier to occur of (i) written notice thereof given to Holdings by the Agent or the Majority Lenders or (ii) the date on which a Credit Party or any of its Subsidiaries has knowledge of such default.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Default on Other Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. A default shall occur in the payment of any amount when due (subject to any applicable grace period), whether by acceleration or otherwise, of any principal or stated amount of, or interest or fees on, any Indebtedness (other than Indebtedness permitted under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) of any Credit Party or any of its Subsidiaries having a principal or stated amount, individually or in the aggregate, in excess of $4,000,000, or a default shall occur in the performance or observance of any obligation or condition with respect to such Indebtedness if the effect of such default is to accelerate the maturity of any such Indebtedness or such default shall continue unremedied for any applicable period of time sufficient to permit the holder or holders of such Indebtedness, or any trustee or agent for such holders, to cause or declare such Indebtedness to become due and payable or to require such Indebtedness to be prepaid, redeemed, purchased or defeased, or require an offer to purchase or defease such Indebtedness to be made, prior to its expressed maturity.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Judgments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Any judgment or order for the payment of money individually or in the aggregate in excess of $4,000,000 (exclusive of any amounts fully covered by insurance (less any applicable deductible) and as to which the insurer has acknowledged its responsibility to cover such judgment or order) shall be rendered against any Credit Party or any of its Subsidiaries and such judgment shall not have been vacated or discharged or stayed or bonded pending appeal within sixty</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">69</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(60)&#160;&#160;&#160;&#160;days after the entry thereof or enforcement proceedings shall have been commenced by any creditor upon such judgment or order.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Any Change in Control shall occur.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Bankruptcy, Insolvency, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Any Credit Party or any of its Subsidiaries shall&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;become insolvent or generally fail to pay, or admit in writing its inability or unwillingness generally to pay, debts as they become due&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;apply for, consent to, or acquiesce in the appointment of a trustee, receiver, sequestrator or other custodian for any substantial part of the property of any thereof, or make a general assignment for the benefit of creditors&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;in the absence of such application, consent or acquiescence in or permit or suffer to exist the appointment of a trustee, receiver, sequestrator or other custodian for a substantial part of the property of any thereof, and such trustee, receiver, sequestrator or other custodian shall not be discharged within sixty (60) days&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that, the Credit Parties and their Subsidiaries hereby expressly authorize the Agent to appear in any court conducting any relevant proceeding during such sixth (60) day period to preserve, protect and defend its rights under the Loan Documents&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;permit or suffer to exist the commencement of any bankruptcy, reorganization, debt arrangement or other case or proceeding under any bankruptcy or insolvency law or any dissolution, winding up or liquidation proceeding, in respect thereof, and, if any such case or proceeding is not commenced by a Credit Party or any of its Subsidiaries, such case or proceeding shall be consented to or acquiesced in by a Credit Party or any of its Subsidiaries or shall result in the entry of an order for relief or shall remain for sixty (60) days undismissed&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that, the Credit Parties and their Subsidiaries hereby expressly authorize the Agent to appear in any court conducting any such case or proceeding during such sixty (60) day period to preserve, protect and defend its rights under the Loan Documents&#59; or</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;take any action authorizing, or in furtherance of, any of the foregoing in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> above.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Impairment of Security, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Any Loan Document or any Lien granted thereunder shall (except in accordance with its terms), in any material respect, terminate, cease to be effective or cease to be the legally valid, binding and enforceable obligation of a Credit Party or any of its Subsidiaries party thereto&#59; any Credit Party or any of its Subsidiaries shall, directly or indirectly, contest in writing such effectiveness, validity, binding nature or enforceability&#59; or, except as permitted under any Loan Document, any Lien securing any Obligation shall, in any material respect, cease to be a perfected first priority Lien, except to the extent that any such loss of perfection results from the failure of the Agent to maintain possession of certificates actually delivered to or representing securities pledged under this Agreement or any other Loan Documents.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If any of the following events or circumstances occur&#58; (i) the FDA or the Department of Justice (DOJ) on its behalf, or any other Governmental Authority (A) makes a final determination that any Product which represented, in the aggregate, 15% or more of Net Sales in any applicable year lacks a required Regulatory Authorization or otherwise takes a regulatory or enforcement action that until and unless successfully resolved through Credit Party responsive action and remediation, dispute resolution, appeal, or other action prohibits or enjoins the distribution of such a Product above such threshold by Credit Party under the then-held Regulatory Authorization, or (B)</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">70</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">initiates enforcement action against, including but not limited to issuing a warning letter with respect to, or proposing a consent decree of permanent injunction with respect to, any Products of any Credit Party or any of its Subsidiaries which represented, in the aggregate, 15% or more of Net Sales in any applicable year, in any case that causes such Credit Party or such Subsidiary to discontinue operating in any applicable jurisdiction or (ii) any Credit Party or any of its Subsidiaries enters into a settlement agreement with the FDA and DOJ or any other Governmental Authority that results in aggregate liability as to any single or related series of transactions, incidents or conditions, in excess of $4,000,000.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Pension Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Any of the following events shall occur with respect to any Pension Plan which would, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;a contribution failure occurs with respect to any Pension Plan sufficient to give rise to a Lien on any Credit Party or any ERISA Affiliate under Section 303(k) of ERISA or under Section 430(k) of the Code&#59; or</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;any ERISA Event shall occur that, when taken together with all other ERISA Events that have occurred, could reasonably be expected to result in liability of the Borrower and its Subsidiaries.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Key Permit Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Any of the following events shall occur&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;any Key Permit relating to FFRct issued by the United States, any state thereof or any instrumentality of the foregoing is terminated, suspended or amended by the Governmental Authority issuing such Key Permit or a court of competent jurisdiction in a manner that (x) results in the cessation of a material portion of the revenue generating business of a Credit Party or any of its Subsidiaries or (y) requires the commercialization of any of the material Products by a Credit Party or any of its Subsidiaries to be stopped or halted for a material amount of time&#59; or</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;any other Key Permit is terminated, suspended or amended by the Governmental Authority issuing such Key Permit or a court of competent jurisdiction in a manner that (x) results in the cessation of a material portion of the revenue generating business of a Credit Party or any of its Subsidiaries or (y) requires the commercialization of any of the material Products by a Credit Party or any of its Subsidiaries to be stopped or halted for a material amount of time&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that, if, after excluding the Net Sales as of the last period for which a Compliance Certificate has been delivered (or was required to be delivered) to the Agent pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for which such Key Permit is necessary, the Credit Parties remain in compliance with the financial covenant set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.4(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (without giving effect to the proviso contained in such Section), as evidenced by calculations in reasonable detail certified by an Authorized Officer of the Borrower to the Agent within two (2) Business Days after such termination, suspension or amendment, no Event of Default shall occur&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that, in each case of the foregoing clauses (i) and (ii), to the extent such termination, suspension or amendment with respect to such Key Permit is of an administrative and technical nature that can be remedied without the consent of any third party or Governmental Authority and is so remedied within five (5) Business Days after the occurrence thereof, no Event of Default shall occur.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(m)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Material Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Any default or event of default shall occur under any Material Agreement, or any Material Agreement shall cease, for any reason, to be in full force and effect other than upon expiration thereof in accordance with its terms unless the Credit Party party thereto determines in the exercise of its good faith business judgment that termination thereof by Credit Party is</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">71</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">beneficial to such Credit Party, or any party to any Material Agreement (other than a Credit Party) shall challenge or repudiate its obligations under such Material Agreement or the enforceability of such Material Agreement, in each case, to the extent that any such occurrence has or could reasonably be expected to have a Material Adverse Effect&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that, for the avoidance of doubt and notwithstanding anything to the contrary in this Agreement or any other Loan Document, in no event shall an Event of Default occur as a result of any termination of the AWS Agreement (x) by the Credit Parties to the extent that, prior to or concurrently with such termination, the Credit Parties have entered into an agreement with another provider for cloud hosting services that (taken as a whole) are not materially worse to the Credit Parties than the cloud hosting services (taken as a whole) provided to the Credit Parties in the AWS Agreement (or, if such cloud hosting services are materially worse, then not materially worse to the Credit Parties than the cloud hosting services (taken as a whole) customarily provided in the market at such time for similarly situated Persons in the same industry as the Credit Parties) or (y) by AWS to the extent that, within thirty (30) days after such termination, the Credit Parties have entered into an agreement with another provider for cloud hosting services that (taken as a whole) are not materially worse to the Credit Parties than the cloud hosting services (taken as a whole) provided to the Credit Parties in the AWS Agreement (or, if such cloud hosting services are materially worse, then not materially worse to the Credit Parties than the cloud hosting services (taken as a whole) customarily provided in the market at such time for similarly situated Persons in the same industry as the Credit Parties).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(n)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Any Patents, the loss of which would constitute a Material Adverse Effect, are found invalid as determined by a court of competent jurisdiction by final and non-appealable judgment.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 9.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Action if Bankruptcy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If any Event of Default described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with respect to any Credit Party or any of its Subsidiaries shall occur, and the outstanding principal amount of the Loans and all other Obligations shall automatically be and become immediately due and payable, without notice, demand or presentment to or on any Person.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 9.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Action if Other Event of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If any Event of Default (other than any Event of Default described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) shall occur for any reason, whether voluntary or involuntary, and be continuing, the Agent or the Majority Lenders may, by notice to the Borrower declare all or any portion of the outstanding principal amount of the Loans and other Obligations to be due and payable whereupon the full unpaid amount of the Loans and other Obligations which shall be so declared due and payable shall be and become immediately due and payable, without further notice, demand or presentment to or on any Person.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE X</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ADMINISTRATIVE AGENT</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 10.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Appointment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each of the Lenders hereby irrevocably appoints Hayfin Services LLP to act on its behalf as the Agent hereunder and under the other Loan Documents and authorizes the Agent to take such actions on its behalf and to exercise such powers as are delegated to the Agent by the terms hereof or thereof, together with such actions and powers as are reasonably incidental thereto. The provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> are solely for the benefit of the Agent and the Lenders, and neither any Credit Party nor any of its respective Subsidiaries will have rights as a third-party beneficiary of any of such provisions. It is understood and agreed that the use of the term &#8220;agent&#8221; herein or in any other Loan Documents (or any other similar term) with reference to the Agent is not intended to connote any fiduciary or other implied (or express) obligations arising under agency doctrine of any applicable</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">72</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">law. Instead, such term is used as a matter of market custom and is intended to create or reflect only an administrative relationship between contracting parties.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 10.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Rights as a Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Person serving as the Agent hereunder will have the same rights and powers in its capacity as a Lender as any other Lender and may exercise the same as though it were not the Agent, and the term &#8220;Lender&#8221; or &#8220;Lenders&#8221; will, unless otherwise expressly indicated or unless the context otherwise requires, include the Person serving as the Agent hereunder in its individual capacity. Such Person and its Affiliates may accept deposits from, lend money to, own securities of, act as the financial advisor or in any other advisory capacity for, and generally engage in any kind of business with, the Borrower or any of its Affiliates as if such Person were not the Agent hereunder and without any duty to account therefor to the Lenders.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 10.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exculpatory Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.The Agent will not have any duties or obligations except those expressly set forth herein and in the other Loan Documents, and its duties hereunder are administrative in nature. Without limiting the generality of the foregoing, the Agent&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;will not be subject to any fiduciary or other implied duties, regardless of whether a Default has occurred and is continuing&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;will not have any duty to take any discretionary action or exercise any discretionary powers, except discretionary rights and powers expressly contemplated hereby or by the other Loan Documents that the Agent is required to exercise as directed in writing by the Majority Lenders (or such other number or percentage of the Lenders as will be expressly provided for herein or in the other Loan Documents)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that the Agent will not be required to take any action that, in its opinion or the opinion of its counsel, may expose the Agent to liability or that is contrary to any Loan Document or applicable law, including for the avoidance of doubt any action that may be in violation of the automatic stay under any debtor relief law&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;will not, except as expressly set forth herein and in the other Loan Documents, have any duty to disclose, and will not be liable for the failure to disclose, any information relating to any Credit Party or any of its Subsidiaries or Affiliates that is communicated to or obtained by the Person serving as the Agent or any of its Affiliates in any capacity.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Agent will not be liable for any action taken or not taken by it (i) with the consent or at the request of the Majority Lenders (or such other number or percentage of the Lenders as will be necessary, or as the Agent believes in good faith will be necessary, under the circumstances as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">9.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) or (ii) in the absence of its own gross negligence or willful misconduct as determined by a court of competent jurisdiction by final and nonappealable judgment. The Agent will be deemed not to have knowledge of any Default or Event of Default unless and until notice describing such Default or Event of Default is given to the Agent in writing by the Borrower or a Lender.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The Agent will not be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or representation made in or in connection with this Agreement or any other Loan Document, (ii) the contents of any certificate, report or other document delivered hereunder or thereunder or in connection herewith or therewith, (iii) the performance or observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of any Default, (iv) the validity, enforceability, effectiveness or genuineness of this Agreement, any other Loan Document or any other agreement, instrument or document or (v) the satisfaction of any condition set</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">73</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or elsewhere herein, other than to confirm receipt of items expressly required to be delivered to the Agent.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 10.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Reliance by Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Agent will be entitled to rely upon, and will not incur any liability for relying upon, any notice, request, certificate, consent, statement, instrument, document or other writing (including any electronic message, Internet or intranet website posting or other distribution) believed by it to be genuine and to have been signed, sent or otherwise authenticated by the proper Person. The Agent also may rely upon any statement made to it orally or by telephone and believed by it to have been made by the proper Person, and will not incur any liability for relying thereon. In determining compliance with any condition hereunder to the making of the Loans that by its terms must be fulfilled to the satisfaction of a Lender, the Agent may presume that such condition is satisfactory to such Lender unless the Agent has received notice to the contrary from such Lender prior to the making of such Loans. The Agent may consult with legal counsel (who may be counsel for the Borrower or any of its Affiliates), independent accountants and other experts selected by it, and will not be liable for any action taken or not taken by it in accordance with the advice of any such counsel, accountants or experts.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 10.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Delegation of Duties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Agent may perform any and all of its duties and exercise its rights and powers hereunder or under any other Loan Document by or through any one or more sub-agents appointed by the Agent. The Agent and any such sub-agent may perform any and all of its duties and exercise its rights and powers by or through their respective Affiliates. The exculpatory provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> will apply to any such sub-agent and to the Affiliates of the Agent and any such sub-agent and will apply to their respective activities in connection with the syndication of the facility as well as activities as the Agent. The Agent will not be responsible for the negligence or misconduct of any sub-agents except to the extent that a court of competent jurisdiction determines in a final and nonappealable judgment that the Agent acted with gross negligence or willful misconduct in the selection of such sub-agents.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 10.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Resignation of Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.The Agent may at any time give notice of its resignation to the Lenders and the Borrower. Upon receipt of any such notice of resignation, the Majority Lenders will have the right, with the consent of the Borrower (unless an Event of Default is in existence), to appoint a successor. If no such successor will have been so appointed by the Majority Lenders and will have accepted such appointment within thirty (30) days after the retiring Agent gives notice of its resignation (or such earlier day as will be agreed by the Majority Lenders) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Resignation Effective</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), then the retiring Agent may (but will not be obligated to), on behalf of the Lenders, appoint a successor Agent meeting the qualifications set forth above. Whether or not a successor has been appointed, such resignation will become effective in accordance with such notice on the Resignation Effective Date.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;With effect from the Resignation Effective Date (i) the retiring Agent will be discharged from its duties and obligations hereunder and under the other Loan Documents (except that in the case of any Collateral held by the Agent on behalf of the Lenders under any of the Loan Documents, the retiring Agent will continue to hold such Collateral until such time as a successor Agent is appointed) and (ii) except for any indemnity payments owed to the retiring Agent, all payments, communications and determinations provided to be made by, to or through the Agent will instead be made by or to each Lender directly, until such time, if any, as the Majority Lenders appoint a successor Agent as provided for above. Upon the acceptance of a successor&#8217;s appointment as the Agent hereunder, such successor will succeed to and become vested with all of the rights, powers, privileges and duties of the retiring Agent (other than any rights to indemnity payments owed to the retiring Agent), and the retiring Agent will be discharged from all of its duties and obligations hereunder or under the other Loan Documents. The fees payable by the Borrower to a successor Agent will be the same as those payable to its</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">74</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">predecessor unless otherwise agreed among the Borrower and such successor. After the retiring Agent&#8217;s resignation hereunder and under the other Loan Documents, the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> will continue in effect for the benefit of such retiring Agent, its sub-agents and their respective Affiliates in respect of any actions taken or omitted to be taken by any of them while the retiring Agent was acting as the Agent.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 10.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Reliance on Agent and Other Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Lender acknowledges that it has, independently and without reliance upon the Agent or any other Lender or any of their respective Affiliates and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Agreement. Each Lender also acknowledges that it will, independently and without reliance upon the Agent or any other Lender or any of their respective Affiliates and based on such documents and information as it will from time to time deem appropriate, continue to make its own decisions in taking or not taking action under or based upon this Agreement, any other Loan Document or any related agreement or any document furnished hereunder or thereunder.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 10.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Agent May File Proofs of Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. In case of the pendency of any insolvency proceeding or any other judicial proceeding relative to the Borrower, the Agent (irrespective of whether the principal of the Loans will then be due and payable as herein expressed or by declaration or otherwise and irrespective of whether the Agent has made any demand on the Borrower) will be entitled and empowered (but not obligated), by intervention in such proceeding or otherwise&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;to file and prove a claim for the whole amount of the principal and interest owing and unpaid in respect of the Loans and all other Obligations that are owing and unpaid hereunder or under any other Loan Document to file such other documents as may be necessary or advisable in order to have the claims of the Lenders and the Agent (including any claim for the reasonable compensation, expenses, disbursements and advances of the Lenders and the Agent and their respective agents and counsel and all other amounts due the Lenders and the Agent under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 3.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) allowed in such judicial proceeding&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;to collect and receive any monies or other property payable or deliverable on any such claims and to distribute the same&#59;</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and any custodian, receiver, assignee, trustee, liquidator, sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Lender to make such payments to the Agent and, in the event that the Agent consents to the making of such payments directly to the Lenders, to pay to the Agent any amount due for the reasonable compensation, expenses, disbursements and advances of the Agent and its agents and counsel, and any other amounts due the Agent under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 3.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 10.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Collateral and Guaranty Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.Without limiting the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;10.8,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> the Lenders irrevocably authorize the Agent, at its option and in its discretion&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;to release any Lien on any property granted to or held by the Agent under any Loan Document (A) on the Termination Date (or such other date on which all Obligations then outstanding have been paid in full), (B) that is sold or otherwise disposed of or to be sold or otherwise disposed of as part of or in connection with any sale or other disposition permitted under the Loan Documents or (C) subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, if approved, authorized or ratified in writing by the Majority Lenders&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;to release any Guarantor from its obligations under its Guaranty if such Person ceases to be a Subsidiary as a result of a transaction permitted under the Loan Documents.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">75</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Upon request by the Agent at any time, the Majority Lenders will confirm in writing the Agent&#8217;s authority to release or subordinate its interest in particular types or items of Collateral, or to release any Guarantor from its obligations under its Guaranty pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Agent will not be responsible for or have a duty to ascertain or inquire into any representation or warranty regarding the existence, value or collectability of the Collateral, the existence, priority or perfection of the Agent&#8217;s Lien thereon, or any certificate prepared by the Borrower in connection therewith, nor will the Agent be responsible or liable to the Lenders for any failure to monitor or maintain any portion of the Collateral.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The Agent is authorized on behalf of all the Lenders, without the necessity of any notice to or further consent from the Lenders, from time to time to take any action with respect to any Collateral or any Security Agreement which may be necessary to perfect and maintain perfected the Liens on the Collateral granted pursuant to any such Security Agreement or protect and preserve the Agent&#8217;s ability to enforce the Liens or realize upon the Collateral.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE XI</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MISCELLANEOUS PROVISIONS</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 11.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Waivers, Amendments, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Except as otherwise provided herein or in any other Loan Document, (i) no amendment to any provision of this Agreement or any of the other Loan Documents will in any event be effective unless the same is in writing and signed by Holdings, the Borrower (and&#47;or any Guarantor or other party thereto, as applicable), the Agent and the Majority Lenders (or the Agent with the written consent of the Majority Lenders) and (ii) no waiver of any provision of this Agreement or any other Loan Document, or consent to any departure by a Credit Party, any of its Subsidiaries or other party therefrom, will in any event be effective unless the same is in writing and signed by the Agent and the Majority Lenders (or the Agent with the consent of the Majority Lenders). Any such amendment, waiver or consent will be effective only in the specific instance and for the specific purpose for which given&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that, notwithstanding the foregoing provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, any term or provision of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (other than the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> pertaining to the Borrower&#8217;s consent) may be amended without the agreement or consent of, or prior notice to, a Credit Party or any of its Subsidiaries&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that such amendment does not add any additional obligations or burdens on such Credit Party or such Subsidiary.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">No failure or delay on the part of the Agent or the Lenders in exercising any power or right under any Loan Document shall operate as a waiver thereof, nor shall any single or partial exercise of any such power or right preclude any other or further exercise thereof or the exercise of any other power or right. No notice to or demand on Holdings, the Borrower or any other Subsidiary in any case shall entitle it to any notice or demand in similar or other circumstances. No waiver or approval by the Agent or the Lenders under any Loan Document shall, except as may be otherwise stated in such waiver or approval, be applicable to subsequent transactions. No waiver or approval hereunder shall require any similar or dissimilar waiver or approval thereafter to be granted hereunder.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 11.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Notices&#59; Time</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. All notices and other communications provided under any Loan Document shall be in writing or by facsimile and addressed, delivered or transmitted, if to Holdings, the Borrower or the Agent, to the applicable Person at its address or facsimile number set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereto, or at such other address or facsimile number as may be designated by such party in a notice to the other parties. Any notice, if mailed and properly addressed with postage prepaid or if properly addressed and sent by pre-paid courier service, shall be deemed given when received&#59; any notice, if transmitted by facsimile or email, shall be deemed given when the confirmation of transmission</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">76</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">thereof is received by the transmitter. Unless otherwise indicated, all references to the time of a day in a Loan Document shall refer to New York City time.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 11.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Payment of Costs and Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. The Credit Parties agree to, jointly and severally, pay promptly on demand all reasonable and documented or invoiced out-of-pocket expenses of the Agent and the Lenders (or any of them) (including the reasonable fees and documented or invoiced out-of-pocket expenses of DLA Piper LLP (US), U.S. counsel to the Agent and the Lenders and of one local counsel in each relevant jurisdiction, if any, who may reasonably be retained by or on behalf of the Agent and the Lenders (or any of them)) in connection with&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;the negotiation, preparation, execution and delivery of (i) each Loan Document, including schedules and exhibits, whether or not the transactions contemplated hereby are consummated&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> that, with respect to legal fees of DLA Piper LLP (US) (U.S. counsel to the Agent and the Lenders) for services rendered as of the Closing Date, the Credit Parties shall have no obligation to pay more than $250,000 (plus the amount of any out-of-pocket disbursements of such counsel), and (ii) any amendments, waivers, consents, supplements or other modifications to any Loan Document as may from time to time be entered into after the Closing Date&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;the filing or recording of any Loan Document (including any financing statements) and all amendments, supplements, amendment and restatements and other modifications to any thereof, searches made after the date hereof in jurisdictions where financing statements (or other documents evidencing Liens in favor of the Agent and the other Secured Parties) have been recorded and any and all other documents or instruments of further assurance required to be filed or recorded by the terms of any Loan Document&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;the preparation and review of the form of any document or instrument relevant to any Loan Document, including any amendments or other modifications thereto.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The Credit Parties further agree to, jointly and severally, pay, and to save the Agent and the Lenders harmless from all liability for, any stamp or other taxes which may be payable in connection with the execution or delivery of each Loan Document, the Loans or the issuance of the Notes, excluding any Other Taxes, which are governed by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 4.3(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. The Credit Parties also agree to reimburse the Agent and the Lenders upon demand for all reasonable and documented or invoiced out-of-pocket expenses (including all reasonable and documented or invoiced out-of-pocket attorneys&#8217; fees and legal expenses of counsel to Agent and the Lenders (or any of them)) incurred by the Agent and the Lenders (or any of them) in connection with (i) the negotiation of any restructuring or &#8220;work-out&#8221; with Holdings or the Borrower, whether or not consummated, of any Obligations and (ii) the enforcement of any Obligations.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 11.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Indemnification.Reimbursement by the Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. In consideration of the execution and delivery of this Agreement by the Agent and the Lenders, the Credit Parties hereby, jointly and severally, indemnify, agree to defend, exonerate and hold the Agent, the Lenders and each of their respective officers, directors, employees and agents (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Indemnified Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;) free and harmless from and against any and all actions, causes of action, suits, losses, costs, liabilities, obligations and damages, and expenses incurred in connection therewith (irrespective of whether any such Indemnified Party is a party to the action for which indemnification hereunder is sought), including reasonable and documented or invoiced out-of-pocket attorneys&#8217; and professionals&#8217; fees and disbursements, of one primary counsel for all Indemnified Parties (and, in the case of an actual or perceived conflict of interest where the Indemnified Party affected by such conflict notifies the Borrower of the existence of such conflict and thereafter retains its own counsel, another counsel for each such affected Indemnified Party), and one local counsel in each relevant jurisdiction, whether incurred in connection with actions between the parties hereto or the parties hereto and third parties (collectively, the</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">77</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Indemnified Liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;), incurred by the Indemnified Parties or any of them as a result of, or arising out of, or relating to (i) the entering into and performance of any Loan Document by any of the Indemnified Parties or (ii) any Environmental Liability, any actual or alleged breach of or non-compliance with Environmental Laws or Environmental Permits, any Hazardous Materials, or any other decision, act, omission or matter relating to the environment, natural resources, health, safety or welfare&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> that such indemnity shall not, as to any Indemnified Party, be available to the extent that such Indemnified Liabilities (A) are determined by a court of competent jurisdiction by final and non-appealable judgment to have resulted from the gross negligence or willful misconduct of such Indemnified Party, (B) result from a claim brought by any Credit Party against an Indemnified Party for breach in bad faith of such Indemnified Party&#8217;s obligations hereunder or under any other Loan Document, if such Credit Party has obtained a final and nonappealable judgment in its favor on such claim as determined by a court of competent jurisdiction or (C) result from a claim not involving an act or omission of any Credit Party and that is brought by an Indemnified Party against another Indemnified Party (other than against the Agent in its capacity as such).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;If and to the extent that the foregoing indemnification may be unenforceable for any reason, the Credit Parties agree to, jointly and severally, make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities which is permissible under applicable law. To the fullest extent permitted by applicable law, no party hereunder shall assert, and each hereby waives, any claim against any other party hereunder, on any theory of liability, for special, indirect, consequential or punitive damages (as opposed to direct or actual damages) arising out of, in connection with, or as a result of, this Agreement, any other Loan Document or any agreement or instrument contemplated hereby, the transactions contemplated hereby or thereby, or the use of the proceeds thereof. No Indemnified Party shall be liable for any damages arising from the use by unintended recipients of any information or other materials distributed by it through telecommunications, electronic or other information transmission systems in connection with this Agreement or the other Loan Documents or the transactions contemplated hereby or thereby. All amounts due under this Section shall be payable promptly after demand therefor. This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> shall not apply to Taxes, other than any Taxes that represent losses, claims, damages, etc. arising from any non-Tax claim.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Reimbursement by the Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. To the extent that Holdings or the Borrower for any reason fails to pay any amount required under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">subsection (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> of this Section to be paid by it to the Agent (or any sub-agent thereof) or any Affiliate thereof, each Lender severally agrees to pay to the Agent (or any such sub-agent) or such Affiliate, as the case may be, such Lender&#8217;s Pro Rata Share (determined as of the time that the applicable unreimbursed expense or indemnity payment is sought based on each Lender&#8217;s Pro Rata Share at such time) of such unpaid amount (including any such unpaid amount in respect of a claim asserted by such Lender)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> that the unreimbursed expense or indemnified loss, claim, damage, liability or related expense, as the case may be, was incurred by or asserted against the Agent (or any such sub-agent), or such Affiliate acting for the Agent (or any such sub-agent) in connection with such capacity. The obligations of the Lenders under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">subsection (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> are subject to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 11.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 11.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. The obligations of the Borrower under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> and this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Section 11.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">, shall in each case survive any assignment by the Lender and the occurrence of the Termination Date. The representations and warranties made by the Borrower in each Loan Document shall survive the execution and delivery of such Loan Document.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">SECTION 11.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">Obligations Several</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">. The obligations of the Lenders under the Loan Documents are several. The failure of any Lender or the Agent to carry out its obligations thereunder will not relieve any other Lender or the Agent of any obligations thereunder, nor will any Lender or the Agent be responsible for the obligations of, or any action taken or omitted by, any other Person hereunder or</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">78</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">thereunder. Nothing contained in any Loan Documents will be deemed to cause any Lender or the Agent to be considered a partner or a joint venture with any other Lender or Lenders or the Agent.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 11.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Any provision of any Loan Document which is prohibited or unenforceable in any jurisdiction shall, as to such provision and such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions of such Loan Document or affecting the validity or enforceability of such provision in any other jurisdiction.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 11.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The various headings of each Loan Document are inserted for convenience only and shall not affect the meaning or interpretation of such Loan Document or any provisions thereof.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 11.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Execution, Effectiveness, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Execution in Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. This Agreement may be executed by the parties hereto in several counterparts, each of which shall be an original and all of which shall constitute together but one and the same agreement.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Effectiveness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. This Agreement shall become effective when counterparts hereof executed on behalf of the Borrower and the Lenders shall have been received by the Agent.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Electronic Signatures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Delivery of an executed counterpart of a signature page to this Agreement by email (e.g. &#8220;pdf&#8221; or &#8220;tiff&#8221;) or telecopy shall be effective as delivery of a manually executed counterpart of this Agreement. Any signature (including, without limitation, (x) any electronic symbol or process attached to, or associated with, a contract or other record and adopted by a Person with the intent to sign, authenticate or accept such contract or record and (y) any facsimile or &#8220;pdf&#8221; signature) hereto or the other Loan Documents or to any other certificate, agreement or document related to any Loan Document or the transactions contemplated hereby or by any other Loan Document, and any contract formation or record-keeping, in each case, through electronic means, shall have the same legal validity and enforceability as a manually executed signature or use of a paper-based record-keeping system to the fullest extent permitted by applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any similar state law based on the Uniform Electronic Transactions Act, and the parties hereto hereby waive any objection to the contrary.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 11.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Governing Law&#59; Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. EACH LOAN DOCUMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT CONTEMPLATED HEREBY AND THEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK). THE LOAN DOCUMENTS CONSTITUTE THE ENTIRE UNDERSTANDING AMONG THE PARTIES HERETO WITH RESPECT TO THE SUBJECT MATTER THEREOF AND SUPERSEDE ANY PRIOR AGREEMENTS, WRITTEN OR ORAL, WITH RESPECT THERETO.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 11.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Register&#59; Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.(a)&#160;&#160;&#160;&#160;The Agent, acting solely for this purpose as a non-fiduciary agent of the Borrower, shall maintain at one of its offices in the United States a copy of each Assignment and Assumption delivered to it and register for the recordation of the names and addresses of the Lenders, and principal amounts (and stated interest) of the Loans owing to, each Lender pursuant to the terms hereof from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). The entries in the Register shall</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">79</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">be conclusive absent manifest error, and the Borrower, the Agent and the Lenders shall treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes under this Agreement. The Register shall be available for inspection by any Credit Party and any Lender, at any reasonable time and from time to time upon reasonable prior notice.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and permitted assigns&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that, the Credit Parties may not assign or transfer their rights or obligations hereunder without the prior written consent of the Agent. The Lenders may freely assign, participate or otherwise transfer any or all of their rights and&#47;or obligations hereunder and&#47;or under the other Loan Documents (in each case, other than to a Disqualified Institution)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that, except in the case of an assignment to a Lender, an Affiliate of a Lender or related funds, (i) so long as no Event of Default pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.1(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> has occurred and is continuing, there shall be no assignment, sale or participation to any Person without the written consent of the Borrower (except in each case with respect to a Disqualified Institution, such consent not to be unreasonably withheld or delayed and such consent to be deemed to have been given if the Borrower has not responded within ten (10) Business Days of a request for such consent), and (ii) any such assignment, sale or participation shall be in an integral multiple of $1,000,000 (or, if less, the entire remaining amount of such Lender&#8217;s then outstanding Loans). In the event of any assignment, the Lender making such assignment shall provide prompt notice thereof to the Agent so such assignment can be reflected on the Register. Each Lender that sells a participation shall, acting solely for this purpose as a non-fiduciary agent of the Borrower, maintain a register on which it enters the name and address of each participant and the principal amounts (and stated interest) of each participant&#8217;s interest in the Loans or other obligations under the Loan Documents (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Participant Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that no Lender shall have any obligation to disclose all or any portion of the Participant Register (including the identity of any participant or any information relating to a participant&#8217;s interest in any commitments, loans or its other obligations under any Loan Document) to any Person except to the extent that such disclosure is necessary to establish that such commitment, loan or other obligation is in registered form under Section 5f.103-1(c) of the United States Treasury Regulations. The entries in the Participant Register shall be conclusive absent manifest error, and such Lender shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Agreement notwithstanding any notice to the contrary. For the avoidance of doubt, the Agent (in its capacity as the Agent) shall have no responsibility for maintaining a Participant Register. Each participant shall be entitled to the benefits of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (subject to the requirements and limitations therein, including the requirements under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;4.3(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (it being understood that the documentation required under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.3(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall be delivered to the participating Lender)) to the same extent as if it were a Lender and had acquired its interest by assignment&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that such participant shall not be entitled to receive any greater payment under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.1 or 4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, with respect to any participation, than its participating lender would have been entitled to receive, except to the extent that such entitlement to receive a greater payment results from a Change in Law that occurs after the participant acquired the applicable participation.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 11.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Other Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Nothing contained herein shall preclude the Agent or any of the Lenders, from engaging in any transaction, in addition to those contemplated by the Loan Documents, with a Credit Party, any of its Subsidiaries or any of their Affiliates in which such Credit Party or such Affiliate is not restricted hereby from engaging with any other Person.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 11.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Forum Selection and Consent to Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH, ANY LOAN DOCUMENT, OR ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN) OR ACTIONS OF THE AGENT, THE LENDERS (OR ANY OF THEM), OR ANY CREDIT PARTY (OR ANY OF ITS SUBSIDIARIES) IN CONNECTION</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">80</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">HEREWITH OR THEREWITH SHALL BE BROUGHT AND MAINTAINED IN THE COURTS OF THE BOROUGH OF MANHATTAN IN THE CITY OF NEW YORK IN THE STATE OF NEW YORK OR IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">PROVIDED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> THAT, ANY SUIT SEEKING ENFORCEMENT AGAINST ANY COLLATERAL OR OTHER PROPERTY MAY BE BROUGHT, AT THE AGENT&#8217;S OR SUCH LENDER&#8217;S OPTION, IN THE COURTS OF ANY JURISDICTION WHERE SUCH COLLATERAL OR OTHER PROPERTY MAY BE FOUND. EACH PARTY IRREVOCABLY CONSENTS TO THE SERVICE OF PROCESS BY REGISTERED MAIL, POSTAGE PREPAID, OR BY PERSONAL SERVICE WITHIN OR WITHOUT THE STATE OF NEW YORK AT THE ADDRESS FOR NOTICES SPECIFIED IN </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">SECTION 11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. EACH PARTY HEREBY EXPRESSLY AND IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY OBJECTION WHICH IT MAY HAVE OR HEREAFTER MAY HAVE TO THE LAYING OF VENUE OF ANY SUCH LITIGATION BROUGHT IN ANY SUCH COURT REFERRED TO ABOVE AND ANY CLAIM THAT ANY SUCH LITIGATION HAS BEEN BROUGHT IN AN INCONVENIENT FORUM. TO THE EXTENT THAT ANY PARTY HAS OR HEREAFTER MAY ACQUIRE ANY IMMUNITY FROM JURISDICTION OF ANY COURT OR FROM ANY LEGAL PROCESS (WHETHER THROUGH SERVICE OR NOTICE, ATTACHMENT PRIOR TO JUDGMENT, ATTACHMENT IN AID OF EXECUTION OR OTHERWISE) WITH RESPECT TO ITSELF OR ITS PROPERTY, SUCH PARTY HEREBY IRREVOCABLY WAIVES TO THE FULLEST EXTENT PERMITTED BY LAW SUCH IMMUNITY IN RESPECT OF ITS OBLIGATIONS UNDER THE LOAN DOCUMENTS.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 11.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. THE AGENT, EACH OF THE LENDERS, AND THE CREDIT PARTIES HEREBY KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVE TO THE FULLEST EXTENT PERMITTED BY LAW ANY RIGHTS THEY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH, EACH LOAN DOCUMENT, OR ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN) OR ACTIONS OF THE AGENT, THE LENDERS OR THE CREDIT PARTIES IN CONNECTION THEREWITH. EACH PARTY ACKNOWLEDGES AND AGREES THAT IT HAS RECEIVED FULL AND SUFFICIENT CONSIDERATION FOR THIS PROVISION (AND EACH OTHER PROVISION OF EACH OTHER LOAN DOCUMENT TO WHICH IT IS A PARTY) AND THAT THIS PROVISION IS A MATERIAL INDUCEMENT FOR THE AGENT AND THE LENDERS ENTERING INTO THE LOAN DOCUMENTS.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 11.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Interest Rate Limitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Notwithstanding anything to the contrary contained in any Loan Document, the interest paid or agreed to be paid under the Loan Documents shall not exceed the maximum rate of non-usurious interest permitted by applicable law (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Maximum Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). If the Agent or any Lender shall receive interest in an amount that exceeds the Maximum Rate, the excess interest shall be applied to the principal of the Loans or, if it exceeds such unpaid principal, refunded to the Borrower. In determining whether the interest contracted for, charged, or received by the Agent or a Lender exceeds the Maximum Rate, such Person may, to the extent permitted by applicable law, (a) characterize any payment that is not principal as an expense, fee, or premium rather than interest, (b) exclude voluntary prepayments and the effects thereof, and (c) amortize, prorate, allocate, and spread in equal or unequal parts the total amount of interest throughout the contemplated term of the Obligations hereunder.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 11.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Acknowledgment and Consent to Bail-In of Affected Financial Institutions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Notwithstanding anything to the contrary in any Loan Document or in any other agreement, arrangement or understanding among any such parties, each party hereto acknowledges that any liability of any Affected Financial Institution arising under any Loan Document, to the extent such liability is unsecured, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">81</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">may be subject to the Write-Down and Conversion Powers of the applicable Resolution Authority and agrees and consents to, and acknowledges and agrees to be bound by&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;the application of any Write-Down and Conversion Powers by the applicable Resolution Authority to any such liabilities arising hereunder which may be payable to it by any party hereto that is an Affected Financial Institution&#59; and</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;the effects of any Bail-In Action on any such liability, including, if applicable&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;a reduction in full or in part or cancellation of any such liability&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;a conversion of all, or a portion of, such liability into shares or other instruments of ownership in such Affected Financial Institution, its parent undertaking, or a bridge institution that may be issued to it or otherwise conferred on it, and that such shares or other instruments of ownership will be accepted by it in lieu of any rights with respect to any such liability under this Agreement or any other Loan Document&#59; or</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;the variation of the terms of such liability in connection with the exercise of the Write-Down and Conversion Powers of the applicable Resolution Authority.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 11.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Judgment Currency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;If, for the purposes of obtaining judgment in any court, it is necessary to convert a sum due hereunder in one currency (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">first currency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) into another currency (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">other currency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), the parties hereto agree, to the fullest extent permitted by law, that the rate of exchange used shall be that at which, in accordance with normal banking procedures, the Agent could purchase the first currency with such other currency at the applicable buying spot rate of exchange in the New York foreign exchange market on the Business Day immediately preceding that on which any such judgment, or any relevant part thereof, is given.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The obligations of the Credit Parties in respect of any sum due to the Agent hereunder or under the other Loan Documents shall, notwithstanding any judgment in a currency other than Dollars, be discharged only to the extent that on the Business Day following receipt by the Agent of any sum adjudged to be so due in such other currency the Agent may, in accordance with normal banking procedures, purchase Dollars with such other currency. If the amount of Dollars so purchased is less than the sum originally due to the Agent in Dollars, the Credit Parties agree, jointly and severally, to the fullest extent that it may effectively do so, as a separate obligation and notwithstanding any such judgment, to indemnify the Agent against such loss. If the amount of Dollars so purchased exceeds the sum originally due to the Agent in Dollars, the Agent shall remit such excess to the Credit Parties.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 11.18&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Specified Repayment Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The parties hereto acknowledge and agree that, to the extent the Specified Repayment Fee is applicable to any repayment or prepayment of principal of any Loan at any time, such Specified Repayment Fee is not intended to be a penalty assessed as a result of any such repayment or prepayment of the Loans, but rather is the product of a good faith, arm&#8217;s length commercial negotiation between the Borrower and the Lenders relating to the mutually satisfactory compensation payable to the Lenders by the Borrower in respect of the Loans made hereunder. In furtherance of the foregoing, to the fullest extent permitted by applicable law, the Credit Parties hereby jointly and severally waive any rights or claims any of them may have under any such applicable law (whether or not in effect on the Closing Date) that would prohibit or restrict the payment of the Specified</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">82</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Repayment Fee under any of the circumstances provided herein or in any other Loan Document, including payment after acceleration of the Loans.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 11.19&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">USA PATRIOT Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Agent and the Lenders hereby notify the Credit Parties that pursuant to the requirements of the Patriot Act, they are required to obtain, verify and record information that identifies each Credit Party, which information includes the name and address of each Credit Party and other information that shall allow such Person to identify such Credit Party in accordance with the Patriot Act. Promptly following any written request therefor, Holdings or the Borrower shall deliver to the Agent such information and documentation in respect of any Credit Party reasonably requested by the Agent or any Lender for purposes of compliance by the Agent or such Lender with applicable &#8220;know your customer&#8221; requirements under the Patriot Act, the Beneficial Ownership Regulation or other applicable anti-money laundering laws.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 11.20&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Erroneous Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If a payment is made by the Agent (or its Affiliates) in error (whether known to the recipient or not) or if a Lender or another recipient of funds is not otherwise entitled to receive such funds at such time of such payment or from such Person in accordance with the Loan Documents, then such Lender or recipient shall forthwith on demand repay to the Agent the portion of such payment that was made in error (or otherwise not intended (as determined by the Agent) to be received) in the amount made available by the Agent (or its Affiliate) to such Lender or recipient, with interest thereon, for each day from and including the date such amount was made available by the Agent (or its Affiliate) to it to but excluding the date of payment to the Agent, at the greater of the Federal Funds Rate and a rate determined by the Agent in accordance with banking industry rules on interbank compensation&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that, without limiting any other rights or remedies (whether at law or in equity), the Agent may not make any such demand under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 11.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with respect to such payment unless such demand is made within sixty (60) days of the date of receipt of such payment by the applicable Lender. Each Lender and other party hereto waives the discharge for value defense in respect of any such payment.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 11.21&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Reaffirmation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Credit Party as borrower, debtor, grantor, pledgor, guarantor, assignor or in any other similar capacity in which such Credit Party has granted liens or security interests in its property or otherwise acts as accommodation party, under any instruments, documents and agreements entered into in connection with the Existing Credit Agreement that will remain outstanding to secure the Obligations hereunder, hereby (a) ratifies and reaffirms all of its performance and observance obligations and liabilities, whether contingent or otherwise, under each of such instruments, documents and agreements and (ii) ratifies and reaffirms such grant of security interests and liens and confirms and agrees that such security interests and liens hereafter secured all of the Obligations hereunder. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">83</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ARTICLE XII</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">GUARANTEE</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 12.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">The Guarantee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each of Holdings, the Subsidiary Guarantors and any other Person that becomes a Subsidiary Guarantor after the Closing Date hereby guarantees to the Agent and the Lenders, and their respective successors, endorsees, transferees and assigns, the full and prompt payment in full when due (whether at stated maturity, by required prepayment, declaration, acceleration, demand or otherwise) and performance of the indebtedness, liabilities and other obligations of the Borrower to the Agent and the Lenders under or in connection with this Agreement, the Notes and the other Loan Documents, including all unpaid principal of the Loans, all interest accrued thereon, all fees due under this Agreement and all other amounts payable by the Borrower to the Agent and the Lenders hereunder or in connection herewith. The terms &#8220;indebtedness,&#8221; &#8220;liabilities&#8221; and &#8220;obligations&#8221; are used herein in their most comprehensive sense and include any and all advances, debts, obligations and liabilities, now existing or hereafter arising, whether voluntary or involuntary and whether due or not due, absolute or contingent, liquidated or unliquidated, determined or undetermined, and whether recovery upon such indebtedness, liabilities and obligations may be or hereafter become unenforceable or shall be an allowed or disallowed claim in any insolvency proceeding and including interest that accrues after the commencement by or against any Credit Party or any of its Subsidiaries of any insolvency proceeding naming such Credit Party or such Subsidiary as the debtor in such insolvency proceeding. The foregoing indebtedness, liabilities and other obligations of the Borrower, and all other indebtedness, liabilities and obligations to be paid or performed by Holdings and&#47;or the Subsidiary Guarantors in connection with this Section shall hereinafter be collectively referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Guaranteed Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#8221;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 12.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Obligations Unconditional</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The obligations of Holdings and the Subsidiary Guarantors under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> are absolute and unconditional, irrespective of the value, genuineness, validity, regularity or enforceability of the obligations of the Borrower under this Agreement or any other agreement or instrument referred to herein, or any substitution, release or exchange of any other guarantee of or security for any of the Guaranteed Obligations, and, to the fullest extent permitted by law, irrespective of any other circumstance whatsoever that might otherwise constitute a legal or equitable discharge or defense of a surety or guarantor, it being the intent of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that the obligations of Holdings and the Subsidiary Guarantors hereunder shall be absolute and unconditional under any and all circumstances other than the Payment in Full of the Guaranteed Obligations. Without limiting the generality of the foregoing, it is agreed that the occurrence of any one or more of the following shall not alter or impair the liability of Holdings or the Subsidiary Guarantors hereunder, which shall remain absolute and unconditional as described above&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;at any time or from time to time, without notice to Holdings or the Subsidiary Guarantors, the time for any performance of or compliance with any of the Guaranteed Obligations shall be extended, or such performance or compliance shall be waived&#59;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;any of the acts mentioned in any of the provisions of this Agreement or any other agreement or instrument referred to herein shall be done or omitted&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;the maturity of any of the Guaranteed Obligations shall be accelerated, or any of the Guaranteed Obligations shall be modified, supplemented or amended in any respect, or any right under this Agreement or any other Loan Document shall be waived or any other guarantee of any of the Guaranteed Obligations or any security therefor shall be released or exchanged in whole or in part or otherwise dealt with&#59; or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">84</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;any Lien or security interest granted to, or in favor of, the Secured Parties as security for any of the Guaranteed Obligations shall fail to be perfected.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each of Holdings and the Subsidiary Guarantors hereby expressly waives diligence, presentment, demand of payment, protest and all notices whatsoever, and any requirement that the Agent or the Lenders exhaust any right, power or remedy or proceed against the Borrower under this Agreement or any other agreement or instrument referred to herein, or against any other Person under any other guarantee of, or security for, any of the Guaranteed Obligations.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 12.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Reinstatement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The obligations of Holdings and the Subsidiary Guarantors under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article XII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall be automatically reinstated if and to the extent that for any reason any payment by or on behalf of the Borrower in respect of the Guaranteed Obligations is rescinded or must be otherwise restored by any holder of any of the Guaranteed Obligations, whether as a result of any proceedings in bankruptcy or reorganization or otherwise, and each of Holdings and the Subsidiary Guarantors agrees that it will indemnify the Agent and the Lenders on demand for all reasonable costs and expenses (including reasonable fees of one primary counsel and one local counsel in each relevant jurisdiction) incurred by such Persons in connection with such rescission or restoration, including any such costs and expenses incurred in defending against any claim alleging that such payment constituted a preference, fraudulent transfer or similar payment under any bankruptcy, insolvency or similar law.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 12.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Subrogation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Until the Guaranteed Obligations shall be satisfied in full (other than inchoate indemnification, expense reimbursement obligations and other contingent obligations for which no claim has been asserted), neither Holdings nor any Subsidiary Guarantor shall directly or indirectly exercise, (i) any rights that it may acquire by way of subrogation under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article XII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, by any payment hereunder or otherwise, (ii) any rights of contribution, indemnification, reimbursement or similar suretyship claims arising out of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article XII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or (iii) any other right which it might otherwise have or acquire (in any way whatsoever) which could entitle it at any time to share or participate in any right, remedy or security of the Agent or any Lender as against the Borrower or other Credit Parties (or any of their Subsidiaries), whether in connection with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article XII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, any of the other Loan Documents or otherwise. If any amount shall be paid to Holdings or the Subsidiary Guarantors on account of the foregoing rights at any time when all the Guaranteed Obligations shall not have been paid in full, such amount shall be held in trust for the benefit of the Agent and the Lenders and shall forthwith be paid to the Agent to be credited and applied to the Guaranteed Obligations, whether matured or unmatured, in accordance with the terms of the Loan Documents.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 12.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each of Holdings and the Subsidiary Guarantors agrees that, as between Holdings or any Subsidiary Guarantor, on one hand, and the Agent and the Lenders, on the other hand, the obligations of the Borrower under this Agreement and under the other Loan Documents may be declared to be forthwith due and payable as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (and shall be deemed to have become automatically due and payable in the circumstances provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) for purposes of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> notwithstanding any stay, injunction or other prohibition preventing such declaration (or such obligations from becoming automatically due and payable) as against the Borrower and that, in the event of such declaration (or such obligations being deemed to have become automatically due and payable), such obligations (whether or not due and payable by the Borrower) shall forthwith become due and payable by Holdings and the Subsidiary Guarantors for purposes of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 12.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Instrument for the Payment of Money</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each of Holdings and the Subsidiary Guarantors hereby acknowledges that the guarantee in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article XII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> constitutes an instrument for the payment of money, and consents and agrees that the Agent and the Lenders, at their sole option, in the event of a dispute by Holdings or any Subsidiary Guarantor in the payment of any moneys due hereunder,</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">85</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall have the right to proceed by motion for summary judgment in lieu of complaint pursuant to N.Y. Civ. Prac. L&#38;R &#167; 3213.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 12.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Continuing Guarantee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The guarantee in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article XII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> is a continuing guaranty and agreement of subordination relating to any Guaranteed Obligations, including Guaranteed Obligations which may exist continuously or which may arise from time to time under successive transactions, and each of Holdings and the Subsidiary Guarantors expressly acknowledges that the guarantee in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article XII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall remain in full force and effect notwithstanding that there may be periods in which no Guaranteed Obligations exist. The guarantee in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article XII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall continue in effect and be binding upon Holdings and the Subsidiary Guarantors until payment and performance in full of the Guaranteed Obligations (other than inchoate indemnification, expense reimbursement obligations and other contingent obligations for which no claim has been asserted).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SECTION 12.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">General Limitation on Guarantee Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. In any action or proceeding involving any provincial, territorial or state corporate law, or any state or federal bankruptcy, insolvency, reorganization or other law affecting the rights of creditors generally, if the obligations of Holdings or any Subsidiary Guarantor under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> would otherwise be held or determined to be void, invalid or unenforceable, or subordinated to the claims of any other creditors, on account of the amount of its liability under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, then, notwithstanding any other provision hereof to the contrary, the amount of such liability shall, without any further action by Holdings, the Subsidiary Guarantors, the Agent, the Lenders or any other Person, be automatically limited and reduced to the highest amount that is valid and enforceable and not subordinated to the claims of other creditors as determined in such action or proceeding.</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;SIGNATURE PAGES FOLLOW&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:line-through">86</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>9
<FILENAME>filename9.htm
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="if89484b57f724c6d88fea68b9c845136_36"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">List of Subsidiaries</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company Name</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Country</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HeartFlow Japan G.K.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HeartFlow U.K. Limited </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HeartFlow Technology U.K. Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>business11ba.jpg
<TEXT>
begin 644 business11ba.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0"N17AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     @   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E         !@     0
M &     !    1TE-4" R+C$P+C,X   R,#(U.C R.C T(#$X.C4X.C4T  $
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M1T(@6%E:( ?I  ( !0 ! "  *V%C<W!-4T94
M          #VU@ !     -,M;&-M<P
M                                #61E<V,   $@    0&-P<G0   %@
M    -G=T<'0   &8    %&-H860   &L    +')865H   '8    %&)865H
M  'L    %&=865H   (     %')44D,   (4    (&=44D,   (4    (&)4
M4D,   (4    (&-H<FT   (T    )&1M;F0   )8    )&1M9&0   )\
M)&UL=6,          0    QE;E53    )    !P 1P!) $T 4  @ &( =0!I
M &P =  M &D ;@ @ ', 4@!' $)M;'5C          $    ,96Y54P   !H
M   < %  =0!B &P :0!C "  1 !O &T 80!I &X  %A96B        #VU@ !
M     -,M<V8S,@       0Q"   %WO__\R4   >3  #]D/__^Z'___VB   #
MW   P&Y865H@        ;Z   #CU   #D%A96B         DGP  #X0  +;$
M6%E:(        &*7  "WAP  &-EP87)A       #     F9F  #RIP  #5D
M !/0   *6V-H<FT       ,     H]<  %1\  !,S0  F9H  "9G   /7&UL
M=6,          0    QE;E53    "    !P 1P!) $T 4&UL=6,
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M 0$            ! @,$!08'" G_V@ , P$  A #$    ?OX
M  "CY[_.O])>@U_^C;,3K&O+5F,/*-28P<ZZLQBF=68U^36FFOR:AAYM7E77
M1J2P<HU%<7*NK7^-L?1C\R_;<B>?[$@
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M+P</;%>..W&7.M.=T3(D            IFU:TMJV0.5CIB:Q?&D
M          .-8H72V?S,?U+^F1NX?;I\_;GX9Q\=>GUZ1T<,X]&KZNO9/HM3
MP;&G;76YF8_"+IX&'KKIW#SZXO\ ;\6]/+UIO2T+IX$VQV^7>7$MB#WGEK"]
M7P+P\OM_H?\ YK?K?T4G6[W70Y[&3LK5$            <:USIXO3PM[3=Q7
MZ/:T2^R^A^F_P#S/SQ^]=Z_?.8NVK&_I<V7O':NU'S/BYR\5H8:]GO\ *L@
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M$Q$KQ-2A:(FTVJHY)B;1"43!,)DD  B"0D      "$"4TQ%7O1(
M          <*UH6]GUY[O5RUX_ H6D         "_+\_V2 5=4-.OLO&HV;R
MU8U>?=',S9@\AZR_^'WN<3,R  !0=F<-^IV[GY^'+/F<-JSGH[/"9(!) )(
M )*G;'=TZEG]#)C3T.W>'*P9-X&K-K)  $=)Y%P      )/8IV)%,15[T2
M                 $(Z98YP]2:6(          %^7Y_LD!$5TA^V;NR'SKG
M88]?Y^VNKY;.?AN_4]7/=/+ZEU\SJR   8?])L9!YT5SG8*=6UE8]_%*.ICU
M,5OA;VIM96O)N4K"<-*YJ304]143+BV29F[;:59MB+Z_>KWM@O*\^:R  /,F
MQ:;O2D      "3T*7Y;3[)BF%7O1(                   0CK,<8.HB0
M        +\OS_9(#P;4Z0_8^Y7M3S&P/@\>2O-;6KWTWYUF+R'IJ/NZN6_*>
ML1(  &(/1;.0^?BK?-PT]DLC'OX\5UV8>I.64VRM8JE#3D$OE;&JE/305/,>
M-&VC/E-:[[Z=9G$3K]ZO>V \IH3$I  4A>SL>X2       !?=]#VS6F%7O1(
M                   <5>"V.,'31(          %^7Y_LD!8'H-C!WJ-ZP?
M7:V]GP;F\;6\NQIZL?2_!Y.\_P!C,WC/93,@  8@]%LY#Y^*M\W$3;],](9(
M"1)" 2")"8")34IQ7+;7E(U^]7O; >4T)B4@ *2O9N/<)PNB[)K:)F-/4F8B
MP2WYC+YV1;H5MB5',F18D7W?0]DQ345>]$@                  !Q5X+8X
MP=-$@          7Y?G^R0%/SVTB^R=BI8]/IC3]NMYRQ?1^)V\^2^RL/T'!
MV-^<?0YD  !B#T6SD/GXJWS<<HI$9:0S$      052<=;8"PU^]7O; >4T)B
M4@ *2O9N/<)TP8=.+4RA*PDW BA4;F,NJ-L=+F-V:9=5U,16K>TQ]%Z;&55A
M?=]#V3%-15[T2                  $8XB[A$<(OCO%TB4%FKOV3JX"^F]#
MZ/\ Y*\WH!^H^]=O#Q;H_GKC2A)2->OJO4T4_1G<S3X;G_0?\L\#2O\ 0G;M
M3OYM_P#\N^>*E@+\OS_9(#@KH]]I[V,?3[/T2^ ^<J>MK:_^[\G@;W7B=K_E
M/T+*GF?3R  (CP9[ZR^ZZ&Q_CM*N<[%X5K&Q[G%;757*9YIB[#K/06"8Q,L%
MVG,YG*+5 3-Z6TJI.,G7WU>[G_R>CRB9LXL9$3?A,VMDST;4V4SXCQ32"Q8G
M%:?0KF--T(Y+:XS6_46,5!.:8M<J1?=]#V3%-15[T2
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M?-]/V,9.OWJ][8#RFA,2D !25[-Q[A(   )DA @D %]WT/;-:85>]$@
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MA:<#>\V=8/J.ATY>#4</%V=^6];.'A_2]JT@  '&L8,];O9 X>.\N9K<KID
M!Q5X+8XP=-$@ 0"0  0 F583*L)E(%^7Y_LD!"   !!R2  !QKCA;D)>=:EL
ML   + J !)49Q^M'%7DF,;EEA6R0  *PD      ""4R"F(J]Z)      #JK7
MYS_HOU/4Q;L_%?.U37P4[8T]-OLOS[WXM;?[\_\ UN4S,@ #IK&M'ONILWX'
MF3*9  #BKP6QQ@Z:) ( !8$  D%06*D@"_+\_P!D@        (!,Q%9E"4)
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M\[VT\_BGU?AOH)^<O8[%>"]'RFT@ &MWM^KL=X;D<[6   $(X)QQ@Z<1(
M       %]WY_MD  !A-'D,3E_G,@P>7H89+B+R*69)*&7<6@<BD&2YBQDU&%
M++F+>+*,H&.;,>RV=HU_.HR:8D,]F"#(1G P$767JB@)P>9=/.>HZC(", )]
M=G1*ZJ/*<CV&,)9%/5#=%(   IB*O>B0      ZZ3;W3S\;P0.48XKBYL=?Y
M6>;1RO,@ &M_N>IL=X3E<I)D   06+@W:=&R5          %T7U:_. F0 "$
M20" 2  02 ""2"0 2<0 2 020202""23B2 0"0 0"0 F0  #BBEK5F^*9
M  #RGRT-]X59%#3RE[D5E.'"K(OZ)TO3]$4>F45=5YY0DUS]CUMC?&<?E,I
M   >3%:TF[X*7          '*\7'.K[E9
M      !Q3T6K5IIW3      %)/R_&SYAT]AK\9X+C,R&O1>9J2?K)/><<;$?
MI]JTNGM<H6WNY-K/G?%F;)    (%>,R2         !-0ZI@@
M                     2=DR3(     !P.)(+++.,S$G DDY$'(BA:$AKC[
M3J[&>*Y?.8)    '$$@         '$$@
M      E!(     D'R*-CS4LI1ML:R'M,^&IAE0S"4@PL?8@D &M_N.KL;X3D
M\KS(   !B\_/,:8G          '<?9,^M9<:P
M                 E62HGRU+1.L\QMH8=,L&EQ=)CXNXR(5@^G)( ->/8]+
M.GE=&I:^.9   #B?DG/FZ 5HRN8Y+8(().XV;,%%IE8,Q&"#K*J4@ ^K)^I\
MYD@                                       $ Z#H3[4 202<3D02
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MD-KC[2&M!81)Q.1UG8<3D<#D"#D<3D<3D020"2"3K.9P).!)@X^I))2UJHJ
M       ...*5M9=>?:[VS/@.;SR)  !:Y^#<W06VXK/8"2   2 " 2" )?7N
M8WH5DM<N@              $ @X@@@$%!+B.(.1P!R(.T@D$$@ @D @D
M   $$EKET I::H@        (CC,XH]!MT[-.:/+:*+<L@ "UC\]E,OW\6B+2
M         )K5[4NF<8   XG(
M  I::H@         =5&&O4;O5DG-GDM+E>)D +>,7X\]XI          (K%J
M71;&  !AD^1A]MRX20                                    "EIJB
M        !"(BV,._L8K[VWLEX?FU#7I-I$2ZXBQXV8@          16+4NBV
M, #%!\V3YZFR9A,W?/K$5\  !        )   !        )   !        (
MA824M-40          .&-T9[:[>UZ'5:^6_.:5[\;7BDVITLOAYTD@
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MBVD7XKK*C(R_T53L*F2[+X*I, =!0L>2AL@U-,%HK9DQ-I&*$8I3F0Q66R5
M]Z,@'U13!!?-]?T2 Z"UL>:GK  :%HU7-WRRDZ.(SP;K&PZ0 3[E;RO@2I::
MH@             $=:UAX\X  Q,9'*D2028X1S,AIIY[R0  BL6I=%L8 @^<
M9C0L\OT[3(I]#SD  CQ+69CS@ 02   4@\)<H!=E\%4F !;F/)0F0 2 " 2
M26&7T""^;Z_HD!!:&/-3U@ )(!(!   3[U;QO@2I::H@             $=:
MUAX\X %K'Q 4STBSBLI\)6T;AK:*)]BN*T;%+[A)V<) "*Q:ET6Q@ 002"2"
M0  =99N//Y$D@D $  D$ CN+UOK]T@!3(FU*9N*82      "/8B\[X.4@!0X
MFVZ9H22      )M%PSAK\T)I::H@             $=:UAX\X $&($5PKA:Q
MUG,OY-LE+1Z2VDY2*P  BL6I=%L8'$TE*R7@58]A9ATE\%I&SQ( .,/.GB
M    "3O1V2  '5#I3       .1Z$<I  0=$3Q.(      .<O0B04M-40
M         ".M:P\><          $5BU+HMC X'S$+M.)8!?)LL:K'K,ZFU9(
M " 2      " 2  " 2      " 2  " 2      ""0*6FJ(             !
M'6M8>/.          "*Q:ET6Q@0" 20"2"20            #H-7BM'(N@M\
MZ3Q%2*25LHYE QX><R$8F+G/ =94380D           %+35$
M  <"PL><D          5=2Z;XD@                  (+3+1,<&=B#7LS6
M8Y+A*H>4JA3SR%]F.SPE6/8=QE8D           %-*D              <2R
M\>?RI          )]+'>E\7.0                   @@D  @D$$@   $@
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MA:P->2+ZW8VD:*4DXSE;G0R4)I8ZHGLV0NIL)GS8?'!B=S+=X<ZI%BY#X3F
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M]MHQIGHMFG= U"=_3C1)1&NNLL)WROZD\N))G+4+E&=7<38-0NL$L\[T^)$
M+0ZSHS)[I.)JFL#>GTQQ<'EHF-LCWHY3C0XKX@E-[:CA+FENB78G94B<V36@
M,=7%42YVDZ?IF47*T=\-S!#AU7F9VGUM.\C4J;E"DT@0VOAB4*525EVG2J3E
MJ,]L'C*,QT2"QC61/6%24M6U1,O4E]*92G01QS*M4Z)7+_B*E,B1XC8+)TEA
M9&;>UX-Y(_%KGG5*\(J8]T%W%AOBQ'$AM@95M%BB>&&4'D/<YM<-+")"1!OF
M+C>LJY1I.4HHC1Y.>UE1LK &BX )S(H(+&V.-6);>,ZR(X'P@R4QL/S:;!S^
M\K96W_97K)<0,?%KP:PJ2 GFKMM^BBTRA-C&="%]O/L/4U&ET.=F3Q_W?LO&
MZ'[/^+]EXW0_9_Q?LO&Z'[/^+]EXW0_9_P 7[+QNA^S_ (OV7C=#]G_%^R\;
MH?L_XOV7C=#]G_%^R\;H?L_XOV7C=#]G_%^R\;H?L_XOV7C=#]G_ !?LO&Z'
M[/\ B_9>-T/V?\7[+QNA^S_B_9>-T/V?\7[+QNA^S_B_9>-T/V?\7[+QNA^S
M_B_9>-T/V?\ %^R\;H?L_P"+]EXW0_9_Q?LO&Z'[/^+]EXW0_9_Q?LO&Z'[/
M^+]DZ/0S.5&JG\\Y;D^1/,%4?)9+C1(=( !%4S#IC0"1O[E2FA],:[U)BMK
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MXOV7C=#]G_%^R\;H?L_XOV7C=#]G_%^R\;H?L_XOV7C=#]G_ !?LO&Z'[/\
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M._'NH<%9HO5<*N%7:J[47M33-5PJX58(N5<*N.&\'J3_ #\:N#3_ "IN?;]
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M$(H,>K.;'2JOC':92&W0)^#&1_U3DZ&U_.I48B-29_WCASK=6BY2<;A8I/\
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M@J^Z[R#JV92K"JWSDQWBD*3?WCF\^RW9;H-^DR !E-'SRXS+C:3KW\MN?;]
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MVY]OT"A^>/S#YH>@3X*NI&R[DO\ .=M/R]$S^9TJ?N*:D@X@H1I+C<8"XS&
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M]E3\)G_G_P!W'U/N5/PF?^?_ '48]R,Y(R[(NXAB.(34LPVDT*WZJ4=X 2$
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MXZAE*EN:)0+E>(?]-8Y7,YS.9<Q/R<L\H2$@^6 T%&BBVHA:[= "22E._07
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MC \:;Q?+>'8K)D+5-2+,S8#4\] 52O16M>@C=2,=SSFL\H&$/IR]B\ML9)Y
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M$R\X9*8RFBF.2V*&7DL-"&E*2RF59<2%/.$(6HO(45E3?=I;*$9 #;?*'@J
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MRC*7P$9\LS?HH[*,I? 1GRS-^BCLHRE\!&?+,WZ*.RC*7P$9\LS?HH[*,I?
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M64\HY19F\/EE>R77#3+D[M72% T"J-$J0G>3H(J1O%4H7SE<4B.2'DKP+,N
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M3! (">@4I\75()W*I%I":ZJ/B]? 8HK@1X*1:K@?DC&D%G+F6V]P=1B$P/\
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M>?F37VHT6.!.O/OFC;3;8)J1F9:((IX57S8<C98J^V2-JH]L)I''C&J<-6&
M3E#@]]"/="0^#'-;H4'O)R&0O[^V/''11?)\C^88ZM%\GO\ \PQU:+Y/?_F&
M.K1?)[_\PQU:+Y/?_F&.K1?)[_\ ,,=6B^3W_P"88ZM%\GO_ ,PQU:+Y.?\
MYACJT7R>_P#S#'5HOD]_^88ZM'\GO_S#'11_)[_\PQT47R>__,,=%'\GO_S#
M'5H_U!_^88ZM'^H/_P PQT4?Z@__ ##'5I/D^3].QT4?R>__ ##'11_)[_\
M,,,U];$J)<M\M :"ODZ> B</EN@-!TD:\!Z.=A#S!-K'9#@IJU7PC9:8U_)>
M<E/$^J=]=TV!=(Z:XXR%\D/U_.N/O@O)IC[X+R:8^^"\FF/O@O)IC[X+R:8^
M^"\FF/O@O)IC[X+R:8^^"\FF/O@O)IC[X+R:8^^"\FF/O@O)IC[X+R:8^^"\
MFF/O@O)IC[X+R:8^^"\FF/O@O)IC[X+R:8^^"\FF/O@O)IC[X+R:8^^"\FF/
MO@O)IC[X+R:8^^"\FF/O@O)IC[X+R:8^^"\FF/O@O)IC[X+R:8^^"\FF/O@O
M)IC[X+R:8^^"\FF/O@O)IC[X+R:8^^"\FF/O@O)IC[X+R:8^^"\FF/O@O)IC
M[X+R:8^^"\FF/O@O)IC[X+R:8^^"\FF/O@O)IC[X+R:8^^"\FF/O@O)IC[X+
MR:8^^"\FF/O@O)IC[X+R:8^^"\FF/O@O)IC[X+R:8^^"\FF/O@O)IC[X+R:8
M^^"\FF/O@O)IC[X+R:8^^"\FF/O@O)IC[X+R:8U%[7WB;3^[CC8?'8)>@DZB
M^;]/^37LLP7E&HIW4"6@%H,ZS'13WNG79A=Q$573E&\-441#3TU\>/3A[ZKC
ME7))/)O_ 'CD[NY]]-XH;M=$[^UQPC4=IR0X70VRVX\2Z\$X-HIEJO?0=$3O
MECD_)I._1%U8W+N_33OJWN]M/!M*""*=;G8UY!.T_P!4D;/>7K;O3O\ UX-X
M&'S:;UWCHM.DT&SUD-P04 5/=;2\Q.<7#U--??\ "OB\>GZ-=<>G'X."[7@X
M<5P+3C#S;A:;(&VX#A;6T@J($*$6JIPT1=5QNG0-IW1-6W!,#37BFH$@EHJ=
M"^KZ>)?>[_APFJ$FUT:HO.TUU4>A5TTT71%1#YG3B&\5#9HW8&C<(ECJ*R'"
M G0%L"YVT38$8H6G,$M>.'XLIEQB3'<-E]AQ-'670+0VS'O**\%3O*GK5][7
MT\?##=C*9'MM:-A(DN$G.:9,4)B()+Q0&V]E7!335PEVM=/^Q&R2:HOSX-@N
M)-Z;*_E!WO%_DM][_JFG'/B"I?W8ERG54G)$J2^9%Q53=>(E5??77Q<.CU,N
MUTX4.)*M8[;[>UIO03:=1M=-.Z$(AP7JEX<6=!6P8TRI@!R"-EP8"&#[/(6W
M$=7< L@@';5[1K049'<H"Z8GYKHXD:%F"VS"['EO<EVBK&BEFPD8&G4-66V
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MIH =FNMM,G*-.!.DVP(,@1=*BV*#X,6<NRAM2G:>MLYM>KRKI'E<C/V9!VA
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M4&"ZJ.27]AJ<[1J\01%4N<N1A+*%A/S)E[*4K*IM3W\MWM(;Z6+BMK95MI(
MXL.3&1IQF]K9?+08V676-6P 9LN572)C5R[DY^OMJ)ZB&-EGM+&B<K@M6%R)
MW-3%@367WH8U8N)9MN;M_P!D52PB;2EHB:DO22]\E]]>E?4)?"7S</5SI]C]
M96V*&UEKE7+[!R$K1)!D(VC:!&?VT(%4EU4>C'X,Y<^7Y/\ +\?@UESY=E?R
M['X-9;^79?\ +\?@YEKY<E_R_'X.Y9^6YGT#'X/9:^6YGT#'X/99^6IGT#IZ
M,3H,&!51JIX.4YNAULYZ755\]WG-262<CLC&MY6H*_!9'=R +E$D$=]F+T_O
MT7]WJ1(]#0UN8I+-]5S'X=BW%D;F)&<)79D&%8NL5<^<QPW<6R,HB\5<;<T0
M,9/I\QY=:=J*/LJWN9)S,F55/03R_<03<CBW#@*,148EGNI<",PW&;=VT88Y
M/C+YNY2BYBHLO]DK/UO]@ZSH#<:309@:"/E^9'9EEVM5NN<WKJ0I"BL;G*TV
MIZKB747<&/62G<PYBL&84:4W*89AV,LWH3;;PJ0&(@2-B1+J@@FN**1G6ROG
M9=%>W-U695*RC/9<JIKTZ:4&QCM18Z/'(Y-))\6GI3C8ONN<W7CBF['T7*-1
M-@U%X_IG.5<,]JGLOR+1^<4PJUI4L1OMW(6.C&RK:.B#BNJT*XS@Q;,<E.V[
M(.:;VOV7FWB.JLW8Y0I)""\PW-DE5DA0Q0="3:3&569&78D";EK-F9[Z^[(;
M=A#<D9KJ;<;!8]:@CMV;[LGE,5)$:>')H*,(H+UDQ40Y]-#K<SNLO?9$\SNW
MI$MX9\QV*#TMM2WS;4=ULF6A+=-;2[(XS)EJBRG6YABW6<K3,=3F>;<,,5L:
M)>RF9,QJ]@KI/*; 0"%KDJERKF+J")IC/>:VK"OK;-R[II65*5R%&F/RHF2=
MV_1&S=K,;[3=M)3DUUR*;)IM.)OMI"QG^P'*MZ\N<:?+35<59G*-2T\.RBU*
M!.8S% 5\4M8D><0M@!-O ZTVXV.G*$TMIU;7.V_V8Y4RA56-AE.ZKLO3\NWN
M68J,O\E&>T3(9?EJ9+["!+&8U3<[S%+$SH^Y(S-'"4%D^Z^W*<(N72RBJ4AD
M&FW=F(3.R;;;>J<5%-?5;_,3U(_P._-^)N0HJ'<V#7-=:BD(QH[G1L/RUVAV
M]474&0>)%X%L8WJY::Y)KJB[<M%V/#O=TK1<.^G#OX;BN[57.=X-,R3$F'B_
M(9E#H"DO>%P6R5> ;PM43\0*9;3XT",/]9*=!I%7O "$NTXX7N6VT(R7H%<*
M.3LM/R8Y=2[OR<IJM? XQ')HK28UT\X8K'>TVDYV-<Q9SFMMKUJ_+3#=-&1%
M]P4P^5V3NG1M)(8VTX[ ZZ8WSU0%E(]U)MWY-J\Y^>LYY\5\*\U$][&D*IK8
MNB<.308S.FG^C;'P^+$K,F8G(TZZ/>L5PL-[$"DKE-=W&KVSYV_='1R;,+V9
MUQ2 2%E$#ULC_0/_ -D:X@_ZC;_V&'H;1[,J\>2O#CHO)^#LM?#HK2;OX71T
MTQ-=J:!++MDK:'*=C3S'=Q]OV)DXP;"AMDN\Z2$T44+3#-M:4W:IX(PPMXU'
MFLMOH!..-+M26]%>3510?R.'N4TJ)IEM2F&>03>_]M0?8UVN_JZT@.=[7:]9
MJ6@BFJJJ\T4%$VB4E5=G5.GG$*:=_O8<RKDO>S9DI2B2[*(*N%SM0<BUNSQ<
M<+51<DIHC*=35-"QV\NT$KQYH@8C"J.!5M&GLGLB:B4PA70S3:!OG-AS]HRM
MIH%LRGV>UT/O?;,Y=SM#Q7BRUMN+TZ;)+WD7$BUJJ7MJZ]&6%O78\UQME%,#
M=V2C"NKSFC:FBKW-$7I5=83]M0#6K7(Z(R6HU@V! ^HKN9!R0V!3;34-.**N
MB+Q75F(XYM2J)XJYQ%ZW)]$>A$OAVF2V/](VXB]'K6OS$^?UN3LMQY+<=FZM
MS ]YKN5>:W8QCD*G2RTKRN*.SUT3BNB8;9:[(5"TTT MMM##800 !00!$Y'P
M011$3WL>V+1_JC/T3'MB4?ZHS]#Q[8='^J,_1,3Y&8,WT]K!K6^V')FH[8/J
M[&0E%6";CMDA](]T'5%5%3O8R],E.;R2]61B=<X<\D#9VBT]TJ)Q]_7[CF?_
M &-._1HR6FG@T[VG0O'IQ7_ZG&_L0]1=>A4T7'#G!WM.][R^IZ?O\/0B<>\F
MG1ZG[_%T>+O>#O8]/3_FOA7'I^CQ:KIX-5TZ5QZ>G?T7PIPZ,>GIP[W@[V/3
MTX]_PX]/'\/O].G#O)CT]-??Z=-4Z%7'IX=?GZ/!ZGZ-/?T7BO'W^_X?4Z%0
M>^2]'Z/?P@IT(FGJY]_T>5O^'2O7Z<>.OO*GOI@H=7&&*RKYR'-",W7GWG5=
M=???<(WGGG'%4B<=<,E\.FB>KXOW='BQZ>+X/>Z->/3B+"L[FJKY<Y=(42;/
MBQ9$I>A-PP\;;AKM:["CJ)::H2DJAABGEW55%MI2(L>LD3XS$Y[:T$=U&-Q'
M"4]>8FFCG0G/UQER D Y?V06BUZR EQ(X5^ZCNR5E&T\XC\L?8T!6H@FZFJF
MNRFN @0+VGG3C8)]N'%L(LB44=%)O>HRRZXZK6VA(X6FFRFSL@G/QE[+<%Z/
M=S;V9=07.UEG#>[42::J?MG GM ;A ;[;1L-]"-.J1&I"FB4M]=28&5TO ^U
MHEK;UNWO%=41::DM/JQ*7H/>1S( 0N*MKQQ#K9-U41;"PV2@07;"*U)EH>NP
M<=@C;-Y'%VD;4 %74X-D6B8N\N0+J$Y;4#P1Y\8WF0VB6/RIWD>TXBS&X0(J
M3'61((CJ*T:"XVXF)4^!>T\V'!W@SID:RBOQH9-BJGRI]MQ19V4'0MM4U05V
M7$1$'&8<NU6Q,;H*VBL>W$67'FP)[=Z#[@-QE9ZJQMPN_4B74RU1,>']_P _
MPJOZ57O^L;_,3U(_P._-^),55<ZK5E=[T%=;71R-!;1$?<#3BCCQ$##9)Q35
MQ05"35(UQ?10FW4D D"U)'>-5R.\X %LN8<K145]TT(D<VME43&[W+6[_P"K
MV!V-/!LZ;.'[>CC!#M(Z+(<9CINVIPMZF2*V&@A)335EP$12)-D]K:31V%,<
MWEA5;MM7"Z[\5Q%W#I__ +@J!LN=]5#:+4B55^ZD1D@"**I$O!$1$U5>/!-$
MXX=K<B16I8MFK,O-,U#2BAJB[+B0D'9<NI+:HJ;N*210+3>RM.:HVMT^]F6]
MZ>V=MLN"P2\5&N@C]IU[:+U$8:1Q!T%7"TUQWO3WO6+\"^M>$4U(FG0%.G:(
MFU1$[VBJJZ)KPQ$GV=+,A0PB60%)>0-A%=9403FKTJNF&&ZNCFR:NLB"Q'?'
M=[IV3(T<D.\7$X"NPWKIU05>E,55.UT083+!+^6\H(3QKIPVB=4R54[Z^#3%
MG7, KLT6QF5X>Z*5%+>@ ^^\&VVG%.D>^N+>MNJ>;!@2P;G1W7T'=A+9T;=!
M=DET5YH@\CKTJ2KZM=6Y;CSI%;(:D+:MP-@=\:.#N6GSW@'NE#:56]=@NDA5
M<&]34DZ$\XFRL@(M>X\@?D \]O#;!?="VH"7?1<)PO--H=5W-?X41>]KHB<Y
M=/?TQ3UE-3S)L&&P<V4ZPC6[*<Z.Z!O171T5IL273BB;Y? BXJZUX-S+(.5V
M IP))DI5<= U1>)-)L,\%TYGOKK;4[G'ET)YIO7CL2$3>1S'7AJCXAIKX-%Y
MJJF'V[2DFQ:NTADR^\>[)EJ1')78SO=..TJFVBZ)P<Z/6M?F)\_K80VZS!6N
M<<<C.09/)G$WJ(+@DNR:*B[(][:14YJIC[]S)\KK_ Q]^YD^5U_@X^_,Q_+"
M_P #'WWF/Y7_ /\ 1C196823OH5MJBIX%16-%1>^G1B%50D-(L!AN,PAEMN;
M#::(IG[HRZ27@FJ\$1-$^XYG_P!C3_[$L5_^IQO[(/5U,D1/3O8ZFO\ \/'<
MU\FF.HODTQU%\FF.HODTQU%\FF.HODTQU%\FF.HODTQU%\FF.HODTQU%\FF.
MHODTQU%\FF.I_P#;QS%_1T*GZ/69]_T>5O\ ATK[@7PC_P"+UMPW155(Y766
M68,*/9J[4P['MC FG,6/:RYU?+L2B"NBUK5._#)N02N29(IS,0<Q5=% KW+"
M7DZ;?2K"WJ;RK)NAA18\OE%7,J')\6Y85IX8$BFEA'=5!D*;9&N.QK:0 9.)
ME;-CMQ;$Z]NR"$M3,A[;(*GLQH\ZWM FBZ<5VD3'8G3D%36V^6Y^=SS59PWV
M>5I'S!$L(E>X$D&D<GJWOXQ$QT,""Z<==>QL$G+&6ZUK(C6;(%K?0+-IV?F;
MMS4V,6%9*R$9'MEZ5);=D#+<>D!)<=4=6-,90?>RKEW.QP>QI*R+89<M[2.Q
M$JK)^UDS^VD=Y]AZ/(BSF'QAV2-;B=NF-&7."8EM5.7LJQ(G:K)QP7*B16P-
MF7ELFGI-=)G3ZYZ\>!@QY/0I#DP(X-:+,UZN.RS$C45-7Q^R/61':[,03HO*
M<OS&Z%F'-J9$=F,DHAL9H'RJ1$)&7F'"D.(1*28S8R5<-5;V%-E>JCPY]_63
M(%XF7+%B>_"E-TM+61HD%]MA(\&1*Y1--EY6YB(V.N,\9KL\N4V5H&:*O+#,
M&GJ9K$M(KU0U+"7RKD\9AA'Y&VT_M,\T]M=5)S4E]8W^8GJ1_@=^;\2RNQ+T
MY)LTPIM=78.S-3147I0G-D2]Y?577T3&98T;[U%NU043JZ-6K0M>]U5)!_.)
M>G[K(L+&2U$AQ6U=>?>)!; 4\*]\EZ!$=2,E1!%573"2[895-DQ2$HE+J4>R
MS VB[02+@AT<BUSO FJT"WKH\Z4H]3#46(PU'CLMBVTRPV+338"FB #8\T1T
M[R>N7X/[O6_NX_#K\_1X,>FGBQ\VO]V/3SX^I-/%_?Z[T\^/3S\,?5X/!QX>
MKZ>GZ?6M?F)\_P"*9G_V-/\ [$L5_P#J<;^R#U%+P)C:)5]Y/ G@]9JJHB>_
MP_>O#O\ #PJG#'7;73OH8]*ZZ)\*]Y$0EX+X,:[;6G^D#9\:F/!>=I[OAP$^
MG":*A(O0J+T^#O=7_.'H]UHOJ=[QITK[GOKM>Z3F\4Z=,+T<-577@B:(O2FO
M-V5XKM$B:*G/3HQM:ILZ:[7N-/STYO1TJBEIT8U11+7JJFA(7OBHDJKW]-$4
M37AM"O#UFT*Z*FG1W\(7AZ?>7O\ JY]_T>5O^'2ON!?"/_B]=Z>#3YL>GP?-
MP^#ACT]_SX]/3T]Y,>GI\'@Q^_P<?#\/O].G#HQZ=_I_0O?3OX]/#K\_'X>/
M2N/3X?GXZ^'CZUO\Q/[O4C_ [\WXE79K@"9/TBJU-W2;1MPR)'VI2)IPY+(3
MG\"YCJ%T!AA">::NHS(-V,)2035P1T64P*KM.Q7^N)BB[!*H+KIJN'VP?;=N
MY+1-P80DA&"GPY4^*:[MAG7;U/9%Q4%M%YVJ3<QSQ-'[A1"+M]=88*3A25U_
M]Z?+4-.EML"[_P!TD39K[<:+%:-]]]TD!MIIM-HS(E\">/@B=.(^8[MEQG+<
M1Y'\LT+XJ/+2#N5_;LEP)P^Z5D%U%2,WLR#3>EPTT\WKU].]ZTK>OA-6%Q/L
MJ^BI(CY*$<[2T=)MAQ]1YQ-,(!N$ J.UH*:Z*N(CF;K;*N9LLO5\R5=R:VN[
M1S,NR8S2OB$,=XZMPPYHK6TX#1BB;9H"["NN9^RK*RE IY$^0F7LF6-8;DFV
MJX4SDKCLV_5X2@RG]AT@$&]VFRBJK2+QK;NMS)EJ-6WN9<OY>CT;V6FYLBH=
MMF%!YQVU.2G;!IB8P_U8[+CK9BB$"B6*#+4"VH<R=DG,UM9E726:$:^ U1U%
M<Y/EH]7J])'>*381QDJ>FLEKW6,O9G;04.TKFG);8)LHQ9,?:]E&V?<(W,;=
MV0ZR H^MSUEE.R5D?(=;EN95LUC68Z%F;(GA.K6)+JMO%*8(U9>(MK755WC?
M>QE3*+W9 R;EYF=DI;NSS5;Y?8.ML+,9<@$6)'*6WR=N6PC2L1P?/38-Q%/;
M%I,@/1\_Y-L',YYM.N^S,,OQV<OQZ8XA*#BQG):MKR:2RZ3KZ204Q7=<%'7&
M9\FW5QES.$>DK:^TCYMRM&Y%"VYA[!5,UL79,7E8HN]#D[Q\!T+:7;V/1%^9
M?3H7'@\::?"*\?@X^M:_,3Y_62\G9+RBF:[BHJ(]U>E)NF*.% CSC<&NAMOO
M1I)2;&?N73::0 ;:;';<<)%X4&6\O9$F3<X6N7?LHMZ2WM8M.UEFL23R(>V,
MW<RT?DR)PN1XC##*;X6U=(VDX)"S6_V,7&HBC'CW$&RS-#A6%9:R;;M4W&:;
M:@RV["(Z1,28\]MQE'([XJK EJ*42Y@R5LV]@Y83KBLK,P-609?RI5N1&IF9
M)$P*T-\V!3F42-R=K54--\FBXN<X2&GI\&GK3LE9A:$[*#9%6A:)>:(N;P%5
MTO8VVUWI+L"6LVWS)2TU#EN+3]N_LEK,X568JB.R*-D[!LRCMQ9,.>TVYO-G
M<&T[H;8%O T*TMVKET(].4 9S,FIMXU@*VQ*%2K%8]!"?+&T,2&"<5AX'R11
M$M4Q&OW+S<UTFY<RX.\@V S6KYMIUXZB36\D6=&GH#1:1WF!(C401%,VQ(K?
M+LWED1N7(@2$./(B28DZ*J)(AS(DH&9,62SM"KC+S8N"A#J*?<,S_P"QI_\
M8EBO_P!3C?V0>HOYPZ_!KIZU]@ ;=*1F;*,9&'G'&8[^_OH8JP^XUH\##XEL
M/DWSMVI*.UP7%?!3*64J.SNNRADV$_6T=M>2:6UC[Z4W%8LIDP1F,-/&XZS+
MY(SJ ()(BN"*#DZJ3)V5:Z==]E.B:ET-+=W*TMP*1Y(PV9EC/ )K"NBIBXK+
M.@H@J"&O1GYR^=#+#:9U:I(O8\B/65R]EZ<,-1:8K1)MV5.^R 6W+*,L-I([
MD=MQP-E0),5U$Q.F.V5O';FU[25%H@2(;J,_;>^<B-MA&!7VQ?>=,!CO.(RX
MNWJF'*^PEVV2NQ[NXNSG/+5)]D-E*>=;#E4:PD:R/L79;=]B2455(!Z,BN+(
MC:[>#IJRZCS'XF;,GU%OO9KS-9%21(&2,?.4UC8?BTUG%!>6N,D)F9=&WJ"3
M*>5*C-Y,:[.E+"S:>7K&<_DJ+E297DX<*DLWC&8-*Y8)%"W1QQL6IQ&WHXP?
M#LDP\O.[_(L'.(,Y05IYV37 UVM8<N8U.^\J[<!FRYK* ;D9LT7=$NNJ^L+\
M[U<^_P"CRM_PZ5]P-$]Y?%Q_$O%^G7 #X!1/W>I'^!WYOQ(VW0%QMP2!P#1"
M P)-D@(2U$A)."BJ:+W\%;9)LNU3^V3HP777F@9<7C]HS64-Z-X!;<%QM.@5
M''(ELY.XZN_[<1-G9Z.[??FSI[RKI[^!M,Z6/;61M;Q8#9NO,NGT_;LI[1V6
MG>5H6VVU3FF3@JNHMM@(  H(B*;(B(IH*"/0*"G0B='W1RMZV3\MRD2S).YW
MUZSHX%9K_60*S47)XZ[+\I0CFBM@>J(B:(B:(G0B)X-.]]P7T[WK9% LYRJE
MMRX=M56C3>^[7VU<X3D20ZSTO,+M$VX"<[0MI.(BJ0)N><U9?&DK(LN,[1Y5
MA/MIF9R2RL??73D\7%:!M%5X8L387>$7/V55%D9)R=G++T');LV0]76LV!-<
MS;01)<A9#T*&H'R*0;2J6Z?<3:3:55;%%V$RO3P[-I)%%FG+E[)G60JKDYFF
M20DCA';$1ERMXA\&Q874MGFKA[-.9K&4E' HFJG+=?3V<ZKG1'W'D?M)LN7%
MW?&3O#CBVR>C@;C>;2M[6,R48SFY>6Y5\_:Y8:-QYR=7QYP)RJ',-P$1Q0>;
MWH.ZJ;BN*1$NOK>R%FJ\BTEO%S9*IGZQB3!"5(KQ@00AO[PI3) *O$VACN5Y
MR(BDJZ)BHSM,;J9E'6Y/EY>.HF1$DF4MV4\\Q(!LVG8VY9 D%%710Z$TQD%F
M-'J&:7*>9F[>?52HB+"EUNX>;=@L10:6,N\4]29--V>JJ8JJKKV3K;L>\B[0
M6[#=U5TK$(I%AERZ)R,U:RJZ*TV3,J W!Y1,8@<=T;+3;0H"$!9PN<H=E#.%
M[)RV4.7#L#J(<8B?E1HB/UJR':9 N8XO.NR3&,PC]>XO(U,A;TQ 8EVEA</[
MD)#T^TW'*W"?;%U0=Y*Q&9065+= ","2:>R:EKZUK\Q/G]9.SKD+,532V5Y3
MPZ:^AWU2]:P9 5KCI5EA#Y-+AO1YL=)#S2@YOH[XZ>Q[6IK0YLR]G2*[G.%E
MK[%<P6.9:;E5?F.!RL[%M]R%5/UQ09,.>XZ<;<&2.-&C,A5,5<)<GW&;$LKQ
M^;7V,W,$FN;89<*)=,6YQF($,PW,1H&N20D)QYT6Q;)UUT]7%S!>YCO+/D<[
M+D7*U-7TLR95\BK/9'K9NR)E_8LVK&<XT\<4D&*@, #@F7.Q#R>N9F$OX%.W
M5,YD"K;E,D,0MB*Y)K)SCS;Z/P6VXL\#)=[O'S:4%V23-SE[8Y:IRS+E7[&N
M1Y!RX[E^J<>6P9LAO;6"Y,DMR[ ),9H! -V/)B<175+GXLH%AGNDAVC[V7UK
MWZ.BE5D8(U2[O)S4N6W8=MR*X35#Y%-CK!%-(9M[PU*"DC,56]'A=E2!V3-E
MN#8DZ1!"=CV%3OYEC+?<3>$VL.9*>>?T UE;QQ1),ZF].:F_97GFZS:SNV#9
MY&U:1X#3<)Q3(MZZSR-2)\4$2WFR@ILHB>OO:Z&".2IE9,CQP4Q!"==:(0':
M+FHJKP125$37G8C,+V/;%598::54O:'I $%=/MOWL"Q890F5$90,CFO6E5*
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M392%7#WW+&P<"%! ?\Y9+[?P(BKT8JZAOCR*&TTX?_6O[.U(>7_.??)QT_\
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M;#IM.&VU#OHD.N2%$MX4E);4\84I^K*DEU4R/.UA/37WF9<E)#;,:5$A+$9
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M5P"!VUL(V7(-992YKKTP(57&K6YS;LG=CNE><C/$X3(-\J<T-P4V],/7\B%
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M?W_'ZG;#DLCD"/I%6;N7%B<J4%=2/RC9W6^W0JYND)3V$VM/62,Q6\<9-1E
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MVN88MPT3++AOLU]$[.BB#AHIL;$@1,R:(2(>:O-51]5]/S%_=^*5F>&4^TA
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MB2](<)XS0^+B[7>3$Z_OYSME;6+N]ERW]-MPA!&P%$%$ &VFA!EEL$0&V@
M1!%,9BR;63&6J'-2M%<QCAQ7G'U:04#=R7&R?8X .NZ<#HX]_!4M!;L]JN4<
ML9@6-= M6(<S77E,))S#RQ7=KGZM*([?/V=I57%_<MWHS9.:39<OV;6O@6<"
MS*,&ZB[^%,CN,?:C2(S&1L!1EI-V',X8J<ZR[X^WM"(M4[C$>)'AU\=!-LV(
MU>TTD-&GQ<,7Q5DM\):.*2(.DG,/;2M;LY=')R](=8HJAL':V7)&6^),C$02
M>)\!/E1H3R:;(F@*H8RUE!V<R5%E*Q[:TD;D41'(TS?/R-LY*-[^0.]DOENW
MG'!Y^SU1%$SM>]D7,CM;F3,E+4U%=<AEN/;T#3-=)-Q4LLNQ.2#,>0"V&'%,
M ;;5[;+>*.*.BJ)$+,V8X-L]-E9N@Y0;R=';KECFT%4Q#WSS[Z&;@/$9DK2$
MP)(B%IZR?_WEL/\ R\+U>QW6.29L-N?V3LN1CDUTA8L]@7 G)O8<@.+,A-/8
MS3BBZX_#WLI_MO-_A8_#WLJ?MO-_A8_#WLJ?MO-_A8_#WLJ?MO-_A8_#WLJ?
MMO-_A8_#WLJ?MO-_A8_#WLJ?MO-_A8_#WLJ?MO-_A8_#WLJ?MO-_A8_#WLJ?
MMO-_A8_#WLJ?MO-_A8_#WLJ?MO-_A8_#WLJ?MO-_A8_#WLJ?MO-_A8_#WLJ?
MMO-_A8_#WLJ?MO-_A8_#WLJ?MO-_A8_#WLJ?MO-_A8_#WLJ?MO-_A8_#WLJ?
MMO-_A8_#WLJ?MO-_A8_#WLJ?MO-_A8_#WLJ?MO-_A8_#WLJ?MO-_A8_#WLJ?
MMO-_A8_#WLJ?MO-_A8_#WLJ?MO-_A8_#WLJ?MO-_A8_#WLJ?MO-_A8_#WLJ?
MMO-_A8_#WLJ?MO-_@XAU+<N?.""SN1EVDI9MA(':4E<ERC1#?<YW$RXKX,9A
MRY(1";NJB?7<>&CDB,8LG_N/*!IWT445,9A.; FL3NPYV.8]13;V.YHY<UV:
MG[APXNHB1.=J:IF$ AS_ '/NDQV6NR;5UUFQ99VSA5-RXD=M_M@F4*1I$F-,
MMM)RDH2SY#82F6E]D9KR/FM XF.R)8=BZQCLN'V-)<+M1E7+N::BH=MD:CI%
M<&9?R'A#,K>CB*".;UQTWEC:)OG,=C/M/,9J,QU!ROLJB5>6<WA:2F=HRL(V
M=+"8^[5;QX=\#$P&VHK:DT!-@Z+(X?N[FK=M^Q+0]EI^3F;+#"2FI]D_(*.V
MY.E-@WM2:Z$V,-@&E,6R?DJV2*AN&Q:9DBR*N^8F9:I6:7*>:\MYA6OEP9$&
M$C(9%L:M&XP.MCLJ0HY 6$\<AHB=43V>P3V.W*<Z6!EC+T+L@YKH7GI,I:XX
ML9IFFKY;CY+)VD) '26O*$&T3?J9@6.R@[ 8>6RR_P!C[+N;*5\&B_I'+LN%
M+(631.<^Y#66P( N\4R3P)CL6]D^V@OLVG9"[+4NQ5HF7=J%3T\6)55[!:@2
MMLB\$PP4MD"C[DE[RIV4JW-]5F*5V;YV>!>R3)9C6KTLJQ)C"PG*:2QM,C"1
MKE.PC6NC2PA85-CV-^KSY!DV!L]A&JE7 [V2U'D9BAU\ 75D.1B 'R9FNOR&
MV]X3:R&V']DC;VDRK=V%3.FS,LY]G5O*38EG(K,L2GED2X^ZZP02E[*[Q V&
M721L5!7%Q_Z/\#)]4^/8[FKFMODS#-I7M*)2U=G X3VQ+;:F2&W!<U<!)#1&
M(*K!(..SUE3EU[EW+T#LE16:[D%996[$:"Q/L6R"5$C?;9U QV(RS'@VM%98
M<V9!JC)9RC0\M4(P(U?5L?9GE2-?5M#<.L%L@R%=<$+(SC1UUR2\Q&C/D;1;
MUO=&VOJ.6KV;,]5!N,M,\BH,RR*RO1&4V4<&(VV8HZ6FIG[I>*XU^S_LJ?MM
M+_@?W8]L'LJI_P#.DGZ/CVPNRK^VDGZ/CVP^RK^V3_T;'MB]E;]L7OHN/;'[
M*_[9/?1<>V3V6/VQ/Z'CAV2NRQ^V)?0L>V9V6/VP7Z#CVS.RQ^U__P#P8]L_
MLLI_\VI_+\>VAV6?VM'^7X]M'LLI_P#-@?R['MI]EK]JVOY;CVT^RU^U3/\
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M/\&/PPRY^KS_ /!C\,,N_J]A_@Q^&&7/U>P_P8_##+GZO8?X,?AAES]7L/\
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MRQPF$8;+*?<>":_H7Q<-=4_0FGAQSD(?!WEX>]X>C]^F-1!5_1PX=Y5[WO\
M?XCQUUQU#^(N.***][5-/_%L_.OW(OS?[Q]=7Y=3,E-02H]_67*':O"".QXB
MO X !MHYMDCJ[DMDFR<#9+1"U&VS([95U@=?'^TZZ+/CN2+":XNZB10%HG"%
M''R'>N[*HRTCKA:[O1;?LEDPW DT4*S2WJA>20L.VA!]KQA)4 W F[R(Y&4V
MQU1Y6UYP+C_T?^RC8D0VF>\YV[MV^2K]ZYAD,Q*\B555%$Z^3)G<>/VR6JKH
M.@G-FQ(0&NR!2Y#4=#5--4!7B#:)$[R;6,\--752ZZ>5[H&VV[&(9N&4!X1
M!%U24B+@B(BKKPQD>*W*C.28]9*5^,#S9/L(MO8<7FA(G UX*FT@]/P>N)?
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M0-FQ)IL3'?ELQ/82<7E"Q8Y5]E4"^Y-NI<Z1FAZ<ZLA^3>LO%$F;S551&E:
M"C#UB8=$WU<=(C4(\5AF,PVFRVRPV#33:=.@-MH("FO'@B8SW_W5NO\ R#V,
M@_[,F?\ &+''(:K,EGE65REI_MI4M0WY6[;0D.-NYS$AG8>U%57=[?L::*FJ
MZ^W9GCY.RQ_*\>W9GCY.RQ_*\>W9GCY.RQ_*\>W9G?A__;\L?RK%9.J.R!FB
MVKNQQ*E1K_.-C!J(6_F[8\KR=1E!@1G+)O4""].8KE;#(S$164J;:\-./1X/
M>QZ>FGO8G6]B[R>OK(KTZ8_L$>ZCL-[3CFPVBNELB&J; JO1IBMSP_?"&6+F
M2D&!8I%F$3\IQQUK<K$!I98/"49_>BZV.[;:12T3#2;UI#D +S3*N@+KK>B&
MA--+[*8_E(C?#0NC$*59DZ23;FGHVFHB,O20F7DI(D!YYLGVE;B[TQWKR]1O
M56D<+ABU=2+8UC=3:S*E\KJ+VN%]R$8B<J&KSBH]7OJJ+&DN[K?#J6[371!(
MWX[0.Z(V9O@V#NO> R41>1==I-@U1=4UQ,R8(R>V\&@B9B?(FA2'VNG3G8+(
M"^CCAK)Y2R:FVK* @\[;VN=@Z&VF6T>S&044&&LMW\D9+XM"Z34%^-7N,S=E
MK4G.2F\.FNI;&+BKKSE-2*4*<Y*SXW:\7ANH7+X211?="03B,*F]9<8;<8--
M@@(D7 ,$ZT+SB*K;!."CS@ITJVQKO#3IU) X:&J;&--_'UYY;._9U3=H.]+3
M;X(VA)ON'L8JG1TX%P'V#9(M@'1=9-HS]R N":M&YPTV0-?R41-G J$EAS>*
M:-[,ADT<(.L *)FCA#TN(".*"=T1 X878,"V2W9;!(NR>ROL9;.J-EHJ*39%
MM)S7/=CZKEA6]DW,^6HK@-MA4UD.C>B,DTFAF#DV$_)VWNN>KNR*\!04X8]N
MS/'R=EC^5X]NS/'R=EC^5X]NS/'R=EC^5XGY@N^SGGMBNKFA<>W55EQ]]TW'
M$:8CQHS=.1ORI;YA&CLAW5YP!U%-LEO;?,$^P:;S?9';P,JS B Y3-.F9K,F
ML0V68<6[LVCV["+!!J*SW$MN0A#ZLJ[OIX5E3#5I94MU'":;WS@LM;3; N.$
M3CK@-IHFO'737%K95F9JYR#2MH_=.O&Y!6M85%(9$]B<W%>89- +9D.-[!J.
MPVA&N,QM2;NLMZ.OK2G9AASHTP%;JVU%4G%#E1F)3T430%CS(K+K>^W:-.*Y
ML;,[,M55/-19$:"])EP&+*\MYL1XVAA &\.98/QP.0#R1AT:CBINF(D.N#R=
M%&UE6T6#%GV#K%;(<K:5FP9.3 &VL55&HC\YL=MB,6KCFB(JMJFN-=>LNFNU
MTD7 4VN^O@5=5VD06QYA+CI5%55X:Z:Z<>COZ?H5$]_7"<5UV>;X=D-KBB(I
M< XZIW^:7,+"ZHNNJ*2>ZT+33:315YZ\U-H='->L8XTYQ:+T(I+HO@X^Z]Y=
M"V?<Z8Z5V>/%.*:(NJZ<43APX=1.A3)<+KJO!.^I(HHBGI_G"B:F/.V=%UYO
M1A..OOHO>3APZ4Z=$3:T331._CT^O]ZKZG[_ (4[^),N/V7\XUT>4^](9KXT
M#+A1X33SA.-Q8Y/5INJS'$D9:5TB<4 3;)2U7'MV9X^3LL?RO'MV9X^3LL?R
MO'MV9X^3LL?RO&D_LL9]S#-O'"HZ;*\:FRQ)DYBL9K9"E;NRJ%;"*3:JY/?>
M]A8B";RJ1;L"K<O9BMW+6Q;4Y!M;2.1:5N1NR"E@OJB;^-"[QZ;M24P8$(X,
MMAZGIZ>_\/'IQTKT:=*]'@QYN'II[G\GO:8;JLR9@9K;!Z(,X([L>:^20R,V
MTEDL=AT&F!-"0G'# 1->.(T^MF,3X$QD'HDN&Z+\61&=YR$P\VJB0&BZ>Z#5
M5;-$(>#LJ3(;BQH[1/R)+SJ,L,,L 9N.NNDJ +;:(9J>UP'7W:ZX=J\MYCB6
M-B#)R.2 ,J.[(BB>P<N$,EACE\9L]$<D1.4,#J.AZ+JLNUM)K%?7PVB>ESI3
MNZCL-@JHI.O'^3KL["JA+U=->&*K+ R'5L[NFDYAKT;:7D[U9#5H77RD:@#1
M+RAG=":(I@:ZZ+PQIJJ=/A%$Z/<].A NO@5>"^HO%>/3Q7C\/A]/!CT\&FGP
M:=[H]4?5?^!OYOQY?3O?<KG*=2_$C3K!^L<:>G$81A&%-9E.H9MB:IJ(*B<W
M&8X5[,K)CEQ/@R8Q5CKKH $:.ZT>]5YIA4YSJ:;(ET8AYAH[*DB0X]!!JB:L
M7I3<A7X\NP>,Q1F,Z"@22 V=5%543UZ,"VWGZ"VV B -AF&^$  $V0 !1G9$
M0%$$13@B(B)@)V>\X1Y,;>([+CU*3)=A.4535H[&:V ,B:)LF\@27@35!;$N
M>D&HJXP0ZVLBLPH49M-!8C1@1MH![_ 434EYQ+JI*JK]Q+\W^\?7=FKL3YFC
M Y)#.%P]9PG"4'9E3;@D)'VR%1=0&UB@XCP+['RIAP23>)B7V.,C19.<,M9F
M(F,D7KXDZ_D]QX_MIJ:Z@JQ$".P9.(4M6J\209L54+E$-<Q7EM+&ROGJR;;9
MPS/,7:?GOHR;Y163=U<&(CZ[MELB5R5(<Y2^JNN( 1I<P-QV^O[R[B-DO$8;
M[K41I4UT5 -83CC9=! 0FG DQUQ^,F,U]LIT=N3;4\VJJX6]#E4Z;/96,TW&
M:3V0T;VU>><V2!IL"4R'FHN1:NQ:)B:S2"^\P:*+C/;"1(L6V71)$476VY0
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M#ERV9KVS(:(7=[REALP/779%075LS$IM-$;=Y)9.3WIQ..J3LE^Q#8EOD8;
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M4H(=((MKI[#J'9)L5$&QW]7W8ZY[6+3V6K1D1&H:VHVBR8%<J;#>Y?HLB1>
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M@D-3HG81I#!P6V+0KN^#L#)VC.3")6/ (@DENC&'4Q)D9:BQ/O&SM*+3,T8
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M,9W4Z-5T:OHU?1J^C5]&KZ-7T:OHU?1J^C5]&KZ-7=NYJ4RP"X<*Z%\]&?M
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M+\0@, DMRUO<FBDDH(\,U6%,&;))9&!\LY#5/.#1,NN"Z$Y@H HV8T,^#('
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MRK=9NU9E*\$ ,@1@[&2IOG-"@FB!>:RUIH?IUW>UR_4S)0VV^R&U04+8 &'
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MD)#>2Q-ATR"Y:#GH_O\ '/7RH;@;5YN71$5AL+Z8CYSEK21 &I[_ &A4U!B
MH(US4&U0?7]UYM1^SP1]!Y =A!!:EG:,YR[&N]IWJ4E[D7+D=6EVVRU8Q 3I
MI\+5&EXZ)*(E3$QB$D",A'IF-,1C6UKS]G76U];8OFNL]*/59WZ=&Z6L9+-J
MD(M82++.$,&EK);$%=-+S<VAQ?3M*UGJ/>3%NDM:1I<>LS*[MVZXX;'V\;L^
MR*YX;;=WW0?C':B@?Q-VNE,F)F1LC(#%L3$_9!;+79I5LD4 )D!E>PP" J&L
MW1A<27*HR^#G*T&T)HK'5!"P9)=93,4S)(8!5:KF.@@D0R"*%D0I*B1*R*1
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M;%:SKHZDYC:8O&=:T(8C&F4['4PZS-0><[WTG>((VBU08S;%V3L9DS%M-EJ
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ME467*\6K?"F..L](QW?C:#V%D=QX4VR=T#KJ=\)Q;_/
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M^JGE_P!5/+_JIY?]5/+_ *J>7_53R_ZJ>7_53R_ZJ>7_ %4\O^JGE_U4\O\
MJIY?]5/+_JIY?]5/+_JIY?\ 53R_ZJ>7_7TEEV&52 ##K(J"TCV4EM[PA/R$
ML8-0",.].@T8!OJ--$*6!;2OL$" +X+F<AJDN]0F-,;5HA[D5$25J$4@AG*
M=%:J!-J; ]9D$RG(%%P8 6\3FO,+9!3(6!G<>/A%O ((B90F<&#LF<3O':0&
M-*1.Y)4\7,(D<""YM,$47\M\HG>$]Q$18([H4P9.XOMM&LQX<;9D9Z9$7+3I
MUB"#I+"JC>*EN23<,3,VM?!E7N5/UYK^JGE_U4FY4.)^ZGEOW4U/+?NIY;]U
MS2N:?3G+_3OYX5SEOK?GQ]?'G=7CX?RK\^*OSXKG+5/9X_SZ+!.BA[V(HB5
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MX_54!67;>L_K]).(@(,4.=^K?%6BRX'>O2^E(PO'OJJ1C<0_K4BR4EXY\?I
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M,ME^MW:76[$UIEVWS8,LA2,J?3?M*XG;]C4NVA[C[A&%+C9VVV&T"T"Z"I@
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M%TB.QOO!FD,DDDDDDDDDDDDECXD=64DDDDDDDDDDDDD_@\
M     #'*[* 7MES+ZK*@\            "7<*-X7R            #-A
M                -2!F7DDYL_T$3:F!MMMMMMMMMMMM_49%">&-MMMMMMMM
MMMMMQ0H                    -869O;D/#GHWVAO2222222222223>_+KC
M\V2222222222222=%                    1L1!XW?8OT$,QT(M'&B%)))
M)!??_P#VIGARRR9223S22222226J*                    Z 8
M  8 0545X   CHQ@D$@DDD05G0  !)))))))-H!0
M,*          # "9Z6$   '#?%$I$U$$!\&(  $<DDDDDDD%U*
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MR>LH 8 ^*QG5MM$'DX$\$%$%P+($#I.810=D\<%X.A0       &IKB
MP7CW"78@B#S<-@ # #U(9?6VQQ^.E  D@$EF &Z,KUH HEH@F(!T*
M Z-'@     C_ #\4 !WH^#U5%0 & -1,8"   $9())))))(8 $T  >T!#U.-
M, #H4        ZOY0    .;Q4A !?.\0GSDA0 P!,<%B    C(S8*18##!80
MF@  6 ## !!: 42@       /D+"    !'( -: )#_2!$-1  & '+;3%   $;
M6 &[!1J0!R$T  )P       *R4       R<2=P  !$MB@!K0!1Q8 );Y8  P
M (#9((  !F;R  )* :!Z18@  )2222222:("@      ))%%B   "!L  -:
M)   )+9: & ";3;:   #0);;:>R;;+$$    02222223( 4       C&88J
M  S<  !K0       2"  P        !L(Y))))))* 3V             "@
M     O6$FT  ,2   -:           &   "((++!!!#% !)(#!)!2:)!) #3
M(5"    4       ;38H'   6   !80          !@   (*(+:;##!8"!(KJ
M911+#*8)0SK8;0   "@      ,Y0G5L  .V   !!0          $(  *3;2;
M::;::22;;;3;33:333;33;30   +,      )#@(=(@+5"@    X@
M  P22222222222222222222222222222222221X      !)  !) &I%4
M *          )<VVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVWQ       )(((
M! !K[80    !          !(;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;:2
M22223 ) !  (!  %H    )(          ));;;;;;;;;;;;;;;;;;;;;;;;;
M;;;;;;;;;;;;;;;3  !) )!( !]@   !(! (( (!!! (
M                         ) 9( (     /L      !( ))))!(! )
M          !)!( ) ( )() !! !)))))  )((         !6]@  !)! (
M )) )!               (!))()! ))((!))( ()(( () !!         $68
M  !#8())(  )  &:               !! !()(((  !  ( (       !! *
M        [>B  )C))))))))))8
M        !0         (L, !$           P   !(
M                   *          1<NU(           &  ((!(
M                            )!0          $KL^:           P
M!!!  !'222222214  $222222204  $22222224 *          !C.<S0
M))0    &    !)  ;H      !!@ /        (P!'       ! A0
M    #\X   "4-0    P !! )  #$(!)!(!!($ !R( ))! ! . (B  )))( #
M4*             H'@   .%9P   &   )((  8I!)18"": H!.1#)!( +1)P
M 71  !3*0(:A0             ",   ).3.    P ( ) !)*5)() !))(%)!
MZ( ((!(( -)#R!!)) ( #4*              1@   +N-0   & !)  ) !0A
M . (#7) @ '1"0*()+8!P $0 *2#2  :A0             ", ! ()! )
MP  )!!  "$!!! ()) $  R)! )!( !. )R !)!)  "4*              1@
M )+P'9N9  &  !!!   !I)))))))(P (Q)))))))+P *Y))))))(J10
M        ",  )!) ( (  P!( (()  "))))))))0  #))))))) 0 !()))))
M))) *              1@  !(()(   & !!!!!(
M             0!0             ",           P!)())
M  !) ( ))  ()            *              !P          <@
M              ! ( ) ) )(            0             !,
M   6                    (  (!  ! (           !(
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M 7?4R#A4H0@62UDPZ4@$<$AJSEMI)DABXP,(+,DTI.% U&D$83&/#%:8"R0
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M_P A=! 3#$R>N>-B[D.0Q&-!7(M* 7&!4AD,AE;("4862"41.1&:% 1XR"V
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M5Y+IV]-J NIC)'A?'6/N,?>73M0;$4N0+6B32R!$12=CH")RV2C#A&]Z AE
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MP-]OQ=TQ]GW#K5XRPMQZ6]"O,_'A1OO[VZ?C&\/DK!Z?'Y/6[_[<#P?:L?\
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MMKJ]ZP_E)EU>];75[UA_< *A=_@];O\ [<#P?:L?^=/<?%8C@^W_ )<];O\
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M*4HG7@9&<8F!Z%*Q)SOAQ9EB6O&65H"' L17PA8P;1'2HS;,T:,DP(XM4F
M D 0;8,881^JEMZ';8]*EMZ';8]*EMZ';8]*EMZ';8]*EMZ';8]*6(8]":4D
M.'2-LN*#*5BV*88QO>K:27(6"8ZX[]:06!-+^TV<2_[WJZBD2DG1<6+N-(=A
M$91AAYEI5E B(D*UL>NN=7YMA&%HH 2-T;X=)RH(*<9D&Q@.^.]-)5B 6O@F
M,39LZ4U@!U(3:;2$WP"$AQEIE5&)F%V8+]<.U$20R9\S;.)L_JGQ>Q##1BV
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M?ST^=J]^/-YBB-\\]+Z=^C5IVZW^:\U]OM&"3*<6];7+2$Z#N&=9'[\YX^_
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MI98!-DUK'$!0(\0B1(HG,6U6N*C-K@%I.MNT#(X0\V:+U@(J #8.!!K.R)T
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M>^_7/??K@D-KW1'U!.VWSPZTAHRIP.W=AUT<9S_SCY?#WWL_\K@'%8^3;@E
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M,TBD?,&U56BP\H.P (%,G1'>5R"NJM@%&FD91Q1@8( $X' '2 <3^#+W?/\
MQ)G?X8(4$@:CV0D7>>Z"2QBF@RL@<"BB*P2,[7V3!(3"1^]"Y5@0O':,#496
MI$:K 8M(92"JQ@WFN(>8^'!?"BE/S*DGF2W.-/"<$/I7J@(&'*T2Y."Q3@AN
M3Y%_ TA*VZ9H>#/S\P_R,;O2O>).L2\MHHL%#@67F7X^K^T?QAL'N&>^]G_E
M//NX,]O[\Y/F_?\ S-32ARBEZBD.U)U68;W$O1:G@H IU0+V/\L(4M/T7H$X
M'05$8XK=>(<4 C"HC"; ,IC]&5SQ3<V^T, A#1BB(<(50:P500715ZFF5#,U
M)\-45>H>:UK7QL R3K"&IJR1<M\$&%(@>7WWKC7;_$CY<#R/MA;IU!X=7=LW
MU/#',W1<*:9/(Z#V36-GG-'=D%$4&4 UH"3_ (_C?G]NQGM[O^7N&>WN_P"7
MN&>WN_Y>X9[>[_E[AGM[O^7N&>WN_P"7N&>WN_Y>X9[>[_E[AGM[O^7N&>WN
M_P"7N&>WN_Y>X9[>[_E[A@:=A(%YV.Q;TT=.)DS^ K 1VA]Y=UZG]\.^NS7I
M_!E[OG_B308Y1[5_6?$'W%4H C.VW)X%U,_-&RJR_OA)G\'%=;L(4ARDPYW[
M_NT"_ *ZS?7J+-2JEX77P]R['=Y!IB9SYO Q>4>:#4>OW %';^*_T-1]""NX
M1%*\0CQ#7&%(E$;FF@S=-%WE>+#):I^"-9=*@I&%L6=A1V<.S:Z>-JNNJCU'
M!GO7;/ \C[9[[V?^0JT!H\O'/Z^>.DJ/4#M;_P!:_?*I6A*$0;VQX(9!FC&A
MO1;D@9  $0V6#"JLV5VLKQ>LXO7XP  !H.CR38IL;#C"M06(%);(!%S0/*[)
M%*\H:"C* E6)%"Z%H'@',1O&9SA"! GPYPC4+YCU+Q3#,>!$$5$$4BCPI"/<
MA.Q_!/W2(H^',T)C)9UU:VSI URN$K&+ B*;?DN#B:"#2)0G(I8CR5G%</5$
M=-4:@7@\U$DK3^*]C'-*'V!\I$.( Y #_AA&@8 M5CVE[2=@!#)9&3_H)YXY
M6D:=OD.-WVQO8MFV(XCFI4&VBN)H<HMY=,5V716[[8BZ#\D&4$![,2>K3=P!
MZ,@Q252BI2(@%H7(Q$]$!$D+U! 351)SMN7W"[BM/!T[.NWSS^_?UG]^_K/[
M]_6?W[^L D@[K8]@IOO3PP%G7OX/^(XY%04)8Y2+8>CZ%0(07$(T;*.#8I;-
M3#@G'3%F1:@E#6CNAW31KFKRKE+5*M>NUMP@@%7; CZ<'?UQU)>9EW\IE2^#
M=E)ELLDTF,$E/V?['K?B24,\AA :##S!;J8FE9_6TP1;AU H')*%T!$*'$ZB
MDW"1 H",+ICS=-0#5S;,+V0E\14_%GP4R%1.C(P8[MT/I"H6Z,PX)45& $T5
M'B8181%TBJSS#I5.2D='J  ]0,*X&9.\ZCU0]BX!P'8'NY;74,HD2$L*5>M2
MM/''3R^$Z4-$.><\-\7^[ML/39L^4 \WI>'1P===?@C7[#^'Q^CX9'_B_OW'
MPO'+/#^E]],%8>IIWY0"F6-!D6ET#R<<AG9VCLD=D(CL@+.DN &&2X =\L%/
M.RC9G?=_)6D4RGH)Y9*<)>L?D*SX+FC&Z/#=6%I5.4Y(VXR98%#V5!\1>%,\
M%:<-]<< 2:T4*8-?F)Q.Y3'K@$9L&(>LLX)QYDB3I_TN#SH ;TBAE1C3;DA,
M%&C)2#DK(S:Q*S/Y/-D>-\CN6GS"+J#-\80LTG0"#U!('K. HC\/>NV>!Y'V
MSWWL_P#()TBJ4@2HJ%%P*B@-830J5HV"(!8%2!O&7"1(EJ=;@:BT8)IU@J28
MW[E?TM5MJM"'Q@2]B7'4?A>P%X0]0@#+(PLJ<.NO^.F9I2QH:U6KN4C3H"%.
MNSSCG3G EN07$44V+?3QVB'@0&<"$/)90 V>2J5(?CNA%/T2D+8;:U;U_@@B
M\)"C+=,6<,^<3IBL;R('>:O,V_OZ)>2!$$+! :X)C3C4*UD <^N3P4%D<.03
M0@7VH)#%8D#U?8@SEWYV*])'EZ;XYGSZ_P""%$JM23OK:=._KWP&YDJU[+*,
M=R,"*KCF])&.TQ@ )R"NRM.3>CSY\YL'SNZGW1Z/7Q,+.Y*O!%O!2;BQ'9I?
M$6<@6["\QEC&HZM4A'-12- !!$;O-:L*W$RAX*_Q$2)$B0ZX%_3==_-G7#32
M-LZ[& !*X,P2?1++EQ;C$(VSA#3NB"=MQ[SC#@\O?;*QI 51(1TMLX97OC*Q
MI=/<Z/I@WD '3S("!UT:*\:Q</63HI(C-V\]&P(!R=]LS;F;%AD,ET<@<E?/
M7;!4MSS/4:.DU+YBG#P+P=AQ\/\ PEE_([VXD1I%0%/Y&02M:]I_F]O6(CU,
M!304$97\8'6@!&1J*\G 5+7U&U ?1D)9R4=S'O1@PC27+N.0)IW]^B0XZ!@@
M@)&&-0PGD2UX(G6*-V:XF2:=II^&JT)NE;JR\2!@2&T;"71P O($- C: 2?G
M;KS [[-:<;LY>M/GW8@HMR+CVX7S.?"YK_(?6+P[AQP9?Z90'A-/Q[=?+#D0
MA/"D*;%:U(5V 'Q")R.RWF3\*T$I32:TV0>=WU08,T[4RMW(%:\I5^:#?2<9
MEJLTCVX]1V3O[#O7R],?\78M.3V5 @G9*P4 F$]782*&X?!&D-F.HP49GLYD
M<>J[JD'I%8*BSM5'P#+Q+/=KX^F6F:*T1M)J'Z*OS:T"@YX&92(QG+Q9-(=Z
M863G_)!?MNRX+TD(<QK585N<%Z$U#@G3X>]=L\#R/MGOO9_I"1'$)08#H*+#
MWQW6 V5O(2/P=81P$,M8$VZ0 ]"(&&*+<2P83 CCW8,L&Z:'3#J0.:/3A(.(
M@:NI(QX9.FKXTPX.NN>_^1;I9>@:C.-*=?'QES21=T4-TIV3D?3QN(\,KW?.
MF,]C(+0<=;U8R"0094O<6NJ K? W8Z%)[2$7.(#Z RBH(!T1A]9L1T85JVH0
MD9<VI)5I[B\KSOE!?-!>8?']KY4J=A#8:7:57&FY).M"(C2#,DDB ! SH$['
MT=?;*HK:&BCH<RHP _H)J)1AZ?ASCZUWA$Y3VK-@HNMVXN0XNP39P(1:FJD7
MQ3I>W3XVL2<N2C.VULT/,36R%L-)/P&U@BNC'Y&F,A*^;S0-L1 5<F$8.=;_
M +XEI>'JDXEA$1+H(C&&G"B7!HU7\5<237$UO;KO->G^"%"WG?H]?GY^';!?
MC;8Z%,]%.!JU JT!:C@=&(/3Q D0\B;[&@\YAH/"='7,8H33QK=SGH@5+K&N
MN>NN^W&6?-SXBA [*('$.06[LYO5K:@9O792)RDX&:?GQT  3C7!TGAX?5\)
M'8]#]>Z^$CL>A^O=?"1V/0_7NOA(['H?KW7PG0(0XT?K 4D>#,@&--"&FSIL
M)W9D@&,BM6V%TR0D E    ! !H  <8<'D9I/1-T#D=HO4\(XB4*JX6*K 55;
MM<-<);0A7D0BCQ"X7=W:DL[BB$"1 %#. V&D8A"P0U ((%X2L;0 I @5"%I3
M>+%+U-[13ED"A4%<X2+522C6 =@E6Z60-T*IM$9 )+!4N 0@4T-H2%G @XB
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M!Y'VQKCD 4H8T:%#8CLCG'+7J]_'6M^'\+(:@9)+!?X*P&_0)Y?,>JN3;-A
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M1D2*+F]8*W_3F.*H/5R2:4+F>=O@T&B@-45VLDHB(2MF[S>VS! :!*!K@L*
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M  TH(1WB&8&E['!53HMZ1ZB=&.^M^=X_Q*4$5L"X B\;%KJ./Q"NH!8O:D0
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ML ]31\)6"7;%"JJ@()55"FJN>^_W^$.QZ'QAV/A#Q]7]_&=?R_;C(>/J_O\
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MO:JP@BS+-2;XM$H/5KJ,DF.G&HCZ='9LH&(1H(.DZTZ/-"L<T5*KVAB@V'Z
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MQ?->_P"W.3YOW_P2#ZZX>E0@*#- 12>9NJZ6$G;<70JJJ-5VK:N_'(&D$$A
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B^?/GW+58LWS >;3J]Z?-2KE+#1'D#36'13<Z]+SQKTS_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>business12ba.jpg
<TEXT>
begin 644 business12ba.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0"N17AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     @   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E         !@     0
M &     !    1TE-4" R+C$P+C,X   R,#(U.C R.C T(#$Y.C Q.C0Q  $
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M1T(@6%E:( ?I  ( !0 ! "  *V%C<W!-4T94
M          #VU@ !     -,M;&-M<P
M                                #61E<V,   $@    0&-P<G0   %@
M    -G=T<'0   &8    %&-H860   &L    +')865H   '8    %&)865H
M  'L    %&=865H   (     %')44D,   (4    (&=44D,   (4    (&)4
M4D,   (4    (&-H<FT   (T    )&1M;F0   )8    )&1M9&0   )\
M)&UL=6,          0    QE;E53    )    !P 1P!) $T 4  @ &( =0!I
M &P =  M &D ;@ @ ', 4@!' $)M;'5C          $    ,96Y54P   !H
M   < %  =0!B &P :0!C "  1 !O &T 80!I &X  %A96B        #VU@ !
M     -,M<V8S,@       0Q"   %WO__\R4   >3  #]D/__^Z'___VB   #
MW   P&Y865H@        ;Z   #CU   #D%A96B         DGP  #X0  +;$
M6%E:(        &*7  "WAP  &-EP87)A       #     F9F  #RIP  #5D
M !/0   *6V-H<FT       ,     H]<  %1\  !,S0  F9H  "9G   /7&UL
M=6,          0    QE;E53    "    !P 1P!) $T 4&UL=6,
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M 0             ! @0%!@<#" G_V@ , P$  A #$    =_@
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MQA&9Q%HC9:8V&<QK,,-S-\M*=HNN8JG*9)EF"TIL%+8&&QF^6E-OAE4
M        "  !$@"(           !  %I2UQ5Y?LB ")8D[Y><@ 1
M        /*+!GM%-E/EUBV)T376;-3TRL"!9,O4>:<!6!; ZA4I[):\KH\P]
M<MH7A+6'MDQU"I#V2UYDT>V#  P                                (
M$0                        "!$   $"(  ! B  " (@$"(,UC9.1
M                        )82Q$4S3$ F$1!*E&9FKIBD
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MR-.X'(=OUHK7<L1D)T[5ME'S1O6$/<.5;Q/DWNE^-%W'EB(U
M                                    ('RQ'5/5.<ZYQ$2!1A=PH4QW
M)BUYD,?7R1         !"'7I\_G9^C>?X9]%UOA\_7R<?<^'BKSWLM8W(W?"
M>QE++;A\X]%QRL[&DNV<FWZ_$WT_V(]IID
M                     "!\LYRG.<!V3SSLDI9\ON4B8N%+%M3,4^OLB
M      "%*6&JGI^N:;/I3F?'Y3TK.X[%QX]ZYIY[NGL3&?7"]UVH\HV'1%];
M?-^Z;YXZWF%R[J$T@
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MA_>K[9F/S7J>6=E?3
M    @? *<I=0N@=@\(ZIW3.8\DL>7%-=I2AG^?7X1       !)%/61I9ZYSJ
MTN2I]'?]?N]J&P9O<IW/+S5<MBUMF+T"?0O/[(>E%V]<RFS_ )ELN>//\[>N
MEZ2K%*FG%K"\8S;S77+S^_IA33ZYW4>DP
M                   ('P" G+[G&=,[1FF<1C:<!?<L,8O&?)]?A$
M 'F5^6D+MO'NWC\MNNY)TGT[?WF(U(Q$LN&*?%O?&V^=U'"O-:_LSYWU;M%J
M*I[*=?.F?,.PS:.^W(N]@$0
M         "!\ @(EP"XA2Q4ALG+-&.);L[QD 8A&7Q]?A$ $D4\:<7.G^=O=
MIR657'_&OL-:SJXU  +?W^+T3]YX'NMY%U:H+>\JW$Y/U[3)\E/M)'G1>8PE
MD=MTC'+8=/N)A-KGQ\YTZ'UN>J+7*J346.TG@^2.R=1NYD]IFIF,@
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MV")VCKG&96GT5D0 47E,/\\?Z7?#M08OH5Q=+ZECUV+9-@?R[O.VOY#N9J@
M    $#@,0C,$Y"0M$5X4OK^)P@TC6+_=7WZX+SO6JBD         "2*=57UA
M\TZ__I[G.3G#^VXU=ER?%:;]]*/YE;'RTT  "!\R1G(6:*T,9RZY8@R+/)*0
M,SBZI@285&;9M^+\GRZGU&'S(GOE;E=G8*',N#%(]4H(MH9G&!I]/9[X (
M   B2DP    ! ^' LH<AL^+/EJR[Y5A<@RT.,D+ %KS)4^B8B #BBG5A]5_+
MV 7TQR/J7N^U+@NE;V?SU[==W5KF,R      )3&LR1.4'&IQGBK%#@'/;H=O
MW7+S(WE?$4@         "53:':]1T;_?GQ?2&P['U+C?=H?Q[W;8W\X[5R
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M-'K;]>;!47+3,          !"$P $(S(                $ "(
M      ('Q[DI:@S\,1"YI4IL".(J$D.4Z1;<KTW2DP             !(81>
M3%CY-LMK/U'=4;E*\9R]ID41
M           ('QN'O%,'2,D2RQ5IF47M.0]HZA,8^E[S=61            !
M+YH)C---XKTTF\#KV5;[;Y&=4JH.M<(P%-BA,
M                        0/DK.T>(4F7.*-/2,A3)$K4ZAR'8/+*V-NI$
M            $(B2BK&'B&0QZU/WZOT=BLL,A13B<;YB[!3!L!)@
M                                      "!\BYL:,;C&\KPITY#(0R]
M/.(DQR'6*B-P!,           "6$4=9&(FEWUON?WN<W<\)@U->P)$LA$UW&
MQ.($LTQE"*XTQ":2I-(1(C*$(S$M4\E-40
M            #C-&QBT=PI8]0D.X5$9OD#T3LG3/(+]&?Q.           "2
M(XO.<%N.[-X]%MGIU_">E[TX.5KH2R4(&#Q<TR4F)(HP4Q'#;LW>T3S<1>?.
M]+>VFN5C=Y[W_3+=3RQUUO?9<&L7R7TZK?O1<US[9[+S)=;G2
M                           ! $I* "!R$P($#B.0F!$           $*
M8XHG";A>]Y6]3U*KMCL9Q+&8LJ<9E87;(*>.EB=8<IH7PURB7E0=MJUY;G9N
ME*\=UNEO[;7:7\['+3)=/MAXX/H48_MSZT+XX:]EYN,:KN_-SND\
M                              !;TQ#,?S%(RP-FQIC+YEMBKBK"<]@J
M4V-$X           !"E!%N+&^U]<LWG:5V'G')5($ 1!"(DKIC35"(@FB?/!
MUI[9>9ZE, JC$3$$E'CQ;TQY8^HO3)5!5<15
M              "WA3)YIBR9(GKF+)7)TSP#S2IRK#RS.(F            $
M(2I'Q]O/\:Z^N[6,R   ((B0!&)A,$$@",3 B0F"8D"(
M                      (       B
M                          4$6Z)@
M                                            5,79(@
M
M  $"(                            (4(5)2F+WPIF^M>6J.*AZUC<5O:
M77(                                                    2FD\M
M05.<1V#D.N6Y,7#(HNV8:&5I=\S6,SR(        )8241@1TC6=/_P!7\MI'
M8;+N7/CXV/N+R<VV/Z2OCWKO9I]
M                   )3X?3:4>D<IYYSGLDACT64,ZC6T9H&1Q<0W/$0
M     2TL/]MQ/SW?8/(._E+;VLAX>=Y54SK61]+(V^U'1\AE-R7;KBZYD,B-
M V;L^7M-4                                                  @
M? 6;63(LZ)(=@[YU"TYXI[)21YAF>7'-S!$        $M#&K:,1\Z'UURGQ[
MKQGKFH,O9]:B>S[>-Y=[UNFK"_K7E.6R3QT;G_CSO?J6]P
M                                   ! ^ 4],SM+]GLEU3B)"Q1Y)BH
M5L>P7R,[3=$1         A)+7)T?6]%'T?SKT,C;UGLV-YO2GJ>2YN]8*@]3
MS&U'Y<Z9:[<-+JG'W.WCYH[//2FJJ
M                  D/B4,<B)<HN47V*"/!,@RUA11[1DX<Q4I]-Q$
M    @<=+YA/I[F-D^B8&XNYX+WLY9^#B;R%$45JN6V;_ #IT3._4O74-]*\2
MV-<BZ-L3XEU&>9
M   @?!44X2',9#GNE.GKF>I@2=@J@ZA=XK$^JDB        "13+179G;,%\V
MWUMR^E[GQK':<5[&7M:+U7)R>/KSZCE_I=^1>L78M:, =NX7CETK9<V-+SN7
MG,M^EFJV"BZ=4SI
M  @? ( #L%\CL&8!19CF7Z.\=LE+M'U'$0        >;Z>.">^:[J.^A-(]7
M'^MO)6SVC&<EQ31>JY2O/+T^@'YNZ%FQJV3A75CAS_3<A>A;=J6[AROU,MA+
ME^=5K=4S^V'E'3NU'H
M    ! ^ 0  J@S#,B3"TK,KLF.0[9=@^H(B       "6*>.F-%_U?P_EYAO.
MV#G&T7PQ.2Z5?G@9O^ U<]*UR[FH9C</S+9+OV%U"FBVMNQ>^9\3G;]/YJ91
M:/,8G"3J.A6-S>O[!^-]8RDP.=
M             @? ( ")<LV=&'1T"XY[)P':.V7=/I^(@       EICBF<%M
MLUS.K4=BY*ZID2TH4RK\T5R33;S+:;C;>XCW=1Z9;3Y+M-@WU]<J95TPI:=.
MS<MS8YAT#+?%Y0
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M *5T/,CS]H4QA?S:^I[YEV#M_<NI>%,QAD7"^Z,!NC<?SYYQUV>/2-8
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MEV,[C%XH4Y39F:ECZI3Y3"E3/4V%FM<Q7+?GUHGSZF\LN\:!BC"!:$^HLG
M    (      B     0/@$ *G-FY:HJ ZQ[!ZAZIXQ<<\$NJ?1J1 !+2MCL>K
MZUOI_P"?K?[)[9B\1[)G=PC?N2)FJ  00@E!,4$D",2F('03KSIC-O#W.EO@
M^:W1_1^N^?Z1XD3SF*96&U\ES<U;JG+1ZQF0        )5/#11@9WGAN(';M
M!N;J?2=FOR[V"M\1>1D  ( '0.^  <)S  XCE!$@1('0/0($0
M      "!\ @!V3:\6L/8!S%8DQ21?PL$9F&_<F !*HEHD13"N%"9,U<@
M  "E"RT+QXCUT_\ )LWM#[=K]&51[TS1!;8NAMO#,K=4[7RT>\9D
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MV]/$<DZ^V22ZEO==WV\.28X9CJ4^LT.QZ6\]-7%+J^-S&N9J*8U4]R?*>J0
M                                     ('P" N@; "BCE*I,D"YY011
M1:8NJ6R,Q3>B1             !(CQ<7[Z^_GC>,O_ICG]1UU4V7@1Q4TX_8
MKF>0N8Z8IJTC\Y^W[SW.JW<O=2['O:XH87JV1>5YSZ]=K2MMF,K-@X[JFT7Z
MVN)Z8B;TM:F];+:QT'Y$C3/=JMYYD
M      "!\ AZ9L!(G:/6+JEQ"NCT3B.T4676*D-RY$             ''3&O
MCYXZ#EAUW4^+9\7=[UB*>+R68US"U=?S7V8R_#33C]C.E=AX6YM=CGHIZ<>O
MK5VO!1=]ZXQ]X+O4:2\,S+'I-%%N;39J \KBO?;$YA[)R+D5@
M                          2'P]GL%T2LSV"IR[I>8\X]$D/5/<*2*R-V
MA,             "PNFYZSFL9"['6-2R"1-*)0U#%["^>;&<KF3Q*;88_::V
MOL/3EMD?:]\9Q4>M3>^,A$T1XY6K*[#NU>$M57'1/--'B1>]YX^CZ>$4@
M                                  #',Q%/1/5.Z<I7![0.0[! [)TB
M^Q7X          (%HRJRE#VBX8-?G,]VS1WK5/0R5G4"9@4H450N_4C*2F--
M_,ON>GHNLX]F^?J;MMBJ*]UK&S"=-O+D]2QYPO1;Y9;1/>]<%:RPWBUMEL^2
M.8YE9+&;_LCW'YFNGD]-F2
M/-*',7RB2N#,DP3+LE\#R#V"0I(JXN"3           E,6RI"CSU2MCG18O3
M=LNMD<=?S/X6:H A"48)<4+08_;_ &/2ULMB=XNCD=5GCPHWPSW5\??S*[GV
M*K3R/&]]:;:GJKBJO3#4'9[9E-L'(*E];",@
M             !8HQ7.Z:XS849!&JHNH8=E1'(5>7M/&-W1,           "
M  1;.FK!;5MUV6[1I'8E&J0  (1$B$H1,%,Q!$54)B$1%Z*J8Q"FJ2JCDHJC
M75,                                      "   ! B")  $0
M      "0Q.1E>IY(KC(   (0F$2F"2$ 2$D1%,$)@F*0
M                                            ($0
M                          4$6Z)@
M                                            5.78(@
M
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M> >87R,P"<                                      $    ")
M   B0  !$$           ")    B0 (D"(
M            /__$ #H0   & @ % 08$! 8" P    (#! 4&!P !"!$5%R@2
M$!,4($!@%B$P-R(Q.% 8(S4V07 D-"8R,__:  @! 0 !!0+ZNZ)I+5<\:X5<
ME=S43G-;OM&&Q2X$9[_#Y:T7<24"GJ[X;IY.P3+7U+<@?I_<MQ(GRLJ0B55&
M@55JSO\ 8R?AFG,HFL/]O$K*99SIZRM2.G <6-;#0S>XHE!Q-EH1FS(125FL
M=8T9(+=BT;FR'B9K]8J32$/^(M5Q.U\F4(E:9P2?V%_7G-;'P[WN]6P?-^(>
M0LMV/<HC<: KE$;;VY'*8TXN;Q,(G'E U:8M,EGT%78\RV+QP:Z1Q]KVFFT-
M6$-#VSR!%^,8EU=9+HHWJ)994<C<&K"Q6VS8G;-M*X.M:K>LB+S9YE\5CACE
M(&)E1HY5&7!S=9E$6)78\RD475/$GC<<W1,]E$S>D$PB;JXF3B&$GN\QB<?4
M6[=;5526<V"Z->GF7Q6.&.4@8F5&CE49<'-UF418E8!:&'ZV[F]VAMLME].E
MA39L?0</=NU99DNLR1S;^KGBH=')X26='KD@6-J],Z-_T^\B-;0JQ[VXCXC'
M8-0D(H:J(Z96E+QVTHI7UOF,G#XWLMTM[C5YUE/4MQO[DV=>,&%(ZWDRK^B*
M?OI[0^4:8G,=JVAGX^X2Z";76<-R&2Z9TY/J_P 7:]\;XHCBHUYD9_L,P_VE
M 5G;J)!:5B8V:D(YE?A9YYG#//(;%X!=#XD0S.2/+DZG<)-@QBN(Y:I3)(9M
M;DAB"MKBBFKX&7Q0UD4LBJF*5ZOEE7LD-;)3Q)PEG;=UQPS)&0BH+5/3QCB:
M?[BA[%*Z^9(1,K)/5."GA>G<,C$ NA_BY'X@FZ]A<J_Z7&)5Q214X]DJJ/UH
M^.$>K. 129WN^)4,TD;^0E6<.W$<E:T.5^R0>962>J<%/"].X9&(!=#_ !<C
M\04DO87*KOL&<1!MG<8BT'F3:^1"$_A1V^:Q(P_2^.5_"6FO(G_95J0A>D!4
MM?%0IVKB%/ALKI^MIL[]C*KU'GJ!Q20O3Y1]4R-_?J[2LM80FB)"KGLPINLY
M^N55/7BM,9"(P9+V*$1B-/!] 4ZJ?$D&BR*6,==0N.:A5;PNO"Y-$XU,VR&U
M!6]?*I?3-93QR>:Q@K_%WJ!1.1/,GHZJIB\/-:0=^2S.IJ\L!9&:V@T.*:J%
MJ%D?&*"Q6-O;W1]4R-_W4%<BAIU1UZH:)?3-93QR>:Q@K_%WJ!1.1/,GHZJI
MB\-S>A:D/LO/OIGG5GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7G
MG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7G
MG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7G
MG7GG7GG7GG7GG7GG7GG7GG7GG5GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7G
MG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7G
MG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG7GG5GG7GG7G
MG5GG7GG5GG7GG5GG7GG7GG7GG7GG5GG7GG7GG7GG7GG7GG7GG7GG5GG7GG7G
MG7GG7GG5GG7GG5GG5GG7GG7GG7GG5GG7GG7E)?XB.L_]6;R8V;#()B?B#K]3
MHJXX@H+[M1S>&W;#B1*N)" I=[XH8!S-XK*^)$P\1]?R'3K<L<:$/^)^!<FN
MY8VZHP6BP#T19\>4&MCLWO*;7TKJXIF=M+O2 &A[WP/-WC ]9WS@.\[WP/.^
M$#UB[B7JINVT<1%9/2T"Q.8'0MYSWG/><]YSWG/><]YSW]O[R5*7>7R<II<M
MZ+1.R0*=&ZB :@/Y?!E;(3(R0@4M*1<3'DS:R2.4L)#>*3%]%D,/F25*42:3
M[J0S$AF*HZQ'$5N_2JDY*LB4-2F"3!.I+/#GH#O%"U$B"]2OWP/XSSV3U@4I
MI'R'#[8?&G<2G3/+4_LU]Q@] <"(><M;T SU[/\ >A%[O9N!T8$)FP!T824(
MNHNNS)FLI&Y$O*%<H(''W]=R?)NF0)^'E5M;Q$?3<1M>&O3829O6"4'X,]1B
MCGO8P;W@4NM:1$BT-D5FMJEQK5'9C"VOKJR.T#FJ:8->ON0*8 L].]YKTZ"$
ML.M#3^K ;&1FA;UAOHY.Q_O$]5II RO-H@6JGYN2)3SG,2=N4KU 24_"]OU7
MO],,(1@O*")81+M8+6]X85GH_C(3\]I20% ]_P LX;'K9Z+B2:!M4QK:7#:7
M8L832]?<?Q6A%EZ(P M;V'WF]>]#K!CV(8.6]EAQ^WZ1U0,WXBS5?J>S%FTF
M"%Z\>>?/A=_?7Z?BI;#3F#X16$&RQX,H0L*0YL.@9H[-GA"'AA7#-G-EP-+/
MH]T];'WRH)=UYBU]QD&>['H0#<"=Z-ZWO0-;,T()GO-@$(S%1I>BG!5L9]4F
M"T"SM_$NZ@8=FAYZ&^I?0/A=_?7Z7\\]6M;NLQF6PG92-.0I5)][]\#-J_RV
M;LT9P1!"M5#+SA+AJ]$ARR*Z;ILWQU>;#INV/#:[ION)OEZD 4;XD5@"Z)3Q
M$FIQ9[_^'2Y.26K=TY):A\VLV4/T#@"0MN;9ZTD.2U8C5(SP&D^E>Y;5E<+G
M[Z_1EN"(Y0>H(3@>K<@[+DPGQ[\LD$G.5F1:AI?,&!>TKF5;O6&&Z!H"C^(Q
M9E.4HJL1Q;7!B*,UCRZ)F5M==I75O)KR:-)8>(>01_*XMIDL3[B ,98FI^5[
M4&K58<"ZB %0Y*#0\QJ,VG^*W&ZY0-R/<J2.CS*E:A>Y'^ZE<5=BSBU><+G[
MZ_1&& *!/+B93WIPDBJ?;3U=8SOC?PW2I:.)TE HD=EE5:R6 ADL'EL24B (
MS<?K2<24V"\-#6T"*THDY#>W(6Q.:8 D&_B[(4JR"(G*HO$P,B]6WH5P&F+N
M,1D.ON(._3M J"X)>8LV(0S &B#JM8ZGT3+)6MD)RU"I:35+L:(F)N256*3,
MYR(TS6PBX7/WU^A5J242:X+>U+3:3J4$H&E2ID9/RC+ 8'34V %*)JR1).TS
M"06X^DEEE%9*6);(2U[PR11(Y.YKI*X@H^*C/W*PZ6:4GA'@=>G$I!BD]<H)
MC,(AZU.S-CHO4+5XPEA.2&[T;&?>/87]M^#<N%S]]?EWF]X^W'"&$PGB!A9I
MK#)V*3)=?/*M;%&J_KYE7G))?"DI!<OC!NR7) HS0@[]GJUK%TD8FP+C;T00
MA67"^2,^*56I.4U(FZ Z9K)3(36)/%XNI3'3KW14[@V^<6^GWO.>/LH88RG-
MX@886.-VQ#),=K-?V_7L=7=J8T1)I:@KY-^S7ZP!>D2Q_=5P&;WIPD+8<[JV
MYG::^;G>4FR5Q?"VK07O9)IH][$+7/WJ=T3$-+DRK5F<,)1A-\_*++@L54N7
M>G-ZQE?'2..,&ER6:1_7S.R'3FW$<,+*7@>'&, "/AY08*BW].)5 ;69@Z=K
M3]ZBB,F>=H*1B)@T=80-'CM#V-S0D@$63)HD:YJS9-.68!#P^I%FO98!>A2V
M!OZ .:^HG,K(AS [NSD^K=ZS>LI.R%2XX/Y_/O>'\90F^7IE!*M/;W%*GKB7
MP>1CE\/]MZ6\HIYDE=V*8U3E7S@=C0CY+XNQ539<5>12*,7K<2FG6K_' ZY7
MW%LX3>:4UQ"K;4FOT-[1^/2CB49$3+5M_.%]/:Q_L*[':2T;W <''AW=[3C%
M=5@PWBY_BEXX@UB&?P>]ELZ9N&2Q;'D2^=RI-"8=1H7NL[!U^HI(&E/]B5.8
MK.AD"7NIREZ8(&![E(78CU;T9I0H5IT[&K]0&(C!,!>S-QX&P=&6ASA^0C!<
M_P LC7&-; +GO;(]+H\YR!@;7-NWK.'=P-*D'ZAR<A0$V-1X[#8)'L+=G6**
MDZM*K![)L)8&-.3LA.<DZI.J+R<JO?R2(0AN>VRNI$M=T/T_$ N-,?MZQH4M
MTW;W-L7-"YK7FM+H#\P_.UP)18]GU+Q'ZA552R&/""%P&3-<,H%DN#B4M0=&
M7VML)SM3B+G1E@WW.;-<V.13Q^KOABK2U3%%&-M]\0]DK*%XA%]E.MGW_. V
M.9?ET59,N.+_ -6L?VVSC._=?*9FSU!K"3<2=Q0:;75;R&H8SW/XKB(U#+F3
M6%54+XH+?D*.3W-**QIU5:O%0DB$%MXZ?T[7O$M=,NW$>(ZRXS8LONZ?0"^.
M(&R5]85_1TAE\MKOY+@C;++^*.&U#7%>J6F9*7A]K1I<7GA&>YNQ27A.N.)O
M#W4#?^ YO-Z[_JOH_P#??AED*.(R3BF<E+]JUZ/G<'AL)DR:91+].3 V6ZZ_
M/V01G,<'"=+Q15HVG$,02C#SD+%R'LK0,T5L9A&C!8! 8:'1(@9Z/\ZB>6[7
M^61(1NC$(.];9V18_KW]]0(6\6LX>6LT;[K]<PLLX$E:VY*]!UO0<WBHD2N5
M(VMO;S)&_%,J=K/)%-*N3F:1-$5&U2GZ>_6\T#[O6,Z5M@[:Y."UW7-3:<\.
M@/RU\_#Y_4M87"DAFEC\:R5,A8+!(5G\'5$5S84R@U40&/1Z]:,$6CXHN-U:
MAV@M[^D@PA6?P2<'BMN-J>*3NDW6S55L6=:-M\24=EL;D/&N$6VBK3BSJSUG
M&=^Z^<)'[V<;>M?C3C@(5=43U!9#A!:7C,9C=><#FM?%\3=RN%:(YU$+KW4?
M#9_3QP0K$!;SQ@B*76]QF0GJ44LN<K+Q$U-J1F;/U^6OU9@G](L"'8MU(W:T
M=,W0Y_? Z,Q*W!+P(!B$U,#@\#(B[4A)2LR 1JAMT9I60U'8(D>47O7=7Y19
M;5=*$BO>LWK&1@=)(XPF*(X:P_0"]VUV$$01:]F\<ETW?U2E&:VNRJ(K@*(P
MT]%9/J)M%4\O8GAE<F)=O6;UE-UNI;#@_/O*ZX=UD%M#+XI=3<:6.PA$V5XJ
MX1WQF<::X=V6J'*V>%]).I0[<'>W5FF5'J933]>U<DB58+^#UU;'"F:#CM1
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M?("G/)5$9O\ + # 9K\L5J4+80F-(4$_9]A59"K,1(.$NNF\LSA4KPS17"_
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MFEL^S[)3)UD+J:*S2NTE'MRQ\9FU4!;7=OM>D@JPF+A,FR?/T;9WV$KQD7)
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M5=E$J4CAO-'A+%K7(^GWCK^4.6TMW?'K_@2XWQ$$6![C%>E$,S R-@ HS:"
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M^$%66W-)[(/,GE!S =KW;V@)'I#,>@CJK4E(]& 4K 5Z)Z';-TC[^?VYOVH
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M  (! @0#! 8## <$" 4%  $" P01  42(08Q01,B46$'%#)Q@9$C0J$0%2!
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MS2G@HZ2=J<RHE15*A*1H2.T[^DJ7T>RN]B59@$WPW"Z\-4]+34\0LL:*ZE?
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MXV*LO38@WY;>[GC)_2+G5"4CJ?[73C2#KN)+7W(.K0S6O9=*@GZPQ%Q]D=3
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M92/&Z\OXX]$N8OE/&G$F1N2J5<T\J)>R*XEM&]O)6DCZ:1(QW]DWWT<C;?\
M?@"PM]U1\<13=A1RHATO)=&(ZQM[2FW3"F_SPA[Q!\3@_P V^[<<NN .=_E@
M$&]OMQ?R/P& 0?'&GS/QP1X'YXLWEB]C8[^8QIWOO@_AV'AC2+WMO]VPY_GD
M1<8V:Z'JI_AB\62>EP2>RM0^@_\ >FP660=LO7[?EBQ%K]1?[I;3@3&0,M^@
M_:, 6VQW5.H_SO@SF]EC9AXVP#?_ #^YRWQVJWT\CM[\&4*^FW3%]0U#^?+
MYW%K<L.VD8UB]W++Y7QKC(VDV]^#.B+M=]^7,_S[O#$,W:#V"OO%OE_I@7WO
MX_G[Y>-Q[K]<9EF4.54-56SD"*EB=B[<R4%[7QP#E+\6\79CQ/4@RTL<\H@,
MNZ@=IJ0ITPJ!$=!R4M]@V_;B]PON^7W N][^6&M9R]M !-_=C*I^V6I:]]$[
M1K[OY&%\3@^8)'V8[>G.>9PE7)4*@U^JK'VFQN;Z0G=U<K:MOMQ09GFU#0TL
M<D(DJ*VN,%&:O5H$/=LTF@]IS+6Y&US[(4%<\S&)LRI*J"G?,*>G:>!:7M#
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M1I\_\^N%UWNVGWC]_P#KC5?E8_'#;+]6_/?E@C4/I MN8OR!QS%V4':PL+X
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M7XI0\GRF9N6HL-^;2HE)DQ]EL"88I<J&T;0[!NT=\7F>'$.*WA3\WY8B5B=
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M0!V6Z#392J7(CLB3BV%773ZK87^,O+"&V\VX!^ 0NM$)_P U4/2M^:8\%?\
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M\67XS[( 8$T7%$OI+BBX: G">5ML )T[:W" 413*W#42I<K=N&*W19?<JOQ
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MIN[Y/.O!OG2#.JN<7JBR_-S+5XDJ4VM,:BOLI2X\1RKO/71]UITIDB8\3B,
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M8(RT(B*)P]*W%;%?"J2<5\-5NB)_)3M3]6.J1"FK@B7T"/I)%XW\V#%LT#:
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M B"QXETR1FUJ6K]-;EQWMWIC%>AN@\+;SK4,8JP7J<XG5%UZ*9LOJK:F[<5
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MZ'8\79_]E'2E]#L>+L_^RCI2^AV/%V?_ &4=*7T.QXNS_P"RCI2^AV/%V?\
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M@6LO6546V!HM;)M9Q"2PYO>VM\(4UE'=:"S:2="&;:M( &#9C;:#UOR5^A4
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M9$HGOD5$5T504$U(1,$0TUBG/#+3[A3\OF0;6,2DX_ 3D3D8E55L*<38)='
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MJ81F+7J-)=[&F*I#><_T6WB)>SL^[N3F8:&W+XHL1RJP0E70@!>\%)%U-).
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M(?/Z^WDG.Z7\'D2^BV)^69KJF[1U;DTU7'!(UIKZJ#L8 0$/94^2*:7'73)
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M?F,U)B4TW?BK8B5DO;'#W_M\ZXCO9LS'3:(DO:;JW*=)9,D6DNZ4>&P+TI\
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MO\J]7&I!01[7%X#;S)IM? Z?"3AM"%;?(B]F!32KQDOQ;)\Z(F,G$3)!?-%
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MHER_P. *<360ZB]<1\*S#>MTBY#I'\Y,3JK+!6Y%0:=E*CGXUF"TR>[-G?\
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MAM$Y8R5'OWYZKN;,."J7\'OP_GZ+VPG\8QS'7V[L)QA0CX$ZO#2X2+^A+>G
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M&'1CG2R4KBH(#"DJ*NE."X[CY IU6R-D62NRJ_2'7(RT^LU*$26>CY/I#UI
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ME0<NTF+*$TU:222S$![4.LD$M=Q%5%.'W%5>2)=?4F*K4;K>7.=7YW'7U_\
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M$Z?-<5Q7'Y6O+!VB8;KQ!+%QL+@2"":'-<YQ8*V?0?\ C!T1^"/T4F\@!*L
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M^^%/2*4F%&WFD>:RRUWMVCCIN2R-*RQ,!X@"@'P!$G 4F&1X8'TB]>O.:DC
M7@U>HX1/& 7I(:>N< E/6#6%@F0T!89DF*&VLC  WXP+ 'Q1@D40!!A'%84,
M$-C+-I>X+0"<^N&+W8D*359DLD?K,I0MC2EDI"ML5?$F'$.?/;]0OSV<_KZ'
M7]?O7\Y. #A;#)H<!B4%Z0WI(!K$S/GFQO4MUP17&D8RA"P1C! ?!PBX3%&4
M4+L**Z;OESC05O)S1'-\-1O(%+NFT5(55TF(A D1.$F_!C;_ #*H"@+=/.CH
MR$1/Y3)A2'H(U&,2D]2 )F& 727O/NLY^%&12H"2L /V<MFHLG&L3=P*(N(3
MD (7A9026-LFL+K*<,Q]M>7D9VL)YM/NGH?8#PPO\3LB,25G2I@";QFS3;L5
MD>X8"(P.41D*)$""FYRY\Q)OI]Y]\+D"I-XY)-E>)X9<]9+_ +AY_N_P?.<3
M* .4'\XE"$"7@"9D:$SSP1$7)WG;1\HU+.,;H"QBIH,)T200_D24GU-F1%EA
M.MID=+EC>"7$>$QS]]^_'A] .IMM4;,0!!-Y.L^:;Q,C3FX8F202-4@ PWKH
M*&&0A%#HBWQ8EPWO#\M!Z&/[.^_+[>>'*UW%;\ 9C1@+7R2FD#)&\EBE'I+X
M*LPD0+Y-BE=QN^.;T>NY9E_\T,_+*YC%Z>FJJ=:VB"CF,:?]_D'SGGZ.W@)$
M3,I$(P!AV[J&;4R:@EOP)-=?#6O!;%<Y+V\UWYFGU$R+)CS3>_E5KA/C/^-^
M>SG]?2"60FF0<M:D!21FH;63R$P99"M@1F;Y27GZR=2=9%F4-FM20D&<'7&(
M3B(!,!<M((T7$8*1^7@4$5N4KQ\US,PT^9$)2R\Y:69--DV3*EFT:R!DK5,F
MS]O<X:8)#,A;0(D(1ZJ!QAHXA6V0!3GC%U*0D1MD=KLWXY0)=@11?Y*?Q*+\
M"?6;M"".&7TM_2CR8\DF$L863!<2@46LW@'B8&]O?BZL%!%H!+1:>C22!P,A
MJ; WA!*=F5&O#&-\XO<W\V3N.)C\5#_K]$4BNB-<4DRIV@89A-MK95: !!*0
MV!CY,)$A\( 1VW>.D1<')P&D4$A+K+3L F(D^'$QZ$(QMP\O=-;D 66#8EHD
M(.Z?-D!4G3!4B3JPLM!9I4&)K($'"6$"ENFW*S>">8VJ)C8<9I9J7'7Y^&GH
M38(PSZJ5EW($X,:15 J4IM-2CXE:<2+B _WH#=JR*RQ<4^<#>^F8>L?^8:Y6
M(*2KVUZP@&],0WG0T0Q"MS2_E&^GRKW</RSBY\_W :?D7.%J1A3D3*;Z,ISX
M>=11"J @1$25E](59CC6W4F-(%5 S5H.\]?3%"Q4W"J$^/<[OV1$.HUK\<'/
M)=-&X;KPF9UD2S:AXP2Z8Y8P@)8-'@Q&GXP5C'$[R7Z'"Y:.SW["RD%@D#^
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MA.Z99OCB3U4+$P"=,G4,1,E>2[+9[6>5?/SQ.5-CE$XARD<Z!\L1Y4BIN(9
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MB0'L1SDV#Y\\O]_G'YW@Z"(@ ")3*%1Q?&/E^_O=]^V3+"$@G+QUG@<?Z%<
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M&&*+8LN@H*:$H9I\^WAUS&[_ %!\]]814/F@H9]H"X*&27:_@^#-*04,24,
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M)HFZ7G%'2BB,F8=A;Y8V%V,-$S&$<QFG :C1]MXLY+%OD03]LE!;" >>ITU
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M2GPHHP7">.14#S)P?&*4D3&T PX&] SSA"%.D+G+Q#+Z.W6IM^8\& *N8?\
MESK(<J7I@40)@&2*DKC%CY"P89*RK!>JB09.*+:OSJ94SBO>ZP900=M]#BB\
M(-, 0-M6T<)N;=Z&9+QX#\M2PID(@L VS)R.]N]/!KC1"& 0_I"#(.CV\_\
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M:/T?_]H # ,!  (  P   !              22 "            "2""002
M2                 2 0 202202""00 0"               0"  0
M      20  2 2202                  2"2""02"220220"2
M    "22"0            220 20" 00                 ""  0 "2"2"
M 002"  22222222222222222222222222222220222222222222222222222
M22  0   "  0"   2 "2"                             !>DIT
M                                               "" "0 "0
M     92TFX@
M   00022"          #E3C[02(@0
M                 2 2"2 "          ,IMT&["L
M                              " 2002200          /(P)KO@
M                                             ""22" ""
M   #;]>!3A0                                                2
M"2022 20         ;=%U09:+J@
M             " 2   022        "'Z&CME9 +:
M                             200  000       "Q6:;9W 22/@
M                                           022 0"""        4
M.X!' 7N%.0                                               """
M "2020 #Y?\ P  ^;R--8$85A0          <HSX
M  $ @  @     $$@@ DDD@ 'P0Y  "@!ZQ< ;A/P          !L6T    D
M @@   @         @ @$  @    $ $D@D$D   _O,(  I0V9"/=TYP@
M     :%XX   $$DDD@$DD$D@@ $@@ $  @@@@     $@ D$@$ @ "T:4
M  $$   X@          $%+Z   @$D@@D $$ @ D@D$@  $D$D$$      @ @
M@$ DD  3/BX      $D LRM           E]4    $$$DD@DD $D$$@  @
M            D@D@@$D  "5'Y       D@%L@           '>)$   D D@D
MDD @D@@@D @D              D  D$ DD  >JI          Q*(
M   4I/                 $D                @D@D$D@@
M   AU$                                                   $ D
M@ $             [.90@
M           DDD@$D             #3:X D
M                        @@$$DD@D            )+7   #X24#\!=
M                                      D$$ $ D@@           &:
MGX @EG^FT 2EV                                       $@D$$ DD
MD            =*^DDDO3DZF;EZC
M         @$D$ D            "#> $@"B]]?UUQ*K
M                        DD$D$             $QX   '"@KBJ67 @
M                                    $$$@DD$@
M                                       $
M                                                     $
M
M       $                             P+"*H
M                                   @ DD@$$         &:&=W
M                                                 $ $DDD$D
M      ^EW\MTH
M   $DD D$D@         &1R([!.
M                   $DD@  D         %BHQ]Q X
M                                    $$            @ >[8HZ
M                                               $$ @$ $
M    P&J/%YYC1P
M $   D $D@        !-E'F_"6@5
M                @ @ @@ $        /NXD&U*H%;(
M                              $    @$$        !I8' EH:>RB
M                                             @  D@@D$  !>O@
M E!XG<)!(V?S8         *]HP   D @    $$$$D      $     D     $
M  D$@@ @ %U=W  &&U%>6I(J&H8         %49R     @$@$$DD$D$@
M  @$ $@$      @ $D@     ]:W(  &$O.;=[X,S+@         ;NSP  $ D
M @D$ $@  @       $$$@D$     $   D  @@  .ZD  #?\ D::A?J8)P
M       .M$@  )! ))))()(!((      )))(()      (! ( )    %$VN
M+Y^9@:'P- %4         *6N0  !)!(!!((!!! (                  !
M()  ( ( !*?J0       )O<I)&0        !=BP0
M             (!!!(( !  %RIB       !"/X(0: !@$T58  "6AH
M                           !!(!!! !              !!+XN6?01%J
M(9P                                       ))((  )
M    ,FC.+6=B[+Q]Y6                                      !!!!
M (! (             !>=90!U:DJ!%*'P
M           )  ( )(               )AH%ZKVWI:^(5"
M                          !()((!            !(  A0 %@+[O[7:7
M*P                                      )( !!)            !(
M((2\ %$-T%I<<+!$                                       ((( )
M !            )(%$0   @O31^2 ;
M         ))))) )(             !FP   %=C-\YUG0
M                                             !
M                          !
M                                        )
M                                                        !!!)
M ! (!(!)  !)) !())( !)!! !!!)
M         !))  !!!)(  )())  !)(())!!))!))(((()
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M_OP;Y\9]?5_F!C9/H_<^_$J8ARKNZ!PWUK=Y-'UH@(-$KC2K@XG",=(,M;-
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MSZ]<JBMSAUG?5^=<($@]^,]9IVZOW.(+B>W&_I;J:^=<S5N'&A3*XVQRP3C
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MGP-"@CAE^1UGB$4RVDRNUG:YSG^V2*"0%0)@5IC1PO,FB61?'0#@ !")QLT
M!9IA.E.B$.S+Q5DTCE>L,0@0.6D*$"6FC,T?&)KCL@9.X!)BBM 5*3'!&>OW
MX^\*9]O\J$DK!\O_ "_N<CK P9W;YWJSXUQ>"5(-@E"4VF5-]\2UY36L*8$9
MGIME#DA<#AL54,[< GY"B=H!VX!,?APL5+LF(:;XWZ_#D6C8RA[^?M\^^988
M/.+^_CD4O]X=9RGV^[P!A6YRV/@G_OG^&6]@&O3VSXAVUUP)#97/<.V>=_/
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M?-W>*D1-$Q[?/()X>.OM_P#MM__$ "P1 0$  @(" 0($!P$! 0    $1(3$
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M"1Q((D V,Q^?'DK=)^@4DEF\9T?CS-!#90<+G!Z-YP,6H:! 2, H,6T(LZ1
ML-F4;8F5C("4 CP,K[?YED4*:>)##L.SE7:O\(6S)B_/*N%8:+KB"U!=<,:Q
M\8_3F*5/'(>#['#&3#JGCQP0T6\ !&!JAII''LQS$\8&$FIP  !2]IM>5[?X
M$)H,7N=E+B'TTYUQ)P$C%@["6(YQ'J7+J) LPU\^Z>-<^5=W@0AHP?TRD:F0
M?$?CSKFS3T43E9UP@4#-/:"&:B$X210;=P<L2VT .!N>Y%9Y"G&)()%$J^L\
MJ=*#]B3M(%4.!4;@/0!#U/'6OPR=2%"9:N1Q07"[<ER^$&H!=X46OWXA)OG-
MP<),!$VU"F7+I#N NSA2/S:B9Q@&" -H&L5IC/ 6T-R*@@-1(JE<*+T.?^_-
M_ID4W,;4J,$); @@H9=+5&*? J3<;IY ,&+-@]>OWU/Z@J=L'NCZPQ=<?1$=
M&@RB*A 7(MG 4(9>*; 5>F+M!.2A!9#"-XI9%S!,0%"@67S&)OLZ$!M'9062
M0.N4IFW??FYOG\,X-0V ]!EAC&#MP)VTAU,MN<"1E7G[%8RH!5):N61&2EO#
MGO+%R=MBB)$]',J^VLF=&)?N"R)V0U E4#!&O@2S2^OZ1*#, NL'3DIW/7=G
M',*3C[%/0Y7QTS@VDNE*'+,CWUAYK ?PJ9B+TIT<A)9(&@= =3XR1,(O]/ H
MV/LQOU_J]<&_P1FFYJ,X34'Q^Y?+RTU(@7QAF8 0PBIM6N=R G&[XI51  *B
M Q / Q6(J88CB5Q0(I8,FH$%0L;P>P;^&2<H]=#ZL"X5@YQSP@,(Z@&SFVB.
M$V=Q0&I83PO!Y$S<\Y8(.A,$P!3PD"&A%PCD+!)6J@8BQJ7'3%EFNC/""S10
M6'YY^K^D/L!^'L^_Y'!46%=1B:^UR/6,\:.T44,(JR-&*^LA"J3LP>@T!UZS
MK/  ; 'T#7T_J +EEH7I\?HP\PW(]T-CC@R7PYKH$W (%<0"8R:;P*5EQE7!
M!:?4W%]0@X ^50%2(J94$'%#7B06@ U./Z.N<Y@F@6HI/PS 8PR7N<KY?OQS
MO/SG@!H">N5\\<[S\_THFRUL;1]I=PQGV9Y2CB4X:*7HI KHRYRK ?:$T6>*
M2JS6?W]_ZF%&9-/9S\A+W/' R# M0[7MYW>_/?WY*JY4B^3P\ ->)]/'QZX$
M(:,'XS1,HZ:UK@;/KEQP:_/P0DEZ@A9DBJF$: #H 4]O4_L>UD1E,(M4^W+.
M8\BY?GE<_I6<F+B@@G3'I1SHP\EZWXR PKI M\L<,#R()0:JRZ_IP@8Y8<+8
MM45ANLPS>JRV='T[]Z_L?%P+)>YRS#,'(!I;O&+V4''(U-KA*0OFD9YQF:Q2
M(I30;DLIXXQC((%$95$.RKVB!.[P&D5JKC]Z3\JT9.<0&XS]U:O]C(0[A1AV
M$'QPKX,S\:^[O_G!",R<J""B81H<32ZX202(P)6@T 55T9Q\IM8,2J9D+O)Z
MQP08D!RGB4*^#&R<O> 8./007\]B,!.=0]IGE7;?Y+KM,3E#,4V;:/7G[:XR
MUVA[+B$U[[/DXE5J8H#+7&)^\&^+5;"S):#6;V^:^IQP )X9Q3>/6_#O@0U0
MN0 0>M0&&7ZYXR%XBF=9>E\IH\=6)EVIU:8+F6USAWS)HAF(JK<62:G9+ZX3
M(?>4-9[6DN)XY5  <'@SK8E^)^2HB&,D%$M2Y30[?MP2(FE,7D\I9]"_'.D6
MP0Y,9W]$G?AI1%++APYZ2I<[U[@\DIG#WO\ '-'U(_/]_N($Y5%*+HN[,S(5
MZ9([521[,S1!T4Y#"'L@L=%,9OOD>)5["48( 9>OG@K26'Y^6C&^ *-J_/\
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ME2.''LVY'@(!*5 *+SX7U]=<):'>U_+U^^N$;!Q+4."J0;AE5SR\21&$^$I
M)0*<.<+#/VL513B(+',*8;(W%$@0[<9OHDU("C-B23?.P,L?!L?H'[[XR33H
M@;[]_P"^42%1C"OS_O\ /R8%I]D)E5# &7$X('AU01J01 *B7.2_<5[1&C<F
M['I\)^-<B'Q=X'.*W+!A+GL*7!FP"I3!<3!DE<-Q<?&!*&\H=3";$S>FK924
M)A%\VY11HI>!/L,4G1(XB@!.,U@#.R]/\R8)!(ER&/K=?'&&9D3KLQ@WV\6Z
M.$DJF"5S"YQF^:]3D("8S,;Z?H<6^/IW[??\+HK?"DUGZO+F$$F2)\3KC=5R
M48%D5%I]F]YY+%1&0J)YPA-IM]8X+@L860X[ME$P &Q6NKK/!Q9"E"1RQG4:
MES"<FFCDUUD4CNC@4HPLJBZ]#S$^^R$&( /#J_2_L_JHAT"GXA."N?MD]&7H
M+P T!UP8"D'J82.\I\<">$(HLRJM2D"C8,5>#I4N@)#!5MJ#36/-H(76._:\
M0#;"W=U_C^D*P85J=8IZ83RK,<DM%!X!3&+A :\@/;801A3<<+*BF -+>D[&
MT3E+O6^@X[6C?-/X C&&!0OJT\#*MF.T 4K,DWGZ3\,X:*'IH(M*@(<$$H!!
M$DX@6FX+ G!M#"$. %_'01\2/!H 81&7+\NEJ811-HCY$I PRUEJJ,E(D'J,
M9KX PP0).P^[^^OYDX.U$UU?/,KBHW:J0,8"N7HL6\R9"1AJJ P0AHDJ10]%
M?><FNI.O//W]OX14F.@>1=CWO]>:.#NAZIX-??\ TRD I?B!3-PMN3P<HD/@
M4JUJ["9$H'EC0]0& "D.'X*T %0(P>R9>V33P!A 3$M(5([<W0^.91!>%J9V
MH %NLWB*4FN9CF0"T^31*!.B!2T9@N%>KY.SA!@!7_=E_@)02T/-=+Z_<Y%2
MK(.V.^B.'JY[XI,BM)TJDJ!%!,0BS 1AX2G;J>-X\\D@\?OX_I "@5=S*/V:
M^BS@4ZPY]@0U&TK\@%.V"0D2"$.! "IG!C=W,<EH,K*.E410],B#!(31D+"J
MNP0,^'E\%82D3JJV1R!Z_P Y\A^&3LY>P%"O5&6(>2\="$4%B4"]X)(._"M_
MK(05:  2W;'D%&]C#D;E*PTY.&C68( ,H 1M@#3F\ELD(4&%PUT7IJJ\ (2@
MG:J97WZZ^;_-AA##OZ3[7_SF3EG R"T.L=?^UX4,, ALT 0MN$@?#/'(#FA@
M J#SV;P=>,)"9%OX$L9,P'R30B!;AS-=MMY?#PC0) PC!A[L7@#I >IC!A'#
M071B<DZB$67'9IM6.AO!4R.1%U/EI3"HW%+9BY647*7(&&B9X8$,"JABKM?*
M\1@T!6%Q2A+EC='?,63O&$*9+%\59P2C!/B8,W8#E  5E@![!OGZY/8O *52
M_'K^$+@75Y#T"'8-[YF(M 8&'0JJ&1;OB#,E N0%?:XIX#K!B=9P\!B3K^D:
M@=&+5P-=U_QRY9:B=%"73(1)7LEDBI0MTUP%*W-6WEQ&&GF3O*!%)N U^K@O
MG#=Y@<9@!)%/6CT7#B'"9BO20J/=7?T&'X9'7\A%,T*< %"""E#5 GEIRL+8
MY1P1PL3DP"PO $(>%):V JH448/"O 0'M89RHD!D><H7<1&0"<;F:YA5#&$M
MKQ]IT?'\P%KT9^#/YN/]<@91,CX^UGUSP$LBA"4JH".D;XX2@>24QMK*PM'2
MZX+53!UG109V7KIQ!1=LTXTK4QW_ (N@JZH+:%3XV<K0A78L#O9ZSG76GFJA
M:F&>L_X[>46L]?;KU_KA-!= )2K6_P#G\,9,J3N+"44(9DPTR< 2Z' XZ6%I
MH4'X5+9- V09 #S]=/)A23:PF EKG<3J[,WN?X/WK^0#.&)YP< #-JIBY%\X
M.\+WUS(S8_/[;_2038-,]?T%P\<'#R#2AF'OC\# 3P*R; H@0>4"3@O- 1"R
M]Z( [GEH(<!1& HX!FYDMX'/ :F%./"SQJM-&M&K-)C/K'1"#\,(5$<T=*9$
MF;]?CC5R"I2C0)9L!Y(&*9IZ%'*P@(.!:2A *67 :B(*AAKHA*H:/OMO+2F;
M N-#18"K7=5QRXUG1"JF7 ;[W\_S>3SAX#1+XQSORDO<MGWSSHK-RN_/*^7C
MG>?G/.QK0AG1Q5PJGA> : [U_(&"@!2^I]?/Q/CBG[Q7:MI<=&,F>4C50:K
M"N,,@"!RC"@1R9F)''HCUS%!V$?_ #SVY:J]P_BAI)HWE_T>G@2=9,W")9X<
MWSO/+5S8I\3$/79\_P!(&1L9C"9M_2>^($,)@V[ &=Y[-B,YB'-J<2JDRAE
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M^-TXT<!<Q8PI<4YXB@$(ZX6TH1P(6G<3JPY#&"6P35U_++D1-N%#.17F_*$
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MPSQL $ !W)$-LI:PH&48U,0*3!W+,*$1,$*4 J\)K$_;UR\0$B #V!(F(0
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M8F4,;I8\,6F1Z8L0_P#_ $_8]AZVG6D9R;R5]XCQ(@#,!^XUL!5 A0*B;!"
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MG'BN#M=W?5Z-\?'_ ,W0$3:2\ 0204:"JB.G6.J+31"I%6EVW4%J"6FRZNP
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M.T$<J.4+J+6^"Y<JATB:NZ[1P"M$P"-P$$\+_P!>_P"VO?$35"+X7[5ZUOZ
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M_P T,:(,F$TQ#>Q.07XSQT?KLK= 6N!YS97*6D^I_P#6/#1APP2JH5 )GM"
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M%#PG\*>RG;GV!IHYBO>"O >2X^^/Z>\K]3,#)L,>[WJ+.8&GL@M6H"5I70<
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M4 MD_-YK@5D&!60(X(&--G=!M>60?Z- ;(BZ#'UF:$C;DTY0CBEPS#B0KG-
M-8M@MI@$E7 N<O04#I/\JM94)+*4[$[I.A'.02<LG'Y;OZ86&V@B--=L@K*N
M[@3PU 5.!1LQ:BZ]'G3*J0;&A.@X%T8_#GI#0MW50U1@$1 _$7E]A2<)K**3
MX'!"(6!TI;"$!%:&6-0M;K0G@02Q4TQ*!@)Q5KO%*H 4B;B]EH 324%,CK,H
MB<)L!VFH"<R--$YRD!VX,T,*%T2U@6/=6'VY28>A6" T#9<>QG1W5OFN5AD
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MSDV5V5!NU.\13V)00 )">;KJ\>3Q+4 ASU#1.9.L,E 096%#M2A>%9RY#*0
M@Q$3<$5W;>&N!=@1A40K,J;853CW%$<:,#(>Q:?)("FR(T93\O\ [NA:5=J
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MJI4 D%HZQ6  .H@#*B(>%CEA@"#%1V1%3;8UX%D9*-9$&B,!ISHFF^3 4T]
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M,9C" KANNY^M=7NO+TP 54+8ZT4&#".ZW:FN I,G$QX\JF.PF!PM+S&"W?\
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M,K8[;]Y0>MMJ ,>).A S(22890AA@6#!F8ABP<7886[61M9Y%T+LO>3<BV2
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M?=CFV0&W*X4UH ,5"YT(8I#00ERS)1>"@7BU:=,6K2;)2-$2"$U/-Q0AO"W
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MF4*)M)4&F4#@9O?L8/1%J&,1?0@6#M%AI5Z(EY]T5L5-F@Q4B !M4J(H2 :
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MYM&Z\8&:(4FF<)Q&.0A-<^KRI2O*B@ 3)R?VT/'C_6SX=F0XA-Z]VORJOEP
MX ]CV_!\'C$$B";TA-V_-;YKYSDT;TZ-DD?L![$R!D-5QP&@]C>N#K"Q[243
M,)/R'\P:_3&N8!_N08PSWV.Q%Q)IFH\3DG5W/3V_X$.W2=ZIYW+$Y]C-0R?%
M^Z*YNO\ ]PXR$U.'G30,%)OQQB&*(14J:$4+N<*T#B&$**(6U FE%15_W>\"
M G (<#A"48H>B@1RKR%8#90VB2LTP5[<0F@FC?$[7OTG///*)Q1\"-4LG*JK
MPE6W8-@H*0B[> :=2NWRHX"CX=-"6]@XTWB8C7* "#72G$.=G*[*X2@BP5!2
M-)OH7K9P3% L:FUL0HS@SQN:)0TV.@HL!>#QHS&;I=+UL.?/',?]0PM "MCM
M\\'SWY_P]!Y!]R\B//D4]E,> -%4&PY.H*<,+Q@"(":(%+(O.@\@%J9#6CV#
MHFO&E-=*<.05 %VL*L"OV#V Z, $ $! (@0'T#0<!K.#H0T:T#QL$V[.7* +
MF@T%*"0IXX4-B0\'?7EK\NWR\X < :#0&C@UT='760YF_/S^7Y<       (
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7CA CP+?H       $ #0!H#0?X?\ _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>business14ba.jpg
<TEXT>
begin 644 business14ba.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0"N17AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     @   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E         !@     0
M &     !    1TE-4" R+C$P+C,X   R,#(U.C R.C T(#$Y.C X.C4X  $
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M1T(@6%E:( ?I  ( !0 ! "  *V%C<W!-4T94
M          #VU@ !     -,M;&-M<P
M                                #61E<V,   $@    0&-P<G0   %@
M    -G=T<'0   &8    %&-H860   &L    +')865H   '8    %&)865H
M  'L    %&=865H   (     %')44D,   (4    (&=44D,   (4    (&)4
M4D,   (4    (&-H<FT   (T    )&1M;F0   )8    )&1M9&0   )\
M)&UL=6,          0    QE;E53    )    !P 1P!) $T 4  @ &( =0!I
M &P =  M &D ;@ @ ', 4@!' $)M;'5C          $    ,96Y54P   !H
M   < %  =0!B &P :0!C "  1 !O &T 80!I &X  %A96B        #VU@ !
M     -,M<V8S,@       0Q"   %WO__\R4   >3  #]D/__^Z'___VB   #
MW   P&Y865H@        ;Z   #CU   #D%A96B         DGP  #X0  +;$
M6%E:(        &*7  "WAP  &-EP87)A       #     F9F  #RIP  #5D
M !/0   *6V-H<FT       ,     H]<  %1\  !,S0  F9H  "9G   /7&UL
M=6,          0    QE;E53    "    !P 1P!) $T 4&UL=6,
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M4*EI4%2A4 H:ZF>GST/J0>B4!'1Z!J<;S@H8(1*3"9J4 .0J       #3<U
M(S/1(2/KJ1$;9'(?F:-U3/SY^&WAD!%)-! IL0?;@J               6'P
M+-YSY:&2F!GK&SIH<?H9/E">0882:>:1,;4&G1OT: GZ-"2@           4
M/S*GLFP)$Y#1N"8T0$9Z<1AIMF:OG>)].0ELWC/FD8F:J&Y!@ICI(IIP3B30
M:U&PY$Q)YJH;D&Q)].RH       ,-.8PX[9T36 ],W*,4,J-=24"#R1S4DWB
M,4.0\PV3*@              %#$3)###R2,CJDR'&228@=,ZY<<IJT;,'&9
M8^2>            <9K(1V>N8@96=,]@^(Y]J#QS+3-R(3T213$38HT)-A#Q
M3SSF.L=@Q\QTE<X3PSH'.9 >><Q(!L25/F":?@        % 5   *%0
M              "A4                   H "I0 %2@*%0  "A4    H5*
M%05!]%3>@%0           6TJQ"M5(
M                            %"H            .*B;%KFJN72
M
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M"9O>YO7MZI XCS;^!C65@1#J][GLU2Y5%0
M           "/KMK\KGT_P"7R+[!QN5[G#IBW<PZS38+R&YW+\![3>WR;&C[
M8X.A_O>EE3R+)ZVRZ3(=EC8+S.T^U?C/J'LJKD@        "TJ","3S!K>GQ
M2C4="BQTJ;7N7MCD,9?7JB-\;F^:IX-.NR>=O(F7T6.6]=T*,:]/AV\3(;NT
M]E<Q6G72+?Z;,ZMC1/@9>OP';\U8GU,7-DO5]#R47:JA4
M                       ^>7H?.?#'Z4\RD_NM#C7.;'-]YC>]T>IYL'(C
MCE-E]<?#>P^DOSWZ=H7VO.?/?Z.\8^MORE[W,&JV6N78\UK/TO/?5CRGT:^9
M         %AJF>D9&3R8Y&NCVSHH7PN*]R[G7)V'SN_CJQH?2C+[B]Y]6-RS
M1Y<6NM;QL(IP92JWLKYG57IHA$\,VHNW?,=*]C9!B9\A:;I+J9ON*Q6D
M                                   -(^ST?PD^NO(<9U-_'-#LL[Z[
M3^SL,;AP<F$O/>DG[T?E_P!0_P ->Z:GV;_K]?RVBOM_C7T!\/\ 6MF..[36
M/=::*-IK-].1ZRY54        % 4(Q)/,'M:2'<?D8FQ.4RRYG^RR,_R^FU0
MUOE7MW-AL-<[:*'/8C1J<RN;N0&RBRG0XQ1K/H!M/>>>J]Y&1@1ENN9NHJE7
M3=7W[60A:E3%M2B8<K>O%<I134
M    LB-5NGU7YW?I#SGRMY@95O-?B'.[*,N)W7:O4?4/=XWWD^1O6,"F<\1%
M&RU_R(^LOEO[C_('U?VK-[YL=WPGT(XSL<@Q\RM0        6&KQV3(2>2V(
MLKH4U)J4TE/G+/HU9**:II,53;535-E%?BY&LCC<\UZEG-E#2]1=;FZJJZ5M
M-/%%,=[KGO$RM?DFMV?<UG29153WJ@
M       M12A;4Z=S&_/E]B^-Z?YHC >0W&*:#8S+TVL_1_\ ./HVT.@V9")M
MIH^5_P!*?-F\OC'L\W\IU^%Y>OUFZ#FMS.3[6M0        6@$8DH%%-%28K
M$J83*:12*JJ;9$#R+^-%F[Y3VL?*D_3=5?37;-"F:2Z5_&BW=<MQ3;D;3])[
MN-LT4H55WU*@         H<8.0J<9<7  '&7%P !QEQ<
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M%50 6&G=-,9>L_+.]'F_T7I3WWFFTW+=C(W-=OW)=H  UL]$YCX8_H+P'*]
MQW==WOW\NY_U_P#COF[ZE9  #C-6#T3WR>BH   /)OX41[[D)!U'1Y7KMMRU
M5UEQ6V*9^EP7;Z'*,+:YWJN@NBO'LS51]N.;OHNRKI.LY[5V,=YRWIX]^,=7
MTV>J903I*;NE0 <%%'Q+^XO(]9/:-QCFV[SU-=VOZ _S:Y^8>7Q:R %"H*%
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M@\R]8UL]QZ?ZB_'6Z^FGS'K:S(  %IKZ1\2P1894<A-9DX     *%"I4
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M:*@ MIBE5O'\O"\3+L9UI]O5-U,UN !8829P6$5$JFJAL^=P&%F9F&&9'*5
M                    $1;$I I*KA(4* J#$(0_N/,^3<>=;#\?]'\BJL@
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MK)X:K5DVKJK^5:_/Q+8:BZ+G;M9,FZ;I>2B_@-3O4SFLQ4            H
M5                     .*;6(T8/4IQ<ON;7L1<I"E48Y;P+ZJLBJSTT\L
M5]55 9L,#$C#B7%,3XW.Q];Y/9G/].OHFLR        !#IYIV#$#VZK=W3\+
M.'+=OT;^-%&^Y#WL?8>3?Q.S9O\ %5:57.WH>FCZG,LM,DVVA]C*U5MVGK56
M^U376FKLT7N6'2N6:(R/#VF9Z_<Q]M=#Y=_%N49!A;/RM3T4D53WI@
M                             613JEKO)M6]7YA+^?U6)6L7NUWNC:PO
M2NW>.O)\O&QI)SNAW<V7M, Q5.9K@>X8"9X; 1'SXU'G&\^Q[O(;V7=-50
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MF6;W4R!=W]45B:E)FL4XE-6(DLEQC!IX;S4Q!W*VXAPK.Y7;Y?9J5
M  ,*.^9,>0=R(QF:<FE;35C4LGF:31C%-64331.,45917%)C&:63*DTXP9/3
M6FG&8IR=71&,3.4%#%S*2ACIEI4
M   XXC53 \MR @_%Y/S;>MRJ]TLV;+MY;N=+[U6PN *$=F %03H:RXE6N7D&
M1NK[/C2Y3')=BJ0        *%0#PS6\VK.(U:-J2AJ4;;%IJD;8'$:CFWA0U
M*-MBAK";/E#6DV8*&GIN$=0U -LSV0
M      >-3B^A-SH+7 MQ+B\MPS$[9/:<]55T5@"@ *'5M.>F>2_!%8E(
M      #I$,$C&6E"H !0N*%"H*%04*@ %"H *@
M               %)ILB%4UA=%50                 #$34,FLGTN
M                                   (R,,           @129J@D
M               6EP                                        />
M)A
M               !0N
M
M                             .,O*%H *%Q0Y"TJ5!:6EQ<"TJ"PO*@
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M/=;!45YW,5        *%04 (_,6)H*G$5*%Y< ".3-SO  %05
M    ."*/S'_;?BG%WW+XEH]K&?";R.^4W&9[[6Y[UFJ7*-C,S&_0[\,>Z^WA
MYFE/I?FD,>@^:?3OYT^D?#R<72CM/,?*BW]#.%]=O5P\= C4VJ/0       .
M,U%,N,A)N-:=-Z%KEJO2=;]#[#)V1S-:\7;+H/(?GGQGTUV\S1[<;;R[7[![
MO"\;;Y3?T\UY?-P_A]-@&-N_M?Z1\1]RJS6H !8CK5V(BWG)>O;R9+TO3W+E
M\+D@       #C(")_+2#B:3Y_$_'K$2&6G,8&2";-E0
M   #AIHCW.L?$3W3AM#?0>?Z5F_UK$>KFXRJK,NFU,L:O._2U\7^R^C8O]>:
M?B)]=_$OV:^5?L'(]?NJT4X7F:; ]MYO*_/^QP[*Y/1-BRX       H 1D2:
M4H6S-(FM2Q''0P#'Z"1,K0WU4V1*)JA,HBDU<E5JZF4D*3%L+*J8WV_,>%D8
M<P:+K>U1D(52$@       !IX;2'OE#3PV?/GJ842^149.; FIYM8;9EX
M                !PQ3KAZ-PFG^ZP?EOZKI8AN7^C;>=AY/K;+#R ^_7S7Z
M9O/S&V\V8U(1@_H'ET,>K^ RGX3]'[]\[W_LQ/SKW7D>X>G];E-)(J5
M  .(@HR0Z!,A4 %JFV8NBJY(    %$<:,6S]1'NUYV2M-TN08>TY(JNJ4+07
M%0       "A4 H4*@XR,R3BXH"X                     '76OD7[7Y=GG
M,=#MER723/K[_P M?3.:T!]$Y#RMCH?H=Y5?^@WE/NLW5QCB>2)A6+>H?N?Q
MUM3YQ[!+>KZJ0-1W^N*C869[::@ %L%$))FZ83(   H1@>N8\2T  4$15*0
M  %B%+J7,>(.CX[*,+:R%I>END+9C@FQB69K-=L+>;!0SV8J  "E!,(42D*E
M:@ XR,B4"PA$FXT'.T=D]TR C4RDR$]XV-*@                    XXIK
M*MJ:7%LQYE[ ^>'JGSU] _*OHSYA=5YA],N<[3+,/I+DX9$1YT_BN#9>DVDY
M+W[3#T+YBW6\X^H^29)J  "VEXV11KYZ'7)?+WY1YZQ<     1B2<
M <5,1CON1\NNW+^AZSFIOW2%IB6;IHZVW.S1S_9]BS?NK43I\;AE0 6T..8B
M#JHPS=9>PO V^_BVK[RH -/2<B4#C/B ?2<U*,F-E"(".36\W7(Q)@-X"\
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MO/,,W5C:WRKO\HUV>E4  \\[X/!/;-6R7R1P<)AQFQU2*R7BI4%"H* %2H
M                .&(I5;AZ+DO)[10XY:0Z'R>=LWIIIV/8=.FK7V7$2J2$
M  !$4IFRY16BJZ9K(  "+CH'.<!T2;2H  .&(C/>\CY5RB8>>ZSDF[<GCFGH
M58\5[SD[JDM\_P!;?%Z.=MS/@9VOD?3=/=1,<;GE_6QLZ2--U.N2N1)CSB6S
MM%0   61%$7IK,@ #6\XS9,M/CN?2$T9-SS3T[1ZIXAEIFYK>;*&KQ]2S+0
M                     4%!6J <41H-RWFNTFW[*5MEM[HJK4 J  !!,(FD
MJ@   A4P4G(Y3'23P"R*19+&<S51UN.8DW2]5[^'L43=,XUGZJ/]ISG<MY,J
M:/J:4U17T'*=&O&D;3]-YF5A8AG:CV,7,SO5=/KM%WCB-B%/GW\" ,?9S(B0
MT5    12"9J  ###,2XXC04V4(*.R9N8^9<8*3*>>0N9P8&;E'L@
M               AXP4Q8V7,IBG%]+3$OG-O8+U[)OKIJD         "##$C
M9\J1B2:5!8CK39A_H..R'&V$BZ7I*JK*[<:;?G/,RM?[^)M<^U'08QFZK"-G
MHKZDCZ3HX\V^AZ]VQF6MWN,ZW<QS-?<H2]GZ7#]MH+U4GZ+K,&LW_;5YG*H
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M'%-.-U5Y/7;I;8O-6;V,KT<3,QN8RBFM%6*T5Y37%(KY42W316JJX
M %A"Y-0--C&C%B3R(RPW3(;,=,R. A4R\W&-0C:LT3)*.@>F;&FCAVR1#=P
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M04*E"I4H4*@%2@!4         H5!0H    "I4M*@H"H!0%2A4J
M  410)1%8FRJ*Q16:KE0%#I$%E"4S+H)IN5             "(32<VA-E"H
M                                                      * J
M            4* J5                                        (Q,
M,*@
M               R0EL%0
M                                 4-:#9,J4!BYE)0J"TQ S ' 8H9F
M=8Q4S,H"H* PTS(P\M+2,CT3'390H"@*$9$G Q8R@ N.H0&=XZ1YA,!G ,-.
M,&;E#S"+"9RA#QA!T#:@J6@PXZ1WS,#B, /1,S!K03*9D4*EY4
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M'0/1 /+/4!4N+"XX#E*%2A4N+3"#*#T"@*%Y0H7'&7%2T \4]TJ7
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ME[S1#+L]DSU%["=P"SB5E+9XJKIH)D-K0,=EANB"9J")=&SU<^G/WU\[6O\
M%7-<\US^M\^*^.N:Y];WKXJY_3XOUK]?3G_6M][46CR#-.UL4,*;..,A\HDH
MNQR4&SV(C&12M\CHC:JC8@R/Q@H'V]*8K0+J!C;ZQC<\"#M0N\]>&5!Y4<51
MM]M>GYO8[8W'C$W=&$WA5*1UM\$*=1A#-8$1>RN3FL)5-3(=Z.?]SV/L-(8M
M-@#,HQ/'-@E1;\I+I#D3CDT*EB_D<MF,B)LF<&.7JL58-BL@$I9R3)U)VTO(
MJT2F\M00O-3XHG&IM(B90(Y+.FOM<O6C--A(!)1>1R:6BS0965.\O].E,@91
M2/7/OY63:X?IG?\ ";M$+XVQR_0J-R>)Z"FZ,2Q<[->%7,HC&Q9Z*4:RK5\D
M3#'MF(Q'5LF*14V1V*/;QI_&AAEBYR=L[?:\>KC_ #"I&$;2,08AS(LNX@8A
M021U^-(NL(:.0?K@&JY\W&V9Q=UK42[M(X,W(*"X!@N)MKL.F*C\>8QUH6A8
M@R>,P8<6?.H*#7<#==#!;M>$C%QSF*C79(1 !0E^%#)A&U<T^*CQB?S.Y?7[
M7)R%-8B!04QPPPMQ;_4.I-?.\&Q$YME6MK?"J3Q<+-WEKVLM:KY8Y6?./R-]
M=[I1>-[5U#M6BD&CQYT$>B)M#6XT2>%&\)KIN*RJH).9-!)7;Z?:E#^PF9N/
MG)L[+M;&K2ZGQ0<.RD,@>MV>6P#K9LEL)R-%^3!]B@PHQ,L4-@Q!RX=3.-,W
MR\NCS8NWG,6<DTII&UR#G8419N24Z&C9*M-2:8-U-8TS>V_7TX],LL<+.):Q
MNK^3E9:F,6#,5+6M;_5-]1<G)80V)842)JN<&V>5KHN.*_/<5D5MA1\Y^-C&
M_P Q@*8I9HL]CM[%I+LS63.=-XS-3FLWT5.QF;N[5M37#+8\=TWL D5P^VXI
MQ_F%$HX$,+&@Y*+1S"+G\@R,5.D! 80>4D,&%/PT:!C3YZ+/8.;P<"P;Y"5@
M@4H'LPT'-LE'D4-J1\R*,X22\1D6,-7A)[\1/'X<*=OFC!'YB(%*M%LW^39L
MW:I<>SFOBHO.P@4H-E*11Q_IW%;!U+%IXW,B78,JBTRO5D,?A>8WQIRM>A(O
M\POJ&/X2.7T]CHU\8J7PT)-!(!X7@TC05P72K>8%<*Y%D&Y8;]H2DLY9OP$C
MF+XNTS-92[V<6KBN+4T9M&"/'I^GKQZ7I\28BT.['3-,XJQ37MZ6]?I3Z4BF
M2OQ2TM0P U'*NX\#(+MVZ#5#_3OUI55-)/92[6533%6Z6:C_ (I^0O>R6&:V
M0)D5(OM4Z\2UY'*X]+VM6X!B;:<:W=*O(14@$HG FB7ZKG7_ -GQ7%<4X_S#
MUX]W'M>/&K!#O1@W3",,VR]K>U9PDV3RE63W+L!0G3 8/&(^O/Z?;<USZWO5
MOI[?YM[KWJW])>I5O4EABR:[5V-G%NG@?@H3Z?M8D$G?2HCFNQZ3HCBG;I0$
M)JP?6D5@"-K>W=%L\9=JM2V<"HX:8@&&MB+)OLFWV=Z*2>7,24?E$K(%VC@N
MO+?V[U?.V-EI(N_4:1C#-?CVOR; 6AWLT7I**-EE,<,<,>*^E$I *$T,+$"*
MTHCIHF]$@7;//[*] I,^F!:WHE,)+&MU;'F<D([&D6Q1P(T,V-&",8G.U%B0
M>0;!9!"[S;D48PU3;+'#$5L!J:%P/<JA?7H/8S(J:V40'C8Z;V@*#2@GME);
M70O:^%X?&9XQD9'SB#4:D=F!FV1>< #^MI#M$S'9:!F(X^0ATN'S<%_0Y5"M
M01.(X\6]O'NROQ6UR3 V4 S*3ZLM&]BQZ2W>,&A%.1#FT>E.&6.>'MO>]2O8
M\8A]*]1UL<XWOB,%UDETUT_V.*XKBG'^8?L_S>_ZE9$T&9V!DCMT$$6Z7'KS
M1(T-$I_GI(:NQBXUJO;TSSQ3Q5EK5;/MDD+4- "1-<6K)5/"^"J>5ZGGY4M/
M+?3V<T\>M6#<YU Q]BJVZCF^3B+3B/3!O[MJZO6V!<6-8AQOH'B.)N13"!8Q
MT"Y5?P'9B\%E$I@DUE)J<AI5'4A&SGD:>Y:PV0Y.MYEIT&4%2IE')"1T]%1P
M0E.-RCGY2(#![]/= N-G'4;*,7\BB^O1@Q2:P@05::SL&;I1.[6;E=*R[ H%
MD.Y[&HX> AFD>"?M\^M_=S7/[G'L?/FPYM%9-E)T+>\P/F\V,3J/!HN\;9,C
M8S9&N1(P="32AZ./&;8@U12301]NSYG\G '"JSE9X->C[7M6D9ZN.*6^G[#^
M6S-F2 2N3$2[1X2=R_\ 9=NV[)#\^9DMQ00>(2]A,V-#X?F),<H9'!@U3CT?
ME!XM'OAHK6,4P>9(HHH)WO;&G4L'8*BU)"NO((#WPP(B(@5Z$4Q_E+VWO6UI
MTO+#34:^(WRM0PD_"D(/*F\PCG[/%<5Q7%JXMZ<5Q:N+>G%<6KBN+5Q7%JXK
MBWIQ:G4"'/YG^V99S*>]2.L)#.85NY[U.P1LIOG>[R,P[8L[@$UUS/\ :$3U
MH/@VY8K.BSKJCUXU6>;W %=4].NX3.Q@VXIE:":WZ<I--1$LM^]>I:K>129%
M%)!+WWM6WUF=:T=?F8H698$QFM9<*C8AMM.,.G&-[7Q]N_7*ZDFO:HR5;DD#
MP=<"7:N5V#O'Z>YT[;,D!AD2:2]%_P#+_?S1:1(L%6L?</U[6M[")@>(2_-R
M,[0R.#1F?H2D@H8I\<K,T/C IBK3TBQ&HWD1$E5HRY(7:M&K)+]*=&A#)1L?
M#.W-.UR>&W+?3V2QTLRC&5J'$7P=^?%,3@&]JZ<G*V;;]DSM*# ",IW+'XM+
M9!L.)QEY,]R1N,PAY+F)+,KMN !GP8R+D(O[DG 1VQNJF+:=AFF1#*9I%=/3
M9%97HWZB9*!E6INI%$H,VE&/R9K?G3'AA\Z].S;-;5O2+)03C6O4WF6GLPG3
M+;^L9PDI@LE^Z7,,0K6*G1:1;\],#N38(::+V]STD:)N9)"FF43T^91<MJ)0
M*'ER1J/LBP46TS8#_;OT&I9U?&FA@=%A.7-[Q4$K))'C]/=.&6+P!!+X/ATG
ME!P,8C\OD1,LS(NR$N]V6>.%LRQ"19B0K$.EZOG[,:AW4V;H9&V+!:OI3J6,
ML5NVR(Q0P,,$)_2G\G%,%?CEA>F,5%-%OX*%Q01K\_/S5X^-EJ3HO"!1DD.#
M#AC:I&N_^?K?3V%V&!46\9N&+H(V#N'\DD*QY:]JT #5'QVWT_8E16.Q\N9.
M)@S$EEK9CLYLF^7T%,3X:3E=:I)6G>@K6QUE]RC&XZW,TG!80DX1 @VPGQ]
MK#R P:6:!(K%XUB,CH (L'CL?CV ^*Q<21M&X[8R7!!)"T000:H?M7OQ6<F!
M)XG=HC&=,(/()<Z'"AHE#V YB:(/C\_(B)"B=D2$O5/E/BQ*2]6^64[4OKMH
M]&3CTX]YP.R/C)AKL_$5;VH6$*G'>L=;XPI"WOE6*><:U(WQ;Q[]*XIQ_F'K
MSZ%"S(.UQ'$9/DDFFEAZ*JIHX9R)X6NRC+?!Q2JR2&&4HR?9?+CTG35HU9(K
MN6[5+*5?G;]B+DZ'"1HM&_&-$-D1MLY^'9<BH7KF,L'5Z_$P^,Y/ X(F-DZQ
M-6C^;4KM7&WPX^SBU;0U>M(EGK%VP<96J#:G-2=PT:MV37]CBN*X]./3BN/[
M&]J;ZJB"=A,8  [^EO6]-8&V9NE *#DE'H@K'W_'H2>HCF.LQF2K_P#9O7%K
MTO#XHY6:,63!'C]B6I.W '73,@-:2J7/H\1C\X)ES#,IF2E_K>C!](;F+ JV
M=>F5Z?29'!?".."6>&&.&+MZT8(7D)$K245P=9XX8)8DY *$W_/2<O2$3875
MMC;&CTMC<8PM*IB?M;7JIBXX8-$MGA%B.2^:;O:[;)R-#(^*$YFBT3:.ATA!
M.EN+5=!&ZOO?BAI1-G%HT/7XM^PO(!Z1>KWJ52\=$4N:VCM##6S=!PDY0YKF
MBKXPT=_K0)^8?M.?Z[BU<5Q7'NXKBWJ4-L U3DN,>1#7'X7:?M3JJZ ;4A4X
M6"UQ:G'^8>G-$CCIPZ# VPC#T*G1XBWY,[(:8#V(QN_*#Q2/=SIFFD698K99
M8)8K2ULKGVR2E:& A0BSU\Q&M\MD($\OE^=R&@,*BT;R>/F3!+YLQ=W_ ",J
M)4TC -EFXEH5)3\>7$Z%A<V*Y2*AC#IDS8,D/LMJS.;PBH1%;Q@95_KMO31)
MVYA4.^2Q[\U(Y'LV%ORA;1\3%-H3.M?Z\@LNBHLJ3.1B&1 $<V>C_P#KY)H2
M B(W^[(Q&,%<(#DN DUOM9&JL@!U*N3<YRF6N8ZZC\]>F"[4K@3EU7OQ3HF]
MD#@8+9"6E+N$6J5S!4_<3'V(S(B7&B4OS\C-4PC(UDL1,#!"=S!\I6$42=98
M)HMDG^R(RU<_B;.D%,M:1S!P[?#QJ/S79W?\E*R--HL#9*+RX*EG^8EI*^,2
M;N:M88);9R]BMD,7/N%Y)#GAPH'B8T7]N4Z<-,&24*U]$-=CP$;"Q=EG!HHJ
M\!ZSA<=)Q+28!X,=Q<"_R&Q\0(?8P:+81XE%P1=G_5_K^T\>-1[?YW>D:^8)
MZC0B8B"SOTO6">+_ &5]K+WWY"/ZJ&.QJ/HX_P ORSMC95RZEZK1HW8M[WXH
ME(T&BR$=<$E21D6'3_,R8Y0Z.#!BCB5CL5;M946H='1 O,Y.8K'5/F&>'J\=
MV*WMG&HHRO*%G=^W2DC24=CHJLI>,4O\4Q)5C$6*^2[P( 0O*<G=6:2TC3>'
MAL,\<,$\>:?R:/BG+$\,(.?](O1HX-CS%Y(A \.FK@JES7Q6KFL# U5 269F
MQ_-J^+T553;IB&=YDK7%J,!1QQI'BK[%[4S/9  NN1EOR?VLW#)'@D$9Y"0\
MIEN<;< -@K&2S<VP)2N^2\S421202?/V@UM^.<DM?''8@UNXDIRDV,=C&/?B
MQ.K1=5_<G(8A#F_SG)#=?)<B-4S2@4(Q[\9?UV8^_M=M#(SG\RN'5?D98_I*
M(@T\UI3'&5^[R-];L1M]3&,@QV>6:2>*\OCJ&5I$2=7_  9F\H:'79+&X@&/
MN4D$4[?Z3N3_  F79.X@"EI,\X-9FI:TC:."@RF:QME(H",S9H#"Q8>#?2.2
M8@HAG)A<IK8E[N1"F>#=&+R@^]>$2LC:RR%SDF=-33_@$:WJX),\!5FF(W[6
M9XL?EG4S9RR3^'&OAM1\4D9E&.&*>!.18-UU6S$<I^9D9NF[F,!'/P2PK3MS
M 88I\['R].([)R. 9/7\>SN\EKZG8ELGBQ+Q=A:[J8/:^6W3NL%X-'%/F5XZ
MK\O,7U6B Q2KE8J"Q^;D%ZN\F#NNR'W=DX8"Y;LVC3#BW^G&@@R0,C<<"R-H
M8B@ ^WDNNFC@!'=9J-WP_7T1&.,(;&TB5XC'K@;1L'8*"A<:C:U3W_CY?I>A
MT":"Z;A6K8PQR$B9+L+_ )#6C(AF<'0,LK@Y^UFV;'Y<UDT(LQE9R9CA(BIX
M.-ESV>#S"K*5A[(-)3&V[DM.8NG=ML)ZH@[-CGM!BT3"6<S,>I2$CA>6>,QR
M4I4U&\K)RS6@Y3R.DO;YGQ<TX*Z\3IKL*',;Y3Y5Q7?VKBL5]=YTS/Z['5\\
M1&OGF(U\\1*OGF(U\]1&OGF)5\\Q&F$G %7'^ER>2LXJ*$SY,JX8;59DK/\
M9C!D5CDB'2@;[./0X(:'Q,6,.GC?T*BQQ=H&)NOF"IS,$8F/U?&GHU-+/!5/
M[0X"&2%J,#"0R578,;O<DT[W;B&S8E^"E7X*-J;AVS<G^ C7X*5(AVR!2R*-
M711I(,V2+?@I5^"C6 AK@6LBE7X*-6#-K%_P$:_!2KL[;N_X*-?@HU<,VN8L
MBC7X*-9!FV1BR*-711I82W5*?Z7N3_!QP:4,6FK@\G7CK,2?*3F 20>&CCJ=
M-&XD<[S?-/:=CC0W7<-A!Z^;)8M5H]()%?-!%1 R3MJQD*>'I]+NQ$2U\,<<
M,?N""+EPS7A4G<.:RYX$0V4#RMO0/")*P>6J]"(7)&!2KT,@TI9NK?2FL*DZ
M!2U7IQ""G=K5>G<+)W.>EX)*;O[4OCEFD(@4M'YCT%VK'_2GH]B20NBG?!DP
M9#FZ(T>U<%HPJ@3( Y"6BML>+?L\6I9N@Y3QPQQM]TNJFW2:;#B;L$Q."23B
MN/=QZ\6]>/7BOI[>+?[X=$HG1,@U!;-2*Z^$Q(E;Z?ZB;FD/C3CRQJVO+&K*
M\L:LKRQJRO+&K*\L:LKRQJRO+&K*\L:LKRQJRO+&K*\L:LKRQJRO+&K*\L:L
MKRQJRO+&K*\L:LKRQJRO+&K*\L:LKRQJRO+&K*\L:LKRQJRO+&K*\L:LKRQJ
MRO+&K*\L:LKRQJRO+&K*\L:LKRQJRO+&K*\L:LKRQJRO+&K*\L:LKRQJRO+&
MK*\L:LKRQJRO+&K*\L:LKRQJRO+&K*\L:LKRQJRO+&K*\L:LKRQJRO+&K*\L
M:LKRQJRO+&K*\L:LKRQJRO+&K*\L:LKRQJRO+&K*\L:LKRQJRO*^JZ\L:LKR
MQJRO+&K*\L:LKRQJRO+&K*\L:LKRQJRO+&K*\L:LKRQJRO+&K*\L:LKRQJRO
M+&K*\L:LKRQJRO+&K*\L:LKRQJRO+&K*\L:LKRQJRO+&K*\L:LKRQJRO+&K*
M\L:LKRQJRO+&K*\L:LKRQJRO+&K*\L:LKRQJRO+&K*\L:LKRQJRO+&K*\L:L
MKRQJRO+&K*\L:LKRQJRO+&K*\L:LKRQJRO+&K*\L:LKRQJRO+&K*\L:LKRQJ
MRO+&K*\L:LKRQJRO+&K*\L:LKRQJRO+&K*\L:LKRQJRO+&K*\L:LKRQJRO+&
MK*\L:LKRQJRO+&K*\L:LKRQJRO+&K*\L:LKRQJRO+&K*\L:LKRQJRO+&K*\L
M:LKRQJRO+&K*\L:LIEL. D_^E>/_ ."+W]>:YKFN:Y].??S[^?Z/9VQL(..Q
MW!LFUO,6QZ\P['I7<VQL+)[DV7>H5N63N9\9."P#%3>44M93J $HJ )('DS#
M[N]Z\JB/BC<Y'R=X-,YOGE;==RX$#1F#R(X&=N_!4@V.RC[I"6OWVR]@2$^U
MFD5V/+"APGM 2)('-F!PI,)L80=)>5 60F+RL=+1R$_-AP#;95X^P=[$62FB
M$^%KV([C!C5A^T +PB"V<'.%([)!TG96^GW3HX&8NXL8*3AUZ"9NA$MM1R5)
M2SJ! 3D'&X0&ETW?SV S"51^*@3+21@QT_#P_7;+8D@1E<+F&QRNRU]NF%69
MO:*[4Q&-AN2;B-[/D!] O)%Q P/LB3#8_P#..2L_E<[?!I+L78\[9ZU*2^4A
MP@^>R)T2CLSD4AT(7V&\!%(7.7\B*??WO1:2OI@5X],\K86M:^5R))H(:15=
M<N7D)PEDEKO2\CF022ZBFD33CDB>A5+;CE 3!/?\'43!39QLA)LGB@A;[C,<
M/4LDS:(9L_\ *ZV-'7LLB!J(25O(KZS.#@<LUM*3Y,=!#HN12""8R&;2:%.U
MB)W5,L+Y2>)RD0YBD2DJH^VHC6(* QI[&QDNUH0/S(S"98W-+ZD?MW & SAN
M_>ZZ-.(^=UX[.G8?K4Z%+QQ*0I,;>_FOU^SV9JX'LYJ@@BW1](9'#(K8"T<,
MY;ID$>."=>PU4S&9]$(H?%Z]UX+?@H%GK^77UM+X^7)SH.)DX#:K369.,L$X
MB9;3P9'I$TV$A!I(N=2@Y]TDF!,233>A[%34;V0%?&7>6NIN[U%.6,UE8Z P
M0H&V8(B4Z0TE\LF_($?CY=CLZWW^5K4%RY9U]*O>ZN1$N/$IDG#XV[CJ:B"*
MPA%VGK.:(S&/VK8NHD":D"V3G'6CF8-)&^-P27E\P$ME45>#M@.4L+9<X_;<
M^C/_ "NE'+?!:4RP9$V%ML1JP0/L$ 4"X3 6K(/BMQ\>-?%C5\K5;+"OCQKX
ML;4N<&-BKG8#!D,^*WI;B]<5Q:OAM[>:(%6(IL*)N2EBD'E+LB.!MQSK[B1Q
M@#+1X+7T3CI'CTOZ\>V41,%,Q;5JV9-N*XKBU<5Q_197IV#*PMY^?8VIZ=;X
MT\+$%\;HY*TS'_HFNGA7*V=X1*"<2(C'R10;Q6S]9YGZT[*[,WG\$1@XLU+:
M7R9KC)Y-8<;M^MJD$E>#7Y>:MF$>SVG\0]HXP>-?W[TY@!C)U&X<8#.@+1RS
MD=3Y@@3SDH(D"BEVI19PY&HRX&$!P^1274&6=]?#.S9!#2+A0X/!-B^THIV#
M\2,HJW-&03!<)+A<?1V*KREJ\G;-T60^/\'W7K-3'#%20NRN8Z-MV[C[6] I
M,^F!:U7O4EG3".D45T7">XG<M-F<=E TH)'9ZT/F+;N"KMC4GCQ)5+:0AW+A
MNPHQ%8,*V@-(2+^LO4EBP"6C]EZ-,PM.]OBK).DD_A4<$4DL!]ZS<-\;144[
MDYMHU19M:RI\89DY2((8%!GI( ;&1"8&36=B'Y%D+;/A><IS<PM2[/+78QR&
MM]FS_P KKBOAQKX,>/AQX^'&U96MQ&(RQBPGX,*^&U?!A7X>%?!C7P8WKX,:
M_#PKCW7O1&2MVCC&/O2^222::?VVU=7K; N+&L0XWTF6H(M)#0L4*!L8_KT[
M-#PJ-OXQ&-<]^3F6O)V[C<:8PN0QX#K\<09R_./2"^JYL.(.]A6^G]7>_%+[
M7@Z-I!M0HP-294#W')5+*RG-[?!9&D+6Y;XYNG6EM3>/AUOH[>-F"+X\:G+R
M1:2'IC([.)/&+-S4C(B!KW D/I\3,QK;["+LV[JN*XM]C>_%8;'C*MA<R F,
MQ#YF_DWVGTHH:'AT;X2&14-%#Q*'%6]>?N>/7^8K%1\18<6]>/ZW+]:0Z?9P
M]H3TR!$E@FI=<1_'M(O\E-NF=!;,OIW8(- -KJ5FLM=NH?$< D7=-7%OH5$L
M33)LU8"62DE,'E1(,NWV#/@^2*,;-)G!5;*B;N2"$/Q<D?M,X7%E,V$: C%A
MC=!M*/LUETFZ>1TD<N+CC,>KQ[,U+86%G&QBY07LM0@/%O6C[[*][U:4-G,@
MKFIS,_DQ#FLI9MD_.1^Y5&D26+[\8LI/LHHFRCIS9C22,=Q.$XZ9F,\#,HO+
MY-A+M<2\E+VG]7?VKND&J4E?K[)EC%@S&,R\;DK T'*M30^WTHV%:'6DF,M(
MV-UD%_":9X6RQ@F=P$F_:?$&0UNIN+7*68*9QB35;]QG_E?V-Z(25))PE''!
M)6V-L;>PJ98AD;#"<ES32323]7$GF36>^\Y/HA'%6NWM>/%V[I!VC[MJK;48
M7A\79Q$%7\[6U]H)V4U>"U?'PXF&KRK;.P]>LX=KUYMS736.3$]#3P,"\^5-
MEQP69CS^=/8=*6\3:$2N\M&7_P#3+?3^LO?BC4WCX+'/:1Z1K8 RT@5AP>+A
MV%)C$47<:;.8X?MZ7_2BS3*6S['#'#&DU\<=PU(3!5L27G#K*%BYU()!< 6P
M/ _9+I.SB(23RDW+'U[4DHJV5T[L]Q(;_P ?L2(_,F1^.'9F]< ')!S(OW^:
M*FV =/\ +GY'0\:P%MZX];Y<4ZD:[]87'463BU<TZF4<8NQQ\<46J(1S )LG
MVW^NW-GO47E[5>U0N>FX2^"F&)T7;]EUK'6SYR%CD>C3=N,&M'5)02$-RA :
M.+,PD5C$:LQ%C1F/RA$^U" 86/LV(P:,Q^UF'4I#8;+M:;Q@VTUN:EDRC<'%
MSR<&HN)YOZ<T]?-AS*+RP!-!.T-T1K4ZL)ZC]?3>0_M7HE*@0NT@V&;E3\SJ
M \R1B9P$4&Y(H*4DW;HWJ_%<6],K\6-;")'7S-F=U_(!99H7:5*V"HO9ZBR:
M*.?Y":N6,;;"QKJ$C,FP]BU&,?9U %5E"W%#4QLR'NFCADX!%EP!JWT]_/IQ
M3/\ RO\ >7<(M4KFBAVXJ.L1JGM*GF BK##$ANU;-VB%%9"W'JAT"^%B<1#%
M\\4DL;WJ!/!:NQ+?3V'R&0D*OFJNJ!+8!2$CC*#-O>U=/!9=R'M[G)1BT=>A
MR2!HWA1/<+5E)(?,0TX#<USZ<US7-<T!E3"0OJ2-?BGN>:YISLV.-=A?K2RM
MT4@1;O@A>5,&\L_;)RXC"NJK6@*=2_=9.5/G0;=3DQ-^G_;R$FUCJGJ+V:2C
MTCUAM5!AMS7@_9&T)#KPG*]D:)Z0HNNWA'5BJ0;S&4%Y=Y>M]/V<_P!;"=&*
MJ*A8^%CK7X;47@@UZXR*S"(9ASXXVA[-IG5!86#1O&,1LV%'GV"; _!#:2F"
MR>ST+]O!@U9 /M:W'%<>[?@];"07M0L8PC# J2?&7XX>J4)6^GNV.H00'1%%
MG@._6OBIG_E?[E[T_DV";A&.+/U<;6M;V/7[0<AW$Y(*$@!XKT=O&K%#\\9D
MEQ04>(2]$UDE?2/G6V.S?;)62Q,!>W%! 3Z0$#QUBW'7M73LP52'V^GLV?M&
M^L+P:-OQR-<_KNF)[-3<0H++P8\2&FY7;(F3%]=ZY',=@!C D$5FLS;I2PAH
MZ2J')!L(>2,P&5CU=F/(JL@1GVSF!HYK^(RL47U<*?20H(V,"C1-S"%W*+1L
MYE^;^*S:1.Y*X%@<XF6%FY'((8QCZ\=WG^V#U5(1F_#@I$\%$:.W0)@1/1)8
MUH.::@VU/M=[6U47EQ6)0W<CB9Z=U<?U^?T_ITS"(OH[7.QM7I;YU+--C%7>
MB]Q[%-8_3]F]N:X]G%J-L&T>/XWM>WI_,X5_%G?I/76*8J*2M)D E F\CCT+
ME)5GC;]B=Q1&8 2HDB&>96YJ]JTQKIXQ<V]^ST[JPJ NL7L9D,&>F3<<@[D(
MY ,+#)'^V5-, Z7Y8_(J8#6(MO5O559)##*1/"MV481LYMZ.9/\ F%VD:_'7
MXHH:'AT1#TB_L4UP0?O6((</=5'R;PG-O;>U;<U\Z&$K\UE:HW%B\K)1T$SC
M02WZ>U9NW<>MZ)Z1[H1A4-^2F!/3S1[) >L8F$CPS40IB\"Q4>")HZW!M]?2
M^$*F=D177P>,*):1CN*$CUL//'@.K(H!%#]2"FSM.)"\)2AI&-)8R8"A*8\T
M%LF0G#4,;QB$?UR+ NU]3QU:( ]7" DHM^WQ;TXKBN+>G%<>G%<6^R+#&I=I
MB]E$8R#G1QM&WH4BRA"4VK+.V%CK]W+#;=HW;M&L>$!',=F.)UTUGB+J0 I*
MZ+%?=>UKT=C0.2(+Z(B"RL>U?#HXK:UOV-GN$/EN!$T'X6N*9_Y7^QS2SA-N
MGD;)GKBHZR'*>O-**X(X9R=5_DG&+OE,,,<+?I1"3,F:_9BQR[9JV9(O2#,:
MAW4V<N*CK$:I2\PC350>?%DUZ&0N/AS-O=?&UZ-ZAA1C-GHN&MUQ(44#:>]9
MR@A?T?$QPRWZ4;W1KF.FHS*P<R&UQ7-N0<@$25K2ZN#=)O/(HZ95QZ\>O%<5
MQ_47M7P\T9C2JCQ'\3\+TO4[E2[LS$XQ<(G:ET4W"0:'FA>3""+LY%' ?8V/
MV4R*JA(Y"#JTCCI69!0Y$7-P1>X(HQ+2/W\_J2DJ+=PE'7!)2V-K6MZN'"#1
M*\E=$KIQB[[/!--/&]$)./9K]MD)NAXQ@*0?D6(Q#O)LS3&+LT7%\L<+.]@7
M).(V*.L,'<$C;]Y@BCA]G.]HQS7*T*%&'JGINGS9^8A7D+MXB0RP+METX/F8
M@!F\Z!:[%3&=,36O09Y+<#V?S>VKC"VUH],XT9EPN7/R\GE,3'DYE$]B);,F
MTB& "#@L#_M+U,8X5 2Z&R+YH!V^WV"M@A%-4N\L@+V/ R2K$"&&+L[?^Z_9
MS7-$S+ 0A\!^1T-&,!3?U(F!HE*Y@\6IO%&RBN.-K6SRQPLO+6RBG9SA>F T
M>*1)GQ0BOSDF,TQBX]JNNX;M$<]B=VSM!24ANV;M![9F6'$5#4BG#8B+QDEG
M/V1J/ Y&EQZ7^LBUAM4\0A827 Q[K6DW;3"3:YF\LAUH0>,@F$ F.;IK""(R
M?WU+\4/-Q/O$JM#/AF2NGUKQ0! 32$I\5R0<V'LDAK#^PD)0Q@6<S=[E!!TR
MDYS  4L<!45)LQ#2!9J9(_;["43O&M2Y*_)_HS_RSV9J8IXYR!Z8S%QQJP6]
M+WXIW+!2"OX<K+4.C0D<K^E$38D3CWLX4K&*_G+VLR8-U):U7R[;)BU#00H3
M1V;1>.9=_GDBI#6[!TL]+!@27?3!*K1=0A=LV;M$G<NCK%PQ.BR+C[.]_P!C
MBN*X]_-<\US7ZUS7/]!S7-?QZ\_KS[#D=:',E(4&S99Z^"9-G+IU'L!QT251
M:.74^-CQ[,8T^WVF&/F1T9Q6Q#24E+&I..$YT[<@<RF<D].:*2-JP5Q OS62
M2>"6%$3HD17>SA*OEA9_3-DS8(OBXP9A\SKO:[5)"5F0($%I68"/B_%EY*Z4
M1'YJ%)S"XW?YOEIB_P GR4U8>GKR%5WXT^KLATA9A'P@J[J6 &N?=I(0H6S(
MMK$(=&2+UO=CGE;Z?8NC@9B[BQ@I.'57O4SW=$HT="G!$C';>"O-ER8;LT7X
MJM-MAY2@OMZ49QI]L24,I:]V.==&'>WV:D>!RXFY1C>SY ?05G(J(.C$PN.E
MBVW3"K)N1:F 8%GKY/4&Z%02\*BOC_R;U)?@>(KHZ<<'I%M%A#R81T2?"/O/
MYVR]>L(>4F)52!&IUV.Z6SF^89M-3]RS?8A.Y*(2J4EF\4F?Y9@YV:V:XQR>
MYES'-%)&Z_._)YLA7R&HWJQL_&LI3$QLF'P ZK%GN&6.>'V\_P 7>(36#UR_
MB]<6IG_E=/R+(:A^8.R2A8@>(2(&A(JWS(0?W[,>(V9A@ /%28@,,N[25[:X
M0T]K&\#CZWS,[=5=O+GM/G^LQ*J4]P<8+N]EO,5149>W#XLQ"?X$Q>4Z# D*
M9GX@/PL;/.J_*2]Y3@%'&]-I)$F.'?S+FA>1K*QG75C!-H$%,G?V6S-7 ]G-
M4$$6Z/I)(OC('_\  33 V3D2T7?:_@ V\A@\A"B98K$(HU>E]@/->. <H<1>
M1LX+K6*2:/9(0>2.#@.$NER&HHA-1S]IK,E&F P>HPC\#6W!$-?WUC(A$2K<
M\<,RN [=C)<Z#FD!D>Q#4;>&7X+[R]3^.O91'=A:Z5E2<F@CTB\E$>(@HH 0
M>GD1>O3K<R'B,@$NKP$I>"9:W4<0J*0\PP,2TRZ$"08=J!'>F>."F$;RS &I
MP+8O8_!'UWT<^WV>EAG%M;K(N(U21%BLZ:?Y4[DBKE:[J,BWB\[NI:Y;$C9H
MNR%TXE[ZEY8"SME,M8M[Y;GCJ=L]KMW6>4P;/*;RN0HUF5/O*S&1EW3)PS%8
MJDTLZ[E'$<DIM:E)6FI5RH-2Z!@,UI*4$EZS(/%;62%K4W3&-:P,F^.ZRN]#
M%BZU%(43?'1  >$^YXHR%$R$8)UA"@Q&^FM<7K!/!/#V\6KBU<5Q7']'>]J^
M*U?%C5[X5:V/I:N+>G%'O^1L"6KN5"4=(V*09NRE[F.B90"< MDR!I&B*+>?
M[(8  S8 )^WE$8<2)V)'YC&5,8TR'FGD,!/G(S70E)+Q?">,-:P]"[#70G\2
M^JX)E?+4NO[T.T]#L%L-50/"O%\(IAJR.8.?%L'KQ="*8ZLC:;R^LH;G7BZ$
M4RU9&\'WC"$UXNA%--61K EAKF)IU\BQZU-H*TL3^2 5?) &D((SL5^1P%?(
MP"@\=R#&?M6,KR.G_0%-W^$OT5-BD\"HJ;'F&PX=*98/FFL-ERA_-LMG24KN
M\9, Y>23R526TC_([?B+V1R0TPVGNR0G8OKN1/=D:Q<;ME.RHY'1#A5T*V%N
MF.1;(+(X_)4&\@FL[FQ2=32&Z[5C6\6C&6S*3LF<G&'"XW6>.T) 8D2FZ&,>
M^>3CZ9?=?SN7](/%1<5Q6@8R+/6A1N%6FVI_Q[0_XJM^OLF?_II5^+'%FMP@
M:^!,('-)Y-6V:.P(($E1W3I[OD0^\-.2;1@U,3I8U:GZKE!I%#$V>/[?0IF[
M2&QDQ-7I*U$<W2;&+FID])6H@H[291PW.G9"U.LE\&T8.3EX2K/X[XB",Z[S
M;Z9<\"2,VL>I?+/!($=V*Z5M4A<$V@4<?V-G;#GX?L]JQ>?FKQP -BX/TU]_
MY2Z?O_#XG8\(@FV8FX4V'M:*PI.<0LE'1T2V,,EX8O(Y]DXANQ9=(X_L<EM*
M2@HCMG<&P8/L'5(+36MXZ5WG_P"(0/\ ^#VM)^G0@5U@=U@?#3*3:A,$V0*7
M'=72G;.KI4QEER$(@<7VMKV:$=-?_?&]R:ZV4<,D1QC;?W7\S.,WEH+-K^(Q
MA\=^50(>*]ID#J+L8L0,CP+N #F+,8RMZD6+,HQ8G%HNIZ&I.@P<AHVBQ&B
MXP"P^\5SP2PLJGDGSZ<>O'KQ;UXMZ\6]./9Q]_Q;TXKBN*XKBU<5Q7'KQ;V<
M6]G%JXMZ<6^\XKBN/3X;5\-JX]KALW=H>/63.OD9ZXH* #1YKQ7'WLW"$)(
M<Q::CBVMX[*(Z._Z3XKC_4S;J8H..Y;3KN.TZ[CM.NX[3KN.TZ[CM.NX[3KN
M.TZ[CM.NX[3KN.TZ[CM.NX[3KN.TZ[CM.NX[3KN.TZ[CM.NX[3KN.TZ[CM.N
MX[3KN.TZ[CM.NX[3KN.TZ[CM.NX[3KN.TZ[CM.NX[3KN.TZ[CM.NX[3KN.TZ
M[CM.NX[3KN.TZ[CM.NX[3KN.TZ[CM.NX[3KN.TZ[CM.NX[3KN.TZ[CM.NX[3
MKN.TZ[CM.NX[3KN.TZ[CM.NX[3KN.TZ[CM.NX[3KN.TZ[CM.NX[3KN.TZ[CM
M.NX[3KN.TZ[CM.NX[3KN.TZ[CM.NX[3KN.TZ[CM.NX[3KN.TZ[CM.NX[3KN.
MTZ[CM.NX[3KN.TZ[CM.NX[3KN.TZ[CM.NX[3KN.TZ[CM.NX[3KN.TZ[CM.NX
M[3KN.TZ[CM.NX[3KN.TZ[CM.NX[3KN.TZ[CM.NX[3KN.TZ[CM.NX[3KN.TZ[
MCM.NX[3KN.TZ[CM.NX[3KN.TZ[CM.NX[3KN.TZ[CM.NX[3KN.TZ[CM.NX[3K
MN.TZ[CM.NX[3KN.TZ[CM.NX[3KN.TZ[CM.NX[3KN.TZ[CM.NX[3KN.TZ[CM.
MNX[3KN.TZ[CM.NX[3KN.TZ[CM.NX[3KN.TZ[CM.NX[3KN.TZ[CM.NX[3KN.T
MZ[CM.A[V=*?]+.]N05C(.;US7-?K1(X*$9\US>N:YKFBLA#!!_-<_HFLDM@>
MD(F,C>:5630P3D(E0_S7-<US7-<US3&0B"17FLY"%2+82$2H?D$C"Q86+VE"
M#8R(;'B4\I/;^NE3WIS7-?K7-ZD\TC,-PYKFF9L60(<WKFN;US2[A%J@5VM
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M3UOY.[5T&7J7T,Y-GS\)"@REMU7:2%BZDI*<TD',Y]T2^V= FYWS!N="WP5
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M8%0K]6>6B28-+E56PSJ[.J<'4,^KWWOES$2FS$@TZ)B=4NH3F7IG"0+]0W?
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MNU]1^CFE4B55I..6<6^GN:5V/:?\T4[9B0DU><.I\XGCVYATE=SU"5$I3_A
MRR,"^$)+8 \!E[!IX1<-@E1 3W_B8GMIJ7(G=+=+DPK)MAI"G25:6NBX&?4B
M K:>M+(W?T-)^HO)YQT9\LL&G.RA?*\2.SM.EW/.7T%Z;/;==4I>.W,(/"/
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MDJ8&]1-$#)%LT8O;=7NBFU3=E2DG&%E !Z9V-HIU7DJ;*,N2KB79Q]'I'?\
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M+*US6HB-EIZ4>6$S;VX0SQ YJ+W\ MD"=+JL!UY$;0IFR&$>A98R;92;A/\
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MZJT%+O\ =*2/LACR2[#8U3 IRBIUQ:U+4\Z4K4I1)X<0MG%+V8HM$LFG2+#
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M2FR$HE:9FIJ74IK7?N+6A -R<F;X+9YBQA##+  890,.7" G(?/2\8"]VE6
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MIQ%7*X2K)(UR3KSBH5NF4U!WLP&1T2G&H\K!*;G7+N]D?2&T%;)9IS'T;)6
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MH(Y?)CR@RYF1()4DJETN8G$CG923R]D4\M.2C"Y:R6U--@)%N2 .[/D8MA&
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M4E1]UX<VMIY6J4D%/5!]'J)8<0DDY]M0 \<X54=IIRZ!*-TEHZ3"W6WE6/\
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MKD2LTMIV51D$X@VI]1 Y9%6G.U[V@9**%:G[H M^@MS@J2.8[SH/$Z0V-\>
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ME%SZ$F'\$ZPDG=A*S@ (N0GM$Y<Q<$X<J?-,SDJW.L+#C,PTVXA7M2#]\?\
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M2EN7:0VT@ )2D#\!&,)[>%N^A*A8_<(J->IM*N9V:2%'LMMI+BO_ -841?O
MCZ>KE0X:71RF77;#//.)19)];<JLHCO'+D(1LO-3QQ5JI.S:202RE)EVT]1Z
M,Y]QR/OB6ILE3&\,NRTVV+9G"=.94>+Q.<3U?I%.1BFYE#:?X 7%?Y4!2O<(
M5M4_.G=T.FO3R57 ?652Z1T-W0+]XR[H%)VAJ?\ [1JOFC!M>09:3=(MF/.
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M;2O@+Q+US920PL2(6\\.%(\T>63<Z8EH-_$P:[7CPT_9W&TK1]<PVSA[RVH
M^$%G:>=40[6&:;]9E#3;EKYVWBR#?O!AZCT '>5J<7,O-C-SSAQ-SK?=MK'N
M%[PS7-G)();IP+I[*4B565>*U(%_;>%;0UU1P26SRYALC)Q3Z&+#^X1\+Q2%
MU)TN"HL)E\AA92O'AO\ Q:>[X0VI6):?5'9A-R,]<_W)*PBW#?%ZWLC;6@.5
M^CKE&'<"R]+N E-Q9MP*/7EW1MOY/$;1,R#LA:7J,IYN'W!B"7DHP 8P,E%
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M[6+W$$0VVS*_[+LN\[;3&^I1_P#V8X9JE:2FS.R"</?-,H^U%H%:VH3DC94
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MQ!S/A>!3I9:,-L21_#A5XJU,.;.TA;BGIB70XI=NWG;+E#-$I#%U"61_#<7
M\/Y09"24G_9VE)Z[I(/P3>!2Z=>X9MXF!3I3U66U>VQ^V/,6/7EF GN;1_\
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M6ED*B]@7:W)Q[VD$V%K$>>UK8[;9%-V=K)>WW9JIBI,RA53G%#43=U1YY1Q
M7$\KLL=+54D(8TM:01'^AG+4[,(^R6?IVER*ASJ.*:&.MB$B+/&T,NVS:D;U
M!TNA>*5;2P221,DC9U24>9Y/F%'6TXE@FHZI7ADW5P87!!]#U\\-9I'0=#=O
MKW']1+ 6%KG%NNJWI@*QY\('ER?ABBRN6H1JF>U+11VUU,G')'@4V,K&Q\*7
MZ7MP9\TAHT:#*P\",+-.2._EM^T/T0Y-EL>OAN0?THUMSYG%C[U[G[,$CZ6
M0W'^!Q1T-57.(Z6%YC](VT!=B;LS64#8VN1?I<[86+)LI57K'_*U2+EJ2!FC
MIXC]'7.!>8V-[1BP8%'VW-9GM=6VA5.YI![M/"%AB4;'W1XGW&H:V8@DZ;7M
M@WW&X\FYOZ;XMJZ:L4F1U=8#+%\Q"@U23S,L<(&_+2;GBWS:O8VU6Q;(\L\;
M YO..0MZ>!""/I6+RVL;$'NV7:V*K.ZZHB6",B*D&K33TX$*(#[P-O$X8WN'
M9MR?/&N_-U^TW\\4U'55K".F@>1FL-(&PZ7+GP@>K$+YG'Y'IJ#?-:Q8Y/\
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MPL8J=/+546U2#J.[%K@JP/)JLZS"NTTT(%/1@D"G@3NX@"1T7QRW;?QEM[D
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M+#]HLR(*0O%3Q$?HX((D O\ JG26!]00<2U-1.;RS22'S9V;]YQ<^?\ +Z8
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MO"P\PUKXI\XS"^BA6CRX-SW4$0OY:F996-OP</1O5-JS/.XX]7O7[Z5AMMX
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M5=1/7N)(F$Z0I#W@D;N+#Q=RH\.YW#6)'/):])E5325,5694*QTJ4\D;:B2
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MVA@05'M, "I. UAQJ &O_FY^-\-L!Y_UDJ&YO]N%4(+#CUW_ 'X"*I) Y^S
M ' &.=B!X>-L.MDT@#3U&*"DAH(>ZI@52Y-CON3<_>?AC2MP;"XX^O\ DL 6
M/Z]M7K;C!53:X&W&UL  "PXP  --A;&E; 6%AQ@@&]^O.+G %OYEKCFV I_O
M>F*3*))XO:*IDH:/Z4TQYY-HH]GE8C=54>*U@V'S.ER]&BRJ/1RIKIE#3N+_
M $%-Q"NUN"2+$A6%\&:64M)*S,[DEBQU,?4D\D]?[(^(^%3OY6_CBE^2OMI.
M-LI,<>D'7+40:2KBX/S<CFQVY /GB#Y'NT42][4-#2R)I:)89];%A<\E(^[(
M.DJ0S[[^&POD@JZ&E6D[1JM)-&H6*I:>.0U>D>\5CLJ'SV -]AB2JH&D8+5Q
M]Y^J"+^G7$EF&YUCTP\*6UIUZ=<4;'39^,9AFU)EM/+-(ZKW*DK<VOL?W8[2
M=H9\]JWDD=NY#GNT/'D#;RM?UWXO; 4+L./Y++I8QG3,"#?UZ8[*=O,TR&JA
M%5*9Z396C('A'%QM<@CE3<_J^39SD'9GME ,_=CE\CH":F$AUJ"HTC6NDI=#
MX=8 >PTEB%"X[0=G9Z&I$T?SE%<K!4);2=(X-B2&VX?=MR+[V(M[S:K=;<_Z
M8;Q6(Y!Q4UBR9;3(Q\:ZOCMQ]V'6X%NG_A@%\4.65682]U31EOUG)"1QK^L[
MML !<]2;64$[88Y5E'N,F9URV\6XI(6ZZ!>]2R]#LEMPRL-.*K,:K,)2\\S,
MR[*"-* 6 LJK9%&POI&YW-S@,WTAHL=^"&&%((NHL/L_LBI*L"0"O3T.)OEB
MKUIUAC1P0J1D^$!A& JVL2>!S;XXKOE+SVJ)*3=Q?H7+V'ILAO\ NQ6=H,WS
M%M516S.+W #%0-B-M-C]IYW\K+4U"S"H]IE$@X;6VL;6NKZKC;GS&QQD/RBR
MTRI!F4/>QBRFH%[[#=FC O\ \M[D^Z ,4':3)L[J8J;+YS)42W+KW;IW847.
MK4  /[UM[=2,9EGV297,*:IKD5^J\W/U'[<=L$K*WO:H9BCY:OBIXE30#<^$
M-XF+D B[%@A*@B$'<2ZPOZ\C$;\;?Y#SQ:VP_D&VJYMJ]W^.%5KQ]-+7N=]0
M!XM@YSW78.=*BT9K:=X*:(VVMJC4@#];9OV1SP<=F,R0U)RRO/>4%0S+W;'9
M6/N6)-U\7E](K;<DXSW*VRFNG@-^Z:SP7_48[&XY]=@+@[#%M-O+Z7\/OPPU
M  \#<#\Q?'C!OR/+K@-J&P(!X/\ ECQ*-]_ZI;\V/A@NHLIV8\#<XABEF?NT
MB9W^@%!?O+]-AL1Y8_)=+EH#YK,!4;$9;"0\I&QO/*IT0J01MJ+D-MNI&*[.
M)ZJ,4D0%+01ENZI8=@MS?QOL\C7W);;5X@J\8 MYGU)N?OP1<6_DN#L-V\N,
M1JTI"*I).P(!+$DV "VYO8?7BKH)J)52;PS%=10D%@" 5U6V!(/N\KUWU 1B
MZ^([_P"N+$<_F-0!(U;^7E@_&V.;V-_X8%QR2W\,:E\\=-L+<C<6/E_X^-5S
M<V7H.OVX)\MSA5U>-A9O+R_D*DJ.N*>FGJG$,,4KR-LJ(K,S'<^$ >+ZNF_K
MBB@C[#Y%)65B*,VK]6E XUPJ!94-B;L1=BUNI N%!-3)-53=]+*\FMB[NSFY
M//V=+  #BP&,HJ(LT2/*JN3N%(*0^6H7(&J]M6I0?%[WJ3BMRZ?+*R>GFN6#
M71CP4WL1Z$6X)\N<;=/Y& <!"?7[.GUX[.9,V:U0UW6FI[.['K;Q!?AMQ\?/
M':O-DJZB.AIC:DI/"+<:K;GZO3S/EB(Z&5U-F4@@BX-P0=CSZX[1J,U[/97F
M>D=Y&KI*>N[*HW^/%_7!-UL.NWYD@F_0>?GBCHZRNF%+14T]54/?1%!%)-*]
MA<Z(HU9FL+G88B^1SY2G19!V9JGCD%T8U&7)M_=]LO\ : <9WV/[2=FI.[S[
M+*JD+6T-(BF"YU619X&DIVDLI.CO-8 N5L=[6V._]>+=%%VX) OI\BWGZ8I,
MDE,(K,P=:&C)MWL@^<FV) AAVD<^H%N6&K21A\XI:=&I<FA]GLI66JD^<J9@
M;<-;3"M_HQGIJNKWPQ>1F,C:KW):YW/GS>_KUQ:WK_,HLMGKI"(4V&\DK'1%
M&OZTCG8  $VY-C;#U=%E2F*@M458-GS!EV06*Z:>,EE W(UF^K?WE*Z7E:1F
M+$NS;DDWN3N3?<W^)OYX#,-K?F6N/=74?B!C2K^\+L/HCI]_7&1=B.U7:.(2
M9-DE74Q]' 2*)MRMHY:AH8Y""IU=VS:>&L=C6_)+\H5!"]1-V:JXHT5I'M)2
M3L54$^&*&IEE=B!LD:,S'PJ"=L2TU132R054+1/$Q219 R.CJ2'22-E#(ZD&
MZD7%MQ@Q-JU1OI'ER/[ <7)&QY-^/JQ&B+<IP>=[X!9SH$?_ !?Y8RKLCG&:
M:6BI>X@/_>*@F..Q .H:AK8$'8JA4[[[8B[&]E<FTR9]G"5'_JU^;4L>%&EB
M]]NC[V)MBO[8Y'DQ-/V:RV$WL#5#2";7L3<%F*^NV^QY&,SS2MS.J>JK)>\E
M;_E MPJ\#!WOZXA;NY6D!(964JUR-/7;?S&,TK(<QRRFJY&_I<&J.3]H6N!_
MPWU*>H;Q>0VM<=<>F&V!)\1VT@#@^EL4N8MEG9WP+W<LH:[]?>/\#:^&8O=M
M5RV]_4[X"D7WYP&+=A65=V#7_P#SK_O%_ABPVP+VW_,=E.S%9VOSRBR.B\$M
M3+=IV#&."&,:Y9I H]W2-" LBO*T<9D37J'9#L'DG9++X*7+J.%:M405-?(J
M25%5(MRSRR$>(ZG8JHTI'J*Q*B60"2*4!-8(/5>=OV1Q;J,5U#09G1R4%=2Q
M5%/.ABDBEC60%3<,OB4^]<@[;C8WQ\M'R61]DJ@9[DD+)D=5,$DIEU2"CG8&
MVEK'13RML$<CN9F1(R8Y4CA8F,"_B\S^/L_K+-W>[$V8[;<8^'V^6--M]6KT
MMBBH*JN8]S">[7WYF.B-!MNQ;;K<[WL"0#CO,MRFWLI6NK5L34LO]'1EO^CC
M*W<@@ 2'8V#H4W7%365-9,9)YFD]6XWZ*!95'HH P=_Y%MNHVM@-J8K:UNN
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MF51'I,,KP'7'3*2"6*3!)))(](5HUBUL>_CCXU^O/UX M_5#A5OBARN>MDM
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MT!6E6VI7W([TAUN#8^[BMS3,:\Z9ZDF,<1*NA$'0!4(4VZ$J6]<6G!W'@_\
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M!;I:_3K^/LPI;2-0 .+XOM^-\7Z6P !@8/\ ,S7,/R505%>3J[A;K%QK9B%
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MQ5$WL >9R!VJ+:PIY>'YMC7QIDJEG.:^96F,-KR0Y"L:SP@7*K51P@F[M]'
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M:\<$UO9OO)3PS6EQ0.I)5V$;>O9+$(3&D=Q2OD\>/>ZV#:R*WH0Z-(=5.OZ
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M,JWFSSQ@D5&J448@AE5K%*URL;E_D&?;5U)40+2V5JVEE"KH<6?9*S-6+83
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M,RL%9,=**8L82K'EMBFDB_#1P3W1VP#'8JZ7"#*>37FW2CTT[%B2;=@CQYG
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M-  DDY3RSLC "$ 44A"D*5K41//GY%VQ_2UDAAJRS&#$D9J-<-T:20C.L8I
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MS+NQE2@Q$'/"LC57S)CHP1'D[AR:A^$&XPV-T-[?-N>?L>OK_9^(^OKE^O\
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M;'&AED,/'?%60APZ\+)!J,?8,+<XZP0*LFV]<ZG'>UQ<0PTG1@GK;*4^.V7
M5Y'UMXE=)FP5,O G"*2@6X>@46),67C80[&9686AP9)*N <A Q)-G*M;*HK(
MG&D"=L..LYTN0D<Q&1MTS7L_'!TMFU<6YCX?M8:P&BN:6W): IY4*TKY)P.
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M=6E8]K-+3HO/8MCB;$$68XH5&*CIZU(=1"57,=O&R)2GM)QN3F[TYHXD:_\
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MAM9\'+\6LB(MF-Q8YHHY51$=,F07R O8V<@6/&Y&179/<76S1R[3?=IB'?\
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M16E 016]ESFN1'Y.:JM<BHN6T6+:U[90X.7".WT@,B/DC4\'* 44IN>ABO\
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M)W[?\O5__>+_ %;?\O5__>?V;>^"N^3>\_ERTYY>35EDG=W[?\OU_P#WB_\
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M\NTZU;S).CPH[PJ,>[&D)9*M>/)NK63B50JJJII&/+++/;\&/^:W^K;\$/\
MF-_JVFVR<R3(<*&X*L'NFI#))(U[,DU:R<2J/S7N&SR9;?@Q_P QO]6WX(?\
MQO\ 5M(MN\DB#&KW!T,W+61S',A$[.K>/XA6OS5>PUOD3;\$/^8W^K;\$/\
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M^,3=-U2',='W:L)I('5R(J9*K&Y!JVUDV1>-MK"!+KZ].*F39\3=NF6#UF&
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M>R$7<,8^,,1E>LEL6/*F/L) 0L&::48A$DD:F3C/&%K!,<Y>:M8U,OC7-?\
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M /GCAWTCMXRL ?/'#OI';QE8 ^>.'?2.WC*P!\\<.^D=O&5@#YXX=]([>,K
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M9>N66;<_,JI^S/R>JY<]LDT_(BM\OE[_ )?7FO)4Y^3R_'\?Z4_L[V_I3/\
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M"-:4:MT]J!9 1R!L(<::%K^3T'*"P[$<GD<C7HCOC]CVPX8%'!B4#=,N.[(
M+^*UO9"<ON0V$=/\!G/3+)>&DJ@-T:*2CELX8%C(*F@S$'(B70?O8T(Z\EU/
MW"AW;\G#D@T-1-YSV)"LX,2?#+EKC3(XY 7*G/-1D:YN:?!=EFU>:9+LZQP%
MB"9AZ8BJ\<"44TFNY_ #(8[K&(-WE3>3!<\MQH[*55'TDUC>K;:2RO@XFBD%
M(ALF$S0*2)(FA:P3U;D_BX\8XFKOW.>)KM/L J:BI2XLGU-E>&"2<E<,5=6/
MBA5&%6++WTZ;)ECCP8^@0%5IB2I<88TWE)B**(1(F("5+89K.8RGKH8K>,LJ
M/*N+!X9*5X%9NP-7<G>6?(APF,1\C6@9\:GCZ6X7E8LG)87D>N M9%F28?[B
MRUBG9<\1P9YD62YM? 6":L/)E15LXX]HTL;2-'* &0QIAN$9K##:1J%$Y$<,
MB([)['(BM=FB]WXAZ_JS\OZMI3HUJ-(S^M'BWMA>;TR3KEEB*KG:9#F+6)$:
M2&]X'#FC621XR*Q@ANGFE7Y97$U;((3IOR':7(6DZCE&/$8D%H]Q"W8VN,%V
MJ6CRM3*]#*L9%F1:VE?OY(P"(UN\LD0>F,,0UYYKGIU>=?8@1$P4;%$]6E)#
MGI+%4 IU82/FY]ZTP[* \BN:1@ZP4B0= .['@TVJ#XLQ#9<97XI#85EU A.O
MA85&X;VQQVKYSPS[>L'X1AIQF<4\\D#'#5B=J7CXLF?B"AB8WPM-E6BUCH7&
MPJF')#/MX]:QG8KX9) 0A<P9WZ8_A'/<,A4Z7\3Q89IU39O@R<.O?'.)9,BE
MJMT6;%"0;3N8U[U8%VER.<TB;I'HJ;84KX8.)P^[ $TSHT<TV,$LIMH-)33M
M0@3/3C'F<01O!\0FMS-0\TA#5[WMC2KN*#>.>]61H]K-#' UY%5RC")B"&BJ
MNAC&C3LM3:BZH9/=TB)BX[Z]1]:J]L'KTW%J!?\  DJTB*_CMRJ 4Z&21X9"
MJF(GWES*A8N'B7]P8T3#LZRQ+(@\2U*I^'9O7M=$9!W+R(^/NA@R9)4FLK\]
ML92YPRFFU%=A6= 3B94< [#@I6[D%BQSH&0X:M3=-DMD()%)H1-YJ=2\8[%#
M>E?K^0VX2'O^/5V],N5UQN<-V%TB-BND<.NI0M:L?ML-MAXTNYECQVF)--M6
MPL.3C8@T<0_BG7%K)O8L=V'B1$9O#)!5@(I@I&C.:TNKI:Q"49UM:3&!"5<E
MLN6)*\S'UGWQ' ,R &;PJHI=.]T-8BN:UC&MP-<7D0;1V==(&Z:09W,/>QFP
M>IV*X7)LEN;N'1VC6J>541=L(6#FDX6IZ1B3YY6C(1(L,-];H4YM+%=NV.>B
M$=H]T[5DFU])MKR3%Q1[86OPX&'AR?98CE5KSL6H-AR:MY6QFP5CE?KCJ(0=
M+9"FUG?J46OW>ANKEEVLDSY9NR^3-<O.O[PY[W(UC$5SG*NEK6M3-SG*ON41
M.]5Y)WJNSHV%XS9>2Z274O6.GCY=ZA<WPEF1JYH@XF0-29/E#RV;8V)RW%O_
M -.EHFF/J[VU\1JJ""/XQ(I7)^%.7/5^+>OKE^O\W=+/291\&U$DL%MVX;2%
MQ7:1B/!.93[QJB9AVN,U8Y+=J/);SV'%6N!$@NES]O5/7\W=MA:N7@Y;L1XC
M]KYW=9@C/J4ZKL[%TPHE&53(-]>V,\#UBY+(1ZFU#W1&E 49A.]R0)&E8N2Y
M+D]BJU<E14Y+WIM58/P+<3ZFVI:2YZ0K8]9)-%(9M6 D+"U%,4+FK)@W]T20
MDR$[-IXU>_-GN2-HL=2$DDB7T:EX&OKHZR[&;;7:B!&IH45'IO9SYQ%BZ7%1
MC'L*\Y!#$0C9F'9%-B##.((E>*VZGQ'$@CD2*LIN'2QB2:FSMZR4!LE6QS"9
M/;*CF[,@(\TVMIU9A3'MU$P_9W%7?GJJ.&<52^EF$B2SF(6U R6/0)9HX]4^
MQLF0G-+,KXRD&U>BVTBW.(EA8FOQNH"8<DBC5MNLC#]I-&'$X)+A&D4W"A,5
M8C!<2.S'$UB:HR(EE@N%18LLK2GN(=1;2(-..14UC9\.+.%9SK-)B!C5BME-
M"C3(RQ(6/+<&O-%C%D-ML4RIF,K.GBXXN*26>])$L;<$Z1BLE,5L;1*&/J"!
M-+IKPL>Z4"H$-K8SC#W*UV&YN'\7X<E7@9IL.RL24PZV'?I7CXB4&$B39$^'
M,'%SF+"O(-5*2.U54.\['^3B5>(*V/81'9JS>L\+&)EEOXDAN1HAVI[DP7L?
MY\VYM4UU1D-?8:8JO+FQ%MJD??JFC$UHY4,;?=3XZ(X>6J1&0:*9=2>;/\W]
M&?F_2B=VV6V;U[.VEB*KLLLDVWIG:%=Y]O!O0A%Y=GG^G:IPQ 7[\MS*QSO)
M$@"1"6-@_+N'$C(KDS_"25B@:[41$VCQ -T BA%'"Q.YH@L0;&_F:U$]CU\G
M/G\GD^/;$%W7AC1)'7DAR#AJYHG/KI;A1[!RZE:LB6D=DN09@V<05VMO:5RK
M7V ].F9%"?)KM345XT5S<T_(=FQ?,K>[V9M58!:4$H3D15:CE"9J>!D"S]R8
M),B#7RJW)<VYHO!2G9S*HCH)^UJ=F!5#\O(@R!15YKN57FNQ)ME,C08@LM<B
M4481(J\D;J(YJ*]R\AL34Y[NRUJNR18V(:6RFX?D]76E(^3-IW*^94SWQRJ8
M<&>Z&:,>.>*.74S9#%8W>2.(@21':B4\*':\.##1ZPV'H\NO#/C1A5]*6C='
ML@;X+[9I0R3RA$WT21%G;HH#Z1:2TE)9$%91:RX-=3$DUL)4L#'GR+A\$#%&
M1M34]:% ](<+O@0P5)#%C//O?7U]>?XG>?[*I/\ Q;/V>[;+2F7FRY?HVRR3
M+S>3;W*;*U.6?]/]*^?8=1!=(* 1YDA"2W!<=7S91I94UA#';DA#.:/)B*@T
M:BN<[-[L]+<_/DFW=_;\NV>E,_/ESV]RGZ-O<IS[_P W=^CR>;;FB+M[E/T;
M>Y;^A/WA:Z"(MO;Y9I70=+G"1?<DFG<NY@ SR\+(>W-/P0RN[.R2,4R&2!9H
MYE##5S:D.62MXMZHTMH5JHBYG0<5'>YB<D=LQ@V-&QB9,8QJ-:UJ=R(U.2(G
MXO1RJF\+A:ZK#3($J[AL<Z9(PI=0RP[^F8C7(U[Y*. :&8R.2#)$IH^Z,Y2+
M J:V,*'7UL2/"A10-TACQHHFA"(;4[FM&U$\Z_"555?9PW;BPK@S?1,4]<XE
M-,H:Y95_!=66<<L:69M<5]@]\^7%FN%/<X)'Q4,]^]8Q4#64E97T];&WO#5]
M7"CP(0-Z4AR[B)$$( ]Z8A2OW8TWA2/(N;GJY<:8[M\4=(F!)5SB"13U5;2F
MA4;WX4PTKJ^E/.B7%!-E:YAEL+$?-@7CG-,-'(_6N->C6XP1B+'V%Z+%]?8U
M9R;^)-FX4Q YEM+L*&PA1X3+'$6&+A)LHU?3&KYKB&8D1P7.9G)!4FZ1I/1\
ME&<LA>DZ!91YL'$19</A(6')>)(L3%,R%P#):STF/FUX#-'N).;V"9BN#[1\
M8WYR8\Z174KJ"F+<U]H4N*K%G"39<;4.A(&61S)2W'"QN#1LN-*E*XL8']SQ
M2RH4J5,PUBGB;]T(19\>H;(PYB57\5( QP0Q(LF<*N9(<Y(V\W; E(CQZNEZ
M3,@S(L:RQA5R:Z1(C&""PC,PE1QGGA%*QHY8!R!% \P%<-I1/&N3FJU)]?U'
M<+8$Z;GVS8/5D[C'U;NE45CUCPVX<=:_@$X]9B#X?@VND:]TW>;=#LV+ F28
M57=8M-92X\4QHU>*1@^PC )..-KA0QGDD9'"Z0\:%,Y!,UOR:[_)B[9I:O-_
MV$">[_\ >6.UOZ]I=CAF\!>U-BC$-AC$M5PD>NT $!SZRTAN;(>R2HR/D1IT
M4S=1GO:;+2-LF6R$^A=+(60R  K9-3&4FAR@B2G9%<#4XCQL< 3HR.02,<%K
M,D>S4HES3>HW,3'-5-0WE17,:Y-34R=DY?(B]^V2=_KZIMJ)VE7N3;65BJWR
M9>3:/ J8$BPLYI6QX4"(/>2)1W^Y&-$YIE[HKW9#&/)[W,:CWH:UNG"EXQNP
MB2Q,-=8*J$U=X*CKR?YH3U0LX[4^_I;4<JN"&,C-GR99F1P#]T0BY(GF3SN<
M[N:UB*Y5[DV-38818E8)RBL;<S7;@*?"896.:XQU3F*H ]CWID2RDQ0KN%#)
MPBY 8FB.>:1(F&<T.(M:ZCQIVA%##(KUU031HZ"BJB!>/<O5[)U0M<5%KS\.
M:HG@*4T2:9&O1D-T-Q'2!R%*,@AAWH3H5I!$8AM>TS$M1B>>?$%09TB?A$L9
MC8;X@2M=*B\*809C9'#*X[-V],NQ#8/>Y')"L!C*,<V*&4P9F.&5C3C0B->Q
MZ-<UR([+FB?)E["8>J^#B1<:QR'CR[+?$AQI(XJR"F%%$\#ILE\J-,:.+QL0
M:EEY*4>L37,LK$Q[ZY;FH[.T49%BJN6I*N$)@X%4S-%YPHXI#F\I$F2[41WL
M>OK_ &?B/K_5^CX^6?-$VS$::_4CD$WJZ4UYY33M!U<(9&,>MB12!>.(]K'J
M,PWKWZ4D,ARW:8T7C'R#B)'BN W2DAS9!6M'G#>]@9S5R6.5^CGDN5X:#+C3
M!=64C=[&.,P]>\LUT*X>::D3GR<N7-KN:*B?BJ%GR&CWBZ !:CB2))?(*-'8
MU2G([\D;%\ZY)FNR[Q2X:IR?P8U8M[,;_I#)J#5#?W*T2'F*W^%C.[N'@11@
M'GJ?IS<\CU[RF*_40Q5^$0CWO7RN7[GU]5^3\<]<_P#@GE3X^7/:775IIA@S
M+FYO".G$"4J2[RQ/:2QL4,>,G#"D22-CM<Q2L$C6D*5^LC_7R^O[?.OL^OKE
M\7^353U]?T[96>-:>N&ONF5E9+G.^37(D04Y?)R[N>6:J3$>++^] GN(<7=T
M4?5RS<=\<LB63XMW*CHGF5>:KU?A*I>1R9/D6(.MY3O_ )FT665/D8YJ?%LZ
MLZN@I6N'NGU_"QTA.&O\&Z-HW"CY9:=WE\6TFPP-8-A.?J(F'['-T35FKMW
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M+AF;9@)87.%=YFV%?P&L<26@U#UW $L,A![MHS='&**W'PL)V\F;,/T>XN2
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MHNL9P)*2+=<-X1JNA^[Q#A:4&JER8T&';XF%AN9+GFM5B_NC.I[RL#7$D*,
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MC6V(Q2@X=NPTU='?4.F1["EE6RF259 EE/*I6L6.L4QC,<&ENFB4"6]57VB
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MQ.PU-PRU#R]V9]Q3V4)T4LQDV@N$A5[K0:#"\4D"UT67$DH@3 12,7;#5V[
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MX@6(+/-,EZRQ3# !?C<&/<#8G_<+R^#M]Y8?PE#<G-IC67&&S\_WG52BJO\
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MG%%BPIU8I!01H*ZL%KYAHY=["$6M@N@+: E[[.'#"E:5)*-=M.!BBV=923R
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M,9G/ Q:)8YJ.+7S9PHT'K42R',@'P9A_#\"0GWO7\>X!^%Q+'H[+'%J>QZ%
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MYF>,)^C\;QVQ7T\^F-C[>?\ F3_3SDX/KDO3A?\ \>\_COWNOOO"%C=1U%
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M=T/Q\[R?PJ(()061"=@'C-@0AB_)L%1&!"&^B^SI/&JX\[R;5B:D^P;_ %A
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MZ04R3=C$4HPAY$\NIF-1%J)8&D9:-E94J*@4EP\^GIE<8^I^"7C?DJGF\.R
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M2%"^PE0''_GT_P"XVB(YBFV>[!.#,E(E1N][1L<8+4,4W:-9$"%']=61>69
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M &R*7RA9[4.%0#]-5=BF:0F$MJ3=6;YAUS#W5SLO&M0!?H? KPN6C!Q<[[9
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M%OXAQ(X(ZWA?)CL9;BV0:^??SWYQTE\I5::*_)8(HT5*7*PS;\BP:4FI<,A
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M*#V7AZ\/!7C'M$O8]$5XKP0<1I_!/F434^6B%A'5]^O^;M\XV<?V>O=]LFX
M%D-"^IP+)R'I\:[^[OSWB#O\:BI?$!>5FN,?#"J(!2P)SU (1_->:)>]& NG
MJ7TCN07)!Q@!8+]*0ET9E.N&OGTT:U''_P 4EY%XB-774T0RFU+BXYC_ /:]
MDT9XE 864FV^@?:=?6)> KR]<"0RUEBC\/6*7[:DT;+^6.**4 >V&@TA  1&
M!',/!@?T0/SY\CHQ ')&'6CYM9W7[:^6Z2,22UB]4<)\RZ<#=$QUTF61&%.%
M[R7?57*CCGS%&&8=,ID=D)+6J,K8*SX5RW7"$@3G MJM%F,E-@U9DBPP#
M  ?XL??JO'']!=VO,AS"(^>)$#WPDBOSTC,&0?(^.M/GK6%BR4J(2:!G:1U
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M=^06Y;$8ER;*@:XN$>=UTA[.9QZ$T%C&&B?GY_+ZN_\ /B7Z^>!;X)\[QG7
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MZ'RDJ\F"0^6,U<EL1N$BLR8JR318-!66\K$;Y6?;]2(E; C(XXR/B[X\1RF
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M(29DC?@DN\%Z##&TD.8V,. SC*9 >[7$NE3OGD\SKV=FS6'WLXG!W*5EX,"
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M#RLHU.1M2R3\C)@%^/V_QZF8Z91X4J-U6428[&P[2Y4\A_4+=XRVL"S):#8
M$ U&*H_5U5I -Z8)7^M19ZA+I!P< 'FAZD/8GVST/O@RT!J4CN-C//[X@ G0
M8$@9)+&W+GL\YG6UI"P8H+'S)]M)>5 AV*L^51V!Q3RB!U[8Z?TW@!6EVAUB
MT=IZ8CE6E- +$HVP(060$80+,L:$'3$.=98CV6A$RG+NZ9#X$*H9B(0##(9R
MLJC1#D=@ $O'E1B*0&YP&!$RSJJL1GAR$G1G \/X8%V,W7S4\BP)J,[$R=94
MI9'&]$$/4P/0 !Q9C005 *8$V@$B!0_:.0#W 2=)0QLAG[9@4EXB593B7#,X
M+3GZQP6&L]\R0D1!68R&4U]=$5-$2Z*Z=@%'^$AZ$3] O-"Z'%+0R,@ZR/GS
M[]\XU[?OP*ENE(4DC"$FN?/-]>];IUD'UC[:_CR0-&0ZOOFF8GJ>-9!V#Z_/
M.0Y)J+NOC?>1\^?(K60=?)G\W[O;B$E%:-4U7I0UMPV(QKE[20!0046<I(P"
M""N#B-$&@C_A^C:+X\*]$!4,['6L%92((\I'1&MAM4 P2=5WRGT8W(@S2 R
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MFDY?,I><V ZE7$Z:LHA9R^TGX\VO*<1\*BN$'Q?SHJP252"S,W5(&MFR?&,
MD[2"L:8(22@)&2P-/$B"!)LR&H^39UF(.?N*=![(18X#B<%I7'88TYW6"P#C
M+DR6=]8^S,@*QJB;)<-0@BA(<WB'M!SG..2.AWK$G+%K3W ]1Z.!&C*1]!R@
M<OC.9J'09 $T$@!(#_+K,/>?IG@ \.%0Q&BU+RE8".'P2+[E3G$6)9I, @^Z
M72&$9:0I:1B:T'K'Y$V4%J;9C8G/(A ^1,DC7".(I6?$8<9V/2,=#'/9WR[8
M'(_34+'3A&M9%);U9Z7+S:@IG!.?^+6&:,A0V2_":L(8W3C=W2H%KTID#;@
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M?P.*E<)7V/3J8+CE+I@U)>? I9M!CFJ)Y7"M.)5XBZ?%=4?A!)ME/U4:Z!&
M&'[)BN+2V!&GD1OGDZ='=S*>+@D*Q+V[1(G5=E-TNO\ X (.=*M^NSI8.$AA
MII;0%B.'<1(PJ6.BFV?.W#8T'RH&A?F&!P$9N>")8"S46R >_P!,>7:3S76Q
M80@P1^R/(2-@K(8S'T@,!.U4 ,5_;)N8D4T J6L_J<6ZOL&%0(4EW1T7.8B[
MIB0C1 .4"??R3R*\GL:P)J6F3<>&( ]C(XP"39N&X"T$3!QJ$V#!%VUV4BP(
M_0#CFCTW,A$29/XR#AD8S<)&K[AFIRG!T=RO6@<@/J Y/@6(7PXH3:+Q/VN
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MTH7EU3^2!N3BO'TPRP[WJ_J3B&[ $^X83/$?.XGYI$J-Y&#AN"GM8QK4;?5
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M4^G& Z.&N!$]$ 3D S[POD3#TA2.E, _H'"1?)0HM0$T?['\'I6'[_D_]_\
M_]H # ,!  (  P   !        000   20"                "00  "0 "
M2"            02""""0" 2" 2 2"""        "222002"0
M         "02" ""0            2 2"""2020"" "" "         ""000
M "0"2                "0"   2 20            00"00      02"2
M2 "222222222""2222222222222222222222222222022222222222222200
M0 "220220"2""20 00            .
M                              "             ;<
M                                                         "0Q
M'0,Q!I            "P#KXQ[MZD[ "26
M            "!,@$T"V(          206*O<_\ ":H7) "E)
M                            '--A0M%>          $ $%;ECG1LQ[.L
MS.+$                                      "D<U8;H*^
M $DE\.U%&4D MV%@H                                        +_+
M+< ^ 5@         $D.S0-;0.,.DD<\7
M           "L/?$!@M9=         @ &DDRA$,<IIF%<V>
M                         "7&.B1G9PR(        $D ?N8-KP.TJ*MJ\
MN(          $D$@  D  $@                #DM2FN 'CA/
M      #<T9%E$GCD@         @ @$@D$$@D@ @               EBPN;
M 2-C@  R"'@  $D@    K5O%*$5"#@T   (89X $@D@$D $@$D@@D
M  $     '2C#$  AE]*  !VDD   @$    'RY#"&-.>E=@  %6;J  @$D  D
M @@@D       D@$$$      0  &@  +8.8  Y_NP  D@@  E3IN+> 1O%.KL
M@  X]W8    $ @      D@    $DD $@@      &_D  @X52  !9Z^  $DD@
M %\Q+/&;C5:74@@  "\I)     $$D            @D@@D@     ?Z1( D W
M"W@  <S@0  @D  O!>S+,=N/MIG(8$  3<(P   D@@D
M      !D!) $@E/B   %28-     @'R?^?JEKJ?GB1@D@ 'K%=  $@@@D$$
M                     ;L^0 @@JN    I<5   L$ R-N6TS $H7V>4/<
M >Z?@  $DDD$ @                            %@<          ,$E#T
MFT]RVMPUX>^[@        $$@D$                      X?E4@^@ @N(H
M         ! "M[V6^)]VORVYY,T            $$
M  %#<"C17 $'F'         $ #BY'RG;S.2NY -(4
M                 OQ>7!3\DD42@         $@:LRP^4<+"N:;1"<
M                               '#(Q)1O$D ?\ P         ( 0 \B
M< XE\.N_Y((                                    (#)<:X_))(]@
M        ) .O^2D5RYMFGP  (
M !%^,S0 )! =U0              )(! (()! (!(
M                !U5LX  (!/@0           ) ( )(!())!! ))
M                                 /$                   !
M                                     )))))))))) '+))))))))))
M))))))))! )))))))))))))))))))))))))))))))))))))))) !))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))
M
M                !)!!  )  (! (                %@2T_*$OD
M     !(!]NYW 34K*&              !)!)! ()(  !
M0X/JZ,&D0          !( M<QIOM;H !  !!(        !(((!!)()! ((!
M              +"+05=;BL2         !()%+IKNS196B\+&C1
M ( )!(   ) )(                @#9P3.ZB)!!        ( )81+6R()"0
M  AL[          ( !))!                      /;=^T1/Q1JF
M  ! !.>._%2P1$%-FHND        !(! )) )                     !S*
MZN'H2BX0X(        )( !90    !/*/Q!(        ( !   )
M            .6I\HR,-P-X  -_6     (  $T    .S#R@*L    TSL  !(
M)())!                     !6X<X38+R*H   ZS0    !         P'P
M!@>1   LXA0 ( )(  ()                     &_KBH 6(08   !%#$
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M ,9Z"   -"8    ""   2=D6VG&#)VR"    "L   0220"  0
M            !K #6C 0  ! 0    00 !C\W\%J*U%Z<S3     ^   0 " "
M22 "                        2 "ST          " " !D7O"9+=D[B1
M8         22  20"00""               #*)5M0$"!^ @         """
M#_N)@!MT@Y[],^BP         "2 " 00 20 2              #CB1Y.H"(
MX           2 ":3]^N&LAFK#5ZVX         2"002"2  "220
M     !X@-MCJ01.0          "23O83@.KZ9 -G-N(^@           00
M"020                *\)!,["2(I(          02#6(&AYEZI+0_+7[P
M         222"2"000 2              #P$[P^QP0!            "",J
MGO&5.RP$<6?HY         02   0 22" " "0            7&+X@"02*,
M             202"2 0"0 " ""           222220  2   "
M    ^T9L 2 "<             "20
M                        "                "2
M                       "
M                                     "2
M                                                    2 "00"0
M00 0"2"2000"" 22   2 0"0" 0 0  "20 "
M       0 "   "20"202   200 02 22 2"2 0200"0 0""202
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M4U!5._B&0RTOAQ"/?RJYE:#O?1_2=L*0, KV&@$5)EI.;.R!^00S>_6<E@B
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M>@04! #H" $2%W*[U@==?[>W_%*LB%OH&@'P&T=/G20QA7T KL#.][?/*MT
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M^6R0SA.71OUN_3\,_P 5FZN;PM.]W/<;)+P>C.]24OB_G_RN@B!8%]=/K].
M=,;+^,GCEEAX(+[]][];\<MT<U&+U<^OV^."0)LB/8+]"S2&KB746W[=?3_W
MBZNB@));7!Z9"2BU4RAFT(8& %K8D"#B$R8H1$5R30P7SW\<>8% J*B@A/BT
MR%3B',4PW5&,0"A!//#3H$*L*M)L#]]4_(>C4[)K"/.' RNIL:D*@5VF,N',
M$(T#8$C*,NT"N, "!IC*S8[ _5TXK7D%DL4_U_=.JU #M"640M(%T0UL>I+9
M%%)@X,I8@L8007T>G*K)3.[=Q+SX*X#. 5?AZ"I@@H%2: J* GL"1C ,=@>.
MD19!^PD K,%T(X MQB(042"TB%[W80"L$(!8N"T:PQP!@Q#,$0HH0'#7H$Y3
MB:0.@QP(HWQ![<'O;(J<> %6QE7% ?9G% D/Y4Z.,/)K8YAX2JQ- +!KD(8J
M+3311V!QJ,1&B 5I_"CV ;Q$+4)0U##K0\7?? 'PTKI$B1IU\8Z<!%MU#$K4
M$V+L]Z1X#OM*Q1TFIHF;Z/1Q;W_ #6ICKXA/QV?GQ'HI,!?Q=_.;]N J=4IW
M:8KIA?.)LZX@0#BL1HM4 1CL!#*^/$BBG'E4M -4&X B(]U5?1":4%G--4AY
MO@NY=]9_AOI>?P(?[F.]\'I-$=*[Y'K$Q^O AR@T]*#^^O7!CJ\W\6G[\WB5
M#Q,^OW]_,^_*4AYAU^%\_EXX(+0$OV]?3A;1==V"SX^>]X)$S"9Y'IU[E^SQ
M@0)E>DH61%LB8$ FIY.>T !7MO:9YZZZRBA!]V>^_HG8P! ZGOD\ *D[1MR!
MP$2!YBE:JRCVUIE-S#H"E-5ZBYY&7FZ@2W#(I.X$16([RC1/7I8P115 &)50
M(? 6Y8(*@ -0%@+) P@>_;]?[HBJKD95'0#)*N.YOI9)-69:J<X<X;$R[%N(
M>'$\8>Y!^B_9N<BSNQ" )PB%=6D4^@E*^&9)26(P^$M B-YUN%*'<]%:^=;.
M!VZ;/C80/S,X0.S@4*M$] %L# 8*G%]3QB>]RM@WALN,H+I(;*+ N*^0U9]Q
M V LAI<NJ:P.$' KPQ0@'?"(&6C(#E[1'F[ Z7@JM6_S ;\+/O;!K]NMZ\F9
M6-A148X1>B;$&I0W>>B%*M@D M"H<J0$Z(6*(@MK2J Y@42,![7MSS'>94R>
MU+F?7)]/CNH*9T#U/\-W(V5)3@>M+6^9'K@!40$+-$ &X2SKR003+D*H6I!$
M\_:S#E&A6!176[F1WZ/%P@=80-C1\FD^CQ-"#V?ZSX_.?/'TA1[?GY^OCKBQ
M(D3R=S>\\_?YXZ5\EN]UR]3O.O/$48D*WMW(Z:O@XVU!5@ ]^X=[X>/:[?WX
MX1*A"J'%"&.B!.\T]%:0 4((FAVJ_'&.[ PB05[@>P:R+.(O$2 4TNOOK+CR
M>Q$!5D$]]U_&7G7O6AQBP2 BZ!'9W%*8314NR!KZCCM-3H-N=X0!KJ@(JG;_
M '"KHTB@H*662RO?A3I>>2#71!(J*!T.'X\7JUVMOF:%\QW?;Q1)$)2L2)5Z
M0ZZY0PL"1!B/4@ ]!G" <0@6AK0582]4[*7M,8K$QI;67"< &B> '3A@LV=^
M>4A2E&9E48F%0%AQ&RPJA1HATWUP$1%T'OS$U2KVO?)@#>!(= S*>QCP,2K6
M+;:(^QZ:G;5[WI.@U7D%9O2G2U8!FOE/*X-@Z=@^. %8UIJJJJ^ZK]7^2?\
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M5DA& !T P ->A!#D:!$I0/6H'TH_'#0MJ-)F<&E!1(BSP0<$"7B[P*L+P+:
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MGUS@+G\:7\WMX7SW\?OU_:144P/(6N(7MM\ G*""A]<T@C05FB(5X@QBU!Z
M.@"/0-$)6 .@" =CUGL$;$6$?$ G\&W8E 8M^E24WI^/"G)@FBX6P& 5H#$7
M)*\I!#C%4/$0M)(Z:K>C!!1HM8Y[3( .H .Z[IK=XP[2$> V$GJMK\[I,*2O
M(BHP58"GE"552K$0#0H"L<835Z\H5H05,/I.>.&P'B0NXL5]B)Q(IXX**$M9
M U@&*JSM)NA$$-5VE#6'+Z.MC8%5D[6A 9J@5D'T-#QGF7=N=B%][/\ WO\
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MCI_?5 KXJPIL''YGSF<7*2/!H&0#9]5[C(LA.2*5EH6 "&XGCT0+Z10=@)-
M3@F<6Y 7O<,^DW([P*Q4!D Z[<N-;5#S>(0-+KLPG>U[JC0 Y-]@K2:1#*CL
M.,1$'(^XQ!J/D+*>%A,$.E@R:_C][, HA SHUB$GS23*R#%%HK,Q4])2FWAL
MZ(E#" ]%@S ..L"J6"CE *G8H3@NV%"&KH!@MN47BS$7HJTP!V*R=@O$,<*"
M\ +JN\J*&R1 O#*%6E1 -@0@V\I @3>@0^Q/'4X2GLWF-Q\<<?/% "NV8*PI
M'LO0/)X-32%)09#.%JBO1X5ZU7"BRV&L( F\-;L6TD&=$&AE(C$UMI&N2M-5
M$5 ]MW@:LCM$<R5\4]/6'6>(>'3/'8.?M>_\)9%D]3L#-^.^&28D* JSR_7[
MGSQ5( 4EJ-@4U)$IT1@^43;5.JE]8POKQQFDRN=3XV:?1^.$% XH=W#!N]_]
M=X-$U&?1:ZZYO/"0( 5'LG"=*_=KP+1$" 3H0W4RMN=<)@C$0U4/MUW?7DXB
M!@>3!J(3X8;#V\OGZ533O']7S>$$5;WG7V_D@,MG6^#?O\^.N(P:$[7HRU<A
MOUZXA+T?W?7W\DX[WO  A@?WDTD,4?#!7Z2>?/&G8-T8=+XP^OK?0V+;B)J0
M#K;""*!4X J5&"TZ(7OJ!UY* :+1%TON5XY BJ2%[5/1OC/K51(TF8-@H8 =
MCRWQ-&&XO0(+$1X88#:"U@S9TPJ+ :*00=*@]/>JVW;R' Z.P.CEN=)E\H>2
M":W@0(B+>1;R,WJM=2E2^5H8P7$BA/*>D!;4:@5L3OW65KS;W( 5D X@,95F
M(^"+!(IK+QAA,'C4G$0]GY5F90-AZQ5'M\JN+S5UNM0N=,?=!QC"\<.M6<@O
M:02]0/NXZ9+++P&E@K"I6',%WC A3( "TB!!*3<0H&KJ!4($&(-0T(-M*!L-
M@CJ! $*2L#*I!6!&)FJ).6(B*A=!&UN4\)-3;863DL*@ 8*E1X#)0 =  AX%
MZ*^=?( 20%+UG@GP?^_X2D0*FOA6'7Q,^_GC4L60(%V?Q *A*0ZP H.QIY@
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M^G)%V2MKX$7ZU^F2HC3LB&LB5UXK\\C*>PB)8TCHWSYX*4>5:>E=?MX]02P
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M<Z5*F5/)[;.:@&$1RKRD2*+%6H-+<+J,JJ(^J#*'6R*0*UP;O?>,.SZ>/=X
M!NO[_P#*M4;5HN0 ,C:52 >,DBTF &;*2D"0'*:M"(DAD#RP5)46$=T^<VU2
M-6%G"I""S4$E!UE,/;#4LHQ1(@!D*7!2L+3_ +*P A?I+I (0\1D8X,E%1!*
M2V4:$$[$WN4AA? ]NC"G.HE(P5E55FCT.3]( /T:Z F,"PEFH"5(5-!T)>U1
M#6AP<5F*" DI%8(A= 7CCSJ>@)SY $A4!P4NHP/ P I6M95!0""Q/ RK!$ U
M@(SKB[-IFOD82*#2!C*818TGL!@(I!CB. 36I>BXT@-"84$XJ(B]0>!(O:SM
M,]=O\_O^?]B $0NA54Q!?MY?QR,)Q1Z]('!R6=XDXF8!0X;J\A .BR0>"[@&
MCYONW$=A@G"=?%1'/AT^_P#T^J[@!1CL8!\#-#R6L>*H "%G2E6-;S2."W '
M18?+MWRLSF$-U\3R_P!N+=7E:C5T.3O]/7#(UQ^2/]_I-YU3H$I/<:)#U[?O
M3.",(,*FY)<Y@U6&0M$44S46H#S(Q4"@HM9H%QX9VK02%J1%%,3D@ %O[0#;
MH1152*&#**<=B!HR#'$@S%AT(;*KB<TK<R5("S%*KQ"[."TTI$J,".BPL(47
M;TU8;1&_-V^_T_Y0QC 4!%LD0744>*'#5BJ#4 5B!:B8(1UO#C2"JC6= J'!
MYTH!4H*E,2JJ0,X"I IZ,A%41C!0(%&)I&B6606],?3<C8!5&T%H>J#91K7K
MBK%8#1;L4:5'*=<)P8:(!8JD(PE54\8+3]$YB !12.WKB!)AU K@%4I0:#1E
M0BO/%Q$JWH%IM/'?%  SQ38;%Z4>Q.M""2"E@#  D;88(#,=$% !>RH:W*@E
M !(![M!&T4G B@2<H@HIWY*.V04XR&KS#X:AU(('4>A,*-A4$%2H014(-@=
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M3K"75^FN34N"J. * PMZTUZ@@ V%*"2GQCF@=(XF_!"!1H0,C$N 8P1XP@"
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M)<]O]OGA"FV@[/#1 /EGG9R0(Y8-L/MD-\F]YSOV)A@0IK"D%@"IQ$T9IP
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MQ:M,;7#?!YAKMG:*I\ "%#%%?0]W\7\""D(ASLBP8;3@9@BHX2@6B"A0!YH
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M[F]VJN+CU!_@L:K1/4$9/% @NZ$ &K6A%K U\A20BUW>9YT]P0,JNAB&7(V
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MS A2I#HM!0Y^9'AUP3*L<>"X%@,H431MRDD(,'3%0Q0I(A0J$ZSAYNE;ZVT
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M*@>+IP,&/R2.T<M%'/$CQLDT.K9>MVHX"@Q2_?-W4-@O!%M63S%?(VD104D
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M:LD$.,U8'D.01+=9MN\,FH@N![!=!\A+"]'-*I7NJ_N_'UXJ]MG%I&3?'O\
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MRH9!$@$J!/;[=H!/CEN_;\9^L_I+! !()HF!$(1V6==&Y_1:0%R I:3N\84
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M3RY!5]B75K52HT8@A.%VX1,"2W10PBO+J6TL@$J0 H&FF1$*U?T>'XIL^?\
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M0A3=B^B#2#+?.V2MW\"P^(KJW)&^*L#S(]8^^/ZP0""(2M *Q4B,G"00B[$
MO8X& 6EJE)"I9(P$ 27@ND--1%^T)^!.DM_Y6#L\)2@#H^'"\P.*(*$!:550
M$QP<-VZ]$J'M:$0\)"]@GPA@"S.DY?F@H%#[13S$)<8AN4%$-:"-780$-7P
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M<!3!/4P$4D0*"EY$2T/>_'QJ2]P7FN9;JK^7FM)XRAP6M$*MHGB24SH$C1Q
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M*#57984.J: IDQK!OTT0ZLQ3T$CGRN#EHVD"FY47*\+'N)57' E*V1,9 )K
M)JHBP:*U[=8Y4Z<@3@IS!,)MWT.?3[N3C26ZOY_G^?Z&9U5%9 KJQ[04X1J=
M @.C;HT77>N'_#<GL1!."<B+&T471.%-Z<3G&A C)%KGD*M230(WD&XB$%$:
M4%$DHB*-*]L7=??QXZ\?^?!3 ]B^]''K:)LY%EM+WV7?&OC'[<2*(]3X,/\
M1*@CPP;KV-TDS.#;DZ*_M8/< >HOCBA[A**X(:$0:4 E@,55=",U".13OSP
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M@IU\?HT_'/D_0_QP>H&@;Z\WV8>=PXF[6M0G97P BUA!H3@&Q*:G #03"L0
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MXO1O 11WM *1K?@A_?AC5/#1_;._7[_]'N/@]X?OV?9X08_*O[='VG%7O?\
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MZTK-6I&GE2%8 ,4L/)C*.7^WZM$9,&ID"6LT4&GUC@(Z@T>[T6*$&):)Q&E
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M'H9T@R==W@5/$4J>X1L]]7./J-XH9.]*A=33Z<3U/0:1[4?7QRIDUT Y9\'
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M*A6AP(S<D<<CB9LU=[ J FE$)H0I!3C:!$:+ :T2#4,%@Q$US( (P"*-E28
M908C8$#MI)0M&J060:,A0C&C2H* CD%P6!(V';19J"W5U+(:GH;INPH-W:!=
M6(ZV+B;J569K>4,@%!D@&;Y E2ZE% AV<<[I$9.Y-,^(VAS2(JFX<#)U,-(1
M $9%W@!&S%"&.PD6XT\SP@H'0+*'(1(%HSKR3@8H*C2<VJBS)$@9_/=M4*[R
MJ]%O( (%#4# :1)>H05-@MSH)I[17H 0.[@Q;8=%SHD.Q3$U" 4=+ZAV(+-
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M170 0  !<FVA)P#QY$-WPF,;V5*ZNGMWNOE_"$4(:"(L@ /8:>MWA^PL>&4
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M4"8A:X6(-0%KL+//BN^NJL,  '#VJ_=6JKM55:JK_P#'+=0:*(:W$5.$TV@
M'K;""[Y&$  '=4B$61*NA00"YEQ[6.B(0MC;!D+">(W:D&J*?CQL?0$O3YYK
MQB4M10OA*:C0(- S#"VT"<D"N#%K:+'-#*)"1YFN,2P$+L"MZ""1PN@5CB V
MS4VNWCE@90O@9C@#L!+$(M2 ($?%#< 9/C%R"CU0A"HH/";X*7#8TI3@G:I)
M>;+2'!3,   %*38:C9.B<D/VJD&5H07=30" D3M0:KXSP*-7Z"XBIJ_$B;E!
MD![Z#RA1-5K\ P-0NG^/?B+KUNR7=Q:G+6@!1BX*;"2HI3J1.=% ^C%@YK/
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MD &2(R3*$/5&W@(AOYQ:(T7Y1!FRR3J""JVJ;'P NI*+.JU5=;ZND#::6"/
MAI-@@D"$D^/6I_[@BMWMV"*1HQ-QI8ZP!WS0-7M;V#C"MP3=%X'@:4%PL*,#
M7V8,,'_W?4+8XVGXP"<<+YW=;OG6M_L]D*C0*4@P0$ " 4;6@@$< ()H'@
M- !!,5H-2D+7@;3EL+01YD):6F090Y1($(7/]_W_ '7C%.EOWPLAU7?W/\+@
M%@["U>E_'<FQ]7^^LB!.?]_:9%OV_B>L"<I6N^]UOQOF .']W_W%$K'NV]O>
M^#[AO!BG67?HE_W[<QFGIHTU9=NB<_Q,%FT?"<'EY"'/Y<AUU97OITL7GV\U
MN!_<I_QE#H#D%@5VJYS-9XR[R++YC900U\HY2A*?1U-(11E (HH-5I "DH!
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M2S^^VV&G;811A;2(1HA8J!4(A\E^TC2H0R$;'=EAJ_2G]N(38[+1\L68'?T
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M/+%6INK:VLW;1T ] !-,/[)$\/&< ] ( ?\ ((J"':>7D2_RT\+VXEP6/0J
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M&2'>SP<6KC6@;LA,8= 4-4,V53]GA4S]Z"..(24\K^6(^<D":=C]8JNMP*%
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MAJ PC9("Z2-2PF09 !01UO*RTC8M!X%; 8=B%'?(7*+Y@R4H-PQ0LJ*-",*
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MHIT4TN)1S">FIIHU][5'H "!1])CF13=13C& M  TONS4U=:9X_^*:)*V^_
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M9%E '*:.@D@M(T1* Q&HK_\ $HH5BP"QL[/6KKP??*86^:,0Z;IT,5>"(7Q
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M!D/1^#(>C\&0]'X,AZ/P9#T?@R'H_!D/1^#-JA3M4M0!2-  MAH__P""&5$
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M:_@,3CAL(EL/2?W;*(X?0!"0HDA$32[)OC;4H_?(K2"HU=NF=8AI&-LRD"%
M#B$ 4$A!0(!AZUKFO&O&_P"^\3PKA31>W4=51]8S(E8@Y%"P6*%H@3;KBPU?
M$22$D7L!M>[%HTA/\"VAQ#<+,@N4J.TM4>5//&"G3> :TX>@5>C6">1E0'8"
M78/F@!H @09,6^R&N.4Q 6"S;NYNNGB=C_")BIS@(",)ZP14*R\7.E1R8BS8
MFS],7P#INTJ"K^A*[;HA["<++3&C ]![Q"&(%&[2R;%'7\?]_M5'@P3?")W:
M0 (;/-JO .J*("[E J4NQ1&KM-6-])HQH$R [W=4L6-H3GHGP"B(T+AL\^>R
MZ9XU]OC'K 1O[5O@)F:YT<#<>16@7Z8YLI/HK4K\."8OK#NA&RF9(K3_  J,
M//X )X &4D!LHN=%)$!=A"A.%:0!*B@D)R(&<$"8J2A$4"@&BAO'J1/ T"C
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M]FI!>=:9N)#CLD+F)5R7>0\B[,AJ_A]0R,%DP9AA(1%8^S=BW4[X6G'!@@.
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M%06?Q_K^D *@%1PI&HF*W<.;>+1&\LP,FQC3<M3332G_ %L\.O&,*)6Z<=$
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MK9)-2^:3Y@J0LYC1+27)2&$)"%!-XU0CT 2BV!-10!//9PL$%>":-R_?_?\
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M21:R(09C$B\/E3E3)KT7GO5 /'FL&55(:@ZD[I=HQ!2^T ]K/01_EO\ CO\
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M X!H-&OZ2'I_=_\ <"$]?T$:&+ EP@IJ@Q>G[C!V;F'&*>>E)(G,U%:/!0Y
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ML3R*R.1U>*HV.S(IH4P2&2=) L/"DD4XF'=-1TNOU(A@[Z&N.T-RRPX6$H+
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M%K2@:-716D+:PJ33G4$@'42^MM'>RW8Y;=T?19,+]D;$-HT00-6)95.B)N(
M[*0!12@@HK4CNV!VGA^=>I$T;G1E.X4/ [U"LM<"G6'82CJB.H@"1 A%Q2TM
M 2L@KHL&NT!85= 30WY:U!0FU2Q::&L X3OE\Q?/5*O5JM5=0 :[D8PT,I%D
MU>&2)&M&U@(A6@E)"8Z0494055/LJM?*WS.!-A4*B@]@=E94+VD     " &@
M T : T&C7[I:V[^7 6RN]JO?EK^#Q>X "*")3L$\K-'CO7>\XZ]^7= J]6 M
MNNYJD)_^WSJB4^=XO(3SX_/5;NM;6U;$$SX@Z(0)*%X>(BF:TWMNU=_=K/\
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M1R(L<GPQ(!  F\*FFU9/E,K2P11QJ#=NT J<!1T"B24%/ O/A_%K&HUNK?H
)/X-'Q_S_ /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>business15ba.jpg
<TEXT>
begin 644 business15ba.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0"N17AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     @   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E         !@     0
M &     !    1TE-4" R+C$P+C,X   R,#(U.C R.C T(#$Y.C$P.C4Y  $
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M1T(@6%E:( ?I  ( !0 ! "  *V%C<W!-4T94
M          #VU@ !     -,M;&-M<P
M                                #61E<V,   $@    0&-P<G0   %@
M    -G=T<'0   &8    %&-H860   &L    +')865H   '8    %&)865H
M  'L    %&=865H   (     %')44D,   (4    (&=44D,   (4    (&)4
M4D,   (4    (&-H<FT   (T    )&1M;F0   )8    )&1M9&0   )\
M)&UL=6,          0    QE;E53    )    !P 1P!) $T 4  @ &( =0!I
M &P =  M &D ;@ @ ', 4@!' $)M;'5C          $    ,96Y54P   !H
M   < %  =0!B &P :0!C "  1 !O &T 80!I &X  %A96B        #VU@ !
M     -,M<V8S,@       0Q"   %WO__\R4   >3  #]D/__^Z'___VB   #
MW   P&Y865H@        ;Z   #CU   #D%A96B         DGP  #X0  +;$
M6%E:(        &*7  "WAP  &-EP87)A       #     F9F  #RIP  #5D
M !/0   *6V-H<FT       ,     H]<  %1\  !,S0  F9H  "9G   /7&UL
M=6,          0    QE;E53    "    !P 1P!) $T 4&UL=6,
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MBIG!F%1<DSBIG%"M#^OYN^_)<&JL@                  "@UZ9X?2
M                4F$F1EU         *37Q=3+@  !@R  8,@ &#(
M 48SK?N^1LKH^+-9              Y;+ :&/1DR,  %!9B^  &K3A YQ/2$
MYU.D2QFACT9,@..3L4_0               @YN.7#F0Z?-7G:A:30QZ,F0''
M)V*?H                      48SJOO^3M7SW%JL             !Y=GF
M::0/Z #QT.U#19Z,GDT=MG%QU(<J'5!T(>2Y[MG%9ZPGAT=%G')W$>:AI$]B
M3B$[H.YS=0              !2>))[:'@@;G-!G31Y[FD3V).(3N@[G-U
M                   %$M#>LYN^?)\&NL@             ><ANDY"+6<?F
M^#JPYU.:#8QST=OG/AOD]/3Q_.LS51ZTGCB8:?.70]*#D$Z'/($[]._3=H
M            !!XH'M6>*1L Y7.J3K\Y!.ASR!._3OTW:
M       42UQWG*V/TG$KSD                 "#GLXK/00VJ  :J,5-_@
M %)Q:=HE8              !!S0;:,^   *3BT[1*P
M   "C#57H.9M7SO#KL
M     &#(                        48QH7U?-WUY'AU[
M       $0A@57D                        "F<03C-5@
M          *,-;]WR=E='Q9K(                   $8?G..<??]ETGX/K
M@                        .<?<]CT+X;K_P!YFJL@
M       48SJOO^3M7SW%JL                    QBG&. ON/I>_\ XAYP
M                        #@C[5W_=WQ;I/WUZJKR
M      !1+0WK.;OGR?!KK(                   #&*<8X"^X^E[_\ B'G
M                        ."/M7?\ =WQ;I/WUZJKR
M       !1+7'><K8_2<2O.0                   *81EP']O\ 1=^?#O.S
M2J@                      $84RX*^V=]W=\8Z?]]>BNL@
M           48:J]!S-J^=X==@                   *9Q@7:[^&OM7HO0
MKX1Y>\<;%5Y                       C$_CKOS3_0WHN[_C'4; Z/A?I6
M0                       *,8T+ZOG;Z\CPJ]@                   "
MG#2/K^=YJ_IGU/L1^.?$W")JK(                      $8Q^4;/)C]9>
MO['^-]+U)\QZ>K8                        _-G7/;\C8_1\:O:
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M&ISD@[ +.889X<X&U 80;F-A%E.D#A<P8ZS,#+T<V'29SL?L>I1E@
M  !K8S,UZ?*8T7HQ(N9D1R2>B!Q>;O,<*#,#Z#-CG\V$6 I-RE^
M     *35!]I\A^1^9AQ83:YP">IYS4; .?#<!49";5.3C:A]Y\9:C>P
M        *329<S!2_&<FN399A)\9CILLYZ.PS6Q;#$S-"\ER,W.;S:YCI^IM
M(^H      # ,@&      #(        ""6#+!D     &#(!@      R
M   #!D                          !1+5_IMGG7^E.1I'Z%NM_*MBF:*A
M1DV%RJ%4LF6:ADLS"RHS;-2HS"S)<J@8P&<   3G-TXD= _,.M]&/S3Y;.^F
MXE6:   B<8_S+\\_T?R>9?K6^Q<^F<PM5PI.2V:+*A4*C.99A94*,LW&;E1F
M%F2V ,AG   #.?VB=F>2XW?7YS\STW\OZK]*PR9  &(9M$U;)K\@
M         &99_7.+M6NYIG.='>UKP<_H1MQ+U.YFC8S4*E1L9J%F:<[(SME1
MLA9F%RJELC.PIC+.QFF-JK-A1F,VQF0  !-1B&;V3XK@>^W\Z_G&RO.<0  "
MP<W/@S_03=H/ZIL5L8M62V<PV&R5QFJ6PHMFRRX7"C93FBV*9V,TQ;-LVS1<
M-C&9   #(2_7AX]BOPUX/O;X%YRO)D !!C"[-.R9&3(
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M #)@ #\&-,L[/+\ &3&/FK3]S=924GZ   !DU?SC?U0\-/<1"X73G9-5V?\
M .SWI\EY>K_<Z*N'NPCT.ONCX!S>&_O^G])SE?358>SO%.PSMOQ&R[:JT9])
M;-\-6.>C?ERV]/E&?HW[,CZ?/+WUG?A7H6:='LV9XK5I#W^VGD9WC\^QI[VG
M(LO.SN[P.K2GON1O;YUHY2^\]AI'Z3RBX7"B]F>)U_T;_P Q_"SE5D!&$3/A
M%^^?,\S?;NOA<*I7*XQLGK]GI_\ D_L\(YVSZ]=6+M)U1[?&R/%;<*]*W?\
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M9C&8K8FXHJY6666667"X6S7NU_-OJ>I_G/%G.0!!C\W8)V@
M       &35_.7_5#XV[B2RRRBH467#92HLM%W+K-^U_$<K2OT?3%8IVWD?G>
M0VWCG;SD/3;L=[[,[,WGJ-]NWU^'*Q&RU67"X7"BH69-I9L*+A6S/%U_1I_,
M?J5U.0#$TQGPE_?7S;F?[=TQ999DV%7;KM^X_G?8:#^H<&-MY#TW(1LQSN8R
M/H.7CG>Z:MF?VXNZY<+;8^TC],[:*K:OA>;B7>:L6]$:[IU;-C>4W:Y]7B^<
M"[5SK_'=LB+R+I[QSO\ $S=-6S9991L+A?NU_-O@]3?.M$Y "#'YNP3M  'Y
MF)&8E)4  "DQ S$ &('Y&L#H, Q I,Q,0,O!AIF125   ,FK^<S^IOQ&.W@H
MIG8O86669+A91=,[.F_AW;:8^@Z=K^$Y>QO*<G&>XUWOJ>58>STU*QOGUF'5
M[FNKMC.*\J]G^5W\3?H?A6'TL3MHLLV&PJ%4K+A1DV&S9OA\_P!&7\S.-%*L
M@(2AX2_OCYAS/]KZ&%EL[%["R]L>%[#J_P#/WHM!?2>JV)Y?E??HW:$^B<7:
M7E>3]L5B?:5DG S\_%V_;585V.NY\N^7_L/!Z8^0=EJ_U6CK;XEVFEO>\>=5
M;;\EOTE[3.T_-7K?TBG;G;GBMVA?I$[C^>[['V3D']%Z)NE65#)L+8V>[?\
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M%,U2NE<XN-53NN%LVNRS)99L*8V>Z_\ -WE]2?.$T $&/S=@G:
M           9-7\Y_P#4S\Y.XTE%&PV%EPLJ%TK**9V+HV&PLLLS"X5*RJ%E
MFPHLHN%TMD*G-Q=%EEEE#9OA^3_1;_,SLHK-64D$XQ3#PG_?/Q?FG[7YDHHV
M&PLJ&PV0J"%F6;79M+-A191<*+*ALI6;#)L*+*I72N<W%64S1L*++8OW6_F[
MVO4OSC*LS@R@88_B[!.T                     R:OYT?ZE_FJ>VX].;BA
ML++++++*A9<*I5*X6S:MA;.TLIBBH6S<KA="RBRBRRX72N%U*C-0MB]F^)YG
M]%'\T>W\T_T+Z3T,^!]#D?$TZ!]KSM5>IYW:'R'H_"_]Z_#>:/M?F392EG8S
M99L*+*-D++A4**A;-JLLV&QG:Q1@V,["H52V0LLHV%%0J&RE<YJ,TG;"YQGW
M6_G#WFW_ "W.X]^J=SZ!?"O-U5?FQ^A/2^@?POSW[\!89V
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M84;"V+9RQ7NA_-WUU=>AU+ZGE=\?$?.JOS3_ $-Z/L3Y1U&S?&\.PXW
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M6667&;C.8SLC-3BXS3%LV6Q;-EE,4S99LA4+A4++++A7N9_.;[_U#\[](SD
M08_-V"=H                    !DU?SQ?U#_G-';]?&;A1;-EEE%%EFPJ%
MEPNE4KA9:K9N&39&*C-QFS846466666669A<+ALA6RO$=Y_0_P#S9_2<U-6+
M AB)>&?[Q_%'-_V?YB73FV:*+++++++*+A=*X7*X64JF;+A<8J,W.;A<+++*
M*-A19991<+A<+I7[F_SE_0O4'SSU#.0!!C\W8)V@
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M,Q68SL-D*+*E19999<*IS4+EMA149V,T64S=.;A<XNG-3.Z,9O\ T_9>[?\
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M   %!@0' P ! @@6%1<@4!,4,#8W$!$Q0!(A.& R-$AP&$$E)S/_V@ ( 0$
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M>1)D3,^'-ECY2!,D5S22Q$MESNZ&EINL;2S8H\:=-@R9DR80S\&=EQQHDV9
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M:=V^ D DA(+/Y;;_ $U<'Y%]LIK\<6/6\%Y@UE8!7D2VVUOMM^SZWG'8XCI
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M3:.E3#8C83"YX<V@H ,L$*TK7 [/^RFT5WJ,V$(;"Q]SL*C&@PWU0 SV[O\
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MAN!N=LW<,QQXURP6MQ6N<\4+B:;"3]J#SZ_Z(1'4MN-OBUPSKEE_%->:$!Q
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MS47\)"!(?&4/S4;\)=SZ/^,H?FHOX2$#1_QE#\U%_"6HD/C*'YJ-P_Z7KBA
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MXTZ\NM<H3&F))DX>861-2"&5KX3*TZ\3N"EM$R@D(42.7Q=>R^+'9_PY.8+
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MND'33F11"BPW2VH+(9KSZDD.';P7Y+2$)TI BZ;U472$*%%9"$K?_; $ FN
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MJ(<I-6%Q9=<T FT<<,!UD@!0-#!T)\W/3AEY"(]T.6B-@WN>?!- 00*;W9X
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ML)L41/[ 9X8_Q0 82U[Z1.^&T?<@]OAQ>?X/-\BYKQ[I$JZN I3T*'&UM8)
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M!8P!<?;@^](13C_, ?"*Y7_R=:%Y6M=%;";*Z1:*"=8W'?1S,+_*-@X+3/\
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M#;,/<:1Y4J/WG':&V8>XTCRI4?O..T-LP]QI'E2H_><)L&V8]5%D>5:BG_\
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M%:UDS*E?D@_5Z3"FR132)/,-FJI?IY[?2O7TJN(%(@4J(M/AQ&8L+3HW+0"
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MG-OP>5KRCES\<QYZLW?!Y6O*.7/QS'GJS;\'E:\H9;_&\>>K-OP>5KRAEO\
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MF_\ I@-2IQ3ATW\."G3I486)+[KC4;6$5DG35MD"[K= 1J+:&J(I:!34J)?
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M2LED7"*AMHJ7XIPOTWX75?"OA6^)4QB!%<E2G6V660)QQQTQ!L!!-1&9GS!
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M2V1>101+KODC/%I055MUQGB;2P<VYNI&8J' S$$-V%F'>(RW&%T':>Z#1R1
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M5!H'4D+=H=8M%OD(2%.:9YQS/F*L0\KK5LLK1H<K,U#<C26J@,W4*5&.8A*
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M !B"ASU'4%Y^3ZS(K6T-U(JI"K.74@TZ63C:"](W,L23=@X3@Z%=#4I %_\
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M17.C)TYVF1@]L6<97F5]VB9?%&04&SN]U!Q&*)P&O04J=;S2R01WD"%Y;-P
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M:=6-!8:F=&R:Z0)P2D5CTE4^.=BV3WV2X/TBFRGJ9+I52(+Q373$>2/&B0#
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M/0:\WN'H<@MTGUG?C60++"#JH\Z'-KWB'-@S8R$:,PED"D1WH\1C1RB,%[2
M.1&*,VT5B8K<]O.36&(J)D4M0R@C F&@#5-,(MR2XER2@VV[>V<10*Q&L='<
M-NWQ78OCH'@JZT;D&IB;LB08KU+(F2B\F[DF25[BE5K!"8J[<<(8[1B9]#=X
MI:>$2YA$B[R,0CXDCW2).$QRM1QH4I@90FZFZGB1JJB*O%1B=I>-R%]*PL6)
M9-A$@JZOW7$AQG@)+F_I$;^D$YI^2Q@@;I:X:_4<(N[>Z8F,8<=U@_%^@>7O
M:Q4B%0LF<LY!)'^EX0E!W>9VRV8S>^FUV_K#,Q>9(2 =QH\VKM.FZI];817+
MMG0&\#>:\+Y$8S-X:J"072NO3Q35-O9-N+*LK8D"5;(!T;O%\0+0)-(!YY+A
MFD,8TAT4ST4ZE<WR%1/J.$7=O=,3&,..ZP?B_0/+WM8J1"H63.6<@DC_ $O"
M$H.[S.V6S&;WTVNW];\C,?)770I,X;P5JM GL?1&.58?FBN=YQKQKR(,*Z!C
M>K'%(4Q?_<KF+:*&>/:,M MR,Q12ALE3=)E8\"G>HW-15D*O3L$URDW]+F'"
M4O\ [E/G_M3_ '^CB]%;54:! CS6,I)0933DLHJM=K.<2.5P'MTC\'H->;W#
M1CD%ND^MF:U!X08P\7M.@CE$0CWRF=9:Q]9D=Y+':8 W\F>',KOKI#M8D,,X
MDFV#7*([WC:C2Q)TC6BL\5=KBL8C?1Y:_!PB_"G/ZZ9&4V2NNA29XW@K5:!/
M8^U!N7HN8B.=YQI!KR(,*Z!C>K7%(8Q?K9VN_MD3Y4R7ZZ57[9HGR5<<-_R?
MKIF+:*$>-:#M MR,Q1RALE3=)U&\*G>HG,15D.7IV":JDWU:YAPE)];.UW]L
MB?*F2_72J_;-$^2KCAO^3]<_G\_]OHXO16]5&@0(\QC*64&4PY+*(K7:CG$U
M5<![=(_!Z#7F]P]#D%ND^MG:[^V3_P#5<D^NE7^V:)\E7'#?\GZZ9&8^2NNA
M29PW@K5:!/8^B,<JP_-%<[SC7C7D085T#&]6.*0IB_6NLAVM@"%(MSNC5PS:
MD205FVCFH]&JP:-4PFZBJ-FX48]>LC6KVR6=K*'#A1\A1Y9!572U%MLD:UK4
M1%(0KG^2P0T(1[W,8%JN<B<1;"&9IX<T I,8S.:-*$[$(-Z(J-<FIKD\'(CD
M]#FHY%^N7VN*^51V ; (<LCQRO#S1PS,JKCP<TS&/1%\'L?I:PHEUC<YCN?!
M<=#8 +<18C9<B"S4I @YC9S(_3M(_F4;E"I-]K"C(YF@C%^NF8MHH9X]HRT"
MW(S%%*&R5-TG<QX%.]1N:BK(5>G8)KE)OZ7,.$I?K62NE^;E"U%KIJ,U/ARM
M/)'^"\W!+RTG#S3<9[5S"M$1EE$RA)<>I@6##W"N*3E>3A;Q(Z1S+I4Z$'+*
M9\_R"C#+*)FT4^IHHT<3 @CB8  1-08A"$U&#&,;>36,&Q$:QC41K43DB(GA
M]<N7#K;%(ISUMK-CK/IHB/5(]F]SPQY( -\GIRND$8GHZ,QW[2L =4 :PLW]
M;E%MS+;6#W;KF[C]YT,)7>4HT)R)()_Z5(3<7R!@:/ZY?/Y_[?1Q>BMJF- @
M1YC&4DH,IAR6416NU'.)KE<![>0_!Z#7F]P]#D%ND_\ =O8YCW5WUW>>N#W?
MUW=N[U\X$+5U?1V&C9W]WETA=>C3Y//6VBE]HO93;X1C.0FC1H62BR"'D,09
M98D-'?*CQZ^"\(5 O4+YQTG8&5PHQW"5J<T7P=Z%3Q\E?%.3D7[/@O-4^#PY
M\&Q+V*7S:\5*.V3+W!9['BG<=!+5C/S\9C6NU*Q'J?DTCNE0"-.[Y_/]_DOT
M5CDV0RNCJJP6X<B-W"D>]R#CQHPD5'&E2CO&  D]L0B:E8/61K<NF]B>7QNS
MUZM*F3LL8Y9O=S]&U8K1OKX[$C%1Z*.0MLD!Z.9HGJUR<5F0TDE)E5;Q!S84
MA$TJX9/2U['>6,P7HX)Q/Y/"9CQD36B_G=H':![%MGV"WEG3=T]^;O>?=J5O
MTSU_=+.AW>\/<NAE[>Q[H37J;CF2]+T7L@HZNXZ+?ZGI.\H0I?3=1M W]G>V
M]_8#NZ->R+GH3*L#Q'LGD9E(Q3HG2YD?+XM6K@S(D:0PRQ)5&7;\Y)V-#)4E
M7;:/\$)X7""K9U!?XW-2NR+';+2Z56RE4S&<C,:-IPO?&D!U.$ S#1BL)'&F
MVI/G\_W^,HHY&*7U/$QXD0<2_L0M'59#U+'/(2H)_AA@5OEN8I41'-0^P;S/
MYV+X[<2S M,PEDA401Q#G;)DA?&8]"E$-XX_C+#R<;2GI\I/?^?S_>_O_+(N
M,=BT[)*_$+NRIK&QA9C%&_G7R) ]UL N/[RDD!CJ=D4+Y"HY4"A7N\K@62T3
M9(!]2:!/@S&M;+KK&.T3S1#;;GB?YHX3"*-W(@2C72-^L(BW%?C%WETD<F(!
M*;'PH>Q(V05!O.@^3EV8Z+K,YHWJUOE.T#UE&-[AO"YXVO41.6L:N1%4;]*N
M;K8O@[2Y6J[GR<_TI]#\_G\^7%IB79KV?W':984#G"R&9!L14]36R&J5'1FV
M18,]ACL((P=+VQFD*(K(CY;QOT7%.^IM<6RW'%8V]QBZ8C)<74[1OQB)I63&
M:3D(CGAC&$]X]R.@SQREXPKLW[EZKV8U]K/[Y[QV.[N[(DZ1M=W] 3J]_HM&
MOO"+M[G/2_3H?VC8EW-W?[ +"N@]X=X]5WMU_7^=Z3H(O0;?1^UZF9KW/;MT
M<WT5C&QQ<GD7M^"A! 2V;3JTTB-(.,B'= L&D57@:+;40V^=UN.QK%:^BQ+M
M([.+;LZE943IL=FEMXE_ FS=Q@FQ3&BPH/3$(<H )I25I(>,L@<>.;?;\_?]
M_P"!>?O>GWN,>%!Q.^R9+RZCU4DM*!I648"^WM+)7N1!P@^E2/V0(C7(^2)R
ML1_SY?/[B>'O>VXL[RS(X-=4095E.*QA"N'%AA><[VC$BD>K1L5=+455XKLD
MHCOD5-J)YH9B +&>]@S$CNU .UA!\BA(WDYOCRY^C^_J:'7TDK)<CR:P)5X[
M11946NZN1'AGL)9IEE.78@0(<..0DB3MR2-5PVLCOUN<P>'9GACL3MK"O/:4
M4B%>"R:GM@0M#9X.O#7UA($^+K:_II$11E#K*P_M6O\ G_L]_P#C^BDWZ0.]
M##F5%?$KDE=$LR7<6T.JCB23T\O;Y$F(1?I<G-!JWEX\^/'Y^C^?[7VO?7\^
MJK15EED>2Y"4T>@QJF:!9\]X&L=(DG/**")75<)"#6?93"MCQ!O1Z[B\F+1P
M^T3L\D8A!R2TC4E7>5^35N4UP;>8B]%#N>EC5YZSK'M4$:0,,V,0ZM85XQJ0
MK/N?/['\_IXL<DZ)+(L1\"/$K>KZ)9\VSL(M;$C-D]/+42O/+8JN2*=6L:YV
MVO+FF&8DR DN3E;+^08R3-I:F%10!222E#TQNL21*DQX3&J6'RW%)J+HVGUD
MNOH_9';7>1U&,U-1WBVI;*G6Y2-'JGNAS]D8!A(<CEC/3;8]S]#&N>RBQS/,
M!3$O90^3%Q^S@93#RB#(LH44LXU?-V*ZL/7E+%"Y\,KF'%)>CQIH<->?S_W?
MZO'BN6GI.^W2;>##L&]Y1JWNRJ.YZ3;GG)8_K>@:C7=W@1),K7R"O-J\?/\
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M^*J3\6<(YV0M(G[$E53Z%^WM0!$_@O;]OA.\X59: \-3&#)!D?N##(83??\
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MVS"P983I !55;&4"R@[S![++.6E7)C-DRC/5\=AVP/,D"QB&U:RDJ$D=5&(
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M<U&8]F]M!$27;T]&E=1UB=+'DVEA5LFI$C*]QT@UL9C3O>5R2' C@1F@YG"
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MN1DE*0\F253'([KXS44CW.5W-&-:Q.:(B,8UK?!G$'_L")_YVPXPK[$6P_\
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M:M?_ --XP#X?T$^1IG'S^%?H\?\ MV_RY9_1B_=_T?J/9!_GJW_YFC\=EO\
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MQ$8C1J1.V'_^X?\ '[%\?]_T<O1H1$:GZWEY/&%5MH-IJZFPF^R2F"<>L2Y
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M58OU#(OMU7R)6_0CCQ@ED2#/:,  C>4I2O5&L8,8_+>]7*G)J(O-?#EP2/*
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M<32YR(YJ*J)[9/0K&6E985KR)S&V?"D0U(B>^QL@8W.1/?7@4>,$DB0<C1!
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MMK<W7(]'/'R=]%B?[9J'Y5B_4,B^W5?(E;]#C'_;==[R+_Z2SX?FOH]_CO\
M0@8+:NRFU>;O;H'T\6J<=T>Z;XIJ=85T;I%_]5+$!G+Q7CL[6OCBB,L)=[75
M47D@QQ8K+6+6U87\M:,V8HXV^NGV^OE\'#L.!/ON_$(6N9;OZ!*9]N!'<Q)
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M+A[()*3R.52"?MN1RM9$OLF-;$=;RY<:JKJ5\,!=JN>@I<V;*FQI01INJ@Q
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M@L9\>TER9<%^3AMVMR+?INI8 K(4>>DT,<0XYAJ[>7$<LQVA@Y*VOPY<*O\
M'Z<]7C30 ZJ%/B6./!LW@KQ1(LB/(CI5R)L=0Q'1V#>1VO3F65Y111*6)>4&
M+1*N/&M 6CF=VDN728LP@M!'S1]4PDAX8HZ]-]H(!YW3OEN[/LMQK%#Y8#'X
M661K&)'N:2H(Q]U&@1XBH2ZF16N1=LSO(20OF_.<G:>+ZAR; Y^$PK&DG1&6
M9\AQV[W'SA+$40HU5,.1CA@*^1J,C0NVE'X*5JMI,#A8Y%J+&K;6TI.T-MQ1
MS:1M-5].,EI#HS]1<FLYE?'6.RME5((X91U(2:,3!Z<@RJCQU^8U67U]&"P@
M0K6HJ[:GL:$,R.,XTN9$"!.KYT<[-Q$L&2HTAKG(%XM'':](F08[,N[2FVDD
M%!%GQBBKFMIA5-/5DLS.BP)$I1!1\J8CX\92E5OBP6Z[ X-?"WY5-F. VMF+
MJ(@NE@4LV.:S-J.=C"]*-JJHA/<<J>Y!,YZ:[_*J+'79A4YA I V%?"M:JJM
MJ:QH02HPS#2Z/7P9]=,BF$U_.>&5%,S6..03];NUX\R#'9EW:4VUD@H(L^,4
M5<QE**JIZLEF9T:#(E*("/E3$='C*4JM\6"W7=G42##WCT.8X9:6K.IC!Z2!
M5-(E@;44[$-TW-OF@.>=_/6,1.>I<0R(,353U>,9;73I>_&'L3+&31EA"V'F
M;))U XAW:PQU$+1H*H]8$<2* $6)DM-VIVW:!10ILD#H=J$.4S;6#%DR8CI/
M1LLZX[M+OTS%,\;9#(RH3;JSS\>7!\7K84UUK"FVF/7EAD=E+$P,(,5U22>V
M#753T?)?*67'ESB*.,^*P;%=Q*>'LX@U':&L\R0.U/$\@@XW4M822JAM[,0+
M-F4S'LA;;)U5.J;@<@^IHS;6AP1M(_<(T;&O?IT:WM:B/)H3R&J]W-51B(U/
M0GAR3Z[XG^V:A^5(OU#(?MU?R+7?6SY_!Q0?;MOERS^C%^[_ */U7YIZ?#T\
M^:>GWM2_ U>#PZ>+TD:386%J8>])/KGVLHDZ=(U2BF(G423$?M-?LA]S ,0T
M1%_O]?M_6S$_VRT7RI%X^?P?1Y#]NL^1J[ZV?/X.*#[=M\N6?T8OW?\ 1_\
MY:Q/]LM%\J1>/G\'T>0_;K/D:O\ K9\_@XQ_[=M\N67T8OW?]'ZW28R^F-(,
M!?\ _"11_P"MB_6S%6-]*9!4E_<QYH3O_D#=]0MG?_60UIT^Y7QX_P#^7^MN
M.M=^N9.*G^3(M)QF?R2)]&/]U_-];K8>VK8U@7O2([]:X<Q5(9&?8%*WP_:&
MWZU_/Y_9X[R>Q5BT48DE2+[3K)#71H@U_P 9463(3_,?4*C(Q,51E$^JF.1$
MY->%7R82K\+B,),:KO>: :?6R/"BC4TF4<4>.)OMB&,]&#8G^4Y43[7/BLJ
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M]6DK[*W) O-=GKPC2:?<RZ+^^NRJJ(LZ-AR$X(!<;YDA)5M9?'5(9@7,D_\
M$JQ--MC!^-=B.FX^*-TZG.0L;+_R&>[8"R"EU4)7F&XG3@<$ZEK@/PY.Z:3X
M_K-H%)T$=(2.";T@1.:O: $5I:J\))[4.Y+WOJ,)( *5949 "W$Q:/J_+DAS
M.VW\;67Y,T><IS,ENZ2 *4@]\Z"SN+;EX%$4G*#518L$4@X*_5:K16\/MW.=
MW]*!9 KOX"@$;N ZCL*:!)Q)6B6UN&_"@6(Z8#XU+:T&-X9LQ#JAAZHP78JH
M.@@8.F(ZD[6]97CP-(F9*[0;IQU&%!0N(^G^$&RYO;3'6+-.RA7),U*@R7K
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M2QN46% $M"I :K1EE,WW^PE4'4%-.^T_YQ.O>N9U.#9:@O+*_BA!\:(+E&]
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M&G%[0S$J:V:^?R[WM>\]=+\I^\DQWTZPR.,K'<6M$5^:->W30()!^ 6(,+8
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M"B KISVBLK8%NQJN@5*)8EOA.D62TGQ'BZ>5ESK,T<!F)=$I.AN#GP9,T9Q
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M.IZ;JTL16BLDQN*HAD"(%BUE+1C2S(MVM]#HH"J84RYN'^<,/^[\";_FD?\
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M(LV$2AM"$$2M0:-*PYFN#,Y-CF(C1]6,W!"R'<F\,OLZ-4 ].ZL[NQ&-RRN
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M"200022"00 0"0       222"22"2 ""0 2  0"0 0#S^?S^?S^?S^?S^?Q
M              "0"22 "02""0 0        "" 00" 0 2"2" 2"0"020(L+
MTL+TL:N.NN.NO!               20"20 2"00""0"           0 2"0
M02022  ""02 52.%2.%2.LJ.LJ.L\@                   20
M            0          "    (  (  (        ?              ""
M0        2"2                "2  "2                       "3
M             """ 00" 0"2 ""                "0" ""
M            !5@               02"0 """0 " 0                0
M"0" 0                      !>                  "20  0    "
M             "0    "                      "0
M                                (                        !_
M                    L                         ">
M             _                     4@
M "*@                       "3                    !>@
M                #/@                       !5@
M    !>@                        #/@                       !>
M                   #"3@                      !R @
M            "0                    "@-@
M _!@                        [                     7@
M                )_@                       "?@
M     ^A@                       U.@                        ?@
M               2   !)"" ""0               0   2"   "0
M       20  0  00"020           2" 20 2                  ""2
M 0  20                02"""022  020          2"202   " 0
M            "2 00 222               "0" "" 2202020      !( )
M)))))(         0A      ( ))))))(         !
M         "EQ8N$T"04&ZT/6N;6VVT7/@  !TH-0-;H:G*P4/6;[6VVVTII
M  A@222222222222222222"#!LX#?-=PB/)@-%$)W$DDE&8@   JLW$]G+@E
M;$I%ID7$DDD$P)   G@                  @ER A$DBU_\ D&D$$@@($A@
M -O@!9!A$DBQ\\;D$ P@DELD!@ /&@ #P                     %@4D$$
M'C ?8D$F@@@@LL!CW9@ 8[6DD  ?#<<_@BB5M$DAA@!R@ 1
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MP?+.*&I;KZ\49L?N< !,   ( *"):)! ))(( )   (6#1 ,B11^@-_N<:)@
M"033IP &2#"3? 8*>7<9L>9A<(20")*: !,                     (622
M#3123N9=[J0JB)*2001IP 'T  03Y=>*^KM GJ4T$JB"0.H !,   (   !
M! (! (!)   (0"402#3*/Y3Z]GB.200:"0-H ("240?S#ZYTOC3:[+$O[G"
M0P !,  ! )8(8))  (8  83(  (>)86000-Y9@S1? F0022::/H $B886<C%
M!@^AK@9'RY<\:(+3J !,   !)0)())  ((!( )   (>2819 &20@4#@T #1:
M4" +5R 'X088*0V0"#3W0R&;32$ 20"H !,                     (>22
M2:!*40" 9":02214"  5]!7H220*(06000!31000+%J02;[T/L
M           (0+2"  *#22"2&,"822237*4&RYC?6"""*)+ "246"12031#S
M6ZVYB                     (9ENE4T"ERF'8*02',FFEOH3,HX,["PVF"
MD_%LC*22X,WENQPTGMWV))))))))))))))))))))!(:43* L"2" ;!206"28
M:8 0?T3Z%" !"_  "0821 &20+080$ \U&^                     (700
M"$BX4  2"+324020)303N(Y$* "5S4&"222: %40 282:#.TMT
M           (0"%@N241<&(R03!!"&6628.4$#0 7\>22O $"0R<N! 02""
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M#(%@D]8-.;-PK<[P$DU3R +H" ##37$%@A75/<!Q?(46>)0 !,      (
M           (00 ""0+20!#G" R6R0*"0"8* $T""0223"2"MU0$"@"R1!("
M'  !,                     (83L""20;1"$EQV00"   :9;* *V3B2"20
M"!"&6;H" "020# &B !,                     (6 #%N20" *#0"3B)L0
M200"_( $, +*." ""032"!#G600 "";(  $                     (2 "
M!$!\"(" 380@F.9822&$R '$D #&#L"(202!"$APW60" ="  -
M           )1RQ)9&# D_DDFE*&]UB*^J8   F;O6TF'ANLTDDVA5KOBJTA
M3H  *&                    6)=Q__ -)IAM'0%$RT1Y%Y4ZG   "QZ?\
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M1L$<B:2(X\O:YW72/>< 2<*IYKU\->F6"13L#;?7C7;M@&$I"B:TVS,\<O7
M&,EHX2_>)ZO'.-13;0%R=O3CXR4H:,A-JNO%_'A$ D%7<N/;7B>.<6P[ W))
M$^7I6+!0IQ5]FVW\U@#&2T<)?O$]7CG&HIMH"Y.WIQ\9*4-&0FU77B_CPB 2
M"KN7'MKQ/'.+8=@;DDB?+TK%@H4XJ^S;;^:P!C):.$OWB>KQSC44VT!<G;TX
M^,E*&C(3:KKQ?QX1*($1(!#"&1I@J50(4<GQ9D):&)6)@0QJ8+,-&M'QQV__
M !02)D)+/L>M3A; 02D 95EE-Q'-01)#F?*/IVU_^**.XAU[^T3Y9-.D@D1
M6!N81:C/FPERB9U4^//A]/\ \3!0-H\[T=?#G'K]"!"$&"DB(Y9B=Y*%>DB4
MIN=ZZ_\ XH A*(2A,=_^R=L8&PKR0$DB9>#IHI@Q4>^(?]UQVO\ _%"RH@(0
M9-Q=9!VBEF1#5U1L.T08%V!+!$"H+WS//;_\4[!2 ;7!YOIMDK#$E<U4"$DP
MP1"\*$#$""!IJ7:+'9Y?'_RCG6G<^T<^-9N$ZR>$/AU_F01%(.LE>^Y\H_\
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M_P#V3MC V%>2 DD3+P=-%,&*CWQ#_NN.U_\ E0 -2K]/^8B1)XV5BI>EG@.
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M%Z;@DE))DL)J5;=( #ND\;L3 C(.MQ"S:G?@&%79OB(Y#TG<3>0ST:#T/SK
M$@Z;)72!Q,S]/^.,DH@]_ 19'3[I%)IN%OIC,JB9=M'3V\?-;OZ\O@S?(6
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M,UUR<,B<Z*DNH>D-W@GPD?#&>,3J2$K=_G48<WC%S< :\O6<EEMP<SQVE\,
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M+::2(1R1H3?4^-U?\Y0:2)'-5,QXHG=\9-*Q BFT.B'24NRX$& 9'P$0JU2
M+7TQK7/8A B83H&"R/"9< +!E9 M$ ,LF*PD98<@;-(4!:$62:((P3WR0$JF
M,  (-KL5J-"$YP(6!$.@;TTL"*EFQ"5#5D5&TVO0J"$D26)6Q:B*)R):$)0N
M8!81$\ " E"Q0W!HY B(X04RHS,@,&E(6I1(A !) 6)4T!)(!4%%2%%"5@"Q
M!I;L.(""5"K$4#9TJDP7<G   X2D!8DB6 ,+;I(<:DF6R].V@SOSWZ%<1DKN
M:UK\8LAHKS[:]\6D)1W_ )BL'3BK#O']QX&B46>737G<9,CS)YS^4X>9SUT;
M]_?_ &W^+Y/_ (N_-[0_?WB@*F8>RXJ<5/WUT'+%F.MQZ^T<]-SJ,)VQ''AW
M=>E9+L)/&'T3\X,WB%Z=/Y]S]+ER3Q)1KTZXI0;YXK?WXF&%='OK['R=<'U/
MOWO.2RP3'EQ._B/.-Y%0[$]":C[RCWSI)N2#B1O?7>6;L8[@5$\7WKM&+'W[
MK;VR7D0MX_?ZCWQ8)^_>_&"+*ZUQ_(X&:AZ=[V,4+B-QIYO6HXB?.O\ &KS^
M7#1X<?B)\LE; CQO]>_CV9BOB_+5],G/ 0^.SL=UHZ01_P##Y'XS9\7YP0EN
MZ\ROUN)XPYG1\ZK7O@71[OZP8#;7EVU[X1B^E1[3'OAS.CYU6O?#<,;-\=2+
M)@\\G0B 02XA@6/,S-RY))  &F49(J%!&T>6' !B%%0L8 9ZP"0*30BTX+9L
M(3!-HR0I10 ZK43,$SO?683)R>"D,L2"A8,H( 2P,;3I061 FDIH124 7 ;K
MTIVQ,WI>RY "RG3:!*\VZ6+&-8#HM%TR==M=M8P2Z8['-=7QZX0BJ*C-Z-V,
M>QC5#*4V*E1Q5^1@5:T((S<PD*T79@MRR"*FV*)0F0BJ(,RH3)51H 3,A6BU
M!?0C%@0$BT=W:&>>/5PII=MDL N2:H.QA"&1X(GL8P7H5E.I[.D<N$]K,0D@
M@ SX.ZM\,E 2!$$((@HT*\*LA>6XI*P)F5@72$D0;'(8 &1!L2@2]60GA!""
MDQ8!RM&<M(+(+$3*U.0$"4&PD81*)TA7DB<8""A@$D'@)-V1D61R4))"2H.3
MH@W"&P\Y$&$-D-4:!%:A8G@"@ZJ76T^L<CKFXT08*(ZDG<O>>^$BRM'0D@BM
M>V\*+UP7VN8]LYW25;V[=,--ZJ/SK(Q'$SSOTPP[/'I<Q[96I"?.Q3PX^<VR
M/D?C_6GF8$#IU\7<?G!U,][(*[7\X$VSY/S&#O4\79Z?W ,53S/'I@M;[W17
M:_G+;,D1<GO'SC45V;JZ7\QMZQBAN/.VBJKYB;+-0F1;6QIGJ'@R=,*.$@M;
M2)V,Q#72=20&0@59119;J:EB>\F3=.D[%(S,2F0BJ$S!DB@;(2":D4+U<AC)
M8N80P!B1=,I(0F;&&AT%(L19BJ2!@)9 1(NB_/!.PP])9Y<U*"HQ!,I>L^KQ
MTQ>O:MB0(FX:+ZSC(D]D(T3*58$!L3(DQNT %S *:  H+3DB"S2R,NIB(]?$
MQIV'4!D.)+W?2.F&ZH<%4[ &'83WQ"Q(TF&&U2D<[\L:K9;(3*=45,DFHRM)
M+(NV! 5!*672,C4,R(\!L>*HKA9QD@;<R$5,3W#))) 0@22012A&PI%(;J98
M&$I)G>113UM_&01R4* 6*FF9C81"*R"G8: 4!.E4B@**:3&L@%,\7U'GS/0=
MPS,(%!0E26Q$(54X"0"173(=LK>A?*@PC26(')UMN_4W#C"$<$T,@IC05-1T
MG+=IZCY<-N8CF[:XC^84[XO=Z[5.#)%37/ZQ$4P]8WY1AM].;WX1_, B;[HG
M7$>.(>Q?53Y?]]_B^3_XOT=LTP'7G\C!)X7?_3CODA73=_\ 'O@!RC#J?:29
MYBX<-<^?/[Z>7)>6^NV17Q?OQUURH<NL$*\)7KK^Z>N4++$^ /?N]?(9VD2[
M4J?Q_P!OKQ)M\OCQ]V'R#.3P?G#L>/W.O:>AVG&QL)-\?7&8KB_L7Z;USBB,
M;2NLI7WQZ.;/+PV:[=/\$PC<']Z_#X.*0PRI._>VCJ-<=L-'W]?!FGWR^E=*
MS0C]<]\8ZPVPN][Y\SML#+3O'A]]/(UC%XD+-19QVU_\/D?C-GQ?G*$L)*U,
M\OJQX=\60T5Y]M>^"(-%'%<=,[Q=36JXB\%=C[=.WMB5P5TOMKWQDJI64H$E
M)-3$UQB\V4H2PEJLLUMECMAX:YC ((%@0V#5:9/*,N2QV88H=]&])C3$JJ7E
M;#S??Q)9>AF @ B6H ()HW1E#/-[!.EIUOIXX DD0H@$@LO0B(\LM/4+872S
M#J!+9=Y9 04C#"C1A00X;1K$O25S*5I3+:SU59YE*6.9(I)%J0*1,' 9(WP@
M0H54LH"S'=ZX^C("[2@@W F!D-.&+"3(L47"B;\3B+B<D5"70 !HD6"5$ $L
M)4I,FXDD!AOVDQF5*;6:O=16HYQ JF$@89$1FK(DB4;RT9@!% E 0U+($6]\
M7(\&#.T,)1($Q.CICLN$4T)"C&EA(64 ,ZY+$0Y\ONZXK(@H# .D&(W48@(D
MF$1E)60@BC<))IP22)B52\$JRL!&]8G"(B#"'<$Q?_<9&B;8!A!(B9N'J.)G
MIF*JT@+9: AXXR4K"!+0I8946"8A8"W*S8L$$HF5AEM9IQD;2H%B !#L0!:"
M*H#%$E2S*5+6!9J5>85ZXZ]SCTN8]LE'>=5KK,8X[W4?G63O+J=3MC3>^"NU
MS'MD14+P,6\%$\UF^1\C\?ZZ\Q\GXQP&3J;\&/F??'+Z\UKPC^X4Z]]?C%8.
MG%6'>/[@M: \?QCES,\U17$?W.J-S-7K3K[Y)*BWY@GM4=LOUJ0AJA7I*!$!
M,Y$$F' 1$@U1(0:8.F1VT#6J7,&'U)IM/M-0H2"!)3-((S1AY:*)-D6Y;!K2
MMU@PF3)GP.\R%+V20C&/;WI"KF=I"L@:$! Q6N!.B0048($T,B&$N0;E-_/>
M40V*IA7G/GEEJ(#@281N6EQ1(&106"(JDE[Y@''3()1=8E"5AR1IN@LZ#,()
M0D@&M !39*T'*Q.[D!&V+O=63%1XM,)!)%6BHT5UPE:*.&>WDG'APXVTT'<E
M]6YP\B0 QR!2E(PFXNS!*40@9) %"DI!1)#=0@4"; !*FT!8I5B-"[=ERE9)
MU7>6CIC(P9=JRKO:==W@R8VD:2DQ,[25TQ,R8B01W))UT+AWQEPFS:][6Y=L
MDX;(A11#"8$PL$W<$K1BW$;R",E1,0.CA\<2$R! 1TD(L4!B.' 8TV@0@&,@
M22@EV\I#$*PJT@ Q J424::I<JP2H<3$>'O'?%*UWJVNU?&2!Q=\S[5K%D=%
M/C[8)Y@=-?K%*UWJVNU?&)#JS<0ZGIXXI?K]/(_WW^+Y/_H@[SM?/[P"P^[^
M0_P!4[5VUD$CI]S62$:A]W7]_P#]7R/QFSXOSE MQ]7BK_!XX,[EF9U!7$7C
M7<LST_'UC+MK6I:UVXP!+98JZ:[<:P2"9GBZ?&/YC0)GMT\XXZ9% +-:4[11
M[X:^HCU)CRG)&98\5Z5KWP*T7O;^L" ;7Q]-7XX1B^E1[3'OAK/!Y]*U7CAL
MIP^$V6=)U\97/<,KZ=)_<8QP4A"R.8%_;\;7+?CIGCG NLS7/$5SK#+F-=;-
M]*^3&A5)B+][/^82MDCKX:@\NFL$V'$[BO3$DA>L2]IW\F0VSV)>UZPHO7!?
M:YCVPI$83AWTJ,C=/KK,J)BIU@VYB.;MKB/Y@*-NN;?3!()F>+I\8_F4!/)Y
M=K^[UDD2LC4RW5]"\@;KKW\HK)&98\5Z5KWPY\IV[DO6"H<%W?I5>6(XJ^]G
M36',Z/G5:]\"Z/=_6# ;:\NVO?-0GI6H\XN,'4SWL@KM?SC,1;.W(>>_?#VO
MP?ZK$=V/9_./1,2^2/;\X,%[-P=_QMP2#KQ=+WC^81-QVB8]L-OIS>_"/YD*
MOI.[Z\5.%X'G>JU[X2HGKM/Q@0#:^/IJ_' @K0%1I-7&N,E[A:5SHF.QC- J
M&!9LGR>?2\"N6NM=M>^"@S.B&.U7OMN<"C4NH^8/S@@0H3$"QZ1KXS8*.>_;
M4Z<BEJ+CRCNUA1>N"^US'MDB8BJO\1TG$<'<USTB",2!EGF5I_<]#KAAV>/2
MYCVSDU/WIDH0$PO2E=2-X2(F$>CQ%SJ9[>$9/RUS=I'$?SC#6%FC:77;J'H=
M,AB59"!GRA1KIQD!<,2D-/C!K7?C"Q':7^)P@$%W;<I6OOR$H1>B.5(AA\.#
MN8H.]1.E*.]^5.L2!:2//HZBWC#23I<^^LX97O9!7:_G &V3I?KK.57PMD]*
M^<)15-[]XC!:WWNBNU_.!-L^3\Q@;U[R4]*P#%4\SQZ8+6^]T5VOYSE&G1?K
M7SBEKUO]<X 3'+/G_MO\7R?^9\C\9L^+\XX"A+=]I1^Y\HQ((URUZQ'M@8-/
MG_.^N^4%B055:[7T[Y,!&=$5T\+\<3>_:&GI>2J^DUKKQ<8^YFXGH5Q&2NYK
M6OQBR&BO/MKWP5&C7%'IC[F;B>A7$87W/;7X]L2N"NE]M>^ APT7Z16079*!
M)G4!;,ZB\$NBD8E4P!,J YN'&F9W6N8[RW'_ '-1:";8Z=BOC)*A7$FB.8PY
M$C+ @";5G0]U QT$64*4I@6+1?3FEYQ0<H:KIQ#-UMJ\ B@8I%00B4:6@2Z'
M)@1,U4?E+Z8\WLXZ=YCVQ&R6!F0I&BSU8]<:42U1EH>NG3S/'&6H-S%7]\]<
MX:%B=+4M#4>MUB!5];-^F+N9[40UVOXPG%^7XF,Z##ZR5VC#LGO/\Q9#17GV
MU[Y,CT-?K$D6H^QK&6I(GX[8LAHKS[:]\$0:*.*XZ9WBZFM5Q%Y](_F.7UYK
M7A']R<%+A&C@B,/:_7^JA'4>OUSAX/R?W#?=^'''1\L7<SVHAKM?QAKIY?F,
M74QWIEKM7QA6(GG?,;UBR&BO/MKWP5&C7%'IC[F;B>A7$8;>4PA$E )B+[U^
M1\2+,$I)]2H0YF#2DJ9DT1L[-Z86E)9.\74UJN(O#4"B20,C**"0F5@!6%2
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M]>'IG',][(*[7UZX$VSY/S&&F]5'YUD:=S?Q'0ZX_;XYH>!\?Z%TZ/D_ ^N
MB;&GJ_''AE1O?>GI?'G@P&VO+MKWP")=!4:?&+C!@9EWX=M<8S"YYC7O'E@P
M&VO+MKWQD!/2NGM<>^!K?M!1TO$)"T=OYBI"J3RL&N'I@G,G2^W;MK(B7R+[
M0S'MD2M@+MN8W7SAPW70DZ6P>5X.I@O]\GUPHUT5/>$R $H>H?S"-33*BE5V
MO*HM)N#TC*)>=%O2YCVR-5N(OKKC(Z%OBR_&/Y@#F)MJ;\8R<VAYPIVC"M-Q
M;<L1V_Y@9[M3;\F1BJ>6-^48;?3F]^$?S(5?2=WUXJ<.9T?.JU[X%T>[^L&
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M[U/?#C4UV[/3N<& H,$.NJT><?\ ,EIF-/@=]W.)"$=:%0=Y77SB#6J\H8'
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M%,;+OK40'.1^60%#:RUQ&S<2K";9A#0O*A%&8 \@DJP$L $+(.!,R3>YEP4
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M)&EG&%47$NF!$@)8*RP TNBL1PWZ1@F2JIC1\133*V"ETB8(S \1OF+42)9
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M(_F KK74OTK!()F>+I\8_F$3AVB8[:PV^G-[\(_F HVZYM],$@Z\72]X_F4
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MZFK\)B?/!677,W.JL]\)43ZO'E@0#:^/IJ_'$H2#KC7G%Q[Y'10[205P%_G
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M%LSU?B<&.HXF9KTP4=9N=5Z8K!,1Q5GC']P7''<_6--[X*[7,>V$N8\I^#(
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M+RK@0++M;5XJ-@U*X]XXQ1O.A)"(R[PEMD7QO;P_^*0"<2R0D# 6TSUI-/\
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M &>=2;G?[/.I-SO]GG4FYW^SSJ3<[_9YU)N=_L\ZDW._V>=2;G?[/.I-SO\
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MMLU./GT:YF>,:3@L[/-MJOO\^O\ O67JZ^='\QUS?.LU;M\J6+GX^TUT>O\
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M6&0!@(*IRSP6;41AMKH2-G'2@6+7&%9R"4)2S.^\Q 7!-R!<DQY+V*4!9HF
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M3U[\_%S01UAPYGQYS_%V;9]T^F%\ ,Q&Z$+ FC03%=("@F4:ZD,H$B4C)F*
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MQY7K7&F;7XWI=AG_ !K Z'X^[$Z^S_7=FV?? 8(J"9@G>"?.D'(.MR;[_:@
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M>^/NS>'Y/H+[3I]V)U]G^ZF9O3W/K!B+;5!L5@LLR6+.YL\_2#8Q'AMTH (
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M.S4YHX2 D\#,CLXH>(UX02.%E-L32,,1(+$;=MZ4OQ^$2VMNC62^&B%ELT@
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M%+BQ$K(UEV. I)U-AYG0@O9L@,1<:&<Y<(2IED%.+*:.,1%3,66.J[AC5O4
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M@(@"%F1 @14$*35D!B? ["=AB(B3$WVJ28DG;7R_@DF))VF_E3:[8W;4H"D
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M+X!6 THTPG!AD(?&80=F!U6B++\FGNL.J\:&YU=#0H%)&=H'SH22#[_*)6>
MC!N961 F4BR K5J[)[0N;&M*RN+7'7[Z,"Y4>FUB*#XAQ=#E2R+KSFX#S$FI
ME<LQJ!(5!$K=035*V\ ^$!BHY(Q7;DB"UGL&%DS0G"8%?%'3!4:3&2@G2S@
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M!L;XUW_C,='N?1-^1[?=B=?9_KHA2=[NWH#B.5O+!V49P>+>U*&: X?S_P
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MD%J$@HTA$%-6A5V5Y85S(7R(&31)NKI8?+EL_9;6S#9SSTN@<R&'.X[AT9L
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MG$+8A)+L2V()LHQ@WHWHQ@$2RXO2^:4.U=^&9\%E%-*OT\Z<W4"*J \09_S
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M/Z?)J3<^S^GR:DW[TF_W'O:I-_OU/_E42I#*8)$"@"(00;#I3$1+C9<>;'G
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M%7-T<X\:>L7SYVJ8;D>I\C[%"..S$Z_#V N*49/;O8XF_EF[]UK3/A\_=_\
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MJ\XMO/QV(.>M0)%LZ;\Q%&Z)7B1_[Q[XI B#K%CQO:D@H$BS)F\$V=?"_AI
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M:R)S:9]ZA(&&)AV^]:@3,WC']_ @YH!S9BHUZ_!7N/CNN/'V_A$X@H@9#UC
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M/]E6;+%;G3>"4.C5GXPC\>GW(@5V>(!+A]P=2993&"9<2WZY,)PHHC5"@-\
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M 7:2FZC9K'J]_P#F<CJ>]:?1903'$O*O&S#H\P_;VIQK]W+$9ZM:9\/G[O\
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M%(7 5!0-?U3[V["XB'4E//BUC.U+VG0C!@@@"2%5P"2B7"CC$\6^:12P/$I
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M%L! =Y%,FVCV1$-86@02 *QN5TSJ1@**S><]U!P+7K%Z@%-*&PL#X'^=NO\
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M+"BK$@0@3/:BLNU*232!VE1E![UX&]'^JSW/RW<*2''$IP_/I+:HW[*QYZS
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M'),,^-<7J_NB"QKSS1G,1K1C7R3?I:U.,ZXO;.^?MZ8B[ V\Z4R6"+W;6ZM
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KT98NG#G8M=T2@1!;P(Q9\18UBA.H@LEB:QF2 O-Q0CD( "( 1;IT>S__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>business1a.jpg
<TEXT>
begin 644 business1a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &2 X4# 2(  A$! Q$!_\0
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M_#T;]F+_ **9_P"4#5/_ )&H ^JJ*^5_^'H?[,?7_A9J_P#@BU/_ .1J0_\
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MS0!]0T5\K?\ #T3]F3_HI?\ Y0-4_P#D:E;_ (*A_LR+C/Q,_+0=3/\ [;4
M?5%%?*O_  ]&_9C_ .BF?^4#5/\ Y&H_X>C?LQ_]%,_\H&J?_(U 'U517RK_
M ,/1OV8_^BF?^4#5/_D:C_AZ-^S'_P!%,_\ *!JG_P C4 ?55%?*O_#T;]F/
M_HIG_E U3_Y&H_X>C?LQ_P#13/\ R@:I_P#(U 'U517RK_P]&_9C_P"BF?\
ME U3_P"1J/\ AZ-^S'_T4S_R@:I_\C4 ?55%?*O_  ]&_9C_ .BF?^4#5/\
MY&H_X>C?LQ_]%,_\H&J?_(U 'U517RN/^"H7[,AZ?$O_ ,H.I_\ R-2-_P %
M1/V8U.#\3/\ R@ZG_P#(U 'U317RJ?\ @J-^S$./^%F_^4'4_P#Y&H_X>C?L
MQ?\ 13/_ "@:I_\ (U 'U517RK_P]&_9B_Z*9_Y0-4_^1J/^'HW[,7_13?\
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M:I_\C4?\/1OV8_\ HIG_ )0-4_\ D:@#ZJHKY5_X>C?LQ_\ 13/_ "@:I_\
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M9%CM_/D\M%/ 7<< 'T Q6?N/K3Y6W=L4RDM%8 W'UHW'UHHI@&X^M&X^M%%
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M ([2_P##U#X&?W_$_P#X*5_^.UE_JMG?_0)/_P !9K[>G_,CZ^HKY _X>I?
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M9[N_U*Z8DS3-UV@DX4= *\-_X>H_ S^_XG_\%*__ !VE_P"'J'P,_O\ B?\
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M.-HFW-MW<$5]&Z/^R.GC+36%O;K+O7&43CD>M?@N(^D3++:_L\9@(M7[M/\
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MOBB.R\Z^1E&YV(4"C^*NV^'6CPZA=B66/<1(!GTK]FS7V,<+*M77NT_>_P#
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MC%K^MN!,+6P658BC7CRR4GI\CPL5)2J)H_I(HHHK^7#V3\7/^"U?_)SOA/\
M[$^V_P#2V]K\^F^\:_07_@M7_P G.^$_^Q/MO_2V]K\^F^\:H HHHI@%%%%
M!116MX7T$>)/$&G::;N"Q%W.D1N+IPD<0)P69CT '>@#,\OTR:GCCDC*JH8%
MQN&>A%7_ !-I]OI>O:E9VLZ7,%O=20QS(VY9%5B ZL."#C(^M26B210Q7,K;
MQ]Q S?=7W'I3BN81T&EV=SJ"1K#&TOD0*LG.<*3Q_6O8;I9_[<T.*/5+J]A^
MPKY<DJG=$>FW'IGC->0>&_&$.BW%R9(S)%<*L;>6<$8/!KOH=776)K![6.9)
M%9$E1),B%2>@.1U]ZW6@(]*OO!M[K%A=:E%<*VHJV7@B)Z#N<=J^;_B;J%UJ
M'BJX-ZH%Q&!&V/0"OLS1?"<-G\/[HZMK8T;46D M_/M3)'+$>1OE7@#ZFOEG
MX[>&39ZS#K$-S;W=I>+L#6V-JLHP1Q3&>5PJOG+\P7YA\WI[UUFK:EIS0QQV
MLHD5,9D*Y8MC^5<DR@#C(J?2YHHM0MVF7? )%,@Z97/-0M"36T^..&WGGNEW
M0L"B)G!9ST-:4.E6NL>%[Q26&HV7S(HYRO<'\*B\?6=K:>(&^P.LVGLJO%C[
MHW+DKGVZ9K)6YGAMY)(F:*W;"L5X#'N,]ZO0$8C+MI*DF;<V14=<[W*"BBBD
M 4444 %%%6;&VBN+N".>?[-"[@/+MW;%R 3@=<>E 'UK^P7=/;ZQKHW;8_(+
M,?0U\N>-B6\6:PW4->3<^OSFNM\+ZU;:-X;\0-9:DUAJ$046\\5U)"\R[CDA
M0ZYR,<8.*\]N9VN)"[DM(Q+,S'))/N:GFJM^]*Z/+H8&-#%5<2GK.WX$-%%%
M4>H%%%% !4D."Q!.T=S4=/CQSDD=^* .U^)UAX4TV_TB'PG?OJ=G_9D#W5Q(
MA5OM1!\Q<>QXK)\(Z+)KVH1VAW_9V;)"XY;M6;8V=QJ#21VT#RD*7D$:[L*,
M<GV'K7:?#KQ)I7A:X%Q>0B>9'^7)ZU5./*K =[I?PLU7^W]-5[5K&=;A(XG;
M[N_(QSZ&O2_VA_A?X@U+3;G438QK<P*+F<VIRK(!M9@![\FJ'A3XV:?=-Y$I
M5HG.$#8,BYQP/7'X5[[HEOI'BSP3JITC69;MTM_*DA@RSQ!\[\KSA1_2M_01
M\[? /6(O&'A.R\'75Q>6%I'=M)-<0R849'Y]*^OO@O?'PVNK>%+C4/MEG(GD
MQ7$HX!Q\C$GVKYG\%_"/4_#UU<?V3IKWME;B1I=9CC8QNIX ;^Z1ZGBOH3]G
MOPOHWBV^NM6COYEU+2W6XEMVD\T20@#(([8P?6@9XK\66O?"M]>VK6>/+NFW
M,JD,ZG[N3W'>O$-6UI-.UB:008$G\9XX[U]+?M->)))/$NLS0S+<V$\@"[V!
MRH.>#@8QTQBO*/$.FZ#X@TE]]RG]I11*(GC90AR.1CJ2* )_A;Y>M:Q;0Z@R
M6=I<-Y:33KR5[ &K'BE=/CUB^@!*1PA@BL>7P>#]37*^&[^^C\3:)!JNH1Z?
M:J/*6; <HHX+;>QQZUK^,/#LMG>3R)<?VG"SAXYF8 R+UR<=,T >7^-)HYH-
MJQ,L@!.TC&0?6O']4A\N<@<KV/K7JWB.:XF+1O&7GD.$*GA1TQ]3Z5YYK6BW
M-F=TB;4///6E+8DY^BG,F#3:Y[%!1110 4444 %?;?[#]Q]F\#>*';;@1/\
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MWD>4T<?PUF^"JQYJ<F[?*[7XI'YIA,=4R_-,+BZ3M*+3_P S]4OA3\5+O7O
MR0RS,T?DCY2WM7PO^U])YVNM,AP%GRM>^? +4G?P_!"K9W0AO_':\._:PL56
M"]E=3YBR94BO\Z/#^,,IXUP]36T:D/NYD?U_FF4TJ6$S6G227-2F_P +G@OC
MBR%YI=C?HGS21!9..X%<%I,82YE.,'%>E7CF3X=QNQRV]1^AKS>QEW74HQ@@
M=Z_U?SRC2_M7!5W\3O\ D?Q#AI2]E./8T,?-7HWPKOXK69DD[RJU><9[UN>%
M;PP:U;C=A7.#73G.&CC<OKX>7VXR7I=/4X<=1]OAIP\C].? ]]'9^#/M:G:&
M50M3ZAJ USPCJJ ^8\<;'!Y[&N2T6Z,_P?TYK4[RH&_;ZXJ7X;SSSIJENXW"
M2!EY^E?XH5,+[.K4K/1PG^3/W?AO(J>,\-YU(RNU&7X-GYQ?$96_X22^R?XC
M6+HMQY,B29^:-P175?%JQ>R\57T90JWF,#GZFN&L9/\ 2-AZ=*_UJR[%QIK
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MI5(VN*^RQ$N6%[7U2'3BI-IGWQ^RUK@\2>%]2TF4^8H =>>>?2O3_"=F=/\
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M-O[3_(TQ?\5(_I(HHHK^9CV#\7/^"U?_ "<[X3_[$^V_]+;VOSZ;[QK]!?\
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MGR1KM73U'_ S_A7#[?\ .:-I_P FNSZU5E9-F'L*78W]:\62:QPT(B'H&)K
MVX97C=HG!^\IP:09Q1SZ5QXR,,QH>PQ<%.'9K0Z:+>'DI4G9KL66NY+C*W4\
MDZ=U=N#6PWBH0:6UG9VJ6BOP[*Q+-7.\^E+CU%88##8;*Z;IX&E&FG_+%+[[
M;FV(KU<7)3Q$W)KNV_S*5]I*WDH8RD<4ECIHL&8AR^[BK^,XVCZTCJ1BO(_L
M'+J>,_M"-+][?XKO=JW?L3[6?+R7T$_A%5[JW:X!VMC\:L'I25ZV*PM/&4G1
MJ[,B,G%W1E+I$RMRXQ]:OV]H(^7Y^E345\]A>&,OP<N:DI??_P  W^L3))I"
MT>U"?QK-_L^5I=S,,?6KU%=N(R7"XFW.Y:>8/$3;N7+.:*UD#$.>.JD5T-GX
MR6S "&8?E7)45ZGU6ER*'0\^M1AB-:BN;^O>)#K6$S(%[[L5QFHZ3-=S%D=0
MGH36I17D9ED6#S:@L/B+\J[.QOA[89<M)61B6VB3PSI(2N%/8U]6?\$]S_QE
M9X3_ -RX_P#1+5\W5](?\$^/^3K/"G^Y<_\ HEJ\&>0X3(<FQM+!WM*$GJ[_
M &6=,JTJLTY'B7Q()_X6)XI_["MU_P"CFKG1S71?$K_DHWBG_L*W7_HYJYP<
M=:^YH/\ =POV1SO<=BBBEKKTZ$B4M)Z4O-"Y>B$%%)SZ44AABCDT<^E'/I2T
MZ7 ,4@^E+2+ZTI6N M+UH4=R<5FMKUJC%2&R#C@5YN/S; Y6HO&UE!2VOUL7
M"G*I\*N:6#25G?\ "16G]V3\J3_A(+;^ZWY5Y'^MF1=,9'[S7ZO5_E-*EXK,
M_P"$AM1V;\J/^$BMO[KTO];<BZXN ?5ZO\K-/Z48-9?_  D5M_=>E_X2.V_N
MO^52N+LA_P"@N/WA]7J_RFGCVI,>U9W_  D-IZ/GZ4+XAM?1ORJ_];,C:_WN
M'WB^KU?Y32_"ND^&/_)2O"W_ &%+;_T8M<=!K$-U/Y:!LUV7PQ_Y*3X6_P"P
MG;?^C%KTZ6887,L/.IA*BG%75T0X2A)*2L?TD4445_#)]*?BY_P6K_Y.=\)_
M]B?;?^EM[7Y]-]XU^@O_  6K_P"3G?"?_8GVW_I;>U^?3?>-4 444#%,!\3&
M.13M#<YP:^B/@E)+\.H+75H% N[QE,LFW(1<\)7@-N($NHW!9HQC.1TKV?X6
M^,#;ZK:VI/FP$_.CKN!/_P"JM8Q[@?H?X3UG0/B5IEF-8:SNY9,*$9MK*X'!
M'H<UQWQ:^&-]X7\1&[%IOM'A.P&,>9@#[C#N/1J\DTCQC#8ZP'L8GB3S%<)$
M 64].E?0-]XY;Q1X CGU*.>3[(>)LGY5!Z$]?YUH!\.>(O#MWXB\1&TT\()9
M7(4,3AOH3T/:O/\ QUIVL?#.2ZTF\MQ$UP/F648;FOM'QEX7\%:+IT'B:T+H
M'&9H7;)3/<>HSZ8-?(?QW\=S^*-4:V<HUM'@1-)\S;>WS4 >.-(68GUIRLRX
M"'G.1CBF,#V!- (ZXQ]*S)L>I^#_ !DNO:=%HVM1?;&@(:WD5,RJ<^OI7T7I
M/B(+X3FM4MK;^SK>/+F0Y;?[YY%?&.FZA)I]]%<VS/$R,#N#$?GBO?;'7;75
MM 2[O86#LGS2(2 Q_P!WO^=6AGF/C-IOLS-%<*X>5@%BR!C)-<*QW#!+$KP:
M](\4^*-.D\+6^CVNFK'<PLS-. RN>?<FO-6E:-B.A[T2V$1,O2K%KI\UYO:*
M,R!!\V*@9MW6O2_ASX2%W:W%^(VN'C&XI]U%^I[GVJ%$HQO!/AZTN-2@&KI(
MMHW]SAF/8>U>K:CX5NKGP[/_ &3:S311'YKAP66).P&:N^"?#DU]>37$6EP2
MQJNYI).0@]"#D UZ=KGBIK+X?WFDF:*WMRN=D:YV^KDC^5:+L(^,]4LVBN'7
M'(X)]#61,NW.>HKK?%(7[6XPT?<+C!9?4UR<S;EK.8B&BBBLB@HHHH ****
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M=%>Y\SQ!PKD>,R^KCN&JC<J6LX-W?*MY+TZF-=:;HT=F^RQA$BX!^7N:\O\
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MAQ?\5'](]%%%?S*>P?BY_P %J_\ DYWPG_V)]M_Z6WM?GTWWC7Z"_P#!:O\
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MU2XMX[B5W :8C!QT'M7*W#?O#CCVJ*C)17;K10W6BL2@HHHH **** "E5BK
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M7-,[TN[L.M3<+ /6F,W-.8[1CO4=9E!1112 _?+_ ()F_P#)A7PR_P![4O\
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M_P!M"YTR8);JURH&3)(^,_H:^5EX<\>XV<:*P+NNZY5\V[(_5UXZ8_$.%/\
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M4^J8O"XF.CC.+_$_;O\ 9I\2+-\,[0LZ@A>=QKX*_P""A>L)J&O311H0&N
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MSW'WC'9*R2OY61_2.!\#\IP_[_.\5*HH]&^57^5CW/PW<6EY9K:Z7$+6VC&
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M)?%&HV]G,1EH/,+/^0!KB_B!^UWX4\&Z1-9^"-SWN2$E-ME1[G<17RE\5/B
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M8_ZD^V_]+;VOBKP7KUS8Z+XGTU&V65]9C[1@9)".&&/QK[5_X+5?\G.^$_\
ML3[;_P!+;VO@O3]1-C'=A8PWVB%HCST!(YZ^U &QJ'C:]:U^QZ?MTZQC)VK
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M.M.NM-6ST^WN1<1R/,3^[C/*_6LR1BQ^;K[U/)[SDV VBBBF,**** "BBB@
MHHHH  <4>E%% 'NGPG^"FL_'71;K2_!NB)=ZS#''O+;5RPSO.]LD9'85^B7_
M  3KNO&6C_!/2?#^DPVY&FWMY/?6\T$;(VVY".K.5+ ;5;&W&3BOFG_@F1K<
M>C^(=<DF7.[@-WSBOT$_X)JPP7'P U*Z\I3*_B;55\PK\VWS\XSUQS7B8?'2
MK8VMA6M(6_$Z)TW"$9O9_H=IJ/[1NG0PPK!X:A>2X@62.87$3Q0M)'OB67 W
M9S@%5!(.,]:TKCXZV]C=:'9S>"[II]0B21KD^3%; '8#(CLWSQY?J!G@\5ZG
M'X(\/1R1NFAZ>KQRM,C"V3*NWWF''4U-<>%=&O%M5GTJSG6T&+=9(%80C&,*
M"/E&/2O8.<\2A_:;TB[2WD@\'331212RR2+)$!"$=E^;(!Y*$\ \%3WJ]J7Q
MTMK6W2=M M898[N6"2Q6ZB:>0I%*Q4J4^1257:Q(SD=C7KLGA#0I+B*=M&L#
M-$"$D^S)N7(VG!QZ#%$O@_0IIKF:31[&2:Y4+-(UNA:0!2H#''/!(^E 'R[\
M:OCA8>/O@G\2-)M/"]Q9#_A&;Z1KYVA*1R+ 6*8'S$@\9'&1UK\$22<5_1W^
MU%X5T;2OV;_B9<V>E6=K<1^&+R!)88%5EC$3?*"!TK^<.J ****8!1110 4^
M)4;?O.#M^7ZTMO&DDR+(_EH3RV,XJY8Z7)?3;8\8)(#8XXIQU 2QU*33@YA;
M8S#&[OCTKT?X!1^#-2^(!B\>&./0GMI9#*S%=DB#>H '7<1MQ[UY_+HMS%$T
MFS>JG!&.13[70;F]TVZO052"W(!#$;B3Z"E5I\\'&^XBIK$\5QJ%U+ @CADF
M=T11@*I)P .W%4:DE#9Y&,G.*CI6Y4,****8!1110 4444 %%%% #@QQ[5[O
M\._@/K?QR\)WC>"-"2YN+,+).S%$P%3]X0Y^;J,XZ9KP:OT-_P"";>L6^G>#
M?%44IV/+#-M;_@!S7D9KC99?AO;Q5W=+[V:TJ<JLN2.Y]T_\$U5,?["/PU1A
MAE?4U/U&IW8KZ/KYT_X)O\_L-_#L_P#3?5?_ $Z7E?1=>FI<RN9!1113 ***
M* "BBB@ HHHH _)'_@KM_P G(>&?^Q1M?_2R\KXBQ7V[_P %=O\ DY#PS_V*
M-K_Z67E?$*\G%?V7PE_R(,+;^0^?K_Q9',:E'LNBWO6SH<_ELI'!ZT^33(II
M&W-S3H]/$)!62ODLJR',,MS>684TG%R;LFKZFU2K"=/E9N:IJDUQ JR.2%Z+
MGBLS3Y#),<BF20O/P9>E$,3V[#;)@U^L8C'8FOCZ==4VH1Z71PQA&,.4]>M%
M:7PU (R<;,$>]>97T,^EZHDX5A)&V<?C5FT\3:K9PF**[Q'_ '35>ZUF]N\&
M:8.?I6^:0PF<8.K@L3"7)/R_X)C@O;8*NJU)JZ=T=:/C%J[VHMK>'8<8R<G%
M5]+LV9IM?UEB2/F4MW/8 'M7+1:C<0MNCD4,/]FG:IK%_J\*Q7%QF)1@*HP*
M_.^'>"LAX4G/%9?1<JUG9RTMV^TU\S[+/N*\[XBC"CCZ]X1UMT_!(YSQ5KTF
ML:E.[<J6_(>E)X=_U<O%2G0(&;)=LFK=KIZ6.[:20WK7SV5Y%GLN(5FV8I<N
MNS3LFM$>%*I25'V<"<_>J2-5Y))P*92,RJVUG53Z$U^LXF_LG9I>NARTFHRN
MU<BO )A\O.*K6]O(&XJX%3. X_.I%8= R_G7S/\ 9,JM3VM2:7HSI=:/8HWE
MJ^TMC-9JL8Y/QKH=W;*\^]5Y+2'<=Q4-]17F9AP_*K-5:-1*W=B55=BWI]T;
M=HY58YZ&NRL?%R6<*@R8XKA5DBB7;YBX_P!ZE$L7_/6/_OJOIJ?LHTXPK58W
M7FO\SS<3A88EIRB;WB7Q(=3P"^(1S]:X'5IOM,A(-;L_V>XP'E0C_>JN;.Q[
MM'_WU7Q_$&78C-Z3PU.K34/\1WX7V>%BH4TSG]/7-Y%]:^O/^"?''[57A/\
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MLM_0_7+_ ()M_P#)B_PX/_375/\ TZ7=?1E?./\ P38;=^PG\-C_ ---3_\
M3G=U]'5WI65F?,U+<\K=PHHHIF84444 %%%% !1110!^2/\ P5V_Y.0\,_\
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M*R'Y0K$?G[5]%:+\4/\ A9VDO;7UBL\\4>-R2D$YK_./C[PDQW#>.GF=!\V
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M-]XU0!1113 **** "E#L.A-)4MO((FRR*X(Q\U #H[AUA:+/[ICN*^]1/C/
MQ2\=JLV%C/?M*EO \[QQM*P1<[4499C[ 572P$=MM+!7/!&<UIV\<\ENSG<(
MTZ-NQQ_6H(=%OIULFCL;AUO9#%:LL9Q.X(&U3W(++P/[PJO?+-;RM#*LD;Q$
MQM'(-I4@X(QZU<9"/4?"D^EW.GH/M=K:1HH6XCDD.Y\_Q >HKLM/;X<^&M*B
MO=1\03:I=O-N:R@=AP.Q[ 5\Y_2GOV/?-5<9WGQ,^*%QXUF2VME%EI-ME(+>
M/@%<\$^II?A6OA;4]4\KQI<W2Z5;IN40$DY]/85P/7BMWPOIIU)[F .4/E%A
MCOBDMR;G5?%?6/"%UKT=OX+L)(M,B0#S)OO2-W-<G8WEUI+-=174EO<X**T3
ME74,"&&?<$C\:S88)IKD11;GDSM^4'-=WX?^%VKZI-$#:RF63!!D0[<8[UH!
MC>#_ !!XHTW4K2/P_JVHZ=/&[&$V<[1E&<!6(P>"0 #[5%J6H>*O".LO;7=Y
MJ&FZA"DD7S2LKA)03(!S]UP3GUS7UE\)_@?I/P_T]O$'BBXC@N5!,%NP^9R!
MD''IFO*_VI?$5E\0-8@U>"-?[1M8_*F:, *T(X3CU7^M8RB4>*^)/B!XF\8P
MQ0Z[KVHZO%$0T:7MR\H4A0H(#'CY0!]!6!1168!1110 49-%% "^8Q_B/I24
M44 %%%% !114L:%E7"Y/TS_GO1H!%4]E</:SB2/!8=B,@CZ4Q,QR!N,@Y -6
M'9I96EPJDG)P./PQ3BK@6H[=);% J8F#<L!PP-=)X;M56996@_>1LN"O0FLC
M2@\;"3;O20;=JUZCX+T5(-0AU#R"\2HK-;^N![UT+06YZ'\)?#_A5[R:\\01
M/"+CF"[C;_43'[H8=U/<5<:.6WUZ[TV*Y0Z1;W7F7'E(&RI_B []:=X3\+R:
MU-+-81M/8R2!KFSQ\R9Z(/\ &M:ZAU3PCJ5S';:;)8V]RY@C2XBW%0>/O$=C
M0,JZ[\$?"/Q(F%QHUT=.NK-2S21J$\XCD,!V/O7*>#])\7_#GQC#/=W4EQ',
MV0\CEB%Z#<,\C%;K>'_$%I(L<THMH%#I)<H_E<D\9'I6LRW#:0+W0XY-2U+2
MT7[5*6\S=@X^4>E 'KOQ=^&\/Q8T?3KR\TU-2O+"W7?]E4DJA Q@_P!!65^S
M?\+--T/QQ=SZLHT6SLX2?LZPLSR@<Y]<U>\ ?$34[R1-4\20MI%E#&)'O!*(
MU?;G("^O2O _BY^UU)-XE1O!"3:=%"S":\:;=+<G/)(["@'8^K_&G[2%E?S&
MVF\+7(T%&>W^UE/)5QT!R>>,9KPWQYI>AZTMW)H5]'.&!D<.QW -VXZ5\[_$
MC]H+Q-\239Q:C>[HH@%6-!M';)('&:;#XH>QTJ&5)3''(,2%&YXIBN2^)_!H
MM\3W"J610J!6R7.> /6N7\77EQI:-ITL$UE<0CRYK.92CH>."#R#QGGUKT7X
M016OC#XF^')-4U);72;!VU*ZDD!9(8(%,K,0,E@-O0 DYXKW77O!.D^,/%7_
M  G=CIEE\3YO$YT>VGFDM;A8]CM+!>S)&P1U;=#&NXCY2_(YJ&R3XH74I;G2
MYHA&\XC ^=5R(P>,GZ].:Q)+23:\HC^4?>]!7W!HOAG0[6PU'P/X=\(Z'?0W
MFEV,DVI7*2F:\WZGL+-(K'8NQ5^ZIQR>X%>5_M/>'=*\,3>%[NPT^VTX:EIT
MS2K9V4MI#,\<[H&6.7Y\;5 W'&< XYJ-QGS2U)4DR%6)]ZCJ&K,H****0"JQ
M7H<4;V]3244 ?OE_P3-_Y,*^&7^]J7_ISNZ^DZ^;/^"9O_)A7PR_WM2_].=W
M7TG4 %%%% !1110 4444 %%%% 'Y(_\ !7;_ ).0\,_]BC:_^EEY7Q"O6OM[
M_@KM_P G(>&?^Q1M?_2R\KX@%?V9PCID.$?]U'SU?^+(IOICWFLPLHW#BO0X
M];/AGQKI=ZK%1&J(WM47@_2[?[&VHS'+(Y"K[XZUF^)]MW,S;LGUKTL;P7AL
M=D^886GOB?>?J:Y?FU7+\QH8NEO2::/T!^'_ ,8H=;\-I!+=@*5XR:X?XF^#
MM)\3+(S/$^_L>M?&OA?XCZQX3_=H6G@SQR<BN_A_:'D\M1+:R,P'/!K_ #0Q
MGAAGN28Z4L+1D]=XIG]DY+Q=PQB4\2ZZHN7Q0DM/3S.@C^!^E6^J+(I5HP<E
M:]Y^'L&D>#85D)150<"OEVX^/S8)2S;=[YK'U+XV:WJ49CMX?*##&[/(KT:G
M!/%G$#CAJM&;Z:IGH8GBK@W+\/.%"O&*ENH+<^@?VBOVA%FL7L-/FW3L-BHI
MZ>]?+FK71\/Z"TS%O[0OAO:3/(4U4M8Y[J\-W>R-/*6W$L?>NAU:QL/$D,:R
MS"WE"XR?NXK^V/#GPIGP7D-:5))8NK%J_P#+=;?>?RIQ=Q<L^Q-.C2AR8:G\
M,?U?FSQV9B\A8YR3WKLD!^SQ9_NBH]<^'UUIL)N$/F6Y.%D3D4]6/DQKZ#%;
M<$Y!F.0XS%PS"%G)1L^CLW?4^4Q-:%:$7!@,UVGAGPK_ &A8"XDC_P!8_P F
M1G('6N,!K1M?$5_8QI'#.RQQ\JN>!7ZEBG55-^Q:4N[U/'Q%.K4ARTG9GU1\
M$=6L_ VI"ZN)T@Q@88XR*^E8M6\,?%%2J75O]LVX!B(_*OS*;QEJ4S#?<?A7
MHWPF^+R^%?$%K<SRG8K ,!Q7\5^('@KC,X^L\0X?&NIB[7Y%"W-:RM'6^B\C
M#(LQSSA'$/&X&K>[3E'H[:?D?5]KX?2W\1W>E3H28V.&'!-/UKPY!I(+FXFA
M;J/G-;/]H:?\58[76O#NJV\=Z5&^&1PK\#G-1W6@V=G,K^*O$-I;KU$9E'(K
M^;L+FV%P^"> S#"R>)C=.+C[UUY63/[JP/'^1XK"4L=5Q].%XKFBY)24K:JS
M_P CBFU&]GA,8=WA)QNS6_IWB3^R]*%C:PK+,Z[<E,GFN]\/^*_AY'MLK*\M
M;B0_*#P173V?A>S^UK?11V\EOC<&"BOCL/Q+B,CJ5+8=TW):<RL_E<YJ?B+D
M&9RJ4\/*,N3724;OY'+>'=*/@KP;>ZFR,]RZ%@&XK\^_C7X@GUGQ1=-,H#/(
M7./K7TU^U)\1M1L9'M;343!;A#F-#@=:^*=4OYM4O'EGE\QV/4FO["^C[PCB
M*4*_%.*DFZR<8K5-:IWUTMZ7/XZS[/JG%N>U,UEI3A>$4_*6Y3$*B7>*^D?^
M">O'[5GA3_<N?_1+5\^S:8UO8I<&16#-MV@U] _\$^?^3K/"G^Y<_P#HEJ_K
M;,Z2HY/BDOY)O[TSGYU4FFCQ/XE?\E%\4?\ 84NO_1K5'X;T7^W)C!NV@#<3
M4GQ*_P"2B^*/^PK=?^CFK7^%^GR:EK3P1\,T3'\J^TRN<80<I[*/Z"5&IB*B
MI4E>3>AT^C^'[/0<LI+2D8R:[OX77[6.NF:/<!GK4\/PUN)E#/NJ]I6A'0YB
M&8K@UXF:YE@<RP-?#0J*<I1:LF?HF0\.8W+,7#&5TU8]XB\1B2R4D]1SFO/_
M !9>64\P\R%"<GG%<EJWCJ6QAV C&,=:XR^\53WDQVNQ%?BG"?AE4R_%/&N7
M*GM:Z/U+.N+<+3I>RFTV>G>'[[3()@YB4$,.WO7K5G\4-,TG3MYE557MTKY&
M6^O68D2,@)]:SM>\2+I,0:\NWD?'$(/\Z]_B3PCRWB>LJF/K2:Z[[?IZGQM+
MQ$H8.BZ4*7.^FQ[+\4/CG<>)5EM]/!BMNAF)KP#7?&D4)>&V_>2G[[^M4K>X
MU?QE/Y$0:QLN[ =:J>,O"=AX;M8U2[>:Y./SK;*^).$N"Z]#AO)*;J2;LU"\
MK?XF?D.=<25\\Q488N?I%=#*OM2-_@D]ZSKC_5FEA7Y!27/^K-?TK.I[3 N=
MK71Y45:5BC4^H0PI%$8CEROS5!TJ:W2&28!V)'I7YKBM817<ZMG?L,L=)NM2
M;;;QM(W3:HR:]6^'?@G5])D6XN;>YMX>I;!7\*L?#_5M-T56EG=()0!M^7D^
M]7_%'Q:N)&"17+"!<@>]?S%Q5FO$>?XO$<.91@;4WI*I-.S2UW:Y4F?(8_&8
MS%S>%H4_=[LMZAX#M_$5P=MT<L>5FYYKU#X:_LX16*VMY>(9F#;U1 ,$5Y-X
M%^-&EV6H(=1L8YU#<D9!/O7T3:_M3>$(+.%(G:W(&-K  CZ5_/\ Q3#Q(R[
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MTT*=23W((8G5\L*Z[X8_\E(\+_\ 84MO_1BUS!]B:Z7X8_\ )2O"W_83MO\
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MN_#>O217B,BABB2JO[J53TP>U=+H5]/I=DVG6UP&C<[9(I!V].?2OT[^.7P
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M]\O^"9O_ "85\,O][4O_ $YW=?2=?-G_  3-_P"3"OAE_O:E_P"G.[KZ3K,
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M0_G?)L8Y\]&H[R@[/S&^'3S,/85]5?\ !/7_ ).J\*?[ES_Z):OE3PU]Z?\
MW:^J_P#@GK_R=5X4_P!RY_\ 1+5^NY#_ ,D5+_!5_P#;COQ'\<\2^)7_ "47
MQ1_V%+K_ -&M2^ XEDUDEAD+&QI/B5_R4;Q1_P!A2Z_]&M2>";V*QU5WEX0Q
ML*_7<#O"W9'GUOAD=CJNI&%)"#A5%8=C;WOB"Z6*'S-['A4K2\2B.2QCGMVW
MQNP!Q7N/[,7PW?Q!=&\%LS$L$3*_F:^>\1^-H<!<.3S6*3J7Y8IZ:GUG!'#U
M'/L8XXEVIP5Y>B/+[?X0>*9D!C28,1D;GKJ_"/[-OB'Q'=*MY+*$Z;<$U^@N
MG_!-+73XWG@"# SN%=EX%\+^'-(O )YXDD!P%/ K_//&?2)XVS&'U/#RC2<]
MI-*+7S?^1^NU\'P?EZEB,-AG5E#I=M?@CXIL_P!AX&R61HIF8CN*\*^*7P9O
M/A3?8F5Y=/D.U]R_=STK]R]*TW2KJQ3RUAE3;@$ 8KP+]I3]G.P\>:'=R6=J
M&D9.54<?6OH<CX^XWX3Q=/-L=CY8W#-KVD-=(O=QU=[>2/G_ .U<ISZ+P6-P
ML*'-I&<5K%]+VZ=S\.?%6BMI]T63YHB<JPZ8K$M[P%B&.#7T%\5?A#J7P^OK
MG3]4AE^PR,?)F(^Z?2OG3Q!IEQI=\49&4YP*_J[.,[PF(P5+BG(I^UP]3>W1
M[:]5KT/S;$Y;B<MQ#P&-5I+9])+NB_;S"28@<\9JW6)H98W,@<;6 Q6T*^FX
M7S"6:8%8I]6SS*T/9RL2#O\ 2LB&3=<.#TW=:UUK+4#[00!_%6_$*FJF'E&5
ME=Z=]$31ZG<>"?!UQXFNH[:&T:XDD; QUQ7T1X<_8MGU6&.2[N#89ZB4;:G_
M &+='2ZO+O4Y+<.MG 3N/8]J]4OM4O?%FI7D]YJ;00Q,0L:G%?QEQ[X@\3U.
M)L1D615E0A2TNDKNV]VU?\3['@O@6OQI4KXFKB71HTGRVBKRDSC(_P!BOPG8
MX74/$YW]U5@*GD_8_P#!#Q,EEK9FN"/D#RC&:M);&XN)!;I<7>#]Y6-.GMY;
M49DLKF$G^/)XK\AGQ5Q=.H_:Y[/F72[7Z'[R_!7).10>)J\UM^;]+H\1^+7[
M*^O>#X1=6ENU[9D$^9 -V /7%?.&LZ#+!*XD#)(IY1A@BOT1T'XB:GX?S;F;
M[;9-]Z"<9%0>.O@KX7^-FCSWVB6L.G>(,%S H&UB!7Z%DOBQB.2.6<80]K2>
MGMHOWH^<DMU^/J?DG$GASG/"=-XK#R>)PZZVM.*\UU7H?FK+;F)B&R#]*9MP
M*]"^(/@FY\+ZM=:=>IY5S!(4=?0BN FC,;LO7'>OT3-\IC@7"OAIJ=&HN:$E
MU3U6GH?#X;$1Q$.>)K^&_P#72_2O1/AC_P E(\+?]A2V_P#1BUYWX<SYDOTK
MT/X8_P#)2O"W_84MO_1BU_0_ U_]6X?]O?FSS<3_ !ON/Z2:***_E$]P_%S_
M (+5_P#)SOA/_L3[;_TMO:_/IOO&OT%_X+5_\G.^$_\ L3[;_P!+;VOSZ;[Q
MJ@"IDC7[.9-XW[MOEX[8ZU#13 &^\:GL;I[.Z2:-MK*<@BH**$!Z=X?O-*UB
M\BNX52UNR0);=ONG_:4^IKW;P?I&E7TL:R3FP88:*=#N"L/6ODO3+MK6Y1EQ
MD'//2O4?"?BB2.=6MKAK*X3EH';,4@]B>AKHCJA7/TL^$?C)CI:^'_$;#4M&
MN0%2<GS"AQCA^H^G:O>-!^#>F7%M%J6A74-[:2 (UK=_O$ [C![^]?F9\-OB
MMJNGZM;R1WS1V>0)H2-P5Q7VW\._C%J%_P"'3'::I;HQRRVY3;AASG(J6BX[
MGI?BK]G'1[K3=0CM]$AM%N$+,\$A^5\=0/2N,7]E^>TTG3'CN)WFB8,5$";3
M]2:Z32_VKHHY8M/OX(Y;Z,?O5#A/EQUYZUA:]^TT+OS9X6\I$?F+S@AQZ 8.
M:G4O0[JP_9RTBWO([Z2SN;DOM:6Q,N$5^[#T^E>FV6GG2I(8K.10BK@0RQ\J
M/0-7DGPY^--QXPAF<"3,*$C<ZAOKC)!KU#PSXFL;Z".634;AI&'SQS*-JMVZ
M"@>A7U+X96^M>*+77+F_N#/ 0T:QM@?3%;'B?QA:>%;"2XN TJQC+;R /SK.
M\1^(BEZUMIJ++=HN[=NR%S[ U\C?M(?%*_@MIO/U:2=[=BIMP $4CL0.M))W
M"4K;'6?M'?$N#Q1X5M;JSG6"=7PEMNRQ'KGM7Y_>.&NM1U24JDDEQ-+G>S8V
MCZ5TOB3X^>(?$N@R6%G:V5M:1 F>XC3,C>V3G%>/KJFM:U>H\=O>7;S2[1#;
MJ=Q^I(K5&;=SVKX=>#;[7)%BBF!2W >2)(RJQ_4CK]*YKQW#;>&]0N(YTC$K
M,21'U '0_4U[IX%M]=\#_#60QPIIE_<1EGFNB&9%Q_.OC_XBZ\UYXDG9+N6Z
MF9F\R7&!UZBF2:.H>+[J.^$=J_E0L@7D]!Z5BZOK$E[-F6<E8_NA?:L6VLV5
MD:2Y&]\DOUVU8@U:QLHG!MO.8-P'/+?[1]J!7.N\&PS75KYH5;6VW$O+)P3]
M*Y?XV:AINM1VQL8@)+?Y!(/[O<?7/>LW5/%]Y?0X^T+;PC^&,8''I7!ZEK$]
MYE3(63/7UI:6 RS1117.,**** "BBB@">WD&T@]JOQL0@9>4/WA64N>U7[6Y
M D ?@'C(Z?C6T7T%8Z;PW@76TR^6S<)(#P#]*[K3-0U"U_XE\LD4\6?GC^O]
MVO/;732UN;A P*_Q+R![UK0(\:B<W&'(RA8G/U%:6"Y[;X0DN]-N&ELF9#*N
M/+9\ \]*[[0=8DL/$MGJ26DNEZM:G,EJK I(/[V#7DWP\_M.:%KEO,O;:%=Y
M*@,T8[GZ=*]0T_QA9^*9+)M0*FZMSLCN]F"1_=;UJ;7*/NWP'\4'M_"-HU[%
MA[PAUE@)CD3/MWS7T7H>K6^J>';>Y9R4>,!C(,-^-?!OAWQ<]]J&C:4UPDZ1
M[5A")\RGTKZ&\2_$34-!\-"UN%AMV5.=ZG]X,=<@\&LVBDSU>'QA#),L%D1+
M$K;7G4G"GT*UT45]'<N!'<1R <\#%?,WPT^)WAZ:&]:ZO9/M&>FXH#]>.1[U
MK^(/C)%INEM?Z?)#"B'!>&3>JG/&1WHL5S,]\UK6K/1[5KB\EV(.B\<FOF/X
M\:EXG\0QRW-LTZZ>RXCC5#SS_LURGCKXD:EJ[V<4NHF6^F(\M8>0X/L>E>T^
M#?B!!X!\(VJ^)(98IR-P$TB2,P_#@4!?FW/FKP5^S5XZ^*RW+7=])I,49Q%-
M=(Q+#M@T^X_X)[^(-)\1B>#Q!;FT;F6YD0DL>X KZ$\4?M2:/I]I%/8DVUL3
MAY)%W@#/7 KE[7]L2VGU"2)8%O+&/_E],97 QV6AAH>$_$[]FA/#%\-0OIR=
M,AAQ%\N#(W<A17S)K&A)+?736L;Q)"^U%8D#)/4_X5]!?&[]I#4-2U:X6VG;
M^RV;8I7G'U)KP_6O%%K-IDLB7>\S?,UI"G).>[5J9%%I+31;"2VNBSS1H"&C
M "Y/8@=?K6-XFU%;ZWL=MJC11KS&HP2>V?6L.\\426XF6>..T61@%3[TD@^M
M8T?C9=.A=$B:24'"^9SM!H$2:HT/[VYGD*A?F\L>HZ"N*U+7'OK@>5&8H!]X
M-WINK>(I+KS&DD4JTA*QQ_UJA=ZLDUKA5(P>3TS_ (T"*-Q,MU=R&48BXQBL
MO5KB*6;; ,1+W_O>],O]0:X8A,A.G3%4,FLW(=A6I***Q&?OE_P3-_Y,*^&7
M^]J7_ISNZ^DZ^;/^"9O_ "85\,O][4O_ $YW=?2=2 445XA^UI\?-9_9[\!Z
M3K>A:/8:W?7^JQ::+?4)'2,;U<ALH0<Y4#TY-5&+G)0CNW;[Q2:C%R>R3?R2
MNSV^BOE.X_:J^)?PK\3>'+?XQ?#O2="\/Z]<+:6VK>'M0:Z6&1L$>9DGC!Z#
MFOJ>ZO+>RQ]IN8;<,< S2JF?ID\UI.E*FE)[/MKMN90JQFW%;K77L]G^!+13
M'FCCB\UY$2+&?,9@%QZYZ5B^+/&-CX4\'ZMXB=X[RTT^V>Y989T_>;1G:&SC
M)K!NRNS=:NR-VBN#^"'Q<T_XY?#71_&.G6DFFPZBC/\ 89YDDEAP[+AROKMS
M7>5I.$J<G":LT9PG&I%2B]&?DC_P5V_Y.0\,_P#8HVO_ *67E?$*]:^WO^"N
MW_)R'AG_ +%&U_\ 2R\KXA6O[)X1_P"1%A/\*/!K_P 61UW@FX6SAOYBNYU0
M8/I5GP;H\OCGQK")ANBC<,?PY'\JJ>"H1=6NI1?QF/@=S7:_L\R1Q>,+BVD
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MOY+/=/Q<_P""U?\ R<[X3_[$^V_]+;VOSZ;[QK]!O^"U7_)SGA/_ +$^V_\
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M[F."\A7Y(R%*/GKCTJ2\\?HL-K;-,)-K%I(3%@O]3WKYET?Q9,T8_>[9T/\
M""N*L-\3Y[>XC1IVF96(._YB/H:7*%SZ#C\<2S>(II/[/9V"C[,MNK;Q^5>K
MZ7IWBO6O#3ZA?66I/'G]U&UL[Y'N2.GTKY7\%_$>ZCUZ*YMKK;<Y $:DCGUK
M[A\ _%_Q'XAT.WLPMU=76/\ 5HVU&^N.*-@N>0ZYX<UC3]%D,\CV]N?W@$ML
M?E&?<"O'[74;>[U*X26:>:&(,PDMTPA]BM?:GQ&634-%=O%IBM[%(MLD=J@9
MP/3/K[U\"?$;7[?P_JUY9Z/YEM;.S!8S+R$]?K3T$<%\0/$%O)JL@;SF!/\
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M+X3_ !U\-+&;"_OS&D@QAUP.E>A^&=2\2?#[7G\0>#'COM.F/F.@.<CKBO\
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M]N(K_P <\3^)'_)1/%(_ZBMU_P"C6KB]:4R0*H'.[%=I\2O^2C>*?^PK=?\
MHUJP;737U&<11IO;KBOO<=ELLVR]X*+MSI(PC/V<^;L;_P /[426=VCG_EG@
M ]*]^_9B\97.EWMS:&<HI*LG/ID?U_2O(-!T4Z5I\S.?WCK]WTK5^&.I#3/$
M4;,VS][@Y.,<U\_XF\+T\RX(KX%KG=*-UZI'WOAWF"H<013^"HG%KU/K[XE7
M<OB;0[B)I&?S8RO7VKXR\0:#J&A:C*B(R_UK[&T^^@N=/1B5=77KFO._B!:Z
M-(R&66-3R,$C-?PCX3\<8O@;&U,-1I<T)[JW:_D?U!Q)PMA>(,$L/6]WDV>G
M4\I^%?PVNO$FH+<2J5A5T+EA][YAD?E7Z3?!N:#P3X>6XED5&5< &OC+P;XR
M\.^'X0BW<:,,=3@<5H>._P!IFWM]':QTQS>7)X41D@#WKBXWCQAXH\00^KX>
M>KM%6LEYW=D>%C,ARO*LF6!E54*2UF[J[^2W]#N/VKOVC)9T:PLYM]U(2B@-
MR!]*^$O%6LOI]K+:LWF3S'S)9.Y)[5H>+?&31WTNH7UQ]IU&3^$GA,UYA?:E
M-JUTSL2Q8Y)S7]D\(\-X#PIR66 I3]ICZWQM;WUMWT5]-3^<N(<YCG=6%#"1
MY,-2^%=_-EN"X,S9%61][-5+*W:,;C5M:_3\H>(EAXRQ*]]ZGQM2U[(?77>!
M?B%=^$+J*6*=E1'&4S@$5R7/;ZUOZ3X-_M":V#2-^^&X84]ZY^),/EV,P4\/
MF:BZ+4N92=M$KM]]/+4\_%1H2I-8CX3[H^"_QOTSXK6 T+5DW7;<0N#G:<>I
MKHH-:L_AWXDFMIH 8SE6P>HS7F7[,_P<L/"=U%JUYJ#;R=ZJ.!GTKV3Q)\*[
M[Q9JS7Z7<15CQZU_DCQ7#(,+GN(H93.7U1WM>Z^X_?O"7.:&-P.(P&9XCFPV
MT4WK;JM-;>IYA\1?V<--^(@GUS2M55=Y\PQM" 1GL<=:Y;X<_LXFWU(%T2Y6
M%OFD=< 5]3^%_";^&+$PS2+.<8VCI3?$EN6T22.!&CFYR(1C=6%+Q#X@IX!Y
M)2Q<GAMDM-%]U[?,^/S+P[P&.SI8;+\7*&%;NXVON^C=G;[SF?$RZ?8>%H-(
MCF0F,8:-2*Q_!OA_2M#M+K6[T*D-JA=3*!@D?6L_1?!M]JNH$M#* &Y9P<5P
MW[5'CRST'PRGAJWDE\^/'F&+@?C6&1Y17SO,*.3X.3E.M+5KHNK9^O<4YEA^
M >&XY1EM7]Y-<D5UUZV5]OD?*7[0'Q _X3KQGJE^)G>#S65-S9 4< #VKQ"1
M@9"0<C-=/K"B\DE?H&8D"N:FC\MR.U?WCQ'E/]CX3"9=AXVI48J*?=K=_/\
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M7J_PIN++4+:20&1[E'R&A.''XU\:6'CF\T^Q%K'%$4!SN.X']#71Z#\=-?\
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M.,8/J .<?6O,B<FBI<P-?6_$FH>(K@27]TUPR\*#@*OTQ60>IHHJ+@%%%%(
MHHH&>W6@ HI>:W+/P;KU] DUMH][/$X7;)';NRG()'('L:'9 ?NK_P $S?\
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M_P!%GD_\)C_[LH_X<;P?]%GD_P#"8_\ NRG<#\HZ*_5S_AQO!_T6>3_PF/\
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M_#C>#_HL\G_A,?\ W91_PXW@_P"BSR?^$Q_]V47 _*.BOU<_X<;P?]%GD_\
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M^(<81T2LM/P,)4*<G=H_/7_AS5X$_P"B@>(O_ >#_P")H_X<U^!/^B@>(O\
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MV_\ \37Z%44O]=.(/^@J7W1_R#ZO2_E/ST_X<U> _P#H?_$7_@/!_P#$T?\
M#FKP'_T/_B+_ ,!X/_B:_0NBC_73B#_H*?W1_P A_5Z7\I^>G_#FKP'_ -#_
M .(O_ >#_P")I?\ AS7X$_Z*!XB_\!X/_B:_0JBC_73B#_H*?W1_R#ZO2_E/
MSU_X<U>!/^B@>(O_  '@_P#B:3_AS5X$_P"B@>(O_ >#_P")K]"Z*/\ 73B#
M_H*?W1_R#ZO2_E/ST_X<U>!/^B@>(O\ P'@_^)H_X<T^ _\ HH'B+_P'M_\
MXFOT+HH_UTS_ /Z"G]T?\@^KTOY3\]/^'-/@/_HH'B+_ ,![?_XFC_AS5X$_
MZ*!XB_\  >#_ .)K]"Z*/]=,_P#^@I_='_(/J]+^4_/7_AS7X$_Z*!XB_P"_
M$'_Q-=Y\$/\ @F/X2^!_Q*TSQEIWC+6]1N[ 2!;:YAA$;[T*G) SWK[.HK&M
MQ=GF(IRI5<2W&2LU:.J^X%AZ2U2/@/7O^"0'@?7M<U'4Y?'GB&.6]N9+ED6"
M#"EV+$#Y>G-4/^'-7@/_ *'_ ,1?^ \'_P 37Z%T5K'C+/XI)8I_='_(/J]+
M^4_/7_AS7X#_ .A_\1?^ ]O_ /$T?\.:_ ?_ $/_ (B_\![?_P")K]"J*K_7
M3B#_ *"G]T?\@^KTOY3\]?\ AS7X#_Z'_P 1?^ ]O_\ $T?\.:_ ?_0_^(O_
M  'M_P#XFOT*HH_UTX@_Z"G]T?\ (/J]+^4_/7_AS7X#_P"A_P#$7_@/;_\
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MT%/[H_Y!]7I?RGYZ?\.:O ?_ $/_ (B_\!X/_B:/^'-7@/\ Z'_Q%_X#P?\
MQ-?H711_KIQ!_P!!3^Z/^0?5Z7\I^>G_  YJ\!_]#_XB_P# >#_XFM#P_P#\
M$@_!'A[7M.U6+Q[XADELKB.Y5&@@PQ1@P!^7IQ7WW12EQEG\E9XI_='_ "#Z
MO2_E"BBBOBSH"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
/"BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>business2ba.jpg
<TEXT>
begin 644 business2ba.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0"N17AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     @   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E         !@     0
M &     !    1TE-4" R+C$P+C,X   R,#(U.C R.C T(#$X.C,U.C$Y  $
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M1T(@6%E:( ?I  ( !0 ! "  *V%C<W!-4T94
M          #VU@ !     -,M;&-M<P
M                                #61E<V,   $@    0&-P<G0   %@
M    -G=T<'0   &8    %&-H860   &L    +')865H   '8    %&)865H
M  'L    %&=865H   (     %')44D,   (4    (&=44D,   (4    (&)4
M4D,   (4    (&-H<FT   (T    )&1M;F0   )8    )&1M9&0   )\
M)&UL=6,          0    QE;E53    )    !P 1P!) $T 4  @ &( =0!I
M &P =  M &D ;@ @ ', 4@!' $)M;'5C          $    ,96Y54P   !H
M   < %  =0!B &P :0!C "  1 !O &T 80!I &X  %A96B        #VU@ !
M     -,M<V8S,@       0Q"   %WO__\R4   >3  #]D/__^Z'___VB   #
MW   P&Y865H@        ;Z   #CU   #D%A96B         DGP  #X0  +;$
M6%E:(        &*7  "WAP  &-EP87)A       #     F9F  #RIP  #5D
M !/0   *6V-H<FT       ,     H]<  %1\  !,S0  F9H  "9G   /7&UL
M=6,          0    QE;E53    "    !P 1P!) $T 4&UL=6,
M 0    QE;E53    "    !P <P!2 $< 0O_; $,  0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_" !$( ? #!P,!$0 "$0$#
M$0'_Q  >  $  00# 0$             !00&!P@! @,)"O_$ !P! 0 " P$!
M 0             ! @,$!08'"/_:  P# 0 "$ ,0   !^_90FIQ@8M0HSV*8
MK2!*0]B1*HHR**\I"5+?*T@32XP$767H5!'%WFP)F E"F(DE#8,W2+P.0
M                         "D/G&8-+A+6(T\RO*PCBA)DCCT(@B2%(0PP
M7"9X,KEF&G!I\2QD@HS(1N&9B(<Z%<1)7EU'TY+Z.0
M          :(F@A>I('B3AT(HH#W*L\#S(TMPUP,8EK&/RJK-T6KOVME[L9+
M:]7O:?:F+5OR.G>>G3FRK3N ;0$,="K+B+.+G,]'T&.P
M            /SIFCYF RN7 91+K*<Y*TL0M(AS I:Q;A&E:0Q8DQY=;9R_]
M1Z6U/G<&RGDM*;W,FF7LMS!UJPGR?F5\1O>9Q(HF22+4*PG"US[.G8
M                      'Y7C3$NHGB@)@OX]SJ2I[D">9YG<AB\B7(^8L7
MH9:;ZSU<1?%^1LNI]/*+<F+:6T)[6>"^E=.O^.<7=FL9MF:8X+@.Q5EFFFQ^
MFPY                            !^7TTC),K#@GCS.AD4]"6*\C"Y2I*
M8K3S/*(EOL7=@?DW#LO7BY$_HG-&"S;5TOIEUI]QM7MA9%\9H;M6M<9<1%$T
M8?-5C Y^O8Y                            !^<,U9/8E22/$BRXB?/<K
M".+?) H2'+M)2JU\TW;]8ZEJ?'N7$9%O3'UF-MC1:(PD?->UL@?6^O(?)>/<
MM6X)F,%G&JIBTUT/VOG(                            /SZ&KA1DF<')
MR5Y[G<\2'*PY(\\R;.3KT;^OM^C!_-^76%NDD?2T\36@^<,)GZ_V8'Y!Q<C3
M-^E]&42\B4-?CYEG[ICD                            'Y^S5X@S@K2Z
M2WBI*8E2B(8DBJ/4H2O.M)E=F]%]2Z+Y+RHJR>,<&VYN=#YJIU*R1Z?6.QCC
MY+QKXB?8RZ9<,HF,36$U+/WD'(                            /SY&IY
M3EPE(>Y-%MGH7&=BV#DDR;/$CCUB:BV*+^P]RC^/\F78XJML,&]Q]N(GYC6Q
M_+GTFYBWO9K?^=:'A9=Q=Q?1V,.&)S#)^^HY
M    !^? U<)(B"O)4]R/.Q(D&=2WRXR8*L@29F/''>C])L>WMMWS^4\?'=6#
M+7R5%/MC,:]9\OSR_17H\>>!Y]G_ #?F5VI6Y*Q;MDS#'QXEI&*C]^QR
M                        #X*FL9;1T)(KCT!7$:210'D4Y2E(2YP>IWF*
M#UN]2>UWK%\%H6%Y_2O"V7<_VFY&^LSZ/_'.996YCO;Z)U[YV[W/X7G8;\SK
M8JM6JK;N8)+9/W\G(     . $                    $\@^#1JJ1)1DL>Q
MW."N.Q2E:49'E049+D,3Q!E%2(S9FQ_:[MP]K9R]%=S?':UE^<T_GG+'M+05
MYR1-)KW73L'TF:W>/AMKY]S[+P4Q;-O!'[^H<@    XAX1,$M2)X22
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MV6^JF_[J^OL80]?T:[%79;P7+E-7!VM?F0 X+?K> KE
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MZ)C5ND!C1$RB\D?&N:Z_GT\B?FQ+=Z)BC))0IWU6]CXQL>$%OKL8H-ZT@GE
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MD$7(?1@V.,,'S7.Y)%^'J85,]&?S38PR8I(LZ@'[^SD    X+?K> KE
M                 $_.+\D=Z:    S 9"(,H2E*LH#D\B?*,KS;DWU,4'S\
M,*ERGH7<4)2&2S94U:,(%I&/2B /W]G(   !P6_6\!7*
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M3A3$*=3W/(ES(Y]'#R/FJ;#&1#3DA#P*0B#H0Y>H+I-WS4<U4+<*<_?T<@
M  '0BHM31(                    JB45[6C\@9H  #D]C/QEHQ*6P39U*0
MH"L+_-VC/YIB:TFX9B$MTLLLT]2&![%>3QF0R::H&(RSR@/W]G(     ""0
M                  " "?R!&@  .Y[EWEJ%$"^C(YT(8N\^@QF4U&-5#/QL
M@:HDV89,:GN09=A0'H7R;1& #')C(LDZG[]SD
M     'Y C0  'H< ZG!R9F)DC3*9]!RXS0TP 1IN<9@-=2E,4EJ$44A7E6>Y
M6&0B#*TBBRC"9^_ Y                            !^0(T    !V/0RP
M7:9?-^SDP(:>%J'D7B9;+5+!+3+F(([E2>)V(\F"E)<D"Y3&!^W\Y
M                     !^0(T    !ZE\F6#9 W1,;&%")-:BVSJ747R1YC
M@Y+G)PDR2( \"I(XCRB*$\B4/VO'(                            /R#
M'S\  !R=S,I?QN ;F&H9IN6@=R/*PABYBK+P)(FSW*PKSL<%"5!(%.0AY$81
M1^RHY                            !^04^?QP  ":-G#9,W)-!S6TMDN
MP@3U!T,@&3 5Y5%4<'L>A;Q6%*31X'4HBX"-/UNG8
M         'Y!SY^'!V!U ,C&W1OB:PFEYP>1T/,Z$B9*+T*PI"Y"//0B2Z3J
M4AW(XK"I/0@R5(D_78<@                            _((?/X'H=SP!
M4&?#?XV</ER8D+@.Q'E&767^7020($ECN3!:A<94%039%D(59$GL=R&/UT'(
M                            /R('SR  !D$V5/I40)\NB%*XJCJ2I?Q>
MQ&$B29%DZ9>+C+8)LO4%M%CEEE&19U*(\S];)R
M      #\H1\P3@  R:;4GT\-)328CRY2%,B%\E><'L3!4E2;8&9SR*$CB0+;
M(,J2WS$AC JR-* _6T<@                            _*\?*4X /0J3
M-1OR;1'S!+1*8\#R,SDL21X$B=C(AL@9^+2.I81=!=A9),FL):I)ECD0=2TC
M]<IR                            #\PQ\ARD .Q<YGL^GIC0^>A$E83I
M>AD8H"1/8E"\C=4N4]B$)HH"O/(@2--=SR+*)(NPLPM4_58<@
M                 _-<?(TL@Z@]3+YN.;]GS4,!'H31>)D4KR,+@+@)TSP9
M_*PH"3*TBSL4AU+8-?"O+.+&+V,DG8_0^<@
M   _-Z?,TUX. 3IL\?1,M<^?I!%XEX$N>I)$L7893,BF1"\B1*4IR7/,CSJ2
M!;Q"%CEG&/#/!;!C _36<@                            _-D:(&N9"%
M>91-O#9D^=Y9IDHN,O\ *0C"H.YM@;3EA$09 *D[GH48.YT*LCSW.A'%CF42
M%,/'Z SD                            'YFS2<\B".Q5F[!=)\YBX#,A
M?Q%D4=BK*(W%-@BV36\S 9<*TB2-*XH"H.A0$P1I)D*3)KH8,/U''(
M                      /SB&BI0$"6X2AM(;F&@Y9!>A?Q#GJ>17DR;0&:
MST,!E495+@/$I"0/ \"N*8IRO)HCR#,*&LI^J4Y
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MY2^CQ/<E3*!MH7V="A,6EVE\'D5IYE&4))'8HBUC5$EC+A^@$Y
M                  !^:\T].22!;A&%CGH3AO\ EG&FQ,E^E,3Y$&3#= D"
MD,DE$6>7,=R>(DH":* A2?+5-1C9$PP?I,.0
M    ?FK-/R;/(C#R*X@"R2G-]B4/GP7<7X5A(G)=1N2669',M$4510% ="L!
MZGH41P6(6 2YKL?J*.0                            ?G3-3"3(PI#Q.
MY&&.B5/H&8#-3B^R_P IB?+;+B-JRTR^S/8*TZ$">YW.#V.A[E&<GB8,/ _1
M"=@                            ?GN-/R6(X]"**4HRRC(1M0:4%87.=
MBD/8H"]S8LN4H#/QV!U(XD22(XI2J)DH2/),CB&/MP<@
M            _/8:ME4=2WSDAB *$V6+<-0C)QD8ARB*TJ3/1/&;"_SJ=BA/
M$]SV.#R*8KB4(T\RG(0Q<?H3.0                            ?G3-,C
M8(^PY\P35,H"%/$V()LTH,AF0B0+=(TE3:0M0VG+F*8A#W.#H>92%PD"2Q4D
M>4YR=#!)^AXY                            !^>0TS,LGWG,J'RK/F@4
M1;I7&X1C4U(,LDH>A&'B707F;G%PG<CSQ*LHRL)8H"$.2X2&.3D\BR3[O'8
M                           'R6/DD<&>#;H@C0DL4C2W3(IMR:G&/2Z3
M)Y:A2%49#-[B6*<Z%$>I[D621+$4>A!$J>A2EOE]'V#.P
M             +2/SBF(#P/8\B5+7*8LTHS/ALT:,%LF4"E)$HC(YO$29)D2
M4I %XD>3A*$"2Q8I<)"DR8Y/JF;#'(                            .#
M'!\>S3@M\HRN(4ARB(XM@SH95-,B^"^2++6)TS0;-&23@%N%>3)*E(6J>),D
MR1!F<V],XG8                             _\0 ,Q   @(" 00! P(%
M! (# 0   @,!!  %!@<1$A,4""%0("(0%2,P-Q87,3(D)SA 03/_V@ ( 0$
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M)UU^QG$*"P?57W1R>EY5-O68BP,EW>1SDR3,[>!P1%,!$"UGKR[9ATYWS?\
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MJEZ>(Z4=2*75+B/!NO?'.><T_M\.VW7:QU5__?[-#/J;MMK]=M;R$E$K=IM
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MG6;>=%>1<VZJ=.Z?1>YTYW.RY%P/]=#/JC_SK_&O<;6E>],LJ7"D)NE L<S
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MR!,A1"8@?//7 Q)S$Q=24*B RSV>5B!7C;C '9[*)RIY6+&J3\17YOZ@ /\
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MNMW'L9_K2N_O"UQ_&OZTKO[=7;M#C@'@Q6N_MUO8_C)=UG%:[^W6NT.-@?\
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M_#U\'Y=V\KKU^7N=.=B>5KYA?U^GP>MK$\_*+&_(>O#B= 5Z^+E>^OX-R.)
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M7T]_O8:E#6<'ZH;T $T!DBH1W:&N]#"B% %&9V>:-BR4)%)P4[+L"&S[*)'
M"$(E&@:\@8#]C&*00!G'*-W=O@J4$=#O + =P#X&#JK1G8[E"898L_6':>Z&
MO=,T#/K\'3I&I.5,U"/IHU4D985O_!P?"M0@:L3L ^P0O' H*.,@5//2(I3*
M/(X"'HE+T26R/,$5!\PL,  /J1K5:I]QE&HW/]&4# $044&Q2"]AUWVO^L8M
M=T =\F!0=0[/5P/O?->(3JN@OV#YB6DEH[Y7V,";#8-K@(T.\-!CMGP ',$@
MD()5\4%25'A04&@:0!?G _//]X;AD2TZ($9RJ0@!W'(N@I( L4;9#FD!1X=P
MB\"/P'&%'YD.0&LQ0YV/430#9']0)-X27J.WM'G]T)D#-C)8]/W E^&(!%L&
M#\012$*Y2@V7O%$Q'11,RB-2(F(;@D5[S2P#5T>B@GI+2)/U!&J;R6HY<P/(
M#K0/&O?$( FLL7]W*N6FA?:)>EHMSH8?I@I1"SQQ";L/L5&H!4/W'#<HK0>\
M*77,>X>-3:HF^UXB$9!D1RP3W[0+ #WEBB7<9&3C\P=05@+.H.SI%^A.M(1)
M%HO)3;4PPP7H@*,XBDEJQJY_Y_=B*U(A04 (I%N!&16A R!+%G&2[Z#1P! 9
M41^8)1T$&"1H^;B45CS>&J%O#/Q&,DA;-Z;0=$GD?$&L-,KMM& :#A _.5 L
M""J,#LNPH;1C$D-AM=XB11NK\[3;1,F&6;+U\]H!&QC6#]@$IZ,;E0+(T$4<
M'8TAQCQ"2(*6@O(89"$BLNB)#!OL$,)7NLP- R;5Z1H8@@04,'@('+ 7K J$
M(8A^WC@(6RZ"Y>%7T8A2)+-[:J IA(%=>5&#;C-YA=S*C$'K9_$MP@'=YQ<R
M7!*K;&W,04"!-*9"N[Z5Z5%OF,B"$6$?44D$CY\]O[N^6R+3!B^,B0%3/,!
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M1W(-?\AF>+4 *,(FCRPRL6QR%,B9Z$Q:$:TY99#5(!DD&# KA%)B=$%M#!"
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M4-XX6;2$V$AYX;V#Y4PE+.@BE2MC3@0](AA!S_OU! B0 T-(:#BJ*]5"76P
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MWSPT1QA_J.5!N.%D5#>/J &"1YVS!./4XA=9#!V8T&O6)'@"R>&_6&%34,/
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M^)2NH@"J7^X*>H\CB$(A5U#5D?GSW_NQ&6$K3^&C?R(-;@L#D2_P*ZWX4#2
M6/&4G3W. (^O>%\5MN(&().<?N/"! Z:N(=[L"?0#43.'H9=4T)*Z0;T/A':
M&IFS:/BZNL+ *(\X[0HYM?+@R/?]&$))LD!R2(,7E4UP$>L 3?J'(U4#O8.#
MTU5,!4OL@ZQH\A>#T@+MX2X8&D AP97N/[Q[<&OAQ_-_Y0?]/Y*!#) *&4&4
MW6U9@P!(D*T/*'@@@)D\>,Q=%@!=1HC>Y])W"Y;!B\0& 1"\VC* ND6O)U,5
M#OYZ1<9MTA,4]8L9%8@0O)HN+620"USM#(V/7B X))9 A2L8:59VL_8BBLV!
ME,7PUEI$IA,( =>G[B7KO$\RV 9;,]!$S0%YI"/&/OV@\]!_=E_+A?4_[0=7
M5J# ?GOXB4'NG0X'S!* 8@-P=2)D=G&+0XH7!"CHS&0TWCO?6H)=2C7>!>#!
M.B^?J( 00M](BWH#@<2L+$Q4!GSE>&9)B4-8<FJ--37.\'[-9G7#$R6I5<,P
M!V?<4W]0  GW\](M1=PX\("/#: (1!I85[:PV06(OK"V5P_Q+Q5;0*.2:?@A
M2M\[0AJ[KMX)B;.BUZS7SC^[ -!"3TGXPA5_R X(4B06U[0"@(\&@WYQ&)&6
M8-U!B@>2PIG,"7P>4(#YFF=1&=H2&A.G/M& 086SVYB_7MB!9S)S IN]=SMF
M)CANVW>9[:&)EF<W >AM'?\ <N#()D,M7M"A@&0'Z$1"UVOW,"@& I6:.'!-
M/84C6:.F>-XYX EW"6;@D0*T7IGT@4E:%WXCWBA>(05!4"Z5"):'\7_>:,ST
M"1R>O_#-5+T+F?G4/;2$%E@#Q,',$-!I,&H74E^E'[<4[@_,-P'YQ"G4'X@1
MZWMS-@+_ !&_*?J$ $N\PU-$\=/W 2L'&@%]HU%*9M3 S6^(" $ ;'?G;,!
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M@QRRW"QT?]X4 +1VYH!2#(UF(1JU>."0(Z!.'O !!'1?B-DWHX#*]L_/U*7
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M6'*'J/\ D?0 :03B(!HK40N 2E%I:\O'?10PHFDU(Z#F'*!$,&=X$S9%K_R
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M2                               2 2 02" 22 "" "0"2
M                    2""  " 20(2YEX000""
M        0"""0" 2 3K0'$@2"2 0                             0
M"022"(<3"JD.2"00                             2""0"0  2O&P!MQ
M2 "0                             "02"0"""269L 9E0 02
M                      "02 20  3Y@022[B2 0
M           "2" 0   9QT0(&^022"                             "
M0220 2""CZ@ 6!   "0                             "    "" 01X&
MZP SR2"                             0"2"    0 VLG,,".0 0
M " @                   P"2 ""200 "%2!;E *MBH     2&0DDDDDDDD
MDDDDDDDDDDDF:"2 "00"" ""  20"6KZP    !P@
M#@" 02"0 202 "00 >! B,A0 ">                      ;02  " 00 "
M"2 20 "2FM*$  3                      ">0022"22  2"0"0200)8J0
M(K&8                      3@2"0 22 0"000"    " ":=%3
M              "<2"22 0"   ""  0 020 &284AI   022 0 R$$$ $
M   3P" 0"0 2""0"   0"02   "8J9H@"2Q>MLPY#2PP"P2B   "<""202"2
M "2  " "0220   3"](H #\[.T)2]FIX3>F'&D  3B20"0022" 022""2" "
M     3#M "<&FL/ZA"G!> 4G(T  ">"2"2""0"""0    "0 0    "8(, 6$
M0H00$@4.&&V 4JD  3@0"2"2  "0   "222 "     3
M     "<  "20"20 0"222  " 0    "8                      3@  0"
M"00"02220  0 "     3                      "<   2 " 0 2"220"
M000    "(                      3@  "2   00222"  "2"     3
M                   ",  "20" 2"2  "022  0     6D
M       &/   """"2  20"""2020      6@                   "!0
M 0 2 "020 22"""20      $                    $$  "00 0" "0" 0
M"2"2 0                               "00" "002"200 020
M                            ""2 "0"0 0"  20
M           "    020 0"202"  0
M2  "0"022" "0 """0                               02 202""02
M""""02""                             2"2""2202""020 020
M                         "  2 0""02 0222" " 0
M                  00020"2"20"2 02
M   0 2220 2"" 02"000 2                             2  "00" "
M222 " "2                               "  22202" 20""000"00
M                             0 "" 22"""0"02""0
M                 ""0022200022 2 2"""
M     "20 2 2200" 02 2 0"                              22  0"
M22200  0" 2""                              "" 0220 """ 0  "2
M"0                             2"0 222"" 2" ""2200
M                   02""2 2""" 00 ""0"20
M       "" " 00 20  ""00  02                             0  2
M00"  20 2 "2" "                             "0    2 20"22 "0
M0 "0                               "" 0""    "0"02020
M                      022"2  ""   002  ""
M           "" " 2  "  2002  "                              0
M"""200   0 00" "                               2 "" ""000" "
M202"220                             2"0 222"22" " 0"20"
M                        """20 """ 0 2"0"
M            " 2200220 0 0 0022"
M "22"0022"0 " ""2222                             #__Q  M$0 "
M 0($!04  P$! 0$    !$2$ ,4%18?!Q@;'1\5"1H<'A$"!@,$!PL/_:  @!
M P$!/Q#_ .JD98!T4,B"1(U6*QW= D+)G *UY?G"C#LBA"YHIXTO!F)")ND0
MG?$ U-VQJ+,P  @!/(MNB1@F'1 9V*(<PH8B3DT_YD@Y/>O$*3!*K6%TU'O;
M&U!(J (F4%:V <#GPH,@N%$:!D@%V_72@""#!)>0 N.%(70C;U$Q=/.B).(2
M'VP9 $H83I0P2" FT-7+(FC 2$$)"@%VY3G_ )?$#,@>^YHUB2>6-$K*!BP6
MD'B+SVH)(  ZQ-WM!(QHA4<H!")9"D3PHWFG042B1C !,HE@W^J ;%[CU%$B
M ,+<78R&7*A9D E$)(,AP>7[27 <0%Q !A8,W.%Z  $U+$@+O#7A1@3BF%8D
M-$_Y4%$'(NCB,1[/.^Q2K02 Q.V'L!>CJ;Q%B,%M48'FAPE=?<?T,@IB'4#[
MI&!&(<=,^7-T4 4@ D8DK.WBH51K*PI?D9FFQ_ [E+K+<8_Y0!D#,JBM% #G
MQ@[UQHQ"(RZ4XMJ]<:,D,EADN>>5J&  "0'N'_2!*1?R#]4P"-EA=:14+"3"
M8&U\UNX+<FN5Q>I!]Z)8B3YB"3\(_P K<.(ZU9X.BMFU_P" MP?8H[C-5F^Q
M_P J!)&A!Y.A-*205+$1\T!#! 0,M"9X<* !$E')/Y%$# OD1_5> UF)$A!F
M6%%YHP?E#!($%GC=7BG"4G&Y,1U_RHB+Q!'NJB0H'"V!QU^J,4S@A#A#B[B<
M:,-K@.T.]&09/)#0W_IU'U1$D&* S,T52&!5"F67:IJ2H7 (LY>'0 4LP<,]
MGA?_ "I#4D(@\4=_-0L!6VU4WU")0$IB,5,9:T4@ @@  ": ,E<.3BB-YI9@
MA193^C1@Q"=8A.3\T00T8!I*PD("DGE6(E]"/KI30AP!S.7[1D1P061FZ6_8
M=H"YD+#@@B.'$4Y4$NE8-,WW2FX 3@X@"PU[$ :,8)(!/*]*308'/XH FU(+
MA# MO?' _P"3*!8)09EA$S4J4BQ!&=+N(MKB:?G(!68)D+B,'P%"T5Q0OB$/
MSQIF,$@!"=W;1948 (' M]CVY<"NIV&;"F%8?A8%$@@((O(U!D<5I3)3 F90
M!VXZ#VPH0! 8",81"W:BH. #*$L()9.3[T7 *)0A3(!P+_@-%IHF@ *4J+L
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ME22!"8,04H20"$BVAHD$ LF92Q&!>&2)N' U'&8S&&CO[,D0%P-L/&P?"FE
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M[?\ ._@/7U G"DC.WOOE(,>9#1Q%PP<Q!N34,0,0$L(!70S[XJB:"2@.D-D
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M !:AK9[N!328,>P'WY-Z%:A'X4B.Z"YD]4?:<*(0 \,LSR]^==3Z%;N?][^
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M/-;N/-;N/-;N/-;N/-;N/-2)F;1CS_\ 0B__Q  J$ $!  (" @(! P0# 0$
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M+,>!69HV###<^*!3W6'&E3'Z]<3VRP$F] XQ%N/#>-U$2(/86]%U,[KR* 1
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MKV!T\V!I6N#-=%AB7.7K@F4D4+"5)[.^]O$O-$*L$N-VF/)YY'(R9XC=?O\
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M27$$.P46X!3K+@26FBQ\8\]X+P5G!B,PW%RY<_.^!#"B;54A*&03RYXP0::
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MP,V\" &XP>KF=]<"T1A:F6Q#K*U,QQG!UK.\&&5&45U"/&;"& .P;8?H<>2
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MZ[G7$!8^+#?C+Q#'0#!<3><SUG@"@N("FV6.=YA-2Z=8ID]1A&*YLI_H"#%
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MN13>'9R)YB("(+Y4C'&%$=D=0P"R-K\?\1A]"_HG^>4 N+7M'+]7^W&P\OZ
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M,EI'/+>4#@ZH<5O4/F!!* *@&U&M.';AC)>K.:/P_MS7Y?O_ +=V/D_?^@Z
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M"7?G>,&M\L:TBK! \>-8#\\82E"22JC>^S6?3P\(_/KU^9N_U-_7['FGX_\
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MMN$'%#27)[7K23O?D@@T16J T.Q_R\71^4 O8Z#+3=^> P7M0 ,ST3=BS@Y
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MLQP.#XL)".V8]8_;BBN(1@V#/MUS-^W18*S5]3K#>LCIFD%4& 8[==3N\*Q
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M/"\N:A!PF[:1+N^3NAV""74[C0N/.3OB.H"08R/BNC\Y)YJ\, X9N?##6^"
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MSG/K6<]:XV38T4$OA&-P=3Q;1YR.DWAOXXAB! ; (B3 K=_-7 +@O%(%7O\
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M&E87L0(Y:3)TY^>7\2(":K7Z-9YHN$1;/6V?7?T-Q&1#$K+WG/[CV*$4M 7
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L 5.H5/0*/1WPYGAM(85F!ZU'F(:S"(I%@WQ\"*E*G&5@%0"H,?(A7^^$_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>business3ba.jpg
<TEXT>
begin 644 business3ba.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0"N17AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     @   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E         !@     0
M &     !    1TE-4" R+C$P+C,X   R,#(U.C R.C T(#$X.C,Y.C(Y  $
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M1T(@6%E:( ?I  ( !0 ! "  *V%C<W!-4T94
M          #VU@ !     -,M;&-M<P
M                                #61E<V,   $@    0&-P<G0   %@
M    -G=T<'0   &8    %&-H860   &L    +')865H   '8    %&)865H
M  'L    %&=865H   (     %')44D,   (4    (&=44D,   (4    (&)4
M4D,   (4    (&-H<FT   (T    )&1M;F0   )8    )&1M9&0   )\
M)&UL=6,          0    QE;E53    )    !P 1P!) $T 4  @ &( =0!I
M &P =  M &D ;@ @ ', 4@!' $)M;'5C          $    ,96Y54P   !H
M   < %  =0!B &P :0!C "  1 !O &T 80!I &X  %A96B        #VU@ !
M     -,M<V8S,@       0Q"   %WO__\R4   >3  #]D/__^Z'___VB   #
MW   P&Y865H@        ;Z   #CU   #D%A96B         DGP  #X0  +;$
M6%E:(        &*7  "WAP  &-EP87)A       #     F9F  #RIP  #5D
M !/0   *6V-H<FT       ,     H]<  %1\  !,S0  F9H  "9G   /7&UL
M=6,          0    QE;E53    "    !P 1P!) $T 4&UL=6,
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M!$@") $0"   (D") B            @(0B2(V  D
M 0(%!:;5DO0VFAR/C,_.7TA]H55:UV.ESHNE(G                   (0C
M,010VMCN6]ASY*:29@1($80E$@1$1]H7K%3(\..YTB8A$QD
M   (0M]YQ3/DL>6RY$@     )A"XX8R[#CN^*LT@               1\TXG
MLWQC-DA,@       "!&(ON*N8ZV*IHC8             ! H;3@^WEMV2Z(
M         3-1BKF^MBO%*Q             (0M62V";67X7D           "
M,,TU<60XJ3             M5YP#9S?/)8@            E$9KJ8<BQUB
M         0**6O=S-3WL             !&(SW3PWFD1          !(:YV\
M]!FE              !,?6L['T<%9$          0,/V+8QL9@  $D@$$
M       +MBIL#4Q3*E@       !!%!-M<[N:6T@  :*K7G>E=>EY,M313?L*
M6Q+@        ((SC3Q9!CK$        $(8)M9;'GN   -;UCAZM>F)<I&PDY
MS:W8!/(         5=*[)TL7T0        *&TZVW,D)ND   1@M8UC"]RR"9
MV;,@         ()KG&GCR#'4       "%6';67&=BQ(   &/Q'']6KZM22]3
MK3GM@          NN*FP-/'/,       "5&LMW/37L     $(0B+
M   BNS=+%5U@      !"W7G7&]G                  "6;:>+(<-(R
M  $L,<RVPS<SD                  )9%JX\TU\<T@     !!&%;.;'<]P
M                 M%RP1L/0P1R   %8EE-K7FVH $$8!M9K/FN
M          $JC7K8^KGUUV=D  "$1DF/'T5\5R?I?* ((UUM[%MRR
M $56LK*8) !"80   !)**QEM7G8)H   0.5/2NOU5Y;R)MH ((UMM[%#ED
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MS_&_OF"7+TI+]&$]#Y9-V1ORVZ/;OYRQ>T?X@^5GM( $(<J^D=?JOS#D-@
M+7DOKO;RI      ",,TT,5APY(VD!*^UQ:\IM_%8 !"::99;#F5\7+OJ^KY.
M?L6FEO2=V3+NR3OR6Z4CH^W?\]ODNRO'>3&;  0ARKZ1U^J_,.0V   @:]V\
MMJRY2H     %SQ4O&@MD63(!-0K)6<.KL  !!,U44S>=>\;>+SU_1F?S"_6O
M3Q7Z+KPR;NQOALGZ*_YI? W'!BGN  A#E7TCK]5^8<AL  !!%IO?7V[F
M  @97KTH-*9)DD DK?JX]=UV_B%@($2"I,9O=YPYU.OCG?GRL_6OT7!GZ1^K
M]:?Q;\GZ,_F_Y>*T;  (0Y5](Z_5?F'(;   "!@^:]@V\JI(    %<ST*V3%
MD   ^RD8MAE-B"?*172ZO1<QG%K<BQ38];>EL-C,MTOK[6RZJ'/'WG3WG\;H
MW?6QA( "$.5?2.OU7YAR&P   %-,ZYW,]-8D    A44KE6C6RUR   )7VN/7
MU-NG3A)B*)4; 7UTI?DY35DTMI9].\6I*F7'6:\S2   A#E7TCK]5^8<AL
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M&&&;F4)RE(!%ZO3!-?9I)N)D9Y;6RS+@FD2     !"'*OI'7ZK\PY#8
M(0*6["=J]HR922"%F4Z>.AU<DB0/.]&F4;45N:?0]< GZ*U=6"4V;C?'L++K
M7ACC(D      0ARKZ1U^J_,.0V      "$(BQYK8CL9*+)<A#--&EBQ9(@ !
M ) )*WR<='-LKG'])B(       (0Y5](Z_5?F'(;        2EEO.-;$T62V
M4<Q95R22 "2" 36S6[VI=U?I,102       !"'*OI'7ZK\PY#8        0@
MA\[*"MK6M31--"1,JT43JU!4HKYBXVK4H2$0        "$.5?2.OU7YAR&P
M        $"($! $0 )           0ARKZ1U^J_,.0V
M          A#E7TCK]5^8<AL                 )2!. 2$:(RC8    !"'
M*OI'7ZK\PY'CML+L=BF'%S+D:B.7C4IW(5)N4@9R><)G)B)OPW"<?'0YDICA
M@)CYRP>@9ODXW.Q3GLYJ.H2X&:G!YT24QN,UL>@M&'=3)D6G2ZXH     A#E
M7TCK]5^8<CPFV%E+J8&9^:@/4,Y *@M1@AJ,^!Z/&MS?)R*<N%Q/3@X0*(VP
M;E,?,X.)3I P@YX*0ZJ+H4QCA>2A,$.7#T./8^(\R/T3]7OOS/GUN+$
M)-ZW6?FW%P[)>K+D845).9$8^5I\2SF<&.%]+69@888^5)DQ:#XF2F/%:9:8
M27DLY<3$S(RA(E8496EA+Z#,8BD9/JK]D     0B(1,<4,HF)&X
M        !" D@     (H)Q;8V,CU-?ZV+.#C891F2FPSZ%Q,7)C,#%SG(R,M
MIA)M4S@V\889>8R5QJ4VL8"6HV,;0            !R%Z;U>MO+N7];1-9Q"
M6,LQCI:S?IBQJ$MAN@RTSDYD.DC7IB!:S/3'#51B)TB<;G09IX]&C=!D0
M         /G6C'::Z:\V,IBJ/H6,O)$D,7+F9@:K-BF$F5 D/J"G,2,U+86<
MR4D,C             )*$1&9FN                          &I_H-O:7
MS6I]+0O/GF;=+P=)FDS 2@,^-PGG@=*&JC SMDU:;),4*DP0V28::[.EC:
M             .<?L^CT1\3SOI)9Q"9B<I'6IKPYQ-[F/&W37QI<Z+(E>2&A
MS5AV6<<&R2J-O'91D0              )(K+K3/L3-9   B0    (D   "(
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M(,)&)$;C+WLM7MBV2:*['5G%TI8![:8X&C'BK[5[1@MV\/:/ENVKZ!:P(9*
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M:3;2Z::<@>OK5E+(42(0V[>81P12IPJ<.]0XC.#<:)BI,I<(G*3ME2@&F)?
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MP=,(,T*EL=$616)RX?$71I*B)#1#1$=49': A).DLL/B_]H " $" 0$_ ?\
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MH4J#2M.J,"35:L2^K7AZ@-D421BP_LZB,Z=D'"H)3A 2H FNO^Z.N/,Y*4Y
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MD$;N<,#T2>W_ +OP?5*CYJ:'Y0X,ME?X=L658MH6S,_$K.:6^Y@))0#1AI-
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MOWP_FXT#JK^,;0.KUO\ _\0 :!   00  P0$!P</!P8(# <  P$"! 4&$1(
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MLTB58ISV0XO 0SRIFL1T(X4I "P]7=*UQ7XTPA?+H981 !62&-', =@>'(9
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M_P#H;V\G/96?$=]#NU^G/X"QOQG_ $-3]ZI_1#V_&9G\J*F7Z5^ L;\5F?\
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M7=7=27+O4=C$?EZ])5RVR'90"+EGDR7'>N7GR:_NVTCD@([XK"L<OS-7;O\
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M<*U=R6QDS R77&(DK>,@CCN:](]:R"I$\,K$WZO:QS45Z9/U,0(<3W])?FQ
MV/'XRNC&K5P[92HH&B$8[I#N,&$J-:KV"8X3&C;V#JI]]C LB(03<045M60X
M]>,*QX9IST*)CD*4.[B@8U1NT(<K6M;H:1416X;J*2B@3EK".LK$]]"UD2X(
M_5Q%20$_[&<P3WA&8XFET[MNZ:W/9V)J^M+)JGVH[9U58C"%2.<YIY(5:(DL
M.CB5*46:.R:K-86Y:'&A5C\239LB[2Z!/Q"6&I:+2FI(E$Z(0A@!<J:$:C@#
M&QF8!(]ZN'6@EFNI4-*NS%=3Y#VR[<]S;U9Z]\\2R)7A@U@2"B5PCS N;&84
MAECDD/;L>?%89D=0P8H>*T))(.O@1X2'.T9"L8<Z WA6[QV3GII>],WKAN(Y
MNAZUPY9&*F3FEL'/GD:[\)KI*M7R\OKT_)E^T_O#V?%<J?)Y%^5N7P%7_$;]
M+_\ #/9R^G)/4G)/T9_+]8\#_-DGG]"_(OT<MG,=R<U53+U<OF\WJ5?+];F-
MW+RM7FQ?6GD_&3GY/+LC7^#(OD7Q5_%7]^Q(5A%CS8ADTE!)&PHWHOX+^6:?
M>N\9J\V]KGL:?@XNI.T_J687Y=$&:]>>?)&AF*N7/3,3DU"PI\8\.4%RM-'D
MB<(K%\RM=DN2^,UV2HY%[*Z417_6?/\ 3G^G-<_6NWM[>3ZGMZ_T\]JFH9GG
M8V,2&JI]Z,YV-*3T;H:O,J_@*NS!,1&L&QK&-3N:UJ9(B(G)$1,LD\WUZ?DR
M_:?WAI$[GIDOXS>7Z/T? 7E\KE5?F["?WD7+U[>WD^L1WR+ZE]L]FR&]SNR_
M+^X[U9(J?7HB^$'\5W>GXKO)\O+;L*F?E:O)W^*>E.6VXN8+"N:BH&8/P4V+
MGGS!):FMJ(Y=2C?K ]43?"(WL[%FU2$O:ENI^H _YPBL3_RF(S4I6,3+.1%:
M1%R(0@([=.R^CE\WKY]^?/R_)R^N):D9F&BA/*B]Z)-FZXL9BY\E7<<:7/O1
MS!>9/>$_)E^T_O#DR[2=IOK3_#/X!R[_ ">OR?3L,2>9$^1$Y_.O/U_7/CO\
MV2>?+SIZMG,=XS55%_1\W+-OH7Z_-JJBIY4[T]6R-D<T_P!(GC?UF^;T]^VI
MBHYJ^;VSV+*$SJ>X=J<D^&-F@Y%_\MB=@4A.[,K7!DN\ILDR54M(:OA.>K06
M<5"&@&[\O"HBNCD5$5=Q(:)^2.T(]C=:^V7R?6>WDY_]_HV%.,S3,OB]8OS;
MDJ0\MU7L\^AP$64W/G]EN1?>$_)E^T_O*Y)V7]IOF]*)ZO?V?@]M?ZO-/[V6
MV7D:F7R]Z_IR^3ZYKO-W_B^79LEG<O(GJR[#OD1,E^3WG4-RM\_F7\9/-LB%
M1!/7R_>.^7R;/CR0ADQS-T%"9C#!*U?O7C>CF/3T.3+8L_"!65\GFYU3)<YT
M$OE=PQN9XA%[6D9'&C:M"-X42.V)7W$&17RQ\U%(;EFW-41PB)F(X<VKI,)Y
M&/\ (1R=WU*ND#JRE2&\41O>"$+PDP^:]E', U^[U=EYE&+[_8,8#$$$ AA$
M)G)HQ#;H&UOX+6MTMS\W+WA/R9?M/[SR\=O:;^M/E_2B;>WR^_%*OD[&?H3F
M[]6RN^,JK\_LOU[X[^?++Y%\WJ[TV<-WC-7)?3\7Z$S^5/J>R_1Y?ER\^WMW
M9KDN?-/(N:(CN;')Y]O;EW<LM/T.YN145%3/;V\_RY]^2KSSR[+6HWG[)^G)
MW/TZ?1MY_3RR[O&1=.6A>]._DB\]OG]EY9)YO&R7)>>K)%]O/W+W+R[N:=_C
M;<EU,_T;N[^JODVR1=+_ (CN2_)YTV6#=UX)H>>A2)D8#E3+>1I#5::.3R:P
MO8[+DN;<TV+.PRXEU7IJ>L%43K6.SGV6(F@<]&M\H6LE.Y(D<C\G.<(C7,(Q
MRL<PB*Q[7-72K7(NES'-=FBHK$<G)K^:.3:5BR8+3(M-42M1[<E97"(F],W/
MG]F26)W]S(K',[)5]Y3\F7[3^];QJ=A_?Z'>V?OS6]RO3GY\W]I?F3L_)[PC
MT\GZ/*FS)+.?+)^7F^\=\V:*OXJ>3ZM'#+@;_* G^3R>5M%UO"I=+V7B(D_C
MITF*-NX1RBTC>XZH?-@W(QRMZ%L+XLH'8NE/O,8O9A%E^FH-:2O2574/N@G2
M(@W)4"1';WBD"C!<-&*9NZ5V("3>CM,)2J2MQ3=UU,:[?;$K;/J_1U@DRNLI
M,0SS#@1B;DCRHQHV#4;"*172W83-%PC9XAP-#L9EZ>RD1(X[4M(QRV,J=*.5
M*WME=O)0=RV'O&G;ENL]EPI0X9]QA<6=%-]Q]>/&$:]!>6<4<<$'$BR(9Y0J
MY\V3(=$%9K*4YAR#N>(2 :4LW#?N7;64 \:4-Q)P>Z?7AA1'WDBBJ<)X.F3J
MD-Y4QHMGB(4K&-ZV"DMS*E(@Y(-5R2/M'M5B< 99-E!FPM_Q+8UA464NIL!"
ME*&/Q8&S(1T!)X<"F"C"$"![]RW9K4Y(U=3G)Y$3T_&Y[>KZF]G15BV'+^<X
M.@,MR)_Q9_!N%)9I[*;]CR,;R$\??M'A11M#&B!%'CA9XH@B8@QC3/GDQC6H
MF?SK[RGY,OVG]Z5CNY?;/96.\G<OG3WQC/C.3YO+]&S&>9,_G]OI]Y>!_-,E
M_LK_ (K^O9PE^]7^TGWKOE3G\N7DV]OI\OS9[!Q4Z'G?1ZLE(&?Q$E-%:>4V
M42/PV_;!=O93&O0KHW$,T-T%1JO1U>W%-4ZS2K(8D#=V5K6K'))1K#*A*J;$
M)X1&-8U#/7N7+DNUCA.!6$%A^X9,2?"+:6\ETED^,V)*^S)LV38"WH!M9ICR
MP[A=;Q*TBIL+#S(074PZYE0E=(U20.K6QN$2$;BG')($Z-X$K3N*]XW+O7+O
M%VER,,THZ^3-&(!Y+I<ZPD<*+M"BB-8RY1(D5JIKX&*Z-&:YC'()-VW*UK7U
MWV+=VCKJR5DV>.6>U<<$D<YMD*6R=&D1"Q8J0"PY8. 9%C"@*&. +&1JJJCI
M%@Q&JP(=X4SN;W$*0LB00TF5),8CRRY<HYCRI#R'*1SWN<J-:F;E7)$].VGO
M>O-Z^GS>^I^3+]I_>^7CM\5?U>I=E145%3EDOO:O^(WZ7_X9[/7TKEZDY)\^
M6?O*.3[WV5/EV9)9SR3)WXG-47Y%Y+Z_>/;Y-M^1.TJ=AOQ4_?\ J]^3\F7[
M3^^:V?;$\G=K]:^?S+\FWT>]7]_'@ELI5;56-F"N!J0TTL**4H(C%8,SV[YX
MT9FT)E:CE5HB+V%AV5B?HZN</'IYEK<CP?/L1XEP8R*#?L2YH[25*GV;2+G#
MSK:\;EEZRC:4'#M+=XQF%ET=9AV:D6WXJOMY&X8>P= KY#%CU><E)I-+G!B,
M,6#JT3V@\5(<U<1;X-@V:6(D2IO9YRQ*XNYEV7"0:LTIE0PB.:VX*$55(RU1
MIKVZ<J>;.NFE#B 3S4G54*ROCV@!A22:3$BT4*?)/$$%PR%EMCMC"0S6..PC
MA-VH[8MZT\'$HRFH^K(%I;R[((&*600%=509M@C(B=F81T1C(I%;&DJ([F9V
M.,<.2HEI$9A^RN:J2B$)$DK%AGD"0@T< ^EIA;HX5=',QVL14&HEVHK&ZMNB
M=]3:UG64FGP\^\3%D9AHF\CC4,NSF1 O'((%DK6-R:5<UA=:M>U<-U6)8DNX
M5\H0!)'L!0YQH':F"J[0T<55:DC)K4PZV;(=I&5=*-&[+#L7$-G6P,9WI[0*
M5=? MQUVN'/L!QH[9QFV$ $X\"$.2D*3:MD$WS'MCL8<+2+AF1B(#+=)P:M[
M$AV3Z\%J=NH-;)O&0R4<6Q5<DX.18LD*72%1,*K!/<!_-JHN7DS:O?EGS[^:
M+WYKS[35R<)W>U>_SIY%3UHJ?+FGD^O0Q4[/>QJ_??A*GD]7R^_I^3+]I_?5
M>/D3Z'?X^G945,E3R>;]_K]XR3O\GK\GT[3:VJLGT]C)@G!!M61P2W5\MP7-
MCS>%D^ D<.=6&<$O9,C5'J:KD>W">+\7_P"3N%,PLLTTNXP?#LA8AQ;)E0G0
M']>*:'70QL>-W%&W;)NZ>XHH[& D/3;'71PV=AA0VUZ^SPK8NDV@B+%EXF%>
MS$O6]7G9&,,0T%&ZO2<,A,T?EDQ[@8NP](KI!R883#=A5VF)<:83 Q '/+BS
M066#I(9<IN\.\<BKF!8 @VJ9I6&1-&!:6NJ\&S3X2C21JV38XUP\:":4C7I(
MPWB6OL+B_K1A+FKX=BVQ',"T*JZ)NF#VP/56<G#>,<08;;9<7;75EBB@M&EG
MDWL9]'BRB>:U$^"W*-*XVOD=;# .1,2(5V[V)@ZZOAWN(C8>N*PMS(63N'R+
M%DU(Z'DE82;(!#24.+QQ .E2VQUDD"TI%&E5$ML-=#D6#%J"U%AB/#,.V%C:
M8-8>Y&1UA)IX(S%E2&A=8*60W6FM^A7L&BX4P]/L,$2,&X(L;"?5SQT[YN*[
M1IUF/C"D=:Q#0</E:Z:1TJPI9CYY&A:)"#CG/O.BJ@D3*(D_ N/78IM##D37
M -7DGWDK=5SGUPI!ICAV4;,1P0XR[IZ+)<U$>_%&#(UGAOW"XPQJ[%UA9G6S
M3&$)DFPB6LNMAQ1QB5T@O%0@#BV)K,!!@(35#WN['LU6_>\TS\J(G+\97)R5
M?/R]#6R6<]*)J_$YJGRHJ\_7]<A3IV>]@U\OI=^[X GY,OVG]^S3LD\_D7\;
M;2],E^A?2WT?7L\S>VO]7FG][+;+R,1$^7O]O5]7V1.?G]'GR17?%179)M2T
M%K=Q(MWB"4.)45?A#S9$@V>Z<2/&&<D2.Y^;4FS$CPT)X-TA"IDH,-7^)8U=
M<R.&RADC6)6@XQVF*D^9'B%@UN^RWF=A)BJ@M)ER%I?L["K+%RWC,VK'X*P2
M*IVP1V#XB6JPDJ%L. *V:ZL9/6Q'"SE$C- W>[29%5(65'B6$ZJ*?<R!#696
M'=$F,"0PACDL!(&2,Z1$=(C.,$PFR'/ 1K?K' =S147+Y>]$_3LX:^1>ROG:
MO-%_LZ?ZVI/)]5&M3-5Y(B=^V\/DY_>C/O6?C?&=]"? 4_)E^T_O^EZ9_I3U
M;9HFL?D5.]/7]<4J_B?(WF[]6?JV5WQE5?G]E^K\_DS\B^E-NB6\CUL(=Q:=
M*- &?:L"/C9((E7.9'"66OA.'$UC50+';IKD<Y&*3+:UZ,..HL+AM2ULCI.Q
M7*A.!++'@/BFB44%(\9TFUO3 8-O6,K?U]/ <X;2%E*V/&I#88Q)X7%EN6XP
MU7LK%XJFD'PE'PU=XJ-<ND&:6KK,-/4\*%(JQO+B&?5!=.3?(!3X.'-0]130
ML419-"D6N$N#'46*VT^&(Y#PH4>:X^)Z+?6YW7,F8><:.^="<(#S([YOK$<G
M>G/V]:<O5LV2SFK$[7G5B^3^HJYIYLUV]N?FV[*9-\KUY(GR??;=E,W^5Z]_
MR>9/1\"3\F7[3_ <V^#=Z/%^5/U[=MO+XS>TU?W?6-;]\].?GS?VE_W?5[\\
M2HJM5%]67<J?3LJE76F:Z&=R:<^6KS\O)LC6HC43N1.7P-/R9?M/\#S;X-WX
M/=\W=MW(]OG9^[9C%3O<B*BIER\OT;,9YDS^5?\ #]/OG)N2?A<O;U;=M=2_
M,FV2(B)Z/@J?DR_:?X+JR34G<N29I\NVK-R+MV7(OKY?X;>)GZLE_1SVYL=\
MR[=RIM[?NV\^W)COF7;Q%^7E^G;FK4^7/;M.<[Z-NRU$]/E^?X0GY,OVG_IE
M/R9?M/\ TRGY,OVG_H;V]O94\GP-/R9?M/\ 4P!!G8OET.#GX;XFWARK\U7A
MIY'MQ.P9[&.:9'JW/<8<1C2R6JJO&!$74P>1O<%TE5/7_754K?<AC&'UQP>H
MW$:>IK%)O#9:-[W"7L:L\V[89Q7C2V((),/X?1YB[V996=E*JXY=R 69)$R=
M)7>&*]SUTM0LJ25@1E*V)AH];BW!]S: ;(I(>-:1M)UZ%4>NJI*.7+&;4C';
MO>O"LE4T1-^1',1<("I\88OQ,**V=-I<%4*W<ZNB$$PPS36OEPV-11$$5=T\
MKQC,!YF,81KEQ%CRL=:&KL*AG$O:LD)D>^@EKX_$EB/B&D#BN.4/:CD9.6(1
MZN#Q+"@.,3EHJ;&UR<-+(NI<.NHXTF3#;'<W*M-HM% 2V.)Z&""&>2+1J20<
M!&.&W$ONQH,;XGD19\X]<?#>$Z]\6'7PXN_ZJE.CG@?SNY4=I"1KU=F/PJ*N
M6V+;C$-]THR)J1L2]50H;N&Z/*L(J>65@+<#)"!A7,?P;:T8(R.;(&*0604Q
M-:/L<07-K>SO=+; XZXL9EE+0 P0%8'B9I3F0(W/>K6:]+=3E1$Y[3XL6)BZ
M^KZH[(]IB2BHFS,/0"N>\?AYI9T<^A7#?NR!B%#):W7$)(:NK; -4%UE91ND
MA,L-8@KP1243RH9(SHTPIIPK"-*8<@0EC]6E?',5HY.[<P^ZA]%!A7"XBF(!
M$F,C0W4L<TJO)91XTF0M@R:TY8[1Z=W7$'KD@3>HW>/9B'HYA1;=]QABNC6%
MK8.C1NI6<6V&X,-DILQTE9JLFL=NWP1"<@9.@SMUV^C"GP5B#$%-.Q!*MZ]H
M*.ZL*CK&8>31Q8 Y'!2([2JAI2L$IM6[WS].6IVR8FW3G=(CY'N(91, ])9,
M<*/=(9D%&O*@=TJ6VX5B)O?YJ:Y9+FH[I'B8RO[ZZF4]E30]%[<S;=:\XUN1
MS@QR2I<D8D4H6H;<*UK]T-V9&Z,K,L*BQ]?4--*X*SQ?18927A6(='(UV]M"
MV$=S&YN32KH^DPW#)'4K'M5V&<9226-M08MEQ8E5,IH\=W^>1C2V2I0K*=6/
MC1QB"1)#79RXQ$W18[7M=HQM?='UAB>G6CNL/5X,0C230$GME6D/7)I9<>4.
M<Z&1F]CF<9D-[NT-0[MW/HJ@7#;_ !/BW&5!AY(-/2C#97]@4U7%4]G-ZSL*
MY@XY9*Y$ERYC7E,\I4W@(TXT9F%4K\4XIQ3PS9<O#V#:=MY95H"#WK73TXJ-
M&&[0K7N"&0<XV/$4@V@,%Y;O'&$&7EL:(T]:ZO@5+9%U07)HAEC%N:N01K00
MX9&M/*DZY,51-=N5E-:YJ<!B6%?2+Z..?.D8C?20Z_#$R..>**"%7RX;QH2>
M%AF+( L-F2LD.WSM+6[4<O#M[<4$PV+8D8DNFLYM5))'=56Q' (>"<!7A4@Q
MO42N<U7,:[3J8BI2](=7TUXKQ%JL*Z(7#V*YLV?$F)- 24K6"FVDL$M&H!1F
M&R&&2R,XDD,L#PKJIJGJO%&),565'77<S#.#*?KNRJ0SX(IN4YKI44(W,:5J
MJ%AS2A#>$I0M"83R2<0X<F&.""I1V4"0'A;6LDB'O70YL,KO!F5J*HW-*^,9
M<]S((UCE:EO&J\;2U:4[9E;%I8!Y]9'&K&#L+-[;GJR)#E%<X4;79\4YPGJ^
M,,2B(1G20ER,&$EB.EOG2&/84.[,Z,:&2*W69T\<MJQ$AA:4Q9"-9'W^\9O*
MJ#*K<88:B7Y5!08@Q10]68=NRZFM&E?9#FRLVE5XU:60&.%B/;OB"5=.U'AN
MOJL6>YF#OXU_4@PS7R;+$AQ++5).%W',IYD/+<)OAR8.:!D=C-FIU=3XAB8F
MK)-GAB#BH3C5D96B!8,>L:I. =D^Q;=*02QGQ P2@$9VLDE -*9F%#+48RL;
MK&4'K&GP=4T39V+.#0A0[V56LG-C!7>1SY#9/>4B"(HQD:(JLQ'U7%Q#"N,*
M!>>ZPO<U7 8CCM8,KD1D'?ECF(5X7QD$R7K'(T-D- A@/-B6AN:C%TNCG6T.
M!AFO%ABM!)PLR7.>)K\6%$<9X8AC<)I#$-.R5A'>-DB]+C<&-QBR:S%KG8H3
M$\B$2!UHLJV$YU"V').3A%.&4\I[!J3W#=%:4KF#8,<^+&B8NO:^J.R-:8DH
MJ)LS#L KGO%X>:6=&/N]0W[L@(A126MUQ'R&KFN&\9&/.NL/XJG @5DZB'#.
MQ'F#(.II;9\ZNX84=L8S)37.=+C':X)HR/&]HZ["HFXCB]<R&Q:7$%A3I$P[
M;$*1 1709))26+X\R0J!CRC5@8ZD<F]*)CD>GMW>WE3_  V+9W$L<2(+)%<[
MM/>1WB "-N9#'?W-$-CG+S=XK7+M'E"U[N2 4@:$8\9$89B/8A!D1KQO1JHC
MF/:U[79HY$<BHGOB?DR_:?ZG1YAW$4/K"FLL*L9-A\3+B;]H?=5*&G$031Y8
M])P"?X$S%73I5=*NV-?X4PSU5;-NJN(DOKG$,W*/*4S3LX:RMI<9=>E$5=UK
M9DF2IFN?03>!/(A5-"[#)+:T#!6T93+)J*E(5L:L5.'EBC/ =K1R'L"4Q P=
M6<U$=T5-LNGTG25;@Q##L,/1,+=&E$%\!RS*XQAVLNJQ#62JX4ED=JR&';)-
M##%D2)$,:!\+TCQK#&>&.A.)0:899P,*X8=BC&<8!!9%/B"Y@2I,AQ  CS(T
M<2OWD,T 0*^0X4B2G\JB4*9)L!R$M) ["8%(TN<,T6_*.7*C-#'2/(DM?OCA
M: +1D>X;1"1NG;!6[&P>]#;$)H:C-X1UW9(Y[].6M[D:B*Y<W+DG/DF6/\(6
M$^-#Q-*QK8'C4AWJ.=(%%BN9(4+',1"\.L0Z&1BYCT9O1FMFOI= %CB&/BBY
M"P;?'(]]0C&,:B_?O<[3S[U7OVQ=@BLL@>[%SL5G%5;Y\::%DZLB0H<W4YK5
M9'XL@QK)8K]R3DNDK<ML5X0Q5,C5>(X'NNB6N&K",Z/96TF>(P  ''4.N60S
M5%5&:3PL1T54EH"(QA-L)8P,"3%ML'8W]V=0(P7-*RCLI\>,QVZ<U=(I,QL2
MV80H\EBZ2M8HS(K[_P#E(@@K&M@=,57B*K4S1NE,PG5%#4Q(;GM[TZP-&!(8
MPB!,L+,CRY(YN/>E"9'W4CI%QA93(.\1N^925IS@AA<YG8\#)--CJ@TR58R/
M<YR*/+^3I_KFGR?S]A1,_D\GG7)-G]*C)?@7&ZU'A;@<HHL2$8C77:3N*SRW
MN]GL@N@=BS)OV2F#:V.G\HZQCP761X%U+F"K6HBNGEBOQ48<+)45/LIS-SED
MOVQV2+R3;%TV=TFT.%76P;\$/HAP3A'"],'?&%NQ,D,#6'N"P9@1M)(L-YJC
MPVM4UPI6OT=!37(CFNQ0C7-<B*BHKL2(Y'(O>BYJFG++3R5/-?L&QK&,E8;8
MQC&Z6L8ES7M:UK6]EK4;DU$RR1.29<LL$XIQZYUO1](.!,.UF&<8S6;MN%)#
MJJM"E,5&JR%%$ ;!PCRMPPJ0CLF.(U"72.Z4PRNE0'1%*O3CL:ZVM\+U=_ Q
M#4$>\\809]\6/%@MB,TB8@G;LY &@L<XT1@W?R@9]'BRVQR>YK;$-C8K@V-A
M>IL+U\2^?Q-/P5W819CYW$;YP1P(#PB-%(\2<2T;H6&(]I$)B"NEW<V=4(]4
MF@B&L444IPG99@>DD"(5FL>M^[U(1KFIA_\ USA_['N?/R_0GGS\5:FZN+'&
M.*G $"0RNQ'=1)=8XCD$;(@HM5 DD#K1,X[I2@*WLR6'9RVZ48Q^E&/T/GNS
M"L*NRM<+5E[7WM,YSS1 !FWI00Z]D,>D0MT_1)*&1"&Y20QB=TR7%5C"SQGU
MD3^=[8N#HV%:67;HMP8DVJ6%=V$64LMIW2"#' KW  6*5XV\2UJ])"J(:[XF
M-D-V&^%1,*PFHA.7;1&\DU9Y)RVC+6".=M=BV79V0HZ$<[JR-;S6R"N&/QPQ
M2&#+-J\&$0'R7*U ZDPK NOY1+L6PI,VKZFPKA[HIP\N(JV<**^/%WL:)>U-
ME$='WBP6H60U99##W I*=MO0A>XAE=7U,6D>&7:S4<(#"B=8"+OG:Y&A1DF1
M5D*\I6";(:\A=&HKL 3H[X\V%*P VP@R&HTH2#+7XFD1)0'KR76QS3 +R=VD
MT+EH78.'27V%NBJ/68<')9TA6.&</6&(+8,F,I75T.\OXY&0(>L\R(%HR1D:
M>-8->Z44XXVW2I.AX@EXKC2*"+N<0S8H84FT:R12BXE8T:%7 :+L:8S@0Q#)
M%:$K%)O4(_IKK+ZPCU4_$-W%#2QIKE"^R.:QD%"*,BII(0PYL8HF:V.>(FMC
M5;KT_P I^OKETV$^_M8D%=YN7-ER38O#&\,CO Y&>GA?&'S<WFFV*\(XJF1J
MK$<!<71+7#<^,Z/96LB>$H @%'46N60S7#JSH3PL18SDE("(,9-NC$-S',!+
M'I-D64&+*$HW)538$_AW;I_:W$O268!2-3?1Y(R-;NWM<_H(TL8W=XV&-F34
M30/B\/\ 8;\5G89V4Y=EOF3;V]N?=M Q+/NWCPT K6PYHZ4%P'#!79-:^94R
M";HK%+I+UHU"&0B,'NT(R*S81X_2NTH3#88)!X-HGL((C4<)['-D9.:YO-')
MXR9=VWW5/S+I/XG;[JGYETG\3M]U3\RZ3^)V^ZI^9=)_$[?=4_,ND_B=ONJ?
MF72?Q.WW5/S+I/XG;[JGYETG\3M]U3\RZ3^)V^ZI^9=)_$[?=4_,ND_B=ONI
M_F72_P 0OZ.[S=Z$Q#?XA#B,+L+OIF3%@1ZJ4,BV@)C8_!0T<!X&M88O$J5"
MJ\VY4>@;7?4BXAE4-+)OX(MQ"O#U<$UO##D9-S%LB =-CBRD2$W8C-;D<W+P
MC\UK[^GJ[N I&&6#;U\2RAJ8>>[*L:8(P=X/-=#]&IN:Z53/9*W@HG5R1FPT
MK^'#P20VC0+8J1=&X2,T*()H-&Z0:(Q&Z4RV)*P]A/#5#),S=ED4U%5U9RC_
M -&0T** CV?@N<J>C:/<6N&,/65O$T)%M+"EK9EC&02JX7#SI$8DD.[<JN9N
MRMT*JJW)=KD <-4 @8B>0F( CIJY@KTAMYOGW(VQT99O+OC;QTU#J_>DU9ZW
M9@K*>N@U-;&1R1J^MB1X,*.CWN*] 18HQ $CR/>1R,8W4]SG+VG*NWND;ANA
M3$.3F]?)3UZ76D@W!>G6G#\=D\+W"<F_[0W.8O954VD"H*.GHQ3#\5+'45D*
MM9*E*B(LF0R$$+3G5$1-\1'$R1$U;2[JOP_20+B>QPYUM#JH$6SFL<]I7,ES
MP 9*D,<5C".:8KT5[&O7M-1=FW%GA'#%C;M5BMM9U!52[%JB^UJV=(B$DHH_
MO,B]G[W+:176<*)8U\L:AE09T8,N')"[QA2(QV$"8;O*PC'-7RILN&@X>HQ8
M<<PHW4 ZF RE<,YG2##6J;'2"K#2'..5J@R(9SBN17JJ[ K:>N@U5=&1S8T"
MMB1X,*.USW$<T$6*,0!(XCWD<C&-17O<Y>;E7:NG6]%3VLVG-Q-3,L:R%.E5
M<C6(N_KI$D)2PC;P ";V,\;]81/SU#:J;3C4=#34QK,R2+(M55P:XE@=%(Y#
MSGQ !=+,CC%5"'4CT4I%S[;L["6/!V%1RK8,B/:R68>J6'LX\Q%26"P,V(A)
M@92*J2!R'$89%5"([:#2RL)X:DT]67?UE2>BJS5E<?PGAH, D5T6(7PQ?"1Q
M#?X4G/MNS)67E56W-:51N+7VL&-8P2."]I!.)$EB,!ZB(UI!JYBJQ[6N;DJ(
MNT6EM<.45G30=QP5385%?-K(?"A='C<+ DQR18_#QWO #="9N@O<(>ECE3:+
M#O,,X>N8D!J-@Q;6EKK"/#:UJ,:V*&7&,..U&-:Q$"UB(U$;W)L&OJ*^#55\
M=-((-=$!!A@;GGI#&C#$$:9JJY,8B9KM+N*K#=#66T]KF3K2OIZ^'8S6/>PK
MVRYL>..3(:\@V$<AB/1SV,>O::B[#AXBHZ>^AB,DD46ZK(5I&%(:QXVG&"<$
MXF&:,A&(5K4>C"/:BY.7-&-:UK&II:UJ(C6M3DC41.2(B<LDY;!'B/#M'?CC
MN5\<=W4P+5@'NR1S@MG1SH-SD1$56(BKDF>S*NKK*^MK!,<(5= AQX<$8W9Z
MALB1QCCL8[-=36C1JYKFG/:135&'J.KIY>_6755U3 A5LKB1("3Q$&, <4W$
M!:T)]X)V]$U!OU-1$V;5TE164]8Q2N;754"+7P6N,Y7&<V)$$*.BE<JN*J#S
M>Y55V:KMUO5X.PM6VRJ1W6D##]3#L=1OMSN-CQ!R<R_\8N\S?]]GLV'B&CI[
MV(PF]9%N:R%:1V%_TC030G&TGX:-U>G:#;@PW0!M:R$RMK;,5/7#L*^N&)X1
MP(,UD=),2$,)2B9% 1@&B(]C6(U[D6._$.&Z&^?#S6(^YIZ^T=%55156.Z;'
M.H<U:BKN].:HB^3:3<0:*GA6TT HLRTB5D*/8RXH&B8"-)FA"R2< 6!"T02D
M<,;1":QJ(-N42[L<-T,^Y@.$^#;S:>OE6<)X'H0+XD\\=\J.X+T1XG!*Q1O1
M'-R5-I\BEHJ>HD6I^*M#UE9"@&LI.LI.(GDBA$^8?6<S][(4A-9BNU9D=FVY
ML\(X8L;=BL5EK.H*J79-47VI6SI$4DE%']XJ%['WN6P(V(**GO(\4[944%Q6
M0K,,:2UKF-D %-"9@3M8]S&E&C7HUSFH[)5V@DNJ*GN"59^*K"6E9"L'UTG-
MCN(@NEA*L0^8A+O8ZC)F-BZNPW+9XC#&41&JP@R-1[",<F3F/8Y%:YKD545J
MIDN?/9HQM:,8VHQC&(C6,:U,FM:U.36M3)$1.2)W?^9 :PMA"%82&*2/ )*
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M3P0BEEN3[X4<C,E5V6Q<3CQAA^9 ;!?,CBC6L,DV:]!ZQP 06O?-=8%?]C)
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MQ;=$6442A;)X=VO4HM\UC]L8B#C21AZTJ>E#%=+!MHU'03S I*B4@8M2L*9
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MY1DA#)LZ2JYJ=)Y<_NM8A-6BLRN@H@4-VP<GU'SO*TK[$(4M;MG-O+*V9LZ
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M%(2M-PL6%<<9;H6N($UF1P+5UW)(LRX;Y8N2V1-$1,\A2R@(ZKB "T[ETU2
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M-,Z$R&)6A04DQB_*T80ABKL2"(EE"GH.H)5 !@( @  10=/0T MP,@) KBF
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M '[I'5N?DP.=) 6EFH'<(WC#';Y&7J$GCZ"+C6,*</7XZ6'ZKZ[T>$&QVZ?
M=J@^]_FH-OKFH-C[_P *@\8/O#'A!4&QE<:N7FZU!M]S\U 8"H-C[;]':H-C
M3VN=FYMXP;<>I?YO4&Q4'WO\W\(-N'0P?P'_V@ , P$  @ #    $    !
M!) !!()!   ( (  ! ( )    )(!(((()()( ) !!!(!)   (     ())( (
M (! ()())!!)!((!  (   !  ( !) !!! (( )( )() !(      ))!(!!()
M(   !!(! !))(((            0YP"0                     )*%96 X
M                   !C7@3='=@QCA@                ,TG      *,H
M                96*0      +6O@             !*6           _
M           !JF           !C             +@            !F
M        4P0            %\0          #D              #$
M    !>     @         'T         +T   #86,         )P
M \    #XM@         )         (T   "RY          $<        %"
M   /W<          !X       !L     (H@          /0       .P
M              .       )4                   (      !,
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MH  "(      1,  %0@"2AKDP0  !=    =     *T   (F/+V-OLQ(  +H
M #@     ?@   XB$+'* =   !=    (I     @$   ZP D8@$    +H   !:
MH   #96R2@3   '>@    !=    !#I   " B $ 'P$&8@     +H    !8(
M #1$VF0 S@3L@     !=     !2Y$ P@RP& !#Z\@      +H      )S@$0
M 2$@ 4:0       !=        1(X $$$&M($        +H        9-=4@4
M'92         !=          0!+Y)(           +H
M         !=                  0 1(     +J 202 2"22"0 20""2  1
MC@    != 20""  "02 "2 "2 "22 ;__ /\ _P#_ *$D$D $@$@$@D@DDDDD
M$D&$DDDDDVN#                  "DDDDDDD:+0D @ DD @D@DDD@
M       !J D @@@ $$$ @ D             GH@@$$ D$ $@D@
M     3                           /PDD@$ $@D D
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M_P#0=[]E_P#H.]^R_P#T'>_9>5!)D00.5M$LL#/&U[&R!D1R3(5("K>2$&@
MAM%KZ>'V^@]Z ER;>Q3EYOK^DT+,7^:P3?$TD6 YA'K4=O+\T.)A>W^34]SS
M^*GN>?Q4]SS^*4+L7T;Z\*[#78:[#78:[#78:[#78:[#2K96VK;3A4]SS^*
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MYN;-#ESK#M!I%/!YU#,#6YF.T0M"7PR.!>Z(QQ?BDH4[,=+IS%^5")3=3Z7
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M=T_0]![U@\GTK/*6Z,7ZSY5B\_8J)>+,L\"KD2$S;G#MH8Q(3BD&]K>A>.M
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M%399C>,",JB5HQ$B(:0B6*@)$CD1$+$W4/0'P019 6A#"B"!S0B )2E 95R
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MC!I3D>SC7(A0]^%H@WNZGT!7B$2_'OC60!R9E-YV;WL#LE$ $R6<1:VFL1^
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M>YJS\A[,4_\ $>E=I: WB(W7V- ]-*[]?IZ>??\ R*,HZO0:E!;LA+$2$%V
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M)S9;F"<Z_P!=,EVP,N(F*&ZXZWT'7CZN[_8__\0 *Q$!  $# P(%! ,! 0
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M>6>LYK2--M/L-8S\?:ERQLCVN6IBL$ZS_E3VR\OC_K4#,81QY7\OU#8\"H#
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M:ARHM<H%* %7-0HQ 6<*T<*>4@'<R2<&!]!H!OI!0+BDTTBPB1%&E0*4) X
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M[*\OEG(15T A>B!2^77W,HJV[!/ -*Z1$J[!)C?!SV2B,A) VHH88.&E7!8
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MGW,IY/N93R?<RGD^YE/)]S*>3[F4\GW,IY/N93R?<RGD^YD ;::=E-E-]_\
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M-"R4PAEF#_O,FO\ .+D^O3Y4?YQ4?5!T6<'#PV$X-63B>T\8%H(IP"@;=6
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M)-T?84:^OQ*7+/A;AC1)O"J^%Z$N,MIQ:K9":8U2?>K3&;F&UPM<=F*9Q*6
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$_P#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>business4ba.jpg
<TEXT>
begin 644 business4ba.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0"N17AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     @   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E         !@     0
M &     !    1TE-4" R+C$P+C,X   R,#(U.C R.C T(#$X.C0S.C4R  $
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M1T(@6%E:( ?I  ( !0 ! "  *V%C<W!-4T94
M          #VU@ !     -,M;&-M<P
M                                #61E<V,   $@    0&-P<G0   %@
M    -G=T<'0   &8    %&-H860   &L    +')865H   '8    %&)865H
M  'L    %&=865H   (     %')44D,   (4    (&=44D,   (4    (&)4
M4D,   (4    (&-H<FT   (T    )&1M;F0   )8    )&1M9&0   )\
M)&UL=6,          0    QE;E53    )    !P 1P!) $T 4  @ &( =0!I
M &P =  M &D ;@ @ ', 4@!' $)M;'5C          $    ,96Y54P   !H
M   < %  =0!B &P :0!C "  1 !O &T 80!I &X  %A96B        #VU@ !
M     -,M<V8S,@       0Q"   %WO__\R4   >3  #]D/__^Z'___VB   #
MW   P&Y865H@        ;Z   #CU   #D%A96B         DGP  #X0  +;$
M6%E:(        &*7  "WAP  &-EP87)A       #     F9F  #RIP  #5D
M !/0   *6V-H<FT       ,     H]<  %1\  !,S0  F9H  "9G   /7&UL
M=6,          0    QE;E53    "    !P 1P!) $T 4&UL=6,
M 0    QE;E53    "    !P <P!2 $< 0O_; $,  0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_" !$( @ $?0,!$0 "$0$#
M$0'_Q  >  $  00# 0$             !P$%!@@#! D""O_$ !T! 0  !P$!
M               ! @,$!08'" G_V@ , P$  A #$    ??PUB/+ W?)%-Q"
MA4% >3QZQ'R?10'D\>LA0XS0XSPDP\<B=3V$*'T?(!4^CZ
M    .G)'MQA68  !'QH>242X;#@ H1^1\:"G6/80H?0!\E3[/H
M           &I9XNF^YY%'L4>4)Z?FH9M$:2D?GI@>9)O^3&><9'Q^IP_/*8
MD8L>TIYRGK^8<:VGD$>GQ&YHL3L;T'IT?8                 !TI)NY-)6
M,0  (?/S&&>'H*><QZJ&HA=3 ":R%364V2/1TT$+R7<^C.#80],3Z
M              !HB><QWB*C)B#C?8VH-(C5XZIG) YZ)'JN?G@.H?I]/SK&
M)$]GM^:3GF*=,S@UN-]3=,\/S;XV4/3T^@                 #I23=R>2J
M(  $0GDX361X:1GI(>4).9GQ["'D <)(Q9B,3=P\7C:8]="$STU/H
M              %"@ !4%"I0 J4*E 5* J4*E "I0%2A4J
M    =*2;N3R51   ^05*    %0 4*E"H*@                     MI@!)
MY]  'R"A0^RH  !AQE1%)+9]  'R5*@                  '2DF[D\E40
M +80J3T?8!TR,B6"H,,+\8D2 ?0      /DJ5                !Y7FA1Z
MF'*:YEU)%+T0H7TN9I8;W':(=/7\\U#%"-#9\T8/0<\8#UL+V:?%^-B"""&S
M<4J8@882>1Z>P)]@               '2DF[D\E40  -=3\_!L0;[$4$IF6$
M&F,D]%X-:C7DXC;LE@@ FXR0Q@B8NQ:B3R"B5RQE2+B/C<0R0W]*@
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M B%0@1(  $2 !$  @*0C6(  @  1   ( $0/DJ50(@  =*2;N3R51
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MEMY^E7HVJE5QJWRUAC=]:::L(7>I22,(CE^E3RV/PN['+<_,E3]>MM-OXF
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MCSMU+K^DN52AO.N9SG<9?;VGS3R6BUJV3&W48ZEG==>.;Q%O-=K^:4X
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M3@>8>8O"6MW%;2*G0+!1D_5O8;/OO&X   Z4DW<GDJB  /S GD" <YGA4
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MMD?R'Y"URT%B=GE[9-D_U!XW>=[9+H  #I23=R>2J(  _,">0(!SF>%0
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MNFCR1+ZGN86]:<<D'SWX@B;SSI$*4]_MEC&VRQ_5#8[GOJK@  =*2;N3R51
M 'Y@3R! .<SPJ     "J'H+P?8<YP5WY@>E]44I4\R6KENU8*3M[UV2MRP6?
M;/B<DRUGT(1M-"K8<;=0'Q+?,LYMM^ME.'H3ZUXG*-?GVL?E7T]JSC[ZS
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M25ZD($HS2'3FSXO)W98YUEM/V^[%XXUJY_Z8TWV3:-HNN:/YV>2NVH$",0
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MZ1W;0UX(]+899=X#V#['X1U$UWL<=<R]6:PY*Q]+_7_%O//RQUO"M5S1,C*
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M/FK+:[>YP["9?'ILM\QJHS?,(_KU4M_8Q   Z4DW<GDJB  /S GD" <YGA4
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MDNMX-Z&]J;'?+_J>Q'AC.:X_1# P+[8\CY;XY\7P]J^RXQ2O?TI8KIF\\F0
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M$:Y?0[R]*'B/PG&>G5\2I9K]%F&ZUN_)DP  .E)-W)Y*H@ #\P)Y @'.9X5
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ME3S#XZCOD&(B3'Y_%[7,_IRL-_WKA=   =*2;N3R51  'Y@3R! .<SPJ
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M,WAWWFEI]R^OOK<^B=_AOF3./)_FC!=>R]WEUZY>ENNXEWOWI/?S\Z9'7I[
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M8  #I23=R>2J(  TS/QREI!SF>%0         >FYH 8.
M8R7<_:23Z8<A^5^,?.*"M-<[C&SCD=%V0RFCY;F\=@UCGH>Q.<^J#8/)Z5<O
M1748J]4^K^Y=YZZ\:X;*7FWS+KWRF]UOPW1H_DV7>66GHW-"Y7,;C'$WACLF
MJXK([K&23<XV0;FPR7(8[MRV>/6L>C;WF25,?E;'="%]&-'8X+QVYZ^V6ZVF
MVR59FP*A8H30[4JY->X:8KK4).FUCLS6]DC=W.M0D:YLLQRMK<<]+3-Y/HY:
M\Y;6TN.*QG>PMA\XJC:\=/CN.RT#8SH'NY9;]ZF27'U&(  '2DF[D\E40 !0
M\Y#P&(9.0S4J        #< G(R \TC&@               5)?/T"F[94H"*
M3&(0^II>PI=V:C]GQ"?JQB2]^:AV+BMT;W*437"TQ_%1Q_2I7-NIW7$J7]+8
MXR_,*E4OW&'TEK&3FC)V(R=A+R0AQ1<*;GA)V8R?4)NM"K;X5^C"LA&L7?2_
M!TH34FAV(TN[&WK&''"?Z.=+RQI\LTG+%]0F^:BJ5++\2U.*6:DE60X5[NJ_
M:%40  .E)-W)Y*H@  4 *@        %  "H               * %0  (0%(
MQ%0A1 (3 5C"D(D$1$5$%"L1"B)"L!&D0J$"(H"H  "%$*H@A1$B0JB0%(*H
MTC+5$410A6*B-0  #I23=R>2J(
M                                    Z4DW<GDJB
M                                                       .E)-W
M)Y*H@
M              #I23=R>2J(                  'R5*@
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M"2ZYH27BI;TEFY)I<!L\SG5YB*QD0FP&WSG<JV&836?U*QF6\RNK8<D8@
M         =*2;N3R51   'P8V8^>4AZ7DW%#4HVW*%#Z!0U)-MP ?)]%"A]%
M "I0J?)]%H+(9B5+01\9R7\X3'3+           0S8['$UOL6W.4YSYBZMZ"
MVDR>C^=.L]EQN:]F6O@;5+5@:WV/:S)\^PZWRW-+/UZN/A7%[YO!L?(=1,#T
MJ4LCJ^'VFR9]7PT16VP>O^X>8]&<+V#&Y9)@JXF.5UAU+,S;<:O8)+K@A7M\
ML<+M\KZC;-PGSQU_ML7T<CLE>Z;CLUQT+7*1'5IRM"2Y1M93O,!MYE^<?<0
M           '2DF[D\E40  ,?/.T]'""SPH)E(.-UR)R9##2-C,R,B4#*#<4
MMQ"I)YJX74DHZYEY$Y*!@14R0CXNAG!N$:($7D]EN+48J2\:J'L.2P
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M*5\2Q^ZDB,:PC26":%($843?2-80I)!6A62:DLQ)5%%2I'X2I*GU&7[/M$
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M.U5%Z@X6,I K^1(5=UYS2PM@,VM;8$%_+!TRDF':91L4,.GQE:#BA,.,:*
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MWK9K!'LBFA?X<@F*+[YP975?]O[843#89Q QOY^X^_?G0QX;^4XVR[4YQ_\
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M)(=0YCY,;CLTCC^9E)0_BFJHD*$DX17M;))-7P#CFG5=)-OM2RM(&$^9&_\
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MFW %03SRLC1$NOFR8=R+<#YZ!@LC!C=JIW,4#=H,A, 17 HL4P*9@W-GH*&
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MH%11S_:L3#F,%.LK$HR9;4W3JKWV\/;X.XF4N42TZT<_&][WY V T]\"KDN
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M$N@C2)HW$3%KPI 487+)(AR76D[I,(3-;066H>V$IG21OK]IA$K.J3<K7[3
MI\XL^>OVF&:,^I._F4;PG#"G/1/O@X0 &<I(A^@.-).S2;B*-.SU(FT**UI
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MK2!]QZ/C\HY^'Z#;*-H=Y/ I_&,/8;FZ\^D,)5LB=5VX1(]#\LZV \I.U*=
M5:_WN,8OP#/8;>4NQ7*\0L#0#PB]RJR=UL75_: C"^$)W$B5NL@H;N0G3YPK
MH4G0VV>M!*U("K90>/C#W0W66[Y',_@!^,4/HCG>MI<GDW:2H9AI:UX8I6&L
M/,H"D,I<2!>Y!U\88J= JQ,D.KK)&@ 1ZK:1TL83^S"B:E6<C;EB;#D;F!:X
MRC* +*[U=L+-CIPBJ5:3IDHY,3"TI2E!T)L;VC$%3F<9XE;EI=1=DT/C=&HL
M%6X^J,.4M%+I<FPE&0H91IX0K>X_Q=3I;_JC+;G?W076VSY1;8'&Y6D6]\5#
M%%$IWYZ;1IQ%[_ P]TEX>;!*7,P'KXQ.=*\FLE$DW=7(W/RBOX@JN('VDAE9
M2JR#87&7V?OC!=!E:7243'5ME,/-V<5K<YDZPD!*4A/"PBY^['$>L1)_XVS_
M +Y/QC"/^0*/_P NE_@(Z3_\[JC_ ,0[_P!R.9]?W-4<%]8?4DW]45!/&T.Y
ML]H:DR\X(PK077)AK*G3,(P7AQ2$LDH_5Y1*4P--H.7D.4,.!K2.LY]P0\,I
MWA#C+$PT6E(2<W:(QKT>-S[+CC;0N03H(Q)@^?H,RM3:5!&J_?%,K+@\BZ=1
MI"'=H;PC40O2$G6'>'UV0/.^NV&% "T3;H28FJBEEE68ZVBH31J$R4(/%7XQ
MA#!ZIH)<6FY+G.,'X01*I:46QI;E$A3VVT)T";=T-H2$Y<T*ETVXB.I-.(-[
M1.T.7<!.1*O 1/8/8FF5@,IY^B(K71HE:7+,]OHQB3HYF)<N*2V1QY14:)/R
M*RE(5:UX1,3+*\J[Q+3XT"C$L^E8&L)XBT2M]/"&U63]=T/.Y1$Y. 7N>45&
MH"Y&:)N:*UZ'E$N2I7C$FW<IAU 0U?N@RRIR<0E/#0>^.BS"B@&G%([#P]44
MNGH8;3<6( AR=#.B;:0JKDIM: M,P#=L>R)ND-3-SLAPMP$8LP"B=97E9%R#
MRC%W19,-/+6ALBR2>$#-0GS+.:&^6)2;*P%7XF_A$G,:"&WMV YFA'#[CT?'
MY1S\/T&BTYVJS[<H@;JB"KU7U$,,R&"Z+M4I2%[.Y'/-:)KI+K3M1$TPZIMA
MM>6U]-F#?X139RG8\PP4.E*YA+-E#TBK)KWQB+"D_2ZNF3;95L9AW*-/04;1
M2Y!G"V&99Y"0AP-)<7ISRZP]TL5EN<?"3F:0ZI*-1YHX0WTSSB4V<D]J?]X!
M$QTQS2F5!N7ZL3?3.%7[[VBLXLJM;=)ZPM(/?^^,*52;IE8E'GIM2D[9!<N?
M0OKSC%I:Q)A=3S*0X>KG9$:[V32)R4?E'%M/(*%)4;@Q/SC,E(N/N>@DGV?7
MMC'^+INOSAI=-6K9D9"$&^]YOMCHGP(:>V)^?1=Q6\"H=NO.+@Z#@G='J'\:
MH526I<NIZ9<2A*1>QBL]*,W,S"I2B2ZG=<N=%SW=D"5QM7%!?E4I5I?,$Y?>
M.$-]&%5F5!R?FW!?4I-U?C#71.PL"\V;<QDXGUYOPB2Z+*1+64L!Y7/B/QB3
MPY2)! "91-PK-^MPA:RX$M-(R-I[(4 ,H!O9(OZ_O!Q'K$2?^-L_[Y/QC"/^
M0*/_ ,NE_@(Z3_\ .ZH_\0[_ -R.9]?W-<=*'; PXNXO>)Y1M"DE;@M&'Z.9
MAY%TWN1&"<* ;->Q],10:6U+2R#D (2(ZPG(4DB][#U0E.;>,)F$,FY/#X0N
M=:?TS"_A#CBVUBQ]4-+1-,Y'K*TM&+,$254EW#U<*N"(QO@=Z@OEZ4:+2<US
MQ.D4Z<;#:4.^>-#>&E[3S#I#P 3KQAJQAT:0#OP-$WB??(OKK%<G'<IRJL,L
M4%W:5%.TUW_QC XETL-;HOF!^$49U ;1EL-!"7N%U0QLU6^<.#*.,&8R:7]\
M)F4DY+Z'C&T2G1%M8>E$S'H W$8@PBW--J\@#>,2]';8SE,OZ)C$F#$2@<6&
M""+PZP[+K5>XRJM%'?S6"C>T2X3EO$N()"4=\3<Q9)UBHSGG;VL3LTM3AWM+
MP%%4235R#:)7<M$Y-@HR ZVC!E.<G:DWF3F1M />(P/242<JQE;R[J;^R%I:
M2A.N4VCJK+^JB(^RVU<%"T-R2&Q;,(<"6AH01VPMQMXY%64(Q1AV5F9-QQI@
M9RDB_A'27@M;4VJ8;9(4%7OK$MGEDI;6=0(E)@@#>AF:-O.AF8W@+PDW2#W?
M<>CX_*.?A^@T6IS%,FT/LN9,MCP!UOWQB'&<Y5T)9>?S63;A;X0=4%E7IG/?
MLO&!\6S&&YY+:7B&E* 5?46N+PBIX>KVPJ,PIDEM*202 =H-;QTA8T9ZNJG2
M+Z=EER94ZZ<.,*4I9)5S,91W^V.5H MP@H5D*VU$+X>$8&Z1VI63;I-3.=M%
MDIS=PL/7&+I##]55M93(U,O#/F![>[A'2U+U>4E1(TM2G=INK*!QN"#VQ@7H
MX4%IJ%2EE;=3@<.>^M['4<AS^';#:&)5E##: FP T[HRY?'7\EN?*-HD:6^O
MK\8&]?+V0IYI#+JW+(+8)N3V1B^M3>):\FC22U+8RA"\E[9LV4\.<82P/(T2
M40MQA*GU *6I6]<D:\;^V&VF6AY)L('X_D))C(._V_D"R.'/N@"U^_7[P<1Z
MQ$G_ (VS_OD_&,(_Y H__+I?X".D_P#SNJ/_ !#O_<CF?7]SB%W+,$7C:W B
M=.AAI9ZTD?7&, 2&W=:W>.6,+TA#4JA60>=V=T3LYU.7L-+")6LJ>>RW]*$.
MVE<W]G\(Q3BE-+"[KM9)/&)3I=9$]LE/>E;CWQA[%\M6T((6"2<O&$(6AL.)
MX$7A4\N^0BXM&-:&W6))\AL%00KEW1B:2=HM1<:U3J5>^,.U';V23>)I.87'
M9#0M#G _7,0GS_9^$?S9^N0BHJ-R(GI4OMJB7:,A.!SAO?C&%L8MRR4)4O@H
M<XH_2"PE* 7!RYQ_A(E4(N7!IWPQTLR2%6VJ?;'^%:1<1?:I]L.])THH_G1[
M8D^D25<5^<'MB1QE*OE(SCVQ)5R7=RV(,*>0^UH =(K5.5,7LCT;<(Q;A3:,
M.DM\CRC%>'Q)N.63;B8I[FSF,O?^,2*LR!ZQ^$2Z=!#WYOZ[HJ;I2E6L5":4
M7"+\1!07%DQ+RA4?&).3L!I"F;))'(1+M+FI]+.NJK>^.C?!!RM3.S_G$GAZ
MHI\L95IIL"U@!$VV=F%J7:R>$3%;:DLUWN%X:QJP59 \./;$A5$SMK.WO#S:
MRW9)S7AN4?#M];7AUK-*J0L<HQ]069F6F5[,72%'A%9;V-1=;X95$>PPRX1:
M&7E6XQ+/$N)UB6-VA]QZ/C\HY^'Z#O9NZ"RVK>OK&JCE5H/UHLALC+O'MAJ;
MJ+6XS-+2V=2+\#[8F$.N+VCKI6>\WC-FMW:?Q,J@=H#IPM&ZO>&XL0W//C1Q
MU94-$FY\WLAU:73>81M;\"K7XWA&T:.B $'46 X0M*5ZCSH3F]+\F8^;VQE0
MC><B?K,C)(VFT2%CT>T1BG$\_4AU2FA7E3E44_VM(P+@M-,;-1GDYYIYPN9E
M<0%<HX;Y5NVW4P@J5<J%M=/5^A#B/6(D_P#&V?\ ?)^,81_R!1_^72_P$=)_
M^=U1_P"(=_[D<SZ_N<2(\N3;L^$/.J:(%^43,RX1QB3-YI.;M_&.B]EI99-M
M=V*4=C*C3ZM&(*@L IS:1AIKK<Y<^;F]]XK;XIT@LI.7*@_".DW%[[CKS8>U
MLI(]6L)FYHS0>#B@2N]_&.B>NOAYEMQZ_E!^$4^>+\DG7-9'X1/51;+BD@V-
M^R),B<E5A6I4DW\1'3#A!H*7.-,V7LS=6O>8HCJY*8R%5MZ$/;5I!!XI%X.[
MPAQ?*-+Z<8S[D33863"Y<!)L(J,B%*)RZPAMZ77=!*;:PU7IZ7MY8Z0]BJ?7
MIMU6X1]NSY-P\J)?$-1"+%]7&/X03_\ 3J^K?7MB1Q7-L&RG5$\8IG2).-/H
M3MCEN(PKCI4V&_+>D 1%!K/66D;][@0ZI*T:<Q&()-MV4<N@$V/PCI'I>5+J
MD-V-CKW0&2S-W4+$KBG;/JZ2!O:1+*'.'R"V;16W"G,/7$SO.Q+2V;E$C3\Q
M&[I>.HI:;N$V-HJ,VJ701FXQT:X=%<GVWW&\^\#?QC"M%8IDBAM+8200?<(6
M0+$<HQ=7%R,J;&RLG'PC&>/W9="\KISZQ3ND>H+GD@OJR9A\8P+C(3"6@M5R
M;<XIE2$RTD@@#@><)*3:)FV7+VIC$%*,S*30MQ2OX1CS#WV?/3#@;(5=:K^,
M2LT2\4*-[&T- 9;Q+*\L->?XQ)&[*?N/1\?E'/P_0;Z6Y0 $\(4<PRGA" $"
MR?G'#Q_CG6+"%;P /*,QRY>4 6X?E5HC=\_-Q[HK#Q;E+7\J1Q[[0S09BJ*+
MTSF6G-:UR-/"*?AJER82OJPV@YDWU\;QH4!%MP<!ZH*$FW=PA2BJU^0L/5^A
M#B/6(D_\;9_WR?C&$?\ (%'_ .72_P !'2?_ )W5'_B'?^Y',^O[G$3?E+^K
MX1.2Y4L6_5A<HHPJ7,NL.=D=$M:2J:9:OZ0'OBGI2NG)<[OPC$2QM%",*9D/
MA2>$8WJ%J>\F]O)J^$8V?2[.O75Z2OC!0A+:2GC'1]43*3K695M]/QC \ZBH
M221>^X/A%8IHVJSZ[12,Z#L_".D^F+?I:U9/YH\NZ*NA<A43?=&T_&*3.;65
M0;]T+>TO"GKP@W,.JRV'="W!>%J!A]E*XFI/>T&EH>E$^E EV ;&&V94<;0_
MU=*@$$6M&9GMA3[+?*_?'7T(5G C!F(%&80E*B/* 6O&!JAM6&25<DQ+N!Q*
M;=D5-G.T4]HC'E 2\PXK)Z)C%TL*=-'2V_\ C%)JE]FW?D(1-6RV[H+WDHK1
MS9O&"W=V))H 1(Z<.V\33AV)]43X,RL-\[QT*4[JX;NG4V_"$79EP5:<QZH:
M5M$DQTB%:9-PA-QLSKX1CBH7F%-*!\ZT2RV9=*'+:V!C ^*"B:;;3V@>^,(5
M54Q)H4=-X?")-[/E\(#87Q_5B>9)0\D#B"(Z5:0/Y0LILK(KE#MY>HK'(+/Q
MAF<&0:Q*/YGAZXIQO+)/W'H^/RCGX?ZAM>,O=!W2#RBL,E[9D>;I>)3*S+H2
MD#AK NHZZ1:W#]$'$>L1)_XVS_OD_&,(_P"0*/\ \NE_@(Z3_P#.ZH_\0[_W
M(YGU_<UM.9V')/,19/$0*7_8BJ4OR!(0;Q@!QRF5%A0.7RB>/KC"U53.4EM!
M7F) ^$8EE%)<*P#&%2L*([XZ0"L2;^OH*^$8I453[N<WWC\88*=EZN$8;FUI
MJ+8OP4!X7$=&$_DE6M[BE(/L$3Z6YC> XIU]<24KD=O:VL8QE^LTIQ*A<;,_
M".D"24U4W;"P#AM[8H,TI#.0J]*')DVT,!Z&7>&L32]S-SM"IJQ.94*GT@VO
M'7&SSAU]!''2*C,I%[&'9U8=L+F$S4RH@ *M&PFG;$!4-TV<5Z*O9!H\Z=,B
MO9'V'4%+RY%6O^K^Z,(85FA,-KV2QOCD8P137)=AD*!&@B4W&QVP[Y1LYHQ:
MEGJCH6G,<AM[(Z2&TN3;N4<%*M[8HREI>&<G15AZH:*EE%NZ,A+(OV"*JD"^
MD%"<][1**2+1)6Y?7")NY:AP99I*N>GQCH?6A:&CIFT_"'3G92%:[HM$DDVL
M!I&,J:J:E7$!-P6S?UVCI&PT^W.NK#9T42-.^.I3BK-$'30:<HP)AV;ZVTLH
M/$<N^,)R+C,D@$:YA\(IR2 F_=#:];DZ98FIMM&U)MP,=*T\RZA\Z:-J$5-Q
M"Z@[E_7/QAK. -8IRCM4^N*5_BJ?7]QZ/C\HY^'^H4WT YF!(-I82ZXGC;6_
M;$Q+2R\N1&EM=><3$L%#+R[/WPA&S&6+G]%7=* I/'-"+HF)1Y)LA+B%.CMM
MQBB]-%!IE+DY-QL*6Q)-M9LQT4D6C&=<E:]7)F>EF\J7G%+O>_%5XRJ3?,;W
M-QZON:PX-O;O'X1+A*\L,2B% :1-TUMU.6PB9:^S9II2=-\?&.BNKN333+:E
M7&9(^$8CE$K90;<1&'I39/6MWQTA-_R-_P#N*C%J?_<'O6KXPPHY#&' .NH/
M/:#XQT<OA,LR+\A\(E%AU*><)E@A.:W?%?.TDG4<LI'NCI.D"F;>7;TC\3$@
M\II93KYT;8JM"28E^7UV1/*RM>$33Y!5K"YVRMXZPFH)'I0Y4;BP,%*II42.
M'7IAQ)2WFU[(I.!'G\AZN>7**?T9%QL%3-O^F)/HM3IY+_ZPQT5-6WF1^S".
MBV52L>13^S%)P#+2BDV:3Q!X1(TEN5"0E-HR6MW1,/[)H^J,8U=AN7>2M0"L
MBK1C)]$U.NY==X_&)*04E6>W.*=*%03&PLT1%6E[WAQ@I)ADD*BGKL/&)@W;
M\(GMU05ZHZ&JCOMHOV?A#'EI=*NX")1H"*@PEY"DVONQC?!J9Y;A#0N;\H;Z
M-E=:!V6E^R,,X*1*%L[(7TY13Z<&&TIRQ+LY0(FBII)(X98J530TU,*6JU@N
M.DW$277)AM"[C*H<80A3\XI?]H_&$2^YZA\HD&_+I]<4Q.662/N/1\?E'/P_
MU"C=6E1X7B;GT&10A/&P^$=86D6/.%/*5''C^C)M;>X?C!SWMZ!YPXA*&,@)
M4M2LW$Z QF0EA*0++T]<:V3?L^YKA(F-.Z*=F4!?M]T2HL@>J  5ZQB1*MN.
MP&\=#]2#;C;2U:[86]6D/RJ9V6:5ES;HAFFIE_*(18@<8Z1YG))O GT51BA2
M%SSG?>_MAEE.0FT4MTL3J,IR[P^,=&M1SMLI4N^B?PBDY2A)3!6LI";Z14V,
MTNO=T*3'2E3VQME9-==8-VYI0[##*U'+K#8O:&AEU$5!:RCCRB=-LQAT[1>D
M2U'F9GS 8EL&U)Y0LA67LM%#Z/WU+1M6%'41AO ##24A4KZ5]8IF%)5@(M+@
M6M$M0Y>P\B(8I$N@#R8A4BRCT!#DLF_FPVC+H$[W* RZ49B(7,;,^4.@C$^)
MI23EUY7 % 'G&-L8N33K@0_ID*8*W9R<)4<P*OQB1IJ"A)4WV&&&$,IT3:'"
M;1-L(<2HJ%^,3DLV,V[&7*Y]=L,/[.VMN$+GSEL514)MO+RCHDJ2D3C02JPS
M#XB*#,-O2*"K7A\(+H0;(T@>43>)ZFLODE:+PFARP<!V0B6IK3=BE($.)6V1
M;LB6< 3=45JI-,L+N0-#&.,6I89F$LO!*B%"*]59B>G',[N9*B8E64!68#6&
M4WT(T[(DI1K:).76\2@"60!]QZ/C\HY^'^H3J+<N,%1("3P'*/\ Q^D'46/"
M,QRY.4#=X00%&YB]_#[FL,YICV?A%/E\J1IS$-"R/"$'RGUVQB%C=*XP#5^I
M59I&:WE1S[XPK5F)RGL9B"<B?A$Z\PVPHZ<(Z4*JWLGT@\E16G]K.JL>?XPP
MCR!/=!=V4R"--8Z,JPK:M)S=GX1AF:VLN@D\Q^$ C*(G5)V"[_JQTK*2$/?]
M4/J"IQ7]XPP>'UV1+BX$(3I$VUF;)BK(RA4,N6?L3Z7XQ@]N7=V>8 \(HE,D
MEH3Y-/'LBF4:5!00VGER$24@RC+9(]D!H)M80T"!"G2D09KMA4RF\,3#*=Y=
MN,3V(Y&58.\F]OPC%6/Y>7SA#@&Z3QC%6/ESJG&TNG6XXPY,/SSI.8JN;11Z
M.2I*U"$,): %N4*,+X0XFZ#$\WQ]43(RJAQXIY\H>GE"^L34YF023[XZ,:FE
MF;;U](?&,)X@0N40G/Z0$2CZ)C+#EVQN\+7A3JKP2;WAMY4(*%M%2^-XGIYM
MA!L8QEB0(:<2E7H'G&-,3+7,NHVAL5'G!F=JK/VQ*+O$D,UO7$HUO"&!9 ^X
M]'Q^4<_#^I$ZT%N7(OPB2:&7A!0$HT$-"Z[Q7TI+!]42$P9*I)=2<ME ^-XP
M)CMM$JVVMX7"4CX1/XU2MA0VP\V.D*O=:#H"[WS1-.YIE1OS_&&%*+-K\HG$
MD/WY6CHW?4)MI*3Z0^,80<(DV\W&XU\(#X#0/.T5*IAME>8ZV,=*=5V@>2%_
MK0E2ES*C?TS\8EAYNL2EKI$! L+1,-D-$\HJS*5I4 -87)+0]F B@55<DI-U
MY;1AK&C:<H<?%LT4W&DNLMA#Z>79$AB9@A-W4\NR&:](J2"5I]L?PAD@G\XG
M3OB8Q3))OY5/M$/XKD_Z5/MA>+))*2=JF_KBJ=(4M+!21,)!M<:QB?I4?&=+
M<WIK%7QQ-5!1_E!4+6M#*U3CMR2;F*33TI4FZ>)B5;:92FPMI#Z@HBW"T*T@
MZGZ[OG"QNVB>:%^'*)UH7,36[[(>S*5#S)4+1AB:-.?2O-EL8POCP,I0DS L
M%",.=($HX$ O))TYQ*XGE9I(LM)TMQ@3TLHWTMZX5-2IM:W#76%U"5;YCVQ/
MXE:ET$)="1:*]CQI(6G;CF(Q/BT38<RO7W2(KZS,3*UDWU,-D)3I$F]O<8IK
MJ=.V\22KD>L'ZMKZ_&&_-'W'H^/RCGX?U(>9"E7AA 0(*A:T(L#XQ6!G;(B?
M8*%%0BAXA53E;[A '?"L?,+;R[;6UO.BL59-0S95WOWPY).*=S#VPAEQMKAR
MB85=VQXQT=-E,ZTH_K#XQA680)-N_:(=G4):X\HQ)6FF67 5:Y28Z0JSUAUU
M*57U,216IPGM5$FRXK+IV1)2B]%& C(1$VDJ9LGLAZ0<6I1(AZF"QN-?5#].
M=2=R\9I^55N*4.<4W$,_+*25.+T[XDND-]I S.G33C".E!Y"?SY_:A?2H[E_
M/']J)KI.?5P>/[4.](TVK@\K]HPO'LZM!\JKAVQ.XLG)A1*G5=G&)B>,T3M'
M#[8:;:/!7.*>M#1%HID\DV]<-OYP+0D'+K"A\H5H?KNCC$W*J<U2.45"37F.
MD34JK6_9"Y>RH$N#RAQA2!=&D2\Q/,N;JE6OWQ0\43$DM&U=4+6YQ1^DQ#*4
M@O=GI0STKRY &V'MC_"BUH [Q_M1,=(J7$Z.^^*UCXK2I(=.J>V*IB"8F5*(
M=5KWQ,U!]1-U$W[XFG<_&,]KB),DJ$4IM2K>N)!@@ \OKZ]W.$BP'W'H^/RC
MGX?U((!_B3J5+21QBI2Z@2-D5:7B<E'E$Y65V\813GPK\RY[51*RCB;795[X
M8EE&UVB!$W++R$)1:)N2>ZP#LR=.R,#$L/ME8M8B*#76FF$ K X14,5RS;!R
MN"]NV,8XP*\P02H[/0B*Q59B;F5YFU*!5%&DES&_LBD9K6M$E(9<F[V0TV$)
MM:'$PG714+804Z)AV22>*8=IHY)B8I:E'S.79#E(5^I#M)<2;!*O?#M-F.05
M#TK,-*MLUJN.^%2[Y_F5^^&Y5WFROWQL'0G1A7OAZ5?.NP5[X,K,YOS"_?##
M#R!8L+O?OB0EGE$795[XD)%:;'*4Q*-%*1 )CC"QJ(2F.67E$[)[2^5.L3M/
M62=SE#],=S7R&$R#H-LAC[/41JV;P9)2.#)/?#THL_S"O?!$PQHEIP<_2AN<
MG$J\QSVJA%5G$VW5W\837)ZULJ_?$S4773OE:3;AE48<G5<EK_8,+F7";!M3
MG?E(_""R^[P85[_E"::^K4L*[.<2-.<2H7EU>^*/(*("MF4Z\(EV$H0+C6WW
M/H^/RCGX?U,4D*@R[)&^A)]8@R$FK^91^R/E'V=)_P!"W^RF!)2H_F4>P1U.
M6_HT^S]T*D990L6T^R/L>15JIEN_]Q/RAF08ESF:2D6[$@0B;F$:)41ZH7-O
MN"RUD^NYAV69=N'$I7?M ^4?8=.*LQEV[]Z$_*$4^5:(V3:$CN XQD2FUA^0
MIO 38_D*0>4;-/9!9;/%(CJS7ZH]@@R4N>+:?8(^SY;^C3^R(^S),\64'_I$
M?94C_P#';_83\H%*D1_H[?[*?E'V=)'_ $=O]D?*/LJ1_H&_V4_*/L>G_P#Q
MVOV$Q]D2'_QVM/["?E"9"5;\UE _Z1\HV+?)('A %ORD7@"WY#;G!8:7Q2(,
MA+'T$_LB/LV5X[-'[(C[/E?U$?LB.H2H_FD'_I'R@TZ4/\RC]D0:5(GSF&[_
M -U/RC[&I_'J[?["?E'V-3__ ([7[ C['I__ ,=O]D1]CTWG*M'_ *1\H-$I
M9_T-G]A/RC[#I8_T5D?]"?E H]/'"7:_8'RC[-DA_,M_LB$R,HG@RW^R/E"6
MFD>8@)]7W7H^/RCGX?U2L(*03?\ CVO^E6$91^7*/RV_):+"+?D*08M_$M]S
MZ/C\HY^'^P_T?'Y1S\/]A_H^/RCGX?[#_1\?E'/P_J3N@BZN) M:*;1YF?<F
M%A8;E95!=F7W-UJ7:X743YRU'=;:3=QQ6@%@I0?2A#BPPYMFPLA"\N3.CDK*
M;D9AJ 3?76.B/"U"Q3/UN7K<JN91)4AV<82E]YC*X@G>):4DJ'#=.D85I$G5
M,;4VCS3.VDIJJ)EERX<4W=HJ4,H=2H+!T\X&\8TP,XG'=0PQA2G+\C8LRG60
MXNP;;*_*S+HS:KOJOAPT!L>C#'*6)J<-#?ZO3]L)R[LL'$=74I+AV)>VJT[M
MTK;0I+J<JFBM*DDT+#=:Q)/.25&I[LZX@9E *0T&Q>V\XZIMI/=F<%]ZW#2G
M]&3=/P/BBIXCICB*U3US29)76B$-I;E&G4+&P=5+OI#JE"]U"Z2@ZI(&'L X
MJQ*RN9I%/<FFFP0I2G9>6;*A?S')MUA+I!!"MF3E/'72*5@2O3F)F,-S$BXS
M-YVUS39<93LY/:H0[,(<4O9NA 4;;,N9E A(401'2/T8U/!DY)B7:<?I\WL6
M6IDNL...3KFT)ED,-';$Y4BUV@%$V2HP]T;XT9IWVHJ@O"4#6U4KK$N70C+F
MS=62Z9FX'H;+-?2U](IU*J-8F$2-,DW9J;<4$AI -P>%R3NH3<BZUE*1S($5
MKHZQCA^4;GJK1W):6*DI4\E^5F$I)_I.K/.EL?VG A-R 3<B'NABJ(P(SB=(
M4:DMS,N0V\KLTR>8VF-KF";EL!S9[4K&;*4YMV*'@/%6(VG':/2')IE@E#DP
MIZ7EVRX+@H0N:=90Y8C79J40??4*!6*54?L>>DGFJ@5(LU8+*@XK(@-ELJ2Y
MF7N)4A2@I6Z#<1A3HJQ"_6J.:[07319N:0W,*$VP%;-2%JWA+OF8:!*0,^5(
MN0DZJ$8YIDI2,45FG4QDM24G..,LM*6MPH0D#0K<)4KGQ))C#N'J6Q1'<6XC
M2Y,4MN;ZE*T]IPLNS\UES%!=393;0&N9"L^XXJUDA*V7,!8B$Q),49S"TULU
MJDYT5.:J;3KX!R2SJ)@(" YIE*1F5JG,V;9J'214:])TUW5A4TEN86A5[L-D
ME]:%IN/S2%E"M4WL>$=(]!H5-?D9S"J%_9+[2I9;F=UY!G6'5I=6'75*/E!Y
MB+@96RI-[F&);"%&PA2*O5,+JK$Y/3+[3COVQ.2*0&EN@ -LYTZA(Y)[=>$.
MT/#N*J14ZGAB3<HT[1I=<W.TI<R[.M+E&PLN/M33V^5"W"PU 24#.' #[O\
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M766Y6:4[=S*A4QMF6Q=10I*"K+&*-L>EO#AG@\JF[:5V6U4OJ1F;S92H*5Y
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MNM;$HU264,AMMH@@&[:4F^O&%]*N/5HE$*K[UI%252Q$M))4@H!"<RTRX4Z
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M7DH$9^[4 Z^Z,CFAV*['L"E 'N[1WP4Z;I4H_P!TW'AQ@A80;MN CF4*%_=
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M2&?*!:I,Y4-+4T%M@;.^=&JAK9S"6&Z;@_#,S-R5\15ZK2FHFG1_[3,'/F#
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M2<>IJ:R7WDSK3#LTHJ>8;9*0&D.&^9!5F4G+O 74;Q@K%F'*7+XBPC5IIW[
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MANG"I.F7JA,Z5]B,^,*$*3"DPZ*&$@UA$(3"$"$H$(."%O[P81$M(E1Q'GE
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MX3G2NIB6^3S:L^HJ;E%CCW8<^3U;THA90PY5)^SRB].S2\=DXE.RKF%/[O\
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M_*W3>(*N[B ,73GE.V;+MM+[+830<J")69<*4U57+/(0R$JSH*PAM-82 !E
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MUK%HSV^=J%<(2I15%@J_E#>+[0^,7 1\P@-C4"L7NNM^<I0]C)2,Q^]2+$N
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MRRD*< KK'YWEI=-!3*%WFPJ[ R]435YWUIHCW0Y/SLRHJ4XH#2E85A&:CB5
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MS]WZ'&%*"!#D^TWV5$8H7,EW]68E4K*:KUQ0,AZOV/BGQA7?/\/WQ._KW?\
MJ%19_P#,D> ^Z!H/ ?0L9CSTAM ,-(3%F@50GFX(V=M)2$=$@Q\IV\4Q*V-,
M-)=(5NU)3_#0Q+I<M.TG%3!Q]LG/QBV&UM)2TUDK(#PCY,EU-_NIR9:Q*%%!
M1]47TM1-G2299*\)#.0'*E(<MF=%I)4EY6'>??%QK47.2(9<7C04]H'/.D?*
M8L-"Q,N-,Y46:T\8E9<L6D\:$$.'XQL>O).R-N2K9F,+1<0,/]H1:*9>U+L-
MOH2%.%@54.>&+7EMS-NBE#B/QA2>U14!I%*T@H$$4AOGQ$8<="<X8HC,ZC2!
M-*IDJ+.M9R5-<6=8E;ZORP[*R#2)F^LW,9I?4D<?&$WOM!"NS,J'K,-7YM%L
MU,VN'K_S;@H9I7M_UB2OG-;X+5,*UYF+N[1W$!#:I@4RR-(L&\,M;%-XM*JY
M4R$7SL"4FI-YQ+->P2*&'DN67:RDBJ:.5'A6+B6L)J30VX<1P@4]47[L)N:E
M5OANI#1%8M^4]'M!Q)%.V?C#K39;TX0XG"HTTC_O#"C4>>4-J.'STA2C2"^H
M5%84ZM1UAAI3CJ4C,G2-F=WBNC\RBJ4YYY:4,;4]H,I="RE2[+B6W"-:@T%*
M19M\C>ZVLWPNKO3[4;/;NL25CL3&Z!*DI<*NM!%OWO,D\I@/!(3D!EPBS=H:
M_2 PX]B25^ZL2BI&\%FX#@45HSTXB-LFR-B99??;DPOYE1Q <8OW<QZRYM]*
MF2A"5*H*4T,;,9[\V6VR-Y@H\",_WHV46^+0L-#2G@NK(%/[(B^ED *??W>?
M:(,6@%[Y85S/" G.'M//."/H#WO/3]DT@FL81I&GZ5!^2F=8J8U@%(U$8D\H
MQ"M*9TJ(MB?]%E"JN%PY Q9\K,VBV)AU154ZZ9:Q+R*& *IS\8!!TBO['Q3X
MPKOG^'[XG?U[O_4*BS_YDCP'W0-!X#Z&7[H\80JD)=B3F]VXW_&(V<VB',":
M_4$?*D:+DBZJOU#\#%C-4G%4Y_? D_2K1:0L?7 ]\;#+%39]W4OMH .ZK6G[
MHC:#:[KDTM*U'L@IIZX24K*7.-8V>6KNUH8KJ1]T;9[N)M2QYA_!7YI9T_=,
M7BL]NS+6F&R*'>J/^*+N6LFSK4DW$FGSC?QC99:@M^[3;1.*K8'/ZHB_%D^B
MVHZ*98C\8F.R]0<(1I"A"AYZ0,H0X!&.N<(<,(F"WE2O&!.)/>3 =;4,LH"4
M'C#K06.R>$&456M3#;=#0&)=]V66%8R*4XQ<.\CZ)MM 62,0X]8EEFTK-->U
M5O[HO9=Y"+06X4T.OOBY$ZB1F4-J.6("+10U:5E*W8!JW3W1M'L9<K/NK2FG
M;/QA!.Z(5X1,#/\ (QJ/5]T-]WSR$*TAW6$JSBPPAR<;"N8BQRFS+L/S38H4
ML*-?[,?* VCS<[:+UGXU$APIUX5(C8Q:A:MY@S+A&-U)[1YJ$70G915U)7=J
M"BJ50:]<$7]4[^<GE)4:8E?&&K3F)><2!4YUKZXV>7EF%*::6X0#ARK%J2C-
MJ6&YC"5J*#G3]V-O5T4M/32VV@,UG3QA,M,V7:B715-'/OC8#>F8<$I+J6>U
M@32OA%Z;(#UCIF"GO2X5[4Q;\L&IMT?O'XQASAX9>><+_'Z ][ST_H++C!6@
M0,'ZSAI%]NQ)M.I/9*A%WG\=FL%O/L)KXTC%B&<4 T_9.*?&%=\_P_?$[^O=
M_P"H5%G_ ,R1X#[H&@\!]"T2$Y=8#AXP'(2^4JJ3D,QXQLQM]P3@;+N62:>L
M1\HNS!:%W%S#:2I>[[P_A)BSVQ*V@MM8I11U\8EBG\^2WV2I)_Q1LBP?^$DX
M1_L/_8(VBMD3CI/,_&&'0$ 5BY4P43S-#F2GXQ>>SOSE=E^J,:O1U?Y8VSV"
M]9EL/.!LI^<5G3A4Q9T^XN=:"E&J%C#T(,?)EGUO68TT\O$>S2O*@C:M900X
MN9:3A4:G%[XF&*]K55,S#**)[4'CXTA8B@@(K"&U<(2T82A8&L%!,-,N%7=)
M$)E7"0$-*]\-6)//)QH0I(Y4@7<GU:I4?[,(NO/!P$,K4.=(;NM:#[R4%A93
M491=2XTQ+.M.B74CM))UB44FRK+JOLJ#>=?"-HM\69=]>%0QX3G%WKY/3-HM
M):4<W!6GC%U)TOV0G>CO#.O,B-J<C+..+4$"IK%H,!FN"'%$DU@<?&&-1ZON
MAO3U_A"],H=.9A-*Q9!PSC13EVA$J7';E30K7^3+X?\ IQMDDG$WGF%K!IOU
M?YS%U[13)6O+J2<)2XG,>,;#K=%L6!*RZW,?S* $U_=$7^NLH!Z90R>)KGXP
MJR'%/=A.%5>7&-G-UIEUQI;M=1PI#\J+-LM2%'+ 3F>D;=IR669D537M<NL6
MNVB8G,+8!5O,J>,; +"F4/23I;50*;/PB\K[:; :0: IE0/\,7E4%3KW\9^,
M4JN)A/9A?#U_0'O>>G]!3*PRPMY6B 3[.$6C?R]5LVY.6==QQ83*[PE*&PX2
MEH]HZ$Z9DZ#H(L_:9;EGGT*VY1:U@]HX2FM/K=@ >VL3M]Y:\+")-,FL&J<R
MHY<,A@!K_:/A%T$/,V84."GSG8!X(ID(.?[*/]8>"N\G6'[*6^_C2.R3B5_%
MSB594PT$*T'"*I/=X?0M]V#K B8)#)(UK2+F6BY)6@R<1S6GXQ>>73;]UG4K
M&,^C*5_@B_:?S+;TTD=D)>6/8J+!M#TRU)-0/UD#WQL=21=))/\ ^G_]@C:,
MZE4ZZD=?C#<NH-A7"+C)0J=:KJ"GXB)61$W8RF@*U9/^6/E%W#2$/3.[ .?#
MQA%EKEK84*9!W[X^34]NTRR.B?NC:A*J>LUQ:1GA/PAI"@M:'=<9I7E$P,&0
M@CXUA<-IK[82UY\F R>$)97Y$%*DY4B3DW'U 4BRKNOND!+6*IUI_I%DW*4K
M 7)?EJ(LVXTDXSB6VE%#2E(8N78J/UF#V0JZ=B 5;4U[H%B6-*+WBEM9&NB8
M;MJQ9484*:53B*?=%\+VRHD' TL#LG3PB]EINVK:*T-DKJ"/?&RVZ#TS/(=6
MT2 H'3K#"463912H8"@:> C:)>,/3#K:55S(B8FBZVHJYPM6(F!Q\88U'J^Z
M$'*%G*'!6$H-8LL89IL\E"+J@3MVGF-:L*'^$"/E!7.7+VH[,(1D2HZ=3%52
M-H8E&F%?WQ\FF_"&7).66YD0WE7PB8E9.\-D9)2HK1\1"=F+>]WQ305Y>N++
MDI*P&LU)24CX1M&VCRLA(NMH='ZD\>D;1KV3%OS<PEI9552N/6+H70G+5M9L
MN(*AO1KXQL>N&S9UE-/+: *&TG3D!%_[90PVY+H5DA!33PBU9G?S+I_>/QA/
M'QA]>4.][Z ][ST_H)YI$U+O2JLL3:J$Z5/"+IW7MNQ[^6B^&29)Q;XQ* PE
M*UZ^H&HZ@5B=NY8\^0[-RK9>P][",_8(EKH61+N;YIE(H:Z>N$I0A(2VD) R
MRZ?L]01%2G0914JU@)P_0M4PYPL#A"3G#^#<9CZT68XE,RS@R(4/C%V5N3MA
M/MNG'\PI(\,(CY0-AORMMS;K#92DO+)R_>,;*K,?M*V)-"DJ6D+0"*<<0BX5
MGO65==*:8$>CC+^Q%]IAEVU'0H?:X\:PVXE2,/U1%TY@,3Z#6G:'QBYT\F9D
ML)4#V/NCY0%E"8D9@E%4AI1]=#%N22)>V%@)H=Z?\T?)YFW&GV 5?[1(&7U<
MHO8RS,V,2I&(EJONBV&'&K0=W>0!(]\.8E=_,PX?=!488)Q4A*%94B2EMX:$
M:Q)W>5,$86JUAG9\]-$%+!SI%A;+'MXDK8-,HLBXLM9J/G)8:8LXG[6LRR L
M+0A. 'U4B\&VNS;*6ME!34 D=NGJI$]\H>KI2VZ*5X+AS;\X1^O(RX*BVMOL
MZM9;;F5T/4Q8^V*<=<"%/KPK57.NIAR\<];S8;9=40O*E*ZQ=VX,U-/IF'&5
M+"EBI(YQ=BR)*[DH'MTEI83F3X=8OM?,8%ML/I"=V00*:Q;=H&<FG%*7BJHQ
M,J.'+2 G6L*41#3BJZ\?PA#BJ:QB)XQ2L);'+K$O1"TJTSC9Y:"ER6X;-<2:
M$>(C;?<A-H6>],[CM[I2@>M(OK84Q(6FX-V0 X>'6-DUXEV',RZTK+:TJ2*U
MX91L]VNCT9AN8F0I.%-0:1/[3[*,F%-*0%8.?&D7GVH+7O W,99Z1?6]T]::
ME(WJE)4FE(LN[,Y:T\WN4*^<6,65=3&S79,W+)8FIB4JKLJ*M.1@VQ*W;LUR
M60I+1#92!ZJ1>RWGIZ:?)>Q(45>RL3BQO"1QA3BN'*'EJIK"C7Z ][ST_H(@
M*UYUC @5HE-3J:"OMUB@I3A&G[100,OHVU90I6<$TAYTJ2$=8DT*;>:</V@8
MN!:C:I?T4G-2-/&-IVQY=ZD3$RRQB*L1J$UUSC8]L'FK*M=+C\N>S,8LT\ 1
M%JR;-C6 9?"$E+-.7U8O>HN6H\I!RJKXPPLBM8LV<+,PE0.D;++:5,D-%7"G
MPC;39:YJR'W$)J-PKVTB]ED3 O M(2?UY'^*-@EWWDN2ZRD]]/W1>.54U9.$
M_P"Z^Z+?"43SHXU/QA]528=@Q+][UP'0*18SJ5N)KI6+J2S#N[Q)!TBQ[/E$
MH3\VGGI&)F7 W:!ER$6U;$PRTK=HK\V8O_;-IN^E%"5Z+B^\];;MI.BKVA&6
M(\>D6=9MM3K_ /MLSR5%C7(MB:: W+JB3Q!@;(K7><2HRKE/ Q8VQRTMXVHR
MRQ0@:&+@[*FY8-+G$4 I7$(F)2R+ORP2V&S1.*O6+X7^:#;C#"P*5 H8MBWI
MF84Y5Q1K7C&\6M14?&''1@-8"JUA>OMAK4>/X0T.S $"$CST@)4:!/.-E3B&
M76@\<JC7U1>:[MGWCLI2482=P4TITC:YL6F1-33TM+X@%+.2>L2UT+8LV;4"
MPM&[<H,N47<G;5E$H!QC#3G'_B"UG4AM)<(II4PIJTYM>:5G%XQ9]R;0M*9;
M1N%*"J5RC9KLA0VXV_,L@8:*S3IH8G#9MVY MHP52GX"-H-XG9EY2F%G#7@8
MFYUPGM$U(K#JBHU@#*'S ^@/>\]/ZDI/"%$Z](*U4A(Q."L!2>R.474M=R4G
M65!=$@A)\*Q<J;L:T[.2B92VXM2!6IYB&K.L:S,;[##:%YD*!X1M(O-V'6DN
MC#0C*+3+4R\MRE:DU\>,.(">[#&+>) XQLK#C#S2M*D5]T7VD!:=B*;2D*Q-
M$'QPQ>792Y,6T'D2A_75KG]J-EUS$V-+,.+8P*24_"+]VBTU(*;"@#@I[HO(
M^IRT%%!R(-:<ZP5?:AX@^R./KAL4S'..V>,67,KEU@E7UHNS>=,M@Q. 4I%B
M7XERV IY-<72)&\<G,E.)Q)KU@LR5I,]E2*%.&E1%Y-GTO-X\"$E*ZUTSK$W
M\G^R[0=4_N$ GO T-3QBS]@MC6>L++#0H>0BR]GEC20%&VJ@\A L"Q&$C$VS
M4=$Q,N63()JE#66>B8MC:!+R*%(9<2FG*D6[M(FYS&A$R=W0BG6)^T53;I45
MDDGG#^>N<.*"*T@DN::<8"<(]4+UAK7STAHY0!E 'QA(B7R<%>[%E7D79;J-
MTY@ (BZNT9+F!E]S'B(&9X1.V78UXI8E+396XG.M#6HZQ;>Q*SWW%.M2J#BJ
M:BD-;#VQ6DM$GL2H:ACC$CL:8113DN*\XLJX<C9*DK6PBHH:Y:1,6K(V9+*2
MQ@0L)IE%\;R.O[QM+I*2":=8M!_TA*L>?*)M*U.] *#PCT<F%-84YP_KGY\_
MA&0T^@/>\]/ZD@P?N@P,E" HE0BS70T HFB@:^?7%V;\OV:M" Z:"G&%;2][
M+85N]HIY\(O7;RK0<4<=03SAQTIJ*ZYP5A42J*S"#PRC9T!\U3I$O)+G& @C
M$G#"[ER[KREEE-4FND3B&+(EG$@!)36E,M(OS;JW]Z@*R[433J5NJ*]:F'5M
M\(<4#I%<X:5\80L4@.I\F$6BXWW5'VQ9EX7FAFX>]76)2_,S+E.%T\.,61M0
MF&<(6^1GQ5"=JC:T@+>'MAS:DAH@)74',F)C:FAP'M^^']I#Q55MTA/C#NT2
M97_MS_>B>OJ^XDIWI-1K6)F>],Q%UPY]8F)=HDEM51]\.-X%90I1(SA\$PTK
M""#S@FH@B$Y&&ETA#F4)5\82N Z$P,*SBK$A:ADG4X"30UK6+#VA/2V!!=(&
M7&+)VC,.M!+KJ2JO$PW?:2J.VC/PB7OI(@ 8T9^$+OG+8>RXF+9OTA(*$+!)
M3SBT;SNS!55PTSXQ-S[4QBQJJ8M%8&+#!&=5:P7$IB8?2?9#RZGZ$][ST_J5
M4_D.HI#0!S.O_:&SQKI$LM(4%$YP)X4%5Y@4UA^9"_K5A]P5UX0AP8HEG!O4
M4-!E&SZ=EVE-%<PA&FM/QBQK=DFV$D33*^!.- ]6L3]Z)-A"BV\R%4/UT?C%
MZ;RLS&/^4MBJ3D%)/WQ>2<;=4YA?!UY1-$%2C6IYPM1*H^^*"$Y0E4$B*B&U
MTA+PUK"9G0E6?C"9O]\_WO\ 6&I]6"F/C"IT_;AR<-<UQZ0GG[_#K ?!%*^^
M-\#E7WPEQ*<@<CUAXII6"H9UATB* Y_EI"2.,-K'GU0"G41BZQB!U,!0&AAI
MP#CQA+B=<7OB6M+<_P"T(-?M0Q;VF)X^T_C$O>(&AWW3O&$7B3AH7_\ %$Q:
MC;YQ;^F7.'9I*JC?BGGK#\PVVO\ 65RYP],I5GBAUX$ZB'5CG#RLX5]">]YZ
M?U,I )$;Q5:"OMC?.\S[8])>^TO^\?QCTAWFKV_ZQO5G57MC&H1Z2XG0GU&&
M[3M!O]5-S3/_ "YAU'^50A%X[?;%$6U:B1R$_-CX.PN\=O.9+MFU#_%/S1__
M +8<M>U2.U:$ZYXS;Y'O<,>F3+@^<=6?XEE7Q)C>*YU]T5_0J><8B>,5,8CS
MC&KG\8WB^<;Y0^L8])=X*5[8](=YJ]L!YPZDQO5_:,%]P<3'I+G7VQZ0[S,%
MYP\3[8"E<8-3Q@9?HU(XF-XL:$^V-\YU_O1OU]?;&^7S/OC?N<S[3&_<^TKV
MF-^[S/MCTE[FKVQZ9,#1;@\%F/SA-_[YX?\ [BOQCTV;_P!^[_\ 45^,>FS7
M^_=_OJ_&/2YCBZL^*C^,>E/?[Q?M/XQZ0Z?K*/KC?.'G[8Q*.OT1[WGI_4ZG
MZ6GY!E%!^6GZ-!^E3]LI RT^F/>\]/\ @@>]YZ?\$#WO/3_@@>]YZ?U* \\A
MSAU]MK!7M8U84A/>)I\!Q)R ]4)TS.9SRSI^-/.46W:#T@PP65X7%S ;42D*
M[)IEV@8G79AJS7WFE4>0PIQ*J T.7 Y<=(L^T5_FB7GIU>)2E4=73"-3P2G+
M3E'YZLZJ$&92AQS"4"BE5"J$=H)P^()!2:@T.C\Y+2K:7'W4I2K2M<_[*:J]
MWC$Q;6\M"3:D)@.,NE <3N\ZE921VP%)R%>&M>,3MJ2$AA1,OI:<6*A%%N*]
M>[2</2OPAZT9=N35.!X*;P' <*C\YA)2"*5!\:19-M,V@%XB$J:;*E )4!1-
M*J*E=D:_:RUA-LV>7"V7PE6@3A72O/'3#_BZQ,3+,LVEYU>%KF>/JUKT&?*)
M:U[-G'%-2\P%N)05E!0X@T&I&-*0KP%8;O"VN=<ED@*90<WJ+J,LTX=30U%<
M-.M(F;9LV7W279D-+61V<"UJPGF$)50'K#<VPZE3S:PME**XQD!3,UK0Y#,U
M (R,3ENLHEGURSB5.)35"L*LC4<%I"5>3%F/.S$FR^\:E;04HT SSX:1-SSJ
MWT24E03"AC6I2:AINNO570Y9I\0L6I+*0M4PF;3EO&=RAHA/%:5(K6G'/+D>
M$R\IB76^#4E%$ C1Q7=KQU.:8LN:F5XV)VF_117U0<"Q5/9%-#_F ,%R?F+0
M?98G=PTRE/9]'0YVB$US70\3S]4*>G)"9:1-/"9:F"&VU!"6R'32E4IRH:^^
MM<J1P%13+3^C#WO/3^I4^IYIE3K&:D"JT4KO&QWD)Y'C76E2#SL]EQ=9J9':
M>'S2#JPT3V6B,NUS44@T\2( *22= *1>IDKDY9Y.B9I!/K!I\#Y,3MJL&RG
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MFG,DU!H-<Z4%:@&2<9E9F12Z7Y&94IM*PO&XAXG5PE1& *((H,:2,LJ$F?\
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MJJIIA!A054D:E-/PAJ1 1,-$'#,+67,J5"Z TSZ>WPCT0%@2N>Y"$MA/'"D
M<^G^L/V6W,2[;*EE*&5(4SS0IK(*US-*\<JU/"%61CETM*?-&UI<;R&2Q7/7
MJ<N'/F+->F5I]*FBO<NI=: ;0@8DG*H2<]<E5RSRSJ'K->2_OFIM2%K1NUU0
ME:5)-/JDT!!XCAXDJ;L[<L.H*RXI\J+JL.'%BY)!H!X9?<91+S"6G.ZA"4(
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M4Z0G$/ :<=(K4D!&>M<H0%I-<-3XC2#VLRG3KI%,22D=FONAM*D A2L0^[C
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M/E";*?6ZVIUIMMP9K6DH37^RW[ZA1KIA!-64%#8!KIES]9X_L)U@?U(__\0
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M5&&)!:2,&*17R1N4I]D950@062D<!SN;7J@JH 3RJU.U[<E]#:_+O=2*N+6
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MTGF8JM1I50LLJOJ JA-J,]E(E/'<(V2-CVMS+#V;([1'093HKU7CBR+3?;=
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MO2/-+N\>G1YH:8[M-2QS8VV')J4R2NLKU0^B6/6/@/9OYV#<K#J=;B7&.KI
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M)R86M<8[*MBX^T5\\G]%))=5BQ80*<<<(1(JOE5:'L#FUF4)I#I<N-4)<-#
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M.P_N97_[T8^D=A_<RO\ ]Z,?2.P_N97_ .]&/I'8?W,K_P#>C'TCL/[F5_\
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M.((;F)Q]$&%'=#,DX*G5A\ZI'VTAW#@FD8VHJJC!,]8Q%55R[_'TSR\&(/\
MNL;\$W%2T,<[(S>Y15_>A^#":V.;GPS<CFIXN+>*^!/.L]C\Z]CE0^PG^MW8
MO=G\6?Q/M_"/QEV$PF:=6.K'%4QDW/'%7(G@QH<NIR]3L/46C/+JP[F]:XR\
M\F)WC/\ A18=[)>QQQI3'!%PWFY>YA$,U%=C+++W,9,1GC5,9C8Q?%A>8OO8
M[AV.#5PN?8X>=H'MY/Z.;%0]M[&66.C"<.RWQ8\&-.M6Y=[+&DK7JGURXU1W
M)X47+&>AF7?QDJ>]CG-^##N'#L+YRQ_LF_'&X/2">U!^4?TB@?Q I?XQ75YQ
MGLV_*3TR)4GA25#7:1*I"?DK)U*F-W>H1G(O2KHY'.%G^_-$Y%31@\(9-O3Y
M#!U*CRVKFR92)WHT,[5X\48[9F3UAV$8O<X\O'P7&Y0Y]2;%XIL &,@\EXJU
M-'0BY\4SX]:85ZPI.7=*NQ<OA5>"*OA5<EQDO#W_ )T1??1.SY?!X\\5<K6.
MV*! Q2)T(5KB.T^-$XKBY[),B;X.(YRK_K1R1*B*WOO$JL54];FBIQQ)A2&Z
M#Q#DCE;WGA<HW?)][TG\BY+X\^I4]:O?Z<-N!BL6LT4<>%<(V]W-@HFQI]=1
M.ESFY,@U-_49 &?ZJY^ :TU!C*AR=:*J+Z$WQ/7CXD1>O$ 6;4>=21V#5S4<
M1VSUJUB9\?4^C+HR[^*3;4/)KI<Z55)3$7CZH]V;NO+>#.1&]'H?>X>F^7@Q
M!_W6-^";BI-#(.)'':JH(SQIGLA\>:Y./!./@PB&D',B<40IGDR7P:G+YUGL
M?G7L<J'V$_UN[%[+X;:_%"W\)Q\N'G-/6B8XXS>O#',;T^NQSLE3Q8R3FK[V
M/7/8O\+"IHTERZ\L\.30Y&YY?'YY,3O&?\*+#O9+\?8RPW-N$<Y,L;,>6K&M
M[B(B]YRXS3;N_EJF,D4K4\+G+\6.#GORZN/SKC(D)<N^NC'. B+_ "<<$3CX
ML.<QO#QX5%:N>.Y7'%F.YQP;CBW+% 3_ &Y/Z.;%1]MPF29X:NGCUX3FXS3"
M\<LL)ET89A!,7GJG!,<&ZB+THO5C:,TMX?6*N-*JY/"W4B8YQE?WTYWSXX@]
M#Z-6;<9N5OP9^]ASFIS5Z,+S<<4PN?9L?[)OQPN#T@GM0?E'](H'\0*7^,5U
M><9[-ORD\_I"G-;W9/6M_+XL(UQBO(J>M<QGO-5,_%QPA$52QG.T9JF1 N]:
MADZ,E^N3ACR\7QHN%V7,&WI>J*N?@:B=>/VP[/IXA3CEDN7=HO1BG4F6TA*M
M0YQDI51TJ@5HTK,IJ=(SVCLX\I-YC+T,:<S'<S0B(V6YB#3I0>K^<KD;I3P)
MT)UX0;T9S4RX9(F?C7I\?3A @5&/SYCF.YS5[_#J[_?Z\)-8QHR*[1*TII:1
M5S5DCAPU*B:%RX=&?9# @!<>0=R-:UO5Q[MZ^M8W+-7+WLNE4P<LE6;R\+C$
M+EI4CE:KB%X]67,8G3DU.O/$:K'?DRJS#Q7JO0UDSF X_6M5!)AE9"F4:L)Z
M)PX,DA:B.7A_K!(CL^MR*O2J^>\OBQY>7PXUP:7*,-?WU6;(7_[A58S^=A'N
MBQF-=]?+'PS^NTH[WD7YL!J!Z@ S7B+&G0MV<^-,AS&J.5$,][^(RL54UHWF
MO0:M5%:BI+&)J 9JUZWOUO5J<4<XKG\>'>5-*\$3ABFW!,&X@ 2W-IDP.;W*
M]VI&+IUM:B.:QRN=DO>SZ<4B\X)MJ$G[&243N&JN9@$XJN2N=K:[P\5]-\O!
MB#_NL;\$W%2U@87,[<E<]S<O0A_6JF%<UJ,:O%&YJY&IEQS7NLD]U7*K43+C
MCKZT3@O%4Z?6Z5TKEJ:URY(J<_/-$\'?\:*OAX\U=+>*OZ.E%QY>7O\ %%X=
MAGL?G7L<J'V$_P!;NQ>S^_YF_@M*@IC+L(O8(_P+AQ'=SDF$TMYF&\WCEA4V
M>.G+P)C-N>-6ASLNC+/&R*U!E[Z].'9(JL3K]_"HO2F.'9]W$[QR/P@\.3^$
M[X\98:Y4SPCE1."?DQL1]?#&T*O7AJ]6>6$YB*N6%]";[V%X?!AV6:IC+N<9
MC<KL(ANCKQGJ;J7Q856JB^]A>&./8X>73B@_[P3^CFQ4?;<)PPWFX3"X?[N$
MPUSN"(U5]Y,)I[E.CW_\<;9[>*KWO%A&JU.C'<-]W&>A/<PY1(J\.YQGS]HB
M]RN>6$%(1,^C&U'T+QPOC[*KBQ_LF_'"X/2">U!^4?TB@?Q I?XQ75YQGLV_
M*3SPXXDS>_/_ (4[I?<X9=]5QI;U-34[K<[),U\:KWL;895:FK4C.K)/&F,B
M(CCM'I,Q,M1&Y<Y.^I4[IJ].&Q=*D:5R+&>G#:MSR1.]K8O->WIX9X&K'Y.1
MN>??7USO=_RPJ\QS4<O?1??[^6.(D7AEW:+P]UO7U]_KPJ-%Q]GPQJ,15[S4
M7FI[F 2.A&+SO8KEJ][#3"XO<)$7+ZY.(_!DOY<*UW!6JJ*G>5%R7X<"CA8I
M#'(P8F-[ISWKDUOAU<?%EA*S5M#I+FH0KW=)"=+0"SX['J;EEKRU$U<,/HT
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MD 80LS7UHQ#:G0C4Q"L*RUA K,BGOJ]7K50$^3'H5)VJ1QE##8K&S*@<JKL
M&*P2:6;5KAE<\+:VZX$Y1X(#1NV="\S46FUC<W/V<B11RT<FDIPZVE6-)B&1
M1#)I+J5,JQ<A/^H4TDH B(HW%DO:C8<9R.34Q\B20(-+FZFO?DJ8K= O60R1
M=%"D0CG*P$>-M:=5X0YL-=E&$ "K&)O,(CQ":B[!JN52*JK>MOTB^C6U3+>#
M0210"M^AU/5VSIR&-Z+-B[9-)6.?SRE]4THC&HW%"H5ZU"%<U%N61VMIES1:
M>VD38M8T*04.IP E+$4<Q$T12Q=*H1I%*B-1$_T:3VH/RC^E2JK5IL>GTV"%
MQY<R45H0 $WI>1[^"<5:UB)SGO<T;$<]S6KOYZ7(I,<[MI3@3]0JH6$X8U')
MJ%->(9*48SE(YE/D/=-!'V._CASGR*?#O.M4H^ZU.E6S6JA D[()]A+B4\YH
MY=C(&4!=F5C7;,PB#=ED]CF\,4OE%Y4*_P!,RH1ZC6>U7_Z[(IL!FX6]3?:
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MDJ7(%%B@8XACG>T8AL;TN(1ZHUK4Z\U3CEQ3CF*2+:;(XV%9M0ECDTO1')K
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M$$5V\,;*?%)*64^ 67J.2&X#W.TN:B?NPGM0?E'])GS(4 M5EQ8<F1%I@"A
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M*:DVY?P[HI-.I+(3G';39U6M^:)U7292QJ'>8L4$L4L@](Y#T<0CN3VK0JI
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MDC@V$\M40*J"^LHK,)V-MS2E77"DB_E,@*VOO1R6CBI\\JYWZ3ULR4SL;,\
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M%.L"[,'#VK%]@<YV<,K3EKK #'EQ)*&:W0UI2,90FAD!L9P='&Q^8.H9^:2
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M -XQ2S@11#34)L.0#"T86"?GN[=J0DHN9G/?,U-/],S$Z=?;'&<P1>YW%_\
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M19$ZJ1R:Z\6I9-=YFD%G1MJTQWO4SN-J$-DUZJBKX@S\\HHL18(\C[IJ9?\
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M*&!7:<S(Q=Q2,XH[FO4 :N,<HS[59#.P>Q6&Q9OY7I1Q'N2C=T,YOI;O-#1
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MU;8J34I";%#(9I!==;%0'E%;-CG,D)[A8F"/R8;DN(08"W*N@<@/0[<_D=/
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M&B5I;4:@A?LPXIA$D$39F)HP;/?=Z@4M&MZAUE/L4ZF18AC>D,N,.<U%G?\
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M-VHMV^:CMQ!K,>?K4 E5+2&VDU"L9".4<VB71&9IG^OFH8;!P_- GG7@4C0
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MJ"H*Q_P8*@[Y1[6J P=X]B/S0>$?XCP@J/\ 4?B@_-!_N/SB_O\ _$!?W_\
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ML045'&%B!MNB\N9$0903/YDC?I.QGIJ[M>O'1-,?\T7]_@$G[H@4#",2TGQ
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MQP<)KZ6$E^GA_,[R<5<+B]Y!E04XB.5!U&O,MAN9ONO,LR6F*GS8KLKRBBS
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M8K2/-NWA-^='==(+%Q54968?37K8/%29-%?]S$\2C 4:S $AEDSI_P!;8F4
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M-@J==8%89Y(^B\74!.=-BJRLW9+\I8%(PA11G26S%5:/KF6P55BA854\7!6
MH%4ZABGO+ _LQ-/-%[5N7W;>KS(@T)36%8Y);N7-'_A%_?X #6,' E"P0(,M
M4AO+)@%6A0U*B)W5><X\B#I!:*SOEQBY,C#:,&$;=WFSW%QS42MY@;6^PQ./
M2JH\XVESJQ29@=.7BLP$A*7*5^D0FF20F5[@*@F6S"YXG8E%2I(RY9,CK7(/
M\(YXWV"V*">C_;^ ;&L;5RV2=.FDS#$(,1W7L$2%@TW!E36*<2J-XZ@Q)$]O
M9#T1'"QJKVP[1WJK3;='X(E/&&A7.)8$*GI#/62A_!G;F(Q-Y03/KPZ<,%].
MB_*P^FA>W@:TX:H#4\ "'?W[9P//O'4G^W$]2'^U$2$B1:L%M/&KPQ\I5H2R
M2#* 94R.@(BZV*0E+IM%6%2B""T;L&+B!!I%QHA!B%I?'0N*.^8.R5"2 'PL
M!C-$64'9K:9-A4"2*(<;4\T&B:8)( U9N2'M^4C?%OX57]7J]^\72R"K,M-:
M5A!@66 $YP1JKRL,R*=*KY%#O>59XE^O0I!N]D(Q?P';_P#>30PR)[_!=%0$
MP=)Z9W7!I1'FBWPHJAHV0$K);7 1(B9TH3&,AA)(5A%C'V\ZZ1+CU4IDM?)R
M$+BX$ .!<&92:R>(0AQ5:EH!8\P.U"IKG]]]&EB,6K%25*"*\MAV#T5LU9T+
MU=R>^;4;F 9B6B1T=]8F;1,21:Z3Q0600Q&9 9BJ(3*7#NX#Z7(E#(+9))%C
M4H5N/?(VS &2J<(:8(\EE(;&C) BB34Y2#KL>M=,_:,X2VP]4#U* !P(*5GK
M2'UN%)3HJ/3T@QJL7D/LH"D$T$D6!9S6<1M/+%K_ /_:  P# 0 "  ,    0
M$$$$ $D$$D@ @@$D$                  #X   $$  @$D $@
M             $ @ $@@$@DD$D D$                  $X      $$@$
M  @                      $@ $D $$@@@$ @D@                  $
M@   $DD@D @DD$@                     $DD$$ D$ @DD$ D@D
M           $@   @$@D D@$@@@                     $    @    $$
M@  $                   $@      D@ D@       @
M $ D@ @ DD@ D$@$ @D                $@   D   $$$@@$  @$D$
M             @@D@@D$   D$@@@ $                 $@   @@D@ D$
M$D$$@@@@@               $ D $@$D DD$$ @D@@                 $
M@   @  @D D$$D DD $ @                    @      @ D
M           $@                                     $&'I$&$!
M!!!  !&  ! !   !! $@   $@
ME$#/+U8B8WFV02P?JU*VQ2;SS22S2R3    $@   D@@      @  @
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M^9=,L*KQBQ)5HR,?B>"$+UKJ[K9(DD,$   $@  $ $@  FAZ !/]2ZG!:
M     "'1$@$@KJM^JW(C'\I?I$PSZU_V=SU($3>"0!$9   $@  $ $@  ""+
M  'JT;-9]        !>9D $@61;UF=,\D6_\Y+9"S\S3"PK;7-2Q[KJD   $
M@  $ $@   S_ ( !'E<0"34V0      9FX !(-26??3AXC<7X)?_ +RV4&,Y
M,UP3-'YI[(\   2   0 2    ;2  3PJ2V,6OH      +!,  2"H#^)OY;13
M1LX.N\V(+RKN;RP+:0,8N?@   2   0 2    "2[ $Z1NCE[3       .*>
M 2  WIOJ#[+2T!X_O.IE(&//V34T!WV$)(\   2   0 2    55S@>TS!V^=
M+D      $!Z2 2!'4.!L. 2W@9M:XV9!=_N4('CXF;#.E$P   2   0 2
M  U<$.8I4ATWT0      '7V  2"JA_U,%PDE/VP[Q1SI#=C$05QWY,L+5-,
M  2   0 2     "R $9(4'1XJ\      (AX2 2"0+VD2,_*G[34GA&=$;=;F
M1ZG%L%?2 4D   2   0 2      2]L,3U:/B=*      "Z,  2 ;9,YMXL;=
M;H/)EC+>:XV-D925XJ(8'RX   2   0 2      +\$:=)3-AEV      //
M 2!-3@52S$YMK=</#Z[UC[^X?>*BR##;#F\   2   0 2      8UR"ZR$R$
M9(      )E.0 2!LVWD?0#'0H/\ 28ROSG0?]J4?P'Q&QM ]   $@  $ $@
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MX &REIQ,    "D02 2!7%3MO;^#1&O9](/FVSL09\5<U5+UI]S0   2   0
M2  -$XR.!P%*  +*ZX0     "F 0 2 3X4X>'H+Y J+Q%?2CN=QNF"N.5)?.
MVD    2   0 2 "/1+.A,'A^=M0M.DR     "D"2 2 P+&/C=I!@@G5T%MSG
M?^LQ]3^W$&S6#L@   2   0 2""'4N$ %;>H:L!20"      "F0  2 11\\O
MZ\=R)RV9$*=<O[P%8)@3 QE,\+\   2   0 2"2<_NH  ]K7"GT@ 00
M"V0  2 '!.]WD)L.,60/''C'2B)8.8WEUJI'1ZT   2   0 2" 2  2   29
M2*,  "      "T 0 2#=K_Y-1,[=A .=X<,D3UH"TRK[MQS@W!$   2   0
M2    2    2434(  "      #S,0 2 I(F\5PLC,H>4"'5A^/< 4E4,7%<+Z
M58,   2   0 2  "     22*EP          ,[F0 2!O8Q7'.Q0;3\+3"*+[
M!=7S&YND+ASTX?8   2   0 2        0")2L          $M   2"^^8OV
M^ XC)Q=QH)'8$.1"5H%^R:8\+PP   2   2 2        02"0
M     0  '/YT5,3[:+S4'MT6(*XA[2,-,%AK/ @   2   0 2        "
M0                 #!JD^CF*C@K-1-&J3,=V"1)KIE4*LP>UT   2   "0
M2          2                 20"[<-@N81>*>>40;-QU7?G%E&!0G2$
M@G,   2   202         ""                    $QC%IEK%2!N)N2#L
M]^ 2P;B#Y/"><>D   2   ""         " "                0   !N0&
MK.'&B 8&5J0$ 0   <ET4$<4F<P   2
M                                          2
M                                                      2
M
M      2                   "                .TGB@D,4I%]F(
M                  2    0" 0 "" 00"2 00""0              'E?'0
M?FWK%OS*(                     2    2"0 2002"  "" " 00
M       /Q03PI"?RCVA,P                     2   "2 2 " 00 "202
M 20"2                                                 2
M                               "RI<%]\41:Z0"XPO(+A'\0
M      2    " "22 022"2020 0""  0           +1C,R(*Z.YU'KT/%[
MA#BM8             2    "  "0"0"0 020" 02 0"0           )0. J
MFU-*X=QK]$QJ\ZB_\             2   """"0  22"0" 0"2"2" "2
M        6>$96S?'I6DPW_-O^O!P\             2     02 0"020  "
M"002 2""           )Y@  I/A$>K=9U0O>+U-#0/XXXM\       2    2
M202 "0               " " " 2" 0*3M;H[=#K7>0!L'$+<$RK]G(]BQL
M      2    0020"00 ""2 0 22 "0""0""2200220 *J?&-,;=!=$]91AF0
MIC<0M:I5V$(       :   " " "00 " ""2 2"  0"2220 "20"00 3_Q  L
M$0$  0,# P0" @,! 0$    !$0 A,4%187&!\)&AL<'1X3#Q$"! 8%!P_]H
M" $# 0$_$/\ P^'=]X/LM/T>Y/\ ^'EIZR]I5+9XT^/_ ,/,^JOEW_\ P\SZ
MJ^7?_P##S/JKY=__ ,/,^JOEW_\ P\SZJ^7?_P##S/JKY=__ ,/,^JOEW_\
M&WGM/Q'K/^((M,_K\U/=Z_KD]:%28CO-JDF-3K2*V8.DU']!_NC-F#:,]_\
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M) E<1:/3[H27E 09V9A_%0G >XVS:D!L$&EK]H)I+"_.9,-*" ;'.WFEUH3
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MF8)*AJ,T64S&YZ=K8E 0HT9L;>9-*<"-<!9]+_1;%(900BT6(TM\4^.%,HC
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M3J1?0;<>%(;..MDZYO;)CI1H(EPG%],;>M8,;XF$QOV_-J=LR97V#,:1QM1
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MZZR4(/4ZV_A7J".+;^]N:70D)1MGED\]*FXECG'I0I9"%C[Z7G3.T@7 "TW
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M/I'J418:=GC%HF/(L[LSK0Q#X3V*OE +D?G0SBQ3(R)]""T7YDIB(Q*>_P#
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M=\Z%"[@ 7@_#:#7F*SZQ72%S3^:]+#]P_=8'A'ZW\[5"MBF8W=XT>OM48+$
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M@(1Q,NP,/'%-89"T:8--,SVI3WQ*::<3?76F9P(9Q..;_4S5TL&/G5[3%"Y
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MFD49WW<#'XMS-- $HL,Q&CS/EZO@<G8G/QI%J)0;TU)%EO[U L*LW1&_GK1
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M@I$4L@!(+&^:<5.$0IIOYQ2LP ]#,FEW4UVBA9RSJY]R''J5(=:>XXX/Q>A
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MO:\\5U$7U7\??\!GU5\N_P#\%:" 7&LSSZ4P 0H$TEZ39[X:)@=1K;S>K@7
MC-IMOW?2I;A#VZS;E?\ FE9KL3C#6V[K2+(S08 /ZS"K:&GD)))!0$RVGZM3
MN\*\K&\^OK>I<V6/DZ]?8_A>.0@<Z&O%O6^:3K5AI&BVF\45G-G8VF_K4&$F
MA.)B.N.]*A+,6L0VO?'3>U#AB070_;/]TRX&^2V2^.MX_=:><E,:-Q^>.*<
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MMSO^4!-)N#F-,^=Z=I9)*.&&3Y[7H,:^%SO'LU9&+%H>MM-M*@YVC 8_7?-
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M&4I$ ]+2WZ4%^1,9 I&#:45?.NC4<F) 44 A"%V3H9MNW=;S_P!AGU5\N_\
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M 3\0_P##YG3Y:Q>OP?\ X?<#3]GY: ,?_A^'_P#$&'_\08?_ ,08?_Q!A_\
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M5<F[/UMJNPRF;.V>S<]IBI6;LQL6FV!SG^J)Q:<:%M7II^$<@IWSZ_P8?^@
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MQSZ13SXDHUD/QGI0@(+@L:NOWYG^$I4<S:#7S-K>E$1BS/?;^^U3%L?%MQF
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M"ZWV^S1:!2 O$/1YZT42DA&QZ3GQTH%56R$D)1M&=HJTA,+]SC[ZE.>;#>V
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MN8E"!G?!'V:M\@R:TAK.VWB&F8_(@*NY',:=9BDP,>++*NWW7C:X7K"XX_=
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MB0;^K;Q2O;A$;',;6G9\5 EB37 7F=;%B=1J-PWJUUV^MB@,]FJV9<F_:UJ
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M[.O'W?[!0P@L;0:[SGO2#9H106%EEFKTWMR\<Z1:HT][^] !!CJT$W69E?\
M633U?S0!8_U0Y/>@"Q_.,8I5RS]^_0_S/3P<_G[!_N@Y]T]NE0V]7\\'BI&+
M#S?&O3_1!B=,?Q8?_P 08?\ \08?_P 08?\ Q0$5<))U)5SMR<(AJ=SPJE)
MAF= RJ*"V<,#!20DZ"EEE,*.H>!)0  G,E[L:4,9E1@,851J"-X,U U9)>0B
M4*($(DODE5!$"C)(%1@H @E(JJ2N2!D!HDF$DD"8I"#]P2"94.%@,@5Z+ZIA
M;06$9!)+Y")2AB9@6"$N6"%01J=TWP8Y8*L*!(+2_*M\F4$DY+$V07(30Q9A
M30*3!8HZ6JZ!J8"@05R@N JB6&%I?Z13<L&76 % ME9EB]&#+DC(D8+3>E^D
M<B#*2<* "2S=N:46,("@'%[2"!:@6\DF<K $D8@@Y6KM940@(LB-H,916A,X
MR%TE99D#"QT*,#P73 2Q((8&-2+0I33DLH)W0"W1@(*)Z;&YGFE,%Y.EU+"@
MPP92%I K@5TE20A93"Z3QCM_\S#_ .*"-(WG>(!E+H  "11J0B2V60@B$N"N
MC6G=W DB_="W3&6I5E?&T7'G-%L3, O?3^VR (2(")5%%@'K86!($R V8YM%
M"Y.99N.-$MV43B"462H#5.Z),A)E#466,R: *%)>)F(6&AOJ,.0*)4 B2;)E
M![)\0%GJ),Q"!0Q;PQ3MA -BV22]Z2+Y%AG#RB6BT@2@+,N:")3D!) 62RA@
M.-5KOD@98%"Y4,T81"(KN-TLO* S:69+,**0P0DH4 *.MG@E-36($@"0,B)7
M*W,UT(9J1*3+(X/#<)EAI%IJ]^:+NV@ E@-V-;1X(A<^(- 96B;+FZP]JL+O
MRF56!DH(\0QR4!@119"4IA%N/$1$0VZB2ZZ43Y9I$PH2A2^Y!$7H9B "VR8C
M3=Y_^9A_\4@6"ZD=F\/:;;-$7"NRKF#'8%66X)';ZOEWHJ0185+(1$%F^L)<
M*!6"*H8%2#<",HB-9@MT5@B  B)B(U!#LSIEI(138))UEIV.,7 , @ YP&2"
M%-2"@,K(K>@)0 *F*-08(*VB3%.5D1$%$;M!3$%""A<0\[Q(<1>!:3%J '"T
MM0R.BGABT12H1MD*L"%MBFUZ0/=%",V;2V#)E)&)7\Y4,FK&C)"V IX@+#$@
MR$ #@6(+4#D $K +&EF:UB"DFI):PQ.5=&9HDPHFL%&H&\"TZJO-7YUH'? (
MPH,6F*. (&\$1 !!"!<"CCB3DH#(H)3$F+MV08!A%"R091:5E1F44*P;5%2
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MEO:0$E2J!95,9*:50(+M*&Z3$ (OO,A!I(""YN S6+RF1<@$6;!JRE6E(H#
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M0T4A 3"$I-D4)#J %"L6.$ $%= ())+B4Q ""\2I9 "Q*=X II(2!:Q 4B4
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MKAE=%[E)56_6!D0 EF1B PZ=(A1%)\*VSA+!;N00$B8 *DI82V4<A00I$0C
MDB66U"8 40994DI$E'6Y4-4VM2"1L%3,SHEJ@'N@<!*! H@6!O5D$3"",QT@
M-X<6J"HP1%$-Z%ERY;(CT$OZ 85Q< DA$0H)Y4"A29 73BBK( !+2(4.(-F\
M42'^-LJ5$$,BV&8L"GRB3G+,0JA8 "(T9Z0+B81"KE8769A2*>D3GEW^[?\
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MA@B2 L6HO%P[@5JV1%*%X*-%XP">BKW  58)%0UX%@*&F.(T4$D*@J$Y'44
M40AH\PD.2:-#B%$+$H$!10!%/^-B*P]9)N/TTX!#18M09A(..#/ROEDW&B#2
MH$NQY3.3N*65A=K#AXFW<LGT_"5XB,KGI/6DEAD(.T,"'B;7,H#ZD:#'Z/P
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MS[* 8NB<6+[_ +Y)DHAS!Y 8L$=_\+ 4=(9S#(8*$QCP!*Q@#,:N25VQ^/\
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MB[D -)AIC@.CNY5S <KL'I!$#@<@$F2C  %VD BHPNN8I[FJ( +="(540(H
MB "1 A*N'J7A%)&<4(D-$H)5$;1%(TF#'%ZU#58)H%@.) &FJ\H<>0GDTJY%
MJY%AP" "K#RE/=%-J557B8@C!:DMDU%BB92R_%B)3.U=Y&5Q #0H AP,@0@
M( -)&9YP+*Z,PYAI@QL U%>S 3(H@42-:(')SDG*ARG$29")A1SMHC5SEE6U
M>*D1WJY)0HED&(I"ERV+C*5P@RYT>QV5X:@,L&A% T*1 *5:KS$$80& - +
MZ0]0PX$(?NJ_*U?=?^'5FOG\G] J$/6ZM3"?(FFJMM3$&H+8@BL"0086H8MQ
M9%,NW"9]=@@8#B#$5(PI#H11),FU7%)B1C(!!&D"T'H"'%^FHP"4DE/6= "
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M(7\#+TLJ_1&)H[!TO[7!([5T_G#ELN*AR%H8XQ9GOUJ.AL@EBF=!">AC$Q0
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M(@> 0@8P8AP)LSC*JX(+5L!5E*6( @@>J[RM:JN5<JJY?^(4:F9'+$S@6 K
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MYY%#AB"U6, \!H.(;L+4N (K"V@@BF D )!$ @+@!(06N4J/\E/#'7F^OKQ
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M6+KPZA)Z\VK'D6HD%D1FY]N,=(!1@AW7;L_]7B:65Z:R[R>.^0  I89O]/\
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MHVOG/!0BJAH#166>I<<#:[\*YRF8DP#9E>7VU55KY4-&3WT3A@U=P0#81=N
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MD"L0!Q.XJEU=\N8]PV(EF?;S.,.5<T@R8)UC!E+Q]I10;)$!050<NSF4# F
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MYDF2 $R'O* MLF\2L@L!A)3WHRM0C7@A&0)E3H3!!WM=\J@D18()^YI.%3C
M8(J[QJ8A@ZXWCNEQE-Y]DA5WSH!&6.5>]^&GQPQ0P/.1R_?O]YF\1A\>OG?%
MFM0VY5+O$KJ7OA*0'#JOW[W]%6:^?R?U%A\_C]+9QEQ9E)5*9PK9VA-40SWT
M(6_3# J.-)"4#4JW2*0]X(8G \RL */F?%R82Y*:K@VYD2B5J_PDV **&?4R
MQ$5SQ(#<$JJ#L#,QA !PA81$5*E9K0=$/EP#H(.RV&?CX[X/4%"[=K)@6^3?
MIIQ =,,SGISW>\/GEP,6F?DR>\W7QP+D&ARW+//MZ^G#D0@@8C8142)IN EM
M!0A1?:+%L3*8SQ\CDT@6T8,@STQ&\O3"PD3%)4IX2HKLJ4W!9=P+&KUOEV@J
M%A03"!"(W(7BI!G$HVH-PHRLJ;@0BR!( ,E9*_K%KT?U_?7B52#B$?%MW,_.
MN(5RM*HQO(546" . .-WD@7@T8:9H(:&M$\6=%8BY8&O>>$3@"):!@(G4P54
M %$S7Z%'?Q^!S;W_ (_2YR 8*7*;O='BXX2C@NB;C<C^T]>/"SP$3.\8SB/Y
MG+ JNDV5?&,KX9V9F$$2KC!GX<MYM(/,EX@- !O3KI'(S@A>*_* U*W=OKS5
MLTRAADR[]M7@!4^%0NU/3UZY/FQ5*U<F6>-8'K/ NI0I6V>#[\I!>1,32=?-
M]:<-4(?A.DN;K/7IS#TQ$] UVW)GUZXJO@KLN6!'4R[CXG%EG6@3S0/?>SF8
M@0BJU0GGHUKWMW&C(O2]&0 AXRK7(!R&#&A_+?/MS&0%1"&O=WK.[X>$+),U
MX;@_GC:%1?Z_;]L\*K53 %KU[8.O'? B&&I,^O\ KW]YX4"Q1HV])W,3/)<I
M#'Y/O@3%DY%/9A"3.8G[Y3'CEAY64^!:?,WCRNB1='=347Y_GB@%;=RV7/!F
M7'4>/4!< 'HY#\]FO'!;VY4DFX&SR/OPK%B.9I!P^!A-]\-1P=(4R"E";73@
M %4O$%I#*X4)TD.!2R'LAPFF/>KGE;17"2* R>N3+WT<$=0S$B,(98DUGMSP
M!Y%(-'D0P34[\WB,3!Y-AUK#=_=> DMN+Q 7+-GC_?!:-S!<#/V?MURH8Q7
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M/VC]^: ?1_9?R?&.8=IL9^DQZ._GEU@[P+[TQ-&O.>1DN6+A])C_ .\+(Z0
MG5P,@\S'OQ(A,Y7>P5XN??QQ81:/2/!9\_..+"&0)X^XIG^,O#8,YX'::E_;
MYY<B)$#[>QCG.N87IIDR@9S7 9K^_%IE/)9:.WN>O %;:/33 W'MGR/,FCR
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M?M<H[?K*F-,(#P?'B:%!S,,5:H<:P'8$-L07-[F1XX@031%62C[0)$UN8"K
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MO5+,]]%Q!D3BFBC@@$#VKV7B1244TP/3S=(^7DG5>T LO9N[S\8X4, Z<LZ
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M1$=L O0I 8!)5ZSZ>3C4QA!LHI@UK%)VFB 5I(/3J)X=@N9)5^B$&. P!Q0
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M<I6>.!("BPU>M)OKM-3FPAU2TS@FR=;UGDP,R>3#C$P/;=KQ?4)D;0C96X,
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M #PY.>.Z;+\#(/2<RH,8&0%8L%)<TPX!D ;HR!B8 ^<4++1_Q*._C\#FWO\
MQ^D8V ++C/\ 8;PD,0.!$+!A JHN<O&$B]0L+A]_QQ,J=/:,)T=)'>.6+!BR
M(R8P0*^:YH''"(8P%@AG$+EPYMXSVB](  "0(;@WOG:ML! PN"R7+V#83"2L
M@ 5N(JJ]ZQX>.FCYU8[I9>[ODH-O C?2YL@W^;CYBVD+ (Y<GMKECCL#HP(0
MJYJX-A"6#'R%!54Y#5QF<M -0O78V:(. 0MX]MJFD4(BFS!KR\80]YAB%"H
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M$40=SO/%-&)M"#T;">DIWQQ5J3&(4+/9WF'+$0H@4!&!-ATU'$O%0M%GQ]B
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M+ $/*JJE=U2O0"L ( ''4-) R();,@T[!Z)JPT(-<**94+D.@-.#FDHO"9&
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M%:5&"CJX1:D8CR1X< "I&$4<8$[)Z0D4M M(6@M#<!$3)Q1J@3:]7.UQC/@
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MYSIIQ4BT!08#'@[,,K)7FK; "J<1*JJDVURYV /.)E1Q.U7K.<YNV[B;([R
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MT?(:400"9+Z+6^8S+Y_*5F-%E=8ES0JM,2(+4UO-+EFC? 6'@BO%7^$)Y&_
M^,EU)RJ79(6XZ:H8/I_A&[U:@@^05EN</7DUXA,<;>\KT CX^L*LG4CR4LPP
MMFH]\"B5@.[0^GUXCS'@56CP% !_/#80@!\F;:U8!=O4=3G+07G?^S+0[/\
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2MC*5"\.6L< ]\RS:WCW_ /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>business6ba.jpg
<TEXT>
begin 644 business6ba.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0"N17AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     @   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E         !@     0
M &     !    1TE-4" R+C$P+C,X   R,#(U.C R.C T(#$X.C4P.C V  $
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M1T(@6%E:( ?I  ( !0 ! "  *V%C<W!-4T94
M          #VU@ !     -,M;&-M<P
M                                #61E<V,   $@    0&-P<G0   %@
M    -G=T<'0   &8    %&-H860   &L    +')865H   '8    %&)865H
M  'L    %&=865H   (     %')44D,   (4    (&=44D,   (4    (&)4
M4D,   (4    (&-H<FT   (T    )&1M;F0   )8    )&1M9&0   )\
M)&UL=6,          0    QE;E53    )    !P 1P!) $T 4  @ &( =0!I
M &P =  M &D ;@ @ ', 4@!' $)M;'5C          $    ,96Y54P   !H
M   < %  =0!B &P :0!C "  1 !O &T 80!I &X  %A96B        #VU@ !
M     -,M<V8S,@       0Q"   %WO__\R4   >3  #]D/__^Z'___VB   #
MW   P&Y865H@        ;Z   #CU   #D%A96B         DGP  #X0  +;$
M6%E:(        &*7  "WAP  &-EP87)A       #     F9F  #RIP  #5D
M !/0   *6V-H<FT       ,     H]<  %1\  !,S0  F9H  "9G   /7&UL
M=6,          0    QE;E53    "    !P 1P!) $T 4&UL=6,
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M 0             ! @,$!08'"/_:  P# 0 "$ ,0   !]_
M               <3SF-:#U","-J@ #"S7,W!-"C?0 J"A0YE#0HWO.P
M                                                     8>?GP/:
M\UD(L-?R:SZ$W&#FIY,Y[ 'YW"2ST_/-XWB/,P]03S\-CB(3S[/U8ER
M                                                    +.?F8-MS
M88TV,'.T7,Z)Q-B3$R4C4(D0D<T@-[#4@ELTG-Z2)2-3]11<0
M                 <3B <CD<#YGW.)0H<RH.J=@ZYV#D     < 5!UCLG(X
ME"A0J <@5*@    H8&1H;#$3%M,W.B882<109\2 1@8:3:0L2 1B3*1D9V6$
MQ\G0^@  *'S*G,J <3B#F4.N=DJ #B4*',J    <"A\#L@XG(Y ZQ]P<3F<2
MAS*@ \/CHGU,0,Q-MR/2,#8 @TF,T)+\>BYK08<;6D9$@$3$_F^94   &IIX
M'GJ$0D;%FO).A !Z FIA:B=32,^Q[!GG6>O1<@     #@<CB5!Q.1R .)0J<
M@#@<BH    .)^?HSHD0YDNEG-?STV/(LS0F(@8V5,'.\9 8D6PG4U3-YS>4Y
M    U-/,LF(L9M(:D&R1$9E!]B.#UI/S^&[1<C"CUX*@ U8+(162V1*3N8Z1
M>7X\WSUW-AS10UM-W36LE\QXNY@AL>;.',   $2'9-(R\$K$5$JD4FWYH636
M6@DXP8D FTS0J     #B>-9NF:7GLB14>)Q^@0H4.!]#R(/7<J#K&JIL29"=
MLY    XFK)&IW#1<WE+&2L2&:!&PIF1KT9R9$6DS<CHH;2&MQEQM^5   !$9
MH4;+&J1'QG)MN:]$T&/&%FTI"9DQ%QGAN^<@ 4.@1\266<[9W <C%SD9,4!\
MC!C(R]E2AS.14'6+$9& ##C+RA:2.C-S)"AUBRGU+@=\&%'3)$.)B)EX*E3D
M  #KGYNC.RQ'Z+3Q4--3V5/'\F8M1&)*)G!>S7(Q<W.,3-"C]41D(   *$;%
MQ,T,+,S*G3+,9*#&3&3*#(BIB)EIB1EH*GT.0  !Q(1)#,H*' 'T*%3B<#'C
M&3)C)#D<SD  >51&)+QJ6222$6(V?-(2[&)DBES,,(B)T+^1B;_&Z9R ,,/#
M,V*,3)#-6"6C)2+S>4\EC=0P@D$O!%9*)]3$CM%Q(F,/-GC%B"C< UF/<T[(
M  -,CSD(7),/?\_/ ;+D1&SAK\:JDD$J'HP>!A[.GCP>BY)!Y;'Z)29P   #
MQ9,5.@60OAM(8&143^:T&V)JB1T;ZD&$;&W!&QFY 9M,>C94   H>-Q(1KL;
M2FH!FA)1$AL2:S VO-4"3#IF GM"9Z  1 :VD^FLY*!\3(3)BA\R CO&=EV+
MT1:7\QLGDF$J 6PTX)D(1+T>9IZ6&9'F<>H9*)@QHN;.%P+ =,[10S<OX( ,
MY)-->"43MFSY4  %"@ !0J5* %#3 LAO64*E"I4J    0(=$@LGL@,V++*8"
M5- SU3)G-3S6<VY(P,M*'R+"3<3F    0(=@ADO)\#'B<B+2Z'6.L2H3,:7G
MQ,E-E#*0               <"I4H4.14% 5                !Q*E0
M      "A0J5!Q*E0
M
M               4*%N($([/D9T3^7HYE0
M                                     <"%CR7/,LTE+, #NFX!Z3'K
MB;)G,J                                  (!(           4*HH@E
M D!,"A5-0       <"*#\^IY!%F.( E6!%$U*G8/4,_0^;'E0       "@*@
M((HLB*I2        "% 5E2%"LJP1"PD     "A2%EJP#$Q^KYRN)DEV;Y%QL
MJ5        .!UJS:8N/G#@CZII9][1=F+[)JFH      .!Y>'YDB."A0 '.9
M[N]@X8;]+6N *F1GZ*3VJ/H5       .*.J=(^<3$V/)EUF96IW5?LGD5D
M     !2KA:D:Y<<&WB)KT^%HRZMY>QVGC%>\5OS34    I KP3$N.VOFC$:8
MI[E:]V\]RT=F9^]G<R)#R)HS,]NY2J     !6*3-KF;$MT8=R*=:59?<[Q>D
M?9:RK_%6]H[<142     X'A&?GH/B 5.1SR1*_NN#/GUOR,P?0/-ZN?#O>ZV
M?&O9\:S2%4434Y'LJ?I6.Z5     *(HG'8OA$9\:F<OG%]ZUTPT]O.K1YXUO
MKYGUY1MC]4KXMRICE*J0     *0^$HVS8]#NESM0\^&.469.&1-XR1,LQLKI
MYYPULVX.KM25BR5*UFMX)  XEFK&EW,W/.3C=B*(S2YEU]N-KE9YL:/=O;M2
M^]GWL^]7ULD*[8397;(J     ?(Q"M\>5ZEJ_<NR>V<2IR/B70R,YEDI?A:+
M_->0    .!X:'YU#@ #FB5_H'"VF^X^#D?W'G\FW<-OQQ"_SGT^B?Y<^L<<5
M_G$\*5 '(]G3]+1S    !0MQ@+-CM,_T5Z=XR1CY3C\S>5U?+.V&#MW2ZF;%
MTE+A3)OO6?TA6BXV5     *&*6I&V2,'S8M3>CSXWO370P-;%EN=J3]?#ZO\
M[8M./9^N++]=C7V<T]G)=?8K%JV 4JXSCP;'ETRUMCS-\7['47<PQYEPR3BS
M9[M:OIWO\.>=OG_53NLG8M/V5^Q]87?*V4V;9/960   (^%9P1EL<X^$U[R;
MR8B0@8^?,N)(Y,IVS+CF=2+6.MLGMCY3!(  '$\Z#\DYU"LJQ/*U>-;9QZCF
M[[_JSY%>>UIW+/AO&6>EAG%.=L8IXC9R+YO\\\XOD?ZEM6ON40 .1^ET]FSD
M   "B+%7+&C-S3;ZSW86Z]+K:O?5\S./TO*2V3$]?9@3T/FC%\+3U9I^F33W
M?1W)2]6I5(   '!$:7B.LE/M;%AF:-;=_4^"-8KX(*B^:+1LQYKGQ>N?+W<6
MC9R2M,-Z&AJ_ZGS?JAX'VDO:F[5('&(B#E[OY]^!Z'5CM\R7.-U(7RXXW6O"
M=J-?;]*,\Q7Z?Y=,G1\QL!R?<]S'F^JGW,,9.-ID?)7:+87Z7*0  'RK.%S;
M&U.$NP7\UQ(".V2R=4L)CQ>C; RXS '6A8ULD1RF   ,+/Q5D&%#E+ZWI/GJ
MO)8-SNE@7)[.VWZ!\#/?U[QETW,%SS8^ICO\<=H;^;^BVL\3^2M+/)_JK3GY
MQ]DX3( &8'[3B?2H  !:5HPQY[97+U$_6EKE->IFQ7FU?LKH3QNCUN;Z&!.#
M['5?L<'NY=727O\ C,HC9]R,VMNW-)HR:]SO2H  !Q(?KMQGFP=W)H_1.$[&
M"+LV*!-O7U)O,C47:LX5:UNC%+7G/I,P7T9KZ7D8WWM3SM]/YK)]'I?H$\3Z
MN1Z9.0.KCMXP^#]O&/4YL$]GE^=&'-L=Q_22SC[D>Y_.[\\[O[.];CPOET=F
M/4?,LWT.URQ3]D6"=O43!UH^8L^V-+:?LY/0?5T/O%:A(%!5C*^,S%LFA.0&
MNAKP7 ^Q]CN'W/D"XFXQFI>RJ+=%NG$WR:I5 !Q/ L_/V<0<DUF>]M8-H_I'
MA=;/!^OS3T^INW^G?DU\ZV"ZYL/0P9/I68B^>]S;_P"?_D2&NA]E\W/BOZAQ
M+F]2EII52(3-3UU/U"'(  'Q(J;/0K;BCH+=7'>]13J9:W"U>Y$>?G%Z&%8M
M_&^/[#2C:YN_>MMXKDQ]WG=ST.]K\WO.7G6K V7W]#ZRK,@ <3$YKKYEIY,=
MG0@;U_G]P?5^1A;#E^6ET<%\YV8Z\#Z[)*SD$SD*+S#LQ;[3$J>@\_JQJ]7K
MU8AAR;*8,OZ'M3)]TI1YS=[P<\3[*)]W!I7W.+8MO%NEYSZ!,#<[&+!*M\-Q
MWFQ'IOF&6=7Q^<</M?;%GR6^;ZX/1:A<+T\2=3CMWC[6=G0V#T]W9O)Q:UM6
MP K;*9<=EC%J_,[B+.:!EX.N?<PHZ9*1EI;CYDF&T9G!4H8U2^0S7ZVJ2 +"
M?AR(N /I,Y+T>7L-],\+(OHN/D'HL'6Z>QE7J-"\=37N=\73Q9K-S\\?>,Z^
MQGQ/X'H'Q/T9MG].^1>>7QW])8IH]?CC4F>*!<S]O)-Y4 %%<09L)9JK='&Z
M5;4O-YM@MDS<D?2(\]>)T)!G;Q+C^UQ/7VYFOKP;AC)M_E;V^I\+TL=HJTMB
M\;6EN3N:]9D #XHUBV,5LOC_ #Z][5P;V?F_<;T'BX\]-Y?R?^7?:]E-;3@/
MYM[3*XMDUHR$O1VHFDUD3T/GX=R;5AFD;:.U;XS>V&CF]#=7)U4:6>9[WDUY
MGU,7]#2M7?XN8ZG:EBG4[6KMURY)CP3=*Y<J]9\[D/I^;DSG3RPY.//]SG6S
MI>8_G?;PETN=MKT.#M9V//X]I;GH5O<#ZH) I#'*Y+%;%C$VJB]FHQ$9\"73
M?PLQXYF'FQ!)A:#@;HDDEP!UZK-%\AO0 #R_/RBG$ G/U'B9]]OX*/\ G]S5
MKY[]0^=,LD>OXV['Z6^87SN\_P"D3QU\L(_+O1ZR?$O=;D<_X5*'*I$GTK8F
MGV7@NIIY\'TNOHW\P_0V#<OT%(4E^BL]T"H /@B*:[/6ETHR="+?"EJ5M=V#
MJ7MWK4[=J^>/$Z4S7MY]Z/H8(Q9-O-+;U!W.7L?O\[UT]%P+?J;%LQUQG-AW
M,R:WTF0!0CC+BU^SXOJK^<SVW"]6_4>2]'O)=_S9][Y'RL\9]+D+EXK+X[T,
MJ='E5YW0DOM\SY<?H=JF7C>EN[_#A?F=JM:XM$6>$I5G]1NGL1OH[7BUXWVF
MQG=X>0>FX<\9]"&N-Z75'@^SPO/CY4S[.8\<)XO6SS]!_/N2;G-E'S/4^5,L
MA<WVWG9CV=8\71N>KL[R=?S,Z='A_;=T=OK:F<4FJ0/G#'J9,!R8[:#+3SC.
ML?$]7BZG$U_/(0D V,+F=4V+)Y,C*E(8U3)DN3'4 XGYJCQ<.(!N9]"^)R+Z
M[SNF/RS[;'O$]".4S>>CJS1]&\W=MS5BKPWH+!Y3;QZ-W:;/\GE?!YS%?*_2
M=,?6>OV:]#\OFCU7S.U8>AH9\Z_1O#'-)>BI^N4Y  Q"F:+L.SW<F/XQ?'Z9
M/O$_*;=V<77LOML7.]?.[B=*7\V+2.^W"G ]5HUZ+Q4DZ>W[D9.CM'Z7REVY
MEXMT=GQQV-;VKSZNW654 XFNVQBPO)3X6Q_F@^C>0VK]/Q_4+3P>=O+]+J-S
M>O,W R6?S>YG':U9<]'R]I/N_P TQ#Y[ZG7_ .'?2NFIQZ_)C'6ZF6YJ>E_H
M>?YU<?;U$XVQ^D#7S]OR'I;SUM/'/4^:M=\=OQWSF<OF_P")^CPO?%];YMBM
M;)]K98@]K\FC''?9S2GR#GH?I5XWI?/?B>ZP[;UM$]_RWJ#;#Z#6U<@V]7K;
M>GLO&K5(%EK?A%8JO%N/H9H>6A>B63TB*@Z9XAEK-A20BV$V&QIEQ4&.TM?;
M1]9@#@?C<-*0#E+T-^H_F?%7HK3._II\O^STHK!:U(IRM?8':^?8M3IV'@^S
MFIX;=/E_-=<]'ZMIWZST,P=_Y[!NE[OT1^D_F+0WYY^B<'T_0TB)'/W9G( H
MB,\6[C,7^<TZ&/-8\63N2M62,@O@ZTVO.3'SK3S6XO1SO/CG3J\[\ZC->^%V
M=HM+M>QWN/,R!CYV>QJ]>EM5*6S*C=28Y I$?!;23!U^O-K#M:GC1]8^?[=>
MB\Q*NSRM#.%ZB4-3<U>^>^HR#D+G&>??KGDMAOJ?A[UQ=Z&OCONHN\KW?IO:
M<,:O0E';Q>H'I^7 .CM>27F>A[#87H-R>A7T7'C%3'96,DG)6%N/UK=P;W-/
M*T77)KZ0]C5C#<QZE;FO>O"_2??O/B\VM7KV[)BB[7V_6[T7D.W;+(F.8SV-
M#>".;4 QNF3LSCAJRWGV,[/*XNQ+!Z8'(&,GCJ8<;$D@EN)H-C#,RH+32?M,
MW"U0.!^%0C$ YVCT-^H?FK3'P'W>2/2>:D[K^8QSE=/)-GAV[%FL_,W[HYTT
M=SY_&O"]]E_ENMJ9S?INZ7R+U/FS]NXF]/SOEQW]4\%"%O9;G>T^)^?_ ,__
M $/T\67B<C]VY(8!Q1#&#>L>/-\X<[Q6U$Q::Y>ZI;IGN67N^M@,5SO:U^K-
M_)&O6\XN#UMVNQ?;K>XOH5AYM^8.2;>MD6)GU'(%$8C$^>5NE6*]+=T]X/4^
M8YJVG)2]:VQV:7_,;YKI8EK;$]4T\8V]R3^_S93X74O';XD9<??QW8UX7U^A
M*&U2W8\>0]Y!/!R[R8'KULX+!&+'\DQ/-;A$RZG'\=H/\9U+P7+/7N>BYN@6
M;)I?$:C;.'8+QWNO?$T%G>BJ^IV.IP\6Z/"W,Q;>VG)]'?\ G='=[M>.Y2 Q
MF,O=G% AUYGZ$AGFH? LY["EZ/F:7&C9<"3B^G9-A2?3,BHB.I6>K-[JHD.)
M^""RS(I$@>@GT+\V:B>.^XXSK[]GIN=G-ARUIX#J]FE(R2O=V0[/@>.ML07K
M]R?]CRW6\!]ZQ79^89]SN'9NKKPA[?'M3Z7Y/I?X[[;9<._0YP_<#"=T)4A2
M$,5W$7LE9ZRW%'<O'PNN*MIAV(M?\^I\,^/'K1&56LL[NHU>[/#+M+'GI7:%
M]3>R\)R&B2=>M;6Y'&*QULZ_G!V.+=]#J<=O#O1WM+Z8[*TUVR^DV0U?/_DJ
M\KWLDK$X['3R77S7J<=VQS(?JO#X[AS0/S^ET\>?*<N/)=NN!X'7KDF;2GV'
MWM:W7K%M<MJKBS"$VEDRW@+YYV.WK7Z/NN+K5O8]=<.Q"N3#J9-)IXWH]J_-
M^WE+J\&(]_A>9?4XV>S;T0HFDVSS^AD3Z?GY3 &<^-U]F_$<O6;(X'(DDTM(
MK+43.;^$-DOD>& &"$?&,';,K,],\,WJR6LQ'])Z_5W[JJG&*_CF^<<G&M;'
M2) W=]?\!U#\K]LLF/H?&+?2(I:W&(H9'AZ^7X/6RON\'&^1]'E/#Z[6KH_%
M[=C\;/G$Y4)=SKW3T/D=N.]\=T1\K]^L.'?H<[Q^P[V_2E;9N@129N?@*=C5
MI65JBWVK:T4GII[Z?K>N1;.I]LVOT[K+9:S%FQJU7O2M76VH<3NJ]PMAU"[;
MM^/;W.2$QQB<<P8M8>)Q[#@V[ETM/:'T_/\ E;6B?O\ )ZGFOHDF:7FORL^2
M[\F5[&47YN>Y,,G7Q=?%L9EM<JS=31A+G=>[8\EGA>;Q8%>@OMICCU!V]>"]
MK%+^IMQO5E!-=\?QRTB+\X^PP?9PY%^A/)ZB8YUQK:YVI $6RQ>._-^Q[FET
M^YZ;P/SV-28:Y+5"39KZ\:VUM3EWJR L^"<MUM75ZU[:K4D8Q,\^#)2QF'ER
M-ZB9"^E3[G1,(,,,.,(+)6U^EO7UMGJ[4) C\8G$UM?\0 9GN<+;GH_']%>%
M]]H()DBA]63Z4Q[,Y?#0CJ?9]N>?]%ULV_G%ZW_);2\.-<NYEN7H?DUY\YT]
M3)^A\"A<9?MO];O72]J1 H:B>6PPUI1TX?!/3+?"9JWVGP[G:RUR+>YUMSX;
MC,VF7P,GK;4K+W)RIS,^QZ=R3W3$I=@[_0S8_P"IWDRA2&-ZV+QA\CPHUR5W
M[[.AO_Z'!GW.O;<^M=];/J;AS?G0\IVK[%[M1ET,^O&7(SW8U\AW>?"5MRVX
M,EDQVZ<S;J+/-O1W';TNV,&FO1T]@M/=C*MLP)=FN/;F'$?@WKM>_JGGI!]#
MS],<-X*A?;4^A'1@&/-DU,EPR:<OQDI3)'D4RK+'N+IY]F];:Y %OI:SS$"V
M88BY&?ES-7R!#LF&GP+^9R;I' ^9>"[G J=@ZY9J9=@IQ<[ .)^2\\U0 ?2L
M[5;_ ,J@S1]W@D]FI0 J?2C9'G><P/)]RD[5]AW,WPN5.C;8UI8Q+47TGQ_.
M/)SHKN?7J5FALT?MA*@%#Q'PQY%87([,N</I"3IO^AVO1R[=U_IL:>.Y9[0.
M^<80_/0E>NC=*UR,Z1A5F10DO"S"BH!\YK^:3J<W6++7U=Z6MNCV4P:>+L5<
MSSUU,_Y\/)=S+$Y:9=++C*C*42-W>!$>#K8IBO\ >:_>T=>V/&\>;V0TL^^=
ML7G+VM"4]7/8ZYLXI.P<1AVSAQ+DY-4NSJ216?+;'F[L5[]J7='5/CC6^8^]
M<N83'QBT4Q$[7K[P\S<SZN:H!QB,39H5G# Z<[,Y,@!K,0&6<XEU)1-Y"IQ,
M?+"= ZY=R](S2,\HL%9D"AX1GYX2@!67UI,IV\]$[T% <HFLJUBY1N2QRMS(
MJ_:8MW_EDOZ'AXPZ/TB-MGP*T[0]KY)<OGGMM2O4>DXE(>QY^FPJ #3>K\SV
MNK5V#ZU?6'.9_0/?;V?ZFIT;TCR+7^%SE\9=HMBUUBGUB:0Y0Z-EKLV5TW=
M!1'B_P!#2\IMO6[=XS"TR=2V6Y=?.;S%&"V@?*Z/*N2]U9?3)FR,OK;*821W
M?/0[J]O'Z2K'=1:(BT5O^GK6R3#6/);OZ/<O7.M39[-+RI$9GEPQ^:PY-;[)
M\:L>Q,T4SZU."DG*X88ROD-)0JM@2V\6#)[2Z6WR"0*(QMD@16$T7(D,RT'
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M=3-ZS:^?G,U     .*+2O:4WM7LJ?9/ Z!CI"1#:WW1D$1]V26Y3>BX*52
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MK       BB:54F.HM@V7!UYKDU<F3UE6Z585F 2
M          !0XFLIX6GE.8:<2@ !4O1Z;'NJ;J%2H
M                                          .)0Q@\_C14UI([/D9V
M;%F[IZ%$BE2H
M               !0H 5* J5
M
M                                     .!JJ969>2>1H268J921J1 ;
M4E2#2<2H!R.0  !Q.D149P1*9T226<T:-["X%"I0 Y%"I0C0C8PTVM+T4.1R
M                                           /B>/A!IO2::&-GKN>
M*9L:3R:R$4FX!KL64VA-.C8D]G#F  #B:>GR-:RTEX.F0H>C9K ?(UV)K.V7
M,U9):)+(4+N1B2V;SFMI%9'YB1Z(&_IR
M              !Q-5C.3X&"$NG:,$+ 2T2&:G$VG A@FDPHR$F(J  "A0$0
M'1+09P8<3$80169*9J4+*8"2Z1\8$3*8Z8Z3R8H= ^A@1)Y*)4
M  __Q  Y$   !@(! @0% @0& @,!   ! @,$!08 !Q$($A 3%" 5%A<A,")
M(S$W8!@D,C,T4"9P-CA!@/_:  @! 0 !!0+_ +O:G4M3-9R,-UI09Y":O<5'
MT+3VT4-MU;G.<YSG.<LDR6NUW36W&^WX++?O1K4MI\YSG/ASG.<^.ZMZ-=-*
MI'\U/^\[!(FAX+H^K;6UW/9^M(':5:F-?):QZ>>CMR@ST_&;0WYO6?U-NJ_-
M]C[-VG>Z_P!0O4_?+7KNA7;=\M1=&N9+JA3UIT5G*GK\)2,$>HR1?Q'4?L"W
M]4FK$7FRG3K4BKOJR<4K2>V7NQ-95':.\-Q/M1W'8KJJP&S=Z[KD-)[FMLO<
M]B[@VC:]K]1J^UDEVG_%_O-^T0D&>N;%(=+VT-O=5U:<U6%A[^_Z;>ENU5V0
MU]TU[,K>HUZX_+N/JIZD705'J%ZG=TTG8]0WG!/GW3Q,=1^NWVE^D^!;VG3\
M;T:T6-D.HJ:)6^I#J0WKKV[ZYM+B\:HZ5?2Z)6U/T>NE&6I!CNFC:B73,ZN5
MSI&I:_IHR^BTM3N]OL)QGISJHZIMH5?9,FT_XO\ W?.<CG/B(\8FH14F<YSG
M(^Q54B(!BJI$0#\G.<^/G)B?QYSG.<YSG.?SS]6K=I:06I=:5EYQC2A4J/F[
M)K:A7!:#K=?K+.Q5*LVYF&L-=A"$A(=.(B-5:W@3UZIUJI-N,?TFHRDXUU/K
M1C+O&+*19P^J]<0!J]5:Y4VDWJ'6-B?1,+$0#&R:RU_;W,%6*Y5VMGHM.N97
M6K]<O8\I0(7W\YS[N<Y\!PZJ:8^T<YSG\?.<X*I"G#PYP/$RJ93A@YSX".<^
M[J:;1+O:6C'L76+#$=5$R=W7AMWUSB.JF9.[FMC[)6VTOLC8UHL%<VE/U76%
M=VS>6-D8[;V59G_5G_1FG_(7U/H-VV92M:LMM2 7V0Z@+TSHMYV0_M&H9_8N
MQ9;8&XK#.&TULO:=JJ]D#J$MDC4M>[$O+_87X=Z_TAA_D'X3L7=MRJLU9[YM
M>RW[YHCZ]O"(ZJID[MUM?;LG.;&V3L>U53:5KM=+TQ"=.%5FZ+>49^UW]CH"
M J5F1T=K,_4-OYQ#62X:\N!+O0E=D;L^J[-1=9I^7GP$>/ <Y_<;B85M_P!1
M&G+<CKK6-%ZCIB4M[#=&Y)FH2^Y[-/R!-W6IO3-L7+=;[3,8:U&UUI?15&N6
MGH3J,L,/J6L;F=;!K]>?M&-#<;VGX2HVSJ"M,)8!ZB['*5B_;NMU%=M.IM\M
M0P5OQ^HSJ.UU4+#2:C\-U34]?[$MSJ[!^'>G](6VEZE%Z.K5P/9-B6[J)N=8
M5NVT9]G<(C=NS4X.M[<M\99@WAM6+K>T-XVFHWKYG^,;BANH:ZREKFY=E P^
MHK6TA=CN=K[<DYMSO:P2=2UPK:5.I+VV?6WS#L9]J9J^V-":5MT.2*U2T9VR
M$TK;H<C'7?HMJ0FK/@TFRT/Z2"M6MY9"PZ[C-FUB1VSKOZH4QLEZ=M':/]!K
M3=M2F9& E=;R05U;IK0<5FU:BF']NDM QKC5DMIN75O\+T\A$0K'7?HMJA^&
M]UCYTJ%-KPU*J/=!2AGDEHAX>'^E#=Q?872MNATX35?P:3<:#(MK%2LEF*A_
MAYM00UJT;7YN,K>EY)&W)ZW\O;=7T;5HUSK#70ZT8_+\.:?_ #=2N[[=0Y_1
M6PE=E:YZCMP7O7ESR\6=M3*CHOJ*OUCV)SG=@& P&4*F3D!"_;9N\#U"AG.<
MXFNDL&X/JO\ +T'\6^"$724,'X1Q/6W9MM31D8ZDJQJ^[QLIKS3=]L-4GM+)
M*.&VB4R4RR:L8VC5=?KLXPI\)TZ7B&KLWHZ#5KM9UU.M"P_3Y)1K6UZ)86?9
MEGU3-.[@YTNY=)7K6+RR6*0T@YL%,A--6)O?;S6/G2GRVE4W]0HFKG-9L?X;
MW6/G2H-NGJV.H9SJAA\]*],\K\H;GJUD<WJET2^WUBIJIHZV$CT[R2C"\:PL
MUHD(#1;"LV"9T',60VSJ2ZV%3KCH"C6"KUO5*T$['0 I4>D:DDZM?/<X70:I
M0USI]C<8_D(^*9MG+=ZW\/MC2<A9!^WFH9W(^/F%[WUKJ\7(1TG'3#+/M[E%
M4T21<S$SC+G.<YSG(^P0<N]\'S]C%LXJ_P!$G'B<Q$JR?@NN@U1B9B*GXZ5E
M8V#8-'39\U\)NRURM)0ENJEE'G.<7L,&UF.<YSG ^_O4.5,NLK-4+UOSI5L+
M:J[)ZQ?ZD9UG7+T-8W8UI]8K=_L+2V: T+II]MFA=)KV9K^PMA5FO2VT=%V&
M-K/4!M?_ .W75]6G<-(=4&Q$)G4N_:Y9]=T"G0>M'ULZU_M0-W.KFTZ=:]"Z
M=ED(DCY.*_#.6ZHU@\+8Z_9$,6L==;2P>#AP@T0B9B*G8[PEIJ'@&,-=:=8U
MXN8B)M#/YY-3\'7&>34_!UMGG/@'X7VRM=QKN(FX:P,_ PE  $#![.\O=+S4
M- ,8:Z4ZR+Q4S#SK?P#W=21CR4UU$4JH:ZK,M9=GS>Z9^Q[/V1IJ:V5<(INT
MV3L]#3TS8-^Q](T9>)"Y1$!/7V"WGKRU3T?L:M;9W4\S86R[TC,+[)V;:IU&
MN7TG4]&5&Q.-GP][FZ'TSSMAW32;)(;]NCMIK"TV&YV8/98O_C]9N%EH_2D\
MF]X16U6>VK]&5;6NP[J?:[C9U^N""=QL5=9(W;;E?E[_ +5NZDELMBM&=/L?
M &NU2D&5OD^I&H;BV."#J^;@FZWKO8TY8&,#L:Z#KBW25^K="GKW948V"VY>
MG>FD;KMVORW5>111IKV)\KJ!:;GW-96SG;]EJ$Y79V[);':;GW-96MGVG8:5
M>(S;^U@IR13$3]V_9F8B-7:9Z6ZI/T/8^J)#2>SNJJ G['>LL5+F]V=2-SZ2
M==H535:EM<].72-$2T+K#0M>GHWJ#H;6Q:=V+4(:_O\ JEZB*E=8G;\Q&J[E
MTYT_Q,SL+9F\;#MBKNKS!);BG^K>O3DGKNUN]N5O3NR5V&UVNNH%_5Z)^'J(
M0<N=P:K62J=TK6VMU/ K$98H/<=;VSNIYDO8=FSF[T+/M&SVR-V%?66MJW<M
MG0%YK%ZMVPYCJS_HS#P)[7L6HR.SH'5(;/L$/=U+UO)UK>P[/G);44Q8]DW;
M:>SK99T=(;&NUL^>4-S[+G:5KJRWYGMC\/4=3:DWFKDXM%8V5([3V[+3EMV1
M;@HDG<MA6JI'G]A:XZ;'DWO"*VJYW?LFL5C5MSV>K=T;]N^3UQ (W:R]0W5G
M_1F'@#VS8NEIY6L:'J6SK^SV$C?]WR>MZM+*3]:]MWHM9V'!P73U3HF;:Z_A
MFE_?]--%?Y.Z7J\VS9Z2J+*FS>IX&;A:/KJ$H9:[KJ$K-LC];5YA:V73G2F:
M\CT]T^0?1&FZQ"RUEU1 V2XQFM*]%V6/T-2V=*J&FZ]4Y^#T#0X")H='A==5
M?V/&J;YG]!JA].'NOH5_?)3I_I4N$%IB%K5GB=5;QA(HFDZ^O'2>J:])HR6L
MMO,IE*GR5AUG6J^SJM>:Z_AF=_O^II>'U\VTY7AUI :?@(-=315,5I#+0M/:
M5V5T;6))S'Z)I\75)+5-=E$+OKJ$OJL_KJ$L5P?=.=*>.+YHZC[#5D=?0LG>
M'W3G2GCC8.G*=LB.>ZCJ3[8_XN,XSC.,X\.,X\. S<E,V-<F&C=)L=/Q'&<9
MQG 9Q^.<UW"3]T<ZQKCJ^,NG.E,W$5K6O15F9=.5*9KM-?PS._Q6L8&(?-='
M5-I$V[5C=^^J>N]W1;G8-!A]E5E!$K=%EI>K,:/N/6EIML-8=55VP12_3[3'
M=?N6EZY<)N0TC27NOYO2E:FK7%Z"IT1&--?PS.__ (;OKN%ORLG0(>5O-BT1
M6)Z:GM(TV8BH/1U.@W'T!K T=[KV%?WQQHRD/D:CIZ"JL^RTM5F-'=:2K"TO
ML*@0^RJRB@5!%/05)3CXK0M;C9UGI:K,:/!Q#: AO^@XSCP$.<X_ZCC]UQ[.
M.?\ WHY>-F:4EM_5T2*_41I=N*745I98['=&IY(S&3CI1+G_ -!<Y;]BTJAM
M[IUJ1+?+-U+;CLN/I*1E%_#G.<;N7#16L]06WJME-ZUURFI.W]>;!#D?[]$<
MN%YJU"BME=7]IG3R$B_E7G/X><36515UOU77^H#KW:U*V:P_L9U),&6+76$2
MPU\:8%[2'"7=H.(VN'5Q!XU=!S^SYPZR:>#(I#GG/C'$)7GMEL+\4Y]4[*!9
M!#N*<I_V/.;IZEZ]KH+5;;'<Y?GW!B3=9<R[==LI[.<BI:4A'^E.JV/G\ W<
M'[#G#KI)X+Y#/7$R0O"#!XRL2+T/6(850ALY_:<Y)W*K0^/MV4]J"_41%IX3
MJ(8GQKOVNJ&8;:HSX64DPD4^?RB/&25PCV>25GF7^ '(EPN & &!A!,46=DD
MVN,+&P>YS^P7=IH8HNN? 49)X,IGKW9L]0^P'3T,+(#B:R2N&(4X*,2!GGN6
MV)+$6+^41SJ#ZF_0B<QC&]G& 7G(RF2S_(ZEP[/$6A$";&: 5WQ[><Y'.G[J
M6<5,4%T7*'Y?Y8XD4DL<O'ZH(D,54@@.")<L[HY; TL,3%GV+O*8;SQ=W7LZ
MU?ZBKW$*4O>-,MW[$ZA4RRM@]*A8IR:DSS*!F:ZH]PG$IL5-V*-W1\@H_P"*
M.TZ*^:J1=FV)!'AK3'RX<_B>/D&1+?=!03L.U%2&;;(GA&+V=(%/#SL9-(A@
M> > >$9/NV.-'K=ZE^0Q@*#A\)\\T2CA$S'PJ)2^T2@.).SIX @<.,59E$Z+
MLQ1_&.=3?4%\)(//M#(6IR$KD77HR*Q-L8^)HIIXN'WML6:4B3%$!X]W.=-'
M4$-67#^7XUW238J[U9<3 /(E/P7M[P']/<&;?LGR_*2&P9F;</FLHNH!DRIF
M7\H"/#&'6/4'9J?(-G2#M'\KV42;8LY5<&F#?Y65^Y)%H#EJ[9B@9S_"*"9_
M+;CE7<>5+-$P\EPY+B0%[#W-] 'BY:/F6GNYR9G&T4G)7V( +[+.5UEIQSY9
M7KT%FS@H@P?.T5:3/A*QX"0,\Q/ P/8R>.&*T;)HR*/XE#E3*X<"N41$?!)+
MNS[!DI.QD0#N\/UA)(VB0SS[&GB=CL;/&-U9JB0Z:I4E#("0Y3EXQ5!-8"K'
M9J //X1SJ(W,EJ^LJK++*^'&<>%=,P)*IB X3@,(.%'%^.#_ ',]5CH_#5.)
MN,*\:+L7/NZ5MV?,\:'XGCTK8IU%5#=PCGG'()5.XO'ZR]PX'VS;,062L#76
M#QW8[-6I*()RHD)U?,,#PX*'4X-H>U%E->,WI'9/QR4QSA1SG)LW^5<HB(!Y
M94K(Z;&4(BH^6DXX$67IC)!&+"B\CUQ.R74$BS=3DME I63&\+UA[3[E#W.-
M]MRMC:IQ>Q[O-.G%=<VREV*<G8*47D);N 7*W*,CSE+A32[AM!LXR,;V62<.
M8\C]XLD3L)X!CV=9LU&EBC'8,9'TZL>_0D6P?@,8"@NL#C#&$YL2)WC]@"Q7
M(Q5 +^O*S-(1HN(:HK%=*,D67VR-DWL,I%2S27;H*^0?P53(J1(YFJH??\%A
MG8RL0NQ[W)['N'B3@!;%K4X:!BVDC)J)B@I49KUS9,W.$'.>,,;G )^JS%Y"
MMME(6E;6BP,N;W0,W(UN7UI?8W9%-_ Z<@W(<WG&,F;@@*!G\;D2G[2EX.!\
M[N,O9^+:I%& 9N!]:FOJ0SQ=]HYR*5PI4K3UJ3K.3N+7I_CI*)HA'*B"S5R1
MTE^&PRBF)#VD*;.\,FE"B@(I 6R3*12N%!>+1:35 LFNP."YHL<\R)+D7LGR
M!"[0(A&V"&<1MBM4))1;M,@LZ'8I6E2U5M$7;H;Q5.5(FS[&K,V^G1+ U[W5
M<2O)TZZRBE,K[*0D[:@WD$*=5"O'C)FUBA:NF9X6,*V45CU460=P'\ R:.9!
ME,1+Y%K'.%V C9/)5K5C<Q2R9RJ$][HQEU%U.X?!,O:6ZV0Z0I$*F7.< V%)
MSGE&S^7@R>N(QVR>-Y%HS5$Q?!R@5=-FN8Y??UE[(X(/M06405BT(^:FI%)T
MD]J)7'QE(<(.?S#^0\_::#S7$FOV:[8?#KE5)B'>PDAQ[ND79'RS=/><P$*X
M7%PKR3DZ90S[9W<" D, _8Q  <^Q<V$</FV\.IN+;1TLXL%=<.HUM+U(@"VV
MS7DYJH5Q!RWCX1F5C#*'Q[/&KN$.50GOEY#T+<_(COB]6&N6&H[0>.';.4J;
MQ>T6'X<Z[(.P)RL"LWCTF[<<39LAQ-@PQ-BPPK-G@-FX8"26,S>DUX00\L4C
M+H*^:B.J]DK46P)J$53\)=V'?M5(S"<EI9\C&6551RXKL<Y>R LS,IE"'1!R
MDD#$ZK=Q-0# 5CI1[)H3/(%PN4.TN1;?U+J08& DO-( 59),X0[%<SI1BDUA
M-;SGJV'N=+ @B)/(0,/)L1+R:>EDX6*1,JJ(#QBC@I,9-I:7/,N)6 <M;(0P
MM)4BF?H6 Q1*.5.2%D_(?REO%V7R%"F P>V3D&D1'72TO[K:_$,90\E(A 4%
M,Z/R-!<KQD8FDT19 1,N%^V%.'!_OBJWE N<A3TM\VNE.C5IRAS=R@DK>R=0
M<NR\1\6;MRP=ZWMR5ZHWND5PP44QP$BX<AQ'@Q<3.4H^84P<E\SN^_/ [+'L
MM3ADUE(&KPL?%L%V<5\804\E.XSS>/::R;&E8LY5#"<"]UX#B$UA;!>/O<<Q
M2%>OQ?NA/G4 ^]5L/5M<:62P0^MOX5ECT'4(7^ ]MDBC(55$V)&Q(V)CA!\7
MINW6\([:P,C*/0D)%5GW"$9YF=/]N4D('%E"HI6.R),3?%3.7\PY1B8J'H+V
MX9"516+7?1A2-FR*7I%4R'RH)"BJI,,)PS-^1,(UZJ*@&YSG(E=R"UEEDPC[
M()N?B3@AJ(]6?J2*"#)&K@,9(%$#![5.5WCM7E3NSNQ#_1L>1%Q(!BJP$"F4
M\UA.V;-VB,M#QTXSNM1<T^7CY$Z)HU_SGV53P>X,8.BOV+4_F-_!0I3E8F,
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M+ZS]W&,FBLO*,FC=BU\-EP*<W53)<9%.!#(U?N*J7@V4Y83QD<;]'BI_ ?\
MMZU++Z^Z#[-=LCA6X(M?@I.T(N$+!XLY%ZP.POSQ+'&Q%>V0LDU*X>-<DCAS
M3\K\.N.[5G<9>MJP152=PER(LK&5BF]E/4&-]:(V>%'QZ6;+\N[B#VS"QTT
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M$2<SNN+.V.K\7@3QEM\H8J<C7H Z?$&/5?KGM>OGMFBJ]TITELK%Q,9"LOV
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ML&?96IAP=6S<M"$)8F,AY1$$3H%<1E-8>NV596S=NX%M,M(9"AO#8"1FXA4
M'4#PTUK'3;JLEH6KM0"C77-S\H)WI6ZHV!,4K]*XTFE@H25CCV35HE(M'8_&
MR9\R.%8/8A_Y7K.W=4J'L<;3 .L*?&OD3H.$^VL4N;_H5TQ1>I8>RI?^N0$_
MWMN5?6)3P*5H) (YYDZQ6#X[8X[86U_9N!UE: DI01UC3@@K9= G*ZWF&<>2
MA((D&3H#'YUK[*T\?M )H) 'H)]"3 HK-*,^@_K3'<]E6CJD*[/.F'E.LY50
MG3<;TZR4.:.+,ZZFF.S^)7M-8HR+EE)*9RG>L'#3%DI:@ I*(]PK%W0[>.K$
M;JV\Z09IUL*UXQ1D?8$Q4Z9I(C2G0IPZDUBEEBI5UE@Z$M(1*PHF=-XBG\2N
MVD*+UV1DD*RK_$.%8(FYQ12UO7P"-2V@.?6$<"1RIQR_P[.75%3(G*X)( \3
M6 7POW5(F4!!7FW.;SY5U:0D1SB@V!61-=6F9HH2:#8)F3H*R!87FX Q0[5P
MH< 8TKL)2!_.DK0DZ 4>K<,P!Y4#E@#:AKZ;!O.^GS%'ZI '@*>2E5M!&N::
MNV\K20FK1ISK4B-"F:P(-H4I)@&KY"<QC4&F6V\M7"2F5^$59VX?8>6!J JL
M2N7F7WV!,9U4[;J=>S'B:MDJ:A/")IQTY@@<:%LX(61XUA:4%02:=MH *1IE
MI]LCA5TC2.,5:$A[*=IK%;8)4A21HIL3Y_&GNI(CZ)WI-*5)K>C]R2=(-*H?
M9  YB>"=(W)Y5?8SAMAU8N;IJW4HP4NK 5KR2-0G^(@)\:QKIJ]ZPFVP1*'D
M:%5TI.8*_@1IMYC>E]*L=SA+]LR\VH0I!9"BKV$:^VFKW%R\>I8+3;ASY$(*
M0).V4:#R'LJYN;_NW 6GF#(_G2_YBE?IZ$BFD9W"A7]WEG7G2&'%*:;8!4E<
M(TGC73C"3T)^4/ ,:ZC,VE^TQ%Y:$ZPE\E;9/@M"D\B!FV-8LU@?3W U8CA;
MK%T^AA2F5HREU+H05>K.C53:LWX5<=4RDYJZ$](E]"<2<:NLYPNZ?RWDB4VS
M\ZO?P]7KF'XD$B,V50M.D6"XAU?J^*6+GK S-I;N&RMR3H B<Q)_9B>)'&AE
M&F?WT"/.BH*U CA]E.M)'&D^D"C1H\/+T'AYTQW/95EVGPGRIM.1*?90M4K3
MG-*;2@Q2UMAOJR=]:N[[J&%H2=P:SJ<+BE<5&F_C\J4)]U.HC7[!1HGLFLX!
MUKI3B:K"SSMNY>M^IB8W&])P/US#%.+>)6^.M&L]Y-8=<)PV_1UMPXT6EA@-
ME4!8!Y<:&2YL4%Y&9IU [)&IS#>*P2S:M,1=0SW%,E<?L:]WV4.ZG_-1W^@G
M?V4#"7/;^E6W:==/_J$4\%':D-KI (H&DGT;[;U@K"BKK%#97LJX;*@FGPAM
M$+5KO$TY<(<.0Q -6&10"D@&!EIO,RYG3QI3ZUZ;S31BGEA:2A6@CVUA76M-
MO)"06X5J=ZQAEDWKJQKJ9\YIYIN93O3&8$YH@#2FT!;Z#O*P*Q.S8M[>WB<Z
MV$K]]81:%3F;7>LF5 "P(BGF65;3-8A:)0.L,C2K=G,]F' UB+\I"#&B(]WH
M''S^CLGS_IZ)^Z*V!\OL^G.*WV&89;'#G0S=/W[+"%0DSG2X2.T"(!0)D<:Q
M17S*VZUC# Q&^O\ #@^U</IZQ-N^XI:'V^UV<R=T*2);6 1P-= ,!2JR5B-\
MUF6ZXH6[2A+0:T^LRD03NE)X:Z3!'JUL4Y>H:_T#W1M2&VD !+2!'AI[A6+X
M2WB#14E.5U([," ? _H2?RVN+-VU6MMY"@H$QIP\9J"3&WG2VP@3F3XC\5)2
M7<HMTJ4OB#^E6.!WER@ M]4A6BUKE)'^7G[ ==ZPW"+>P;2$9W%)_P 1>IV@
MP/P__MXP8K_XA+=LX1AUUER*ZY;"W4Z*ZN$*2D'P)61YFODJ98P_HYAV-X4I
MQQE;R['&&5J)1F"RKUA($ +ZI;0U,9DC]HUT@Z(DW=TVQ;OW+&+N.75BZGML
MEUZ(MKB?[N04EMW1/:^L["E+MDX#CF$-O=99W#"V9+)#:DJ0I,%.2=1X1&AK
M_P":G3%BV'5Y7#:PP3<- E2VTA/UARRHD#69),J.I)K"_EYQ)AQ*,9PQAY&3
M,OU1*TO>R241.O\ =D^.T='.D=ATGPQK%,.5+;AR+;5 6R[ *FU@&)3(V.H(
MV,I'P?/['+)H)TH:>@1QJ4_$5N)K+K12*BHT]M,#L>RK=[J+I*U Y1$T]CC9
MRI8;6I?*)UIO'KI",K]N4SMV3M0O;=Y&=2RE?+04[<C,5YI TT-70=N$%8[H
M%)(DCQ@T$QJ*4Z4Z$4M:UZ0*U&_TEJ@Q1,\ZW!'")J[==;M;E]HHSM9\H5L8
M$B:N[9KI!;L>OO=6I.512RJ!(\ZM[>VMK1++1+B6T@"=3E JYZ-HQ?%$/M(;
M;0U"E(4(4<IU4*LFFVV RO=I&5LJ[NFU8<ALWC[R2"I"5(7E[NAU'G0+6RB0
M.KSHYY^$^%(Q%H/%EW2594D;9J==;:;S'-R'G_2CC>'CLEY"5I.525* UXU;
M7#%TB67$J/@:AQL$K':X#A%*,,K5Q(-6$9W/%PFEH0-:T\*['Q% )4=*[ICA
MZ,/8+KHX[4E+5BQ)@'>KG'(G+PI[%EW!F=M*Z]<S6"WX3V%'4JXT5!: H<J"
MXWI+T4M9==0A/XHJX#>&X.MQ8A2FS^::OL34JX>@S*U$4V^XM4FDK[!YQ5HK
M(4K5^W5\]ZZNR"8@6K:3Y_'_ &IE*K, @4W?J=T7H-J6Y:A,A0S>=8K<EU/5
MI&L:5;K-NDA7>-7!6N5&D@QK0X^?T5;#[MNG[/Y2,42UTAP&S>S&VLT'%W$)
M,=<6E+AD\L_49$G@7":Z2''\=PUO'KKU=FPZU;5JVV86ALDZY=2"2@]XYCEG
MNQ/1=UEW <++.B19M(,\7$)RN'S*PH^WTA42*?L[6Y'US2%GA(UCEFW'E-7G
M1=AW5A75GDK4>PI&GM!\ZMNA[,Y;ETJ)_8!F#R4?Z59X%A^%ZI0@G7M/G,L_
M_P CPT'F:9Q!CUYRP_Q@T'LI&[:CE!3X D S&XWI!T<GQKY8< ..]$7TH[]H
MXFZG75 !2I/O*3M^&-*^0]AE70N^PQ6JF\0N"M)X=8RTE)\Y;5_I%='<32Z\
M]A3H"7;5:BT5:?4I.7CXGW2=(IYI!.524+3$CB#RWK&.BS^%XE\YX=;6%QA.
M(/I7C>&8@$"W205*7?L*<^K:=2"22KN'7M-D(;O>A373+%,0N>C]C;V&'6B%
MMM7$.(9O7T*)2&U*F2Z#(2$H0VC+F 497\FM[==#\<>Z-8VDV;-TX?5T+ 2A
M6(*4CJSF.F5U RME!(6HMGNG-68*)4(UG;;[%I.:?"BG2A^M 4$ [UU:>=90
M!4:T?THUP]M6_<]E.=9J4C3_ &K#[MNU6''6DKC7:CB]GB-N7$L(06_JXR@;
M#>KN^;2Z4"4Z\*LFC<J&7-U7$GG5\^BU;ZA&LB/TIU/5+G]OM^^FWA4-K&8Q
M-.*"=JS%6I^DM,FNK^/@4Z<C9'Y^%=);&\78H38N:OJ3F2)DYIG4#2/'>G,-
M;P["9N7_ /Q26\T9OX=M==ZZ/W%Q<.%L)*T=3F!.T?'&G/6;6\84VPI0=0E"
MUI28$G76L1N$6-L'HSKRSD&I)BL!*+BW5<=26"X[*TJ&4F:OOJNT#HX>J1X3
MM3UBVBQ4\=;A))3SF-#SI./,^HO"Z3E=0%-)!W*P.]K2W4/O.+*5DJ63(V@U
M@=RAIQ"3<%K4=Y66D+0XE.1[KA'>"LVO*:N3D:(\*M$G,K_,32YTI?932G3-
M6SG \Z7N".=)VK!TMH2IQPP-2/9I6+XBMYSJTQD C2CQUF: B?.I\!3+G5+#
M@.H.W"L+N47%M+A ('#RI=V@+*9&AC>D7#1_%^=(NFF7T.9I"8.M=(.DB,0L
M_504IA,=G?:E6B"LJ63,Z>5!*4;"L^FG'2F+=UUJ(.7>16%HA2,Y,MPD>0I+
M#+S0S4K#4+2H)) CAO->IOHN%@J7D!-.*^OS;Y1&O(5<!+I"CI'*E=LY(TBG
MV@WM]%(D3RJ?NPY41!^QX5\L%TE/2;"PQF-Q\WAIX?X8;+ZU)">.>%$JW3JD
M#4*K"\%OD=%$LOK*TXQ?6C;*;@DIM6EI7]>C]B9B8,-YM#*370O&?F*[?Z-X
MHX65)?465/J  @A(3),95P % Y1H>[V@2G3*9!&XVI0RP9$D;>%*[(!C<3K1
M*.S X?G4GA6B5 J"CXQQKI]BMU96UBQAY!OK_$664M+.5/JZ1G>=<64PAMGL
M%:\R0@'.HY4JKH_:O7%RWC5Y>6C]XNV]32FP<S6#=N'>LA*R5*<=SCM*)$'.
M@9@!%VEMM4)E((E2E;2>1KI9B'78-?8?8->OW3C#K02RE3@!4@ZG+N4'7+P.
M^U?(U:W]I:XRW<LK9>>OP$(4DI2 D.2OR[0'/7PJYPU%BKYQ;;3ZR@YGU#3,
MW))"?R3X\M35LZEZV2ZC4N *2#ND$3J.$3_N:Z;BXOK[ ,'#ZVK*^O$F_2%9
M>N;;*"MG/!D+S=E/=*PDD$I3%M:6>&63;%JVW;V["1D2@!(3E'>5^94HZJ,D
MDZU\H3KN,NW>.VHR6MI>(L+=Y1RJ<NT@Y#;Z:PE/6* U;!3F,J&;HNN[/1["
MO7W ]=KLV''7QF)7F;"@25)22<I3F,:J!.I,T>'D/@^/TQ^M,:(TXGX_E2BJ
MNU\321.]0GF?CVU">9^/;1T$#6I,[49X\O1QRTVI*$[TXL%! 64^1K.I!(!S
M#^*FS<!/U?923JD3!/&K'#&KB''Q*J=<39,%MIM ]FM*6IY1+F]7&J_96QJ2
M>)J?;1,_10,R@GF8H865@%,[?G7S2KC-8AA;C=HZM DY2/RJQN;WKUM/H24(
M)R2.1K&[._NKIY*$EQAQ"IW)23P3X#A6$8C?X7<=4<-N%-AKJ IMHE1$][_,
M>4TGI.9ZLX;B6;8%;78'C76NW^53J"A(@P1"M.%8>$BW $IRN2!SCAY5=I4[
M&;0!6<>!IE1= ! (3V8/&*Z2X*'SU[8*"!W&]$$\R.?.FBNS"DO-#5>^7A5I
M;^NOY@A8; F4\*Z-NI^N0DDLM.*3*N]G'#RJ\D,K=<T3KECCRJQ$HS\SI1%.
MC,F>5%"LV@II)D$U @'B*2HG2G;OJK4-(/:X_F:ZU2]5;_048%6-^MM&0'A2
MWW2J=:3<.CB:7<O*.63%+3E[15-%?6'\J<28H$A0)VFL%::<LY('=_2DE*'E
M ?M5ZV\&X1.U)Q5]A!ZP'57C3ETT;4O*B2-_91O&EJ49'>-)6VOC1;&<1RJ]
M'T4]U7QP^[C<4O?[$[5\I[3ESTWPZ$CJ;+#V'K@C@QZP 2?^=Y*/**NFK=O
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M##3L)%FZK*08S!10H#NZB9V\S7RE*9Q'HK97=C<(5;(NT)RMKD =6H1III-
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MO,%M\OSTU_.GK];XR$"/CXVH(2G8;_;D ZFLJ3NE)\Q75M_NT?Z10;0-@!Y
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M GT51Z29[)]8]YFAVB8]4UD5QHR.7RT5H*D<J4G,:R&DB!Y./JJ\/QOOSI]
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M)X[CNU\:Z2-73>,7OG(,K?<6C?5M2I3'JTH48S#E2F^*3K5AC6)X:L*M;IU
M!G)G.0D<TS6'?A9Q=A :NK=IQ TSMI.<CUFKK\++V4IM;5:5$3F=&D^HUB73
M#'L7S)>O7$-J_P!6RLI3X1,T3$];*BHDYID[<2>>^] (.W.K>Y-NZE.Z%$YN
M[C-8JM&(=9;F"UU43I,]K7_AT4.1K ;^5/8>X3-NXK(>;:2/:03/A,Z 4E24
MK"AG5E.D_92,57<VR6$.+8NT*RL7"29"3_JU9=2/M\=388PO 64>>7*[RY=@
MN $*ZH'?P"2.\DSPVZ2K1CMHB_8[90D)S#4A.L@CN.\[">(BB,H*#Z4_(KH3
M-34TIW*=*ZT]]3FU\@\B-_55]_*^_=5MJ0@\:O6HT3N:<3<,OI !RD TRPEU
MK,L:Q5VXU:M%28SS%839*>_RM<C6:4K, #P$4\V>%=8\T<B08.M!Q:AVJ:V]
M?PFC">%3X4#JCO6 /&NBMY;M7(\_;[+2905 <#IO2L9\^O7>IMB& GJT.=7F
M;2I2@D*/ Y9S'A U($D=(,,2X+=UIZV;5F"'PD0["AV2K+$I';.F0*.DZ$U;
M6=J+&[9=5);>4ZT51)A"1RUDCOX>%8:PN]>4SLW,3M KI2V6;I+.?,&V\H\
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M:'?1B@!2AKIRH T9%!7?0U5'/^%*MP54&4I TX5I3C6;V4]AV=V3SJUM4,I
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M1ZO4=*8:260-M!J-Z C2AWT?(.R<W&KU/6LE7=PK.E.<*W"C%)6#3+2G53K
MJWMTH2#2C)TTK+&H)JWW))VK'F@;@+Y&:MEA;8"MQI2VC.FU(94" -0>=6]D
M)"H,[TL9"!'"EC/O5WUEMVFT%:>.DU9XHY<WGFRFB@:ZD1M4$$[;UKW5KW5K
MW4I"RG,DIT(!'C.WLI(.8#@:XJ'(Q\UA1/"H4@P>UWIVJ?U5>RI[C[*]1]E;
MZ#TM]>5:1&ZN/*C'">^?+QFNCJB[@EXD_P"SO+>1XAH?WC5LI*\184OL_&H4
MJ.<SQJ\)5=W1YO.?;I]5,W#UO):6I!/%)@^T:TW<OK=EQQ3A/%PYC]<U=.2H
M#14 =H\>?O\ ;1X9=/"HI84I$ Q!D$1]X/\ 'U5A&*+;;<M;FX#2 .PL* 6#
ML"">/U3ZZ=Q-A\+M+I;KS@<):NT:Y4:0A1XI[C]ID,J2A]M33K1A0CM=L=^F
MQ]YK'X0D/C*%+;22/UM95[]PK%,)&+83=O);B^8"KFRN4"'V[EM,M]6X(4,Y
M 01.75*XS(01@O26QN\,L#=7C2;PVZ/.$.+2E76H[#A4A*4I07%I+@0 (2H0
M(RSTZMQB&"/K94V7;1IW$6'4F2/-F%N?%J$_0U$:*.7QKHMB:\4P?"[G*H%-
MBTETE 1G>R!3RH3V8SDD1EA) RBL&>#6)6RE1DZU)5.XG0Z\(D[\*4IRQQVY
M1E"F,3;+?;$CJWC ([YD>NGFPU=/-#5+3JV_^513]U&),;3Y/LKM"9VX10)/
M C^T*@T9$<SW:4<^8) @;E1&D=W?2EI)(00K+HKN5Q%;T1Y-*$<ZA/O%:40#
MI0; I*!O0'&CK02!7&:4D'6IY?"6!ES$Q6IU2I)'M^RI%2*),0D35LDE]E(R
M@*4D*S;=\>JG2EM2DRE4$QEY=_?2KN#L*L;@N.@:#;:ED@0/>=?OH)"5%7TH
MX[>^U=H.9X X^S96O&GRDD0 F=^$J_P%+E *^,4Z/C5JD]I1)F@J.5(N"$D;
M4J%*D]KN-.(+Z4P,@0J<J- 2.=9%JD$#E6 7GFKJ+<I24NPVH*_1.A([Z9MT
M#&;]M,]5E<6/&=J?/QJQR)I*!20E*@<Q\.%><(_13XQ2GPXXF5'3:*N%*6I"
MA]"/7'.G$J2%9OI&?;PJT/9CNI28/D*JFC)IW_1U>!J\?MV7R'% '>*8O&7G
M@VVH:FK.U#3:<VZM?;2AII21K1&E-F)K%+4NRJD!;3L<!0?28'&FAL8IM92*
M4<YGU5%+0C)F4KCZ)-8!T9?Z08GU-BY8LN*T27UEL23&JDI61&_HG[Z_,9TL
M3)_&'1]07VA_]0>T[O\ 0Z_,?TL_IW1_]O?_ /#K\Q_2S^G='_V]_P#\.OS'
M]+/Z=T?_ &]__P .NEOX/\8Z(VZ+S$;JQ=E0"465RX\#I.H6RUK WF@K1#VT
MA)C^UK66-?T^U[?FCB24:&"32LP4TS])W*G/RG29K"OP4])\4L$7V&IM[IER
M" JX*7>UKLMM*$R-8+DCC!D5^9KIT?\ 8&?VIG^]7YF^G0_V!K]I9_O5^9SI
MU_\ ;V?VEG^]WTO\#_3=IM3J\.:R(!*E]>V83O\ 1).G(2:N;9VSNWK1Y,.L
MN*0KQ22#]E$@G01P^!T8N@A%[9JVN&E0.?T5>W2GD*8N5H/IMNG[=#S\*4HJ
M)4=R3/DDA0(HJ*_5Y7'"G1(U.GM]_75RAU:4%H,A683FVRQJ21QVI;*D,MKA
MC)D&?JP?2X\M=*4A"G);ZQMR9!V%7XO(07'NL3HG+F)IC(Y:=6/04,BQST@@
MQMQXTQA>&6;/4L6S0S$];#;<.)7.?K%>DX3)$*[.7L@90$U:6-NY=W]D^'1*
M7NJ96?B!8O\ 8EK<;J4""8!4.R5A67!L-M\)M6K!E3BF&LR4=8K-E"E9BD:
M!,DD1]=87:FXNR-FF94M7(!7VD;>TSL;R^;N;HW"8*;"W['ZZTZC7V1WU<+S
MNEW27NVKQ695]>U;3Y$MK<RI0 <RH XR::_!GTXN;9%TU@-VY:NQU;R.J2%
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M6_:9N,EN$ZYNM5]U?@SL\7QIYR^O$]5:L**=B%%Q,'CPBE95! $CJT!/C'D
MG7R912TA:<IK$++JU2W)TXU:V:UKE6;U4PR$)C[?(?($A6A2".^BIRU=SL+4
MR3'\F2C904#V=9"@".\5^,\2_I]Y^T.Z=WI5^,\1_I]Y^TN_WJ_&>(_T^\_:
M7?[U?C/$?Z?>?M+O]ZG[R[N$]6_<OO(WRNNK6/8HFH"NX#@-OFK@ZQ&22-9D
M;TI4H0CBB,J_I:=]6W2#'K5"46N,XI;(2(";>^N64^QMQ('L[Z_*OI1_6/'/
M^JWO_>K\K.E']8\<_P"JWW_?K\K.E']8\<_ZK>_]ZORLZ4P4GI'CA21!2<4O
M2D^(+VO@=*<?=>=6^\M3KJS*EK.91)XD_!L'S;W3;@^CKX]WKV^OA6)M(=>\
M^:,E21F2/1._:]A]@[JY^/DBOO\ +ZA1(3N :2M)86F8S*T0.'9W/(D</WFD
MH2W*U;CGKX<J=)??"@=&T^B/1,<3WU;!%N0$24NKSKS<"K@GD-".=?160D*U
M[)/*@TO\9JO"%2;?S4(S=E*>L#F;;4YIWX&E #(/T@!ZZP,E3&(V8"<[K2LJ
MH[7HE/LU%*OD,.+P]05UCR29[@.U/_+MO1.:.41ZJTX>1*E(4E:24J29!' B
MF^GG2]EE-NUTAQ5MA  0RB[<#:8$"$;?57YP.FFD])<7,:#_ "QS0<AK7Y?]
M,_ZR8M^V.5^7_3/^LF+?M;G[Z_+_ *9Z_P"<F+]H0K_+'>T--X.NU7MY<7[Z
MKB\><?>7JIQPRI1)UDZ5H*S<JFLW.NS[Q12F)KC29X4V)BH^ 3K2%>%.F2/#
MX %&L,QO$L#N1=X7<JM+D1E>0$*4F#.@6E2?JH_A5Z?*7UAZ27Q4.88CV=3'
MU4K\*W3Y1E72.\)_LVW_ &*_.IT\_K#>?\MM_P!BOSI]/ H*_*&\S#8Y;>?_
M .%7OX1NF6),KMK['+JY8=D.-N=3"@K0C1H$?\)%0HZCCJ3WTAKF35B@1'?1
M^)8&4B5JT/",F;U;1K]]'M3)(UT@Z[;SO-)N74-EM+A"#N! WWUW$\8@]]'>
M9GC5TKXDCNI("LY/Z1I02/)ZS25%(C?QHJG@*9N%,-K"4I.:09JQ3\6K4]HR
M?711,Q19FNI4#I75N5D6D\:E0,P*?=*X! &G"K!>X\#[?<TO:E;^6?MI!&2O
MPIV;UQ?X.4MEUE5VPVE,$@.D[Q6 6",*P]D)1U69M*W$)$9G2-=*4<P"HC,F
M:-#X#B4*3VMZ9:;3J*,</(?(W&M7)&;X)H?-C0^2UW%-7"0P6G3V5;<"E6X/
M@3ZIWD&CHH@[S[0>(]]]/AD32W8OD,I!DHSN> ( GP^\"9K$'L@"!QJU;*>V
MOZ6@\2*SG*M'TFR3ZB=_4KE^E32S#?>F3X\J=@&8XTU*W#G]%#>8>(K!QYHT
M[B#T)20I+8.Y)_P.TSOIQ7<V;UXX5(/G"W%+"A$I"E%13.^@)'>**>(VJ9^0
M<F:,TDFIHS6O=4P*&IIIN1,4E,?!BAI2O@"C2]_@C?WYTQ!1WU JS*4H,G7-
MI]WK^J@^R6^J&VO+3-)^W:E99X>J/W^OAIIK$GL^_N*T_P /\!5Y_)'PH'57
M]HT9-#X$Z>NK(?%4MPI40.=%Y7?27CQKKO?V?QH.)(UI1%.^EZJM%Y%COT]_
ML]=:J\(IQ)2:-2:DS23V8J^PRVORP'TSYN^FX08U"T[4D@9.R"$QH=J/TCSD
MQP'<.ZC0^ ML+W)]5)0$B-:RY?)%102 DJFG3F5Z_@Q\WCY,&#-*3FF>-'7+
M.X $\X^"=IH&E@ZD:\J"%'$4NJA 3;E"O2E94J0/T4Y.S'HF=-9TN$]?=)3N
M >'W^JGDCJTY)^*[0\4CCW&C_IC.FCS&LSN-?N'J\:2M39(C3P^P_;^^M3J8
M_C[_ %T 5'* -!)(Y"KF["\%M4(@+;N>K,#3JPA8!,<>!-8,_P">/XDZ0";7
M$KBTZS<%;4!02=\H!3[0.=#;6B9X1\@H32O*34U.E-)S*I"<@CRDT/@144?(
MGE2P )HF3\*T6#V54O0C+J.^H.D&$\:5<6[0[3JI\:1B#+AT7]=%Y7T-10N'
M$B  ??:GGWG$E.4:UYJ1.^IFNI5RI3:@:R*K*1O1H J6!PIHEMJ!RHS),4?
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M0:Q5;=JXP[EZV[>6BUMFR>R%J.BXTX_2S=G0Z4PPM*4EY6=P@%4;9NX$ P.
MCU>0?)<:(D4XF*2=8I7D'I>_.@8<]^=-F4BEF**AQWK9V2=*2M,"*)FD_?\
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MJ(=K*J;?(^/CXVYX^/VV_K3EC]7PG/XM?'Q;X^Q/''Q\>_DF.7Q\>WES_'C
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MY8\/;[?'U_9W^&!:(P1TQ,VVU)$,Q"VLA"^I4#4.HA1434E[*2)]WX_M^SY
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MJH/S9.7JA$F,3(4^307W@X\-^,XY'=\J44^N$;9&FBFH-T)"3'1W_P"J&_\
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M=<88Z^,AKK2MY;=JZ27(<N'3R"93ZK%>A#,2!&=>B@XB:F)%RZ._#K&2=O\
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M:S/=JM4623#;CXSJB_YV7(;=,VN.>ZZ4\$QT747(?0YF3+N;H,O+,^9TG2*
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MT8IM4J=7R!F7,,?.5)ILNJY=C4C-F7))-SWT TB5RER8,.KM-HT,GAQE.),
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M3<8;VN)I;X;2,*9O #\=Q'&W$0D5%1=E3U*OV;>%_P <K;=G'DYI\UO]-?\
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M*4F>,R/13$E9A),J6I;%8=! R#AH=TMV4MXX$!IM<DP"5%;DU*J5=H74N*J
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M&JC-('>Z#Y%I\2E.BGA=Z(Z1)](B^3)E2="1'*J+T!%5%<<=:%&GS04NJ()
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MW#%?6M\3*8[>53&*@^R;&JQM*#JAQX[G,'+ BJ'H.VL2)SPE5RC,@<1\=<B
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MJN'6I#3J3H@LQ3*4O%-N/H%^.C;I*=V%:<0V;=G2NR8EF::";='A(O) ;0.
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MK8@&\*I!BR'*O*XG(&61TPHYWOI-F.B.$GS7G#8])N^*K5S116IRVQ 5[@C
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MS2;DE^\@LBJ*6N*IX8BO#R-AM4_FV_M\%V^XH+\["L%R7=KPO?</?9+>_ -
MBHL]I@D*VRN X33GO:9$%7Z\-PHB=M %N_-&0M:^UM[8TISYD2\R7O5?'WX[
ML;8C"MR0%<DD/CU<=0_TU'WX4].[UG'53YRZ1_HHB(B)ZL..+S<5$W_-3_\
M-\GW?7LN*[2+*(P*E,893E^#(\112]AQB:-/45\+[?LQ5!GUFF1)TVK7ZO*F
M1V'E9;C-@'8=,345(CW3921;+LN&ZZS6(LAN-$)GJ,,VR"3J*ZJX:/'V]*CH
MM;M(FRIMA"2_:2^Z%?WI9?9X?<^/Z\.1[V6HUJFQ?:C?&EK[OP=%Q]?Q^I?=
MX73&ZW_7X_(3X^/Z\?'QW6_KWQGN8OS:7!@:EN*?A\V,VHZT1534*G;]'DM\
M-K AC#+MH:#-XR'J5%MYU1*PVLWI'2B=Y+?%N(XEE7;6O[[<O=C\I]:"O[,<
MFU]UOVVQVXXE_-_:E\#H9T*BW*WA[O#=?=C,%>,+'5:HS :7QC4MCB:Q7Z+D
MB>Z'Z3.E=Q6\KA--O/Q;3& <%"34S^41/SE85W3;OMA191E74[1*  (![2MZ
MU5?7A1==!U^*^XVYHY)?M"GU+A?;ADOSQ7%]B33NGM&V.*GHK&.]_%L2%/L7
M%,G(FIV.C8MK]$G0..I>-TU%IWV*R]R85Z^QL=6MS+4!$Z&WLUZ=^ZWACB+\
MQY$1+I?8ROX\EV]W+#YWN9S9KH%S1-*I&2WJ1N1; WV%-S7GJ6Z>M,(C#!G>
MRIW>'A[$PG%;1OU+S[OZ\)85W\+]VE=K)]F#5"(>[6AZ+.BJ%MLEE$DW%45"
M'LGJ%5' $':V.X_G[E>]^5U7ZL)MM<N7\K"HO=LG]/&WI&B_SKK^S$R0J?\
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M>VR.AQ&'+M.&*RJ$_2ICBTUU6TDL1R\FO,_P,N.]8&D8=;L8-]ES?@OB#C1
M*1PI,EV T8&8QU8?)Y6]_.A'>-TD54_)Z?S%3;!1CCOQR851X#K#D8VS%-R<
M:74Y=-E760>*(*[K%C\-N?'AMEI"0\\CQFZ>LE)U#<55U$MO-6$-//'9H6F3
MNFI)P&P1<["IMLFNRI?2A>S"GY%C$/._6S#W><:%+^R^/P>BQ");=CRI&$M_
M4:@6%%,H.."2=U08M[M[+]>%)S)!%?N*9%_::?J7VX<ZOD71Q$1"TS8R<N7)
M<)JR42[WLM18_?@ JV6AI<545#?*8#RDG>" W?FGBONP@-CPQ3YHKLF-C7#D
M?6/;%4NJ+W[>.),J#58I \Z3B,.<9NVK>VI+CAGRK!!V$B[NLN<4=O%%02PT
M'5D:+:^FS2W\2Y?7B)FR7!%U^"X+M&%Y+Z9(70:BH[W)A27J>I5T/HKZ)K%H
MA^0]#EM"]'D K;C9I=%%?U$/I 2;@:"8V)$5#@O 3E.?U'3I5NPZ',F#Y($M
MO9%;[.M+NBFF^G=.P-A$4Y(@^KVWY[]_9]%-1K[ 3':]%.2=V"47E%?"_P"^
M^!6Z&[J75W;;8-A]28_/).R7OQYB0)E^:7:3W7OB"[J329/"2GOV$;U*BIR7
M#JB=F[RQ'L[:2<OS1.P/@F ?=U"KXH3+:W0SOLAVVV^CXX6MU$^,":7 XVO6
MCB%V6P%.SIM=>2KLN^&HLEZ9K"6[);-AYR,K2*TTRR@:2#5PVD<$@+4)*NR7
MQU!VIR)RQ6$)X'>&A!*>34$92:1$=-H%;U'SUD:);!&7IF6L_:N]O=RMZML?
M'K^JZV0;[+X[8"K5=I^+DFEO_A\JQ,G5WV[%Y(IYV0EWT^4)07ZJS^1<:F/-
MH$6! CM0X4)EJ+$BQP1MB/'8!&VF6@&R #8"@H*<K>V_XE76+!+;N3:[JBKO
M="1+KH/?5I0E0O.(!KJ U%P":=C/:M"\[(J&*I:Z*VH]H3$E!P.T)67 F/(T
M$D]BCV?Z-K;KM; +X)I7W8^/[?LQ_4NWUI;[47&N7*CQ0^G)>:8#^<Z8HF%1
MRN17B3YL%'J@M_"\)M\4]Y)Z]K86$Q-X$E2TLLU!KJBR^7]ZD:Z727DC.L9%
MT559$5$C56BLOT2W1?JW3WIM@$=!1[8V6UA7?FBV^4/LOA&64NZ6WBC:%V=1
M65+KNN@4427M)<0)QQO?M.GVC-;*JDMK[V3P39!$$L*""(*?B?KP>>*+$MEC
M-,DW)HLCYNDYA=UNRF2$4[$:J:7)T0O11[KD>S0MQQ/\0?5F2=X=M6FVVKT>
M:]_AZL,M-FD%T%N\;NH>$VA.*X=T'8K67Z6FWJ7!%#J3%1J#I>;==?!"C,JB
MZE:;D'V7%7Y_,17:V%>>$WT](G0-)(I;>Y.-D:)S[U]W+[CKPZU:9CN&XV"*
M2N_1! 3TUU>*62V^')!T]]EDS(T[&P"2ZD3;N1%YK;&_VX9C, KKS[H,M-CZ
M3CCIB  /B1DJ"B>O!9#HY@1-DRYFZI-K<ZI66>TM.;/FE,H[A*T+>R/S0>?.
M^EFW[?D1VY+)_>K1#8GYDE6)!<80E./2FC2UI-4<:X2HA ZU"ZS*"ZM"CC;+
M+8--,@#33+:"+;3;:(C;;8HB(  .P"*(@C9$1$LB?B)E%J\1N;39[),28[G)
M1+D8*/:;>:)!<9>!1<8=$7&S0A14*.XCTNA37#*BU90[+X*JJD.226!JHL#L
MXW8!>$>.PF@E!K;X_5SY^S[OQX+\?5BF*X:DY'96(?>I'%)6EOZR$4*_KY87
MT1:7GV-D39=_7LF+[H"K?;L_JQ^4#U"MKEXI=>_O]2(J\[*G9O;X^N_/^K%B
M1<:+_OP@O&+C1J@@Y9!-M>X3OV++W%I3?9?22V@VFD=^:?#'SB?5>_[++WX]
M%$]B)]S5N@=_K7PQ9-D_%:501DMBO5WE2_M:-/G-FE_\VO;'O0I\)P'([K#_
M *.^I$/MAIY"8**HH.)YHT[0$N.#683<DM"@,G8)+2> 24T$2;JO#+6"%?L;
MJJK,H/6ZM$V4F&^$LZ.@<O-H[%ZP'*Z,&IV])A/3,A?;D15;(N(K[#K!(A7V
M4N$+:Z2Y@CAE94NO?CS1:NPH=GTD(MTV[1-"O.ZOBB]V]\%Q5 4LVJJ:M]U[
MKK[;O-/2-O\ EKW(S19]41Y\AX84PY[I."J;H(,(Z*JBILOFT\1[U!ZKYA6G
M0D%/P>I1H<NI.HG=P1T.,D7*\E]#&U^ 5TN>ST@61W)^GZ$?7;=I\'@:Y<T1
MLE_[J(C\9U#^=PVR44_G("_T<--=7F +VR/:$017X_MO9%!8\QIS6.I!X@(Y
MOXMD6M%1;H0\TMW+LFQ(OO3QMX\O7CN]R_V?M^XO*UM^5D3U^ IWKW<[+OA)
M4@$6 !<[)^%$*V5M+730))9Q1(KVTH0EJ1$ .R(II%!V1!2R(B)RV1+>KY3D
M28R+[#G,2[E[C D[3;@+VA<%1(5M8L%):0I5.4MI(BFIB_()(#;2O*SB(C1W
M15("V74K79^ES3X_5RYICL$/LY8Y"6_TL6,A%/HICM67[<:D(FR\06WZL4*B
M+4)#,4NM2I+@$.KA-Z6]-RMSUK>WUCWOUR6'5J!2E10XO]\520(ZF(K=[:B>
M+MDNE11._=%P]4Y:<,#74#7(&& _)CS70#:(FUT6ZKO? PX:*L9A=*%9.VH[
M*YRY=P^KVX?JKPH75T1(X%MQ9KM^KMVY$B'YYU4]%MM;]V#0W%<TN*XZ:KZ<
MA5535?9X=RW3']O/PY+Z6^_=X%>V(>8\WLOTG)R$+[,8M4>J9A!.T*14V<A4
MQ[;74%4'7V5M3[JZDV+$IE+AQZ?3H+(QX<**T+$>.R'H@VT*(@VNMUM<R4B.
MZK^,79&90IYF0V":VRW^;<4>#=5<CDH\05+0ZR2J6 A<"GR%8$A%4>?&X 5A
MT^;6XIJ%-T;,1MK; KBA W3J=NJVUO2BLO+DC;=^6Z:TLO9[KXWDPX7_ *'3
M]2_SIKLP?>@C[$Q^%UFJ'?F(2G(S:_\ 91."W_1]7)$QQ":0S7TC--9E[3)%
M+[<;,W]W]6%18Y?5?]FWL2V!:!PZO30V2!42<)UH$[H<U=3[6R6$'N.TG)MO
MTK)'/7"GKOY.J "T]J2U^KN75F7RW**;I"F[C0+V4^M?W;71;7NGR!'Z1(GV
M_L[_ .2@HJKL(,C=/I_-2W96VZ:E%4WWTCR-0+2)^+I;F?>J]^]D\$[DY)V4
M7\75,N5V($REU>*<64POI6+M \R5KMR8SHA(C/CVV7VP<"Q"F)-"J@F_!=5V
M10:QHTL5BF:[-OBJ7$93*$#<^->\=[DI,.1WG?EV=_O>19MW\W?LN?R;_5?
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MK2]R"MV]K#H3!1YD<VM2^:4ALA[]RHJHM^[0KB;<^Y)<1EVT)B*;FJ_\*V8
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M6?4<2(D:8]#*CC!$;(3GUX<+ G9?J\,@QQ,'^$53#X(G$'%)FY %P""GR"-
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M7L7[',E?]/Q.T220G$QCDM*C%O&D:<U?)N>\K?YF0W(22  "A[ #OH=V^:H
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MK\@/3>&0I*S;J0: R)5O"%[>=5C:"1$2L!U@T:22( $@/4&*0>0<FT#6$VU
M0KM__M DSJ47F+#,M+2UQ(3#!D_/?^L6C97<!">.#=DDI3/(J!$A+(.2&JFR
M/:2V(0'.D0"Q801,H!(MY V0RJ%==.$F;+0UQ@2LKFJH$@+T,1&Y#QD%STTH
M8("A$X5IR1 DAU2$'IA1)R1%S$XO3JDEP3.QS4C=U9)DW5\<\'3@:\9#491X
M[]L].#7.$;UT_3LFY<G6^N!RXH;Q#D5@ H.XD+8++"@[C$*OZ<(E1$_9;%@
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MBA?C11/U%)F,*]X/PM6(D$FHBSC ]!#Y3>X'J>E@.K6C[S4YGHU2MX6.@9L
MA)KP:\#;?6.$2XUGXS;I_/M89 <B])=F)@5M&!%1.&0^H^I^?O(].@.S,GV?
M7+$@-R+?RL#L8U)G\QD60O$$-YPOG4'Q'",EP"P/['XC&NQYF'V<WGN*#>F
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MV9N=[(*#Z!I"!V,I[3[9"(,4B6G)C0HV4B6AKZR7]O8/X='<^[&4_0GY)/\
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M.4DL K&!B@,U#)I&38##NN1Y?0F,<A.&T6+4I!,P"#!XD !9Z7J%[A+%[UY
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M95 _V^["U853#!$;G^[5_P /E(.%0N*)2'4X*6"#&1\G5A(, G!',)_/'O\
M.I#F<=Q,'!QH0RD#0H.&"0)E=H$B0@5'PNTO$7+1I JD*)>E02R-P,5TZN.,
MSL$QV)92M<O'"ESRM1;<R]#(ZS;^#]WXDW6GM+6L50GZ4)H)2;!,Z^A^?C]X
M:!B*>T]E&?)X$D(ZL"=\N3.&[T9IR0$VI;]3)0P#N$*_O+AMRD$_[FV48G3'
MH/ODE7J5_P",4 \ N;X[\8R)8XE$=H^_KFA3(0D:W<5RX!7N1A@H$(16E0!
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MKDY/RO[R?&?'N/ZRD+$L)8&=<M.S@_//M&1QFX/[90'N%B^>.F NS@LL]_\
MF*$2X;8K]J/:\4$H1N9?7>*%!V*W@"@>:^P$XCG+<KSV\0]\%J@G>!/[G.M.
MRD%64'!]\.H V]('HE5CK>2D!VSQ@I;Q:;<58!:0K0:!+<F(PHXNYE,/5B8
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M5>Y' B@ Q%.!X*F:):X_?A[A)/ 5E D5M15F])60VD"XF^[&HD6P(\C(43"
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M$N$BX)%, I9#P-:T(M" XT#)&XIXD@0BSR@V :)@T?U[\7=3?];,\\\\B/\
M)*->$O)6$N&3O(QD7P54.#SC?) F267@*RR!KA"7@!^?GSO_ (4EGYYZCLJ)
M%&<A!,J4I,LBG>0'#<D(1:7*4YXI#%\;(?;\=2^WU[M;K?V*:EZN48XK#))5
M0L0)RH.%!,!PF0N3F$<EFP=;!R$$25K6/GQFP5WDX3)<D*+0R % 7O-7 @1Y
M,1!?(H9V#U,4G:P?3MG=/P#IZ7_>?<Y3/4!%8\>/X ?GW>ARW^\KW)81.R)6
MC$SPX7/@LYGVL*" 00:/G%?X4*-R=%.$]=J9.8HR3G\Z0"2,!CXXXYDDQ;!P
MZ(O&@#W\?>&$["9A)S^K)JGK]X_"2=]X#687"W-&\#89O'HT""43[<=)[)0%
M#DD. 37DDPU)E\CE(%#ET$CB*A2OU+P.HE1KB4Z8<M ] 9=1SGBT0\_G&?,Z
M$@5.1P$R &.")*J;XG1=I[)X05O0E=CR ',#-[U<O1A>+K(-58D10 T=/\;+
M]\\)IKF^NF2LK;D+I,F#2:NDQE!!"1%B]+ B0EHP]C3E#.(I(PT5A>JDJ2:\
M/(7UP^341NJ9$ZX@R.O+IL&](<H@P45"AT0Q=7;10P2"H0 % P2Y;"TS ,JH
MHQR?7 EJ1NUHFPK8 /JB);681^=B9;I ,";N"D<0*$@A"VVLNL'Q9#])D"H,
MA)FQ-@7E%"F8)@YRND@>TQW.9*M)B#13UK)4'DE)1)P(=MK,0D<X"!]:'?\
MWSU-UJ[,&.\!-#R,D3-$1B0K())V954.@(\)#+#'%$]I6=$P5Q-<3F5,3R)4
M6XVNUHMP4D"!E=$/*YH+232A)*+LB3JX '5ML&(!,(L'$7A&H:8+&%*X6OFH
MC$A:JT1\<0F^D><BRZF3O55LP#)S$^0S\Y-+P\4E*)7UT"!# R+&"GU[(8BH
M&.6/O16[Q3;G+ ^$(*H@H3AZ.A55@1_MGYXUT_R(?Q_7LV='6W%]B@5)=(AZ
M< 5@)%;(98"%(N="B$1R()^AJLDPFI(1TAPMP'M'V@^^=K[9LCY,^]4&*KHZ
M:W?3GJ=H*YT2X-@DRZPD4<L3GZSW)X\QNB V=05DB;7YY4!EID<58&([I)D#
M:9AGE"6*X"8U:)!P0R3K6Y$XE(#"ARL(\@H, #%T2!A 80("->?GS=[7_&D_
M/UKWG).I*O9^)"1N"L*C/@C>4(D^[RQ$,?/;9ZW%Q?U*M<Y+%X@!7#0KP;W3
M,ZP@:^@!N&QE)$ X0&P223 --"Q6*=<]9OV1,)93S 2) -ZT,)6*6<ED_GR_
M6<M';^Y\>A6-YW&PHFU( Y6X*UO +#(RA=@#O??2,998(4/Q,&&2$$2OEE^&
MNKM5*_XDGY^F3[8_0VY](#&="B8NW#;=29(9R-">1),]D4B!U9#9)[*DDD&
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MWIG1)4Y0V,-R9;G%R&X"E%[.,(++0=D4ST[RQ]LGHR#(=_GY]9N\"/GS[?\
MPJ3\^1Y+SY:>A9#4$.R29)RT6[7C<_Y<9+ _67!U(!6Z$V$0=)SSGC4I$W8?
M;S<=A]$>K.$A^3Z_54?K\?[F#OG#7CL&#DN"-CQW9T7U)R$L5!LJ0=!"":,1
M/+_S3Z=-6R/_ -\A_%4W'.S1I)B\B]?,HPS4D,7Z()0<&>MN40)O=5!8,3.]
M'.:K1L;ITX<1%TH+4))"PLZ&#P&*SPH$0.P* <(=V97%+RQ4S%A/ ,-4O0Y%
M \)0C>0D9UN3&A%0B<K+5S-;*TPE@+$\$0Q67X@24"LI2\GC&;;I^*)> )&0
MUQTXVJ7.Y_J/_P"!P?:-L>VI[Q.0W_=>.GI&>24GXNYLXXMD<@^5^,CY6,H[
M>.H].W[V"14;\_(]-=# CY\CT_\ \&*S6HG7^^>PQ&F$!Q/<><[UZ QP]3:(
M$KT=@("U9KQ9]!IL<(NDTEV<1UFB("4A-2P W JE\F$F6<8[HQL-G*)2FR/6
M0K&!6:QG(8:>"F,2,7TG6AEX=P#NG3P8UY9'Q8TR$:2APWPY,:[PJTH@MHGU
ML-Z)95%$I3#B@)@N+=^#E\IW$P8C3#X"&W%@Z4R=ZZCG0^2F0BI A*(K?B]T
M2EM0=YLPE&I84)W$2:Y,3(TNXQ1R6]':0Y.A*)39K!GD>Y[G+PGG?/\ @6*Y
MA?;W:J:=G7'M>,L$,\XA) PO82\B)?"@E%P8 M:517+I8K@W/N8H2K#NOIMQ
MB&LG&FF.+6%40Y9GM',3R04F)*B0+F1LS$?(O]=OL2M,W>Z\J+:H<&>> "0)
M-#IM<^TY)/776 V&IG/PBTV1)W\C.A>P*=/[-'+OM.^XG3&](9G@K8L0) E"
M#J@X==SV'2Y &V-];\/+&B4BY'HX+_:V'@9G4<MP&E@SKBO#,=83T,:').'=
M\9CKX+$*@83X)UZCSPT))R@ES?;S6J!*HO)A*(!*&4;7[L4"I/)F;@5E;64,
M8HFJ?."'ENC GQ\8B?.IB6N:UGTU$LQV)9"=U&R9"?Q9Z/)W^PR'_P O.2;&
MBX-*Q$K6$Q8C .-'%!HS=2R<Z&%*+.4\*W!L@(1C/W7&YR-C7I_L>^J\Q>(4
M/^'09!-TMO\ "PNE9VL\&<])^K8YW++,2+59TJ+IY+?EPW&9*4C="' F4J$F
M1PO@SE3)).,?PLV;^$4T>#N@5KVG_@==#"A<ROO?>WA+.,0 >\#NRDB=,"R8
MTR'",PADU.),LEQ!Z_TB)E2(GY>.3RAOFL,8KJSZW9!((B"U>9?J9GM]]ESJ
MB:M>(BV2S;8A68>J^P"%!.(C.0@B]D(L-NH42B.H1-?,.?)*<+4HXDN,2@-F
M:3)>+F<DS^9JX'6,9GMEWYR;"1RM" @SRB\!4G.GHBU0I41%"88,)K'(#6?K
M6D!@E?\ 30< PD/D^*L[.!@F^06'\2G 5;7L9<WQJD\3'>1+@&1Y);*;G9*=
M9K*WL2JQL*G#;7)DUXVQ>^,ALX.BJ#+VO"%%K9IAH13FU+8F9EE@=W"ZRXN8
M)$"%,9C$]*+- Q&1>5( JGN=FQBM@FFVO"SA$FECL:0]T>#(P!9+E_FX*UH&
M30"ZX](K"D26<G_LT+#XH>+(I2?]]-ALB>C)+$__ "[)GM''HS$S;:+2-127
M14P -7 OPK#$9<0[RZ.&A/56XLH/HPAS(5S;Z#*8LF[A""!)0$CFFO$+.US=
MIE<Y6MN"+3K]VZHS/#1W];T\%\N*-1N9UKR"+4N5<AB'*P(AUA FJ3*5D&?T
M&,1"N:F"ZVYOJK2Q=B(<F5U\D8S'5SK0X_IIUL#PKBH@%4[],-K"2DETZX!$
MRJY-SE2056DZ]-I"L_P91D._O,[VLO-77$9ZMSOEZ]>@-! "#!A_.R&4I"29
MJX\V4I+B()N3?$Z:CC9JQ,+1C$OKG9.>:@/;1"QMWY#RIJP=(CM*+)2^BMI2
M6Q0+(T#200<$@#FV3EA3E&T#1?+("8L>574H#H$$R^.WB.2]?83$T*>##U%2
MMY6ME:?C!0GM_F:@JX2%G(%189O"Z&?5B<LO-V.>JC"?.=DBF$8>&#\@8CVX
M]8O?("\H3K3G,P/U'*7E.^! LJ>['-1,E@I>,79TIDXMA!&3+P<QD+#)0Y>]
MT@N5ZEE"NLM0,UFRDS%; ^*,5")5#P!AX_LBS.GT2$MWD*ZM0#7R;?=OS_ZO
M_]H # ,!  (  P   !                             "0"2""" 0 ""
M                                                          ""
M00""202  "
M       "0" 0"202 "20                             020" " "20
M    02" "000      2"  "2 202 2   "" "" 0  "0    ""22 "" 0  "
M0  200   0    "222 0 "       02"0 20 0      202220020"    ""
M0"0"200  2"202  0022     200202"0     """2"" 0"2     "2  2
M002"    " " 00"0"  ""20 2"2" " 0 " """"02"220   "0  00""220
M   "00  0"0222    " 20""""   "2 """ "020 22   "" 200 220  "0
M" ""00  0    ""  022 2"0     2"" 0" "  "202 "20 20 0002 2002
M0000 0   2 "0"2"""      "2 20   "0     02"200"0
M   0 2                   0
M
M                                         " "00
M                                                  222"0 2
M                                )            0$][TV        0
M22 2$0          "0 &=         "8)!,@     ")*10"        "[7?<
M>@      ""  ";^ "00        TH52          M>%F     )RNF>88:
M    - SZ26"B       2 9K*PCD00      682_-5_4      2AIU( *]D
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M       &'ID.5!      !E!Z9@59    %#(!\B@        D4>\7!
M$@  G  $DD       "@TEL7O       *-$^JF)
M           $    $DD@
M                     $@ D@  @
M                                 $$$D
M
M                                                  $$$D$DD DD
M       @@D$@ D$$@
M$ @@$@$$ $   DDD@@ DDD$@$@@
M           D@ D$@@@$   @$$@D@D  @D$ @@            __Q  L$0$
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M)2W5UB:Q9T.UKX]\49"Q-PN])\YJ0<=%%T."\[1.&CLKZJ,=:]+H@8:M^Z#
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M"]6&E$6I*!+&FL%G'4,"T5-HDB0S"9RT4C%^V:0%DA$@V*&0[9*,(0S4A0*
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M\? S13F>)D!;-T >[)F+"*0L &46-D%N%U)4E)27,B-.%K(%E)T"#0I""+%
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MR>'O:E6$6S$<=M7OP4Z0V",STU^2M1?SD9H%30AWQ3EZOS2)& 'T.C]4SX3
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MP5G(H1!I0+Q( >1E,A(JG%.&LNLQ@W : %PPFDY8 F%H8&$006!(Q<H(F&)
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M2S>BDL,),EXI<T+:,D48)FL*O 2"%N7%0 FD1&BJ!(*"S*JF@I@Q<O2F+HB
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M_>V;XJ\6,W#IQB8?:D3#8FZ[%L<1WI<%! 9)%F,9L9VG6LV,@'"ERT;\:<W
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M&$M833><12Y#V GV\TK XW@!D<1N'Q1A#_(_%8M(BVEJQYYYQ2"BES'^8O\
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M_+(98XQ\^=(2L)9P7S?]Z"#/).U1\\?R%0DI''SKZZH6C['%QZ:D<,_G_B9
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M8Z:32(9G:FN?P<:B $!'GIQ\XT,4O)H+QC58J"XVC.=USH8()'297L;:@C0
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M:$GK1/;0,+(U'2/KO&I$' !70B_0]-*3*O/I]4G22),A$;=^^DY,)Q?W^;Z
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M+,0R\(N ]8-U&YV-)("';%08'B6M&3#!!>'!@,@44A(HH!9%A&278P<(LJ9
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MV^^EF.A'_B0@)9%VJ!KZP]-]/6$B%,++) (39,,(.*U52D@$RV4#"4 L@LR
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M:B/$9I.G30(20%JAF_I]73FZ<<[1^=1QASLM8V:VVG3Z6+F[QYSH)EBL2V^
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MY]=]99<S\]_7IJ6V1N^7YOJ5N2NWU-%"<@3#%K&W6-%"9 W#?UWXZ]=380+
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M^SUHVA]--J >61F8P9N(F;NRX,"*!219>#$!)5$(E)*S$ETL1H6V">HT7CD
MY0NOEC6E9$TH=JJI./ZSH0 M!6C'WZ_715!*,I(F8RY[5Z NSAV7TVZKK8-I
M+,2DB986<5<N@-FH&8IQ4>L/M.I9"P&TWW]#[9=$Q<?.9W_C4AD'H?GS/Z 0
M"&NU:#2=$-?X\:SQL 'I .PQF"W2P$,8@/8B^32LO]1M&;1TF#8TYC;?FN\Z
M9592LS4SG,3JV57-LZC$5&Q1Y_Y$++.H]?;\:0[CSU/[//34?['I^'UZ:C_8
M]/P^O34?[.WX?7IH 97SJ/+[?C0 0?\ 3"1PG$'K6HC"F]5:VUS$=M6 0APG
MZZ]NA@[?]$7-XB-O]_2 P1H8U)V.^7WGY>;TP['SY^-*2U408;_$GG6+![\\
MU>W.MY@F$YSWG&WYU05:LACYVQI9X\$?HL[!VK_@&,>N_CC160]'Y[SI%LE5
M-,3GG.BZFZV_UH.!ID 798=L']&ER OE,3$[3G2J7^4:XAG2F7V/QI)BVMIK
M] C=>]__ ';_ /_$ "T0 0$!  (" 0,#!0 " P$!  $1(0 Q05%A$'&!()'P
M,*&QP=% X5!@\7" _]H " $!  $_$/\ YI00C&/"NFDP@1B(9 <CGSHBZVOG
MPZY$@1=S5?%?3SOU9-9YE8NJ+9&#+?4]JCQ!!!#M3;(&8M,1#$1 1-<0$5*H
M&4$$10AY6HBNHFP(-NB"U;>6&,G::02(ET5$ T-6T['G0+@0$B *&P4S#V-H
M#$'B5416>^G,4OEM@5,AK#L5< JSU.^& ,GZ4]3LS7@X T4MI[ "_'IRYQ@:
M(JJ#*B@%(H +$)72%:"RHM#01A3!U &R!$2* W?HSQO0H5 EB8-$W8C(IA"/
M!3B!00TE5!ZZ6"0 ]GA0<>%!6%I9MD*Y"U42=@; 6;"J% *-H4 I$R"KICX0
M6H*!N,!5^R3-4!*.>=%&5P*%.G8#",8?_<URJ'@_C,6&)&V'Q8 E*X;BBH;@
MN61"/N WBJP1 R4\$5N'QP%%.6" Y,;' +Z"7Q9)&7X/;UX<@L8P=PE\DA.^
MP>$6PJN.^3UG^ -6!?&[7G0-LK-KD@G+^=Y;7DI*1\%%!XJX:6V"U<S[?!U>
MTR,S3F+:.4:9Z/.)PAE%2OQ*<(X7])A)MYF4/NTX.80;,[$O-P.5]%E2X>!T
M &I=O$WY=C;Q3J#6@YW2"K3IGR3;V3TV\_OWTJRWW+4EOE7)-K[24#L?Z*OM
MVE_CD4?ZF;V^HHK99@%@\ +_ /W26!\*"10&/+]1C3@(Y=W'8(=,]EZ#]!Q7
M,;/,%D[^]<_5XZZ3=FM^>1HV2<ZIE.!$>:Q6=8W^*IH$940-+3APJ;WM&'+.
MYOEE8$)'H,YNE?)Z%)HIRJ>S0;T$G/TPM6&1; I'$YW :#(W&X#SJPN)*JQQ
M*8$!;AR^DB@"R4<D>N+!Y&(4N1=%O\<-@PF7QQCA^VW>1VBG>FCNL#2I9MO@
M!V/8>/\ @/APG]>631**-'6KEYT&(="XE>?]&H8@!;U[O]L1MSD&#G/N7GF'
M<L!$;M*( !I*0(@,'_S2((IE@36!05[)90XW1!*B*4G/5!$!&N CV0230859
M?*2]3!*F $%I(BG!)Q,%8[B 1!%="-I05M)<WJF@414,"0$C8.5\ &].!N/3
M-!AQ#=U"GD$8K"@L @Y<<#T,$B]H<I5$4C@TH-C$C1&P8!(0X'XR+$F@%C*:
M!\430;]=;[#."UT?%<91U0$$""4J!\)]URUOL,X+71\5QE'5 00()2H'PGW7
M]28 E71 %$&H+"&<X=1'4-0H0E@65($\4Z](H]%8@EI1#% HS@&$JQ!<=#TC
MXTHA[!)UEWL[ [H#R2JPD0B"RT0Z/I.EAQ!A2F#I5A1 Q8,ETXNRB5LHL49>
M6B$1TG94 (@/"DRHE.<8@" L#D[B:! %(@Y3%2&K% B@]C0^,(3% "Z :(J0
M:[$".5D4H)1'-!-'7Z%!( *@B!!#031A!9U-X3&L:8F'24B:()6E*"D4,W,/
M8/VJ24-#^D"&HG23V+V,H*2-#N(C$3;!-N5GY0!.W)T8;J$8HN==KJR]"IJ4
M%)=(H@$%P)"P-AE!?&-F9A6DHA($5PM^@$DI,FKU&M])+BEU48',Q@2>;!J'
MS,?K@9H.[?'3R#(/HXTH%@<=)93:%^OUH6,ZQ4X4 VKVV2^6@=<-?(NK[DDC
MEF$1#!.IVDX;!(U:J?>O&0_;! IWT=QW_$:,R$(V3("X]QC2&QP5!BI>I"&-
M; .7SA>^@,4R( "EAH!T/1P<6DICPU7=!.+ &Y$I]A7GW'.QW@@L)M16STX9
M=F,XZ2QWV$PA@?K 0?(NX01O0TP[T'OFXC#"8&] #DLA8(+<DU66H@@H!:H(
M'D::1%$MGJS*D9LLK^AA J%"5Q+BPW5DH:H+HG8K2.! *XH%AP54@2O0$%EJ
MJW)TW P5(0-+!E06*BA:$BG)2L&&K"HQ9X#Y"C.0K^2XH6(TV2OB4J1J=)TO
M5U#K 1 1^D1@IVCT&;N8%HA@BJ >DKM!&/50@&J\8H839T]8(*R %C%"HOI1
M(D3$P*6L 001%_HL 2KH@"B#4%A#.< A 5Y"L$!0"JAY"!] 644U;AI2 Q[0
M'@10%1%:F]"J(5":*8 50*PB#0#B[)L\P%D"2H-4U82I8)5Q'\(MO8I2 "'U
M1]*E^A22V9W%(#'M >!% 5$5J;T*U$" ?"^1L0+1R &N 4-'R%@&H%%(8$3@
M!1I>PSWFHRQ1D/70AT@;0:L+ ( N@$5=22[)3(4T '0(Q3A**^S)6#!V-]((
M)17]#%GFOW.<+W?!P@P.,NPVF_OEV0ZN/$GXJRW"+QL&RGZ5&2U5MPBW,T1,
M*V&EV5$9NXD^I;&1CL3:;<_SL3L9_F=>CN(2_%9' #$CZ!?CL)H6UZRXP&T0
M0*D'@8T>"#>%% T&2TQ#A&EH4F263CBF7&>'D-CSJU>&7^A^4&G:M#^]68#5
MQN #AA_66SMU6PU+^AAC77H=\7[G@T\_%X5-B9?.L#G</$%*"[3;Z4&ZP->,
MZ#+X0@: B 1D<J*"Q'8 =/Z(T8)"8$%816$0&'P^I+!@N 9\9'QJ4 (_!N"'
M?9LC^SXO+I5?2_0$=QH7K07:\$>^NSW%9R'8.I0?I:'P?:+R>CI^$)]?*'6?
MMJ#!+XV@P_FS[/(V5GV"7 $)7ML*?X+ V"_M4AOQ-1?@K5A7)[8E_AB83N8+
M2Z+=YW(G-KR*TP893;T"MXB@4U+A]$A)5##BRX_K3@@&5 ^7,,59M"-*$5 J
ME>TI@QBCO@?-H-#Y)0F+&6:A90 4P5)$/S1FQ$^!>$54$2M@H!HU213 RL,"
M "E%1%*<"Z=QB&& :&?8T:(H!=MK^@38@ID+NH!1A$"@71Y:1"H(TW 68709
M4#9XH9*00>^)<+(W8?5P'LU&" *)1; $-\)31.N\M!H.G<1T1^[_ $B1T)JJ
M%(@E*@ J^^"ER "<WDB#B:0D3$N*&#-UZFX^=\L&M]-7 Y6)LO0&OUY?TO1C
M.(P^RORW$AL HQ357O\ 0Q2AH>%GQK0]PY2D,-U&2YG5'4R>(#;!7-,)^?5]
MZ]UQW[*2JV"2<9M3''!'!.$/KCQYR\:E_5,?TU+8[?SNR_XPY3(^']=:_3&W
M2&"C8]PZYAPCJ6A9=4NEM(#Z(([,GC*I/BL*MM (,&I&[]#>9".U&636FZ\N
M\MXN=P<Y5\4AV9% 2%$&-!H)*D_T5H*!$:$P!TM1,Q'ECE^$9V_%\V<,^'92
M+LJ]G 1OUP*@QY*W]7?C@8A4G9UK81=8@\]":,+(7<]6(<*O[,1:AP<I!Y]
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M4H_3A*C\^RI-!/RR$ODCBJQH"5(05.335(HH]$22'90 .+TA!*.LN":Q3D.
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M![T1:58P-AL<)>SXMW92\Y*-%$@*T*(JM6@T2D:7_43X2L?,])_5!.V"DE?
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MH80&'7(+F@) IF;'0%'H<=O/O&P$%KB:%DP518@=ED%/5+G#;)! &.+!$$>
MI@8.07NAX)5QJG$5:8<KD0B\UIFS\%873R/P&54W":9S2&@? T5(]56.QE$C
MG6LUD&>2$%%1$2PL&11H 26 IW4@KHD#A45[+)"PB&E>N02(^T4(R#E\:#0
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MG F7$@&%"NBZ%7@!Z0"'ZU=RHM0O3<ZA1L&!<!:$^$\Z4$ LLPH H5EEA!8
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M2X#4# !0\[^E?\/.*TD=U%% ;M>[;>12'6+@\ZUL#QE_':]$/D*UJ_1&EJD
MK@8J[Y5AFO7.EP #85Y PF)O*"KOU4@A>,DPDN>7DH32P<D-\NO76,I7@YD$
M \'.E!IE42(4;OC" ;"*8T6B(,6VI0Z'"6AI]Y\#^_G[Y>5QB0W_ -D]?$ZO
M$7?T"75,?'QPV*@ 01(4#".C"8<%!G,K0ND$$]7-FSAQSFQ;>,6FI)6YFGF(
MIG%X^/Z^\DJT1<7@1+9>[@UGE@3P_07Y 50E%*14 51*F8\.>79I^^^9U3!
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M_D!9S &-V=H6[-!?,92J44R!9B.)]#=-TR@1G:0>P5+IV #A7<\-:0%>%$:
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MH.IH'!+;J*4((Q)5N(+=1DZ_0P"+'S)[H0>QZB60],J$"+Q#?@$Y==*^H5Z
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M()[;M\C-X.QJ4(351?8:A]^:3!0&5-OX#"'D[>(I$-N'(("8KKL)U%E-MZJ
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M6YA I)&&XEDJ_&#BQ&F6&#YA>$1R*!1D9ISD0M@A\# %:>IBQPEI_%P1RIL
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M^[J5..A"0B 1;[HC^/BG? G4C2!=[^^\OLI #(&DJ(X)(TTED8,!EUE'P/!
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MVO(A.=T'D0"]F<01H!6E10U!!4BL10E^\:4&I3'0.A0. KO"G/#V>'"GFU>
M& 6Z0XI)6#T 7H<VG1@HON29UKYD!RV !ENZ-TQH'P#50@9W[V"0; & 20H>
MU/8B]L%5.(!$Q!" ,@@HIW1$8@?45-E@.L=L#I=C!GJ*YVT O705]#X*11GG
MKX4_U^T_0B:%\_ABB-/0V!..5,#!0 41[W@C4(8!'0J#P!.21G\^WXZ?D>?X
M'^_T >[?]<M"!1% *!EH8 :*=-*;D./2U&)@\%;VA"&ZA6/U  O*$3!L6ID$
M>*(#'HQ5!5AF%"N<B8 ]PBJ7D^2TTM!G*]LM @N<)5!VW<8A9-9Q0SG0#U'/
MC]&.IC9 @0M]9GXV !J[MLJW=U\W51V<NZ!GC_?S[?IXYUHN@#OFRBAP\SJL
M_P!YX;:=VKW^@*U2)@/2#8W1#06Q>"H!K:J>:2<PVX8$4*HZ]$"4+1PJ(T<N
MGOKW7UT#S+: %47H5^8LP_QYXATN4CR_''QU^[5U"*#>BWHD_**X+ X2BR"'
M!2OA_P"0\(L.(9!QAFD!%'#@E-J1%H[5KC0!;Q&@EHO"2[';F<+OU?4+:+6!
MY@@(+40&"J)N33^\$%[-G?X<@7S^\YTI-H41P4Z"%6AD=XO=:A  ?<82%+4/
M X!8CAQIJLI-B@=,$]7.+HH[+Q6CU%UQJ0 < >7A@Z"^6R-KW;U"0 G-XIY-
M'*P57L;07.-$,9B?"TJ+U$2J.V$+?9!3KQ(O*(Q=VM=>4%J460*<'GO&;YP:
M?O\ O?T$[54I =B"F"("=G 5T\-5N&<D,,":85HHKZ-[*%5<FUZ%@],S"#;D
MC:B/ P!9?M 'PNAD)*!*BJ.9DI+H()\)V:GV@*66"ES9CGF1\X_'$8PX2+@;
M+#!\B'!#.@E;"HZ(A5%*BN$XQEX6JE0*W7]R$QT?;H^?CSP7N)#*[U\_/[_V
MPWX/+W#Y^/V_NNA$1GE12ZU9& L7@")X%2PX2J":3H+Q1]"1"9X!Z:F=<S"\
MSV.1L@<%A590N^$3VHB8!'D#X]8/G+9$#W*KR$<6BEE:I9-7QT'"L)U*IN&P
M+;EKE%8GI5R?NT !+QIAOJ98115GLY"IKT/O,DTL5)>U)*1O#)L9*-HYA1,Y
M:C3H#4! E4(D+V"TRZH0'"KYN(&0\"O44#NOCO@HKOA0@.K:OH*H(C%VT[5M
MX$TY7U<"S+H5:Q"Z!B3#!,S"!2$'BM:$ NIO%KQ'D8@((!'N8D78#VH(FZ+(
M&DR,(I@'I JU%TJ @00@>D6T@AB2A1=<7C <0=7M.-)R^.*0#8-=Y."GR8RA
M?*G!TN9FK<[)I))%)Y%Q$Y= *K .# )!Y*KB40Q(B'9ML9/B;P7T-  %0*BU
M-#TAG.P<R@R2$5)-2"6Q2.%P!G%*D8CDIB9DV*+V/UBA2IO;O_[]NOL'Z =L
M058.5[&-P]]SG<]B.@B;0PIP\J!=X)-1I1"%OWJ=5L'80:PPH-4K:2J%, *A
M4 =PR7-"$!VN5]$1,[%WG4WT=L[!^/?K@CI"-$T-&U:PK"PMD;^7ID7'L\H$
MFW[R]09J@*\+P(;:CV&_-$D1!$S("?0\F$!AG=_OQJO(P S"[UZ/[<8173/<
M@?E;\22<4!!P@93\*!2%AW*JX)5]*6?9_P UY<J79/M*B]6&0Z Y#F_< &%!
M5!!5#EP(B#SK: 0L1J\-C-8<P"RC00B 4K>0#>5<.-)TY% A[ 011[D [(G:
M>&"2J48,6IYV-JCP66!8YA#J!38Y#-5556=WH@82%K JM7ZS;TYZ\*^1[J/F
M.([P;*PH7@5?&3 #X *"0!$4&DJ"HP=&"OU2;J-N^(]G77\O,S?5.*D;4"E:
M= AP2-RR05YIR08DE4D$1L 4I5["NBD A]3C\'9GQ\:;/]<0B 0M$8Z7 8+D
M*]PYB@14&$\.PI0$ 1HNN#WC0V$0G ,BBJ,3VMA<GK<6VO>T0_B5@.F)-*H2
M.>:'$<J;"E+N_P#J TB(R&E6>93@F;$12@9!RPTHU*P*U05UBF"8IQ=TQFNE
MITHB1[# &IA&\9$"')AF #\96=_ABJA."*E*:92JD;*$583C#L+Y!_FO &5A
MMRI#,SMSO]IO22_AM*(*LT<+,)008]E!U[5M555:_I7?7]GF"&F,$M2U&!M>
M^A2!)G JD0^)W]_W9OQQQ5:R>/'@\S\^YR-14Z\?'Q_/?$0"#V,89UQG8"]H
M7P1 (DKMB&:3%.AD0D "6<FP(^>HF"$T:I 4=?.9#4F* J;<'C*2$211<(XZ
MR?4P*"&.RFJU$!O2""]:5Q^[I']^V20J5%B9[_/7?GHYC@3<#?BZI%[OQRM!
MOD" <3:CN" &$@.W"B(@>0BH!-&<B[8"C8^Q,O<0MRTJD*=:]_;QRM[U2IV=
M 9/FW[\[-,&B!:5(2FA(A^=(U0<CU@6",@L8F10*@BX "!7Z =GH?L-'JW4!
MFM'#B"QY>+:E>C%XNG(@-V-2E!H'&AA5D"AX5F<!Y (0M*?C$FHU-V,'%Q>[
M=V!ZV8%6)SOH:1X0!M9C/L1.1S- 55 %PBC+  )QK1PVM4>5D5<>K"HEER;4
MRB]2^!*E.V!P'N@X8Y-Y+*A#.'R)X,6C^'""8JJL$!8*LBO;?:"XR**?"A>&
M615N!92P=83#OTG*T[>$*I8J&   ,(IKG1V@(;YT( #DUP4#@90P:%5%<<05
MB>"*Y#0 #YD0 H%B@N48B&U!F@"?*.3R;TP6V;/ &/9K8*JE5D+0'';.IL!-
M&HIXN"K1*@9XLM+AB3N3&N$@124$;6HZOD.L#WKF?^."\,*R DTG1T'++7MD
M:;D)D$'1K\<$;<E0%<">6?C[BK\- )5(+[( =<-&&A2!H4+3K"Z=.!"@HH "
M0!U:@!UA4J@Q8!*UKHI..2T"ZI$YVP\+*W$B*0$2H-!\@3F5(@O!.IY2.4J!
M1:)0U8O$"(BZ/N*?7W^EEH)0:?:I:9O(@H503@5C3X7AV%73%8+Y^O%]TUAI
M%$;D0$JO0*I$?J=5"&?J<!S67&T@'"+'4,$4'VU 3$MM1"S+PL7,(20,%QI&
MB *BM;).5TX-5*1T#>D$$:CD?I2W7?Y_?SQO6"8<ERQ9.?9,<24G' 4)%F!\
M\!#R-6.B0:TUD%P:K^:R4K*_I8P$X3Y5W .SL7M"$\ZDP#V][='OD>5/S_V<
M.!#1&LJ,: !#D4'),N1T8LY6-F67@V-6DP$%"42W N"^6LY^0XBC,[&<:< #
MAU)@UMS[QAI\Y@OE<"D%S)T+HQ:6M0Z(&J7>(\H?DO\ ^<_D//D/C9_F_P#Y
MRUP1)Y#;U@?@R?)51QM\O*=P(^O#YWB0(#+FM=C='^SA5U5(EJ2_%0J:JND5
M2;'I'N<-X"WP,M>HJ";<"J:*$\K]_L'^K]U_2E\K [A3B7IXWHP*-6D12-;%
M!8?5D137KWUR@0Z6N5'NF=(:13%3.+!1  I0'7=D\3KBWQ/WWY:NOQGQ]34O
M7M,K.WQ\?^^2"*R;:6HH&L4.+8W'K<).TDC/D%L !I)R &L"'L".0:C28#N$
MC4GD"# V"'&@D^0;I(QV-U3T-@CD?;0N-YI*\DFDH< & .XBJ6G/*0V"A"B&
M@U&"6&2\#BV#I-W7RHE>&6/F\1Z>\$/./ON;<Z.90 <5J?@\!8?NK^[>+9\
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M5\\/9I3[@&:F.E\<,=C!9 L.@ADPG0H;]G['_>7[/V/^\OV?L?\ >7[/V/\
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MVG?+DGPQ G:+J$6;7$21[WF$&)5L%.30$\,*,ZE5-U<?'#@@8=5>@U:H J,
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M6I1Y?#YXM5ZJL^_!RUH 15&B"%,!$ "\V3>,F L(37(,+WY*YG*X'P_P !T
M'X)_)^M(5$ECKL!$)'8# XY"=+/ 7J#3:#;0(,J6D^P/$!R";V(0(C4?*=P
M'>@,N6X?;_WPF;!EG8_=7)/V;+P:2DO8PAH3R,\_2G%CY#%[K()BMWQ++X%@
MB!9/4T$-3DK'56BI&(4 @(0J531.T]8'XZLMQ#70' GI00"M5#@CA1]B" L1
M![MNCX.").P?#&R2@.TSQQ4H<M=0DL=&+SP2X+C-:5&A)!4<. ,Z.GE%F0QG
MAO+/9 BIGB:)U&#3USJY$Q)JDT78!B2*Q!&&0E #X[=O>_T&O+_K[S@* A"I
MVK<OA2\ &D2(2+*8FX''(Y<NA,:XKT:[C%JJVS(H#%<WXXW%Y:)PX3A0#SN!
M44]-8H=H'ABX._:$XQD]0:&7;W(,BAL@$"<;"@;#&IX3DIX1SG8!(9OE2X96
M(,;5[TXWMR(: '\)70.II1U<8)Q0F72*L;CG+K_Y]R"+1&#\B/!D+*%"8D@$
M/:Q6F00%-"O0"$PZ\% +349 ^[L?2^.ARRX20'A[[L7S==AVQJC-!K"Y!946
M]7T1&/H%\( 0L^57\KK]U5:K> !#ZH%K1X(%&,[@*K ;*1I&36MO$  0:@'*
M<T:-)H4.KQ2F4@DLH3ZC(U&$-@)51Z$";-/?KB#[ 2]2C4W03))5YY;K  ,5
M"140Z!7V;N=0(AHH%5Q$\^9Q<-@.ZBEH-\,[(3E/0W'K@*W6;#SJ #&27<P\
M 3+OPY7QE.RBY*2J61N40P>M)P BX?V8V Z*]N&9;]9\U7Q*YX_!//L"1D$&
MC4K\BE'4A:'T!#^Y6&Y""@$LHI%/.T-:"JE*U2PP%A""/Z(%'S,KH81@5&WP
M2>37(S.TL&\%])HR/%(Z\V,3L^(#0'+PYU!5GB>[%#<P8-,7H+B%&LHQ'LJ$
M0XIQ+]MJU1JIE:F&AN\5%C$-&!XBD!5 O*.=B1%="I!"H2<!]E8["EKC'$O
M#!PT;6-P,+BBH101!7J*  BC>O*7IF46!AB0=1 #M47^%Y_"\=9HK=@#N2D>
M4."TM;V%=/LFZ.% !"X#PDB%B,VFL.U7W=9Z%U]JJJK_ $!!+G18#H!Z T>
M$ 0C[YP2V$&=;EYQ^[ +4,B.=_5"A1*4%M,-U7#%C]0[>$ *+1,/E<V)\3*A
M,./;#7X!*7*Z' 1.'\$D!4+3M8U285V$:UX,*F=VC/ B'8PD/'MXP3/(O"2;
M6'5QNW%)X'&5(!V1.1"L2P\@&D1&2!27/&'<](2MS[_;>>$4]6K>'IKJ4!:J
MAA:S#"0 #Y^AC6- /$1L!8JXD0 T%@4&'@8WD\'TNJ4AC6X,&C+@!  0   Z
M   , ##^B@(01T 5!@"(T1)0?P\8N0FD*<%L(IP,CBE$O#A[K8!C*4$@P#9T
M0+ANO0H-D[_':=A\<G#"@-@="?(6T 0E%/"[#51(">V!TUS0*( %(A" .6<<
MZL0&31 K"K)M! @4A)S(4OVDRH5=*H4U1P.=QU4-BJ%+FJ 2MD3:!-'8AJ0-
M#.K7BQ$,J4B313T80-<C\#EDUR:'A=V$@6Z+:!J8+LK2A  $R3?4CC@(L0N
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MJ6O*JDB%4! H%:0YV#!94V(09\ AQ-I8406KD6DKCCRE<"16H/!*<P#P5#@
M:$CPO#\"4\E7JO<.BNL"I50_TA"/DGA#YH4C$@"8:WKOP5>\YSA.#@\$!.L!
MI\JB+>6=7<>WX!Z *) #]+ !-4? )$OM@5, B>4IDW "/V9 >'0"&#\0:-@P
M[/@F1]6O*B&0B"%,(-#"4(0/C$$$0<X)#6"ES61A2$MDNUQVAX._!#Y M=X#
MTN--<?A$3\)Q7MKX6K+8UQ>]$ 5,XI)"B9@Z1" JX KE5XJ6!\'7* *4(B0
M/GENO! /T'IY]$UH/35@E*)0+.8*_OOB=:'@KJ"!;#^FHC,;/6)EE!(M*M![
M#B"=%'=B8G3S/1(XQ02$Y X+O-^HZX1 W JFT(A3,OH/L(6B  2#O4#=+81(
MH\%TB4=SB&A$X6C<FR.Z"OGD":4"'FPHF.PEIQ.A(C^B:8&L$X)F39V!L\"2
M#*<(3,AF.K*TR811-VI9;J<C9%Y@,A+>5(0TEXI02GD<1)B1,?$@Z6^0BE5
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M@Y$SHU%,TP,\\3OWCWGJ_+DC_P"F6=AH[$NEZ/,<_OCKLUKJU$S_ 'P#6#,
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=YZG/1%5R#RY/=:0& @ JP *E,\HI=4JU_P#*_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>business7ba.jpg
<TEXT>
begin 644 business7ba.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0"N17AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     @   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E         !@     0
M &     !    1TE-4" R+C$P+C,X   R,#(U.C R.C T(#$X.C4R.C4W  $
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M1T(@6%E:( ?I  ( !0 ! "  *V%C<W!-4T94
M          #VU@ !     -,M;&-M<P
M                                #61E<V,   $@    0&-P<G0   %@
M    -G=T<'0   &8    %&-H860   &L    +')865H   '8    %&)865H
M  'L    %&=865H   (     %')44D,   (4    (&=44D,   (4    (&)4
M4D,   (4    (&-H<FT   (T    )&1M;F0   )8    )&1M9&0   )\
M)&UL=6,          0    QE;E53    )    !P 1P!) $T 4  @ &( =0!I
M &P =  M &D ;@ @ ', 4@!' $)M;'5C          $    ,96Y54P   !H
M   < %  =0!B &P :0!C "  1 !O &T 80!I &X  %A96B        #VU@ !
M     -,M<V8S,@       0Q"   %WO__\R4   >3  #]D/__^Z'___VB   #
MW   P&Y865H@        ;Z   #CU   #D%A96B         DGP  #X0  +;$
M6%E:(        &*7  "WAP  &-EP87)A       #     F9F  #RIP  #5D
M !/0   *6V-H<FT       ,     H]<  %1\  !,S0  F9H  "9G   /7&UL
M=6,          0    QE;E53    "    !P 1P!) $T 4&UL=6,
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M*8?,HAU)+H/0;BT1J 4: 5?D" !$5I.;>)V'>KOU8AG"[<XA56C;MPBE
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M^I]2WSQF.+D<SZC,WQV>)^4F-O'DJ@>U*\TK[.KY$^1XCV%9+;,(F33]'1$
M&@!^0(B7E5>FVE8=B=JX%H0(D*-A^LZ*:K._(\YLO6NT9E<KIYR@&%#ER:6$
M@ !>QF*-/K.M;LW,Y\WD;)<WD6-LXZ1]MK5Q4#]+9O2 "!^(,P    "-7T1V
MY]XX/*7HG+U"['V4G[80J=M]8J/>6].GRI6UN!GF[3^1:)^:_16%>?[B!
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M2/DE3ZJTW&O8O\^ZGH;I/B/GUJ_J?/W8^:\R_$?JNAXV;+2D     ?O\
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MIN$]#W% QME\K%R2M)0  ?O\     ('.LY^!6QZ6M9ZW<2*=+#?,_-0CA9$
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M%<;I.@NSY#P:_8=;MGB[MW<::H"!^(,P "97VW\??#TWP?U;)@CF.\UP\_\
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M7-_%U%$E7:_:=GUFU''<W]MT65JY&0-/RG0RJCT7[56CVE!*B>(OHW:(@ T
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M^YLD5D_,&?8V(,8'0XL<H94"@GT*D>L\9EDR\78=;R8 &C!P8*4:%EM $2
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MLJAM0:XE>,L&S1D0T2-=39TP4;)FS11#YEM J9=QAHL<M R6?JU(@ T /R!
M       &2S8XTG(   57W2G0CF>X]57/'I.*V3U_2[T<OO=!NX\_Q"=..:[/
M \G?+I.(WG !*?B&-?@      ?6,[IM[Z2M*O:VM@9?%R1C&HK       $3]
M_8    ! T:..A5RDGK+5,5&H1M(8M,=DI7"\S'9\BXC.@->#,1EHP<8Z,]F%
M"JG18]Y7"TBJE5,=&NI?!CXV3/TM$P -*C\;9(        1(   "J_J.D'/]
MMZ+,^:_3\-MMJNGWTYW><T^TX"PY0Z8\MW. [\/T(=%Q&VX )3\:YI:
M ")-6J-(TK)*D        3&^)^PD     @6-&7!F*R91\<GP/>8Y-*S)A63!
MI\R!]#YG@)2<SH>8QJ5 MHIQ=IFDK9C@RF>(II:QZ3T&<"FF##] ZYT@6X@
MMZ-?Q8UIKG5            "J_(TZ2<_W'RA+F]TO"[9:SI]YN:WW.#LO/[4
MG9Z+<QWODO1_23T/#W!*@ D.'D)?G-G#YJ@               "H'Z[5=_U
M    (%KQN8LC+FQ*WII*.%#%9817#+)ALQ:5(JAZSS'F/B?4KAE\P^7^8C*H
M>PH!G,NDQ,40J)<QFX]9JV93.U:YTC7+X8T50!3HUTY3_,5*&J*DH
M    JO2E>FG,=MY;EWG!T/!;)X'3[W\OON?/<>?V-6'5[GNVZ_['F]C,[6U&
M5 ! L2W>X,7+?$M&W"4              $QE8_1$N=0C("V    ! M>-RD1N
M%+-+./B"M%)/F0( ^A\R<D)B!4CS'O*0 2D3WD3PGJ/>? \Q$RL>A7[U7Q/&
MBJ *?&MGQOE,+E/           !]BZ;5^2JV[F/5(W:_:N6]?Q_A5F.$II+P
MECU"5 !!2R(9/GI2W#%A*              #T&8SV*QE#($K0    $"UXW*1
M&X                 /O5?$\:*H I\:V?'(*                 %;PECU
M"5 !!2QX9/PH                 "4,@2M     0+7C<I$;@
M      ^]5\3QHJ@"GQK9\<@H                 5O"6/4)4 $%+'AD_"@
M                )0I$K5I%TESEXE@E_DQ9Y[BXB!:\;E(C<  &-S)
M-63*IE$ Q\4TQ0;"%S     ^]5\3QHJ@"GQK9\<@H  /B:6FR!D@QZ9#-?2X
M3*IZR!8A:9?)=X*.4DNX %AE^   *WA+'J$J ""ECPR?A0
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M4:Z&2U-7U:P;$&NQ52T3:5&WD=>#,Q?R7U2P@9 -53/9.50L8O@J)B4Z<GI
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MI42]BW%<]@!6\)8]0E&"JA44L>&1\*5                 "4,@2M"! F(
M%G%Y @6Y&Y0XW      ! B"!$        'KK6])XL50!Y(ULF.1%0  0(@
M        $"( "MYRQ_;*@ @I9D+_ (Z2                 %1E"[Y6@
M !X8ULZ-V"0                57#*U7JVXJ@"6BS8W/'2X
M    !ZJV[TE;FJ $%*%2Y;L;J@                $;QE;]\H@    !%1(R
MMU=D5                K$K=S2MS   \L:VI&?C2BD              !!'
MV(W5*'KE0  2EMQN4:-R                )U+B6JU*,9      H'S/$J
M             /2?=2-0  $*(1>.M9*@              /H>Q2(J   4>=7
MS                ]=*?2E$JS5                       0(@   ^493
M(S51J                    $"(               /G!+.7VC!*H
M                     U0['9;6<=KIHTC(
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MJC1%0         "6M86ZSR?_Q  Y$   !@(  P4'! (!! ,!   ! @,$!08
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MJ31T[<O'CBRV-XV"5E",6=DL3!N)C&'HIO\ +R_]O1NG[;=8"(#(2DG+' 1
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M_7!)Q,L7@$T G/K]OQB[6R1LT88HE'\<>[;< A-W-IL[8.LQK.PZ?M"-W!K
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M8@2]0PJA!D=B1B3EK4WR(+K>#&$QR)F%QDR._4$29)G(QKPAQ\9?(\ F0=&
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M2VESD.0Q[%.*L![^(Y$[,O4(C-3#^?D_EZNUXKL":G-@TO62T[/R]D?]-<*
MO=:OPY/8K3P5.=_\JWF%1D4T_/3OA ;PM:(H9.K"NC%SMA1"UZ(,4VL^G;'W
M2^:&-X1VX3C81-H>857D3$(G -S',H="09RS:1AW,>(Y&23Z(>K*J+JX0YB#
M'^SJC6INR3-@4'\7M >/@Q*J0B(KX51-^6=A?!BB"0*NTC$!),3&:./UILTA
M8&$G!^SGJ;<^.43D.@F.(%\:5&EN7>7I@B6:@#&0>'_VN=;B4\>(&,"_^9[0
M91M9Z^":4UL!FX&5KZZ"<LIYPM9)L<2$%H*:I44VZ2'C/Y20 U0*!Y%J=06Y
M4N$58O89IZ? K.FR3@9[I[2<@ZB]+1\XRVK7N1C=0TR8E'4W)_@:">+&B%_-
M!7JK9B@_UVKRX[%.T/KN6-QD805P7=S"B3"]J)KP%:$?.:J@E#7-4AIKLW'%
M3373MC[I?-8E*=W).UF2#89=X=Y,J<3G,<W' ROK'=,3?OWTNLHS*MPLQK+(
M_C=H(IA5_P!J > H8!ACU)RSH\#/0%4RICJ*%3'(2'-(*N7T15V9W+I@)73H
MJBCDBISB*8 J)E8Y^HV<*L6%VB7<6[K3YD8ZR&L7I0Q1?S)0OZ9;$S'M$(((
MO;X5-R$"V+[6=O"MDCJH8U+Q5<^$3++"V%8OD1:+Q-9-V]*&>T"GQH'G&4D^
M)*A-/W%RZ>U']BJM+&AIO9T7/L9P?G!E%U#(W".=]GF\)K:VU=LBJ7#8RL>X
MO757B>8]HJ(A(6)99TVFR^"49BMYDWQ;UFV@KZ?IWAYF$447-9O]<QV:OLOT
M[8^Z7S&1$U'189B5103&3]12(%]I-!Q<\8<G<BJR90P*UQ8?8":^.(B0:Y'1
M$C*.;RL6NPX_C]H-7P+E\&/9%!LI-3BAL.L7RS@H90>7\IRN4H:Q?^8#L@)S
M#@[LYB'<<5VIF^>:82E\8J(B5NG4(Z1D75T63FI5L0S(FMY!!&2ED.;3A%EE
M$KD=1.S1ABHJW5LI+L*HS*LYF9#SDUB))-6D8N!?- F)D\8D4(9\+9NFZDQ3
M?JF*)RE3\INCX4TZ6MPN_3VH_L5E?V988-J>ZT5^+@43+?-0!:[Z(B-AW2!+
M+;5OTTR'KJ1T4Y*E)@NXMZZ<>G8#$-,022CEY-Q@&C-B.$AB:5X>9F:XVBH"
MV$\B<[-?V8Z=L?=+Y@9"R172#LRIS2D<+O#<0SCW!B9RO8/ $0QK+R+;"7%9
M-B<QCG'\?M!@/FKI%.$K'"Z--,EDL AE2_X8BN"A7"2I@UXH#=U/I.D7*!TO
M+=F65*X57.HH3RL!,05/^@2SQ6/K:$@J1]$RQ9!O$/TXUW"2+&4/YBB+F[ME
M(ZTMEDS*4]\$A#PS]9!XFBJJU$7:*:BSE,C@Q% <*."E*H4RH/2N\(5P1--T
M!DO"9$QQ2 U'*GZRZ>U']BOP=?7Z3HLGLFHPBE>^1 AQ>4(ZF;(#SW,R0Z4E
M6Q_WS*ZH,K8K_P#"TPY"+6:;)*5&[)C[9[-7V7Z=L?=+YJ2IT5"KIRN$FY!J
MXE(\J0CWH/028=(_C]H,1)BKLX@V6R3AFTKDC6G[ SMFY(H4A>*[KRAUR]\J
M0M3A1>6(LD@0LD4@<57 ILA& 245Q)0WB;*I3L(OYJ*<=,JQZK.S-BN6=K?L
MA'8SQ1'8SUD^6003 M021+7TA7)E-F7*CA04O&X(T+@1J+DBJ"!U!A13%. $
MA6\ P%O()IIN9A1R""\JS%/7DT^6V!T]J/[%?@U)2OI3FS-CP\_%_(@!X.]=
MHB"5Y14]IV<X*3L.8R1YLIRL+HH"L/4_%QK;ATXKUS*8)SLVAX=,].V0X;3^
M<41##2SLZ#.5<LBGD(URD/Y^]8<TA6CB3S/,*D!B++J*E @NV\4\2?4AD1J9
M!5FOK@J0NY]'E)%4H*XL5LVSS#JD2DG+2&4\)S.%2)%BII>.4;2T1:%%J>O'
M,?\  CJ.D3)@1XR4/9%F;A5)R*)JH\0)D@UDH^1K<V[BY%M*-'8.6)U,*GX3
M$B$?-,4&CJ0DFB2LU;DTFZDLR7*TICF?CWJ"$2XT57/;^U>GM%1;B8TL/Y=?
M#_J];G,5"]K?]99O#[<AC(JNY;BHRN \(FBI KE4#RX:ZN2EG-%1QXO5'0.=
MH:&7A-Q?@A^'I;5$ALE/YDRT;OT;?4Y2LS8-@*)D_$9L@[\YYR*:]@DV+%J^
M15>C2%C>W[Z"!Y=(Y7"KXQ5E0 &B:JX+E,'DI*H^;@E)RZGG-TZ]892.5MT>
MU;O8QLLL5P53F7 .3JE/_F9P9NH2TQ]A1EZPD#5%ZYCBM[J=BW]XCL57%H>K
M(JV-4ZQ)W@6*:2,F8E;BHE@I-K."'<D5-H/6Z]$KW3*-V[R/VIK]]K6Y_E0!
MA(\U^40;7=,.=L?_ )J$XMSS J)L[ X*XKU#_3*J)QB6]0?WB^QC=!FPZ!SM
M;ZQ7GHTW]&U;.'KC1^N0UK0OF/?JV"N1EE9S^NK' '=S;%GCRXKJK/[,N996
M94<.&44ZF5U7\34DYJ11DR*"KQ$$TE%'"2AVP)KN%_U O^Q(I042,(KI%5,W
M1LR:CJ))Y[$Z41(%:NC"9=(Z1,4=\PW2-Q7K]D-""[AVKXK*,*+DK45%W<<B
MU)"UEY)XC6H6,&0M9&*<Y:)-^>HP5PLN:IT,VJ2J7U.ES]':&K*[M2"V'IB]
MZV<?DP9O"[J/^D+LKQE+.'"<B!\3N844%E8VXI5RC!Q#752G[#%U*G1M2;-O
MH]*Y2F/N'LJN#.9.)DX9W^>&5>D6NZ/-)=G./UXI\U[]7N?5VORAAUWK\V>[
M?7?#W;Z[X(TFF-DS:ZU\?"ZVUV7/=MKH!-K;71Q'6VNA#W<:\ ?=MKKC[M]>
M9[MM=#@:WUV7/=MKO@>AT95,->4 ,4HU*6(;6VNSC[M]=X76VNR9[M==9[MM
M=<4J!1&XJT&BKB&N->%-[OJ%@4FF!AJ)1SF/KZ@JXAK^A-CI))(IXE]7I<_0
M[G.M]>/5O=9K'/=9K'/=9K'/=9K'/=9K'/=9K'/=9K'/=9K'/=9K'/=9K'/=
M9K'/=9K'/=9K'/=9K'/=9K'/=9K'/=9K'/=9K'/=9K'/=9K'/=9K'/=9K'/=
M9K'/=9K'":PUJF*--J#?%J73G)E=9:V6.37]#3P]5K"H*Z^H2Z;?7.O68\
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M#G[9A4]-_C+O[9]L&?F_QE[]LPJT)S\:>^</MA=I3WXT_P#.'VPJTY_\;?\
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MENARZ=3N S.[&"V N[>./B^-YHHI;EULH33^TZ(":"F*R#RD8H\\!2RY4(&
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MH2+H.ZI/&\8>6B6TKE'YB@;<0!AR5%3=VE3OK3#HBVG.Y%H+FY95YFT/%;.
M*12BL-FM[B:T.&&*I"6EM' W,EQ >HI2VZYZP*S(RO&]C0#/*&G%2LW+]JO]
MT6W+^PI6L<; XTK6@SW$!5 /%E%MN6S/+6DMA0;O"E"GP2QAA0;B<\#U H8E
MKC\F_?4A:CJ'S4DWS47<% $$"E*X5KCA92B[*A]Y.K<I]Q3QWX4Q\V<4I5PI
M4F_XIPRX16%$]XODD[Q2AZXTE_I::5OV,?U1WJ>4GI$2OW+&%J%<(4J%*YX4
MJ%*A2H4J%*@+*4$@XWCP/R>(/&%/*4:*. -<@/4!$P\44NG.\3@D^,KB##+H
M*EUH:C'+Y0X0)H&^U3%8I45P]/#[4A4HRBJYAU6)( !'GJ:C[#=':TIK44>4
MX'*4 4G9-<E9_5%IL * 8J**(54X8<* <\2SK4G(.*F  5TQ3O KSC\J''&;
M1L\H9\7&AXU)XG=7KI$^ZY*V5+8F\A5!J^=2LXG_  C$@;S@UM+QX8(Q],:I
M*'V&KBETH5.+4HTRRR%:_P#B)=Y0M>?8H;A:H#NY X818[!6N9LR94H-OK*D
M!7Y*BK#JQZHTCFBS-2%F2#TO1F[>UAR)H=V7'SPA9>NM34LX0ILWIB7K<20C
MY6!'6>@19@)DK;:))80=AQ7*/W3&L63VPJS)-M;34VPHO4<153C("SRS3#AA
M3*A,:8L2<FI):6\I:A6X57@G$X ;AOS,*)U:%$Y[N$*4>,*5"E0I7/"E<\*5
M3&N,*.-[?QC1D)4B<)%3?:J?U5_!_P"D'E'H'UQ[E7]&37]Z/W4=@"L 0@(O
M@*<4@[KII7IB[X8H5X5!^7C7"&++L^3F)E^7E)=DOD%];3:4K6K&A41GB3GQ
M,*LF3*E3Z).55/$7>V=6-?<KR2O.[OIE6.X5BS#K3[]G2*WTUO/O-)*Z[J*S
MSA<A+]KJEW6)539P$N^D%)3^0@[N,)T:T>2S_14BBZI*T*2P@%I8-0I.&R:[
MQC$U8]G3Z&S:,E+S37WK7MI<Y. I>\T,V-9<HYVW+64PPXTFYK@RE*U(7XJ5
M9W=Y&6^&K)LR45,S,A*R[4Q,J0I\M(2DK-:U<IBK$DX\3$S9\A.-J:G95B89
M5=O-*0E;6!"ALD4P4 KF(KG"K'LN:EQ)=J2+THG 2[C:5!(X7,H;T<L9MQL]
MS[/;,K>[7U;* XV5#:U>&S7?=B3T%FGM*Y^U9],C,V;-7*,NU6ZI*&=64J;4
MF[T;1P.(RI)2%G6<TMN1DVY0-GDH;#8./-04B[?:UL(3LA92EQ(O!;9%2H'#
M 19MFV;9KC[TE*,RB9@E<PEAM+:UKW%5W,D[SB879MG3TPU.35GM*F6ROM9]
MQI)>3>P44J.(J *TX")>R+,E1,]K69+,N3!J_JV4H+QQ-72.4<2:GB8E+%LJ
M6:4ENSY1AIY2E3;"&DI#JSA>NCE*--HFI-(3HAHV"Y<LFR0V\0I2%2[="0:U
M<%VAQXQ,6)9L^$LS=GR3TFT*!M325-) Y(;2<,QZ(TJT&MJWIUF5EGY*6T=9
M+?@&U*2_LKJ4I135A- FAS!K@1$I9S,A)HLQMM#DLTVA+;:P"V<!K*C+'=2&
M-&-'I6;[=18<@EPXE],LC6U(\5=*^F$V/9+DZFT52$L9L(*&YIYI';3:*'8;
M<I>2DU.%:4)XF'M%["FY@S<W85G32D&H<,LA;P_**B*C$5AAI+: EI"6Y<8-
M)0*)',.B (I $)^HQI[_ %/MK_XC_P#EKA?+7^FK]X]X<CT&-!?ZR69^D[_D
MJA7>*[!0I1!2Y<IGC2L*N"]K-O68'U1*2,C(N#5L%@K*CX) 2%$[U4SAU"$K
M*'-MISQ7(%E6:@N7)5I*'#582@ +/%7'K@6190V46?)U!!31I(*"#>PX8X].
M,/R<C-;+\@S,*(HV5-!81=&ZN4,6 [+VWW0"&D,A!!0:@WB>%*4N\]>;?#EF
M21?,X9.6<6!0$H!/5YS#,C9TNVM2&VPMPWBT +I5OJ-]>,&S9.^9M<A)IIA>
MU8UG 73!;I*%M#-2LX:Q.S0'=OB6DY1A"$H0AF@-4M )"LSETUAJ7L^],38E
M4F:6+E]2!6F6>=-_3#%G2\O+J3JT)9422AH4&))RZ36$2K*)<L,R;*9>N-]%
M!G7UXQW*LL!"FY.5K4$*0V-DI-ZO-CCTP_*RDQ11E6'G$<G8O4(&''FZ(G+&
MFIR;:<?2A$K*J!2T@$.*KB2:DC!65T8I-#SJ:DG&]2I+A3< 0R\!=RQH(E[.
MDF4)N2[33H)+BFT@+WW<>C".U).^MXRX!.!5=&L<I@.FE<.%8%F2%Y+Z)=M"
MVZW4N( 6;U:\^1/GA*6P=8OP8&2489<T7BI1-5W?%O\ U03!->\<Y"NKUQI+
M_2LST(_=$<.\3RD](]<2QHT?MOA:L3"E0I4*5"E&%*A2H4K[>R%.* I4T.8J
M:>;*%+A;A6#55:#>:\3O@.%%;I(YP2#Z#&O6AS68[&><+F):>;"7'=64UQSK
M7COKS\(6[+2[C08JY=(UB\3OQ52IIAN K$Y,%U2B#=%Y1X85P,.S2]7J%J+]
M[DBI5<ITY0B;>E$W$J+=[@2F'9I]31#S[BVQB$I42 <2,-V_TPJ>F%R]"Z^;
M@\$+QPZ!T<(%ISFJ3>??2Z.3MGT= @SDRA9?[:?UZ\S?-3NSSBRK5E)-17.F
M8?F]HLJK>2*@UO$FOHB<G0_./33B-M1\'<Y0X>:.ZUHW;G;DTVC$7 M0!'..
MBD*GYQE*FDS;X9>^ZH:<.U^D,C_J81:<\PC42TU,,L[M6LI)WF]0XXQ,36]S
M7S"SF7-O'KA;BU8E-T>*(4J%*A2H6J%*A:H4J-%S5N<_O&OW5_!_Z0>4>@?7
M'N5?T;-?WO\ _*('8 @)&9&(RYNQG7GSA-4X)PBXFE" 8(#A"E[13R2<:=$!
M(H4D;)S&XQFE*?%3R1N'1!6I0NDDIX;H2D)K04)SYX ],)2E!JD!).9$7 57
MJ"]Q@84IF,HI6M<:YPG*GB\-T##+"!O/'.*G#/#D\W1 *LZFIA(KB8N)^2(W
M!(P3PW0 !@(2..<$DBARX0<:<T)*DU"20%<JF_I@8)"1R1D.%8 @#L(Y748T
M]_J?;7_Q'_\ +7"^6O\ 25ZSWFXQH/\ UCLS])W_ "EQO/8/85V3!432IRRK
M"S?Q5CTP3%,:[XO%-*$BF5(4JN9K!)I2N'"*8UW\=\*)4**Q'"+ZL!>.&4*W
M12F45PIN.Z%*-VY79^3N@42*##F$ W,4[/1!42:DP14A1Q(R/"%9UWG/GBI\
MV4$U-3B8..<*)P[TF%GP:NJ-(OZ5F/U/W>]3RD]/UB&5>#P@JVCC"E0I4*5"
ME0I4*//"E0I4*5"E4R.<*5SPM7/GG!V<L(K=Y)I7.F^%JKF84:&HP]<.*O<K
M:Z84<+NXYB"N@H#00M=:5W<86K?"U8UW\84O?7'C"U5H34D0HPM=,C"EJ^5"
MUDYDF%*A2N>%*YX6KGA2N>%*A2HT84=5-X_?&OW5_!_Z0>4>@?7'N4BMFS7]
MZ/W40!%( [*8 BD =D0!V4P!%( [ '8 @=D" *=@"L 12 .RCE=1]4:>_P!3
M[:_^(_\ Y:X7RU_I*]9[S<?MQC0?^L=F?I._Y2XWGJ["NPKL$T@GL$Q6O848
M)BM>\5V#!,5BL U["NPJ"8)KWA@F#R%1I#_2LS^I^Z.]'+3TPTO9(YX484J%
M*,*5"E0I4*,*5"U0I4+5"E0M4*5!5"E0M4*,*5"E0I4*5"U0I4$PI4.*A2H4
MJ%*A:H4J%JA2H4J%*C1<^"F_[QK]U?P?^D>,>A,>Y0%*LV92G,O9_J-Q-3#-
MGM*<=< 2D$K*CET1;_NHKEEZBS6&W4"\-84U5YQ$]IU;\XLE,R_+@G[VI21"
MM)K>P(MB?Y_#JCWS:0>5Y[Y]4>^;2#RO/?/JCWSZ0^6)[Y]4>^C2'RQ/_/JC
MWT:1>69_Y]4>^G2+RS/_ #ZH]].D7EF?^?5'OITB\LS_ ,^J!I3I$/\ WFT.
MN86?28]]6D?EJT/GU1[ZM(_+,_\ /JCWU:1^6K0^?5'OKTD\M6A](7'OLTE\
MMVA](5'OLTE\MVA](5'OLTE\MVA](5'OMTF\MVC](5"M*])3_P"^6GU3;H]
M4!'OKTE\NVI],>_BA.ENDP_]]M+KFG#ZR8]]VD_ERT?I"X]]^D_ERT?I"H]]
M^D_EVT?I"H]^&E'EVTOI*X]^&E'EVTOI*X]^&E'EVTOI*X]^.E/EZTOI*X]^
M.E/EZTOI*X]^6E7EZTOI*XE]/=*)9=56S:#]?$+ZU*-/DCUQH_[MEJR3K;-I
M,ZV7) )6DE_IQ,:+Z9V'I*E/:,P.VBG%A:DWA48U3'N@(_V0MDC,2;]$_P#;
M76H]4+^Z+/%1]?>;XT&%[2FRQ^4]_E*B>G)2ST..3+J6PD5%5 99YQ;/NA/E
M3C-G"ZC:&L4*K.8"D@'9XB]4GQDII0NZ0VP\HJ-HS@.\)>4@#HN78[M6OY3G
M_I3W\<=V;7\IS_TI[^..[-K>4Y[Z4]_''=FUO*4]]*>_CCNQ:WE*>^DO?QQW
M8M7RE/?27OXX[L6KY1G?I+W\4=U[5\HSOTEW^*.[%J^49WZ2]_%'=>U/*,[]
M)=_BCNM:GE"<^D._Q1W6M/RA.?27?XH[K6GY0G/I+O\ %'=:T_*$Y])=_BCN
MM:?E"<^DN_Q1W5M/RA.?27?XH[JVGY0G/I+O\4=U;3\H3GTEW^*.ZEI?C\W]
M(=_BCNG:/X_-_2'?XH[IVC^/3?TAW^*.Z5H_CTW](=_BCNG:/X]-_2'?XH[I
MVC^/3?TAW^*!:EHC_P!=-=;[BO6HQW5M+\=F/G#'=2T?QQ_]LQW4M'\<?_;,
M=U+1_''_ -LQW4M'\<?_ &S'=2T?QQ_]LPFUI])O&;>-.*S%FZ3WB&W:G=56
M<,/MS":H4#6E16-)-FVY@;MCHY C>>\'*3TPA5 3SP\^$FF_@,_33[990M:U
M>-3'=ZHQ.9/[1'H!I%/TOVE>V+HY_.?;%Q/#TGVQJT?)]<:IOY(C4M?(3&H9
M_LT^:.UV/[)'[(CM:7_L6_V1':DM_8-?L".TY7\79_83[([2E/Q9GYM/LCM*
M3_%F/FT^R.T)+\5E_FD>R.Y\C^*2_P RCV1W/D/Q.6^9;_ACN=(?B4K\PW_#
M'<RSOQ&4^8;_ (8[F6=^(2GT=K^&.Y5F>3Y/Z,U_#'<JS/)\E]&9_@CN19?D
MZ2^BL_P1W(LKR;(_16?X([CV3Y,D/HC'\$=Q;(\EV?\ 1&/X([B6/Y*L[Z'+
M_P#UQW#L;R59WT.7_P#KCN%8GDFSOH<O_P#7'<&Q/)%F_0I?_P"N#H_89_\
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MNDI*_P E1\R3&BI3,KM6TT+*FYR=6&^ 2PI0J.F]Z(>:1,MJ;<2E:5)*5)6
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M-K2I5/U@N* H"B=HA(I^B*1>JE(X?&@2,H!(-0:&%+4OE$GI@I'"!AE [ -
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MX@)HC>I.R#>"$G0W2PV_9Z6)IK46E)B[-HNW0HUNAP<"J@*D_LX8)YXKES?
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M-$@*-XBVK.LIY<E8=E2K2YEY\*=FT5=5+I:-[:=VU)OU-X5V0@@IRA"+C:
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M@(H. B@X"*#@(H. B@X"*#@(H. B@X"*#@(H. B@X"*#@(H. B@X"*#@(H.
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M-L ]R% ^K9?T(]C; /<A0/JV7]"/8VP#W(4#ZME_0CV-L ]R% ^K9?T(]C;
M/<A0/JV7]"!P;8 [D,/_ %;+^A'L:X [C\/_ %;+^A'L:X [C\/_ %;+^A'L
M:X [C\/_ %;+^A'L:X [C\/_ %;+^A'L:X [C\/_ %;+^A'L;8 [C\/_ %;+
M^A'L;8!W8/P_]6R_H1[&V >Y##_U;+^A'L;8![D*!]6R_H1[&V >Y"@?5LOZ
M$>QM@'N0H'U;+^A'L;8![D,/_5LOZ$>QO@'N0P_]6RWH1[&^ NY"@?5LOZ$#
M@VP%W(4#ZME_0CV-L ]R% ^K9?T(]C; /<A0/JV7]"/8WP#W(4#ZME_0CV-L
M ]R% ^K9?T(]C; /<A0/JV7]"#P;8![D*!]6R_H1/<%F YI'%C#-(ER00%,2
M3+1U^<D)4#S6,8F_@XT*;EW'J!..R$X 2EI]>>3)VZ@W=&EPFSB1<[]D8JP9
M7L(32F*G*$)4H\5-("E2KP3MXMPI3<C800%7W9;$CE#81W]HMSP#N/9#;;IV
M>UN$V3O.R DC1/+5NZ;VZ8P+P*XDQ6EJH3(];*2\4J#SPL^\T;:R[:@4Y5"^
M5:^A00I*KQ1N /!]*RJ<8-47E 4:C[K8[_<DY6=^WBA;0C47AG@RP&RBQPG0
M75<ZZ=+D_:B$\'& U$YL&X?%MG^C)?T(]C7 '<?A_P"K9?T(]C7 '<?A_P"K
M9?T(]C7 '<?A_P"K9?T(]C7 '<?A_P"K9?T(]C7 '<?A_P"K9?T(]C7 '<?A
M_P"K9?T(]C7 '<?A_P"K9?T(]C7 '<?A_P"K9?T(]C7 '<?A_P"K9?T(]C7
M'<?A_P"K9?T(]C7 '<?A_P"K9?T(]C7 '<?A_P"K9?T(]C7 '<?A_P"K9?T(
M]C7 '<?A_P"K9?T(]C7 '<?A_P"K9?T(]C7 '<?A_P"K9?T(]C7 '<?A_P"K
M9?T(]C7 '<?A_P"K9?T(]C7 '<?A_P"K9?T(]C7 '<?A_P"K9?T(]C7 '<?A
M_P"K9?T(]C7 '<?A_P"K9?T(]C7 '<?A_P"K9?T(]C7 '<?A_P"K9?T(]C7
M'<?A_P"K9?T(]C7 '<?A_P"K9?T(]C7 '<?A_P"K9?T(/!Q@)-LN#</JY_\
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MNL/!07="A=)"@3H1X.8D:P"K,H$&PM8G?SV]L=O@(CABEPQPDXF:;T2W-2Y
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MF'$H=#>[CDCC"1R5%69-DD"-OJG9'"E_J-B+^S)L^$,.POLE?I'R^T[8#='
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MY*4(* M*KW7F-QR;#*=YY_;'<?4QMH_(=+3W[:/>]X@[N^J/X,_\P5G^T/\
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M^HV(O[,G/^'=A?9*_2/E]IVP[T<"O^T_#/\ O4U_RZ;]Y  %AH!L$6$6&R
M"2!J=L6'C]6PO??S^I8#P[?4L!INBT;-D6%K;H  %@+#FBPV6$6&G1LZ(Z=\
M$ [1>+ : :1E3?-87Y_:'U (WB.&O_:=B?\ WF4_Y=*1VQ[P]H-H[\<%A_\
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MG9SQA3'5!Q?+I<I\TGJ@)!5*+6./3<=L@'S]$<)YM@+$5N4?6V: OKM8<O\
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M>EIEF2Q+*9I-1"!,(2KCQNS+4HVM?7O12*O(5V11/2$RV\P\D$+;6%9+[M-
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M*XLL(F>7LU<EG6/%9PCO&'%9GWG!VSBU?XE*/[_#\,RYM^R"O*;6O&:^T6O
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M]\5W#LW02P)I25%_-8I)/8]_X!:\7AMQ35[7%[?9?S^][Q'-WU1,_P P4_\
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M.F>,#90S,E2FMPTVC\>?X2-H\,#=W_/$QQOK'32V@*2*A/9B1>QZGDK?9?\
M%H?<6L 'Q1/T>5J4JIMV6:*MQ4G6):55A^64E ]S^0-GBB5Q"P[R%A*3LAM+
M;B.,2Y?HO 7F)%K9?>NV$9@T5+5J +_9#6*&#76Y*X*5E2<N[9 &;.W\NQ'>
M.L<(K3M.5*/RQ4T.7QBF^3?FO:,"XH]V];IIPN+<')4X;D:;H!W>&_?]ZRWU
MYH4[N O NO71(3SZ7@J3?;YH.6PLI*N]M'?][S*YSZESS^UEYAZ75F8=6TKG
M0;&'IAYY6=UQ3BOE*-S[V+[ +DPIIU(NIL@'?E@'VN5/,(N?%!%]L7^R+"Q3
M;0[1   RC0#=[\$WUYMW/&?,0FUKZ?;$A06)EO._-I93MU(&P\Y(BMTKUN6T
MMM7&,S%^+4-G)T_?MY]F^G4UVI/&70<BVTJ4>G0J$+2N7<6TJ]VU%*@?O_&D
M42IJI<ZEX+*6E9<Z 396N\;[13ZDT_+M/(L>,2/!"%7OS<\:WVPK=ZEAS>I8
M'4BY&P\T.*(940;&QUBN$E\G;J==\2#MEW(Z=1%4EDUFF/M! 6\T+LJ(U;*;
MWRG=>UC"@6L[*TV6%:WVBQV>?X0-H\,#=W_/&.*_/T2A4'J-!4A^HU#C=";9
M9>3MLB@8D:J* 'B.-.T=/EC,XI0"= =1MV#;XH=;2HEF9L<PTO\ 9$[A]P3!
M7+WRWOI^Z)!F>8(2X591WXY.5-MN_P!ZWB'TER7>M\@^0Q,S*Y+$BYI:C9IX
M?YC:)%_JMF6F$;T _P"41B^G>NE+F0H>Z  M_P!W4^2*6ZJ3JTHI)LM+I2?'
MEAEP+9:';!"2>FZ1[UKE5:&0A*2M>MHJV*9"FWXW;VH%M;11\<2U3>XA,BY8
MFV?B_MO"4-@9V\PSZD*W? P+P?>J?DZK9"]A,3$C3YB12E"4YU)YA%5HCE.*
M5J[![,4^""+&-P\/P8'[85NR[8#CZR$EQ24\]R/#%*$O7*5,4]Q5YN52%2M^
MR/;*M?;LW;K1279B5K#8&BR[Q;@V:7RVMWHQ,RTQ6)U%N2L-*%OE*0"?MUBQ
M!L=J?P/NC!-:XS^(NFYV-_NAE0XM#?;)&OAU$6]J=AAT^X*[T5(!3SF;GAA"
M 3%&4D%T<Y(\95>,7TKJ&HNO)%FIE6=O32_;_;KX8YO@]N6D[A?R0=Z=^D5&
M5E9K#M/1,,MNE-0G",Z;VO+RGEM%0ITK*2^>6EVF5C6[:0DQ2:JKL773F1L)
M.HA"T/ *%E$;.B!FWWZ/?+CL=YV0SR>,0K7,-_>,8UH#J)LS3;?(4O,JPTT.
MEXPH^7*-)HV*"5 G?II$ZQGD7[GL6W/V3&'Z2_4ZPI!:.5#ZSGMS+)VPRD-,
M-,$#C&D@*7O5II<]'O @JMNO =SW:M8KV&,75WUAD%-  S"P0@[?'XX99GL1
M3B4YG'%NK]T&I2T+Z9>:^^*!AB6HDHC.$J>(!UM>\./I;02[9L(!(W7BG5%F
MHJ>XH@AK;;PQ>^O3\,2O(0H;0=/W0W6GFT(]T7I;?TQQB*W21H%K90==I&:)
MALLON-JV@V@BQ^$;M2;[ANBE5!=,GVIQO3(>6C<4G0BV_;^Z*=2J55J@S69-
M]M+R@I3LHI2<H7DL.1N).O3H8Q'(5 52;F)QOD%6BT7RE(%DC7HVP"K;ES!7
M.+DVC"<E,*J+;X2I*4[]>F)<Z#GL+G>=(&SU# ]2US$\;-&VEQNA]DN3 TN.
M5>"KB7'Q;9LBA5<=5S#;CEO=59;G=G.D5BGMUR3"0E)6VFZ'+:@_OB>DW9"8
M<9=2H93IS'O00#V/P8Z1;W6_./NA;^>78E[_ )-YURWZ:&T_^B)AD3-VML3\
MB[*3*RBX%];13:N6EA#AOK")A$PA)3NV^^ <M)YKP.7,:1B1Z54PXRX!F-K;
M(HC*9:FRI3L.?RPX%N,*&Y:%W\1C#K<C+A0:2GJDJ7?07[(^&-USV9V^\%*B
M1:%+0V.7 J,J'D7MOYHQ=)SE<J+<O+ NM%7Y47(0._% PU*4270I*4N3%AQK
MFW7O]$/NI::,V\KDH%P+\T8KQBX_F;ESE#=TZ;[Z1P;-OB0F9EXD\<+B_AYX
M1V"1S7^T_#-+'[(<2"UWHP0_=#[*C?.!:,2-<5570-.V^SS_ (V0HZ][X1(2
M3\_--2S""M3AMH-@VWB6X-U+LM3]U)%UMWV:=Z$X$JDJ^EZ0F5LCH)3L[T2M
M!?=8,O5%=4+(MF.I^V#@F2;2M61-D;K#2\4^ERDHUF0A((Z(:38!7/ V>HJ$
M^H#:\3[VA%X8R9W%*[4'[XGIYM4U,H!&TCRPZEUEYQQHD'C%+N--%*)'EMX(
MPSB$/LIEK^[6LKGC%%':J,LV^PD<<P%%ZPU-]0/-?[+F%I+;BD'<8[_P@:&X
MV\\*EFGLQ6A*CTB%4J7SW#+8/0F&9<,"PW^^ \E7/NA*2AI:]]CK%3=+LRO/
M=0S;^_%'(,@D'4)')Z.]#Y*)5P@D6!MX;Q)NVGCQ?).;M81JV@G;;W@C0JO8
M)BLU0YN+;4>;2*;*/SI*U%7(MMZ8DY1$NGL$YN>VL.+8:2IQ]10VD7VVO&,,
M7JF%*D)'C0U<IS(W^**'AR;JLP%NH7Q2% G.#9=^?GBG2#=.D4,H2$ )V#2$
M^]2LB]-)<6T+AJV8;S?FAUKBS;E!=]4G=;H@[.G>/@+@-NC;:,&.!4[Q0VJ!
MV=XQBALHK+B%Z\Q.[2%7S%.\[X+@2G(;7)L#XX(LD#? $*%A>#8N:;+?="1=
M YQ?O[?4RG;!< -K?9&;P>])[)-]D':>:):FS,R&E-H*LYML)&VPUB7P[3:6
MCCJM,W=.7(S< <JW:[3:^WO:11*929*\RS=)/*#FF9(Z#M%Q%2Q])4QQ4NPV
MIY8T4X #XS_UA/"BU8)5*J3EO8V&MX=X34[6I9.;G4F'^$J?4L%#"-.R21R5
M#I%Q>PC#E>;KK(4TA <_I&_D^"$ )4 ->=)W0XL$6RV@((UVWBW1"4W!TA*$
M'LEV\,3CB6$D-K+BE;KW/@@N<A;DTM+*0/Z4Y3X(K^)F$*4S(.*N,P6M)Y/@
M._OQ)3#CLRLK))6,USM.T>:)UE!8<((0JPY6SIMT[_NBD3W4\VTXGDJS956T
MO<Y>?R[/%$M.I0>+<(*7@+W[:X_?%1PS3)Q)>2E32E<HEJPU._FBI8=3*I_B
M?'ODWSA=CEM\G*/+KY(]::@FY,L\1NY"_)MA3$R#JPL?W#;3\:PH[;BRN:+W
M^"Z[HY7XO&;-[Y>T+5F;*.>*O(<6M*_EF*.G+) =$3G\C=Z1%'D>,FE+YE1;
M+R?D^\/A996$<T(HZWY@K7>UXEY=$HD)0!KMAY\,BYW0_/L3ZA*GL5:&.M2G
M-+#BY<+0=<Y2##,JS+M@,,!M V$)MF\]HS*7H8T]ZIM053W,XU2;9T?*'>A^
MFR=?ENJI(AJ9 N4"POX!$S+/RKA:?1E4GHV^?X">581A&5XAY<YN:3?Q@QB&
M9ZKJ3SXW&T9M4KY_N-HJ*BUD=&Q*[GPW_?##O'M)6(4O+ <S(Z-?O\T2;W&@
MJZ;?;:%\A:D\UH"[JM#\XF6XL*_I+CQ0@H<&>)J8"2@#IALYAX!Y( M[P?)%
MN2HGYL211(883.  OE*BUT\K39KS12F1B8(FIQ5W)1:N,2.V23=(L? -=W?,
M8AG&Y"DM,-@2[SR5);/8E5M#;O".5G672"OI-S Y))("K_9').ZT:IT396;H
MBD5V<HLPEV6T-^4B]LPZ1X=OGBA8GDZBTEVX$PH#CF]+HYM-UXS)>2%)C</4
M)4-!OVQ,KEI=DK>7ETYXK.,9&3642QXYW79901;GYHJ^()ZI$A]\I1N0THC3
MIBV\WUV'GB5*4N"VTW'3SQ/LNJD5E.WDJ[Z4D*5LWV!AV8,E/-%6C2CJ#W_/
M]\2569=0VIU65QD#7G%MBOQNN+1(8AD'F^+,RRWNY:P/$?QINA+TIQUTS4NX
M%<RP;0%R&09G6-GRA"Y6FN((]R<S[TV-HJ&"Y-UI<PQ8+L2+6\D34LY*O+:<
M24Y%$#F(Z/Q]OPOQ>&,BAKR3!).T#P>\.--NVXQ"5VV9A>T)2E RH 2.80M
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M[X:=S) .T^+P1WH 3N \7J8?>2TZ^.W6CDG?R;WMXQ%2F;&;F';J&91-[GG
M'W#FWZ12%EQ+@3J@*%CWR3 ^)""=D75!S>. /AK#[K*[LN%M>X@VCUWJ>;+U
M6O-SYC#S[KZKO.%Q6\DW]34<JVR,.UM*;R]0/N%K#-LV=.D3]"DIQU;\DZ$
MZH2"+'O6A-$EV&U&??".;E >6'^+#JDM*S-@\D^^S0SM'O11ORLV.8IBJ?S[
M2/\ S_V8WGPQ6?YPI'??\D3O\C=_0^XQAX?Z-1^DO]LP]JPX.="O(8H)R2:T
M?(6K[5F'.747D_(R?:(0.0.\/>S%X_'_ $@>W)M&<*TUOS1?3IYH4F\.M95)
M<(!R7M<7&OCL>8]'@B9F!Q.GV\_[HD6M.,/;1M'@AINV>^\'R'[XHJBXF:;[
M(-N<VXYK^00X.+ME')OLYOW??"22D'H@>I3%<7,<8=B6U7\-HK4RVQ*S[BR
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MH4U<:$IYR(2TL'LS;OQEL!<Z^KMV^TO_ %>W'P1N,30_TM3S_P"/Y(I6E:K
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M6IQ"$I6OLU 6*K<Y]124K3D6 I/R3L@RS!2E):04I[$6T'>BYBYYX"4I45@
M*.TC;ZB?;';\2CWU7Q*-OME?$R?;';\2I]]5\2C;[97Q,GVQV_$J??5?$HV^
MV5\3)]L=OQ*GWU7Q*-OME?$R8O;FM]O@BGR+U2G96GRY0'YR88EF"LV3QC[J
M6D9R+G)F6+D VYHQMP>U[ 9IB:ZJ24:HV\[+>M[JWK!@M!SCN,:;RGW5%K7U
MS;+03;8"8%]^D';\2I]]5\2C;[97Q,F)*GS]1?#,A*3,ZX$YE,RK#LP[EN!F
MR,H6JP) O;>(PKA#%;6*:*^YAJO(;;JE-6M:Z5/)0VVW-LK6M2E,@(2E*2I:
MU$) !)($?PC*+7*NY@[UJI%4J9:E*BB8ZADIB:+*E&1R!WB4+R$Y%9<ULV4Y
M0<JK3E K=(3>JTJI2(4;),_(S,J"=3E!?;;N=-FVP@!=R5$6.P#=!V_$J??5
M?$HV^V5\3)C"F+*C@^I^N5+1++F5,J8_C32G6LBEM.*Y*763>[2;<KGB@?PA
M,<5"NTVG/RU!XF;GI*5=R24RE?%S#[;*BA75BLJ@E9*5$*3>Q*%".&/A/Q'P
M?JPWZR,4QX567G7IL3S#SV4RYE<G%<6^S8>[JS7O?2Q3E.;&7"CB#'K3+=79
MIR$L.!UOJ*7>9.<(<0+\9,OW&5:M/M@+"B18W&V\';\2I]]5\2C;[97Q,F/'
MW^:*'/,TRLTVJ/(6M$C/2<RXE%LSC<O,-O*2D&P*K((3<@=,<+O"33.$)= 7
M3)&=D?6J7FVGQ/)93QAF#+%/$\2XO1/$&^:VT;3<QJG5.7[XVZD6.^#M^)4^
M^J^)1M]LKXF3ZIUVZ^J=OQ*GWU7Q*-OME?$R?;';\2I]]5\2#W@_$@]X/Q(G
MWU7Q(GWA7Q(GWA7Q(GXZR],7!W;/ZF$0K8KP?'1:+FH-K??]W3L$<I/91;^I
MAOF3X;PIJ^4WY[_CQ>3GA-]_QSA%EIU.(N,0E?%X;J3B,POE6GB<JATC<85M
M/?\ OC>?!_4PQB*689P+P?3#;2$/S771U0ZE-EO<35&D-9SOR)Y*>80G9\<X
M-['$O_Z8JG_^$*VGO_?&\^#[_P"IAV1B;_9]P;__ ,L_YLS">Q'XW_'.%ZO2
MZ2_/^NZ)Q<G/TY^GN=0ED3*4S"V2I:./4&[A+:K7S#,1=)$*]B-:0IOV0"O?
M?U@*+]%OO$ <$?;>R!FWY?6"T6X(OSA?J_YXMP1?G"_5_P \6X(OSA?J_P">
M+<$7YPOU?\\6X(OSA?J_YXMP1?G"_5_SQ;@B_.%^K_GBW!%^<+]7_/%N"+\X
M7ZO^>+<$7YPOU?\ /%N"+\X7ZO\ GBW!%^<+]7_/%N"+\X7ZO^>+<$7YPOU?
M\\6X(OSA?J_YXMP1?G"_5_SQ;@B_.%^K_GBW!%^<+]7_ #Q;@B_.%^K_ )XM
MP1?G"_5_SQ;@B_.%^K_GC_W1[O9!OT^L'F,8AZT[M]:HK^6RN/\ 7_J'-FY.
M3BNH1:W99LVO8VWQY/AE&ZW^JCUP^NW4O%'BO6CJ?C^.SHMGZJ]RXK)QE^WS
M9+:9H5[$H3KU_ [_ .8+>?QP/8A(%CP@D[[=;\6X(OSA?J_YXMP1?G"_5_SQ
M;@B_.%^K_GBW!%^<+]7_ #Q;@B_.%^K_ )XMP1?G"_5_SQ;@B_.%^K_GBW!%
M^<+]7_/%N"+\X7ZO^>+<$7YPOU?\\6X(OSA?J_YXMP1?G"_5_P \6X(OSA?J
M_P">+<$7YPOU?\\6X(OSA?J_YXMP1?G"_5_SQ;@B_.%^K_GBW!%^<+]7_/%N
M"+\X7ZO^>+<$7YPOU?\ /%N"+\X7ZO\ GC)P/*&5SV1==F4X?&S77E)/B,8M
MK] J%-P_0\/-55$A0!4\CM8ZEZI>-3F&II1)E#Q-D*2I(  .7+>ZLQA.@L-0
M-]^?XYTW@'OB,OR21^CH/%&7I5]Y[\9?G+\<9?G+\<9?G+\<9?G+\<9?G+\<
M9?G+\<9?G+\<9?G+\<9?G+\<9?G+\<9?G+\<9?G+\<9?G+\<9?G+\<9?G+\<
M9?G+\<9?G+\<9?G+\<9?G+\<9?G+\<9?G+\<"X4 "2#>]]HMLM"B57MM3XB8
M2;I!W]&SX8H*T*5 6Y]D74?D'O']T:JV@HM\G2\9?G+\<9?G+\<9?G+\<9?G
M+\<9?G+\<9?G+\<9?G+\<9?G+\<9?G+\<9?G+\<9?G+\<9?G+\<9?G+\<9?G
M+\<9?G+\<9?G+\<9?G+\<9?G+\<9?G+\<9?G+\<9?G+\<"R3VRB=F^%)0E:3
M[HK;H-1X>]%C<Y<H3I8;^F\?_\0 <Q   0," P,%!@L/$ 8%"@4% @$#! 41
M !(A!A,Q%")!46$5(S)Q@9$'$" S0E*5H:+1\!8D,#4V0&)R@K&RML'3U#=#
M1U!3<W:&DI26IK75X?$E-&-TL[0(9'6#DQ<F1%2$HZ3"Q-)55F!WA<,G9J>W
M_]H " $!  8_ OHK]0J4IN'#C@KCS[IY1!$]]55500%$53)4%$4E%%.-LE ;
MW:<SNE5&W"SK==6(3;@91TYIR'!+-<38'(J*1N[35!NZWRQ";AB*)?F(D-MK
M*G;<B7V1+;'U6;3>[U5U_P#B4Q]5FTWN]5/TK'U6[3>[U4_2L?5;M-[O53]*
MQ]5FTWN]5/TK'U6[3>[U4_2L?59M-[O53]*Q]5NTWN]5/TK'U6;3>[U4_2L?
M5;M-[O53]*Q]5NTWN]5/TK'U6[3>[U4_2L?5;M-[O53]*Q]5NTWN]5/TK'U6
M[3>[U4_2L?5;M-[O53]*Q]5NTWN]5/TK'U6[3>[U4_2L?5;M-[O53]*Q]5NT
MWN]5/TK'U6[3>[U4_2L?5;M-[O53]*Q]5FTWN]5/TK'U6;3>[U4_2L?59M-[
MO53]*Q]5FTWN]5/TK'U6;3>[M4_2L?59M-[O53]*Q]5FTWN]5/TK'U6[3>[]
M41/^:PFZVJK1=6_G.R]?_:N49K=J6Z\--UQF-6H>F\>$!AST2]LPN-)R1Q4_
M<RCMYOW4..%DT>5F<;LDF$]WN9%.W@NLW71;+E= G&G++D<*RV]7\OE_AKT8
M?IU/!:U6654'&67$&%$<]I+E)?O@^R99$U%443(%M?,%3;I3/0Q3&&V1X_N[
MR2)!<+:/BBW7F)C,6UFT=[6[W6)[ KJI7R,R!#V66^5-$3JQ]5NTWN]5/TK'
MU6[3>[U4_2L?5;M-[O53]*Q]5NTWN]5/TK'U6[3>[U4_2L?5;M-[O53]*Q]5
MNTWN]5/TK'U6[3>[U4_2L?5;M-[O53]*Q]5NTWN]5/TK'U6[3>[U4_2L?5;M
M-[O53]*Q]5NTWN]5/TK'U6[3>[U4_2L?5;M-[O53]*Q]5NTWN]5/TK'U6[3>
M[U5_2L?5;M-[O57]*Q]5NTWN]5?TK'U6[3>[U5_2L?5;M-[O57]*Q]5NTWN]
M5?TK'U6[3>[U5_2L?5;M-[O57]*Q]5NTWN]5?TK'U6[3>[U5_2L?5;M-[O57
M]*Q]5NTWN]5?TK'U6[3>[U4_2L9AVLVC5;6[Y6*@\/\ )=DD-].I<(1U4:HU
MQ6/5([;Z6_?F4CR4\>_5$Z0+#%-J;:T6L/90:!PT*!+=+P6X\E40A<.W-:?
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MH"W21@LS.[IR'5G( 2\[2L92RN_ZO=UUS<$ZKZYEPD8JCLR%6*(LSYGSK/\
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MB&@@K3+3X.(39(IFK^4T5%",YU8V>VKV=AQH5$V@IP(,>)&;B-LRVTWR*3+
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MM 12-41$NE\.=S6'ZCN<F^Y T<O=9\^3>;A'-VCF[/)G7GY"R^"6-*+5N/\
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MMAQTT)  >9]D?9C*CJ-6XZI=4LOW_BPW4)PYY#HYV6S6XM-EX*J/#.MK]?#
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M$/GU]ETX0VR4E2V9-?O=75BMJG#/#_LV'AE$ ?!#35;\U-;<-.W"(KAYD3P
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MHFM_/Z288<D:A-IP@]IX2NL[I_3IYRN>-,1J:P&\D,U)&UMP3DS_ 'TRZ-V
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MQ8K;U4)G(/-WSSCJ<%O[#G]?#HP:RWW6XS9)NHPW;$12R(-A6R]?EPK"I\\
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M(F&A;IJY1N&](5!O*G22VZ<4)]TVM^-7IAY!YR"HS&2YJ^/U6W/\6?QQV?\
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M+VWGW-UZ4P@M #8JG. .:J#V(EM5Q2RL=RJ<)0SZK_K35N/JMN?XL_CCL_\
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M<259PX[;G>]2/,CC%BY[;J$@@EV^! X<>'FY!*9:F0LY9B%MVZ&TI)QW3P.
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MH:=.&9$P"=DNB1M1UMNT3V*G?QW\F'"J-0>B(*HC<>.A6(=?:B5_*FGEQR"
M\@TF74^5#,D>$<AI-TL=XLPHSSVQ-O,U<D#,GKF$Y.2F-[W8?107H0LI*G%.
MM."V[,$W.9(0 ='%%!X+X*+X)?<:CY<%DL3D=2CD'2WSR(F[%J@9R);>"JJ2
M\;X$$_\ 2'10^P1YZ)_*M[^&9D-U69+!9FG$$2455%'P20@*Z*J*A(J*F'9,
MAPG7WW7'GG2\)QYPL[AEHFI$MU[<;31(.ZDU-8<6;2Z?*%7F7W8DA5DFTS=$
M.8TP>\805S$8(MB0-!VG)P)E3!3S<L MR2*WN<A-1R84&P'P&VMV(9!MPQ/J
M;XM@_49DF<\+**C0NRGC?<1M%(E04)Q;(1$5O"55]+N]-5([*,.\G0UR$HJE
MC?.]MVT@H=E74DSK9<NM5VJE*I4BB"VC-N<+ZTV&+CIY5UR"@<H%I=7%> 27
M1R[U2W>Y:R-QXS-\RA'83*&9>DB7,96TS&J)HGUELGX5D;K6;*J^VI75QP.A
M<. ]7;A%&PV'7,B:K@.>H+[).BWBP2"N@\X%X77I_)@7';!Q3+TJ/CPY8U12
M15%Q1L">/MQF5R[H%SR!5LN&G'V!._@WM>_6G5B77'(0.J*J8)DS*ED33P5X
MX&,-J7"%VQ"CN7,V*VMP&U\"TLAIL6QX7S$1=*Z<3+MQR6'F"/[)PM#<^QLG
M >.G3?7TT)%X:XNNBVXXIM4R7<8=W9C^ZLN=[=&_7D521>M,;HLM0&3'0MP@
MHHD#@61'%5.:O0JIJBBJ].*Y!;3=-W-&6B*Z-AJHB*]-D54OQQ5J?,=1M'B
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M85>WG4SC@FQXKTKH/CO@>#EM3+V/B3K7" RME+FW75!'MPK*HCA<"RKP7Q8
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MXN]SY^H=.C%0MPY9(M_XBX$SMEUTZ>'3@'I!D4> J.&ME5.;KQ\F&XD5#2/
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M*JD&FLQ(W+IBE8A;)&R1F+G3*].>BQR(1>5<1(D5H6(T5D8\9EO0&6&>]LM
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M '?C]3G83^B&S_\ =^/U.=A/Z(;/_P!WX_4YV$_HAL__ '?C]3G83^B&S_\
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ML-L[%J]=DTIW9;;25(9JE<JM5.;(:G4,V'IKL^2\Y*<C"\^$9UY3*(TI-QU
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M$=\[@&0OE[_;\LHK=/H ?=?AE@9-6J4&F1S<1H7ZA+8AM&\0D0-"Y(-L%<)
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M(7(KCL9M@%QZ,#V[!'CVMI+9NY$WQ WLK23; UNID+9.NJ*+=H2,ERCO%4X
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M'HK53%LVHE;K-/"INR94%7MWRQJGQI+<+EHWCF99&''!;=LV ,M@"[%0GLH
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ML3#!T>'Q0%!@_]H " $!  $_(?U1HIY0H-SCXT^:O9RD4).-J;<;&();U.B
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M_D/B?;Y+9OX'PN7IQGI\AR?#MXXG_3^V:EH-TK#$J0,2M"IT9]NI(JC@:2U
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M?781Z>,X%I,Z.4=G/6L64U >TA]W.;IK 6Q(Q=-G7&UNH"'??3FAFMD+!.Y
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M\O4OKD="DC72T!1Z#;> 'ZIB!F$CDVK.LF\LZ I&BI0^YFAEQ6"\ZE I+K"
MN 1I-GJ5Z_'^8V&_1]DX_NG'\#]?A[?&)2"@H*4:+3U@Z8DV8'?2=_WDB6+)
M5-+U3.US@8#B JLM8PH\X\8'I[CU2:C>2"KO(03&+)@X!IPLHKQ&MA"-)CR?
M $#8=6T$IU+$:EJ)8@VBVY;V9N^GOZS\RO3X'/YZ<3]&/6>,.BD-S-5P%"((
M12Z#@2D:E^MG7S'7ID>4(XMLTN:"-:J2V9*%OE)5BHBQQ@S!ZKP1K,3>;"F7
M(TGG)Y%&">^1Y]U_N04L/+1(:<<I-->39ZXL*C6RJ4](CQ-LPA(E(R'H@EY
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M(&3"AW!36:>A/S*]/C-7#V&GDC\]PPF4\'P BX8%/-*^O@Y&8G 4R3<@_O\
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M!RGGUQ@UD#&2+DKP\7D[M8216NKQBE9( AT'/6\-X8X(-KA]_3$"&PN12-B
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M@)5@3')8-L>F!N)%,Y1&16+-3JJKD&>"ISB+(CJ$(PDPID\@;\DRLH6H7D[
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MQ).HLQW?ZS8=[&;B7W&$$BA%/AV^N1VREJ&I#[><GD (F(@5CTXC)$.5)*3
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MOU]]?U#&R?Q M+[+(2*8 D04 Y84-^X=Q\QC!]IDS[6P=>@PL/.VB?CCXW(
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M("EN3= ;<)VGMPT^F7RQ<?*R-B R9(,9RS21NK87LKB\GU;2""(54'DC V6
M#9R],TO5[X"X\V,4,S2]HC$#"2Z8AO/4EYR9D4TG>VJ<UWG>(2.019!TJUYK
MG*1P/:&Y*WG;1E0@&H!D<4WW7.0'35LQ8N*XQ5-DG8' J9XU>),JH$PH'?\
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M9F,.AB#+&*!M@J+OKDD1J'+4&TY(AMX,MZQ1US%1>>V:P&85:N-?26/.,8H
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M6[Y./M"4G);FMN9F<HSO9PX7!$P.762<]\_UI5Y?OG=W!_0QP 0B0>I+'8K
MV">R;\VOUS;P(X3H\CSB:%B(A<CIVYUU'.6Z-N362IJR&^-PTIZ89U /;08C
M@ 8A*DD@,FF38X<BP+7+$4R@B#@S_27C%P(@6D $=(KC2C;6F=RBN;>9EY7J
M\W((!]F;X1'V0_>HG/><Y*>(74KZN1RW0QZ3[L5LF\UGU_89+U:&P.C D[8(
M*R ".@P':<<#E5:;$@O) Q4BI-2"2E($P@[#!=K\(:>4(.#/YGUE9\RKY5YS
MV;@_P!XP^:SCT/VS^_N(_44>RF-2,>R+AD%5@I_TB1(D2)$B1(D2)$B1(D2)
M$B1(D2)$^A0KT%MW#8=AGV+D=XR=3HSKUU*H9T4242I[J_ +GU8H9 &(V"L*
M[G'IA1PAZQ@"$R)$23C;%:V S%F$@$A,8V8Q\U5<3-F6        !0  : #1
MG\/X_H^:Q^!CW]=_7*L#]X"BF!%@!-8J8% 0RHR5;5M?^\2)$B1(D2)$B1(D
M2)$B1(D2)$B1(D2)$B1(F5_ZB2"?[X)0I3 RY<1*"ZH&E(6Y_'T:/'!Y;S^5
M]7;Y>7G]3^O_ !PI@^83IX/Q_P")U\/X^81_](Q_7_CA3!\PG3P?C_Q.OA_'
MS"/_ (YA2,!7LM&C.&.7E/DS<P>_#J.?@>L,8;9&1$"LX<T">;".@!)>&_37
M2X1/+(B[Q1>R3(0B!61_(SW]S?2O)S\)W6UW=C3^B6)<7^HD2,[/:U@^']?.
M%Z>3\Q6YM)&B9>&2HVY.Y,],P)7Z6?M;S6OIL=F@\$DEGX_=L2I^32ZT0"SK
MTO1A\L!,V]OVU9_J2-(M:HSWO,-PO)/85L6F?R@L7J,,#275'DCC]0,'S"=/
M!^/GM)45#L* GMLIE+I2H-L!ETGLP AU#5+EI"LIF[--VG0@D(X4N429&FFD
M&9(L;\.WYB@7&QZ122BJ\0Y2!K=!7.P'G%(>-U;9\8)! S>4ZT8MX48"? L6
ML/""$L=D$U *)0\5W@!#3BT>@&X_Z,JPKAR-'/4F7SJWG.BH/B6OX(GP(IC2
M6.?-]2NO&/&B"<>^@Q/:84R!!\4+0=#E+T@Q5D@B%L)@['N@HZ^V$_FZ^'\?
M,(_^.8FSBN:!S.=.2,H+V.P&<12ASO-D ](_AT8):4HOQ"N<C(>(4?0(DY"W
M!WX6SJ D5<*I5BK/2:79KS\V^@U_"'_0*P*Q2OCZMH/._I7U<]39Y57JP2]6
M OX?U\X7W]S#<;?U<BVU&:RC:K&/!(ZS@C%=J^5H3PN-8>F:6B["QG(<+Y.P
ME0F&G](>8X.2R"T5 >$0XNJ76;OU8C(W*%@1P>W01XSKCW8&1JG6 %"Y(OFJ
M&<$/8:!L*[E',,HP4QP[4FF#GT>L@3N9888^\(3",8:(XDW)6A-A^&7&!]W+
M\!2K2 OS,NY*+5<SNSL?#A;',:HXP=+T[AI23828U3J<(EK\F*P6*" 8$Y>E
M-+_6:"##B2XI@ >CY9 ;DI_$-P$;3P!L%R\*O78Y"\--"RA)^&%HVZO&#CCN
M1O\ ..)E+F#YA.G@_'SB]8(V1@"Q38EJ0&7 X^XI,7Z*=X%<G@AV/63MB)7'
M$F ^)F9?Y%F&JI=?DP<ZNOV[B[YC]R3:,/>$>X?.'!G*Y+##)V&*'.W7";,P
M,QP#F,^IUX-N7B7GD#G"SDBX_8P!27N<^2%H,(%$.5EO)L[1IP"8"_=7&>"X
M&HG"F76#2=:4YB8(^_4/ZL\ D5,9EO%.*K5>3A8#11JFA%%$> DPF1^\)^ #
ML1*T:!';-"2QO@Y''!TH_@*5A=5 @63X"F*"5F'U5"03D;2BOY^OA_'P$>,0
MS>.>*GC-$QA)$H[X$[%51*1Q></_ (Y@$_$;(@H_"!KRC@RJ'^0<4FQL#RA4
MLLR,$3$ ]6H;\@)>M >-^D=6H[+(.!0X4WZ3A@K2S@< .,E)*X*1A @GC*"=
MUA $9D3-X6?$*A7NB)+?RJ6D$)M1?D-/X/Z^<+U>!'"CH\K*HEZ,5:4"E14
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MI;/I$&5*9P3@<0#UH1#CJ_'3R\$6$-U8 Q*-.TV8&5M*N"?#1G:ZT260)5S
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MMSUV[$\$^L(UFP/R=_X!^H]^Z0B>'M?3#J!1AT\J!>#,"AO0]R"2+0R2PC7
M2.&]A4EAF^/+EH2LLTDKNL9) 8P1Q4DU8RM?YQ$7F).MR5YSO D!DOBGRO\
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M6@-SQ_>?WX'1Z?K2FGQ?X'OSC1&;G]GG_P '>B7M*_0P\2-RC^0%3UGM@"!
M4';YX#63UVQKS!/6,BC\ D!UZ1/N/_!]^XQ^(Z3- /G>O3-ZU$^U?.X)8\_.
M *)$1.H[Q!#K=#TZC+7$8R4BN@B/Y_\ !:%;H.?7C)UD=T\NKJ'C_@I?"C^2
ML5X^A^P!_P" &&&&&&&&&&&&&&&&&&&&&&&&&&&&&&/O2ZEOJE^_Z+C A).1
M)/IB\^C/[?W]/_ K#############################K?GU4_O_;  @ .
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M[?N&0@*,+@0R:0'3@ 1X   3JYZ0]UXIZS  !ZP /Z#8N8(!1Z.:5DHC81N
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M       2$    !")2 24 02  "02 "2 "! !2 #4KR00       2.KL: #0
M   !* F%G@     !1@    (<2022 20""00"0"2"20  "028#&1L      "&
M=IEZ  2     $3 .5@            !=:6B 22D02K7 20 "2    2 >#\Q*
MR220   #$#"L  "0    C]5M:NS;           +FE&  2  2,X8  " 2
M "084;(&L0 22   ,?[.2  2    !O/H20TN           #NE;IT  221L*
M ""2 9OB  20-   & ""03FZ2B]R20 "0 #;W-V8""GZ/           -QQE
M60  "5E=("22"2,N  "02   02 "209)220020  2  &?"1]D"<0XP
M    ">.-5T@ "0E#=  " 'T!O@ 2 0  "9" 2 1%&0  2   "0   DBY8'QB
M&X:@         ?IU&2" 00'D<0" 004_,\ "00   "2222 30D "  2  2
M '<5:2"=9GL\         ! /WV20 "#OY> " #JSH0@ 2  [  """  !36PJ
M:T*- "0#KRUYP\_P0\-/28@       "02P0" "0:&(H  2>A9)T "0 :6 "2
M""   FYEK7:N8 2 4(C<_P"I*\(:<C=Y        $@SP$-0$@"NL  @M<KSL
M@ $@ %TTP@$ $@\^Q!@IILH D Q":H:&5Y<M<;E_TH       D@D@FI  @$*
M<  D$#/_ (  ) !O)WI )))(X6$,L'L,0!(!2FL !A=P2OCSMQ70      !
M((![/;! #68 C:#5A]( !( "?MQ)!   )RM75_M>P ) &*V]23Y XQ30T\F@
M       ))(!?9.() )! )@(( )(  )   ((()   !(Y/[,#_ $( 2 =(D+-N
M<B&10)*C4T       00"0;JB0"1#:!+BMP" "  2  !#00#3D>NP&)(:XM*@
M"0 %#C\<)B"K ;.P($@      "0022N2&("3-0'O^"202  "0   " 0"89]
M*)3.L0@( 2 >!BM2<1KZ_1NU""P       02 "=W(40N_P"<.^1L$DD  $@
M  $  _)$F 0HE@7A 8 D +[0 > YF?PZX"&R@       D@D$E:.;FT+</M!B
MD$D   D   $$ $)L DD$#0MVK# $@!='   $(MR/8#JX,       $   D2 )
M)9X9RRD(0$ $  $@    * _A D@@=6A<TPH D F5XX  '#FD.^8"0@
M @@@DD$ DC'URO)/ D     D   $%-'Y D@$!*"?XY3 $@  7R   "F3P0P!
MM@       $@DD$DD),&DW?O?@@$ @  $@D@/8Q5WH D@@.UMEB9  D  +8(
M 4\*.3J4!EP       DD@$DD DD  S$D D @@$  D$$F[DI2D@  D";@WCZJ
M $@  3?  #9"6&?5&0\       $$ $@$D $D]I$$@$ $DD@ $DD$^@VU0D $
M $UOY6#\8 D  CX  $A&=(]?:MH        D@$D@@ $DD @D$$$$ $   DD@
M        @$$7OWC9O $@       N2D$(?LV        $D$  $@@D$@   @@D
M@$@  $  D       @@ K63:+T0 D      (<"8#4/6I0        D $@$D$
M$$@ $@@$@$D   $@ @@      @  \+[7SB $@     'W4;T2!)4
M$ $@@@@ D@  @D$ $$D@@ $ @       $D  8VEY:M  D      5+AFZ&!1@
M         D@ $DD  DDD $$DD@$D$  D        DD  $^"E3#@ $@     $
MPKOWD4^          $@D$$$@$D D $ $D@$DD  $D$      D    B3_ )-6
M  )      ']="!(S$          (  !()!!! )(! !  )))  )((     ! (
M   ",*P\( !(      XD94#@6@         !! !)! )! ( ( !))(    !(
M      !!   !75 +Z  )      )E$#R<HH          ((( !((!)( )!! )
M !!                 #$L0 (          6_0             ! Q )! !
M(!!)(! () (+(  :             T3A@P0 ("      !1T       (2
M )))! ( () ()(((()(!)0 )2            (SP$4   (
M  !10    !(#EDLEMMMMLEELMDDLEX !"]MMMMMMMMMMMLH>ZS'  (7EMMMM
MMMMMMMMMMMMGB     )                  +  (                  (
M !*                  0    !(                 !8 !
M       !  )0                 "( ( ()  !        !)     +  (
M )((! )( ) !(   ( !*                  1   !!(  (+:)+;!(( #;)
M  !8 !   !)((*2:;+33    !.,90  ""             # )!( )    *(
M* (()(#(   +  (    (!)+2:("3)    ((@J   ")(())(!       1))))
M!(      ((!( !( (  !8 ! !(()(!!!!((!!)!  !-HY0   0! #:: )((
M   "  !(()        ((((      +  ( (((20!))  !28330 ))<*  ()
M #3   ()(   0((! !(      ( ))!      !8 ! !!!(9 (!!() 9 ;0 !"
M7'                  "!((( )      !))(        !  !   )(  (( (
M   !(  (  *                 (0     "2                ,R !F
M               /@ "D                #0      *
M )0   10              !2   "0                #      $GDDDDDD
MDDDDDDDDDDL   $]DDDDDDDDDDDDDDEDD   $DDDDDDDDDDDDDDDEK<
M                  (   !K@                    (
M  &P                           .T
M          +$                           !6@           ()   (
M!)  ( (           !5                             6
M(^ ( )) ) !( ().           (6                           !.?_
M /\ _P#_ /\ _P#_ /DL" "     202 0/\ _P#_ /\ _P#_ /\ _P#_ +;_
MQ  K$0$  0,# P,#!0$!       !$0 A,4%187&!D<'1\!"AL2 P0.'Q4&#_
MV@ ( 0,! 3\0_< _DVCYO-$&=80!<NC7EH8I(_ PP2P -B&2^XNRCKP3!&JE
M*P*Y5O32"!"A7)K#&UNE?#-_4TLG/.3?[YI"8SL9];]%4'.NCRTU5_>8SO\
M2-%;4TQS^:H1=FJV[P8'-;Z=&)Y_KSMT%W73KZ<:AWX<^OT[Q&U/,4_=:CRK
MU/%47>/6S7N/R\_QL5!OP9M?IWP<BZ/)5HJ]IL9'OKX!OZVF3/N$S5(Q-ZB_
MDU,1GRT7)-+>XF81%=<24D.!F  K=N;DH0!2954L2AC"Z2"[IGA(D-'DH("]
MM7+AN_+1^A'*A,G4=/GM(BC2-F#;;7+??+J$;A"02$JRFFY)+3);*JP+D6&&
M[),(0FKJ4@V;FPDVRO8L@JUV1*J8B<R^U(P-(L$W?C,5\:W]7R"OC6_J^05\
M:W]7R"C1 Y^75]!AX@\_8^@ADU^H=*'(N<6,9M2&2Z^W2U8SG:3;E\TJ(U\[
MD[=?HH8DWZ".?O7XHT0.?C'-?'=^.?D%?'=^.?D%?'=^.?D%&B"S\8Y^J)$6
MQR93'%)_AO\ XH=T>#[1%+Z73V/G8KYQOQS\@I8L;O4XW/2G"/:/L6X-VH9S
M@*<@E,"!)6&;,AEZ I2H$P"1N@0O$E:4-1X @,1$,0\(,MZ4 BT$<+GY%1$"
MRQ?K[_H4WF S=%G']T%D.9Z>;TF"LE<9G 6A&Y")!%("4,V9,W $X$C1BP26
M6G &= @+18TK8\YV8YM-2A C0NNSJM[NN*'@N@7P6OYJR@,XL?GK:KB"3]L9
MO::)P =;G7757M:AT4[C.9ORQU:LHDY6\NO/WXH>+6SOC%[Q0X9.C<O7JU*L
M?03C'Y41'-LGY?6@8M;7L8U11XA%G6UG?EH>+&US&-444)+?9SK?E\T+%G&O
MB9C14_K7S:VORT.8'&C&,Z)H$(1?=T^.*/I[P$8B/RK8^^E&,\GY% F#QIQC
M.B:$6#KT/L=]:'BUC4Q,PZ4& BW_ +N:T9]"3&?PJ/U;7'2W<UL^<Z..R:'#
ME(B26XZJ&$3*C1,RB1S&W5=$8E-I#D!B8B+I+!1@%0!#P88C,(S(,TP@!"Z&
MVACYF?W;]]9T"$8@F5("50%$@SA+<ZD(%#$$Q%X0<9$(+#8Q$F#OEI;!;V@%
MYU)[WMQ2D#:9[OTD<&=Z*8O&KKKEB@&G?6H"8OSIFD2)UGK;Z73''K4'+YWQ
M:<9H)$W?M^*+:QBUG/UU]O6H"8OSIFD2)UGK;Z73''K4'+YWQ:<9H)$W?M^*
M+:QBUG-0;'BM1['DO488Z/YBH"8OSIFBDSKYU^DIA2@+$'C^JC=C%U3B<&=]
M)[8&I$$GH) F8XGI4#V09 ";"P3 -D,(-X-J!R(3$@(6B<$@!(3\:?:_G]$A
MG+ 7^9Q3%!@0.JI*1@B5P%W-2MW:2G2)L 8 6R6@8) CM:\+3QQ="591)Q46
M.+%R>8\5;+EWG3[?[40D"S(=7YWQO]='?T^FCOZ?1(1%YSVJ#E=^V:5<J]:D
MZ?,T"43;?Z$1/R?\K(O@\6I4)BWZ-'?T^C2(U\Z4V]W-[F*877W:977V*D.Q
M$;_25HU(_-!03'2,_-*)2JY"CD$VOCTHURBAVF=6"_QH020$I$)< A,A(N65
MB>MC72(B!T9Y[8H#QD8V'U\_I241! @K<F0$)F48*#BA$=C5!"QFT#$7C:T4
M8@+,P0XO@[E[?FBEL#6Y$N)[^*9U\MSKSMQBFLRQ]W'/K@IKYM$QIC%_-(1,
M:]/G>OD]LW\581<=^/[=XXI.;XG7&;^*@2Z\C,]]CKEQ:HL_;MB_FH[SU#[>
MK$\TU\VB8TQB_FD(FW3G_-Z:^;1,:8Q?S4,2[V/GKVJ+/V[8OYKDNZ:6CY&]
MZ9FYI'/]$^K5[3TTQ?SS7R>V;^*3,L:;Z<^N*=RG-\8YUYS3*:]>WS.E)S?$
MZXS?Q5@B>_S!URXIF;FD<_T3ZM))$<[6C'^YTI.;XG7&;^*TY[STPSYIG7RW
M.O.W&*;O41W9F&@5#U*1.4QVL6X:UTU5"BQ5NIM-3XE8,PRDDR%L)BU<L:*$
M%QRO^S^WS_E E8BV<7/[T[4Z^-1(MFN)8 S!(,4%EPR68P^_#2@R,PY@CCGD
MI3*\]?=H;++A%KF=_P G2@GD2VHVG)GUTO0 DN2$SBZYRR:VO3)'<8"!?2\F
MO2-;.0H1(R9$Z_WBAD$0DN2\F8BZEW!3F$BF4FR=9@34G>:'(R0-D0\S.G2A
MI5EPR NQ89X,Q1P!@<S<EG6TN)A[4W(DCN+,$.VE[:W*$<R-4MOA\\5;@FH0
M$F8<V9S-#?)0!7R ;A% M:5S#>-$J>B+3'*'"!90T6)6#5F"EN6HA();$:0Q
M;[PBR4G!Q"N&)1+&_+>&1($,78%M>2+,ZQGDM^%VM(2Z."_>"@2TS%QQ(PP;
M%3Y<R2")>#5TR%V+2.ZY"@+LM^LQ,M[-(*OQML.N4:7U'DJ9=8%/2(#XF\YS
M2%A:[ %429B"8Z4V4((D4L95!,YL[128\A#(34/ZU@Q*(_:J-)$Y@_/%0;'B
MI@A& ,&R3#'--"G46S9SIJYWJ612!I*W NZ-^H:UK@%*K\BB1.*-:4KY"!L(
M!.8D^_Z$'.XG#HFS1 *, 9!,'(381;31'$!L'S.+JKOO4&FX+^:2Y<F)BTYI
M3*\TJY5Z_2*$W  NV->R=\4]"KT%@NZ,VF\6+NU7I<A4)VHC9L#?-2HLL)&)
MNVU3I&)I#-8THR7S-XGJ0R4ZD!6"#0NW]P+:4D3W-$RSIOQ4P1(DD6)PO!IY
M=TC<AF$P&<3-TU>M*BW9*&+D%CG[4-"@1K"% Z?-[0CRPPNLZ\LQ;2=X*6BA
M26%$GAC\N(J-W(!>':[ Q)&,=Z8QKD V4B,$DL:E+;3?4EDB."+?&(+LP43>
M9O//>VE *<)+7 8#?#/?<I&IJ#)L.>_3K4=%22PP;V33#-X V-_@M&(%F"65
ML6,WB@[D".C"!,9)(7,E%!*Q*SC*4C0>3Q2+*WD0R6BTF3.*F(0-B)G7^JEW
M?+4%UG;?M/6E,RP=;5$2NSA,8GS6A:E<ZMW\T5?PIF0D$>XB2-K58S29P% N
M+BF-4R03(-Y2_P!H_0$VM//X^;4&2F(,*81UL.A+ 3=!K(7K!BQ.^>^S"N7[
MXQ$7M-.Q=@TUXG?+%[%.ZO9STO?+-,Q/W>OG7TK-=[I;K?++#FF3,'+?MYWM
MUJ!%CFTZ998RQ&]3F7F?M>>MJD65G&.)ETRP!FHJ*YETG\3?^HJ0(AB23_+9
M/&S+(PUN[&$]->6*@1W!+%\;:3/^4[5UB?+*/.E)N;RWR\7TF]6P*;2[-U?&
MGC6GJ1*ITEBS?'.1MBI^M4R-PDT)S'$F\7T_<NM&N//6Q3H-@ )A&>)85=\7
MI@)<%8,MS)WSHA-) HR%@)9T3DYUM3& [!)F83&NF&;49<S2A6Q',Z3KTO60
M@RJ"&99>Y$9@FDTH8PC9CE*3.NL44&AHPDS,] T^U*9$%M"[[/66EW#>^,<V
MG[U'$,<8VS?UVM5]RG+??72^U# L7YS=CS]^*.$,1M:<8ATGM2+6R!V/>,E0
M.Q44E-UL:Q>UJ)7"$R&"<#)Y?VUPT?G^J@3NGEF+]8^[3:L@MV5$+U,6G&9J
M*E.87&)C1L<5R5?GF_TE;I., #+MWZZ4X26)J$33&G-+]'B=E@@498&$R:>"
MD<*L0K)=%J3H4^#%%:18&)TD@0":;0@!44D*!+8(!DP@=+.P0N!!-X- '*//
M"$@N4@("Q%UEPD:X74) "8A25?"8H\F E@NAS&9.R&K<R&C@\':=L*)C6DE(
M$3?97!+4K(!),!2$C82W#WX3@8Z=+_'6"PB^= (",#+:.?(IF3 +*V\G!+P9
M"\K(:&1J0K__  68@B2<DBH8J@9DEA%1*Q,JKFH7TUR!!P"DV;VHSW+B&-RI
M*639,UTL;09"4>+"02]%$<%+ 0*BB7)B9<]2PWPP>J))06.IA0D))#C!<E4:
M!S/)9)&34(H\;L33PR4"\BKQ2L0D@G"S"%(P+,9=]@DT1&  ( 0J1P9WHIB\
M:NNN6*G+H)+RMI37:WI4%D-%Q3WOH^V+4N!'[D^R/-ET^J21T_-$6F4&-"LY
MO10&@C-H(QVS]-/;U_063>X+D1$;\^] ,-EFK [N8NXM36$BSP0!BM"7^3$T
M:"(SE0RB(HA$ 9&:!>#FC.B5U3,JLS<$R!4MJ#(1$0L$(E(OL@QJ$@&(+1 L
M)3-\HB@%46V D,X**&SN$$4%)(A98T";)Q9% EN7; 8&KI)EON2$;A (#:"P
M8M1,&+9CI:^^;U+:4" J&$E"\RVPE@)5J&XC,)1!:S#$F1L$*MY)$G4$9)"@
M4(PKD*1@&,A$( 90!HNX&L-,WD"!BB((7S' 42NL A,R$-R&)H.9%HA,E?(2
M03:G)IP)9@4!3,2<,FB+32XD"<!@1= &BX135N1 J62P!"!:1J-'H,A7HJ!)
M$+Y"<"R(C@ZD,;XBVEZ:OPI[Q\]:LB>?2I.#QYO&:D<&-_H:]#1JB67-^M .
MPR-HL-+E@YM1ZOY?T73HEZ7DB_9OIQ0$ +'%S#T-'B:O!E)<1MB(US3.OEN=
M>=N,4UF6/NXY]<%-?-HF-,8OYI")C7I\[U\GMF_BK"+COQ_;O'%6")F^9OC-
M]+Q%&-212",!) J[+HF@M&1;- 0F4RNX+*30$*R(2 5T;8"(M#<FE91 ! M"
M(FZNHW9F@AI"$(+89<T$2$VE0@(9[A8(YP0V;F+4A<NMCG7/&]19^W;%_-!Q
M6'2H LB,**-HF<T:X<2P48,@6O*64OFD;A$U%R)1"LVC-3Y<2(E& 4@ 03(9
M&Y0@BDJ$KC".S>40#%$Y\M"1J8!<U3,$NZ1&,1 F4*8"9A(.R987)9NK.HB8
M$X!)2LRA!'5L$K9H('PF9:C$3%D[@@(ALH*A8 0SJO&)+U+;660*PDP7C.%D
M81J8$BS+UQAZGW:9U\MSKSMQBDMZ^OAUVIF;FD<_T3ZM7\O;TOCOEQ37S:)C
M3&+^:TV7F-(W[.J4RA8Q/2<)]L.8IAY=2U(YB-$+[?MB2&XLCN42F"R:#X"M
M2%,.&(Y*%AJ>+Q2+ *";#&=O6A+K&M#$F9V<8Q/WM2<402FMKG4=Z:-89BQM
M0Q6$#F&*+(C0;HL(O"+U4)0/ESF10@0$9E(**%E7)T699,AJETR-I6J<RF0A
MB)*!158'"!D1$V@(DF/H86$#&@"!*2H$9(!) A$X2)$<E#Z@+2!BJ[#2K2(H
MBZLO'(VF-@"R!":*&4(H%!8]BA'I] K636 @C$")23@&9  (1YKTJ2JUPM(R
M*$=65O$ZID)%#%!"D<3"'K:E2-8L;%LA. LE1WS55/V^[/2X$5.1 "*3U6$P
M8!5H49( - A".JD*(.+\(;A\0F$6(4!]SLD[+29S. PB(S$]O5$;C7K+U*9A
MJ@>5_N5@R55/G(,E07L3%7J/"&W.%=T"@S(9+%0%\3X^.JZ5AB 2)XT\D;"0
M4QEB)=8UH-CP5:PRZ=)HMEP*K>42/-Z3=LD;0PG:+4.<BNK!'@/T=)<VM@IL
M\LY_AO3$7;S/B/PUS//7W:5<J]>6?HTB%,^E2[OEIQ11)E;3\U[5(!$"%W2<
MWM;>=J%I4$J8(Q+JQ28P!]@1U R9S$[ !, &?B2ER$Z4@I;@FB6EQ-+'-A9A
M2H30T,,).$C(V6:P+WFB"#"7"N*W6LE7-;9B8!H$:Q<#$JXG9"HL@L7S P,A
M+%(KY#71B0 &_$O,3<%5I L)X"Q)%P*99&?@,K3((82U6L"MCS#X:Q9<0JA)
MNE1$D::H!.P8M3O T,/A58Q:*T4',^Q><S*7 $JJH1-!M@$X"D&QEA,Q2L 8
M$, P !0!!F%]"M-M(R(<+  H)%,8,)>*":"!L)8"&H5^1EIA*0,#0.9H@PXH
MC9G@@&S U2;<<P@,"C5A9-JFI!6& )+'[XL32LS'>#\TZ)77$_-:EW?/UM+9
M(&2;H::H58W4NIO3IR>K^@$VOK?W3F26^J[OWL<U,8$X+3@'3.7KO3NKV<]+
MWRS3,3]WKYU]*S7>Z6ZWRRPYIG6V[D^3O]ZG(GSDZWMEBE@B>^OWQWUQ5HEW
MN9>,W"<:5;J%+!,%D R6$6;T.DH '&(G<&C:\5:<00MF#L P!.((*DPEX +W
M8@",-HG$$U' D! P&&93$K1$Y&51-KMA#-H!,1E5"B:377((A'"$LR7,H0TO
MC0)6H R%I3,R8O2GI(%P"\W)!;2TPPP@F"'#(EN->A-ZQ9J5<!QLDF.]ZB8J
MYI$@4V(!3+:\6:B(P040FY":(AEDXB8Q@M@!-P5.#.2EG*A +,&V]!*C4*(D
MF"-G$FA=26%99IH[,!1PJ)$0"#%R07C2+\B.RP@S?,VU)R8W+1)VA+(AL%2:
MB+2$2X ,DJ*-3RYPW$P):%+Z2S;%7W*<M]]=+[4]A5SB\S=[7^^+5R+O<OTO
M@FYBF(B2_-.]OM2;F\M\O%])O3P&I>?7NVYQ4,21QK9S?B]]* @DX2N"^NW[
M;CO^1^AJW(X,[T4Q>-777+%,6:=8L]V(+5 M#1,91>P9=,)% CUZR9,7*E+*
M2*M6$*5#*HRUN:D234=S%6B4K9$D-%;"S2S1[\< 10SNM9(I796RH\0DB0"1
M&<QV< $ 000(%VD;,TDF.O.N,E>R1)9.!)(1&DI&91+*2JM"GINI83ED PA
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M,-XHW"8F/4WZQS-++<92)>)GWVP75<JQB=/ZXQ]#F!D$Z)IU\>U$S5E)A!Z
M'.:/5/"Q_ @",18CK\F@)W(6!WW[]Z5BY[A6II*#'WJ54Y208Q@[_&AY:"6$
MABS]G6W:FGG%JC&A]K:[T>0,2(ZF92/Q2#D'K?\ @L#89\B7MM:9XJ^6#E"'
M0OOK'!;-$"4RZG!F6!A 0K,@H3Q*W# DP6<KI;H,6H23U'+.J^^E(4M^-/'S
MQ1;"S@^;U 8 ^J%GR%CH.G-1FG3@Q@&0LL!V1$+I&XPBLQ#0'PW)1:VD$"P.
M($I"!7#4(Z"<0^/(S)9(V_E?+X*9T%,)WHSS/^+_ +07X1%W_.D4"(66129\
M:VC6DQ@D28F=.]!,C$8>DV^_^_HT=_3]&KMZ_J&R;Q]FF,G:=_O2D!+2I.W!
MO%*LG4U9^>O%^[_MGG/]?HU=O7^*$L[1B,2UYX?M0VM XO#NFO7>;14&WZ#:
MSZCL?.M(8((NK=2W">:RM[NLOZ_@/);;GMQ1VQOSOC>AP7QP&LWHY"-IMM&+
MM=/6:FJ/>2\YUM%%R-J!&-&+<T5!,KK<YZ?)_A0=S%OD5 $Y%CJ$]87Y<278
MTHD&1*WWK((""DYY11G)UYT_RK(5F9Q/V[U")A&\6J9UF.9C]# -Y_"GX:@"
M28,YG2SSG32G%RCBF;0S ?;::(#.!L5P(1U+\E!U#R40C5K"#6J!@ 0#>-RS
MXCIEU_D)$+(P>K>K4+(9UH[(D5Y4C3H(WP]K2(86]XMK-M\SN&D'9H$B.,3A
M9M8[TZ*]U+W+MRYC>*:$Y#,NJVO;:_YI;=).!;&XE(/+>H1WP$=/M4N[Y:5<
MJ]?T2F%*:S*N,]_J"[5YVQK16 D+6F7QAM]G6F>AG$,_A_-\] N&RYTB?]O$
M1S-$P4$()R,+.3/R##K*Q0[1\TM4A7EHS\XGOX^LIA2FLRKC/?\ 3&M[>+[^
ME(L@>TO>]2"3/!I.>M154-)OK$Z'MVI+4@2Z1,OSI^W!L>/UZ,'E>8O2)5RI
MHY;_ +8$72X %="3S5_09(IN8RB\CX=J6)<$@U&;?9\0RS/Z)3"E-\WZWJ P
M!7 >#YK2B*"F&+D[4H0JFW3]]8+)](^?[3JP"O5+Q$S$#WSR:'28",A]%MA8
MDT -[1)=11P,@$*4+D%+)+W(T  (""'%!-H1,I1&A&XFR@4<@% 0!;AR ,*8
MBEUXP#KO>W)_2X@T+19D_%6!RM/+I41I$\1/Z"+*2F.)FFA74[8<>:1$,"<%
MV;<9ZT"N-I D%K,!AYM2*H3$36"Q4"(4L[C+ )0S# 038B=4($&(&""'RY_C
M_?\ YU]E08KG(9;2<Z=*!(4H B+S@B/\YI:U$*&;2O$;*+D8;T)""0+#*1]K
M)0! XFQ(0K>V:;, J RZC>>L\VIO\L2$8&V>(_7J[>OU5K>?L5!=",VDR/QS
MQ5N#DQN0]+?#4;0NX=>>.EZ-:A$3:S]]G2?L)\2VL&I.9[]\U# MZ5[:Z=_T
MZNWK^D^#FFCZ3+\^?8F#$;9O"V!UHBVUTD3Z<6^^*P BTS'7^<Z1'<";WS46
M]LTMED2$1N)"/FG*K4Y"<)O,D ,3,A:6WV^Y/\<[QK%*X2)N+D-S#KS@WJ^!
M$)($V8$2:DS<MFK.^=+$8)BAF+&"6@(F%FBS @%E,LFF"",BH19E@(=("T5"
M$)2PB G'(SI>_ &*]LEHW3K$3,W"W"I-@173ECBE79TCOS0LNOS[/Z'>-_2:
MF6)D7B8YJ'6& F;??WSYJ;T6,JZ&LZ]9SS4ZI;DY"=  V$!B*%R$1!4. A.2
M@#: C+"R=YF/;$C!O_&^1PI6)>U]-_O;^JDMQ4P0RB^B\>*EBF:ADB"!KMQM
M+$Z,I08$3=G>FP!!M$X&71;W.E"%T@R6Q#=KB]"J%MQGS3.7+=O4&QX*(1 &
M?3].KMZ_542U$T>U*X*%5W7XU(D<22Z>FL)^:4-A)L"+LG]9UM3.%%AO 0LQ
M/]T 8X&$E/),OFI& <-"8_$<?IE,*4UF5<9[_0D(S;$,3-,&8:\+,ZOWHX3I
M2S<K.8QTQR<I(,*2.=/:@<'@"7E_6CUJ_;DOJ:)Q$;<4(=+T.?M;R]P!H86F
M9O\ CKC[TD(Q=;:-NLG:/YBKE#$!B=IWOK]AHE8F6(T;6TBVMQB85 L"EBC#
M=&TCO&&IBE"(P(HA(3#.2,1!$?R)2 9B6+E]^==XBHW2 Y+3"D1%E(7@30']
M#QH9C!/%%)4K1*),A$2XZC(  10"R-S D&V8FZJ9BISAD6)@S:EK$&!2Y$T2
MU4;C($X/.:2X$9Q:9S0M>7AT\U!L>"B$0!GT^EEF]B>LCZ>*861H1>?CIO0J
MD 6!*EM8Y]:)AA#>197DUL0>+=RH$VR@"MO8X4$._LIC@A%-GD"H&<,Y*P@J
M)\2!D+0@*0E +%XQ-N+VI8%9))>8XXS_ !6_<<?+?>@2R8$G4GO$#4J-H';%
M;\\7TB[M4"CF$-(S_?4>^_XM($JC7FA@(@&HX%YLW=:9$TAN+-[L>^OZ-'?T
M_3J[>OU&%YL/&U"#W-_G^5/U$9<%20(MSVH=$0(3))6.DW_R<D%!8BP,9N_C
MO-^5)".C&OM11A1U8N_G]6KMZ_2?'N,A,RZ\AY:$S)8(F4O'SH4VEHDHLDQ\
M.*2LF+Q+[Z@]^U.,H<)6[ @]OZJ^%0/,>/FU16H+DX^24>,%Q:+Q'?)UG;5:
M DLXW@QH (T9W_F1EC$2_CUH1@99FU[_ 'ZZ\TY"" K#R&T_F)J8R-7BP<1:
M+A%'+ )) FD?>?;GG=_CLMQ A6Q E5;$"GFI,QE(!(2$"M[(O<Q+?!N$0S9=
M (@2+U(*TP#5+E%TK(%K!"(.$$$FQ;H-&T7[TL31NJMYF9OWO>FU5YUO-\9O
M'MQ02P1/QH083>?IH[^GTF$+W]+WH.LSKSKS.(MBB&D.'45PS'^[@\X?@Q4!
M=0)&$&R4P*KEY%!!R5(A%?M6"11&0!888*$#5Y*?*.V& B2+%*I':(QAPTBV
MLJ*#,<C"'28O:)TV^3?^+SJ8=JPKJY=6T?BU! #!*&TYCK0,5F)O1,-BX2&T
M?$U:MH0DQ%Q<6?-]J&6Q0"5=6YJ7=\OUT=_3].KMZ_6,S>"SF&'M% TV&6Q9
M-^3:W-6Q]/3P3,ZI.]*Q@8) G<3G7>HS R"1TS??-KZ%(.!)*X9))^;7Q<RC
M$X+%\,%N./U2F%*:S*N,]ZD;:02*"DUR)T[@S@1SN8N+)C4M0CD@$D;0('6.
M-KTZW(X*K!-B+YZ8HN"4NP&;O-_.UZBKD@*S+-RW'WN4'TO@1 1[N.CI25DJ
M5X+MO\YJP1:+=CX';]J1-DA5&P..3%*5*$BJ7%;,G"Z) (YB$V:B\'0<>#^#
MKQ/SJ4$: LHN*NZ].^M%V012FYIK;%[>(HEB%E)+88'3DL1.HC2!C"X&BZ$K
M$K>()J"*R'WD3K%0R!ZDO:KD@- 8G2 )S?4P\4L)]]DT))F^'UJ(60S:'']5
M*=#[;?.:95*2<P/K\\H7&,WG5_STI4 @V+>4B;QY^%!!#DSUUS^R7V+)266L
MQZY*$I6$:NA'C#>V:5_;(4$HE  PL"S3*NJ."TL$0AV!-*<$$,H0,01*2C 5
M)%P$E3 8A7LI J%.24(R&Y4VC8F13*A!+80F%4  W(A#K&K$0R+U<O(W9#L3
MDE@9#+!$D&28+P)*0T5!$UH3+B<?-":!<!V!UQ?S4ZLIQ*:;5)N>2DIER\QB
M88E\6[TJ(,F&"^_-!+E>6#A"7CB@96(!FK,3)O\ Y:*1BF+,UV%XA L'<;9;
M+C9B-6I9D&Y^3I"U+8NME(W@H QR7LN!Q$"[JJ>^;2) XE0&I;N9H7P#R,JA
M2;@E(A'J0HP1L,B1( B:8<6 OE,MPP(H7B9FGQHV<1:1F)&0$R-ZA)!, ),P
M7)MTRO6D1$71&IU]/XH1#EF6)V\7^-#VE._G[[5 !H7AF-C]&COZ?IU=O7ZW
ML9C3O0A(^P;H]7BB%,D1D!Y,:?X2A,VG+U^W+6Z<YZ(YV(G3\5#P30WMW\>;
M'22M+;UB5)_OW_7J[>M#J#*D@)6=+9WI17+",!,*0-G::/UY1@4%C9AP=J0
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M9:1GX5G!=*M))$Q59(-PHE9@8*%SDC",)D64$BQ5'>L?F#LR0G*2284PQYL
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M0$)4Q"0(9D_"&\VO3O'*S+:E0U 7%UHG:I:UTH$BE@D6D:G L,;#*RA+  A
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M(G:BV+=+?CZ@D)]&8-J6]0#+53 "26U[1)0K$='CD@E)8*)$+YU ER06J"@
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M@]:TC3;3Q0HEG ):^80AX093% ].@MR*E"'%:-%7%CL, &Q@!B2VZT5 0$@
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M?4C&T 42ZQ2SYZD2,65Z/.4VI&ZK^H(0])+8"CW4RZ"AG-P1LE-O_8*"907
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M[F9H^24K@B8T%PQ$:R%'/F0F87JYE;@(*$X@*;#<H5F19F49<LR*$'8B$1#
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M\SK[_(*_S.OO\@K_ #.OO\@K_,Z^_P @K_,Z^_R"O\RK3!#DC/7>KG!&DR=
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M-? 4LZ!T(_F9G3U?XN(.0>M0;'@J P!^A!R#UJ#8\%0& /VD'(/6H-CP5 8
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M)Y3ZZS;(5,K!X*\,J\_QNYR#'SNG#Y*LW"6W;\'1KV,O#%CTQY8USVVO,.-
M0 9P$,Y?T80& *%'$G-\-N=&';'".>_1Y)HK1)0L"@Q#1!@*P9%62&1$Z^*=
M>!(J2DC(P*ZHRSAA/<'EUY##X=6BP&0"8!HD?/TE$! 0DJ>6D/O$$9K;%NE*
MTG"'#9]+WB@&!J (O& $R"2ZJ,!B#:TBR(EIXB4!%0_2PETH (>SW%:. DQ(
MDQ-%F#(Q"$"0%N4"H>"$AA %.Z2F5KIMCP>,AR#"/"W#H^.16,T4'>QHHK6A
M!".JFQ&EZ- 6909O*W(M1VRKSK:( 8#5H!G&X" <:(%USQ(-(<KW :5C;45
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M&,Y^ZOGH3,&\<GMH"$(U0)8E\X%. Y7 DG;@7>'CK F>!Z_HQ,[V_31@!@+
M\=0J#!7EF"OA^QI(IO\ C5>WW=*NZOG_ "V7Z7]ZW?'DU]1_=\O3\_NX^OXU
M LSX\;ZX>OX_;;*>73OJ'1[?JU(;$Y[[[T 'S/["*S!M?'>Z# /(T*R^?>@#
M;_O[=[T^Y^EOXWM^Q_2,W+Y'W_T!I(IO^-*NZOGJ&6?UZZ&EF'XT_P#=)Y4^
MU_Y^C\_9'R'8:RU^$%Z^U_7#)OP=^G,UE%WS3KK'%_69-\?7SUP]?Q^VMVUX
MX/3Y_;%)Q_S]OJ';2KNKY_NX>OX_=P]?Q_/9?I?WKY/34AI5AL"9Z/O-**F3
MP #.( 1Y-M4=4:V7,;MD#C?4-(@4JX [>,XY-'@BH*>"7'SQU\Y_.H['\N]?
M!OSKX-^=?!OSKX-^=?!OSKX-^==(Y\XW_P!6#!C2N[^?]VOG/YU\Y_.OG/YU
M'8_EWKX-^=?!OSKX-^=*%6>@>P'H?I5"@_F?N[7P;\Z^#?G7P;\Z^#?G7P;\
MZ^#?G7P;\Z^#?G7P;\Z9)A$[XHV1='I(:N!-R!10$,I5");1O1;Q(J10$,C9
M.2T"!:RM09E$YTQEZN^[<]X\D_9+V($3?<QZV3QT <747D0KYH^$#?2UU(H5
M82C%&C0-)%:+"VP2,J50!L6" P%JJ$8V&*;;;_XDV;-FS9LV;-FS9LV;-FS9
MLV;\!^/G+^@+X/\ ./OV_H"2HN)@O92^,ONZ^<_G7SG\Z^<_G7SG\Z^<_G7S
MG\ZJ@\.SAO)0O+WNLV[.F0VJI<'B TK 64 .2ARIR(KR4[7RW.2L,1X%<:O>
M>)G ,"*[!^QDEW2%RYX-_;2% K%,KKAJCM;IV3"H@QAY6!=@*.AFJ D)<D%
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MPB2*8P3S\#C9D'TZ_P ;F\FSR?HH[ -[+NXW/,WZLLH%C@Q5LH3X+<IH_-T
MDH2R6QH#M2T6& 4P P 7DK;3#3!'A K9CC?'EIKW; #=EK0W)0DW2(HVR7$(
MSSY:3&7GGQ?T(2 ;_C36U7;?U_00&YFDMZOMJ5<(12X_]SJQ"2$MPR]Y]GG5
MPP.#L,4F_!G+H[P.W1%:7<:0,$WS%CP@*A:/49/:()4\0FHW=)G"9WF$H@ 5
M),"#D7Z?-H0%*K<]'EG;>;?XJ!78GU9I85LK., SZU]-,O1X$@8>P9GAI20(
MXXV7$^<;:>$5"ISQCZW?J:8; &M\+O.7'IXZG71L\0S[_P C=?-SN<G6G9N&
M4XVVXDGWZTU.@LJW,6/V^[HIX,R!NP>_=R>&C17$+DS^'O[:#1I#(R[=,Y[T
M&&^+WG%]/X+)VW_O\^FJR,%5Q_[XN>-4R&$78R&5_/ILD^JD*H6G [[8VY)H
M& : U!) [DS]Q7+(J,"'ON?'2E-NN;HL<YV]]*421*&:?=],Z9(1RDFZ^TXV
MZ_S 3.]#IX_2[Z(HRKB3##VAH8\ 'A![^8T1J%@V("H8QR'._"FS.AZW_P V
MX_R$?W0C JN(&=GIX4(,PE2F1K@8^+T"A\R8_!!=VQC;Z!B"LB1=UJLYP\M=
M*!E$:M%ZAO#8Z\3.$1!<+[8R:S)BYM,&MKU^[^G#U_&N7I^?TD?@?GX^%UY4
M,V\;U)J@0J1=C'HG/]Z6<B8F$ CG"8HGEHH$IWW!!3SE4W9&M!!<BRF;'-3G
M%-50R AF)R2\3@R-5B5 N&"YVJ\9Z-MT$V1=_'K_ !4'#D_K.MT7*""Y@[^^
MN;SWS[[Z323HP^^B4YA25P_W]]89AH@>-4C=(@AA ACK^0@\""N3_P!\G5GR
MCMS/QUCJ:&6 )=#H<]?31?5802EKTV/'PU&:J&0R&' F^V\N-.2K:X55NV]^
M]\]-0*Q5W?/QVWS_  (6R*E0?/R^NB,Y%R96PH>.VC4QJIR;IA]_'6' @N\]
M>?QI7Z$ !!2V"#MGRU1I;!,IE4RF_A[EH[CAW?B.GO1KZ"<+R29C7;O2$80'
M'ST_Y_%#!4.>!$<A>AQ=$HAB4I.09G(-QR[ (7#7<A&$':\^/T_G$-]G?YO_
M 'H G(78^MX^&AI (/8YO[YMXKH+O(ROL>G/'FR&0RBHD;/7/OU-2D'LWI3'
M?$?O<XK6RU=V[7T#52OI/SC2@+%.+,[XQB&_OQITQ+QPL1FV\OE=(!6E)N%2
MSKZ[_H-0N*HOGQ/#&=4 ^+PU"9"ME)><9\-4[/?O;0C8V?P,,1IHLV&<ESQI
MJX86@[98F7>&<[YWT!^5(+<@"49;L\Q76(KY"8(+*KCK!NMP6!R18K& F*]:
M4G51*8E[39Q%3<@L(=C*N+?<Q>,&DEWH!,>"O>(-TQZ+,5)Q"HG29%=#R8,S
M+. *\*4KN\ZH"#86ZD3SVOYT) <X)Y_/'*Z+I=TS9\[TIW3YFKOA,R1[XW_&
MK0V_.&^V]VVT?,6&"=#PPYZT8EHRP1=UZ^LUC)9RVH21#&[(PNR2,%BHT5<I
M CC#T8E@ ")!:#@, -E6%71LHE* F4ID5!9=VE*4:7 4:YG2=2FG9 T[D B%
MRM"JK6.HQ$0$.8P52XI6BH(6)&TQ(88(M>RR0#19EJ6W([BB-R";2S4$*<%7
M)RIB2 )QFP70@60,0CXWUV[YN/\ %_[[_CUTHRR^[K5 O'Y]?#^1\2.\_.@&
ME$AF[\78_O22<.[=/@%QO[;FL2X(\<KO]?[TH Y3S-_CYZ=\I3:\O8''O:;0
MHS(">9_S^"^%<I>O#Z_^:!E96^;]\[?G1AR"0,P99GQNGN,R5QP[E<>OCC0%
MVZD9O+EE^2ZH[/,RURGC/?RT<H2)YBD]#\.@E&!GTLDN^WCK" 2&?-5_//\
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MYV1V8I8NGFS9"(\CT6<^IIGQ4@;L!S)Q^-*0)N2[NUY]?"Z$['EA!.0R&?\
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MS3,40,TE@$"#&\"K"Y"NQH$.&4L=Q(N#+WR;:W.'KFZ<J@;X93!I"2!$%R1
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M#D3<1:2"6+D$8.R[B0L<9^FVH8,L1WF"EG ;H!MIIR%,JR0F)=Q<DH.&U1)
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MVW74 :+F3??W\_EQP""DW&XO%GIX&D37>"AP(P>=Q;MK-6!B66B9\I3VPN"
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MAKAII!UX9O%ZP"<,  +T  <!QC4WO?\ S^%\FMI\O_3"1A PG &!X@![ =9
MX ^)&T'CGYY X ^&VGCM\?/JX%X)H9SI=\/*:Z4<><3IB/>?!E@JUOVS&%0%
M%T.EPX4 BW* 3ML''++5 .C2#K"$YA"^/B%0]R>)ORQ<VY3"8TZ3 QD3$[F[
MWU@Y2F62/JA.#AA,%]N3$#]LL<VYBQ9T8D0"AXU](*M5!8:E3L"=(X>2!!H;
M1#=/O-45%5WOXK243Y\2][0-&;8PZ"^ 72QF]Q@[YA?=2V+F 0Z-0U+43!C]
M%0TJL5:0O19@UCK3XT"M5Z<5$O0_&H1%;*V8GS]^_P!^?>$;0>.?GD#@#XD;
M0>.?GD#@#"-H/')?.)NFN:2SBR65^O\ CYGM^&'6! CO #9OW7]_&<'H'XRG
MH?GWPBL?GZZ_&*3?#6EKLGW#3?+Z [.4H1P2C.7]OA%<D1E35[C?MSH;TE.*
M.GW2*6Z(3 *9]-=@U5KI83\:8W'>TB5!L_J6"JX*@(2.-(E-2P*K<W_MKQ%W
MS0XKB,B+R4 Q"/*SI!4#5VCEP0:@\^UQ0LH=*?+4VY*F0?AAOI"-K-9B=9A^
M^^@KZP#Y&5$1B-'P]/)LZ;JN/:!L;;KM-Z<H[($Q2AL'C$@9=UL\\52ED#E2
M4BOBU86?  %FD)1A%O4/;HEIM889RYINTQ!)RCB=36J\ $R8N)RNB\QAF?9\
MJ[P^J%!G4ND)_'QD&1X<BGD^OI+O,%B<A"J@S@0"JJH"WAZW@!7?R[/'Z8G+
M@X/'[W_/,6YOE^3X5#^G^6^FOW[XOQV(\*-+A8 $^:+&-*K8I)BZ(3<!N,[L
M0"(0YUV)6UZRY3,I%QTK'6)@,H,I@932^*.:FL,&$COU)-[%4X6'44S)G;(Q
MP!1<$Z$$ >_!P2*"@)<>&L>,'(*#8/EFVL4NCGW0[Q-,@\CP G&57PM/H,\F
M-H5)/"^R712_I; 4.F,L$%V(#(K.V8R=<5#:)0IB&+2H.PF3BJCIU)<K8,?]
M*.,M BO*,S)5T! ZS%.0*@5D=D5K"N$(64:LY.E%SBJI$X6$YW7HL5-RL+VZ
MNS #@#V^?[]?X$;0>.?GD#@#$+KH_!^$3B^_]'\/W/IGU]O7RX-^J?1GP(V@
M\<_/(' 'PVT\=OCY]7 ;()J/GY\,?IG6H?B4>O4'W!Q#B4=4\PT5D5RAPT[0
MN!((@*$'(F"ZWZ^OM2-PL5K1E"U@S.&&4WE&81BK6+@J36QT93 H'9:\)8=+
M$9#>&1+=!DFK<O%Z*+(Z7DP0^;P@1;&N(XBEAO3*A"*$3!HJ9,\;*=@('57
M\M0]I@FW2U!C6"$+45;;G-Y1^<Z'%" I9GXK( .9(3 D@5*LO."0;09@*ZU+
MF2B<)4K-/726:7+P'R$:(J6"H BB;$L'9"&E=P*Z.NM;O'3\L@< ?$C:#QS\
M\@< 81M!XY^>0. /\G,]OPPZP)!^G_+QG!Z!^,IZ'Y]\@+'YGG],IZ'Y]\E'
M5.\NI]9WXOF?"#:<_OR^7PA;-^?A#QZ?+QB#R7W^/]2>D1/H@GJ#UD/!H0]!
MV/9V'Y&_^?8!] !X #0?PUQ]O3(6_I[>/68H$9'TO'1XP"78Z'9OT?;$" ;1
MFH-:/(K'K<<H%H(%1 +"(A+R &@AH %F@++ AT=;[X)IQI=LY_?WSB*K[O>0
MDAS>..>/KBJ MX>MX 5W\NSQ^F)RX.#Q^]_PS;M_#.AT_I]\^GA];\X?T_X.
M',WY_A_[]^?KWGZ'_0T-N>\AX/H=6?E^KD.)KQD))KQ_%!Y!G&0M[D^6=CV(
MCX2Q]RL\7*P*PL.BHAP5;R!U:!4)9?6 'V ]@. Q!TX $"'\B-H/'/SR!P!E
M-%_[\LTK%^G@#CXAZ9-V>./O_#]EXP'#\!(V@\<_/(' 'PVT\=OCY]7 ;()J
M/GY\,?I\2-H/'/SR'@^GP(V@\<_/ :%4K1%[$STZD/4OL+8X'9O$&D%%'<43
MS%!%401IBKRK[Y#QAX="E9QSWU<!L@@Z9_?<_>LAXPFJ#P;+Y\X (@"1$(B<
M).)UB 0 0Q!$B8Z0 M"94%5)O(;4XJ[>7G-M/';X^?5P&R":CY^?#'Z? C:#
M)*>^0. /B1M!XY^>0. ,(V@\<_/(' '^7F>WX8=8-$_8PIZ'Y]\@+'YGG],I
MZ'Y]\G?C^\NIQYFK[^?]&;OZ>WB]X@;[]-Z\>,V*[G ["W$< KXGU_?7-K.7
M[X.W?;Y_[/7_ )&D!Y^N(JON]X:(!]/QXQ5 6\/6\ *[^79X_3$Y<'!X_>_\
M.91R/@<3^G_X&1M!XY^>0. ,IHO_ 'Y82BO'6/2/#^Z/N4]O1S]AT9]L[?+^
M_P"&Q>0^SFI>,TC:#QS\\@< ?#;3QV^/GU<!L@FH^?GPQ^GQ(V@\<_/(' 'P
M(V@\<_/(' 'PAX/H?$\.A2LXY[ZN TTEYG/_ &?O7P(V@\<_/(' 'QVT\=OC
MY]7 ;()J/GY\,?I\"-H/'/SR!P!\2-H/'/SR!P!A&T'CGYY X _S<SV_# TO
MA?=P^5U\K_\ 7#5A5 !8+:(&/*/?&%#_ 'S ()HDZC4N:Z(ED,;.+:E['08$
M$O>75DPF%T;3(G#$0NB9MJL:><-/9YKLIX( EJZC+<HE%D3A'33IB6W)KCR9
M2L*I$RBW&AZL#2.BFD.7)M34@"V<M&5M#<PPW8$A6(I$EN]=&0PJZ00-2/*'
M;$*.D<H*2)N024VC=]R2-V20  +A)*S85+6,@ <!(3C'J^E3>RM=@9.-2DL6
MMHYH0B*<+$MI/%5:3"1$ K6X[C L47"($-D"Y34V!GHA9.QWAF%^9"LL:4D5
M&"'<Z(A"+2-HUI]V>/FWCO&Z6"9$&HT7=\$[Q8KK$<B^DTVNO%N+9-%? HRQ
M)2U=[3T<ZN:AI5*:><*]U60@04VNDC5F&N"=Q$.%7"MD-[<(VU"C1829J&*X
MN(*1P8S 62TT&CG";W6149-"&#M9J9LPZ2E*\IM]%GI%WHB028;0E1'\"#P2
M(3>4=$@,B*I!+D(5Q::#8ITMK&I9$*JNIA0U6#7C1XOW]?X-.M3GP_UZ>KZ9
MP=KP+8Z_3VO2XBS2.^!B0J(>9;VR0:H=9RNX 8ZYCV<K<A=:BF=/:[Y./Z??
M_44*%"A0H4*%"A0H4*%"A0H4_J?[_>CX9_U/S_?]A\,Y@Q=A3F_8+ $K[@J9
M/F/_ )]7'JK@5;)Q\>+>]88+I-/X/8KR8G>H%6O;7_UYRF5V*W/2L<B)I%K7
M#5-<3;W9C70^K91BYT?-$YI?0OYA@!S6RH-(MCSDU2$I0.XA!6-Y1?759OGE
MGFK?..[B:/[Z\_W?X/A06%GCU^^!"&@(*D%>5$VP.P9OCM1IMA+[0@F64[LZ
M) V:.JKCQ13%#L%3E0"U0!T%^<?W?W_89Z?[#^/C_?H<!\9 @3X/_"#!COW[
MM[<N/ ?R+5JUJS?U;]_O;@7'\&O7KV? 98?];\YFY-/)WKK^]F"V80JT4-@3
ML)B@YK5,%@)5:_1)0?>0 G-1,H*0. !L=4$BF#V(E6KRV;_Q<SV_#.3]<XD9
M%L8H*U>^)\^\84%V,A7I7R>-=9N])0<AM0^I'P9+](A"%1X$T)]4@J$@2*9(
MIH?1L>30QM@C-H4Z]:Y"LY93#;>D 0-35Q9&RL4(4F$;TI>#*R*MI$6DV"TA
M.<208J6L"$710,+YPD%X(0T);'$[:;<=2LYSR="S9+RWB4.B@!%%7M=HN[/;
M-2[9%V_GBV["=X)-/!*!1*+M '@88G"&J((*@21 I#>#YX !BH@=$%DXF!V%
M"*&G(0(U0;3QAG)F>KV$&[8D3C!\-K68@#T9"N$4UQE(*:)H9:$5T9AM0AZ$
M$(QV%W'FX2C4D;^X7U8%X'GKS^W$%):NU*LZ79[LXQTT%D! PG1/ ;788 ?U
MD$Z@$1L<)=7&_P!//J*@@MFH93(6ZUJXTEJ*.SA" 5B7+1H !5Y, MM($0T*
M*#?+@R1R2C46TE0CA-8GDRM&^$07P(TDN+,EE";&@E1-J@+8"RBXA@C0:0&Y
M?!DBYB6Z110@2BG:G>#;0^%Q2U!P?B<?4L)BZ##BPE45>M?2YX_@+/Q=NS\<
MO]<Y&\88 M9%U0%I*1N8D]#LU&952  JQ4Z52J7;NKYM]]WG+-4FS9CO?_Y[
M_P"RH'&\2B 9R43B@]&'-E1&M J^5BNUF\@12H0ZOG=_7G& F[P)N1?H^9[X
M(")34Z5Z_>/6EMQFX\=\''R]L60D3TY\<W]F'@V+OIM..&%.&'C&"QM3P>PU
MPC05%64TK2!&3!1PQHR7.TI15;0G:*D4-F:4U\K][[?]_AN8URT! @4'8BB5
MFAB/5?7;0[],C&OT:&!A&EE5;R-WACH.0AIU#<[]<\K1^I\NOM_O=MI[<\_;
MZGSQ'046Z:'Y7K]\J".FB !8/>B*\ST,U%02DCM.*#"T&@+["8(( 7!B/\7-
M^\N\.L&P]'0:IVJ!);,-M)"-1K#:U52;=X9*V;32-5=!SP#VF<!Z052\%)XK
M81:L20 $H0(L&6-NC)SC#=3T!*#IM<VLA 0:P[5&TUQL&JTAJTO 6*$6\,#(
M8W6&02M.PZQUPU&50-2V+O8YP#8<K"V"A9!V%XQ36DE0N58!2MC KG![#\R3
M[E9XKFS@PGDP4@M4[;,-5&Q!- R9P>K&;7)522"H(P=F[L(#.('B#2DC (:T
M'#\2J1L@J@(2[5T8>7QHS1D4"D;/6'U=_(I&6#@>](<,&O 26,J=*M:X>H:0
MPY99%8A#WP9<]@A=(@ F^G@^"1@Q!%:!>BM@]WK'0@@[I WH&FQMZRD"$2*N
M@*M&4-#UD&+,Q9&D:0H6(/)CG);)\Z*E"L3AH+,0/Z0SD&T@UR43MZGO*&J
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MTJ[8HM=GZ!H*KNE=5?)^;_<PGE1"%L]J$\:^^HMZ/E_>)2$\_!S!P#EVQ="
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M!;">:E8&&!IM*[424$)2 3:*"+(B."A  5:M:Q*NO%":*J20, &C#9(,N(
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MG]X&(-GSBN*_ JOEK@\N\^$S,DX+5!+!S4TV= #I9SJ\9LX&R,!);./G[3#
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MR\6T8!!,9H"$"%[/2OQ['L:/8^1Z<\^K7U7E?7X-* @*<:A$00X.RXGQ7J4
MT#$1V=[V44!Z$3BN>CFO"'@.]&*"G1.!E/)OO\HX@72CFK 22^F@&9I@0+BT
M<^$@UVY,4Q+$[-:2I5"&!$X  M0!JUL:+.,%T]PYCJI#NG.$%%W(MW%.=Z5&
M[\_Q^XP/'L_M_AK (D4(T$D+:AG5>O =D+*'J@/936-#M;H&0R @2Z$TEE*J
M!$"$Y0^(I8I$8I2C&<E!CJ@]8/"Z*^B (JA 2'/NT@%4&1=3E'PY<(; T00
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M *3$>)MZ7W%SLP1+@"QO7M!!X*+/*_Q^XP/'L_M_@M(%:3^M^G.]9L^1OO\
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M )-&T,=%JE(TPA4H0RK03PAFC4RL"P)HT5DC($'(T\8"T>M>Z766P!G% I#
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M&?QW&^?^8ENHA5X,@<-$JA*X9Q";Z%00Z L$PO.:H$N*2 1.22TX\S@1X$
M( ;Y0/#5R>Z7)-+)$ $G:9,"XO3L\X&X0*1$ I2,CK I,W%H0<#!^R\08ZJA
M2B1-RKTV(V @$BD'B&<^6_:LBMP:555+;<X#WO\ /U\?0_@\?/\ (_A[0._/
MKX3KW/VY>*""#M(CMA0Q$<D=J%FT6FCAJC6P""I;$0/I'0($>3N$*!9506PK
M &Z!RVJ_"OGGGU^'HP.E-EC\JSQ<4E3"%71OCZOU^-M J\<WWUP M^F:HE!-
ME "QFTX]<FPXA !"XE"M"@X_*W9F+HD<ZX6#B#0F+Z$E[]9)CK&Q-22Z5B3)
M_CVY4V,D "BZ& E(YIZ1(H/!A"&2;I/&-0@=#W,7- 8MLPJ1;)0L1U%,$0@8
M .5U?$+/Q2SD(JD/=QG*SMX4\@R&A(QAZ>\,0"J@.@%JE+R @<O!85NE3#WO
M!E4@C"BV@0:?HL6!'#4D]:7"+9_D(#LEJVF[[M_]Y_T'CY_D8'72*]$$I1@,
M@.5O;$+?)!V=NZ#HT2.R5:(*4 5J4?=$Y7FL.L#: ,+88&-$LS+K(8GEK3)@
MZ]#SG&*T'3M/?$=-1ZI@#1*O!WA(%O:7HR&0:=N#)3U+1A.0@Z:([P'$HG49
M#04!)Y8"&@/>5,.#+^<'0<*)3U! H %@Y0!Z(XBG'33II')HH@H$G0CP(H0*
MPW\+PBA$MP:U27UF1\KY$#"4BS<WL/!C#=\8#!H/#8#8";D8GWR^([14[NT2
M2608=1X:8P;\QVV N$ !!9MZN5+.\Q'C;)9!&QJ=UXX@. B  <A*B!9NJ,+V
M'882RZ!RJ!-H[@0<#DXHFPIQZ.W)B@;QAEA*&B@!SA.<O,:&%;Y!P Y[)6G$
M H#01QC-0]RJ56)W8 2X\.H==II#3AKA-Y14PQ0\1)HSWZP:M.(2P@S=Z][:
MFRLM>R23MV) U8QNW(@FBD506=TV&3)8?:4+P8IZ8FB!7IB\33F)A-M#J'TJ
MR"A&A.N41146CZ.D>PL.C@D_C]Q@>/9_;_@%+..SI*,?2@[[!Y#'&SJ$JNI:
M7F80PA46Z("0&B0&\#"JJM7:O*^7XH0!2H"@<*./3/3)8*BC*##&$$9').8
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MOH@XD1"0":G.4?(VDG)*'- 4#;C"/7((<TTA1Y1C?H( ,!2@"*<- ,/U&@!
MB<O%Y--YY>W:^7R_#CBX%4\"'/\ YK#_ '%VCHM"B[0T1BY9C'4QM6N1M(N0
MPRN0K'8<()=$BUX L8PBK'%5#9B'?$<F  %D (PVP0=!]9(ED@E"@X8JZAJ0
MIZJA+2E:JN4<D5$X!$MC4<JE X'TT37C8VK1Z@G,!C0*HEM& >>ZZ>T5+'!
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MI25P5MO9I,XZ=:%'\79$6LHO"37[)()#('V88'EF"'0AA#,4=X?4F!#HT%
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M399B/E!%M?8:)C@%*GXBT$31[XY5:*Q%A1C2,\U^?)COPU*,IJ=:-H6C#OG
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MJ8J0*%M64@1;N,'%=%7>'D18"LV@;<.FI@H0 >1IL0VA"5; A8F 22 )(Y6
MX5CAM0((!)%<:2"47E 6IT@\HK@6&#=8.  MT7M8DND0%UJ0PT.$28K1LDF0
MZE]+$XP-5:4OFG:"" A>I4K"7)LRT0;A+:9<8OS%&07<:"/3A#,A+>T4DNA4
M>< 6BZ&^8-/!(6+CH88H0Z!YJ"D:<?7*8,X0C5$]U5!KOD""6S*$U&F!X XU
MS79XAT&K7O\ BS!>;7_&ZAF&!UVG( "(@"HV3A)S_K;\&(5#/:RBKS&Q* @V
M2RXW*EBE(^I1CY*#[@]81C@IA=J&P81[ 4N/]Z\(!9$F(\!A6^V-;O[2P*6Z
M_P 0&_5-% PAK0(5J<44-2 NLGJ49 \+Z%X*!*?]!E\2'$Y<^-064PXJM57R
M[=[?OO\ @H_?Z#_W"<,I1:$MBQ101'&&],;1"5%W<JK(F5QLSX-82G#".3Q0
M(07*'B+=:.T<"96'K"DU4"Z ;*&:<"!*?( 1L5:>-D79Z&N EJQ4L7OV6T(V
M*%@?6:QJFFZ$60=P43(0@PTD $3L%:Y LQ2!#D1(51K2:#%2/.[]7]G5/X/'
MS_(_S>SFI0Y_K[Y*Z" /?7!+' NZO5PU&)0^RDO>RNQBA79P-UN9C)@E\CA<
M7'=:B0)K, /86DL""I"#'!<[\-HBH+2A:JGP!F@$NW"'!?7E@U3(J$N+"HL:
M)2@CH.AJ(BV>?[KA;TK8&L1^01F5*0)J_%<40D]KIT7CK@-<D^=FL4AV$L4"
M^L( 0=W1"X%F]RA.+)[<UG+FVK&QP;:TVH  -?'!- >W^H\?/\C*%@KM,WE!
MV=FLLE;\D[<@-DB,=;,H)0@V6*KAMV#O8Z*411I0FC9Y6;662I$;+LA.(N$7
M:U0?)LEJW+ML7G&=3BWA$243G[C6HK\IZ#16Z<'N@-SB2\]C#;443M0$U+EI
M)L"B'E):HW(;"(H CO5K@D!CF\""M0!]PTFG8,,J.(]JG?"8=3_Y%@EU^*%I
M01FKC=IW=*Z$HMYK-R6AH^=E"P@(K(@]J,Q1BX@%(ESC'O9F, -%*VCIJ3O!
M%D-(\*2)K [3\PPR"+2K%"E9RB($ HC(\@EN)-"G#J831 02D8(_?YTA10>0
M(ZE5?:" $F\1X< 30JF2H.:(=#@TX:Q:#/MZ@L7AJM#B,@B  D4F@@+&O1?U
M:%:!+,T1?.AATBH&X6MPO(6MI%<-A DC@4  %$F)"C#S451AY%SJ*JN) 7TH
M 4T1039RO/<$CF\<@(-BM8- (D WN(X' 0VUI6P2! @RV<!(E:&J!^TI80#A
M (<!&4-[,&>&K=-")O$,U@MO%,P@52<CB[T@^B0>]U[M[_BRSQ]%7M251)F+
MLR?-N$XD%/B4_8BMJ;GCS6L'@KFJ4!N2"?X==^[W="'?A'LIPO\ D1$>XV\!
MM0[9H\"]+AWKM!Q<!*EP1$7@/@5T5U)KVZE55555555Y6]O;R_Q06^AZS?\
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MS>L!-MG0T]FV<RW7?./TY5K^7IX]#_1GN"(B#1=EL;"Z!0E&:<(6E20$8/\
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M8'SPLPF$0$$ ::%( !'H!(&!VU@QJ91N0!:I34ZTTQB(1TP G2-,(JXTX.
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M(?*:\*@*%_T,?%0X)BXU*0'.L(63S,JS:E5< 0$)D\7;S<I34-[5!'A<93'
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MP   0(3.6O/-WMR<ZA\Q;<Z]!\%*L<154X57EPUIJE&J)XX3$. $"8 $  !
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#<__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>business8ba.jpg
<TEXT>
begin 644 business8ba.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0"N17AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     @   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E         !@     0
M &     !    1TE-4" R+C$P+C,X   R,#(U.C R.C T(#$X.C4W.C$R  $
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M1T(@6%E:( ?I  ( !0 ! "  *V%C<W!-4T94
M          #VU@ !     -,M;&-M<P
M                                #61E<V,   $@    0&-P<G0   %@
M    -G=T<'0   &8    %&-H860   &L    +')865H   '8    %&)865H
M  'L    %&=865H   (     %')44D,   (4    (&=44D,   (4    (&)4
M4D,   (4    (&-H<FT   (T    )&1M;F0   )8    )&1M9&0   )\
M)&UL=6,          0    QE;E53    )    !P 1P!) $T 4  @ &( =0!I
M &P =  M &D ;@ @ ', 4@!' $)M;'5C          $    ,96Y54P   !H
M   < %  =0!B &P :0!C "  1 !O &T 80!I &X  %A96B        #VU@ !
M     -,M<V8S,@       0Q"   %WO__\R4   >3  #]D/__^Z'___VB   #
MW   P&Y865H@        ;Z   #CU   #D%A96B         DGP  #X0  +;$
M6%E:(        &*7  "WAP  &-EP87)A       #     F9F  #RIP  #5D
M !/0   *6V-H<FT       ,     H]<  %1\  !,S0  F9H  "9G   /7&UL
M=6,          0    QE;E53    "    !P 1P!) $T 4&UL=6,
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M 0             ! @,$!0<&"/_:  P# 0 "$ ,0   !^_@
M                                   !R\?D4,=)            #8!^
MR0V: B4Y8MBC:N38\TRP   $#*#;(
M                 !\_H?DNO79N;'C]9UY2];2T)BX6K,4R?6%HK:T
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MVV)B)ACR?L/P9.@()$2)Y6S:&X]C2\Y+!!'K"X5D!)(G56CU.CJYP
M                                         . S\?X  !?NMJ_0']<>
M0YY]GPJ?1R\.?E7US8F/C^7"YMV^#^OUGO\ <T5EN!Y@$Q<45=E62%KA^VN)
MW^ 01S[-=NV1+K53D)4Q[2E)87.$:O28T,OT"D
M                          #@4_'Z   ;A]!^?[M_7/CN8?0\^R<W:V+]
M%Q_FM^*/;LPXO(RO4Y&&?$^G\Y9NEN!3 9M@8(ES,AM62T2IMZ;!6?V_5;]
M".?D9Y>M?$W>MKV>:V+0J,=*_9UKOCVI@#0">@
M      "4XN->            &YCJTG      .!C\?@  !4YJ=U_J;S'8'W?S
MN>?5<C"_ENKH7\S>F=&^5?#\U\CU2]_:>7<[<CU*VQNYE,:4)01*V8KKUOJ;
M*M)5^V2K?@ .?4;CF*A-UB:4LS%XUO<JQ7Y+^Y. <_G0   !"(EK,)K&;%$2
MD@LG6    $#4:,8A-*9( $"0D/<   @C'9B)!$+3O6MLO@  ,"3^'.T5MJ
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MC'B_&+&?FJ#8A=37Y:S:!JDR0HRTF4%B,G1K37S_ +:,=O0      ^?1^0@
MF1,GI3A\[G#M[W@M+,@1B?>NQO'%W=$['S,@  (HW/LX\ZM2VE&"%;_KQU<O
M1$@('SUU>_WYL\&MBMMO.M,71U97J9_R-"_.;?/H^!K'/S-VZOUEZI8<_G0
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M)FXE6495EO*@HRZEO*TQXNY92L,DAF,1C-ZTF;7\&3',&S5L?BMD*-?:^?\
M;+CMZ      'SO/R)@ $;+BCI&DZ]EAYCI0Q-]BU3&[C%^>      /VTG28!
M YJF=R3.6QAM<7NDQ/"5;6]OF]D1]%Z18 <_G0 ! DH^,7[7^_\ LU^*O/\
M1WW&]QW[1O?3C\N<2:U4DJ:^/Y&_KS\P?7C\??J/5/U7RV-=KG] >>_=@
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M+@4AY%R+:51 \"N*<R)&J-?/^WC';W    (%NO-DR70
M     $2>M<DQU]0 "6(^'/[N](R?BZWM2$1Z5Y?M7Y[VI\]ZT^=]:?/X#]/\
M#W3X'Z-VKXAZG&T@   <\&]$>Y6)@!!-4620202@1B$B2(I@61'J:53T"  #
M5T/Q7YL>\,^*A6]RJ*,JR@*@HRZ%">)0D"XE 2%T(&S3TA83)#6TJB:ZFUMC
M]OF.?8    @:WW<U!>20                      $LOU,64X:  25?#W]T
M>A;>^)T@1&<7I7C>V/A^E>![5XN!]SX_JOR[N=P^%^I36D   2F@#H$
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M4PB4H$0   8L9-$3S( A++=3%EF&@
M             '*WI76ZF\RY,UD90-;;>:ARR2
M!"68:F/*<.,                                            #E;TK
MK=3>9<F:R,D+7D67):,2                      !/$9'BK[@
M                                   '*WI76ZF\RY,UD9!!$+
M                  3;K3C>:WG8        !&%YQ1?L=8BI*@QWQFFQ($@
M       5<TRG-K3S$4E?.LV"N7R0              !$OEJU=JD\K>E=;J;S
M+DS61D                         !KC>RVZ;H         "-Z[.Y^*IB(
M"*X%K[MEQ[ )         1.<[7/O^3 6@6&M\>KF(               %RG'
MEE\<QRMZ5UNIO,N3-9&0                         &LMW-26E,@
M   $(;,T<-9$0(1&OM;?M5<P          S7/HY'DPI0,?K:P5SD     :K+
M2;J +<8Z49D!?P     FX,67Y,<3E;TKK=3>9<F:R,@
M        -9;N:DO)(        !"&S-'#61$"$1K_ %M^TUS0!$ @"(,6)3*R
M!$  @1!FN?1R/)A2@8_6U@KG(     ^8BN7*\C$QEB>YE]1*\<*V=/VQ7ST
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MA<#-<^CD>3"E"(Q[%EL.7,I4 <FF^S-@1!A14&6F/%678$  1 (&(&8&'F8
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M3&QHFB3L<T4=  A          1D@D($2 "         3$  !!(
M      '*WI76ZF\RY,UD9  <#P_)#>N0XZUY44G[\9+8#5\SXCEA6!YGJ9(M
M]"F3TC)AMHYQB=&1JC*LE<4I?))FYIVWH;&]/F-SF3[/G46>NH<&&S9<O[6J
MVWQ%<![6?/N-@FEH%/0$H'.5)^/.+8ZRRX^RK8NE;.>R]FB#6QN4V,= @
M                                         '*WI76ZF\RY,UD9  <$
M0_)S>MQQ5K);[M/T[B_/NRT'MSH?3C4>IC\ST+_-^T]'J6TP7/BUU.OI[+JD
MY5>F*TOFDJQE^^_Y&^]WO\AN_+;]"?*?/WV;YO3F*EBS9OVO5C=V38X(]O[?
M?/B/"]M?%H3+'0"4.:<63\_^IT^VLNO]A=S0HS3IU":2.1#>AFYT"
M                                      <K>E=;J;S+DS61D !P4?DH
M5NT5S&ZSXU;5)D; Z>>FY^#&,+")CIO/7G_6R]/Z76N-K6#)KZKMJ:ZV<'G%
M;U>N*8+9[:]VM/V"_.'VG5GPV]\W/>?F.!/3N%IO'6Q9\W[7J3H/V/K<Q^K]
MOKOQKB=I^4<G0MXZ DAR-2WYY=/I_0_/K_<+8TN9Y;:,_)3GPLQ?SH
M                                        Y6]*ZW4WF7)FLC( #@@_
M)$K?(KYXF29E^NN][R+X#@P^M6/1-[V=?L;;U<2^>^I]+6I<FOI_/J;HZ.#2
MN&MAQUQ;7G9ULF3VMYTG,>7LX+V=:Z8[:!IKV7/E_:YCMO=',OH?4Z:\YYD;
M1H&70-R''%+?GDT^GWCGU_NYGTN<[.EBK)36)BAXG0(
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ML=!ARXC6 !$LMI_:7>_18 .?SH 0XPI;\X>MN_1F^#[X;6O*:H-@EZ .?SH
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MF>ECQ+F5YSL;L(44&2+Y6;G+Q+,5B+<S4;#D2:4TJ=!
M                            '*WI76ZF\RY,UD92FESC4T@:V,?*<\3Q
M*<\3R/)/FMYGB7:$U9]Y+/!7P5LQ5'HGU7]%?96<]"<]3T,B-FF[CO0V4:+*
M4@1%4; (!!,"4SLV2
M  <K>E=;J;S+DS61D($1"G*0\#P/ \3P/ \3R/$\20\R4B3$YZ'L>I['J5![
MGL5![%05AZ@@ 1    02D($0
M        #E;TKK=3>9<F:R,A @1     ! $0  0(@   @1        ($2(
M                                          !RMZ5UNIO,N3-9&4$8
M;LY\;RS"0                      0]3/-3%=Z5
M                          Y6]*ZW4WF7)FLC(C66WL4F60
M            ! RW3Q99CH
M      !RKZ5V>I?,N),F6LX_T,N+9)I;RK(@89!#()70 %/*WEX@  ,>,@E&
M5FA0P&3@6*1"S#*6FF,9A=I7NS'ZMCW*@  D !"66ZF++,-
M                                -%?8;^#=K/-$E>1?5^S]$/SC\[+7
M$2!\R<<8A1[VC$JUVH59J69^D]K_ ##BOO6N4%O-NF!GB5I10Q>7TVR/C_C;
MU,U-!5CZ 9\F4>@=+-.17A/Y'FV.;:.Q)KOJWECXX8*?07).@X6HV":1.OCF
MZ6];.FK6WE:P$)9;J8LLPT
M       A A"66*[V;'RDM9,@:_,VAR]$7RK64LOLOIOQ.ID7@P,K2Y$"G/$R
M6&%2Z.-0%88T5AG\SD^:WM6,"Q1F$N2*QT+,["ER/6,T+M*Z$2PDQX&ISM,C
M,@0EENIBRS#0                                              (0
MAK/?S4EY)  $"(  ! B    "!$      @1! B "$LNU,65X:
M                                   01A6?)CNSD@
M         3TKGNKBO-
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M&ET$PZFSJ'?/TXUO!)&J;EJ]G;AKC(P+%$+6O7Q<<H0SZ6CA;"2RR_AQ(NR
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MY]7[18V57B=>1SRUV#'VM:_IWU.&K=R1/7C:"<5MP9%''W8[W3]5KSW5>O\
MYN7#H*KKK AG.,>)YWIE<&'EO <BQ<$,YQ@V5LGP=[W$552P=PNJ7^ .18F
M;Q8S&JRR)<R]L-F34G#.<2MA(1:4L#A-NYD$BXF)WRG"CK*RSE^9&/\ UV7^
M7[5ZNR]):(_$Q1LD^IC7PW'MVG;)HWR_8CY?LQT T'030=!MAT&W'0C<%I*9
M,="-QT(W'0J& ?6_<;&M/$,:O[QG5V,#.L\8!M<8(FE2D%$NAFPZ&;#H9L.A
MFPZ&;#H9L.AFPZ';#H=L.AVPH7Q!4ZIT[ZHZ,%?BCJN12[,XML/D1<E!T)A\
MR-09S\RM0#&RM0X'S8U8/FQJT?-C5H^;&K1\V-6CYL:M'S8U:/FQJP'V7J13
M,&BI/6/TY&V]:9M3:)V[/PE7T)3_ "T,>A=%-PBKEWJ78)W-FV]:(*%8P$9]
MK7BI$*LTG6+_ "R>-W[?TRCQU&$K;-:/KWVW+]NURG)MSN(WW2]5O_2E?S_F
MFEI$Y%WKMWA"0>M4\R\ED)O7:(+)R!<J.G*Y4I)Z@51TX65YO)8*U?O&0YO)
M]BBZRV JLLX/%O7;3*E@G%\2,@\=N<3MEPF\F9]ZC&24O'ES/64Q555TEW,W
M*O6++\+R3^7[<E78"8P]TQK=\'7P_P!%-DWP^5 9T!4<#.A*E@9T/4QG154&
M=&U89TA6<#.DZX,Z6KHSIB &=,P0^34(,Z;AA\G(<?)R'&--PHQIN$&-,P61
MC2\ ,:5KV1C25;&-(5G(QHVKC&BJKD8T/4LC&@ZED8^'^I9!?A\J&0TT!0B!
MCI[7#$1T/$Q)/Z8YBIDG"%V=LV-8-HQEZ,C<%2Z@K^B9YHM&?;UVD1>KG@HT
MP9L6C HR)/8\+$WWCVV!QS?NMECKM+CVTFV=-..;]_&MP5XW4,G--E)3C405
MRD<QG*1!Q[7 24*J7L=1C-XHG%LTEXWW2]5R_2-?_-YHY"S@[@S:1<M$\S#[
M(0D7;;.)F1QE=^Y=)H2;MN15XLNXYR]P5N\6:X.]4.B4^2&(J9-3CELE*<Q<
M1LJ1AA2TH+!]/$?/26-F3"U@8G*RG4VB6+0W\#E_E5R\FGCYBV_"[$_D_HN[
M \)1X"#RR#RDQY*0\E(>2D/)1'DHCR41Y*0\E(>2D/*3'EICP$'@(/"4=V/Z
MW(W5<NGJYHJG<IB/P'?CTFP4Q;&R=ZPV!'/F\FR^UK;.,5P8[5N*\WQ2(DC2
MO+>^V9Q7<SOF; ->,+G4VKX*EF>S V17=W4C%;>G-<?PP:1%E5L*43!'DU(S
ML\9,#S"".]T_5=?PI]>_,4?('RJ?!U&[PJ!,R*><H/?(&),V,KO,KD1>E1(J
MXPHOB13P5NY30(JNFHF0WASW_P")5<BF"G\.._\ #+A/*8243(<ZB>3XS@+*
MMSA-3!%7DD@Z8H_A<T_Y/M+N"(8YF.9CF8YF.9CF8YF.9CF8YF.9CF8YF.9C
MF8YF.9CF8YF.9CF8YF.9CF8YF.9CF8YF.9CF8YF.9CF8YF.9CF8YF.9CF8YF
M.9CF8YF.9CF8YF.9CF8+)%[R'*?'IR-IDDI_9B>O-RI$Z W0.@-T#%!W0.@M
MS#H/<HZ#W&.A-Q"R4K8#*-T8[<.*G]K7*::M:X-ID(H(M\?;[O6>/9**99-?
M%&^Z?JN_Z-KWYAG$9G+A1FIANNR33RZC0@X;)##QB'"[=4B+AB0BBC<SC#J,
MP5JHS2PJ=J8A?#C/^'Q',RR0N28S_A[LN$<D9F1*NBO7>%=+P'DQ[R,0R1]7
MBHN56V5WCJ(68D_6"?\ )]IT;)U_[C&&_P /IR-A2"T!MCZBY4?47*CZBY4?
M47*C'Q%2H^HB5'U#2@Q\0DH+1N*0M$'HA,Y:M]K6_P#EPW]-%_XMG^J\_HN,
MD4&!^HF(ZC8CJ-B.HV(ZC8CJ-B.HF(ZC8CJ-B.HV(ZC8CJ-B.HV(ZC8CJ-B.
MHV(ZC8CJ-B.HF(ZC8CJ-B.HF(ZC8CJ-B.HF(8O4GUI3_ "_M+_G_ -QC/6XC
M(UX?D$&.008Y!!CD$&.0P8Y#"#D4(.10HY%"A%!%N3[.?X2$7,P\IUE8AUE8
MAUE8AUE8AUE8AUE8AUE8AUE8AUE8AUE8AUE8AUE8AUE8AUE8AUE8AUE8AUE8
MAUE8AUE8AUE8AUE8AFT7!V*[!\E0[9$STC%YM/:D"=7XFUD#S?Q(8F8C-'JV
M<]#5@=#5H=#5P=#U\=#P Z&@!T- #H: '0\ $J'73GQK^M#&O:F/EY3AG7M4
M&=?UH'HT*5ST1!#HB"'0\$.AX(=#P0Z'@AT/!#HB"'1$&&53B&+TOQ1R6,(?
M$U.NCQ.Q]US[LGB\/I_ZC[G'O)]?\[TW':-Z8[)L^T]BPTK9]D7VKZRK5\V*
MTV/V0NUL%D(K;^MYQYK_ 'C5+S'UC9=(N3J-W!K>7%;V;1[:X@=NZYL\O";Y
MKUFDZIL**DVSK:] 9L:U;*]<8^K[6>*Q4!L"WNH\FV]=*SCG8U,9M6MVJ[UX
M(>8:S3?9-F?4ZBQ>T-D1,ZE>MS6*V3&^9/Y7ZYL5XG'UMVI<$=B1-U,BT=[&
MIK%$N]=2G5+MO71ZW\^]1<.K?J>A56^V-?NX9GM:@2.6%F@Y29],9_>74?'O
M<.]?4QUDVK:8,ZLJ SJRJ#.K*N,ZLK0SJVNC.K8 9U;"#.K(<9U7%#.JXT9U
M7'CY5LA\JF8^5;$8U6P&-61HQJR*&-60XQJR#&-60 QJRNC&K*T,:LJXQJRI
MC&K*>"ZMI> SH=.9ANT:M"^C:ZCW@<:O_#Y7#Y7!?7[VRVS),IY])M:EF-RV
M7619C:6XM=*3FNXW5RNM-B51RVEH?4<8J60FM;75U$+T^=+L=+6-\>T:@4J=
M1N,+1+_#Z/9:QO$W9J3%;%0P2J7F.M4A0;LSUI(:8GX^M:EJTC ([:U?<[!<
M[O3Y:2MT)IVV1;2YZQGI?:&G=<VFLV"5B&$XRI^OXRL'VQ!2EEUUK[35'IZ4
M:TVU2;M+Z:MQ-60M5K%<-L:"NDI-LM:[)K%;>:_V-+UIS2IC.R7&K+FK7V]1
ME\;B94+945I-[K'8<DSV_&,&^H]'QKW%2],9^W-I>E?\_P"RA6*TUEFL>P8_
MV"5@X6>;XQ@N/3&?MS:7I<ER5?\ N,87."_MO:7I7;$7'+!RP<L'+!RP<L'+
M!RP<L'+!RP<L'+!RP<L'+!RP<L'+!RP<L'+!RP<L'+!RP<L'+!RP<L'+!RP<
ML'+!RP<L'+!RP<L'+!RP<L'+!RP<L'+!RP<L&(PO>0A4R_MO:7]X7<$0QF25
M',5QS%<<Q7',5QS%<<Q7',5QS%<<Q7',5QS%<<Q7',5QS%<<Q7',5QS%<<Q7
M',5QS)<-WI5<^A=<B!<R2HYDN.9+CF2XYDN.9+CF2XYDN.9+CF2XYDN.9+CF
M2XYDN.9+CF2XYDN.9+CF2XYDN.9+A.2_'&>_':8V"8,]SW\:J.-5'&JCC51Q
MJHXU4<:J.-5'&JCC51QJHXU4<:J.-5'&JCC51QJHXU4<:J.-5'&JCC51QJHX
MU4<:J.-5'&JCC51QJHXU4<:J,/5 DJ57'9M+^\.C^-?^E[^[*1O&GVOS9RX_
MIHXV3(=KW/X?V%KG.%NS:7]X7_/_ *9O^1VO?]S_ $T=^3VOONVV[56BQ]/V
M+2K^EVNW2#%I7[!$6F&K=H@[?&R4K%PS;[C7\_LVE_>%_P _^F0_([7W^Z^U
M+3D+ ((3L&Z6_P"_LQWY/:^^[?7<; ;^4O6K%;=2+=8&]WLUKGX"X;"G+=+[
M,A).0F=,_#]<*GC6;*=N4S1KE(%M^AJNBQ;0'VVOY_9M+^\+_G^K55GV)%52
M@WYSK_X>(;:MV3B-?[6L<Y=)+8>X;7JK8"6S;!6X223J.RXW:M_9'F]WW.+@
MZ9?W5TM?J0_)[7O^Y&]VT"\VUK6VM]>:XA+[?(JZJ;TLK:7G+S>I:X\A/9]7
M[14V)9ZYL;:5EKL^3:]YL4U3IASM:M0VL:[ V'XA+(2(HVG[8WAJ9 [8V.J:
M\[LL]:DFLG,DV57-JR-NGJEN:V2MR3NDU64-47QS>XP1OY/:^^[)147,M(N
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M$XU\L8S%T3/+W?=P+D<"Y' N1P+D<"Y' N1P+D<&Y[\L7.!P+K X)SW<"Z'
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MU@W1?<?7XH(34-UJ;D.UU '!IZW?O@K1DVTULFTK,UIO,K PJN2K11#G5!
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M#!1G!@6C=(!4EIN.'\WPE.) %UA.^/BNLUH=<)W(L+A,EL*\&P-*F]H'.5"
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MKBN*XKBN*XKBN*XKBN*XKBN*XBWW]]"9W]2/BPM?9]8OU=-EIM%,765JC6[
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M^.'B#T!S'S6]&'?WK?\ 9_)7TW[G47H]]JUGC]8Q]H,E?3?N=1>CWVK6>/\
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M1^2;NFT8G=ZAKP[R%=R-(SAM0;'[DS[D?D@$9LV@\8^"_P J;&.K4C2,]K$
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M@NBB(R]0Y596M#W':A_)XLHC_O%&H>$O2G^ZO\7:R?\ 6*-[);_H7^+M9/\
MK%%]DM_T+_%ULG_6.+[);_I1_D[64!_WCC?^G_Z5_B\V7_K%&_\ 3_\ 0O\
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MQ;T/BN&>D+K&L2\; /7H+UW,Y>Q-'1#3M=(.0HW.P,SLK7.G<O\ Y1M+2?\
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M5]JOM5]JOM5]JOM5]JOM5]JOM5]JOM5]JOM5]J<\4R3S4_2 H?E/_\0 >A
M 0," P,#" \/#0L)!0<% @$#! 41  82$R$Q%")!!Q4C,C-18=,0(#9"<8&1
MDI6BH]'2X? 6)# T-U)VDY2AL;*VU^(U8&)R<W5W@I>SP<34)4!#1%"6M+7"
MU?$(%U-C972$M]8F)T5&@T=79'"%IL/D5J3&X__:  @! 0 &/P+]<=>S'30$
MI\9H&HAG;0P\^6A'R11(54$OLT(5#:JWM$5O4F'9DS--??DOD1+HJ4L$WJI:
M1;;-$TCT):Z EE7%ES-7T7O==IUT]'LV/-/7O9:=X_'FGKWLM.\?CS3U[V6G
M>/QYIZ][+3O'X\T]>]EIWC\>:>O>RT[Q^/-/7O9:=X_'FGKWLM.\?CS3U[V6
MG>/QYIZ][+3O'X\T]>]EIWC\>:>O>RT[Q^/-/7O9:=X_'FGKWLM.\?CS3U[V
M6G>/QYIZ][+3O'X\T]>]EIWC\>:>O>RT[Q^/-/7O9:=X_'FGKWLM.\?CS3U[
MV6G>/QYIZ][+3O'X\T]>]EIWC\>:>O>RT[Q^/-/7O9>=X_$>I0,T5E29=$S9
MD3WY##P734VXT^X;9"2)YY%2Z(MK7Q0:\ZVC3M5I<66ZV/:"ZXVFVT?L"<15
M!%WH-DXZO*R>LM3++N78TB3$9KD6D#7*K6Y$)YR),=I[+X2(%/IC$QB3%CRW
MX-4*J.,[=D8D18;U4V2]5?JDZET**A0.ITZ"B8MDA;1OJ7&V"=E%.R$&^^[<
MJX^JOG_V.ZEOYM?^&/JL9_\ 8[J6?FUQ]5C/_L=U+/S:X^JQG_V.ZEGYM<?5
M8S_['=2S\VN/JL9_]CNI9^;7'U6,_P#L=U+/S:X^JQG_ -CNI9^;7'U6,_\
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MEY]%23"EOR)%,?5;6>".;A+!DM6W'"V+;Z&22V7BV;C)MU$&2;JLTG!GQ2-
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M]VI51-)-L#3FVU;HSM&$Q>1$)EQ>V> 8R*=CU2;ZD>Y6\^YRA /8!\O3^_\
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M\;3@N@?!;B8\>/3X?HP.J!(V:J@'I702AVVDNE?KDZ.C&2/WAB_A/RO4R,.
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MT1%TFYJ;./K041",5U7<$'!3_%F!;,2 '@W\F(3%0,'$LNG28%VI(@BS*DO
MD93;;;?!AI6%+>X#8DP.P-Q4W")ZD,=(=HJX9:BO-$X;*.M1D?:<DHRJ:Q[
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M;FV%4X8:+9G#=805:0A< FU$R<VMGE4EY_.X6OS5PW2Y50=?@,S)%1;AEL]
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M.5ZQKQZ8H+S*&(C/IS?9$%"NDW5YTB3SW?P'[0?P)]#>_=7/QE_RD]_]/_\
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MM>H?C,=JUZA^,QVK7J'XS':M>H?C,=JUZA^,QVK7J'XS':M>H?C,=JW[9/\
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MAS(YZ5#6Q)CPFWF2T$HZFS%=*JG!<#17\J9;>HP23FC27:'3'*8,QPB-R6,
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MZ6%NA B$?:Z-VA724FV[/QFVF^=O!QYTKIITHB; -Q(JJI+:Q"HHAC9Q?/\
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MGFU(.Q*@QG&;!8M.S!)&@]Y;EU CC[L@@!L3?Y,>MTU1Q%<V;#*#SR;<54;
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M?#C3)#B(ZX](3JG4O*JY;DTBH=2YEZ)%R)2WX&6I=8<+,M.5R$@3)\"K5-T
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M4B7L]7#:<G;<0+^=113T>A?,UF#V&J/]F3'F:K_L/4=_@^EU_!@&JC FP'7
MU@$Z)(B.&"&@ZQ"0VT2IJNBKI]/&3?W@@_B>5ZFR)>Z]3_)R733=/_9VG;^=
MS?5Q;E;]_KMC%5?2LB"OIX(4DNB2JBHYL8RJ@HBW$1X+=;;UX=&!(IKQMH2*
M3.QA()IHTJ.JVM$4[FJWU)VJ;L=JOM?Z3QVI>JW\+':EZK?PL=J7JA\+%Q>D
MLHGG6DB:?17;M&OJ+:W#?;":9TYKFV5 &FKKTJ:ZNRQ30353%%4;-J("EKX2
MU3J/!$7F4OGV(E7=R+<5BM=O2BZ1[V! S>?)$WNN[!'#6Z]LC2-,HJ<+-@FY
M$OCM2]I_02XR;]@'5*_*+J3X>_=3_&7^]VOW-O\ %3RCG\3\0?[W/]V7\0/*
M-_Q_]GRWRZ=R_>\C_@GAZ47\&&<Q;21RUFCR*(+2$WR3DLB=&GFXH;-7N4([
M&; 2VXM[/6FQ5=)!Y/R^70GD>KOW;MWAW;^%E446]E6V*37IDVHO=8T?<IE(
MU1$I,:H/QY40ZL33<$9\BHC!ENPVN45%R''!PB8AM/D;Q?+BG'COW+Y3Y>CC
MY=/D?+IQ\NGCZN/EZ'T /XWXA>3U//X3<K?U[Z!FC_PG\^F(NED)"B[KV#J*
MK3VDK[)Q$45T&G-5$7?>W3A'"RS2D% 45:^>A:U'?G?3*$!IYSLG:\ Z4K54
MJ%(E1F*G1VJ=';H8MN$T^W-9D;<^6R$\ZV2%<EU72]\4JD0(]>5Z!6CJ;CM9
M;A(CK#D9QC8CR27=-)%J'O"BXVJ16Q%"C$D78JK#B,&\2HZA2]1J6T1/0%.\
MF"V,86M6R'9M K;=F]5S57)+BZEU=[>G3A.Q\>'.'A?=;OWX)X;8LK>E?V1"
MB^C:Z;E_H7&AJ,XZ=E70U8RLB7)4$5(S$1N1$G:HEU7 H;5E.^GG#SE%+K:Q
M\+<%Z<75@T3A==P]'3YW>2=._'<_;!Z'UW1CN?MP^'CN?MP^'CN?MP^'CN?M
MP^'CN?MP^'CN?M@^%@4V>\N'.#X7J>'%E;LO3<A0MR<ZX<44.=?&]NW[903<
MO#I1.%O5QW)?1N.[[ZX[G[8./3OU?>QW+VP?"7[]O1QFN%5^O49ZNE$Y%.I$
M:',<B\F9>:-Q4ER8S>UNZFR0A<%.A>G =EST) PTRXK=+I "ZXVV@G)5M9VE
MMU_NIM@N@=2:4W842DY_W]HO(J."CQ1.$U=6I5XK>RVZ;8H$ND,51EJGTER&
MZM5:9:?=<62CFI-B^^)63MUN"ZE[7&3?WA@_S?E>ILB%+#_V R@-X6K;V/*\
M)LM.E45%%#4VS1;@\+1I<A1,(VK%3?5O4A//-"3A;R+6JZAUCT"@(ICN%0&V
M%+0Z%ETV= FEWHBW1#1+ISK7^N14P;JHI(V*EI3BNGH2]DPGSI**_'2C?-X<
M>R7\\B;L.:8\B.K7$9" BKOLBIH,DLOD?+Y?+OX!XW*W(U:4V;H]B$M",V)M
M%30&FSA71=3C>WVNT=(7D'826RTW7:L:13?P4T(@O?5;21?774=)%@VUBRGE
M ]"[% 7@EU7GF&[T[^# 1^13FMH>@7'0:$+J6CSKQJGJ>&^,G?8!U2ORBZD^
M%<1.8YO]!>F_H_WL@#T\5Z$[^$%. HB>IY3:IP+<7@5.'WD_O;O^!.G"(O$E
MUKZ?Q>414XC^#I_H_P A;3H2_J_\/)ZGG\)N5OZ]] S1Z$7^>3%/=84!>&0&
MR)PM#8N;2S9.'P $/3<EW)B0XV_3) I),'T6;2E%7HFEE'=F\B$@IJ1&706R
MH2[NE#DS>MIRG%%LB2H4]@5LTA(0@V: (:"&Y+Y];<<%I8@+9;$B5:#OYM[I
M=[G"F_>.[HMOPXRXR.T:,FSTO 8H8$HE8AN))J1=*WX)?IQW%.]V_@MT(O#
M,"2(#2 +?8XQ&&S6X:7"9UHNJRW1<"X9MN.!=$=-F,9V^L(E8U*"*O,2]DNM
MN.&JM ?;9G-0YD!L^3Q;#%J#)1I+>S1E!)3;-;.=L'1B,+,<6A;=5137J#6J
MKJ4S,-.Y54BU6'HOAV)(=@%$>V:FPU4J;LC540F=" Y="TA?3NV>_!N$S#TB
MBF6BJ0W530*F0Z1<4E<T"5@L2WQ2WQ2$]UV8*0PV$M!<9 -DBC*VR-"T6EQ%
M7?T&J;\ TC4#48*:*E6@J&@5M=21TDOOYJ:M9I=53FX:=%(B[:4<4064@JCC
M5]1&1:6D;72NDM6_=W\ ULX&MP5)%Z[0- B):54SVJ@.]1W:M2IT=XAV8KI(
MAN+B*BZ2T]MO$MZ+O%;*EL=R]OB)L@%M[;"C1D7-!Q21 (N.Y"5+[ELF_$V.
MKE'DG'50?DFM-0SVC1*1@[(90W%()'0ADAHBIW/="H+<N@L.5('^3RI#\)V-
MIBM(9*Y);;>=;,T5-F*B._2*#S=QDCE(-!==BKH<I ZC:D.,6)AP6U4MJWJ:
M5QI%)M0ONQ)?<"GW#6^]HJD-36_/(A '+*BJND1;12O=$2PIB'H2&Z4Z-RIL
M1F .R"Z)9XGMFB&-[JF^_>P?).MS8.'SFRJ-+)TE%7&;H#Y$5KBX*FBZ;:5Z
M4PRLWDAM-F2- Q-AO$!NHJDFF+J-4L*W,DT#N'SR8!@=.S"VBXQU(=)(26,F
M=:(BIPO@7WNZ%K(R^O4C'?9!%!MT]]<9-_>&#_-^5ZF?*M.S3(>3%12U6$TR
MY TK<=X].^X\;7WV5#5ZECP.YK(34&F[),+MAZ-LA*T!">HM*#I<NHQ#IRNC
M=P=@,PVQT. 2H>EX6E-=:\Q>=J7:;-Q!-%?Y=L5:V:H2-(YVN_4JW)>*:;(*
MW3?<EU(@,H+(JN]4V@3U6W-NHZ#W;O"GHX>"(VTV>K46P&2+:@I+HYLAQS27
MU^DMZ[[>2B,'!!D$)!VJR>QJ0)9"03:0$W!8",4\Z-B0<(V+M*4KJJHQRO7I
M4=!*WL7B)&FFPUF0EL6Q:U$32-*Z(A>+L15>T!]#T>=2Q..<Z_GU-4(1U6'5
MI%_EK6I[6:W)F<^"/(.XU"/Q3C=!4+CJ1#"]\:T88%Y74Y,3*3M6K:+?:;9U
MP3L0BJ$B(@KJ%!33J/)WV =4O\HNI/BRI=,=S]L:?>1;8[E[=SX6.Y>W<^%C
MN7MW/A8[E[=SX6.Y>W<^%CN7MW/A8[E[=SX6.Y>W<^%CN7MW/A8[E[=SX6.Y
M>W<^%CN7MW/A8[E[=SX6.Y>W<^%CN7MW/A8[E[=SX6.Y>W<^%CN7MW/A8[E[
M=SX6.Y^W<^%BP"@IZ']/E;+94Z;X[FGI$:?>1<=S]NY\+'<_;N?"QW/V[GPL
M=S]NY\+'<_;N?"QW/V[GPL=S]NY\+'<_;N?"QW/V[GPL=S]NY\+'<_;N?"QW
M/V[GPL=S]NY\+'<_;N?"QW/V[GPL=S]NY\+'<_;N?"QW/V[GPL=S]NY\+'<_
M;N?"Q<&T1>^MU7VU_+74$OX%5/P8[3VQ^_CM/;'[^.T]L?OX[3VQ^_CM/;'[
M^.T]L?OX[3VQ^_CM/;'[^.T]L?OX[3VQ^_CM/;'[^.T]L?OX[3VQ^_CM/;'[
M^.T]L?OX[3VQ^_CM/;'[^.T]L?OX[3VQ^_CM/;'[^.T]L?OX[3VQ^_CM/;'[
M^.T]L?OX[3VQ^_CM/;'[^.T]L?OX[3VQ^_CM/;'[^.T]L?OX[3VQ^_CM/54O
MZ5Q;R>IY_";E;^O?0,T_M8O\^F(RRT=6*A_/",**/*UOU[-2YNI4PZC-U94R
MV>T3GDRA791Q.UN(JB+IW7QP3U,=JGJ>GA(5'ITRIRN.PA,D\HW^O)$V;=MV
M]PD'SO$DPTQ7Z1.I+D@5-A);>E'P%;&39"I@NE;:AU\W6/-\HTAKI%2L16OI
M%45%*W@%5[WHX:TUI=D0$KJE3'D<:=W6$6D(D<;+2EW!)-^GF]XFR*[::T1Q
M$0-7G0+2HDHZMQ**W5>&&%;E.N&8ZGP($;!@Q+M!);Z^9SM>D4WVONP\XY.=
M&3JLQ$%@31\57MRD6!MH12ZVYYJMK(J:K:9M0<B,[,CVP,\JYX\&T:'9\;;U
M7<'>YV/G8R=%3+>X@H2@EE;-004TZM^Y554\D)&@=MUX=9VOGMER".>S_:ZE
M4K<+J7URXX)\M_X=^"4FP5=:\12_!/!CN+5]_G1Z>/1TXYK#2=ZP#[V.>RVO
MH@GO8^EV5_\ IIT<.CHP5HC"<TM^Q'O>%,?+P83T_P 9,9-_>&#_ #?E>IH*
M.&W_ .P.3%U-Z=6[+M.^N0D^]A?GN5OOYYI>/HLK;T$LF/IN3P[[/JW1A-^[
M"KRN5844E5%;)=*"M[)L2)? (IJ5;(F(P+(EH4@;-<P[EI$'"5Q$9TMD@IQ=
MTKSRW7X&(:[MVU:F76TW]"$8HAVZ=/!?)^G)?G4[9KHL._L6^_%>G?Q1=^!I
M57>K]-DO.*U'6532*.^>J^J,]%COD\V2;]N*%':$25PVE$L.E&S%%D[(%=<%
MFH07E;%-QF0M:R$=2BF\;(6X4YRX=9&L%J2R:I+@QD+]P-QME'.*=JBJO>5.
M"6<)Y%WHX2B2DG1O 1#T+)C)WV =4O\ *+J3_K<ZGG\)N5OZ]] S5^TC?SR8
M9_;_ .T6"OWR_&P@QFSD$MN8R*N.[U04L"(2K<E%-PDN_AWAC3*;.BR3YK;$
MF)(9-PK;M*.-B2HMKENWCJX8I'6TXNF9!9FU.H@ZT2RIKH(4C;20W*,5Y58;
M:%2:CZ-)"//U=;SF/1J10MJXS5HR 7*:F_87TCH8]EB-,MH)DFE''>>.YO>Q
M4:)4Y-1@\O=HU1;F--MR:?4VV D-;V=3;L29',76'-5[Z@5+IN^7A^7I>0/I
M_BECY=Y,0) BAJQ*8=$52Z*HN"O:].*H: T*N4IQP-#8[[M@=]R<U4O=%[^(
M,A!#9QX;0/GH'6V;((KE]UUMN7T\5O9(T:O5VI2!$VPU*P3EVU3=N'3Z71CF
MMBV,9@8Z:104/21*I63O*NCTD[WDM_OZ[_JZ-Y!?MU_ GD#'@1'I3Q62S0$5
ME\*VM@I+]*<0!'4O2=K75=*8)IP% P6Q"2;T7T]Z8+=YTOP+CU,)Z?XR8R=^
M\,#^:\B9EEB=M*W3XPS)</8OILHYI%)'-NK21CW38RZ6WB--JEQW+;R.IK_!
M_DW\G:=Y-7G-DZ)#(H;&IAPFG 297J9#4Q-M4<YJ/J2B"ZC1%!.VQ6&%G539
MTB,#JF$R4IR#WD^+2*\C9HB;)M.E5VAKYVP!/GOKRW*TVH(,B89Q@-FITEDQ
M';/$FT4WST*N_0A774N*]D2/3*JV_0X92^O#HQNM<[8N06I(1B:?-Y%$JC'1
MDC;07]E+LC6P';?+Y?+O8=B4BL2X46G*PDMX)&QCLRT4ET1FX(1I4UQ! AF-
M3)QP=RL)'9<$R-7:D[4*O*NJ\JG3'MH*D-BT+')FP6[FCINDR&@!72EB!N'M
M^32&4? 'WE?5H]1-N-@XZBR%"P@?9W73U.F"'LQ &_\ A]^^(U/-Q3A2G-BC
M1<[8NN;FR;7B(Z[(0)8;$I="8R=]@'5*_*+J3_K<ZGG\)N5OZ]] S7^YQOY\
M<4UJ9+"GQ'I(-R9YM&^$-@G=+LHF6NR.HPVI.;,.<6FP\ZV)3<=\9<=N0\#$
ML&S9&4P+I"S)!L^>V#[:(XC3MW@U6<7"R:>9L/HJ:9#2=F:TD+G8SXC?9\_?
M8F]0%<25%:"HS&9E/J;9]=\N5AR4["EMR#LY)BSFT<6C5%\=3[+C0M(V:(KS
MB1W4'$FD0)KBJY/ESXK%7=!PT!X=\:'*;-8CZ,B//;:?=/4NT-$VBIB4W$IU
M-9B(XZ\W_=9 <-GE)QB[#L=).=BVNS QV:*B]K?&:H%6>IKU.5950E2(53@/
M'US@O1&J:M*>36M4>&.ZK*Q$TJC)ON]L*KB36Z.ZQ5(4,5Y2TTNBJ,J*\X>M
MEW'G035=704VVT15)1W ORZ>CSM[=_2G3WL!Z?XI8Z?314[V(A+P%]I=_@,5
M_!A@D[E/ICT5>]<HRDB^J*8J5M6X5(5\+D=K5A_G60VI2&*=-C;MZG1WL'9+
M=T_GW?);_?YW_5L;'JX/]N7X$PB>%/PXB5=6FD>?C\JDRE1%-+;]*$N_H[^'
MU@ZBV*JC@."B73O_ +5<,5>&&S8J-]J HFE'AWK:W?WX/]J?XJX]3 >@OX4Q
MD[]X:?\ S28MJ3Y?>]7^G&=%54LN6H^_OVCY3O\ *ZWX<17&XO4^2^EX=WD=
M37[ ,G?D[3O)J(L")R%J>5N3 2HB')^:JBK'&Z[M[NBR]"[^C&96FM22H95:
M^S)-1FM=C2+%X"V^P<3@H,EB#($1%7<EYJYJ%?2@YNHNZUK#VW-M:^Z_!,2Z
MW'C;.I3F]G)?VTE1(55M>;'-XHS1&K+6T-MD3/9CJ5</3 FC"CQVR)_2PTY-
M=<512*Q#<E.+#C.O.JC:N2XDH$UIS0[JVF8'ICB5:L2 =J\=[7R:33M*JSV%
M$M&J"/NO5=I[9(Y>>_3I8J&ER+\OE\O3PS,C KCD/:;1L>W)D[*I"GGE%03<
MO 2-4WICY>GQWV3P[ULM\+4W$[#"6S=_\)*(%X7W6:$M?@,P1.TW9.^P#JE?
ME#U)_P!;G4\_A-RM_7OH&;/W*-_/CB.HCK(2)1!0VFI=1;MGQ._UJ;^GHPYK
M#9DIF1-Z5'01%<@TKO%$X(*\.&'3:C19"NVW2V6Y#8V,#2P."2(NH$Z.U4DX
M*N'9ALM,$\MS;8 6V4+IV;8H@@'2@HEL([$>-&U*[\6]V7]VGG-JA#M4'N3R
M)M&R1%$D2^&I*BC#VA.4NM+LQ?='C(V8"#0J2(G::;E?:7NN(;41IM8HM2F:
MMMHC3:RYDI0=9=J,1M7&&) ,"PL5QJSK1(2:D<5VX52GOJTC3.V:?8E-MOMB
M1\X0!'T<UFX"=CTW<2RDO-Q&E:%:*ITR#5'6E%1V;\D#;?Z>!NQR=WI>YKT8
MC[1=+:N@ADF]4"_/44WJ1"-R041=5K6TWQ1_F9JYU*6BFDEKDC3&RCJVFDGW
M&Q0CD;5%'0YO 5YJ6OB.BIN5UO5OZ-:8R^@[@6(\NG]J(CP]!<59.QIR=&FA
MT@B$YMT#NJVN5NU35T"B<$Q,;NT"BQ-<-#XV F]2-_LKDBV3H1>]@;<Y7!.W
MAU/N^%,=S3UX='\;"D0;DWKSA_H5<-_OZ[_JV-CU<%^Z+^!,7^7RM?#F3ZLZ
M#+[(*TTCAZ4?8.VE$)5[8%Q4"ASVP<E"2MR'R;V;&[FJJ7YPCBFT9:@S5)E/
M)[ELM@-+).+J01'O\U?O8(4^M+\"X]3 >@7]&,GIWZ!3_P"93!%URS*FI26W
M*Z8J<Z]]Y4DRMOOSB4_#:^,PY+=F5@:72:.U/C2&WX:3S>)JB$HO.+ 6.K:%
M49&YN,);FNR):Q4^K1ZAF%V13)L:<P#\N K)/171>:1Q&J8RXH:P34(NAJ&Z
M7\CJ:_8!D[\G:=Y.8);1*#D67EN2V2+I5#CYHHSP6*RH-R!$153IQGQU;JVY
M'FD*J6YIUZKPRU$2"B*@DNJS=E73WKXID4F]!,9%S#*NMM9]<<TT=5NG'2"1
M&R!;\72Z?(:IM-2(Y*I=%=S!$C3P<=@SYB308;B26VY,14%T&G&MKM=("^XC
MHNL./,NA(D02AD;$62T8$;\&7%G,H_'?AR38C&5Q73)C/L,R8KPV-M67([[_
M )$B?!<"F2047'WMEMHJ,[04DOG%VK/.::4WNQ&.K9VTDI)BM9<K0H%9R_4B
M&1947;19Z+(B24TB":'+.[*P"O)4C&:"3F@<G?8!U2ORBZD_ZW.IY_";E;^O
M?0,U^%N-_/)AEQLE$P55 DZ%N7J8(S4B,R(R(MZJ1+<E5>*JJ[]_D)USVB1=
M*ZMEIVM]*Z-&M%'M[:K_ .#UKAE*=(=C-[)-J4ILGM3WGU%8H+9GAH)43AS^
M;=%6=)FTBJRIJ)UF:I\HI6C9F6WFRTU,#'1KN<=J0V[K?34((UK-(?+7%?.H
MTYJHO0B7LCKDTTDQW'S[9A@(XQS1741]Z03P  #SCVHOFRYJ)0V7,;;U*6YL
M4W"VEU013>"6U<4QRR8YM'=BPP/'F,1V0:9 47M401U**;M9DO%5P/I_BKB"
ME1)P*<LR*E0-E%5X(.U;Y432)O4T8VFBW!=Z;\9=^8!^&;BC(ZZ)2G94B*,0
M76DI;CZRN<E4(=IRI!W$-C.ZXH,IUW4*L.@+::%-L5WHJ@GG;"EUZ"LG3BMR
M-L(-;6GMF"]MK740+;PV7T\/K%NIL]=7N=I34#/-+T4LJ8CG<M2<U>%M6T)>
M/1O7U< O74N5--@[&AA0%C;=YT1VP/5%-S@@2N[,SN*""6Z,/?M%X>_T^BF[
M#?[_ #O^K(WD&O\ UY)[0/(0V3-LQWB8%I)/3QL3JLUQNVG2KSBIZ';8YUU5
M>-^*K@E7ZPU]JN/4P/I_A3&3E_[!@?S7D9ASH[)AE3:M2&8,>."N\L!X0HX.
M$\*LHR+7]RU4%%\R7:IJ ;>3U-?L R=^3M.\G,*KILDS+"KK34&E,UT35K%=
MRC:]T7<J;L=4L$&YHZ^+9#N5&AK%/<W)^YF07X:-^*5K)"0^IS6N.E7;L9QA
MM"I';:(*B7,;U:4M>V_#TN1M=BRFH]A&DS'K71.QQH;3\EXKKN!EHR7ZW%,=
MI,>H-$Q37HU:2?!D0EZWN_/,%%9D@V_%+E"J>F2RQ)5WDPB"L$\J-LL-@TRT
M"-M-MB(-MMBFD6VP%$00%$1!%$1$2UO)J7*YTKD 3W8B4YGDK<1UB.VR)B\\
M,7EKFT>VVW!)>R*Y1S%6TMB!F>B;-UN8U'HN8H#A(VA0$D(3558+=JEPQ6Q@
M1*IQ@$6QWN8R=]@'5*_*+J4>ET?K<ZGG\)N5OZ]] S1_X1/=TP'I^1\OENX[
MM^-G(A2CJ&P(4?:<;%C;[2X.$T0$9-@%FB!%&ZW*]]RQ:O(I@R*C-=<ZV4V7
M/5V*L9G4)5>=&%IIXH_*!6/%BN.,B\\VZ;FT8%4(ZC5UY0 F+[[#8@"S.<"!
M&: $V -(G;M@B-@R"@TBJ5\3GCDC,)R01<J"^S>3SA-ZMZ-BWH; .((&DO.^
M2WZ/WD157H7H]["!#B2VYFH=;KKH$T0[$-8@* A(6WUF*WW-$C?G4LV@ 6I3
M!$3MKDI(ED'BJE>R(.^ZXH\9_L#K--D&K#BHIZ2-%L=NU)..A=_3T8S-VH:&
MX#_.*VO9*N@43I5>CP)AE17GO/5)D5U62SC!]MW]73?CA$^MD*FY4Z'B1;<$
M3AT[K=%[8CVFYCV[C+*R&EIHN1 /F;5I@]NBD*H3I1W$W;K$G.P76B55'W45
M6W0J,-J/V-&Q[*"M.$B+MM8*R:7%!116U[MH**J]?7N"7_\ AD;'<W/6%AQ'
MC!I>4%N,D%>T#H*V+(^S]L!?]K'=F_7C\+'= ]>'PL7VK7KP^%@T1UJ^S.W9
M!XZ%1$XKTX3L1^M5?1WX#4)#="M<53SR8R;^\,'\3RO4T^P#)OY.T[R<TH-M
M1'E\4NFI+EF:C#P7<O'=X;8SXKJJ&HI4=VVE-393Z7$'5WD7<AKQW]Z^(BEN
MT=3RHB \U?\ YJBH9:TWJA:!+?\ 76Z/(KD*>TL>K/U5^7J<TZ:C!/="=@.D
MJ[9AF.*-.,+SH3VV:5+K=?E\O?\ (<:+4@N 0%H,VSTDBH6AQM1< [+S3 A,
M2LHJBI@8\9IMAAN^EIH=()J,C)=W$C,B,U7G$:D9<XE5<9.^P#JE_E%U)_UN
M=3S^$W*W]>^@9E_;0OY[$2*VJ;60>R;NJ(FH]2)=55$2W'TL "LHBN&K;=W8
MPB1"#CJHA*^@W1MLSMYZR#TX35%<'G-"A+L].IQS9!<]KH34XBAN5;+SO#A$
M2(YQT[]G>]ULFC;*J+V_[8;N(N[##4I%CNL08D?9$B$B-,HX#>RT+;9$J.%S
MN?M%=3@B8[LGK%QW9/6%CNR>L7'=D]8N /::N?IMI5.@E_H\AAYM=+C3K9@5
MKZ31P=):?/67@G?MBD3GB)YYZ//VCI>?(G&E*_>-+[P[5!443=BOODG,=CTV
M.T2[[/+KLNE-Z;D+G='IX8%?\'+J#GVF,YNMQXI@GT%$N\XZ@V5$2[ADB>EJ
M2V.\G"VMWAWK7X8,5$>?Q+G7W\;WPR\HH>FNN<VVH2_N?%6Q(O$5M:UTOP7=
MA7URU366WK-!+& 8M@XB*XBLJKRL;30BE:Q:@'>"W54*6F6:>;",CM3&FER>
M_.#;$8&(-*2ASM"C9![GTHMJ%23'6CJ;2*I;]F+9)W;N1J"N(UP;<,K)A!&D
MPH.D]5X;:B7 DTD1.%<5O>UMRBF.YG]['<S^]CN9X[1S#6D232)(NK]L.,EK
M_P!@POQ?*]33[ ,F_D[3O)S4J+94/+RHO>5,ST947=O32O.NG>QG5Y-SDAR>
MMD3C_=:G(B^J#G/7G)N[^&VFTTBUU/:DB(B63S61O255XW\*]_R%L(C.CH;E
M/DWT.1Y%KC9U.<+9J([4;Z31$U(JB-E+23;[)[&7'-+.1Y(B*FV702;]39CS
M3;453RN3OL ZI?Y1=2?];G4\_A-RM_7OH&8_W2%_/8B-11(Y+SHLQP!+F;SQ
MJVT ITJ1D*6_XI)1XH39Q':FS(CNU: +R/4MD)$P4:)Y%+7$)N5$T*:2HW9&
MB)K1A+RG53HNI6WV+FZN'.U*J)T[TXX^F#[_ !3CP_!NQO?)=R)OLNY.">@G
M1CNR^UQW9?:X[LOM<=V7VN  S4]^Y-W&RXVCD=X&_KR!43>@K:Z[EOVZ?L53
M 6[X_?5$Q26/.<BF%HZ!(' #4G>U#9%[^D?K4Q413I.F=/1K<O\ T8[6_9ZJ
M@]%EV+V_T+7W82_'?^%?)"#I2R379FN_GCCMQM'>3FA=./.5-V_!K#9*2TQ$
M<J+5/6:RDQV(VA:Y<.E..I)D( :B78QR>V6HQ%03!0(E.=?#8//.Q@J%3V>Q
MC-N2)#[C:24:T  ..N7#HYJ"9*BK)E1=BS=I4LZV?,D@CK)!92,VE;,%VB]J
MJ[-><EL?+_CT>53T_P 8<9*_>&'^!?*]33[ ,F_D[3O)S6O'?0D7HW+F2D(O
MWL9L.XZB6=:_.0T*KQ"3CQX%][" BW3_ )OJDOAW9IA6]"XGP\A;)?P)Q6W0
MEU1+KP2ZV[^*C5(M/TQY)1Q"#4#6'.D#'CB*R&[(ZD349$R,>6*.'L-K=@#'
M6W)9U:#1;@XFEQIT"47671WZ76C11).&ZX*0*B^4R=]@'5+_ "BZD_ZW.IY_
M";E;^O?0,P_N\#^=7$1YMYR.XR^+K;[*V>9-L]8NM*F]'&U34%K<Y$WX-ES-
MM1-MUN6PZ)1!(5;G['EC!<S4C;XL,"XVW;F-"WVF[%GJF;B B:5Y([:Y:D).
MA4L(BO.O;%FG5?&V\MFK=E^MLOJ^6#P77H[R]_\ !CDLB8X\PFE1:);@*BV+
M8D"<$5&T0-WG;)P1,#<EXA^.*8I &-]I#G@A<%32ZEMZ;]_>X+Z6*KWV7*?O
M\&LUW)AG>F^15"5?1C.;L)?IO^%?)MPN))?O:N;ZN^WQXI6>GI]3A5BEQH)N
MY4C4M=G*JM*A!"9Y+5D<:CL4J:K0/2D=;22T!NLBVYJUC*FL3'J<<OE8/K$:
MVB&U*VG*8Z-FEB9T.[D)%LB M[HF COSU$&M(MMC28?-: S)IEHP75R92<)W
M8V1M7+&2:Q%<:W)4C6J;TY$ #P2UD!T$%.^J>IA;<+_+O_C>4^7UR8R5^\43
M_:\KU-/L R;^3M.\G-J[^WR_PX[\S49/Z<57_"(NI53A_CD<MW>6W%<3&]*(
MOS$5&RWWH(9AI:(*^OX^#RE2>@4EZKTVJC%E@W'F0HYPJH N,5!7DGR(XI&F
M1VX#C*Q%?7E@2U>9:VVW,)D-305N#K+P[*3$D-[GXDME558\N,=VGV3W@8^>
M!0-8L,S^>)FVV#8IJ)0C#J?=-!5=#(:FFU<+FBZ^R!+K=%,?+WL9.^P#JE_E
M%U)_UN=3S^$W*W]>^@5[_O5._GEQ!947W$>D-M*$4-I)-''-*A':XN/G?2R*
M;U<4;(O!9C#B5:-L)3C(LRHVSDMH!HFSDBX+>S> =S@6NA6W!O116-RHP4;E
MMVM!(I7YJ:%WCI%-]L<5QQP2.K(W JBC#>T*_1KWI8;\2OX.G [$I*EY_; C
M:<.U&RWON5;^AX,:FRG:]UE<906K[KIJ_!CBO3TX;OTK;U45.G 2&*Q&EOE:
M\5L7D=916@-5-3!&UTG=A4$E74&JW.7 \[I&^[]D.*1^P@3%]T3%8;'?J<IP
MV_;$?J81?^CD5$/49>]7T>]CY=]?):&Q+J738-YK?<J G22IZ.Z^[#B/+/:4
M2W"C5O.B7.VEE3^*G"R7P*Q^5F*VU;5K3:Z\T1456Z)O5,<5[_X?>QQ7![3E
M"V$-.Q1"*ZFB<Y%6UK8162D*EN>3X(WSE2Z:4%=Z)?"$*SMKI#MVD%E2\]I+
MO+YV^.*XW^#\9,9(_>*+^$_*]33[ ,F_D[3O)S8(H1+JH&X452W9EHZJJ6OP
M1+JMBW(MTZ4GKR5[1OW*V[YV4P9"JZ4WFG,XJFE4T[AQ.VD=QLAR540NX!#N
M6OTE>*[B0M-TOO2W[+RKTF53(QR7P1MZ2 DS)=040&U-YE0<(V40=@\I;1C2
MA,D"BBHZZQ4BEL25CZY%4VU0J[,.,W8*8Q--X$6+ME=D"](!QU#>>V@R'G=L
M'W_E_1PQD[[ .J7^474G_6YU//X3<K?U[Z!7/^^4[^>+$:9&=)B3$>"1'?;+
M2XP^T>T9> D[4FW!%46RVXVOO3E;E;JTF5/!9=7?DA<W*FZXX3RCH--J!<SL
MA67HTK?=OJ\\2[4NP%IMWK;7?9-W@PG)Y#KB]*.L[.WAU:BNI+CML'\]OQT-
M-"[!"N:*J7%;*ETM==^[=; IRN0^T*)97T+C?H!55$TV3"#R^4\JH@FV^-F[
M=&COHED3?CM_PX!'7MFWOU%I5;<U>]A%2I;2ZKS1:<0DX<=3")[95\&$+EA;
ME1=[9=!(O0'@Q'B$^V*1F39$A%W40NGJ)%YG19,2(3<UBTM67'#()0N L:^@
M4LT8KJ5>\GH]_E .@Z>T?<76+HI>0! 7G$7IO>W'&M9"CZ#9;N.[>'.X\5W[
ML?39_:U^!CZ;/[6OP,-N1Y!*8E?AITVNMTYG&]K)BYU&2UM1U/;)-VTW#W$=
MF#>E+HFGB(CNW)9+U:H:[67L2V[UMSO0F_"*Q(=<6_.1QC9I;>MT74N]5Z.F
MZKCMDP:\I>CZDMJ8[9=Z*B+O&Z=/HHF$ 93\AH.UV]QLO#<*&2#Z*)X,"V,Z
M4ZND!<9<'L I9;:-_.T\-_?QVR??QN6]D_VDQD?]XHWX3\KU-/L R;^3M.\A
M+Z]Y:>8V;BWW\4;$E%-W;+S>B]U3':R-RZ5^<Y?WNP;TW=LF[" B/(J\-<9]
MH?0U.-B/I7OY#\DA<,8[3CQ R&T>-&@(]#+:=T=.VEL//DJ"F]<0JDU%JL4)
MS"2&XT^ES(\QH5OV.0SLRV3J:5NVI*N\>_CM971_B4RW.NJ;]CNM:Q="72^*
M/"<BU)TJT4D67H\%YV/$Y-'2215$[(4-'!5 :1P=1.7#<HEBVB5QT_2<JU^-
M^X[T\*;KX[23]Q3./VC"H"/;DXN1Y#*=&Z[K8(J[TW(M]R^'&3OL ZI?Y1=2
M?];G4\_A-RM_7O*HLN7&BH5]*R)#3*%:U[;0DOIU#>W"Z8U!.AFG?&4R2>JA
M8^G8GW0U\+%99C/-R73FTW2U'<%YTNRE?2VVI$MDWKNM;&Z!.3T(SWI\ [R_
M?Q])3_N:1\''TE.^YG_@X^DYWW._\''TG-^YW_@X^DYOW._\''TG-^YW_@X^
MDYOW._\ !Q])S?M#_P ''TG-^T/_  <7Y',^T/>A];Z&/I*;]S/_ (-./I.=
M]S/_  <?2,_[ED?!Q])3_N:1\''TG.^YY'P<+>+-LB*J]@?W(F]5[7=9-]\(
MJ1IBHN]%1EZRIWTL.],?2DW[0_\ !Q]*3?M+_P ''TI-^T/_  <?2DW[0_[V
M/I6;]H?]['TI-^T/^]CZ4F_:7_@X^E)OVA_X./I2;]H?^#C?$F6\+#]O3YN,
MDMNS(K3@T*.A-N2&FS%4(]Q"9(0DG2BI?'ZHP?NN/\/%SJE/!.^4V,B??<QM
M8LAB2U?3M([H/!>R+;6V1#JLJ*J<;$/D=3M)#S4?D^2LK0GML8MHW*B42''D
ML$I*B;1E]AYLD[[96NB7QJZXP=*^>Y7'TW[U]?Q\<76?%TIONDML?/*&\A<3
M=JYO2FK=WL?J@-^V_59U.U0KKI239!LI*MDT;M2IS$LA,.*ZV::Q-9#DE%U=
M(N.FX2C]:J+I7H3R% MXFBBJ<+H6Y4W*B[_!AN.T!@TRB(V*/OW#2.E.=M=2
M[NB]N/3A"%#NE[=F>5-_'F$XH+Z:>'CB-R8V!8N_RQ'$?1U0)I4:Y.;1#I)'
M+*>KG6[14MO6^SM>Z6E5#CX>S#9-_!-U^B^.<2 #8;R,^:B)Q53<55MWU.^$
M%N9&,EX"#[1$J:T'@BK=%*P[DXJB<5QE&V_9Y ZHNTZ=&VS%U+=EJ^MVNP>T
M:NWV)VOH.WZV^IY_";E;^O>4^7RXX:B9D@'*&-M%BO,29,23&5S0KBM/1W 5
M=6@;B2&VMANVNE%0@RYGW--(:WJW&E%'GL!?SHDT,!Q!3OFIEX5OA>19YY:G
M1KG28AV[Z@<1U$Z-VV)-_;85.NTM[]RKL+[R/*ROWL?3-5]FZ5_:,?3-4]FJ
M4O\ _/C?(J?LQ2_[1C?(J/LQ2_'XWOU#V6I7C\=WG^RU*\?CZ8J'LM2O'X^F
M:A[+4OQ^/IN?[+4OQ^/IR?[+4OQ^+++FDFY=)52E*BV74E[O=]$7TL*9234E
MM<N6T;?;=_TGJ]_'TV?W91O&8W32^ZZ-XS&^:7W71O&8WRC7_P 91_&X=;)]
MQ0>:-IP>64E-3;B:3&^UW71=_@NF ::DS@;;$0 !J].T@([D1/GC[W#=CZ:J
M'LO3_P"T8^F:A[+T[^T8^F*A[+T[^T8[O4?9BF_VC'=ZC[,TSQ^.[5'V9IGC
M\=TJ/LU3/[1CNE2]FJ7_ &C';U+V:I?]HQV]1]FZ9_:,(G7 V?W2N1=WHHR3
MQ=/0'QIR_.@POKD9D2YAHGH+'C"OKT]' #F3-&9*\"=M&!YFGQC\!)\]2--K
MIS'VUW]& HN6H"4^GB:N[+;/R"<>)! G77I+KKIN*( -U+M1%.")CY?+P;D5
M;^KB2]0<W9JRDQ,D/3)5.HJ97ETYR;*=*1*EM1\T98S$L!V5(==D2VZ:Y#BR
M9;KTQY@YC[[Q?57S_P"QO4L_-KCZJ^?O8WJ6>C_]VO?Q]5?/_L;U+/S:X^JO
MG_V-ZEGYM<?58S_['=2S\VN/JKY_]CNI9^;7'U5\_P#L=U+/S:X^JOG_ -C>
MI9^;7'U5\_\ L=U+/S:X^JOG_P!C>I9^;7%EZJ^?K+Q_N;U+/S:X3_WJY^]C
M>I7Z/_W:]_?]_CB3+=J%2KE8F@TU-KE9.&Y4)$>,KBQHH-TZ'3J7 A,$\\;4
M*F4^%%5YU^4XT<Q^0^Y^MOJ>?PFY6_KWT#G *^B**N.Y)]_'<_OKCM%]7W\<
M%]7XL<%QP7'!<=/WL</P8X?>QVOM<=I[7'<T];CN8^LQW,?68[FGK<=HGK<=
MK[7':^UQP_!C@N.G'!<<%]7':EZ[WL=I[;'<_OKC<T/R]''-$1]!/UW=3S^$
MW*W]>_\ R3ZGG\)N5OZ]Y56FUL(\5OO55Z/2_P HW$E3T%5,<[MPW'WOUN=3
MS^$W*W]>\J]^ZG^,O^4GOXG^W^MSJ>?PFY7_ *]Y26U!G1I;M/D'$FML/ X<
M22WN-A\155;=%45%$K;T5$X+A[]U/\9?*?+Y?*^&7<PU^BT)J02MQG:S5(5,
M;D. *&01SG26!?) MJ0$2UU5;VQ(JM+K]%J5+B[59=1I]5@38$860VCZORXT
MAV.UL6M3CFMX$9!%,R7B+$^GRXT^%+:!^-,A2&9420R:7;=CR(ZFR\V2<'&W
M%%=]M7%/*.OO.-LLLMFZ\\Z8MM--@.HW''"YC;;:)J,S5!046ZIABHTJ=#J=
M/DBI1IT"4S-B2 $E%29E1C-ARQHH%H([$-E5%W8^7X.G^CMEW(N/^%_Z/3YJ
M)PMQ\I_3\E3CP\%[\<0(D^I4^%*JKKC-,BS)D>,_4'FQVCC$%MUX"DNMASC;
M:1XP%0N(WQ_P_ GW[JGH>0]4*I.ATV!&%"DS:A*8A0XX*0@A/2I+C3#**1"
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MTA,#UI!:-=5BYBR-SG!!O&H^9B:Z@\SC7,O8">.@R,WBD7.=*H>1&!T[]/&
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MEDR3(R?XD3Q $+7S'OUQ<!1B$$5'DA3&ZW.O=1:>(GQR[\(03 W1$&QQ!@U
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M!V$MD"Z(S6!FEU9F4QPB9A2.F+=^K>O\:#I[]N,H$E 0 (;%)TJ2;N YDX>
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M/XAIH0;GQR;8MD<.,DU"@,$@(VN93&<\TR-XD(CVV#1<=&U8;-N(XLSH)D,
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M>??3#YE.-&0.?PP.%\5/9^TAW(U.2L?_ %
M   .CYL& G<,;3PYGRD&(4F2 IMIA:@!/D,*#IKW^VH+DWD+"GRBQ)&DVK\
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MU4&<;71BE:X=]=',7%0; 9/W 5G]W+%0JC$&*A)^T-PQHV9,8(>NK T3YL_
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MXK2_*Y8$;L/&9_\  ((((((((((((((((((((((((((((((("1CYH]$,  (
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M&"W<H=I)FB\3H< )28Q&N&;GI*"A7=]N($B0H@@_YSS[+MEY]],/FIX/@PN
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MRZ2C*D!W65#*6#$)P+A'24(8$9 96(8"Q'TV\XT=9'P(VP9@&0!!BPQA[K6
M"2N7,E.22G"C>(.+LL[E[Z!@A91CMDN@-JJ1B;3D!,J9THI%6VA"EXL<#S[T
ME0(E5R%A3HX%-&4:Q"S8./> N>MPA9_^</LNV7GWTP^%"?O]/LUB[H9)P 3W
ME88$^30XZ:G8 #J26(R)]V"90Y='U0I1T9@R#<">5O6X%2P=\GMW >F([]BX
MRXK?DE<A^ZR(Y!WO6L);+T<([#$[F 5VHD$Z HA>X&K(X# ]*!'4MUF@##T,
M\29O&]G']##[)+!J(9[Y#,1.J9(N1D+I!IA!&AI#@P;39Q-9D?6;$UZ3]T9+
MI,9B/)IO#$)@#0PBQ38RPB63V-XD@^Y!/!5MMYN6,$LY8DD&G.)UKBBN$"CR
MAY:V]O,,:"X#HP%-BPH#'">Y/NU5@"" +A\(.#-9:A,RO6P^D^2P\ECO>>R?
M:W^!AL^/.!1@D4: J([D8,Y&]55"6T[;#Q$@'_G ON,+QR$ZO)[+MEY]],/C
M!T^-JOU]01..U]']DSH7P_*IB.#P_4XL?MG\,4_?BG].(WZ XMQZ,(Y>GZ8G
M^O\ $8MNGB?SBW#Z<7_;^ /\-D&.#*$S]S]X/V??#2?I^F1_H,!H] 9_26'Z
M6/N."Y/)^&'.^:SA+YOYS[RQ?RSZ&$5Y _\ 7>R[9>??3#Y)]U^\GW7[R?=?
MO)]U^\GW7[R?=?O)]U^\GW7[R?=?O)]U^\GW63[K]Y/NLKW&5[C)]U^\GW7[
MR?=?O)]U^\GW7[R?=97N,GW7[R?=?O)]U^\GW63[K]Y/NOWD^Z_>3[K*]QD^
MZ_>3[K]Y/NOWD^Z_>3[K]Y/NOWD^Z_>3[K]Y/NOWD^Z_>3[K]Y/NOWD^Z_>3
M[K]Y/NOWD^Z_>3[]N3_SOLNV7GWTP^#DS$4-$E,IUT=?+%6V^JVSX_\ T$Q6
M>T'4Q.(^=5LMB>)_SGLNV7GWTP_^I$_O[.>_W9_8]#I_SGN>V#GQ<\\2?N:.
M?3U[R3B2H_\ 2#Z$42R7Y0GU[%KU@VL=)3A6)4?I+!-DQ@4N1PEL%!9G $UC
M$;="!^Z%V,DB_*OW,$.LT)AT;"@B.I>/L34=/WI=UI<M<D\MZ5N52=2&Q"$/
M>4WY/,-2H@).H=V> 0,82Y@XKFATH4C]R)&W-P*>(+SV8PZV@-*WAU42U"RN
MZ4%-5'805/Y+6.' ?Y:'U[%KU@VL=)3A6)4?I+!-DQ@4N(3"L-;@?&\M/%/.
MAJ&%2Q*!@:Q6Y)VV1OT-(8GY6L.T3.E;?"18<(.418@:)R9ACKU>A$.Y**H,
M!<F/\?\ ?V<W_P"<Q!"5BOQ96XV/J=R^(C88@"U.O&%,YV7>#(\#5)88;CJ2
M.T1! F@QCU;-EZ9$MJ,23EJW>V*\Z9?DZ^^1QL22=WKB E= 020L\G?FI+F.
M!A8'^"S=))?O+$[B[.E4V#BL%2DZL.CL^/B:7>X>#-H(#B1C\#-NRF^_AL&/
M)O8W#MQFP,%5Q55E?:&99A(I*IPW\"+\&U/4 ".0*K+& /U<*4C,%!6-&973
M2A!Z- V<H:/159488(Q*3Y[&_4T' E;%I3QJB-R!'3!E[]<$^HWS5^LFB"=0
M%$"C9O@.;8'SGVBL_,C%OH]?-I3V0&(Q'?K[EX.6]'/P((A RU1A>2^0Q44X
MT9"#WD*>"HIGEUP@/7X=".G&?3IV>&J:29UNPR[:3.&P)IW>N("5T!!(KEBX
MA+\^SLX(ECD+=<[D":QXT6G/1_):AQ,D:/M=P/"8<P^'5"T$ JU:ZJ",\4$G
M;&0HXS"22-*SE_!,$&[ 7@V\Q0/R-&+8TPEGZZ@Q953'7,$^43 .:='%3MAL
M>H9U72URJXH@:*.95QTPH,7S$3T9+[Q8J6LW\C_?V<W_ .=R#(,UK:P7#Y4W
M$H:T8%<5(5"38V :#IKQZ>#M*L>+;U;^3ZTL!.Q!RR,<@F3L746Z)\$5>86-
M%=8;FXHSK+>LM/8J6-L\N91]H-LE3W)0UAU'?%QBO[3]7&RRS?T:.LK@.<')
M$:T02L_DSA#:)'N5$%/+V0%4)W+K)Q&!1&BPK[,'A4',,P B^BYIF/*"8>#=
MJFDP!H@Q7/*!>CC<R,L,LAL ?B;)DYG\"<88<5=8X=B3AV LEAI"$$<-J@PW
M##)) RT8Y%AX''6FD49BE)P!1881?KPU@K!F'W4G0#;W!RA)P04#:C.!<P(S
M62F<A%-X(DM';.]3"19;I9GJN5,51 99^Z+H#OQA080BI?!00,0145D[%U%N
MB?!%7F'8VV[GZ R4""5[B!X,+"CA<3"):7-&$(G&B48AQ3L3;T12\J*3R,O/
MO(P:TD+9HH:"K1MK$!RD\#;OM-_K0C & 1I0!EK;(EJM 2LOUB[]NC#I"/ H
MIE21F@T*F(]9.$&H/BB+R?3@@X1;@!K 5"1'3BL=#'  % ([<H((!% (P_)?
MW]G-_P#H,X^6)[_/WO/QKMGO[?H]#IG?FK\+/3C/U'E=>'W'J_"6^^^]S?F#
MXDY^*/#IGZCRZ>';/QKMG^^?7/?UG[WXY[]=^N=^?W3ZE9[]^AG?G.O??>(;
MZV'H9U.N^][>R;W\/U'D6'@-Y_7T(/0HZ&='DT]/#/QKMGO\_<G/?Y^_P]_G
M[WGXUVSMQT]/T>AG7OOOK?H>AG3M,=IW'CSUSW]OT>A\/U'EJ/"*S\:[>X,[
M9T[1':-1X<9!???>-3G[7SV>/)YYSWZ:S^_HCU%/4IS>_?N#Y/[^SFWB_P"@
MCB\7T%7E6#AN7E2;R]<\Z^V?G/;+]K-^UF_:S?M9OVLW[6;]K-^UF_:S?M9O
MVLW[6;]K-^UF_:S?M9OVLW[6;]K-^UF_:S?M9OVLW[6;]K-^UF_:S?M9OVLW
M[6;]K-^UF_:S?M9OVLW[6;]K-^UF_:S?M9OVLW[6;]K-^UF_:S?M9OVLA7SQ
M2?.&T2^7.<Z8'MFSF)7Q7_H>//\ ^B9[^V?_V@ , P$  @ #    $
M                                           ()))))))))))))( 3
MUP                                                      .Q[!
M3C       $/2 %4LKCP#0
M          )!((5@    )H35<@)'\N%\^P
M                       !$$ ,E2EE +4ED8$ 1LLVM[(
M                                     (   #YY]( ) I(X )1$AU $
MT                                                 !  !-??3=3
M  #)=  6"9_O;:                            !))))))))))))((
M   !(   B$];@9  C!H !S!-9X      J#D:     "J  )(   +UI   (%__
M /\ _P#_ /\ _P#_ /\ AH      $ -Q>.9&SH@ CZY!/EA]&:LD   "!)X5
M     EW  $D@ D&]-@   V)I))))))))MLE      $ #N71O]]#  $D&4<5-
MA&6F    JX^A/T8   $F0   C'KLP9V   @A))-MM))))))B@      $ ,I@
MF*>M  WT W%.]5:F^X   &_>R$#<    $    DNF2GR=P   0 D@    D@D
M$T        @3   QP@ "@).0%'HEMPQ   WO</KH!0    @   $(!H AO=
M C  D$$ D@D$D B       @ 2:0 ,9L  P*VV@@ O]#^H  !AIE@^CO    $
M    @'.)%A.@  $X $  $$D $ D$4       @!;C "U$  ' )/0 C^J7:T
M ,ZAM]A,0    @ $D@$OH($E(   'D@ $DDD@M!; &       D @E( 1\
M&R24  >*- 0@  "(3O #GI    $  $@$$    $   $4 @$$ $@&?LMD4
M  $@ $H F5      $@ $L$HM    &5Q7JGY@    @  ]P      @   B  D@
M@@ DB080.       D @2!+ +MP   $$  ]T)C(D  "P.6'U\H    $  BC
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M@  !/(!((( ())!( -    !#)))))))))))))))))))))))!T  &?F80L6
M   V)/5!7*:B)V   $9! (!(() !%-*B    &&2222222222222222222222
M29   @/QWCG0   )          !   !CFVWVV^VVW_\ ]I4    1@
M                9@ # +J]" @    0            22" "   R0B@ "0@
M 0!#^4 !59:8YOVFNDM>GL52VD^A #,            ""            ""
M0""""602&"02  0 64/H !RYFPQHR6@H_(FAUNTU @ 9@
M            " 0      2        !C]@ 135Q 3" " :MHJ:2  2= #,
M                                           "X3(
M          9                                              7!&
M$DDDDDDDDDDDDDDDDDDDDDDFL
M          "X!,                       $-;;;;;;;;;98!)O[;;;;;;
M;;(\@M)))))))))))))))+0 7                          "$DDDDDDD
MDDLH#D$         8@# VVVVVVVVVVVVVVVAT"X
M     -MMMMMMMMMLM":DDDDDDDDDDDL",DDDDDFDDFDTDDDDD, 7
M                  !@    "    !X1"2 "2"20   !@1@     &I6'0
M  !@"X                          ,  08%S0) !!";/<\(P*@M].X(B-
M@     4DPFP     YB7                          !@ (/\ :A7P "*G
M@1$-3(\(PBT3UC%   D@$@)LDD$@  "=EN  $$DDDDDDDDDDDD   @@    $
M#  -@@R@B  0#2IU(P$GCV"'/9[XP  $@  DD@$@D@  3[]P  2.W[3;>R7]
MC;^2$  [H4DDSL8 $[  TB$  > ! "@"3!>MLH 8!8 $DD$D  $$DDD   8
MN  $>66VRV66TRV2[S@  +$$!(E#   "V0F0D #PA  "P$%(!/5 # Q( $)$
M@$   $HL,@ # %P  G:/@9$EI(60$CZH  7T$FQEPX          >$1
M      8$8   )  @D @@)D   8 N  $,YE&O@DD@D$AX/@ !1@@W<2B#;;;;
M;;;;;T8D[;;;;;;;;;:&HM!))))))))))))))):(%P  5N5:IF>5BP#J#\0
M ,\  *8\[_\ _P#_ /\ _P#_ /[X$!M))))))))-FX @VVVVVVVVVVVVVVVV
M( N  %E 6F]BLZP[TD2;@ #*$@#*  &VVVVVVVVVP0$%EMMMMMMMML   (
M               %P  SR?N4@_/"8P9: L(]"DH8@$
M                             N  $JUTUDD[Z 6[5F;+^="5]$ $
M                                          %P  #@E;ZL;^VZ3PO3
M3Z' %3$$D                                               N  $
MNTBW7$W@'#=399(J5 LV  $
M         %P  S44V4 )<*QG#K0SFT@J'< @@
M                       N  &:60 D2-I0V22"Q@ $%3S@ @
M                                    %P  GDB22"8; &LRVV(  @":
MD                                                 N  $(FD@$Q
MOZ%>"T C@ $ $0$@D
M   %P  /H2@R 4N8AS^2 <  @%% $
M                 N  %U"BKDP'D3!&F/#  $!@$$DD
M                              %P@ KY/X#-/,A.<#<GX D6;0@#D
M                                            N $ $@ !)M2! %%$
M@  @ VT $4@                                              %P$
M"V626W_?;^2W^26R2VR22230$
M           N D      D   @   $        $@
M                        %P@X                      "3
M                                      N )
M    $8                                             E3, $BR24
M"222RBR2'VF$"220  S
M    %0"Q AO770B^6RU6;C;O;?6^2< &8
M                  U:38$&LE.-)M)9=-P20^F=)M 8 S
M                                 0X   @@ @@ @ @D  $  $$@D &8
M                                               N-MMMMMMMMMMM
MMMMMMMMMMMMM5
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MO:?6)Z1LG)MOG?*TQ?$V1]0TZ[\Y5MF7LGF_.U;)R8VZ:/.U+%A//W[:^AD
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M:-4X)*^H^S$!BR1<B9O*WPJ;J^!)B8NBXZ3K-QQER22YZ$AF02-[-XIXS P
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M-Y/1G0;WH:Z(O/72,M*GJ=_JD18R6ZG].'T]A7EZ_P"CV'S6'Z>Q_C6(W8I
MK!(^V'EL:@(+(A2$8,(8M@EAA%$$(ZMMR9-FR.9&&8R<:8Q^[FO3^&\B'IGV
MH%E:N,01-\[:X$U H!Q@IF4&!DZ#^AF+$MH+Z[14AD8USC#9MQ1)G?KM]E1H
M\1]E1H\1]E1H\1]E"1P1OLY^F'K_ "&D B4FF,%P#!2X9M"2,9+IOJN,,3AM
M2YG"<;#I3<K8FL990 )5D )4%%OGI8F65\I*\"T LN"P08$96)73,RI 7$\F
M0^8J2D-: 682PFR&)("R09(5.=-S<NK9#:"D0*(6TH$K5NO3D2A: F]Q"(1
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MCF+T!(BS&.4Q J9.7>GE@I&VE[3+AT&:+";N$=O7TJ2U@5P%9&^!C.,X5/\
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M@2U'1[?= 6"?X%*R2]_CY<J@@ K0@E,&2!!)B2@DY^'7$KQ1$#-@+P61!SE
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M5(5319/Q!@CU: 2B%Q3&^/,U LL8B<XTZ4.^LI[4@LKX)<=?Q XDU!H<%0&
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M63>]8A=0NJX\Q5Z;HA<0,'3;\-"UK_=2ZM-5E6V?I6-Z?)3D3!&>F?:: 2P
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M_@ 8""YT:,FX0VLDIUK!96>B$G2@&:.F3*30 ")4%B1"?Q XDU!H<%2)0PC
M^>E0X0<?=!-F$OB?=2_[Z?10C#OI1Q1ZH^]07@,Y.T9="H%E)=<Z H*":[E(
M.)/7K/Q1;"W2WM4!<(9F=]>N^-8*F+BZY7J77\X'H^U Z"W#"CLY\84E A1N
M!$!I&5)BRDBL0RA]_P#T?@]*SZOFCW7L?SPG7X?ZSLO9KR>E.^H\UHKQVC^&
M7Z^6=:Z^_P"JS9V\L:?RQO3Y/Z,#T?:O"Z%>+VKP&M8G1_\ 1O!Z5GU?-'NO
M8_GA.OP_UF>Q)R4U*Z1.9:+5>RX8+=+L];%\:2E,PN<<LZO"[#.<#]G\2L&,
M\8\QJ#@(3=GPEHV@-!%A#']WI?E9-I4C3<MK02!5M>7._P#+&]/D_HQJ (W4
MD9(B>I?&F+"8.#6&=<'TXH"&+ RA$:")@C7;_P!)X/2L^KYH]U['\\)U^'^L
MPZ/D_"N[]RL/I\*\1K^*+=,^>L46A#.=<##OM1&CD 2XF)LHETW*C""5TS9[
MKATTJ5)R6/7H>/\ +&]/D_I=A;.WC5I3"V,#9Z7M2E%P7V];?^D\'I6?5\T>
MZ]C^4]P$E3"&*.2:T!(2X0P;(P79PP2(*@ H R=>^Y$X6SZ?PG%IQR]=*\KU
M<O.&<[:_P&01<F,S,IT'F4&!8B><>DZ5&R"Y,1 2,S[VHW62 806;>E7E'-C
M!3CUC7\ I;6BF^V>9HYN.N-)R5*P=]IJ"9@E9F,Z@T/Q.+3CEZZ5Y7JY><,Y
MVU_&-Z?)_38O8WP[UG)CKGS4NKS_ .D\'I6?5\T>Z]C^1-PL"71Q+G&65($$
MEN(DI!I<>A1>(6&)0Q#(;0]67^$+@34.CPU"8B>G\)+C'UV/7UIA3::)?BWD
MU)9+T39R.<::R2;YW=<KN=+7F3O/X5 -9>GC4*3L1M;&V-0LSGM;V^?X0N!-
M0Z/#4)B)Z?C&]/D_HF) P+=@MQT+EX9M2D:6MM>Y?3=IB$T/8_\ 2^#TK/J^
M:/=>Q_*4F,R'IX4@HH*8*"G33TJ"8%V6Q=U=7>H-#@J#0X*@T."H# #T_$#B
M34&AP5!H<%0:'!4&T':![1466<&!M&$:1E&%2)A79;8NKJUY?\587@=+34&A
MP5 8 >GXO8R[8UY?\5 QAZ?JH-#@J P ]/Q XDU!H<%0& 'I_0*7*064%U>L
M^Y4!@1_"6!BR=[_]/7:G>!8NN4N(A&=DA"X7<4+%T;V]K\[?^?\ !Z5GU?-'
MNO8_N(K)-ODJ#0X*@T."H-#@J P ]/X83K\/\,;T^3\83K\/^2!QBU[Z_=1E
MFG7/8AI:U6=SS#?R_P#Y_P 'I6?5\T>Z]C^Z4P8J75Y:EU>6I=7EJ75Y:EU>
M6I=7EJ75Y:E<5?7^$I@Q4NKRU*XJ^O\ EA,P3TU_]!X/2L^KYH]U['_XCX/2
ML^KYH]U['X]A\TH4"IVM'[U<9M3,V8N6Y]%;3CI]%;3CI]%;3CI]%;3CI]%;
M3CI]%;3CI]%;3CI]%;3CI]%;3CI]%;3CI]%;3CI]%;3CI]%;3CI]%;3CI]%;
M3CI]%;3CI]%;3CI]%;3CI]%;3CI]%;3CI]%;3CI]%;3CI]%;3CI]%;3CI]%;
M3CI]%;3CI]%;3CI]%;3CI]%;3CI]%;3CI]%;3CI]%;3CI]%;3CI]%;3CI]%;
M3CI]%;3CI]%;3CI]%;3CI]%;3CI]%;3CI]%;3CI]%;3CI]%;3CI]%;3CI]%;
M3CI]%;3CI]%;3CI]%;3CI]%$B"))CST[Z_\ G/!Z5GU?-'NO8_'L/FL'I\4Q
M/5]__HX^CY_\X@@#=!,*Q-R&*4FJM*\$ &VQ!AA0DQ$H2(5FVTQ Y6EI)KU2
M!;.<6NZ8^L4G,LD@*. LLACA,S.!3)+K7$UU[;=*03),F5W'^$ABQ_FD,6/Q
M"LN<(GQ_=#L89;+!Z010 EC9)SB?,_S)K_@Q]#[_ /G%:!JH-@8$9")96]BD
M()"S9<,04I<6ZS("3E=DS-(.#3!P-!9T\@SF7A6^8Q<TLCF3-JJ096!(!"TE
M3>),A#H492(EPE@O.-)2X%MVUY^/X.6=\/1]-[^\4<>7VSRY<I@NC8G/!Z_5
M&H\].I)/1Z-2ENRS?-?,2 N[W=/-/A3+*P#F1E>_ZX_"2"US/*&PY_53!E6S
MF+8[&TG(X.H^CME+]U+5TQ>\8>-;CAE/:6/1^&A#%GKO?!?TTL&YLXOO_P J
M5KL==E\PZZRU<8Q>KVGUJYBP:)IG+,]+7)J75Y:ES5YRSCK6)=Y=,ZW.7:SY
MK26E8F+MO6>;<Q5Q=LH'2U%PJDB$P()>:$8S00#LQH,6$C#*-[Y-*68<,;\P
M;Z>H4<>7VSRY<K1-L,?W:W!3B89X]3V\U+0BU\K:U+=F2[(QWGTFU7,7 SZ^
M>-2!=E..FZ/G6IU-M]\?1+:D5<Q<'/IOYQ6XQO?'$U?"+4NI]/W;GXK NXN?
M71<XS/3"I:O+]TU65;:[G\<?0^__ )S'&H+$$&!D4A"!#"28Z30P0!,$H@.(
M$V:)DL*9XL0*5EB[&+X%2V2Q=&\Q_#X_$&$6\\[85B$(=O/^WJ$X& 87M/G-
M;!P5"9@GSG;3\06(L85L'!4!$'F^-;!P5L'!5B(1I!6P<'?6M@X\XK8."M@X
M*@T."KBP7QMI6)8OC8Z5#0XJ3)?;3S#[H PM&E.*XV8<32GE9.*W\TZ6_,!E
MMYS7GG%0.)-7)A/0\G?&MAP5L%MBM@X*@T."M@X*V#@K86OAU^Z0Q8UP)D2/
MF:@, /3^./H??_T.'U^"O+U_^CCZ'W_] BQ&HO2D#%LX3E;*K&)KC?IC4FIR
M5)J<E2:G)4FIR5)J<E2:G)4FIR5)J<E2:G)4FIR5)J<E2:G)4FIR5)J<E2:G
M)4FIR5)J<E2:G)4FIR5)J<E2:G)4FIR5)J<E2:G)4FIR5)J<E2:G)4FIR5)J
M<E2:G)4FIR5)J<E2:G)4FIR5)J<E2:G)4FIR5)J<E2:G)4FIR5)J<E2:G)4F
MIR5)J<E2:G)4FIR5)J<E1"'/)S$3YI5Q5Z__ (I__\0 +!$!  $"!0,$ @(#
M 0$      1$ (3%!46&1<:'P@;'!T2#A$/$P0&!0</_:  @! @$!/Q#_ ."I
M )@F-288G]=:4RD8R263$8$FUXF&S$4D/G1[C_UZ+$:B]*(V#F3&VYO2@'',
MKK;.<'.\5)M<[3<S.+TD$ AVG",EM8_A"E)VQOVK8\=-]BL! B^'0U=J@T."
MB!8"^G7_ $!!N3-H^?3&L8@G3"^=R,R\:A2T2)B@3'7TG'69SN4@=&+>F-\Z
M",5;9LGX"F"G1CVJY*J[JWUQOZS1%#!!9A9@;6E7H.#:TA9N7B'K8L)PQMDX
M)1, )1E$:6;KYDB5Y0M'5S-[3JTHW +%@M;JNWDJ,9#U/#YH%R$$X-V;$C:6
MQ[14,\TQEXWWB/0,UB+B(DMCG&6,7OB+,?\ 40N!-1&4>D=?X4 N?/X2F#%2
MZO+4KBKZ_P"1%!C6WV?JMOL_5;?9^J=/K(MN*$)B)V?3+2I!:IOAA\;41IFV
MSK0C@^F?X) ,=;?#4M'+2+%?9?HK?Y.V_D=*( SZSIZ],.UZ\I=OD4C=8]70
M>QJ6CEI%BOLOT5N^(WV..DSD)C=S@SOI$;5+1RTW#EMO1,6W>;=O7_I93!BE
M7%7K_$KBKZ_A;2&O&0VR>^Q-1_F,MP)3L(2 XIB"06J0!!)*3O$.Y>M\I1;$
MAD*))EDF&>2U@T(A "W8A8FTW:5T-N' 2VM#A>[.45$"A($(1D,&RU\-J+T5
M;B-+R:Q;%TBY(FG418)8,,32\QG^"%*3MC?M6QXZ;[%0M#$3!%L-7(*=E#CB
MC%NM(K8DY;)B[X5M=FWP*VNS;X%;7 ^Z%E EB8O"F%-\;];U 8 >GX3!"+;X
M2..4X5M=FWP..M/8:,MC6]C"MC@;;[O&];' VWW>-ZV.!MON\;T 6U9;.M[R
M?W6UV;? K1@Z091V5#5R?="H<$8O;%B:]EGXO/?:H%1DD%]A_?K&5,LG'KJ=
MHT]_^L&[A),("A(!B]I2;4;RRT")0!$25_NLXH0!N&0,<N*10 E"&:*Q+"3&
M<*9;-17")"+@I1=(B8E %VR P09;G8.(;3_%U LB&MRR(B-+*[()(2)2$H%A
M#$LIL;,!83!167',"3?\^F.7E_9J0W2V=O8\TKQ+7B6O$M %V;ZK[_DF;3,1
MZ/L>9UGU;])\.F,4$F<\)=W&WM.];OZV]*W5;K2EE?3+WM?>\;U)<5NP?;)'
M>@YO/N[@PVK^P/KOVH196_6. \[]3AJ1<G62=M]?2E5E\NOS_P!8R"W6%D*<
M'.V1TA1%*,"&"3[X%/Q4*H,R0RL"<M:-LV)&#")D3@46.;$<@9(QFU$\K="X
M3;!P,%FR%45*W\S"5 BRIL)2#9P#<&%ZV1!52C64.0W;L&00,L%A%!."56\8
M20D+TC,)#2AL)!9?"<'2]]X_)JLJVUW/PPG7X?R,^CVOQ;?8FM"W278RM;.]
ML;5"(M,RVC$_J>_\B$VFUMJ;"&T F;YX5,@1),%C OCXN4S P+<$+.4N($9'
M_8K_ &0121+7C;/#.@U<1MQZYNX3?)TIP\*Z6PFV'F5+$3$*:&,]W*:L1;"A
M70NEI,^]7>%T"'Z]J3')4/A!#="QJ@"<TA9H)X$; DB8#00 4&S.(@]@A"+2
MB$!$FC"2I"6/0-HMFS"@"<A+E$1SMAEZ8OY8WI\GX83K\/Y#'F\_%;W8I20Z
MS_,,3%O/NB)8#/WDZ4%<O8,(L.N,Z6ZZ02%A>V/K=_4_Y;# 4MPRQ+U8" H2
MVR&1P%L2A4"$F3QOE=.;##M:^Y,8L7V;NGQJ*F!,2;OK<@]6I+8P6_T+FT\8
M6UI>6;EKVBX29Y6J'D"YS#'Q%[5B$SQVL6G!UU_R3&4Y1;SU+E2U:X!C&Y&)
MY-2N2>@::=?'_1W7G6*<Z3<MK;">U;I+WGYAI@2B99.6A]#:;4(TQFV<WMH&
M&_I^<+8GTQI4:6EO/K;&I;]Z2W[TEOWI+?O26_>DM^]);]Z2W[TEOWI+?O26
M_>DM^]);]Z2W[TEOWI+?O26_>DM^]);]Z2W[TEOWI+?O26_>DM^]!DJ.%NOJ
M>E%G0G*UE+D;3X?Z>2Z7RSVH14O\$6M31 +%)(AK-H=4C"=0+:_(10. YHL@
MS:%,"J G'FZ0H.*D1(J/\211,D$Q(,!S*0L9H)4%!0HL:G% >0!]BP(;IZPT
M^ FQ20[&Q"Q)*%*^79 +8<P(A,S L$I@&)A<B$++)**=\I@<34YK#T(,LL)&
MA%H 7)2X7;7]3 8LM\. 3'!UO+2I*QTH[.(23-!88HS@R,KQ^,I@Q4NKRU+J
M\M2ZO+0W5(22NCMKM4AFF4$0F!I<2Q#A&$DY!B @))& J](ML-*V"OX:Z @6
M"Y(,AAAKA3(V;PSSRM>K:1+@LB8&9A#+#.]%J;<"YANA*V07L9;@X!,D2DRN
M.86PRO1,;%,Q>,F<9TG6S2&](""A+80!<H9)QR2Y?7.'(0R!#UDO,V2J](B,
M$"I@Y@9"J#=*V%%&K:N1(!<(JN6HG@2L$BDO0GKA>H$HB' <2%D=;&2$@80/
M,W]^DT+$7+SJ88^7X_QVD4H!BL!FT>94-#L6"FY>Q)DJPD@SJ3$R:0"Z) (A
MHB/&3:8P;#. 8Z%'MQ\7 B0ISQ%UTJ81:1,P$K9$EF]Z/)-2IT)T"("  6PE
MUU]]#&I@"S&=J4& XD8&6N7^1@WL-LLXU0Z7+YF-#<,69@M*(&-LV=<"00V*
M E@)LY&@@<RS_H#'"<B?-+5=?+# MK@W-&Y>A&(8L0(81B2N,W/B@,&]@G=#
M"VCD:M2.LA;YSC QK_5JE!I+^O7&8@G:'\[@[QSKA:A8F(DQUMOA5L$8]H]O
M]BX-GQVUHD=^S+^_7_35(C-#TH0FT79U8NO0GR0JX^D @XDV&!$)=;,*G>RH
MT]U(6E4P(H8HB;A8NNBQ)+0 +D6V+CJ7S'.L,A0 F1=M,#&&A3T-HX15!+M%
M($LRE-F8#\2-Y0"V &<H4!H  K& E"ZE9( 4%@(0IH%Z,$9 P0MI!.*2@ABQ
M&&ZX!UQ:D#*VMF8 3;!U;7VK"]2BM-Q-IQDF4 ,:+%A,ZD2ZA=%P+?XA0YNB
M8O&&WK0XAA2F!<!FD3E>\F2Y;.3%"99##9I(JW5C5$T!9/#*=6$*]H1& H@M
MJ8EHBB N1B2-KX^J"*EA,D!,01>!A):5B0EA6T"SH1J8&$VN4"\-C.$WOU]1
MT:96PB\VP7F$F22T,F(TX2,$8! A%EGJW2HDE,(-*MB%L22P-0 !28B%@2X#
M"7"@HJ;0!$HDOA>;8ZIYNVDCC8:8<@%,JU.*I4%Q!+6 3$T^HGTZVVR]<O\
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M819EF6L6$[>3V%J<@'4#IDB+YV;YXTY20A:WO#=ZPVMC0,QNF:VY)C^D*E8
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M;3-H)%-6.XS(;1G& J7M.LC?\W!Z-+%#88Y6.#EJP_N5.T4X2;&+93YI#A-
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ML7.]SK2PDRQWZ8L^7M4A+9P/.,?G^",Y],GSI1'"0F;6]<<\(X<"EI=:9T,
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M8 $0$A= 12$Q<*!)V$FE$8(2 G%$9DHTS0J,,HZ:1G> P:#DB&X9")8P,%F
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MK.)CXQH8$3)BA.&LT7B;WLMHG*YTPUK+?QZ]_N@W,CF+E\:V.!MON\;U:M@
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M)@FC0(O<7: *"%LM0.(/I6&%LO32H-#@K*,M,JEU>7\X'$FH# BD$AN3,.M
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MU+J\M2ZO+4NKRU+J\M2ZO+4NKRU+J\M2ZO+4NKRTU65;:[GX)[A[*P'0]O\
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M+>2O&N 9%K';9]:B2&T$6W7/I2F1>45J6CU>M7VT@4&S(GT_($V"%[_&\^U
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MUXK&7(V7*,*0L8"Q<8E(EE$)8:VPC7N4/B4@RQ,)#STH$.%: J&!Q->=@"$
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MB&4/O6-Z?)3!"!P;/GF2;NC*4PC8SF+4@)G3""W$;9]J1_G @0 @ @,8YHR
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MR?EE';>E0$&&7BWQO70RR\6CMO1XC,SAL9]O[_P^_P#PF>[]FNR_Z1/</96
MZ'M^8C!2K,6M)M7]]0284Z_=3U\GW4]?)]U/7R?=3U\GW4]?)]TD@G-O;M/D
MUO'?ZH#%DC>O&:E#UC[_ +JP-Z$;68]GW6&%LO32E%5B;8NV_2@;)(2 RX7&
MUUSUM0CYY82R#""18B28L @Z,,Q$#F<4=IP",L657ASEUR<'TJ#0X*@T."H-
M#@J#0X*@T."@"P!;+J?X%'H'O4RDM#MCA\U*9 0Q+$1OOE2RJW7WO+-]9NK-
MMJPP_P"D3W#V5@.A[?XHL>?.U=??]5U]_P!5U]_U77W_ %77W_5"I7DCYVTJ
M.CV^Z L$UXS17C]2N\IW1_ @H20P3:@Q#2 A85=@)2Y4F=(.G'.7,/)34Q8-
MTL%E*LH5#$R@%BQ()(LPL>GQ&]0:'!1 L!?3K^&-Z?)_@]A\T<72WHH4=R3&
M5[#@VSJU[(G;O&?_ $J>X>RL!T/;\E&(00H#1NM2J=!)3-CS(0DD8-FC4;L1
M,N$1Q%&6FA9B_P!U+J\M-5E6VNY_#0LQ?[J75Y:DB68O=HAP+FAL^]2!0; 1
M>1L]?ZBI&W!"8S$S@7BL,  6L!,)XQK%B@&-@ZVO0YG!X9'F?2O'^U1+;AG#
M,WJ# F7&%M<N3=?2,ZA8!9$6P$=&UJEN6SLF$&U8"PG ];]=_2I=7EJYO>V=
M]-:@T."B!8"^G7^,;T^3_%E&6F7%0&!'_2I[A[*P'0]OR$18)$8#7=Z)41EQ
M)!$I97D7F!TE5"FC@2Z'^D5A.OP_QC>GR?QA.OP_P9],O22M 7+;6M0R(PH<
MKS=R/5HS&)O:_P 9<=B#2TI@;SZNK4D _N/,#.A2$1I&3.V%O+5&CQ'T4#/2
MTQC8RO@5&H"+Y&CYWI'ANWB,P\W_ (PG7X?XQO3Y/XPG7X?XQO3Y/\)OYI^_
M^G3W#V5@.A[?E@CF,FS0H"P#.!9!H$(<;4C)4J71Q5Q5_B!Q)J#0X*@, /3^
M('$FH-#@HMA;I:@,%ST^BE&*Y:B_:?FB$YA##E1:Y9U+5*XL_P P:%2ZO\0.
M)-0:'!4!@!Z?Q XDU!H<%0& 'I^0+A>I:/'AY:G"267)).,(G'IJ5*82A*I,
MX1++8B<EPP9(*#(T#V\MBX_CEEG['.Q\3_T*>X>RL!T/;_2"D&OW4]3O]4@R
MQA]?ZGI//PE3L<_:IG$.?M2R6@<L=-UVXI1*)B,76?QAT?\ H4]P]E8#H>WX
M2&+%2:G)4FIR5)J<E2:G)4FIR5)J<E2:G)4FIR5)J<E2:G)4FIR5)J<E2:G)
M4FIR5)J<E2:G)4FIR5)J<E2:G)4FIR5)J<E2:G)4FIR5)J<E2:G)4FIR5)J<
ME2:G)4FIR5)J<E2:G)4FIR5)J<E2:G)4FIR5)J<E2:G)4FIR5)J<E2:G)4FI
MR5)J<E2:G)4FIR5#4Y*D<$?7_H$]P]E8#H>WX1-HG:)KR_I7E_2O+^E>7]*\
MOZ5Y?TKR_I7E_2O+^E>7]*\OZ5Y?TKR_I7E_2O+^E>7]*\OZ5Y?TKR_I7E_2
MO+^E>7]*\OZ5Y?TKR_I7E_2O+^E>7]*\OZ5Y?TKR_I7E_2O+^E>7]*\OZ5Y?
MTKR_I7E_2O+^E>7]*\OZ5Y?TKR_I7E_2O+^E6:/2/^@3W#V5@.A[?QUJ+((9
MW M >F.KG03(3TK:<=/HK:<=/HK:<=/HK:<=/HK:<=/HK:<=/HK:<=/HK:<=
M/HK:<=/HK:<=/HK:<=/HK:<=/HK:<=/HK:<=/HK:<=/HK:<=/HK:<=/HK:<=
M/HK:<=/HK:<=/HK:<=/HK:<=/HK:<=/HK:<=/HK:<=/HK:<=/HK:<=/HK:<=
M/HK:<=/HK:<=/HK:<=/HK:<=/HK:<=/HK:<=/HK:<=/HK:<=/HK:<=/HK:<=
M/HK:<=/HK:<=/HK:<=/HK:<=/HK:<=/HK:<=/HK:<=/HJ?)Y!\%;*IL2^E0L
M0),&6O-NE]?^=3W#V5@.A[?SA='M_P"DP>G_ #D E@[)$G;6A !YJPAK(RN<
MW+U"Q3(T&:ZLNES$'2AI+:4RF>()"C-R@\/ DIQ+0$%!!0:P%82)>_B4HH20
MR;8F7L\_@:,(6"</ H.1&-XBSG-\";U)$R0X,VJ34Y*DU.2I-3DJ1P1]?XD,
M6*DU.2I-3DJ34Y*DU.2I-3DJ34Y*W#DH#=&VS[U.6!]")YI3%@[%2:G)6X<E
M2:G)4&"TRHQAEYO11#*$ZGU\O4H%F^R'4IQ-33<IX#L2 J8)9ZA?'&F0@P"P
M2QBAG7,BD8!U8+,7O-H[5*W&#"R=W?:E8+);1 NV-*7I)(7PPRH"%L<,\7"Y
MT+8E*BV,)F#+]U)J<E2:G)4FIR5)J<E2:G)4C@CZ_D162;?)1"+,7UM_SF%<
MBZ+BUP4JL^,&C(02D1M@A;R@(*$9D(-@E+':1H,5<.2#+I8SQLW"0L*G$%84
M< KV]X,4:D*AQ6$U"XMIP0:R(0G=C1]LWU_!A&0;8X-]+8WTM>*3/IG=<YRO
MG[N2^D YX8N-_+UTJGMYZUTJ5=('"W,OF=JEU>6D!Z653#KWJ<0Q4]O/6I[>
M>M3V\]:GH=_NIQ%N/#M72I@,KA:WSQO3L78,M6V-_DJW0O/>WW4]!]/W4]#O
M]U/;SUI.0XHG#G7.FLA(7RP],NN&=13DRL\6")27;(!<)%&\ &P$+-:T0.YW
M=)8K95)G#LTMUX3)8PG9-[QRY17'*)F'H)@G MZ4BZ,]9S0X8^2(R-IM;"&]
MK%YK)&#ZCMAS4DYX8XX<QZYU/;SUKI5/;SUJ>WGK72I3:V.$_>L:=:EJ\OW3
M595MKN?AC>GR5VS\?\XC$#UH 0 F4R6I "T(F)@1EZ'2U)),4;&!]F'4OI>A
M<1/>&;L?#J@BV&P$%B03)G.=   0%@/PB?/3YJ#0X** ,V >O&'M7E%'BL@B
M3,:BR<=/HK:<:8<95!H<%8!!:,M,*VG'3Z*RH>1GCD5M..GT5M+?KZ*VWD?1
M6V\CZ*VGD?1Q2N(MMI:@\!4$1!$S$9E9\,NT1[%;;R/H\6MIY'T>+1@ )^"/
MCYQK&)O&$WPZT:N^0!&(8@9&Y>E(=Z>$ETE=PI56D$#<A!P(PBH-"MA4$0%K
M%NGT4W(;A@-XBMEWK9>0_!XM8=EL.WT5M..GT5M..GT5%DXZ?16TM^OHH+ 8
MSAGA2&+&N!,B1\S4!@!Z?AC>GR5VS\?\^AV<G.H$*Q%K[XUV![/_ $<;T^2N
MV?C_ *"0QC2]$ 8@CI!BQSZ41DA.=C[C?7*:VSMM]O&];9VV^WC>ML[;?;QO
M6V=MOMXWK;.VWV\;UMG;;[>-ZVSMM]O&];9VV^WC>ML[;?;QO6V=MOMXWK;.
MVWV\;UMG;;[>-ZVSMM]O&];9VV^WC>ML[;?;QO6V=MOMXWK;.VWV\;UMG;;[
M>-ZVSMM]O&];9VV^WC>ML[;?;QO6V=MOMXWK;.VWV\;UMG;;[>-ZVSMM]O&]
M;9VV^WC>ML[;?;QO6V=MOMXWK;.VWV\;UMG;;[>-ZVSMM]O&];9VV^WC>ML[
M;?;QO6V=MOMXWK;.VWV\;UMG;;[>-ZVSMM]O&];9VV^WC>ML[;?;QO6V=MOM
MXWK;.VWV\;UMG;;[>-ZVSMM]O&];9VV^WC>ML[;?;QO6V=MOMXWK;.VWV\;U
M$87/#;/K;]5#..-[,JWA.A]?]!A.OPU@.A[?^G__Q  K$ $!  (! P(%! ,!
M 0     !$0 A,4%187&1$""!L? PH<'18.'Q0%#_V@ ( 0$  3\0_P C/B]+
MV,](:\BG-5VIJ%$1% BC6&@%AC=C!'"<)_Z2Q8L6+%BQ8L6+%BQ8L6+%BQ8L
M6+%@OAWP?QP'R .I,TRH*% OIKI.5EI4+\DC(W0 A5$0WMH+4KD/@R_:)U(*
M/Q?LF0FHH@2XFT#0+2H@@A-$5V3@C2S]'-FS9LV;-FS"[ -R!N[_ )*>7.:>
M#D=B&[@: -%&(0FD!0\GE)#2F*NBQ2?Z;L1O"HHQV@H*/Q;,7\J,&G"@.TIN
MJ!4!;@I6H>(&7.'/'SF@H*# H<<E!(^J!I4"82VBK7]9,.%P1]&IHF(KF$<$
MBA4(;/7QTP\*U"('YJW+R>**OT"L\W7L:A=.A^N0D\I)2$G0EM8 C,*=]8HY
MY+Q-LGI.@(J56T;()6V#@K4'2HTD?D3"$+0-F4C;!>[8EP-&?-.B*TM!E< 5
M!05*J W1L1"&T!2)6QPH@W(LEYSAE$$F83+@.!> %K$LZ &\2)D.^'N,7B+^
M8.LF#" 4$:4'3AS,-#M=8T6EB:7EI&6I@@"Q;N:IX$0+>4FQ;^' #ZJ4,S08
M+PAYB 4R%4M-7;;R'QY:8#MV,6E&'?9">EYW@0YD")\B:P_R3/I&AQ9X>3-)
M-5J=9I<KQ6,I7<$/84.PIPYP="S;J@IOJ!=P#@, X1LT7A9ZBL>2O?* *0(%
M8"T!P#P<7?."G"GIK/(]W+VI6NVT5%WM%6]U?A76W7&^-KKMM7U7O^FB&R6(
M^-_?.6T+JI>=4\EO3CFX6:0Z] JHFCA+6Z,WZ[Q$^W&=?.?\+,/VL;WH[)U;
M>LY\Y6" %% LO/:I675Y#!M)-A8-4U%0[< ?(SET=>&M^-7?TQYL$7H48=5L
M34TU14B&(^6J=4#U,V+6KS&#@F:#A!WT83QLQKW0Q+!*!M0;$15NB*82 %IL
ME":E%5:M;LN_OLU0^@6?[;[_ 'R;WY[_ #=9>Q!0)4K9DHT(FE)0&\L9 0[8
M5XTAWDY-"84S+YRP< ^#1Z"!KH-'8UG$.%6: 5TWZP/)U.=+ A+Z+-O?]O\
M)"-P=F^XH^H\8\'H_=^=!24-NAFPN^F]^^)641L.0,)Y,M"&T"E*)CZTG98
M,5:AB!B"B)\"3K$.!(=HT>[O8MDS22$)1T7G6IQQIZ=$A!H7DH: D>H%_P"9
MK/9+C,AL4S>0NM#OROHI"(>" @#2Q #1HE7:#(6T/@R@Q!!D$XIJP&C$+3')
M1K 84%S')^$/=JEWP4PUA3-8T/%# J.B>R\T9TN.&\W6QENOU/M\8$",\D +
M)@ 4 -MARIL@A&*@:JVH39W7M\BT-I6EU-_MT\<Y$9VP*"99LX.X;#61.BL)
MR<N&:6@Q/&<Y9%67%#5B, -:OHZAOU48, C5]:.D$,2'U8L"05ASI$:: .$Q
MXP!)(;TS:6D 8#S! ;VSX3->6EQ5^[Y>^+BKBJ] 6 LY =$E*=$4ZX$T(#A4
M-0AH > &C_)(+S_MX\'I_+\Y8#LJ(;0!/NH@K"ZTB"C&F_Q.1F;F.^L$9DXJ
M;\P>9$>O@!^J+P3*W5L,:/%<-M2O^!%ILXE<6VA89,T-=]ASY1'&"KH9:6L+
M^]@[N3VX5T>*Q3<!V!J<*&AT42@1A'-0VA0#=E":Y,BT+!!"%00V=JXW 0 %
M4X>=/D[9L-!HUI 0\D =@$X,!:#-;[.\BW>VY3R;TCS.O,P*K@?!$?UADH'$
M5(]AA [2E#1!#8B"M,Q!(B)@IRHMO-WFQA!$#$#(B@JO%2B@(24P0NQ?CMV\
M?)#L>V+04P,)=B0(-T$V&;2&%#'HPD1MBD@2\\R!B)";5!]2)();Y'G"2O(@
MN\/7!!Q@;QA%HO, S\JE=':"V;B67*@W.L'$*6G3H,(E0\_3>S  \8@([:[,
M!DPT"#K)+3.CL+)"V@!4D""UH^J@^+"ZW=ZPC."[H:\=^+B ; P0NV%38(O>
M82)0  5180JJKU5>5_R6&\>C^7YCKZ:]S#:)TA4J@M :20HO98""!%%]$ 2C
MG*0VHW*)Q*5$=HAE4@ES2'1UM Y<M8'2.I54=*3DN*# NFUMA-P@%E8![/LG
M['(7AHRYD&XH*RCI^,K IT7QVO7$"FP:-'%$2>#+LAR#QNX;C0'JK@7^BCWQ
M3YO2)>R%/6LA[X<1M8(@1I!A6,MRYF[<NG4D3H&!#!5^RJ3@D+5!@:H*Q(\R
M*+J95,8$@T"ADJ[!@N#:DI$P7"BCV7F:MO.(8KT]!V9]=]O-7Y4@%(<EB"!5
M4*I%M,#$%:\A[Z0565J,QU,1!V-XB9S]V@PZ3<QW2*)@((*I:K-FT45702 :
M&+H]H! &6<51JH;352[HG<_X]U4"/&#-M>=JS[WR]?!C=D6CN@.GNS;^\'D'
MZ9 X ^F !  [!#V_^W72@I=H"C (%JP!4A03A*SB10GEF!'_ *'CQX\>/'CQ
MX\>/'CQX\>/'CQX\>/(>?G5=" ;A4D%0P/IK6!F?P,FLPZ@@ HT 0"S<#T $
M_6 U.'/#RX\>C^7YX$]8)VA$:$J; B9JL!*;(7YH)PL(@?DQIUE%0 ,.^*H<
MP*Z\N]]!\5V->.A":\%#&B%L:!U%S&.8D$0X52LG/^42YAJ<<!W!XM#\.J^-
M_(B4L_QK;:*I!"PG3^A9J,A2OVF//N+*A!V0>6HKN?1%M *K$BA4%&T1M;\5
MT:BJ 6X;)"ZL%0]+CD%8372Q&O+"'!2#=4%7)X4635$ IPI%4IEL[#ALOIQG
M"OD"N<O.2+0=O)4$N:6&G!KQ3$=$E.I%5?E!X'2?LEVJ::O?$\J,0=SM*AR%
M,J+TO()6VU0E4))H$($AQ->"&SJ >'C945 *738 21NJL"N,;"73-1$0LN!%
M <#ENRV# '-)#A-KL;:A7< NKI=-VZU1V6[N,4$H&2B"-$WU8/ 'ZA.YJ\[G
M;>,26</<KJ_W.-=,K@G<;+PZOW;>=ZSE8O=Z/%Z2\;[8VR*S0W;'\Z>F6'(3
M>M_S[G3KURKI$TD'8Z=!.^_[Q IL>B@;==WV)C%O"EE[WGKKRUY_3J:8FS5W
M&$ZBZ3F.DA^!C:5$< -ED)+M#TB 6U/!4)ASFA W0[$(%+L:04?FA0H4*$)8
M:&G:H$#50/26ZP9IM048!@1=I\E"?Z!0LHGW'F#*4*%"A0H4)U=%&!W>J@8=
M@2RMD4C*VSU6X8T*& QQN>1T>3D+10*XR8A""+([RFG<(W%''QTKM*]C:JX:
M3DO(5\XDU'\1.G@^NBA9R,6%&@6!6FL8B-@-!O@?T\K]O_1^_?OW[]^_?OW[
M]^_?OW[]^_?OWZI4)TAFZC@UM14HX22S5Z*J697N2()03T!,:*R@T2[_ %B-
MBQSPB#ZCL>F=#U?X_M^(MT.NO_'MB/ ;DW?VFO/BX@4!JH-%YG5Z<]^-N*(K
MO6,S5]EGF8JDS0>,DNS-10U64H@\AQ"U'N],#@2GK6@AO"";J<DX0""[-@AP
M<);+5P!X'[7 .UH@WT*?;#.+L$F$DY#OL%S(."0\$$)78#H08E5145/81>0A
MNF-G2(Q2 0E(C^*.UE7*%3^"/8=^D$@, 2/<$$$-5!,E 3LM4!5#@NB[9VK\
M6@C%H/4:>@4I6<_19:2V0!6G@!MF)D'1\<#\#M2S.FG0**;.W>E).C (J?-F
M%+8O0 $ C",*(D82 Z&B!R#-67.]2%[!T[=)A ]3M18Q@*AUZ0!.&HUN(+80
M3A6RT("-&XIP^1Z_MSI=9D,$VJ6.^!UONZ-S_ 0 AXH<K"@V]Z'T*HNJF $<
M\)NWKG.X)G ZY3@TCGK!A732>6*RFQF[#*)9$SGW(S&-%=7U^.+1^ VQ4G"V
M;,=R=TFU!Y0ER53%T!PZ#LZ4DX=MZ.,;9_#<\\_V_P!?"=.C[#>OV[K,'H)J
MA;TTT:X]C?Z#0(+8@7H_6]2=NI17)=$Q!MPD,$<<#<8:$]?B/O@&,,V&$"B8
M/@#6T&.8DM(4&HF0V$!;PQ)2B%HJ:5ST#!6&1LQ)]134P!P7%+VK08X1.EO,
M -C9S==/N>O'?]/B'1:J E0J+UT"NX"XD>F EP/(]7?>6 2OJEF&E*L)LZF6
M"2DWNOF"1!;Q4 :H(*)5* @H\)>^HS@Q/??AGND_I'AL%T&JJ*K8G334<B"(
MT?(27G9H8LV";6%!J(A(G<)?XCX0F(FB!-@[-[V!'U$$[)<A&'.D&TE"HA50
M2L-0Q2&]%J=;47 3=K&)U^;,0YNX&DL"I10J4%6JH;KS,?@(L1MCY] T![N\
MBP!LB-X9<*W&(K.Q3KT9OG_#86&X&YO-3QIUNQ[ #W-'-:(5J6BG4U#7>7_Q
M*@V(I!4!.C<L1#%5RC3'!X,$^UM=$'**1W">\.3EV%E"6$+G_8+@S)%@T"JH
M+<"D3IH0Y)P]+Z$#Z5G:O?\ 6 W.&/#SX\'Q*WM-=.KT^_KFQZAJO TG@(*V
MG318/D\'%MW)&D S"Y6#A[NTQ\P ]PFE58[3M$".KO$;0%V%-6Q02V\=G<R,
M0!2!*TR ((48B.3TJU2C*;8(@I1-;\"]CF'BZWS  *-95!@A%5A6C/+=NB:0
MD>9.AJ2FBB@%X-DI$FIL0[D[4X.[EI^1>W\OMXS7[W4A^P]<*%WM\E2Q2D?)
M1CW*#Z@],[AZ-G2D=VP=]0>3-C2N6M;S7G!1HH]QW^;<KQ6=OK?OOUS>%0IA
MU00UQ=L]8<XB]!!!X 1HJ>C4NF"@.-)(<WEVA#$9.H%K&(00.&AG<':->6TT
M&%2-V-BE: [%%M:+( ;O@3"QF6M1J#!-=C#.,J\DI@55:ATC3F;0.FD.0)88
M)$W+BC1]9H29*OH)U.,C2(;>C8<-2"9-L7$O]9TC-/\ +Y0XX?4"$-BZJ-@@
MZ]Z&?=.Z\,A=9>A5X*.6$:42DA(VWM*##0#NT^)"(']+]OF6;>.OM<-HVE0
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M;ANX2*%QP8'\7<9>=-=[PFJPA8S_ #?5@4%]-%XO2N$^RVP L2 B=88BG:)
MS,*P612H?.)MU.Y?3>4&UT#MNT US=:XVW5QXW#R$*-!&,7'+;^\9@5P4R#1
M0Z@H.!00!!- FSD,#J]"?<5;.\4*::&TLZ=B)8^4*V!O"84 -4Q#DJ@EVV"
MAI_) HJX*96@ID8'AP0$'16DD$(0%2"; "FX1I" )P^@%SF6%Y'4J)8E;PD
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MA;0 SGA])*BH<$O"A(BEU0((1$<=!K#>A @*^>CY"BPS:A'M3)A. M58P0/
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MB?O(V+R,@[@P<&R@%>F >RF(*F_$GLF#(=,:?S\":D>GJ1=M=NPZ<!ONF H
M"W8!I78WM'N2M<AOK^WPC90!$M +I"2<D[ETQDRQK+DAU"NK@$'"<#UL8)'+
M"N72:IAB!Z#\/+0*++M)NXE0(X*I*M9!9T%O8*M@/SD201H)1\+AI.T$0;4%
M1=RJ#P;6@94W&-*Y>D#I">)L8O))-62E1,ZJ+S\2*LQ^C_M"=# DO+YW:AY-
MF$OB]$;AT@HN&#9II+C<5]: A,!*N^XZ"%C4:3'&+Z4!W(XW>#8%E2E1(T.4
M'2 +(_?2J$2IMH%)Z/)8% 4#0!8':A";A!0%3Y $@LPC$  &LS// -3.R0?[
M<F0%B4&5#%+T719)*FRR(YD ]D=N:SL"6D7?A-BOE@D23C0BPA"S03#9X@V$
MDMZ?>%I.NFA4T]@T*&2A4N0AP'M( GZ!_P XH8E.%PZ=*LW'5_,8O5 U*<JU
MXE3 @6N@9$2/K >0G3/;&>#A_6Y9/K=3/V]\Y/5^[\>OZ?SALU(I]!]'@KZA
MB9W-,'7-^P1X=,!/:Q8;@3$=)B"T)9QOO;U*\?Z/DW&C4YX]?:^^ K:&@\DD
M>=;'D8FA R#/SMQE0'ZRY[$F"=VLH2\$$ @:]WH<]"0^D)Z&5>5Z?MQ[=,KW
MYV^7O\G"4K5>#MT2V2ZP1HY!0O%HP+( H%A<A/$YJQ82!P3)VT6ZKM6$B%-?
M];/_ *V:SCRB@(/,)X JO:BJ]%%UD@.( 5U+T/D>AODX9)7V9$ZC'5P9!A,N
M#"%8@M0KG6M.IF?"Y-3BLH>/UN[^^+K?5;'2TJ;8"F>A):)DM%C.@U]>R"K^
M$Y'6["?JO&KR )XIV$3MP.W?,*8"@_$C43:>XBQ.7<:7DF?R\G@!384#[!?.
MI.YIG_'\WK'111/"I%3MI>]!YRU4S$>NF'57*4R@- 0*[!6U89WJ P,.:#RQ
M 4WP@4T#AR)!51$$*Q#V6", / :&@\ 0[&C60['L9#L>V(/(/J8/7F9'"1$%
M5""PB&02'/&18V$L"*" 70 BNF)10V-<$K(H*VH EDBPD%*)@(!;==+.@7H
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M0=)3L_J<'T?M^@$V!V(IW$$?"<XL^,%BD+"N2(ANC<EO#;5)%"!85+M[J S
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M+%2U$)9OM8&!:7)8:GP/8&<T <\\M>R9LHZ5GE)?WGA_6@_]I^VAOQK$DU9
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M84M* EQ76MG1>9%/$44JZ(:I(J.H#:-DI!LP)2[P L JK *JJLZJJO55^/\
M'&0HPIH84.P_!2;Z\:NCHNKUY&#O -HZ@+H50@ 5:G,32EBBHZ;3B* "%Y3O
M3\D&>.,AK1IIKKCK1HYP)Q(31(WWBK,P0@*+5^ G$(NBL5TAU2UA6&E)#72I
M!ZHL3=84D9;G1@#A#T/[?GZ& $VOL_1W?R9!:!ND>6N._7SC>VT:8!&.#K&5
M\8-0\+I8$%3-52>H2HB7UEM@?=:=S5(H#(CDC@ -&F!O3=0VKU('Z3!G+GL_
MM_> 6%^*#R7AWW&C]'9YP!4 5%!R"'ET-]"82RX"J=#:!X4FZ9]D/.$J#+[2
MS%2?"Z%QLUEE.@N0)L:5:;>LEC0$_3X/H_;] )TLHO$=3>X\><Y,>=A (H0I
MJC1O#R)$TB@K%9:B ARA>(+OPX,$ E1=SS#9%2"-(*S*?%K:OX&A>2:HRLH(
M(U@PA!I4#$&RPTPV6Q%$I"R%6.A#"Y)9,HNI,728@#D(0F*%H0JNFS(S2X*3
M0D4&)!2C(1TJ0,Z<XU9W^Q?T*EB!HX+S"RZE!  <9@O30#% 4P3TP;%06%MA
M-AW8^8+"#?2&G$::(#O2SQ*P) JP LP(,+:PBEXPJ8%$JC&.VRPA!;4%8)#)
MHB3T5<S.8.<@'$Z?3T.UI,DG9*U>Z%QTB K\E$^]F'!CH5$I'K3;J(",X+8V
M6&HUF!E29%<:D[1>41(0K#IZML&U@G6QO-P -"DXZ UX-'8_2XFTWU(MJ$VJ
M=.0J ()E;E=!I6S-<BLEIY &S09428,1:2E0T>A_RRB/\Z32B-)3!Q6+$2!Q
M$ %0!HX 0>'CL\WJ-6*=]O&E%=8DN36Q]"$HU(J< XVBZ$%9:V!:#HES4*CP
M*"<K=])UYUB&SZ"_8X12 \W=[-SJH,LOW)T;XZO;^GH\X,+P:XQ3E[IZ_'/T
M'L=C)"P)JO1^HH5U"RG02:%2-Y$G+<5#Q!,' 201 #J&B+ 0KCB ]8K+8#]+
M,,I$E[#JDTV0 *JPM$!&JLD"M8FO*J$%;YV@$#U3L3%_G>^C[& 95(SSWB\H
M&1>GZA\63)/GZ*OVXCL7ZO\ /+?TOVQ,P@0V@0"&X0'4#R&#O.Z"IA*3X+@B
M%*8J:<C>$("*H%8'FJH%<=ET+85Z%)%VC?&!X5?'=%G%:&$"ZQE=B7;B*P2+
M%HD2"P2V4R.>\<#0?+Q6<*&/ 00*PHJZ C5)=U4E4U$"H"UK2H8DWA 1$082
M&$H!<($TZW]]I^=(D2)$B3N!Z?U<GT)/,OG/% 7PPFKWBXG,L#7EIL#9NU H
M",,D*IB172=L]0B"2!G<P:7E!R'#LV(N%EP8^9ZTSD6T0XB\V !R-D-O#/I\
M!3IS=\?[Q!1HZ035DY\GCK,')'$2<@_$>'674X8P4<5(WUQM!0[Z),Y[N#*#
MH<"0873U(/$"185U=5"P7K%9>[W_ $EVOJ/$R<)@%481PD)== R"G+7GCLX"
M0V<#\BG4)U1FK?S\N.@6%V)U(!6HV"1!@Q>3BL!(^8CX1*7B:1@*)G KB%6%
M8+-H6"]96=J_I/3<W[S<_; 05,@%;5J6"D#*$EXGP_:\HE1:O$BF%2Q0ZN(
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M^N2>T88CK]'GE/\ V.G)XY1$$AS%ECM-<#"\##ERG<]S%74]_P#?[9"W7O\
MQ9FX5UNN&%VG"2CI$HDP)5"P"J$"4!31;!;\YITUT]9P!0DK111AKKJ,+T*V
MX:Z33OND/L?\_2/,:3-4,/BY* 10 :T \C-B=R!C_P!;00)PDT/P947U&P"-
M,,"ANP"#?AZ58ZP[U'ID6<CY (*"+;\BLO2I]"V@RK_Q?!6+4V;^.<'9W.71
M\O?/;%3F4H/P]H)N5(0:FG.G2%<P(H6J2B\"1848Y".T!4"62R&B#-*95=8Z
MDRJ<28#, IUZ4GF<C@EVC6%!5HE)$M]Y?0A"*  &4TJK FZL((,%U "B@H!H
M$>F 7O0>(DZK0+X*'1MTWH78&(<HG2*A@(S8E'B533^9L_K5 ASY# "8".IU
M6'2RU0UTEV_/N^3GB(JIL2 \B"1WFP$*Q84)!I;/H<PXZ)()9&PXK' Z!)6B
M1DY<@VXRJ(99%="5++T8<Z>L-($:5=@2&'B"#!S-%%K*["-/. B(S. 74B,&
M*OE"A404!8\AVB=]6@@2%L;=F.H#<NA24HH,+HF<0]"*0+IC0,%'%%:%NG0@
M3E5&&0W8,,J"W@,!:2(8 <2=(1V -?H@K'RPD5)\J:FNBS8WHR8T3,355+$_
M\8>C4LI8BW.F[IAGXQJ+Z!3P*7.M 0B!JJ\$N#QLX0,?[';%UMKVU!HEDYT&
M"."QTH0D::K8?8)3%>">44$)9!8/CYB2^,0>O*)"/_RL!2?@,EE:-K56'2/(
MD2>+B%!!@20B = _25).X/I\.LGFS7_<AVYY\_&',WWR',WWQ!Y!]0?OG[H1
M^YB_*>J85Y3U3X4H,5N_LX[K^N/Q'X]7G<3UQ6Y7/;E<\N SJDD?CRLAP&2?
M XDZ4D_'PP50UY07W/@NA<'TT>NVLG&/H7VP=@4T&NVCC(=CV,@\ER#R7X(,
MH,:7H]SL[?\ T*"L8!J%4 P6*G85Z1833Y$@?N*(!@FU;C1RT_I6Q(ZR 2D0
MH"#IOQVZX-K8<;1./5]&9?A_H?UD?Z3%/]/K_!]G"!4$J"!$1&$YHDY,%,8=
MU>3=&J3L9%^)"2$&1HG7FICJW70CLG7! !.'3;KEB[G<X_C])SUJE%*2BUIE
M(@>;-VS<:"(B(T=DTCCCUB H!@#JK0'\.CU.BZ=,B32^!=.5"L:1%)MU5L?'
M>;]0;+]9:$%=D$H(0-3=W&,0X#CJ8+O:0TZB$UV<3H?Y(G;:!#%$AFKMW))Z
MAO5C9*REKB."UM,2'D,N2]D80C$1&<4<%149 R]-IQ+N^<@];F)=A,:FJ@<X
M"!@*)L!0*PY.D'W(9&+&PPH$%^R'^-DVQ;%TFO8U?!%=!Y]@2PW+N,]-\\SB
M-ZXX7;-X&BU\H:= M:!/@J24"D#2!'+:2! =%5^J(^KU^?><GBZ6&C+')#7H
M).BQP('W@/)J1NQ0,.[Y^.%22M<:3)'Z=5V2H<)7@5P+$,P@<]A*X&!(M]0
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M]5V]W;O_ .BJ<,TOJ(/T G9!-AA.'@#P&'8&@X.GS()$$WI*;$>>XH^%,<,
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M<DB:O#V9QO\ ?(3<_P E'R/\?^S6H(B"(B)1'2(Z1.3(%@%:^6!7NP#T Z8
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MSA;>^?D?X_\ MZV'8YO!SW]?/QAV/8_5@\ER'8]C(' 'T^:'8^"#R#Z_H ;
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M#7.O'"*]?,XX5,@*IVT4LC)];8@8OA6A"W3*Q7:LR*BI\.!_YNX7FI"3M_\
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MP=DZ23*G#+SYMOO7N]W( @B"]" DX0==2 ( !  0$-"! >X"A>FL%)&22:@
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M1H@(EB(Z2N_+A! R:$N6N>.AQMW<W=BI$H45,0DKB-X(0I4MS$B33G)SG 5
MO:[6N_U2X!@S$4"Q",P6*:01G*=^)9.^XR=D>'TX/E8EE5*8! D1BQ)L&Z@
M4B+'"Z.?2X!,Z7)(HN2("&;P!-G_ .RRFBU@L)J9NM"A(W958J$^#_L7]ZOJ
MOP4H@[@#=54'.+HZ5Z3!%OL()=KWA5E ";SJ"3;UC$")U(4NH,>C( ".%G9J
M 'U;!#:00]4@^H >8'FH/\;2)WI^=,U'R7\^_P"W_IM<'T?MGW7V/_$5KO?.
MGR6Q^H/J8:4:0$:1(QP"8["58$ @6>*UGJJO=;S\\7@^C]LY_+(IPSTQWSO1
MWVB>FK]4TPT1H>0XTJ:XTJ^JN""+LM:VP1M(H=7 @(03!<&^.,K ^P'@2#N
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M/3B?/7>^=/DMC]0?4S^>?=?=/5.5^8TB:2Q.2BH\E2,Y%.%QV"V  [!  Z
M.!!(X:LU89U*A_T%9R_^#=-==MD=Y[.Z^, )X2$'-$DKP\/(PUKO=NFR'H<'
MI\.>&Y>@^^.!Z'V^84?,>$F^/7-A8)Q",PP5,:;Z8(H[?*2T'@A)4^A9T-D&
M50'=2:1DE)F36U/M9$>/CP]#:N/"$ST  3$A&K#"7W5+N.)JP55N X! H3UM
M2/H4Z*U>>%CCF)<!3IFM6RWN(T8P1D_'>-<,.<O<\N:B@H0JLH0R=_EYZ_Q,
MJB@?YW">ZJMJ& .-TA'1G!5((MA#_/N%7.F#P&(B9XR(-.4R YE$=&M:+V.$
MIT79T1N:]6@ID4<)\1>#/_%(]]FF:,E-R&=**EN4#*/_ &3<5),*Y.J +FF4
MEC(LL9:#>&QI!I .(!P(#3<$!A]6HP-G^J%_C 2DIR0C=AN/V1H4L@!&H!$6
M0O!4M*TBGX7M^5\@"5K0+A$$T< *_P"][%;LH!D.4D3>JL[D=#%VD1D40:WH
M%#BL.L4(",!\0170H<V)2IG&XU4ZPQ+\&_$5&CHH 1$ *+'+&N--*?+HKD9>
MPOF[2:KF@<X4)77$4Z3TDTX'%CQ(AJV-]0(9+?Z$1YD-K>(%PO0-'>$&2AUK
MQ,(!,/+UO4^7&Y;.#5[?1@?OGE9O*S>5F\K-Y6;RLWE9O*S>5F\K-Y6;RLWE
M9O*S>5F\K-Y6;RLWE9APC$>:_MI[ZSJ<Q4*UUG#PB\][#F;>7O./@Z%[#@E-
MNTU6<YI(A4;DX O8G.L$,70%[@;=Z!N=MKFMCMV^/4YY7_3^![^,\K_I_ ]_
M&>5_T_@>_C/*_P"G\#W\9Y7_ $_@>_C/*_Z?P/?QGE?]/X'OXSRO^G\#W\9Y
M7_3^![^,\K_I_ ]_&>5_T_@>_C/*_P"G\#W\9Y7_ $_@>_C/*_Z?P/?QGE?]
M/X'OXSRO^G\#W\9Y7_3^![^,.HO^G]'Z^,OU^UWXNW37CUH$RI(5M9/I4V5
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M4' #20SAI@J*BR#_ %P8D1NAL&M"2V=$[Z5N'" 59LH/\&;:C#O@HJC-4<L
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M7#1F6-74+%F4ST4N*F.=+#<*2P&D0-&(I+&VJ,.0['L9#L>QD.Q[&4.CIT,
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&GH_?'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>heartflowlogo.jpg
<TEXT>
begin 644 heartflowlogo.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_X0]N17AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     @   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E    *8   !(     0
M $@    !    1TE-4" R+C$P+C(R   R,#(U.C R.C T(#$U.C T.C(P  $
M : #  $    !          @   $$  $      0   0$$  $    L     @$#
M  ,    , 0   P$#  $    &    !@$#  $    &    %0$#  $    #
M 0($  $    2 0   @($  $   !4#@        @ "  ( /_8_^  $$I&248
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M^KS:CX?N9O+DMIN/?:1G&=N2&&.G(]?0_BE\1/\ A%_ ]M>Z5(OV[55 LV8
M[%*AC)@]< C\6%8&J?!WPK]JM-.U3QEK3SW,F+>WN+R-B[ $\ KZ9Y_#O6-\
M>?"TFF^#_"S6C22V6D(;)G?EL%4",<<?\LR#[D4 5O#7P7U/QKI=OXB\2^)+
MD27T?GQ1@>:^UL%6+,<#(YP!Z<UROQ*\/^*O \%EHU]K4VH:.[M+9S<KM8##
M+R25ZCC)'?UKZ,\!>)+#Q+X/TR[LYHBZVZ)/"C<Q2!0&4CKP>GM7D/[1/B;3
M;T:9H-K.D]U;2M/<>6P(BRN I]SG./IZT 3_ !FEDB^%?@YHY'1BL62K8/\
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MQY:;P<AB 23R.F<>N:].U/3;/6--N-.U"!9[2X0I+&W1@?Y?7M5NB@#Q2_\
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M<E)'0B!865H@!^D  @ $ !4  P ;86-S<$U31E0
M             /;6  $     TRUL8VUS
M                                   -9&5S8P   2    ! 8W!R=
M 6     V=W1P=    9@    48VAA9    :P    L<EA96@   =@    48EA9
M6@   >P    49UA96@   @     4<E120P   A0    @9U120P   A0    @
M8E120P   A0    @8VAR;0   C0    D9&UN9    E@    D9&UD9    GP
M   D;6QU8P         !    #&5N55,    D    ' !' $D 30!0 "  8@!U
M &D ; !T "T :0!N "  <P!2 $< 0FUL=6,          0    QE;E53
M&@   !P 4 !U &( ; !I &, ( !$ &\ ;0!A &D ;@  6%E:(        /;6
M  $     TRUS9C,R       !#$(   7>___S)0  !Y,  /V0___[H?___:(
M  /<  # ;EA96B        !OH   ./4   .06%E:(        "2?   /A
MML1865H@        8I<  +>'   8V7!A<F$       ,    "9F8  /*G   -
M60  $]    I;8VAR;0       P    "CUP  5'P  $S-  "9F@  )F<   ]<
M;6QU8P         !    #&5N55,    (    ' !' $D 30!0;6QU8P
M   !    #&5N55,    (    ' !S %( 1P!"_]L 0P ! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\( $0@$N!M) P$1  (1
M 0,1 ?_$ !X  0 " P$! 0$!           !"@(("0<&!00#_\0 ' $! 0$
M @,!              $"!@<#! 4(_]H # ,!  (0 Q    'OX
M       #\GR;\0^O]3Q7ZOU?(_I?2\Q^A]#S[W?=^,]KVOF_/['Y7E\WY^O)
M_I'['B\?Z_B\7U_K>O\ ;^GZGI'H^AZI\_YWL7R_E^X?)^/Z;Z'H9
M                                  'GGM_3\-^GR7QSZ7(?*??^YYM[
MOV/A_:^E\C['O?A^7V_Q_+Y_\J_MQG]?Q>O]'X?3^T];Y_WWJ_*],]'XWK?S
M_A>T_-XY[C\OC?[GC\
M
M
M
M
M
M                                ^1]GSZJ<C^]JSR/[VM7WON>&_6^M
M_+=A=&DT4H*EF7*6"%A9EE2_8^KZNQGP_A;/_ X[M5Q[C>P7QOA_[0
M                              ,3POZG)-4/O<XUD^YS36[[/+_@/=^J
M        /Z,8]J^9QS97XO#]H_A<)VM^#P?[GUOG@
M
M
M
M
M
M                                                  >?>[[.DW+>
M2:4<LY+K/R#[G\VMQ-1;*RLRSFH6E-)HT 5+,UE$$6Q+,LJNHE^X]3T]Q^,<
M4W:XIQ#:SCO&_P"J0                                 ?Y&LGV^9:1
M\G['TTY)V'YM[WV            !_MG.Q?QN([J<9ZZW=XSUQZ=Z7QP
M
M
M
M
M
M
M /YM-/.4?>Y\<WY5J/R;[_\ A=RUB0U*S*MAJ%E96<V94+2KMFF@"I<IJ8@A
M869J1=8KZ%Z/I;Y</X5T'X9P?U7Y_P X
M   >>>W]/G_RWM+03EG:7F'N_=@C2*              _P!<S:;X'".@G$^J
MMTN-==_WYP
M
M
M
M
M
M              /Q?+KG]S?DO-OGG+?*OH>^65+#4K*FH(:E9E742Q;*RN6=
M(0M*;310"IK*68@A8:F60U_M&Y?%^)],>!]>[&?$^&
M           /#?J<AYH\U[?T=Y1V3_#OS&BIK*)RBHTB@             /1
M?1^1T:X;U'T+XCU3]-X?4
M
M
M
M
M
M                       'YN[SRYUR/F1V%ROX+W?<A32:9TE+*EA9:R:A
M86%EJ1-1;"RLRS-3"%IHTFB@%364LQ!"PUE*4NW/&^,=5.O.MM@?C?%
M                      'C/TON\K^>=T:4\E[%_P [H I2FBIK*)B"-(H
M            ?6^KZ/2OA?3G1WAO4?[?C\
M
M
M
M
M
M                                   &E_+/L<E^S>7>2?3]V&BRT6&C
M14TSI+*E+#4KDU"PL+*RIJ)8ME9FLI4(6FC2:* 69J99B#%364O^AO=Q#AG5
MSKKK;T#T_3                         'R/L>YRRYYW)SUYCVG_)ORH33
M-* "E-%-3+.4D5%10            'HWH?(ZN\"Z-WJXOUIF
M
M
M
M
M
M                                               >8_0\_'WM/EFG
M_*?L0U*PU#6*FBRT:A314TSI+*E+#4KDU"PL++4AK%2RN4U,K(+31M*4 U,L
MYLD&-U,OTWK^OU8Z\ZWZ%\*X1_M                        @T5Y5V'R0
M[$[O^)]KZ0-%*$)IFE !2FBFIEG*2*QI0            VC^!PGL3UW^?_9/
MG?!
M
M
M
M
M
M T"YO]CD=VARCYWS^5*FC134-%AK%3134M0IHK.TJ65*6&I:E2PL++4REQM+
M*Y34RL@M-&TI0#4RSFR08M;1<?X[V<ZNZK]2^?\ /
M   'POM>_P ;^R>]-.>2\]!HI04I2A*E9I0 4IHIJ99RDBL:4
M/U_#X.K' NC>CG#NI/\ 4
M
M
M
M
M
M                 ^8]C7&_M?DVDW+_ *ZU:4TS4TE-&H66H6&L5-%EHU"F
MDTFDJ:D*:A<FI6%A8:R5*7&TLM92S*R"Z72:2E -3+.;)]-X/7[']8=6[L<4
MXJ                     -3N0\PXN=F]\_!^U],JZ2@&BE!2E*$K-2E !3
M1319S<H&-12@          -M^.\#[0];?G?[CUOG@
M
M
M
M
M
M                                   >)?8]CAWW'R?R#ZOM%3:4TI:5
M-)4TFBFBFH:Q6&BFI6&C14TFDJ:D*:A<FI6%Q4UDI8EBZ&34RS*R"Z72:2E!
M2SFY'2/@G ^L'777/]68                   ,#F1SKM;E?V!W#_CKR%0A
MD4T4 T4H*4I0E9J:  *:*:+.;E QJ*4         !Z1Z'R.WO6/YMV+^1Q0
M
M
M
M
M
M                                                    #4/E7N\3
MNW^2_.>?R%A9"E3;.EJEI4TE32:*:-%AK%8:*:EHL-%32:9IJ0L-2U*RL+BU
M*RI8:B5634RSFH"Z-&DI04NW'&>,]L^J.J?I?!X0                 !^7
MOR<9NS>[]&>6=A2N30*:*ADA=)2@&BE!2F@$K-30 !31HJ69<H&-12@
M   /U?%X>S/6WYXWBXSUP
M
M
M
M
M
M             !H+SCZ''/MG[O\ +O:5*SJ&I:@D*5G9HJEI4TFF::*:AHIK
M%8:*:EHL-&DJ:9T60T4U*E+BU*RI8:A2Y+,LYJ%I32:- >\_&^-W8Z@ZC^_]
M/U                 !\MY_9X<=K=]:O_?Y;#4+"ER:E04T5#)"Z*E!2E*"
ME- ,U*F@ #1314N4LQ!%1H        /],NLO7_1'2?AO40
M
M
M
M
M
M                                     './L#W^1O:?V,;HILT5*S4W
M"FI 5-)I-+5+325-,TT:*:A8:A8:-%-2L-&DJ:9T60U"RU*EA8:E9E6Q-1;*
MRLS4Y(6E-I37KOS/E]X^GNH?4/G^B                /B_9]SA%VWWYX!]
MCDA311#4+"ER:E0:*5#)!I:E!2E*"FB@,U-)0 #1314N4LQ!&D4       !U
M!X)TKU/X-TJ
M
M
M
M
M
M !SC[ ][D9VG]2+H&BFH:EHT5*SJ)J6H60%32:32U2TTE33--&BFBXM0U"FB
MRU#132:9TE+(:A9:E34+"RLRKJ)8ME96<V94+2F_5/F_/[V=.=0>H?/]$
M            ?B^7R\$NW>_-=OM<D-&C12FBB&H6%+DU*@T4K)"#12@I30!3
M10A*FDH !HIHJ:RB<HJ-(H      #I[P7I;JGP7I0
M
M
M
M
M
M                              #0#G7M<;^VOI0T:-%*#131HT:*E9U$
MU+10"II-E*I::33-3131J%-0L-0IJ5-0T4TFF=)2RI8:E94U"PLK*IJ%BV5F
M69J80M]4^=Z'>SIOJ/U#Y_H@             #_*N)?:G=>E'*N<)60*:-E*
M4T4L+"PIK)94I2E9(2K4I04IH IHH0E324 %*4T5-91,01I%      =7^O\
MHOICPOI\
M
M
M
M
M                                                        #3WE
MOEX<=T?0_FUMG64T#1HT4H-%-&C1HK-3431J5 *FDVE6M#14TS4T:*:A34+#
M4-%EHIJ&BIIG265*6&I7)J%A865E4U"Q;*RUEFH]4^;\_O7TYU)ZC\_T@
M          .4_879_,7GW:$K(:2I60*:-E*:*4L+"PLM2LJ4I4J$)5I4H*:*
M :*4(325* "E-%-3+.4D5%10    RR[/=;?G??#BW68
M
M
M
M
M
M                              '@_P!S7 7O7W?P?/8:-&HFISI-2&C1
MHT"E*:-&RE9J:B:-%D!I-)HI6AHK.DJ:-%-%AJ&H6&BRT:+#14TSI*65*:++
M186%EJ0UBI97*:]4^;\_O;TUU+ZA\_T@            -"^7\VXR=G]Q1E&M
MKJ+J5D-)4K(&C1HI312EA<5++4K*E*5*A"4JZ0"FB@&BE"$TS2@ I3134RSE
M)%8TH   ?H^+Q=Y.JOS!LW\7AX
M
M
M
M
M
M            'R/MJ^/?7L>4_3U#4M2LK#1J&ISM-3*4IHT:!2FBFC94J5-1
M-E+(#2:37]F9^GXY_/K7YGDW_GK3.DJ:-%AJ6H6&L5-%-2U"FBL[2I94I8:E
MJ5+"PLM3*7&TOJWS?0[V],]3^H_/](           #6'[W(N#_;W=OYWD\J:
MC-2B-;B[FTLAI*E9 T:-%*:*4L+BT65E94I32/\ 7./U_#X/Z<Y_/WYORO)[
M0!HI04I2A":9I0 4IHIJ99RF(TQI0  ^\]/Y=@_J+\J>B^I\H
M
M
M
M
M
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MKR/"[*"E*4)4K-* "FBFBSFS$D5C2@!L]\'A?>GJK\P_TS(
M
M
M
M
M
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M>8XW104I2A*S4I0 4T4T6<W*!C44H=3>!=)=0^$=,
M
M
M
M
M
M                          >0?7S7B_0/A_&\EE31HIHJ:34RS-0T:EK)
M84IM-1-3-3*4T:_UEW/XAZO23KWY^S''?7          ^=\^]"N:_9YM=@<@
M\K^C[::*:*:AK%8:*:EHL-%32:2IJ0IHU*RL+BUZK\WT>]W3/5?J/S_3
M     _CU>%';O<&J7(N2S+*EBZB65EHUBT60K-B5*MBZ7:ZD*5FI4>B^E\[H
M]PGK?H!P[K[ZWU_5          \6^E]SF]S7M;0OEO9/YOD\Y2@I30"5FIH
M IHIHLYN4#&O[<^.P+U)^5???E<9
M
M
M
M
M
M            P."O>_J:K<IQ#4S26<ZE31HIHJ:34RS-0T:R:E84T:B:F;2[
M=\5\'6'J[T/=?B^(           #^/3G_P X^WRT[(Y'\-[GL,TT4T:A36*P
MT4U+18:-)4TS34AHIJ5+ZI\[T>]O3'5WJ/S_ $P       !_E7'3L_L[0+F/
M-H(6%F:D+#4+*RT:Q:+(E2Q*E6XW<ZT:D^I];U>G_ .L.B?"^O/U?'XP
M       /,?>^KRLY[W'HERSL?&Z*4H*4T E9J:  -%*:2S+E&P'R.*6 ^IOR
MQ_5,@
M
M
M
M
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M@ &BFBI>O77G0?1;A_5
M
M
M
M
M
M  'X?GS7/_1'RO._HYQ:AJ&BPU"PT:F6<Z2RT4T:*:2IK*:2PUNKP[/9#J/U
M_KO4@               U&Y1]'C!VWRGX?W?.:2II*FC134+#4-0IHLM%AHT
MFDK.BR&O5/G>EWNZ9ZQ]1^=Z@        _QKCIVAV;H!S/F94N4U,00L+,U(
MNL52RLM0W"ED^G]?U^QG6/4F[G%>'               #\7R>;D;V+W5S[Y?
MV<4H*4T 4T4(2II*  :+]=ZWHV,^F_R7]?X/2
M
M
M
M
M
M                   ',/L[T.5W:7SH:Q:+#4-0U#18:A8:-3+.=3*:-%-%
M-?ZYUU>ZLG2_KCQY                 \X]_P W#WN+E>O'W??4M-)IFIHI
MHL-&H6&H4U*FC4*:33.DI?5OG>EWMZ9ZS]1^=Z@        _RKCEVAV9H#S/
MF@!4UE+,00L+,U(:QM2RLM^S_*^1W(ZFZ:]?^;\L                #0+E
MW8W'SLCO'\_7F6I2@I30!310A*FDH +TKX3U!UEX#TB
M
M
M
M
M
M                        !\M[6*X_Z,^#\M[2%@A<5AHU"PU#4-%AJ&H4
MU,K.IFI4U^AX]=K.FKNQPP                 !^)YKQ*[?Y3I_RGZA2J71
M4TS4T4U#134+#4-%-2IJ&BIIG7JOS?2[W=,]:^H_.]0        ?Y5QS[0[*
MT YIS--% *FLI9B"+8FLI2EV8^#Q_N5U+T[]9Z_K@                 :H
M\@Y?P^[4_07SWF]M"5:5*"FB@&BE"$TE2C]CQ^O8XZ:_)OH'J?-
M
M
M
M
M
M                                ',3L[Y?+3M+Y<-0U"PU"P0N*PT:A
MJ%AJ&C4+#4*:G-_2\6^Y727EVZXGH                  #\_=XE]P<FTSY
M;]-*FRE:&BIIFIHT4U"FH:A8:++4-2L-%]4^9ZG>_I?K;U'YWJ@       #_
M "KCGVAV1H!S3F)HTFB@%F:F68@Q79CX/P.[O4/3O[?B\8
M    &N/VN3<(.VOT3\Y['N)4(2E72 4T4 T4H0FF;TLX3U!UDX#TF
M
M
M
M                                  /%31Y-1$UR/&4\T/RS _2/33VI
M=E#;^7>1?6Z      'ETFMUH   ^FC;R@
M
M            /R_+FN1^C>,?#^]C%84U#4-0U"PL$+BL-&H:AK%31J%_VSKM
MWTI[6ZG#/(                   !^?MQ*[@Y+IIRWZ8-)I-%6J-%9TE31H
ML-2L-0UBIHLM&H7U3YOJ=[^ENN?4?G>J        /\JXY=H=D: \SY@%IHVE
M* :F7U?YGS; 73/3'VWJ^J                   !J]][E?"/MK]#?F>3V"
MFD(0E*: *:* :*4?2^OZ=D;I7\F?2^'U@
M
M
M
M           !X/)R&LY9)JC8@     9UM[+U-7KI->UT    !R?2KFP   -K
MEN?-@
M                                            :(<\^9QM[DX_#1J&
MBXK"PT:AJ&H6%@Q6%AHU#4-8M=;^IO<Z2]<>P                    !^?
MMQ*[AY)IIRSZ<+(#2:31I2C16=)4T:*:AHL-8J:++7JGS?4[W=+=>>H_.]4
M       ?Y5QR[1['T YKS"9606FC:4OT_K^MW]Z8Z<]L^5\L
M        #1CE?/N*W:'?$6RI2FD(0E724 T4H!HO7CKGHKHQPWJT
M
M
M
M                              :Y2< +.5=S_'         _1.KK7?E=
MA5    Y/I5S8   &URW/FP
M
M ."/?G$];N2>G#1J&H4U#1<%-0T6&H:A86#%8:AK>/@_M]K>E_H
M             ?G[<2NX>1::<M^E$T65!2II-%6K2II*FDIHT6&BPUBT7U3Y
MOJ=[^ENOO4?G>L        /\JXX]I=C<_N:\NR:F696077]6)W1ZAZGVUXWQ
MX                     #D=V+W%S=YOVD65E94I32$,BKI* :*4>X_)XY8
M?Z=_+P
M
M
M                                           _@DX-6<(6?Q0
M     ?NUWTF^Z$?UV@  <GTJYL   #:Y;GS8
M
M               \<^SZU>G]#\*Q6&L6H:A34-0T:A87%34-%AJ&H7%?4?E^
M6PM^?/L_2^MH                      ?G[<2NX^0::<M^@FHSJ6H4LA2I
MM*:4M*FDJ:313134-8KZI\WU>]W2W /4?G>L        /\JXY=I=B<_N:\NA
MH9-3+,O8'J_K?H?PGAX                      _-WNOSW%^C/!_K\BQ:A
M2RN30*:*A#(IHH!HM@KI_P#,.PWQ^-
M
M
M
M      #S&2JO<Z$H            +$\WW%M   Y/I5S8   &URW/FP
M
M                                !S"[0X_S$[0X\6"%AJ&L6H:A34-0
MT:A87%34-&H7NOT7]O;'B?L@                      #\_;B5W']_33EW
MOE2IIG1HL+(4K.RFE+2II*FDT4T:+ZG\WUN]G2W O4?G>L        /\JXX]
MI=AZ <UY:6&H7H_P/A?77K/K\                       :_?8Y!7X[B_1
M?\^O(4UBL*65R:!314,D+I*4=)N$=3]:NONEP
M
M
M
M            /()*B=SJ\@            _J+K,WL3:  !R?2KFP   -KEN?
M-@
M                                        "OK^AN#>*_:]2%Q6%+!#
M6*FL6H:A3<+#1J%A<5W7X5]'M?TI]H                        ?G[<2N
MX_N::<N]XV4TA-,ZAJ6H)"E9V:*I:5-)IFFBPUZI\WUN]G2W!/4?G>N
M   /\JXX]I=@\_N:\ME=P>+\>[D]0=9?TR                        <@
M.R.X>=W-.RRE-"&H6%+DU*@T4J&2%UZC\_X]C[I;\LR
M           #C1)Q N0      !9_:W74                     #G/)7!N
M0      !WO:ZSJ
M
M                                       /C8I^W&HZ
M =3&K4#0   Y/I5S8   &URW/FP
M
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MW[4                     #ENE5M@       61YOM+:
M
M
M          *M\SRCN0     !^E;Z0?1R?-KYQ7YL@   %Q*;W:M   ')]*N;
M    VN6Y\V
M                                                !S^[#X_R0[>X
M=$T;BZ-8M%2XK"PT((:Q:AJ%AJ&M\N!_6['=-_?
M     _@VXD]Q_8TTY=[AHIJ&I:-%2QG2:EJ%D!4TFC15+325G7J?S?7[V=*\
M(]1^=X        !_E7QWM>?[;U/                          .3G8?:_
M-+G/9I31HT4IHI86%A2Y-2H-%ZQ]=]+]+>#]6
M     #A$E?!@       6\6]^U                      Y;I5;8
M%D>;[2V@
M
M                                <N9*K-P    !]&=0IKI9;NM+[V?U
M4!_+'@IIU9SY3F GD* #>QJX T   !R?2KFP   -KEN?-@
M
M                        <8^Z^$:6\W^%%1*FHFC<79<6BI<5AJ%$+BL-
M3-V#?SWS#V[XGL@                         #\_;B5W']?33EWN%!HIH
MT:-%2LZB:EJ%D!4TFRE4M->I_+]?O9TIPOU'YW@
M              \V][Z%<+N[]'_RZ\K(%-&RE*:*6%A84UDLKMYQOA'=3J?\
M_                            #A$E?!@       6\6]^U
M           Y;I5;8       %D>;[2V@
M
M                                                       #\**5
MMQX$@   '^M=FYKOK->KT    !^='+]."%SJF@M93?3JT   #D^E7-@   ;7
M+<^;
M                                           KJ?I#K#S[Z/K)J%C5
MQI*FHFC<7<-0J6%A8:A1LIQGZ7>3H7EP                           _
M/VXE=R?4TTY;[AHI0:*:-&C16:FHFC4J 5-)M*M:>I_,\'>SI3AOJ/S?
M                               !P\[7[LTRY3S0TE2L@4T;*4T4I86%
MA?JO7]2S)T9^5O\ 6                            .$25\&       !;
MQ;W[4                     #ENE5M@       61YOM+:
M
M
M           ..:5GV    /IRTNWTN4      #\Z3AW7)%FYTW_2    <GTJY
ML   #:Y;GS8
M                                                 \_^CZU=7](]
M4LZBZ+#2:A8U<:2IJ)LU%W%L326%A>O/3_*M_>O_ +(
M          'Y^W$KN3Z>FG+?9-&C1H%*:*:-E*S4U$T:+(#2:31?5/G>OWKZ
M4X?ZC\WP                                  #2GE/,>(G:W=D74K(:
M2I60-&C12FBE+"V+NE?S-['\WXP                           '")*^#
M        MXM[]J                     !RW2JVP       +(\WVEM
M
M
M                    %,MC4=   !_26P)OI':        /C8^RH    <GT
MJYL   #:Y;GS8
M                                                   U+Y?\/B7W
MEUN:BV&DU#1J&DL6Q;C2:B5-FXNHNO\ 3.K'/YMY_P#;>CY@
M               !^?MQ)[E^CIIRWVIE*4T;*"E-%-&RI4J:B;*60&DUZG\S
MP=[.E>(>H_-\(                                 'XGE\M:'O3]&_D
M;\T:W%W-I9#25*R!HT:*4T7MCU;T5N_Q7@H
M  '")*^#        MXM[]J                     !RW2JVP       +(\
MWVEM
M
M KA)XY(      !8'79FT                 #5)*8#    '<1JQ0T
M        .3Z5<V   !M<MSYL
M
M  <Z.RN(<L>VN"1-1-1-&HNH5-0T:AI+%UC44FHSHUL!Q[Z??'H#G8
M                       _/VXE=S>]IER_V&=S-3*4ILT4%*:-&C14J:34
M34K"R#U/YOA[V=)\3]1^;X0                                 .$G;
MG=>I?(^5QFI5L747<VRI2I6:@&C1HO43@/5/4S@/50
M         '")*^#        MXM[]J                     !RW2JVP
M    +(\WVEM
M
M        I4L:TH      !<*>3>(                  X1LU[V0  !Z$MW*
M:^XM              ')]*N;    VN6Y\V
M
M            .2'</7^A78/$U1::B:C-AHU%U$T6&C4-)8NL:BNB_6O*.K/4
MW+                              /S]SB5W-[NF?+_,:3<34S4RE-&C1
M04IHT:-%2II-)J%+ZI\WU^]G2?%?4?F^$
M      <P^>]B\J^P^SY"LV)4JV+J+M=9!2I6:@I=Y>)\%[5]7])@
M                   <(DKX,       "WBWOVH
M'+=*K;        LCS?:6T
M
M                 "E2QK2@      %PIY-X@                 "I8SSF
M9   ';EJQFT              !R?2KFP   -KEN?-@
M
M                   #B3WMU?JIR[C\36,I51::B:C-AI=0U$T:A34-)>RG
M2_.MV.#_ '                              !^?MQ*[F]K33E_FA2FTU
M$U,U,I31HT4%*:-&C14J:9T:]3^;X.]G2?%?4?F^(
M             #4SD?)>$G;O=1K%HLA6;$J5;%TNUU(4K-2[+?"XQWZZ?Z"
M                           X1)7P8       %O%O?M0
M        .6Z56V       !9'F^TMH
M
M                         %*EC6E       +A3R;Q
M  %&2X\ND   %P6;WGM               Y/I5S8   &URW/FP
M
M                           !P,_0_4/B7W?DE+#>,L2EBEIJ,ZB:AI;#
M431J&N_OYZ[+]N^'[X                              'Y^YQ([G]G3/
MEWER:E2PIN)J9M+,I31HT4%-%-&C1I":]3^7XN]G2?%_4?F^(
M                     >=>[[M;7O/OZ%E9:-XJ61*EB5*MQNYUHU(7U3YO
MRK'G2/YS                            X1)7P8       %O%O?M0
M                 .6Z56V       !9'F^TMH
M
M                                  %*EC6E       +A3R;Q
M           \SBB_?&   /HR]K/)^I0              ')]*N;    VN6Y\
MV
M                                       *[_Z4Z2^!^AZF+12E-0UC
M+$T(I;#3.HFH:6INR9^9>W/W/!L                               ?G
M[G$GN?SZ9\NV:-2U*PLM0U$TFYS94IHV4H*:-%-E->I_+\/>SI'C7J/S?$
M                             !@E8GOS]!_E>3S+J)865EHWBI9$J6)I
M"V+MK?[_ (/7LY=#?F@                           #A$E?!@
M6\6]^U                      Y;I5;8       %D>;[2V@
M
M                                             4J6-:4       N%
M/)O$                 #3]*:;    W$6Y0V               .3Z5<V
M !M<MSYL
M                                              5N_P!/]#_C^;PI
MJ&H:Q:*4IK%J)8FA%+J)4U]#ZWM61?S-VZ
M      /S]SB/W1Y=,^7ZRFDL-2U+4K"FC432;G-E2FC92@T4U#4M>I_,\7>S
MI#CGJ/S?$                               !7%[Q[R\J^A].%F:D76*
MI966H;A2R)4L9T%U:'Z#_,W],@                           X1)7P8
M      %O%O?M0                     .6Z56V       !9'F^TMH
M
M                                                   %*EC6E
M    +A3R;Q                  Y[25'+@   =.&K6C0
MY/I5S8   &URW/FP
M                                                     !6H_4OY
MX_RUI-'D2IN%Q:AHI2FL6HEB:$5Z9\OZ%AG\X=N
M            ?G[G$?NG>F?,*FIEF:34++<K*EAHTFXFIS94ILT4H-%->I?,
M\?>WI#CWJ/S?&                               *]W=7<_@7V/NS$$+
M#4RR&L;4LM2U#4*61*FK-71'YN^E\'A                           '"
M)*^#        MXM[]J                     !RW2JVP       +(\WVEM
M
M                                                         I4L
M:TH      !<*>3>(                 ',9*IC    [#-69F@
M    !R?2KFP   -KEN?-@
M                                                          "M
M/^I_SC$U#6-T;-L[-)J%Q:AHI34+#437K?QOIV"/SKVT
M                 /S]N(_=+3/F T5-3+.=&H:EJ5E2PT;349U,LJ:-&BE!
MKU/YF.]G2'P/4?F^,                              "OSW1W'KK]S[I
M4UE+,01;$UE*4N*ER:-0U"ELQ=#_ )S^N]?UP
M   !PB2O@P       +>+>_:@                     <MTJML       "R
M/-]I;0
M
M  *5+&M*       7"GDWB                 !RW2JVP   .R+5EMH
M          <GTJYL   #:Y;GS8
M
M    K4?J;\VKJ+4L34-8W1M-FV=&H7%N%*4UZW\;ZM@7\Z=N@
M                      ?G^2<1^Z)IGS"%-&BIJ<ZF4U#4M2LJ:+#<34YT
MFI#1HT:'J?S/'WLZ0^'ZC\WQ@                             "OSW3W
M%KK]O[I0#4RS+,08VIK*4L6Q*7)HU9@Z(_._UWK>N
M        .$25\&       !;Q;W[4                     #ENE5M@
M   61YOM+:
M
M      !2I8UI0      "X4\F\0                 .6Z56V   !V1:LMM
M              #D^E7-@   ;7+<^;
M
M        %;']3?FS^>Y34-+8M342XM1='D3::31K%J&H7T/YOOV'?S;W.
M                               /S_).(_='CTSYA"FC1314U.=3*:AJ
M6I65AHT:B:G.YE!HT:]3^9X^]G2'Q/4?FX
M    KQ]V]Q>%_8^N:-I2@&IEG-D@QNIEF4L6Q+9VZ$_/'[7B\8
M                 X1)7P8       %O%O?M0                     .6
MZ56V       !9'F^TMH
M
M               %*EC6E       +A3R;Q                  Y;I5;8
M '9%JRVT               .3Z5<V   !M<MSYL
M
M                 5R?T_\ F_\ !]GU2PU$VEAI;%J:B:Q6+LV;9VE-?J>'
MV+)'YA[S                                   _/\DXC=U>+3+F&)EF
M:-%-%-%9W,LS18:EK)H&H:-,[34R@UZG\S/>SI#XWJ/S<
M              "MKWQW1YS[WT&06FC:4H!J99S9(,6I7^C,M#] ?GD
M                      #A$E?!@       6\6]^U
M    Y;I5;8       %D>;[2V@
M
M                     4J6-:4       N%/)O$                 #EN
ME5M@   =D6K+;0               Y/I5S8   &URW/FP
M
M                      !7R_2OYT\Y^G\V&@4L-1-IJ%6Q=)8FL5B[-IM-
MV,?S+WO]7ZGG                                   _/\DXC=U>#3'F
M7C2S-3-3*:*:-%32:F69J%-RN30-0TFXFIFIE]3^;CO9T?\ )]1^;@
M                      ?R:M8']!]X?R;WDU,LRL@NETFDI04LRSFR?6>O
MZMF'H;H4                           #A$E?!@       6\6]^U
M                 Y;I5;8       %D>;[2V@
M
M                                  4J6-:4       N%/)O$
M          #ENE5M@   =D6K+;0               Y/I5S8   &URW/FP
M
M                                   !PC_1/YZ\'Y%QV9Y$\B:AH%+#
M<32:AJ*6LZQ:A8OD[N?GONO8#CGVP
M   !^?Y)Q'[K]73+F/CA8:364J:F4T:*:*FDLS4S4*;EK)2PII-Q->J?,QWM
MZ.^7ZC\W(                           'D/T_>KE]Z]Q%A8:&34RS*R"
MZ-&DI04OM'R?DV*.D>DP                           .$25\&
M!;Q;W[4                     #ENE5M@       61YOM+:
M
M                                             !2I8UI0      "X
M4\F\0                 .6Z56V   !V1:LMM               #D^E7-@
M   ;7+<^;
M                                               '&+O?HC4GFO"(
M;*GDF;9\D-&@4L-Q-)J&HHTEZV]-=L[U]?<T
M            _/\ ).)'=?J:9<Q\)8:Q4U,TEG.I4T:*:*FDU,LS4-2U+4K"
MFC7J?R\][>COG>H_,R                           -*^6<AX@]N=EXM2
MLJEBZA965F6<U 71I-%+M9QSCG>3I[J(                           #
MA$E?!@       6\6]^U                      Y;I5;8       %D>;[2
MV@                  #^9/*8\@/BCXPQ!]!7VD>IK["?04
M                    !_&>11Y&?(6?%P!]8?9K[(GK:_U4
M                          /EH\C/,:^33Y:/6*W04          4J6-:
M4       N%/)O$                 #ENE5M@   =D6K+;0
M   Y/I5S8   &URW/FP
M                                                        !RO[
MBZ;Y^]E]8)J&C4-&IFV?(FX;*4%AN)I-0N]O7O/.M73?:H
M                      _/\DXD=U^CIGS'P0T:+BU#19FDLYU+131314TF
MIEF:-&I:E2^I_,G>SHWT?4?F9                           Y.]D\VYG
M<_YG*RN*PU*RI8FHM+DLRSFH6E-= >%<.[']7]:
M       <(DKX,       "WBWOVH                     '+=*K;
M  LCS?:6T                #YF-';-($T_-5DU\/QD    _P!:]DEV<7<
MW47?&/8K0                           /AXT732&S40U93P*S\^    /
MVUV2-MY=VUW^-K+<P    #0B3FF@      &YB]5[0    *[DR      !UP:V
MSH     8&L,FB9IK9J<:W)Y98@ =+&K8#0          I4L:TH      !<*>
M3>(                 '+=*K;    [(M66V@              !R?2KFP
M -KEN?-@
M                                             #0CLCK3E-W/TDFH
M:C.BPT:AHU,VSY$\D-%*#4->K?&^UW__ #AWX
M             !^?Y)Q*[K^=IIS'P8M0U#136*PT69I-3FRT4T4T:2IK+.BP
MU+4M>J?,G>SHWTO4?F0                          5^.Z^SM<_N_6-0L
MM2I86&I695L-0LK*SFS*CK)UOU[TLX'PD
M#A$E?!@       6\6]^U                      Y;I5;8       %D>;[
M2V@              #R:.6=G,E-"F?PP        #*ML9KIJ=4Y=L;0
M                   /"TY6',EG1]/X         #W=>I*]=)K;B@   .'2
M5V&       .O"V=&P    *";Q@      6I&^I"@   ?XQH>G*>SF:GB:
M#I8U; :   '%J2MQ<                      6I&^I"@  #4).8R     :
MM'*YD   ;CKTO4         =.5V]4    #D^E7-@   ;7+<^;
M        ^0C3*S4--6#7H\43RD^,K\N0?Z5]"OI1ZSE[W;LH;7KN=+LG9_JH
M             Y<IJ>@   [7+Z0H                    'GDG-^M=4^@-
MVI=[*_W4                    #2^3FS8  !_:=GIOS?EG$>(7Z$_-B;-K
MI-0U&=%AHU#1J9Y&=IY(:*4=_?S?^AO5_C_4
M             _/\DXE]U_,TSYCZY36+4-0T6&H6&C4RLZRE-&BFBFDU,LS2
M:A?5?F7O;T;ZGJ/S(                         /A/<\]:SO[MC_&;2EE
M2PU*RIJ%A9695U$L6RLKW5Z=ZIV]XSQ\                           #
MA$E?!@       6\6]^U                      Y;I5;8       %D>;[2
MV@             ?XQSK3C!<\VT_@            !N,O9QKK1+]%0
M               '\4<T$XOV<];G_&           !%;UR]SVNEQ_JH  X=)
M788       Z\+9T;     H)O&      !:D;ZD*  !\[''E.)MSK:@     '2
MQJV T   .+4E;BX                      M2-]2%   '(9FL8R
M            !9S:Z\M     <GTJYL   #:Y;GS8                 T]D
MYDV<YDTSK^"0       #U->@R]*5Z5GWZ@           <D$K!,   "R3-]H
M[0                   ,#B SP L^4D &W2V>IK;BT
M   51F>9C(  '2=JV*U\U[7J5V?U)^2?\M9*SLV:7:6&HSHU"FH:-3/(SY$W
M#73?J?M3H[U?V0                                     /S_).)O=?
MRM-.8^MBL-&H6&H:AHL-0L-&IEG.DU*FBFBFDU,LYUZI\R][>C?6]1^8
M                     YX<ZY'QZ[2YP4TFF=)2RI8:E<FH6%A965346V4^
MA.E?0/2]8                           #A$E?!@       6\6]^U
M                  Y;I5;8       %D>;[2V@            ?X)RSC@K<
MZH(              !ZVO<=>TDOTUH                   '\4<FDX+W.M
MJ              #==;&<UO%: !PZ2NPP      !UX6SHV    !03>,
M "U(WU(4 #^=.0!7_9\:0      #I8U; :   '%J2MQ<
M      6I&^I"@  #D,S6,9                    LYM=>6@    .3Z5<V
M  !M<MSYL               #RXX^IR#9UB0           ?N+TP7LBO0H_U
M4          ?*R4<M8^*@  #=9;BS8                   %>]GA&R  !]
MVMOUK;10                  !Y-)1^UC\V   +4C?4A1P1_27Y<\A^YQZ%
MQJ**SLV:7:6)J)HU#4*:-SG?K?Q?O=]OS?\ H;)0
M                !^?Y)Q.[K^5IKS'U8(7%8:-0U"PU#18:AJ%-3FS-3-%-
M%-&BIKU7Y5[W=&>'U'Y@                        5^^[>P=;_O\ U9:+
M#1HJ:9TEE2EAJ5R:A86%]0^=Z5D3HCIX
M<(DKX,       "WBWOVH                     '+=*K;        LCS?:
M6T            :)25Q=9TZD                 ]R6Q UU77,
M         &@<E<.YU+0               #_ %KLM-6(IKZ^@.'25V&
M  .O"V=&P    *";Q@      6I&^I"@#71*Q":*L@       =+&K8#0   XM
M25N+@                     "U(WU(4   <AF:QC(
M  %G-KKRT    !R?2KFP   -KEN?-@              >"2<*;.0MS\]
M          &UB]VYKJPO]M          5F&>/3(  "KIN=[/V@
M        :1R4\=8Q@   ;B+<C:_U4                  #B))7.N   /2U
MO$37[-HY.=U=$:+=B]6KI-)87&HHK.S9M=)8FHFC4-0T7MKT!^@-G^)<K
M                                   _/\F>)_=?R=-^8^KBL+!"XK#1
MJ&H:Q4T:A8:A34YU,LS13131KU/Y=[W]%8]2^8
M &OWV_>KW]X]APN*FBRT:+#16=)I+*E+#4K+6]?#N,=I^J.NP
M                !PB2O@P       +>+>_:@                     <M
MTJML       "R/-]I;0          !\')75LX]W.,                  #
MH\U9CE]KM                 ^'DKG6<?KG&                 !LRMJ:
M;VMH<.DKL,       =>%LZ-@    4$WC       M2-]2% YC25@[GXA
M   !TL:M@-   #BU)6XN                      +4C?4A0  !R&9K&,@
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M:A86#%86&C4-0UBT4U"PU"IJ9J99FBFC7J?R]=[^BL^I?,H
M         '%+MSE^CG,/N&C4+#6*FBFI:A316=I4LJ4O9?JOK_?SA?&0
M                       !PB2O@P       +>+>_:@
M     <MTJML       "R/-]I;0          -&$JYL^#(
M    !Z0MG>:Z6V@               :8I5D9U\0                  #[!
M;3$UTDMX=)788       Z\+9T;     H)O&      !:D;ZD*.+*5O[C_ !@
M       #I8U; :   '%J2MQ<                      6I&^I"@  #D,S6
M,9                    LYM=>6@    .3Z5<V   !M<MSYL
M  <L9*WMSY&@                 BNJDU9#E]6M        '^24J6=;D
M]R6[?-_UT                 !Y_)1SN/GP    =?FK-S0
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M#                    /T2SY-^,U788       Z\+9T;     H)O&
M !:D;ZD+Q=2MK<(         '2QJV T   .+4E;BX
M   M2-]2%   '(9FL8R                   !9S:Z\M     <GTJYL   #
M:Y;GS8            ^+*UC/)ID                   >KK9X:Z.J
M   .#25^&   !;D;Z$*                 !QD2M<P    !]B7CF_K5
M              KEL\1V0  -N5N9M@ <2OT'^9-<.5\*BV#%%J6&L5AI=,ZA
M86+(M32;-FO>^-\J[G_G;]&_[30
M     _@WGBEW7\/3?F7HXJ:AHL-0U"XJ,5AJ&BPUBU#1HL-8J:364J:]4^5K
MO?T5OU+YF@                    !PF[GY;J1RGZA4TE32:*:*:AK%8:*:
ME34-%V*^#\RP5TCUJ                            !PB2O@P       +
M>+>_:@                     <MTJML       "R/-]I;0        !_,5
MS4XG,                       =B6K*Z_V*             .$<S7OUE
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M185-0N+4-&DL+!&K FD\G5OIGO+?7K?LL
M           #^#R9XI]U_!TXYCZ,+"XJ:AHL-PL+BL$+#4-&H:Q6&C18:A8:
M37JOR==\.BO-ZE\O0                    TAYC]+B;V]RM*:4M*FDJ:31
M31HL-8K#134M=9>L^'=+NO\ BX                            '")*^#
M        MXM[]J                     !RW2JVP       +(\WVEM
M     _C2L:G)%D                       #K0U9XFO[*            '
M F3@3<                              #KPMG1L    "@F\8      %B
M9O@NS\"@          Z6-6P&@  !Q:DK<7                      %J1O
MJ0H   \I37-0    - $KZ,   #W-;2[8         V,3U90    .3Z5<V
M!M<MSYL           :%R51[GS]      !E6U\N]R[?R[/'NR^FGUM#^2//C
MQVS7PU0328T.L\]D       ZT-6;E_64       5(V>=[(  'UJWD)KZ^T
M              #5F*7.O&@     = %MV-@                #F1)5*N
M /UB\+/)ZC0 'QWO?/K]_IS\?_Q^3Q000IHU"XU%A4U#6*Q:FTL-08ZG[OK>
M[WA_.'Z>]2^/]D                                      #^#>>*G=
MG']..8_/AHU"PN*FH:-0U"XM000L-0T:Q:A8:-%Q:A?5?E;[X=$>SZE\O0
M                 ^#]WR5XN]^7?$>YYBE9V:*I:5-)IFFBFH:*:Q7_ %EL
MB=!]:>E>AZX                            '")*^#        MXM[]J
M                    !RW2JVP       +(\WVEM        '^,5EKGD$R
M                       !V7:LJM            </I*ZEP
M                   !UX6SHV    !03>,      #[%?CD           Z6
M-6P&@  !Q:DK<7                      %J1OJ0H         Y;I5;8
M &RRW5FP              !R?2KFP   -KEN?-@          <Y)*I]Q\\
M    ;EKUU:ZA1[5:      /X#163E'9R@L^'D      Z9S5J!?V;0      .
M3DE7:X   %GB;ZZ6@                5WV>&;(     '^I=E;V"4
M          "JDSS 9   ZA-6JF@  .._>_YMU'YOUN;-008A31J%Q(L6IK%8
M:BZ32:A?>>-\K[A?GK])?I>+S
M    ?P>3/%7NOCFG',?G&X6&C4+"XM%AHU#4+BU!!#6*FC6+4+#937J?RM][
M^B/;]2^7H                  ?SV<*.Z>2ZG<F^C"EE05-)I-+5+325-,T
MT:+#6W'&/D]V>FN#@                            #A$E?!@       6
M\6]^U                      Y;I5;8       %D>;[2V@       "OHSP
M>9                          L/S?<VT          #E_)58UC_*
M                          .O"V=&P    *";Q@
M=+&K8#0   XM25N+@                     "U(WU(4         <MTJML
M   #99;JS8               Y/I5S8   &URW/FP         !H!)4PN/P0
M    !72^:[PS6[E         #XV3CO7"MGR%     !T]:M0K_<H      ^:D
MHYW/PB   =!5MSM@               #\Z*0=QY @      [[M=]6@
M         !Y=%'J^/\D   M?-]+E   UCY?P;B]^@?RS"Q-1-&S4$&*E*:BW
M%(HJ;Q6%BZ36[/7O9O7+I+OB5
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M         !K')3AN?C4                               '7A;.C8
M %!-XP                  .EC5L!H   <6I*W%P
M  !:D;ZD*         .6Z56V   !LLMU9L               <GTJYL   #:
MY;GS8         &J$E/G6?B)     -N5LCS6]EH           ^2CA SPUL_
M)0    #LVU91:       K2,\;F0  /\ :KN.=^ZV@               <TTJ
M?L       ;!K=CF_]J                XGLUPV0  /7EN^3?Z5   ?YIPF
M_2/Y%\@^_P 6-PU#6,J:-FH(,0T4WB19 MB:AJ%Z.]5=S]+NI>XP
M                              !_!Y,\6.Z^,:<\Q^9#4-8J:-0L-PIK
M$AHU"FH:AK%8((:Q:-0L->I_+\O>[H?W_4?E[                 YS<_\
M?Y$=J?96FC1HJ5G2:-% *FDTFEJEIKUCY7KV+^AN"?TY
M             #A$E?!@       6\6]^U                      Y;I5;
M8       %D>;[2V@      #5^2F[<_*H        !E6\DUU%7H=&U-O]0
M/'HT'3F=9S)3Y-         /7;;G>=>J6@        ?CQ3IN-04
M  'MJ[FKLN>T2^C5_:?F)YBOB::PFFEGE,@              Z\+9T;
MH)O&                  !TL:M@-   #DPG!!D     #7ZS\J       /<U
M^C       +'TUT8M         '+=*K;    V66ZLV               .3Z5
M<V   !M<MSYL         >:Q3?N-?4    '])WEFN]:_IV@            :
MCR5<[G5=     +*4WV:M      &CJ4]6   !8,:[P-                55
MV>7;(  ']Y_    "WG-[\V@               4V&-.D   [DM6(V@   -*N
MP.K>3'>'YJ*#1N&H:QE39HU!B0&C4-0L618:B7I5U+W;T?ZJ[@
M                             '\'DSQ9[JXMIWS+Y>*PU#4-8M%-8J;A
M36*PIJ&H4UBU"P0N*PT:]3^7Y.]?0_T_4OE[                YZ\\]WCY
MVO\ 6PM!HIHT:-%9J:B:-2H!4TFRE[ ]6<9Z'\$^*
M          !PB2O@P       +>+>_:@                     <MTJML
M     "R/-]I;0      /S)*=EFG+(        _0KKO-=PY=HK0      /B(X
M_,\,;/&4        '5-JTRT        !P#9X'L@         #;9>MTO3A=D+
M0   !@:IIS'3D>FM2             =>%LZ-@    4$WC
M_9K827VU?O#[)/X#SA?!TV;EM3W0          I4L:TH      !<*>3>(
M              '+=*K;    V66ZLV               .3Z5<V   !M<MSY
ML        # JBL\T&0   !Z MIZ:Z'6@             #Y22L59RS9    '
M[9<3;V^4     # I8LZR,@  ;-+=2;               'F$E'G6/R(   L/
M3=>;6/\ *   .O+5G-H               :F24QK@  !5T3.]J+0   /Y=8X
M._I;\=>7_9XVFX66@;-0U#6,J;-&H,2 T:AJ"*BSI3U+W?T?ZI[A
M                               '\'DSQ:[KXMIWS'Y0A<5AJ&H:Q:-0
ML-&H4UBL*:AJ&H6&H6"%Q7T;YWE[H]&_4]X^%Y0             !BG,7LCW
M>5G9GT(:-&C0*4IHT:-%9J:B:-%D!KT?YWAL9]"<,_6\<
M               X1)7P8       %O%O?M0                     .6Z5
M6V       !9'F^TMH      '":9KV7(        W\:LI2[/6@        ?+I
MPBDX5ZS^9        BK:&=]';0       -:$IA,_CH         -_FN^LN_-
MH       _P 8YRIP)LTI9            Z\+9T;     H)O&
M!^L=#FND:[Y1M%;^B              "E2QK2@      %PIY-X@
M        <MTJML   #99;JS8               Y/I5S8   &URW/FP
M   ..$E:*X    'LJVX&MIU               '\Q7,9XGL@   #:NZN2YU^
MY0     '"5FO:R   +B4\F[5               <36:XK(  'IJWA)JIO9SV
M9   ^M6\=-?8V@              5UF>'C(  &ZJW%VP    --N>]7\D.\_R
M_A;#14V4T#9N&L5B:31LL&)"E-0U!THZF[MZ/=5=Q
M                    #^#R9XN=U\3T[YC\O%2C%86&X7%J&C4+#1J&BXK"
MPT:AJ&H6%@_=\&^QG3WTMX^#^V             /GO.XX]N^YHYS3VISM+,T
M4IHT:!2FBFC92LU-1-RL+V*ZIXYT'X+\H
M   <(DKX,       #;M?0                      #RPU70       61YO
MM+:      /"TI6L_,H       /[2PI-]Q*_W4          :8R57KGP)
M   !LZMSZ:_1M       %45GF:R        !Z_;9%FNI"@        #_ "3D
M@5S6?.4           Z\+9T;     H)O&           !ZRO;J7L2UZA0
M             I4L:TH      !<*>3>(                 '+=*K;    V
M66ZLV               .3Z5<V   !M<MSYL        >-24LKGX5    /6+
M;?N=;+V@               # K=L\6F0   !WZ:[Y-      >)24BKC^4
M[0-63&@              *:#.H3(  ';1JQPUR?2KFP   +.$WU\M
M       'YL4@=8\CD   LHM]FU     _RLX@_HO\@^%\DX4;Q7&V&C2:-%!L
MW#6*QG1HV7$@A2F^D_4W=W1WJKN(
M       ?P>3/%SNOB6GO,?DPL-8J48K#4-0N+4-&H6&C4-%Q6%AHU#4-0L+O
M9P7W.M_4OT?L/3V           !JUR;7&SMWVO)OJ^20U#4-,[F:F4I39HH*
M4T:-&BI4U[;\;U[#/1'%?ZL@                             !PB2O@P
M                                      !9'F^TMH      K#L\BV0
M     !].6H9OI):           !Y3)4TLTT9       %FF;[!V@      :42
M4ZM80        .@S5H^:]7H          #Q*2K!<Z/H          .O"V=&P
M    *";Q@          ?WG<::[SK]A:                 *5+&M*
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M?'=K>,>F                              !PB2O@P
M                       !9'F^TMH     &L\4M[X_XP      #]LMCS?0
MJT            #X*2H99J&R      !L2MU:;_MH      50F.:"
M#KJU9EFOTJ            _ BKQ<\N60         .O"V=&P    *";Q@
M      #V];3K6\"@                 "E2QK2@      %PIY-X@
M          <MTJML   #99;JS8               Y/I5S8   &URW/FP
M    -0)*:^L?Y0   !9U;Z[J                  /B)*;=SK<@   '71JS
MPT     !RGDJUW    M3S?46T             "N*SQ-9   W-6X^V!6Z9XL
M,@  ?Z5=BF]AE              JO,\M&0  .KK5H]H      <L.Y_SEHSV3
MTM!!"&I:-8KA=%-)N%E2FS>*Q-1*;-%Q.DW4W>'1SJKN4
M                        ?P>3/%[NOAVGW,?CQ=Q;$J:A<5A2P0L-0UBU
M#4*:AJ&C4+"XJ:AHL->E_,\W1GKKW]].!^Y]AZ>P       ->.03G-V%-&>;
MW^'>BII-3+,U#1J6LE+"FDW$U,U,I31HT4%+O5PKT^TW4'Q0
M                  !PB2O@P
M   !9'F^TMH     %9AGCTR      !%6?L[ZWV@             >*R4W+GR
M!       +5K?3]0     -:Y*5FL?Y0       !UL:L[M?T@            '
MYL58KGF$R         .O"V=&P    *";Q@         ;0K;B:]I4
M          "E2QK2@      %PIY-X@                 <MTJML   #99;
MJS8               Y/I5S8   &URW/FP       *IS/,1D   #JHU:8:
M                 &E$E/76/Y(   ']A=0GDV0H     ?/E'2X\^D   Z:-
M6N&@            !^.4>6/,4   LHM]FU T\DIK7    [XM=^V@
M    !YK%'C6/Q)   +;$WT4M      'S_L^EPM_2/XR\]^M\ L-000AJ6C6*
MX713::*#1LWBL2Q-&S?27J;O#HWU5W*
M          /X/)GB_P!V<+T]YA\4W#:ZQM2IJ%Q6%+!"PU#6+4-0IJ&H:-0L
M+BIJ&C7Z/CWMMQ+VMR>&^WM5Q7V?3?F>0    ?Q;FO/(,:C\MQI+S2>'?:DY
MU*FC1314TFIEF:AHUDU*PIHU$U,VEF4IHT:^Z]+%B+H/X/VGJ9
M                     '")*^#
M      %D>;[2V@    #S(H_WQ_@0      !V$:LT-               <]$J
M0L8       Z(-6W&@     *[S/#1D       #>^:MRK^Q:             !
M\Y)4 N=-4         Z\+9T;     H)O&         /?UN%S?L5
M          "E2QK2@      %PIY-X@                 <MTJML   #99;
MJS8               Y/I5S8   &URW/FP      !K')2TUC_*   !Z MU.;
M]9H                   "N(SQ.9    [0M62V@     *V#/&)D  #],O#3
MR>IT            !R[2JNP  !]);>*SO[Z@!328U 0  #WU;L[7]"@
M       <6DK<,   >XK=PF_ZZ       UPY9P/C)^@?R+_/K&-A34+!BA2RT
M:P:QM*;312E-F\5B:B:Z3=3=Y]&NJNYP
M          !_!Y,\8.[.$:>\S^*S8FC<-KJ%AI+"XK#0@AK%8:AJ&H4W"PT:
MA87%34-&H:^_^?Y?<OA^;UCY/F^\]#7[G@W_ *1_'N_)>WGS?Z,\<^QGPK[F
M?Q_-36*PT69J96=2T4T4T5-)K*5-&C4M2L++4-1-)N<V5E>Y/3'R]QN)>L
M                             !PB2O@P
M              !9'F^TMH     XC)7,8       ]A6ZC-_=4
M    *R;/']D      ?[U=VSOV^T    #^2*0=QXT@       ](6YVU[2H
M           &O,E,NX^-        !UX6SHV    !03>,        #Z$N*3>V
M]H                   %*EC6E       +A3R;Q                  Y;
MI5;8   &RRW5FP              !R?2KFP   -KEN?-@      "N(SQ.9
M  L5-]PE                    'GJ4F6?.T   'UZWB)O[6@    !I3)3I
MN   !8\:[8-             5/F>:C(  '6IJT$T !Q52MZP   +=4WT"M
M           IR,:7(  !WC;L$J       !S@[9Z"YY=K=!+K"3 Q%&H6#% :
MEN%Q:QM*;B:E2FC<-0UTEZD[UZ,]5=T
M          #^#>>,/=G!]/N9?%C2)4L39N+HUBT5+BL+#0@AK%J%AJ&H:-0L
M-&H6%Q:+#1J&H7%J""&L5-&L6H:AHL-0L-%F:9U,LM%-&BFDJ:RFDL-2U+4K
M"FC4371OK[UNN_5/H@                               #A$E?!@
M                                  "R/-]I;0    !3>8TT0      "
MS&WV)4               #QR*35Q\V@      L8-=O&@    -#)*@UP
M  !9S;Z\J               !Q62MXP        .O"V=&P    *";Q@
M   6+&^X"@                   "E2QK2@      %PIY-X@
M      <MTJML   #99;JS8               Y/I5S8   &URW/FP      /
MQ9*.ESYP@   ]C6[/-_14                    !P69K^,@   69V^PJ@
M    4MV-6T   W'6Y*V            /((I WQ_P   %NR;Z 6@ ><Q1XOC_
M     #KDU9Z:            &J\E+K6)@  95=:SO9"T       #^>XXY]^?
MD_6GE_6^--:A<;,(QL*:A8,4!J6X7%K&U=,Z-%*:-]).I.]^C'57=0
M                                 _@WGC%W;P;3_F'Q(6+8TB5-1-&X
MNRXM%2XK"PT(7%8:AJ%AJ&C4+#<*7%8:-0IJ&H:Q6""&L6BPU#4-0T6&H6&C
M4RLZRE-&BFBFDU,LYT:A9;E979+CN>]W1GH_H8
M          #A$E?!@                                      "R/-]
MI;0    / I*2&L(      'O2W7YO].@               !6]9XJL@     #
M?QJW@T    !7;9X;L@      #<I;C;7^Z@               ?PI3%N=6Y
M      .O"V=&P    *";Q@       #:=;FDU^C:                    *
M5+&M*       7"GDWB                 !RW2JVP   -EENK-@
M      #D^E7-@   ;7+<^;       YFR51;@   "PBUW;:
M       'G$4?]>/YJ   !T,:MP-      <,IFO!<@  15T+/DVKH
M   #AHS7>9   V(6Z]-_[4  *MS/*1D  #ZM;QTU]G:           !7A9X8
ML@  ;X-6_&@        /EO<^=Q1_0_X]\O\ L\9A,4QIK4+BF!C8:+"XD(66
MC4-8VXJ:39H%Z1]2=]=&>JN[
M   !_!O'&/NW@NG_ #'X4-)J%C5BHE3431N+LN+18EA8:A1"XK#4-0UBIHUB
MIN%-8D-&H:A36+4+!"XK#1J%AJ&H:+#4+#1J99SI-2IHIHT5-3+.=&O2?G+!
M/0_K>@>A                                 .$25\&
M                          +(\WVEM     XNI6U8       L*-=V&@
M              -6XI;Z\:      /TR]3/)]A0    IF,:C(       +7<WT
MQM                 Y1)5P8        Z\+9T;     H)O&        +3\W
MU-M                     I4L:TH      !<*>3>(
M'+=*K;    V66ZLV               .3Z5<V   !M<MSYL      "LDSR 9
M   'Z=7@\^3U:@                     *Q3/(AD   ?H%YJ;]"M     '
MCD4@KX_XP  #N>U8=:            I<L:LH  !8':[RM   <\4J0L   "S4
MWV"4           ?P12'N/&D   LV-]@%         'EWV..<5_T-^._D_>^
M5#4+"8ICHNH7!,3&PIJ%Q(0LM&H:PMA32;+TDZD[[Z,=5=V@
M                          #^#>.,G=G ]/\ F7P8:+#2:A8U<:2IJ)LU
M%W#4*EA86&H40N*PU#4-8M%-8M&H4UBL*:AJ&H6&H6"%Q6&C4-0L-0T:A8:A
M34YLS4S13131HOTWJZ[[=$^/WCX<
M '")*^#                                       %D>;[2V@    55
MV>7;(      _UJ[[GR>U4                 *:#.H3(      ML3?12T
M #SV2BW<?X@      &Q:W66OZ%                 _-BD=<>+(       .
MO"V=&P    *";Q@       >]+=EF_P"V@                    *5+&M*
M      7"GDWB                 !RW2JVP   -EENK-@
M#D^E7-@   ;7+<^;      &!1\8\90   =+FK7S0
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M1<5A34-0T:Q6%@A<5AHU#4-8J:-0L-0IJ<ZF69HIK]7Q:[M='W:7C
M                           #A$E?!@
M            "R/-]I;0    *-['D:      #=%;C;8
M%?EG@RR      ._<UWQN@   .>$E2*X       '?UKO>T
M  !7DF>%UR       .O"V=&P    *";Q@       =[6N_P"T
M         *5+&M*       7"GDWB                 !RW2JVP   -EENK
M-@              #D^E7-@   ;7+<^;      &L\4J[XP   +-S?7Y0
M                 !^=%&:X\]0   =J6K(;0     '+*2K!<   "VLWT64
M         "M:SQE9   Z/M6S6@   .!;/ =D  #*KK^=[%V@          5:
M&>53(  '7=JSJT          !KSRG@G'WOK\D_C>QZ<+"14-0L&*08ZJW%<4
MP(L-&L2%ADLM&\5QMZ1]2=_]&.J>\
M        !_#Y,<9NZ^O]/N9<>-1;#2:AHU#26+8MQI-1*FS<74742I86&L5*
M,5AJ&H7%J&C4+#1J&BXK"PT:AJ&H6%@Q6%AHU#4-8M%-0U"PJ:F:_3\6NXO2
M?EV^XEH                                  <(DKX,
M                          61YOM+:    /#XI!WQ@      =UVK"K0
M               '.B2I5<      #IXU:P:    X<)7:8       %SV;VOM
M                 TH2G4P       .O"V=&P    *";Q@       7,)Y-O*
M                     %*EC6E       +A3R;Q                  Y;
MI5;8   &RRW5FP              !R?2KFP   -KEN?-@     #D/)6+N
M J\+/)[.                       56F>7#(   W/6XZV     !^')1VN?
M.$   ZQM6B6@         !\Y%'6X^ 0  "U$WU*4   #P62DIK'^$   =[&K
M #0          \\BCKKQ_@0  !;S;WY4           :[\IX'R [Z_)'X_L^
MF7&6""*AJ%@Q2*QM6XKA<XD!HUB00A9:-](>I/T!T6ZJ[Q
M                         '\FL\>NZ.O]*><\9C.H:-1=0J:AHU#26+K&
MHI-1G1HW%U%U$J6%AK%2C%8:AJ%Q:AHU#4*:AHN"FH:+#4-0L+!BL-0T6&H:
MQ:-%AK]OP:[C=(^UMIQ38                                  '")*^
M#                                       %D>;[2V@   #G"E3%@
M    "U2WU#4                 #R:2C9<      #9);K38   %9=GCVR
M    ![(MXAL                  ?RQ1@UCSR0      #KPMG1L    "@F\
M8       ]:6\:U_JH                     I4L:TH      !<*>3>(
M              '+=*K;    V66ZLV               .3Z5<V   !M<MSY
ML      5S&>(S(   V)6[&V                       .)#-<ID   ?NVW
MOIO]$      K=L\5V0  /IK;R&=?;6@         <HDJX,   >HK>#;_ &
M   5)&>=S(  'O2W:6_Z0         #C+)6MN   -AUNOS?^U
M :\\HX'R"[Z_)'XOL>EC2V%B6%Q14-0L&*8U%JW%<$PL*4UB0D!KI%U)^@NB
MW57>8                                       _P ;.5/;?!>>W9'#
MS4349L-&HNHFBPT:AI+%UC44FHSHV;BV&H5-08M0I8(6&H:Q:AJ%-0U#1J%A
M<5-0T6&H:A<5&*PU#18:Q:^V]+R=SNC_ 'MC^.>0
M               <(DKX,
M61YOM+:    .*"5PF       -H5^M@                  :9:D0     !^
ME5\Z>3^P   %1)G0!D      #J,MJ9L                  "I<SSD9
M   Z\+9T;     H)O&       .GS5JYH                     "E2QK2@
M      %PIY-X@                 <MTJML   #99;JS8
M Y/I5S8   &URW/FP     !4E9YVL@  #JLU:6:
M  &AR5!&    +K4WLE:     !II%-Z^,   6:IOL%:         !4F9YV,@
M =O&K&#0    '*5*MK    MQS?0FT         "G@SI$R  !W_:[VM
M       :\\IX'R$[X_(_X_G]3&S&L;8HU$L)B*AJ&L4A,:BU=8I@86%+#4+"
M=(>I/T%T6ZJ[T                                        Y^]B<3Y
M3]N<!_DWE::B:C-AI=0U$T:A34-)K&V*BU+&=&X;74+"IJ%Q6%+!"PU#6+4-
M0IJ&H:-0L+BIJ&C4-0L+BL$+#7MWQ//W(Z/^GZS\K8
M                 '")*^#        ZK->YP                     !K
M37,QD       61YOM+:    *ZC/#YD
M   "[]/)[=0   I4,:U(      !WY:[YM                   5Y6>%K(
M     '7A;.C8    %!-XP      !WV;[[*                     !2I8U
MI0      "X4\F\0                 .6Z56V   !LLMU9L
M   <GTJYL   #:Y;GS8      I/L:YH   ._37?)H
M    ><11:OC    MI-]&E      %,%C5%   -^&K>C0         \-2D=<?S
M0  (JY_G>UUH    'X,E'BY\X0  #K4U:":         &L4E+#6$  #_ &J[
M;GR>\T             ->>4<"Y"]\_D;\?S^F6&L;,:QTA2Q+"XHMQ4N)"8U
M%K6L),3"PIJ%Z0]2?H/HIU5WF
M    !K9R?XW&WNSK;X#W_4+%+349U$U#2V&HFC4-0II-8VQ46LV)HW#;6L53
M26%Q6%+!#6*FL6H:A3<+#1J%A<5-0T:AJ%Q7>#A'N]C.G?I?O^#0
M                            X1)7P8       %O%O?M0
M         .6Z56V       !9'F^TMH    J]L\EV0
M              +D$WN9:   *)EQ\-(      !:&F^LUH
M   ''"2M%<       =>%LZ-@    4$WC       %HR;ZP6@
M        4J6-:4       N%/)O$                 #ENE5M@   ;++=6;
M               ')]*N;    VN6Y\V      *&;'SZ   "T"WUK4
M                "B8Q\,@   LTM]@U      '#U*ZK   '^E79\^38&@
M      .#;-?=D  #=5;B[8     %<%GBBR  !].MXZ;^WH        "O8SPF
M9   Z$M6XV@             !KURG@7(?OC\C?C>?TL0I8:QLPTBC42P8D$6
MPIK%(3"EK6L),#$5T@ZD_0G13JKO4
M        #XOWO6Y%=R==ZC<RX[$L2EBEL-,ZB:AI;#431J&H:*FL;8TB5+$V
M:-Q=8VII+BL+#0@AK%J%AJ&H:-0L-&H6%Q:+]!Z_EZU]2_7W[X#[H
M                              X1)7P8       %O%O?M0
M           .6Z56V       !9'F^TMH    J9,\X&0
M                +;K?0]0  !0;N/YY       +=TWO]:
M    !S22J P      !UX6SHV    !03>,       6_V][5
M        I4L:TH      !<*>3>(                 '+=*K;    V66ZLV
M               .3Z5<V   !M<MSYL     #XJ*)%\8   %NAOH(H
M                 %*]C6-   !85:[KM      #R62C[K'Y\   =_FN]S0
M       _R2E2SK<@  %E=OLJH     &H<E,^X   %F6;[#V@       #^.2D
M9<^)(  !:%F^L]H              &O7*> \A^^/R+^1Y_4@@Q"FH,*QTBH5
M-08D$6PL+!"84UJ%Q3 Z/]2_H/HGU5WL
M           !":1<\XQRM[;Z^^/]WU\6HEB:$4NHE3434-+J&HE-0U#2:A8M
MC2)4U$T;BZ-8M%2XK"PT((:Q:AJ%AJ&C4+#<+MCQ/W^P'3_VO4OE^4
M                               #A$E?!@       6\6]^U
M             Y;I5;8       %D>;[2V@   "HDQH @
M                 %JF;ZAV@  ?*Q0]OC       %R6>3<>@
M       -%9*?MP      !UX6SHV    !03>,       73V]G5
M           I4L:TH      !<*>3>(                 '+=*K;    V66
MZLV               .3Z5<V   !M<MSYL     #Q:*/E\8   %R:>3<:@
M                     *>S&CB   #N^U8-:       JBL\S60  -CUNL-?
MZJ       !H@E0)@  #Z=;Q<W]U0      ILL:<H  !O4U<":        '.J
M2I1<   ?=+>-FOI;0              !KURG@/(GOC\A_C>?TC1J"#$*:Q,:
MQTBH5-0N)"1;#4+"0F%-:A>CO4OZ#Z(=5=Z@
M               #Y+W/7YB]J\$T.[!XA_/J&L6HFHE$6K8FDL34-+J&HEAH
MU#2:A8U8J)4U$T;B[+BT5+BL-0HA<5AJ&H:Q7T[YGL]6NJ/O;K\)^A(
M                                 .$25\&       !;Q;W[4
M              #ENE5M@       61YOM+:    *AS&@B
M                   6D&^KB@  ?)11 OC       %T*>3:J@
M        -,HIP7Q@      =>%LZ-@    4$WC       %X*>3VJ@
M             *5+&M*       7"GDWB                 !RW2JVP   -
MEENK-@              #D^E7-@   ;7+<^;      \!2DBP   !=,>3:
M                      J/L\\V0  !VZ:L9-       <ODJJ,   "X+-[S
MV@       5E&>/S(  '7)JSTT      !Q<9K;,@  95=6GDV4        *N;
M/)]D  #LBU9;:                &OG*> <BN]_R'^+['I00T4U!B0%-8F.
MF-14-)K%(6+(6&H6$Q3'3H[U+^ANA_5?>H
M              'CGVOF\QNU>!Z?<TXSA1J%AJ)J)1%+J)I-8RFEUBTFH:+#
M2:A8U<:2IJ)HW%W%L326%A8:A1"_9^E['2?K3[W0KKSZ_P"KXM
M                             #A$E?!@       6\6]^U
M           Y;I5;8       %D>;[2V@   "H<QH(@
M               %I!OJXH  'R440+XP      !<WGDVUH
M    #26*=M\8      '7A;.C8    %!-XP      !>:GD]2H
M         "E2QK2@      %PIY-X@                 <MTJML   #99;J
MS8               Y/I5S8   &URW/FP     / 4I(L    796]AU
M                  J3L\ZV0  !VI:LAM       ?CE'ECS%   .R;5EEH
M      ?))1Q8^.   +>4WOU:      !Y[)1VUCYZ   .\;=@E0      !\'%
M'.X^;0  "X;-[OV@                :^<HX!R+[V_(/X_L>E%N-L$-%-08
MD!J%@QTQJ*-1+B014+#4+"=&NI_T)T.ZK[V
M                'B?W?E\[NRN%:6\XXM^=Y<%-0U"QG4*(U2Q-)K&:*NL6
MF=1=%AI-0L:N-)4U$V:B[BV)I+"^J?*]SHAUS]W?;@/V/V_!L
M                             <(DKX,       "WBWOVH
M          '+=*K;        LCS?:6T    5'F.>B
M               6KF^GR@  ?E%"AXP      !</F]W;0
M   .?R5%&       .O"V=&P    *";Q@      "\^\GIH
M      !2I8UI0      "X4\F\0                 .6Z56V   !LLMU9L
M              <GTJYL   #:Y;GS8     '@TE(RX    N=O)MB
M                5%&.?R   #N3-6([H       5QV>);(  'WRWCF_H
M    #D2E8E@  #8U;K37^J@      "KLSR<9   ]T6[;-_UT      !QPDK1
M7   &SRW2V\P                 :^<HX!R-[V_('XWL>B6%QUJ"%A318,2
M%+"PN&I%14-)<5A(J&H7HSU-^A>AO5G>H
M              'Q7O>KHYSWB>D'/>*>+?<^4:!J&H7'.BJBTL32:QFC46PT
MFH:-0TEBV+<:342IO]+Q>;;GB/V=\. _;VOXC]/_ 'E
M                        '")*^#        MXM[]J
M     !RW2JVP       +(\WVEM    %4]GF&R
M          !;JF^@5H   H7W'X<@      %KV;Z7V@
M<J9*M-P      !UX6SHV    !03>,       7GWD]-
M    *5+&M*       7"GDWB                 !RW2JVP   -EENK-@
M           #D^E7-@   ;7+<^;      \HBC5?&   !</F]W;0
M              *:C&GR   #OXUWP:       &H$4TKXP  !::F^J5H
M %0UG05D  "P:UW?:        Y\25&K@   6WIOH=:      !3Z9T89   L-
M-]TE                  &OO*.O^1W>WY _']CTL2 L+CK4&*E*:Q((#4+%
M85%1;"Q+"P19T8ZF_0_0SJSO8
M       #Q/[OR]0.:<9U-YAQWP/D/Q_\-"EAJ)K&4JHM+$U$U$T:BZB4U#1J
M&DOU/J^QM-Q7[&WG#?L[=\/^Q]-ZOE
M             X1)7P8       %O%O?M0                     .6Z56V
M       !9'F^TMH    K2,\;F0                                 +
MD;R;D@   H[W'C<@      %DAKM(T                  !PP9KQ,@
M =>%LZ-@    4$WC       %Y]Y/30                     "E2QK2@
M    %PIY-X@                 <MTJML   #99;JS8               Y
M/I5S8   &URW/FP     /RY*%>L?YP   +74WTRM
M    I#L>%H   +&TWVVM        IF,:C(  !TF:MC-      #7E*3MQ_G
M _K+O$\GM-        ?SI2=9U]0  #K&U:):      &M92IOCQ@  ?V%WN>3
MV6@                  -?>4=?<CN]_Q]^1Y_3+"XD!8NL;8,5*:+B00I87
M&L:QI;"Q+!T7ZF_0W0OJWO<
M      #YGVO!KGR;XFOG(_C^%\@^1XS]OYOFOU/1_P -2&HFL92JBTU$U&;#
M7[O@]GU_XWT/;/A?3]^X]]/8OC?U?</@^_\ [R@
M                      #A$E?!@       6\6]^U
M    Y;I5;8       %D>;[2V@   #@:SP%9       ^U7]R
M             +E37N-H   IJL:>H      !VG:LBM
M 5D&>03(      '7A;.C8    %!-XP      !>?>3TT
M     I4L:TH      !<*>3>(                 '+=*K;    V66ZLV
M            .3Z5<V   !M<MSYL      47V/,T   %DEOM&H
M             _/BAG?'^>   "TM-]5K0       .)*5R6   /[R\#/)ZY0
M    ' )."#   '2=JV*T        !P1F> -R  !](MXR;^\H     "OLG!Q@
M  #I*U;':                    U^Y1U]R0[V_'GY'G]/&V%+BL$!8NL;<
M2%*:+B00I8:QLQK&HM-=%^I?T-T)ZM[W
M                  _@\F//?I>I\+[_ *GQ_O>M^#Y_%_'O,&4?J>+S_3>K
MY?L_1]KT/YWN?:>CYP
M    !PB2O@P       +>+>_:@                     <MTJML       "
MR/-]I;0   !R2DK 7       %BAKN(T
M *J+/,%D      #=VZN'S0                  %,9C4Q       .O"V=&P
M    *";Q@      "\^\GIH                     !2I8UI0      "X4\
MF\0                 .6Z56V   !LLMU9L               <GTJYL
M#:Y;GS8      IN,:;(   .VK5C=H                       :V12FOC
M   N&3>\%H       'ED4>=>/\R   +%LWV_M     '\Z4E;GP60  "U3-]0
M[0        /"XI(:\?\ -   %EV;['V@    #^8I)L>$(  !:A;ZEJ
M              -?^4=?<D>]?QU^1Y_3C5Q6%A2XK! 6+K&W$A2FH6""%+#6
M-F-8Z=%NI?T1T)ZM[X
M                                                         '")
M*^#        MXM[]J                     !RW2JVP       +(\WVEM
M   &F4E."X       Z6M6OV@                             !7B9X8,
M@      ?J5>FSY/LJ                  \RDHS7'^(      !UX6SHV
M !03>,       7GWD]-                      *5+&M*       7"GDWB
M                 !RW2JVP   -EENK-@              #D^E7-@   ;7
M+<^;      %6UGE*R   -^&K>C0                       Y=,U6&0
M+T$\GIE        "J@SS"9   V[6YBV     .?$E1JX   ]66[_-_KT
M    *E3/.AD  #>5;@[8     Y[25'+@  #TI;P\U^W:
M    !K_RCKWDCWM^-OR?-ZAN&HMQJ%A86%@@+C=1;B0IHL+!"P%AK&SHIU1^
MB.@_5O?
M                                              '")*^#
MMXM[]J                     !RW2JVP       +(\WVEM    'S<41[X_
MSP      ?4+>;F_J:                              Y%I6'8
M%JAOJ(H                 ').2K_<       #KPMG1L    "@F\8
M O/O)Z:                      4J6-:4       N%/)O$
M     #ENE5M@   ;++=6;               ')]*N;    VN6Y\V      .#
MLS7UN0  !]A;>KSO]&@                      *[K/#5D   >Q+>*;
M      YE252+@   7-'DVX     *O;/)=D  #N*U8G:          Y7259+@
M  !5U7.]E[0    *OS/)1D  #M:U8_:                      U_Y1U[R
M1[W_ !G^3['I,Z39N+K&V#%2PU"0L!K&W&V"%-%A8,0I>B75'Z(Z#=7=\@
M
M                                   #A$E?!@       6\6]^U
M                 Y;I5;8       %D>;[2V@    4W&--D       M"S?6
M>T                             #562E[<       #J8U:@:
M          J:L\W60      !UX6SHV    !03>,       7GWD]-
M              *5+&M*       7"GDWB                 !RW2JVP
M-EENK-@              #D^E7-@   ;7+<^;      '.N2I/<    7"9O>.
MT                      "FZSIJR   .ES5KYH        #\M*/S/E"
M=P6K%;0    ^%BCE?'\T  !5T2;VH4         #\.2CU<^:(  !W<:L(-
M  #XJ*.-\?RP  !<IF]P[0                     !K_RCKODEWO\ C+\C
MV?2-,U-)LW%UC;!BIJ"%Q :QMQM@A31J"#$Z)=4?HGH-U=WT
M
M                         !PB2O@P       +>+>_:@
M       <MTJML       "R/-]I;0    *ZC/#YD      #=]JX:T
M                     !_+%%VX\_0      #]:KNN=^PV@
M    :_24GKC^4       '7A;.C8    %!-XP      !>?>3TT
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M'I&S1IG2:31N+K&V(QM-0L&(6%BW&V"&BFH.B/5'Z*Z"=7=\@
M
M                         #A$E?!@       6\6]^U
M       Y;I5;8       %D>;[2V@    <ZTJ3L       "W%-]"K0
M                      *I#/,ID       =RVK$+0                %
M;%GC"R       !UX6SHV    !03>,       7GWD]-
M    *5+&M*       7"GDWB                 !RW2JVP   -EENK-@
M           #D^E7-@   ;7+<^;       IYLZ/L@  #8U;K37^J@
M              <44K@L    7'IO<ZT         :F24QK@   6R)OI):
M!3U8T=0  "R]-]CK0          -2BF/?',   6UYOHK:   !4%8T-0  "QG
M-]N;0                       / .4==<DN]_Q9^1[/H0T;-&RLU-ILWC;
M"XU"FH6#$+"QK6)!#1>B'5'Z*Z"=7=]@
M
M        <(DKX,       "WBWOVH                     '+=*K;
M   LCS?:6T    #\62C7<_ H      !MTMR.;_OH
M         <:$K5,       #Z5;JDU[G:               !K=)2ZUC\F
M     .O"V=&P    *";Q@      "\^\GIH                     !2I8U
MI0      "X4\F\0                 .6Z56V   !LLMU9L
M   <GTJYL   #:Y;GS8      '!Z9KZ7(   %O2;WXM
M     IJ,:?(   /8%O"-?T*         !388TZ0  #JLU:6:   &LA2NOC0
M /JUO%S7VUH           IP,:9(  !U>:M'-   #7>*3U\>   /U2\)/)ZG
M0                        \ Y3USR2[W_ !5^3Y_2$74*;-FBLZ32;-8W
M46XD*:A<2 L+%N-L+T/ZH_1?03J[OP
M
M      <(DKX,       "WBWOVH                     '+=*K;
M LCS?:6T     5D6>0+(       L'M]W5
M  'CI1]>/^<       '3MJUBT               /\DJ3)SQ9        '7A
M;.C8    %!-XP      !>?>3TT                      I4L:TH
M!<*>3>(                 '+=*K;    V66ZLV               .3Z5<
MV   !M<MSYL      #6B2E5K"   !U":M5-                     #1*2
MH!<    =H6K);0          XJ25OK@  #Z O'3R??4  !7J3A0P  !UX:LZ
M-            <8DK8,   ?1%XJ;] M   X!)P08   Z?M6K6@
M              !X!RGKCDCWQ^)?R//Z4SR3="&H4V;-)I*SH\AK&V+<2&BP
MN) 6%QUKH?U1^C.@75W?@
M                                                        '")*
M^#        MXM[]J                     !RW2JVP       +(\WVEM
M   &A\E0.X       'Z1;HF]\K0                ,#\B3]JT
M "HNQS[0       "S/-]A;0              .)*5R6         .O"V=&P
M   *";Q@      "\^\GIH                     !2I8UI0      "X4\F
M\0                 .6Z56V   !LLMU9L               <GTJYL   #
M:Y;GS8       ITL:4H   /]:N;YWMA:                    !4Q9YPL@
M   7#'DW@          !YF4=[X_QX   LN-]D%  '\*4B&?&$   M]S>^-H
M          'P$4=M>/YN   +*LWV7M  '^"4F6? $   M=S?3&T
M                #P'E'7/)/OC\2?C^Q\_%34O),TJ&H:-&S25-,[-PU%L+
MC4-%A<2 O0WJG]'= >K^_0
M                                                        !PB2
MO@P       +>+>_:@                     <MTJML       "R/-]I;0
M   !@4RV-2D       'IJV_VMH%                _P2N0GB!:CE_JM
M       ')>2KW<        ?OK;M:W@4             #GQ)4LUG\V0
M   #KPMG1L    "@F\8       O/O)Z:                      4J6-:4
M       N%/)O$                 #ENE5M@   ;++=6;
M ')]*N;    VN6Y\V       ./B5EF    .D[5L5H
M <_TJ)7$P   -L5N=M@          "JTSRX9   WK:N M  #F_)4SN   -E%
MNIM?ZJ            *OK/)5D  #=UJX>T  - )*B5P  !ZY;=^SO]*@
M                     !X%RCKCDGWQ^(OR/8]&&H,0W,W-T6%AHV;*FDTS
MHW#474&-L*7$A>AG57Z.Z ]7=_
M:?\ .. ?TYWM'P_FWZGA\P
M                    '")*^#        MXM[]J
M !RW2JVP       +(\WVEM      Y(25@K@       #V%;;<UMA:
M      !\[)61LY1LCMPU8T:          'X<4A[CR=        /1EMQ36XEH
M            &D$E22Y^-0         =>%LZ-@    4$WC       %Y]Y/30
M                     "E2QK2@      %PIY-X@                 <M
MTJML   #99;JS8               Y/I5S8   &URW/FP      !\W%(S6/*
MI    +6DWTXM                   'X\4U;C55    +,LWV'M
M  '-:2IY<   95==SY-C:  JQL\KV0  +";?=E0            .?\E1.X
M 5=/SO9VT "L2SR)9   [CM6)6@                          !X#RGK;
MDIWS^'OQ_/Z,S9N%A<0\DS4W186&C9LJ:9J;-PU&M8D+"EZ%]4_H_?\ ZO[^
M                                 U%YOP'CQWK^=/Y]Y_:];W-H^'\Z
MVPX5SS:3AW./N/G_ $0        /D?<]7Z[T_:
M                         '")*^#        MXM[]J
M      !RW2JVP       +(\WVEM      _/*6[&M:        ?=VV@LZZ7V@
M             :YR59[G3= !8[;[8J          .$#-?)D        ??K:J
MFN@=H           '-&2K;<?)@         '7A;.C8    %!-XP      !>?
M>3TT                      I4L:TH      !<*>3>(
M  '+=*K;    V66ZLV               .3Z5<V   !M<MSYL       #A(S
M7N9    ]B6YQ->I6@                  5]$X/,    >W6W8<[_=H
M      ?G12#N/($   [XM=^V@!YO)1WN/PP  ?W5=ZF_9%             _
MQBE!<:\(  !W8:L*- #Y"2CC<_((  (JZ'G>U5H
M      '@7*.MN2W?'X>_&]KY^,J:ELW!B0IY)FY4N-IHV;*FF=)LW"Q=8U"]
M"^J/T?O]UA^@                                -;^5\.XM]_?FC\SS
M>"+"IK%<IY/9_@<FV2XGS/8?B_+O>N-\J]+^1];-0   !_G9X[]SXNL7+>):
MJ\RXAT"ZS[+VKX?RP
M    <(DKX,       "WBWOVH                     '+=*K;        L
MCS?:6T      <N)*K5P        ,SM(U81E^TM            _BCC'<U[4^
M.0 #^DM53?3FT         #X>2DMK'FD        #^^N_N=]TJ_N4
M  #\>. USPIN?\H          '7A;.C8    %!-XP      !>?>3TT
M                I4L:TH      !<*>3>(                 '+=*K;
M  V66ZLV               .3Z5<V   !M<MSYL       #Y"2D_<^1(   !
MT6:ME+_8H                 '.R2I?<?S    %EAOLHH            KN
M,\-F0  -@UNQS?\ M0'%E*W+   '2Y;7S8             '!=FOVR  ![.M
MW=K^Y0.1"5BF   -TUN,M@                            >!<HZVY*]\
M_AK\GS^E%N-)8FI;-PN*0TFYNYE6XJ;-&S25G2;-Q=0O0CJK]'[_ '5_Z!
M                             \3^_P :XE?H7\O?.>UZ134+C46%36+4
M+%U]#ZGO^N?#Y#Z=\?[?WGSOJ_5^E[WZ?B\Y?Y[/F?<]'X/Z/S_*OL_&\8^]
M\+YKVO3_ *<>7L3T9WSN!PCFH
M            '")*^#        MXM[]J                     !RW2JVP
M       +(\WVEM      &!4A9YZ,@        >RKWS:Z^R_KT         !_
MDG-2*_%SJ4@   ^G6WA-;JV@         <1V:Y;(         W(6QJUO>H
M      '.>2NA<ZM(           .O"V=&P    *";Q@      "\^\GIH
M                 !2I8UI0      "X4\F\0                 .6Z56V
M   !LLMU9L               <GTJYL   #:Y;GS8        X^)668    '
M;!JQXT                 -6I*?5SYZ@   &URW+F_T             :KR
M4NM8F   +?#>^B@4W&--D   M7S?3VT             #Q"2D9<?R@  %L]O
MHZH%1!G0)D  "R<WV>4                             >!\HZUY+]\_A
MO\7V?G)J6H7&HE34MF\2%A4W-W*EQ:-&S1IFII-F^A'57Z1W\ZP_00
M                       'F7UOB<0_T/\ EGXCZ/RX(,5*4UBL5"+4WBL+
M%TFDU!%N-%32;-_[9\O7OH_OC<_@?/0
M                  !PB2O@P       +>+>_:@
M<MTJML       "R/-]I;0      -=9*8]S\J@         ]JM[)R]<)??[0
M      /+).4YQFUG5>0    #UBVXC-;!J         /RY*:-SJJ@
M BN@TUVT7I OZ8     !^!)S$.)UFCS(            Z\+9T;     H)O&
M      +S[R>F@                     %*EC6E       +A3R;Q
M           Y;I5;8   &RRW5FP              !R?2KFP   -KEN?-@
M     #^=*@C.BR    #O:WW_ %                &N<E0W6?$9    /]:M
M\3>]Z@            "G(QI<@  '81JS0T-3(IBZ\<P  /65N_M?J*
M        *F3/.!D  #JLU:6:'@,E):X_R  !^_5XK/D]#H
M               #P/E'6W)OO;\._C>U\S"S&DU+4+B0J;ELUB00TGDR:+%L
M-&C9HTS4WT(ZI_2N_G6'Z#                             ^,][YO$7]
M$?E3R[[7'\94T;-008AHIK%8L@6Q-0U#46II-0N-D6_Z9\G6WI+OO=_K[L0
M                                               #A$E?!@
M 6\6]^U                      Y;I5;8       %D>;[2V@      #C5)
M6HN          !E6W\O1-=YEVZE]SL_U4   >/QJ39I&G/E-&+/XH      &
MSZW!IOT>@        !I!)3\N?Y4          'I=O2>7?U=S%V0CZ&@ /D8U
ME33$Y]V<Y$^(0             =>%LZ-@    4$WC       %Y]Y/30
M                "E2QK2@      %PIY-X@                 <MTJML
M  #99;JS8               Y/I5S8   &URW/FP        -9I*:ES\N@
M  [:-6+9?Z[0              -0Y*FESXT@    [8-6/&@
M.+[-;-D  #[=;R$U]+;729X@,@  =RFK$30              '+5*KK   '[
M]7BL^3T.N!R<!&   .K35I)H                              #P3D_6
MW)OO?\-_D>QZ$5A<X:D$S2:QU8B%3<MFL2%A3R9318MAHT;-EZ$=3_I??SJ_
M]"@                           ?@>SZG%']"?E3Q#D?#S1N&X7&5-FC4
M&) :-0U%018:B:A8:BZ366==7>E^^-[>NNRP
M                        !PB2O@P       +>+>_:@
M      <MTJML       "R/-]I;0       *N3/*!D            ?16^XQZ
MA7U\OZ9^<?)IYF>)'R"         #?9JVS-?NT         *_"<&F
M     !_K7I2^@'^\?R'FM? )C                Z\+9T;     H)O&
M   +S[R>F@                     %*EC6E       +A3R;Q
M        Y;I5;8   &RRW5FP              !R?2KFP   -KEN?-@
M   #CJE9U@    #I U: E],M              Y5I659^10    ;9K<5FOI+
M0             /.HHZWQ_A   %HQOJ7%'^Y\H0  *NEYWM#:
M   !^-%'NX\P0  "R@WV7*4#.NZ   6UYOHK:
M        /!>3];<GN]OP[^-[/SAB19A<X:D+,VFL:BHFIFC<-0L$-3-RV(MA
MHV;Z$]3_ *9W[ZO_ $,                          !^=Y/#QI[^_+.M7
M+^OTW"RT#9N%AK&5-FRP8D!HU#45"11J)J)KJ=TYWQOYUIVD
M                                     !PB2O@P       +>+>_:@
M                   <MTJML       "R/-]I;0       /EXJ#W.F;(
M                       '6)JT)-?[4        !_!)4=N=!$
M                      '7A;.C8    %!-XP      !>?>3TT
M             I4L:TH      !<*>3>(                 '+=*K;    V
M66ZLV               .3Z5<V   !M<MSYL         "LXSQV9     ]FM
MLLYUTMM            'G4E=.SD'<S     ]!MN,YULE:              !
M5E9Y6L@  =&FNS*U3&   -XUN$M@               5SF>(C(  &ZJV)9JH
M+<   >X+=PFO[+0                               /!N3];<H>]/P_^
M/[/S\+G&R"#&S#4QN869LN*XTFIFC<-00L-3-RVJ&H7H3U/^G-^^K_T2
M                     !_A<<B^]/S+J'SOJN%PMAHJ;*:!LW#6*Q-)HV6#
M$A2FH:@QLZ>=0=[=#.K^V@
M           !PB2O@P       +>+>_:@                     <MTJML
M      "R/-]I;0       !Y*E/QG7!                           +"S
M?=90        !Y;)3MN==T                               Z\+9T;
M    H)O&       +S[R>F@                     %*EC6E       +A3R
M;Q                  Y;I5;8   &RRW5FP              !R?2KFP
M-KEN?-@         ?C25+[GGX@    $5TPFK"LNU%H          _(CCLG ?
M6?*Y     /UZMH9WT%M               '.&2IC<   ?U5NQ-:.L@  696^
MPZ@               :HR4P-8F   K>V:T29   [PM6"V@
M                  /!N3]:\H^]/P]^1['HPN-F%SC9!!C9AJ8W,+,V7"U$
M-3-FX:A,0W,\DM*Z#]4?I[?OJ[]%                         0G+3N;\
MZZ*=E=*0A9:-XKC;#1I-E*#9N&L5C.C9HN)!"EZ3]3=X]'>JNX@
M                                         .$25\&       !;Q;W[
M4                     #ENE5M@       61YOM+:        !X3)45N=<
MT                          ]'6X'-;16@         :VR5 [GR%
M                         !UX6SHV    !03>,       7GWD]-
M                *5+&M*       7"GDWB                 !RW2JVP
M  -EENK-@              #D^E7-@   ;7+<^;          'Q*5(F=)D
M   '^U=.)KM0UO\ I_NH       'ET<AK.*3/A2     #^NK2<WU.4
M         #^%*1#/C"      #ZY;Q<U]G:                *=#&E2
M  #*KJT\FR@                                 /!^3=:\I>\_P_P#D
M>Q\Z+<;8MP9QU,4@@QLPUG&R&IFDUCIB)J9LW#4&(;EOH3U/^G]^NK_T6
M                     .<W:W1'.3MK\^E-8D$(:EHUBUC4-&DT:*4V:AK%
M8SHV:+T4ZK[LZ6=2]T@
M         #A$E?!@       6\6]^U                      Y;I5;8
M    %D>;[2V@        #QB2I;<ZF(                        !]^MMV
M:W0M           U-2I&SY"@                     'H"^U+JJR
M.O"V=&P    *";Q@      "\^\GIH                     !2I8UI0
M   "X4\F\0                 .6Z56V   !LLMU9L               <G
MTJYL   #:Y;GS8          'P<5,KC1Q      ![LO3Y>C,N\A]W:    /\
MDUIEY^V<SK.>TS^4      ?IU:$F^JJ@                5YDX6,
M#L U9L:                 XTR5J;@      ;V+< ;
M                 'A')NM.4_>?X?\ Q_/Z,)%F-L6PN&LX60D&)%F&LX46
M9I-8:1!J9LW"PN)T)ZG_ %%OWU?^C@                      !HSV/T[R
MZ[G_ #5AK.$86%+#4$$(66S6*X7132;*4ILWBL3703J_NKIUU!WC*@
M                                            #A$E?!@       6\
M6]^U                      Y;I5;8       %D>;[2V@         ?#15
MQN.;2                        >Q%LR;V^M            UN2I8SKN@
M                   'TY;8F^%EG--D      =>%LZ-@    4$WC
M%Y]Y/30                     "E2QK2@      %PIY-X@
M     <MTJML   #99;JS8               Y/I5S8   &URW/FP
M  !\M)5SLYD,@      #_6MB)=GE]T/5#ZE?ZS\:/@+/'S7<U73X!
M!]NMJ":Z*V@                #6*2EAK"      +@4WO5:
M    !\(E'1GYE      +-+?8-0
M/".3=:<J.\_PY^3Y_1AJ%Q3&R+8MA<-9QLQ9A<3'6<+,;$U+4+"PL34MFH7H
M1U/^H]^>K_T<                      -).P^H>6O='YE_SN,:BU=8I@86
M%+#4$$(:EHUBN%T4VFBE+OAUIW1U*Z:[\R4
M                          #A$E?!@       6\6]^U
M        Y;I5;8       %D>;[2V@         #^63@Y9P-9_B
M            !N&MK&:]XM             \MDJQ)H%<@
M    ?9K:]FM_+:G[/--D      =>%LZ-@    4$WC       %Y]Y/30
M                "E2QK2@      %PIY-X@                 <MTJML
M  #99;JS8               Y/I5S8   &URW/FP           /YC@(SP<N
M?\H                    V:6U<UM(H                  IX,Z1,@
M #9E;J#>8                 *P;/(]D     ?5K>.FOL[0
M                      !X3R;K7E5WC^'/Q_8^=%&H;@Q3&R+8MQ7'6<+F
M$A<3'6<+,:2RW"XU$J:EOH1U/^I-^.K_ -(                     #2;L
M/I_EOW/^9/\ /4A36*0F-1:UK"3 QL*:A8,4*66X7%K&U:F]X.N.X>K'2OZ(
M_P!%                                                    '")*
M^#        MXM[]J                     !RW2JVP       +(\WVEM
M         &D,E8ZYUB0                    #*NT$U8H7Z)0
M    /X). ]G"1/Y4                  'N*VNVMP%%3]GFFR      .O"V
M=&P    *";Q@      "\^\GIH                     !2I8UI0      "
MX4\F\0                 .6Z56V   !LLMU9L               <GTJYL
M   #:Y;GS8            '.]*Q;/BZ                  !77W.K'R_8V
M@                  <:I*U%P     +#3?=)0                 -!9*A
MMP     .NC5GAH                                    >$\FZTY5]X
M_AS\GV/0Q2"*-PUB0F-D6Q=8V868V0SBL&.LX7.-J:F:BW&HEZ$=3_J;?GJ[
M])@                   #2?L/I[EWW/^8_\Z@Q((MA86"$PIK46XR8&-A3
M4+!B@-2W"[G]?=O]9.D?TA_K-
M                  <(DKX,       "WBWOVH                     '
M+=*K;        LCS?:6T           #\*.&=SPFN?E8
M   &Q"V4VNB*@               :0R5G+G51                 !T8:L^
MR^KV@5/V>:;(      Z\+9T;     H)O&       +S[R>F@
M        %*EC6E       +A3R;Q                  Y;I5;8   &RRW5F
MP              !R?2KFP   -KEN?-@            #S^*\]SQRN?\(
M              V#6R/-=(K0                   /@8HYWQ_.@    _0J
M[[GR>OT                 !_DE*5G7)     +>#>_B@
M                     >$\FZSY6=X_AK\CV?12I<;((HW#6)"8V1;%UC9A
M9C<P8D5A<XW.-J:EJ%Z#]3_J???J[])@                  #2KL+I[E]W
M+^8_\=8QTBH5-0N*01;"PU"8IC36HMQDP,;"FH6#%-P^!=M];>C?TS_1-@
M                                                  #A$E?!@
M    6\6]^U                      Y;I5;8       %D>;[2V@
M     >-2<&K./5GX4@                 ]!7NNO;27Z"T
M   #\N3BZ<%;GS-               !Z MAEKL;+_M0 J?L\TV0     !UX6
MSHV    !03>,       7GWD]-                      *5+&M*
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MPU"PF*8TUJ%PLQC&PNV?!NU^N_17Z>_JSY
M                            .$25\&       !;Q;W[4
M         #ENE5M@       61YOM+:             !XU)Q8LXYIY6@
M           ]I7M4O9Q?O5                   ^(DXM5Q.9\@0
M      ?O'9)KO6OJ*@ "I^SS39      '7A;.C8    %!-XP      !>?>3T
MT                      I4L:TH      !<*>3>(                 '
M+=*K;    V66ZLV               .3Z5<V   !M<MSYL
M :-2<,+.:%S_ #0            ![2O:=>SZ_>J
M!XW)3,N?*D   'H5MRW.O?;0                  /P8IUW&HJ   #^TMR3
M>_=H                                      \+Y-UGRP[P_#'Y7F^?
MC=86XU%J6%B2*BTUBU!BS&D76-N*87.-D$$5A<8:G0;J;]5;[]7?I8
M           :6=@]-\P>YOR_A8:@Q("FL3'3&HM+$N)!%0L-0L)BF.BZA=G^
M&=E]@.A_U/\ W>/S
M          #A$E?!@       6\6]^U                      Y;I5;8
M     %D>;[2V@              ?CG-.3E!9S=L^8D            'T5O1^
M7KC+TH7]*@                    /QI.7AR!LY[W/\L           >R+V
M&7M#+[#:   *G[/--D      =>%LZ-@    4$WC       %Y]Y/30
M              "E2QK2@      %PIY-X@                 <MTJML
M#99;JS8               Y/I5S8   &URW/FP               !X+)R*L
MY2)JZ@          ^BMZ/2];5Z6Q^E:                       -/I*H%
MSXF@  ]9MM<YUNU:                   !XM)4ZN=04  'T99S;ZK*
M                                   /"^3=9<L>\/PM^3Y_GFDUC;A;
MA2U-00D$6F\5A,4C2+K%<;,+G&R""*Z!=4?JC?7J_P#2@
M TN[!Z:YB=R_ES_+2"%A2FH,2%+"PN&I%8U+42XD+%D+#4$&R7$>Q^PG0WZL
M_2\7G
MX1)7P8       %O%O?M0                     .6Z56V       !9'F^T
MMH                ^:C0"SGHFAJ:C)^:        #_ 'K:27?1>B"]#8^P
MM                        \FCFI9SE30=/*4        V'7HLO4"7H O]
M]    "I^SS39      '7A;.C8    %!-XP      !>?>3TT
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M3Y_GQ46I4UA;CJX45-00F(M-8M8I%D5%UBN-SA9C9!T"ZH_4^^?6'Z5
M          &F'8'3/,7N7\M_YW,!87'6H,5*4UB00&H6*PJ*BV%B6%A(K8?B
MG8O8?H3]7_K>'V0
M         !^1'Y(       /H:_L                      /SX_"
M !^RGZEH                  ^>C55-5:UN3P8\;/*3Y!/C(^?H?KU]7'V9
MZ>>P+[P;&+M)&W:_:4                           ,#7B-0+-64UU/$#
MR9/A:^1/S8_L/JJ^[CUH]RMV/C;-=TH]JM      'S\?Q       _0K]T
M  ^2@       ?46?ZJ                     !\P?XP      !]$?UT
M              /SX_"   !_M7TX               /SH_#   !_0?2T
M                !XS&K5FO,>)6>5GPY\V?G'[\?:5]X>OGO2[,QLVOT=
M                           ?D1B?LT                       !^?
M'YI]%0                                          \,Y+UCRT[P_"
MOY7G]#%8,:6I4UA;C;AH5-00F-&H:A<4BR+<;87"YQU.@'5'ZFWRZP_2H
M           TQ[!Z7YD=R?EC_.R&BPN) 6+K&V#%2FBXD$!J%QK&L:6POO7%
MN?=C.@_UK^UX/;
M
M
M
M
M
M                                                \-Y+UARW[O\
MPK^1['SX7%8:A,:6II+A;A;CH5-08I%&H:A<4BS&V+8MW^ZI_4N]_6/Z3
M          &F78'2G,KN3\JXK#474&-0T7$A8"Q=8VP8J4T7$@@-0N->V<=Y
MOV/Z!_7GT'K>Z
M
M
M
M
M
M                                               !X=R7K#EQW;^%
MOR?/\Z*QTA<5A8,:6IJ)<=7"W&C26#%(HU#4+BF-D6[^]5?J;>[K+]*
M       #3+L'I'F7W+^4<-1-,Z31N&HUK$A84N*P0%BZQMQ(4IJ%@@]BX_S3
ML?T%^O\ Z;U/H
M
M
M
M
M
M                                                 >'<EZPY<=V_
MA;\OS?/&-D:8U"XM08D:%342XZUA6-&DL1C9%&H:Q6$W?ZU_2G03JK]1_P"L
MV          (313LS\^\Z^VOR]_GK)HV;*FF=)LW"QK6)"PL+"P0%BZQMQ(4
MUZS\+F'9#H']@_5^E]0
M
M
M
M
M
M                                                       #P[DO
M6'+CNW\+?E^;YX QJ-3&L5AJ#$C0J:B7#6L:QM*EQ2"*-PNPW$>W.F/3?[#^
MN]'[8         ^?]GYW,_N3\GZE\[Z13<W<RK<5-FS1I*SI-FXNH7&H6%A8
M6" UC;Z=\;EG9#H#]C?9>A]<
M
M
M
M
M
M
M #P[DO6'+CNW\+?E^;YX $$5&IC6*PU!C44:9L6X76%1:5-8LP17T7I_;W]Z
MK_5&WO >]_Z,^0       8LZI<YZ;YR=N_E+XGZ7'C>)"PJ;F[E2XM&C9HTS
M4TFS<76-L1C::A8/1/D\F['= ?LO[KYWVP
M
M
M
M
M
M
M            /#N2]8<N.[?PM^7YOG@  01J16%0U"XD6Q85G4-8:N%1:E2X
MV0>B?)YCNWUM^D=J^#=W?L^#W@    !_!Y/!JUS?IG1CLS\X>.\BX!"XD*FY
M;-8D$-)Y,FBQ;#1HV:-,Z32:-Q=8VQ'WGS.2=B^@/V;Z#\S[X
M
M
M
M
M
M
M                            'AW)>L.7'=OX6_+\WSP   ((U,:QJ%AK
M$BHHTS<;K&W"HM2PL2?I>+W]B.(]N;#<3[8]JXYV+Z5\?E_]WC\X _EWXO./
MK<4\6Y'U[KURWJO6CF74'SWN?(PN<-2"9HUBL$*FY;-8D+"GDRFBQ;#1LT;*
MS4VF_M/G\A[$= _M'TCY/(P
M
M
M
M
M
M
M   /#N2]8<N.[?PM^7YOG@    01IC9C4-0N)%0&DN-UA;CI"I86$@S>7Z7T
MON?M^K],U^'[7S?EO=^)_CY/'C;BF%SC9!!%F%SAJ0LS::QJ*B:F:-PU"P0L
MSR2V(NH4V;-?6_.^[V&Z!_;'J/QN4
M
M
M
M
M
M
M           >'<EZPY<=V_A;\OS?/      BHK&S&H:Q6%BR*32:QMPMPT*F
MH(3&BF\5Q2+(J+K%<;,-9Q2"#&S#4QL@F;+BN-)J9HW#4$+#4S<W8AKZ;TOL
M]@^@/V]ZU\/EX
M
M
M
M
M
M                                                       'AW)>
ML.7'=OX6_+\WSP      (K&R*QJ&L5@QI:E36%N%N.A4U$19C18;A<4BR+<;
M87&S"YQL@@QLPUG&R)9;-84B&IFS<-0F*FOHO3^SU_Z"_;_L?P.;
M
M
M
M
M
M
M                                    >'<EZPY<=V_A;\OS?/
M  BL;(K&W%86#&EJ5-86X6XZ%34$)C1J&H7%(LBW&V+<&<=3%((,;,-9PL-3
M-)K&L:34S9O]OUOJ=>>@OW%[9QWG@
M
M
M
M
M
M
M             'AW)>L.7'=OX6_+\WSP        ,;(K'2%Q6%@QHIJ)<;<-
M7&BIJ#%(HU#6*PD68VQ;"X:SA9"008ZF%SA8:F:36&G['K?2ZY=!_N7W;C78
M8
M
M
M
M
M
M                                              'AW)>L.7'=OX6_
M+\WSP         ,;(TQK%86%Q(T*FHEQNL-,:-,V#&R*-0U"XIC9%L6PN&LX
MV8I!B8ZSA9C9^EX/>ZU]"_N?8'BW98
M
M
M
M
M
M
M                'AW)>L.7'=OX6_+\WSP          ,;(TQJ%Q:@Q(T*F
MHEPNL-(M*EB,;(HW#6)"8V1;%N*X:SC<PD+_ &>+V^KW1?[=V+XEVH
M
M
M
M
M
M
M                                         !X=R7K#EQW;^%OR_-\\
M           019&F-8K#4&-0+4U$N&M85%)HN*011N&L2$QLBV+K&S^CQ^?J
MCT?^V-E>']M
M
M
M
M
M
M
M>)<CZTY=]V_A;\3V/E@           ""-2*QK%8:Q(J*2IJ&L-7"HM2I<;((
MHW#6)"?VX]KJ/TE^U]E.']L@
M
M
M
M
M
M
M             >4?<X'RY[M_"_R'O\;             $$:F-8U#4+B144:9
MN+6.KA46I8EA(J*^@]3[74WI#]M^[\9[)
M
M
M
M
M
M
M                        ^,^AQSF)W3^(/(?O]<@             ""-3
M&L:AJ%Q(J*-,W&ZPMQJ+4OI?Q>;=2^D?VUZ5\CEP
M
M
M
M
M
M
M                               '\._5Y_=K?DS4+G_YT
M    $5%F-8U#6*P14!I-8V[0\)[SZ/\ 3_Z^_:\'T
M
M
M
M
M
M
M                                  !KGRWI_G9VY^.?DO?XZ
M        !%8V16-L+BL'[_J_9Z%]2_KS:S@_>(
M
M
M
M
M
M
M                                'X/L_+T0[/\ ROJ+S_\ ._\ E?&
M               (K&QK6TG!N^>@'5/ZR^K]+[@
M
M
M
M
M
M
M                                   \N^UP?0SM'\J:[\MZ:
M         'NG&.UM].KOU=[)Q_L0
M
M
M
M
M
M
M                          >0?>Z^TJ['_-&MW,>E?\->$
M  9-;"<2[@W5ZX_3/N/&^S0
M
M
M
M
M
M
M                      !\7]'CFJ/.>A-6.<=$>>?6X8           /M_
MF\JVCX1WIMEP3O\ ] ^7RL
M
M
M
M
M
M
M                        0GE/V^"ZZ<OZ;\"Y5U-X]R#KG^/R>J
M /Z,^QZU\#L'WWBW;&Q7$>X_8>/]A9-
M
M
M
M
M
M
M                                    #^#R>MY3]S@?E/W>!>:_9X5\
M%]3BGQ_T.._->[\+\CS>E_%Y/6']6?/^QZ_O?2>G]SZ_T.0?=_+Y5Z3\;FGJ
MGP^>^M_"Y]^GX?=
M
M
M
M
M
M                                     '__Q  T$   ! ,&!0(& P$!
M 0$    $!08' @,(  $P-T!0$146&" V8! 2$Q07-2%PD( Q(B/_V@ ( 0$
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M  !%8+6FY26GQ8]K1F#3*K1T6YI:]M&Y/7/5"%0Y WB<VAY<V,>FW)+9*O\
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M/%WJ:RD1S5)>9.:C2(V2JB!*Q-^=::UXQ>=)J*ZG<[=%TA0BM"#P PK%Z/\
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MM;E^W'C6&M.=K[SHN1'W1OO"Y0P-6A!X 85B]2VKE?/[$<]QI:4"S9LR?-L
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MUD:-%2:2)J^""&7#X5:9S8U%N:6K17HW;7ES8QZ;<DMDJ_R@P&:S8V"LC*?
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M9(25_]H " $# 0$_ >AD2YDTW94M<Q6I"5+/@D&)-@6Q/:Y03DO_ *8)D?\
MC*1$K<=:J_UBZ60/XIBEJ\)<M2<-+K'5$K</IG6CVIE4[ZOKKFCK'ZO4>J)>
MXJS1^LJ*R8>I4I"?#@E'/^+JZX1N2L1/O4\V9_/43A_X:Y<)W.6(C*SY1_F5
M.7_SS#XYZWA-BV.DN+-H_P#%(0L>"@1WF$V79:2Z;-H$G6FCIP?A+C^CK/\
M_0:/_P"%D?\ T1_1MG$,:"B;_P!ED9:OU<?T19)!']&6?B&PHZ<>!3+!!ZP7
MTO!L&Q59V;2X?NHNY_RD?&%;EK!7_80G!G14522.MN&NOJO PO<78J_=];E?
MR3P?_$ES,OSB9N$I"_ U]0C5PDN5-[/<X%]#Y?'";N#JP_ 5],O5PLN;)?\
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M%0^^\/#]</%Z+T/O/ 5%Z']AX"H>'WGAX>',/#P\/#F'AXO0\/#P\7H>',/
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M.VO?>']EX?V+T/OO#[WI0L?U>T*:V)2&EUZ. J2!@*J0GB*)US:=@-? +/\
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M]>VF+QV B\=@(O'8"+QV B\=@(O'8"+QV B\=@(O'8"+QV B\=@(O'8"+QV
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MO.8#J*4@8D@ :R2S1)EB3*ERA]1"4^ #GM)QZ;Q!<8&)$^_Q5>\/^*'WGB]
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M1=5VI.D'J^>ORG2ER5E"QV'0H:Q]@-S7_P"R4'\DW_QYN]>A_8<PXWGB]OO
M5%[?K/ZW5?\ M$[_ ,173)R[Q\^8C+HXY';2.8C+O/R_OL5GX>7,-78/+H4Y
M';2.13I[OGT"<CMI'(IS\?+^\=]YX>'B] 5J,7]8@*&N'AX>'AX?>>+T6*?_
M #K0?^T(^PYUP\/#P\/#F+T=\/%Z'W[T!4/ 5#[]Z J'&_-E)G(NK_PG2D[9
MC3$V4J4HI4.PZ%#6.G]S9_\ ,E!_),_\>;#CV'AQ[#PXWG,7M]X"HK/ZW5?^
MT3O_ !%=,G+O'SYB,NCCD=M(YB,N\_+^^Q6?AY<PU=@\NA3D=M(Y%.GN^?0)
MR.VD<BG/Q\O[QY@X.;,EN_!K6A\GN**7;0[.Q/5C#P\/O/#P\/ 5J,!>OX0%
M#08>'AX>'AXLPM:- =5;2GPGRS^7V((;$90\/#P\/JAX>',/#ZH> J+V\\/
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MJH6S^KRILWL)3P0ZG^EP['T/O/#[SP^\\/#[[P\!4/O[JYO!V)5#3-7(E_\
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MY@Z8JZ4R3?1C*^*#J/5J.C(XYN(>'AX>'WWAX>'AX>'B]#PYB]#P\.(>+T/
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M\X4P2"5*X%*O6)20G%1F4YF74 %YJ9>& B]#]?C#F J J']AX"HO1A^<-O/
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M_P G]T5;1(3=III%91,S>JU"E%*0S-P,Q,R0S?LKV$!47H?8;SP%0%0X]AS
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M_'RZ!.1VTCD4Y^/ES1WY)GZ%;3MM^?)CFX_'H!7EAMW\@G>.7QY$9?#;;1T
M>0&7;RA 4"" 00000X(.8(T@_&-WVYI6YFWI\J5+:SJZ]5V<H9)DJ4.%I?=
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M^SJ$%4I3X)643?>EIA:)DM2Y<Q!0N6I:%RUA25H6DE*D+2H7DK27!<!0(ND
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M@,N\_+E3EV[?=S #H(_GMM\>>G$])MS,?8I6?AY<PU=@\NA3D=M(Y%.?CY=
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M7CL!%X[ 1>.P$7CL!%X[ 1>.P$7CL!%X[ 1>.P$7CL!%X[ 1>.P$7CL!%X[
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MCCRIJ'1,01,EDN'O/&V.\Y_* J+T!48?E&/;\(O$9X=N(@+U_" 1H.^^PB]
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M?]9^K+H:V8K^TY(IJE2OTG]5-_2+BZGI52DH2I:U!*$@J4I1 2E*0ZE*4<
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M]Z//1],MQ<NU[7EJEV-+4#3TZ@4+M):#W%-(DX+6/U[7$87E!*4RTI0A(0A
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M:6F29TLJES9:D+0HH(,,.SLACK!^$/KPWGC PVHPY&</#P%0^^\/#"&,.1G
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MW/%$REL.15U*+I%9:A-HSKZ<IB4U-ZGDK&=ZGD22X!S 8 ) 2D!*4@!*0&
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M0(  Y(%1RS4^+ J/-B4I$J4$CB3 S]=*N+=/6?9$\74#9[:\+MO]Y8_OF_\
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ME*05*42  !F22<@ ,R3ZZTDTR4YSEC@ZREO-#U^DD+7N*+4^@C^?'25^BU
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M)0.8,CEBH/+'#RL5%:7V&LVUB+8Z3<,W!&]"C[DH_LK)03MZ:!L3^^%E7?\
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MN)^#<!PLXMB3-M!YD>ZW*AZ+""-83N+AAM)&8*YW&DI2D!*0$I2 E*1L  @
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MX]+%61PU;5:OQ>3_ *TU^3AD>_8JZO\ HK5+7WJ?>W[X]E,_D_P5LRZ[?/\
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M]Y0\(MYS0=G/L3L=&].0= U500E2;6Z8O6&KJU<2\P\D*0XG,*'XI4DY*2H
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MU!J3OJ:FIXU%0>2>YJ/94>4TPT/U.=Q7"FNCFY>6;8ZF]5Q;H'H>DZT.IFM
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MK%"$GWM/I>3@5'+-3Q%1PK,5(J.!J3OK*H-3QJ:QO'+3 [0W%P=9Q4IMK=)
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MH>M2UGJM-IVK<6>JGUDD)"E5CV.W6.WA?=)1;H)%K;3*&6SQB IU< N.1),
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M?S"U>B-O-+Z&70+<DUA^)V6*,\_9/I=3 UT;'&E'T76STD':!/15M0I2<S\
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MV9BG(:<$BHY5NBJBHXS#2SKPV,U99,'#D52K2W9LZ4>=U]XKK^"V ^2TRV/
MRRV@M--H@-B(HB>G0@3=[4<...>%AWO(@J7E/TXC5$'7B<B&NY>LN7<.FKNT
M>J4F6U-@RAS-/M7M^$!B2(;3H+PN,N"#C9HHF*$EO0\B=.D-1(<5LGI$A\T!
MIIL.9$2_[$YDMA%%5439ZBT G8.'4)0=>3.U,K%E\I[R28@KS;B61QSRI?,8
M[/IR/.@27HDR*XCL>3'-6W6C'M$A_F)/)(;B2**JBLT:O$S!Q%9 9/1N)6/E
M8Y"Q-^ZAW5'?KD71289_DPW\/X;<;D5[5J9,LCD>CW2R@/FO5(;^0N9J*7U]
M#=16$=D27G7Y#YDZ\\\9..NN&N8W''#52,R)54B)555Y^G]_$595,D&/?&DN
M'E8E"B9=XV64^CRP3ZW( 5Y(#HNM<&S-6HTD7V'$1'6U5$D0W[7.++:155E]
MN^J+<3'*ZT3C)@X7H215:O+:APHPW<=<7FOF--"G$Z\XO"TTVA&X6@ILK#>\
M@8?CN7ATW/J\0W09D]1T<D$B\#?$S%%<C><]X^]Z>$P(@,"0A(5RD)#J)"2:
MHJ+JBIJBZIM'PYBZ2(3N!FG5EXK#.)2R!&GFN@2UN(M2BL,GD^HR+'(_DP9&
M&,+2?[J:M52JL%]C>PXD-P?^L.QY\5^ ^0"],NL13)5(B52(B55(B5;JJJNJ
MJJZJJZW^\$:C2SSM.6;G4]TBZ+/81?(=1/)<"ZDP^*9V35?*;)QMQJJTIVZ+
M8)<0U3I,"3:Y1Y IR5.;;B>#>;LXVMN7H*36*Q)2-#C)^-U]U;[N-&;NBO2'
ME2S;:?A&9 V!F*.R?@M+BF?>VEMDJML"JJF^?7D_-,+(X]9!%.!D&P4D+[P8
MV%\6R[@N1BDUJ027;70&X-1=7F"Z)'FN+F$EW<DE!1=;_DOY&%\+R;U-<S-5
MJK):4U%T.'#-/^L/->>']H^0'PRZQ%55557557555>U?O#;JM*<TT;FPG%7H
MT^->Y,/BG)>:LO(F=@^,=,XDU5:4[HM@EQ#5.DP)-KE'D"G;VMN)X-YNSC:V
MNB>@)52J$AN+"ALD_(D.K8&VP_\ 4B6PM@-S<,A !(R1%5_PC%'AJ;=)@*7D
M-KH4I]$X5ERK(3GE;H<C D2 IG]X<7"F*9/@^"/1JN\7UKS6J?/<+]RY!%E$
MO@M&'EW60VOY+UW#6'9"=_G@RSYC>O>AAT+H#1<DJ+P$*@NO1&EWFCY,D"JJ
MJJJMU5=555YJJ]JK]XK=5I3FFC<V$XJ]&GQKW)A\4[>UEY$WC#G$.F82:JU)
M=TT"7$-4Z3 DVN<>0"=O:VXG \W9QM;<NO$XX0@ "IF9J@@ "ER(B701%-55
M=$35=EHM'>),-P'?+&X]]Y;=TZ4::+T1I;I#:+R[=*-$,FP8^\6/A'$LI2EZ
M,T2I/EK(%!X:=+=)=9"6RPWBUD:1S)7]UOOY+OO=3#!S$M0:O&%40PIL8E45
MGO@MT(UL80V23*;J*ZXA-,JT\X^^XX\^\9.O/.DIN.N&68W'#)5(S,E4B(E5
M55;K]X[=5I3FFC<V$XJ]&GQKW)A\4[>:LO(F=ASB'3,)-5:DNZ:!+B&J=)@2
M;7./(!.WM;<3@>"SC:VNB==D8-P_(\"*[NO3V3^NFB\5*8,?W(/[_,27>%>)
MH(/BY]XR$*JBHJ*BHNJ+V*B^O8,.UQ]._P#$:^"R#T6KQ6AU)=$'IT<$\,E[
MR&TZ0ER1^W\ER<Y[(_49&=FDP%763*R^6XB*AI$C7%R2XBCIE: D=>;VEU2I
M2"E3IKQ/2'CYD1=@HG"#8"B VV*(#;8B (@HB?>2W5*4Y=%L$V$XJ]&GQKW)
MA]$[>:LO(F\8<X@TS 355I+NF@2XAJG28$FURCR!3M[6W$\&\W9QM;<NMGAR
MA/IW^FM6F26UXZ1$='F))Y,^2"^!USQFEZ3PF<8MKKJJ\U[5_']Y#$V&^Y&E
M170?CR&24'67FB0FW ).1"27_P#7;PRM,UZGB 52(*Y=YYHSXX<^C2%\H4S=
M'>NT2V5HG/Y+>96:H]N84)I7'%2RN.+R;89!5'>/OFJ-,A=,QDER%+DDBL5!
M5 5\%!AH2DU A"J[J.WRNNJF^Y9-\\1N6%%$!]!Y@9=,?N@;,D_G1-D(:;/(
M52Z$D.0J*GR*C=E3;*["EMK:]CC/ MN5[$"::+KLHF) 2<Q)%$D[=477EKZ$
M;JM*<NFC<V$XJ]&GQKW)A\4[>:LO(F=@^(=,PDU5J2[IH$N(:ITF!)M<H\@4
M[>UMQ/!O-V<;6W+K-F%;?K]0 QID0N)&D3A*H2A_[NP6C8+;I3W@@X D&T_-
MF/N29<ITWY$AXE-UYUPLQN&2ZJ1*MU]!Y&P-PE\T!4BT^0;KLNZI\YS+Y6[B
M/G:][7R@MKV6U^>WV)J7_P!QE?HME0X<H%&^9#CO"HVYYKAI;Y>7H2)6Z6>6
M1%/B;*^ZDL%H]%?1+9F7AT+M%<IAE,!5(E;II>"D)E>8)45V'+!!W\-^W[HR
MI)K:SK9-O!=MP%7^2U556R)JJKHB(G-57U;=ZZ:ZO[':2Z8L**V&I3$N#D\D
M[6DXFX2+R:4WN$I"B/7A6DX>JDMHUL,GHQ,PU7\LD;F(GRW>T[=A*HRJ32 T
MS <AR;)3UV;B-E&*WY8.OR:[(M5Q#5)OK&#'BTX57U*KW?(LO9IE*W:B[)GH
M[T\T_=)U1G&O-5U;8?CQU]2W9[$^6^6/A2@)^&[2XDAWE;Z](:==U[>/7FNN
MR+%I\&,HJI(L>(PS8ET54W8#9532_J^H5MT < O* Q0@+MU$KHNNNJ<]EZ50
M*+)S7S=(I4%Z^9++?>,%>Z:+?FFFQ;["M,#->_0Q>IW._DI3W8R#STRVMI;D
MEB6*M8IA+?(D:<+S8^I%&<Q*<(4]6]0EOY?*RE1\3LNKV,U* ;"?_>8KTB__
M -T3E?MLAD-);JC(+]>I,IJ3F^4(SO1YY)_^:?CMLL:I09<"0/-B;&>BO);U
MMO !_P"SK[=5I;FFC<V$XJ]&GQKW)A\4[>UEY$WC!\0Z9P)JK4EW30)<0U3I
M,"3:Y1Y IV]K;B>#>;LXVMN75WJM/7.XMV:?"%;.SYBBJ@R&BY6TMG?>5,K+
M2*O$XK;9RZS57M],EN9BM?=LMIHW'8!2+=QV L#876R)<E(U(EZZD>#$DS7R
MY,Q&'9#R]FC;0F:_S;"7>3O:T5O"U:0U"M?[J,I'-3Y?@NGX]D*LXFC,\KM4
MR$[*OZ[2)3D/+\GP4OQ::ITMRLU,_.W\T&&E^00A1X[@BG/Z\2WYE;AV3<X6
MIQY>72^D5#^?I[\G-R\Z_;ZUNG1*!1(MK6Z/2H+-LODVW; ^3=;>KLV0&P%L
M!\D %!%/Q"ED3U_46DQ8\A+*-GV6W>%>8^$$M%[4Y;+TK#% ?5?..D0-YK:^
M5U&$<&^5+J))>UETV+-AUJ.:\G(4R?%4.7DMMRMQV<B9)-5LE]=E6G5:M4\U
MOPO%$G,)ZLH;B,]I^%)*^G+55(J56J54D'D$D)%-?-/P11)K&;Y#D"-K\=[(
MIK-PW4":#59$$!J3"#]V3D I"-C_ .+D5.1(BZ;*)(HD*J)"26(23145%U14
M71476_7DZ01G0:D3;-582Y;G6S509!+^&BYE5P12[\?>-6S[D@:?8<!YA]L'
MF76R0VW6G!0VW&S&XD!BJ$))=%%45%M_):K@^DOVJ-19O6'6BXH=.=32)=/)
M?J _7!6Q#"YI:6V:=<!RET:1T0^4^9\"@VY*0/R,F_MVI&%XD^YV!W$U<=D%
MYT.CMHPU?LO.E@;K@KVH,*.7J/85I>'J>V\.54ER&UG3$(?.&7-60^U==5%H
MP"]N'A&WCUCU"'%G1RYL3([4EE?QMO 8+_-L9QH;]#DER=I3R@SF[+PI"/Q4
M#UBP$=53ST778W:%*B5^.FJ-72G5"WJW,APHAV3M&:AFODLI=!V6)5:?,ITD
M?W";'=CN6["$71',"I91,;B2*BHJHO76ZK2G-%LW-A.*O1I\:]R8?%.WFK+R
M>$8/B'3.!M56E.Z:!+B&J=)@2;7*/(%.WM;<3P;S=G&UMRZK+K%5?2/"A-[Q
MPN9DJKE;99#3>/O.*+33:>49(FB:H[4YEVHS=V:; 0KMPHE]!_"?=LCDEW]T
M=Y(+0--AUL(E.A2I\H_(CPX[LEXOQ-LB9JGK6VFP.U=R)AZ,655%]>FS\A=H
MQ(Q[H51.82)C#B*J(H7S91<G,RJ_)1-3J+RMQ4*_-N'%W(6MIEDN2DYK?E9(
MU-@PZ?'3DQ"C,Q6M.7@V  ?]G4"2M42G5 E2V^?C-]*%+6\'+!!E-Z(B>#='
M338W</U*;1G=5&/(_NE!]:".<FYK:+R4SDR+:+D6RYC=*F+5H89EZ91E*:*"
MEU4G(V0)S2"*9C,HVZ']]6VRB2*)"JH2*EE14T5%1>2IUP<$59[5$-S#[[A<
MQ3,X_3%)?N4S/PTY9$>814RQVU_DLY=9DY3>1-Q3HJ_WY4'4+<,Z*B[L<I/2
M"14RQVW%'CR"4NI3WBD3)S[DF2\7,W72S%HF@BG( &P@""(H@HB=:%ML2,S5
M!  12,R71!$4NJJJZ(B:KLW)JJ#ARGE8LTT%<J+@K^]TY" VUTUZ:Y%5+H0@
MXFS;K5-2J3PLO?"KY)CJ&FN9EA0&)'5%\@VF$>%-%>+GU8H=6I\2HQ2OX&8P
MV^"*J*F<-X*[MQ$7A<;RN NH$BZ['(PK..D/K=4@3E<ETXEOH(/\<V*GK4NF
M\D00'96ZY2I$9K-E;F@F_I[Z\TW4QK,RI*FNZ(@?'D;0K=.N-U6E.::-S83A
M+T:?&O<F'Q3MYJR\B9V#XPTS";55I3NF@2XAJG28$FURCR!3M[6W$\&\W9QM
M;71.IORI+H,1XS3C[[SA96V6605QUUPET$&P%2)5Y"E]NCPR<:P[3G"2GQUN
M!2G410*HR1O]<<12&."_M>.N7*CKCZGUKHU"IDB<J$B.O".[B1[]LF6XH1V=
M-4$W,YV7=@:Z;-R<75$YKMD):73")B**_</SB1)+Z6T5([<-1+D\X/-(E&IL
M.FL=H161;5Q4\YYSZX^?X;QF?R]6-:O265EDFE2B_!*B*VL)=):1%>RIY(2A
M?:_P>FSDK#$I*Y%3,70G]U$JC8<["1$,2;9$U4"BNFMA;BDNSL.?%D0I3!97
MHTIEQA]LO4;3J"8K^-.M,2XKIL28SS;\=YM<KC+S)H;;@%V$!BA(O8J;,3[@
M%3BY8M8C#INI@C]> .:1Y@^'8[!\(QF(V#7^2R555$1$NJKHB(G-57U;&$1U
M5H='5V)3$1>"06:TFHV6RWED HU>RC%;8N(FKM^LM3)0K0J,>4TFS6BZ1);6
MVL*$J@XXA"MQ>>)B.J:@XXO#L*TN"CL^UCJL[)(J)W2Q9'<@C&!4T5N*VR!)
MY:&O%UIR/*9:DQWA4'6'VP>9=!>8N-.(0&*]J$BILY,PF\E%F\1=[WU<=I3Y
M=B-EQR8"JN95R])8\D6X[(I?98%<IS\!_56U<3,S(!%MO(T@,S,AN_G-&5EX
M2RDBHG6FZK2G-.%N;"<5>C3XU[DP^*=O:R\B;Q@^,-,PDU5:2[IHW+B&J=)@
M2;7./(%.U.;;B>#>;LXVMN74B;<$3 Q4# T0A,22Q"0KH0DFBHNBIHNS^),.
M,$Y0C)7)T%M%(Z.9+JXVG,J:2_PPU7*7@,I!UANGT:!(J$MS]R8"^0>UQXUL
MVPT/G.O&#8]I;-3L8R.G2.$TH\(R"$WR7++E)E>E+V$VQN&D5+;Q\%V:AT^+
M'A1&4RM1HK+;##:?@-M"(I\MDU75>M)'KM-9EJ JC$I+M38U_P#N\INSH)?B
M5I55DR1-XV>ST_#A'7Z8-S*.@HE7C!\K \,X1^[BHCRZKT01%3V4211(542$
MDL0DFBHJ+JBHNBHNJ+UF/.,B6E3,L.L,CKFB&6D@![7H9^';\XA1UFXH\2[-
M/L."ZR^V#S+H*A XTX*&VX!)H0F*H0DG-%1?Y+$<.P'<M4Q TX+ZBO'%H^K<
M@_6)3BS1&M+*T,Q443;&_6$I]#A'*<3*K[R\$2(V2VWLN0O R&BY4U<<RJ++
M;A\.S,^J(W7:X&4T>?;3O?"<_P#DHAHJ&8*O#*DYW<P"ZRW%+AZ\Y3JS CU"
M&YJK,@+Y2ULXT:*CK#HW7*\R;;HW7*:7V>J>$E>J]/2YN4LDS56(//P&7[(M
M)KP@(RQ11%&I'&[LHDBB0JJ$BI945-%14[%1>:+UINJTIS31N;"<5>C3XU[D
MP^*=O-67D3.P?&&F82:JM)=NFC<N(:ITF!)M<H\@4[>UMQ/!O-V<;6UT3J1-
MN")MF*@8&B$)B26(2%="$DT5%T5-%V?Q)AQ@CH1DKDZ"VBD=',EU<;352II*
MOXX:\)> RD'5F*EB%7J'1BRN"RHVJLYI=? M."J0VB3D_) C)%0FXS@%O$&G
MT.GL08Z9<ZMI=Z08W\+*D%=Z2[JO&Z9**<(Y0L*==<D&VE+K=N"KPVQSN+ZI
M\>X-SA[,YJ$D401"0()D+H]7C7C.D21*E'NY EHGW#MD5MU$\J.^+;P^5E5M
M1<+K#F$*@]>92FU?I)&O$_3<WA(R*NI' <-%;&ZET5U! 4;BE;^2OF5.>ZC,
M.!&=E27%\UID%,LJ><96RM@G$X:B HI$B;5&NS+B4U]599OF2+$;\'%BBJ(B
M+N&! ".R;P\[I)F,NL,U6L;ZDX>51,#RY9]3#G:"V:*C4<D_OYT5!;IT=J1Q
MJVU3*-"9@0VM=VTG$X:I8GGW2NZ^^5DS.ND;BV1,UD1$] .SX>[I&(;*23FP
MM'G'V#4V03CORZ6TG20O<^D  L[.4RMPG(<H-0OQ,R&KJ@OQ7A\&^R5M#!>%
M;MF@."0#UENJTIS31N;"<5>C3XU[DP^*=O-67D3.P?$&F<2:JU)=TT"7$-4Z
M3 DVN4>0*=O:VXG@WF[.-K:Z)U(FW!$VS%0,#1"$Q)+$)"NA"2:*BZ*FB[/X
MCPXP1T(R5R=!;12*CF2ZN-IS*FDJ_CAKPEX#*0=39IE(AO3ITA>!EE.2><XX
M:V!IEN]W'G2!IM-3)$V9JE<1FL5]+&"*.>G4T^SHK3@ITB0'_?'PX"1%CM,D
M*N'Z ?@5**Q-A204'H\AM'&S%?D7D0\P,;&V2(8$)(BI(K.%!>J-)',Z_3>)
MZH4X.9*RNISHH>O]M,AJXCR"X_UBGUJGGEET^0#X7OE<%-'8[EM59D-*;#J)
MJK;A65%VI]:IYYHM0C@^'W39+HZPYZG8[J&RZG8X!6NG\E?$P9"<XG=U4:RH
M%R;15Z#".WW9)TQT"U1 ADFA]7!IH"<<<(0;;;%3,S-<H@ BBD1$2H@BB*JJ
MMDVCU[&; O2N!Z%0'$0F(_(P=J@ZH\__ /(+X%KE*WQDK+'H,Z96HJ/MZE'?
M&PRH3RI9'XC]E5IQ-,R:MNBF1YMQNXK\($IE&?<48%7:!4:<\X6)0\719F6_
M@B7*Z@F<<W! \G66ZK2G-- FPC5>C3XU[DP^*=O-67DXV'.,=,X&U5:2[IHW
M+B&J=)@2;7./(!.WM;<3P;S=G&UMRZD3;@B;9BH&!HA 8$EB$A70A)-%1=%3
M1=G\28;8(Z$9*Y.@MHI'1S)=7&TYE327\:PU7*7@,I!U'HE,;W45E1Z?4WA+
MHD)LONE3Z[(-$7<107.Y9556VA<=#H5)8N\X@K.J+R"4V>X/G/.(G"T%UW,9
MO*RRBJJ(KANN.>@WZYAAMJ%7.)V5 3*U#JQ\R,=1;B3SYJYHQ)/5] =-R2KT
M.9'=BRHSA-2(\ALFGF706Q XV:(0DG:BHG5Y6#9CG@9N\J%(4E\F8V%YD4?D
MD1PZ2 Z()1GUU)[^2NJ-9FK:-3HCTIQ+H*N;L;@R"KIO7W,K+2><X8CV[3ZQ
M4#WDNH2#D.KYHYM :#U-,-H#+0^:V CV=68APV'94J4Z#,>.R"N.O.N+E!ML
M!U(B79JL5H&9N)7!S!^Z1Z.)CJS&\QV7JHOS-<OUJ*J-[QV3Z%D4ZI169L*4
MVK3\9\<[9BO^T3%;&VX"BXTX@N-D)BBH=2IV]FX:><1&Y"\<BG..+PQIV5$X
M%+A8EH* Y<6W,CRBCG66ZK2G/4W-A.*O1I\:]R8?%.WFK+R)G8<XQTSB;56I
M+NFC<N(XJ=)@2;7./(!.WM;<3P;S=G&UMRZD3;@B;9BH&!HA 8$EB$A70A)-
M%1=%31=G\28<8(Z$9*Y.@MHI'1S)=7&TU4J:2_PPUX2\!E(/'[Q5.%08CHI/
MJ*CJ:Z$4.#=%%V60+<B6[48%1QZY$TR]'I-(B-PX48; V&I$2^6\\XO&\^ZN
MKCKBJ9+S6UD3T*<R,C<'$;#5HLZV5N8@VR1:CE3,XW9,C+^KL:]TWC:*R4FE
MU6*Y#G1'-V^PYS1>:$))<'&C&QM.MD3;@$)MDHJB]6B5&$ZK,N#(:E1G1Y@\
MR:. ORI=.(>1#=%T7:EUV-9 J$87'&[WW$D%5J5'_P#L)(.M7\Y!S=O\E; P
M?$=^NY:G5T$M<@JJ4^*=NPC0Y9MEKX.&XFBI?JL>#"8<DRY;H,1X[0YW'GG"
MR@ "G-55;?[5TV&?/%F9B62W\(E60VZ>!IK"@JJ::+:3)2Q2%X4LRB"OH=^)
M+8;DQ9+9LOQW@1QIUIQ,I@8%H0DFBHNQU:D@[)PS)<X2U<=I+KB\,646JE')
M5RQ91<]&'UWV0Y'66ZK2G--&YL)Q5Z-/C7N3#XIV]K+R>$8/C#3,)-5:DNZ:
M!+B&J=)@2;7*/(%.WM;<3P;S=G&UMRZD3;@B;9BH&!HA 8$EB$A70A)-%1=%
M31=G\1X<8(Z$9*Y.@MHI'1S)=7&TYE327^&&O"7@,I!XWPN\8H, VSJLP>%3
MOQ# BDNG2I"(MRL0QFO#&BJK+;T>G4V*S"@Q6T;8C,!D; >:_*1F5S<<)2<=
M<(G'"(R(E]#KG0(=<C-$E-JB(MQ\Y(LQ!U?AN%?L)R.1$ZQS=;>E4JJ1SBS8
M;JM/-&G_ )7&UY.,NC9QET>!QLA,55%ZM/PA*=\%-0ZE2D+S9;(?#F _\:*
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M)[GGM- ^D7^,JIO-GGA4TN]$"RYAW,(C%UT%311D3"DO@7[VXV-U047JO?\
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MEN0J^J)<E34BN++#3;+0)8&F@%ML$]0@"((I\B)]03+[3;S1I8VG0%QLT]1
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MH+$&*%A0E!D;$\[E04.1(<SR)+MKO/N..EQ&O7X7ME1_=U;\3W//::!](O\
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MN]ISZHB>'@&RI$(;\7VQW:F_1S6!688"55P[,=!9\*^4=^R0Y4G4XG"0 FM
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M9O3.99:F YSWL\D;C;1:U0*E%JM+F!GCS(;B.-&G:*^<VZ"\+K+H@\R=P=;
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MMX^IT/E=NET.34LW+,*/2Y]*R=MCW!]G@]51 [XXTQ%*2[>\Z%"IL!2%/KR
MKXU+(1_N9*AHUYPO;+GJN.'[_OM6HR9?Q;C#K//MS9ODMM^W<9?.]._W)M=N
ML8YC\-LK=4HAAFUXUWV''#7FB*B&*6'2RW7;X#CJMQ]$_;=*@S>*ZYE\"_ T
M4;(B>:5RS%?*A=YL=46</F]\Z5.I2^;SZ*_6;6XM4O>PZ#F5 <6/1Z77FVK^
M$HU:AKG%%\IMFJK2Y3ETU$!C[U>63-IM_P#$6%<048;*J.U"E38\<D312"2;
M/1W$3DJ@X2>OK]>]@:I^<6%O2=)_S/7_ '>?B<+Q<,T*JUZ3&Q$Y(D,4J$_.
M=886FR6T=<!@#(6]X0CG6R9E1.>WVN<9?T?J/Z#;[7.,OZ/U']!M]KG&7]'Z
MC^@V^USC+^C]1_0;?:YQE_1^H_H-OM<XR_H_4?T&WVN<9?T?J/Z#;[7.,OZ/
MU']!M]KG&7]'ZC^@V^USC+^C]1_0;?:YQE_1^H_H-OM<XR_H_4?T&WVN<9?T
M?J/Z#:53:E%?@U""^Y%F0Y39,R(TADE!UA]HT0VW6S11,"1%%4LO4(U6HV"<
M3U2F3!,HL^#1YLF)(%MPV35EYIH@-!=;-LK*MC A75%V^USC+^C]1_0;?:YQ
ME_1^H_H-OM<XR_H_4?T&WVN<9?T?J/Z#;[7.,OZ/U']!M]KG&7]'ZC^@V^US
MC+^C]1_0;?:YQE_1^H_H-OM<XR_H_4?T&WVN<9?T?J/Z#;[7.,OZ/U']!M]K
MG&7]'ZC^@V^USC+^C]1_0;?:YQE_1^H_H-OM<XR_H_4?T&P4S$-(J%%J'[(*
MN_T*IQ78<G<.I$W;NY>$3W9Y2R%:RV6W53]IJ)]&;XGN<^V6'_>+'H&%[94?
MW=6_$]SSVF@?2+JM3Q/7Y*1:;2XY/.+IO7W%X8\.,"JF]ERWE!B.W?B=,<RB
M"$23<2U@E;;)5CTJFB:G'I-+;(ECPF.5RXE=E/9163*<=>RBA"V'BFHT9EV1
M)D. RQ'8;-UYYYPD!MIEIM"-QQPE00 !4B)4045=HN).ZHW821N1#P<TX0N6
M7B!<02&2%6UM8EI<8\R709KX$C\+9B% BQH4.*V+,:)$8;C18[0Z"TPPR(--
M-BGD@ "*)R3KF2LQ$A5MEM0I^)(#8!4XJVX&WUX1J,(5_O.6I"-S6,<9TU>V
M2-78R2:7)-4I>(((N'2Z@FJ[M35,T.<(HN]@2<KJ92<861&R2#\6SW.\4RE+
M$5*C+W@J#Y\=:I48/VD\1+<ZG3&AX3\J9 %#-%?BR'I/CL0Q66M[4Z(VF):2
MB6S+)I .N26@3(1$<FF.3XK0#E4GW6KE:Z+XC%& )3O%$,,2T@%M?H[ZM0:P
MVFN;(T^E-= !0DS2Y!*HKY7H$Z%&=STW!<1*2*"1*!5:1EE5=W*2)E<;-8].
M<LBHI4ZZ$J+I]7(EML.'&BFP$E\1NVP4G>)'1Q?-WJLN(%^:BJ>)H:ON[RI8
M;OA>H74<Z]ZVVN]SI(B"J[VDNP<SA(JN/B_<S-#+T%B6JLN[VFP)'>&C*BDH
M=[:0IQT=:S()(W-E]+J*"HIEZ8H]GB,1X_ELW8I;'['J.X8K;OA-1N34W6BM
M9'8L#HT=51?K54<14U\4U78S>:90U57[)Q.4Q]41Z_W71G=V^E] :627:O5X
M^&<32.+A9I55>+RO-;@SG"\[D,:22\>C+RY\AE]Z#T26RW(C2&S9?8>!#:=:
M-,I@8%H0DFBHNQ56E"Y)PW)<X2U-VE.N+PQ91:J3!+PQ91>5HP^N^R&_UENJ
MTISU-S(;BKT:?&O<F'Q3^=EY/",.<0^<)-56DN^H)D,U3I4"3:Y,2 3^%6G4
M\&^'&VO-!] R,,X9D(5:)%:J-1:6XTA%T*/')-%J:IH9II _*_VLI$JD1*I$
M1+<B)=5557555=55>?5I>*I06DUJ\6!?R@ID9WPA^M.F3 Y*GUN(PX.CGI[N
M<_EF)O[&A]1P/_&7\\,0>CC]IJ)]&;U'&'M0U[IB=0E3YK[<6'"C/RY<EXLK
M4>+&;)Y]]TET%MIH#,RY((JNTBI@3K>':8KL##,%Q,BM4]'.*:^U=42=4C%)
M$E=2;#H\3.8107J;,*#%D39DEQ&HT2(RY)DONEY+;+#(FZZX78 "1+V)LQ4<
M=34PC33R.=[&1;FX@?;6RY3',L*E*0+H4@I<EHTR/4X=FRPYAV(E0#G6ZBB5
M&M$7$BD$^2)%$SH5C:IXQ&#L.9I5%.H'3,14>G5J =U6-4HK4IL25,N\:W@J
M3+R)Y+S*MO!YABNST[N<U4J#,52-*)677YM&/U-QIZ"]5(*)KK(2K9EL*;D=
M=N]^+*',I9J1#'E$&]ITY!\Z#4&LT24EM2%IU7&KV>;;*XIU),)5F5DPMBR2
MTT)O&B,TFO%E9AS<Q*@LQYW!!G%H*?!)+A"W%._4Q[E=!E:)N)F,'FBYKX.1
M3J'F1>2>#J$\;+Q= :S)EE-+U9I^B8;DQZ8[JE:K-Z52E!5MO&7Y(H[.!%6R
M][F)A)9>'A*S<C'&*)E4<YG3: T-.AH7W!U"6,B7);M=55J+3G+JB(7"N<.\
M&#*)%>!149LB+WSJ*$/)4J5369.'5;\+XI>VB62WBK+JBZ*B\E3U+LXM7P92
M DFA?#Z4SWEGYR7-O3D4M8A2#0M4Z6D@>:$*BJBKLC F+'&"YMTK$S*/-^3<
MD2L4YH' 3/HV!TEY<A>$D*H7<,\2X9G,016R5B(*5&CE?-EO48:NL,&:"2BQ
M+6/(L*JK*(E^N5[V!JGYQ86]%[FG0)M0>NB;J%%?E.77DF1@#*Z]FFP+%[GF
M*T%Q$4"F4B3305%NJ%GJ(Q1RJB70E6RIE5%L0W%3PI'AH7_>L0X?NB*-T(@C
MU.0X/W.51WB%Y0)LVK@89BYRL2/ULB5I,V7,YT6%)14MQ^"5TLMN'/P;?9[
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M+LS*2EIB6MMY26KXA!J9NW434H-.R= A)GN;1[EZ8W?*LT[(O42;<$3 Q4#
MT0@,"2Q"0K="$D545%2RHMEV?ETZ'^PVMN\0SZ"RV$ W/NIE#NU"=1>)36&M
M.D..+G<DGJA.RZC 2L8?#5,1487I,!L%443O@V38R:8=S$%64VD8G>"/*?\
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M?V^/']6L'_\ #^WQX_JU@_\ X?V^/']6L'_\/[?'C^K6#_\ A_;X\?U:P?\
M\/[?'C^K6#_^']OCQ_5K!_\ P_M\>/ZM8/\ ^']OCQ_5K!__  _M\>/ZM8/_
M .']OCQ_5K!__#^WQX_JU@__ (?V^/']6L'_ /#^WQX_JU@__A_;X\?U:P?_
M ,/[?'C^K6#_ /A_;X\?U:P?_P /[?'C^K6#_P#A_;X\?U:P?_P_M\>/ZM8/
M_P"']OCQ_5K!_P#P_M\>/ZM8/_X?V^/']6L'_P##^WQX_JU@_P#X?V^/']6L
M'_\ #^WQX_JU@_\ X?V^/']6L'_\/[?'C^K6#_\ A_;X\?U:P?\ \/[?'C^K
M6#_^']OCQ_5K!_\ P_M\>/ZM8/\ ^']OCQ_5K!__  _M\>/ZM8/_ .']OCQ_
M5K!__#^WQX_JU@__ (?V^/']6L'_ /#^WQX_JU@__A_;X\?U:P?_ ,/[?'C^
MK6#_ /A_;X\?U:P?_P /[?'C^K6#_P#A_9:#BS$W?6DK)8F=%[S8?@_"(^?<
MN;^FTJ')X-X7#OLA7XA73J.,/:AKW3$\?6L5U#*?0(ZC B*5EJ%4?NW3X(ZH
MOAI"COB"Y,Q1??RJC2[5*NU9\I52JTV1/FOE^Z2)+A.&J)YH(JY6P3A;;00&
MPBB=19B0V'I4N2Z#,>-':-Y]]YQ<K;333:$;CADMA $4E71$VAXH[I\=J94.
M"3"PDI"["AZ9FSKI#<)LE%XEIP$4)NPC*.6I.1V@:: 6VVQ$&VP% !L 3*(
M(V$1$41!%$1$1+)IU=2J#*4O$;+>6GXEA,ATUO*B[N//#@&IP+_WN\0NM(I=
M#D12<<4SHN)8>1"4RIU3CYG*95HPK;I$&0HC?FF]CNBW)CJ2"^T%QS=0I6)&
MR=6G*7>^OQ&[_#*+*($E!D1>-V.HMSHJ?]ZBLWX%)%CS8;S<F)+89E19#)(;
M3\>0V+K+S1IH;;K9"8$FA"J*G47*'39*.X<P<;]-B*T5V9E651&KS[B2@Z(O
M-) BN)<58BJ\TMI1YNIMT3"M*?J,I<I2'D10A4]A205E5"82;F)''[HUSN%9
MM@'7B!LHU6Q.,?%V* RN(Y):S4*FNV142GT]Y+2G6C1<D^H 3ET!UB+"<1;]
M4421" D42$DN)"NBHJ+HJ*FBHNBIM)K.!NC83Q"69TJ>+>3#E2=5;JA1VA4J
M2Z6MG8+91KZ'!S$3XOT+$]*DTFI1U6[3XHK;S=U$9$20"DQ+BN67=R([CC1=
MA7143J]>]@:I^<6%O0O>W"="G5B0BCOC8#)#AB:V1R=.>5N'#;]12'F\W(,R
MZ;,SNZ/6RGN\)K0,/FXQ#302W<RKN@$M_P ]MUN$Q"RJB$U.<1=N@X5P_2Z&
MPHB+BP8H!(DY;J*S)A9IDTQNMG9C[SEM,WH/NC>V6(/>+_4,!_D=4]_U;T*?
MM-1/HS?$]SGVRP_[Q8] PO;*C^[JWXGN>>TT#Z1=3K.+*JJ*Q3(RDQ&SB#E0
MGN>#@T]C-^ZRI! W=$+=-;R02;MHU2K8EK3ZR*G6)CLR2?FBIKX-AD?W./&:
M0(\=I-&F&VVTT'Q4##.'HROS9I\;I(?18$453?SYSH >XB1A5%,\JJ1*#+0F
M\XTV;="HZ=(EOD$FM5AUL1EU:?DRJZ=LVYBLIF"#"0R;BM*:YG)#TF0_Z"LN
MJ+HJ+R5/4NTON@X(@H.''5WN(:-&3["277+%4(3*)PT=\C#?1PTIKJJ8(E//
M+!\4]W+*W)U%)%1P@XZJ^3QR*I117\'PM4AIZN^(J>D=OQV)L*.H.:KTM]J(
M9Z"S4F;2:6^2JBV%BH,QG3]8"0W2]]GHTALFI$=UQA]HTL;3S1J#K9IV$!HH
MDGK3Q%<P1)<M'Q+!2HTT5NJ)5:,+AO-@G(5E4MR2\Z2]E-:'GSZ_B:KLN[VF
MQ)7>2CJ*ENUIE(4HK;S69$) G/I)J.4D11*8J*B6MXBOX\E-78H,;O+2C)%^
MRE3#/-=;7EGB4Q-PY?S*JED]6S.)HS6>H8+G=+)4\I:-4U9AU(43+<MV^-.E
MKQ"@,1I"Z^)GX1E.YIN$)]XHD29EHM8)V5'RIY9='GA46S746FW(H72XCU^3
M.F/#'B0X[TN4^?D,QX[9//.GS7(VV!&5NQ-L1XJDYD*M523*9;-5)8\+-NJ?
M%NO9$@MQXZ?(WR3Q%8QM*9RRL43>@TXR#B2CT<W&W'&B7S)=3.2#J)H2TYE;
MK9+>+(#%# T42$DS"0EHHDBZ*BIHJ+HJ:+M(B-BO>V7>92SUMT9PES1U7[N(
MYF97525M&G2MO43K$?#.)9'%PL4JJO%Y?FMPISA>?R"-))>+1IY<^0R^]!Z)
M+9;D1I#9,OL/"AM.M&F4P,"NA"2+9478JK2A<D8;D.<):F[2G7%X8TDN9,$J
MY8LHN>C#Z[[(;_6F*7B-'JS1@06VI%T*JP&TL@H#AJB36 31&9!(Z V1J2C;
M8L*%1HL]BH1#TSLEQ-E^]OLF@O1W4_>G@ [67+E5%7K+L5#2K5U$L%*BN)9D
M^Q:A)1#"(*?O5G)1<-F,A;T>EUF7F;!26) 8NW A"7FQV,R\5M"?=)R0::&Z
M2(*)U>%2;$D(%Z957ATW-.8(=]8M<KL@B"*PMERO/":ID U1J.PV#+##8,LM
M-H@@TTT* VV IH( "((HG)$MZ?[G/Y9B;^QH?WH8P]J&O=,3Q[>!Z:_>C8.(
MDG;LER2\1O@B2\_FDE*9M ;2V9N4=23,HF.7J$&B42"_4:K47QC0X<8<SCSA
M?S"  **;KIJ+3+0FZZ8-@1(W6JR,6KXYDM*CT]$WL.BMN)QPJ-O0$D,@X)52
M(!D/IG99W,4W >ZS+PYB: W.I\H;@5A&5!DH*HS/ITA1(HDV/F7=O#=%%39>
M!V,Z\RXH21<J&&9SYC0\0 *;N0-LZ0YPA?HE39#RVBRMR4 WXA&V+B-=0E8&
MJ+^:JX0LY3LZ\<C#LIQ=TB:7+O7,(HI+>P1I-/:%+#U"J5&*_NJ]5T6B8>02
ML\$^8V>]J 6,7$2EQ!?F"ZB$ RPALN)9]-E55NJZJJZJJKS55]?4PJ<M7:'@
MQEU4DUHV_#U$FRRN0Z*T:6?=0D4'IAIT.)8K[^0*138H.%J8S38+2(KBCQRI
MC]K%+GRB\-+DN><XXO"EFVA;9$&QZN=$Q530FL)G.'+;LS4:9(,<O2J;,RJ<
M=[0<PJAQY" +<MB0S=M5?>0JOA63(5NG8A8:400BN3<.J-"I]!G947*A$K$K
M(9Q7"RN--=6KWL#5/SBPMZ#8A08S\R9*=!B-%BM&_(D/.+E!IEEI"<=<,M!
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M<$20X%GY.'*HKTK#=4<2^_BB2;R#(,40.^%.WC;4I$0-Z!L2Q; ) @/4Z][
MU3\XL+>@(N&Z(&1%^$5.I&.:-2::!B+\Z1J.:RD+<=A"0Y,@VVA4;DX$+#6'
M8HQXD44)]]43I51FD(I(J$YSF[)D$*755RM-HW'81N.RTV/HCNC>V6(/>+_4
M,!_D=4]_U;T*?M-1/HS?$]SGVRP_[Q8] PO;*C^[JWXGN>>TT#Z1=1Q#B5#%
M)[<;H-% E^NUF?>/!L*B2.)&,BGNMVXX\1Y+CY6SCSQDXZZ9..N&2D;CADI&
M9DNI$1*JD2ZJJW\32,,49G?5&LS6XC":Y&D*Y/RGE3R8\2.+LJ2?F,,N%V;4
M?"E&!$ATJ*+1/*" [.EEQS*A(LJ_")LDG'W-50,VZ"S8 B>B6.Z718^6GUUX
M8>)&FAX(U:R?!JC8=!;JK+:MR%L*)/8WAF;U0T\35< 37K0L3M+4J2ADN5NN
M4UE5D--C= 1:C2P,G2LI$5*B-CY2^.HN-XS=H^)X/>^HFG95Z*#;3+CFG#TF
ME'%::2ZW[W/+IV_5PZC"=)B9 E1YL1\%L;,F*Z+[#H+V$VZ FB^M-L/8JAY4
M9KE*BSB;#,J1Y)AEFP[DB*JPI@OQ"+DI,JHJHV5>MN4..[DJ.-)@4@$121P:
M5&R3*N\*HJ)E(!BTYT5S9FZDMA\X/JZ70Z:TKT^KU")38;2>?)FOA'93U(.=
MQ,Q+81&Y$J(E]J)AJGHG0Z'3(=-9+(@*ZD5D6SD."BKX:2XAR'US$I/.&2D2
MK=?J,24=EG<TR9)[^4410A;2EU8CD-LLY[D3<&1TFFH68LQ0BN5[^(PQBE"-
M(].J30U$0YNTF8BPZHW9502)8+[ZM9M$?%H]%%%1MYEP'6G0%QIULD-MQLT0
M@,#%5$P,50A(542145%MURB8(BOY9&))JU*IM@9(7>BD$!1VW11416Y54-EY
MO-F13IAV2XW3ZO#.%&T/=U6ILC.-M+DQ2X]Y54D>4&K-/8D&/&.8T$!7,0[-
M1V&P988;!EEIL4%MIIH4!ML!300 $011.2(B)U!3C /?JG(;U//1%?&UWH!E
MRROVNTI:-R!!;B!O9C;< FW )0,#11,#%;$)"NHD*HJ$BI=%T7K,?#6)9''P
MLTJJO%Y?FMPIKA>=R&-))>+1EY<^0S^]!Z)+9;D1I#9LOL/"AM.M&F4P,"T(
M231478JI2Q<D8;D.<*ZF[2G37AC22U4F"7ABRBYZ,O+OLAO]?RTS$%8A!IX*
M/490,+;EF8WFY*WX0+HJIR5=D0ZM'GB/(9M-A+_ KD9J,Z7KN3BE\MM-DZ90
MJ&^G;T;I\7U\E=E3+:6]?:O;9/A&$%S62Y,UOA(NW@.E7!/4F\<_'MKABH7[
M?A\?] G_ *)^+9,N&JDNG%>;%2Q770?!EF2UES*@ZJJ9=,Q)NL*S#]>\JC+=
MO5;+#=O_ +/X=O@>$XS/RR:L[)UOSRM0(G9YN9==<W9MEC0Z#!_#;B2GGNWM
MD37&?_T%[_S;*CV)IK \D&GA&IMO]."PPZOXR<(OEY;*]4)TR<\NJNS)+TEQ
M5]:F\9E_MZ\B(EU71$3FNW?*I-9<0UAH"DB8\=/AW1QFG)=,PN*N5Z<FGAT!
ME47HHF7W@]SG\LQ-_8T/[T,8>U#7NF)XW#^ XKEGJ[*6M544O?O;3"W<%D_-
M5N542)].U#I::I?7Q]&PG2N%^J24%Z2HJ3<&"UX6=/=1/W.+&%QW+=%<- 9%
M<[@[4K#=$8Z-2Z/#;AQ&^%340U-YXA$$<DR72<DRG<H[Z0ZXZJ(I^@6\>T:-
MDH>*WR&J@T"[J#B2Q./.+9,H-UEL3F"BZE-:J!703:%/'-/L.$T\RX#S3H+E
M-MULD-MP"35# T0A5-45-L+XK&V>L4EAV6*(B"%28S0ZJT"(JINVJE'E-M\E
M4!%505N*>+=D/N RPPV;SSKA(+;330J;CADN@@ (I$J\D157;$V*GR->_%5D
MOQ1-24F:<VO1Z7&XM?@M.9C1^2?6_)'DG4*3A>ALJ]4:M*&.W="5N.UJ<F9)
M4450BPXXN29!V7*TT2I=;)M3,*T4/@\%J\F60(#]2J#B"LRI2;*7AI3B7RYB
M1AD6HS:[EAM$Z_/PS5$%MQQ.D4FH9<SM+JK0ET68WVY>(F9+:+X>*Z\U<5)"
M&J8=K<98E5I$QV%-85<R(ZVNAMFFCK#P*+T=X>!]AQMT%R&*]3KWL#5/SBPM
MU^GT6DQ7)M2JDMB%!BM:F](D&C;8^H4NMS,E1ML$)QPA 55&*.SNI-;G;J9B
M2J@.LZHY5LRT2IG[WT]#./ ;7*EE=E$V$B9(S>B>Z-[98@]XO]0P'^1U3W_5
MO0I^TU$^C-\3W.?;+#_O%CT#"]LJ/[NK?B>YY[30/I%U&B8 B.?!L/L)6:L(
MEH=6J;5H+3@W\N%2UWS961<M6-/%3>Z758P],K*.TS#6\&YQZ6R\H5&>"$/
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MJ.6Q2I HMFPOQ#$C9S",VMM%-TTWKKGWB]SG\LQ-_8T/[T,8>U#7NF)XQVE
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MH4.J-6LJ*10'W]W=%RN[LTL0HJ-OLN \R\ .LO-&+C3K3@H3;C;@JHFV8JA
M8JHD*HJ*J+U:C8*BNY9.*)O3:B(GKWHHQMN VZ*>9*J;D5QM577O>ZEE[/J\
M+X8R$46;4FWJHHV3)2("%.JBYEX1(H4=YIE5YON- B$1()"VV(@ "@  (@@
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M_::B?1F]1QA[4->Z8GBZ;&L2#3\&TMG5;H3CU3K<LG!]5P?:;5%[6K\OO&P
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M*;:C2718PO5I)\-*E/.+EI$MS*J][Y;SEH;[A(%/>7<FJ0G1*'U:H4FH-(_
MJD*73IK*\GHDU@XTEI?D<9=,%_'M7\*3T+?4:H/1@=(5'I4-;.P)HH0AP3(3
MC$D%RHF5W3J4'$F&YSD"J0',S;@\33[1?7HDMGR9$.0/ ^P>AIJF5P0,>E1<
MD#$, &QKU!)S,[$=+3I46_%(ID@K[A^V9LO@\C*\/'UM1+=U/%D^.9T2@H?/
M7=C4*H0*AQ::T=_N7YQMG&BJ-GY$:?B"OSGJC5:D^4B5)>6ZJJZ VV/DM1V
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M-45%3DJ+JBIL(PZ_-)H>3$TAJ#.7[D0FH_NQ^1I6[=BIL(U>BP)R)H3D)YZ
MZOX2BXDUHB^04:%>7#SV!)J5*DFNAK(B])8%?P7()R'2'Y5C@M[\-M53H.(:
M4\9<FEF-,2%__-I"M/\ _P"CV0A5%14145%NBHO)47M1>Q>WQ:D2H(BBD1$M
MA$4U555=$1$U55Y<UV7IN(:?G1/K,1Q:@]?[E6H*2" E[-YD]:J@Z[$%#H\V
M>?)'Y[C<!B_80MM]*?='\$TBESY:*H0H<LH'2G198@T)HH[SCCJY&VQDYG9Z
MF2K:P21%56^5-+=]JN23L3S 59$DRWZ0!=\N-'<*^\>+E*EWNYJTTNYS$_\
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M4>IU9@2($H+"I(#X**.M9D5 D1SR/QG+7:?:;='B%-JUA:KMJ$ZC3G8I$H$
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M185J=$U6ZHP^ FOEB7+9Z=W.:^,H.(TH.(E%F1HET;B5B.VD=XC6XMMS8L,
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M'<MK!9$1$\15O\ST#W>'CZ][ U3\XL+=<PE[,T'W7%]'=T;VRQ![Q?ZA@/\
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M_=S7GI-__LS/<?S,I\O9MNX<2-$;Y9(S#3 63LRM"*?[/Y/_ /_$ "X0 0$
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MP @@YI"3]W"4@")2?TP@6[OYU[,_/OAF[8+^8B>7*"DJUOK9DZWI/'?G-?\
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MH48IL= $=W:9;NHO[NH@#\/H*G9$42K&83K,GPY]F:R9,W]YKZR=9D>DR=$
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MM1"C=^"?#GV9K(]89/'^;$GM2V.TEY&S]$)_BE5 %$ \_.0X@34W;6)G?/\
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MH72(@<W0R1YY=Y*YRJ)^T'E^&& GLMDW3'=L@CSO> TD$3>/N&UPZ0=MP7]
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MVTE@_"XX=&A<VG)8VIT+Z.UW*CQ;*S%?[YO)\""K2 SF34'[,SF/'Q"!HTF
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M/#L!7<UB=I !$R%905#:FUM7S=N^UALTO:B*>RSTQ"!H<1!,W(O(1;O4A8Q
MN(B!E#Z&*IK!ET#S3X8"4$\!5_,=,SB/##KOPB^5TF1\$,G@AD\297/)DVE1
M;?;G$01,)?&W82(0;](0)?J9) %$(;^\E:BFI?((@REPR.?9D^,F3XS?WFLG
M29.LR/69/!,V992?REN8FS]!D<UT \?[7N>3]H!]I,=XH&TQ:.LHP/\ >\,
M$(X8W&_1#4,F)L-.:C:(,5 "N#6-^0CFP%*/**_L\.L(#$LNM -HB>X0QO=W
MU.@CPRO^Z>' ^2W,VN@Z/51KNOEU"F6QH.;]-SM()1I#M/VO2X.@<#"!#&B
M)6(_PJ?N7\((-+<,V5YA!7G8OBHD(S"RV6:1CDY>\<N*>**([@.% RUOS$L
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MLO#;NL8')HB(JF;L+%:HJ8!TN@ >=B^FIDW<8=C-?FALM/[)XQQ#&B (G *
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M$_ DABQ0)_/(/]IF-E06&9O/LR9.L,G@F3I,G6&1S[,GPXF3-_>:R89V ^(
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MV"HGD7RXM\=,4C<>1V>3,X'G!ID17DR4W7$,2"*7:.]2(/UA-^RG9:9T9+$
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MF=IV#U_VB/)PX9$VG7"AR3KD@)2>>:0Z3D?.[RFH^S2/Z< ](UKBGBO/<7E
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M?B>&H>F+Y!6IP.PI[P4S7\%EUH M$3W"'JM"UDT(LS5UE3EW-T4\01*MZ'5
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M9'K,G6=/LR?&1ZPR>"9'I,G69'MGV9/AQ,F;^\U]9'I,F3I,CG&"P&P4*[F
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MA$'VPZ:D389YH(!H _:[&.(8T0 P;L=+;K0+OG3^Y8I+<5Q:4.'O8K7D6-7
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M.3(^"&3PG_AD3/\ &3I,G29/SGV9#'__  3\B?I6IXZQ.<I W\A/@QQ:1QY
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MH;TV^G'C2 W*H."3Y _D"2H0$5 @B((W)$)== ^3HLAYC3)1-:6YADFX;Y'
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MK8PT0O9']H[.-$KP'&W[IG0>,<0QH@"0N8BT.4::5QO)JDWX$2N%7E8UFOV
M1%Y7""CVX9I6M@$<J:NH*4\F3MVW&48&$@;]+OQQM2>D^\G227D+>:@W:JUJ
MMT?*W+S2 .4*J@WD0#X&6^Q@F/&)O49V$"@L$#5@1+E1%$1&(Z1.1-;UL\BE
M4O:O:!RK'E$!E:<H^%0J&R7R.I9 C@"M\U1M@A]RZ/\ 2;**,[T&(9]R7=@
M%%;Q];HGE3)DR9O-/)GXN;.3-9/C)DR/7_62;:/X()QI'6$!AJ>1D&'<';\/
M-Q!20?-T)B:Z] ^1!'#SIP)2Y1&TDA:(UBY0^^DS3S2ZAK/H<:>A,,G]JI).
M[)GE,\).J"2EA'L3IU]2,N[Q&$E[Q9H0?5GE3):K^ZAT'C'$,:( I="0ANUM
M\0#-Y4EZYY&]$$GE#WVU2;_/@T@8SEJB\C6TVM"UJ/-*9(- 3/\ OTDP0#TW
M&CI7";C:#H%!XTVM5:[)>N.:3R?0W;=XN,\Q<$N#^0)*E054JBJJK?'H,EJI
M4',1,F&.$_\ @&#3>OJ2=Q=/P71*E@'47R U.<3(\5P3Y+)$V/[])C8T<\9!
M "K43"L594HJOC.5UL60J.#D6\B9"1;V%[J-M[G]%ZDV46*[T'(9]!S4+=(-
MUS[\\7(9/*F3)DS9FWXRNSFSDS63$^>B.?Z[##9_!!>-(ZP@,[[NY7&,($B=
M_0X;E<U+W(;4_?8M8P4K*"43\(NKJY95/"E/:.MB'H6,J8JC34--F$]A-?L
MBKP.4 &<7N;,1JX4W_=4.=!XQQ#&B 3$;@B5*,G A@-$R$901#8&TE'R0 XO
M44A#C $"^VD=G)$TX93AH[/)?01N+2\:@BR@>GN_*2JB=4%#;'Y#V:!H'KN+
MC0*HN/:%X.]+M4-]^1%N!<H00VXZ?\CMJCQ&2U:D[+]4/^\UX1X2N9]-4\@I
M9PT=KP4;'+O2XC!]TYL:#4>41X]^A"%,0\1L4-\C<< %'  @DF$+^Z:/U)LH
MHS/85#*(G:B;H0V$?Z5FBN7(/&3RIDR9,WD7XRNV\V<F:<F3/]!MM/\ X'Y!
MK'6$!D6G,=P)"L?0EB0&)W6<$5 J&.\,LS(A7Q4P_9/(G *  *HP "J\8EF.
MI@KM) " ]/W(06"QOU.17HC:*C.N2^) $0KU\]9$FL)"HC]UZ5'0>,<0QH@"
M0N9",H$MB(GDDC'^S)2-R ((F;QO:'J._AH[VP#;*&H^HP/MEKY-WBF2)8+0
MP7C^G#?HI2W,"3>YU3">H&!3P"E0=>1R)E"3T4/:7GXV(IBZGUIFT%'-O0S4
M#8[7A4B+Y (:F@'YWRBY/5<F]J;%W.W?@D@<>T?-]MDK;K>-\BFJ=7 [GC-"
MR?CO0^]54DXDQ08V&=7PC9Q,)9Y!FU/6W;LJ21&3[L-=XGV4794[%0RCG8Q$
M !VIQZLT3)TKER&3RID>D^,KWR+\97;>7Y,UG^EF@G_A_ \XTCK" Q$8! %!
M$&B(Q'G+#-4MBJ_66V=GH.%XX6Q8K 8YG%3JEW6T]BN[(N>A]ZJI)Q)B@PR2
MG<S3GH]&>%1T-0 6$<8YI =E6MB23_\ 8/I[X%^JL$KLF@EIZ$&=$3IO24GY
M QG?BIHJ&"-"EO7-:(\G@8 4K4XO=)NH9'04%5>/W7.@\8XAC1 #%UFHV@(L
ME>@_DA5/]BF[7&,'M<;+4F41XU;P .%5555JNU7E7>][?)8QO$6]OH'8=SU)
M1 =B%_6(Y#R$!0T!#A_&?8H0@)%0Y>PIE4H^1(26X3IU=A8V -?L B#P.  '
MJ^-H6K_"6..K#>.W-;\6B,@&^,($U?&:D3TY[)O(PE_%DNC5>!94[F'(M-#Y
ME :)9BK[OKO$FA%V5;"H91R?I@"$*U%NE9HF3K<ID,CY:.3(]LKWR+\91QO/
M]:I%<_0PZP,D.(UH<M@&YRI"W%DU:6IV*E<7XW&[EBHB.GS^ZPZP@,.7',]C
MH2*5"CT.@>3RBT+@"!2:Y_QIE1Y[![\D+^?<:T+FO3>'NA^'43I#]:$<?>"$
M%8 1Z=HM/3($8W@;$!\)Q W?+RTI^(#AZ+MJ5  00WN6B8 :<W:$"[#Z-*0
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M1*7*!J<I MHR(4/($->.OWXEPW #?#<^(22]UCM@A68SNU4#=2]1>2GCE"6
M8MP4N<00-+%WK T-]9PEEUH M43W"&"IV)172C"/D#B+$E%)NT%9";^%PVT3
M#A/)A5AF1-H>EQG%.^$>,!4 56 ;5> -[WHP:?.I8$.U&+DQ'O*"$3Z.79DT
M-0RB3&I =B#JV>K-$_E_G-_%^LO6'@7-/1/*G2&?Z$X*9^@HUAC9([9U&H!H
ML)G*5+)XOZ"J!!$HG@F,_0D_T8A4*,2)G"!X[_VBD56*NB\@C?WP#+8W@[^;
M<,-H<[_,"1E.^CX^RW5T[PP#GA5 T#8:'EA_^ 1T\$4 !A+I<HR.';- @I@!
MAK$ ?BP^Z!BC'+ZR(ED9-#T8<L'.3#5$QJ-/I?[@ =80&,HFHX>Z.)M%IZ,
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MS25I!Z%9$('WY_#IX>EV?NEN&41S_,+L"54/M9HC/QS9ER&)?C_\<GY_O_\
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MZV\@9$-"(ZH=J+$$=.,LTE80>Q61" Z1>M2!=:GYT?/D.G\<,-N&M>K^@(D
MES[.O*D=#L,IY*WS% ++OKMI,CB'+[.5R]'\/]9/S_?_ .YQSKP3)TO1IR>+
M_6^!?O>J$&<H])@4IQUT+D9#N_M9@2# H!8GX2>&&3PS(^%'J"90"H8 VE #
M:Z,,M^,C0U=5H7\G]QXZP@,1>(R@1 ]7S1=DF1%<G:I:VIS^=AQ]$.  $ )
M#Y ;\W!LC:E7),-HS=#EH_<)OO _!G_1C.<S^1^EE+L;O(C#['5H&JP.-]OR
M#M;I#\281QZ*32;CR!NWO>D[6Q3\ 7R$1>+:[6LL@QUXLH)^D<,;6#=E75[O
MU8W=4,VQ#20% Z4QS,IY++!BB/JF&8-!<U7?[;'0@: Z8P9J;6!!DW9*")."
ML!F<,JJ.H"HQ WQ&*O*[8*JK?WH.@\8XAC1 .;EV40&OF#1\ZTD?/8D0*3"6
M!'*5"3WX!+2?KOD>:8=W9!VX,@KTL'<!K"8RLN^4$;/%G[1"8A/PLG*?S%M]
M='7@*0M(7P$AKTB,16=RB_)%1F8(HOD:]JFPR\@"RQ07\/@15X:+*:[+N5+9
M 8;& A 'C1,@&4$ VID)5S0TYS"]5Y'9_L##KW@"X: T$ :9#!W4 948.1E#
MQ\B1!=_.+CU5RYK]@$5>!R@ P+SR#4* 68^03;I5+VKVE,*Q^@2 X0.GAXH5
M:Z7X92D2XT+L#9U&7N$Z3)B'+[97*=/^361^?[ZSCG7@F1Z7+FLG@_T?PUKW
MB!#T4@>*)D /[ \!$ZUQW/Z4@GD"0)D\,,GAF1\&S*58'*KV/GX#!'L)!-QB
MR$ZP_P!R('6$!FI]TR#NL,><XQKGGKU"E.5#S]XT5ON[BL2LX:.6%EUH!M43
MW"'I'T$R'D%T9U(80HY+BK-KT?W\!,\Z#QCB&-$ T;J2<:0KZD-YA!U2^00Y
M%8D.\N"$05"M>F4;_JR0+***C<F,O*84,XB D04!5ZS@55556J[5>5=[WM\L
MLV5H(T]G76%6A-F)%Y^^)R<OL$EL$0;KZ36ES1Y$ZXX SLS\]=U$7(<(_@):
M;L$V>0#M".S01-ASV)__ !2G8^9[.7"^1C>M(L1:@WY\&!Y+,;DY:UYB?( A
M*YCAQX3"ZBS0)8*-L0^:# /T$UHB>!THR1W)AE$DWS%V!+.NY5:'#T3)B9'U
ME'&7*=(_\UF_O_&?>O"CTKER&3I_I? K7NUH'IPVE54@X\X!C[1'.8B*56QA
M5T\Y^+B)V\F'B0R>&9,YP+< 6"GX_N4PW#K" SG*5AUM7Q\>@K;3 'N4B6DP
M?>+.!,SL!8"@ )3Z62=]@V@B"U1S*ZUQ%8:N47<<?P$ Z#QCB&-$ 2_7%$>%
M /[ <M_F0=A02[#CYBPHB*(T32)PCK>M.2)4&XK@(S0(%=9C-.VU,:A*?3?S
M$Q,6.B[:$Q9W?6\L5U5QC',(D3<$0 TBMYGI]B?W22"!^6 HA&+"MM6;^B7[
M#WM+I?@$)OBGA\@$9@S4(H@E4AH8PX.A&$!; #)'D7/$]PB4V<(\/[$/9'L9
MO=) &K@(BB(C$=(G(FMZV>-$R!904#8&1M'+_?=XCV7CCSR([?8^"0NH!\?H
M0_0B9M%*,EV'0S!@GXPNQ#=!_"W3,ACAZ)DQ,3]91QE^<UDQ_D^O_F1^_P#&
M7^7WX4Z5RY#/]+X-&_#X!#[I% 50 JN@#E7$;+:-N0UO7,FUF=;FG'XXB<^3
M#)X9DZ_ZT]X!^Y@)XCK" SC YSH'JZ2W6P+ 0]YFT2\%GW;<LT"D7:FA ('B
M!GZO2>21H&>F7E[( K&@GG5QP>+^LT'!0_\  0+E*.@\8XAC1 +\3P->;CL.
M\]^/FY'8"U0/-J Z&QD$U^[%(%' A398E*H"E%:[#S>09;V]:M>!T/O55(.)
M,57HJ3@C12,/D7%W0,%@!D6T 6<3@&37BP6)B6A\VA &WM:$BM(P&;7D"*[&
M]C 1]BPBF+J?6F;4$<V]#-0,KO>%0(/GE!9L ($XB(#P!XQK8A@#%>UCV+2Z
MX "5-%P6+SP;^P,SGZH&4 "N,8!1P.]RN&M#]"VA&SP>*,T=#<,HDH^<78FU
MADJZ#^63\Y,ATUTG0F)R&7YS3T_L^O\ YF_O_P#<IX)UKG^EHRI>YT(>Q^*Z
M1$HS\[./PYUF3K<B_P"_XQ^.(G/DS)X?]*_H$_<ZE@1UA 99Q%#G1RU!!RB*
MR(FG[)X_[HP':(@^HD9][JSVA>B#%0O4%O-15S  A14[C9X$CEO:+<*#"/;K
MJD).&R*84D?:!3(7&TTW:WSU^[,8AT'C'$,:( E"KU5T8*(8@!Q*HCQ2%560
MW5Y\$)?$&--]-ISM!3)DX>MJH41F>:5QQ0@%_$D>I@V5\.L(:RU,'Y9-?L B
MKP.4 &/"V4* N[-B&4Q8 L:G"&)MNV<$P4=>CY #>":&6$#"YJNM:K'?G!%)
M??UC7;6^PN*31"+ "WD9I]DVSTY U*!3,+X#SRT'R;ZBVK;%A[)=RA+M$4H#
MM,_/73.(&:P[T)%/]#K6#9X/3"L70_#+G4]C"[$-D'P)KB/2?&3)TUTF3$^3
M'XY!ES3G_;S^S_.;^_K_ .93K,G3_0\!4O<20/E=T,;8(-4'@7,M56JM;M5[
MORO=<0X_')/!,CUN1?C_ +^V7DGDS)BI8+LQZ,]#6,L     0#0!P!VG[GCK
M" P"=G2+I)\$MOV:0P(%3W*:3IE2,5H/D!M."^AFE@3B HT"0O5# H'>R;:"
ML(*<T:\1*P.M+<-_; ;PRK=O=P1_7@25P-T"_=OQ2]'$X.@\8XAC1  A71OS
MY9,8B!]^*( <"DO0J\W&N@Z;IHP*1,<11!NA1V+O=4L#XTC'%5.!HLC&5R*.
M6"#NXF8R$HPFQ'D$>1P:0YW0X=SF@L&R*70=#RAEQO1W+[?S]@[VHF8;D4A,
M:7Q/V$"(0=BA[V4SR+"T$DC@@Y: 3\PQE<__ (( 7(,D)#T'&/>Y;N5+7^3F
MN,#9>4%A1Y]EM@[ (2V7JC=%*&*)D(R@B&P-I*/G=[<VBSY0OHA]D77W2R0Q
M ALV; ;A))SV<+2B$U\V*/*#SM$Z$KFOT.XAL\%II-72O#*)@+N;H"50=/5^
MB=$<U]9/C)DQS72&3'Y&/QR)ES3B7/[/\YO[^LO6&?Z?D"G[>  \-.W$1M7=
MP2LET]3+!\IE"HM5S\,CU1EY)X4>M^<B_&+[;R3QHH5*LT\H  6 :F00
M @ : .#]T1UA 8G95K8DD_\ V!G(0C[B"&HK(L+G</,4:@,T@?;QQN7I:NQ
M(R[0N[;;HS_6"7^B%=X"@A"-4KDE=!A)WRYL1)KVI1JDCSH4%7<QM;E5VK 5
MK^[L11-!P=!XQQ#&B /[JD(6N^8&!BDDX_1M2W%0(N,Z\%N,:*&.,1/:MKUR
M4D-LAL&)T%K'>=--'V=M=Y;F-^+1&0#?-" T@787EV1-LK (P   " $  @''
MLH%H&R$B,2GFB9:#):J5!S$3)A@!XQK8A@#%>UC]$:.?)!XHS5T/@RYH%YY=
MBBM1]_M)UF3-YKZR=)CF/2&3$^3ITRYSB7\_]\Y_,?YS?W]9>G^M(PI>V@ .
M63;Q6&U=&D#>'!TO1&*O*Y2:&JO29O(=\_#(]4_6+^\D\$R=;^,I^,7]^"S>
M"11Z"M<*-9Q!YJD. P"0-!^Z@ZP@,X''A)=X;UKYCA*G;E90\6'VP8H.^(Q!
MY7;!5 +FB%MI#RT1(/-)*WKJT 'UQ<>V'8D3\ EUARIQ#3_M+G-9A9=DW!]&
MJU@3XR)[/8@!^C+-@P@+9 JV7JCI5M^\'OUP=!XQQ#&B 1,'+%E,[#"-3M%
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M\ID^,F/=US B_9$94N"AY-$BF2(0 ?ZCUYZ*1/!Z7*D=;L,_G_(878B5(/\
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M +\*<K9#7)QZ!S1+ALK26EH;R1O#EPU!%'P* $X>G.B%XCY^ 450'0<>#H!
M  ! T:_JJTG5NR"/>)I[C*"K2F/?^]J]X3:0?+>H\]F;<1X-GS7L_FY":FS:
MTQC1]47OMRB[XO%O1S[ZTVMG ZC2A6:H@\Q_:0";%$<^CZ%7QG$TR1XG56K!
M[Q*?>XD=_P"S&E&3ND3:@>R'?>G-#L$[L4V>22MAJ,E;[^<@H1P\* CN8,5B
M1KQ[$NA#F@@PNWZ(010&X4)4#",CN64<#+[\ANR "@H .M )<  T.W]/_P#_
MV@ , P$  @ #    $                   %,D'[4\$SE
M                            ?%&:MLM:J0
M
M
M
M
M
M                                                   ,@&FFR /Q
MMV_OT0                                    $.(        !Z.P
M
M
M
M
M
M
M      !6R< :@$V !\,'^%3\                                 !Y
M             3P
M
M
M
M
M
M                      "!:+#R +P PP >!G]Q6\
M             !S1@              #A0
M
M
M
M
M
M                                      .4X!#98?$!4 &D 3@,U.B:
M                              4R#AL               7
M
M
M
M
M
M                                                      /*"2G
M;1)1< ?@&B@ < W!N(                           !2@ "2<!@
M       !BP
M
M
M
M
M
M          !@ 08"4P#*(#:&;D TP 2 'X"4
M !+0PP  00,              !U@
M
M
M
M
M
M                          !T::*"!02R ;1#9114$VT0"!@X&:
M                  '000&&  ""!@,             R
M
M
M
M
M
M                                           !F2"910:*2F039(;,
M[:@FV" 0<'L                       .P0  "  P "20,!@
M ,>
M
M
M
M
M                                                           /
MR 0P0***:12D0"*"3!G; $T 0"#A@                      &F$"" "0
MV  00,!L           #0
M
M
M
M
M
M                6"" "F 00+##842 1038)Y0 F@2 ![X
M       DP$&T@00 2 &  2"#@-@          L
M
M
M
M
M
M                                *"8 0@@42" !88#"BP; "8!)J*DT
MR0 /                   'S02 $PD"" "  P "0!\!L         )P
M
M
M
M
M
M                                                 B$'1 "@$2PB
M3**3 8&5" #3 +!!4 FP!V                 !T9!0"0 F"@"0"0 V  0
M>!L         F
M
M
M
M
M
M     +00 &K "F@B&&01;2+20RA11;8>< 8@&F*0                % 0#
M"* 0 $T4 2 0 &  ""#P,        !P
M
M
M
M
M
M                      N" (  N( 6TD0PR"#013" E#*+)#X@+P T@
M            !720" 830""$FF@" 2 &P  00<-@       *
M
M
M
M
M
M                                      '0"000" %0 2P$R D0+*""
M80$X!#9*3F#\ "@              #$$#0"0!"8  0@BP"0"0 V   "3@,
M     P
M
M
M
M
M                                                       ?>""2
M""20&K "6&B &@!90 " 0F 91(;<Q8@Z              #80@J2"0 "2" 2
MD$2 0 00&   ""!@     !0
M
M
M
M
M
M           )#(*\02  20 S; 0 404P"#000 "48"+(#**:JP
M  !8P+"&%1 2" :10"4@F 2 "" PP  00,!@   '@
M
M
M
M
M
M                           !<+:9(D "0 02"V9(" 7J2B0:**#104R"
M;)#9G;<            $[.F,800C 2003 * 0CZ4"   0&&  "2!L,  !4
M
M
M
M
M
M                                            ,@\A;"+< "  "  6
MJ%)P!FD="#9132*2B01029(QP           V )9P!B "D120""!0R@ "B'R
M0 2  P ""!L!@ &
M
M
M
M
M
M $0"E59 ;5@    2EP      !LL""+8:1"D0"*"+!6          &P@  )*
M] "4("0E@       ,?B "0 V "00<!L @
M
M
M
M
M
M                  9B  4J9()8N  2L          -R 00+# 842#0 3-P
M         TG.$ 8!/0&@ 6 30          ]@0 0 &  2"#@,J
M
M
M
M
M
M                                  -S1>2"2]3*!), ,
M '*$"1188# RP0 ;<         *-FOTB#0,Z#B!60           !-P2 2
MP " 1\%@
M
M
M
M
M                                                   ""+*#P02'
M(P0+>              #^PR3+:102&5"*+         +_A@_PG2*)F T0
M          ! @"0"  P  00?0
M
M
M
M
M
M        4* 98"N" 0Z'6                /2&"01:"*20BI1:
M!0#P,_N**91(                -$T 0 0 V  "">
M
M
M
M
M
M                         "(;0## 40""(L                 BF0$B
M#9002" G!         ! "<!GYU;1P                 ,D6@2 2 &P  $
M
M
M
M
M
M                                         #9 )!:"8+#L &
M            "@$P T1+* (0"4X         &4 #@&8,HP
M    X@B0" "  P
M
M
M
M
M                                                          *9
M+ !:(2113YP                  !D&"B"& 18 "( =0         6F "0
M_P @                  !XI!, $ $$!AX
M
M
M
M                  Q]FG5(      #@   (
M
M                6@4R2 "D04BQ@                   #\$($$%,@TD4
M$"S@        #)MH@$#(                    0@A -H$@ @@#@
M
M
M
M                                <O@     5W     "@   4
M
M                                 &TP"V6$"4DB,
M      <F @$ @LD$RB@E8         )!-L$%                      *@
M$(!A @ $&@
M
M
M                                                -4        #V
M@   "@   4
M                                                  .D2F"R6P@4
M#@                     #L2@ $D I@D&40\@         4,)KX
M               6"T$A!,($$!
M
M
M
M    .L          "S@  "@   4
M
M      "$&0F0262F&.@                      <L8V $$ %, @@6T
M     &R@!                       6& 4$@(-I @D
M
M
M
M                    !\            !   "@   4
M
M                       !T4DP$B"VRBD                       #@
MEADP HA L@$ +         !"R<                        \D2&@D )AH
M8
M
M
M                                     -             =@  "@
M4
M                                         @4BBF$@44T
M                >D$,.B % (EADUT         ."(
M       4$@R6@$ !,(                             .VVVVVVVV
M                  #VVVVVVVVD
M
M                                                     #<
M        8   "@   4
M                                                         5N@
M2@$2P@&]                         !L @@-6 %-!$,,_@        %"
M                        /D @&$4 @@+
M                                   "@       (
M
M
M          #@      27     <   "@   4
M
M              145X"D B0D$                          )D 0 #<0
MMA,AJ<         D                         !FD@$ 0F@$&@
M                                                    "@
M (
M
M                           ,     -!8 ; 0 #    "@   4
M
M                                !@B/ 4 "%8
M        #8@@@$ *B %@)D=@                                  "\
M(6@$@"DP"@
M         "@       (
M
M                                           !8    %8     ;<!@
M   "@   4
M                                                ;KBL$C9V@#
M                          8DD$$D@-6 $L-&0
M                4@!4D$@  DT
M                          "@       (
M
M
M     !@       >6    "@   4
M
M     U;M<5@'U.F                            # @D  $@!FV @ @
M                                 06$,*@ D$ @
M                                           "@       (
M
M
M                  @   -         (    "@   4
M
M                     "Q>SI$BB@4 @
M :H $  @D%LRP$#4                                  "L8P@A& D@
MD
M"@       (
M
M       !)))))))<                  4    $              "@   4
M
M                                      !DPK4= C48L
M                  #.X $  $  M"& R
M       !3@#$ % BD\
M                 "@       (
M
M                        4                          4   #<
M           "@   4
M                                                       #H$#U
M;'H$:H                              =6K     D E@&R@
M                        # 34!Z $H0X
M                                  "@       (
M
M                                         4
M            "@              "@   4
M
M            "%= @<C8=$P                              #,2Q<
M@ D@DL,T@                                 @P">@-  L4
M                                                   "@
M(
M                                                          4
M                         0   !@              "@   4
M
M                             " $?KD-(O#<
M           >T 6< $$ D$$AAD                                #)
M$" 9T/$ <
M        "@       (
M
M               4                         !    -
M  "@   4
M                                               " $#I<QA%8
M                            #M@@4'SDD$$@$$-
M               !OA&D43<!H
M                         "@       (
M
M                                4                         "@
M   <               "@   4
M
M    D@0DB5+CN@                                ?T.D"R^<$@@@"
M(                                =_<44RB>IY
M                                          "@       (
M
M                                                 4
M               #    (               "@   4
M
M                    !I@@V$$4I<
M   #D @44FT7D@D$$5@                               4#/3JF"V3B
M@                                                          "
M@       (
M
M      4                         "    (               "@   4
M
M                                     !Y=!@&PD6@@
M                     :  %B"DT'\@$@@,
M       <G (P9>@TQ@
M                "@       (
M
M                       4                         "@   4
M          "@   4
M                                                      #DEKME
M PDA                                  "@D@A,4T@BO$$@3
M                        8 $ !V#7T$@
M                                 "@       (
M
M                                        4
M      "@   4               "@   4
M
M           "=XD/=)HR&                                   5@D$
M$IB6F05 @G\                              1M$ @X. :]
M                                                  "@       (
M
M                                                         4
M                       "@   4               "@   4
M
M                            #@7/$A?()G@
M             "#$@@@I(6@BE $Y                              $)
MM@@$'!X8
M       "@       (
M
M              4                         "@   4
M "@   4
M                                             " D"Y<@+L-8
M                               53P$$ I=64$58"8
M              "6AA- $  X
M                        "@       (
M
M                               4                         "@
M  4               "@   4
M
M  !>0DDC+<K=4                                   "D&8 @ %>NR
M6KU@                           !"644)I$@ T
M                                         "@       (
M
M                                                4
M              "@   4               "@   4
M
M                   #T'3TDD];I0
M      4 BT7D @O4P 23@                           "F >0"I--D$
M                                                          "@
M       (                    OY_C[
M       )#_K/                                       )0<@
M     4                         "@   4               "@   4
M
M                                    !T4 #>$$FKX
M                       "VDFPJ\$$EVD$ $
M     "@FP X0U )H
M               "@       (                 *G1     \$<
M                     +_<@   !/;P     /\ _P#_ /\ _P#^@    !__
M /\ _P#_ /\ 0     $^6W             %
M  H   %                H   %
M
M       94QH /T((.                                     !(H!%E
M,X()#J=)!                           5%%MAY %X"
M                                              H       "
M           T7         !%8                         HK
M '.            %             H    SO         "
M        %          0   %                H   %
M    "%6:@#@^(5              @   %                     #%KH
M                   P   J)9*F-! ^I!0
M            AA- ,,!Q ((1 H                          #"4 ALD/
MB K
M   H       "              &YX            'B
M     "2(           &\H          %             H   68
M  "                      %    H                    H     H
M %                  _8        & (                "
M          $,  K                     P   0\@2(9PI)&IP
M                             %(D%H)AD*P!! +1
M         !A!3@,HDI.!
M                    H       "             %7               "
MO                    "7               ?          %
M   H  L8           "                      %    H
M        H     H   %                 G            V-
M  =   #                    !   &H                   '(    '(
MU"93>$I'"                                      A $(A!-%/0()!
M*8                        #(,!*8!E$!P
M                                     H       "             Y
M                 "$                   ;                !&
M      %             H !0            "                      %
M    H                    H     H   %               #Y
M       'R              !X                   \    ]
M         "   '8 P!&!; ;YD*
M    %@H M$%(HIQ!)(O                        <%!  +9 ,LP
M                                                      H
M  "            \@                   H                 \(
M             #0        %             H 2             "
M                %    H                    H     H   %
M       '_                !H         %    X
M H    !                   '   ! !%&:$P3"*5O
M                      @DE E(@A%%^()&X
M!(HH-%)3()X
M           H       "                                 V
M           X                   2        %             H$H
M          "                      %    H                    H
M     H   %              2                  RX        %X   ^
M                 #X                        P   ' "O#0Y8Z"09%
M0                                       @EL(% )$ !CP(^
M                !@(%%%-(I2,@
M                            H       "           4
M          !T               [                    #8       %
M           H'              "                      %    H
M                H     H   %             #
M U         @   %                        #H
MH   X  0@X9_+N9++O                                       ;ED
MIA@H!,@(LP#X                     '!3 ((%AA$*
M                                             H       "
M    D                       %(             #X
M      J       %             N(              "
M       %    H                    H     H   %            '8
M       #0         %.        ?   $                         0
M                'P      #(+D".R=8+1
M              !HMLA%,M  M!!FY                     H(0*(!  L,
M
M  H       "         !H                        F
MP                              %             &
M "                      %    (         '          (     H
M%            >       C.:P"=!@       "(       "   "X
M        1      H                 "   'P  &[9",@0I3BL
M                                8%%-% LE((E(-KH
M       @!0")80)E%O
M                   H       "         Q
M   %            "                               %
M  X               "                      %          H   %
M             H   %           '8      8X       Y       Q
M  "    P                 (      =                 &   &   $0
M'_(;[)]#4Q                                       !)!HIAH!DHI
M$H(4                   [5H!301##(,(
M                                    H       "         H
M                     0           5
M     %                             "                      %
M         H   %                H   %           ;     '&
M    8P     $(      #P   8                &8      %
M       W        I+ [@+')&8?8
M       M) ,M,-!,E$(H!@                  0 ?$ (:2(89H
M                                                     H
M "        &X          %<M89P          Z          #0
M                      %                             "
M               %          H   %                H   %
M  '@     /            7P     H       (   +                %
M      #P                (   >   &Q%$)#?!7;/K
M                        %<@H!EE@I(@(@M!                 #0!
M"8 );29 H
M          H       "        :         !0X    "B          X
M      7            *>UHD               %
M         !MMMMMMI       'MMMMMMMO          H   %
M    H   %          W     _8             ?     &       (   #
M               $   #    0                X   X    P!)HH)?X&@
M(_                                        K%L$)LLD$I@ D!@
M             2!!((#5@!+!4
M                           H       "       #@        !7
M  ">         P         H          '_      (;P            !0
M                   #Y:0^          !0
M *   !0               *   !0        !     !F               P
M    !R      (@  !P               /0  !B   "               !P
M   6    -&H "302_P #<&
M  & "D""RV"F2T 4H              #M@D  DDAFR C\
M                                              "@       (
M   ,        #,         'T       #,        %          1@
M  ;(            4                  #R>               4
M                   "@   4               "@   4         (
M#$               "$     (      $   #               "@  !/
M!,               $   ,     (%,D$ 2,)\ ](
M                   "$0"4&P6F 6R2 4@             .Q, $@ @D$,P
M2@                                      !
M   !        (      "H       !Z@          ?@       ?@       8
M         "@         6H           4                 #]
M          4                         "@   4               "@
M  4        #H    1@                2@    $      =@  "@
M        #   #@    ,              #0         0V5I, D"XA7@A
M                                     ".B@4 V"TP"VV&D@
M    !J$6X $  $  L4@
M                             (      "        /@           #X
M       !       !D        "8           <@          4
M       !M@                 4                         "@   4
M              "@   4        !    !\                 "8    %@
M     "   #,              <   :!(   (              !@  #H
M " B"X)D D5 OL<                                        ,,$46
M@&$2F2R4Q/          !/*R@BK  @  D!
M                                              (      )@
M !\             .       #H      #@        !            !0
M       4                *@                  4
M          "@   4               "@   4        >@   "
M          -    !@     #    8              4   < $   $@
M           !       *4 0',B  3(%^@
M            2-!@2B$&0D0262E6@        Z@I4R0"U<  @ D
M
M   (      $       9              #X              .@        0
M             )          4               !0
M 4                         "@   4               "@   4
M  0    <                   #D   !X     "0   8             "8
M     ,    @             (   #       7@P@REY@ D"ML4
M                             "1C:D"T6DP$BBVBB$D     \R\D$%ZF
M4"28 $$W
M                    (     "4       (               '@      0
M      4        +@             !\         4               )
M                  4                         "@   4
M     "@   4       !T   #8                    ,    (      4
M /                 "8 #@  "4             0   +       "OT""B4
MY,$@DU(                                        1ALYL 4"BV$@T
M4TT#]/<7OD65'@@DN$@@47SB@
M                                     (     #        8
M        "@      '@    #(       #T               -@        4
M             #L                    4
M "@   4               "@   4       "    "
M  %    )      ,    @            !           <             4
M  0        <C[$TTV7IB$ 2(
M    #?!."O 2@$2T@&FF&@F2BD4 RRG<$ AT.DBR\@
M                                                      (
M#@                       !(       @    #@
M               4                                    4
M                  "@   4               "@   4       /    9
M                    @   "@     !   #@            +@  !@ #,
M              !X  "<        =SCCD@FFRIA@@!@
M                      :+8-41X"D 20D RVP4$0$0V@&& X@$$ H44%
M
M           (     ?@      =                 <      !      @
M     >@                T        4              /@
M         4                         "@   4               "@
M 4       ,    $                     !4   !      !@  #8
M      $   /   (   )@           #@  !          B#<9( "T"P-($X
M                                       #S]<!@B/"4 "V"@V66"4R
M 2"T$PV%8 @ %C@
M                            (     0       $
M8@     !X    #@       ,                          4
M    8                     4                         "@   4
M             "@   4           #X                          !\
M     #,   4            <   4   0                )
M   /40*CY$DRD45I$                                        ?3=
MKBL C9V@ 4@0F&P026 "T0DBBGL$$@M
M                                             (     (       H
M                 #       ,    ?@      !T                 9
M      4             !H                     4
M         "@   4               "@   4      "(   !
M           ,    $      (   )@          !@  !D   3@  #
M     ,   )@         "-B@A5G\@&@BB-\
M              "CV;MD5@"YND 2DV"RP"F00 4B"D46X@FX
M
M  (     (      !@                  @      <    ,       "@
M              !@       4              @
M4                         "@   4               "@   4      !
M                            (    (      8   "@           @
M"     @  ",               $           "Z,@FH/+$"0&R,
M                                %1>CI$BB@>-T0"@&@6F 6R2@2DT0
M@"_"@
M                   (    #       "@                 !@      (
M            #@                 "@       4             #
M                 4                         "@   4
M    "@   4      #    $                            ,      ?
M             9   "    #D   $          !4   0           #4'-D
M$T!ZD@0$V\                                       #L^K4] C$8E
MALB@4 V"4P62V$"@$B !8
M                                    (     @      "
M        !@      $    4       (                  !0       4
M           >@                     4
M"@   4               "@   4      !@   <
M  "@   "      "@  ",              :         *          !   #
MX            /OFT8@FAO:@FD#
M       3D#E;'HD:C!-L&46@R$2"2R4PP4 F2@
M                                                     (    "
M       __P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#Y      !    &
M   '                   &       %             $
M        %                          H   %                H
M%       @   !                        (    X      P   "
M    &   '     $    8              H              %>DCY M"3]!
MD&                                        %T(').'1&P&&3(%HI!
M@)$%MD )EHN                                             '_\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ \        @    "
M                             ,    P       0
M  0      !0                                   !0
M             *   !0               *   !0      .    0
M               ,    "      !P             "   ,P    !\
M        R   <             !Z",[:QQ32&.J!*
M                     %.N0TBX-R,@W<* +113"0**:*!:F
M                                                         *
M      @    ,                                  &            @
M                   @      !0             @
M   !0                         *   !0               *   !0
M   ,                             @   (      !@   <         "
M   &      .   ,@         P  !@              (300K1C_ "BC,?8\
M                                        #RM<UI%X[$8)@MT"4"B6
M$ T4PR
M               "@       (    !
M    "            (                   4       4             $
M                      4                         "@   4
M         "@   4      (    0                        $   "@
M   ,@  "@        5@  "      #@   (        #X   ,
M   6"F@'V7G^6T<?8@                                       !RB
M5+CM,+G9;!*BO 4@$2$@&4H
M                                "@       (    !@
M                     #@  !@       8                   ,
M  4             $                      4
M     "@   4               "@   4      (    8
M        8    @      #   #T        4   9       4            !
M@  !,               "0@$TC^F\1R0+CT
M                6D4)(9A@6[+@-41X"@ 2045
M                                                 "@       (
M                                      "@  #@       (
M           (       4             (                      4
M                      "@   4               "@   4      4
M0                            "@      "@   ,        8
M   4   &        "    @                $P@@VD<DR:"B!5
M                                 #+D6A)G"M6;]<5@D7.T "J
M
M      "@       (                                       "@  #
M@       8                   8       4             ,
M             4                         "@   4
M"@   4      4    $                            "@      "8   ,
M       "L   <       .@  "        +   #@                "+N$$
M&T3A$FL40$                                          '$B%) ,1
MJK=KBL VIT^@
M                       "@       (    !@
M            "@           <                           4
M       4                      4                         "@
M 4               "@   4      <                             <
M   #@       $   :       "   "T           !X       8   .
M             )0>  $V"*LPQ@#
M         "9D$0] %B+V9(D44*7
M                                        "@       (    !
M                             !@   0       8
M  (       4             4                      4
M             "@   4               "@   4      ,    ,
M                4   !        (   #       !    @       #@   <
M       (                      #8:#P0$VD4UBZ P
M                            0V@"+H F1;CI'!D
M                                                         "@
M      (     @                                 "    0       $
M                   4       4             4
M    4                         "@   4               "@   4
M   =@   (                        ,   !        #@  !       $@
M  ?        "L          "$  !X                   > B B"$&D"U\
MVO@                                           !'% E= @>_IC
M
M              "@       (    "@      !)))))))))))))))))))))))
M)))+@   ,       <                   4       4             4
M                     4                         "@   4
M        "@   4      #                            !,   !
M       #X          0         ,   9      "   #
M     !] ' $20@T@BKR(
M      68M4[\
M                               "@       (    !        @
M                         0       0                   <
M 4             4                      4
M    "@   4               "@   4      !@   0
M      #    #@       #<   (     "@   ,         (   #      1
M                       !<P$J @2D6D$5W
M
M                                                "@       (
M  !@                                      $       7
M         !\       4             4                      4
M                     "@   4               "@   4      #    (
M                        @   #         0   <     !@  !8
M   !   !@     ,   )@                    !-#* V G"4&D AD
M
M
M     "@       (    !4      #(                              0
M        @                 #        4             4
M            4                         "@   4               "
M@   4      !@   #                       #@   <         8
M     #    @         !@  #L     (   $                      ;!
MD"2&,$>4@TT%@
M
M                      "@       (     <       8
M                <       !                  !        4
M      4                      4                         "@
M4               "@   4      #@   !@                      #
M  8         5   "@    +@  $@         #H   $    !<   <
M               #HALD0450CPD"FD
M
M                                       "@       (     $
M  8                              )       !L
M-@       4             4                      4
M            "@   4               "@   4      !<   "@
M               @   <          @  #(        (           <   ;
M@   "   #                        8$D($B:B"#^$$$
M
M                                                        "@
M     (     4       #@                             "        $
M                 $        4             4
M   4                         "@   4               "@   4
M   (   #T                      0    <         #@   ,    ,
M(           3   !@   "@  !                        #:T$!@#ZT(
M080@T
M
M             "@       (     -        X
M       "        9@               !T        4             4
M                    4                         "@   4
M       "@   4       <    <                      ,    T
M    <        <  !,           #@  "@   +@  ?
M        &+P $HD\6A2#L"@
M
M                              "@       (              (
M                         <       !                4
M4             4                      4
M   "@   4               "@   4       <@   ,
M    !@   !@          8   ?       #@           "   #L       8
M                          4H&$@(,#B@C0>0
M
M                                               "@       (
M  !@       ?                 "<           ,        ,
M                 4             4                      4
M                    "@   4               "@   4       !@   7
M@                    "    "           2@      '@  !
M   !4   8  "\   <                          ;&D<@$AE#]4$0%
M
M
M    "@       (     "<       !                 6S@          (
M        (@             #0         4             4
M           4                         "@   4               "@
M   4            #                     '    ,           "   !
M   ,   &@                   #@  "8
M!800(P  @(=($^                                   =@
M
M                     "@       (      (        +@
M  !H"@          +         $             +          4
M     4                      4                         "@   4
M               "@   4       #0    ,                   !,
M,           !@  "(  0   0             ,   %@ "    @
M                  0DDBCT$@$-GB &
M     "H,O@        #
M                                      "@       (      1@
M   "<              ?@             @        +@           #\
M        4             4                      4
M           "@   4               "@   4        $    )@
M                 H           #,   $ #L  "T             ;
M@ =   ;@                           #L; &T;JD@A(=0,
M                      &R%</L8    ":3
M                                                       "@
M    (      !         <\            (H  ?          #D
M"X@         !&@          4             4
M  4                         "@   4               "@   4
M   =@    $                  =@   "             <   /     #@
M            "@  #D     4                             :; X 6:
M<4$@) +@                              #0!N$F(*X*SDL4P
M
M            "@       (      "(         *(          5\   #(
M        $          D         /@           4             4
M                   4                         "@   4
M      "@   4              4                 !H    6
M    /   "@!@  #              #L   $ (   0
M          !B84;DR#PF $-DL                              +#N O
MAD0A@B LK@
M                             "@       (       =          0L
M       /4     0@         -@         9       #X             4
M             4                      4
M  "@   4               "@   4        "\    "
M .@    D             "@    ;   :@              0    !L  "H
M                            3A#A>X&D9^P@AA
M           !<4D-\%]L^@D"P8
M                                              "@       (
M   !           1T:@   *<T      #H         !H          " #  #
MM9              4             4                      4
M                   "@   4               "@   4         =
M 7@              !X     @             "@  !,$   4
M    0   5    "                               !>!0'SW T"/VD@8
M                            "@F"@E_@: B) ?@
M
M   "@       (                     ".B!-          ;
M              TW@@               4             4
M          4                         "@   4               "@
M  4         "     "<              5     =@             !<
M3H   L               ;   "7@  !@
M   +X8N@;"$2 ->@"                           !5J@ $T@O\C1D34
M
M                    "@       (        )
M       X         /@                               4
M    4                      4                         "@   4
M              "@   4          0     1@            *X     ,
M             8   "@  #@                @  !\   /@
M                     5?2:$@^0FD%\PL
M >0%-D$ 2,)\$Y<
M                                     "@       (        "L
M                                  #\
M       4             4                      4
M          "@   4               "@   4          '@    #;@
M      +      5@               ,   7                    !X
MP   4                                 &=+Z!0DF, 0TKF
M                 !X$V5I @D"\ =@H
M                                                      "@
M   (         <@                         #<          =@
M                        4             4
M 4                         "@   4               "@   4
M     T      @4        88     "@                '@      )@
M             ,      "0                                 #TKCG
M (D'"@"" $                        ! B@""-)D $U L
M
M           "@       (         #D                         9@
M         "L                      :       4             4
M                  4                         "@   4
M     "@   4           +@      ,M@    72,      4
M    "       0                 8      #@
M             <]'=649& N<DD3@                       !'T&4 P/L
M@@ 3!@
M                            "@       (          +@
M             #\            '@                    !H       4
M            4                      4
M "@   4               "@   4           #X       "M'@+*(
M  #,                 !D      ,                 7      "
M                              #$UK[HAC7WGL8$X
M       #<!IJ@PDREY@ &8
M                                             "@       (
M     #E@                      /@            #X
M      ;@       4             4                      4
M                  "@   4               "@   4            2D
M                   ,@                         P
M    "@     )@                                   !P$%?O#L8J<8
M;!@                     'RBE,?4"BB2Y$;
M
M  "@       (           #4                     %D
M  .H                  #4        4             4
M         4                         "@   4               "@
M 4             !                   'L                   8
M  "                  #@     <
M     "(V@#+]6!S%S>!4                    "'N^6T83X$4PV4
M
M                   "@       (            *T
M  #T                8@                 )@        4
M   4                      4                         "@   4
M             "@   4             !,@                !L
M             ;@    '                  "T     0
M                       3A.H@)?H9B3N8:@                   #<V
M\?RP3B+D@FG@
M                                    "@       (             <
MP                 !'@                ![                88
M      4             4                      4
M         "@   4               "@   4              #C
M       ##@                          0
M !X                                     #6(-]$A7!1L0=#X
M             #*D=$SZ"R#<>(',
M                                                     "@
M  (              <X                4@                  #C@
M           ?D          4             4
M4                         "@   4               "@   4
M        !P              4@                     #X    <
M             (@   /@                                      6,
M5!WH&+D2_2!V                  :$&TCE NL40*CR@
M
M          "@       (               3*              +
M             !O4           (L           4             4
M                 4                         "@   4
M    "@   4                #W@          "U@
M     ?   !@                   #\  !@
M                5I+<BE 5\A;Z08                 &  DV"JND\"BA
M0
M                           "@       (                #&V@
M     'VL                        (=        !UH            4
M           4                      4
M"@   4               "@   4                  >X       &EX
M                      !AN<\                     8>AE@
M                                 .%A+BD58F\D)_3@
M   +Z#P0$6D4UBZ,B@
M             ;__ /\ _P#_ /\ P                      -_P#_ /\
M_P#_ /\ P                  %U]@DA$_".@
M     (H8G(./S8P      -__ /\ _P#_ /@     ?_\ _P#_ /\ _P#0
M                  /_ /\ _P#_ /\ Z                  W_P#_ /@
M              !?_P#_ .0                   !JK0DHZ'@
M                   !D                        -
M                             /#1@QW2*8(N5UQP              *:
M"("((0:2+7S<P
M
M
M
M
M
M                                               C!8\$GR0)!4CN
M"              F.D2? 0!"#23:\
M
M
M
M
M
M
M    #/Z*7@.001**U^P            /2$SQ "@2!*1:>
M
M
M
M
M
M
M                      8#R!!Z0P""I2>F0          *5200D.(#8"0)
M0R
M
M
M
M
M
M                                       #  <18=2&$ ;"#@
M   !U-.* 0$@% ; 1T0
M
M
M
M
M
M                                                         8
M/B*#2&0@!4N(        QR9!Z3 "&R!-1(<
M
M
M
M
M
M
M              #   !R;!("T$&ZP8     !BPN<#2,_800@2)A@
M
M
M
M
M
M
M                                8    .?282&$@[_J@  6U0H"=[@:
M#'[00&!0
M
M
M
M
M
M                                                 #     !AJ!2
MTPB#0@71Q/\ 3%T#80F0%KP #P
M
M
M
M
M
M
M        &       !T2,I%4BJ$7DA.Z+0$'R$T@L&'
M
M
M
M
M
M
M                          P       CNB'!CZ$<0R\KI?0(GD1@"&'4
M
M
M
M
M
M
M                                           &        $=BUX,/D
M@&"+E<<X!&@Y4$1
M
M
M
M
M
M
M P         _P4O)5@DB47XYJRA$T%P<
M
M
M
M
M
M
M                  &          'D6GTBH$-:&M?= (:^W@
M
M
M
M
M
M
M                                    P           \DP:D/0 J$#+
M]Z=C$
M
M
M
M
M
M                                                     &
M      ?D6&\ABEFT 9?JY@
M
M
M
M
M
M
M          #$            #DBB4MI(-U$!(@
M
M
M
M
M
M
M                            $              <^PPD/!![HE
M
M
M
M
M
M
M                                              4
M #GT&@ABH,4
M
M
M
M
M
M
M   /<                NB5MI'@
M
M
M
M
M
M
M                     9@                =00Z
M
M
M
M
M
M
M                                       *@                CR(
M
M
M
M
M
M
M                                                         C@
M              #@
M
M
M
M
M
M
M              !Y              9T
M
M
M
M
M
M
M                                 /            -H
M
M
M
M
M
M
M                                                  "YF@
M #D@
M
M
M
M
M
M
M         #(2(^VH&H$
M
M
M
M
M
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M2X2O"P*U0Y7- D/-U% F0_;%ZZ008F4F+MV8/8$L6C(A*\X;1V)J?\I-H;B
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M\\AEL,! 9$$JC8?$F'>W'B073$@U$8/$" H<+#F,EG\I2E%#\C..6((0J?\
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M4P%_^:<=V)(ZD5A Q,V.(-"0P6VUPW812VN@NL<;4(UY/GI4=1._G>C8>_\
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MI0B(3! 0OT?LX!0(L"@1$$2&53]CF )6P$[3<S,V,K1<9NP%* @\-H$&UPA
M&)2^,0-&8:$8:-LZ?- </U$8:-LZ?-".'_R,W\??WF@ZV[T.H\Z&9OV_E#:Q
MQ\C]!;FN*]0QQ6TP"+J-QS?]JMZ4F((_^9U>H(&0)M5P:AVB#OL.(QM, N6O
M-#,WXYZ_[0=;=_.E",-NIYPHVCS>/FZ@.&_1]Z&9OV_E!=W'W]XH1AMU/:C;
M.GS0'#_&@M9X^37&/-TT+1_I1MG3YH#AAZ/G"AF;T'6W>AY&>-Z#J1YYMH1P
M_09F]!UMWH6C;C;VH>I._P ^*&UCCY%2YF^VAF;G>@N[TJ1PS06L\?)H.I'>
MA'#0IAH>L/9\Y4)KR;?'?ZBF%J6H>GO1L*;G'M1M'3S^T!P\M?J*87S=1MG3
MYH#AY>?SZRF%.<_':C;.9YYLJX@21"$&4+ V5&-*YLLX=B* Q>X(>A^O@M(L
M51 K[<0HK.+DR,;+"<3*7XNWZ!3#0M3I0'7K;SK]8-7G?UHVSI\T(X?J!K/&
M] U.E".'_P CUOVH+FU"F&AZW[4!UCC;\YI E'#)PJ^+&- F."IDH281X0K-
M+UG#*1 )19(1&P/_ )E*=N!RQJM S$&50SIHH)*1-R($R(+#*A'"?0189/.9
M4-1]?:A-'HWH>L/9\Y4%W<??WBA&&W6C;.GS1L/1O0];]J&W<:$8;=:-LZ?-
M!TAV]J&9OQSU_P!H.LG?SI0M&3J11MG3YH#AOT?>AF;^M!VP^:_Y06L\?)H.
MMN_G2A&Y]!ZW[4%W<??WBA3"^;J-LZ?- </+S^5*84H>L-!<V?-:X4,W\?)J
M&H^OM0CAFA3"^;J'J3O\^* Z\GST^HIA?-U#U)W^?%;!Y/GI1M'3S^T!P_41
MA\X-&V=/F@.'ZEY.ZE"0%)A;](!1G<9# EP"",%+&S_6DMA"39+8!PJRA*#7
MI1@F2((:@H!2H:&9OV_E#:QQ\CZBF&C;.GS4FISMZ_41KUOYUJ&H^OM0CA^H
M&L\;_-!UMZ>>30CA_P#(];T-K''R*%,-"U.E <,/?SK^:,Y ,!*5@B*H* %D
M@@+HEAY14@__ )D.2[( S"[=K_$2%U,@,)MK>!+& S,@1KU\]*-JV\\FMX/'
M/OUH.LG?SI4CA'Z :SQO\T%S;O\ RAV/1KA/FZ*"[N/D4,UGC>H:CZ^U&P]'
MU^:'K?MYTH;6./D4(UGC>H:CZ^U&P]&*'K#V?.5!<VX^_P#E(89.I4-1]?:C
M8>C>AZW[4';#T[T,W\?/6:#K;O4CAGZ#,W[?RAM8X^10C#1MG3YH#AH4PM2U
M#T]Z&UCCY%<*&;S?[T'62I'"-"F%\W4;9T^: Z\GST^LIA3G/QVHVSI\UL'D
M^>E1U$[^=Z$<)_>GU$8Z-&V=//>A'"?WI6119$1N)$,FHBC)K"7K0'XM8AA&
M5&=@KA/\$#'B0 "K0,_J05 4  JE@ )55  9D 5"CVW;J6B(21!0BAXFDQG0
M0'@ $06"AM8X^1_X%,-#,W[?R@.L<;?41AHVSI\T!P_4+6>/DT%S;O\ RA'#
M/U"UGCY-!<V[_P _\BF&AF;]OY0FL<;?%2,/G#!RHVSI\U)J<[>OY8^V15L+
MEA((YJ1=(^;H(=(F '_YC=5L9$"R7)@;D+(I "$ UX4*I=*"B%%599DF&H^O
MM0CA/J(W\:-JSM/)]:%M'S=7&.)[34CAGZ!:SQ\F@N;=_P"4;#T;4/6'L^<J
M X8>CYPH+7KYZT%S;O\ RC8>7Q0M3I0FL<;?%"-_&7^T%S;O_*'8]&I:AZ>]
M#:QQ\BAFL\;T'6W>C8>CZ_-#,W[?R@[8>G>AZP]GSE07<[\=?[]!3#0S-^W\
MH36.-OBA&O)\]*-LYGGFRA'"?WI0IA?-U#U)W^?% =>3YZ5PH9OX^_O-<8XG
MM/T%,-&V=/F@.'ZBF&C;.GS1L,[GYO0=9._G2A'"?41KR?/2@ZVWGKY-;%EL
MY@A;!&,,$T8CLPD,*)-S9+A^G=\6@>+J2=@%X LD@HQ061<<3LRHH&9OQSU_
MV@ZV[U(X9H4PT/6_:A-8XV^/_ IAH6ITH#KUMYU^HC7DW(HVSI\T(X?J%K/'
MR:#K;O\ ^!F_C[^\T'6W?_R*8:EJ'I[T)K'&WQ4&KSOZT;9T^:$</Y)JRLQ1
M@LP%@!#%.PA,E&9LF20A_P#,0,@HL)B_-[-W<DB(T9&,  "P! #< 9C%2.$:
M$:]?/2C:.GG]H6C.Y_NM<8\W34CAGZ@:SQO1#:<'_*);'U^.E!=W'W]X^HS-
MZ#K;O0M&W&WM0]2=_GQ0=L/3OCO0S-Z#K;O0M'HV]J-LZ?- 6S?HT%K/'R:#
MK;O0M'HV]J'K?U]J#D8>CUQWH>V>-^]!<V[_ ,HV'E\4+4Z4'1CM0];]J"[N
M/O\ 04PT+4Z4)K'&WQ0C7D^>E1U$[^=Z$<)_>E"F&C;.GS0'7D^>E2F&*'K?
MMYTH+FW'W_SZ"->OGI1MVWGM?S2@.'ZB->3YZ4;9T^:V#/'R?Y0=9._G2I'#
M/UB*!@UUMY=^ 6DE5 $I"R!$$HAA$?TJ*B'%J\%V(-+!$\H"NCTLGDD21I,:
M8IA?-U#U)W^?% =>3YZ4.I[4/6'L^<J"[N/O[Q]!3#4M0]/>@.O_ (D8?.&#
ME1MG3YJ34YV]?J(UZW\ZU#4?7VH1P_49F]!<V]/_  /6_:@N;?\ D4PT;9T^
M: ZT(PR=O.E0U'U]J$</XX)OF %F1)Z@((;G=G465AP\F@?_ ,PI(LI&PE-A
MX)#;55  L%@8 (0+6-(P02F!"UGCY- WF_R];R3OYQKC'$]IJ1PS06L\?)HX
MCAX5O)]??K0=9._G3ZRF&*&9OQSU_P!HAM/3YZ42V/!_VAM8X^1]1ZW[4%W<
M??WBA:-N-O:C;.GS0'#?H^<*&9OV_E!=W'W]XH6C[<M*-LZ?- <-^C[T,S>@
MN;>E"T;<;>U#U)W^?% <,/1\X4,S>@ZV[T/27?WHVSI\T'1_G^T/6_;SI0FL
M<;?04PT;9T^: X: UGC>@ZR=_.E".$H4PT;9T^: X:E,*<Z'K?MYTH;6./D?
M01KR?/2HZB=_.]2.$?J(UY/GI1Q'!_RMX/'/OUH.MN_G3Z,7*500*L7PT,,T
M=<$H97L/Q90\% 'Z..@ ) =026\  %NH!$=%!"9;@+"8'Z!F;]OY07=Q]_>/
MH*87S=1MG3YH#AY>?RI3#%<)\W10VL<?(^@IAHVSI\T!U_\  C#1MG3YH#A^
MH6L\?)H+FW?^4(X9^DIABAZW[4%W<??WC_P,S?M_*&UCCXG7_P B,/+2C;.G
MS0CAH1K/&]!UMWH1P_C2TEF9%"YE(.AEO_F )N"G+6E)8R2O";;FJV-HL!$7
M8@M!&W%OH(PT+4Z4%UCC:AF_CY-&\]5^E"W/FZ@N[C[^\5PH9OX^31Q'FZA;
MG;H\]G2@N;<??_*D<,_49F_KYRK>)QQ[=:.;>/G\H#KR?/3Z2F&*&9OV_E#:
MQQ\BA&'^E&V=/F@:/\:'K?M07=Q]_>*$8;=:-LZ?- </\:'K?M07=Q]_>*%H
MVXV]J-LZ?- <,/1\X4,S?U\XE!=W'W]XH1AMU/:C;.GS6T><&AZD^>;*$UCC
M;X^@C#RTHVCI[/FZA'#BAF_C[T'6W?SI4CAFA&O)\]*-LZ?-".&A3#4]0>WG
M:@.O)\]/H!K/&]0U'U]J$<)]0-9XWHAM.#_E$MCZ_'2ELE)XL('8EP!AXA4+
MHD!K+A_)")!P#?\ 0*^ETF@ P%V<9D FIP8PH"&8+"&:8>L/9\Y5O$XX]NM'
M-O'S^4!UY/GI0ZCS*'K?M07=Q]_>/H(P\O/Y1MG3YH#AH4PM2U#T]Z$UCC;Z
M",-&V=/FA'#_ .!&O)N11M'3V^:$</U&;^/O[S0=;=_J*8:&9OV_E#:QQ\CZ
MBF&AF;]OY0FL<;?'_D1AHVSI\T(X:"UGCY-!<V[_ ,H9N?B$#@!< )GN"0-"
MZ?\ Y?4@"6NVD;=U@=I8L)5F)-GA:T8Q#C"AZD[_ #XHQOR?Z_-1U$[^=Z$<
M)_>GT$8:-LZ?- 6S?HT,W\??WFC>3T\Y42V/#QH;6./D4.H\RAF;GFM VIYN
MHEL>'C0VL<?(^LIA2N$^;HH&BG'R.M&U?>>>;* Z\GST^@IABAF;]OY0FL<;
M?%",=&C;.9YYLHV'O_*&9OV_E#:QQ\BA&L\;U#4?7VHV'E\4,S?M_*&UCCY%
M",-NI1MG3YH&C_&AZW[4-K''R*$8;=:-LZ?-;%\X-&T=/;YH#KU\]/H(UHVC
MI[?-$L/\KA/$]HH.MN_G2N%"->3YZ5'43OYWH1PG]Z4(PT;=]_Q0''1S]!F;
M\<]?]H.LG?SI4CA'ZA:SQ\FC6C!Q> (B0A4$D#3C'"9E4L^75Q(*C=?G&&4,
MI( E20 O@F0IPQP1!S*J6 "I*4;6./D?64PQ0];]J!HIN?(HVSI\T!UY/GI0
MIAH9F_;^4-K''R/H(UZ^>E&V=//>A'"?WI0IA?-U#U)W^?% =>MO.OT$:\GS
MTH&ITH1P_P#@1KUOYUJ&H^OM0CA^HS-Z"YMW_GU%,-#UOVH#K'&WU%,-2U#T
M]Z$UCC;X_P#(&L\;_- U.E ;CCE0S-Z#K;O4CAG\(&FEMZUON85*4/\ \O*>
M%N,Q+(@7P+*&3094   !8 B(+03<MI$1.I6\G<Y^>]0U'U]JD<,T(P^W3%&T
M=//[6\G<Y^>]0U'U]J$<)]!3#1MG3YH#AOT?>AF;^M;Q../;K1M7WE =>3YZ
M4.H\RAF;UO$]/.)1M7-IY%":QQM]13"U+4/3WHV%-SCVHVSI\T!P_04PT+4Z
M4!QG90C7D^>E1U$[^=ZV#R]RN"WG7M0FL<;?%"-_&7^T%S;O_*-AZ/K\T/6_
M:A->MJ$:]?/2C;MO^*!H^<-:&9OV_E#:QQ\B@-9XW^:AJ/K[5L7S@T;1T]OF
MA'"?WI] -9XW^:AJ/K[42P\8DH>L/9\Y4%W<??WCZ :SQO4-1]?:A'"4(PT;
M9T^:$</T&9N=ZXQQ/::D<,_2">0XL('8F 61R@KQWBVLA1\A0(@%0 3^; -(
M#-Z(:W&0A &2 X9^DIA2AZWWZ^=* [N/U%,+0S(/G3M6P8X^1_:-LZ?- <-"
MF&A:G2A-8XV^/H(UY/GI0=2.]2.$>="F&C;.GS4FISMZ_0#6>-_F@ZV[T(X?
M_ 6L\?)H+FW?^4(X9^DIABAZW[4%W<??WCZBF&A:G2@.O)LS]13&N:-LZ?-
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M[>OU$8>6E&V=/FA'#_Y&;^/O[S0=;=Z'4>90];]J&UCCY'WF ]M0NY19(4B
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MMM2X+:2603?\ Z5X.,Z)[[^#@)3;(7,D][)I%B"IXQ D=.62G<"0LL#1JUQ
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MO\]ZB+ DC'@1- D&A04(Z^0%BD"+@2"I'X8B!0-0#(A"(@B(B21%"" LXAE
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MI%&V=/FMH\X-&V=//:@.O7ST^D*02/)$%6]XT!2 4(P*2"JEVP@A .F"'\(
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MMO3SR:-"&1@P()(6X" 1@48%Z2!*%L J2$8$F"_X0(E/HH9$+I0B(B21 T0
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M )04W+M95M$S:$1EY9H32-[":MTN:H0NR:,6QRMLQB2\9C,?<[(^R8>'J?\
MZ4ETM462 $:)<6P"4C+4/3WH.C';'9H>M^WG2AM8X^1]!F_CYZS0=;=_.E#T
M9[T'4CSS;0]'QW:4;9T^: X?J,W\?/6:#K;OYTH>C/>@ZV]/?UH>C.+9_P [
M4;1T]OFC9Y/AI1$Y@7.)=B-#!O7]8A!X@I*1$N(WM#(7(HLX&R0 +E@$*<7$
MK%!'#]13"^;J-LZ?-;!G<_SXJ.HG?SO4CA'Z",-&V=/F@Z0[>U#,WXYZ_P"T
M'6W?SI0M&3J11MG3YH&C_&AF;^M!=W'W]XH1AMU/:C;.GS0'#_&@M9X^37&/
M-TT+1[S4S1($LX%47 P@$H2#RF6OX6N,$@28$?P@1*?10R(72A$1$DB!HR((
MD! #6 @A(@6@I036.-OJ*86I:AZ>]&PIN<>U&V=/F@.'Z#&5BRDX"J0V4KQ*
M2%@(FZ P0 H?K )>,U-#@*W4AW,,* $4!($B#"(B(HB!2A'#]!F_C[^\T%S;
MO_/_ !*88H>M^U!=W'W]X^HIAH6ITH#KUMYU^HC7DW(HVSI\T(X:**L!A8@@
M#!95/90__K:0NL:,_P "5R8%!)I.!M+$W=EP(XI!&E5559NO;TV\,?ABC(IP
M88XD4&018P"'J89+"2NY6MXB6),ZZR.BDYA2?M=D?9,/#U/_ -*CLDV2&3+4
ME6 3!PH/1GO0=2.];11MG3YH=&-WEEH>I/GFRA-8XV^/H/6_;SI0>#YK_E#V
MB;[]R]!UD[^=*'HSBV?\[4;9T^:$</TE,,4/6_;SI0>#YK_E#VB;[]R]/&PJ
M%""YWU((6";#]<_9(@H4B%Q'K9')0U0&< )23 OE A%&P>3YZ4;9T^:$<=/?
MZB->3YZ4;9T^:V#.Y\G^5#4?7VH1PGT$:SQO4-1]?:C8>C%#UA[/G*@N[C[^
M\4(PVZU#4?7VHV&^YOSUH>M_7SR:&UCCY%",-NM&V=/FC8>C>AF;\<]?]J"*
M2 3R!$2-I4!# K7S).4*V:4<B !!?\) "1!0!D0NE<2(C0!#7A$ $0E:%9L&
MY6*87S=1MWW_ !0''1S]13"^;J'J3O\ /B@RV&&*Y@)91 3-KRO*F%1*);:A
M$L(2_K5$Y DAU-@UE;I'7A0&O)O\]Z"YMW_E".'Z#UOVH+FW_D9F_;^4-K''
MR/K(P^<,'*C;.GS4FISMZ_59[ 8E'([2:&!L#/\ _6M_\)F^FO*-;-)&T+;D
M+<I;PI;@I59;L:^$$;/\_&%&1AXSIC&NQMHZT!B;N[37'6+9,4D3:^I<PSQ$
M9WSOA/\ WV1]DP\/4_\ TF[$,&]T"0+D)L$P"))5*LK:5;JSSEDSC8'1CM0]
M;]O.E!X/FO\ E#VB;[]R]!UD[^=*31MVZ:>M&V=/FMB^<&C:.GM\T!UZ^>E2
MF&*'K?MYTH+K'&U#XGFO^T'6W?SI0]&>]&V=//>A'#]+1#-IC274OB& 0&PU
M@,!H:WVK=UF[^O#LI!02(7F?<2+D'!ZP$F88 D(7LC$*",-&T=//[6P9W/\
M)_E1U$[^=Z$<)_>GU$8Z-'$;Q\_M;P>.??K0=9._G2I'"/T$;^,O]H+FW?\
ME#L>C4M0]/>@N[CY%#-9XWH.MN]&P]'U^:'K?M0VL<?(H#6>-_FH:CZ^U19!
M(@N VZF!&!%DK0*19F_18L5D@287_"0 D04 9$+I7$B(T 0P $/@ @=8-H5
MEBXH'63OYTJ1PC0IA?-U&V=/F@.O)\]/IH89$!R&<NV7A^O%%C?< B%AB2):
M'++C5BH$H7(-@E#*"6H>GO07=Q\BN% :SQO07-N_\^@IAH9F_;^4-K''R/\
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M7KYZ5KT#:B38B528F7?WP@11&0T_I#?28!:6Z #.!>X=D^%0U'U]J'HCQO\
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M#U/T&+J!JMA;3&J@EB4-NB8L"[72(2#;I*HZBE6)O!!PV;@T/Y'YPC>6@FY
MQ<T)N872S '"#L7T<+&EF;!K7G^_C'#LNCJ2NK*< ?L=H\D\!"I$G;#LC=OA
MD'U_43 KEG,6(>J,&=;UGCF_V8F'#&7#>'2(5G8+K29M>^G^;/U#A;P:8(7?
MD+[T^P)0T>! $PFTQAUM%\-^OFR-T8L[OK"=19D1"(#0HDV*4"ND3J0G0MY:
MC?'L^<J$UCC:A&'^E2.2.'L_Q*NPCV>C4'L^34$:8+8_SK6]GA9YGG.C:CG9
MZXH.U'?;N6H?$\U_V@ZV[^=*'HSWH.MO3W]:'HSBV?\ .U&T=/;YHV>3X:'J
M3YYLH)2\+&5DELY(42 _XU$ !$! V1'31'-Q*5D.)E3 "6[G:S& T-HZ>WS0
M'7EK]0M>ODT'63OYTH>C.+9_SM1MG3SWK:N7P^M&T=/;YH.C&+8_WO0]8>SY
MRH;6./D4(PT;9T^: X;]'WH9F_;^4%W<??WBA&&W4]J-LZ?- <-^C[T,S>@N
M;>E",-NI[4;9T^:4$+RV:&Z<"9,)$2BHNRL,<]/EE_8W<+H+"$!"2SZ)=&BR
MZVF[$3G0@%MFC:.GM\T!PWZ4!KR;_/>@ZV]/>C8>7Q0M3I0'##IM/,T%K/'R
M:"YMW_E+HS&G^_R@ZD=Z$</T"UGCY-!<V[_RC4-O-*EJ'I[T%W<?(J %!)(D
MYHUC4MDP)_=>9N_!8N?J_KNR/P3S-WY+^"K(03%[ZZ;6-8*8R%][;N'3.923
M$ YXYO\ IS DFB8'4DOM&T2 E$)IM(]]MY3>20R_H_\ = -ZZ;,Q?$33&V4Z
M,NX]%OC"7S=YO>6<S?65_2P;S,._,-X<;F"9@*+DC).F3<FWLW!87Z^9N_ 9
MO#^GY?9/_@=2]K$[9SK&&+*885)E5OQTX&>B7RQ/X>7V0\S=^N=D_9,3C_']
M5B\?X?<[(^R8>'J?G;=ULEMZKK;+J4DVN[7!P.\C-E0(LLJNDNS2-D&D_HAD
M:D1P-RW'.TG1*%8=MKS_ "2[C 2D/Q4D3,C&V2Y&_P!"W^S>)LOB;,#+H#'%
M_4',:LXC)AF)L"<6T_;)1=9VA=5F5F;:"X3/Z=W&FXS>23)=Q-8"/_>9Q+_"
MZR*\#<O:/JFBRH2 !!3++,AN<Q\]:!"8>SYRK1')S:GGI0H21(8A/.]<!X6=
M\G^4)K'&WQ0B+[,W/[;A4CDC:F.FG+ILNR'L]&@-9XWHCM.YYRI?3#?F8Y4+
MO=]GV>5!T8[4/6_;SI0>#YK_ )0]HF^_<O0=9._G2AZ,\YH2ZA8381($L(AK
M_P >!0!( 0-D1TT1S<2E@J+D2IPBRI8T]V:AU(\\VT;/)\-&T=/;YH#A^HS?
MQ\]9H.MN_G2AZ,]Z#J1YYMHV7E\:=*-LZ?-&SR?#0]2?/-E#:QQ\BA&'EY_*
M-NV\\]Z!H]X?>AZW[4%W<??WBA&&W6C;.GS0=(=O:AZW[4%W<??WBKIU+VQ$
M3$-P=VVS:%16T9TYZ?.=9$_7VID-Z$;KD5$2)N* X;]'WH9F]!=W'W]XH1AM
MU/:C;.GS0'#?H^<* UGC>H:CZ^U"T?Z4;9T^: X8>CYPH9F]!UMWH>1GC>@Z
MD>>;:$</T&9O0=;=ZN%"F5A2Q@D[\FP_=O,W?@L7/U?UW9'X)YF[\@I)>1-V
M,1L-Z (Q+2",$S&F.[GKL@/U*4PZ8==SQTBYMUH829"Y-])31')-S#:[]"L7
M;&A%WASO,P8BR5HD)L:<YNN6=X "!^G3)&<:7UYEKC:;R3(,K6B))F.&TVN;
MQ+ _1YF[\!F\/Z?E]D_41*,]B=7?K#9R['/'-]?+JK^)E]D/,W?KG9/V3$X_
MQ_58O'^'W.R/LF'AZGYJA=E=)0F8G,:R92R D*W E#3IJP!.8RP6_2FF[8G]
MV^LJJH%.W)HFVR9V2-]I( S^$.+WMK_FRC=%C)9@'DR"H,N(V?85Q8ALSI8N
M3:V0TL;*<WLC%\[R_P#-F[],!J[5=@74+8--;"M,E<2SC&R'-OMO(\3=B8-K
M KQ/Z>8%-"Z9+'>)U^S$1L$8AF9;X25B\P1?3ZCW-\TBX!$"H*!<FFL@1)>B
M:%T*-F]2X^O1A[4(B^S-S^VX5!N[G3_:&S"]'COZ4.SD]<GIQH<)GN/GI0.8
M>#?F><-LFIZ>M2XFQO\ -7;3N>_K4:EX=+/3/2:"UGCY-$=4[GG*E[Z/\H7,
M:;GY>%!T8YQ0]8>SYRH.U'?;N6H2!1&1" ,) P% 0&\C5YP0L1A-BP"+LO\
MCZ*  EP!LB.F1$A)$I(:C,1,HA)5:[\&$U&UCCY%#VB;[]R]!UD[^=*'HSBV
M?\[4;9T^: X?J/6'L^<J#P?-?\H>T3??N7H.LG?SI0]&<6S_ )VHVSI1L/+X
MHVCI[?- =>OGI0&L\;U#4?7VHV'?9]3WH9F_;^4-K''R*$:SQO4-1]?:C8>7
MQ6UOJZ7EW-R(,02(E&])YWZNV<GZV%$#=+XMU&BFPI$J(L,I * "Q ! 6TDM
M07=Q]_>*$8;=:-HZ>WS1L/1O0];]J"[N/O[Q0C#;K1MG3YH&C_&AF;\<]?\
M:#K)W\Z4(PSNS_E&V=/F@.&_1]Z&9OV_E!VP^:_Y06L\?)H.MN_G2E"$4( +
M(L $RMS<A2I+!;)(QI9$KTPAR7_=>9N_!8N?J_KNR/P3S-WXY&P[&05UQB+'
M1HW96^_TV;$,FAC]9CCD3,^7M_@.<^O+1M-K<&!_/0-N4;->K0&7<1*RRM_:
MYPT +&[7]3>9)RPQ>=CMGWM0@(LF3U0WEG,7AB8\S=^ S>']/R^R?H+"\Y@,
M%F6^8N6Q?&;SKF[K/O\ BY?9#S-WZYV3]DQ./\?U6+Q_A]SLC[)AX>I^7'8N
M["UUP$QL*$LM\ZS,VU+W$OB,C]2BM#.31]LY+FC&1!;)ILUR9+78VR8G\*Z3
MIJ$V>.\(!LIF/LC(960'<EHG,I"NU;X?TW$6PVQE>)8B+BXO]Q0C>SILUZEN
M=(=2.(WUS:Y)CG^FM-I?=!(8./M]@V.FXS:&')9Q-(&/_*@<P]%NBZ3@0@6U
M,;\G^OS4K:7XGO?=NY.Q?;#/"VG>HV7X>V>U!:SQ\FD,VX8Z?[0FA-KJ$B>7
M;A0N@[/?UVVH4)D[GG*@.QVP_P ^: X:EUOQ]\_RKHSW'K-0Y+QLSTSVH9F'
M%G,<O[[UO8XW.O\ FZE/BYT:"[.6>C0=&,6Q_O>A&,,R6Q8%(BK 3H'$@$@2
M@ I$1&1?^.1  1 0-D1TT1S<2D1N NJ;(S+4OCKPI*88H>M^WG2@\'S7_*"U
MGCY-!UMW\Z4/1GO1MG3SWH1P_24PQ0];]O.E!=8XVH?$\U_V@ZV[^=*'HSWH
M.I'GFVC9Y/AHVSI\T(X:"UGCY-!UMWHV'E\4+4Z4)K'&WQ06L\?)J1+KD)PC
M;C$(OH()0$I3'#.=\1OA%F1_6P<8(:("[01)V2^!: UGC?YH.MO3SR:-AZ/K
M7"?-T4%W<?(H9K/&]0U'U]JU%YO/>AZW[>=*&UCCY%"-9XWJ&H^OM1L/1H>L
M/9\Y4%S;C[_Y0M&W)HVSI\T;#T;T/6_:K300C-R-&S'-ED:1^[\S=^"Q<_5_
M7=D?@GF;OQ0=?/ H"ROJS8MIMC,PNB&)_7RP((L+KN7IHL-J+S#OV[>F(UVV
MV?F(D&Q.PONX!&P6;V+SKF[K/O\ K!2$83'KY\TAT:#<'8SMD=F7[^;P_I^7
MV30H)1L!)FXSP+;I$NW&[65RN>.U=MI5G;^-E]D/,W?KG9/V3$X_Q_58O'^'
MW.R/LF'AZGY4P2L$Q;5O8-N[1RQ>I9BQH>JNKIB(6 E_%!<"QL%CI5SF-GKQ
MSKM_%O)=(;.,:F_&LS0,39+;N3 XV3QFB<DM?O;;Z?@E[6A$6))VQ/%>TQ>2
M*9+/!-D?X?[]AYYC.;SKL;G-<_3.\&YODR[+,@FA-K1]Q*-I9O?=.S9&Z>/Z
M0V%Y8V=>.;!,\Z4I,+;; 07MDSM=/L&.)G;8L=^B_P#Z1S792-*!(4X$4L,A
M$VG;[X[T(PT(SU+/G2@=YLRW7U[U*@B.,H=QZ<]$EI?@SQW[+0\:OGP]J"UG
MCY-0[3N><J$W;51VT[4*T)A9L^NNV6A$"IC-SJ38UQ0'/4N>=:$=3S=FI=;\
M??/\KB3C<[0]J@7+Z2I]+T/6'L^<JWL;G'G2M"=FLGP?RD4HJA/EPJD. MJ%
M_P >@8@PB$(CIHCFXE*C2N]:LK*L[NUPJ;9T^: X??IFA3#'Q0]8>SYRH.U'
M?;N6H?$\U_V@N;>;?>*'M$WW[EZ#K;O0CA^@IACXH>L/9\Y4':COMW+4%K/'
MR:#P?-?\H>T3??N7H.LG?SI0]&<6S_G:C:.GM\T(X??IFAF_C[^\T'6W?SI0
MM'HV]J-LZ?-3A-ER;))F]F\#&W(L@9+DX=-S&'-\)9V_JXV<H$DS;)2)A+,%
M@MH^;J"YMZ?4+6>/DT%S;O\ RC8=\3_*EJ'I[T-K''R*"UGCY-!<V[_RMH\W
MGO0M3I0FL<;?% :SQO\ -!<V[_RAV/1KA/FZ*$UCC:AFL\;U?"&SDA;!TP8J
M&/W?F;OP6+GZOZ[LC\$\S=^(O,']V],3KLMM82(UEVVP;M%X+R_9)(%N%Q&Q
MVCB^.$4Q/F?2.@=OREQ-HLZ+ZSMF95W$_?\ -X?T_+(&< S?.AQ7=QM-+,K'
MM.S<1QO=?Q\OLAYF[]<[)^R<0>(/09W[<YS%O ]*MX'I5O ]*MX'I5O ]*MX
M'I5O ]*MX'I5O ]*MX'I5O ]*0P$A: 9#0S#_0/LDA,-FT:A-Y@MSQC%6\#T
MJW@>E6\#TJW@>E6\#TJW@>E6\#TJW@>E6\#TJW@>E6\#TJW@>E6\#TJW@>E6
M\#TJW@>E6\#TJW@>E6\#TJW@>E< ,X ZA&[9C.)^WV1]DP\/4_)4"7#@WIQF
MQB<7L,0*473!H&P-.(SKF5^]GCBU&L1&V)YG\*=E0UEP+/-AI!I-HA;;L$-K
MYRYJ"+ DQ$Z<3UUV6*F%2VE@#LL#A[MZ5U3ME>K_ %Y_64N9C2W^34ZEZO#K
MOT%-[;$+BB[VU8)%]CD\PMPWX&IHN-\#T,+Z+;92]$;[QO;7X-6E&1+PL2&R
MY;I^!)9<&>RSTU,-HBY$FR'B9W6OPB)F/P1<=$X7,AV5VOV%".S(3?;MR9=+
MVQ*7Z0Q=F(3=#PO.)G]&,2[$DDXQ)-Q8EV-RU^\^2^(#]UWC1]2Y:\N0MEW?
MI5B"W])?.TEG;O\ L!*!JP3_ &NMH"8F"Q,6L9C_ -0NPR)"*"*M 2(14O>:
MDI<C#@:"[!"#)G:>0\YJ_'S/Q:I")M.WWQWH1AHW.8^>M0<HAML_RI@O&MY1
MYS/<.->$N=K]3GCZ#-YL<]:(ZIW/.5"7QO7:,4+1.QI=6-S[_P"4!SVN<?)H
M&1Z9Z9K>B$69F.)&=] HO#N2=M-LG*H2_<?Z45994"@$&&.6PJ@U4BG.L2ZF
M3)(_Y! Q!A00B.FB.;VV,P;P0I&2ZI85VBR@&ITI=&8T_P!_E&T=/;YH1PT*
M8:'J3YYLH.C':AZW[>=*#P?-?\H>C)U[_-!UMWJ1PS]!3#0]2?/-E!T8[4/6
M_;SI0>#YK_E#XGFO^T'6W?SI0]&>]!U(\\VT!N._?TS0S?V>OCOH+FW'W_RG
M9N+$3"T29LR2)$LR1"F-#4U'8[$Z)MT_46$Q3,A$NM BO:[%#;:27*983*JI
MM8,!] -9XWHAM.#_ )1+8^OQTH+FW'W_ ,^HS-Z#K;O0M&W&WM0]2=_GQ0=L
M/3OCO0S?Q]_>:#K;O0M'HV]J-LZ?- 6S?HT%K/'R:"YMW_E(XM,@#*DH 2Z#
M;#(EL,\ GZ2SB"RXB/W?F;OP6+GZOZ[LC\$\S=^&#FMK=K;?6HI&N7E@W;76
MX6S^ST%>('6QE?35&YP'Y1T^!6^]Q3"XF<P_\!F\/Z?EJ=X>JSRFSO0B\_CY
M?9#S-WZYV3^*=D?9,/#U/T/9'V3#P]3\A02WF8EG>X0)%HF$&Y%EE9>VMHBT
MZ! 8@T^Z/4YL](G;$@;]L6C#:P;[%QF;V.PJ^"Q&@ [)")WKNW_?OI9I!F0
M,P#O9(7F=Y:[/#&PRTU"^X@#;M4,);;H[89AC6%,WB_WN&:.S<^(R:BB._SJ
M)!=A(1'/WQ*ZEKV(=+65Y<OLJ=XME.ZQN(-?TB<1MNZV)C9:1DC0Y^\3DM%Y
MWYSRM680@838&8R8U:QB/TF0;"\[7?=2(>*_8U-A&^^[*0"##P?8# ?$$'N8
M!PYP%1\LOY\U+L>SYRH;6./D5&RW#VQVHX'?A_IZ5):>CZ?XT*8>6E",VX>?
MV@.8=FCYYI4*;WO\I/GA2]_J=B>W.H2.R/\ 2AF;^M8;QC-S^VVXH#BVU7\G
M^[:ET3:T>GQ6]\;Y_O*@ZV[^=*'8]'VJZ)![/;VI2+&2X4#*"K*0)&^[N#G6
M%2(9NB#?_D$#$&%!"(Z:(YO;9#9O0"JX=56L7!,DI0%W<?/6*"UGCY-!<V[_
M ,I-&>/DT'4CSS;0CAH4PT;9T\]J#HQBV/\ >]#UA[/G*@[4=]NY:AF;\<]3
MYH.MN_G2I-OT%,-&T=/;YH.C&+8_WO0]8>SYRH.V'IWH?$\U_P!H+FSO]_>A
M[1-]^Y>@ZR=_.E#L>C6JF@O<TF.%F)TN*(-]R-D=CLXX2Y)^G0 4@!55@ +J
ML  JI:95R)'F'&@D-D$)@2"N\GU]^M!UD[^=*$<,^;OJ,S?CGK_M$-IZ?/2B
M6QX/^T-K''R/J/6_:@N[C[^\4(P_THVSI\T!PWZ/G"AF;T%W<??WBA&&W4]J
M-LZ?-6Z4C41$[11G+>+^]>9N_!8N?J_KNR/P3S-WX9 @6R^YLG:EW.\J_M@&
M)P+I> 3.,[8NP,F5_'6ULJJ'%UO&H.W+(6D+RW66[G,W=^=9F?\ @,WA_3]G
ME]D/,W?KG9/XIV1]DP\/4_0]D?9,/#U/QU G1@Q+UL&N5)(O(JE65\X %@+!
M8M]R\ZYL:S[T"THW%W?.F%YO"ZS1!@#>9UR\,Q!Z_BW/FXWE(O;KP8BH2BXX
MPZ0FDRLCAR6EAMO$F.''I&MV#[EB'&CLUA=C>";);6;\&4]=L<7=,;?O[')L
M1YB>LEK[:2$1BQ:Z-Q>(B<HV_8=XV\@2_I(<<6O^BUZ'F#7.WA0(Z8(V8&)S
M%W:YS/WW)&8<;VO)SQMB']%UM*Q$P78FUC$TLJNK+'\^P$ ;VEOMW8P!%M>8
MAG_VA(MH_)0:YC,F #$WWC#_ #I- T#BV3S(X+?=0&[&\]PY&ZM[KICI_M8;
MCV>GQ0'6./O4;+<(]JN:3PMV7O/*I[Z4(B^S-S^VX5!NX8YG^T!B8=EX>U^U
M0L,='.2W+C2C-M^?2:N?#_2AZP]GSE6T>(^[YNH&F43%G?YH6[>L>,9Z=:,;
M\G^OS07-NY1.)X<8(Y.R;3Y\1)+CAT3_ )! SAI19!R.$<W$V)S9YU0@3S+6
M$PRIB@.C&+8_WO0]8>SYRH;7KY%#VSQOWH+FW>A[1-]^Y>@ZR=_.E".&?FA&
M&C:.GM\T#1Z2/3+0]2?/-E!T8[4/6_;SI07-GS6I'#/T$8:-LZ?-&SR?#0]2
M?/-E!T8[4/6_;SI0>#YK_E!:SQ\FH,;<@&COEE-QM**4/>1LFHFCPZ.21_36
MS.:Z0P$0!DN)<I4"YMQ]_P#/H%K/'R:(;3@_Y0MSMT>>SI07-N/O_E2.&?J,
MS<[T#:GFZCFWCY_* Z\GST^DIABAF;]OY0V[CY'6A&&W4]J-LZ?- T?XT/6_
M:K_C(\,A68;%B0(:O[SS-WX+%S]7]=V1^">9N_"+#?I-]MTV3RF+)(WG7-W6
M??\ '$X&-H*=JB-+VR.W-YWVGDA4]Y:-6NMG?,4"+L.XGU3TMI6\=#2.U%]&
MO-;C>ULS4G0$ZS_!YVZU/2&1Q;PVG?"Z24S!N9B3,Z\BQ^..LPERQDN;_:T[
MA)#.!:RSM+CDYD.7\50)<$? 3:6.(7TI2J\OB;QF-37?_P !F\/Z?L\OLAYF
M[]<[)_%.R/LF'AZGZ'LC[)AX>I^-("JP9#5G QM=;$<F99>6RW7TRRZS]M7-
MAPQF\6Q.'=:\,406-+.KK:;<P-Z2S^3,7]2T;QM&L/")M0-RS:V1MOW-9NT6
MILPS)H^8QC)J?<DLYT5NY@G/#*<0'WS8V++&]3;=O>2WV$PR<3=VS3>]H00F
M2=DQP6M,VDG]$L)K@M:7G;*^9#=^ P$MFSFPZ\T,:I&,IR2U^]MOI^BL6]!>
M8"[;2ZAV*1:W_L2-C=OH7>;@':3F:O*NK/V " ) @)""(B,(R(HD4V*](#+@
M .$2.XK>];/7_:(ZIW/.5!<]5VS_ '9:AG".YL^<O>A@?VYC:8-F.%>)<WR<
M.-"YOPST_P H34TL[_-*C?&.'2\'"K[)VQ;L^]2-IOLP]&]!:SQ\FE-IW.,?
MZT%]RSS]K%0L(;9L]>3!2(G]B/5.O2K\W!'U*'K?MYTJ#$O7W^:$M$]QZ_RC
M)G?ETL^E0*B2 2)<A(.1P'_(D#.&E%D'(X1S<38U&[@E9$JJM0SS"S1-GD^&
MC;.GS1LO+XUZ4/4GSS90FL<;?%#-_'W]YH/#S;YQH#6>-_F@ZV[^=*D<,T(U
MZ^>E&T=/;YHV>3X:'K??AW^6H=&'SKWH>L/9\Y4)K'&WU$:]?/2C:.GM\UM7
M+X?6C;.E!T8Q;'^]Z'K#V?.5&4MA+ BPMP2\.2(B)HZDB7&R.=PD]&21_288
MJ"$1T&9,6#4N% VB"  & SU;Q9D6AF_C[^\T;R>GG$HEL>'C0VL<?(H=1YE#
M-_'R:!M3S=1+8\'_ &A-8XV^LIA2AZPUO$XX]NM&W?>>1Z4!P\FS?C]!3#%#
M,W[?R@.[C!_:O'H\9",.1 "\AN-(D4K@DR63*RJWG>_O?,W?@L7/U?UW9'X)
MYF[\%@EF#-]= D8;6S:5&&EEEW6[=#290C-W\3-CD=H(S-IM*T%F(3F9X02S
M?# X=:"S/%8>1?IR58P!&((2>:%\R[\5>;WW^=N%W[-XAO&!N=(3M6T,S*6Y
M:@:1$19O%.P[+-O<WJO!LD),DS&^\629O)[X_$09BV'21]'9&$&*WRI=+:<I
MOI%[D9%?P_C9_>]2(:,&DX7VL,1AO^3-I&M['A,5-"X;KS'2-[>+Z3>)%UO$
M(&FC.TR01F;5L=C5<]SUO0&DNV4CHG'6MPZT(<6CF9=JX<Z1OEK=]12&U.F1
MS=S6,VUI>TQ@GU0(G:[[WI*6&#*7#6Z2'Y^;P_I^SR^R 5!F#D+!A+OXUN#P
MWUN#PWUN#PWUN#PWUN#PWUN#PWUN#PWUN#PWUN#PWUN#PWUN#PWUN#PWUN#P
MWTB,.;:XQ%YC'*/P"*8+A%P;WUQ8W9.%;@\-];@\-];@\-];@\-];@\-];@\
M-];@\-];@\-];@\-];@\-];@\-];@\-];@\-];@\-];@\-]0@',,PCE-X4Q>
M[/7\7LC[)AX>I^A[(^R8>'J?B]@RNAYC?@<4B[ P?U-NW9C[88BZS8NXV&_K
MLV@N;II:X-]H7W(1A3=GAOQ$9T(@M;2+_F(-DDZ)P\C5%"DN+DYTW"7AV71Z
MQ]M(S<C.NUS=+3KKK;[T3:,V#?-@+,J!I97;?9@D6MZ)CDK.EP6Q^A98V2[Y
M;YV!$&1A;[ D06(EV3,>GV1D&UYVK)GJ,["0UC]$\-EL!<F9=;K=;VV'V#9;
M78B<!=M?6(X//[.PA*B0BB!@):($J\M]NF3D7RQ4024Y6Y+Z5,;D.[_?[6]'
M%FSYIKNK#>,9N?VVW% <\Y>>M#.$>-GCC^<ZD1+U]_FM['<\Y4!V.V'^?- <
M-1L?Z?&Z&*\M[?ZT!PT%K/'R:(;3N><J"_U7'3WJ,'L\].ALOM81OVV[X[ZT
M*88H1DV7+-O-U 8EWP^_SRJ;A&Y0RS"4T?\ (YEN#A@!"#D;B.;B;"ZEZ%VK
M9%:@ERRRI!:]?)H.LG?SI0]&<6S_ )VHVCI[?-;5R^'UHVSI0'##T?.%#UOV
MH/!\UH9OX^>LT'6W?SI]!&O)H.I'GFVC9Y/AHVCI[?-!T8Q;'^]Z&9OV_E":
MQQM]0-9XW^:#J1YYMHV>3X:-LZ?-$DD4T YQHD*KW;TH.\F$<FH7OL<)BUW]
M#(!8LKWN&#$66+>^0$1$%@#&A8W%B(M.L-"F&C;.GS0'#?H^]#-_9Z^.^C>3
MTGS:4;5]Y0'7D^>E#J/,H9F];Q/3SB4+<GG+M1P-V/CO]13"U+4/3WHV%-SC
MVHVSI\T!P\O/Y].20D6 ME8);F2_?>9N_!8N?J_KNR/P3S-WX"%QZQFV9(,W
M9C.D5,@;..;2X,X,1AU7\(%8"78$]J#JZMCGP;,"9+-6,$&P&_%NI809!Q=_
M %!M:<0(\1LW;S;;:]+8D=UQY9+Y2Q'%2&EK0F'TB<P@-3/X;PGA;C;;=[Q%
ME?Q'%I9=2)"W.^<EMH_CC;.+@:74;:1>@LRO0B-A>SJ.R2IT(M$A#?:VG?+;
M@S]S-A.U2[N,CL),$81FY;2Y,V#"&^4MXO99,$ R3%LJ1(:7"<EOS,WA_3]6
M+ >0OH-#:!>+H)R4>G])&Y0C;.W2"_7@PE2ZGC1RW\*GM._M0MIW]GTYE._N
M%Y[C9-XUB*UG6^"[[#.NL;,TPLB;PG4/Q\O#T/P-/!9^E[(^R8>'J?H>R/LF
M'AZGXKO#;"YO.D9#=(LY@?MB5#3+H&U=."3IF!" #F[=AL-<$Y5E(_.U_FWC
MRFVH0L25E;#4EQ,L;0MED"6;I]I*DSY9XXU_IDDB]H,C-FQT9E$2TB??,2BR
M2;+S,;ADXC$9/_;LY+NKJZQ,/]L_H=^2ZZV+L8! <ZQS65=5<;_Y]@6+0JW<
MQ'&"$+,SG2(82\WOVG''9]AYLV+\GA)=F]F"9_0-A="^TV!&R8G.N&Y_[[SY
M!X@-:$MC,ZRIK$L,-RY]J<9-"M19?A$4:3/B3C)=)0AR@@E2C*B=D0YTQPM;
M2@8'8]B(Y3OJ<$LJZ'A>#<":VU($2D\Q-N="%F1W6=+)WZ43U'L^<JWO7W_R
MA(M#:XVX[(XS0[&>SK\&"I$2]??YJ'=W/?I0'8[8?Y\T)L.[X:AT>M_GO4ID
MYE^V>DT!N..5#-YL<]:(ZIW/.5#3IO4=IC;>KL)W%Y>T4P^;>YWF^*%,-23)
MBE=9A8FP87_D9E^#A@)"#D;B)"2)3<URZ@Y\S4$=GU$A:SQ\F@ZV[^=*'HSW
MH.I'GFVC9Y/AHVCI[?-&R^<'-#,W[?R@Z*=N]#UOV\Z4%W<?/6/H%K/'R:#K
M;OYTH>C.+9_SM1M'3V^:-GD^&AZWH#KRU^H6O7R:#K)W\Z4!M$!+@:,XUA+C
M%HJT4!/$CM-2S!9O((C\['F?=<6JR RE<MI+JQ,I&6(0*!HP0VBVRYBQ9M;9
M1M'3S^U@O.YS[^M<8\W34CA'Z"-:-LZ?- T?XT/6_:C>C=I[>E&W?>>1Z4!Q
MT<U*88H>M^U;Q../;K1M7WE =8]?.OU%,+YNH>I._P ^*7*5V-^Q5M(2N"H4
M0X)\\K4;ZJO//[[S-WX+%S]7]=V1^">9N_ .#>D<"X\WT+F/P]5L(<48Q>UK
MR[;D406+$];:[=LXF8@8_$F>'K%X1S?)BS.RD.(&"VCF^]H3(RZ+LDB1CSGF
MV>'X0R#%Y9M8<KR,G%@0?PIB5P$WLS.#:N+#!=)>IE5<NSH[,Z6,:8_$'EF[
M%YY&32[HR3% 8$WZ_P"WR 9_!'DE[=K[?2D&!"V$L\6S,N9EB"=BR\CEO E_
M9-H A98_*S>']/T\+8%UC^U(F4Y76PVBR3HC&C4$67,RL)P F^[<:FRP0Z!(
M\;ZM80RS!2[;[>F_^O/\_+P]#\#3P6?I>R/LF'AZGZ'LC[)AX>I^(H-[.,E\
M[M0MF69+_:$O/CMY+:Q-^$U@@Q&NO%X6W& F_P"@'KYX-7%++D,<3-]8G-X
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MGK_M!<VX^_\ GT UGC?YH.I'GFVA'#])3"E#U)\\V4'1CM0];]O.E!X/FO\
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M8F(Q%OL! $;V<*PS$V2QQWOOB19-*2@)@H6R57&R!5,X"1 2I"!=$>SQB_\
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MJ6G66=^RK-#&;F]L<-'C3:P#:%'\4GOPH6UF\L[W]>52,J+MN?VO$N<R^.=
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MKG:M#];EX>A^!IX+/TO9'V3#P]3]#V1]DP\/4^_.N(%O.0PAD\)^T &+[DZ
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M_0#6>-Z#K;OYTH1P^;ZV>?YYQ^@Q<:'K??KYTH;6./D?49OXYZ^]!<VX^_\
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M(PVZGM4'#I_O]Y5!]!\_G.IS8WW[_-!L)&#=\'6@.'W]Z#?+"XWM0@#-!_\
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MS_>5;V.%S^WH#OVH_P H36^S6_FGU'J#YYI0VL<?(^GC]!&O6YYPH.MO/-M
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M;Y_O*MZFS4\Y<Z YOP\_M <)_:X4*8:'K?MYTH;6./D5%>/T"UGCY-!UMO\
M/FA'$/T$8:-HZ>WS0'#5CNJ':$C:2=@?_H@\S=^"Q<_5_7=D?@GF;ON)B-L<
MEY]MTS0A3?9M<TX6N[9'\")C1WV$F%B<7FV%J+OGG#CM_>WK=#ULAO93BQ^"
M.1G?,)><1;2,9FK3;"2+L=.(@0M.W/Z*Q,X!6&)O :W5B;ZP@859=N>/\W'M
M^%F\/Z?F9/%]?UV7AZ'X&G@L_2]D?9,/#U/T/9'V3#P]3\ 3O#>VCK;00#.7
M7'V2PDWL\3/-8>":*/ZUR#819.IXR2Z#3[)D6D&4=0)V3MW3$U>?]VQ+$[9O
MVA?QCEMOD;LS)I<;):VT^PLFK<XGN2YV-GV9BZ2%[XF;3IE.[I5YUS=UGW_]
MB4,3KLWL7MFUR)O$4MP+;LP:'2.%E@L_D$)9&%XZ+8O,;D=?L.)U9Q.#!$Q9
M5X%I^SB5T)AF.#&)8)G+9O6]EEF^NV_J_P#L)8-I?G'(O2]+!P+$QK!S=9?V
M;49_%(!HJ6M$ODPPCJ"ZE5N5XZDAN9)]*G=&^SJ8WVBA:)A9LZ^T3*SBB%K]
MQYRK_5=L_P!HGJ/9\Y4%B7B+_?3TS0XAC'#_ #%KT(SV8<WDX\.];5ZV>O\
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M->/)QC&;Z[(_\*!VMFELKF&UG@U(^QI U1?.F9F]XO(-M']V@"7*( -JEP
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M;7+WLFT9W<3@WOB(G\&.,3F0.$MNNVUX*2VKNL=?81-:6$P,R$ZYEE4MA4-
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M:F>G^5O1Q9L^::[J"P+'''70VXJ<)UGCB.G7A1QYP$41"]UU!83]T#*IOA8
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M;I>]\9UMEOEG?:MX-UQU#AIMO4RLA=5)SA12=[?&*&<(\;/;EI4B)>OO\U:
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MGZ7LC[)AX>I^A[(^R8>'J?F(.9W"[8U-39B]B-1&\T<B3P(==NN']/WGR#Q
M:A9,\7J_P9WHK7AIB+[-EL$&I+$?I[EM&31ALD:K9R0#8E^Z(N-HX"@D8O,[
M$F?TUD5,N+:FN^<#,$Z/W3$K@F;8OOM$-BW?\6#,? ! R*X-'?._Y<""NTD$
MHQ<&C?C?WI+BU08EQ^6.=&YS'SUHGJ/9\Y4-K''R*@WC.SR_&G9>ON'\J8)[
MW[_-!<V]*D<,T@V0342?+TC4G&1W9GG&[6D-)-U[:29OL)C;0CA^JF#BL[%N
MI2>(Z4?R.<[J8A9.)A[EN^RB.T[AYPJ+"G,?/7;5F+SNL=<)RM>B47C$ DZD
MV.!0B[:^2$YA8T_E0"*FD ,YD" #*GZNEG,?'$L(*7$(K*#%I/!@JZ:(ZA92
M=SSEZT;*^)N'+#LQSV%J&-EC,[IY,O"U*P RX)U*'8]'VH>M^U3!/>W?YI+B
MW?\ M07.WDT,U'%G,>;?>@\../.-#L>C[4IDC?9VN= XYF!ET".K_=MJ@697
M;I%ISCG>A3%]ZCEG^\J-%G=A\Y5$!AC SLV+QSTQ6U!.9N:WD.A#K>FT +XB
M!>EGI0K0.2.K?UH60D\SSANKY9?SYJ#B.\O+V(_D&,R6B5M!%,G/"B'^H!^Q
M@ZP  ! /_5^9N_!8N?J_KNR/P3S-WY2;VY_T>IK?9%E#BSLBS%N)P!,%D*HR
M?W;>TFCT_4BDV X#D93NQ-X, &)F\KEQG9K:S=FP3]"DV0=!U.?"\1%W#"AQ
M<M#A,62\9O>["Q^ELS@Q!:5R]Q@C5S:R2F@'*,7^-6=,L?\ C+[X9O#^GYF3
MQ?7]=EX>A^!IX+/TO9'V3#P]3]#V1]DP\/4_-[SIF>MNNL:TEFX31B'!9MOL
MWM=D4CM#*.D;MR:X28C/Z1$'3&-+8=7DPJL9H(QOOK?=%B-C.BI;]5;&36^C
M:-M[\":22;%!OILOSZ:/VP5 NO\ ?+M,8,"!:+&KFZ9C*N-/THXO>VO^;*,.
M+-S,$EXOHVOL+M_N!$%[;=N6#1,B81,,J?\ %OP*G8.!D5T2O//Y<Y=KR'9H
M"(6L\?)H.MM_GS0B6N:_)RI+BW?U?-E1B9.O;VFH-W<Z?[1/8]GSE0FL<;4I
MI'"WQ4S#ZGO6H[^Y_=U!UMW\Z5(X9J DF+F1.9#2+2B-LRXRSWI#).^[M9<C
M_P *8GB08C#)VJ419JD(VR+><V<S4U$)M9RCL3.Q9;U#M.YYRH#+'-?/EJT$
M\256%/6A$C3HQ_4P2-K+:-J%2@I!6:)OU(GL<ZN( HBB+B<B+\Y]-C-J,T21
MFQTB>@\<T)&)M>QMEBA6@<D=6_K0C,FS4\\UJ'>(WN-UBYQBD$0AWPCJ][ZT
MLB$G$PG4DMK-"T>C;VHVSI;CY:IR=&S2-'K4&)XGDT/6'L^<J"[N/O[Q0Q<:
M0XNU37E(<(@-C:(&$W&XSJL;-5W5,,71$@DX0X.ENPM&=LHVZ3_:-&>SYRJ<
MV6=VVZEIUEG?LHPL;99)O+(< (>-8R0[2SVM5D>1  I81B5) 4COUF+2(# 0
M$(@/^M\S=^"Q<_5_7=D?@GF;OS&[)L;G^[[)-G(IRH;P/+"\=<6932(@C[\)
M.F29B9_2AL#BN(WN#^VB^0EV.FNV),1(&1-G;!;^6TX1',/T8WV,;I9(</)Z
M4AN.=BY"T2%M"(9I@+OAS?+>,WG:23BWZ 6'/89B=DW#5>)0+E%)OH;PMIJF
MR 2EYK>_>^WU_P#.7WPS>']/S,GB^OZ[+P]#\#3P6?I>R/LF'AZGZ'LC[)AX
M>I^>DY)#_0(6M-H$LX7;R4Q%G.="+YP2Q=(_0@N"8OD0-!<<M<10#+"Y]P:Z
M-X+Q94SC3D;O8BQ":?K+6Y"TX;KDE@".7VSE;F"VK9TV>HZ/Z@"6R,XFVN^S
M#C"N,_:,N!"[RP7M"V8O$Z32\UO?O?;Z_P#&JS(E:P'@+&BOM:E6)0%BCOM.
M>SAYY.WI?C7^T%K/'R:#K;OYTJ1$D34R;II+$6ZL]7TJW?W]GI2&;<,=/]HX
M'%S/G2A-8XVI;2.'D4EAGM_:T"?-UJ$UCC:I'#-!"28Q=$YD-,,+N[D1O4?>
M#)S+GOU"_P#X3JE*L7&=RP;HZ8A/',7')8[ZXH6'.HVVL?%8;QC-S^VVXH8S
M>^(9P( U2+K].79B6OQ9NW45'%;<C*K2BO"RUA5G)WO/.@ZR=_.E#L>C[4I"
M%ES1.9YTJ3)N7'=F>C=K1QKYL/(EZG/%"7[V/3?RH5H3"S9]==LM"R$[GG"]
M*0ETLMQR)MR0S;9@D>3"Q'D:U"89'8D)QH1A]O:C;.GGM2Y$YV]J=EZ_!VBH
MN8Z1[>6H>L/9\Y4)K'&U2Q&38W-N&U)TG@EMKESC4+8I :'OI%G^#K+0'"FY
MN=9GN<*%(C=#[-G6@2J5@+(!2&I!L#@JY\4-1@ !!_UWF;OP6+GZOZ[LC\$\
MS=^<W)).&YKT=Y$3 TYBVZZ9C2Y'=2C.)S;9)SB;3,V08_0HW@C:L;"W"9L/
M!Q03-W0UQA6Q=@+$,7O;$#(%N@0&=-EYE_47VV9$<6O<<D@WV2(64.D.[#<R
M,NK$V(2]*,EMBX/$VV880<3^:"MB;3 6C?PV[=9O00EN[#'!<[9,C#6-QNX;
M-\0Q=SG_ -Y??#-X?T_,R>+Z_KLO#T/P-/!9^E[(^R8>'J?H>R/LF'AZGZ%A
MS> OHC$.<$$R$6*;[IM,,*V=8=UY=E0C#9WV]?S$;P1M6-A;A,V'@XH!=B'(
MU8VNEU+-ZO;$#(%N@0&=-EYE_7=S9CG.T;DVD)-:9+ZW%V;[[+I=&R3)]D)0
M<YTVNV-F<[6*@P8QO<M]BS/.#3]1A\3F1AUFVD7HW"8626YN6U]^I>S(?8!;
M&6#3S3R:""#-Y6(F-FJ$Q=<NW_CRDB- <!J&F%:<B81 (*BU- G >L/9\Y4%
MUVY_K\^U6X<;]P[1S^@S>;'/6@ZR=_.E1L&-_M2=+/G/S%6[SK\U#M.YYRH#
MOVH_RA-32SO\TI+N].9[4LPSV?.=3,G\?.5":QQM]$9&-Z/4AY4K1'<D/-/&
M-](A(3HG-)#=,3_X3E92D2/+3DA!BDTI-J9W?X6+T.Y+W/1LS>-^E6&B/<B=
MM32#05!@B#WPB4[*"% <-!:SQ\FI>2.'G\H6AZ-:B'%G9Q/[>@N;<??_ "AU
M'F4I !#&1ZGIPV5#5,VOG$7(COPJ%*(VV&FR8F>>V@-\;UPR>R4+HG8_Y4%E
M3%G'P=*A1+?2QY+MQ&^:08@WQ;HCT&-6U":QQM0C%&T=/;YK@/9]Z=EZ_%<B
M>9YYK0]2?/-E#:QQ\BI8C)L;FW#:H8AFQ4(@,HSL-,#/<#,&   P1 G_ %_F
M;OP6+GZOZ[LC\$\S=^@%OBV9GK>>^:<@C.@OC9%G-A<3L=H.E[._=$[Z1A)&
MQB-='7B:.?RX58G.-..SFQH-H#:0OI=VMNU&RH#0XK.8T;7<6G?-7F57C^LF
M-OGOB-=#-(;Q#>Y;A)<C: 33LHE]S!MEB^;+GHBD3%D=M]+-MNGY G!;:V+9
MNYX$NZ@F;[BQ9VY9.$/2I0".0VM86Q-LMWC]G+[X9O#^GYF3Q?7]=EX>A^!I
MX+/TO9'V3#P]3]#V1]DP\/4_1YS<+0\18O;%V#$@C,K8D[DN#:!JW7Q%.D#P
MOC7:'&.D?CPJQ.<:<=G-C0;0"U0VQ=_A&-<Z5 :3O4W@(C%W%R8G%;[LQK/J
MOJ\_V-@CC1B$WD]S#K<$"<,"88TTC5B)O>9G_P!BA"%[K8-DI+?0B6\#>@ @
MW7U=Z:?PRK+^JW(0R7Y;(ARE]F22E+E\)S''K9QH,B'_ *!4&SR789O8#-JL
M,W7L@L:];N(+S_R#\'Q-\@1R=%A1!;B4,@Z;IR=*#K;OYTHU#TH1DYEGSI0V
ML<;=7'?Z0D=D?Z4,S?UH/#CCSC3&4-]-O+S%6X4\W1_:M<(TU[Q/4HCJG<\Y
M4!S?AY_: X:2XMW/.%1)*>AUEQ0];[]?.E":QQM\?0(23&+HG,AI5I#M/5(<
M+1SI'(3?IF,X)WHXM1?XO]$')/&DT>W/7T_H\>_;C%^ZI[/UP FA5OIQNWK5
ME14/]1&O6YYPHVSIY[T!P^]#-_KUJ7D3ACSE4C*=XQ_:@B3YZ6[4%W._W\X4
M(N.>=2.$[RR<Q+;O8K1T+4S<!PM#QJQA$VNB<)&W:=\5(PEMZ]"?[4K1'8]W
MT-M 2%$V"3G_ +4D2>"YG19G&KPI"\!VY1I)OV&+T)K'&U0:OKZT'4CSS;4;
M*>CT^*=EZ_%7PX$2LU<L.+AJ6HLR@&(.PX'%)*_]?YF[\%BY^K^N[(_!/,W?
MHTQKN?FD+R!O+@-(.:8R%)T> W(M,I&^P?"4X0V/H,+R([TH81'>9X;?PR5B
M[E@E7;MN_P"T:Q'%!TTFR^@U'5UP;-;NN>+9H!@N;;O,QVJ5SB]BT7.'&T6T
M?V4K9+#(-R<3"9Y;(6E-$M!#;5E&=="/9V632;+.=$X*D4AHP92YU)/;\(FN
M)B9M;=,3RFH3=DW3SNAAMH<E & ,S-U-,R9O(&EJRR]?'I:U]OV\OOAF\/Z?
MF9/%]?UV7AZ'X&G@L_2]D?9,/#U/T/9'V3#P]3],RS)."YOM#,EFZ.MKR4MB
M2^EP,-F[M[*G-F=-C#K?J/ZI+1WH2=23O_/O@V K=@);&>'FRB"X$J2H)MDN
M.03K)0-9/1'%O\*BZ##JF;:\V8.N]9Y&#0X:!K8VV5_:S-MO"$$VS.ZV\2S2
M$HPZC<SMN(B-2C<*Q03G&@U0F#CS"L2(C.MMNG/R:);!*Z1+1<DBVY&;PQ.N
M)B9S0-4782%HVPIH@68;C41K; $6G.Z]GB;X_63'FWSG2VT=Q9XFDM[018#3
M:UTD9G9!!9P:1,B<2.']W6Z5,L"::.Z <X>]!RG2WH40)JR'BU)@@)T_JRNH
M"L8(F/\ DW)NS Z*4'&=_-C:#ED^) "L9QU#.^=A:(WYX5;H<&6TXS;;$;Z$
MUCC:A:/1M[4(SU+/G2A-32V'EIQS?Z7/A_I0]8>SYRH#K''WI 7N:5,RCS:5
M(7)._;^YK#>,9N?YTH#L=L/\^:D=CN^*3I;O48F3=[>U#U)\\V4)K'&WT49B
M':6[%GF.^E:,\<Z[#A:#C3@63B?<D[[/IER[=VP]V-E;"#^AKMZ1+$OE@H@D
MG:&P(2"6695XWGE_H,U'%G,>;?>@ZV[^=*D<,_0#6>-_F@ZVW^?- R/3/3-#
M,WXYZ_[5T:IU)/\ #PJ6J=L,?VIF3^/G*AM8X^10C#5S+<VE*WMK+K<XU=ER
ML7-Q+<HYU*!9)8@CS)(Y\KW!H\18^<Z Q'!9SF/8IB%T8F3N7[[*WCK#R7/#
M_(!@LNJ7T,[: Z\FW+_*(LF +<#,.)EC(:!. @MU2L_[%N"3"G;TJ7:]6I=K
MU:EVO5J7:]6I=KU:EVO5J7:]6I=KU:EVO5J7:]6I=KU:EVO5J7:]6I=KU:EV
MO5J7:]6KO?+/;YQQ8_6S&+;YC9'G"I=KU:EVO5J7:]6I=KU:EVO5J7:]6I=K
MU:EVO5J7:]6I=KU:EVO5J7:]6I=KU:EVO5J7:]6I=KU:56^",RSN+],W;7/T
MXIJ[XL>=8J#$'2)VW+ZXF_"I-$M@?5:.V0M&'7CX[Y62(RCZ$]>>8I>T7=:+
M6F0;&9MJ-6L&Z-2UX9WW;;(;(6CI?N25_N/:O\YYZ5_N/:O\I]O:KC(SODG%
MG&DZW]=P?X4)H8.+)ZGI4MC.EW&X'5-*C:ZDZ@6UU;,QK.EKF%UA2^300<&'
ME4!, )L&]R;'1S/*9:EQ+ '#9C_-VL?N6^8>(,<)&MP1-T4=^K#3!&VFQ=!V
MQH=GN-6Q3)L.(3H8.F,4LQ$K6D#C >'58S%>!X)CF]S-LVJ3:%9Z\KSO12O]
MA[5_N/:MOY&[^.*0SDV-^=;HTT,\_F<WJ;*$ 7E-T/4Q&7+1<2D;A=NW+MW*
M"G+LL(R7F'1=I-J 'J571Q.Q#)&[#4I,03&+'0+Q)+OA;6^]*:IN%C9CG/=J
M7:]6I=KU:EVO5J7:]6I=KU:EVO5J7:]6I=KU:EVO5J7:]6I=KU:EVO5J7:]6
MI=KU:E<J\WAC<?X?<EVO5J7:]6I=KU:EVO5J7:]6I=KU:EVO5J7:]6I=KU:E
MVO5J7:]6I=KU:EVO5J7:]6I=KU:EVO5I<WO?7_=OZZ49X78W5+M>K4NUZM2[
M7JU+M>K4NUZM2[7JU+M>K4NUZM2[7JU+M>K4NUZM2[7JU+M>K4NUZM2[7JU*
MW<QK?_8_2S&+;YC9'G"I=KU:EVO5J7:]6I=KU:EVO5J7:]6I=KU:EVO5J49X
MW8W_ *&4QSAOI_OO4NUZM2[7JU+M>K4NUZM2[7JU+M>K4NUZM2[7JU+>[?>^
MD]=OZJ6TPQHW"9+"/#VQ490[D7TD5,RC?08C,RIP>]1VH0:"SKP:]8*3N-+-
M\8T:L:KMHWPXY6VD"/6U[UX/#9UJ5!*@,Q8X7X6DMF^;;YJ(-UXPORU<^#-
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M,,M$),35OG@V%@KSS%#L>C[4/6'L^<JB WC SLVEPYZ8HU03MN;[AMQ;;>M
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M:-^-_>DN+5!AGS8VH1D1W6HGJ/9\Y4%W>G6EL433B*J&@1TS=-U*(H+>%/\
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M?S3ZV$[9&Y(;$)P!6#.,+P(26 ")KG_TA1 [, (I4BF/T0<8F"A2^T^MJ W
M$#;,[[E[\]-E0M)XKGG+;5A*2;5/+- <-"->3BC0EG-I'B)TS6H1_>3?^6J)
MH8;\Z0QGD+%^-!UMW\Z4.QZ/M0S-^S077;G^OS[59[;SC;Y^@C6>/O0=9._G
M2HV#&_VI+$6ZL]7THLKPDZW<>YQ+7@!1.P0YB0 !U8P@C2*&+'B&,EIEC$OT
MDSB"[.3TF:.@&:15N)AF-'_EL?N/,9-9")V;:,+<*DEO H!4,&RT1.)$P9<
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M_*%H]&WM0C)LN6;>;J&SWL]<>MJ\X>_EJN?#_2AZP]GSE07<[_?SA2 VAO\
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M!L85$TX6:E$,+";_ .I9A&D+"-R(5% )%6%;$W,+736DE,VXJN+%0@014_\
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M&DI4/*RS:_H03HCF"TNI:$4)V7+54D!40<16L0A]3)  #_Y__P#_Q  N$0$
M 0(#!@4% 0$! 0     !$2$Q $%187&!D:'P,+'!T>$0($!0\7!@D(#_V@ (
M 0(! 3\0_31,:)'YF,_0Q2L.)NF!+A-T> J@U9$"\EL*5N-W8@)7A+H.15,Q
MF:D(M2SU&KKJ,1&6%94IE+082$KVN4DI(SE+D-[R4P;"R"J(H*HG668EPX*X
M(@G2HD[46:S.%#.6-*20&&"90P6:X<A^!@H7@J01% 0H&1&*#"Q")%@,U "(
MN('>F(B:$P14[G)G(5HP;"X) TUF$8$BP-$+#Z@F%U((2-F2%4@: 5):W K
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MHBJ@"JQ@TQ)1:"4E1G F4$C0C5)LPN0*P*!B<E^1@$H$X;3&$ U"MH!&3(D
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M4<2)!2I$DY) SB!FLKE*P$R))10)*1+L$%6LP04LP#-^Q#<PZ7G\8@9)M^3
MR]>GI@;.-_<?G3&8B*W0M?5!,DD05/5(;E7(.0!()EL72*P1E(0Y50F4B/\
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M^?M@1L_D'M4P(2"!561#08P.AQ@$SX":\M,F C_S'H4 4*K8JL"4L+0*:2,
M600,HI"B^MDMJ=Z?S$%GYX6Q,N>9YWP)G&^GQ]4&Y.$MJ=?7"&4[J_/CH-S"
M<J7OW[X0RG=7Y\3=BNG+YC$S_$\_JARXG?GA>2.^G?3")<>]N)2RG&?CIB#9
MR_OKPQ%AAV_WRPAE.ZOS]L#<G"<J=>^> 80(B0@P1$1RW2-PQ8=Q2961"2I%
MUCB? ,\%&P8@!!$$_4@H!4@ *JL !55H!5<&7=H%)FC400:")CE[ 8.0" *
M "Q0^JF1Y>6'2\_C")<Q+G7?[WZXHYQOKU#I''"KW-2OB+91N[C"RU>GKX4#
M<G"<J=<+-N[V]IP(SG?7$,Q\_; C9_&,FE@D(*>40() ,8.YEH3>E 3,"84_
M^8P[XVZ0 X10GC,/$\8+^@9C3*%$EAC[G;''WG$-GD^^)ED=Z. -GZH-S",G
MGA1<IL[]/'0;F'2\'W_N%&6O3/\ OBUS\Y]# CPX>?U4RC=3"\H>CWQPB7'
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MC9+TA!?S@3.&4$ "H0 %5@)P9VPD*'69@H2%<9Q5!N'KSPZ7G\847./?K^)
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M01=F1)38 ##*K0LQ "!)9HA,KT\7,412+$2ZO*4O1574$S>"</+YE)!!*5:
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MFST(X(ES[T&YATKQZ=UPHRW1;W\L=]SZ> @W#UYX3DQUPHRXG?G]KQ'#@"5
M *JH!5Q.$<!),HTI8J(B<-J*DJF2"0P'4E)(/Q8DC0M@DL")0!D11@[\" T$
MU6DD+RJ" 8Y,0$PSR#,$8K"4,IW5^?'0;F$Y4O?OWPHRXGA5^A#RBA#)H.VO
M)@04$DEJH6N-!&M,07\,)7Q(^2J. JJ!B"QUK#2!1. DB2"P<ZGO6V%%SZ3-
MR=I1\H>)B!LQOIU)/+")<^]!N#OPG*3KWSPLV[O;VGZ 9SOKB&8^?M@1LGV0
M6BFF$MJ/3"S;N]O:?I!Z*11\KXU2=(<HO/Q!@J#"UD9HI9FZI,!"P0K;' 'X
MQ@T5> U29D;MI&7$CS14"8D 52@-(EH.XD>V5< T:-9/"2[-WM[1A>5>GAI;
M4Z^N$LIW=S@+.=_<X"WIU],#"-F5!IF!1+U8U$ (5!*!8*Y\J0$[_P L04 H
M !55@ *JM *KAA8L!F&,I#TRA 1]$.7$[\\.EY_&%%S[T&YATTV.%%SB5W]T
MMQ\%!N8=+S^,*,N)WYX>/EH!A((:,*BC@&(HS%H1HKH)("JA^2?*QKMD!L@)
MKAA8T#KH0Q2 )$0(P594"E4$AP&62*B)=+S^,*+GCH;F'0\_?XPHRUZ9_P!\
M"OPH^Q$. [:TX$%!)):J%KC01K3$%_">LYY<("* 01$$9P.0#("0.TNA(!!%
MP)93N[G R]<3<(VF?3TXX<ZD[SMY81+B;\"EG$ZG*GD1TQ!D\Z?'7AA$N?>@
MW#$,E\_;"S;N[G%MF!EZG>>-\=[)Q(V1^J;BJ1<8R806*47%2'%DO"7"A'5L
M*56@R6]4#0EH4(/RGPX%XATB2L4(@7U<4K +2\U*RP$LC1J $R$) E!1$1$4
M1&OAI=F[V]HPLM7PD&YA+:G7UPHRG=7!]$"RD3$UBHF2X8IL)%"X;("C)$_\
ML1@,A)&*\A$4B%$/]R'+B=^>%Y([Z=],(EQ[V_>AN8=+SWZY<O/")<C=4\_7
M$:([O9A>'W)&Z!4@*Q<D@ %$DD3"\8Y@3E3(9S^<<VD(<J(9$%%Q+!ALTTJI
M@,BO>6@J[H! "0*@1%%#,E$1&#"&YATO/XPHN>.AN8=+S^,*+G'+[J_"I-B(
M7&@Z3SG J<*DU +'!&M.87\(PSGU(("* 1$1!&<%W4V#H%H$J4 (8E!N=]Y8
M3DIOKWUPHRXG?G@>=>F.,Y?'.,2R3R]\(EQP*6<2-R-U.C)Y8C1YT\V.N$2Y
M]Z#<,)R8V=_.$LIW=SB4LQ@9>N^_/^XB (3("" )3)Q YP3IV%PQ- IBD*7!
M?FLJGKX826!%F%4K *]")YIJA$05+3(42YXB<J=<+-N[V]I\)!N8@$*@($F(
MB0&N59_Y7OK#:@*T"3+P!$2#X< 15"*HNU1G1#P5,N)3XZ87E#T>^.$2X_>A
MN8=+P?CO;B1<3J<4MUQ&E=WM?G] H&!+A) 5900V3&AY-4 JAEJHLM0'] H<
MM)\ZK<$NHPQBFBD86"*D2%&$A5^K0W,.EY_&$,GS\O'0Y=]ZX=#S]_C")<^R
MNVJ:4$)7&B5:<XU2A4EJH6RR2].87\(PSGU(("* 1$1!&<'F4V J/0$5* 'Z
MDH-P]>>'339\X?<'=,3S!WQ[8XSI[=3"\H>CWQPB7$WX%+.)&Y&[V?1,561Z
M/7P+8_G2MB-?%')@10QD&(I*6V:1#_H42ZYD3-%$JR2I%$46,"9)#53!G($L
M$ZG*GD1TQ!D\Z?'7AA$N>&@W,);4Z^N$LIW=SX$PQ% I)FT@3I*P23&PQ+2L
M^R]6<Z&?_*\I_6]: E,X;18Y/C*91NIC=/>V,0ER/O!ZD9]3@$I !)I(IJ*@
M$Q# -:N+PDJJJJJJLJM55JJW?T;[;AQ&60"RP*4?,"J0!+%14*4$8K RPS'S
M]L"-F?JARC=3$LD\O?")<\=3*-U/C"\F>F$2Y'TK\*GV(AP':TQP*G"I-0"Q
MP1K3F%_">LYY<("* 01$$9P:938*@=@$J4"41]H0W,.EY_&-X=3VP.R":4/3
M$*8>*(X?W"S;YXA+D8%+.*;MU>B^O#%5TZY/)^R2\)LRF!ND"IH!B5#&<-27
M6M ,]P(_21<KU.;(E&U5)1,8/# X@KX2D%PA$A478[VXD;D;J=&3RQ&CSIYL
M=<(ESPT&YB&2^?MA#*=U?G[A:+73*@A=701@)?\ E=.>:) $"5K/FI QL1+@
M%7FV]9H_ @;DX2VIWI_,+RAZ/?'")<3?]4L[S**0 55ZX6:0,T+$%&*1E,_3
M$4\2LKH*04P(GWLE3Y5%@7"!EV"E$>?N8G;'/YYX"WIU],"-GZH=FZ#TPLM7
MIZX1+D>.ME&[N,+R1Z83J-"J*$+C(IKSG J<*DU +'!&M.87\)ZSGEP@(H!!
M$01G!_51()AJ KV 6N%L)N13KA$N?:AN<>_7#I>?QC>'4]L5W![VSZ8AYIL_
ML^>%EJG>7TE:YHUQ3=NKT7UX8+"? H-1 @"@0Y$,*9?Z* M\&4"!8E5_2M&5
M2RY$E$[9TRN#+D;VK#&*R".@2BG*G7"64[NYP*6<2-R-WL^B8JLCT>OB(-S#
MH>?O\849?4>B$")12, 9@D 0@XD#7J1$!$% %*49?^5HJ]]I1)(E50W>HA^&
M@W!WX3E)U[YX%+Y$RID "Q=6 6F*O9$M*@220EAB8?U X8EK\7A02([+8RPY
M$ODP!M8#]$0;G'/#K<_<Q-PD[S/7 <Z=<2-F?JME&[N,+RKTQ"7(\>$E%7B@
MD5,G:DZ8,?9)):J%LK"-:<POX3UG/+A 10""(@C.#[J= 5%H"*E@0F!&7KY]
M\,5Y)Y=\#$\D>^\_N6RC=W&%Y([Z=],7+FNGMB#8;SOUQ):K;V8%20\PB0"H
MJHJH 8C1JI7H#8 !@HB'Z<4M41(-S;'(A "&,2$3!(MDSRA-(CZ(-S"6U.OK
MA#*=U<"EG%'*-UN2^O#%5TZY/)\1!N8=+S^,*+G'+ U)1 67A*I%4!H?_7NX
M7=7N^(UFE:ZZ4K.S:EAB-L<.L2-9V&F>(VM-T/29W/# &;+6NMX&AO\ 2<1=
M&J5=-YF5I5F-L%V79+#-5-+>4F4''.K7A:F<7S+X@Z:ONC?U22<01M=O'E%(
MI5ILB(K.CE:K:1J=::PY0YZ0:-]T[2DTQ%(<R].79$90XWM7K"U!R>UH^.[=
MNK-+0>S0U?!VPTV/M7*VS_2F7%^PRCM"&5H%6A@V8<!+DI0TOH% _%-!GQH0
M@<B %4!</+5"EJ#  G,Q,_JLX8EK\7A02([+8RPY _DP VL#[ 0Y=]ZX657H
M\_YB"Y/>I@+LW^_O'V);4PO*O3QJM AXJ(2C0':PS U !+50MR2].S^&>LYY
M<("* 01$$9P YR0(@50$M$)0EA47./?KB4LIC=/>R,59P[J>:'/TPO*O3OG]
MR'+B=^>'@!,089*$!0P@L,5USD&0$V8FMT_5(25G9+-0*B+: FP&>U8D)D&Y
MHH$$ (?5!N81D\\*,N5>^6)6N:-<4W;J]%]>&(<J[O:_3Q!3422R@$):J0J%
ML15']A7G),#**"(O_P!<-<IMO-NS29*S&4PZ[*I7RAO:EIR,;XMTKE;G6T91
M2,K=KF0\Z4B7Q;;J6B6N6<1L@:)).('I*26+1,:[6N3&$3U,\J&5=Y%9)OLO
M?;;SN=S_ *_6<+(M>,DXF%7"7XTCA+ 14%*A@$6W?]8<,2U^+PH)$=EL9:\@
M?K; -K"^XD.S=B94?,X4^,17.=,!=F_W]X^L#<G"<J=<+-N[V]I\2I H\J@I
M<L.J3G KAJ@-4BQ;)+T[/X9ZSGEP@(H!!$01G 1G1! "4!*D@#!2#<PZ7G\8
M47,"EEQ/,$[WXAV>+OUX86;=WM[3]2C/+JLK@^%4Q?$L2UX^0,6,I3!'ZP"L
M>M R*[J *P"&,0""@1$1$D1*(E1*)]T&YWON\<.EY_&$,GS\L2YUW^]^N&62
M=?-,0Y5W>U^GA!5%, *A H0)++G(_P#K:=BKD7]NM<L$@5SJ Z3QLVBD3BQ%
M+4H6#*A>NB4NB?ATBQMX1%RELFKP,1'';/>=&UMR5K?3XXUZ_P"NYJ7$%[RJ
MZG. GXB#(- 1((RLCU#%_KKIB6OQ>$">C(IC:+V)R8 0AQ=5X2C+B=^?WJ91
MNIB*SWNKB"Y/3K&!LXW]Q]4&YA+:G7UPEE.[N?"J$*/H4+<!VU\",,DDM4BQ
M4;)>F(+^$]9SRX0$4 @B((S@T#D 5 C (J$ * ^I0WYYX=-=GSA$N/>W I9>
M]F*J"=MN^F%/VT-CY@$J8@%8ABM=$"6,RHA!#,!3]:PRHF7 A8%&J*6?@D-S
M#I>?QA1<Q+G7?[WZXJS3?7R#$.5=WM?I]]0!SK,22)9(M)!T!G_ZUMP,NPXT
MP"O6B3F:\;SE3+9DUM&]SSWY[1_&:W*-;WO?5HZ+7-G"4O><ZG**<9FU*E_7
MV>]ID_ZU+D <I0I0D\8A@"      " "@ ;/Q)7VU3=1I+1%D4H\K]6 15,*0
M$P/U[AB6OQ>%!(CLMBDK>0?T(19JL T-S#I>?QA1<^Z!N3A+:G>G\Q!9[W6Q
M,N>9YWP)G&^GQ]4&Y.$Y4ZX0RG=7Y\"J (>612Y8=L>3 C)M2:E"Q4L)>F,+
M^$]9SRX0$4 @B((S@@3F0$0E 2I0)0 QX=\8Q,_Q//ZH<N)WYX7DCOIWTPUV
MF%)B"L.3*&2?U\4YPG!!;4 UD;(DF-!6@B&5*5%4E.C^$ARXE&<.AY^_QA$N
M8ESKO][]<4W;Z]0]..%7N:E?MLUUDU#45H.^VW?_ *RZI3GK8YP9X#*GG ;I
MZ%JT+_E-]*=;#MVBZ1%/]:*ZU3+!()N*E85-S\10%4 JJ@ "JY$=,*]!X(W
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M^Y!N8=+S^,7L]M7^<<!;TZ^F!&S/UB:LCU!)X';S,@C J)JDV4W<;)>G9?\
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ML%U_PG-W'G_\1"BZ5OKP<K$D6\'+88]HIEL:;#!3E?;7E/+=G_MS))!!)N"
M0P),&!)N3N[],#9\^X^JV7+N,+RAZ/?'$ZG&U-/C ,RNI?G,]7%-&]1YA;AQ
MP[QOMS*''UQ&IPM37YQ/,'OETQ#LH[?/M-V%Y5-G?E.+;,!9\^YP'.3KWRQ&
MAPO77YQ42'Q@@@41<628?WR"95I12%!1X-,4TK^&U@!#J@%?7P-P>&$Y2=>^
M>$,N)7YZ>.@W#UYX=#S]_C"B_/[-<,-1(6X#W)S@:Z:WB+&X9K,M_P"%0F(G
MVI&QF,*Y)J^Q+:CTPLV[O;VG%MF!&?![\L!S(ZX$;)Z\OL@;DX2VIWI_,+RK
MT[YXA+D?4-1+ST1#.0L@(%_PK-W'G_\ $0I6^G"C:]9GB94\!9>:\>KQWS-_
M]OIT2; *&& 90ADH(:!A#<]^=\2+N#WZ8@N3M//N,"9QOI\?5+L[[M&%Y5Z=
M\\07G<]S@.9"YGGW.(',WJ-*7"7B:81JG1S*8WAY>V-@/GM[(Q#LQO[]<)9<
MNYQ;9A22N!$/9G7.4F)E?WP)E6E%(4%'@TQ.V^<9*  -I0^W4&X>O/"<F.N%
M&7$[\_'0W,.EY_&$2Y]*Z:M/ BVM!TF'@:Z<99T+<"^)##_PB<V&"8@+1$4+
MIO '[4&X._"<I,+-IL]L6V8 SG?7$,Q\_; C9/M2VIY=\<+-N[V]IP#PR]F*
M:))%J;"H(@_PG-W'G_\ $0A-(&VN;6&[%:BW@\'A?2,BCQ XWK+_ +@8F\5K
M+K3-4L6)@?M0Y<<\0:&W+H^F)'F'?K@#GS[\OI&M=^$Y4ZX2M7=?O=. */7N
M<&@ITMWPP@UH[J)/.7?&W#M1R=2CP],;P\O9Q!L.TOWQP(J2;)D(S9@)$C"%
M*O[\/.X2BL* 1'8TQ/W^<%Y  -H0?O\ 0W,.EY_&%&7$[\_'0W./?KATO/XP
MJ,S,"" %;NE1Q-=,-4@L;AVM.S_P9S&"6E0+32&9DHM2^(TZP>N$2Y]Z#<,0
MR7S]L+-N[N<6V8&7KOOS_N YR8D;(_8Q!*QD:$!"*$7I%/\ "<W<>?\ \0G9
M?+?X+Y'?-9K&F*7[Y>G^X4HH>.9T1#E"!)34\!#EQSPA<[GN/+$BSB?WUX8
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M"0PO_ N&@YI*JLJF 23G+CC.GMU,+RAZ/?'")<3?@4LXD;D;O9]$Q59'H]?
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M,)(1$D$E:P8IHRDOWI=F[VPO*O3OGA$N)O\ "A!%Z6""IK43:O\ A>;N//\
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M78IB&<K-:YQH:R9F_+]6%69B\E*Y%JS&<ZM &('80%F)ZYB96FD'YV9N?/\
MQ!KKW?KKG%9, 7:W%,ZY4@N4O2K;\5BU+Q-M#=EGKG?$FI4I8V[*RA09F!/Q
M:1E;WFD7R%WFR+I8K%T'3G&;E!0Q?ON1[A*?@9<HRMP(VF(9@)FVW;--.%G/
MP+AUIER:96(SBPGZ83$H#G363C$3,0NV'Q(K;39EU+M<V39^DRK3/=I;KK@
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M!9GO1IC)Y'D/OB2SWN:X$;&I?Y[KB2@C?V1Y83E3KWSQ3M#C\]Z8DN=[[XV
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MB21KN^!GXU5Q-M_/W\B]K_@7[[D>X2E9OP[=.LNP'@A3C,\*MX9M9_X&F?\
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M]^Z_>[$1E&^_7[T&YA.2G?>>.$Y_/IB;A#WG;G@16YQZ_&)'H5./]X8.6<T
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M[W1BN<.ZCR??$SW'G]VKWMC[O[;83_R1>#B @,7\ 0'&#Q UB_(I!B7 19C
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M"93$9>!EH]-(=)?.UAW3/QJSIMK"GZ$2[,,HI @)(0P&.Y5J911&0%"P+(>
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MFU[?@]]WO;RQQBU\W<3SCJ^!.>L1?89Z\-WZ0ZZ0<FP@5##HI0X)F-H*,1
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MG.^OSB&8^?M@1L_6 TIY<3VC.IC@=U'K)U,6+5\[1YG?^::C$Y3#&%!0.@
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M'=O<4A+#>+FZBVOLE@KX$U*=U^.;%O "E,Z<:L.:H --*L^!WYZYS68A(O\
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M?GIIND239&W4ROLI?<%/]9LVOY_.W0,Z^"PFTML:;MN?FK?4[BCOM1DN5/U
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M]H)@5 %5@"JK8#-< 9">J) 4B8J&3]X>=2W?SB7,DMG<=,+RKT[YX34W2??
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M;/W#+UZ>D4YUP%V=Z_S"#<'?B')YU^>;B=3E+Z3T\.&YY!-8*M22$$+$1?\
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MNX=T>F)EG&S\],!<XWTQ[,-O;+)N=OT<A^4D/D=$!2RQ<&&2R!8. @"B"!
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MPAH"%?  !G0;,5(@@*1J@">$*6<&LY?. -G[0,YWUQF"-O?LXBV#WJ>V%%S
MBGGWWE@-9IWWI@1L_1#<P MP >^!B19Q/[Z\,20$&NX"AL$0PD(1&%#-R7P5
MAL&ZP %%4_ZK$,,U"!2C(5P<$Z-#4S:(*5(U-6*NQ2MY<J@S(DS^V5$F^[--
M<JQLQ/5$E^, IVRA!D0Q%T(D%DEJ&$T9LJ$.,H8LI,+JVXHA2)8I-N14"9A!
M$KQK0@$SC?3 BSB+</>C[XDL][FN%FW=[>TXE9J:);UQ"+QL:'C$G<8HSU>Q
M\X]\57#T>N$2C]]3.=].H=(XXG6F_P![=?K W)^Q.5.O?/"&4[J_3)E;U@RR
M,95H%> "H% 53 0-!8LD_P#20Z?W((K"&@(5\  &=!LQ4B" I&J )X@BSPRP
M:SE\X$;/V3[]]Y8&7J;??WG"W!'4[KRQMA[[TPHN8$9SOK@.=.LX$;?1#ERH
M][\0+,FC7K_//&TC=4CC[_ C9GI@V45 T@)0@E"@AF<2-_$$4V:B55@C7,&+
MDDI5*+D@I!)5#)E),$H<)F1,FX%0D%P$ 80!D*DF"JPB659!A9/JJ4DJ)*D3
M$Q!-*B9QOI]!2W?GZ9UP:$=[XZ\,1:OLIR+=,2+N_+RQ(N<>Z+NC V<;^XP(
ML^V(MAOT[WXDL][KX0RG=7$ZP[[\R'KB#G&QH>-S"&COJ/0WVQ59'H]<0ER/
MNB\7V=Q._%=CT?GIB3.F_P![<)^XI0:,(5%)Y0@\$(AI$JTH %!0* ?^DSM/
M[D$5A#0$*^  #.@V8J1! 4C5 $\81G@UG+V<"-G[1F<^?>^?/%=R7+XYF'6D
MWG\PB7$WX&9SO[GYKO#G3R[[G$SW'G]$.7$Q%B6_I77B=<0S&K>5V\\_7 C:
MO/U^R3,Y4^.F!BS&Q[CBQB19WY/","9QOI\8B\7V=Q._ $QTCUIO:;L&HY?/
MOPQ$D=*=/C$%GO=;$B@X]TWUP!SYTX;>&!$9QK7K?KB2SCW7SQ!L\.ZAOG"6
M4[NYQ.I/1YE7C@R3N*CBWZ1A#<5LJ=/*F6,T5CGROB$N1]T&5-WM;IBN_P ^
MO'3$]^VO#Z%Z(ES8S8.0$*'<,5KYD)8 "*Q+_P!*+4_N016$- 0KX  ,Z#9B
MI$$!2-4 3\ #.=]?G$,Q\_; C9^R4LQ@>=>G?+'"Z?'KA>5>G?/Z#W][.ZX"
MWI]5LHW=QB#9XN_7AC:'>FO3%R2IKE]DE9.5(].F!2W T]SK.)ET=Z/O@#;$
M!,4G3VMTP!G)IY%?<P!N=(G@^^=L18Z4Z8@L][FF)ED=Z. -GT< 9SOKB2RN
MO=3$&JX=UW4P@X9GGLXXDS!Z/3 &BS:GN]S3",QZ'][SQ+>:E?G[U1)6%XYL
MR!D01 )1=NB!CH 11(1?_2JG]R"*PAH"%?  !G0;,5(@@*1J@"?A!9SO[G 6
M].OI@1L_8*5&.]+8'F#WWECA=/CUPO)'OO/$)<C R]<!SI]5LHW=QBC. 4FC
MSTWOR#(Z*7[W8O4MK]13CQ\\=Z?'?,4MP-/.G7$RQ.]N -GZ![>]KZ\,37&^
MD^<8R'QQ+\HSKB+#)WE[8-+E[. -G &<[ZXDN1WJ5Q%NGO4QP)XGMB9F2=T#
MSCSQ(WKH-1Q*<XMA&W>J<_GA.$,IW5^LXES5:?9I@H +"*@5*'(4BIJIG_\
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MPBJE4I'8<Q!) :@0@-0D$31R:-14)3K E )(S^C$;=\OK@+>G7TPF/827+%
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MS1-),L'$$ )D !-%(P*I3"5I HE9H4Q 0B)(J42$4ZBJC%*J555O7_S^_\0
M+A !  $" P4( @,! 0       1$ (3%!\%%A<9&A$#! @;'!T>$@4&!P\9"
M_]H " $!  $_$/TQ%]%'@ 9J9E',2A.W8U3E\GB*4"0D$$M(9BBPJ!?J?B7\
M9"$)VJY%[0SM6ZH !<UGL\@EH2"!) 0B!H&'XW&I<("*J^5O$$@H33.3H4-
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M--.XG2G(50RCW@#&\V?*:>7 FH\216Z+F1FU$XG9P/:\$0(H)?M!\/()Y5M
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MB5?NG-D)2BY_8Z ,/1\E8FP$0JGX0#[:0"LTE0_!.5NM(8=,=<Z&8WXX\_\
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M2I2#(;USG_K!8132+(AX@#VM4^*6>_4O(HI"VQ1%<N1X42"@#?"D).R'5O\
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M:,C6_P"+O!HL(\L<#6EJ"_(@@]-64A+FZSAW\  EVQ4,%::!3M+1+1;0=)D
M/[;?:QWAK(PZL4)P44T3$CZ[$'$IV'G\_5*,M:V]L#"WIR?:*O>22^'N/LM(
M]SLP>%[4O)GI2)B/8@XD_=)RDZZYTEERU/:0<3)YF)DA1,!^X/M6VK_ZS$)
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M@Y(%_8BINH +=\9A)^O495_!@ -R:Q<-V AKA :*=2(Q%&AW(#EV*91PM]5
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ME/+W2D6R<=CYY\ZD8O)PUJ:D8/,_WWH#@]_;MJV N+=.= 4K"\0Q-^OTQO\
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MF4'\2;*4JT7%&VQ7E6R0E+VS=<QJD4 H:!$48GX)=W#X^(I>5^G<*91PM]5
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MTG*W6EF_6L)[%LN6HI>4/1UYU/-.MJO<:R!8\:(]1(E'>X.OCGC.9!TH0%,
M$WH>'Q7)+TZ-92A.F^^"JZ.D*D'@"-D;?N*N;^-O0UMJ36'/#\ G\%Q0Q:I7
M8?TG[&4OC#-^)5O_ .G4TBR(!F]_&4@A?")V -T!V!5U&?H04$[H!]?#@IX0
M/C_2I^[&@P=TNRLDL33 [\ 5DMP.((4"R*!X$!V(RI) D!D&#Y*=P*A[P5MJ
MSG^XIO.G$Y&#WTBB88;NK&%S @"O"3CES-%@=]6,)Q12Q>8-J/D/> 3A^'&S
M/C(&M*8.H);@BD'O6DOIP[6E !%?X#(I+D*QLWW^^X%!;HCD^5NIN2:\J2M)
M.0/ K:DM9^T* :TUZ(.649]H%):S!*J"<#^F_6-9Z]K#0W>?#B;#C;HPN,1>
M#WVN]'*(C+24?H641'Q)2J  0FP /^IDFP<W+ SNZ!K"W;,_"M^I&>F(E4F+
MN=.Y@:G>C)[JS2 %3CAKW#IXY0[&"/D$%?H!Q]UF,RO&WN*JXUR')+?65K15
MP8EPL$06IFVTM&2?#+9,\O.,[AGG-?%$6,-0I0R8%*&(A;(X 6_'@A=XV$C6
ML3H[C2#'!EP.\^$'S('E]%(2)A</V@Y^ /6Y\;M]710;<3S20[E3*.%OJI9)
MZ?-(F)^"V4<-12\D=:S_  0<2DY,<=?--Q_>CO-L%$D?\1B?P)/)G6 (EQ!K
M"YS#<A*@4@EINP\_GZI1EK6WM2[M:PBEF%];/B>Q3*.%OJEY,\=?%(F)V(.(
M/&L<BG77G-,,0&M85#P4=_KI.%+W)[?>Z:3LAY=*@X,F_P!_]J[$W@C7)K>#
MZ[M,4B8E(.(4G*W77.DLN6IKC4/!(@(*HR!P@W<E66268,8GC2H8P200!1HJ
MR=V#:^RE$-F*>'I4MRV<FO2K-!UUJ&")QUUJ1P9\#'ECLQ<^-:UMZ5)PX^DX
M34\QP@UA"X[^(7$$R_T\ ?[_ !^ND[222222222222222222222222222222
M2222222222222229/&WC=>PMH2O] B7TB)=7UR8#G1AJA(Y$A)'@9L##WJ2E
MYW2$J!J6?CJ4Y4-)'&IKF4YQ#QMIX=+9XY9X$HM<GSF;7H+L_/\ P6>"/M9
M#<_-U3A>'2&DS\#2D\## )V23^0B8WPAI)61;'!Y'AKC$#([LTSI!'!!X/\
M2_"# "10-#91"'K.NA)745*+Q6(43^]*25K"OK$Y5/T+I!FY(D*J*97(1XD
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MN$'M2S"_3WI$Q/P2[L<,.7Q2\K]-<ZA,2.W*7@*S WS'!_B*NE;^>N]16I"
M$P;/PXPRPH6DCLZ'$IV7G]4HQ/CGAV0.)-)RMUUSI9OUK">Q;+EJ*7E#T=>=
M(F)'UV(.)5F*-V)N^\:4$0-I_ENE0\&..O>E[!-U^C>D[Q]_K=%0<$3?ZZ7A
M3+$5K6%.V'SO\>E(F)'U2#B4[+SU\T!$14H1!<1+$2R1>\X-1?)*JC:ZCU0Y
M;[&#'4^0OM*\4JY)940"GB8ZCK1"#!P"Z%E+K)<C@C6M9<^S'$\GINI.2G/Y
MJW8-V.O)H&=G8^!NWO:"OBT11H0HRYE))J830?T\FB#I=HG0(7ZOCO GH;S=
MP%!S-PK/R0N7IA$YD_%9.3-%8F,)>>K2=9A_O Y42D9EQS>+<%/DQLA> //G
M0!?4+A;[]#^9P!VD3)<WP;8K)'L_NR*/2S*N&7(G/Q!?E.@1" ;<_P#0?B#B
MT<Y9^ZD" E$VDBD3!B<5_P!]1O!R$J!0@U011ABX\/I*(<Y_4%T]8UGKVLNX
M 6>B>ZP>4"\BK]K\]@U%N!6BW9A=H_THC2L)2J  0FP /_W5JQL:+/@5#RC>
MH$+-I1?I"611%U<][ZV!=?4R,IK)B;V"N$OS:M8F7P(<9/C!!B7"P1!:F9?2
M>.3$4XL>JF;DO<4.Q"5) $E, Q?(&G6?J:-L'=9.P;]BHT6T>B.-.-A1BB5V
MB>H+=QS$DRYF\JQ>/_ 08Y&R-#!#7!O\RYUZP$P(B!+.G/L' JM;O854;$2F
M'(6:A2$!M0U,(""QWMBP52F"E#SOTURIR4+Y4S')L?DMT*<0).$]L3_J>GY+
M91PU%+,+]/?\4N%O2EF_6L)[/H/"4L,U?\13DZ?3JS)@Q(0 F$]RP9^-JRM)
M%=#*>%^U#EK6VG8>?S]4B8G8@XD_=)RDZZYTEERU-<:4RCA;ZI>5^FN=0F)'
M8AQ*D8AN=>U*F8;?7ZPJ%@QN=>[2\R>M1R4=>?6K=@ZQ]^=,L16[TT'&IY(Z
MY=:1,:0<2A$&@.8("M*U?4I53X07B*6G=)T4BND8[WXDQ/#-V0%I7J;&JB5+
M3DC921;22=!&.,3*-JRL6%**OW/+ZJ9<9Z<JS!;?\_[07&WIKR_"SCMS,]TU
MN*>;'K4C(&['7 :A@V=]N]2RIY<!"H  5.=*L7Q"$\9"!_3R1B:(,*'EEFQ+
M@@$EL--E]%8=YG@"NXUR4R:NCP,@/X2$*NH[C?&-.,X=)@7@0A-TSZ4/PDRW
M !6?M.HL/!UY/ 9=70@ A2(.S!&)ZG#M!396U$\$Q@N4S$,Y/%JQ/\JA5@$%
M+87E6@&7/IJ81F"]^*[^5=@?^X'R2+;3P:$+T!@=:X\,TH_^H777B?ZQK/7M
M9<%@M&9J%.[.0SYK((63<^7@(R00O;@C_3C\9?\ CBUAJ4*['I50:DMGW4QZ
MA?'F,3<!(@;OAZ ZV%DO%K0R,/([@W2?AZXI9LCQR ;<R_2M)R%293W$Z%LG
M1@I.4-M![92O%!](VEOH]QNP6[E2(+1_H+JFD:=AH\$/',]NPQX**;<M%W$1
MY30"8"3-9N_5FH1\,Z$C<05DH.)27"W7WI+*>&I[)3!2AYWZ:Y4Y*3LM&F[K
M26"/&S[G6L )^%^/'Z^/Q2X6I>5^GXIRMUHGG]-CS,E+_$=9K^_VQQ!S07 (
M;C]A^I1P0&EE=CF7QZXG2DMQ]S7.D,IX7[5,HX6^J7DSQU\4B8G8@X@\:3DQ
MQU\TAE/"_P!]B7=K6$4O*_37.H3$CL0Y:UMJ1Z#KVI?D-;=Y4F#&Y]-32\R?
M*:CDIKGUIAB W>FAXU?M72?KRJ>2)KRZU"8D5(X)C$H32:6IA'& !U"<'DSF
M+52/ +."8FD5,!'? FBZGFS$4'"P=4;'S4D'0 X9D47 RAW%FN)MI83^$I@I
M0\R>E>5T^J2P9Z>]08GMRRH+C;C\_P"5(X,]E\X].E^<^5(.(.S6.RLD*1YG
M):D8@\->A0'/R=>G=!'+NI1"Y7^GXN*FB(M>G^\63_ (8@.Q"5) $E, Q?(%
M'4<FD8: \<+*C.$EO)U9$J_I?]GD9!X7@$T.2!#+3[OGFC!WW))WB3'7\&'@
M#]/FL@A9-SY>!Y[,PW59*8?X4J@ $)L #_\ C/RJ%6 04MQ=D1@QQIO ?[>I
M:3@% =L,9#L$!JD=_P!1.RCB"W-]8UGKVLDSX^N3B+R=TU662GM$D&A?U."X
M9A::"G94I?3L_P"E==8$1D?N>&PTV7T5AVF4=UF1H &0^R.]Y?RD%CVPA+!
M<&T NF]J!NB#L?S+_>GNC/YA@'QN_P"7)FQ@B $"B@I89_??RQH[B)I2 M%,
MDN-4<XK^!IQE?S(4UK7<[80^"TE8=P<\:$!F;"<OWLN7E(43GKWE K1<!#W
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M*S#-P>7@V_;.Y[B&I&+@7=5.Z\+#V5BB<DHB!@_G%05.JB:O82GO(39XAR"
M_"=R(I"^!H/X47U[PVR;J.O 9#HE1/<=6(1QA!-0A$\88U$CR[J$,IJXBT!)
M(0(_T_3(QR'*^[4/G0.QXV?)/JE%Q3TW F7.D&) G4X\[5Q)QN=(>E*XFTN:
MXT@XE.R\_JE&)4#B327"SN^/B*@X,GMZGE?I3#9(\O9=;*2YF[#HXGG266N&
M/3MNT0[3XPU>:7,/&S2L0G'M0<2DN%NOO2&4\+_=2MX4HN\ZF7S+^)-J63Z;
M69F5K6OM6=R>)SKUJY2#B#QJR84ZG7YJ7,DW7Z-0\+.S?LOZ%+ROTUSJ$Q([
M$.6M;:D>@Z]J7Y#6W>5)@QN?34TAE/"_WVI=VM812\K]-<ZA,2.Q#B?//&H3
M!GC\GN-*.1OQZF&MM);KW&D,IX7^^U3*.%OJEY,]*1,2.Q!Q*3DQQU\TAE/"
M_P!]B<K==<Z6;]:PGM0Y:UMJ#%Y/^1T*7YCTQXY^50?0=>U+F3C?'_.E1R4U
MSZTPQ ;O30\:OVKI/UY4EE/#4]B'+S->M.R\Z48E(.)/W2<I.NN=)9<M34V<
MB4PFH!J0:U1XLW:J HZW\;B$VP.U)AJM?USW^F3)DR9,F3)DR9,F3)DR9,F3
M)DR9,F3)DR9,F3)DR9,F3)DR9,F3)AXV,,0RX>U2@\7$M18T8(6B$_W\&HRP
M\<K;GVM7:$=Q XFD$@2(PBA_ ,J5S&I]%);]_P#U K)X+!("B1^L:**DS!B\
M$,H2_P *(G]2_6-9Z]K+QKTT<X*6/.Y @,?*4BP;H)!_8F_ 1602VF@JD%>Z
M6U%:$\LI?0D=_P *1643*'N-5@,[D)'&>%QPRY\8C> +;:J"#]E%MUUL"1O]
MM7^<.Q"5) $E, Q?()P$FLA0;CF N7=Q[BF=VZ]H$[I2?DAI^'4N0= >X(F"
M^?-3:\"%X6/1:L^-":_0@MOT/YG ':1,ES?S-L)G#E8HV 5L%,/SX!.2\HL\
M:B9M]-#>4U:A7'J@VH[3$N F*(<HX?% X7XX\_\ *482>G/_ &LA)Z\RH'!C
M<_)[Q4/^(\XPI#E3LO/ZI$Q*@<2:3E)U^^M(-S??ICR:162,MILSA.=J9W0[
MOK$ZTEE/#4]J\HWGQ]>U P1.3RO2L0G'M0<2GO+[/2:)"2_B0!@K&A:\,*X*
MGY$S.C="U:1E7M$Q'L0<2?NK)E'4UOO5]H;K]&]9!UYWI9OUK">U#EK6VH,7
MD^V7I2_(:V;VH/H.O:E&6M;>U.5NM+-^M83VH<M:VU"9SQL\S'EYTHX(RTFN
MM.P\_GZI1EYY=JV7+44O*'HZ\Z1,2/KL0XE.P\_GZI1EK6VH'$FDY6ZZYTAE
M/"_:IE'"WU4&#.Y]-12_(:V;VH.+R=>U;7S?96\3TW:9IAB UK"H>"CO]=)P
MI>5S=KTGL0Y>>=+RON<=<J6=82+3>.A1%"(9ULV-_J:PU=@#II%D1!#-]U09
M8*0 /X*(L6=M4,2)9+O< $@ @AJR]BM;X#.S]0NNWR7G\\VXZ#*(AMH=^L+$
M=DSGXA4_2F-_4M:!>L:SU[67 3:@-PA9N.U[BWOI.["*4ZDW]ENT6VO>WTJ3
M7<PSY^EG %'W[ B8UK"S!\9M1;[ANP6[E2(+1_H83E^+PY3SD&_@R$5?W-=2
MMF 1W%VNV%,'0/&E'?3X2'.2>:)Z%[CY!;QH@5(!/5.:[Q4Q%G@#PC&M,XL'
MNI.X!:XA7)/AELN>7C&>/8*+TPVQ5XUZ'D&V0RQ*I9"SE$9/.E&)VK91PU%2
M['HZXOE2C!3C)U^J9VD9_9;6^H'!C:/S2)CGA2'+S->M2R3T^:1,2D'$'C2<
MK==<ZMW.?WEPI,8AVX\\'7)G=>_K?H]*49>9AV0.)-)PY/AH.')\4B8G9O[S
M,]V;@@^/XEIBYS#BD0(*N"8M35P+.KJU8=4I=VM812\K]-<Z1,1./8@XE2,2
M;FY]=:5VAM+]'SO60=>=Z2RY:GM4RCA;ZJ#!G<^FHJ38;[_[ZU!P'<XZ\J48
MG9 XDTG*W77.D,IX7[8<':6JS8]'X]*98D<;9;2W6G9>?U2C$[4N[6L(I>5^
MFN=0F)'8AQ/GGC3LO/ZI1B4@XD_=)RDZZYTEERU/:MERU%0<&>.O>E'(=IU=
M_7Y@X#N<=>5;0\_NI&)..&O)I4S#:=7=T^)($%)SBD@2R+ID@5178X@,J6_J
M=-(LB),!(,.TCYA2Q7\&+%(<25G&B:8NY )<U? 0)D,1/:<3;[38:AGZBDP]
M:K!0C1O ;^L')." .>K!?U(@P"/K&L]>U@1M'-)VYTP"J3W0Z+$AR+R%1N_9
M1E4GGZ_P"&4Y)W<*BY29=^_BT"BBO*Q:*SI[BTESL 6LV60 Q"3#N)N5T)9R
MT1A"!X-H/!_I?A!@%8HR]&( 7<#L9ZPR!(U2\1*\(4KWU]@'JN11X",!*=Q.
MQU,_^% RB\)$!$[V>*HZ\4[6V2MXHL1^]Q-%U@(A$\+/Z#]R@2HL;4XM-P^C
M'TABB.P1"7WD'$IV7G]4HQ.U#E'#XIW1X6=>=.$4W/\ D<Z9]PMSBW2H'!/.
M3Y.M(F)2F4<+?5+ROZZU%(F)2#B4G*W77.DS$#S^&G%$O-YYTK)DRS]/BH,G
MU].Q!LDZVXTC"[=<Y?"4'#DI-N3U\KDRH&1G\2;IG# 1$"$29(A-U.]A'?%5
M4ARV>,-Y#.;Q9@;LDI+NUK"*687UL^)J$Q([$.)4)A+==UQI=YC<OQWF[ZJ2
M8?KG?K267+4]JV7+45!P9XZ]Z4<AVG5W]?F#B'CCKR*1,3L0<2?NDY2==<Z2
MRY:GM@)2W#X;59.'0^D4RQ(;XV\YP?.G9>?U2C$[4Y6ZZYTLWZUA/:ARUK;3
MLO.D3$I!Q*3DQQU\TAE/"_WVIRL[M>D5!P1-_KI>%,L16M84LYLX;Y2H,* 9
M>#J3<P*IVL/]4@FD61(KO=V3(1-J<':#^#+%K?!- E*0W&+W!H;&=!K_ "U0
M(G@!3B6%!$=I17D3].(Y>%7[@A-_6;G27*UDC23NB  A6_J1]8UGKVL8N,"Y
M]9B(6]U))HR_T8@=PL@'['[J;XFA#"E[E:8R-C_&,8S,,> V9!L"?]S^!XA"
MBE#^(5/^XN \'^E^$& 1CP2!!N$*\!1DAW#"06\:(%2 WU3@>*$'.Q[\)NOH
MSBP:"4Y2$39]Q3NPUII53CZ2%>"$-3^X@J,$MXBT'+P#*B*60NSCP3+C 48Q
MC/#]!A N=;]@@H&, \W#AJ)^ D&WV(<J=EY_5(F)V0.)-)<H]-<(]*V)RL\O
M]I+!<V'XP?.*\CA;SC!>7I #F>=OK6%(F)2V4<-12S"_3WI$LVI!Q/GGC3MD
MUK;399(<^,GORQJ7<[\-UR/2E9,F6?I\4HQ.Q!Q*>=3X<0HW3*)_$U4O\*H@
MM3$XZR]Z;4^T65N7&9[Q#\]HJ\%*P(5 XDTG*W77.D,IX7[4.6M;:@8,[OD7
MIAR.O4PJ#BUZ^M(93PO]]J<K.[7I%0<$3?ZZ7A3+$5K6%;P?7=IBD3$[$'$I
M.3''7S2&4\+_ 'VP96X?&'2K,AX6>LU#Q)<OJG9>>OBD3$[('$FDY6ZZYTAE
M/"_:IE'"WU2\F>.OBD3$I!Q*=AY_/U2C+6MM$G!2*R"Y>ZF[=-%2!1#R\/M+
M-'6<, ( @ " +!N_O!-(LB2&I5("9@0M3Q(N)G5-K]0-(N0&X!A--PWZN2!7
M=XR=!L (&)/ZN]8UGKVL.FP&=N6M!"0W-^Q;(@MXO#C*\E/<A29"<AMR9S0B
M;!WZP@7!P>,Y=S*FS:@\R,$IQP7O@A!B*\"0"][C/J"$1V&7W/$EJ^ P_G@Q
M(XJ0[CW!-<#O6,07S[":.+.!>U8LU%X*Q5=5Z<ZB7< Y$0.7Z-D _P!%_P"!
M-DZ U%6K@W$4+H:8?3S[F&/DN%NOO264\-3^"'+S->M2R3T^:1,3L@<2:2X6
MZE;G3='MYTLM/!^[.ME,9AO+3P,.51A#/&U]E\?*?2D3$I+A:EY7Z=B'$J9@
MC6T^*5VF_#J6\J5W._:[RW,I(DN>7J6]*48E2/\ /@1#D 8?Q2OZ,APSQ'0&
M/E&A'MT[V$'X$DW Q6*UB$80@@XD_=)RDZZYTAE/"_:ARUK;4#!DV.//?OPI
M38;_ +*BX.N)\4HRUK;VIRLU;L'6/OSIEB*W>F@XU/)'7+K2)B1]=B#B4[#S
M^?JE&6M;>V!A;TY/M%7,I-WPOH^5(]SLP>%[4O*_2D3$>Q!Q)^Z3E)UUSI++
MEJ>U;+EJ*'>)8R9R=A&6LV##[N 0WDLQ4"42#)51^43_ +RJOII%D21U*I(#
M,B%H>)%Q,Y<U4.;D"KW!^H0^B,8*F%P-S_6>I,RC 8'E*7"2HX_U=ZQK/7M8
M=66GL?\ D; 4M(+^Z[HRPF1D1\ E9"#W8> /\N3%C),@*- #0PS^^_EC1W$3
M2=8/O]Z2\ _#&> QXTH/C,9QPSF6C\C7J4[AQAJE;3C2EL>*;^ .2GZ$MD+M
M B$DVK3A-6(H4]P(R:XU%&# TNU\",R4A%F0%+<[,"657(P)TQ)]P@0A1W@,
MD&$)J@?I$H57,FFB @#G$S;%&6IZ#_[7E?IKG6P<-%)RMUI#*>%_O\%,HX6^
MJ7E?UUJ*1,3L0<0>-(=W4ZUN=-T>WG60?+9Y-O>F,R6X]E]'RJ[!'H\GL3E;
MK2S?P^/B>Q#C4S!&MI\4SD<3'9B6UA2^#"[;>EM;:PA60G T5B,G^*LJ@F&N
M0C,!.B8SFS.%DZC<J<*WPR*1@F"'+RA$GX(.)2<F..OFD,IX7^^U3*.%OJH&
M#)OQY_-3D1SOYF-.R\_JE&)V0.)-1R4=>?6K=_7X:OVKI/UY5/)$UY=:A,2.
MQ#B4[+S^J48GQSP[('$FK,%.IUJ]Y)+X>X^RUP$;+=$]J7E?I4)B1V(.)0D0
MC2(A$D4M+]D-1*@' H5RTEF.J@- 4*.4_JXFD61#]216TH8\Q#B7\&K2H?6.
M )!.3N $.0%=^H9**(>!%Q#D0@H74EF&_P!119^>S-C7]H6%+Z2*]8UGKVLV
M&H\"I(L3[I]1<3Z31 C$\+RT+^Q@^HHP$>T@BUPW^)F1;-T3*E)X[' ]PI D
M>UV454L7AM/Y2"U[82E@D.+W]JA!*3H!4*=Q8 ,Q4$ZI%;%8U '@_P!+\(,
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M%(\ 2)-DCGV92^][]0<P[X8C(S=_[1 QDD5ZQK/7M8)"XA)*DTGC%5W)R_\
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M;#\(9$J/?\D:(PMC@2$51XU3W'(52?G)U;%WN=)1@CW8CQ4@YV-!-U](1;1
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M7N*;6V2MXJL5^]W,!$[V>*HZ\4@:FQ<@1B [W"NTC#"H@W4 23^Q40->T#
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MRB;D2_?J>+&;"U5-5,M&QT$[$)4D(2 P3!\Q_,H+KD'^!M2D_!V  )@V8=-
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M3-1K[4D6R\ [*-YA=1*S$K(R#L"LXF:>=)/J DDHUI@DD^LAO06A=>PPXI[
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M8FQ *H4)DO4]P';EPI"0Q$;5,'F=G!6@O0*%2=Y==_J0X=47]6">AAIRM F
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2LQ%$(I5P0 C3    @C_G]__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>picture4.jpg
<TEXT>
begin 644 picture4.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 6E#]X# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 444A(4$DX H Y;XH?%'PQ
M\&O!&I^+?&&K0Z-H6GIOFN)CR3_"B*.7=CP%4$D]*_&3]J[_ (*I?$/XT7]Y
MHW@"YNOA]X*(,8^RR!=2O%Y!:69>8P1_!&1CD%FKF/\ @H[^V%<_M,_%N?1M
M$O=_P[\-3O;Z6D+'R[V4?+)>-Z[N0GHF.A9L_(= #YII+F:2::1I99&+O(Y)
M9F)R22>IIE?7_P"QU_P3<\;_ +4EI%XDU&[_ .$+\!,Q$>K7%N99[X@X(MXB
M5W+U!D)"@]-Q! _0KPU_P1\^ .BV*1:A%XD\07 'SW%[JOEDGOA840 ?G]30
M!^&U:GAGQ5K7@O6;?5_#^K7VAZK;MNAOM.N'@FC.<Y5T((Z>M?LE\0O^",7P
MA\0:?)_PB>O^(O">I8/EO+,E];9[;HW57.#Z2#O7YB_M0?LB^/OV3_%,&F>+
MK2.XTV]W'3M<L"SVEVH/(#$ K(!@E&Y&0>002 ?9G['/_!7+6=+U33_"?QNE
M74](F80Q>+HX@MQ:YP%^TQH,2)ZNH#CJ=_;]:;&^MM4L;>\L[B*[L[B-9H;B
M!P\<J, 596'!4@@@C@@U_*]7ZN_\$=/VI[[5#J/P4\1WK7*VL#ZCX=EG<EDC
M4CSK5?\ 9&?,4=AYG;  !^I=?D+_ ,%OO^2E?#'_ +!%U_Z.6OUZK\A?^"WW
M_)2OAC_V"+K_ -'+0!^:-?T!?\$OQC]A?X8_[NH_^G*ZK^?VOZ!/^"88Q^PS
M\,?^N>H?^G&ZH ^I**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "O(_P!KS_DU/XQ?]BAJW_I)+7KE>1_M>?\ )J?QB_[%#5O_ $DE
MH _FSK[G_P""-_\ R=U<_P#8M7O_ *-@KX8K[G_X(W_\G=7/_8M7O_HV"@#]
MP:*** "BBB@ HHHH _GY_P""G7_)\WQ/_P"NEA_Z;K:OEVOJ+_@IU_R?-\3_
M /KI8?\ INMJ^7: /ZF/#IW>'],)[VL7_H K0K.\._\ (OZ7_P!>L7_H K1H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO+[]J#XQ7EOIE[)_PK[0)GM=%M5?]W<%25>\8=VD(.W/W4VC@EL@'T[\<O\
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M^P[\4/\ KA9?^E]M7T_7S%_P4N&?V'_BA_U[V?\ Z76] '\^E?I!_P $1_\
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MEMN4]BHE+ ]MM?SL5^ZO_!7>21/V-=4"#Y6UFP#_ .[YA/\ ,"OPJH ^Z_\
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M?LAQW^DV5A;^*?"-]*+B71;Z9HO)EQ@R02 'RRP #95@=HXR,T ?T#U\E?\
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M-?7]%% '\_/_  4Z_P"3YOB?_P!=+#_TW6U?+M?47_!3K_D^;XG_ /72P_\
M3=;5\NT ?T[_  =^(6C?%;X6^%_%OAZY%WI&K6$4\$G<<89&'9E8,I'8J178
MU_/I^QS^WOXV_9%O)["UMT\3^"KR7SKKP_=S-&$DZ&6WDP?*<C /RE6 &1D
MC[[_ .'V7PF_L<2_\(1XS_M79DVOEVGD;L=/-\_=CWV?A0!]$?\ !03XF6OP
MM_9#^(]]/.L5SJFFR:)9IG#2370,.%]PCN_T0GM7\[]?1?[8_P"VSXN_:^\4
M6\FHP+H7A/379M,\/P2F18F(P997P/,D(XW8  )  R2?G2@#[G_X(Z^$)=?_
M &LY=7$9-OH6@W=RTG97D*0*/J1*_P#WR:_<&OA#_@DC^S;>?"#X)7WC;7K-
MK37_ !L\5Q##,N)(=/C#>1D'H9"[R>ZM'GIQ]WT ?S(_';XD7WQ>^,GC/QEJ
M$S3W&L:I/<KO.=D6\B*,?[*1A$'LHJY^SG\(G^//QP\&^ 5NFL8]<OU@GND&
M6BA +RLH[L(T<C/&<9XK(^+_ (!O/A7\5/%OA"_A:&ZT74[BR*L,95)"%8>S
M+A@>X(-2?!GXHZC\%/BIX8\<Z3#%<W^A7T=Y';S$A)@#AHV(Y 92RY'K0!_1
MG\&_@!X ^ 7AV#1O WAFQT2&.,1RW4<0-U<XQEIIB-\C'&>3],  5Z%7QQX-
M_P""LG[._B3P[#?ZMXFO_"NH&/=+I6H:3=2RHW0J'@CD1N>AW=.2!SCPO]I#
M_@LOH=GI-SI/P9T>XU'595VCQ%K<'E6\&>K10$[I&';?M /56'! /F/_ (*Z
ME?\ ALS5MK!C_9%AN /0^6>#^&#^-?%U:GBCQ1JWC;Q%J.O:]J%QJNLZC.US
M=WMTY>2:1CDL3_G%9= '].7P/;=\%O !]?#^GG_R6CJS\2_BSX.^#FA0:UXV
M\16/AG2I[E;.*[U"3RXWF97<(#ZE8W/_  $U4^!?_)$?A[_V+NG_ /I-'7@_
M_!3[X0W_ ,7OV1O$<>EPM<ZEX>N(O$$-NB%FD6$.LP&.<B&25AZ[<=Z .Z_X
M;L_9^_Z*WX8_\#!_A7H.C:OX!_:"\#0ZA9-HGCOPG>,Z)))#'=VLI1BC#:X(
M)!!'2OYC*^_/^"=W_!1G2/V9_"]WX \?:?J%WX5EO&O+#4M.599+!G \Q'C)
M!:,D;\J=P);Y6W< 'WW\3O\ @EY^SW\2HYGB\(R>$+^3.+SPU=-;;<^D+;H?
M_(=?EW^W-^P%K7['TVF:S::Q_P )-X(U:X-I;Z@\/DSVUQM+B&902"2JN593
MSL;(7 S^KUK_ ,%)?V;;O3S>K\4;%(AU26QO$E_[]F'<?P%?GI_P4T_;V\&?
MM+>&= \"?#Y;R_T33]2_M6[UB[MVMUFE6.2*-(D;#[=LLA)8+SMXXH _/FOV
MU_X(S^+KS7OV5]5TFZD:2+0_$=S;6H;HD,D4,VT?]M))6_X%7XE5^]'_  2M
M^$.H_"7]DG29-6A>VO\ Q1?S>(#;RH5>.*1(XH0<_P!Z.%)![24 =+_P4F\#
M3^/?V+_B/;6D7FW>GVT.KI_LK;3QRRG\(EEK^?*OZG=5TNTUS2[S3;^!+JQO
M(7M[B"0962-U*LI]B"1^-?SB_M8?LXZU^R_\9M:\'ZG#,^FB1KC1]1D3"WMF
MQ/ER ]-P'RL.S*P]* /LC_@B3\1;/1_B1\1?!5S*D=SKFGVNHVBNV-[6KR*Z
M+ZL5N0V.N(R>QK]?:_EX^'OQ U[X5^-M%\6^&+^33->TBY6ZM+J/G:PZ@CHR
ML"593PRL0<@FOUO^#_\ P6@^'FN:';Q?$;PYJWAC75"K--I,0O+*4XY=?F$B
M9Z[2K8S]XT ?HQ7S3\;/^"A7P>_9^^(5]X*\7ZAJMOKMG'%++':Z<\R;9$#K
MAAQT85X;\4O^"S7PKT#0[L>!M#UOQ7KF"ML+R 65F&P<,[EC(0#CY0F3ZCK7
MY%_%CXH:_P#&CXC:]XV\3W"W.N:U<FXN&C7:B\!4C09.$1%5%!)("CD]: /V
MJ_X>Z_L[_P#06U[_ ,$\G^-?8^D:E%K6DV6H0*ZP7<"3QK(NU@K*& (['!Z5
M_-E^S+\$]2_:$^.'A3P/I\#R17]XC7\R@XM[-"&GE)[80-CIEBHZD5_2K%&D
M,:1QHL<: *J*,!0.@ ]* /QV_P""VWA.:Q^-G@#Q*8BMMJ7A]]/63LTEO<.[
M#Z@72?F*_..OWB_X*F?L^W7QP_9KN=2T>U:Z\1>#YSK%O'&I:2:W"%;F)0!R
M=F),#DF$#O7X.T ?O9_P2M^)%IX^_8Z\+V$<ROJ'AN:XTB\CW LI$K21''4
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M]\.-;EMXV(%_I5L;^U8=F\V'<%R.<-@^H%?T<44 ?RVR>$==BG\E]%U!)O\
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MX5ZIJOPM\::9IEGXEL)[F]O/#UW##!&LZ%G=VC 50!DDG K]_P"BB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?(EW!C(OIC8.N>/V<_9$_:/_ .&JO@S:^/?^$>_X1?S[RXM/[/\ MOVO;Y3
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MNU&<8:KOZ2_.^E_4O$:U(.6CTM_X#_EJ>TT5\B_MP?M^?\,9Z]X5TW_A!/\
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MQ+\7:AX+^&WB'Q-H>C#Q1?Z9I\M_;Z5'<^1]MV(7\M9 CX+ ''RG)QZUE/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MIU7Y,_\ !<;_ )&3X0_]>FI_^AVU<]3XZ?K_ .VLVI_#/T_5'PE_PUC\;_\
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M*T> O@?XJO/"OA+0YOB'KMC*8;Z:&\%K86\@R&03;',CJ1@A5VCINR"!Y3X
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M]-6U/4@+@(YQO,"1E5(]/,;ZU]\^,O&FA_#SPQJ/B+Q+JMMHNAZ?$9KJ^O)
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M /@A[_R(WQ5_["-C_P"BI:K!1:I5E+=<W_IPQQ<DZM)QV=O_ $AGZ;U\Y?\
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M<G\6.FFOY/\ X!H45\1_M(?\%7OA=\#];O?#WAVRN?B+XCLW,5PFG3K!8PR
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M+P_\%OM*OO"NM _#"^T?Q']ED&E[=22^M3<8.PS$I"P0'!.T$G&/>OE3PI\
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M*WBE=*M1JK(00;ORE\[&./O[NG%?F]KG_!;S^Q=:U#3_ /A2_G?9+B2#S/\
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M&DS)$HSV$:H![ 5^E'[#]C^QKXT^"_A;1+K3/!$_CEK.*+5[;Q=##_:$U\5
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MFS_@M;_R<GX0_P"Q4A_]*[JOI/\ X(H?\F[^,_\ L:'_ /26WK/!?P:OS_\
M3B.G&_QJ?I'_ -(.)_X+2?'S4-)T_P *?"72[IK>VU.(ZSK"QD@RQK(4MXS_
M +.])'(]43TKYJ_X)N?L0Z5^U=XHUW6O&$MW%X*\/&*.6WLW\I[^X?+"+?U5
M JY;;AOF4 C.1M_\%DH[A?VMK-IN8F\-69AX_A\VX!'_ 'UN_.OK3_@BC);G
M]G'Q@B%?M2^*9#+SSM-K;;?Y-4X**<*M1[J__I7*ON1&*;YH4UHM/RYG][_
MV/CY_P $E_@WKGPRUD_#O0;OPGXNM;:2XL)H=1NKN.XE525BD2:23Y7(QE,$
M$@\XP?SN_9A^$OQ]^"?QZ\$^+K+X4?$"Q2RU.%;QSX9OE1[5W"3H_P"Z^Z8V
M;KTX/:OZ 7=8U9F8*JC)9C@ >M>7I^U7\%))EB3XP> 6E9MH1?$]D6)SC&/-
MZU5%NG6YUKMI_7?8FJE4I.#TWU_KL2_M/?\ )MGQ6_[%35?_ $DEK^>K]FW_
M ).(^%__ &-&F?\ I5'7]"O[3IS^S7\5B.1_PBFJ?^DDM?SU?LV_\G$?"_\
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M7RDW2';\S=EP3GKQG@]*_H._;G_Y,_\ BW_V+US_ .@U^'O[#?\ R=]\(_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!U=N?>OU*^''P]T7X4^!M&\(^'+>2UT/2(!;6D,DK2LD8)(!9B2>O4U\9?\
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M?4+R3Q=\)=2NY+BRM8/[;TB.1B?(&\)<1KGHI9XG"CC)<]S7D_\ PY4^-_\
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ME_\ !)_]G.Q\(QZ1=>%;_4=0$/EOKDVKW273R8QYFU)!$#SG:(]O3(-?F/\
M\$N9K:']M[X??:,99;]8B>SFRGQ^F1^-?OW75.$8T8)+>[_2WX7^9C&4I59-
M]+?\/_78_G4_;3_94U#]DGXP2^&'O)-5T"^A^W:-J,BA7FMRQ7;(!QYB$%6Q
MP>& &[ ^]/\ @A[_ ,B-\5?^PC8_^BI:\V_X+>?\E6^&O_8%N/\ T?7I/_!#
MW_D1OBK_ -A&Q_\ 14M88&3G1JM]+K[II?H5C(J-:E;NG]\&S]-Z***1H%?S
MJ_M\_P#)Y'Q9_P"PU)_Z"M?T55_.K^WS_P GD?%G_L-2?^@K7'+_ 'F'^&7Y
MQ.B/\&7JORD?KC_P2I_Y,C\$_P#7SJ'_ *6351_X*F?M":E\"_V<'L= NI+'
MQ#XLNO[)@NH7*R6\&PO/(A'(.T! 1R/-R.15[_@E3_R9'X)_Z^=0_P#2R:OF
MO_@N/%<FQ^$,@R;,2:FIXX$A%L1G\ ?R-=N8ZU.7NTOZ]=OF8X'J^W,_NN?$
M7[$G[+TG[67QOM?"=Q>3:;H-K;/J.K7MN 94MT*KMCR" [LZJ"00,DX.,']:
M-<_X)._LXZIX;GTZS\)W^CW[Q>6FL6NM7;W$;8^^%DD:(G/."F/:OD;_ ((@
MR6B_$SXG1OM^W-I%J8N>?+$S;\>V3'^E?KW6U6*]G!);K]6OT.:G)N<V^CM^
M"?ZG\T/QI^&.O?LR?'37?"4FH21ZSX:U!6M=3M28G8#;+!.F#E25*-P>">O%
M?OG^QK\<)OVB/V</!WC6]VC5[BW:UU((,#[5"QBD8#L&*[P.P<"OR,_X*V36
MLW[:&OK;LC21Z98).%ZB3R0<'WVE/P(K[X_X(YQW2?LBRM/GR7\17AM\C^#9
M"#C_ ($&K+"3=7#24_LZ_<^6_P ]_N-<5%4Z\''[7ZQYOPZ'W-1114E!1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!^*/_!:'_DZ30/\ L5K;_P!*;FO=_P#@A[_R(WQ5
M_P"PC8_^BI:\(_X+0_\ )TF@?]BM;?\ I3<U[O\ \$/?^1&^*O\ V$;'_P!%
M2U6"_@U?G_Z6A8[^-1^7_IMGZ;UXQ^V=I%KKG[)_Q:M;R,2PCPW>S 'L\<32
M(WU#*I_"O9Z^4?\ @II\9=.^$_[)OBNSFN$75_%,)T/3[;=\\GF\3,!Z+%O)
M/J5'<5R8G^#)=U;YO1?B=.'_ (T7V=_DM6?@UX3U*;1_%6C:A;[_ +1:WL,\
M?EC+;ED5ACWR*_I^U]S)X6U)R,%K*0_^.&OYL/V=? %S\4OCMX"\*VD1E?4]
M9MHI /X8A(&E8^RHKL?85_2CXD 7PWJ@' %I+_Z :Z\5_N+_ .W_ ,D<N'_W
MQ?\ ;OYL_E[\-_\ (Q:7_P!?47_H8K^I.#_4Q_[H_E7\MGAO_D8M+_Z^HO\
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MLUE*<:E/V<U;\'K_ )=+&BA*%3GB[_E_3ZGV=\ O^"7O[07P9^-7@OQK#?\
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M'DYX/F>[<?RD:5XJGBN1;+F_-'LE%%%9C"BBB@ HHHH **** "BBB@ HHHH
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MY_VNOV\?%WQ^^,-UXB\(ZSXC\$^&8+:.RL--M=4E@=XT+-YLJQ/M\QBYR!G
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M%K,W@/7(_#LB1>('TV==.DDQM6Y,3>43GMOVU_.[\-?BEJ_[//[0EQXF\?\
M@BV\:^(+"XF34M'\7HS2?:6/S2DN&Q,&Y#LK=<XS@C]X/VMOC)>?L]_LY^,_
M'6F6JWFI:5:(MG'*I9!-+(D,;N!U56D#$<9 QWK\3/V;?#<O[;7[7&AZ;\6/
M&%_>-K+S37=Y<7&)[@1HTBVT)/RQ@D8"J %7(4#BLZ2E/%-T^VOEN]/EO\K%
M3M#"+VFU_P#+?\+?,]R/_!2[X.RW?VR;]CKP++?$[FN?.L]Y;UR=.)S^->^_
M#/\ X+2?#21;73O$7PYUGP=9J5BC.CS0WUO OJ5Q"P4>BJ3CH.U>Y?\ #J_]
MF;_HGTW_ (/=0_\ C]?G+_P4T_9!^'O[+/B+PA+X$U"ZACUZ.X:?0[VX\]K8
M1F,+)&Q&[8V]AAR3E3@]0&ZBIM)K<%3=2[6Z/VE^&OQ.\+_&#P=8>*O!VM6V
MO:#?+NAN[8G&1U5E(#(X/!5@"#U KJ*_+3_@AYJ^K2Z;\5]+>25M"AET^XBC
M;/EI<.)U<K[E43/^ZM?J7715@H25MFD_O1A3DY)WW3/,OVGO^3;/BM_V*FJ_
M^DDM?S:^&_\ D8M+_P"OJ+_T,5_3UX\\'V?Q"\$>(/"VHRSPZ?K>GW&FW$EJ
MRK*D<T;1L4+ @, QP2",]C7Q'8_\$7_@G87EO<Q^*/'QDAD610VH66"0<C/^
MA^U98?\ =XI59;>[^#;.BL^?#>R6_O?BE_D?>L'^IC_W1_*I*:J[%"CH!BG4
M/<RBK12"OC;_ (*U_P#)EOB+_L):?_Z4+7V37F?[1'P!\/?M,?#"]\">*+S4
M[#2+N>&X>;2)8X[@-$X=0&DC=<9'/R_E7/6@YQ27=/[FF;TY*+N^S_)GXU?\
M$EO^3U/#?_8.U#_TG:OWAKY*_9W_ .":/PP_9H^*%CX[\,:[XMO]7LX)H(X=
M6O+62W*RH48E8[9&S@\?-^=?6M=U2:E&"716_%O]3CIP<93;ZN_X)?H?SW_\
M%)_^3W?BC_U]VO\ Z105^NG_  33_P"3)/AE_P!>]U_Z5S5ROQN_X)9_"GX^
M?%/7_'WB#Q!XRL]8UJ2.6X@TV]M$MU*1)&-BO;.P&$'5CSFOHOX'_!W1O@#\
M+="\!>'KF_O-'T=)([>?4Y$>X8/(TAWLB(IY<]%'&*RP[]GA?92W]W\$[_F:
MUE[2O[1;:_B'QT^%EE\;/@_XN\#W^T0:WI\MJDC#/E2XS%)]5D"-_P !K^<'
M1_$'BCX)^-M72RFET?7[2.^T6\7^)!)');3H??#-CT(![5_1YXH^/WPQ\#W]
M[8>(?B)X5T._LO\ CYL]0UJVAGA^4, T;.&!(((&.<CUK^??]L/XB>&OBQ^T
MQ\0/%GA"#R?#VI:B9+9]I7S\(JO/@\CS'5I,'!^?GFN3_E]IM*+O_7FF_4ZO
M^75GT>G]?)>A]%_\$?\ X+_\+ _:0N?&-W!YFF>#;(W*,W3[9,&CA'OA?.;V
M*"OVYKX\_P""5OP3/PD_96TG5+RW\G6?%\QUNXW#YA"P"VR_3RU#X]937V)7
MI8CW6J7\JM\]W^.GR//H^]>IW_+I_G\S\'/VB/VHOVE?@=\<?%_A#4/B7XDL
MSIFI2BU220;9;8N6@D7*\JT94_CBOT.^&/\ P5J^ GBCP;I][XJ\07G@W7C$
MHO-+NM+N[G;* -Q22"*163.<$D'&,J.E>Z?M!_LE_#']IW388/'7AY;N^MD*
M6FKV<AM[VV!SPLB_>7))V.&7/.W-?(>L?\$2/AO/<;M*^(/BFR@_YYWD5M<-
M_P!]*D?OVKCI<T*:I2UMU_K\=SKJ<LY^TCIY?U^!\'?\%#OCUX*_:,_:)N?%
M/@2UD31X]/@L9+^:W\A]0E0N3.4(#8VLB N V$&0.!7Z:?\ !(OX8:O\/?V5
M!J.L026K^)]6FU>UAD4JPMC''%&Y'^WY18>JLI[U/\(_^"2OP,^&.M0:MJ5O
MJWCN\A97CA\17$;6B,#G/DQ(@<?[,A=?:OM&.-(8TCC18XT 5548  Z "MZ7
M+1I2A'5O_._Y_<OPRJ.5:HI/1+_*WY?UW_&#_@M;_P G)^$/^Q4A_P#2NZKZ
M3_X(H?\ )N_C/_L:'_\ 26WKW+]J'_@GS\._VM/&^F^*?%^L^)].U"PT]=-B
MCT2ZMXHC&LDD@+"2"0[LR-R"!@#BNW_9=_96\)_LE^#-3\,^$-0UG4K#4+\Z
MC+)K<\,LHD,:1X4QQ1C;B,=03DGFHPW[JG4C+=W_ /2K_D:XE^UJ0E'I;\(V
M_,^0/^"QG[-6J>.O".@_%;P_8R7UQX;A>RUF*!"T@LF;>DV!SMC<ON]!)N/"
MDU\2_L$_MP3_ +'OB[5TU/2KC7?!NNB,:A9VCJMQ!)'G9-"&(5FPS*5)7<"/
MF&T5^_DD:31M'(JNC JRL,@@]017QG\8O^"3OP-^*FL3:MIUKJG@._F8O*GA
MR=$M9&/?R)$=4^D>P>U94N:C)\NS_7?\=?)_@5.6M%<VZ_3;_+T_'Q/X]?\
M!9;P9JOPUU?2OAIX<\1#Q/J%L]M#?:U#!;P66]2IE 260NZYR%P!G!SQ@_ G
M[%_P!UC]HK]H'PQH%C9O-I5K=Q:AK-UM/EV]G&X9RQ[%L;%'=F'O7Z/>'_\
M@B;\,;.Z$FL^.O%6IP@@B&U6VML^Q)C?@^V*^U_@O\!/ ?[/?A?^P/ 7AVVT
M&P9M\[QY>>Y?^_+*Q+R'DXW'@<# XKHH\M*I[;KI^&W]=3&KS5*?LNG^>_\
M6R*7[3HQ^S7\5@!@?\(IJG_I)+7\]7[-O_)Q'PO_ .QHTS_TJCK^D7QYX/L_
MB%X(\0>%M1EGAT_6]/N--N)+5E65(YHVC8H6! 8!C@D$9[&OC?P1_P $@?@Y
MX!\9Z#XFT_Q+XYFO]&OX-1MX[F_LVB:2*19%#A;0$J2HS@@X[BHP_P"[Q2JR
MV]W\&V:UFIX;V4=_>_%)+\CZ>_:0\)ZCX\_9_P#B/X=TA6DU75/#]]:6L:'!
M>5X'"J/J2!^-?SD?#'Q:/AI\4O"OB:YL/M@T'6+74);&3Y3+Y,RN8SGH3M(Y
MK^GZOC_]HC_@E[\(/C]XFO/$ZC4O!?B.\9I;JYT)XQ!=2GK)+"ZLN[/)*%"Q
M)+9)S6<'.E75:/E^#;7YE2Y:E)TI>?XZ/\C/U+_@KC^SQ9^$O[6M]:UB_P!3
M,0<:##I$RW08C[A=P(<CN1(1QP37Y)_M=?M(:[^U1\6I/'.L:4NB64ELMGI5
MB@+"*UC=\ R8'F-O9R6QC)(  &*_3WX?_P#!&/X/^&M4AO?$FO>(_%\<39^P
M231V=M*/1_*7S/\ OF1:]5^/W_!-OX2_M!W_ (;GU&36O"MMX?TT:58Z?X6D
MM;6V2 .S@;'MY.<NW0@<],Y-$XIR4]]?DM'K^@H2:BX^7WZK_A_D>4?\$5_^
M38?%'_8VW'_I):5Y/_P7'_X^?A!_N:I_.UK[X_9@_9=\*_LF^!+_ ,)^$=0U
MC4=.O=1?4Y)=:FBEF$C1QQD QQ1C;B)>,9R3SZ<]^U5^Q/X'_:^D\-OXRU7Q
M!IIT$3BV_L.X@BW^=Y>[?YL,F<>6N,8ZGK6N*?MJD)1Z<OX1M^8L,_9*2EUY
MOQ9\5_\ !#7_ %GQD^FD_P#MY7ZIR_ZM_H:\!_93_8I\#_L?MXE/@W5?$&I_
MV_\ 9Q=?VY<02[/)\S9L\J&/&?-;.<]!T[_0#+N4@]QBJQ4E65H_RI?A8QIQ
M<7)OJ_\ (_EEU+_D-77_ %\-_P"A&OZBO#O_ "+^E_\ 7K%_Z *^%I_^"+OP
M2N+J2=O%/CX.[ER!J%CC).?^?.OO.RM4L;."VC+&.&-8U+=2 ,#/Y41DE05-
M[W_0VQ#]IB958[._XLGHHHK,D**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Q_P#^"WG_
M "5;X:_]@6X_]'UN_P#!#G_D.?%W_KVTS_T*YK[3_:F_8.\ ?M=>(-#UCQAJ
M_B33;G2+5[2!-#N;>)&1GWDN)8)"3GT(JW^RK^Q#X%_9!NO$=QX.U;Q#J3ZZ
MD$=R-<N8)0@B+E=GE0QXSYC9SGH.E+!_N834^O-^,FT/$_O6N7^[^%K_ )'T
M+1113$>!_MY^#M4\>?LA?$[1]&CEGU%M+^TQPPC+R+#(DSH!W)6-ACOG%?@_
M^S/\5[/X'?'KP3X[U'3WU33]$U!;BXM8L>8T9!5BF>-ZABRY(&5'(ZU_2WUX
M-?%'QQ_X),_!SXO>)+SQ!I4VJ> ]4O',D\.BM&;*20G+/Y#J=I/HC*OMFLZ?
M-1K^UCY?>OZ_JYI/EJT?92\_Q27Z?UU?XR_X*Z?L_P#A_P *R:CHVK:KXHU;
MR\Q:-:Z7/;R;R.%>295C4 ]2&;V#5^/7[27QK\0?M$?%S6/'_B.QCTVYU?8U
MM:0H1'%;(/+B56(!? 7!?N0>G0?K7\+?^".OP9\#ZQ;:GXBU#7?',D#;A8ZA
M,EO9,0<@M'$H=L8Z%]IYR".*[GX_?\$R_A/^T-XVM_$VLZAXC\/S6^GP:9#8
M>'9[2VM(H801&%C>V<C ..#C & *<H+F4UJ_R5OSO;Y7)C-V<=E^?_ _4H?\
M$F?^3*?#'_80U#_TI>O+_P#@M5X#U#7/@CX,\3VD,DUKH.L/%>%%R(H[B,*K
MMZ#?&BY]7%?9?[//P#\/_LT_"^P\!^&+S4K_ $BSFFGCFU:6.2X+2N78%HXT
M7&2<?+T]:[KQ!X?TSQ5HM[H^LZ?;:KI5]$T%S97D2RQ31L,%65A@@^]5BE[:
MW+TY?PM_D3AG[&_-_>_&_P#F?@%^P9^V)'^Q[\1M9U;4=#GU_0=:LEM+RWM)
MA'-&R/N25-WRL1EQM)&=_48Y_:/]E']J70?VMOA_J/BWP]I&I:-966I/ICP:
MGY?F,ZQ1R%AL9AC$H'7/!KPWQK_P2 ^ 'BS46NK"+Q+X25B6-MHNJ*8LGT%Q
M',0/8$"O>_V8/V7?"O[)O@2_\)^$=0UC4=.O=1?4Y)=:FBEF$C1QQD QQ1C;
MB)>,9R3SZ;QFI0:J;I:???\ S,W#EE>'5Z_=_P ,?BA_P4G_ .3W?BC_ -?=
MK_Z105^NG_!-/_DR3X9?]>]U_P"E<U<K\;O^"6?PI^/GQ3U_Q]X@\0>,K/6-
M:DCEN(--O;1+=2D21C8KVSL!A!U8\YKZ+^!_P=T;X _"W0O 7AZYO[S1]'22
M.WGU.1'N&#R-(=[(B*>7/11QBL\._9X7V4M_=_!._P"959>TK^T6VOXGY=?\
M%C?V:]3T;XA6/QCTFR>XT'5X(K#6)8DS]ENXQLB=\=%D0*H/3='@G++GF/\
M@GC_ ,%'])_9M\)S_#[X@V-]=^%/M+W6FZEIL:RRV+2',D;QDC=&3EP5RP);
MA@?E_9G7-#T[Q-H]YI.KV%MJFEWD30W-E>1++#-&PP5=&!# CL17Q!\2O^".
MOP4\::K<ZCH%]X@\$R39/V+3KE)[-&.3D),C..3T#@8X %94>:AS16L7_G?\
M]K>GKK5Y:UI/1K]%;\CSG]K3_@K3X U;X4Z]X8^%+ZSJ7B+6;1[--9:![*&P
M1QM>12Q$AE )VX4 $YW<8/RQ_P $^[GXO?'?]ISPG9_\)KXMO_#VBW4>KZR\
MVL7,ENMO$VX1R N5/F.%3:>NX\8!K['\-_\ !$_X6V-TLFM^-O%6KQJV[R;;
M[/:JPX^5B8W..O0@\]J^U_@Y\"_ OP!\*KX=\!^';70--W>9+Y.7EN'_ +\L
MK$O(W;+$X' P.*WH\M*?M=W_ %;[OQ,:O-4A[-:+^K_UT.'_ &Y_^3/_ (M_
M]B]<_P#H-?A[^PW_ ,G??"/_ +&*U_\ 0J_H*^*WPWTSXP?#?Q%X*UF>[MM*
MUVS>QN9K%U2=$<8)0LK*#]5(]J^5OA3_ ,$F_A'\'_B1X=\:Z-XB\:W.JZ%>
MQWUM#?7UF\#NAR X6U5BOT8'WK/#_N\4JTMO=_!MO\QXA>TPTJ4=WS?BD?:M
M?B)_P66_Y.UT_P#[%>S_ /1]S7[=U\L_M,?\$Z?AO^U5\1(?&?BS6_%6GZI%
M81:<L.C7=M%#Y:.[ D26\C;LR-GYL<#BL9Q<I0:Z/]&OU-X245)/JOU1YI_P
M1G_Y-1U3_L9[O_T1;UT7_!6SP#?^-OV0=1N]/ADN'\/:K:ZO-'$NX^2H>%VQ
MZ*)MQ] I/:O=/V9OV9_#'[*GP]G\'>$[_5M1TR:^DU!I=:FBEF$CJBD QQQK
MMQ&/X<\GFO5KJUAOK6:VN88[BWF0QR0RJ&1U(P58'@@CC!KHQ=J_P]H_?%+]
M48X6]'XN\ON;?Z,_G-_8U_:7D_91^-UEXW;26UNP:UFL+ZQCF\J1X9-I)1B"
M-RLB, 1@XQQG(_;']D7]M+PS^V%:>)KCPWH6K:(F@O!',-4\K,AE#D;=C-T\
MLYSZBO.?B-_P27_9_P#'^IS7]IIFL^#9IG,DD?AR_$<18G)VQS)*J#_90*!V
M KU']E7]C/P5^R#:^(K?P=JFO:DFNO!)<G7+B"4H8@X79Y4,>,^8<YST'2M(
MS4H-5-TM/O\ ^',Y1<97AU>O]?<>]T445B:GXF_\%//V(]6^$?Q"U7XG>%-,
MDNO .O7!NKW[,A8:5=NV7#@?=B=CN5N@+%#CY=WEG[(/_!03QY^R3%-H]I:P
M>*O!EQ*9Y-!OI6B,,A'+P2@$Q$X&0593C.W)S7[_ -Y9V^I6<]I=P1W5K.C1
MRP3('21",%64\$$<$&OC?XL?\$F?@/\ $S4YM2TZQU7P)>2LSNGANY1+9F/_
M $PE1U0#^['L%9TN:C[L?A_K3_+Y>II4Y:WO2W_K7U[GSWJ'_!<A&L)!8_!U
MDO2N$:X\1;HU;U(%L"P]LC/J*_/;]H+]HCQI^TY\0IO%OC.\CGO6006ME:H4
MMK.$$D10H22!DDY)+$G))K].;/\ X(C?#U+TM=?$7Q--:9.(H;>WCDQGCYRK
M#I_LU]%? 7_@G9\$_P!GS4;;5M'\/2Z_XAMSNAUGQ',+N>)LY#(@58D8=F5
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M)#,%3<2. 7(YQF@#ZNHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "OR9_P""XW_(R?"'_KTU/_T.VK]9J^>/VJOV'_ O[7U[X<NO&6K>(M-D
MT&.>*V&AW,$0<2E"V_S89,D>6N,8ZGK6,XN4H-='^C7ZFL)**DGU7ZH^"?\
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M1>QF*YL;Z%9H9D/\+(P((KGJQE-J:?O+\>]_ZWLS>G)03A;1_P!?UY:'X_\
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MP/\ DZOXO?\ 8UZG_P"E,E?O/^QK_P FG_"+_L5]/_\ 1"UX/\2/^"1_P?\
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M.7-4J>TG_5^O]>?<****S- HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2[G?7)X975U38 IBBC &/4&G1Y:4)P77;_P)._SW)K<U2<)=O_D6OPV/S_\
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M]LKF-H9[>X0/'*C##*RG@@@D$&NC%6K-2ANN6WJDD_U1AA;T4U/9N7W-M_\
M!]3\ /V"?VS7_8^^(FI7>I:;<:SX0UR%(-4L[,K]H1HRQBFB#$*67<XVD@$.
M>1@5]K?&G_@M'X2_X0N[M?A;X8UN?Q3<(8X+SQ!;PPVUID8\S:DKM(P[+\H]
M2<8/>?%#_@CA\'_&FN7.J>&]7UWP1]H?>VGV;QW-FF>OEI(N]<GMO('0 #BN
MT_9^_P""6_P<^ _B2T\221ZCXU\06;K+:SZ^\;06T@Z21P(BKN!Y!??@@$8(
MS3O[:*C4T2^^P6]E)RAK?[OZ_ _"SQ/)J\WB359-?^U?V[)=2O?_ &X,)_M!
M<F3S W(?=G.><YK^C']C7_DT_P"$7_8KZ?\ ^B%KPGXF?\$D?@]\4_B%XC\8
MZGXA\;6FI:[?S:C<PV-_:+ LLKEW"![5F"Y)X+&OK3X9^ =/^%?P]\.>#M)F
MN;C3-"L(=.MI;QE:9XXT"J7*JJEL#G"@>U53DE0<&K-M:>B?^85%>MS)W6NO
MS1TU%%%9E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR3C+'@#/ ' [4 ?O+KW_  5 _9LT&X:!OB']NE7K]@TJ]F7\'$.T_@:70/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS]CGMMLRHCE-LT:,?ED0Y QSUX-$??3<=4O^&_,)>Z[2T_JYZ#1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%?*G[1'_!2CX0_LV>/)?!VNC7=>
MU^W56O;?0+2*46990RK(TLL8W%6!PI;&><5[G\&?C-X5^/GP]T[QIX-OSJ&B
M7VY5:2,QR12*</'(AY5E/4=.A!(()(^_'GCJ@E[C49;G<4444 %%%% !1110
M 4444 %%%% !161XN\5Z5X%\+:MXCURZ^PZ-I-K)>WESY;R>5#&I9VVH"S8
M)PH)/85\V?\ #T;]F+_HIG_E U3_ .1J5U>P[.U^A]545\J_\/1OV8O^BF?^
M4#5/_D:NZ^&O[;OP*^+E_%8>&?B9HMS?S.(X;.^9[">9ST6..X6-G/LH-4DW
ML2VEN>X445Q/Q>^,_@[X#>#9/%?CK6/[#T".>.W:[^RS7&)')"KLA1VYP><8
MJ7)1U;*2;V.VHKP[X.?ML_!?X_>+SX7\!>,_[>UT6SW9M?[+O;?]TA4,V^:%
M%X++QG/->XU5FMR;I[!1112&%%%% !1110 4444 %%%% !17S1^TU_P4%^%7
M[*OB6T\.>*#K.L>()H5N'TW0;6.:2WB;.UY&DDC0;L'"ABW? !!/I?[/O[1'
M@O\ ::\ IXM\$7LUQ8"8VUQ;7<7E7%I, &,<J9(!PRG()!!X)HC[Z<HZI?\
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MW)34E=!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MN 3Y:/%-)AB 2 ^W/09) HC[\N2.K"7NQYI;'UK1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
M.?VA/CAH?[.OPCU_QYK^9+738?W-JC8>ZN&.V*%3ZLQ SV&3T%>C5^5/_!;K
MXD7*R?#?P%#(5M&6XUNZC_O."(83^ \_\ZYZTFDHQWD[?J_P3-J44VW+9:_U
MZNR/S^^/W[1/CO\ :>\?2>(?&&I2WT[.4L-,@R+:RC8\101]NP)Y9B 6)-?1
M7PO_ ."1/QR^(GAJVUK4&T'P4ER@DBL-?NI5O-I (+1Q1.$R/X6(8="HJW_P
M2)^"&G_%#]HR[\2ZQ:1WFG>#;(7\,4JAD-Y(^R!B#_= D<>C(I[5^X5=OLX4
MJ<4MWK^/YG+[256I*_3_ "O]VI^"'QY_X)?_ !I^ _A6Z\33VVE>+M$LT,MW
M-X;GDFEM8QUD>*2-&*CJ2@; !)P 37"_LB_MD>,_V3?&T%YI5W-J'A*ZG4ZM
MX=ED)@N4X#.@/"3 =''H V5XK^B=T61&1U#*PP589!'I7\\O_!03X*6/P'_:
MH\7:#I%LMGH5XT>K:?;QC"Q13KN**.RK)YB@=@HKGC5E1JI='_5OFOR-Y4XU
M:;[K^K_)_F?O_P"!?&VD?$CP;HOBG0+I;W1=8M([VTG48W1NH(R.Q&<$'D$$
M5NU\!?\ !&?XD7'BK]G'6_"UU(9&\,:PZ6^3]VWG42JO_?SSC^-<=_P6.^+7
MCCX87'PL'@WQGX@\)"\74?M(T/5)[+S]IM]N_P IUW8W-C/3)]:VQ'+2J**V
M=K?-7,L/>M!M[J_X.Q^EU%?A%\%/^"DWQ(^$/P>\=6-QXJUCQ=XXUB[M8](O
MO$E[-J":7"$E\^9!,S MDQA4^[GYF!"[3WG_  3G^+7QA^*7[87A;4_%OBCQ
M?XAT*YCOVF>^NKB2PW?9I" %SY2@-C"@  XP*J-/GJ.">B5[_*]OT]293Y:?
M.][[?.Q^T-%?%G_!17]O23]E71;'PQX1CMKSXAZS T\<EP \6F6^2HG9/XW8
MA@BGCY6+9 "M^3]G\</VCOCUXNF72?%_Q"\6ZY)NG-EH-U=OY:Y&66"W.V-,
MX^ZH45SPE[1M16B_K\.IO*/(DY/<_>;]I[_DVSXK?]BIJO\ Z22U_.]\!_\
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MGE"I?1^(Y;JU+]0DCPS/&"><*_7!X.#7W'_P35_X*'^)/CIXHD^&7Q,G@O\
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M%$/'-I\6-#^&_P 2?$5UXI\.:_,MC8ZCJTIFN[&Z8XB!F;+2([$(0Y."RD$
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M32+:,$G&80$(7'WG9FXY8UO4G=02Z+7[V9TXV<F^KT^Y'] U%?ST_ /_ (*
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MHHH **** "BBL/QQXPT[X>^"]>\4ZQ(T6E:+83ZC=NHRPBBC9WP.YPIP.YH
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MX^?\D+^(W_8MZE_Z2R5_,G7]-GQ\_P"2%_$;_L6]2_\ 262OYDZ /=?V%?\
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M->U?L&?\GB_"7_L.0_R:@#^BZOSP_P""V7_)N_@D_P#4U1_^DES7Z'U\"?\
M!:+19M0_9;\/WT2EET_Q5;23<?=1[:Y3/_?3(/QH _%*OVF_X(I_\FO^+/\
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M ()4X\DDGMI\KJ__  #]Q**_G%\>?$[]H[P=?6M]XR\4_$_P_=767MIM9O\
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MB99:1=N'3496O;'3\MT\L($A4'/ 0 <U[3^PS_P4;^(/P[^*&A>&?B!XGO\
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M=53IRV][\$W=?=9_,TQ4%3Y)QT;M^+M;]5\CUK_@N/\ \?/P@_W-4_G:T_\
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M"\2_M+?$W5/#,D4^AWGB"\EM9K<AHY096RZ$<%6;+#'8BOI(?L._MO1^'_\
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MOYXO^"B'_)Z7Q5_["2?^D\5<=:?M,6IOJI?G$WI0]GAW'LU^3/V0_P""=?\
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MXKT']A_]B7]FS]H']F?P?XMU7P(FJ>(7B>TU>9=;U",_:XG*N62.X"J6 5\
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M^C>)/&5WJNAW:WEM#?7EHT#NN<!PMLK$<]F'UH ^U*\I_:F^",7[1/P#\8>
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MCJ05(]0:[V3]ISXQ31M')\6/'$B,,,K>([P@CT(\RNH_8;_Y.^^$?_8Q6O\
MZ%7]&K*'4JP#*1@@C@UVRA^Z4[[MK[K?YG!&=ZKA;9)_??\ R/Y@O ;>%=7\
M:V\OQ#U37;?0I9/,O;K1;:.[O9"6!./.D103DDN2Q']UJ_H._8V\._"+P_\
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M^;]-5Y;%U^:52$I:/\URO_@/Y7/R6_X*R?\ )ZGB?_KPT_\ ])TK[@_X)#_
MCP3I_P  ;+XE'0[>[\::I>W4+:K=H))+>**4QK'!D?NP0,DCEB>20 !\/_\
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M_P#D][XC_P"_9?\ I%!7ZK_\$N?^3'/AU]=0_P#2^XJ<)_N3_P"W?R9MC/\
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MUD__ $JWY:'X$?LFW$EK^U%\))(G*/\ \)7IB[AZ&ZC!'Y$U_2C7\U7[*?\
MR<]\)/\ L;=*_P#2N*OZ5:Z9?[M#_%+\HF$?XLO1?FPHHHKD-PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ K\Q/\ @N%_R)OPI_Z_[_\ ]%PU^G=?F)_P7"_Y$WX4_P#7_?\
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M+]K76_$NK>+]2O+3POX>:"-K/3G6.:\FDW,%+D'8@5#G R=PP5QFOT3\9?\
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MIG?#XFTUQM.#Q=1]Z_HM^.GC67X;_!;QWXJM\?:=&T.\OH<G \R.%V3_ ,>
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M'_Q2@U.UCN5LM%GU*W+J"8IX%\R-U/8@KC([$CH:\<_X([?\F@G_ +&*]_\
M08:][_;0_P"32OB__P!BOJ'_ *(:GF/\.2[17_I*?YZ^H9>[S3_O/_TIK\M#
M\)/V+[B2V_:R^$CQ.4?_ (26Q7(]#*H(_(FOZ0J_FZ_8W_Y.N^$G_8SV'_H]
M:_I%KJE_N\/\4ORB8Q_CR](_G(****Y#I"BBB@ HHHH **** "BBB@ HHHH
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M-$@Y=U!*E1EBNW .W!_-/X*_M,?%3]F'5-57P+XCNO#<MV?+O[&:VCFB=T)
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M %UU7^5I7ZF45-:]:2D]+6_#2Q=!JA>VMT_Q31^3G_!#G_D.?%W_ *]M,_\
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MHC16N)?UB<I[7=_QN9X=>PBH[V5OPL?BI_P19_Y.C\2?]BE<_P#I7:5]Y_\
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M'Z/_ /!%#X+[8?&_Q4O;?EBN@:;(P[#;+<,/Q\A<^S"OU1KRC]E?X*Q?L]_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5\H?\%2?^3(?'_P#OV'_I;!7U?16=2'/'
ME]/S-*<_9S4NQ_.3^PW_ ,G??"/_ +&*U_\ 0J_HVHHKI<[TU"VS;^^W^1S*
MG:HZE]TE]U_\SY<_X*8?#G_A8_[&_CF.*(2WFBQQ:W!QDKY#AI"/^V1E'XU^
M*7[*'Q//P;_:.^'OBYI?)MK#5H5NW)P!;2'RIO\ R'(]?TH45E0_<UO:K:Z=
MO3_-61K6_>TO9/S5_7_+5_,XSXP?"O0OCE\,?$'@CQ#&9='UJU,#O'C?$W#)
M*A/&Y&"L/=17X(?'K]DWXN?L;^.EU&ZLM0CT_3[I9]*\9:,K_9R58&-_,7F&
M3./D<@Y!QN&"?Z(J1E#*58 @\$&HY7&?M(.S_JWS_KL7S7AR35T?A O_  5J
M_:*7PO\ V3_;^D-=[-G]LG2(?M?UQCRL^_EUYK\#?V7OBW^V5\0'O;&QU&\@
MU&[:?5?&&K*_V6,LV9)&E;_6R<_<4ECZ 9(_H'/PW\)-J'V\^%]%-]G/VG^S
MX?-SC&=VW/2NB50BA5 50,  <"M8\O-SR5W_ %_70S?-R\D79')_"7X:Z5\'
M/AKX;\$Z(&_LS0[*.SA>3[\FT?,[?[3-EC[L:_''_@LM_P G:Z?_ -BO9_\
MH^YK]NZ*SJIU9J<GK>_X/_,JG:G!PBM+6_+_ "/S^_X(K_\ )L/BC_L;;C_T
MDM*^YO&W@[2?B%X0UGPQKMJM[HVKVDEE=V['&^-U*L,]C@\'L:VZ*VKR5?XE
MI9+[DD133I[/6[?XW/Y]?VIOV%_B9^RCXNNM1MK#4-8\'6\YN--\5Z8C,(D5
MLH9RG,$B\<G )&5)[=-H/_!6+]HC0_"HT8^(-+U*98_+CU:_TN.2\0 8!R,(
MQ'JZ,3WS7[R5SMU\.?"E]?B^N/#&C7%Z#N%S+I\329!SG<5S6,>:,>1NZ-)<
MKESI69_/3X!^#OQF_;:^)UYJ5A8:GXJUC5+G?J7B2_4I:0'@%I9L;$"KC$:\
M[5 13@"OWL_9O^!^F_LY_!?PUX TN8W<>EP'[1>%=IN;AV+RRXR<!G9L#/ P
M.U>DPPI;QK'$BQQJ,*B#  ] *?6RDHP]G!67]?AY?\ R<7*?/-W?]?B?@U_P
M5D_Y/4\3_P#7AI__ *3I7Z0?\$F?^3*?#'_80U#_ -*7K[%HK*@O8TY0WO\
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MKSTJ?P%_P4<_:-^$.M+;W7C2^UM+24BYTGQ7;BZW$=4D=P)UP>RNIK]<)/\
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M?_)[WQ'_ -^R_P#2*"OU7_X)<_\ )CGPZ^NH?^E]Q7U912HOV5!T=]M?2_\
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M 0":_H:USPKHGB9%36-'T_547HM]:I,!_P!] U+H_A_2_#MO]GTK3;/3(/\
MGE9P)$OY* *T^.SJ:V,_AOR:7/A/_@E_^PSKG[.]GJOC_P ?6RV/C'6;86=I
MI6\.^GVA8.WF$$CS)&5/E&=H4 G+$"7_ (*P?LF^)?CSX%\/>,/!=A+K.O\
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M_B[FE9^V45M:WX#)?]6_T-?RSZE_R&KK_KX;_P!"-?U-T5G!<M55?ZW-.?\
M=NG;=I_=?_,SO#O_ "+^E_\ 7K%_Z *_-O\ X*Q_L8>,_BGXBT?XI> M&N/$
M<]K8+INKZ58(9+K8CLT4T<8^:3[[*P7+#"D C)'Z:T458^UES;.]_P"OO,Z/
M[J/)NK6/YLOAU\>OC'^S#<:EI/A?Q'KG@A[E]UWILL6U3( !N,,RD!\ #=@'
M  SBOW__ &8?%6J^./V=?AMXAUR\?4-9U30+.[O+N0 --*\2LS$  #))Z#%>
MG45MS^XXO5Z:^E]/Q_ SY?>YEMK^@5\A_P#!5S_DR+QI_P!?>G?^EL-?7E%<
M]2'.K>:?W.YM"7*[^OXJQ_.Q_P $_P#_ )/+^$__ &&%_P#1;U_1/1170YW@
MH=FW]]O\C!0M-S[I+[K_ .84445F:'QY_P %-/V4]<_:;^#>FR^$;=+WQ;X9
MNWO+2R9E1KN%UVS1(S8 <[8V&2 =F.XK\:/#^N?%O]E;QDU_IY\2_#?Q#L\F
M3S[:6T>1,YV/'(H#KD X8$9 /:OZ6J*SA%TY.47O_E8N4E.*C);?YW/B;3O
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M+TU3MLV_OM_D2H6J.?=)?=?_ #"BBBLC0**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH AO+.#4+6:UNH([FVF1HY
M89D#I(I&"K \$$<$&OB_XJ?\$C_@3\1M8GU33(-:\#7$S,[V_A^Z06I8G.1%
M+&X0?[,951V%?:U%3RJ]^I7,[6/S9C_X(B> Q=[I/B1XC:UW$^6MI;J^WL-V
M",^^W\*]K^"__!+;X%?!O6(-7;2;_P :ZK;N)8)_%%PEQ'"P[B!$2)O4;U8@
M\@U]=T5I&3CL9RBI;B !0 !@4M%%24%%%% !1110 4444 %%%% !1110!\-^
M,/\ @D#\&O''C37/$VH^(_'"WNL:A/J-Q#!?V:PB261I&50;0L%RQ RQ.._>
MO=_V?_V-?A/^S-)-=>!_#*V^L3Q^3-K%],US>.G=0[GY%.!E4"@X&0<"O;:*
M(?NX\L=$$O?=Y:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;HL'B"T9OR$F:_F@HH _J0TOQEH&N8_LW7--U#=T^RW<<N?^^2:V*_E75BK
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BL;Q9XRT'P)HTV
MK>(]9L-"TR$%I+O4;A((UP,_>8@9]J^*/C5_P6 ^$7P]GGL/!UIJ'Q$U% 0)
M[,?9;$-C@&60;FY[JA'O0!]X5RWC[XI>#_A7I?\ :/C'Q/I/AFR/W9M4O(X
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW#$EQ@$9!Y$87IU-?&VM:YJ/B35;G4]6OKC4M1NG,D]W=RM)+(Q[LQ.2:I4
M/GGDNII)II&EFD8N\DC%F9B<DDGJ2:9110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH>A5U/S(PP?E8 T =91110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7!VGNCCJK#NIP:ZF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]@N<0M^,KG^M:-%%D+F?<J-I-HT>PVZ;<8X&#^?6H&\/6#')A;\)7']:TJ*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M W2(>A(SC'T_G6U;ZU9W*J5F5=W0/\M(1>HI <\CD4M !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445!>7UMIL#3W=
MQ%:PKUDF<(H_$T 3T5Y7XJ_:6\#>%Q(JZA)JTZ@_N]/B+@GTWG"_D:\1\9?M
MQ:K\\?A[P];6:XP)]0D:5OKM7:!^9K6-*<NAFZD5U/L*J.K:[IN@P>?J>H6N
MG0_\]+N98E_-B*_/'7OVCOB)XH\P7/B>ZMHG_P"65CMMU ],H ?S-<!?WMSJ
M4S3W=Q-=3'K),Y=C^)K54'U9'M5T1^AVM?M*?#;0E8R^*;6Y9?X+)7N"?H4!
M'ZUP&N_MP>#K#*Z;I6K:F_\ >9$A3\RQ/Z5\0NP'-5I)MOO6BHQ,W5D?5.L?
MM^:A\PTWP9;PCLUU?M)G\%1?YUP>M?MY?$:Z8_9++0].3MY=K([?B7D(_2O#
M&D5^]59X4<?RJO9P70GGD^IZE??MH?%NZR$\216@[B#3[?\ ]FC)KGKO]J+X
MI7C R>-=24Y_Y9%(_P!%45YU<6A5CBJ$T;+GCFKY8]B.:7<]'?\ :&^),RD'
MQSKN#R=M](O\C47_  O+XAW# MX\\2#_ '=6G7^3UYJTQ7KFGQW!&/2GRKL'
M,SU"+XZ?$6,J5\=^(3MX^;4I6_FW-7(?VA/B9#ROC?6CSGY[IF_G7F$-U[U:
MCN,U'*NP[L]?L?VL/BQIY 3Q?/(!VGM8)<_]]1DUTFG_ +;/Q-M=OG7VG7G_
M %WL4&?^^-M> JX;VI_!QCI1R1?0?-+N?5>E_M\^*(PHO_#FD77K]G>6$G\V
M:NRTC]OK3)M@U/PC=V_]YK2\6;\@RI_.OB4$BIDEV\&E[*'8KVDC]$]#_;(^
M&NKLBSW][I+-_P _MFV!]3'O%>A:#\7/!7B9E33/%.DW4K=(1=(LA_X 2&_2
MORR68'ZU,K U#H1Z,I57U/UT!SR.12U^5WAWXB^*?"3*VC>(=2TX+P$@N6"?
MBN<'\17J?A?]LSXAZ"46_FLM?@'!%Y;A'_!H]OYD&LG0ET-%574^_J*^9/"?
M[=7AK4-D?B'1;[1Y2/FFMB+B+/\ XZP_(U[5X/\ C!X,\>JO]A^(K&\F;'^C
MM)Y<W/\ TS?#?I63A*.Z-%)/9G8T445!04444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%4]4UBRT
M6W,]]=16L7]Z1L9]AZGZ4 7*9+,D$;22.L<:\EF. /QKROQ)\<H(0\6BVQG;
MI]HN!A?J%ZG\<5Y;KWBK5?$DQ>_O99P3Q'G"#Z*.*RE42V ]O\1?&+0-$W1P
M2-J=P/X+?[OXL>/RS7F7B#XW:_JF]+/RM+A/ \D;I/\ OH_T K@V[U"PK!U)
M,!]]J%UJ4YFN[F6YE/5YG+']:KTK=: *S*0Y5IZ]J0<4Y:!CUIR]:11ZTX"@
M3'BG+3:?02*M/ IH%/6J ,4\4BBG 4P%4>U.44@IU "TZDQ3AUH ,&G"BE%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^()X<+,/.7UZ-6W9ZG;WO^K?#?W&X-4I)D.+B6Z***H@**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HK
MJZAL;6:YN9H[>WA0R232L%1% R68G@  9R:JZ]KVG>%]&O-6U:]AT[3+.)IK
MBZN'"1Q(!DLQ/05^*?\ P4!_X*,ZG\?[Z[\#> KJ?2OAW"[1W-Q&2DNL$$<O
MW$0QPO\ %GYL\  'IG[?G_!4*;Q(NI?#OX.ZB]OI3;K?4O%%N2LEPO1H[8]5
M0]#)U(Z8SFOS'9VD9F8EF8Y+$Y)/K244 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQX;M;D->7$TJ<*ZS@K@\9.1[@_3-9UOX@T-;N%[=Y;W[.[2+'"3F0D\"1CU
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M]^WV98L*5)1!@<\?4TW1?$RVI*Q?:+L!?+XC+@CT)[YK!::_U*WN7(BCFG7
MMU V0J>F?>F:;;ZBA>&XOHXH&X*PO\Q]1@#WI.*'S.YVS-/;VWGM,L$?WF@A
M10WT/'%>W?!W]I[QS\&;:WC\.ZPMYI?F*6TK4"TL#9QE<'#1^Q6OGRWNH&LX
MHV1X+>-=HD.<]>3_ #YJK_PE%C8K%:0'[<^5V!AU//WC^('X5*5MBW+N?KW\
M'OVY_!GCZ6TTOQ.O_"%:].0B"\DW64[E0<1SX 4G)PK[3QCDU])HZR(KHP9&
M&0RG((]:_GOD^(5W$'M;F-OLO\<,V60D=AGD]>GM7T5\ _VYO'/P>FL[.&^A
M\0>$D(631]29@\2Y/^IDY*D9Z9*].*KF:W%9/8_8BBO*/@E^TQX)^.FGPG1=
M06UU@H7ET>[8+<1XZX'1P/5<^^*]7JQ;!1110(**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD9@JDDX
M ZDUSVJ^+H;;=':CSY/[_P#"/\:8&[<7$5K&9)I%C0=V-<WJ7C(<I9IG_IHX
M_D*YN\U"?4)=\\C.>P[#Z"H,U7*3<GN;R:\D+S2-(W^T:S[L_*:M52O&^4U8
MCD_$#?NVKSV\7=(U=WX@?Y6^E</*NZ1JZ(;'++<P=0ARIXKG+A=CUV%]%E3Q
M7*ZE'M8UO$S8R/#+6=J5KYD9P*MV\G:IYH_,0\4P/*/$.GE9"0*Y=LQ/TXKU
M'7M-W@G%<#J>G^6Q./TJB-BBDV><TK,&[\=Z@VF,_I1D_AUJ;#%D'<=*B;Y>
MM.+8]ZK22GZYI *TG7FH?.YX-1R2<GTJ/=GF@9.TH%4;R8;<9I\DH5?7BLB[
MN">*"B*9@S8%,QDXIBL6;WJPJX[4Q(7[J\=,T^'US4$C=*E@.<]Z:$7HAZ=*
MOV^>/\:SHS[\UH6O:J$;-NW SQ6SH[#[9'GUK"MSQ6E9R^7<1$'D&F)['T/X
M+M$D@0XKT>PT]=HXKR_X>Z@)+>+GM7K>ER%E%<M3<UIRT$;2D;M2?V$C?PUL
MPQ;C5^&V'<5CJ:W1RC>&D;^#]*IW'@^*0',8/X5WJVZ^E*ULOI1=H?*F>0ZE
MX#@DSF$?E6-_PKNW5B?*7\J]INK%#GBL^;3T]*M39#IH\CE\"P2#;Y0!^E=_
MX#^(7BSP'LMA=-JVF+P+6\)8H/\ 9?J/U'M6E_9B[\XJ;^RD/.WFDY7T8U&V
MJ/:/"/Q.TCQ8JQJ[6-Z1S;7'!/\ NMT;^?M775\VPZ6%P0,'J*[+P_X_U+05
M6*Z)O[1>,.?G4>S?XUSN/8Z%+N>P45D:!XHT[Q)#OLYPT@'SPMPZ?4?UK7K,
ML**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^([C"2= W8_X4*71BE#JC8HHHJS(**** "BBB@ HHHH **** "BBB@ HHHH
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MZ-NHJHNZN)HOT4450@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ***1F"J23@#DDT +5#5-:MM)CS*VZ0_=C7[QK#UOQHD1:
M"PP[]#,>@^GK7*23/<2-)(Y=V.2S')JE$5S3U;Q#<ZHQ5F\J'M&O3\?6LS(I
MM%63<=13:,T .JC>M\IJYNK/OF^4TQ,X[Q$WRM7'?Q&NL\1-\K5R.<&NF.QS
M/<K7B_+7*:L!S75W;?*:Y;5>2:UB1(R(/O&M%>4J@B[7K1A'RBK9*,W4K42(
MU</K&G?>.*]$NH\J>*YG5+7<3Q20V><7=CM8G&*I-%MR.U==?6?!XK#N;?9G
MCFJ),AH^IJK-&-QK3>/WYJO)%^=)@9+PY8]ZC9=HK1>+;5&X^4&I*1FW4F%/
M-8\TGS'GBKM]+R1VJI#"9F''>J0B2UAW'-69!M&!5JVM2J"J]XI%(90=CFIX
M,;1BJK'YCW%6H<;<FF27(^,<U?M6_*LZ)OR[5=MV.::$;,#9 YQ5M),,.><U
MGP-\H[5:SC'/%6#/:_AG>%HXUSS7OFAKNC6OFKX5W69D6OIKPZN84^E95%U,
MX.SL=!;Q]*OJF%J.W08%6]O%<[-T5V.VHFG"T^Y.U:QKFY*L1FH:-8R+LTP*
MFLZ2XYZU%]J+<56>0EJ19?23=5R/Y@,UF6K9K4A^[28R;A144_S)BGYJ-J0S
MG=0GNM/F%S9SR6UQ&<K)&V"*ZGP?^TE#8W$>G>+E%N"=JZI&OR?]M%'3ZC\0
M*PM4A#*:\T\7:4+B*08KHIPC4TD<]2<J:YHGVW9WD&H6L5S:S1W%O*NY)8F#
M*P]01UJ:O@'X:_&+Q+\'-2,5J[:AH;/F73)V)49ZF,_P-]./45]F_#7XK:!\
M4M)^V:/<_OHQB>SF^6:$\=1W'/WAP:C$86=#7==RZ&*A6TV?8[&BBBN([ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>2U\=B,-5PM1TJJLT?HF#QE''457P\KQ?]6?F%%%%<QVA1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 *Q5@0<$<@BOV9_X)<_MS_\
M+7\/P?"KQSJ!?QCI4/\ Q*M0N&^;4K9<_NV/_/6,8'^TH!Z@Y_&:M/POXFU7
MP7XBT[7=$OIM-U?3ITN;6[MVVO%(IR"#_G- ']2M%?-O[#7[7VE?M9?"R.]E
MDAM?&FE*L&M::ORD/CB=!_SS?KQT.17TE0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTNA>)QA;>\?V64_R-,;78ZBBD!R,CD4M!(4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[<)"HPO'0#M61K&C1W%HP"Y*KZ?I7CSKSE*[9]+2PM.$4K'RMKG@,7(D11N
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M[VJ&8Y.!CCF@#P6^TNR4G%K"/^ "N?O=/MAG%O$/^ "OHJ;X!^'6^]?ZT?\
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MK(ARK#(-/K0P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"K+DI;R8_,5]<^"+$V]MO<8+'.*\O#RU2?0_'N/JUJRCVBOQ;.I@MQ%"S-P
M,FN6M[]+YGE7[A8X^E=-XBNQ8^$]8N1]Z&SF<?4(<5XOX$\127>GQ,[8+ &O
MH*.(49\G<_.LEPTL11JUNS2/"_VP/A^-'\36GBBUCQ;:F/+N-HX$ZCK_ ,"7
M!^H-?/%?H;\5O!J_$CX=ZGI"J&NF3SK4^DR\K^?*_P# J_/6:%[>9XI%*2(Q
M5E/4$<$5\-G^#^KXKVD5[L]?GU_S^9_2G!N8O&9?]7J/WZ6GR^S_ )?(9111
M7S)]\%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!^X__  2X_:Z_X7O\*1X)\17@D\;>%85B+R$[[VRZ1R\]67A&^BG'-?<-
M?S,? 3XTZ[^S[\5M!\<^'Y2MYILP,L&XA+F \20MC^%ER/K@]J_HX^$?Q2T+
MXU?#?0/&WANY%SI&L6PGB.>4;)#QMZ,CAE(]5- '7T444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %4=5U1--M]Q&Z5ON)Z_P#UJFOKV.PMVED/T7N3Z5QUQ<O?3M+*<D]!
MV'M04D5+J:6\F:65MSL>3_2J^TKFK<C 4U6'H#4FERFZG%1JS=^E7)G7:?EJ
MJTG7 -(M,;YVW.3^=)]J"]Z:T?F=0:KS6H"G!YI:CT+@OABHFN0W-8<T5PK$
M*Q(JW9P3G[QJ>9E<J-6&X]ZL?:.*I)!)QG IS*ZGIFJ4F3RHF^T?,1BG>?VQ
M55I-HR1S5234$7(Z&CF'RFO&R]ZF0K6'#>&7A3Q5^-'Z@TKBL:#!<57DRO3K
M3%:3OS0Q;O3YA6(GF;/2CS%"DFDZYJ&8'@#@4<P[$BR9DP.:O0"J-O"=V:OQ
MJ5JMR&6EQQQ4RKNJ!1Q3ED*\"F(D^[SFAF%-^]36&.],0Y1S4E1K4F10)B%:
MX[XIQAO!NJ@_\^[_ ,JZ]I!T!KD?B9\WA'5 3_R[O_*E+8:W/C59&2;C@[1W
MK9\-K&\8*8C(S\K'CKVK!W#SB6/51C\JU?#+9/+8Y_.O).\]6T:T,UJA5U1X
MSG=W'_ZZ^=/#-A9^*?VXKG4C;1;]*T:;YDC !) 16./XOG//O7T+I\XMM"N)
M"V"$/S?W?>O)OAKX+N=%_:,\2:M(A,>H>'DGC8_PDS*"/R45M)VB.FN:2N>@
M^(K<233<<YQ^M<I-#MC91_$#DFNWU:/=*[$@+7,7$98'Y,\\5X50^HI;'!ZE
MHL5Y(C;0<8[=1Z&N:U;P_F%E5.IP17HL]O\ )R,!3CGFN?U"W#LQP6P.":Y]
M3J1\\>*_"$>FWIFDYAF.U^/NMT!/X5YSXF\ +--(T#YDV;E7&#G^OUKZ5US2
MX[Y6CD0F-\@^@KS+4?#LUNS0N_RJ<12'L.PKT:-=I[GG5L)&:V/GZ^TN_M\I
M=VDC-'QN YQ_6LH6H^T HDBG/)QC%?0-_H,UU($NK63Y?NRPKQ6+-X+.IRK;
M6MLUV['EMI7'OR*]&.+6S1Y$\O=_=9YII^CQ7G$K*LG;<._UIVH>%;A8PP_>
M <Y4<\5Z+<?#74=+VHMHUPBGE5'/TK:T_P +_9W#3V]X@(^XULS#\2*3Q*6J
M8U@FU:2L>!M;F-@/)S@XW5G7EN\LI>5L@< >U?0FL?"^;4)FDM[.20.>(T0C
M)]/;\:X[Q!\(;^Q@:9XC"?\ GBW)'N2.M=,,5"74X:N!J0U2T/)?+9^$7/O3
ME2[R0D>!TW;<UMZEX9O+#!*,F?XJR&EN+<DO*WMFNZ,N;8\MQ<=&0FWNI.73
M:H/H!4<RX;8AR5Z\TLU[(YY._P#E4.YF%:&1+]LF10A^Y_M*.*;N922OS#WI
M55I,D\JH^;U%7-(TF^UF\%IIMA<:C<-]V&TA:5R/HH)I:(-65(R6*D-_C7U3
M_P $^_#8F_:*\/WL]J&AACFE3S,##!#AAZD&OFK^P]1TV^EL;NTGLKM.7M[J
M(Q2+^# &NZ^'EUXCTOQ7HMQX<DO4UNUD66"&W5F8E3G@#L?\:RJ:QL:QT9^Y
MT8(JTD8X)/-<O\,=8U'Q)\/] U/6+1['5;JT22YMY%VLDF.01VY[5U6X+WJ5
ML=#>HLD(;BH?)$8)/%.EN>,#DU5DF9@>U+0:.B\.^*!I\JVMP?\ 1F.%<_P'
M_"NX5@P!!R#R"*\::-F;)KM?"/B QJEE=-\O2-V[>QI*5M&*4=+H[&BBBM#$
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBLCQ)XB@\.:>T\OS2GB.+NS?X4#2<G9%#
MQMXT@\)V(QB6^E!\F'_V8^U>._VI<ZG=R7-U(9)I#EF-,U>ZN-;U"6\NW,DT
MAR?0#L!["BWCV5E=MGMPITZ5*V[->V?I5U6K.MZNJU="/#J;L>6INZFEJ3=5
M&)(K5*IJN&J16XH&2;J,TS=1NH ?FES4>ZC=0 ]FXK(U)OE:M1V^6L?46^5J
MI"9Q.N?>-9D:UHZP<R&J4(R*Z>ASCO+S4,MONJXJ\4[:*!F5]A'IS2M:B-:T
MVV@5F:A=+&IYIB,C5+@1J>:X#7M4Y(#5N>(-6 5L&O.M4OC(Y.>];)&4G=E.
M_O"Q))KGK^["AN:LWUU@$YKF[^Z+YY_#-,6Q5OKK>QP>/2JD,9D;FG+"9FK5
MLK$LPX_2@$2:=8[CTXZ5U6G6 4"JFG6>TCBNCLX.@Q4EEFSM<*.,5K11#9^%
M16\>,5>"@1TAF%JZ':?2N*U"WW/]37=ZFI*FN7NK<-)CWJD2S+MK/:,8S3IK
M4;3Q6Q!:X7WHFM>.E'41R=Q9=?6JOV,CMVKIY;+.>.:@-B/3'X4R3#6S^7I3
M_LIQP*VA8CTJ06&[M3'8PXH3#,C=,'M7NGPY\1+#;QJS<_6O)'L=H^[5O3]7
MDTOG) %9U/A+IKWCZSTO7D:-<,/SK2_MD'^(?G7S5I/Q,>%0ID_,UT-G\2O/
M8#?G\:\>5;E>I]?3RN52*<3VZ36/>J%Q?&3O7 6?BPW&#GK6Q#K(D7ZTHUDR
M*F5SI[HV))3NI\,GS5EK>>9[58CN/F%=4)J6QXU:A*B_>-^W;.*U+:L6QD#8
MK<M1TK4Y2VG6K*=*ACP*D5J@![GY:YKQ!_JWKHV^Z:Y_74W1-]*J.XGL?.'Q
M?O#;VLIS@BO#=-UQ[B; ;/->Y?&#2Y+FUF"CL:\1T'0)(W.5/7TKZO"2_=GR
MV)7[TV_M[&/DG-<KKUVRL6)Q773:>8TZ5Q?BQ?+B8#C KJ,+6.<;62DW#=ZU
M=/U@R2#+?K7 37C?:CS6IH]TTDV <G-97-;'VS^RU^U5-\+;R+0/$4TEQX4N
M&PLG+-9,?XE'=/4?B*_12UNH;ZVBN+:9+BWE4/'+&P974C(((ZBOQ9TFPDNH
M0V":^U_V._C=<^';6'PAK\[2:2S8LIY#DVS'^ G^X3^1KQ<=A5)>UAOU/7P6
M)<;4Y[=#[4HI 0P!!R*6OGSW0HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ IK,(U+,0JJ,DGH!3J\7_:"^*D?A;0+NSMY=C!3Y\@/_
M (Y_C6%>M&A!SD;4:4JTU")XQ^UE\?GG8:%HTN5W;%"G[[?WC[>E?.MS/%X!
M\-MJ=Z^_4[KIO^]DU6\*7$OC[QQ-J5P3+ KG;NZ8%<;\7M<D\3?%"QT>$YM[
M5AE1TS7Q\I2KU.:?4^KC&-&')#H;J0_V7HDVO7Q\RZN!N4-V]*^7?B]XGN-6
MFE 8YR<_2OJ#XP%M+\.V=N#M4)T_"OCWQ4LE]>S^6"Q+;<5Z.'M>YP5;V/.K
M?3;[5M0CM+"WEN[J9MJ0PJ69B?0"JWB3P-K_ (4NI(]6TFZL64C<9(SM&??I
M7Z<_L;_LPV?@_P /0^)]9LUEUJ\0.GF+S"A&0H]#ZU]$:]\*O#7BZ/R-4T>W
MN8\@E7C!''L:^EIIVNSP*DHQGR[GX4V4+M<)@$<^E>G>';B[TDQ2J&B48/UK
M[^_:0_9_\%0M$-*L+:UN A!6) O;C@5\K^.=#M-+TV&#RU611M) KEG)2.F,
M>79FAX:^-4ME"D,I,D6,$D]*W[GQE!J"^=%)@$9PQKPI85MVQ =Y8]*V1</]
MF6 OY;'D\UQ2IIZH[(U&E9GI[>);)2J3%&+]#7-:ZMLTY:*0)W!KSO4)F20;
M)V+*?6E7Q$YC\N8%\CALU/LRN?4ZVYO+@0;0WF@=P:YR[U"9&8R(V*IQ>();
M0XPS)4[Z[]J4(4!#>M/V?D+G\QBZ\JQE9#N4]CVJA+)!,Q,3_A4]U:P7&/N@
M^U=9X'^">M>,)!/96S);]II1@'Z5#<8K4UA3G5=H*YQ2V,Q_>'D=AUJS##/(
MW[X"*+O7L/B+]G[Q+X;TIKBW@6[=5R54'->!:Q)JOVZ2VO$>U9#AHV&"*49>
MT^%EU:$Z/QHZ&37[7304M4\R7UK/FU"ZU+YII2!V45C16[1GA68^N*TK>SO9
M<;(6^I%5RI&&K+UO;\@NVU:V+2\B@7;$-SUEPZ#?3 -(2!70:7X<;((95]>Y
MJ)2T+466[-)F(,CCGHM=MX3T)[R\C:483-5-!\+^9(K;6<UZSX4\,!6CR,5S
MN[.N$3TGP'HL5G#'Y:]J]4T]PD:C&#7#Z#;BSB0+Z5U^GR^8N#D&A'3:R.UT
MF0';CK76V\*W-L5QU&.E<%I+&-EP:[_1V+*.:ZH+FT.:H['SU\4+UM+U.XM9
M  F?EKRR:X\R.1@<\\5Z[\?])?\ X2**11\KKR:\NCT=FCVC..M==&3IQ/+Q
MU%56C.LYBL@KJ=*D,A7 XIND>&5D7++S71Z;H8MF&!G\*2Q#YK'/++H>RT1;
MLXV916U::>TH%.T_3]VWY:ZK3=+S@XXKUZ=1RB?&8K!VG8K:7H9X.*['3+#R
MP!CBI])TL;1Q6]'IXC' Q3FSKPV'Y=2M'$%%2XJ5X]O:H^,UPRW/86P"EHHJ
M"KA3OI24JT#%HHI1B@0M+110 HI:*55+' !/T% [ JEB  2?:K2O#!#NXDD[
M;2, ^Y[5GW5R%C<%WCMU&?,3&';OSV _I7'>)/%BQPN+>.*TB4Y>X,6YB?10
M>_N:T2MJQJ-S;\2>)+;0E'F2I'<R9VQ ^9S^%<!JOCBZE!G-Q%%:AL%F5-H_
M#U^M<CJ7BBTU34<V%O>:A<!L//<?*/J/;GL*W6M;+3HE?41:V)526\EF9VXX
MS@8__52=S=+0FN_B7X::");C4([B51N 10>1^5+9_%/19IRUI=^2\8XV':3D
M]"#U%>>^)/$'@>.<>;IU]/)G)$*_*&]>1FH--O?!NN;$MK-87Y3]\@&,]5RH
M&.IJ+LOE5MCZ"T;QDU]#&BOY^?F&'&<?UK17QE;QN1,C18X8MV]Z\/L=-L=/
M=9K$ZI ,[0(V+J3TSGM^==987FU3NOI"PQ_H]^"A.>V?7\<5=V9.*/6[/6+3
M4(1+!/'*A.-T;9&:M;AZUX[#J$-M<$J)+"0CYGB/[L_[P'0^^,5T.E^+IH9)
M+>Z8;U8X;() SU]Q].E!GRGH6X>M)N'K7,:;XMM[NX-K(3!,Q(3?T8CC JPV
MJ$#)X[U:CS;!RGLOP\\8";9I5W)E^D#L>O\ LG^E>@U\L)K312!TD*NIR"#R
M#7NOPW\=1>+M-,4K@:C;C$B_WQV<5KRM+4?*SLJ***"0HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D
M9@BEF.% R2:6N>U[5/,8VT3?(/OD=SZ4F[%1CS.Q2U;4C?3$@XA3[H/\ZTM!
MTDPG[7<)MD_Y9(PY0=R1V)_,#ZD55T/2A>,+B7F%&X7^^P_H/Y_0@ZVKZC]A
MM^/]:W"C^M3%=6:3E;W49^OZGG-K$?\ ?;^E8!7;4G+,6/)/)IK59B,HHI*
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M^HB_M@3_ *Q>&']:R&PRD$9!JG;3OI=\''W#U'J* .SHID,BS1JZ'*L,BGT
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M>-==MQ]@UFV4C,5VBC<<=E<%7'LWM7NU !1110 4444 %%%% !1110 4444
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MB>+I,;;"3V^4TUO''C63C[%)CM\M+F7<.5]CWYHX_P"\OYU$8H^S+^=>!_\
M"3>.)3Q:2 ?2G+K7CIEP+<BCVB[CY7V/>Q''_?7\ZECCBP/G7/UKP$7WCQ^D
M>W\12;O'K'J5'UH]I'N/E?8]^E2#;RZ_G6'JOE"-MLB@_6O'OL_CQ^LV/QJ)
MM"\;S,2]U^M1*<6K7*C%IWL=_)=>7(1YJ@?6ND\-WD;.NZ53^->,'P?XOE.6
MN1FI;?P?XOA.4O\ 9]*\RIAU/[1]AAL[6'BE[-OYGU9I=U"-N)5S]:ZW3[J
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M?0Y/)^HKN)_!FC3+YMTTLT8(;]]\R\]R% ST]:CO/"^G%MEO=6T4>T+Y<T+
M#_@6X?K4&CB3>%=:\,Z.K6W_  DEX6QN3SI,)]"=N*[#2_$-C#-N42LLARS
MB=&_')Q^5<:WPSDO($\J6UNY  PV_,".O8=N:6S\&MIIF5DFM9&;F2V)VJW^
MXW4?2M+LQ<4>P:?-%JY22W3RI%!)!ZMCT/OTP15#4A]LM7MY!]FU"%0X*DJ.
MV2G]W@C\17 :?K5YX;\M+M_.MFE\O[9:@CRV/3>O45T5]K7]O:>JPNC:C /,
MA=3PZ_Q#/U _,5=[F#BT6=)\9-'MMM5VSF-\+.!MD&.AQZX'7VKJ+/QREFZ6
M]R6G@W@)<*,GZ,!_DYKS'2_%MCXGC9A&!?VX"2VN#EO]H=\'GW!K274+:"^@
M #SV,Q"-V://&3[@\?D:+M:H-#UN^W-^^MI!+&6"_*1WZ&F>&_&UYX5UJWU&
MU8^9"W*D\.O=3[&LG3S]FO(8@FZ$C[Y'#-DG(]/<>M)JVDRZ;=/&X^[@^HP>
M0:]:A-5%:1M3M+W6?:?A?Q)9^+-#M=4L7WP3KG&>4;NI]P:U:^5_@7\1#X1\
M0#3;R7&E:@P4[ND4G\+>P/0_AZ5]45S5(>SE8YZD/9RL%%%%9&04444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445%<
M7"6L+RN<*HS_ /6H H:UJ7V.+RXS^^<?]\CUK L+-M1NQ"I*C&Z1P,[5_P 3
MT'XGG!IEQ/)>7#.07DD;"J/?@ 5U>EV/]GV:1$[I#\TC#NQZ_AV'L!6?Q,W?
MN*W4F;R[.W[)%&N/H!7(7ETU_=-*WW>BCT%:GB*^RPM4/N_^%8^W:M:& UN*
MA+9XITC4R@!:*** "BBB@ I*6DH 6KUC!A=YZGI56WB\Z0#MWK44;>!TH =2
M4M&* $]J&8*"S< =S1GI7D?QN^)HT*S?2-/E_P!-F7$CJ?N+_C0!S'QI^*YO
MII=#TJ;$"G;/*I^]["O(M/L6OIL=$'5J@MXY+Z?'+,QR6-=1:VZ6L:HOXF@"
M:&)8(PB# %2BF4N>,4 24ZF4[/>@!PI130V.U.S0 HIP]:;3LT +2TF:,T *
M.M/J/-.5LT 244@S3_;K0 BTIIRK[4_RJ (<4_!ZU)Y)]*40D=J (>:*E,=-
M,= #*<II"*.E "T444 %%%% !11]: * ,G5])$ZF6(8D'.!WKOOA#\3FL9DT
M;4Y/W).V*1S]T^AKE_:L76-.*D7, VLO) _G0!]<JP8!@<@]#1_*O+/@[\11
MK5JNDWTF+N(8C9C]\>GUKU3TH 05%=0^=$?4=*FI.U $OAO4-K&U<X[K_A71
M5Q5TK6TZ31\<YX]:ZVQNUO;5)5[CGV- %BBBB@ HHHH **** "BBB@ HHHH
MBNK=+RW>&3[K#''4>A%<=-')8W;1,<2QG(8#&1V8>Q_H1VKMJS=<TYK^U#1#
M,\1W(./F'=>?7\.0.U3)7-(2Y62Z5J U"WR>)5X<?UJ[7&Z;?&SN$E&2AX8>
MHKL$=9$5E.589!HB[A./*QU%%%49A1110 4444 %%%% !1110 4444 %%%%
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MKJ.552:[J/$L>" P(Y!Y%>2>&;L90AJ],TN^#PJ":^OHU>9:G!F=&\M#X?\
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MX/Y5&U0M-Q&P^@V27 5M4B,6W<64<]>F/6D;1=(6.W9]4P60%U5<E203C\,
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHH ***%4L< 9/M0 45;M='OKV01P6<\SG^%(R36U%\-O%$R[AH=XH_VHBO\
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M_?-(S'UJ%JYM#H5Q[:=<_P#/%ZB;3[G_ )Y'\Q_C3&J)A1H/4>VFW'_/,?\
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M+0 44F:6@ J]8Q[4+^M4E4NP K55=J >E "[CZT<T4M !NKR+X^>.O[%T?\
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M(KI:X;5)_M6J2MGC.!6AB6+7Y8_2JM])N;'>K7^KAK,GDW.: $S2$_-TIO\
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MZ92-?^!T ?B5XBUZ\\5>(-3UK49/.U#4KJ6\N)/[TDCEV/XDFL^BB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH NZ']K_MK3_L!*WWVB/[.1U$FX;?U
MQ7Z#RP,MJ Y#/M^8@8!-?%WP!T ^(/BMHB%=T5JYNW]M@RI_[ZV_G7VQKDT>
MGZ3<7,K;8H8R[,>P R:^]X=IN-"I5>S?Y?\ #GX_QKB%+%T,/%:I7^][?A^)
M\@_'#XE:G=>(=3\.VDPM]+MW\N3RN&F; +!CZ DC'M7HW[-7B0>)/ ^H^';_
M !<)9'RPDG(:"4'Y?H"&_ BOF;5M0DU;5+R^E_UES,\S?5F)/\Z]._9IU[^R
M_B$;-FQ'J%L\6/\ :7YP?R5A^->+@L;.>8*<W=2;7R>R_(^KS3*J<,F=&G&T
MH)2OYK=_=<[OX-_"RY\(Z]K>I7T( CEDL[%FY9E#D-)[9"@ ^YKV&SML$,?P
MJ25O,G)/(SFK$> O'6OT+!X6GA*:I4]D?G&,QM7&U/;5=W;\#S[XZ>+&\*^
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M+EX')7/#Y]5)ZUS'B?QHVM7N-Q$<?0-QGM4.+3LT;QJ1:NF=%9W"WD90G#,
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M?-J6N7MRQR9)6.?QH FT&/S+K<?X173J:PO#D?[EGQUXK<'8T 2BG?SIBTM
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M+?'ID4>EPG@,/GD^N3P/RKRZBOD\7Q)F&*]U2Y%_=T_'<]FCE6&HZM<S\_\
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M_?66HH)H9!W!4]/PKT6WM_#6E:;+XUCTQ=(GS'(+.VF<F#>O!5#_  DY7T'
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MU/I&BHX)EN((Y4.4D4,I]B,BI*R&%%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH CN(1<V\L+$JLBE"5ZC(QQ7'6<S6MU$[
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MR1NZ#X9FUR.1HE9R@+-M[ =ZZ/2_AK=PZ[IL-Y'+;)/,H#.O!Z$_H16!X?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!C^([A8X(U)[EOR_P#UU\C_ +1'BK[*\BJVYS\J@>I_^M7TWXTOO+NI
M<MA(8AD>_7^HKY1\2:"?%_BI[RY&;&!CM4_QG-?-YE4N^4][ 4TO>9YIX9\$
MC4($O=00A"=RHW\7UKUSX?\ @%_$&I1D1;;=#A1CC%,MM-_M+48;6!,Q[@H5
M1U]J^E_ 7A*+P_I<99 )6&3Q7/@\-+%3O+X4=6*Q"P\/=^)E[PUX9MO#]BD<
M: -CDXK=1MJ$TQS3&?:I%?81BHJT=CY:4G)MO<\[\<3FXFD!/ XQ7G[0_.:[
M;Q@VVZ>N1906%=*V.9EW38^!WK5AMPDFZJ&GX4"K\D_R\50AFI7 ,.WVKFS(
M5<UJW&6S68\?S&A@)YV[BG=.:82(^:@EN,]#4@7XV%6(V(K*AF.>M:=NP; Z
MT :,$GRU)Y>>1UJ*-,58533 U]'O"W[I^E8?Q%\+Q:WH]Q"5R64XXJ[9R;)@
M1Q5_5;I5B&[H:3CS%QDXM-'PWJ&GRZ3J-Q9R##1N5J&1,KFO5/C5X5%CKBW\
M*?NIN&^M>=FS+1].U?,U:;IS<3[2C556FI(Y:^XSBL::3]YC%;FKPLC<5C3+
MM4YI(J3L56F\OBJ[7!/? I[*3SFJ\C#.-V*V2L<_-<FCF.>M789CW-5+6U,F
M-IS5SR'C&,4RT222%EJH'(;)Z5-DJM4YI/+:H-#JO#&L&&\0$\9KW[PQ=+>+
M V<]*^7[&4PR+)TP<U[?\,_$23-#$[=_6LI*S&]5<Z7XS:D\-E%90Q;O.7EL
M5X1#X7D7=\N2QS7TIXZT^'6#;%,.5')KEU\*KC[GZ5%2#DSJPN-AAH62U/&/
M^$;E7^#]*Z#1]+FMXQQBO2?^$54_P5-'X;"K]VE3I<LKFE?-/:0Y3@RT\2]Z
MQ]:O+GR2%)KT^X\-;L_+7-Z]X<V1L-O-?0TJ_*CX/&)UI7/)YM2N(LEG(JN?
M$;1\&0_G5[Q)IK0[NU><ZM,\+GYN];K$79Q_5SM_^$L(_P"6GZU-'XF#8_>9
MKR"XU:6-B0U/M_$,@/+?K5^TN-4N4]ZT7Q GFJ=V:]-T#7T95^:OEK1_$WEL
M"S_K7>Z/X[CA5?WN/QK*7O$WY6?3MCKB%/O"K+:TA_BS7@$/Q.BC0#S1^=2K
M\4HO^>P_.N*4=392T/=FUA3T85YM\;OC5;_#'PU)+$ZOJLRGR4)^Y_M'^E8N
MG>._M4,ER7(MXQDL3U/H*^-OVD_'T_B#6YM\K'<V-N>@]*Z*5*_ORV%*5]$>
M5?$[XD:AXHU2ZU.^N9+B>5C@LQ-><R:]/-&0S<FG^(KKSIDC'11FLA1NJW)W
M-E%1/8_V8=-_MSXP:,6P[0OYB1M@J[= ISZY[>E?O!X$T)/"O@_0=)B184A@
M4D*!GUZCN<U^*G[#49O/C9X4TZ31I;MKC4(T6:)"H"<LQ=NZ@A3@^G:OW'NM
MMG-Y4:_NXUV(J]  ,8'TK&KL=.'^)F5-?8N\=@< <#%>:?$6Z:^U!;8$MDX[
M^A-=N)C<:A)M +AQP!Z'T]*Y.]T\ZMXPAV M$#\Q)P,]\5X]:\E9'T&'M&5_
M(Y%O!\GV6.1APR?P\8!X_H:\M\??"+0YI#>*9-,U!C\UW8D*S<?Q#[KCI]X&
MOIOQ5,FFZ>,(,*HX]/?\J^<O'FN)*\X:4 [MI4-T [5QU(^S?NL]G#_OU>6Q
MX7?>"-9LY&>XL;?6[8?Q6[_9Y\>NUOE)^A%=!X9T'POMC-UH&J17(_@GTZ27
M)[8*A@3^-4/$WC1[>-UBE8(@" =#P?\ Z]6OA7X^U/4-198DEDLHV_>7 7"*
M21_%[8JXS<M&:RP\(:HEOX]=^(?B!?#6DZ=/X<T".4)<EHPEQ=X/*[1PB#N.
MI]JW?'G@.R\'Z?!#Y0W,WS,?F=SC))/Z5[MI-C8Z3#;ZL=MQ>.N[SDZ8/3%>
M=?&"[CU>[M_+/[V0<KU.":<](BA'FEHM#Y8^-6BN? LE];;H_+.WS.@^;@?K
M7S?-X=N-+2*,V[I(O4%J^T/CG90:'\/)].NUP"5F0]0R*RL3^E<5\7/AG!#<
M12Z>B2QS1>?!)'RKKUX/?(KNHU'3B>'BZ"KS]#P'0-<_L6,&0&-B^-H&0?PK
MN]'\0:7K3+M,?F \[#R#6(WA6#4F\MV\I^1M8<'V_ UTWA'X$LUWYXNELXV<
MEYY),CGOC&3@=JTE.G+U."G2J49:ZHZFS\$67BZ2"$003R2$XW*"0WH&ZC\*
M]$\$Z5XH\&:E#9^'M2^UJ67;I6J[IHG..B2CYU^IW#BN;\*Z/KWPN\60ZG$Z
MZQH>%:93& 8SW(]!7TO\'[$>//$,FII;M9VEJ2T4*XR20>A[<FHC+6US2:LK
MV)M+_:B\#>$+LZ)\1+:[\)^+[.'SETS45$L5RI! :VD7Y7RV ,X(P>*X-OAO
M>_%CQ;HFF:.CZ=IYLDOM7D8E'59&^1#COL ( _O5YE^T=\(M:_:2_:+%PT,F
MF^"]-MDTNQO-JDZE,CL94AYR5WAP6Q@!?>OOKX>^ X?"<-Y<%$6\OC'O5!\L
M<<:!(XQ[!1^M:XJ$:T8T_O+P=66$G*NEK:R]>_R-C0?#=GH6EVFGV4"V]I;1
MK%%&@X"@5K+8C;TJS#&/2IY,*O2HVT1R.[=V93VH]*C^SC<,5<FD S4"."U;
M1,VBW;VXXJYY/RTRW -7=GR&MC%G.:FOEY->;^+=2^SH^3@UZ;K:_(U>'_$B
MY,,,ISZU4'J-PYD?4/P=\1+XF^'.CW8?>\<9MW]=R$K_ " _.NTKYP_8G\5'
M6/"?B73&?<UAJ"R@=PLB#'ZQM7T?6DE9LY&K:!1114B"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@#GO$TVZ:*(?PKN/X_P#ZJG\,0[;>>8H59WVAL\,H
M'7\RP_"LS6Y/,U*;T7"_I6_H<:Q:3;;"S*Z^9\W7YCN_K6:^(VEI!(O4E+16
MAB>?^)Y?,UN;T&!^E36>5M\UGZP_F:U='/\ &15]#LM0/:@#,O'W2=:K\BG7
M39D-1[OQH =N-'/?I3-U&[CK0 _<:.:C]NE+F@!^3ZT<]J9NHR* +%MS<)GU
MKH*Y_3QNNDKH!0 M%)10!XI^U%=>7X6L8<_ZR;-?,4/,B#W%?1/[5DW_ !+]
M(3./F8XKYVM>;B/ZB@#N;<?N4'3BIE-0QG"@5+0 ZAFQ30:1C[T 1R-5"X;W
MJU,U9]PU %6X;WKU']F#2QJ'Q.BG89%K"T@^O2O)[AJ]]_8^M1)KVM7!/*0*
MH_$T ?5-%%% !1110 4444 %%%% !1110 4444 %%%% 'S/^V)IH:3PY>@<X
MEB)_(U\U20<5]9?M;6_F^'="?'(NG'_CE?,$UO\ *>* .>DAP3Q5=UQ6K<0X
M)K.N!CZT 4)5^:E@&TTDO6EB;'% &_I[G:*W;9NE<[IK\#FMZW;I0!N6;?-6
M[8MTKGK-N16[8M0!T=FWRBKX^Z:S;(]*TEZ&@"M/5)^M7IJI/UH 90:** "C
M\*** (KI=UO(/]DUZ1\ Y]VAWD1/W9,UYU+_ *M_I7<_ .3]SJ4?^T#0!Z_1
M2?A2#GK0!GZ@?+O8'''(KOXCNC0^PKS[5_E:$^]=]9MNM83_ + _E0!-1110
M 4444 %%%% !1110 4444 %%%% !7.^)X=MQ!,$/S*49\\<'*C]6_*NBK)\2
MQJVFB1BP\J16&.Y/R\_]]4GL7%VDB/PS-N@EB/\ "VX?C_\ JK:KFO#<FV^9
M?[R'^8KI:4=AS^(****HS"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\
MK?\ @N!XUQ%\+?",9Y+7NJSC/IY<47'XRU^5-?;_ /P6#\72^(/VO)=*,FZ'
M0=$L[-4[*SAK@GZGSE_(5\04 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !116QX1\*W_C7Q%9:-IL7F75T^T>B#J6;T &351BY-1BKMF=2I"C!U*CM%
M:M]D?;_PW\0'QS\.M$U3),LUN$F/_31"4<_BRDUK01FS=PQR.U;?@/P+;>#O
M">GZ-:G,%G"$WMU9N2S'ZL2?QK/U9HUO)%7!*\?C7ZS0A.,8.?Q6U^X_EF->
ME6QE3ZNOW=VUZ7T.,U;Q!JJ^(O(MK9$L88\S3R<EW/W8U^@^8GW4=ZY#]HKQ
M$MA\+9+=P//U*:.!%[@ [V/Y+C\17H&LW5II=C<ZC?RK!:6R&221N@ _K7Q[
M\4_B5=?$C7%G93;Z=; I:6V?NJ>K'_:.!GZ 5X^:8Q8>C.#E>4]$O+^OQ/T#
MA_ RS#%TZL8VA3:;?=K5+UO]R.H_9Z\)1:IK5WKEUD0::H$7.,RMGG\%!_,5
M]*Z5<I)$K(X=#T93D&O"_P!G53>>$/$]MT*2Q.#_ +RL/_9:R_A=\2)?"?C>
M_P!"U*Y(TJ:ZE2,R'B"3><'/8'H?J#6.68JE@J%&,EI.^OG<]K-L+6S'%8EQ
M=W2M9>5KZ??<^E[R.*^M9;>9%DAE4HZ,,AE(P0:^*/B3X)G\"^*;JQ:-A9LQ
M>UE;H\9/'/J.A^E?9GG';UXKCOB7X)M_'_A][&1EBNXSYEM.1]Q_0^QZ'_ZU
M>KG&"^O4;Q^..W^1Y&0YB\MKVG\$M_+S^1\=T5>US0[WP[JD^GW\+074+893
M^A![@^M4:_+Y1<6XR5FC]EC)3BI1=TPHHHJ2@HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ I8RJR*6&Y0>1ZBDKK_A-X1?QMX^TG3 FZ R
MB6<XR!&O+9_E^-7"+G)16[.?$UX86C.O4=HQ3;^1]D:E:WY^ 7V?P3IL5O<W
M]E'&ENP$11'7]X?=L>O7-?.G@C]E?Q-XAN,ZOC1[93RI^>5OH!P/QKZJ\=?$
MC2/A)X3_ +0U1&=&/E6MG%C=*P'"CT '?M7R%\0OVEO%_CII8(;K^Q-,8\6M
MB=K$>C/U/Z5]!C*>&HM>T;<NR/PWA6IGF+IUE@(QA3G)OVDM7Z+^:WI:]]3V
MN\\5>#/V8_#MS9Z-+'J'B21?D@C<.^\C >5AT ]/:OD&]O)=0O)[J=M\TSM(
M[>K$Y)_.HF9I&+,2S,<EB<DFDKQ*U;VMDE9+H?K.4Y/#+.>I*;J59_%)[NVR
M\DC0T/0+_P 1WGV73[=KB;&X@=%'J3VI-;T&_P##M^UGJ-NUM<* VUNX/0CU
M%>B_L\R[O%-_:D?ZZU)_[Y(/]:V?VG-)%GJ'AZZ[RVK(W_ 7./T-?/2QTHX]
M81K1K]+GU7LDZ7M.IXE1117LG,%%%;WA/P'K_CG4(K+0]*N=0GD.!Y49*CW+
M= *F4E%7D[(F4E%7D[(K^%/#.I>+]?L]*TFW>XO;B0*BJ,[?5CZ =<U^K'@'
M09-'TFU2?!F6-58CU  ->9?LU_LTVWP7\.3ZSXEN;6'5;A09[B5@J0)U"!C^
MOK7M6D^(]"UI=VDZG;:A$#MWV\@89_"O.AB(8QM47=(_$.,,V>*J*E3C^[AU
M[MF]&=RCUK\A?C!*LWQ4\6R)PK:G<$?]_#7[!V]O\J$<@D5^0[^%]0^)7Q.U
M:WT^)F^T7\KR2XRL:ESDDUO&I&FI.3LD;>'\?W^(J=+1_-_Y'H?[*?PS?Q)X
MC.N7$6ZVMSY<.X=6[L/H./Q-=G^V-\5&TV2W\!:-<>6L2++J<D38)8CY8L^@
M')^H':O6]';1OV=?A)<:K<*JBSAV6T+?>N+@CY5]\GD^P-? >O:Y>>)=:OM5
MOYFGO;R9IYI&/+,QR:^;P,GFF-EBI?PX:1]?^!^9^KQI^WK^UELMCUO]E[XM
M-\/?&D=A=S%-+U!PIR>(Y>BG\>A_"OMSX]?!^T_:,^%NRT6,>)=.0W&FS'@L
MV/FB)]' _ X/K7Y<@E2"#@BOO_\ 8T^.3>)M%72-0GW:G8 (Y<\RQ_PO_0^X
M]ZC/<-4HN./P^DH[_P!?@SEQ^'<9K%4MT? ]_8W&EWT]G=PO;W5N[12Q2##(
MP.""/4&H*^V_V]O@"JE/B=X>M<V\V(]8CA7HYX6?'O\ =;WP>]?$E?0Y?CJ>
M88>->'S79]4>KAZRQ%-304445Z1TA7M7[,?@6R\3:]?ZK?Q+<)IH3R89!E3(
MQ/S$>P7]?:O%:^A/V1]XN/%#!CL5+?*>I)DY_3]:[<$D\1%21\KQ15J4<GKS
MI2L[)7]9)/\ !GL'Q<\;+\/?!%YJ494WSD06H89!E;.#^ !;\*^)=4U2[UJ^
MFO;ZXDNKJ9BSRR'))KZ&_:TU1UT_PYIX'RR/-<,?H%4?S;\Z^;ZZ<RK.I5Y+
MZ(\;@G 4\/ERQ-O?J-Z^2=DO32X4445Y)^AA7MO[,=FK:CKUVRG?'%%&K8X^
M8L3S_P !%>-:?83ZI?06=K&9;B=Q'&B]2Q.!7U_\-?!$?@GPS!IRE9+ASYMQ
M,!]YS_0< ?2O:RFA*I753I$^-XHQM/#X)T&_>G^2=V_T-N&S:3SI#][M^%=%
MX=5[B58%.)",H??TKR;XT_$4>"=/M-+L)?\ B<7CJS!3S%"&Y)]"V,#VS7M7
M@*S-YK$+@?NXQR?QKZU3A.HZ4=U:_P S\8S.E4HX&.)JJT97Y?E;\-2E\4/A
M?IWQ*^'>HG76CTN33(Y);?4YN/L[J,D$]U.,$?ES7Y[U] _MB>(M1C^*%]I,
M.I7(TJ6WAF>S65O*+[<9VYQT53^M?/U?(YK4C+$."C9QT;[GZIP/E^(P66JK
M5J\T:MI1C;2%UJOF]^GWL****\8_10HHHH **** "BBB@ HHHH *_53_ ((?
M>-/^2I^$9#_SY:K ,_\ 72*7C_OU7Y5U]O\ _!'WQ=)X?_:\BTL2;8M=T2\L
MV3LQ0+< _4>2?S- '[DT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!R7C)TGNH(6/\ JU+8]S_^JN;^SPKSQ6AXD26ZUJY8'Y00H_ 8K$DM
M9PW6LW<ZHVLD7E\E1CBG(L6[C%8[6=QZT^&UG#?,3BIU[%,Z2 JJCFFS,/K5
M&WMW"]33FMW'.36J,63K$K<BHYH!CIWJ)6*\%C2R$E>&-(H3R57MS2B-6[55
MED=1]ZDAN)%/3-(":>S$BD$5G26>QLYQ6G)>>HJE-?1YP5R:RG&YK!V)8V2-
M1\U+]JC;C=5">Z5^BXJC)-M/0_G4>\B]&S:8Q]<@U'N#9P16%+>,O]ZFV]Z6
M;DGZ5-Y%)1-QH6D[\5+%!BJ"W&Y?XJ!=-D<D4TY(3L:9 7MBJEU)M'%1+<,Y
MY:GLH?J?UJN:0K(I;2[<BGX6%<FGR )T-49%:1CR:M$FA#= ?2K<=QNZ5C1J
MXZ'\ZU+//&:I,B1>CD.VFR-GFG?*%JM))Z51*$DDJG.Q)XXI\NYNAJ)5+-ST
MJ2T-C9MPQFM.W^903UJ.&V&,]*M*BQKUJEH2Q?NG-30L'."U5R=W:FJI63-5
M<DOMIZR+SUIBV7E_2GQW!Q@FG^9NIB&M"JU&S*O05)R]-:/"Y(J;#3())"3Q
M63X@NA'I\V[^Z?Y5L,R=.AK,UZR2ZT^5>Y4@?E4,TCN?G;XR);Q#J#=OM3G(
M[\U2L&,;/SCO5_QY#]E\1ZC#WCNG'7KS6+9S8<Y';&:\DZ4=%H<V-07INSZU
M[7I%QNM!DY.*\)T6?_3EXY!^F17M>A,'LQ@C&*VB9G0?#VZVZY,,\YKZ/\+W
M"_9SSSBOF+P>PAUZ0YY-?0?A)II58*C]/0UU4O(SJ6.JN-0"MCD\U1U2.#4[
M"X@NX%FMI8VCDB<<,I&"#[59CLVCDW2C QGFLO49I;Z3R(%SZD\ 5V1A?<Y9
M3ML?D;^V5\ X_@3\1TU+2K"9_"&J.SV?G2%Q%+P7@+=<#.1D\COQ7@4D8O+2
MZY&],,B \\DY_G7[E_$'X2^'OB3X+U#PSX@M1>V-\FV5APZ'^\C?PL.Q%?FO
M\<O^"=_CCP+</?>#Y$\4:6I=@L9$5RB9R-R$@,<9SM/;IVJVD1J?)MB6G9'<
MD^6Z[V;L,XY_+]*Z'7-:AN%L(;8A1;+B3<.K9))/KS_2J2^#_$UO?7NE?V'?
M?:B%\^V\IMZ8.03Z8(/7WK&U;3]4L;B3[?;30R#EO,7;T_KQ4N*;!2E%;%Q-
M8.GM-A@TS$'<><U!_:4DY*"1B2N!M[^WZUI^$/AO?^,HS+:W5M$!P/-8Y8^P
M _G7MOPY^!.DZ-"USJER;S4VX$:CY(U(P2/4GU[5RU*]*EZG32PU:K9VLCP/
M2O"&K^(KB,6UA</#(P43;#MY.!S^=?1'@?X*Z3X;CM[BZC-[>A_F:105''0?
MGT]J]DM]+LK&QBBM((X+? VQQ_P #&1GOCBH+FQ@521&Q5^<%C^/%>-6QLZN
MBT1[=# PI.\M68=Y:1^4'#;1'CY<\9^G%<_JNK!(S&J*KYY[$G\/\\59UVY-
MG%-M()/0 \ #CD]JX"ZOIHVVM(I<CEEY ]OIUKFIQYCT92Y4:D4&H^*]=L]&
MTR/[1J%ZXA0)V)//T ')^E?H-\#_ (4V/PO\'VFEV@$D^!)<W!'S2RD<L?;L
M!V KQK]DGX,/HFG_ /"3ZI;E=2OES C]883T.#T+<'Z8KZPL;<1Q@?RKZ3"4
M%"/,SQ\15<G9%R!=O"\8J21S@]O:EB7;FHKB4 8[FO1//*DKA5.>/QK+T=AJ
M'BZTA(R(5:8Y]A@'\S5B\DVJ2:J_#0&\\5:Q<XW1PQI"I^I)/\A0]ARTBV>K
M6_:K4:_-S56+Y<59W?+[UB<)95:7BJRR4XS<4")FD"BH6FW-C-1[RWTIRCIB
M@0]E,D;*W3UIEN@52,5-'TZU$LFQRN<8XH$.:,JV8^_5>QI-R=#F,U+N].E)
MLW<XH YCQQ\._#'Q,T6;2?$^CV&OZ=*,-;WT(D ]QGE3[C!KY@US_@F[X$MI
MKJ3PAJ^H>&5GS_H<Q^UP)G^[N(<#VW&OL)H5;C I/+:/^%9/<\&DTI*S&M-4
M?F[-_P $Z/B!X/UE[[2]3T?Q%:Y)\N-VMYL?[KC:3_P*OE[XC>#M:\!_%"6P
MUC3KK2=2A9)/*N$*-C/#J>X]",CBOW 59')+;4 _NC/\Z\]^,7P+\)?'#1XK
M'Q1I_G26Y+6NHVI$=S:D]=C8/![J00?2L726Z*YM+'K'PO\ %2^./AQX9U]7
MWG4=.@N')Z[V0%A^#9%=17G_ ,"?!4GPY^&>F>&7U#^U(]-:6*&Z*;&:,R,Z
MAAV(#8_"O0*KU **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KPW
MQEJGV_Q-?R!MRK)Y:_1>/Z5[7>W(L[.>X;[L4;2'\!FOFB6^,TCNQRS$L?J:
MB4N4Z:-/VES0\\>M,><>M9K70]:C:[]ZS]H=7U<TS<#UH$X]:R/MGO2B[I^T
M']7-I;@>M.\\>M9"W73FG?:O>CV@?5S5\\>M)YX]:R_M7O1]J]Z/:!]7)-8N
M@MJW/:O@K]HK0['QEX^N([N%Y?)CP-O.*^VO$E]Y=D_../6OE]OA1XG^('B;
M5]1TL9BW[0<5]3PY[.IC/WNUNI\WG]*I3PT?9;W/EN'X5Z']COE-O*UTH/EJ
M%KPO7M)GT;4I89HFB(/"L*_1^W_9D\;V%T9]@=F'.5SBOG_XQ_LD_$/4M8-Y
M%I,UR6SGRTX%?;9KA*$J"E0M==CYC+L17C6<:U^5]^Y\J1,,C-?3'[._Q#\)
M>"8XKB724O\ 6U/R&8@J#V(%<'-^RK\2+?KX:OC_ +L)-00_ #XBZ3,LJ^&M
M45E.05MG_P *^>P52IA*G.X7^1[F*A#$T^53LS[.\1?$36OB-#975VRPV4!#
MQVUN,#=ZD5]6>'O%4_C[X5Q66DP@WFQ;:XB;&4!&"?RK\[?AWK'C?28TL-;\
M.ZFL0X$_V23Y?J,5];?L_:YJFDZ]!&T,T=CJ \AI"I7#G[IP1QS7WU;ZMC<*
MJM#XJ>MG_D? 4OK6%Q4J&)^&II='3_";X':I\/?B NH:Q;K?6K%F20X*0CU^
MHIW[3GQCM+O1AIGA\>;<V]PDK7B\*I4YPI[GWK?^,'C.]TVS_P"$?MY'+L,7
M,N2<]]@]O6O![S3#>QD2*T@ZA6'&*UP>!ECY1QV*>J7NI;>K./&9G'+O]CPR
MV>K?Y'J.N^'/"_[7/PMAT+5YX;'Q;:PAX9< R(^/OKZJW<"OSQ^,'[.?C+X)
MZNT&OZ5*MEO(BOX5+02CU#=C['FOI;POX1N_"_B0:I%J$R3JP:/YR-O<#-?2
M>E_&@:KH\FE>+M*M];LI$V2;D!W#IRI&#7F8W)*R]ZG&\>U]5Z=&O(]W!<08
M>ZC.5G^'_ /R=\07NFWFI!]*L'TZT6*-/)DE,C%@H#.2?[QR<=LU;U#[5?:3
M9ZA,;=8E_P!#C6,JLA"#.YE')'S8W'KT[5];_$[]F7P)KVM7%WX76[TF&8EU
MM\Y5?90>U>:W'[*Y@N ?[99+;."&BRX_7%>3/(\;K)1NG\OO1ZD.(,NDTG.S
M7=-_<SP..NE\-^#-9\29>QL998$(#W&TB-,^K=*^@M)^#/A?PW")C%]K:%,R
M3W2EOJ=O05!K/Q?LO!5G#::/I=YJB0SJ[0W,+Q69P,JI& 6Z]..*/[&CAH\^
M+J)+LMP_MJ>*ER8*DY>;T7]?,^G/V<_A1X(_9O\ A+;?$#Q/?6MGKU_$7.I7
MH^:",YQ';H>2S =1R<^E>1?%3]MS1_B!+>:.?#TDOA96;RK:9@3<L/NR2C/!
M)))'...]?-7Q*^*/C'XL:P;[Q%<W%P8?DAM5C*0VRYP$1 ,*!TKFM(L1>:I:
MVUPYMHI)5225AC8I(!//H*\?VG)/]VOZ_K^D>S]7YX\U9_<>X_\ "R/A5)).
MP\#R!9G678&7Y'"$$*>R9P=O<YYQQ7)_&)-'M].\,#2O#-YH(>S5FN+OC[9\
MB_O%7/<MG=WR.E='=?"KX?:?<O+_ ,)L7M%8[%C:.20A4=FS@>JJHXY+<9'-
M<=\;M?;5?$=E:IK\WB*SL;1(8;J;;E3T91@#@;0!ZXSWK/,G..&G[1)-VVMW
M,L*J;K1]FY-:[W_4X2-JLQM3M#T/4?$%U]FTRRGO[@*7,5O&7;:.IP.W3\ZG
MTO1]0U:XD@LK*XO)HU+O';Q,[*HZD@#@"OBK,^A"-JZ#P_X<NM;668-':6$&
M//OKD[88O8GJ6]%4$GTJCH"Z?"TEWJD%S<6\6 D,'RK+(>BM)_ , G@$G'&.
MHL:QXDN]>:%9=D%I ,6]G;KLAA'HJ^OJQR3W)IJV[$>[_#.WT;Q#\./%'AS1
MXY9)MV\W-QQ+<,4PI"CA%R,8Y/J>U>%LCPR-'(I1U)5E/4$<$5U7P:\</X'\
M:VERSA;2X/V>XW=-C'[WX'!_.NJ_:*\%CPWXR75+8;K#6$^TJRC"B3^,?CPW
M_ C5/WE<\>G)X?&RI2VGJO5;K]3S*-JZSP?>0WJ7&@7LBQ6FH%3#-(<+;W(X
MCD)[*<E&]FS_  BN/C:NL\(>%8M?CGN;R^_LZQBEAMC,(C*QEE)"*%!'&%9B
M<\!>Y(%3&]]#V'L9T]M-8W4MM<1M#/"YCDC<8*L#@@^X-202M$ZNC%64Y# X
M(-=-;^%KWQ#K6LOJ^H"!M-E2UN;A86F=Y-WE( J\MRIRQ].Y-3:Y\.9_#>CR
MWM]?1HZW$UND4<,CK(T4AC/[P#:,E6P"<X%5RR6J%=;'2^!_&$VI?Z/.1]IB
M&X./^6B^_O7I6GZJ)  3S7SCI.H2:9?0W,1^:-LX]1W'Y5[1I.H1WUO%<V[[
MD<9'^!K],X?S6=6FZ<Y7E'\4?(YG@XPESQ6C/0K6\'<U:O;T_P!GW C^9S&P
M4#J3BN/M]0:/KTJVNJ<<-7VCQ%.:U/G_ &4D]"\VJV_]EIG[0EU)I\>F/#Y!
M*Q*) 7DS_%D#A1SEC^-#3YA8:/-!%%,]Q>2[9Y/+(VP*00H]V/)_W5'K5RQG
M:X?/:NAMV\M*\6&5PDN939WRQDHZ.)+K>J0ZI=6MO" S?;?.!C@:-A&%"KYQ
M8?-( .OUYYK7FN 8^M/M;E=;A2!R/[0C7;$Y_P"6RCHA_P!H=CWZ>E9%[>>3
M&V[@CKFNO#898>+BWL<U:HZTE(I:A?\ DJPSS7G6F>)KC_A*Y(U<M$TI">Q%
M:7BGQ +6&1@<N1A1[U2^&'@YM<NGU*XF:"W@.0P&=Q[]:^7S'%U<1C*5##O5
M.[]#VL/2A0P\ZM;9JWS.R^)-NEYX1\YQ\\;*ZGZ\'^=>+K7M7Q'NK7_A#Y8[
M>7S5W*NX_6O$U-?/\2\KQ<6NL5^;/2R9OZN[]_\ (F6G4Q33Z^2/>"N4OCYW
MC.T7KL0FNKKD[9?/\;2-_P \X\5UX57JHY,4[4F?5_[.-D?[/O;AA]Y\9^E?
M/W[4A.L?&"WM(V&4@/X9/_UJ^E/@9&;'P>\N,!LL*^-?C%X@DUGXM:U=*V#"
M1$I!],UW57[TFSAH+W::7FSFM6TX:9=>4)5FXSN2J5/EF>:0N[%F/4FF5Y[W
MT/66VH5M>#M=/AOQ+I^HXW+!*&9?5>C#\LUBT4)V=P.[^+'AB/2-6BU&T?SM
M/U!?-BE4?+SSQ^!!_$UPE>M^"YE^(WP_U#PO<'.IZ9&;O3Y&.,H#RA^A;\F]
MJ\F93&S*PPRG!![5I47VELR8]F-K[B_99_:"A^(D-AX(\3DMKMNA^R7;=+M$
M7HQ_YZ!1^(&>N:^':U?"OB2]\&^)-,US3G\N^T^X2XB/J5/0^Q&0?8FG2JNE
M*Z%.*DK,_6*ZTF*/.U0 /:N4OO+M)'WG"]JO>$?B%I_C[P?IVO:=(&M;R(.%
MS\R-T9&]U.0?I7*^--25(9,'!Q7T2E[MSSK:V,#Q)K";7PU7/#%NK6/FOU89
MKSI;BXU2]*[69%/)KT#2Y&2R"K\NT5E&7,[EM61?;5OL;8/W0:Y;Q!XTT_3[
MZUNM2GDAL8Y0\IA7<^T<D 9[]/QI=>U1(;61V;H,U\Q_&#XA;[6:VA?][)E%
M /3/&:SK5>2)4(\S/K+X5_$3PW\7O"VIII%M(--MKRXL&CNH]KRQ.N\%ADY^
M\R]>@]Z_-WQ+IJZ/XAU2P3[EK=RPK]%<@?H*^U_V2;"3P;\+]274EAMY[F\>
M\7$H:0+Y2A591]T\$\U\2Z]>?VAK6HW6=WGW,DH/KER:XL4I*G!5%:1O35I2
ML9C5%4S5$:\TZ")J[?X!>$K#QM\2M/TS5&*V,BS22E7V$8! .?J17$MQ4%G-
M):K!+#(\,R899(V*LIZY!'0U=.2C-2:O8SDFXM(_;?\ 9OCMM/\ A;I^D6U\
M]\NF,]OF20R-&I.Y4+'K@-@>PQVKU&O@+_@F/\5-:\3:]XW\/ZWJDVI%;2VO
M+;[0V60(S(^/KYD>3UXK[]K.LXRJ-Q6C+IIJ*3"BBBL#0**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***1FVJ2>@H
M \I\=.UU->HK8$CD%O\ 9''\J\6\5WD6FQ^3"-I]NPKUGQUJ"6D3G^)N?Q/:
MN7\,?#@ZW?QWVI#,8;>(C^F:^6J4IXJKRP/HJ52&'I<TS2^#'@-F5-7O(\;A
M^Z1AT'K]37M.X*-HZ=*YZ;6[;1K58(5^Z, "IM-U&6\PQ&!UKZJC05"FH1Z'
MS]:LZTW-FQ(PC4L:PKC5!)<,H/%6-8O_ "X"H.&(KE[>0B8LQ[UTQCU.=R,S
MQ9\\A:N19N:ZKQ)('%<IM);I6O0R+]JV0*OJORU2LXSQ6D%VK2 IR1D]:S;K
M"=ZTKR<*, UB7,F_/>@"M-)NS5<?-4C*6IH4BF!&S,O0U8M-0>%AFF;=U.6#
M<: .FT[4$N  3S6O'#NZ=*XRU1X6!6NHTF_WL%8X^M $DRM;2!NV:FU7_2M)
M+KU K0N[-;BW)')Q67;2;898'_"J0'"^)M+3Q1X==&&9$&/H17B%QIIMVDC9
M<.F5-?1FF6X2^N8#]UB2!7F'Q T(:?K#N!A)1G\:\O&T[^\CVLOK6O39XOJU
MAN+<5@_V/)<D*%)Y["O2'TDW4Q1%W,376^'O \%GMFG4,_7&*\R,>K/3J5U!
M:GE^A_">^UC;E?(C/5CUKL;'X"Z1;J&N"TTG?O7IL86) J#:!V%2!LU9Y4L1
M-O0\Z;X-Z-'_ *I)$/L:K7WP<AFC(MYOF[;Q7J*_2GKCZ46''$U%U/G77/A7
MJVG;BD!E3U6N/NO ^M2,0EA,3Z[:^O.#V'Y4BPQ_W%_*@W6-EU1\@MI-Q80^
M7<Q-%(.H85V_PMTN[O-45DC;RA_%CBO<M4\'Z5K#AKBU1F]<"M#2]'L]'B\N
MUA6(>PI<MS5XY<ONK42#31'&JMR>^:F&GKZ5;#4X-5V/+=6=[W*HT]>RTO\
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MMEVK"L^U;]CU% &[9]JTUZ5F6?:M-?NT 0SU1?K5Z:J,E #!111UH *,444
M-D_U;?2NT^ O^LU/ZC^=<7(?W;?2NV^ JG_B9-_M"@#V#-&>:2B@#.UHC9&?
M>N[TUMUC;G_8'\JX/6O]3'_O5W>E_P#(/M_]P?RH M4444 %%%% !1110 44
M44 %%%% !1110 56U&,RV%PJJ'8QMM4]SCC]:LT4 <AH\GEZE ?4[?S&*Z^N
M(C#6=PH8Y>)\$^X-=O41-JG1A1115F(4444 %%%% !1110 4444 %%%% !11
M10 4444 ?SL_\% /$7_"3_ME?%>\W[_*UAK+.>GV>-(,?AY5?/M=7\6_$/\
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M)(V@6O\ 2OSJNIOM.J:E-_STNI"/^^C6U9_$_,B@K."\O\AM%%%<1Z 4444
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M><XK4W4R0>7(R'JIQ3=U?//L=LI.3NR<-3U:JZM4BMZU))84T\-4*M3U;\Z
M)E:G9J,-2J: )13LU%NI0:8B4-3MU1;C2AJH1+NHWU#NJ6TM9]0F6&WC,LK=
M%6GOL(P/$5YY<+<XKRC4_A_XE^(EP\.DV9$&?GN[@^7"GN6/]*]]OM+TKP_<
MK'>0G7-6ZBSB.(8O^NC?TK!UR\N]7;R]4O-ELIS%I]J/+@3V('WOQKMIX=[R
M.><[Z(\%M?V8? NCWXN/$5[>>--30Y:STW]W:(1V:3O^==5:::WAN$CP]H7A
M_P ,Q1G 6.V\Z7;VRQQ797%[#I\+(B#"C@ ?I7$ZUKP2-LC/&=^.WKFNVRBM
M#&,2"Y\1>,8':9?$%OM8#*&T7"_@#5*35/%<T)2;5[1V<XS]C'/_ (]6-?\
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M(V>2=&W&:1WR&]!@G&/I5<UEL0Z<XMW+,?Q#G\,V]KX>FN+F^L=0C^T2SV^
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MSCRIU?\ )@:_28'/(Y%5+<X:WQ"T445)@%%%% !1110 4444 %%%% !1110
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ME<MK$;+J]V3T9E(^FQ1_2NDTD[M-M_\ =K..[-I?"BY1116AB%%%% !1110
M4444 %%%% !1110 4444 %8GCC5?[#\%^(-2SM^QZ?<7&?39&S?TK;KS']J#
M6!X?_9M^*NHDX-MX6U-UQ_>^RR;?UQ0!_-+1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %=W\"]+76/BUX;@<95;@S_C&C2#]5%<)7I?[-__ "67
M0!NVY^T?^B)*Z\&E+$TT_P"9?F>5FTG3R[$2CNH2_P#26?=FY;>SD9CM ')-
M<5/(M]%%=Q\Q3(LB_0C(J?XM7USI?PQ\27-N^V9+"7:PZC*D9_6LOX1ZC%XJ
M^&V@7F=SM9)$Y_VXQL;]5-?IU>JI550ZVO\ C8_FFC0E'"/&=.;E_"Y\)ZI>
M2:CJ5W=R_P"MGF>5_P#>9B3_ #JM71_$;03X9\>:[II&%@NY-@_V"=R_^.D5
MSE?E-2+C-QENC^I,/4A5HPJ4_A:37HT%?3^BQGQY^S_ C_O;F&TDM>>?FC)"
M?H$KY@KZ>_9E+W'PWU>%AF-;]ROXQID?H/SKV,I?-6E3>TDT?*<4_N\)3Q,=
MX3B_T/F&ECD:*171BCJ<JRG!!'<5-?1K#?7$:?=21E&/0$U!7B[,^Q3YE<^C
M?@[\>AJ$EKHGB)PMTV(X;X\+(>P?T/O7T)#AU%?G=7M'PI_:(O/"WE:=X@,F
MH:8HVI<#YIH1_P"S#]:^WRG/>2U'%O3I+_/_ #/S;/.&74OB, M>L?\ +_+[
MCW3XH?"73OB;8PI/(UG>VY)ANHU!(!ZJ?45\S>,/@3XK\(M-+]B.HV2'BXM/
MGX]2O45]8>&_BAX5\5;5T[6;:29A_J9&V/\ D:[*.W4KDCGUKV\9EF$S+]]!
MZ]T_S/D,'GV89':A./NK[,DU]W7]#\Y&TJ]5@IL[@-Z&)L_RKK?#OP7\8^)E
M22UT::*%^DUS^Z7]:^[&T>VD8,8X]PYR5!-3BS3/WMQKR*?#<$_WE1M>2M_F
M>M7X[K.-J-%)^;;_ ,CY%TW]DWQ-=%?M6H6%F._S-(?T%=OH?[(VD6Y5M4U6
MZO3WC@41K^?)KZ N+JRT_FYN(;<?]-I%3^9K O?C%X*TJZCM9=>L?M+N$$:2
M;CDG';BNY93E^'UFE\V>#4XESS&^[1;_ .W8_K9LQ_#OP,\):#L-KH5N\B_\
MM;D&1OUX_2NYM=%ALXPD,<4"CHL:!0/P%<EX\^-6B_#](6U*.[(FSL:" LI/
MH6Z UX[KW[9!\PKH^@;EZ>9>S8/UPM;SQ>!P/N72?9+_ "//HY9G.<I55&4T
M^LGI^+/I@6:]6D_6H9(5#X5J^0KC]KCQ?(Q\JUTZ(>GE%OYFEM/VMO%<+9N+
M'3[@>@C*?R-<O]NX.]KO[CT/]2\WM>T?_ CZZN-/BNE E2.8>DBAA^M9%]\/
M?#^JC_2]%T^;ZVZ@_F!7SG#^V/JJ@;_#EDQ]1.XK3M_VRAY?[_PW^\_Z9W''
MZBF\VP%3XI?>G_D8?ZK9[1UIT[>DE_F>P3?!#P-/)E_#%@3ZA6'\C5_3_A#X
M0TWYK?P[I\9_ZY;OYYKYVUC]L+Q!<.PTW2+&R3^$REI3^/2N;G_:F\?S9Q?V
ML7_7.V45Y\LRRZ#]V-_2*.^/"_$E>-IUN5=G4?Z71]CP^"]!BY71M.!_Z](_
M\*M)H5A#@16-K$/]B!1_(5\2P_M,_$&&X$O]LB0?\\WA4K^6*2__ &F/B#?#
M UK[+_U[PJO]*G^V,)TB_N7^9@^!<ZE*TJT;?XI?Y'W1';K$NU!M'HO%$D+[
M?XL?C7P!<?'7Q]=J5E\4WY7T# ?R%9K?%+Q>S;SXBU$GU\]JREG='I!_@7'P
MZQTM9UX+[W^B/T*\GY2#R:C^QCOQ7PWIO[1OC_3+;R%UUYU'1KB-78?CBMS0
M?VKO&FF7:-?O;:K;9^>*6(*Q'LPZ5<<XPSM=-'+4X!S:FFX2A*WF]?O1]+?$
MWQI>>$='9=+M//U&08B>2-FC4^IQUKY;\80_$GQA))-?WEQ>*_6VMY"BK[;!
MBOJKP3\1-*^)GAP:GI3*TB<3VDOWX6]"/3T-9=QXLM$:X$FD+(\9S^[(4M^=
M:XJC'%)2]I[KVML<V3XZIDTI4OJB=6+U<MU]^WR?F?#FI:/?:/-Y5]:36LGI
M*A%4Z^W=2_X1CQ7IF;NS4(1S#>Q@%3_GTKBF^%_A?PU:WNN)I'VRVA4R%4!D
M('HJUX-3+&G>$TT?I>&XQISCRUZ$E/:RV;^?_!/E=6*L"#@CD$5W7@WXU^+O
M!,T9L]5EGME/-M=$R(1Z<\BO9O"\/@7XS6]]IEII(M;N&/(!C6.09X#J1UP>
MHKG=4_8\\167AO5M9AU>RGCT^)IFA9&1F51DX)XSBN;ZO6I6G0E==T=53/<K
MQ3EA,VI^SEHN6:O>^UG_ ,,>G>"OVPM U&WBBUI)M+N3PVY/,BSZAAR!]:]D
MT_4_"'Q6T':'L-;L'&&1P) ,_JOZ5^9];?A/QIK7@?41?:+?RV,_1MA^5QZ,
M.A%=M'-JB]VLKH^=S/P\PE2];+:CIU%JM;K[]UZZGU-\5/V,[.\2;4/!ER+.
M<_,--N&S$WLC_P /T-?*WBGP?K/@K4GL-;TZ?3KE?X9DP&]P>A'TKZ[^$/[5
M^D^(!;Z;K[?V5J+ +YC_ .HD;V/\.?0U[5XJ\&^'OBEH9T[6+6*]MI%S&XQN
M0_WHW'0UT3P>'QD?:8=V?X?\ ^=PO%.<\,UE@\[IN</YOM6[I[2^>OF?F%17
MH'QJ^$>H?"'Q=-ITX>;3I<R65X5P)8_3_>'0BO/Z^;G"5.3A):H_=,)BJ..H
M0Q.'ES0DKIC[>XDM9XYH7:*6-@Z.IP5(Y!%>S?#7XK^*?%WC[0H-:UBXOK:U
M5A'&Y 4<?>('4\#DUXM77_"WS4\51S1$J8HV.[\J\[&8>GB*<N:*;L[.VUSV
M<#3=;$TZ:ZM'ZJ?#_P 5G^S(D5NB@5\$_MY6-TOQR?4IT(BO[&!HF[$(NP_J
MM>\_!/QQ--JMO8W4N-Y"J2>M>@?M0_ &/XR> 2MB%'B/30T]DW]_CYHC[-@?
M0@5^*X'V?#6=1EB-(S35^R?7[TKGU.<9?]67LNNZ\S\N:*FO+.?3KR:UN8F@
MN(7,<D;C#*P.""/K4-?NZ::NCX@****8#X)I+::.:)VCEC8.CJ<%2#D$5^FO
M[(GQXC^(7A.WCNY5&J6@$%Y'GJ<<.!Z,.?KD=J_,>NZ^#/Q0N_A/XXL]9@+-
M:$^5=P*?]9$3S^(ZCZ>]?.9[E:S3"."7OK5?Y?,PJTU4C8^B?V^_V>SX5\1?
M\+#T.W_XDVK2 :@D8X@N3T?V5_\ T('U%?'BJ68 #)/  K]C]#N=!^-7PXGT
MF^\O4='U:TV<'.Y&&00>Q!P0>Q KXN^'_P"RW<?#/XG:Z_B.);FWTR;9IDCC
M*7"D!A-CV4@8[-N]*\3A+-98N+RW$/\ >4]K]8_YK;[O,\O&9A#+<)*O6UY=
MEW?1'@GAOX!^-?$T$4\.DM:V\F"LEXPB!'K@\U]2?"7X0V?POT-XU<76IW(!
MNKK& <=%7T4<UW3:W92+=?9Y4N9;8[9(XV!96QD*?0D$?G7RC\5OVF-8\36]
MSHVE6;Z#:L3%.S-FX;L5R/N_A7ZA3=*@^9ZL_,IXK..*G]6A%0IW5_3I?J_D
M4OVEOB/;>+?$5MH^FRB;3]*W!IE.5DF;&['J  !^=>,T45PU)NI)R9^L9?@:
M678:&%I;1_'N_FPHHI54LP ZDXK,] ^T/AO:-H?@_P /6[<-':QEQ[D9/ZFO
M*OVO-?2^\5:)I4?*V5F9BW^U*W3\D7\Z]RCA$/E1J/E50H_ 5\P_M)2%_BUJ
M*$\1VUJH_P"_"'^M?:9DW2P7LULVE_7W'XKPU%8K.O;RW2G+YMI?^W'3?LQ^
M"K;5+R[UZ9?,GM9/(MU_N,5RS?D<#\:^BOB'\1+?X6^!;K5)SF[93!9Q ?ZR
M<J=N?88)/L*\(_9%CD,WB%Q(P3-NH7MG]YD_RKM/VR-)<?#WP]>J6*1:@8WQ
MTR\;$$_]\'\ZK!U'A\M=6DO>L_SM<Y<XIPQ_%$,%BI7@VE\N6]OF]/F?(DDC
M32/([%W8EF9N22>]-HHKXD_= HHHH **** "BBB@ HHHH **** "BBB@#^HW
MP/JO]N>"_#^I9W?;-/M[C/KOC5OZUMUYC^R_K \0?LV_"K40<FY\+:8[9_O?
M98]WZYKTZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R_$C;=%N1_>
M 7\R*U*P?&DWDZ..<;I5'\S_ $I,J.Z.);2TDY(X^M1MH<1_Y9U82\5?<U*N
MH*PZXJ/=.G4H-IHB'RQ@>U,CT\[LL./2M)[A7'6HO."=Z- U(I+4[.E9=U8R
M;N#C\*V&N5[U5FN$;O2T&KF?;VK+)DY)JYY+=<4J3HW<9JPDR]R*6@V)'E>V
M*<TRG@FG;T]152X==W!IW%8L&95Z4^%T;J:JPX;O5GY0.!1<"1F5ONTBVYZF
MHT<;O:K#7";>#3T)U(9;<]J(+=E/-/69?6G^< *>@>\2%2HX[4SSBO:H9+CW
MQ432!AG-426FF++5&XW[L@4?: IZT_[1N%+H,SYO-ST-595FQQG-:K$&HVQ4
M6+N8ZR2+]Y<5/',R\A:MLH.015BWMPV.!4\KN5S%-;Q^PI_G22CIBKXLU)[5
M.EFH7H*KE?4AR1BM)(*KR22.PW#BMN:W7<>U5YK,!<BGRL.8AM4&WFG2N$R,
MU49S$S &J[L\C'G@TKZ#2+ZS#O4JS#/%4%4Q]ZM0C=@]*5QE^*4L.!5B-SWX
MJI'(B#EA3Q<*> :M&;-6%E-2N5VYK'65U^[S39KB8K@+57)L:,MTB]*IW%DV
MJ1;.?*;[S"J]I:W%U<*&.%SS73,J0QK&@P!3C=[DR?*4K.QBTVSCM[>,1Q(.
M%'%3JN<;CBEW;NM17,FT@"M3 BOI@,JO2LE06D1O]JKEVV5-4TX91[U8C93"
M?.>156ZF+Y)X]JF9OD%9]Q(3NJ2D1,0S9]ZDC&<8J*)2V:M*NQ23Q0,JWK?*
M0*X;Q?;;M/E*C/K7:W&64G-<QKF)(7B'0\$TT5'<^ =6TZ]TG]L M!NB;4=*
MG@21>O*E1^I%;&L:XGQ/\([1A;VV=K2]5<9BN$.&&/?[P]0?8UZ5\8/"T/AW
MXO\ A7QE(52VLX+I)G;@?ZO<OZK7Q;X%^(]UX=\>^*M=M8VN[/4[PYM')$4J
M;SEO9@!P?<TI1YD>A3J>S:\RYX^^']R]C/"8&>%AC?UY]:^?IK*[\/ZD89@4
MD4Y'N/6OO2QUSP_X\L1_8]_$;I_]98W&U9T/IM)^8>Z_E7AOCSX3R:]=74*V
M<MO=PG*2;> 23Q[BN76.C.FM357WXO5'#>&_$'VJ%0Y'3!S74VT;WTD<4 WN
M[85>Y).,#ZUY"UK>>&]2DM+I6AFB/(['W'M7O/[-?A+5_&WC?3+Q;*:30["X
M6:ZOMN(TV_,%)/!)..!SS7'*E>5D.G4;5GN?7G@7P:OPX\!PZ:GR7#GS;RXZ
M%Y2.0.^!]T5Q/B:W2V$LD.Y7=2ID!YZ8(Q^5>@^(-8:_D\L-\D?.!TS7*W5F
M+M3E<\8&3Q7K1BHJR+W/(]2A2..9E7RPV2Q/)8XKSJZM_.DD?:WH,].N*]6\
M9+YDOD1#.>3UZ5QMY8;50+C/ 'J.>E#,V>G?LC_&23P#XI'A[4IL:-J<NV)I
M&XBE/ ^@/'XX]:^[+Q@8MRG*D94^HQG-?E3KUBUBJM&2CI\R.O9A7W-^R3\8
ME^,GA=-%OV8ZSI*JMT^/OQYP'S[]/K5IG+.RU9[SX3T?'F:C*N'D&V'V7U_&
MNL\ER 05X]*9Y:I&%4!5& %':I+<J>5;IUJ;G!*7,[EF%LK@CFIT6H1\W(J>
M/I[U)#%VGTIR+3U7.,T[;M/7B@0^-*:PQD$4[/ (IK]":!"1E=P]:?<IOA(_
M$57VG=D5/'(?NL*"D55'2I5!-)Y>UBO;-/.(U.>M RO?7 MX36+9PM>W.6^[
MU-.U2X:XNA$#\J_>K4L;;[/ .SMR:8B4J$7 %-6'<V:F^]UIZX4;CTI"+NBL
M(=0A'][(_2NIKAM/O0VK6P!X\P#\S7<U$AA1114C"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#QG]HJ\^31+4=S+*?\ QT#^M>*'GM7JO[0TV[Q)IL.?
MN6F_\W8?^RUY0:WC2YE<S^LNG[J8AJ-N]*SU&T@Z57L4'UR?<6GK46[-/6G[
M%"^MS[DZCCM2BHU-/H]BA?6Y]QX-.4]:CHWA5)H]BA?6I=SSGXG3&3RX0>9)
M%4#\:^K_ (?6?V#PAIL.,;85_E7R7XE7^U/%FEVP^;=<+Q^-?96C0_9]+M8Q
M_#&!^E>IAZ?LXG#4JNM-MERG+3:6NH@=1114 %%%% !3B-RTVE6@#SOQ9&?#
M>G:M9NCMI=]#(T+KDF&;:2%_$@$>]=_I[R/96[2_ZUHU+_7 S^M0ZMI<&LZ?
M-:7"YCD7!QU'H1[BL#P[J5QHU\N@ZDY>11_HMRW_ "V0=C[@?Y]>EOVT+K=;
M_P"?^9DO<EY'744#I6#XPU6XT^SM+:S<17NH7*6<,K#(C+ LSX[E45R!W(%<
MJ5W8V>USH:*C@4QQ(A9G*@#<W4^Y]ZDI#"BBBI8QMQ<+;6\DS_<C4NWT R:_
M"?Q5J9UCQ5K%^S^8UU>33%O7=(QS^M?MC\5-:_X1WX9>+-4_Y\])NI_^^87.
M/TK\-0WS5Y^+>B1U4.I<C:K,;52C:K,;5YQUEV-JLQFJ4;5M>&M&F\1ZY8Z9
M;E5FNYEA5G.%7)QD^PZ_A3WT CC:K,;5MZ[X/CLI=(.CW,NK6VJ!A;$P>7*S
MK(8RNP$]2 1SR&'>M!OAKJ<?B:]T4\36$)GO9C&X2!54%\\9(!.T$#YB1C.1
M5<DNPN9'MO[-S6OQ+^'GBWX:ZA(/-F3[?IK.?]7,.Z_CM)]B:\$U/2[K0]3N
MK"]A:WNK65H98V'*LIP1^=3^ _%=[X)\5Z=J]C*T4]K,K_*<;ES\RGV(R*^J
M_&U[\-?BCXUNM#\5V+^&?$Q1!%K4#!4GW(&0L.AX(^]^=<;YJ<G*UXO\&<#;
MP]24K7C+73HSY*C:K$;5ZEXT_9G\8>%KZ3[!:?\ "0Z=G,5YI^&W+VRF<@_F
M/>O.-0T74-%N6M[^SN+.9>L<\;(WY$5U\LK)M'=&49*Z8U#5B-JJKE>HQ4\;
M5)1;1JL1FJD;58C:@"VIJ>,U6B4M@ 9-;]CX/UN]@$\6F7)A/20QE5/T)ZT#
M2<G9;D^A^%=5\01O)IUE)=JC;6\L D'&>E=+9?"G7.)-16#1K8<M-?S+& /I
MG)_*I?#_ ("N=,_TG5M2_LBW R5BEPY_+@5KSZQX)L%),$^KS=,SS.?QZBH]
MM!;1;?D=GU.K%7J-1]=_N.R^$/A#1+'6EU2QO+G4I+ [FNS'Y5LO'(&>6XS[
M8ZU@^/OBH_BGXB17:/MTZU;R(0#QMS@M^)_D*@T/XQ2+=6VFVFGP6>EL1'Y,
M:YX/!SZYKG_B5X17PIK2&WW?9+E/-B#<[>>5S['^E<M&4HXQ5IJS7PK\R:U*
M,L.XP=UU9ZCXZT-_'WA&*]A_>:GIZ$LJ\F:/U^H_E7A3*8V*MP17H7PO\>7%
MG=164CMTPCJ><8Z?E6A\2? \,D#:WIBCRFYFC7M_M#^M?9XC!?7*3QF&=TMU
MU7?[OR/F*6*^JU%AJ^[V?1GF"FI5J$94X-2*:^9/<$O&VVDK?[)K(^'$7F;3
MCYI+CTY/-7M:E\K2[AO134_PDL_,DTM<9+S GWKU,"O>;/*Q[]Q(^IOB)J)T
M/X0W3AMI6U(X_P!VOSTL<M;ACR6)8_B:^ZOVFKX:7\'+I<[=T6T?E7PQ:KMM
MHQ_LBHJ/W?F;45[[\DB6BBBN8[ HHHH *[SX&"6;XI:+:PS2V[W?G6OF0N59
M=\$BY!'H2#^%<'6[X%\52^!_&&DZ_# MT^GSB;R&;:) ,@J3VR"1FK@[238I
M;,]O\"_$#0_C58IX/^)-I]HU.Q@D:P\11R"*?" DI(^,#@'D@@XY&>3YLWPW
M2Z>62U416O\ :!L(_M,_SALX!8J,$#*@D=STQTQ_ VR^\1:H"FQ9]-U%@H/W
M?]'D8 '\*O:GKEWX;L-&2WN[@V]_9)J'E+(4".Q9&XS@GY/O=<$5T*2E&\S)
MII^Z9OB[P<_A9$6X"B610Z>7*)%*DD=1[@URC5U?B[4KK4M/TRYFGDNXIX0L
M<KG/E^7E3%]5X^H8'O7*MTK"=KZ&D;VU&U+%I]U<VTT\-K--!"0LDL<;,J$Y
MP"0.,X/7TJ-%+LJCJ3BN^\)P^+O"<GVGPUJ&JZ>;Y67=9QL5N%3EN!D-M^G%
M*,7(4G8Q?"_PI\5>,MCZ;I,BV[.(Q=7C"W@W$X #N0"?89->C?%*^T?X3^!M
M#\%^'I4;Q3#<+?ZIK-J?F\U>5$;]2H;&.WR>]9>G^.YM-U);SQ9=:IJVL>8(
MEN+R0M]G5L<(C?<XR21R1@# SG@?B/:W-KXRU(73,[2/YL;,<_NR,J/P''X5
MZBI1HX65:+]YNWHG??UM;T)7O,]T\7:[:>.O"GA[Q-( MIKS&*]@5L11ZI&H
M652.B^:N''OGUKP3Q]X)G\'Z@N%9K"XR8)&ZCU1O<?J*;I_CG4])\&ZOX9A\
ME]-U&XANW$J;FBEBSM>,Y^4G(!/<#%?6P^%&E_M _#V34]*U".V6\M%GAC*Y
M\F['#*W]U5?*GOAL]*ZZ=6CC<,Z-72<5>+[^3_K\M4W[/T/AYJA>M77M%OO#
M>L7NE:E;M:W]G*T$\+]5=3@CW^O>LMZ^=-BO<<^6/5Q_C7=^"=-TRZT.^:_N
M_LMPL9>U4G D?)X)VGT [?>SGC!X2;F2(>Y/Z?\ UZ?Y\D8PDCJ/16(JX2Y7
M<SDKJQZCXGAT#PK<:1JGA_47OWC)N94E4;H'1QL&0HSG&>GI7[3Z?>1ZE8VU
MW$<Q3QK*G^ZP!'\Z_ *6\GDC*--(RD<@L2*_=;X.ZA_:WPC\$7V=WVG0[&;/
MKNMT/]:5>7-9E4X\IU]%%%<IJ%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %9OB"Q34=-:"0 HSJ3GV.?Z5I5B^+[F
M6UT25X?]9D ?K32YG8+VU$5X;&U"@A545SM]=K))N!K@_P#A)-0N+PPRN57I
M6W'.8XQN;)QUKN4.4Y7*YL&0*-W<UEZG=>:K &EFNMMN3GM6?(Q>(N>E'4#,
MC.)JW[.$M&*YRV<RWFWWKL[.WVVX)':F(RYK4LU,>-(5Y/-6[ZX2'/K6-=3/
M(I)X% $=Y?)&#7/7FJ-)D+4]X6D;'6J+0B-23UH K/(['DTQL+R339[@)T-4
M9+HN< T"+$MP%S4'V@M5=MS5)&G(IB+49-:5FN<50C7BK^GL-X%(#26'<M7-
M/_=R 4^WA#Q^M((S#(#5 ;$UOYL(8=13&4M;\]:MZ;()H]M.FM=NX8XH \]\
M8#S(\]U(KM/!<?VC13&>ZURWBJW^^.H(S76?#UPM@@/7%5+6 1/-/$UB=/U>
M=",!CN%9.[%=_P#%+3A'<1W*CO@_C7GI:OGJT>6;.Z+NKDBM[U*K555OFJ9&
MK"Y195JD4U K5)NHN!,#3\U$K4X&F ^G;JCS2[J '[J-U,W5H:+HMQKEQY<*
M[4'WY&^ZM4DY.R(8FDZ7<:U>);VZY8]6[*/4UT]S=1Z-9RV6DML*_+<Z@5R2
M>ZI_C3X[46\SZ7IY:&UB.+N]Q\TA'_+-3V]S^%<_XRU06MF\2-Y<:\!%'2O6
MHT5#5[G-*7-Z%RRA@C\.7]W%&KF+.3US[D^M>$ZAXTE;7)%SQNVM_2O6/!>J
MC5/#.MV:M@^26V^XKY?\07#0ZA<DMAD9@,^O_P!:MY:"C9G;Z]K[QQL4($;'
MKG!Z\\5R4]P9X<L_RMSM_P!D]L5SEUKS7D0\V3#8P<DD\'^M7M.N%DBC._<S
M'A3][_(I;E6L4?$$<L+*9"<J<X]?:J%KJ1211,,)TVKWZ8KH/$=F;=8W5@QS
MC.._7)KC[JX;S\D#_@7;WJ.I=S$^,'B[_A&_ ^L7<+M',\7DQ'/.YN*^)8I-
MS;G?ECD_6O?/VF/$C+HVG::I8-/(92OHJC _4U\\QL=PJS)G5:7<+C:.![UT
M^GW&TK]:XC39@I'-=/92' ;./?K71$R9LR7'F1DG/TKSOQHI;#$8YKLVDXW;
ML'-<EXPP]N3C'-3+8J+U.Z^%<@NO"%L.IC=T_(__ %Z]Z\.V:R:3:%!AMO45
M\Y_!&[$VCZA;9^>&82 >S#_ZU?3'A.;[/H^GR,F4;CIWKY*LK5)(^UH2YJ46
M?9/P_NAJ'@'22K;BD 5CGGBO?/AT!<>$;>UB9HP9"TC$C]*^8_@GJBW7A,VH
M^]&['Z9KZ"^'NJ(-*EA*E9$<E6[%<>WISS587^(1C;^R15^(E_Y*C:-D3$AF
M(QE0".!7S_>:?'J%U+J[QL;>+"1LS >;(> 5]3S7MWCBUEF9I9I6BB3"K'$A
M=A[_ %Q_.N>O-.98HMB?ZQMJ1R+Q F/F?&,YP1UKTGN>5'0^9_''A-M6UVS2
M)T2YW>9/M8R;1@G!XY; .5'>IO%'P_T?Q%X1MH+Z'YI,F-E4<Y)P?TZUZ9J7
MAVU\,6\E[?DHF6#>8^)?( P$R3P6)8Y]\5R7CC7H]:TUK^U,=M(R>1#$6 AB
M13QUQGY0!WZUQRIZ[GK4L1R6Y3X=^)WP?N+&]FN+0+=P%L!@.37->'?'?B?P
M;BS5Y+RT4;?LMV2VSG^%NH_E[5]6^)-/>XW2,;!B3G-NQ*'<0N1Z_,< ]\&N
M%U7X<SWMT9'M$<;=Q?;@8YYQ37-]I7.UXBE-WEN>;:-\0+^\U2WNH_#VV2)Q
M+N,JXSG/IWYZ^U>D6G[60\+Z7);_ -BW-G*+N*;?&?,BP",\]CR?8[1ZU9T+
MP-=6-_;0/I\<@D)?:(P58+SUJCX_^'-WXFTV>*&S2!/*,B10H!D+R<#U [>U
M4I+L<M94I1]T[WPG\;+?QG=7D_V9MU\@1Y"V"S@$%ORQCZ5L^)/#\.H:L;:5
MI)1!$&6\;ARQ.#N[<?+S[UY+\&_ UWH\:+/PT<D>V1OE^7<S;\?2OH[PM;1>
M-;/2=319$@6YE%S\P5WC .&QZ#('3L :IW:L>?&T9<R//=,T-HYHUE,;3(W[
MI?X.<#)_'FOHJV\36?P5^#.H^)9=AFN(RT#2_*96QD<^YX_"O.]-\.PQZEJT
MVH7"6.GZ8IGNKQP,1Q+D DXQG"AL#UKYY_:*^-"?$VY2QT>>6/PY9Q"W@LR<
M+E>C^AS@?E6V$H7GS/H3C\1RTU!/5E3X3_M!WD?Q+NY->OY&357_ '=PSG$$
MO\/&?NGH17TW;_$BRDN)'N984FC^_#,^S'N">H^E?FA?7)69@<JRMD&OJ_\
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M)ZAP,&NLKY<_8_\ '8CDO_"]S*!N/VBV!/\ WT*^HJ %HHHH **** "BBB@
MHHHH **** "O&?VF/&0T7PG%H\$F+K4F^8 \B)>3^9P*]?O+J*QM9;B=Q%#$
MI=W8X"J!DDU\._%+QQ)X\\87NI;C]F4^5;)_=C!X_/K^- ')R2;5K,N)=S=:
MEN9JH22'F@!)&J%^%S1N+-23?=P* *,GWJ(8]TE1R9W&M#3X-S#B@#5T^WVJ
M.*Z&SAZ51T^S)7(4X^E;MK;;5!/'XT 7;.*MJU7:!6/%<1P]\_2KD.K1*1D-
M]: -^%L 5,TG%946K6[8_>X_WABIQ=1R=)%;Z&@"65\U">M#,324 +12"EH
M*.**.U &?KDGEV+ ?Q'%>Z_#.S^P^#;!2.67<?QKP76 ;BZM+9>2[@8_'%?2
M^DVHL-+M+<<".)5_2@"YDT9-)D49H SM8;+VZ^K5Z- NV&,>B@?I7G&H_O-0
ML8QR6<?S%>E#@ 4 +1110 4444 %%%% !1110 4444 %%%% !1110!S/B3']
MH+Z^6#^IK7T-MVEP_B/U-8OB0_\ $V _Z8+_ .A/6OX?;.FI[,1^M0OB-I?
MC2HHHJS$**** "BBB@ HHHH **** "BBB@ HHHH *\"_;XO6L/V./BS*AP6T
M22+\'94/Z,:]]KYN_P""C4_V?]BCXIOTS80I_P!]74*_UH _GHHHHH ****
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M**]]KYN_X)RS_:/V*/A8_7%A,G_?-U,O]*^D: "BBB@ HHHH **** "BBB@
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M/QEX:?2[J.9-R,K;MPR,5Z9X2U/4-8\-RV2WLYN0@>V?S#G@?=SGI[5J>/\
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M:=C<3<CL*0S4T>U$4T4S\-N!'YUWM<-YNUUQTR*[FID,****@ HHHH ****
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MS>=^RU\/VZXLY%_*>0?TJ9[#B>WT445B6%%%% !1110 4444 %%%% !1110
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MBKW']F3XN?\ "*ZO_P ([J<VW3;QOW+L>(Y/\#0!]BT4U6#*"#D4Z@ HHHH
M**** "BBB@!"P'6F/-''RSJO^\0*RO$EC!J%ND5PGF1MG*Y(_E7F6L? ;PUK
MA9MVH6<C?Q0WCD?DQ(H YS]I+XL)';MX5TF;S)9,-?2QG(5>T>1W/4U\W,CL
MN0C'\*^@-5_92/S/IGB%P3T2[AS^JG^E<=JG[//C;2\F"&WU&,=X)@#^1Q0!
MY))8W+MQ"QIO]C7<G6/;_O,*Z[5/"'B/0<B_T6\@ ZL821^8K'.H+&Q#J5/N
M* ,V+P[/_$Z+^.:LCPVKCYY_^^5J]'J$4F/F%65N$;H10!EQ^%+(-N<R/CMN
MQ6E;Z7:VH_=PJ#ZDDU,&!Z&I: %!(7 X'M2CI3:<.E #EIZFF 4]: %I_P"E
M,IU $T=Q)']V1E_&IUU.X7^(-]150>M+0!I1ZR^<,@/';BIUU>,_>5A6.OK3
M^W- &XE_ _1\?6IED1ONL#^-<]3E8KT)H WO"%B=<^(-C#@LD;!V^@Y-?1U?
M+VG:E<Z5="YM9F@FQC>AP:Z>S^*WB"UP&N5G'I(H- 'O5%>2V/QLG7 NM/C<
M=VC8BM^R^+^C7&!,D]N>_&X4 =<J^=XFTV/_ &E/ZY_I7I%>0Z!XRT6\\4VT
M_P!OC2%1]Z3Y>=IX_,UZK:ZE:7J*UO<Q3*>A1P: +-%)N ZT9% "T444 %%%
M% !1110 4444 %%%% !1110!S?B6/%[')_>C"_D3_C5_PXV=/(]'(_05F^))
M"=25.PB4_F6_PK3\.C&G_5R?Y5'VC9_ :E%%%68A1110 4444 %%%% !1110
M 4444 %%%% !7R[_ ,%.+C[-^PU\3WSC,5@G_?6H6R_UKZBKY?\ ^"FD'VC]
MASXGIZ0V+_\ ?-_;-_2@#^?>BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *5>&!]Z2B@#],(W/E<="*YFVMI[,Q1Q,%MX%"DGCH.3_6NB\,W":YX
M9TR_C.5NK2.<'U#(&_K7G?[16J77AOX2:M<V+M#/<%+8R+U57<*_YC(_&OTW
M$34:7M>B5S^1,#2G7Q<<%'1SDHZ]'>WX'Q'K5]_:6LW]YG=]HN))<^NYB?ZU
M3HHK\S;N[G]<QBH145LA4X=3[U]7?M..NK?"^RNHCE5NH+G_ ("R,!_Z&*^4
M*^E]-^*?@CQ=\'9=.\2S&'4[.Q6W-IR&G=% C>,CO\JDYZ'->K@9Q]G5I2=N
M9=?(^)XBI5HXG!8VE3<U3GJHJ[M*W3Y'S11117DGW 4444 %%%% !1110 5T
M'@"PTC5/&&EVVO7@L-*DF GG(X ]#Z GC/;-<_151ERR3:O8RK4W5IRIJ3BV
MFKK=>:/</VC/B98ZQ)9^%/#T\<NBV #2RP?<EDQA0/\ 94?J?:O#Z**VQ%>6
M(J.I(X<MR^EEF&CAJ6J6[>[;W;]0HHHKG/3"BBB@ HHHH **** "BBB@ IT<
MCQ,&1F1O53@TVB@>VQT^C_$'4]+C2)RMW"O\,OWL?6N^NMFM:3#>6DC1.RB6
M&1#AHW'((/J#7C:J68!023T KUWP/I-U9^&TBN@49V+JC=5!KFJ)1M):,^UR
M2O7QO/A*UYPY>NMO+YGMGPD^,%OXZ\/RVFLW,5IKNG+BX,C!1,HX\P>_J*\T
M^+WA;PYXOU![_29VM]4)_>ND1\F?W/H??O4-II-G8,[10HKN=S-CDFI6U"TC
M.#/"#G'WQ7=6S6I6IJDXI^9\YEGAC@,LQD\:\1*-]HQLHI=5JG=>6ECSBT^%
MMU))^_N42/\ V 236_H.A:OX%U./4_#NKS6=['ZCY7'HP[BN_;0=46Q>\.G7
M*VJ+O:9HR%"]<Y]*YUO$&F<;KR 9_P!L5YWM*U.2E9H^W_L?(\51E1YHS6S]
MY/Y/4]PT7XL>&_B=X0ETCQ_9PV%SMV2[P6B<X^^C#D'^5?)WQ0\"P>"O$<L.
MF7T>K:/+^\MKN(Y^3/W6]".E>EQM#,H:-E=3_$IR*;)9Q3##*K ]01D5V5<Q
MGB(I58JZZ]3Y#+_#C!Y16G4RZO.,)_8=G%>:T37W[?(\$HKW;^P[-E(-O%C_
M '!7-ZU\-[.\W26I-K*>R\K^5<ZKQ>YZM?AG%4X\U.2E^!]$_L:Z7);^!8IG
M&!<7,CC/H#C/Z5XG^V3&D?QTU,HVXM:VQ8>A\I:^E/V?/$WAVRT+3-"BNDM;
MZWA$?DS_ ";V Y*D\'-?)'[05U=>(?CAXLVH\LB7SV\:@9.U/E _(5]#7G#Z
MG!1=_P#AC^<,DP>-CQ?BIXFE*F^66C33:<HVMW6FZ.?^&NG?;-=,Q7*P)G_@
M1X']:]KLUVA5KBO OAZ31=/V.H^TR-ND/8>@KN[6W*RQ@D'-?)5I<TC^R^',
M'+"X1*2]YZOYG(_&N?R_#$$/]Z=?T!_QKQ"O6OCM>#=IMJ#SEY"/;@#^1KR6
MNO#JU,^!XJJ>TS2:7V4E^%_U/9/V5/%[^&?BA;P>85AOT,97U9>5_3=7O7[?
M&AQZSX'\)^)XU'FVMPUE*^.2KKN0?@4?\Z^3OA-'-)\1="\C.]9]V5[  YK]
M"?%FL>#8?AQ!/X\-NVBP3I*L=RI<-,%;:%4=6P6XK\YS^7U'.<-C:<7*75+=
M[K\CQL/[^'G%GYG6]K-=-MAADF;TC4L?TJ__ ,(KK?E^9_8]_P"7UW?97Q^>
M*^O+K]L3X<: QBT3P;-<1IPDBPPP#\L$UF_\-Y6S7 C/A%ELNC!;D;L?3&*^
MBCF>:5-88)I><DF>1*ZV/D%E*L01@C@@T5]MZGX(^''[4/AR?4O#[Q:5XAC7
MYI(XQ'(C=A+&/O+_ +0KY*\4?#?Q!X1\62^'+W3Y7U-6PD<*EQ*IZ,F.H/K7
MK8+,J>+O"2<)QWB]_P#@HRA6C)N+T:/KGX8W$?A?]EO[5:MMNQI=W<1E>HD(
M=MWX'^5=!^P/XP>^\$FPDDW/I]X\8R>=K8<?^A$?A56U\*?\(/\ LK7W]O'[
M)=6FBS1O&2.))5*HA]PSJ*\X_8-\06]IKVM:82ZW4FR<<_*5'RG ]<D?F*^/
MSZFL9E6)DM>62?X_Y,\?)5'VM>2UO)ZGH'[7?[-FI_$#XZ)KEE-#::9?V$#7
M,[<MYB9CP%[_ "(G/O7&?'_Q!I'P]^#</@6VN%GOIXH;58=P,D<4;*Q=_0DH
M!CW->R?M]>+/$?A/X>^%]2T#4&T^*XN9+2[DB4;SE R -V^Z_3KFOSENKJ>^
MN'GN)I)YG.6DD8LS'W)KNX2J3Q>4T)S>D;QM_A=ORL=&+R^KB,9&I6E[D&G%
M+OY_,BHHHK[D]<**** /KK]F_P 5#6O <%JSYN=-D-NP[[>J'Z8./^ FKG[4
MWA ^(OAS%J\:;KK2)?.X&287PKC\#L;Z UXM^S-X@?2_'<M@2?)O[=@5_P!M
M/F!_+?\ G7UK]EC\0:?=Z;=+YMI=0O!*OJC*5/Z&ON<&UC<#[*7:WW;?H?@F
M=1ED>?+%4]KJ?R?Q+\T?G;7T[^R]X_EU:U/ARY&Z?3T\R"3NT);!4_[I(Q['
MVKYU\4:'+X8\2:II$QW2V-S);LWKM8C/XXS7JG[)Z.WQ,N-JY7^SY-Q_[:1U
M\Q@93I8F,?.S/TKBBC1QF2U:CU27-%_UW1H_MC>'SIOQ*L=24?)J>G1R,W^V
MA,9'_?*I^=>#U]@?MSZ(B^%_!6I_\M(Y9[<^X948?EL/YU\?T\RI^SQ4UWU^
M]&/!>*>+R'#R>\4X_P#@,FE^"04445YA]N%%%% !1110 4444 %%%% !1110
M!_0-_P $Q[C[1^PU\,'SG$5^G_?.H7*_TKZBKY?_ ."9<'V?]ASX8)ZPWS_]
M]7]RW]:^H* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KD_'V?+LO3+
M_P!*ZRN8\;X\NTSZM_2D]BX?$<I"L3#E:6:%.H%)\X7H*=EFZBLCH&1_+4ZC
M<?2FJNT^M/W;><55A7)\;5J"28=*4W6>,4WR]W/>F20LP89J"1$;ZU8DA;G%
M1K"=P)% RK)^[^Z*C^T$#D5J20JR=.:S;B,KGBIL4B/S!(0",5;BM=R@U0C;
M:PR*TX+Q5'-"&T(UOZBH9+0.O2K37T=1+?(S<=:8M2E'IXC?=BK*KMX JTKJ
MRYZFE"#KBF)L@B7IVJ\JC:!FJ4TGDCI5==0(XIW%8T98QCK5*2,KTJ/[<#WI
MZW ;K2"PS<3QFI8UYI"Z?2J\MSMZ4#+VT>M31_6LF*ZWM@U:CD/7M1<"\T?'
M6F="*K&X.>^*:9C3%8LL1GFHY&&.#51IF8TQI&49H"Q(ZDMUJ2+Y14,,FYL&
MI]RJ>330AS9^M*%++Q0D@[<BI%D&>E,"O(KK@BI89",9J;&X<5-9Z:9/WDOR
MIV'K2\D)M(GM8QMWMT[5)-/E#BI)(PJ;5&%'0509OF K5:&+(6;:X/O5EB=M
M59NOXU:^\M405923Q4+-UQ4TO'UJL3S5")-ORU2O,#J:M,WR\5F:@&D4CM0!
M4T^Z2XOY$'( XK3EA1XR&4$5D6-J+>\1ATS@UNM]TT%(\8^)6@I%-YT2[1GG
M%<]I.GCR17J/C*Q%T I&0:Q+'PZD:X XZTT#-#PO9F:.*/''>N^2(11JH'&*
MQO#5B(8RV.!P*Z!ERM S(U"$2*ZD9!&*_/SQYI+>$?VAO$ECL*0WGEWL2XP#
MO4!OU4U^AEU'E<5\8_M=:"=(^*7@W7E3"7<<MC(W;*D.N?S:I9TT7[UCFM:T
M\7$+ KDXXVCD\5Y/J&GG3;]F"]\^GIFO<_)%Q:B0\[EXX%<1XL\+F;,J)C'S
M#CI0>IT+WPNU(7D\=F_S,S@KGMR*]TU[4OF=%(49)-> ?!729V\57%Y(C1VM
MC'N9I <;SPH_/G\*]HCL[_Q'?"TTVVDO)U7S'"X 49(RQ/ %+F4=6"C=F3<1
MM<L JEC[<BKUOI!M[<EES)GVK=AT.71IA;7T+0W3<X8#!''*GO5R2U#QKM'
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MZ;:-?30VQ9$1<!6)"(6;LH+;B3V0CKBK?Q9L]%\)ZHF@Z)?R:G<VT0CU&^W
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M_?@ YQCK7[#?L*P^1^RCX"7UANF_.[F/]:SJ:*S+B>\T445@:!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7->/L_
MV"".TJ_R-=+6!XX3=X<G/]UE/_CP']:N'Q(F6QY+=3-@BL"^<C)K:O) N:P;
MN8-7HHY#.@91<DD8W5W?A=1(@[@<5PKPG[PZ]:[/P?<;H6!-#V&CH-0DVPE%
MZU#I=F(\N_6EFD56+.< <\US&M^.8-/W(C#=Z"LQG3ZQJ,<43#<.!7D?B[Q
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M2G#FFTY: %I5I*5: ' <TO\ %B@4HH 56*\@U:M]1NK;!BN)(_\ =<BJE/H
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MGW_0++\/\P^I8C^0^L**^4/^'BG@G_H6]?\ ^^8/_CE+_P /%/!'_0N>(/\
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M/^AYTC_O\?\ "O4CE6822E'#S:?]V7^1K[&I_*_N/3J*\R_X:8^%G_0\Z/\
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ML81F/]E_X?@]38N_3'6:0_UK\9&K]M_V8]..E?L[_#BW*[6_L&SE(]WB5_\
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M'N_&3^?->6>(+>2\L?/=MP7C<3G&.Q_2DQ(X?X?VTDWQ7\.Q ?.U_&V%Y'#
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MGGOH8V:1I)B-Q9NHXZ#BMS38F_L5P1D*"#Z9[U#$SR*C9[C;_2D,MZHP\DC
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M,54P]^3J?G?_ ,.\?B/_ -!GPO\ ^!=Q_P#&*/\ AWG\2/\ H+^&/_ NX_\
MC%?HA17U/_$1,]_FC_X"=7]I8CR^X_.[_AWG\2/^@MX9_P# NX_^,4G_  [U
M^)/_ $%?#/\ X%S_ /QBOT2HI_\ $1,]_FC_ . A_:5?R^X_.S_AWK\2?^@I
MX:_\"Y__ (Q2?\.]_B5_T$O#9_[?)_\ XS7Z*44?\1%SWO'_ ,!_X(?VE7\O
MN/SJ_P"'>_Q*_P"@CX;_ / R;_XS2?\ #OGXE_\ 00\.?^!DW_QFOT6HI_\
M$1<\[P_\!_X(_P"TJ_E]Q^='_#OGXE_\_P#X=_\  R;_ .,TG_#OOXF?\_OA
M[_P,E_\ C5?HQ11_Q$;/.\/_  '_ ((?VE7\ON/SF_X=^?$S_G\\/?\ @9+_
M /&J3_AW[\3?^?OP_P#^!DG_ ,:K]&J*?_$1L\[P_P# ?^"']I5_(_.7_AW]
M\3?^?GP^?^WV3_XU2?\ #O\ ^)W_ #\:!_X&R?\ QNOT;HH_XB-GG]S_ ,!_
MX(?VE7\C\X_^& ?B=_SWT'_P-?\ ^-UZ-\ ?V4O'/P@^(<7B'6Y-+;3EMI8'
M%I<L[Y8#'!0=P.]?:U4]6C\S39QZ+N_+G^E<6.X[S?'X:IA:W+RS33M'H_F3
M+,*U1<LK69@>'5?^VP1]P6\@/UW)C^M=77):*[KJMN%.%8L']QM)_GBNMK\Z
MCL<%3X@HHHJC,Y7XA0>9HZ28Y205YQ^->L>+;?[1H-TO<#</PKR6@!,TF?SI
M&(I,^M #N.:-V:;D4<4 .HIO%'% #LT!O6F\4<4 /5L,*ZRQ;=:QGVKD,BNH
MTE]UFE %^DIN3ZTGXT /HIN31S0!\Z_M2>#3_HGB"WCZ?NIL#\C7S]IMX;2\
MCESC!YK[P\9>'(?%?AN]TV89$T9"GT;M7PEKFDS:#JUU8W"E)8'*$'VH ]!A
ME$T*NO1AD5,M<]X5U(7%L8&.73I]*Z -0 \4_P"]]:8M.4T -9<<U%)'G-62
MHZTQEH S9H>M5)8?:M>2.JDD- &3)'[5!M,;!E)5AT(K3EBJH\?:@#UKX6_M
M'ZMX+\K3]6W:GI8.!N/[R,>Q[_2O=D_:8\$26RR+>RLY&3%Y9W#VKXGDCJ$J
M5^8'!H ^O-8_:NT>W5AI^G37+=C(=HKS;Q1^TIXIUQ7CLWCTN%N/W(R_YUXC
M'J$B?>^>K$>I1MUXH U-0U*[U:Z:XO;F6YF;DR2L6-5^U0_:HS_%2^>G][B@
M#VW]E^0?\)'JZ9Y-LI _X%7T=7R'\#/%D'AWX@6GF2 0W:FW;G@$]#^=?7*S
M9Z8Q]: '^U(::TBGO2[LCCF@ I&H[4AH 2DWD'K2TR@"59V7O3TOG7^*J[4V
M@#235"O4U9CU13U-8='2@#I%O8GZFG_N7]*YA9&4\&I!>2)W)H WI=/@N%*L
MJLIZJPR*Y;6?A'X6US<;O1+.1FZND>QOS7%:,>J.M6(]9/>@#RO6/V6O#5YN
M-E+>Z<W;RY1(H_!O\:X?5/V6]<L\MIFN07*]DN$:,_F,BOI6/5D;K4RWT;]2
M* /CW4/A)XYT7)DTAKN,?QVKK)^F<_I7,WDU[I+F._L;BT8=IHBO\Q7W46@D
M'2H+G2[2]0I-$DJ?W9%##\C0!\.0:O!(!\U74N$DZ-7U3J_P:\)ZR6,VB6BN
MW5X5\L_^.XKD-3_9GT23)L;J\LF[#<)%_7G]: /"MP]:<M>C:I^SGKEKDV&I
MV]T.RS*8V_J*Y34/ACXOT?=YNDRSJ/XK<B0?IS0!C4JU7N/M6GMLNK2:W8=I
M8RI_6HTU*,]3^= %VG5!'=(YZBIMP]: %I124HH 44[I35I^/3I0 4M'I10
M=33J:M/H *44E+[4 %3V]]<6C PW$D3#H4<BH/T%+0!TVG_$?Q+IH'DZO<$#
MC;(V\?K71Z?\=O$-MC[0EM=COOCVD_B*\W[TM 'O_AGQ'/XLLYM4GMQ;--+@
M(I)&%55R/Q!KXA^-WP-^(GBCXL>)]5T[P=JU[87-XS07$-N621   P/<<5]L
M>!;1K+PEID;=3'YG_?1+?UKU2WC\FWB3^ZH'Z5]-P[Q!6X>Q-3$4(*3DN76_
M=/IZ'HT<1+#:Q5[GY-_\,W_%#_H1-;_\!&I/^&<?BA_T(FN?^ C5^M-%?H'_
M !$_,/\ H'A_Y-_F=7]J5/Y4?DK_ ,,Y_$__ *$37/\ P#?_  I/^&=/B?\
M]")KO_@$_P#A7ZUT4_\ B)^8?] \/_)O\P_M2I_*C\D_^&=?B=_T(>O?^ +_
M .%)_P ,[_$[_H0]>_\  &3_  K];:*/^(H8_P#Z!X?^3?YA_:M3^5'Y(_\
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M?1?_  7P_P#Q-'_$4J'_ $"/_P "7^0?VK'^3\3\<:*_8S_A6WA'_H5M%_\
M!=#_ /$T?\*T\(?]"KHG_@NA_P#B:?\ Q%'#_P#0*_\ P)?Y#_M6/\GXGXYT
M5^Q?_"L_!_\ T*FA_P#@NA_^)I/^%8^#O^A3T/\ \%L/_P 31_Q%'#_] LO_
M  )?Y!_:L?Y/Q/QUHK]B?^%7^#/^A1T+_P %L/\ \32?\*M\%_\ 0H:#_P""
MR'_XFG_Q%'#?] LO_ E_D']JQ_D/QWHK]A_^%5^"O^A/T'_P60?_ !-)_P *
MI\$_]"=H'_@K@_\ B:/^(HX;_H%E_P"!+_(/[5C_ "'X\T5^PO\ PJ?P1_T)
MOA__ ,%<'_Q%)_PJ7P-_T)GA_P#\%<'_ ,13_P"(HX;_ *!9?^!+_(/[5C_(
M?CW7MO[']V+?XS6\9./M%E/']< -_P"RU^B__"H_ O\ T)?A[_P50?\ Q%5M
M0^&OA31;&XO=+\+Z-IU]$A,=Q9Z?%%*OKAE4$9&1]#7DYMXB8;,L!7P:P\DY
MQ:O=:77H9U,RC4@X<NY@* ?0TUE&?2HH=_'%3%6[U^$GEDL+H !G]:F61/6J
M@4_W:1@WI3$7]T;< U!+&F3S4$:.<=13GC;'3-,0_:C#KDTTM'&:9&".>E1R
M$L^,T 2/(#_#3=S-QC%3PP< \5(RHGI0!GO;LQ^[2Q0E6Y7BK)G5>XIK3*>A
MYH"Y*L:;<GK2[D4]*K-=;>E,^T;N<XH#4O;D/:HIF7!QQ526<C[IJK)/)@Y!
MHN-%AL,V.U/^RHW6J2S>N:F6[/8&INRK"2:6C'.VH7T]5S\M6!>%NS4UW=@0
M,YJ1E%K%,]!3H[55[4[;+N[FGR0SJF[8<4K#&_8XSU%,:SCS3?M#*IQUIGVA
MR>A-3=%69*(57[M-;AL5"UPXSQ47F2,V>:7,BN4LM3XN>U5TWR>U3HCBJ3N2
MT7(Y%7CO0\BFJX4_4U#(SJ>,YK0SL758+DGI6GHH^T7&[JJ]ZP45Y%Y!KJ="
ML_LEHN1\S?,:J"NR*CM$NW.?M"^FVLE#YAE'N:U[CDAOP-8GF"WU @]&XKI.
M8SYF:VE)!Q5J&Z,G4T:I;_Q=>]4;63''X50%Z_\ E,3C^\ :TE^Z*S9&#P@>
M^:T%^Y4@$N-I%94GRL<UI/5*Z7#9Z4T!#4<S86G#[M,D[<TP(@3ZU97[HJ!>
M]3Q\J*"45KY-T;?2J?AB$"XN&[KP*U9$W(16%#=?V7J>[HC<,!Z4="CK/PQ2
M;:<LBR*&4Y4C(Q0HYJ1"QI1<)F,C%2+3BN[O3N'F?,\.CIX=\:>*-.5?+C:[
M-U&.VR4;O_0BWY5DZDHAFF#+@Y[5Z'\6M+.G>--)U) 1'>0M:R<<;D.Y?T9O
MRKB?%4/DKN P&]:H]:G+FBF;WAE=VCVI5<@@\_\  C6C)"=V>.:S_"$@;P_9
MG _B_P#0C6M(VX[ACBK6Q3,^ZCVSAL<#@5+-+F/UZ43KO+9ZUI>$]*_MK6TC
M(S!'^\D^GI^>*3(E+E5SN? FAG2]+$LJXN;D^8_L/X1^5=5TQ38UVJ ./I3J
MRN>9)\SNQZT_RP>@HC':IMO%(17:-@P(Z4Q90TFT#++UJ.]OB)!;08-P1R3T
M0>I]_:GV-FMK'C)9CR6;J3ZT 3*Q]*?YK4O':FM0 W<3U-.I%YJ15H %6EI_
M2FGK03<94;FGO44KX!]*!HY'Q],/L=O&3PTPS^%;'A./;I<3$?>^:N:\<R>9
M]F4?WFQ^0KL=$B\FQA3^X@'Z5?09<N)!#"['^$9K(TQBV7(Y(R?QJ;Q!<".S
M90>9"$'XU'I@VPYQ4@:2=14R_> '4U N:L\0KD_?/Z4@."_:"U#^R_@OXOD5
MBCM8/'N!P1OPG_LU?FK_ &A=?\_,W_?PU^K.H>"])^(]C<:!KMNUWI5TN9X5
ME:(L%8,/F4@CY@.AKF_^&)O@_P#]"S-_X,KG_P".5^L<(<5Y=P_A*E'%PDY2
ME?W4FK62ZR7F>Q@L73P\'&:=VS\R_P"TKO\ Y^IO^_A_QI?[4O/^?N?_ +^-
M_C7Z9?\ #$OP@_Z%J;_P97/_ ,<I/^&)/A!_T+D__@RN?_CE?>?\1)R3_GU4
M_P# 8_\ R1Z']IT.S_#_ #/S/_M:]_Y_+C_OZW^-+_;%_P#\_MQ_W];_ !K]
M+O\ AB/X0_\ 0NW'_@RN/_BZ3_AB+X0_]"]<?^#*X_\ BZ/^(D9)_P ^JG_@
M,?\ Y(/[3H=G^'^9^:?]LZA_S_7/_?YO\:7^V]1_Y_[K_O\ -_C7Z5?\,0_"
M+_H7[D?]Q&X_^+H_X8@^$7_0!NO_  8S_P#Q='_$1\C_ .?53_P&/_R0?VE0
M[/[E_F?FM_;NI?\ 00NO^_[?XTO]OZF/^8C=_P#?]O\ &OTG_P"&'_A'_P!
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M[C\X?^$HUD=-7OO_  )?_&E_X2K6_P#H,7__ (%/_C7Z.?\ ##/PF_Z!-_\
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M1PN&3G/\+<>E>21M5F-JU51HGE1>W[F)JS',VW;DX]*HQM5B-JQ++L9->W^
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MM7QUXH\-ZU;QR:)I*Z0Z"4S*+@.)-V-@'ICD?C^-="IQ<;W,7)WL>5M7[O\
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M7]Y Y'&#VS[=*P=.OI=,OH+J$XDB8,/\*]T\00V_CGP'.8C'+<11^<FTAB&
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MB@<K^G2J'A[X<6G@75+M[=Y)C-&H5I2"5&3D#'T7\JF6Q<%>1W/AF/==2O\
MW4Q^9_\ K5T=9/AR'R[-I#UD;]!Q_C6M1'8)OW@HHHJB HHHH **** "BBB@
M HHHH **** "BBB@ HHHH _$3_@L?X-D\/\ [5EIK07]QKV@VUP&]9(FDA8?
M@L:?G7PE7ZR_\%P/!:S>'?A=XN1"'M[J\TJ5^Q$B)+&/P\J3\S7Y-4 %%%%
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M*** /QK_ ."A?A$>%OVJ/%#JI6'5H[?4H_??$JN?^^T>OF\J#D@8XQ7Z%?\
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MHSB0#G/I6-\/?"^I>*/&%EX;A&%DE&Z8#_5QKR[$^P_I7ILT*PZ4JOM<JPV
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M,RXMQGU##VC"[:6VBZRW?_!&?'/XJ6O@WPYJ'ARR9)]9U2 P3+U%O"PPQ/\
MM,#@#L"3Z5T/[#L$4G@K4R<>8=5<-]!#%C^M?&^H:A<ZM?3WEY,]Q=3N9))9
M#EF8]2:^D?V*?%#V.LZ[I3',;I'=HOH0=C?GN7\J^-S;%RK0E5>B7Y'Z1_J_
M# 91+#4G>;:<GW>B^Y+8]W^"OG^,?AUK.GW0)N;B34K&96ZY,TRX/X$5^=[#
M:Q%?JI\-/"\7AK6O$4BD):W%]+J6>@'F@2/]/F+5^5]U()KF60# 9RV/J:Y<
M-759-K;07#5EB\9R;/E?I?FT(Z***[#[\**** "BBB@ HHHH **** "BBB@
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M;W$9^-JC@'/\J,;@ :5068?3G_"E;JQQG'3%0,;QN '2E7U/IBDP<'\^M*&
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M^%]'T2UQ]GTVSALX\#'RQH%''X5JT45@4%%%% !1110 4444 %%%% !1110
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M2N8^.6J"T\%R")@KR#;\O)S4L#Y(\9:N^LZW<22^8PW-@>P]?I7EGB.W6_\
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M..OYT\Y^<L,EAD<8QD\"D P,HM5Z'/!7MDXS@^U$,:0W2IORN<9Z;1C@^_\
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MU #LTE-S^-+F@!V11NIF[FEW4 +FLCQ5X5T_Q=I,MAJ$(DB<<-W4^HK6W>]
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MXB?Q)KT]R2?)4[(5]%'2L*BBO82459'\]UZT\15E6J.\I.[/2O@_'N:Y;_;
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M;)2?F,LJE$ ]U&6^B&OS&KZ;_;L^(!U?XBVO@^SFSIOA^%?.13\K74@#,?\
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M(AWCJVUNN36I-Y<F\L&RO3 &!Z?6LQ(9(9,_-EQG';Z&MC(U=0C@6V22/:A
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M3@]CC(]C6#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$^IY)_E^==U5#0]-72=+@ME'*KECZL>35^L&[L HHHI %%%% !1110 4444
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M $KX=\)1VLEW9B^;;;.V9&]B:^M_VB/$4-A\&Q8&38\D2Q_I7QK:S$0HHVG
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MT/S/_P #%?4M8R>I2"BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%%
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M;6*QM8;>",100H(XXUZ*H& !^%2T45Q'6%%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH *^YO^"0OP='Q"_::?Q3=P++IO@ZQ>]!;./M4N8H1]0#(W/\
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M>E*X#%&TXS5N-MR8S6<[%:EMYNU# GDJ>*%5C!Q@]<U7.9#@<FK8MF9 &?\
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M4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:H=B6#$GK[U0B#PW'#'?.[DJH;KT)XXXKM]/:"XC?#?,S8#!A[?I7 7(:RD
M \U6!)X[=Q]*W=#6":9&5EC^7<5 (Y^E BSJTAAO)YIQYB(A.XGICH/_ -5?
M+'C"^;5-:O+O>"\C#@=.#V]J^B/'6J7$&F3Q[W$>-Q]0.OZU\U:KM6XE^9D
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MM06H ?WZXI=P]:CW&GPJ99D0=6.* -RSC\NW0=R,U+1Q]** "BBB@ I:*2@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 362QR7D"RMMB+J&)[#/->WOX6T#6(1Y4-K.@& T)!('U
M%>%5)#<2V[!HI&C8="I(K&I!SV=CW\KS*E@%.-:BJBE;?R^3/5[[X3:;-DP2
M36_LK;A^M8\WPAF#?N[\;?\ :BY_G7-6?CK7;$ 1ZC*P]),./UK5C^+&M(N&
M6WD/]XQX_D:SY:T=F>Y]<X?Q&M2BXOR_X#_0TH_A#+CYK_GVC_\ KUTND^&[
M_38?*GN5O$481BF&'L3GFN#F^*6NR?<DAB_W8@?YU$OQ,\0#_EZ0_P#;%?\
M"I<*LMVC6CF&1X67-1A-/^N\CLO$'@F#5MSO"8I\<31]?Q]:\_E\&ZNEP\:6
MCR!3@.I !]^M>C^ O$.I:_93R7^UU5ML<@0+GUZ5U M0QSBL_:2IOE9ZT\GP
M>;PCBJ5X\WHG\SR_0_AE/<,LFHR>6G_/*,Y8_4]J](TC0;?3;=8K>%88QV4=
M?K6E#;A:I>(O$=GX9L#<7+<]$C7[SGT%92J2J.Q[N#RO!953=5Z6W;+5U>6N
MDV[37,J00KU=SBN%\1?%RVAC:'28S/+T\^080>X'?\:X'Q-XJO/%%YYMPVR)
M?]7"I^51_C[UC5U0PZ6LCXO,N*JU1NE@O=CWZO\ R_,N:CK-]JUP9KNYDFD/
M=FZ?0=J]/^%?B":_LI;2XD,CP$;68Y.TUY)79?"V[,.OR1=I(LG\#_\ 7K2K
M%.#/&R+&5:>90E*3?,[/SO\ \$]MNH!=Z?/$PR)(V3'U!%?,<Z>7-(G]UB/U
MKZAMI-T8'>OFC6D$>L7JCH)F_F:Y\+NT?6<:03AAZG^)?D4J***[S\M"BBB@
M K]'/V/W&K? O2X%/S/'<6_X[V6OSCK[A_8)\9)<>%]4T)I/])L+KSD7_IG(
M.O\ WT&KYGB&#E@N:/1I_H>3F=-SH771GQ/JD1@U.[C889)G4@^S&JU>I?M-
M>!?^%??&CQ%IR%3;3S?;8 O\,<HWA?J-V/PKRVO?H58UJ4:L=FDSTJ<E."DN
MH4Z*5X9%DC9D=3E64X(--HK<UO;5'567Q.\0V*JHO?-4=I45C^>,UT>G_&VY
M3 OM/CE]6A<K^AS7F5%9.E"6Z/<H9YF6'^"L_GK^=SU^7XV6"QYCTV9W]&<
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M 4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFEZ7::'IEIIUA EK8VD*0001C"QQJH55'L  *M445RG4%%%% !1110 4444
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MTS=1NH ?NHW4S/O0&]Z 'YHR*9NHS[T /R*-U,S1N]Z '[NU&:9GWQ1N]\T
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M %?$_P"T9\:I/$U]+:6LA33X25B0'K_M'WKZ*_;)EUWX?V<TUO(!X>U0[49
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M7R_#OC!C]JV#Y(=149<=>/,4;QQU#T ? E%%% !1110 4444 %%%% !1110
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MJY.#VKZ[UVUEDC;]V3Q7A_Q&\&W.K02HL+9.>U:Q9SU(W/SRU+5KO3;^5%.
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M=?0<=S7WG7-4E?1'1"-M6%%%%8FH4444 %%%% !1110 4444 %%%% !1110
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MD_4U.^!]:@D:@")CMJ"1J?(U5Y&Z\T 1R-4FDM_Q-K3_ *Z+_.JTC5)I+?\
M$WM/^NBT >J;B*-U1;O>C=[T 3!O>C=4.[WI=QH DW4;O>H]WO2;O>@"7=1N
MS4>[WI-U $NX?6C=Z5%FC=B@"7=^=)O/XU'N/K1N/M0!+NHWG\*BS^-&[WH
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MU..?QH  W)R,9Z?G3EX&/[PIK?,Q&3D=S2AB<YP O;% #\ 8 Y..<4YF^8#
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MM$=M*GRJ[W"BBBL3<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M13E5[$^I_I^?I6[HVCFZ833#]R.BG^+_ .M3-'TDWC^;(,0*?^^O:NG50J@
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M=;X"D^Z]*U[&Y'R@$\5U6EWCKC)XK&2-8L^/O&/[.?BSP?++,&.I6/)#1KG
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M$&%YJ-I))N_% ]1NK71F5E2N=7[1:S;T9@:Z);5CVI#IID_AJ"T+IGC*]LP
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M1VLG[@'&_I\OJ*]L_:"^(D&BZ?\ V9;2;7(PQ3^Z#R#[XKY.U"^6ZEP=P!X
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MZ=*6A3D9%% #9&PO%5W.*FD["JUPPCC+.0B^K' H JS29)-59&/XUC:WX_\
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M)+>)"5\Z1=SM[XZ#]:\Z2E.HW#H?KN'K8/+<GIT\=M-;+=]?UU-FW^#-BO\
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M6K:2+MY.#6.)&3C&>].2X8<8H4ANG<MZDB7,+1L,JPP36=X8\0!;V31[I_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M S9%9O6H'C8UNB!&XX!JU!ID<G6G<+'(R0OZ&H_);TKNUT"-N@J1?"ZMVIW
MX..%O2KT*%?X?TKL!X47^[4T?A7_ &: .35GZ**GCM99#TKL8/"HS]VM.W\-
MJN#MI7*T.*M])=L9!K2@T=O[M=E#H:+_  U<CTM5[5-P./AT4_W:M1Z'_LUU
MT>G@=JG6Q [5-QG*1Z&/[M68M% _AKIELP!TJ5;,>E*X',MH*OP5JW#X51EX
M6N@6U Q5R&/;4-B.4;PFN?NU)#X;6-N5[UUZX]*5PGEL<8XXI<S"Q\E?M87
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MP9#WSC%?9583J7T1O&'5C8XTAC2.-%CC0!551@ #H *=116!L%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 UT612K ,IX(-<WJNBM9YEART
M/<=U_P#K5TU)UX/(I-7*C)Q/FSXN?!L>)(;C5M AC76<;WM2PC2Z/UZ*_N>#
MWQUKYF_XJ?1]6!713;W-O)\T<Y8,".Q'%?H?JF@GF6U'N8_\/\*XK7O"=AKS
M;KB!5N5&T3;?F^A]147<=&:N*GK$^45^*OB2/_6^&H&_W)F']*>/B]JJ_?\
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MQ /RKZC7X?K_ ,\_TJ5/ *C^#]* /FB'X:HO2#]*N1_#W;TBQ^%?2<?@)/\
MGG^E6H_ <?\ <S^% 'S9'\/VX_=_I5J/X?M_SSX^E?24?@5!_P L_P!*F7P.
MO:/]* /FU? #=/*I_P#P@+=X^:^E!X'C_P">=*?!*<?N_P!* /FAO 9_YYU!
M)X&*Y_=X_"OIF3P0AR-@JG-X'3!^3GZ4 ?,\W@TK_P L_P!*JR>$<?\ +.OH
M^X\"@Y_=\_2LNX\!8_Y9_I0!\^2>$_5/TJG-X3'/R5[[<>!CSB.LRX\%LO\
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M0@@C% $-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX[B/^T,)/#U:2N[<K73^OU())&ED9W8N['+,QR2?4TE%%?2GQ04444 %%%%
M!1110 4444 %%%% !1110 4444 %=/\ #/X:^(/B]XZTCPCX7L6U#6M4G6""
M)> ,]78_PJHR2>P%<]9V<^HWD%I:PR7-U/(L44,2EGD=CA54#DDD@ 5^YW_!
M-_\ 8?B_9J\#_P#"5^*[*-OB1KD(\]7^8Z9;DY6!3V<C!<^OR]!R >V_LG_L
MRZ!^RO\ ">R\*:0([G49,7&K:H$P][<D89CWVCHH/0?4U[/110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%5FS@ 4<@<YT$&KQ-C) J[%J$+=Q7@WB3XA#1;\Q[]N/>NB\*^*VUNQ,ZON
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MJV, 5U%CIL-@F$&YSU<]35B.-(4"(H51T I]4HV)E-R"BBBJ,PHHHH ****
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MQI-VES:R&*5#D$=#['U%8U*:GZGOY3FT\NGRO6#W7ZKS_,]@\;7ZQ^%=0WD
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M.7/''4;.E)))KIZ_UY&311174?$!1110 4444 %%%% %G3(_-U*T3^]*@_\
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ME&3YEN?@7;W'S8K6M9NF.*^UOVC/^":U[I#76O\ PJD?4+7F23P[=/F9..1
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M)X_\$VY_BW/8?$;XH6$EKX)C83:?HLP*2:L0>&D'58,_B_3IDT ,_P"";?\
MP3QE^+UY8_$_XC6#P^![>02:7I<ZE6U=U/\ K&': $?\#(P.,FOV7M[>*UMX
MX((TAAC4(D<:A550,  #H .U-L[.WTVS@M+2".UM;>-8H8(4")&BC"JJC@
M  #IBIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /!/V@OV+OAW^T''/>:A8_P!A^)7'&N::BK,QQ@>:O248
M]>?<5^8?[07[%OQ%_9]DFO;ZP_MSPS&>-<TR-FB5>@\U>L1[<\>YK]MZ9-"E
MQ"\4J+)$ZE61QE6!X(([BI:3 _G/\PMR, U)E<9!YZ]:_7OX_?\ !./X=?%K
M[5J?AQ/^$&\1R;G\W3XP;.9SD_O(. ,D\E-O3H:_.;XW?LA_$WX!W$CZ]H<E
M]HP)V:WI8,]JR@G!8@9C.!G#@?C6;BP/'E' P?FI58[2,XR>34(;USGI3E88
MR3[@5(%I#VR3[BI5.[C^'W-5(Y#C(Y9N]3)(5;H#GCKQ0!95LAL'/MWIZR?4
M>O-0B0J/3U__ %T[=N7&.0>OM0!=L[IK6[AF0\QN'&WV-?JG^SSXH76O!=A.
M6#9B&>_:ORA1_F]?QK[T_8?\7B_\,?V>[9:W;R^OY4HOEE<N.JL?3VH?&7PE
MH>L1:/J.J1V=]*=J1297)^N,5TT^L:5'M!U&$%AD N,_SKY2_:B\%V,FK6&M
M8-O< [?M"1!V'YD8KY?\;^*M6\*S-+9:[-<D8.^9F!&?;)KLO9CM&Q^F^I:S
MICQ,O]IQH/[RN*Y5&TZ.=KA=8EN$SR/,R!7YIWD>N>(O#2:D?&#P7\DF!:K.
M0Q'K@XQ^-7-'^)OB[P%HOV0ZA)<6Q.3)(XD?Z Y_2DV^@)Q/TJD\9Z?;?*'#
MD=.>M9UY\0E9&6&/<".H&:_.W3/CUXH\3-):Z<CF9 3RK'/TJUX'_:H\6^!?
M$SKK\,=W9QMAX=PWC_Z_UJ;OJ4I1/MFWU65=6DN"C_.<MV&:ZU?&:6L&9'VC
M_:-?'-]_P4 MV>3'ATQ1'[FZ49/Z8KRKQY^VI>:XLJ6UBUHIXX(_I7(Z&MT>
MLLP]U*>MC[H\4_'SP]X:5Y+F]C5AVW<UX)XZ_;BMK-Y(]*MGN1_"Y^537QOJ
MGQ2&N#S[ESY[<$ECTKE]1\06\A89R#W!-)4-=3&>-_E1[#\0/VJO%OBHNIO&
MM(<Y\N$D<>F:\;USX@:UJCDRW\[@^KFLWSX;R38A)9J9)I<G]PFNJ,5'2QY\
MYRF[W*\?B75K6420:A<1/URLA']:]7^&O[3_ (B\'R11:A<S:C:KV=LG%>90
M^&[B?A8R3Z5N:5\,=2U)P(X';)XPIHJ0IS5I(NC4K4W>#/LGPK^VMX?NH8UN
M':V8CD,>A-=QI_[57A2ZCWMJD8X'!-?)'A7]D_Q!XB9?+M9=A_CV$"O;/!O[
M!<S^6^IW#QCJ5C_QKS986'V6SV(XN?\ R\2/3+K]J'PHJETO?-(/1 34=I^T
M:VNN8M+TF[G!X$A&U2/RKI_"W[*?A#PL$D>RCNI5ZM)\W\Z["30=&T.+R;>*
M"VVC 50!BLOJJ[E/'+:*N>:W_CC6;BU+"U^S'_:[GVK \)_"#Q#\1/&=CJ>H
M-);Z;;S+*6<D%\'/ _QKVG3]*T9)!/< 7+CD C(%=*OB2*W18K>'8@'"@5K#
M#PB[G-+$U)GJD'B:*SM8H(XP0B!.G!P*\*_:$^ ?A_XX:>TRN-!UY6WQZE:*
M S<8P_\ >'UK5N?$UY-\L4,GI]TUDW,FMWO$<4J^YXKK<E;4Y(Q<7=,^1/%?
M[(/Q \,L39>*H;ZV Q]XJW\S65X/^&D_@WQ+97^OWINIX6YRV0/2OJ#Q)X+\
M6ZHI\B7RQWR2:\3\:?LY^.=2G:6WNWE;.5 SP:Q?+?16-HSDO,]3D^*]E%'&
M7G1?Q%-D^+VFA2PNXU0?,6W5X O[*?Q;UJ=;2TMKB=V/"J#D_E7O?P;_ ."5
M?B?7+BWOOB9XKETC3LAFTK2I-]S(.#M:0Y5 >>@8_2M8Q;V8Y5^7=&/9_&>Y
M\8:Y!H/A/3KG7]6G8K';6D9=F(ZG [#N>@KZQ^#O[,NOW4<6J?$.ZCM]V'31
MK)]Q'M+)^7"_G7M/PE^!_@CX'Z FD>#- MM(@V@2SJ-]Q.0 -TDK99SP.IQZ
M8KNZUC3MJV<T\5*2M'0J:7I-GHEC'9V%M':6L8PL4*[5'_UZMT45J<04444
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M*VM88[>WB7:D42A54>@ Z5-116)L%%%% !1110 4444 %%%% !1110 4444
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MUK:_!N_OIA^[6,9!VQQ]?TKM?#O[-QFV//'QC),@/YU/-)[&GLXQW9\9Z/\
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M7"W/BF]DT[3V.?L$)(&/0GO6+J+9%*+?Q%7XF?M5++<2Z3X.LVU6\R4\Z/\
MU:'W/?\ "L?X>^ _'WC'45U+6;N5!(VX(<A0#V KZ4\ ?LQ^'O!T,?EVD;R+
MCYF7FO6-/\*V=BJA(U4 <8%9\LI#O&.AY/X5^&OV.)!<,TS=\UW5CX+MXU $
M"_B*[)+6"'&%%6K>UEN6VP0M(?\ 97-;*%E8ES['+1>$85_@5/H*L+X:M5^\
MH/X5WEGX.O+C#3,MNA['EOR%;ECX1L+3#.AN']9#Q^55R$<YYMI_A!+]MMO9
M^;_M;>!^-=5I?PQM5P]Z$'_3.(?S-=PB+&H5%"J.@48%.JN5$<[*>GZ39Z3'
MY=I;1P+WV+R?J:N4459 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>A- 'SE1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^PZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMA11102%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*=113)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!2UK1=/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.GF:':MC\XZS;C]E_P"#5TI6;X2>!9E)R1)X;LF!/KS%0!_-)17]+=O^R_\
M!JU4+#\)/ L*@Y C\-V2@'UXBK2@^ OPRM23#\.O"<)/7R]#M5S^4= '\R57
MM-T+4M9;;I^G75\W3;;0-(?T!K^G2Q^&'@[2V5K+PEH=HRC :#384('IPM=)
M'&D,82-%1%Z*HP!0!_,OI/[/_P 4->91IGPW\7:ANZ?9=#NI,_E'7I'AW_@G
MS^T3XH9!:?"G6X W?4?*LL?7SG3%?T144 ?ACX?_ ."/_P"T'K6W[9;>&]!W
M=?[0U</M^ODI)^E>O^#?^"('B.XD1O%?Q0TO3T'+1Z-ILET3[!I&BQ]=I^E?
MK?10!\"^"_\ @C+\%]!57U_6?$_B>;C*O=1VL)_X#&F[_P ?KWOP+^P/^S_\
M.VADTKX7:)<3Q<K-JR/J+Y]<W#/@_2O?Z* *>DZ/8:#9)9Z98VVG6B?=M[2%
M8HU^BJ !5RBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBOA#]J7_@K)X#^"6M7GACP3IO_  L/Q+:L8KFX
MBN1#IMK(,@J90&,KJ<95!MY(W@@@1*2B[=2HQ<M3[OHK\/-<_P""QGQ\U6??
M9Q>%-&CSQ'9Z6[C'H3+*YKIO ?\ P6G^*VBWT(\5^$_#/B;3E&)%M$FL+EO<
M2;Y$'_?O\JT6I+T/V=HKP3]EO]M+X<_M8Z1*_A>\ET_Q!:Q^9>^'M2"I=P+G
M&]<$K)'G'SJ3C(W!2<5[W3E%Q=F3&2EL%%?CQ\1O^"Q/QF\'_$+Q1H-GX9\"
M2V>EZI=6,+SV%Z9&2*9D4L1=@$X49P ,]A7ZR?#;Q'<^,?AWX6U^]2**\U72
MK6^F2 $1J\L*NP4$DA<L<9)..YJ:?[RE[:.VGXZK\AS?)4]D]]?PM_F='17Y
MZ?\ !43]MCXD?LVZ[X3\*?#V:#0Y]4LWU"XUN:SCN9,"38(HUE5HQT)8E2?F
M7&.<ZO\ P2Y_;+^(/[35OXRT+X@/#J]]H*6]S#K<%JENTBRLX,<JQJL>1LRI
M51D;LYQFBC^^4G'I?\-QU?W-N;K;\=OT/O:BBB@ HHHH **@OIVM;*XF4 M'
M&S@-TR 37XQM_P %I/C:MX8?^$6\ ;?,V?\ (/OLXSC_ )_*(?O*BI1W=OQ*
MY7R<_0_:.BH[>0S6\3G@LH8X]Q4E/8SC)22DNH4444B@HHKRF_\ VL/@KI5]
M<V5[\6O!5I>6TC0S6\VOVJ21.I(964OD$$$$'IBE?6P'JU%5=+U2SUS3;34=
M.NH;ZPNXEGM[JW</'-&P#*ZL."I!!!'4&K54TT[,2=]4%%%%(84444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MIX/^+N@+K?@OQ)IOB;2R=K7&FW"RB-L9V. <HV"/E8 ^U?EQXJ_X(@>(=/\
M#-S=>'_BG8ZUKD<>^+3KS16LX96'\'GB>0CV)3'3..M?$7P>^,7C_P#9!^,C
M:II$EQI.MZ3=M9:MH\[$17*H^V6VG4'!&01GJIPRG(!K6#@Y^SD[/^OO\[;$
M24U'GBKK^ON\K[G])U?/WQ/_ &^/@1\&O'&I>$/&/CK^Q_$6G%!=6?\ 9%_/
MY>]%D7YXH&0Y5E/!/6O5_A7\1M*^+OPX\.>,]$9FTO7+&.]A#?>0,N2C?[2G
M*GW4U^$W_!3O_D][XC_[]E_Z105E4YJ=54VN]_E8TIJ-2DZB\K?,_;"X_:B^
M%=C\(]/^)]WXTL+'P/J"LUGJEXLD!N2"P*1PNHE9\HWR!-QVGBH/@)^U-\./
MVF%UU_A[K,VLPZ*\4=W++936P!D#%-HE52<[&[5^+/P0_9A^.7[;GAOP_8Z*
MEO:>"?"5M)IMAJ6LSO;Z?"S2M+(J!5=I)&9\L40X 0,1A:_43_@GS^Q7X@_8
M[TOQC!K_ (ATW7I=>>TD3^S8Y%6$Q+*&!+@9SY@P<=JZN2*<W+1?9[[Z7]5K
MT.;G;C'EU?7MYV]'IU.Q\??\%"OV?_A?XRU;PIXF\??V9K^E3FWO+3^QM0E\
MJ0 $KOCMV5NHY!(KT;4/VB/AOH_PMTSXC:EXOT[2_!FIVZ7-EJFH,UN+E&7<
MH2-P)&<@$[ N[CI7X-?M\_\ )Y'Q9_[#4G_H*UZA^S[^Q[\:?V[]$T'4M3UQ
M="^'WAVS31M+U'55=HEBB 4I:6ZX\P[@-[DJ"V1N)7:./#RG7P\:B7O-)OLK
MK7\;6U.FLHTJSB]E=>=[Z?A>Y^DB_P#!53]FIM0%L/'=SY9./M1T.^$?U_U.
M[_QVOIOP;XUT#XA^&[+Q!X9UBSU[1+Q=]O?V$RRQ2 '!PP/4$$$=000>:_"'
M]L__ ()[^*/V/]+TC7IO$%KXM\+ZA<?8O[0M[9K:6"XVLX22(LX 958A@Q^Z
M00.,^?\ P"^)OQIO-#U/X,_"R_U26+QC<QF73--;$K%58/MDR/)1EQYC94%8
MQN(4'.T&JB<8:R7Y^?RUN1).#3EI%_D?ME\4O^"@7P#^#^M3:/K_ ,0K*;5H
M25EL])@FOVB8'#([0HR(P/568$>E:7P5_;>^"W[0.M_V)X-\:V]UKA!9-+OH
M);.XE !)\M957S" "2$+$ 9.*_/+2_\ @B/XYN/"#W=_\1M"LO$OE%TTJ*RE
MEMM^.$:YW*1[D1-CMFOS]U33_$7P@^(=W8RO/H?BKPWJ30L]O)B2UNH)""5=
M3U5EX(]*4'&,^2H_N_3O]_W!)2E#G@M/,_J$HKSK]G7XD3?&#X$^ _&=TH2\
MUK1[>ZN548 F* 2X'IO#8]J]%JZD'3FX/IH1"2J04UU"BBBH+"BBB@ HHHH
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MQX@L+"\B1RC/#+<(CJ&'()5CR.17[N?\%&/^3*_BE_UX1?\ I1%7X=_LI_\
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MWQ8\%:5XM\*ZA_:OA[5(S-9WGDR0^:H8J3LD57'*D<@=*_GY_;Y_Y/(^+/\
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M>-O&5CHEKJ42SV43+)+<W,9 (>."-6D9>1D[<#/)%:_P5^-WA+]H+P-%XO\
M!5[-J&A2SR6R3S6[P,7C.&&UP#U]J_&OX=_L,_'_ /;BDC^(^L7&GZ%I-[%#
M%97_ (@FDC$MK&H2-;:%$=O+55&TMM5NH)R37Z=?LT_"P?L)_LJZGI_C#7+7
M5+7P^;[6;N^L8V5/*QYFT*W.["X]R173)1IJ<JNEM5]_7Y'/%RJ.$::NWH_N
MZ?,]R\??$KPK\*_#\FN>,/$.F^&M)1MGVO4[E849L$A%W'YF.#A1DG'2OFN^
M_P""JW[-=G=^2GCFZNE!P9H-$O=@Y_VH@3^ K\;_ -H#X^>-_P!KKXO/K6KO
M<7ES>W(M-&T.W9GCM(W<+'!"G]XG;D]6;D]L?:7@G_@B+XEUCPG9WWB;XFV7
MAW7IH_,ETJTT=KV. D9"-/Y\>2.APA .<%AR<H*HX>TDK+^OO\[;&TW!2Y(N
M[_K^M=S]'O@W^U9\)OV@':'P'XXTW7+U5+MIY+V]X%&,MY$RI(5&1\P7'O7K
M%?S<_'CX%^//V-_C%'H>K7;6.LV>S4-*UO29G19H]QV3POPRD,I!'!!4]L$_
MM#_P3O\ VK+G]J;X'K>:Z\;>,] F&G:NR*%%P=N8K@*.!O7.0,#<CX &!6T%
M&K3<Z;VW_+\]&MU]]LI.5.:A/KM^?Y:W/2_CE^U9\+/V;;G1[?XC>*/^$=EU
M9)7LE_L^ZNO-6,J'/[B)]N"Z_>QG/%2? W]J3X8?M)'61\.?$W_"1'1_)^W?
MZ!=6OD^;O\O_ %\2;L^6_P!W.,<XR*_._P#X+C?\C)\(?^O34_\ T.VK0_X(
M:_ZSXR?32?\ V\J<,O;0G*7V;_A*Q=?]TU;^[^-C]52=H)/05\L3?\%0OV9+
M>9XI/B7M=&*L/[!U/@C@_P#+M7U++_JW^AK^675_^0M>_P#7=_\ T(UASOVG
M)TM<V4$Z3GU32^^_^1_4M8WL.I65O=VS^9;W$:RQO@C<K $'!Y'![U\[^./^
M"B7[/?PX\7:OX7\1?$#^SM=TFY>TO;7^Q=0E\J53AEWI;LK8/=217NG@?_D2
MO#__ &#[?_T6M?SP?MO?\G=?%O\ [&*[_P#0S5UG[/$^Q6WO?@TOU,J/[S#^
MU>_N_BF_T/WRU[]HSX:^%OA?I?Q$UGQ?I^D^#]4MH[NPU"]+0FZ1TWH(XF42
M,Y7G8%W=>*\1A_X*J?LU3:@+;_A.[E$)P+E]$OA%_P"B=P'U%?G!\ OV-/C5
M^W=H^B:WK&N+H'@30[*+1M*U+5D=H_(A4)LM+=<;P"OSN2H+;OF9@0.<_;._
MX)Y^*OV0-)TKQ!+K]KXM\+7]Q]B_M"WMFMI;>X*LRI)$6? 95;#!C]T@@<9J
MI^[F^;1-Z=[=+^;^7S%#]Y&T=6EK^MO3^K'[O^#_ !EH7Q \.V>O^&M7L]=T
M6\7?;W]A,LL4@!P<,IQD$$$=000:V:_';_@B[\8]5TGXM>)?AK-<O+H.KZ<^
MJ06[N2L-U"R*S(.V^-CN]?+3TK]+_P!JOXXQ?LY_ /Q;X\,27%YI]L$L;>3[
MLMU(PCA4_P"SO8$^P-57Y:,5/HU?S[6^_;N31YJLG#JG;R[W^YDGQI_:F^%7
M[/*Q#Q]XTT_0KJ90\5@ ]Q=NIR P@B5I-N01N*[>.M>9^"O^"F'[.GCK6X-)
MM?B!'IMW.VV)M8L;BSA8^\TB"-?^!,*_#/3[3QM^TI\8+>V\^Z\3^-_%.H!/
M.N9,O-*YZLQX5%'X*J]@*_0.3_@A[KH\)>?'\5]/;Q-Y&_[ VC.+/S<?ZO[1
MYQ?;G^/RLX_@J8J48>TJ+3R_K7[OD5)Q<N2#U/.O^"SDB3?M/^'9(W62-_"M
MJRLIR"#<7."#Z5]1?\$4/^3=_&?_ &-#_P#I+;U^4WQNTKQ[X/\ &">"/B&U
MTNL^$8!H\-O=,'-O;AVEC1''WH_WI9#DC:P X  _5G_@BA_R;OXS_P"QH?\
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M]L3X5_$[X5?#KPS:>,=/B\:)I-KILV@W#F*Z^TQ0!75$8#>/D8AER,5E@O\
M<8Q6_N?DQXI-8QR>RYOS7^1\@?\ !<;_ )&3X0_]>FI_^AVU=!_P0Y_Y ?Q<
M_P"OC3?_ $&XKG_^"XW_ ",GPA_Z]-3_ /0[:N@_X(<_\@/XN?\ 7QIO_H-Q
M58'^#5_[>_\ 2T/&?'3_ .W?_23A?^"WFIW$OQ4^&VGL&%K!HUQ.A_A+O/M;
M'OB-/TKM_P#@AWHEJ-)^+&K[5-Z9]/M V.1&%G;'T)/Z"M3_ (+7?"&_UKP=
MX&^(UC TUMHLTVEZB47/EQSE6AD8]E#HRY]9%'>OFG_@EE^UAX<_9R^)VOZ+
MXTO?[+\,>*H88SJ4@)BM+J)F\MI,?=1A(ZEN@.TG !(C :1J4WO[WXOF_%:?
M.Q6,3?)-;>[^"M^#U^1^Y=>77'[*_P %;RXEGG^$'@*>>5B\DLGAFR9G8G))
M)BR23WKFOB1^W!\$?AMX+OO$,_Q)\-:R((3)!I^BZK!>75VV/E2..)V8Y.!N
M(VC.20.:_$:U_:>^/GQ0^(J6.A_$_P >1:AK^J>79Z99>)+U8T>:7"1(HDP%
M!8  < "E&]2JJ<5=_P!:%2]VFYR=E_6OR/Z(;^".UT.YAAC6&&.W9$CC4*JJ
M%(  '0 5_+?)G^U&QU\X_P#H5?U!VMA/I7@N&RN;F2]N;;3Q#+<S,6>5ECP7
M8GDDD$D^]?R^2?\ (4;_ *[?^S5KAU_MZ2=_AU_[>9<7?"WM;7]#WO\ ;P\:
M?$KQ=^T=XBB^)UO_ &=JNFL+6QTR&0O:VMGC=#Y+$#<K*0Y? +%B2!]T?JA_
MP2A\/_#/3_V9;34O S_:O$-Y+M\3W%R@%TMZH_U)QTB56S'C@ABWWBU6/^"B
M'[%L7[3WPKM]>\.6J#XC>';4O8,HP=0@ W/:,>F2?F0GHV1P')K\H?V._P!J
M37OV0?C)%K*Q7$VA7+BR\0:*Q*F:$-@D*<8EC.2N>^Y> QJ<+)1YL/+1]^^N
M_H^OGKMOS5$Y0A7CJK+3Y;?+IY:>G]%-%8G@KQGHWQ$\)Z3XF\.W\6IZ)JEN
MEU:7<)^62-AD'U![$'D$$'D5MT23BVGN7&2DDUL%?S&_''_DM7Q _P"QAU#_
M -*9*_IRK^:+]IO0Y_#7[1GQ/TVXA,$D'B740$.?NFY=E//4%2#GWKDE_O$/
M27YQ.B/\&7JOR9_0M^S;_P F[_##_L6--_\ 26.OBK_@MMJEQ#\$O %@FX6M
MQX@>60C[NY+=PH/_ '\;\J]=_9%_;;^#FN? ?X<Z/>^/='T?Q)9Z59Z1<Z3J
M$_V><7,<:1%45_OAF *E<@Y'.<BJG_!5OX-7WQ8_96O;[2;9[O4O"E['K8AC
M&7>!4>.? _V4D+_2.NO,]9SFMN:]_+F3_+\#GR_2,(=>6WSY6OST/AO_ ((P
M:+:ZA^U!KU]-M:>P\,W#P*P&0SSP(6'_  $L/^!5^UU?SP_L#_M&:?\ LQ_M
M%Z3XHUP2_P#".7EO)I6J20J7>*"4J?-"CE@CI&Q Y(!P"<"OW$E_:V^"4.AM
MJ[?%KP6;$1^;N77;9GQCH$#[BW;;C.>,9KHJR3IP?96?WM_DS&FFJDUW=_P2
M_0_)W_@LEH]KIO[6-C=V\2QS:AX;M)[@J,;W66>,,??:B#_@(KZP_P""*>JW
M%U^SMXPL92S6]IXF<P[CP-]M 6 _$9_&OSA_;F_:&M/VFOVB]>\7Z4DJ>'XH
MX]-TKSE*NUM$#AR.V]V=\'D!@#R*_7'_ ()<_!>_^#O[*.D-J]L]IJWB6ZDU
MV:"08>..142$$=B8HT;';>:PP:<:%1O2_P"LKI?<OP-L4U*M!+I;\(V?XGUS
M1114C/Y@/BM_R5#QA_V&;S_T>]>T>#?^"='[0WQ \)Z1XFT#X??;]$U:UCO;
M*Z_MK3H_-A=0R-M>X#+D$<, ?:O%_BM_R5#QA_V&;S_T>]?T-_L:_P#)I_PB
M_P"Q7T__ -$+6.!@G@83ZI17WI_Y&F)D_K4H]W+\U_F?D)X/_P""2G[1?B34
M!;ZEX=TGPI#GFZU;6;>1/RMFF;]*_2G]BO\ X)X^$_V2VDU^ZO\ _A+?'MQ$
M86U>2'RH;2-OO1V\>25ST+DEB!QM!(/UM175&;BO=,)04MS\;_\ @MIJES-\
M<O 6G.'^QV_ATSQ$_=WR7,@?''7$:9_"OG/]E_XD?M+^ _#NM1_ VP\47&CW
M-TK:A)H/AH:I'YZI\H=S;R;6VD?+D<'.*^X/^"UWP=O=5\-^!_B78V[36VDO
M+I&I.BD^6DI#P.WHN\2+D]Y%'>O$_P#@DS^UEX8^!OB[Q+X+\;:I#H>A^)3#
M<6>J7;A+>WNHPRE97/"*ZL/F)P"@SC.:Y\'&\9PO9WE\]>:WW._KH;8N5G"I
M;2R^6G*W]^_E=E;_ (:(_P""A'_0*^(W_AOT_P#D*OFO7OV:OCYXFUS4=8U+
MX0^/[C4=0N9+NYF'A2\3?+(Q=VVK"%&6).  !V%?T!>./VA?AK\./"<OB7Q!
MXXT*QT=8FF2;[?&YN !G;"JDM*Q'14!)["OR5U'_ (+#?'+5/$UU;^'],\-M
M9W%XR:?;2:7)).8V<B)#B;YGP5''4TU:5102O+^M/G^@M5#F;T/UV^"<>I1?
M!7P)'K-O/:ZNF@6*WD%U&T<L<PMT#JZMRK!L@@\@U_-3XX_Y'7Q!_P!A"X_]
M&-7]._AE]3D\*Z2VM",:RUE$;WR5VIY^P>9M'8;LX%?S$>./^1U\0?\ 80N/
M_1C4L1)RQKD^JEMZH>'2C@[+^[^3/Z<? _\ R)/A_P#[!]O_ .BUK<K$\#_\
MB5X?_P"P?;_^BUK;KLQ'\:?J_P SEP_\&'HOR/YM/VP/^3J_B]_V->I_^E,E
M?NW^P_\ \FA_"+_L7+3_ - %?A)^V!_R=7\7O^QKU/\ ]*9*_=O]A_\ Y-#^
M$7_8N6G_ * *YL+_ +DO^W?R9U8S_?I?]O?FCX+_ ."XFJ7+:]\)=-RPM%MM
M1N/]EG+P+^8 _P#'J9_P0[T>UF\2?%K5653>V]IIUM&Q W".1YV?!]"8D_(5
MZM_P6;^#-]XR^#GACQYIML]R_A.\DBOA&,E+6X" R$>BR1QCVWYZ"OBW_@F)
M^U-H7[-?QJU"W\77)L/"OBBU2QN;\@E+2='W0ROC^#YG4GMO!/ -/ M)U(/?
MWOQU7WKW2<8KPA+II^#U_P S]XZ_G\_X*=:/;:+^VY\1H[2-8DG>SN751@>9
M)9PNY_%B3]37[1>)OVPO@CX3\-W6MWGQ5\(SV=O$9=EAK-O=32@#.V.*-V=V
M/8*":_ 7]H[XN3_M"?'GQ?XY2UE@77+\O:6C?-(D*A8X4(&?FV(@..^<5SM.
M5>*2V3_&VGS_ $-XM1I2;ZV_X?Y+3YG[+_\ !)O5+C4OV*_#$<^XK9W]_;Q%
MCG*?:&?CVRY'X5^8'_!3O_D][XC_ ._9?^D4%?L=^P_\';SX$_LN^!/">IQ&
M#6([1KR_A;&Z.XG=IGC/NF\)_P !K\<?^"G?_)[WQ'_W[+_TB@KHQ7^]);V3
M7S5DW\V883_=YOOK\F[H_5;_ ()<?\F.?#KZZA_Z7W%?5M?*?_!+G_DQSX=?
M74/_ $ON*^K*Z\9_O$_5G/1^#YO\V?SJ_M\_\GD?%G_L-2?^@K7[6?L#_P#)
MF_PF_P"P)'_Z$U?BG^WS_P GD?%G_L-2?^@K7[6?L#_\F;_";_L"1_\ H35P
M8'_<(^D/_26;8K_?7_V_^<3R7_@K[&DG['-ZS*&9-;L2I(Z'<XR/P)_.O@7_
M ()!_P#)Y%A_V!+[_P!!6OOS_@KU_P F;W__ &&K#_T)J^ _^"0?_)Y%A_V!
M+[_T%:,#_&K>K_\ 3:#&_P &E_V[_P"EG[I5_.G^WM&L?[8WQ9"*%']MR'"C
M')523^=?T65_.K^WS_R>1\6?^PU)_P"@K7/+_>8?X9?G$Z8_P9>J_*1^SW_!
M.^1I/V+?A478L?[-<98YX$\H _  5]&5\Y?\$Z_^3*_A5_V#I/\ THEKZ-KU
ML5_O%3U?YGFX3_=Z?^%?D%%%%<IU!1110 4444 %%%% !1110 4444 %%%%
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M+3_T 5^17_!63_D]3Q/_ ->&G_\ I.E;XW_>U_BE^3,,%_NS_P *_.)^C_\
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M8'^#5_[>_P#3B#&?QJ7JO_2&?<5?@3_P50_Y/A\??]<M._\ 2&"OWVK\"?\
M@JA_R?#X^_ZY:=_Z0P5SS_BP^?Z'=1_AU/3_ -N1^GO_  2I_P"3(_!/_7SJ
M'_I9+73_ /!1M5?]BGXI!E##[!">1GD7,1!KF/\ @E3_ ,F1^"?^OG4/_2R:
MNH_X*,?\F5_%+_KPB_\ 2B*M\TVJ>AAE_P#%A_B_]N/QW_X)T?\ )ZWPK_["
M$O\ Z335^JW_  4^^/OCS]G?X':!X@^'VN_\(_J]UK\5E-<?8X+G="8)W*[9
MHW4?,BG(&>.M?E3_ ,$Z/^3UOA7_ -A"7_TFFK]^/&OP[\*_$K3(M.\7>&='
M\5:?#*)X[36K"*\B20 @.$D5@&PS#.,X)]:UJQ<J$4G;WG_[:84I*->3:O[O
M_P D?A%_P]&_:=_Z*9_Y0-+_ /D:O=/V'OV_/CS\8/VI? OA#Q=X[_M?P[J<
MUPEW9_V/80^8%MI74;XX%<895/!'2OTU_P"&3O@A_P!$;^'_ /X2]C_\:K3\
M,_L[_"GP7KEKK/A[X9>#M"UBU)-OJ&F:!:6]Q"2I4E)$C#+D$C@]"113DHR3
MDKH<TY1:3LRE^T/^T#X(_9M^'LWBSQS=&.P$@AM;.&,2W%Y.02L42$@%B 3D
MD  $D@5^9?C+_@LYX_UO7EM/AO\ #;0=+AF?R8$U-9M0O)B3A=HB:(!CQ\N'
MYXR:V/\ @N%=:C_PEGPIMF9QI(LKZ2-<G:9O,B#GZA=GYU4_X(IWG@.T\6^/
M?[5FT^'Q[)%;+I7VQD69K7]YYX@W<YW>7O"\X"]JPP\77<I-Z*^GH[?\'R73
M376O)45%):NVOKK_ %YZ&#XE_:J_;Q\7:/>R?\(/X@TG2)()%G%OX'=(S$RG
M<=TT3' 7/(/XU\$> _\ D>?#O_81M_\ T:M?O]^V%^U_\.OV>/AQKMOK.LVN
MH>)[VQE@L?#EG.KW<SNC*K.HSY4>3DNPQP<;C@'\ ? ?_(\^'?\ L(V__HU:
MVP<D\9&RTO'7YO3Y?J88R+6$FV^DORW^?Z']1=?S&_''_DM7Q _[&'4/_2F2
MOZ<J_F-^./\ R6KX@?\ 8PZA_P"E,E<4O]XAZ2_.)V1_A2]5^3/Z.?@5_P D
M1^'O_8NZ?_Z31UX9_P %1-6N=)_8C^(#6I<-<&RMI&3J(WO(0WX$<?C7NGP+
M_P"2(_#W_L7=/_\ 2:.N9_:X^$L_QR_9O\>^"[.,2ZEJ&G,]BC'&ZYB82PC/
M;+QJ/QKKS+XZODV_N=VOF<N6NT*/HOEIO\C\/_\ @GCHMKKW[:'PLMKQ5:%-
M2:Y"N,@O%!)*G_CZ+^5?T/5_,O\ !7XC7_P#^-WA;Q>;.7[7X;U6.>XLG!CD
M94;;-$<_=8KO7GH37] /@W]LKX(^-_"UGKUE\4?"MG:W$(E-OJ>KV]I<P<9*
MRQ2.&1AW!'TR.:W;4J$6GLW^-M?G^AG9QK2NMTOP;_S/AS_@N)HMJ=*^$^KB
M,"]$VH6ID Y:,K P!^A!_,UQO_!$+5KB'XG?$S3%#?9;C1[:Y?G@/'.57\<2
MO^1KRW_@J9^U=X=_:-^*FAZ-X-O!J?ACPG#-"NIQY\J\N967S6C]8U$:*&_B
M(8C(P3]2?\$6/@S?^'? /C+XCZC;O!#XAFBT_3?,7!DA@+F20?[)D?;]8C6&
M!32J3>WO?CHOO>IOC'=4Z:WT_!\WX+3\#@_^"XW_ ",GPA_Z]-3_ /0[:M#_
M ((:_P"L^,GTTG_V\H_X+BZ'=-)\)-8$;&R0:E:-(!PLC?9W4$^X5O\ ODUY
M1_P21_:6\$? OQUXUT+QQJ]OX=M?$T%JUIJEZVRV26 R_NY'/";EF)#-A?DP
M2"1DP,ER58=7S?\ I5_R'BT_=ET]W]%^A^U4O^K?Z&OY9=7_ .0M>_\ 7=__
M $(U^\_[0W_!2SX-?!SP;=W.@^*=-\?^)98F%AI.@72W,;28P#-,F4C0'&<G
M<1T4U^"-S.UU<2S, &D<N0.F2<US+6LY+:UCHNHT7%[MI_<G_F?U$^!_^1*\
M/_\ 8/M__1:U_/!^V]_R=U\6_P#L8KO_ -#-?T/^!_\ D2O#_P#V#[?_ -%K
M7\\'[;W_ "=U\6_^QBN__0S6N*_W[_P/\XF&%_W+_P !_*1^Y/[#W_)H?PC_
M .Q<M/\ T 5XQ_P5\56_8YOB0"5UNQ()'3YF%>T?L/\ _)H?PB_[%RT_] %>
M,_\ !7K_ ),WO_\ L-6'_H34LR^*7^-?^EH6 ^"/^%_^DL^ _P#@D'_R>18?
M]@2^_P#05K[<_P""SFI7%G^ROHMM#N$-UXGM4F*]"JP7# '_ ($H/X5\1_\
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M=W[35I^U5\?+WQ7I-E)8Z!9VL>EZ8LZ[9I8(V=O-D&3AF>1SCLNT=0:_1/\
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M7_)6/!7_ &&[+_T>E?TH?%S_ ))3XT_[ M[_ .B'K^:_X1?\E8\%?]ANR_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %?"'[4W_!)OP'\;=:O/$_@C4O\
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ML_&_QM_P1N^-'B3QEKVK6WB?P&EM?W]Q=1++J%Z'"O(S ,!:$9P1G!-?JE\
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MU:I#;S:D[I;JPE1R79$=@,*>BGG%>MT5=;]_=3ZDTG[%J4>CO^-S\K_V4?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
=110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>picture5.jpg
<TEXT>
begin 644 picture5.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ,^ P,# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)^UEX9>Z\/W/]G>(K-5_M'P_=L!<6Y(^\O\ STC/]Y?H<&@#WRBBB@ HHHH
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M-N!G!]EZ"OH<'D6,Q5I./+'N_P#+<\VMF%&CI>[\CQOP_P##W7/$BJ]M:&*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5^E/\ P1M_:0?PYXXU?X0:Q=D:;KBMJ&CK(W$=XBYEC7)XWQKNP!UC
M]Z_-:NH^%OQ!U'X4?$CPUXQTIBNH:'?PWT0!QOV."4/LPRI]B: /Z@**SO#F
MO6GBGP]I>M6#F2QU*UBO+=CWCD0.I_(BB@#^=3]MCQPWQ#_:P^*6LF9IXO[=
MN+.!F/\ RRMV\A,>VV,5XG6OXPOSJOB[6[UF+M<WT\Q8G).Z1CG]:R* "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBOPX^\"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.)^L4M=UN)1117SYZ(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!+=_P#'U-_OM_.HJEN_^/J;_?;^=14 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 445M^%?"-]XMU!;>U0K$#
M^\G8'8@]SZ^U:TZ4ZTU3IJ[9,I1A%RD[(R['3[C5+J.VM86GGD.%1!DFO9O!
M?P>M=/C2ZUI5N[K@BW!S&GU_O']*ZWPKX,T[PC:B.TBW3L,27#C+O_@/:MZO
MTG+.'Z>'M5Q/O2[=%_FSYC%9C*I[E+1?B-CC6&-410B*,!5& !2[J**^O/%U
M$YI:*<J,W04Q#:7&>U6([4=6.?85.BJG08HL,JQVKOU^45:AM8UZC<?>GTM5
M8DE7CZ5(M0JV:D4TF,F6GU$M2"D(E6G"F*:>*@!:***!C6J%A5@U$]-"*<BU
M U6Y%JLRUH!$:BD%34QQ3'T*S5$[8J9ZB84Y$HA,OX5X]\3/AS-]KFU?2XC+
M%)\T\"#YE;NP'<&O7W6H3'Z'%>)F&#ACJ7LJGR?5,[\-6>'GSQ9\JD%201@C
MM17T=J_@G1];<O=6,;R=Y%&QC]2*RC\*/#__ #YN/^VS?XU\'4X=Q,7[DDU\
MT?0QS*DUJCP:BO<3\']!9CA+H>PEZ?I5NS^#OA]&^:VFF_ZZ2G^F*QCP_C)/
MI]__  #.KF^&I*\KG@=%?1[? _P[?1[1:RVS?WHYFS^N:YO6OV;KA=SZ3J:2
M=Q%=+M/_ 'T/\*RK9'BZ2NDI>C_SL8T\]P51VDW'U7_#GBE%;_B#P'KWAFX,
M5_ILZ#M(BET;Z,.*P*\*=.=.7+-69[E.I"K'F@[KR"BBBH- HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** );O_CZF_WV_G452W?_ !]3?[[?SJ*@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -SP;X6G\6ZU%9
MQ96)?GFD_N)GD_6OH_2-(M=#L(K.SB$,$8P .I]SZFOG?P#XHD\*^((I\_Z/
M+^ZF7_9)Z_AUKZ)2],BJRE2K#((]*_1>&OJ\:,I+^)?7TZ6/F\S]K*:7V2Y2
M57\YF[TY6[YK[923V/!::)Z4+FF*:<*U5B+DB@#MS4BFHEIXJR63J:?4*M4B
MFI+3'"G4VE6D,>IP:D!J&I%:F2B934JFH%-2*:@9,IJ2H14BFI8B2BD!I:0!
M3&%/IK4 0,.*K2+UJVU5I>]6@*S5')4C5#(U4/H0.>:C:G/43-3D)"LNZD\H
M=Z533JE),8SRQ33&6XJ44%]M#BB&V-CMPO)K5L85ZGBL6ZU)+6,D\GTK+'B9
MRY#/M4=A7C8W%0H0:1YU:A5J.]CT"%E1L9K0AV-7G>F^+(IKQ8=V2W3FNRL[
MG=C!KYNCC'4=SP,;1K45<V_LJ2QLK+E6!!'8@]:^;?C%\$)/#(FUK1(S)I7W
MIK<<M;\]1ZK_ "KZ?TRW-Q$#4]Q8AD>.1 \;#:RL,@@]C7=B,/2S"ER5-^CZ
MHY,LSJOEU;GB[I[KO_71GYZT5Z=\=OAFO@'Q$ES9(1I&H;GA7M$X^\GZY'M]
M*\QK\WQ%">&JRI5-T?N^$Q5/&T(XBB[QD%%%%<YUA1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@"6[_X^IO\ ?;^=15+=_P#'U-_OM_.HJ "BBB@ HHHH **** "BBB@
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M+WEOYK_-'V'#.=O#U%@J[]R6S[/MZ/\ ,^7:***_/C]<"BBB@ HHHH ****
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MCW_R[GBX_-:&!]V6LNR_7L>(>%_@OXA\21B:2$:;;'I)=9!/T7K6_>_LZZE
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M E9<IGTW#BOG\1@<1AFU4@[=^GWGVF#S?!8])T*B;?39_<<_1117">P%%%%
M!1110 4444 %%%% !1110!+=_P#'U-_OM_.HJEN_^/J;_?;^=14 %%%% !11
M10!]1_LU:";'P/-?."&OKAG&?[JC:/UW5Z-KMQ'I^GW5S*=L<,;2,?8#-,\
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MXBU+Q!-YFH7DMRW8,?E'T'2LZBBOF9SE4DY3=WYGKQBHJT59!1114%!1110
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M=MI<<VYD/"2?W1Z _P Q7T#YE?7X'&1Q5)3CIW1\=F&!E@ZSIRU[/N<;\6_
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M+1?K^!Z3#:EEXKQ7X]?$B>QFE\+:>[1':IO)E."01D1CVQC/Y5[5K.J1^'=
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MHYW2;6C;7WII?B?'M%%%?#G[X%%%% !1110 4444 2W?_'U-_OM_.HJEN_\
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MG7T?<\/%Y9CLAJO&96^:GUAOI^J\]T?)\D;PR,CJR.IPRL,$'T(IM?;WQ5^
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MZBZK.K//+@Y6/)SC/L*^//%%Y%J/B75KN Y@GNYI8SZJSDC]#7IWQ'_:(O\
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M\!/$P< [+=''U$J8K\^J^T/VO_&T>A?#RT\.03*+S5IE:2-3R($.23[%MH_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!G_QH ^9J^GOV'='$VN^(=09>4CA@1O]XLS#_P =6B']A?6)O^9JL1_VZO\
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M[M7^%SZKT'3Y+RQO(0^Q9HVA)]-RD9_6O@Z_LWT^^N+64%9()&B8'J"I(/\
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M#W1?+B:_D7YI/ECS_=[FHG+EC<]++L(\9B8TNG7T.MTC38[&WC@B7;&@P/\
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M<Q)"J.>@]Z3X9^/+#XQ>!Y=0M;>:RM[@RV<L,Q!9#C!P1UX85G+8H^:_A?\
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M_:X HY)4'<!]5S6LFI(_)\IQ5?)\T]A6E:-^67;LG^M^Q\)4445SG[@%%%%
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M_E_P-ON.W^%]XWV>6+/"29'XC_ZU6OC##OLM,G[AW3\P#_2L;X8R;;NZ7/\
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M5,!3>,CRR6FN[71OL_\ APHHHH/?"BBB@ HHHH **** "BBB@ HHHH ****
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MJ'P(Z>)/^1E/T7Y(^R_V0_%(U3P*^F/*6GTVX9 K=HW^9?UW?E7EG[8G@_\
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ME%>4?$GQ8-4NO[-MSFWMWR[C^-QQ^0KTCQ)?_P!E:%>W(.UHXSM/^T>!^M>
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MQKBG1<?>@?HV7Y]2QL5A,PBG?2_1^O9_UH<GXF\+W7AF\\J<;XFYCF4<-_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%% !1110!+=_\?4W^^W\ZBJ6[_X^IO\ ?;^=14 %%%% !1110 4444 %%%%
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MFN [G\ 5'X&OGNM<HA*G@J:EUU^_4O!Q<*$4PHHHKV#M"BBB@ HHHH ****
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M44 %%%% !1110 4444 %%%% $MW_ ,?4W^^W\ZBJ6[_X^IO]]OYU%0 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#CZF_WV_G452W?_'U-_OM_.HJ "BBB@ HHHH **** "BBB@ HHHH ****
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 2W?_'U-_OM_.HJEN_\
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M** "BBB@ HHHH **** "BBB@"6[_ ./J;_?;^=15+=_\?4W^^W\ZBH ****
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M7SS3X9Y+=MT4C1MZHQ!K"6'3^%GT^&XJQ$%RXB"FON?^1]!C2;96W"-%/J%
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M\=3?9_!]Z<??"I^;"N.MK.*/T'('['+L166ZO^$3QBBBBNP_/@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH EN_\ CZF_WV_G4537RF.]N%8899&!
M'XFH: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %/AN)+:19(I&BD7HR'!%,HH&FT[H
MWKKQMJM]I,EA<3"6-\9D*X?'ID5@T44E%1V-JV(JXAIU9.36FH4444S ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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71GNS'JS'NQY-=+10 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>prospectussummary1b.jpg
<TEXT>
begin 644 prospectussummary1b.jpg
M_]C_X  02D9)1@ ! 0( @0"!  #_X0"N17AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     P   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E         "!     0
M ($    !    1TE-4" R+C$P+C,T   R,#(U.C R.C U(#$T.C,R.C,P  $
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M0   ;6YT<E)'0B!865H@!^D  @ % !, '  R86-S<$U31E0
M                     /;6  $     TRUL8VUS
M                                           -9&5S8P   2    !
M8W!R=    6     V=W1P=    9@    48VAA9    :P    L<EA96@   =@
M   48EA96@   >P    49UA96@   @     4<E120P   A0    @9U120P
M A0    @8E120P   A0    @8VAR;0   C0    D9&UN9    E@    D9&UD
M9    GP    D;6QU8P         !    #&5N55,    D    ' !' $D 30!0
M "  8@!U &D ; !T "T :0!N "  <P!2 $< 0FUL=6,          0    QE
M;E53    &@   !P 4 !U &( ; !I &, ( !$ &\ ;0!A &D ;@  6%E:(
M     /;6  $     TRUS9C,R       !#$(   7>___S)0  !Y,  /V0___[
MH?___:(   /<  # ;EA96B        !OH   ./4   .06%E:(        "2?
M   /A   ML1865H@        8I<  +>'   8V7!A<F$       ,    "9F8
M /*G   -60  $]    I;8VAR;0       P    "CUP  5'P  $S-  "9F@
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M P$1  (1 0,1 ?_$ !X    & P$!               %!@<("0,$"@(!_\0
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M$?!DQ(EA07%?XH2R,4IOF DR3\ <F$Z(PR46  #.2XKPC;6EPTB9X\WQ$
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MWJZI7NKHY2  #D> R!*;)*\= 29'L182&R.4+ A 74'2( KT0VD<)7N4)U
M>@XK'!M4&DY\0   $Z[3-V%W*7CM]/,,B9T5<Y%[N]?DU[J[&K?<=H?SN>H%
M1_T+^4"5[BQO+9.0=8YP4#TMDCC]^8A(;5OIB$>-[.= &6R7JZJ7JKHY2 'H
M4HGQ<"S).#ZD/"48P@Q!JA@/L-F,87%G2& J7F%H"OPJ F R!SR957- UISM
M'QWR(   L[ZVS[J\[%P'CM]/L,B)K5>%QN-C1]R^(881F!UTYV<P_5762CWG
MQ[UAEWTL:B6X1%<=TXWNVNDSVF&>=!G8O!O4U1OM71RD   ]#P$YAW"!8D1X
MQH3?#$T0&(,2THZ#0'(+/)&-,W\8IH^&24?5TG>1!E"T*,:N:)K^,$0  G#S
M,R[%K?AO'9Z>X8PV?\ <E@ZQRS9IUT_3QW'QX[W:7"+.FKDI,DL[K=)6EKK?
MDK;8-?\ [7= N9<6]+42_P!<IR4FF ^CS%C(RA&XU#(.F*D-S?"\W30-<LI+
MS@'';-+%^:+<(^#- Y [O/3-@C^+(;)"%7'AKTI@ !87G'7/79@?8W'9Z>X8
MTO<%CGIX#[ZSYTHN[^[7=(\R>_N$,I;,87'HEB2DMEIM5^?SNA8=1^DGJCC-
M?7J#Y>0:Y62]"O=]JO1U%O\ 7L<D 6@,A8B+$B&:X=#MAT;9\#8VPL/)KEEY
M=8 XIYX1;C$ %O)!^N>EO$["+;#-":0AU2@EZ$P@ "?'$QGK_KY-QV>GN&1[
MX=7II\!-HN>STRLDJ^H>9(;3CN2FGVKT2R;$V=?=5X[<W\V/I]77ZJ>91+VC
MQG<U[ZLK3W V3OZKPO2U"O\ 7L<I8@ "W+@"!X@!6#FAH'9*$7!E"@;09P(R
MR8NI <4\Z+<0,H^/*/Y+3+JB9\:D?H(Z#J11WEE9J@U*<P/H\,'<K(X[/3W#
M(T857Z"_G\W=H5]M-65_A&86;>26Y=1OT9>8Y+F7$4?6=ON>^>;U*A7OAYM[
M-^K2Z\\;]2K[=X->;:[[>EJ)?Z^CEX&//0_9925T&^.\*(.2:XZ87&\)4C"$
M86D^"YP^'%1.BW$I*21]<L>6C#"FX7$O,IK7E#X7[ (<2G+J31E2M)+(FZ,^
MM3F$#N0=S<CCL]/<,8[(N#+OQM] 5CK[M;N4[+%?V$\VHR8!UZKMZ\7?#H/K
MBQ_Q7V@S9/ZGG725C^Y/H53!]!^L]X>N]]O2U$R" !SAD0 T+-1M!J!T@^'/
M)"C^'TW32-8:<:@<DE<6I@.*>=%N)]XK(>88>*+L*3C33N7"=JH2MXEMJC/7
M0@QJ5'H$U";0X\SN'<W(X[/3W#&?[ZL1=:N5L]77HIRK@_:E'=X,Q!6FPX7S
M#/ N+)K7.H[73> MMW#SXD[I99>EKA>KT]1;_7\<[(WID)_D&20QY 3&%J9Q
MP@M/AA-LUQJ"0I;8 XIYT9)Y9V\F-SB>*\\M?$LK^1FF=!6I""QFEG6GK7(L
MI4]&4HA$HXDSMR1[FY''9Z>X9'3->+[X\VO;9_?/DPV#D>^?)ZR"CKXC7]\R
M&&Q5?4LWF$OOE2WMZ]72]/46_P !#GW"@:PFR(H2XNPA)@$DA&A^>#9,9\-@
MC82^+80'%3.CIRI9GU8VF4YX=3RPH2H=&1B*BD@6SPG@FK[0CPE;I MIQP4)
MG7DCW-R..ST]PR-UPIIK4N^KSLRJ?=N<!LNA)DQKS>7#].<+5_1EG?GHJ*ZU
MMV21O!QF&&P&$)ZP7/H3[IM=Z6HF05XG/J'@@A.E@Q"P4(HQ6E@IO">%@;9J
MF0;PC>6G%BH#BGG1AF/ARULL53Z!VIE29Z$WU&9(7D$TD>)8)B0))]>G%VY7
M<W(X[/3W#&3[ML[S:2;#6F>%6XDB,XZ)HF]>^EX@=1XFO?2C#9$:C=6V?>.G
MJ%I=NSD_3EC8/:S1RJ3:/-N@C/N%>GJ'D%>)SZAJ: CCX3$(GCB!D3I%X&9L
M&P>#4$B-.2_+9P'%/.BW$83PO"K1KYJT]:B;B(NJ1<R6=]H(C3RMY"5-T9M>
M6;Q(\P.Y!W-R..ST]PQH>U[+8I\U7L- 7U!T2GMT)>)[]#<WG']:=8?NPMO/
M>@>-=%X1^JU=WJ3Y.QDV0YTZO/?7NN#=O:>_6W37IZB7^!90N;@5A6%0\PS0
MJC5);CD#LFD93P;)JB')A%BP#BMGC%>,/9O$AJ\&)J2.1+/-*HBD,Y"0FI3:
M\(X)8XZ;X =R#N;D<=GI[AC5]Q6*=?SM>J,6-RM>2[(^/.K0WN2J'US\_<^R
M-MDWHY@]M7F+ZYH&OK:RV7Y4H\'Z1I.]->ON@/*J-Z>HU_@H4*DHQA1L1T1E
M1Q36%625)#F@8SX ,@O" D$6?@.-N,L=HS:ZDW$U40>YH/1-&6DQJD(GP@52
MQQ2Q   @?:5W P<=GI[AB%[@Q[-K'WA,_P ./4F..Y'1[![NZ -!K"<'TYPQ
M^-9,"G)YC=Y2LQ[M DU:V;8C97S?J<]3)KO^/?+T]1K_  "*"R8)+0J7$V2;
M(QCD!224):A>>C*?37/HGB1A9D Y/T&$C3RPG3DTWP  'J+Y!\   !=TT@:$
M.IGDQXZO3O#&*[%MOOE2$^'W%993:49BES)^J;B;=YVS8H2*OK>Q)_/[H\^K
MUK5V%=A)7,\>M6XE\O3U(O\  (H&%4;Y@$:9!SQL0^%L3L#P*12FH:9[(^$Y
M"SD!_\0 ,A   00! @0$!00" P$      P$"! 4&  <($!(3$10R-Q46(#$V
M%R$B(Q@D,S1!)?_:  @! 0 !!0*RKL,6Y;4;?D/3;<X#<5_$T,F';B_,^2Z^
M9\EU\SY+IN39(Y?FG)/#)<CD"E?,^2Z^9\EU\SY+KYGR77S/DNOF?)=;9P,L
MR([/0\Q4?EFX-O39&?<K.#W,/=[(<CLI.YMP*38;DY=$R9ISJWOEUWRZS3,<
M@H;$F\60O)<[C9QC<6JGVTJ!WRZC/<_EN4C78PR.[Q<!IT=TM:[IZ3*,6O[%
M8JM&QQ$:YQ L6?7UUVF5[8,+&"(U7)1J2@T$V<*5!':FCN _I9YACYX;M8O#
M[$N 93RW.W?SZGS$6^NYS0)OYN-$=F&7WN;7'.!5R[#4F&:,[P7Z]B;)8U8S
MT$_Y,]QC(<B6GV7$MSD6V]D;-!XQN)2S)F-SY&><\[P5,UM,QVO'(%88A=6N
M+K^ZZB<N(FYE46W55N7&-&A7D$Z $V3I6M$4A'HQ#AZI-[45Y;3-&^-EDEA,
M% RR?"7$\TBY+ R_#8.20A1#5TD,IX3XZ1ZU8F%[CAC%H FJ/:'K6WY;L,G!
MSF6VV1S^I'<QM<KB1X-=5$(K"+'5&K^WU;2%Z)+/1N'Q$;GX]G;^*K=0;HW%
M!NW->;B8WBCN#Q+;PGTWB(WN>Z3Q*[RPU_R@W<TO%5NFUR<5>ZBZ_P HMVO!
M>*O=)-?Y6;HZ_P K-T=<-&Z.7;D\N*[K_24+Y+$!;28NH.36HGMW#NET+-[]
MB2;2SD(B3)3FU2O*V")&6.-D5:6//KK:5C=IC=?N'5H$,$_[X[8,LJ^.XG<8
M,9'9+DD2OA\.>2R[S-.6]<N2FYZ2C?161139^-U@_B]@"$Z#:B/&G-;_ %V:
M"-)^G9NN=)1GHW@]U$K9$V;28Y83X\6/5UMKB6RM%G=1DF,W6WV07-@<DU/M
M#JR3YCL+D07U^&8U:UV4;)VU3"EQ21"I]^"K[:XEHR2]LA4,54%51VG^'Q@J
M&M"CV-&UQ6 9H?\ 0@G%ZY#6=!%&($R/WA;99;2Y5@F3PQI2CG$@S*:_E0BU
M^9PY0YUB<H<GJ9L"/P;3'SLZY;V>ZO.'#DSY Q]3L<\L,V.P&VD7)HQXMQ$(
M66H9"19)NGN?1M/;_!7,]&\'NI62A]C;/#X(MK;B;&BR^&C.!4USQ6U\18>2
M"Z;)OVVNQH%E9;HT8(5'BV5RJJX/8#<S=["8D)RL<C^"O[:XA'=.W2/;IG4Y
ML=1C8]%"UG6X4@:">C>[IXE:]@^ESR,0C6(/6+^0L<VW3P2UJXEDPL0\,CHQ
M*>47N@NJZL@Y=E);1G!'^7<M[/=7G%E289:ZH<^,D1T.RPJP1CMP@=JV8KQD
MD%[DE[?!>?VU@)RKFK/1N_[IUKG-N=MLH%%V;R=4.+%[ ]<7=2Q-<X=<L::O
M;]ME)G<G99.^*X<UW;D;99K$DP=R8@ 8A,=_L<%?VUQ!-Z]O&Q'NTJN:T3&^
M#F*5Z#5B.!+T)L@2%D=U.IB:>,?C.DN:.)\0%9666V=AATY"/E0JWS+YU?Y$
MDJ3)EZO3=.N"+\NY;V>ZO.DK'33QA=9KB4./(QF0V%+W (I["FL<2!$G2DM)
M4N#TQE^C /SAGHW@]U*AJK=U^7%@X)D*]ME<9GPW);$;L,MB#94M].UUQ\)R
M6QJ&A@6+.S*C6DB,;XE?Y%1SPH-_!7]M;_,0FW[ONK)#GN&]FE1C=(Y7.8TB
MZ>SPT-1C?T]G3F-.MH1[&8]<G25/:Q]+9O52P2LCZM;$\]RF4"2#ED$X(ORW
MEO9[J\JZ'1R*_'X4:JJV <2QQ^LQ:]H)$BJQ7)-Q QGUKE7P$1\1\1\FP$1/
M!>> ?G#/1O![J5!DCV_P$GFLB DB;$@OBQ,N0D/$\F_8[?36N4,S(]SI\FK[
M["N!!+(7'Y3*;'+@O>E\%7VUQ#D06W2R4>V.;M-[LC1AZ5O;TCE1A6O72MZ&
MN7Q$TP4U<D9J@ :9:6D<JT\H[V2Y1$>Y"(1LGH&QWAU<$7Y;RWL]U=)K;W!I
MF1"/6,!H\Z1'/:S E6'4EZ<K%UT)Q]HK7-<^H5SC6D-T64O/ /SAGHW@]TPL
M_P!EA6(,L"$AX%N*-?9!D9<I/>&\W.;Z22NTHRJ;3VM 3'I@H[\DNP.A22=T
MW!7]M<2*-7;2*5K#.[)W)]E?U/7^IR.+W%?WWE(K%3]DE$_KL)"--B*/?:S#
MK\-LF(Z60J/(YJMT8*DAN3I7@B_+>6]GNKH;%<NW-O\ "VW ZS):?)L7#2US
ME574UB6!(M9BV-?)1K#0XKI<C&:!&2<ZK(T&Q?\ ?E@'YPST;P>ZG/\ DFOY
M:\%U_P"?MK[<NMR:ZG+KI;K@LY<5%@M9M5&NPV"#.@V (,@4:X8^@I&I+\$B
MJK-&1&.DS& 6RL^]H!W2'87$))L+-I9%5<>9B2^A>XQG<T WEW2B]\_!%^6\
MM[/=77\46BM3Q%Q^YC_ \[MK61)\="3Q)68]16F$36#9(PFN63:W$.MK-9W+
MA3);DYX!^<,]&\'NH^%)ERPT,2%IB=C6*;=EREV9[<7&".M#>,-J?LZ3)[U=
M6VL\Q]K+@$6RPG(*^*<TT#O/2=<%?VUQ?>SHC%"^MRT@M1;E#!!9N:UEYX-^
M*HX7Q5!HV^\7R9[IFD.8)6"FRY.%TY:*N6_)*IFVE?EALAQ@U$8Q10BRYI99
M-<$7Y;RWL]U>4>1VB87?%D'RF;(/-Q_;>POZ/*<<E8K=Q+J)&QF#6K;-913<
M(ERK =@&]$Y"/7^7+ /SAGHW@]U*=C05FU^$'RF3N%7NA7NSN4CQC+-Z:BON
M=OK4KF4R:Q3"C7<QN"UM!5'W$.&=\8@S<>W3PF#!$J>#^"K[:XO_ &<Y,*0:
MUTE\N,1/ _Q B-?)(\HB>"L"-B1X3;8N)85#HXN7Y?YZ3.N1I430GJI1R?,.
M'7T-X9G+@B_+>6]:>.ZO+Q_? IU,*XW Q]85G49E>T@KB[L;T[CQFU-#D,W'
MCNO\BRN08#ZZKLYQ)DCG@'YPST;P>ZD&Y+'E<+[HHXF^!V&SK';!S-8Y(=N'
MM5D-.2$9NMN+^L86;=SFV.YT(%9DNV^X+.G-,:!,Q.TC>6E<%7VUQ?\ LYSI
M)3 F.G6BD=HI6N>PJ,(KG&=MMC8([<WS/R\9&3>N#,6,\UBP\W&BK: NJ^;%
MDS1-$77!%^6\MSQD+O9)K#39Z5<QY&U%@_2TUBQL^)-JS*OCIOWD2NXW4:=)
MAN/-E2E^C;Z,=^9,]&\'NH5%\_M%DBT4W<"Z^*6F.)_L[!%[&W>>N5^9)]L:
M(9EW9*J6V[YV+EM)-?&G3MT9'P2W7OOX*_MKB_\ 9SFFJHBS8!0$$]RJKD>$
MB4,1+"9>L6MP[':+YAN=PTKH2G7M##W5;27,NLE&EQLP7):P]>77!%^6\MVS
MNC;QRYQY#OB]CTNE2'*V5(8ISFD.Y=HB,\/J@"QE8FV%K61+%GHW@]U'JP1W
MS)D5+83THL=1_G-DKKR6#YS9=RW3[5Q>Q,J9U-=P\XDCL,AA &AF53I"7+6A
M?P5?;7%_[.<X<&78&!02:E.@3M(QP]!_Y-O<=/*E;DWZCBXW*=2X_8H>29SO
M%J*K5B*]"8]$_P#I[CDB3-'$T;N"+\MY?!J)Q75.$""E5A)&<1L#&DV]YI]V
MD5H,M)CSY/T^.MJ\-D7SV>C>#W4.]JGI -)5V+QS'"AC9)-:UV.8=<R?]--*
MNHEI+ *08CBU45T@Q[%M956,A3GX*OMKB_\ 9SDFH=M85['D(5U(%Q5)VR)A
M^WTB:3(LRJZ&/"FNO[O+(D(([=!MC]OLNC_Q*UKD)1V42'$DQ23-3JR?&UP1
M_EO*ZXFL8PJQ;Q=89T_Y=88TF^O$1CFZ&*\FM5Z^6*T:CAE:?#+T<14\/JV+
ML?+53/1O![IR&.\P.<]L.BD##+F%='L3V\NV2REEG2].\.D8G)HH7M=!FOBK
M96Q9;"!*XG!7]M<7WLY]">*K1P"MUB> C8RQR&+K(7QY=@%W699498DD\@[O
M)+($.F.C5KY+7?#I@6M0P].GDD!X.Z\43,>6[_B_<$MDD49;>Q+S1CW)"C(9
MRUX8KA0R-GX]-BW-7EM46JN/IVE,K#,]&\'NI'B2)*DBN"Y@"%<L*2TAS#CD
M'*"5VFND.)'@3Y#@;?9?+%:4&2U#W39;'#G2'/X+.7%,%DC:8S.V3GC-:I]8
MICE7CU=FFXDJZT0\A[%?XOCC[DB/4.9H,("(V.)KNV[7BQ^H_BKW@:[3J^,5
MO"G '$R[EO+> #N$Z_"Y7+U+KH=X4\\T>%\"AUT''\0?8MM,>)#2A[4=N<PP
MV"$&X;OHV9K?,@9Z-X/=0!'LJMJMF7Y1%I\-P:@G9AM!B&6T&;8Y.I9\'_MZ
MCQQN?C53%QO'>]D-HSHO ,W8P<%+8(-PS\%O+B<&A-KIB=,I-+IC%(_;3'_-
M2MT[)XGM PC2CU$JRSG0J^,!A1^"?P<P\<HV($C],@*=JQWB4K1]+F,8SA<5
M?F/EO9[K<RVDF358I"HW0\@QB+;8S@JV!9.>5H%R#'^]66MZ<Z:L1N[OT;67
M;Z73/1O![J1GKW\=ECQ#9S(\VL+&?MUOCD>/$W:QL.3P35R1SZH#QFV5C%23
M:[B;C7X[^@W=R6KUDV1/S"BE-_V^"SEQ-N:W;#)(OEK+E0)_O;<Q'UE1EEHM
MI<M<Y!5\,LQL83XZ"3J5&%DMH,.:P,C':SJBU=:UIX*E?,IJOJ.+M'(G1KA?
M_)N6]GNKR:US]5CVT@\%QO&+'',FL)F$VV(Y +)R;Q&4-I!L)[VW0GR8DP+9
M,9[?!>> O<N;L]&\'NH'J6RQZ>S)]E[FG-YC#<</9S]Q[X>+8Q)D#&/5.(AK
M.V*L>PS_ &VMKBWI]F3#BT>.XV&DOQL9:\%G+B95$VQS('47EBE9)D2,OE_+
M6)-F.:2*-TA8L9(D4;7O: #I+J/&(\(1N\1)$%'Z3MH$Y/+1EC/1.VV::5!C
M$;PS1G@RGEO7[JZJFP72\0Q5AY=]'?.QR$>2C8U<KY>+.QNJRC<&WQZ#96.0
MP[*M95(:@DB($LX;>XK.> ?G#/1O![J5L-SYNV^X28^'(H^+WQ:?(\<PV/?Y
M#/R>9'0GGM4DNFKBT675&=-:R-Y<='?,;=6 ,6I9A?-2N"SEQ*M1VV>0PAGK
MM0XSY1=NJ:+#;GF1LOK*) 5= KW1=#\3ZIL?FV21Z!L$[4;KPZ'.Z=*O]\L"
M.:7&RL(_&Y9Y\V'.J(^P39#\BY;U^ZNL'Q&5E%A6U!:C4SN"H\=JV6UAD/Q:
MC/MI6@-=[JV;+7)J6M<*26D&+&;\*]^6WI8QC>LX^E^L _.&>C>'W4BRE'#'
M!6<9L2&0A8PXQ/B"AT^2R;'TY':@V=G525WAS P<7W1F0S[DYZS*#!.5FN"S
MEQ+B4^V+V2!:EU,%718L8:D$5<(B0R-D C1QQSH\VE KV8$Q\*'?]^,"CMO/
M1W.:T8OYNZG(]_<UU/ZW17>8RJUFUX^'>SE3LAY;U^ZK&=2[;O?5S7XK\P-D
MX#*FUD+X+C1791"G4V-8TZ1!RF ?%;+;(])86-A)B'J<C<(D@Z/ZRJK'$<KF
MZP#\X9Z-X/=3KZ=))\-(]C5<1"+_ %)I%'R[P==T2:\S'UYJ.FO-1](<#UX+
M.7$F51;:24[H/*,<LMK8CML,BC&#N'0RJ ]%8^;',C=IJD(36#RP>7''B2 2
M(\:+):]7/DN7J=TJ+^96E\!HTBO#E<R,9.'J&^+>\MZE\-U@O128G(% U<Y+
M'F8QE.\MG:1+>\=8G4CD3&<PM:!VX>4V-V';BGDV)\B@6-:"WB>)[$S&N*;K
MTJZ76 ?G#/1O![J/B>98RKDR"Q*..-R0*MA+:*6.:-_SZ!C4P.J3:V9D 6;,
MUFK/9&6YMG2RJN1%_P"QP6<N)[Q_2V/*[J&>-660O,-KE)!)56]?EU+?X[98
MY/B29!&-4O5 .4;J4PDB6$5IQ4\YR#:,:Z\&HB2'#T=&$'-?-B@JVOL+?9F<
M.1><MZ_=4;U&ZDG/ERSPA2L%OX_9F_*LVPJVUWE)/0%!R)4C("T-+\KU][F#
MI5;>9$I]2SM>O_J\L _.&>C>#W4@#,9U%22LEG81B^!XOK)=FL3S:IS?![7'
M)HAN'+T._P#B,IR1*O5[?"KV4LF@MI6]^-1BZ&SMS>"SEQ/*B;7-Z$TUJL:5
M>I)M<FJV?,B3\\3OX]!?_)@T<0+7=VHEH.GHR+*BGAH9SNOQ<5'-;U=!NYX9
M"0BP(HXU54<.ISFN^6]?NKJ-()%-M)G&-9G1[BXR_'K+&MQ0TM7FF4@R>\BV
M)CLHKF/1669[I#GU7S$X@"S'/1RKR\>6 ?G#/1O![J1"D%78!5,JL5R+(#&E
M;#;IS:'(.)NGK[+%;4*>=U1JY;BV\5N-XSR"931S+ $_*XE[)H"_M/X+.7$<
M 4C;=8@&:>#1(S&:D"$H*"M\W;9W9MF.KH!0HQ1J1[D,6+W"PL<=($_K>ACN
M;IC".<BHUS!O*UK%<2SIPS'[*5$*MM.6]#7/W77]EZ'HV)+DP9%ON$?)Z]C&
M$)6X?<V.L?VVG-J+Z"\4Z>H4*URHG7I5^C /SAGHW@]U*<:G'M9D(Y51FV(D
MK9>&07):;N9Z2RJ+.4,DW6$X9.L+H&,6&67.4XC DFC8UAE0[/K]D/".ON6'
M!9RXB7=.W"RVQUPG;JUSV%<UEE03S]/<PMC&S+^'+BW4<'< :/V7T$8$B?2"
MC$LD&B,57*[I5NE>[Q*G0Q%&P:N<W5A'*>/L-.D'NN6Y8#2-[UJ_/EFUDF/2
M\D54UCF?9#C)Y'$3<S63-T8%@.7(&<ZO5?JP&!+^<&>C>#W4QUS6,98$HK>9
MG%#.K9.8A75S8EC.C?O(U S.UH"46Y,&W93;D2YT&OQ<2.W,V^M<I6QQBPII
MG!9RXE'JS;.-XO7;+<4>!W&:[B[7YE7G[;#>8DQ#2AAS&EC'=#UT-+';U(_!
MFE/.5I?$@NE_1UZ&[P<>,5Z/\8S.A&:GE;&!L0:+)M.6Y6VV9V&Z,W:K<684
M^U&X1X/Z-[@:_1O<#7Z-[@:_1O<#7Z-[@:_1K<#P_1K<#7Z-[@:_1O<#7Z-[
M@:_1O<#7Z-[@:K=I<G#'P;!\GK9;/1N^J+NG&FEBM+/*9&JUKA7A0:/X')Y1
MG=UW'>(KZQCB29)0L3<W-( 8^]&X,9+S<K)LCA\%G+B47PVS'([30+WM=I4?
M)8C]&CJ1]59S\?FY/%%<5]8=3C._R[,=R%]+(KY[I^E9H SL4 G(220GC_V7
MR1_OFEB]Y.'^*V/(Y?_$ $\1  $# @0# P0,# 0%! ,   $" P0%$0 &$B$'
M$S$B05$0%#)A"" C,S1 <7.!D;&R%18D,$)$4G*#H<'P4\/1\4-05&*2)6.C
MX46"XO_:  @! P$!/P'X@EM:D*7W)/\ ?V>6;),4P6T<KFU!<I+3DE99AL^:
MI:4OSAY*5J"W.:"TVE)44)6OT1MYQ-=DT^&S%;;E38LB2M$IU26V_-ZBY3[)
M<90X5H>*6WF5E";M.W6$%)&/PJMX4[S9II*IL*3+<\Z=+:&C$J#U/=:2M+:N
M82MK6@Z4ZD7)TVPY+?07641?.I<2&S+G-1W0EMLO,F2B/&6ZE)DR#''.""EN
MX4VV%%QQ(Q)GO,N1TLP5OHFEX0EE]$=3_)83(<YC+B"N-I0M((=_2.G<I59)
M)2DJ3H44I*D7U:%$#4C4-E:3<:ALJUQU\M0D*AQ6GT)#CK]1B4YM"CI1KE(?
M6%K6+J2E/)L;)43?IA^>_&;D(>8;3-8JM.IFD.DQ5BHQ');,DNZ ZTE*6]+C
M:VN8A75.XP].EQ8RI+T1EYIO1S7(TOLMEV0B,T@\UE*EK4ZM%] TI2L7/8<L
MRMU:-3S/FZ]2QR^8EWL@]E6M( [0WTVNGH=_^54FC&5E>M5+3<1;=KO39/:^
MNWEDI=4&N4W&D(3J\Y@S4WBR^T%-*Y@0XIE: .6KW-:5(-QI7V@BDDFF)DK2
M^U"I\V.L!;J"E^35'IK"&2DI<,>-&>\V05KU$)%T$[B=3N:]3U1XT-R-#IST
M%423V&079KD@.-I#;B3I:7R^T 25N?*5,34//RXJ8B'Y\.(U(:6ISDQ)<*&(
M+4B.4H!D,I90TH1UH9[;5B2A9 ?CNNN4=>L+-/7.5)6KLJ=,F(TPE:$H&G4I
MQ"EK3=(0D]F_M*E&,Z&Q%%K)JT*8]J.D*BL-R4/(! )YBN<G1Z/0]L=\RG-J
MIZ(D-IE*DU6'4'$.E7+DHCLR&EMR%J#JW"L.MI[87V$6O9(&'(;KM)F0 S$C
M./NQ5-(CJ5R+-38TQU:SRD%+BRV[Z*"%'05*!4JQW)/_ "$XOBYP/;4C.]+I
M&5*QE:0RM<^LA7(=3Z"-0LF_]?)(J4MM]Y"%(TH<6E(Y:>@-AN1_/#;]8<0'
M$MHTGI?E8E3ZA#&J46VDGIV6U*N>[2-S]&&ZY(=][<OZ^0+?=PY7)+7OB[>O
MS?4/K"=OYX5F):393[0VO;ECO^C#=<D/&S3B%_(TG^HQ^%IO[2/DY:/],)>K
M*D!P-(TJZ>]8Y]8&Y;0!XD-?TQ^$I^K3=K5X6;_TQS:R;$-MV_A_UQKK7^&W
M_P#%CF5K_#;]?O73%.E/23(#I!Y10$V2$]2Y?I^Z/'XZ<7^7!Q;R)]M6*QYI
MFZB4VQ)FV(5^S8V_V\DSX5(^><^\<-U2+#@IUK',0#9!/?<D7OXXX4^Q^S%Q
M98&8ZU.1E>@+D%BFRIX434'!;F)C(58+2D*![T]>IZ90RSP2X2<08N4\SSHU
M5GR5)CJGU.-$>I,=Q1L@RN:A266774A&O]$K'08XP5_AQEQQ%&KW#7+LJDU@
M*C1Y=,H].CRS!=#:E5"EU1IC4EWEK2MEQ*M_&U\<8.%-*RW"IN=<ES'9^2ZS
M*4FG2)B$\V!-:0>92JKR^PLI*396P6-[7OBC4QH10\!I4H7MX*5NH>( .P'<
M-L*ZJ'@5#^9&)]:9I-+2^^K2TEDJ4=]K 7M]>!Q+B5!N6W!.MUH*2@ J]+<"
M^_\ ?=AO-.;5UMMIDE$M^2A$>&ZAQQN3J6+(O>S6Y3OO>]L27,^9599G9URV
M[2Z4_H"9[*E.1DK<V0A2U*(0KLDE)'>#WX@S69K"7FE!:' %)4.ECTL<=WT8
MI/ODW]]O[7OCIP.OD/D'MJCEY$ZNTJL$C5!U;6W%C<;^OR3/A4CYYS[QQ+B*
M2]&DOI*X3KK24MV-B5+";$]_C]&*]G&50<[</<@4IA+%,BTW+L=S0H);0)40
M/+64 6!W"EK)N;W..-LN9FCC!G9U#CD5-/J\V"V #=8CN<H*L=/N:D E*K6O
MZ)Q0JG.XL<(5TE] <S;PE1KT+<YCU2H#I=#2@G9=XP82@>G?6D7!QEIB37N"
M7$RBR6W9,"F-Q:[36@TIQ;,R,^?.0VD)U (2H\Q2>@N5;8R_)YT4A:AS"I:C
MN.\W_J!ASWQS]Y7VG&9Y4K,%>H63FEEI$^:F XM.Y0AZP6HH%B;(WZ]_7&?>
M%4/AS6LL+IKCJHE21YG.NRM#:GV@T4+U%2DFY6NWCXGNS%E*-YHBHP1:7 *)
MZ=">T51_= !8W'H^O'#O\6^/O#&-3:G%C3"Z@L52(XXA;C*HS302[I24+2L%
M8[@<5W*]1X0YR7DR9(>FTEU*YE&DNM*9U1P-/FZ=>KF>;CL]E1.D D 8"TE%
MPI)VOL0>Z_\ +%(W<G?OM_:]\=/3 Z^4^1/MYWPJ1\\O[QQ-T)HC#J[ L$.M
MD].8A?9Z>)Q5\I5#,G$GAK5V+::A0<N29)0"/=T0=(%^@U%('[(WO88S]+;D
M<7.("V[<O\8*FPDC<+Y$MU*S<;;*'T]<< *P_3.,E-IZ%_D.:'?Q>J31MH>9
MGDMMZ[[^YK5K&G<8@Y2:@TWB;2XD9L&3EVM)99;LA)Y;#B[;D &R2LGO[[G%
M'6ZS-D1P+66LVN/1!M_3#G5?RJ^TXH%"5(XR9$.I(\\KC.ZCV;.) '\TG;'L
MM\C&D94RE5?<RENK12X4WVYA92";]VJP^F_3"&];&E2+ZVE-J3?N(TJQPRXE
M5/@OFUQZ8IZ5DZ4XX9<2,E(=:?D:$><%Q6D\K2VD*0%=Q-L>R@SE2LUUOAK5
MZ%(:<U-3+EIU#J^1)6- =T*5I-KI.JQVQ%;]Q*MO1Z7\4[_V,4GWR;^\U]KW
MQXX&#@8/D'MIGPJ3\ZY]XXJQ2,OMH*AVC:]SI])77Y/DQ0,ST>G\#*;GUMZ,
MNIT?*S=,BJ<*2^U4F&DL(2I&K5=/,U(4%=+&PZ8H\F159M5J<KMRI]0FRG5J
MZJ6^ZI:E#U%1\=\<,Y(I'&#)\V2X6V6<ST=TJ3N=(FLA0MM<[["_CB?#13G<
MYU-Q12PG+U<6X1O=+D)^VD;#HL7/=Z\4]*W*O,?:%V@M;8/>2"3?Y,*])7[Q
M^W%8,FCU3*698ATRJ/6H4S7<Z$L"2RE>JUB;-J6;8]D%7XF<N"'GZI<=QQN'
M3YL!7,2-;J.4M24#4I6L<LBVV]A?PI3W-ID!Q:@%KC!1!OJN5'TO[.)E$I]1
M:6W(:2ZV]V5I(N+[[[@'OQ*9I.7LQ-LE9<1K2&&7EZT,>IH'T?&P[\4]XN-M
M%LW:6TA0Z]"BXMX[8I'ODW]]O[7?CIQ?^[8&#B^+W\@Z>VF?"I'SSGWCBJ(U
MTAI(&Z>T.^]E*VMC\9ZD*3^"/.Y/F>KG.QP\H,*D&P+O*O;=(%@0;'OQ1)WF
MJ2I2MM5[VZ)\/6?ZXX>4J7G7B9EBFT]%UJKE.4I8_0;1)0XXX>G90VA2NO=Z
M\<5*C%A\/L_RD/H;:;H,J&'SWDQRA.PZJ<*2+ [8RQ[S()'I.J*3WV-B#_/#
MGIN?OJ^\<5UP2Z8]"M_P%M#N](#O[NG7NQ0,K5J>(L.KUF>_2*<ZI<6$'U<L
M)*M00M.I25@=UTBWAB.E,9A##2$V;N$*6 24=R-K=#B77XT0J\XTMJ0#V4[
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MO[L?(_9<_P#CU1_+FO\ \MA%#[+SBTMHKM1UK("?%FG=2N@WC6W)]OUXXWY
MRODAO*;N6F)+**TW5ER3(F2)?,$1JBKCE'>%J+?^?/DA-KZDA7JBWWN.GS2=
M(OAD7\6-L+5I]]S;[<)%A<_A=,.)OO\ .I4IIK*-5CJ59QQ+V@7ZW!Z>CAB;
M</LF&_3+M(_4V<9GX*YNSSQ0JKT>*Y#R_/?:>77UMGNG)#3:7"UY+<!! 1M=
M0 OOCBCVE.'_ &:$4_AYD>+3:U666-=3E.NH2TQ)<&A3;\F/I6]42I)<6TN_
M=AI90>N,W9HXZ<8LM3\X0HU;728Q5)3\EJGJ0PA:2X"'$NDEM*%@6^K;%!XM
M<=*-G9R#E*7F%ZJT@"H2(GRO488Y$1T:D$&2EE]:O$GNKW\I>P&^.R?VH$<=
MZ?.R]F*&U1,\4*.IQYIWF(74FVWTH?):>42F4T%C9%TGJ.NW'GBY4J;F-.3X
MT94>FQS"D+(6M!4-2]2E)2H)*EVNHVW&*8YS(E/>\E-0W!?^:IMI8_,<,<-J
M9+S3GW-N;'A&HU+JTZI+U:4H5&85(D.W4H&PT@=.OJCJ,9"X@\%,W/5%K(,F
MG5RJ4J"9/R5W-3,YU?*> 8A(D\LOKYK:?&RHA-TG2;C&:NUIVA<AYWE2\Q4G
MY/H#"UL,Y;J--?CQ5PVE:QJ=!0KO*VOY1UI1.E5CZHQD/M4< .,E78H&;\O/
M9$K]6UH8K#>GY(YB=.AOFI3WI3KCBU>)T^J$@],9\R1+R751'=6)%/>3S*;,
M1H*9;*A="]3?@5U'0WMUWOB-<26>MPZW_P"-..TA_HGAB3U[A6[GS/\ %LL=
M?O@=/F$VWPA.LCV>> -)VZ8_+\;_ ![L$7Z^W 5^;&Q!^S"Q8_-=,O6C0]9C
M;6BYZ?H^//T<,!?A[DP#_P"6Z1[_ /F3.*7G"DU)FK9:AS&_EW+K,ER4V%(+
MP0EO6AXM"R@@+6A&XL"H>>V.)+.8<UYISCG6;4R6:-F>-$>:<5?GR)\HW=U$
M@!"6W$[V.XM?' ^N4#A/V><@/54I>8S3%BO2-!1XA+;CLN%6H.<WE-+6O0-.
MI6VVV.U?P_B\(N+66>+&6@/WBYZ<D*DMQ6[18[#[43O+?/U+0I+3[_>4ZK'1
MS/P4DC@AF>%E[M;T>10ZO$5 K+=#$P,26%0N=)=8BJ'.0M31+S:DK4+BZA[3
MCM/9:G-9NC5I$6\%R%!0XH)("G4*>0I!5TU63XD]0#O[<4C>ET;P[&!$\/M'
M=6O!_9CMX<6:IPYR4QEK+R41Y6>V:FJL/,O)"TPHRFF41R DGF**CX;H5UVQ
MV*\YRF.-^6F)$]3*)TE,1>IS27G)04@-)2;%7C.D ;ZE  7...G#3+/&?).9
MLJ/0F&:]$8??RY44H"WQ64P7&V6]*"A9#Q0ID^(^,6TZL&DS(LJ71GVU4NKT
M28\TGPJ;>94VLMFP59=M2#J]AO??'92XCO\ '#*-;X3YZ=8E9MR7%+^5*M(D
M-F=-A\KZ9,>.>6\\([3-U%*G=+?B-AOB11)].JX@2&7T*:EI9*W&7&]12\$
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MD2*WG%J,B+-EQZ<PPE#T>',=22IQW6%K2RXVH DA/+-K6Q1QRJ72@ ?HH$,
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M(79N^H)4F]MU6OOCM'YSC\).$M7<HC;42HU>%+IL'EL!*D-+94A;RB ;N6=
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M<:Z$AZ!),<*W\/\ &4[^Q.^^,U3E94SA4*#)46DTO.3U7C,J%T'G/JC+NO\
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M25^*R3A50X6S,JQJC46Z<F8Y&/,#<934GGI2KQ;(4%(4+:5!1!/6QOC+>?\
M*67<P][;B)E)07 TGD:T _@J)*0DE/L'V8RI0LV]HOBO3(U"HXJ,./)[U.;C
MJ9AICQV!92RB0I-PA+15X HGJ!OAFA,M1J!2XS"51Z(S2T-)=MJ:[A$98+:7
M" D_R>RD #:X\L=JG_47W_OF<]MM;>6MOLM]\#IZ&PHGW838?']]L?'Q\;8.
M";BW[,>02/5!V'Q_;Z+;[#'^.P&#M\?'Q]F!]O[/C_'!PZGS&![\'IZ.&/W/
M,F_BW2?U)G&48R7(A<Y2M+3I2E"CTW!)'LM[,9IR)1,T/.2,Q06I4:R&^4XV
MT[<!5TZ0N]R#8VPWP6X)2),B,C+M%<EI-EH3&CE]!ONHCDA-P;]%=<0.&W#7
M(:F9T>CT2.EU&L<R*R%'E'98*4D@HU?GOC-'&+*M B-AAZ&ZTBPY9<TZ18DZ
M4@ @;;;6.*96<N<0:(G,T!N"Y*@2DK;*$),ADH3H*&W5 +T+"SJ )&!N!Y7'
MVC^_%8B5\RDKI:TVU:O&TE:K@W'B)"@"-COT.,QT"LYAILRB9PR;3<\Y>G%[
MO=)F1T.*2E])07(CCA7W53-]27&;+O8^6,M=@W@H:N_5JC0<W*IRUAR+EVI3
MVA2XOCNN/&6Q],46Z\S\%6V.TYV,: J-2/X&>%]?3*?<4F8FAE,MJ-RPZH.J
M>DN-O!QR[:5H_DP@)4DZE*QV/>S#6>"U#J6;\QQ'7<YU*,&8M#DM-MU"F-K"
MDJ DMOO)YCB5Z]E6L=P#BC3ZW,D+9K%&E0DA12"^HDC<C^43ZY%AXOPL=J@?
M^HON.9F_L;;RT ?K-]_O@=,)3JPE(2/CX\L:L==OCX^O%OS^@[8O<^CK\?!]
M'Q\?V8^/CV84?\<*%C@]/1PQ^Y[DS\7*3^I,X?S)!H@#$_,M,HW>1WAB-4*O
M'ISS@'\UMXA:]12;6Z^W'[^:,YN<ZY?TB]]>88:D=/,<RU_9[\,5_**'5RHF
M9,M=Y6YJ<?:K$%U:CN2#9Y'AOOU(OA5:HU8.@UJC50IV#7RC$5I"O)(#KMM5
MMQM?%4I_#T6<K;.1B%$(O47Z7S=AL%%X:K 7T7\NF*5+R;%0FF9;G9<8"CJ1
M!I%2IC+3O^[;97NG^KC^D0@#UE$W2CVDD=0GS(&_EAGB!D:2ZN/&S&P^^A3S
M3C+!<=*7(R^6Z%*2P2GQ7Z].F'LYY4BI"I-?8C)ZZGN>!]1LQ<W]G3#W%/AR
MTY])G:EMD?@\UX ?U>1;!XM\-!J"<\4VZNJT/J2H?[(*F;@'S_)C^%OAGX3^
M_.F^ 6 Y^V_7;E;G%/XF9#K$V) I^;H<V=*>+#$4O$$J%PD(LU=0(Z>T>>.U
M1_J)[",R+^U;>6K_ &;;?? Z89MCS.-)P?+]OI.^ +'T]/CX^-L?9\?']N+C
MWX4H87N<'IZ.&/W/,F_BW2?U)G&:.%$#B+&$R0B,](IT=<5M#R-2U*%RE"%C
MQ#UO;??$OL^YMJ=9=A4>FQH\5I92ZX^\N.PD)U$J+I2KQ6W0@;K5X??B'D'@
MQP:@7XG9AIS]9EH#G*4^ZV6FPD:FA'"@I:.9_P"U\%_MQPQJ? C,DAQ61'*'
M,G)0AQ3(D+:D$>/2&VGG5AXFR]DCRWZC':&RP\Q*+_);3'6X'$+TZ;#E*\ L
M.B+;?GQPO.C/N6 %&RZQ&87_ +;2RX%H5_LJL-0]V$B^I/EN.MK;$=?*WM\L
M</$\/(U4KT/*U=I=<K3=1J J,-B4'943FRU&2IY-UE?*>"T63;U3TMCC5VQN
M&?"S,M1RA5<GY@S;7(:^[MLTCY+9AEXA/A6I3O>CI*@#]&.BM6%]KJ=6^8[3
M>S(W*1NI*JE4939#9VU+##0;*COT5MB+VC^"]7EM0N(W#3-?"J8I82*M2WOE
M3+X2;!!FM2)#4MMM3I<25QT*L$)M^$,5'A32W\OLYNRSF.#5LN3VN\4^>PIU
M34AK5H44%?BLE=TV4=0MOOCA(T4<4,I-!6L-U8!*AT.DK&H?7CM5?ZC>YS-*
M?ZJ499L/LOM]\#IA"B#@;V^K'V8Z_D^/CV8N![/V?V8OJZ&_HV'7].U_MQ<'
MI\?'7XM@X)Z>RV%?9\=,7PHB_P!F#@]/1PQ^Y[DS\7*3^I,XRT\IB&^4I0M(
M?\23ZRP;70GWGH-\=KKM7#@VTC+>6)##^9WF%.SGW&FWV*:V\5@,(LX!WM*$
MJZI*TJ*=S;&=^(6>>(E==K=;=K=2ISC[CLYZ&R45-"'5+4.07+M\KQW2F]^E
ML</4YPI99S5PRS*:E*H#C%1G9?G*Y&8X2&W"ZU=&C1(=5RG W'-D/$!&JYQP
M5XV9:[5&0IF2LSNFG\0J0Q-<7%<;33E/R6KM,794XI8F'6CO,5*?"!K3>V^3
MJ5,H/%.A4>HHY,RGYCBQWT':RD+<%Q<#8@@WM;"NJO/UMO;U_3B-P5H_!O*7
M&G-M,G/R,R5RBYOK#U38-W(D6;'F2Q3VDE#82ZVX\LJ/K 7\6V.$\5O,&9ZU
MGS,(5/A05KD//O:R^$,:U#QJ\'B6@Z[K%\0LY\6N+]<G4#@SE6I5*G4]QOG*
M0@,1D$V"$/RUMO-@E=RA(*=M[D8XO4GC/E\]UXG9*JE-<6 EE^2RI32DZG$I
M;8>2PAIQ(4EQ6E))&ZCC]S[XE3*N]6^!]?YDBG5IN3,HK*VR.[3(S+S[@4Z?
M$RU9OU0"DKO?KC+5#3EWCCEZGMI*&/EUD,I-S9 6H6U;7 M:^.U5UR/_ +[-
M?_ARS]\#IZ&W+&V.9CW86+J^/<,)N@Z?;Y>7[?0H:A;W_'Q^3"46.+85A7EZ
M%=?0>GHX8_<]R9^+E)_4F<1I/<:)4IK?C>A-RI+:?:IIM*A_C^W'&O.52SQQ
M-GNU-P+<GSW]G"I24Z9#C>FRR2"$CS]NV.'62N%'!7A-DZN9CR?%SO6,]1V)
MZTS6HJF:=',=M#G+YK5R1S%Z0G4K5I.I%KX[1W!O+^0Z?0.T7PB4^C+T^8Z]
MF2B.HY:8,!Y4<2H:6F0US=".]JC!86MIUM'ATK&JB9Q@Y7XXY#SUD^>7?EYN
MF&6&/HF'!%GQU)?<0WRUAYYGZ!_5XU&^H;#'%/*U-_A+X=YU@M\@5NH4MRH
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MGJDTG9YD,G<JVL%[K\^_$U?DWQ5V6/,,V2WI_*8X39%3>""F@EGJ"@U81&Q
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MU\EA(#]/^&-7 ]=_\,?CD^O'X],?CD^G_I@*LJDG0#'NE?R._O5Y)7!(/O\
M;%&GC.^!E+'K==6[\%7ME(X:%1IS."K(R+FN&]&WAAMBU\B;B0?!$Z7O<<<>
M<4HO02R9T]9UZQPBSD([]4@MU548,D+=7OO88CRY>KSM^OGB02R%Y4XB]A;N
M&&,KZ2?O3]8_],)YOFCM;Y/LP.K<+JS'TACX%<H;B>/T83=VS#M$BS8&6(,@
M(SW[9PS1D+8:CCKW8+3*UK<1PL/LQ%24S;S,^H4YLFNNG?CI!</NVV-1Y<W?
MYXW?Y>F_\-/_ %$&+Y0,S<!RU^S$-3*?VQ'(C[OO0>DO?:^OAB@V_LR7WOVW
MLN)',0DRQUD:BUUM^^J/1/$:8IP\^ZVD!D-1 -TTB(PZKE?40<3U4JQ;Z=%6
M5UL+V](KS/?WX$33F2 ]>T;G)FXCJ\%]8Q"U)6RTH8HV59)$RLA%AES6(/BM
MC@M6.TLLC([R/JQNHU'=?!"9HPY'P@&NO'C^K$5(D4E)0PQV>4MF=I.=VZW:
M^FV)VDS!9':SBY'A]ES@*0 $%K\W/><'Q-_+T1^<>Q_O\&$^2OV8]T'YV[;^
M_2X+\H]/IQNX(BY[@/K_ /7&2?>UD]QF@H5WQ6_)I!U5(]N!$T5902DV'G2"
MV;E\72_,7PT<@L5/L(Y%3S4\1B+Y8\D<DT+1Q5"B57(/6209E(TY@@XDJX:N
MFI:.+\;4U;%(D]9"-?U>./A>D"3::-1[-J9D_GG*#AGV%M*CVG(@N:(;VFK[
M=XIY5L_\1[XFIJN-X)H&*212*596'$$'7$?RL>Z5_([^]/DF*\1M_89^B=\+
MQT[0;0-A8HX2AXFVJN;<VY8437.52%2,75?$G"L*C(T;77*+>H8.Q=H2#S[=
M6A+B]VM86YXW$N:&-FZDH]($Z<.'MQ' ]1FTRB^I]N,KA1&OIWM?V858GD4,
MXS&,\5OWX@$9,A* %I-3FM@VOOT%\P/5]5N.)J6OI2P3L.C==O9QP)@64-^*
MC;0X+/>XY>.,N3.LG&1."7PJ>@IU;@6;$XB[%C=<U\P]N"S)NTB.9RMM/KQM
MRGCA*B#95+\-8 2?MIA;V>7IO_#3_P!1!@,.6*:/,24ME72_($#O&(JFF14>
M*7<5\3)JJE?QM_#M6[0OIIB0"92JS% >*\=&'/48]]]FT\TU-'??O\&0&CTD
M*=<.RJ>)"$)Z1P^R]I"39U>CHM3'5:/ 6B2>',H-K/')&X\'!Q23Q349J*<9
M&2*.X)7LR.3Q!Q!$RT\TL?6EBHX+;J%&5#)+^:"PO;O&(ZQPX6:%YHC*'B$B
M]FZ=76SAN%A=<+'??:_"&60@7OV5N>0 OSP8-"@=K(O&[ CB./+!T]A-['Q_
M Z(_./8_W^#"?)7[,>Z!\[=M_?I<;F/@S@N>2J/28\@!?#;.V;>"A@LE541:
M/._/X0_[7UXB@VL8!.V7-GJ(]7MVGOJ<23;$\W:;=LT1B=77.5ZMBNJ-XCAB
M38&V8I4EBO[V53J0)UL3YJ[6L3_[(\^'/"(XLRRA6!Y$8.-E[/*W2*&CIA=N
MKU8XD/V?JQLS94L-]GT, K-HP0Z)432=:-&//EQQ%4[6VFNP::I!:BV=211S
M58@]%IENN0$<+\;XBJJ/I*LT\?86HCW$W>>?UX7;M/NS)-E6I* ==@OXRX.N
M:VOB,(O+/ICW2OY'?WI\DN;@>D.PA_\ R'P+[M2.&&RL[!A<\P#X81$+A+=;
M0"WKTQO(Y";:^&*::,]99%"LAMSX'%'7U ^%ZN9W/;N.1Y85AI<BV87!]M\&
MXLG-;GCX7XX5DD>.-"+K>V;7EWX\YD5DW:#+9;-?D>>'G:?,TAT1M&UQV6BD
M0B[IIF'KPB2,CKRMV]/'EC*F92HX#6_KXXROULW=;3"9G"JIL!\;Z.>'A@C.
M\=;&5>5_#$CR*=^P(U&61SZ^..D.?\7[TTK*+W-S6M^KR]-_X:?^H@\D<T1*
MO&P8$:<#?$O17;,?F^U6A.25)=T\TBK:%R#I*0>8ZV)8S4*ZF23*Q!#9@>$B
M>BW*X)4^&*?951LV.I1?/=],J(LA\YE22-4?MQH<I6:QZVA&$VO!1>8,U'!!
M40B1I0T\+S'>B1R7:Z.B=8WM&.6&@6X9[6;JJ!;B.%]>X<<2>=QR_MF@GHVG
MBRAU,TD+HXSYELNZ^O&R*"ABJ:639T6Z%29\XJ(3#%&QD6[*&,J/)9 H^$//
M#HUVNQ.;CZ[7X$X/#P)'6]F/7^!T1^<>Q_O\&$^2OV8]T#YV[;^_2XKVCT.:
M($\['/IA]HQ:RF,R,1Q9W7/<GV_5AJ^N:>=IZB=::!9Y(HH((93'FZANTI-_
M 8V;LZ>KEJ=B;6<4L8J&+2TTHM>.0\#:]XY-,RC77$.UXBGG,!WD4HL'ZB[Q
M3?CRQ1U8_P#%QPU#_+:X?Z64GV^2A!_]\AM_/&)(NS#*VS!*3P LFC=V*I=U
M(JQ?!QEN!5$4+;\VVH&(3&7!W@%DYXIZN19UIC "V<#+>U@;<@<0CGFUQ[I7
M\CO[T^22.7L>_P!L5OYL[XND8(8V%UN/\<(#'PX '+AF965^.4=FWCWXL"!(
M;W4\L0QZ')(K<K6!OP/'$.Q8)1**=1G4]E2!PL-#Z\$RY2>*J4T4<K#&:6]U
MX6T ]F$:.Q56%^-^.(J6DF9PR*73G>W+#TM1$\5CU&=#=OXYP+!FC330WN>_
M7!D2RGFN74XSA0!DMU 0;^./2+\&[OHP8V*WO=54@GU>'MPT>[6U^,@P99:G
M+ C=</\ _;?0"^-L/2=;?;-I@9+W!'G+&P]OEZ;*BEF;;;A0-23N(-!@@Z$'
M48#Y3D8E0W(D $B_> 1].(JJDGDIZB!Q)%-$Q5T9=001_P"F$IND4"5-=#;<
M[4B&2=K+:U2O"7Y7:\<90V8'A8?8#SQ>FHYY1<=F._5[[7Q554M)' 8AU/.Z
M=Q*?SE/=[,+OPD2H2&93VB#K\7[=,'=-(P_.M]6ITP1RQX>/X/1'YQ['^_P8
M3Y*_9CW0/G;MO[]+BMI_0EA^AUU7VXJ-@UA :(-!EYVX(_J(-O9BI2HAF\R,
MTDU)5Q(9/-3*^>2*5?2B8ZJPU%\;+CHEFDAI*U:VIJV4Q*62P5$O[?7BAZ/4
M\F>251$.L#D3+:20]RJMP2<4]-"0\=((Z<2<FR7NP];$V\+>39T\2J\*STT[
M%B%TNK\R+Z< ,;=AV2T6^I13.!+((KR1(,H 8C,+X5>FG1ZNH*Y4R-64UYH:
MC*,N>\.9.&N/.-G; DK7B.E5M"JD5,W<M,H&;VDXE7::00U6T,B[/I(E"M'"
M/38>BEM!?4DX#?\ Q,>Z7_([^]7DE.GY<V-QU_?GQER*"W6#]WA;%76;.DB#
M4?H2L%:1K:9%O?7$]%M>*6":&0QO$Z7X'1@W,=Q&"[\&X&W+$^>.-9"C""22
MPNQ&EL2^=EH&DDN'6^4K?B6_5A1&_+63->^%S26OPS+VL!9PB>O0-W:8>)3N
M]Q>V7TO5A;9N'IB_'OP(N*]Z:&^"+6:]N%SC=D2#F74_JPC(^<D@%3VL#KJ&
M;XHZX\"<,7S7;LCCIWZ:X=(V$B@%RM\KFVML;>II8FBCI]ETV0'A?SQAIY>D
M\4")))^R&24));(PIZ6.=PU]+%(VTY\,;2G8K33;U_-J;L+,^\^$6,GJY8UU
MX_8<13R!1'%M2IISUU)+F&#50#UDZO:&GEN-+=V$FHIXY52WP55&)DL#>W6U
M%^%[WPJUNQ*&R*H7S622$$^GF[6C=PMBI2MZ*4,K3YB)-[UXR>8)0X>6& 4\
M;&XCS%LOMT_#Z(5/F\VX/2#8[B7*<A3WQB3-?NNI'LPGR5^S'N@?.W;?WZ7%
M6Q O=+'V/?$6T:8LL3M:=5]*.]R?8?UXC:K:ED^"&KL"6TYCC?E@T^Q-G*'D
M.4392J+?0'AUN_NQ.AE>JVA.,E16'A$I[4%.NN5?1)\+#$7_ #%\E.:,)&5C
MA(O9[Y5&NHMKW82MKUJZ+;(&7S_9<Y@+J!KGC[!MP-^6*BAI]N;*VCG0Q&FV
M^(X*N(,",T$ZM\*>5N-[8\[VA4;^3-=8('!B /C<C3ECWPH'%X8@J4VNJ1K;
MJZV)MRQEK*::!HWUWD;J/7<C@<>Z5_([^]7DE*WO[_;$&GC.^"\VI4V4,N-Y
M64;STDHRL8&(.4]R7RDXD%5LN?WQ,1W$YC"SJ>YB.UKBICC!,&9MSG[5N5\*
MXO=""G6MP/+$:I B[2I8[OEU9[#TL3T4^9'@<H%U77"2RW+ =5;W PKQEE8'
MM+Q&)'DU%M)6/6)]6.J5+-Q3E;"Z(ENU:^,Z7.5M2IU^O#YDNW#-BZ"]SWVT
MPJ!$SR$#75M>)Q<'4<3Z6OKP[39E5P3G MP\?'&WIJ?-?S"G0AN[SEC?Z?+T
MHVU0[-5Z*?;4DL4OOC01.\8CCC;J/4JZWLRV8 D<K'&=MD0@#LJ-J[-L/&WG
M>C-Q;O.*>G?9BN\,TK=;:NS2HC,<*H!^V_S&T_QQ^2(/TILS_58_)$'Z4V9_
MJL?DB#]*;,_U6/R1!^E-F?ZK'Y(@_2FS/]5C\DP?I39O^JQ^2(/TILS_ %6/
MR1!^E-F?ZK'Y(@_2FS/]5C\D0?I39G^JQ^2(/TILS_58_)$'Z4V9_JL9*_HZ
M)I_.2V\3:FR\JTYB4!;>?+=A)F:W"Q[7+&R8=H;(E^ VWL]J=AM+9KPTU(FT
M4G)W:5N<E=;BTAUZM\+\D?9CW0;?_J[;@]HKY@?KQ(L8C(D*DY\WHWX6/CBS
MI ?&SZ?7C-NHFUO8YK?;BT=)1CD=)+D>O-AI#%&N8DV&>POZV.$DN%RL&L =
M?(I/6R\,VOJ&##"\,:'XM-!G]DF3/]>-\)I-Y>][\^.!3TNV7CC'(T]+(?YT
ML+M]>+#;$,HY"?9E!+;V[@8GH=JMLR6*HW9=X]DT<-0-VXD&[G1!)'<CK93U
ME)!XX]TK^1O]ZO)+;C[_ &Q/Z]\=89F-[^.$DL%MP!UPEV-V-].6#91H>L>!
M/=KAW;EHGYN!-32,ZL>NN:V;P]6$VY3QI!,G6JT"VSD>/?ZL93(0OQ=3C=IQ
M<\<(\BF5'8*Z^O&_B C211DOJPOXX:,LQXYVT^K#31GX%3:TAN<WJQO&<MF6
MY4G3 DC LOCW>&$DD7X11JU^7@.&(BM\JV!\5Y\>.$HX<RP"U[GM8VJZ6RR[
M-IR>_-YR>_R__\0 *! !  (" @$#! ,! 0$      1$A #%!46%Q@9$0(*'P
ML<'1X?$P_]H " $!  $_(9[CA4GEZD=7$..&T1-\03RZ&22"]WI>@@:$.CG"
MC,J8N.$W#F#[(L6*%L^0!ZN>E,U]%/#\3'B;R:!__!9> J3]Z+%BQ8L6 \/O
M85I,SI,?Z;IA$ 010&!Z,:[!,#3N8S$MZ,$N.EZE@7MB(ND<*)E%@\)>,,U7
M1M3N\RC2/J$%"LD5$X4H! PR[8KUDIS_ ,;+_P ;))T!K"42M('RI3;T'D!E
MJ3F41N+I_1:-4D#1'8$"T\Z\BDR?^-E?/4F*F^@Z/I63GMTWT.<4#D$HIN1Y
M\X<5#STWC3A@L/9_>,*B(TEW '-.##"N)"@Q-XJ_S,BT^6\4BU,H=^ALQV2H
MFL-:Q8*&F+_W^LW<0\D[5;WD?\;7N4*=&.[A[).18K^LW_YYGGWR;DT19(0>
MO>6'@!2O.#U=ST7X/GC#<I73A$:*//60B)6@.FTZU> !1@1:@%\_X^I=W27!
M0CM@49R7(B2?IA+##9&,M@]QQ^22C6%&"PVC$(0.1+-9/J"YHDN&@EEY"T2G
M#(F8!E =11<3##XSW(]?O)L;HT$5>(<_9=?I6+.L]<3+ZPGA<B_>!IE3BN8:
MY[W,R45L8J(4,G(<M6X$X/%>BQ#K6U]4/+O77[+OK#@+3Q,D:MP0YGEJB24C
MYD8-F[DH54UH^88&=H-[A7[*]1=M=CDJ3/<=D& ;;6L=]2&-2@ ^SUBL@*:H
M=QP9ZG-X0!ESJ2I]4Y#W2Q.G*"O74<X7D<0-,"O4498RBS(;0 WO% \Q1N.G
M>OG $R4V';]?."J9?:SF,\X%)$T* 79 ]#D(=EM'2]6 9'AH>1B+&]882R?8
M2):].\%_0%#'NK\ZO(77_P!=$]8K\X"O(H)'"8J?\Q44M([H@J&,KT "9!NP
M$BXA^K0*F2G.IQ@1,<)W) ^0 =)8UB#P@>K5&E-SJG[) 7 69&G"%[W@BNQI
M@AR*U8 IDY 0BR1"Q'M'MBV<U2#;"06F"4?<Y!"_5,GLL^,_9=<91H?#T?YB
M*N&4$;$]^HN/C#O&0X"Y3#M@,4$E\&^&_,Y#HBJM.H(]JLAO@23-(NV D85.
MI04@7PQ@Z1=&=YSF.@PE+^<0!:T!_?G^]!_$L60=2?3=-9;FD9 6@O\ F13+
M\"AFQH(FQM:2#MU"Y,,D(Z)Y#RT>,.3ETN@B/P[R,<!0C4<#;-(Y#R#=WQDF
M<R<$M'\F&YW$@Y*[)KC)*S*[3E>%LR!?(1]$*O(_YP&3:6D>CEOR6 ,>\1UB
M_8K.XQ( W.L#(0Q[</VO7 Y&1"*0P>WL,#Y@=8=?H%XQ$B/$<5Z++#_K(+K3
MDC0FO!V5O)DQ9YA:6$4^HM \=Y6LL"EGG 5L$?&!?V5]C0V'%1.H 4LN"TN.
M'"P@S H;Q''T@825618!NLF9$DR-#R7A(MK-JB7&?4T"%.U'-0:VO.^ E[G[
MH%Q- C# FK3+)G[+K] \WX"(U@3HHNI1&#K<%E)]0\E)45P2+SKBDI!")>[D
MD68HRL8)()57RO ,F[1$"2&RPA,:.I% 0F@?A&;O_$@XC]%,7)7 DG? 9,":
M^1H]W^XS]BB/$GQ+<4Y_<[E^IQ%;TC/,X0&PAR<XJ>I_)]6LQ8E22Z0?SQ@@
M^F6@[?++L:0Q0',R9*."#=X  <LF.1H=:_)&196+!3:RSYQ*UA6#P&N<V R)
MPCQT=X61W+EM2N]8^)"D0$5QT=Y#(*''6Z-GDRV20]'MA/=:Q3ZQK>Y@+5T8
MI@$Y\VBSSE!#,1R)_P PFPB0Q2*D6128IK1G)3:->5P6XZ8HM'8W\8_=B+H8
M_P!#$IOI((\$OS]^-QC2,S+!H"5U\X"51%@%V)('(G#,N$1?!)HH(%</E/4F
MEP*1L! S9A*!I$O)&%D\X^L-RD%EM>B:,E7%E.H@7C=@/3"8J,B)5*14D!C[
M09<5M.I+B-&R0)G[+K]((!9\&J([+<1)Z.5U,3NW/"]UVXHVD'2&).X1I*,Y
M:1!6<-(# @+05D71_!4DU"FDV=8ND7-!#U<FL_7=<%*SF2(%^4>8C!%B%=(2
MS=IOG$KH71E9(A,DT.*\,4F"C MDQ?&#5L&1%G+Q PQLJG3ACL?#Z^:B1&B!
M&;LO1SG%80' /(Z[_C)39J)=P?X. 6A3N]6[;\8(;/+#R/\ SO)(1O=;:V>G
M%&,+T'&CZ+-YKA,F#:#?LSD3,ZP3P#B;C)"'-F/4O*?G)[JX2@I\'.,JP8D3
M9! CBLB6@P%,P*S<T5>/;@;1Z*H+DDAG6'RMTCV7J.5KSAI08(X5.K;%\Y-+
M(E2.P!MQ&L&&#3OFDK'48>@-N^BXE><4MVYZ?>XR!08Z$:^0)O$@+!*02-$*
M1:4%9.SH,DE 715V8;^MN1,-@)IMLLB^"L4&*N7<AK6&FE@,'@!Q&)[9&F!&
MDFC5*BEEYO%4J3]@X07/,5 P2A"^<_9=?ITAA'5=$735)8Q&.#1[ #>*TO;"
M8R]*M0D!S3;PYL9_ZFGV#MB_)*ER*3B#!-1D\()&"V!O/K&(>$/\&#"8<BX<
M+T#67N[,4C.H_M6>HS!W&0^R3B'TM$@ E8H8E.N3GA=XR(7*CAP(  /X8_ZY
MS?I)KPM%P!$^8X,!T:)Q"'X>,E>%%;TS?;"U<U+1X$=?NL.\9L.)/+R>F,#M
MHP<"+UDA7)'6M E>S*DB.8Y5W&!%-6CQQ^\9 C0D%I%2[ZR/1 0;E$,M34Y,
M2A8T*@P#JP\CW17*7B: !EDQVT8%$6I(;)Y.\"&-0&A.^B=/ICSB19%XZY.>
M3+NTJY]>W.(VX85[#_\  CC7MZ/RP58)%&]HASC9-3.@  0<#!B:02!L,JX"
M-FR1.+^PB2=BI:"A%]4DEY8GD D,JA9VN/'P3RN0E((1G'P4>Z&- Z,Q>+(9
MH**VPD!*$%+P0_:4_9=?H-ERC$04+''K^,LB062NX66"&$#Q#KSBJ)--D':!
MC9D8'VB.MGTPDL!H"0<)<V18')>YWF5W@C]6@,6,LMXPIJ&>C%* Y@T2F[@!
MGWPMM#DDCI.0^,C[M."E"8B=GYS=FJ&*Y,ND"K$KK%I)I-)&/GZV2 28EB"*
MN D$W#81'RR,N+1.^>,#Y<D_V#QK#&@J\QQ[8*M ZS#:<)?D(P,<><LJ2V25
MT@N<TM(4%&XN$P268)DRT%#IAHOJ1 2!@O,1.\G6 ;7D)5])C+Y\#3"Q?OEB
M1?#$?^F<=)) HL^.\FYR$5X,$Z^<6Q:1L?+&&X'3#0HO<WCFP4^ H>A]_'&E
MMT$DA9!-"E3&LWS!2#C]11$L<T#9X60L@6Z)"\AW MY%3;%098=6Y24Q#C20
MB#N:RBX,&(Q.P9HK+ D#>DZ\H_G$#VCYJM+<CJ>L.@#7-56,2*Q,O!G+BU1V
M,+[NOM*?LNOT"H$'@2>2?#/MC652*BD.5@;:G(,7H"$^R$73BS9 Y6G>C;V&
M.< 2S%G 1!Z&284G:"<)P!LQ^\F4>8,BS7AR).62Y$3$BC5:=&<^#4"3S7KK
M)FP0((C<UQCK!)"V]7R'(VTX\3'X^KA %$-Z49-Y5D)XZ.!(3\U/HX[O)Y6!
M2]'CJ9BOX,($PB$%W^\A19$,<&BU[R:V<R06@67WD/(ZR8TL<?LY+7T)$\(1
M_/ID4\_#Z"KU&04)A+QU<8$FNU43:-0PTCR403CV:<MIL7(1K'^<!<LN&T^Q
M&%K)F:/5*/C).0NDC+\GICWBILQ)H]'O-[65Y$H?C[N.,2F_;>3:BIL^)%H2
MK)2AG!@* 5RD4 I Q<.\3&A[5X#+E?K6"L*MHF5^6U9QJ9'WHB)9>E 3;!C7
M-A L)$+A1-<X5"5FB5<AKDR0@FQ)T8CQ('@QE<Y(+5W<]QWEC=YL.!TQV5QF
MWV%/V77Z91JP)EXH#XR=\@,P$!#%[AP#L-J&XE&[#"_.)7'H9",2A!4#;>!_
M=&T831 "D(Q1PB*@LU1H]\^*>!")?(1?3]WDJ0#)T7Y&/5(,7XK 4*80L@W7
MSK(-",M%< %'\KG#D @Z/8/ZSV/T$\>54AJD?./$Y8)3#I<Y$90-0O4<,\XP
M"$ XD;I"N.\"K((2QH'/:X1^U8=T'7"\8(AQL_*-1.\BP")-)%JN9Z-8W!6.
M"Z.7<Y X0R2LN!$R>N61+/5!/4^7#R%89M[NC],D%J%V4+,&&BCXA!"II<UC
MS/BNR0?+"20L*#TOKUP]R&UI>SKO%X'J(3,QWPQU"B@E,\GW<<<-L+668?7(
MIR6DL!43XDG9-8T<]J?%M&2DO&.A,G(8*X$E0IQS_O C*O+B((I[?=6]UD/;
M46C6XDE@+ LL,K3M>[$QPAD#VC(1Z,]9$U'KBP@XV[&F1K=F&(J2CD\K.1(:
M?84_9=<. ^SR,3_.?LP]Q]Y_MR)"'U+_ #DPC0\91+!!*@5,$M>^?]?G$6WZ
M#_6#P'H1_&,+*B<H7YP_4P=)CQJUR'JXN_J_&?UOH!_8&+QZ@\G(V<":F["D
M+ES^(@:)_.L0ZPAB7V6GKAR^@< Q0F5UW&!$C@LPL5/1SE(BYT<.<?GVP$B2
M12*V[3EKKVS5FR:SHXR$(*3ESX\8K=+/:*@5$^<2&ZTWTWIB\Y9'H"B_V\7)
M99HT;K\89\Z&KF ?<F"-2#LSU$?#O3DR^[EIX)X./SK$((-.B92]F.PRI1H2
M,0>;^WCC,(*8:#!Q4LO?&Q&A+@6)GF?QC691!G;#9E(=&@X_-8[A7(ZA'B8G
M+MWZF V#*-28F%P8VS83H+05-ALN\6PSUD#\_7>#E!Q1$ 11-I>.<GTY#2'D
M+"8@V<$3)9C%A5H^-$<XQ/!(G7C["G[+K](,!D#S4#7JO\N4BCD7SB^80Z,*
MK)P-!"U.A=/6\E=.027"!PUX(<,ZF9$P#''2T*.<CX9!M2V;D0ZZSTL/P&.H
MMRD!0N)J+MQ)%!$,07$?$KCR+0&\AN0W<^+QVS>.6)4AJEX7B5S4?W"3T<83
M>8]_VQRG*SZJOUZHO,2P3EBL2C$YE$T5IZ$X?AKF><NS*/&3O(,3R"J/&^<.
M0XD "TFH!UG;Y  TZ[.9OIZS34D9UVY+_ID(FN;+H)WF^+=^K<M@].,"(:PB
MG#-OKFH@"2*=0XNHP1T4X +EJ'QD,K*%*!OTPH_I(G1"L]:,H80NO7V9,PIK
M(:;_ *8DJQ!P1Q-RO7)]/NXXQ36-"70:C&ZILR6X:.!1..TDPE9PD* CPN#(
MW0$F%P]$98$8"!K0-E!D$RIU F_D!J<*DJ XWBS./A&WB)4(CM(L/4Q1MMD,
M#"L%"'H!!@Q;ILG&5D)2S2=$4<E,D@9GE^PI^RZ_2B!_^GA//3^&40HH0D,9
M;"7,1D>PM"" @E0=D3A6U<2:02J^@Q ;Q4O9(8 0+0IV"Z,<<G-I2IX<9IZ?
MX&$F["R(3P*)%G9D022$ISQ*B,0L3MB5L:?(=5.#I8'MH089ORO'="[C [E:
M^ [R(=(^/L.BL_G)]LB*Y (.P;G'V%ER!0[M[3E,9Y>859)PD4P#1X 7&)]T
M"L"(.V,2+0C&V7Y1Z><-/\YXD.SB\/D"N0U=07C6![4(L*AW7K)1<4K>"1$G
M3!O\GQ@GR?.0/V2F9973ZUE%RQKW*60V]Y-\$$)ZA4L,9MWQ/7V\4<$( EEB
M@,1*1$[KZ")8Y')-BN0ZFT==LACH^?%N5>,-;0"++)7@W$18BV!D$HL!:RNW
M%:,P]I2YIW7@R"$Z705!X97QB:?$_H@= !.1A06[(75I[8/<XU.0*SJ#@U 3
M]I3]EU^E%U!APA0$I)YDJ-XUA,4,1#CCEZG)TG40E)G?*JYZPR+=7VGR-?1,
MQBQI,3N6S.W2X6))M)(\0/+03FGH63[\TD_,-"5?$,8\F?Q$%T35VFYREH*>
MA/HQQ&(EU3C[FA2J#=L9,R3&(C(>8 <'.!:UMSY@_7[W!5F:-NE,SHS)CJT+
M9"ZIWC8'4TC?R>>L>!I0(GJ:IR<<9D/1/%K*&D;M"*E'X.L=E;KH/08[,$G]
M)\;%X<.N9"&E9?:\*\RFQZNOSC"A5Z9ZT?X[R0<\1.39K$7Z<(7 7+"%253(
M'5_;QUK+VD1.9$='(2M<@)&183B';'HB:@4MA)"R9>L 4X85=H\[]3'R\\KQ
M,*P+"Q$X 9AR60;I; ,KC$2MN,&3 BQOV_[6&'+ ^;R(Z^EVNF>SUB8\3&7&
M)2#DJR/)H#[5'^.A416(V-G8Y^RZ_2COX]ZCIY&L1'4&B'.TGS@!D[@@!.O<
M$[R6TDQ_6WQM_#K(EU_;G$;:;@7B]E.=Y^YZ,)\H@H"'DS&\,] MN^O"UZR)
M+//^ RHT($#"3;[%K6(K#0%:H!8-LP;+QZ-2MP1#V._OXE9#!AM[Y.'1A<,4
M:Y,@.#L)I]9C!U;T)#<)$QQA$@Z)-6PMVGK>2SDM0+.U$5'%]861;IPY^Y\Y
MO0*"G.IE[L8T,<Q[P81?$YN_)8'QO7GC-Y1=G+9P;3QP;8Q B1D5SB*.8!I5
M9H%Y*E+/-;E;]KB@(-*H_1%WUAIQ/%S"G8%T+-HG'8Z76W55+\QE6>B5P<2N
ML9,0Q7<!?"8\9+]%'8,!TD@EW]5'FGC$R[/.* 4W]S9"RS.DFJU :GF"]3I^
M&30],M)!G[+K]+X@*%[H(8@O(^,$<;EI(O'U.5,O$R]:.,1*LMD$U]:9RL88
M4SZ:H$Q<-_G#O 1%HJ[A+=69I[_X.(] 9,.8VO\ S6'\VAUCHSV(ASUD98!3
ML@B:K&6+' @:/G-K$)K#Q%>O> >C N.B?/WL2K0.A'Y-%VD&3H1 CV8MJ%K
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MWT\8T,TH$@=G&$(14PJ9?'U&'"-90 HM,EF;D@:A63/$9X;8C24VZ/&5:A*
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M2KP09AW&)9?I^M C.AF/.;?3=71$N%0O:$B>7Q''> %C5\-R G9A@0K*2AX
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MI3Y,'8# 8"Z=O;(*,624=C9N%LXR"K9!45(C9>L&&1EKMSTCCZ__V@ , P$
M @ #    $)!DEITDDH)T(?(&/(! )(! )  ! - @$     (\E0 4V )(()()
M))!(  @ ) N  ,$8PUO+C$!  (!)!()(  ( :R(@ ()C 5E7X2! )(!))!!
M   ,!F;@! /L^#VPQD!(!(!!()!(   !LL< !(.JP-KRG^ ) !!)( )!   !
ML?P^ ((T'A..H,!((! )! !   -D_&V"@(.3L;#_ *:@ 00" "00   "+#2C
M*T"#?$76A+NB0 0022  0  "H%= /4"#8UFNYF @00022"" 0  2G+,4RD"#
M7;HF>P%B22"2 00 "   <A0I3L"#5ST7(=Y 2222 0000 " +8;$:H""?L>W
M[[N@ 22 " 00  #7>V.29 !",H)YAV$  " 20 0   !="$*(  ,!>OZW:-(
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M*@%.(8% >U#<7INPQD.8T<>KHOQ0'65PCQZ5R!X0 NE<$ISZ7:?'?0-AJ/\
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M>M:8UTCBZ#V0"Y2$ $JWC'Q[)E\MZ!DN09OC] 774*SY_3E%U7)"D$ZXT)R
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MG[&@1F3\\R-:"X\>O:9?UMY T![4+4LQ_'KU.!,'O,+16\ $"#!3(1,T9Y9
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M0)!*4&GO,IF02-+. D7"4C*RO<)-H:1>EXT8,C =WIQW&"$049KH+#-[#A'
M 8N,BICDS;3AQ5K5H,<#ARA!3IPJ0MF56T?D$R_ZC!,0<A400X/:ZQ80/1"H
M84YM\:H2"1.BC/\ 5TCP1V6(5HH0R+A2Q<<4F(7ZVE^LT1;H>''DW[\[UOCJ
M>/7MK/LZ/7\<W?EK]GXYKE\,]C73Q?IH]Y@SDEUG;;@*$'%9KDX3DG2]%A#K
M_$IF\1]2^Y*3 F:CL5_IO7C2(A6="@1H^JKHPA>&7TB!#),VU"Y.XU4HQ(_+
MY<JX)U42!0( 6"I2M0_'O; ;* 9U.-Y[MXPP! 3!&#C @OU6 K*2+ +(F_$6
M@/6!B# F\O5+X49)@%@!10+G5^3Y/W7XV%$8NA:"BYMQ+Y8UCF(FH60I46EZ
ME[=3CJY)#B4$"QZMYN]/N<W?+\GL0=G\\(2$OCY>/!&GC4JW/A_?UZ^ZPJEB
MS8$5*W X4F&YO%F514(!J$HQ-F<<&E83,0$Y@$(- 9Q2D*5HDA7$*RL*H$CW
M("JM 2L%9B&!!4?8^$IA<0 P,%5K6&9[9\YZ?CD0F:=T3J4*#"&'HWF3"QH@
M>!0\ B/"4<T9J3NDC@"\I%\*A"@8(A=%M.4=F@F%552K*L6X8P1@!<LY5>IT
M\J<Q#V_/]/B5C L4\7RX-![\Z,^?^O[Q\/8$;78_+^Z3U]LUYDYN^7Y/;T>O
MXY_?TX22&_D=C]MX-!]S@$IH%$)X$\_-.N(64(,2))5D<E:)9CEJ; 8\0F3*
M9?/J\& 5;#*2K@'IG<UTC05 %9R*)D:5CE 8<5"EOZSE%++<@>7 7158!BKH
M\+R,Y5) !+1IVUX\&P:L0RQVA6NFYTX BRU"CGHHQPX+Y3,'D<,"H3<I1T7.
M#L L*6&J/MAJG1BIHL)QZLJ  +W8 >^IWYF/JY?/#T;\2BJ9\\>G]Z^(0#MR
M4EU\OK[/,QO6/KP*AG<L/^OA?I[!2>-X@YZGZ]BAO^_O[IP&3I?8)*'I?[7G
MG[B >YP+!$'$G0[-SH$P4O!I;@=$018'1*5QHY([#>)8XB0*,1PBZLQ5#C$9
M1P=I.&Y983<@KZJTZ@>' +&5"DA6.,JN96$>"@/4!QN[YENQ ?M0&(4K+*\*
M'9!JP^,)$V(U"?!B,!V::FM#!M2"?D9_, ?Y3+_R1KH!(66B@P<2L#D(,"BS
MK?F,SXZ^7[_C*D<FGJ<2S?H^/R=3KP2FJ=3[M.4[GS]M#;.,9$=_CD70O(]G
MY/+(3KCO/^K[K"61=8<N3EGJDZX.- V4&I13?!$ @."+X.!Y<O@*G!@.@P-2
MP^(1(#4D+N5E5=B-&>8( .(&33%;TR[F^& N,'VX>18E-Y3:&;A5WPVDD$]#
M;-1 BP4:UF;,E:04UP05EN,(#D/4@RJA&DB3WMU::JBJ/"!6C*PBP=D<%7??
M?7R_?\51Z,3Y/G_8]O\ ?W]T\_9H_?A_8]'VW#S_ +IUSV_7.KT_/-U7/C5?
MO]?>80:IWPH"E24(]&&'EMY3"Y6"2G':!X\^.X!T[3)$7C+.(R9#1M0C&6H.
MJV'38)$-W(O\E@YN(TQDHDN )S9YG3Q.E_/'+\',J(K&6,HXR87CN]M $ABU
MD"(EFPQ/[@B:U3$!,[-#6EL0(DDPFP'K>+/MWXJO "(FX1'@Q9C119&%5F'7
M2XY_''H]-_$4<&%K9Y=MX]=\C4V$(3I#VP['R. XP]-_FWUM\>0['R.0['RY
ML_NO*]WYO,EK9T<GF7^SR'8^1R!J9RPGSP?GWV#<0D8E&G*9F9U1PO*R704K
MS:+$<HO"3R1Y9UA^J[/##0UD*R&0-3*$H)M"Y11= 2&>&PKGXI55!"3UU:*!
M-@)UR:\-\&.GD Z"B,J-+2\&F:_7@J-%<2D36A,B?!$@U^($%HEU @"0A6(H
MMD:D\B2H";8'(F@D#3"/#!Y^?-.G.'K\1 YJ/GGN9+/QX<8W,D(DLIGO#D'6
M2)2:@1CR2&1OZW[85>K]/+VI2/7D]WZ?K@*G:9\;?[P_PL&=@SPI6@M#IE'%
M.M&MJ,!#KP-9,,0'<=5PDC@LI58S(SQXAL^)W(6BBX:0"KRO,,B12P73XQP@
M B "T&(@8AH$M"V]HCUSUS>(6@]E&\H1@38KBK!)TH+6 DK*0!_ E.%=9XY#
MAX&^18K6>=[E(4;5<',5P0RK$JN2<,G"#(I08!,T2[CO>O@_O3X@J&"F'PO7
MUO (4P"NL[6.I9.EXLK0J]ZWOCTGEG_-<Y-L)Y;?YK)F>WD$(74;D9;KB9/K
M0<9B.(=!*1V)LG!RL$=-0( @AR ,,\,]P@80!O2I8REYJ+2J,:/( ;.K;(!Y
M'#HF4P*1PSSZ\(C&(PMUT4[]9P%"A1[M2E:B@^/""I:2M'(6*2L@X/7$ZJ4*
MEH8J7KR-K[D]**L>+0>(4$CH@Q]2\C2<%=C9*\V%94JN65$*-,AAQI;KIKXC
M_\0 *!$! 0 " @$#! (# 0$      1$A,0!!46%Q@1"1H;$@0,'1\.'Q_]H
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MB"ZQVY%QT!V=M1%P9Q'I(J.@_*&9P- FXJ[3[.W>IG1Q:I8S;MLUTICO<X-
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MQI]_65[6J8QG7%7_ *G[^_I9U]=WQ^SZ,*(4,H6^3RD]\<2+5/E9E:,9I([
M.$GD%<E"<@[A1V8<@BQP&.1B8<F2TPO2T%+2ZA(<AR"F$,+A2Z!<[%$7(&4"
M6<9X?(\B;-/^;KCV619F%-CD#B4Q$SA8ZR90AU1>1\ &?%G@F*ZV'"5*@8$V
M)KTP@1XT2A)<,LA495X!EY=\N3*]V]\\>6'^+^QJ^?V_1R)YX!$!DWDW>^1.
MPM,!CT<^:^TMPJAZ&D2YTGA?EC"$)F[??;^/'IPAF_"UC,$A?UGBHA214RM
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MN 3<'2^!^EA>XCXH8U9P3KQYHP&G0(PS@<_J3KU!F@AE%1?#MU<[@F1,D 0
ME:8$*54 &X(AR! +YE_(*'RT9QAY?FX3+:=P0"DAQ\FNHHU#2BX(8>%%,QD"
MV&I)2$"K8,1>"\ME"*H05Y8Q9=N=00(BX$N-N ]F-46SVCCSU1C53^^,X_L%
M@=2?&CW_ 'R($&2D$P.KJ,WUKGK/M/GQUK?WWQI,J>LW^_4_WPGJ_/\ N_6@
MQOU_]_SPR11U@[B++">>!4[*]S?\K ;E"&/OOFX>92IDBWI *<WZ>8G<;.X]
M39Z\=EI*905H !/-@DAD&("UA<94G0\)PP3?*7#7$*LX:"M6*-HQ $R3!PSI
MN\NY*S%*CJY81E\%Z;+J(6XYPIJ)18!(#$P8G+O?-$$&1[<*=@T2Z630I %3
M)8DSCE_;3;0H&%T*$N7>*C3 M89I#7%4/4':B0EQ94')X%05JR]D0 @8WB:[
M0Q1*?&<8\_V$*3.#[H4^_P# T>W_ '1^CV^O09>^%#9$\6L.KL"+<C6<6WTW
MR,:Q=*+YIB?SV*YA5,1-:Y.4B#KZ9\:T"86D7QZ\9$WW.O (H%RD0S,+1H5D
M@6O0(5D[&IULTEE:UB4#NR\L3G]R#)P:N#)5LF"3@8PW14B<D?CX$&"#G$'+
M< S15%"&T0L#2&@\#C3/,@[A)1(1C"+"YPH4!ED8O!#8P!<ODG5 A,ATYO#A
M0L"+$'#1%-^C4+'3C5*YI34AB%<B%@$4X$R4E\XY4)'U?S>U]=^O]C 1 0W=
MA%]S]^SCXST\Y\^WI^^7C7_E7+"]==S1R"CDF,*-CWX_\,9^I2.\>.9EF-L.
M]WNRN_OGB."9LLLZ\>WI9UQJH9:]8N"[BPR;F=<4H^/0VZE_D:CG!06@ 8?<
M;'U^F"^.0Q(=8( $D$BH0<\RFL"/\%5 3%PO I_><-E2 74BO%\U%Y.,04BD
MB0*$!JD.*5% &)0B@?#'@QNP1,.R0R@=(R80",Z0CA&3B0<(!3C3!)T1/:F$
M<9:MF7 3$HQQWPTS(! Y[%0Z:W("%\3"U!.TJZ-7E[^!3+%DP6D5,X.A 2(+
MC=R1@VRZP=9@*F* !BG]@X9\]^%_[JZSKD/'=^?/\"!L3?K)N^>NIRZ9)FZT
M 7KTE\FI4D]J:/&"[OKG?P8-B0PQ.B].O%=9!Y12K&$Q*$W,%>O2X7ABA@V^
MC<S7?SF.N&2/QC3==?;^(5"ND (#&! 3;IGUV+QP,&1*<=L#<,<M=;M\B0&#
M",61QR3<CBHAG"T#6N!$LMTF,P8E$!D%)LAC5X284&"K#C$A5 Z;\Q$$'KBK
M ,T%!M B#36C0XIKQW/.:& 38URN@XC9[$ M56QR#2J]F"-&:'H<!385* .G
M'&[0X^DC!6#P7"K2@X0Q^,CN"V[#84."BE'(A4 8+), XQ_8.),5=T5<N<GI
MU^/X61Q;F UDN06+)87E-#"D50 Q<KA*.9C/!!PJ]J8>].INF,:.0(9KL.VB
MX2&U\0]>-<K<>?;S,TSVQBWE,#AJC7)>LX(#Z%<XK*@M$?$W=9SW,3MY&HR<
M!)/^_/I_':<\00",UZSO.:A].PH9./DJS@!I0\$OCP6SUT$0^4XX*V]%)C4)
M51;EL$Q:(-[5"HI##AP@..2"+&"E$/(5"&()2TR,O'"UD472(HVZ1&CI,\NJ
M2+EH522%>D)1%,D07/5,+"FB99+46(*Q@$0FY&N<Y'*O"@)$RWC;&,3A-"VE
MJA8[&1)98$$#08IG/*E$@%_R>/[&KY_;]=9.OG\=\(HI)P1RUTD<19!,<J"S
MH5&@^!<YQ?\ /' 'J)9%LE4]WWWGA,-E\PZ<]I+B%O24XX*#*'(ZQ"M\D2:F
M'FG-K*+EMO5CL#J2D2A%"Y[[-2+@D/0OF@2H4MZ8&V2_ECGF $?<]^G^#"@H
M!I0NTAH@K4/IX]V'DR'VUR@8G!SZ:7&9!M"UE(KWQM0 C10, >+K+H#A;SF#
MW!\H!<="L'9J^D3"V3R10 BP1, VM5"N. (I.N)[)%+**RO9<9:KC*ZXT]($
M*<"0H'(D;QOS1[OX)0(*B&7%+#@4_G[4BX1<8?@@9#J BYHJ5?\ (T5$0L95
M/S1("<K(5) @\&CC1#93WC?LOEM?[&KY_;_ 1,\N3TWYB2=-IM.)DM"(>#X,
M.,V:3A7!(QC$:Y0C#+'&%WF)%PEAF8;->*VN!R9XP:Z5;AP^IK)DP4PUO!+L
M:?C5NWS<O=6\)F&<)L82-LWAOY@8#"T7#&/<.T[^^N#*VN3CJ3U=[<Y3K^&[
MX_9]''.DQO'+5_=JC%.S5W48&_\ V1*<!+:("J0XBX!J!Q601RJ/ 9+E.'JC
MD=00IA+E'*U$30JA!$XPXPF8/ .F:P $J5.F3=;1&!F(FQX91Z!G$"W%"!17
MF!TBP&=O1I$O:J< JX*Q,F(W#5-!M#X,LD(Q47Y?A(4(3JVI#S:GAN< ("$"
M817\C?=M^?[&KY_;] ;& H&4Y2X,($]1V/+@J#T"Q$EIE?/07GC'H]2DR=9R
M+O+$E"%1'0\,T\[+?4=<0C K+AKIGS2GK4XOH$,PO1H0*NIJHX54AI8+F"XI
MC<KCTV-I '[N.G67X-7A;YV=2]Z$S,(A]CBQPF1"Q/1U#6!P+HIR@V9)\_,B
MW=)GK@+G]_\ EOQCSKESX9)G'V/Q^?IN^/V?2)/_ (Y.2J<S[#!*P"$7 YC+
MR,CN5%( ES+PZ#!8%C88*:,L</":;76CX9YMJM<Z-]S!13(4B)EY0=H<S![B
M[P0'BC4J(E1L9%HIA<]\%'^X+894Y VG@;^EJ!6 @ A@TD/>4@)'R$5X$W[G
MMA(Z,)2M1G#'TL=X@D0J@& I!4&@!06*X T64!* M!XYMN*;Z_L:OG]OT5>3
MI"GC+J.4P?!>"!I ;"ZUM&<7\<I,CK*[6^H$U7 L!KD,'(K50;VJ=-,S/PQP
M20L&O)FF=.+9F=<20*$@(I5T*H[P/?0*-UI5_&;=U\NL\@T*:TQ'T9ZD7T\
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M1MY;_P ].V!-.SV*+;]5.6Q7QUH\:W46E":[!3*JCUF!K BT865+Z0XF<6E
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MX@CARSFGJ<6VV';((* ^>&&G $8'!" ,6,=!2_9:,<^TW)HWL3AMNA!I2LH
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M/KS/N5A=^72CT/!V+V?1#$EE#'BVY5% LGHQ$4H_LQ[;O+W09PCA.BC 4:\
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M%ZY* HK*;N'["IH@>M_=_L]_3*PBJ(#2.A-=YQL4_%>>ZR[1(05.!,E@2+-
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MIHN^N$V$&*RK.ZL8GQ)Q2EHSA1&#$L3OR)4[%:[,0*('I5P9AQP+HS5'V8/
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M78>P7$KQ)6K  S4MB!LA2G7VL*\*LR'8$6 $1DMMAPT30U,E:ARH )PR^,9
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M\0V#AY$529JK_#SFY(</$CY<%*2PRFL&!Y<I)P)@F>O #O!J+9XXY1PF4
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MPB.C B(EF+&HA:J@K6J=% Z>(F.3R?A6Y#H\'<FEF':8C]@7M7"# @OK8O\
M)T_5?@%P,$ -F\R&;&M$!F#$J25<(!A\@-L,1$*0UDM?WR%)\@.V?0Y:"*"C
M2H%A0&L3O. P@H.8$T*PZ $.%W)/)DR$FT8*\#751);D$:0$.R9,Y") WTD]
MW/NP]B47KBJAV#3N?1""R^CVZ==_].^ ?X,@ ,34@UKKQ>,M008A0XT"DW:P
M<<,&R;=J !1"VQ%2_>=#1@*0AT2\UY7)TJ+%!([N1'P),^'D1B.Q'*,S"GAF
MU&--IV3> IC$KJZ ^*" K;R+A494-'H\E/0AWPTS@JI+T?DQGXP4I-71%SI
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MBE^PB2I^13AW1,"[+[[]OORDX4'21LD9-NA@@@4\&V-0 @T=5J'%M,Z66'L
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M^%!V)CH&X3B@0.;8CN8*R[3PG!?&D-DM=I=M;Q'#$2+R$: (L1^JM#Z:-:!
M#:M3BZP$4[C% B8B(QX9(&KIQ0IZB]\,;2M*0"9D2(IQQ](2+EIO7;F@-:@I
M*7#JCIJ=M7A*_P $A" "F19A;K:[,)ZU(5;E  CP\DP0C@1P7JG T^1:OIR)
M&.M%U7C(ADJB>Z2 'BRVSEAJ]D'&ZSN^)WWS4PG7G]2[^?\ [S)JR]WX]_<H
M0VD_0*&Y[96YT=]\J-AZL$ 83*S I7D^DM:>\TFT#PXK36D9!K!BF\!MS.,5
MF()@91%Y=U-;#.FLH7W<!9L2.^%;*5Z9^N6^^!94ITE#H#D.]I6AF0FC4$/&
M4]!4;*,$, Z,!8AW2 $5Q;#B:<#Z!@LC1HPCZF"L) .V,@.*=/O'O#^U].UE
M".(T4.SKS?/&D':BB*"8,( )'9>*V&"@<*KSI1L$4\J'(/"X$JH.Q0SL<&IH
M ' TE\W IK2<F2DQ4B;_ "S(MF$!$!2A!VLYJ(S("TR%48*!9G7"6P* 6!#P
M,\G0NSD]%0V J>%,89/DX>X_*"Q$$X2==WKCWNE2R"41+W/#/+O@B (:5EOP
MUC%=X**<!(.FFU*SK.^3FIY(Y(4,8&,;,Y+..4A #@MUBF\ (57JMUM5&O?O
MOFCFCBL;$5%=>LOCB,_B %6THV%?>./</6@6"C:F;F)]3)5';))UE-L)X!8V
MN@*&GO\ L,!0LS=3L3U"BJ?199"22-$4-'I-)C. 8I'X*ATH@E )4,9V%?;+
M @XN+T!>SBIW8%%5</N )90 =H @&GG@^HU"L/P+,/C>IQ5E\?\ ;]MQP2F
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MAG(1+/$GJ^9]^?NCQX\>.!5R#2R79=PGQ;5-.I!E2S&@I4(>3 %_R?OEEB4
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&9=[^O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>prospectussummary3ba.jpg
<TEXT>
begin 644 prospectussummary3ba.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 3S! <# 2(  A$! Q$!_\0
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MI>&>#\)D,%6JI3K]9=%Y1[>N[\MC]=RG(Z.714Y^]4[]O3_/<***0FOT(^F
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M4444#"BBBI ****904444QA1110 4444AA1113&%%%% PHHHH*"@F@F@"@
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M$\8?VU\7K'0XVS%HM@JN,YQ+-^\;Z?)Y5?+Q-?UMP+EZP.1T6U[U2\W\]O\
MR5(_9^'\-]7R^#MK+WG\]OPL!--HHK[\^F"BBG 4  %+110 444TFF,":2BB
M@H***6D 4ZBB@ I":":;3&%%%%!04444@"G 4 4M PIM%)5#"BBB@H****D8
M4M%'2F =*2BBJ*"BBB@84445(!1110,****H84444 %%%%24%%%%,84444R@
MHHHH&%%%%( HHHH ****!A1114C"BBBF,****HH****0!1114@%%%%,84445
M104444 %%%%24%%%%, HHHIE!1110,****D HHHIE!1113&%%%% !1112&%%
M%%,84444#"BBB@H*":": *  "BBB@H****!A1110 4VBE H  *6BB@H****
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MO^3=])_Z_+K_ -&FOS3U.S.FZE=VC,&-O*\18=#M8C/Z5^EG["W_ ";OI/\
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M$/[9W@K4_ASHLWC;Q-;:=XH$;1WL(MI3N9790_R(5&]0K8' +$5X!^W%\2O
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M_)>Q_P!@JY_FE?J-'_DAG_UZ?ZGW4O\ DF?^X:/TEK\:/B!_R/OB3_L)W/\
MZ-:OV7K\B/CQX'U;X?\ Q7\1Z;JUNT,DEY+=028.R:&1V9)%/<$'\"".H-?'
M>%U6$<5B:;?O.,;+O9N_W71\_P #SBJM>#>K2_"]_P T<!7ZP?LKW\FI?L]^
M")9"2RV/DC)SPCL@_117Y26UM->7$5O;Q///*XCCBC4LSL3@* .22>U?K_\
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M]\Q/^%?F?(<"?QJ_HOS9Q=?M3HO_ "![#_KA'_Z"*_%:OVIT7_D#V'_7"/\
M]!%>EXJ?!@_^W_\ VPZ./?\ F&_[?_\ ;3\_O^"BG_)9-!_[ $7_ *47%?-W
MA/PGJ_CCQ!9:'H5C)J.J7C[(;>+&6.,DDG@  $DD@  DU](_\%%/^2R:#_V
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MIN_S/Q=\4_\ (S:O_P!?DW_H9K](?V%O^3=])_Z_+K_T::_-[Q3_ ,C-J_\
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M>E_>D_E>S]#\ZOB?XVF^(WQ"\0>)9RV=2O))D5\92/.(T./[J!5_"O;OV/\
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M'XAQ6)RNNJD7L[V?;1JZ\MT?3?Q(_8/^'_BZWFF\/K<>$M3.YE:U=IK9F/\
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M)<09;+"4FE--.+=[76][)O9OH<&?Y7+-\&Z%-I3335]O/:_1L_3W]HCX>_\
M"SO@YXET..,R7K6QN+,+@$SQ?.@!/3<5V_1C7Y^_L7_\G+^#OK>?^D<]+_PV
ME\9?^AQ_\I=E_P#&:\S\,_$#7O!WC./Q7HUZMCKT<DLJ726\156D5E?$94H
M0[#&W SQC KYC(>%\TRS*<;EF(G!JK&7+9RTE*+B[WBM-MK]=#QLJR/'8++L
M3@*THOVB?+9O1N+3O=+3;:_4_92OQ]^-G_)9/'7_ &';[_T>]=U_PVE\9?\
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M;FY7<KN]K1EI:V[O>XL7P1C*DU.E64FU[SDW=RN[]'I:V[ON>2^*?^1FU?\
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MWL^&R?A?,<LQL*OMDZ:>J3DKZ6VM;\3S\"OT;_8(^)/_  EGPHG\.7,N^_\
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MD%\?[^S'_CM?+7@?]K+XH^ K:&TLO$TU]8Q?=M=4C6Z7'8;W&\ =@& %=_\
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MFT4E4,****"@HHHJ1A2T4=*8!TI***HH****!A1114@%%%% PHHHJAA1110
M4445)04444QA1113*"BBB@84444@"BBB@ HHHH&%%%%2,****8PHHHJB@HHH
MI %?2/[ ?_)>Q_V"KG^:5\W5I>'_ !-K'A/4/MVB:K?:->[#']IT^X>"3:>J
M[D(.#@<>U>/F^"EF6 K8.$K.<6K]KGG9CA98W"5,-%V<E:Y^TE?C1\0/^1]\
M2?\ 83N?_1K5L?\ "\OB/_T4#Q3_ .#JY_\ BZXRXN);NXEGGE>:>5B\DDC%
MF=B<DDGJ2>]?&<(\)UN'*E:=6JI\Z2T36U^_J?/\/Y%4R>5252:ES6V\K_YD
M=%%%?IA]H%%%% !1114E!1113 ****904444#"BBBI ****904444QA1110
M4444AA1113&%%%% PHHHH*"@F@F@"@  HHHH*/TR_88A1OV>=)+(I/VRZY(_
MZ:FOH,L%4DG '4U^..A?%#QEX7TY-/T;Q;KND6"$LMK8ZE-!$I)R2%5@ 2:;
MKGQ,\7^*+-K36?%6MZM:L<F"^U&:9#_P%F(K\+S+PZQ.8YA6Q?UF,8U).6S;
M2;OW1^3XS@JMC,95Q#KI1G)O9MJ[OY'UM^VU^TQIFJ:-+\/O"E_'?F9P=7OK
M9]T:JI!$"L.&)8 L0<#;MY)8#XDHHK]5R/)</D.#C@\-KU;>[?5O].R/T/*\
MMHY3AEAJ&V[?5OO_ %T"FT4H%>^>L %+1104%%%% !112$T# FDHHH*"E H
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M*4"@  I:**"@HHHH ***0F@8$TE%%!04H% %+0 4444 %%%-)H&!-%%%!04
M9H S3J!A1110,*0F@FDH&%%%%!0444H%  !2T44 %-HHH*"BBB@84444 /IU
M%%0?"!2$T$TVF,****"@HHHI %. H I:!A3:*2J&%%%%!04445(PI:*.E, Z
M4E%%44%%%% PHHHJ0"BBB@844450PHHHH ****DH****8PHHHIE!1110,***
M*0!1110 4444#"BBBI&%%%%,84445104444@"BBBI ****8PHHHJB@HHHH *
M***DH****8!1113*"BBB@84445(!1113*"BBBF,**** "BBBD,****8PHHHH
M&%%%%!04$T$T 4  %%%%!04444#"BBB@ IM%*!0  4M%%!04444 %%%(30,"
M:2BB@H*4"@"EH **** "BBFDT# FBBB@H* ,T 9IU PHHHH&%(30324#"BBB
M@H***4"@  I:** "FT44%!1110,**** "BG44#L/I":":;4GP@4444%!1112
M *<!0!2T#"FT4E4,****"@HHHJ1A2T4=*8!TI***HH****!A1114@%%%% PH
MHHJAA1110 4445)04444QA1113*"BBB@84444@"BBB@ HHHH&%%%%2,****8
MPHHHJB@HHHI %%%%2 4444QA1115%!1110 4445)04444P"BBBF4%%%% PHH
MHJ0"BBBF4%%%%,84444 %%%%(84444QA1110,****"@H)H)H H  ****"@HH
MHH&%%%% !3:*4"@  I:**"@HHHH ***0F@8$TE%%!04H% %+0 4444 %%%-)
MH&!-%%%!04 9H S3J!A1110,*0F@FDH&%%%%!0444H%  !2T44 %-HHH*"BB
MB@84444 %.HI":"@)HI** '4445)\*%%%%( IP% %+0,*;1250PHHHH*"BBE
MVGT/Y5A.K3I_')+U9,IQA\3L)2T@Y..]3+;RM]V)V^BFN;^T,'_S^C_X$O\
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M]<S_ (4QK.=>&AD!]T-']H8/_G]'_P "7^8_K6'_ .?B^]$-%3?8YST@D/\
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M6A;^'M5O/]1IEY/_ -<X';^0K0C^'WBF893PUK#C_9L)3_[+1_:&#_Y_1_\
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MKF&_Y^Q^]%2E JTNE7O_ #Z3_P#?IO\ "D.GW2G!MI@?^N9H_M#!_P#/Z/\
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M+3I(E4'O6-=VXB&15:WU$QR8S0!VDNI>7'A36%>:HVXG-)]H$D6<UCWTA&:
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MBV,"G:?J+0G!.*Z'58UD4@"N>:Q*OF@#4;41-@$THMXI1G/-4H[4\5953&M
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M?4U!=&)82P(S7,3ZV8Y]H;C- '9W%PK#.:R)KP+)@55M[[SU'S592&-V!)%
M%J"8,M3A/,[4^WAB"CI5G:JC(H ACMU3DUG:I(L:G%6+R\,:D"N=O+EI7(SQ
M0 Z*Z!DP:O)+&Q&:I6<*LV35RZC$<>5H U;-XBN*GD@#].E<M:WC1RX)XKH8
M-001@EN: +L=J%6LW48#SBH;O6BF0IK+FU9Y,Y)H CN%VL<FJY3;R*5IO,.<
MTUIE1>30!9M=2%L>3BK,WB*/;C-<CJ5^JYPV*P)M9"L?WE '3:QK"R9YKDK[
M4 S$9JK=:@TP^4YK)D,C/DYH O33%LX-4Y)'8\U/#)&J_.XS5+4+Z- =I% #
M+B-64DUS^H3>2W%7OM9D)YXJE>6_F9)- $-IJ6UN36B^L!8^#6!) 8VI,,PQ
M0!8N=2\Y\$U>TU(Y"":Q/L,K-D*36C:PS0+G!% &]<74=K"2,5QFN:L9F*@T
M_6=1D52N2*YQY"[9)H$#98DFFT;J*"0HHHH .<5H>%_^1IT__?%4,?+6AX5_
MY&K3_P#?% S]@?V755?!-L<]A7MD\1N,@5XI^S"F[P1;#V%>W;3'DB@HI+I[
M0MD5?M9G5@I%+"QD;!I\FR%@<T :7V-98]Q'-9&H1^7D 5I0:DK1X!JM<$3-
MTH Y]U8-G%7[&9N!5O\ LPR#(%59;=[=N!0!;FRRU"MJ).M2P;F4;A4K$*,#
MK0!2DAC@Y[U9M;I67&!52XA:1NO%3VL(C[\T ,OL]JJ1V[MDUHW:_N\@5FQW
M31N01Q0 YYOL[8:I8;R)L<U7GQ<4^WM8UZL,T :/RW$>!S6'J6EF-BV.*VX=
ML+#!XJZZ1W4>".: .;TR\6W8*16\LB31YK-N-)V2[ATS5@,(8<9H JWB_,<5
M28F'G-27,Q+'!JOM:0\]* +]E,9N#TJAXJ6*.Q<GKBM.TC6.'(ZXKA?'FI21
MPR $XQ0!XCXV>.:[=>.M)X/A6"X5E]:R?$-WYEVQ)YS72^";$W++M&: /</"
M=\GV=0:ZQHUN(_EKA]'T^6WA!P178:'(<A7/'O0!'#&]K,",]:Z33[A9TD#?
MW#2R6\$D>?ES555$"R[3_ : /R[_ &_%5?$!V_\ /0U\;+WK[ _;RD+^(#SG
M]X:^0!WH$Q:***"0HHHH *** <4 7=-F,4@STS74Q31R0CGFN+5CN&.*Z"P8
MM".:"RYSYGRUL62DJ,UBHQ5QFMJTD7R^M %V-O+-5-3NOE.*'<R-P:@GT^2?
MG- &',#</BI(M+<#(%:D6E^2^6-:RM!'#VR* ,"WC>%L&MBTN%4C-9EY>*)#
M@5%'=9H ]&\/W<*2*3BNO&O)''\I%>1Z3=2;Q@UT7VAPHRU 'H&F^(&DF W=
MZ]!T'Q']GVY;BO!++4&CE&#7:Z5J$DT:X)H ^@]-\11W$8^;)JU<:CN%>:>%
MIY.-S&N]AC\U!ZT 3+,6.13YIMT1%1K:LK5=AMU8?-0!SLD[0R$@5HZ?K#8P
M16A-IL3C.!5":UCMVR,"@"Y)</)RM.@G?H],LYE/!J:9D7F@!?+#2<5LV6GQ
M21_-UK$M[@-6G#?&->* (M1TU%;Y:AM+$+UI\NH;GYI?MRL,#@T 3-"E5KR.
M)8C0V]N0<UG:@)60@9H S;N$2;MM<7X@4Q,3VKKUWJQ!K%UZW213F@#A?MRQ
MOS76>"?$!MM0BVMWKS[7D:&5MG S4OA6\=+Z,L_>@#[U^&^N->6L637K44:F
M%6KYD^$GBB&&.%'E&>.]?2>DWR7UFA1MW':@"_'<;5P*@D9I&.*>D)J6WC'F
M<]* *7EMN!(JR;420Y K2N+5/+R/2H[,K]WK0!R%Y!)'(>.].LXW+9-=E?:9
M"Z;L#-8DEL(VPHH =:R*O!HNE63H*9)&8USTHM9T=L,>: (8R86]*O1W2,G)
MJ'4(1Y>5-8+32*Q&30!I7EPS.0G2OD3]I#P"/"_BQ=6M8O+L-5S(5485)A]\
M?C][\37UM9QM,<M7(?&SP:OB[P#J%FL8:ZA0W%N>XD49Q^(R/QK[7A#.7DN:
MTZDG^[G[LO1]?D]?O/K.%\U>59E"I)^Y+W9>CZ_)ZGPW1117]AG]2%35'^5(
M_P"\<G\*@C2-%SWJEK5\1?-&O\  _K5![B0KQ7\?<:8YX_/,1*^D'R+_ +=T
M?XW9_*/$&)^LYC5?2+Y5\M/SN:-QJ!4[0W%,C4S#.:Q_WC-WK6T^0JH#5\0?
M.CUAD5ABMNP+1)DU+901RJ":DNE$2$+0!2U"^=OE6J]G!*S;B:;G=)R*Z#3[
M5?+S0!E79;RRI-<Y<61>;(]:ZO4K5FD.VH+7169MS"@"OI%B[8!K8?3FC7-3
M06ZVZU)-<+MQF@"G',T;8)JTUX52J'F)YG6I]RNN* *EU.93@5GR1D-DULLL
M:CWJI,@D; H J12%.E3O,77%68;$8R:)XT48% &),"K9%1-=2*N :O26ID;B
MI$TDL,XH I6;/.V&/%79M/VID$4V2U:VY JA<ZI(F5- $5P_D9YK"U#4F&?F
MJ6_U L#FN1U;5"K-B@!^HW[-GYJP)'>23KQ5:ZU)V8BJK7Q09H W8;E85^8T
MVYOU93M/-<E=:TX; J?3;MKA@&Z4 7)I)I9#@\4CVYVY8UHR1I'#NSSBN;U'
M52KE0: +3SK!5=M0#'%06J->=:U(-$!YH IJHG-7+72PS#-6/[-\GI4L,+J>
M* -:QT6/R\D"L_7&CLHVQBK8O&MX3DXKA_$VL/([*#0!BZK>">4XK.I68LQ)
MI*"0HHHH$% ZT4+UH =FKWA<_P#%5:>?^F@K/;K6CX77_BJ=/_WQ5,9^P'[+
M\@_X0FV^@KV]ILY%>'_LPK_Q0]M]!7M*PLTAQ4E%JW!SFI9+%KH@"FQV[Q\X
MJQ#,\;=* )[?06CCW&J=Y&]NQQ6W#=/(N".*9/'$W+GF@#*M;R3I4DDBS2 -
M4[+"F=IK+O)C&^10!LFT7[."O7%9,D;"6FQZM+Y> ,TV*9Y).10 ^X/E)DUG
M"^^8XK1O,%?FXK-2&/S.M $@U L=IJVMFEPF0.:6WL8),'=S6O;VB1Q\'- '
M*7T3VY.VJ<,DK2#)K<UJ';DBL[3PK28- &E&H$.3UQ4,=ZT4F,\5<NH"(,KZ
M5R=U>20SD8H Z&^U4K'UK"?5I)I-H/%6K-6OE^85/_9*0ON/% #+:U>90QJP
MUJR\&M.R,,<>,BJM]=(K<4 0-,EK"2Y[5Y+\1_$,/E2*IYQ74>,O$!L[5R#C
MBOFKQGXVDN+B1,YYH HW4K7M^3G(S7K/PW00;,K7C'AV:2\OER.":^C_ (>Z
M3 L*,[8.* /2--47$"@#M6K;Z<8^152W:.WA'EG-:&GW1G;:10!8C3:,&JUW
M*(UE_P!PUJ36_P O%0V^DB9I2YXV&@#\H_VYY-^OG_KH:^217V-^WQ9I;>("
M%.?WA_G7QPO>@3'4444$A1110 4;AWH%!&Z@!54YS6C9WQCPM9N3C K6TFV2
M4C=UH*-:W;SL9K5AAVIFJT,"1@8-6?/"KC- Q\<FUL5HQR?NZS+7]X^:TQ'\
MN* *=U(V350(S=^*TYK/<N:R[JX^S@@=: (Y+$2'-)]C$=4AJ4F[&*?]JD?J
M* -O3I!'(*W?,\R/BN6LKK:036DNI'@"@#<T^/=(,^M=MI,BVZKFN0\/J9V!
M(KM[>Q/E@B@#K]!U95E0 UZSX=VW:*:\+TB%X[A2?6O7/"M\T:+CF@#LKBU5
M1Q61=3M"W6K[7#R+DUD7JL[4 2I>%AUIS6[7/-4X83WJVEY]GP.U $;0M:TH
MD^T,%JPUY'<C!I(X0K9% %^RTOY0:T/L(5:KVEQM&,U=9RR\4 9D]DI-5/L>
MV3(J_=%ADUE-?^7)AN* -.-65:J7T@5#FKEO>))'65J[;E(% &1/<#<<5BZI
M&TJGBM^"Q,G)I]QIJ>6<T >.^(+4JS9%85I)]EFW#CFN_P#%FGHN[%<!=6K1
ML2* /2?!/B:2&ZCVN1R.]?:'PEUTWUC$&;/RBOST\.WTD-VGUK[)^"FMLMM"
M">PH ^GH81*H(H:!5;FJ&GZH&ME.>U-N+YF;CF@#59?,CP#Q4,5N(FS5-+QE
M6IH9FDH GNIFV]:H;@6R:AU*[=>,4FFPR7+=* *NJ:@(UVBLRP=YI@1ZUO:I
MHQQDBJ$%JMMS0!JK:EH>>:Q[BT(D/%;EC)YF%SQ5JXLX]NXT 8UC&8^O2HM0
M8/P*T&>*/(#5FS,LDO!H ^%?BYX9'A+XA:Q8(NV#S?.A_P!QQN'Y9(_"BO4?
MVNO#ZVNM:%K$:@"Z@>VD(_O(01G\'/Y45_:/#..>99/AL3)W;C9^L?=?XH_K
M+A_&/'Y70KMW;C9^JT?XH^2;YGFU.X8=#(<?G5F"%FX-:"VL<DA;WJ_#9H!Q
M7\<8NJZ^(J59;RDW][N?RG7FZE64WU;9D-9E5SBJJB;S  #72_9UZ&IH;6'O
MC-<IB.T.UE= 3FM2XLAM^8T6]W':QXK'UCQ!MR : )/LJ>;VK8M2J(!FN*M]
M:,DF2:UH]4^4<T =7%;Q.<G!JOJ%Q';H0HQ69::IE>34=],)AG- $?VQY"<5
M7NII#ZTZWFCC/-3RNDR\4 9L.\R#)K5A8;>351H2HR*A,YC;F@"_,N[I5?SA
M%R:1;L%>M9UY=!<\T 7YM9$:X%9W]J-*_6LZ2X5NIJ(W"1<YH ZJQF5@"QJU
M-JL-NISBN#F\1?9\@&LR]\0-<<!J .JU;Q,G*J:P)-2^T$G-<S<WCY)8U4.N
MI#QNYH VM6NMD9.>:\^UG5&60X-;\^H?;EP#FL>ZT)[ALXH Q5U#<>:GC9;B
MK+>&77G%+%IC0MR* ,VXL!UQ3K69+4^]:5S;G9BL::T?S/:@"[=:L9(]JFL1
MH'GESFM%;3Y<FI8855A0!+IMNT8%;,<QC7DU! 5CCJI>7A!P* -&2\'<U&NH
M*F?FK&:5F7.:RKR\,>>: -C6-:VJ0K5QMY<-<2$DYIUS=&5CS58M0(2BBB@D
M**** "BBB@!3S6AX5Y\5:>/^F@K.S^=:?A,?\59IV?\ GH*!G[&_LOV!;P';
M,!V%>T1H(93N%>6_LJW$2^ +53UVBO5M1422ML]:"B?[9%TQ3))%VY%48[-V
MYJ<V[J.E $\%\0<5,\GFFLY5*-DU/]J6-: +)M<KD&JK:>9&YYJ:WO@[8K4M
MXQ)S0!BR6/EKP*EL[7GD5HWC)$.:AM;B*1NM %:^T\NN0*S_ .S]JGUKIYKB
M"./DC-8\MU$S'!XH Q=LMO)WQ6C%J7EQ\G!I;B>)EQWK%OFVC*T 6;RZ:Z;
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MCRU4HYHH^>*K:AJ\:J1N% #[K4(E8@$54DF64?**QFF6XFX:NBT>SCD4%B*
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M@U8AVM@D\5S^UO,SGO4[7CHF%- &S?21>5CBLBWMT:3(K.N+R9^]%O>2*>M
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M5"UGY'(H O2W,C)P>:Q[R.XE8D9JW'(^>1Q5Z,KCYA0!B6=K.L@)S7465Q)
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M^DP/W_P__P"174_Z^/\ ])@?,EUX&DTUAN! J&.P2!@<G(]Z]$\2:@+F,X0
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M*MZKJYF8@5C,Q8Y- $K73MWJ-F)/--HH)N'6E.*0&B@04444 %%%% !1110
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M<?E;^W-&8M>.?^>AKY)6OKW]O!@?$38_YZ'^=?(2TB6.HHHH)"BBB@ HHHH
M**** "BBB@ HHHH *0TM+Q0!;LYO+ K123<,UCP\-S6M R,N,T%DHF"U(MQ[
MU5GC(Z55D:1: -Q&5EY(S3)(%85CV]Q)NK061V&* -314BCNDZ=:^C/A=<1+
M)'BOF:R#1W"GWKW3X6WV)XP6H ^BUN@8UVT1LSL*IZ;(LD*\YK3A H N6L.?
MO&K,LBP#BJ+3&-:6WS=-B@!)G-P<=:=!9K'AC6FNFB*/<16=.S,Q5: +*W"I
MP*LJRR+S6=#9R?>85+)<+"N,\T 6'CB526Q63=:C'"^U2*@O+J2;(2LW^S)Y
M9-QS0!K2:INBP#61-NF;(-/GL98TX%%E&X.&% "PQLG6M"&Z,:XJ-;=V;I6E
M9Z29.6% &+/,\DG0UI643E1Q6B^EQQGD5HV-FF!Z4 9BVKMR:BD<Q,,FNAN(
MUC4XKF-28[SB@#3M=8$0"YJ2XU%77.:YF,L7JZRL8^/2@"/4-0=B0IJC')([
M9-+_ ,M,&IC(D8H 4JNWYJC^4-Q56XN3)D"F0A\\T ;D*B11DTZ14A4MFLQ9
MF6H+J\=E(- &!XRU0"W<>U?._BN]>2XD"GO7M'C&5GA<#FO+++PO<ZYJZQ!"
MVYL4 6_A1X%OO%>J1)%"SY/89K[[^#?P#OM-A@EDA8< \K6O^QI^SW!9V]M?
MWEN,8SR*^X+/0;.QA$<<*A1[4 ?(_P"T-HITGX'^($9<%1;?^E,5%=O^V/;Q
MQ_!SQ*4XXMO_ $JBHK^D?#;_ )%%7_KX_P#TF!^_^'__ "*ZG_7Q_P#I,#Z,
M^RQ-_ *BDTR"08*#\J\Y\&?&K2?$65$Z[LXY:O1K74H+N,-'(IS[U_-Y^ &+
MJG@^WOE("J/PK@==^%*RLS*N?PKV(8[4A4-U'%(#Y#\9_!=Y]^(,_A7@WCCX
M(O"LA^SD#Z5^E-QI-M=9#H#^%<'XZ^'MI>V,ICA&<>E 'Y-^,?A++&K[83^5
M>-:[\.[F"1CY3 CVK],_&7PSVLZF#CZ5X[XI^%*/%(1!S]* /B70]6U'PG=*
M0[A5/2NN\7^/CXKTF&V+?/MP>:WOB%X >QFDQ$0/I7CMY9SZ;=%AD;37!6P=
M.I-5+:HZ:=9Q]U[,@_X5O=W99T5F#'/2I[?X9W\//EM^5=KX*\;)$Z17)'XU
MZO97%KJ$0>,*<UQU\76HRY6C[+ Y3@\;3YH2U/G]O ][''S$WY5EWGANYAR#
M$WY5]/-I\$BX*#\JS;CPO97&=T8_*LHYD_M(Z:O#,+?NY:GRQ=:3,K<H13K6
MT=,9%?0NK?#NVN(V,<8!KSG7/"<FFS'Y/E^E>E1QD*VB/E\;E%?!ZM71QS+M
M7D5G7<8DSBNAN+3@C&#63<69&:[CP];ZF3#&4;VJV\(DC.12K'L;FK*[&7 Z
MT <;JUAMD) K(>(IUKLM1M6<G K$FTUCG(H$8M%6;BU,=5J!!1110(**** "
MBBB@ HHHH **** "BBB@ HHHH *7=244 %%%% !T[U;T/_D.6G^]5.KNAC_B
M>6F?[PH&?H7\#Y%7PQ#]!7<W]S\QQ7GOP6^7PS#CTKOI(3*QXH*&V/[V09KJ
M[;3?-M^G:L33-.82 XKK+>46\&#Z4 <G?6/V::I;68;<4NM7 DD.*JV"EF&:
M -5)PM))<;>:8T.T9JK<3 *10!:CN1,VVK1@C"\US\-SMDR*LSZ@Q7@T :P$
M2],56FO$7(X%9T5PSCDU4O&DYP: +=Q,LAX-56//%58%DW?,:MQXW#- $R;]
MAZU2FG9)*Z"WC22$\<UD7MB?.) XH >+@O%@=<5=T?P_)J;Y8?*15?2[%IYT
M7'&:].T33DM;=>.:^9SK,?JE/D@]6>E@L/[:5Y;(\+^(?@TV:EU6O+M/U231
MM44[BH4U]6?$#2DNM-D;;DA37R#XY1[.^DV\<UIDN/\ KE#W]T1C*'LI^[L?
M3/P]^(R26T:&7G'K7MW@[Q0))$;=D9KX"^'^OW"WB+O.,^M?6_PXO'FMHV)Y
MQ7T1P'T?JVLV=WHA$H4G;WKX:_:(:Q1KHHJYYZ5]$^)M:DMM+8*Q'%?&?QHU
M.>\DN 6)SFF@/-?AEXD%OXR2$-A<U]?:/?":SC8'/%?!?A=I;'Q<DN<?-7V9
MX+OFN-(@8G/RU^<\2T;58U$?19;/W7$],T^^Z<UU5CJ):, -7FEK=F,]:Z'3
M=3*XR:^+IS=-\T7J>TTI74CT+3KQED&3740:@ODR#/\  :\\M=1'E;L\U/;^
M("OF#=_":_5<ES#Z[2Y9;H^4QN'5&5X['Y[_ +<SA_$#'K^\-?)*]Z^IOVTK
MK[1KA.<_.:^6EZ&OI=]CS!:***0@HHHH **** "BBB@ HHHH **** "BBE!H
M -QJ6*X:,]:BZTE S12_W<&I'D61>E98;%6K=MU!1,KA*NPSA@*HE1N&:LQJ
MJJ* -FV53@YYKN/!FN'3KI#FO,ENV4X4UO:+=,)%)- 'U7X3\5+=(@+5Z+8W
M FC!'-?,O@C7/+F12_?UKZ"\,:A'-;I\V>* .F: RKP*MZ?:^0<D5-9[&C!I
M\T@3I0!+=7&Z/:*QU.V;)%75F5NM-FA1UXZT 2->*T6!UK+FMVF<\U:2V(.>
MU/5=K<4 ,L]*[GFKRV:[MH6HX[EH^*4:AM>@"6320Z\K6?)IJ0MG%:JZD62J
M<\OG4 5@J)VJU#<%5X%4G4@U:M<-QB@".:Z>1L8J[9SM&O-68M+\SY@*;<VI
MA7@4 -FD,@K'N;4R/P*MM.5XJW8PB1@6H R$TIU;.*NI8%EQBN@G6)(>G-9W
MG*AH P[G22K9 K*N-.DW' -=K&5N&'%2MI:%2V* . 33F3DU;AL2W05O7%DJ
ML1BK>FV*$<B@#EYM/<=JHW5J54Y%=[=VL:J>!7-:K&BJU 'E^OPAF8,.*O?#
M6SM5\06Q>-3\XJ?6K=)F('6NA^&_A7S=3AD*\;J /TF^ DUK_P (G;I$BJ<#
MI7I6HWB6EM(Q;! KP7X1ZM_8NDPQ@X %=#XF\:2R0NH? (H \M_:O\0C4/A3
MXCB#9W?9_P!+F(T5YE^T!KAN? ^L0E\[O*XSZ3(:*_I'PV_Y%%7_ *^/_P!)
M@?O_ (?_ /(KJ?\ 7Q_^DP/F+P?\6M6\,72.9Y ,YY)KZ.\ ?MB/;M'%<SC\
M37FWB+X)Q&(F)5!QV%>-^+/ASJ6@,TL(? /8&OY4P^<87$NREJ?AM3"5:>K1
M^HWP]_:0TOQ(L:-<)N/O7M6FZQ;:I;B6*0,"/6OP_P#"OQ,UCP?>+O>1 I]Z
M^H?AM^V--96D44\[$\#EJ]I>\KHXMG9GZ5TDT:S(589%?/'PY_:4T[Q%'$)9
MU!;U:O<M'\2V6L1*T,R/GT- &7K_ ()MM2C8B-<GVKR?Q1\-8T#CR^/I7T)P
MPXK \2:>)K9R%R<4 ?"GQ.^$<=Q'*RQ<\]J^0/B1\,Y=/GE(B.,^E?IKXMTX
MM+(CIQ7A'Q#^']OJ$<C>6,_2@#\T-;L)]+F) *$&NO\ AWX_,$RV\[\=.37I
M'Q5^&ZVIE98\?A7SSJ&FS:/?;TRNTUA6HJM'E9Z&"QD\'552#/JVUO$NH4=3
MD$9J5OFZ5Y'\.O&CW7EP3,?3FO6E(=05;-?)5J+HR<6?K^#Q<,9352 H;'6J
M6H:+!JB$,HR:L.K*:(W96K&+:=XG7.,:D>62N>:^*O OV-&DC7BO,=03R&96
M&"*^GKRW6]MV1QG(KQ+XC>%6LS)-$OR]>*^@PF+4O=GN?GN=9.Z;]O06G4\U
MN'4U!'-AJ:-S,01S0L)#5[1\-UL66*,.:I7 3!Q5Q8]RU1O+=NU SGM4ASDB
ML<J0:Z*\A)0\5@S*8W/% $5%%%! 4444 %%%% !1110 4444 %%%% !1110
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M4(Q[5S=YJ+QY!XH Z6$VTC8.*MS:':74?\->9S:U+'(2&_6K-OXJN5Z$G\:
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M*BCN'9JN8#+DCF@#1T#5IK>507.*]>\*^)_]6&?]:\*$QCDXK?TG7'MV7YJ
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M%(K&U*WV.3B@1FT444""BBB@04444 %%%% !1110 4444 %%%%  !FK>C?\
M(:M1_M"JN15K1>=:M?\ >H&C[F^$UNK^&XC[5V\-B6D.!7'?"!?^*;B^@KT2
MVF2*0YH*)+>%H%J&;=+)BKLEPD@P*8L8'S4 36EB-H+47T:QQG%0_;RK!11<
M,TT)Q0!@W%YM<C-55<RR#%1W5N_V@_6M73[$;030!:LX2(P:G,>YN:LPLD:X
MJ"XD"GB@"16\E>*L6X:X/2J$<F[K6I9S)"N: *NI+]C0GI6";TS28SWJ_P"(
M-2$P*K67I=HTDFXT =3I"X49K3NE#1\5GVR^4HQ4WVAN0: ,XH5D_&M2PU1[
M%@03BLNZF"OFHWOHUBY-9U*<:T7"6S&I.+YD>EZ?KR7D !?!Q274^Y6YSQ7A
MNJ>/CH=PNV3"Y]:ZWPO\1K36(@K/E_K7Y=FV4RPLW.FO=/J,'BE45I;GCGQR
MM&COGDQP6K3_ &=]06'5H S8^85)\=)(IK<.A!R:X3X7:LVFZ@C!L8:OM\EJ
M.6%C=;'BXZ#A6/V,^$-U!-X;@(()VUD_$F\1$D"^]>7_ +/_ ,0//T6")I.=
MOK7>>+,ZE&S#G->]8X#YL^)%PTEO-D<<U\@_$:$/=2<=S7VM\1M)$=C,2/6O
MC7XC1A+Z7TR: .A^!<92/IQNKWC []*\/^"<\<<)+D 9KMO&OQ#M=%A=(Y!O
MQC@U^4YK0G7Q[A%'U6%J1IT$Y,L^/?%$&DZ;,BN-Y6OF75O.\0:A([,6!S71
MZSXFF\27#;G)7-6-%T9=Q..U?:93EGU&'-+=GBXO%.O*RV/F;XF:>;&YQC'-
M<)FO6?CG"(;W '\5>3"OHO0\X****"0HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ I\+E'&*910,ZS1YE91D\UKFW$W2N'L[YK=QSQ79^'
M]06X==QH*+]OHYQG%3-8A1BNEACC,((]*R+V-_,.!Q0!BRV8W&JK9@;K6I.K
M*#FLFX5F:@"W#<%UZU<AU PX&[%9L<+"/BH_LLSMD4 =7:ZLZXP_ZU<_X2*:
M(<2'\ZY:#?$OS&I&D+4 =7'XIG88\P_G36UJ21LLQKG[<'C-332;* .PL=<:
M-1\U=/HOC9[9E'F8_&O+K2ZW#K4SWQC/!YH ^AM-^(A:-5,GZUVO@[7AJU]$
MN=V37R;:Z]-&P^8U[Y\"+IKRX21SG:U<&/K_ %?#2J&^'A[6HHGUCI?E6MF@
MP <5-+J 7H:P/M^,*#VIC719NM?BDZCJR<Y=3[2,5%**-UM0..M8GB/Q9!I-
MF[O*%..YK)\0>)H-%L7ED< @>M?+OQ.^*5UJUU)#;RGRP?6O8RW+9XZ:25HG
M)B<0J$;7U-7XF?$Z?5KJ2.&4A<XX->:VL-SJET-Q9MQK)CNI;N7+'))KU?X=
M^'/MDL#,F<D5^M8>A3P\%3IJQ\G4J2J2YY'>?"_X4B^\J1XLYP>E?2'A[X?V
MVD6ZGRE&!Z58^&OAF*ST^$[,?*.U=-XFU*/3;5N0,"N@S,O[1:Z7R2JU&WQ7
ML]!;<)5!'O7B?Q"^(1M=X23'XU\[>.OB?>%9-DQ_.@+GUY\1OVCHK[3)8$N!
MG:1UKXA\77$WC/Q/M0&19'Z]>]<>OBK5]:NQ&C.VXXKZ!^#OP[W(EW>QYD^\
M,UY68XZG@:3DWKT.K#X>5:5NATOA'X:P6G@]%,(\['I7*^%?"C6'B:7>GRF3
MC(]Z^B]+L$V>6!\NVN5O-#CAUE75>=]?*\/8R=;%3C/KJ>KF%%1I1DNAO^+-
M#+_"O44B4>81#C_OZE%=A:Z>VK:"]@J%S(%^4#K@@_THK^K^!LVA@<MJ4Y=9
MM_\ DL?\C]$X-S*&"R^=.76;?_DL3Q2^X4\URVL2#RS6_K$GEQGFN-U"X:3-
M?AY^.')ZS&9F( S7.7&BE\G;7<I9_:).16Q:>%Q<("5H \OTW29;2X5U!'.:
M]:\-S?:K4*QYQBJEQX;\D'"T:9#+9W 4 XS7%BJ'MH:;GNY1F#P5;5^ZS?DT
M\YXIK6.!6O:KYT0SUI)H=N:^4G3E3E[Q^M4*T,1#GIO0PVMMM4;[3([R,K(
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M_NNAJ>$EHS52X5I&XI5N?)C()H K7L7[W)J]ITB*H ZUB7E_O?CFI;&=@<T
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MZ$?A51N*][^(WAW3[>W=D*AO:O"+I0MPX'3- R*BBB@D**** "BBB@ HHI*
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MI%^:@#,C\R.0D5L6M^^T*31%:KSFHIHQ&W% &BO[SGO4=S&2M)8S X'>KLJ
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M8^4_%=QYUTWUK K?\56YANWSZU@_PU]FC\0EI)B4444$A1110 4444 %%%%
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MQ-R123QB/I4UJZJG%5KR8;CF@#,N+]H6/-01ZF)GVTM[&LF<5!IFGAKA<^M
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M=6>1^/%5;HX[FN4/2N@\5W0N9L^]<\<U]9L?DC$HHHI$A1110 4444 %%%%
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M!\7+?%K:!^IQP:YGQ)\2KS4GDCA8[2<5@:'9WFK:FFY68L:]_"X)Q?/,_/\
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M!3[S<R]*W%L5:7I4LVDJ8^E '*VLC0R 5T5O:_:H@:IR:>L<F<5?L[Y(!MH
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M6*SYFV^];-K:E8=U %.]F*]Z;I\GF2"H-2E^8K2:>VQLT =A;%8T!-.DN W
MK'CO/E S09FZYH UH57=GO4DS?+CM5'3Y]S &KUU(H3@4 9-\O!Q6"[2+,?2
MMV9M^:R[N(\D"@"K>W1,6/:J&G[OM()'%6&Y.#5JS5-PX H ZC3[I?+5:[3P
M3IGVS5H@!G)%<#8Q[G7!KW7X'^'9-6\06J*F[)':@#[Y_9/\#F.""9D_A!K[
M/A06UJJCL*\E^ OA/^Q?#]JQ3!V"O5-3N1;VYSQQ0!Y9\4KE?(ER>U?$'Q<U
M9$DG&[N:^J/C!XJCMXIP7QP:^"?C!XL6::?8_<T >/\ CZ^CF60 Y->-W4+/
M=$CUKKO$&J--(VYN,UB6[Q.V3C- "P,T<.#59LRR5HS+E<**M:3H,M],,*>M
M %.Q\.M=L&VUO0:"]FI.W'%>@^'/!CPPAG0_E2^(K&*T@88 .* /FWQXN+C'
MO7(UV7Q"(-XV/6N-H$PHHHH)"BBB@ HHHH **** "BBB@ HHHH ***!0 <DT
MH!<@"C;GI6UH.C27TZ@*3DT#+WA#PK/K%_&JH3DU]1?"OX)W-Q)&SP''':J7
MP#^&376IV[/#D?2OOSX=_#J"U@BQ",X]*"CCOAO\)8]-CC8PC(]J]BCL5TNS
M VA0!756OAU;&W#;-H KR_XF>/;?089HRZ@@$=: .<\>?$:WT&&3,@4@>M?*
M?Q4^/SRPRQPS9^AK'^-/Q.;49IDBGX)/0U\XZA>2WT[&1RP)H U/$GQ"N]49
MBTC$'WKA[K4'N9LDDUKS6:LAK-CL0LW-  N&09JYIK/&V5I)+8*HQ5S2U"]1
M0!T.EZM+"RY/%>@:+JBW2*N>:\R,BIBNF\+ZHL<Z ^M '::EH[3QE@*Y*]TD
MQN1BO5;.2*\LP !G%9UWX=$S%MM 'G]CI7F=16_8Z*L8!*UL)I*VW:I6*QK@
M4 %GY<9 (%:,EPFWBLA<ENE39^6@"]CS$-4U=HY,XXJ:QDRQ!Z5->*N,** *
M\FHMT%+:WSQO\_2K6GZ6)CD]*;J=F(1\HZ4 7?[855ZTW[>LZG)KG?F8XS6G
M9V,DB<9H ;,REN#56XA\P<<T^\T^>!B><4VQWO)AA0!26-X><5:MY/,(!K8E
MT\-']VH(--96SMH M0Z6C1[JK36J1-C-6)YGACP*Q+BXED?J: +S*K<+2PZ8
M7.35?3H99)!U-=(MJ\<.2* *UM%]EP15F2Y29<'K5>-&E;;3I=-D3D9H K26
MZAMU3PZ@MN,4^&P>3@YH;09)&X!H ]<_8_U#[3^TMX0'_7Y_Z1ST5?\ V/\
MPW+9_M#>$[AE("_:^?K:3#^M% ',7%GY'05 MN9N*UM2O(50\BL-=34.0IH
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M1H D8;T_2NT\/^#9YU7?'^E=C;^"EMX\[<'Z4 7?V<M%2T^+OA^55QM^T?\
MI/(**[+X(Z3]D^)>C-CE?._]$R44 ?%>I74CKP3573V9I!NKH9=)^4@BJ36/
MDMP* -FQA5HZ@O(!&V13]/8HO-5]0NOWF* *9WLV*F;?&F:M64(EYJ6ZC$:^
MU &'YLDDF#FMNPC"1Y/%58TCW9J>8GR_DH EN)$/&\5/I\2,WW@:YJ>.=I.*
MUM)5XN6- '3.B+'P<&L*\8^9P>]3W%X0N,U2C8RR<T 7(YBL)K,EN&::M1HQ
MY?%9,P\N3- '0:5,JIS4]Y?HHXZUD6+[UP*N26?F#)H B&H<]*BN+W<AIMQ
M(15-SN!H H7+AWXXJQ;6QE3K56X0JV:T-/D)7% %&XM_+>I(K=9UQ5R[M]]0
M0PM%DT <EXJ\/JT3D5XGXAT%UO.!QNKZ"UR8LA!KS[5M-2:0L13 [;X!V(@B
M&X<YKW]HQD8->$_"F86LRH#CFO<%D+8.:_(,\BUBW<^NP.M)%DZ/#J"%95#
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M&5;< YK,\/JD<BY&*Z>_$8M<KUQ0!RTD99\YJ:*(8Y-9US,_G$#UJ2.:0**
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MN-%^&*P;7:/]* /.;'PE+<1@[#6I:^#S"X+J:]4M]'@LVV%0,5)=Z?!MR"*
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MPW'.":L[E85DJP<_*:M0JWK0 ZYN/*!YK!O,7DF!S6K?P.RG%9EFIBN!N'%
M#8-+:+YL5+YYA;!KHPT4EN  ,XKG[^TS(2* +=M<"2G7%IYZ&J5M&T8%6UO"
MG!% '+:QI)!.!7(ZF/LJG->F7S+<(:\\\56IPV* //=>U=55AGFN$O=4+R$
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M^H2VS=30!K:U8IY)QZ5YSJ4?ERL,5V$VL&>/#&N5U?#.3F@#+HHHH("BBB@
MH7YFQ14UK'YD@XH&:-C:[<,16LEO%<)C S4MK;IY(!QG%*L.R3Y3048UYIOE
M294<5I:6WEJ 16F+=)E&>M6+?2E[4 4Y/FP15^SDQ'@FGW&FM''G%9:RLDFW
MI0!=GA69^E2K8KY=2V\6Y >]3KD<8H QV4P25U7AU?.QFLIK-9&R:WM#C$3J
MHH WX='-Q( @R:].\ _#ZZNIHCY1(R.U)\-?#(U2ZB+ID9K[#^'W@FPL[&)W
MC4$"@!_PL^'MO:6<;7$2@X[BN\U@Z5I,.,1@CZ5SGBCQ9;^';-Q"ZIM'8U\U
M?$#XVS&XD1;@_G0!]2:+XRTJ.[ =T S7HZ?$/0;33]QFC! ]J_,+4/B[?QL9
M(KE@>O!KG]2^/FMM"T8NI/SH _2?5_CUX?T^9LW,8Q[BO-_B!^TYH:6<@BN8
MR<>M?FIXB^*6OWTK%9YCGW-<W_:_B#6&P\LI!^M.S8^63V/HCXG?'*/Q!?3+
M#("I/:O)9&EUB[#\D$U2\.^#KJZD62<L2?6O2-+\.QV<:_(":Z*=%R>IW4<+
M*4ES%?2;'R(0NW!K:LU*M4\-JHQQ5E;7TKTDK:'T$8\JY2W:R!EP:LM"'7BJ
M"(4J]9MN.":BI+EC<QKU/9P9'&ODM4>H3%H6QZ5%JTYM^:R8-1-PS*3GBO(;
MN[GR[ES.YX)\6E/VT_[U><UZ7\8!_I6>G->9BD9BT444 %%%#4 &<UHZ7%\^
M:J6L.]AFNGTNSCV]LT%%NU4LH K4L+=_-3ZU%#;B/ITKH_#]I]JN(UQGF@9[
MC\#[=_MEN3G&17W=X-O(K/2$)/\ #7R;\&?"I589,8Z&OHBZNCI>CG]YC"T
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M@NO-CA(+&LA87:;<>>: -ZZB2XCW8K+6SBD?!ZU)=Z@;6#;CM6)!?2S77RY
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MV'#9JI#:O)T%:EFAA8 B@9LPJ74 596U=>2*=I\:L :TY-J0\T#.?NK[[/\
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M]?5/PA\$11^4[+Z=J /5OASX9:QTZ-MN,+4?Q(UI[&PD3=CBNNO;Z+0='.W
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MD4 *ZBWC&14VGW$4D@SBJ>H7/F*<54TO+70'O0![A\.5MYKV)"JXS7V'\/\
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MAUYI%->CZ3H/V>$;DS^% 'G<>ERVXR\>*:T:,<$8KT'5+2+!&P"L2/0TN).
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M#P%&7E3(KW+PZH.Q2M>;?#W0@9DXXKVW1]'2 1G% 'JGP/M?)\=Z0<?\]?\
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M5!K?;)DU/;WGEQA3UJ5+<W!W9XH 6*7:H K4M[C]WS6/)^Y8"M*&6-K<YZT
M8'B"$W#MMK.TVUDBDK7O<ESMJO#(\; MTH TXW*J-W2FM,I/R]:16-XNV,'-
M-72KF)P2#B@#=T-W1@>U>N^#O%PTT(,UY5H=G-(5!4_E7=Z7H+E5;!H$>^Z-
MXF35[7!;M69K'EV[2L"/NFN&T.^ETY@H) K?NKA[Z%SG)VF@9\-_M3:MLUC@
M_P 9KP>'6WQ7N7[36DEM6)?^^:\0AT^*->>M "MK#8Z9J:WU8]6%59H43I5=
ML-PM &S)K"[>!4<=\+AL$<5CB-\XP:V=+LUD(R* .Q\'Z?%+=1GCK7UQ\)K5
M8;9=OI7REX6M#'=)M]:^KOA<3'8KD?PT ,^,%\T-E(N['RU\7>-+@S:A(">]
M?5WQKO&,+@'M7R#XAD9M1??TS0!>\,Z6))E)]:]F\,6@MXUXKROPK-$K)FO8
M?#MS;LB@D4 = )MR@ U=L;=VYSD4D-O;R %2/SK5LS'&H':@#*OHB..]58H7
MK=NHXG.<51N"JJ=M %G30%8;C6I-=1JG49KE!=2(>*L0RR3'YLT =#8W/F3
M*,UZ-X*9EN4RO>O.-$"+,OK7IWA>14D4F@#W?0KR..Q&?2N7\6SFX9MGZ4RS
MU9%MPN[M5^S6UNVS*0?QH X[2]%N;BXR5;&:[&U\+-)& 1BM5+FQL0 A7-6K
M?6HV^Z10!SMQX';<"!6QH_@]%QN7FMNWU-9F"FMI9(HH=PX- $5CHL5JHZ5-
M,ZQ_=[5G3ZP-Q -9-UK#ANN10!M3ZJ80<#-8EYKSL_ I]O>1W0P]+):V_7%
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M4[9/EJE:WH7&6K?TJ.*[<9Q0!0\F21<@&J%S932/CFN\>PACC[5G2Q0HV>*
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MAQD&N$CO'N)L+SS726%M-Y8;M0!U,=R64 &HIHY%;=DU!8[EQFI=2OA%&<4
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MMK4%<D5KM:VJ+DCFLZZN!&V(^E $4T:1\XJLVI1P_*HYHFWR+6;]CW3#/K0
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M#[2Q3J>V:]E\-78:",$\T =S869@MP0V>*K7%[Y,G-7=/9WAXY%86O;ED.*
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M8 "L+2+YG  Z5T5O?);X9S@T 79;/RX]QK&NFZX-6-0\0)+'M0UC>8\Q)ZT
M-#/YW6M[3H!(HRM9%I"/.RYQ70QWUM;Q85LG% $&J206\)!'-<A=:@AD(3UK
M0UZ[DN&(3D5C0:3+*X..M $PU-X>AK6TF22_D'6FV?AOS,;ZV[:*+2%RN":
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M<J*OZAIUHMN2H&: ,.3667)%9LWB"223:6(%78[>.24IT%5=8\.[8C)'(H-
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MJ]=:]':I@\FN3M->CC7;Q4@D6^;(;- '4Z;?'4) 5R*[?1,PLI8UPFAXM]O
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MO#9QY/ZUW5N_EQXH @6W6&/!(!I8?)5LLZXJGJ"S29V5B36.H2<+0!Z%I_\
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MO4:9OK0 V767OI"7/6L[5+,21EAUJO'.,\5?@83#:QXH Y.)6M[CIQFMZ/4
M8PIXIVI6,2?,HYK)5&\P8Z4 ::V)N>14L=D8..E:FB>6(OG%4=<O%AD(0XH
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MRR@F@#@=0OYE3Y@:@TFX^U3!378Z[H,/E'"]JY6SL_L]U\HQ0!V>DZ%%(H;
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MC?))_.+\Z*^E_P!@3X>R?#[]F3PTEQ$8KW5VEU:967:?WK?N\_\ ;-8_SHH
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MWQE<XH DTWQ1<:7>)AB #7M7@[XLM##&LK\5\ZWZEKK<AXKHM(ODCA4,X!H
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M%[XDNY6.3C\:O:%K,DSX8Y-<_HNBWVK7  C;!KN+#P/<V.':-A^% "W23W3
M*N17?_#_ ,,RR/$[)W]*S=#TM6=1(.GK7J&@S0:;"N"HQ0!ZIH>G0V]C$"J@
M[:K:Y)';QLR8S7(7/CY+>+:'Z>]<9KWQ EN-P0D_C0!>\4>))H6*\8K@-:\2
MR>4Q&,U6U37)KK)?-<9K.I,S%0: ([SQ66N"KFK<>LQRQ[ABN<BTA[Z7=5ZX
MLS8PX]J +<FO;6PM=O\ !/PC=_&'XJ>&?"4"EO[2O$CF9<_NX0=TKG'3"!C7
MCEU>"-B<\U^D_P#P2;^!\L>CZS\6-6MR'O2VFZ-YB_\ +)6Q/*OU8;,_[#4
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MA-+E\&NGU*6#RS@BN/O9U$IYQ0!H0PI)VK0M[.+NM96GW42XRU;$>H6XC.7
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MR(KQL"K*PR"#U!%? 7[5'[*K^ ]5G\7>%K5I?#5P^^[LXUR;!SU('_/(^O\
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M3UH Q+.SD*AB"*EGA?&%!KH6CB5<#%2V5K%)(-PXH YBVLIV;)4UT6DZ?O\
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M?L&VOP52U\7^/!;:QX\(W0VZ8DMM+SG[A_CDQ_'CC)"^M?8] !1110 4444
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MI-<Y=$^::** '6_2M.R4;QQ110!N_P#+N?I7(:U_K#]:** ,E.U:5CRPHHH
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@Q1K]%4 "BB@"[1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>prospectussummary4b.jpg
<TEXT>
begin 644 prospectussummary4b.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 3S! <# 2(  A$! Q$!_\0
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MC7[&#Z/63^73YZ^1Z5+ SGK/1'WW\0/V\/A]X3,L&BI=^*[Q#@?95\FWZ?\
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MFDZTB ZTH% %+02V%%%%(AL****1FV%%%%!F%%%%!(4M%%!#84[I1TIOWJ"
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MK,Q))_$FH:_6X\W*N;<^:FX\SY=N@44451BV%*!0!0300!- % %+00%%%%!
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M2^'?_0@^&/\ P36W_P 17P=^VUX9TCPK\9(++1-*L='LCI4$AM]/MD@CW%Y
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ML??"*.VE=?"6&5"0?[2O/3_KM7SE_P $_?\ DJ6O?]@=O_1T5?>5Y_QYS_\
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M))X Q7Q'!W"V-X>K5JF*G%J:27*V]F][Q1<IJ4;(JTM%%?J)SMA7ZQ?L\?\
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MR\TK;;O3H[&]%Q2J5(]W;[M#X\\1?%;QEXNU)[[5O$^J7=PTGF#-TZHC?["
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M444C-L****#,****"0I:**"&PIW2CI3?O4$!]ZG444$!11100V%%%*!FD0V
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MPG_/Z/\ X$O\R>2?8Z&BN>_X6-X4_P"AGT;_ ,&$7_Q5'_"QO"G_ $,^C?\
M@PB_^*H_M#!_\_H_^!+_ #(<)]F=#17/?\+&\*?]#/HW_@PB_P#BJ/\ A8WA
M3_H9]&_\&$7_ ,52^OX3_G]'_P "7^9FX3[,Z&BN>_X6-X4_Z&?1O_!A%_\
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M$/\ \51_PL?PG_T-&B_^#"'_ .*I?7\)_P _H_\ @2_S)=*I_*_N.BHKG?\
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MKD+J^N+Z3S+FXEN'_O2N6/YFH:*_.L3CL7C)<V)JRF_-M_F0%%%%<(@HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "K5CJU]I;[[*\N+1^NZ"5D/
MZ&JM%5&4H/FB[,4HJ2LU<]"T'X^>-]!P%UE[Z,<>7?*)O_'C\WZUZMX3_:RL
M[C9#XBTI[5NAN;$[T^I0\C\":^9Z*^IP/%.;Y>U[.NY+M+WE^.WR:/!Q60Y=
MC$^>DD^ZT?X?J?H%X9\9:+XPL_M.CZC#?)CYEC;YT_WE/(_$5LU^=VF:K>Z+
M>)=6%U-9W*'*RP.48?B*]_\ AK^U$\/EV/BY#(OW1J4"?,/]]!U^H_*OUW)>
M/\+C&J.81]E+O]E_K'YW7F?G69\(XC#)U,&_:1[?:_X/Y^1])@4$U7T_4K75
MK.*[LKB.ZMI5W)-"P96'L15@"OU:,E)*47=,_.Y7BVGN %+115&384444$G/
MTH% %*3BO0/Z^; G%<K\0/B)IGP]TO[3>MYMS(/W%HI^>0_T'O3OB%X^L?A]
MH;7UV1)</E;>WS\TK?X#C)KX]\3>)K_Q=K$^I:C,9KB4_@@[*H[ 5^:\7<70
MR.'U;"VE7E]T5W?GV7S>F^,I6T1=\:>/=8\>:@;K5+C<JG]U;Q\1Q#T _KUK
MG:**_F'$8BMBJLJU>3E)[MZLY@HHHKG **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*WXG]<S>M@HHHK\C,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7KOD9OS.:AHHK^?Y-R;;/VT****0!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%*JEF 4$D] *V--\&ZYJ^#:Z7<R*?XRFU?S.!6M.E4JOEIQ;?DKDRE&*
MO)V,:BNRA^$/B>7[UE'%_OSI_0FGS_!_Q+#&SBUBEP,[8YE)KM_LW&VO[&7W
M,P^M4+VYU]YQ5%*ZM&S*PVLIP0>QI*\TZ0HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@"UIEW]AOHI\XVY_4$455HKJI8FI1CRP9SU,/"J^:2"BBBN4
MZ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI_Q(Z2_1_/\ .XE%%%>.?4!1110 4444 %%%% !1110 4444 %%%% !1110
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M,M47WVU]->#=/6UT^TB P$11CZ"N"I%-H^0XGQ<J&%C2B_C>OHCL-#L5MXP
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M#],U]0>'TVI&/:OG/P-&#XAMSV\S^AKZ2T1?E4_2N"6Z/S3BZ;]K3AV7YO\
MX!UUG]VK\8JC8CY!6A'713/Q_&2L<+\<O^29ZL?]S_T,5\SZ'(=XKZ._:&OA
MIOPIUB=ERBF(-[ N 37S-HLX9D93N5AD$=Q4.2]M;J?I?",6\KFWMSO\HGK7
MAV7]T*[;3VW**\Z\.W&$%=[I<P:,"OHZ,URV*S"#W#QIX4M?&GA>]TF['[NY
MC*A\<HW56'N#7P1K&EW&AZK=Z?=(8[BUE:)U/J#BOT2B;*8KYS_:B^&WF)%X
MKL(?F7$5\J#J/X9/Z'\*^=SW!^VI>W@M8[^G_ /5X2S3ZKB7@ZK]V>WE+_@[
M>MCYMHHHK\^/V<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *]'^#7CQ?#.K-87C[;"[888]$?L?H:\XHK
MKPN)GA*T:U/='-B</#%4I4:FS/L'7M)AUK3Y(G02QR+@KZ@U\T^.? MSX5O7
M=$9[!C\DG7;[&O0_A3\7$>.#1=9<B7(C@NF/#>BM[^]>E:]H=OJUJZ.BNK#D
M$9!K]%Q&'P^?8=5J+]Y?>O)GPF'K5\EKNE57NO\ 'S1\D(ID=5499C@5]:>"
MM)3P[X9L;55VF.(;O]X\G]:\SE^#MH-4AGBE>W5) YC RIP<X'I7K-Y-]GT\
MD>E<V1Y=4P<JM2LK/9?J;9WC(8J-.%)Z;_Y'@OQP\1#5O$4=G&^Z.U7YA_M'
M_P"M7F]:OBG[1)KU[-<1NC22LP+#&1GC]*RJ^%QM:6(Q$ZDNK/LL'1CA\/"G
M'H@HHHKB.P**** "BBB@ KW;X5W#7'A*VW$GRV9!GV->$U[U\,[,V?A.S##:
MTFZ0@^YKZ7(+_6FUV_5'FX^WLOF=@E/IB4^OTV)\K+<D'6IEJ!:F6NN+,&/6
MG*::M+6Q!*IJ134*U*AI,%N2BG+3%IU2:=!ZFI5:H:D6F22[J,T 4[%0,8W2
MH6J=A4,@JD!$:3-+36H#H+2TW-+0,?FE#4RG T$CZ:U&:2@0C4S)4U(:8: &
M2M^[)]JY:Z^:1_K71WC^7"QKFI&RQ)KS,8]$CNPJU;,^X%9URIK3N*I2+VKY
M^HCUXE[P?^YU*"3_ *:J*^D-#YAC^E?..CJ8463H0X.:^A_#=P)K6)AW4&N2
MM'EY6?FW%T/>IS\FOZ^\[2SX2KT3<UFV<F4%:-N*F$C\<QRV/,?VGLM\%?$6
M#CY8S_X^*^1_ACK'VRU:TD;,MO\ =]U/2OJS]JR8P_!76MIQNE@0_0R"OA;P
MYK3Z#JL-TN2@.)%'=>]>'BZ_L<7&72VI^U<#89XC(ZL5OSNWW1/J#192@6N[
MT:ZX'->8>&-6AU"TAGA??'( RFN_T>;Y1@U]7AZMTF88ZF[.+1W5K)N44W4]
M/@U2PN+2YC$MO/&8Y$;H5(P15"PNAM&36FLP8#TKUHM25F?$SBXSYD?!WQ'\
M!WOP]\37&G7,;>06+VTW:6//!!]>QKEJ^Y_BA\.;'XC>'Y+*X CNH\O;7(',
M;_X'N*^,/%GA/4O!>M3:9J<!AN(^0PY5U[,I[@U^;YIELL%4YHKW'MY>1^Z9
M#G4,SHJ%1VJQW7?S7Z]C'HHHKPCZL**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH  2#D<&O8OAW\:(K.UAT
MW7=Q1?E2\ZX'8,/ZUX[17H8+'5L!4]I1?JNC.+%82EC(<E5?\ ^O;&\L-9A6
M>SN([F)N0T; T[4[?SK8H#QBOD_1]>U#0;@3V%W);2?[!X/U'>O1M'^/-[$J
MQZG9)<KT,D)VM^72OO<-Q)AJ\>7$KD?WK_,^/Q&1UZ3YJ#YDODSK]3\.PS*T
M<L*31G^%US7G?B7X;F/?/IQV@#)@;^AKU/0?%VD>+HR;.<";^*&3Y7'X=ZN7
MFE@H>*G$9?0Q=/GIVDNC1K0Q]3#SY*FC[,^875HV*L"K*<$'M25Z;XJ^';7U
M[+/:,(Y6Y*,/E)KD+CP+K5NQ!LF<?WD((KX.M@:]&37*VCZZGB*=2*=S!HK:
M7P7K3?\ +A)^8_QJ1/ NMN0/L3+[LP_QK!8>L]H/[F;>TAW1@T5U]K\,M4F8
M>:\, _WMW\JZC1/A996TRR7<K79'\&-J_P#UZ[*66XFJ[<MO4SEB*<>IQ/A'
MP?=^);Q,(4LU8>9*W QZ#U->^V-LEK D2#:B *H'8"H]/L8K6)8XD6-%X"J,
M 5=5<5]YEN7QP4.\GNSP<5B'6=N@]*?35%.KZ*)Y,MQXJ1>U1BIEKJB8#A3J
M;3JV('KVJ5:B6IEIL%N/6G"D6G+4&@M2K4:]:F44,E#U%.VT+3JD!A6HI%XJ
M<U&PH0RJU)4DBU'5 ,I<TK4PT /I:CW4NZ@!^:,U'NH\PTR22D+4SS*:7H$5
M-4D_<XKGI*V=5D^45C2=*\7%N\SU,*O<N5):JNM7)!3(8?-F5?>O)E'F=CT$
M[(O6L/EVZK[9KV3P'>>?I=L2<D+@_AQ7DVS Q7H'PWNLV[1D_P"K?^?-3CJ?
M+2BUT/B.)*?M<(I]G^9Z[I[945K6YZ5B::V[%;,).17CQD?B6.CHF>6_M1:>
M^H_!?7E0X\GRK@_17&?YU^?M?I'\:;=;CX6>*DD3>ITZ4[?H,C^5?FY7SV8Z
MU$_(_<?#NI?+:E/M/\TO\CN?AMXV70+C[%>-MM)&RLAZ1G_ U]#Z+JJLBD-D
M'G(-?']>H?"SX@-:R1Z1?2?(QQ!,QZ?[)_I75EV.]FU2GMT/JLXRQ5HNO36O
M5?J?3MG?!U!!K=L[@,H&>:\[TO42%7GFNAM=4QCFOMJ-9=3\LQ.#UT.O!W+B
MN ^+GPRM_B)X=>)55-4MP7M)SQAO[A/]TUV>F7/VB/-6N&KNJ4X8FFZ<U=,\
MNA6JX*NJM-VE%GYYZAI]QI-]/9W<307,+E)(W&"I%5Z^L?CM\&X_%]C-K>EQ
M;=;MTRT:C_CX0=O]X#IZ]*^3V4HQ5@58'!!ZBOR['X&>!J\DMGL^Y^\93FE+
M-*'M8:26Z[/_ "["4445YA[04444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:^\%M0M,N+5)U*.H=3U!&17DXC),-6C[BY7Y?Y'T6!XLS#"S_?/VD>SW^_\
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MF9_A^:E&NNFC^9['#6)Y*L\.^NJ]5_P/R/-Z***^%/T,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *FAOKFW&(KB6
M,?[#D5#133:V$TGN7O[>U+;@ZA=$?]=F_P :K374UPV99I)#ZNQ-1453G)Z-
MDJ$5L@HHHJ"PHHHH **** "BBB@ HHHH T]+\+ZOK5O-<6&FW-W!""TDD499
M5 Z\UF5]F?LNZE8ZWX!L[/RU5[.1XID4??).<GZ@U\S?&'P6_@'XB:QI13;
M)3+;XZ&)_F7'X''X5;C9)GS6!SAXK'U\#4CRN&WFKV?Z/YG&4445!]*%%%%
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MJ^TK4(O)O;.9H)H_1E.#5"OI3]M3X2S>&?&0\8V@:33=:?\ ?\<0W 4<$^C
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MV/<5Y=7R%2G*E)PDM4?N^$Q=''48XBA*\7_7WA11169UA1110 4444 %%%%
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M'*G^_CT]:^:SG!>T_P!IIK5;_P"9]7D.8>R?U6J]'MZ]CQFBBBOBS[T****
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M??\ S/G\'5>#JNG/X7^!^<-%+)&T4C(ZE'4X96&"".U)7Z*?5!1110 4444
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M%% !1110 4444 %%%% !1110 4444 %%%% !113[>%[B>.*,%GD8*H'<DX%
M;:GVG\*;=H_ASX>5P0PM$Z_B:ZJXLQ'%N/2HO"VD_P!E:'I]EP?L]O'$3ZE5
M )K0UB,&W*'@$$&OU:E'DI1B^B1_-.(K>TQ$YK9MO[V<O=.%;Y>!UKP']H[5
MC+J&D:>&XCB:9E]V.!_(U[Y<*6<U\L_&S5!J7Q"OE4Y2U5+<?@,G]2:^9S6I
M:BUW9][PS3]KC%-_93?Z?J<)1117QY^LA7U#\,?$B^-O $,;MNO; "WF!ZG
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M//Z9KY.KV\WDO:1@NB/B.#Z;^K5:\MY2_+_APHHHKP#[\**** "MW0?'6O\
MAF17T[5;B +_ ,L]Y9#[;3Q6%15PG*F^:#LS.I3A5CRU(IKS/;_#/[4&I6:K
M'K6G1WZC_EM;GRW_ "Z5Z'I?[2/A&\0>?+=6+]UEAW#\US7R;17LTLYQ=)6<
MN;U/F,3PSEN(?,H.+\G^FJ/KZZ_:)\%VT99;^>X/]V*!L_KBN?U#]J;08?\
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M5F$G+$R_KH8\-4U3RJC;K=_BPHHHKSCZ<**** "BBB@ HHHH **** "BBB@
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MQ4.:F_EV-:=6-57B?3G[(]T+7PSX@?9N/VN/'_?%<9^U;,]QXTTF5SEFL/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5?;5I5%U/UG(\ \LRVCA);Q6OJW=_BPHHHKE/="BBB@ HHHH **** "BBB@
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M<K#,.70>QSD?4^E>)U[F'KPQ%)58;,[HR4XJ2"BBBN@L**** "BBB@ HHHH
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M1_&'Q"^)NL^(M/O=+CL[PQ%$GF=7&V)$.0%/=37G,G[$?CF+.;[1_P )W_\
MB*WR^*I86E3ZI*_KU!*RL?/=%>^_\,7^-LX^W:1_W_?_ .(H_P"&+_&W_/\
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MM:%:3E!W2T^[<]#@W"SPN404U9R<I:^;T^])!11161]P%%%% !1110 4444
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M8WMWCAFF8*OF''!8\#(S6]^UIXML==\6:5I^FWT-[;6-L=[02!U61FY&1QG
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M$,<"PY]69L_R6O%T1I'5%!9F. !U)KZ_^'7@M? _@VULBN+J0>=<MZR$#(_
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MURVA]6P5&C_+&*_ ****1Z04444 %%%% !1110 4444 %%%% !1110 4444
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M$$70M:W#*/7E"?U'XT5(I^\CSN&,[G&M'+ZOP/X?)]O1GS)1117,?K(4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 ;'@_PO=>,O$EAH]FI,UU(%+
M9V+_ !,?8#)K[NT?P=!H.DZ=I5I&0EO&L2^I '4X[FO$_P!D#PS&MKK?B&1
MTV];2 L.G&YB/S'Y5[W\0/B)H_PB\)RZOJ#+/?2 K:V9;#W$GI[*.YKYK'XJ
M4JOL*:N_U/BLVE4Q6(C2AM'IW;_R/D;]J/18]&^*L^Q]SW-K#/(O]UMNW'Y*
M#^->1UM>,O%VH>.O$M_KFIR>9>7<F]MOW5'0*/8# 'TK%KWZ,90IQC+=(^LP
MU.5&A"G+=)(***DMH6NKB*%!EI&"C\36QU).3LCT+X>Z7]GTUKEEP\S<'_9'
M3^M=O!'C%4M/M5M;>*%!A8U"BM.%:\N<N9W/VS+\*L+0A271?CU+,*U8;Y5J
M.->!5'Q#JBZ1I=S=N1^[0D ]SV'YUCN['LRG&C3<Y/1:G'?$3Q<VGC[!:28N
M6&9'7^!?3ZFL7P7XXFM;A+2]D+QL<)*QY4^AKC;JZDO+B2>9B\DC%F8^M1+D
ML .M>HJ4>7E9^-UL[Q,\9]:@[);+I;L>^:WIL7B319;9\$LN4;&=K=C7B=K/
M=>&->AF7,=W93JX_WE.?Z5[)X9D9;2-6)/RC/Y5P/Q6LHK?7()D&UYH\OCN0
M<9KGHRY9.!]+Q'A88O!PQMK-63\TS[G\!^)+3Q?X8L=1@99K:\A#%>HY&&4_
M0Y&*^(OCI\/?^%;_ !#O]/A4C3Y_])M#CCRV).W_ ("<C\*]%_91^)D6CZE/
MX7OYQ%#=OYMFSG $G\2?B.1[BO=_CM\+HOBEX#G6"-3K-BK3V4G=B!\T>?1A
M^N*QYOJ]6SV9_->%;R',I4I_PY?ET?RV?S/@.NW^&NIM%<3VI/R_ZQ?Y'^E<
M5)&T4C(ZE'4[65A@@CM6UX+E\OQ!!SC<&7]*]"HN:+/V'*ZSH8RG./>WWZ'K
M?C"T35/"=\C#)6(R+[,O(KPBOH-@)-'N5;D&%Q_XZ:^?*Y\/LT?4<607M:-7
MJTU]W_#GZ-? G_DC?@__ +!Z?S-5/CA\)(OBUX72TCE2UU2T<RVD[C*Y(P4;
MV/'Y"J7[-?BO3?$7PGT&SL[F.2]T^#[-<6VX>8C*3R5ZX(P0:]5\I_[C?E78
M?!GRA8WOQ]\+Z6/#D&F/=1QKY,5\525D7H,2$]O4CC%>C_L__!*Y^'JWFN>(
M)%NO$M_D,V[?Y*$Y(W=V8\D^PKVCRG_N-^5'E/\ W&_*@#RW]H3P;XF\;>"X
M;+PQ<&.Y2Y$DT*S>5YT>TC&[V)!P?2NB^!OA[6_"7PYTO3?$$YGU2'>7S)YA
M12Q*IN[X&!78>4_]QORJ2".16^XWY4GJ@/GGX@_L\^+?#'CB;QK\+[[R+J:1
MII=/601LK,<L%S\KH3_":H:MJW[1WQ$L6T*XT==$MKA?+GNTC2WRIX.7W$@$
M?W:^J;59!QL;\C5[9(R_<;\C7)*33U0['D7P7^"EE\&_#DENLJWNKW>'O+P+
M@,1T1?11^O6M[QDVKIX9U3^P8DFUEH&6T61PB^8> 23QQG/X5V%S%(?^6;?D
M:RY89-Q^1ORKH@VUJ!XQ^SE\(;_X:Z3JEYKJ1_V]J,W[PK()-L:\@;NY+$L?
MPKV*G>4_]QORH\I_[C?E6@A%^\*_-+XJ?\E*\4?]A*X_]&&OTBUC5[+P[I\V
MH:I<QV-E"I>2:=@H 'UZGVK\S/&.LIXB\6:SJD2[8KR[EG13U"LY(_0T 8]7
M]&\/ZEXAN?L^FV4U[+U*Q(3CZGH/QJBJM(RJJEF8X"@9)/I7VS\)_ \/A7P7
MIUJ;=8KIHA+<G'+2,,G)]LX]L5VX7#O$2:O9(^;SS.%E%&,U'FE)V2_4\R^#
M_P "9=%O8]8\0QQO=1\V]GD,(S_?;L3Z#M7N=[:C[$YQTJZ8X[?JRBN!\:?'
M#PIX;LY8AJ$=]=("1;6IWEF'121PO/J:^DA"EA:=KV1^/UL1CL[Q//RN4NR6
MB7Z">-/'EO\ #'PW<:N2C:C(IAL;=N=\A_B(_NJ.3^ [U\R_#.9]:^+&B7%V
MV^:?4!/(W3+Y+Y_.L+Q5XJU#QCK4^I:C,9)I#\JY^6->RJ.P%-\)ZO\ V!XH
MTG4C]VTNHIF'J%8$C\J^9QF(>(^%:+8_6<KR59?A)PD[U)K5]M-$O)?B?</Q
M18V_P;\72CJ;!T_/ _K6A\%=1;4/".A71.YI+.%F/JVP9_7-6[C3H?&7@W6=
M(#!H]1LI(XR#P=RG:?SQ6!^S3#)_PKG0DD4B2.-T*_21Q_2O!HUERRN?G&(H
M)Y<TMU/\'%__ ")\>?&#2?[#^*7BJR'(CU&8C\6+?UKD*]6_:DMTMOCEXE5
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M5\QU!^QY9F%/,L-&O#?JNSZK^N@4444'JA1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH **** "BBB@ HHHH **Z+P3X!UGX@:H++2+4RD8\V9N(XAZL?Z=:]PTW]D
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M^6K?EA?^!5\%UC0O).1\WPEAY1HU<3+[;LO1=?O?X!11174??!1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBBBNL^#"BBB@ HHHH **** "BBB@ HHHH ***=%$\\B1QHSR.0JJHR23T %
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI7+*C,"54D*,G Z5W1DI*Z/S?$X6KA*KHU59H2BBBJ.0**** "BBB@ HHHH
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MU\1Q6MO:*YCB8NTCKC)Q@ ?K7&445[,8J*LCDQF+JXVLZ]7=A1115'&%%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXNG&&F<N1Z9/2J]%%6<$I.<G*6["BBB@D**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2=W'L%%%%4<H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >N_LF^ +GXH
M?'[POX:M$,D]X+H@!<_<M9G/_H-%?2G_  1M\"R^(OVI+_Q"4'V7P[H=Q*7(
MZ2S,L* ?56E/_ :* /7/^"VWPIE6^^'WQ(M8 86CFT*^E5.58'SK?)]]TXY]
M!ZU^65?T>?MF?!$?M!_LW^,_"$,*RZM):&\TO.>+R']Y$!C^\5V'V<\5_./<
MV\MG<2V\\;0SQ.8Y(Y%(9&!P01V(- $=%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV71]'MEMH5/+/@?,[GNS'+$^I- '64444 %%%% 'Q1_P4<_83B_:8\+IXO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#LU_LH> /V6?"HTKPAIVZ_F11?:U> />7C#J7< 87/(1< 5[)110 4444
M%%%% !1110 4444 %%%% !1110!R?CCX2^"?B9:M;^+?".B>)8F7;C5-/BN"
M![%U)'X5\B_M,?L _ #1? ][KFF_#JTT[4D!VR6=]=PH.,_ZM9@G_CM%% 'Y
M9_%/X9^&_#:N=.TW[/C&/W\K?PD_Q,>XKPFBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *DMU$EQ$K#*LP!_.BB@#Z+^%/PC\)^)&@&I:5]IW'G_2
M9E_CQ_"X[5^K7P0_X)\_L]1^$=-U>7X9Z??7\R;I'U"ZNKI"?]R65E'X"BB@
M#Z@\(_#_ ,,> +$6?ACPYI/AVT"A?)TJRCMDP.V$45OT44 %%%% !1110 44
)44 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>prospectussummary5b.jpg
<TEXT>
begin 644 prospectussummary5b.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 3S! <# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHJIJVK66A:?/?ZC=PV-E N^2XN'"(@]2351BY-1BKMC2;=D6ZSM>\1:
M7X7TV34-8U&UTNQC&7N+R98D'XL17R1\9_V_+32YI]+^'UI'J,JY0ZQ>*?)!
MSC,<?!;ZM@>QKXW\;?$7Q)\1M4;4/$>L76JW&?E\Y_D3V51PH^@K]5R7P]S#
M,$JN-?L8/H]9/Y=/GKY'UN!X;Q.(2G7?)'\?NZ?/[C[]^('[>7P^\)M+!HB7
M?BN\0X'V1?)M^G_/5Q_Z"IKP#Q=_P4$\?:UF/0]/TSP[$<X=8S<RC_@3_+_X
M[7R]17Z_E_ N1X%)NE[27>;O^&D?P/L\/D& P^\.9]WK^&WX'I.M?M)?%#Q
MK+=^.-856ZK:W!MP?PCVUQ=YXNUR^8M=:SJ%PQY)ENI&)_,UE4WK7V5' X7#
MJU&E&*\HI?DCVH4*-+2$$O1(=)(\S;G9G;U8YHHHKM-0HHHH ****"0HHHH$
M%%%% @HHHH$%%%% !1110 4444 %%%% @HHHH)"BBB@ HHHH ****!!11102
M%%%% !1110 4444$A1110 4444""BBB@D**** "BBB@04444$A1110 4444
M%%%% !11102%%%% !1110(****"0HHHH ****"0HHHH$%%%% !1110 4444
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M**** "BBB@ HHHH$%%%%!(4444 %%%% !11102%%%% !1110(****"0HHHH
M****!!11102%%%% !1110 4444 %%%%!(4444 %%%% @HHHH)"BBB@ HHHH)
M"BBB@04444 %%%% !1110 4444$A1110 4444 %%%% @HHHH)"BBB@ HHHH
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M%%% @HHHH$%%%% !1110 4444 %%%% @HHHH)"BBB@ HHHH ^]O!/[!'P_\
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M+2_SW^9^:8G-<3.M.5*;4;Z>A^0WQH^'+_"?XG:]X8+2206<_P#HTLN-TD#
M-&Q( !.UAG QD&N)K[5_X**?#W9-X:\;6\8 <'2KMAGJ,R0G\O-&?85\55_0
MW#>9_P!KY50Q<G>35I?XEH_OW^9]Y@\1]9P\*O=:^NS_ !"BBBOI3L"BBB@
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MX; YAF$/;SK./:[?](_0+QE^Q#\+?%%I.+'2I_#E\Y++=:;<N0I_ZYN63;[
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M&(81)X??6[F,8-SJES)(7]RBE8__ !VNKN/V<?A?=0M$_@30U5NICLU1OS4
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M+[DK7ZGQ#1Q=3AR-7!5)0G3C&7NMIM):K3RN_5'T>:1J?57.E)IQUT=M.O\
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M!!R-W3:>>U>14X?X@H8%9KA,=*J[)VA*;;OVWYK=4<]3!XVC2]O2JN7HV_\
MASRO]I#]EO5?@3<0ZC;73:SX7NI3'%>%-LD#\D1R@<9(SAAP<'@=*\,K]%_C
MK^T5\)/B!\(?%>A0^*K6]O+FQD-K#]FG!:=1OBP3'@'>JU^=%?K'".8YCF&
M?]J4Y1JP=KN+CS*VCLTM>CL?1Y?7K5J-Z\6I+3:U_,_1/X,?LG_"KQ9\)_"6
MLZKX6^U:E?:;!<7$W]HW:;Y&0$G:LH Y[  5X_\ MK_ WP1\(_#_ (8N?">B
M?V5->74T<[?:YYMZJBD#$CMCDGI7UY^SM_R0GP'_ -@>V_\ 18KY_P#^"CW_
M "*O@O\ Z_;C_P!%K7Y#D.;9C6XICAZF(G*'/-<KE)JR4K*U[:'S678BM4QR
MA.;:][2[[,^$54LP &2> !7VK\$/V!H;_2[76?B)=7$4DP65-#LG"%%/($TF
M"<GNJXQ_>[#YK_9YL+34_CAX'M[X!K9M5@8JW0LK!E!]BP%?KC7V'B!Q'C<J
M=+!8*7(YIMR6]KV23Z=;O?8[<XQU6C-4:3M=7;_KT/*]%_9;^%.@P^5;>"-,
MF7^]>JUTWYRLQ[53\1_LC_"?Q,C>=X0M;&4J0LNFR26Q7CJ%1@I/U!KY:_;"
M\1?%[P_\2]4N'U'7M+\( H-.FTR:2&S\LJ.&:,@>9NW9#_-Z<8J+]E7]K#4_
M"_BB72O'_BFXNO#$\#LEUJ9DN9+>88*X?#/M(R-IR.F,<Y^3AD&?SRY9OA<?
M*I)KFY8RFY=[7OK)=5\CA>$QD:*Q%.JY/R;_ *9B_M*?L@7OP9L6\1:#>3:S
MX6#JDWGJ/M%F6.%+E0 RDX&X 8) ([GYPK].O&'[3OP9\5^$]9T6Z\86TUOJ
M%G+;.AM;CD.A7_GGUYK\Q:_4>#<RS3'82=/-:<HU(-6<HN/,GZI7:MJUY=3W
M\NK5JU*U>+4EW5KA1117Z >J%%%% !113@*  "D)H)I*"0HHHH$%%%% !111
M02%. H I: "FDT$TE!(4444""BBB@ HHIP&*  #%+110!+:W3V<ZS1G#KG!^
MHQ14!-%1*G"3O)7)=F.G_P!=)_O'^=,I\_\ KI/]X_SIE4MC['H%%%%,0444
M4""BBB@04444""BBB@ HHHH **** "BBB@04444$A1110 4444 %%%% @HHH
MH)/V)^%/_)+_  ?_ -@>S_\ 1*5!\2/B]X2^$=K97/BS5O[)AO7:.!OLTTV]
ME )&(T;'!'6I_A3_ ,DO\'_]@>S_ /1*5\R?\%'_ /D5_!7_ %^7'_H"5_'&
M4Y=2S;/8X*NVHSE*]K7TN]+IKIV/Q[+L+#&8N-"HVD[[;Z)L]8_X;1^#?_0X
M_P#E+O?_ (S6!XH_;R^%VAVY;3;C4O$4Y^['9V;1#/\ M--LP/H#]*_-BBOW
M"GX:Y-"2E*=22[.4;?A%/\3[B/#F#B[MR?S7Z)'M'QY_:G\4?'+_ $"5%T3P
MVCATTJVD+;V'1I7P"Y!Z# 4<<9&:\7HHK])P.!PV6T%AL)!0@NB_J[?F]3Z&
MC1IT(*G2C9(_6C]FG_D@?@7_ +!<7\J\0_X*-?\ (@^$_P#L)O\ ^BC7M?[,
M<R7'P!\#,AR!IL:?B"0?U!KQC_@HQ;R-\.O"TP0F)-596;L"86P/_'3^5?S#
MD>G&$;_\_9_^W'YGE?\ R-(^LOR9\!5ZQ\#/V;?%/QVNI9-,$>G:);N([G5K
ML'RU;@E$4<N^#G P!QDC(SY/7Z_?!;PG;>"/A1X5T:UB6-8-/A:3: -\K*&D
M<X[EV8_C7[5QIQ%6X?P<'ADO:5&TF]DEN[=7M;I^1]AG.8SP%.*I?%*_RM_P
MYXEX4_X)\^ -)CA?6M2U;7[E5Q(OFK;0,?4*@WC_ +[-=K%^QW\&M-4N_A*/
M&.6N-1NF'ZRXKSW]NKXV>)?AS9:#X?\ #=[+I#ZK'--<W]N=LVQ2JA$;JF2Q
M)(P>!@CG/P+J>JWNM7DEWJ%Y<7]W(<O/=2M)(WU9B2:^'R;)^(>(L+',*^92
MIQG>R5^CMLG%+5'CX3!X_'4E7J8AQ3[7_1I'[%^"_"GA[P;HHTWPS8VNGZ8L
MC.(;0Y3><9/4\\"O#OV^/^2!M_V%+;^3U>_89TF\TOX Z>;RVEMOM5Y/<P^:
MI4O$Q 5P#V.#@]QSTJC^WQ_R0-O^PI;?R>O@\MP[PG%=+#RJ>T<:MN9];/?=
M_F>'@8^SS2,&[VDU?O:^OS/DC]B^V2Y_:0\)[V51']JD"L?O$6LN /?G/X&O
MU&K\I/V4];A\/_M">"KNX<1QM>-;;CTW31/$H_.05^K=?0>)T9+-J,WLZ:_"
M4O\ ,[.(D_KD7_=7YL_(GX^7\^I?&WQU/<.9)/[9NHP3V59651^"J!^%<%7L
M?[7'@FY\$_'CQ,)(&BM=4G.IVLAZ2++\S$?23>OX5X]'&\TBQQJSR,0JJHR2
M3T %?O\ E%6G6R[#U*3]UPC;[E^1]]1E&=*,X[-(_3?]A_\ Y-ST#_KXN_\
MT>]97[?'_) V_P"PI;?R>NV_99\"ZK\.O@?X>T?6H1;:EB6XEM^\7F2,ZHW^
MT PR.QR*XG]OC_D@;?\ 84MOY/7\SX6K"MQBJE-WBZ[::V:YF?G&%DIYMS1=
MTYR_-GY^_#G_ )*%X7_["EK_ .CEK]D:_&KP#<):^.O#D\AQ''J5L['V$JDU
M^RM?6>*7\?"/RE^:._B3^-3]/U/S8_;V_P"2^R_]@RV_]FKYSKZ6_;_TVXM?
MCC#=21,MO=:5 T4F/E;:SJPSZ@C]1ZU\W6MK->W,5O;Q23W$SB..*)2SNQ.
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MB3%YQ"KA<:^:5-)J75IZ6?IWZ]3V\IQE3%0E&KJXVU]3EZ***_7#W@HHIP%
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M_P#AF7?VU/AY_P (+\<-2NH(O+T_74&IPD+A=[$B49]=ZLW_  ,5]W?LT_\
M) _ O_8+B_E7YG?$GXT>,?B]]@/BW5UU8V&_[,WV2"$IOV[AF-%SG:O7/2ND
M\,_M6_%/P?H%AHND>*/LFF6,0AMX/[/M7V(.@W-$6/XDU6<\+YIFV2X3 2J0
M]K2W;<K-)-*SY;WM:]UW*QN7XC%8>E3<ES1WW_R/I_\ X*-?\B#X3_[";_\
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MV>'?VL/BKX3T&PT;2O%/V73;&%;>WA_LZT?9&HP!N:(D\=R2:Y_XD?'/QO\
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MHH$%%%% !113@,4  &*6BB@ II-!-)02%%%% @HHHH **<!10*XL_P#KI/\
M>/\ .F4^?_72?[Q_G3*2V/L HHHIB"BBB@ HHHH **** "BBB@04444$A111
M0 4444 %%%% @HHHH)"BBB@ HHHH ****"0HHHH ****!!11102%%%% !111
M0(****"0HHHH **** "BBB@ HHHH)"BBB@ HHHH$%%%%!(4444 %%%%!(444
M4""BBB@ HHHH **** "BBB@D**** "BBB@ HHHH$%%%%!(4444 %%%% !111
M0(****"0HHHH ****"0HHHH ****"0HHHH$%%%% !1110 444X"@  I":":2
M@D****!!1110 4444$A3@* *6@ II-!-)02%%%% @HHHH ***<!B@  Q2T44
M %-)H)I*"0HHHH$%%%% !3@* *6@04444""?_72?[Q_G3*?/_KI/]X_SIE);
M'UX4444QA1110 4444 %%%% @HHHH)"BBB@ HHHH ****!!11102%%%% !11
M10 4444$A1110 4444""BBB@D**** "BBB@04444$A1110 4444 %%%% !11
M102%%%% !1110(****"0HHHH ****"0HHHH$%%%% !1110 4444 %%%%!(44
M44 %%%% !1110(****"0HHHH **** "BBB@04444$A1110 4444$A1110 44
M44$A1110(**** "BBB@ HHIP%  !2$T$TE!(4444""BBB@ HHHH)"G 4 4M
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M*P/^%@>%_P#H9-(_\#HO_BJ/^%@>%_\ H9-(_P# Z+_XJC^T,'_S^C_X$O\
M,7UBC_.OO1OT5@?\+ \+_P#0R:1_X'1?_%4?\+ \+_\ 0R:1_P"!T7_Q5']H
M8/\ Y_1_\"7^9/MZ7\Z^]&_16!_PL#PO_P!#)I'_ ('1?_%4?\+ \+_]#)I'
M_@=%_P#%4?VA@_\ G]'_ ,"7^8>WI?SK[T;]%8'_  L#PO\ ]#)I'_@=%_\
M%4?\+ \+_P#0R:1_X'1?_%4?VA@_^?T?_ E_F+ZQ2_G7WHWZ*P/^%@>%_P#H
M9-(_\#HO_BJ/^%@>%_\ H9-(_P# Z+_XJC^T,'_S^C_X$O\ ,7MZ7\Z^]&_1
M6!_PL#PO_P!#)I'_ ('1?_%4?\+ \+_]#)I'_@=%_P#%4?VA@_\ G]'_ ,"7
M^8>WI?SK[T;]%8'_  L#PO\ ]#)I'_@=%_\ %4?\+ \+_P#0R:1_X'1?_%4?
MVA@_^?T?_ E_F'MZ7\Z^]&_16!_PL#PO_P!#)I'_ ('1?_%4?\+ \+_]#)I'
M_@=%_P#%4?VA@_\ G]'_ ,"7^8O;TOYU]Z-^BL#_ (6!X7_Z&32/_ Z+_P"*
MH_X6!X7_ .ADTC_P.B_^*H_M#!_\_H_^!+_,GV]+^=?>C?HK _X6!X7_ .AD
MTC_P.B_^*H_X6!X7_P"ADTC_ ,#HO_BJ/[0P?_/Z/_@2_P P]O2_G7WHWZ*P
M/^%@>%_^ADTC_P #HO\ XJC_ (6!X7_Z&32/_ Z+_P"*H_M#!_\ /Z/_ ($O
M\Q>WI?SK[T;]%8'_  L#PO\ ]#)I'_@=%_\ %4?\+ \+_P#0R:1_X'1?_%4?
MVA@_^?T?_ E_F+V]+^=?>C?HK _X6!X7_P"ADTC_ ,#HO_BJ/^%@>%_^ADTC
M_P #HO\ XJC^T,'_ ,_H_P#@2_S%[>E_.OO1OT5@?\+ \+_]#)I'_@=%_P#%
M4?\ "P/"_P#T,FD?^!T7_P 51_:&#_Y_1_\  E_F3[>E_,OO-^BL#_A8'A?_
M *&32/\ P.B_^*H_X6!X7_Z&32/_  .B_P#BJ/[0P?\ S^C_ .!+_,/;TOYE
M]YOT5@?\+ \+_P#0R:1_X'1?_%4?\+ \+_\ 0R:1_P"!T7_Q5']H8/\ Y_1_
M\"7^8>WI?S+[S?HK _X6!X7_ .ADTC_P.B_^*H_X6!X7_P"ADTC_ ,#HO_BJ
M/[0P?_/Z/_@2_P P]O2_F7WF_16!_P + \+_ /0R:1_X'1?_ !5'_"P/"_\
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M/_ Z+_XJC^T,'_S^C_X$O\Q>VI?S+[S?HK _X6!X7_Z&32/_  .B_P#BJ/\
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M/_ Z+_XJC^T,'_S^C_X$O\Q>VI?S+[S?HK _X6!X7_Z&32/_  .B_P#BJ/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[;TBO[S_ $6[]+'M9EC5@<,ZOVMEZGFOBCQ)>>+-<NM4OGW3SMG:/NHO91[
M5ET45_'=:K4KU)5:KO*3NV^K9^02E*I)SD[MA11161 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?X67WGA\18EU<2J*V@OQ>OY6"BBBOR8^4"BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5<T7_ )#%C_UWC_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]?&5:4J,N2:U/&E&4':2L/58HFPY"G\J>VHV"\&]B'_;45YIX^U74Y=2MK*
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M $:U<[71?$C_ )*'XH_["EU_Z-:N=K^=L?\ [W6_Q2_-GSU?^+/U?YA1117
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MO-+J'CC3;> >9("[8Z_=5F_I6Y\-MRZ//(>,[C7(W]V9/B59;6/R+.20<?\
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M GO(4Z26H\S=] ,FO+]2T>_T>9H;^RN+*53@I<1-&0?H17[--![5S'B+X?\
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MYO,E;FLQJ?-<>8Q.:@9Z_4$K*QX@UJ8:5F!IA-, +4VBFDT (QJ)FI[&H6-
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M'ZT^U;9=0MZ.#^M?EI^>G[">%[G[=\-T=3NS;#O_ + K\L?C?"(?BAKRC/\
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MKTJ.01YN:>IC+%.UD>U>+?BDUQ&X\W]:\-\6^+)+Z1QN)!K'O->DFSER?QK
MO;DODDU]-A\%3PZT1QSJ.16NKDLY)JJTM,GDW5!N]Z]$Q+*R8J99JH[Z>LE
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M&O\ KUE_]%ST5_3/AE_R)ZO_ %]?_I,#ZC*_X+]?T1YA\2/^2A^*/^PI=?\
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MLU0H ]/\0?M&>,]<;]W?G3DQC;:Y0_F#7 :AXAU/5F+7NH7-TQY)EE+5GT4
M=?\ "WPC<^._&MCID+LH+"65\_=0$9/ZBONN"(Z?9F)F+%>,FO!?V8?A_=:-
M;OXAN8C%+=+L@W#G9G)/T/%>Y>(M22QM7DE<  9)H ^>OVB/$4\UD;19F6/!
MW*#P>17SE7=?%?QLOBK7'6WS]FB) .?O^_2N%H **** "BBB@ HHHH ****
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M%-S0 Y>M2+4=/!H D6G]*C!I=U #B::U&ZC/% $;5$U2M434 1M2;J5N],-
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MP_JVF:UI[2-Y<C.(6"9XR"Q[5^A-C!=1[E64JP[9I[P7 ;<[LQ^M 'YX6?\
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M-.I36VZ_7_,^>S# ^Q]^!X51117S!X 4444 %%%% !1110 5=T/_ )#>G_\
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M_:.L$_\ 7:+_ .-5D7/[/_AB%B([W56/O-'_ /&Z /FWPU_R7;PW_P!>LO\
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M<EA@_0BOR^^.7@UO!/Q'U.TP%@G=KJ *I $;,V!^E ' 4444 %%%% !1110
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M: '+4BU&M2K0!(O2HY$R*E6E*[J *!RM+]X5::'-0M 1TH BI,4N".HIRT
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MH4 ?03R--*RCDD\GM5RTACM_F)R>O6L.UOFR=O4]35QK@K'G.: +M_J0/&<
M55AU(E@J<^^*RV$EY*0O3/K6K:6(MXP30!JQW1\K)-.M=2"R8R,U@:MK"V48
M4-R?K5*RNI6_>,>3VH [:>^W<9S21V:QKYCG\*R=-F,A#/R:T+R]*QX)YH ^
M:/BVV[]JKP@?^H.W\KNBHOBEN_X:D\'ENK:.Q_2[HK^F?#+_ )$]7_KZ_P#T
MF!]1E?\ !?K^B/F[XFQM#\2/%<;?>35KM3]1,]<U7;_'2U-C\;/B#;$;3#XA
MU"/'IBYD%<17\XXR7/B:DN\G^9\Y5=ZDGYL****Y#(**** "BBB@ HHHH *^
MM?V-_'7DVC:3(^&MYBR@GJK9)_*ODJNT^#_BR3PCX\TR[$OEP/((YL]"IXH
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M )BJV#R*5[6"9<X&?I0!Y+\>H1_PISQ2X_Y],_\ CZU^?]?H?^T)"L/P:\6
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MR1GL>O\ *@#*HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!>:/=02#3Y"9;&X8<2Q$D Y]1@C\*\SH **** "BBB@ HHHH **** "BBB@
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MH%?HM\2]/.I>$]3A7@M ^/RS7Y[ZU'MU2Q!'S"%T/U5@*]O)G;&17J>EEO\
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MO3RV7+C*;\SLP<N7$TWYHV/",N#M'0C-<Y\4KBYC\":Y<QR-%/ [21R*<%2
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M+[5IO<>>I-8]XNULB@#C/CU<[O@[XI'K:?\ LZU\ 5][_'&16^#GB@=_LO\
M[.M?!% !7T_^QHVS3_%A_P"FMK_*6OF"OJ/]B^'S--\7'TEM?Y2T ?17GNPX
M!IH65S\H)-2%EC;D4];PL0J(!_P&@"2ULY68;SBMV&WBBC[$UGV:,W+59FF$
M2]>: )#:Q,VX@432P0QD#&:QKK4GW8!P*A29Y<Y)- #KYEF8^E06\D<#C:.:
MDDA>3H*FM]+/WFH \Z_:4OGF^"/B!.=I\C_T<E?!U?>'[2]J8_@KX@8#"@P?
M^CDKX/H *^N?V,I''@O7D7H=14G_ +]BOD:OK_\ 8K4-X+U_/7^T5_\ 1:T
M?2UI.RQA>@QR:2[F>X4QQ_=[FH,G 4<"KL>R&W/'./Z4 8K:>?,"CKFM9; 6
ML*^8?F/;%0P2;93(WX5%>:@6D)SGVH V;&&)4["M/[,KV[%1@ =:Y+3[]I)O
MG;:@Z]JUM2\2)Y?E0'"].G_UZ ,^XLD>\W-@FM":94@" <UF0W(SN)RQI]Q<
M+'$68T <G\!3G_@I]\(?^P/??^D6HT5!^SU<?:/^"G/PB;M_9-\/_)'4:* /
MC?\ :R_Y.G^,G_8YZS_Z735Y57JO[67_ "=/\9/^QSUG_P!+IJ\JH **** "
MBBB@ HHHH **** "BBB@ HHHH **** .L\,^+7@N(DNI2CJ D5P3G:,\*?;/
M?M7T%\/_ !Q)(ZV-^P4E1C)X8'N*^4:ZOPQXPDL4CM;J1O*C.89,\QGTSZ=*
M]_+LQ>'?LZGPGIX+&2PL_+L?96L>'M,\:Z4=$UF,26THQ;W)ZQGKC\P*^0?B
MA\*]4^&NM36UU&SVN[]W/C@@YQWKZ.^&_P 0K;6;%;2\D42J,#<1[UZ=>6FC
M>*]!FT7Q';+<VTR%(;S^*+(P-Q] ?YU]#C<'3QL%.._1GT.*PM/&P56EN?G9
M17K/QE^ &L_#.Z>\B3[?HDK$PW5N"Z!3G )%>35\+5HSHRY)JS/CZE.5*7+)
M!1116)F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,!6P^K5T>0T4$$'!X-%>4>:%%%% !1110 4444 %%%% !1110 4444 %%%%
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M$H **** "BBB@ HHHH W/ ]Y]A\7:5-G:!<("?8G']:_3SX+ZDL^F6PWAL*
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M5FU6+;R1G'K6?K,T<41P?U^M &;JVMLV0.*XS5)FDW%F-:-]=!I#6+?2ALT
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MQ?\ \I&OA/\ ]>.H?^F^_HI?V,EV_P#!1OX3#_IPU#_TWW]%>V<!\Q?M9?\
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M: .7>Q*]:JR(4[5UTFFMW1A^%4+C2MPX4Y^E '*S77DU3E\0+#WK;U'09O\
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MV#T!..]6OBCXD73KB/0],/V:TA0+,L>5WR#*L2.^<5N?"RS#^*/M'_/)4?\
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M "=/\9/^QSUG_P!+IJ\JKU7]K+_DZ?XR?]CGK/\ Z735Y56YY84444 %%%%
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MG7Q9<PR QPPK&.JD=:^*[7XO>+K,.(]8D ==K;HT;C\5JU;?&WQ?;R(QU/S
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M_$?_ *$* />-&F$%UL<94_X&OH/X MY7C2R53PS?^RM7S9#.P92W6O>/V?\
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M6<'T;"O3?@W=?9X]3]VC_DU>95Z+\)XS)#J0 _BC_DU48GK2S>;AE."*]?\
M@#K#P>*!$QXN(C;]3W9:\4L49& [5Z7\*;@6OC'1&)POVN//_?0KP,[AS85O
ML?><(RYL17P[^W3E]ZLSZ%AO-EY=P_W977\CBLO5YL,Q-/U!A9^);@$X64M(
M/Q<U:U#2AJ%JVPC<1GI[5ZF$J>UH0GW2/B:T>2I*/F<Q)?H,BJRZMY<G!K*U
MK3KW3;AE969,]< >M9?[U^<&NLQ/9O ]PL>FWVI2?=6-XU]=V 17B_CZ\:XF
MFN0<M(Q;GWS7I\WF:;\-;2-1B2XE60^X*8KRSQ/:N+4EQC_)KY_!RYI5\6^]
MEZ1/=IT/;UL/@UU:_%G@OQBUG_BD[RT(RTFP_3#C_"OGRO>?C+8G^P;N?'W=
MH_\ 'Q7@U>IA(M45)[RU?S.CB*K&68U*-/X*?N1](_\ !NPKN_AV=MG<MW\S
M^@KA*[WX>8_LVZ/_ $V'\A78?-';:;.R7T)R?OCO[U]C_ F077@#5(3_ ,_)
MD_*,5\76=R!?1#/1A_.OKW]F^Z\^SO;<_<:"5_\ QQ:^4SQ<O)/M^CN?H.2?
MO<GQ=)]'%_I^IT]PQ: 8Z8K(W>2Q8UOW 58R@YQQ6#=6<MU*(HQR37U2U5S\
M^(!J'F3;5&:K:A>.Q(/ Z<&N@.CQ:+8?, 9FZGD5R4SM<WB(O0N!^M#T0S8^
M(;&U^%EA"#@SH2WX2U\P>+K^166",D;<YY(]*^E_CG(NGZ!H5AG#>5)D?\#!
MKYBUZ0-<NP&<G_"OE<K7M9\_G.7WRLOP1^@5G]3R2K+9U90A\HQYG^+1Z)_P
M3Y5E_P""@OPLWG)-OJ1Y_P"P=>T4_P#X)_N7_P""A'PL)_Y]]1'_ )3KVBOJ
MS\^/ /VLO^3I_C)_V.>L_P#I=-7E5>J_M9?\G3_&3_L<]9_]+IJ\JH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MEM;J6RN$FB8HZGJ*BHI[; >I>"_&9MYEGAD9 O,L.?N^X]J^I? ?BJ#Q)IQA
MDDRX ()_G7P=97CV-U'/'C<AS@]#[&OI_P#9@6/QAXUT^%F\O2GFWW$:MS"
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M@2*8B/YCYEJBNZ\=PT+#\* /PLKWW]@>[DL_VQ_A.\9*LVMQQG'HRLI_0FO
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MK[.HO,T@];?U<^F_AKXB \I@PPU>JZA(MW;QOU'0U\N>"=6DT>^>QG?]Y$V
M?7WKZ#\*ZTFK68B<_,!7Z+1J*M34^JW/O,'76)HQEU6Y3\?> 8_%7@&_T].&
M^]&<_=;.17P_>V<VGW4MM.ACFB8JRGL17Z)Z3<QVUS]GN<F&0;6]QV-?-'[3
M7P@FT'5IM>LH]UH_,VT?DWXU\_G&%=2/MH[K\O\ @'CYKAW+][$^?:***^-/
MEPHHHH *N:*"=9L O+?:(\?]]"J=;'@Q!)XPT)6&5:_@!_[^+0!Z+#?M<H5/
M./:NE\"Z>IU9)T^5E()_6FZ7X50:A(O\';CZ^]=#HNEG2]6C*CY&//;M7+BE
M>A->3_(]S(Y^SS7"R_OQ_P#2D?85O_IGA;3I>^YQ^6*@M_\ 2,PGGTI?#DXD
M\#Z;(!\K2RC\B*AL[@0ZDF>F:\W)7_L,%VO^;-^(H\F:XA?WF:*6ILSAAQ5;
M4K955+B,8*')KH-85)+9&4 '']*S8;=KB%HC_$,5[A\X>]?!^<"SLI.^Q#^@
MK=_:AOFG^$>IC/'V=O\ T U@_"^V-O9VZ_W47^0J;]I&<M\*=33.3Y+?^@&O
MG,%K@ZLN[E^;/J,%_P C;"KM*'YH_+#X[Q[O#%TQYQ&I_4U\Q5]1?&J$OX/U
M%C_#&/\ T*OEVO:PO\"'HCCSS_D9XC_&_P PKTWX./MBU3_>C_DU>95Z-\)6
MVQZE_O1_R:ND\,]1&HF&MW0=2%Q.@SR.?Y5Q]QG;D5H^$YBNI >W]17'C/\
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MOP==7+/I6H:3;M<D1,25BE5 61U^Z<C!QD'FOM?_ ()A_L:ZQ^SG8>(?BO\
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M4C%9_P"QO^R'!K\=KXO\60%T#K):6+ CH58,W^%?H5'H=K9V:1PQA%4< =J
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M7B5K9_Z8..]?/9#_  /E'\C[SB/_ '# _P#<3_TH]+_8Z4K_ ,%&OA$#_P!
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M ()R^*&B8IXDT_?C@-%(,_I7V1<_&S2;$@>9& /4XI8?CYHLAQOC<GJ%.<4
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MP_6NZ^%?C"[N?B9X2BG2.0R:O9H9,8(!F0=N*\WKJ?A3_P E0\'_ /89L_\
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M.JQW+6\OD]?,V';U'>AIV9=-VFGYGU+\#9/.\(ZE#W7?)_XXM:C3;HQS7/?
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MBOXM'U/I,C_W#,/^O:_,\6\=,/\ A%+T=SL_]"%>05Z7XRNO,T*[7/\ =_\
M0A7FE>B?%A76^"HRUO,>WF#^5<E7IGPOTE=2T&_.0KK/P3G^Y0!T>DV?S*1[
M?TKU?P?=/;K"?^>;!NO88KRFWCN=+F <%ESU KT?PGJ23Q@'@D?T%<^(IJI2
ME%GLY/BYX+'4JL>]GYIZ-'U1\+]1_M"02J>'MVR/J*\[\574FG^+K_/W?/.,
M&NI^ <QDGN@?NI"W\A53Q9IL6H:G>2J V7)SDUX6!J.MC9S?\D;_ 'GHYYA(
M8&M4PT-HS=O3?]3:\#:R)[J$'_/-=5XVU(C4KF+/1CW^E>4^%Y#I^K0KG W
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBBB@ HHHH _3/_@C7^T=8^&?$&O?"/6[Q;>/6I1J.B^:P"M<A=LL0S_$Z*A
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MN8Q[]/>N_P#V<_VZOBS^S):_V;X7UM+WPZ6+_P!AZM'Y]LI)R3&,AHR3UVD
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MM)\%YI\$O"8L8]YDKRCP_I:6_C:X15 "NO\ Z!7O_P 4[%7^">I*XS_J<?\
M?Y:JI+V^"<N\;_@>QD<_JV=89]JD?SL?&?[/=Y]N_P""HWPMDSG_ (EMZ/\
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M'RC(KZ\6--/MB<[ !2Z3I<>F6:*JA55<=*\\^,/Q#@\+Z%=2R2+&D:99MV*
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M49)- 'MW[*7P3?XF>+!J%[;L^DV+*2>@=\Y _3]:_4OPCX?ATG3X8HXPBH,
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M'_"OX)^'OAIH=K:V]M$TL:_/,T:[W/J3@9-;W@7P%IW@?P];:?I\*Q0PH
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M1G_98BH:* -FW\::]9KM@UB]B7T2=A_6H;KQ1J]]G[1J=U-GKOE8_P!:S**
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M^U_\57S=H:_998STSG^M?0'P7N-NK0C/<?UKQL6KUGYPD?;X*5\@K+M6@_\
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M8R7>7]=6??YQKDF&MTG+\D<7X]9F\+WG_ /_ $(5Y#7MWQ"M0G@V_?'(V?\
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M ).G^,G_ &.>L_\ I=-7E5>J_M9?\G3_ !D_['/6?_2Z:O*J "BBB@ HHHH
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M\,;J?QKX)AEO_"%TQDGMHU,CV#$J,':N A+<$^]?'<<;RR*B*SNQPJJ,DGT
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M:^7#5'Y/\B<.KU8KS1SGQLT-+R\NYMHSQ_2OEK7K,JH4\[?_ *U?;7Q"T?\
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M(O%ES(9"Z(Q 'I7%TZ65II&=SN9CDFFT %%%% !0K%2"#@CN*** /KC]E/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *[7X/\ P]N_B3XYT_2K>(R1
M>8K3MV5-PS7%=>!7Z&_L+_!=_#^CKK]]"5NKY%8!AT3((_G0!]0_"_P+:>$/
M#]K:6\*PQ11JH51TP /Z5Y5^U]\:(_AKX%NOLLVS4YALME'7=D<].U>Y^*M<
M@\*^'[BXE=8UC0L2>V!7Y'_M*?&!_BYX\DN86;^SK4>7"I/!YY;^7Y4 >5:A
M?3:E>S75Q(TL\S%W=NI)J"BB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *O^'QNU[31ZW,?_H8JA6AX=./$&EG_IZB_P#0Q0!]"Z>XA7GBM[2;@"08
M(.:YB9]L>Y>M7_#-YY]T(R>1_P#7KDQ?^[U/1GT/#O\ R-\+_CC^:/KS]GZZ
M$OAO5.@PH_\ 0C72W5J%U!#GAC_2N-^ ZFS\':O*>/E'_H9KK);X7"JZGYA7
MD95K5Q#\U_Z2@SK^/IWE_P"E,IW$)L;O!X!YYK=T*X5M6LR".7 KGO$5T9/+
MD!YQC]*G\(7)EUBS4GI(#7I9A_N=7_"_R/(PO\>'JCQ'XX)N\:7S$\'(_P#'
MFKQ*XMBDT@Z@DG]:]I^,EQ]J\7Z@I/*NR_\ CS5XY=2$7#H?\\UQ97HI+RC^
M1]CGW[S+<#4[*:^Z3.+\:1E?#NI#_8S^HKQNO8_'4W_$EU%?6/\ ]FKQRO=/
MA KNOAM&)+?4,_WD_DU<+7<_#7/EWP']Y/ZT >CZ/IIFF7:,\U[1\+_"<FJZ
MQ8P+&Q4R*3CZ@5YWX/L6F=3MY)P/KQ7U/\%_#2:;;OJ<JX6*)G&>FX;3ZUX.
M8U[1:6T?Q?1'W65T_P"S<&\8_P")5O&/E'[4OT1W.O6JK]@M4)(MX$0^Q7BH
MI-++6VX GBH9=3^U3R.2#N8G]:O6>J!8S&QXQ7H8'#_5L/&EV/C<14]M5<SD
M+RU,<YW9'/\ 6NY\ R?+<#TB;^E<IK6UIRP/?_&NG\ L&><>L3?TKFS;_<Y_
MUU-<%_'B1^*[I/L\GX_UKYQ^(/\ I-X @!)!_F:]Z\<,8%FP>,G^M> ZO,)]
M<4,<KR/_ !ZKQ+OAX)=>4^EX:7+CZE5_8A-_^2L\-^+5K)#X/U/<A4 ISC_;
M6OGJOK_X^:7 OPMUBYC7##RO7O*M?(%>H?&A7NO[/TRP^&]5+''^E _^."O"
MJ]<^#]V;;PSJ84\M<8_\<H ],O-86XNBBD$*2/UI%EW2Q@=<BL>P@<YD;JQS
M6U8QAKA,]1S7/B'RT9/R/8R>FZN8T(+K)?F?5WPOA,?P]@+<;FB;_P =K>OF
M6X;8ISVK \,7!T_X:Z5C@RQQ-^E:.DS&>7<>@KQLC7^S-_WG^AZ'$M15,TK2
M7=_FS<TF 6.Q6."W/)KZ"^%=TG]I:>68 *C?R-?-EUJ!:YW \*:]9\"^*$L=
M/2\+C]TG\P?:M<V^"E_CC^:/'P?Q3_PO\CT/]I[QU8Z7X5N8'FB\PIC:>?XE
M]Z_);Q]J*R9 (SD\?B*^GOVEOB]+XFU-[9)EVD= <_W3_=]J^0/$5PUU=2'.
M1G_"NN7OXN*_E3?WZ'T-'_9>'JT^M:I&/R@N9_BT>F?\$^6W?\%!?A8?^G?4
MO_3=>T4[_@GY'Y?_  4$^%0_Z=M2/_E.O:*]$^./-/C=\*/$'Q,_:Z^,%KI%
MH70^--8#SOD(@^W3<Y_PKWGX4_L*:!I<,-QXE1M7NF3YHS*R1@G'3 YKZF\3
M:!I'AGX@>-+F"UBCGN=>U"YED"#+.]U(S$GZDUPOB+XK6VCM)L=?W:ECEL8
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDN+N[D2$[E2%&PH4]1QUXKK/VN;J6Z_:H^,/FR,^SQAJZ+N[*+V4 ?D*\EH
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M@ HHHH *O:"<:YIQ_P"GF/\ ]"%4:N:+_P ABQ_Z[Q_^A"@#UV&XQ? #I_\
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MJ=Y;ZA"=\>V2ZD<*Q[,-V,>U?-% !1110 4444 %%%% !1110 4444 %%%%
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MX#7HGQH5ZA\+K?S?#6I'TG_]DKR^O7_@RBR>&]44]?M'_L@H K7&Z*XQCO\
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MUN5E; S]T[L?I7G=>^?L6FW_ .%O6_G#+;/D^M 'Z@>&83#900QKL55 _2N
M_:?^*T/PN^'=W=,P:X*A44M@EB< 5Z;H?RKN[!<C\J_.7]OKXF7&O>.XO#:/
M_HUD!)(/5ST_0T ?,/B/7KKQ1KEYJEXVZYNI#(_X]JS:** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *T?#G_ ",.E_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[,18.VNATW:% I/56*C)QDI+H='I]P;>2)@<?* :^A6OA=?"&UE!R5N(U_\
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MX)]_\I!?A9_U[ZE_Z;KVBI/V 8_+_P""A'PL'_3MJ/\ Z;KVB@#Y_P#VLO\
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MUY_P2ZF34I3;>-[%M.S\F\OYN,=\1XZU]M)XBTJ;.V9/P-/;4=-5=WG+CZT
M>$_!/]B/P'\']0AUBYDE\2ZY$/W37.#%$W'S*,#GZU[=XJ\1VWAW1Y[F>6.W
MCC4G;D# KEO'7Q?\.^!].EGNKZ&#:I.6;V[<>U?G_P#M(_M9/\0(9](T":9;
M5R!)=9QO7T (S0!Y9^TEX\3XB?%[7=5@D\VV\P11,.A"J%S^E>8444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%:'AUO+\0:8W]VZB/_CXK/JWHYQJUD?^FZ?^A"@#UJ\OI+ZZ;+$JN,?E4VG-
MMF%48%\N$'N:NZ:N9-QX H [S09,-R><U]&_#:8_\*PU5L\-$P_\B"OEW1;[
M=>1*",;O6OIGP'(;?X.74IXR) ,]_P!X*^4S3_>(1[N'YL_0,-KP^I+[,Y_C
M&)>T*- \;'KNK8^,DGDM"_0?9X__ $&N2T.\,CQCWKI/CHK-8V>WO#&.G^Q7
MH8G3'T/27Z'Q]+7#5/5?J> ^(M26WCGES@*&.:\<O?%D][>NJ/@;B.,CO7I'
MC&$MITJ ]0V[CVKR!;7R[H[<GG^M=6$]Z52IW?Y:'T7$#]C2PF"7V*:?SE[S
M_,N>)I=WA>_:1MTC1]^>XKR2O4/$<6/#MX7//E\#\17E]>B?&A79?#U=WVOZ
MK_6N-KM/AU_R^?5/ZT =OM+5T?A&SW7#/CC:<'WR*Q84W&NO\+1"-2<]C_2N
M'&_P&?5\+Q4LTIM]+O[D>J>#;6.WC#$?,?\ ZU>W>(Y!_P (+IR],^6?_'37
M@FA71_=J",<?TKVKQE<?9_"6BJO0P0M^AK@QO\?#1_O?H>33DY*O-]?\REX-
M41^(+0@#+2*/_'A7/_%"U$>K:DV<9:0_J:M^#[XMXFT]>WGI_P"A"L/XT7SK
MXBN$W#!+<8_VFK#$RY,;)]X/\SU,EINM7H07_/R)Q#W<=O9@;OFQ_2N0UVZ:
MY4@'C_\ 75V93*YWN%7W%,6PAN/D4[C[&O;PL>6C!>1PYY45;,\1-=9R_,\L
M^(EL5\*WSGKE/_0A7C%?1WQ:T);/P!J4X/(\OCG^^M?.-=)X@5Z7\+E/]BWQ
M'_/<?^@UYI7J_P (XQ)H&H>OVD?^@B@#O_"1\R].>H'^%?H3^S)9[O#=D^W(
MVC_T%:_/C0(S;ZD&['C]17Z0?LFR)<^$+91R5 4\_P"PM>=MC/6/ZGV;?-PW
M;^6K^<6>F^*HQ';J>]?.?Q<C22\0G[PCQ_X\:^BO'S?8V5/5OZU\O?%V_P :
MQ*N<%01^IKFJ^]F-)=HR_0^;AIA9ONT8GP[@VZS>@<;K:7_T"OF_Q7#Y=S(G
M0J2*^B/A9?>=X@NHV[VTO_H%>#^.+;_B878[J_\ A7FO3-W_ -N_E(^TRJ\L
MCQL?[M_NG$\WO<JQS69N&[GI6Q><L5<8-4);$-\RM7UA^>'KW_!/Z,1_\%!_
MA9CH;?43_P"4Z]HH_P""?RE?^"@WPL!_Y]]1_P#3=>T4 > _M9?\G3_&3_L<
M]9_]+IJ\JKU7]K+_ ).G^,G_ &.>L_\ I=-7E5 !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %:&@^(+_PUJ45]IUPUO<1G(93U]C[5GT4 ?=OP$_:03Q9I
M)L[\K'>18#Q;@/7YEYZ5]+_"[XI0:I>7&@7J1:AI%VACE@F 9&4\%2,^]?D-
MI6KWFAWL=W87,EK<I]V2)BI'Y5]D_LI^/;SQ5>&XN=HNUD524_BP>N.W:@!_
M[>'[%]C\(X8?'G@F.9O#%\Y^U6."_P!A<GKN P$.0!GWKXHK]TOBYH-O\0/V
M=_%6AW:+*9M*F>/<N<2+&60_7<!7X::A:M8WUS;-]Z&1HS]02* (**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ JWH_.KV(_Z;I_Z$*J5;T?_D+6/_7=/_0A0!ZFS;F"BKLC?8K'/\3=
M/SJG80^9,":O:PF_8@Z+0!:\.RG[?;GU:OK;P^@A^!JD?Q-+_P"ABODOP[&!
MJ5L/1_Z&OK?3$*_ ^S7^_+,/_'A7RF:_[WAUW:_4^_P&O#E>_2I^<3G_  [(
M=RFNQ^/%UY/AW37'WBJ#/_;.N6T6S,<.[%=#\=86F\'Z3*.!N4'\(Z[\=[N+
MPTO.7Y'R>%7-2J1]/S/FSQ9>-]C"#EI,_J*X1K9;92[#+=J[S7HPVTMT45R$
M\1OKI8U^[G%=N!_@)][GM<4M?VI.*VBHK[HHX_Q1))-I-YQA O\ 6O-Z]T\7
M:"EKX+U.;'*PY_45X77>?)!7:?#G_E\^J?UKBZ[7X<_\OGU3^M 'HMJN!FNH
MT"8!64==I_I7)I,%VJ.M=)X;C9[A2>F/\*X\9'FH2/I>'*JI9K0OLW;[]#T3
MPO$TC*S<#(_I7LWQ&N!#X8T11_S[0_R:O)-&81QH!QR/Z5ZOX^@-QX=T%?\
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M)"X<@  9 SFN/^)_[<6K^((Y;30(&MHFR//E+ D8[ -Q7RLSLV S$@=,FDH
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M9K37H">F"/U%<)\<E,/C?6#C@S'^0KU2&Q"WENX !# ?J*\]^/EGM\87K?\
M/1V/Z+6>8>[CZ;[K\I1/3X6]Y5X_W*G_ *;D>!WVV63=C!%,2U%PO!P:M7UF
M4D.*BM,PR#/2OJC\_/3/V";<VO\ P4,^%BGO;:B?_*=>T5?_ &'5,G_!1+X5
ML@R%LM0+>W_$OOA_,BB@#Y[_ &S;%M/_ &M/C!$ZE2WBG49<$=GN'<'\0PKQ
MJOKC_@JIX5/AG]M;QC.L @@U>VL=1B & V;:.-V_&2*3\<U\CT %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "KVA<ZYI_\ U\1_^A"J-7M".W6]//\
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MV;_V6M^V0OJ-OW^=?YBOKWX-_LFPZKX[3QYXRMED@MW\W3-*F7(9N,32@^F
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M_P"NR?\ H0H ]+CD\L#GFO5O!L(DL8UQ_G)KQYI-UP@%>U^$-MOI*D\'']:
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M#:Z,GBK1L?\ /W$/_'Q7J/Q"N&7QI<JO3)/_ (\:\J^%MN?^$HT;/_/W$?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHHHSKXZ/J_R.7A3_ )&,/5'@\S%=V#52V<M-R<\T45]'2_AQ]$?,X[_>ZO\
MBE^;,/XND_\ "O=2^L?_ *&M?-M%%:G"+& S@'I7W#_P3]^&GAOQW)=VNN:=
M]N@:Z7*>?+'_  CNC T44 ?K1X/_ &3?A#X/:&XT[P'I;3J RR7P>\(/J/.9
M\?TKUBTLX+"W2WM8([:!!A(H4"JH] !P*** )J*** "BBB@ HHHH **** /_
!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
